ザワールドダーツ

<ウェブサイト名>

<現在の時刻>

出典: 標準

-->日本語EnglishResearchers Database-->AllResearcher NameAuthor NameSearchAdvanceKUDO MasatoshiDepartment of Medicine Professor/Senior StaffResearcher InformationURLResearch funding numberJ-Global IDResearch InterestsResearch AreasMajor subjects overseenAcademic & Professional ExperiencePublished PapersBooks etcConference Activities & TalksMiscAwards & HonorsResearch Grants & ProjectsLast Updated :2024/05/05Researcher InformationURLhttp://kaken.nii.ac.jp/d/r/10298953.ja.htmlResearch funding number10298953J-Global ID201401099345286424Research InterestsHepatocellular carcinoma   肝腫瘍の画像診断   Conrast-ehnaced ultrasonogaraphy   EOB-MRI   Radiofreuqency ablation (RFA)   Transarterial chemoembolization (TACE)   肝動注化学療法   Molecular targeted therapy   血管新生阻害治療   Immunotherapy   Immune checkpoint inhibitor   Research AreasLife sciences / Medical systemsLife sciences / GastroenterologyLife sciences / Tumor diagnostics and therapeuticsAcademic & Professional Experience1999/04 - Today  Kindai UniversityFaculty of MedicineProfessor and ChairmanPublished PapersAdverse Events as Potential Predictive Factors of Activity in Patients with Advanced HCC Treated with Atezolizumab Plus Bevacizumab.Mara Persano; Margherita Rimini; Toshifumi Tada; Goki Suda; Shigeo Shimose; Masatoshi Kudo; Federico Rossari; Changhoon Yoo; Jaekyung Cheon; Fabian Finkelmeier; Ho Yeong Lim; José Presa; Gianluca Masi; Francesca Bergamo; Elisabeth Amadeo; Francesco Vitiello; Takashi Kumada; Naoya Sakamoto; Hideki Iwamoto; Tomoko Aoki; Hong Jae Chon; Vera Himmelsbach; Massimo Alberto Iavarone; Giuseppe Cabibbo; Margarida Montes; Francesco Giuseppe Foschi; Caterina Vivaldi; Caterina Soldà; Takuya Sho; Takashi Niizeki; Naoshi Nishida; Christoph Steup; Mariangela Bruccoleri; Masashi Hirooka; Kazuya Kariyama; Joji Tani; Masanori Atsukawa; Koichi Takaguchi; Ei Itobayashi; Shinya Fukunishi; Kunihiko Tsuji; Toru Ishikawa; Kazuto Tajiri; Hironori Ochi; Satoshi Yasuda; Hidenori Toyoda; Chikara Ogawa; Takashi Nishimura; Takeshi Hatanaka; Satoru Kakizaki; Noritomo Shimada; Kazuhito Kawata; Atsushi Hiraoka; Fujimasa Tada; Hideko Ohama; Kazuhiro Nouso; Asahiro Morishita; Akemi Tsutsui; Takuya Nagano; Norio Itokawa; Tomomi Okubo; Michitaka Imai; Hisashi Kosaka; Atsushi Naganuma; Yohei Koizumi; Shinichiro Nakamura; Masaki Kaibori; Hiroko Iijima; Yoichi Hiasa; Silvia Foti; Silvia Camera; Fabio Piscaglia; Mario Scartozzi; Stefano Cascinu; Andrea Casadei-GardiniTargeted oncology 2024/04 BACKGROUND: In the context of patients with hepatocellular carcinoma (HCC) treated with systemic therapy, the correlation between the appearance of adverse events (AEs) and reported efficacy outcomes is well-known and widely investigated. From other pathological settings, we are aware of the prognostic and predictive value of the occurrence of immune-related AEs in patients treated with immune-checkpoint inhibitors. OBJECTIVE: This retrospective multicenter real-world study aims to investigate the potential prognostic value of AEs in patients with HCC treated with atezolizumab plus bevacizumab in the first-line setting. PATIENTS AND METHODS: The study population consisted of 823 patients from five countries (Italy, Germany, Portugal, Japan, and the Republic of Korea). RESULTS: Of the patients, 73.3% presented at least one AE during the study period. The most common AEs were proteinuria (29.6%), arterial hypertension (27.2%), and fatigue (26.0%). In all, 17.3% of the AEs were grade (G) 3. One death due to bleeding was reported. The multivariate analysis confirmed the appearance of decreased appetite G Necrotizing Fasciitis of the Serratus Anterior in a Patient Treated With Infliximab and Prednisolone for Ulcerative Colitis and Rheumatoid ArthritisNatsuki Okai; Yasuo Otsuka; Sho Masaki; Masatoshi Kudo; Tomohiro WatanabeCureus Springer Science and Business Media LLC 2168-8184 2024/04Current Trends and Advancements in the Management of Hepatocellular Carcinoma.Andreas Teufel; Masatoshi Kudo; Yuquan Qian; Jimmy Daza; Isaac Rodriguez; Christoph Reissfelder; Ezequiel Ridruejo; Matthias P EbertDigestive diseases (Basel, Switzerland) 2024/04 Hepatocellular Carcinoma (HCC) remains a significant global health burden with a high mortality rate. Over the past 40 years, significant progress has been achieved in the prevention and management of HCC. Hepatitis B vaccination programs, the development of direct acting antiviral drugs for Hepatitis C and effective surveillance strategies provide a profound basis for prevention for HCC. Advanced surgery and liver transplantation along with local ablation techniques potentially offer cure for the disease, Also just recently, the introduction of immunotherapy opened a new chapter in systemic treatment. Finally, the introduction of the BCLC classification system for HCC, clearly defining patient groups and assigning reasonable treatment options, has standardized treatment and become the basis of almost all clinical trials for HCC. With this review, we provide a comprehensive overview of the evolving landscape of HCC management but also touch on current challenges. A comprehensive and multidisciplinary approach is crucial for effective HCC management. Continued research and clinical trials are imperative to further enhance treatment options and will ultimately reduce the global burden of this devastating disease.Impact of body mass index on the prognosis of unresectable HCC patients receiving first-line Lenvatinib or atezolizumab plus bevacizumab.Margherita Rimini; Bernardo Stefanini; Toshifumi Tada; Goki Suda; Shigeo Shimose; Masatoshi Kudo; Fabian Finkelmeier; Changhoon Yoo; José Presa; Elisabeth Amadeo; Virginia Genovesi; Maria Caterina De Grandis; Massimo Iavarone; Fabio Marra; Francesco Foschi; Emiliano Tamburini; Federico Rossari; Francesco Vitiello; Linda Bartalini; Caterina Soldà; Francesco Tovoli; Caterina Vivaldi; Sara Lonardi; Marianna Silletta; Takashi Kumada; Naoya Sakamoto; Hideki Iwamoto; Tomoko Aoki; Vera Himmelsbach; Margarida Montes; Atsushi Hiraoka; Takuya Sho; Takashi Niizeki; Naoshi Nishida; Christoph Steup; Masashi Hirooka; Kazuya Kariyama; Joji Tani; Masanori Atsukawa; Koichi Takaguchi; Ei Itobayashi; Shinya Fukunishi; Kunihiko Tsuji; Toru Ishikawa; Kazuto Tajiri; Hironori Ochi; Satoshi Yasuda; Hidenori Toyoda; Chikara Ogawa; Takashi Nishimura; Takeshi Hatanaka; Satoru Kakizaki; Noritomo Shimada; Kazuhito Kawata; Fujimasa Tada; Hideko Ohama; Kazuhiro Nouso; Asahiro Morishita; Akemi Tsutsui; Takuya Nagano; Norio Itokawa; Tomomi Okubo; Taeang Arai; Michitaka Imai; Hisashi Kosaka; Atsushi Naganuma; Yohei Koizumi; Shinichiro Nakamura; Masaki Kaibori; Hiroko Iijima; Yoichi Hiasa; Mara Persano; Silvia Camera; Silvia Foti; Luca Aldrighetti; Stefano Cascinu; Andrea Casadei-Gardini; Fabio PiscagliaLiver international : official journal of the International Association for the Study of the Liver 2024/03 INTRODUCTION: Overweight is a negative prognostic factor in the general population in the long term. However, the role of body mass index (BMI) in the short-mid term in advanced tumours is unclear. The present analysis investigates the role of BMI weight classes in a large sample of patients affected by HCC and receiving atezolizumab plus bevacizumab or lenvatinib as first-line treatment. METHODS AND MATERIAL: The cohort included consecutive patients affected by BCLC-c and BCLC-B HCC patients from a multicenter international study group who received atezolizumab plus bevacizumab or lenvatinib as first-line therapy. Population was stratified according to the BMI in under-, over- and normal-weight according to the conventional thresholds. The primary objective of the study was to evaluate the prognostic and predictive impact of BMI in patients affected by advanced or intermediate HCC. Survival curves were estimated using the product-limit method of Kaplan-Meier. The role of stratification factors was analysed with log-rank tests. RESULTS: 1292 consecutive patients with HCC were analysed. 466 (36%) patients were treated with lenvatinib and 826 (64%) patients were treated with atezolizumab plus bevacizumab. In the atezolizumab plus bevacizumab arm, 510 (62%) patients were normal-weight, 52 (6%) underweight and 264 (32%) overweight. At the univariate analysis for OS, underweight patients had significantly shorter OS compared to normal-weight patients, whereas no differences were found between normal-weight versus overweight. Multivariate analysis confirmed that underweight patients had significantly shorter OS compared to normal-weight patients (HR: 1.7; 95% CI: 1.0-2.8; p = .0323). In the lenvatinib arm, 26 patients (5.6%) were categorized as underweight, 256 (54.9%) as normal-weight, and 184 (39.5%) as overweight. At the univariate analysis for OS, no significant differences were found between normal-weight versus underweight and between normal-weight versus overweight, which was confirmed at multivariate analysis. CONCLUSION: Our analysis highlighted a prognostic role of BMI in a cohort of patients with advanced HCC who received atezolizumab plus bevacizumab, while no prognostic role for low BMI was apparent in patients who received lenvatinib.Hereditary hemorrhagic telangiectasia with hepatic arteriovenous shunt diagnosed due to liver damageSatoru Hagiwara; Toru Takase; Itsuki Oda; Yoriaki Komeda; Naoshi Nishida; Akihiro Yoshida; Tomoki Yamamoto; Takuya Matsubara; Masatoshi KudoClinical Journal of Gastroenterology Springer Science and Business Media LLC 1865-7257 2024/03 Abstract A 53-year-old woman was diagnosed with liver dysfunction in August 20XX. Computed tomography (CT) revealed multiple hepatic AV shunts, and she was placed under observation. In March 20XX + 3, she developed back pain, and CT performed during an emergency hospital visit showed evidence of intrahepatic bile duct dilatation. She was referred to our gastroenterology department in May 20XX + 3. We conducted investigations on suspicion of hereditary hemorrhagic telangiectasia (HHT) with hepatic AV shunting based on contrast-enhanced CT performed at another hospital. HHT is generally discovered due to epistaxis, but there are also cases where it is diagnosed during examination of liver damage.Indigo naturalis as a promising novel treatment for type 2 autoimmune pancreatitisKen Kamata; Masatoshi Kudo; Tomohiro WatanabePancreatology Elsevier BV 1424-3903 2024/03Adjuvant and neoadjuvant immunotherapies in hepatocellular carcinoma.Josep M Llovet; Roser Pinyol; Mark Yarchoan; Amit G Singal; Thomas U Marron; Myron Schwartz; Eli Pikarsky; Masatoshi Kudo; Richard S FinnNature reviews. Clinical oncology 2024/02 Liver cancer, specifically hepatocellular carcinoma (HCC), is the sixth most common cancer and the third leading cause of cancer mortality worldwide. The development of effective systemic therapies, particularly those involving immune-checkpoint inhibitors (ICIs), has substantially improved the outcomes of patients with advanced-stage HCC. Approximately 30% of patients are diagnosed with early stage disease and currently receive potentially curative therapies, such as resection, liver transplantation or local ablation, which result in median overall survival durations beyond 60 months. Nonetheless, up to 70% of these patients will have disease recurrence within 5 years of resection or local ablation. To date, the results of randomized clinical trials testing adjuvant therapy in patients with HCC have been negative. This major unmet need has been addressed with the IMbrave 050 trial, demonstrating a recurrence-free survival benefit in patients with a high risk of relapse after resection or local ablation who received adjuvant atezolizumab plus bevacizumab. In parallel, studies testing neoadjuvant ICIs alone or in combination in patients with early stage disease have also reported efficacy. In this Review, we provide a comprehensive overview of the current approaches to manage patients with early stage HCC. We also describe the tumour immune microenvironment and the mechanisms of action of ICIs and cancer vaccines in this setting. Finally, we summarize the available evidence from phase II/III trials of neoadjuvant and adjuvant approaches and discuss emerging clinical trials, identification of biomarkers and clinical trial design considerations for future studies.Role of leucine-rich repeat kinase 2 in severe acute pancreatitisYasuo Otsuka; Kosuke Minaga; Masatoshi Kudo; Tomohiro WatanabeFrontiers in Immunology Frontiers Media SA 15 1364839 - 1364839 2024/02 Introduction Intrapancreatic activation of trypsinogen caused by alcohol or high-fat intake and the subsequent autodigestion of the pancreas tissues by trypsin are indispensable events in the development of acute pancreatitis. In addition to this trypsin-centered paradigm, recent studies provide evidence that innate immune responses triggered by translocation of intestinal bacteria to the pancreas due to intestinal barrier dysfunction underlie the immunopathogenesis of acute pancreatitis. Although severe acute pancreatitis is often associated with pancreatic colonization by fungi, the molecular mechanisms linking fungus-induced immune responses to the development of severe acute pancreatitis are poorly understood. Leucine-rich repeat kinase 2 (LRRK2) is a multifunctional protein that mediates innate immune responses to fungi and bacteria. Mutations in Lrrk2 is a risk factor for Parkinson’s disease and Crohn’s disease, both of which are driven by innate immune responses to gut organisms. Discussion In this Minireview article, we discuss how activation of LRRK2 by the recognition of fungi induces severe acute pancreatitis.Objective Response to Systemic Therapy Is a Strong Predictor of Overall Survival in Patients with Unresectable Hepatocellular Carcinoma.Masatoshi KudoLiver cancer 13 (1) 1 - 5 2024/02Emergency digital cholangioscopy-assisted electrohydraulic lithotripsy for basket impaction with an entrapped bile duct stone.Akane Hara; Kosuke Minaga; Yasuo Otsuka; Hidekazu Tanaka; Mamoru Takenaka; Masatoshi KudoEndoscopy international open 12 (2) E271-E273  2024/02A meta-analysis and real-world cohort study on the sex-related differences in efficacy and safety of immunotherapy for hepatocellular carcinoma.Lorenz Balcar; Bernhard Scheiner; Claudia Angela Maria Fulgenzi; Antonio D'Alessio; Katharina Pomej; Marta Bofill Roig; Elias Laurin Meyer; Jaekyung Che; Naoshi Nishida; Pei-Chang Lee; Linda Wu; Celina Ang; Anja Krall; Anwaar Saeed; Bernardo Stefanini; Antonella Cammarota; Tiziana Pressiani; Yehia I Abugabal; Shadi Chamseddine; Brooke Wietharn; Alessandro Parisi; Yi-Hsiang Huang; Samuel Phen; Caterina Vivaldi; Francesca Salani; Gianluca Masi; Dominik Bettinger; Arndt Vogel; Johann von Felden; Kornelius Schulze; Marianna Silletta; Michael Trauner; Adel Samson; Henning Wege; Fabio Piscaglia; Peter R Galle; Rudolf Stauber; Masatoshi Kudo; Amit G Singal; Aleena Itani; Susanna V Ulahannan; Neehar D Parikh; Alessio Cortellini; Ahmed Kaseb; Lorenza Rimassa; Hong Jae Chon; David J Pinato; Matthias PinterJHEP reports : innovation in hepatology 6 (2) 100982 - 100982 2024/02 BACKGROUND & AIMS: Sex-related differences in the immune pathogenesis of hepatocellular carcinoma (HCC), particularly related to oestrogen-dependent secretion of pro-tumourigenic cytokines, are well-known. Whether sex influences the efficacy and safety of immunotherapy is not known. METHODS: We performed a restricted maximum likelihood random effects meta-analysis of five phase III trials that evaluated immune checkpoint inhibitors (ICIs) in advanced HCC and reported overall survival (OS) hazard ratios (HRs) stratified by sex to evaluate sex-related differences in OS. In a real-world cohort of 840 patients with HCC from 22 centres included between 2018 and 2023, we directly compared the efficacy and safety of atezolizumab + bevacizumab (A+B) between sexes. Radiological response was reported according to RECIST v1.1. Uni- and multivariable Cox regression analyses were performed for OS and progression-free survival (PFS). RESULTS: In the meta-analysis, immunotherapy was associated with a significant OS benefit only in male (pooled HR 0.79; 95% CI 0.73-0.86) but not in female (pooled HR 0.85; 95% CI 0.70-1.03) patients with HCC. When directly comparing model estimates, no differences in the treatment effect between sexes were observed. Among 840 patients, 677 (81%) were male (mean age 66 ± 11 years), and 163 (19%) were female (mean age 67 ± 12 years). Type and severity of adverse events were similar between the two groups. OS and PFS were comparable between males and females upon uni- and multivariable analyses (aHR for OS and PFS: 0.79, 95% CI 0.59-1.04; 1.02, 95% CI 0.80-1.30, respectively). Objective response rates (24%/22%) and disease control rates (59%/59%) were also similar between sexes. CONCLUSION: Female phase III trial participants experienced smaller OS benefit following ICI therapy for advanced HCC, while outcomes following A+B treatment were comparable between sexes in a large real-world database. Based on the ambiguous sex-related differences in survival observed here, further investigation of sex-specific clinical and biologic determinants of responsiveness and survival following ICIs are warranted. IMPACT AND IMPLICATIONS: While immune checkpoint inhibitors have emerged as standard of care for the treatment of hepatocellular carcinoma, there are conflicting reports on whether the efficacy of cancer immunotherapy differs between females and males. Our study suggests ambiguous sex-related differences in outcomes from immunotherapy in hepatocellular carcinoma. Further investigation of sex-specific clustering in clinicopathologic and immunologic determinants of responsiveness to immune checkpoint inhibitor therapy should be prioritised. SYSTEMATIC REVIEW REGISTRATION: PROSPERO CRD42023429625.Incidence of Hyper Progressive Disease in Combination Immunotherapy and Anti-Programmed Cell Death Protein 1/Programmed Death-Ligand 1 Monotherapy for Unresectable Hepatocellular Carcinoma.Tomoko Aoki; Masatoshi Kudo; Kazuomi Ueshima; Masahiro Morita; Hirokazu Chishina; Masahiro Takita; Satoru Hagiwara; Hiroshi Ida; Yasunori Minami; Masakatsu Tsurusaki; Naoshi NishidaLiver cancer 13 (1) 56 - 69 2024/02 INTRODUCTION: Programmed cell death protein 1 (PD-1)/programmed death-ligand 1 (PD-L1) signaling blockade is the most effective strategy for the treatment of immune evading hepatocellular carcinoma (HCC). While immune checkpoint inhibitor has revolutionized the concept of cancer treatment, it has also led to unexpected tumor growth. Regulatory T cells express PD-1 and cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) receptors, which are proliferated and activated by antibody binding, and their ratio to CD8+ T cells is altered, which is one of the causes for hyper progressive disease (HPD). We examined the frequency of HPD in anti-PD-1/PD-L1 monotherapy and combination therapy with vascular endothelial growth factor (VEGF) antibody and anti-CTLA-4 antibodies. METHODS: This was a prospective and retrospective cohort study which enrolled 198 patients with unresectable HCC from January 2015 to December 2021 at the Kindai University Hospital. Fifty-eight patients received anti-PD-1/PD-L1 monotherapy, 119 patients combination with VEGF antibody, and 21 patients combination with anti-CTLA-4 antibody. We defined HPD as tumor growth rate (TGR) ratio ≥4, ΔTGR ≥40%, and tumor growth kinetics ratio ≥4. RESULTS: The HPD rate was 10.3% (6/58) in anti-PD-1/PD-L1 monotherapy, 1.7% (2/119) in combination with VEGF antibody, and 4.8% (1/21) in combination with anti-CTLA-4 antibody (p = 0.034). The odds ratio for HPD in the combined anti-CTLA-4 antibody group was 0.433 (95% confidence interval [CI]: 0.05-3.83) when compared to the anti-PD-1/PD-L1 monotherapy group and 2.93 (95% CI: 0.25-33.79) when compared to the combined VEGF antibody group. CONCLUSION: The frequency of HPD in unresectable HCC compared to anti-PD-1/PD-L1 monotherapy was decreased with the combination with anti-VEGF antibody and not increased with anti-CTLA-4 antibody. Anti-PD-1/PD-L1 combined with anti-CTLA-4 antibody is now available in real-world and needs to be further validated with accumulated clinical practice.Safety and Efficacy of Lenvatinib in Very Old Patients with Unresectable Hepatocellular Carcinoma.Silvia Camera; Margherita Rimini; Federico Rossari; Toshifumi Tada; Goki Suda; Shigeo Shimose; Masatoshi Kudo; Changhoon Yoo; Jaekyung Cheon; Fabian Finkelmeier; Ho Yeong Lim; José Presa; Gianluca Masi; Francesca Bergamo; Francesca Salani; Mariarosaria Marseglia; Elisabeth Amadeo; Francesco Vitiello; Takashi Kumada; Naoya Sakamoto; Hideki Iwamoto; Tomoko Aoki; Hong Jae Chon; Vera Himmelsbach; Massimo Iavarone; Giuseppe Cabibbo; Margarida Montes; Francesco Giuseppe Foschi; Caterina Vivaldi; Sara Lonardi; Takuya Sho; Takashi Niizeki; Naoshi Nishida; Christoph Steup; Masashi Hirooka; Kazuya Kariyama; Joji Tani; Masanori Atsukawa; Koichi Takaguchi; Ei Itobayashi; Shinya Fukunishi; Kunihiko Tsuji; Toru Ishikawa; Kazuto Tajiri; Hironori Ochi; Satoshi Yasuda; Hidenori Toyoda; Chikara Ogawa; Takashi Nishimura; Takeshi Hatanaka; Satoru Kakizaki; Noritomo Shimada; Kazuhito Kawata; Atsushi Hiraoka; Fujimasa Tada; Hideko Ohama; Kazuhiro Nouso; Asahiro Morishita; Akemi Tsutsui; Takuya Nagano; Norio Itokawa; Tomomi Okubo; Michitaka Imai; Hisashi Kosaka; Atsushi Naganuma; Yohei Koizumi; Shinichiro Nakamura; Masaki Kaibori; Hiroko Iijima; Yoichi Hiasa; Mara Persano; Silvia Foti; Fabio Piscaglia; Mario Scartozzi; Stefano Cascinu; Andrea Casadei-GardiniTargeted oncology 2024/01 BACKGROUND: Data concerning the use of lenvatinib in very old patients (≥ 80 years) are limited, although the incidence of hepatocellular carcinoma (HCC) in this patient population is constantly increasing. OBJECTIVE: This analysis aimed to evaluate the efficacy and safety of lenvatinib in a large cohort of very old patients (≥ 80 years) with unresectable HCC. PATIENTS AND METHODS: The study was conducted on a cohort of 1325 patients from 46 centers in four Western and Eastern countries (Italy, Germany, Japan, and the Republic of Korea) who were undergoing first-line treatment with lenvatinib between July 2010 and February 2022. Patients were stratified according to age as very old (≥ 80 years) and not very old (Hemophagocytic lymphohistiocytosis induced by nivolumab/ipilimumab combination therapy: A case of lung adenocarcinoma that responded to early steroid pulse therapy.Satoru Hagiwara; Junko Tanizaki; Hidetoshi Hayashi; Yoriaki Komeda; Naoshi Nishida; Akihiro Yoshida; Tomoki Yamamoto; Takuya Matsubara; Masatoshi KudoCancer reports (Hoboken, N.J.) e1960  2024/01 BACKGROUND: Immune checkpoint inhibitors have been reported to have excellent therapeutic effects on various malignant tumors. However, immune-related adverse events can occur, targeting various organs. CASE PRESENTATION: A 49-year-old male with lung carcinoma was started on carboplatin + pemetrexed + nivolumab (every 3 weeks) + ipilimumab (every 6 weeks), and nivolumab/ipilimumab was administered in the 3rd course. Subsequently, fever and fatigue developed, and grade 3 liver damage was also noted, so he was admitted to Kindai University Hospital. A bone marrow aspirate examination was performed on the third day of illness, and a definitive diagnosis of hemophagocytic lymphohistiocytosis (HLH) was made. It was determined that immediate therapeutic intervention was necessary, and pulse therapy with methylprednisolone was started on the third day of illness. After 3 days of pulse treatment, a rapid recovery of platelet values, a decrease in ferritin levels, and a decrease in lactate dehydrogenase were observed. Subjective symptoms such as fever and fatigue also quickly improved. CONCLUSION: Early diagnosis and treatment for HLH resulted in a positive response. The number of HLH cases may increase in the future due to the expansion of immune checkpoint inhibitor indications.A Case of an Splenic Artery Aneurysm and Focal Nodular Hyperplasia Associated with an Abdominal Vascular Abnormality of Hereditary Hemorrhagic TelangiectasiaSatoru Hagiwara; Koichi Nakagawa; Yoriaki Komeda; Naoshi Nishida; Akihiro Yoshida; Tomoki Yamamoto; Takuya Matsubara; Masatoshi KudoInternal Medicine Japanese Society of Internal Medicine 0918-2918 2024 In October 2021, a 51-year-old woman developed a skin rash. Abdominal computed tomography revealed a large splenic artery aneurysm and an intrahepatic portovenous shunt. As her splenic artery aneurysm was at risk of rupture, she was referred to the Kindai University Hospital and underwent coiling surgery. In October 2023, approximately two years after she had been initially referred, contrast-enhanced ultrasound revealed findings suggestive of focal nodular hyperplasia. No reports have confirmed the occurrence of liver masses in patients with hereditary hemorrhagic telangiectasia, which is considered to be an interesting finding when investigating the mechanism of tumor development.Correction to: Consensus report from the 10th Global Forum for Liver Magnetic Resonance Imaging: developments in HCC management.Bachir Taouli; Ahmed Ba-Ssalamah; Julius Chapiro; Jagpreet Chhatwal; Kathryn Fowler; Tae Wook Kang; Gesine Knobloch; Dow-Mu Koh; Masatoshi Kudo; Jeong Min Lee; Takamichi Murakami; David J Pinato; Kristina I Ringe; Bin Song; Parissa Tabrizian; Jin Wang; Jeong Hee Yoon; Mengsu Zeng; Jian Zhou; Valérie VilgrainEuropean radiology 2023/12【肝細胞癌治療のパラダイムチェンジ】Wnt/βカテニン経路活性化と肝癌免疫療法の効果盛田 真弘; 青木 智子; 西田 直生志; 工藤 正俊消化器内科 (株)医学出版 5 (2) 70 - 79 2023/12 HCCにおける抗PD-1抗体単剤療法に対する奏効率は20%前後であり,ICIが奏功するサブグループを特定することは臨床的に重要である.ICIの効果と腫瘍免疫微小環境は密接な関係があると考えられている.腫瘍免疫微小環境にはさまざまな分類が提唱されているが,過去の検討からICIの効果を得るためには腫瘍へのリンパ球浸潤や免疫チェックポイントの発現状況も重要な因子の1つである.そのなかで,Wnt/βカテニン経路活性化は腫瘍内へのリンパ球浸潤に乏しい"immune exclusion"をきたすことが基礎的検討で示されている.少数例ながら,Wnt/βカテニン経路活性化をきたしたHCCはICIの奏功が得られづらいことが臨床データにおいても示されている.HCCの診療においてもICIが広く使用されるようになっており,Wnt/βカテニン経路活性化と臨床的意義について,これまでの報告を基に解説する.(著者抄録)Atezolizumab in Combination with Bevacizumab for the Management of Patients with Hepatocellular Carcinoma in the First-Line Setting: Systematic Literature Review and Meta-Analysis.Arndt Vogel; Richard S Finn; Marie-Hélène Blanchet Zumofen; Carolina Heuser; Javier Sanchez Alvarez; Michael Leibfried; Catherine R Mitchell; Sarah Batson; Gabrielle Redhead; Vincent E Gaillard; Masatoshi KudoLiver cancer 12 (6) 510 - 520 2023/12 BACKGROUND: In 2020, atezolizumab-bevacizumab became the new standard of care (SOC) for first-line unresectable hepatocellular carcinoma (HCC) patients, following a decade where sorafenib was the preferred first-line treatment. In the last few years, a number of novel systemic treatments with non-inferiority and superiority to sorafenib have been approved as first-line treatments. OBJECTIVES: The objective of this systematic literature review (SLR) and network meta-analysis (NMA) was to compare randomised controlled trial evidence for atezolizumab-bevacizumab with globally relevant pharmacological comparators for first-line treatment of patients with unresectable HCC. METHODS: Randomised controlled trials investigating first-line treatment of HCC in adults with no prior systemic treatment were eligible for inclusion into the SLR and were retrieved from Embase, MEDLINE, and Evidence-Based Medicine (EBM) Reviews. Interventions of interest for the NMA included atezolizumab-bevacizumab, sorafenib, lenvatinib, durvalumab (including in combination with tremelimumab), cabozantinib (including in combination with atezolizumab), camrelizumab (including in combination with rivoceranib), pembrolizumab (including in combination with lenvatinib), and tislelizumab. Random effects NMA was conducted for survival endpoints within a Bayesian framework with an informative prior distribution for between-study heterogeneity. The hazard ratios for relative treatment effect were estimated with 95% credible intervals (CrIs). RESULTS: The SLR identified 49 studies, of which eight formed a connected evidence network permitting the indirect treatment comparison of atezolizumab-bevacizumab with comparators of interest. The indirect comparisons suggested an improved overall survival (OS) with atezolizumab-bevacizumab versus most comparators. All indirect treatment comparison results for atezolizumab-bevacizumab included the null value within the 95% CrI (n = 1) for OS and progression-free survival (PFS). CONCLUSIONS: The results of the NMA indicate atezolizumab-bevacizumab is associated with superior or comparable OS and PFS together with a manageable safety profile compared with globally relevant comparators in the unresected HCC indication. The findings support that atezolizumab-bevacizumab remains SOC for the management of first-line unresectable HCC patients.Current Therapeutic Strategies for Hepatocellular Carcinoma in Japan.Masatoshi KudoLiver cancer 12 (6) 497 - 509 2023/12Genetic/epigenetic alteration and tumor immune microenvironment in intrahepatic cholangiocarcinoma: Transforming the immune microenvironment with molecular targeted agentsNaoshi Nishida; Masatoshi KudoLiver Cancer S. Karger AG (in press) 1 - 14 2235-1795 2023/12 [Refereed] Background: Intrahepatic cholangiocarcinoma (iCCA) is often diagnosed at an advanced stage, leading to limited treatment options and a poor prognosis. So far, standard systemic therapy for advanced iCCA has been a combination of gemcitabine and cisplatin. However, recent advancements in the understanding of the molecular characteristics of iCCA have opened new possibilities for molecular-targeted therapies and immunotherapy. Summary: Reportedly, 9–36% of iCCA cases have an inflamed tumor immune microenvironment (TME) based on the immune gene expression signature, which is characterized by the presence of immune cells involved in anti-tumor immune responses. The majority of iCCA cases have a non-inflamed TME with a lack of effector T cells, rendering immune checkpoint inhibitors (ICIs) ineffective in these cases. Interestingly, alterations in the fibroblast growth factor receptor (FGFR2) gene and IDH1/2 gene mutations are often observed in the non-inflamed TME in iCCA. Several mechanisms have been reported for the role of driver mutations on the establishment of TME unique for iCCA. For example, IDH1/2 mutations, which cause an increase in DNA methylation, are associated with the downregulation and hypermethylation of antigen processing and presentation machinery, which may contribute to the establishment of a non-inflamed TME. Therefore, inhibitors targeting IDH1/2 may restore the DNA methylation and expression status of molecules involved in antigen presentation, potentially improving the efficacy of ICIs. FGFR inhibitors may also have the potential to modulate immunosuppressive TME by inhibitingthe suppressor of cytokine signaling 1 and activating the interferon-γ signaling as a consequence of inhibition of the FGFR signal. From this perspective, understanding the molecular characteristics of iCCA, including the TME and driver mutations, is essential for the effective application of ICIs and molecular-targeted therapies. Key Messages: Combination approaches that target both the tumor and immune system hold promise for improving the outcomes of patients with iCCA. Further research and clinical trials are needed to validate these approaches and optimize the treatment strategies for iCCA.α-FAtE: A new predictive score of response to atezolizumab plus bevacizumab for unresectable hepatocellular carcinoma.Federico Rossari; Toshifumi Tada; Goki Suda; Shigeo Shimose; Masatoshi Kudo; Changhoon Yoo; Jaekyung Cheon; Fabian Finkelmeier; Ho Yeong Lim; José Presa; Gianluca Masi; Francesca Bergamo; Elisabeth Amadeo; Francesco Vitiello; Takashi Kumada; Naoya Sakamoto; Hideki Iwamoto; Tomoko Aoki; Hong Jae Chon; Vera Himmelsbach; Massimo Iavarone; Giuseppe Cabibbo; Margarida Montes; Francesco Giuseppe Foschi; Caterina Vivaldi; Caterina Soldà; Takuya Sho; Takashi Niizeki; Naoshi Nishida; Christoph Steup; Masashi Hirooka; Kazuya Kariyama; Joji Tani; Masanori Atsukawa; Koichi Takaguchi; Ei Itobayashi; Shinya Fukunishi; Kunihiko Tsuji; Toru Ishikawa; Kazuto Tajiri; Hironori Ochi; Satoshi Yasuda; Hidenori Toyoda; Chikara Ogawa; Takashi Nishimura; Takeshi Hatanaka; Satoru Kakizaki; Noritomo Shimada; Kazuhito Kawata; Atsushi Hiraoka; Fujimasa Tada; Hideko Ohama; Kazuhiro Nouso; Asahiro Morishita; Akemi Tsutsui; Takuya Nagano; Norio Itokawa; Tomomi Okubo; Michitaka Imai; Hisashi Kosaka; Atsushi Naganuma; Yohei Koizumi; Shinichiro Nakamura; Masaki Kaibori; Hiroko Iijima; Yoichi Hiasa; Mara Persano; Valentina Burgio; Fabio Piscaglia; Mario Scartozzi; Stefano Cascinu; Andrea Casadei-Gardini; Margherita RiminiInternational journal of cancer 2023/11 Atezolizumab plus bevacizumab (AB) and lenvatinib can be alternatively used as first-line systemic treatment of unresectable hepatocellular carcinoma (HCC). However, no direct comparison of the two regimens has been performed in randomized clinical trials, making the identification of baseline differential predictors of response of major relevance to tailor the best therapeutic option to each patient. Baseline clinical and laboratory characteristics of real-world AB-treated HCC patients were analyzed in uni- and multivariate analyses to find potential prognostic factors of overall survival (OS). Significant variables were incorporated in a composite score (α-FAtE) and it was tested for specificity and sensitivity in receiver operating characteristic (ROC) curve and in multivariate analysis for OS. The score was applied in uni- and multivariate analyses for OS of a comparable lenvatinib-treated HCC population. Finally, comparison between treatments was performed in patients with low and high α-FAtE scores and predictivity estimated by interaction analysis. Time-to-progression (TTP) was a secondary endpoint. OS of AB-treated HCC patients was statistically longer in those with α-fetoprotein Comparing the impact of atezolizumab plus bevacizumab and lenvatinib on the liver function in hepatocellular carcinoma patients: A mixed-effects regression model approach.Takeshi Hatanaka; Satoru Kakizaki; Atsushi Hiraoka; Toshifumi Tada; Masashi Hirooka; Kazuya Kariyama; Joji Tani; Masanori Atsukawa; Koichi Takaguchi; Ei Itobayashi; Shinya Fukunishi; Kunihiko Tsuji; Toru Ishikawa; Kazuto Tajiri; Hironori Ochi; Satoshi Yasuda; Hidenori Toyoda; Chikara Ogawa; Keisuke Yokohama; Hiroki Nishikawa; Takashi Nishimura; Noritomo Shimada; Kazuhito Kawata; Hisashi Kosaka; Atsushi Naganuma; Yutaka Yata; Hideko Ohama; Hidekatsu Kuroda; Kazunari Tanaka; Takaaki Tanaka; Fujimasa Tada; Kazuhiro Nouso; Asahiro Morishita; Akemi Tsutsui; Takuya Nagano; Norio Itokawa; Tomomi Okubo; Taeang Arai; Michitaka Imai; Yohei Koizumi; Shinichiro Nakamura; Masaki Kaibori; Hiroko Iijima; Yoichi Hiasa; Masatoshi Kudo; Takashi KumadaCancer medicine 2023/11 AIM: This retrospective study compared the impact of atezolizumab plus bevacizumab (Atez/Bev) and lenvatinib (LEN) on the liver function in patients with hepatocellular carcinoma. METHODS: We included 526 patients who received Atez/Bev and 731 who received LEN March 2018 and July 2022 in this study. We conducted a 1:1 propensity-score-matched analysis and identified 324 patients in each group for inclusion in the present analysis. Nonlinear mixed-effects regression models were employed, allowing for the evaluation and inclusion of cases where treatment was interrupted due to disease progression, adverse events, or loss to follow-up. These models were used to compare the ALBI score between the Atez/Bev and LEN groups. RESULTS: Following propensity score matching, the mean ALBI scores in the Atez/Bev and LEN groups were -2.41 ± 0.40 and -2.44 ± 0.42 at baseline, and -2.17 ± 0.56 and -2.19 ± 0.58 at 12 weeks, respectively. Although the ALBI score significantly worsened during treatment in both groups (p Visualization of Gastrointestinal Bezoar Movement Causing and Releasing Small Bowel Obstruction on Computed Tomography in a Patient With Diabetes MellitusHironobu Sugimori; Sho Masaki; Hajime Honjo; Masatoshi Kudo; Tomohiro WatanabeCureus Springer Science and Business Media LLC 15 (11) e49133  2168-8184 2023/11 Although delayed gastric emptying promotes gastrointestinal bezoar formation in patients with diabetes mellitus (DM), the association between movement of gastrointestinal bezoars and glycemic status remains unclear. We report a case of small bowel obstruction (SBO) caused by impaction of the migrated gastric bezoar into the small bowel in a patient with DM. Correction of hyperglycemia and lactic acidosis led to normalization of gastrointestinal motility, followed by expulsion of the impacted bezoar and resolution of SBO. This case suggests a link between hyperglycemia, metabolic acidosis, and gastrointestinal motility based on visualization of gastrointestinal bezoar movement in the gastrointestinal tract using computed tomography.A comparative analysis of the therapeutic outcomes of atezolizumab plus bevacizumab and lenvatinib for hepatocellular carcinoma patients aged 80 years and older: A multicenter study.Takeshi Hatanaka; Satoru Kakizaki; Atsushi Hiraoka; Toshifumi Tada; Masashi Hirooka; Kazuya Kariyama; Joji Tani; Masanori Atsukawa; Koichi Takaguchi; Ei Itobayashi; Shinya Fukunishi; Kunihiko Tsuji; Toru Ishikawa; Kazuto Tajiri; Hironori Ochi; Satoshi Yasuda; Hidenori Toyoda; Chikara Ogawa; Keisuke Yokohama; Hiroki Nishikawa; Takashi Nishimura; Noritomo Shimada; Kazuhito Kawata; Hisashi Kosaka; Atsushi Naganuma; Yutaka Yata; Hideko Ohama; Hidekatsu Kuroda; Tomoko Aoki; Kazunari Tanaka; Takaaki Tanaka; Fujimasa Tada; Kazuhiro Nouso; Asahiro Morishita; Akemi Tsutsui; Takuya Nagano; Norio Itokawa; Tomomi Okubo; Taeang Arai; Michitaka Imai; Yohei Koizumi; Shinichiro Nakamura; Masaki Kaibori; Hiroko Iijima; Yoichi Hiasa; Masatoshi Kudo; Takashi KumadaHepatology research : the official journal of the Japan Society of Hepatology 2023/11 AIM: Elderly patients are believed to have a reduced immune capacity, which may make immunotherapy less effective. The aim of this study was to compare the therapeutic outcome of atezolizumab plus bevacizumab (Atez/Bev) and lenvatinib (LEN) for advanced hepatocellular carcinoma (HCC) in patients aged 80 years and older. METHODS: From March 2018 to July 2022, 170 and 92 elderly patients who received LEN and Atez/Bev as first-line treatment, respectively, were retrospectively analyzed. RESULTS: The median ages of the Atez/Bev and LEN groups were 83.0 (8.01-86.0) and 83.0 (82.0-86.0) years (p=0.3), respectively. Males accounted for approximately 70% of the patients in both groups. The objective response rate was 35.9% in the LEN group and 33.7% in the Atez/Bev group (p=0.8), whereas the disease control rates in the LEN and Atez/Bev groups were 62.9% and 63.0%, respectively (p=1.0). The median PFS in the LEN and Atez/Bev groups was 6.3 months and 7.2 months, respectively, which were not significantly different (p=0.2). The median OS was 17.9 months in the LEN group and 14.0 months in the Atez/Bev group. This difference was not statistically significant (p=0.7). In multivariate analyses, the choice of treatment (LEN vs. Atez/Bev) showed no association with PFS or OS. The Atez/Bev group had a significantly higher rate of post-progression treatment (59.0% vs. 35.7%, p=0.01) and a lower rate of discontinuation due to adverse events (69 [40.6%] vs. 19 [20.7%], pBaseline neutrophil-lymphocyte ratio and platelet-lymphocyte ratio appear predictive of immune treatment related toxicity in hepatocellular carcinoma.Sirish Dharmapuri; Umut Özbek; Hiren Jethra; Tomi Jun; Thomas U Marron; Anwaar Saeed; Yi-Hsiang Huang; Mahvish Muzaffar; Matthias Pinter; Lorenz Balcar; Claudia Fulgenzi; Suneetha Amara; Arndt Weinmann; Nicola Personeni; Bernhard Scheiner; Tiziana Pressiani; Musharraf Navaid; Bertram Bengsch; Sonal Paul; Uqba Khan; Dominik Bettinger; Naoshi Nishida; Yehia Ibrahim Mohamed; Arndt Vogel; Anuhya Gampa; James Korolewicz; Antonella Cammarota; Ahmed Kaseb; Peter R Galle; Anjana Pillai; Ying-Hong Wang; Alessio Cortellini; Masatoshi Kudo; Antonio D'Alessio; Lorenza Rimassa; David James Pinato; Celina AngWorld journal of gastrointestinal oncology 15 (11) 1900 - 1912 2023/11 BACKGROUND: A well-recognized class effect of immune checkpoint inhibitors (ICI) is immune-related adverse events (IrAEs) ranging from low grade toxicities to life-threatening end organ damage requiring permanent discontinuation of ICI. Deaths are reported in 300 was significantly associated with a lower incidence of grade ≥ 2 IrAEs (OR = 0.40; P = 0.044). Similarly, a trend was observed between NLR > 5 and lower incidence of grade ≥ 2 IrAEs (OR = 0.58; P = 0.097). Multivariate analyses confirmed PLR > 300 as an independent predictive marker of grade ≥ 2 IrAEs (OR = 0.26; P = 0.011), in addition to treatment with programmed cell death ligand 1 (PD-1)/cytotoxic T lymphocyte-associated protein-4 (OR = 2.57; P = 0.037) and PD-1/tyrosine kinase inhibitor (OR = 3.39; P = 0.01) combinations. Antibiotic use was not associated with IrAE incidence (OR = 1.02; P = 0.954). Patients treated with steroids had a > 2-fold higher incidence of grade ≥ 2 IrAEs (OR = 2.74; P Characteristics and outcomes of immunotherapy-related liver injury in patients with hepatocellular carcinoma versus other advanced solid tumours.Ciro Celsa; Giuseppe Cabibbo; Claudia Am Fulgenzi; Bernhard Scheiner; Antonio d'Alessio; Giulia F Manfredi; Naoshi Nishida; Celina Ang; Thomas U Marron; Anwaar Saeed; Brooke Wietharn; Matthias Pinter; Jaekyung Cheon; Yi-Hsiang Huang; Pei-Chang Lee; Samuel Phen; Anuhya Gampa; Anjana Pillai; Caterina Vivaldi; Francesca Salani; Gianluca Masi; Natascha Roehlen; Robert Thimme; Arndt Vogel; Martin Schönlein; Johann von Felden; Kornelius Schulze; Henning Wege; Peter R Galle; Masatoshi Kudo; Lorenza Rimassa; Amit G Singal; Paul El Tomb; Susanna Ulahannan; Alessandro Parisi; Hong Jae Chon; Wei-Fan Hsu; Bernardo Stefanini; Elena Verzoni; Raffaele Giusti; Antonello Veccia; Annamaria Catino; Giuseppe Aprile; Pamela Francesca Guglielmini; Marilena Di Napoli; Paola Ermacora; Lorenzo Antonuzzo; Ernesto Rossi; Francesco Verderame; Fable Zustovich; Corrado Ficorella; Francesca Romana Di Pietro; Nicola Battelli; Giorgia Negrini; Francesco Grossi; Roberto Bordonaro; Stefania Pipitone; Maria Banzi; Serena Ricciardi; Letizia Laera; Antonio Russo; Ugo De Giorgi; Luigi Cavanna; Mariella Sorarù; Vincenzo Montesarchio; Paola Bordi; Leonardo Brunetti; Carmine Pinto; Melissa Bersanelli; Calogero Cammà; Alessio Cortellini; David J PinatoJournal of hepatology 2023/11 BACKGROUND&AIMS: Immune-related liver injury(irLI) is commonly observed in patients with cancer treated with immune checkpoint inhibitors(ICIs). We aimed to compare incidence, clinical characteristics and outcomes of irLI between patients receiving ICIs for hepatocellular carcinoma(HCC) versus other solid tumours. METHODS: Two separate cohorts were included: 375 patients with advanced/unresectable HCC, Child-Pugh A class treated with first-line Atezolizumab+Bevacizumab from AB-real study and a non-HCC cohort, including 459 patients treated with first-line ICI therapy from INVIDIa-2 multicentre study. IrLI was defined as treatment-related increase of transaminases levels after exclusion of alternative aetiologies of liver injury. Incidence of irLI was adjusted for the duration of treatment exposure. RESULTS: In HCC patients, incidence of any-grade irLI was 11.4% over a median treatment exposure of 4.4 months(95%CI 3.7-5.2), compared to 2.6% in INVIDIa-2 cohort over a median treatment exposure of 12.4 months(95%CI 11.1-14.0). Exposure-adjusted-incidence of any-grade irLI was 22.1 per 100-Patient-years(PY) in HCC patients and 2.1 per 100-PY in non-HCC patients(pTreatment options for solitary hepatocellular carcinoma ≤5 cm: Surgery vs Ablation: A multicenter retrospective study.Kazuya Kariyama; Kazuhiro Nouso; Atsushi Hiraoka; Hidenori Toyoda; Toshifumi Tada; Kunihiko Tsuji; Toru Ishikawa; Takeshi Hatanaka; Ei Itobayashi; Koichi Takaguchi; Akemi Tsutsui; Atsushi Naganuma; Satoshi Yasuda; Satoru Kakizaki; Akiko Wakuta; Shohei Shiota; Masatoshi Kudo; Takashi KumadaJournal of liver cancer 2023/11 INTRODUCTION: The aim of this study was to compare the therapeutic efficacy of ablation and surgery in solitary Hepatocellular carcinoma (HCC) measuring ≤5 cm with a large HCC cohort database. METHODS: The study included consecutive 2067 patients with solitary HCC who were treated with either ablation (N=1248) or surgery (N=819). The patients were divided into three groups based on the tumor size and compared the outcomes of the two therapies using propensity score matching. RESULTS: No significant difference in recurrence-free survival (RFS) or overall survival (OS) was found between surgery and ablation groups for tumors measuring ≤2 cm or >2 cm but ≤3 cm. For tumors measuring >3 cm but ≤5 cm, RFS was significantly better with surgery than with ablation (3.6 and 2.0 years, respectively, p = 0.0297). However, no significant difference in OS was found between surgery and ablation in this group (6.7 and 6.0 years, respectively, p = 0.668). DISCUSSION/CONCLUSION: The study suggests that surgery and ablation can be equally used as a treatment for solitary HCC no more than 3 cm in diameter. For HCCs measuring 3-5 cm, the OS was not different between therapies; thus, ablation and less invasive therapy can be considered a treatment option; however, special caution should be taken to prevent recurrence.Correction: Consensus report from the 10th global forum for liver magnetic resonance imaging: multidisciplinary team discussion.Bachir Taouli; Ahmed Ba-Ssalamah; Julius Chapiro; Jagpreet Chhatwal; Kathryn Fowler; Tae Wook Kang; Gesine Knobloch; Dow-Mu Koh; Masatoshi Kudo; Jeong Min Lee; Takamichi Murakami; David J Pinato; Kristina I Ringe; Bin Song; Parissa Tabrizian; Jin Wang; Jeong Hee Yoon; Mengsu Zeng; Jian Zhou; Valérie VilgrainEuropean radiology 2023/11Fontan術後に発症した切除不能肝細胞癌の1例萩原 智; 上嶋 一臣; 西田 直生志; 依田 広; 三長 孝輔; 南 康範; 田北 雅弘; 青木 智子; 盛田 真弘; 千品 寛和; 松原 卓哉; 大丸 直哉; 稲村 昇; 工藤 正俊肝臓 (一社)日本肝臓学会 64 (11) 567 - 574 0451-4203 2023/11 症例は30代男性.幼少期に完全大血管転位III型に対してFontan手術が施行され,近医に定期的に通院していた.20XX年7月腹部USで多発肝腫瘤を指摘され当院紹介受診となった.造影CTにて最大13cmの多発肝細胞癌と判明した(BCLC stage B).画像上は門脈圧亢進所見や明らかな肝形態異常を認めなかったが,肝生検でCongestive Hepatic Fibrosis Score 3であり,実際には線維化の進展を認めていた.肝内多発のため外科手術やRFAの適応外であった.また最大径の腫瘍は肝外に突出しており,腹腔内破裂の危険性もあることから,まずTACEを施行した.再発に応じて各種抗癌剤治療を行い,生存中である.画像上は肝線維化を示唆する所見はなかったが,Fontan術後の特殊な循環動態では,肝線維化が進展している可能性があり,本症例を通して肝癌サーベイランスの重要性を再考する.(著者抄録)Fontan術後に発症した切除不能肝細胞癌の1例萩原 智; 上嶋 一臣; 西田 直生志; 依田 広; 三長 孝輔; 南 康範; 田北 雅弘; 青木 智子; 盛田 真弘; 千品 寛和; 松原 卓哉; 大丸 直哉; 稲村 昇; 工藤 正俊肝臓 (一社)日本肝臓学会 64 (11) 567 - 574 0451-4203 2023/11 症例は30代男性.幼少期に完全大血管転位III型に対してFontan手術が施行され,近医に定期的に通院していた.20XX年7月腹部USで多発肝腫瘤を指摘され当院紹介受診となった.造影CTにて最大13cmの多発肝細胞癌と判明した(BCLC stage B).画像上は門脈圧亢進所見や明らかな肝形態異常を認めなかったが,肝生検でCongestive Hepatic Fibrosis Score 3であり,実際には線維化の進展を認めていた.肝内多発のため外科手術やRFAの適応外であった.また最大径の腫瘍は肝外に突出しており,腹腔内破裂の危険性もあることから,まずTACEを施行した.再発に応じて各種抗癌剤治療を行い,生存中である.画像上は肝線維化を示唆する所見はなかったが,Fontan術後の特殊な循環動態では,肝線維化が進展している可能性があり,本症例を通して肝癌サーベイランスの重要性を再考する.(著者抄録)Development and clinical validation of a novel algorithmic score (GAAD) for detecting HCC in prospective cohort studies.Teerha Piratvisuth; Jinlin Hou; Tawesak Tanwandee; Thomas Berg; Arndt Vogel; Jörg Trojan; Enrico N De Toni; Masatoshi Kudo; Anja Eiblmaier; Hanns-Georg Klein; Johannes Kolja Hegel; Kairat Madin; Konstantin Kroeniger; Ashish Sharma; Henry L Y ChanHepatology communications 7 (11) 2023/11 BACKGROUND: Alpha-fetoprotein (AFP) and des-gamma carboxyprothrombin (DCP), also known as protein induced by vitamin K absence-II (PIVKA-II [DCP]) are biomarkers for HCC with limited diagnostic value when used in isolation. The novel GAAD algorithm is an in vitro diagnostic combining PIVKA-II (DCP) and AFP measurements, age, and gender (biological sex) to generate a semi-quantitative result. We conducted prospective studies to develop, implement, and clinically validate the GAAD algorithm for differentiating HCC (early and all-stage) and benign chronic liver disease (CLD), across disease stages and etiologies. METHODS: Patients aged ≥18 years with HCC or CLD were prospectively enrolled internationally into algorithm development [n = 1084; 309 HCC cases (40.7% early-stage) and 736 controls] and clinical validation studies [n = 877; 366 HCC cases (47.6% early-stage) and 303 controls]. Serum samples were analyzed on a cobas® e 601 analyzer. Performance was assessed using receiver operating characteristic curve analyses to calculate AUC. RESULTS: For algorithm development, AUC for differentiation between early-stage HCC and CLD was 90.7%, 84.4%, and 77.2% for GAAD, AFP, and PIVKA-II, respectively. The sensitivity of GAAD for the detection of early-stage HCC was 71.8% with 90.0% specificity. Similar results were shown in the clinical validation study; AUC for differentiation between early-stage HCC and CLD was 91.4% with 70.1% sensitivity and 93.7% specificity. GAAD also showed strong specificity, with a lower rate of false positives regardless of disease stage, etiology, or region. CONCLUSIONS: The GAAD algorithm significantly improves early-stage HCC detection for patients with CLD undergoing HCC surveillance. Further phase III and IV studies are warranted to assess the utility of incorporating the algorithm into clinical practice.Atezolizumab plus bevacizumab versus active surveillance in patients with resected or ablated high-risk hepatocellular carcinoma (IMbrave050): a randomised, open-label, multicentre, phase 3 trial.Shukui Qin; Minshan Chen; Ann-Lii Cheng; Ahmed O Kaseb; Masatoshi Kudo; Han Chu Lee; Adam C Yopp; Jian Zhou; Lu Wang; Xiaoyu Wen; Jeong Heo; Won Young Tak; Shinichiro Nakamura; Kazushi Numata; Thomas Uguen; David Hsiehchen; Edward Cha; Stephen P Hack; Qinshu Lian; Ning Ma; Jessica H Spahn; Yulei Wang; Chun Wu; Pierce K H ChowLancet (London, England) 2023/10 BACKGROUND: No adjuvant treatment has been established for patients who remain at high risk for hepatocellular carcinoma recurrence after curative-intent resection or ablation. We aimed to assess the efficacy of adjuvant atezolizumab plus bevacizumab versus active surveillance in patients with high-risk hepatocellular carcinoma. METHODS: In the global, open-label, phase 3 IMbrave050 study, adult patients with high-risk surgically resected or ablated hepatocellular carcinoma were recruited from 134 hospitals and medical centres in 26 countries in four WHO regions (European region, region of the Americas, South-East Asia region, and Western Pacific region). Patients were randomly assigned in a 1:1 ratio via an interactive voice-web response system using permuted blocks, using a block size of 4, to receive intravenous 1200 mg atezolizumab plus 15 mg/kg bevacizumab every 3 weeks for 17 cycles (12 months) or to active surveillance. The primary endpoint was recurrence-free survival by independent review facility assessment in the intention-to-treat population. This trial is registered with ClinicalTrials.gov, NCT04102098. FINDINGS: The intention-to-treat population included 668 patients randomly assigned between Dec 31, 2019, and Nov 25, 2021, to either atezolizumab plus bevacizumab (n=334) or to active surveillance (n=334). At the prespecified interim analysis (Oct 21, 2022), median duration of follow-up was 17·4 months (IQR 13·9-22·1). Adjuvant atezolizumab plus bevacizumab was associated with significantly improved recurrence-free survival (median, not evaluable [NE]; [95% CI 22·1-NE]) compared with active surveillance (median, NE [21·4-NE]; hazard ratio, 0·72 [adjusted 95% CI 0·53-0·98]; p=0·012). Grade 3 or 4 adverse events occurred in 136 (41%) of 332 patients who received atezolizumab plus bevacizumab and 44 (13%) of 330 patients in the active surveillance group. Grade 5 adverse events occurred in six patients (2%, two of which were treatment related) in the atezolizumab plus bevacizumab group, and one patient (Leucine-rich repeat kinase 2 promotes the development of experimental severe acute pancreatitisYasuo Otsuka; Akane Hara; Kosuke Minaga; Ikue Sekai; Masayuki Kurimoto; Yasuhiro Masuta; Ryutaro Takada; Tomoe Yoshikawa; Ken Kamata; Masatoshi Kudo; Tomohiro WatanabeClinical and Experimental Immunology Oxford University Press (OUP) 0009-9104 2023/10 Abstract Translocation of gut bacteria into the pancreas promotes the development of severe acute pancreatitis (SAP). Recent clinical studies have also highlighted the association between fungal infections and SAP. The sensing of gut bacteria by pattern recognition receptors promotes the development of SAP via the production of proinflammatory cytokines; however, the mechanism by which gut fungi mediate SAP remains largely unknown. Leucine-rich repeat kinase 2 (LRRK2) is a multifunctional protein that regulates innate immunity against fungi via Dectin-1 activation. Here, we investigated the role of LRRK2 in SAP development and observed that administration of LRRK2 inhibitors attenuated SAP development. The degree of SAP was greater in Lrrk2 transgenic (Tg) mice than in control mice and was accompanied by an increased production of nuclear factor-kappaB-dependent proinflammatory cytokines. Ablation of the fungal mycobiome by anti-fungal drugs inhibited SAP development in Lrrk2 Tg mice, whereas the degree of SAP was comparable in Lrrk2 Tg mice with or without gut sterilization by a broad range of antibiotics. Pancreatic mononuclear cells from Lrrk2 Tg mice produced large amounts of IL-6 and TNF-α upon stimulation with Dectin-1 ligands, and inhibition of the Dectin-1 pathway by a spleen tyrosine kinase inhibitor protected Lrrk2 Tg mice from SAP. These data indicate that LRRK2 activation is involved in the development of SAP through proinflammatory cytokine responses upon fungal exposure.Real-World Data on Short-Term and Long-Term Treatment Results of Ustekinumab in Patients with Steroid-Resistant/Dependent Ulcerative ColitisYoriaki Komeda; George Tribonias; Masashi Kono; Kohei Handa; Shunsuke Omoto; Mamoru Takenaka; Satoru Hagiwara; Naoko Tsuji; Naoshi Nishida; Hiroshi Kashida; Masatoshi KudoInflammatory Intestinal Diseases S. Karger AG 8 (4) 161 - 166 2296-9403 2023/10 Introduction: Ustekinumab is an IgG1 kappa monoclonal antibody directed against the common p40 subunit of interleukin-12 and interleukin-23, which activate Th1- and Th17-mediated immune responses, respectively. It has proven efficacy for the treatment of moderate to severe ulcerative colitis (UC) in the UNIFI Phase III clinical trial; however, data on its efficacy in the real world is limited. In this study, we aimed to assess the real-world efficacy of ustekinumab.Methods: This observational study included 30 patients with UC who received ustekinumab from April 2020 to April 2022. We examined demographic information, disease type and activity (Mayo score, partial Mayo score [PMS]), use of biologics, concomitant use of predonisolone (PSL), 8-week ustekinumab clinical response rate, remission induction rate, 44- and 152-week remission maintenance rate, continuation rate, and 44-week steroid-free remission rate. The primary outcomes were the short- and long-term efficacy of ustekinumab.Results: Included patients (53% women; mean age: 41.2 years [16–80 years]) had an average disease duration of 86 weeks. Mayo’s score (median) was 7.4 and the PMS was 5.4. Two (7%), 24 (80%), and four (13%) patients had a Mayo endoscopic sub-score (MES) of MES1, MES2, and MES3, respectively. The median serum CRP was 1.0 mg/dL. Five patients had no history of biotherapy (naive), while 8 and 17 had a history of one and two or more biologic agents, respectively. Eight patients were PSL-resistant and 22 were PSL-dependent. The 8-week clinical response rate was 73%, and the clinical remission induction rate was 70%. The remission maintenance rates at 44 and 152 weeks were 67% and 63%, respectively. The ustekinumab retention rate was 67% (86-week mean follow-up period). Regarding biologic failure cases, the clinical response rate in the failure group with up to one biologic agent (including naive cases) was 84.6%, which was higher than the 58.0% rate in the failure group with two or more biologic agents (p=0.06). Steroid-free remission rates at 44 and 152 weeks were 63% each. In the logistic regression analysis parameters for discontinuation of ustekinumab, only PMS remained significant after multivariate analysis (p=0.018).Conclusion: Our study showed short-term and long-term ustekinumab effectiveness, especially with comparative low disease activity.Comparison of prognostic impact of atezolizumab plus bevacizumab versus lenvatinib in patients with intermediate-stage hepatocellular carcinoma.Toshifumi Tada; Takashi Kumada; Atsushi Hiraoka; Masashi Hirooka; Kazuya Kariyama; Joji Tani; Masanori Atsukawa; Koichi Takaguchi; Ei Itobayashi; Shinya Fukunishi; Kunihiko Tsuji; Toru Ishikawa; Kazuto Tajiri; Hironori Ochi; Satoshi Yasuda; Hidenori Toyoda; Chikara Ogawa; Takashi Nishimura; Takeshi Hatanaka; Satoru Kakizaki; Noritomo Shimada; Kazuhito Kawata; Fujimasa Tada; Hideko Ohama; Kazuhiro Nouso; Asahiro Morishita; Akemi Tsutsui; Takuya Nagano; Norio Itokawa; Tomomi Okubo; Taeang Arai; Michitaka Imai; Hisashi Kosaka; Atsushi Naganuma; Tomomitsu Matono; Tomoko Aoki; Hidekatsu Kuroda; Yutaka Yata; Yohei Koizumi; Shinichiro Nakamura; Masaki Kaibori; Hiroko Iijima; Yoichi Hiasa; Masatoshi KudoLiver international : official journal of the International Association for the Study of the Liver 2023/10 BACKGROUND & AIMS: The study goal was to compare the outcomes of patients with intermediate-stage (Barcelona Clinic Liver Cancer [BCLC]-B) hepatocellular carcinoma (HCC) who received atezolizumab plus bevacizumab (Atezo/Bev) or lenvatinib (LEN) as first-line systemic therapy. METHODS: A total of 358 patients with BCLC-B HCC treated with Atezo/Bev (n = 177) or LEN (n = 181) as first-line systemic therapy were included. RESULTS: The median progression-free survival (PFS) times in the Atezo/Bev and LEN groups were 10.8 months (95% confidence interval [CI], 7.8-12.6) and 7.3 months (95% CI, 6.3-8.5), respectively (p = .019). In the propensity score-matched cohort, the median PFS times in the Atezo/Bev (n = 151) and LEN (n = 151) groups were 10.2 months (95% CI, 7.0-12.3) and 6.9 months (95% CI, 5.9-8.1), respectively (p = .020). Restricted mean survival times of PFS were significantly higher in the Atezo/Bev group than in the LEN group at landmarks of 12 and 18 months (p = .031 and .012, respectively). In a subgroup analysis of patients with HCC beyond the up-to-seven criteria, the median PFS times in the Atezo/Bev (n = 134) and LEN (n = 117) groups were 10.5 months (95% CI, 7.0-11.8) and 6.3 months (95% CI, 5.5-7.3), respectively (p = .044). CONCLUSIONS: The use of Atezo/Bev as first-line systemic therapy in patients with BCLC-B HCC is expected to result in good PFS.【薬物療法によって変貌する肝細胞癌治療:2023 Update】Early stage肝細胞癌 肝細胞癌での腫瘍免疫微小環境とアジュバント療法における免疫チェックポイント阻害剤の役割西田 直生志; 工藤 正俊肝胆膵 (株)アークメディア 87 (4) 381 - 387 0389-4991 2023/10カボザンチニブ投与により著明に腫瘍縮小を認めたMET遺伝子増幅を伴う肝細胞癌の1例萩原 智; 上嶋 一臣; 西田 直生志; 工藤 正俊肝臓 (一社)日本肝臓学会 64 (10) 514 - 516 0451-4203 2023/10 カボザンチニブは血管内皮増殖因子受容体や肝細胞増殖因子受容体(MET)を標的とする分子標的薬であり、主に腫瘍増殖抑制を期待する薬剤として使用されている。今回、肺転移により症状増悪した肝細胞癌患者(50歳代男性)に対して、FoundationOne CDxがん遺伝子パネル検査によりMET遺伝子増幅を確認したうえでカボザンチニブを投与し、著明な腫瘍縮小が認められたので報告した。肝がん局所治療の多様性とその到達点 切除不能HCCに対するABC conversion療法とclinical CRの現状青木 智子; 西田 直生志; 工藤 正俊肝臓 (一社)日本肝臓学会 64 (Suppl.3) A773 - A773 0451-4203 2023/10予後改善に向けた胆道癌の集学的治療 "non-inflamed type"の胆管癌における抗原提示分子のメチル化と発現低下西田 直生志; 工藤 正俊肝臓 (一社)日本肝臓学会 64 (Suppl.3) A786 - A786 0451-4203 2023/10【Stenting Bible~Renewal~ステントと挿入・留置手技にこだわる!!】ステント治療のトラブルシューティングおよび偶発症マネージメント SEMS迷入に対するトラブルシューティング竹中 完; 大塚 康生; 益田 康弘; 高島 耕太; 田中 秀和; 福永 朋洋; 吉田 晃浩; 山崎 友祐; 大本 俊介; 三長 孝輔; 鎌田 研; 工藤 正俊胆と膵 医学図書出版(株) 44 (臨増特大) 1337 - 1341 0388-9408 2023/10 遠位悪性胆管狭窄に対する経乳頭的胆道ドレナージにおいて自己拡張型メタリックステント(self-expandable metallic stent:SEMS)の中でもポリウレタンやPTFEなどの膜で被覆されたcovered SEMS(CSEMS)は腫瘍増殖を防ぐことができるとされる一方でさまざまな要因によりCSEMSは逸脱・迷入を起こし,閉塞性黄疸,閉塞性胆管炎の再燃を引き起こす。CSEMS迷入に対する最大のトラブルシューティングは「迷入させないこと」であり,事前議論,胆管造影,適切なデバイス選択がまず行われなくてはならない。迷入に対しては「乳頭拡張をしておく」,「カバーの腐食・ingrowthの可能性を確認する」,「迷入したCSEMSのカバーが外巻きか内巻きかを確認しておく」,「迷入したCSEMSと胆管狭窄部との位置関係を確認する」といったtipsを理解し,引き抜き法か翻転抜去法を選択する対応が求められる。ただしまずはドレナージ不良に対する治療を最優先すべきであり,無理な迷入SEMSの抜去は決して行ってはならない。(著者抄録)Albumin-Bilirubin Grade Analyses of Atezolizumab plus Bevacizumab versus Sorafenib in Patients with Unresectable Hepatocellular Carcinoma: A Post Hoc Analysis of the Phase III IMbrave150 Study.Masatoshi Kudo; Richard S Finn; Ann-Lii Cheng; Andrew X Zhu; Michel Ducreux; Peter R Galle; Naoya Sakamoto; Naoya Kato; Michitaka Nakano; Jing Jia; Arndt VogelLiver cancer 12 (5) 479 - 493 2023/10 INTRODUCTION: Atezolizumab + bevacizumab showed survival benefit in patients with unresectable hepatocellular carcinoma (HCC) versus sorafenib in the Phase III IMbrave150 study. This exploratory analysis examined the prognostic impact of a baseline albumin-bilirubin (ALBI) score. METHODS: Patients with treatment-naïve unresectable HCC, ≥1 measurable untreated lesion, and Child-Pugh class A liver function were randomized 2:1 to receive atezolizumab 1,200 mg + bevacizumab 15 mg/kg every 3 weeks or sorafenib 400 mg twice daily. Overall survival (OS) and progression-free survival (PFS) were assessed in the intention-to-treat population by ALBI/modified (m)ALBI grade. Time to deterioration (TTD; defined as time to 0.5-point increase from the baseline ALBI score over 2 visits or death) of liver function and safety were investigated. RESULTS: Of 501 enrolled patients, 336 were randomized to receive atezolizumab + bevacizumab (ALBI grade [G] 1: n = 191; G2: n = 144 [mALBI G2a: n = 72, G2b: n = 72]; missing ALBI grade: n = 1) and 165 to sorafenib (ALBI G1: n = 87; G2: n = 78 [mALBI G2a: n = 37; G2b: n = 41]). Median follow-up was 15.6 months. OS and PFS improved with atezolizumab + bevacizumab versus sorafenib in patients with ALBI G1 (OS HR: 0.50 [95% CI: 0.35, 0.72]; PFS HR: 0.61 [95% CI: 0.45, 0.82]). In patients with ALBI G2 or mALBI G2a or G2b, PFS was numerically longer with atezolizumab + bevacizumab versus sorafenib, but no OS benefit was seen. Median TTD in the intention-to-treat population was 10.2 months (95% CI: 8.0, 11.0) with atezolizumab + bevacizumab versus 8.6 months (95% CI: 6.2, 11.8) with sorafenib (HR: 0.82 [95% CI: 0.65, 1.03]). Safety profiles of atezolizumab and bevacizumab were consistent with previous analyses, regardless of ALBI grade. CONCLUSION: ALBI grade appeared to be prognostic for outcomes with both atezolizumab + bevacizumab and sorafenib treatment in patients with HCC. Atezolizumab + bevacizumab preserved liver function for a numerically longer duration than sorafenib.All Stages of Hepatocellular Carcinoma Patients Benefit from Systemic Therapy Combined with Locoregional Therapy.Masatoshi KudoLiver cancer 12 (5) 395 - 404 2023/10Low‐dose gemcitabine plus nab‐paclitaxel versus standard‐dose gemcitabine plus nab‐paclitaxel in elderly patients with metastatic pancreatic cancer: A randomized Phase II trialKen Kamata; Hajime Imai; Hisakazu Matsumoto; Yukitaka Yamashita; Takao Kato; Katsuhisa Nishi; Shunsuke Omoto; Kosuke Minaga; Kentaro Yamao; Tomoko Hyodo; Sung‐Woon Im; Akane Hara; Tomoe Yoshikawa; Rei Ishikawa; Ayana Okamoto; Tomohiro Yamazaki; Atsushi Nakai; Kazuomi Ueshima; Yasutaka Chiba; Mamoru Takenaka; Tomohiro Watanabe; Masayuki Kitano; Masatoshi KudoJGH Open Wiley 7 (9) 659 - 666 2397-9070 2023/09 Abstract Background and Aim A multicenter, open‐label randomized Phase II trial was conducted to determine whether low‐dose gemcitabine plus nab‐paclitaxel (GnP) could improve tolerability and show equivalent efficacy to the standard‐dose GnP for elderly patients with metastatic pancreatic cancer. Methods Consecutive patients aged ≥65 years with metastatic pancreatic cancer who presented at one of four Japanese referral centers between November 2016 and January 2021 were enrolled. The 60 patients were randomly assigned to low‐ or standard‐dose groups with a 1:1 ratio. Patients in the low‐dose GnP group received gemcitabine at a dose of 250 mg/m2 and nab‐paclitaxel at 125 mg/m2. Results Low‐dose GnP significantly decreased the rate of cases requiring dose reduction (16.7% vs 63.3%). The response rate (36.7% vs 33.3%) and progression‐free survival (7.3 vs 8 months) were comparable between the low‐ and standard‐dose groups as determined by independent review. The difference in the median overall survival between the two groups was not significant (7.9 vs 12 months). The proportion of patients with hematologic and non‐hematologic treatment‐related adverse events was comparable between the two groups. Conclusion Low‐dose GnP had an equivalent efficacy to conventional therapy; however, it did not reduce adverse events.Plain language summary of the HIMALAYA study: tremelimumab and durvalumab for unresectable hepatocellular carcinoma (liver cancer).Ghassan K Abou-Alfa; George Lau; Masatoshi Kudo; Stephen L Chan; Robin Kate Kelley; Junji Furuse; Wattana Sukeepaisarnjaroen; Yoon Koo Kang; Tu Van Dao; Enrico N De Toni; Lorenza Rimassa; Valeriy Breder; Alexander Vasilyev; Alexandra Heurgué; Vincent C Tam; Kabir Mody; Satheesh Chiradoni Thungappa; Yurii Ostapenko; Thomas Yau; Sergio Azevedo; María Varela; Ann-Lii Cheng; Shukui Qin; Peter R Galle; Sajid Ali; Charu Gupta; Mallory Makowsky; John F Kurland; Alejandra Negro; Bruno SangroFuture oncology (London, England) 2023/09 WHAT IS THIS SUMMARY ABOUT?: This is a summary of results from a phase 3 clinical study called HIMALAYA. HIMALAYA looked at treatment with one dose of a medication called tremelimumab combined with multiple doses of a medication called durvalumab (the STRIDE regimen) or multiple doses of durvalumab alone. These treatments were compared with a medication called sorafenib in participants with unresectable hepatocellular carcinoma (HCC). HCC is a type of liver cancer that is difficult to treat because it is often diagnosed when it is unresectable, meaning it can no longer be removed with surgery. Sorafenib has been the main treatment for unresectable HCC since 2007. However, people who take sorafenib may experience side effects that can reduce their quality of life, so alternative medicines are being trialed. Tremelimumab and durvalumab are types of drugs called immunotherapies, and they both work in different ways to help the body's immune system fight cancer. WHAT WERE THE RESULTS OF THE STUDY?: Participants who took STRIDE lived longer than participants who took sorafenib, whilst participants who took durvalumab alone lived a similar length of time as participants who took sorafenib. Participants who took STRIDE or durvalumab had a lower relative risk of experiencing worsening in their quality of life than participants who took sorafenib. The side effects that participants who received STRIDE or durvalumab experienced were expected for these types of treatments and could mostly be managed. WHAT DO THE RESULTS OF THE STUDY MEAN?: Overall, STRIDE is more effective than sorafenib for people with unresectable HCC. Clinical Trial Registration: NCT03298451 (HIMALAYA) (ClinicalTrials.gov).カボザンチニブ投与による腫瘍の著明な縮小、腫瘍マーカーの低下を認めたMET遺伝子増幅を伴う肝細胞癌の1例八田 寛朗; 萩原 智; 上嶋 一臣; 大丸 直哉; 松原 卓哉; 盛田 真弘; 千品 寛和; 田北 雅弘; 南 康範; 依田 広; 渡邉 智裕; 西田 直生志; 工藤 正俊日本消化器病学会近畿支部例会プログラム・抄録集 日本消化器病学会-近畿支部 119回 99 - 99 2023/09新型コロナワクチン接種後にIgA血管炎を発症し、コロナ感染を契機に再燃を繰り返した1例勝部 滉平; 永井 知行; 駒谷 真; 有山 武尊; 栗本 真之; 岡井 夏輝; 吉田 早希; 半田 康平; 正木 翔; 河野 匡志; 米田 頼晃; 本庶 元; 松井 繁長; 渡邉 智裕; 辻 直子; 樫田 博史; 工藤 正俊日本消化器病学会近畿支部例会プログラム・抄録集 日本消化器病学会-近畿支部 119回 91 - 91 2023/09Drug-Off Criteria in Patients with Hepatocellular Carcinoma Who Achieved Clinical Complete Response after Combination Immunotherapy Combined with Locoregional Therapy.Masatoshi KudoLiver cancer 12 (4) 289 - 296 2023/09Pembrolizumab as Second-Line Therapy for Advanced Hepatocellular Carcinoma: Longer Term Follow-Up from the Phase 3 KEYNOTE-240 Trial.Philippe Merle; Masatoshi Kudo; Julien Edeline; Mohamed Bouattour; Ann-Lii Cheng; Stephen L Chan; Thomas Yau; Marcelo Garrido; Jennifer Knox; Bruno Daniele; Valeriy Breder; Ho Yeong Lim; Sadahisa Ogasawara; Stéphane Cattan; Yee Chao; Abby B Siegel; Iván Martinez-Forero; Ziwen Wei; Chih-Chin Liu; Richard S FinnLiver cancer 12 (4) 309 - 320 2023/09 INTRODUCTION: KEYNOTE-240 showed a favorable benefit/risk profile for pembrolizumab versus placebo in patients with sorafenib-treated advanced hepatocellular carcinoma (HCC); however, prespecified statistical significance criteria for overall survival (OS) and progression-free survival (PFS) superiority were not met at the final analysis. Outcomes based on an additional 18 months of follow-up are reported. METHODS: Adults with sorafenib-treated advanced HCC were randomized 2:1 to pembrolizumab 200 mg intravenously every 3 weeks or placebo. Dual primary endpoints were OS and PFS assessed per RECIST v1.1 by blinded independent central review (BICR). Secondary endpoints included objective response rate (ORR), assessed per RECIST v1.1 by BICR, and safety. RESULTS: 413 patients were randomized (pembrolizumab, n = 278; placebo, n = 135). As of July 13, 2020, median (range) time from randomization to data cutoff was 39.6 (31.7-48.8) months for pembrolizumab and 39.8 (31.7-47.8) months for placebo. Estimated OS rates (95% CI) were 17.7% (13.4-22.5%) for pembrolizumab and 11.7% (6.8-17.9%) for placebo at 36 months. The estimated PFS rate (95% CI) for pembrolizumab was 8.9% (5.3-13.6%) and 0% for placebo at 36 months. ORR (95% CI) was 18.3% (14.0-23.4%) for pembrolizumab and 4.4% (1.6-9.4%) for placebo. Immune-mediated hepatitis events did not increase with follow-up. No viral hepatitis flare events were reported. CONCLUSION: With extended follow-up, pembrolizumab continued to maintain improvement in OS and PFS and was associated with a consistent adverse event profile compared with placebo in patients with sorafenib-treated advanced HCC. Although KEYNOTE-240 did not meet prespecified statistical significance criteria at the final analysis, these results together with the antitumor activity of second-line pembrolizumab observed in KEYNOTE-224 and the statistically significant and clinically meaningful OS and PFS benefits of second-line pembrolizumab in patients from Asia observed in KEYNOTE-394 reinforce the clinical activity of pembrolizumab in previously treated patients with advanced HCC.【早わかり消化器内視鏡関連ガイドライン2023】胆膵 IPMN国際診療ガイドライン山崎 友裕; 鎌田 研; 大本 俊介; 三長 孝輔; 竹中 完; 樫田 博史; 工藤 正俊消化器内視鏡 (株)東京医学社 35 (9) 1310 - 1316 0915-3217 2023/09Piercing technique for mucosal hyperplasia at an uncovered part of a partially covered stent after endoscopic ultrasound-guided hepaticogastrostomy.Yasuo Otsuka; Kosuke Minaga; Akane Hara; Yasuhiro Masuta; Mamoru Takenaka; Masatoshi KudoEndoscopy international open 11 (9) E811-E813  2023/09Glove box method: Simple and effective right-hand free method for interventional endoscopy.Mamoru Takenaka; Tae Hoon Lee; Masatoshi KudoDigestive endoscopy : official journal of the Japan Gastroenterological Endoscopy Society 2023/08Guselkumab in Patients With Moderately to Severely Active Ulcerative Colitis: QUASAR Phase 2b Induction Study.Laurent Peyrin-Biroulet; Jessica R Allegretti; David T Rubin; Brian Bressler; Matthew Germinaro; Kuan-Hsiang Gary Huang; Nicole Shipitofsky; Hongyan Zhang; Rebbecca Wilson; Chenglong Han; Brian G Feagan; William J Sandborn; Julian Panés; Tadakazu Hisamatsu; Gary R Lichtenstein; Bruce E Sands; Axel Dignass; Orest Abrahamovych; Halyna Afanasieva; Lilia Aitova; Engin Altintas; Romain Altwegg; Pavel Andreev; Kazuki Aomatsu; Monika Augustyn; Paola Balestrieri; Jakob Begun; Luciana Brunatto; Diego Bulgheroni; Elena Bunkova; Mercedes Cabello; Qian Cao; Flavio Caprioli; Rute Cerqueira; Baili Chen; Chou-Chen Chen; Chou-Pin Chen; Cheng-Tang Chiu; Chang Hwan Choi; Michele Cicala; Olena Datsenko; Pieter Dewint; Eugeni Domenech; Joris Dutré; George Duvall; Juan Fernandez; Rafal Filip; Ronald Fogel; Sharyle Fowler; Toshimitsu Fujii; Masayuki Fukata; Yohei Furumoto; Antonio Gasbarrini; Beata Gawdis-Wojnarska; Cyrielle Gilletta; Paolo Gionchetti; Eran Goldin; Oleksandr Golovchenko; Maciej Gonciarz; Can Gonen; Gaston Gonzalez Segura; Oleksii Gridnyev; Tibor Gyokeres; Xavier Hébuterne; Charlotte Hedin; Per Hellström; Ida Normiha Hilmi; Ivo Horný; Gyula Horvat; Namiko Hoshi; Ludek Hrdlicka; Shunji Ishihara; Olha Ivanishyn; Byung Ik Jang; Odery Junior; Takashi Kagaya; Shuji Kanmura; Marina Karakina; Nakai Katsuhiko; Jaroslaw Kierkus; Hyo Jong Kim; Tae-Oh Kim; Young-Ho Kim; Gyula G Kiss; Jochen Klaus; Dariusz Kleczkowski; Maria Klopocka; Taku Kobayashi; Iwona Kobielusz-Gembala; Ja Seol Koo; Adam Kopon; Tetiana Kravchenko; Masatoshi Kudo; Kwang An Kwon; Paula Lago; David Laharie; Ian Lawrance; Jaroslaw Leszczyszyn; Yan Li; Milan Lukas; Christian Maaser; Atsuo Maemoto; Hiroyuki Marusawa; Matthew McBride; Shoba Mendu; Pal Miheller; Hideharu Miyabayashi; Wolfgang Mohl; Gregory Moore; Satoshi Motoya; Narayanachar Murali; Mohammed Naem; Koichi Nakajima; Yasunari Nakamoto; Stéphane Nancey; Joaquim Neto; Michio Onizawa; Yohei Ono; Yohei Ono; Taro Osada; Marina Osipenko; Danuta Owczarek; Bhaktasharan Patel; Kamal Patel; Elina Petrova; Elena Poroshina; Francisco Portela; Lyudmyla Prystupa; Monserrat Rivero; Xavier Roblin; Jacek Romatowski; Grazyna Rydzewska; Simone Saibeni; Hirotake Sakuraba; Mark Samaan; Michael Schultz; Joerg Schulze; Shahriar Sedghi; Ursula Seidler; Sung Jae Shin; Mykola Stanislavchuk; David Stokesberry; Takayoshi Suzuki; Hiroki Taguchi; Lyudmila Tankova; Lena Thin; Alexander Tkachev; Leyanira Torrealba; Nataliia Tsarynna; Zsolt Tulassay; Tetsuya Ueo; Ekaterina Valuyskikh; Olga Vasilevskaya; Manuel Viamonte; Shu-Chen Wei; Roni Weisshof; Katarzyna Wojcik; Byong Duk Ye; Hsu-Heng Yen; Hyuk Yoon; Kosuke Yoshida; Andriy Yurkiv; Osamu Zaha; Qiang ZhanGastroenterology 2023/08 BACKGROUND & AIMS: The QUASAR Phase 2b Induction Study evaluated the efficacy and safety of guselkumab, an interleukin-23p19 subunit antagonist, in patients with moderately to severely active ulcerative colitis (UC) with prior inadequate response and/or intolerance to corticosteroids, immunosuppressants, or advanced therapy. METHODS: In this double-blind, placebo-controlled, dose-ranging, induction study, patients were randomized (1:1:1) to receive intravenous guselkumab 200 or 400 mg or placebo at weeks 0/4/8. The primary endpoint was clinical response (compared with baseline, modified Mayo score decrease ≥30% and ≥2 points, rectal bleeding subscore ≥1-point decrease or subscore of 0/1) at week 12. Guselkumab and placebo week-12 clinical nonresponders received subcutaneous or intravenous guselkumab 200 mg, respectively, at weeks 12/16/20 (uncontrolled study period). RESULTS: The primary analysis population included patients with baseline modified Mayo scores ≥5 and ≤9 (intravenous guselkumab 200 mg, N=101; 400 mg, N=107; placebo, N=105). Week-12 clinical response percentage was greater with guselkumab 200 mg (61.4%) and 400 mg (60.7%) versus placebo (27.6%; both PDiagnosis of an intraductal papillary neoplasm of the bile duct with fibrovascular stalks using detective flow imagingShunsuke Omoto; Mamoru Takenaka; Tomohiro Fukunaga; Ayana Okamoto; Yoriaki Komeda; Seok Jeong; Masatoshi KudoEndoscopy Georg Thieme Verlag KG 55 (S 01) E1012 - E1014 0013-726X 2023/08Immune Checkpoint Inhibitors for Child-Pugh Class B Advanced Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis.Enrui Xie; Yee Hui Yeo; Bernhard Scheiner; Yue Zhang; Atsushi Hiraoka; Xinxing Tantai; Petros Fessas; Tiago de Castro; Antonio D'Alessio; Claudia Angela Maria Fulgenzi; Shuo Xu; Hong-Ming Tsai; Swetha Kambhampati; Wenjun Wang; Bridget P Keenan; Xu Gao; Zixuan Xing; Matthias Pinter; Yih-Jyh Lin; Zhanjun Guo; Arndt Vogel; Takaaki Tanaka; Hsin-Yu Kuo; Robin K Kelley; Masatoshi Kudo; Ju Dong Yang; David J Pinato; Fanpu JiJAMA oncology 2023/08 IMPORTANCE: Immune checkpoint inhibitors (ICIs) are increasingly used in patients with advanced hepatocellular carcinoma (HCC). However, data on ICI therapy in patients with advanced HCC and impaired liver function are scarce. OBJECTIVE: To conduct a systematic review and meta-analysis to determine the efficacy and safety of ICI treatment for advanced HCC with Child-Pugh B liver function. DATA SOURCES: PubMed, Embase, Web of Science, and Cochrane Library were searched for relevant studies from inception through June 15, 2022. STUDY SELECTION: Randomized clinical trials, cohort studies, or single-group studies that investigated the efficacy or safety of ICI therapy for Child-Pugh B advanced HCC were included. DATA EXTRACTION AND SYNTHESIS: The Preferred Reporting Items for Systematic Reviews and Meta-Analysis guideline was followed to extract data. A random-effects model was adopted if the heterogeneity was significant (I2 > 50%); otherwise, a fixed-effect model was used. MAIN OUTCOMES AND MEASURES: The objective response rate (ORR) and overall survival (OS) were considered to be the primary efficacy outcomes of ICI treatment for Child-Pugh B advanced HCC, and the incidence of treatment-related adverse events (trAEs) was set as the primary measure for the safety outcome. RESULTS: A total of 22 studies including 699 patients with Child-Pugh B and 2114 with Child-Pugh A advanced HCC comprised the analytic sample (median age range, 53-73 years). Upon pooled analysis, patients treated with ICIs in the Child-Pugh B group had an ORR of 14% (95% CI, 11%-17%) and disease control rate (DCR) of 46% (95% CI, 36%-56%), with a median OS of 5.49 (95% CI, 3.57-7.42) months and median progression-free survival of 2.68 (95% CI, 1.85-3.52) months. The rate of any grade trAEs in the Child-Pugh B group was 40% (95% CI, 34%-47%) and of grade 3 or higher trAEs was 12% (95% CI, 6%-23%). Compared with the Child-Pugh A group, the ORR (odds ratio, 0.59; 95% CI, 0.43-0.81; P Impact of Smad4 and p53 mutations on the prognosis of patients with pancreatic ductal adenocarcinoma undergoing chemotherapy.Ken Kamata; Mamoru Takenaka; Naoshi Nishida; Akane Hara; Yasuo Otsuka; Hidekazu Tanaka; Shunsuke Omoto; Kosuke Minaga; Kentaro Yamao; Yasutaka Chiba; Kazuko Sakai; Kazuto Nishio; Tomohiro Watanabe; Masatoshi KudoInternational journal of clinical oncology 28 (11) 1511 - 1519 2023/08 BACKGROUND: This prospective cohort study evaluated the feasibility of using endoscopic ultrasound-guided fine-needle biopsy (EUS-FNB) samples for comprehensive mutational analysis of cancer-related genes using microtissues. METHODS: Fifty patients with suspected pancreatic cancer presenting consecutively at the Kindai University Hospital between January 2018 and January 2019 were enrolled. Cancerous tissues from EUS-FNB were obtained from each tumor and subjected to histological examination and mutational analysis. The primary endpoint was the collection rate of EUS-FNB specimens suitable for comprehensive cancer panels using deep sequencing. Clinical history and genetic variations between the disease control and progressive disease groups of patients on chemotherapy were evaluated as secondary endpoints. RESULTS: The collection rate of EUS-FNB specimens suitable for comprehensive cancer panels using deep sequencing was 93.6%. The cancer panel was sequenced for 25 patients with pancreatic cancer treated initially with systemic chemotherapy. Mutation in p53 and Smad4 were positively and negatively associated, respectively, with disease control at the initial evaluation. The median time to progression in 15 patients with p53 and without Smad4 mutations was 182.0 days; whereas, it was 92.5 days in other 10 patients; this difference was significant (p = 0.020). CONCLUSIONS: Tissue samples from EUS-FNB were suitable for mutational analysis. Pancreatic cancers with p53 and without Smad4 mutations responded better to chemotherapy and had a better prognosis than those others.Report of the 23rd Nationwide Follow-Up Survey of Primary Liver Cancer in Japan (2014-2015).Hiroko Iijima; Masatoshi Kudo; Shoji Kubo; Masayuki Kurosaki; Michiie Sakamoto; Shuichiro Shiina; Ryosuke Tateishi; Osamu Nakashima; Takumi Fukumoto; Yutaka Matsuyama; Takamichi Murakami; Arata Takahashi; Hiroaki Miyata; Norihiro KokudoHepatology research : the official journal of the Japan Society of Hepatology 53 (10) 895 - 959 2023/08 In the 23rd Nationwide Follow-up Survey of Primary Liver Cancer in Japan, data from 20,889 newly registered patients and 42,274 previously registered follow-up patients were compiled from 516 institutions over a 2-year period from 1 January 2014 to 31 December 2015. Basic statistics compiled for patients newly registered in the 23rd survey was cause of death, past medical history, clinical diagnosis, imaging diagnosis, treatment-related factors, pathological diagnosis, recurrence status, and autopsy findings. Compared with the previous 22nd survey, the population of patients with hepatocellular carcinoma (HCC) was older at the time of clinical diagnosis, had more female patients, had more patients with non-B non-C HCC, had smaller tumor diameter, and was more frequently treated with hepatectomy. Cumulative survival rates were calculated for HCC, intrahepatic cholangiocarcinoma (ICC), and combined hepatocellular cholangiocarcinoma (combined HCC and ICC) by treatment type and background characteristics for patients newly registered between 2004 and 2015 whose final outcome was survival or death. Median overall survival and cumulative survival rates for HCC were calculated by dividing patients by combinations of background factors (number of tumors, tumor diameter, Child-Pugh grade, or ALBI grade) and by treatment type (hepatectomy, radiofrequency ablation therapy [RFA], transcatheter arterial chemoembolization [TACE], hepatic arterial infusion chemotherapy [HAIC] and systemic therapy). The same values were also calculated according to registration date by dividing patients newly registered between 1978 and 2015 into five time period groups. The data obtained from this nationwide follow-up survey are expected to contribute to advancing clinical research and treatment of primary liver cancer in the world. This article is protected by copyright. All rights reserved.Comparison between Atezolizumab Plus Bevacizumab and Lenvatinib for Hepatocellular Carcinoma in Patients with Child-Pugh Class B in Real-World Clinical Settings.Hideko Ohama; Atsushi Hiraoka; Toshifumi Tada; Masashi Hirooka; Kazuya Kariyama; Joji Tani; Masanori Atsukawa; Koichi Takaguchi; Ei Itobayashi; Shinya Fukunishi; Kunihiko Tsuji; Toru Ishikawa; Kazuto Tajiri; Hironori Ochi; Satoshi Yasuda; Hidenori Toyoda; Chikara Ogawa; Takashi Nishimura; Takeshi Hatanaka; Satoru Kakizaki; Noritomo Shimada; Kazuhito Kawata; Atsushi Naganuma; Hisashi Kosaka; Tomomitsu Matono; Hiroshi Shibata; Tomoko Aoki; Fujimasa Tada; Kazuhiro Nouso; Asahiro Morishita; Akemi Tsutsui; Takuya Nagano; Norio Itokawa; Tomomi Okubo; Taeang Arai; Michitaka Imai; Yohei Koizumi; Shinichiro Nakamura; Hiroko Iijima; Masaki Kaibori; Yoichi Hiasa; Masatoshi Kudo; Takashi KumadaOncology 101 (9) 1 - 11 2023/08 INTRODUCTION: Systemic treatment is generally recommended for Child-Pugh (CP) A status patients with an unresectable hepatocellular carcinoma (uHCC). This study aimed to elucidate differences regarding therapeutic efficacy between lenvatinib (LEN), a multi-molecular target agent, and atezolizumab plus bevacizumab (Atez/Bev), a newly developed immune-combined therapeutic regimen for CP-B patients affected by uHCC. METHODS: From April 2018 to July 2022, 128 patients with uHCC treated with Atez/Bev (n = 29) or LEN (n = 99) as the initial systemic treatment were enrolled (median age 71 years; males 97; CP score 7:8:9 = 94:28:6; median albumin-bilirubin score -1.71). Therapeutic response was evaluated using RECIST, version 1.1. Clinical features and prognosis were retrospectively examined. RESULTS: There were no significant differences between the Atez/Bev and LEN groups in regard to best response (CR:PR:SD:PD = 0:5:12:7 vs. 5:22:25:20, p = 0.415), progression-free survival (PFS) (median 5.0 [95% CI: 2.4-7] vs. 5.5 [95% CI: 3.4-7.9] months, p = 0.332), or overall survival (OS) (5.8 [95% CI: 4.3-11] vs. 8.8 [95% CI: 6.1-12.9] months, p = 0.178). Adverse events (any grade/≥ grade 3) were observed in 72.4%/17.2% (n = 21/5) of patients treated with Atez/Bev and 78.8%/25.3% (n = 78/25) of those treated with LEN (p = 0.46/0.46). DISCUSSION: This retrospective study found no significant differences regarding PFS or OS between CP-B patients given Atez/Bev or LEN as initial systemic treatment for uHCC.Serum leucine‐rich alpha‐2 glycoprotein in monitoring disease activity and intestinal mucosal healing for biotherapy‐naïve cases with ulcerative colitisMasashi Kono; Yoriaki Komeda; George Tribonias; Saki Yoshida; Kenji Nomura; Kohei Handa; Tomoyuki Nagai; Satoru Hagiwara; Shunsuke Omoto; Mamoru Takenaka; Naoshi Nishida; Naoko Tsuji; Hiroshi Kashida; Masatoshi KudoJGH Open Wiley 7 (8) 579 - 583 2397-9070 2023/08 Abstract Background and Aim Serum leucine‐rich alpha‐2 glycoprotein level has been reported to be a useful biomarker in assessing mucosal healing in patients undergoing biotherapy, where mucosal lesions caused by ulcerative colitis are difficult to assess endoscopically. However, no such reports have been reported in biotherapy‐naïve cases. Methods Sixty‐eight patients with ulcerative colitis (UC) who were biotherapy‐naïve at Kindai University Hospital between October 2021 and October 2022 were enrolled. We prospectively examined the correlation between leucine‐rich alpha‐2 glycoprotein (LRG), C‐reactive protein (CRP), erythrocyte sedimentation rate (ESR), and Geboes scores with clinical endoscopic activity using the Mayo endoscopic subscore (MES). Results Mucosal healing was achieved in 39 (57%) patients. Univariate analysis revealed that the factors associated with mucosal healing were LRG (P = 0.0024), CRP (P = 0.1078), ESR (P = 0.0372), and Geboes scores (P = 0.0075). Logistic regression analysis identified LRG and Geboes scores as independent factors associated with mucosal healing assessed using MES (P = 0.0431 for LRG and P = 0.0166 for Geboes scores). Conclusion LRG was found to be the easiest marker to monitor disease activity and mucosal inflammation in UC patients with biotherapy‐naïve cases, with a performance equivalent to that of Geboes scores.異所性静脈瘤の治療戦略 異所性静脈瘤に対する内視鏡治療の検討松井 繁長; 樫田 博史; 工藤 正俊日本門脈圧亢進症学会雑誌 (一社)日本門脈圧亢進症学会 29 (3) 71 - 71 1344-8447 2023/08異所性静脈瘤の治療戦略 十二指腸静脈瘤の血行動態とIVR治療鶴崎 正勝; 小寺 卓; 上月 瞭平; 浦瀬 篤史; 逢坂 友也; 松井 繁長; 杉本 幸司; 石井 一成; 工藤 正俊日本門脈圧亢進症学会雑誌 (一社)日本門脈圧亢進症学会 29 (3) 73 - 73 1344-8447 2023/08異所性静脈瘤の治療戦略 異所性静脈瘤に対する内視鏡治療の検討松井 繁長; 樫田 博史; 工藤 正俊日本門脈圧亢進症学会雑誌 (一社)日本門脈圧亢進症学会 29 (3) 71 - 71 1344-8447 2023/08異所性静脈瘤の治療戦略 十二指腸静脈瘤の血行動態とIVR治療鶴崎 正勝; 小寺 卓; 上月 瞭平; 浦瀬 篤史; 逢坂 友也; 松井 繁長; 杉本 幸司; 石井 一成; 工藤 正俊日本門脈圧亢進症学会雑誌 (一社)日本門脈圧亢進症学会 29 (3) 73 - 73 1344-8447 2023/08Relationship of Atezolizumab plus Bevacizumab Treatment with Muscle Volume Loss in Unresectable Hepatocellular Carcinoma Patients: Multicenter Analysis.Atsushi Hiraoka; Takashi Kumada; Toshifumi Tada; Masashi Hirooka; Kazuya Kariyama; Joji Tani; Masanori Atsukawa; Koichi Takaguchi; Ei Itobayashi; Shinya Fukunishi; Kunihiko Tsuji; Toru Ishikawa; Kazuto Tajiri; Hironori Ochi; Satoshi Yasuda; Hidenori Toyoda; Chikara Ogawa; Takashi Nishimura; Takeshi Hatanaka; Satoru Kakizaki; Noritomo Shimada; Kazuhito Kawata; Atsushi Naganuma; Masaki Kaibori; Takaaki Tanaka; Hideko Ohama; Kazuhiro Nouso; Asahiro Morishita; Akemi Tsutsui; Takuya Nagano; Norio Itokawa; Tomomi Okubo; Taeang Arai; Michitaka Imai; Yohei Koizumi; Shinichiro Nakamura; Kouji Joko; Hiroko Iijima; Hisashi Kosaka; Yoichi Hiasa; Masatoshi KudoLiver cancer 12 (3) 209 - 217 2023/08 BACKGROUND/AIM: There is no known report regarding the relationship of atezolizumab plus bevacizumab (Atez/Bev) treatment with muscle volume loss (MVL) in unresectable hepatocellular carcinoma (u-HCC) patients. This study aimed to elucidate the clinical relationship between MVL and Atez/Bev. MATERIALS/METHODS: From September 2020 to December 2021, 229 u-HCC patients treated with Atez/Bev and with muscle volume data obtained by computed tomography at the baseline available were analyzed (median age, 74 years; males, 186 (81.2%); ECOG PS 0/1, 221 (96.5%); HCV:HBV:alcohol:others = 81:33:40:75; Child-Pugh A, 212 (92.6%); modified albumin-bilirubin (mALBI) grade 1:2a:2b = 79:60:90; BCLC 0:A:B:C = 1:24:87:117; median observation period, 6.8 months). Japan Society of Hepatology criteria were used for definition of MVL and prognostic factors were retrospectively evaluated. RESULTS: Multivariate Cox-hazard analysis of prognostic factors for progression-free survival (PFS) showed elevated alpha-fetoprotein (AFP) (≥100 ng/mL) (HR 1.848, 95% CI 1.264-2.702, p = 0.002), mALBI grade (≥2a) (HR 1.563, 95% CI 1.035-2.359, p = 0.034), and MVL (HR 1.479, 95% CI 1.020-2.144, p = 0.039) as significant factors. For overall survival (OS), significant factors included elevated AFP (≥100 ng/mL) (HR 3.564, 95% CI 1.856-6.844, p IMbrave150: Efficacy and Safety of Atezolizumab plus Bevacizumab versus Sorafenib in Patients with Barcelona Clinic Liver Cancer Stage B Unresectable Hepatocellular Carcinoma: An Exploratory Analysis of the Phase III Study.Masatoshi Kudo; Richard S Finn; Peter R Galle; Andrew X Zhu; Michel Ducreux; Ann-Lii Cheng; Masafumi Ikeda; Kaoru Tsuchiya; Ken-Ichi Aoki; Jing Jia; Riccardo LencioniLiver cancer 12 (3) 238 - 250 2023/08 INTRODUCTION: The phase III IMbrave150 study established atezolizumab + bevacizumab as standard of care in patients with unresectable hepatocellular carcinoma (HCC). This exploratory analysis reports efficacy and safety results in patients with baseline Barcelona Clinic Liver Cancer (BCLC) stage B disease. METHODS: Patients with systemic treatment-naive unresectable HCC and Child-Pugh class A liver function were randomized 2:1 to receive 1,200 mg of atezolizumab plus 15 mg/kg of bevacizumab or 400 mg of sorafenib. Co-primary endpoints were overall survival (OS) and progression-free survival (PFS) per independent review facility (IRF)-assessed Response Evaluation Criteria in Solid Tumours (RECIST) version 1.1 in the BCLC stage B subgroup. Patients in this analysis had BCLC stage B disease at baseline per electronic case report form. Secondary efficacy endpoints included the objective response rate (ORR) and change in the sum of longest diameters (SLD) of target lesions from baseline per IRF RECIST 1.1 and modified RECIST (mRECIST) for HCC. RESULTS: Of 501 enrolled patients, 74 (15%) had BCLC stage B disease at baseline (atezolizumab + bevacizumab, n = 49; sorafenib, n = 24). For this group, median follow-up was 19.7 months. A trend toward improved OS and PFS per IRF RECIST 1.1 was observed with atezolizumab + bevacizumab versus sorafenib (OS: hazard ratio [HR]: 0.63; 95% confidence interval [CI]: 0.29, 1.34; PFS: HR: 0.64; 95% CI: 0.36, 1.12). ORRs per IRF RECIST 1.1 and HCC mRECIST were 43% and 50% with atezolizumab + bevacizumab and 26% and 30% with sorafenib, respectively. Percentage change in SLD of target lesions from baseline per IRF RECIST 1.1 and HCC mRECIST showed durable responses with atezolizumab + bevacizumab treatment. Safety data were consistent with known profiles of atezolizumab and bevacizumab, as seen in the overall study population. DISCUSSION/CONCLUSION: Efficacy benefits were observed with atezolizumab + bevacizumab in patients with baseline BCLC stage B disease, consistent with the intention-to-treat population.Sequential therapies after atezolizumab plus bevacizumab or lenvatinib first-line treatments in hepatocellular carcinoma patients.Mara Persano; Margherita Rimini; Toshifumi Tada; Goki Suda; Shigeo Shimose; Masatoshi Kudo; Jaekyung Cheon; Fabian Finkelmeier; Ho Yeong Lim; José Presa; Gianluca Masi; Changhoon Yoo; Sara Lonardi; Francesco Tovoli; Takashi Kumada; Naoya Sakamoto; Hideki Iwamoto; Tomoko Aoki; Hong Jae Chon; Vera Himmelsbach; Takashi Niizeki; Margarida Montes; Caterina Vivaldi; Caterina Soldà; Bernardo Stefanini; Atsushi Hiraoka; Takuya Sho; Naoshi Nishida; Christoph Steup; Massimo Iavarone; Giovanni Di Costanzo; Fabio Marra; Emiliano Tamburini; Giuseppe Cabibbo; Francesco Giuseppe Foschi; Marianna Silletta; Masashi Hirooka; Kazuya Kariyama; Joji Tani; Masanori Atsukawa; Koichi Takaguchi; Ei Itobayashi; Shinya Fukunishi; Kunihiko Tsuji; Toru Ishikawa; Kazuto Tajiri; Hironori Ochi; Satoshi Yasuda; Hidenori Toyoda; Chikara Ogawa; Takashi Nishimura; Takeshi Hatanaka; Satoru Kakizaki; Noritomo Shimada; Kazuhito Kawata; Fujimasa Tada; Hideko Ohama; Kazuhiro Nouso; Asahiro Morishita; Akemi Tsutsui; Takuya Nagano; Norio Itokawa; Tomomi Okubo; Taeang Arai; Michitaka Imai; Hisashi Kosaka; Atsushi Naganuma; Yohei Koizumi; Shinichiro Nakamura; Masaki Kaibori; Hiroko Iijima; Yoichi Hiasa; Claudia Campani; Elisabeth Amadeo; Federico Rossari; Valentina Burgio; Stefano Cascinu; Mario Scartozzi; Andrea Casadei-GardiniEuropean journal of cancer (Oxford, England : 1990) 189 112933 - 112933 2023/08 INTRODUCTION: The aim of this retrospective proof-of-concept study was to compare different second-line treatments for patients with hepatocellular carcinoma and progressive disease (PD) after first-line lenvatinib or atezolizumab plus bevacizumab. MATERIALS AND METHODS: A total of 1381 patients had PD at first-line therapy. 917 patients received lenvatinib as first-line treatment, and 464 patients atezolizumab plus bevacizumab as first-line. RESULTS: 49.6% of PD patients received a second-line therapy without any statistical difference in overall survival (OS) between lenvatinib (20.6months) and atezolizumab plus bevacizumab first-line (15.7months; p = 0.12; hazard ratio [HR]= 0.80). After lenvatinib first-line, there wasn't any statistical difference between second-line therapy subgroups (p = 0.27; sorafenib HR: 1; immunotherapy HR: 0.69; other therapies HR: 0.85). Patients who underwent trans-arterial chemo-embolization (TACE) had a significative longer OS than patients who received sorafenib (24.7 versus 15.8months, p Consensus report from the 10th global forum for liver magnetic resonance imaging: multidisciplinary team discussion.Bachir Taouli; Ahmed Ba-Ssalamah; Julius Chapiro; Jagpreet Chhatwal; Kathryn Fowler; Tae Wook Kang; Gesine Knobloch; Dow-Mu Koh; Masatoshi Kudo; Jeong Min Lee; Takamichi Murakami; David J Pinato; Kristina I Ringe; Bin Song; Parissa Tabrizian; Jin Wang; Jeong Hee Yoon; Mengsu Zeng; Jian Zhou; Valérie VilgrainEuropean radiology 2023/07 The 10th Global Forum for Liver Magnetic Resonance Imaging was held in October 2021. The themes of the presentations and discussions at this Forum are described in detail in the review by Taouli et al (2023). The focus of this second manuscript developed from the Forum is on multidisciplinary tumor board perspectives in hepatocellular carcinoma (HCC) management: how to approach early-, mid-, and late-stage management from the perspectives of a liver surgeon, an interventional radiologist, and an oncologist. The manuscript also includes a panel discussion by multidisciplinary experts on three selected cases that explore challenging aspects of HCC management. CLINICAL RELEVANCE STATEMENT: This review highlights the importance of a multidisciplinary team approach in liver cancer patients and includes the perspectives of a liver surgeon, an interventional radiologist, and an oncologist, including illustrative case studies. KEY POINTS: • A liver surgeon, interventional radiologist, and oncologist presented their perspectives on the treatment of early-, mid-, and late-stage HCC. • Different perspectives on HCC management between specialties emphasize the importance of multidisciplinary tumor boards. • A multidisciplinary faculty discussed challenging aspects of HCC management, as highlighted by three case studies.急性膵炎の致命率改善への集学的治療 地域連携モデル構築による重症急性膵炎死亡率低減への取り組み竹中 完; 大本 俊介; 高島 耕太; 田中 秀和; 福永 朋洋; 吉田 晃浩; 山崎 友祐; 三長 孝輔; 鎌田 研; 亀井 敬子; 松本 逸平; 竹山 宜典; 工藤 正俊膵臓 (一社)日本膵臓学会 38 (3) A169 - A169 0913-0071 2023/07地域連携システムを用いた南大阪地区早期膵癌発見・診断プロジェクト吉田 晃浩; 竹中 完; 高島 耕太; 田中 秀和; 福永 朋洋; 山崎 友裕; 大本 俊介; 三長 孝輔; 鎌田 研; 亀井 敬子; 松本 逸平; 竹山 宜典; 工藤 正俊膵臓 (一社)日本膵臓学会 38 (3) A370 - A370 0913-0071 2023/07急性膵炎の致命率改善への集学的治療 地域連携モデル構築による重症急性膵炎死亡率低減への取り組み竹中 完; 大本 俊介; 高島 耕太; 田中 秀和; 福永 朋洋; 吉田 晃浩; 山崎 友祐; 三長 孝輔; 鎌田 研; 亀井 敬子; 松本 逸平; 竹山 宜典; 工藤 正俊膵臓 (一社)日本膵臓学会 38 (3) A169 - A169 0913-0071 2023/07地域連携システムを用いた南大阪地区早期膵癌発見・診断プロジェクト吉田 晃浩; 竹中 完; 高島 耕太; 田中 秀和; 福永 朋洋; 山崎 友裕; 大本 俊介; 三長 孝輔; 鎌田 研; 亀井 敬子; 松本 逸平; 竹山 宜典; 工藤 正俊膵臓 (一社)日本膵臓学会 38 (3) A370 - A370 0913-0071 2023/07Usefulness of detective flow imaging endoscopic ultrasound for the diagnosis of rectal wall thickening.Yasuhiro Masuta; Kosuke Minaga; Yasuo Otsuka; Mamoru Takenaka; Masatoshi KudoEndoscopy international open 11 (7) E651-E652  2023/07A MULTICENTER PROSPECTIVE VALIDATION STUDY ON SELECTIVE ENDOSCOPIC RESECTION OF SESSILE SERRATED LESIONS USING MAGNIFYING COLONOSCOPY IN CLINICAL PRACTICEDaizen Hirata; Hiroshi Kashida; Tsuguhiro Matsumoto; Chikara Ebisutani; Akira Teramoto; Mineo Iwatate; Santa Hattori; Mikio Fujita; Wataru Sano; Yoriaki Komeda; Yasushi Sano; Yoshitaka Murakami; Masatoshi KudoGastrointestinal Endoscopy Elsevier BV 97 (6) AB447 - AB448 0016-5107 2023/06A Phase 2, Prospective, Multicenter, Single-arm Trial of Transarterial Chemoembolization Therapy in Combination Strategy with Lenvatinib in Patients with Unresectable Intermediate-stage Hepatocellular Carcinoma: TACTICS-L TrialMasatoshi Kudo; Kazuomi Ueshima; Issei Saeki; Toru Ishikawa; Yoshitaka Inaba; Naoki Morimoto; Hiroshi Aikata; Nobukazu Tanabe; Yoshiyuki Wada; Yasuteru Kondo; Masahiro Tsuda; Kazuhiko Nakao; Takanori Ito; Tetsuya Hosaka; Yusuke Kawamura; Teiji Kuzuya; Shunsuke Nojiri; Chikara Ogawa; Hironori Koga; Keisuke Hino; Masafumi Ikeda; Michihisa Moriguchi; Takashi Hisai; Kenichi Yoshimura; Junji Furuse; Yasuaki AraiLIVER CANCER KARGER 13 (1) 99 - 112 2235-1795 2023/06 Background:Transarterial chemoembolization (TACE) is the standard treatment for unresectable intermediate-stage hepatocellular carcinoma (HCC), but recurrence after TACE is common. The present phase II, prospective, multicenter, single-arm trial, the TACTICS-L trial, investigated the efficacy and safety of TACE plus lenvatinib (LEN), a drug that more strongly promotes vascular normalization and has a better ORR than sorafenib (jRCTs031180074). Patients and Methods:Participants were patients with HCC who had not previously received systemic therapy, hepatic arterial infusion chemotherapy, or immunotherapy, and who were ineligible for resection or percutaneous ablation therapy. LEN was to be administered 14-21 days before the first TACE, stopped 2 days before TACE, and resumed 3 days after TACE. Key inclusion criteria were unresectable HCC, Child-Pugh A liver function, 0-2 prior TACE sessions, tumor size Adjuvant atezolizumab-bevacizumab after curative therapy for hepatocellular carcinoma.Masatoshi KudoHepatobiliary surgery and nutrition 12 (3) 435 - 439 2023/06Oral administration of ovalbumin protects mice from concanavalin A-induced hepatitis through suppression of interferon-gamma responsesTomohiro Watanabe; Kosuke Minaga; Hajime Honjo; Masatoshi KudoBiochemical and Biophysical Research Communications Elsevier BV 674 117 - 123 0006-291X 2023/06 The liver is a tolerogenic organ that exhibits hypo-responsiveness to antigens circulating in the portal vein. Antigens that are orally administered at high doses reach the liver. In our previous study, we demonstrated that administering ovalbumin (OVA) orally at high doses generates unique CD4+ T cells and tolerogenic dendritic cells, both of which can suppress T helper type 1 (Th1) responses, in the livers of two groups of mice: DO11.10 mice with transgenic CD4+ T cell receptors for OVA and BALB/c mice that received OVA-specific CD4+ T cells through adoptive transfer. This study aimed to investigate whether oral administration of OVA at high doses inhibits the development of hepatitis in the presence of OVA-specific CD4+ T cells. Oral administration of OVA at high doses inhibited the development of OVA-specific and concanavalin A (Con A)-induced hepatitis in DO11.10 mice, and these effects were associated with the downregulation of Th1 responses. Furthermore, the adoptive transfer of CD4+ T cells from the liver of OVA-fed DO11.10 mice inhibited the development of Con A-induced hepatitis in recipient BALB/c mice through the downregulation of Th1 responses. Finally, oral administration of OVA at high doses inhibited the development of Con A-induced hepatitis in BALB/c mice bearing naïve OVA-specific CD4+ T cells. These results suggest that the oral administration of antigens at high doses suppresses Th1-mediated hepatitis in an antigen-non-specific manner in the presence of antigen-specific CD4+ T cells.Regorafenib versus Cabozantinib as a Second-Line Treatment for Advanced Hepatocellular Carcinoma: An Anchored Matching-Adjusted Indirect Comparison of Efficacy and Safety.Philippe Merle; Masatoshi Kudo; Stanimira Krotneva; Kirhan Ozgurdal; Yun Su; Irina ProskorovskyLiver cancer 12 (2) 145 - 155 2023/06 INTRODUCTION: The tyrosine kinase inhibitors regorafenib and cabozantinib remain the mainstay in second-line treatment of advanced hepatocellular carcinoma (HCC). There is currently no clear evidence of superiority in efficacy or safety to guide choice between the two treatments. METHODS: We conducted an anchored matching-adjusted indirect comparison using individual patient data from the RESORCE trial of regorafenib and published aggregate data from the CELESTIAL trial of cabozantinib. Second-line HCC patients with prior sorafenib exposure of ≥3 months were included in the analyses. Hazard ratios (HRs) and restricted mean survival time (RMST) were estimated to quantify differences in overall survival (OS) and progression-free survival (PFS). Safety outcomes compared were rates of grade 3 or 4 adverse events (AEs), occurring in >10% of patients, and discontinuation or dose reduction due to treatment-related AEs. RESULTS: After matching adjustment for differences in baseline patient characteristics, regorafenib showed a favorable OS (HR, 0.80; 95% CI: 0.54, 1.20) and ∼3-month-longer RMST over cabozantinib (RMST difference, 2.76 months; 95% CI: -1.03, 6.54), although not statistically significant. For PFS, there was no numerical difference in HR (HR, 1.00; 95% CI: 0.68, 1.49) and no clinically meaningful difference based on RMST analyses (RMST difference, -0.59 months; 95% CI: -1.83, 0.65). Regorafenib showed a significantly lower incidence of discontinuation (risk difference, -9.2%; 95% CI: -17.7%, -0.6%) and dose reductions (-15.2%; 95% CI: -29.0%, -1.5%) due to treatment-related AEs (any grade). Regorafenib was also associated with a lower incidence (not statistically significant) of grade 3 or 4 diarrhea (risk difference, -7.1%; 95% CI: -14.7%, 0.4%) and fatigue (-6.3%; 95% CI: -14.6%, 2.0%). CONCLUSION: This indirect treatment comparison suggests, relative to cabozantinib, that regorafenib could be associated with favorable OS (not statistically significant), lower rates of dose reductions and discontinuation due to treatment-related AEs, and lower rates of severe diarrhea and fatigue.Surveillance, Diagnosis, and Treatment Outcome of Hepatocellular Carcinoma in Japan: 2023 Update.Masatoshi KudoLiver cancer 12 (2) 95 - 102 2023/06Exposure-response analysis for nivolumab plus ipilimumab combination therapy in patients with advanced hepatocellular carcinoma (CheckMate 040).Bruno Sangro; Thomas Yau; Anthony B El-Khoueiry; Masatoshi Kudo; Yun Shen; Marina Tschaika; Amit Roy; Yan Feng; Ling Gao; Urvi ArasClinical and translational science 2023/05 This analysis was conducted to inform dose selection of a combination of nivolumab plus ipilimumab for the treatment of sorafenib-experienced patients with hepatocellular carcinoma. CheckMate 040 is an open-label, multicohort, phase I/II trial in adults with advanced hepatocellular carcinoma that evaluated nivolumab monotherapy (0.1 to 10 mg/kg once every 2 weeks [Q2W]) and the following three combinations of nivolumab plus ipilimumab: (1) nivolumab 1 mg/kg plus ipilimumab 3 mg/kg every 3 weeks (Q3W) for four doses, followed by nivolumab monotherapy 240 mg Q2W (arm A); (2) nivolumab 3 mg/kg plus ipilimumab 1 mg/kg Q3W for four doses, followed by nivolumab monotherapy 240 mg Q2W (arm B); and (3) nivolumab 3 mg/kg Q2W plus ipilimumab 1 mg/kg every 6 weeks continuously (arm C). Exposure-response relationships (efficacy and safety) were characterized using nivolumab and ipilimumab concentrations after the first dose (Cavg1) as the exposure measure. Objective tumor response (OTR) and overall survival (OS) improvements were associated with increased ipilimumab exposure (OTR: odds ratio 1.45 [95% CI, 1.13-1.86]; OS: hazard ratio 0.86 [0.75-0.98]), but not nivolumab exposure (OTR: odds ratio 0.99 [0.97-1.02]; OS: hazard ratio 1.08 [0.89-1.32]). Hepatic treatment-related and immune-mediated adverse events were more common in arm A than in arms B or C. Nivolumab 1 mg/kg plus ipilimumab 3 mg/kg Q3W for four doses, followed by nivolumab monotherapy 240 mg Q2W had the most favorable benefit:risk profile in patients with advanced hepatocellular carcinoma.Activation of the aryl hydrocarbon receptor inhibits the development of experimental autoimmune pancreatitis through IL-22-mediated signaling pathwaysKen Kamata; Akane Hara; Kosuke Minaga; Tomoe Yoshikawa; Masayuki Kurimoto; Ikue Sekai; Natsuki Okai; Naoya Omaru; Yasuhiro Masuta; Yasuo Otsuka; Ryutaro Takada; Shiki Takamura; Masatoshi Kudo; Warren Strober; Tomohiro WatanabeClinical and Experimental Immunology Oxford University Press (OUP) 0009-9104 2023/05 Abstract The aryl hydrocarbon receptor (AhR) is a ligand-activated transcription factor expressed in hematopoietic and non-hematopoietic cells. Activation of the AhR by xenobiotics, microbial metabolites, and natural substances induces immunoregulatory responses. Autoimmune pancreatitis (AIP) is a chronic fibroinflammatory disorder of the pancreas driven by autoimmunity. Although AhR activation generally suppresses pathogenic autoimmune responses, the roles played by the AhR in AIP have been poorly defined. In this study, we examined how AhR activation affected the development of experimental AIP caused by the activation of plasmacytoid dendritic cells producing IFN-α and IL-33. Experimental AIP was induced in MRL/MpJ mice by repeated injections of polyinosinic-polycytidylic acid. Activation of the AhR by indole-3-pyruvic acid and indigo naturalis, which were supplemented in the diet, inhibited the development of experimental AIP, and these effects were independent of the activation of plasmacytoid dendritic cells producing IFN-α and IL-33. Interaction of indole-3-pyruvic acid and indigo naturalis with AhRs robustly augmented the production of IL-22 by pancreatic islet α cells. The blockade of IL-22 signaling pathways completely canceled the beneficial effects of AhR ligands on experimental AIP. Serum IL-22 concentrations were elevated in patients with type 1 AIP after the induction of remission with prednisolone. These data suggest that AhR activation suppresses chronic fibroinflammatory reactions that characterize AIP via IL-22 produced by pancreatic islet α cells.Analyses of cytokine gene expression and fecal microbiota in a patient with Cronkhite‐Canada syndrome successfully treated with prednisoloneHajime Honjo; Yasuhiro Masuta; Yasuo Otsuka; Sho Masaki; Kosuke Minaga; Masatoshi Kudo; Tomohiro WatanabeDEN Open Wiley 4 (1) e222  2692-4609 2023/05 [Refereed] Although prednisolone treatment is effective in Cronkhite-Canada syndrome (CCS), its mechanisms of action are poorly understood. We performed analyses of cytokine expression and fecal microbiota in a patient with the concurrent occurrence of CCS and rectal cancer, in whom regression of polyposis was achieved by prednisolone. Regression of CCS polyps was accompanied by downregulation of proinflammatory cytokine expression and alterations in microbiota composition; a decrease in Bacteroides fragilis and Peptostreptococcus anaerobius with the promotion of inflammation. We could not completely exclude the possibility that alterations in fecal microbiota composition might be influenced by the presence of advanced cancer. However, this case suggests that the administration of PSL might lead to the regression of CCS polyps through alterations in gut microbiota composition and suppression of proinflammatory cytokine responses.The “echo-free space” technique: a safe and reliable method for endoscopic ultrasound scope insertionShunsuke Omoto; Mamoru Takenaka; Tomohiro Fukunaga; Kota Takashima; Yoriaki Komeda; Seok Jeong; Masatoshi KudoEndoscopy Georg Thieme Verlag KG 55 (S 01) E698 - E699 0013-726X 2023/05Non-Inflamed Tumor Microenvironment and Methylation/Downregulation of Antigen-Presenting Machineries in Cholangiocarcinoma.Naoshi Nishida; Tomoko Aoki; Masahiro Morita; Hirokazu Chishina; Masahiro Takita; Hiroshi Ida; Satoru Hagiwara; Yasunori Minami; Kazuomi Ueshima; Masatoshi KudoCancers 15 (8) 2023/04 Cholangiocarcinoma (CCA) is a refractory cancer; a majority of CCAs represents a non-inflamed tumor phenotype that should be resistant to treatment, including immune checkpoint inhibitors (ICIs). In this study, we aimed to understand the molecular characteristics associated with non-inflamed CCAs. The genetic/epigenetic status of 36 CCAs was obtained from the Cancer Genome Atlas (PanCancerAtlas). CCAs were classified based on immune class using hierarchical clustering analysis of gene expressions related to tumor-infiltrating lymphocytes. The associations between immune class and genetic/epigenetic events were analyzed. We found that the tumors with alterations in FGFR2 and IDH1/2 had a "non-inflamed" tumor phenotype. A significant association was observed between the non-inflamed group and the downregulation of genes involved in antigen presentation (p = 0.0015). The expression of antigen-presenting machineries was inversely correlated with their DNA methylation levels, where 33.3% of tumors had an upregulation/low-methylation pattern, and 66.7% of tumors had a downregulation/high-methylation pattern. All tumors in the "inflamed" group exhibited an upregulation/low-methylation pattern. In contrast, 24 of 30 tumors in the non-inflamed group represent the downregulation/high-methylation pattern (p = 0.0005). Methylation with downregulation of antigen-presenting machineries is associated with the "non-inflamed" tumor phenotype of CCAs. This evidence provides important insights for developing new strategies for treating CCA.Role of β-Catenin Activation in the Tumor Immune Microenvironment and Immunotherapy of Hepatocellular Carcinoma.Masahiro Morita; Naoshi Nishida; Tomoko Aoki; Hirokazu Chishina; Masahiro Takita; Hiroshi Ida; Satoru Hagiwara; Yasunori Minami; Kazuomi Ueshima; Masatoshi KudoCancers 15 (8) 2023/04 Recently, the therapeutic combination of atezolizumab and bevacizumab was widely used to treat advanced hepatocellular carcinoma (HCC). According to recent clinical trials, immune checkpoint inhibitors (ICIs) and molecular target agents are expected to be key therapeutic strategies in the future. Nonetheless, the mechanisms underlying molecular immune responses and immune evasion remain unclear. The tumor immune microenvironment plays a vital role in HCC progression. The infiltration of CD8-positive cells into tumors and the expression of immune checkpoint molecules are key factors in this immune microenvironment. Specifically, Wnt/β catenin pathway activation causes "immune exclusion", associated with poor infiltration of CD8-positive cells. Some clinical studies suggested an association between ICI resistance and β-catenin activation in HCC. Additionally, several subclassifications of the tumor immune microenvironment were proposed. The HCC immune microenvironment can be broadly divided into inflamed class and non-inflamed class, with several subclasses. β-catenin mutations are important factors in immune subclasses; this may be useful when considering therapeutic strategies as β-catenin activation may serve as a biomarker for ICI. Various types of β-catenin modulators were developed. Several kinases may also be involved in the β-catenin pathway. Therefore, combinations of β-catenin modulators, kinase inhibitors, and ICIs may exert synergistic effects.The Society for Immunotherapy of Cancer clinical practice guideline on immunotherapy for hepatocellular carcinoma.Masatoshi KudoHepatobiliary surgery and nutrition 12 (2) 256 - 260 2023/04当院における難治性腹水に対するデンバーシャントの有用性浦瀬 篤史; 鶴崎 正勝; 小寺 卓; 上月 暸平; 平山 歩; 石井 一成; 青木 智子; 工藤 正俊日本インターベンショナルラジオロジー学会雑誌 (一社)日本インターベンショナルラジオロジー学会 38 (Suppl.) 143 - 143 1340-4520 2023/04胃静脈瘤に対するCANDISを用いたB-RTOの中期成績と肝予備能温存における効果小寺 卓; 鶴崎 正勝; 浦瀬 篤史; 上月 瞭平; 平山 歩; 石井 一成; 青木 智子; 工藤 正俊日本インターベンショナルラジオロジー学会雑誌 (一社)日本インターベンショナルラジオロジー学会 38 (Suppl.) 216 - 216 1340-4520 2023/04消化管がんに対する超音波診断(EUS含む) 当院におけるスキルス胃癌および下部消化管粘膜下腫瘍に対するEUS精査症例の検討田中 秀和; 鎌田 研; 高田 隆太郎; 三長 孝輔; 竹中 完; 松井 繁長; 樫田 博史; 工藤 正俊超音波医学 (公社)日本超音波医学会 50 (Suppl.) S211 - S211 1346-1176 2023/04外科医療におけるビッグデータの有効活用 術後死亡予測率を指標とした肝細胞癌切除基準の確立 日本肝癌研究会全国集計データ解析荒牧 修; 松山 裕; 久保 正二; 國土 典宏; 黒崎 雅之; 村上 卓道; 椎名 秀一朗; 工藤 正俊; 坂元 亨宇; 中島 収; 福本 巧; 飯島 尋子; 江口 晋; 副島 雄二; 幕内 雅敏; 高山 忠利; 岡村 行泰日本外科学会定期学術集会抄録集 (一社)日本外科学会 123回 PD - 4 2023/04B型肝炎診療の未来予想図(現状と課題) 免疫チェックポイント阻害剤投与に伴うHBV再活性化および抗ウイルス効果についての検討萩原 智; 西田 直生志; 工藤 正俊肝臓 (一社)日本肝臓学会 64 (Suppl.1) A51 - A51 0451-4203 2023/04遺伝・代謝性肝疾患の未来予想図(現状と課題) Erythropoietic porphyria(EPP)関連肝障害における瀉血治療の有効性萩原 智; 西田 直生志; 工藤 正俊肝臓 (一社)日本肝臓学会 64 (Suppl.1) A111 - A111 0451-4203 2023/04NASH/ASHの病態解明とTransrational Research 非アルコール性脂肪肝疾患におけるDNAメチル化に関連する臨床的・病理学的特徴萩原 智; 西田 直生志; 工藤 正俊肝臓 (一社)日本肝臓学会 64 (Suppl.1) A208 - A208 0451-4203 2023/04非硬変肝から発生したFontan術後HCCの1例有山 武尊; 萩原 智; 西田 直生志; 工藤 正俊肝臓 (一社)日本肝臓学会 64 (Suppl.1) A324 - A324 0451-4203 2023/04B型慢性肝炎患者に対するTAFの効果および安全性の検討萩原 智; 盛田 真弘; 千品 寛和; 青木 智子; 田北 雅弘; 南 康範; 依田 広; 上嶋 一臣; 西田 直生志; 工藤 正俊肝臓 (一社)日本肝臓学会 64 (Suppl.1) A425 - A425 0451-4203 2023/04高アンモニア血症に対するレボカルニチン自体の効果について萩原 智; 盛田 真弘; 千品 寛和; 青木 智子; 田北 雅弘; 南 康範; 依田 広; 上嶋 一臣; 西田 直生志; 工藤 正俊肝臓 (一社)日本肝臓学会 64 (Suppl.1) A432 - A432 0451-4203 2023/04切除不能HCCに対するABC conversion療法と造影超音波によるclinical CRの補助診断青木 智子; 南 康範; 依田 広; 千品 寛和; 田北 雅弘; 萩原 智; 上嶋 一臣; 鶴崎 正勝; 西田 直生志; 工藤 正俊超音波医学 (公社)日本超音波医学会 50 (Suppl.) S598 - S598 1346-1176 2023/04診断の鍵となる所見 膵・胆管合流異常の診断におけるEUS・造影ハーモニックEUSの意義の検討山崎 友裕; 鎌田 研; 高島 耕太; 田中 秀和; 福永 朋洋; 吉田 晃浩; 大本 俊介; 三長 孝輔; 竹中 完; 工藤 正俊超音波医学 (公社)日本超音波医学会 50 (Suppl.) S200 - S200 1346-1176 2023/04膵腫瘍(嚢胞性疾患も)の超音波およびEUS診断 膵腫瘍の造影ハーモニックEUS診断鎌田 研; 大塚 康生; 田中 秀和; 中井 敦; 山崎 友裕; 大本 俊介; 三長 孝輔; 竹中 完; 北野 雅之; 工藤 正俊超音波医学 (公社)日本超音波医学会 50 (Suppl.) S230 - S230 1346-1176 2023/04胆管病変に対するDetective flow imaging(DFI)の有用性について大本 俊介; 竹中 完; 吉田 晃浩; 福永 朋洋; 田中 秀和; 高島 耕太; 山崎 友裕; 三長 孝輔; 鎌田 研; 工藤 正俊超音波医学 (公社)日本超音波医学会 50 (Suppl.) S586 - S586 1346-1176 2023/04消化管がんに対する超音波診断(EUS含む) 当院におけるスキルス胃癌および下部消化管粘膜下腫瘍に対するEUS精査症例の検討田中 秀和; 鎌田 研; 高田 隆太郎; 三長 孝輔; 竹中 完; 松井 繁長; 樫田 博史; 工藤 正俊超音波医学 (公社)日本超音波医学会 50 (Suppl.) S211 - S211 1346-1176 2023/04希少疾患の内視鏡診断(全体) 弾性線維性仮性黄色腫に合併する消化管病変の内視鏡所見三長 孝輔; 山下 幸孝; 工藤 正俊Gastroenterological Endoscopy (一社)日本消化器内視鏡学会 65 (Suppl.1) 823 - 823 0387-1207 2023/04【US Today 2023 超音波検査・診断最前線 腹部領域の最新動向を中心に】腹部領域の技術と臨床の最新動向 AI超音波診断の最新動向と今後の展望西田 直生志; 工藤 正俊INNERVISION (株)インナービジョン 38 (5) 40 - 43 0913-8919 2023/04 医療ではリアルタイムの対応が必要な場合が多く,厳しい時間的制約の下でのタスクはヒューマンエラーにつながりやすい。一方,人工知能(AI)の導入により,医療関係者は多様なデータから適切に処理された必要な情報をわかりやすい形で得ることができるようになり,医療の効率化とヒューマンエラーの防止が期待できる。加えて,疾患診断のみならず,予後予測や最適な治療アプローチの提案など,超音波診断の分野でも,さまざまなタスクを行うAIモデルが報告されている。本稿では,腹部超音波診断をサポートするAIにフォーカスして,その開発状況を概説する。(著者抄録)Identification of Atezolizumab Plus Bevacizumab Prognostic Index via Recursive Partitioning Analysis in HCC: The ABE Index.Mara Persano; Margherita Rimini; Toshifumi Tada; Goki Suda; Shigeo Shimose; Masatoshi Kudo; Jaekyung Cheon; Fabian Finkelmeier; Ho Yeong Lim; José Presa; Gianluca Masi; Changhoon Yoo; Sara Lonardi; Tiziana Pressiani; Fabio Piscaglia; Takashi Kumada; Lorenza Rimassa; Mario Scartozzi; Stefano Cascinu; Andrea Casadei-GardiniAnticancer research 43 (4) 1599 - 1610 2023/04 BACKGROUND/AIM: The purpose of this study was to ascertain a novel prognostic index via recursive partitioning analysis (RPA) in hepatocellular carcinoma (HCC) patients being treated with the combination of atezolizumab plus bevacizumab (ABE) in first-line setting. PATIENTS AND METHODS: A total of 784 patients with HCC were included in the analysis. RESULTS: RPA identified three groups of patients: high-risk [Child-Pugh B (CP-B) patients; CP-A and Albumin-Bilirubin (ALBI)-2 patients; CP-A and ALBI-1 patients with macrovascular invasion (MVI), and alpha-fetoprotein (α-FP) ≥400 ng/ml]; intermediate-risk [CP-A and ALBI-1 patients with aspartate aminotransferase (AST) normal value (NV), and αFP ≥400 ng/ml, but without MVI; CP-A and ALBI-1 patients with AST increased value (IV), and neutrophil-lymphocyte ratio (NLR) ≥3, but without MVI]; low-risk (CP-A and ALBI-1 patients with AST NV, and αFP Impact of body mass index in patients receiving atezolizumab plus bevacizumab for hepatocellular carcinoma.Mathew Vithayathil; Antonio D'Alessio; Claudia Angela Maria Fulgenzi; Naoshi Nishida; Martin Schönlein; Johann von Felden; Kornelius Schulze; Henning Wege; Anwaar Saeed; Brooke Wietharn; Hannah Hildebrand; Linda Wu; Celina Ang; Thomas U Marron; Arndt Weinmann; Peter R Galle; Dominik Bettinger; Bertram Bengsch; Arndt Vogel; Lorenz Balcar; Bernhard Scheiner; Pei-Chang Lee; Yi-Hsiang Huang; Suneetha Amara; Mahvish Muzaffar; Abdul Rafeh Naqash; Antonella Cammarota; Valentina Zanuso; Tiziana Pressiani; Matthias Pinter; Alessio Cortellini; Masatoshi Kudo; Lorenza Rimassa; David J Pinato; Rohini SharmaHepatology international 2023/04 BACKGROUND: Atezolizumab plus bevacizumab (Atezo/Bev) is first line-treatment for unresectable hepatocellular carcinoma (HCC). Body mass index (BMI) has demonstrated predictive value for response to immunotherapy in non-HCC cancer types. Our study investigated the effect of BMI on safety and efficacy of real-life use of Atezo/Bev for unresectable HCC. METHODS: 191 consecutive patients from seven centres receiving Atezo/Bev were included in the retrospective study. Overall survival (OS), progression-free survival (PFS), overall response rate (ORR) and disease control rate (DCR) defined by RECIST v1.1 were measured in overweight (BMI ≥ 25) and non-overweight (BMI Advances in Immunotherapy for Hepatocellular Carcinoma.Satoru Hagiwara; Naoshi Nishida; Masatoshi KudoCancers 15 (7) 2023/03 Immune checkpoint inhibitors (ICIs) aim to induce immune responses against tumors and are less likely to develop drug resistance than molecularly targeted drugs. In addition, they are characterized by a long-lasting antitumor effect. However, since its effectiveness depends on the tumor's immune environment, it is essential to understand the immune environment of hepatocellular carcinoma to select ICI therapeutic indications and develop biomarkers. A network of diverse cellular and humoral factors establishes cancer immunity. By analyzing individual cases and classifying them from the viewpoint of tumor immunity, attempts have been made to select the optimal therapeutic drug for immunotherapy, including ICIs. ICI treatment is discussed from the viewpoints of immune subclass of HCC, Wnt/β-catenin mutation, immunotherapy in NASH-related HCC, the mechanism of HPD onset, and HBV reactivation.Survival outcomes from atezolizumab plus bevacizumab versus Lenvatinib in Child Pugh B unresectable hepatocellular carcinoma patients.Margherita Rimini; Mara Persano; Toshifumi Tada; Goki Suda; Shigeo Shimose; Masatoshi Kudo; Jaekyung Cheon; Fabian Finkelmeier; Ho Yeong Lim; José Presa; Francesca Salani; Sara Lonardi; Fabio Piscaglia; Takashi Kumada; Naoya Sakamoto; Hideki Iwamoto; Tomoko Aoki; Hong Jae Chon; Vera Himmelsbach; Marta Schirripa; Margarida Montes; Caterina Vivaldi; Caterina Soldà; Atsushi Hiraoka; Takuya Sho; Takashi Niizeki; Naoshi Nishida; Christoph Steup; Masashi Hirooka; Kazuya Kariyama; Joji Tani; Masanori Atsukawa; Koichi Takaguchi; Ei Itobayashi; Shinya Fukunishi; Kunihiko Tsuji; Toru Ishikawa; Kazuto Tajiri; Hironori Ochi; Satoshi Yasuda; Hidenori Toyoda; Chikara Ogawa; Takashi Nishimura; Takeshi Hatanaka; Satoru Kakizaki; Noritomo Shimada; Kazuhito Kawata; Fujimasa Tada; Hideko Ohama; Kazuhiro Nouso; Asahiro Morishita; Akemi Tsutsui; Takuya Nagano; Norio Itokawa; Tomomi Okubo; Taeang Arai; Michitaka Imai; Hisashi Kosaka; Atsushi Naganuma; Yohei Koizumi; Shinichiro Nakamura; Masaki Kaibori; Hiroko Iijima; Yoichi Hiasa; Valentina Burgio; Mario Scartozzi; Stefano Cascinu; Andrea Casadei-GardiniJournal of cancer research and clinical oncology 149 (10) 7565 - 7577 2023/03 INTRODUCTION: The best first-line treatment for patients with advanced hepatocellular carcinoma (HCC) and Child-Pugh (CP) class B remains unknown. The aim of the present study was to perform a real-world analysis on a large sample of patients with unresectable HCC with CP B treated with atezolizumab plus bevacizumab Vs Lenvatinib. METHODS: The study population included patients affected by advanced (BCLC-C) or intermediate (BCLC-B) HCC patients not suitable for locoregional therapies from both the Western and Eastern world (Italy, Germany, Republic of Korea and Japan), who received atezolizumab plus bevacizumab or Lenvatinib as first-line treatment. All the study population presented a CP class of B. The primary endpoint of the study was the overall survival (OS) of CP B patients treated with Lenvatinib compared to atezolizumab plus bevacizumab. Survival curves were estimated using the product-limit method of Kaplan-Meier. The role of stratification factors was analyzed with log-rank tests. Finally, an interaction test was performed for the main baseline clinical characteristics. RESULTS: 217 CP B HCC patients were enrolled in the study: 65 (30%) received atezolizumab plus bevacizumab, and 152 (70%) received lenvatinib. The mOS for patients receiving Lenvatinib was 13.8 months (95% CI: 11.6-16.0), compared to 8.2 months (95% CI 6.3-10.2) for patients receiving atezolizumab plus bevacizumab as first-line treatment (atezolizumab plus bevacizumab Vs Lenvatinib: HR 1.9, 95% CI 1.2-3.0, p = 0.0050). No statistically significant differences were highlighted in terms of mPFS. The multivariate analysis confirmed that patients receiving Lenvatinib as first-line treatment have a significantly longer OS compared to patients receiving atezolizumab plus bevacizumab (HR 2.01; 95% CI 1.29-3.25, p = 0.0023). By evaluating the cohort of patients who received atezolizumab plus bevacizumab, we found that Child B patients with ECOG PS 0, or BCLC B stage or ALBI grade 1 were those who had benefited from the treatment thus showing survival outcomes no significantly different compared to those receiving Lenvatinib. CONCLUSION: The present study suggests for the first time a major benefit from Lenvatinib compared to atezolizumab plus bevacizumab in a large cohort of patients with CP B class HCC.Usefulness of the Measurement of Psoas Muscle Volume for Sarcopenia Diagnosis in Patients with Liver Disease.Takushi Manabe; Chikara Ogawa; Kei Takuma; Mai Nakahara; Kyoko Oura; Tomoko Tadokoro; Koji Fujita; Joji Tani; Mitsushige Shibatoge; Asahiro Morishita; Masatoshi Kudo; Tsutomu MasakiDiagnostics (Basel, Switzerland) 13 (7) 2023/03 Computed tomography (CT) is often used in the diagnosis of sarcopenia. In this study, we validated the assessment of sarcopenia by the psoas muscle volume using versatile software. The study involved a retrospective analysis of data from 190 patients with liver disease who underwent grip-strength testing and abdominal pelvic computed tomography. To assess sarcopenia, SYNAPSE 3D was used to obtain the skeletal muscle index, the psoas muscle index (PMI), and the simple method. We also used the recently proposed PMI cutoff values, for which the usefulness has been evaluated (O-PMI). The cutoff value of the psoas muscle volume index (PMVI) was determined using one of the diagnostic methods as the gold standard. All diagnostic methods showed that patients with sarcopenia had shorter survival, with O-PMI having the highest hazard ratio (HR) (HR, 6.12; 95% confidence interval [CI], 2.6-14.41; p Real-World Data for Atezolizumab Plus Bevacizumab in Unresectable Hepatocellular Carcinoma: How Does Adherence to the IMbrave150 Trial Inclusion Criteria Impact Prognosis?Margherita Rimini; Mara Persano; Toshifumi Tada; Goki Suda; Shigeo Shimose; Masatoshi Kudo; Jaekyung Cheon; Fabian Finkelmeier; Ho Yeong Lim; José Presa; Gianluca Masi; Changhoon Yoo; Sara Lonardi; Fabio Piscaglia; Takashi Kumada; Naoya Sakamoto; Hideki Iwamoto; Tomoko Aoki; Hong Jae Chon; Vera Himmelsbach; Tiziana Pressiani; Margarida Montes; Caterina Vivaldi; Caterina Soldà; Atsushi Hiraoka; Takuya Sho; Takashi Niizeki; Naoshi Nishida; Christoph Steup; Masashi Hirooka; Kazuya Kariyama; Joji Tani; Masanori Atsukawa; Koichi Takaguchi; Ei Itobayashi; Shinya Fukunishi; Kunihiko Tsuji; Toru Ishikawa; Kazuto Tajiri; Hironori Ochi; Satoshi Yasuda; Hidenori Toyoda; Chikara Ogawa; Takashi Nishimura; Takeshi Hatanaka; Satoru Kakizaki; Noritomo Shimada; Kazuhito Kawata; Fujimasa Tada; Hideko Ohama; Kazuhiro Nouso; Asahiro Morishita; Akemi Tsutsui; Takuya Nagano; Norio Itokawa; Tomomi Okubo; Taeang Arai; Michitaka Imai; Hisashi Kosaka; Atsushi Naganuma; Yohei Koizumi; Shinichiro Nakamura; Masaki Kaibori; Hiroko Iijima; Yoichi Hiasa; Valentina Burgio; Lorenza Rimassa; Mario Scartozzi; Stefano Cascinu; Andrea Casadei-GardiniTargeted oncology 18 (2) 221 - 233 2023/03 BACKGROUND: Atezolizumab plus bevacizumab has recently been approved as a new first-line standard of care for patients with unresectable hepatocellular carcinoma (HCC). OBJECTIVE: We performed a real-world study to evaluate the impact of the IMbrave150 trial inclusion criteria on the safety and efficacy of treatment outside of clinical trials. METHODS: We analyzed patients treated with atezolizumab plus bevacizumab for unresectable HCC from four different countries. No specific inclusion and exclusion criteria were applied, except for the absence of previous systemic therapies for HCC. The entire population was split into two groups according to concordance with the inclusion criteria as reported in the IMbrave150 trial in 'IMbrave150-in' and 'IMbrave150-out' patients, and safety and efficacy in the two groups of patients were evaluated. RESULTS: Overall, 766 patients were included in the analysis: 561/766 (73%) in the 'IMbrave150-in' group and 205/766 (27%) in the 'IMbrave150-out' group. Median overall survival (OS) and median progression-free survival (PFS) were 16.3 versus 14.3 months (hazard ratio [HR] 0.48, 95% confidence interval [CI] 0.35-0.65; p  0.0001). No statistically significant differences were reported in the 'IMbrave150-in' and 'IMbrave150-out' groups in terms of safety profile. CONCLUSION: Adherence to the IMbrave150 trial inclusion criteria favorably impacts the prognosis of patients receiving atezolizumab plus bevacizumab. Among patients who did not meet the IMbrave150 inclusion criteria, those with ALBI grade 1 could benefit from the treatment.Contrast-Enhanced Harmonic Endoscopic Ultrasound-Guided Puncture for the Patients with Pancreatic Masses.Yasuo Otsuka; Ken Kamata; Masatoshi KudoDiagnostics (Basel, Switzerland) 13 (6) 2023/03 Endoscopic ultrasound-guided fine-needle aspiration (EUS-FNA) is useful for the diagnosis of pancreatic masses. According to three meta-analyses, the sensitivity, specificity, and accuracy of EUS-FNA are 84-92%, 96-98%, and 86-91%, respectively. However, the occurrence of false-negative and false-positive results indicates that the diagnostic performance of EUS-FNA needs to be improved. Contrast-enhanced harmonic endoscopic ultrasonography (CH-EUS) is used for the characterization of pancreatic masses and can be applied to improve the performance of EUS-FNA. When CH-EUS is used to evaluate intratumor blood flow, an avascular area inside the pancreatic mass that is considered to be fibrosis is often detected. This area can be avoided by performing EUS-FNA under CH-EUS guidance. In this review, we summarize the data on contrast-enhanced harmonic endoscopic ultrasound-guided fine-needle aspiration (CH-EUS-FNA), which suggest that its benefit is still a matter of debate. Of eight studies analyzed, only one showed that CH-EUS improved the sensitivity of EUS-FNA. The future challenge is to determine under what circumstances CH-EUS-FNA is useful.消化器診療におけるAIの現状と展望 B-mode超音波検査による肝腫瘤診断を支援する人工知能の開発西田 直生志; 工藤 正俊日本消化器病学会雑誌 (一財)日本消化器病学会 120 (臨増総会) A36 - A36 0446-6586 2023/03進行肝癌の治療戦略 免疫複合療法時代における切除不能肝細胞癌へのcancer-free strategy青木 智子; 西田 直生志; 工藤 正俊日本消化器病学会雑誌 (一財)日本消化器病学会 120 (臨増総会) A85 - A85 0446-6586 2023/03【マイクロバイオームが切り拓く肝胆膵の新未来】膵疾患 マイクロバイオームと自己免疫性膵炎三長 孝輔; 吉川 智恵; 原 茜; 瀬海 郁衣; 栗本 真之; 大塚 康生; 益田 康弘; 鎌田 研; 工藤 正俊; 渡邉 智裕肝胆膵 (株)アークメディア 86 (3) 377 - 385 0389-4991 2023/03当院における膵管断裂症候群(DPDS:disconnected pancreatic duct syndrome)に対する治療成績についての検討福永 朋洋; 大本 俊介; 竹中 完; 工藤 正俊; 栗本 真之; 大塚 康生; 田中 秀和; 高島 耕太; 吉田 晃浩; 山崎 友裕; 三長 孝輔; 鎌田 研日本消化器病学会雑誌 (一財)日本消化器病学会 120 (臨増総会) A283 - A283 0446-6586 2023/03【胆膵疾患と腸内細菌の現状と展望】膵臓 腸内細菌の慢性膵炎・自己免疫性膵炎発生における役割三長 孝輔; 原 茜; 瀬海 郁衣; 栗本 真之; 大塚 康生; 益田 康弘; 吉川 智恵; 鎌田 研; 工藤 正俊; 渡邉 智裕胆と膵 医学図書出版(株) 44 (3) 235 - 241 0388-9408 2023/03 膵臓に慢性炎症性変化をきたす疾患は慢性膵炎と自己免疫性膵炎に大別される。これらの慢性炎症性膵疾患の病態生理は十分に解明されておらず,病態生理の理解に基づいた根治療法は開発されていない。近年,膵臓の慢性炎症性疾患である慢性膵炎と自己免疫性膵炎の病態形成における腸内細菌の関与を示唆する報告が相次ぎ,注目を浴びている。われわれは主に自然免疫反応の観点から,これらの慢性炎症性膵疾患の病態生理の解明に取り組む過程で,それぞれの病態形成に炎症性サイトカインであるI型IFN・IL-33が重要な役割を果たしていることを見出した。さらに,これらのサイトカインの産生には腸内細菌が深く関与しており,病的な膵臓・腸管間免疫ネットワーク機構が膵臓の慢性炎症や線維化に関与していることを明らかにした。腸内細菌は,根治療法が存在しない慢性膵炎および自己免疫性膵炎の新たな治療標的として有望である可能性があり,今後の研究が期待される。(著者抄録)消化器診療におけるAIの現状と展望 B-mode超音波検査による肝腫瘤診断を支援する人工知能の開発西田 直生志; 工藤 正俊日本消化器病学会雑誌 (一財)日本消化器病学会 120 (臨増総会) A36 - A36 0446-6586 2023/03進行肝癌の治療戦略 免疫複合療法時代における切除不能肝細胞癌へのcancer-free strategy青木 智子; 西田 直生志; 工藤 正俊日本消化器病学会雑誌 (一財)日本消化器病学会 120 (臨増総会) A85 - A85 0446-6586 2023/03当院における難治性潰瘍性大腸炎患者に対するウステキヌマブの治療成績の検討吉田 早希; 米田 頼晃; 杉森 啓伸; 大丸 直哉; 松原 卓哉; 吉川 馨介; 野村 健司; 半田 康平; 正木 翔; 河野 匡志; 永井 知行; 本庶 元; 松井 繁長; 辻 直子; 樫田 博史; 工藤 正俊日本消化器病学会雑誌 (一財)日本消化器病学会 120 (臨増総会) A357 - A357 0446-6586 2023/03Long-Term Survival of More than 5 Years with Maintenance Therapy Using Single-Agent Pemetrexed in a Patient with Diffuse Malignant Peritoneal MesotheliomaYasuo Otsuka; Yoriaki Komeda; Masayuki Takeda; Takayuki Takahama; Masashi Kono; Mamoru Takenaka; Satoru Hagiwara; Naoshi Nishida; Hiroshi Kashida; Masatoshi KudoCase Reports in Medicine Hindawi Limited 2023 1 - 4 1687-9627 2023/02 A 76-year-old woman presented with lower abdominal pain and nausea and was referred to the gastroenterology department in our institution. Previous contrast-enhanced computed tomography (CE-CT) for follow-up after breast cancer surgery had indicated a soft tissue mass below the right diaphragm, which was considered a benign change. CE-CT performed at the first visit to our department revealed further thickening of the soft tissue mass with extension to the liver surface. In addition, ascites and nodules were observed in the abdominal cavity. Histopathological examination of a biopsy specimen revealed peritoneal invasion of atypical epithelioid cells with trabecular and glandular patterns. The tumor cells were positive for AE1/AE2, calretinin, WT-1, D2-40, HEG1, EMA, BAP1, and MTAP and negative for carcinoembryonic antigen, MOC-31, Ber-Ep4, ER, PgR, TTF-1, claudin 4, and desmin. A diagnosis of epithelioid mesothelioma was made. The patient received chemotherapy with cisplatin (75 mg/m2) and pemetrexed (500 mg/m2). After six courses of combined chemotherapy, pemetrexed was administered as a single agent. At the time of writing this report, she was undergoing over the 30th course of chemotherapy without any significant side effects. Diffuse malignant peritoneal mesothelioma is a rare, fatal, and progressive disease. Our patient achieved long-term survival of more than 5 years with maintenance therapy using single-agent pemetrexed.Clinical Practice Guidelines for Hepatocellular Carcinoma: The Japan Society of Hepatology 2021 Version (5th JSH-HCC Guidelines).Kiyoshi Hasegawa; Nobuyuki Takemura; Tatsuya Yamashita; Takeyuki Watadani; Masaki Kaibori; Shoji Kubo; Mitsuo Shimada; Hiroaki Nagano; Etsuro Hatano; Hiroshi Aikata; Hiroko Iijima; Kazuomi Ueshima; Kazuyoshi Ohkawa; Takuya Genda; Kaoru Tsuchiya; Takuji Torimura; Masafumi Ikeda; Junji Furuse; Masaaki Akahane; Satoshi Kobayashi; Hideyuki Sakurai; Atsuya Takeda; Takamichi Murakami; Utaroh Motosugi; Yutaka Matsuyama; Masatoshi Kudo; Ryosuke TateishiHepatology research : the official journal of the Japan Society of Hepatology 53 (5) 383 - 390 2023/02 The 5th version of the Clinical Practice Guidelines for Hepatocellular Carcinoma was revised by the Japan Society of Hepatology, according to the methodology of evidence-based medicine and partly to the Grading of Recommendations Assessment, Development and Evaluation system, which was published in October 2021 in Japanese. In addition to surveillance-diagnostic and treatment algorithms, a new algorithm for systemic therapy has been created, as multiple drugs for hepatocellular carcinoma can be currently selected. Herein, new or revised algorithms and evidence on which the recommendations are based are described. This article is protected by copyright. All rights reserved.Breakthroughs in hepatocellular carcinoma therapies.Amit G Singal; Masatoshi Kudo; Jordi BruixClinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association 2023/02 ▪▪▪.A case of transcatheter arterial embolization for intraperitoneal hemorrhage due to giant hepatic segmental arterial mediolysisHiroki Kato; Satoru Hagiwara; Naoshi Nishida; Yoriaki Komeda; Akihiro Yoshida; Masatoshi KudoClinical Journal of Gastroenterology Springer Science and Business Media LLC 1865-7257 2023/02 This study aimed to demonstrate the effect of transcatheter arterial embolization (TAE) on hepatic segmental arterial mediolysis (SAM). The patient, a 68-year-old female, suddenly developed right upper abdominal pain in October 2021, which was initially relieved. However, she was rushed to a local hospital the next day when her abdominal pain recurred. An abdominal computed tomography scan suggested a ruptured hepatic aneurysm; therefore, she was transferred to our hospital and admitted on the same day. On the first day after admission, she underwent emergency catheterization and N-butyl-2-cyanoacrylate (NBCA)/lipiodol embolization for an aneurysm in the hepatic S6. A multi-detector computed tomography on hospital day 8 to probe for extrahepatic lesions revealed multiple beaded irregularities in the superior mesenteric and bilateral renal arteries. A head magnetic resonance angiography performed on the ninth day showed no aneurysms or irregularities. She did well after TAE, did not have rebleeding, and was discharged on hospital day 16. Rupture of an aneurysm associated with SAM occurs frequently in the colonic and gastroepiploic arteries, and rupture of a hepatic aneurysm is relatively rare. TAE hemostasis was able to save the patient by preventing intraperitoneal bleeding caused by hepatic segmental arterial mediolysis.Real world data of systemic therapy for hepatocellular carcinoma in Japan: HERITAGE study.Yoshinari Asaoka; Ryosuke Tateishi; Yasuhide Yamada; Hiroko Iijima; Naoya Kato; Mitsuo Shimada; Etsuro Hatano; Takumi Fukumoto; Takamichi Murakami; Hirohisa Yano; Kengo Yoshimitsu; Masayuki Kurosaki; Michiie Sakamoto; Yutaka Matsuyama; Masatoshi Kudo; Norihiro KokudoJournal of Clinical Oncology American Society of Clinical Oncology (ASCO) 41 (4_suppl) 510 - 510 0732-183X 2023/02 510 Background: Currently 6 regimens are available for advanced hepatocellular carcinoma (HCC) in Japan, including atezolizumab plus bevacizumab (AB), sorafenib (S), and lenvatinib (L) for first-line treatment and regorafenib (R), ramucirumab (RAM), and cabozantinib (C) for the second-line treatment. In real-world clinical practice, the number of combinations of treatment sequences is enormous. We have launched a nationwide registry of systemic therapy for HCC named Hepatoma Registry of Integrating and Aggregating Electric Health Records (HERITAGE). Methods: The HERITAGE is linked to the nationwide follow-up survey of the Japan Liver Cancer Association; cases treated with systemic therapy between 2015 and 2022 were included in the current study. Information on treatment efficacy and duration was collected and registered on each treatment regimen. Results: As of June 2022, 6,400 treatment lines (S 2,319, L 2559, AB 768, R 406, RAM 251, C 71) in 4,307 cases were enrolled. The response rates, disease control rates, and median treatment duration of each sequence of regimens are shown in the table. The 1st line regimen, S, L, and AB, were also used as the second and later lines in Japan and found as effective as if used as the 1st line treatment. Limitation: No adjustments for clinical conditions were performed. Conclusions: We have demonstrated the efficacy of various treatment sequences in a sufficient number of cases. Clinical trial information: UMIN000046567 . [Table: see text]【上部消化管内視鏡のトラブルシューティング】静脈瘤に対する内視鏡治療 十二指腸静脈瘤の内視鏡治療(EVL,clipping)後に出血をきたした松井 繁長; 樫田 博史; 米田 頼晃; 辻 直子; 工藤 正俊消化器内視鏡 (株)東京医学社 35 (2) 202 - 203 0915-3217 2023/02Achievement of Complete Response and Drug-free Status by Atezolizumab Plus Bevacizumab Combined with or without Curative Conversion in Patients with Transarterial Chemoembolization-Unsuitable, Intermediate-stage Hepatocellular Carcinoma: A Multicenter Proof-of-Concept StudyMasatoshi Kudo; Tomoko Aoki; Kazuomi Ueshima; Kaoru Tsuchiya; Masahiro Morita; Hirokazu Chishina; Masahiro Takita; Satoru Hagiwara; Yasunori Minami; Hiroshi Ida; Naoshi Nishida; Chikara Ogawa; Tetsu Tomonari; Noriaki Nakamura; Hidekatsu Kuroda; Atsushi Takebe; Yoshifumi Takeyama; Masaaki Hidaka; Susumu Eguchi; Stephen L. Chan; Masayuki Kurosaki; Namiki IzumiLIVER CANCER KARGER 12 (4) 321 - 338 2235-1795 2023/02 Introduction: Atezolizumab plus bevacizumab therapy is extremely effective in the treatment of intermediate-stage hepatocellular carcinoma (HCC), with a response rate of 44%, as reported in the IMbrave150 trial. When tumor shrinkage is obtained, achieving complete response (CR) is possible in many cases using curative conversion with resection, ablation, or super selective transarterial chemoembolization (TACE) with curative intent. This concept, i.e., curative conversion by combining systemic therapy and locoregional therapy, has not been reported before. This multicenter proof-of-concept study was conducted to show the value of curative conversion in immunotherapy-treated intermediate-stage HCC meeting TACE-unsuitable criteria.Methods: This study included 110 consecutive Child-Pugh A patients who received atezolizumab plus bevacizumab as first-line treatment for unresectable and TACE-unsuitable intermediate-stage HCC at seven centers in Japan. CR rate, drug-free rate, time to CR, change in liver function, efficacy in positron emission tomography (PET)-positive HCC, progression-free survival (PFS), and overall survival (OS) were assessed in patients who achieved CR using resection, ablation, super selective TACE with curative intent following atezolizumab plus bevacizumab or atezolizumab plus bevacizumab alone.Results: Clinical or pathological CR was achieved in 38 patients (35%) (median observation period: 21.2 months). The modalities of curative conversion in 35 patients were as follows: resection, 7; ablation, 13; and superselective TACE, 15. Three patients achieved clinical CR with atezolizumab plus bevacizumab therapy alone. Among the 38 CR patients, 25 achieved drug-free status. PFS was not reached, and three patients experienced recurrence after reaching CR. Regarding OS, there were no deaths in any of the CR patients. The albumin-bilirubin score did not deteriorate after locoregional therapy or resection. Of seven PET-positive patients who achieved CR with atezolizumab plus bevacizumab followed by curative conversion, five achieved drug-free status.Discussion/Conclusion: The achievement of CR rate by curative conversion in patients treated with atezolizumab plus bevacizumab as the preceding therapy for unresectable and TACE-unsuitable intermediate-stage HCC was 35%. Overall, 23% of patients achieved drug-free status and no recurrence was observed from this patient subgroup with CR and drug free status. Thus, achieving CR and/or drug-free status should be a therapeutic goal for patients with intermediate-stage HCC without vascular invasion or extrahepatic spread.Prioritized Requirements for First-Line Systemic Therapy for Hepatocellular Carcinoma: Broad Benefit with Less Toxicity.Masatoshi KudoLiver cancer 12 (1) 1 - 6 2023/02Role of the prognostic nutritional index in predicting survival in advanced hepatocellular carcinoma treated with atezolizumab plus bevacizumab.Margherita Rimini; Mara Persano; Toshifumi Tada; Goki Suda; Shigeo Shimose; Masatoshi Kudo; Jaekyung Cheon; Fabian Finkelmeier; Ho Yeong Lim; José Presa Ramos; Gianluca Masi; Changhoon Yoo; Sara Lonardi; Bernardo Stefanini; Takashi Kumada; Naoya Sakamoto; Hideki Iwamoto; Tomoko Aoki; Hong Jae Chon; Vera Himmelsbach; Margarida Montes; Caterina Vivaldi; Caterina Soldà; Atsushi Hiraoka; Takuya Sho; Takashi Niizeki; Naoshi Nishida; Christoph Steup; Masashi Hirooka; Kazuya Kariyama; Joji Tani; Masanori Atsukawa; Koichi Takaguchi; Ei Itobayashi; Shinya Fukunishi; Kunihiko Tsuji; Toru Ishikawa; Kazuto Tajiri; Hironori Ochi; Satoshi Yasuda; Hidenori Toyoda; Chikara Ogawa; Takashi Nishimura; Takeshi Hatanaka; Satoru Kakizaki; Noritomo Shimada; Kazuhito Kawata; Fujimasa Tada; Hideko Ohama; Kazuhiro Nouso; Asahiro Morishita; Akemi Tsutsui; Takuya Nagano; Norio Itokawa; Tomomi Okubo; Taeang Arai; Michitaka Imai; Hisashi Kosaka; Atsushi Naganuma; Yohei Koizumi; Shinichiro Nakamura; Masaki Kaibori; Hiroko Iijima; Yoichi Hiasa; Valentina Burgio; Angelo Della Corte; Francesca Ratti; Francesco De Cobelli; Luca Aldrighetti; Mario Scartozzi; Stefano Cascinu; Andrea Casadei-GardiniOncology 101 (5) 283 - 291 2023/01 INTRODUCTION: The prognostic nutritional index (PNI) is a multiparametric score introduced by Onodera based on the blood levels of lymphocytes and albumin in patients with gastrointestinal neoplasms. Regarding hepatocellular carcinoma (HCC), its prognostic role has been demonstrated in patients treated with sorafenib and lenvatinib. The aim of this real-world study is to investigate the association between clinical outcomes and PNI in patients being treated with atezolizumab plus bevacizumab. METHODS: The overall cohort of this multicentric study included 871 consecutive HCC patients from 4 countries treated with atezolizumab plus bevacizumab in first-line therapy. The PNI was calculated as follows: 10 × serum albumin concentration (g/dL) + 0.005 × peripheral lymphocyte count (number/mm3). RESULTS: For only 773 patients, data regarding lymphocyte counts and albumin levels were available, so only these patients were included in the final analysis. The cut-off point of the PNI was determined to be 41 by receiver operating characteristic (ROC) analysis. 268 patients (34.7%) were categorized as the PNI-low group, while the remaining 505 (65.3%) patients as the PNI-high group. At the univariate analysis, high PNI was associated with longer overall survival (OS) (22.5 vs. 10.1 months, HR 0.34, p A Multicenter Prospective Validation Study on Selective Endoscopic Resection of Sessile Serrated Lesions Using Magnifying Colonoscopy in Clinical PracticeDaizen Hirata; Hiroshi Kashida; Tsuguhiro Matsumoto; Chikara Ebisutani; Akira Teramoto; Mineo Iwatate; Santa Hattori; Mikio Fujita; Wataru Sano; Yoriaki Komeda; Yasushi Sano; Yoshitaka Murakami; Masatoshi KudoDigestion S. Karger AG 1 - 8 0012-2823 2023/01 Introduction: Sessile serrated lesions (SSLs) have malignant potential for colorectal cancer in the serrated pathway. Selective endoscopic resection of SSLs would reduce medical costs and procedure-related accidents, but the accurate endoscopic differentiation of SSLs from hyperplastic polyps (HPs) is challenging. To explore the differential diagnostic performance of magnifying colonoscopy in distinguishing SSLs from HPs, we conducted a multicenter prospective validation study in clinical practice. Methods: Considering the rarity of diminutive SSLs, all lesions ≥6 mm that were detected during colonoscopy and diagnosed as type 1 based on the Japan narrow-band imaging expert team (JNET) classification were included in this study. Twenty expert endoscopists were asked to differentiate between SSLs and HPs with high or low confidence level after conventional and magnifying NBI observation. To examine the validity of selective endoscopic resection of SSLs using magnifying colonoscopy in clinical practice, we calculated the sensitivity of endoscopic diagnosis of SSLs with histopathological findings as comparable reference. Results: A total of 217 JNET type 1 lesions from 162 patients were analyzed, and 114 lesions were diagnosed with high confidence. The sensitivity of magnifying colonoscopy in detecting SSLs was 79.8% (95% confidence interval [CI]: 74.7–84.4%) overall, and 82.4% (95% CI: 76.1–87.7%) in the high-confidence group. These results showed that the sensitivity of this study was not high enough, even limited in the high-confidence group. Conclusions: Accurate differential diagnosis of SSLs and HPs using magnifying colonoscopy was challenging even for experts. JNET type 1 lesions ≥6 mm are recommended to be resected because selective endoscopic resection has a disadvantage of leaving approximately 20% of SSLs on site.Cabozantinib in Japanese patients with advanced hepatocellular carcinoma: Final results of a multicenter phase 2 study.Naoya Kato; Masatoshi Kudo; Kaoru Tsuchiya; Atsushi Hagihara; Kazushi Numata; Hiroshi Aikata; Yoshitaka Inaba; Shunsuke Kondo; Kenta Motomura; Naohiro Okano; Masafumi Ikeda; Manabu Morimoto; Shingo Kuroda; Akiko KimuraHepatology research : the official journal of the Japan Society of Hepatology 2023/01 AIM: Cabozantinib showed a favorable benefit-risk profile in Japanese patients with advanced hepatocellular carcinoma (HCC) in an open-label, phase 2 study (NCT03586973). This analysis presents cumulative data to final database lock. METHODS: Patients with previously treated, advanced HCC received cabozantinib 60 mg/day. Progression-free survival (PFS) and tumor response rates in prior-sorafenib and sorafenib-naïve cohorts were assessed by independent radiology committee (IRC) and an investigator. Liver function was evaluated by albumin-bilirubin (ALBI) score. RESULTS: Median cabozantinib exposure was 5.6 months. In the prior-sorafenib cohort (n = 20), median PFS was 7.4 months per IRC assessment and 5.6 months per investigator assessment. In the sorafenib-naïve cohort (n = 14), median PFS was 3.6 months and 4.4 months per IRC and investigator assessment, respectively. Six-month PFS rate per IRC and investigator assessment in the prior-sorafenib cohort was 59.8% and 49.5%, respectively, and in the sorafenib-naïve cohort was 16.7% and 35.7%, respectively. Disease control rate by both IRC and investigator assessment was 85.0% in the prior-sorafenib cohort and 64.3% in the sorafenib-naïve cohort. Median overall survival (Kaplan-Meier estimate) was 19.3 months and 9.9 months in the prior-sorafenib and sorafenib-naïve cohort, respectively. Mean ALBI score remained relatively constant in patients able to continue treatment. The most frequent adverse events were palmar-plantar erythrodysesthesia syndrome, diarrhea, hypertension, and decreased appetite. No new safety concerns were identified. CONCLUSIONS: Cabozantinib showed efficacy and a manageable safety profile in Japanese patients with advanced HCC. This article is protected by copyright. All rights reserved.Safety and Effectiveness of Lenvatinib in Patients with Unresectable Hepatocellular Carcinoma in Real-World Clinical Practice: An Observational Post-Marketing Study in Japan.Junji Furuse; Namiki Izumi; Kenta Motomura; Yoshitaka Inaba; Yoshio Katamura; Yasuteru Kondo; Kazuhisa Yabushita; Katsuaki Motoyoshi; Masatoshi KudoDrugs - real world outcomes 2023/01 BACKGROUND: Lenvatinib was approved for use in unresectable hepatocellular carcinoma (uHCC) in Japan in 2018. Patients with diverse clinical characteristics receive lenvatinib treatment in clinical practice. Thus, it is crucial to evaluate the safety and effectiveness of lenvatinib in real-world clinical settings. OBJECTIVE: This study aimed to evaluate the real-world safety and effectiveness of lenvatinib for uHCC in clinical practice in Japan. PATIENTS AND METHODS: Between July 2018 and January 2019, patients with uHCC who were administered lenvatinib for the first time were enrolled in this prospective, multicenter, observational post-marketing study (NCT03663114). Patients were orally administered lenvatinib and followed up for 12 months. For safety, adverse drug reactions (ADRs) were evaluated. For effectiveness, the objective response rate (ORR) was calculated to evaluate tumor response. Overall survival (OS) was estimated using the Kaplan-Meier method. RESULTS: Data of 703 patients (median age, 73 years; 80.2% males) were analyzed. The median (range) treatment duration was 25.3 (0.3-68.9) weeks. The mean ± standard deviation initial dose was 7.37 ± 1.65 mg in patients with body weight  10%) were decreased appetite, fatigue, hypertension, proteinuria, palmar-plantar erythrodysesthesia, hypothyroidism, and diarrhea. The median OS of the 703 patients was 498.0 days. In 494 patients assessed using the modified Response Evaluation Criteria in Solid Tumors (mRECIST), the ORR was 39.5% (95% confidence interval: 35.1-43.9%). Patients with better liver or renal function at baseline achieved significantly higher ORR than those with worse liver or renal function. CONCLUSIONS: In patients with uHCC in real-world clinical practice in Japan, treatment with lenvatinib was generally well tolerated, and no new safety concerns were identified. The ORR and median OS were similar to or better than the results of the Japanese subset of the global Phase III REFLECT trial. Our results demonstrated that clinically meaningful treatment responses were achieved with lenvatinib in real-world clinical practice.Crosstalk between NOD2 and TLR2 suppresses the development of TLR2-mediated experimental colitisNatsuki Okai; Yasuhiro Masuta; Yasuo Otsuka; Akane Hara; Sho Masaki; Ken Kamata; Kosuke Minaga; Hajime Honjo; Masatoshi Kudo; Tomohiro WatanabeJournal of Clinical Biochemistry and Nutrition The Society for Free Radical Research Japan 74 (2) 146 - 153 0912-0009 2023 Nucleotide-binding oligomerization domain 2 (NOD2) is an intracellular sensor for muramyl dipeptide (MDP), a degradation product of bacterial cell wall peptidoglycan (PGN). PGN stimulates cell-surface Toll-like receptor 2 (TLR2) independently of NOD2, indicating the presence of crosstalk between extracellular TLR2 and intracellular NOD2 upon exposure to PGN. NOD2-deficient mice were sensitive, while TLR2-deficient mice were resistant to experimental colitis induced by intrarectal administration of PGN. Severe colitis in NOD2-deficient mice was accompanied by increased expression of nuclear factor-kappa B-dependent cytokines and decreased expression of autophagy-related 16-like 1 (ATG16L1). MDP activation of NOD2 enhanced autophagy mediated by TLR2 in human dendritic cells. mRNA expression of TLR2 tended to be higher in the colonic mucosa of patients with active ulcerative colitis compared to that of those in remission. Induction of remission was associated with increased mRNA expression of ATG16L1 in both ulcerative colitis and Crohn's disease patients. Conversely, mRNA expression of receptor-interacting serine/threonine-protein kinase 2 was higher in the inflammatory colonic mucosa of patients with active disease than in the non-inflamed mucosa of patients in remission, in both ulcerative colitis and Crohn's disease. These findings highlight the role of NOD2-TLR2 crosstalk in the immunopathogenesis of colitis.Reciprocal regulation of protein arginine deiminase 2 and 4 expression in the colonic mucosa of ulcerative colitisYasuo Otsuka; Yasuhiro Masuta; Kosuke Minaga; Natsuki Okai; Akane Hara; Ryutaro Takada; Sho Masaki; Ken Kamata; Hajime Honjo; Kouhei Yamashita; Masatoshi Kudo; Tomohiro WatanabeJournal of Clinical Biochemistry and Nutrition The Society for Free Radical Research Japan 0912-0009 2023Cytokine and Chemokine Profiles in Ulcerative Colitis Relapse after Coronavirus Disease 2019 VaccinationYasuhiro Masuta; Kosuke Minaga; Yasuo Otsuka; Natsuki Okai; Akane Hara; Sho Masaki; Tomoyuki Nagai; Hajime Honjo; Masatoshi Kudo; Tomohiro WatanabeJournal of Clinical Biochemistry and Nutrition The Society for Free Radical Research Japan 74 (2) 127 - 135 0912-0009 2023 Coronavirus disease 2019 (COVID-19) vaccines are highly effective; however, vaccine-related adverse events, including autoimmunity, have been reported. Case reports describing relapse or new-onset of ulcerative colitis (UC) after COVID-19 mRNA vaccination are available. However, the molecular mechanisms underlying the development of colonic inflammation associated with COVID-19 mRNA vaccination are poorly understood. Furthermore, it is unclear whether the relapse of UC after COVID-19 vaccination is driven by unique cytokine responses that differ from those of UC not associated with vaccination. mRNAs derived from COVID-19 vaccines are potent inducers of type I IFN response. We encountered three cases of UC relapse after COVID-19 vaccination. mRNA expressions of IFN-α, IFN-β, IL-1β, and IL-12/23p40 showed higher tendency in the colonic mucosa of patients with UC associated with vaccination compared with those not associated with vaccination. In contrast, the expressions of C-X-C motif chemokine ligand 9 (CXCL9) and CXCL10 were comparable. Immunofluorescence analyses also showed higher expression of IFN-α in the colonic mucosa of patients with UC associated with COVID-19 vaccination than in those not associated with vaccination. Taken together, these data suggest that the colonic mucosa of patients with UC who relapsed after COVID-19 vaccination was characterized by enhanced type I IFN responses.Expression of Concern: Unique Association between Global DNA Hypomethylation and Chromosomal Alterations in Human Hepatocellular Carcinoma (Expression of Concern of Vol 8, art no E72312, 2013)Naoshi Nishida; Masatoshi Kudo; Takafumi Nishimura; Tadaaki Arizumi; Masahiro Takita; Satoshi Kitai; Norihisa Yada; Satoru Hagiwara; Tatsuo Inoue; Yasunori Minami; Kazuomi Ueshima; Toshiharu Sakurai; Naosuke Yokomichi; Takeshi Nagasaka; Ajay GoelPLOS ONE PUBLIC LIBRARY SCIENCE 18 (1) 1932-6203 2023/01Circumferential Stenosis of the Second Part of the Duodenum Caused by Eosinophilic GastroenteritisHajime Honjo; Kosuke Minaga; Akane Hara; Ryutaro Takada; Yasuo Otsuka; Yasuhiro Masuta; Sho Masaki; Shigenaga Matsui; Masatoshi Kudo; Tomohiro WatanabeInternal Medicine Japanese Society of Internal Medicine 0918-2918 2023 Isolated eosinophilic gastroenteritis (EGE) of the second part of the duodenum is rare. We herein report a case of EGE limited to the second part of the duodenum that caused circumferential stenosis due to massive wall thickening. A boring biopsy was useful to verify the accumulation of eosinophils. Induction of remission by prednisolone was accompanied by a marked reduction in the mRNA expression of IL-6, C-C motif chemokine ligand 17 (CCL17), and CCL26 without any reduction in prototypical EGE-associated T helper type 2 cytokines (IL-5, IL-13). Thus, the enhanced expression of IL-6, CCL17, and CCL26 might be involved in the development of EGE in this case.Familial Adenomatous Polyposis with Atypical Clinical Morphology and Genetic VariantsYoriaki Komeda; Hideki Ishikawa; Teruhiko Yoshida; Mineko Ushiama; Saki Yoshida; Kenji Nomura; Masashi Kono; Shunsuke Omoto; Mamoru Takenaka; Satoru Hagiwara; Hiroshi Kashida; Masatoshi KudoInternal Medicine Japanese Society of Internal Medicine 0918-2918 2023 Familial adenomatous polyposis (FAP) is caused by pathogenic variants of the APC gene on the long arm of chromosome 5. An analysis showed an association between germline APC gene variants and clinical signs of FAP; however, attenuated FAP has also been reported in cases with pathogenic variants. In contrast, a phenotype of FAP with no APC germline pathogenic variant and with few signs has been reported. We herein report a 16-year-old girl in whom the presence of multiple large bowel cancers from a young age and several small bowel cancers reflected a carcinogenic tendency higher than that typical for FAP.【膵癌の早期診断-診療ガイドラインの改訂を踏まえて】Stage 0,IA膵癌の診断と治療 EUSの有用性吉田 晃浩; 鎌田 研; 三長 孝輔; 山雄 健太郎; 竹中 完; 工藤 正俊臨床消化器内科 (株)日本メディカルセンター 38 (2) 178 - 182 0911-601X 2023/01 <文献概要>Stage 0,IA(腫瘍径20mm以下)膵癌の診断において,空間分解能に優れる超音波内視鏡(EUS)は膵癌の直接あるいは間接所見の検出に有用である.また,コンベックス型EUSを用いることで病理診断を目的としたEUS下穿刺吸引法(EUS-FNA)も実施可能である.EUSは膵癌診療において,診断や治療方針決定のためには欠かせない検査法といえる.近年,膵癌診断において,造影ハーモニックEUSの有用性が報告されている.EUSとそれに続くEUS-FNAや造影ハーモニックEUS等を駆使してもStage 0,IA膵癌の診断には苦慮することが多く,内視鏡的逆行性胆管膵管造影をはじめとするその他の画像診断を併用し,総合的な診断を行うことが望ましいと考えられる.IL-6応答亢進を伴う潰瘍性大腸炎関連脊椎関節炎の一例藤田 峻輔; 本庶 元; 高田 隆太郎; 原 茜; 益田 康弘; 半田 康平; 三長 孝輔; 渡邉 智裕; 工藤 正俊; 辻 成佳日本消化器病学会近畿支部例会プログラム・抄録集 日本消化器病学会-近畿支部 118回 88 - 88 2023/01Regulation of type I IFN responses by deubiquitinating enzyme A in inflammatory bowel diseasesYasuhiro Masuta; Yasuo Otsuka; Kosuke Minaga; Hajime Honjo; Masatoshi Kudo; Tomohiro WatanabeJournal of Clinical Biochemistry and Nutrition The Society for Free Radical Research Japan 73 (2) 103 - 107 0912-0009 2023 The development of Inflammatory bowel disease (IBD) is driven by excessive production of pro-inflammatory cytokines including TNF-α, IL-12, and IL-23. This notion is supported by the remarkable clinical success of biologics targeting these cytokines. Recognition of cell wall components derived from intestinal bacteria by Toll-like receptors (TLRs) induces the production of these pro-inflammatory cytokines by macrophages and dendritic cells in human IBD and experimental colitis model. Although sensing of bacterial nucleic acids by endosomal TLRs, specifically TLR3, TLR7, and TLR9 leads to robust production of type I IFNs, it remains debatable whether TLR-mediated type I IFN responses are pathogenic or protective in IBD patients. Additionally, recent studies identified deubiquitinating enzyme A (DUBA) as a novel negative regulator of TLR-mediated type I IFN responses. In light of these observations and their potential applications, in this review, we summarize recent findings on the roles of type I IFN responses and DUBA-mediated negative regulation of these responses in human IBD and experimental colitis model.Outcomes of beta blocker use in advanced hepatocellular carcinoma treated with immune checkpoint inhibitors.Y Linda Wu; Grace van Hyfte; Umut Özbek; Marlene Reincke; Anuhya Gampa; Yehia I Mohamed; Naoshi Nishida; Brooke Wietharn; Suneetha Amara; Pei-Chang Lee; Bernhard Scheiner; Lorenz Balcar; Matthias Pinter; Arndt Vogel; Arndt Weinmann; Anwaar Saeed; Anjana Pillai; Lorenza Rimassa; Abdul Rafeh Naqash; Mahvish Muzaffar; Yi-Hsiang Huang; Ahmed O Kaseb; Masatoshi Kudo; David J Pinato; Celina AngFrontiers in oncology 13 1128569 - 1128569 2023 BACKGROUND: In patients with cirrhosis, portal hypertension increases intestinal permeability, dysbiosis, and bacterial translocation, promoting an inflammatory state that can lead to the progression of liver disease and development of hepatocellular carcinoma (HCC). We aimed to investigate whether beta blockers (BBs), which can mediate portal hypertension, conferred survival benefits in patients treated with immune checkpoint inhibitors (ICIs). METHODS: We conducted a retrospective, observational study of 578 patients with unresectable HCC treated with ICI from 2017 to 2019 at 13 institutions across three continents. BB use was defined as exposure to BBs at any time during ICI therapy. The primary objective was to assess the association of BB exposure with overall survival (OS). Secondary objectives were to evaluate the association of BB use with progression-free survival (PFS) and objective response rate (ORR) according to RECIST 1.1 criteria. RESULTS: In our study cohort, 203 (35%) patients used BBs at any point during ICI therapy. Of these, 51% were taking a nonselective BB. BB use was not significantly correlated with OS (hazard ratio [HR] 1.12, 95% CI 0.9-1.39, P = 0.298), PFS (HR 1.02, 95% CI 0.83-1.26, P = 0.844) or ORR (odds ratio [OR] 0.84, 95% CI 0.54-1.31, P = 0.451) in univariate or multivariate analyses. BB use was also not associated with incidence of adverse events (OR 1.38, 95% CI 0.96-1.97, P = 0.079). Specifically, nonselective BB use was not correlated with OS (HR 0.94, 95% CI 0.66-1.33, P = 0.721), PFS (HR 0.92, 0.66-1.29, P = 0.629), ORR (OR 1.20, 95% CI 0.58-2.49, P = 0.623), or rate of adverse events (OR 0.82, 95% CI 0.46-1.47, P = 0.510). CONCLUSION: In this real-world population of patients with unresectable HCC treated with immunotherapy, BB use was not associated with OS, PFS or ORR.Successful initial tofacitinib treatment for acute severe ulcerative colitis with steroid resistance: a case series.Yoriaki Komeda; Masashi Kono; Hiroshi Kashida; George Tribonias; Sho Masaki; Ryutaro Takada; Tomoyuki Nagai; Satoru Hagiwara; Naoshi Nishida; Mamoru Takenaka; Hajime Honjo; Shigenaga Matsui; Naoko Tsuji; Masatoshi KudoAnnals of gastroenterology 36 (1) 97 - 102 2023 BACKGROUND: The standard therapy for acute severe ulcerative colitis (ASUC) is intravenous corticosteroids; however, 30% of ulcerative colitis (UC) patients do not recover with corticosteroids alone. Few studies have reported the efficacy and safety of tofacitinib for ASUC with steroid resistance. We report a case series of successful first-line treatment consisting of tofacitinib (20 mg/day) administered to ASUC patients with steroid resistance. METHODS: Patients diagnosed with ASUC at our institution between October 2018 and February 2020 were retrospectively evaluated. They were administered a high dose of tofacitinib (20 mg) after showing no response to steroid therapy in a dose of 1-1.5 mg/kg/day. RESULTS: Eight patients with ASUC, 4 (50%) men, median age 47.1 (range 19-65) years, were included. Four patients were newly diagnosed, and the median UC duration was 4 (range 0-20) years. Six of the 8 patients were able to avoid colectomy. One patient (patient 2) had no response; however, remission was achieved after switching from tofacitinib to infliximab. One patient (patient 6) with no response to tofacitinib underwent total colectomy. Only one patient (patient 4) experienced an adverse event, local herpes zoster, treated with acyclovir without tofacitinib discontinuation. CONCLUSIONS: Clinical remission without serious adverse events can be achieved with high probability and colectomy can be avoided by first administering high-dose tofacitinib to steroid-resistant ASUC patients. Tofacitinib may be one of the first-line treatment options for steroid-resistant ASUC.Ulcerative Colitis-associated Spondyloarthritis Successfully Treated with Infliximab in the Absence of Enhanced TNF-α ResponsesShunsuke Fujita; Hajime Honjo; Ryutaro Takada; Akane Hara; Yasuhiro Masuta; Yasuo Otsuka; Kohei Handa; Kosuke Minaga; Shigeyoshi Tsuji; Masatoshi Kudo; Tomohiro WatanabeInternal Medicine Japanese Society of Internal Medicine 0918-2918 2023 Although concurrent occurrence of spondyloarthritis (SpA) and ulcerative colitis (UC) is sometimes seen, the profiles of cytokines have been poorly understood in UC-associated SpA. We herein report a case of UC-associated SpA successfully treated with infliximab. Profiles of cytokines in the serum and colonic mucosa were characterized by an enhanced expression of IL-6 but not TNF-α. Successful induction of remission by infliximab was associated with the downregulation of IL-6 expression but no significant alteration in TNF-α expression. These findings suggest that some cases of UC-associated SpA might be driven by IL-6, and infliximab might be effective in cases lacking enhanced TNF-α responses.Progression patterns and therapeutic sequencing following immune checkpoint inhibition for HCC: an international observational study.Thomas Talbot; Antonio D'Alessio; Matthias Pinter; Lorenz Balcar; Bernhard Scheiner; Thomas U Marron; Tomi Jun; Sirish Dharmapuri; Celina Ang; Anwaar Saeed; Hannah Hildebrand; Mahvish Muzaffar; Claudia A M Fulgenzi; Suneetha Amara; Abdul Rafeh Naqash; Anuhya Gampa; Anjana Pillai; Yinghong Wang; Uqba Khan; Pei-Chang Lee; Yi-Hsiang Huang; Bertram Bengsch; Dominik Bettinger; Yehia I Mohamed; Ahmed Kaseb; Tiziana Pressiani; Nicola Personeni; Lorenza Rimassa; Naoshi Nishida; Masatoshi Kudo; Arndt Weinmann; Peter R Galle; Ambreen Muhammed; Alessio Cortellini; Arndt Vogel; David J PinatoLiver international : official journal of the International Association for the Study of the Liver 43 (3) 695 - 707 2022/12 [Refereed] BACKGROUND & AIMS: Different approaches are available after progression of disease (PD) to immune checkpoint inhibitors (ICI) for hepatocellular carcinoma (HCC), including continuation of ICI, treatment switching to tyrosine kinase inhibitors (TKIs) and cessation of anticancer therapy. We sought to characterise the relationship between radiologic patterns of progression and survival post-ICI, also appraising treatment strategies. METHODS: We screened 604 HCC patients treated with ICIs, including only those who experienced PD by data cut-off. We evaluated post-progression survival (PPS) according to treatment strategy at PD and verified its relationship with radiologic patterns of progression: intrahepatic growth (IHG), new intrahepatic lesion (NIH), extrahepatic growth (EHG), new extrahepatic lesion (NEH) and new vascular invasion (nVI). RESULTS: Of 604 patients, 364 (60.3%) experienced PD during observation. Median PPS was 5.3 months (95%CI: 4.4-6.9; 271 events). At data cut-off, 165 patients (45%) received no post-progression anticancer therapy; 64 patients (17.6%) continued ICI beyond PD. IHG (HR 1.64 [95%CI:1.21-2.22]; p=0.0013) and nVI (HR 2.15 [95%CI:1.38-3.35]; p=0.0007) were associated with shorter PPS. Multivariate models adjusted for progression patterns, treatment line, and ALBI grade and ECOG-PS at PD confirmed receipt of ICI beyond PD with (HR 0.17, 95%CI 0.09-0.32; pClinical outcomes with atezolizumab plus bevacizumab or lenvatinib in patients with hepatocellular carcinoma: a multicenter real-world study.Mara Persano; Margherita Rimini; Toshifumi Tada; Goki Suda; Shigeo Shimose; Masatoshi Kudo; Jaekyung Cheon; Fabian Finkelmeier; Ho Yeong Lim; Lorenza Rimassa; José Presa; Gianluca Masi; Changhoon Yoo; Sara Lonardi; Francesco Tovoli; Takashi Kumada; Naoya Sakamoto; Hideki Iwamoto; Tomoko Aoki; Hong Jae Chon; Vera Himmelsbach; Tiziana Pressiani; Takumi Kawaguchi; Margarida Montes; Caterina Vivaldi; Caterina Soldà; Fabio Piscaglia; Atsushi Hiraoka; Takuya Sho; Takashi Niizeki; Naoshi Nishida; Christoph Steup; Massimo Iavarone; Giovanni Di Costanzo; Fabio Marra; Mario Scartozzi; Emiliano Tamburini; Giuseppe Cabibbo; Francesco Giuseppe Foschi; Marianna Silletta; Masashi Hirooka; Kazuya Kariyama; Joji Tani; Masanori Atsukawa; Koichi Takaguchi; Ei Itobayashi; Shinya Fukunishi; Kunihiko Tsuji; Toru Ishikawa; Kazuto Tajiri; Hironori Ochi; Satoshi Yasuda; Hidenori Toyoda; Chikara Ogawa; Takashi Nishimura; Takeshi Hatanaka; Satoru Kakizaki; Noritomo Shimada; Kazuhito Kawata; Fujimasa Tada; Hideko Ohama; Kazuhiro Nouso; Asahiro Morishita; Akemi Tsutsui; Takuya Nagano; Norio Itokawa; Tomomi Okubo; Taeang Arai; Michitaka Imai; Hisashi Kosaka; Atsushi Naganuma; Yohei Koizumi; Shinichiro Nakamura; Masaki Kaibori; Hiroko Iijima; Yoichi Hiasa; Antonella Cammarota; Valentina Burgio; Stefano Cascinu; Andrea Casadei-GardiniJournal of cancer research and clinical oncology 149 (9) 5591 - 5602 2022/12 PURPOSE: The purpose of this study is to compare response rates of lenvatinib and atezolizumab plus bevacizumab, in first-line real-world setting. METHODS: Overall cohort included Western and Eastern hepatocellular carcinoma (HCC) patient populations from 46 centres in 4 countries (Italy, Germany, Japan, and Republic of Korea). RESULTS: 1312 patients were treated with lenvatinib, and 823 patients were treated with atezolizumab plus bevacizumab. Objective response rate (ORR) was 38.6% for patients receiving lenvatinib, and 27.3% for patients receiving atezolizumab plus bevacizumab (p Feasibility and efficacy of endoscopic reintervention after covered metal stent placement for EUS-guided hepaticogastrostomy: A multicenter experience.Kosuke Minaga; Masayuki Kitano; Yoshito Uenoyama; Keiichi Hatamaru; Hideyuki Shiomi; Kenji Ikezawa; Tsukasa Miyagahara; Hajime Imai; Nao Fujimori; Hisakazu Matsumoto; Yuzo Shimokawa; Atsuhiro Masuda; Mamoru Takenaka; Masatoshi Kudo; Yasutaka ChibaEndoscopic ultrasound 2022/12 BACKGROUND AND OBJECTIVES: Although the use of a long metal stent is favored for EUS-guided hepaticogastrostomy (EUS-HGS) for the relief of malignant biliary obstruction (MBO), endoscopic reintervention (E-RI) at the time of recurrent biliary obstruction (RBO) is challenging due to a long intragastric portion. This study evaluated the feasibility and safety of E-RI after a long partially covered metal stent (L-PCMS) placement during EUS-HGS. MATERIALS AND METHODS: We performed a multicenter retrospective study between January 2015 and December 2019 examining patients with MBO who underwent E-RI for RBO through the EUS-HGS route after the L-PCMS placement. Technical and clinical success rates, details of E-RI, adverse events (AEs), stent patency, and survival time were evaluated. RESULTS: Thirty-three patients at eight referral centers in Japan who underwent E-RI through the EUS-HGS route were enrolled. The location of MBO was distal in 54.5%. The median intragastric length of the L-PCMS was 5 cm. As the first E-RI attempt, E-RI via the distal end of the existing L-PCMS was successful in 60.6%. The overall technical and clinical success rates of E-RI were 100% and 81.8%, respectively. Liver abscess was noted in one patient. A proximal biliary stricture was associated with the clinical ineffectiveness of E-RI in multivariable analysis (odds ratio, 12.5, P = 0.04). The median survival and stent patency duration after E-RI were 140 and 394 days, respectively. CONCLUSIONS: Our study findings suggest that E-RI for RBO after EUS-HGS with a L-PCMS is technically feasible and clinically effective, without any severe AEs, especially for patients with distal MBO.Hepatobiliary and Pancreatic: Multiple pancreatic masses with rich vascularityS Yoshida; K Minaga; T Watanabe; M KudoJournal of Gastroenterology and Hepatology Wiley 38 10  0815-9319 2022/12【胆膵EUSのトラブルシューティング】治療的EUS Peripancreatic/pancreatic fluid collection(PFC)ドレナージ 穿刺ルートが拡張できない三長 孝輔; 大塚 康生; 益田 康弘; 竹中 完; 工藤 正俊消化器内視鏡 (株)東京医学社 34 (12) 1971 - 1975 0915-3217 2022/12Atezolizumab plus Bevacizumab versus Sorafenib for Unresectable Hepatocellular Carcinoma: Results from Older Adults Enrolled in the IMbrave150 Randomized Clinical Trial.Daneng Li; Han Chong Toh; Philippe Merle; Kaoru Tsuchiya; Sairy Hernandez; Wendy Verret; Alan Nicholas; Masatoshi KudoLiver cancer 11 (6) 558 - 571 2022/12 INTRODUCTION: The efficacy of systemic first-line treatments in older adults with unresectable hepatocellular carcinoma (HCC) has not been well-studied. We compared the safety and efficacy of atezolizumab plus bevacizumab versus sorafenib as a first-line treatment in younger versus older patients with unresectable HCC. METHODS: This global, phase 3, open-label, randomized clinical trial (IMbrave150) recruited patients aged ≥18 years with locally advanced metastatic or unresectable HCC, an Eastern Cooperative Oncology Group performance status score of 0 or 1, and Child-Pugh class A liver function who had not previously received systemic therapy for liver cancer. Patients received either 1,200 mg atezolizumab plus 15 mg/kg bevacizumab intravenously every 3 weeks or 400 mg sorafenib orally twice daily until loss of clinical benefit or unacceptable toxicity. Primary endpoints were overall survival (OS) and progression-free survival (PFS). Secondary outcomes were the incidence of adverse events and time to deterioration of patient-reported outcomes (PROs). This subgroup analysis evaluated safety and efficacy endpoints in patients Real Life Study of Lenvatinib Therapy for Hepatocellular Carcinoma: RELEVANT Study.Andrea Casadei-Gardini; Margherita Rimini; Masatoshi Kudo; Shigeo Shimose; Toshifumi Tada; Goki Suda; Myung Ji Goh; Andre Jefremow; Mario Scartozzi; Giuseppe Cabibbo; Claudia Campani; Emiliano Tamburini; Francesco Tovoli; Kazuomi Ueshima; Tomoko Aoki; Hideki Iwamoto; Takuji Torimura; Takashi Kumada; Atsushi Hiraoka; Masanori Atsukawa; Ei Itobayashi; Hidenori Toyoda; Naoya Sakamoto; Takuya Sho; Wonseok Kang; Jürgen Siebler; Markus Friedrich Neurath; Valentina Burgio; Stefano CascinuLiver cancer 11 (6) 527 - 539 2022/12 INTRODUCTION: In the REFLECT trial, lenvatinib was found to be noninferior compared to sorafenib in terms of overall survival. Here, we analyze the effects of lenvatinib in the real-life experience of several centers across the world and identify clinical factors that could be significantly associated with survival outcomes. METHODS: The study population was derived from retrospectively collected data of HCC patients treated with lenvatinib. The overall cohort included western and eastern populations from 23 center in five countries. RESULTS: We included 1,325 patients with HCC and treated with lenvatinib in our analysis. Median OS was 16.1 months. Overall response rate was 38.5%. Multivariate analysis for OS highlighted that HBsAg positive, NLR >3, and AST >38 were independently associated with poor prognosis in all models. Conversely, NAFLD/NASH-related etiology was independently associated with good prognosis. Median progression-free survival was 6.3 months. Multivariate analysis for progression-free survival revealed that NAFLD/NASH, BCLC, NLR, and AST were independent prognostic factors for progression-free survival. A proportion of 75.2% of patients suffered from at least one adverse effect during the study period. Multivariate analysis exhibited the appearance of decreased appetite grade ≥2 versus grade 0-1 as an independent prognostic factor for worse progression-free survival. 924 patients of 1,325 progressed during lenvatinib (69.7%), and 827 of them had a follow-up over 2 months from the beginning of second-line treatment. From first-line therapy, the longest median OS was obtained with the sequence lenvatinib and immunotherapy (47.0 months), followed by TACE (24.7 months), ramucirumab (21.2 months), sorafenib (15.7 months), regorafenib (12.7 months), and best supportive care (10.8 months). CONCLUSIONS: Our study confirms in a large and global population of patients with advanced HCC, not candidates for locoregional treatment the OS reported in the registration study and a high response rate with lenvatinib.Implications of the TACTICS Trial: Establishing the New Concept of Combination/Sequential Systemic Therapy and Transarterial Chemoembolization to Achieve Synergistic Effects.Masatoshi KudoLiver cancer 11 (6) 487 - 496 2022/12Hepatitis B Virus Treatment and Hepatocellular Carcinoma: Controversies and Approaches to Consensus.Soo Ki Kim; Takako Fujii; Soo Ryang Kim; Atsushi Nakai; Young-Suk Lim; Satoru Hagiwara; Masatoshi KudoLiver cancer 11 (6) 497 - 510 2022/12 BACKGROUND: Long-term therapy with nucleos(t)ide analogs (NAs) such as entecavir (ETV) and tenofovir disoproxil fumarate (TDF) favorably affects the incidence of hepatocellular carcinoma (HCC) on the basis of data from randomized or matched control studies. Recent data suggest a lower HCC incidence after 5 years of ETV or TDF therapy in chronic hepatitis B (CHB) patients, especially those with baseline cirrhosis. SUMMARY: Three controversial issues remain to be resolved regarding hepatitis B virus (HBV) treatment and HCC. (1) The efficacy of antiviral treatment for the prevention of HCC is not established. The guidelines of the American Association for the Study of Liver Diseases (AASLD), the Asian Pacific Association for the Study of the Liver (APASL), and the European Association for the Study of the Liver (EASL) for the management of HBV infection state that antiviral treatment of HBV with interferon and NAs prevents the development of HCC. Among experts in CHB treatment, however, there is disagreement on the HCC prevention effects of antiviral treatment. (2) The rationale for antiviral management in patients with high HBV DNA and normal levels of alanine aminotransferase is unclear. The AASLD, EASL, and APASL guidelines do not recommend antiviral treatment for immune-tolerant CHB patients, and the terms and methods of treating such patients remain to be clarified. (3) The efficacy of first-line treatment with NAs, including ETV, TDF, and tenofovir alafenamide fumarate (TAF), to prevent HCC in CHB patients remains unknown. Several studies have produced controversial results regarding the effects of NAs on the risk and prevention of HCC. In the present review, we discuss these 3 issues, citing recent studies and clinical management guidelines from major international associations. KEY MESSAGES: Suggested approaches for reaching a consensus including applying the propensity score matching method, performing randomized controlled studies, and performing clinical studies with larger numbers of subjects and longer follow-up.Treatment of portal hypertension in patients with HCC at the era of Baveno VII.Dominique Thabut; Masatoshi KudoJournal of hepatology 2022/11 Portal hypertension (PHT) and hepatocellular carcinoma (HCC) often coexist, and their association impairs the prognosis of patients with cirrhosis. The interplay between those two complications is of major importance to propose adequate therapeutic options to patients with HCC, as well as to prevent and manage complications of portal hypertension. Recommendations on management of PHT have been deeply revised in last Baveno VII conference, redefining screening and extending indications of prophylaxis. PHT can preclude locoregional therapies, and TIPS placement can be discussed in HCC patients. New systemic therapies of HCC can influence the level of PHT and favor bleeding. In all patients, PHT complications should be prevented and treated adequately, especially if they present with advanced HCC. Those specific aspects will be discussed in the present review, taking into account the very recent data in HCC field.Neutrophil-to-Lymphocyte and Platelet-to-Lymphocyte Ratios as Prognostic Biomarkers in Unresectable Hepatocellular Carcinoma Treated with Atezolizumab plus Bevacizumab.Yue Linda Wu; Claudia Angela Maria Fulgenzi; Antonio D'Alessio; Jaekyung Cheon; Naoshi Nishida; Anwaar Saeed; Brooke Wietharn; Antonella Cammarota; Tiziana Pressiani; Nicola Personeni; Matthias Pinter; Bernhard Scheiner; Lorenz Balcar; Yi-Hsiang Huang; Samuel Phen; Abdul Rafeh Naqash; Caterina Vivaldi; Francesca Salani; Gianluca Masi; Dominik Bettinger; Arndt Vogel; Martin Schönlein; Johann von Felden; Kornelius Schulze; Henning Wege; Peter R Galle; Masatoshi Kudo; Lorenza Rimassa; Amit G Singal; Rohini Sharma; Alessio Cortellini; Vincent E Gaillard; Hong Jae Chon; David J Pinato; Celina AngCancers 14 (23) 2022/11 Systemic inflammation is a key risk factor for hepatocellular carcinoma (HCC) progression and poor outcomes. Inflammatory markers such as the neutrophil-to-lymphocyte ratio (NLR) and platelet-to-lymphocyte ratio (PLR) may have prognostic value in HCC treated with standard of care atezolizumab plus bevacizumab (Atezo-Bev). We conducted a multicenter, international retrospective cohort study of patients with unresectable HCC treated with Atezo-Bev to assess the association of NLR and PLR with overall survival (OS), progression-free survival (PFS), and objective response rates. Patients with NLR ≥ 5 had a significantly shorter OS (9.38 vs. 16.79 months, p < 0.001) and PFS (4.90 vs. 7.58 months, p = 0.03) compared to patients with NLR < 5. NLR ≥ 5 was an independent prognosticator of worse OS (HR 2.01, 95% CI 1.22-3.56, p = 0.007) but not PFS. PLR ≥ 300 was also significantly associated with decreased OS (9.38 vs. 15.72 months, p = 0.007) and PFS (3.45 vs. 7.11 months, p = 0.04) compared to PLR < 300, but it was not an independent prognosticator of OS or PFS. NLR and PLR were not associated with objective response or disease control rates. NLR ≥ 5 independently prognosticated worse survival outcomes and is worthy of further study and validation.Atezolizumab plus bevacizumab versus lenvatinib for unresectable hepatocellular carcinoma: a large real-life worldwide population.Andrea Casadei-Gardini; Margherita Rimini; Toshifumi Tada; Goki Suda; Shigeo Shimose; Masatoshi Kudo; Jaekyung Cheon; Fabian Finkelmeier; Ho Yeong Lim; Lorenza Rimassa; José Presa; Gianluca Masi; Changhoon Yoo; Sara Lonardi; Francesco Tovoli; Takashi Kumada; Naoya Sakamoto; Hideki Iwamoto; Tomoko Aoki; Hong Jae Chon; Vera Himmelsbach; Tiziana Pressiani; Margarida Montes; Caterina Vivaldi; Caterina Soldà; Fabio Piscaglia; Atsushi Hiraoka; Takuya Sho; Takashi Niizeki; Naoshi Nishida; Christoph Steup; Massimo Iavarone; Giovanni Di Costanzo; Fabio Marra; Mario Scartozzi; Emiliano Tamburini; Giuseppe Cabibbo; Francesco Giuseppe Foschi; Marianna Silletta; Masashi Hirooka; Kazuya Kariyama; Joji Tani; Masanori Atsukawa; Koichi Takaguchi; Ei Itobayashi; Shinya Fukunishi; Kunihiko Tsuji; Toru Ishikawa; Kazuto Tajiri; Hironori Ochi; Satoshi Yasuda; Hidenori Toyoda; Chikara Ogawa; Takashi Nishimura; Takeshi Hatanaka; Satoru Kakizaki; Noritomo Shimada; Kazuhito Kawata; Fujimasa Tada; Hideko Ohama; Kazuhiro Nouso; Asahiro Morishita; Akemi Tsutsui; Takuya Nagano; Norio Itokawa; Tomomi Okubo; Taeang Arai; Michitaka Imai; Hisashi Kosaka; Atsushi Naganuma; Yohei Koizumi; Shinichiro Nakamura; Masaki Kaibori; Hiroko Iijima; Yoichi Hiasa; Valentina Burgio; Mara Persano; Angelo Della Corte; Francesca Ratti; Francesco De Cobelli; Luca Aldrighetti; Stefano Cascinu; Alessandro CucchettiEuropean journal of cancer (Oxford, England : 1990) 180 9 - 20 2022/11 BACKGROUND AND AIMS: Atezolizumab plus bevacizumab and lenvatinib have not been compared in a randomised controlled trial. We conducted a retrospective multi-centre study to compare the clinical efficacy and safety of lenvatinib and atezolizumab with bevacizumab as a first-line treatment for patients with unresectable HCC in the real-world scenario. METHODS: Clinical features of lenvatinib and atezolizumab plus bevacizumab patients were balanced through inverse probability of treatment weighting (IPTW) methodology, which weights patients' characteristics and measured outcomes of each patient in both treatment arms. Overall survival (OS) was the primary end-point. RESULTS: The analysis included 1341 patients who received lenvatinib, and 864 patients who received atezolizumab plus bevacizumab. After IPTW adjustment, atezolizumab plus bevacizumab did not show a survival advantage over lenvatinib HR 0.97 (p = 0.739). OS was prolonged by atezolizumab plus bevacizumab over lenvatinib in viral patients (HR: 0.76; p = 0.024). Conversely, OS was prolonged by lenvatinib in patients with non-alcoholic steatohepatitis/non-alcoholic fatty liver disease (HR: 1.88; p = 0.014). In the IPTW-adjusted population, atezolizumab plus bevacizumab provided better safety profile for most of the recorded adverse events. CONCLUSION: Our study did not identify any meaningful difference in OS between atezolizumab plus bevacizumab and lenvatinib. Although some hints are provided suggesting that patients with non-alcoholic steatohepatitis/non-alcoholic fatty liver disease might benefit more from lenvatinib therapy and patients with viral aetiology more from atezolizumab plus bevacizumab.【肝の超音波を知り尽くす-肝腫瘍の診断と治療支援】腫瘍診断 AIによる腫瘍診断西田 直生志; 工藤 正俊臨床消化器内科 (株)日本メディカルセンター 37 (13) 1653 - 1661 0911-601X 2022/11 <文献概要>超音波検査(US)は非侵襲的であり,頻用される画像検査法であるが,非専門領域の臓器の検査を行うことも多く,初学者ではしばしば診断に苦慮する場面が少なくない.また多くの症例を短時間で検査する場合,微小病変の見逃しのリスクが増える.今日までに多くのUSを支援する人工知能(AI)の報告があるが,USは反射波を利用した検査であるため,表示画像が体格や体位の影響を受け,またパラメーターの設定が複雑であるため,AIによる診断支援モデルの開発が困難であった.さらに肝臓領域のUSは正常構造物が複雑であり,多くの画像を学習させる必要があった.われわれは,日本超音波医学会の事業として肝腫瘤の検出と鑑別をBモード超音波で行うAIを開発している.本稿では,肝臓領域のUSを支援するAIの報告を概説し,またわれわれが開発している肝腫瘤診断支援AIについて紹介する.How should a therapeutic strategy be constructed for acute cholecystitis after self-expanding metal stent placement for malignant biliary obstruction?Mamoru Takenaka; Masatoshi KudoClinical endoscopy 55 (6) 757 - 759 2022/11Reproducible safety and efficacy of atezolizumab plus bevacizumab for HCC in clinical practice: Results of the AB-real study.Claudia Angela Maria Fulgenzi; Jaekyung Cheon; Antonio D'Alessio; Naoshi Nishida; Celina Ang; Thomas U Marron; Linda Wu; Anwaar Saeed; Brooke Wietharn; Antonella Cammarota; Tiziana Pressiani; Nicola Personeni; Matthias Pinter; Bernhard Scheiner; Lorenz Balcar; Andrea Napolitano; Yi-Hsiang Huang; Samuel Phen; Abdul Rafeh Naqash; Caterina Vivaldi; Francesca Salani; Gianluca Masi; Dominik Bettinger; Arndt Vogel; Martin Schönlein; Johann von Felden; Kornelius Schulze; Henning Wege; Peter R Galle; Masatoshi Kudo; Lorenza Rimassa; Amit G Singal; Rohini Sharma; Alessio Cortellini; Vincent E Gaillard; Hong Jae Chon; David James PinatoEuropean journal of cancer (Oxford, England : 1990) 175 204 - 213 2022/11 BACKGROUND: IMbrave150 has established the superiority of atezolizumab plus bevacizumab over sorafenib in patients with unresectable hepatocellular carcinoma (HCC). METHODS: We generated a prospectively maintained database including patients treated with atezolizumab plus bevacizumab for unresectable HCC across Europe, Asia and USA. Clinico-pathologic characteristics were assessed for their prognostic influence on overall survival (OS) and progression-free survival (PFS) in univariable and multivariate analyses. Overall response rate by RECIST v1.1 and treatment-related adverse events (TRAEs) per CTCAE v.5.0 were reported. RESULTS: Out of 433 patients, 296 Child-Pugh A and ECOG performance status01 patients received atezolizumab plus bevacizumab in first line and were included. Patients were mostly male (82.7%), cirrhotic (75%) with history of viral hepatitis (65.9%). Overall, 68.9% had Barcelona Clinic Liver Cancer C-stage HCC with portal vein tumour thrombosis (PVTT, 35%) and extrahepatic spread (EHS, 51.7%). After a median follow-up of 10.0 months (95% confidence interval (CI): 9.4-10.4), median OS and PFS were 15.7 (95% CI: 14.5-NE) and 6.9 months (95% CI: 6.1-8.3), respectively. In the response-evaluable patients (n = 273), overall response rate was 30.8%. Overall, 221 patients (74.6%) developed TRAEs, with 70 (23.6%) reporting grade 3 or higher TRAEs; 25 (8.4%) patients had bleeding events. OS was independently associated with baseline Albumin-bilirubin (ALBI) grade and PVTT. Shorter PFS was associated with AFP≥ 400 ng/ml, worse ALBI and presence of EHS. CONCLUSION: This global observational study confirms the reproducible safety and efficacy of atezolizumab plus bevacizumab in routine clinical practice. Within Child-Pugh-A criteria, the presence of PVTT and higher ALBI grade identify patients with poorer survival.High-fat diet aggravates experimental autoimmune pancreatitis through the activation of type I interferon signaling pathwaysIkue Sekai; Kosuke Minaga; Akane Hara; Yasuo Otsuka; Masayuki Kurimoto; Naoya Omaru; Natsuki Okai; Yasuhiro Masuta; Ryutaro Takada; Tomoe Yoshikawa; Ken Kamata; Masatoshi Kudo; Tomohiro WatanabeBiochemical and Biophysical Research Communications Elsevier BV 0006-291X 2022/11Cronkhite-Canada Syndrome Mimicking COVID-19-related Symptoms.Kayo Miyawaki; Takaya Komori; Yoshihiro Ishida; Yuri Sakaguchi; Hajime Honjo; Masatoshi Kudo; Atsushi OtsukaActa dermato-venereologica 2022/10Artificial intelligence models for the diagnosis and management of liver diseases.Naoshi Nishida; Masatoshi KudoUltrasonography (Seoul, Korea) 42 (1) 10 - 19 2022/10 With the development of more advanced methods for the diagnosis and treatment of diseases, the data required for medical care are becoming complex, and misinterpretation of information due to human error may result in serious consequences. Human error can be avoided with the support of artificial intelligence (AI). AI models trained with various medical data for diagnosis and management of liver diseases have been applied to hepatitis, fatty liver disease, liver cirrhosis, and liver cancer. Some of these models have been reported to outperform human experts in terms of performance, indicating their potential for supporting clinical practice given their high-speed output. This paper summarizes the recent advances in AI for liver disease and introduces the AI-aided diagnosis of liver tumors using B-mode ultrasonography.A case of HCC successfully treated with infliximab-steroid sequential therapy for small bowel perforation due to atezolizumab/bevacizumab combination therapy.Satoru Hagiwara; Yoriaki Komeda; Naoshi Nishida; Akihiro Yoshida; Masatoshi KudoCancer reports (Hoboken, N.J.) 5 (11) e1721  2022/10 BACKGROUND: Although reports of gastrointestinal perforation after immune-related adverse events (irAE) enteritis are rare, the anti- vascular endothelial growth factor (VEGF) effect of bevacizumab may be involved in gastrointestinal perforation. We report a rare case of gastrointestinal perforation in a patient with hepatocellular carcinoma treated with atezolizumab/bevacizumab combination therapy and infliximab before steroid use. CASE: A 72-year-old man, who received seven courses of atezolizumab/bevacizumab for hepatocellular carcinoma due to hepatitis B, was admitted to our department with idiopathic abdominal pain and diarrhea (grade 2 [G2]). Computed tomography (CT) and colonoscopy confirmed edema in the gastrointestinal tract. Perforation of the jejunum was observed in a CT performed on the third day and an emergency operation was performed. Intraoperative findings showed severe edema of the jejunum and leakage of feces into the abdominal cavity. The patient was diagnosed with irAE enteritis comprehensively with severe wall thickening on CT and colonoscopy, negative stool culture, and pathological findings of CD8-positive cells. Infliximab was administered before initiating steroids, to prevent reperforation. The enteritis improved by the 22nd day; however, CT performed on the 35th day of illness showed relapse of gastrointestinal wall thickening and G2 diarrhea symptoms; therefore, prednisolone (PSL) 60 mg/day was started on the 36th day of illness. After introducing PSL, enteritis did not reoccur, and the patient was discharged on the 63rd day of illness after admission. CONCLUSION: There are no reports of gastrointestinal perforation by atezolizumab/bevacizumab for hepatocellular carcinoma, and prior administration of infliximab. We therefore report the clinical course and management.Prognostic Factors for Overall Survival in Patients with HCV-Related HCC Undergoing Molecular Targeted Therapies: Beyond a Sustained Virological Response.Yasunori Minami; Tomoko Aoki; Hirokazu Chishina; Masahiro Takita; Satoru Hagiwara; Hiroshi Ida; Kazuomi Ueshima; Naoshi Nishida; Masatoshi KudoCancers 14 (19) 2022/10 BACKGROUND: The treatment of the hepatitis C virus (HCV) has reduced the risk of hepatocellular carcinoma (HCC)-related mortality. Many patients with advanced HCC have achieved longer survival through systemic chemotherapy. However, survivors of HCC may develop liver cancer during and after treatment. Therefore, the present study investigated prognostic factors for survival in patients with HCV-related HCC in the new era of molecular targeted therapy. METHODS: A total of 359 patients with HCV-related HCC treated with first-line chemotherapy were reviewed. A Cox proportional hazards model and Kaplan-Meier curve were used to identify prognostic factors associated with survival outcomes. RESULTS: The median follow-up duration was 16.0 months (range, 1.0-115.7) and the median duration of first-line systemic therapy was 3.73 months (range, 0.7-86.9). The achievement of a sustained virological response (SVR) (p  <  0.001), albumin-bilirubin (ALBI) grade II/III (p  <  0.001), Barcelona Clinic Liver Cancer (BCLC) stage C (p  =  0.005), extrahepatic spread (p < 0.001), baseline AFP (alpha-fetoprotein) level ≥ 90 (p = 0.038), baseline DCP (des-γ-carboxy prothrombin) level ≥ 500 (p < 0.001), and a fibrosis-4 (FIB-4) index ≥ 4 (p  =  0.003) were identified as prognostic factors for overall survival. CONCLUSIONS: The achievement of SVR was most strongly associated with overall survival. Other factors, such as the BCLC stage, extrahepatic spread, baseline tumor marker (AFP/DCP) levels, ALBI grade, and FIB-4 index need to be considered in the management of patients with HCV-related HCC.Activation of NOD1 and NOD2 in the development of liver injury and cancerNaoya Omaru; Tomohiro Watanabe; Ken Kamata; Kosuke Minaga; Masatoshi KudoFrontiers in Immunology Frontiers Media SA 13 1004439 - 1004439 2022/10 Hepatocytes and liver-resident antigen-presenting cells are exposed to microbe-associated molecular patterns (MAMPs) and microbial metabolites, which reach the liver from the gut via the portal vein. MAMPs induce innate immune responses via the activation of pattern recognition receptors (PRRs), such as toll-like receptors (TLRs), nucleotide-binding oligomerization domain 1 (NOD1), and NOD2. Such proinflammatory cytokine responses mediated by PRRs likely contribute to the development of chronic liver diseases and hepatocellular carcinoma (HCC), as shown by the fact that activation of TLRs and subsequent production of IL-6 and TNF-α is required for the generation of chronic fibroinflammatory responses and hepatocarcinogenesis. Similar to TLRs, NOD1 and NOD2 recognize MAMPs derived from the intestinal bacteria. The association between the activation of NOD1/NOD2 and chronic liver diseases is poorly understood. Given that NOD1 and NOD2 can regulate proinflammatory cytokine responses mediated by TLRs both positively and negatively, it is likely that sensing of MAMPs by NOD1 and NOD2 affects the development of chronic liver diseases, including HCC. Indeed, recent studies have highlighted the importance of NOD1 and NOD2 activation in chronic liver disorders. Here, we summarize the roles of NOD1 and NOD2 in hepatocarcinogenesis and liver injury.急激な経過を辿ったClostridium perfringens肝膿瘍・多臓器ガス壊疽の1例原 茜; 大塚 康生; 三長 孝輔; 渡邉 智裕; 工藤 正俊; 梶山 博日本消化器病学会近畿支部例会プログラム・抄録集 日本消化器病学会-近畿支部 117回 91 - 91 2022/10COVID-19ワクチン接種後のI型インターフェロン反応を特徴とする潰瘍性大腸炎再発の一例益田 康弘; 三長 孝輔; 渡邉 智裕; 工藤 正俊日本消化器病学会近畿支部例会プログラム・抄録集 日本消化器病学会-近畿支部 117回 102 - 102 2022/10空腸瀘胞性リンパ腫から形質転換した腹部Double Expressor Lymphoma(DEL)の1例高田 隆太郎; 三長 孝輔; 渡邉 智裕; 工藤 正俊日本消化器病学会近畿支部例会プログラム・抄録集 日本消化器病学会-近畿支部 117回 103 - 103 2022/10胆膵内視鏡施行時のプロポフォールを用いた鎮静における当院での取り組み 胆膵田中 秀和; 竹中 完; 高島 耕太; 福永 朋洋; 吉田 晃浩; 山崎 友裕; 大本 俊介; 三長 孝輔; 鎌田 研; 工藤 正俊Gastroenterological Endoscopy (一社)日本消化器内視鏡学会 64 (Suppl.2) 2188 - 2188 0387-1207 2022/10代謝性肝疾患の標準治療確立のためのエビデンス構築 NAFLD関連肝癌における背景肝のエピゲノム変異の蓄積萩原 智; 西田 直生志; 工藤 正俊肝臓 (一社)日本肝臓学会 63 (Suppl.3) A654 - A654 0451-4203 2022/10B型慢性肝炎患者におけるETVとTAFの効果・安全性の比較萩原 智; 西田 直生志; 工藤 正俊肝臓 (一社)日本肝臓学会 63 (Suppl.3) A768 - A768 0451-4203 2022/10発症早期から進行期までを観察しえたirAE胆管炎の1例萩原 智; 西田 直生志; 工藤 正俊肝臓 (一社)日本肝臓学会 63 (Suppl.3) A793 - A793 0451-4203 2022/10irAE腸炎による消化管穿孔に対してステロイド前のinfliximab先行投与により救命できた1例萩原 智; 西田 直生志; 工藤 正俊肝臓 (一社)日本肝臓学会 63 (Suppl.3) A794 - A794 0451-4203 2022/10Reevaluation of Makuuchi's criteria for resecting hepatocellular carcinoma: A Japanese nationwide survey.Osamu Aramaki; Tadatoshi Takayama; Yutaka Matsuyama; Shoji Kubo; Norihiro Kokudo; Masayuki Kurosaki; Takamichi Murakami; Shuichiro Shiina; Masatoshi Kudo; Michiie Sakamoto; Osamu Nakashima; Takumi Fukumoto; Hiroko Iijima; Susumu Eguchi; Yuji Soejima; Masatoshi MakuuchiHepatology research : the official journal of the Japan Society of Hepatology 53 (2) 127 - 134 2022/10 AIM: Although Makuuchi's criteria are widely used to determine the cut-off for safe liver resection, there have been few reports of concrete data supporting their validity. Here, we verified the utility of Makuuchi's criteria by comparing the operative mortality rates associated with liver resection between hepatocellular carcinoma (HCC) patients meeting or exceeding the criteria. METHODS: A database was built using data from 15 597 patients treated between 2000 and 2007 for whom values for all three variables included in Makuuchi's criteria for liver resection (clinical ascites, serum bilirubin, and indocyanine green clearance) were available. The patients were divided into those fulfilling (n = 12 175) or exceeding (n = 3422) the criteria. The postoperative mortality (death for any reason within 30 days) and long-term survival were compared between the two groups. RESULTS: The operative mortality rate was significantly lower in patients meeting the criteria than in those exceeding the criteria (1.07% vs. 2.01%, respectively; p Activation of nucleotide-binding oligomerization domain 2 by muramyl dipeptide negatively regulates Toll-like receptor 9-mediated colonic inflammation through the induction of deubiquitinating enzyme A expressionYasuhiro Masuta; Kosuke Minaga; Masayuki Kurimoto; Ikue Sekai; Akane Hara; Naoya Omaru; Natsuki Okai; Yasuo Otsuka; Ryutaro Takada; Tomoe Yoshikawa; Sho Masaki; Ken Kamata; Hajime Honjo; Yasuyuki Arai; Kouhei Yamashita; Masatoshi Kudo; Tomohiro WatanabeInternational Immunology Oxford University Press (OUP) 2022/09 Abstract Mutations in nucleotide-binding oligomerization domain 2 (NOD2) are associated with Crohn’s disease (CD). Although NOD2 activation contributes to the maintenance of intestinal homeostasis through the negative regulation of pro-inflammatory cytokine responses mediated by Toll-like receptors (TLRs), the effects of NOD2 activation on interferon (IFN)-α responses induced by TLR9 have been poorly defined. To explore the cross-talk between NOD2 and TLR9, human monocytes or dendritic cells (DCs) were stimulated with NOD2 and/or TLR9 ligands to measure IFN-α production. The severity of dextran sodium sulfate (DSS)-induced colitis was compared in mice treated with NOD2 and/or TLR9 ligands. Expression of IFN-α and IFN-stimulated genes (ISGs) was examined in the colonic mucosa of patients with inflammatory bowel disease (IBD). NOD2 activation reduced TLR9-induced IFN-α production by monocytes and DCs in a deubiquitinating enzyme A (DUBA)-dependent manner. Activation of DUBA induced by the co-stimulation of TLR9 and NOD2 inhibited Lys63-linked polyubiquitination of TRAF3 and suppressed TLR9-mediated IFN-α production. NOD2 activation in hematopoietic cells protected mice from TLR9-induced exacerbation of DSS-induced colitis by down-regulating IFN-α responses and up-regulating DUBA expression. Colonic mucosa of patients with active and remitted IBD phases was characterized by the enhanced and reduced expression of ISGs, respectively. Expression levels of IFN-α and IL-6 positively correlated in the active colonic mucosa of patients with ulcerative colitis and CD, whereas DUBA expression inversely correlated with that of IFN-α in patients with CD. Collectively, these data suggest that DUBA-dependent negative effect of NOD2 on TLR9-mediated IFN-α responses contributes to the maintenance of intestinal homeostasis.Overall survival and objective response in advanced unresectable hepatocellular carcinoma: A subanalysis of the REFLECT study.Masatoshi Kudo; Richard S Finn; Shukui Qin; Kwang-Hyub Han; Kenji Ikeda; Ann-Lii Cheng; Arndt Vogel; Francesco Tovoli; Kazuomi Ueshima; Hiroshi Aikata; Carlos López López; Marc Pracht; Zhiqiang Meng; Bruno Daniele; Joong-Won Park; Daniel Palmer; Toshiyuki Tamai; Kenichi Saito; Corina E Dutcus; Riccardo LencioniJournal of hepatology 78 (1) 133 - 141 2022/09 BACKGROUND & AIMS: Validated surrogate endpoints for overall survival (OS) are important for expediting the clinical study and drug-development processes. Herein, we aimed to validate objective response as an independent predictor of OS in individuals with unresectable hepatocellular carcinoma (HCC) receiving systemic anti-angiogenic therapy. METHODS: We investigated the association between objective response (investigator-assessed mRECIST, independent radiologic review [IRR] mRECIST and RECIST v1.1) and OS in REFLECT, a phase III study of lenvatinib vs. sorafenib. We conducted landmark analyses (Simon-Makuch) of OS by objective response at 2, 4, and 6 months after randomization. RESULTS: Median OS was 21.6 months (95% CI 18.6-24.5) for responders (investigator-assessed mRECIST) vs. 11.9 months (95% CI 10.7-12.8) for non-responders (hazard ratio [HR] 0.61; 95% CI 0.49-0.76; p Clinical predictor of urinary protein as adverse event associated with atezolizumab plus bevacizumab treatment for unresectable hepatocellular carcinoma.Atsushi Hiraoka; Takashi Kumada; Toshifumi Tada; Masashi Hirooka; Kazuya Kariyama; Joji Tani; Masanori Atsukawa; Koichi Takaguchi; Ei Itobayashi; Shinya Fukunishi; Kunihiko Tsuji; Toru Ishikawa; Kazuto Tajiri; Hironori Ochi; Satoshi Yasuda; Hidenori Toyoda; Chikara Ogawa; Takashi Nishimura; Takeshi Hatanaka; Satoru Kakizaki; Noritomo Shimada; Kazuhito Kawata; Atsushi Naganuma; Hisashi Kosaka; Hideko Ohama; Fujimasa Tada; Kazuhiro Nouso; Asahiro Morishita; Akemi Tsutsui; Takuya Nagano; Norio Itokawa; Tomomi Okubo; Taeang Arai; Michitaka Imai; Yohei Koizumi; Shinichiro Nakamura; Hiroko Iijima; Masaki Kaibori; Yoichi Hiasa; Masatoshi KudoOncology 100 (12) 645 - 654 2022/09 BACKGROUND/AIM: Adverse events (AEs) of urinary protein from monoclonal antibodies against vascular endothelial growth factor (VEGF) are factors that often inhibit systemic therapy for unresectable hepatocellular carcinoma (uHCC). This study aimed to elucidate risk factors of urinary protein in the early period (The usefulness of texture and color-enhanced imaging for balloon endoscopy-assisted ERCP for hepatic-jejunal anastomotic stenosis.Mamoru Takenaka; Shunsuke Omoto; Tomohiro Fukunaga; Masatoshi KudoGastrointestinal endoscopy 97 (1) 146 - 147 2022/09肝細胞癌の微小環境と再発予防における免疫チェックポイント阻害剤の効果西田 直生志; 上嶋 一臣; 工藤 正俊肝臓 (一社)日本肝臓学会 63 (Suppl.2) A465 - A465 0451-4203 2022/09腹部超音波動画からの肝腫瘍検出AIシステムの開発目加田 慶人; 西田 直生志; 工藤 正俊肝臓 (一社)日本肝臓学会 63 (Suppl.2) A467 - A467 0451-4203 2022/09進行肝癌の薬物治療の課題と展望 切除不能肝細胞癌におけるhyper progressive disease(HPD)の頻度と有効な後治療青木 智子; 西田 直生志; 工藤 正俊肝臓 (一社)日本肝臓学会 63 (Suppl.2) A537 - A537 0451-4203 2022/09肝細胞癌の微小環境と再発予防における免疫チェックポイント阻害剤の効果西田 直生志; 上嶋 一臣; 工藤 正俊肝臓 (一社)日本肝臓学会 63 (Suppl.2) A465 - A465 0451-4203 2022/09腹部超音波動画からの肝腫瘍検出AIシステムの開発目加田 慶人; 西田 直生志; 工藤 正俊肝臓 (一社)日本肝臓学会 63 (Suppl.2) A467 - A467 0451-4203 2022/09進行肝癌の薬物治療の課題と展望 切除不能肝細胞癌におけるhyper progressive disease(HPD)の頻度と有効な後治療青木 智子; 西田 直生志; 工藤 正俊肝臓 (一社)日本肝臓学会 63 (Suppl.2) A537 - A537 0451-4203 2022/09【進化する肝細胞癌の薬物療法:2022 update】免疫療法の基礎と臨床 肝細胞癌の新たな免疫クラス分類盛田 真弘; 西田 直生志; 工藤 正俊肝胆膵 (株)アークメディア 85 (3) 345 - 353 0389-4991 2022/09【進化する肝細胞癌の薬物療法:2022 update】免疫療法の基礎と臨床 Wnt/β-catenin変異を有するHCCの二面性(Inflamed and non-inflamed)青木 智子; 西田 直生志; 工藤 正俊肝胆膵 (株)アークメディア 85 (3) 369 - 374 0389-4991 2022/09Clinical Practice Guidelines for Hepatic Arterial Infusion Chemotherapy with a Port System Proposed by the Japanese Society of Interventional Radiology and Japanese Society of Implantable Port Assisted Treatment.Kazuomi Ueshima; Atsushi Komemushi; Takeshi Aramaki; Hideki Iwamoto; Shuntaro Obi; Yozo Sato; Toshihiro Tanaka; Kiyoshi Matsueda; Michihisa Moriguchi; Hiroya Saito; Miyuki Sone; Takuji Yamagami; Yoshitaka Inaba; Masatoshi Kudo; Yasuaki AraiLiver cancer 11 (5) 407 - 425 2022/09 Hepatocellular carcinoma is one of the leading causes of cancer-related death both in Japan and globally. In the advanced stage, hepatic arterial infusion chemotherapy (HAIC) is one of the most commonly used treatment options for liver cancer in Japan, and implantation of a catheter system (called a port system) in the body is a treatment method that has evolved mainly in Japan. The Guideline Committee of the Japanese Society of Interventional Radiology and the Japanese Society of Implantable Port Assisted Treatment jointly published clinical practice guidelines for HAIC with a port system to ensure its appropriate and safe performance in Japanese in 2018. We have written an updated English version of the guidelines with the aim of making this treatment widely known to experts globally. In this article, the evidence, method, indication, treatment regimen, and maintenance of the system are summarized.Endoscopic submucosal dissection with reinforcement using a laparoscopic approach for a duodenal cavernous hemangiomaSho Masaki; Yoriaki Komeda; Yasumasa Yoshioka; Mamoru Takenaka; Masatoshi KudoVideoGIE Elsevier BV 2468-4481 2022/09The "straighten pigtail" technique for selective replacement of a pigtail plastic stent.Mamoru Takenaka; Tomohiro Fukunaga; Akihiro Yoshida; Shunsuke Omoto; Masatoshi KudoEndoscopy 54 (S 02) E1083-E1085  2022/09Efficacy of an easy loop-forming guidewire in endoscopic transpapillary gallbladder drainage with gallstones impacted in the cystic duct.Mamoru Takenaka; Kae Fukunishi; Kota Takashima; Tomohiro Yamazaki; Masatoshi KudoEndoscopy 2022/09Hepatectomy versus sorafenib for advanced hepatocellular carcinoma with macroscopic portal vein tumor thrombus: a bi-institutional propensity-matched cohort study.Shohei Komatsu; Kazuomi Ueshima; Masahiro Kido; Kaori Kuramitsu; Daisuke Tsugawa; Hiroaki Yanagimoto; Hirochika Toyama; Yonson Ku; Masatoshi Kudo; Takumi FukumotoJournal of hepato-biliary-pancreatic sciences 30 (3) 303 - 314 2022/09 AIM: Sorafenib was previously considered a first-line treatment for hepatocellular carcinoma (HCC) patients with macroscopic portal vein tumor thrombus (PVTT). This case-matched analysis was performed to evaluate the best first-line treatment for HCC in patients with macroscopic PVTT. METHODS: The HCC patients with Vp2 (PVTT invaded into a second-order portal branch), Vp3 (first-order portal branch), and Vp4 (main trunk or contralateral portal vein) PVTT who underwent hepatectomy and those treated with sorafenib were included. Treatment results were compared between the two modalities for each PVTT category, and a propensity analysis was performed for patients with Vp3 and Vp4 (Vp3/4). RESULTS: The median survival times (MSTs) of patients with Vp2, Vp3, and Vp4 PVTT who underwent hepatectomy were 21.4, 13.6, and 14.9 months, respectively; the MSTs for those with Vp2, Vp3, and Vp4 PVTT who received sorafenib treatment were 6.9, 5.5, and 3.6 months, respectively, with a significant difference. In a propensity-matched cohort of patients with Vp3/4 PVTT (36 patients in each), the MST of patients who underwent hepatectomy (15.1 months) was significantly better than the patients treated with sorafenib (4.5 months). CONCLUSION: Hepatectomy can be associated with prolonged survival in HCC patients with macroscopic PVTT.Disruption of the intestinal barrier exacerbates experimental autoimmune pancreatitis by promoting the translocation of Staphylococcus sciuri into the pancreasTomoe Yoshikawa; Kosuke Minaga; Akane Hara; Ikue Sekai; Masayuki Kurimoto; Yasuhiro Masuta; Yasuo Otsuka; Ryutaro Takada; Ken Kamata; Ah-Mee Park; Shiki Takamura; Masatoshi Kudo; Tomohiro WatanabeInternational Immunology Oxford University Press (OUP) 2022/09 Abstract Autoimmune pancreatitis (AIP) and IgG4-related disease (IgG4-RD) are new disease entities characterized by enhanced IgG4 antibody responses and involvement of multiple organs, including the pancreas and salivary glands. Although the immunopathogenesis of AIP and IgG4-RD is poorly understood, we previously reported that intestinal dysbiosis mediates experimental AIP through the activation of IFN-α- and IL-33-producing plasmacytoid dendritic cells (pDCs). Because intestinal dysbiosis is linked to intestinal barrier dysfunction, we explored whether the latter affects the development of AIP and autoimmune sialadenitis in MRL/MpJ mice treated with repeated injections of polyinosinic–polycytidylic acid [poly (I:C)]. Epithelial barrier disruption was induced by the administration of dextran sodium sulfate (DSS) in the drinking water. Mice co-treated with poly (I:C) and DSS, but not those treated with either agent alone, developed severe AIP, but not autoimmune sialadenitis, which was accompanied by the increased accumulation of IFN-α- and IL-33-producing pDCs. Sequencing of 16S ribosomal RNA revealed that Staphylococcus sciuri translocation from the gut to the pancreas was preferentially observed in mice with severe AIP co-treated with DSS and poly (I:C). The degree of experimental AIP, but not of autoimmune sialadenitis, was greater in germ-free mice mono-colonized with S. sciuri and treated with poly (I:C) than in germ-free mice treated with poly (I:C) alone, which was accompanied by the increased accumulation of IFN-α- and IL-33-producing pDCs. Taken together, these data suggest that intestinal barrier dysfunction exacerbates AIP through the activation of pDCs and translocation of S. sciuri into the pancreas.Usefulness of the double-guidewire technique for endoscopic procedures in the field of biliary and pancreatic diseases.Mamoru Takenaka; Masatoshi KudoClinical endoscopy 2022/08 The double-guidewire method has been increasingly used in endoscopic procedures for biliary and pancreatic diseases in recent years, including endoscopic retrograde cholangiopancreatography and endoscopic ultrasonography-related procedures. In addition, double-lumen catheters with uneven distal and proximal lumen openings have been introduced, making it possible to easily create a double-guidewire situation, and the usefulness of the double-guidewire technique using uneven double-lumen cannulas has been widely reported. Although the advantages of using two guidewires depend on the particular situation and the appropriate use of the two guidewires, deepening the knowledge of the double-guidewire method will contribute greatly to troubleshooting in daily practice. In this review, the usefulness of the double-guidewire technique is discussed with respect to two main areas: selective insertion of guidewires and devices and biliary cannulation.Impact of older age in patients receiving atezolizumab and bevacizumab for hepatocellular carcinoma.Mathew Vithayathil; Antonio D'Alessio; Claudia Angela Maria Fulgenzi; Naoshi Nishida; Martin Schönlein; Johann von Felden; Kornelius Schulze; Henning Wege; Anwaar Saeed; Brooke Wietharn; Hannah Hildebrand; Linda Wu; Celina Ang; Thomas U Marron; Arndt Weinmann; Peter R Galle; Dominik Bettinger; Bertram Bengsch; Arndt Vogel; Lorenz Balcar; Bernhard Scheiner; Pei-Chang Lee; Yi-Hsiang Huang; Suneetha Amara; Mahvish Muzaffar; Abdul Rafeh Naqash; Antonella Cammarota; Nicola Personeni; Tiziana Pressiani; Matthias Pinter; Alessio Cortellini; Masatoshi Kudo; Lorenza Rimassa; David J Pinato; Rohini SharmaLiver international : official journal of the International Association for the Study of the Liver 42 (11) 2538 - 2547 2022/08 BACKGROUND AND AIMS: Combination atezolizumab/bevacizumab is the gold standard for first line-treatment of unresectable hepatocellular carcinoma (HCC). Our study investigated the efficacy and safety of combination therapy in older patients with HCC. METHODS: 191 consecutive patients from eight centres receiving atezolizumab and bevacizumab were included. Overall survival (OS), progression-free survival (PFS), overall response rate (ORR) and disease control rate (DCR) defined by RECIST v1.1 were measured in older (age≥65 years) and younger (ageVALIDATION OF THE EASY-TO-USE LENVATINIB PROGNOSTIC (LEP) INDEX TO PREDICT PROGNOSIS IN ADVANCED HEPATOCELLULAR CARCINOMA PATIENTS TREATED WITH LENVATINIB.Margherita Rimini; Wonseok Kang; Valentina Burgio; Mara Persano; Tamoko Aoki; Shigeo Shimose; Toshifumi Tada; Takashi Kumada; Takuya Sho; Eleonora Lai; Ciro Celsa; Claudia Campani; Matteo Tonnini; Emiliano Tamburini; Atsushi Hiraoka; Koichi Takaguchi; Naoshi Nishida; Hideki Iwamoto; Ei Itobayashi; Kunihiko Tsuji; Naoya Sakamoto; Toru Ishikawa; Hidenori Toyoda; Masatoshi Kudo; Takumi Kawaguchi; Takeshi Hatanaka; Kazugiro Nouso; Goki Suda; Giuseppe Cabibbo; Fabio Marra; Angelo Della Corte; Francesca Ratti; Federica Pedica; Francesco De Cobelli; Luca Aldrighetti; Mario Scartozzi; Stefano Cascinu; Andrea Casadei-GardiniHepatology research : the official journal of the Japan Society of Hepatology 2022/08 BACKGROUND: The identification of new prognostic factors able to stratify HCC patients candidate to first line therapy is an urgent. In the present work we validated the prognostic value of the LEP index. MATHERIALS AND METHODS: Data of Eastern and Western patients treated with lenvatinib as first-line for BCLC stage B or C HCC were recollected. LEP index was composed by three class of risk according with our previously study. The 'low risk'group includes patients with PNI >43.3 and with previous TACE. The 'medium risk' group includes patients with PNI >43.3 but without previous TACE and patients with PNI 急性膵炎後のWONに対する画像診断および経皮的ドレナージの役割上月 瞭平; 鶴崎 正勝; 浦瀬 篤史; 小寺 卓; 平山 歩; 石井 一成; 大本 俊介; 竹中 完; 工藤 正俊日本医学放射線学会秋季臨床大会抄録集 (公社)日本医学放射線学会 58回 S439 - S440 0048-0428 2022/08【肝疾患における画像診断の進歩-腹部超音波、CT、MRI-】人工知能を応用した超音波画像診断西田 直生志; 工藤 正俊消化器内科 (株)医学出版 4 (8) 36 - 43 2022/08 超音波検査は肝疾患スクリーニングの画像検査として頻用されるが、リアルタイムの判断が必要であり、初学者では診断に迷う状況が起こりうる。また、短時間で多くの検査を行うことが多く、見逃しなどのヒューマンエラーのリスクがある。近年、医用AIの開発が進められており、AIによるヒューマンエラーの回避が期待されている。超音波診断領域では、AIによる肝線維化や脂肪肝などのびまん性肝疾患のステージング、肝腫瘤の検出と鑑別支援に関する報告が多く、さらに肝細胞癌の超音波画像による治療後の予後推定など、疾患マネージメントに関わる報告も散見される。一方、超音波検査では、音響的に異なる境界面から戻ってくる反射波を基に生体構造を画像化するため画像の視認性が悪い状況があり、また機種の違いによる画像の多様性がAI学習の際に問題となる。さらに、医用画像AIの社会実装には、AIのブラックボックスとしての性質、学習に伴う性能変化、責任の所在に関する考え方など、多くの課題が残されている。本稿では、肝疾患領域の超音波検査に関連するAIの開発動向を概説し、AIによる超音波診断支援の課題について言及する。(著者抄録)【肝疾患における画像診断の進歩-腹部超音波、CT、MRI-】人工知能を応用した超音波画像診断西田 直生志; 工藤 正俊消化器内科 (株)医学出版 4 (8) 36 - 43 2022/08 超音波検査は肝疾患スクリーニングの画像検査として頻用されるが、リアルタイムの判断が必要であり、初学者では診断に迷う状況が起こりうる。また、短時間で多くの検査を行うことが多く、見逃しなどのヒューマンエラーのリスクがある。近年、医用AIの開発が進められており、AIによるヒューマンエラーの回避が期待されている。超音波診断領域では、AIによる肝線維化や脂肪肝などのびまん性肝疾患のステージング、肝腫瘤の検出と鑑別支援に関する報告が多く、さらに肝細胞癌の超音波画像による治療後の予後推定など、疾患マネージメントに関わる報告も散見される。一方、超音波検査では、音響的に異なる境界面から戻ってくる反射波を基に生体構造を画像化するため画像の視認性が悪い状況があり、また機種の違いによる画像の多様性がAI学習の際に問題となる。さらに、医用画像AIの社会実装には、AIのブラックボックスとしての性質、学習に伴う性能変化、責任の所在に関する考え方など、多くの課題が残されている。本稿では、肝疾患領域の超音波検査に関連するAIの開発動向を概説し、AIによる超音波診断支援の課題について言及する。(著者抄録)【肝胆膵疾患とサルコペニア】胆道・膵疾患 急性膵炎とサルコペニア竹中 完; 田中 隆光; 山崎 友祐; 大本 俊介; 三長 孝輔; 鎌田 研; 工藤 正俊肝胆膵 (株)アークメディア 85 (2) 229 - 238 0389-4991 2022/08Durvalumab plus tremelimumab in unresectable hepatocellular carcinoma.Masatoshi KudoHepatobiliary surgery and nutrition 11 (4) 592 - 596 2022/08Current status of primary liver cancer and decompensated cirrhosis in Japan: launch of a nationwide registry for advanced liver diseases (REAL).Kazuya Okushin; Ryosuke Tateishi; Arata Takahashi; Koji Uchino; Ryo Nakagomi; Takuma Nakatsuka; Tatsuya Minami; Masaya Sato; Mitsuhiro Fujishiro; Kiyoshi Hasegawa; Yuichiro Eguchi; Tatsuya Kanto; Shoji Kubo; Hitoshi Yoshiji; Hiroaki Miyata; Namiki Izumi; Masatoshi Kudo; Kazuhiko KoikeJournal of gastroenterology 57 (8) 587 - 597 2022/08 BACKGROUND: We developed a nationwide database that stores data of patients with primary liver cancer (PLC) and decompensated cirrhosis (DC) on an admission basis. METHODS: A database was constructed using the National Clinical Database, a nationwide registry platform for various diseases in Japan. Mutual data exchange was possible with the Nationwide Follow-up Survey of Primary Liver Cancer in Japan by the Liver Cancer Study Group of Japan. The stored data on the admission of patients with PLC, DC, or both, included treatment details as well as patient characteristics. RESULTS: A total of 37,705 admissions (29,489 PLC, 10,077 DC, and 1862 for both) in 21,376 patients from 224 hospitals were analyzed. The proportions of patients with hepatitis B, hepatitis C, and non-viral etiology were 11.9%, 36.2%, and 42.6%, respectively, in PLC, and 7.5%, 23.8%, and 55.0%, respectively, in DC. The mean ages (± standard deviation) on admission with PLC and DC were 73 ± 10 and 68 ± 13 years, respectively. The Barcelona Clinic Liver Cancer (BCLC) stage for PLC was 0, A, B, C, and D in 22.0%, 17.1%, 29.6%, 15.1%, and 5.1%, respectively. Treatment modalities for PLC were resection, ablation, transarterial chemoembolization, and systemic therapy in 18.4%, 22.8%, 33.7%, and 11.4%, respectively. A vasopressin receptor V2 antagonist was used in 38.2% in addition to conventionally used loop diuretics and aldosterone antagonists for DC. CONCLUSIONS: The distribution of treatment options for PLC on admission differed from that of the initial treatment. Newly introduced drugs are widely used in patients with DC.Glasgow prognostic score predicts survival in patients with unresectable hepatocellular carcinoma treated with lenvatinib: a multicenter analysis.Toshifumi Tada; Takashi Kumada; Atsushi Hiraoka; Masashi Hirooka; Kazuya Kariyama; Joji Tani; Masanori Atsukawa; Koichi Takaguchi; Ei Itobayashi; Shinya Fukunishi; Kunihiko Tsuji; Toru Ishikawa; Kazuto Tajiri; Hironori Ochi; Satoshi Yasuda; Hidenori Toyoda; Takeshi Hatanaka; Satoru Kakizaki; Noritomo Shimada; Kazuhito Kawata; Takaaki Tanaka; Hideko Ohama; Kazuhiro Nouso; Asahiro Morishita; Akemi Tsutsui; Takuya Nagano; Norio Itokawa; Tomomi Okubo; Taeang Arai; Michitaka Imai; Atsushi Naganuma; Tomoko Aoki; Yohei Koizumi; Shinichiro Nakamura; Kouji Joko; Yoichi Hiasa; Masatoshi KudoEuropean journal of gastroenterology & hepatology 34 (8) 857 - 864 2022/08 OBJECTIVE: The use of Glasgow prognostic score (GPS), calculated using the serum C-reactive protein and albumin levels, to predict the outcomes of patients with unresectable hepatocellular carcinoma (HCC) treated with lenvatinib was investigated in this study. METHODS: A total of 508 patients with Child-Pugh class A HCC treated with lenvatinib were included in this study. RESULTS: The median overall and progression-free survivals were 20.4 months [95% confidence interval (CI), 17.7-23.2 months] and 7.5 months (95% CI, 6.8-8.5 months), respectively. The median overall survivals of patients with a GPS of 0, 1, and 2 were 28.5, 16.0, and 9.1 months, respectively (P Pancreatic colonization of fungi in the development of severe acute pancreatitisYasuo Otsuka; Ken Kamata; Kosuke Minaga; Tomohiro Watanabe; Masatoshi KudoFrontiers in Cellular and Infection Microbiology Frontiers Media SA 12 940532 - 940532 2022/07 Acute pancreatitis is a common emergent disorder, a significant population of which develops the life-threatening condition, called severe acute pancreatitis (SAP). It is generally accepted that bacterial infection is associated with the development and persistence of SAP. In addition to bacterial infection, recent clinical studies disclosed a high incidence of fungal infection in patients with SAP. Moreover, SAP patients with fungal infection exhibit a higher mortality rate than those without infection. Although these clinical studies support pathogenic roles played by fungal infection in SAP, beneficial effects of prophylactic anti-fungal therapy on SAP have not been proved. Here we summarize recent clinical findings as to the relationship between fungal infection and the development of SAP. In addition, we discuss molecular mechanisms accounting for the development of SAP in the presence of fungal infection.Progression from early to advanced stage of immune-related cholangitis.Satoru Hagiwara; Takeshi Yoshida; Naoshi Nishida; Hiroshi Ida; Kazuomi Ueshima; Yasunori Minami; Masahiro Takita; Tomoko Aoki; Masahiro Morita; Hirokazu Cishina; Yoriaki Komeda; Akihiro Yoshida; Hidetoshi Hayashi; Kazuhiko Nakagawa; Masatoshi KudoHepatology research : the official journal of the Japan Society of Hepatology 52 (10) 888 - 892 2022/07 AIM: We report a rare case of immune-related cholangitis in which the natural course could be demonstrated. CASE PRESENTATION: Eight courses of pembrolizumab maintenance therapy were given as first-line treatment for squamous cell lung cancer; however, the patient was subsequently hospitalized due to a rapid increase in hepatobiliary enzymes. On endoscopic ultrasound, the common bile duct was dilated to 11 mm, and the wall, throughout its length from the papilla, was thickened. Endoscopic retrograde cholangiopancreatography showed no obvious stenosis in the lower bile duct; however, a parapapillary diverticulum was found, and papillary incision and bile duct plastic stent insertion were carried out. However, the liver disorder did not improve and overt jaundice appeared subsequently; therefore, an immune-related cholangitis was suspected, and prednisolone (PSL) 35 mg/day was introduced from day 59 of admission. Following PSL initiation, a decrease in serum bilirubin level was observed; however, significant decrease was not observed in alkaline phosphatase. Given the history of recurrent infectious cholangitis, magnetic resonance cholangiopancreatography was carried out on day 70 of admission. The intrahepatic bile duct showed stenosis and dilated findings, which was considered to be a factor for repeated infectious cholangitis. CONCLUSION: No previous case reports have described the changes and progression in bile duct images in immune-related adverse events. Therefore, this case is noteworthy for considering the progression of immune-related cholangitis.Alterations of autophagic and innate immune responses by the Crohn’s disease-associated ATG16L1 mutationNatsuki Okai; Tomohiro Watanabe; Kosuke Minaga; Ken Kamata; Hajime Honjo; Masatoshi KudoWorld Journal of Gastroenterology Baishideng Publishing Group Inc. 28 (26) 3063 - 3070 1007-9327 2022/07 Crohn's disease (CD) is driven by the loss of tolerance to intestinal microbiota and excessive production of pro-inflammatory cytokines. These pro-inflammatory cytokines are produced by macrophages and dendritic cells (DCs) upon sensing the intestinal microbiota by the pattern recognition receptors (PRRs). Impaired activation of PRR-mediated signaling pathways is associated with chronic gastrointestinal inflammation, as shown by the fact that loss-of-function mutations in the nucleotide-binding oligomerization domain 2 gene increase the risk of CD development. Autophagy is an intracellular degradation process, during which cytoplasmic nutrients and intracellular pathogens are digested. Given that impaired reaction to intestinal microbiota alters signaling pathways mediated by PRRs, it is likely that dysfunction of the autophagic machinery is involved in the development of CD. Indeed, the loss-of-function mutation T300A in the autophagy related 16 like 1 (ATG16L1) protein, a critical regulator of autophagy, increases susceptibility to CD. Recent studies have provided evidence that ATG16L1 is involved not only in autophagy, but also in PRR-mediated signaling pathways. ATG16L1 negatively regulates pro-inflammatory cytokine responses of macrophages and DCs after these cells sense the intestinal microbiota by PRRs. Here, we discuss the molecular mechanisms underlying the development of CD in the T300A ATG16L1 mutation by focusing on PRR-mediated signaling pathways.Pancreatic neuroendocrine carcinoma with unique morphological features mimicking intraductal papillary mucinous carcinoma: A case reportHidekazu Tanaka; Kosuke Minaga; Yasuo Otsuka; Yasuhiro Masuta; Ken Kamata; Kentaro Yamao; Mamoru Takenaka; Tomoko Hyodo; Masatomo Kimura; Tomohiro Watanabe; Masatoshi KudoFrontiers in Medicine Frontiers Media SA 9 2022/07 Background Pancreatic neuroendocrine carcinoma (PanNEC) is a rare disease entity with rapid progression and poor prognosis. Here, we report a PanNEC case with unique morphological features mimicking intraductal papillary mucinous carcinoma. Case presentation A 69-year-old Japanese man was referred to our hospital for further evaluation of weight loss and deterioration of diabetes mellitus. Contrast-enhanced computed tomography showed a solid and cystic mass with hypo-enhancement at the tail of the pancreas. The main pancreatic duct (MPD) was diffusely dilated without obstruction, accompanied by marked parenchymal atrophy. Multiple peritoneal and omental nodules were observed, suggesting tumor dissemination. Endoscopic retrograde cholangiopancreatography revealed that the mass correlated with the dilated MPD. During pancreatography, a large amount of mucus was extruded from the pancreatic orifice of the ampulla. Based on these imaging findings, intraductal papillary mucinous carcinoma was suspected. Per-oral pancreatoscopy (POPS)-guided tumor biopsies were conducted for the lesion's solid components. Histopathological examination of the biopsied material confirmed small-cell-type PanNEC with a Ki-67 labeling index of 90%. Due to his condition's rapid decline, the patient was given the best supportive care and died 28 days after diagnosis. Conclusion Although rare, PanNEC, which correlates with the MPD and is accompanied by marked dilation of the MPD, does exist as one phenotype. In such cases, POPS-guided biopsy could be a useful diagnostic modality.Bispectral index-guided propofol sedation during endoscopic ultrasonography.Ayana Okamoto; Ken Kamata; Takeshi Miyata; Tomoe Yoshikawa; Rei Ishikawa; Tomohiro Yamazaki; Atsushi Nakai; Shunsuke Omoto; Kosuke Minaga; Kentaro Yamao; Mamoru Takenaka; Yasutaka Chiba; Toshiharu Sakurai; Naoshi Nishida; Masayuki Kitano; Masatoshi KudoClinical endoscopy 55 (4) 558 - 563 2022/07 Background/Aims: Bispectral index (BIS) monitors process and display electroencephalographic data and are used to assess the depth of anesthesia. This study retrospectively evaluated the usefulness of BIS monitoring during endoscopic ultrasonography (EUS). Methods: This study included 725 consecutive patients who underwent EUS under sedation with propofol. BIS monitoring was used in 364 patients and was not used in 361. The following parameters were evaluated: (1) median dose of propofol; (2) respiratory and circulatory depression; (3) occurrence of body movements; (4) awakening score >8 at the time; and (5) awakening score 2 hours after leaving the endoscopy room. Results: The BIS group received a significantly lower median dose of propofol than the non-BIS group (159.2 mg vs. 167.5 mg; p=0.015) in all age groups. For patients aged ≥75 years, the reduction in heart rate was significantly lower in the BIS group than in the non-BIS group (1.2% vs. 9.1%; p=0.023). Moreover, the occurrence of body movements was markedly lower in the BIS group than in the non-BIS group (8.5% vs. 39.4%; pUtility of contrast-enhanced harmonic EUS for diagnosis of portal vein invasion by pancreatic cancer.Atsushi Nakai; Ken Kamata; Tomoko Hyodo; Takaaki Chikugo; Akane Hara; Yasuo Otsuka; Hidekazu Tanaka; Tomoe Yoshikawa; Rei Ishikawa; Ayana Okamoto; Tomohiro Yamazaki; Shunsuke Omoto; Kosuke Minaga; Kentaro Yamao; Mamoru Takenaka; Yasutaka Chiba; Tomohiro Watanabe; Ippei Matsumoto; Yoshifumi Takeyama; Masatoshi KudoEndoscopic ultrasound 11 (5) 401 - 406 2022/07 Background: The value of contrast-enhanced harmonic EUS (CH-EUS) for diagnosis of portal vein invasion in patients with pancreatic cancer was evaluated. Patients and Methods: This single-center, retrospective study included consecutive patients with pancreatic cancer who underwent both surgical resection after preoperative EUS, CH-EUS, and contrast-enhanced computed tomography (CE-CT) examinations between April 2015 and August 2017. CH-EUS evaluation was performed during the late phase. Portal vein invasion on EUS and CH-EUS was defined as no continuity in the line of the vessel wall. Definition of portal vein invasion on CE-CT was based on the Loyer's criteria. The accuracy of three modalities for diagnosis of invasion into the portal vein was compared using the McNemar's test. Results: Eighty-eight patients (mean age: 71.0 years, ratio of male to female: 48:40) were eligible. Postoperative pathological results were as follows: seven cases of portal vein invasion; 81 cases without. Diagnostic accuracy of EUS, CH-EUS, and CE-CT for diagnosing invasion into the portal vein was 72.7%, 93.2%, and 81.8%, respectively. The differences between CH-EUS and CE-CT (P = 0.0094) and CH-EUS and EUS (P = 0.0022) were significant. EUS and CE-CT were comparable. Conclusion: CH-EUS is useful for diagnosis of portal vein invasion by pancreatic cancer.アノテーションが不完全な教師データを用いた腹部超音波画像からの肝腫瘍検出池田 裕亮; 道満 恵介; 目加田 慶人; 西田 直生志; 工藤 正俊日本医用画像工学会大会予稿集 (一社)日本医用画像工学会 41回 192 - 193 2022/07 腹部超音波検査の支援を目的として,機械学習を用いた超音波画像からの肝腫瘍検出に関する研究がおこなわれている.中島らの研究ではYOLOv3を用いて検出を行っていた.しかし,学習データには画像1枚に1つの腫瘍のアノテーションしか付与されていなかった.転移性肝がんは1枚の超音波画像に複数箇所写っている場合があり,アノテーションのない腫瘍は学習に悪影響を与えている.そのため,アノテーションの不完全性を考慮した肝腫瘍検出手法が必要であった.これに対して本研究では,YOLOv3の損失関数に腫瘍の種類に応じた重みを加えることで,アノテーションがない腫瘍に対する検出および検出精度の改善を試みた.実験の結果,転移性肝がんに対する再現率の向上が確認された.また,適合率は低下したものの,転移性肝がんにおいてはアノテーションが入力されていない腫瘍部分を検出できていることが確認でき,提案手法の有効性が示唆された.(著者抄録)アノテーションが不完全な教師データを用いた腹部超音波画像からの肝腫瘍検出池田 裕亮; 道満 恵介; 目加田 慶人; 西田 直生志; 工藤 正俊日本医用画像工学会大会予稿集 (一社)日本医用画像工学会 41回 192 - 193 2022/07 腹部超音波検査の支援を目的として,機械学習を用いた超音波画像からの肝腫瘍検出に関する研究がおこなわれている.中島らの研究ではYOLOv3を用いて検出を行っていた.しかし,学習データには画像1枚に1つの腫瘍のアノテーションしか付与されていなかった.転移性肝がんは1枚の超音波画像に複数箇所写っている場合があり,アノテーションのない腫瘍は学習に悪影響を与えている.そのため,アノテーションの不完全性を考慮した肝腫瘍検出手法が必要であった.これに対して本研究では,YOLOv3の損失関数に腫瘍の種類に応じた重みを加えることで,アノテーションがない腫瘍に対する検出および検出精度の改善を試みた.実験の結果,転移性肝がんに対する再現率の向上が確認された.また,適合率は低下したものの,転移性肝がんにおいてはアノテーションが入力されていない腫瘍部分を検出できていることが確認でき,提案手法の有効性が示唆された.(著者抄録)【胆道・膵疾患を診る-早期診断・早期治療のために】Overview 急性膵炎・急性胆管炎update竹中 完; 大本 俊介; 三長 孝輔; 鎌田 研; 工藤 正俊内科 (株)南江堂 130 (1) 13 - 19 0022-1961 2022/07 <文献概要>▼急性膵炎と診断した後はまず重症化のリスクを判断し,重症化した場合,もしくは重症化が高率に予想される場合には適切な施設への搬送と適切な治療をシステマティックに行うことが求められ,「Pancreatitis Bundles 2021」の積極的活用が望まれる.▼「Pancreatitis Bundles 2021」で改訂された内容として,軽症急性膵炎には予防的抗菌薬は使用しないこと,経腸栄養は経胃でも可であること,感染性膵壊死に対するステップアップ・アプローチ,などがあげられる.▼急性膵炎診療における地域連携ネットワークの重要性は「急性膵炎診療ガイドライン2021」でも強調されており,各地域それぞれのネットワークづくりが求められる.▼急性胆管炎の診断には長らくCharcot 3徴(発熱・黄疸・腹痛)が用いられてきたが,実際にはCharcot 3徴をきたさない急性胆管炎が多く経験され,「急性胆管炎・胆嚢炎診療ガイドライン2018」では急性胆管炎の診断は「全身の炎症」「胆汁うっ滞」「胆管病変」の3因子を用いて行われている.▼急性膵炎・胆管炎,いずれの病態も重症度評価は頻回に行い,当初は軽症の症例でも重症化する可能性を常に念頭に置き,重症化のタイミングを逃さないようにすることが肝要である.【胆道・膵疾患を診る-早期診断・早期治療のために】ここまで進んだ膵がん早期診断 早期膵がんを疑う画像所見とは?山雄 健太郎; 竹中 完; 鎌田 研; 三長 孝輔; 工藤 正俊内科 (株)南江堂 130 (1) 69 - 71 0022-1961 2022/07 <文献概要>▼膵がんは予後不良ながん腫であり,その改善のためには早期診断・早期治療が必須である.▼早期膵がんを疑う画像所見としては「尾側膵管拡張を伴う限局性主膵管狭窄」がその代表である.しかしながらこの所見は慢性膵炎などの良性膵疾患でも認められる.▼近年,早期膵がん症例のCTにおける「主膵管狭窄部周囲の限局性膵実質萎縮」が良悪性診断に有用との報告が散見される.この所見を認めた場合は早期膵がんの可能性を考慮し,胆膵専門医へ紹介することが推奨される.Liver Cancer Study Group of Japan Clinical Practice Guidelines for Intrahepatic Cholangiocarcinoma.Shoji Kubo; Hiroji Shinkawa; Yoshinari Asaoka; Tatsuya Ioka; Hiroshi Igaki; Namiki Izumi; Takao Itoi; Michiaki Unno; Masayuki Ohtsuka; Takuji Okusaka; Masumi Kadoya; Masatoshi Kudo; Takashi Kumada; Norihiro Kokudo; Michiie Sakamoto; Yoshihiro Sakamoto; Hideyuki Sakurai; Tadatoshi Takayama; Osamu Nakashima; Yasushi Nagata; Etsuro Hatano; Kenichi Harada; Takamichi Murakami; Masakazu YamamotoLiver cancer 11 (4) 290 - 314 2022/07 This paper presents the first version of clinical practice guidelines for intrahepatic cholangiocarcinoma (ICC) established by the Liver Cancer Study Group of Japan. These guidelines consist of 1 treatment algorithm, 5 background statements, 16 clinical questions, and 1 clinical topic, including etiology, staging, pathology, diagnosis, and treatments. Globally, a high incidence of ICC has been reported in East and Southeast Asian countries, and the incidence has been gradually increasing in Japan and also in Western countries. Reported risk factors for ICC include cirrhosis, hepatitis B/C, alcohol consumption, diabetes, obesity, smoking, nonalcoholic steatohepatitis, and liver fluke infestation, as well as biliary diseases, such as primary sclerosing cholangitis, hepatolithiasis, congenital cholangiectasis, and Caroli disease. Chemical risk factors include thorium-232, 1,2-dichloropropane, and dichloromethane. CA19-9 and CEA are recommended as tumor markers for early detection and diagnostic of ICC. Abdominal ultrasonography, CT, and MRI are effective imaging modalities for diagnosing ICC. If bile duct invasion is suspected, imaging modalities for examining the bile ducts may be useful. In unresectable cases, tumor biopsy should be considered when deemed necessary for the differential diagnosis and drug therapy selection. The mainstay of treatment for patients with Child-Pugh class A or B liver function is surgical resection and drug therapy. If the patient has no regional lymph node metastasis (LNM) and has a single tumor, resection is the treatment of choice. If both regional LNM and multiple tumors are present, drug therapy is the first treatment of choice. If the patient has either regional LNM or multiple tumors, resection or drug therapy is selected, depending on the extent of metastasis or the number of tumors. If distant metastasis is present, drug therapy is the treatment of choice. Percutaneous ablation therapy may be considered for patients who are ineligible for surgical resection or drug therapy due to decreased hepatic functional reserve or comorbidities. For unresectable ICC without extrahepatic metastasis, stereotactic radiotherapy (tumor size ≤5 cm) or particle radiotherapy (no size restriction) may be considered. ICC is generally not indicated for liver transplantation, and palliative care is recommended for patients with Child-Pugh class C liver function.Selection of Systemic Treatment Regimen for Unresectable Hepatocellular Carcinoma: Does Etiology Matter?Masatoshi KudoLiver cancer 11 (4) 283 - 289 2022/07Final Results of TACTICS: A Randomized, Prospective Trial Comparing Transarterial Chemoembolization Plus Sorafenib to Transarterial Chemoembolization Alone in Patients with Unresectable Hepatocellular Carcinoma.Masatoshi Kudo; Kazuomi Ueshima; Masafumi Ikeda; Takuji Torimura; Nobukazu Tanabe; Hiroshi Aikata; Namiki Izumi; Takahiro Yamasaki; Shunsuke Nojiri; Keisuke Hino; Hidetaka Tsumura; Teiji Kuzuya; Norio Isoda; Michihisa Moriguchi; Hajime Aino; Akio Ido; Naoto Kawabe; Kazuhiko Nakao; Yoshiyuki Wada; Sadahisa Ogasawara; Kenichi Yoshimura; Takuji Okusaka; Junji Furuse; Norihiro Kokudo; Kiwamu Okita; Philip James Johnson; Yasuaki AraiLiver cancer 11 (4) 354 - 367 2022/07 Introduction: Several clinical trials comparing the efficacy and safety of transarterial chemoembolization (TACE) plus molecular-targeted agents versus TACE alone revealed no clinical benefits in progression-free survival (PFS) or overall survival (OS). Here, we report the final OS analysis from the TACTICS trial, which previously demonstrated significant improvement in PFS with TACE plus sorafenib in patients with unresectable hepatocellular carcinoma (HCC) (NCT01217034). Methods: Patients with unresectable HCC were randomized to a TACE plus sorafenib group (N = 80) or a TACE alone group (N = 76). Patients in the combination treatment group received sorafenib 400 mg once daily for 2-3 weeks before TACE, followed by 800 mg once daily during on-demand conventional TACE sessions until time to untreatable progression. In this trial, TACE-specific PFS was used. TACE-specific PFS is defined as the time from randomization to progressive disease (PD) or death from any cause, and PD was defined as untreatable progression, caused by the inability of a patient to further receive or benefit from TACE for reasons that include intrahepatic tumor progression (25% increase vs. baseline) according to response evaluation criteria in cancer of the liver, the detection of extrahepatic spread, vascular invasion, or transient deterioration of liver function to Child-Pugh C after TACE. Results: At the cut-off date of July 31, 2020, 131 OS events were observed. The median OS was 36.2 months with TACE plus sorafenib and 30.8 months with TACE alone (hazard ratio [HR] = 0.861; 95% confidence interval [CI], 0.607-1.223; p = 0.40, ΔOS, 5.4 months). The updated PFS was 22.8 months with TACE plus sorafenib and 13.5 months with TACE alone (HR = 0.661; 95% CI, 0.466-0.938; p = 0.02). Post-trial treatments with active procedures/agents were received by 47 (58.8%) patients in the TACE plus sorafenib group and 58 (76.3%) in the TACE alone group (p = 0.01). In post hoc analysis, PFS and OS benefit were shown in HCC patients with tumor burden beyond up-to-7 criteria. Conclusions: In TACTICS trial, TACE plus sorafenib did not show significant OS benefit over TACE alone; however, clinical meaningful OS prolongation and significantly improved PFS was observed. Thus, the TACE plus sorafenib can be considered a choice of treatment in intermediate-stage HCC, especially in patients with high tumor burden. Trial Registration: NCT01217034.Does first-line treatment have prognostic impact for unresectable HCC?-Atezolizumab plus bevacizumab versus lenvatinib.Atsushi Hiraoka; Takashi Kumada; Toshifumi Tada; Masashi Hirooka; Kazuya Kariyama; Joji Tani; Masanori Atsukawa; Koichi Takaguchi; Ei Itobayashi; Shinya Fukunishi; Kunihiko Tsuji; Toru Ishikawa; Kazuto Tajiri; Hironori Ochi; Satoshi Yasuda; Hidenori Toyoda; Chikara Ogawa; Takashi Nishimura; Takeshi Hatanaka; Satoru Kakizaki; Noritomo Shimada; Kazuhito Kawata; Atsushi Naganuma; Hisashi Kosaka; Hiroshi Shibata; Tomoko Aoki; Takaaki Tanaka; Hideko Ohama; Kazuhiro Nouso; Asahiro Morishita; Akemi Tsutsui; Takuya Nagano; Norio Itokawa; Tomomi Okubo; Taeang Arai; Michitaka Imai; Yohei Koizumi; Shinichiro Nakamura; Kouji Joko; Hiroko Iijima; Masaki Kaibori; Yoichi Hiasa; Masatoshi KudoCancer medicine 12 (1) 325 - 334 2022/06 BACKGROUND/AIM: A comparison of therapeutic efficacy between atezolizumab plus bevacizumab (Atez/Bev) and lenvatinib treatment given as first-line therapy for unresectable hepatocellular carcinoma (u-HCC) in regard to progression-free survival (PFS) overall survival (OS) has not been reported. We aimed to elucidate which of those given as initial treatment for u-HCC has greater prognostic impact on PFS and OS of affected patients, retrospectively. MATERIALS/METHODS: From 2020 to January 2022, 251 u-HCC (Child-Pugh A, ECOG PS 0/1, BCLC-B/C) treated were enrolled (Atez/Bev-group, n = 194; lenvatinib-group, n = 57). PFS and OS were analyzed following adjustment based on inverse probability weighting (IPW). RESULTS: There was a greater number of patients with macro-vascular invasion in Atez/Bev-group (22.7% vs. 8.8%, p = 0.022). In lenvatinib-group, the frequencies of appetite loss (38.6% vs. 19.6%, p = 0.002), hypothyroidism (21.1% vs. 6.7%, p = 0.004), hand foot skin reaction (19.3% vs. 1.0%, p 胆膵内視鏡治療の工夫とリスクマネージメント 胆嚢結石を合併した総胆管結石に対する内視鏡治療戦略の検討 術前にとるか術後にとるか高島 耕太; 三長 孝輔; 鎌田 研; 竹中 完; 工藤 正俊日本消化器内視鏡学会近畿支部例会プログラム・抄録集 日本消化器内視鏡学会-近畿支部 108回 49 - 49 2022/06非代償性肝硬変による直腸静脈瘤出血に対して内視鏡的組織接着剤注入術を施行した1例加藤 弘樹; 松井 繁長; 田北 雅弘; 上中 大地; 今村 瑞貴; 原 茜; 野村 健司; 瀬海 郁衣; 高田 隆太郎; 河野 匡志; 正木 翔; 永井 知行; 本庶 元; 米田 頼晃; 上嶋 一臣; 渡邉 智裕; 西田 直生志; 辻 直子; 樫田 博史; 工藤 正俊日本消化器内視鏡学会近畿支部例会プログラム・抄録集 日本消化器内視鏡学会-近畿支部 108回 89 - 89 2022/06胆膵内視鏡治療の工夫とリスクマネージメント 胆嚢結石を合併した総胆管結石に対する内視鏡治療戦略の検討 術前にとるか術後にとるか高島 耕太; 三長 孝輔; 鎌田 研; 竹中 完; 工藤 正俊日本消化器内視鏡学会近畿支部例会プログラム・抄録集 日本消化器内視鏡学会-近畿支部 108回 49 - 49 2022/06【膵神経内分泌腫瘍-新たなる胎動2022-】画像診断 膵神経内分泌腫瘍の内視鏡診断大塚 康生; 鎌田 研; 山崎 友裕; 大本 俊介; 三長 孝輔; 竹中 完; 樫田 博史; 工藤 正俊肝胆膵 (株)アークメディア 84 (6) 783 - 788 0389-4991 2022/06安全に内視鏡治療できた小腸pyogenic granuloma(化膿性肉芽腫)の一例有山 武尊; 米田 頼晃; 加藤 弘樹; 瀬海 郁衣; 原 茜; 野村 健司; 高田 隆太郎; 正木 翔; 河野 匡志; 永井 知行; 本庶 元; 松井 繁長; 辻 直子; 樫田 博史; 工藤 正俊日本消化器内視鏡学会近畿支部例会プログラム・抄録集 日本消化器内視鏡学会-近畿支部 108回 82 - 82 2022/06Surgery versus Radiofrequency Ablation for Small Hepatocellular Carcinoma: A Randomized Controlled Trial (SURF Trial).Tadatoshi Takayama; Kiyoshi Hasegawa; Namiki Izumi; Masatoshi Kudo; Mitsuo Shimada; Naoki Yamanaka; Masafumi Inomata; Shuichi Kaneko; Hisashi Nakayama; Yoshikuni Kawaguchi; Kosuke Kashiwabara; Ryosuke Tateishi; Shuichiro Shiina; Kazuhiko Koike; Yutaka Matsuyama; Masao Omata; Masatoshi Makuuchi; Norihiro KokudoLiver cancer 11 (3) 209 - 218 2022/06 Introduction: It remains unclear which surgery or radiofrequency ablation (RFA) is the more effective treatment for small hepatocellular carcinoma (HCC). We aimed to compare survival between patients undergoing surgery (surgery group) and patients undergoing RFA (RFA group). Methods: We conducted a randomized controlled trial involving 49 institutions in Japan. Patients with Child-Pugh scores ≤7, largest HCC diameter ≤3 cm, and ≤3 HCC nodules were considered eligible. The co-primary endpoints were recurrence-free survival (RFS) and overall survival (OS). The current study reports the final result of RFS, and the follow-up of OS is still ongoing. Results: During 2009-2015, 308 patients were registered. After excluding ineligible patients, the surgery and RFA groups included 150 and 151 patients, respectively. Baseline factors did not differ significantly between the groups. In both groups, 90% of patients had solitary HCC. The median largest HCC diameter was 1.8 cm (interquartile range [IQR], 1.5-2.2 cm) in the surgery group and 1.8 cm (IQR, 1.5-2.3 cm) in the RFA group. The median procedure duration (274 vs. 40 min, p Combination Immunotherapy with Anti-PD-1/PD-L1 Antibody plus Anti-VEGF Antibody May Promote Cytotoxic T Lymphocyte Infiltration in Hepatocellular Carcinoma, Including in the Noninflamed Subclass.Masatoshi KudoLiver cancer 11 (3) 185 - 191 2022/06非代償性肝硬変による直腸静脈瘤出血に対して内視鏡的組織接着剤注入術を施行した1例加藤 弘樹; 松井 繁長; 田北 雅弘; 上中 大地; 今村 瑞貴; 原 茜; 野村 健司; 瀬海 郁衣; 高田 隆太郎; 河野 匡志; 正木 翔; 永井 知行; 本庶 元; 米田 頼晃; 上嶋 一臣; 渡邉 智裕; 西田 直生志; 辻 直子; 樫田 博史; 工藤 正俊日本消化器内視鏡学会近畿支部例会プログラム・抄録集 日本消化器内視鏡学会-近畿支部 108回 89 - 89 2022/06Integrated use of PD-1 inhibition and transarterial chemoembolization for hepatocellular carcinoma: evaluation of safety and efficacy in a retrospective, propensity score-matched study.Brett Marinelli; Edward Kim; Antonio D'Alessio; Mario Cedillo; Ishan Sinha; Neha Debnath; Masatoshi Kudo; Naoshi Nishida; Anwaar Saeed; Hannah Hildebrand; Ahmed O Kaseb; Yehia I Abugabal; Anjana Pillai; Yi-Hsiang Huang; Uqba Khan; Mahvish Muzaffar; Abdul Rafeh Naqash; Rahul Patel; Aaron Fischman; Vivian Bishay; Dominik Bettinger; Max Sung; Celina Ang; Myron Schwartz; David J Pinato; Thomas MarronJournal for immunotherapy of cancer 10 (6) 2022/06 BACKGROUND: Immune checkpoint inhibitors (ICIs) have revolutionized treatment of advanced hepatocellular carcinoma. Integrated use of transarterial chemoembolization (TACE), a locoregional inducer of immunogenic cell death, with ICI has not been formally assessed for safety and efficacy outcomes. METHODS: From a retrospective multicenter dataset of 323 patients treated with ICI, we identified 31 patients who underwent >1 TACE 60 days before or concurrently, with nivolumab at a single center. We derived a propensity score-matched cohort of 104 patients based on Child-Pugh Score, portal vein thrombosis, extrahepatic metastasis and alpha fetoprotein (AFP) who received nivolumab monotherapy. We described overall survival (OS), progression-free survival (PFS), objective responses according to modified RECIST criteria and safety in the multimodal arm in comparison to monotherapy. RESULTS: Over a median follow-up of 9.3 (IQR 4.0-16.4) months, patients undergoing multimodal immunotherapy with TACE achieved a significantly longer median (95% CI) PFS of 8.8 (6.2-23.2) vs 3.7 (2.7-5.4) months (log-rank 0.15, pClinical implication of immune checkpoint inhibitor on the chronic hepatitis B virus infectionSatoru Hagiwara; Naoshi Nishida; Hiroshi Ida; Kazuomi Ueshima; Yasunori Minami; Masahiro Takita; Tomoko Aoki; Masahiro Morita; Hirokazu Cishina; Yoriaki Komeda; Akihiro Yoshida; Hidetoshi Hayashi; Kazuhiko Nakagawa; Masatoshi KudoHepatology Research Wiley 1386-6346 2022/05Connected or disconnected: What's next after successful transmural drainage of pancreatic fluid collection?Kosuke Minaga; Masatoshi KudoDigestive endoscopy : official journal of the Japan Gastroenterological Endoscopy Society 2022/05Therapeutic efficacy of atezolizumab plus bevacizumab treatment for unresectable hepatocellular carcinoma in patients with Child-Pugh class A or B liver function in real-world clinical practice.Takaaki Tanaka; Atsushi Hiraoka; Toshifumi Tada; Masashi Hirooka; Kazuya Kariyama; Joji Tani; Masanori Atsukawa; Koichi Takaguchi; Ei Itobayashi; Shinya Fukunishi; Kunihiko Tsuji; Toru Ishikawa; Kazuto Tajiri; Hironori Ochi; Satoshi Yasuda; Hidenori Toyoda; Chikara Ogawa; Takashi Nishimura; Takeshi Hatanaka; Satoru Kakizaki; Noritomo Shimada; Kazuhito Kawata; Atsushi Naganuma; Hisashi Kosaka; Hideko Ohama; Kazuhiro Nouso; Asahiro Morishita; Akemi Tsutsui; Takuya Nagano; Norio Itokawa; Tomomi Okubo; Taeang Arai; Michitaka Imai; Yohei Koizumi; Shinichiro Nakamura; Kouji Joko; Hiroko Iijima; Masaki Kaibori; Yoichi Hiasa; Masatoshi Kudo; Takashi KumadaHepatology research : the official journal of the Japan Society of Hepatology 52 (9) 773 - 783 2022/05 BACKGROUND/AIM: Atezolizumab plus bevacizumab (Atez/Bev) treatment is recommended for unresechepatocellular carcinoma (u-HCC) patients classified as Child-Pugh A (CP-A). This study aimed to elucidate the prognosis of patients treated with Atez/Bev, especially CP-A and -B cases. MATERIALS/METHODS: From September 2020 to March 2022, 457 u-HCC patients treated with Atez/Bev were enrolled (median age 74 years, male:female = 368:89, CP-A:CP-B = 427:30, Child-Pugh score [CPS] 5:6:7:8:9 = 271:156:21:8:1). Therapeutic response was evaluated using RECIST ver.1.1. Clinical features and prognosis were retrospectively evaluated. RESULTS: There were no significant differences between CP-A and -B patients in regard to best response (CR:PR:SD:PD = 16:91:194:81 vs. 0:7:13:8, p = 0.739; objective response rate/disease control rate = 28.0%/78.8% vs. 25.0%/71.4%). Analysis performed using inverse probability weighting adjustments of clinical factors other than those related to hepatic reserve function with a p value Case Report: New-Onset Rheumatoid Arthritis Following COVID-19 VaccinationTomohiro Watanabe; Kosuke Minaga; Akane Hara; Tomoe Yoshikawa; Ken Kamata; Masatoshi KudoFrontiers in Immunology Frontiers Media SA 13 2022/05 Efficient protection against coronavirus disease 2019 (COVID-19) has been achieved by immunization with mRNA-based vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). However, efficient immune responses against this novel virus by vaccination are accompanied by a wide variety of side effects. Indeed, flares or new-onset of autoimmune disorders have been reported soon after the COVID-19 vaccination. Although pro-inflammatory cytokine responses play pathogenic roles in the development of autoimmunity, cytokines charactering COVID-19 vaccination-related autoimmune responses have been poorly understood. Given that mRNA derived from COVID-19 vaccine is a potent inducer for pro-inflammatory cytokine responses, these cytokines might mediate autoimmune responses after COVID-19 vaccination. Here we report a case with new-onset rheumatoid arthritis (RA) following COVID-19 vaccination. Serum concentrations not only of arthrogenic cytokines, interleukin-6 (IL-6) and tumor necrosis factor-α (TNF-α), but also of type I interferon (IFN) were elevated at the active phase in this case. Induction of remission by methotrexate and tocilizumab was accompanied by a marked reduction in serum concentrations of type I IFN, IL-6, and TNF-α. These results suggest that production of type I IFN, IL-6, and TNF-α induced by COVID-19 vaccination might be involved in this case with new-onset RA.C-reactive protein to albumin ratio predicts survival in patients with unresectable hepatocellular carcinoma treated with lenvatinib.Toshifumi Tada; Takashi Kumada; Atsushi Hiraoka; Masashi Hirooka; Kazuya Kariyama; Joji Tani; Masanori Atsukawa; Koichi Takaguchi; Ei Itobayashi; Shinya Fukunishi; Kunihiko Tsuji; Toru Ishikawa; Kazuto Tajiri; Hironori Ochi; Satoshi Yasuda; Hidenori Toyoda; Takeshi Hatanaka; Satoru Kakizaki; Noritomo Shimada; Kazuhito Kawata; Takaaki Tanaka; Hideko Ohama; Kazuhiro Nouso; Asahiro Morishita; Akemi Tsutsui; Takuya Nagano; Norio Itokawa; Tomomi Okubo; Taeang Arai; Michitaka Imai; Atsushi Naganuma; Tomoko Aoki; Yohei Koizumi; Shinichiro Nakamura; Kouji Joko; Yoichi Hiasa; Masatoshi KudoScientific reports 12 (1) 8421 - 8421 2022/05 We investigated the impact of C-reactive protein to albumin ratio (CAR) on predicting outcomes in 522 patients with unresectable hepatocellular carcinoma (HCC) treated with lenvatinib. We determined the optimal CAR cutoff value with time-dependent receiver operating characteristic curve analysis. Additionally, we clarified the relationship between CAR and liver function or HCC progression. Median overall survival was 20.0 (95% confidence interval (CI), 17.2-22.6) months. The optimal CAR cutoff value was determined to be 0.108. Multivariate analysis showed that high CAR (≥ 0.108) (hazard ratio (HR), 1.915; 95% CI, 1.495-2.452), Eastern Cooperative Oncology Group performance status ≥ 1 (HR, 1.429), and α-fetoprotein ≥ 400 ng/mL (HR, 1.604) were independently associated with overall survival. Cumulative overall survival differed significantly between patients with low versus high CAR (p What is the most appropriate diagnostic strategy for evaluating a small common bile duct stone?Mamoru Takenaka; Masatoshi KudoDigestive endoscopy : official journal of the Japan Gastroenterological Endoscopy Society 2022/05Expression levels of cellular inhibitor of apoptosis proteins and colitogenic cytokines are inversely correlated with the activation of interferon regulatory factor 4.Sho Masaki; Tomohiro Watanabe; Yasuyuki Arai; Ikue Sekai; Akane Hara; Masayuki Kurimoto; Yasuo Otsuka; Yasuhiro Masuta; Tomoe Yoshikawa; Ryutaro Takada; Ken Kamata; Kosuke Minaga; Kouhei Yamashita; Masatoshi KudoClinical and experimental immunology 207 (3) 340 - 350 2022/05 Cellular inhibitors of apoptosis proteins 1 (cIAP1) and 2 (cIAP2) are involved in signaling pathways mediated by Toll-like receptors (TLRs) and tumor necrosis factor (TNF)-α. Excessive activation of TLRs and TNF-α underlies the immunopathogenesis of Crohn's disease (CD) and ulcerative colitis (UC). However, the roles played by cIAP1 and cIAP2 in the development of CD and UC remain poorly understood. In this study, we attempted to clarify the molecular link between cIAP1/cIAP2 and colonic inflammation. Human monocyte-derived dendritic cells (DCs) treated with siRNAs specific for cIAP1 or cIAP2 exhibited reduced pro-inflammatory cytokine responses upon stimulation with TLR ligands. Expression of cIAP1 and cIAP2 in human DCs was suppressed in the presence of interferon regulatory factor 4 (IRF4). This effect was associated with inhibition of cIAP1 and cIAP2 polyubiquitination. To verify these in vitro findings, we created mice overexpressing IRF4 in DCs and showed that these mice were resistant to trinitrobenzene sulfonic acid-induced colitis as compared with wild-type mice; these effects were accompanied by reduced expression levels of cIAP1 and cIAP2. Pro-inflammatory cytokine production by mesenteric lymph node cells upon stimulation with TLR ligands was reduced in mice with DC-specific IRF4 overexpression as compared with that in wild-type mice. Finally, in clinical samples of the colonic mucosa from patients with CD, there was a negative relationship between the percentage of IRF4+ DCs and percentages of cIAP1+ or cIAP2+ lamina propria mononuclear cells. These data suggest that the colitogenic roles of cIAP1 and cIAP2 are negatively regulated by IRF4.New treatment paradigm with systemic therapy in intermediate-stage hepatocellular carcinoma.Masatoshi KudoInternational journal of clinical oncology 2022/05 Since the approval of sorafenib for the treatment of unresectable hepatocellular carcinoma in 2007 (in 2009 in Japan), five more regimens have been approved: lenvatinib, and atezolizumab plus bevacizumab for first-line treatment, and regorafenib, cabozantinib, and ramucirumab for second-line treatment, which are currently available for clinical use. The positive results of durvalumab, a programmed cell death ligand 1 antibody, plus tremelimumab, an anti-cytotoxic T-lymphocyte-associated protein 4 antibody, were also presented at the 2022 American Society Clinical Oncology Gastrointestinal Cancers Symposium as superior to sorafenib in prolonging the overall survival; this combination is expected to be approved by the end of 2022. These systemic therapies are changing the treatment paradigm not only for advanced hepatocellular carcinoma but also for intermediate-stage hepatocellular carcinoma. This review focuses on the role of systemic therapy in intermediate-stage hepatocellular carcinoma.EUS-guided drainage of the gallbladder using a novel 0.018-inch guidewire for preventing bile leakage (with video).Mamoru Takenaka; Shunsuke Omoto; Masatoshi KudoEndoscopic ultrasound 2022/05A novel and effective EUS training program that enables visualization of the learning curve: Educational Program of Kindai system (EPOK).Shunsuke Omoto; Mamoru Takenaka; Fauze Maluf-Filho; Masatoshi KudoVideoGIE : an official video journal of the American Society for Gastrointestinal Endoscopy 7 (5) 165 - 168 2022/05 Video 1A novel training method for endoscopic ultrasound operators, the Educational Program of Kindai system enables visualization of a trainee's learning curve and difficult-to-learn areas. This visualization helps both the trainer and the trainee to structure learning and teaching methods in real time.Performance evaluation of the Elecsys PIVKA-II and Elecsys AFP assays for hepatocellular carcinoma diagnosis.Henry L Y Chan; Arndt Vogel; Thomas Berg; Enrico N De Toni; Masatoshi Kudo; Jörg Trojan; Anja Eiblmaier; Hanns-Georg Klein; Johannes Kolja Hegel; Ashish Sharma; Kairat Madin; Vinzent Rolny; Marcus-Rene Lisy; Teerha PiratvisuthJGH open : an open access journal of gastroenterology and hepatology 6 (5) 292 - 300 2022/05 Background and Aims: Prothrombin induced by vitamin K absence-II (PIVKA-II) is a serum biomarker linked to hepatocellular carcinoma (HCC), showing superiority to alpha-fetoprotein (AFP) for early disease detection. We aimed to assess the clinical and analytical performance of the Elecsys® PIVKA-II immunoassay in diagnosing HCC and evaluate PIVKA-II's technical performance. Methods: Serum samples from adult cases (i.e. patients with a first-time HCC diagnosis; n = 168) and disease controls (i.e. patients without HCC with an at-risk condition; n = 208) were assessed. An AFP cut-off of 20 ng/mL was used to differentiate between HCC cases and disease controls. Clinical performance of the Elecsys PIVKA-II assay was compared with that of comparator assays (Lumipulse G PIVKA-II, μTASWako DCP, ARCHITECT PIVKA-II) using receiver operating characteristic curve analysis to determine the area under the curve (AUC) values. Results: The Elecsys PIVKA-II assay compared favorably with comparator assays. Using a 28.4 ng/mL cut-off, the Elecsys PIVKA-II assay detected HCC with 86.9% sensitivity and 83.7% specificity. Clinical performance of the Elecsys PIVKA-II assay (AUC: 90.8%) was equivalent to that of comparator assays (AUC: 88.3-89.6%). Relatively high PIVKA-II concentrations were observed for cholangiocarcinoma and pancreatic cancer with the Elecsys assay in specificity panel analyses, indicating that high PIVKA-II concentrations should not be used alone in the absence of other clinical data. Conclusions: The Elecsys PIVKA-II assay showed good analytical performance under routine laboratory conditions, comparing favorably with comparator assays. These findings support the suitability of the Elecsys PIVKA-II assay as an aid in HCC diagnosis.Comparison between gradient and spin-echo (GRASE) and compressed sensing sequences for single breath-hold three-dimensional magnetic resonance cholangiopancreatography in patients with T1 hyperintense bile.Daisuke Morimoto-Ishikawa; Tomoko Hyodo; Mamoru Takenaka; Yuko Matsukubo; Isao Numoto; Makoto Itoh; Masato Ohmi; Ken Kamata; Yu Ueda; Miyuki Wakana; Masatoshi Kudo; Shigeyoshi Saito; Kazunari IshiiEuropean journal of radiology 150 110279 - 110279 2022/05 PURPOSE: To compare image quality and the detectability of gallstones in patients with T1 hyperintense bile between single breath-hold three-dimensional (3D) magnetic resonance cholangiopancreatography (MRCP) with gradient and spin-echo (GRASE) and with compressed sensing (CS). METHODS: We retrospectively evaluated patients who underwent MRCP using GRASE and CS and had hyperintense bile on T1-weighted fat-suppressed images. The relative duct-to-periductal contrast ratios (RCs) of each bile duct segment were calculated. Pancreaticobiliary duct visibility, motion artifacts, background suppression, and overall image quality were scored on a 5-point scale. The Wilcoxon signed-rank test was used to analyze differences in qualitative and quantitative results. Diagnostic performance in detecting common bile duct (CBD) and gallbladder stones was assessed using receiver operating characteristic (ROC) curves. RESULTS: In total, 96 patients were included in the study. RCs of all bile duct segments in GRASE MRCP were significantly lower than those in CS MRCP (p Patterns and outcomes of subsequent therapy after immune checkpoint inhibitor discontinuation in HCC.Rohini Sharma; Anjana Pillai; Thomas Urban Marron; Petros Fessas; Anwaar Saeed; Tomi Jun; Sirish Dharmapuri; David Szafron; Abdul Rafeh Naqash; Anuhya Gampa; Yinghong Wang; Uqba Khan; Mahvish Muzaffar; Chieh-Ju Lee; Pei-Chang Lee; Anushi Bulumulle; Sonal Paul; Dominic Bettinger; Hannah Hildebrand; Mohammed Yehia; Tiziana Pressiani; Ahmed Kaseb; Yi-Hsiang Huang; Celina Ang; Masatoshi Kudo; Naoshi Nishida; Nicola Personeni; Lorenza Rimassa; David James PinatoHepatology communications 6 (7) 1776 - 1785 2022/04 The availability of immune checkpoint inhibitors (ICIs) for the management of advanced hepatocellular cancer (HCC) has changed the treatment paradigm. There are emerging questions regarding the efficacy of subsequent anticancer therapies. The primary aim of this retrospective, multicenter study was to examine the types of anticancer treatment received after ICIs and to assess the impact on post-ICI survival. We established an international consortium of 11 tertiary-care referral centers located in the USA (n = 249), Europe (n = 74), and Asia (n = 97), and described patterns of care following ICI therapy. The impact of subsequent therapy on overall survival (OS) was estimated using the Kaplan-Meier method and presented with a 95% confidence interval (CI). A total of 420 patients were treated with ICIs for advanced HCC after one line of systemic therapy (n = 371, 88.8%): 31 (8.8%) had died, 152 (36.2%) received best supportive care (BSC) following ICIs, and 163 patients (38.8%) received subsequent anticancer therapy. Tyrosine kinase inhibitors (TKIs, n = 132, 80.9%), in particular sorafenib (n = 49, 30.0%), were the most common post-ICI therapy followed by external beam radiotherapy (n = 28, 17.2%), further immunotherapy (n = 21, 12.9%), locoregional therapy (n = 23, 14.1%), chemotherapy (n = 9, 5.5%), and surgery (n = 6, 3.6%). Receipt of post-ICI therapy was associated with longer median OS compared with those who had received BSC (12.1 vs. 3.3 months; hazard ratio [HR]: 0.4 (95% CI: 2.7-5.0). No difference in OS was noted in those patients who received TKI before ICIs compared with those who received ICIs followed by TKI. Conclusion: Post-ICI therapy is associated with OS in excess of 12 months, suggesting a role for therapeutic sequencing. OS from TKI therapy was similar to that reported in registration studies, suggesting preserved efficacy following ICIs.How Compatible Are Immune Checkpoint Inhibitors and Thermal Ablation for Liver Metastases?Yasunori Minami; Haruyuki Takaki; Koichiro Yamakado; Masatoshi KudoCancers 14 (9) 2022/04 Cancer immunotherapy, which reactivates the weakened immune cells of cancer patients, has achieved great success, and several immune checkpoint inhibitors (ICIs) are now available in clinical practice. Despite promising clinical outcomes, favorable responses are only observed in a fraction of patients, and resistance mechanisms, including the absence of tumor antigens, have been reported. Thermal ablation involves the induction of irreversible damage to cancer cells by localized heat and may result in the release of tumor antigens. The combination of immunotherapy and thermal ablation is an emerging therapeutic option with enhanced efficacy. Since thermal ablation-induced inflammation and increases in tumor antigens have been suggested to promote the cancer-immunity cycle, the combination of immuno-oncology (IO) therapy and thermal ablation may be mutually beneficial. In preclinical and clinical studies, the combination of ICI and thermal ablation significantly inhibited tumor growth, and synergistic antitumor effects appeared to prolong the survival of patients with secondary liver cancer. However, evidence for the efficacy of ICI monotherapy combined with thermal ablation is currently insufficient. Therefore, the clinical feasibility of immune response activation by ICI monotherapy combined with thermal ablation may be limited, and thermal ablation may be more compatible with dual ICIs (the IO-IO combination) to induce strong immune responses.Pembrolizumab monotherapy for previously untreated advanced hepatocellular carcinoma: data from the open-label, phase 2 KEYNOTE-224 trial.Gontran Verset; Ivan Borbath; Mark Karwal; Chris Verslype; Hans Van Vlierberghe; Adel Kardosh; Vittorina Zagonel; Per Stal; Debashis Sarker; Daniel H Palmer; Arndt Vogel; Julien Edeline; Stephane Cattan; Masatoshi Kudo; Ann-Lii Cheng; Sadahisa Ogasawara; Bruno Daniele; Stephen L Chan; Jennifer J Knox; Shu-Kui Qin; Abby B Siegel; Michael Chisamore; Ken Hatogai; Anran Wang; Richard S Finn; Andrew X ZhuClinical cancer research : an official journal of the American Association for Cancer Research 2022/04 PURPOSE: KEYNOTE-224 cohort 1 demonstrated that pembrolizumab was efficacious and tolerable in patients with advanced hepatocellular carcinoma (aHCC) previously treated with sorafenib. We report results from KEYNOTE-224 (NCT02702414) cohort 2, which enrolled patients with aHCC and no prior systemic therapy. EXPERIMENTAL DESIGN: KEYNOTE-224 was an open-label, multi-country phase 2 trial. Eligible patients in cohort 2 had aHCC not amenable or refractory to locoregional therapy and not previously treated with systemic therapy. Patients received pembrolizumab 200 mg intravenously every three weeks for {less than or equal to}2 years. Primary endpoint was objective response rate (ORR) by central imaging review per RECIST v1.1. Secondary endpoints included duration of response (DOR), disease control rate (DCR), time to progression (TTP), progression-free survival (PFS), overall survival (OS), and safety/tolerability. RESULTS: Between Sept 4, 2018 and Feb 20, 2019, 51 patients were allocated in cohort 2. The median time from the first dose to data cutoff (Jan 19, 2021) was 27 months (range, 23-29). ORR was 16% (95% CI, 7-29) and was similar across key subgroups. Median DOR was 16 months (range, 3-24+), and DCR was 57%. The median PFS was 4 months (95% CI, 2-8), and median TTP was 4 months (95% CI, 3-9). Median OS was 17 months (95% CI, 8-23). Grade {greater than or equal to}3 treatment-related adverse events occurred in 16% of patients. CONCLUSIONS: In patients with aHCC with no prior systemic therapy, pembrolizumab provided durable antitumor activity, promising OS, and had a safety profile consistent with previous observations. These findings support further evaluation of pembrolizumab-based regimens for HCC.Efficacy of EUS-guided celiac plexus neurolysis in combination with EUS-guided celiac ganglia neurolysis for pancreatic cancer-associated pain: a multicenter prospective trial.Ken Kamata; Makiko Kinoshita; Ikuharu Kinoshita; Hajime Imai; Takeshi Ogura; Hisakazu Matsumoto; Kosuke Minaga; Yasutaka Chiba; Mamoru Takenaka; Masatoshi Kudo; Masayuki KitanoInternational journal of clinical oncology 2022/04 OBJECTIVES: This study evaluated the efficacy of endoscopic ultrasound-guided celiac plexus neurolysis (EUS-CPN) in combination with EUS-guided celiac ganglia neurolysis (EUS-CGN) for pancreatic cancer-associated pain. METHODS: This multicenter prospective trial was registered in the University Hospital Medical Information Network (UMIN000031228). Fifty-one consecutive patients with pancreatic cancer-associated pain who presented at one of five Japanese referral centers between February 2018 and March 2021 were enrolled. EUS-CGN was added in cases of visible celiac ganglia. The primary endpoint was effectiveness, defined as a decrease in the numerical rating scale (NRS) by ≥ 3 points. NRS data were prospectively acquired at 1 week after the procedure to evaluate its effectiveness and the extent of pain relief. RESULTS: The technical success rates of EUS-CPN and EUS-CGN were 100% and 80.4%, respectively. The overall efficacy rate was 82.4% [90% confidence interval (CI) 71.2-90.5, P Role of phlebotomy in the treatment of liver damage related to erythropoietic porphyria.Satoru Hagiwara; Naoshi Nishida; Hiroshi Ida; Kazuomi Ueshima; Yasunori Minami; Masahiro Takita; Tomoko Aoki; Masahiro Morita; Hirokazu Chishina; Yoriaki Komeda; Akihiro Yoshida; Ah-Mee Park; Masako Sato; Akira Kawada; Hajime Nakano; Hiroshi Nakagawa; Masatoshi KudoScientific reports 12 (1) 6100 - 6100 2022/04 Liver damage affects the prognosis of patients with erythropoietic protoporphyria (EPP). However, there is no radical cure for EPP patients with severe liver damage. This study aims to investigate the effectiveness of phlebotomy in patients with severe liver damage. We examined seven patients diagnosed with EPP and liver damage between 2010 and 2020. Of the 7 cases, phlebotomy was performed in 3 cases with severe hepatic disorder, and the improvement effect of hepatic disorder was observed in all cases. In addition, as an additional study, we also investigated the mechanism by which liver damage becomes more severe. Liver biopsy samples were stained with hematoxylin and eosin and immunohistochemistry was used to examine the expression of adenosine triphosphate-binding transporter G2 (ABCG2). Liver biopsies were performed in 3 of 7 patients with EPP. Of these three patients, ABCG2 expression was low in two patients, especially in the protoporphyrin (PP) deposition area. Two patients with reduced ABCG2 expression subsequently developed severe liver damage. However, the causal relationship between the decreased expression of ABCG2 and the exacerbation of liver damage has not been directly proved, and further investigation is required in the future. This study demonstrated the effectiveness of phlebotomy in EPP patients with severe liver damage.Reply to Response to "'A Case of Ulcerative Colitis Relapse Characterized by Systemic Type I Interferon Responses After COVID-19 Vaccination'" by Mungmunpuntipantip and Wiwanitkiton.Yasuhiro Masuta; Tomohiro Watanabe; Kosuke Minaga; Masatoshi KudoInflammatory bowel diseases 28 (8) e113  2022/04小型肝細胞癌に対する腹腔鏡下肝切除、開腹肝切除と経皮的ラジオ波焼灼療法の治療成績の比較 SURF trial付随研究増田 崇; 遠藤 裕一; 長谷川 潔; 河口 義邦; 高山 忠利; 泉 並木; 山中 若樹; 工藤 正俊; 島田 光生; 金子 周一; 馬場 秀夫; 小池 和彦; 小俣 政男; 幕内 雅敏; 松山 裕; 猪股 雅史; 國土 典宏日本外科学会定期学術集会抄録集 (一社)日本外科学会 122回 SF - 8 2022/04肝がんのマネジメント-発がん予防・内科治療・外科治療・再発予防 Phase 2根治後NIVOLVE試験における奏効症例の特徴青木 智子; 西田 直生志; 工藤 正俊肝臓 (一社)日本肝臓学会 63 (Suppl.1) A35 - A35 0451-4203 2022/04治療起因性肝障害のマネジメント-DILI・HBV再活性化・irAE・IRIS 免疫チェックポイント阻害剤投与に伴うirAE肝障害・HBV再活性化についての検討萩原 智; 西田 直生志; 工藤 正俊肝臓 (一社)日本肝臓学会 63 (Suppl.1) A95 - A95 0451-4203 2022/04【胆石症の診療方針】関連疾患 胆道ジスキネジア竹中 完; 山崎 友裕; 大本 俊介; 三長 孝輔; 鎌田 研; 工藤 正俊臨床消化器内科 (株)日本メディカルセンター 37 (5) 571 - 575 0911-601X 2022/04 <文献概要>胆道ジスキネジアは胆嚢,総胆管,十二指腸乳頭部に至る胆道系に器質的な病変が認められないにもかかわらず,右季肋部痛を主体とする胆石症様の腹部症状を呈する病態であり,Rome IV診断基準における機能性消化管障害の病型分類の"機能性胆嚢・Oddi乳頭括約筋障害(gallbladder and sphincter of Oddi disorder)"にあたる.問診により胆道痛の定義を満たすが,胆石,総胆管結石や他の器質的疾患を認めない症例のなかで,胆嚢がある症例にgallbladder disorderを疑い,胆嚢摘出後で血液検査にて肝酵素逸脱,もしくは画像検査にて胆管拡張を認める症例に胆道型乳頭括約筋機能異常(SOD)が疑われる.食事療法や生活習慣改善でも症状の改善が認められない場合に薬剤投与治療が施行され,薬物療法が無効な症例には内視鏡的乳頭切開術がおもに行われる.本病態は疑わなければ絶対に診断できない病態であるため,まず疑うことができるか,が最も重要なポイントとなる.潰瘍性大腸炎関連腫瘍の臨床学的特徴と内視鏡治療時の取り組み米田 頼晃; 樫田 博史; 工藤 正俊; 高田 隆太郎; 正木 翔; 河野 匡志; 永井 知行; 本庶 元; 松井 繁長; 辻 直子Gastroenterological Endoscopy (一社)日本消化器内視鏡学会 64 (Suppl.1) 828 - 828 0387-1207 2022/04【革新的技術が変える肝疾患診療】AIによる超音波診断西田 直生志; 工藤 正俊消化器・肝臓内科 (有)科学評論社 11 (4) 465 - 474 2432-3446 2022/04肝がんのマネジメント-発がん予防・内科治療・外科治療・再発予防 Phase 2根治後NIVOLVE試験における奏効症例の特徴青木 智子; 西田 直生志; 工藤 正俊肝臓 (一社)日本肝臓学会 63 (Suppl.1) A35 - A35 0451-4203 2022/04治療起因性肝障害のマネジメント-DILI・HBV再活性化・irAE・IRIS 免疫チェックポイント阻害剤投与に伴うirAE肝障害・HBV再活性化についての検討萩原 智; 西田 直生志; 工藤 正俊肝臓 (一社)日本肝臓学会 63 (Suppl.1) A95 - A95 0451-4203 2022/04A Mouse Model of Acute and Chronic Pancreatitis.Kosuke Minaga; Tomohiro Watanabe; Ken Kamata; Masatoshi Kudo; Warren StroberCurrent protocols 2 (4) e422  2022/04 Pancreatitis occurs in two forms defined by its chronicity. Acute pancreatitis (AP) occurs suddenly and only lasts for several days. Consequently, most patients with AP recover without permanent damage to the pancreas, and about 20% of patients with AP have severe disease. In contrast, chronic pancreatitis (CP) is a long-lasting inflammation that causes permanent damage to pancreatic tissue; consequently, this form is marked by the emergence of persistent endocrine and exocrine pancreatic insufficiency. Despite these differences, AP and CP share central mechanisms of disease: in both forms, inflammation is initiated and/or sustained by the intrapancreatic activation of pancreatic digestive enzymes followed by the autodigestion of pancreatic tissues. In addition, in both forms enzymatic damage is accompanied by changes in intestinal permeability and entry of commensal organisms into the pancreas where they elicit innate immune responses that ultimately dominate and define pancreatic inflammation. In the murine models of AP and CP described here, both of these elements of pancreatitis pathogenesis are taken into account. Thus, in one approach mice are administered high doses of cerulein, a cholecystokinin analog with the ability at this dose to induce excessive activation of the cholecystokinin receptor expressed in pancreatic acinar cells and the release of active trypsin that causes both direct and indirect acinar damages due to entry of commensal organisms and stimulation of innate immune responses. In a second approach mice are administered low doses of cerulein, which causes little or no damage to the pancreas unless given along with nucleotide-binding oligomerization domain 1 (NOD1) ligand, which in the presence of low-dose cerulein administration induces a pathologic innate immune response mediated by NOD1. These approaches are adopted to produce AP when cerulein or cerulein plus NOD1 ligand is applied only once or to produce CP when a similar regimen is applied multiple times. © 2022 Wiley Periodicals LLC. Basic Protocol 1: Cerulein-induced acute pancreatitis Alternate Protocol 1: Acute pancreatitis induced by cerulein and NOD1 ligand Basic Protocol 2: Cerulein-induced chronic pancreatitis Alternate Protocol 2: Chronic pancreatitis induced by cerulein and NOD1 ligand Support Protocol: Isolation of pancreatic mononuclear cells.Artificial intelligence (AI) models for the ultrasonographic diagnosis of liver tumors and comparison of diagnostic accuracies between AI and human experts.Naoshi Nishida; Makoto Yamakawa; Tsuyoshi Shiina; Yoshito Mekada; Mutsumi Nishida; Naoya Sakamoto; Takashi Nishimura; Hiroko Iijima; Toshiko Hirai; Ken Takahashi; Masaya Sato; Ryosuke Tateishi; Masahiro Ogawa; Hideaki Mori; Masayuki Kitano; Hidenori Toyoda; Chikara Ogawa; Masatoshi KudoJournal of gastroenterology 57 (4) 309 - 321 2022/04 BACKGROUND: Ultrasonography (US) is widely used for the diagnosis of liver tumors. However, the accuracy of the diagnosis largely depends on the visual perception of humans. Hence, we aimed to construct artificial intelligence (AI) models for the diagnosis of liver tumors in US. METHODS: We constructed three AI models based on still B-mode images: model-1 using 24,675 images, model-2 using 57,145 images, and model-3 using 70,950 images. A convolutional neural network was used to train the US images. The four-class liver tumor discrimination by AI, namely, cysts, hemangiomas, hepatocellular carcinoma, and metastatic tumors, was examined. The accuracy of the AI diagnosis was evaluated using tenfold cross-validation. The diagnostic performances of the AI models and human experts were also compared using an independent test cohort of video images. RESULTS: The diagnostic accuracies of model-1, model-2, and model-3 in the four tumor types are 86.8%, 91.0%, and 91.1%, whereas those for malignant tumor are 91.3%, 94.3%, and 94.3%, respectively. In the independent comparison of the AIs and physicians, the percentages of correct diagnoses (accuracies) by the AIs are 80.0%, 81.8%, and 89.1% in model-1, model-2, and model-3, respectively. Meanwhile, the median percentages of correct diagnoses are 67.3% (range 63.6%-69.1%) and 47.3% (45.5%-47.3%) by human experts and non-experts, respectively. CONCLUSION:  The performance of the AI models surpassed that of human experts in the four-class discrimination and benign and malignant discrimination of liver tumors. Thus, the AI models can help prevent human errors in US diagnosis.Cross‐wired metal stents for endoscopic bilateral stent‐in‐stent deployment in malignant hilar biliary obstruction: A multicenter, single‐arm, prospective studyKentaro Yamao; Takeshi Ogura; Hideyuki Shiomi; Takaaki Eguchi; Hisakazu Matsumoto; Zhao Liang Li; Hiroaki Hashimoto; Yasutaka Chiba; Mamoru Takenaka; Tomohiro Watanabe; Masatoshi Kudo; Tsuyoshi SanukiDEN Open Wiley 2 (1) e20  2692-4609 2022/04 Objectives: The endoscopic bilateral stent-in-stent (SIS) deployment is a challenging procedure. Such difficulty is mainly caused by sticking of the tip of the delivery sheath into the self-expandable metal stents (SEMSs) mesh, requiring an additional dilating procedure. Herein, we assessed the clinical results of using cross-wired metal stent for endoscopic bilateral SIS deployment (BONASTENT M-Hilar) in patients with malignant hilar biliary obstruction (MHBO) in both high-volume and non-high-volume centers. Methods: We prospectively enrolled consecutive patients with MHBO between February 2016 and December 2018 at eight centers. Results: Forty-six patients were enrolled during the study period. The proportions of technical success were 93.5% (43/46) and clinical success (CS) on intention-to-treat and per-protocol analyses were 91.3% (42/46) and 93.0% (40/43), respectively. The proportion of an additional dilating procedure during the primary procedure was 50.0% (23/46). Recurrent biliary obstruction (RBO) on intention-to-treat analysis occurred in 32.6% (15/46) of cases. Almost all of the events were caused by stent ingrowth (14/15). The median survival time and time to RBO were 255 and 349 days, respectively. The probability of stent patency at 3, 6, and 12 months was 86.5%, 63.9%, and 47.6%, respectively. Conclusions: The cross-wired metal stent had excellent technical and CS, although non-high-volume centers were included in this study (UMIN000021441).Preliminary evidence of safety and tolerability of atezolizumab plus bevacizumab in patients with hepatocellular carcinoma and Child-Pugh A and B cirrhosis: a real-world study.Antonio D'Alessio; Claudia Angela Maria Fulgenzi; Naoshi Nishida; Martin Schönlein; Johann von Felden; Kornelius Schulze; Henning Wege; Vincent E Gaillard; Anwaar Saeed; Brooke Wietharn; Hannah Hildebrand; Linda Wu; Celina Ang; Thomas U Marron; Arndt Weinmann; Peter R Galle; Dominik Bettinger; Bertram Bengsch; Arndt Vogel; Lorenz Balcar; Bernhard Scheiner; Pei-Chang Lee; Yi-Hsiang Huang; Suneetha Amara; Mahvish Muzaffar; Abdul Rafeh Naqash; Antonella Cammarota; Nicola Personeni; Tiziana Pressiani; Rohini Sharma; Matthias Pinter; Alessio Cortellini; Masatoshi Kudo; Lorenza Rimassa; David J PinatoHepatology (Baltimore, Md.) 76 (4) 1000 - 1012 2022/03 BACKGROUND & AIMS: Atezolizumab plus bevacizumab (AtezoBev) is the standard of care for first-line treatment of unresectable hepatocellular carcinoma (HCC). No evidence exists as to its use in routine clinical practice in patients with impaired liver function. APPROACH & RESULTS: In 216 HCC patients consecutively treated with AtezoBev across 11 tertiary centres we retrospectively evaluated treatment-related adverse events (trAEs) graded (G) according to CTCAE v5.0, including in the analysis all patients treated according to label (n=202, 94%). We also assessed overall survival (OS), progression-free survival (PFS), overall response (ORR) and disease control rates (DCR) defined by RECIST v1.1. Disease was mostly secondary to viral hepatitis, namely Hepatitis C (n=72; 36%) and Hepatitis B infection (n=35, 17%). Liver function was graded as Child-Pugh (CP)-A in 154 patients (76%) and CP-B in 48 (24%). Any grade trAEs were reported by 143 patients (71%), of which 53 (26%) were G3 and 3 (2%) G4. Compared to CP-A, CP-B patients showed comparable rates of trAEs. Presence and grade of varices at pre-treatment esophagogastroduodenoscopy did not correlate with bleeding events. After a median follow-up of 9.0 months (95%CI, 7.8-10.1), median OS was 14.9 months (95%CI, 13.6-16.3), while median PFS was 6.8 months (95%CI, 5.2-8.5). ORR and DCR were respectively 25% and 73%, with no difference across CP classes. CONCLUSIONS: This study confirms reproducible safety and efficacy of AtezoBev in routine practice. CP-B patients reported similar tolerability compared to CP-A, warranting prospective evaluation of AtezoBev in this treatment-deprived population.Comparison of Radiation Exposure between Endoscopic Ultrasound-Guided Hepaticogastrostomy and Hepaticogastrostomy with Antegrade Stenting.Mamoru Takenaka; Madan M Rehani; Makoto Hosono; Tomohiro Yamazaki; Shunsuke Omoto; Kosuke Minaga; Ken Kamata; Kentaro Yamao; Shiro Hayashi; Tsutomu Nishida; Masatoshi KudoJournal of clinical medicine 11 (6) 2022/03 Fluoroscopy forms an essential part of endoscopic ultrasound-guided hepaticogastrostomy (EUS-HGS) and hepaticogastrostomy with antegrade stenting (EUS-HGAS). To date, no study has assessed and compared radiation exposure between EUS-HGS and EUS-HGAS. This study aimed to compare the radiation exposure parameters between EUS-HGS and EUS-HGAS. This retrospective single-center cohort study included consecutive patients who underwent EUS-HGS or EUS-HGAS from October 2017 to March 2019. The air kerma (AK: mGy), kerma-area product (KAP: Gycm2), fluoroscopy time (FT: min), and procedure time (PT: min) were assessed and compared between the two procedures. Altogether, 45 and 24 patients underwent EUS-HGS and EUS-HGAS, respectively. The median AK, KAP, FT, and PT were higher in the EUS-HGAS group than in the EUS-HGS group. A comparison revealed no difference in the technical success rate, complications rate, adverse event occurrence rate, and re-intervention rate between both procedures. This is the first report in which radiation exposure was used as a comparative parameter between EUS-HGS and EUS-HGAS. This study revealed that radiation exposure is significantly higher in EUS-HGAS than in EUS-HGS. Increased awareness on radiation exposure is warranted among gastroenterologists so that they choose the procedure with lower radiation exposure in cases where both procedures are indicated.Prognostic and predictive factors in patients with advanced HCC and elevated alpha-fetoprotein treated with ramucirumab in two randomized Phase III trial.Josep M Llovet; Amit G Singal; Augusto Villanueva; Richard S Finn; Masatoshi Kudo; Peter R Galle; Masafumi Ikeda; Sophie Callies; Louise M McGrath; Chunxiao Wang; Paolo Abada; Ryan C Widau; Elena Gonzalez-Gugel; Andrew X ZhuClinical cancer research : an official journal of the American Association for Cancer Research 2022/03 PURPOSE: Ramucirumab is an effective treatment for patients with advanced HCC (aHCC) and baseline AFP {greater than or equal to}400 ng/mL. We aimed to identify prognostic and predictive factors of response to ramucirumab in patients with aHCC with AFP {greater than or equal to}400 ng/mL from the Phase III REACH and REACH-2 randomized trials. EXPERIMENTAL DESIGN: Patients with aHCC, Child-Pugh class A with prior sorafenib treatment were randomized in REACH and REACH-2 (ramucirumab 8 mg/kg or placebo, biweekly). Meta-analysis of individual patient-level data (pooled population) from REACH (AFP {greater than or equal to}400 ng/mL) and REACH-2 was performed. A drug exposure analysis was conducted for those with evaluable pharmacokinetics data. To identify potential prognostic factors for overall survival (OS), multivariate analyzes were performed using a Cox proportional hazard regression model. To define predictors of ramucirumab benefit, subgroup-by-treatment interactions terms were evaluated. RESULTS: Of 542 patients (316 ramucirumab, 226 placebo) analyzed, 8 variables had independent prognostic value associated with poor outcome (geographical region, ECOG PS {greater than or equal to}1, AFP >1000 ng/mL, Child-Pugh >A5, extrahepatic spread, high neutrophil-to-lymphocyte, high alkaline phosphatase and aspartate aminotransferase). Ramucirumab benefit was present across all subgroups, including patients with very aggressive HCC (above median AFP; HR: 0.64; 95%CI:0.49-0.84) and non-viral aHCC (HR: 0.56; 95%CI:0.40-0.79). While no baseline factor was predictive of a differential OS benefit with ramucirumab, analyzes demonstrated an association between high drug exposure, treatment-emergent hypertension (Grade {greater than or equal to}3) and increased ramucirumab benefit. CONCLUSIONS: Ramucirumab provided a survival benefit irrespective of baseline prognostic covariates, and this benefit was greatest in patients with high ramucirumab drug exposure and/or those with treatment-related hypertension.レンバチニブ投与例におけるinflammation-based prognostic systemの予後予測における有用性 多施設共同研究齊藤 郁美; 多田 俊史; 熊田 卓; 平岡 淳; 厚川 正則; 青木 智子; 谷 丈二; 豊田 秀徳; 柿崎 暁; 糸林 詠; 能祖 一裕; 畑中 健; 高口 浩一; 石川 達; 福西 新弥; 川田 一仁; 田尻 和人; 島田 紀朋; 日浅 陽一; 工藤 正俊日本消化器病学会雑誌 (一財)日本消化器病学会 119 (臨増総会) A332 - A332 0446-6586 2022/03肝疾患の遺伝子解析による病態解明と臨床展開 線維化非進展例からのNASH関連肝癌発症様式の検討萩原 智; 西田 直生志; 工藤 正俊日本消化器病学会雑誌 (一財)日本消化器病学会 119 (臨増総会) A214 - A214 0446-6586 2022/03消化器癌における免疫治療と分子標的治療の基礎研究と臨床 肝細胞癌における腫瘍微小免疫環境と免疫チェックポイント阻害剤の効果西田 直生志; 上嶋 一臣; 工藤 正俊日本消化器病学会雑誌 (一財)日本消化器病学会 119 (臨増総会) A41 - A41 0446-6586 2022/03病態からみた肝癌治療アルゴリズムの今後 肝癌診療ガイドラインにおける肝動注化学療法の立ち位置と今後の展開上嶋 一臣; 田北 雅弘; 工藤 正俊日本消化器病学会雑誌 (一財)日本消化器病学会 119 (臨増総会) A79 - A79 0446-6586 2022/03消化器癌における免疫治療と分子標的治療の基礎研究と臨床 肝細胞癌における腫瘍微小免疫環境と免疫チェックポイント阻害剤の効果西田 直生志; 上嶋 一臣; 工藤 正俊日本消化器病学会雑誌 (一財)日本消化器病学会 119 (臨増総会) A41 - A41 0446-6586 2022/03肝疾患の遺伝子解析による病態解明と臨床展開 線維化非進展例からのNASH関連肝癌発症様式の検討萩原 智; 西田 直生志; 工藤 正俊日本消化器病学会雑誌 (一財)日本消化器病学会 119 (臨増総会) A214 - A214 0446-6586 2022/03A Case of Ulcerative Colitis Relapse Characterized by Systemic Type I Interferon Responses after COVID-19 Vaccination.Yasuhiro Masuta; Tomohiro Watanabe; Kosuke Minaga; Masatoshi KudoInflammatory bowel diseases 28 (8) e110-e111  2022/02Endoscopic Reintervention for Recurrence of Malignant Biliary Obstruction: Developing the Best Strategy.Mamoru Takenaka; Masatoshi KudoGut and liver 2022/02 Drainage therapy for malignant biliary obstruction (MBO) includes trans-papillary endoscopic retrograde biliary drainage (ERBD), percutaneous transhepatic biliary drainage (PTBD), and trans-gastrointestinal endoscopic ultrasound-guided biliary drainage (EUS-BD). With the development of chemotherapy, many MBO cases end up needing endoscopic reintervention (E-RI) for recurrent biliary obstruction. To achieve a successful E-RI, it is necessary to understand the various findings regarding E-RI in MBO cases reported to date. Therefore, in this review, we focus on E-RI for ERBD of distal MBO, ERBD of hilar MBO, and EUS-BD. To plan an appropriate E-RI strategy for biliary stent occlusion for MBO, the following must be considered on a case-by-case basis: the urgency of the drainage, the cause of the occlusion, the original route of drainage (PTBD/ERBD/EUS-BD), the initial stent used (plastic stent or self-expandable metallic stent), and in the case of self-expandable metallic stents, the type used (fully covered or uncovered). Regardless of the original method of stent placement, if the inflammation caused by obstructive cholangitis is severe and/or the patient is in shock, PTBD should be considered as the first choice. Finally, it is important to keep in mind that in many cases, performing E-RI will be difficult.Randomized Phase 3 LEAP-012 Study: Transarterial Chemoembolization With or Without Lenvatinib Plus Pembrolizumab for Intermediate-Stage Hepatocellular Carcinoma Not Amenable to Curative Treatment.Josep M Llovet; Arndt Vogel; David C Madoff; Richard S Finn; Sadahisa Ogasawara; Zhenggang Ren; Kalgi Mody; Jerry J Li; Abby B Siegel; Leonid Dubrovsky; Masatoshi KudoCardiovascular and interventional radiology 45 (4) 405 - 412 2022/02 PURPOSE: Transarterial chemoembolization (TACE) is the standard of care for patients with intermediate-stage hepatocellular carcinoma (HCC). Lenvatinib, a multikinase inhibitor, and pembrolizumab, a PD-1 inhibitor, have shown efficacy and tolerability in patients with HCC, and adding this combination to TACE may enhance clinical benefit. PROTOCOL: LEAP-012 is a prospective, double-blind randomized phase 3 study. Adults with confirmed HCC localized to the liver without portal vein thrombosis and not amenable to curative treatment, ≥ 1 measurable tumor per Response Evaluation Criteria in Solid Tumors 1.1 (RECIST 1.1), Eastern Cooperative Oncology Group performance status 0 or 1, Child-Pugh class A and no previous systemic treatment for HCC are eligible. Patients will be randomly assigned to lenvatinib once daily plus pembrolizumab every 6 weeks plus TACE or placebos plus TACE. Dual primary endpoints are overall survival and progression-free survival per RECIST 1.1 by blinded independent central review (BICR). Secondary endpoints are progression-free survival, objective response rate, disease control rate, duration of response and time to progression per modified RECIST by BICR; objective response rate, disease control rate, duration of response and time to progression per RECIST 1.1 by BICR; and safety. STATISTICS: The planned sample size, 950 patients, was calculated to permit accumulation of sufficient overall survival events in 5 years to achieve 90% power for the overall survival primary endpoint. DISCUSSION: LEAP-012 will evaluate the clinical benefit of adding lenvatinib plus pembrolizumab to TACE in patients with intermediate-stage HCC not amenable to curative treatment. ClinicalTrials.gov NCT04246177.腸内細菌に対する炎症性サイトカイン応答の増強を示すクローン病関連脊椎関節炎の一例福西 香栄; 本庶 元; 岡井 夏輝; 河野 匡志; 鎌田 研; 三長 孝輔; 米田 頼晃; 辻 成佳; 渡邉 智裕; 工藤 正俊日本消化器病学会近畿支部例会プログラム・抄録集 日本消化器病学会-近畿支部 116回 108 - 108 2022/02浸潤性膵管癌、腺扁平上皮癌が重複膵管に同時発生した1例加藤 弘樹; 大本 俊介; 原 茜; 大塚 康夫; 益田 康弘; 高島 耕太; 吉田 晃浩; 福永 朋洋; 岡本 彩那; 山崎 友裕; 鎌田 研; 三長 孝輔; 竹中 完; 筑後 孝章; 工藤 正俊日本消化器病学会近畿支部例会プログラム・抄録集 日本消化器病学会-近畿支部 116回 111 - 111 2022/02制御性T細胞に依存性しない寛解導入が得られたCollagenous Colitisの一例瀬海 郁衣; 本庶 元; 今村 瑞貴; 松原 卓哉; 河野 匡志; 原 茜; 栗本 真之; 吉川 馨介; 益田 康弘; 大塚 康生; 高田 隆太郎; 吉川 智恵; 鎌田 研; 三長 孝輔; 松井 繁長; 木村 雅友; 渡邉 智裕; 工藤 正俊日本消化器病学会近畿支部例会プログラム・抄録集 日本消化器病学会-近畿支部 116回 117 - 117 2022/02EUS-FNAにより診断が可能であった、後腹膜DLBCLの1例大丸 直哉; 松原 卓哉; 今村 瑞貴; 田中 秀和; 半田 康平; 河野 辰哉; 木下 大輔; 川崎 俊彦; 水野 成人; 若狭 朋子; 大谷 知之; 山田 薫; 花本 仁; 工藤 正俊日本消化器病学会近畿支部例会プログラム・抄録集 日本消化器病学会-近畿支部 116回 113 - 113 2022/02肝炎ウイルスコントロール下における課題へのアプローチ ICI投与とHBVフォローにおける問題点盛田 真弘; 萩原 智; 西田 直生志; 工藤 正俊日本消化器病学会近畿支部例会プログラム・抄録集 日本消化器病学会-近畿支部 116回 73 - 73 2022/02免疫チェックポイント阻害剤をめぐる諸問題 免疫チェックポイント阻害剤投与後に発現した肝障害の臨床的、病理学的検討萩原 智; 上嶋 一臣; 西田 直生志; 工藤 正俊日本消化器病学会近畿支部例会プログラム・抄録集 日本消化器病学会-近畿支部 116回 79 - 79 2022/02上・下腸間膜動静脈奇形に伴う門脈圧亢進からの難治性腹水及び循環血液量低下に伴う血圧低下に対し血管内治療(IVR)にて改善しえた1例上原 広樹; 田北 雅弘; 杉森 啓伸; 岡井 夏輝; 野村 健司; 盛田 真弘; 千品 寛和; 青木 智子; 萩原 智; 依田 広; 南 康範; 上嶋 一臣; 西田 直生志; 工藤 正俊日本消化器病学会近畿支部例会プログラム・抄録集 日本消化器病学会-近畿支部 116回 88 - 88 2022/02腸内細菌に対する炎症性サイトカイン応答の増強を示すクローン病関連脊椎関節炎の一例福西 香栄; 本庶 元; 岡井 夏輝; 河野 匡志; 鎌田 研; 三長 孝輔; 米田 頼晃; 辻 成佳; 渡邉 智裕; 工藤 正俊日本消化器病学会近畿支部例会プログラム・抄録集 日本消化器病学会-近畿支部 116回 108 - 108 2022/02浸潤性膵管癌、腺扁平上皮癌が重複膵管に同時発生した1例加藤 弘樹; 大本 俊介; 原 茜; 大塚 康夫; 益田 康弘; 高島 耕太; 吉田 晃浩; 福永 朋洋; 岡本 彩那; 山崎 友裕; 鎌田 研; 三長 孝輔; 竹中 完; 筑後 孝章; 工藤 正俊日本消化器病学会近畿支部例会プログラム・抄録集 日本消化器病学会-近畿支部 116回 111 - 111 2022/02膵癌診療の進歩と今後の展望 地域連携システムを用いた膵癌早期診断 MAGURO projectの成績益田 康弘; 山雄 健太郎; 竹中 完; 工藤 正俊日本消化器病学会近畿支部例会プログラム・抄録集 日本消化器病学会-近畿支部 116回 57 - 57 2022/02制御性T細胞に依存性しない寛解導入が得られたCollagenous Colitisの一例瀬海 郁衣; 本庶 元; 今村 瑞貴; 松原 卓哉; 河野 匡志; 原 茜; 栗本 真之; 吉川 馨介; 益田 康弘; 大塚 康生; 高田 隆太郎; 吉川 智恵; 鎌田 研; 三長 孝輔; 松井 繁長; 木村 雅友; 渡邉 智裕; 工藤 正俊日本消化器病学会近畿支部例会プログラム・抄録集 日本消化器病学会-近畿支部 116回 117 - 117 2022/02Response Evaluation Criteria in Cancer of the Liver version 6 (RECICL 2021 Revised Version).Masatoshi Kudo; Masafumi Ikeda; Kazuomi Ueshima; Michiie Sakamoto; Shuichiro Shiina; Ryosuke Tateishi; Kazuhiro Nouso; Kiyoshi Hasegawa; Junji Furuse; Shiro Miyayama; Takamichi Murakami; Tatsuya Yamashita; Norihiro KokudoHepatology research : the official journal of the Japan Society of Hepatology 52 (4) 329 - 336 2022/01 Response Evaluation Criteria in Solid Tumors (RECIST) is inappropriate to assess the direct effects of treatment on hepatocellular carcinoma (HCC) by locoregional therapies, such as radiofrequency ablation or transarterial chemoembolization. Therefore, establishment of response evaluation criteria solely devoted to HCC is needed in clinical practice, as well as in clinical trials of HCC treatment, such as systemic therapies, which cause necrosis of the tumor. Response Evaluation Criteria in Cancer of the Liver (RECICL) was revised in 2021 by the Liver Cancer Study Group of Japan based on the 2019 version of RECICL, which was commonly used in Japan. The major revised points of the RECICL 2021 is inclusion of RECIST 1.1 and modified RECIST as response evaluation criteria in systemic therapy for HCC. We hope this new treatment response criteria, RECICL, proposed by the Liver Cancer Study Group of Japan will benefit the HCC treatment response evaluation in the setting of daily clinical practice and clinical trials as well, not only in Japan, but also internationally This article is protected by copyright. All rights reserved.Value of artificial intelligence with novel tumor tracking technology in the diagnosis of gastric submucosal tumors by contrast-enhanced harmonic endoscopic ultrasonography.Hidekazu Tanaka; Ken Kamata; Rika Ishihara; Hisashi Handa; Yasuo Otsuka; Akihiro Yoshida; Tomoe Yoshikawa; Rei Ishikawa; Ayana Okamoto; Tomohiro Yamazaki; Atsushi Nakai; Shunsuke Omoto; Kosuke Minaga; Kentaro Yamao; Mamoru Takenaka; Tomohiro Watanabe; Naoshi Nishida; Masatoshi KudoJournal of gastroenterology and hepatology 37 (5) 841 - 846 2022/01 BACKGROUND AND AIM: Contrast-enhanced harmonic endoscopic ultrasonography (CH-EUS) is useful for the diagnosis of lesions inside and outside the digestive tract. This study evaluated the value of artificial intelligence (AI) in the diagnosis of gastric submucosal tumors by CH-EUS. METHODS: This retrospective study included 53 patients with gastrointestinal stromal tumors (GISTs) and leiomyomas, all of whom underwent CH-EUS between June 2015 and February 2020. A novel technology, SiamMask, was used to track and trim the lesions in CH-EUS videos. CH-EUS was evaluated by AI using deep learning involving a residual neural network and leave-one-out cross-validation. The diagnostic accuracy of AI in discriminating between GISTs and leiomyomas was assessed and compared with that of blind reading by two expert endosonographers. RESULTS: Of the 53 patients, 42 had GISTs and 11 had leiomyomas. Mean tumor size was 26.4 mm. The consistency rate of the segment range of the tumor image extracted by SiamMask and marked by the endosonographer was 96% with a Dice coefficient. The sensitivity, specificity, and accuracy of AI in diagnosing GIST were 90.5%, 90.9%, and 90.6%, respectively, whereas those of blind reading were 90.5%, 81.8%, and 88.7%, respectively (P = 0.683). The κ coefficient between the two reviewers was 0.713. CONCLUSIONS: The diagnostic ability of CH-EUS results evaluated by AI to distinguish between GISTs and leiomyomas was comparable with that of blind reading by expert endosonographers.Clinical Significance of the Duality of Wnt/β-Catenin Signaling in Human Hepatocellular Carcinoma.Tomoko Aoki; Naoshi Nishida; Masatoshi KudoCancers 14 (2) 2022/01 Combination therapy with immune checkpoint inhibitors (ICIs) and vascular endothelial growth factor inhibitors has been approved as a first-line treatment for unresectable hepatocellular carcinoma (HCC), indicating a critical role of ICIs in the treatment of HCC. However, 20% of patients do not respond effectively to ICIs; mutations in the activation of the Wnt/β-catenin pathway are known to contribute to primary resistance to ICIs. From this point of view, non-invasive detection of Wnt/β-catenin activation should be informative for the management of advanced HCC. Wnt/β-catenin mutations in HCC have a dual aspect, which results in two distinct tumor phenotypes. HCC with minimal vascular invasion, metastasis, and good prognosis is named the "Jekyll phenotype", while the poorly differentiated HCC subset with frequent vascular invasion and metastasis, cancer stem cell features, and high serum Alpha fetoprotein levels, is named the "Hyde phenotype". To differentiate these two HCC phenotypes, a combination of the hepatobiliary phase of gadolinium-ethoxybenzyl-diethylenetriamine (Gd-EOB-DTPA)-enhanced magnetic resonance imaging and fluoro-2-deoxy-D-glucose-PET/CT may be useful. The former is applicable for the detection of the Jekyll phenotype, as nodules present higher enhancement on the hepatobiliary phase, while the latter is likely to be informative for the detection of the Hyde phenotype by showing an increased glucose uptake.Feasibility and efficacy of endoscopic reintervention after covered metal stent placement for EUS-guided hepaticogastrostomy: A multicenter experience.Kosuke Minaga; Masayuki Kitano; Yoshito Uenoyama; Keiichi Hatamaru; Hideyuki Shiomi; Kenji Ikezawa; Tsukasa Miyagahara; Hajime Imai; Nao Fujimori; Hisakazu Matsumoto; Yuzo Shimokawa; Atsuhiro Masuda; Mamoru Takenaka; Masatoshi Kudo; Yasutaka ChibaEndoscopic ultrasound 11 (6) 478 - 486 2022 BACKGROUND AND OBJECTIVES: Although the use of a long metal stent is favored for EUS-guided hepaticogastrostomy (EUS-HGS) for the relief of malignant biliary obstruction (MBO), endoscopic reintervention (E-RI) at the time of recurrent biliary obstruction (RBO) is challenging due to a long intragastric portion. This study evaluated the feasibility and safety of E-RI after a long partially covered metal stent (L-PCMS) placement during EUS-HGS. MATERIALS AND METHODS: We performed a multicenter retrospective study between January 2015 and December 2019 examining patients with MBO who underwent E-RI for RBO through the EUS-HGS route after the L-PCMS placement. Technical and clinical success rates, details of E-RI, adverse events (AEs), stent patency, and survival time were evaluated. RESULTS: Thirty-three patients at eight referral centers in Japan who underwent E-RI through the EUS-HGS route were enrolled. The location of MBO was distal in 54.5%. The median intragastric length of the L-PCMS was 5 cm. As the first E-RI attempt, E-RI via the distal end of the existing L-PCMS was successful in 60.6%. The overall technical and clinical success rates of E-RI were 100% and 81.8%, respectively. Liver abscess was noted in one patient. A proximal biliary stricture was associated with the clinical ineffectiveness of E-RI in multivariable analysis (odds ratio, 12.5, P = 0.04). The median survival and stent patency duration after E-RI were 140 and 394 days, respectively. CONCLUSIONS: Our study findings suggest that E-RI for RBO after EUS-HGS with a L-PCMS is technically feasible and clinically effective, without any severe AEs, especially for patients with distal MBO.EUS-guided drainage of the gallbladder using a novel 0.018-inch guidewire for preventing bile leakage (with video).Mamoru Takenaka; Shunsuke Omoto; Masatoshi KudoEndoscopic ultrasound 11 (6) 520 - 521 2022【AIの足音は肝胆膵診療に聞こえてきたか!】肝臓学とAI 超音波画像でのAIを用いた肝腫瘤検出と鑑別診断西田 直生志; 山川 誠; 目加田 慶人; 椎名 毅; 工藤 正俊肝胆膵 (株)アークメディア 84 (1) 37 - 45 0389-4991 2022/01【AIの足音は肝胆膵診療に聞こえてきたか!】肝臓学とAI AIを用いたHCCに対するTKIの効果予測池田 裕亮; 道満 恵介; 目加田 慶人; 西田 直生志; 工藤 正俊肝胆膵 (株)アークメディア 84 (1) 63 - 68 0389-4991 2022/01[Current status of biliary drainage for acute cholangitis].Mamoru Takenaka; Masatoshi KudoNihon Shokakibyo Gakkai zasshi = The Japanese journal of gastro-enterology 119 (4) 285 - 294 2022Newly Developed Modified ALBI Grade Shows Better Prognostic and Predictive Value for Hepatocellular Carcinoma.Masatoshi KudoLiver cancer 11 (1) 1 - 8 2022/01The Systemic Inflammatory Response Identifies Patients with Adverse Clinical Outcome from Immunotherapy in Hepatocellular Carcinoma.Ambreen Muhammed; Claudia Angela Maria Fulgenzi; Sirish Dharmapuri; Matthias Pinter; Lorenz Balcar; Bernhard Scheiner; Thomas U Marron; Tomi Jun; Anwaar Saeed; Hannah Hildebrand; Mahvish Muzaffar; Musharraf Navaid; Abdul Rafeh Naqash; Anuhya Gampa; Umut Ozbek; Junk-Yi Lin; Ylenia Perone; Bruno Vincenzi; Marianna Silletta; Anjana Pillai; Yinghong Wang; Uqba Khan; Yi-Hsiang Huang; Dominik Bettinger; Yehia I Abugabal; Ahmed Kaseb; Tiziana Pressiani; Nicola Personeni; Lorenza Rimassa; Naoshi Nishida; Luca Di Tommaso; Masatoshi Kudo; Arndt Vogel; Francesco A Mauri; Alessio Cortellini; Rohini Sharma; Antonio D'Alessio; Celina Ang; David J PinatoCancers 14 (1) 2021/12 Systemic inflammation is a hallmark of cancer, and it has a pivotal role in hepatocellular carcinoma (HCC) development and progression. We conducted a retrospective study including 362 patients receiving immune check-point inhibitors (ICIs) across three continents, evaluating the influence of neutrophiles to lymphocytes ratio (NLR), platelets to lymphocytes ratio (PLR), and prognostic nutritional index (PNI) on overall (OS), progression free survival (PFS), and radiologic responses. In our 362 patients treated with immunotherapy, median OS and PFS were 9 and 3.5 months, respectively. Amongst tested inflammatory biomarkers, patients with NLR ≥ 5 had shorter OS (7.7 vs. 17.6 months, p Switching from entecavir to tenofovir disoproxil fumarate for HBeAg-positive chronic hepatitis B patients: a phase 4, prospective study.Fumitaka Suzuki; Yoshiyuki Suzuki; Yoshiyasu Karino; Yasuhito Tanaka; Masayuki Kurosaki; Hiroshi Yatsuhashi; Tomofumi Atarashi; Masanori Atsukawa; Tsunamasa Watanabe; Masaru Enomoto; Masatoshi Kudo; Naoto Maeda; Hiroshi Kohno; Kouji Joko; Kojiro Michitaka; Koichiro Miki; Kazuhiro Takahashi; Tatsuya Ide; Shigetoshi Fujiyama; Tomoko Kohno; Hiroshi Itoh; Sakiyo Tsukamoto; Yuko Suzuki; Yoshiaki Kawano; Wataru Sugiura; Hiromitsu KumadaBMC gastroenterology 21 (1) 489 - 489 2021/12 BACKGROUND: Tenofovir disoproxil fumarate (TDF) is widely used and recommended as first-line treatment for patients infected with the hepatitis B virus (HBV). However, current data are limited regarding the efficacy and safety of switching to TDF for the treatment of chronic hepatitis B in hepatitis B e-antigen (HBeAg)-positive patients who are virologically suppressed with another nucleos(t)ide analogue. The primary objective of this study was to evaluate the hepatitis B surface antigen (HBsAg) reduction potential of switching from entecavir (ETV) to TDF at week 48 in HBeAg-positive chronic hepatitis B patients with undetectable serum HBV-DNA. METHODS: In this multicenter, single-arm, open-label, phase 4 clinical study, 75 participants currently treated with ETV 0.5 mg once daily were switched to TDF 300 mg once daily for 96 weeks. RESULTS: At week 48, 3/74 participants (4%) achieved 0.25 log10 reduction of HBsAg levels from baseline (the primary endpoint). Mean HBsAg reduction was -0.14 log10 IU/mL and 12% (9/74) achieved 0.25 log10 reduction by 96 weeks. No participants achieved HBsAg seroclearance. HBsAg reduction at weeks 48 and 96 was numerically greater in participants with higher alanine aminotransferase levels (≥ 60 U/L). Seventeen participants (25%) achieved HBeAg seroclearance up to week 96. No participants experienced viral breakthrough. All drug-related adverse events (18 participants [24%]) were mild in intensity, including an increase in urine beta-2-microglobulin (15 participants [20%]). CONCLUSIONS: In conclusion, HBsAg reduction was limited after switching from ETV to TDF in this study population. Further investigation is warranted to better understand the clinical impact of switching from ETV to TDF. ClinicalTrials.gov: NCT03258710 registered August 21, 2017. https://clinicaltrials.gov/ct2/show/NCT03258710?term=NCT03258710&draw=2&rank=1.Objective Response Predicts Survival in Advanced Hepatocellular Carcinoma treated with Systemic Therapies.Masatoshi Kudo; Robert Montal; Richard S Finn; Florian Castet; Kazuomi Ueshima; Naoshi Nishida; Philipp K Haber; Youyou Hu; Yasutaka Chiba; Myron Schwartz; Tim Meyer; Riccardo Lencioni; Josep M LlovetClinical cancer research : an official journal of the American Association for Cancer Research 28 (16) 3443 - 3451 2021/12 PURPOSE: Due to the increased number of sequential treatments used for advanced HCC, there is a need for surrogate endpoints of overall survival (OS). We analyze if objective response (OR) is an independent predictor and surrogate endpoint of OS. EXPERIMENTAL DESIGN: A systematic review of randomized clinical trials (RCTs) in advanced HCC published between 2010 and 2020 was conducted to explore OS surrogacy of OR by RECIST and mRECIST. In parallel, RCTs exploring the impact of OR on OS in a time-dependent multivariate analysis were integrated in a meta-analysis. RESULTS: Out of 65 RCTs identified in advanced HCC, we analyzed 34 studies including 14,056 patients that reported OS and OR by either RECIST (n=23), mRECIST (n=5) or both (n=6). When exploring surrogacy, the trial-level correlation between OR odds ratio and OS hazard ratio was R=0.677 by mRECIST and R=0.532 by RECIST. Meta-analysis of five RCT assessing predictors of survival in multivariate analysis found that patients with OR by mRECIST presented a pooled HR for OS of 0.44 (95% CI, 0.27-0.70, p胆膵内視鏡 治療困難症例を克服するための工夫 当院における胆管ステント迷入に対する経乳頭的re-interventionへの取り組み大塚 康生; 山雄 健太郎; 竹中 完; 工藤 正俊日本消化器内視鏡学会近畿支部例会プログラム・抄録集 日本消化器内視鏡学会-近畿支部 107回 76 - 76 2021/12小腸ポリープからの出血によると思われる黒色便の1例大丸 直哉; 松原 卓哉; 今村 瑞貴; 河野 辰哉; 半田 康平; 田中 秀和; 木下 大輔; 川崎 俊彦; 水野 成人; 若狭 朋子; 大谷 知之; 工藤 正俊日本消化器内視鏡学会近畿支部例会プログラム・抄録集 日本消化器内視鏡学会-近畿支部 107回 108 - 108 2021/12【膵Interventionの最前線】悪性胃十二指腸閉塞に対する内視鏡的消化管ステンティング山雄 健太郎; 竹中 完; 高島 耕太; 吉田 晃浩; 岡本 彩那; 山崎 友裕; 大本 俊介; 鎌田 研; 三長 孝輔; 工藤 正俊肝胆膵 (株)アークメディア 83 (6) 899 - 904 0389-4991 2021/12【胆膵疾患、一歩進んだ診断のコツ】早期膵癌発見における膵実質萎縮の意義と検出方法山雄 健太郎; 竹中 完; 高島 耕太; 田中 秀和; 吉田 晃浩; 岡本 彩那; 山崎 友裕; 大本 俊介; 鎌田 研; 三長 孝輔; 工藤 正俊消化器・肝臓内科 (有)科学評論社 10 (6) 655 - 660 2432-3446 2021/12難治性胆膵疾患に対する内視鏡診療の取り組み 膵上皮内癌および良性膵管狭窄症例に特徴的なEUS所見の検討 多施設共同後ろ向き研究山雄 健太郎; 竹中 完; 南 竜城; 大花 正也; 工藤 正俊日本消化器内視鏡学会近畿支部例会プログラム・抄録集 日本消化器内視鏡学会-近畿支部 107回 53 - 53 2021/12胆膵内視鏡 治療困難症例を克服するための工夫 当院における胆管ステント迷入に対する経乳頭的re-interventionへの取り組み大塚 康生; 山雄 健太郎; 竹中 完; 工藤 正俊日本消化器内視鏡学会近畿支部例会プログラム・抄録集 日本消化器内視鏡学会-近畿支部 107回 76 - 76 2021/12診断に難渋した小腸GISTの一例福西 香栄; 永井 知行; 杉森 啓伸; 岡井 夏輝; 高田 隆太郎; 河野 匡志; 正木 翔; 米田 頼晃; 本庶 元; 松井 繁長; 渡邉 智裕; 辻 直子; 樫田 博史; 工藤 正俊日本消化器内視鏡学会近畿支部例会プログラム・抄録集 日本消化器内視鏡学会-近畿支部 107回 127 - 127 2021/12肝癌治療効果判定基準(第6版)(2021年改訂版)工藤 正俊; 池田 公史; 上嶋 一臣; 坂元 亨宇; 椎名 秀一朗; 建石 良介; 能祖 一裕; 長谷川 潔; 古瀬 純司; 宮山 士朗; 村上 卓道; 山下 竜也; 國土 典宏; 日本肝癌研究会肝癌治療効果判定基準作成委員会肝臓 (一社)日本肝臓学会 62 (12) 823 - 829 0451-4203 2021/12How should radiation exposure be handled in fluoroscopy-guided endoscopic procedures in the field of gastroenterology?Mamoru Takenaka; Makoto Hosono; Shiro Hayashi; Tsutomu Nishida; Masatoshi KudoDigestive endoscopy : official journal of the Japan Gastroenterological Endoscopy Society 2021/11 Fluoroscopy-guided endoscopic procedures (FGEPs) are rapidly gaining popularity in the field of gastroenterology. Radiation is a well-known health hazard. Gastroenterologists who perform FGEPs are required to protect themselves, patients, as well as nurses and radiologists engaged in examinations from radiation exposure. To achieve this, all gastroenterologists must first understand and adhere to the International Commission on Radiological Protection Publication. In particular, it is necessary to understand the three principles of radiation protection (Justification, Optimization, and Dose Limits), the As Low As Reasonably Achievable principle, and the Diagnostic Reference Levels (DRLs) according to them. This review will mainly explain the three principles of radiation exposure protection, DRLs, and occupational radiological protection in interventional procedures while introducing related findings. Gastroenterologists must gain knowledge of radiation exposure protection and keep it updated.Accumulation of Genetic and Epigenetic Alterations in the Background Liver and Emergence of Hepatocellular Carcinoma in Patients with Non-Alcoholic Fatty Liver DiseaseSatoru Hagiwara; Naoshi Nishida; Kazuomi Ueshima; Yasunori Minami; Yoriaki Komeda; Tomoko Aoki; Masahiro Takita; Masahiro Morita; Hirokazu Chishina; Akihiro Yoshida; Hiroshi Ida; Masatoshi KudoCells MDPI AG 10 (11) 3257 - 3257 2021/11 The incidence of hepatocellular carcinoma (HCC) related to non-alcoholic fatty liver disease (NAFLD) is increasing worldwide. We analyzed 16 surgically resected HCC cases in which the background liver was pathologically diagnosed as NAFLD. Specimens with Brunt classification grade 3 or higher were assigned as the fibrotic progression group (n = 8), and those with grade 1 or lower were classified as the non-fibrosis progression group (n = 8). Comprehensive mutational and methylome analysis was performed in cancerous and noncancerous tissues. The target gene mutation analysis with deep sequencing revealed that CTNNB1 and TP53 mutation was observed in 37.5% and TERT promoter mutation was detected in 50% of cancerous samples. Furthermore, somatic mutations in non-cancerous samples were less frequent, but were observed regardless of the progression of fibrosis. Similarly, on cluster analysis of methylome data, status for methylation events involving non-cancerous liver was similar regardless of the progression of fibrosis. It was found that, even in cases of non-progressive fibrosis, accumulation of gene mutations and abnormal methylation within non-cancerous areas were observed. Patients with NAFLD require a rigorous liver cancer surveillance due to the high risk of HCC emergence based on the accumulation of genetic and epigenetic abnormalities, even when fibrosis is not advanced.Early experience of atezolizumab plus bevacizumab treatment for unresectable hepatocellular carcinoma BCLC-B stage patients classified as beyond up to seven criteria - Multicenter analysis.Atsushi Hiraoka; Takashi Kumada; Toshifumi Tada; Masashi Hirooka; Kazuya Kariyama; Joji Tani; Masanori Atsukawa; Koichi Takaguchi; Ei Itobayashi; Shinya Fukunishi; Kunihiko Tsuji; Toru Ishikawa; Kazuto Tajiri; Hironori Ochi; Satoshi Yasuda; Hidenori Toyoda; Chikara Ogawa; Takashi Nishimura; Takeshi Hatanaka; Satoru Kakizaki; Noritomo Shimada; Kazuhito Kawata; Atsushi Naganuma; Takaaki Tanaka; Hideko Ohama; Kazuhiro Nouso; Asahiro Morishita; Akemi Tsutsui; Takuya Nagano; Norio Itokawa; Tomomi Okubo; Taeang Arai; Michitaka Imai; Yohei Koizumi; Shinichiro Nakamura; Kouji Joko; Hiroko Iijima; Yoichi Hiasa; Masatoshi KudoHepatology research : the official journal of the Japan Society of Hepatology 52 (3) 308 - 316 2021/11 BACKGROUND/AIM: Although systemic therapy is recommended for patients with multiple intermediate stage unresectable hepatocellular carcinoma (u-HCC) classified as beyond the up-to-7 criteria (UT-7 out/multiple) as a transcatheter arterial chemoembolization (TACE) unsuitable condition, few reports have examined the therapeutic efficacy of atezolizumab plus bevacizumab combination therapy (Atez/Bev) in such cases. This study aimed to elucidate the therapeutic response of Atez/Bev in u-HCC patients classified as UT-7 out/multiple. MATERIAL/METHODS: From September 2020 to September 2021, 95 u-HCC Japanese patients classified as UT-7 out/multiple/Child-Pugh A were enrolled from 21 institutions (median age 76 years, males 73, Child-Pugh 5:6 = 68:27, TNM stage II:III = 17:78). Therapeutic response was retrospectively evaluated using Response Evaluation Criteria in Solid Tumors (RECIST), ver. 1.1 and modified RECIST (mRECIST). RESULTS: Atez/Bev was given as first-line treatment to 52 (54.7%). Objective response rate (ORR)/disease control rate (DCR) at six weeks of RECIST and mRECIST were 17.7%/84.7% and 42.5%/86.2%, respectively. Median PFS was 8.0 months (median observation period: 6.0 months). Child-Pugh A/modified Albumin-bilirubin grade (mALBI) 1 and 2a at baseline, 3, 6, and 9 weeks, were 100%/69.4%, 89.8%/57.3%, 94.8%/65.3%, and 91.4%/60.0%, respectively. Among adverse events (any-grade, >10%) during the present observation period, general fatigue was most frequent (23.2%), followed by urine protein (21.1%), appetite loss (20.0%), and hypertension (13.7%). CONCLUSION: Atez/Bev treatment showed favorable therapeutic response with less influence on hepatic function, suggesting it as a useful therapeutic option for patients with such condition.Current Perspectives on the Immunosuppressive Niche and Role of Fibrosis in Hepatocellular Carcinoma and the Development of Antitumor Immunity.Tomoko Aoki; Naoshi Nishida; Masatoshi KudoThe journal of histochemistry and cytochemistry : official journal of the Histochemistry Society 70 (1) 221554211056853 - 221554211056853 2021/11 Immune checkpoint inhibitors have become the mainstay of treatment for hepatocellular carcinoma (HCC). However, they are ineffective in some cases. Previous studies have reported that genetic alterations in oncogenic pathways such as Wnt/β-catenin are the important triggers in HCC for primary refractoriness. T-cell exhaustion has been reported in various tumors and is likely to play a prominent role in the emergence of HCC due to chronic inflammation and cirrhosis-associated immune dysfunction. Immunosuppressive cells including regulatory T-cells and tumor-associated macrophages infiltrating the tumor are associated with hyperprogressive disease in the early stages of immune checkpoint inhibitor treatment. In addition, stellate cells and tumor-associated fibroblasts create an abundant desmoplastic environment by producing extracellular matrix. This strongly contributes to epithelial to mesenchymal transition via signaling activities including transforming growth factor beta, Wnt/β-catenin, and Hippo pathway. The abundant desmoplastic environment has been demonstrated in pancreatic ductal adenocarcinoma and cholangiocarcinoma to suppress cytotoxic T-cell infiltration, PD-L1 expression, and neoantigen expression, resulting in a highly immunosuppressive niche. It is possible that a similar immunosuppressive environment is created in HCC with advanced fibrosis in the background liver. Although sufficient understanding is required for the establishment of immune therapies of HCC, further investigations are still required in this field.ATP-binding cassette transporter G2(ABCG2)の発現低下はerythropoietic porphyria(EPP)における肝障害の重症化と関連する萩原 智; 西田 直生志; 工藤 正俊肝臓 (一社)日本肝臓学会 62 (Suppl.3) A737 - A737 0451-4203 2021/11Segmental arterial mediolysis(SAM)に伴う肝動脈瘤破裂に対して肝動脈塞栓術を施行した1例加藤 弘樹; 千品 寛和; 瀬海 郁衣; 盛田 真弘; 青木 智子; 田北 雅弘; 萩原 智; 南 康範; 依田 広; 上嶋 一臣; 西田 直生志; 工藤 正俊肝臓 (一社)日本肝臓学会 62 (Suppl.3) A824 - A824 0451-4203 2021/11超音波画像ナショナルデータベース構築とAI支援による次世代超音波診断システムの実用化工藤 正俊; 西田 直生志; 椎名 毅医療情報学連合大会論文集 (一社)日本医療情報学会 41回 176 - 180 1347-8508 2021/11A Novel Treatment Strategy for Patients with Intermediate-Stage HCC Who Are Not Suitable for TACE: Upfront Systemic Therapy Followed by Curative Conversion.Masatoshi KudoLiver cancer 10 (6) 539 - 544 2021/11Early Antibiotic Exposure Is Not Detrimental to Therapeutic Effect from Immunotherapy in Hepatocellular Carcinoma.Petros Fessas; Muntaha Naeem; Matthias Pinter; Thomas U Marron; David Szafron; Lorenz Balcar; Anwaar Saeed; Tomi Jun; Sirish Dharmapuri; Anuhya Gampa; Yinghong Wang; Uqba Khan; Mahvish Muzaffar; Musharraf Navaid; Pei-Chang Lee; Anushi Bulumulle; Bo Yu; Sonal Paul; Neil Nimkar; Dominik Bettinger; Hannah Hildebrand; Yehia I Abugabal; Tiziana Pressiani; Nicola Personeni; Naoshi Nishida; Masatoshi Kudo; Ahmed Kaseb; Yi-Hsiang Huang; Celina Ang; Anjana Pillai; Lorenza Rimassa; Abdul Rafeh Naqash; Elad Sharon; Alessio Cortellini; David J PinatoLiver cancer 10 (6) 583 - 592 2021/11 Background and Rationale: Immune checkpoint inhibitor (ICI) therapy is an expanding therapeutic option for hepatocellular carcinoma (HCC). Antibiotics (ATB) taken prior to or early during ICI therapy can impact immunotherapy efficacy across indications; however, the effect of ATB is undefined in HCC. Methods: In a large international cohort of 450 ICI recipients from Europe, North America, and Asia, we categorized patients according to timing of ATB focusing on exposure within -30 to +30 days from ICI (early immunotherapy period [EIOP]). EIOP was evaluated in association with overall survival (OS), progression-free survival (PFS), and best radiologic response using RECIST 1.1 criteria. Results: Our study comprised mostly cirrhotic (329, 73.3%) males (355, 79.1%) with a Child-Turcotte Pugh class of A (332, 73.9%), receiving ICI after 1 therapy line (251, 55.9%) for HCC of Barcelona clinic liver cancer stage C (325, 72.4%). EIOP (n = 170, 37.9%) was independent of baseline clinicopathologic features of HCC and correlated with longer PFS (6.1 vs. 3.7 months, log-rank p = 0.0135). EIOP+ patients had similar OS, overall response, and disease control rates (DCRs) compared to EIOP. The effect of EIOP persisted in landmark time analyses and in multivariable models, confirming the independent predictive role of EIOP in influencing PFS following adjustment for covariates reflective of tumor burden, liver function, and ICI regimen administered. In patients receiving programmed cell death-1 receptor/ligand inhibitors monotherapy, EIOP was also associated with higher DCRs (61.4% vs. 50.9%, p = 0.0494). Conclusions: Unlike other oncological indications, ATB in the 30 days before or after ICI initiation is associated with improved benefit from immunotherapy, independent of disease and treatment-related features. Evaluation of the immune microbiologic determinants of response to ICI in HCC warrants further investigation.Higher Enhancement Intrahepatic Nodules on the Hepatobiliary Phase of Gd-EOB-DTPA-Enhanced MRI as a Poor Responsive Marker of Anti-PD-1/PD-L1 Monotherapy for Unresectable Hepatocellular Carcinoma.Tomoko Aoki; Naoshi Nishida; Kazuomi Ueshima; Masahiro Morita; Hirokazu Chishina; Masahiro Takita; Satoru Hagiwara; Hiroshi Ida; Yasunori Minami; Akira Yamada; Keitaro Sofue; Masakatsu Tsurusaki; Masatoshi KudoLiver cancer 10 (6) 615 - 628 2021/11 Introduction: Immune checkpoint inhibitors (ICIs) are promising agents for the treatment of hepatocellular carcinoma (HCC). However, the establishment of noninvasive measure that could predict the response to ICIs is challenging. This study aimed to evaluate tumor responses to ICIs using the hepatobiliary phase of gadolinium-ethoxybenzyl-diethylenetriamine (Gd-EOB-DTPA)-enhanced magnetic resonance imaging (MRI), which was shown to reflect Wnt/β-catenin activating mutation. Methods: A total of 68 intrahepatic HCC nodules from 18 patients with unresectable HCC and Child-Pugh class A liver function who received anti-programmed cell death 1 (PD-1)/programmed death-ligand 1 (PD-L1) monotherapy were enrolled in this study. All patients had viable intrahepatic lesions evaluable using the hepatobiliary phase of Gd-EOB-DTPA-enhanced MRI within the 6 months prior to the treatment. The relative enhancement ratio was calculated, and the time to nodular progression (TTnP) defined as 20% or more increase in each nodule was compared between higher or hypo-enhancement HCC nodules. Then, the progression-free survival (PFS) and objective response rate (ORR) per Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1) were compared between patients with and without HCC nodules with higher enhancement on hepatobiliary phase images. Results: The median PFS was 2.7 (95% confidence interval [CI]: 1.4-4.0) months in patients with HCC nodules with higher enhancement (n = 8) and 5.8 (95% CI: 0.0-18.9) months in patients with hypointense HCC nodules (n = 10) (p = 0.007). The median TTnP of HCC nodules with higher enhancement (n = 23) was 1.97 (95% CI: 1.86-2.07) months and that of hypointense HCC nodules (n = 45) was not reached (p = 0.003). The ORR was 12.5% (1/8) versus 30.0% (3/10); the disease control rate was 37.5% (3/8) versus 70.0% (7/10), respectively, in patients with or without higher enhancement intrahepatic HCC nodules. Conclusion: The TTnP on HCC nodules with higher enhancement and the median PFS in patients who carried higher enhancement intrahepatic HCC nodules were significantly shorter than those in hypointense HCC nodules with anti-PD-1/PD-L1 monotherapy. The intensity of the nodule on the hepatobiliary phase of Gd-EOB-DTPA-enhanced MRI is a promising imaging biomarker for predicting unfavorable response with anti-PD-1/PD-L1 monotherapy in patients with HCC.Changing the Treatment Paradigm for Hepatocellular Carcinoma Using Atezolizumab plus Bevacizumab Combination Therapy.Masatoshi KudoCancers 13 (21) 2021/10 Atezolizumab plus bevacizumab combination therapy was approved worldwide for use in 2020. A 30% objective response rate with 8% complete response (CR) was achieved in a phase 3 IMbrave150 trial. Here, the change in the treatment strategy for hepatocellular carcinoma (HCC) using atezolizumab plus bevacizumab combination therapy is reviewed. The phase 3 IMbrave150 clinical trial was successful because of the direct antitumor effect of bevacizumab, which shifted the suppressive immune microenvironment to a responsive immune microenvironment, in addition to its synergistic effects when combined with atezolizumab. The analysis of CR cases was effective in patients with poor conditions, particularly tumor invasion in the main portal trunk (Vp4), making the combination therapy a breakthrough for HCC treatment. The response rate of the combination therapy was 44% against intermediate-stage HCC. Such a strong tumor-reduction effect paves the way for curative conversion (ABC conversion) therapy and, therefore, treatment strategies for intermediate-stage HCC may undergo a significant shift in the future. As these treatment strategies are effective in maintaining liver function, even in elderly patients, the transition frequency to second-line treatments could also be improved. These strategies may be effective against nonalcoholic steatohepatitis-related hepatocellular carcinoma and WNT/β-catenin mutations to a certain degree.Endoscopic ultrasound-guided biliary drainage with a 22-gauge needle and a 0.018-inch guidewire: Can it be the new standard?Kosuke Minaga; Mamoru Takenaka; Masatoshi KudoDigestive endoscopy : official journal of the Japan Gastroenterological Endoscopy Society 34 (1) 79 - 81 2021/10Analysis of Progression Time in Pancreatic Cancer including Carcinoma In Situ Based on Magnetic Resonance Cholangiopancreatography Findings.Kentaro Yamao; Masakatsu Tsurusaki; Kota Takashima; Hidekazu Tanaka; Akihiro Yoshida; Ayana Okamoto; Tomohiro Yamazaki; Shunsuke Omoto; Ken Kamata; Kosuke Minaga; Mamoru Takenaka; Takaaki Chikugo; Yasutaka Chiba; Tomohiro Watanabe; Masatoshi KudoDiagnostics (Basel, Switzerland) 11 (10) 2021/10 BACKGROUND: Pancreatic cancer (PC) exhibits extremely rapid growth; however, it remains largely unknown whether the early stages of PC also exhibit rapid growth speed equivalent to advanced PC. This study aimed to investigate the natural history of early PCs through retrospectively assessing pre-diagnostic images. METHODS: We examined the data of nine patients, including three patients with carcinoma in situ (CIS), who had undergone magnetic resonance cholangiopancreatography (MRCP) to detect solitary main pancreatic duct (MPD) stenosis >1 year before definitive PC diagnosis. We retrospectively analyzed the time to diagnosis and first-time tumor detection from the estimated time point of first-time MPD stenosis detection without tumor lesion. RESULTS: The median tumor size at diagnosis and the first-time tumor detection size were 14 and 7.5 mm, respectively. The median time to diagnosis and first-time tumor detection were 26 and 49 months, respectively. CONCLUSIONS: No studies have investigated the PC history, especially that of early PCs, including CIS, based on the initial detection of MPD stenosis using MRCP. Assessment of a small number of patients showed that the time to progression can take several years in the early PC stages. Understanding this natural history is very important in the clinical setting.ここまで進んだEUSとその関連手技 超音波内視鏡ガイド下腹腔神経叢ブロック(EUS-guided celiac plexus neurolysis:EUS-CPN)関連手技の現状竹中 完; 岡本 彩那; 山崎 友裕; 大本 俊介; 三長 孝輔; 鎌田 研; 山雄 健太郎; 工藤 正俊日本超音波医学会関西地方会学術集会 (公社)日本超音波医学会-関西地方会 48回 64 - 64 2021/10IPMNの壁在結節におけるDetective flow imaging(DFI)の有用性について高島 耕太; 大本 俊介; 吉田 晃浩; 岡本 彩那; 山崎 友裕; 三長 孝輔; 鎌田 研; 山雄 健太郎; 竹中 完; 工藤 正俊日本超音波医学会関西地方会学術集会 (公社)日本超音波医学会-関西地方会 48回 83 - 83 2021/10腹部超音波スクリーニング支援のための深層学習による撮影断面推定に関する初期検討目加田 慶人; 道満 恵介; 小川 眞広; 西田 直生志; 工藤 正俊日本医用画像工学会大会予稿集 (一社)日本医用画像工学会 40回 301 - 303 2021/10 本稿では,腹部超音波スクリーニングにおいて撮影された画像に対して,それが25断面撮影法のどの断面に対応しているかを推定する深層学習手法の初期的検討について述べる.25断面撮影法は腹部スクリーニングにおける診断の網羅性を保証するものであり,画像から撮影された断面が推定できることで腫瘍等が腹部のどの位置に存在しているのかを把握できる.25の断面画像には比較的類似した見えの画像も含まれているため,画像特徴の類似した断面をまとめたクラスとして扱う分類器に加えて,同一クラスと判定された画像をいずれかの断面に分類する分類器を利用する2段階の分類アルゴリズムを開発した.25断面を記録した267例の検査データセットを対象とした評価実験の結果,25クラス分類を単純に適用した場合の正解率が0.790であったのに対して,2段階の分類をする本手法により正解率が0.836に向上したことを確認した.(著者抄録)がん微小環境を標的とした消化器がん治療の新展望 肝細胞癌におけるWnt/βカテニン経路活性化と腫瘍免疫環境盛田 真弘; 西田 直生志; 工藤 正俊日本消化器病学会雑誌 (一財)日本消化器病学会 118 (臨増大会) A535 - A535 0446-6586 2021/10がん微小環境を標的とした消化器がん治療の新展望 肝細胞癌におけるWnt/βカテニン経路活性化と腫瘍免疫環境盛田 真弘; 西田 直生志; 工藤 正俊日本消化器病学会雑誌 (一財)日本消化器病学会 118 (臨増大会) A535 - A535 0446-6586 2021/10腹部超音波スクリーニング支援のための深層学習による撮影断面推定に関する初期検討目加田 慶人; 道満 恵介; 小川 眞広; 西田 直生志; 工藤 正俊日本医用画像工学会大会予稿集 (一社)日本医用画像工学会 40回 301 - 303 2021/10 本稿では,腹部超音波スクリーニングにおいて撮影された画像に対して,それが25断面撮影法のどの断面に対応しているかを推定する深層学習手法の初期的検討について述べる.25断面撮影法は腹部スクリーニングにおける診断の網羅性を保証するものであり,画像から撮影された断面が推定できることで腫瘍等が腹部のどの位置に存在しているのかを把握できる.25の断面画像には比較的類似した見えの画像も含まれているため,画像特徴の類似した断面をまとめたクラスとして扱う分類器に加えて,同一クラスと判定された画像をいずれかの断面に分類する分類器を利用する2段階の分類アルゴリズムを開発した.25断面を記録した267例の検査データセットを対象とした評価実験の結果,25クラス分類を単純に適用した場合の正解率が0.790であったのに対して,2段階の分類をする本手法により正解率が0.836に向上したことを確認した.(著者抄録)【肝胆膵疾患におけるバイオマーカーの意義を探る】膵疾患のバイオマーカー 自然免疫反応からみた自己免疫性膵炎・IgG4関連疾患の血清バイオマーカー IFN-α・IL-33原 茜; 三長 孝輔; 吉川 智恵; 鎌田 研; 渡邉 智裕; 工藤 正俊肝胆膵 (株)アークメディア 83 (4) 617 - 623 0389-4991 2021/10膵癌発癌から上皮内癌・浸潤癌への進展期間の検討 長期間にわたる回顧画像から見えてきたもの山雄 健太郎; 竹中 完; 工藤 正俊日本消化器病学会雑誌 (一財)日本消化器病学会 118 (臨増大会) A760 - A760 0446-6586 2021/10The radiation doses and radiation protection on the endoscopic retrograde cholangiopancreatography procedures.Mamoru Takenaka; Makoto Hosono; Shiro Hayashi; Tsutomu Nishida; Masatoshi KudoThe British journal of radiology 94 (1126) 20210399 - 20210399 2021/10 Although many interventions involving radiation exposure have been replaced to endoscopic procedure in the gastrointestinal and hepatobiliary fields, there remains no alternative for enteroscopy and endoscopic retrograde cholangiopancreatography (ERCP), which requires the use of radiation. In this review, we discuss the radiation doses and protective measures of endoscopic procedures, especially for ERCP. For the patient radiation dose, the average dose area product for diagnostic ERCP was 14-26 Gy.cm², while it increased to as high as 67-89 Gy.cm² for therapeutic ERCP. The corresponding entrance skin doses for diagnostic and therapeutic ERCP were 90 and 250 mGy, respectively. The mean effective doses were 3- 6 mSv for diagnostic ERCP and 12-20 mSv for therapeutic ERCP. For the occupational radiation dose, the typical doses were 94 μGy and 75 μGy for the eye and neck, respectively. However, with an over-couch-type X-ray unit, the eye and neck doses reached as high as 550 and 450 μGy, with maximal doses of up to 2.8 and 2.4 mGy/procedure, respectively.A protective lead shield was effective for an over couch X-ray tube unit. It lowered scattered radiation by up to 89.1% in a phantom study. In actual measurements, the radiation exposure of the endoscopist closest to the unit was reduced to approximately 12%. In conclusion, there is a clear need for raising awareness among medical personnel involved endoscopic procedures to minimise radiation risks to both the patients and staff.TNF-αおよびIL-6の関与が考えられた好酸球性胃腸炎の1例瀬海 郁衣; 吉川 馨介; 高田 隆太郎; 原 茜; 吉川 智恵; 鎌田 研; 三長 孝輔; 渡邉 智裕; 工藤 正俊日本消化器病学会近畿支部例会プログラム・抄録集 日本消化器病学会-近畿支部 115回 81 - 81 2021/09Detective flow imaging(DFI)にて特徴的な血流血管を観察し得たIntraductal papillary neoplasm of bile duct(IPNB)の2例上中 大地; 岡本 彩那; 大本 俊介; 原 茜; 大塚 康生; 益田 康弘; 高島 耕太; 吉田 晃浩; 山崎 友裕; 三長 孝輔; 鎌田 研; 山雄 健太郎; 竹中 完; 工藤 正俊日本消化器病学会近畿支部例会プログラム・抄録集 日本消化器病学会-近畿支部 115回 98 - 98 2021/09【TACE再考】Intermediate stage肝癌の新たな治療戦略 薬剤先行投与によるconversion治療工藤 正俊; 青木 智子; 上嶋 一臣; 西田 直生志肝胆膵 (株)アークメディア 83 (3) 475 - 483 0389-4991 2021/09B-mode超音波検査による肝腫瘍検出・診断を支援するAIモデルの開発西田 直生志; 工藤 正俊肝臓 (一社)日本肝臓学会 62 (Suppl.2) A457 - A457 0451-4203 2021/09薬物性肝障害の実態 免疫チェックポイント阻害剤投与後に発現した肝障害の臨床的、病理学的検討萩原 智; 西田 直生志; 工藤 正俊肝臓 (一社)日本肝臓学会 62 (Suppl.2) A515 - A515 0451-4203 2021/09Gd-EOB-DTPA-enhanced MRI肝細胞相で高信号の肝細胞癌は、PD-1/PD-L1療法への一次耐性を反映し予後不良である青木 智子; 上嶋 一臣; 盛田 真弘; 千品 寛和; 田北 雅弘; 萩原 智; 南 康範; 依田 広; 鶴崎 正勝; 西田 直生志; 工藤 正俊肝臓 (一社)日本肝臓学会 62 (Suppl.2) A552 - A552 0451-4203 2021/09【膵疾患に対する内視鏡診療のすべて】膵疾患に対する内視鏡治療 EUS下膵管ドレナージ術の実際竹中 完; 福永 朋洋; 高島 耕太; 田中 秀和; 吉田 晃浩; 岡本 彩那; 山崎 友裕; 大本 俊介; 三長 孝輔; 鎌田 研; 山雄 健太郎; 工藤 正俊消化器内視鏡 (株)東京医学社 33 (9) 1459 - 1466 0915-3217 2021/09 近年膵管内圧上昇による病態の治療として、外科的減圧治療、内視鏡的逆行性膵管ドレナージに加え、新たなドレナージ方法としてEUS下経消化管的膵管ドレナージ(EUS-PD)が報告されその有用性が報告されている。EUS-PDとは「胃や十二指腸から、EUSを用いて拡張膵管を描出し、EUS-FNAの要領で膵管にアクセスして内視鏡的にドレナージを行う手法」であるが、治療成績に関してはおおむね80%以上と高いものの手技成功率は63〜100%とばらつきがあり、最新のメタ解析では手技成功率は81.4%、臨床改善率は84.6%とされ、偶発症発症率は21.3%とされている。偶発症には出血や穿孔、頻度は低いながら重症膵炎なども報告されており、EUS-PDは同じEUS下ドレナージ治療であるEUS-BDと比較すると依然確立されていない適応を、慎重に検討する必要がある手技であると考えられる。本稿ではその適応と手技の実際について解説を行う。(著者抄録)EUS-FNAにて術前診断できた食道schwannomaの1例福西 香栄; 松井 繁長; 杉森 啓伸; 高田 隆太郎; 正木 翔; 河野 匡志; 永井 知行; 米田 頼晃; 山崎 友裕; 山雄 健太郎; 竹中 完; 本庶 元; 渡邉 智裕; 辻 直子; 樫田 博史; 工藤 正俊; 白石 治; 安田 卓司日本消化器病学会近畿支部例会プログラム・抄録集 日本消化器病学会-近畿支部 115回 79 - 79 2021/09Adjuvant Immunotherapy after Curative Treatment for Hepatocellular Carcinoma.Masatoshi KudoLiver cancer 10 (5) 399 - 403 2021/09Ramucirumab for Patients with Intermediate-Stage Hepatocellular Carcinoma and Elevated Alpha-Fetoprotein: Pooled Results from Two Phase 3 Studies (REACH and REACH-2).Masatoshi Kudo; Richard S Finn; Manabu Morimoto; Kun-Ming Rau; Masafumi Ikeda; Chia-Jui Yen; Peter R Galle; Josep M Llovet; Bruno Daniele; Ho Yeong Lim; David W McIlwain; Reigetsu Yoshikawa; Kenichi Nakamura; Kun Liang; Chunxiao Wang; Paolo Abada; Ryan C Widau; Andrew X ZhuLiver cancer 10 (5) 451 - 460 2021/09 Background: Intermediate-stage hepatocellular carcinoma (HCC), as defined by Barcelona Clinic Liver Cancer (BCLC) stage B, is heterogeneous in terms of liver function and tumor burden. REACH and REACH-2 investigated ramucirumab in patients with HCC after prior sorafenib, with REACH-2 enrolling only patients with baseline α-fetoprotein (AFP) ≥400 ng/mL. An exploratory analysis of outcomes by BCLC stage was performed. Methods: A pooled meta-analysis of independent patient data (stratified by study) from REACH (AFP ≥ 400 ng/mL) and REACH-2 was performed. All patients had Child-Pugh A, Eastern Cooperative Oncology Group performance status 0-1, prior sorafenib treatment, and either HCC BCLC stage B (refractory/not amenable to locoregional therapy) or BCLC stage C. Patients were randomized to ramucirumab 8 mg/kg or placebo every 2 weeks. Median overall survival (OS) and progression-free survival were estimated by the Kaplan-Meier method. Treatment effects in BCLC stage B and C were evaluated by Cox proportional-hazards model; prognosis of BCLC staging for OS was evaluated by multivariate Cox proportional-hazards model. Tumor responses were evaluated according to Response Evaluation in Solid Tumors v1.1. Liver function was assessed with albumin-bilirubin score. Results: Baseline characteristics were generally balanced between treatment arms in each BCLC stage. BCLC staging trended as an independent prognostic factor for OS (B vs. C; hazard ratio [HR] 0.756 [95% CI 0.546-1.046]). Consistent treatment benefit was observed for ramucirumab versus placebo across BCLC stages. Median OS for ramucirumab versus placebo was 13.7 versus 8.2 months; HR (95%): 0.43 (0.23-0.83) and 7.7 versus 4.8 months; HR (95%): 0.72 (0.59-0.89) for BCLC stage B and C, respectively. Adverse events (AEs) were consistent with observations from both studies; hypertension was the most frequent grade ≥3 AE. Liver function was preserved throughout the study and similar between treatment arms in both BCLC stages. Conclusions: Ramucirumab provided a better survival benefit irrespective of BCLC stage and was well tolerated without compromising liver function during treatment.Baseline Liver Function and Subsequent Outcomes in the Phase 3 REFLECT Study of Patients with Unresectable Hepatocellular Carcinoma.Arndt Vogel; Catherine Frenette; Max Sung; Bruno Daniele; Ari Baron; Stephen L Chan; Jean Frédéric Blanc; Toshiyuki Tamai; Min Ren; Howard J Lim; Daniel H Palmer; Yuko Takami; Masatoshi KudoLiver cancer 10 (5) 510 - 521 2021/09 Introduction: Baseline liver function among patients starting treatment for unresectable hepatocellular carcinoma (uHCC) impacts survival and could impact efficacy outcomes and safety profiles of treatments. This post hoc analysis of the phase 3 REFLECT study examined the efficacy and safety outcomes for lenvatinib and for sorafenib in patients with uHCC, assessed by Child-Pugh score (CPS) and albumin-bilirubin (ALBI) grade. Methods: Efficacy and safety were assessed in patient cohorts from REFLECT according to study entry baseline ALBI grade and CPS. Results: Lenvatinib treatment generally provided survival benefits in all groups. Median overall survival (OS) among patients with an ALBI grade of 1 was consistently higher than among patients with an ALBI grade of 2 for both the lenvatinib and sorafenib arms (lenvatinib: 17.4 vs. 8.6 months; sorafenib: 14.6 vs. 7.7 months, respectively). Median OS among patients with a CPS of 5 was consistently higher than among patients with a CPS of 6 (lenvatinib: 15.3 vs. 9.4 months; sorafenib: 14.2 vs. 7.9 months, respectively). Progression-free survival and objective response rates for these ALBI grades and CPS demonstrated similar patterns. Among patients who received lenvatinib and experienced a treatment-related treatment-emergent adverse event leading to withdrawal, 6.6% had an ALBI grade of 1, while 13.3% had an ALBI grade of 2, and 7.9% had a CPS of 5, while 12.1% had a CPS of 6. Conclusions: Better liver function at baseline, as measured by ALBI grade or CPS, may be prognostic for better survival outcomes in patients with uHCC undergoing treatment with lenvatinib or sorafenib.Improved Tumor Response to Lenvatinib Re-Treatment after Failure of Immune Checkpoint Inhibitors in a Patient with Advanced Hepatocellular Carcinoma.Satoru Hagiwara; Naoshi Nishida; Masatoshi KudoLiver cancer 10 (5) 535 - 538 2021/09Utility of contrast-enhanced harmonic endoscopic ultrasonography for T-staging of patients with extrahepatic bile duct cancerYasuo Otsuka; Ken Kamata; Tomoko Hyodo; Takaaki Chikugo; Akane Hara; Hidekazu Tanaka; Tomoe Yoshikawa; Rei Ishikawa; Ayana Okamoto; Tomohiro Yamazaki; Atsushi Nakai; Shunsuke Omoto; Kosuke Minaga; Kentaro Yamao; Mamoru Takenaka; Yasutaka Chiba; Tomohiro Watanabe; Takuya Nakai; Ippei Matsumoto; Yoshifumi Takeyama; Masatoshi KudoSurgical Endoscopy Springer Science and Business Media LLC 36 (5) 3254 - 3260 0930-2794 2021/08 BACKGROUND: The value of contrast-enhanced harmonic endoscopic ultrasonography (CH-EUS) for T-staging in patients with extrahepatic bile duct cancer was evaluated. METHODS: This single-center, retrospective study included consecutive patients with extrahepatic bile duct cancer who underwent surgical resection after preoperative EUS, CH-EUS, and contrast-enhanced CT (CE-CT) examinations between June 2014 and August 2017. The capacity of these modalities for T-staging of extrahepatic bile duct cancer was evaluated by assessing invasion beyond the biliary wall into the surrounding tissue, gallbladder, liver, pancreas, duodenum, portal vein system (portal vein and/or superior mesenteric vein), inferior vena cava, and hepatic arteries (proper hepatic artery, right. and/or left. hepatic artery). Blind reading of EUS, CH-EUS, and CE-CT images was performed by two expert reviewers each. RESULTS: 38 patients were eligible for analysis, of which eight had perihilar bile duct cancer and 30 had distal bile duct cancer. Postoperative T-staging was T1 in 6, T2 in 16, and T3 in 16 cases. CH-EUS was superior to CE-CT for diagnosing invasion beyond the biliary wall into surrounding tissue (92.1% vs. 45.9%, P = 0.0002); the ability to detect invasion to other organs did not differ significantly between the two modalities. The accuracy of CH-EUS for T-staging of tumors was better than that of CE-CT (73.7% vs. 39.5%, P = 0.0059). CH-EUS tended to have a better accuracy than EUS for the diagnosis of invasion beyond the biliary wall into the surrounding tissue (92.1% vs. 78.9%, P = 0.074) and T-staging (73.7% vs. 60.5%, P = 0.074). CONCLUSION: CH-EUS is useful for T-staging of extra hepatic bile duct cancer, especially in terms of invasion beyond the biliary wall into the surrounding tissue.Value of Low-Mechanical-Index Contrast-Enhanced Transabdominal Ultrasound for Diagnosis of Pancreatic Cancer: A Meta-analysis.Yasunobu Yamashita; Toshio Shimokawa; Reiko Ashida; Christoph F Dietrich; Mirko D'Onofrio; Yoshiki Hirooka; Masatoshi Kudo; Hideaki Mori; Atsushi Sofuni; Masayuki KitanoUltrasound in medicine & biology 47 (12) 3315 - 3322 2021/08 The incidence and mortality rates of pancreatic cancer (PC) are increasing. It is important to discriminate PC from the other pancreatic lesions; however, differential diagnosis based on conventional transabdominal ultrasound (US) remains challenging even though US is often the first examination performed. Transabdominal contrast-enhanced ultrasound (CEUS) has high diagnostic accuracy for PC. This meta-analysis aimed to examine the utility of low-mechanical-index CEUS with enhancement for PC diagnosis. A systematic meta-analysis of all potentially relevant articles was performed. Fixed-effects or random-effects models were used to investigate pooled sensitivity, specificity, positive likelihood ratio (LR) and negative LR. The study enrolled 983 patients from nine eligible studies. The pooled estimates of sensitivity and specificity were 92% (95% confidence interval [CI]: 0.89-0.94) and 76% (95% CI: 0.71-0.81), respectively. The diagnostic odds ratio (DOR) for CEUS was high (53.62). The area under the summary receiver operating characteristic curve was 0.95. Funnel plots revealed no publication bias, and there was no significant relationship between the DORs and study characteristics, including continent, type of contrast agent, contrast agent dosage and scan phase. Only number of patients affected diagnostic ability. This meta-analysis indicates that CEUS with enhancement pattern is useful for diagnosis of PC.Diagnostic Value of EUS-Guided Fine-Needle Aspiration Biopsy for Gastric Linitis Plastica with Negative Endoscopic BiopsyRyutaro Takada; Kosuke Minaga; Akane Hara; Yasuo Otsuka; Shunsuke Omoto; Ken Kamata; Kentaro Yamao; Mamoru Takenaka; Satoru Hagiwara; Hajime Honjo; Shigenaga Matsui; Takaaki Chikugo; Tomohiro Watanabe; Masatoshi KudoJournal of Clinical Medicine MDPI AG 10 (16) 3716 - 3716 2021/08 Due to the tendency of gastric linitis plastica (GLP) to cause extensive submucosal infiltration, a superficial endoscopic biopsy sometimes yields no evidence of malignancy, hindering definite diagnosis. The present study was a single-center retrospective analysis of 54 consecutive patients diagnosed with GLP between 2016 and 2020 to evaluate EUS-guided fine-needle aspiration (EUS-FNA) biopsy outcomes in patients with negative endoscopic biopsy findings. A pathological GLP diagnosis was achieved by endoscopic biopsy in 40 patients (74.1%). EUS-FNA biopsy with a 22-gauge needle was performed in 13 of the remaining 14 patients, and GLP diagnosis was confirmed in 10 patients, with a median of three needle passes. The remaining four patients were laparoscopically diagnosed with GLP. The diagnostic ability of EUS-FNA biopsy for GLP was 76.9%, and EUS-FNA biopsy contributed to GLP diagnosis in 18.5% (10/54) of all cases. None of the 13 patients exhibited EUS-FNA biopsy-related adverse events. Univariable and multivariable analyses revealed an absence of superficial ulcerations as a predictor of false-negative endoscopic biopsy findings in patients with GLP. These results suggest EUS-FNA biopsy as a minimally invasive and safe alternative diagnostic modality for GLP in cases where conventional endoscopic biopsy fails to verify malignancy, although prospective studies with larger cohorts are warranted to confirm these findings.Efficacy of lenvatinib for unresectable hepatocellular carcinoma based on background liver disease etiology: multi-center retrospective study.Atsushi Hiraoka; Takashi Kumada; Toshifumi Tada; Joji Tani; Kazuya Kariyama; Shinya Fukunishi; Masanori Atsukawa; Masashi Hirooka; Kunihiko Tsuji; Toru Ishikawa; Koichi Takaguchi; Ei Itobayashi; Kazuto Tajiri; Noritomo Shimada; Hiroshi Shibata; Hironori Ochi; Kazuhito Kawata; Satoshi Yasuda; Hidenori Toyoda; Tomoko Aoki; Takaaki Tanaka; Hideko Ohama; Kazuhiro Nouso; Akemi Tsutsui; Takuya Nagano; Norio Itokawa; Taeang Arai; Tomomi Okubo; Michitaka Imai; Yohei Koizumi; Shinichiro Nakamura; Koji Joko; Yoichi Hiasa; Masatoshi KudoScientific reports 11 (1) 16663 - 16663 2021/08 It was recently reported that hepatocellular carcinoma (HCC) patients with non-alcoholic steatohepatitis (NASH) are not responsive to immune-checkpoint inhibitor (ICI) treatment. The present study aimed to evaluate the therapeutic efficacy of lenvatinib in patients with non-alcoholic fatty liver disease (NAFLD)/NASH-related unresectable-HCC (u-HCC). Five hundred thirty u-HCC patients with Child-Pugh A were enrolled, and divided into the NAFLD/NASH (n = 103) and Viral/Alcohol (n = 427) groups. Clinical features were compared in a retrospective manner. Progression-free survival (PFS) was better in the NAFLD/NASH than the Viral/Alcohol group (median 9.3 vs. 7.5 months, P = 0.012), while there was no significant difference in overall survival (OS) (20.5 vs. 16.9 months, P = 0.057). In Cox-hazard analysis of prognostic factors for PFS, elevated ALT (≥ 30 U/L) (HR 1.247, P = 0.029), modified ALBI grade 2b (HR 1.236, P = 0.047), elevated AFP (≥ 400 ng/mL) (HR 1.294, P = 0.014), and NAFLD/NASH etiology (HR 0.763, P = 0.036) were significant prognostic factors. NAFLD/NASH etiology was not a significant prognostic factor in Cox-hazard analysis for OS (HR0.758, P = 0.092), whereas AFP (≥ 400 ng/mL) (HR 1.402, P = 0.009), BCLC C stage (HR 1.297, P = 0.035), later line use (HR 0.737, P = 0.014), and modified ALBI grade 2b (HR 1.875, P 胆嚢病変に対するDetective flow imaging(DFI)の有用性について高島 耕太; 大本 俊介; 大塚 康生; 吉田 晃浩; 吉川 智恵; 岡本 彩那; 山崎 友裕; 三長 孝輔; 鎌田 研; 山雄 健太朗; 竹中 完; 工藤 正俊胆道 (一社)日本胆道学会 35 (3) 519 - 519 0914-0077 2021/08特別鼎談 最新の肝癌薬物療法を語る工藤正俊; 土谷 薫; 長谷川 潔肝胆膵 163 (179) 2021/08 [Refereed]X線透視下胆管擦過細胞診・胆管生検の診断能についての検討田中 秀和; 水野 成人; 橋本 和彦; 大谷 知之; 若狹 朋子; 福永 朋洋; 工藤 正俊胆道 (一社)日本胆道学会 35 (3) 425 - 425 0914-0077 2021/08【ここまできた肝細胞癌の薬物療法:2021 update】免疫療法の動向 WNT/β-catenin経路の活性化と免疫療法の効果盛田 真弘; 西田 直生志; 工藤 正俊肝胆膵 (株)アークメディア 83 (2) 197 - 207 0389-4991 2021/08膵疾患におけるinterventional endoscopyの進歩 Walled-off necrosisに対するContrast enhanced EUS-guided cyst drainageの有用性竹中 完; 高島 耕太; 田中 秀和; 福永 朋洋; 吉田 晃浩; 岡本 彩那; 山崎 友裕; 大本 俊介; 三長 孝輔; 鎌田 研; 山雄 健太郎; 工藤 正俊膵臓 (一社)日本膵臓学会 36 (3) A200 - A200 0913-0071 2021/08胆嚢病変に対するDetective flow imaging(DFI)の有用性について高島 耕太; 大本 俊介; 大塚 康生; 吉田 晃浩; 吉川 智恵; 岡本 彩那; 山崎 友裕; 三長 孝輔; 鎌田 研; 山雄 健太朗; 竹中 完; 工藤 正俊胆道 日本胆道学会 35 (3) 519 - 519 0914-0077 2021/08X線透視下胆管擦過細胞診・胆管生検の診断能についての検討田中 秀和; 水野 成人; 橋本 和彦; 大谷 知之; 若狹 朋子; 福永 朋洋; 工藤 正俊胆道 日本胆道学会 35 (3) 425 - 425 0914-0077 2021/08膵疾患におけるinterventional endoscopyの進歩 Walled-off necrosisに対するContrast enhanced EUS-guided cyst drainageの有用性竹中 完; 高島 耕太; 田中 秀和; 福永 朋洋; 吉田 晃浩; 岡本 彩那; 山崎 友裕; 大本 俊介; 三長 孝輔; 鎌田 研; 山雄 健太郎; 工藤 正俊膵臓 (一社)日本膵臓学会 36 (3) A200 - A200 0913-0071 2021/08【ここまできた肝細胞癌の薬物療法:2021 update】免疫療法の動向 WNT/β-catenin経路の活性化と免疫療法の効果盛田 真弘; 西田 直生志; 工藤 正俊肝胆膵 (株)アークメディア 83 (2) 197 - 207 0389-4991 2021/08Plasmacytoid Dendritic Cells as a New Therapeutic Target for Autoimmune Pancreatitis and IgG4-Related DiseaseKosuke Minaga; Tomohiro Watanabe; Akane Hara; Tomoe Yoshikawa; Ken Kamata; Masatoshi KudoFrontiers in Immunology Frontiers Media SA 12 2021/07 Although plasmacytoid dendritic cells (pDCs) able to produce large amounts of type 1 interferons (IFN-I) play beneficial roles in host defense against viral infections, excessive activation of pDCs, followed by robust production of IFN-I, causes autoimmune disorders including systemic lupus erythematosus (SLE) and psoriasis. Autoimmune pancreatitis (AIP), which is recognized as a pancreatic manifestation of systemic immunoglobulin G4-related disease (IgG4-RD), is a chronic fibroinflammatory disorder driven by autoimmunity. IgG4-RD is a multi-organ autoimmune disorder characterized by elevated serum concentrations of IgG4 antibody and infiltration of IgG4-expressing plasmacytes in the affected organs. Although the immunopathogenesis of IgG4-RD and AIP has been poorly elucidated, recently, we found that activation of pDCs mediates the development of murine experimental AIP and human AIP/IgG4-RD via the production of IFN-I and interleukin-33 (IL-33). Depletion of pDCs or neutralization of signaling pathways mediated by IFN-I and IL-33 efficiently inhibited the development of experimental AIP. Furthermore, enhanced expression of IFN-I and IL-33 was observed in the pancreas and serum of human AIP/IgG4-RD. Thus, AIP and IgG4-RD share their immunopathogenesis with SLE and psoriasis because in all these conditions, IFN-I production by pDCs contributes to the pathogenesis. Because the enhanced production of IFN-I and IL-33 by pDCs promotes chronic inflammation and fibrosis characteristic for AIP and IgG4-RD, neutralization of IFN-I and IL-33 could be a new therapeutic option for these disorders. In this Mini Review, we discuss the pathogenic roles played by the pDC-IFN-I-IL-33 axis and the development of a new treatment targeting this axis in AIP and IgG4-RD.Safety, Efficacy, and Pharmacodynamics of Tremelimumab Plus Durvalumab for Patients With Unresectable Hepatocellular Carcinoma: Randomized Expansion of a Phase I/II Study.Robin Kate Kelley; Bruno Sangro; William Harris; Masafumi Ikeda; Takuji Okusaka; Yoon-Koo Kang; Shukui Qin; David W-M Tai; Ho Yeong Lim; Thomas Yau; Wei-Peng Yong; Ann-Lii Cheng; Antonio Gasbarrini; Silvia Damian; Jordi Bruix; Mitesh Borad; Johanna Bendell; Tae-You Kim; Nathan Standifer; Philip He; Mallory Makowsky; Alejandra Negro; Masatoshi Kudo; Ghassan K Abou-AlfaJournal of clinical oncology : official journal of the American Society of Clinical Oncology JCO2003555  2021/07 PURPOSE: This phase I/II study evaluated tremelimumab (anticytotoxic T-lymphocyte-associated antigen-4 monoclonal antibody) and durvalumab (antiprogrammed death ligand-1 monoclonal antibody) as monotherapies and in combination for patients with unresectable hepatocellular carcinoma (HCC), including a novel regimen featuring a single, priming dose of tremelimumab (ClinicalTrials.gov identifier: NCT02519348). PATIENTS AND METHODS: Patients with HCC who had progressed on, were intolerant to, or refused sorafenib were randomly assigned to receive T300 + D (tremelimumab 300 mg plus durvalumab 1,500 mg [one dose each during the first cycle] followed by durvalumab 1,500 mg once every 4 weeks), durvalumab monotherapy (1,500 mg once every 4 weeks), tremelimumab monotherapy (750 mg once every 4 weeks [seven doses] and then once every 12 weeks), or T75 + D (tremelimumab 75 mg once every 4 weeks plus durvalumab 1,500 mg once every 4 weeks [four doses] followed by durvalumab 1,500 mg once every 4 weeks). Safety was the primary end point. Secondary end points included objective response rate (ORR) by Response Evaluation Criteria in Solid Tumors v1.1 and overall survival; exploratory end points included circulating lymphocyte profiles. RESULTS: A total of 332 patients were enrolled (T300 + D, n = 75; durvalumab, n = 104; tremelimumab, n = 69; and T75 + D, n = 84). Tolerability was acceptable across arms, with grade ≥ 3 treatment-related adverse events occurring in 37.8%, 20.8%, 43.5%, and 24.4%, respectively. Confirmed ORRs (95% CI) were 24.0% (14.9 to 35.3), 10.6% (5.4 to 18.1), 7.2% (2.4 to 16.1), and 9.5% (4.2 to 17.9), respectively. An early expansion of CD8+ lymphocytes was associated with response across arms, with highest proliferating CD8+ lymphocyte levels occurring in the T300 + D arm. The median (95% CI) overall survival was 18.7 (10.8 to 27.3), 13.6 (8.7 to 17.6), 15.1 (11.3 to 20.5), and 11.3 (8.4 to 15.0) months in the T300 + D, durvalumab, tremelimumab, and T75 + D arms, respectively. CONCLUSION: All regimens were found to be tolerable and clinically active; however, the T300 + D regimen demonstrated the most encouraging benefit-risk profile. The unique pharmacodynamic activity and association with ORR of the T300 + D regimen further support its continued evaluation in HCC.Case Report: Regulatory T Cell-Independent Induction of Remission in a Patient With Collagenous ColitisHajime Honjo; Tomohiro Watanabe; Mizuki Tomooka; Takuya Matsubara; Masashi Kono; Ikue Sekai; Akane Hara; Masayuki Kurimoto; Keisuke Yoshikawa; Yasuhiro Masuta; Yasuo Otsuka; Ryutaro Takada; Tomoe Yoshikawa; Ken Kamata; Kosuke Minaga; Shigenaga Matsui; Masatomo Kimura; Masatoshi KudoFrontiers in Medicine Frontiers Media SA 8 2021/07 Collagenous colitis (CC), a prototypical microscopic colitis, is a chronic inflammatory disorder of the colon. The diagnosis of CC depends on the pathological examination. The colonic mucosa of patients with CC is characterized by the presence of a substantially thickened collagen band (>10μm) under the surface epithelium. In addition, intraepithelial and lamina propria lymphocytes are markedly increased in patients with CC. However, the roles played by the lymphocytes accumulating in the colonic mucosa of patients with CC are poorly defined. Recent studies indicate that T cells infiltrating the colonic mucosa of patients with CC are mainly represented by CD4+ T cells, CD8+ T cells, and forkhead box P3 (FOXP3)+ regulatory T cells (Tregs). Given that activation of CD4+/CD8+ T cells and FOXP3+ Tregs usually mediates pro-inflammatory and anti-inflammatory responses, respectively, alterations in the colonic numbers of these adaptive T cells might be related to the resolution of colitis in patients with CC. We determined alterations in the composition of colonic T cells by extensive immunohistochemical (IHC) analyses in a case of CC successfully treated with budesonide and metronidazole. Colonic lamina propria immune cells mainly comprised CD3+ T cells, CD4+ T cells, CD8+ T cells, CD68+ macrophages, and FOXP3+ Tregs, but not CD20+ B cells or myeloperoxidase (MPO)+ granulocytes in the active phase. During remission, the numbers of CD3+ T cells, CD4+ T cells, CD8+ T cells, and CD68+ macrophages did not change significantly in the colonic lamina propria, whereas FOXP3+ Tregs were markedly decreased, suggesting that induction of remission was achieved in a Treg-independent manner. Thus, our study indicates that accumulation of FOXP3+ Tregs in the colonic mucosa of patients with CC might be a counter-regulatory mechanism reflecting persistent inflammation and that induction of remission might be achieved without activation of Tregs.Integrative analysis of gut microbiome and host transcriptomes reveals associations between treatment outcomes and immunotherapy-induced colitis.Toshiharu Sakurai; Marco A De Velasco; Kazuko Sakai; Tomoyuki Nagai; Hiroki Nishiyama; Kentaro Hashimoto; Hirotsugu Uemura; Hisato Kawakami; Kazuhiko Nakagawa; Hiroyuki Ogata; Kazuto Nishio; Masatoshi KudoMolecular oncology 2021/07 Immune checkpoint inhibitors (ICIs) are widely used to treat various malignancies. Although the gut microbiome is known to influence the efficacy of ICIs on epithelial tumors, the functional interactions between gut taxa and colonic mucosa remain poorly understood. Here we performed transcriptomic profiling and 16S rRNA sequencing to investigate the relationships between mucosal gene expression and microbial composition with ICI responses and gastrointestinal immune-related adverse events (GI irAEs). In responders, genes related to DNA repair and cell cycle signatures were enriched in responders whereas signatures related to innate immune response, NFAT and IFN-γ signaling pathways were enriched in nonresponders. Gut microbial composition revealed an association between moderate GI irAE and favorable response to ICI therapy. Favorable therapeutic responses to ICI and GI irAE treatments were associated with taxa classified as Enterobacteriaceae and were related to ribonucleoprotein complex biogenesis, cytokine-mediated signaling pathway, tRNA metabolic process, and ribonucleoprotein complex assembly in the colon. These findings open new perspectives for improving the efficacy and safety of cancer immunotherapy.Can the Entire Ablative Hyperechoic Zone be Regarded as a Necrotic Lesion After Radiofrequency Ablation of the Liver?Yasunori Minami; Masahiro Morita; Hirokazu Chishina; Tomoko Aoki; Masahiro Takita; Satoru Hagiwara; Hiroshi Ida; Kazuomi Ueshima; Naoshi Nishida; Masatoshi KudoUltrasound in medicine & biology 47 (10) 2930 - 2935 2021/07 Developments in image fusion technology made it possible to visualize the ablative margin on ultrasound (US). The purpose of the present study was to assess the ablative area of radiofrequency ablation for hepatocellular carcinoma and compare it with the ablative hyperechoic zone with a non-enhanced area on contrast-enhanced US/contrast-enhanced computed tomography (CEUS/CECT) in the same cross-section. This retrospective study included 25 patients with 27 hepatocellular carcinomas. The long and short dimensions of the ablative hyperechoic zone were measured using B-mode US, and those of the non-enhanced area were assessed with CEUS/CECT on the same cross-section measured with B-mode US, using image fusion techniques. The technical effectiveness of ablation with an adequate ablative margin in a single session was determined in all patients. The long and short dimensions of the ablative hyperechoic zone ranged between 15.0 and 40.7 mm (mean: 27.3 ± 6.9 mm) and between 14.0 and 33.0 mm (mean: 23.3 ± 5.8 mm), respectively. R values for the long and short dimensions were 0.99 and 0.98, respectively, between B-mode US and CEUS, and 0.96 and 0.92, respectively, between B-mode US and CECT. The ablative hyperechoic zone may be regarded as a necrotic lesion after radiofrequency ablation.Immunohistochemical characterization of granulomatosis with polyangiitis exhibiting spontaneous regression.Yasuhiro Masuta; Yoriaki Komeda; Ikue Sekai; Akane Hara; Masayuki Kurimoto; Keisuke Yoshikawa; Yasuo Otsuka; Ryutaro Takada; Tomoe Yoshikawa; Ken Kamata; Kosuke Minaga; Osamu Maenishi; Tomohiro Watanabe; Masatoshi KudoAsian Pacific journal of allergy and immunology 2021/07 BACKGROUND: Granulomatosis with polyangiitis (GPA) is characterized by granulomatous inflammation, vasculitis, and elevated levels of serum proteinase 3 (PR3)-anti-neutrophil cytoplasmic antibody (PR3-ANCA). OBJECTIVE: We tried to characterize immune cells accumulated into the lung lesions of a GPA patient exhibiting spontaneous regression. METHODS: Transbronchial lung biopsy (TBLB) samples were subjected to immunohistochemical analyses. RESULTS: Multiple lung nodules were detected by CT. TBLB showed granulomatous inflammation and small vessel vasculitis. This case was diagnosed as GPA based on pathological findings and elevation of PR-3 ANCA levels. Spontaneous disappearance of multiple lung nodules was observed in CT. CD3+ T cells and CD20+ B cells accumulated in the inflammatory lesions surrounding the vessels whereas granulomatous inflammation was mainly comprised of CD3+ T cells and CD68+ macrophages, but not B cells or myeloperoxidase+ neutrophils. CONCLUSIONS: We characterized immune cell compositions of the lung lesions of a patient with GPA exhibiting spontaneous regression.Castor oil as booster for colon capsule endoscopy preparation reduction: A prospective pilot study and patient questionnaire.Kota Takashima; Yoriaki Komeda; Toshiharu Sakurai; Sho Masaki; Tomoyuki Nagai; Shigenaga Matsui; Satoru Hagiwara; Mamoru Takenaka; Naoshi Nishida; Hiroshi Kashida; Konosuke Nakaji; Tomohiro Watanabe; Masatoshi KudoWorld journal of gastrointestinal pharmacology and therapeutics 12 (4) 79 - 89 2021/07 BACKGROUND: Preparation for colon capsule endoscopy (CCE) requires a large liquid laxative volume for capsule excretion, which compromises the procedure's tolerability. AIM: To assess the safety and utility of castor oil-boosted bowel preparation. METHODS: This prospective cohort study including 20 patients (age range, 16-80 years; six men and 14 women) suspected of having colorectal disease was conducted at Kindai University Hospital from September 2017 to August 2019. All patients underwent CCE because of the following inclusion criteria: previous incomplete colonoscopy in other facility (n = 20), history of abdominal surgery (n = 7), or organ abnormalities such as multiple diverticulum (n = 4) and adhesion after surgery (n = 6). The exclusion criteria were as follows: Dysphagia, history of allergic reactions to the drugs used in this study (magnesium citrate, polyethylene glycol, metoclopramide, and castor oil), possibility of pregnancy, possibility of bowel obstruction or stenosis based on symptoms, or scheduled magnetic resonance imaging within 2 wk after CCE. The primary outcome was the capsule excretion rate within the battery life, as evaluated by the total large bowel observation rate, large bowel transit time, and bowel creasing level using a five-grade scale in different colorectal segments. The secondary outcomes were complications, colorectal lesion detection rates, and patients' tolerability. RESULTS: The castor oil-based regimen was implemented in 17 patients. Three patients cancelled CCE because they could tolerate castor oil, but not liquid laxatives. The capsule excretion rate within the battery life was 88% (15/17). The mean large bowel transit time was 236 min. Approximately 70% of patients had satisfactory colon cleansing levels. CCE detected colon polyps (14/17, 82%) and colonic diverticulum (4/12, 33%). The sensitivity, specificity, and diagnostic accuracy rates for detecting colorectal polyps (size ≥ 6 mm) were 76.9%, 75.0%, and 76.4%, respectively. The sensitivity, specificity, and diagnostic accuracy rates for detection of diverticulum were 100% each. Twelve patients (71%) rated CCE as more than "good", confirming the new regimen's tolerability. No serious adverse events occurred during this study. CONCLUSION: The castor oil-based regimen could reduce bowel preparation dose and improve CCE tolerability.胆膵疾患に対する内視鏡診断・治療の工夫 膵上皮内癌におけるEUS所見の検討 多施設共同後ろ向き研究山雄 健太郎; 竹中 完; 樫田 博史; 工藤 正俊日本消化器内視鏡学会近畿支部例会プログラム・抄録集 日本消化器内視鏡学会-近畿支部 106回 59 - 59 2021/07胆膵内視鏡のトラブルマネジメント 胆道Plastic StentドレナージのRe-interventionにおけるSnare Over The Guidewire法の有用性吉田 晃浩; 竹中 完; 山雄 健太郎; 樫田 博史; 工藤 正俊日本消化器内視鏡学会近畿支部例会プログラム・抄録集 日本消化器内視鏡学会-近畿支部 106回 77 - 77 2021/07内視鏡で保存的に回収できた胃石の1例杉森 啓伸; 本庶 元; 原 茜; 益田 康弘; 吉田 早希; 高田 隆太郎; 河野 匡志; 正木 翔; 永井 知行; 米田 頼晃; 櫻井 俊治; 松井 繁長; 渡邉 智裕; 辻 直子; 樫田 博史; 工藤 正俊日本消化器内視鏡学会近畿支部例会プログラム・抄録集 日本消化器内視鏡学会-近畿支部 106回 98 - 98 2021/07カプセルおよびバルーン小腸内視鏡で比較的早期に発見し根治手術を行った原発性小腸癌の1例吉田 早希; 米田 頼晃; 原 茜; 益田 康弘; 高田 隆太郎; 正木 翔; 河野 匡志; 永井 知行; 本庶 元; 松井 繁長; 櫻井 俊治; 辻 直子; 樫田 博史; 工藤 正俊日本消化器内視鏡学会近畿支部例会プログラム・抄録集 日本消化器内視鏡学会-近畿支部 106回 100 - 100 2021/07内視鏡で保存的に回収できた胃石の1例杉森 啓伸; 本庶 元; 原 茜; 益田 康弘; 吉田 早希; 高田 隆太郎; 河野 匡志; 正木 翔; 永井 知行; 米田 頼晃; 櫻井 俊治; 松井 繁長; 渡邉 智裕; 辻 直子; 樫田 博史; 工藤 正俊日本消化器内視鏡学会近畿支部例会プログラム・抄録集 日本消化器内視鏡学会-近畿支部 106回 98 - 98 2021/07カプセルおよびバルーン小腸内視鏡で比較的早期に発見し根治手術を行った原発性小腸癌の1例吉田 早希; 米田 頼晃; 原 茜; 益田 康弘; 高田 隆太郎; 正木 翔; 河野 匡志; 永井 知行; 本庶 元; 松井 繁長; 櫻井 俊治; 辻 直子; 樫田 博史; 工藤 正俊日本消化器内視鏡学会近畿支部例会プログラム・抄録集 日本消化器内視鏡学会-近畿支部 106回 100 - 100 2021/07Immunological Microenvironment Predicts the Survival of the Patients with Hepatocellular Carcinoma Treated with Anti-PD-1 AntibodyMasahiro Morita; Naoshi Nishida; Kazuko Sakai; Tomoko Aoki; Hirokazu Chishina; Masahiro Takita; Hiroshi Ida; Satoru Hagiwara; Yasunori Minami; Kazuomi Ueshima; Kazuto Nishio; Yukari Kobayashi; Kazuhiro Kakimi; Masatoshi KudoLiver Cancer 10 (4) 380 - 393 2235-1795 2021/07 Introduction: Although immune checkpoint inhibitors (ICIs) have been considered as promising agents for the treatment of advanced hepatocellular carcinoma (HCC), previous clinical trials revealed that the response to anti-programmed cell death protein 1 (anti-PD-1) monotherapy was as low as 20%. Identifying subgroups that respond well to ICIs is clinically important. Here, we studied the prognostic factors for anti-PD-1 antibody treatment based on the molecular and immunological features of HCC. Methods: Patients who were administered anti-PD1 antibody for advanced HCC at Kindai University Hospital were included. Clinicopathological backgrounds and antitumor responses were examined in 34 cases where tumor tissues before treatment were available. Transcriptome analysis was performed using 40 HCC samples obtained from surgical resection, and immune status was compared between 20 HCCs with activating mutations in β-catenin and those without the mutations using transcriptome-based immunogram. Results: Univariate analysis showed that the disease control rate was significantly better in patients with α-fetoprotein Efficacy of Over-The-Scope Clip Method as a Novel Hemostatic Therapy for Colonic Diverticular Bleeding.Koichiro Kawano; Mamoru Takenaka; Reiko Kawano; Daisuke Kagoshige; Yuta Kawase; Tomonori Moriguchi; Hiroshi Tanabe; Takao Katoh; Katsuhisa Nishi; Masatoshi KudoJournal of clinical medicine 10 (13) 2021/06 Colonic diverticular could bleed recurrently, and, sometimes, fatal massive bleeding could occur. However, the choice of endoscopic hemostasis remains controversial. Although the over-the-scope clip (OTSC) method has been reported to be effective, it has not been fully evaluated due to the small number of cases. This study aimed to evaluate the efficacy of the OTSC method for colonic diverticular bleeding. Between August 2017 and December 2020, 36 consecutive patients, including those who could not be treated using endoscopic band ligation (EBL) and those in whom re-bleeding had occurred after EBL, underwent the OTSC method for hemostasis of colonic diverticular bleeding at Hyogo Prefectural Awaji Medical Center. The procedure success rate, adverse events rate, early phase re-bleeding rate (within 30 days following primary hemostasis), and the requirement rate for additional transcatheter arterial embolization (TAE) or surgery were the outcomes assessed. The outcomes were procedure success rate 100%, adverse events rate 0%, early phase re-bleeding rate 8.3%, and additional TAE or surgery rate 0%. These results suggest that the OTSC method is a safe and effective treatment for managing colonic diverticular bleeding.Usefulness of the Novel Snare-over-the-Guidewire Method for Transpapillary Plastic Stent Replacement (with Video).Akihiro Yoshida; Mamoru Takenaka; Kota Takashima; Hidekazu Tanaka; Ayana Okamoto; Tomohiro Yamazaki; Atsushi Nakai; Shunsuke Omoto; Kosuke Minaga; Ken Kamata; Kentaro Yamao; Yoriaki Komeda; Naoshi Nishida; Masatoshi KudoJournal of clinical medicine 10 (13) 2021/06 Unsuccessful stent replacement in transpapillary biliary drainage with plastic stents (PSs) has a significant impact on patient prognosis; thus, a safe and reliable replacement method is required. We aimed to compare the snare-over-the-guidewire (SOG) method, wherein the PS lumen is used as an access route to the biliary tract and the PS is removed with a snare inserted via the inserted guidewire, with the conventional side-of-stent (SOS) method, wherein the biliary approach is performed from the side of the PS. This retrospective single-center study included 244 consecutive patients who underwent biliary PS replacement between January 2018 and July 2020. The procedural success rates were compared between the two methods. A predictive analysis of unsuccessful PS replacement was also performed. The procedural success rate in the SOG group was significantly higher than that in the SOS group (p = 0.026). In the proximal biliary stenosis lesion, the same trend was observed (p = 0.025). Multivariate analysis also showed that the SOS method (p = 0.0038), the presence of proximal biliary stenosis (p Ramucirumab in patients with previously treated advanced hepatocellular carcinoma: Impact of liver disease etiology.Peter R Galle; Masatoshi Kudo; Josep M Llovet; Richard S Finn; Mark Karwal; Denis Pezet; Tae-You Kim; Tsai-Sheng Yang; Sara Lonardi; Jiri Tomasek; Jean-Marc Phelip; Yann Touchefeu; Su-Jin Koh; Guido Stirnimann; Kun Liang; Kenyon D Ogburn; Chunxiao Wang; Paolo Abada; Ryan C Widau; Andrew X ZhuLiver international : official journal of the International Association for the Study of the Liver 2021/06 BACKGROUND & AIMS: Hepatocellular carcinoma (HCC) is a common complication of chronic liver disease with diverse underlying etiologies. REACH/REACH-2 were global phase III studies investigating ramucirumab in advanced HCC (aHCC) following sorafenib treatment. We performed an exploratory analysis of outcomes by liver disease etiology and baseline serum viral load. METHODS: Meta-analysis was conducted in patients with aHCC and alpha-fetoprotein (AFP) ≥400 ng/mL (N=542) from REACH/REACH-2 trials. Individual patient-level data were pooled with results reported by etiology subgroup (hepatitis B [HBV] or C [HCV] and Other). Pretreatment serum HBV-DNA and HCV-RNA were quantified using Roche COBAS AmpliPrep/COBAS TaqMan. Overall survival (OS) and progression-free survival (PFS) were evaluated using the Kaplan-Meier method and Cox proportional hazard model (stratified by study). RESULTS: Baseline characteristics were generally balanced between arms in each subgroup (HBV: N=225, HCV: N=127, Other: N=190). No significant difference in treatment effect by etiology subgroup was detected (OS interaction p-value= 0.23). Median OS (ramucirumab vs placebo) in months was 7.7 versus 4.5 (HR 0.74; 95% CI 0.55-0.99) for HBV, 8.2 versus 5.5 (HR 0.82; 95% CI 0.55-1.23) for HCV, and 8.5 versus 5.4 (HR 0.56; 95% CI 0.40-0.79) for Other. Ramucirumab showed similar overall safety profiles across subgroups. Worst outcomes were noted in patients with a detectable HBV load. Use of HBV antiviral therapy, irrespective of viral load, was beneficial for survival, liver function, and liver-specific adverse events. CONCLUSIONS: Ramucirumab improved survival across etiology subgroups with a tolerable safety profile, supporting its use in patients with aHCC and elevated AFP.NOD2 deficiency protects mice from the development of adoptive transfer colitis through the induction of regulatory T cells expressing forkhead box P3.Ryutaro Takada; Tomohiro Watanabe; Akane Hara; Ikue Sekai; Masayuki Kurimoto; Yasuo Otsuka; Yasuhiro Masuta; Tomoe Yoshikawa; Ken Kamata; Kosuke Minaga; Masatoshi KudoBiochemical and biophysical research communications 568 55 - 61 2021/06 Nucleotide-binding oligomerization domain 2 (NOD2) is an intracellular receptor for muramyl dipeptide derived from the intestinal microbiota. Loss-of-function mutations in Nod2 are associated with the development of Crohn's disease, suggesting that NOD2 signaling plays critical roles in the maintenance of intestinal immune homeostasis. Although NOD2 activation prevents the development of short-term experimental colitis, it remains unknown whether the sensitivity to long-term experimental colitis is influenced by NOD2. In this study, we explored the roles played by NOD2 in the development of long-term adoptive transfer colitis. Unexpectedly, we found that Rag1-/-Nod2-/- mice were more resistant to adoptive transfer colitis than Rag1-/- mice and had reduced proinflammatory cytokine responses and enhanced accumulation of regulatory T cells (Tregs) expressing forkhead box P3 in the colonic mucosa. Prevention of colitis in Rag1-/-Nod2-/- mice was mediated by TGF-β1 because neutralization of TGF-β1 resulted in the development of more severe colitis due to reduced accumulation of Tregs. Such paradoxical Treg responses in the absence of NOD2 could explain why Nod2 mutations in humans are not sufficient to cause Crohn's disease.Novel troubleshooting technique for the migration of a biliary plastic stent using a thin balloon catheter (with video).Mamoru Takenaka; Atsushi Nakai; Masatoshi KudoJournal of hepato-biliary-pancreatic sciences 2021/06 Plastic stents (PSs) are commonly used to for obstructive jaundice (1, 2), but there are difficulties associated with removing migrated PSs. (3-5) A 75-year-old woman presented with obstructive jaundice due to hilar cholangiocarcinoma, and two PSs were inserted. After two years, re-intervention for the occlusion of PSs was performed. However, the right PS was migrated in the common bile duct above the papilla.Cumulative radiation doses from recurrent PET/CT examinations.Makoto Hosono; Mamoru Takenaka; Hajime Monzen; Mikoto Tamura; Masatoshi Kudo; Yasumasa NishimuraThe British journal of radiology 94 (1126) 20210388 - 20210388 2021/06 Positron emission tomography (PET)/computed tomography (CT) is an essential imaging modality for the management of various diseases. Increasing numbers of PET/CT examinations are carried out across the world and deliver benefits to patients; however, there are concerns about the cumulative radiation doses from these examinations in patients. Compared to the radiation exposure delivered by CT, there have been few reports on the frequency of patients with a cumulative effective radiation dose of ≥100 mSv from repeated PET/CT examinations. The emerging dose tracking system facilitates surveys on patient cumulative doses by PET/CT because it can easily wrap up exposure doses of PET radiopharmaceuticals and CT. Regardless of the use of a dose tracking system, implementation of justification for PET/CT examinations and utilisation of dose reduction measures are key issues in coping with the cumulative dose in patients. Despite all the advantages of PET/MRI such as eliminating radiation exposure from CT and providing good tissue contrast in MRI, it is expensive and cannot be introduced at every facility; thus, it is still necessary to utilise PET/CT with radiation reduction measures in most clinical situations.Atezolizumab plus bevacizumab treatment for unresectable hepatocellular carcinoma: Early clinical experience.Atsushi Hiraoka; Takashi Kumada; Toshifumi Tada; Masashi Hirooka; Kazuya Kariyama; Joji Tani; Masanori Atsukawa; Koichi Takaguchi; Ei Itobayashi; Shinya Fukunishi; Kunihiko Tsuji; Toru Ishikawa; Kazuto Tajiri; Hironori Ochi; Satoshi Yasuda; Hidenori Toyoda; Chikara Ogawa; Takashi Nishimura; Takeshi Hatanaka; Hideko Ohama; Kazuhiro Nouso; Asahiro Morishita; Akemi Tsutsui; Takuya Nagano; Norio Itokawa; Tomomi Okubo; Taeang Arai; Michitaka Imai; Yohei Koizumi; Shinichiro Nakamura; Kouji Joko; Hiroko Iijima; Yoichi Hiasa; Masatoshi KudoCancer reports (Hoboken, N.J.) 5 (2) e1464  2021/06 BACKGROUND: Although atezolizumab plus bevacizumab (Atez/bev) treatment has been developed for unresectable hepatocellular carcinoma (u-HCC), changes in hepatic function during therapy have yet to be reported. AIM: This retrospective clinical study aimed to elucidate early responses to Atez/Bev. METHODS: From September 2020 to April 2021, 171 u-HCC patients undergoing Atez/Bev treatment were enrolled (BCLC stage A:B:C:D = 5:68:96:2). Of those, 75 had no prior history of systemic treatment. Relative changes in hepatic function and therapeutic response were assessed using albumin-bilirubin (ALBI) score and Response Evaluation Criteria in Solid Tumors (RECIST), ver. 1.1, respectively. RESULTS: In initial imaging examination findings, objective response rates for early tumor shrinkage and disease control after 6 weeks (ORR-6W/DCR-6W) were 10.6%/79.6%. Similar response results were observed in patients with and without a past history of systemic treatment (ORR-6W/DCR-6W = 9.7%/77.8% and 12.2%/82.9%), as well as patients in whom Atez/Bev was used as post-progression treatment following lenvatinib (ORR-6W/DCR-6W = 7.7%/79.5%), for which no known effective post-progression treatment has been established. In 111 patients who underwent a 6-week observation period, ALBI score was significantly worsened at 3 weeks after introducing Atez/Bev (-2.525 ± 0.419 vs -2.323 ± 0.445, p Comparison of radiation exposure between endoscopic ultrasound-guided drainage and transpapillary drainage by endoscopic retrograde cholangiopancreatography for pancreatobiliary diseases.Mamoru Takenaka; Makoto Hosono; Madan M Rehani; Yasutaka Chiba; Rei Ishikawa; Ayana Okamoto; Tomohiro Yamazaki; Atsushi Nakai; Shunsuke Omoto; Kosuke Minaga; Ken Kamata; Kentaro Yamao; Shiro Hayashi; Tsutomu Nishida; Masatoshi KudoDigestive endoscopy : official journal of the Japan Gastroenterological Endoscopy Society 34 (3) 579 - 586 2021/06 OBJECTIVES: The transpapillary drainage by endoscopic retrograde cholangiopancreatography (ERCP-D) cannot be performed without fluoroscopy, and there are many situations in which fluoroscopy is required even in endoscopic ultrasound-guided drainage (EUS-D). Previous studies have compared the efficacy, but not the radiation exposure of EUS-D and ERCP-D. While radiation exposure in ERCP-D has been previously evaluated, there is a paucity of information regarding radiation doses in EUS-D. This study aimed to assess radiation exposure in EUS-D compared with that in ERCP-D. METHODS: This retrospective single-center cohort study included consecutive patients who underwent EUS-D and ERCP-D between October 2017 and March 2019. The air kerma (AK: mGy), kerma-area product (KAP: Gycm2 ), fluoroscopy time (FT: min), and procedure time (PT: min) were assessed. The invasive probability weighting method was used to qualify the comparisons. RESULTS: We enrolled 372 and 105 patients who underwent ERCP-D and EUS-D, respectively. The mean AK, KAP, and FT in the EUS-D group were higher by 53%, 28%, and 27%, respectively, than those in the ERCP-D group, whereas PT was shorter by approximately 11% (AK; 135.0 vs. 88.4, KAP; 28.1 vs. 21.9, FT; 20.4 vs. 16.0, PT; 38.7 vs. 43.5). The sub-analysis limited to biliary drainage cases showed the same trend (AK; 128.3 vs. 90.9, KAP; 27.0 vs. 22.2, FT; 16.4 vs. 16.1, PT; 32.5 vs. 44.4). CONCLUSIONS: This is the first study to assess radiation exposure in EUS-D compared with that in ERCP-D. Radiation exposure was significantly higher in EUS-D than in ERCP-D, despite the shorter procedure time.Pharmacodynamic Biomarkers Predictive of Survival Benefit with Lenvatinib in Unresectable Hepatocellular Carcinoma: From the Phase 3 REFLECT Study.Richard S Finn; Masatoshi Kudo; Ann-Lii Cheng; Lucjan Wyrwicz; Roger Kai-Cheong Ngan; Jean-Frederic Blanc; Ari D Baron; Arndt Vogel; Masafumi Ikeda; Fabio Piscaglia; Kwang-Hyub Han; Shu-Kui Qin; Yukinori Minoshima; Michio Kanekiyo; Min Ren; Ryo Dairiki; Toshiyuki Tamai; Corina E Dutcus; Hiroki Ikezawa; Yasuhiro Funahashi; Thomas R Jeffry EvansClinical cancer research : an official journal of the American Association for Cancer Research 2021/06 PURPOSE: In REFLECT, lenvatinib demonstrated an effect on overall survival (OS) by confirmation of noninferiority to sorafenib in unresectable hepatocellular carcinoma. This analysis assessed correlations between serum or tissue biomarkers and efficacy outcomes from REFLECT. EXPERIMENTAL DESIGN: Serum biomarkers (VEGF, ANG2, FGF19, FGF21, and FGF23) were measured by ELISA. Gene expression in tumor tissues was measured by the nCounter PanCancer Pathways Panel. Pharmacodynamic changes in serum biomarker levels from baseline, and associations of clinical outcomes with baseline biomarker levels were evaluated. RESULTS: 407 patients were included in the serum analysis set (lenvatinib n=279, sorafenib n=128); 58 patients were included in the gene-expression analysis set (lenvatinib n=34, sorafenib n=24). Both treatments were associated with increases in VEGF; only lenvatinib was associated with increases in FGF19 and FGF23 at all timepoints. Lenvatinib-treated responders had greater increases in FGF19 and FGF23 versus non-responders at C4D1 (FGF19: 55.2% vs 18.3%, P=0.014; FGF23: 48.4% vs 16.4%, P=0.0022, respectively). Higher baseline VEGF, ANG2, and FGF21 correlated with shorter OS in both treatment groups. OS was longer for lenvatinib than sorafenib (median, 10.9 vs 6.8 months, respectively; HR, 0.53; 95% CI, 0.33-0.85; P=0.0075; P-interaction=0.0397) with higher baseline FGF21. In tumor tissue biomarker analysis, VEGF/FGF enriched groups showed improved OS with lenvatinib versus the intermediate VEGF/FGF group (HR 0.39; 95% CI 0.16-0.91; P=0.0253). CONCLUSIONS: Higher baseline levels of VEGF, FGF21, and ANG2 may be prognostic for shorter OS. Higher baseline FGF21 may be predictive for longer OS with lenvatinib compared with sorafenib, but this needs confirmation.Nontraumatic tube method for detecting a vessel responsible for colonic diverticular hemorrhage.Koichiro Kawano; Mamoru Takenaka; Reiko Kawano; Daisuke Kagoshige; Takao Kato; Katsuhisa Nishi; Masatoshi KudoEndoscopy 54 (5) E240-E241  2021/06β-カテニン陽性の肝細胞癌に対してアテゾリズマブ+ベバシズマブ療法が奏効した1例喜田 行洋; 小川 力; 金澤 秀晃; 坂上 純也; 真鍋 卓嗣; 松浦 賢史; 久保 敦司; 松中 寿浩; 玉置 敬之; 柴峠 光成; 辻 晃仁; 工藤 正俊日本消化器病学会四国支部例会プログラム・抄録集 日本消化器病学会-四国支部 115回 57 - 57 2021/06Surveillance, Diagnosis, and Treatment Outcomes of Hepatocellular Carcinoma in Japan: 2021 Update.Masatoshi KudoLiver cancer 10 (3) 167 - 180 2021/06Management of Hepatocellular Carcinoma in Japan: JSH Consensus Statements and Recommendations 2021 Update.Masatoshi Kudo; Yusuke Kawamura; Kiyoshi Hasegawa; Ryosuke Tateishi; Kazuya Kariyama; Shuichiro Shiina; Hidenori Toyoda; Yasuharu Imai; Atsushi Hiraoka; Masafumi Ikeda; Namiki Izumi; Michihisa Moriguchi; Sadahisa Ogasawara; Yasunori Minami; Kazuomi Ueshima; Takamichi Murakami; Shiro Miyayama; Osamu Nakashima; Hirohisa Yano; Michiie Sakamoto; Etsuro Hatano; Mitsuo Shimada; Norihiro Kokudo; Satoshi Mochida; Tetsuo TakeharaLiver cancer 10 (3) 181 - 223 2021/06 The Clinical Practice Manual for Hepatocellular Carcinoma was published based on evidence confirmed by the Evidence-based Clinical Practice Guidelines for Hepatocellular Carcinoma along with consensus opinion among a Japan Society of Hepatology (JSH) expert panel on hepatocellular carcinoma (HCC). Since the JSH Clinical Practice Guidelines are based on original articles with extremely high levels of evidence, expert opinions on HCC management in clinical practice or consensus on newly developed treatments are not included. However, the practice manual incorporates the literature based on clinical data, expert opinion, and real-world clinical practice currently conducted in Japan to facilitate its use by clinicians. Alongside each revision of the JSH Guidelines, we issued an update to the manual, with the first edition of the manual published in 2007, the second edition in 2010, the third edition in 2015, and the fourth edition in 2020, which includes the 2017 edition of the JSH Guideline. This article is an excerpt from the fourth edition of the HCC Clinical Practice Manual focusing on pathology, diagnosis, and treatment of HCC. It is designed as a practical manual different from the latest version of the JSH Clinical Practice Guidelines. This practice manual was written by an expert panel from the JSH, with emphasis on the consensus statements and recommendations for the management of HCC proposed by the JSH expert panel. In this article, we included newly developed clinical practices that are relatively common among Japanese experts in this field, although all of their statements are not associated with a high level of evidence, but these practices are likely to be incorporated into guidelines in the future. To write this article, coauthors from different institutions drafted the content and then critically reviewed each other's work. The revised content was then critically reviewed by the Board of Directors and the Planning and Public Relations Committee of JSH before publication to confirm the consensus statements and recommendations. The consensus statements and recommendations presented in this report represent measures actually being conducted at the highest-level HCC treatment centers in Japan. We hope this article provides insight into the actual situation of HCC practice in Japan, thereby affecting the global practice pattern in the management of HCC.Avelumab in Combination with Axitinib as First-Line Treatment in Patients with Advanced Hepatocellular Carcinoma: Results from the Phase 1b VEGF Liver 100 Trial.Masatoshi Kudo; Kenta Motomura; Yoshiyuki Wada; Yoshitaka Inaba; Yasunari Sakamoto; Masayuki Kurosaki; Yoshiko Umeyama; Yoichi Kamei; Junichiro Yoshimitsu; Yosuke Fujii; Mana Aizawa; Paul B Robbins; Junji FuruseLiver cancer 10 (3) 249 - 259 2021/06 Introduction: Combining an immune checkpoint inhibitor with a targeted antiangiogenic agent may leverage complementary mechanisms of action for the treatment of advanced/metastatic hepatocellular carcinoma (aHCC). Avelumab is a human anti-PD-L1 IgG1 antibody with clinical activity in various tumor types; axitinib is a selective tyrosine kinase inhibitor of vascular endothelial growth factor receptors 1, 2, and 3. We report the final analysis from VEGF Liver 100 (NCT03289533), a phase 1b study evaluating safety and efficacy of avelumab plus axitinib in treatment-naive patients with aHCC. Methods: Eligible patients had confirmed aHCC, no prior systemic therapy, ≥1 measurable lesion, Eastern Cooperative Oncology Group performance status ≤1, and Child-Pugh class A disease. Patients received avelumab 10 mg/kg intravenously every 2 weeks plus axitinib 5 mg orally twice daily until progression, unacceptable toxicity, or withdrawal. Endpoints included safety and investigator-assessed objective response per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 and modified RECIST (mRECIST) for HCC. Results: Twenty-two Japanese patients were enrolled and treated with avelumab plus axitinib. The minimum follow-up was 18 months as of October 25, 2019 (data cutoff). Grade 3 treatment-related adverse events (TRAEs) occurred in 16 patients (72.7%); the most common (≥3 patients) were hypertension (n = 11 [50.0%]), palmar-plantar erythrodysesthesia syndrome (n = 5 [22.7%]), and decreased appetite (n = 3 [13.6%]). No grade 4 TRAEs or treatment-related deaths occurred. Ten patients (45.5%) had an immune-related AE (irAE) of any grade; 3 patients (13.6%) had an infusion-related reaction (IRR) of any grade, and no grade ≥3 irAE and IRR were observed. The objective response rate was 13.6% (95% CI: 2.9-34.9%) per RECIST 1.1 and 31.8% (95% CI: 13.9-54.9%) per mRECIST for HCC. Conclusion: Treatment with avelumab plus axitinib was associated with a manageable toxicity profile and showed antitumor activity in patients with aHCC.Pembrolizumab as Second-Line Therapy for Advanced Hepatocellular Carcinoma: A Subgroup Analysis of Asian Patients in the Phase 3 KEYNOTE-240 Trial.Masatoshi Kudo; Ho Yeong Lim; Ann-Lii Cheng; Yee Chao; Thomas Yau; Sadahisa Ogasawara; Masayuki Kurosaki; Naoki Morimoto; Kazuyoshi Ohkawa; Tatsuya Yamashita; Kyung-Hun Lee; Erluo Chen; Abby B Siegel; Baek-Yeol RyooLiver cancer 10 (3) 275 - 284 2021/06 Introduction: KEYNOTE-240 investigated the efficacy and safety of pembrolizumab plus best supportive care (BSC) in sorafenib-treated patients with advanced hepatocellular carcinoma (HCC). Results for the subgroup of patients from Asia are described. Methods: Adults with advanced HCC previously treated with sorafenib were randomized 2:1 to pembrolizumab or placebo plus BSC. Here, the Asian subgroup comprised patients enrolled in Hong Kong, Japan, Korea, the Philippines, Taiwan, and Thailand. Primary endpoints were progression-free survival (PFS) per blinded central imaging review and overall survival (OS). Secondary endpoints included objective response rate (ORR) per blinded central imaging review, duration of response (DOR), and safety. Results: The Asian subgroup included 157 patients. As of January 2, 2019, the median follow-up in this subgroup was 13.8 months for pembrolizumab and 8.3 months for placebo. The median PFS was 2.8 months for pembrolizumab (95% confidence interval [CI] 2.6-4.1) versus 1.4 months (95% CI 1.4-2.4) for placebo (hazard ratio [HR] 0.48; 95% CI 0.32-0.70). The median OS was 13.8 months (95% CI 10.1-16.9) for pembrolizumab versus 8.3 months (95% CI 6.3-11.8) for placebo (HR 0.55; 95% CI 0.37-0.80). ORR was 20.6% (95% CI 13.4-29.5) for pembrolizumab versus 2.0% (95% CI 0.1-10.6) for placebo (difference: 18.5%; 95% CI 8.3-27.6). The median DOR was 8.6 and 2.8 months for pembrolizumab and placebo, respectively. Any grade treatment-related adverse events (TRAEs) occurred in 63 patients (58.9%) receiving pembrolizumab and 24 patients (48.0%) receiving placebo; 14 (13.1%) and 2 (4.0%) patients experienced grade 3-5 TRAEs, respectively. No treatment-related deaths occurred. Conclusion: Pembrolizumab demonstrated antitumor activity and was well tolerated in the Asian subgroup of KEYNOTE-240. A trend toward greater benefit with pembrolizumab in the Asian subgroup was observed compared with the overall cohort, supporting further evaluation of pembrolizumab treatment in this population.Lenvatinib versus sorafenib for first-line treatment of unresectable hepatocellular carcinoma: patient-reported outcomes from a randomised, open-label, non-inferiority, phase 3 trial.Arndt Vogel; Shukui Qin; Masatoshi Kudo; Yun Su; Stacie Hudgens; Tatsuya Yamashita; Jung-Hwan Yoon; Laetitia Fartoux; Krzysztof Simon; Carlos López; Max Sung; Kalgi Mody; Tatsuroh Ohtsuka; Toshiyuki Tamai; Lee Bennett; Genevieve Meier; Valery BrederThe lancet. Gastroenterology & hepatology 6 (8) 649 - 658 2021/06 BACKGROUND: Hepatocellular carcinoma is the third-leading cause of cancer-related death worldwide. Preservation of health-related quality of life (HRQOL) during treatment is an important therapeutic goal. The aim of this study was to evaluate the effect of treatment with lenvatinib versus sorafenib on HRQOL. METHODS: REFLECT was a previously published multicentre, randomised, open-label, non-inferiority phase 3 study comparing the efficacy and safety of lenvatinib versus sorafenib as a first-line systemic treatment for unresectable hepatocellular carcinoma. Eligible patients were aged 18 years or older with unresectable hepatocellular carcinoma and one or more measurable target lesion per modified Response Evaluation Criteria in Solid Tumors criteria, Barcelona Clinic Liver Cancer stage B or C categorisation, Child-Pugh class A, Eastern Cooperative Oncology Group (ECOG) performance status of 1 or lower, and adequate organ function. Patients were randomly assigned (1:1) via an interactive voice-web response system; stratification factors for treatment allocation included region; macroscopic portal vein invasion, extrahepatic spread, or both; ECOG performance status; and bodyweight. Patient-reported outcomes (PROs), collected at baseline, on day 1 of each subsequent cycle, and at the end of treatment, were evaluated in post-hoc analyses of secondary and exploratory endpoints in the analysis population, which was the subpopulation of patients with a PRO assessment at baseline. A linear mixed-effects model evaluated change from baseline in PROs, including European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire Core 30 (QLQ-C30) and hepatocellular carcinoma-specific QLQ-HCC18 scales (both secondary endpoints of the REFLECT trial). Time-to-definitive-deterioration analyses were done based on established thresholds for minimum differences for worsening in PROs. Responder analyses explored associations between HRQOL and clinical response. This study is registered with ClinicalTrials.gov, NCT01761266. FINDINGS: Of 954 eligible patients randomly assigned to lenvatinib (n=478) or sorafenib (n=476) between March 14, 2013, and July 30, 2015, 931 patients (n=468 for lenvatinib; n=463 for sorafenib) were included in this analysis. Baseline PRO scores reflected impaired HRQOL and functioning and considerable symptom burden relative to full HRQOL. Differences in overall mean change from baseline estimates in most PRO scales generally favoured the lenvatinib over the sorafenib group, although the differences were not nominally statistically or clinically significant. Patients treated with lenvatinib experienced nominally statistically significant delays in definitive, meaningful deterioration on the QLQ-C30 fatigue (hazard ratio [HR] 0·83, 95% CI 0·69-0·99), pain (0·80, 0·66-0·96), and diarrhoea (0·52, 0·42-0·65) domains versus patients treated with sorafenib. Significant differences in time to definitive deterioration were not observed for other QLQ-C30 domains, and there was no difference in time to definitive deterioration on the global health status/QOL score (0·89, 0·73-1·09). For most PRO scales, differences in overall mean change from baseline estimates favoured responders versus non-responders. Across all scales, HRs for time to definitive deterioration were in favour of responders; median time to definitive deterioration for responders exceeded those for non-responders by a range of 4·8 to 14·6 months. INTERPRETATION: HRQOL for patients undergoing treatment for unresectable hepatocellular carcinoma is an important therapeutic consideration. The evidence of HRQOL benefits in clinically relevant domains support the use of lenvatinib compared with sorafenib to delay functional deterioration in advanced hepatocellular carcinoma. FUNDING: Eisai and Merck Sharp & Dohme.Safety and efficacy of lenvatinib by starting dose based on body weight in patients with unresectable hepatocellular carcinoma in REFLECT.Takuji Okusaka; Kenji Ikeda; Masatoshi Kudo; Richard Finn; Shukui Qin; Kwang-Hyub Han; Ann-Lii Cheng; Fabio Piscaglia; Masahiro Kobayashi; Max Sung; Minshan Chen; Lucjan Wyrwicz; Jung-Hwan Yoon; Zhenggang Ren; Kalgi Mody; Corina Dutcus; Toshiyuki Tamai; Min Ren; Seiichi Hayato; Hiromitsu KumadaJournal of gastroenterology 56 (6) 570 - 580 2021/06 BACKGROUND: REFLECT was an open-label, phase 3 study comparing the efficacy and safety of lenvatinib versus sorafenib in patients with unresectable hepatocellular carcinoma (uHCC). Based on phase 2 study (Study 202) results, body weight-based dosing for lenvatinib was used in REFLECT to minimize dose disruptions and modifications needed to address dose-related adverse events. This post hoc analysis of REFLECT data assessed lenvatinib efficacy and safety by body weight group. METHODS: The study randomly administered lenvatinib (n = 476) or sorafenib (n = 475) to patients with untreated (no prior systemic therapy) uHCC. Lenvatinib starting-dose data were stratified by body weight: patients weighing Report of the 22nd Nationwide Follow-Up Survey of Primary Liver Cancer in Japan (2012-2013).Masatoshi Kudo; Namiki Izumi; Norihiro Kokudo; Michiie Sakamoto; Shuichiro Shiina; Tadatoshi Takayama; Ryosuke Tateishi; Osamu Nakashima; Takamichi Murakami; Yutaka Matsuyama; Arata Takahashi; Hiroaki Miyata; Shoji KuboHepatology research : the official journal of the Japan Society of Hepatology 52 (1) 5 - 66 2021/05 In the 22nd Nationwide Follow-up Survey of Primary Liver Cancer in Japan, data from 21,155 newly registered patients and 43,041 previously registered follow-up patients were compiled from 538 institutions over a 2-year period from 1 January 2012 to 31 December 2013. Basic statistics compiled for patients newly registered in the 22nd survey was cause of death, past medical history, clinical diagnosis, imaging diagnosis, treatment-related factors, pathological diagnosis, recurrence status, and autopsy findings. Compared with the previous 21st survey, the population of patients with hepatocellular carcinoma (HCC) was older at the time of clinical diagnosis, had more female patients, had more patients with non-B non-C HCC, had smaller tumor diameter, and was more frequently treated with hepatectomy. Cumulative survival rates were calculated for HCC, intrahepatic cholangiocarcinoma, and combined hepatocellular cholangiocarcinoma (combined HCC and intrahepatic cholangiocarcinoma) by treatment type and background characteristics for patients newly registered between 2002 and 2013 whose final outcome was survival or death. Median overall survival and cumulative survival rates for HCC were calculated by dividing patients by combinations of background factors (number of tumors, tumor diameter, or Child-Pugh grade) and by treatment type (hepatectomy, radiofrequency ablation therapy, transcatheter arterial chemoembolization, hepatic arterial infusion chemotherapy and systemic therapy). The same values were also calculated according to registration date by dividing patients newly registered between 1978 and 2013 into five time period groups. The data obtained from this nationwide follow-up survey are expected to contribute to advancing clinical research and treatment of primary liver cancer in the world. This article is protected by copyright. All rights reserved.Patient-reported outcomes with atezolizumab plus bevacizumab versus sorafenib in patients with unresectable hepatocellular carcinoma (IMbrave150): an open-label, randomised, phase 3 trial.Peter R Galle; Richard S Finn; Shukui Qin; Masafumi Ikeda; Andrew X Zhu; Tae-You Kim; Masatoshi Kudo; Valeriy Breder; Philippe Merle; Ahmed Kaseb; Daneng Li; Sohail Mulla; Wendy Verret; Derek-Zhen Xu; Sairy Hernandez; Beiying Ding; Juan Liu; Chen Huang; Ho Yeong Lim; Ann-Lii Cheng; Michel DucreuxThe Lancet. Oncology 2021/05 BACKGROUND: Understanding patients' experience of cancer treatment is important. We aimed to evaluate patient-reported outcomes (PROs) with atezolizumab plus bevacizumab versus sorafenib in patients with advanced hepatocellular carcinoma in the IMbrave150 trial, which has already shown significant overall survival and progression-free survival benefits with this combination therapy. METHODS: We did an open-label, randomised, phase 3 trial in 111 hospitals and cancer centres across 17 countries or regions. We included patients aged 18 years or older with systemic, treatment-naive, histologically, cytologically, or clinically confirmed unresectable hepatocellular carcinoma and an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1, with disease that was not amenable to curative surgical or locoregional therapies, or progressive disease after surgical or locoregional therapies. Participants were randomly assigned (2:1; using permuted block randomisation [blocks of six], stratified by geographical region; macrovascular invasion, extrahepatic spread, or both; baseline alpha-fetoprotein concentration; and ECOG performance status) to receive 1200 mg atezolizumab plus 15 mg/kg bevacizumab intravenously once every 3 weeks or 400 mg sorafenib orally twice a day, until loss of clinical benefit or unacceptable toxicity. The independent review facility for tumour assessment was masked to the treatment allocation. Previously reported coprimary endpoints were overall survival and independently assessed progression-free survival per Response Evaluation Criteria in Solid Tumors 1.1. Prespecified secondary and exploratory analyses descriptively evaluated treatment effects on patient-reported quality of life, functioning, and disease symptoms per the European Organisation for Research and Treatment of Cancer (EORTC) quality-of-life questionnaire for cancer (QLQ-C30) and quality-of-life questionnaire for hepatocellular carcinoma (QLQ-HCC18). Time to confirmed deterioration of PROs was analysed in the intention-to-treat population; all other analyses were done in the PRO-evaluable population (patients who had a baseline PRO assessment and at least one assessment after baseline). The trial is ongoing; enrolment is closed. This trial is registered with ClinicalTrials.gov, NCT03434379. FINDINGS: Between March 15, 2018, and Jan 30, 2019, 725 patients were screened and 501 patients were enrolled and randomly assigned to atezolizumab plus bevacizumab (n=336) or sorafenib (n=165). 309 patients in the atezolizumab plus bevacizumab group and 145 patients in the sorafenib group were included in the PRO-evaluable population. At data cutoff (Aug 29, 2019) the median follow-up was 8·6 months (IQR 6·2-10·8). EORTC QLQ-C30 completion rates were 90% or greater for 23 of 24 treatment cycles in both groups (range 88-100% in the atezolizumab plus bevacizumab group and 80-100% in the sorafenib group). EORTC QLQ-HCC18 completion rates were 90% or greater for 20 of 24 cycles in the atezolizumab plus bevacizumab group (range 88-100%) and 21 of 24 cycles in the sorafenib group (range 89-100%). Compared with sorafenib, atezolizumab plus bevacizumab reduced the risk of deterioration on all EORTC QLQ-C30 generic cancer symptom scales that were prespecified for analysis (appetite loss [hazard ratio (HR) 0·57, 95% CI 0·40-0·81], diarrhoea [0·23, 0·16-0·34], fatigue [0·61, 0·46-0·81], pain [0·46, 0·34-0·62]), and two of three EORTC QLQ-HCC18 disease-specific symptom scales that were prespecified for analysis (fatigue [0·60, 0·45-0·80] and pain [0·65, 0·46-0·92], but not jaundice [0·76, 0·55-1·07]). At day 1 of treatment cycle five (after which attrition in the sorafenib group was more than 50%), the mean EORTC QLQ-C30 score changes from baseline in the atezolizumab plus bevacizumab versus sorafenib groups were: -3·29 (SD 17·56) versus -5·83 (20·63) for quality of life, -4·02 (19·42) versus -9·76 (21·33) for role functioning, and -3·77 (12·82) versus -7·60 (15·54) for physical functioning. INTERPRETATION: Prespecified analyses of PRO data showed clinically meaningful benefits in terms of patient-reported quality of life, functioning, and disease symptoms with atezolizumab plus bevacizumab compared with sorafenib, strengthening the combination therapy's positive benefit-risk profile versus that of sorafenib in patients with unresectable hepatocellular carcinoma. FUNDING: F Hoffmann-La Roche and Genentech.Impact of hepatitis C virus on survival in patients undergoing resection of intrahepatic cholangiocarcinoma: report of a Japanese nationwide survey.Masaki Kaibori; Kengo Yoshii; Kosuke Kashiwabara; Takashi Kokudo; Kiyoshi Hasegawa; Namiki Izumi; Takamichi Murakami; Masatoshi Kudo; Shuichiro Shiina; Michiie Sakamoto; Osamu Nakashima; Yutaka Matsuyama; Susumu Eguchi; Md; Tatsuya Yamashita; Md; Tadatoshi Takayama; Norihiro Kokudo; Shoji KuboHepatology research : the official journal of the Japan Society of Hepatology 51 (8) 890 - 901 2021/05 AIM: We reviewed the data of a nationwide follow-up survey to determine the impact of hepatitis C virus (HCV) infection on the outcomes of hepatectomy for intrahepatic cholangiocarcinoma (ICC) of the mass-forming (MF) type and combined mass-forming and periductal infiltrating (MF+PI) types. METHODS: In total, 956 patients with ICC who underwent curative hepatic resection were included in this cohort study, and patients were classified according to virus status. Patients were classified according to virus status as follows: HCV-related ICC (n=138, 14.4%), hepatitis B virus (HBV)-related ICC (n=43, 4.5%), and non-virus-related ICC (n=775, 81.1%). To control for variables, we used 1-to-1 propensity score matching to compare outcomes after surgery between the HCV-related (n=102) and the non-virus-related ICC cases (n=102). RESULTS: We successfully matched HCV-related and non-virus-related ICC cases with similar liver function and tumor characteristics. Patients with HCV-related ICC had significantly shorter recurrence-free survival (RFS; hazard ratio [HR] 0.62, 95% confidence interval [Cl] 0.42-0.92, P=.016) and overall survival (OS; HR: 0.57, 95% Cl: 0.37-0.88, P=.011) than patients with non-virus-related ICC. Cox proportional hazard analysis demonstrated that HCV-related ICC offered a worse prognosis than non-virus-related ICC. CONCLUSIONS: HCV infection increases the risk of recurrence and worsens OS in patients after curative resection for MF and combined MF+PI type ICC. This article is protected by copyright. All rights reserved.Biomarkers in autoimmune pancreatitis and immunoglobulin G4-related disease.Akane Hara; Tomohiro Watanabe; Kosuke Minaga; Tomoe Yoshikawa; Ken Kamata; Masatoshi KudoWorld journal of gastroenterology 27 (19) 2257 - 2269 2021/05 Solitary organ autoimmune disorders, formerly known as autoimmune pancreatitis (AIP), autoimmune sialadenitis, and autoimmune sclerosing cholangitis, are now considered organ-specific manifestations of systemic immunoglobulin G4-related disease (IgG4-RD). AIP and IgG4-RD are characterized by elevated serum concentration of IgG4 antibody (Ab), accumulation of IgG4-expressing plasmacytes in the affected organs, and involvement of multiple organs. It is well established that enhanced IgG4 Ab responses are a hallmark of AIP and IgG4-RD for diagnosis and monitoring disease activity. However, a significant fraction of patients with AIP and IgG4-RD who develop chronic fibroinflammatory responses have normal serum concentrations of this IgG subtype. In addition, disease flare-up is sometimes seen even in the presence of normalized serum concentrations of IgG4 Ab after successful induction of remission by prednisolone. Therefore, it is necessary to identify new biomarkers based on the understanding of the pathophysiology of AIP and IgG4-RD. Recently, we found that activation of plasmacytoid dendritic cells producing both interferon-α (IFN-α) and interleukin-33 (IL-33) mediate murine AIP and human IgG4-RD. More importantly, we provided evidence that serum concentrations of IFN-α and IL-33 could be useful biomarkers for the diagnosis and monitoring of AIP and IgG4-RD activity after induction of remission in these autoimmune disorders. In this Frontier article, we have summarized and discussed biomarkers of AIP and IgG4-RD, including Igs, autoAbs, and cytokines to provide useful information not only for clinicians but also for researchers.CheckMate 040 Cohort 5: A phase I/II study of nivolumab in patients with advanced hepatocellular carcinoma and Child-Pugh B cirrhosis.Masatoshi Kudo; Ana Matilla; Armando Santoro; Ignacio Melero; Antonio Cubillo Gracián; Mirelis Acosta-Rivera; Su-Pin Choo; Anthony B El-Khoueiry; Ryoko Kuromatsu; Bassel El-Rayes; Kazushi Numata; Yoshito Itoh; Francesco Di Costanzo; Oxana Crysler; Maria Reig; Yun Shen; Jaclyn Neely; Marina Tschaika; Tami Wisniewski; Bruno SangroJournal of hepatology 2021/05 BACKGROUND & AIMS: Patients with advanced hepatocellular carcinoma (aHCC) and Child-Pugh B liver function are often excluded from clinical trials. In previous studies, overall survival for these patients treated with sorafenib was ∼3-5 months; thus, new treatments are needed. Nivolumab, alone or in combination with ipilimumab, is conditionally approved in the United States to treat patients with aHCC who previously received sorafenib. We describe nivolumab monotherapy outcomes in patients with Child-Pugh B status. METHODS: This phase 1/2, open-label, non-comparative, multicentre trial (27 centres) included patients with Child-Pugh B (B7-B8) aHCC. Patients received intravenous nivolumab 240 mg every 2 weeks until unacceptable toxicity or disease progression. Primary endpoints were objective response rate (ORR) by investigator assessment (using Response Evaluation Criteria in Solid Tumors v1.1) and duration of response (DOR). Safety was assessed using National Cancer Institute Common Terminology Criteria for Adverse Events v4.0. RESULTS: Twenty-five sorafenib-naive and 24 sorafenib-treated patients began treatment between November 2016 and October 2017 (median follow-up, 16.3 months). Investigator-assessed ORR was 12% (95% CI 5-25%) with six patients responding; disease control rate was 55% (95% CI 40-69%). Median time to response was 2.7 months (interquartile range, 1.4-4.2), and median DOR was 9.9 months (95% CI 9.7-9.9). Treatment-related adverse events (TRAEs) were reported in 25 patients (51%) and led to discontinuation in two patients (4%). The most frequent grade 3/4 TRAEs were hypertransaminasemia (n=2), and amylase increase and aspartate aminotransferase increase (n=2 each). The safety of nivolumab was comparable to that of patients with Child-Pugh A aHCC. CONCLUSIONS: Nivolumab showed clinical activity and favourable safety with manageable toxicities, suggesting it could be suitable for patients with Child-Pugh B aHCC. LAY SUMMARY: In patients with advanced HCC, almost all systemic therapies require very good liver function, i.e. Child-Pugh A liver function. The evidence from this study suggests that nivolumab shows clinical activity and an acceptable safety profile in patients with HCC with Child-Pugh B status who have mild to moderate impairment of liver function or liver decompensation that might rule out other therapies, so should be further studied. CLINICAL TRIAL NUMBER: NCT01658878.Successful use of two guidewires with different properties using a double-lumen catheter for postoperative biliary stricture.Mamoru Takenaka; Tomohiro Yamazaki; Yasuo Otsuka; Rei Ishikawa; Masatoshi KudoEndoscopy 54 (5) E190-E192  2021/05当院における大腸ESDの工夫正木 翔; 櫻井 俊治; 高島 耕太; 山田 光成; 永井 知行; 米田 頼晃; 樫田 博史; 工藤 正俊日本大腸肛門病学会雑誌 (一社)日本大腸肛門病学会 74 (5) 326 - 326 0047-1801 2021/05第22回全国原発性肝癌追跡調査報告(2012〜2013)工藤 正俊; 泉 並木; 久保 正二; 國土 典宏; 坂元 亨宇; 椎名 秀一朗; 高山 忠利; 建石 良介; 中島 収; 村上 卓道; 松山 裕; 高橋 新; 宮田 裕章; 田村 利恵; 上妻 智子; 日本肝癌研究会追跡調査委員会肝臓 (一社)日本肝臓学会 62 (5) 251 - 299 0451-4203 2021/05 第22回全国原発性肝癌追跡調査においては,2012年1月1日から2013年12月31日までの2年間の21,155例の新規症例と43,041例の追跡症例が538施設から集計された.基礎統計は,第22回新規登録症例を対象として死因,既往歴,臨床診断,画像診断,治療法別の各因子,病理診断,再発,剖検についてまとめた.第21回調査と比較し,肝細胞癌における臨床診断時の高齢化,女性の増加,非B非C肝癌の増加,腫瘍径の縮小の傾向が,治療においては切除の割合の増加,局所療法におけるラジオ波焼灼療法の増加が認められた.2002年から2013年まで新規登録症例の中で最終予後が生存または死亡となった症例(追跡不能症例を除く)について肝細胞癌,肝内胆管癌,混合型肝癌の治療法別,背景因子別生存中央値・累積生存率を算出した.肝細胞癌については腫瘍個数,腫瘍径,肝障害度,Child-Pugh分類を組み合わせることにより背景因子を揃えて,治療法別(肝切除,局所療法,肝動脈塞栓療法(TACE)),肝動注化学療法・全身薬物療法(分子標的治療)の累積生存率を算出し,また,1978年から2013年までの新規登録症例を5期に分け,累積生存率を算出した.新規登録症例数は経時的に増加し,肝細胞癌,肝内胆管癌,混合型肝癌ともに予後の改善が著しいことが明らかとなった.本追跡調査が原発性肝癌の研究および診療の進歩に役立つことを期待する.(著者抄録)【消化器癌;診断と治療のすべて】消化器癌の診断・病期分類・治療・成績 肝細胞癌 集学的治療青木 智子; 上嶋 一臣; 工藤 正俊消化器外科 (株)へるす出版 44 (6) 855 - 861 0387-2645 2021/05Clinicopathological analysis of hepatic immune-related adverse events in comparison with autoimmune hepatitis and graft-versus host disease.Satoru Hagiwara; Tomohiro Watanabe; Masatoshi Kudo; Kosuke Minaga; Yoriaki Komeda; Ken Kamata; Masatomo Kimura; Hidetoshi Hayashi; Kazuhiko Nakagawa; Kazuomi Ueshima; Yasunori Minami; Tomoko Aoki; Masahiro Takita; Masahiro Morita; Hirokazu Cishina; Hiroshi Ida; Ah-Mee Park; Naoshi NishidaScientific reports 11 (1) 9242 - 9242 2021/04 Immune checkpoint inhibitors (ICIs) targeting programmed cell death 1 (PD-1) and cytotoxic T-lymphocyte antigen-4 (CTLA-4) are widely used to treat advanced metastatic cancers. Neutralisation of PD-1 or CTLA-4 by ICIs results in immune-related adverse events (irAEs). The clinicopathological features of twelve patients with hepatic irAEs were evaluated and compared to those of ten patients with autoimmune hepatitis (AIH) or graft-versus-host disease (GVHD). No significant difference was seen in serum levels of transaminases, whereas serum levels of IgG and anti-nuclear antibody were higher in patients with AIH than in those with GVHD or hepatic irAEs. Inflammation was limited to the liver lobes in patients with GVHD or hepatic irAEs, whereas patients with AIH exhibited both portal and lobular inflammation. Immunohistochemical analyses revealed a predominant infiltration of CD8+ T cells and defective accumulation of regulatory T cells (Tregs) expressing forkhead box p3 (FOXP3) in the lobular areas of patients with hepatic irAEs and GVHD. In contrast, periportal lesions of patients with AIH were characterised by an infiltration of CD4+ T cells, CD8+ T cells, CD20+ B cells, and FOXP3+ Tregs. Overall, the activation of CD8+ T cells in the absence of activation of Tregs potentially underlies the immunopathogenesis of hepatic irAEs.Comparison of efficacy and safety of entecavir and switching from entecavir to tenofovir alafenamide fumarate in chronic hepatitis B: Long-term effects from a prospective study.Satoru Hagiwara; Naoshi Nishida; Kazuomi Ueshima; Akihiro Yoshida; Yasunori Minami; Masatoshi KudoHepatology research : the official journal of the Japan Society of Hepatology 51 (7) 767 - 774 2021/04 AIM: Both entecavir (ETV) and tenofovir alafenamide fumarate (TAF) are widely used to treat chronic hepatitis B (CHB) in Japan. However, it remains unclear whether the efficacy of TAF in decreasing the hepatitis B surface antigen (HBsAg) level, and its safety, are superior to those of ETV. This study aimed to report the long-term effects and safety of 96-week ETV and TAF treatment in patients with CHB. METHODS: A prospective comparative observational study was undertaken on the following two groups: patients with CHB who received continuous ETV (n = 32) and patients with CHB who were switched from ETV to TAF upon request (n = 48). The HBsAg, urinary β2-microglobulin (β2MG)/creatinine (Cr), urinary N-acetyl-β-D-glucosaminidase (NAG)/Cr, and serum alanine aminotransferase (ALT) levels, estimated glomerular filtration rate (eGFR), and bone mineral density (lumbar spine and femur) at 96 weeks were compared. RESULTS: The two groups did not significantly differ with respect to mean age, male / female patient ratio, or rate of hepatitis B e antigen-positive status. The mean changes in serum HBsAg level and eGFR at 96 weeks were not significantly different between the two groups. The β2MG/Cr and NAG/Cr levels at 96 weeks were similar between the two groups. Additionally, the bone mineral density of the lumbar spine and femur as well as the serum ALT did not significantly differ. CONCLUSIONS: When compared with patients who received continuous ETV, those who were introduced to TAF after ETV showed similar effects in terms of the decrease in HBsAg level and safety.Should Contrast-Enhanced Harmonic Endoscopic Ultrasound Be Incorporated into the International Consensus Guidelines to Determine the Appropriate Treatment of Intraductal Papillary Mucinous Neoplasm?Tomohiro Yamazaki; Mamoru Takenaka; Shunsuke Omoto; Tomoe Yoshikawa; Rei Ishikawa; Ayana Okamoto; Atsushi Nakai; Kosuke Minaga; Ken Kamata; Kentaro Yamao; Yoriaki Komeda; Tomohiro Watanabe; Naoshi Nishida; Keiko Kamei; Ippei Matsumoto; Yoshifumi Takeyama; Takaaki Chikugo; Yasutaka Chiba; Masatoshi KudoJournal of clinical medicine 10 (9) 2021/04 This study aimed to investigate whether the incorporation of contrast-enhanced harmonic endoscopic ultrasound (CH-EUS) into the international consensus guidelines (ICG) for the management of intraductal papillary mucinous neoplasm (IPMN) could improve its malignancy diagnostic value. In this single-center retrospective study, 109 patients diagnosed with IPMN who underwent preoperative CH-EUS between March 2010 and December 2018 were enrolled. We analyzed each malignancy diagnostic value (sensitivity (Se), specificity (Sp), positive predictive value (PPV), and negative predictive value (NPV)) by replacing fundamental B-mode EUS with CH-EUS as the recommended test for patients with worrisome features (WF) (the CH-EUS incorporation ICG) and comparing the results to those obtained using the 2017 ICG. The malignancy diagnostic values as per the 2017 ICG were 78.9%, 42.3%, 60.0%, and 64.7% for Se, Sp, PPV, and NPV, respectively. The CH-EUS incorporation ICG plan improved the malignancy diagnostic values (Se 78.9%/Sp, 53.8%/PPV, 65.2%/NPV 70.0%). CH-EUS may be useful in determining the appropriate treatment strategies for IPMN.Effect of Diameter and Number of Hepatocellular Carcinomas on Survival After Resection, Transarterial Chemoembolization, and Ablation.Yoshikuni Kawaguchi; Kiyoshi Hasegawa; Yasuhiro Hagiwara; Mario De Bellis; Simone Famularo; Elena Panettieri; Yutaka Matsuyama; Ryosuke Tateishi; Tomoaki Ichikawa; Takashi Kokudo; Namiki Izumi; Shoji Kubo; Michiie Sakamoto; Shuichiro Shiina; Tadatoshi Takayama; Osamu Nakashima; Takamichi Murakami; Jean-Nicolas Vauthey; Felice Giuliante; Luciano De Carlis; Fabrizio Romano; Andrea Ruzzenente; Alfredo Guglielmi; Masatoshi Kudo; Norihiro KokudoThe American journal of gastroenterology 116 (8) 1698 - 1708 2021/04 INTRODUCTION: Most studies predicting survival after resection, transarterial chemoembolization (TACE), and ablation analyzed diameter and number of hepatocellular carcinomas (HCCs) as dichotomous variables, resulting in an underestimation of risk variation. We aimed to develop and validate a new prognostic model for patients with HCC using largest diameter and number of HCCs as continuous variables. METHODS: The prognostic model was developed using data from patients undergoing resection, TACE, and ablation in 645 Japanese institutions. The model results were shown after balanced using the inverse probability of treatment-weighted analysis and were externally validated in an international multi-institution cohort. RESULTS: Of 77,268 patients, 43,904 patients, including 15,313 (34.9%) undergoing liver resection, 13,375 (30.5%) undergoing TACE, and 15,216 (34.7%) undergoing ablation, met the inclusion criteria. Our model (http://www.u-tokyo-hbp-transplant-surgery.jp/about/calculation.html) showed that the 5-year overall survival (OS) in patients with HCC undergoing these procedures decreased with progressive incremental increases in diameter and number of HCCs. For patients undergoing resection, the inverse probability of treatment-weighted-adjusted 5-year OS probabilities were 10%-20% higher compared with patients undergoing TACE for 1-6 HCC lesions A case with Crohn's disease-associated spondyloarthritis exhibiting enhanced pro-inflammatory cytokine responses to Toll-like receptor ligands.Hajime Honjo; Tomohiro Watanabe; Natsuki Okai; Masashi Kono; Ken Kamata; Kosuke Minaga; Yoriaki Komeda; Shigeyoshi Tsuji; Masatoshi KudoAsian Pacific journal of allergy and immunology 2021/04 BACKGROUND: Despite the high incidence of spondyloarthritis (SpA) as an extra-intestinal manifestation of Crohn's disease (CD), the immunopathogenesis of CD-associated SpA remains largely unknown. OBJECTIVE: We tried to explore molecular mechanisms accounting for the development of CD-associated SpA in a patient successfully treated with infliximab. METHODS: Peripheral blood mononuclear cells (PBMCs) before infliximab treatment were stimulated with Toll-like receptor (TLR) ligands to measure pro-inflammatory cytokine responses. Endoscopic biopsy samples before and after infliximab treatment were subjected to quantitative polymerase chain reaction. RESULTS: PBMCs from this CD-associated SpA patient exhibited higher production of pro-inflammatory cytokines upon stimulation with TLR ligands than PBMCs from healthy controls. Induction of remission by infliximab was associated with the downregulation of pro-inflammatory cytokine responses in the small intestinal mucosa, which is continually exposed to TLR ligands. CONCLUSIONS: Excessive pro-inflammatory cytokine responses to TLR ligands might underlie the immunopathogenesis of CD-associated SpA.Therapeutic efficacy of lenvatinib as third-line treatment after regorafenib for unresectable hepatocellular carcinoma progression.Atsushi Hiraoka; Takashi Kumada; Takeshi Hatanaka; Toshifumi Tada; Kazuya Kariyama; Joji Tani; Shinya Fukunishi; Masanori Atsukawa; Masashi Hirooka; Kunihiko Tsuji; Toru Ishikawa; Koichi Takaguchi; Ei Itobayashi; Kazuto Tajiri; Noritomo Shimada; Hiroshi Shibata; Hironori Ochi; Kazuhito Kawata; Satoshi Yasuda; Hidenori Toyoda; Ogawa Chikara; Tsutomu Tamai; Satoru Kakizaki; Hiroki Tojima; Tamon Nagashima; Takashi Ueno; Daichi Takizawa; Atsushi Naganuma; Hideko Ohama; Kazuhiro Nouso; Akemi Tsutsui; Takuya Nagano; Norio Itokawa; Tomomi Okubo; Taeang Arai; Michitaka Imai; Yohei Koizumi; Shinichiro Nakamura; Kouji Joko; Kojiro Michitaka; Yoichi Hiasa; Masatoshi KudoHepatology research : the official journal of the Japan Society of Hepatology 51 (8) 880 - 889 2021/04 AIM: Multiple molecular agents have been developed for treating unresectable hepatocellular carcinoma. This study aimed to elucidate the clinical efficacy of sequential treatment with lenvatinib after regorafenib failure. METHODS: From June 2017 to October 2020, 63 patients with Child-Pugh A and treated with regorafenib followed by sorafenib were enrolled (median age 71 years, 52 men, Barcelona Clinic Liver Cancer B:C = 23:40). They were divided into two groups, those treated with lenvatinib after regorafenib treatment (R-L group, n = 47) and those who did not receive lenvatinib after regorafenib (non-R-L group, n = 16). Prognostic factors were retrospectively analyzed after adjustment with inverse probability weighting. RESULTS: Serum albumin level at the start of regorafenib and reasons for discontinuation of regorafenib were significantly different between the R-L and non-R-L groups, whereas the albumin-bilirubin score, Child-Pugh class, and tumor burden were not. Progression-free survival was also not significantly different (median 4.1 vs. 3.8 months, p = 0.586). As for overall survival, the R-L group showed better prognosis after introducing regorafenib and after introducing sorafenib, following inverse probability weighting adjustment (MST 19.7 vs. 10.3 months, 33.8 vs. 15.3 months, p -2.27) at the start of regorafenib (HR 2.074, p = 0.041) and the presence of lenvatinib treatment after regorafenib failure (HR 0.355, p = 0.004) were found to be significant prognostic factors in Cox proportional hazards multivariate analysis, after inverse probability weighting adjustment. CONCLUSION: These results show that lenvatinib is a good sequential treatment option after progression under regorafenib therapy in unresectable hepatocellular carcinoma patients with better hepatic reserve function.肝癌に対する局所療法(肝切除、アブレーション、TACE、他)の最前線 US-US overlay fusionガイドを用いたラジオ波焼灼術の最前線南 康範; 西田 直生志; 工藤 正俊肝臓 (一社)日本肝臓学会 62 (Suppl.1) A179 - A179 0451-4203 2021/04肝癌の基礎研究と臨床応用 Gd-EOB-DTPA-enhanced MRI肝細胞相はPD-1/PD-L1抗体単独療法の非侵襲的なバイオマーカーである青木 智子; 西田 直生志; 工藤 正俊肝臓 (一社)日本肝臓学会 62 (Suppl.1) A187 - A187 0451-4203 2021/04肝疾患におけるビックデータとAI(人工知能)の臨床応用 超音波画像ビッグデータベース構築と腹部超音波B-mode検査における肝腫瘍検出のAI支援西田 直生志; 目加田 慶人; 工藤 正俊肝臓 (一社)日本肝臓学会 62 (Suppl.1) A203 - A203 0451-4203 2021/04進行肝癌に対する薬物治療法の新たな展開 肝細胞癌における腫瘍免疫環境と抗PD-1抗体有効群の選別盛田 真弘; 西田 直生志; 工藤 正俊肝臓 (一社)日本肝臓学会 62 (Suppl.1) A20 - A20 0451-4203 2021/04Sequential Therapy for Hepatocellular Carcinoma after Failure of Atezolizumab plus Bevacizumab Combination Therapy.Masatoshi KudoLiver cancer 10 (2) 85 - 93 2021/04What Can Be Done to Solve the Unmet Clinical Need of Hepatocellular Carcinoma Patients following Lenvatinib Failure?Atsushi Hiraoka; Takashi Kumada; Toshifumi Tada; Kazuya Kariyama; Joji Tani; Shinya Fukunishi; Masanori Atsukawa; Masashi Hirooka; Kunihiko Tsuji; Toru Ishikawa; Koichi Takaguchi; Ei Itobayashi; Kazuto Tajiri; Noritomo Shimada; Hiroshi Shibata; Hironori Ochi; Kazuhito Kawata; Satoshi Yasuda; Hidenori Toyoda; Hideko Ohama; Kazuhiro Nouso; Akemi Tsutsui; Takuya Nagano; Norio Itokawa; Korenobu Hayama; Taeang Arai; Michitaka Imai; Yohei Koizumi; Shinichiro Nakamura; Kouji Joko; Kojiro Michitaka; Yoichi Hiasa; Masatoshi KudoLiver cancer 10 (2) 115 - 125 2021/04 Background/Aim: An effective postprogression treatment of lenvatinib (LEN) against unresectable hepatocellular carcinoma (u-HCC) has not been established. We aimed to elucidate the clinical role of continuing LEN beyond progression of disease (PD). Methods: From March 2018 to October 2020, 99 u-HCC patients, in whom PD was confirmed (male:female = 78:21, median age 72 years, Child-Pugh A = 99, Barcelona Clinic Liver Cancer stage A:B:C = 2:43:54, LEN as first-line = 55), were enrolled (stopped LEN at PD [A group], n = 26; continued LEN beyond PD [B group], n = 73). Radiological response was evaluated with RECIST 1.1. Clinical features and prognostic factors for overall survival (OS) were retrospectively investigated using inverse probability weighting (IPW) calculated by propensity score. Results: Median time to progression, best response, and modified albumin-bilirubin grade (mALBI) at both baseline and PD did not show significant difference between the groups. Postprogression treatment in the A group was best supportive care in 17, sorafenib in 4, regorafenib in 3, ramucirumab in 1, and hepatic arterial infusion chemotherapy in 1. After adjusting with IPW, the B group showed better prognosis in regard to OS after PD and OS after introducing LEN than the A group (10.8/19.6 vs. 5.8/11.2 months, p Therapeutic efficacy of ramucirumab after lenvatinib for post-progression treatment of unresectable hepatocellular carcinoma.Atsushi Hiraoka; Takashi Kumada; Toshifumi Tada; Chikara Ogawa; Joji Tani; Shinya Fukunishi; Masanori Atsukawa; Masashi Hirooka; Kunihiko Tsuji; Toru Ishikawa; Koichi Takaguchi; Kazuya Kariyama; Ei Itobayashi; Kazuto Tajiri; Noritomo Shimada; Hiroshi Shibata; Hironori Ochi; Kazuhito Kawata; Hidenori Toyoda; Hideko Ohama; Kazuhiro Nouso; Akemi Tsutsui; Takuya Nagano; Norio Itokawa; Korenobu Hayama; Taeang Arai; Michitaka Imai; Yohei Koizumi; Shinichiro Nakamura; Kojiro Michitaka; Yoichi Hiasa; Masatoshi KudoGastroenterology report 9 (2) 133 - 138 2021/04 Background: Lenvatinib is used for unresectable hepatocellular carcinoma (u-HCC) as first-line, as well as second- and third-line therapy in Japan. We evaluated the therapeutic efficacy of newly developed ramucirumab when given after lenvatinib for post-progression treatment. Methods: Of 385 patients with u-HCC and treated with lenvatinib at 16 different institutions in Japan between May 2018 and January 2020, 28 who received ramucirumab as the next treatment were enrolled and therapeutic responses were evaluated in a retrospective manner. Results: The median age of the 28 patients given ramucirumab was 70 years and the median albumin-bilirubin score was -2.19. Of the 28 patients, 23 were male, 21 were classified as Child-Pugh A and 7 as Child-Pugh B, and 25 were Barcelona Clinic Liver Cancer Stage C. Ramucirumab was given as second-line therapy in 14, third-line in 9, and fourth-line in 5. Therapeutic response was obtained in only 26 patients; the objective response rate was 3.8% (1/26) and the disease-control rate was 42.3% (11/26), with a median period to progression of 2.0 months. The reasons for discontinuation of ramucirumab were progression of disease in 16 and Grade 3 adverse events (gastrointestinal bleeding, ascites) in 2. Conclusions: The anticipated therapeutic efficacy of ramucirumab for post-progression treatment following lenvatinib was not seen in our early experience.Combination immunotherapy with anti-VEGF/TKI for hepatocellular carcinoma: present and future perspective.Masatoshi KudoHepatobiliary surgery and nutrition 10 (2) 241 - 245 2021/04Combination therapy for advanced hepatocellular carcinoma: do we see the light at the end of the tunnel?Ti Zhang; Philippe Merle; Huaqi Wang; Haitao Zhao; Masatoshi KudoHepatobiliary surgery and nutrition 10 (2) 180 - 192 2021/04 Importance: Combination therapies of anti-PD-1 and anti-angiogenesis regimens are emerging rapidly and exhibit more promising anti-tumor efficacy for advanced hepatocellular carcinoma (HCC), and consistently it is the hotspot in clinical studies. Objective: To elaborate several issues which are warranted further consideration as more regimens are being investigated in combination therapies. Evidence Review: We searched PubMed, MEDLINE, Cochrane Library and Google Scholar by 2021 February for publications on combination therapies for HCC. Findings: Several clinical issues are worth reconsidering, such as the evaluation on appropriate primary endpoints in phase III clinical trials as for different practical problems, the translation of surrogate endpoint objective response rate (ORR) benefits into overall survival (OS) benefits, and whether conversion surgery contributes to initial expectations of long-term survival or not. New concepts in novel immunotherapy and targeted therapy in combination with loco-regional therapies may improve overall survival for HCC. Conclusions and Relevance for Reviews: Comprehensive understanding of the mechanism of immunotherapy and targeted therapy contributes to better prognosis of advanced HCC and more explorative combination therapies are needed.Report of the 21st Nationwide Follow-up Survey of Primary Liver Cancer in Japan (2010-2011).Masatoshi Kudo; Namiki Izumi; Norihiro Kokudo; Michiie Sakamoto; Shuichiro Shiina; Tadatoshi Takayama; Ryosuke Tateishi; Osamu Nakashima; Takamichi Murakami; Yutaka Matsuyama; Arata Takahashi; Hiroaki Miyata; Shoji KuboHepatology research : the official journal of the Japan Society of Hepatology 51 (4) 355 - 405 2021/04 In the 21st Nationwide Follow-up Survey of Primary Liver Cancer in Japan, data from 22,134 new patients and 41,956 previously followed patients were compiled from 546 institutions over a 2-year period from 1 January 2010 to 31 December 2011. Basic statistics compiled for patients newly registered in the 21st survey were cause of death, medical history, clinical diagnosis, imaging diagnosis, treatment-related factors, pathological diagnosis, recurrence status, and autopsy findings. Compared with the previous 20th survey, the population of patients with hepatocellular carcinoma (HCC) was older at the time of clinical diagnosis, had more female patients, had more patients with non-B non-C HCC, had smaller tumor diameter, and was more frequently treated with hepatectomy and with radiofrequency ablation. Cumulative survival rates were calculated for HCC, intrahepatic cholangiocarcinoma, and combined hepatocellular cholangiocarcinoma (combined HCC and intrahepatic cholangiocarcinoma) by treatment type and background characteristics for patients newly registered between 1998 and 2011 whose final outcome was survival or death (excluding unknown). Cumulative survival rates for HCC were calculated by dividing patients by combinations of background factors (number of tumors, tumor diameter, and Child-Pugh grade) and by treatment type (hepatectomy, local ablation therapy, transcatheter arterial chemoembolization, and hepatic arterial infusion chemotherapy). The same values were also calculated according to registration date by dividing patients newly registered between 1978 and 2011 into four time-period groups. The data obtained from this nationwide follow-up survey are expected to contribute to advancing clinical research and treatment of primary liver cancer.NASH limits anti-tumour surveillance in immunotherapy-treated HCC.Dominik Pfister; Nicolás Gonzalo Núñez; Roser Pinyol; Olivier Govaere; Matthias Pinter; Marta Szydlowska; Revant Gupta; Mengjie Qiu; Aleksandra Deczkowska; Assaf Weiner; Florian Müller; Ankit Sinha; Ekaterina Friebel; Thomas Engleitner; Daniela Lenggenhager; Anja Moncsek; Danijela Heide; Kristin Stirm; Jan Kosla; Eleni Kotsiliti; Valentina Leone; Michael Dudek; Suhail Yousuf; Donato Inverso; Indrabahadur Singh; Ana Teijeiro; Florian Castet; Carla Montironi; Philipp K Haber; Dina Tiniakos; Pierre Bedossa; Simon Cockell; Ramy Younes; Michele Vacca; Fabio Marra; Jörn M Schattenberg; Michael Allison; Elisabetta Bugianesi; Vlad Ratziu; Tiziana Pressiani; Antonio D'Alessio; Nicola Personeni; Lorenza Rimassa; Ann K Daly; Bernhard Scheiner; Katharina Pomej; Martha M Kirstein; Arndt Vogel; Markus Peck-Radosavljevic; Florian Hucke; Fabian Finkelmeier; Oliver Waidmann; Jörg Trojan; Kornelius Schulze; Henning Wege; Sandra Koch; Arndt Weinmann; Marco Bueter; Fabian Rössler; Alexander Siebenhüner; Sara De Dosso; Jan-Philipp Mallm; Viktor Umansky; Manfred Jugold; Tom Luedde; Andrea Schietinger; Peter Schirmacher; Brinda Emu; Hellmut G Augustin; Adrian Billeter; Beat Müller-Stich; Hiroto Kikuchi; Dan G Duda; Fabian Kütting; Dirk-Thomas Waldschmidt; Matthias Philip Ebert; Nuh Rahbari; Henrik E Mei; Axel Ronald Schulz; Marc Ringelhan; Nisar Malek; Stephan Spahn; Michael Bitzer; Marina Ruiz de Galarreta; Amaia Lujambio; Jean-Francois Dufour; Thomas U Marron; Ahmed Kaseb; Masatoshi Kudo; Yi-Hsiang Huang; Nabil Djouder; Katharina Wolter; Lars Zender; Parice N Marche; Thomas Decaens; David J Pinato; Roland Rad; Joachim C Mertens; Achim Weber; Kristian Unger; Felix Meissner; Susanne Roth; Zuzana Macek Jilkova; Manfred Claassen; Quentin M Anstee; Ido Amit; Percy Knolle; Burkhard Becher; Josep M Llovet; Mathias HeikenwalderNature 592 (7854) 450 - 456 2021/04 Hepatocellular carcinoma (HCC) can have viral or non-viral causes1-5. Non-alcoholic steatohepatitis (NASH) is an important driver of HCC. Immunotherapy has been approved for treating HCC, but biomarker-based stratification of patients for optimal response to therapy is an unmet need6,7. Here we report the progressive accumulation of exhausted, unconventionally activated CD8+PD1+ T cells in NASH-affected livers. In preclinical models of NASH-induced HCC, therapeutic immunotherapy targeted at programmed death-1 (PD1) expanded activated CD8+PD1+ T cells within tumours but did not lead to tumour regression, which indicates that tumour immune surveillance was impaired. When given prophylactically, anti-PD1 treatment led to an increase in the incidence of NASH-HCC and in the number and size of tumour nodules, which correlated with increased hepatic CD8+PD1+CXCR6+, TOX+, and TNF+ T cells. The increase in HCC triggered by anti-PD1 treatment was prevented by depletion of CD8+ T cells or TNF neutralization, suggesting that CD8+ T cells help to induce NASH-HCC, rather than invigorating or executing immune surveillance. We found similar phenotypic and functional profiles in hepatic CD8+PD1+ T cells from humans with NAFLD or NASH. A meta-analysis of three randomized phase III clinical trials that tested inhibitors of PDL1 (programmed death-ligand 1) or PD1 in more than 1,600 patients with advanced HCC revealed that immune therapy did not improve survival in patients with non-viral HCC. In two additional cohorts, patients with NASH-driven HCC who received anti-PD1 or anti-PDL1 treatment showed reduced overall survival compared to patients with other aetiologies. Collectively, these data show that non-viral HCC, and particularly NASH-HCC, might be less responsive to immunotherapy, probably owing to NASH-related aberrant T cell activation causing tissue damage that leads to impaired immune surveillance. Our data provide a rationale for stratification of patients with HCC according to underlying aetiology in studies of immunotherapy as a primary or adjuvant treatment.Serum alpha-fetoprotein and clinical outcomes in patients with advanced hepatocellular carcinoma treated with ramucirumab.Andrew X Zhu; Richard S Finn; Yoon-Koo Kang; Chia-Jui Yen; Peter R Galle; Josep M Llovet; Eric Assenat; Giovanni Brandi; Kenta Motomura; Izumi Ohno; Bruno Daniele; Arndt Vogel; Tatsuya Yamashita; Chih-Hung Hsu; Guido Gerken; John Bilbruck; Yanzhi Hsu; Kun Liang; Ryan C Widau; Chunxiao Wang; Paolo Abada; Masatoshi KudoBritish journal of cancer 124 (8) 1388 - 1397 2021/04 BACKGROUND: Post hoc analyses assessed the prognostic and predictive value of baseline alpha-fetoprotein (AFP), as well as clinical outcomes by AFP response or progression, during treatment in two placebo-controlled trials (REACH, REACH-2). METHODS: Serum AFP was measured at baseline and every three cycles. The prognostic and predictive value of baseline AFP was assessed by Cox regression models and Subpopulation Treatment Effect Pattern Plot method. Associations between AFP (≥ 20% increase) and radiographic progression and efficacy were assessed. RESULTS: Baseline AFP was confirmed as a continuous (REACH, REACH-2; p Effect of ramucirumab on ALBI grade in patients with advanced HCC: Results from REACH and REACH-2.Masatoshi Kudo; Peter R Galle; Giovanni Brandi; Yoon-Koo Kang; Chia-Jui Yen; Richard S Finn; Josep M Llovet; Eric Assenat; Philippe Merle; Stephen L Chan; Daniel H Palmer; Masafumi Ikeda; Tatsuya Yamashita; Arndt Vogel; Yi-Hsiang Huang; Paolo B Abada; Reigetsu Yoshikawa; Kenta Shinozaki; Chunxiao Wang; Ryan C Widau; Andrew X ZhuJHEP reports : innovation in hepatology 3 (2) 100215 - 100215 2021/04 Background & Aims: The albumin-bilirubin (ALBI) grade/score is derived from a validated nomogram to objectively assess prognosis and liver function in patients with hepatocellular carcinoma (HCC). In this post hoc analysis, we assessed prognosis in terms of survival by baseline ALBI grade and monitored liver function during treatment with ramucirumab or placebo using the ALBI score in patients with advanced HCC. Methods: Patients with advanced HCC, Child-Pugh class A with prior sorafenib treatment were randomised in REACH trials to receive ramucirumab 8 mg/kg or placebo every 2 weeks. Data were analysed by trial and as a meta-analysis of individual patient-level data (pooled population) from REACH (alpha-fetoprotein ≥400 ng/ml) and REACH-2. Patients from REACH with Child-Pugh class B were analysed as a separate cohort. The ALBI grades and scores were calculated at baseline and before each treatment cycle. Results: Baseline characteristics by ALBI grade were balanced between treatment arms among patients in the pooled population (ALBI-1, n = 231; ALBI-2, n = 296; ALBI-3, n = 7). Baseline ALBI grade was prognostic for overall survival (OS; ALBI grade 2 vs. 1; hazard ratio [HR]: 1.38 [1.13-1.69]), after adjusting for other significant prognostic factors. Mean ALBI scores remained stable in both treatment arms compared with baseline and were unaffected by baseline ALBI grade, macrovascular invasion, tumour response, geographical region, or prior locoregional therapy. Baseline ALBI grades 2 and 3 were associated with increased incidence of liver-specific adverse events and discontinuation rates in both treatments. Ramucirumab improved OS in patients with baseline ALBI grade 1 (HR 0.605 [0.445-0.824]) and ALBI grade 2 (HR 0.814 [0.630-1.051]). Conclusions: Compared with placebo, ramucirumab did not negatively impact liver function and improved survival irrespective of baseline ALBI grade. Lay summary: Hepatocellular carcinoma is the third leading cause of cancer-related death worldwide. Prognosis is affected by many clinical factors including liver function both before and during anticancer treatment. Here we have used a validated approach to assess liver function using 2 laboratory parameters, serum albumin and bilirubin (ALBI), both before and during treatment with ramucirumab in 2 phase III placebo-controlled studies. We confirm the practicality of using this more simplistic approach in assessing liver function prior to and during anticancer therapy, and demonstrate ramucirumab did not impair liver function when compared with placebo.Across-the-papilla side-by-side placement of 6-mm fully covered metallic stents for malignant hilar biliary obstruction: a novel concept that may facilitate reintervention.Mamoru Takenaka; Tomohiro Yamazaki; Yasuo Otsuka; Kota Takashima; Rei Ishikawa; Masatoshi KudoEndoscopy 54 (3) E102-E105  2021/03Three-Dimensional Radiological Assessment of Ablative Margins in Hepatocellular Carcinoma: Pilot Study of Overlay Fused CT/MRI Imaging with Automatic Registration.Yasunori Minami; Tomohiro Minami; Kazuomi Ueshima; Yukinobu Yagyu; Masakatsu Tsurusaki; Takuya Okada; Masatoshi Hori; Masatoshi Kudo; Takamichi MurakamiCancers 13 (6) 2021/03 BACKGROUND: We investigate the feasibility of image fusion application for ablative margin assessment in radiofrequency ablation (RFA) for hepatocellular carcinoma (HCC) and possible causes for a wrong initial evaluation of technical success through a side-by-side comparison. METHODS: A total of 467 patients with 1100 HCCs who underwent RFA were reviewed retrospectively. Seventeen patients developed local tumor progressions (LTPs) (median size, 1.0 cm) despite initial judgments of successful ablation referring to contrast-enhanced images obtained in the 24 h after ablation. The ablative margins were reevaluated radiologically by overlaying fused images pre- and post-ablation. RESULTS: The initial categorizations of the 17 LTPs had been grade A (absolutely curative) (n = 5) and grade B (relatively curative) (n = 12); however, the reevaluation altered the response categories to eight grade C (margin-zero ablation) and nine grade D (existence of residual HCC). LTP occurred in eight patients re-graded as C within 4 to 30.3 months (median, 14.3) and in nine patients re-graded as D within 2.4 to 6.7 months (median, 4.2) (p = 0.006). Periablational hyperemia enhancements concealed all nine HCCs reevaluated as grade D. CONCLUSION: Side-by-side comparisons carry a risk of misleading diagnoses for LTP of HCC. Overlay fused imaging technology can be used to evaluate HCC ablative margin with high accuracy.Ramucirumab in patients with advanced hepatocellular carcinoma and elevated α-fetoprotein: Outcomes by treatment-emergent ascites.Masatoshi Kudo; Masafumi Ikeda; Peter R Galle; Tatsuya Yamashita; Richard S Finn; Kun Liang; Chunxiao Wang; Sachi Sakaguchi; Paolo Abada; Ryan C Widau; Andrew X ZhuHepatology research : the official journal of the Japan Society of Hepatology 51 (6) 715 - 721 2021/03 AIM: The REACH and REACH-2 trials investigated ramucirumab versus placebo in patients with advanced hepatocellular carcinoma (HCC). Ascites is common in HCC and is associated with poorer outcomes. This exploratory, pooled meta-analysis of patients with baseline α-fetoprotein (AFP) ≥400 ng/ml investigated outcomes by treatment-emergent (TE) ascites in REACH and REACH-2. METHODS: A pooled meta-analysis of independent patient data for participants (N = 542) with baseline AFP ≥400 ng/ml (stratified by study) from REACH and REACH-2 was carried out. Overall survival (OS) and progression-free survival (PFS) were evaluated by Kaplan-Meier estimator, and OS further assessed by Cox models. The effect of TE ascites on OS was evaluated by multivariate Cox models. RESULTS: Treatment-emergent ascites developed in 66 patients (20.9%) in the ramucirumab group and 33 patients (14.8%) in the placebo group. When adjusted for treatment duration, the incidence rates per 100 patient-years of any grade TE ascites were 59.1 and 71.9 for the ramucirumab and placebo groups, respectively, and the incidence of grade ≥3 TE ascites were 13.4 and 19.6, respectively. Treatment-emergent ascites was associated with TE hypoalbuminemia (odds ratio 4.9; 95% confidence interval 2.5-9.3), but not TE proteinuria or hypertension. One patient discontinued ramucirumab treatment due to TE ascites. Ramucirumab treatment improved OS and PFS compared with placebo, irrespective of TE ascites. CONCLUSIONS: When adjusted for treatment duration, the incidence of TE ascites was no higher in patients who received ramucirumab than in those who received placebo. Ramucirumab was well tolerated and provided a survival benefit irrespective of the development of TE ascites.A case with hepatic immune-related adverse events caused by nivolumab exhibiting impaired accumulation of regulatory T cells.Ikue Sekai; Satoru Hagiwara; Tomohiro Watanabe; Masatoshi KudoClinical journal of gastroenterology 14 (4) 1191 - 1196 2021/03 Systemic administration of anti-programmed cell death 1 (PD-1) antibody (Ab) has achieved remarkable success in metastatic cancers. The blockade of PD-1-mediated signaling pathways sometimes cause immune-related adverse events (irAEs) due to restored anti-cancer as well as anti-self immunity. Although the liver is a preferential organ for irAEs, the immuno-pathogenesis underlying hepatic irAEs has been poorly understood. We describe a 57-year-old man with Stage IV lung cancer who underwent the first-line regimen composed of carboplatin and paclitaxel. Nivolumab treatment (3.2 mg/kg, every 3 weeks) was initiated when the disease progressed after the first chemotherapy. Sequential occurrence of irAEs involving the multiorgan systems was observed. He developed hepatic irAEs (Grade 3) after endocrine, lung, and cutaneous irAEs. Lobular hepatitis characterized by predominant infiltration of CD8+ T cells was seen in the liver biopsy specimens. Interestingly, defective accumulation of regulatory T cells (Tregs) expressing forkhead box protein P3 (FOXP3) was evident in this case with hepatic irAEs as compared with typical cases with autoimmune hepatitis. This case suggests that hepatic irAEs are characterized not only by lobular infiltration of CD8+ T cells but also by defective accumulation of FOXP3+ Tregs.A novel method of papilla fixation for difficult biliary cannulation without using a pancreatic duct guidewire: non-guidewire fixation method.Mamoru Takenaka; Koichiro Kawano; Reiko Kawano; Takao Katoh; Katsuhisa Nishi; Masatoshi KudoEndoscopy 54 (1) 101 - 102 2021/03急性膵炎からアプローチする膵癌早期診断山雄 健太郎; 竹中 完; 工藤 正俊日本消化器病学会雑誌 (一財)日本消化器病学会 118 (臨増総会) A397 - A397 0446-6586 2021/03肝癌における薬物療法の診療体系 切除不能肝細胞癌に対するアテゾリズマブ+ベバシズマブ併用療法の経験(IMbrave150試験より)青木 智子; 上嶋 一臣; 工藤 正俊日本消化器病学会雑誌 (一財)日本消化器病学会 118 (臨増総会) A114 - A114 0446-6586 2021/03肝予備能の評価法:検体検査と画像検査 切除不能肝細胞癌へのレンバチニブ療法におけるFIB-4 index、ALBI scoreの有用性青木 智子; 上嶋 一臣; 工藤 正俊日本消化器病学会雑誌 (一財)日本消化器病学会 118 (臨増総会) A118 - A118 0446-6586 2021/03消化器領域におけるAI研究の進歩 腹部超音波B-modeでの肝腫瘤検出・診断支援システムの開発西田 直生志; 工藤 正俊日本消化器病学会雑誌 (一財)日本消化器病学会 118 (臨増総会) A28 - A28 0446-6586 2021/03胆膵の内視鏡診断と治療 膵腫瘤におけるDetective flow imaging(DFI)の有用性の検討大本 俊介; 竹中 完; 工藤 正俊日本消化器病学会雑誌 (一財)日本消化器病学会 118 (臨増総会) A90 - A90 0446-6586 2021/03消化器領域におけるAI研究の進歩 腹部超音波B-modeでの肝腫瘤検出・診断支援システムの開発西田 直生志; 工藤 正俊日本消化器病学会雑誌 (一財)日本消化器病学会 118 (臨増総会) A28 - A28 0446-6586 2021/03The Asian Federation of Societies for Ultrasound in Medicine and Biology (AFSUMB) Guidelines for Contrast-Enhanced Endoscopic Ultrasound.Masayuki Kitano; Yasunobu Yamashita; Ken Kamata; Tiing Leong Ang; Hiroo Imazu; Eizaburo Ohno; Yoshiki Hirooka; Pietro Fusaroli; Dong-Wan Seo; Bertrand Napoléon; Anthony Yuen Bun Teoh; Tae Hyeon Kim; Christoph F Dietrich; Hsiu-Po Wang; Masatoshi KudoUltrasound in medicine & biology 47 (6) 1433 - 1447 2021/02 The Asian Federation of Societies for Ultrasound in Medicine and Biology aimed to provide information on techniques and indications for contrast-enhanced harmonic endoscopic ultrasound (CH-EUS), and to create statements including the level of recommendation. These statements are based on current scientific evidence reviewed by a Consensus Panel of 15 internationally renowned experts. The reliability of clinical questions was measured by agreement rates after voting. Six statements were made on techniques, including suitable contrast agents for CH-EUS, differences between contrast agents, setting of mechanical index, dual imaging and duration and phases for observation. Thirteen statements were made on indications, including pancreatic solid masses, pancreatic cancer staging, pancreatic cystic lesions and mural nodules, detection of subtle pancreatic lesions, gallbladder sludge and polyps, hepatic lesions, lymph nodes, subepithelial lesions, visceral vascular diseases, guidance of fine needle aspiration and evaluation for local therapy. These international expert consensus guidelines will assist endosonographers in conducting CH-EUS according to evidence-based information.A unique profile of serum cytokines in type 1 autoimmune pancreatitis and chronic rhinosinusitis.Tomoe Yoshikawa; Kosuke Minaga; Akane Hara; Ikue Sekai; Yasuo Otsuka; Ryutaro Takada; Ken Kamata; Tomohiro Watanabe; Masatoshi KudoAsian Pacific journal of allergy and immunology 2021/02 BACKGROUND: Type 1 autoimmune pancreatitis (AIP) is a pancreatic manifestation of IgG4-related disease (IgG4-RD). Although AIP and IgG4-RD are characterized by multiple organ involvement including salivary glands, lung, and kidney, co-occurrence of chronic rhinosinusitis (CRS) and AIP/IgG4-RD has been poorly defined. OBJECTIVE: We explored molecular mechanism accounting for the co-occurrence of CRS and AIP/IgG4-RD. METHODS: Serum concentrations of IFN-α and IL-33 were measured by enzyme-linked immune-sorbent assay. RESULTS: We encountered a patient with concurrent type 1 AIP/IgG4-RD and CRS. Induction of remission by prednisolone (PSL) for type 1 AIP/IgG4-RD led to a marked improvement of CRS. Serum cytokine analysis after PSL treatment revealed a marked reduction in serum concentrations of IFN-α and IL-33, both of which are candidate pathogenic cytokines for AIP/IgG4-RD. CONCLUSIONS: Given that IL-33 is shared as one of pathogenic cytokines by type 1 AIP/IgG4-RD and CRS, enhanced IL33 responses may cause concurrent type 1 AIP/IgG4-RD and CRS.Endoscopic papillotomy and papilloplasty: Effects on sphincter of Oddi functionality and outcomes.Mamoru Takenaka; Masatoshi KudoDigestive endoscopy : official journal of the Japan Gastroenterological Endoscopy Society 33 (6) 924 - 926 2021/02Utility of a 20G needle with a core trap in EUS-guided fine-needle biopsy for gastric submucosal tumors: A multicentric prospective trial.Ken Kamata; Akira Kurita; Satoru Yasukawa; Yasutaka Chiba; Hiroko Nebiki; Masanori Asada; Hiroaki Yasuda; Hideyuki Shiomi; Takeshi Ogura; Makoto Takaoka; Noriyuki Hoki; Reiko Ashida; Minoru Shigekawa; Akio Yanagisawa; Masatoshi Kudo; Masayuki KitanoEndoscopic ultrasound 2021/02 Background and Objectives: Differential diagnosis to estimate the malignant potential of gastric submucosal tumor (g-SMT) is important for decision-making. This study evaluated the use of a 20G needle with a core trap for EUS-guided fine-needle biopsy (EUS-FNB) for g-SMT. Methods: This multicentric prospective trial was registered in the University Hospital Medical Information Network (UMIN000021410). Consecutive patients with g-SMT who presented at one of the nine Japanese Referral Centers between June 2017 and November 2018 were enrolled. All patients underwent EUS-FNB using a 20G needle with a core trap. Samples obtained with the first-needle pass were used for central pathological review. EUS-FNB was evaluated in terms of (i) technical success rate, (ii) adequacy for histological evaluation, (iii) rate of complications, (iv) accuracy for histological diagnosis of gastrointestinal stromal tumor (GIST), and (v) concordance between GIST mitotic index determined by EUS-FNB and after tumor resection. Results: The study included 52 patients. The technical success rate of EUS-FNB was 100%. The adequacy rate for histological evaluation was 90.4% (P Tissue Harmonic versus Contrast-Enhanced Harmonic Endoscopic Ultrasonography for the Diagnosis of Pancreatic Tumors: A Prospective Multicenter Study.Shunsuke Omoto; Masayuki Kitano; Mitsuharu Fukasawa; Reiko Ashida; Hironari Kato; Hideyuki Shiomi; Kazuya Sugimori; Atsushi Kanno; Yasutaka Chiba; Shinichi Takano; Naoki Yamamoto; Takeshi Ezaki; Haruo Miwa; Akitaka Yokomura; Masato Hoshikawa; Takamitsu Tanaka; Masatoshi KudoDigestive endoscopy : official journal of the Japan Gastroenterological Endoscopy Society 34 (1) 198 - 206 2021/02 OBJECTIVES: This prospective multicenter study aimed to assess and compare the accuracy of tissue harmonic endoscopic ultrasonography (TH-EUS) and contrast-enhanced harmonic endoscopic ultrasonography (CH-EUS) for differentiating pancreatic carcinoma from other pancreatic tumors. METHODS: Consecutive patients with solid pancreatic tumors were prospectively enrolled between August 2013 and December 2014. To assess the accuracy of TH-EUS and CH-EUS, we compared four parameters of TH-EUS (fuzzy edge, irregular periphery, hypoechogenicity, and heterogeneous internal echogenicity) and four parameters of CH-EUS (hypoenhancement and heterogeneous enhancement in early and late phases, respectively) to investigate which parameter of each method was most suitable to diagnose pancreatic carcinomas. Inter-observer agreement and the diagnostic ability of pancreatic carcinoma using TH-EUS and CH-EUS were assessed and compared. RESULTS: A total of 204 patients were enrolled. For the diagnosis of pancreatic carcinoma, inter-observer agreement by experts and non-experts was 0.33-0.50 and 0.35-0.50 for TH-EUS, respectively, and 0.72-0.74 and 0.20-0.54 for CH-EUS, respectively. Irregular periphery was the most accurate diagnostic parameter among TH-EUS findings for differentiating pancreatic carcinomas, with sensitivity, specificity, and accuracy of 95.0%, 42.9%, and 77.5%, respectively. Late phase hypoenhancement was the most accurate diagnostic parameter among CH-EUS findings for differentiating pancreatic carcinomas, with sensitivity, specificity, and accuracy of 90.8%, 74.6%, and 84.8%, respectively. The accuracy of CH-EUS (late phase hypoenhancement) for diagnosis of pancreatic carcinoma was significantly higher than that of TH-EUS (irregular periphery) (PCorrection: Impact of age on sorafenib outcomes in hepatocellular carcinoma: an international cohort study.Saur Hajiev; Elias Allara; Leila Motedayеn Aval; Tadaaki Arizumi; Dominik Bettinger; Mario Pirisi; Lorenza Rimassa; Tiziana Pressiani; Nicola Personeni; Laura Giordano; Masatoshi Kudo; Robert Thimme; Joong-Won Park; Tamar H Taddei; David E Kaplan; Ramya Ramaswami; David J Pinato; Rohini SharmaBritish journal of cancer 2021/02Impact of Multi-Drug Sequential Therapy on Survival in Patients with Unresectable Hepatocellular Carcinoma.Masatoshi KudoLiver cancer 10 (1) 1 - 9 2021/02Clinical-Radiomic Analysis for Pretreatment Prediction of Objective Response to First Transarterial Chemoembolization in Hepatocellular Carcinoma.Mingyu Chen; Jiasheng Cao; Jiahao Hu; Win Topatana; Shijie Li; Sarun Juengpanich; Jian Lin; Chenhao Tong; Jiliang Shen; Bin Zhang; Jennifer Wu; Christine Pocha; Masatoshi Kudo; Amedeo Amedei; Franco Trevisani; Pil Soo Sung; Victor M Zaydfudim; Tatsuo Kanda; Xiujun CaiLiver cancer 10 (1) 38 - 51 2021/02 Background: The preoperative selection of patients with intermediate-stage hepatocellular carcinoma (HCC) who are likely to have an objective response to first transarterial chemoembolization (TACE) remains challenging. Objective: To develop and validate a clinical-radiomic model (CR model) for preoperatively predicting treatment response to first TACE in patients with intermediate-stage HCC. Methods: A total of 595 patients with intermediate-stage HCC were included in this retrospective study. A tumoral and peritumoral (10 mm) radiomic signature (TPR-signature) was constructed based on 3,404 radiomic features from 4 regions of interest. A predictive CR model based on TPR-signature and clinical factors was developed using multivariate logistic regression. Calibration curves and area under the receiver operating characteristic curves (AUCs) were used to evaluate the model's performance. Results: The final CR model consisted of 5 independent predictors, including TPR-signature (p Consensus report from the 9th International Forum for Liver Magnetic Resonance Imaging: applications of gadoxetic acid-enhanced imaging.Dow-Mu Koh; Ahmed Ba-Ssalamah; Giuseppe Brancatelli; Ghaneh Fananapazir; M Isabel Fiel; Satoshi Goshima; Sheng-Hong Ju; Nikolaos Kartalis; Masatoshi Kudo; Jeong Min Lee; Takamichi Murakami; Max Seidensticker; Claude B Sirlin; Cher Heng Tan; Jin Wang; Jeong Hee Yoon; Mengsu Zeng; Jian Zhou; Bachir TaouliEuropean radiology 2021/02 OBJECTIVES: The 9th International Forum for Liver Magnetic Resonance Imaging (MRI) was held in Singapore in September 2019, bringing together radiologists and allied specialists to discuss the latest developments in and formulate consensus statements for liver MRI, including the applications of gadoxetic acid-enhanced imaging. METHODS: As at previous Liver Forums, the meeting was held over 2 days. Presentations by the faculty on days 1 and 2 and breakout group discussions on day 1 were followed by delegate voting on consensus statements presented on day 2. Presentations and discussions centered on two main meeting themes relating to the use of gadoxetic acid-enhanced MRI in primary liver cancer and metastatic liver disease. RESULTS AND CONCLUSIONS: Gadoxetic acid-enhanced MRI offers the ability to monitor response to systemic therapy and to assist in pre-surgical/pre-interventional planning in liver metastases. In hepatocellular carcinoma, gadoxetic acid-enhanced MRI provides precise staging information for accurate treatment decision-making and follow-up post therapy. Gadoxetic acid-enhanced MRI also has potential, currently investigational, indications for the functional assessment of the liver and the biliary system. Additional voting sessions at the Liver Forum debated the role of multidisciplinary care in the management of patients with liver disease, evidence to support the use of abbreviated imaging protocols, and the importance of standardizing nomenclature in international guidelines in order to increase the sharing of scientific data and improve the communication between centers. KEY POINTS: • Gadoxetic acid-enhanced MRI is the preferred imaging method for pre-surgical or pre-interventional planning for liver metastases after systemic therapy. • Gadoxetic acid-enhanced MRI provides accurate staging of HCC before and after treatment with locoregional/biologic therapies. • Abbreviated protocols for gadoxetic acid-enhanced MRI offer potential time and cost savings, but more evidence is necessary. The use of gadoxetic acid-enhanced MRI for the assessment of liver and biliary function is under active investigation.Current status of endoscopic re-intervention for hilar malignant biliary obstruction.Mamoru Takenaka; Masatoshi KudoDigestive endoscopy : official journal of the Japan Gastroenterological Endoscopy Society 33 (5) 746 - 748 2021/02Cost-Effectiveness of Lenvatinib in the Treatment of Patients With Unresectable Hepatocellular Carcinomas in Japan: An Analysis Using Data From Japanese Patients in the REFLECT Trial.Shunya Ikeda; Masatoshi Kudo; Namiki Izumi; Masahiro Kobayashi; Mie Azuma; Genevieve Meier; Janice Pan; Mika Ishii; Shuichi KanekoValue in health regional issues 24 82 - 89 2021/01 BACKGROUND: Hepatocellular carcinoma (HCC) is one of the leading causes of cancer-related mortality in Japan. Prognosis is poor, and until recently sorafenib was the only treatment option available for patients with unresectable disease. Lenvatinib is the first therapy to demonstrate noninferiority to sorafenib. An analysis was conducted using clinical data from Japanese patients in the phase III REFLECT trial to assess the cost-effectiveness of lenvatinib versus sorafenib for first-line treatment of unresectable HCC in Japan. METHODS: A partitioned survival model was implemented adopting the perspective of the Japanese healthcare system, with costs and outcomes modeled over a lifetime horizon and using a discount rate of 2%, as per Japanese guidelines. Population data from the Japanese subpopulation of REFLECT were used to extrapolate outcomes, and costs and resource use were based on Japanese sources. The Japanese tariff was applied to EQ-5D data collected during the REFLECT clinical trial to obtain utility values reflecting the preferences of the Japanese population. RESULTS: Compared with sorafenib, lenvatinib is dominant because it is associated with a reduction in incremental costs of \156 799 and incremental quality-adjusted life-years of 0.31. These results were robust to changes in key assumptions, and probabilistic outcomes aligned with deterministic outcomes. CONCLUSION: Given the use of Japan-specific data in the cost-effectiveness model, it is expected that the use of lenvatinib as a first-line treatment in Japan will be associated with cost savings and improved clinical outcomes versus sorafenib for patients with unresectable HCC.Probiotic-Derived Polyphosphate Prevents Pancreatitis.Kosuke Minaga; Tomohiro Watanabe; Masatoshi KudoDigestive diseases and sciences 2021/01Dual-Energy Computed Tomography of the Liver: Uses in Clinical Practices and Applications.Masakatsu Tsurusaki; Keitaro Sofue; Masatoshi Hori; Kosuke Sasaki; Kazunari Ishii; Takamichi Murakami; Masatoshi KudoDiagnostics (Basel, Switzerland) 11 (2) 2021/01 Dual-energy computed tomography (DECT) is an imaging technique based on data acquisition at two different energy settings. Recent advances in CT have allowed data acquisitions and simultaneous analyses of X-rays at two energy levels, and have resulted in novel developments in the field of abdominal imaging. The use of low and high X-ray tube voltages in DECT provide fused images that improve the detection of liver tumors owing to the higher contrast-to-noise ratio (CNR) of the tumor compared with the liver. The use of contrast agents in CT scanning improves image quality by enhancing the CNR and signal-to-noise ratio while reducing beam-hardening artifacts. DECT can improve detection and characterization of hepatic abnormalities, including mass lesions. The technique can also be used for the diagnosis of steatosis and iron overload. This article reviews and illustrates the different applications of DECT in liver imaging.Transverse colonic volvulus due to mesenteric fibromatosis: a case report.Akihiro Yoshida; Yasutake Uchima; Naoki Hosaka; Kosuke Minaga; Masatoshi KudoBMC gastroenterology 21 (1) 11 - 11 2021/01 BACKGROUND: Colonic volvulus, a condition in which a colonic segment partially twists around its base, is the third leading cause of large bowel obstruction after colonic neoplasms and diverticular disease. However, volvulus of the transverse colon is the rarest type of large intestinal volvulus. Moreover, the occurrence of transverse colonic volvulus secondary to a benign tumor originating from outside the intestine has never been reported. We hereby report a case of transverse colonic volvulus caused by mesenteric fibromatosis. CASE PRESENTATION: A 53-year-old female with a history of rheumatoid arthritis and thyroid tumor presented with abdominal pain for 1 day. Abdominal computed tomography revealed intestinal torsion at the hepatic flexure. Twisted and obstructed mucosa of the transverse colon was observed during colonoscopy, but no tumor invasion of the mucosal surface was detected. A solid mass of a mesenteric origin with involvement of the transverse colon was observed during surgery. The mass was diagnosed surgically as transverse colonic volvulus induced by a mesenteric tumor. Hence, the patient underwent a right hemicolectomy. Histopathological results indicated mesenteric desmoid-type fibromatosis. The postoperative recovery was uneventful, and the patient was discharged 8 days after surgery. CONCLUSIONS: Although mesenteric fibromatosis is rare, this disease should be considered when managing transverse colonic volvulus resulting from nonmucosal tumors.A case with eosinophilic gastroenteritis exhibiting enhanced TNF-α and IL-6 responses.Ikue Sekai; Tomohiro Watanabe; Keisuke Yoshikawa; Ryutaro Takada; Akane Hara; Tomoe Yoshikawa; Ken Kamata; Kosuke Minaga; Masatoshi KudoClinical journal of gastroenterology 2021/01 Eosinophilic gastroenteritis (EGE) is a chronic allergic disorder characterized by infiltration of eosinophils in the gastrointestinal (GI) tract and hypereosinophilia. Although T helper type 2 (Th2) responses play pathogenic roles in EGE, roles of innate immunity cytokines including IL-6 and TNF-α have been poorly defined. Here, we describe a case of EGE exhibiting accumulation of eosinophils in the upper GI mucosa and hypereosinophilia. Induction of remission by prednisolone reduced expression levels not only of Th2 cytokines but also of IL-6 and TNF-α in the GI mucosa. Moreover, induction of remission was accompanied by a marked reduction in serum levels of chemokine C-C motif ligand 17 (CCL17, TARC), IL-6 and TNF-α, implicating that both Th2 and innate immune responses were involved in the development of EGE in this case. Collectively, this case suggests possible involvement of IL-6 and TNF-α in the development of EGE.Cabozantinib in Japanese patients with advanced hepatocellular carcinoma: a phase 2 multicenter study.Masatoshi Kudo; Kaoru Tsuchiya; Naoya Kato; Atsushi Hagihara; Kazushi Numata; Hiroshi Aikata; Yoshitaka Inaba; Shunsuke Kondo; Kenta Motomura; Junji Furuse; Masafumi Ikeda; Manabu Morimoto; Meguru Achira; Shingo Kuroda; Akiko KimuraJournal of gastroenterology 2021/01 BACKGROUND: To evaluate the efficacy and safety of cabozantinib in Japanese patients with advanced hepatocellular carcinoma (HCC) who had progressed following one or two lines of systemic therapy including sorafenib. An exploratory evaluation in sorafenib-naïve patients was performed. METHODS: In this open-label, single-arm, phase 2 trial, patients received oral cabozantinib 60 mg once daily. The primary endpoint was progression-free survival (PFS) rate at Week 24. Secondary endpoints included PFS, overall survival (OS), objective response rate (ORR, best response of complete/partial response), disease control rate (DCR, objective response or stable disease) and safety. RESULTS: Thirty-four patients received cabozantinib across 17 centers (prior sorafenib cohort, n = 20; sorafenib-naïve cohort, n = 14). PFS rate at 24 weeks was 59.8% [90% confidence interval (CI) 36.1-77.2%] in the prior sorafenib cohort, 16.7% (90% CI 4.0-36.8%) in the sorafenib-naïve cohort and 40.1% (90% CI 24.8-55.0%) overall. Median PFS was 7.4 months for the prior sorafenib cohort, 3.6 months for the sorafenib-naïve cohort, and 5.6 months overall. OS rate at 6 months was 100.0%, 78.6% and 91.1%, respectively; DCR was 85.0%, 64.3% and 76.5%, respectively. The ORR was 0.0% for both cohorts. All patients required dose modifications due to adverse events, the most common of these were palmar-plantar erythrodysesthesia syndrome and diarrhea. Three patients (8.8%) discontinued due to adverse events other than disease progression. CONCLUSIONS: Cabozantinib 60 mg/day has a favorable benefit/risk profile for Japanese patients with advanced HCC who have previously received one or two lines of systemic anticancer therapy including sorafenib. (Clinical trial registration: NCT03586973).Deep-learning framework based on a large ultrasound image database to realize computer-aided diagnosis for liver and breast tumorsMakoto Yamakawa; Tsuyoshi Shiina; Koichiro Tsugawa; Naoshi Nishida; Masatoshi KudoINTERNATIONAL ULTRASONICS SYMPOSIUM (IEEE IUS 2021) IEEE 1948-5719 2021 The quality and quantity of training data is vital for computer-aided diagnosis (CADx) based on deep learning. However, the biomedical industry lacks large database of ultrasound images. Therefore, The Japan Society of Ultrasonics in Medicine (JSUM) is currently constructing an ultrasound image database for liver tumors, breast tumors, and heart diseases. As of August 2021, the project has collected more than 140,000 ultrasound images and videos. This database contains ultrasound images, their corresponding labels, and annotation information. That is, the ultrasound image data contains information related to the size and location of the tumor. In this study, we developed a CADx to classify liver tumors and breast tumors by utilizing approximately 71,000 liver tumor and 14,000 breast tumor ultrasound images from the abovementioned database. We classified liver tumors into four classes: cysts, hemangiomas, hepatocellular carcinomas, and metastatic liver cancers. Similarly, we classified breast tumors into four classes: breast cancer, fibroadenoma, cysts, and others. We used a convolutional neural network based on VGG19 for these classifications, and evaluated the accuracy of each case unit by k-fold cross-validation, thereby achieving an accuracy of 91.1% and 85.2% for four-class classification of liver tumor and breast tumor, respectively. In addition, the accuracy, sensitivity, and specificity of the benign/malignant classification based on this result was, respectively, 94.3%, 82.8%, and 96.7% for liver tumors and 89.9% 92.6% and 86.6% for breast tumors. Furthermore, when compared with the results obtained in a previous study that utilized a small database, using a large database provided a higher accuracy for both liver and breast tumors.Efficacy of endoscopic ultrasound-guided fine-needle aspiration for esophageal schwannoma.Shigenaga Matsui; Tomohiro Yamazaki; Osamu Shiraishi; Masatoshi KudoAnnals of gastroenterology 34 (4) 597 - 597 2021Impact of COVID-19 on Hepatocellular Carcinoma Management: A Multicountry and Region Study.Mihir Gandhi; Wen-Huan Ling; Chien-Hung Chen; Joon Hyeok Lee; Masatoshi Kudo; Rawisak Chanwat; Simone I Strasser; Zhu Xu; Soh-Han Lai; Pierce Kah-Hoe ChowJournal of hepatocellular carcinoma 8 1159 - 1167 2021 Purpose: The COVID-19 pandemic has altered healthcare priorities which may adversely impact cancer management. We aimed to evaluate the impact of the pandemic on the diagnosis, treatment, and consultation methods for patients with hepatocellular carcinoma (HCC). Patients and Methods: We conducted a survey among 27 hospitals from 14 Asia-Pacific countries, collecting hospital-level information on the number of newly diagnosed HCC cases during a pre-pandemic period (February to May 2019) and for the same period during the pandemic (February to May 2020). Information was also collected on delays in diagnosis and treatment, changes in treatment modalities and complication rates, changes in patient enrollment in clinical trials, and modes of patient consultation. The information was stratified by the Barcelona Clinic Liver Cancer (BCLC) stage. Results: The survey included cohorts of 2789 and 2045 patients newly diagnosed with HCC during the pre- and pandemic period, respectively. A decline of 26.7% in new HCC cases was reported during the pandemic compared to the pre-pandemic. A sizable proportion of institutions reported delays in diagnosis (48.2% in BCLC 0/A/B and 51.9% in BCLC C), delays in treatment (66.7% in BCLC 0/A/B and 63.0% in BCLC C), changes in treatment modality (33.3% in BCLC 0/A/B and 18.5% in BCLC C), an increase in treatment complications (about 15% across all BCLC stages), and no growth in clinical trial enrollments during the pandemic. Furthermore, there was a decline of 27.3% in face-to-face patient consultations and an increase of 18.3% in video/telephonic consultations during the pandemic. A considerable variation in changes in HCC management was observed among countries. Conclusion: The COVID-19 pandemic has significantly impacted the management of HCC among Asia-Pacific countries. The impact varies according to the disease stage and country. Well thought-through long-term strategies are required to ameliorate the negative impact of the pandemic on HCC patients.ALBI score and outcomes in patients with hepatocellular carcinoma: post hoc analysis of the randomized controlled trial KEYNOTE-240.Arndt Vogel; Philippe Merle; Chris Verslype; Richard S Finn; Andrew X Zhu; Ann-Lii Cheng; Stephen Lam Chan; Thomas Yau; Baek-Yeol Ryoo; Jennifer Knox; Bruno Daniele; Shukui Qin; Ziwen Wei; Yanna Miteva; Usha Malhotra; Abby B Siegel; Masatoshi KudoTherapeutic advances in medical oncology 13 17588359211039928 - 17588359211039928 2021 Aims: This post hoc analysis evaluated albumin/bilirubin (ALBI) score, an objective measure of liver function, in patients receiving pembrolizumab plus best supportive care (BSC) compared with placebo plus BSC in the KEYNOTE-240 study. Methods: Patients with confirmed hepatocellular carcinoma (HCC) and progression after/intolerance to sorafenib, Child-Pugh class A liver function, and Eastern Cooperative Oncology Group performance status of 0-1 were randomly assigned 2:1 to pembrolizumab 200 mg or placebo intravenously every 3 weeks plus BSC for ⩽35 cycles or until confirmed progression/unacceptable toxicity. Outcomes were assessed by ALBI grade. Results: Of 413 patients, at baseline 116 had an ALBI grade 1 score (pembrolizumab, n = 74; placebo, n = 42) and 279 had an ALBI grade 2 score (n = 193; n = 86). Change from baseline in ALBI score to the end of treatment was similar in both arms [difference in least squares mean, -0.039; 95% confidence interval (CI): -0.169 to 0.091]. Time to ALBI grade increase was similar in both arms [median for pembrolizumab versus placebo: 7.8 versus 6.9 months; hazard ratio (HR) = 0.863 (95% CI: 0.625-1.192)]. Regardless of baseline ALBI grade, a trend toward improved overall survival was observed with pembrolizumab [grade 1: HR = 0.725 (95% CI: 0.454-1.158); grade 2: HR = 0.827 (95% CI: 0.612-1.119)]. Conclusion: Pembrolizumab did not adversely impact liver function compared with placebo in patients with HCC, as measured by changes in ALBI scores. A trend toward improved overall survival was observed with pembrolizumab in both ALBI grade groups. ClinicalTrials.gov identifier: NCT02702401.IL-33 as a Critical Cytokine for Inflammation and Fibrosis in Inflammatory Bowel Diseases and Pancreatitis.Masayuki Kurimoto; Tomohiro Watanabe; Ken Kamata; Kosuke Minaga; Masatoshi KudoFrontiers in physiology 12 781012 - 781012 2021 IL-33 is a pleiotropic cytokine that promotes inflammation and fibrosis. IL-33 is produced by a broad range of cells, including antigen-presenting cells (APCs), epithelial cells, and fibroblasts. IL-33 produced by the innate immune cells has been shown to activate pro-inflammatory T helper type 1 (Th1) and T helper type 2 (Th2) responses. The intestinal barrier and tolerogenic immune responses against commensal microbiota contribute to the maintenance of gut immune homeostasis. Breakdown of tolerogenic responses against commensal microbiota as a result of intestinal barrier dysfunction underlies the immunopathogenesis of inflammatory bowel diseases (IBD) and pancreatitis. Recent studies have provided evidence that IL-33 is an innate immune cytokine that bridges adaptive Th1 and Th2 responses associated with IBD and pancreatitis. In this Mini Review, we discuss the pathogenic roles played by IL-33 in the development of IBD and pancreatitis and consider the potential of this cytokine to be a new therapeutic target.Intestinal Microbiota and Gene Expression Reveal Similarity and Dissimilarity Between Immune-Mediated Colitis and Ulcerative Colitis.Kazuko Sakai; Toshiharu Sakurai; Marco A De Velasco; Tomoyuki Nagai; Takaaki Chikugo; Kazuomi Ueshima; Yurie Kura; Takayuki Takahama; Hidetoshi Hayashi; Kazuhiko Nakagawa; Masatoshi Kudo; Kazuto NishioFrontiers in oncology 11 763468 - 763468 2021 Immune checkpoint inhibitors (ICIs) have become the standard of care for several cancers. However, ICI therapy has also been associated with various immune-related adverse events (irAEs). Clinical manifestations of immune-related colitis resemble those of inflammatory bowel diseases such as ulcerative colitis (UC). The composition of the bowel microflora is thought to influence the development of inflammatory bowel disease and irAE colitis. We profiled the gene expressions and microbe compositions of colonic mucosa from patients with solid cancers receiving anti-PD-L1 antibody treatment; we then compared the expression profiles associated with irAE colitis with those associated with UC. The pathway enrichment analysis revealed functional similarities between inflamed regions of irAE colitis and UC. The common enriched pathways included leukocyte extravasation and immune responses, whereas non-inflamed mucosa from patients with irAE colitis was distinct from patients with UC and was characterized by the recruitment of immune cells. A similarity between the microbiota profiles was also identified. A decreased abundance of Bacteroides species was observed in inflamed regions from both irAE colitis and UC based on a microbiota composition analysis of 16S rDNA sequencing. Pathways associated with molecule transport systems, including fatty acids, were enriched in inflamed and non-inflamed irAE colitis and inflamed UC, similar to Piphillin-inferred KEGG pathways. While UC is characterized by local regions of inflammation, ICI treatment extends to non-inflammatory regions of the colonial mucosa where immune cells are reconstituted. This analysis of the similarity and heterogeneity of irAE colitis and UC provides important information for the management of irAE colitis.異所性静脈瘤の診断と治療松井繁長; 樫田博史; 工藤正俊食道・胃静脈瘤 改訂第4版 313 - 318 2021食道・胃静脈瘤松井繁長; 工藤正俊消化器疾患 最新の治療2021-2022 77 - 80 2021Lack of response to immunotherapy in non-alcoholic steatohepatitis related hepatocellular carcinomaMasatoshi KudoHepatobil Surg Nutr 10 (4) 522 - 525 2021 [Refereed]Case Report: Concurrent Occurrence of Abdominal Double Expressor Lymphoma and Jejunum Follicular Lymphoma.Ryutaro Takada; Tomohiro Watanabe; Ikue Sekai; Keisuke Yoshikawa; Akane Hara; Yasuo Otsuka; Tomoe Yoshikawa; Ken Kamata; Kosuke Minaga; Yoriaki Komeda; Takaaki Chikugo; Yasuyuki Arai; Kohei Yamashita; Masatoshi KudoFrontiers in oncology 11 656219 - 656219 2021 Double expressor lymphoma (DEL), defined as overexpression of BCL2 and MYC, is an aggressive subtype of diffuse large B cell lymphoma (DLBCL). Here we report a case of a 64-year-old female diagnosed with abdominal DEL transformed from jejunum follicular lymphoma (FL). 18F-fluorodeoxyglucose (FDG)-positron emission tomography showed diffuse accumulation of FDG into the peritoneum and small bowel wall. Double balloon-assisted enteroscopy revealed whitish submucosal tumors in the proximal jejunum. Aggregation of atypical lymphocytes positive for CD20, CD79a, and BCL2 was seen in the jejunal biopsy samples. These atypical lymphocytes were monoclonal since cell surface expression of Ig light chains was limited to κ chain by flow-cytometry. Thus, immunohistochemical and flowcytometric analyses data were consistent with FL of the jejunum. Neoplastic lymphocytes obtained from ascites were positive for CD10, CD20, CD79a, BCL2, and BCL6. Fluorescence in situ hybridization (FISH) showed formation of BCL2/IgH fusion gene and extra copies of MYC, the former of which is a characteristic chromosomal abnormality of FL. These genetic alterations and protein expression profiles of ascitic fluid cells were consistent with those of DEL transformed from FL. Given that a significant population of patients with indolent FL of the gastrointestinal tract developed into aggressive DLBCL, it is likely that primary FL of the jejunum transformed into the abdominal aggressive DEL in this case. This case is unique in that concurrent occurrence of FL and DEL was confirmed by immunohistochemical and FISH analyses and that abdominal DEL transformed from jejunal FL was highly suspected.Artificial intelligence-based endoscopic diagnosis of colorectal polyps using residual networks.Yoriaki Komeda; Hisashi Handa; Ryoma Matsui; Shohei Hatori; Riku Yamamoto; Toshiharu Sakurai; Mamoru Takenaka; Satoru Hagiwara; Naoshi Nishida; Hiroshi Kashida; Tomohiro Watanabe; Masatoshi KudoPloS one 16 (6) e0253585  2021 Convolutional neural networks (CNNs) are widely used for artificial intelligence (AI)-based image classification. Residual network (ResNet) is a new technology that facilitates the accuracy of image classification by CNN-based AI. In this study, we developed a novel AI model combined with ResNet to diagnose colorectal polyps. In total, 127,610 images consisting of 62,510 images with adenomatous polyps, 30,443 with non-adenomatous hyperplastic polyps, and 34,657 with healthy colorectal normal mucosa were subjected to deep learning after annotation. Each validation process was performed using 12,761 stored images of colorectal polyps by a 10-fold cross validation. The efficacy of the ResNet system was evaluated by sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV), and diagnostic accuracy. The sensitivity, specificity, PPV, NPV, and diagnostic accuracy for adenomatous polyps at WLIs were 98.8%, 94.3%, 90.5%, 87.4%, and 92.8%, respectively. Similar results were obtained for adenomatous polyps at narrow-band imagings (NBIs) and chromoendoscopy images (CEIs) (NBIs vs. CEIs: sensitivity, 94.9% vs. 98.2%; specificity, 93.9% vs. 85.8%; PPV, 92.5% vs. 81.7%; NPV, 93.5% vs. 99.9%; and overall accuracy, 91.5% vs. 90.1%). The ResNet model is a powerful tool that can be used for AI-based accurate diagnosis of colorectal polyps.Case Report: A Case of Intestinal Behçet's Disease Exhibiting Enhanced Expression of IL-6 and Forkhead Box P3 mRNA After Treatment With Infliximab.Keisuke Yoshikawa; Tomohiro Watanabe; Ikue Sekai; Ryutaro Takada; Akane Hara; Masayuki Kurimoto; Yasuhiro Masuta; Yasuo Otsuka; Tomoe Yoshikawa; Sho Masaki; Ken Kamata; Kosuke Minaga; Yoriaki Komeda; Takaaki Chikugo; Masatoshi KudoFrontiers in medicine 8 679237 - 679237 2021 Behçet's disease (BD) is a rare inflammatory condition characterized by oral and genital ulcers, skin lesions, as well as ophthalmological, neurological, and gastrointestinal manifestations. BD involving the gastrointestinal tract is known as intestinal BD. The mucosa of the gastrointestinal tract of patients with intestinal BD exhibits enhanced levels of proinflammatory cytokines, such as IL-1β, IL-6, and TNF-α. These proinflammatory cytokines play pathogenic roles in the development of BD, as evidenced by the fact that biologics targeting these cytokines effectively induce BD remission. It should be noted, however, that the molecular mechanisms by which the blockade of these cytokines suppresses chronic inflammatory responses in BD are poorly understood. Herein, we report a case of intestinal BD resistant to prednisolone that was successfully treated with infliximab (IFX). The induction of remission by IFX was accompanied by a marked elevation of IL-6 and forkhead box P3 (FOXP3) at mRNA level. This case suggests that induction of remission by IFX is mediated not only by the suppression of TNF-α-mediated signaling pathways, but also by the promotion of IL-6 expression and accumulation of regulatory T cells expressing FOXP3.Antacid exposure and immunotherapy outcomes among patients with advanced hepatocellular carcinoma.Tomi Jun; Umut Ozbek; Sirish Dharmapuri; Camille Hardy-Abeloos; Huili Zhu; Jung-Yi Lin; Nicola Personeni; Tiziana Pressiani; Naoshi Nishida; Pei-Chang Lee; Chieh-Ju Lee; Hannah Hildebrand; Neil Nimkar; Sonal Paul; Petros Fessas; Muntaha Naeem; Dominik Bettinger; Uqba Khan; Anwaar Saeed; Yi-Hsiang Huang; Masatoshi Kudo; Lorenza Rimassa; Thomas U Marron; David J Pinato; Celina AngTherapeutic advances in medical oncology 13 17588359211010937 - 17588359211010937 2021 Background: Antibiotic exposure has been associated with worse outcomes with immune checkpoint inhibitors (ICIs) in cancer patients, likely due to disruption of the gut microbiome. Other commonly prescribed medications, such as proton pump inhibitors (PPIs) and histamine-2-receptor antagonists (H2RAs), are also known to disrupt the microbiome, but data on their association with ICI outcomes are conflicting. Methods: We conducted a retrospective, multicenter, international cohort study including 314 hepatocellular carcinoma (HCC) patients treated with ICIs from 2017 to 2019 to assess the association between PPI or H2RA exposure (up to 30 days before ICI) and overall survival. Secondary outcomes included overall response rate (ORR) and development of any treatment-related adverse events (AEs). Results: Baseline PPI/H2RA exposure was not associated with overall survival in univariable (HR 1.01, 95% CI 0.75-1.35) or multivariable analysis (HR 0.98, 95% CI 0.71-1.36). Baseline PPI/H2RA exposure was not associated with either ORR (OR 1.32, 95% CI 0.66-2.65) or AEs (OR 1.07, 95% CI 0.54-2.12) in multivariable analysis. Conclusions: Our results suggest that exposure to PPI/H2RA prior to ICIs does not adversely affect outcomes in HCC patients.RIPK2 as a New Therapeutic Target in Inflammatory Bowel Diseases.Hajime Honjo; Tomohiro Watanabe; Ken Kamata; Kosuke Minaga; Masatoshi KudoFrontiers in pharmacology 12 650403 - 650403 2021 Inflammatory bowel diseases (IBDs) are becoming more frequent worldwide. A significant fraction of patients with IBD are refractory to various types of therapeutic biologics and small molecules. Therefore, identification of novel therapeutic targets in IBD is required. Receptor-interacting serine/threonine kinase 2 (RIPK2), also known as receptor-interacting protein 2 (RIP2), is a downstream signaling molecule for nucleotide-binding oligomerization domain 1 (NOD1), NOD2, and Toll-like receptors (TLRs). RIPK2 is expressed in antigen-presenting cells, such as dendritic cells and macrophages. Recognition of microbe-associated molecular patterns by NOD1, NOD2, and TLRs leads to the interaction between RIPK2 and these innate immune receptors, followed by the release of pro-inflammatory cytokines such as TNF-α, IL-6, and IL-12/23p40 through the activation of nuclear factor kappa B and mitogen-activated protein kinases. Thus, activation of RIPK2 plays a critical role in host defense against microbial infections. Recent experimental and clinical studies have provided evidence that activation of RIPK2 is involved in the development of autoimmune diseases, especially IBDs. In addition, the colonic mucosa of patients with IBD exhibits enhanced expression of RIPK2 and associated signaling molecules. Furthermore, the blockage of RIPK2 activation ameliorates the development of experimental murine colitis. Thus, activation of RIPK2 underlies IBD immunopathogenesis. In this review, we attempt to clarify the roles played by RIPK2 in the development of IBD by focusing on its associated signaling pathways. We also discuss the possibility of using RIPK2 as a new therapeutic target in IBD.Intestinal Dysbiosis and Autoimmune Pancreatitis.Tomoe Yoshikawa; Tomohiro Watanabe; Ken Kamata; Akane Hara; Kosuke Minaga; Masatoshi KudoFrontiers in immunology 12 621532 - 621532 2021 Autoimmune pancreatitis (AIP) is a chronic fibro-inflammatory disorder of the pancreas. Recent clinicopathological analysis revealed that most cases of AIP are pancreatic manifestations of systemic IgG4-related disease (IgG4-RD), a newly established disease characterized by enhanced IgG4 antibody responses and the involvement of multiple organs. Although the immuno-pathogenesis of AIP and IgG4-RD has been poorly defined, we recently showed that activation of plasmacytoid dendritic cells (pDCs) with the ability to produce large amounts of IFN-α and IL-33 mediates chronic fibro-inflammatory responses in experimental and human AIP. Moreover, M2 macrophages producing a large amount of IL-33 play pathogenic roles in the development of human IgG4-RD. Interestingly, recent studies including ours provide evidence that compositional alterations of gut microbiota are associated with the development of human AIP and IgG4-RD. In addition, intestinal dysbiosis plays pathological roles in the development of chronic pancreatic inflammation as dysbiosis mediates the activation of pDCs producing IFN-α and IL-33, thereby causing experimental AIP. In this Mini Review, we focus on compositional alterations of gut microbiota in AIP and IgG4-RD to clarify the mechanisms by which intestinal dysbiosis contributes to the development of these disorders.Image Guidance in Ablation for Hepatocellular Carcinoma: Contrast-Enhanced Ultrasound and Fusion Imaging.Yasunori Minami; Masatoshi KudoFrontiers in oncology 11 593636 - 593636 2021 The ultrasound (US) imaging technology, including contrast-enhanced US (CEUS) and fusion imaging, has experienced radical improvement, and advancement in technology thus overcoming the problem of poor conspicuous hepatocellular carcinoma (HCC). On CEUS, the presence or absence of enhancement distinguishes the viable portion from the ablative necrotic portion. Using volume data of computed tomography (CT) or magnetic resonance imaging (MRI), fusion imaging enhances the three-dimensional relationship between the liver vasculature and HCC. Therefore, CT/MR-US fusion imaging provides synchronous images of CT/MRI with real-time US, and US-US fusion imaging provides synchronous US images before and after ablation. Moreover, US-US overlay fusion can visualize the ablative margin because it focuses the tumor image onto the ablation zone. Consequently, CEUS and fusion imaging are helpful to identify HCC with little conspicuity, and with more confidence, we can perform ablation therapy. CEUS/fusion imaging guidance has improved the clinical effectiveness of ablation therapy in patients with poor conspicuous HCCs. Therefore; this manuscript reviews the status of CEUS/fusion imaging guidance in ablation therapy of poor conspicuous HCC.Refractory case of ulcerative colitis with idiopathic thrombocytopenic purpura successfully treated by Janus kinase inhibitor tofacitinib: A case report.Yoriaki Komeda; Toshiharu Sakurai; Kazuko Sakai; Yasuyoshi Morita; Arito Hashimoto; Tomoyuki Nagai; Satoru Hagiwara; Itaru Matsumura; Kazuto Nishio; Masatoshi KudoWorld journal of clinical cases 8 (24) 6389 - 6395 2020/12 BACKGROUND: Concomitant ulcerative colitis (UC) and idiopathic thrombocytopenic purpura (ITP) is a rare phenomenon. The management of UC with ITP can be challenging, since a decreased platelet count augments UC. CASE SUMMARY: A 24-year-old man with UC and steroid-resistant ITP experienced UC flare. Although continuous infusion of cyclosporine was initiated, UC did not improve. The administration of tofacitinib subsequently led to the induction of remission. The patient has maintained remission of UC and ITP for over one year on tofacitinib treatment. Whole transcriptomic sequencing was performed for inflamed rectal mucosae obtained before and after the initiation of Janus kinase (JAK) inhibitor, suggesting that distinct molecular signatures seemed to be regulated by JAK inhibitors and other conventional therapies including tumor necrosis factor lockers. CONCLUSION: Tofacitinib should be considered in refractory cases of UC with ITP.第21回全国原発性肝癌追跡調査報告(2010〜2011)工藤 正俊; 泉 並木; 久保 正二; 國土 典宏; 坂元 亨宇; 椎名 秀一朗; 高山 忠利; 建石 良介; 中島 収; 村上 卓道; 松山 裕; 高橋 新; 宮田 裕章; 田村 利恵; 上妻 智子; 日本肝癌研究会追跡調査委員会肝臓 (一社)日本肝臓学会 61 (12) 645 - 691 0451-4203 2020/12 第21回全国原発性肝癌追跡調査においては、546施設から2010年1月1日から2011年12月31日までの2年間の22,134例の新規症例と41,956例の追跡症例が集計された。基礎統計は、第21回新規登録症例を対象として死因、既往歴、臨床診断、画像診断、治療法別の各因子、病理診断、再発、剖検についてまとめた。第20回調査と比較し、肝細胞癌における臨床診断時の高齢化、女性の増加、非B非C肝癌の増加、腫瘍径の縮小の傾向が、治療においては切除の割合の増加、局所療法におけるラジオ波焼灼療法の増加が認められた。1998年から2011年まで新規登録症例の中で最終予後が生存または死亡となった症例(不明を除く)について肝細胞癌、肝内胆管癌、混合型肝癌の治療法別、背景因子別累積生存率を算出した。肝細胞癌については腫瘍個数、腫瘍径、肝障害度、Child-Pugh分類を組み合わせることにより背景因子を揃えて、治療法別(肝切除、局所療法、肝動脈塞栓療法(TACE))、肝動注化学療法の累積生存率を算出し、また、1978年から2011年までの新規登録症例を4期に分け、累積生存率を算出した。新規登録症例数は経時的に増加し、肝細胞癌の予後の改善が著しいことが明らかとなった。本追跡調査が原発性肝癌の研究および診療の進歩に役立つことを期待する。(著者抄録)画像診断における人工知能の応用と超音波AIの開発西田 直生志; 工藤 正俊肝臓 (一社)日本肝臓学会 61 (12) 623 - 636 0451-4203 2020/12 近年、社会機能の種々の場面で人工知能(artificial intelligence:AI)を導入する試みがなされている。医療においても、医療従事者の負担軽減や見逃し防止を目的としてAI診断の導入が始まっており、内視鏡検査のAI診断補助、胸部レントゲンの病変スクリーニング、病理検査のAI遠隔診断など、既に実用化、あるいは実用化が近いものが出てきている。加えて、病変検出や診断のみならず、治療法選択などの疾患マネージメントを視野に入れた報告もなされている。画像診断支援はAIに親和性の高い分野であり、本邦でも重点的にAI開発がなされるべき分野として、日本医療研究開発機構の臨床研究等ICT基盤構築・人工知能実装研究事業の枠組みでの大規模なデータベース構築とAI開発が進んでいる。一方、超音波分野のAI開発に関しては、画像データの取得に際して術者依存性が高いこと、機器ベンダーや機種が多く、さらに画質パラメータが複数あるなど、画像の多様性が高く、データベース構築やAI開発に際してのハードルとなっている。本稿では、医療分野での画像診断領域AIの現状を概説し、特に超音波AIにフォーカスして、その特有の問題点を取り上げ、近未来の超音波AI支援システム展開において取り組むべき課題を述べる。(著者抄録)消化器早期がん内視鏡スクリーニング〜検診も含めて〜 微小膵癌診断のためのスクリーニングEUSの意義と位置づけ山雄 健太郎; 竹中 完; 樫田 博史; 工藤 正俊日本消化器内視鏡学会近畿支部例会プログラム・抄録集 日本消化器内視鏡学会-近畿支部 105回 45 - 45 2020/12食道平滑筋腫上に発生した表在癌に対して内視鏡的粘膜下層剥離術を施行した1例吉田 早希; 松井 繁長; 友岡 瑞貴; 益田 康弘; 高田 隆太郎; 高島 耕太; 河野 匡志; 正木 翔; 永井 知行; 米田 頼晃; 櫻井 俊治; 本庶 元; 辻 直子; 樫田 博史; 工藤 正俊日本消化器内視鏡学会近畿支部例会プログラム・抄録集 日本消化器内視鏡学会-近畿支部 105回 66 - 66 2020/12Application of artificial intelligence in medical imaging and AI-aided US diagnosisNaoshi Nishida; Masatoshi KudoKanzo Japan Society of Hepatology 61 (12) 623 - 636 0451-4203 2020/12消化管止血に対する工夫〜こういうときどうする〜 胆管空腸吻合部静脈瘤出血に対する小腸内視鏡による内視鏡的静脈瘤硬化療法高島 耕太; 松井 繁長; 米田 頼晃; 工藤 正俊日本消化器内視鏡学会近畿支部例会プログラム・抄録集 日本消化器内視鏡学会-近畿支部 105回 54 - 54 2020/12食道平滑筋腫上に発生した表在癌に対して内視鏡的粘膜下層剥離術を施行した1例吉田 早希; 松井 繁長; 友岡 瑞貴; 益田 康弘; 高田 隆太郎; 高島 耕太; 河野 匡志; 正木 翔; 永井 知行; 米田 頼晃; 櫻井 俊治; 本庶 元; 辻 直子; 樫田 博史; 工藤 正俊日本消化器内視鏡学会近畿支部例会プログラム・抄録集 日本消化器内視鏡学会-近畿支部 105回 66 - 66 2020/12Gut microbiome alterations in type 1 autoimmune pancreatitis after induction of remission by prednisoloneK. Kamata; T. Watanabe; K. Minaga; A. Hara; I. Sekai; Y. Otsuka; T. Yoshikawa; A.‐M. Park; M. KudoClinical & Experimental Immunology Wiley 202 (3) 308 - 320 0009-9104 2020/12Limited Impact of Anti-PD-1/PD-L1 Monotherapy for Hepatocellular Carcinoma.Masatoshi KudoLiver cancer 9 (6) 629 - 639 2020/12Recent Advances in Systemic Therapy for Hepatocellular Carcinoma in an Aging Society: 2020 Update.Masatoshi KudoLiver cancer 9 (6) 640 - 662 2020/12 Systemic therapy for hepatocellular carcinoma (HCC) has changed markedly since the introduction of the molecular targeted agent sorafenib in 2007. Sorafenib increased the available treatment options for patients with extrahepatic spread and vascular invasion and improved survival in patients with advanced HCC; however, various shortcomings such as low response rates and relatively high toxicity (e.g., hand-foot skin reaction) prompted concerted efforts aimed at developing new molecular targeted agents to provide more treatment options and second-line agents for patients with disease progression or intolerance to sorafenib. Despite many attempts to develop new drugs between 2007 and 2016, all first-line and second-line clinical trials conducted during this period failed. However, between 2017 and 2019, 4 drugs (lenvatinib as a first-line agent and regorafenib, cabozantinib, and ramucirumab as second-line agents) emerged in quick succession from clinical trials and became available for clinical use. In addition, nivolumab and pembrolizumab were approved as second-line agents after sorafenib. A recent phase III trial (IMbrave150) showed that combination immunotherapy with atezolizumab plus bevacizumab increases overall survival compared with sorafenib therapy; Food and Drug Agency already approved this combination therapy, and worldwide approval is expected soon. This review describes the recent advances in systemic therapy and the use of tyrosine kinase inhibitors (sorafenib, lenvatinib, regorafenib, and cabozantinib), monoclonal antibodies (ramucirumab and bevacizumab), and immune checkpoint inhibitors (nivolumab, pembrolizumab, and atezolizumab) in elderly patients and the similarity of their efficacy and safety profiles to those in the general population.EZ-ALBI Score for Predicting Hepatocellular Carcinoma Prognosis.Kazuya Kariyama; Kazuhiro Nouso; Atsushi Hiraoka; Akiko Wakuta; Ayano Oonishi; Teiji Kuzuya; Hidenori Toyoda; Toshifumi Tada; Kunihiko Tsuji; Ei Itobayashi; Toru Ishikawa; Koichi Takaguchi; Akemi Tsutsui; Noritomo Shimada; Masatoshi Kudo; Takashi KumadaLiver cancer 9 (6) 734 - 743 2020/12 Introduction: The ALBI score is acknowledged as the gold standard for the assessment of liver function in patients with hepatocellular carcinoma (HCC). Unlike the Child-Pugh score, the ALBI score uses only objective parameters, albumin (Alb) and total bilirubin (T.Bil), enabling a better evaluation. However, the complex calculation of the ALBI score limits its applicability. Therefore, we developed a simplified ALBI score, based on data from a large-scale HCC database. We used the data of 5,249 naïve HCC cases registered in eight collaborating hospitals. Methods: We developed a new score, the EZ (Easy)-ALBI score, based on regression coefficients of Alb and T.Bil for survival risk in a multivariate Cox proportional hazard model. We also developed the EZ-ALBI grade and EZ-ALBI-T grade as alternative options for the ALBI grade and ALBI-T grade and evaluated their stratifying ability. Results: The equation used to calculate the EZ-ALBI score was simple {[T.Bil (mg/dL)] - [9 × Alb (g/dL)]}; this value highly correlated with the ALBI score (correlation coefficient, 0.981; p Promising anticancer therapy: combination of immune checkpoint inhibitors and molecular-targeted agents.Toshiharu Sakurai; Naoshi Nishida; Masatoshi KudoHepatobiliary surgery and nutrition 9 (6) 777 - 779 2020/12 [Refereed][Invited]Health-related quality-of-life impact of pembrolizumab versus best supportive care in previously systemically treated patients with advanced hepatocellular carcinoma: KEYNOTE-240.Baek-Yeol Ryoo; Philippe Merle; Amit S Kulkarni; Ann-Lii Cheng; Mohamed Bouattour; Ho Yeong Lim; Valeriy Breder; Julien Edeline; Yee Chao; Sadahisa Ogasawara; Thomas Yau; Marcelo Garrido; Stephen L Chan; Bruno Daniele; Josephine M Norquist; Erluo Chen; Abby B Siegel; Andrew X Zhu; Richard S Finn; Masatoshi KudoCancer 127 (6) 865 - 874 2020/11 BACKGROUND: Health-related quality of life (HRQoL) is an important outcome measure and prognostic indicator in hepatocellular carcinoma (HCC). KEYNOTE-240 (NCT02702401) assessed the efficacy and safety of pembrolizumab plus best supportive care (BSC) versus placebo plus BSC in patients with HCC who previously received sorafenib. This study presents the results of a prespecified exploratory analysis of patient-reported outcomes. METHODS: Patients completed the European Organization for Research and Treatment of Cancer Core Quality of Life Questionnaire (EORTC QLQ-C30) and its HCC supplement (EORTC QLQ-HCC18) electronically at baseline; at weeks 2, 3, 4, 6, 9, 12, and 18; and then every 9 weeks until 1 year or end of treatment, and at the 30-day safety follow-up visit. RESULTS: The HRQoL population included 271 and 127 patients randomly assigned to pembrolizumab and placebo, respectively. From baseline to week 12, changes in both scores were similar between pembrolizumab and placebo; global health status/QoL scores were stable. The proportions of patients who improved, remained stable, or deteriorated across all functional domain and symptom scores were generally similar between pembrolizumab and placebo. Time to deterioration was similar between the 2 arms based on the prespecified analysis of EORTC QLQ-HCC18 domains of abdominal swelling, fatigue, and pain. CONCLUSION: Pembrolizumab preserved HRQoL during treatment for advanced HCC. Combined with efficacy and safety results from KEYNOTE-240, these findings support a positive benefit/risk profile for pembrolizumab in a second-line treatment setting for patients with HCC who previously received sorafenib.Pattern of progression in advanced hepatocellular carcinoma treated with ramucirumab.Maria Reig; Peter R Galle; Masatoshi Kudo; Richard Finn; Josep M Llovet; Andrea L Metti; William R Schelman; Kun Liang; Chunxiao Wang; Ryan C Widau; Paolo Abada; Andrew X ZhuLiver international : official journal of the International Association for the Study of the Liver 2020/11 BACKGROUND & AIMS: Radiological progression patterns to first-line sorafenib have been associated with post-progression and overall survival in advanced hepatocellular carcinoma, but these associations remain unknown for therapies in second- and later-line settings. This post hoc analysis of REACH and REACH-2 examined outcomes by radiological progression patterns in the second-line setting of patients with advanced hepatocellular carcinoma treated with ramucirumab or placebo. METHODS: Patients with advanced hepatocellular carcinoma, Child-Pugh A and Eastern Cooperative Oncology Group Performance Status 0 or 1 with prior sorafenib were randomized to receive ramucirumab 8mg/kg or placebo every 2 weeks. Among 625 patients with ≥1 progression pattern (new extrahepatic lesion [including new macrovascular invasion], new intrahepatic lesion, extrahepatic growth or intrahepatic growth), data were analysed by trial and for pooled individual patient data for REACH-2 and REACH (alpha-fetoprotein ≥400 ng/mL). Cox models evaluated prognostic implications of progression patterns on overall and post-progression survival. RESULTS: Post-progression survival was worse among those with new extrahepatic lesions in REACH (HR 2.33, 95% CI 1.51-3.60), REACH-2 (HR 1.49, 95% CI 0.72-3.08) and the pooled population (HR 1.75, 95% CI 1.12-2.74) compared to other progression patterns. Overall survival was also significantly reduced in those with new extrahepatic lesions across studies. Ramucirumab provided an overall survival benefit across progression patterns, including patients with new extrahepatic lesions (HR 0.56, 95% CI 0.39-0.80) in the pooled population. CONCLUSIONS: The emergence of new extrahepatic lesions in the second-line setting is a poor prognostic factor for post-progression survival. The benefit of ramucirumab for overall survival was consistent across progression patterns.Clinical importance of muscle volume in lenvatinib treatment for hepatocellular carcinoma: Analysis adjusted with inverse probability weighting.Atsushi Hiraoka; Takashi Kumada; Kazuya Kariyama; Toshifumi Tada; Joji Tani; Shinya Fukunishi; Masanori Atsukawa; Masashi Hirooka; Kunihiko Tsuji; Toru Ishikawa; Koichi Takaguchi; Ei Itobayashi; Kazuto Tajiri; Noritomo Shimada; Hiroshi Shibata; Hironori Ochi; Kazuhito Kawata; Satoshi Yasuda; Hidenori Toyoda; Hideko Ohama; Kazuhiro Nouso; Akemi Tsutsui; Takuya Nagano; Norio Itokawa; Korenobu Hayama; Taeang Arai; Michitaka Imai; Yohei Koizumi; Shinichiro Nakamura; Kouji Joko; Kojiro Michitaka; Yoichi Hiasa; Masatoshi KudoJournal of gastroenterology and hepatology 36 (7) 1812 - 1819 2020/11 BACKGROUND AND AIM: This study aimed to elucidate the clinical importance of muscle volume loss (pre-sarcopenia) in patients receiving lenvatinib as treatment for unresectable hepatocellular carcinoma (u-HCC). METHODS: Of 437 u-HCC patients treated with lenvatinib at specific institutions in Japan between March 2018 and May 2020, 151 with available computed tomography imaging data from the time of lenvatinib introduction were enrolled. Pre-sarcopenia was diagnosed based on a previously reported cut-off value calculation formula [psoas muscle area at level of middle of third lumbar vertebra (cm2 )/height (m)2 ]. Clinical features and prognostic factors for overall survival (OS) with inverse probability weighting were investigated retrospectively for their relationship with pre-sarcopenia. RESULTS: Cox hazard multivariate analysis showed alpha-fetoprotein (≥400 ng/mL) (hazard ratio [HR] 2.271, P Mucosal microbiota and gene expression are associated with long-term remission after discontinuation of adalimumab in ulcerative colitis.Toshiharu Sakurai; Hiroki Nishiyama; Kazuko Sakai; Marco A De Velasco; Tomoyuki Nagai; Yoriaki Komeda; Hiroshi Kashida; Akiyoshi Okada; Isao Kawai; Kazuto Nishio; Hiroyuki Ogata; Masatoshi KudoScientific reports 10 (1) 19186 - 19186 2020/11 Given that sustained remission is the ultimate treatment goal in the management of patients with ulcerative colitis (UC), the decision to stop anti-tumor necrosis factor (anti-TNF) treatment in UC patients is difficult. The aim of this study was to evaluate mucosal microbiota and gene expression profiles associated with long-term remission after discontinuation of anti-TNF therapy. In nine UC patients who received anti-TNF therapy for 6 months, microbiota isolated from uninflamed mucosae and gene expression in inflamed and uninflamed mucosae were investigated at week 0 and at week 24. At treatment initiation, Fusobacterium sp. and Veillonella dispar were over-represented in the relapse group compared with the non-relapse group. After treatment, Dorea sp. and Lachnospira sp. were over-represented in the non-relapse group. In the relapse group only, a significant shift in gut bacterial community composition was found between week 0 and week 24. Gene expression of ALIX (PDCD6IP) and SLC9A3 was significantly higher in the non-relapse group than in the relapse group. Lastly, we used machine learning methods to identify relevant gene signatures associated with sustained remission. Statistical analyses of microbiota and expression profiles revealed differences between UC patients who did or did not keep remission after the discontinuation of TNF inhibitors.Trial registration: UMIN000020785: Evaluation of adalimumab therapy in mesalazine-resistant or -intolerant ulcerative colitis; an observational study (EARLY study).超音波画像ビッグデータベース構築とAI支援肝腫瘍検出・診断システムの開発 AMED臨床研究等ICT基盤構築・人工知能実装研究事業での取り組み西田 直生志; 山川 誠; 椎名 毅; 目加田 慶人; 工藤 正俊超音波医学 (公社)日本超音波医学会 47 (Suppl.) S544 - S544 1346-1176 2020/11進行肝癌に対する免疫チェックポイント阻害薬後レンバチニブ療法の画像評価青木 智子; 依田 広; 盛田 真弘; 南 知宏; 田北 雅弘; 萩原 智; 南 康範; 上嶋 一臣; 西田 直生志; 工藤 正俊超音波医学 (公社)日本超音波医学会 47 (Suppl.) S167 - S167 1346-1176 2020/11鑑別診断において造影超音波が有用であった多血性の肝内胆管癌の1例盛田 真弘; 南 康範; 青木 智子; 田北 雅弘; 萩原 智; 依田 広; 上嶋 一臣; 西田 直生志; 工藤 正俊超音波医学 (公社)日本超音波医学会 47 (Suppl.) S275 - S275 1346-1176 2020/11トルバプタン不応の難治性腹水に対する腹腔-静脈シャント(デンバーシャント)の有用性青木 智子; 南 康範; 鶴崎 正勝; 盛田 真弘; 南 知宏; 千品 寛和; 田北 雅弘; 萩原 智; 依田 広; 上嶋 一臣; 松井 繁長; 西田 直生志; 樫田 博史; 工藤 正俊日本門脈圧亢進症学会雑誌 (一社)日本門脈圧亢進症学会 26 (4) 244 - 248 1344-8447 2020/11 デンバーシャント術は難治性腹水症に対して行われる腹腔-静脈シャント術である。2014〜2018年にデンバーシャント術を施行した7例を対象とし、非代償性肝硬変に伴うトルバプタン不応腹水への有効性と安全性を検討した。奏効の内訳は、(1)腹満感など自覚症状の改善:57%、(2)体重・画像など他覚的所見の改善:71%、(3)治療内容の改善:腹水穿刺の中止29%、利尿薬減量71%であった。総合評価からデンバーシャント術の奏効率は86%であった。術後合併症は、播種性血管内凝固症候群(n=3)、創部し開(n=1)、特発性細菌性腹膜炎(n=1)、肝性脳症(n=1)、右心不全(n=1)を認め、保存的治療で軽快した。腹水コントロール不良で基礎疾患の病勢進行により術後30日目に永眠した症例が1例いた。デンバーシャント術は非代償性肝硬変症に伴うトルバプタン不応の難治性腹水に対して施行可能で有効な治療法と考える。(著者抄録)【進化するEUS】診断的EUS 造影ハーモニックEUS三長 孝輔; 原 茜; 田中 秀和; 大本 俊介; 鎌田 研; 山雄 健太郎; 竹中 完; 工藤 正俊消化器内視鏡 (株)東京医学社 32 (11) 1641 - 1649 0915-3217 2020/11【肝細胞癌治療のパラダイムチェンジ-進化する薬物療法2020 Update Part II-(分子標的治療)】レンバチニブ REFLECT試験のサブ解析上嶋 一臣; 工藤 正俊肝・胆・膵 (株)アークメディア 81 (5) 835 - 840 0389-4991 2020/11【肝細胞癌治療のパラダイムチェンジ-進化する薬物療法2020 Update Part II-(分子標的治療)】レンバチニブ 切除不能肝細胞癌へのPD-1/PD-L1療法不応後二次治療として投与したレンバチニブ逐次治療の有効性青木 智子; 上嶋 一臣; 鶴崎 正勝; 工藤 正俊肝・胆・膵 (株)アークメディア 81 (5) 874 - 880 0389-4991 2020/11進歩する化学療法時代に注意すべき肝細胞癌の遠隔転移吉田 早希; 青木 智子; 上嶋 一臣; 盛田 真弘; 千品 寛和; 田北 雅弘; 萩原 智; 南 康範; 依田 広; 鶴崎 正勝; 西田 直生志; 工藤 正俊肝臓 (一社)日本肝臓学会 61 (Suppl.3) A924 - A924 0451-4203 2020/11難治性腹水に対するデンバーシャント術の試み家村 郁衣; 青木 智子; 上嶋 一臣; 盛田 真弘; 千品 寛和; 田北 雅弘; 萩原 智; 南 康範; 依田 広; 鶴崎 正勝; 西田 直生志; 工藤 正俊肝臓 (一社)日本肝臓学会 61 (Suppl.3) A946 - A946 0451-4203 2020/11【肝細胞癌治療のパラダイムチェンジ-進化する薬物療法2020 Update Part II-(分子標的治療)】免疫療法時代における分子標的治療の今後を考える工藤 正俊; 古瀬 純司; 山下 竜也; 森口 理久肝・胆・膵 (株)アークメディア 81 (5) 761 - 779 0389-4991 2020/11Analysis of Patient Outcome after Non-curative Resection for Hepatocellular Carcinoma Using Nationwide Survey Data in Japan.Taku Aoki; Keiichi Kubota; Shoji Kubo; Susumu Eguchi; Namiki Izumi; Norihiro Kokudo; Michiie Sakamoto; Shuichiro Shiina; Tadatoshi Takayama; Osamu Nakashima; Yutaka Matsuyama; Takamichi Murakami; Masatoshi KudoWorld journal of surgery 45 (2) 607 - 614 2020/10 BACKGROUND: Non-curative (debulking) hepatic resection for hepatocellular carcinoma (HCC) is occasionally applied for selected cases with bulky tumors or for oncologic emergency cases; however, the clinical usefulness of this procedure has not yet been fully evaluated. The aim of the present study was to evaluate the patient outcomes of non-curative hepatic resections for HCC using data from bi-annual nationwide surveys conducted in Japan. METHOD: Data of 1084 non-curative hepatic resections for HCC were collected. The patient outcomes were compared with those of curative resections, transcatheter arterial chemoembolization (TACE), and hepatic arterial infusion chemotherapy (HAIC). RESULTS: Patient survival after the non-curative resection was poorer than that after curative resection (P Exploratory Analysis of Lenvatinib Therapy in Patients with Unresectable Hepatocellular Carcinoma Who Have Failed Prior PD-1/PD-L1 Checkpoint Blockade.Tomoko Aoki; Masatoshi Kudo; Kazuomi Ueshima; Masahiro Morita; Hirokazu Chishina; Masahiro Takita; Satoru Hagiwara; Hiroshi Ida; Yasunori Minami; Masakatsu Tsurusaki; Naoshi NishidaCancers 12 (10) 2020/10 Although programmed cell death protein 1 (PD-1)/PD-ligand 1 (PD-L1) blockade is effective in a subset of patients with hepatocellular carcinoma (HCC), its therapeutic response is still unsatisfactory. Alternatively, the potential impact of the lenvatinib in patients who showed tumor progression on PD-1/PD-L1 blockade is unknown. In this work, we evaluated the safety and efficacy of lenvatinib administration after PD-1/PD-L1 checkpoint blockade. The outcome and safety of lenvatinib administered after PD-1/PD-L1 blockade failure was analyzed retrospectively in 36 patients. Tumor growth was assessed every 4-8 weeks using modified Response Evaluation Criteria in Solid Tumors. The mean relative dose intensity of lenvatinib was 87.6% and 77.8% in patients receiving a starting dose of 8 (interquartile range (IQR), 77.5-100.0) mg and 12 (IQR, 64.4-100.0) mg, respectively. Since lenvatinib therapy initiation, the median progression-free survival was 10 months (95% confidence interval (CI): 8.3-11.8) and the median overall survival was 15.8 months (95% CI: 8.5-23.2). The objective response rate was 55.6%, and the disease control rate was 86.1%. No particular safety concerns were observed. Lenvatinib demonstrated considerable antitumor effects with acceptable safety in patients with progressive and unresectable HCC when administered right after PD-1/PD-L1 blockade failure.Impact of age on sorafenib outcomes in hepatocellular carcinoma: an international cohort study.Saur Hajiev; Elias Allara; Leila Motedayеn-Aval; Tadaaki Arizumi; Dominik Bettinger; Mario Pirisi; Lorenza Rimassa; Tiziana Pressiani; Nicola Personeni; Laura Giordano; Masatoshi Kudo; Robert Thimme; Joong-Won Park; Tamar H Taddei; David E Kaplan; Ramya Ramaswami; David J Pinato; Rohini SharmaBritish journal of cancer 2020/10 [Refereed] BACKGROUND: There is no consensus on the effect of sorafenib dosing on efficacy and toxicity in elderly patients with hepatocellular carcinoma (HCC). Older patients are often empirically started on low-dose therapy with the aim to avoid toxicities while maximising clinical efficacy. We aimed to verify whether age impacts on overall survival (OS) and whether a reduced starting dose impacts on OS or toxicity experienced by the elderly. METHODS: In an international, multicentre cohort study, outcomes for those aged 7 cm) (39 vs 33%, p Utility of contrast-enhanced harmonic endoscopic ultrasonography for predicting the prognosis of pancreatic neuroendocrine neoplasms.Rei Ishikawa; Ken Kamata; Akane Hara; Hidekazu Tanaka; Ayana Okamoto; Tomohiro Yamazaki; Atsushi Nakai; Shunsuke Omoto; Kosuke Minaga; Kentaro Yamao; Mamoru Takenaka; Yasunori Minami; Tomohiro Watanabe; Yasutaka Chiba; Takaaki Chikugo; Ippei Matsumoto; Yoshifumi Takeyama; Yuko Matsukubo; Tomoko Hyodo; Masatoshi KudoDigestive endoscopy : official journal of the Japan Gastroenterological Endoscopy Society 33 (5) 829 - 839 2020/10 [Refereed] BACKGROUND AND AIMS: Pancreatic neuroendocrine neoplasms (PanNENs), including Grade 1 (G1) or G2 tumors, can have a poor prognosis. This study investigated the value of contrast-enhanced harmonic endoscopic ultrasonography (CH-EUS) for predicting the prognosis of PanNENs. METHODS: This single-center, retrospective study included 47 consecutive patients who underwent CH-EUS and were diagnosed with PanNEN by surgical resection or EUS-guided fine needle aspiration between December 2011 and February 2016. Patients were divided into aggressive and non-aggressive groups according to the degree of clinical malignancy. CH-EUS was assessed regarding its capacity for diagnosing aggressive PanNEN, the correspondence between contrast patterns and pathological features, and its ability to predict the prognosis of PanNEN. RESULTS: There were 19 cases of aggressive PanNEN and 28 cases of non-aggressive PanNEN. The aggressive group included three G1, four G2, three G3 tumors, three mixed neuroendocrine non-neuroendocrine neoplasms, and six neuroendocrine carcinomas. CH-EUS was superior to contrast-enhanced computed tomography for the diagnosis of aggressive PanNEN (P 急性膵炎におけるプレサルコペニアの臨床的意義に関しての検討田中 隆光; 竹中 完; 吉田 晃弘; 田中 秀和; 吉川 智恵; 石川 嶺; 岡本 彩那; 山崎 友裕; 中井 敦史; 大本 俊輔; 三長 孝輔; 鎌田 研; 山雄 健太郎; 松本 逸平; 竹山 宜典; 工藤 正俊日本消化器病学会雑誌 (一財)日本消化器病学会 117 (臨増大会) A789 - A789 0446-6586 2020/10膵癌早期診断のための3D CT解析による膵実質萎縮の検討山雄 健太郎; 竹中 完; 石川 嶺; 沼本 勲; 鶴崎 正勝; 渡邉 智裕; 工藤 正俊日本消化器病学会雑誌 (一財)日本消化器病学会 117 (臨増大会) A721 - A721 0446-6586 2020/10消化器領域から見たIgG4関連疾患研究の進歩 IRF7-I型IFN-IL-33経路がIgG4関連疾患の病態に果たす役割とバイオマーカーとしての有用性三長 孝輔; 渡邉 智裕; 工藤 正俊日本消化器病学会雑誌 (一財)日本消化器病学会 117 (臨増大会) A678 - A678 0446-6586 2020/10肝癌診療の現状と未来 肝細胞癌における腫瘍免疫環境と癌関連分子の遺伝子変異西田 直生志; 盛田 真弘; 工藤 正俊日本消化器病学会雑誌 (一財)日本消化器病学会 117 (臨増大会) A513 - A513 0446-6586 2020/10早期胃胎児消化管上皮類似癌の1例岡井 夏輝; 松井 繁長; 正木 翔; 栗本 真之; 大丸 直哉; 友岡 瑞貴; 益田 康弘; 高田 隆太郎; 高島 耕太; 河野 匡志; 永井 知行; 米田 頼晃; 本庶 元; 櫻井 俊治; 辻 直子; 樫田 博史; 工藤 正俊日本消化器病学会近畿支部例会プログラム・抄録集 日本消化器病学会-近畿支部 113回 94 - 94 2020/10拡大観察から見たPPI関連胃底腺ポリープの特徴友岡 瑞貴; 辻 直子; 高島 耕太; 正木 翔; 河野 匡志; 永井 知之; 米田 頼晃; 本庶 元; 櫻井 俊治; 松井 繁長; 渡邉 智裕; 樫田 博史; 工藤 正俊Gastroenterological Endoscopy (一社)日本消化器内視鏡学会 62 (Suppl.2) 2088 - 2088 0387-1207 2020/10小腸内視鏡診療ガイドラインでのカプセル内視鏡検査の運用の実際米田 頼晃; 樫田 博史; 櫻井 俊治; 松村 まり子; 高島 耕太; 正木 翔; 河野 匡志; 山田 光成; 本庶 元; 永井 知行; 松井 繁長; 辻 直子; 渡邉 智裕; 工藤 正俊Gastroenterological Endoscopy (一社)日本消化器内視鏡学会 62 (Suppl.2) 2113 - 2113 0387-1207 2020/10膵神経内分泌腫瘍治癒切除後の肝転移再発を認め切除された一例杉崎 俊亮; 川崎 俊彦; 福永 朋洋; 野村 健司; 米澤 真衣; 半田 康平; 河野 辰也; 橋本 有人; 木下 大輔; 水野 成人; 若狭 朋子; 太田 善夫; 辻本 智之; 橋本 和彦; 石川 原; 工藤 正俊日本消化器病学会近畿支部例会プログラム・抄録集 日本消化器病学会-近畿支部 113回 83 - 83 2020/10内視鏡的乳頭切除術後胆管狭窄に対する予防的金属ステント留置の有用性岡本 彩那; 竹中 完; 田中 隆光; 田中 秀和; 吉田 晃浩; 吉川 智恵; 石川 嶺; 山崎 友裕; 中井 敦史; 大本 俊介; 三長 孝輔; 鎌田 研; 山雄 健太郎; 工藤 正俊Gastroenterological Endoscopy (一社)日本消化器内視鏡学会 62 (Suppl.2) 2136 - 2136 0387-1207 2020/10KINDAI20を用いたコンベックスEUSの教育について大本 俊介; 竹中 完; 工藤 正俊Gastroenterological Endoscopy (一社)日本消化器内視鏡学会 62 (Suppl.2) 2164 - 2164 0387-1207 2020/10【肝細胞癌治療のパラダイムチェンジ-進化する薬物療法2020 Update Part I-(免疫療法)】免疫療法の基礎 肝細胞癌における微小免疫環境と免疫チェックポイント阻害剤西田 直生志; 工藤 正俊肝・胆・膵 (株)アークメディア 81 (4) 643 - 650 0389-4991 2020/10消化器領域から見たIgG4関連疾患研究の進歩 IRF7-I型IFN-IL-33経路がIgG4関連疾患の病態に果たす役割とバイオマーカーとしての有用性三長 孝輔; 渡邉 智裕; 工藤 正俊日本消化器病学会雑誌 (一財)日本消化器病学会 117 (臨増大会) A678 - A678 0446-6586 2020/10急性膵炎におけるプレサルコペニアの臨床的意義に関しての検討田中 隆光; 竹中 完; 吉田 晃弘; 田中 秀和; 吉川 智恵; 石川 嶺; 岡本 彩那; 山崎 友裕; 中井 敦史; 大本 俊輔; 三長 孝輔; 鎌田 研; 山雄 健太郎; 松本 逸平; 竹山 宜典; 工藤 正俊日本消化器病学会雑誌 (一財)日本消化器病学会 117 (臨増大会) A789 - A789 0446-6586 2020/10消化器癌化学療法の進歩と課題 切除不能進行肝癌に対する免疫チェックポイント阻害薬不応後の二次治療を見据えて青木 智子; 萩原 智; 上嶋 一臣; 工藤 正俊日本消化器病学会近畿支部例会プログラム・抄録集 日本消化器病学会-近畿支部 113回 54 - 54 2020/10鑑別診断に造影超音波が有用であった多血性の肝内胆管癌の1例吉田 早希; 南 康範; 盛田 真弘; 青木 智子; 田北 雅弘; 萩原 智; 依田 広; 上嶋 一臣; 西田 直生志; 工藤 正俊日本消化器病学会近畿支部例会プログラム・抄録集 日本消化器病学会-近畿支部 113回 103 - 103 2020/10肝癌診療の現状と未来 肝細胞癌における腫瘍免疫環境と癌関連分子の遺伝子変異西田 直生志; 盛田 真弘; 工藤 正俊日本消化器病学会雑誌 (一財)日本消化器病学会 117 (臨増大会) A513 - A513 0446-6586 2020/10内視鏡的乳頭切除術後胆管狭窄に対する予防的金属ステント留置の有用性岡本 彩那; 竹中 完; 田中 隆光; 田中 秀和; 吉田 晃浩; 吉川 智恵; 石川 嶺; 山崎 友裕; 中井 敦史; 大本 俊介; 三長 孝輔; 鎌田 研; 山雄 健太郎; 工藤 正俊Gastroenterological Endoscopy (一社)日本消化器内視鏡学会 62 (Suppl.2) 2136 - 2136 0387-1207 2020/10KINDAI20を用いたコンベックスEUSの教育について大本 俊介; 竹中 完; 工藤 正俊Gastroenterological Endoscopy (一社)日本消化器内視鏡学会 62 (Suppl.2) 2164 - 2164 0387-1207 2020/10胆膵領域癌に対する診断の取り組み 膵腫瘤性病変におけるDetective flow imaging(DFI)の有用性について田中 隆光; 大本 俊介; 竹中 完; 工藤 正俊日本消化器病学会近畿支部例会プログラム・抄録集 日本消化器病学会-近畿支部 113回 60 - 60 2020/10Detective flow imaging(DFI)にて特徴的な腫瘍内血流を観察し得たIntraductal papillary neoplasm of the bile duct(IPNB)の1例尼崎 雅也; 大本 俊介; 吉田 晃浩; 田中 秀和; 石川 嶺; 岡本 彩那; 山崎 友裕; 中井 敦史; 三長 孝輔; 鎌田 研; 竹中 完; 工藤 正俊日本消化器病学会近畿支部例会プログラム・抄録集 日本消化器病学会-近畿支部 113回 85 - 85 2020/10拡大観察から見たPPI関連胃底腺ポリープの特徴友岡 瑞貴; 辻 直子; 高島 耕太; 正木 翔; 河野 匡志; 永井 知之; 米田 頼晃; 本庶 元; 櫻井 俊治; 松井 繁長; 渡邉 智裕; 樫田 博史; 工藤 正俊Gastroenterological Endoscopy (一社)日本消化器内視鏡学会 62 (Suppl.2) 2088 - 2088 0387-1207 2020/10小腸内視鏡診療ガイドラインでのカプセル内視鏡検査の運用の実際米田 頼晃; 樫田 博史; 櫻井 俊治; 松村 まり子; 高島 耕太; 正木 翔; 河野 匡志; 山田 光成; 本庶 元; 永井 知行; 松井 繁長; 辻 直子; 渡邉 智裕; 工藤 正俊Gastroenterological Endoscopy (一社)日本消化器内視鏡学会 62 (Suppl.2) 2113 - 2113 0387-1207 2020/10消化管腫瘍の診断と治療における工夫 胃底腺型胃癌の内視鏡診断と治療益田 康弘; 松井 繁長; 櫻井 俊治; 工藤 正俊日本消化器病学会近畿支部例会プログラム・抄録集 日本消化器病学会-近畿支部 113回 67 - 67 2020/10早期胃胎児消化管上皮類似癌の1例岡井 夏輝; 松井 繁長; 正木 翔; 栗本 真之; 大丸 直哉; 友岡 瑞貴; 益田 康弘; 高田 隆太郎; 高島 耕太; 河野 匡志; 永井 知行; 米田 頼晃; 本庶 元; 櫻井 俊治; 辻 直子; 樫田 博史; 工藤 正俊日本消化器病学会近畿支部例会プログラム・抄録集 日本消化器病学会-近畿支部 113回 94 - 94 2020/10予後延長を目指した肝細胞癌全身薬物治療の展望工藤 正俊; 黒崎 雅之; 森口 理久; 小笠原 定久; 寺島 健志肝臓クリニカルアップデート 医学図書出版(株) 6 (2) 227 - 236 2189-4469 2020/10Efficacy and Safety of Nivolumab Plus Ipilimumab in Patients With Advanced Hepatocellular Carcinoma Previously Treated With Sorafenib: The CheckMate 040 Randomized Clinical Trial.Thomas Yau; Yoon-Koo Kang; Tae-You Kim; Anthony B El-Khoueiry; Armando Santoro; Bruno Sangro; Ignacio Melero; Masatoshi Kudo; Ming-Mo Hou; Ana Matilla; Francesco Tovoli; Jennifer J Knox; Aiwu Ruth He; Bassel F El-Rayes; Mirelis Acosta-Rivera; Ho-Yeong Lim; Jaclyn Neely; Yun Shen; Tami Wisniewski; Jeffrey Anderson; Chiun HsuJAMA oncology 2020/10 [Refereed] Importance: Most patients with hepatocellular carcinoma (HCC) are diagnosed with advanced disease not eligible for potentially curative therapies; therefore, new treatment options are needed. Combining nivolumab with ipilimumab may improve clinical outcomes compared with nivolumab monotherapy. Objective: To assess efficacy and safety of nivolumab plus ipilimumab in patients with advanced HCC who were previously treated with sorafenib. Design, Setting, and Participants: CheckMate 040 is a multicenter, open-label, multicohort, phase 1/2 study. In the nivolumab plus ipilimumab cohort, patients were randomized between January 4 and September 26, 2016. Treatment group information was blinded after randomization. Median follow-up was 30.7 months. Data cutoff for this analysis was January 2019. Patients were recruited at 31 centers in 10 countries/territories in Asia, Europe, and North America. Eligible patients had advanced HCC (with/without hepatitis B or C) previously treated with sorafenib. A total of 148 patients were randomized (50 to arm A and 49 each to arms B and C). Interventions: Patients were randomized 1:1:1 to either nivolumab 1 mg/kg plus ipilimumab 3 mg/kg, administered every 3 weeks (4 doses), followed by nivolumab 240 mg every 2 weeks (arm A); nivolumab 3 mg/kg plus ipilimumab 1 mg/kg, administered every 3 weeks (4 doses), followed by nivolumab 240 mg every 2 weeks (arm B); or nivolumab 3 mg/kg every 2 weeks plus ipilimumab 1 mg/kg every 6 weeks (arm C). Main Outcomes and Measures: Coprimary end points were safety, tolerability, and objective response rate. Duration of response was also measured (investigator assessed with the Response Evaluation Criteria in Solid Tumors v1.1). Results: Of 148 total participants, 120 were male (81%). Median (IQR) age was 60 (52.5-66.5). At data cutoff (January 2019), the median follow-up was 30.7 months (IQR, 29.9-34.7). Investigator-assessed objective response rate was 32% (95% CI, 20%-47%) in arm A, 27% (95% CI, 15%-41%) in arm B, and 29% (95% CI, 17%-43%) in arm C. Median (range) duration of response was not reached (8.3-33.7+) in arm A and was 15.2 months (4.2-29.9+) in arm B and 21.7 months (2.8-32.7+) in arm C. Any-grade treatment-related adverse events were reported in 46 of 49 patients (94%) in arm A, 35 of 49 patients (71%) in arm B, and 38 of 48 patients (79%) in arm C; there was 1 treatment-related death (arm A; grade 5 pneumonitis). Conclusions and Relevance: In this randomized clinical trial, nivolumab plus ipilimumab had manageable safety, promising objective response rate, and durable responses. The arm A regimen (4 doses nivolumab 1 mg/kg plus ipilimumab 3 mg/kg every 3 weeks then nivolumab 240 mg every 2 weeks) received accelerated approval in the US based on the results of this study. Trial Registration: ClinicalTrials.gov Identifier: NCT01658878.Histological diagnosis and grading of pancreatic neuroendocrine tumor by endoscopic ultrasound-guided fine needle biopsy using a 25-gauge needle with a core trap: A multicenter prospective trial.Ken Kamata; Reiko Ashida; Satoru Yasukawa; Yasutaka Chiba; Nobuyasu Fukutake; Hiroko Nebiki; Akira Kurita; Makoto Takaoka; Takeshi Ogura; Hideyuki Shiomi; Masanori Asada; Hiroaki Yasuda; Minoru Shigekawa; Akio Yanagisawa; Masatoshi Kudo; Masayuki KitanoPancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.] 20 (7) 1428 - 1433 2020/10 [Refereed] OBJECTIVES: Preoperative grading of pancreatic neuroendocrine tumors (PanNET) is challenging. The aim of this study was to prospectively evaluate the use of a 25-gauge needle with a core trap for diagnosis and grading of PanNET. METHODS: This multicenter prospective trial was registered with the University Hospital Medical Information Network (UMIN000021409). Consecutive patients with suspected PanNET between June 2016 and November 2017 were enrolled. All patients underwent endoscopic ultrasound-guided fine needle biopsy (EUS-FNB) using a 25-gauge needle with a core trap. Samples obtained after the first needle pass were used for central pathological review. EUS-FNB was evaluated in terms of (i) technical success rate, (ii) adequacy for histological evaluation, (iii) complication rate during the procedure, and (iv) concordance between PanNET grading on EUS-FNB and that after analysis of the resected tumor. RESULTS: Fifty-two patients were enrolled. Of the 36/52 patients who underwent surgical resection, 31 were finally diagnosed with PanNET and were eligible for analysis. The technical success rate of EUS-FNB was 100%. The rate of adequacy for histological evaluation was 90.3%. There were no complications related to EUS-FNB. The concordance rate between PanNET grading on EUS-FNB and that after analysis of the resected tumor was 82.6% (95% confidence interval = 61.22-95.05, P = 0.579). CONCLUSIONS: EUS-FNB using a 25-gauge needle with a core trap is feasible, providing histological samples are of sufficient quality for diagnosis and grading of PanNET.Guidelines and Good Clinical Practice Recommendations for Contrast-Enhanced Ultrasound (CEUS) in the Liver-Update 2020 WFUMB in Cooperation with EFSUMB, AFSUMB, AIUM, and FLAUS.Christoph F Dietrich; Christian Pállson Nolsøe; Richard G Barr; Annalisa Berzigotti; Peter N Burns; Vito Cantisani; Maria Cristina Chammas; Nitin Chaubal; Byung Ihn Choi; Dirk-André Clevert; Xinwu Cui; Yi Dong; Mirko D'Onofrio; J Brian Fowlkes; Odd Helge Gilja; Pintong Huang; Andre Ignee; Christian Jenssen; Yuko Kono; Masatoshi Kudo; Nathalie Lassau; Won Jae Lee; Jae Young Lee; Ping Liang; Adrian Lim; Andrej Lyshchik; Maria Franca Meloni; Jean Michel Correas; Yasunori Minami; Fuminori Moriyasu; Carlos Nicolau; Fabio Piscaglia; Adrian Saftoiu; Paul S Sidhu; Ioan Sporea; Guido Torzilli; Xiaoyan Xie; Rongqin ZhengUltrasound in medicine & biology 46 (10) 2579 - 2604 2020/10 [Refereed] The present, updated document describes the fourth iteration of recommendations for the hepatic use of contrast-enhanced ultrasound, first initiated in 2004 by the European Federation of Societies for Ultrasound in Medicine and Biology. The previous updated editions of the guidelines reflected changes in the available contrast agents and updated the guidelines not only for hepatic but also for non-hepatic applications. The 2012 guideline requires updating as, previously, the differences in the contrast agents were not precisely described and the differences in contrast phases as well as handling were not clearly indicated. In addition, more evidence has been published for all contrast agents. The update also reflects the most recent developments in contrast agents, including U.S. Food and Drug Administration approval and the extensive Asian experience, to produce a truly international perspective. These guidelines and recommendations provide general advice on the use of ultrasound contrast agents (UCAs) and are intended to create standard protocols for the use and administration of UCAs in liver applications on an international basis to improve the management of patients.Navigator-triggered and breath-hold 3D MRCP using compressed sensing: image quality and method selection factor assessment.Daisuke Morimoto; Tomoko Hyodo; Ken Kamata; Tomoya Kadoba; Makoto Itoh; Hiroyuki Fukushima; Yasutaka Chiba; Mamoru Takenaka; Tomohiro Mochizuki; Yu Ueda; Keizou Miyagoshi; Masatoshi Kudo; Kazunari IshiiAbdominal radiology (New York) 45 (10) 3081 - 3091 2366-0058 2020/10 [Refereed] PURPOSE: To examine whether MRCP using a combination of compressed sensing and sensitivity encoding with navigator-triggered and breath-hold techniques (NT C-SENSE and BH C-SENSE, respectively) have comparable image quality to that of navigator-triggered MRCP using only sensitivity encoding (NT SENSE) at 1.5-T. METHODS: Fifty-one participants were enrolled in this prospective study between July and October 2018 and underwent the three 3D MRCP sequences each. The acquisition time and relative duct-to-periductal contrast ratios (RC values) of each bile duct segment were obtained. Visualization of the bile and main pancreatic ducts, background suppression, artifacts, and overall image quality were scored on 5-point scales. Mean and median differences in RC values and qualitative scores of NT C-SENSE and BH C-SENSE relative to NT SENSE were calculated with 95% confidence intervals (CIs). RESULTS: Acquisition time of NT SENSE, NT C-SENSE, and BH C-SENSE were 348, 143 (mean for both), and 18 s (for all participants), respectively. The RC value of each bile duct segment was inferior, but the lower limits of the 95% CIs of the mean differences were ≥ - 0.10, for both NT C-SENSE and BH C-SENSE. The visualization score of the intrahepatic duct in BH C-SENSE was inferior to that in NT SENSE (lower 95% CI limit, - 1.5). In both NT C-SENSE and BH C-SENSE, the 95% CIs of the median differences in the other qualitative scores were from - 1.0 to 0.0. CONCLUSION: NT C-SENSE and BH C-SENSE have comparable image quality to NT SENSE at 1.5-T.Identification of serum IFN-α and IL-33 as novel biomarkers for type 1 autoimmune pancreatitis and IgG4-related disease.Kosuke Minaga; Tomohiro Watanabe; Akane Hara; Ken Kamata; Shunsuke Omoto; Atsushi Nakai; Yasuo Otsuka; Ikue Sekai; Tomoe Yoshikawa; Kentaro Yamao; Mamoru Takenaka; Yasutaka Chiba; Masatoshi KudoScientific reports 10 (1) 14879 - 14879 2020/09 [Refereed] IgG4-related disease (IgG4-RD) is a multi-organ autoimmune disease characterized by elevated serum IgG4 concentration. Although serum IgG4 concentration is widely used as a biomarker for IgG4-RD and type 1 autoimmune pancreatitis (AIP), a pancreatic manifestation of IgG4-RD, a significant number of patients have normal serum IgG4 levels, even in the active phase of the disease. Recently, we reported that the development of experimental AIP and human type 1 AIP is associated with increased expression of IFN-α and IL-33 in the pancreas. In this study, we assessed the utility of serum IFN-α and IL-33 levels as biomarkers for type 1 AIP and IgG4-RD. Serum IFN-α and IL-33 concentrations in patients who met the diagnostic criteria for definite type 1 AIP and/or IgG4-RD were significantly higher than in those with chronic pancreatitis or in healthy controls. Strong correlations between serum IFN-α, IL-33, and IgG4 concentrations were observed. Diagnostic performance of serum IFN-α and IL-33 concentrations as markers of type 1 AIP and/or IgG4-RD was comparable to that of serum IgG4 concentration, as calculated by the receiver operating characteristic curve analysis. Induction of remission by prednisolone treatment markedly decreased the serum concentration of these cytokines. We conclude that serum IFN-α and IL-33 concentrations can be useful as biomarkers for type 1 AIP and IgG4-RD.ATG16L1 negatively regulates RICK/RIP2-mediated innate immune responses.Hajime Honjo; Tomohiro Watanabe; Yasuyuki Arai; Ken Kamata; Kosuke Minaga; Yoriaki Komeda; Kouhei Yamashita; Masatoshi KudoInternational immunology 33 (2) 91 - 105 2020/09 [Refereed] Polymorphisms in the autophagy-related protein 16 like 1 (ATG16L1) and nucleotide-binding oligomerization domain 2 (NOD2) genes are associated with Crohn's disease (CD). Impaired interaction between ATG16L1 and NOD2 underlies CD immunopathogenesis. Although activation of the receptor-interacting serine/threonine kinase (RICK, also known as RIP2), a downstream signaling molecule for NOD2 and multiple toll-like receptors (TLRs), plays a pathogenic role in the development of inflammatory bowel disease, the molecular interaction between ATG16L1 and RICK/RIP2 remains poorly understood. In this study, we examined the physical interaction between ATG16L1 and RICK/RIP2 in human embryonic kidney 293 (HEK293) cells and human monocyte-derived dendritic cells (DCs) expressing excessive and endogenous levels of these proteins, respectively. We established that ATG16L1 binds to RICK/RIP2 kinase domain and negatively regulates TLR2-mediated nuclear factor-kappa B (NF-κB) activation and proinflammatory cytokine responses by inhibiting the interaction between TLR2 and RICK/RIP2. Binding of ATG16L1 to RICK/RIP2 suppressed NF-κB activation by downregulating RICK/RIP2 polyubiquitination. Notably, the percentage of colonic DCs expressing ATG16L1 inversely correlated with IL-6 and TNF-α expression levels in the colon of CD patients. These data suggest that the interaction between ATG16L1 and RICK/RIP2 maintains intestinal homeostasis via the downregulation of TLR-mediated proinflammatory cytokine responses.Phase Ib Study of Lenvatinib Plus Pembrolizumab in Patients With Unresectable Hepatocellular Carcinoma.Richard S Finn; Masafumi Ikeda; Andrew X Zhu; Max W Sung; Ari D Baron; Masatoshi Kudo; Takuji Okusaka; Masahiro Kobayashi; Hiromitsu Kumada; Shuichi Kaneko; Marc Pracht; Konstantin Mamontov; Tim Meyer; Tomoki Kubota; Corina E Dutcus; Kenichi Saito; Abby B Siegel; Leonid Dubrovsky; Kalgi Mody; Josep M LlovetJournal of clinical oncology : official journal of the American Society of Clinical Oncology 38 (26) 2960 - 2970 2020/09 [Refereed] PURPOSE: The immunomodulatory effect of lenvatinib (a multikinase inhibitor) on tumor microenvironments may contribute to antitumor activity when combined with programmed death receptor-1 (PD-1) signaling inhibitors in hepatocellular carcinoma (HCC). We report results from a phase Ib study of lenvatinib plus pembrolizumab (an anti-PD-1 antibody) in unresectable HCC (uHCC). PATIENTS AND METHODS: In this open-label multicenter study, patients with uHCC received lenvatinib (bodyweight ≥ 60 kg, 12 mg; 直腸NENに対する治療の適応と工夫 当院での直腸NENの治療成績からみた治療方法の検討永井 知行; 樫田 博史; 益田 康弘; 友岡 瑞貴; 高島 耕太; 高田 隆太郎; 正木 翔; 河野 匡志; 米田 頼晃; 本庶 元; 櫻井 俊治; 松井 繁長; 渡邉 智裕; 辻 直子; 工藤 正俊日本大腸肛門病学会雑誌 (一社)日本大腸肛門病学会 73 (9) A70 - A70 0047-1801 2020/09直腸NENに対する治療の適応と工夫 当院での直腸NENの治療成績からみた治療方法の検討永井 知行; 樫田 博史; 益田 康弘; 友岡 瑞貴; 高島 耕太; 高田 隆太郎; 正木 翔; 河野 匡志; 米田 頼晃; 本庶 元; 櫻井 俊治; 松井 繁長; 渡邉 智裕; 辻 直子; 工藤 正俊日本大腸肛門病学会雑誌 (一社)日本大腸肛門病学会 73 (9) A70 - A70 0047-1801 2020/09全身化学療法により生存利益を得られる切除不能C型肝細胞癌の特徴青木 智子; 上嶋 一臣; 盛田 真弘; 千品 寛和; 田北 雅弘; 萩原 智; 南 康範; 依田 広; 西田 直生志; 鶴崎 正勝; 工藤 正俊肝臓 (一社)日本肝臓学会 61 (Suppl.2) A647 - A647 0451-4203 2020/09切除不能肝細胞癌に対する免疫チェックポイント阻害薬不応後のレンバチニブ二次療法青木 智子; 上嶋 一臣; 盛田 真弘; 千品 寛和; 田北 雅弘; 萩原 智; 南 康範; 依田 広; 西田 直生志; 鶴崎 正勝; 工藤 正俊肝臓 (一社)日本肝臓学会 61 (Suppl.2) A654 - A654 0451-4203 2020/09Impacts of COVID-19 on Liver Cancers: During and after the Pandemic.Stephen Lam Chan; Masatoshi KudoLiver cancer 9 (5) 491 - 502 2020/09 Background: The pandemic of coronavirus disease 2019 (COVID-19) has diverted resources from healthcare services for patients with chronic medical illness such as cancer. COVID-19 also causes organ dysfunction, complicating cancer treatment. In most countries with an outbreak of COVID-19, modifications of cancer management have been adopted to accommodate the crisis and minimize the exposure of cancer patients to the infection. In countries where COVID-19 numbers are subsiding, medical teams should also be prepared to resume normal practices gradually. Here, we aim to review the literature on the impact of COVID-19 on patients with hepatocellular carcinoma (HCC) as well as discuss modifications to the management of HCC during and after recovery from the pandemic. Summary: Based on current data, 10-40% of patients with COVID-19 have hepatic injury characterized by an elevation of transaminases and/or hyperbilirubinemia. Multiple mechanisms contribute to the hepatic injury, including direct viral entry to hepatocytes/cholangiocytes, immune-mediated hepatitis, hypoxia, and drug-related hepatotoxicity. In patients with HCC, COVID-19 may exacerbate existing chronic liver disease and complicate the management of cancer. Cancer patients generally have a higher risk of infection and worse outcome, especially those who have recently undergone cancer treatment. Although HCC is under-represented in COVID-19 series, mitigation measures should be implemented to minimize the exposure of patients to the virus. A decision on the treatment of HCC should be balanced with consideration of the availability of medical resources, the level of infection risk of COVID-19, and the risk-benefit ratio of the individual patient. In areas where the COVID-19 outbreak is subsiding, clinicians should be prepared to manage a surge of HCC patients with higher disease burdens and complications. Key Messages: Mitigation measures to protect at-risk patients, such as those with cancers, from SARS-CoV-2 infection should be exercised and the impact of COVID-19 on this group of patients should be thoroughly studied.Gd-EOB-DTPA-MRI Could Predict WNT/β-Catenin Mutation and Resistance to Immune Checkpoint Inhibitor Therapy in Hepatocellular Carcinoma.Masatoshi KudoLiver cancer 9 (5) 479 - 490 2020/09Endoscopic Ultrasound Fine-Needle Biopsy May Contribute to the Diagnosis of Malignant Lymph Nodes.Mamoru Takenaka; Shunsuke Omoto; Masatoshi KudoClinical endoscopy 53 (5) 508 - 509 2020/09 [Refereed]A novel teaching tool for visualizing the invisible bile duct axis in 3 dimensions during biliary cannulation (Compact Disc method).Mamoru Takenaka; Tomoe Yoshikawa; Kosuke Minaga; Kentaro Yamao; Masatoshi KudoVideoGIE : an official video journal of the American Society for Gastrointestinal Endoscopy 5 (9) 389 - 394 2020/09 [Refereed]Hepatic Arterial Infusion Chemotherapy versus Sorafenib in Patients with Advanced Hepatocellular Carcinoma.Kazuomi Ueshima; Sadahisa Ogasawara; Masafumi Ikeda; Yutaka Yasui; Takeshi Terashima; Tatsuya Yamashita; Shuntaro Obi; Shinpei Sato; Hiroshi Aikata; Takumi Ohmura; Hidekatsu Kuroda; Takamasa Ohki; Kengo Nagashima; Yoshihiko Ooka; Masahiro Takita; Masayuki Kurosaki; Kazuaki Chayama; Shuichi Kaneko; Namiki Izumi; Naoya Kato; Masatoshi Kudo; Masao OmataLiver cancer 9 (5) 583 - 595 2020/09 [Refereed] Background: Prior to the approval of sorafenib, hepatic arterial infusion chemotherapy (HAIC) was offered to patients with advanced hepatocellular carcinoma (HCC) in East Asia, particularly Japan. According to the Japanese guidelines, HAIC is recommended as one of the treatment options in patients without extrahepatic metastasis (EHM). Methods: The present cohort study compared the use of HAIC and sorafenib on outcomes of patients with advanced HCC. Consecutive patients with advanced HCC who received HAIC or sorafenib as a first-line systemic therapy were enrolled from 10 Japanese institutions. The primary outcomes were overall survival (OS) in patients with macrovascular invasion (MVI), but without EHM, and OS in patients without both MVI and EHM. Results: Between 2009 and 2016, 2,006 patients were enrolled (541 HAIC patients, 1,465 sorafenib patients). After propensity score matching, the OS of patients with MVI but without EHM was significantly longer in the HAIC group compared with the sorafenib group (10.1 vs. 9.1 months for the HAIC and sorafenib groups, respectively; n = 170 for each group; hazard ratio [HR] 0.668; 95% confidence interval [95% CI] 0.475-0.935; p = 0.018). There was no significant difference in OS between patients without both MVI and EHM (12.2 vs. 15.4 months for the HAIC and sorafenib groups, respectively; n = 76 in each cohort after propensity score matching; HR 1.227; 95% CI 0.699-2.155; p = 0.475). Conclusion: HAIC is a potential front-line treatment choice in a subpopulation of patients with advanced HCC with MVI but without EHM.Successful biliary cannulation using a novel rotatable sphincterotome in a patient with situs inversus totalis.Akihiro Yoshida; Kosuke Minaga; Osami Takeda; Hajime Hanno; Shigenori Takayanagi; Toshio Dozaiku; Masatoshi KudoEndoscopy 52 (9) E333-E334  2020/09 [Refereed]Sorafenib treatment by Child-Pugh score in Latin American patients with hepatocellular carcinoma.Laura L de Guevara; Lucy Dagher; Vanessa Mv Arruda; Keiko Nakajima; Masatoshi KudoFuture oncology (London, England) 2020/08 [Refereed] Aim: To evaluate sorafenib treatment in Latin American patients with unresectable hepatocellular carcinoma in the real-world GIDEON study. Patients and methods: Sorafenib administration, safety and efficacy were analyzed by Child-Pugh status. Results: Of 90 evaluable patients (37% Child-Pugh A, 46% Child-Pugh B and 3% Child-Pugh C at study entry), 97% started sorafenib at 800 mg/day. Patients with Child-Pugh B7 had the longest median treatment duration of sorafenib (33.1 weeks). Sorafenib-related adverse events occurred in 58% of patients with Child-Pugh A (21% grade 3/4) and 46% with Child-Pugh B (7% grade 3/4). Conclusion: Sorafenib had a similar safety profile across patients with Child-Pugh A and B and is a treatment option for both groups.炎症性疾患における最先端の内視鏡診療 下部 UC/CD以外のIBD MDS関連IBDに対する治療方法の検討河野 匡志; 櫻井 俊治; 工藤 正俊Gastroenterological Endoscopy (一社)日本消化器内視鏡学会 62 (Suppl.1) 1047 - 1047 0387-1207 2020/08EPLBD後にfood impactionによる胆管炎を繰り返した一例福永 朋洋; 水野 成人; 松村 まり子; 高田 竜太郎; 秦 康倫; 木下 大輔; 奥田 英之; 川崎 俊彦; 野村 健司; 米澤 真衣; 河野 辰哉; 半田 康平; 石川 原; 橋本 和彦; 工藤 正俊胆道 日本胆道学会 34 (3) 601 - 601 0914-0077 2020/08急性膵炎局所合併症に対する内視鏡治療 当院におけるwalled-off necrosisに対するstep-up approachの成績と内視鏡治療不成功の要因解析大本 俊介; 竹中 完; 工藤 正俊Gastroenterological Endoscopy (一社)日本消化器内視鏡学会 62 (Suppl.1) 1091 - 1091 0387-1207 2020/08【胆膵疾患の最新画像診断】3D-CT解析を用いた膵実質萎縮による膵癌早期診断山雄 健太郎; 竹中 完; 田中 秀和; 田中 隆光; 吉田 晃浩; 石川 嶺; 岡本 彩那; 中井 敦; 山崎 友裕; 大本 俊介; 鎌田 研; 三長 孝輔; 渡邉 智裕; 工藤 正俊胆と膵 医学図書出版(株) 41 (8) 713 - 718 0388-9408 2020/08 膵癌は予後不良な癌腫であり、予後改善が急務である。小膵癌の場合、CTやMRIでの直接指摘が困難であるため、尾側膵管拡張を伴う主膵管狭窄などの間接所見が診断の契機となる。しかしながら主膵管狭窄は慢性膵炎などの良性疾患でも認められる。近年、上皮内癌を含む腫瘍径10mm以下の微小膵癌において膵実質の部分萎縮(やせ)が診断の指標になるとの報告が散見される。ただし膵臓は膵頭部が膨大している、門脈から腹側へ圧排を受けるなどの構造をしているため、通常のCTでは萎縮がやや評価しにくい。3D-CTは本来立体構造をした膵臓をそのまま3D画像として可視化できるため、この技術を用いて膵臓を抽出することで膵実質の萎縮を直感的かつ簡便に評価できる。3D-CTによる膵実質の萎縮評価は膵癌の早期診断および予後改善に寄与すると考える。(著者抄録)急性膵炎局所合併症に対する内視鏡治療 当院におけるwalled-off necrosisに対するstep-up approachの成績と内視鏡治療不成功の要因解析大本 俊介; 竹中 完; 工藤 正俊Gastroenterological Endoscopy (一社)日本消化器内視鏡学会 62 (Suppl.1) 1091 - 1091 0387-1207 2020/08【これ一冊ですべてわかる消化器超音波検査】(第VI章)超音波とAI AIによる肝腫瘤検出・判別支援システムの開発西田 直生志; 山川 誠; 椎名 毅; 工藤 正俊臨床消化器内科 (株)日本メディカルセンター 35 (9) 1166 - 1174 0911-601X 2020/08EPLBD後にfood impactionによる胆管炎を繰り返した一例福永 朋洋; 水野 成人; 松村 まり子; 高田 竜太郎; 秦 康倫; 木下 大輔; 奥田 英之; 川崎 俊彦; 野村 健司; 米澤 真衣; 河野 辰哉; 半田 康平; 石川 原; 橋本 和彦; 工藤 正俊胆道 日本胆道学会 34 (3) 601 - 601 0914-0077 2020/08【肝胆膵における結石診療のベストプラクティス】胆嚢結石症 Confluence stoneとMirizzi症候群はどう違うのか Biliobiliary fistulaと合わせて竹中 完; 石川 嶺; 岡本 彩那; 山崎 友裕; 中井 敦史; 大本 俊介; 三長 孝輔; 鎌田 研; 山雄 健太郎; 工藤 正俊肝・胆・膵 (株)アークメディア 81 (2) 305 - 312 0389-4991 2020/08A Paradigm Change in the Treatment Strategy for Hepatocellular Carcinoma.Masatoshi KudoLiver cancer 9 (4) 367 - 377 2020/08 [Refereed]Efficacy and Safety of Ramucirumab in Asian and Non-Asian Patients with Advanced Hepatocellular Carcinoma and Elevated Alpha-Fetoprotein: Pooled Individual Data Analysis of Two Randomized Studies.Chia-Jui Yen; Masatoshi Kudo; Ho-Yeong Lim; Chih-Hung Hsu; Arndt Vogel; Giovanni Brandi; Rebecca Cheng; Ioana Simona Nitu; Paolo Abada; Yanzhi Hsu; Andrew X Zhu; Yoon-Koo KangLiver cancer 9 (4) 440 - 454 2020/08 [Refereed] Objective: REACH-2 and REACH were randomized, placebo-controlled, double-blind, multicenter phase 3 trials which showed survival benefits of ramucirumab treatment in patients with advanced hepatocellular carcinoma (HCC) and elevated alpha-fetoprotein (AFP). We evaluated the efficacy and safety of ramucirumab in Asian and non-Asian patients with AFP ≥400 ng/mL from REACH-2 and REACH. Methods: We pooled Asian and non-Asian patients from the REACH-2 and REACH trials and performed an individual patient data meta-analysis. Overall survival (OS) and progression-free survival were evaluated using the Kaplan-Meier method. Hazard ratios (HRs) were estimated with a stratified Cox regression model. Results: In the pooled REACH-2 and REACH patient population, 291 Asian patients were randomly assigned to receive ramucirumab (n = 168) or placebo (n = 123), and 251 non-Asian patients received ramucirumab (n = 148) or placebo (n = 103). The median OS was significantly longer in the ramucirumab arm in comparison to the placebo arm for Asian patients (8.08 vs. 4.76 months, stratified HR 0.73 [95% CI 0.56-0.95], p = 0.0189) and non-Asian patients (7.98 vs. 5.22 months, stratified HR 0.65 [95% CI 0.49-0.86], p = 0.0028). The overall response rate (ORR) and disease control rate (DCR) were significantly higher in the ramucirumab arm compared to the placebo arm for Asian patients (ORR: 4.2 vs. 0.8%; DCR: 53.6 vs. 33.3%) and non-Asian patients (ORR: 6.8 vs. 1.0%; DCR: 59.5 vs. 41.7%). The most common grade ≥3 treatment-emergent adverse events reported in the ramucirumab arm were hypertension (7.7%), decreased appetite (1.2%), and ascites (1.2%) for Asian patients and hypertension (16.9%), ascites (8.8%), asthenia (4.7%), and fatigue (5.4%) for non-Asian patients. Discussion and Conclusion: This pooled analysis of the REACH-2/REACH trials demonstrates significant benefits, with a manageable safety profile, of ramucirumab treatment in Asian and non-Asian patients with advanced HCC and baseline AFP ≥400 ng/mL.Ramucirumab in the second-line for patients with hepatocellular carcinoma and elevated alpha-fetoprotein: patient-reported outcomes across two randomised clinical trials.Andrew X Zhu; Ryan D Nipp; Richard S Finn; Peter R Galle; Josep M Llovet; Jean-Frederic Blanc; Takuji Okusaka; Ian Chau; David Cella; Allicia Girvan; Jonathon Gable; Lee Bowman; Chunxiao Wang; Yanzhi Hsu; Paolo B Abada; Masatoshi KudoESMO open 5 (4) 2020/08 [Refereed] BACKGROUND: Symptoms of advanced hepatocellular carcinoma (HCC) represent a substantial burden for the patient and are important endpoints to assess when evaluating treatment. Patient-reported outcomes were evaluated in subjects with advanced HCC and baseline alpha-fetoprotein (AFP) ≥400 ng/mL treated with second-line ramucirumab. PATIENTS AND METHODS: Patients with AFP≥400 ng/mL enrolled in the REACH or REACH-2 phase 3 studies were used in this analysis. Eligible patients had advanced HCC, Child-Pugh A, Eastern Cooperative Oncology Group performance status 0/1 and prior sorafenib. Patients received ramucirumab 8 mg/kg or placebo once every 2 weeks. Disease-related symptoms and health-related quality of life (HRQoL) were assessed with the Functional Assessment of Cancer Therapy Hepatobiliary Symptom Index (FHSI)-8 and EuroQoL-5-Dimensions (EQ-5D) instruments, respectively. Time to deterioration (TTD) (≥3-point decrease in FHSI-8 total score;≥0.06-point decrease in EQ-5D score, from randomisation to first date of deterioration) was determined using Kaplan-Meier estimation and the Cox proportional hazards model. Both separate and pooled analyses for REACH AFP≥400 ng/mL and REACH-2 patients were conducted. RESULTS: In the pooled population with AFP ≥400 ng/mL (n=542; ramucirumab, n=316; placebo, n=226), median TTD in FHSI-8 total score was prolonged with ramucirumab relative to placebo (3.3 vs 1.9 months; HR 0.725; (95% CI 0.559 to 0.941); p=0.0152), including significant differences in back pain (0.668; (0.497 to 0.899); p=0.0044), weight loss (0.699; (0.505 to 0.969); p=0.0231) and pain (0.769; (0.588 to 1.005); p=0.0248) symptoms. TTD in EQ-5D score was not significantly different between ramucirumab and placebo groups (median 2.9 vs 1.9 months). Results in the individual trials were consistent with these findings. CONCLUSIONS: Ramucirumab in second-line treatment of advanced HCC demonstrates consistent benefit in the delay of deterioration in disease-related symptoms with no worsening of HRQoL. Taken with previously demonstrated ramucirumab-driven survival benefits in this setting, these data may inform patient-clinician discussions about the benefit-risk profile of this therapy. TRIAL REGISTRATION NUMBER: NCT01140347; NCT02435433, NCT02435433.A new era of systemic therapy for intermediate and advanced stage hepatocellular carcinoma.Masatoshi KudoHepatobiliary surgery and nutrition 9 (4) 530 - 533 2020/08 [Refereed]Association between Genetic and Immunological Background of Hepatocellular Carcinoma and Expression of Programmed Cell Death-1.Naoshi Nishida; Kazuko Sakai; Masahiro Morita; Tomoko Aoki; Masahiro Takita; Satoru Hagiwara; Yoriaki Komeda; Mamoru Takenaka; Yasunori Minami; Hiroshi Ida; Kazuomi Ueshima; Kazuto Nishio; Masatoshi KudoLiver cancer 9 (4) 426 - 439 2020/08 [Refereed] Background and Aim: Immune checkpoint inhibitors are promising agents for the treatment of hepatocellular carcinomas (HCC) refractory to conventional therapies. To enhance the efficacy of this treatment, immunological and molecular characteristics of HCC with programmed cell death ligand 1 (PD-L1) should be explored. Methods: Clinical backgrounds, PD-L1 expression, and the amount of CD8+ tumor-infiltrating mononuclear cells (TIMCs) were analyzed in 154 HCCs. The expression of 3 stem cell markers and co-inhibitory receptors on tumor cells and TIMCs, respectively, were examined by immunohistochemical analysis. Somatic mutations in the 409 cancer-associated genes and TERT promoter were determined; HCCs were classified based on the presence of gene alterations affecting the 8 oncogenic pathways. The results were validated using the dataset from the Cancer Genome Atlas. Results: The expression of PD-L1 in the HCCs was positively correlated with progressive tumor features, the presence of cytokeratin 19 (CK19), Sal-like protein 4 (SALL4), and the mutations of genes involving the phosphatidyl inositol 3-kinase (PI3K)-Akt pathway. Although CD8+ cells were densely infiltrated in PD-L1-positive tumors, these TIMCs frequently expressed multiple co-inhibitory receptors. However, a subset of PD-L1-positive tumors characterized by activating mutations of the PI3K-Akt pathway showed a low degree of TIMCs. Conversely, PD-L1-negative HCCs were associated with mutations in the β-catenin pathway and a small number of TIMCs, although the expression of co-inhibitory receptors was rare. Conclusions: PD-L1-positive HCCs frequently showed an inflamed phenotype with stem cell features; a subset of PD-L1-positive HCCs with mutations in the PI3K-Akt pathway showed a non-inflamed phenotype. In HCCs with dense infiltration of TIMCs, CD8+ cells expressed multiple co-inhibitory receptors, suggesting T cell exhaustion. On the other hand, PD-L1-negative HCCs showed mutations leading to β-catenin activation and exhibited a non-inflamed background. These characteristics should be taken into consideration for developing novel combination therapies using immune checkpoint inhibitors.Verrucous antral gastritis in relation to Helicobacter pylori infection, nutrition, and gastric atrophy.Naoko Tsuji; Yasuko Umehara; Mamoru Takenaka; Yasunori Minami; Tomohiro Watanabe; Naoshi Nishida; Masatoshi KudoGastroenterology report 8 (4) 293 - 298 2020/08 [Refereed] Background: There have been few studies in the English literature regarding verrucous gastritis (VG). The present study investigated the clinical and endoscopic features of verrucous antral gastritis, especially focusing on Helicobacter pylori infection, nutrition, and gastric atrophy. Methods: We performed a retrospective study of patients who underwent routine endoscopy with indigo carmine chromoendoscopy and a comparative study was conducted between VG-positive and VG-negative groups. VG was subdivided into classical and numerous types based on the number and distribution of verrucous lesions. Demographic, clinical, and endoscopic data including body mass index (BMI), serum albumin and cholesterol, gastric atrophy, reflux oesophagitis, Barrett's oesophagus, and H. pylori status were collected. Univariate and multivariable analyses were performed to identify factors associated with VG. Results: We analysed the data of 621 patients undergoing routine endoscopy and found that VG (n = 352) was significantly associated with increased BMI (1.12 [1.05-1.18], P Recurrent abdominal pain caused by nephroptosis.Saki Yoshida; Mariko Matsumura; Kiyoshi Maekawa; Kosuke Minaga; Ken Kamata; Masahiro Nozawa; Tomohiro Watanabe; Masatoshi KudoClinical journal of gastroenterology 13 (4) 621 - 625 2020/08 [Refereed] Nephroptosis is a benign disorder defined as a significant descent of the affected kidney as the patient moves from supine to erect. Patients with nephroptosis sometimes manifest symptoms including abdominal pain, back pain, nausea and hematuria, while the majority of those are asymptomatic. Downward migration of the affected kidney induced by a postural change from the supine to the upright position underlies the pathophysiology of nephroptosis. The diagnosis of nephroptosis is difficult since routine imaging examinations are conducted in the supine position alone. Here, we report a case presenting recurrent abdominal pain due to unknown causes. This patient was successfully diagnosed as nephroptosis by ultrasonography and drip infusion pyelography, both of which were performed in both supine and upright positions. This case report strongly suggests that we need to take into consideration a possibility of nephroptosis when we encounter with patients complaining abdominal and/or back pain due to unknown causes.Randomised, multicentre prospective trial of transarterial chemoembolisation (TACE) plus sorafenib as compared with TACE alone in patients with hepatocellular carcinoma: TACTICS trial.Masatoshi Kudo; Kazuomi Ueshima; Masafumi Ikeda; Takuji Torimura; Nobukazu Tanabe; Hiroshi Aikata; Namiki Izumi; Takahiro Yamasaki; Shunsuke Nojiri; Keisuke Hino; Hidetaka Tsumura; Teiji Kuzuya; Norio Isoda; Kohichiroh Yasui; Hajime Aino; Akio Ido; Naoto Kawabe; Kazuhiko Nakao; Yoshiyuki Wada; Osamu Yokosuka; Kenichi Yoshimura; Takuji Okusaka; Junji Furuse; Norihiro Kokudo; Kiwamu Okita; Philip James Johnson; Yasuaki AraiGut 69 (8) 1492 - 1501 0017-5749 2020/08 [Refereed] OBJECTIVE: This trial compared the efficacy and safety of transarterial chemoembolisation (TACE) plus sorafenib with TACE alone using a newly established TACE-specific endpoint and pre-treatment of sorafenib before initial TACE. DESIGN: Patients with unresectable hepatocellular carcinoma (HCC) were randomised to TACE plus sorafenib (n=80) or TACE alone (n=76). Patients in the combination group received sorafenib 400 mg once daily for 2-3 weeks before TACE, followed by 800 mg once daily during on-demand conventional TACE sessions until time to untreatable (unTACEable) progression (TTUP), defined as untreatable tumour progression, transient deterioration to Child-Pugh C or appearance of vascular invasion/extrahepatic spread. Co-primary endpoints were progression-free survival (PFS), which is not a conventional one but defined as TTUP, or time to any cause of death plus overall survival (OS). Multiplicity was adjusted by gatekeeping hierarchical testing. RESULTS: Median PFS was significantly longer in the TACE plus sorafenib than in the TACE alone group (25.2 vs 13.5 months; p=0.006). OS was not analysed because only 73.6% of OS events were reached. Median TTUP (26.7 vs 20.6 months; p=0.02) was also significantly longer in the TACE plus sorafenib group. OS at 1 year and 2 years in TACE plus sorafenib group and TACE alone group were 96.2% and 82.7% and 77.2% and 64.6%, respectively. There were no unexpected toxicities. CONCLUSION: TACE plus sorafenib significantly improved PFS over TACE alone in patients with unresectable HCC. Adverse events were consistent with those of previous TACE combination trials. TRIAL REGISTRATION NUMBER: NCT01217034.Possible involvement of autophagy in esophageal ulcers in anorexia nervosa.Sho Masaki; Tomohiro Watanabe; Kosuke Minaga; Ken Kamata; Yoriaki Komeda; Masatomo Kimura; Masatoshi KudoClinical journal of gastroenterology 13 (4) 473 - 476 1865-7257 2020/08 [Refereed] Although patients with anorexia nervosa (AN) present with various gastrointestinal disorders, little has been understood regarding the incidence and pathophysiology of gastrointestinal ulcers related to AN. A 20-year-old woman with a past history of AN was hospitalized for further examination of dysphagia and chest pain. Her nutritional status was very poor as evidenced by very low body mass index. Esophagogastroduodenoscopy detected longitudinal and geographical ulcers in the entire circumference of the cervical and upper esophagus. Enhanced expression of autophagy-related proteins, LC3B and p62, was seen in the esophageal epithelium surrounding the active ulcers. Expression of these autophagy markers disappeared from the esophageal epithelium soon after the nutritional rehabilitation. Given the fact that starvation and malnutrition are potent inducers for autophagy, these findings suggest that autophagy might be involved in the development of gastrointestinal ulcers in patients with AN.A randomized, double-blind, placebo-controlled, phase 3 study of tivantinib in Japanese patients with MET-high hepatocellular carcinoma.Masatoshi Kudo; Manabu Morimoto; Michihisa Moriguchi; Namiki Izumi; Tetsuji Takayama; Hitoshi Yoshiji; Keisuke Hino; Takayoshi Oikawa; Tetsuhiro Chiba; Kenta Motomura; Junko Kato; Kentaro Yasuchika; Akio Ido; Takashi Sato; Daisuke Nakashima; Kazuomi Ueshima; Masafumi Ikeda; Takuji Okusaka; Kazuo Tamura; Junji FuruseCancer science 111 (10) 3759 - 3769 2020/07 [Refereed] A previous randomized phase 2 study of hepatocellular carcinoma revealed that the c-Met inhibitor tivantinib as second-line treatment significantly prolonged progression-free survival in a subpopulation whose tumor samples highly expressed c-Met (MET-high). Accordingly, this phase 3 study was conducted to evaluate the efficacy of tivantinib as a second-line treatment for Japanese patients with MET-high hepatocellular carcinoma. This randomized, double-blind, placebo-controlled study was conducted at 60 centers in Japan. Hepatocellular carcinoma patients with one prior sorafenib treatment and those with MET-high tumor samples were eligible for inclusion. Registered patients were randomly assigned to either the tivantinib or placebo group at a 2:1 ratio and were treated with twice-a-day oral tivantinib (120 mg bid) or placebo until the discontinuation criteria were met. The primary endpoint was progression-free survival while the secondary endpoints included overall survival and safety. Between January 2014 and June 2016, 386 patients provided consent, and 195 patients were randomized to the tivantinib (n = 134) or placebo (n = 61) group. Median progression-free survival was 2.8 (95% confidence interval: 2.7-2.9) and 2.3 (1.5-2.8) mo in the tivantinib and placebo groups, respectively (hazard ratio = 0.74, 95% confidence interval: 0.52-1.04, P = .082). Median overall survival was 10.3 (95% confidence interval: 8.1-11.6) and 8.5 (6.2-11.4) mo in the tivantinib and placebo group, respectively (hazard ratio = 0.82, 95% confidence interval: 0.58-1.15). The most common tivantinib-related grade ≥3 adverse events were neutropenia (31.6%), leukocytopenia (24.8%), and anemia (12.0%). This study did not confirm the significant efficacy of tivantinib as a second-line treatment for Japanese patients with MET-high hepatocellular carcinoma. (NCT02029157).Guidelines and Good Clinical Practice Recommendations for Contrast Enhanced Ultrasound (CEUS) in the Liver - Update 2020 - WFUMB in Cooperation with EFSUMB, AFSUMB, AIUM, and FLAUS.Christoph F Dietrich; Christian Pállson Nolsøe; Richard G Barr; Annalisa Berzigotti; Peter N Burns; Vito Cantisani; Maria Cristina Chammas; Nitin Chaubal; Byung Ihn Choi; Dirk-André Clevert; Xinwu Cui; Yi Dong; Mirko D'Onofrio; J Brian Fowlkes; Odd Helge Gilja; Pintong Huang; Andre Ignee; Christian Jenssen; Yuko Kono; Masatoshi Kudo; Nathalie Lassau; Won Jae Lee; Jae Young Lee; Ping Liang; Adrian Lim; Andrej Lyshchik; Maria Franca Meloni; Jean Michel Correas; Yasunori Minami; Fuminori Moriyasu; Carlos Nicolau; Fabio Piscaglia; Adrian Saftoiu; Paul S Sidhu; Ioan Sporea; Guido Torzilli; Xiaoyan Xie; Rongqin ZhengUltraschall in der Medizin (Stuttgart, Germany : 1980) 41 1 - 24 2020/07 [Refereed] The present, updated document describes the fourth iteration of recommendations for the hepatic use of contrast enhanced ultrasound (CEUS), first initiated in 2004 by the European Federation of Societies for Ultrasound in Medicine and Biology (EFSUMB). The previous updated editions of the guidelines reflected changes in the available contrast agents and updated the guidelines not only for hepatic but also for non-hepatic applications.The 2012 guideline requires updating as previously the differences of the contrast agents were not precisely described and the differences in contrast phases as well as handling were not clearly indicated. In addition, more evidence has been published for all contrast agents. The update also reflects the most recent developments in contrast agents, including the United States Food and Drug Administration (FDA) approval as well as the extensive Asian experience, to produce a truly international perspective.These guidelines and recommendations provide general advice on the use of ultrasound contrast agents (UCA) and are intended to create standard protocols for the use and administration of UCA in liver applications on an international basis to improve the management of patients.Purpura-free small intestinal IgA vasculitis complicated by cytomegalovirus reactivation.Mariko Matsumura; Yoriaki Komeda; Tomohiro Watanabe; Masatoshi KudoBMJ case reports 13 (7) 2020/07 [Refereed] IgA vasculitis (Henoch-Schönlein purpura) affects various organs, including the skin, gastrointestinal (GI) tract, joints and kidneys. Its clinical course typically consists of two phases: initial appearance of purpura and delayed onset of arthralgia, GI symptoms and haematuria. We report the case of an adult patient with IgA vasculitis of the small bowel, without skin involvement, complicated by cytomegalovirus (CMV) enteritis following prednisolone administration. Single-balloon enteroscopy revealed mucosal oedema, redness, erosions and transverse ulcers of the duodenum and jejunum. Jejunal biopsy specimens showed IgA deposition in the capillary walls. CMV reactivation was confirmed by PCR and immunostaining using jejunal biopsy specimens. This case report strongly suggests that adult patients with IgA vasculitis can present with isolated GI involvement, without characteristic skin purpura. Furthermore, CMV reactivation needs to be considered in patients with IgA vasculitis showing poor response to glucocorticoids.Prediction of Survival Among Patients Receiving Transarterial Chemoembolization for Hepatocellular Carcinoma: A Response-Based Approach.Guohong Han; Sarah Berhane; Hidenori Toyoda; Dominik Bettinger; Omar Elshaarawy; Anthony W H Chan; Martha Kirstein; Cristina Mosconi; Florian Hucke; Daniel Palmer; David J Pinato; Rohini Sharma; Diego Ottaviani; Jeong W Jang; Tim A Labeur; Otto M van Delden; Mario Pirisi; Nick Stern; Bruno Sangro; Tim Meyer; Waleed Fateen; Marta García-Fiñana; Asmaa Gomaa; Imam Waked; Eman Rewisha; Guru P Aithal; Simon Travis; Masatoshi Kudo; Alessandro Cucchetti; Markus Peck-Radosavljevic; R B Takkenberg; Stephen L Chan; Arndt Vogel; Philip J JohnsonHepatology (Baltimore, Md.) 72 (1) 198 - 212 0270-9139 2020/07 [Refereed] BACKGROUND AND AIMS: The heterogeneity of intermediate-stage hepatocellular carcinoma (HCC) and the widespread use of transarterial chemoembolization (TACE) outside recommended guidelines have encouraged the development of scoring systems that predict patient survival. The aim of this study was to build and validate statistical models that offer individualized patient survival prediction using response to TACE as a variable. APPROACH AND RESULTS: Clinically relevant baseline parameters were collected for 4,621 patients with HCC treated with TACE at 19 centers in 11 countries. In some of the centers, radiological responses (as assessed by modified Response Evaluation Criteria in Solid Tumors [mRECIST]) were also accrued. The data set was divided into a training set, an internal validation set, and two external validation sets. A pre-TACE model ("Pre-TACE-Predict") and a post-TACE model ("Post-TACE-Predict") that included response were built. The performance of the models in predicting overall survival (OS) was compared with existing ones. The median OS was 19.9 months. The factors influencing survival were tumor number and size, alpha-fetoprotein, albumin, bilirubin, vascular invasion, cause, and response as assessed by mRECIST. The proposed models showed superior predictive accuracy compared with existing models (the hepatoma arterial embolization prognostic score and its various modifications) and allowed for patient stratification into four distinct risk categories whose median OS ranged from 7 months to more than 4 years. CONCLUSIONS: A TACE-specific and extensively validated model based on routinely available clinical features and response after first TACE permitted patient-level prognostication.膵管狭窄症例におけるCT間接所見の検討 微小膵癌と良性膵管狭窄症例の比較山雄 健太郎; 竹中 完; 松本 逸平; 竹山 宜典; 沼本 勲男; 鶴崎 正勝; 工藤 正俊膵臓 (一社)日本膵臓学会 35 (3) A345 - A345 0913-0071 2020/07自己免疫性膵胆道疾患診療の課題と展望 転写因子IRF7の活性化からみた自己免疫性膵炎の病態解明三長 孝輔; 渡邉 智裕; 工藤 正俊日本消化器病学会雑誌 (一財)日本消化器病学会 117 (臨増総会) A200 - A200 0446-6586 2020/07血清IFN-α/IL-33が治療効果判定に有用と考えられた自己免疫性膵炎の1例原 茜; 三長 孝輔; 吉川 智恵; 鎌田 研; 渡邉 智裕; 工藤 正俊日本消化器病学会雑誌 (一財)日本消化器病学会 117 (臨増総会) A299 - A299 0446-6586 2020/07急性膵炎に対する局所合併症治療 Walled-off necrosisに対するLAMS with 10 FrENCD持続洗浄治療の有用性について竹中 完; 石川 嶺; 岡本 彩那; 中井 敦史; 山崎 友裕; 大本 俊介; 三長 孝輔; 鎌田 研; 山雄 健太郎; 松本 逸平; 竹山 宜典; 工藤 正俊膵臓 (一社)日本膵臓学会 35 (3) A209 - A209 0913-0071 2020/07「KINDAI20」を用いたコンベックスEUSの教育について大本 俊介; 竹中 完; 工藤 正俊膵臓 (一社)日本膵臓学会 35 (3) A330 - A330 0913-0071 2020/07PanNETG1/G2における造影ハーモニックEUSの悪性度評価の有用性に関する検討石川 嶺; 鎌田 研; 田中 秀和; 岡本 彩那; 山崎 友裕; 中井 敦史; 大本 俊介; 三長 孝輔; 竹中 完; 工藤 正俊膵臓 (一社)日本膵臓学会 35 (3) A367 - A367 0913-0071 2020/07EUS施行時の鎮静方法の検討岡本 彩那; 鎌田 研; 河野 辰哉; 田中 秀和; 石川 嶺; 山崎 友裕; 中井 敦史; 大本 俊介; 三長 孝輔; 山雄 健太郎; 竹中 完; 工藤 正俊日本消化器病学会雑誌 (一財)日本消化器病学会 117 (臨増総会) A389 - A389 0446-6586 2020/07肝癌薬物療法の最前線 TACE不適Intermediate-stage肝細胞癌に対するLenvatinib先行投与の有用性青木 智子; 上嶋 一臣; 工藤 正俊日本消化器病学会雑誌 (一財)日本消化器病学会 117 (臨増総会) A52 - A52 0446-6586 2020/07チロシンキナーゼ阻害薬時代に注意すべき肝細胞癌の遠隔転移大塚 康生; 青木 智子; 南 知宏; 田北 雅弘; 萩原 智; 南 康範; 依田 広; 上嶋 一臣; 西田 直生志; 工藤 正俊日本消化器病学会雑誌 (一財)日本消化器病学会 117 (臨増総会) A291 - A291 0446-6586 2020/07自己免疫性膵胆道疾患診療の課題と展望 転写因子IRF7の活性化からみた自己免疫性膵炎の病態解明三長 孝輔; 渡邉 智裕; 工藤 正俊日本消化器病学会雑誌 (一財)日本消化器病学会 117 (臨増総会) A200 - A200 0446-6586 2020/07血清IFN-α/IL-33が治療効果判定に有用と考えられた自己免疫性膵炎の1例原 茜; 三長 孝輔; 吉川 智恵; 鎌田 研; 渡邉 智裕; 工藤 正俊日本消化器病学会雑誌 (一財)日本消化器病学会 117 (臨増総会) A299 - A299 0446-6586 2020/07EUS施行時の鎮静方法の検討岡本 彩那; 鎌田 研; 河野 辰哉; 田中 秀和; 石川 嶺; 山崎 友裕; 中井 敦史; 大本 俊介; 三長 孝輔; 山雄 健太郎; 竹中 完; 工藤 正俊日本消化器病学会雑誌 (一財)日本消化器病学会 117 (臨増総会) A389 - A389 0446-6586 2020/07急性膵炎に対する局所合併症治療 Walled-off necrosisに対するLAMS with 10 FrENCD持続洗浄治療の有用性について竹中 完; 石川 嶺; 岡本 彩那; 中井 敦史; 山崎 友裕; 大本 俊介; 三長 孝輔; 鎌田 研; 山雄 健太郎; 松本 逸平; 竹山 宜典; 工藤 正俊膵臓 (一社)日本膵臓学会 35 (3) A209 - A209 0913-0071 2020/07PanNETG1/G2における造影ハーモニックEUSの悪性度評価の有用性に関する検討石川 嶺; 鎌田 研; 田中 秀和; 岡本 彩那; 山崎 友裕; 中井 敦史; 大本 俊介; 三長 孝輔; 竹中 完; 工藤 正俊膵臓 (一社)日本膵臓学会 35 (3) A367 - A367 0913-0071 2020/07膵管狭窄症例におけるCT間接所見の検討 微小膵癌と良性膵管狭窄症例の比較山雄 健太郎; 竹中 完; 松本 逸平; 竹山 宜典; 沼本 勲男; 鶴崎 正勝; 工藤 正俊膵臓 (一社)日本膵臓学会 35 (3) A345 - A345 0913-0071 2020/07Partial Pancreatic Parenchymal Atrophy Is a New Specific Finding to Diagnose Small Pancreatic Cancer (≤10 mm) Including Carcinoma in Situ: Comparison with Localized Benign Main Pancreatic Duct Stenosis Patients.Kentaro Yamao; Mamoru Takenaka; Rei Ishikawa; Ayana Okamoto; Tomohiro Yamazaki; Atsushi Nakai; Shunsuke Omoto; Ken Kamata; Kosuke Minaga; Ippei Matsumoto; Yoshifumi Takeyama; Isao Numoto; Masakatsu Tsurusaki; Takaaki Chikugo; Yasutaka Chiba; Tomohiro Watanabe; Masatoshi KudoDiagnostics (Basel, Switzerland) 10 (7) 2020/07 [Refereed] BACKGROUND: This study aimed to evaluate and identify the specific CT findings by focusing on abnormalities in the main pancreatic duct (MPD) and pancreatic parenchyma in patients with small pancreatic cancer (PC) including carcinoma in situ (CIS). METHODS: Nine CT findings indicating abnormalities of MPD and pancreatic parenchyma were selected as candidate findings for the presence of small PC ≤ 10 mm. The proportions of patients positive for each finding were compared between small PC and benign MPD stenosis groups. Interobserver agreement between two independent image reviewers was evaluated using kappa statistics. RESULTS: The final analysis included 24 patients with small PC (including 11 CIS patients) and 28 patients with benign MPD stenosis. The proportion of patients exhibiting partial pancreatic parenchymal atrophy (PPA) corresponding to the distribution of MPD stenosis (45.8% vs. 7.1%, p The AFSUMB Consensus Statements and Recommendations for the Clinical Practice of Contrast-Enhanced Ultrasound using Sonazoid.Jae Young Lee; Yasunori Minami; Byung Ihn Choi; Won Jae Lee; Yi-Hong Chou; Woo Kyoung Jeong; Mi-Suk Park; Nobuki Kudo; Min Woo Lee; Ken Kamata; Hiroko Iijima; So Yeon Kim; Kazushi Numata; Katsutoshi Sugimoto; Hitoshi Maruyama; Yasukiyo Sumino; Chikara Ogawa; Masayuki Kitano; Ijin Joo; Junichi Arita; Ja-Der Liang; Hsi-Ming Lin; Christian Nolsoe; Odd Helge Gilja; Masatoshi KudoUltrasonography (Seoul, Korea) 39 (3) 191 - 220 2020/07 [Refereed] The first edition of the guidelines for the use of ultrasound contrast agents was published in 2004, dealing with liver applications. The second edition of the guidelines in 2008 reflected changes in the available contrast agents and updated the guidelines for the liver, as well as implementing some nonliver applications. The third edition of the contrast-enhanced ultrasound (CEUS) guidelines was the joint World Federation for Ultrasound in Medicine and Biology-European Federation of Societies for Ultrasound in Medicine and Biology (WFUMB-EFSUMB) venture in conjunction with other regional US societies such as Asian Federation of Societies for Ultrasound in Medicine and Biology, resulting in a simultaneous duplicate on liver CEUS in the official journals of both WFUMB and EFSUMB in 2013. However, no guidelines were described mainly for Sonazoid due to limited clinical experience only in Japan and Korea. The new proposed consensus statements and recommendations provide general advice on the use of Sonazoid and are intended to create standard protocols for the use and administration of Sonazoid in hepatic and pancreatobiliary applications in Asian patients and to improve patient management.Endoscopic ultrasound-guided radiofrequency ablation of porcine liver.Shuya Maeshima; Yoshiyuki Ida; Ryo Shimizu; Yuki Kawaji; Takashi Tamura; Junya Nuta; Keiichi Hatamaru; Masahiro Itonaga; Masatoshi Kudo; Masayuki KitanoJournal of medical ultrasonics (2001) 47 (3) 435 - 443 2020/07 [Refereed] PURPOSE: Animal studies of endoscopic ultrasound-guided radiofrequency ablation (EUS-RFA) of the liver have rarely been reported. We assessed the effectiveness and safety of EUS-RFA in pigs. METHODS: We conducted four experiments using newly designed RFA electrodes. In the first experiment, we ablated excised liver using 19 G electrodes with active electrode tips with lengths of 1, 1.5, and 2 cm. The second experiment was performed with the same electrodes as those used in the first experiment, but with the electrodes inserted into the livers of live pigs under EUS. In the third experiment, we tested the electrodes for water permeability. In the fourth experiment, we performed EUS-RFA on live pigs, using 19 G electrodes in 7/12 pigs and 18 G electrodes in 5/12 pigs. Complications were evaluated after 7 days of survival. RESULTS: The newly designed RFA electrodes achieved ablation of the liver. In the first experiment, the maximal sizes of the ablation areas were 27, 26, 24, and 25 mm at 10, 20, 30, and 40 W, respectively, with the 2-cm electrode. In the second experiment, the maximal vertical sizes were 22, 23, 22, and 23 mm at 10, 20, 30, and 40 W, respectively, with the 2-cm electrode. In the third experiment, the 18 G electrode had better water permeability than the 19 G electrode. In the fourth experiment, all pigs survived. Complications occurred in 1/5 (18 G electrode) and 4/7 (19 G electrode) pigs. CONCLUSION: We performed EUS-RFA in pigs and concluded that it may be feasible to perform RFA of lesions near the stomach.Liver Resection for Multiple Hepatocellular Carcinomas: A Japanese Nationwide Survey.Yasuyuki Fukami; Yuji Kaneoka; Atsuyuki Maeda; Takashi Kumada; Junko Tanaka; Tomoyuki Akita; Shoji Kubo; Namiki Izumi; Masumi Kadoya; Michiie Sakamoto; Osamu Nakashima; Yutaka Matsuyama; Takashi Kokudo; Kiyoshi Hasegawa; Tatsuya Yamashita; Kosuke Kashiwabara; Tadatoshi Takayama; Norihiro Kokudo; Masatoshi KudoAnnals of surgery 272 (1) 145 - 154 2020/07 [Refereed] OBJECTIVE: The aim of the study was to evaluate the survival benefits of liver resection (LR) compared with transarterial chemoembolization (TACE) for patients with multiple hepatocellular carcinomas (HCCs). BACKGROUND: Despite significant improvements in diagnostic imaging and the widespread application of screening programs, some patients with HCC continue to present with multiple tumors. The surgical indications for multiple HCCs remain controversial. METHODS: Among 77,268 patients with HCC reported in a Japanese nationwide survey, 27,164 patients had multiple HCCs. The exclusion criteria were Child-Pugh B/C, treatment other than LR and TACE, >3 tumors, and insufficient available data. Ultimately, 3246 patients (LR: n = 1944, TACE: n = 1302) were included. The survival benefit of LR for patients multiple HCCs was evaluated by using propensity score matching analysis. RESULTS: The study group of 2178 patients (LR: n = 1089, TACE: n = 1089) seemed to be well matched. The overall survival rate in the LR group was 60.0% at 5 years, which was higher than that in the TACE group (41.6%, P Treatment of Hepatocellular Carcinoma (HCC) during the COVID-19 Outbreak: The Working Group Report of JAMTT-HCC.Masatoshi Kudo; Masayuki Kurosaki; Masafumi Ikeda; Hiroshi Aikata; Atsushi Hiraoka; Takuji Torimura; Naoya SakamotoHepatology research : the official journal of the Japan Society of Hepatology 50 (9) 1004 - 1014 2020/06 [Refereed] This contingency guide was formulated on the premise that delivering standard treatment for hepatocellular carcinoma (HCC) has come under strain due to the COVID-19 pandemic. Measures required are likely to vary largely across regions and individual institutions, depending on the level of the strain imposed by the pandemic (e.g., number of inpatients infected with COVID-19 and the availability of resources, including personal protective equipment and inpatient beds). Also, models suggest that second and third waves of COVID-19 will occur before effective vaccines and medicines become widely available in Japan (expected time, 2-3 years). This guide should serve as a good reference for best practices in the management of HCC in light of the possible risk of impending collapse of the healthcare system due to a surge in COVID-19 infections.Improved liver metastasis detection using Kupffer-phase imaging in contrast-enhanced harmonic EUS in patients with pancreatic cancer (with video).Kosuke Minaga; Masayuki Kitano; Atsushi Nakai; Shunsuke Omoto; Ken Kamata; Kentaro Yamao; Mamoru Takenaka; Masakatsu Tsurusaki; Takaaki Chikugo; Ippei Matsumoto; Yasutaka Chiba; Tomohiro Watanabe; Masatoshi KudoGastrointestinal endoscopy Elsevier BV 93 (2) 433 - 441 0016-5107 2020/06 [Refereed] BACKGROUND AND AIMS: Kupffer-phase imaging visualized by Sonazoid distribution into normal liver tissues upon phagocytosis by Kupffer cells, potentially aids in improving liver metastasis detection compared with fundamental B-mode EUS (FB-EUS). However, the diagnostic performance of Kupffer-phase imaging in contrast-enhanced harmonic EUS (CH-EUS) remains unclear. Hence, this study aimed to evaluate the usefulness of CH-EUS-based Kupffer-phase imaging for diagnosing liver metastasis from pancreatic cancer. METHODS: We retrospectively analyzed consecutive patients with pancreatic cancer who underwent contrast-enhanced CT (CE-CT) and FB-EUS, followed by CH-EUS, from 2011 to 2017. The diagnostic ability of CH-EUS against that of CE-CT and FB-EUS for left-lobe liver metastasis was compared. Subsequently, the influences of CH-EUS on the determination of clinical stage and patient management for pancreatic cancer were assessed. RESULTS: We enrolled 426 patients with pancreatic cancer. The left-lobe liver metastasis was present in 27.2% of patients. The diagnostic accuracy of CE-CT, FB-EUS, and CH-EUS was 90.6%, 93.4%, and 98.4%, respectively. The sensitivity and diagnostic accuracy of CH-EUS for left-lobe liver metastasis were significantly higher than those of FB-EUS or CE-CT. The sensitivity of CH-EUS for detecting small liver metastasis (全身疾患/薬物副作用と消化器内視鏡 ダビガトランによる食道粘膜傷害の検討益田 康弘; 松井 繁長; 辻 直子; 樫田 博史; 工藤 正俊日本消化器内視鏡学会近畿支部例会プログラム・抄録集 日本消化器内視鏡学会-近畿支部 104回 39 - 39 2020/06【知っておきたい新たな処置具-特徴とその開発意図】ERCP関連 Uneven Double Lumen Cannula竹中 完; 三長 孝輔; 鎌田 研; 山雄 健太郎; 工藤 正俊消化器内視鏡 (株)東京医学社 32 (6) 862 - 864 0915-3217 2020/06【IgG4関連疾患の新展開】IgG4関連疾患と自然免疫渡邉 智裕; 吉川 智恵; 原 茜; 鎌田 研; 三長 孝輔; 工藤 正俊炎症と免疫 (株)先端医学社 28 (4) 310 - 314 0918-8371 2020/06 IgG4関連疾患の病態生理については明らかになっていないものの、研究者らは自己抗原の同定・獲得免疫反応の解明・自然免疫反応の解明の3つのアプローチから病態に迫っている。IgG4関連疾患の病態にかかわる自然免疫担当細胞として、形質細胞様樹状細胞・M2マクロファージ・好塩基球が同定されている。さらに、IFN-α・IL-33などのサイトカインが慢性炎症や線維化を誘導すると考えられている。IgG4関連疾患の発症にかかわる自然免疫反応の解明は、病態生理の解明のみならず新規治療法の開発にもつながる可能性がある。(著者抄録)Better Efficacy of Ramucirumab in Japanese Patients than in the Global Population with Unresectable Hepatocellular Carcinoma.Masatoshi KudoLiver cancer 9 (3) 232 - 244 2020/06 [Refereed]A Changing Paradigm for the Treatment of Intermediate-Stage Hepatocellular Carcinoma: Asia-Pacific Primary Liver Cancer Expert Consensus Statements.Masatoshi Kudo; Kwang-Hyub Han; Sheng-Long Ye; Jian Zhou; Yi-Hsiang Huang; Shi-Ming Lin; Chung-Kwe Wang; Masafumi Ikeda; Stephen Lam Chan; Su Pin Choo; Shiro Miyayama; Ann Lii ChengLiver cancer 9 (3) 245 - 260 2020/06 [Refereed] The Asia-Pacific Primary Liver Cancer Expert (APPLE) Consensus Statement on the treatment strategy for patients with intermediate-stage hepatocellular carcinoma (HCC) was established on August 31, 2019, in Sapporo, Hokkaido during the 10th Annual APPLE Meeting. This manuscript summarizes the international consensus statements developed at APPLE 2019. Transarterial chemoembolization (TACE) is the only guideline-recommended global standard of care for intermediate-stage HCC. However, not all patients benefit from TACE because intermediate-stage HCC is a heterogeneous disease in terms of tumor burden and liver function. Ten important clinical questions regarding this stage of HCC were raised, and consensus statements were generated based on high-quality evidence. In intermediate-stage HCC, preservation of liver function is as important as achieving a high objective response (OR) because the treatment goal is to prolong overall survival. Superselective conventional TACE (cTACE) is recommended as the first choice of treatment in patients eligible for effective (curative) TACE, whereas in patients who are not eligible, systemic therapy is recommended as the first choice of treatment. TACE is not indicated as the first-line therapy in TACE-unsuitable patients. Another important statement is that TACE should not be continued in patients who develop TACE failure/refractoriness in order to preserve liver function. Targeted therapy is the recommended first-line treatment for TACE-unsuitable patients. Especially, the drug, which can have higher OR rate, is preferred. Immunotherapy, transarterial radioembolization, TACE + targeted therapy or other modalities may be considered alternative options in TACE-unsuitable patients who are not candidates for targeted therapy. Better liver function, such as albumin-bilirubin grade 1, is an important factor for maximizing the therapeutic effect of systemic therapy.Benefits, Open questions and Challenges of the use of Ultrasound in the COVID-19 pandemic era. The views of a panel of worldwide international experts.Fabio Piscaglia; Federico Stefanini; Vito Cantisani; Paul S Sidhu; Richard Barr; Annalisa Berzigotti; Maria Cristina Chammas; Jean-Michel Correas; Christoph Frank Dietrich; Steven Feinstein; Pintong Huang; Christian Jenssen; Yuko Kono; Masatoshi Kudo; Ping Liang; Andrej Lyshchik; Christian Nolsøe; Xyaoyan Xie; Francesco TovoliUltraschall in der Medizin (Stuttgart, Germany : 1980) 41 (3) 228 - 236 2020/06 [Refereed]Ramucirumab after prior sorafenib in patients with advanced hepatocellular carcinoma and elevated alpha-fetoprotein: Japanese subgroup analysis of the REACH-2 trial.Masatoshi Kudo; Takuji Okusaka; Kenta Motomura; Izumi Ohno; Manabu Morimoto; Satoru Seo; Yoshiyuki Wada; Shinpei Sato; Tatsuya Yamashita; Masayuki Furukawa; Takeshi Aramaki; Seijin Nadano; Kazuyoshi Ohkawa; Hirofumi Fujii; Toshihiro Kudo; Junji Furuse; Hiroki Takai; Gosuke Homma; Reigetsu Yoshikawa; Andrew X ZhuJournal of gastroenterology 55 (6) 627 - 639 2020/06 [Refereed] BACKGROUND: The global, randomized, phase 3 REACH-2 study (ClinicalTrials.gov identifier: NCT02435433) found significantly longer overall survival (OS) for second-line ramucirumab versus placebo (hazard ratio [HR]: 0.710, 95% confidence interval [CI] 0.531-0.949, P = 0.0199) in patients with advanced hepatocellular carcinoma (HCC) and alpha-fetoprotein (AFP) ≥ 400 ng/mL. This prespecified subgroup analysis evaluated the efficacy and safety of ramucirumab in the Japanese patients enrolled in the study. METHODS: Patients with advanced HCC and AFP ≥ 400 ng/mL after first-line sorafenib were randomized 2:1 to ramucirumab (8 mg/kg intravenously) or placebo every 2 weeks. Hazard ratios for progression-free survival (PFS) and OS (primary endpoint of the overall study) were estimated using the stratified Cox regression model. We also pooled individual patient data from REACH-2 with data from REACH (NCT01140347) for patients with AFP ≥ 400 ng/mL. RESULTS: In the Japanese REACH-2 subpopulation, there were improvements for ramucirumab (n = 41) versus placebo (n = 18) in PFS (HR 0.282, 95% CI 0.144-0.553) and OS was numerically prolonged (HR 0.599, 95% CI 0.303-1.187), consistent with the significant benefit seen in the overall REACH-2 study population. In the ramucirumab and placebo arms, respectively, the objective response rate was 7.3% and 0%, and the disease control rate was 70.7% and 33.3%. The most frequently reported grade ≥ 3 treatment-emergent adverse event was hypertension (ramucirumab: 15%; placebo: 11%). CONCLUSIONS: Ramucirumab after prior sorafenib improved PFS and OS compared with placebo, with a manageable safety profile, in the Japanese REACH-2 subpopulation, consistent with the overall REACH-2 study results. Ramucirumab is the first agent to demonstrate clinical benefit for Japanese patients with HCC in the second-line setting.Trial Design and Endpoints in hepatocellular carcinoma: AASLD Consensus Conference.Josep M Llovet; Augusto Villanueva; Jorge A Marrero; Myron Schwartz; Tim Meyer; Peter R Galle; Riccardo Lencioni; Tim F Greten; Masatoshi Kudo; Sumithra J Mandrekar; Andrew X Zhu; Richard S Finn; Lewis R RobertsHepatology (Baltimore, Md.) 2020/05 [Refereed] Proper trial design is critical for the success of clinical investigations. Hepatocellular carcinoma (HCC) is a complex disease that has several unique properties. In 2008, after the approval of sorafenib, a panel of experts proposed guidelines for trial design and endpoints in HCC that have been instrumental during the last decade and provided a framework to allow an homogeneous analysis of reported investigations. Since then, several phase III studies have been reported and novel challenges have emerged. A panel of experts conveyed by AASLD organized a Special Topic Conference on trial design and endpoints to address those emerging challenges. This review summarizes the analysis and conclusions of those discussions and provides novel recommendations on the selection endpoints, stratification variables and targeted populations in the complex arena of HCC. We have covered the full spectrum of the disease, from surveillance/ chemoprevention, to neoadjuvant and adjuvant trials after curative therapies, and trials in intermediate and advanced stages of HCC. We explore the prospects for incorporating biomarkers and liquid biopsy into conventional clinical trials. In addition, we address the need for obtaining tissue and blood samples in all investigations and propose novel primary endpoints such as progression free survival with restrictive rules and patient reported outcomes. This up-dated set of recommendations is timely considering the advent of more potent combination therapies in all areas of HCC management, the increase in adverse events associated with those combinations, and the evidence that several lines of effective treatments will benefit a given patient. We herein articulate a framework to facilitate capturing the efficacy of novel therapeutic strategies with the goal of improving the outcomes of patients suffering from this disease.Immune Phenotype and Immune Checkpoint Inhibitors for the Treatment of Human Hepatocellular Carcinoma.Naoshi Nishida; Masatoshi KudoCancers 12 (5) 2020/05 [Refereed] Immunotherapies are promising approaches for treating hepatocellular carcinomas (HCCs) refractory to conventional therapies. However, a recent clinical trial of immune checkpoint inhibitors (ICIs) revealed that anti-tumor responses to ICIs are not satisfactory in HCC cases. Therefore, it is critical to identify molecular markers to predict outcome and develop novel combination therapies that enhance the efficacy of ICIs. Recently, several attempts have been made to classify HCC based on genome, epigenome, and transcriptome analyses. These molecular classifications are characterized by unique clinical and histological features of HCC, as well immune phenotype. For example, HCCs exhibiting gene expression patterns with proliferation signals and stem cell markers are associated with the enrichment of immune infiltrates in tumors, suggesting immune-proficient characteristics for this type of HCC. However, the presence of activating mutations in β-catenin represents a lack of immune infiltrates and refractoriness to ICIs. Although the precise mechanism that links the immunological phenotype with molecular features remains controversial, it is conceivable that alterations of oncogenic cellular signaling in cancer may lead to the expression of immune-regulatory molecules and result in the acquisition of specific immunological microenvironments for each case of HCC. Therefore, these molecular and immune characteristics should be considered for the management of HCC using immunotherapy.Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma.Richard S Finn; Shukui Qin; Masafumi Ikeda; Peter R Galle; Michel Ducreux; Tae-You Kim; Masatoshi Kudo; Valeriy Breder; Philippe Merle; Ahmed O Kaseb; Daneng Li; Wendy Verret; Derek-Zhen Xu; Sairy Hernandez; Juan Liu; Chen Huang; Sohail Mulla; Yulei Wang; Ho Yeong Lim; Andrew X Zhu; Ann-Lii ChengThe New England journal of medicine 382 (20) 1894 - 1905 2020/05 [Refereed] BACKGROUND: The combination of atezolizumab and bevacizumab showed encouraging antitumor activity and safety in a phase 1b trial involving patients with unresectable hepatocellular carcinoma. METHODS: In a global, open-label, phase 3 trial, patients with unresectable hepatocellular carcinoma who had not previously received systemic treatment were randomly assigned in a 2:1 ratio to receive either atezolizumab plus bevacizumab or sorafenib until unacceptable toxic effects occurred or there was a loss of clinical benefit. The coprimary end points were overall survival and progression-free survival in the intention-to-treat population, as assessed at an independent review facility according to Response Evaluation Criteria in Solid Tumors, version 1.1 (RECIST 1.1). RESULTS: The intention-to-treat population included 336 patients in the atezolizumab-bevacizumab group and 165 patients in the sorafenib group. At the time of the primary analysis (August 29, 2019), the hazard ratio for death with atezolizumab-bevacizumab as compared with sorafenib was 0.58 (95% confidence interval [CI], 0.42 to 0.79; PSerum Levels of α-Fetoprotein Increased More Than 10 Years Before Detection of Hepatocellular Carcinoma.David M Hughes; Sarah Berhane; C A Emily de Groot; Hidenori Toyoda; Toshifumi Tada; Takashi Kumada; Shinji Satomura; Naoshi Nishida; Masatoshi Kudo; Toru Kimura; Yukio Osaki; Ruwanthi Kolamunage-Dona; Ruben Amoros Salvador; Tom Bird; Marta Garcίa-Fiñana; Philip JohnsonClinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association 19 (1) 162 - 170 2020/05 [Refereed] BACKGROUND & AIMS: Ultrasound (US)-based screening has been recommended for patients with an increased risk of hepatocellular carcinoma (HCC). US analysis, however, is limited in patients who are obese or have small tumors. The addition of serum level of α-fetoprotein (AFP) measurements to US analysis can increase detection of HCC. We analyzed data from patients with chronic liver disease, collected over 15 years in an HCC surveillance program, to develop a model to assess risk of HCC. METHODS: We collected data from 3450 patients with chronic liver disease undergoing US surveillance in Japan from March 1998 through April 2014, and followed them up for a median of 8.83 years. We performed longitudinal discriminant analysis of serial AFP measurements (median number of observations/patient, 56; approximately every 3 months) to develop a model to determine the risk of HCC. We validated the model using data from 2 cohorts of patients with chronic liver disease in Japan (404 and 2754 patients) and 1 cohort in Scotland (1596 patients). RESULTS: HCC was detected in 413 patients (median tumor diameter, 1.8 cm), during a median follow-up time of 6.60 years. In the development data set, the model identified patients who developed HCC with an area under the curve of 0.78; it correctly identified 74.3% of patients who did develop HCC, and 72.9% of patients who did not. Overall, 73.1% of patients were classified correctly. The model could be used to assign patients to a high-risk group (27.5 HCCs/1000 patient-years) vs a low-risk group (4.9 HCCs/1000 patient-years). A similar performance was observed when the model was used to assess patients with cirrhosis. Analysis of the validation cohorts produced similar results. CONCLUSIONS: We developed and validated a model to identify patients with chronic liver disease who are at risk for HCC based on change in serum AFP level over time. The model could be used to assign patients to high-risk vs low-risk groups, and might be used to select patients for surveillance.Novel concept of bared type metallic stent for endoscopic bilateral stent-in-stent placement in patients with hilar malignant biliary obstruction (with video).Mamoru Takenaka; Atsushi Nakai; Masatoshi KudoJournal of hepato-biliary-pancreatic sciences 27 (5) 282 - 283 1868-6974 2020/05 [Refereed] Highlight Takenaka and colleagues report on a novel bare uncovered self-expandable metal stent developed to be compatible with only 0.025-inch guide wires. This unprecedented feature makes the delivery tip thinner and more flexible than the conventional type and useful for endoscopic bilateral stent-in-stent placement in patients with hilar malignant biliary obstruction.Revisionary antireflux metal stent placement for stent occlusion after endoscopic ultrasound-guided hepaticojejunostomy.Kosuke Minaga; Mamoru Takenaka; Ayana Okamoto; Shunsuke Omoto; Ken Kamata; Kentaro Yamao; Masatoshi KudoEndoscopy 52 (5) E152-E153  0013-726X 2020/05 [Refereed]【US Today 2020 超音波検査・診断最前線-表在(乳腺・甲状腺)領域の最新動向を中心に】表在(乳腺・甲状腺)領域の技術と臨床の最新動向 AI超音波診断の最新動向と今後の展望椎名 毅; 山川 誠; 西田 直生志; 工藤 正俊; 津川 浩一郎; 中島 康雄INNERVISION (株)インナービジョン 35 (6) 47 - 49 0913-8919 2020/05 人工知能(AI)による医療画像診断の研究は、かつては医師の思考過程をいかにまねるかに注力していた。すなわち、画像から所見(特徴量)を抽出し、疾患と特徴量との関係性について医師の専門知識と経験をモデル化する必要があったが、いずれも容易ではなかった。しかし、近年のビックデータ時代の到来と、深層学習(deep learning)を中心とする機械学習の進歩により、特徴抽出やモデル化の処理が不要となり、さらにAI画像診断の精度が飛躍的に向上したことで、実用化が一気に加速化した。実際、眼底写真、病理標本、皮膚病変、胸部X線、内視鏡などのAI診断で、すでに専門医と同等レベルか、それを凌駕する結果が報告されている。ここで重要なのは、AIに対して大量かつ良質な教師データを与えることであるが、超音波画像データの取得に際しては、術者依存性、機種依存性、多くの画質パラメータなど、画像の多様性が高く、データベース構築やAI開発に際してのハードルとなっていた。このため、日本超音波医学会(以下、JSUM)は、2018年から日本医療研究開発機構(以下、AMED)の「臨床研究等ICT基盤構築・人工知能実装研究事業」で、超音波画像の大規模なデータベースの構築とAI診断システムの開発に取り組んでいる。本稿では、このプロジェクトの試みの一例として超音波画像から肝腫瘤および乳腺腫瘤タイプを推定するAI診断技術の開発の現状を紹介したい。(著者抄録)Phase I study of bintrafusp alfa, a bifunctional fusion protein targeting TGF-β and PD-L1, in patients with pretreated biliary tract cancer.Changhoon Yoo; Do-Youn Oh; Hye Jin Choi; Masatoshi Kudo; Makoto Ueno; Shunsuke Kondo; Li-Tzong Chen; Motonobu Osada; Christoph Helwig; Isabelle Dussault; Masafumi IkedaJournal for immunotherapy of cancer 8 (1) 2020/05 [Refereed] BACKGROUND: Patients with biliary tract cancer (BTC) have poor prognosis with few treatment options. Bintrafusp alfa, a first-in-class bifunctional fusion protein composed of the extracellular domain of the transforming growth factor (TGF)-βRII receptor (a TGF-β 'trap') fused to a human IgG1 antibody blocking programmed death ligand 1 (PD-L1), has shown clinical efficacy in multiple solid tumors. METHODS: In this phase I, open-label trial expansion cohort, Asian patients with BTC whose disease progressed after first-line chemotherapy received bintrafusp alfa 1200 mg every 2 weeks until disease progression, unacceptable toxicity, or withdrawal. The primary endpoint is safety/tolerability, while the secondary endpoints include best overall response per Response Evaluation Criteria in Solid Tumors version 1.1. RESULTS: As of August 24, 2018, 30 patients have received bintrafusp alfa for a median of 8.9 (IQR 5.7-32.1) weeks; 3 patients remained on treatment for >59.7 weeks. Nineteen (63%) patients experienced treatment-related adverse events (TRAEs), most commonly rash (17%), maculopapular rash and fever (13% each), and increased lipase (10%). Eleven (37%) patients had grade ≥3 TRAEs; three patients had grade 5 events (septic shock due to bacteremia, n=1; interstitial lung disease (reported term: interstitial pneumonitis), n=2). The objective response rate was 20% (95% CI 8 to 39) per independent review committee (IRC), with five of six responses ongoing (12.5+ to 14.5+ months) at data cut-off. Two additional patients with durable stable disease had a partial response per investigator. Median progression-free survival assessed by IRC and overall survival were 2.5 months (95% CI 1.3 to 5.6) and 12.7 months (95% CI 6.7 to 15.7), respectively. Clinical activity was observed irrespective of PD-L1 expression and microsatellite instability-high status. CONCLUSIONS: Bintrafusp alfa had clinical activity in Asian patients with pretreated BTC, with durable responses. Based on these results, bintrafusp alfa is under further investigation in patients with BTC (NCT03833661 and NCT04066491). TRIAL REGISTRATION NUMBER: NCT02699515.【US Today 2020 超音波検査・診断最前線-表在(乳腺・甲状腺)領域の最新動向を中心に】表在(乳腺・甲状腺)領域の技術と臨床の最新動向 AI超音波診断の最新動向と今後の展望椎名 毅; 山川 誠; 西田 直生志; 工藤 正俊; 津川 浩一郎; 中島 康雄INNERVISION (株)インナービジョン 35 (6) 47 - 49 0913-8919 2020/05 [Refereed] 人工知能(AI)による医療画像診断の研究は、かつては医師の思考過程をいかにまねるかに注力していた。すなわち、画像から所見(特徴量)を抽出し、疾患と特徴量との関係性について医師の専門知識と経験をモデル化する必要があったが、いずれも容易ではなかった。しかし、近年のビックデータ時代の到来と、深層学習(deep learning)を中心とする機械学習の進歩により、特徴抽出やモデル化の処理が不要となり、さらにAI画像診断の精度が飛躍的に向上したことで、実用化が一気に加速化した。実際、眼底写真、病理標本、皮膚病変、胸部X線、内視鏡などのAI診断で、すでに専門医と同等レベルか、それを凌駕する結果が報告されている。ここで重要なのは、AIに対して大量かつ良質な教師データを与えることであるが、超音波画像データの取得に際しては、術者依存性、機種依存性、多くの画質パラメータなど、画像の多様性が高く、データベース構築やAI開発に際してのハードルとなっていた。このため、日本超音波医学会(以下、JSUM)は、2018年から日本医療研究開発機構(以下、AMED)の「臨床研究等ICT基盤構築・人工知能実装研究事業」で、超音波画像の大規模なデータベースの構築とAI診断システムの開発に取り組んでいる。本稿では、このプロジェクトの試みの一例として超音波画像から肝腫瘤および乳腺腫瘤タイプを推定するAI診断技術の開発の現状を紹介したい。(著者抄録)IMbrave 050: a Phase III trial of atezolizumab plus bevacizumab in high-risk hepatocellular carcinoma after curative resection or ablation.Stephen P Hack; Jessica Spahn; Minshan Chen; Ann-Lii Cheng; Ahmed Kaseb; Masatoshi Kudo; Han Chu Lee; Adam Yopp; Pierce Chow; Shukui QinFuture oncology (London, England) 16 (15) 975 - 989 2020/05 [Refereed] Hepatocellular carcinoma recurs in 70-80% of cases following potentially curative resection or ablation and the immune component of the liver microenvironment plays a key role in recurrence. Many immunosuppressive mechanisms implicated in HCC recurrence are modulated by VEGF and/or immune checkpoints such as PD-L1. Atezolizumab (PD-L1 inhibitor) plus bevacizumab (VEGF inhibitor) has been shown to significantly improve overall survival, progression-free survival and overall response rate in unresectable HCC. Dual PD-L1/VEGF blockade may be effective in reducing HCC recurrence by creating a more immune-favorable microenvironment. We describe the rationale and design of IMbrave 050 (NCT04102098), a randomized, open-label, Phase III study comparing atezolizumab plus bevacizumab versus active surveillance in HCC patients at high-risk of recurrence following curative resection or ablation. The primary end point is recurrence-free survival. Clinical Trial Registration: NCT04102098.Activation of interferon regulatory factor 7 in plasmacytoid dendritic cells promotes experimental autoimmune pancreatitis.Kosuke Minaga; Tomohiro Watanabe; Yasuyuki Arai; Masahiro Shiokawa; Akane Hara; Tomoe Yoshikawa; Ken Kamata; Kouhei Yamashita; Masatoshi KudoJournal of gastroenterology 55 (5) 565 - 576 2020/05 [Refereed] BACKGROUND: Excessive type I IFN (IFN-I) production by plasmacytoid dendritic cells (pDCs) promotes autoimmunity. Recently, we reported that a prominent feature of both experimental autoimmune pancreatitis (AIP) and human type 1 AIP is pDC activation followed by enhanced production of IFN-I and IL-33. However, the roles played by interferon regulatory factor 7 (IRF7), a critical transcription factor for IFN-I production in pDCs, in these disorders have not been clarified. METHODS: Whole and nuclear extracts were isolated from pancreatic mononuclear cells (PMNCs) from MRL/MpJ mice exhibiting AIP. Expression of phospho-IRF7 and nuclear translocation of IRF7 was examined in these extracts by immunoblotting. Pancreatic expression of IRF7 was assessed by immunofluorescence analysis in experimental AIP. Nuclear translocation of IRF7 upon exposure to neutrophil extracellular traps (NETs) was assessed in peripheral blood pDCs from type 1 AIP patients. Pancreatic IRF7 expression was examined in surgically operated specimens from type 1 AIP patients. RESULTS: IRF7 activation was induced in pancreatic pDCs in experimental AIP. siRNA-mediated knockdown of IRF7 expression prevented AIP development, which was accompanied by a marked reduction in both pancreatic accumulation of pDCs and production of IFN-α and IL-33. Notably, in peripheral blood pDCs isolated from patients with type 1 AIP, nuclear translocation of IRF7 was enhanced as compared with the translocation in pDCs from healthy controls. Furthermore, IRF7-expressing pDCs were detected in the pancreas of patients with type 1 AIP. CONCLUSIONS: These findings suggest that the IRF7-IFN-I-IL-33 axis activated in pDCs drives pathogenic innate immune responses associated with type 1 AIP.Effect of surgical margin width after R0 resection for intrahepatic cholangiocarcinoma: A nationwide survey of the Liver Cancer Study Group of Japan.Yukihiro Watanabe; Yutaka Matsuyama; Namiki Izumi; Shoji Kubo; Norihiro Kokudo; Michiie Sakamoto; Shuichiro Shiina; Tadatoshi Takayama; Osamu Nakashima; Masatoshi KudoSurgery 167 (5) 793 - 802 2020/05 [Refereed] BACKGROUND: Data are inconsistent regarding the effects of a wide surgical margin for intrahepatic cholangiocarcinoma on recurrence-free survival and overall survival. This study was performed to investigate the effect of surgical margin width in patients undergoing R0 resection for intrahepatic cholangiocarcinoma, using a nationwide database in Japan. METHODS: In total, 635 patients with intrahepatic cholangiocarcinoma who were treated by an R0 resection from 2000 to 2007 were identified from the database of a Japanese nationwide survey. Patients were divided into quartiles of the surgical margin width as follows: marginal (Scientific Rationale for Combined Immunotherapy with PD-1/PD-L1 Antibodies and VEGF Inhibitors in Advanced Hepatocellular Carcinoma.Masatoshi KudoCancers 12 (5) 2020/04 [Refereed] A successful phase III trial for the combination of atezolizumab and bevacizumab (the IMbrave150 trial) in advanced hepatocellular carcinoma has recently been reported. This is groundbreaking because nivolumab and pembrolizumab, both programmed cell death-1 (PD-1) antibodies, have failed to show efficacy as first- and second-line therapeutics, respectively, in phase III clinical trials. Immunotherapy with a combination of atezolizumab and bevacizumab resulted in better survival than treatment with sorafenib for the first time since sorafenib was approved in 2007. The high efficacy of the combination of PD-1/programmed death ligand 1 (PD-L1) and vascular endothelial growth factor (VEGF) antibodies is not only due to their additive effects on tumor growth, but also to their reprogramming of the immunosuppressive microenvironment into an immunostimulatory microenvironment. These results were confirmed in a phase Ib trial that showed significantly longer progression-free survival in the atezolizumab plus bevacizumab group than in patients that received atezolizumab alone. These results demonstrate that immunotherapy with a combination of PD-1/PD-L1 and VEGF inhibitors is effective and may result in a reprogramming of the tumor microenvironment. The results of an ongoing phase III trial of a PD-1 antibody in combination with the VEGF receptor tyrosine kinase inhibitor (TKI) are highly anticipated.Phase I Study of the Bifunctional Fusion Protein Bintrafusp Alfa in Asian Patients with Advanced Solid Tumors, Including a Hepatocellular Carcinoma Safety-Assessment Cohort.Toshihiko Doi; Yutaka Fujiwara; Takafumi Koyama; Masafumi Ikeda; Christoph Helwig; Morihiro Watanabe; Yulia Vugmeyster; Masatoshi KudoThe oncologist 25 e1292 - 1302 2020/04 [Refereed] LESSONS LEARNED: Bintrafusp alfa had a manageable safety profile and demonstrated preliminary clinical activity in heavily pretreated patients with solid tumors (including hepatocellular carcinoma) with no or limited treatment options. Findings from this study suggest bintrafusp alfa may be a novel therapeutic approach for patients with advanced solid tumors. Additional trials are needed to further explore safety and efficacy of bintrafusp alfa in specific tumor types. BACKGROUND: Bintrafusp alfa is a first-in-class bifunctional fusion protein composed of the extracellular domain of transforming growth factor-β (TGF-β) RII receptor (a TGF-β "trap") fused to a human immunoglobulin (Ig) G1 antibody blocking programmed death-ligand 1 (PD-L1). Bintrafusp alfa is designed to neutralize TGF-β signaling by "trapping" and sequestering all TGF-β isoforms, and this trap function is physically linked to PD-L1 blockade in the tumor microenvironment. METHODS: NCT02699515 was a phase I, open-label, dose-escalation study of bintrafusp alfa (3, 10, and 20 mg/kg every 2 weeks) in Asian patients with advanced solid tumors, including a hepatocellular carcinoma (HCC) safety-assessment cohort. The primary objective was safety and tolerability; the secondary objective is best overall response. RESULTS: As of August 24, 2018, 23 patients (including 9 in the HCC cohort) received bintrafusp alfa. Eight patients experienced treatment-related adverse events (TRAEs). Three patients had grade 3 TRAEs (13.0%; hypoacusis, hyponatremia, hypopituitarism, increased blood creatine phosphokinase, and intracranial tumor hemorrhage); one had grade 4 hyponatremia (4.3%). No treatment-related deaths occurred. In the dose-escalation cohort, two patients had a confirmed partial response, and 3 had stable disease (SD), for an overall response rate of 14.3% and a disease control rate (DCR) of 35.7%. In the HCC cohort, one patient had SD (DCR, 11.1%). A dose-proportional pharmacokinetics profile was observed at doses of >3 mg/kg. CONCLUSION: Bintrafusp alfa had a manageable safety profile and preliminary efficacy in heavily pretreated patients with advanced solid tumors, including HCC.Ramucirumab in elderly patients with hepatocellular carcinoma and elevated alpha-fetoprotein after sorafenib in REACH and REACH-2.Masatoshi Kudo; Peter R Galle; Josep M Llovet; Richard S Finn; Arndt Vogel; Kenta Motomura; Eric Assenat; Philippe Merle; Giovanni Brandi; Bruno Daniele; Takuji Okusaka; Jiří Tomášek; Christophe Borg; Vincenzo Dadduzio; Manabu Morimoto; Marc Pracht; Min-Hua Jen; Nora Drove Ubreva; Ryan C Widau; Kenta Shinozaki; Reigetsu Yoshikawa; Andrew X ZhuLiver international : official journal of the International Association for the Study of the Liver 2020/04 [Refereed] BACKGROUND & AIMS: Limited data on treatment of elderly patients with hepatocellular carcinoma (HCC) increase the unmet need. REACH and REACH-2 were global phase III studies of ramucirumab in patients with HCC after prior sorafenib, where patients with alpha-fetoprotein (AFP) ≥400 ng/mL showed an overall ssurvival (OS) benefit for ramucirumab. These post-hoc analyses examined efficacy and safety of ramucirumab in patients with HCC and baseline AFP ≥ 400 ng/mL by three prespecified age subgroups (Dual-frequency MR elastography to differentiate between inflammation and fibrosis of the liver: Comparison with histopathology.Keitaro Sofue; Minori Onoda; Masakatsu Tsurusaki; Daisuke Morimoto; Norihisa Yada; Masatoshi Kudo; Takamichi MurakamiJournal of magnetic resonance imaging : JMRI 51 (4) 1053 - 1064 1053-1807 2020/04 [Refereed] BACKGROUND: Differentiation between inflammation and fibrosis is an important clinical distinction in patients with chronic liver disease, which has been difficult so far with MR elastography. PURPOSE: To investigate whether dual-frequency MR elastography can estimate necroinflammation of the liver and improve diagnostic performance for the staging of liver fibrosis. STUDY TYPE: Retrospective. SUBJECTS: In all, 30 patients (14 males, 16 females) with chronic liver disease. FIELD STRENGTH/SEQUENCE: 1.5T/dual-frequency MR elastography at 60-Hz and 80-Hz vibration frequencies. [Correction added on November 12, 2019, after first online publication: The field strength in the preceding sentence was corrected.] ASSESSMENT: Necroinflammation activity and fibrosis were assessed using the METAVIR scoring system. Stiffness values at 60-Hz (G60-Hz ) and 80-Hz (G80-Hz ) were obtained with an MR elastogram. The difference value between G80-Hz and G60-Hz (ΔG) was calculated. Four values (G60-Hz , G80-Hz , G60-Hz - ΔG, and G80-Hz  + ΔG) were generated to estimate necroinflammation and fibrosis. STATISTICAL TESTS: The ΔG were correlated with necroinflammation activity grade and fibrosis stage using Spearman's rank correlation. Diagnostic performance of the four values for necroinflammation activity grade and fibrous stage was assessed by using area under the receiver operating characteristic curve (AUC). RESULTS: The mean value of G80-Hz (6.23 ± 3.67 kPa) was significantly higher than that of G60-Hz (5.27 ± 3.14 kPa) (P アテゾリズマブによる重症肝炎に対して血漿交換を使用した1例金村 宙昌; 林 秀敏; 原谷 浩司; 米阪 仁雄; 中川 和彦; 萩原 智; 工藤 正俊; 大谷 知之; 伊藤 彰彦肺癌 (NPO)日本肺癌学会 60 (2) 149 - 150 0386-9628 2020/04画像診断の新展開 人工知能を用いた腹部超音波からのリアルタイム肝腫瘤検出支援西田 直生志; 工藤 正俊肝臓 (一社)日本肝臓学会 61 (Suppl.1) A203 - A203 0451-4203 2020/04肝癌に対する分子標的治療および免疫治療 進行肝癌に対する免疫チェックポイント阻害薬不応後のレンバチニブ療法の有効性の検討青木 智子; 上嶋 一臣; 工藤 正俊肝臓 (一社)日本肝臓学会 61 (Suppl.1) A85 - A85 0451-4203 2020/04B型慢性肝炎患者(CH-B)に対する,ETVとTAFの前向き比較観察研究萩原 智; 盛田 真弘; 青木 智子; 田北 雅弘; 南 康範; 依田 広; 上嶋 一臣; 西田 直生志; 工藤 正俊肝臓 (一社)日本肝臓学会 61 (Suppl.1) A423 - A423 0451-4203 2020/04超音波及びワークステーションを用いた新しいレンバチニブの治療効果判定の試み野村 貴子; 小川 力; 柴峠 光成; 正木 勉; 工藤 正俊肝臓 (一社)日本肝臓学会 61 (Suppl.1) A374 - A374 0451-4203 2020/04A phase 1 study of oral ASP5878, a selective small-molecule inhibitor of fibroblast growth factor receptors 1-4, as a single dose and multiple doses in patients with solid malignancies.Noboru Yamamoto; Baek-Yeol Ryoo; Bhumsuk Keam; Masatoshi Kudo; Chia-Chi Lin; Futoshi Kunieda; Howard A Ball; Diarmuid Moran; Kanji Komatsu; Kentaro Takeda; Musashi Fukuda; Junji Furuse; Satoshi Morita; Toshihiko DoiInvestigational new drugs 38 (2) 445 - 456 2020/04 [Refereed] ASP5878 is a selective small-molecule inhibitor of fibroblast growth factor receptors (FGFRs). This study investigated safety, tolerability, and antitumor effect of single and multiple oral doses of ASP5878 in patients with solid tumors. This phase 1, open label, first-in-human study comprised dose-escalation and dose-expansion parts. Primary objectives of the dose-escalation part were to identify the dose-limiting toxicity (DLT), maximum tolerated dose, and recommended dose of ASP5878 for the dose-expansion part. Nine dose cohorts of ASP5878 were evaluated (0.5─2 mg once daily; 2─40 mg twice daily [BID]). A single dose of ASP5878 was followed by a 2-day pharmacokinetic collection, and then either 28-day cycles of daily dosing (ASP5878 ≤ 10 mg BID) or 5-day dosing/2-day interruption (ASP5878 ≥ 20 mg BID). The primary objective of the dose-expansion part was to determine the safety of ASP5878 (16 mg BID) administered in 28-day cycles of 5-day dosing/2-day interruption in patients with urothelial carcinoma, hepatocellular carcinoma, or squamous cell lung carcinoma with FGFR genetic alterations. Safety was assessed by monitoring adverse events (AEs). Thirty-five patients were enrolled and 31 discontinued in the dose-escalation part; 51 patients were enrolled and 51 discontinued in the dose-expansion part. In the dose-escalation part, 66.7% of patients in the 20 mg BID 5-day dosing/2-day interruption group reported DLTs of hyperphosphatemia. The recommended dose for the dose-expansion part was 16 mg BID. Common AEs included retinal detachment, diarrhea, and increased alanine aminotransferase. One death occurred that was not related to ASP5878. ASP5878 was well tolerated with manageable toxicities including hyperphosphatemia.画像診断の新展開 人工知能を用いた腹部超音波からのリアルタイム肝腫瘤検出支援西田 直生志; 工藤 正俊肝臓 (一社)日本肝臓学会 61 (Suppl.1) A203 - A203 0451-4203 2020/04 [Refereed]B型慢性肝炎患者(CH-B)に対する,ETVとTAFの前向き比較観察研究萩原 智; 盛田 真弘; 青木 智子; 田北 雅弘; 南 康範; 依田 広; 上嶋 一臣; 西田 直生志; 工藤 正俊肝臓 (一社)日本肝臓学会 61 (Suppl.1) A423 - A423 0451-4203 2020/04 [Refereed]A New Era in Systemic Therapy for Hepatocellular Carcinoma: Atezolizumab plus Bevacizumab Combination Therapy.Masatoshi KudoLiver cancer 9 (2) 119 - 137 2020/04 [Refereed]Ultrasound fusion imaging technologies for guidance in ablation therapy for liver cancer.Yasunori Minami; Masatoshi KudoJournal of medical ultrasonics (2001) 47 (2) 257 - 263 2020/04 [Refereed] With advances in imaging technology, images from ultrasound (US) and computed tomography (CT) or magnetic resonance imaging (MRI) can be displayed simultaneously and in real time, according to the angle of the transducer. CT/MR-US fusion imaging improves the visualization of inconspicuous hepatocellular carcinoma (HCC) and helps us to understand the three-dimensional relationship between the liver vasculature and HCC. US fusion imaging guidance facilitates improvement in the treatment response for HCC with poor conspicuity, and the rates of technical success of ablation and local tumor progression for inconspicuous HCC range from 94.4 to 100% and 0 to 8.3%, respectively. Moreover, the development of image fusion has made it possible to compare and overlay pre- and post-ablation US images. This US-US fusion imaging allows side-by-side comparison of the ablative margin, while US-US overlay fusion can visualize the ablative margin because the tumor image is projected onto the ablative hyperechoic zone. Thus, US-US overlay fusion guidance is highly effective for safety margin achievement in local ablation therapy for HCC, providing a lower risk of local tumor progression. This manuscript reviews the current status of ultrasound fusion imaging for percutaneous ablation therapy of HCC.The chances of hepatic resection curing hepatocellular carcinoma.Alessandro Cucchetti; Jianhong Zhong; Sarah Berhane; Hidenori Toyoda; KeQing Shi; Toshifumi Tada; Charing C N Chong; Bang-De Xiang; Le-Qun Li; Paul B S Lai; Giorgio Ercolani; Vincenzo Mazzaferro; Masatoshi Kudo; Matteo Cescon; Antonio Daniele Pinna; Takashi Kumada; Philip J JohnsonJournal of hepatology 72 (4) 711 - 717 0168-8278 2020/04 [Refereed] BACKGROUND & AIMS: The popular sense of the word "cure" implies that a patient treated for a specific disease will return to have the same life expectancy as if he/she had never had the disease. In analytic terms, it translates into the concept of statistical cure which occurs when a group of patients returns to having similar mortality to a reference population. The aim of this study was to assess the probability of being cured from hepatocellular carcinoma (HCC) by hepatic resection. METHODS: Data from 2,523 patients undergoing resection for HCC were used to fit statistical cure models, to compare disease-free survival (DFS) after surgery to the survival expected for patients with chronic hepatitis and/or cirrhosis and the general population, matched by sex, age, race/ethnicity and year of diagnosis. RESULTS: The probability of resection enabling patients with HCC to achieve the same life expectancy as those with chronic hepatitis and/or cirrhosis was 26.3%. The conditional probability of achieving this result was time-dependent, requiring about 8.9 years to be accomplished with 95% certainty. Considering the general population as a reference, the cure fraction decreased to 17.1%. Uncured patients had a median DFS of 1.5 years. In multivariable analysis, patient's age and the risk of early HCC recurrence (within 2 years) were independent determinants of the chance of cure (p Response to the Letter to the Editor 'Reply to "Clinical Safety and Efficacy of Secondary Prophylactic Pegylated G-CSF in Advanced Pancreatic Cancer Patients Treated with mFOLFIRINOX: A Single-center Retrospective Study" by Dr. Peng Chen'.Kentaro Yamao; Tomohiro Watanabe; Masatoshi KudoInternal medicine (Tokyo, Japan) Japanese Society of Internal Medicine 59 (6) 879 - 879 0918-2918 2020/03 [Refereed]Clinical utility of treatment method conversion during single-session endoscopic ultrasound-guided biliary drainage.Kosuke Minaga; Mamoru Takenaka; Kentaro Yamao; Ken Kamata; Shunsuke Omoto; Atsushi Nakai; Tomohiro Yamazaki; Ayana Okamoto; Rei Ishikawa; Tomoe Yoshikawa; Yasutaka Chiba; Tomohiro Watanabe; Masatoshi KudoWorld journal of gastroenterology 26 (9) 947 - 959 2020/03 [Refereed] BACKGROUND: Although several techniques for endoscopic ultrasound-guided biliary drainage (EUS-BD) are available at present, an optimal treatment algorithm of EUS-BD has not yet been established. AIM: To evaluate the clinical utility of treatment method conversion during single endoscopic sessions for difficult cases in initially planned EUS-BD. METHODS: This was a single-center retrospective analysis using a prospectively accumulated database. Patients with biliary obstruction undergoing EUS-BD between May 2008 and April 2016 were included. The primary outcome was to evaluate the improvement in EUS-BD success rates by converting the treatment methods during a single endoscopic session. Secondary outcomes were clarification of the factors leading to the conversion from the initial EUS-BD and the assessment of efficacy and safety of the conversion as judged by technical success, clinical success, and adverse events (AEs). RESULTS: A total of 208 patients underwent EUS-BD during the study period. For 18.8% (39/208) of the patients, the treatment methods were converted to another EUS-BD technique from the initial plan. Biliary obstruction was caused by pancreatobiliary malignancies, other malignant lesions, biliary stones, and other benign lesions in 22, 11, 4, and 2 patients, respectively. The reasons for the difficulty with the initial EUS-BD were classified into the following 3 procedures: Target puncture (n = 13), guidewire manipulation (n = 18), and puncture tract dilation (n = 8). Technical success was achieved in 97.4% (38/39) of the cases and clinical success was achieved in 89.5% of patients (34/38). AEs occurred in 10.3% of patients, including bile leakage (n = 2), bleeding (n = 1), and cholecystitis (n = 1). The puncture target and drainage technique were altered in subsequent EUS-BD procedures in 25 and 14 patients, respectively. The final technical success rate with 95%CI for all 208 cases was 97.1% (95%CI: 93.8%-98.9%), while that of the initially planned EUS-BD was 78.8% (95%CI: 72.6%-84.2%). CONCLUSION: Among multi-step procedures in EUS-BD, guidewire manipulation appeared to be the most technically challenging. When initially planned EUS-BD is technically difficult, treatment method conversion in a single endoscopic session may result in successful EUS-BD without leading to severe AEs.Efficacy of a modified double-guidewire technique using an uneven double lumen cannula (uneven method) in patients with surgically altered gastrointestinal anatomy (with video).Mamoru Takenaka; Kosuke Minaga; Ken Kamata; Kentaro Yamao; Tomoe Yoshikawa; Rei Ishikawa; Ayana Okamoto; Tomohiro Yamazaki; Atsushi Nakai; Shunsuke Omoto; Yoriaki Komeda; Toshiharu Sakurai; Tomohiro Watanabe; Naoshi Nishida; Yasutaka Chiba; Chang-Il Kwon; Seok Jeong; Tae Hoon Lee; Masatoshi KudoSurgical endoscopy 34 (3) 1432 - 1441 0930-2794 2020/03 [Refereed] BACKGROUND: Balloon enteroscopy-assisted endoscopic retrograde cholangiopancreatography (BE-ERCP) has been reported to be effective for patients with surgically altered gastrointestinal anatomy. However, selective biliary cannulation remains difficult in BE-ERCP. We examined the usefulness of a modified double-guidewire technique using an uneven double lumen cannula (the uneven method) for BE-ERCP in patients with surgically altered gastrointestinal anatomy. METHODS: To clarify the usefulness of the uneven method for selective biliary cannulation in BE-ERCP in comparison to the pancreatic guidewire (PGW) method, 40 patients with surgically altered gastrointestinal anatomy who underwent BE-ERCP with successful placement of a guidewire in the pancreatic duct were evaluated. The uneven method was used in 18 cases (uneven group) and the PGW method was used in the remaining 22 cases (PGW group). RESULTS: The technical success rate of biliary cannulation was higher in the uneven group than in the PGW group (83.3 vs. 59.0%; P = 0.165). In addition, the time to biliary cannulation were significantly shorter in the uneven group than in the PGW group (6 vs. 18 min; P = 0.004; respectively). In the PGW group, post-ERCP pancreatitis (PEP) occurred in 3 of 22 cases (13.6%). No adverse events, including PEP, occurred in the uneven group. CONCLUSIONS: The uneven method may be a useful option of selective biliary cannulation in BE-ERCP for the patients with surgically altered gastrointestinal anatomy.【肝膵内視鏡治療におけるトラブルシューティング】ERCP関連治療における偶発症予防とトラブルシューティング 失敗しない内視鏡的胆管結石除去術竹中 完; 中井 敦史; 大本 俊輔; 三長 孝輔; 鎌田 研; 山雄 健太郎; 工藤 正俊消化器内視鏡 (株)東京医学社 32 (3) 358 - 364 0915-3217 2020/03 [Refereed]【EUSの現状と将来】診断 造影ハーモニック超音波内視鏡の実際と将来展望鎌田 研; 原 茜; 岡本 彩那; 山崎 友裕; 中井 敦史; 大本 俊介; 三長 孝輔; 山雄 健太郎; 竹中 完; 工藤 正俊肝・胆・膵 (株)アークメディア 80 (3) 403 - 411 0389-4991 2020/03 [Refereed]Severe Immune-Related Hepatitis Treated With Plasma Exchange.Hiroaki Kanemura; Hidetoshi Hayashi; Satoru Hagiwara; Tomoyuki Otani; Koji Haratani; Kimio Yonesaka; Akihiko Ito; Masatoshi Kudo; Kazuhiko NakagawaJournal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 15 (3) e39-e42  2020/03 [Refereed]Utility and Safety of a Novel Fully Covered Metal Stent in Unresectable Distal Malignant Biliary Obstruction.Kentaro Yamao; Mamoru Takenaka; Takeshi Ogura; Hiroaki Hashimoto; Hisakazu Matsumoto; Masashi Yamamoto; Tsukasa Ikeura; Akira Kurita; Zhao Liang Li; Hideyuki Shiomi; Yasutaka Chiba; Masatoshi Kudo; Tsuyoshi SanukiDigestive diseases and sciences 65 (12) 3702 - 3709 2020/02 [Refereed] BACKGROUND: Self-expandable metal stents (SEMSs) are widely used in patients with distal malignant biliary obstruction. A SEMS that can avoid occlusion as much as possible is desirable. AIMS: The aim of this multicenter single-arm prospective study was to assess the clinical effectiveness and safety of a novel fully covered braided SEMS. METHODS: We enrolled consecutive patients with distal malignant biliary obstruction between February 2016 and November 2017 at ten tertiary-care medical centers. RESULTS: We included 79 patients with a median age of 76 years; 47 (59.5%) patients were men. The technical and clinical success rate was 98.7% and 93.6%, respectively. Recurrent biliary obstruction occurred in 14 patients (17.9%); stent ingrowth, overgrowth, migration, and other occurred in five (6.4%), four (5.1%), four (5.1%), and one (1.3%) patients, respectively. All reinterventions in patients with recurrent biliary obstruction were successful via the transpapillary approach. Adverse events occurred in 15 patients (19.2%); cholangitis, pancreatitis, and others occurred in ten (12.8%), three (3.8%), and two (2.6%) patients, respectively. The stent patency probability at 6 months was 48.5%. Median time to stent patency was 171 days, median time to recurrent biliary obstruction was 536 days, and median survival time was 195 days. CONCLUSIONS: We confirmed the utility and safety of a novel fully covered braided SEMS with low axial force and high radial force in patients with malignance biliary obstruction. This novel SEMS is recommended in patients with distal malignant biliary obstruction.薬の知識 ラムシルマブ(サイラムザ) 肝細胞癌への適用について上嶋 一臣; 工藤 正俊臨床消化器内科 (株)日本メディカルセンター 35 (3) 333 - 336 0911-601X 2020/02 <文献概要>はじめに 分子標的薬の登場により,肝細胞癌診療は大きく変化した.肝細胞癌に対する二次治療薬としてレゴラフェニブに続き,ラムシルマブが使用可能となった.ラムシルマブは肝細胞癌に対するはじめての点滴静注製剤であり,ほかのキナーゼ阻害薬と比較して副作用がマイルドであることが特徴である.本稿ではラムシルマブについて,臨床成績およびその使用の実際について概説する.術前診断が困難であった肝多血性腫瘍の1例大丸 直哉; 川崎 俊彦; 高田 隆太郎; 福永 朋洋; 橋本 有人; 秦 康倫; 木下 大輔; 水野 成人; 橋本 和彦; 石川 原; 若狭 朋子; 太田 善夫; 工藤 正俊日本消化器病学会近畿支部例会プログラム・抄録集 日本消化器病学会-近畿支部 112回 93 - 93 2020/02【慢性膵炎診療2020】基礎研究・病態 腸内細菌は慢性膵炎発症に関連するのか渡邉 智裕; 三長 孝輔; 原 茜; 鎌田 研; 工藤 正俊肝・胆・膵 (株)アークメディア 80 (2) 241 - 246 0389-4991 2020/02 [Refereed]【慢性膵炎診療2020】診断 早期慢性膵炎のEUS所見は特異的か 加齢や他疾患の影響は竹中 完; 中井 敦史; 大本 俊介; 三長 孝輔; 鎌田 研; 山雄 健太郎; 渡邉 智裕; 松本 逸平; 竹山 宜典; 工藤 正俊肝・胆・膵 (株)アークメディア 80 (2) 295 - 302 0389-4991 2020/02 [Refereed]Endoscopic sclerotherapy under balloon-assisted enteroscopy for hemorrhagic jejunal varices after choledocho-jejunostomy.Kota Takashima; Shigenaga Matsui; Yoriaki Komeda; Tomoyuki Nagai; Sakurai Toshiharu; Hiroshi Kashida; Masatoshi KudoEndoscopy 52 (2) E41-E42  0013-726X 2020/02 [Refereed]Challenges of combination therapy with immune checkpoint inhibitors for hepatocellular carcinoma.Ann-Lii Cheng; Chiun Hsu; Stephen L Chan; Su-Pin Choo; Masatoshi KudoJournal of hepatology 72 (2) 307 - 319 2020/02 [Refereed] Immune checkpoint inhibitor (ICI) therapy targeting anti-programmed cell death-1 (anti-PD-1) or its ligand (anti-PD-L1) is the backbone of numerous combination regimens aimed at improving the objective response and survival of patients with hepatocellular carcinoma (HCC). Clinical trials of immuno-oncology regimens in other cancer types have shed light on issues of study design, including how to choose candidate regimens based on early-phase trial results, statistical considerations in trials with multiple primary endpoints, and the importance of predictive biomarkers. In this review, the updated data from early-phase trials of combination immunotherapy for HCC are summarised. Since the most extensively tested combination regimens for advanced HCC comprise anti-PD-1/anti-PD-L1 agents plus antiangiogenic agents, the relative benefit and antitumor mechanism of antiangiogenic multikinase inhibitors versus specific VEGF/VEGFR inhibitors are discussed. Other critical issues in the development of combination immunotherapy, including optimal management of immune-related adverse events and the value of ICI therapy in combination with locoregional treatment for HCC, are also explored.Requirement of Additional Surgery after Non-Curative Endoscopic Submucosal Dissection for Early Colorectal Cancer.Yoriaki Komeda; Tomohiro Watanabe; Masatoshi KudoJournal of investigative surgery : the official journal of the Academy of Surgical Research 1 - 2 2020/01 [Refereed]Pembrolizumab As Second-Line Therapy in Patients With Advanced Hepatocellular Carcinoma in KEYNOTE-240: A Randomized, Double-Blind, Phase III Trial.Richard S Finn; Baek-Yeol Ryoo; Philippe Merle; Masatoshi Kudo; Mohamed Bouattour; Ho Yeong Lim; Valeriy Breder; Julien Edeline; Yee Chao; Sadahisa Ogasawara; Thomas Yau; Marcelo Garrido; Stephen L Chan; Jennifer Knox; Bruno Daniele; Scot W Ebbinghaus; Erluo Chen; Abby B Siegel; Andrew X Zhu; Ann-Lii ChengJournal of clinical oncology : official journal of the American Society of Clinical Oncology 38 (3) 193 - 202 0732-183X 2020/01 [Refereed] PURPOSE: Pembrolizumab demonstrated antitumor activity and safety in the phase II KEYNOTE-224 trial in previously treated patients with advanced hepatocellular carcinoma (HCC). KEYNOTE-240 evaluated the efficacy and safety of pembrolizumab in this population. PATIENTS AND METHODS: This randomized, double-blind, phase III study was conducted at 119 medical centers in 27 countries. Eligible patients with advanced HCC, previously treated with sorafenib, were randomly assigned at a two-to-one ratio to receive pembrolizumab plus best supportive care (BSC) or placebo plus BSC. Primary end points were overall survival (OS) and progression-free survival (PFS; one-sided significance thresholds, P = .0174 [final analysis] and P = .002 [first interim analysis], respectively). Safety was assessed in all patients who received ≥ 1 dose of study drug. RESULTS: Between May 31, 2016, and November 23, 2017, 413 patients were randomly assigned. As of January 2, 2019, median follow-up was 13.8 months for pembrolizumab and 10.6 months for placebo. Median OS was 13.9 months (95% CI, 11.6 to 16.0 months) for pembrolizumab versus 10.6 months (95% CI, 8.3 to 13.5 months) for placebo (hazard ratio [HR], 0.781; 95% CI, 0.611 to 0.998; P = .0238). Median PFS for pembrolizumab was 3.0 months (95% CI, 2.8 to 4.1 months) versus 2.8 months (95% CI, 2.5 to 4.1 months) for placebo at the first interim analysis (HR, 0.775; 95% CI, 0.609 to 0.987; P = .0186) and 3.0 months (95% CI, 2.8 to 4.1 months) versus 2.8 months (95% CI, 1.6 to 3.0 months) at final analysis (HR, 0.718; 95% CI, 0.570 to 0.904; P = .0022). Grade 3 or higher adverse events occurred in 147 (52.7%) and 62 patients (46.3%) for pembrolizumab versus placebo; those that were treatment related occurred in 52 (18.6%) and 10 patients (7.5%), respectively. No hepatitis C or B flares were identified. CONCLUSION: In this study, OS and PFS did not reach statistical significance per specified criteria. The results are consistent with those of KEYNOTE-224, supporting a favorable risk-to-benefit ratio for pembrolizumab in this population.Deficiency of Gankyrin in the small intestine is associated with augmented colitis accompanied by altered bacterial composition of intestinal microbiota.Toshiharu Sakurai; Hiroki Nishiyama; Tomoyuki Nagai; Susumu Goto; Hiroyuki Ogata; Masatoshi KudoBMC gastroenterology Springer Science and Business Media LLC 20 (1) 12 - 12 2020/01 [Refereed] BACKGROUND: Gankyrin (GK) is an oncoprotein which regulates inflammatory responses and its inhibition is considered as a possible anti-inflammatory therapy for inflammatory bowel disease (IBD). METHODS: In this study, we investigated the role of GK in epithelial cells using mice with intestinal epithelial cell-specific GK deletion in (i) the entire small intestine and colon (Villin-Cre;Gankyrinf/f) and (ii) the distal intestine and colon (Cdx2-Cre;Gankyrinf/f). RESULT: Unexpectedly, GK-deficiency in the upper small bowel augmented inflammatory activity compared with control mice when colitis was induced with dextran sodium sulfate. Biochemical analyses have revealed GK-deficiency to have caused reduction in the expression of antimicrobial peptides, α-Defensin-5 and -6, in the upper small bowel. Examination of human samples have further confirmed that the reduction of GK expression in the small bowel is associated with colonic involvement in human Crohn's disease. Through the sequencing of bacterial 16S rRNA gene amplicons, bacteria potentially deleterious to intestinal homeostasis such as Helicobacter japonicum and Bilophila were found to be over-represented in colitis induced Villin-Cre;Gankyrinf/f mice when compared to Gankyrinf/f control mice under the same condition. CONCLUSION: These results highlight the distinct site dependence of the pro- and anti-inflammatory functions of GK and provide important insights into the pathogenesis of IBD.Navigator-triggered and breath-hold 3D MRCP using compressed sensing: image quality and method selection factor assessment.Daisuke Morimoto; Tomoko Hyodo; Ken Kamata; Tomoya Kadoba; Makoto Itoh; Hiroyuki Fukushima; Yasutaka Chiba; Mamoru Takenaka; Tomohiro Mochizuki; Yu Ueda; Keizou Miyagoshi; Masatoshi Kudo; Kazunari IshiiAbdominal radiology (New York) 45 (10) 3081 - 3091 2366-004X 2020/01 [Refereed] PURPOSE: To examine whether MRCP using a combination of compressed sensing and sensitivity encoding with navigator-triggered and breath-hold techniques (NT C-SENSE and BH C-SENSE, respectively) have comparable image quality to that of navigator-triggered MRCP using only sensitivity encoding (NT SENSE) at 1.5-T. METHODS: Fifty-one participants were enrolled in this prospective study between July and October 2018 and underwent the three 3D MRCP sequences each. The acquisition time and relative duct-to-periductal contrast ratios (RC values) of each bile duct segment were obtained. Visualization of the bile and main pancreatic ducts, background suppression, artifacts, and overall image quality were scored on 5-point scales. Mean and median differences in RC values and qualitative scores of NT C-SENSE and BH C-SENSE relative to NT SENSE were calculated with 95% confidence intervals (CIs). RESULTS: Acquisition time of NT SENSE, NT C-SENSE, and BH C-SENSE were 348, 143 (mean for both), and 18 s (for all participants), respectively. The RC value of each bile duct segment was inferior, but the lower limits of the 95% CIs of the mean differences were ≥ - 0.10, for both NT C-SENSE and BH C-SENSE. The visualization score of the intrahepatic duct in BH C-SENSE was inferior to that in NT SENSE (lower 95% CI limit, - 1.5). In both NT C-SENSE and BH C-SENSE, the 95% CIs of the median differences in the other qualitative scores were from - 1.0 to 0.0. CONCLUSION: NT C-SENSE and BH C-SENSE have comparable image quality to NT SENSE at 1.5-T.Report of the 20th Nationwide follow-up survey of primary liver cancer in Japan.Masatoshi Kudo; Namiki Izumi; Shoji Kubo; Norihiro Kokudo; Michiie Sakamoto; Shuichiro Shiina; Ryosuke Tateishi; Osamu Nakashima; Takamichi Murakami; Yutaka Matsuyama; Arata Takahashi; Hiroaki Miyata; Tadatoshi TakayamaHepatology research : the official journal of the Japan Society of Hepatology 50 (1) 15 - 46 1386-6346 2020/01 [Refereed] In the 20th Nationwide Follow-up Survey of Primary Liver Cancer in Japan, data from 21 075 new patients and 40 769 previously followed patients were compiled from 544 institutions over a 2-year period from 1 January 2008 to 31 December 2009. Compared with the previous 19th survey, the population of patients with hepatocellular carcinoma (HCC) was older at the time of clinical diagnosis, included more female patients, included more patients with non-B non-C HCC, had smaller tumor diameters and more frequently received radiofrequency ablation as local ablation therapy. Cumulative survival rates were calculated for HCC, intrahepatic cholangiocarcinoma, and combined hepatocellular cholangiocarcinoma (combined HCC and intrahepatic cholangiocarcinoma) by treatment type and by background characteristics for patients newly registered between 1998 and 2009 whose final outcome was survival or death. Cumulative survival rates for HCC were calculated by dividing patients by combinations of background factors (number of tumors, tumor diameter, and Child-Pugh grade) and by treatment types (hepatectomy, local ablation therapy, and transcatheter arterial chemoembolization). Cumulative survival rates and median overall survival in patients treated by resection, transcatheter arterial chemoembolization, and local ablation therapy were calculated. The same values were also calculated by the registration date by dividing patients newly registered between 1978 and 2009 into four time period groups . The results of the analysis show that the prognosis of HCC is improving dramatically. It is expected that the data obtained from this nationwide follow-up survey will contribute to advancing clinical research, including the design of clinical trials, as well as the treatment strategy of primary liver cancer in the clinical practice setting.REFLECT-a phase 3 trial comparing efficacy and safety of lenvatinib to sorafenib for the treatment of unresectable hepatocellular carcinoma: an analysis of Japanese subset.Tatsuya Yamashita; Masatoshi Kudo; Kenji Ikeda; Namiki Izumi; Ryosuke Tateishi; Masafumi Ikeda; Hiroshi Aikata; Yasunori Kawaguchi; Yoshiyuki Wada; Kazushi Numata; Yoshitaka Inaba; Ryoko Kuromatsu; Masahiro Kobayashi; Takuji Okusaka; Toshiyuki Tamai; Chifumi Kitamura; Kenichi Saito; Katsuya Haruna; Kiwamu Okita; Hiromitsu KumadaJournal of gastroenterology 55 (1) 113 - 122 0944-1174 2020/01 [Refereed] BACKGROUND: A phase 3, multinational, randomized, non-inferiority trial (REFLECT) compared the efficacy and safety of lenvatinib (LEN) and sorafenib (SOR) in patients with unresectable hepatocellular carcinoma (uHCC). LEN had an effect on overall survival (OS) compared to SOR, statistically confirmed by non-inferiority [OS: median = 13.6 months vs. 12.3 months; hazard ratio (HR) 0.92, 95% confidence interval (CI) 0.79-1.06], and demonstrated statistically significant improvements in progression-free survival (PFS) and the objective response rate (ORR) in the overall population. The results of a subset analysis that evaluated the efficacy and safety of LEN and SOR in the Japanese population are reported. METHODS: The intent-to-treat population enrolled in Japan was analyzed. RESULTS: Of 954 patients in the overall population, 168 Japanese patients were assigned to the LEN arm (N = 81) or the SOR arm (N = 87). Median OS was 17.6 months for LEN vs. 17.8 months for SOR (HR 0.90; 95% CI 0.62-1.29). LEN showed statistically significant improvements over SOR in PFS (7.2 months vs. 4.6 months) and ORR (29.6% vs. 6.9%). The relative dose intensity of LEN and SOR in the Japanese population was lower than in the overall population. Frequently observed, related adverse events included palmar-plantar erythrodysaesthesia syndrome (PPES), hypertension, decreased appetite, and proteinuria in the LEN arm, and PPES, hypertension, diarrhea, and alopecia in the SOR arm. CONCLUSIONS: The efficacy and safety of LEN in the Japanese population were similar to those in the overall population of REFLECT. With manageable adverse events, LEN is a new treatment option for Japanese patients with uHCC. TRIAL REGISTRATION ID: ClinicalTrials.gov. No. NCT01761266.A Study on Liver Tumor Detection from an Ultrasound Image using Deep LearningTakahiro Nakashima; Issei Tsutsumi; Hiroki Takami; Keisuke Doman; Yoshito Mekada; Naoshi Nishida; Masatoshi KudoINTERNATIONAL WORKSHOP ON ADVANCED IMAGING TECHNOLOGY (IWAIT) 2020 SPIE-INT SOC OPTICAL ENGINEERING 11515 0277-786X 2020 The ultrasound examination is a difficult operation because a doctor not only operates an ultrasound scanner but also interprets images in rea time, which may increase the risk of overlooking tumors. To prevent that, we study a liver tumor detection method using convolutional neural networks toward realizing computer-assisted diagnosis systems. In this paper, we propose a liver tumor detection method within a false positive reduction framework. The proposed method uses YOLOv3 [1] in order to find tumor candidate regions in real-time, and also uses VGG16 [2] to reduce false positives. The proposed method using YOLOv3 [1] and VGG16 [2] achieved an F-measure of 0.837, which showed the effectiveness of the proposed method for liver tumor detection. Future work includes the collection of training data from more hospitals and their effective use for improving the detection accuracy.【ここがキモ!いまはこうする 肝疾患vs.薬物療法 肝機能評価&薬物性肝障害マネジメントに強くなる】(第8章)肝硬変と肝腫瘍 肝細胞がん患者へのアプローチ(手術療法と薬物治療)上嶋 一臣; 工藤 正俊薬事 (株)じほう 62 (2) 448 - 455 0016-5980 2020/01 <Key Points>・肝細胞がんは、慢性B型肝炎(肝硬変)や慢性C型肝炎(肝硬変)などの慢性肝疾患を背景に発症する悪性腫瘍であり、その治療にあたっては、肝予備能を最大限に考慮することが重要である。・肝予備能が良好で、腫瘍が限局している場合には手術療法(肝切除)が選択される。・切除困難な場合には、RFA(ラジオ波焼灼療法)、TACE(肝動脈化学塞栓療法)などの局所療法が選択される。・腫瘍量が多い場合(両葉多発など)や、脈管浸潤、遠隔転移症例には分子標的薬による化学療法が選択される。・いずれの治療を選択した場合でも、肝予備能に留意することが重要であり、予備能を低下させるような治療は避けるべきである。(著者抄録)Artificial Intelligence in Medical Imaging and Its Application in Sonography for the Management of Liver Tumor.Naoshi Nishida; Masatoshi KudoFrontiers in oncology 10 594580 - 594580 2020 Recent advancement in artificial intelligence (AI) facilitate the development of AI-powered medical imaging including ultrasonography (US). However, overlooking or misdiagnosis of malignant lesions may result in serious consequences; the introduction of AI to the imaging modalities may be an ideal solution to prevent human error. For the development of AI for medical imaging, it is necessary to understand the characteristics of modalities on the context of task setting, required data sets, suitable AI algorism, and expected performance with clinical impact. Regarding the AI-aided US diagnosis, several attempts have been made to construct an image database and develop an AI-aided diagnosis system in the field of oncology. Regarding the diagnosis of liver tumors using US images, 4- or 5-class classifications, including the discrimination of hepatocellular carcinoma (HCC), metastatic tumors, hemangiomas, liver cysts, and focal nodular hyperplasia, have been reported using AI. Combination of radiomic approach with AI is also becoming a powerful tool for predicting the outcome in patients with HCC after treatment, indicating the potential of AI for applying personalized medical care. However, US images show high heterogeneity because of differences in conditions during the examination, and a variety of imaging parameters may affect the quality of images; such conditions may hamper the development of US-based AI. In this review, we summarized the development of AI in medical images with challenges to task setting, data curation, and focus on the application of AI for the managements of liver tumor, especially for US diagnosis.抗PD-1/PD-L1抗体や抗CTLA-4抗体併用のRationale. 特集“肝細胞癌治療のパラダイムチェンジ—進化する薬物療法2020 Update Part I—(免疫療法)”南 康範; 工藤正俊肝胆膵 81 703 - 708 2020ICI-Anti-VEGF/TKI併用療法のrationale. 特集“肝細胞癌治療のパラダイムチェンジ—進化する薬物療法2020 Update Part I—(免疫療法)”盛田真弘; 工藤正俊肝胆膵 (株)アークメディア 81 (4) 677 - 683 0389-4991 2020肝細胞癌における微小免疫環境と免疫チェックポイント阻害剤. 特集“肝細胞癌治療のパラダイムチェンジ—進化する薬物療法2020 Update Part I—(免疫療法)”西田直生志; 工藤正俊肝胆膵 81 643 - 650 2020アテゾリズマブ+ベバシズマブ併用療法登場後の進行肝細胞癌に対するシークエンシャル治療の今後. 特集“肝細胞癌治療のパラダイムチェンジ—進化する薬物療法2020 Update Part I—(免疫療法)”工藤正俊肝胆膵 81 625 - 633 2020WNT/β-catenin変異と免疫チェックポイント阻害剤の治療抵抗性—EOB-MRIのbiomarkerとしての可能性-. 特集“肝細胞癌治療のパラダイムチェンジ—進化する薬物療法2020 Update Part I—(免疫療法)工藤正俊肝胆膵 81 613 - 624 2020免疫チェックポイント阻害剤の単剤治療はなぜ限界があるのか. 特集“肝細胞癌治療のパラダイムチェンジ—進化する薬物療法2020 Update Part I—(免疫療法)”工藤正俊肝胆膵 81 603 - 612 2020特別座談会「免疫療法の登場により肝細胞癌の治療は新たなステージに」, 特集“肝細胞癌治療のパラダイムチェンジ—進化する薬物療法2020 Update Part I—(免疫療法)”工藤正俊; 池田公史; 小笠原定久; 坂元亨宇肝胆膵 81 585 - 601 2020超音波デジタル画像とAI診断西田直生志; 工藤正俊臨牀検査 64 850 - 857 2020Contrast-enhanced ultrasonography with sonazoid in hepatocellular carcinoma diagnosisMinami Y; Kudo MHepatoma Research 6 46  2020 [Refereed]The AFSUMB consensus statements and recommendations for the clinical practice of contrast-enhanced ultrasound using sonazoidLee JY; Minami Y; Choi BI; Lee WJ; Chou YH; Jeong WK; Park MS; Kudo N; Lee MW; Kamata K; Iijima H; Kim SY; Numata K; Sugimoto K; Maruyama H; Sumino Y; Ogawa C; Kitano M; Joo I; Arita J; Liang JD; Lin HM; Nolsoe C; Gilja OH; Kudo MJ Med Ultrasound 28 59 - 82 2020 [Refereed]Optimal corpping for input images used in a convolutional neural network for ultrasonic diagnosis of liver tumorYamakawa M; Shiina T; Nishida N; Kudo MJpn J Appl Phys 59 SKKE09  2020 [Refereed]Author response to: comment on: “Significance of the surgical hepatic resection margin in patients with a single hepatocellular carcinoma”Aoki T; Kubota K; Kubo S; Kudo MBr J Surg 107 470  2020 [Refereed]Aoki T, Kubota K, Kubo S, Kudo MAuthor response to; comment on; “Significance of; the surgical hepatic resection margin; in; atients with; a single hepatocellular carcinoma”Br J Surg 107 465  2020 [Refereed]Management of Hepatocellular Carcinoma in Japan: Current Trends.Masatoshi KudoLiver cancer 9 (1) 1 - 5 2020/01 [Refereed]Endoscopic ultrasound-guided biliary drainage for malignant biliary obstruction with surgically altered anatomy: a multicenter prospective registration study.Kosuke Minaga; Mamoru Takenaka; Takeshi Ogura; Takashi Tamura; Taira Kuroda; Toyoma Kaku; Yoshito Uenoyama; Chishio Noguchi; Hidefumi Nishikiori; Hajime Imai; Ryota Sagami; Nao Fujimori; Kazuhide Higuchi; Masatoshi Kudo; Yasutaka Chiba; Masayuki KitanoTherapeutic advances in gastroenterology 13 1756284820930964 - 1756284820930964 2020 [Refereed] Background: Endoscopic treatment for malignant biliary obstruction (MBO) in patients bearing surgically altered anatomy (SAA) is not well-established. Although endoscopic ultrasound-guided biliary drainage (EUS-BD) has emerged as a new treatment option for MBO, limited data are available regarding the efficacy and safety of EUS-BD in patients with SAA. We conducted a multicenter prospective registration study to evaluate the efficacy and safety of EUS-BD in this population. Methods: This study involved 10 referral centers in Japan. Patients with SAA who were scheduled to receive EUS-BD for unresectable MBO between May 2016 and September 2018 were prospectively registered. The primary endpoint was technical success and the secondary outcomes were clinical success, procedure time, procedure-related adverse events (AEs), stent patency, and overall survival. Results: In total, 40 patients were prospectively enrolled. The surgical reconstruction methods were gastrectomy with Roux-en-Y reconstruction (47.5%), gastrectomy with Billroth-II reconstruction (15%), pancreaticoduodenectomy (27.5%), and hepaticojejunostomy with Roux-en-Y reconstruction (10%). EUS-BD was performed for primary biliary drainage in 31 patients and for rescue biliary drainage in nine patients. Transmural stenting alone (60%), antegrade stenting alone (5%), and a combination of the two techniques (35%) were selected for patients treated with EUS-BD. Technical and clinical success rates were 100% (95% confidence interval, 91.2-100.0%) and 95% (95% confidence interval, 83.1-99.4%), respectively. Mean procedure time was 36.5 min. Early AEs were noted in six patients (15%): three self-limited bile leak, one bile peritonitis, and two pneumoperitonea. Late AEs occurred in six patients (15%): one jejunal ulcer and five stent occlusions. Stent patency rate after 3 months of survival was 95.7% (22/23). Median overall survival was 96 days. Conclusion: EUS-BD for MBO in patients with SAA appears to be effective and safe not only as a rescue drainage technique after failed endoscopic retrograde cholangiography but also as a primary drainage technique. Clinical Trial Registration: UMIN000022101.COMPARISON OF THE EFFICACY AND SAFETY OF ENDOSCOPIC ULTRASOUND-GUIDED CHOLEDOCHODUODENOSTOMY AND HEPATICOGASTROSTOMY FOR MALIGNANT DISTAL BILIARY OBSTRUCTION: MULTICENTER, RANDOMIZED, CLINICAL TRIALMINAGA Kosuke; KATO Hironari; KAMADA Hideki; OKUDA Atsushi; SAGAMI Ryota; HASHIMOTO Hiroaki; HIGUCHI Kazuhide; CHIBA Yasutaka; KUDO Masatoshi; KITANO Masayuki; OGURA Takeshi; SHIOMI Hideyuki; IMAI Hajime; HOKI Noriyuki; TAKENAKA Mamoru; NISHIKIORI Hidefumi; YAMASHITA Yukitaka; HISA TakeshiGASTROENTEROLOGICAL ENDOSCOPY Japan Gastroenterological Endoscopy Society 62 (7) 817 - 826 0387-1207 2020 [Refereed] Background and Aim: Endoscopic ultrasound-guided biliary drainage (EUS-BD) can be carried out by two different approaches: choledochoduodenostomy (CDS) and hepaticogastrostomy (HGS). We compared the efficacy and safety of these approaches in malignant distal biliary obstruction (MDBO) patients using a prospective, randomized clinical trial.Methods: Patients with malignant distal biliary obstruction after failed endoscopic retrograde cholangiopancreatography were randomly selected for either CDS or HGS. The procedures were carried out at nine tertiary centers from September 2013 to March 2016. Primary endpoint was technical success rate, and the noninferiority of HGS to CDS was examined with a onesided significance level of 5%, where the noninferiority margin was set at 15%. Secondary endpoints were clinical success, adverse events (AE), stent patency, survival time, and overall technical success including alternative EUS-BD procedures.Results: Forty-seven patients (HGS, 24; CDS, 23) were enrolled. Technical success rates were 87.5% and 82.6% in the HGS and CDS groups, respectively, where the lower limit of the 90% confidence interval of the risk difference was -12.2% (P=0.0278). Clinical success rates were 100% and 94.7% in the HGS and CDS groups, respectively (P=0.475). Overall AE rate, stent patency, and survival time did not differ between the groups. Overall technical success rates were 100% and 95.7% in the HGS and CDS groups, respectively (P=0.983).Conclusions: This study suggests that HGS is not inferior to CDS in terms of technical success. When one procedure is particularly challenging, readily switching to the other could increase technical success.Effects of Subsequent Systemic Anticancer Medication Following First-Line Lenvatinib: A Post Hoc Responder Analysis from the Phase 3 REFLECT Study in Unresectable Hepatocellular Carcinoma.Angel Alsina; Masatoshi Kudo; Arndt Vogel; Ann-Lii Cheng; Won Young Tak; Baek-Yeol Ryoo; Thomas R Jeffry Evans; Carlos López López; Bruno Daniele; Soamnauth Misir; Min Ren; Namiki Izumi; Shukui Qin; Richard S FinnLiver cancer 9 (1) 93 - 104 2020/01 [Refereed] Introduction: Understanding the relationship between subsequent-line therapies and overall survival (OS) is important for maximizing OS for patients with hepatocellular carcinoma. Objective: In this post hoc analysis, we investigated OS in lenvatinib- and sorafenib-treated patients from the REFLECT study, who then received subsequent anticancer medication during the survival follow-up period. Methods: The follow-up period commenced at the first off-treatment visit after stopping the study medication and continued until study termination, withdrawal of consent, or death. OS and objective response rate were calculated for patients who did or did not receive poststudy anticancer medication for both treatment arms, as well as for the overall cohort. We investigated the subset of patients who responded to first-line treatment and subsequently received anticancer medication. Results: The OS for patients initially randomized to first-line lenvatinib (versus first-line sorafenib) and who then received any subsequent anticancer medication was 20.8 vs. 17.0 months (hazard ratio [HR] 0.87; 95% CI 0.67-1.14). The OS for patients who initially received first-line lenvatinib (versus first-line sorafenib) and who did not receive any subsequent anticancer medication was 11.5 vs. 9.1 months (HR 0.90; 95% CI 0.75-1.09). Responders to first-line lenvatinib who received subsequent medication had a median OS of 25.7 months (95% CI 18.5-34.6); responders to first line-sorafenib who received subsequent medication had a median OS of 22.3 months (95% CI 14.6-not evaluable). Conclusions: In this post hoc analysis of all patients in the REFLECT study who received subsequent anticancer medication, OS was increased compared with patients who did not receive any subsequent anticancer medication. In a subset analysis of responders who had received subsequent anticancer medication, use of first-line lenvatinib led to a slightly longer median OS; more research is needed on the benefits of using first-line lenvatinib compared with sorafenib.Post-Progression Treatment Eligibility of Unresectable Hepatocellular Carcinoma Patients Treated with Lenvatinib.Atsushi Hiraoka; Takashi Kumada; Shinya Fukunishi; Masanori Atsukawa; Masashi Hirooka; Kunihiko Tsuji; Toru Ishikawa; Koichi Takaguchi; Kazuya Kariyama; Ei Itobayashi; Kazuto Tajiri; Noritomo Shimada; Hiroshi Shibata; Hironori Ochi; Toshifumi Tada; Hidenori Toyoda; Keisuke Yokohama; Kazuhiro Nouso; Akemi Tsutsui; Takuya Nagano; Norio Itokawa; Korenobu Hayama; Taeang Arai; Michitaka Imai; Kouji Joko; Yohei Koizumi; Yoichi Hiasa; Kojiro Michitaka; Masatoshi KudoLiver cancer 9 (1) 73 - 83 2235-1795 2020/01 [Refereed] Background/Aim: Post-progression treatment following tyrosine-kinase inhibitor (TKI) failure in patients with unresectable hepatocellular carcinoma (u-HCC) is important to prolong post-progression survival (PPS), which has a good correlation with overall survival (OS). This study aimed to elucidate the clinical features of progressive disease (PD) in patients treated with lenvatinib (LEN). Materials/Methods: From March 2018 to June 2019, 156 u-HCC patients with Child-Pugh A were enrolled (median age: 71 years, Child-Pugh score 5:6 = 105:51, BCLC A:B:C = 8:56:92, modified albumin-bilirubin grade (mALBI) 1:2a:2b = 59:42:55, past history of sorafenib:regorafenib = 57:17). Clinical features were retrospectively evaluated. Results: The median observation period was 8.5 months. Median OS was not obtained, while median time to decline to Child-Pugh B (CPB) was 11.4 months, median time to progression (TTP) was 8.4 months, and the period of LEN administration was 7.3 months. When we compared predictive values for time to decline to CPB based on Child-Pugh score and mALBI, values for Akaike information criterion (AIC) score and c-index of mALBI were superior as compared to Child-Pugh score (AIC: 592.3 vs. 599.7) (c-index: 0.655 vs. 0.597). Of the 73 patients with PD, 32 (43.8%) showed no decline to CPB or death. After excluding 3 without alpha-fetoprotein data at PD determination, only 14 (20.0%) of 70 showed REACH-2 eligibility. Non-mALBI 1/2a at the start of LEN was a significant risk factor for decline to CPB during LEN treatment (HR 2.552, 95% CI: 1.577-4.129; p Multiple Gastrointestinal Stromal Tumors of the Duodenum Associated with Neurofibromatosis TypeShigenaga Matsui; Hiroshi Kashida; Kenji Nomura; Yoriaki Komeda; Masatoshi KudoAdv Res Gastroentero Hepatol Volume 14 Issue 3 - January 2020 2020/01 [Refereed]Significance of the surgical hepatic resection margin in patients with a single hepatocellular carcinoma.T Aoki; K Kubota; K Hasegawa; S Kubo; N Izumi; N Kokudo; M Sakamoto; S Shiina; T Takayama; O Nakashima; Y Matsuyama; T Murakami; M KudoThe British journal of surgery 107 (1) 113 - 120 2020/01 [Refereed] BACKGROUND: The impact of a wide surgical margin on the outcome of patients with hepatocellular carcinoma (HCC) has not been evaluated in relation to the type of liver resection performed, anatomical or non-anatomical. The aim of this study was to evaluate the impact of surgical margin status on outcomes in patients undergoing anatomical or non-anatomical resection for solitary HCC. METHODS: Data from patients with solitary HCC who had undergone non-anatomical partial resection (Hr0 group) or anatomical resection of one Couinaud segment (HrS group) between 2000 and 2007 were extracted from a nationwide survey database in Japan. Overall and recurrence-free survival associated with the surgical margin status and width were evaluated in the two groups. RESULTS: A total of 4457 patients were included in the Hr0 group and 3507 in the HrS group. A microscopically positive surgical margin was associated with poor overall survival in both groups. A negative but 0-mm surgical margin was associated with poorer overall and recurrence-free survival than a wider margin only in the Hr0 group. In the HrS group, the width of the surgical margin was not associated with patient outcome. CONCLUSION: Anatomical resection with a negative 0-mm surgical margin may be acceptable. Non-anatomical resection with a negative 0-mm margin was associated with a less favourable survival outcome.Nutritional Index as Prognostic Indicator in Patients Receiving Lenvatinib Treatment for Unresectable Hepatocellular Carcinoma.Atsushi Hiraoka; Takashi Kumada; Toshifumi Tada; Shinya Fukunishi; Masanori Atsukawa; Masashi Hirooka; Kunihiko Tsuji; Toru Ishikawa; Koichi Takaguchi; Kazuya Kariyama; Ei Itobayashi; Kazuto Tajiri; Noritomo Shimada; Hiroshi Shibata; Hironori Ochi; Kazuhito Kawata; Hidenori Toyoda; Hideko Ohama; Akemi Tsutsui; Norio Itokawa; Korenobu Hayama; Taeang Arai; Michitaka Imai; Shinichiro Nakamura; Kojiro Michitaka; Yoichi Hiasa; Masatoshi KudoOncology 98 (5) 295 - 302 2020 [Refereed] BACKGROUND/AIM: Few studies have examined the details of nutritional status in patients with unresectable hepatocellular carcinoma (u-HCC) undergoing systemic chemotherapy with lenvatinib. We evaluated the prognostic/predictive value of nutritional status using Onodera's prognostic nutritional index (O-PNI) for overall survival among patients with u-HCC treated with lenvatinib. METHODS: Three-hundred and seventy-five u-HCC patients treated with lenvatinib were enrolled (median age 72 years; Child-Pugh class A/B/C: n = 312/60/3; BCLC stage A/B/C/D: n = 2/159/212/2). We examined median survival time (MST) and time to progression (TTP) in all patients (n = 375), prognosis according to the O-PNI (high/low: >40/≤40) in 298 patients with lymphocyte findings, and the prognostic/predictive values of Child-Pugh stage, albumin-bilirubin (ALBI)/modified ALBI (mALBI) grade, and O-PNI for Chemotherapy grade (OPNIC grade 1/2/3: O-PNI >40/≤40 to >36/≤36). RESULTS: The MST and TTP were 16.6 and 8.0 months, respectively. The MST and TTP according to the O-PNI (>40/≤40) were "not reached" (NR)/12.4 months (p The Efficacy of Sonazoid-enhanced Ultrasonography in Decision-making for Liver Abscess Treatment.Masahiro Morita; Chikara Ogawa; Akina Omura; Teruyo Noda; Atsushi Kubo; Toshihiro Matsunaka; Hiroyuki Tamaki; Mitsushige Shibatoge; Hiroshi Seno; Yasunori Minami; Kazuomi Ueshima; Toshiharu Sakurai; Naoshi Nishida; Masatoshi KudoInternal medicine (Tokyo, Japan) 59 (4) 471 - 477 2020 [Refereed] Objective The usefulness of contrast-enhanced ultrasonography (CEUS) for making decisions in the treatment of liver abscess is unknown. Methods We evaluated the internal blood flow in the arterial-predominant phase by CEUS using Sonazoid® in 21 patients. The stain area rate was evaluated in maximum parting plane of abscess in CEUS. Patients were divided into two groups: the vascular phase enhancement (VE) group, in which ≥50% of the abscess cavity was enhanced (12 patients), and the vascular phase non-enhancement (VNE) group, in which Radiofrequency ablation for hepatocellular carcinoma: Clinical value of ultrasound-ultrasound overlay fusion for optimal ablation and local controllability.Yasunori Minami; Tomohiro Minami; Masahiro Takita; Satoru Hagiwara; Hiroshi Ida; Kazuomi Ueshima; Naoshi Nishida; Masatoshi KudoHepatology research : the official journal of the Japan Society of Hepatology 50 (1) 67 - 74 1386-6346 2020/01 [Refereed] AIM: To retrospectively investigate the potential benefit of ultrasound-ultrasound (US-US) overlay fusion guidance for local controllability of radiofrequency ablation (RFA) in the treatment of hepatocellular carcinoma (HCC). METHODS: Patients (n = 101) with 121 HCCs (mean ± SD, 1.8 ± 0.7 cm) who underwent RFA guided by US-US overlay fusion were included in the retrospective study. By overlaying pre/postoperative US, the tumor image could be projected onto the ablative hyperechoic zone. The ablative margin could thereby be evaluated three-dimensionally during the RFA procedure. As a control group, all 325 patients with 453 HCCs who underwent conventional RFA during the same study period were selected. RESULTS: The total number of RF needle insertions per tumor for ablation was significantly more in the US overlay fusion group (mean 1.9 vs. 1.2; P Corrigendum to "Nivolumab in advanced hepatocellular carcinoma: Sorafenib-experienced Asian cohort analysis" [J Hepatol 71 (2019) 543-552].Thomas Yau; Chiun Hsu; Tae-You Kim; Su-Pin Choo; Yoon-Koo Kang; Ming-Mo Hou; Kazushi Numata; Winnie Yeo; Akhil Chopra; Masafumi Ikeda; Ryoko Kuromatsu; Michihisa Moriguchi; Yee Chao; Huanyu Zhao; Jeffrey Anderson; Christine Dela Cruz; Masatoshi KudoJournal of hepatology 71 (6) 1278 - 1278 0168-8278 2019/12 [Refereed]【消化管症候群(第3版)-その他の消化管疾患を含めて-】胃 炎症性・非腫瘍性 胃嚢胞松井 繁長; 辻 直子; 樫田 博史; 工藤 正俊日本臨床 (株)日本臨床社 別冊 (消化管症候群I) 152 - 155 0047-1852 2019/12Biology and significance of alpha-fetoprotein in hepatocellular carcinoma.Peter R Galle; Friedrich Foerster; Masatoshi Kudo; Stephen L Chan; Josep M Llovet; Shukui Qin; William R Schelman; Sudhakar Chintharlapalli; Paolo B Abada; Morris Sherman; Andrew X ZhuLiver international : official journal of the International Association for the Study of the Liver 39 (12) 2214 - 2229 1478-3223 2019/12 [Refereed] Hepatocellular carcinoma (HCC) is one of the most common causes of cancer-related deaths globally due, in part, to the majority of patients being diagnosed with intermediate or advanced stage disease. Our increased understanding of the heterogeneous molecular pathogenesis of HCC has led to significant developments in novel targeted therapies. Despite these advances, there remains a high unmet need for new treatment options. HCC is a complex disease with multiple pathogenic mechanisms caused by a variety of risk factors, making it difficult to characterize with a single biomarker. In fact, numerous biomarkers have been studied in HCC, but alpha-fetoprotein (AFP) remains the most widely used and accepted serum marker since its discovery over 60 years ago. This review summarizes the most relevant studies associated with the regulation of AFP at the gene and protein levels; the pathophysiology of AFP as a pro-proliferative protein; and the correlation of AFP with molecular HCC subclasses, the vascular endothelial growth factor pathway and angiogenesis. Also described are the historical and current uses of AFP for screening and surveillance, diagnosis, its utility as a prognostic and predictive biomarker and its role as a tumour antigen in HCC. Taken together, these data demonstrate the relevance of AFP for patients with HCC and identify several remaining questions that will benefit from future research.Novel concept using a plastic stent for endoscopic ultrasound-guided hepaticogastrostomy adjusting the length according to the patient's anatomy.Mamoru Takenaka; Kosuke Minaga; Tomoe Yoshikawa; Ayana Okamoto; Atsushi Nakai; Shunsuke Omoto; Masatoshi KudoEndoscopy 51 (12) E362-E363  0013-726X 2019/12 [Refereed]Intestinal dysbiosis mediates experimental autoimmune pancreatitis via activation of plasmacytoid dendritic cells.Ken Kamata; Tomohiro Watanabe; Kosuke Minaga; Akane Hara; Tomoe Yoshikawa; Ayana Okamoto; Kentaro Yamao; Mamoru Takenaka; Ah-Mee Park; Masatoshi KudoInternational immunology 31 (12) 795 - 809 0953-8178 2019/11 [Refereed] Autoimmune pancreatitis (AIP) is a pancreatic manifestation of a newly proposed disease entity, IgG4-related disease (IgG4-RD), characterized by enhanced IgG4 antibody responses and involvement of multiple organs. We have previously reported that innate immune activation contributes to the development of AIP and IgG4-RD, as these diseases are characterized by the production of IFN-α and IL-33 by plasmacytoid dendritic cells (pDCs) that mediate chronic fibroinflammatory responses. In this study, we investigated the roles played by innate immunity against intestinal microflora in experimental AIP induced in MRL/MpJ mice by repeated administrations of 100 µg of polyinosinic-polycytidylic acid [poly (I:C)]. Bowel sterilization with a broad spectrum of antibiotics inhibited pancreatic accumulation of pDCs producing IFN-α and IL-33, and thereby suppressed the development of AIP. Mice treated with 10 µg of poly (I:C) developed severe AIP equivalent to that induced by 100 µg of poly (I:C) upon co-housing with mice treated with 100 µg of poly (I:C). Fecal microbiota transplantation (FMT) from donor mice treated with 100 µg of poly (I:C) led to the development of severe AIP in the recipient mice upon injection with 10 µg of poly (I:C). Induction of severe AIP in mice with 10 µg of poly (I:C) was associated with pancreatic accumulation of pDCs producing IFN-α and IL-33 in the co-housing and FMT experiments. These data collectively suggest that innate immune responses against intestinal microflora are involved in the development of experimental AIP, and that intestinal dysbiosis increases sensitivity to experimental AIP via activation of pDCs.【超音波TOPICS2019〜第45回超音波ドプラ・新技術研究会報告集〜】eFLOWを用いた後血管相のdefectの評価の初期経験小川 力; 盛田 真弘; 野村 貴子; 工藤 正俊Rad Fan (株)メディカルアイ 17 (15) 24 - 26 1348-3498 2019/11 今回日立製作所のARIETTA850の新しいversionで搭載された、eFLOWを用いた後血管相の評価の初期経験を報告する。同テクノロジーは容易な操作で、明瞭な後血管でのdefectの評価が可能であり、また分化度の違いによりdefectの程度に違いが認められる可能性も示唆された。(著者抄録)【膵炎大全II〜膵炎・Up to date〜】膵炎の治療 重症急性膵炎のマネジメント 集中治療と特殊治療の適応について大本 俊介; 竹中 完; 工藤 正俊胆と膵 医学図書出版(株) 40 (臨増特大) 1163 - 1168 0388-9408 2019/11 重症急性膵炎の死亡率は10.1%と高率であり、基本的治療のみならず集中治療やOption(特殊治療)の実施を検討する必要がある。集中治療には、臓器不全対策、輸液管理、栄養管理、早期経腸栄養、感染予防、abdominal compartment syndrome(ACS)対策があげられ、Optionとしては、動注治療や血液浄化があげられる。臓器不全対策は、発症早期の高度の全身性炎症反応症候群(systemic inflammatory response syndrome:SIRS)と発症後期のbacterial translocationが播種性血管内凝固症(disseminated intravascular coagulation:DIC)、臓器不全の誘引となることが知られており、この両者の病態を検討することが重要である。SIRS対策としては血液浄化と動注治療があり、感染対策として、重症例に対する予防的抗菌薬投与、早期経腸栄養が実施される。腹腔内圧を測定し、ACSを予防し適切な加療を行うことが膵炎の予後改善に寄与する可能性がある。DIC合併膵炎の治療として遺伝子組み換え型ヒト可溶性トロンボモジュリン(recombinant human soluble thrombomodulin:rTM)が有用である可能性が示唆されており今後のさらなる検討が期待される。(著者抄録)膵癌/胆道癌における早期診断の進歩 膵癌診断のための新たなアプローチ法の提案 3D CT解析による膵実質萎縮の検討山雄 健太郎; 竹中 完; 工藤 正俊日本消化器病学会雑誌 (一財)日本消化器病学会 116 (臨増大会) A573 - A573 0446-6586 2019/11鑑別診断において造影超音波が有用であった多血性の肝内胆管癌(腫瘤形成型)の1例友岡 瑞樹; 盛田 真弘; 南 康範; 依田 広; 南 知宏; 青木 智子; 田北 雅弘; 萩原 智; 上嶋 一臣; 西田 直生志; 工藤 正俊肝臓 (一社)日本肝臓学会 60 (Suppl.3) A926 - A926 0451-4203 2019/11 [Refereed]Scientific Rationale for Combination Immunotherapy of Hepatocellular Carcinoma with Anti-PD-1/PD-L1 and Anti-CTLA-4 Antibodies.Masatoshi KudoLiver cancer 8 (6) 413 - 426 2019/11 [Refereed]Conversion of percutaneous transhepatic gallbladder drainage to endoscopic ultrasound-guided hepaticogastrostomy by the intentional expansion method.Mamoru Takenaka; Ken Kamata; Masatoshi KudoDigestive endoscopy : official journal of the Japan Gastroenterological Endoscopy Society 31 (6) 718 - 718 0915-5635 2019/11 [Refereed]Objective Response by mRECIST Is an Independent Prognostic Factor for Overall Survival in Hepatocellular Carcinoma Treated with Sorafenib in the SILIUS Trial.Masatoshi Kudo; Kazuomi Ueshima; Yasutaka Chiba; Sadahisa Ogasawara; Shuntaro Obi; Namiki Izumi; Hiroshi Aikata; Hiroaki Nagano; Etsuro Hatano; Yutaka Sasaki; Keisuke Hino; Takashi Kumada; Kazuhide Yamamoto; Yasuharu Imai; Shouta Iwadou; Chikara Ogawa; Takuji Okusaka; Fumihiko Kanai; Yasuaki AraiLiver cancer 8 (6) 505 - 519 2235-1795 2019/11 [Refereed] Objective: In SILIUS (NCT01214343), combination of sorafenib and hepatic arterial infusion chemotherapy did not significantly improve overall survival (OS) in patients with advanced hepatocellular carcinoma (HCC) compared with sorafenib alone. In this study, we explored the relationship between objective response by mRECIST and OS in the sorafenib group, in the combination group, and in all patients in the SILIUS trial. Methods: Association between objective response and OS in patients treated with sorafenib (n = 103) or combination (n = 102) and all patients (n = 205) were analyzed. The median OS of responders was compared with that of non-responders. Landmark analyses were performed according to objective response at several fixed time points, as sensitivity analyses, and the effect on OS was evaluated by Cox regression analysis with objective response as a time-dependent covariate, with other prognostic factors. Results: In the sorafenib group, OS of responders (n = 18) was significantly better than that of non-responders (n = 78) (p Can Localized Stenosis of the Main Pancreatic Duct be a Predictive Factor for Early Detection of Pancreatic Cancer?Mamoru Takenaka; Kentaro Yamao; Masatoshi KudoClinical endoscopy 52 (6) 523 - 524 2234-2400 2019/11 [Refereed]Clinical practice guidelines for hepatocellular carcinoma: The Japan Society of Hepatology 2017 (4th JSH-HCC guidelines) 2019 update.Norihiro Kokudo; Nobuyuki Takemura; Kiyoshi Hasegawa; Tadatoshi Takayama; Shoji Kubo; Mitsuo Shimada; Hiroaki Nagano; Etsuro Hatano; Namiki Izumi; Shuichi Kaneko; Masatoshi Kudo; Hiroko Iijima; Takuya Genda; Ryosuke Tateishi; Takuji Torimura; Hiroshi Igaki; Satoshi Kobayashi; Hideyuki Sakurai; Takamichi Murakami; Takeyuki Watadani; Yutaka MatsuyamaHepatology research : the official journal of the Japan Society of Hepatology 49 (10) 1109 - 1113 1386-6346 2019/10 [Refereed] The fourth version of Clinical Practice Guidelines for Hepatocellular Carcinoma was revised by the Japan Society of Hepatology, according to the methodology of evidence-based medicine and partly to the Grading of Recommendations Assessment, Development, and Evaluation system, which was published in October 2017 in Japanese. New or revised recommendations were described, herein, with a special reference to the surveillance, diagnostic, and treatment algorithms.Correction: Urine protein:creatinine ratio vs 24-hour urine protein for proteinuria management: analysis from the phase 3 REFLECT study of lenvatinib vs sorafenib in hepatocellular carcinoma.Thomas R Jeffry Evans; Masatoshi Kudo; Richard S Finn; Kwang-Hyub Han; Ann-Lii Cheng; Masafumi Ikeda; Silvija Kraljevic; Min Ren; Corina E Dutcus; Fabio Piscaglia; Max W SungBritish journal of cancer 121 (7) 625 - 625 0007-0920 2019/10 [Refereed] This article was originally published under a standard license to Publish, but has now been made available under a CC BY license. The PDF and HTML versions of the paper have been modified accordingly.An amendment to this paper has been published and can be accessed via a link at the top of the paper.DLBCLに発症したリンパ管拡張症に対してステロイド投与、食事療法が奏効した1症例大塚 康生; 米田 頼晃; 正木 翔; 筑後 孝章; 吉川 馨介; 高島 耕太; 橋本 有人; 山田 光成; 本庶 元; 永井 知行; 櫻井 俊治; 松井 繁長; 渡邉 智裕; 辻 直子; 樫田 博史; 工藤 正俊日本消化器病学会近畿支部例会プログラム・抄録集 日本消化器病学会-近畿支部 111回 91 - 91 2019/10膵頭十二指腸切除後の胆管結石に対して細径上部消化管内視鏡下のEHLが有用であった1例福永 朋洋; 水野 成人; 松村 まり子; 高田 隆太郎; 河野 匡志; 秦 康倫; 木下 大輔; 奥田 英之; 川崎 俊彦; 工藤 正俊胆道 日本胆道学会 33 (3) 636 - 636 0914-0077 2019/10肝細胞腺腫の1例山根 雅智; 秦 康倫; 松村 まり子; 福永 朋洋; 高田 隆太郎; 河野 匡志; 木下 大輔; 奥田 英之; 川崎 俊彦; 水野 成人; 日向 聖; 石川 原; 井上 雅智; 若狭 朋子; 太田 善夫; 工藤 正俊日本消化器病学会近畿支部例会プログラム・抄録集 日本消化器病学会-近畿支部 111回 76 - 76 2019/10Deep neural networkを用いた超音波デジタル画像における肝腫瘍病名判別の試み西田 直生志; 工藤 正俊肝臓 (一社)日本肝臓学会 60 (Suppl.2) A566 - A566 0451-4203 2019/10 [Refereed]EUS施行時のプロポフォール持続注入による鎮静の有用性の検討岡本 彩那; 鎌田 研; 竹中 完; 吉川 智恵; 石川 嶺; 山崎 友裕; 中井 敦史; 大本 俊介; 三長 孝輔; 山雄 健太郎; 工藤 正俊Gastroenterological Endoscopy (一社)日本消化器内視鏡学会 61 (Suppl.2) 2182 - 2182 0387-1207 2019/10 [Refereed]LENVATINIB AS AN INITIAL TREATMENT IN PATIENTS WITH INTERMEDIATE-STAGE HEPATOCELLULAR CARCINOMA BEYOND UP-TO-SEVEN CRITERIA AND CHILD-PUGH A LIVER FUNCTION: A MULTICENTER PROPENSITY-SCORE MATCHED STUDYKudo Masatoshi; Ueshima Kazuomi; Chan Stephen L; Minami Tomohiro; Chishina Hirokazu; Aoki Tomoko; Takita Masahiro; Hagiwara Satoru; Minami Yasunori; Ida Hiroshi; Takenaka Mamoru; Sakurai Toshiharu; Watanabe Tomohiro; Morita Masahiro; Ogawa Chikara; Wada Yoshiyuki; Ikeda Masafumi; Ishii Hiroshi; Izumi Namiki; Nishida NaoshiHEPATOLOGY WILEY 70 133A - 134A 0270-9139 2019/10 [Refereed]Comparison of the Diagnostic Performance of Newly Designed 21-Gauge and Standard 22-Gauge Aspiration Needles in Patients with Solid Pancreatic MassesKosuke Minaga; Tomoe Yoshikawa; Yukitaka Yamashita; Hiroko Akamatsu; Maiko Ikenouchi; Tatsuya Ishii; Hisakazu Matsumoto; Hiroyoshi Iwagami; Yasuki Nakatani; Keiichi Hatamaru; Mamoru Takenaka; Takuji Akamatsu; Yoshito Uenoyama; Tomohiro Watanabe; Kazuo Ono; Yasutaka Chiba; Masatoshi KudoDigestive Diseases and Sciences Springer Science and Business Media LLC 64 (10) 2982 - 2991 0163-2116 2019/10 [Refereed]Switching from entecavir to tenofovir alafenamide versus maintaining entecavir for chronic hepatitis B.Satoru Hagiwara; Naoshi Nishida; Hiroshi Ida; Kazuomi Ueshima; Yasunori Minami; Masahiro Takita; Yoriaki Komeda; Masatoshi KudoJournal of medical virology 91 (10) 1804 - 1810 0146-6615 2019/10 [Refereed] Tenofovir alafenamide (TAF) is a newly developed prodrug of tenofovir (TFV). We divided 48 chronic hepatitis B patients who had taken entecavir (ETV) for ≥2 years into two groups: the ETV continuation (n = 24) and the TAF switching (n = 24) groups, and compared the antiviral effects and safety until 48 weeks after the start of the study. There were no significant differences in the alterations in the serum levels of HBs antigen (HBsAg) level between the ETV continuation and the TAF switching groups at 24 or 48 weeks. We also examined the effect of baseline HBsAg level on the decrease of HBsAg during the treatment; in the TAF switching group, the decrease of HBsAg level at 48 weeks was more significant in patients with low baseline HBsAg (800 IU/mL) (change of HBsAg; - 0.029 vs - 0.132 for high and low baseline HBsAg, respectively, P = .007). Also, the effect on renal function was found to be comparable between the TAF switch group and the ETV continuation group. In this study, switching from ETV to TAF may represent higher efficacy for a decrease of HBsAg than a continuation of ETV among the patients with low baseline HBsAg level.A New Treatment Option for Intermediate-Stage Hepatocellular Carcinoma with High Tumor Burden: Initial Lenvatinib Therapy with Subsequent Selective TACE.Masatoshi KudoLiver cancer 8 (5) 299 - 311 2235-1795 2019/10 [Refereed]Newly Proposed ALBI Grade and ALBI-T Score as Tools for Assessment of Hepatic Function and Prognosis in Hepatocellular Carcinoma Patients.Atsushi Hiraoka; Takashi Kumada; Kojiro Michitaka; Masatoshi KudoLiver cancer 8 (5) 312 - 325 2235-1795 2019/10 [Refereed] Background: Because of the rapid progression of antiviral treatment options and the increasing frequency of nonviral-related hepatocellular carcinoma (HCC) due to the aging of society, the number of HCC patients with good hepatic function has been increasing and a more detailed method of assessment of hepatic function is needed. The Child-Pugh classification (CP) is used worldwide as an assessment tool for hepatic reserve function, even though it has some weaknesses. Recently, the albumin-bilirubin (ALBI) grade, calculated based on only albumin and total bilirubin, was proposed, and recent investigations have suggested that ALBI grade instead of CP can be used as an assessment tool for hepatic function as part of therapeutic strategies such as Barcelona Clinic Liver Cancer staging and a practical guideline presented by the Japan Society of Hepatology as well for total staging scoring systems. There has been an increasing number of reports showing that it has better capability than CP for HCC patients who undergo not only curative but also palliative treatments. Transcatheter arterial chemoembolization (TACE) is a major palliative treatment used for unresectable HCC, and the idea of TACE-refractory status has been proposed to indicate the possibility of switching to a tyrosine kinase inhibitor (TKI). However, TKI administration requires a maintained hepatic reserve function, thus the importance of assessment of hepatic function in patients undergoing TACE treatments has increased. We consider that ALBI grade might also play a significant role as part of a detailed assessment of relative changes in hepatic function during treatment. In this review, we evaluate the practical usefulness of ALBI grade for assessing hepatic function and HCC prognosis. Key Message: A detailed assessment of hepatic function is required for recent HCC therapeutic strategies. ALBI grade may be a powerful tool to improve treatment options for affected patients.Prediction of Prognosis of Intermediate-Stage HCC Patients: Validation of the Tumor Marker Score in a Nationwide Database in Japan.Atsushi Hiraoka; Kojiro Michitaka; Takashi Kumada; Namiki Izumi; Masumi Kadoya; Norihiro Kokudo; Shoji Kubo; Yutaka Matsuyama; Osamu Nakashima; Michiie Sakamoto; Tadatoshi Takayama; Takashi Kokudo; Kosuke Kashiwabara; Susumu Eguchi; Tatsuya Yamashita; Masatoshi KudoLiver cancer 8 (5) 403 - 411 2235-1795 2019/10 [Refereed] Background/Aim: Adequate assessment of transcatheter arterial chemoembolization (TACE)-refractory status has become more important for switching treatment in intermediate-stage (BCLC-B) hepatocellular carcinoma (HCC) patients treated with TACE. The usefulness of a previously proposed tumor marker score for predicting prognosis of BCLC-B HCC patients treated with TACE was investigated. Methods: Using a nationwide database, we examined the records of 1,306 naïve BCLC-B HCC with Child-Pugh A who were treated from 2001 to 2007, after excluding those with missing data (hepatic function or tumor markers) or cases with a single large tumor. Alpha-fetoprotein (AFP) ≥100 ng/mL, fucosylated AFP (AFP-L3) ≥10%, and des-gamma-carboxy prothrombin ≥100 mAU/mL were markers used to define positive cases. The number of positive tumor markers was used as a prognostic score, and its predictive value was evaluated in a retrospective manner. Results: Median survival time became shorter along with increased score (0, 1, ≥2 = 4.8, 3.8, 3.2 years, respectively; p Effective use of the Japan Narrow Band Imaging Expert Team classification based on diagnostic performance and confidence level.Daizen Hirata; Hiroshi Kashida; Mineo Iwatate; Tomomasa Tochio; Akira Teramoto; Yasushi Sano; Masatoshi KudoWorld journal of clinical cases 7 (18) 2658 - 2665 2019/09 [Refereed] Five years have passed since the Japan Narrow Band Imaging Expert Team (JNET) classification was proposed in 2014. However, the diagnostic performance of this classification has not yet been established. We conducted a retrospective study and a systematic search of Medical Literature Analysis and Retrieval System On-Line. There were three retrospective single center studies about the diagnostic performance of this classification. In order to clarify this issue, we reviewed our study and three previous studies. This review revealed the diagnostic performance in regards to three important differentiations. (1) Neoplasia from non-neoplasia; (2) malignant neoplasia from benign neoplasia; and (3) deep submucosal invasive cancer (D-SMC) from other neoplasia. The sensitivity in differentiating neoplasia from non-neoplasia was 98.1%-99.8%. The specificity in differentiating malignant neoplasia from benign neoplasia was 84.7%-98.2% and the specificity in the differentiation D-SMC from other neoplasia was 99.8%-100.0%. This classification would enable endoscopists to identify almost all neoplasia, to appropriately determine whether to perform en bloc resection or not, and to avoid unnecessary surgery. This article is the first review about the diagnostic performance of the JNET classification. Previous reports about the diagnostic performance have all been retrospective single center studies. A large-scale prospective multicenter evaluation study is awaited for the validation.RICK/RIP2 is a NOD2-independent nodal point of gut inflammation.Tomohiro Watanabe; Kosuke Minaga; Ken Kamata; Toshiharu Sakurai; Yoriaki Komeda; Tomoyuki Nagai; Atsushi Kitani; Masaki Tajima; Ivan J Fuss; Masatoshi Kudo; Warren StroberInternational immunology Oxford University Press (OUP) 31 (10) 669 - 683 2019/09 [Refereed] Previous studies have shown that inhibition of receptor-interacting serine/threonine kinase (RICK) (also known as RIP2) results in amelioration of experimental colitis. This role has largely been attributed to nucleotide-binding oligomerization domain 2 (NOD2) signaling since the latter is considered a major inducer of RICK activation. In this study, we explored the molecular mechanisms accounting for RICK-mediated inhibition of inflammatory bowel disease (IBD). In an initial series of studies focused on trinitrobenzene sulfonic acid (TNBS)-colitis and dextran sodium sulfate (DSS)-colitis we showed that down-regulation of intestinal RICK expression in NOD2-intact mice by intra-rectal administration of a plasmid expressing RICK-specific siRNA was accompanied by down-regulation of pro-inflammatory cytokine responses in the colon and protection of the mice from experimental colitis. Somewhat surprisingly, intra-rectal administration of RICK-siRNA also inhibited TNBS-colitis and DSS-colitis in NOD2-deficient and in NOD1/NOD2-double deficient mice. In complementary studies of humans with IBD we found that expression of RICK, cellular inhibitor of apoptosis protein 2 (cIAP2) and downstream signaling partners were markedly increased in inflamed tissue of IBD compared to controls without marked elevations of NOD1 or NOD2 expression. In addition, the increase in RICK expression correlated with disease activity and pro-inflammatory cytokine responses. These studies thus suggest that NOD1- or NOD2-independenent activation of RICK plays a major role in both murine experimental colitis and human IBD.潰瘍性大腸炎関連大腸癌の予防における内視鏡的粘膜下層剥離術の役割(Role of endoscopic submucosal dissection for ulcerative colitis-associated cancer prevention)櫻井 俊治; 坂井 和子; 永井 知行; 樫田 博史; 筑後 孝章; 根津 理一郎; 西尾 和人; 工藤 正俊日本癌学会総会記事 (一社)日本癌学会 78回 P - 3296 0546-0476 2019/09Long-term outcomes of EUS-guided transluminal stent deployment for benign biliary disease: Multicenter clinical experience (with videos).Ogura T; Takenaka M; Shiomi H; Goto D; Tamura T; Hisa T; Kato H; Nishioka N; Minaga K; Masuda A; Onoyama T; Kudo M; Higuchi K; Kitano MEndoscopic ultrasound 8 (6) 398 - 403 2303-9027 2019/09 [Refereed]Nivolumab in advanced hepatocellular carcinoma: Sorafenib-experienced Asian cohort analysis.Thomas Yau; Chiun Hsu; Tae-You Kim; Su-Pin Choo; Yoon-Koo Kang; Ming-Mo Hou; Kazushi Numata; Winnie Yeo; Akhil Chopra; Masafumi Ikeda; Ryoko Kuromatsu; Michihisa Moriguchi; Yee Chao; Huanyu Zhao; Jeffrey Anderson; Christine Dela Cruz; Masatoshi KudoJournal of hepatology 71 (3) 543 - 552 2019/09 [Refereed] BACKGROUND & AIMS: Nivolumab, an immune checkpoint inhibitor, is approved in several countries to treat sorafenib-experienced patients with HCC, based on results from the CheckMate 040 study (NCT01658878). Marked differences exist in HCC clinical presentation, aetiology, treatment patterns and outcomes across regions. This analysis assessed the safety and efficacy of nivolumab in the Asian cohort of CheckMate 040. METHODS: CheckMate 040 is an international, multicentre, open-label, phase I/II study of nivolumab in adults with advanced HCC, regardless of aetiology, not amenable to curative resection or local treatment and with/without previous sorafenib treatment. This analysis included all sorafenib-experienced patients in the intent-to-treat (ITT) overall population and Asian cohort. The analysis cut-off date was March 2018. RESULTS: There were 182 and 85 patients in the ITT population and Asian cohort, respectively. In both populations, most patients were older than 60 years, had BCLC (Barcelona Clinic Liver Cancer) Stage C disease, and had received previous systemic therapy. A higher percentage of Asian patients had HBV infections, extrahepatic metastases and prior therapies. Median follow-up was 31.6 and 31.3 months for the ITT and Asian patients, respectively. Objective response rates were 14% and 15% in the ITT population and Asian cohort, respectively. In the Asian cohort, patients with HBV, HCV or those who were uninfected had objective response rates of 13%, 14% and 21%, respectively. The median duration of response was longer in the ITT (19.4 months) vs. Asian patients (9.7 months). Median overall survival was similar between the ITT (15.1 months) and Asian patients (14.9 months), and unaffected by aetiology in Asian patients. The nivolumab safety profile was similar and manageable across both populations. CONCLUSION: Nivolumab safety and efficacy are comparable between sorafenib-experienced ITT and Asian patients. LAY SUMMARY: The CheckMate 040 study evaluated the safety and efficacy of nivolumab in patients with advanced hepatocellular carcinoma who were refractory to previous sorafenib treatment or chemotherapy. This subanalysis of the data showed that treatment responses and safety in patients in Asia were similar to those of the overall treatment population, providing support for nivolumab as a treatment option for these patients. Clinical trial number: NCT01658878.難治性腹水に対して行われたデンバーシャント術の報告青木 智子; 田北 雅弘; 大塚 康生; 南 知宏; 萩原 智; 南 康範; 依田 広; 上嶋 一臣; 西田 直生志; 鶴崎 正勝; 工藤 正俊日本門脈圧亢進症学会雑誌 (一社)日本門脈圧亢進症学会 25 (3) 146 - 146 1344-8447 2019/09 [Refereed]A novel technique for stent dysfunction after endoscopic ultrasound-guided hepaticogastrostomy with antegrade stenting.Ayana Okamoto; Kosuke Minaga; Mamoru Takenaka; Tomoe Yoshikawa; Ken Kamata; Kentaro Yamao; Masatoshi KudoEndoscopy 51 (9) E255-E256  0013-726X 2019/09 [Refereed]Response Evaluation Criteria in Cancer of the Liver version 5 (RECICL 2019 revised version).Masatoshi Kudo; Masafumi Ikeda; Kazuomi Ueshima; Michiie Sakamoto; Shuichiro Shiina; Ryosuke Tateishi; Kiyoshi Hasegawa; Junji Furuse; Shiro Miyayama; Takamichi Murakami; Tatsuya Yamashita; Norihiro KokudoHepatology research : the official journal of the Japan Society of Hepatology 49 (9) 981 - 989 1386-6346 2019/09 [Refereed] Response Evaluation Criteria in Solid Tumors (RECIST) is inappropriate to assess the direct effects of treatment on hepatocellular carcinoma (HCC) by locoregional therapies, such as radiofrequency ablation and transarterial chemoembolization. Therefore, establishment of response evaluation criteria solely devoted to HCC is needed in clinical practice, as well as in clinical trials of HCC treatment, such as systemic therapies, which cause necrosis of the tumor. Response Evaluation Criteria in Cancer of the Liver (RECICL) was revised in 2019 by the Liver Cancer Study Group of Japan based on the 2015 version of RECICL, which was commonly used in Japan. The major revised points of the RECICL 2019 are as follows: (i) CEA and CA19-9 have been newly added as tumor markers that should be recorded for use as criteria in the response evaluation for intrahepatic cholangiocarcinoma; (ii) the criteria now state that the details of molecular targeted therapy should be specified; and (iii) specific methods for overall evaluation are now described. Also, as an assessment of overall TE4 requires that TE4 is achieved in all nodules (even non-target lesions), the same calculation methods described above are used. We hope this new treatment response criteria, RECICL, proposed by the Liver Cancer Study Group of Japan will benefit the HCC treatment response evaluation in the setting of daily clinical practice and clinical trials as well, not only in Japan, but also internationally.Large balloon expansion method for re-intervention after endoscopic ultrasound-guided hepaticogastrostomy for stent obstruction.Mamoru Takenaka; Atsushi Nakai; Masatoshi KudoDigestive endoscopy : official journal of the Japan Gastroenterological Endoscopy Society 31 (5) e99-e100 - e100 0915-5635 2019/09 [Refereed]Comparison of the efficacy and safety of endoscopic ultrasound-guided choledochoduodenostomy and hepaticogastrostomy for malignant distal biliary obstruction: Multicenter, randomized, clinical trial.Kosuke Minaga; Takeshi Ogura; Hideyuki Shiomi; Hajime Imai; Noriyuki Hoki; Mamoru Takenaka; Hidefumi Nishikiori; Yukitaka Yamashita; Takeshi Hisa; Hironari Kato; Hideki Kamada; Atsushi Okuda; Ryota Sagami; Hiroaki Hashimoto; Kazuhide Higuchi; Yasutaka Chiba; Masatoshi Kudo; Masayuki KitanoDigestive endoscopy : official journal of the Japan Gastroenterological Endoscopy Society 31 (5) 575 - 582 0915-5635 2019/09 [Refereed] BACKGROUND AND AIM: Endoscopic ultrasound-guided biliary drainage (EUS-BD) can be carried out by two different approaches: choledochoduodenostomy (CDS) and hepaticogastrostomy (HGS). We compared the efficacy and safety of these approaches in malignant distal biliary obstruction (MDBO) patients using a prospective, randomized clinical trial. METHODS: Patients with malignant distal biliary obstruction after failed endoscopic retrograde cholangiopancreatography were randomly selected for either CDS or HGS. The procedures were carried out at nine tertiary centers from September 2013 to March 2016. Primary endpoint was technical success rate, and the noninferiority of HGS to CDS was examined with a one-sided significance level of 5%, where the noninferiority margin was set at 15%. Secondary endpoints were clinical success, adverse events (AE), stent patency, survival time, and overall technical success including alternative EUS-BD procedures. RESULTS: Forty-seven patients (HGS, 24; CDS, 23) were enrolled. Technical success rates were 87.5% and 82.6% in the HGS and CDS groups, respectively, where the lower limit of the 90% confidence interval of the risk difference was -12.2% (P = 0.0278). Clinical success rates were 100% and 94.7% in the HGS and CDS groups, respectively (P = 0.475). Overall AE rate, stent patency, and survival time did not differ between the groups. Overall technical success rates were 100% and 95.7% in the HGS and CDS groups, respectively (P = 0.983). CONCLUSIONS: This study suggests that HGS is not inferior to CDS in terms of technical success. When one procedure is particularly challenging, readily switching to the other could increase technical success.【進化する肝細胞癌の薬物療法-2019 Update(Part 1)】レンバチニブ レンバチニブの奏効とALBI Grade上嶋 一臣; 工藤 正俊肝・胆・膵 (株)アークメディア 79 (2) 227 - 231 0389-4991 2019/08Adjuvant therapy after radical surgery for hepatocellular carcinoma: still an unmet need.Yasunori Minami; Masatoshi KudoHepatobiliary surgery and nutrition 8 (4) 414 - 416 2304-3881 2019/08 [Refereed]Real-world virological efficacy and safety of daclatasvir/asunaprevir/beclabuvir in patients with chronic hepatitis C virus genotype 1 infection in JapanTakaguchi, Koichi; Toyoda, Hidenori; Tsutsui, Akemi; Suzuki, Yoshiyuki; Nakamuta, Makoto; Imamura, Michio; Senoh, Tomonori; Nagano, Takuya; Tada, Toshifumi; Tachi, Yoshihiko; Hiraoka, Atsushi; Michitaka, Kojiro; Shibata, Hiroshi; Joko, Kouji; Okubo, Hironao; Tsuji, Kunihiko; Takaki, Shintaro; Watanabe, Tsunamasa; Ogawa, Chikara; Chayama, Kazuaki; Kumada, Takashi; Kudo, Masatoshi; Kumada, HiromitsuJOURNAL OF GASTROENTEROLOGY SPRINGER JAPAN KK 54 (8) 742 - 751 0944-1174 2019/08 [Refereed] BackgroundThe virological efficacy and safety of the direct-acting antiviral (DAA) regimen consisting of daclatasvir, asunaprevir, and beclabuvir (DCV/ASV/BCV) for patients chronically infected with hepatitis C virus (HCV) genotype 1 have not been previously evaluated in Japanese real-world settings.MethodsIn a Japanese nationwide multicenter study, the rate of sustained virologic response (SVR) and safety were analyzed in 91 patients who started the DCV/ASV/BCV regimen between November 2016 and July 2017. SVR rates were compared based on baseline patient characteristics.ResultsMore than 60% of patients had a history of failure to achieve SVR with interferon (IFN)-free DAA therapy. Overall, 50 of 91 patients (54.9%) achieved SVR. Multivariate analysis identified a history of failure with IFN-free DAA therapy and pretreatment HCV RNA levels as factors significantly associated with treatment failure. Whereas the SVR rate in patients without a history of IFN-free DAA therapy was 91.7% (33 of 36 patients), it was only 30.9% (17 of 55 patients) among patients with a history of IFN-free DAA therapy. The rate of discontinuation due to an adverse event was 4.4%.ConclusionsMany patients treHepatic portal venous gas associated with Klebsiella oxytoca infection in the absence of preceding antibiotic treatmentHidekazu Tanaka; Tomohiro Watanabe; Tomoyuki Nagai; Kosuke Minaga; Ken Kamata; Yoriaki Komeda; Masatoshi KudoClinical Journal of Gastroenterology Springer Science and Business Media LLC 12 (4) 316 - 319 1865-7257 2019/08 [Refereed]Contrast-enhanced harmonic endoscopic ultrasonography for evaluating the response to chemotherapy in pancreatic cancer.Hidekazu Tanaka; Ken Kamata; Mamoru Takenaka; Tomoe Yoshikawa; Rei Ishikawa; Ayana Okamoto; Tomohiro Yamazaki; Atsushi Nakai; Shunsuke Omoto; Kosuke Minaga; Kentaro Yamao; Toshiharu Sakurai; Tomohiro Watanabe; Naoshi Nishida; Yasutaka Chiba; Masayuki Kitano; Masatoshi KudoDigestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver 51 (8) 1130 - 1134 2019/08 [Refereed] BACKGROUND AND AIMS: Contrast-enhanced harmonic endoscopic ultrasonography (CH-EUS) is used for the diagnosis of pancreatic cancer (PC). Here, we examined the usefulness of CH-EUS for evaluating therapeutic responses in PC. METHODS: The study included 23 patients with PC who received chemotherapy. Patients underwent contrast-enhanced computed tomography (CE-CT) and CH-EUS before chemotherapy and at the time of evaluation of the therapeutic response. Patients with a ≧50% reduction in serum carbohydrate antigen 19-9 levels after chemotherapy were defined as "super responders". The incidence of an avascular area in the tumor on CH-EUS after chemotherapy was compared between "super responders" and non-super responders. RESULTS: Nine patients were included in the "super responders" group.Tumor reduction rates did not differ significantly between CE-CT and CH-EUS in the "super responders". The appearance of an avascular area was detected in 7 of 9 super responders (77.8%) and in 4 of 14 non-super responders (28.6%), and the difference was significant (P = 0.036). The mean survival time of patients with an avascular area after chemotherapy was longer than that of without an avascular area. CONCLUSIONS: Detection of avascular areas by CH-EUS after chemotherapy may predict long-term survival of patients with PC.Paradoxical ulcerative colitis during treatment with secukinumab for psoriasis.Shusuke Uchida; Naoki Oiso; Yoriaki Komeda; Masatoshi Kudo; Akira KawadaEuropean journal of dermatology : EJD 29 (4) 444 - 445 1167-1122 2019/08 [Refereed]Lenvatinib as an Initial Treatment in Patients with Intermediate-Stage Hepatocellular Carcinoma Beyond Up-To-Seven Criteria and Child-Pugh A Liver Function: A Proof-Of-Concept Study.Masatoshi Kudo; Kazuomi Ueshima; Stephan Chan; Tomohiro Minami; Hirokazu Chishina; Tomoko Aoki; Masahiro Takita; Satoru Hagiwara; Yasunori Minami; Hiroshi Ida; Mamoru Takenaka; Toshiharu Sakurai; Tomohiro Watanabe; Masahiro Morita; Chikara Ogawa; Yoshiyuki Wada; Masafumi Ikeda; Hiroshi Ishii; Namiki Izumi; Naoshi NishidaCancers 11 (8) 2019/07 [Refereed] Although transcatheter arterial chemoembolization (TACE) is the standard of care for intermediate-stage hepatocellular carcinoma (HCC), this is a largely heterogeneous disease that includes a subgroup of patients who do not benefit from TACE. The treatment strategy for this subgroup of patients currently remains an unmet need in clinical practice. Here, we performed a proof-of-concept study that lenvatinib may be a more favorable treatment option over TACE as an initial treatment in intermediate-stage HCC patients with large or multinodular tumours exceeding the up-to-seven criteria. This proof-of-concept study included 642 consecutive patients with HCC initially treated with lenvatinib or conventional TACE (cTACE) between January 2006 and December 2018. Of these patients, 176 who received lenvatinib or cTACE as an initial treatment and met the eligibility criteria (unresectable, beyond the up-to-seven criteria, no prior TACE/systemic therapy, no vascular invasion, no extrahepatic spread and Child-Pugh A liver function) were selected for the study. Propensity score matching was used to adjust for patient demographics. After propensity-score matching, the outcome of 30 patients prospectively treated with lenvatinib (14 in clinical trials, one in an early access program and 15 in real world settings) and 60 patients treated with cTACE as the initial treatment was compared. The change of albumin-bilirubin (ALBI) score from baseline to the end of treatment were -2.61 to -2.61 for 30 patients in the lenvatinib group (p = 0.254) and -2.66 to -2.09 in the cTACE group (p Clinical Safety and Efficacy of Secondary Prophylactic Pegylated G-CSF in Advanced Pancreatic Cancer Patients Treated with mFOLFIRINOX: A Single-center Retrospective Study.Kentaro Yamao; Mamoru Takenaka; Tomoe Yoshikawa; Rei Ishikawa; Ayana Okamoto; Tomohiro Yamazaki; Atsushi Nakai; Shunsuke Omoto; Ken Kamata; Kosuke Minaga; Satoru Hagiwara; Toshiharu Sakurai; Naoshi Nishida; Yasutaka Chiba; Tomohiro Watanabe; Masatoshi KudoInternal medicine (Tokyo, Japan) 58 (14) 1993 - 2002 0918-2918 2019/07 [Refereed] Objective Although modified FOLFIRINOX (mFOLFIRINOX, mFFX) is widely used for patients with advanced pancreatic ductal adenocarcinoma (PDAC), maintenance of the standard dose intensity is often difficult due to the high incidence of neutropenic events. Pegylated granulocyte colony-stimulating factor (G-CSF) (Peg G) is a long-lasting G-CSF agent that is applicable for prophylaxis against neutropenic complications. The aim of this study was to assess the clinical safety and efficacy of mFFX combined with secondary prophylaxis using Peg G in advanced PDAC patients. Methods Advanced PDAC patients who had received more than two cycles of mFFX were analyzed. The clinical safety and efficacy were compared between patients in the Peg G group and those in the non-Peg G group in a retrospective manner. Results Among 45 patients treated with mFFX, 28 exhibited grade 3-4 neutropenia or febrile neutropenia. Among these 28 patients, 4 who received only 1 or 2 mFFX cycles were excluded from this study. Finally, 11 patients in the Peg G group and 13 in the non-Peg G group were enrolled. The combination therapy with Peg G and mFFX markedly prolonged the progression-free survival compared with the non-Peg G group, and its effects were associated with a reduced incidence of neutropenic events as well as lower rates of dosage reduction, delayed chemotherapy due to neutropenic events and altered blood cell counts after chemotherapy. Conclusion The scheduled administration of secondary prophylactic Peg G prolonged the progression-free survival in patients treated with mFFX. The combination therapy of Peg G and mFFX may be recommended in patients who exhibit grade 3-4 neutropenic events after prior mFFX cycles.Usefulness of Ustekinumab for Treating a Case of Myelodysplastic Syndrome-associated Inflammatory Bowel Disease.Masashi Kono; Toshiharu Sakurai; Kazuki Okamoto; Tomoyuki Nagai; Yoriaki Komeda; Hiroshi Kashida; Kosuke Minaga; Ken Kamata; Mamoru Takenaka; Satoru Hagiwara; Tomohiro Watanabe; Naoshi Nishida; Eisuke Enoki; Hiroaki Inoue; Itaru Matsumura; Masatoshi KudoInternal medicine (Tokyo, Japan) 58 (14) 2029 - 2033 0918-2918 2019/07 [Refereed] Autoimmune diseases including inflammatory bowel disease (IBD) occur in association with myelodysplastic syndrome (MDS). MDS-associated IBD frequently demonstrates a complicated course. We herein report the first case with MDS-associated IBD that was successfully treated with ustekinumab (UST), an anti-interleukin (IL) 12/23p40 monoclonal antibody. A 63-year-old man with a 7-year history of MDS was referred for examination of diarrhea, abdominal pain and fever. A blood examination revealed a marked elevation of C-reactive protein. Colonoscopy showed multiple ulcers in the terminal ileum. He was resistant to anti-tumor necrosis factor (TNF)-α antibody and azacitidine. Subsequently, UST treatment reduced colonic IL-17 and IL-6 expression and the patient currently maintains a state of remission.Impact of Baseline ALBI Grade on the Outcomes of Hepatocellular Carcinoma Patients Treated with Lenvatinib: A Multicenter Study.Kazuomi Ueshima; Naoshi Nishida; Satoru Hagiwara; Tomoko Aoki; Tomohiro Minami; Hirokazu Chishina; Masahiro Takita; Yasunori Minami; Hiroshi Ida; Mamoru Takenaka; Toshiharu Sakurai; Tomohiro Watanabe; Masahiro Morita; Chikara Ogawa; Atsushi Hiraoka; Philip Johnson; Masatoshi KudoCancers 11 (7) 2019/07 [Refereed] BACKGROUND: This study investigated the impact of baseline liver function according to the Child-Pugh score and ALBI (albumin-bilirubin) grade on the outcomes of patients with unresectable hepatocellular carcinoma treated with lenvatinib. METHODS: A total of 82 lenvatinib treated patients were included. The correlations of baseline liver function according to the Child-Pugh score and ALBI grade with treatment outcomes, including objective response rate per mRECIST (modified Response Evaluation Criteria in the Solid Tumor), time to treatment failure, treatment duration, and likelihood of treatment discontinuation due to adverse events, were assessed in patients with hepatocellular carcinoma treated with lenvatinib. Patients were divided into four groups: (1) Child-Pugh score 5 and ALBI grade 1 (group 1), (2) Child-Pugh score 5 and ALBI grade 2 (group 2), (3) Child-Pugh score 6 (group 3), and (4) Child-Pugh score ≥7 (group 4). Univariate and multivariate analyses were performed to identify the factors contributing to the objective response rate and likelihood of discontinuation due to adverse events. Results: Among the 82 patients analyzed, group 1 had the highest objective response rate (57.1%) and the lowest likelihood of treatment discontinuation because of adverse events (11.1%) among the four groups (p Heterogeneity of Epigenetic and Epithelial Mesenchymal Transition Marks in Hepatocellular Carcinoma with Keratin 19 Proficiency.Naosuke Yokomichi; Naoshi Nishida; Yuzo Umeda; Fumitaka Taniguchi; Kazuya Yasui; Toshiaki Toshima; Yoshiko Mori; Akihiro Nyuya; Takehiro Tanaka; Takeshi Yamada; Takahito Yagi; Toshiyoshi Fujiwara; Yoshiyuki Yamaguchi; Ajay Goel; Masatoshi Kudo; Takeshi NagasakaLiver cancer 8 (4) 239 - 254 2235-1795 2019/07 [Refereed] Objective: Keratin 19 (K19) expression is a potential predictor of poor prognosis in patients with hepatocellular carcinoma (HCC). To clarify the feature of K19-proficient HCC, we traced epigenetic footprints in cultured cells and clinical materials. Patients and Methods: In vitro, KRT19 promoter methylation was analyzed and 5-aza-2'-deoxycytidine with trichostatin A (TSA) treatment was performed. Among 564 surgically resected HCCs, the clinicopathological relevance of K19-proficent HCCs was performed in comparison with hepatocytic (HepPar-1 and arginase-1), epithelial-mesenchymal transition (E-cadherin and vimentin), biliary differentiation-associated (K7 and NOTCH-1) markers, and epigenetic markers (KRT19 promoter/long interspersed nucleotide element-1 [LINE-1] methylation status). Results: KRT19 promoter methylation was clearly associated with K19 deficiency and 5-aza-2'-deoxycytidine with TSA treatment-stimulated K19 re-expression, implicating DNA methylation as a potential epigenetic process for K19 expression. After excluding HCCs with recurrence, TNM stage as IIIB or greater, preoperative therapy, transplantation, and combined hepatocellular cholangiocarcinoma, we assessed 125 of 564 HCC cases. In this cohort, K19 expression was found in 29 HCCs (23.2%) and corresponded with poor survival following surgery (p = 0.025) and extrahepatic recurrence-free survival (p = 0.017). Compared with K19-deficient HCCs, lower KRT19 promoter methylation level was observed in K19-proficient HCCs (p Immuno-Oncology Therapy for Hepatocellular Carcinoma: Current Status and Ongoing Trials.Masatoshi KudoLiver cancer 8 (4) 221 - 238 2235-1795 2019/07 [Refereed]B-Mode Ultrasonography versus Contrast-Enhanced Ultrasonography for Surveillance of Hepatocellular Carcinoma: A Prospective Multicenter Randomized Controlled Trial.Masatoshi Kudo; Kazuomi Ueshima; Yukio Osaki; Masashi Hirooka; Yasuharu Imai; Kazunobu Aso; Kazushi Numata; Masayuki Kitano; Takashi Kumada; Namiki Izumi; Yasukiyo Sumino; Chikara Ogawa; Kohei AkazawaLiver cancer 8 (4) 271 - 280 2235-1795 2019/07 [Refereed] Background: Current practice guidelines recommend the use of ultrasound (US) as an initial surveillance tool for hepatocellular carcinoma (HCC) in patients with liver cirrhosis. Patients with liver cirrhosis, however, frequently have coarse liver parenchyma, masking the presence of tiny nodules during B-mode US. Contrast-enhanced US (CEUS) with Sonazoid has a long-lasting, stable Kupffer phase, which makes it possible to scan the entire liver to depict small lesions. In addition, defect reperfusion imaging (reinjection imaging) enables to determine whether the detected nodule is HCC or not. This prospective, multicenter, randomized, controlled trial was conducted to demonstrate the usefulness of Kupffer phase surveillance in the detection of small HCC compared to B-mode US. Methods: A total of 23 institutions joined this study. In total, 656 patients with hepatitis B- or C-related liver cirrhosis were randomized either to the B-mode US surveillance group (n = 313) or the Kupffer phase CEUS with Sonazoid surveillance group (n = 309). The primary endpoint was the maximum size of HCC at the time of the first detection. Secondary endpoints included time to HCC detection, number of tumors, and Barcelona Clinic Liver Cancer stage at the first detection, and sensitivity, specificity, and accuracy of each method in the diagnosis, and the cumulative detection rate of HCC. Results: The mean HCC size at the first detection was significantly smaller in the CEUS (13.0 ± 4.1 mm; n = 28) than in the B-mode US group (16.7 ± 4.1 mm; n = 26) (p = 0.011). Of the 38 patients with HCV cirrhosis diagnosed with HCC by US alone, mean tumor size at the first detection was significantly smaller in the 20 patients diagnosed by CEUS alone than in the 18 diagnosed by B-mode US alone (12.7 ± 3.1 vs. 17.6 ± 7.0 mm, p = 0.012). In contrast, among the 16 patients with HBV cirrhosis diagnosed by US alone, mean tumor size at the first detection was similar in the 8 patients diagnosed by CEUS alone and the 8 diagnosed by B-mode US (13.6 ± 6.0 vs. 14.5 ± 2.7 mm, p = 0.715). Conclusion: Kupffer phase CEUS surveillance with Sonazoid is extremely useful for the early detection and confirmation of HCC using a reinjection technique. Kupffer phase CEUS with Sonazoid contrast combined with the reinjection technique is, therefore, recommended as first-line screening tool for HCC in patients with liver cirrhosis, especially those with very coarse liver parenchyma.Stereotactic Body Radiation Therapy as an Alternative Treatment for Patients with Hepatocellular Carcinoma Compared to Sorafenib: A Propensity Score Analysis.Dominik Bettinger; David J Pinato; Michael Schultheiss; Rohini Sharma; Lorenza Rimassa; Tiziana Pressiani; Michela E Burlone; Mario Pirisi; Masatoshi Kudo; Joong Won Park; Nico Buettner; Christoph Neumann-Haefelin; Tobias Boettler; Nasrin Abbasi-Senger; Horst Alheit; Wolfgang Baus; Oliver Blanck; Sabine Gerum; Mathias Guckenberger; Daniel Habermehl; Christian Ostheimer; Oliver Riesterer; Jörg Tamihardja; Anca-Ligia Grosu; Robert Thimme; Thomas Baptist Brunner; Eleni GkikaLiver cancer 8 (4) 281 - 294 2235-1795 2019/07 [Refereed] Background and Aims: Stereotactic body radiation therapy (SBRT) has emerged as a safe and effective treatment for patients with hepatocellular carcinoma (HCC), but its role in patients with advanced HCC is not yet defined. In this study, we aim to assess the efficacy and safety of SBRT in comparison to sorafenib treatment in patients with advanced HCC. Methods: We included 901 patients treated with sorafenib at six tertiary centers in Europe and Asia and 122 patients treated with SBRT from 13 centers in Germany and Switzerland. Medical records were reviewed including laboratory parameters, treatment characteristics and development of adverse events. Propensity score matching was performed to adjust for differences in baseline characteristics. The primary endpoint was overall survival (OS) and progression-free survival. Results: Median OS of SBRT patients was 18.1 (10.3-25.9) months compared to 8.8 (8.2-9.5) in sorafenib patients. After adjusting for different baseline characteristics, the survival benefit for patients treated with SBRT was still preserved with a median OS of 17.0 (10.8-23.2) months compared to 9.6 (8.6-10.7) months in sorafenib patients. SBRT treatment of intrahepatic lesions in patients with extrahepatic metastases was also associated with improved OS compared to patients treated with sorafenib in the same setting (17.0 vs. 10.0 months, p = 0.012), whereas in patients with portal vein thrombosis there was no survival benefit in patients with SBRT. Conclusions: In this retrospective comparative study, SBRT showed superior efficacy in HCC patients compared to patients treated with sorafenib.深層学習による超音波画像からの肝腫瘍検出に関する初期的検討堤 一晴; 中島 崇博; 道満 恵介; 目加田 慶人; 西田 直生志; 工藤 正俊日本医用画像工学会大会予稿集 日本医用画像工学会 38回 48 - 48 2019/07 [Refereed]Prognostic factor of lenvatinib for unresectable hepatocellular carcinoma in real-world conditions-Multicenter analysis.Atsushi Hiraoka; Takashi Kumada; Masanori Atsukawa; Masashi Hirooka; Kunihiko Tsuji; Toru Ishikawa; Koichi Takaguchi; Kazuya Kariyama; Ei Itobayashi; Kazuto Tajiri; Noritomo Shimada; Hiroshi Shibata; Hironori Ochi; Toshifumi Tada; Hidenori Toyoda; Kazuhiro Nouso; Akemi Tsutsui; Takuya Nagano; Norio Itokawa; Korenobu Hayama; Michitaka Imai; Kouji Joko; Yohei Koizumi; Yoichi Hiasa; Kojiro Michitaka; Masatoshi KudoCancer medicine 8 (8) 3719 - 3728 2019/07 [Refereed] BACKGROUND/AIM: We assessed suitable factors indicating newly developed lenvatinib (LEN) treatment for unresectable hepatocellular carcinoma (u-HCC) by investigating real-world clinical features of patients. MATERIALS/METHODS: One hundred fifty two u-HCC patients, who receive LEN treatment from March to December 2018, were enrolled. (Child-Pugh score [CPS] 5/6/7/8 = 76/61/13/2, modified albumin-bilirubin grade [mALBI] 1/2a/2b/3 = 53/35/60/4). Clinical features were evaluated retrospectively. RESULTS: Overall-response rate (ORR)/disease control rate (DCR) at 1 month after starting LEN were 38.7%/86.0%, respectively. Estimated median time to progression (TTP) was 7.0 months, while median survival time was not reached within the observation period. CPS (≥7) and past history of tyrosine-kinase inhibitor (TKI) were not significant prognostic factors. mALBI ≥2b was an only significant prognostic factor (HR 4.632, 95%CI 1.649-13.02, P = 0.004) in Cox-hazard multivariate analysis. In patients with Child-Pugh A, c-index/Akaike's information criterion (AIC) of prognostic predictive value of mALBI were superior to CPS (0.682/135.6 vs 0.652/138.7), while those of stopping LEN also showed that mALBI was better (0.575/447.3 vs 0.562/447.8). Additional analysis of patients with good mALBI (1/2a) revealed that time to stopping LEN was significantly shorter in those with the adverse event (AE) of appetite loss (any grade) than those without (P = 0.006) and body mass index (BMI) was also lower in patients with that AE (20.3 ± 3.0 vs 23.6 ± 4.0kg/m2 , P Urine protein:creatinine ratio vs 24-hour urine protein for proteinuria management: analysis from the phase 3 REFLECT study of lenvatinib vs sorafenib in hepatocellular carcinoma.Thomas R Jeffry Evans; Masatoshi Kudo; Richard S Finn; Kwang-Hyub Han; Ann-Lii Cheng; Masafumi Ikeda; Silvija Kraljevic; Min Ren; Corina E Dutcus; Fabio Piscaglia; Max W SungBritish journal of cancer 121 (3) 218 - 221 0007-0920 2019/07 [Refereed] BACKGROUND: Proteinuria monitoring is required in patients receiving lenvatinib, however, current methodology involves burdensome overnight urine collection. METHODS: To determine whether the simpler urine protein:creatinine ratio (UPCR) calculated from spot urine samples could be accurately used for proteinuria monitoring in patients receiving lenvatinib, we evaluated the correlation between UPCR and 24-hour urine protein results from the phase 3 REFLECT study. Paired data (323 tests, 154 patients) were analysed. RESULTS: Regression analysis showed a statistically significant correlation between UPCR and 24-hour urine protein (R2: 0.75; P Tu1955 COMPUTER-AIDED DIAGNOSIS BASED ON CONVOLUTIONAL NEURAL NETWORK SYSTEM USING ARTIFICIAL INTELLIGENCE FOR COLORECTAL POLYP CLASSIFICATIONYoriaki Komeda; Hisashi Handa; Ryoma Matsui; Toshiharu Sakurai; Tomohiro Watanabe; Hiroshi Kashida; Masatoshi KudoGastrointestinal Endoscopy Elsevier BV 89 (6) AB631 - AB631 0016-5107 2019/06CLINICAL UTILITY OF ENDOSCOPIC ULTRASOUND-GUIDED DRAINAGE USING CONTRAST-ENHANCED HARMONIC IMAGING IN CASES WITH DIFFICULTIESMinaga Kosuke; Takenaka Mamoru; Yoshikawa Tomoe; Okamoto Ayana; Ishikawa Rei; Yamazaki Tomohiro; Nakai Atsushi; Omoto Shunsuke; Kamata Ken; Yamao Kentaro; Kudo MasatoshiGASTROINTESTINAL ENDOSCOPY 89 (6) AB299  0016-5107 2019/06 [Refereed]ENDOSCOPIC UTRASOUND-GUDED CHOLEDOCHODUODENOSTOMY USING A THIN STENT DELIVERY SYSTEM IN PATIENTS WITH UNRESECTABLE MALIGNANT DISTAL BILIARY OBSTRUCTION: A PROSPECTIVE MYLTICENTER STUDYItonaga Masahiro; Kitano Masayuki; Hatamaru Keiichi; Tamura Takashi; Nuta Junya; Kawaji Yuki; Takenaka Mamoru; Minaga Kosuke; Kudo Masatoshi; Ogura Takeshi; Higuchi Kazuhide; Chiba YasutakaGASTROINTESTINAL ENDOSCOPY 89 (6) AB315  0016-5107 2019/06 [Refereed]LONG-TERM OUTCOMES OF EUS-GUIDED TRANSLUMINAL STENT DEPLOYEMNT FOR BENIGN BILIARY DISEASE: MULTICENTER CLINICAL EXPERIENCEOgura Takeshi; Takenaka Mamoru; Shiomi Hideyuki; Goto Daisuke; Hisa Takeshi; Tamura Takashi; Kato Hironari; Nishioka Nobu; Minaga Kosuke; Kudo Masatoshi; Higuchi Kazuhide; Kitano MasayukiGASTROINTESTINAL ENDOSCOPY 89 (6) AB297  0016-5107 2019/06 [Refereed]VALUE OF THE BISPECTRAL INDEX MONITOR DURING ENDOSCOPIC ULTRASONOGRAPHY UNDER SEDATION WITH PROPOFOL AND MIDAZOLAMOkamoto Ayana; Kamata Ken; Takenaka Mamoru; Yoshikawa Tomoe; Ishikawa Rei; Yamazaki Tomohiro; Nakai Atsushi; Omoto Shunsuke; Minaga Kosuke; Yamao Kentaro; Kudo MasatoshiGASTROINTESTINAL ENDOSCOPY 89 (6) AB602 - AB603 0016-5107 2019/06 [Refereed]LINEAR EUS TRAINING BY USING SYSTEMATIC SCREENING PROTCOL FOR THE PANCREATOBILIARY SYSTEMOmoto Shunsuke; Takenaka Mamoru; Ishikawa Rei; Okamoto Ayana; Nakai Atsushi; Yamazaki Tomohiro; Minaga Kosuke; Kamata Ken; Yamao Kentaro; Kudo MasatoshiGASTROINTESTINAL ENDOSCOPY 89 (6) AB584  0016-5107 2019/06 [Refereed]THE USEFULNESS OF NOVEL CANNULATION METHOD USING A UNIQUE, DOUBLE LUMENS CATHETER (UNEVEN METHOD) FOR THE PATIENTS WITH SURGICALLY ALTERED GASTROINTESTINAL ANATOMYTakenaka Mamoru; Yoshikawa Tomoe; Ishikawa Rei; Okamoto Ayana; Yamazaki Tomohiro; Nakai Atsushi; Omoto Shunsuke; Minaga Kosuke; Kamata Ken; Yamao Kentaro; Kudo MasatoshiGASTROINTESTINAL ENDOSCOPY 89 (6) AB223  0016-5107 2019/06 [Refereed]EXAMINATION OF ACTUAL RADIATION EXPOSURE DOSE OF THE PATIENTS WHO PERFORMED EUS-GUIDED DRAINAGE (EUS-BD/EUS-PD/EUS-CD)Takenaka Mamoru; Hayashi Shiro; Nishida Tsutomu; Hosono Makoto; Yoshikawa Tomoe; Ishikawa Rei; Okamoto Ayana; Yamazaki Tomohiro; Nakai Atsushi; Omoto Shunsuke; Minaga Kosuke; Kamata Ken; Yamao Kentaro; Kudo MasatoshiGASTROINTESTINAL ENDOSCOPY 89 (6) AB444 - AB445 0016-5107 2019/06 [Refereed]Recent Updates on the Relationship between Cancer and Autoimmune PancreatitisAyana Okamoto; Tomohiro Watanabe; Ken Kamata; Kosuke Minaga; Masatoshi KudoInternal Medicine Japanese Society of Internal Medicine 58 (11) 1533 - 1539 0918-2918 2019/06 [Refereed]Cost-effectiveness analysis of lenvatinib treatment for patients with unresectable hepatocellular carcinoma (uHCC) compared with sorafenib in Japan.Kobayashi M; Kudo M; Izumi N; Kaneko S; Azuma M; Copher R; Meier G; Pan J; Ishii M; Ikeda SJournal of gastroenterology 54 (6) 558 - 570 0944-1174 2019/06 [Refereed]Intracystic papillary neoplasm preoperatively diagnosed by high-quality cytology derived from endoscopic nasogallbladder drainage.Akane Hara; Ken Kamata; Mamoru Takenaka; Takaaki Chikugo; Masatoshi KudoGastrointestinal endoscopy 89 (6) 1257 - 1259 0016-5107 2019/06 [Refereed]Novel sphincterotomy device that orientates blade along the axis of the bile duct in patients with Roux-en-Y anastomosis.Takenaka M; Yoshikawa T; Okamoto A; Nakai A; Minaga K; Yamao K; Kudo MEndoscopy 51 (6) E132 - E134 0013-726X 2019/06 [Refereed]The IFN-α-IL-33 Axis as Possible Biomarkers in IgG4-Related Disease.Kosuke Minaga; Tomohiro Watanabe; Ken Kamata; Mamoru Takenaka; Satoru Yasukawa; Masatoshi KudoThe American journal of gastroenterology Ovid Technologies (Wolters Kluwer Health) 114 (6) 1002 - 1003 0002-9270 2019/06 [Refereed]Autoimmune hepatitis and IgG4-related disease.Kosuke Minaga; Tomohiro Watanabe; Hobyung Chung; Masatoshi KudoWorld journal of gastroenterology Baishideng Publishing Group Inc. 25 (19) 2308 - 2314 1007-9327 2019/05 [Refereed] IgG4-related disease (IgG4-RD) is a chronic-fibroinflammatory disorder affecting a wide range of organs. Elevation of serum IgG4 concentrations and abundant infiltration of IgG4-expressing plasma cells are key diagnostic features of this autoimmune disease. Although common organ involvement of IgG4-RD includes the salivary glands, pancreas, and bile duct, hepatic involvement is less well established. Recently, five studies identified a subtype of autoimmune hepatitis (AIH), called IgG4-associated AIH (IgG4-AIH). IgG4-AIH is diagnosed based on significant accumulation of IgG4-expressing plasmacytes in the liver in patients who met the diagnostic criteria for classical AIH. Although four of the five reports regarded IgG4-AIH based on hepatic accumulation of IgG4-positive cells alone, one report diagnosed IgG4-AIH based on both hepatic accumulation of IgG4-positive cells and elevated serum concentrations of IgG4. IgG4-AIH diagnosed based on the latter criteria may be a hepatic manifestation of IgG4-RD whereas IgG4-AIH diagnosed based on the former criteria may be a subtype of AIH. In this review article, we summarize and discuss clinicopathological features of IgG4-AIH.Subgroup analysis of efficacy and safety of orantinib in combination with TACE in Japanese HCC patients in a randomized phase III trial (ORIENTAL).Hisashi Hidaka; Namiki Izumi; Takeshi Aramaki; Masafumi Ikeda; Yoshitaka Inaba; Kazuho Imanaka; Takuji Okusaka; Susumu Kanazawa; Shuichi Kaneko; Shinichi Kora; Hiroya Saito; Junji Furuse; Osamu Matsui; Tatsuya Yamashita; Osamu Yokosuka; Satoshi Morita; Hitoshi Arioka; Masatoshi Kudo; Yasuaki AraiMedical oncology (Northwood, London, England) 36 (6) 52 - 52 2019/05 [Refereed] A randomized, phase III trial of orantinib in combination with transcatheter arterial chemoembolization (TACE) did not prolong overall survival (OS) over placebo (ORIENTAL study). A subgroup analysis was conducted to evaluate the efficacy and safety of orantinib in Japanese patients enrolled in the ORIENTAL study. The data of Japanese patients from this study were analyzed. The overall survival (OS), time to progression (TTP), and time to TACE failure (TTTF) were compared between orantinib and placebo arms using stratified log-rank test. Since TTTF in patients with Barcelona Clinic Liver Cancer stage B (BCLC-B) showed favor outcome in this study, the OS and TTTF according to BCLC staging system were also analyzed. The subgroup analysis consisted of 219 and 213 patients in the orantinib and placebo arms. Median OS was 32.5 vs 33.0 months (p = 0.906), median TTP was 4.7 vs 3.1 months (p = 0.011), and median TTTF was 25.3 vs 18.2 months (p = 0.160) in the orantinib and placebo groups, respectively. Patients with BCLC-B in the orantinib and placebo groups showed a median OS of 33.7 and 30.1 months, respectively (p = 0.260), while the corresponding median TTTF were 25.3 and 14.0 months (p = 0.125). The Japanese population safety profile was similar to all over population in the ORIENTAL study. No significant differences were observed in the OS and TTTF though the TTP was significantly improved in the orantinib arm. The OS and TTTF showed a tendency to be prolonged following orantinib treatment of Japanese HCC patients with BCLC-B in the ORIENTAL study.好酸球性食道炎の臨床的特徴の検討正木 翔; 松井 繁長; 工藤 正俊; 大塚 康生; 松村 まり子; 高島 耕太; 河野 辰哉; 岡元 寿樹; 河野 匡志; 山田 光成; 永井 知行; 米田 頼晃; 櫻井 俊治; 渡邉 智裕; 辻 直子; 樫田 博史Gastroenterological Endoscopy (一社)日本消化器内視鏡学会 61 (Suppl.1) 963 - 963 0387-1207 2019/05Rapid and extensive intrahepatic metastatic recurrence of hepatocellular carcinoma with very small portal vein tumor thrombus after surgery and sustained virological response of HCV with direct-acting antivirals.Soo Ki Kim; Soo Ryang Kim; Susumu Imoto; Naomi Shida; Yumi Fujii; Takako Fujii; Masahiro Kido; Hisoka Kinoshita; Yu-Ichiro Koma; Yoshitake Hayashi; Toshiyuki Matsuoka; Masatoshi KudoPathology international 69 (5) 306 - 308 2019/05 [Refereed]【肝疾患を取り巻くAI・技術革新】肝細胞癌に対する焼灼療法におけるナビゲーション南 康範; 南 知宏; 田北 雅弘; 萩原 智; 依田 広; 上嶋 一臣; 西田 直生志; 工藤 正俊肝臓クリニカルアップデート 医学図書出版(株) 5 (1) 39 - 42 2189-4469 2019/05 [Refereed] ラジオ波焼灼術(RFA)で良好な局所制御を得るには十分なablative marginが必要であるが、超音波(US)観察の制限のためablative marginをRFA治療中に評価することは困難である。しかし、新たなフュージョン画像技術である「US-US fusion imaging」では治療前後のUS画像の対比、「US-US overlay fusion」では治療前後のUS画像の重ね合わせによってablative marginについてUS画像の客観性ある画像情報が得られるようになった。とくに、US-US overlay fusionによるablative marginの可視化はRFA治療における局所制御の向上がもたらされ、より精度の高いRFA治療(precision RFA)に貢献する有用な画像技術である。(著者抄録)Endoscopic submucosal dissection of duodenal adenocarcinoma arising from Brunner's gland.Tanaka H; Matsui S; Kashida H; Kudo MAnnals of gastroenterology 32 (3) 316  1108-7471 2019/05 [Refereed]Efficacy and Safety of Chemotherapy Following Anti-PD-1 Antibody Therapy for Gastric Cancer: A Case of Sclerosing CholangitisMasashi Kono; Toshiharu Sakurai; Kazuki Okamoto; Shou Masaki; Tomoyuki Nagai; Yoriaki Komeda; Ken Kamata; Kosuke Minaga; Kentarou Yamao; Mamoru Takenaka; Tomohiro Watanabe; Naoshi Nishida; Masatoshi KudoInternal Medicine Japanese Society of Internal Medicine 58 (9) 1263 - 1266 0918-2918 2019/05 [Refereed]Hemorrhage from metastasis of a 5-mm renal cell carcinoma lesion to the gallbladder detected by contrast-enhanced endoscopic ultrasonography.Takenaka M; Okabe Y; Kudo MDigestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver 51 (5) 743 - 743 1590-8658 2019/05 [Refereed]Pembrolizumab for the Treatment of Hepatocellular Carcinoma.Masatoshi KudoLiver cancer 8 (3) 143 - 154 2235-1795 2019/05 [Refereed]【肝胆膵外科の臨床研究 update 2019】肝胆膵外科における蛍光法(光力学診断法)青木 武士; 古泉 友丈; 藤森 聡; 草野 智一; 野垣 航二; 田代 良彦; 箱崎 智樹; 富岡 幸大; 平井 隆仁; 山崎 達哉; 村上 雅彦外科 (株)南江堂 81 (6) 673 - 680 0016-593X 2019/05 [Refereed][Invited] <文献概要>光力学診断法は,消化器外科領域のみならず各外科領域において横断的に臨床応用され,その手術支援の有用性は高く評価され,近年大きな注目を集めている.光力学診断法は肝胆膵外科領域においては,インドシアニングリーン(ICG)蛍光法を中心に解剖学的・腫瘍学的に精緻な手術を実現するnavigation surgeryの役割を担い,さまざまな手術支援に応用されている.光力学診断法のさらなる発展は,術中診断・治療成績を向上させ安全・確実な手術に寄与する大きな可能性を有している.Lusutrombopag Reduces Need for Platelet Transfusion in Patients With Thrombocytopenia Undergoing Invasive Procedures.Hidaka H; Kurosaki M; Tanaka H; Kudo M; Abiru S; Igura T; Ishikawa T; Seike M; Katsube T; Ochiai T; Kimura K; Fukuhara T; Kano T; Nagata T; Tanaka K; Kurokawa M; Yamamoto K; Osaki Y; Izumi N; Imawari MClinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association 17 (6) 1192 - 1200 1542-3565 2019/05 [Refereed]Endoscopic ultrasound-guided choledochoduodenostomy using a thin stent delivery system in patients with unresectable malignant distal biliary obstruction: A prospective multicenter study.Itonaga M; Kitano M; Hatamaru K; Tamura T; Nuta J; Kawaji Y; Takenaka M; Minaga K; Kudo M; Ogura T; Higuchi K; Chiba YDigestive endoscopy : official journal of the Japan Gastroenterological Endoscopy Society 31 (3) 291 - 298 0915-5635 2019/05 [Refereed] BACKGROUND AND AIM: When endoscopic retrograde cholangiopancreatography (ERCP) fails in patients with malignant distal biliary obstruction, endoscopic ultrasound-guided choledochoduodenostomy (EUS-CDS) is an alternative. It has high technical and clinical success rates, but also has high adverse event rates. This prospective cohort study was aimed to evaluate the clinical efficacy and safety of EUS-CDS with our newly developed partially covered self-expandable metal stent with a thin delivery system. METHODS: Patients consisted of all consecutive patients in three tertiary referral centers with unresectable malignant distal obstruction in whom ERCP failed and in whom EUS-CDS with the thin delivery system was selected as the second-line approach. Rates of clinical success, technical success, technical success in cases not requiring fistulous tract dilation, adverse events, and stent dysfunction were determined. RESULTS: In the 20 patients, technical and clinical success rates were 95.0% (19/20) and 100% (19/19), respectively. In 31.6% (6/19), the delivery system was successfully inserted into the bile duct without requiring a fistulous-tract dilatation device. These patients had significantly shorter procedure times than patients requiring fistulous-tract dilatation (12.7 ± 3.1 vs 23.2 ± 2.1 min; P レンバチニブ著効症例の残存病変評価に造影エコーが有用であった一例盛田 真弘; 小川 力; 重福 亜紀奈; 野田 晃世; 久保 敦司; 松中 寿浩; 玉置 敬之; 柴峠 光成; 工藤 正俊超音波医学 (公社)日本超音波医学会 46 (Suppl.) S662 - S662 1346-1176 2019/04Radiofrequency ablation of liver metastasis: potential impact on immune checkpoint inhibitor therapy.Minami Y; Nishida N; Kudo MEuropean radiology SPRINGER 29 (9) 5045 - 5051 0938-7994 2019/04 [Refereed] Percutaneous radiofrequency ablation (RFA), a generally accepted alternative therapy for patients with liver metastases, is a minimally invasive approach with a favorable safety profile and a lower rate of major complications. The use of RFA or combined RFA plus resection can produce total tumor clearance in patients with unresectable liver metastases. However, the relatively high rate of local tumor progression has prevented the widespread use of RFA. Furthermore, its efficacy is controversial because there have been no comparisons for its effect on overall survival compared with standard options such as systemic chemotherapy. Meanwhile, immunotherapy has become a major research focus for oncology based on the recent successes reported for immune checkpoint inhibitors for melanoma, non-small cell lung cancer, gastric cancer, and other cancers. Immune checkpoints negatively regulate T cell function, and inhibition prevents the blockade of the immune system by cancer cells to prevent their destruction. Unfortunately, only some patients (Cabozantinib for advanced hepatocellular carcinoma.Masatoshi KudoHepatobiliary surgery and nutrition 8 (2) 153 - 156 2019/04 [Refereed]Risk factors for local recurrence and appropriate surveillance interval after endoscopic resectionYoriaki Komeda; Tomohiro Watanabe; Toshiharu Sakurai; Masashi Kono; Kazuki Okamoto; Tomoyuki Nagai; Mamoru Takenaka; Satoru Hagiwara; Shigenaga Matsui; Naoshi Nishida; Naoko Tsuji; Hiroshi Kashida; Masatoshi KudoWorld Journal of Gastroenterology Baishideng Publishing Group Inc. 25 (12) 1502 - 1512 1007-9327 2019/03 [Refereed]Cytokines produced by innate immune cells in IgG4-related diseaseTomoe Yoshikawa; Tomohiro Watanabe; Kosuke Minaga; Ken Kamata; Masatoshi KudoModern Rheumatology Informa UK Limited 29 (2) 219 - 225 1439-7595 2019/03 [Refereed]腫瘍マーカースコアによる肝予備能良好なBCLC-B肝細胞癌に対するTACE予後予測 肝癌研究会データベース解析平岡 淳; 道堯 浩二郎; 熊田 卓; 泉本 並木; 角谷 眞澄; 國土 典宏; 久保 正二; 松山 裕; 中島 収; 坂元 亨宇; 高山 忠利; 國土 貴嗣; 柏原 康佑; 江口 晋; 山下 達也; 工藤 正俊日本消化器病学会雑誌 (一財)日本消化器病学会 116 (臨増総会) A286 - A286 0446-6586 2019/03 [Refereed]Validation of Modified ALBI Grade for More Detailed Assessment of Hepatic Function in Hepatocellular Carcinoma Patients: A Multicenter Analysis.Atsushi Hiraoka; Takashi Kumada; Kunihiko Tsuji; Koichi Takaguchi; Ei Itobayashi; Kazuya Kariyama; Hironori Ochi; Kazuto Tajiri; Masashi Hirooka; Noritomo Shimada; Toru Ishikawa; Yoshihiko Tachi; Toshifumi Tada; Hidenori Toyoda; Kazuhiro Nouso; Kouji Joko; Yoichi Hiasa; Kojiro Michitaka; Masatoshi KudoLiver cancer 8 (2) 121 - 129 2235-1795 2019/03 [Refereed] Background/Aim: The frequency of hepatocellular carcinoma (HCC) in patients with good hepatic reserve function has been increasing in Japan along with the progression of antiviral therapies and aging of the society. We evaluated the usefulness of modified albumin-bilirubin (ALBI) grade as a tool for assessment of hepatic reserve function. Materials/Methods: We enrolled 6,649 naïve HCC patients treated from 2000 to 2017 and divided them into training (Ehime Prefecture group: E group, n = 2,357) and validation (validation group: V group, n = 4,292) cohorts. Child-Pugh classification and ALBI and modified ALBI (mALBI) grading were compared using with Japan Integrated Staging (JIS), ALBI-TNM (ALBI-T), and mALBI-T scores, which were calculated based on TNM stage and each assessment tool, retrospectively. Results: In the E group, Akaike's Information Criterion (AIC) and c-index values for mALBI-T (13,725.2/0.744) were better as compared to those of ALBI-T (13,772.6/0.733) and JIS score (13,874.7/0.720), with similar results observed in the V group (mALBI-T: 27,727.4/0.760; ALBI-T: 27,817.8/0.750; JIS: 27,807.5/0.748). Although there were some significant differences between the groups with regard to clinical background factors (age, etiology, tumor size, tumor number, treatment modalities), for all patients the AIC and c-index values of mALBI-T (45,327.1/0.755) were also better than those of ALBI-T (45,467.7/0.744) and JIS scores (45,555.8/0.739), indicating its superior stratification ability and prognostic predictive value in patients with HCC. Conclusion: The detailed stratification ability of mALBI grade for hepatic reserve function is suitable for the recent trend of HCC patients, while mALBI-T may provide a more accurate predictive value than existing total staging scoring systems.Rendezvous within biloma technique combining percutaneous and endoscopic approaches: a novel biliary recanalization methodAyana Okamoto; Kosuke Minaga; Mamoru Takenaka; Tomoe Yoshikawa; Toshimitsu Iwasaki; Masakatsu Tsurusaki; Masatoshi KudoEndoscopy Georg Thieme Verlag KG 51 (03) E42 - E44 0013-726X 2019/03 [Refereed]Clinical efficacy and safety of endoscopic ultrasound‐guided gallbladder drainage replacement of percutaneous drainage: A multicenter retrospective studyKosuke Minaga; Yukitaka Yamashita; Takeshi Ogura; Mamoru Takenaka; Yuzo Shimokawa; Takeshi Hisa; Masahiro Itonaga; Hironari Kato; Hidefumi Nishikiori; Atsushi Okuda; Hisakazu Matsumoto; Yoshito Uenoyama; Tomohiro Watanabe; Yasutaka Chiba; Kazuhide Higuchi; Masatoshi Kudo; Masayuki KitanoDigestive Endoscopy Wiley 31 (2) 180 - 187 0915-5635 2019/03 [Refereed]炎症性腸疾患治療の最前線 ステロイド抵抗性潰瘍性大腸炎に対するシクロスポリンの使用経験河野 匡志; 櫻井 俊治; 工藤 正俊日本消化器病学会近畿支部例会プログラム・抄録集 日本消化器病学会-近畿支部 110回 66 - 66 2019/02ピロリ陰性時代の上部消化管診療 胃底腺型胃癌の臨床的特徴の検討河野 辰哉; 松井 繁長; 櫻井 俊治; 工藤 正俊日本消化器病学会近畿支部例会プログラム・抄録集 日本消化器病学会-近畿支部 110回 57 - 57 2019/02【自己免疫性膵炎2019】AIPの病因・病態 腸内細菌叢からみた発症機序渡邉 智裕; 鎌田 研; 吉川 智恵; 三長 孝輔; 工藤 正俊肝・胆・膵 (株)アークメディア 78 (2) 189 - 195 0389-4991 2019/02 [Refereed]Current status and perspectives for computer-aided ultrasonic diagnosis of liver lesions using deep learning technology.Nishida N; Yamakawa M; Shiina T; Kudo MHepatol Int Feb 21. doi: 10.1007/s12072-01 (4) 416 - 421 1936-0533 2019/02 [Refereed] An ultrasound (US) examination is a common noninvasive technique widely applied for diagnosis of a variety of diseases. Based on the rapid development of US equipment, many US images have been accumulated and are now available and ready for the preparation of a database for the development of computer-aided US diagnosis with deep learning technology. On the contrary, because of the unique characteristics of the US image, there could be some issues that need to be resolved for the establishment of computer-aided diagnosis (CAD) system in this field. For example, compared to the other modalities, the quality of a US image is, currently, highly operator dependent; the conditions of examination should also directly affect the quality of US images. So far, these factors have hampered the application of deep learning-based technology in the field of US diagnosis. However, the development of CAD and US technologies will contribute to an increase in diagnostic quality, facilitate the development of remote medicine, and reduce the costs in the national health care through the early diagnosis of diseases. From this point of view, it may have a large enough potential to induce a paradigm shift in the field of US imaging and diagnosis of liver diseases.Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial.Zhu AX; Kang YK; Yen CJ; Finn RS; Galle PR; Llovet JM; Assenat E; Brandi G; Pracht M; Lim HY; Rau KM; Motomura K; Ohno I; Merle P; Daniele B; Shin DB; Gerken G; Borg C; Hiriart JB; Okusaka T; Morimoto M; Hsu Y; Abada PB; Kudo M; REACH; study investigatorsThe Lancet. Oncology 20 (2) 282 - 296 1470-2045 2019/02 [Refereed] BACKGROUND: Patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations have poor prognosis. We aimed to establish the efficacy of ramucirumab in patients with advanced hepatocellular carcinoma and α-fetoprotein concentrations of 400 ng/mL or higher. METHODS: REACH-2 was a randomised, double-blind, placebo-controlled, phase 3 trial done at 92 hospitals, clinics, and medical centres in 20 countries. Eligible patients were aged 18 years or older and had histologically or cytologically confirmed hepatocellular carcinoma, or diagnosed cirrhosis and hepatocellular carcinoma, Barcelona Clinic Liver Cancer stage B or C disease, Child-Pugh class A liver disease, Eastern Cooperative Oncology Group (ECOG) performance statuses of 0 or 1, α-fetoprotein concentrations of 400 ng/mL or greater, and had previously received first-line sorafenib. Participants were randomly assigned (2:1) via an interactive web response system with a computer-generated random sequence to 8 mg/kg intravenous ramucirumab every 2 weeks or placebo. All patients received best supportive care. The primary endpoint was overall survival. Secondary endpoints were progression-free survival, proportion of patients achieving an objective response, time to radiographic progression, safety, time to deterioration in scores on the Functional Assessment of Cancer Therapy Hepatobiliary Symptom Index 8 (FHSI-8), and time to deterioration in ECOG performance status. We also pooled individual patient data from REACH-2 with data from REACH (NCT01140347) for patients with α-fetoprotein concentrations of 400 ng/mL or greater. Efficacy analyses were by intention to treat, whereas safety analyses were done in all patients who received at least one dose of study drug. This trial is registered with ClinicalTrials.gov, number NCT02435433. FINDINGS: Between July 26, 2015, and Aug 30, 2017, 292 patients were randomly assigned, 197 to the ramucirumab group and 95 to the placebo group. At a median follow-up of 7·6 months (IQR 4·0-12·5), median overall survival (8·5 months [95% CI 7·0-10·6] vs 7·3 months [5·4-9·1]; hazard ratio [HR] 0·710 [95% CI 0·531-0·949]; p=0·0199) and progression-free survival (2·8 months [2·8-4·1] vs 1·6 months [1·5-2·7]; 0·452 [0·339-0·603]; pNew diagnostic technique to evaluate hepatic steatosis using the attenuation coefficient on ultrasound B mode.Yohei Koizumi; Masashi Hirooka; Nobuharu Tamaki; Norihisa Yada; Osamu Nakashima; Namiki Izumi; Masatoshi Kudo; Yoichi HiasaPloS one 14 (8) e0221548  2019 [Refereed] PURPOSE: We have developed a diagnostic technique to evaluate hepatic steatosis using the attenuation coefficient (ATT) in ultrasound B mode imaging. A controlled attenuation parameter (CAP) by vibration-controlled transient elastography (VCTE) has also been used to evaluate hepatic steatosis. As that method uses ultrasound A mode, visualizing the liver in real time is difficult. We designed this clinical study to evaluate the diagnostic advantage of our technique using ATT compared to CAP. MATERIALS AND METHODS: The study group included 94 patients with chronic liver disease who had undergone both ATT and CAP assessment at the time of liver biopsy. The M-probe and XL-probe were used for CAP measurement. Data for ATT and CAP were compared as a function of the steatosis grade. RESULTS: The area under the receiver operating characteristic curve (AUC-ROCs) for ATT and PAC as a function of the steatosis grade were as follows: grade 1, 0.74 and 0.81; grade 2, 0.80 and 0.85; and grade 3, 0.96 and 0.98, respectively. CONCLUSION: The accuracy of steatosis grade diagnosis using ATT was the same as that using CAP, with no significant differences and with the added advantage of B mode ultrasound being more convenient and rapid, compared to A mode ultrasound, particularly for patients with subcutaneous fat thickness ≥2 cm.Computer aided diagnosis system developed for ultrasound diagnosis of liver lesions using deep learningMakoto Yamakawa; Tsuyoshi Shiina; Naoshi Nishida; Masatoshi Kudo2019 IEEE INTERNATIONAL ULTRASONICS SYMPOSIUM (IUS) IEEE 2330 - 2333 1948-5719 2019 The Japan Society of Ultrasonics in Medicine (JSUM) is currently constructing an ultrasound image database. This database collects B-mode images of liver tumors and breast tumors, and B-mode videos of heart disease. In the past year, 31,000 liver tumor images have been collected from 11 institutions and 14,000 breast tumor images have been collected from 5 institutions. We are developing computer-aided detection (CADe) and computer-aided diagnosis ( CADx) systems for liver and breast tumors based on deep learning using this database. In this paper, we report on CADx to estimate liver tumor types as a first trial. The data used in this study are 159 cyst cases (338 images), 68 hemangioma cases (279 images), 73 hepatocellular carcinoma (HCC) cases (241 images), and 24 metastatic liver cancer cases (122 images), collected at one facility. We developed the CADx system that estimates four types of liver tumor using a convolutional neural network based on VGGNet. The accuracy of the developed 4-class classification CADx was 88.0%. The accuracy by tumor type was 98.1% for cysts, 86.8% for hemangiomas, 86.3% for HCC, and 29.2% for metastatic liver cancer, with increasing accuracy observed for larger data sets. We also developed CADx to estimate whether a liver tumor is benign or malignant. The accuracy of this 2-class classification CADx was 94.8%, the sensitivity was 93.8%, and the specificity was 95.2%. Both 4-class classification and 2-class classification CADx had relatively high accuracy. However, in this study, we used only a small amount data collected from a single facility. In the future, we plan to verify our results using a larger amount of data collected from multiple facilities. In addition, we prototyped CAD software and are currently developing it with feedback from doctors.Non-B Non-C related hepatocellular carcinoma with sarcomatous change due to epithelial mesenchymal transitionKim SK; Fujii T; Kim SR; Imoto S; Fujii Y; Yuasa K; Ohtani A; Kobayashi H; Yamamoto M; Koma Y; Kumabe T; Nakashima O; Kudo MAnn Case Reports 5 2019 [Refereed]Multiple HNF-1α inactivated type hepatocellular adenoma due to intrahepatic portosystemic venous shuntHayakumo T; Kobayashi H; Ohtani A; Hayashi Y; Koma Y; Kumabe T; Nakashima O; Kudo MAnn Case Reports 5 2019 [Refereed]Differential diagnosis of small HCC focusing on pseudolymphoma and bile duct adenomaKim SK; Fujii T; Kim SR; Imoto S; Fujii Y; Yuasa K; Kobayashi H; Ohtni A; Koma Y; Kudo MAnn Case Reports 21 2019 [Refereed]Ramucirumab in advanced hepatocellular carcinoma in REACH-2: the true value of alpha-fetoproteinZhu AX; Finn RS; Galle PR; Llovet JM; Kudo MLancet Oncol 20 e191  2019 [Refereed]Rationale 301 study: Tislelizumab versus sorafenib as first-line treatment for unresectable hepatocellular carcinomaQin S; Finn RS; Kudo M; Meyer T; Vogel A; Ducreux M; Macarulla TM; Tomasello G; Boisserie F; Hou J; Li X; Song J; Zhu AXFuture Oncol 15 1811 - 1822 2019 [Refereed]Long-term antitumor effect of lenvatinib on unresectable hepatocellular carcinoma with portal vein invasionTakeda H; Nishijima N; Nasu A; Komekado H; Kita R; Kimura T; Osaki Y; Kudo MHepatol Res 49 (5) 594 - 599 2019 [Refereed] Lenvatinib is a novel multikinase inhibitor that has recently shown antitumor activity against hepatocellular carcinoma (HCC) in a phase III trial. We report the case of a woman in whom lenvatinib showed long-term antitumor activity, and in whom computed tomography (CT) scans revealed a series of suggestive radiological changes on the intratumor vascularity. A 68-year-old woman with hepatitis C virus-related liver disease presented with multiple HCCs. Following previous therapy, including six sessions of transcatheter arterial chemoembolization, we introduced lenvatinib monotherapy. Lenvatinib could rapidly cause hypovascularity in the main hypervascular target lesion, and portal vein tumor thrombosis also became undetectable 11 months after the initiation of lenvatinib. These radiological changes suggested that lenvatinib could exert not only anti-angiogenic activity but also direct antitumoral effect. Of note, CT scans during lenvatinib treatment revealed the target lesion as a low-density area in the early arterial phase, whereas scans during drug interruption due to proteinuria showed that the lesion was enhanced in the arterial phase. Finally, near-complete response could be achieved as the best response. We successfully managed various adverse events including proteinuria and hypertension, and the patient was able to continue this lenvatinib therapy for more than 4 years with well-controlled general condition. We report the first case of a patient with HCC in whom lenvatinib monotherapy demonstrated long-term antitumor activity. Suggestive radiological changes reflecting intratumor vascularity as presented here should be considered in patients receiving lenvatinib for HCC.Objective response by mRECIST is an independent prognostic factor of overall survival in systemic therapy for hepatocellular carcinomaKudo MLiver Cancer 8 73 - 77 2019 [Refereed]Efficacy and safety of elbasvir/grazoprevir combination therapy for chronic hepatitis CHagiwara S; Kudo MBiomedical Journal of Scientific & Technical Research 2019 [Refereed]Utility of FIB4-T as a prognostic factor for hepatocellular carcinomaKariyama K; Nouso K; Toyoda H; Tada T; Hiraoka A; Tsuji K; Itobayashi E; Ishikawa T; Wakuta A; Oonishi A; Kumada T; Kudo MCancers 11 2019 [Refereed]Combination cancer immunotherapy with molecular targeted agents/anti-CTLA-4 antibody for hepatocellular carcinomaKudo MLiver Cancer 8 1 - 11 2019 [Refereed]Sorafenib: Key lessons from over 10 years of experienceEscudier B; Worden F; Kudo MExpert Rev Anticancer Ther 19 177 - 189 2019 [Refereed]Case of endoscopic ultrasonography-guided pancreatic duct rendezvous stenting in which initial contrast medium injection was useful for the second punctureOmoto S; Takenaka M; Kudo MDig Endosc 31 e20 - e21 2019 [Refereed]VALUE OF ADDITIONAL ENDOSCOPIC ULTRASONOGRAPHY FOR SURVEILLANCE AFTER SURGICAL REMOVAL OF INTRADUCTAL PAPILLARY MUCINOUS NEOPLASMSKAMATA Ken; CHIBA Yasutaka; WATANABE Tomohiro; SAKURAI Toshiharu; NISHIDA Naoshi; CHIKUGO Takaaki; MATSUMOTO Ippei; TAKEYAMA Yoshifumi; KITANO Masayuki; KUDO Masatoshi; TAKENAKA Mamoru; MINAGA Kosuke; OMOTO Shunsuke; MIYATA Takeshi; YAMAO Kentaro; IMAI Hajime; NAKAI Atsushi; TANAKA HidekazuGASTROENTEROLOGICAL ENDOSCOPY Japan Gastroenterological Endoscopy Society 61 (4) 417 - 426 0387-1207 2019 [Refereed] Background and Aim: This study evaluated the utility of endoscopic ultrasonography (EUS) combined with contrast-enhanced harmonic EUS (CH-EUS) for surveillance of the remnant pancreas after surgery for intraductal papillary mucinous neoplasm (IPMN).Methods: This was a single-center, retrospective, descriptive study. A total of 134 consecutive patients who underwent surgical resection for IPMN between April 2009 and March 2015 were evaluated. Rates of recurrence and development of IPMN-concomitant pancreatic ductal adenocarcinoma (PDAC) during follow up were assessed. Clinical findings of patients with recurrence or development of PDAC were also evaluated.Results: Of 134 resected IPMN 56 (41.8%) and 78 (58.2%) were classified as benign and malignant, respectively. Patients were followed up for a median of 29 months, 33 (24.6%) by both contrast-enhanced computed tomography (CE-CT) and EUS, and 101 (75.4%) by computed tomography (CT) alone. Thirteen patients (9.7%) showed tumor recurrence, five with intra-pancreatic recurrence and eight with extra-pancreatic metastases. An enhancing mural nodule within the dilated main pancreatic duct was successfully detected by EUS in one patient, but not by CE-CT. Two patients developed IPMN-concomitant PDAC during follow up. EUS combined with CH-EUS successfully detected small IPMN-concomitant PDAC in two patients, whereas these lesions were not detected by CT. CH-EUS was useful for better visualization of the margins of IPMN-concomitant PDAC in one of these two patients.Conclusion: Endoscopic ultrasonography combined with CH-EUS may improve follow up of patients with resected IPMN.慢性膵炎と自己免疫性膵炎の発症に関わる自然免疫反応渡邉 智裕; 工藤 正俊近畿大学医学雑誌 44 (1・2) 3 - 7 2019 [Invited]第20回全国原発性肝癌追跡調査報告(2008〜2009)工藤正俊; 泉 並木; 久保正二; 國土典宏; 坂元享宇; 椎名秀一朗; 高山忠利; 建石良介; 中島 収; 村上卓道; 松山 裕肝臓 60 258 - 293 2019 [Refereed]Important Clinical Factors in Sequential Therapy Including Lenvatinib against Unresectable Hepatocellular Carcinoma.Atsushi Hiraoka; Takashi Kumada; Masanori Atsukawa; Masashi Hirooka; Kunihiko Tsuji; Toru Ishikawa; Koichi Takaguchi; Kazuya Kariyama; Ei Itobayashi; Kazuto Tajiri; Noritomo Shimada; Hiroshi Shibata; Hironori Ochi; Toshifumi Tada; Hidenori Toyoda; Kazuhiro Nouso; Akemi Tsutsui; Takuya Nagano; Norio Itokawa; Korenobu Hayama; Michitaka Imai; Kouji Joko; Hironori Tanaka; Tsutomu Tamai; Yohei Koizumi; Yoichi Hiasa; Kojiro Michitaka; Masatoshi KudoOncology 97 (5) 277 - 285 0030-2414 2019 [Refereed] BACKGROUND/AIM: We evaluated clinical factors related to improved prognosis of unresectable hepatocellular carcinoma patients (u-HCC), who were treated with tyrosine kinase inhibitor (TKI) sequential therapy, including lenvatinib (LEN). MATERIALS/METHODS: We enrolled 84 u-HCC cases treated with TKIs including LEN from March 2018 to January 2019 (median age 71 years, 63 males, Child-Pugh score (CPS) 5/6/7 = 62/21/1, tumor-node-metastasis stage of Liver Cancer Study Group of Japan 6th (TNM-LCSGJ) II/III/IVa/IVb = 12/30/5/37, Barcelona Clinic Liver Cancer stage B/C = 33:51). Clinical findings at introduction of the initial TKI were retrospectively evaluated. RESULTS: The median albumin-bilirubin (ALBI) score at introduction of the initial TKI (sorafenib [SOR]/LEN = 80/4) was -2.56, and the past number of transarterial catheter chemoembolization was 3 (IQR: 2-5) (second-line: regorafenib [REG]/LEN/SOR = 31/49/4, third-line: LEN/REG = 31:1). The total period of administration with TKIs showed a good relationship with overall survival (OS) (r = 0.946, 95% confidence interval [CI]: 0.918-0.965, p -2.27) was the only significant factor at the start of the initial TKI for poor prognosis (hazard ratio 2.319, 95% CI: 1.064-5.052, p = 0.034), while CPS (≥6) was not. Although there was no significant difference in TNM-LCSGJ (p = 0.213), the prognosis of patients with mALBI 1/2a (n = 66) showed better prognosis as compared to those with mALBI 2b (n = 18) (1-year/2-year/3-year OSR = 89.1/69.8/66% vs. 82.4/47.1/23.5%, p = 0.029). CONCLUSION: Good hepatic function (mALBI 1/2a) at introduction of the initial TKI is a requirement for improved prognosis of u-HCC undergoing TKI sequential therapy.Targeted and immune therapy for hepatocellular carcinoma: predictions for 2019 and beyondMasatoshi KudoWorld J Gastroenterol 25 789 - 807 2019 [Refereed][Systemic therapy for hepatocellular carcinoma:recent advances and future perspective].Kudo MNihon Shokakibyo Gakkai zasshi = The Japanese journal of gastro-enterology 116 (1) 8 - 17 0446-6586 2019 [Refereed]Liver damage related to immune checkpoint inhibitors.Nishida N; Kudo MHepatology international SPRINGER 13 (3) 248 - 252 1936-0533 2019/01 [Refereed] Recently, immune checkpoint inhibitors are becoming one of the key agents of systemic treatment of cancer. The anti-cancer mechanism of this type of agent is totally different from that of conventional therapies; blockade of regulatory receptors and ligand of immune checkpoint molecules arose anti-tumor immunity with durable response. However, owing to its unique action to host immune system, immune checkpoint inhibitors sometimes induce immune-related adverse events (irAEs) which has not been observed for conventional chemotherapies. It has been reported that irAEs are manageable by discontinuation of immune checkpoint inhibitors and corticosteroid. However, severe irAEs might lead to the unsuccessful management of cancer treatment. It is conceivable that irAEs during the treatment of immune checkpoint blockade might mimic the autoimmune disease of the specific organ, such as autoimmune hepatitis (AIH). However, detail of the pathogenesis of irAEs has not been well estimated. In this review, we specially focused on this important issue and discussed the liver toxicity of this type of agent in the context of comparison of clinical and pathological findings of liver damage related to irAEs and AIH.Current status of radiation exposure to crystalline lens in ERCP (endoscopic retrograde cholangiopancreatography)Mamoru Takenaka; Makoto Hosono; Atsushi Nakai; Shunsuke Omoto; Kosuke Minaga; Ken Kamata; Kentaro Yamao; Shiro Hayashi; Tsutomu Nishida; Masatoshi KudoJournal of Japanese Society of Gastroenterology 116 (12) 1053 - 1055 0446-6586 2019 [Refereed]Gankyrin Contributes to Tumorigenesis and Chemoresistance in Sporadic Colorectal CancerToshiharu Sakurai; Yoriaki Komeda; Tomoyuki Nagai; Ken Kamata; Kosuke Minaga; Kentarou Yamao; Mamoru Takenaka; Satoru Hagiwara; Tomohiro Watanabe; Naoshi Nishida; Hiroshi Kashida; Kazuhiko Nakagawa; Masatoshi KudoDigestion S. Karger AG 100 (3) 1 - 9 0012-2823 2018/12 [Refereed]Nivolumab-Induced Hemophilia A Presenting as Gastric Ulcer Bleeding in a Patient With NSCLC.Kato R; Hayashi H; Sano K; Handa K; Kumode T; Ueda H; Okuno T; Kawakami H; Matsumura I; Kudo M; Nakagawa KJournal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 13 (12) e239 - e241 1556-0864 2018/12 [Refereed]Phase I/II study of first-line combination therapy with sorafenib plus resminostat, an oral HDAC inhibitor, versus sorafenib monotherapy for advanced hepatocellular carcinoma in east Asian patients.Tak WY; Ryoo BY; Lim HY; Kim DY; Okusaka T; Ikeda M; Hidaka H; Yeon JE; Mizukoshi E; Morimoto M; Lee MA; Yasui K; Kawaguchi Y; Heo J; Morita S; Kim TY; Furuse J; Katayama K; Aramaki T; Hara R; Kimura T; Nakamura O; Kudo MInvestigational new drugs 36 (6) 1072 - 1084 0167-6997 2018/12 [Refereed] PURPOSE: Resminostat is an oral inhibitor of class I, IIB, and IV histone deacetylases. This phase I/II study compared the safety and efficacy of resminostat plus sorafenib versus sorafenib monotherapy as first-line therapy for advanced hepatocellular carcinoma (HCC). EXPERIMENTAL DESIGN: In phase I, resminostat (400 mg or 600 mg/day on days 1 to 5 every 14 days) was administered with sorafenib (800 mg/day for 14 days) to determine the recommended dose for phase II. In phase II, patients were randomized (1:1) to sorafenib monotherapy or resminostat plus sorafenib. The primary endpoint was time-to-progression (TTP). RESULTS: Nine patients (3: 400 mg, 6: 600 mg) were enrolled in phase I, and the recommended dose of resminostat was determined to be 400 mg/day. Then 170 patients were enrolled in phase II. Median TTP/overall survival (OS) were 2.8/14.1 months with monotherapy versus 2.8/11.8 months with combination therapy (Hazard Ratio [HR]: 0.984, p = 0.925/HR: 1.046, p = 0.824). The overall incidence of adverse events was similar in both groups (98.8% versus 100.0%). However, thrombocytopenia ≥ Grade 3 was significantly more frequent in the combination therapy group (34.5% versus 2.4%, p Liver Ultrasound Elastography: An Update to the World Federation for Ultrasound in Medicine and Biology Guidelines and Recommendations.Ferraioli G; Wong VW; Castera L; Berzigotti A; Sporea I; Dietrich CF; Choi BI; Wilson SR; Kudo M; Barr RGUltrasound in medicine & biology 44 (12) 2419 - 2440 0301-5629 2018/12 [Refereed]肝門部胆管癌における胆道再建後の吻合部再発に対し胆管および門脈にステント留置術を行った2例門場 智也; 鶴崎 正勝; 小田 晃義; 沼本 勲男; 柳生 行伸; 柏木 伸夫; 石井 一成; 鎌田 研; 工藤 正俊IVR: Interventional Radiology (一社)日本インターベンショナルラジオロジー学会 33 (3) 318 - 318 1340-4520 2018/11Dual-energy computed tomography for non-invasive staging of liver fibrosis: Accuracy of iodine density measurements from contrast-enhanced data.Sofue K; Tsurusaki M; Mileto A; Hyodo T; Sasaki K; Nishii T; Chikugo T; Yada N; Kudo M; Sugimura K; Murakami THepatology research : the official journal of the Japan Society of Hepatology 48 (12) 1008 - 1019 1386-6346 2018/11 [Refereed] AIM: To investigate whether iodine density measurements from contrast-enhanced dual-energy computed tomography (CT) data can non-invasively stage liver fibrosis. METHODS: This single-center, prospective study was approved by our IRB with written informed consent. Forty-seven consecutive patients (26 men and 21 women; mean age, 63.1 years) with chronic liver disease underwent contrast-enhanced dual-energy CT of the liver (non-contrast, arterial, portal venous, and equilibrium phase images), followed by liver biopsy. Iodine density of liver and aorta were obtained by two independent observers. Iodine uptake of the liver (Δ Liver), representing the difference in iodine density between equilibrium phase and non-contrast images, was calculated and normalized by aorta (Δ Liver/Aorta). We accounted for contrast agent distribution volume by using hematocrit level. Accuracy of iodine density measurements for staging liver fibrosis was assessed by using receiver operating characteristic (ROC) curves. Multivariate linear regression analysis was used to assess the impact of independent variables (liver fibrosis stage and patient-related confounders) on iodine uptake. RESULTS: The Δ Liver/Aorta significantly increased and moderately correlated with METAVIR liver fibrosis stage (ρ = 0.645, P Acute Pancreatitis with Disturbed Consciousness Caused by HyperparathyroidismYasuo Otsuka; Ken Kamata; Kosuke Minaga; Mamoru Takenaka; Tomohiro Watanabe; Masatoshi KudoInternal Medicine Japanese Society of Internal Medicine 57 (21) 3075 - 3078 0918-2918 2018/11 [Refereed]肝細胞癌薬物療法の最新の進歩工藤 正俊肝臓 (一社)日本肝臓学会 59 (11) 587 - 603 0451-4203 2018/11 2007年に分子標的薬ソラフェニブがSHARP試験とAsia Pacific試験において肝細胞癌に対する予後延長効果が示されて以来、肝細胞癌の薬物療法は大きく変化した。遠隔転移、脈管浸潤に対する治療選択肢が増え、進行性肝癌でもある程度長期生存が得られるようになったが、ソラフェニブは腫瘍縮小効果が乏しいことや手足症候群などの比較的強い副作用から、ソラフェニブに代わる新規分子標的薬やソラフェニブ治療で病勢が進行した後の2次治療薬の開発が望まれてきた。ただし2007〜2016年までの10年間、多数の薬剤の開発が試みられたものの、その全ての臨床試験がことごとく失敗に終わった。しかしながら、2017年と2018年の2年間で立て続けに4剤(レゴラフェニブ、レンバチニブ、カボザンチニブ、ラムシルマブ)が臨床試験に成功し、臨床現場で使用可能となりつつある。また免疫チェックポイント阻害剤の治験や免疫チェックポイント阻害剤と分子標的薬との併用の治験も進行中であり肝細胞癌の薬物治療は今後も大きく変化し肝細胞癌治療のパラダイムシフトが起こりつつある。(著者抄録)Novel metallic stent designed for endoscopic bilateral stent-in-stent placement in patients with hilar malignant biliary obstruction.Takenaka M; Yamao K; Minaga K; Nakai A; Omoto S; Kamata K; Kudo MEndoscopy 51 (2) E30-E31  0013-726X 2018/11 [Refereed]Mechanistic Insights into Autoimmune Pancreatitis and IgG4-Related DiseaseTomohiro Watanabe; Kosuke Minaga; Ken Kamata; Masatoshi Kudo; Warren StroberTrends in Immunology Elsevier BV 39 (11) 874 - 889 1471-4906 2018/11 [Refereed]Innovative therapeutic endoscopy良性胆管・膵管狭窄に対する内視鏡治療 良性胆道狭窄(慢性膵炎)に対するfully covered metallic stentの有用性竹中 完; 山雄 健太郎; 工藤 正俊Gastroenterological Endoscopy (一社)日本消化器内視鏡学会 60 (Suppl.2) 2010 - 2010 0387-1207 2018/10良性胆管・膵管狭窄に対する内視鏡治療 良性胆道狭窄(慢性膵炎)に対するfully covered metallic stentの有用性竹中 完; 山雄 健太郎; 工藤 正俊日本消化器病学会雑誌 (一財)日本消化器病学会 115 (臨増大会) A630 - A630 0446-6586 2018/10当院でのirAE大腸炎の臨床的特徴櫻井 俊治; 川上 尚人; 工藤 正俊日本消化器病学会雑誌 (一財)日本消化器病学会 115 (臨増大会) A441 - A441 0446-6586 2018/10膵癌の門脈浸潤診断における造影ハーモニックEUSと造影CTの診断能の比較検討中井 敦史; 鎌田 研; 竹中 完; 石川 嶺; 岡本 彩那; 大本 俊介; 三長 孝輔; 山雄 健太郎; 兵頭 朋子; 松本 逸平; 竹山 宜典; 工藤 正俊Gastroenterological Endoscopy (一社)日本消化器内視鏡学会 60 (Suppl.2) 2126 - 2126 0387-1207 2018/10EUS施行時の鎮静に対するBISモニターの有用性の検討岡本 彩那; 鎌田 研; 竹中 完; 石川 嶺; 中井 敦史; 大本 俊介; 三長 孝輔; 山雄 健太郎; 工藤 正俊Gastroenterological Endoscopy (一社)日本消化器内視鏡学会 60 (Suppl.2) 2126 - 2126 0387-1207 2018/10術前水平方向進展度診断にSpyGlass DSが有用であった遠位胆管癌の2例東原 久美; 三長 孝輔; 岡本 彩那; 榎木 英介; 石川 嶺; 中井 敦史; 大本 俊介; 鎌田 研; 山雄 健太郎; 竹中 完; 工藤 正俊Gastroenterological Endoscopy (一社)日本消化器内視鏡学会 60 (Suppl.2) 2153 - 2153 0387-1207 2018/10New Diagnostic Method for Hepatic Steatosis Using Attenuation Measurement By Ultrasound B Mode: Comparison with Controlled Attenuation Parameter.Koizumi Yohei; Hirooka Masashi; Yada Norihisa; Tamaki Nobuharu; Izumi Namiki; Kudo Masatoshi; Hiasa YoichiHEPATOLOGY 68 1311A  0270-9139 2018/10 [Refereed]Systemic Therapy for Hepatocellular Carcinoma: Latest Advances.Kudo MCancers 10 (11) 2018/10 [Refereed]Ramucirumab as Second-Line Systemic Therapy in Hepatocellular Carcinoma.Kudo MLiver cancer 7 (4) 305 - 311 2235-1795 2018/10 [Refereed]A case of EUS-guided pancreatic duct rendezvous stenting in which initial contrast medium injection was useful for the second puncture.Omoto S; Takenaka M; Kudo MDigestive endoscopy : official journal of the Japan Gastroenterological Endoscopy Society 31 (1) e20 - e21 0915-5635 2018/10 [Refereed]Value of contrast-enhanced harmonic EUS with enhancement pattern for diagnosis of pancreatic cancer: a meta-analysis.Yamashita Y; Shimokawa T; Napoléon B; Fusaroli P; Gincul R; Kudo M; Kitano MDigestive endoscopy : official journal of the Japan Gastroenterological Endoscopy Society 31 (2) 125 - 133 0915-5635 2018/10 [Refereed] BACKGROUND: Current imaging modalities are limited in their ability to distinguish pancreatic cancer (PC) from non-neoplastic pancreatic lesions. The diagnostic use of contrast-enhanced endoscopic ultrasonography (CE-EUS) has increased, and its utility has been reported. Recently, contrast-enhanced harmonic EUS (CH-EUS) was reported to facilitate imaging of parenchymal perfusion and microvessels in pancreatobiliary diseases, leading to a high diagnostic accuracy for PC. The present meta-analysis aims to investigate the usefulness of CH-EUS with enhancement pattern for PC diagnosis. METHODS: A systematic meta-analysis of all potentially relevant articles identified in PubMed, the Cochrane library, and Medline was carried out. Fixed-effects or random-effects models were used to investigate pooled sensitivity, specificity, positive likelihood ratio, and negative likelihood ratio with 95% confidence interval (CI). RESULTS: The study enrolled 887 patients from nine eligible studies. Pooled estimates of sensitivity and specificity were 93% (95% CI, 0.91-0.95) and 80% (95% CI, 0.75-0.85), respectively. Subgroup analyses were carried out on the main results after excluding two outliers. Area under summary receiver operating characteristics curve was 0.97. No publication bias was found using funnel plots. No significant relationship was found between the diagnostic odds ratios and the characteristics of the studies including continent and contrast agent. CONCLUSIONS: This meta-analysis showed that CH-EUS with qualitative analysis of enhancement pattern is useful for the diagnosis of PC, and has high sensitivity and accuracy, regardless of the type of contrast agent used. This modality may provide improved diagnostic accuracy for PC in clinical practice.Molecular Scoring of Hepatocellular Carcinoma for Predicting Metastatic Recurrence and Requirements of Systemic ChemotherapyNaoshi Nishida; Takafumi Nishimura; Toshimi Kaido; Kosuke Minaga; Kentaro Yamao; Ken Kamata; Mamoru Takenaka; Hiroshi Ida; Satoru Hagiwara; Yasunori Minami; Toshiharu Sakurai; Tomohiro Watanabe; Masatoshi KudoCancers MDPI AG 10 (10) 367 - 367 2018/09 [Refereed] Hepatocellular carcinoma (HCC) causes one of the most frequent cancer-related deaths; an HCC subset shows rapid progression that affects survival. We clarify molecular features of aggressive HCC, and establish a molecular scoring system that predicts metastasis after curative treatment. In total, 125 HCCs were examined for TP53, CTNNB1, and TERT promoter mutation, methylation of 8 tumor suppressor genes, and 3 repetitive DNA sequences to estimate promoter hypermethylation and global hypomethylation. A fractional allelic loss (FAL) was calculated to represent chromosomal instability through microsatellite analysis. Molecular subclasses were determined using corresponding and hierarchical clustering analyses. Next, twenty-five HCC patients who underwent liver transplantation were analyzed for associations between molecular characteristics and metastatic recurrence; survival analyses were validated using a publicly available dataset of 376 HCC cases from the Cancer Genome Atlas (TCGA). An HCC subtype characterized by TP53 mutation, high FAL, and global hypomethylation was associated with aggressive tumor characteristics, like vascular invasion; CTNNB1 mutation was a feature of the less-progressive phenotype. A number of molecular risk factors, including TP53 mutation, high FAL, significant global hypomethylation, and absence of CTNNB1 mutation, were noted to predict shorter recurrence-free survival in patients who underwent liver transplantation (p = 0.0090 by log-rank test). These findings were validated in a cohort of resected HCC cases from TCGA (p = 0.0076). We concluded that molecular risks determined by common genetic and epigenetic alterations could predict metastatic recurrence after curative treatments, and could be a marker for considering systemic therapy for HCC patients.Corrigendum to 'Ramucirumab as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib: Patient-focused outcome results from the randomised phase III REACH study' [Eur J Canc 81 (2017) 17-25].Chau I; Peck-Radosavljevic M; Borg C; Malfertheiner P; Seitz JF; Park JO; Ryoo BY; Yen CJ; Kudo M; Poon R; Pastorelli D; Blanc JF; Chung HC; Baron AD; Okusaka T; Bowman L; Cui ZL; Girvan AC; Abada PB; Yang L; Zhu AXEuropean journal of cancer (Oxford, England : 1990) 100 135 - 136 0959-8049 2018/09 [Refereed]Value of additional endoscopic ultrasonography for surveillance after surgical removal of intraductal papillary mucinous neoplasmsKen Kamata; Mamoru Takenaka; Kosuke Minaga; Shunsuke Omoto; Takeshi Miyata; Kentaro Yamao; Hajime Imai; Atsushi Nakai; Hidekazu Tanaka; Yasutaka Chiba; Tomohiro Watanabe; Toshiharu Sakurai; Naoshi Nishida; Takaaki Chikugo; Ippei Matsumoto; Yoshifumi Takeyama; Masayuki Kitano; Masatoshi KudoDigestive Endoscopy Wiley 30 (5) 659 - 666 0915-5635 2018/09 [Refereed]Novel quantitative assessment system of liver steatosis using a newly developed attenuation measurement method.Nobuharu Tamaki; Yohei Koizumi; Masashi Hirooka; Norihisa Yada; Hitomi Takada; Osamu Nakashima; Masatoshi Kudo; Yoichi Hiasa; Namiki IzumiHepatology research : the official journal of the Japan Society of Hepatology 48 (10) 821 - 828 1386-6346 2018/09 [Refereed] AIM: The present study has developed and evaluated the effectiveness of a new echo attenuation measurement function combined with an ultrasonic diagnostic system for the accurate diagnosis of liver steatosis. METHODS: A multicenter prospective study involving patients with chronic hepatitis was carried out. All patients underwent liver biopsy, and attenuation coefficient (ATT) was measured on the same day. The fat area (%) of biopsy specimens was quantitatively evaluated. Correlations between ATT, steatosis grade, and fat area were evaluated. RESULTS: A total of 351 patients were enrolled in this study. The median values of fat area for steatosis grades S0, S1, S2, and S3 were 0.6%, 3.2%, 6.4%, and 15.5%, respectively. A significant correlation was found between fat area and steatosis grade (P Cannulation method for intradiverticular papilla with long oral protrusion using biopsy forceps for axis alignment.Takenaka M; Minaga K; Kudo MDigestive endoscopy : official journal of the Japan Gastroenterological Endoscopy Society 30 (5) 700 - 701 0915-5635 2018/09 [Refereed]Development of pre and post-operative models to predict early recurrence of hepatocellular carcinoma after surgical resection.Chan AWH; Zhong J; Berhane S; Toyoda H; Cucchetti A; Shi K; Tada T; Chong CCN; Xiang BD; Li LQ; Lai PBS; Mazzaferro V; García-Fiñana M; Kudo M; Kumada T; Roayaie S; Johnson PJJournal of hepatology 0168-8278 2018/09 [Refereed]Extremely High Objective Response Rate of Lenvatinib: Its Clinical Relevance and Changing the Treatment Paradigm in Hepatocellular Carcinoma.Kudo MLiver cancer 7 (3) 215 - 224 2235-1795 2018/09 [Refereed]Proposal of Primary Endpoints for TACE Combination Trials with Systemic Therapy: Lessons Learned from 5 Negative Trials and the Positive TACTICS Trial.Kudo MLiver cancer 7 (3) 225 - 234 2235-1795 2018/09 [Refereed]瀉血治療が奏効した骨髄性プロトポルフィリン症関連肝障害(Erythropoietic Protoporphyria-related Hepatopathy Successfully Treated with Phlebotomy)Yoshida Akihiro; Hagiwara Satoru; Watanabe Tomohiro; Nishida Naosihi; Ida Hiroshi; Sakurai Toshiharu; Komeda Yoriaki; Yamao Kentaro; Takenaka Mamoru; Enoki Eisuke; Kimura Masatomo; Miyake Masako; Kawada Akira; Kudo MasatoshiInternal Medicine (一社)日本内科学会 57 (17) 2505 - 2509 0918-2918 2018/09 [Refereed] 症例は27歳男性で、小児期から光線性皮膚症に罹患しており、約1年前に全身性エリテマトーデスと診断されていた。この時点で肝胆道酵素値などが著明に上昇しており、最終的に骨髄性プロトポルフィリン症(EPP)関連肝障害と診断された。今回、全身疲労と血清中のAST、ALT、GGT、総ビリルビン値が再び上昇した。肝生検により、EPP関連肝障害の増悪であると診断した。血漿交換を計5回施行したが血中のAST、ALT、プロトポルフィリン値が低下しなかったため、200〜400mLの瀉血を毎週行ったところ、血清中の肝酵素値、AST、ALT、プロトポルフィリン値は著明に減少し、症状も軽減した。ENBD tube guided scope insertion technique for internal drainage in a case of difficult selective biliary duct guiding.Takenaka M; Minaga K; Kudo MDigestive endoscopy : official journal of the Japan Gastroenterological Endoscopy Society 31 (1) e1 - e2 0915-5635 2018/08 [Refereed]肝外胆管癌における造影ハーモニックEUSの有用性についての検討大塚 康生; 鎌田 研; 竹中 完; 石川 嶺; 岡本 彩那; 中井 敦史; 大本 俊介; 三長 孝輔; 山雄 健太郎; 筑後 孝章; 兵頭 朋子; 中居 卓也; 竹山 宜典; 工藤 正俊胆道 日本胆道学会 32 (3) 567 - 567 0914-0077 2018/08Heterogeneity of Epigenetic and Epithelial Mesenchymal Transition Marks in Hepatocellular Carcinoma with Keratin 19 ProficiencyNaosuke Yokomichi; Naoshi Nishida; Yuzo Umeda; Fumitaka Taniguchi; Kazuya Yasui; Toshiaki Toshima; Yoshiko Mori; Akihiro Nyuya; Takehiro Tanaka; Takeshi Yamada; Takahito Yagi; Toshiyoshi Fujiwara; Yoshiyuki Yamaguchi; Ajay Goel; Masatoshi Kudo; Takeshi NagasakaLiver Cancer 1341-1926 2018/08 [Refereed]A novel method of biliary cannulation for patients with Roux-en-Y anastomosis using a unique, uneven, double lumen cannula (Uneven method).Takenaka M; Yamao K; Kudo MDigestive endoscopy : official journal of the Japan Gastroenterological Endoscopy Society 30 (6) 808 - 809 0915-5635 2018/08 [Refereed]Neurilemmoma Mimicking a Multilocular Cystic Lesion of the Liver: A Case Report.Yoshida A; Yamao K; Takenaka M; Nakai A; Omoto S; Kamata K; Minaga K; Miyata T; Imai H; Matsumoto I; Takeyama Y; Chikugo T; Kudo MInternal medicine (Tokyo, Japan) 57 (23) 3377 - 3380 0918-2918 2018/08 [Refereed] Neurilemmomas are benign tumors arising from the sheaths of peripheral nerves. They appear rarely in the abdominal cavity. We herein report an 80-year-old man with a multilocular cystic neurilemmoma mimicking a liver lesion. Preoperative images showed a lesion in the porta hepatis. Although a preoperative diagnosis was difficult, surgery was undertaken because of the possibility of malignancy. Histologically, the tumor consisted of spindle-shaped cells with positivity for S-100 protein. The final diagnosis was a neurilemmoma. Porta hepatic neurilemmomas are rare. When we encounter a multilocular cystic lesion of the liver, neurilemmoma should be considered in the differential diagnosis.A randomized controlled trial of lusutrombopag in Japanese patients with chronic liver disease undergoing radiofrequency ablation.Tateishi R; Seike M; Kudo M; Tamai H; Kawazoe S; Katsube T; Ochiai T; Fukuhara T; Kano T; Tanaka K; Kurokawa M; Yamamoto K; Osaki Y; Izumi N; Imawari MJournal of gastroenterology 54 (2) 171 - 181 0944-1174 2018/08 [Refereed]【急速に変貌する肝細胞癌の薬物療法2018 Update】ほかの分子標的薬の動向 ラムシルマブの第III相臨床試験結果小川 力; 工藤 正俊肝・胆・膵 (株)アークメディア 77 (2) 398 - 408 0389-4991 2018/08Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trialAndrew X Zhu; Richard S Finn; Julien Edeline; Stephane Cattan; Sadahisa Ogasawara; Daniel Palmer; Chris Verslype; Vittorina Zagonel; Laetitia Fartoux; Arndt Vogel; Debashis Sarker; Gontran Verset; Stephen L Chan; Jennifer Knox; Bruno Daniele; Andrea L Webber; Scot W Ebbinghaus; Junshui Ma; Abby B Siegel; Ann-Lii Cheng; Masatoshi Kudo; Angela Alistar; Jamil Asselah; Jean-Frederic Blanc; Ivan Borbath; Timothy Cannon; Ki Chung; Allen Cohn; David P Cosgrove; Nevena Damjanov; Mukul Gupta; Yoshivasu Karino; Mark Karwal; Andreas Kaubisch; Robin Kelley; Jena-Luc Van Laethem; Timothy Larson; James Lee; Daneng Li; Atisha Manhas; Gulam Abbas Manji; Kazushi Numata; Benjamin Parsons; Andrew S. Paulson; Carmine Pinto; Robert Ramirez; Suresh Ratnam; Magnus Rizell; Olivier Rosmorduc; Yvonne Sada; Yutaka Sasaki; Per I Stal; Simone Strasser; Joerg Trojan; Gina Vaccaro; Hans Van Vlierberghe; Alan Weiss; Karl-Heinz Weiss; Tatsuya Yamashita; KEYNOTE-224 investigatorsThe Lancet Oncology Lancet Publishing Group 19 (7) 940 - 952 1474-5488 2018/07 [Refereed] Background: Immune checkpoint blockade therapy has shown promising results in patients with advanced hepatocellular carcinoma. We aimed to assess the efficacy and safety of pembrolizumab in this patient population. Methods: KEYNOTE-224 is a non-randomised, multicentre, open-label, phase 2 trial that is set in 47 medical centres and hospitals across ten countries. Eligible patients had pathologically confirmed hepatocellular carcinoma had previously been treated with sorafenib and were either intolerant to this treatment or showed radiographic progression of their disease after treatment an Eastern Cooperative Oncology Group performance status of 0–1 adequate organ function, and were Child-Pugh class A. Participants received 200 mg pembrolizumab intravenously every 3 weeks for about 2 years or until disease progression, unacceptable toxicity, patient withdrawal, or investigator decision. The primary endpoint was objective response, defined as the proportion of patients with complete or partial response in all patients who received at least one dose of pembrolizumab, which was radiologically confirmed by use of the Response Evaluation Criteria in Solid Tumors version 1.1 by central review. Safety was also assessed in all treated patients. This trial is ongoing but closed to enrolment and is registered with ClinicalTrials.gov number NCT02702414. Findings: Between June 7, 2016, and Feb 9, 2017, we screened 169 patients with advanced hepatocellular carcinoma, of whom 104 eligible patients were enrolled and treated. As of data cutoff on Feb 13, 2018, 17 (16%) patients were still receiving pembrolizumab. We recorded an objective response in 18 (17% 95% CI 11–26) of 104 patients. The best overall responses were one (1%) complete and 17 (16%) partial responses meanwhile, 46 (44%) patients had stable disease, 34 (33%) had progressive disease, and six (6%) patients who did not have a post-baseline assessment on the cutoff date were considered not to be assessable. Treatment-related adverse events occurred in 76 (73%) of 104 patients, which were serious in 16 (15%) patients. Grade 3 treatment-related events were reported in 25 (24%) of the 104 patients the most common were increased aspartate aminotransferase concentration in seven (7%) patients, increased alanine aminotransferase concentration in four (4%) patients, and fatigue in four (4%) patients. One (1%) grade 4 treatment-related event of hyperbilirubinaemia occurred. One death associated with ulcerative oesophagitis was attributed to treatment. Immune-mediated hepatitis occurred in three (3%) patients, but there were no reported cases of viral flares. Interpretation: Pembrolizumab was effective and tolerable in patients with advanced hepatocellular carcinoma who had previously been treated with sorafenib. These results indicate that pembrolizumab might be a treatment option for these patients. This drug is undergoing further assessment in two phase 3, randomised trials as a second-line treatment in patients with hepatocellular carcinoma. Funding: Merck & Co, Inc.Ramucirumab Safety in East Asian Patients: A Meta-Analysis of Six Global, Randomized, Double-Blind, Placebo-Controlled, Phase III Clinical Trials.Yen CJ; Muro K; Kim TW; Kudo M; Shih JY; Lee KW; Chao Y; Kim SW; Yamazaki K; Sohn J; Cheng R; Zhang Y; Binder P; Mi G; Orlando M; Chung HCJournal of global oncology (4) 1 - 12 2018/07 [Refereed]Systemic therapy for intermediate and advanced hepatocellular carcinoma: Sorafenib and beyondJean-Luc Raoul; Masatoshi Kudo; Richard S. Finn; Julien Edeline; Maria Reig; Peter R. GalleCancer Treatment Reviews W.B. Saunders Ltd 68 16 - 24 1532-1967 2018/07 [Refereed] The hepatocellular carcinoma (HCC) treatment landscape changed a decade ago, with sorafenib demonstrating survival benefit in the first-line setting and becoming the first systemic therapy to be approved for HCC. More recently, regorafenib and nivolumab have received approval in the second-line setting after sorafenib, with further positive phase 3 studies emerging in the first line (lenvatinib non-inferior to sorafenib) and second line versus placebo (cabozantinib and ramucirumab). A key recommendation in the management of patients receiving sorafenib is to promote close communication between the patient and the physician so that adverse events (AEs) are detected early and severe AEs can be prevented. Sorafenib-related AEs have been identified as clinical biomarkers for sorafenib efficacy. Healthcare professionals have become more efficient in managing AEs, identifying patients who are likely to benefit from treatment, and assessing response to treatment, resulting in a trend towards increased overall survival in the sorafenib arms of clinical studies. The rapidly changing treatment landscape due to the emergence of new treatment options (sorafenib and lenvatinib equally effective in first line regorafenib, cabozantinib, and ramucirumab showing OS benefit in second line with nivolumab approved by the FDA based on response rate) underscores the importance of re-assessing the role of the first approved systemic agent in HCC, sorafenib.Reintervention for stent occlusion after endoscopic ultrasound-guided hepaticogastrostomy with novel use of a precut needle-knifeKosuke Minaga; Mamoru Takenaka; Ayana Okamoto; Shunsuke Omoto; Takeshi Miyata; Hajime Imai; Masatoshi KudoEndoscopy Georg Thieme Verlag 50 (7) E153 - E154 1438-8812 2018/07 [Refereed]Endoscopic ultrasound-guided biliary drainage using a newly designed metal stent with a thin delivery system: a preclinical study in phantom and porcine modelsKosuke Minaga; Masayuki Kitano; Masahiro Itonaga; Hajime Imai; Takeshi Miyata; Kentaro Yamao; Takashi Tamura; Junya Nuta; Kenji Warigaya; Masatoshi KudoJournal of Medical Ultrasonics Springer Tokyo 45 (3) 391 - 397 1613-2254 2018/07 [Refereed] Purpose: This study was designed to evaluate the feasibility and safety of a newly designed self-expandable metal stent for endoscopic ultrasound-guided biliary drainage (EUS-BD) when it was delivered via three different stent delivery systems: a 7.5Fr delivery catheter with a bullet-shaped tip (7.5Fr-bullet), a 7Fr catheter with a bullet-shaped tip (7Fr-bullet), or a 7Fr catheter with a tee-shaped tip (7Fr-tee). Methods: This experimental study utilized a porcine model of biliary dilatation involving ten pigs. In the animal study, technical feasibility and clinical outcomes of the stent when placed with each of the delivery systems were examined. In addition, a phantom model was used to measure the resistance of these delivery systems to advancement. Results: Phantom experiments showed that, compared with 7Fr-bullet, 7Fr-tee had less resistance force to the advancement of the stent delivery system. EUS-BD was technically successful in all ten pigs. Fistulous tract dilation was necessary in 100% (2/2), 75% (3/4), and 0% (0/4) of the pigs that underwent EUS-BD using 7.5Fr-bullet, 7Fr-bullet, and 7Fr-tee, respectively. There were no procedure-related complications. Conclusion: Our newly designed metal stent may be feasible and safe for EUS-BD, particularly when delivered by 7Fr-tee, because it eliminates the need for fistulous tract dilation.Outcomes of endoscopic biliary drainage in pancreatic cancer patients with an indwelling gastroduodenal stent: a multicenter cohort study in West JapanKentaro Yamao; Masayuki Kitano; Mamoru Takenaka; Kosuke Minaga; Toshiharu Sakurai; Tomohiro Watanabe; Takahisa Kayahara; Tomoe Yoshikawa; Yukitaka Yamashita; Masanori Asada; Yoshihiro Okabe; Keiji Hanada; Yasutaka Chiba; Masatoshi KudoGastrointestinal Endoscopy Elsevier BV 88 (1) 66 - 75.e2 0016-5107 2018/07 [Refereed]A novel biliary cannulation method for difficult cannulation cases using a unique, uneven, double-lumen cannula (Uneven method).Takenaka M; Arisaka Y; Sakai A; Kobayashi T; Shiomi H; Masuda A; Kudo MEndoscopy 50 (8) E229 - E230 0013-726X 2018/06 [Refereed]SIMILAR EFFICACY AND SAFETY OF ENDOSCOPIC ULTRASOUND-GUIDED BILIARY DRAINAGE VIA HEPATICOGASTROSTOMY AND CHOLEDOCHODUODENOSTOMY APPROACHES FOR MALIGNANT DISTAL BILIARY OBSTRUCTION: A MULTICENTER, PROSPECTIVE, RANDOMIZED TRIALMinaga Kosuke; Kitano Masayuki; Ogura Takeshi; Shiomi Hideyuki; Hoki Noriyuki; Nishikiori Hidefumi; Yamashita Yukitaka; Hisa Takeshi; Kato Hironari; Kamada Hideki; Takenaka Mamoru; Higuchi Kazuhide; Chiba Yasutaka; Kudo MasatoshiGASTROINTESTINAL ENDOSCOPY 87 (6) AB147  0016-5107 2018/06 [Refereed]NEW METHOD FOR DIFFICULT BILIARY CANNULATION USING THE NOVEL UNEVEN DOUBLE LUMEN CANNULA (DLC METHOD)Takenaka Mamoru; Nakai Atsushi; Omoto Shunsuke; Miyata Takeshi; Minaga Kosuke; Kamata Ken; Yamao Kentaro; Imai Hajime; Kudo MasatoshiGASTROINTESTINAL ENDOSCOPY 87 (6) AB209 - AB210 0016-5107 2018/06 [Refereed]Sorafenib plus low-dose cisplatin and fluorouracil hepatic arterial infusion chemotherapy versus sorafenib alone in patients with advanced hepatocellular carcinoma (SILIUS): a randomised, open label, phase 3 trial.Masatoshi Kudo; Kazuomi Ueshima; Osamu Yokosuka; Sadahisa Ogasawara; Shuntaro Obi; Namiki Izumi; Hiroshi Aikata; Hiroaki Nagano; Etsuro Hatano; Yutaka Sasaki; Keisuke Hino; Takashi Kumada; Kazuhide Yamamoto; Yasuharu Imai; Shouta Iwadou; Chikara Ogawa; Takuji Okusaka; Fumihiko Kanai; Kohei Akazawa; Ken-Ichi Yoshimura; Philip Johnson; Yasuaki AraiThe lancet. Gastroenterology & hepatology 3 (6) 424 - 432 2018/06 [Refereed] BACKGROUND: Hepatic arterial infusion chemotherapy plus sorafenib in phase 2 trials has shown favourable tumour control and a manageable safety profile in patients with advanced, unresectable hepatocellular carcinoma. However, no randomised phase 3 trial has tested the combination of sorafenib with continuous arterial infusion chemotherapy. We aimed to compare continuous hepatic arterial infusion chemotherapy plus sorafenib with sorafenib alone in patients with advanced, unresectable hepatocellular carcinoma. METHODS: We did an open-label, randomised, phase 3 trial (SILIUS) at 31 sites in Japan. Eligible patients were aged 20 years or older, with advanced hepatocellular carcinoma not suitable for resection, local ablation, or transarterial chemoembolisation; Eastern Cooperative Oncology Group (ECOG) performance status 0-1; Child-Pugh score 7 or lower; and adequate bone marrow, liver, and renal function. Patients were randomly assigned (1:1) via an interactive web response system with a computer-generated sequence to receive 400 mg sorafenib orally twice daily or 400 mg sorafenib orally twice daily plus hepatic arterial infusion chemotherapy (cisplatin 20 mg/m2 on days 1 and 8 and fluorouracil 330 mg/m2 continuously on days 1-5 and 8-12 of every 28-day cycle via an implanted catheter system). The primary endpoint was overall survival. The primary efficacy analysis comprised all randomised patients (the intention-to-treat population), and the safety analysis comprised all randomised patients who received at least one dose of study treatment. This trial is registered with ClinicalTrials.gov, number NCT01214343. FINDINGS: Between Nov 4, 2010, and June 10, 2014, 206 patients were randomly assigned (103 to the sorafenib group, 103 to the sorafenib plus hepatic arterial infusion chemotherapy group). One patient in the sorafenib plus hepatic arterial infusion chemotherapy group withdrew after randomisation. Median overall survival was similar in the sorafenib plus hepatic arterial infusion chemotherapy (n=102) and sorafenib monotherapy (n=103) groups (11·8 months [95% CI 9·1-14·5] vs 11·5 months [8·2-14·8]; hazard ratio 1·009 [95% CI 0·743-1·371]; p=0·955). Grade 3-4 adverse events that were more frequent in the sorafenib plus hepatic arterial infusion chemotherapy group than in the sorafenib monotherapy group included anaemia (15 [17%] of 88 vs six [6%] of 102), neutropenia (15 [17%] vs one [1%]), thrombocytopenia (30 [34%] vs 12 [12%]), and anorexia (12 [14%] vs six [6%]). INTERPRETATION: Addition of hepatic arterial infusion chemotherapy to sorafenib did not significantly improve overall survival in patients with advanced hepatocellular carcinoma. FUNDING: Japanese Ministry of Health, Labour and Welfare.Alpha-fetoprotein kinetics in patients with hepatocellular carcinoma receiving ramucirumab or placebo: an analysis of the phase 3 REACH studyIan Chau; Joon Oh Park; Baek-Yeol Ryoo; Chia-Jui Yen; Ronnie Poon; Davide Pastorelli; Jean-Frédéric Blanc; Masatoshi Kudo; Tulio Pfiffer; Etsuro Hatano; Hyun Cheol Chung; Katerina Kopeckova; Jean-Marc Phelip; Giovanni Brandi; Shinichi Ohkawa; Chung-Pin Li; Takuji Okusaka; Yanzhi Hsu; Paolo B. Abada; Andrew X. ZhuBritish Journal of Cancer Nature Publishing Group 119 (1) 1 - 8 1532-1827 2018/05 [Refereed] Background: Post-hoc analyses of AFP response and progression and their relationship with objective measures of response and survival were performed in patients from REACH. Methods: Serum AFP was measured at baseline and every 3 cycles (2 weeks/cycle). Associations between AFP and radiographic progression and efficacy end points were analysed. Results: Median percent AFP increase from baseline was smaller in the ramucirumab than in the placebo arm throughout treatment. Time to AFP progression (HR 0.621 P < 0.0001) and to radiographic progression (HR 0.613 P < 0.0001) favoured ramucirumab. Association between AFP and radiographic progression was shown at 6 (OR 6.44, 95% CI 4.03, 10.29 P < 0.0001) and 12 weeks (OR 2.28, 95% CI 1.47, 3.53 P = 0.0002). AFP response was higher with ramucirumab compared with placebo (P < 0.0001). More patients in the ramucirumab arm experienced tumour shrinkage and AFP response compared with placebo. Survival was longer in patients with AFP response (13.6 months) than in patients without (6.2 months), irrespective of treatment (HR 0.457, P < 0.0001). Conclusions: Treatment with ramucirumab prolonged time to AFP progression, slowed AFP increase and was more likely to induce AFP response. Similar benefits in radiographic progression and response correlated with AFP changes.Dysbiosis-Associated Polyposis of the Colon—Cap PolyposisKazuki Okamoto; Tomohiro Watanabe; Yoriaki Komeda; Ayana Okamoto; Kosuke Minaga; Ken Kamata; Kentaro Yamao; Mamoru Takenaka; Satoru Hagiwara; Toshiharu Sakurai; Tomonori Tanaka; Hiroki Sakamoto; Kiyoshige Fujimoto; Naoshi Nishida; Masatoshi KudoFrontiers in Immunology Frontiers Media SA 9 918  2018/05 [Refereed]膵NETの最新の画像診断と治療 造影ハーモニックEUSによる膵神経内分泌腫瘍の悪性度評価石川 嶺; 鎌田 研; 竹中 完; 田中 秀和; 中井 敦史; 大本 俊介; 宮田 剛; 三長 孝輔; 山雄 健太郎; 今井 元; 工藤 正俊膵臓 (一社)日本膵臓学会 33 (3) 346 - 346 0913-0071 2018/05重症急性膵炎の予後不良予測因子および被包化壊死(WON)合併予測因子の検討大本 俊介; 竹中 完; 松本 逸平; 竹山 宜典; 工藤 正俊膵臓 (一社)日本膵臓学会 33 (3) 410 - 410 0913-0071 2018/05造影ハーモニックEUSは膵癌の術前治療の効果判定に有用か?田中 秀和; 鎌田 研; 竹中 完; 石川 嶺; 中井 敦史; 大本 俊介; 三長 孝輔; 宮田 剛; 山雄 健太郎; 今井 元; 工藤 正俊膵臓 (一社)日本膵臓学会 33 (3) 505 - 505 0913-0071 2018/05Regional Differences in Efficacy, Safety, and Biomarkers for Second-Line Axitinib in Patients with Advanced Hepatocellular Carcinoma: From a Randomized Phase II Study.Masatoshi Kudo; Yoon-Koo Kang; Joong-Won Park; Shukui Qin; Yoshitaka Inaba; Eric Assenat; Yoshiko Umeyama; Maria José Lechuga; Olga Valota; Yosuke Fujii; Jean-Francois Martini; J Andrew Williams; Shuntaro ObiLiver cancer 7 (2) 148 - 164 2018/05 [Refereed] Background: An unmet need exists for treatment of patients with advanced hepatocellular carcinoma (HCC) who progress on or are intolerant to sorafenib. A global randomized phase II trial (ClinicalTrial.gov No. NCT01210495) of axitinib, a vascular endothelial growth factor receptor 1-3 inhibitor, in combination with best supportive care (BSC) did not prolong overall survival (OS) over placebo/BSC, but showed improved progression-free survival in some patients. Subgroup analyses were conducted to identify potential predictive/prognostic factors. Methods: The data from this phase II study were analyzed for the efficacy and safety of axitinib/BSC in patients from Asia versus non-Asia versus Asian subgroups (Japan, Korea, or mainland China/Hong Kong/Taiwan) and predictive/prognostic values of baseline microRNAs and serum soluble proteins, using the Cox proportional hazards model. Results: Of 202 patients, 78 were from non-Asia and 124 from Asia (37 Japanese, 36 Korean, and 51 Chinese). No significant differences in OS were found between axitinib/BSC and placebo/BSC in non-Asians, Asians, or Asian subgroups. However, in an exploratory analysis, axitinib/BSC showed favorable OS in Asians, especially Japanese, when patients intolerant to prior antiangiogenic therapy were excluded from the data set. Axitinib/BSC was well tolerated by non-Asians and Asians alike. The presence of 4 circulating microRNAs, including miR-5684 and miR-1224-5p, or a level lower than or equal to the median protein level of stromal cell-derived factor 1 at baseline was significantly associated with longer OS in axitinib/BSC-treated Asians or non-Asians. Conclusions: Axitinib/BSC did not prolong survival over placebo/BSC in non-Asians, Asians, or Asian subgroups, but favorable OS with axitinib/BSC was observed in a subset of Japanese patients. A patient population that excludes sorafenib-intolerant patients might potentially be more suitable for clinical trials of new agents in advanced HCC. Since these results are very preliminary, further investigation is warranted. The potential predictive/prognostic value of several baseline microRNAs and soluble proteins identified in this study would require validation in prospective studies on a large cohort of patients.Ultrasound-ultrasound image overlay fusion improves real-time control of radiofrequency ablation margin in the treatment of hepatocellular carcinomaYasunori Minami; Tomohiro Minami; Satoru Hagiwara; Hiroshi Ida; Kazuomi Ueshima; Naoshi Nishida; Takamichi Murakami; Masatoshi KudoEuropean Radiology Springer Verlag 28 (5) 1986 - 1993 1432-1084 2018/05 [Refereed] Objectives: To assess the clinical feasibility of US-US image overlay fusion with evaluation of the ablative margin in radiofrequency ablation (RFA) for hepatocellular carcinoma (HCC). Methods: Fifty-three patients with 68 HCCs measuring 0.9–4.0 cm who underwent RFA guided by US-US overlay image fusion were included in this retrospective study. By an overlay of pre-/postoperative US, the tumor image could be projected onto the ablative hyperechoic zone. Therefore, the ablative margin three-dimensionally could be shown during the RFA procedure. US-US image overlay was compared to dynamic CT a few days after RFA for assessment of early treatment response. Accuracy of graded response was calculated, and the performance of US-US image overlay fusion was compared with that of CT using a Kappa agreement test. Results: Technically effective ablation was achieved in a single session, and 59 HCCs (86.8 %) succeeded in obtaining a 5-mm margin on CT. The response with US-US image overlay correctly predicted early CT evaluation with an accuracy of 92.6 % (63/68) (k = 0.67 95 % CI: 0.39–0.95). Conclusion: US-US image overlay fusion can be proposed as a feasible guidance in RFA with a safety margin and predicts early response of treatment assessment with high accuracy. Key points: • US-US image overlay fusion visualizes the ablative margin during RFA procedure. • Visualizing the margin during the procedure can prompt immediate complementary treatment. • US image fusion correlates with the results of early evaluation CT.Immune checkpoint blockade for the treatment of human hepatocellular carcinoma.Nishida N; Kudo MHepatology research : the official journal of the Japan Society of Hepatology WILEY 48 (8) 622 - 634 1386-6346 2018/05 [Refereed] Hepatocellular carcinoma (HCC) is one of the most common cancers with a high recurrence rate. Currently, tyrosine kinase inhibitors (TKIs) are the first-line treatment for cases refractory to conventional therapies. However, the acquisition of somatic mutations can result in TKI resistance. Clinical evidence suggests that acquired immunity contributes to the suppression of tumor recurrence, indicating the potential of induced antitumor immune reaction for the treatment of HCC. Recently, immune checkpoint inhibitors have become available for the treatment of malignancies. They are effective regardless of the response to prior therapies and a durable effect can be expected, which should be attributed to an adaptive immunity to HCC components. The results of phase I/II trials of nivolumab, an anti-programmed cell death-1 antibody, showed that 20% of patients showed objective response and that nivolumab was effective regardless of prior sorafenib treatment and viral status. Nivolumab received expedited Food and Drug Administration approval in 2017 for the treatment of advanced HCC after failure or intolerance to sorafenib. However, the majority of the patients remain refractory, likely due to the solid immune suppressive status, which involves many stromal cells, humoral mediators, and suppressive checkpoint molecules. Therefore, current clinical trials are focusing on how immunosuppressive conditions in HCC might be overcome using immune checkpoint inhibitors in combination with different types of immune checkpoint blockades, TKIs, and other conventional treatments. The development of immune checkpoint inhibitors is rapidly progressing and these inhibitors are likely to be key agents for HCC treatment in the near feature.Contrast-enhanced Harmonic EUS Imaging of Pancreatic Mucinous Cystadenocarcinoma.Tanaka H; Kamata K; Takenaka M; Kudo MInternal medicine (Tokyo, Japan) 57 (20) 3051 - 3052 0918-2918 2018/05 [Refereed]Nucleotide-binding oligomerization domain 1 and Helicobacter pylori infection: A reviewKosuke Minaga; Tomohiro Watanabe; Ken Kamata; Naoki Asano; Masatoshi KudoWorld Journal of Gastroenterology Baishideng Publishing Group Inc. 24 (16) 1725 - 1733 1007-9327 2018/04 [Refereed]肝臓 診断 肝腫瘍の悪性度診断〜Bモード・エラスト・Sonazoid造影〜 肝膿瘍治療指針におけるソナゾイド造影の有用性盛田 真弘; 小川 力; 大村 亜紀奈; 野田 晃世; 久保 敦司; 松中 寿浩; 玉置 敬之; 柴峠 光成; 大西 宏明; 工藤 正俊超音波医学 (公社)日本超音波医学会 45 (Suppl.) S308 - S308 1346-1176 2018/04肝臓 診断 肝腫瘤の診療ガイドラインを考える 新しい造影法導入後の問題点小川 力; 盛田 真弘; 野田 晃世; 大村 亜紀奈; 久保 敦司; 石川 哲朗; 松中 寿浩; 玉置 敬之; 柴峠 光成; 工藤 正俊超音波医学 (公社)日本超音波医学会 45 (Suppl.) S313 - S313 1346-1176 2018/04肝臓 診断 肝腫瘤の診療ガイドラインを考える 肝腫瘍の視認性に関する低音圧造影tissue harmonic imagingの有用性南 康範; 河野 匡志; 工藤 正俊超音波医学 (公社)日本超音波医学会 45 (Suppl.) S314 - S314 1346-1176 2018/04肝癌研究会追跡調査よりみた高齢肝細胞癌に対する外科的切除の意義 Annals of Surgery海堀 昌樹; 吉井 健悟; 横田 勲; 長谷川 潔; 高山 忠利; 久保 正二; 權 雅憲; 泉 並木; 角谷 眞澄; 工藤 正俊; 熊田 卓; 坂元 亨宇; 中島 収; 松山 裕; 國土 典宏日本外科学会定期学術集会抄録集 (一社)日本外科学会 118回 773 - 773 2018/04Gastric Inverted Hyperplastic Polyp Mimicking a PapillaShigenaga Matsui; Hiroshi Kashida; Masatoshi KudoAmerican Journal of Gastroenterology Nature Publishing Group 113 (4) 462  1572-0241 2018/04 [Refereed]Induction of Complete Remission by Azacitidine in a Patient with Myelodysplastic Syndrome-Associated Inflammatory Bowel DiseaseMasashi Kono; Yoriaki Komeda; Toshiharu Sakurai; Ayana Okamoto; Kosuke Minaga; Ken Kamata; Satoru Hagiwara; Hiroaki Inoue; Eisuke Enoki; Itaru Matsumura; Tomohiro Watanabe; Masatoshi KudoJournal of Crohn's and Colitis Oxford University Press (OUP) 12 (4) 499 - 502 1873-9946 2018/03 [Refereed]Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trialMasatoshi Kudo; Richard S Finn; Shukui Qin; Kwang-Hyub Han; Kenji Ikeda; Fabio Piscaglia; Ari Baron; Joong-Won Park; Guohong Han; Jacek Jassem; Jean Frederic Blanc; Arndt Vogel; Dmitry Komov; T R Jeffry Evans; Carlos Lopez; Corina Dutcus; Matthew Guo; Kenichi Saito; Silvija Kraljevic; Toshiyuki Tamai; Min Ren; Ann-Lii ChengThe Lancet Lancet Publishing Group 391 (10126) 1163 - 1173 1474-547X 2018/03 [Refereed] Background: In a phase 2 trial, lenvatinib, an inhibitor of VEGF receptors 1–3, FGF receptors 1–4, PDGF receptor α RET, and KIT, showed activity in hepatocellular carcinoma. We aimed to compare overall survival in patients treated with lenvatinib versus sorafenib as a first-line treatment for unresectable hepatocellular carcinoma. Methods: This was an open-label, phase 3, multicentre, non-inferiority trial that recruited patients with unresectable hepatocellular carcinoma, who had not received treatment for advanced disease, at 154 sites in 20 countries throughout the Asia-Pacific, European, and North American regions. Patients were randomly assigned (1:1) via an interactive voice–web response system—with region macroscopic portal vein invasion, extrahepatic spread, or both Eastern Cooperative Oncology Group performance status and bodyweight as stratification factors—to receive oral lenvatinib (12 mg/day for bodyweight ≥60 kg or 8 mg/day for bodyweight < 60 kg) or sorafenib 400 mg twice-daily in 28-day cycles. The primary endpoint was overall survival, measured from the date of randomisation until the date of death from any cause. The efficacy analysis followed the intention-to-treat principle, and only patients who received treatment were included in the safety analysis. The non-inferiority margin was set at 1·08. The trial is registered with ClinicalTrials.gov, number NCT01761266. Findings: Between March 1, 2013 and July 30, 2015, 1492 patients were recruited. 954 eligible patients were randomly assigned to lenvatinib (n=478) or sorafenib (n=476). Median survival time for lenvatinib of 13·6 months (95% CI 12·1–14·9) was non-inferior to sorafenib (12·3 months, 10·4–13·9 hazard ratio 0·92, 95% CI 0·79–1·06), meeting criteria for non-inferiority. The most common any-grade adverse events were hypertension (201 [42%]), diarrhoea (184 [39%]), decreased appetite (162 [34%]), and decreased weight (147 [31%]) for lenvatinib, and palmar-plantar erythrodysaesthesia (249 [52%]), diarrhoea (220 [46%]), hypertension (144 [30%]), and decreased appetite (127 [27%]) for sorafenib. Interpretation: Lenvatinib was non-inferior to sorafenib in overall survival in untreated advanced hepatocellular carcinoma. The safety and tolerability profiles of lenvatinib were consistent with those previously observed. Funding: Eisai Inc.パンクレリパーゼ摂取による腸管内および便の腸内細菌叢に対する影響の検討永井 知行; 櫻井 俊治; 工藤 正俊; 西山 拓輝; 岡崎 能久; 東 慶直; 渡邉 智裕; 五斗 進; 緒方 博之日本消化器病学会雑誌 (一財)日本消化器病学会 115 (臨増総会) A335 - A335 0446-6586 2018/03汎用性の画像ソフトを用いた自動抽出機能による大腰筋測定法の有用性盛田 真弘; 小川 力; 工藤 正俊; 大村 亜紀奈; 野田 晃世; 久保 敦司; 松中 寿浩; 玉置 敬之; 柴峠 光成日本消化器病学会雑誌 (一財)日本消化器病学会 115 (臨増総会) A344 - A344 0446-6586 2018/03画像支援ソフトを用いたHCC診療に対する当院の取り組み小川 力; 盛田 真弘; 大村 亜紀奈; 野田 晃世; 久保 敦司; 石川 哲朗; 松中 寿浩; 玉置 敬之; 柴峠 光成; 工藤 正俊日本消化器病学会雑誌 (一財)日本消化器病学会 115 (臨増総会) A388 - A388 0446-6586 2018/03膵体部の膵神経内分泌腫瘍に合併した膵性胸水の一例河野 辰哉; 山雄 健太郎; 中井 敦史; 大本 俊介; 鎌田 研; 三長 孝輔; 宮田 剛; 今井 元; 松本 逸平; 竹山 宜典; 田中 伴典; 筑後 孝章; 林 暁洋; 工藤 正俊日本消化器病学会雑誌 (一財)日本消化器病学会 115 (臨増総会) A395 - A395 0446-6586 2018/03十二指腸穿破をきたした正中球状靱帯症候群による膵十二指腸動脈瘤の一例高島 耕太; 大本 俊介; 三長 孝輔; 竹中 完; 中井 敦史; 宮田 剛; 鎌田 研; 山雄 健太郎; 今井 元; 米田 頼晃; 松井 繁長; 工藤 正俊日本消化器病学会雑誌 (一財)日本消化器病学会 115 (臨増総会) A355 - A355 0446-6586 2018/03Lenvatinib May Drastically Change the Treatment Landscape of Hepatocellular CarcinomaMasatoshi KudoLiver Cancer S. Karger AG 7 (1) 1 - 19 1664-5553 2018/03 [Refereed]Combination Cancer Immunotherapy in Hepatocellular CarcinomaMasatoshi KudoLiver Cancer S. Karger AG 7 (1) 20 - 27 1664-5553 2018/03 [Refereed]Treatment Optimization for Hepatocellular Carcinoma in Elderly Patients in a Japanese Nationwide Cohort.Kaibori M; Yoshii K; Hasegawa K; Ogawa A; Kubo S; Tateishi R; Izumi N; Kadoya M; Kudo M; Kumada T; Sakamoto M; Nakashima O; Matsuyama Y; Takayama T; Kokudo N; Liver Cancer Study; Group of JapanAnnals of surgery 270 121 - 130 0003-4932 2018/03 [Refereed]Impact of resection and ablation for single hypovascular hepatocellular carcinoma ≤2 cm analysed with propensity score weighting.Kenichi Takayasu; Shigeki Arii; Michiie Sakamoto; Yutaka Matsuyama; Masatoshi Kudo; Shuichi Kaneko; Osamu Nakashima; Masumi Kadoya; Namiki Izumi; Tadatoshi Takayama; Yonson Ku; Takashi Kumada; Shoji Kubo; Takashi Kokudo; Yasuhiro Hagiwara; Norihiro KokudoLiver international : official journal of the International Association for the Study of the Liver 38 (3) 484 - 493 1478-3223 2018/03 [Refereed] BACKGROUND AND AIMS: Small hypovascular hepatocellular carcinoma (HCC) ≤2 cm is biologically less aggressive than hypervascular one, however, the optimal treatment is still undetermined. The efficacy of surgical resection (SR), radiofrequency ablation (RFA) and percutaneous ethanol injection (PEI) was evaluated. METHODS: The 853 (SR, 176; RFA, 491; PEI, 186) patients were enrolled who met Child-Pugh A/B, single hypovascular HCC ≤2 cm pathologically proven, available tumour differentiation and absence of macrovascular invasion and extrahepatic metastasis. Overall and recurrence-free survivals were compared in original and a propensity score weighted pseudo-population with 732 patients. RESULTS: The median follow-up time and tumour size were 2.8 years and 1.47 cm respectively. In original population, multivariate Cox regression showed no significant difference for overall survival among three groups. In pseudo-population, Cox regression also revealed no significant difference for overall survival among them, although SR (HR, 0.56; 95% CI, 0.36-0.86) and RFA (HR, 0.75; 95% CI, 0.57-1.00) groups had significantly lower recurrence than PEI group. The overall survival rates at 3 and 5 years for the SR, RFA and PEI groups were 94%/70%, 90%/75% and 94%/73% respectively. Corresponding recurrence-free survival rates were 64%/54%, 59%/41% 48%/33% respectively. Subgroup analysis revealed no significant survival benefit of SR compared with non-SR. No treatment-related death occurred. CONCLUSIONS: For patients with single hypovascular HCC ≤2 cm, no significant difference for overall survival was first identified among 3 treatment groups. The SR or RFA could be recommended, and PEI would be alternative to RFA.Transrectal endoscopic ultrasound-guided paracentesis for diagnosis of malignant ascites in the pelvisKosuke Minaga; Mamoru Takenaka; Ken Kamata; Masatoshi KudoDigestive and Liver Disease Elsevier B.V. 50 (3) 311  1878-3562 2018/03 [Refereed]Alleviating pancreatic cancer-associated pain using endoscopic ultrasound-guided neurolysisKosuke Minaga; Mamoru Takenaka; Ken Kamata; Tomoe Yoshikawa; Atsushi Nakai; Shunsuke Omoto; Takeshi Miyata; Kentaro Yamao; Hajime Imai; Hiroki Sakamoto; Masayuki Kitano; Masatoshi KudoCancers MDPI AG 10 (2) 2072-6694 2018/02 [Refereed] The most common symptom in patients with advanced pancreatic cancer is abdominal pain. This has traditionally been treated with nonsteroidal anti-inflammatory drugs and opioid analgesics. However, these treatments result in inadequate pain control or drug-related adverse effects in some patients. An alternative pain-relief modality is celiac plexus neurolysis, in which the celiac plexus is chemically ablated. This procedure was performed percutaneously or intraoperatively until 1996, when endoscopic ultrasound (EUS)-guided celiac plexus neurolysis was first described. In this transgastric anterior approach, a neurolytic agent is injected around the celiac trunk under EUS guidance. The procedure gained popularity as a minimally invasive approach and is currently widely used to treat pancreatic cancer-associated pain. We focus on two relatively new techniques of EUS-guided neurolysis: EUS-guided celiac ganglia neurolysis and EUS-guided broad plexus neurolysis, which have been developed to improve efficacy. Although the techniques are safe and effective in general, some serious adverse events including ischemic and infectious complications have been reported as the procedure has gained widespread popularity. We summarize reported clinical outcomes of EUS-guided neurolysis in pancreatic cancer (from the PubMed and Embase databases) with a goal of providing information useful in developing strategies for pancreatic cancer-associated pain alleviation.膵・胆管合流異常に合併した共通管内乳頭状腫瘍の1例幕谷 悠介; 松本 逸平; 大本 俊介; 筑後 孝章; 川口 晃平; 松本 正孝; 村瀬 貴昭; 亀井 敬子; 里井 俊平; 中居 卓也; 竹中 完; 工藤 正俊; 竹山 宜典日本消化器外科学会雑誌 (一社)日本消化器外科学会 51 (2) 114 - 121 0386-9768 2018/02 [Refereed] 膵・胆管合流異常に合併した共通管内乳頭状腫瘍の1例を報告する.症例は75歳の男性で,6ヵ月間に2度の急性膵炎を発症し保存的加療で軽快した.急性膵炎の原因精査および加療目的で当院へ紹介となった.ERCPでは膵・胆管合流異常を認め,共通管内に7mmの結節様陰影欠損像を認めた.上部内視鏡検査では乳頭部からの粘液排出は認めず,超音波内視鏡検査では共通管内に乳頭状の腫瘍が描出された.造影CTでは膵頭部に拡張した共通管と内部に増強効果を持つ8mmの腫瘤を認めた.尾側の主膵管の拡張は認めなかった.膵・胆管合流異常に合併した共通管内乳頭状腫瘍と診断し,亜全胃温存膵頭十二指腸切除術を施行した.病理肉眼所見では共通管内に発育する有茎性の乳頭状腫瘍で,組織像は管状構造増生を主体とする腺腫であった.免疫組織学的染色ではMUC1,MUC2陰性,MUC5AC陽性で胃型腺腫と最終診断した.(著者抄録)[Hepatitis C Virus-Induced Cryoglobulinemic Vasculitis].Minami Y; Kudo MBrain and nerve = Shinkei kenkyu no shinpo 70 (2) 133 - 137 1881-6096 2018/02 [Refereed]Transarterial chemoembolization with miriplatin vs. epirubicin for unresectable hepatocellular carcinoma: a phase III randomized trial.Masafumi Ikeda; Masatoshi Kudo; Hiroshi Aikata; Hiroaki Nagamatsu; Hiroshi Ishii; Osamu Yokosuka; Takuji Torimura; Manabu Morimoto; Kenji Ikeda; Hiromitsu Kumada; Tosiya Sato; Ikuko Kawai; Toru Yamashita; Hiroshi Horio; Takuji OkusakaJournal of gastroenterology 53 (2) 281 - 290 0944-1174 2018/02 [Refereed] BACKGROUND: This prospective study investigated the superiority of transarterial chemoembolization (TACE) with miriplatin over TACE with epirubicin regarding overall survival (OS) in patients with unresectable hepatocellular carcinoma (HCC). METHODS: Patients with unresectable HCC were randomized 1:1 to receive TACE with miriplatin or epirubicin in lipiodol. The primary endpoint was OS; secondary endpoints were percentages of patients who achieved treatment effect (TE) 4 (100% necrotizing effect or tumor reduction), duration of time to TACE failure, and adverse events (AEs). OS was compared using a stratified log-rank test adjusted for clinical stage, Child-Pugh class, and institution. RESULTS: Of 257 patients enrolled from August 2008 to August 2010, 247 were analyzed for efficacy and toxicity (miriplatin, n = 124; epirubicin, n = 123). Baseline characteristics were well balanced between the two groups. Median OS times were 1111 days for miriplatin and 1127 days for epirubicin (adjusted hazard ratio 1.01, 95% confidence interval 0.73-1.40, P = 0.946). TE4 rates were 44.4% for miriplatin and 37.4% for epirubicin. Median times to TACE failure were 365.5 days for miriplatin and 414.0 days for epirubicin. AEs of grade 3 or higher, including elevated aspartate aminotransferase (miriplatin, 39.5%; epirubicin, 57.7%) and elevated alanine aminotransferase (miriplatin, 31.5%; epirubicin, 53.7%), were less frequent in the miriplatin than the epirubicin group. CONCLUSIONS: OS after TACE with miriplatin was not superior to that after TACE with epirubicin; however, hepatic AEs were less frequent with miriplatin. CLINICAL TRIAL REGISTRATION: JapicCTI-080632.肝がんの新しい薬「消化器病の薬」工藤正俊消化器のひろば (13) 8  2018 [Refereed][Invited]CONTRAST-ENHANCED HARMONIC ENDOSCOPIC ULTRASONOGRAPHY FOR DIFFERENTIAL DIAGNOSIS OF LOCALIZED GALLBLADDER LESIONSKAMATA Ken; NISHIDA Naoshi; KASHIDA Hiroshi; CHIKUGO Takaaki; CHIBA Yasutaka; NAKAI Takuya; TAKEYAMA Yoshifumi; LISOTTI Andrea; FUSAROLI Pietro; KUDO Masatoshi; TAKENAKA Mamoru; KITANO Masayuki; OMOTO Shunsuke; MIYATA Takeshi; MINAGA Kosuke; YAMAO Kentaro; IMAI Hajime; SAKURAI TosiharuGASTROENTEROLOGICAL ENDOSCOPY Japan Gastroenterological Endoscopy Society 60 (9) 1611 - 1620 0387-1207 2018 Background and Aim: Differential diagnosis of localized gallbladder lesions is challenging. The aim of the present study was to evaluate the utility of contrast-enhanced harmonic endoscopic ultrasonography (CH-EUS) for diagnosis of localized gallbladder lesions. Methods: One hundred and twenty-five patients with localized gallbladder lesions were evaluated by CH-EUS between March 2007 and February 2014. This was a single-center retrospective study. Utilities of fundamental B-mode EUS (FB-EUS) and CH-EUS in the differentiation of gallbladder lesions and sludge plug were initially compared. Thereafter, these two examinations were compared with respect to their accuracy in the diagnosis of malignant lesions. Five reviewers blinded to the clinicopathological results evaluated microcirculation patterns in the vascular and perfusion images.Results: In the differentiation between gallbladder lesions and sludge plug, FB-EUS had a sensitivity, specificity, and accuracy of 82%, 100%, and 95%, respectively, whereas CH-EUS had a sensitivity, specificity, and accuracy of 100%, 99%, and 99%, respectively. FB-EUS-based diagnosis of carcinomas based on tumor size and/or shape had a sensitivity, specificity, and accuracy of 61-87%, 71-88%, and 74-86%, respectively. Additional information regarding irregular vessel patterns in the vascular image and/or heterogeneous enhancement in the perfusion image on CH-EUS increased the sensitivity, specificity, and accuracy for the diagnosis of carcinomas to 90%, 98%, and 96%, respectively. There was a significant difference between FB-EUS and CH-EUS in terms of carcinoma diagnosis.Conclusion: CH-EUS was useful for the evaluation of localized gallbladder lesions.IgG4渡邉 智裕; 工藤正俊消化器病学サイエンス 2 (3) 41 - 41 2018 [Invited]自然免疫反応が膵臓の慢性炎症に果たす役割渡邉 智裕; 三長 孝輔; 鎌田 研; 工藤 正俊膵臓 33 (4) 737 - 741 2018 [Refereed][Invited]学会レポート「第54回米国臨床腫瘍学会(ASCO)」工藤正俊肝胆膵 77 522 - 532 2018 [Refereed]肝細胞癌の切除・RFA後のアジュバント・ネオアジュバント療法工藤正俊肝胆膵 77 506 - 511 2018 [Refereed]腫瘍免疫抑制環境の成立とチロシンキナーゼ阻害剤の作用-チロシンキナーゼ阻害剤と免疫チェックポイント阻害剤併用のコンセプト-西田直生志; 工藤正俊肝胆膵 (株)アークメディア 77 (2) 499 - 505 0389-4991 2018 [Refereed]どのようにしてcold tumorをhot tumorに変えるか工藤正俊肝胆膵 77 449 - 455 2018 [Refereed]ニボルマブの臨床試験のアップデート平岡 淳; 道堯浩二郎; 工藤正俊肝胆膵 77 419 - 424 2018 [Refereed]レンバチニブのQOLと費用対効果上嶋一臣; 工藤正俊肝胆膵 77 306 - 309 2018 [Refereed]レンバチニブとソラフェニブの有効性および肝機能の変化-REFLECT試験への登録症例の経験から-上嶋一臣; 工藤正俊肝胆膵 77 278 - 283 2018 [Refereed]REFLECT試験の結果を振り返る、レンバチニブの高い奏効率の臨床的意義工藤正俊肝胆膵 77 263 - 270 2018 [Refereed]TACEとソラフェニブ併用試験(TACTICS)の概要と成功要因-過去の失敗試験との比較からTACE併用試験のendpointを考える-工藤正俊肝胆膵 77 231 - 240 2018 [Refereed]TACEによる肝予備能低下‐ALBI score/gradeによる評価-平岡 淳; 道堯浩二郎; 熊田 卓; 工藤正俊肝胆膵 77 224 - 230 2018 [Refereed]特別座談会「肝細胞癌薬物療法のパラダイムシフトを語る」工藤正俊; 池田公史; 古瀬純司; 北野滋久肝胆膵 77 183 - 210 2018 [Refereed][Invited]Utility of endoscopic ultrasound in hemorrhage from recurrent duodenal varicesMatsui S; Kashida H; Kudo MAnn Gastroenterol 31 636  2018 [Refereed]Management of hepatocellular carcinoma in Japan as a world-leading modelMasatoshi KudoLiver Cancer 7 134 - 147 2018 [Refereed]Cabozantinib as a second-line agent in advanced hepatocellular carcinomaMasatoshi KudoLiver Cancer 7 123 - 133 2018 [Refereed]Cystic duct antegrade stenting for cholangitis after the long-term deployment of lumen-apposing metal stents for calculous cholecystitisMamoru Takenaka; Ken Kamata; Kosuke Minaga; Atsushi Nakai; Shunsuke Omoto; Takeshi Miyata; Kentaro Yamao; Hajime Imai; Toshiharu Sakurai; Tomohiro Watanabe; Naoshi Nishida; Masatoshi KudoEndoscopic Ultrasound Medknow 7 (5) 349 - 349 2303-9027 2018 [Refereed]肝癌診療の最前線工藤正俊日本内科学会雑誌 107 (9) 1934 - 1943 2018 [Refereed]切除不能な肝細胞癌に対するスチバーガの位置づけと適正使用のポイント―ネクサバールとスチバーガによるsequential therapy を視野に入れた治療戦略―工藤正俊; Josep M. Llovet; Ann-Lii Cheng; 泉 並木; 古瀬純司; 山下太郎医学書院 Cancer Board Square 4 2018 [Refereed]開発中の肝癌治療薬 特集:肝癌―診断・治療の最新知見― V.特論工藤正俊日本臨床 76 343 - 352 2018Nucleotide-binding oligomerization domain 1 and Helicobacter pylori infection: A review.Minaga K; Watanabe T; Kamata K; Asano N; Kudo MWorld J Gastroenterol 2018 [Refereed]How to perform Contrast-Enhanced Ultrasound (CEUS).Dietrich CF; Averkiou M; Nielsen MB; Barr RG; Burns PN; Calliada F; Cantisani V; Choi B; Chammas MC; Clevert DA; Claudon M; Correas JM; Cui XW; Cosgrove D; D'Onofrio M; Dong Y; Eisenbrey J; Fontanilla T; Gilja OH; Ignee A; Jenssen C; Kono Y; Kudo M; Lassau N; Lyshchik A; Franca Meloni M; Moriyasu F; Nolsøe C; Piscaglia F; Radzina M; Saftoiu A; Sidhu PS; Sporea I; Schreiber-Dietrich D; Sirlin CB; Stanczak M; Weskott HP; Wilson SR; Willmann JK; Kim TK; Jang HJ; Vezeridis A; Westerway SUltrasound international open 4 (1) E2 - E15 2509-596X 2018/01 [Refereed]Autoimmune Pancreatitis Mouse ModelKen Kamata; Tomohiro Watanabe; Kosuke Minaga; Warren Strober; Masatoshi KudoCurrent Protocols in Immunology Wiley 120 (1) 15.31.1 - 15.31.8 1934-3671 2018/01 [Refereed]Sustained antiviral effects and clearance of hepatitis surface antigen after combination therapy with entecavir and pegylated interferon in chronic hepatitis BSatoru Hagiwara; Naoshi Nishida; Tomohiro Watanabe; Hiroshi Ida; Toshiharu Sakurai; Kazuomi Ueshima; Masahiro Takita; Yoriaki Komeda; Norihiro Nishijima; Yukio Osaki; Masatoshi KudoAntiviral Therapy International Medical Press 23 (6) 513 - 521 1359-6535 2018 [Refereed]Supplementation of pancreatic digestive enzymes alters the composition of intestinal microbiota in miceHiroki Nishiyama; Tomoyuki Nagai; Masatoshi Kudo; Yoshihisa Okazaki; Yoshinao Azuma; Tomohiro Watanabe; Susumu Goto; Hiroyuki Ogata; Toshiharu SakuraiBiochemical and Biophysical Research Communications Elsevier BV 495 (1) 273 - 279 0006-291X 2018/01 [Refereed]Orantinib versus placebo combined with transcatheter arterial chemoembolisation in patients with unresectable hepatocellular carcinoma (ORIENTAL): a randomised, double-blind, placebo-controlled, multicentre, phase 3 studyMasatoshi Kudo; Ann-Lii Cheng; Joong-Won Park; Jae Hyung Park; Po-Chin Liang; Hisashi Hidaka; Namiki Izumi; Jeong Heo; Youn Jae Lee; I-Shyan Sheen; Chang-Fang Chiu; Hitoshi Arioka; Satoshi Morita; Yasuaki AraiThe Lancet Gastroenterology and Hepatology Elsevier Ltd 3 (1) 37 - 46 2468-1253 2018/01 [Refereed] Background Orantinib is an oral multi-kinase inhibitor. This study was done to evaluate the efficacy of orantinib combined with conventional transcatheter arterial chemoembolisation (cTACE) in patients with unresectable hepatocellular carcinoma. Methods This randomised, double-blind, placebo-controlled, phase 3 study was done at 75 sites in Japan, South Korea, and Taiwan. Patients with unresectable hepatocellular carcinoma, no extra-hepatic tumour spread, and Child-Pugh score of 6 or less were randomly assigned (1:1) by interactive web response system using a computer-generated sequence to receive orantinib or placebo, within 28 days of cTACE. Randomisation was stratified by region, Child-Pugh score (5 vs 6), alpha fetoprotein concentrations (< 400 ng/mL vs ≥400 ng/mL), and size of the largest lesion (≤50 mm vs > 50 mm). Orantinib at 200 mg, twice per day, or placebo was given orally until TACE failure or unacceptable toxicity. The patients, investigators, and study personnel were masked to treatment assignment. The primary endpoint was overall survival, analysed in the full analysis set (patients who had received at least one dose of study drug). This study is registered at ClinicalTrials.gov, number NCT01465464, and has been terminated. Findings Between Dec 10, 2010, and Nov 21, 2013, 889 patients were randomly assigned to receive either orantinib (445 patients 444 treated) or placebo (444 patients all treated). The study was ended at interim analysis for futility evaluation. Median follow-up was 17·3 months (IQR 11·3–26·4). There was no improvement in overall survival with orantinib compared with placebo (median 31·1 months [95% CI 26·5–34·5] vs 32·3 months [28·4–not reached] hazard ratio 1·090, 95% CI 0·878–1·352 p=0·435). The main adverse events in the orantinib group were oedema, ascites, and elevation of aspartate and alanine aminotransferases. The most frequent adverse events of grade 3 or worse in the orantinib group included elevated aspartate aminotransferase (189 [43%] patients in the oratinib group, 161 [36%] patients in the placebo group), elevated alanine aminotransferase (150 [34%] patients in the oratinib group, 132 (30%) patients in the placebo group), and hypertension (47 [11%] patients in the oratinib group, 39 [9%] patients in the placebo group). Serious adverse events were reported in 200 (45%) patients in the orantinib group and 134 (30%) patients in the placebo group. Interpretation Orantinib combined with cTACE did not improve overall survival in patients with unresectable hepatocellular carcinoma. Funding Taiho Pharmaceutical.Meeting Report; 第54回米国臨床腫瘍学会(ASCO 2018)工藤正俊The Liver Cancer Journal 10 54 - 61 2018 [Refereed][Invited]Impact of avascular areas, as measured by contrast-enhanced harmonic EUS, on the accuracy of FNA for pancreatic adenocarcinomaKen Kamata; Mamoru Takenaka; Shunsuke Omoto; Takeshi Miyata; Kosuke Minaga; Kentaro Yamao; Hajime Imai; Toshiharu Sakurai; Naoshi Nishida; Takaaki Chikugo; Yasutaka Chiba; Ippei Matsumoto; Yoshifumi Takeyama; Masatoshi KudoGASTROINTESTINAL ENDOSCOPY MOSBY-ELSEVIER 87 (1) 158 - 163 0016-5107 2018/01 [Refereed] Background and Aims: EUS-guided FNA (EUS-FNA) is used for the diagnosis of pancreatic adenocarcinoma, but sometimes the method results in a false negative. Occasionally, an avascular area may be observed within the pancreatic adenocarcinoma tumor during contrast-enhanced harmonic EUS (CH-EUS). The aim of this study was to evaluate whether the diagnostic sensitivity of EUS-FNA for pancreatic adenocarcinoma was affected by the presence of avascularity on CH-EUS. Methods: Two hundred ninety-two patients with pancreatic adenocarcinoma who presented at Kindai University Hospital for EUS-FNA and CH-EUS between June 2009 and August 2013 were retrospectively evaluated. This was a single-center retrospective analysis of prospectively collected data held in a registry. The overall sensitivity of EUS-FNA for the diagnosis of pancreatic adenocarcinoma was calculated. The sensitivities of cytology, histology, and the combination of cytology and histology were also evaluated. These variables were individually evaluated according to the presence or absence of an avascular area on CH-EUS to assess whether the diagnostic sensitivity of EUS-FNA for pancreatic adenocarcinoma was related to the presence of an avascular area within the tumors. Results: The overall sensitivity of EUS-FNA was 90.8% (265/292). The sensitivities of EUS-FNA for lesions with and without an avascular area were 72.9% (35/48) and 94.3% (230/244), respectively, with the difference being statistically significant (P <.001). Conclusions: EUS-FNA has lower sensitivity for pancreatic adenocarcinoma with avascular areas on CH-EUS.Contrast-enhanced harmonic endoscopic ultrasonography for differential diagnosis of localized gallbladder lesionsKen Kamata; Mamoru Takenaka; Masayuki Kitano; Shunsuke Omoto; Takeshi Miyata; Kosuke Minaga; Kentaro Yamao; Hajime Imai; Tosiharu Sakurai; Naoshi Nishida; Hiroshi Kashida; Takaaki Chikugo; Yasutaka Chiba; Takuya Nakai; Yoshifumi Takeyama; Andrea Lisotti; Pietro Fusaroli; Masatoshi KudoDigestive Endoscopy Blackwell Publishing 30 (1) 98 - 106 1443-1661 2018/01 [Refereed] Background and Aim: Differential diagnosis of localized gallbladder lesions is challenging. The aim of the present study was to evaluate the utility of contrast-enhanced harmonic endoscopic ultrasonography (CH-EUS) for diagnosis of localized gallbladder lesions. Methods: One hundred and twenty-five patients with localized gallbladder lesions were evaluated by CH-EUS between March 2007 and February 2014. This was a single-center retrospective study. Utilities of fundamental B-mode EUS (FB-EUS) and CH-EUS in the differentiation of gallbladder lesions and sludge plug were initially compared. Thereafter, these two examinations were compared with respect to their accuracy in the diagnosis of malignant lesions. Five reviewers blinded to the clinicopathological results evaluated microcirculation patterns in the vascular and perfusion images. Results: In the differentiation between gallbladder lesions and sludge plug, FB-EUS had a sensitivity, specificity, and accuracy of 82%, 100%, and 95%, respectively, whereas CH-EUS had a sensitivity, specificity, and accuracy of 100%, 99%, and 99%, respectively. FB-EUS-based diagnosis of carcinomas based on tumor size and/or shape had a sensitivity, specificity, and accuracy of 61–87%, 71–88%, and 74–86%, respectively. Additional information regarding irregular vessel patterns in the vascular image and/or heterogeneous enhancement in the perfusion image on CH-EUS increased the sensitivity, specificity, and accuracy for the diagnosis of carcinomas to 90%, 98%, and 96%, respectively. There was a significant difference between FB-EUS and CH-EUS in terms of carcinoma diagnosis. Conclusion: CH-EUS was useful for the evaluation of localized gallbladder lesions.A case of successful transluminal drainage of walled-off necrosis under contrast-enhanced harmonic endoscopic ultrasonography guidanceKosuke Minaga; Mamoru Takenaka; Shunsuke Omoto; Takeshi Miyata; Ken Kamata; Kentaro Yamao; Hajime Imai; Tomohiro Watanabe; Masayuki Kitano; Masatoshi KudoJournal of Medical Ultrasonics Springer Science and Business Media LLC 45 (1) 161 - 165 1346-4523 2018/01 [Refereed]編集; 消化器内科診療レジデントマニュアル工藤正俊2 - 431 2018 [Refereed]座談会「肝癌治療のシミュレーション・ナビゲーションを語る」. 特集「肝癌治療のイノベーション-シミュレーション・ナビゲーション技術の新展開-」工藤正俊; 大城幸雄; 小川 力; 宮山士朗肝胆膵 77 1241 - 1263 2018 [Refereed][Invited]Hepatic Guideの有用性. 特集「肝癌治療のイノベーション-シミュレーション・ナビゲーション技術の新展開-」南 知宏; 南 康範; 工藤正俊; 鶴﨑正勝; 柳生行伸; 村上卓道肝胆膵 77 1161 - 1165 2018 [Refereed]US-US fusion imagingとUS-US overlay fusion. 特集「肝癌治療のイノベーション-シミュレーション・ナビゲーション技術の新展開-」南 康範; 南 知宏; 千品寛和; 田北雅弘; 萩原 智; 依田 広; 上嶋一臣; 西田直生志; 工藤正俊肝胆膵 (株)アークメディア 77 (6) 1139 - 1144 0389-4991 2018 [Refereed]座談会; 肝細胞癌の薬物療法の最先端工藤正俊; 山下竜也; 森口理久; 池田公史; 上嶋一臣; 鳥村拓司肝臓 59 517 - 544 2018 [Refereed][Invited]香川県下におけるSorafenibの使用とその傾向小川 力; 筒井 朱美; 妹尾 知典; 永野 拓也; 高口 浩一; 谷 丈二; 森下 朝洋; 米山 弘人; 正木 勉; 守屋 昭男; 安東 正晴; 出口 章広; 國土 泰孝; 工藤 正俊The Liver Cancer Journal (株)メディカルレビュー社 9 (2) 160 - 161 1883-9347 2017/12Transarterial Chemoembolization in Combination with a Molecular Targeted Agent: Lessons Learned from Negative Trials (Post-TACE, BRISK-TA, SPACE, ORIENTAL, and TACE-2)Masatoshi Kudo; Tadaaki ArizumiOncology (Switzerland) S. Karger AG 93 (1) 127 - 134 1423-0232 2017/12 [Refereed] The multikinase inhibitor sorafenib is the first oral molecular targeted agent with proven prognostic benefit in unresectable advanced hepatocellular carcinoma (HCC). However, as with other drugs, sorafenib has its limitations, and various clinical trials have been conducted to develop novel molecular targeted agents for use alone or in combination with existing locoregional therapies. Despite this, clinical trials of molecular targeted agents combined with transarterial chemoembolization (TACE) have not reported major treatment outcomes to date. In this review, we describe previous clinical trials of combination therapy with TACE and a molecular targeted agent in patients with unresectable HCC.New Paradigm in Gastrointestinal Cancer TreatmentMasatoshi KudoOncology (Switzerland) S. Karger AG 93 (1) 1 - 8 1423-0232 2017/12 [Refereed]A Social Program for the Early Detection of Pancreatic Cancer: The Kishiwada Katsuragi ProjectHiroki Sakamoto; Satoshi Harada; Nobu Nishioka; Kazuo Maeda; Takamasa Kurihara; Tateki Sakamoto; Kazuhide Higuchi; Masayuki Kitano; Yoshifumi Takeyama; Masafumi Kogire; Masatoshi KudoOncology (Switzerland) S. Karger AG 93 (1) 89 - 97 1423-0232 2017/12 [Refereed] Objectives: The early-stage pancreatic cancer (e-PC stage I/II) detection rate is quite low at approximately 25%. The aim of this study was to evaluate the feasibility of a social program (the Kishiwada Katsuragi project) wherein our hospital, which specializes in PC, and primary care medical offices (PMOs) used clinical findings to detect e-PC. Methods: Patients with a score of ≥2 points on clinical findings were enrolled: symptoms of abdominal pain/back pain (1 point), new-onset diabetes (1 point), high amylase (AMY) and/or pancreaitc AMY (P-AMY) (1 point), high carbohydrate antigen 19-9 (1 point), and ultrasonography (US) findings including direct (e.g., a solid pancreatic tumor) and/or indirect findings (e.g., dilatation of a pancreatic diameter of ≥2.5 mm and/or cystic lesions) (2 points) were evaluated using the protocol for social programs. Results: Between November 2014 and December 2016, 244 patients were enrolled by 41 PMOs as cooperative facilities, and 15 e-PC cases (53.6%) of the 28 PC patients were detected. The mean clinical finding score of the e-PC group (3.13 ± 1.9) was significantly higher than that of the overall non-PC group (2.1 ± 0.4) (p < 0.05). "High AMY/P-AMY" and "symptoms" were significantly more frequent in the e-PC group than in the non-PC group (p < 0.05). Although the sensitivity of direct findings by US was 40.0%, that of indirect-findings was 93.3% in the e-PC group. Nine and 6 of the 15 patients with e-PC were enrolled via general internal medicine offices (GIMs) and other PMOs without GIMs (general surgery, n = 3 urology, n = 2 otolaryngology, n = 1). Conclusion: This social program with collaborations between medical centers that specialize in PC and PMOs used clinical findings, suggesting that not only GIMs but also other PMOs and indirect findings by US may play an important role in improving the e-PC detection rate.Electronic hydraulic lithotripsy by antegrade digital cholangioscopy through endoscopic ultrasound-guided hepaticojejunostomyYasuo Otsuka; Ken Kamata; Mamoru Takenaka; Kosuke Minaga; Hidekazu Tanaka; Masatoshi KudoENDOSCOPY GEORG THIEME VERLAG KG 49 (12) E316 - E318 0013-726X 2017/12 [Refereed]Utility of contrast-enhanced harmonic EUS for evaluating the effects of steroid therapy in a case of immunoglobulin G4–negative focal autoimmune pancreatitisKen Kamata; Mamoru Takenaka; Kosuke Minaga; Masatoshi KudoGastrointestinal Endoscopy Mosby Inc. 86 (6) 1177 - 1179 1097-6779 2017/12 [Refereed]Oncogenic Signal and Tumor Microenvironment in Hepatocellular CarcinomaNaoshi Nishida; Masatoshi KudoOncology (Switzerland) S. Karger AG 93 (1) 160 - 164 1423-0232 2017/12 [Refereed] During tumor development, several immunosuppressive molecules are released from cancer cells and contribute to the establishment of immunosuppressive tumor environment. In tumor tissues, cytokines, chemokines, growth factors, and metabolites are present and could counter the effects of immune checkpoint inhibitors. From this point of view, monotherapy of anti-PD-1/PD-L1 antibody might not be enough to exert a sufficient antitumor effect additional blockade of immunosuppressive molecules in tumor microenvironment could enhance the antitumor effect of anti-PD-1/PD-L1 antibody. Importantly, the production of immunosuppressive molecules in cancer cells is attributed to the activation of cellular signaling through genetic and epigenetic alterations and environmental stimulation, such as inflammation and hypoxia. In this review, we focus on the establishment of immunosuppressive microenvironment of hepatocellular carcinoma in the context of activation of oncogenic signals, and discuss how the immunosuppressive condition could be overcome using tyrosine kinase inhibitors.Immuno-Oncology in Hepatocellular Carcinoma: 2017 UpdateMasatoshi KudoOncology (Switzerland) S. Karger AG 93 (1) 147 - 159 1423-0232 2017/12 [Refereed] Clinical trials are currently ongoing to evaluate the utility of antibodies against programmed cell death 1 (PD-1), programmed cell death-ligand 1 (PD-L1), and cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) as monotherapy or combination therapy in patients with hepatocellular carcinoma (HCC). Results of combination treatment with the anti-PD-L1 antibody durvalumab and the anti-CTLA-4 antibody tremelimumab in HCC were presented at the 2017 annual meeting of the ASCO (American Society of Clinical Oncology). Response rates were 25% in all 40 patients and 40% in the 20 uninfected patients, both of which are encouraging. Transcatheter arterial chemoembolization and radiofrequency ablation can activate tumor immunogenicity by releasing tumor-associated antigen and by inducing the migration of cytotoxic T lymphocytes to small intrahepatic metastatic nodules. Subsequent administration of anti-PD-1 antibody could control these small intrahepatic metastatic nodules. In a nonclinical study, the combination of pembrolizumab and lenvatinib inhibited the cancer immunosuppressive environments induced by tumor-associated macrophages and regulatory T cells. This, in turn, decreased the levels of TGF-β and IL-10, the expression of PD-1, and the inhibition of Tim-3, triggering anticancer immunity mediated by immunostimulatory cytokines such as IL-12. Studies such as these may provide insight into the appropriate molecular targeted agents to be used with immune checkpoint inhibitors.Systemic Therapy for Hepatocellular Carcinoma: 2017 UpdateMasatoshi KudoOncology (Switzerland) S. Karger AG 93 (1) 135 - 146 1423-0232 2017/12 [Refereed] Systemic therapy for hepatocellular carcinoma (HCC) changed drastically after the introduction of the molecular targeted agent sorafenib in 2007. Sorafenib provides an additional therapeutic option for patients with extrahepatic spread or vascular invasion, resulting in improved survival even among patients with advanced HCC however, the toxicity of sorafenib and its unsatisfactory antitumor effects remain unsolved issues. The development of novel molecular targeted agents as alternatives to sorafenib has been limited by difficulties unique to HCC. Recent studies have demonstrated the efficacy of two molecular targeted agents, the second-line agent regorafenib, which is used after sorafenib failure, and the first-line agent lenvatinib, which has been shown to be noninferior to sorafenib. Another category of agents that are attracting considerable interest are immune checkpoint inhibitors such as anti-PD-1/PD-L1 or CTLA-4 antibodies, which kill cancer cells via a unique mechanism. The therapeutic effects of some of these agents are currently under investigation in phase III studies. The most recent topics of interest are the combination of anti-PD-1/PD-L1 therapies with other immune checkpoint inhibitors, such as anti-CTLA-4 antibodies, or with a tyrosine kinase inhibitor, or with locoregional therapies such as resection, ablation, or transarterial chemoembolization.A Case of Pancreatic Carcinoma in situ Diagnosed by Repeated Pancreatic Juice CytologyTakeshi Miyata; Mamoru Takenaka; Shunsuke Omoto; Ken Kamata; Kosuke Minaga; Kentaro Yamao; Hajime Imai; Masatoshi KudoOncology (Switzerland) S. Karger AG 93 (1) 98 - 101 1423-0232 2017/12 [Refereed] Repeated pancreatic juice cytology via endoscopic nasopancreatic drainage (ENPD) has a high diagnostic yield and might be useful for the diagnosis of early-stage pancreatic cancer. A 67-year-old man presented with a pancreatic cyst occasionally detectable in the body of the pancreas by ultrasonography (US). No obvious pancreatic tumor was detected by US, computed tomography (CT), magnetic resonance cholangiopancreatography, and endoscopic ultrasound (EUS) (although the latter did reveal a weak, low echoic area). Endoscopic retrograde pancreatography showed irregular narrowing of the main pancreatic duct (MPD) at the pancreatic body. Pancreatic juice cytology was also performed, but did not give evidence of a malignancy. Therefore, the patient was followed up. CT and EUS performed after 3 months showed the same findings as did endoscopic retrograde pancreatography however, the results of repeated pancreatic juice cytology performed via ENPD tube revealed a suspected malignancy on 2 of 6 occasions. Therefore, we performed a central pancreatectomy. Histopathological examination of a resected specimen revealed carcinoma in situ in the narrow MPD at the body of the pancreas. In the current case, repeated pancreatic juice cytology via ENPD was effective. A weak low echoic area around the MPD stricture on EUS might be related to the inflammatory change accompanying carcinoma in situ of the pancreas.The Feasibility of 18-mm-Diameter Colonic Stents for Obstructive Colorectal CancersSatoshi Ogawa; Tatsuya Ishii; Kosuke Minaga; Yasuki Nakatani; Keiichi Hatamaru; Takuji Akamatsu; Takeshi Seta; Shunji Urai; Yoshito Uenoyama; Yukitaka Yamashita; Masatoshi KudoOncology (Switzerland) S. Karger AG 93 (1) 43 - 48 1423-0232 2017/12 [Refereed] Objectives: This study aimed to evaluate the characteristics and the feasibility of 18-mm-diameter stents for obstructive colorectal cancer, comparing the clinical courses with 22-mm-diameter stents. Methods: We retrospectively compared 33 consecutive cases treated with 18-mm-diameter stents (bridge to surgery [BTS] in 25, palliative therapy [PAL] in 8) with 27 consecutive cases treated with 22-mm-diameter stents (BTS in 21, PAL in 6) for obstructive colorectal cancer between May 2013 and November 2015 in our institution. Results: There were no significant differences between the 18-mm and 22-mm groups in technical success rates (97 and 96%, respectively) and clinical success rates (100 and 100%, respectively). As a BTS, the rates of complications and stoma formation were not significantly different between groups. For PAL, although the rates of complications and stent patency were similar, stent occlusion occurred in 1 patient (12.5%) in the 18-mm group. Conclusions: The 18-mm-diameter stents were similarly effective when compared with 22-mm-diameter stents. Because 18-mm-diameter stents are easy to handle and produce less mechanical stress, they have the potential to decrease the perforation rate and mitigate the stent's impact on the tumors. 18-mm-diameter stents can be useful and safe, especially as a BTS.Portal vein stenting for portal vein stenosis caused by bile duct cancerKen Kamata; Mamoru Takenaka; Masakatsu Tsurusaki; Masatoshi KudoDIGESTIVE AND LIVER DISEASE ELSEVIER SCIENCE INC 49 (11) 1282 - 1282 1590-8658 2017/11 [Refereed]Endoscopic ultrasound-guided choledochoduodenostomy with novel use of contrastenhanced harmonic imagingKosuke Minaga; Mamoru Takenaka; Ken Kamata; Takeshi Miyata; Kentaro Yamao; Hajime Imai; Masatoshi KudoENDOSCOPY GEORG THIEME VERLAG KG 49 (11) E281 - E282 0013-726X 2017/11 [Refereed]Rescue EUS-guided intrahepatic biliary drainage for malignant hilar biliary stricture after failed transpapillary re-interventionKosuke Minaga; Mamoru Takenaka; Masayuki Kitano; Yasutaka Chiba; Hajime Imai; Kentaro Yamao; Ken Kamata; Takeshi Miyata; Shunsuke Omoto; Toshiharu Sakurai; Tomohiro Watanabe; Naoshi Nishida; Masatoshi KudoSURGICAL ENDOSCOPY AND OTHER INTERVENTIONAL TECHNIQUES SPRINGER 31 (11) 4764 - 4772 0930-2794 2017/11 [Refereed] Treatment of unresectable malignant hilar biliary stricture (UMHBS) is challenging, especially after failure of repeated transpapillary endoscopic stenting. Endoscopic ultrasonography-guided intrahepatic biliary drainage (EUS-IBD) is a recent technique for intrahepatic biliary decompression, but indications for its use for complex hilar strictures have not been well studied. The aim of this study was to assess the feasibility and safety of EUS-IBD for UMHBS after failed transpapillary re-intervention. Retrospective analysis of all consecutive patients with UMHBS of Bismuth II grade or higher who, between December 2008 and May 2016, underwent EUS-IBD after failed repeated transpapillary interventions. The technical success, clinical success, and complication rates were evaluated. Factors associated with clinical ineffectiveness of EUS-IBD were explored. A total of 30 patients (19 women, median age 66 years [range 52-87]) underwent EUS-IBD for UMHBS during the study period. Hilar biliary stricture morphology was classified as Bismuth II, III, or IV in 5, 13, and 12 patients, respectively. The median number of preceding endoscopic interventions was 4 (range 2-14). EUS-IBD was required because the following procedures failed: duodenal scope insertion (n = 4), accessing the papilla after duodenal stent insertion (n = 5), or achieving desired intrahepatic biliary drainage (n = 21). Technical success with EUS-IBD was achieved in 29 of 30 patients (96.7%) and clinical success was attained in 22 of these 29 (75.9%). Mild peritonitis occurred in three of 30 (10%) and was managed conservatively. Stent dysfunction occurred in 23.3% (7/30). There was no procedure-related mortality. On multivariable analysis, Bismuth IV stricture predicted clinical ineffectiveness (odds ratio = 12.7, 95% CI 1.18-135.4, P = 0.035). EUS-IBD may be a feasible and effective rescue alternative with few major complications after failed transpapillary endoscopic re-intervention in patients with UMHBS, particularly for Bismuth II or III strictures.Gankyrin induces STAT3 activation in tumor microenvironment and sorafenib resistance in hepatocellular carcinomaToshiharu Sakurai; Norihisa Yada; Satoru Hagiwara; Tadaaki Arizumi; Kosuke Minaga; Ken Kamata; Mamoru Takenaka; Yasunori Minami; Tomohiro Watanabe; Naoshi Nishida; Masatoshi KudoCANCER SCIENCE WILEY 108 (10) 1996 - 2003 1349-7006 2017/10 [Refereed] Most hepatocellular carcinomas (HCC) develop as a result of chronic liver inflammation. We have shown that the oncoprotein gankyrin is critical for inflammation-induced tumorigenesis in the colon. Although the invitro function of gankyrin is well known, its role invivo remains to be elucidated. We investigated the effect of gankyrin in the tumor microenvironment of mice with liver parenchymal cell-specific gankyrin ablation (Alb-Cre;gankyrin(f/f)) and gankyrin deletion both in liver parenchymal and non-parenchymal cells (Mx1-Cre;gankyrin(f/f)). Gankyrin upregulates vascular endothelial growth factor expression in tumor cells. Gankyrin binds to Src homology 2 domain-containing protein tyrosine phosphatase-1 (SHP-1), mainly expressed in liver non-parenchymal cells, resulting in phosphorylation and activation of signal transducer and activator of transcription 3 (STAT3). Gankyrin deficiency in non-parenchymal cells, but not in parenchymal cells, reduced STAT3 activity, interleukin (IL)-6 production, and cancer stem cell marker (Bmi1 and epithelial cell adhesion molecule [EpCAM]) expression, leading to attenuated tumorigenic potential. Chronic inflammation enhances gankyrin expression in the human liver. Gankyrin expression in the tumor microenvironment is negatively correlated with progression-free survival in patients undergoing sorafenib treatment for HCC. Thus, gankyrin appears to play a critical oncogenic function in tumor microenvironment and may be a potential target for developing therapeutic and preventive strategies against HCC.A case of small invasive gastric cancer arising from Helicobacter pylori- negative gastric mucosa: Fundic gland-type adenocarcinomaYoriaki Komeda; Tomohiro Watanabe; Shigenaga Matsui; Hiroshi Kashida; Toshiharu Sakurai; Masashi Kono; Kosuke Minaga; Tomoyuki Nagai; Satoru Hagiwara; Eisuke Enoki; Masatoshi KudoJGH Open Wiley 1 (2) 74 - 75 2397-9070 2017/10 [Refereed]肝細胞癌に対する分子標的治療. 特集「肝癌診療A to Z」.工藤正俊肝臓クリニカルアップデート 3 (6) 155 - 163 2017/10 [Refereed]Gankyrin induces STAT3 activation in tumor microenvironment and sorafenib resistance in hepatocellular carcinomaToshiharu Sakurai; Norihisa Yada; Satoru Hagiwara; Tadaaki Arizumi; Kosuke Minaga; Ken Kamata; Mamoru Takenaka; Yasunori Minami; Tomohiro Watanabe; Naoshi Nishida; Masatoshi KudoCancer Science Blackwell Publishing Ltd 108 (10) 1996 - 2003 1349-7006 2017/10 [Refereed] Most hepatocellular carcinomas (HCC) develop as a result of chronic liver inflammation. We have shown that the oncoprotein gankyrin is critical for inflammation-induced tumorigenesis in the colon. Although the in vitro function of gankyrin is well known, its role in vivo remains to be elucidated. We investigated the effect of gankyrin in the tumor microenvironment of mice with liver parenchymal cell-specific gankyrin ablation (Alb-Cre gankyrinf/f) and gankyrin deletion both in liver parenchymal and non-parenchymal cells (Mx1-Cre gankyrinf/f). Gankyrin upregulates vascular endothelial growth factor expression in tumor cells. Gankyrin binds to Src homology 2 domain-containing protein tyrosine phosphatase-1 (SHP-1), mainly expressed in liver non-parenchymal cells, resulting in phosphorylation and activation of signal transducer and activator of transcription 3 (STAT3). Gankyrin deficiency in non-parenchymal cells, but not in parenchymal cells, reduced STAT3 activity, interleukin (IL)-6 production, and cancer stem cell marker (Bmi1 and epithelial cell adhesion molecule [EpCAM]) expression, leading to attenuated tumorigenic potential. Chronic inflammation enhances gankyrin expression in the human liver. Gankyrin expression in the tumor microenvironment is negatively correlated with progression-free survival in patients undergoing sorafenib treatment for HCC. Thus, gankyrin appears to play a critical oncogenic function in tumor microenvironment and may be a potential target for developing therapeutic and preventive strategies against HCC.Nucleotide-binding oligomerization domain 1 and gastrointestinal disordersTomohiro Watanabe; Naoki Asano; Masatoshi Kudo; Warren StroberPROCEEDINGS OF THE JAPAN ACADEMY SERIES B-PHYSICAL AND BIOLOGICAL SCIENCES JAPAN ACAD 93 (8) 578 - 599 0386-2208 2017/10 [Refereed] Nucleotide-binding oligomerization domain 1 (NOD1) is an intracellular sensor that detects small peptides derived from the cell wall component of intestinal microflora. NOD1 is expressed in both non-hematopoietic cells such as epithelial cells and hematopoietic cells such as antigen-presenting cells. Detection of its ligand by NOD1 leads to innate immune responses through activation of nuclear factor kappa B and type I interferon as well as induction of autophagy. Innate immune responses through NOD1 activation play an indispensable role both in host defense against microbial infection and in the development of gastrointestinal disorders. Of particular importance, NOD1-mediated innate immune responses are associated with mucosal host defenses against Helicobacter pylori (H. pylori) infection of the stomach and with the development of pancreatitis. In this review, we discuss the molecular mechanisms by which NOD1 activation leads to the development of H. pylori-related gastric diseases and pancreatitis.Contrast-enhanced harmonic endoscopic ultrasonography for differential diagnosis of submucosal tumors of the upper gastrointestinal tractKen Kamata; Mamoru Takenaka; Masayuki Kitano; Shunsuke Omoto; Takeshi Miyata; Kosuke Minaga; Kentaro Yamao; Hajime Imai; Toshiharu Sakurai; Tomohiro Watanabe; Naoshi Nishida; Takaaki Chikugo; Yasutaka Chiba; Haruhiko Imamoto; Takushi Yasuda; Andrea Lisotti; Pietro Fusaroli; Masatoshi KudoJOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY WILEY 32 (10) 1686 - 1692 0815-9319 2017/10 [Refereed] Background and Aim: The study aims to evaluate contrast-enhanced harmonic endoscopic ultrasonography (CH-EUS) for the differential diagnosis of submucosal tumors (SMT) of the upper gastrointestinal tract. Methods: Between June 2008 and May 2015, 157 consecutive patients with submucosal lesions of the upper gastrointestinal tract were evaluated by CH-EUS. This was a single-center retrospective analysis of prospectively collected data in a registry. The data from 73 patients who later underwent surgical resection were analyzed in this study. Surgical specimens served as the final diagnoses. The two CH-EUS variables of blood flow (hyper-enhancement vs hypo-enhancement) and homogeneity of enhancement pattern were evaluated. Results: The final diagnoses were 58 gastrointestinal stromal tumors (GISTs) and 15 benign SMTs (two lipomas, five leiomyomas, five schwannomas, two glomus tumors, and one ectopic pancreas). On CH-EUS, 49 of 58 (84.5%) GISTs presented with hyper-enhancement, whereas 4 of 15 (26.7%) benign SMTs showed hyper-enhancement; 21 of 58 (36.2%) GISTs showed inhomogeneous contrast enhancement, while only 2 of 15 (13.3%) benign SMTs demonstrated inhomogeneous contrast enhancement. If hyper-enhancement was considered to indicate GISTs, the sensitivity, specificity, and accuracy were 84.5%, 73.3%, and 82.2%, respectively. If inhomogeneous enhancement was considered to indicate GISTs, the sensitivity, specificity, and accuracy were 36.2%, 86.7%, and 46.6%, respectively. In lesions of less than 2cm, hyper-enhancement was a more sensitive indicator of GISTs than inhomogeneous enhancement. Conclusions: Hyper-enhancement and inhomogeneous enhancement were found to be a characteristic of GISTs. CH-EUS was useful for discrimination of benign SMTs from GISTs.Validation of serological models for staging and prognostication of HCC in patients from a Japanese nationwide surveyHienori Toyoda; Toshifumi Tada; Philip J. Johnson; Namiki Izumi; Masumi Kadoya; Shuichi Kaneko; Norihiro Kokudo; Yonson Ku; Shoji Kubo; Takashi Kumada; Yutaka Matsuyama; Osamu Nakashima; Michiie Sakamoto; Tadatoshi Takayama; Masatoshi KudoJOURNAL OF GASTROENTEROLOGY SPRINGER JAPAN KK 52 (10) 1112 - 1121 0944-1174 2017/10 [Refereed] Background Two serology-based scoring models for prognostication of patients with hepatocellular carcinoma (HCC), the BALAD and BALAD-2 models, were applied to a Japanese cohort of a nationwide follow-up survey of HCC. The ability of these models to predict the progression of HCC and the deterioration of liver function and to assess prognosis was evaluated. Methods BALAD and BALAD-2 scores were calculated in 24,029 patients from a cohort of Japanese nationwide survey based on the serum levels of five markers (bilirubin, albumin, lens culinaris agglutinin-reactive alpha-fetoprotein, alpha-fetoprotein, and des-gamma-carboxy prothrombin) measured at the time of HCC diagnosis. The associations of these scores with the progression of HCC and liver function and with survival rates were analyzed. Results There were good correlations between BALAD and BALAD-2 scores and the progression of HCC and Child-Pugh class. Both scores accurately categorized patients into risk groups with different survival rates. BALAD-2 showed superior discrimination of patient survival compared with the original BALAD. Conclusions Serology-based scoring models for prognostication, especially the BALAD-2 model, were useful for staging and prognostication of survival in a cohort of Japanese patients with HCC from a nationwide survey.EUS-guided approaches for bile duct stones: A single-center experienceMinaga Kosuke; Takenaka Mamoru; Kamata Ken; Miyata Takeshi; Yamao Kentaro; Imai Hajime; Omoto Shunsuke; Nakai Atsushi; Yoshikawa Tomoe; Watanabe Tomohiro; Kudo MasatoshiJOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY 32 240  0815-9319 2017/09 [Refereed]肝細胞癌に対する薬物療法のエビデンスとトピックス上嶋一臣; 工藤正俊日本消化器病学会雑誌 114 1621 - 1628 2017/09 [Refereed]肝動脈化学塞栓療法(TACE)の適応の再考①BCLC-Bの亜分類とTACEの適応有住忠明; 工藤正俊The Liver Cancer Journal 6 26 - 29 2017/09 [Refereed]Nationwide surveillance of bacterial respiratory pathogens conducted by the surveillance committee of Japanese Society of Chemotherapy, the Japanese Association for Infectious Diseases, and the Japanese Society for Clinical Microbiology in 2012: General vYanagihara K; Watanabe A; Aoki N; Matsumoto T; Yoshida M; Sato J; Wakamura T; Sunakawa K; Kadota J; Kiyota H; Iwata S; Kaku M; Hanaki H; Ohsaki Y; Fujiuchi S; Takahashi M; Takeuchi K; Takeda H; Ikeda H; Miki M; Nakanowatari S; Takahashi H; Utagawa M; Nishiya H; Kawakami S; Morino E; Takasaki J; Mezaki K; Chonabayashi N; Tanaka C; Sugiura H; Goto H; Saraya T; Kurai D; Katono Y; Inose R; Niki Y; Takuma T; Kudo M; Ehara S; Sato Y; Tsukada H; Watabe N; Honma Y; Mikamo H; Yamagishi Y; Nakamura A; Ohashi M; Seki M; Hamaguchi S; Toyokawa M; Fujikawa Y; Mitsuno N; Ukimura A; Miyara T; Nakamura T; Mikasa K; Kasahara K; Ui K; Fukuda S; Nakamura A; Morimura M; Yamashita M; Takesue Y; Wada Y; Sugimoto K; Kusano N; Nose M; Mihara E; Kuwabara M; Doi M; Watanabe Y; Tokuyasu H; Hino S; Negayama K; Mukae H; Kawanami T; Ota T; Fujita M; Honda J; Hiramatsu K; Aoki Y; Fukuoka M; Magarifuchi H; Nagasawa Z; Kaku N; Fujita J; Higa F; Tateyama MJournal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy 23 (9) 587 - 597 1341-321X 2017/09 [Refereed]Contribution of C1485T mutation in the HBx gene to human and murine hepatocarcinogenesisSatoru Hagiwara; Naoshi Nishida; Ah-Mee Park; Yoriaki Komeda; Toshiharu Sakurai; Tomohiro Watanabe; Masatoshi KudoSCIENTIFIC REPORTS NATURE PUBLISHING GROUP 7 (1) 10440  2045-2322 2017/09 [Refereed] Although Hepatitis B virus (HBV) X gene mutations are frequently detected in HBV-related human hepatocellular carcinoma (HCC) patients, causative HBx mutations in the development of HCC have not yet been determined. We herein identified C1485T and C1653T mutations in the HBx gene as independent risk of HCC for HBV through the analysis using serum from chronic hepatitis B patients. We generated transgenic mice expressing wild-type (WT-HBxTg) and mutant (C1485T-HBxTg) HBx to assess the carcinogenic potential of mutated HBx. C1485T-HBxTg mice were more susceptible to diethylnitrosamine-induced hepatocarcinogenesis than WT-HBxTg mice and control non-Tg mice. The promotion of hepatocarcinogenesis in C1485T-HBxTg mice was accompanied by the activation of beta-catenin and Jun N-terminal kinase (JNK) signaling pathways as well as the production of reactive oxygen species, whereas the activation of nuclear factor-kappa B in the livers of C1485T-HBxTg mice was attenuated. These results demonstrate that the HBx C1485T mutation contributes to human and murine hepatocarcinogenesis.High glucose stimulates expression of aldosterone synthase (CYP11B2) and secretion of aldosterone in human adrenal cells.Shimada H; Kogure N; Noro E; Kudo M; Sugawara K; Sato I; Shimizu K; Kobayashi M; Suzuki D; Parvin R; Saito-Ito T; Uruno A; Saito-Hakoda A; Rainey WE; Ito S; Yokoyama A; Sugawara AFEBS open bio 7 (9) 1410 - 1421 2017/09 [Refereed] Aldosterone synthase is the key rate-limiting enzyme in adrenal aldosterone production, and induction of its gene (CYP11B2) results in the progression of hypertension. As hypertension is a frequent complication among patients with diabetes, we set out to elucidate the link between diabetes mellitus and hypertension. We examined the effects of high glucose on CYP11B2 expression and aldosterone production using human adrenal H295R cells and a stable H295R cell line expressing a CYP11B2 5'-flanking region/luciferase cDNA chimeric construct. d-glucose (d-glu), but not its enantiomer l-glucose, dose dependently induced CYP11B2 transcription and mRNA expression. A high concentration (450 mg·dL-1) of d-glu time dependently induced CYP11B2 transcription and mRNA expression. Moreover, high glucose stimulated secretion of aldosterone into the media. Transient transfection studies using deletion mutants/nerve growth factor-induced clone B (NGFIB) response element 1 (NBRE-1) point mutant of CYP11B2 5'-flanking region revealed that the NBRE-1 element, known to be activated by transcription factors NGFIB and NURR1, was responsible for the high glucose-mediated effect. High glucose also induced the mRNA expression of these transcription factors, especially that of NURR1, but NURR1 knockdown using its siRNA did not affect high glucose-induced CYP11B2 mRNA expression. Taken together, it is speculated that high glucose may induce CYP11B2 transcription via the NBRE-1 element in its 5'-flanking region, resulting in the increase in aldosterone production although high glucose-induced NURR1 is not directly involved in the effect. Additionally, glucose metabolism and calcium channels were found to be involved in the high glucose effect. Our observations suggest one possible explanation for the high incidence of hypertension in patients with diabetes.Impact of Advanced Age on Survival in Patients Undergoing Resection of Hepatocellular Carcinoma: Report of a Japanese Nationwide Survey.Kaibori M; Yoshii K; Yokota I; Hasegawa K; Nagashima F; Kubo S; Kon M; Izumi N; Kadoya M; Kudo M; Kumada T; Sakamoto M; Nakashima O; Matsuyama Y; Takayama T; Kokudo N; Liver Cancer Study; Group of JapanAnnals of surgery Ovid Technologies (Wolters Kluwer Health) 269 (4) 692 - 699 0003-4932 2017/09 [Refereed]免疫チェックポイント阻害薬の役割, 肝がん. 特集「なぜ免疫チェックポイント阻害薬はがんに効くのか」工藤正俊消化器病学サイエンス 1 (2) 35 - 41 2017/09 [Refereed][Invited]悪性胆管狭窄に対するドレナージ 十二指腸ステント留置下の胆道ドレナージの成績の検討山雄 健太郎; 竹中 完; 工藤 正俊胆道 日本胆道学会 31 (3) 427 - 427 0914-0077 2017/08肝癌における免疫チェックポイント阻害剤と既存治療との組み合わせ治療 (根治後アジュバント・TACE併用・ほかの免疫療法) 開発の現状と今後の展望. 特集「肝細胞癌の化学療法が変わる」.工藤正俊肝胆膵 75 (2) 522 - 528 2017/08 [Refereed]レンバチニブ第III相試験 (REFLECT試験)からみえてきたもの―いかに効果を引き出すか―. 特集「肝細胞癌の化学療法が変わる」.工藤正俊肝胆膵 75 (2) 466 - 471 2017/08 [Refereed]ソラフェニブ・レゴラフェニブ sequential療法の効果を考察する. 特集「肝細胞癌の化学療法が変わる」.上嶋一臣; 工藤正俊肝胆膵 75 (2) 437 - 439 2017/08 [Refereed]TACE併用 (Post TACE, BRISK-TA, SPACE, ORIENTAL, TACE-2) ―標的分子と結果の概要・失敗原因の考察―. 特集「肝細胞癌の化学療法が変わる」.有住忠晃; 工藤正俊肝胆膵 75 (2) 398 - 406 2017/08 [Refereed]動注化学療法は生き残れるか―エビデンスからみた動注化学療法の今後―. 特集「肝細胞癌の化学療法が変わる」.上嶋一臣; 工藤正俊肝胆膵 75 (2) 363 - 367 2017/08 [Refereed]分子標的治療時代におけるIntermediate stage肝癌の亜分類の重要性を考える.有住忠晃; 工藤正俊肝胆膵 75 (2) 253 - 256 2017/08 [Refereed]特別座談会「急激に変貌する肝細胞癌の薬物療法を語る」, 特集 肝細胞癌の化学療法が変わる.工藤正俊; 池田公史; 古瀬純司; 小笠原定久肝胆膵 75 (2) 187 - 208 2017/08 [Refereed]Rapid Screening of Primary Aldosteronism by a Novel Chemiluminescent Immunoassay.Morimoto R; Ono Y; Tezuka Y; Kudo M; Yamamoto S; Arai T; Gomez-Sanchez CE; Sasano H; Ito S; Satoh FHypertension (Dallas, Tex. : 1979) 70 (2) 334 - 341 0194-911X 2017/08 [Refereed] Measurement of plasma aldosterone and renin concentration, or activity, is useful for selecting antihypertensive agents and detecting hyperaldosteronism in hypertensive patients. However, it takes several days to get results when measured by radioimmunoassay and development of more rapid assays has been long expected. We have developed chemiluminescent enzyme immunoassays enabling the simultaneous measurement of both aldosterone and renin concentrations in 10 minutes by a fully automated assay using antibody-immobilized magnetic particles with quick aggregation and dispersion. We performed clinical validation of diagnostic ability of this newly developed assay-based screening of 125 patients with primary aldosteronism from 97 patients with essential hypertension. Results of this novel assay significantly correlated with the results of radioimmunoassay (aldosterone, active renin concentration, and renin activity) and liquid chromatography-tandem mass spectrometry (aldosterone). The analytic sensitivity of this particularly novel active renin assay was 0.1 pg/mL, which was better than that of radioimmunoassay (2.0 pg/mL). The ratio of aldosterone-to-renin concentrations of 6.0 (ng/dL per pg/mL) provided 92.0% sensitivity and 76.3% specificity as a cutoff for differentiating primary aldosteronism from essential hypertension. This novel measurement is expected to be a clinically reliable alternative for conventional radioimmunoassay and to provide better throughput and cost effectiveness in diagnosis of hyperaldosteronism from larger numbers of hypertensive patients in clinical settings.Liver Resection for Hepatocellular Carcinoma Associated With Hepatic Vein Invasion: A Japanese Nationwide SurveyTakashi Kokudo; Kiyoshi Hasegawa; Yutaka Matsuyama; Tadatoshi Takayama; Namiki Izumi; Masumi Kadoya; Masatoshi Kudo; Shoji Kubo; Michiie Sakamoto; Osamu Nakashima; Takashi Kumada; Norihiro KokudoHEPATOLOGY WILEY 66 (2) 510 - 517 0270-9139 2017/08 [Refereed] Because of the rarity of hepatic vein tumor thrombus (HVTT) compared with portal vein tumor thrombus (PVTT) in patients with hepatocellular carcinoma, little is known about this disease entity. The aim of this study was to evaluate the prognosis of each treatment modality for HVTT through an analysis of data collected in a Japanese nationwide survey. We analyzed data for 1,021 Child-Pugh A hepatocellular carcinoma patients with HVTT without inferior vena cava invasion registered between 2000 and 2007. Of these patients, 540 who underwent liver resection (LR) and 481 who received other treatments were compared. Propensity scores were calculated, and we successfully matched 223 patients (49.0% of the LR group). The median survival time in the LR group was 2.89 years longer than that in the non-LR group (4.47 versus 1.58 years, P < 0.001) and 1.61 years longer than that in the non-LR group (3.42 versus 1.81 years, P = 0.023) in a propensity score-matched cohort. After curative resection, median survival times were similar between patients with HVTT in the peripheral hepatic vein and those with HVTT in the major hepatic vein (4.85 versus 4.67 years, P = 0.974). In the LR group, the postoperative 90-day mortality rate was 3.4% (16 patients). In patients without PVTT, the median survival time was significantly better than that in patients with PVTT (5.67 versus 1.88 years, P < 0.001). Conclusion: LR is associated with a good prognosis in hepatocellular carcinoma patients with HVTT, especially in patients without PVTT.Imaging and clinicopathological features of nivolumab-related cholangitis in patients with non-small cell lung cancerHisato Kawakami; Junko Tanizaki; Kaoru Tanaka; Koji Haratani; Hidetoshi Hayashi; Masayuki Takeda; Ken Kamata; Mamoru Takenaka; Masatomo Kimura; Takaaki Chikugo; Takao Sato; Masatoshi Kudo; Akihiko Ito; Kazuhiko NakagawaINVESTIGATIONAL NEW DRUGS SPRINGER 35 (4) 529 - 536 0167-6997 2017/08 [Refereed] Background Nivolumab demonstrates promising efficacy for the treatment of non-small cell lung cancer and other malignancies. The clinical benefit of nivolumab, however, may be hampered by specific immune-related adverse events (irAEs), and little is known regarding nivolumab-related cholangitis. Methods A computerized search of our clinical database identified 3 metastatic non-small cell lung cancer patients with nivolumab-related cholangitis. All patients were treated with in-travenous nivolumab monotherapy (3.0 mg/kg) every 2 weeks until disease progression or irAEs occurred. Clinical data regarding the duration of nivolumab treatment, symptoms, laboratory abnormalities, pathological findings of liver parenchyma biopsy specimens, and management of nivolumab-related cholangitis were analyzed. Results Our analysis revealed that nivolumab-related cholangitis was characterized by (1) localized extrahepatic bile duct dilation without obstruction; (2) diffuse hypertrophy of the extrahepatic bile duct wall; (3) a dominant increase in the biliary tract enzymes alkaline phosphatase and gamma-glutamyl transpeptidase relative to the hepatic enzymes aspartate and alanine aminotransferase; (4) normal or reduced levels of the serum immunological markers antinuclear antibody, antimitochondrial antibody, smooth muscle antibody, and immunoglobulin G4; (5) the pathological finding of biliary tract cluster of differentiation 8-positive T cell infiltration from liver biopsy; and (6) amoderate to poor response to steroid therapy. Conclusions Nivolumab-related cholangitis is associated with distinct imaging and clinicopathological features that distinguish it from acute cholangitis of common etiologies and other immune-related cholangitis. Further studies are warranted to establish the optimal management of patients with this irAE.Ramucirumab as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib: Patient-focused outcome results from the randomised phase III REACH studyIan Chau; Markus Peck-Radosavljevic; Christophe Borg; Peter Malfertheiner; Jean Francois Seitz; Joon Oh Park; Baek-Yeol Ryoo; Chia-Jui Yen; Masatoshi Kudo; Ronnie Poon; Davide Pastorelli; Jean-Frederic Blanc; Hyun Cheol Chung; Ari D. Baron; Takuji Okusaka; L. Bowman; Zhanglin Lin Cui; Allicia C. Girvan; Paolo B. Abada; Ling Yang; Andrew X. ZhuEUROPEAN JOURNAL OF CANCER ELSEVIER SCI LTD 81 17 - 25 0959-8049 2017/08 [Refereed] Purpose: To report patient-focused outcomes as measured by quality of life (QoL) and performance status (PS) in REACH, a phase III placebo-controlled randomised study, assessing ramucirumab in advanced hepatocellular carcinoma (HCC) patients who received prior sorafenib. Methods: Eligible patients had advanced HCC, Child-Pugh A, PS 0 or 1 and prior sorafenib. Patients received ramucirumab (8 mg/kg) or placebo (1:1) on day 1 of a 2-week cycle. QoL was assessed by FACT Hepatobiliary Symptom Index (FHSI)-8 and EuroQoL (EQ-5D) at baseline; cycles 4, 10, and 16; and end of treatment. PS was assessed at baseline, each cycle, and end of treatment. Deterioration in FHSI-8 was defined as a >= 3-point decrease from baseline and PS deterioration was defined as a change of >= 2. Both intention-to-treat and pre-specified subgroup of patients with baseline serum alpha-fetoprotein (AFP) >= 400 ng/mL were assessed. Results: There were 565 patients randomised to ramucirumab and placebo. Compliance with FHSI and EQ-5D was high and similar between groups. In the ITT population, deterioration in FHSI-8, EQ-5D, and PS was similar between ramucirumab and placebo. In patients with baseline AFP >= 400 ng/mL, ramucirumab significantly reduced deterioration in FHSI-8 at the end of treatment compared with placebo (P = 0.0381), and there was a trend towards a delay in the deterioration of symptoms in FHSI-8 (HR 0.690; P = 0.054) and PS (HR 0.642; P = 0.057) in favour of ramucirumab. Conclusions: We report one of the most comprehensive data sets of QoL and symptom burden in patients undergoing systemic therapy for advanced HCC. Ramucirumab was associated with no worsening of QoL. In patients with baseline AFP >= 400 ng/mL, the significant survival benefit observed in patients treated with ramucirumab was coupled with a trend in patientfocused outcome benefits. Clinical trial registration: NCT01140347. (C) 2017 Elsevier Ltd. All rights reserved.企画: 肝胆 特集「肝細胞癌の化学療法が変わる」工藤正俊肝胆膵 75 (2) 2017/08 [Refereed][Invited]【内科医が知っておくべき肝癌治療最前線】日本における新薬開発と今後の展望上嶋 一臣; 工藤 正俊消化器・肝臓内科 (有)科学評論社 2 (1) 92 - 98 2432-3446 2017/07粘膜下腫瘍様形態を呈した胃神経周膜腫(perineurioma)の1例. 早期胃がん研究会症例.松井繁長; 樫田博史; 田中梨絵; 高山政樹; 峯 宏昌; 足立哲平; 米田頼晃; 永井知行; 朝隈 豊; 櫻井俊治; 工藤正俊; 筑後孝章; 月山雅之胃と腸 52 (8) 1098 - 1106 2017/07 [Refereed]Fatal liver gas gangrene after biliary surgery.Miyata Y; Kashiwagi H; Koizumi K; Kawachi J; Kudo M; Teshima S; Isogai N; Miyake K; Shimoyama R; Fukai R; Ogino HInternational journal of surgery case reports 39 5 - 8 2017/07 [Refereed]Achievement of long-term stent patency in endoscopic ultrasonography-guided right bile duct drainage after left hepatic lobectomy (with video)Minaga K; Takenaka M; Miyata T; Yamao K; Kitano M; Kudo MEndosc Ultrasound in press 2303-9027 2017/07 [Refereed]Asia-Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 updateMasao Omata; Ann-Lii Cheng; Norihiro Kokudo; Masatoshi Kudo; Jeong Min Lee; Jidong Jia; Ryosuke Tateishi; Kwang-Hyub Han; Yoghesh K. Chawla; Shuichiro Shiina; Wasim Jafri; Diana Alcantara Payawal; Takamasa Ohki; Sadahisa Ogasawara; Pei-Jer Chen; Cosmas Rinaldi A. Lesmana; Laurentius A. Lesmana; Rino A. Gani; Shuntaro Obi; A. Kadir Dokmeci; Shiv Kumar SarinHEPATOLOGY INTERNATIONAL SPRINGER 11 (4) 317 - 370 1936-0533 2017/07 [Refereed] There is great geographical variation in the distribution of hepatocellular carcinoma (HCC), with the majority of all cases worldwide found in the Asia-Pacific region, where HCC is one of the leading public health problems. Since the "Toward Revision of the Asian Pacific Association for the Study of the Liver (APASL) HCC Guidelines" meeting held at the 25th annual conference of the APASL in Tokyo, the newest guidelines for the treatment of HCC published by the APASL has been discussed. This latest guidelines recommend evidence-based management of HCC and are considered suitable for universal use in the Asia-Pacific region, which has a diversity of medical environments.肝動脈化学塞栓療法(TACE)の適応の再考 (1)BCLC-Bの亜分類とTACEの適応Tadaaki Arizumi; Masatoshi KudoThe Liver Cancer Journal 9 (1) 26 - 29 2017/06 [Refereed]Stent migration during EUS-guided hepaticogastrostomy in a patient with massive ascites: Troubleshooting using additional EUS-guided antegrade stentingKen Kamata; Mamoru Takenaka; Kosuke Minaga; Shunsuke Omoto; Takeshi Miyata; Kentaro Yamao; Hajime Imai; Masatoshi KudoARAB JOURNAL OF GASTROENTEROLOGY ELSEVIER SCIENCE BV 18 (2) 120 - 121 1687-1979 2017/06 [Refereed] EUS-guided hepaticogastrostomy (EUS-HGS) is useful for treating obstructive jaundice. However, stent migration may sometimes occur both during and after the procedure. This report describes a patient with pancreatic cancer and massive ascites who underwent EUS-HGS combined with EUS-guided antegrade stenting (EUS-AS), with additional EUS-AS playing a role in troubleshooting for stent migration during EUS-HGS. (C) 2017 Pan-Arab Association of Gastroenterology. Published by Elsevier B.V. All rights reserved.Objective response by mRECIST as a predictor and potential surrogate end-point of overall survival in advanced HCCRiccardo Lencioni; Robert Montal; Ferran Torre; Joong-Won Park; Thomas Decaens; Jean-Luc Raoul; Masatoshi Kudo; Charissa Chang; Jose Rios; Valerie Boige; Eric Assenat; Yoon-Koo Kang; Ho-Yeong Lim; Ian Walters; Josep M. LlovetJOURNAL OF HEPATOLOGY ELSEVIER SCIENCE BV 66 (6) 1166 - 1172 0168-8278 2017/06 [Refereed] Background & Aims: The Modified Response Evaluation Criteria in Solid Tumors (mRECIST) was developed to overcome the limitations of standard RECIST criteria in response assessment of hepatocellular carcinoma (HCC). We aimed to investigate whether objective response by mRECIST accurately predicted overall survival (OS) in patients with advanced HCC treated with systemic targeted therapies and also to preliminarily assess this endpoint as a potential surrogate of OS. Methods: Individual patient data from the BRISK-PS randomized phase III trial comparing brivanib vs. placebo (the first to prospectively incorporate mRECIST) were used to analyze objective response as a predictor of OS in a time-dependent covariate analysis. Patients with available imaging scans during follow-up were included (n = 334; 85% of those randomized). Moreover, a correlation of the survival probability in deciles vs. the observed objective response was performed to evaluate its suitability as a surrogate end-point. Results: Objective response was observed in 11.5% and 1.9% of patients treated with brivanib and placebo respectively, and was associated with a better survival (median OS 15.0 vs. 9.4 months, p < 0.001). In addition, objective response had an independent prognostic value (HR = 0.48; 95% confidence interval [CI], 0.26-0.91, p = 0.025) along with known prognostic factors. Finally, objective response showed promising results as a surrogate of OS in this trial (R = -0.92; 95% CI, -1 to -0.73, p < 0.001). It was an early indicator of the treatment effect (median time to objective response was 1.4 months). Conclusions: Objective response by mRECIST in advanced HCC predicts OS and thus can be considered as a candidate surrogate end-point. Further studies are needed to support this finding. Lay summary: There is a need to identify surrogate end-points for overall survival in advanced hepatocellular carcinoma. We studied patients from the phase III BRISK trial, comparing brivanib treatment with placebo after sorafenib progression. We demonstrate that objective response is an independent predictor of survival and qualifies as a potential surrogate end-point for overall survival in this patient population. Clinical trial number: NCT00825955. (C) 2017 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.S-1 versus placebo in patients with sorafenib-refractory advanced hepatocellular carcinoma (S-CUBE): a randomised, double-blind, multicentre, phase 3 trialMasatoshi Kudo; Michihisa Moriguchi; Kazushi Numata; Hisashi Hidaka; Hironori Tanaka; Masafumi Ikeda; Seiji Kawazoe; Shinichi Ohkawa; Yozo Sato; Shuichi Kaneko; Junji Furuse; Madoka Takeuchi; Xuemin Fang; Yoshito Date; Masahiro Takeuchi; Takuji OkusakaThe Lancet Gastroenterology and Hepatology Elsevier Ltd 2 (6) 407 - 417 2468-1253 2017/06 [Refereed] Background Unresectable advanced hepatocellular carcinoma is a heterogeneous disease, for which sorafenib is the first targeted agent approved for first-line therapy, and treatment options for patients with sorafenib-refractory advanced hepatocellular carcinoma are limited. We assessed the efficacy and safety of S-1, a chemotherapeutic agent based on fluorouracil, in patients with sorafenib-refractory advanced hepatocellular carcinoma. Methods We did a randomised, double-blind, placebo-controlled, phase 3 study done at 57 sites in Japan. Patients with advanced hepatocellular carcinoma who were ineligible for surgical or local-regional therapy and judged refractory to sorafenib (ie, had progressed on sorafenib or had discontinued sorafenib because of adverse events) were randomly assigned (2:1) to receive oral S-1 (weight-banded 80 mg/m2 [80–120 mg per day]), or placebo, twice per day for 28 days consecutively, followed by a minimum 14 day drug-free period. This cycle was repeated until disease progression or the patient became intolerant to the study treatment. Patients were stratified by site and presence or absence of extrahepatic metastasis or vascular invasion. The primary endpoint was overall survival, assessed in the full analysis set (ie, all patients who were treated with study drug except any individuals who were found not to have hepatocellular carcinoma or who were found to have active double cancer). Patients, medical staff, investigators, and the sponsor were masked to treatment assignment. Blinding was maintained even after study treatment concluded. This study is registered with JapicCTI, number JapicCTI-090920, and has been completed. Findings Between Oct 26, 2009, and Aug 22, 2012, we screened 399 patients. 65 patients were excluded due to not meeting criteria (n=61), declining to participate (n=3), or other reasons (n=1). 334 patients were randomly assigned to receive either S-1 (n=223) or placebo (n=111). One patient in the S-1 group did not receive treatment, and was thus excluded from analyses. At data cutoff, median follow-up was 32·4 months (IQR 24·0–34·7) in the S-1 group and 32·9 months (23·7–39·5) in the placebo group. Median overall survival was 11·1 months (95% CI 9·7–13·1) in the S-1 group and 11·2 months (9·2–12·8) in the placebo group (hazard ratio 0·86, 95% CI 0·67–1·10 p=0·220). The most frequently reported adverse events were skin hyperpigmentation (123 [55%] of 222 patients in the S-1 group vs nine [8%] of 111 patients in the placebo group), decreased appetite (104 [47%] vs 21 [19%]), fatigue (102 [46%] vs 20 [18%]), diarrhoea (77 [35%] vs 14 [13%]), and increased blood bilirubin (77 [35%] vs 14 [13%]). Serious adverse events were reported in 90 (41%) of 222 patients in the S-1 group and 24 (22%) of 111 patients in the placebo group. Five treatment-related deaths were reported in the S-1 group. Interpretation S-1 did not prolong overall survival in patients with sorafenib-refractory advanced hepatocellular carcinoma. Further research is needed to identify subgroups of patients who might benefit from S-1. Funding Taiho Pharmaceuticals.Magnetic resonance elastography in the assessment of hepatic fibrosis: a study comparing transient elastography and histological data in the same patientsMasafumi Toguchi; Masakatsu Tsurusaki; Norihisa Yada; Keitaro Sofue; Tomoko Hyodo; Minori Onoda; Isao Numoto; Mitsuru Matsuki; Izumi Imaoka; Masatoshi Kudo; Takamichi MurakamiABDOMINAL RADIOLOGY SPRINGER 42 (6) 1659 - 1666 2366-004X 2017/06 [Refereed] Purpose: To evaluate the quantitative measurement of liver stiffness (LS), compare the diagnostic performance of magnetic resonance elastography (MRE) and ultrasound-based transient elastography (TE), and evaluate two different MRE-based LS measurement methods. Methods: Between October 2013 and January 2015, 116 consecutive patients with chronic liver disease underwent MRE to measure LS (kilopascals; kPa). Of the 116 patients, 51 patients underwent both TE and liver biopsy, and the interval between the liver biopsy and both the MRE and TE was less than 90 days. MRE-derived LS values were measured on the anterior segment of the right lobe (single small round regions of interest per slice; srROIs) and whole right lobe of the liver (free hand region of interest; fhROI), and these values were correlated with pathological fibrosis grades and diagnostic performance. Results: Pathological fibrosis stage was significantly correlated with srROIs (r = 0.87, p < 0.001), fhROI (r = 0.80, p < 0.001), and TE (r = 0.73, p < 0.001). For detection of significant fibrosis (>= F2), advanced fibrosis (>= F3), and cirrhosis, the area under the curve (AUC) associated with the srROIs was largest, and there was a significant difference between srROIs and TE (0.93 vs. 0.82, p = 0.006), srROIs and fhROI (0.93 vs. 0.89, p = 0.04) for detection of >= F2. For advanced fibrosis and cirrhosis detection, AUCs were not significant (0.92-0.96). Conclusions: MRE and TE detected liver fibrosis with comparable accuracy. In particular, the srROIs method was effective for detecting of significant fibrosis.Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trialAnthony B. El-Khoueiry; Bruno Sangro; Thomas Yau; Todd S. Crocenzi; Masatoshi Kudo; Chiun Hsu; Tae-You Kim; Su-Pin Choo; Jorg Trojan; Theodore H. Welling; Tim Meyer; Yoon-Koo Kang; Winnie Yeo; Akhil Chopra; Jeffrey Anderson; Christine dela Cruz; Lixin Lang; Jaclyn Neely; Hao Tang; Homa B. Dastani; Ignacio MeleroLANCET ELSEVIER SCIENCE INC 389 (10088) 2492 - 2502 0140-6736 2017/06 [Refereed] Background For patients with advanced hepatocellular carcinoma, sorafenib is the only approved drug worldwide, and outcomes remain poor. We aimed to assess the safety and efficacy of nivolumab, a programmed cell death protein-1 (PD-1) immune checkpoint inhibitor, in patients with advanced hepatocellular carcinoma with or without chronic viral hepatitis. Methods We did a phase 1/2, open-label, non-comparative, dose escalation and expansion trial (CheckMate 040) of nivolumab in adults (>= 18 years) with histologically confirmed advanced hepatocellular carcinoma with or without hepatitis C or B (HCV or HBV) infection. Previous sorafenib treatment was allowed. A dose-escalation phase was conducted at seven hospitals or academic centres in four countries or territories (USA, Spain, Hong Kong, and Singapore) and a dose-expansion phase was conducted at an additional 39 sites in 11 countries (Canada, UK, Germany, Italy, Japan, South Korea, Taiwan). At screening, eligible patients had Child-Pugh scores of 7 or less (Child-Pugh A or B7) for the dose-escalation phase and 6 or less (Child-Pugh A) for the dose-expansion phase, and an Eastern Cooperative Oncology Group performance status of 1 or less. Patients with HBV infection had to be receiving effective antiviral therapy (viral load < 100 IU/mL); antiviral therapy was not required for patients with HCV infection. We excluded patients previously treated with an agent targeting T-cell costimulation or checkpoint pathways. Patients received intravenous nivolumab 0.1-10 mg/kg every 2 weeks in the dose-escalation phase (3+ 3 design). Nivolumab 3 mg/kg was given every 2 weeks in the dose-expansion phase to patients in four cohorts: sorafenib untreated or intolerant without viral hepatitis, sorafenib progressor without viral hepatitis, HCV infected, and HBV infected. Primary endpoints were safety and tolerability for the escalation phase and objective response rate (Response Evaluation Criteria In Solid Tumors version 1.1) for the expansion phase. This study is registered with ClinicalTrials.gov, number NCT01658878. Findings Between Nov 26, 2012, and Aug 8, 2016, 262 eligible patients were treated (48 patients in the dose-escalation phase and 214 in the dose-expansion phase). 202 (77%) of 262 patients have completed treatment and follow-up is ongoing. During dose escalation, nivolumab showed a manageable safety profile, including acceptable tolerability. In this phase, 46 (96%) of 48 patients discontinued treatment, 42 (88%) due to disease progression. Incidence of treatment-related adverse events did not seem to be associated with dose and no maximum tolerated dose was reached. 12 (25%) of 48 patients had grade 3/4 treatment-related adverse events. Three (6%) patients had treatment-related serious adverse events (pemphigoid, adrenal insufficiency, liver disorder). 30 (63%) of 48 patients in the dose-escalation phase died (not determined to be related to nivolumab therapy). Nivolumab 3 mg/kg was chosen for dose expansion. The objective response rate was 20% (95% CI 15-26) in patients treated with nivolumab 3 mg/kg in the dose-expansion phase and 15% (95% CI 6-28) in the dose-escalation phase. Interpretation Nivolumab had a manageable safety profile and no new signals were observed in patients with advanced hepatocellular carcinoma. Durable objective responses show the potential of nivolumab for treatment of advanced hepatocellular carcinoma.Clinical significance of Akt2 in advanced pancreatic cancer treated with erlotinibEri Banno; Yosuke Togashi; Marco A. De Velasco; Takuro Mizukami; Yu Nakamura; Masato Terashima; Kazuko Sakai; Yoshihiko Fujita; Ken Kamata; Masayuki Kitano; Masatoshi Kudo; Kazuto NishioINTERNATIONAL JOURNAL OF ONCOLOGY SPANDIDOS PUBL LTD 50 (6) 2049 - 2058 1019-6439 2017/06 [Refereed] Akt2 is an isoform of Akt, and an association between Akt2 and resistance to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) has been suggested in pancreatic cancer (PC) in vitro. In this study, we investigated the association between Akt2 expression as evaluated using immunohistochemistry and the outcome of patients with advanced PC who had received treatment with erlotinib (an EGFR-TKI). Although the difference was not significant, patients with high levels of Akt2 expression tended to have a poorer response and a shorter progression-free survival period after treatment with erlotinib plus gemcitabine than those with low expression levels (P=0.16 and 0.19, respectively). In vitro, an Akt2-amplified PC cell line and Akt2-overexpressed cell lines exhibited resistance to anti-EGFR therapies, including erlotinib, but combined treatment with BYL719 (a PI3K inhibitor) cancelled this resistance. Our findings suggest that Akt2 might be associated with the resistance to anti-EGFR therapies, especially the use of erlotinib against PC, and that this resistance can be overcome by combined treatment with a PI3K inhibitor. Akt2 expression could become a predictive biomarker for erlotinib resistance in PC.A Case of Type II Enteropathy-Associated T-Cell Lymphoma in a Patient With Ulcerative ColitisYoriaki Komeda; Hiroshi Kashida; Toshiharu Sakurai; Masashi Kono; Tomoyuki Nagai; Yutaka Asakuma; Satoru Hagiwara; Shigenaga Matsui; Tomohiro Watanabe; Takaaki Chikugo; Masatoshi KudoAMERICAN JOURNAL OF GASTROENTEROLOGY NATURE PUBLISHING GROUP 112 (6) 833 - 833 0002-9270 2017/06 [Refereed]超音波内視鏡を用いた膵疾患診療 基本から応用まで EUSガイド下神経ブロックの成績と治療効果予測因子の検討三長 孝輔; 竹中 完; 宮田 剛; 中井 敦史; 大本 俊介; 鎌田 研; 山雄 健太郎; 今井 元; 渡邉 智裕; 工藤 正俊膵臓 (一社)日本膵臓学会 32 (3) 329 - 329 0913-0071 2017/05Follow-Up Examination of the Recurrence After Endoscopic Treatment of Colorectal TumorsYoriaki Komeda; Hiroshi Kashida; Toshiharu Sakurai; Yutaka Asakuma; Tomoyuki Nagai; Shigenaga Matsui; Tomohiro Watanabe; Masatoshi KudoGASTROINTESTINAL ENDOSCOPY MOSBY-ELSEVIER 85 (5) AB392 - AB392 0016-5107 2017/05 [Refereed]Investigation on the Efficacy of Alteration of Treatment Methods for Difficult Cases in Eus-BdKosuke Minaga; Mamoru Takenaka; Masayuki Kitano; Hajime Imai; Kentaro Yamao; Ken Kamata; Takeshi Miyata; Shunsuke Omoto; Tomoe Yoshikawa; Masatoshi KudoGASTROINTESTINAL ENDOSCOPY MOSBY-ELSEVIER 85 (5) AB493 - AB493 0016-5107 2017/05 [Refereed]Improved Diagnosis of Liver Metastases Using Kupffer-Phase Image of Contrast-Enhanced Harmonic Endoscopic Ultrasonography in Patients With Pancreatic CancerKosuke Minaga; Mamoru Takenaka; Masayuki Kitano; Hajime Imai; Kentaro Yamao; Ken Kamata; Takeshi Miyata; Shunsuke Omoto; Tomoe Yoshikawa; Masatoshi KudoGASTROINTESTINAL ENDOSCOPY MOSBY-ELSEVIER 85 (5) AB53 - AB53 0016-5107 2017/05 [Refereed]Outcomes of Biliary Drainage in Pancreatic Cancer Patients With an Indwelling Gastroduodenal Stent: A Multicenter Retrospective Study in West JapanKentaro Yamao; Masayuki Kitano; Takahisa Kayahara; Etsuji Ishida; Hiroshi Yamamoto; Tomoe Yoshikawa; Kosuke Minaga; Yukitaka Yamashita; Masanori Asada; Yoshihiro Okabe; Yukio Osaki; Juri Ikemoto; Keiji Hanada; Mamoru Takenaka; Masatoshi KudoGASTROINTESTINAL ENDOSCOPY MOSBY-ELSEVIER 85 (5) AB327 - AB328 0016-5107 2017/05 [Refereed]Integration of the cancer-related inflammatory response as a stratifying biomarker of survival in hepatocellular carcinoma treated with sorafenibJessica A. Howell; David J. Pinato; Ramya Ramaswami; Tadaaki Arizumi; Carlotta Ferrari; Antonello Gibbin; Michela E. Burlone; Giulia Guaschino; Pierluigi Toniutto; James Black; Laura Sellers; Masatoshi Kudo; Mario Pirisi; Rohini SharmaONCOTARGET IMPACT JOURNALS LLC 8 (22) 36161 - 36170 1949-2553 2017/05 [Refereed] Background and Aims: Response to sorafenib is highly variable in hepatocellular carcinoma (HCC). Baseline inflammatory parameters and treatment toxicities may improve survival prediction in patients on sorafenib therapy. Results: 442 patients with advanced stage HCC on sorafenib were recruited (follow-up 5096 person-months at risk). 88% had BCLC stage B or greater HCC and 72.3% had Child-Pugh A cirrhosis. On Cox multivariate regression, previously-treated HCC (HR 0.579, 95% CI 0.385-0.872, p=0.009), Cancer of Liver Italian Program (CLIP) score (HR 1.723, 95% CI 1.462-2.047, p < 0.0001), baseline red cell distribution width (RDW; HR 1.234, 95% CI 1.115-1.290, p < 0.0001) and neutrophil to lymphocyte ratio (NLR; HR 1.218, 95% CI 1.108-1.322, p < 0.0001) were significant independent risks for shorter survival, whilst sorafenib-related diarrhoea was associated with prolonged survival (HR 0.533, 95% CI 0.373-0.763, p=0.001). The combination of RDCLIP score (CLIP score multiplied by RDW) >= 70 and no treatment-related diarrhoea had good utility for predicting 3-month survival (AUC of 0.808 (95% CI 0.734-0.882), positive predictive value of 86.4% and negative predictive value of 83.3%), compared with CLIP (AUC=0.642) or BCLC score alone (AUC=0.579). RD-CLIP score >= 35 and no treatment-related diarrhoea had an AUC of 0.787 for predicting 12-month survival. Methods: Patients with HCC were consecutively recruited from three tertiary centres (Japan, Italy and UK) and clinical data were prospectively collected. The primary study endpoint was overall survival (OS) after commencing sorafenib. Conclusion: The novel prognostic index of CLIP score combined with inflammatory marker RDW and treatment-related diarrhoea has good accuracy for predicting overall, 3 month and 12 month survival in patients on sorafenib.Chronic Fibro-Inflammatory Responses in Autoimmune Pancreatitis Depend on IFN-alpha and IL-33 Produced by Plasmacytoid Dendritic CellsTomohiro Watanabe; Kouhei Yamashita; Yasuyuki Arai; Kosuke Minaga; Ken Kamata; Tomoyuki Nagai; Yoriaki Komeda; Mamoru Takenaka; Satoru Hagiwara; Hiroshi Ida; Toshiharu Sakurai; Naoshi Nishida; Warren Strober; Masatoshi KudoJOURNAL OF IMMUNOLOGY AMER ASSOC IMMUNOLOGISTS 198 (10) 3886 - 3896 0022-1767 2017/05 [Refereed] In previous studies, we found that human IgG4-related autoimmune pancreatitis (AIP) and murine AIP are driven by activation of plasmacytoid dendritic cells (pDCs) producing IFN-alpha. In the present studies we examined additional roles of pDC-related mechanisms in AIP pathogenesis, particularly those responsible for induction of fibrosis. We found that in murine AIP (MRL/Mp mice treated with polyinosinic-polycytidylic acid) not only the pancreatic infiltration of immune cells but also the development of fibrosis were markedly reduced by the depletion of pDCs or blockade of type I IFN signaling; moreover, such treatment was accompanied by a marked reduction of pancreatic expression of IL-33. Conversely, polyinosinic-polycytidylic acid-induced inflamed pancreatic tissue in murine AIP exhibited increased expression of type I IFNs and IL-33 (and downstream IL-33 cytokines such as IL-13 and TGF-beta 1). pDCs stimulated by type I IFN were the source of the IL-33 because purified populations of these cells isolated from the inflamed pancreas produced a large amount of IL-33 upon activation by TLR9 ligands, and such production was abrogated by the neutralization of type I IFN. The role of IL-33 in murine AIP pathogenesis was surprisingly important because blockade of IL-33 signaling by anti-ST2 Ab attenuated both pancreatic inflammation and accompanying fibrosis. Finally, whereas patients with both conventional pancreatitis and IgG4-related AIP exhibited increased numbers of acinar cells expressing IL-33, only the latter also exhibited pDCs producing this cytokine. These data thus suggest that pDCs producing IFN-alpha and IL-33 play a pivotal role in the chronic fibro-inflammatory responses underlying murine AIP and human IgG4-related AIP.緩和医療における内視鏡の役割 切除不能悪性胃十二指腸狭窄症例に対する胃十二指腸ステント留置の予後予測因子の検討山雄 健太郎; 竹中 完; 工藤 正俊Gastroenterological Endoscopy (一社)日本消化器内視鏡学会 59 (Suppl.1) 858 - 858 0387-1207 2017/04On-target sorafenib toxicity predicts improved survival in hepatocellular carcinoma: a multi-centre, prospective studyJ. Howell; D. J. Pinato; R. Ramaswami; D. Bettinger; T. Arizumi; C. Ferrari; C. Yen; A. Gibbin; M. E. Burlone; G. Guaschino; L. Sellers; J. Black; M. Pirisi; M. Kudo; R. Thimme; J. -W. Park; R. SharmaALIMENTARY PHARMACOLOGY & THERAPEUTICS WILEY 45 (8) 1146 - 1155 0269-2813 2017/04 [Refereed] Background Hepatocellular carcinoma (HCC) is the sixth most common cancer worldwide and has high mortality despite treatment. While sorafenib has a survival benefit for patients with advanced HCC, clinical response is highly variable. Aim To determine whether development of sorafenib toxicity is a prognostic marker of survival in HCC. Methods In this prospective multicentre cohort study, patients with advanced-stage HCC receiving sorafenib were recruited from five international specialist centres. Demographic and clinical data including development and grade of sorafenib toxicity during treatment, radiological response to sorafenib and survival time (months) were recorded prospectively. Results A total of 634 patients with advanced-stage HCC receiving sorafenib were recruited to the study, with a median follow-up of 6692.3 person-months at risk. The majority of patients were male (81%) with Child-Pugh A stage liver disease (74%) and Barcelona Clinic Liver Cancer stage C HCC (64%). Median survival time was 8.1 months (IQR 3.8-18.6 months). 94% experienced at least one sorafenib-related toxicity: 34% diarrhoea, 16% hypertension and 37% hand-foot syndrome (HFS). Twenty-one per cent ceased sorafenib due to toxicity and 59% ceased treatment due to progressive disease or death. On multivariate analysis, sorafenib-related diarrhoea (HR 0.76, 95% CI 0.61-0.95, P = 0.017), hypertension (HR 0.531, 95% CI 0.37-0.76, P < 0.0001) and HFS (HR 0.65, 95% CI 0.51-0.81, P < 0.0001) were all significant independent predictors of overall survival after adjusting for age, severity of liver disease, tumour stage and sorafenib dose. Conclusion Development of sorafenib-related toxicity including diarrhoea, hypertension and hand-foot syndrome is associated with prolonged overall survival in patients with advanced-stage HCC on sorafenib.Reply to the Letter to the editor 'Sorafenib plus hepatic arterial infusion chemotherapy with cisplatin versus Sorafenib for advanced hepatocellular carcinoma: randomized phase II trial' by Fornaro et al.M. Ikeda; S. Shimizu; T. Sato; M. Morimoto; Y. Kojima; Y. Inaba; A. Hagihara; M. Kudo; S. Nakamori; S. Kaneko; R. Sugimoto; T. Tahara; T. Ohmura; K. Yasui; K. Sato; H. Ishii; J. Furuse; T. OkusakaANNALS OF ONCOLOGY OXFORD UNIV PRESS 28 (4) 903 - 904 0923-7534 2017/04 [Refereed]Ramucirumab as second-line treatment in patients with advanced hepatocellular carcinoma: Japanese subgroup analysis of the REACH trialMasatoshi Kudo; Etsuro Hatano; Shinichi Ohkawa; Hirofumi Fujii; Akihide Masumoto; Junji Furuse; Yoshiyuki Wada; Hiroshi Ishii; Shuntaro Obi; Shuichi Kaneko; Seiji Kawazoe; Osamu Yokosuka; Masafumi Ikeda; Katsuaki Ukai; Sojiro Morita; Akihito Tsuji; Toshihiro Kudo; Mitsuo Shimada; Yukio Osaki; Ryosuke Tateishi; Gen Sugiyama; Paolo Benjamin Abada; Ling Yang; Takuji Okusaka; Andrew Xiuxuan ZhuJOURNAL OF GASTROENTEROLOGY SPRINGER JAPAN KK 52 (4) 494 - 503 0944-1174 2017/04 [Refereed] Bckground REACH evaluated ramucirumab in the second-line treatment of patients with advanced hepatocellular carcinoma. In the intent-to-treat population (n = 565), a significant improvement in overall survival (OS) was not observed. In patients with an elevated baseline alpha-fetoprotein (AFP) level (400 ng/mL or greater), an improvement in OS was demonstrated. An analysis of the Japanese patients in REACH was performed. Methods An analysis was performed with the subset of the intent-to-treat population enrolled in Japan (n = 93). Results The median OS was 12.9 months for the ramucirumab arm (n = 45) and 8.0 months for the placebo arm (n = 48) [hazard ratio (HR) 0.621 (95 % confidence interval (CI) 0.391-0.986); P = 0.0416]. The median progression-free survival was 4.1 months for the ramucirumab arm and 1.7 months for the placebo arm [HR 0.449 (95 % CI 0.285-0.706); P = 0.0004]. The objective response rates were 11 % for the ramucirumab arm and 2 % for the placebo arm (P = 0.0817). The grade 3 or higher treatment-emergent adverse events occurring in more than 5 % of patients with a higher incidence for the ramucirumab arm (n = 44) than for the placebo arm (n = 47) were ascites (7% vs 2 %), hypertension (7 % vs 2 %), and cholangitis (7 % vs 0 %). In patients with a baseline AFP level of 400 ng/mL or greater, the median OS was 12.9 months for the ramucirumab arm (n = 20) and 4.3 months for the placebo arm (n = 22) [HR 0.464 (95 % CI 0.232-0.926); P = 0.0263]. Conclusion In the Japanese patients in REACH, ramucirumab treatment improved OS, including in patients with a baseline AFP level of 400 ng/mL or greater; improvements in progression-free survival and objective response rate were also demonstrated. The safety profile of ramucirumab was acceptable and well tolerated in Japanese patients.Phase 2 study of lenvatinib in patients with advanced hepatocellular carcinomaKenji Ikeda; Masatoshi Kudo; Seiji Kawazoe; Yukio Osaki; Masafumi Ikeda; Takuji Okusaka; Toshiyuki Tamai; Takuya Suzuki; Takashi Hisai; Seiichi Hayato; Kiwamu Okita; Hiromitsu KumadaJOURNAL OF GASTROENTEROLOGY SPRINGER JAPAN KK 52 (4) 512 - 519 0944-1174 2017/04 [Refereed] Background Lenvatinib is an oral inhibitor of vascular endothelial growth factor receptor 1-3, fibroblast growth factor receptor 1-4, platelet-derived growth factor receptor alpha, RET, and KIT. This phase 2, single-arm, open-label multicenter study evaluated lenvatinib in advanced hepatocellular carcinoma (HCC). Methods Patients with histologically/clinically confirmed advanced HCC who did not qualify for surgical resection or local therapies received lenvatinib at a dosage of 12 mg once daily (QD) in 28-day cycles. The primary efficacy endpoint was time to progression (TTP) per modified Response Evaluation Criteria in Solid Tumors v1.1; secondary efficacy endpoints included objective response rate (ORR), disease control rate (DCR), and overall survival (OS). Results Between July 2010 and June 2011, 46 patients received lenvatinib at sites across Japan and Korea. The median TTP, as determined by independent radiological review, was 7.4 months [95 % confidence interval (CI): 5.5-9.4]. Seventeen patients (37 %) had partial response and 19 patients (41 %) had stable disease (ORR: 37 %; DCR: 78 %). Median OS was 18.7 months (95 % CI: 12.7-25.1). The most common any-grade adverse events (AEs) were hypertension (76 %), palmar-plantar erythrodysesthesia syndrome (65 %), decreased appetite (61 %), and proteinuria (61 %). Dose reductions and discontinuations due to AEs occurred in 34 (74 %) and 10 patients (22 %), respectively. Median body weight was lower in patients with an early (< 30 days) dose withdrawal or reduction than in those without. Conclusion Lenvatinib 12-mg QD showed clinical activity and acceptable toxicity profiles in patients with advanced HCC, but early dose modification was necessary in patients with lower body weight. Further development of lenvatinib in HCC should consider dose modification by body weight.Multimaterial Decomposition Algorithm for the Quantification of Liver Fat Content by Using Fast-Kilovolt-Peak Switching Dual-Energy CT: Clinical EvaluationTomoko Hyodo; Norihisa Yada; Masatoshi Hori; Osamu Maenishi; Peter Lamb; Kosuke Sasaki; Minori Onoda; Masatoshi Kudo; Teruhito Mochizuki; Takamichi MurakamiRADIOLOGY RADIOLOGICAL SOC NORTH AMERICA 283 (1) 108 - 118 0033-8419 2017/04 [Refereed] Purpose: To assess the clinical accuracy and reproducibility of liver fat quantification with the multimaterial decomposition (MMD) algorithm, comparing the performance of MMD with that of magnetic resonance (MR) spectroscopy by using liver biopsy as the reference standard. Materials and Methods: This prospective study was approved by the institutional ethics committee, and patients provided written informed consent. Thirty-three patients suspected of having hepatic steatosis underwent non-contrast material-enhanced and triple-phase dynamic contrast-enhanced dual-energy computed tomography (CT) (80 and 140 kVp) and single-voxel proton MR spectroscopy within 30 days before liver biopsy. Percentage fat volume fraction (FVF) images were generated by using the MMD algorithm on dual-energy CT data to measure hepatic fat content. FVFs determined by using dual-energy CT and percentage fat fractions (FFs) determined by using MR spectroscopy were compared with histologic steatosis grade (0-3, as defined by the nonalcoholic fatty liver disease activity score system) by using Jonck-heere-Terpstra trend tests and were compared with each other by using Bland-Altman analysis. Real non-contrast-enhanced FVFs were compared with triple-phase contrast-enhanced FVFs to determine the reproducibility of MMD by using Bland-Altman analyses. Results: Both dual-energy CT FVF and MR spectroscopy FF increased with increasing histologic steatosis grade (trend test, P <.001 for each). The Bland-Altman plot of dual-energy CT FVF and MR spectroscopy FF revealed a proportional bias, as indicated by the significant positive slope of the line regressing the difference on the average (P < .001). The 95% limits of agreement for the differences between real non-contrast- enhanced and contrast-enhanced FVFs were not greater than about 2%. Conclusion: The MMD algorithm quantifying hepatic fat in dual-energy CT images is accurate and reproducible across imaging phases. (C) RSNA, 2017The oncoprotein gankyrin promotes the development of colitis-associated cancer through activation of STAT3Toshiharu Sakurai; Hiroaki Higashitsuji; Hiroshi Kashida; Tomohiro Watanabe; Yoriaki Komeda; Tomoyuki Nagai; Satoru Hagiwara; Masayuki Kitano; Naoshi Nishida; Takaya Abe; Hiroshi Kiyonari; Katsuhiko Itoh; Jun Fujita; Masatoshi KudoONCOTARGET IMPACT JOURNALS LLC 8 (15) 24762 - 24776 1949-2553 2017/04 [Refereed] Although long-standing colonic inflammation due to refractory inflammatory bowel disease (IBD) promotes the development of colitis-associated cancer (CAC), the molecular mechanisms accounting for the development of CAC remains largely unknown. In this study, we investigated the role of gankyrin in the development of CAC since gankyrin is overexpressed in sporadic colorectal cancers. We analyzed gene expression of colon tissues obtained from 344 patients with IBD and CAC and found that expression of gankyrin was much higher in colonic mucosa of patients with refractory IBD than in those with IBD in remission. Expression of gankyrin was upregulated in inflammatory cells as well as tumor cells in colonic mucosa of patients with CAC. Over-expressing studies utilizing tagged ganlyrin-cDNA identified physical interaction between ganlyrin and Src homology 2-containing protein tyrosine phosphatase-1 (SHP-1). Importantly, the interaction between ganlyrin and SHP1 leads to inhibition of STAT3 activation and to enhancement of TNF-alpha and IL-17 in inflammatory cells. To further address the role of gankyrin in the development of CAC, we created mice with intestinal epithelial cell-specific gankyrin ablation (Vil-Cre; Gankyrin(f/f)) and deletion of gankyrin in myeloid and epithelial cells (Mx1Cre; Gankyrin(f/f)). Gankyrin deficiency in myeloid cells, but not in epithelial cells, reduced the activity of mitogen activated protein kinase and the expression of stem cell markers, leading to attenuated tumorigenic potential. These findings provide important insights into the pathogenesis of CAC and suggest that gankyrin is a promising target for developing therapeutic and preventive strategies against CAC.Cost-effectiveness of EOB-MRI for Hepatocellular Carcinoma in JapanAkihiro Nishie; Satoshi Goshima; Hiroki Haradome; Etsuro Hatano; Yasuharu Imai; Masatoshi Kudo; Masanori Matsuda; Utaroh Motosugi; Satoshi Saitoh; Kengo Yoshimitsu; Bruce Crawford; Eliza Kruger; Graeme Ball; Hiroshi HondaCLINICAL THERAPEUTICS ELSEVIER 39 (4) 738 - 750 0149-2918 2017/04 [Refereed] Purpose: The objective of the study was to evaluate the cost-effectiveness of gadoxetic acid-enhanced magnetic resonance imaging (EOB-MRI) in the diagnosis and treatment of hepatocellular carcinoma (HCC) in Japan compared with extracellular contrast media-enhanced MRI (ECCM-MRI) and contrast media-enhanced computed tomography (CE-CT) scanning. Methods: A 6-stage Markov model was developed to estimate lifetime direct costs and clinical outcomes associated with EOB-MRI. Diagnostic sensitivity and specificity, along with clinical data on HCC survival, recurrence, treatment patterns, costs, and health state utility values, were derived from predominantly Japanese publications. Parameters unavailable from publications were estimated in a Delphi panel of Japanese clinical experts who also confirmed the structure and overall approach of the model. Sensitivity analyses, including one-way, probabilistic, and scenario analyses, were conducted to account for uncertainty in the results. Findings: Over a lifetime horizon, EOB-MRI was associated with lower direct costs ((sic)2,174,869) and generated a greater number of quality-adjusted life years (QALYs) (9.502) than either ECCM-MRI ((sic)2,365,421, 9.303 QALYs) or CE-CT ((sic)2,482,608, 9.215 QALYs). EOB-MRI was superior to the other diagnostic strategies considered, and this finding was robust over sensitivity and scenario analyses. A majority of the direct costs associated with HCC in Japan were found to be costs of treatment. The model results revealed the superior cost-effectiveness of the EOB-MRI diagnostic strategy compared with ECCM-MRI and CE-CT. Implications: EOB-MRI could be the first-choice imaging modality for medical care of HCC among patients with hepatitis or liver cirrhosis in Japan. Widespread implementation of EOB-MRI could reduce health care expenditures, particularly downstream treatment costs, associated with HCC. (C) 2017 Elsevier HS Journals, Inc. All rights reserved.Immunopathogenesis of pancreatitisT. Watanabe; M. Kudo; W. StroberMUCOSAL IMMUNOLOGY NATURE PUBLISHING GROUP 10 (2) 283 - 298 1933-0219 2017/03 [Refereed] The conventional view of the pathogenesis of acute and chronic pancreatitis is that it is due to a genetic-or environment-based abnormality of intracellular acinar trypsinogen activation and thus to the induction of acinar cell injury that, in turn, sets in motion an intra-pancreatic inflammatory process. More recent studies, reviewed here, present strong evidence that while such trypsinogen activation is likely a necessary first step in the inflammatory cascade underlying pancreatitis, sustained pancreatic inflammation is dependent on damage-associated molecular patterns-mediated cytokine activation causing the translocation of commensal (gut) organisms into the circulation and their induction of innate immune responses in acinar cells. Quite unexpectedly, these recent studies reveal that the innate responses involve activation of responses by an innate factor, nucleotide-binding oligomerization domain 1 (NOD1), and that such NOD1 responses have a critical role in the activation/production of nuclear factor-kappa B and type I interferon. In addition, they reveal that chronic inflammation and its accompanying fibrosis are dependent on the generation of IL-33 by injured acinar cells and its downstreaminduction of Tcells producing IL-13. These recent studies thus establish that pancreatitis is quite a unique form of inflammation and one susceptible to newer, more innovative therapy.Semiquantitative prediction of early response of conventional transcatheter arterial chemoembolization for hepatocellular carcinoma using postprocedural plain cone-beam computed tomographyYasunori Minami; Masahiro Takita; Masakatsu Tsurusaki; Yukinobu Yagyu; Kazuomi Ueshima; Takamichi Murakami; Masatoshi KudoHEPATOLOGY RESEARCH WILEY 47 (3) E113 - E119 1386-6346 2017/03 [Refereed] AimTo investigate whether plain cone-beam computed tomography (CT) immediately after conventional transcatheter arterial chemoembolization (c-TACE) can help to predict tumor response semiquantitatively in patients with hepatocellular carcinoma (HCC). MethodsAnalysis was carried out retrospectively on 262 targeted HCCs in 169 patients treated with c-TACE. Dynamic CT was performed at baseline and 1-4months after c-TACE. Receiver-operating characteristic curve analysis was undertaken to evaluate whether voxel values of cone-beam CT could predict a complete response and to identify the cut-off value. Final tumor response assessment and early prediction using the retention pattern of iodized oil, the cut-off value of the density, and the combination of the cut-off density value and retention pattern of iodized oil in HCCs on postprocedural cone-beam CT were compared. ResultsComplete response was obtained in 72.9% of lesions. According to the pattern of iodized oil uptake, the sensitivity, specificity, and accuracy for predicting complete response were 85.9%, 70.4%, and 81.7%, respectively by excellent uptake on cone-beam CT. The area under the curve was 0.86 with the optimal cut-off at a voxel value of 200.13. According to not only the density but also the homogeneity of iodized oil retention, the sensitivity, specificity, and accuracy values for predicting complete response were 86.4%, 95.8%, and 88.9%, respectively. The predictive accuracy was significantly better than that of the pattern of iodized oil retention only (P=0.019). ConclusionThe combination of density and visual estimate of homogeneity is superior to either alone in predicting tumor response of c-TACE in HCC patients.Endoscopic ultrasonography-guided choledochoduodenostomy using a newly designed laser-cut metal stent: Feasibility study in a porcine modelKosuke Minaga; Masayuki Kitano; Chimyon Gon; Kentaro Yamao; Hajime Imai; Takeshi Miyata; Ken Kamata; Shunsuke Omoto; Mamoru Takenaka; Masatoshi KudoDIGESTIVE ENDOSCOPY WILEY 29 (2) 211 - 217 0915-5635 2017/03 [Refereed] Background and AimEndoscopic ultrasonography (EUS)-guided choledochoduodenostomy (EUS-CDS) is increasingly used in the treatment of malignant distal biliary obstruction. Standardized use of this technique requires improvements in instruments, including more convenient and safer devices. The present study was designed to evaluate the resistance force to migration (RFM) of a newly designed laser-cut metal stent and the feasibility of EUS-CDS using this stent. MethodsThis experimental study used a porcine model of biliary dilatation involving five male pigs. The new stent is a fully covered laser-cut stent with anti-migration anchoring hooks. The RFM of the new stents was compared with those of three commercially available covered metal stents using a phantom model. In the animal study, after ligation of Vater's ampulla with endoscopic clips, the dilated common bile duct was punctured under EUS guidance, followed by EUS-CDS using the new stent. One week after the procedure, the stents were removed endoscopically and the fistulas were assessed after the pigs were killed. Technical feasibility and clinical outcomes were evaluated. ResultsAmong the four stents, the new stent had the highest RFM. Metal stent placement was successful in all five pigs, with no procedure-related complications occurring during and 1 week after endoscopic intervention. All stents remained in place without migration and were removed easily using a snare. At necropsy, fistulas were created between the bile duct and duodenum in all pigs. ConclusionEUS-CDS using a newly designed metal stent was feasible and effective in this porcine model of biliary dilatation.The albumin-bilirubin grade improves hepatic reserve estimation post-sorafenib failure: implications for drug developmentD. J. Pinato; C. Yen; D. Bettinger; R. Ramaswami; T. Arizumi; C. Ward; M. Pirisi; M. E. Burlone; R. Thimme; M. Kudo; R. SharmaALIMENTARY PHARMACOLOGY & THERAPEUTICS WILEY 45 (5) 714 - 722 0269-2813 2017/03 [Refereed] Background Drug development in hepatocellular carcinoma (HCC) is limited by disease heterogeneity, with hepatic reserve being a major source of variation in survival outcomes. The albumin-bilirubin (ALBI) grade is a validated index of liver function in patients with HCC. Aim To test the accuracy of the ALBI grade in predicting post-sorafenib overall survival (PSOS) in patients who permanently discontinued treatment. Methods From a prospectively maintained international database of 447 consecutive referrals, we derived 386 eligible patients treated with sorafenib within Barcelona Clinic Liver Cancer C stage (62%), 75% of whom were of Child class A at initiation. Clinical variables at sorafenib discontinuation were analysed for their impact on post-sorafenib overall survival using uni- and multivariable analyses. Results Median post-sorafenib overall survival of the 386 eligible patients was 3.4 months and median sorafenib duration was 2.9 months, with commonest causes of cessation being disease progression (68%) and toxicity (24%). At discontinuation, 92 patients (24%) progressed to terminal stage, due to worsening Child class to C in 40 (10%). Median post-sorafenib overall survival in patients eligible for second-line therapies (n = 294) was 17.5, 7.5 and 1.9 months according respectively to ALBI grade 1, 2 and 3 (P < 0.001). Conclusions The ALBI grade at sorafenib discontinuation identifies a subset of patients with prolonged stability of hepatic reserve and superior survival. This may allow improved patient selection for second-line therapies in advanced HCC.【膵癌の早期診断最前線】膵癌早期診断におけるEUSの役割鎌田 研; 竹中 完; 北野 雅之; 大本 俊介; 三長 孝輔; 宮田 剛; 山雄 健太郎; 今井 元; 工藤 正俊膵臓 (一社)日本膵臓学会 32 (1) 38 - 44 0913-0071 2017/02 膵癌早期診断におけるEUSの果たす役割は近年大きくなりつつある。リスクファクターを有する症例や膵管内乳頭粘液性腫瘍の精査あるいは経過観察にEUSを用いることによって実際に早期膵癌が発見されたとする報告が数多くみられる。EUS機器の進歩、EUS-FNAの普及によって膵癌の存在診断・質的診断能は確実に向上してきている。本稿では、膵癌、特に小膵癌の存在診断におけるEUSの役割について解説する。(著者抄録)Ramucirumab as Second-Line Treatment in Patients With Advanced Hepatocellular Carcinoma Analysis of REACH Trial Results by Child-Pugh ScoreAndrew X. Zhu; Ari David Baron; Peter Malfertheiner; Masatoshi Kudo; Seiji Kawazoe; Denis Pezet; Florian Weissinger; Giovanni Brandi; Carlo A. Barone; Takuji Okusaka; Yoshiyuki Wada; Joon Oh Park; Baek-Yeol Ryoo; Jae Yong Cho; Hyun Cheol Chung; Chung-Pin Li; Chia-Jui Yen; Kuan-Der Lee; Shao-Chun Chang; Ling Yang; Paolo B. Abada; Ian ChauJAMA ONCOLOGY AMER MEDICAL ASSOC 3 (2) 235 - 243 2374-2437 2017/02 [Refereed] IMPORTANCE REACH is the first phase 3 trial to provide information on hepatocellular cancer (HCC) in the second-line (postsorafenib) setting categorized by Child-Pugh score, a scoring system used to measure the severity of chronic liver disease. This exploratory analysis demonstrates the relationship between a potential ramucirumab survival benefit, severity of liver disease, and baseline a-fetoprotein (aFP). OBJECTIVE To assess treatment effects and tolerability of ramucirumab by Child-Pugh score in patients with HCC enrolled in the REACH trial. DESIGN, SETTINGS, AND PARTICIPANTS Randomized, double-blind, phase 3 trial of ramucirumab and best supportive care vs placebo and best supportive care as second-line treatment in patients with HCC enrolled between November 4, 2010 and April 18, 2013, from 154 global sites. Overall, 643 patients were randomized and included in this analysis; 565 patients considered Child-Pugh class A (Child-Pugh scores 5 and 6) and 78 patients considered class B (Child-Pugh scores 7 and 8). INTERVENTIONS Ramucirumab (8mg/kg) or placebo intravenously plus best supportive care every 2 weeks. MAIN OUTCOMES AND MEASURES Overall survival (OS), defined as time from randomization to death from any cause. RESULTS In the randomized population of 643 patients (mean [SD] age, 62.8 [11.1] years) in this analysis, a potential ramucirumab OS benefit was observed for patients with a Child-Pugh score of 5 (hazard ratio [HR], 0.80; 95% CI, 0.63-1.02; P =.06) but no apparent benefit for patients with Child-Pugh scores of 6 or 7 and 8. In patients with baseline aFP levels of 400 ng/mL (to convert ng/mL to mu g/L, multiply by 1.0) or more, a ramucirumab OS benefit was significant for a score of Child-Pugh 5 9HR, 0.61; 95% CI, 0.43-0.87; P =.01) and Child-Pugh 6 (HR, 0.64; 95% CI, 0.42-0.98; P =.04), but was not significant for Child-Pugh 7 and 8. The overall safety profile of ramucirumab, regardless of Child-Pugh score, was considered manageable. Regardless of treatment arm, patients with Child-Pugh scores of 7 and 8 experienced a higher incidence of grade 3 or higher treatment-emergent adverse events, including ascites and asthenia, and special-interest events, including liver injury and/or failure and bleeding, compared with patients with Child-Pugh scores of 5 or 6. CONCLUSIONS AND RELEVANCE In unselected patients, a trend for ramucirumab survival benefit was observed only for patients with a Child-Pugh score of 5. In patients with baseline aFP levels of 400 ng/mL or more, a ramucirumab survival benefit was observed for Child-Pugh scores of 5 and 6. Ramucirumab had a manageable toxic effect profile. These results support the ongoing REACH-2 study of ramucirumab in patients with advanced HCC with underlying Child-Pugh A cirrhosis and baseline aFP levels of 400 ng/mL or more.The ALBI grade provides objective hepatic reserve estimation across each BCLC stage of hepatocellular carcinomaDavid J. Pinato; Rohini Sharma; Elias Allara; Clarence Yen; Tadaaki Arizumi; Keiichi Kubota; Dominik Bettinger; Jeong Won Jang; Carlo Smirne; Young Woon Kim; Masatoshi Kudo; Jessica Howell; Ramya Ramaswami; Michela E. Burlone; Vito Guerra; Robert Thimme; Mitsuru Ishizuka; Justin Stebbing; Mario Pirisi; Brian I. CarrJOURNAL OF HEPATOLOGY ELSEVIER SCIENCE BV 66 (2) 338 - 346 0168-8278 2017/02 [Refereed] Background & Aims: Overall survival (OS) is a composite clinical endpoint in hepatocellular carcinoma (HCC) due to the mutual influence of cirrhosis and active malignancy in dictating patient's mortality. The ALBI grade is a recently described index of liver dysfunction in hepatocellular carcinoma, based solely on albumin and bilirubin levels. Whilst accurate, this score lacks cross validation, especially in intermediate stage HCC, where OS is highly heterogeneous. Methods: We evaluated the prognostic accuracy of the ALBI grade in estimating OS in a large, multi-centre study of 2426 patients, including a large proportion of intermediate stage patients treated with chemoembolization (n = 1461) accrued from Europe, the United States and Asia. Results: Analysis of survival by primary treatment modality confirmed the ALBI grade as a significant predictor of patient OS after surgical resection (p <0.001), transarterial chemoembolization (p <0.001) and sorafenib (p <0.001). Stratification by Barcelona Clinic Liver Cancer stage confirmed the independent prognostic value of the ALBI across the diverse stages of the disease, geographical regions of origin and time of recruitment to the study (p <0.001). Conclusions: In this large, multi-centre retrospective study, the ALBI grade satisfied the criteria for accuracy and reproducibility following statistical validation in Eastern and Western HCC patients, including those treated with chemoembolization. Consideration should be given to the ALBI grade as a stratifying biomarker of liver reserve in routine clinical practice. Lay summary: Liver failure is a key determinant influencing the natural history of hepatocellular carcinoma (HCC). In this large multi-centre study we externally validate a novel biomarker of liver functional reserve, the ALBI grade, across all the stages of HCC. (C) 2016 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.造影超音波検査でのnodule in nodule type HCCの評価三野 智; 小川 力; 盛田 真弘; 野田 晃世; 出田 雅子; 久保 敦司; 松中 寿浩; 玉置 敬之; 柴峠 光成; 工藤 正俊超音波医学 (公社)日本超音波医学会 44 (1) 71 - 71 1346-1176 2017/013D-GPS markerを用いたRFA治療の試み盛田 真弘; 小川 力; 三野 智; 野田 晃世; 出田 雅子; 久保 敦司; 松中 寿浩; 玉置 敬之; 柴峠 光成; 工藤 正俊超音波医学 (公社)日本超音波医学会 44 (1) 73 - 73 1346-1176 2017/01Stress Response Protein RBM3 Promotes the Development of Colitis-associated CancerToshiharu Sakurai; Hiroshi Kashida; Yoriaki Komeda; Tomoyuki Nagai; Satoru Hagiwara; Tomohiro Watanabe; Masayuki Kitano; Naoshi Nishida; Jun Fujita; Masatoshi KudoINFLAMMATORY BOWEL DISEASES LIPPINCOTT WILLIAMS & WILKINS 23 (1) 66 - 74 1078-0998 2017/01 [Refereed] Background: Colitis-associated cancer (CAC) is caused by chronic intestinal inflammation and often results from refractory inflammatory bowel disease (IBD). Stress response proteins Cirp and heat shock protein A4 are involved in the refractory clinical course and development of CAC. RNAbinding motif protein 3 (RBM3) is induced in response to various stresses and is upregulated in several cancers. However, the role of RBM3 in CAC is unclear. Methods: We assessed RBM3 expression and function in 263 human intestinal mucosa samples from patients with IBD and in Rbm3-deficient (Rbm3(-/-)) mice. Results: Expression of RBM3 was correlated with the expression of stress response proteins Cirp, heat shock protein A4, and HSP27 in the colonic mucosa of patients with IBD. Significant correlation was observed between the expression of RBM3 and that of Bcl-xL or stem cell markers. RBM3 expression increased and significantly correlated with R-spondin expression in the colonic mucosa of patients with refractory IBD, a condition associated with increased cancer risk, and RBM3 was overexpressed in human CACs. In the murine CAC model, Rbm3 deficiency decreased R-spondin and Bcl-xL expression and increased apoptotic cell number in the colonic mucosa, leading to reduced tumor multiplicity. Transplantation of wild-type and Rbm3(-/-) bone marrow did not alter tumor burden, indicating the importance of RBM3 in epithelial cells. Conclusions: Our findings indicated that RBM3 was required for efficient inflammatory carcinogenesis in the murine CAC model and suggested that RBM3 could be a predictive biomarker of CAC risk and a new therapeutic target for cancer prevention in patients with IBD.Serum microRNA profile that predict initial effect of sorafenib in patients with advanced hepatocellular carcinomaNishida N; Arizumi T; Hagiwara S; Ida H; Sakurai T; Kudo MLiver Cancer 6 113 - 125 2017 [Refereed]The usefulness of endoscopic ultrasonography in the diagnosis of "Early-Stage" chronic pancreatitisMamoru Takenaka; Masayuki Kitano; Masatoshi KudoGastroenterological Endoscopy 59 255 - 264 0387-1207 2017/01 Chronic pancreatitis is one of the risk factors for pancreatic cancer and is considered to be an irreversible and progressive disease. However, the conventional diagnostic criteria of chronic pancreatitis had the problem of being able to diagnose only advanced chronic pancreatitis. Based on the hypothesis that the early stage of chronic pancreatitis is a reversible disease, the diagnostic criteria of "early-stage" chronic pancreatitis were developed in Japan for early detection and early treatment of chronic pancreatitis. Endoscopic ultrasonography (EUS) plays an important role in detecting "early-stage" chronic pancreatitis. Many EUS image findings of "early-stage" chronic pancreatitis are mentioned in the Rosemont criteria for the EUS diagnosis of chronic pancreatitis.Evaluation of shear wave dispersion caused by fibrous structure and tissue viscosity using hepatic fibrosis progression and histological modelsShiori Fujii; Makoto Yamakawa; Kengo Kondo; Takeshi Namita; Masatoshi kudo; Tsuyoshi Shiina2017 IEEE INTERNATIONAL ULTRASONICS SYMPOSIUM (IUS) IEEE 1948-5719 2017 [Refereed] Shear wave elasticity imaging has been utilized for chronic hepatitis diagnosis. The relationship between hepatic fibrosis and elasticity or viscosity has been described recently. Therefore, it is expected that viscosity analysis will improve the accuracy of staging fibrosis, in addition to elasticity measuring. However, fibrous structures affect dispersion slope analysis, so it is necessary to investigate the effect of fibrous structure on dispersion slope analysis. In order to simulate shear wave propagation in liver tissue, we use two types of models representing fibrosis progression. One is created using a potential function, and the other is created from hepatic histological sections. Simulating shear wave propagation in these models without viscosity in order to examine the effect of fibrous structure alone, dispersion analysis was applied to the particle velocity data. We evaluated the dispersion slope and shear wave phase velocity at 200 Hz (c (200 Hz)). In both models, the dispersion slope increased significantly with fibrosis progression. The resulting dispersion slope is about 30% of the dispersion slope in in vivo measurements, indicating that the effect of fibrous structure is large enough for viscosity analysis.Malignant Transformation of Hepatocellular AdenomaKwok WY; Hagiwara S; Nishida N; Watanabe T; Sakurai T; Ida H; Minami Y; Takita M; Minami T; Iwanishi M; Chishina H; Kono M; Ueshima K; Komeda Y; Arizumi T; Enoki E; Nakai T; Kumabe T; Nakashima O; Kondo F; Kudo MOncology 92 (Suppl 1) 16 - 28 2017座談会; 切除不能な肝細胞癌に対するスチバーガ治療~2nd line治療における世界初のエビデンス創出およびネクサバールとのsequential therapyへの期待~工藤正俊; 黒崎雅之; 池田公史; 小笠原定久Medical Tribune Web 2017 [Refereed]肝生検での診断が可能であった、AFP-L3陽性の細胆管細胞癌(CoCC)の一例小川 力; 工藤正俊第17回肝血流動態イメージ研究会記録集 93 - 96 2017 [Refereed]膵炎における腸管免疫機構破綻と重症化機序渡邉智裕; 三長孝輔; 鎌田研; 山雄健太郎; 竹中完; 工藤正俊肝胆膵 75 991 - 996 2017 [Refereed]肝癌診療のブレイクスルー―世界に誇る肝癌診療の構築. 特集: ターニングポイントを迎えた肝癌診療工藤正俊クリニシアン 659 712 - 715 2017日本における新薬開発と今後の展望上嶋一臣; 工藤正俊消化器・肝臓内科 2 (1) 1 - 7 2017Treatment Stage Migration Maximizes Survival Outcomes in Patients with Hepatocellular Carcinoma Treated with Sorafenib: An Observational StudyClarence Yen; Rohini Sharma; Lorenza Rimassa; Tadaaki Arizumi; Dominik Bettinger; Huay Yee Choo; Tiziana Pressiani; Michela E. Burlone; Mario Pirisi; Laura Giordano; Anisa Abdulrahman; Masatoshi Kudo; Robert Thimme; Joong Won Park; David James PinatoLIVER CANCER KARGER 6 (4) 313 - 324 2235-1795 2017 [Refereed] Background: Level I evidence supports the use of sorafenib in patients with Barcelona Clinic Liver Cancer (BCLC) stage C hepatocellular carcinoma, where heterogeneity in efficacy exists due to varying clinicopathologic features of the disease. Aim: We evaluated whether prior treatment with curative or locoregional therapies influences sorafenib-specific survival. Methods: From a prospective data set of 785 consecutive patients from international specialist centres, 264 patients (34%) were treatment naive (TN) and 521 (66%) were pre-treated (PT), most frequently with transarterial chemoembolization (n = 413; 79%). The primary endpoint was overall survival (OS) from sorafenib initiation with prognostic factors tested on uni- and multivariate analyses. Results: Median OS for the entire cohort was 9 months; the median sorafenib duration was 2.8 months, with discontinuation being secondary to progression (n = 454; 58%) or toxicity (n = 149; 19%). PT patients had significantly longer OS than TN patients (10.5 vs. 6.6 months; p < 0.001). Compared to TN patients, PT patients had a better Child-Pugh (CP) class (CP A: 57 vs. 47%; p < 0.001) and a lower BCLC stage (BCLC A-B, 40 vs. 30%; p = 0.007). PT status preserved an independent prognostic role (p = 0.002) following adjustment for BCLC stage, a-fetoprotein, CP class, aetiology, and post-sorafenib treatment status. PT patients were more likely to receive further anticancer treatment after sorafenib (31 vs. 9%; p < 0.001). Conclusion: Patients receiving sorafenib after having failed curative or locoregional therapies survive longer and are more likely to receive further treatment after sorafenib. This suggests an incremental benefit to OS from sequential exposure to multiple lines of therapy, justifying treatment stage migration in eligible patients. (C) 2017 S. Karger AG, BaselCharacterization of Pancreatic Tumors with Quantitative Perfusion Analysis in Contrast-Enhanced Harmonic Endoscopic UltrasonographyShunsuke Omoto; Mamoru Takenaka; Masayuki Kitano; Takeshi Miyata; Ken Kamata; Kosuke Minaga; Tadaaki Arizumi; Kentaro Yamao; Hajime Imai; Hiroki Sakamoto; Yogesh Harwani; Toshiharu Sakurai; Tomohiro Watanabe; Naoshi Nishida; Yoshifumi Takeyama; Yasutaka Chiba; Masatoshi KudoOncology S. Karger AG 93 (1) 55 - 60 0030-2414 2017 [Refereed]Risk Factors for Postoperative Bleeding in Endoscopic Submucosal Dissection of Colorectal TumorsKazuki Okamoto; Tomohiro Watanabe; Yoriaki Komeda; Tatsuya Kono; Kouta Takashima; Ayana Okamoto; Masashi Kono; Mitsunari Yamada; Tadaaki Arizumi; Ken Kamata; Kosuke Minaga; Kentaro Yamao; Tomoyuki Nagai; Yutaka Asakuma; Mamoru Takenaka; Toshiharu Sakurai; Shigenaga Matsui; Naoshi Nishida; Takaaki Chikugo; Hiroshi Kashida; Masatoshi KudoOncology S. Karger AG 93 (1) 35 - 42 0030-2414 2017 [Refereed]Detection of High-Grade Pancreatic Intraepithelial Neoplasia without Morphological Changes of the Main Pancreatic Duct over a Long Period: Importance for Close Follow-Up for ConfirmationKentaro Yamao; Mamoru Takenaka; Atsushi Nakai; Shunske Omoto; Ken Kamata; Kosuke Minaga; Takeshi Miyata; Hajime Imai; Toshiharu Sakurai; Tomohiro Watanabe; Naoshi Nishida; Ippei Matsumoto; Yosihumi Takeyama; Takaaki Chikugo; Masatoshi KudoOncology S. Karger AG 93 (1) 81 - 86 0030-2414 2017 [Refereed]Computer-Aided Diagnosis Based on Convolutional Neural Network System for Colorectal Polyp Classification: Preliminary ExperienceYoriaki Komeda; Hisashi Handa; Tomohiro Watanabe; Takanobu Nomura; Misaki Kitahashi; Toshiharu Sakurai; Ayana Okamoto; Tomohiro Minami; Masashi Kono; Tadaaki Arizumi; Mamoru Takenaka; Satoru Hagiwara; Shigenaga Matsui; Naoshi Nishida; Hiroshi Kashida; Masatoshi KudoOncology S. Karger AG 93 (1) 30 - 34 0030-2414 2017 [Refereed]Chronic Pancreatitis Finding by Endoscopic Ultrasonography in the Pancreatic Parenchyma of Intraductal Papillary Mucinous Neoplasms Is Associated with Invasive Intraductal Papillary Mucinous Carcinoma.Takenaka M; Masuda A; Shiomi H; Yagi Y; Zen Y; Sakai A; Kobayashi T; Arisaka Y; Okabe Y; Kutsumi H; Toyama H; Fukumoto T; Ku Y; Kudo M; Azuma TOncology 93 Suppl 1 61 - 68 0030-2414 2017 [Refereed]Clinical Analysis of Esophageal Stricture in Patients Treated with Intralesional Triamcinolone Injection after Endoscopic Submucosal Dissection for Superficial Esophageal CancerKazuki Okamoto; Shigenaga Matsui; Tomohiro Watanabe; Yutaka Asakuma; Yoriaki Komeda; Ayana Okamoto; Ishikawa Rei; Masashi Kono; Mitsunari Yamada; Tomoyuki Nagai; Tadaaki Arizumi; Kosuke Minaga; Ken Kamata; Kentaro Yamao; Mamoru Takenaka; Toshiharu Sakurai; Naoshi Nishida; Hiroshi Kashida; Takaaki Chikugo; Masatoshi KudoOncology S. Karger AG 93 (1) 9 - 14 0030-2414 2017 [Refereed]Validation of Newly Proposed Time to Transarterial Chemoembolization Progression in Intermediate-Stage Hepatocellular Carcinoma Cases.Hirofumi Izumoto; Atsushi Hiraoka; Yoshihiro Ishimaru; Tadashi Murakami; Shogo Kitahata; Hidetaro Ueki; Toshihiko Aibiki; Tomonari Okudaira; Yuji Miyamoto; Hiroka Yamago; Ryuichiro Iwasaki; Hideomi Tomida; Kenichiro Mori; Masato Kishida; Eiji Tsubouchi; Hideki Miyata; Tomoyuki Ninomiya; Hideki Kawasaki; Masashi Hirooka; Bunzo Matsuura; Masanori Abe; Yoichi Hiasa; Kojiro Michitaka; Masatoshi KudoOncology 93 Suppl 1 120 - 126 0030-2414 2017 [Refereed] BACKGROUND/AIM: Determination of failure of transarterial chemoembolization (TACE) for treatment of Barcelona Clinic Liver Cancer stage B (BCLC-B) hepatocellular carcinoma (HCC) has become important because of the development of tyrosine kinase inhibitor (TKI) treatment. We evaluated the usefulness and efficacy of the newly proposed time to TACE progression (TTTP). PATIENTS AND METHODS: From 2006 to 2016, 192 BCLC-B HCC patients [median age 72 years, male/female ratio = 149/43, Child-Pugh score 5/6/7 = 106/56/30, albumin-bilirubin (ALBI) grade 1/2 = 64/128, Kinki criteria B1/B2 = 64/128] were enrolled. TTTP was defined based on a previous report and first imaging performed 3 months after initial TACE had been used to obtain baseline images. The patients were divided into three groups according to TTTP (100 ng/mL) (HR 1.540, 95% CI 1.035-2.291, p = 0.033), and TTTP (Comparative Study of Clarithromycin- versus Metronidazole-Based Triple Therapy as First-Line Eradication for Helicobacter pyloriTeppei Adachi; Shigenaga Matsui; Tomohiro Watanabe; Kazuki Okamoto; Ayana Okamoto; Masashi Kono; Mitsunari Yamada; Tomoyuki Nagai; Yoriaki Komeda; Kosuke Minaga; Ken Kamata; Kentaro Yamao; Mamoru Takenaka; Yutaka Asakuma; Toshiharu Sakurai; Naoshi Nishida; Hiroshi Kashida; Masatoshi KudoOncology S. Karger AG 93 (1) 15 - 19 0030-2414 2017 [Refereed]ALBI Score as a Novel Tool in Staging and Treatment Planning for Hepatocellular Carcinoma: Advantage of ALBI Grade for Universal Assessment of Hepatic FunctionAtsushi Hiraoka; Kojiro Michitaka; Takashi Kumada; Masashi KudoLIVER CANCER KARGER 6 (4) 377 - 379 2235-1795 2017 [Refereed]Validation and Potential of Albumin-Bilirubin Grade and Prognostication in a Nationwide Survey of 46,681 Hepatocellular Carcinoma Patients in Japan: The Need for a More Detailed Evaluation of Hepatic FunctionAtsushi Hiraoka; Kojiro Michitaka; Takashi Kumada; Namiki Izumi; Masumi Kadoya; Norihiro Kokudo; Shoji Kubo; Yutaka Matsuyama; Osamu Nakashima; Michiie Sakamoto; Tadatoshi Takayama; Takashi Kokudo; Kosuke Kashiwabara; Masatoshi KudoLIVER CANCER KARGER 6 (4) 325 - 336 2235-1795 2017 [Refereed] Background/Aim: Recently, albumin-bilirubin (ALBI) scoring/grading, consisting of only albumin and total bilirubin, has been proposed. We examined the efficacy of this grading system for determining hepatic function in patients with hepatocellular carcinoma (HCC). Methods/Materials: The prognoses of 46,681 HCC patients based on results obtained from a nationwide survey conducted in Japan from 2001 to 2007 were evaluated using (1) Japan Integrated Staging (JIS), consisting of Child-Pugh classification and TNM staging (TNM), (2) modified JIS (m-JIS), consisting of liver damage grading and TNM, and (3) ALBI-TNM (ALBI-T), consisting of ALBI grading and TNM, and the results were compared. A subanalysis was also performed to define a cutoff value for ALBI scores for a more detailed stratification of hepatic function. Results: ALBI-T, JIS, and m-JIS each showed good capacity for the stratification of prognoses. Although the Akaike information criterion for ALBI-T was nearly equal to that for JIS and m-JIS, the Kaplan-Meier curves and median survival times obtained with ALBI-T were always superior to the corresponding scores. When the indocyanine green retention test (<30%) was used as an additional cutoff value for ALBI score (-2.270, area under the curve 0.828) to divide ALBI grade into 4 levels (modified ALBI [mALBI] grade), mALBI grade was able to stratify the prognosis of patients at any TNM stage in order of grade. Modified ALBI-T (mALBI-T), using mALBI grading and TNM, produced a more detailed stratification for prognosis. Conclusion: The predictive value for prognosis of ALBI-T was found to be equal to that of JIS and m-JIS. In addition, mALBI grading and mALBI-T, as proposed in the present study, might provide a more detailed assessment of the hepatic function and prognosis of HCC patients. (C) 2017 S. Karger AG, BaselLenvatinib in Advanced Hepatocellular CarcinomaMasatoshi KudoLIVER CANCER KARGER 6 (4) 253 - 263 2235-1795 2017 [Refereed]New Era of the Management of Liver Diseases and Liver Cancer: State-of-the-Art Progress in 2017Masatoshi KudoDIGESTIVE DISEASES KARGER 35 (6) 493 - 497 0257-2753 2017 [Refereed]Serum IFN-lambda 3 Levels Correlate with Serum Hepatitis C Virus RNA Levels in Symptomatic Patients with Acute Hepatitis CSusumu Imoto; Soo Ryang Kim; Keisuke Amano; Etsuko Iio; Seitetsu Yoon; Shigeya Hirohata; Yoshihiko Yano; Toru Ishikawa; Shinji Katsushima; Toshiki Komeda; Toyokazu Fukunaga; Hobyung Chung; Hiroyuki Kokuryu; Yutaka Horie; Takashi Hatae; Aya Fujinami; Soo Ki Kim; Masatoshi Kudo; Yasuhito TanakaDIGESTIVE DISEASES KARGER 35 (6) 531 - 540 0257-2753 2017 [Refereed] Background: Recent genome-wide association studies demonstrated that 2 single nucleotide polymorphisms (SNPs), upstream of the interferon-lambda (IFNL) 3 gene, are associated with the spontaneous clearance of hepatitis C virus (HCV) in symptomatic patients with acute hepatitis C (AHC). Although these 2 SNPs, rs8099917 and rs12979860, have established their significant roles in the innate immunity response to spontaneously clear HCV in patients with AHC, the detailed mechanisms of their roles remain largely unknown. Aim: This study is aimed at clarifying the factors affecting IFNL3 production and assessing the roles of IFNL3 in AHC. Materials and Methods: A total of 21 AHC patients who visited the hospital within 10 days after symptom onset were assessed. As controls, 23 healthy volunteers (HVs) were examined. Serum IFNL3 levels were quantified using an inhouse, IFNL3-specific chemiluminescence enzyme immunoassay (CLEIA) kit. Serum IFNL1, IFN-alpha, IFN-alpha, and IFN-beta induced protein-10 (IP-10) levels were assayed using commercial enzyme-linked immunosorbent assay (ELISA) kits. Results: At baseline, serum IFNL3 levels were higher in AHC patients than in HVs (p < 0.0001). The higher levels in AHC patients did not differ between patients with the rs8099917 TT genotype and those with the non-TT (TG/GG) genotype (p = 0.546). Serial measurement of serum IFNL3 levels did not predict the outcome of conventional AHC. However, serum IFNL3 levels at baseline correlated positively with the HCV RNA levels (p = 0.005). Following HCV eradication, serum IFNL3 levels reduced to within the range obtained for HVs. Baseline serum IFNL1 levels did not differ significantly between AHC patients and HVs (p = 0.284). Serum levels of IFNL1 and IFNL3 at baseline also showed no correlative power (p = 0.288). Serum IFN-alpha and IFN-beta were detected together with remarkably high serum IFNL3 levels in only one patient who progressed to acute liver failure (ALF). Conclusion: These findings indicate that serum IFNL3 levels at baseline are higher in AHC patients regardless of the rs8099917 polymorphism, and primary HCV infection triggers the production of IFNL3. As a first line of defense in the innate immune system against invading HCV, increased IFNL3 levels play an important role, but serum IFNL3 levels are not the principal determinant of the clinical course of conventional AHC. (C) 2017 S. Karger AG, BaselNon-Hypervascular Hypointense Hepatic Nodules during the Hepatobiliary Phase of Gadolinium-Ethoxybenzyl-Diethylenetriamine Pentaacetic Acid-Enhanced MRI as a Risk Factor of Intrahepatic Distant Recurrence after Radiofrequency Ablation of Hepatocellular CarcinomaTakayuki Iwamoto; Yasuharu Imai; Takumi Igura; Sachiyo Kogita; Yoshiyuki Sawai; Kazuto Fukuda; Yoshitaka Yamaguchi; Yasushi Matsumoto; Masanori Nakahara; Osakuni Morimoto; Hiroshi Ohashi; Norihiko Fujita; Masatoshi Kudo; Tetsuo TakeharaDIGESTIVE DISEASES KARGER 35 (6) 574 - 582 0257-2753 2017 [Refereed] Background: Non-hypervascular hypointense hepatic nodules during the hepatobiliary phase of gadolinium-ethoxybenzyl-diethylenetriamine pentaacetic acid (Gd-EOB-DTPA)-enhanced MRI have been reported to be associated with intrahepatic distant recurrence (IDR) after hepatectomy or radiofrequency ablation (RFA) for hepatocellular carcinoma (HCC). IDR is categorized into hypervascular transformation of non-hypervascular hypointense hepatic nodules and new intrahepatic recurrence. The aim of this study was to evaluate the relationship between non-hypervascular hypointense hepatic nodules on Gd-EOB-DTPA-enhanced MRI and IDR after RFA, focusing on new intrahepatic recurrence. Methods: Ninety-one consecutive patients with 115 HCCs undergoing pretreatment Gd-EOB-DTPA-enhanced MRI and RFA for treatment of HCC were enrolled. Results: Of the 91 patients who underwent RFA for HCC, 24 had non-hypervascular hypointense hepatic nodules on pretreatment Gd-EOB-DTPA-enhanced MRI. Recurrences were observed in 15 and 19 patients with and without non-hypervascular hypointense hepatic nodules, respectively. Of the 15 recurrences in patients with non-hypervascular hypointense hepatic nodules, 10 patients had new intrahepatic recurrences. The cumulative incidence of new intrahepatic recurrence was significantly higher in patients with non-hypervascular hypointense hepatic nodules than in those without non-hypervascular hypointense hepatic nodules (p < 0.0001). Multivariate analysis revealed that the presence of non-hypervascular hypointense hepatic nodules and Child-Pugh score were independent risk factors for new intrahepatic recurrence. Conclusions: Non-hypervascular hypointense hepatic nodules during the hepatobiliary phase of Gd-EOB-DTPA-enhanced MRI were a useful predictive factor for IDR, particularly for new intrahepatic recurrence, after RFA. (C) 2017 S. Karger AG, BaselTHE REGULATION OF AIRWAY SMOOTH MUSCLE CONTRACTION.Kudo MArerugi = [Allergy] 66 (6) 798 - 803 0021-4884 2017 [Refereed]Cyclocarya paliurus extract activates insulin signaling via Sirtuin1 in C2C12 myotubes and decreases blood glucose level in mice with impaired insulin secretion.Yoshitomi H; Tsuru R; Li L; Zhou J; Kudo M; Liu T; Gao MPloS one 12 (8) e0183988  2017 [Refereed]Evidence and topics of drug therapy for hepatocellular carcinomaKazuomi Ueshima; Masatoshi KudoJournal of Japanese Society of Gastroenterology Japanese Society of Gastroenterology 114 (9) 1621 - 1628 1349-7693 2017 [Refereed]Management of developmental enamel defects in the primary dentition.Wada K; Kanazawa H; Kudo M; Kindaichi J; Miyashin MJournal of oral science Nihon University School of Dentistry 59 (3) 457 - 460 1343-4934 2017 [Refereed] This study attempted to identify appropriate materials for restoration of enamel defects in the primary dentition, which were classified by severity and region with the modified developmental defects of enamel index. To identify the most appropriate materials, we used restorative materials to protect teeth and evaluated clinical outcomes of restoration. Three materials were used for restoration or repair after dislodgement of restorations. Our findings in this case suggest that, because of its durability and esthetic advantages, adhesive resin is beneficial for patients with enamel defects, particularly for restorations of less than two-thirds of the extent of the defect.Transarterial Chemoembolization in Combination with Molecular Targeted Agent: Lessons from Negative Trials (Post-TACE, BRISK-TA, SPACE, ORIENTAL, and TACE-2)Masatoshi Kudo; Tadaaki ArizumiOncology Suppl (in press) 2017 [Refereed]Validation of Newly Proposed Time to Transarterial Chemoembolization Progression in Intermediate-Stage Hepatocellular Carcinoma Cases.Hirofumi Izumoto; Atsushi Hiraoka; Yoshihiro Ishimaru; Tadashi Murakami; Shogo Kitahata; Hidetaro Ueki; Toshihiko Aibiki; Tomonari Okudaira; Yuji Miyamoto; Hiroka Yamago; Ryuichiro Iwasaki; Hideomi Tomida; Kenichiro Mori; Masato Kishida; Eiji Tsubouchi; Hideki Miyata; Tomoyuki Ninomiya; Hideki Kawasaki; Masashi Hirooka; Bunzo Matsuura; Masanori Abe; Yoichi Hiasa; Kojiro Michitaka; Masatoshi KudoOncology 93 Suppl 1 (in press) 120 - 126 2017 [Refereed] BACKGROUND/AIM: Determination of failure of transarterial chemoembolization (TACE) for treatment of Barcelona Clinic Liver Cancer stage B (BCLC-B) hepatocellular carcinoma (HCC) has become important because of the development of tyrosine kinase inhibitor (TKI) treatment. We evaluated the usefulness and efficacy of the newly proposed time to TACE progression (TTTP). PATIENTS AND METHODS: From 2006 to 2016, 192 BCLC-B HCC patients [median age 72 years, male/female ratio = 149/43, Child-Pugh score 5/6/7 = 106/56/30, albumin-bilirubin (ALBI) grade 1/2 = 64/128, Kinki criteria B1/B2 = 64/128] were enrolled. TTTP was defined based on a previous report and first imaging performed 3 months after initial TACE had been used to obtain baseline images. The patients were divided into three groups according to TTTP (100 ng/mL) (HR 1.540, 95% CI 1.035-2.291, p = 0.033), and TTTP (A social program for the early detection of pancreatic cancer, the Kishiwada project: A multi-center studyHiroki Sakamoto; Satoshi Harada; Nobu Nishioka; Kazuo Maeda; Takamasa Kurihara; Tateki Sakamoto; Kazuhide Higuchi; Masayuki Kitano; Yoshifumi Takeyama; Masafumi Kogire; Masatoshi KudoOncology Suppl (in press) 2017 [Refereed]Hand-Foot Syndrome and Post-Progression Treatment Are the Good Predictors of Better Survival in Advanced Hepatocellular Carcinoma Treated with Sorafenib: A Multicenter Study.Chikara Ogawa; Masahiro Morita; Akina Omura; Teruyo Noda; Atsushi Kubo; Toshihiro Matsunaka; Hiroyuki Tamaki; Mitsushige Shibatoge; Akemi Tsutsui; Tomonori Senoh; Takuya Nagano; Kouichi Takaguchi; Joji Tani; Asahiro Morishita; Hirohito Yoneyama; Tsutomu Masaki; Akio Moriya; Masaharu Ando; Akihiro Deguchi; Yasutaka Kokudo; Yasunori Minami; Kazuomi Ueshima; Toshiharu Sakurai; Naoshi Nishida; Masatoshi KudoOncology 93 Suppl 1 (in press) 113 - 119 0030-2414 2017 [Refereed] OBJECTIVE: To determine the relationship between treatment outcomes and hand-foot syndrome (HFS), and the relationship between survival rate and post-progression treatment after sorafenib therapy. METHODS: The study assessed 314 patients with advanced hepatocellular carcinoma (HCC) treated with sorafenib at 5 general hospitals in Kagawa Prefecture, Japan. RESULTS: At the start of sorafenib therapy, 23.6% of the patients had HCC of a Child-Pugh class other than A. The initial sorafenib dose was 800 mg in 9.2% of the patients and 400 mg in 64.3%. Time to progression was 129 days (95% CI: 87.3-170.7) and the median overall survival (OS) was 392 days (95% CI: 316.0-468.0). The OS of the patients with Child-Pugh class A HCC was significantly better than that of the patients with Child-Pugh class B HCC (p EUS-Guided Pancreatic Duct Drainage for Repeat Pancreatitis in a Patient with Pancreatic CancerKen Kamata; Mamoru Takenaka; Kosuke Minaga; Toshiharu Sakurai; Tomohiro Watanabe; Naoshi Nishida; Masatoshi KudoOncology S. Karger AG 93 (1) 87 - 88 0030-2414 2017 [Refereed]Detection of High-Grade Pancreatic Intraepithelial Neoplasia without Morphological Changes of the Main Pancreatic Duct over a Long Period: Importance for Close Follow-Up for ConfirmationKentaro Yamao; Mamoru Takenaka; Atsushi Nakai; Shunske Omoto; Ken Kamata; Kosuke Minaga; Takeshi Miyata; Hajime Imai; Toshiharu Sakurai; Tomohiro Watanabe; Naoshi Nishida; Ippei Matsumoto; Yosihumi Takeyama; Takaaki Chikugo; Masatoshi KudoOncology S. Karger AG 93 (1) 81 - 86 0030-2414 2017 [Refereed]Primary Hepatic Adenosquamous Carcinoma Associated with Primary Sclerosing CholangitisKentaro Yamao; Mamoru Takenaka; Hajime Imai; Atsushi Nakai; Shunske Omoto; Ken Kamata; Kosuke Minaga; Takeshi Miyata; Toshiharu Sakurai; Tomohiro Watanabe; Naoshi Nishida; Ippei Matsumoto; Yosihumi Takeyama; Takaaki Chikugo; Masatoshi KudoOncology S. Karger AG 93 (1) 76 - 80 0030-2414 2017 [Refereed]Needle Tract Seeding: An Overlooked Rare Complication of Endoscopic Ultrasound-Guided Fine-Needle AspirationKosuke Minaga; Mamoru Takenaka; Akio Katanuma; Masayuki Kitano; Yukitaka Yamashita; Ken Kamata; Kentaro Yamao; Tomohiro Watanabe; Hiroyuki Maguchi; Masatoshi KudoOncology S. Karger AG 93 (1) 107 - 112 0030-2414 2017 [Refereed]Association between the Risk Factors for Pancreatic Ductal Adenocarcinoma and Those for Malignant Intraductal Papillary Mucinous NeoplasmKen Kamata; Mamoru Takenaka; Atsushi Nakai; Shunsuke Omoto; Takeshi Miyata; Kosuke Minaga; Tomohiro Matsuda; Kentaro Yamao; Hajime Imai; Yasutaka Chiba; Toshiharu Sakurai; Tomohiro Watanabe; Naoshi Nishida; Takaaki Chikugo; Ippei Matsumoto; Yoshifumi Takeyama; Masatoshi KudoOncology S. Karger AG 93 (1) 102 - 106 0030-2414 2017 [Refereed]Utility of Endoscopic Ultrasound-Guided Hepaticogastrostomy with Antegrade Stenting for Malignant Biliary Obstruction after Failed Endoscopic Retrograde CholangiopancreatographyHajime Imai; Mamoru Takenaka; Shunsuke Omoto; Ken Kamata; Takeshi Miyata; Kosuke Minaga; Kentaro Yamao; Toshiharu Sakurai; Naoshi Nishida; Tomohiro Watanabe; Masayuki Kitano; Masatoshi KudoOncology S. Karger AG 93 (1) 69 - 75 0030-2414 2017 [Refereed]Chronic Pancreatitis finding by Endoscopic Ultrasonography in the Pancreatic Parenchyma of IPMNs is Associated with Invasive IPMCMamoru Takenaka; Atsuhiro Masuda; Hideyuki Shiomi; Yosuke Yagi; Yoh Zen; Arata Sakai; Takashi Kobayashi; Yoshifumi Arisaka; Yoshihiro Okabe; Hiromu Kutsumi; Hirochika Toyama; Takumi Fukumoto; Yonson Ku; Masatoshi Kudo; Takeshi AzumaOncology Supple (in press) 2017 [Refereed]Characterization of Pancreatic Tumors with Quantitative Perfusion Analysis in Contrast-Enhanced Harmonic Endoscopic UltrasonographyShunsuke Omoto; Mamoru Takenaka; Masayuki Kitano; Takeshi Miyata; Ken Kamata; Kosuke Minaga; Tadaaki Arizumi; Kentaro Yamao; Hajime Imai; Hiroki Sakamoto; Yogesh Harwani; Toshiharu Sakurai; Tomohiro Watanabe; Naoshi Nishida; Yoshifumi Takeyama; Yasutaka Chiba; Masatoshi KudoOncology S. Karger AG 93 (1) 55 - 60 0030-2414 2017 [Refereed]Magnifying Narrow Band Imaging (NBI) for the Diagnosis of Localized Colorectal Lesions Using the Japan NBI Expert Team (JNET) ClassificationYoriaki Komeda; Hiroshi Kashida; Toshiharu Sakurai; Yutaka Asakuma; George Tribonias; Tomoyuki Nagai; Masashi Kono; Kosuke Minaga; Mamoru Takenaka; Tadaaki Arizumi; Satoru Hagiwara; Shigenaga Matsui; Tomohiro Watanabe; Naoshi Nishida; Takaaki Chikugo; Yasutaka Chiba; Masatoshi KudoOncology S. Karger AG 93 (1) 49 - 54 0030-2414 2017 [Refereed]Risk Factors for Postoperative Bleeding in Endoscopic Submucosal Dissection of Colorectal TumorsKazuki Okamoto; Tomohiro Watanabe; Yoriaki Komeda; Tatsuya Kono; Kouta Takashima; Ayana Okamoto; Masashi Kono; Mitsunari Yamada; Tadaaki Arizumi; Ken Kamata; Kosuke Minaga; Kentaro Yamao; Tomoyuki Nagai; Yutaka Asakuma; Mamoru Takenaka; Toshiharu Sakurai; Shigenaga Matsui; Naoshi Nishida; Takaaki Chikugo; Hiroshi Kashida; Masatoshi KudoOncology S. Karger AG 93 (1) 35 - 42 0030-2414 2017 [Refereed]Computer-Aided Diagnosis Based on Convolutional Neural Network System for Colorectal Polyp Classification: Preliminary ExperienceYoriaki Komeda; Hisashi Handa; Tomohiro Watanabe; Takanobu Nomura; Misaki Kitahashi; Toshiharu Sakurai; Ayana Okamoto; Tomohiro Minami; Masashi Kono; Tadaaki Arizumi; Mamoru Takenaka; Satoru Hagiwara; Shigenaga Matsui; Naoshi Nishida; Hiroshi Kashida; Masatoshi KudoOncology S. Karger AG 93 (1) 30 - 34 0030-2414 2017 [Refereed]Prophylactic Suturing Closure Is Recommended after Endoscopic Treatment of Colorectal Tumors in Patients with Antiplatelet/Anticoagulant TherapyToshiharu Sakurai; Teppei Adachi; Masashi Kono; Tadaaki Arizumi; Ken Kamata; Kosuke Minaga; Kentaro Yamao; Yoriaki Komeda; Mamoru Takenaka; Satoru Hagiwara; Tomohiro Watanabe; Naoshi Nishida; Hiroshi Kashida; Masatoshi KudoOncology S. Karger AG 93 (1) 27 - 29 0030-2414 2017 [Refereed]Clinical Significance of Bmi1 Expression in Inflammatory Bowel DiseaseMitsunari Yamada; Toshiharu Sakurai; Yoriaki Komeda; Tomoyuki Nagai; Ken Kamata; Kosuke Minaga; Kentaro Yamao; Mamoru Takenaka; Satoru Hagiwara; Shigenaga Matsui; Tomohiro Watanabe; Naoshi Nishida; Hiroshi Kashida; Masatoshi KudoOncology S. Karger AG 93 (1) 20 - 26 0030-2414 2017 [Refereed]Comparative Study of Clarithromycin- versus Metronidazole-Based Triple Therapy as First-Line Eradication for Helicobacter pyloriTeppei Adachi; Shigenaga Matsui; Tomohiro Watanabe; Kazuki Okamoto; Ayana Okamoto; Masashi Kono; Mitsunari Yamada; Tomoyuki Nagai; Yoriaki Komeda; Kosuke Minaga; Ken Kamata; Kentaro Yamao; Mamoru Takenaka; Yutaka Asakuma; Toshiharu Sakurai; Naoshi Nishida; Hiroshi Kashida; Masatoshi KudoOncology S. Karger AG 93 (1) 15 - 19 0030-2414 2017 [Refereed]Clinical Analysis of Esophageal Stricture in Patients Treated with Intralesional Triamcinolone Injection after Endoscopic Submucosal Dissection for Superficial Esophageal CancerKazuki Okamoto; Shigenaga Matsui; Tomohiro Watanabe; Yutaka Asakuma; Yoriaki Komeda; Ayana Okamoto; Ishikawa Rei; Masashi Kono; Mitsunari Yamada; Tomoyuki Nagai; Tadaaki Arizumi; Kosuke Minaga; Ken Kamata; Kentaro Yamao; Mamoru Takenaka; Toshiharu Sakurai; Naoshi Nishida; Hiroshi Kashida; Takaaki Chikugo; Masatoshi KudoOncology S. Karger AG 93 (1) 9 - 14 0030-2414 2017 [Refereed]Preface: New Paradigm in Gastrointestinal Cancer TreatmentMasatoshi KudoOncology Supple (in press) 2017 [Refereed]Role of Immune Checkpoint Blockade in the Treatment for Human Hepatocellular CarcinomaNaoshi Nishida; Masatoshi KudoDIGESTIVE DISEASES KARGER 35 (6) 618 - 622 0257-2753 2017 [Refereed] With the development of molecular targeting therapy, several treatment options for advanced hepatocellular carcinoma (HCC) have become available in cases where curative and other palliative treatments, such as radiofrequency ablation, surgical resection, and transarterial chemoembolization, are not applicable. However, with the detection of a variety of mutations in cancer-related genes in a single tumor, molecular heterogeneity is commonly observed in HCC. Therefore, mutations in the major cellular signaling pathways underlie the development of resistance to molecular targeting agents. On the contrary, immune checkpoint inhibitors have proven effective in patients who are refractory to conventional treatments and molecular targeting therapy. Several clinical trials are currently investigating the efficacy of immune checkpoint inhibitors both individually and in combination with other types of anticancer agents. In this review, we focus on the potential of immune checkpoint blockade in the treatment of human HCC. (C) 2017 S. Karger AG, BaselSorafenib-Regorafenib Sequential Therapy in Advanced Hepatocellular Carcinoma: A Single-Institute ExperienceKazuomi Ueshima; Naoshi Nishida; Masatoshi KudoDIGESTIVE DISEASES KARGER 35 (6) 611 - 617 0257-2753 2017 [Refereed] Objectives: Previously, no therapeutic agent has been known to improve the overall survival compared with placebo in patients with hepatocellular carcinoma (HCC), who have progressed after sorafenib. In this patient population, regorafenib was first demonstrated to confer a survival benefit in the RESORCE trial, and subsequently it was approved as a second-line treatment for patients with advanced HCC. An open-label expanded access program (EAP) of regorafenib was implemented for compassionate use. We investigated the efficacy and safety of regorafenib based on our experience of the RESORCE trial and the EAP. Methods: Data from 5 patients from the RESORCE trial and 6 from the EAP were analyzed retrospectively. All patients had tolerated prior sorafenib and were progressing during sorafenib treatment. Results: The median progression-free survival was 9.2 months (95% CI 2.3-16.1). One patient achieved a partial response and 7 achieved stable disease. The objective response rate was 9.1%, and the disease control rate was 72.7%. No treatment-associated mortalities were observed. Grade 3 hypophosphatemia was observed in 2 patients, grade 2 anorexia was observed in 5 patients, and grade 3 neutropenia was observed in 2 patients. Grade 2 and grade 3 thrombocytopenia were observed in 2 and 3 patients, respectively. All treatment-related adverse events were improved by reduction or interruption of regorafenib. Five patients showed decreased serum albumin levels. Conclusion: Sorafenib and regorafenib sequential therapy presents a safe and effective treatment option for patients with advanced HCC. (C) 2017 S. Karger AG, BaselHepatic Function during Repeated TACE Procedures and Prognosis after Introducing Sorafenib in Patients with Unresectable Hepatocellular Carcinoma: Multicenter AnalysisAtsushi Hiraoka; Takashi Kumada; Masatoshi Kudo; Masashi Hirooka; Yohei Koizumi; Yoichi Hiasa; Kazuto Tajiri; Hidenori Toyoda; Toshifumi Tada; Hironori Ochi; Koji Joko; Noritomo Shimada; Akihiro Deguchi; Toru Ishikawa; Michitaka Imai; Kunihiko Tsuji; Kojiro MichitakaDIGESTIVE DISEASES KARGER 35 (6) 602 - 610 0257-2753 2017 [Refereed] Background/Aim: We evaluated the relationship of hepatic function with repeated transarterial catheter chemoembolization (TACE) and prognosis after sorafenib treatment in various patient cohorts. Methods: Study 1 comprised of 212 Barcelona clinic liver cancer stage-B (BCLC-B) HCC patients classified as Child-Pugh A (CP-A) and who had received repeated TACE treatments (r-TACE) (naive: recurrence = 66: 146). Study 2 comprised of 435 patients with unresectable HCC classified as CP-A in who sorafenib was introduced (naive: recurrence = 37: 398; CP score 5: 6 = 282: 153; macrovessel invasion [MVI]+: extrahepatic metastasis [EHM]+ both negative = 124: 226: 143). Changes in hepatic function along with CP and albumin-bilirubin (ALBI) score/grade during r-TACE in Study 1, and prognosis after introducing sorafenib in Study 2 were evaluated. Results: Hepatic function worsened to CP-B in 9-14% with each TACE procedure, while 18-21% had a change of classification from ALBI-1 to ALBI-2. When the prognosis of patients with the best CP score of 5 was analyzed, those with ALBI-1 (n = 154) had a better outcome than those with ALBI-2 (n = 128) (MST 17.5 vs. 9.9 months; p = 0.01), while ALBI-1 (n = 43) patients also showed a better outcome than ALBI-2 (n = 34) patients with a CP score of 5 without MVI/EHM (MST: 17.5 vs. 10.0 months; p = 0.029). The Akaike's Information criterion for ALBI-grade (MST: grade 1 vs. 2 = 16.9 vs. 10.4 months; p = 0.001) was also better than that for CP (MST: score 5 vs. 6 = 14.4 vs. 10.5 months; p = 0.003) (3195.6 vs. 3197.5) in all 435 patients. Conclusion: The rate of patients with downgraded hepatic function during r-TACE, especially with regard to ALBI-grade, was not low. ALBI-grade was shown to be a better hepatic function assessment tool than CP in patients receiving sorafenib treatment. Strict judgment of TACE-refractory status in patients with unresectable HCC is needed to improve prognosis before downgrading the hepatic function. (C) 2017 S. Karger AG, BaselHemodynamic Changes on Cone-Beam Computed Tomography during Balloon-Occluded Transcatheter Arterial Chemoembolization Using Miriplatin for Hepatocellular Carcinoma: A Preliminary StudyToru Ishikawa; Michitaka Imai; Takashi Owaki; Hiroki Sato; Yujiro Nozawa; Tomoe Sano; Akito Iwanaga; Keiichi Seki; Terasu Honma; Toshiaki Yoshida; Masatoshi KudoDIGESTIVE DISEASES KARGER 35 (6) 598 - 601 0257-2753 2017 [Refereed] Background/Aim: Balloon-occluded transcatheter arterial chemoembolization (B-TACE) using miriplatin (MPT) is anticipated as a new strategy for hepatocellular carcinoma (HCC). This study was aimed at evaluating the hemodynamic changes with/without balloon occlusion of the hepatic artery, correlation of cone-beam CT (CBCT) pixels, and CT value after B-TACE for HCC. Methods: A total of 52 patients with HCC, who underwent B-TACE using MPT in addition to the balloon-occluded CBCT hepatic arteriography, were studied. Results: After balloon occlusion, CBCT pixel values increased in 37 lesions, whereas it decreased in 15 lesions. Intratumoral CT values after B-TACE were lower with decreased CBCT pixel values than with increased CBCT pixel values. Conclusion: Hemodynamic changes on CBCT during balloon occlusion can be used to predict the efficacy of B-TACE using MPT. (C) 2017 S. Karger AG, BaselTime to Transcatheter Arterial Chemoembolization Refractoriness in Patients with Hepatocellular Carcinoma in Kinki Criteria Stages B1 and B2Tadaaki Arizumi; Tomohiro Minami; Hirokazu Chishina; Masashi Kono; Masahiro Takita; Norihisa Yada; Satoru Hagiwara; Yasunori Minami; Hiroshi Ida; Kazuomi Ueshima; Ken Kamata; Kosuke Minaga; Yoriaki Komeda; Mamoru Takenaka; Toshiharu Sakurai; Tomohiro Watanabe; Naoshi Nishida; Masatoshi KudoDIGESTIVE DISEASES KARGER 35 (6) 589 - 597 0257-2753 2017 [Refereed] Background: Transarterial chemoembolization (TACE) is recommended for patients with hepatocellular carcinoma (HCC) in Barcelona Clinic Liver Cancer (BCLC) stage B. However, because of the heterogeneity of HCC in BCLC stage B; various subclassification systems have been proposed to predict the prognosis of patients. Previously, we proposed the Kinki criteria for precise classification of HCC cases in BCLC stage B. In this study, we compared the time to TACE refractoriness in HCC patients with Kinki criteria substages B1 and B2-HCC. Summary: Between January 2006 and December 2013, 592 HCC patients (substage B1, n = 118; substage B2, n = 170) underwent TACE. Time to progression under TACE treatment was defined as the time to untreatable progression (TTUP). TTUP and changes in liver function were analyzed in patients with substages B1 and B2-HCC. The median TTUP was 25.7 months (95% CI 19.3-37.3) and 16.4 months (95% CI 13.1-20.2) in patients with substage B1-HCC and substage B2-HCC, respectively (p = 0.0050). In patients with substage B2-HCC, median Child-Pugh scores after the first TACE session was significantly different from those after third and fifth TACE sessions (first-third, p = 0.0020; first-fifth, p = 0.0008). Key Message: TACE refractoriness occurred earlier in patients with substage B2-HCC than those with substage B1-HCC; deterioration of liver function with repeated TACE was more obvious in HCC cases with stage-B1 tumor. Shorter TTUP and impaired liver function due to repeated TACE could be responsible for the shorter survival in patients with substage B2-HCC. (C) 2017 S. Karger AG, BaselImpact of Tumor Factors on Survival in Patients with Hepatocellular Carcinoma Classified Based on Kinki Criteria Stage B2Tadaaki Arizumi; Tomohiro Minami; Hirokazu Chishina; Masashi Kono; Masahiro Takita; Norihisa Yada; Satoru Hagiwara; Yasunori Minami; Hiroshi Ida; Kazuomi Ueshima; Ken Kamata; Kosuke Minaga; Yoriaki Komeda; Mamoru Takenaka; Toshiharu Sakurai; Tomohiro Watanabe; Naoshi Nishida; Masatoshi KudoDIGESTIVE DISEASES KARGER 35 (6) 583 - 588 0257-2753 2017 [Refereed] Background: Tumors classified based on the Barcelona Clinic Liver Cancer (BCLC) stage B hepatocellular carcinoma (HCC) are heterogeneous in nature. Previously, the Kinki criterion was proposed for a more precise subclassification of tumors in BCLC-stage B. However, tumors in sub-stage B2 include various size and number of HCCs even with the Kinki criteria, which could lead to heterogeneity for overall survival (OS). In this study, we assessed how the size and number of tumors affect the OS and time to progression (TTP) in patients with Kinki criteria stage B2 tumors and treated with transarterial chemoembolization (TACE). Methods: Of 906 HCC patients treated with TACE at Kindai University Hospital, 236 patients with HCC considered as Kinki criteria stage B2 were examined. They were classified into the following 4 groups according to the maximum tumor diameter and number of tumors: B2a group, tumor size <= 6 cm and total number of tumors <= 6; B2b group, size <= 6 cm and number >6; B2c group, size >6 cm and number <= 6; and B2d group, size >6 cm and number >6. The OS and TTP of patients in each group were compared. Results: There were 131 patients (55.5%) in the B2a group, 58 (24.6%) in the B2b group, 41 (17.4%) in the B2c group, and 6 (0.03%) in the B2d group. Comparison of the survivals revealed that the median OS was 2.8 years (95% CI 2.0-3.5) in the B2a group, 2.8 years (95% CI 2.0-3.3) in the B2b group, 1.9 years (95% CI 0.8-4.0) in the B2c group, and 2.3 years (95% CI 1.2-ND [no data]) in the B2d group, respectively (p = 0.896). The median TTP in B2a, B2b, B2c, and B2d sub-substage HCC were13.2, 12.1, 13.8, and 11.5 months, respectively (p = 0.047). The median TTP in B2a + B2c sub-substage patients was longer than that in B2b + B2d sub-substage HCC patients (14.0 months and 10.4 months; p = 0.002). Conclusion: No significant differences were observed in the OS among HCC patients subclassified based on the maximum tumor diameter and tumor number in Kinki criteria stage B2. Consequently, Kinki criteria stage B2 HCC is a homogeneous subgroup in terms of OS prediction. However, shorter TTP in B2b + B2c sub-substage HCC patients than that in B2a + B2c sub-substage HCC patients suggests that different treatment strategy, such as systemic therapy with targeted agents instead of TACE, may be suitable to preserve the liver function. (C) 2017 S. Karger AG, BaselNon-hypervascular hypointense hepatic nodules during the hepatobiliary phase of Gd-EOB-DTPA-enhanced MRI as a risk factor of intrahepatic distant recurrence after radiofrequency ablation of hepatocellular carcinoma.Iwamoto T; Imai Y; Igura T; Kogita S; Sawai Y; Fukuda K; Yamaguchi Y; Matsumoto Y; Nakahara M; Morimoto O; Ohashi H; Fujita N; Kudo M; Takehara TDigest Dis 35 (6) 574 - 582 2017 [Refereed]Hepatocellular Carcinoma after Achievement of Sustained Viral Response with Daclatasvir and Asunaprevir in Patients with Chronic Hepatitis C Virus InfectionHiroshi Ida; Satoru Hagiwara; Masashi Kono; Tomohiro Minami; Hirokazu Chishina; Tadaaki Arizumi; Masahiro Takita; Norihisa Yada; Yasunori Minami; Kazuomi Ueshima; Naoshi Nishida; Masatoshi KudoDIGESTIVE DISEASES KARGER 35 (6) 565 - 573 0257-2753 2017 [Refereed] Background: Interferon-based antiviral therapies against hepatitis C virus (HCV) infection have been shown to reduce the incidence of hepatocellular carcinoma (HCC) in patients with sustained viral response (SVR). Recently, direct-acting antivirals (DAAs) have been proven to be much more effective in achieving SVR than interferon-based therapies. However, whether DAAs can efficiently prevent the occurrence of HCC after SVR remains controversial. To clarify this issue, we analyzed the clinical features of patients in whom HCC developed after achievement of SVR with DAAs for chronic HCV infection. Summary: Among patients who achieved SVR with daclatasvir and asunaprevir (n = 100), HCC developed in 17 patients (HCC group; n = 17) and did not develop in 83 patients (non-HCC group; n = 83) during a mean observation period of 15 months. A multivariate Cox proportional hazards analysis identified past history of HCC and male sex as significant risk factors for the emergence of HCC after DAAs. Sixteen cases with HCC after DAAs were in the very early or early stage (16/ 17, 94.1%), and one case was in the advanced stage (1/17, 5.9%) with portal venous tumor thrombus. Radiofrequency ablation and/or transarterial chemoembolization were performed in most cases as curative therapy (16/17, 94.1%). Key Messages: SVR by DAAs did not completely prevent the occurrence of HCC. However, even if HCC did develop after SVR, curative anticancer therapy was applicable in most cases. (C) 2017 S. Karger AG, BaselUnique Characteristics Associated with Sustained Liver Damage in Chronic Hepatitis C Patients Treated with Direct Acting AntiviralsMasashi Kono; Naoshi Nishida; Satoru Hagiwara; Tomohiro Minami; Hirokazu Chishina; Tadaaki Arizumi; Kosuke Minaga; Ken Kamata; Yoriaki Komeda; Toshiharu Sakurai; Mamoru Takenaka; Masahiro Takita; Norihisa Yada; Hiroshi Ida; Yasunori Minami; Kazuomi Ueshima; Tomohiro Watanabe; Masatoshi KudoDIGESTIVE DISEASES KARGER 35 (6) 556 - 564 0257-2753 2017 [Refereed] Background and Aims: Direct-acting antivirals (DAAs) dramatically improve the sustained virological response (SVR) of chronic hepatitis C (CHC) patients. However, continuous liver damage after SVR may be a risk of hepatocellular carcinoma (HCC). We clarified pretreatment characteristics related to sustained liver damage after SVR. Methods: A total of 286 CHC patients were treated with an interferon-free DAA regimen. Among them, 250 patients achieved SVR for 12 weeks after the end of treatment (SVR12); these individuals were classified based on a-fetoprotein (AFP) and alanine transaminase (ALT) levels posttreatment. Baseline characteristics significantly associated with AFP > 5 ng/mL and ALT level >= 20 IU/L after SVR were clarified using multivariate analyses. Results: Among the pretreatment factors examined, serum AFP values and the presence of fatty liver (FL) were significantly associated with abnormal AFP (p < 0.0001) and ALT levels 12 weeks after SVR12 (SVR24; p = 0.0109). For 126 patients who showed an increase in baseline AFP level, FL, fibrosis-4 (FIB-4) index, and albumin levels before treatment were related to abnormal AFP at SVR24 (p = 0.0005, 0.0232, and 0.0400 for FL, FIB-4 index, and albumin, respectively). Similarly, for 150 patients with abnormal baseline ALT levels, FL was associated with an ALT level = 30 IU/L after SVR (p = 0.0430). Conclusions: High FIB-4 index, low albumin level, and FL before DAA treatment were associated with a risk of sustained liver damage with AFP and ALT elevation after SVR; patients with these factors should be carefully monitored for emergence of HCC. (C) 2017 S. Karger AG, BaselHepatocarcinogenesis Is Associated with Serum Albumin Levels after Sustained Virological Responses with Interferon-Based Therapy in Patients with Hepatitis CYasuko Umehara; Satoru Hagiwara; Naoshi Nishida; Toshiharu Sakurai; Hiroshi Ida; Yasunori Minami; Masahiro Takita; Tomohiro Minami; Hirokazu Chishina; Kazuomi Ueshima; Yoriaki Komeda; Tadaaki Arizumi; Tomohiro Watanabe; Masatoshi KudoDIGESTIVE DISEASES KARGER 35 (6) 548 - 555 0257-2753 2017 [Refereed] Objective: It is a generally accepted fact that eradication of hepatitis virus C inhibits the subsequent development of hepatocellular carcinoma (HCC). On the contrary, a significant population of patients developed HCC despite sustained virological responses (SVRs) to interferon (IFN) therapy. Methods: A total of 415 patients with chronic hepatitis C, who were treated at our hospital between 2004 and 2014, were enrolled for this study. We examined the risk factors for HCC development after IFN therapy. Results: After analyzing various clinical parameters, it was concluded that a serum albumin (ALB) level <4.0 g/dL and the presence or absence of SVR achievement were risk factors for the development of HCC. When analyzing pre-and posttreatment factors, only a serum ALB level <4.0 g/dL was considered a significant risk factor. The presence or absence of liver fibrosis progression was not identified as a risk factor. Conclusions: In patients with a serum ALB level <4.0 g/dL before IFN therapy, hepatic carcinogenesis after SVR achievement need to be considered. Furthermore, the serum ALB level may be more useful than the degree of fibrosis for the prediction of HCC after SVR in chronic hepatitis C. (C) 2017 S. Karger AG, BaselComparison of Sofosbuvir Plus Ribavirin Treatment with Pegylated Interferon Plus Ribavirin Treatment for Chronic Hepatitis C Genotype 2Kayo Seo; Soo Ki Kim; Soo Ryang Kim; Aya Ohtani; Mana Kobayashi; Airi Kato; Eri Morimoto; Yuka Saijo; Ke Ih Kim; Susumu Imoto; Chi Wan Kim; Yoshihiko Yano; Masatoshi Kudo; Yoshitake HayashiDIGESTIVE DISEASES KARGER 35 (6) 541 - 547 0257-2753 2017 [Refereed] Background: Sofosbuvir plus ribavirin (RBV) therapy showed higher sustained virological response at 12 weeks after treatment (SVR12) than pegylated interferon (peg-IFN) plus RBV; however, liver function, fibrosis, and hepatocellular carcinoma markers have not been assessed so far. Summary: Patients (n = 21) receiving Sofosbuvir plus RBV and those (n = 24) receiving peg-IFN plus RBV were enrolled in this study. Changes in alanine aminotransferase (ALT) and alpha-fetoprotein (AFP) levels, platelet (PLT) counts, FIB-4, and aspartate aminotransferase-to-platelet ratio index (APRI) in both groups were assessed in patients achieving SVR12. Also, fibrosis regression was assessed using pathophysiological biomarkers, such as hyaluronic acid, bone morphogenetic protein 7 (BMP-7), and connective tissue growth factor (CTGF) in the Sofosbuvir plus RBV group. In both groups, while the reduction in ALT levels was significant that of AFP was not. Compared with the baseline, although serum PLT count at the end of treatment (EOT) was significantly higher in the Sofosbuvir plus RBV group, it was significantly lower in the peg-IFN plus RBV group. Although a significant decline in fibrosis markers such as FIB-4 and APRI was observed between the baseline and at EOT in the Sofosbuvir plus RBV group, no significant change of these markers was observed in the pegIFN plus RBV group. Moreover, BMP-7 and CTGF were significantly lower at EOT than the baseline in the Sofosbuvir plus RBV group. Key Message: The treatment with Sofosbuvir plus RBV results in not only a higher SVR, but also improves the liver function and the degree of fibrosis. (C) 2017 S. Karger AG, BaselSerum IFN-lambda 3 Levels Correlate with Serum Hepatitis C Virus RNA Levels in Symptomatic Patients with Acute Hepatitis CSusumu Imoto; Soo Ryang Kim; Keisuke Amano; Etsuko Iio; Seitetsu Yoon; Shigeya Hirohata; Yoshihiko Yano; Toru Ishikawa; Shinji Katsushima; Toshiki Komeda; Toyokazu Fukunaga; Hobyung Chung; Hiroyuki Kokuryu; Yutaka Horie; Takashi Hatae; Aya Fujinami; Soo Ki Kim; Masatoshi Kudo; Yasuhito TanakaDIGESTIVE DISEASES KARGER 35 (6) 531 - 540 0257-2753 2017 [Refereed] Background: Recent genome-wide association studies demonstrated that 2 single nucleotide polymorphisms (SNPs), upstream of the interferon-lambda (IFNL) 3 gene, are associated with the spontaneous clearance of hepatitis C virus (HCV) in symptomatic patients with acute hepatitis C (AHC). Although these 2 SNPs, rs8099917 and rs12979860, have established their significant roles in the innate immunity response to spontaneously clear HCV in patients with AHC, the detailed mechanisms of their roles remain largely unknown. Aim: This study is aimed at clarifying the factors affecting IFNL3 production and assessing the roles of IFNL3 in AHC. Materials and Methods: A total of 21 AHC patients who visited the hospital within 10 days after symptom onset were assessed. As controls, 23 healthy volunteers (HVs) were examined. Serum IFNL3 levels were quantified using an inhouse, IFNL3-specific chemiluminescence enzyme immunoassay (CLEIA) kit. Serum IFNL1, IFN-alpha, IFN-alpha, and IFN-beta induced protein-10 (IP-10) levels were assayed using commercial enzyme-linked immunosorbent assay (ELISA) kits. Results: At baseline, serum IFNL3 levels were higher in AHC patients than in HVs (p < 0.0001). The higher levels in AHC patients did not differ between patients with the rs8099917 TT genotype and those with the non-TT (TG/GG) genotype (p = 0.546). Serial measurement of serum IFNL3 levels did not predict the outcome of conventional AHC. However, serum IFNL3 levels at baseline correlated positively with the HCV RNA levels (p = 0.005). Following HCV eradication, serum IFNL3 levels reduced to within the range obtained for HVs. Baseline serum IFNL1 levels did not differ significantly between AHC patients and HVs (p = 0.284). Serum levels of IFNL1 and IFNL3 at baseline also showed no correlative power (p = 0.288). Serum IFN-alpha and IFN-beta were detected together with remarkably high serum IFNL3 levels in only one patient who progressed to acute liver failure (ALF). Conclusion: These findings indicate that serum IFNL3 levels at baseline are higher in AHC patients regardless of the rs8099917 polymorphism, and primary HCV infection triggers the production of IFNL3. As a first line of defense in the innate immune system against invading HCV, increased IFNL3 levels play an important role, but serum IFNL3 levels are not the principal determinant of the clinical course of conventional AHC. (C) 2017 S. Karger AG, BaselAbility of Cytokeratin-18 Fragments and FIB-4 Index to Diagnose Overall and Mild Fibrosis Nonalcoholic Steatohepatitis in Japanese Nonalcoholic Fatty Liver Disease PatientsNatsuko Kobayashi; Takashi Kumada; Hidenori Toyoda; Toshifumi Tada; Takanori Ito; Masayoshi Kage; Takeshi Okanoue; Masatoshi KudoDIGESTIVE DISEASES KARGER 35 (6) 521 - 530 0257-2753 2017 [Refereed] Background: Several laboratory markers used in lieu of liver biopsy are reportedly useful in the diagnosis of nonalcoholic steatohepatitis (NASH). In the present study, we investigated the diagnostic impact of various non-invasive markers for predicting NASH. Methods: A total of 229 nonalcoholic fatty liver disease (NAFLD) patients who underwent liver biopsy were enrolled for the study. The diagnostic ability of various markers to diagnose NASH from NAFLD was investigated. Results: A total of 140 patients were histologically diagnosed with NASH. Of these, 104 had degree 0-2 fibrosis (F0-2), and 36 had degree 3-4 fibrosis (F3-4). Multiple logistic regression analysis identified hyaluronic acid (HA) (OR 1.014; 95% CI 1.002-1.026; p = 0.024), FIB-4 index (OR 2.097; 95% CI 1.177-3.735; p = 0.012), and cytokeratin-18 fragments (CK-18F) (OR 1.002; 95% CI 1.001-1.002; p < 0.001) as factors independently associated with the diagnosis of NASH. The areas under the receiver operating characteristic curves (AUROCs) of HA, FIB-4 index, and CK-18F for the diagnosis of NASH were 0.77, 0.76, and 0.72, respectively. In addition, FIB-4 index (OR 1.907; 95% CI 1.063-3.419; p = 0.03) and CK-18F (OR 1.002; 95% CI 1.001-1.002; p < 0.001) could differentiate between NASH and NAFL, even when NASH patients with advanced fibrosis (F3-4) were excluded. AUROCs of FIB-4 index and CK-18F for the diagnosis of NASH with mild fibrosis (F0-2) from NAFLD were 0.70 and 0.70, respectively. Conclusions: FIB-4 index and CK-18F have good diagnostic abilities not only for NASH overall, but also for NASH with mild fibrosis. (C) 2017 S. Karger AG, BaselDiagnosis of Fibrosis and Activity by a Combined Use of Strain and Shear Wave Imaging in Patients with Liver DiseaseNorihisa Yada; Nobuhura Tamaki; Yohei Koizumi; Masashi Hirooka; Osamu Nakashima; Yoichi Hiasa; Namiki Izumi; Masatoshi KudoDIGESTIVE DISEASES KARGER 35 (6) 515 - 520 0257-2753 2017 [Refereed] Objective: Performing shear wave imaging is simple, but can be difficult when inflammation, jaundice, and congestion are present. Therefore, the correct diagnosis of liver fibrosis using shear wave imaging alone might be difficult in mild-to-moderate fibrosis cases. Strain imaging can diagnose liver fibrosis without the influence of inflammation. Therefore, the combined use of strain and shear wave imaging (combinational elastography) for cases without jaundice and congestion might be useful for evaluating fibrosis and inflammation. Methods: We enrolled consecutive patients with liver disease, without jaundice or liver congestion. Strain and shear wave imaging, blood tests, and liver biopsy were performed on the same day. The liver fibrosis index (LF index) was calculated by strain imaging; real-time tissue elastography, and the shear wave velocity (V-s) was calculated by shear wave imaging. Fibrosis index (F index) and activity index (A index) were calculated as a multiple regression equation for determining hepatic fibrosis and inflammation using histopathological diagnosis as the gold standard. The diagnostic ability of F index for fibrosis and A index for inflammation were compared using LF index and V-s. Results: The total number of enrolled cases was 388. The area under the receiver operating characteristic (AUROC) was 0.87, 0.80, 0.83, and 0.80, at diagnosis of fibrosis stage with an F index of F1 or higher, F2 or higher, F3 or higher, and F4, respectively. The AUROC was 0.94, 0.74, and 0.76 at diagnosis of activity grade with an A index of A1 or higher, A2 or higher, and A3, respectively. The diagnostic ability of F index for liver fibrosis and A index for inflammation was higher than for other conventional diagnostic values. Conclusions: The combined use of strain and shear wave imaging (combinational elastography) might increase the positive diagnosis of liver fibrosis and inflammation. (C) 2017 S. Karger AG, BaselClinicopathological Study of Autoimmune Hepatitis Cases That Were Difficult to Differentiate from Drug-Induced Liver InjuryAkemi Tsutsui; Kenichi Harada; Koichi Tsuneyama; Tomonori Senoh; Takuya Nagano; Koichi Takaguchi; Midori Ando; Satoko Nakamura; Koichi Mizobuchi; Masatoshi KudoDIGESTIVE DISEASES KARGER 35 (6) 506 - 514 0257-2753 2017 [Refereed] Aim: Acute-onset autoimmune hepatitis (AIH) histopathologically presents with features of acute hepatitis and lacks a specific diagnostic method. Also, AIH is often difficult to differentiate from drug-induced liver injury (DILI). We aimed to investigate the final clinical diagnosis of these cases, and compare the clinical, biochemical, and histological characteristics of AIH vs. DILI. Methods: We examined the Digestive Disease Week Japan 2004 (DDW-J) scale scores, AIH scores, clinical data, and pathological findings in 20 patients in whom it was difficult to differentiate autoimmune liver disease from DILI. Results: In cases with a DDW-J scale score of >= 5, there was a good correlation between the final diagnosis and DDW-J scale assessments, but in cases with a DDW-J scale score of <= 4 they did not correlate well. The scores for pathological findings, such as cobblestone hepatocellular change (p = 0.015), interface hepatitis (p = 0.012), and prominent plasma cells in portal areas (p = 0.011), were higher in the AIH group than in the DILI group. Conclusion: This study showed that DDW-J scale was useful for differentiating AIH from DILI in cases with a DDW-J scale score of >= 5. The histologic features of AIH were characterized by cobblestone hepatocellular change, interface hepatitis, and plasma cell infiltration of the portal region. (C) 2017 S. Karger AG, BaselAbdominal Ultrasound Findings of Tumor-Forming Hepatic Malignant LymphomaShogo Kitahata; Atsushi Hiraoka; Masatoshi Kudo; Taisei Murakami; Marie Ochi; Hirofumi Izumoto; Hidetaro Ueki; Miho Kaneto; Toshihiko Aibiki; Tomonari Okudaira; Hiroka Yamago; Yuji Miyamoto; Ryuichiro Iwasaki; Hideomi Tomida; Kenichiro Mori; Masato Kishida; Hideki Miyata; Eiji Tsubouchi; Masashi Hirooka; Yohei Koizumi; Tomoyuki Ninomiya; Yoichi Hiasa; Kojiro MichitakaDIGESTIVE DISEASES KARGER 35 (6) 498 - 505 0257-2753 2017 [Refereed] Aim/Background: Evaluations of abdominal ultrasonography (US) findings of primary and secondary tumor-forming hepatic malignant lymphoma (HML) have not been adequately reported. In this study, we elucidated US and contrast-enhanced US (CEUS) findings in patients with HML. Materials/Methods: From January 2006 to March 2017, 25 patients with HML were enrolled (primary 7, secondary 18), each of whom was diagnosed pathologically. They were divided into 2 groups based on tumor diameter (cutoff, 30 mm). US imaging findings were retrospectively analyzed. Results: All tumors in patients with a small HML (<30 mm in diameter, small group, n = 14) were revealed as homogeneous hypo-echoic type (100%), with penetrating sign observed in only 1 patient. Tumors in 11 patients in the small group, examined with CEUS, showed homogeneous enhancement in the early vascular phase (91%) and a washout pattern in the portal phase (100%), and they were revealed as defective in the post-vascular phase (100%). In the large group (>= 30 mm; n = 11), tumors were revealed as a heterogeneous hypo-echoic lesion in 10 (91%) and penetrating sign was observed in 8 (73%). Dilatation of the distal intrahepatic bile duct by the tumor was observed in 4 patients in the large group. In 7 large group patients examined with CEUS, imaging findings in the early vascular phase varied, with 5 (71%) showing a washout pattern in the portal phase and 5 (71%) revealed as defective in the post-vascular phase. Conclusion: We found that US imaging features of HML differ depending on the tumor diameter. (C) 2017 S. Karger AG, BaselImpact of age on survival in patients undergoing resection of hepatocellular carcinoma: report of a Japanese nationwide survey.Kaibori M; Yoshii K; Yokota I; Hasegwa K; Nagashima F; Kubo S; Kon M; Izumi N; Kadoya M; Kudo M; Kumada T; Sakamoto M; Nakashima O; Matsuyama Y; Takayama T; Kokudo NJ Hepatol in press 2017 [Refereed]Identification of a HBx mutation that enhances human hepatocarcinogenesis through the activation of the JNK and Wnt pathways.Hagiwara S; Nishida N; Sakurai T; Park AM; Komeda Y; Kitano M; Kudo MBMC Cancer in press 2017 [Refereed]Treatment response and tolerability in elderly patients with chronic hepatitis C: subgroup analysis in ReGIT-J study.Nishikawa H; Enomoto H; Saito M; Aizawa N; Tsuda Y; Higuchi K; Okazaki K; Seki K; Seki T; Kim SR; Hongo Y; Jyomura H; Nishida N; Kudo M; Osaki Y; Nishiguchi SActa Gastro-Ent Belg in press 2017 [Refereed]Second IA of the GIDEON (Global Investigation of therapeutic DEcisions in HCC and Of its treatment with sorafeNib) non-interventional studyLencioni R; Kudo M; Venook A; Ye SL; Bronowicki JP; Chen XP; Dagher L; Furuse J; Geschwind JF; Guevara LL; Papandreou C; Sanyal AJ; Takayama T; Yoon SK; Nakajima K; Lehr R; Heldner S; Marrero JALiver Int in press 2017 [Refereed]New Era in the Treatment of Chronic Liver Diseases and Liver Cancer: State-of-the Art Progress in 2017Masatoshi KudoDigest Dis 35 (6) 493 - 497 2017 [Refereed]Endoscopic treatment of tracheoesophageal fistula using the over-the-scope-clip systemShigenaga Matsui; Hiroshi Kashida; Yutaka Asakuma; Masatoshi KudoAnnals of Gastroenterology Hellenic Society of Gastroenterology 30 (5) 578 - 578 1792-7463 2017 [Refereed]A Case of Waldenstrom Macroglobulinemia with Temporary Appearance of 7S IgM Half MoleculeMayumi Imoto; Koji Yoshida; Yasuhiro Maeda; Ken-Ichi Nakae; Masatoshi Kudo; Ikunosuke Sakurabayashi; Toshiyuki Yamada; Toshinori KamisakoCLINICAL LABORATORY CLIN LAB PUBL 63 (5-6) 983 - 989 1433-6510 2017 [Refereed] Background: We encountered a rare case of Waldenstrom macroglobulinemia with temporary appearance of 7S IgM half molecule and with monoclonal proteins binding to agarose gel. Methods: The patient's serum and urine were analyzed using sodium dodecyl sulfate-polyacrylamide gel electrophoresis and immunoblotting. The N-terminal amino acid sequences of the IgM with abnormal mass (68 kDa) were determined and compared with those of known immunoglobulin. Results: The 68 kDa IgM consisted of a defective Et chain (36 kDa) and an intact kappa chain. N-terminal amino acid sequence analysis demonstrated that the defective It chain had the variable region of IgM. The agarose gel-binding ability of the IgM-w M-protein was lost after reduction or alkaline treatment of serum. Conclusions: The 7S half molecule IgM in the present case may miss a large part of the constant region of the mu chain.アミロイドーシスを疑う胃病変.松井繁長; 樫田博史; 河野匡史; 岡元寿樹; 米田頼晃; 永井知行; 朝隈 豊; 櫻井俊治; 渡邉智裕; 工藤正俊消化器内視鏡 29 (4) 756 - 758 2017 [Refereed]The Overall Survival of Patients with Hepatocellular Carcinoma Correlates with the Newly Defined Time to Progression after Transarterial ChemoembolizationTadaaki Arizumi; Kazuomi Ueshima; Mina Iwanishi; Tomohiro Minami; Hirokazu Chishina; Masashi Kono; Masahiro Takita; Norihisa Yada; Satoru Hagiwara; Yasunori Minami; Hiroshi Ida; Yoriaki Komeda; Mamoru Takenaka; Toshiharu Sakurai; Tomohiro Watanabe; Naoshi Nishida; Masatoshi KudoLIVER CANCER KARGER 6 (3) 227 - 235 2235-1795 2017 [Refereed] Aim/Background: The ultimate aim of any treatment for hepatocellular carcinoma (HCC) is to improve overall survival (OS); however, the clinical significance of time to progression (TTP) after transarterial chemoembolization (TACE) is unclear. This retrospective study examined the association between OS and the newly defined time to TACE progression (TTTP) to assess whether TTTP can be an alternative to OS in HCC patients with Barcelona Clinic Liver Cancer (BCLC) stage B. Methods: Between January 2006 and December 2013, 592 patients with HCC (BCLC B1, n = 118; BCLC B2, n = 170) underwent TACE. TTTP was then redefined as time to progression from the first image taken after TACE. The relationship between TTTP and OS was then examined based on survival time. Results: Survival analysis revealed significant differences in the OS of patients with BCLC B1 and those with BCLC B2 (median OS: 42.3 months, 95% confidence interval [CI] 34.4-50.7; and 29.3 months, 95% CI 26.1-37.6, respectively, p = 0.0348). The median TTTP values were 9.5 months (95% CI 7.0-10.9) and 5.3 months (95% CI 4.6-6.7), respectively (p = 0.0078). There was a moderate positive correlation between OS and TTTP for both B1 (R-2 = 0.6563, p = 0.0045) and B2 (R-2 = 0.6433, p = 0.0052) substages. There was also a positive correlation between OS and TTTP for the combined B1 and B2 substages (R-2 = 0.6590, p = 0.0024). Conclusions: There was a moderate correlation between the TTTP and OS of patients with HCC after TACE therapy, where the patients with short TTTP represented short OS, indicating that TTTP is an alternative parameter for survival analysis of HCC patients with BCLC stage B tumors who undergo TACE. (C) 2017 S. Karger AG, BaselImmune Checkpoint Blockade in Hepatocellular Carcinoma: 2017 UpdateM. KudoLIVER CANCER KARGER 6 (1) 1 - 12 2235-1795 2017 [Refereed]Stent migration into the abdominal cavity after EUS-guided hepaticogastrostomyKosuke Minaga; Masayuki Kitano; Yukitaka Yamashita; Yasuki Nakatani; Masatoshi KudoGASTROINTESTINAL ENDOSCOPY MOSBY-ELSEVIER 85 (1) 263 - 264 0016-5107 2017/01 [Refereed]IgG4-Related Disease and Innate ImmunityTomohiro Watanabe; Kouhei Yamashita; Masatoshi KudoIGG4-RELATED DISEASE SPRINGER INT PUBLISHING AG 401 115 - 128 0070-217X 2017 [Refereed] An increased number of clinicopathological studies on autoimmune pancreatitis, cholangitis, and sialoadenitis have led to the recognition of immunoglobulin G4-related disease (IgG4-RD) as a novel disorder, characterized by elevated levels of serum IgG4 and infiltration of IgG4-expressing plasma cells in the affected organs. Although the immunological background associated with the development of IgG4-RD remains poorly understood, recent studies have suggested involvement of the innate immune response in its pathogenesis. Peripheral blood innate immune cells, such as plasmacytoid dendritic cells and monocytes isolated from patients with IgG4-RD, promote IgG4 production by B cells. Activation of the innate immune response by microbe-and/or damage-associated molecular patterns stimulates production of type I interferon and B cell-activating factor by innate immune cells and results in IgG4 production by B cells. Elucidation of the innate immune response associated with IgG4-RD may help identify a new therapeutic target for this immune disorder.Stress Response Protein RBM3 Promotes the Development of Colitis-associated CancerToshiharu Sakurai; Hiroshi Kashida; Yoriaki Komeda; Tomoyuki Nagai; Satoru Hagiwara; Tomohiro Watanabe; Masayuki Kitano; Naoshi Nishida; Jun Fujita; Masatoshi KudoINFLAMMATORY BOWEL DISEASES LIPPINCOTT WILLIAMS & WILKINS 23 (1) 57 - 65 1078-0998 2017/01 [Refereed] Background: Colitis-associated cancer (CAC) is caused by chronic intestinal inflammation and often results from refractory inflammatory bowel disease (IBD). Stress response proteins Cirp and HSPA4 are involved in the refractory clinical course and development of CAC. RNA-binding motif protein 3 (RBM3) is induced in response to various stresses and is upregulated in several cancers. However, the role of RBM3 in CAC is unclear. Methods: We assessed RBM3 expression and function in 263 human intestinal mucosa samples from patients with IBD and in Rbm3-deficient (Rbm3(-/-)) mice. Results: Expression of RBM3 was correlated with the expression of stress response proteins Cirp, HSPA4, and HSP27 in the colonic mucosa of patients with IBD. Significant correlation was observed between the expression of RBM3 and that of Bcl-xL or stem cell markers. RBM3 expression increased and significantly correlated with R-spondin expression in the colonic mucosa of patients with refractory IBD, a condition associated with increased cancer risk, and RBM3 was overexpressed in human CACs. In the murine CAC model, Rbm3 deficiency decreased R-spondin and Bcl-xL expression and increased apoptotic cell number in the colonic mucosa, leading to reduced tumor multiplicity. Transplantation of wild-type and Rbm3(-/-) bone marrow did not alter tumor burden, indicating the importance of RBM3 in epithelial cells. Conclusions: Our findings indicated that RBM3 was required for efficient inflammatory carcinogenesis in the murine CAC model and suggested that RBM3 could be a predictive biomarker of CAC risk and a new therapeutic target for cancer prevention in patients with IBD.Immune Checkpoint Inhibition in Hepatocellular Carcinoma: Basics and Ongoing Clinical TrialsMasatoshi KudoONCOLOGY KARGER 92 50 - 62 0030-2414 2017 [Refereed] Clinical trials of antibodies targeting the immune checkpoint inhibitors programmed cell death 1 (PD-1), programmed cell death ligand 1 (PD-L1), or cytotoxic T-Iymphocyte-associated protein 4 (CTLA-4) for the treatment of advanced hepatocellular carcinoma (HCC) are ongoing. Expansion cohorts of a phase I/II trial of the anti-PD-1 antibody nivolumab in advanced HCC showed favorable results. Two phase III studies are currently ongoing: a comparison of nivolumab and sorafenib in the first-line setting for advanced HCC, and a comparison of the anti-PD-1 antibody pembrolizumab and a placebo in the second-line setting for patients with advanced HCC who progressed on sorafenib therapy. The combination of anti-PD-1/PD-L1 and anti-CTLA-4 antibodies is being evaluated in other phase I/II trials, and the results suggest that an anti-PD-1 antibody combined with locoregional therapy or other molecular targeted agents is an effective treatment strategy for HCC. Immune checkpoint inhibitors may therefore open new doors to the treatment of HCC. (C) 2017 S. Karger AG, BaselAlbumin-Bilirubin (ALBI) Grade as Part of the Evidence-Based Clinical Practice Guideline for HCC of the Japan Society of Hepatology: A Comparison with the Liver Damage and Child-Pugh ClassificationsAtsushi Hiraoka; Takashi Kumada; Masatoshi Kudo; Masashi Hirooka; Kunihiko Tsuji; Ei Itobayashi; Kazuya Kariyama; Toru Ishikawa; Kazuto Tajiri; Hironori Ochi; Toshifumi Tada; Hidenori Toyoda; Kazuhiro Nouso; Kouji Joko; Hideki Kawasaki; Yoichi Hiasa; Kojiro MichitakaLIVER CANCER KARGER 6 (3) 204 - 215 2235-1795 2017 [Refereed] Aim/Background: The purpose of this study was to evaluate the validity of 3 classifications for assessing liver function, the liver damage and Child-Pugh classifications and the newly proposed albumin-bilirubin (ALBI) grade, in order to examine the feasibility of evaluating hepatic function using ALBI grade with the hepatocellular carcinoma (HCC) treatment algorithm used in Japan. Methods: We analyzed the medical records of 3,495 Japanese HCC patients admitted from 2000 to 2015, which were comprised of 1,580 patients hospitalized in the Ehime Prefecture area and used as a training cohort (Ehime group), and 1,915 others who were used for validation (validation group). ALBI score used for grading (<= -2.60 = grade 1, greater than -2.60 to <= -1.39 = grade 2, greater than -1.39 = grade 3) as well as clinical features and prognosis (Japan Integrated Staging [JIS], modified JIS, ALBI-TNM [ALBI-T] score) were retrospectively investigated. Results: For prediction of liver damage A, the values for sensitivity and specificity, positive predictive and negative predictive values, and positive and negative likelihood ratios of ALBI-1 and Child-Pugh A were similar among the 2 groups. Akaike information criterion results showed that prognosis based on ALBI grade/ALBI-T score was better than that based on liver damage/modified JIS score and Child-Pugh/JIS score (22,291.8/21,989.4, 22,379.6/22,076.0, 22,392.1/22,075.1, respectively). The cutoff values for ALBI score for indocyanine green retention rate at 15 min (ICG-R15) < 10, < 20, and < 30% were -2.623 (area under the curve [AUC]: 0.798), -2.470 (AUC: 0.791), and -2.222 (AUC: 0.843), respectively. The distribution of ICG-R15 (< 10%, 10 to < 20%, 20 to < 30%, and >= 30%) for ALBI grade 1 was similar to that for liver damage A. There were only small differences with regard to therapeutic selection with the Japanese HCC treatment algorithm between liver damage and ALBI grade. Conclusion: ALBI grade is a useful and easy classification system for assessment of hepatic function for therapeutic decision making. (C) 2017 S. Karger AG, BaselEndoscopic ultrasound-guided gallbladder drainage for acute cholecystitis: Long-term outcomes after removal of a self-expandable metal stentKen Kamata; Mamoru Takenaka; Masayuki Kitano; Shunsuke Omoto; Takeshi Miyata; Kosuke Minaga; Kentaro Yamao; Hajime Imai; Toshiharu Sakurai; Tomohiro Watanabe; Naoshi Nishida; Masatoshi KudoWORLD JOURNAL OF GASTROENTEROLOGY BAISHIDENG PUBLISHING GROUP INC 23 (4) 661 - 667 1007-9327 2017/01 [Refereed] AIM To assess the long-term outcomes of this procedure after removal of self-expandable metal stent (SEMS). The efficacy and safety of endoscopic ultrasound-guided gallbladder drainage (EUS-GBD) with SEMS were also assessed. METHODS Between January 2010 and April 2015, 12 patients with acute calculous cholecystitis, who were deemed unsuitable for cholecystectomy, underwent EUS-GBD with a SEMS. EUS-GBD was performed under the guidance of EUS and fluoroscopy, by puncturing the gallbladder with a needle, inserting a guidewire, dilating the puncture hole, and placing a SEMS. The SEMS was removed and/or replaced with a 7-Fr plastic pigtail stent after cholecystitis improved. The technical and clinical success rates, adverse event rate, and recurrence rate were all measured. RESULTS The rates of technical success, clinical success, and adverse events were 100%, 100%, and 0%, respectively. After cholecystitis improved, the SEMS was removed without replacement in eight patients, whereas it was replaced with a 7-Fr pigtail stent in four patients. Recurrence was seen in one patient (8.3%) who did not receive a replacement pigtail stent. The median follow-up period after EUS-GBD was 304 d (78-1492). CONCLUSION EUS-GBD with a SEMS is a possible alternative treatment for acute cholecystitis. Long-term outcomes after removal of the SEMS were excellent. Removal of the SEMS at 4-wk after SEMS placement and improvement of symptoms might avoid migration of the stent and recurrence of cholecystitis due to food impaction.Early diagnosis of pancreatic cancer by EUSKAMATA Ken; TAKENAKA Mamoru; KITANO Masayuki; OMOTO Shunsuke; MINAGA Kosuke; MIYATA Takeshi; YAMAO Kentaro; IMAI Hajime; KUDO MasatoshiSuizo Japan Pancreas Society 32 (1) 38 - 44 0913-0071 2017 [Refereed] The role of endoscopic ultrasonography (EUS) in the diagnosis of early pancreatic cancer is expanding. In cases with risk factors or in IPMN assessment or follow up, there have been several reports regarding the early diagnosis of pancreatic cancer using EUS. Currently, with the development of EUS equipment, EUS-guided fine needle aspiration has become more common and with advances in ERCP related procedures, pancreatic cancer detection and its qualitative diagnosis is improving. In this report, we would like to refer to the detection of pancreatic cancer, especially in small pancreatic cancer with EUS including diagnosis with contrast enhanced harmonic EUS.IPMN経過観察におけるEUSの有用性. 特集「今IPMNをどう診るか」鎌田 研; 竹中 完; 北野雅之; 工藤正俊肝胆膵 74 583 - 586 2017 [Refereed]Albumin-Bilirubin Grade and Hepatocellular Carcinoma Treatment AlgorithmMasatoshi kudoLIVER CANCER KARGER 6 (3) 185 - 188 2235-1795 2017 [Refereed][Invited]A New Era of Systemic Therapy for Hepatocellular Carcinoma with Regorafenib and LenvatinibM. KudoLIVER CANCER KARGER 6 (3) 177 - 184 2235-1795 2017 [Refereed][Invited]CD68-Positive Cells in Hepatic AngiomyolipomaHitoshi Tochio; Eriko Tamaki; Yukihiro Imai; Nobuhiro Iwasaki; Kazushi Minowa; Hobyung Chung; Yoshiki Suginoshita; Tetsurou Inokuma; Masatoshi KudoONCOLOGY KARGER 92 35 - 39 0030-2414 2017 [Refereed] Four resected specimens of hepatic angiomyolipoma in which uptake of Sonazoid was observed in the postvascular phase of Sonazoid-enhanced ultrasonography were analyzed. Macrophage localization in the tumor was revealed pathologically by immunohistochemical staining for CD68. CD68-positive cells were observed in the tumor in all cases. The density of CD68-positive cells was 100/mm(2), and the ratio of CD68-positive cell density in the tumor to that in the surrounding parenchyma was 32-171%. These results suggested that the uptake of the contrast agent Sonazoid was related to the density of CD68-positive cells. (C) 2016 S. Karger AG, Baselimmunological Microenvironment of Hepatocellular Carcinoma and Its Clinical ImplicationNaoshi Nishida; Masatoshi KudoONCOLOGY KARGER 92 40 - 49 0030-2414 2017 [Refereed] Despite recent advances in the treatment of hepatocellular carcinoma (HCC), the prognosis of patients with advanced stage of disease remains unfavorable. Several immune therapies have been applied to HCC, and their responses have not been satisfactory. The immune response to cancer is determined by the balance between the antigenicity of the tumor and the microenvironment of cancer tissues. Generally, accumulated genetic mutations are observed in HCC, which may lead to increased neoantigens on cancer cells with high antigenicity. However, cancer cells may evade the immune system because of alterations in molecules and cellular pathways involved in antigen processing and presentation. In addition, hypoxia in tissue induces several cytokines, chemokines, and immunosuppressive molecules from HCC cells and stromal cells. These cells also produce cytokines that attract regulatory T cells infiltrating tumor tissues and contribute to establishing an immunosuppressive microenvironment. Some cancers show a good response to immune checkpoint therapy. However, prolonged stabilization of disease for this treatment is reportedly 12-41% in patients with advanced cancer. Therefore, immunosuppressive forces in the microenvironment of HCC may cause resistance to immune therapy, and modification of the tumor microenvironment may restore normal anticancer immunity. In this review, we focus on the immunological microenvironment of HCC tissues and discuss how the immunosuppressive environment of HCC should be modulated to achieve a favorable response to immune therapy, such as immune checkpoint therapy, in HCC. (C) 2016 S. Karger AG, BaselInfluence of Liver Inflammation on Liver Stiffness Measurement in Patients with Autoimmune Hepatitis Evaluation by Combinational ElastographyNorihisa Yada; Toshiharu Sakurai; Tomohiro Minami; Tadaaki Arizumi; Masahiro Takita; Satoru Hagiwara; Hiroshi Ida; Kazuomi Ueshima; Naoshi Nishida; Masatoshi KudoONCOLOGY KARGER 92 10 - 15 0030-2414 2017 [Refereed] Objective: In order to evaluate the influence of liver inflammation on liver stiffness measurement (LSM) by the simultaneous use of shear wave and strain imaging (combinational elastography), shear wave and strain imaging were compared before and after initial therapy for autoimmune hepatitis (AIH). Methods: Nine AIH patients initially treated with steroid were enrolled. Transient elastography and real-time tissue elastography were performed just before and 1 month after the start of initial steroid treatment. Blood samples, LSM, and the liver fibrosis index (LFI) were compared. Results: Aspartate aminotransferase (p = 0.002) and alanine aminotransferase (ALT) (p = 0.015) were significantly decreased after initial treatment. The LSM was 15.5 +/- 9.6 kPa at baseline, decreasing to 7.2 +/- 2.3 kPa after initial treatment p = 0.034). The LFI was 1.67 +/- 0.67 at baseline and 1.61 +/- 0.66 after initial treatment; no significant change in LFI was recognized (p = 0.842). Between Delta ALT and Delta LSM, a significant regression equation could be calculated as follows: Delta ALT = -0.55 + 0.654 x Delta LSM. Conclusions: Combinational elastography was useful in evaluating not only the degree of liver fibrosis, but also the degree of liver inflammation in AIH. (C) 2017 S. Karger AG, BaselA New Horizon Liver DiseaseMasatoshi KudoONCOLOGY KARGER 92 1 - 2 0030-2414 2017 [Refereed]Outcome of Combination Therapy with Sofosbuvir and Ledipasvir for Chronic Type C Liver DiseaseSatoru Hagiwara; Naoshi Nishida; Tomohiro Watanabe; Toshiharu Sakurai; Hiroshi Ida; Yasunori Minami; Masahiro Takita; Tomohiro Minami; Mina Iwanishi; Hirokazu Chishina; Kazuomi Ueshima; Yoriaki Komeda; Tadaaki Arizumi; Masatoshi KudoONCOLOGY KARGER 92 3 - 9 0030-2414 2017 [Refereed] Introduction: Recently, the treatment of chronic hepatitis C has markedly advanced. A phase III clinical study of combination therapy with sofosbuvir (SOF) and ledipasvir (LDV) was conducted in Japan, and the additive therapeutic effects were reported. In this study, we report the results of treatment in our hospital. Methods: Of 147 patients with chronic type C liver disease who had consulted our hospital since September 2015 and received SOF/LDV therapy, in 91 subjects a sustained virological response of 12 weeks (SVR12) could be evaluated. Results: In all 91 patients, end treatment response was achieved. Subsequently, recrudescence was noted in 1 before the completion of treatment (week 12); an SVR12 was achieved in 90 patients (99%). The following adverse reactions were observed in 3 patients (3.3%): bradycardia, paroxysmal atrial fibrillation, and heart failure with QT prolongation, which were associated with heart disease. Conclusion: A favorable SVR was achieved by SOF/LDV therapy even in elderly patients, those with liver cirrhosis, or those having undergone radical treatment of liver cancer. Furthermore, a high tolerance was demonstrated, but adverse reactions associated with the heart may appear in patients with heart disease as an underlying disease; strict management during treatment is necessary. (C) 2016 S. KargerAG, BaselMalignant Transformation of Hepatocellular AdenomaWing Yee Kwok; Satoru Hagiwara; Naoshi Nishida; Tomohiro Watanabe; Toshiharu Sakurai; Hiroshi Lda; Yasunori Minami; Masahiro Takita; Tomohiro Minami; Mina Lwanishi; Hirokazu Chishina; Masashi Kono; Kazuomi Ueshima; Yoriaki Komeda; Tadaaki Arizumi; Eisuke Enoki; Takuya Nakai; Tsutomu Kumabe; Osamu Nakashima; Fukuo Kondo; Masatoshi KudoONCOLOGY KARGER 92 16 - 28 0030-2414 2017 [Refereed] The patient was a 20-year-old male in whom a hepatic hyper vascular mass accompanied by intratumoral hemorrhage was detected on examination for epigastric pain. Based on the enlargement of the mass and diagnostic imaging, hepatocellular adenoma (HCA) was suspected and hepatectomy was performed. The lesion was diagnosed as malignant transformation of P-catenin-activated HCA. There are only few reports of cases with malignant transformation of HCA in Japan; it is necessary to accumulate cases to investigate it. (C) 2016 S. Karger AG, BaselContrast-Enhanced Tissue Harmonic Imaging versus Phase Inversion Harmonic Sonographic Imaging for the Delineation of Hepatocellular CarcinomasMasashi Kono; Yasunori Minami; Mina Iwanishi; Tomohiro Minami; Hirokazu Chishina; Tadaaki Arizumi; Yoriaki Komeda; Toshiharu Sakurai; Masahiro Takita; Norihisa Yada; Hiroshi Ida; Satoru Hagiwara; Kazuomi Ueshima; Naoshi Nishida; Masatoshi KudoONCOLOGY KARGER 92 29 - 34 0030-2414 2017 [Refereed] Objective: To compare contrast tissue harmonic imaging (THI) with low mechanical index (MI) and conventional contrast harmonic imaging (CHI) with respect to lesion visibility of hepatocellular carcinoma (HCC). Methods: One hundred and twenty-five patients (84 men and 41 women, age range 39-94 years, mean age 74 years) with 100 naive HCCs and 30 lesions after radiofrequency ablation (RFA) for HCC were evaluated. One hundred and four patients had liver cirrhosis of Child-Pugh class A, and the remaining 21 had Child-Pugh class B cirrhosis. The lesion conspicuity and intratumoral echogenicity during the postvascular phase were compared using conventional CHI and contrast THI with low MI. Results:The MI values ranged from 0.20 to 0.30 on conventional CHI and from 0.30 to 0.35 on contrast THI. Regarding HCC lesion conspicuity, contrast THI with low MI was clearer in 79 lesions (60.8%), equal in 34 lesions (26.2%), and less clear in 17 lesions (13.1%) when compared with conventional CHI. The lesion conspicuity with contrast THI was significantly better than that with conventional CHI (p < 0.01). All of the postablative lesions were well delineated in patients who received RFA. Conclusion: Low-MI contrast THI was superior to conventional CHI with respect to lesion visibility of HCCs and might offer good imaging for the guiding of RFA. (C) 2016 S. Karger AG, BaselDiagnosis of Hepatocellular Carcinoma with Non-Invasive Imaging: a Plea for Worldwide Adoption of Standard and Precise Terminology for Describing Enhancement CriteriaFabio Piscaglia; Masatoshi Kudo; Kwang-Hyub Han; Claude SirlinULTRASCHALL IN DER MEDIZIN GEORG THIEME VERLAG KG 38 (1) 9 - 11 0172-4614 2017/01 [Refereed]Stress Response Protein RBM3 Promotes the Development of Colitis-associated CancerToshiharu Sakurai; Hiroshi Kashida; Yoriaki Komeda; Tomoyuki Nagai; Satoru Hagiwara; Tomohiro Watanabe; Masayuki Kitano; Naoshi Nishida; Jun Fujita; Masatoshi KudoINFLAMMATORY BOWEL DISEASES LIPPINCOTT WILLIAMS & WILKINS 23 (1) 57 - 65 1078-0998 2017/01 [Refereed] Background: Colitis-associated cancer (CAC) is caused by chronic intestinal inflammation and often results from refractory inflammatory bowel disease (IBD). Stress response proteins Cirp and HSPA4 are involved in the refractory clinical course and development of CAC. RNA-binding motif protein 3 (RBM3) is induced in response to various stresses and is upregulated in several cancers. However, the role of RBM3 in CAC is unclear. Methods: We assessed RBM3 expression and function in 263 human intestinal mucosa samples from patients with IBD and in Rbm3-deficient (Rbm3(-/-)) mice. Results: Expression of RBM3 was correlated with the expression of stress response proteins Cirp, HSPA4, and HSP27 in the colonic mucosa of patients with IBD. Significant correlation was observed between the expression of RBM3 and that of Bcl-xL or stem cell markers. RBM3 expression increased and significantly correlated with R-spondin expression in the colonic mucosa of patients with refractory IBD, a condition associated with increased cancer risk, and RBM3 was overexpressed in human CACs. In the murine CAC model, Rbm3 deficiency decreased R-spondin and Bcl-xL expression and increased apoptotic cell number in the colonic mucosa, leading to reduced tumor multiplicity. Transplantation of wild-type and Rbm3(-/-) bone marrow did not alter tumor burden, indicating the importance of RBM3 in epithelial cells. Conclusions: Our findings indicated that RBM3 was required for efficient inflammatory carcinogenesis in the murine CAC model and suggested that RBM3 could be a predictive biomarker of CAC risk and a new therapeutic target for cancer prevention in patients with IBD.Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trialJordi Bruix; Shukui Qin; Philippe Merle; Alessandro Granito; Yi-Hsiang Huang; Gyrogy Bodoky; Marc Pracht; Osamu Yokosuka; Olivier Rosmorduc; Valeriy Breder; Rene Gerolami; Gianluca Masi; Paul J. Ross; Tianqiang Song; Jean-Pierre Bronowicki; Isabelle Ollivier-Hourmand; Masatoshi Kudo; Ann-Lii Cheng; Josep M. Llovet; Richard S. Finn; Marie-Aude LeBerre; Annette Baumhauer; Gerold Meinhardt; Guohong HanLANCET ELSEVIER SCIENCE INC 389 (10064) 56 - 66 0140-6736 2017/01 [Refereed] Background There are no systemic treatments for patients with hepatocellular carcinoma (HCC) whose disease progresses during sorafenib treatment. We aimed to assess the efficacy and safety of regorafenib in patients with HCC who have progressed during sorafenib treatment. Methods In this randomised, double-blind, parallel-group, phase 3 trial done at 152 sites in 21 countries, adults with HCC who tolerated sorafenib (>= 400 mg/day for >= 20 of last 28 days of treatment), progressed on sorafenib, and had Child-Pugh A liver function were enrolled. Participants were randomly assigned (2: 1) by a computer-generated randomisation list and interactive voice response system and stratified by geographical region, Eastern Cooperative Oncology Group performance status, macrovascular invasion, extrahepatic disease, and a-fetoprotein level to best supportive care plus oral regorafenib 160 mg or placebo once daily during weeks 1-3 of each 4-week cycle. Investigators, patients, and the funder were masked to treatment assignment. The primary endpoint was overall survival (defined as time from randomisation to death due to any cause) and analysed by intention to treat. This trial is registered with ClinicalTrials.gov, number NCT01774344. Findings Between May 14, 2013, and Dec 31, 2015, 843 patients were screened, of whom 573 were enrolled and randomised (379 to regorafenib and 194 to placebo; population for efficacy analyses), and 567 initiated treatment (374 received regorafenib and 193 received placebo; population for safety analyses). Regorafenib improved overall survival with a hazard ratio of 0.63 (95% CI 0.50-0.79; one-sided p<0.0001); median survival was 10.6 months (95% CI 9.1-12.1) for regorafenib versus 7.8 months (6.3-8.8) for placebo. Adverse events were reported in all regorafenib recipients (374 [100%] of 374) and 179 (93%) of 193 placebo recipients. The most common clinically relevant grade 3 or 4 treatment-emergent events were hypertension (57 patients [15%] in the regorafenib group vs nine patients [5%] in the placebo group), hand-foot skin reaction (47 patients [13%] vs one [1%]), fatigue (34 patients [9%] vs nine patients [5%]), and diarrhoea (12 patients [3%] vs no patients). Of the 88 deaths (grade 5 adverse events) reported during the study (50 patients [13%] assigned to regorafenib and 38 [20%] assigned to placebo), seven (2%) were considered by the investigator to be related to study drug in the regorafenib group and two (1%) in the placebo group, including two patients (1%) with hepatic failure in the placebo group. Interpretation Regorafenib is the only systemic treatment shown to provide survival benefit in HCC patients progressing on sorafenib treatment. Future trials should explore combinations of regorafenib with other systemic agents and third-line treatments for patients who fail or who do not tolerate the sequence of sorafenib and regorafenib. Funding Bayer.Removal of diminutive colorectal polyps: A prospective randomized clinical trial between cold snare polypectomy and hot forceps biopsyYoriaki Komeda; Hiroshi Kashida; Toshiharu Sakurai; George Tribonias; Kazuki Okamoto; Masashi Kono; Mitsunari Yamada; Teppei Adachi; Hiromasa Mine; Tomoyuki Nagai; Yutaka Asakuma; Satoru Hagiwara; Shigenaga Matsui; Tomohiro Watanabe; Masayuki Kitano; Takaaki Chikugo; Yasutaka Chiba; Masatoshi KudoWORLD JOURNAL OF GASTROENTEROLOGY BAISHIDENG PUBLISHING GROUP INC 23 (2) 328 - 335 1007-9327 2017/01 [Refereed] AIM To compare the efficacy and safety of cold snare polypectomy (CSP) and hot forceps biopsy (HFB) for diminutive colorectal polyps. METHODS This prospective, randomized single-center clinical trial included consecutive patients >= 20 years of age with diminutive colorectal polyps 3-5 mm from December 2014 to October 2015. The primary outcome measures were en-bloc resection (endoscopic evaluation) and complete resection rates (pathological evaluation). The secondary outcome measures were the immediate bleeding or immediate perforation rate after polypectomy, delayed bleeding or delayed perforation rate after polypectomy, use of clipping for bleeding or perforation, and polyp retrieval rate. Prophylactic clipping after polyp removal wasn't routinely performed. RESULTS Two hundred eight patients were randomized into the CSP (102), HFB (106) and 283 polyps were evaluated (CSP: 148, HFB: 135). The en-bloc resection rate was significantly higher with CSP than with HFB [99.3% (147/148) vs 80.0% (108/135), P < 0.0001]. The complete resection rate was significantly higher with CSP than with HFB [80.4% (119/148) vs 47.4% (64/135), P < 0.0001]. The immediate bleeding rate was similar between the groups [8.6% (13/148) vs 8.1% (11/135), P = 1.000], and endoscopic hemostasis with hemoclips was successful in all cases. No cases of perforation or delayed bleeding occurred. The rate of severe tissue injury to the pathological specimen was higher HFB than CSP [52.6% (71/135) vs 1.3% (2/148), P < 0.0001]. Polyp retrieval failure was encountered CSP (7), HFB (2). CONCLUSION CSP is more effective than HFB for resecting diminutive polyps. Further long-term follow-up study is required.MicroRNAs for the Prediction of Early Response to Sorafenib Treatment in human Hepatocellular CarcinomaNaoshi Nishida; Tadaaki Arizumi; Satoru Hagiwara; Hiroshi Ida; Toshiharu Sakurai; Masatoshi KudoLIVER CANCER KARGER 6 (2) 113 - 125 2235-1795 2017 [Refereed] Background: Several studies suggest the role of circulating microRNAs (miRNAs) as biomarkers of hepatocellular carcinoma (HCC). However, the serum miRNA profile associated with the response to sorafenib remains to be elucidated. The aim of this study was to clarify the specific miRNAs in serum that could predict the early response of HCC to sorafenib treatment. Summary: Analyzing the sera from 16 HCC patients, we selected five miRNAs that showed differences in serum levels between patients with and without tumor responses among 179 known secretory miRNAs by using locked nucleic acid probe -based quantitative PCR. Through further analysis using a validation cohort that included 53 HCC patients who underwent sorafenib treatment and 8 healthy control subjects, we found that miR-181a-5p and miR-3395p showed significant differences in serum levels among patients with partial response (PR), stable disease (SD), and progressive disease (PD), where PR patients showed the highest and PD the lowest levels. We also analyzed the factors associated with disease control (DC; PR or SD) 3 months after the initiation of sorafenib treatment; patients with DC showed a significantly higher level of serum miR-181a-5p than non -DC patients or healthy control subjects (p = 0.0349 and 0.0180 for DC vs. non -DC and control vs. non -DC by Tukey-Kramer test, respectively). We further conducted multivariate analysis among HCC patients with Barcelona Clinic Liver Cancer stage C using extrahepatic metastasis, serum decarboxyprothrombin, and miR-181a-5p levels as covariables; serum miR-181a-5p was the only independent factor for achieving DC (p = 0.0092, odds ratio 0.139, and 95% confidence interval 0.011-0.658). In addition, miR-181a-5p level was also the only independent factor affecting overall survival (p = 0.0194, hazard ratio 0.267, and 95% confidence interval 0.070-0.818). Key Messages: A high serum level of miR-181a-5p before treatment is associated with DC after the initiation of sorafenib. (C) 2016 S. Karger AG, BaselMolecular Targeted Agents for Hepatocellular Carcinoma: Current Status and Future PerspectivesM. KudoLIVER CANCER KARGER 6 (2) 101 - 112 2235-1795 2017 [Refereed][Invited]Hepatocellular Carcinoma: Therapeutic Guidelines and Medical TreatmentMasatoshi Kudo; Franco Trevisani; Ghassan K. Abou-Alfa; Lorenza RimassaLIVER CANCER KARGER 6 (1) 16 - 26 2235-1795 2017 [Refereed] Western and Eastern perspectives on therapeutic guidelines for hepatocellular carcinoma (HCC) have many commonalities but may also differ in certain aspects, as described in this article. In view of the limited therapeutic options for advanced HCC, evidence-based therapies are few, and thus there is a dependence on consensus-based guidelines. This article focuses on the Italian Association for the Study of the Liver guidelines and the Japanese approaches to therapy, while drawing attention to certain controversies from other academic bodies where applicable and appropriate. Copyright (C) 2016 S. Karger AG, BaselObservational registry of sorafenib use in clinical practice across Child-Pugh subgroups: The GIDEON studyJorge A. Marrero; Masatoshi Kudo; Alan P. Venook; Sheng-Long Ye; Jean-Pierre Bronowicki; Xiao-Ping Chen; Lucy Dagher; Junji Furuse; Jean-Francois H. Geschwind; Laura Ladron de Guevara; Christos Papandreou; Tadatoshi Takayama; Arun J. Sanyal; Seung Kew Yoon; Keiko Nakajima; Robert Lehr; Stephanie Heldner; Riccardo LencioniJOURNAL OF HEPATOLOGY ELSEVIER SCIENCE BV 65 (6) 1140 - 1147 0168-8278 2016/12 [Refereed] Background & Aims: GIDEON (Global Investigation of therapeutic DEcisions in hepatocellular carcinoma and Of its treatment with sorafeNib) is a prospective, observational registry study evaluating the safety of sorafenib and treatment practices in hepatocellular carcinoma patients. This large global database allowed for assessment of the use and tolerability of sorafenib in patients with liver dysfunction. Methods: Baseline characteristics and medical/treatment history were collected in patients for whom a decision to treat with sorafenib had been made. Adverse event, dosing, and outcomes data were collected during follow-up. Results: In the overall safety population (n = 3202), 1968 patients (61%) had Child-Pugh A status and 666 (21%) had Child-Pugh B. The majority of Child-Pugh A (72%) and Child-Pugh B (70%) patients received an initial sorafenib dose of 800 mg, consistent with the label, and dose reduction rates were 40% and 29%, respectively. The type and incidence of adverse events were generally consistent across Child-Pugh subgroups. The incidence of drug-related adverse events leading to discontinuation was similar between Child-Pugh A and Child-Pugh B patients (17% and 21%). In the intent-to-treat population (n = 3213), median overall survival (months [95% confidence interval]) was longer in Child-Pugh A patients (13.6 [12.8-14.7]) compared with Child-Pugh B patients (5.2 [4.6-6.3]). Conclusions: In clinical practice, the safety profile of sorafenib appeared to be consistent across Child-Pugh A and Child-Pugh B patients. Findings suggest sorafenib may be safely used in some Child-Pugh B patients and indicate the importance of careful patient evaluation when making treatment decisions. Lay summary: The GIDEON (Global Investigation of therapeutic DEcisions in hepatocellular carcinoma and Of its treatment with sorafeNib) study is a large prospective registry of patients with liver cancer who were treated with sorafenib. The aims were to evaluate the safety and tolerability of sorafenib among those in which the liver was not functioning properly. The study showed that the safety profile of sorafenib was consistent across patients with preserved liver function and those in which the liver was not functioning properly, and therefore, suggesting that sorafenib may be a valid treatment for some patients with liver impairment. (C) 2016 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.Safety and efficacy of sorafenib in Japanese patients with hepatocellular carcinoma in clinical practice: a subgroup analysis of GIDEONMasatoshi Kudo; Masafumi Ikeda; Tadatoshi Takayama; Kazushi Numata; Namiki Izumi; Junji Furuse; Takuji Okusaka; Masumi Kadoya; Satoshi Yamashita; Yuichiro Ito; Norihiro KokudoJOURNAL OF GASTROENTEROLOGY SPRINGER JAPAN KK 51 (12) 1150 - 1160 0944-1174 2016/12 [Refereed] GIDEON was a prospective, global, non-interventional study evaluating the safety of sorafenib in patients with unresectable hepatocellular carcinoma in real-world practice. The aim of this subgroup analysis was to assess the safety and efficacy of sorafenib as used by Japanese patients. In Japan, 508 patients were valid for safety analysis. Efficacy and safety were evaluated by the Child-Pugh score. The number of patients with Child-Pugh A and B was 432 (85.0 %) and 58 (11.4 %), respectively. The median overall survival time and time to progression in patients with Child-Pugh A and Child-Pugh B were 17.4 and 4.9 months, 3.7 and 2.3 months, respectively. The most common drug-related adverse events (AEs) included hand-foot skin reaction (47.8 %), diarrhea (35.8 %) and hypertension (24.2 %). The incidences of all or drug-related AEs were similar between patients with Child-Pugh A and B. However, all or drug-related serious AEs, AEs resulting in permanent discontinuation of sorafenib and deaths were observed more frequently in patients with Child-Pugh B compared with Child-Pugh A. Duration of treatment tended to be shorter as the Child-Pugh score worsened. Sorafenib was well tolerated by Japanese HCC patients in clinical settings. Patients with Child-Pugh B had shorter duration of treatment and higher incidence of SAEs. It is important to carefully evaluate patients' conditions and assess the benefit and risk before making a decision to treat patients with sorafenib.Removal of diminutive colorectal polyps: A prospective randomized comparative study between cold snare polypectomy (CSP) and hot forceps biopsy (HFB)Yoriaki Komeda; Hiroshi Kashida; Toshiharu Sakurai; Teppei Adachi; Hiromasa Mine; Tomoyuki Nagai; Yoshihisa Okazaki; Yutaka Asakuma; Shigenaga Matsui; Masatoshi KudoJOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY WILEY-BLACKWELL 31 268 - 268 0815-9319 2016/11 [Refereed]A validation study of the Japan NBI Expert Team (JNET) of NBI magnifying endoscopy classification for the treatment of colorectal tumorsYoriaki Komeda; Hiroshi Kashida; Toshiharu Sakurai; Yutaka Asakuma; Tomoyuki Nagai; Hiromasa Mine; Teppei Adachi; Shigenaga Matsui; Tomohiro Watanabe; Masatoshi KudoJOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY WILEY-BLACKWELL 31 307 - 308 0815-9319 2016/11 [Refereed]The oncoprotein gankyrin promotes the development of colitis-associated cancer by mediating STAT3 and ERK activationToshiharu Sakurai; Hiroshi Kashida; Yoriaki Komeda; Tomoyuki Nagai; Shigenaga Matsui; Masatoshi KudoJOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY WILEY-BLACKWELL 31 136 - 136 0815-9319 2016/11 [Refereed]The usefulness of computed tomography immediately after ERCP for early detection of post ERCP pancreatitisTakeshi Miyata; Mamoru Takenaka; Masayuki Kitano; Tomohiko Matsuda; Syunsuke Omoto; Ken Kamata; Kosuke Minaga; Kentaro Yamao; Hajime Imai; Masatoshi KudoJOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY WILEY-BLACKWELL 31 248 - 248 0815-9319 2016/11 [Refereed]Second-line ramucirumab therapy for advanced hepatocellular carcinoma (REACH): an East Asian and non-East Asian subgroup analysisJoon Oh Park; Baek-Yeol Ryoo; Chia-Jui Yen; Masatoshi Kudo; Ling Yang; Paolo B. Abada; Rebecca Cheng; Mauro Orlando; Andrew X. Zhu; Takuji OkusakaONCOTARGET IMPACT JOURNALS LLC 7 (46) 75482 - 75491 1949-2553 2016/11 [Refereed] Purpose: REACH investigated second-line ramucirumab therapy for advanced hepatocellular carcinoma. Results: Median overall survival was 8.2 months for ramucirumab and 6.9 months for placebo (HR, 0.835; 95% CI, 0.634-1.100; p = 0.2046) for East Asians, and 10.1 months for ramucirumab and 8.0 months for placebo (HR, 0.895; 95% CI, 0.690-1.161; p = 0.4023) for non-East Asians. Median overall survival in patients with baseline alpha-fetoprotein >= 400 ng/mL was 7.8 months for ramucirumab and 4.2 months for placebo (HR, 0.749; 95% CI, 0.519-1.082; p = 0.1213) for East Asians (n = 139), and 8.2 months for ramucirumab and 4.5 months for placebo (HR, 0.579; 95% CI, 0.371-0.904; p = 0.0149) for non-East Asians (n = 111). The most common grade >= 3 treatment-emergent adverse events in East Asians and non-East Asians included hypertension and malignant neoplasm progression. Materials and methods: A post-hoc analysis of East Asians (N = 252) and non-East Asians (N = 313) in the intent-to-treat population was performed. Conclusions: In East Asians and non-East Asians, ramucirumab did not significantly prolong overall survival. In patients with baseline alpha-fetoprotein >= 400 ng/mL, a potentially larger survival benefit was observed in both subgroups. Safety for East Asians was similar to non-East Asians.Factors predicting through-the-scope gastroduodenal stenting outcomes in patients with gastric outlet obstruction: a large multicenter retrospective study in West JapanKentaro Yamao; Masayuki Kitano; Takahisa Kayahara; Etsuji Ishida; Hiroshi Yamamoto; Kosuke Minaga; Yukitaka Yamashita; Jun Nakajima; Masanori Asada; Yoshihiro Okabe; Yukio Osaki; Yasutaka Chiba; Hajime Imai; Masatoshi KudoGASTROINTESTINAL ENDOSCOPY MOSBY-ELSEVIER 84 (5) 757 - + 0016-5107 2016/11 [Refereed] Background and Aims: Endoscopic gastroduodenal stenting for malignant gastric outlet obstruction recently has become more effective, but the factors that predict gastroduodenal stenting outcomes are poorly defined. This multicenter retrospective cohort study evaluated the clinical outcomes of gastroduodenal stenting in malignant gastroduodenal obstruction and identified factors predicting clinical ineffectiveness, stent dysfunction, and adverse events. Methods: All consecutive patients with malignant gastroduodenal obstruction who underwent through-the-scope gastroduodenal stenting from 2009 to 2014 at 4 tertiary-care medical centers were identified. Clinically ineffective stenting was defined as symptom recurrence and a gastric outlet obstruction scoring system (GOOSS) score < 2. Results: Of the 278 patients (mean age +/- standard deviation [SD] 71.7 +/- 11.4 years), 121 (43.5%) and 87 (31.3%) had pancreatic and gastric cancer, respectively. Technical success was achieved in 277 patients (99.6%). GOOSS scores rose from 0.5 +/- 0.6 to 2.6 +/- 0.8. Stenting was ineffective in 32 patients (12.6%). Stent dysfunction that caused symptom recurrence during follow-up developed in 46 patients (16.6%). Adverse events occurred in 49 patients (17.7%). Three or more stenosis sites (odds ratio [OR] = 6.11; P < .01) and Karnofsky performance scores <= 50 (OR Z 6.63; P < .01) predicted clinical ineffectiveness. Karnofsky performance scores <= 50 predicted stent dysfunction (hazard ratio [HR] = 3.63; P < .01). Bile duct stenosis (HR = 9.55; P =. 02) and liver metastasis (HR = 9.42; P <.01) predicted stent overgrowth. Covered stent predicted stent migration (HR = 12.63; P < .01). Deployment of 2 stents predicted perforation (HR Z 854.88; P < .01). Conclusions: Through-the-scope gastroduodenal stenting tended to be ineffective in patients with poor performance status and long stenosis sites. Stent dysfunction occurred more frequently in patients with poorer performance status. Deployment of 2 stents was a risk factor for perforation. Identification of these risk variables may help yield better gastroduodenal stenting outcomes.Survival benefit of liver resection for hepatocellular carcinoma associated with portal vein invasionTakashi Kokudo; Kiyoshi Hasegawa; Yutaka Matsuyama; Tadatoshi Takayama; Namiki Izumi; Masumi Kadoya; Masatoshi Kudo; Yonson Ku; Michiie Sakamoto; Osamu Nakashima; Shuichi Kaneko; Norihiro KokudoJOURNAL OF HEPATOLOGY ELSEVIER SCIENCE BV 65 (5) 938 - 943 0168-8278 2016/11 [Refereed] Background & Aims: The presence of portal vein tumor thrombosis (PVTT) in patients with hepatocellular carcinoma (HCC) is regarded as indicating an advanced stage, and liver resection (LR) is not recommended. The aim of this study was to evaluate the survival benefit of LR for HCC patients with PVTT through the analysis of the data from a Japanese nationwide survey. Methods: We analyzed data for 6474 HCC patients with PVTT registered between 2000 and 2007. Of these patients, 2093 patients who underwent LR and 4381 patients who received other treatments were compared. The propensity scores were calculated and we successfully matched 1058 patients (66.1% of the LR group). Results: In the Child-Pugh A patients, the median survival time (MST) in the LR group was 1.77 years longer than that in the non-LR group (2.87 years vs. 1.10 years; p <0.001) and 0.88 years longer than that in the non-LR group (2.45 years vs. 1.57 years; p <0.001) in a propensity score-matched cohort. A subgroup analysis revealed that LR provides a survival benefit regardless of age, etiology of HCC, tumor marker elevation, and tumor number. The survival benefit was not statistically significant only in patients with PVTT invading the main trunk or contralateral branch. In the LR group, the postoperative 90-day mortality rate was 3.7% (68 patients). Conclusions: As long as the PVTT is limited to the first-order branch, LR is associated with a longer survival outcome than non-surgical treatment. Lay summary: The presence of portal vein tumor thrombosis in patients with hepatocellular carcinoma is regarded as indicating an advanced stage, and liver resection is not recommended. We performed a multicenter, nationwide study to assess the survival benefit of liver resection in hepatocellular carcinoma patients with portal vein tumor thrombosis using propensity score based matching. As long as the portal vein tumor thrombosis is limited to the first-order branch, liver resection is associated with a longer survival outcome than non-surgical treatment. (C) 2016 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.Bile duct adenoma in patient with chronic hepatitis C: As a benign neoplasm by pathological and imaging studiesSoo Ki Kim; Soo Ryang Kim; Susumu Imoto; Chi Wan Kim; Toshiyuki Matsuoka; Osamu Nakashima; Motoko Sasaki; Tsutomu Kumabe; Masatoshi Kudo; Toshio Fukusato; Fukuo KondoPATHOLOGY INTERNATIONAL WILEY-BLACKWELL 66 (11) 640 - 642 1320-5463 2016/11 [Refereed]Needle-Tract Seeding on the Proximal Gastric Wall After EUS-Guided Fine-Needle Aspiration of a Pancreatic MassKosuke Minaga; Masayuki Kitano; Eisuke Enoki; Hiroshi Kashida; Masatoshi KudoAMERICAN JOURNAL OF GASTROENTEROLOGY NATURE PUBLISHING GROUP 111 (11) 1515 - 1515 0002-9270 2016/11 [Refereed]Sorafenib plus hepatic arterial infusion chemotherapy with cisplatin versus sorafenib for advanced hepatocellular carcinoma: randomized phase II trialM. Ikeda; S. Shimizu; T. Sato; M. Morimoto; Y. Kojima; Y. Inaba; A. Hagihara; M. Kudo; S. Nakamori; S. Kaneko; R. Sugimoto; T. Tahara; T. Ohmura; K. Yasui; K. Sato; H. Ishii; J. Furuse; T. OkusakaANNALS OF ONCOLOGY OXFORD UNIV PRESS 27 (11) 2090 - 2096 0923-7534 2016/11 [Refereed] Sorafenib (Sor) is acknowledged as a standard therapy for advanced hepatocellular carcinoma (HCC). This trial was conducted to evaluate the effect of addition of hepatic arterial infusion chemotherapy with cisplatin (SorCDDP) to Sor for the treatment of advanced HCC. We conducted a multicenter open-labeled randomized phase II trial in chemo-na < ve patients with advanced HCC with Child-Pugh scores of 5-7. Eligible patients were randomly assigned 2:1 to receive SorCDDP (sorafenib: 400 mg bid; cisplatin: 65 mg/m(2), day 1, every 4-6 weeks) or Sor (400 mg bid). The primary end point was overall survival. A total of 108 patients were randomized (Sor, n = 42; SorCDDP, n = 66). The median survival in the Sor and SorCDDP arms were 8.7 and 10.6 months, respectively [stratified hazard ratio (95% confidence interval), 0.60 (0.38-0.96), P = 0.031]. The median time to progression and the response rate were, respectively, 2.8 months and 7.3% in the Sor arm and 3.1 months and 21.7% in the SorCDDP arm. The adverse events were more frequent in the SorCDDP arm than in the Sor arm, but well-tolerated. SorCDDP yielded favorable overall survival when compared with Sor in patients with advanced HCC. UMIN-CTR (), identification number: UMIN000005703.膵・胆道癌の早期発見における内視鏡の役割 pTis/pT1a膵癌の診断における内視鏡の役割山雄 健太郎; 北野 雅之; 工藤 正俊Gastroenterological Endoscopy (一社)日本消化器内視鏡学会 58 (Suppl.2) 1819 - 1819 0387-1207 2016/10Prognostic sub-classification of intermediate-stage hepatocellular carcinoma: a multicenter cohort study with propensity score analysisRamya Ramaswami; David J. Pinato; Keiichi Kubota; Mitsuru Ishizuka; Tadaaki Arizumi; Masatoshi Kudo; Jeong Won Jang; Young Woon Kim; Mario Pirisi; Elias Allara; Rohini SharmaMEDICAL ONCOLOGY HUMANA PRESS INC 33 (10) 114 - 121 1357-0560 2016/10 [Refereed] There is significant heterogeneity in the clinicopathological characteristics of intermediate hepatocellular carcinoma (IHCC). This also translates to treatment as transarterial chemoembolization (TACE) is used as firstline therapy for patients with IHCC; however, in Asia liver resection (LR) is preferred. Prognostic tools are required to help guide clinicians in deciding treatment options. This study evaluates the prognostic impact of the Intermediate Stage Score (ISS) on overall survival (OS) in a large, multicenter cohort study of patients with IHCC treated with TACE or surgery LR. Consecutive patients from centers in Japan, Korea, Italy and the United Kingdom who underwent TACE or LR between 2001 and 2015 were enrolled. Propensity score (PS) adjustment was used to remove residual confounding and applied to LR (n = 162) and TACE (n = 449) to determine the prognostic significance of ISS. Among 611 patients, 75 % were men and 25 % women, with a mean age of 70 years. ISS is a valid prognostic tool in the BCLC-B population with a median OS ISS 1-51, 2-38.3, 3-24.3, 4-15.6, 5-16 months (p < 0.0001). ISS was analyzed within each treatment modality, and this was a valid prognostic score among those treated with TACE and LR (p < 0.001 vs. p = 0.008). In the PS-adjusted model, ISS retained its prognostic utility in TACE and LR groups (p < 0.001 vs. p = 0.007). ISS optimizes prognostic prediction in IHCC, reducing clinical heterogeneity, and is a useful tool for patients treated for TACE or LR.Nucleotide-binding oligomerization domain 1 acts in concert with the cholecystokinin receptor agonist, cerulein, to induce IL-33-dependent chronic pancreatitisT. Watanabe; Y. Sadakane; N. Yagama; T. Sakurai; H. Ezoe; M. Kudo; T. Chiba; W. StroberMUCOSAL IMMUNOLOGY NATURE PUBLISHING GROUP 9 (5) 1234 - 1249 1933-0219 2016/09 [Refereed] Nucleotide-binding oligomerization domain 1 (NOD1) fulfills important host-defense functions via its responses to a variety of gut pathogens. Recently, however, we showed that in acute pancreatitis caused by administration of cholecystokinin receptor (CCKR) agonist ( cerulein) NOD1 also has a role in inflammation via its responses to gut commensal organisms. In the present study, we explored the long-term outcome of such NOD1 responsiveness in a new model of chronic pancreatitis induced by repeated administration of low doses of cerulein in combination with NOD1 ligand. We found that the development of chronic pancreatitis in this model requires intact NOD1 and type I IFN signaling and that such signaling mediates a macrophage-mediated inflammatory response that supports interleukin (IL)-33 production by acinar cells. The IL-33, in turn, has a necessary role in the induction of IL-13 and TGF-beta 1, factors causing the fibrotic reaction characteristic of chronic pancreatitis. Interestingly, the Th2 effects of IL-33 were attenuated by the concomitant type I IFN response since the inflammation was marked by clear increases in IFN-gamma and TNF-alpha production but only marginal increases in IL-4 production. These studies establish chronic pancreatitis as an IL-33-dependent inflammation resulting from synergistic interactions between the NOD1 and CCKR signaling pathways.Unique features associated with hepatic oxidative DNA damage and DNA methylation in non-alcoholic fatty liver diseaseNaoshi Nishida; Norihisa Yada; Satoru Hagiwara; Toshiharu Sakurai; Masayuki Kitano; Masatoshi KudoJOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY WILEY-BLACKWELL 31 (9) 1646 - 1653 0815-9319 2016/09 [Refereed] Background and AimNon-alcoholic fatty liver disease (NAFLD) is an increasing cause of hepatocellular carcinoma (HCC). Previously, we reported that DNA oxidation induced epigenetic alteration of tumor suppressor genes (TSGs) and contributed to HCC emergence. Here, we examine the associations between clinicopathological characteristics of NAFLD and advanced oxidative DNA damage that is associated with TSG methylation in the NAFLD liver. MethodsLiver biopsies from 65 NAFLD patients were analyzed for clinicopathological features and oxidative DNA damage using immunohistochemistry of 8-hydroxydeoxyguanosine (8-OHdG). Abnormal DNA methylation in the promoters of 6 TSGs, HIC1, GSTP1, SOCS1, RASSF1, CDKN2A, and APC, was examined using MethyLight. Associations between clinicopathological characteristics, methylation of TSGs, and accumulation of 8-OHdG were analyzed. ResultsWe found that aspartate aminotransferase/alanine aminotransferase ratio, the fibrosis-4 index, and serum -fetoprotein (AFP) level were associated with degree of 8-OHdG, and AFP was an independent factor among them (P=0.0271). Regarding pathological findings, hepatocellular ballooning and stage of fibrosis were also associated with oxidative DNA damage (P=0.0021 and 0.0054); ballooning was an independent risk for detecting high degree of 8-OHdG in hepatocytes (odds ratio 7.38, 95% confidence interval 1.41-49.13, P=0.0171). Accumulation of methylated TSGs was significantly associated with deposition of 8-OHdG (P=0.0362). ConclusionsPatients with high serum AFP and high degree of ballooning showed accumulation of oxidative DNA damage that could be a seed of DNA methylation responsible for hepatocarcinogenesis. These characteristics could be risk of HCC; such patients require urgent intervention such as lifestyle modification.Randomized, open-label phase 2 study comparing frontline dovitinib versus sorafenib in patients with advanced hepatocellular carcinomaAnn-Lii Cheng; Sumitra Thongprasert; Ho Yeong Lim; Wattana Sukeepaisarnjaroen; Tsai-Shen Yang; Cheng-Chung Wu; Yee Chao; Stephen L. Chan; Masatoshi Kudo; Masafumi Ikeda; Yoon-Koo Kang; Hongming Pan; Kazushi Numata; Guohong Han; Binaifer Balsara; Yong Zhang; Ana-Marie Rodriguez; Yi Zhang; Yongyu Wang; Ronnie T. P. PoonHEPATOLOGY WILEY-BLACKWELL 64 (3) 774 - 784 0270-9139 2016/09 [Refereed] Angiogenesis inhibition by the vascular endothelial growth factor receptor (VEGFR) and platelet-derived growth factor receptor (PDGFR) inhibitor sorafenib provides survival benefit in hepatocellular carcinoma (HCC); however, angiogenic escape from sorafenib may occur due to angiogenesis-associated fibroblast growth factor receptor (FGFR) pathway activation. In addition to VEGFR and PDGFR, dovitinib inhibits FGFR. Frontline oral dovitinib (500 mg/day, 5 days on, 2 days off; n = 82) versus sorafenib (400 mg twice daily; n = 83) was evaluated in an open-label, randomized phase 2 study of Asian-Pacific patients with advanced HCC. The primary and key secondary endpoints were overall survival (OS) and time to tumor progression (TTP) as determined by a local investigator, respectively. Patients included in the study were ineligible for surgical and/or locoregional therapies or had disease progression after receiving these therapies. The median OS (95% confidence interval [CI]) was 8.0 (6.6-9.1) months for dovitinib and 8.4 (5.4-11.3) months for sorafenib. The median TTP (95% CI) per investigator assessment was 4.1 (2.8-4.2) months and 4.1 (2.8-4.3) months for dovitinib and sorafenib, respectively. Common any-cause adverse events included diarrhea (62%), decreased appetite (43%), nausea (41%), vomiting (41%), fatigue (35%), rash (34%), and pyrexia (30%) for dovitinib and palmar-plantar erythrodysesthesia syndrome (66%) and decreased appetite (31%) for sorafenib. Subgroup analysis revealed a significantly higher median OS for patients in the dovitinib arm who had baseline plasma soluble VEGFR1 (sVEGFR1) and hepatocyte growth factor (HGF) below median levels versus at or above the median levels (median OS [95% CI]: sVEGFR1, 11.2 [9.0-13.8] and 5.7 [4.3-7.0] months, respectively [P = .0002]; HGF, 11.2 [8.9-13.8] and 5.9 [5.0-7.6] months, respectively [P = 0.0002]). Conclusion: Dovitinib was well tolerated, but activity was not greater than sorafenib as a frontline systemic therapy for HCC. Based on these data, no subsequent phase 3 study has been planned. (Hepatology 2016;64:774-784)総胆管結石の内視鏡的治療と手術 経乳頭処置困難総胆管結石症例に対するEUSガイド下治療山雄 健太郎; 北野 雅之; 工藤 正俊胆道 日本胆道学会 30 (3) 403 - 403 0914-0077 2016/08Evaluation of anti-migration properties of biliary covered self-expandable metal stentsKosuke Minaga; Masayuki Kitano; Hajime Imai; Yogesh Harwani; Kentaro Yamao; Ken Kamata; Takeshi Miyata; Shunsuke Omoto; Kumpei Kadosaka; Toshiharu Sakurai; Naoshi Nishida; Masatoshi KudoWORLD JOURNAL OF GASTROENTEROLOGY BAISHIDENG PUBLISHING GROUP INC 22 (30) 6917 - 6924 1007-9327 2016/08 [Refereed] AIM: To assess anti-migration potential of six biliary covered self-expandable metal stents (C-SEMSs) by using a newly designed phantom model. METHODS: In the phantom model, the stent was placed in differently sized holes in a silicone wall and retracted with a retraction robot. Resistance force to migration (RFM) was measured by a force gauge on the stent end. Radial force (RF) was measured with a RF measurement machine. Measured flare structure variables were the outer diameter, height, and taper angle of the flare (ODF, HF, and TAF, respectively). Correlations between RFM and RF or flare variables were analyzed using a linear correlated model. RESULTS: Out of the six stents, five stents were braided, the other was laser-cut. The RF and RFM of each stent were expressed as the average of five replicate measurements. For all six stents, RFM and RF decreased as the hole diameter increased. For all six stents, RFM and RF correlated strongly when the stent had not fully expanded. This correlation was not observed in the five braided stents excluding the laser cut stent. For all six stents, there was a strong correlation between RFM and TAF when the stent fully expanded. For the five braided stents, RFM after full stent expansion correlated strongly with all three stent flare structure variables (ODF, HF, and TAF). The laser-cut C-SEMS had higher RFMs than the braided C-SEMSs regardless of expansion state. CONCLUSION: RF was an important anti-migration property when the C-SEMS did not fully expand. Once fully expanded, stent flare structure variables plays an important role in anti-migration.Regional differences in sorafenib-treated patients with hepatocellular carcinoma: GIDEON observational studyMasatoshi Kudo; Riccardo Lencioni; Jorge A. Marrero; Alan P. Venook; Jean-Pierre Bronowicki; Xiao-Ping Chen; Lucy Dagher; Junji Furuse; Jean-Francois H. Geschwind; Laura Ladron de Guevara; Christos Papandreou; Arun J. Sanyal; Tadatoshi Takayama; Seung Kew Yoon; Keiko Nakajima; Robert Lehr; Stephanie Heldner; Sheng-Long YeLIVER INTERNATIONAL WILEY-BLACKWELL 36 (8) 1196 - 1205 1478-3223 2016/08 [Refereed] Background & AimsTreatment approaches for hepatocellular carcinoma (HCC) vary across countries, but these differences and their potential impact on outcomes have not been comprehensively assessed. Data from the multinational GIDEON (Global Investigation of therapeutic DEcisions in HCC and Of its treatment with sorafeNib) registry evaluated differences in patient characteristics, practice patterns and outcomes in HCC across geographical regions in patients who received sorafenib. MethodsGIDEON is a non-randomised, observational registry study conducted in 39 countries across five global regions. HCC patients in whom a decision to treat with sorafenib was made in clinical practice and according to local practices were included. Results3202 patients were evaluable for safety analysis: Asia-Pacific (n = 928), Japan (n = 508), Europe (n = 1113), USA (n = 563) and Latin America (n = 90). Patients in Japan had earlier-stage disease at initial diagnosis compared with patients in other regions (Barcelona Clinic Liver Cancer stage A; 43.7% vs 9.1-24.3%). Use of locoregional therapies before sorafenib, including transarterial chemoembolisation, was more common in Japan (84.4%) and Asia-Pacific (67.2%) compared with the USA (49.4%) and Europe (43.5%). Treatment patterns with respect to sorafenib also differed, with a shorter duration of treatment reported in the USA and Asia-Pacific. Time from initial diagnosis to death was longer in Japan compared with other regions (median, 79.6 months vs 14.8-25.0 months). ConclusionsData from GIDEON highlight regional variations in the management of HCC and patient outcomes. Greater standardisation of management may help optimise outcomes for HCC patients.Randomized phase II placebo controlled study of codrituzumab in previously treated patients with advanced hepatocellular carcinomaGhassan K. Abou-Alfa; Oscar Puig; Bruno Daniele; Masatoshi Kudo; Philippe Merle; Joong-Won Park; Paul Ross; Jean-Marie Peron; Oliver Ebert; Stephen Chan; Tung Ping Poon; Massimo Colombo; Takuji Okusaka; Baek-Yeol Ryoo; Beatriz Minguez; Takayoshi Tanaka; Toshihiko Ohtomo; Stacey Ukrainskyj; Frederic Boisserie; Olga Rutman; Ya-Chi Chen; Chao Xu; Eliezer Shochat; Lori Jukofsky; Bernhard Reis; Gong Chen; Laura Di Laurenzio; Ray Lee; Chia-Jui YenJOURNAL OF HEPATOLOGY ELSEVIER SCIENCE BV 65 (2) 289 - 295 0168-8278 2016/08 [Refereed] Background & Aims: Codrituzumab, a humanized monoclonal antibody against Glypican-3 (GPC3) that is expressed in hepatocellular carcinoma (HCC), interacts with CD16/FccRIIIa and triggers antibody-dependent cytotoxicity. Codrituzumab was studied vs. placebo in a randomized phase II trial in advanced HCC patients who had failed prior systemic therapy. Methods: Patients with advanced HCC who had failed prior systemic therapy, >= 18 years, Eastern cooperative oncology group (ECOG) 0-1, Child-Pugh A were randomized 2: 1 to biweekly codrituzumab 1600 mg vs. placebo. Patients were stratified based on GPC3 immunohistochemical expression: 2+/3+, 1+, and 0. Primary endpoint was progression free survival. Secondary endpoints include overall survival (OS), tolerability, pharmacokinetics, and an exploratory endpoint in biomarkers analysis. Results: 185 patients were enrolled: 125 received codrituzumab and 60 placebo: Median age 64/63, 85/75% male, 46/42% Asian, ECOG 0 65/63%, 74/77% having vascular invasion and/or extrahepatic metastasis. 84%/70% had prior sorafenib. Drug exposure was 98.4% of planned dose, with an identical adverse events profile between the 2 groups. The median progression free survival and overall survival in the codrituzumab vs. placebo groups in months were: 2.6 vs. 1.5 (hazard ratios 0.97, p = 0.87), and 8.7 vs. 10 (hazard ratios 0.96, p = 0.82). Projected Ctrough at cycle 3 day 1 based exposure, high CD16/FccRIIIa on peripheral immune cells, and GPC3 expression in the tumor, were all associated with prolonged progression free survival and overall survival. Conclusions: Codrituzumab did not show clinical benefit in this previously treated HCC population. Whether higher codrituzumab drug exposure or the use of CD16 and GPC3 as potential biomarkers would improve outcome remain unanswered questions. Lay summary: Codrituzumab is a manufactured antibody against a liver cancer protein called glypican-3. In this clinical trial, codrituzumab was not found be effective against liver cancer. It was suggested though that a higher dose of codrituzumab or selecting patients with high level of glypican-3 or its mediator CD16 might improve outcome. (C) 2016 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.APPLE NewsMasatoshi KudoLiver Cancer S. Karger AG 5 (3) 1664-5553 2016/07 [Refereed]Role of ABCG2 in Liver Injury Associated With Erythropoietic Protoporphyria REPLYSatoru Hagiwara; Naoshi Nishida; Masatoshi KudoHEPATOLOGY WILEY-BLACKWELL 64 (1) 306 - 306 0270-9139 2016/07 [Refereed]Predictors of pain response in patients undergoing endoscopic ultrasound-guided neurolysis for abdominal pain caused by pancreatic cancerKosuke Minaga; Masayuki Kitano; Hiroki Sakamoto; Takeshi Miyata; Hajime Imai; Kentaro Yamao; Ken Kamata; Shunsuke Omoto; Kumpei Kadosaka; Toshiharu Sakurai; Naoshi Nishida; Yasutaka Chiba; Masatoshi KudoTHERAPEUTIC ADVANCES IN GASTROENTEROLOGY SAGE PUBLICATIONS LTD 9 (4) 483 - 494 1756-283X 2016/07 [Refereed] Background: Interventional endoscopic ultrasound (EUS)-guided procedures such as EUS-guided celiac ganglia neurolysis (EUS-CGN) and EUS-guided broad plexus neurolysis (EUS-BPN) were developed to treat abdominal cancer-associated pain; however, these procedures are not always effective. The aim of this study was to explore predictors of pain response in EUS-guided neurolysis for pancreatic cancer-associated pain. Methods: This was a retrospective analysis of prospectively collected data of 112 consecutive patients who underwent EUS-BPN in our institution. EUS-CGN was added in cases of visible celiac ganglia. The neurolytic-spread area was divided into six sections and evaluated by post-procedural computed tomography scanning. Pain intensity was assessed using a visual analog scale (VAS), and a decrease in VAS scores by 3 points after neurolysis was considered a good pain response. Univariable and multivariable logistic regression analyses were performed to explore predictors of pain response at 1 and 4 weeks, and complications. Results: A good pain response was obtained in 77.7% and 67.9% of patients at 1 and 4 weeks, respectively. In the multivariable analysis of these patients, the combination method (EUS-BPN plus CGN) was a significant positive predictive factor at 1 week (odds ratio = 3.69, p = 0.017) and 4 weeks (odds ratio = 6.37, p = 0.043). The numbers of neurolytic/contrast spread areas (mean SD) were 4.98 +/- 1.08 and 4.15 +/- 1.12 in patients treated with the combination method and single method, respectively (p < 0.001). There was no significant predictor of complications. Conclusions: EUS-BPN in combination with EUS-CGN was a predictor of a good pain response in EUS-guided neurolysis for pancreatic cancer-related pain. The larger number of neurolytic/contrast spread areas may lead to better outcomes in patients receiving combination treatment.Combined sequential use of HAP and ART scores to predict survival outcome and treatment failure following chemoembolization in hepatocellular carcinoma: a multi-center comparative studyDavid J. Pinato; Tadaaki Arizumi; Jeong Won Jang; Elias Allara; Puvan I. Suppiah; Carlo Smirne; Paul Tait; Madhava Pai; Glenda Grossi; Young Woon Kim; Mario Pirisi; Masatoshi Kudo; Rohini SharmaONCOTARGET IMPACT JOURNALS LLC 7 (28) 44705 - 44718 1949-2553 2016/07 [Refereed] Background: The prognosis of patients with hepatocellular carcinoma (HCC) undergoing transarterial chemoembolization (TACE) is variable, despite a myriad of prognostic markers. We compared and integrated the established prognostic models, HAP and ART scores, for their accuracy of overall survival (OS) prediction. Results: In both training and validation sets, HAP and ART scores emerged as independent predictors of OS (p<0.01) with HAP achieving better prognostic accuracy (c-index: 0.68) over ART (0.57). We tested both scores in combination to evaluate their combined ability to predict OS. Subgroup analysis of BCLC-C patients revealed favorable HAP stage (p<0.001) and radiological response after initial TACE (p<0.001) as positive prognostic factors. Patients and Methods: Prognostic scores were studied using multivariable Cox regression and c-index analysis in 83 subjects with Barcelona Clinic Liver Cancer (BCLC) A/B stage from UK and Italy (training set), and 660 from Korea and Japan (validation set), all treated with conventional TACE. Scores were further validated in an separate analysis of patients with BCLC-C stage disease (n=63) receiving initial TACE. Conclusion: ART and HAP scores are validated indices in patients with intermediate stage HCC undergoing TACE. The HAP score is best suited for screening patients prior to initial TACE, whilst sequential ART assessment improves early detection of chemoembolization failure. BCLC-C patients with low HAP stage may be a subgroup where TACE should be explored in clinical studies.EUS-guided gallbladder drainage for rescue treatment of malignant distal biliary obstruction after unsuccessful ERCPHajime Imai; Masayuki Kitano; Shunsuke Omoto; Kumpei Kadosaka; Ken Kamata; Takeshi Miyata; Kentaro Yamao; Hiroki Sakamoto; Yogesh Harwani; Masatoshi KudoGASTROINTESTINAL ENDOSCOPY MOSBY-ELSEVIER 84 (1) 147 - 151 0016-5107 2016/07 [Refereed] Background and Aims: EUS-guided bile duct drainage (EUS-BD) is a well-recognized rescue biliary drainage method after unsuccessful ERCP. EUS-guided gallbladder drainage (EUS-GBD) was recently used to treat acute cholecystitis. The aim of this study was to assess the efficacy and safety of EUS-GBD for malignant biliary stricture-induced obstructive jaundice after unsuccessful ERCP as well as unsuccessful or impractical EUS-BD. Methods: Between January 2006 and October 2014, 12 patients with obstructive jaundice due to unresectable malignant distal biliary stricture underwent EUS-GBD after ERCP failed. EUS-GBD was performed under the guidance of EUS and fluoroscopy by puncturing the gallbladder with a needle, inserting a guidewire, dilating the puncture hole, and placing a stent. The technical and functional success rates, adverse events rate, overall patient survival time, and stent dysfunction rate during patient survival were measured. Results: The rates of technical success, functional success, adverse events, and stent dysfunction were 100%, 91.7%, 16.7%, and 8.3%, respectively. The median survival time after EUS-GBD was 105 days (range 15 - 236 days). Conclusions: EUS-GBD is a possible alternative route for decompression of the biliary system when ERCP is unsuccessful.New endoscopic ultrasonography techniques for pancreaticobiliary diseasesKen Kamata; Masayuki Kitano; Shunsuke Omoto; Kumpei Kadosaka; Takeshi Miyata; Kosuke Minaga; Kentaro Yamao; Hajime Imai; Masatoshi KudoUltrasonography Korean Society of Ultrasound in Medicine 35 (3) 169 - 179 2288-5943 2016/07 [Refereed] Endoscopic ultrasonography (EUS) is widely used to evaluate pancreaticobiliary diseases, especially pancreatic masses. EUS has a good ability to detect pancreatic masses, but it is not sufficient for the differential diagnosis of various types of lesions. In order to address the limitations of EUS, new techniques have been developed to improve the characterization of the lesions detected by EUS. EUS-guided fine needle aspiration (EUS-FNA) has been used for diagnosing pancreatic tumors. In order to improve the histological diagnostic yield, a EUS-FNA needle with a core trap has recently been developed. Contrast-enhanced harmonic EUS is a new imaging modality that uses an ultrasonographic contrast agent to visualize blood flow in fine vessels. This technique is useful in the diagnosis of pancreatic solid lesions and in confirming the presence of vascularity in mural nodules for cystic lesions. EUS elastography analyzes several different variables to measure tissue elasticity, color patterns, and strain ratio, using analytical techniques such as hue-histogram analysis, and artificial neural networks, which are useful for the diagnosis of chronic pancreatitis and pancreatic cancer.Histologic diagnosis of pancreatic masses using 25-gauge endoscopic ultrasound needles with and without a core trap: a multicenter randomized trialKen Kamata; Masayuki Kitano; Satoru Yasukawa; Masatoshi Kudo; Yasutaka Chiba; Takeshi Ogura; Kazuhide Higuchi; Nobuyasu Fukutake; Reiko Ashida; Tomoaki Yamasaki; Hiroko Nebiki; Satoru Hirose; Noriyuki Hoki; Masanori Asada; Shujiro Yazumi; Makoto Takaoka; Kazuichi Okazaki; Fumihiro Matsuda; Yoshihiro Okabe; Akio YanagisawaENDOSCOPY GEORG THIEME VERLAG KG 48 (7) 632 - 638 0013-726X 2016/07 [Refereed] Background and study aims: Endoscopic ultrasound-guided fine needle aspiration (EUS-FNA) with 25-gauge needles yields small volume samples that are mainly processed for cytology. Using 25-gauge needles with a core trap may overcome this limitation. This trial compared 25-gauge needles with and without a core trap in terms of their ability to obtain histologic samples from solid pancreatic masses. Patients and methods: Consecutive patients with solid pancreatic masses who presented to eight Japanese referral centers for EUS-FNA in April-September 2013 were randomized to undergo sampling with a 25-gauge needle with a core trap (ProCore) or a standard 25-gauge needle. Tissue samples were fixed in formalin and processed for histologic evaluation. For the purpose of this study only samples obtained with the first needle pass were used for comparison of: (i) accuracy for the diagnosis of malignancy, (ii) rate of samples with preserved tissue architecture adequate for histologic evaluation, and (iii) sample cellularity. Results: A total of 214 patients were enrolled. Compared to the first pass with a standard needle (n=108), the first pass with the ProCore needle (n=106) provided samples that were more often adequate for histologic evaluation (81.1% vs. 69.4 %; P=0.048) and had superior cellularity (rich/moderate/poor, 36%/27%/37% vs. 19%/26%/ 55%; P=0.003). There were no significant differences between the two needles in sensitivity (75.6% vs. 69.0 %, P=0.337) and accuracy (79.2% vs. 75.9 %, P=0.561) for the diagnosis of malignancy. Conclusions: In patients with solid pancreatic masses, a 25-gauge EUS-FNA needle with a core trap provides histologic samples of better quality than a standard 25-gauge needle. There was no difference in accuracy for the diagnosis of malignancy between the needles. Clinical trial number: UMIN000010021.ResponseMasayuki Kitano; Hajime Imai; Ken Kamata; Masatoshi KudoGastrointestinal Endoscopy Mosby Inc. 83 (6) 1303  1097-6779 2016/06 [Refereed]Modified single transluminal gateway transcystic multiple drainage technique for a huge infected walled-off pancreatic necrosis: A case reportKosuke Minaga; Masayuki Kitano; Hajime Imai; Kentaro Yamao; Ken Kamata; Takeshi Miyata; Tomohiko Matsuda; Shunsuke Omoto; Kumpei Kadosaka; Tomoe Yoshikawa; Masatoshi KudoWORLD JOURNAL OF GASTROENTEROLOGY BAISHIDENG PUBLISHING GROUP INC 22 (21) 5132 - 5136 1007-9327 2016/06 [Refereed] We report a successful endoscopic ultrasonography-guided drainage of a huge infected multilocular walled-off necrosis (WON) that was treated by a modified single transluminal gateway transcystic multiple drainage (SGTMD) technique. After placing a wide-caliber fully covered metal stent, follow-up computed tomography revealed an undrained subcavity of WON. A large fistula that was created by the wide-caliber metal stent enabled the insertion of a forward-viewing upper endoscope directly into the main cavity, and the narrow connection route within the main cavity to the subcavity was identified with a direct view, leading to the successful drainage of the subcavity. This modified SGTMD technique appears to be useful for seeking connection routes between subcavities of WON in some cases.【肝不全-その常識は正しいか?-】慢性肝不全 その常識は正しいか? 肝癌合併は肝硬変患者の予後を規定する上嶋 一臣; 工藤 正俊救急・集中治療 (株)総合医学社 28 (5-6) 431 - 435 1346-0935 2016/05 <Point>肝癌は肝硬変をベースに発症することが多いため、その治療にあたっては肝予備能の評価が最も重要である。肝癌・肝硬変ともに最終転帰は肝不全であり、いずれの治療においても肝機能温存を目指すことが重要である。(著者抄録)Removal of Diminutive Colorectal Polyps: A Prospective Randomized Comparative Study between Cold Snare Polypectomy (CSP) and Hot Biopsy Forceps (HBF)Yoriaki Komeda; Hiroshi Kashida; Toshiharu Sakurai; Yutaka Asakuma; Yoshihisa Okazaki; Tomoyuki Nagai; Hiromasa Mine; Teppei Adachi; Rie Tanaka; Mitsunari Yamada; Masashi Kono; Toshiki Okamoto; Shigenaga Matsui; Masatoshi KudoGASTROINTESTINAL ENDOSCOPY MOSBY-ELSEVIER 83 (5) AB392 - AB392 0016-5107 2016/05 [Refereed]EUS-Guided Intrahepatic Biliary Drainage for Treatment of Obstructive Jaundice in Patients With Malignant Hilar Biliary Stricture After Ineffective or Unsuccessful Transpapillary ApproachKosuke Minaga; Masayuki Kitano; Hajime Imai; Kentaro Yamao; Ken Kamata; Takeshi Miyata; Tomohiko Matsuda; Shunsuke Omoto; Kumpei Kadosaka; Tomoe Yoshikawa; Masatoshi KudoGASTROINTESTINAL ENDOSCOPY MOSBY-ELSEVIER 83 (5) AB521 - AB521 0016-5107 2016/05 [Refereed]Reply to: "Impaired Expression of Multidrug Resistance-Associated Protein 2 and Liver Damage in Erythropoietic Protoporphyria" REPLYSatoru Hagiwara; Naoshi Nishida; Masatoshi KudoHEPATOLOGY WILEY-BLACKWELL 63 (5) 1744 - 1745 0270-9139 2016/05 [Refereed]TACE Treatment in Patients with Sorafenib-treated Unresectable Hepatocellular Carcinoma in Clinical Practice: Final Analysis of GIDEONJean-Francois Geschwind; Masatoshi Kudo; Jorge A. Marrero; Alan P. Venook; Xiao-Ping Chen; Jean-Pierre Bronowicki; Lucy Dagher; Junji Furuse; Laura Ladron de Guevara; Christos Papandreou; Arun J. Sanyal; Tadatoshi Takayama; Sheng-Long Ye; Seung Kew Yoon; Keiko Nakajima; Robert Lehr; Stephanie Heldner; Riccardo LencioniRADIOLOGY RADIOLOGICAL SOC NORTH AMERICA 279 (2) 630 - 640 0033-8419 2016/05 [Refereed] Purpose: To evaluate transarterial chemoembolization (TACE) use prior to and concomitantly with sorafenib in patients with unresectable hepatocellular carcinoma (HCC) across different global regions. Materials and Methods: GIDEON is an observational registry study of more than 3000 HCC patients. Patients with histologically, cytologically, or radiographically diagnosed HCC, and for whom a decision had been made to treat with sorafenib, were eligible. Patients were enrolled into the registry from 39 countries beginning in January 2009, with the last patient follow-up in April 2012. Detailed data on treatment history, treatment patterns, adverse events, and outcomes were collected. All treatment decisions were at the discretion of the treating physicians. Documented approval from local ethics committees was obtained, and all patients provided signed informed consent. Descriptive statistics, including minimum, median, and maximum, were calculated for metric data, and frequency tables for categorical data. Kaplan-Meier estimates with 95% confidence intervals were calculated for survival end points. Results: A total of 3202 patients were eligible for safety analysis, of whom 2631 (82.2%) were male. Median age was 62 years (range, 15-98 years). A total of 1511 (47.2%) patients underwent TACE prior to sorafenib; 325 (10.1%) underwent TACE concomitantly. TACE prior to sorafenib was more common in Japan and Asia- Pacific compared with all other regions (362 [71.3%] and 560 [60.3%] vs 12-209 [13.3%-37.1%]). Adverse events were reported in 2732 (85.3%) patients overall, with no notable differences in the incidence of adverse events, regardless of TACE treatment history. Overall survival was 12.7 months in prior-TACE patients, 9.2 months in non-prior-TACE patients, 21.6 months in concomitant-TACE patients, and 9.7 months in non-concomitant-TACE patients. Conclusion: Global variation exists in TACE use in sorafenib-treated HCC patients. The combination of TACE with sorafenib appears to be a well-tolerated and viable therapeutic approach. (C) RSNA, 2016Epigenetic regulation and development of hepatocellular carcinomaNaoshi Nishida; Masatoshi KudoJournal of Japanese Society of Gastroenterology Japanese Society of Gastroenterology 113 (5) 775 - 784 1349-7693 2016/05 [Refereed]Acute spinal cord infarction after EUS-guided celiac plexus neurolysisKosuke Minaga; Masayuki Kitano; Hajime Imai; Takeshi Miyata; Masatoshi KudoGASTROINTESTINAL ENDOSCOPY MOSBY-ELSEVIER 83 (5) 1039 - 1040 0016-5107 2016/05 [Refereed]【肝細胞癌の分子解析と悪性度診断】肝細胞癌の発生とエピゲノム制御西田 直生志; 工藤 正俊日本消化器病学会雑誌 (一財)日本消化器病学会 113 (5) 775 - 784 0446-6586 2016/05 [Refereed] 細胞形質の多様性はゲノムのみならずエピゲノム情報によっても規定され、後者はゲノム情報読み取りの制御機構といえる。肝細胞癌において、エピゲノム変異を示す遺伝子はゲノム変異よりも遥かに多様である。またエピゲノム制御機構の破綻は、癌の発生のみならず幹細胞様形質の獲得にも重要であると想定される。近年の高速シークエンス技術の発達により、肝細胞癌でもエピゲノム情報の維持に関わる種々の遺伝子の変異が明らかとなり、さらに環境因子のエピゲノム情報に及ぼす影響やその機序も解明されつつある。今後は、肝細胞癌のマネージメントにおいて、ゲノム・エピゲノム変異の包括的な情報が重要になると予想される。(著者抄録)自己免疫性膵炎の診断・治療におけるEUSの役割大本 俊介; 北野 雅之; 工藤 正俊Gastroenterological Endoscopy (一社)日本消化器内視鏡学会 58 (Suppl.1) 706 - 706 0387-1207 2016/04胆膵疾患の造影エコー診断up-to-date 造影ハーモニックEUSの定量的血流評価による膵腫瘍診断大本 俊介; 北野 雅之; 工藤 正俊超音波医学 (公社)日本超音波医学会 43 (Suppl.) S318 - S318 1346-1176 2016/04消化器疾患の診断と治療におけるEUSの役割 EUSガイド下ドレナージを中心としたWONの治療成績及び内視鏡治療不成功因子の解析(Role of EUS in Diagnosis and Treatment of Digestive Diseases EUS-guided interventions for walled-off pancreatic necrosis: clinical outcomes of a step-up approach and risk factors for failed endoscopic treatment)三長 孝輔; 北野 雅之; 今井 元; 山雄 健太郎; 鎌田 研; 宮田 剛; 松田 友彦; 大本 俊介; 門阪 薫平; 工藤 正俊超音波医学 (公社)日本超音波医学会 43 (Suppl.) S322 - S322 1346-1176 2016/04The Oncoprotein Gankyrin Links Inflammation and Tumorigenesis in Inflammatory Bowel DiseaseToshiharu Sakurai; Hiroshi Kashida; Rie Tanaka; Toshiki Okamoto; Mitsunari Yamada; Teppei Adachi; Hiromasa Mine; Tomoyuki Nagai; Yutaka Asakuma; Yoriaki Komeda; Yoshihisa Okazaki; Shigenaga Matsui; Masatoshi KudoGASTROENTEROLOGY W B SAUNDERS CO-ELSEVIER INC 150 (4) S83 - S83 0016-5085 2016/04 [Refereed]Prospective Randomized Controlled Study of Helicobacter pylori Eradication in JapanTeppei Adachi; Shigenaga Matsui; Rie Tanaka; Mitsunari Yamada; Hiromasa Mine; Tomoyuki Nagai; Yoshihisa Okazaki; Yutaka Asakuma; Yoriaki Komeda; Toshiharu Sakurai; Hiroshi Kashida; Masatoshi KudoGASTROENTEROLOGY W B SAUNDERS CO-ELSEVIER INC 150 (4) S881 - S881 0016-5085 2016/04 [Refereed]Gastric PerineuriomaShigenaga Matsui; Hiroshi Kashida; Masatoshi KudoAMERICAN JOURNAL OF GASTROENTEROLOGY NATURE PUBLISHING GROUP 111 (4) 453 - 453 0002-9270 2016/04 [Refereed]Report of the 19th follow-up survey of primary liver cancer in JapanMasatoshi Kudo; Namiki Izumi; Takafumi Ichida; Yonson Ku; Norihiro Kokudo; Michiie Sakamoto; Tadatoshi Takayama; Osamu Nakashima; Osamu Matsui; Yutaka MatsuyamaHEPATOLOGY RESEARCH WILEY 46 (5) 372 - 390 1386-6346 2016/04 [Refereed] The 19th Nationwide Follow-up Survey of Primary Liver Cancer in Japan comprised 20 850 primary liver cancer patients newly registered at 482 medical institutions over a period of 2 years (from 1 January 2006 to 31 December 2007). Of these, 94.7% had hepatocellular carcinoma (HCC) and 4.4% had intrahepatic cholangiocarcinoma (ICC). In addition, follow-up data were obtained regarding 34 752 patients who were registered in the previous survey. Epidemiological and clinicopathological factors, diagnosis, and treatment were examined in newly registered patients. Compared with the 18th follow-up survey, the present follow-up survey suggested an increase in the number of elderly and female patients, a reduction in the number of hepatitis B surface antigen-and anti-hepatitis C virus antibody-positive patients, and a reduction in tumor size at the time of clinical diagnosis. In terms of local ablation therapy, the number of patients receiving radiofrequency ablation therapy increased. The cumulative survival rates for newly registered patients between 1996 and 2007 were calculated for each histological type (HCC, ICC, and combined HCC and ICC) and stratified according to background factors and treatments. The cumulative survival rates of newly registered patients between 1978 and 2007 were calculated after dividing individuals into groups according to registration date (1978-1987, 1988-1997, and 1998-2007). The data obtained from this follow-up survey will contribute to the medical management of primary liver cancer and facilitate future research.Urgent endoscopic ultrasound-guided choledochoduodenostomy for acute obstructive suppurative cholangitis-induced sepsisKosuke Minaga; Masayuki Kitano; Hajime Imai; Kentaro Yamao; Ken Kamata; Takeshi Miyata; Shunsuke Omoto; Kumpei Kadosaka; Tomoe Yoshikawa; Masatoshi KudoWORLD JOURNAL OF GASTROENTEROLOGY BAISHIDENG PUBLISHING GROUP INC 22 (16) 4264 - 4269 1007-9327 2016/04 [Refereed] Acute obstructive suppurative cholangitis (AOSC) due to biliary lithiasis is a life-threatening condition that requires urgent biliary decompression. Although endoscopic retrograde cholangiopancreatography (ERCP) with stent placement is the current gold standard for biliary decompression, it can sometimes be difficult because of failed biliary cannulation. In this retrospective case series, we describe three cases of successful biliary drainage with recovery from septic shock after urgent endoscopic ultrasound-guided choledochoduodenostomy (EUS-CDS) was performed for AOSC due to biliary lithiasis. In all three cases, technical success in inserting the stents was achieved and the patients completely recovered from AOSC with sepsis in a few days after EUS-CDS. There were no procedure-related complications. When initial ERCP fails, EUS-CDS can be an effective life-saving endoscopic biliary decompression procedure that shortens the procedure time and prevents post-ERCP pancreatitis, particularly in patients with AOSC-induced sepsis.【肝臓治療の最前線-最善の医療を目指す取り組み-】Intermediate Stageの肝癌治療を考える TACEから分子標的薬への切り替えのポイント上嶋 一臣; 工藤 正俊クリニシアン エーザイ(株) 63 (3) 335 - 342 0387-1541 2016/03Intermediateから進行肝細胞癌治療の最前線 BCLC Bの細分類と治療選択有住 忠晃; 上嶋 一臣; 工藤 正俊日本消化器病学会雑誌 (一財)日本消化器病学会 113 (臨増総会) A107 - A107 0446-6586 2016/03Contrast-enhanced harmonic endoscopic ultrasonography for assessment of lymph node metastases in pancreatobiliary carcinomaTakeshi Miyata; Masayuki Kitano; Shunsuke Omoto; Kumpei Kadosaka; Ken Kamata; Hajime Imai; Hiroki Sakamoto; Naoshi Nisida; Yogesh Harwani; Takamichi Murakami; Yoshifumi Takeyama; Yasutaka Chiba; Masatoshi KudoWORLD JOURNAL OF GASTROENTEROLOGY BAISHIDENG PUBLISHING GROUP INC 22 (12) 3381 - 3391 1007-9327 2016/03 [Refereed] AIM: To assess the usefulness of contrast-enhanced harmonic endoscopic ultrasonography (CH-EUS) for lymph node metastasis in pancreatobiliary carcinoma. METHODS: All patients suspected of pancreatobiliary carcinoma with visible lymph nodes after standard EUS between June, 2009 and January, 2012 were enrolled. In the primary analysis, patients with successful EUS-fine needle aspiration (FNA) were included. The lymph nodes were assessed by several standard EUS variables (short and long axis lengths, shape, edge characteristic and echogenicity), color Doppler EUS variable [central intranodal blood vessel (CIV) presence] and CH-EUS variable (heterogeneous/homogeneous enhancement patterns). The diagnostic accuracy relative to EUS-FNA was calculated. In the second analysis, N-stage diagnostic accuracy of CH-EUS was compared with EUS-FNA in patients who underwent surgical resection. RESULTS: One hundred and nine patients (143 lymph nodes) fulfilled the criteria. The short axis cutoff >= 13 mm predicted malignancy with a sensitivity and specificity of 72% and 85%, respectively. These values were 72% and 63% for the long axis cut-off >= 20 mm, 62% and 75% for the round shape variable, 81% and 30% for the sharp edge variable, 66% and 61% for the hypoechogenicity variable, 70% and 72% for the CIV-absent variable, and 83% and 91% for the heterogeneous CH-EUS-enhancement variable, respectively. CH-EUS was more accurate than standard and color Doppler EUS, except the short axis cut-off. Notably, three patients excluded because of EUS-FNA failure were correctly N-staged by CH-EUS. CONCLUSION: CH-EUS complements standard and color Doppler EUS and EUS-FNA for assessment of lymph node metastases.Kupffer phase image of Sonazoid-enhanced US is useful in predicting a hypervascularization of non-hypervascular hypointense hepatic lesions detected on Gd-EOB-DTPA-enhanced MRI: a multicenter retrospective studyTatsuo Inoue; Tomoko Hyodo; Keiko Korenaga; Takamichi Murakami; Yasuharu Imai; Atsushi Higaki; Takeshi Suda; Toru Takano; Kennichi Miyoshi; Masahiko Koda; Hironori Tanaka; Hiroko Iijima; Hironori Ochi; Masashi Hirooka; Kazushi Numata; Masatoshi KudoJOURNAL OF GASTROENTEROLOGY SPRINGER JAPAN KK 51 (2) 144 - 152 0944-1174 2016/02 [Refereed] Background It remains unknown whether Kupffer-phase images in Sonazoid-enhanced ultrasonography (US) can be used to predict hypervascularization of borderline lesions. Therefore, we aimed to clarify whether Kupffer-phase images in Sonazoid-enhanced ultrasonography can predict subsequent hypervascularization in hypovascular borderline lesions detected on hepatobiliary-phase gadolinium-ethoxybenzyl-diethylenetriamine pentaacetic acid (GdEOB-DTPA)-enhanced magnetic resonance imaging. Methods From January 2008 to March 2012, 616 low-intensity hypovascular nodules were detected in hepatobiliary-phase images of Gd-EOB-DTPA-enhanced MRI at nine institutions. Among these, 167 nodules, which were confirmed as hypovascular by Gd-EOB-DTPA-enhanced MRI and Sonazoid-enhanced US, were evaluated in this study. Potential hypervascularization factors were selected based on their clinical significance and the results of previous reports. The Kaplan-Meier model and log-rank test were used for univariate analysis and the Cox regression model was used for multivariate analysis. Results The cumulative incidence of hypervascularization of borderline lesions was 18, 37, and 43 % at 1, 2, and 3 years, respectively. Univariate analyses showed that tumor size (p = 0.0012) and hypoperfusion on Kupffer-phase images in Sonazoid-enhanced US (p = 0.004) were associated with hypervascularization of the tumor. Multivariate analysis showed that tumor size [HR: 1.086, 95 % confidence interval = 1.027-1.148, p = 0.004] and hypo perfusion on Kupffer-phase images [HR: 3.684, 95 % confidence interval = 1.798-7.546, p = 0.0004] were significantly different. Conclusions Kupffer-phase images in Sonazoid-enhanced US and tumor diameter can predict hypervascularization of hypointense borderline lesions detected on hepatobiliary-phase Gd-EOB-DTPA-enhanced MRI.A case of psoriasis vulgaris complicated with antimitochondrial M2 antibody-positive liver dysfunction after infliximab treatmentMasashi Kono; Naoko Tsuji; Nobuto Ozaki; Nozomu Matsumoto; Takehisa Takaba; Naoki Okumura; Masanori Kawasaki; Takafumi Tomita; Yasuko Umehara; Satoko Taniike; Hideki Endo; Ken Ochiai; Shunji Maekura; Masatoshi KudoActa Hepatologica Japonica Japan Society of Hepatology 56 (12) 655 - 660 1881-3593 2016/01 [Refereed] A 51-year-old man with psoriasis vulgaris presented general malaise and liver dysfunction after 9 months of infliximab therapy. Viral blood tests (HBs antigen, anti-HBc antibody, anti-HCV antibody) were negative, while antimitochondrial M2 antibody titer was high, His autoantibody status before the therapy was unknown. His liver function normalized after stopping infliximab and starting the administration of ursodeoxycholic acid and bezafibrate. A liver biopsy specimen showed non-specific inflammatory change without chronic nonsuppurative destructive cholangitis. Several cases of infliximab-related hepatitis have been reported, and many of them were antinuclear antibody-positive, resembling autoimmune hepatitis. Only one case of primary biliary cirrhosis (PBC) after infliximab therapy has been reported, while a high ratio of PBC-psoriasis overlap was reported in England. Infliximab-immunomediated liver dysfunction is a novel disease group, and the further accumulation of cases is needed.第19回 全国原発性肝癌追跡調査報告(2006~2007):(日本肝癌研究会追跡調査委員会)工藤 正俊; 泉 並木; 市田 隆文; 具 英成; 國土 典宏; 坂元 亨宇; 高山 忠利; 中島 収; 松井 修; 松山 裕; 田村 利恵; 前原 なつみ; 上妻 智子肝臓 一般社団法人 日本肝臓学会 57 (1) 45 - 73 0451-4203 2016 第19回全国原発性肝癌追跡調査においては,482施設から2006年1月1日から2007年12月31日までの2年間の20,850例の新規症例と34,752例の追跡症例が集計された.追跡症例の有効回答率は60.0%であった.基礎統計は,第19回新規登録症例を対象として死因,既往歴,臨床診断,画像診断,治療法別の各因子,病理診断,再発,剖検についてまとめた.第18回調査と比較し,肝細胞癌における臨床診断時の高齢化,女性の増加,非B非C肝癌の増加,腫瘍径の縮小の傾向が,治療においては局所療法におけるラジオ波焼灼療法の増加が認められた.1996年から2007年まで新規登録症例の中で最終予後が生存または死亡となった症例(不明を除く)について肝細胞癌,肝内胆管癌,混合型肝癌の治療法別,背景因子別累積生存率を算出した.肝細胞癌については腫瘍個数,腫瘍径,肝障害度を組み合わせることにより背景因子を揃えて,治療法別(肝切除,局所療法,肝動脈塞栓療法)の累積生存率を算出し,また,1980年から2007年までの新規登録症例を3期に分け,累積生存率を算出した.新規登録症例数は経時的に増加し,肝細胞癌の予後の改善が著しいことが明らかとなった.本追跡調査が原発性肝癌の研究および診療の進歩に役立つことを期待する.Endosonography, contrast agents, and elastographyMasayuki Kitano; Kosuke Minaga; Masatoshi KudoEndoscopic Imaging Techniques and Tools Springer International Publishing 187 - 208 2016/01 [Refereed] Recent advances in endoscopic ultrasonography (EUS) imaging technology has led to the evolution of the image-enhanced EUS modalities called contrast-enhanced EUS and EUS elastography. These modalities can depict tissue structure in detail and thus are clinically useful for diagnosing pancreatobiliary and upper gastrointestinal diseases. Moreover, they complement EUS-guided fine-needle aspiration (EUS-FNA) by correctly diagnosing lesions with EUS-FNA false-negative findings and by identifying the most appropriate target site of EUS-FNA. This chapter focuses on the upcoming techniques of imaging in the field of EUS and how these techniques improve the diagnostic ability of EUS, particularly in terms of characterizing conventional EUS-detected lesions.Reply: Hepatocyte damage due to protoporphyrin depositionHagiwara S; Nishida N; Kudo MHepatology 64 306  2016 [Refereed]切除不能肝がん、レゴラフェニブ投与でOS延長~約7年ぶりの有望な結果~工藤正俊Medical Tribune Web 2016 [Refereed]座談会; 肝癌に対する肝動注化学療法のエビデンスと今後工藤正俊; 山下竜也; 池田公史; 上嶋一臣The Liver Cancer Journal 8 13 - 19 2016 [Refereed][Invited]Risk of Hepatocellular Carcinoma in Patients with Hepatitis C Virus Who Achieved Sustained Virological ResponseM. KudoLIVER CANCER KARGER 5 (3) 155 - 161 2235-1795 2016 [Refereed]Breakthrough Imaging in Hepatocellular CarcinomaM. KudoLIVER CANCER KARGER 5 (1) 47 - 54 2235-1795 2016 [Refereed]Defect Reperfusion Imaging with Sonazoid (R): A Breakthrough in Hepatocellular CarcinomaM. KudoLIVER CANCER KARGER 5 (1) 1 - 7 2235-1795 2016 [Refereed]Proposal of a new staging system for intrahepatic cholangiocarcinoma: Analysis of surgical patients from a nationwide survey of the Liver Cancer Study Group of JapanYoshihiro Sakamoto; Norihiro Kokudo; Yutaka Matsuyama; Michiie Sakamoto; Namiki Izumi; Masumi Kadoya; Shuichi Kaneko; Yonson Ku; Masatoshi Kudo; Tadatoshi Takayama; Osamu NakashimaCANCER WILEY-BLACKWELL 122 (1) 61 - 70 0008-543X 2016/01 [Refereed] BACKGROUNDIn the current American Joint Committee on Cancer/International Union Against Cancer staging system (seventh edition) for intrahepatic cholangiocarcinoma (ICC), tumor size was excluded, and periductal invasion was added as a new tumor classification-defining factor. The objective of the current report was to propose a new staging system for ICC that would be better for stratifying the survival of patients based on data from the nationwide Liver Cancer Study Group of Japan database.METHODSOf 756 patients who underwent surgical resection for ICC between 2000 and 2005, multivariate analyses of the clinicopathologic factors of 419 patients who had complete data sets were performed to elucidate relevant factors for inclusion in a new tumor classification and staging system.RESULTSOverall survival data were best stratified using a cutoff value of 2cm using a minimal P value approach to discriminate patient survival. The 5-year survival rate of 15 patients who had ICC measuring 2cm in greatest dimension without lymph node metastasis or vascular invasion was 100%, and this cohort was defined as T1. Multivariate analysis of prognostic factors for 267 patients with lymph node-negative and metastasis-negative (N0M0) disease indicated that the number of tumors, the presence arterial invasion, and the presence major biliary invasion were independent and significant prognostic factors. The proposed new system, which included tumor number, tumor size, arterial invasion, and major biliary invasion for tumor classification, provided good stratification of overall patient survival according to disease stage. Macroscopic periductal invasion was associated with major biliary invasion and an inferior prognosis.CONCLUSIONSThe proposed new staging system, which includes a tumor cutoff size of 2cm and major biliary invasion, may be useful for assigning patients to surgery. Cancer 2016;122:61-70. (c) 2015 The Authors. Cancer published by Wiley Periodicals, Inc. on behalf of American Cancer Society.Contrast-enhanced harmonic endoscopic ultrasonography for differential diagnosis of pancreatic cystsKen Kamata; Masayuki Kitano; Shunsuke Omoto; Kumpei Kadosaka; Takeshi Miyata; Kentaro Yamao; Hajime Imai; Hiroki Sakamoto; Yogesh Harwani; Takaaki Chikugo; Yasutaka Chiba; Ippei Matsumoto; Yoshifumi Takeyama; Masatoshi KudoENDOSCOPY GEORG THIEME VERLAG KG 48 (1) 35 - 41 0013-726X 2016/01 [Refereed] Background and study aim: Comparison of fundamental B-mode endoscopic ultrasonography (FB-EUS) and contrast-enhanced harmonic endoscopic ultrasonography (CH-EUS) in the differential diagnosis of pancreatic cysts according to presence of mural nodules. Patients and methods: Between April 2007 and April 2012, FB-EUS and CH-EUS data were prospectively collected from 581 consecutive patients with pancreatic cysts, and were retrospectively analyzed from 70 with subsequent cyst resection. Presence and height of mural nodules as detected on FB-EUS and CH-EUS were evaluated, and thence accuracies of both methods for diagnosing mucinous versus nonmucinous and malignant versus benign cysts. Results: On pathological examination 48 cysts were mucinous and 22 were nonmucinous; 30 cysts were malignant (high grade dysplasia or invasive carcinoma) and 40 were benign. If presence of a mural nodule was considered to indicate a mucinous cyst, FB-EUS and CH-EUS accuracies did not differ significantly (respectively: sensitivity 85% vs. 79%; specificity 46% vs. 96%; accuracy 73% vs. 84%, P=0.057). If presence of mural nodule was considered to indicate malignancy, CH-EUS was significantly more accurate than FB-EUS (respectively: sensitivity 97% vs. 97%; specificity 75% vs. 40%; accuracy 84% vs. 64%, P=0.0001). For diagnosing malignancy by evaluating mural nodule height, the area under the receiver operating characteristic (AUROC) was 0.84 and 0.93 for FB-EUS and CH-EUS, respectively (P=0.028). Presence of a mural nodule of height >= 4mm on CH-EUS was a sign of malignancy (false-positive fraction 0.2; true-positive fraction 0.93; odds ratio 56.0). Conclusions: CH-EUS is more accurate than FB-EUS for diagnosing malignant pancreatic cysts.Inclusion of Journal of Medical Ultrasonics in MEDLINE.Kudo M; Kanai HJournal of medical ultrasonics (2001) 43 (1) 163  1346-4523 2016/01 [Refereed]Hepaticogastrostomy guided by real-time contrast-enhanced harmonic endoscopic ultrasonography: a novel techniqueKosuke Minaga; Masayuki Kitano; Tomoe Yoshikawa; Shunsuke Omoto; Ken Kamata; Kentaro Yamao; Masatoshi KudoENDOSCOPY GEORG THIEME VERLAG KG 48 E228 - E229 0013-726X 2016 [Refereed]Survival Benefit of Locoregional Treatment for Hepatocellular Carcinoma with Advanced Liver CirrhosisSatoshi Kitai; Masatoshi Kudo; Naoshi Nishida; Namiki Izumi; Michiie Sakamoto; Yutaka Matsuyama; Takafumi Ichida; Osamu Nakashima; Osamu Matsui; Yonson Ku; Norihiro Kokudo; Masatoshi MakuuchiLIVER CANCER KARGER 5 (3) 175 - 189 2235-1795 2016 [Refereed] Background & Aims: Hepatocellular carcinoma (HCC) with decompensated liver cirrhosis (LC) is a life-threatening condition, which is amenable to liver transplantation (LT) as the standard first-line treatment. However, the application of LT can be limited due to a shortage of donor livers. This study aimed to clarify the effect of non-surgical therapy on the survival of patients with HCC and decompensated LC. Methods: Of the 58,886 patients with HCC registered in the nationwide survey of the Liver Cancer Study Group of Japan (January 2000-December 2005), we included 1,344 patients with primary HCC and Child-Pugh (C-P) grade C for analysis in this retrospective study. Among the patients analyzed, 108 underwent LT, 273 were treated by local ablation therapy (LAT), 370 were treated by transarterial chemoembolization (TACE), and 593 received best supportive care (BSC). The effect of LT, LAT, and TACE on overall survival (OS) was analyzed using multivariate and propensity score analyses. Results: Patient characteristics did not differ significantly between each treatment group and the BSC group, after propensity score matching. LAT (hazard ratio [HR]) = 0.568; 95% confidence interval [CI], 0.40-0.80) and TACE (HR = 0.691; 95% CI, 0.50-0.96) were identified as significant contributors to OS if the C-P score was less than 11 and tumor conditions met the Milan criteria. Conclusions: For patients with HCC within the Milan criteria and with a C-P score of 10 or 11, locoregional treatment can be used as a salvage treatment if LT is not feasible. Copyright (C) 2016 S. Karger AG, BaselSafety, Tolerability, and Efficacy of Sofosbuvir Plus Ribavirin in Elderly Patients Infected with Hepatitis C Virus Genotype 2Naoshi Nishida; Masashi Kono; Tomohiro Minami; Hirokazu Chishina; Tadaaki Arizumi; Masahiro Takita; Norihisa Yada; Hiroshi Ida; Satoru Hagiwara; Yasunori Minami; Kazuomi Ueshima; Tashiharu Sakurai; Masatoshi KudoDIGESTIVE DISEASES KARGER 34 (6) 632 - 639 0257-2753 2016 [Refereed] Background: An interferon-free regimen including sofosbuvir and ribavirin (RBV) for patients with hepatitis C virus (HCV) genotype 2 (G2) infection leads to a drastic improvement of sustained virological response (SVR). However, the safety, tolerability, and efficacy in patients aged 75 or older have not been completely understood. Summary: Fifty-six patients with HCV G2 infection who were treated with sofosbuvir and weight-based dose of RBV were enrolled. Thirty-seven patients aged and 19 patients aged were classified as the aged and non-aged groups, respectively. The aged group was characterized by significantly more number of women, history of hepatocellular carcinoma, low serum albumin (ALB) level, low hemoglobin (Hb) concentration, low estimated glomerular filtration rate (eGFR), and high fibrosis-4 index (p = 0.0029). Forty-one patients were evaluated for SVR at 12 weeks after the end of therapy (SVR12); of them, all but one completed the treatment scheduled for 12 weeks. The aged group showed lower SVR12 rate than the non aged group (81.3%for aged and 96.0%for non-aged groups). Although the Hb concentration and eGFR are significantly lower in the aged group throughout the clinical course, all patients in the aged group completed the 12-week treatment with a gradual increase of serum ALB level. Key Messages: The combination of sofosbuvir plus RBV is tolerable and beneficial in patients aged >75. However, intensive management of anemia by dose reduction of RBV is necessary, which could lead to a low SVR12 rate compared to that observed in patients younger than 75 years. (C) 2016 S. Karger AG, BaselCases with Refractory Ascites and a Delayed Response to TolvaptanSatoru Hagiwara; Naoshi Nishida; Hirokazu Chishina; Hiroshi Ida; Toshiharu Sakurai; Yoriaki Komeda; Masayuki Kitano; Masatoshi KudoINTERNAL MEDICINE JAPAN SOC INTERNAL MEDICINE 55 (22) 3273 - 3277 0918-2918 2016 [Refereed] The patient was a 67-year-old female with liver cirrhosis due to hepatitis C. She was administered furosemide at 20 mg/day and spironolactone at 25 mg/day, but the ascites did not improve. Despite the additional administration of tolvaptan at 3.75 mg/day, the response to ascites was still poor. While the dose of tolvaptan was thereafter increased to 7.5 mg/day on the 7th hospital day, the ascites still persisted. However, she continued to receive tolvaptan (7.5 mg/day) because the worsening of her subjective symptoms was mild and she wished to do so. The ascites was later found to have almost completely disappeared on computed tomography (CT) at 6 months.抗血栓薬服用患者における検査・治療について青山真吾; 足立哲平; 松井繁長; 樫田博史; 工藤正俊近畿大学医学雑誌 41 129 - 134 2016 [Refereed]EUSガイド下胆嚢ドレナージ術竹中 完; 北野雅之; 鎌田 研; 三長孝輔; 大本俊介; 宮田 剛; 山雄健太郎; 今井 元; 工藤正俊消化器内視鏡 28 1669 - 1678 2016 [Refereed]EUS-guided Biliary Drainage -Recent Advances-Kitano Masayuki; Minaga Kosuke; Imai Hajime; Kudo MasatoshiTando Japan Biliary Association 30 (4) 689 - 698 0914-0077 2016 [Refereed] EUS-guided biliary drainage (EUS-BD) has been increasingly used as an alternative in patients with biliary obstruction in whom standard ERCP failed. Its potential and efficacy has drawn attention and many articles about EUS-BD have been published in the past few years. Various endoscopic approaches have been described for EUS-BD. There are two major approach routes; transgastric intrahepatic approach and transduodenal extrahepatic approach. Biliary drainage may be achieved by three different methods; transmural biliary stenting, transpapillary rendezvous maneuver, and antegrade biliary stenting. The choice of drainage route and method depends on the individual anatomy and location of the biliary stricture. A recent systematic review and meta-analysis that included 42 studies with 1192 patients who underwent EUS-BD revealed that the cumulative technical success rate and the adverse event rate were 94.7% and 23.3%, respectively. The development of a new dedicated device for EUS-BD would help to refine the technical aspects and minimize the possibility of complications, making it a more sophisticated and promising procedure.WONに対する内視鏡的ドレナージ三長孝輔; 北野雅之; 竹山宜典; 大本俊介; 宮田 剛; 鎌田 研; 山雄健太郎; 工藤正俊肝胆膵 73 41 - 51 2016 [Refereed]急性膵炎診療における地域連携モデルの構築大本俊介; 北野雅之; 工藤正俊; 松本逸平; 竹山宜典肝胆膵 72 1003 - 1007 2016 [Refereed]Through-the-mesh technique after endoscopic ultrasonography-guided hepaticogastrostomy: a novel re-intervention methodKosuke Minaga; Mamoru Takenaka; Takeshi Miyata; Yasuhiro Ueda; Masayuki Kitano; Masatoshi KudoENDOSCOPY GEORG THIEME VERLAG KG 48 (S 01) E369 - E370 0013-726X 2016 [Refereed]Regorafenib as Second-Line Systemic Therapy May Change the Treatment Strategy and Management Paradigm for Hepatocellular CarcinomaM. KudoLIVER CANCER KARGER 5 (4) 235 - 244 2235-1795 2016 [Refereed][Invited]Feasibility of Extracted-Overlay Fusion Imaging for Intraoperative Treatment Evaluation of Radiofrequency Ablation for Hepatocellular CarcinomaYuki Makino; Yasuharu Imai; Takumi Igura; Sachiyo Kogita; Yoshiyuki Sawai; Kazuto Fukuda; Takayuki Iwamoto; Junya Okabe; Manabu Takamura; Norihiko Fujita; Masatoshi Hori; Tetsuo Takehara; Masatoshi Kudo; Takamichi MurakamiLIVER CANCER KARGER 5 (4) 269 - 279 2235-1795 2016 [Refereed] Background and Aims: Extracted-overlay fusion imaging is a novel computed tomography/magnetic resonance-ultrasonography (CT/MR-US) imaging technique in which a target tumor with a virtual ablative margin is extracted from CT/MR volume data and synchronously overlaid on US images. We investigated the applicability of the technique to intraoperative evaluation of radiofrequency ablation (RFA) for hepatocellular carcinoma (HCC). Methods: This retrospective study analyzed 85 HCCs treated with RFA using extracted-overlay fusion imaging for guidance and evaluation. To perform RFA, an electrode was inserted targeting the tumor and a virtual 5-mm ablative margin overlaid on the US image. Following ablation, contrast-enhanced US (CEUS) was performed to assess the ablative margin, and the minimal ablative margins were categorized into three groups: (I) margin <0 mm (protrusion), (II) margin 0 to <5 mm, and (III) margin >= 5 mm. Margin assessment was based on the positional relationship between the overlaid tumor plus margin and the perfusion defect of the ablation zone. Tumors in group I underwent repeat ablation until they were in groups II or III. The final classifications were compared with those obtained by retrospectively created fusion images of pre- and post-RFA CT or MR imaging (CT-CT/MR-MR fusion imaging). Results: Treatment evaluation was impossible using CEUS in six HCCs because the tumors were located far below the body surface. Of the remaining 79 HCCs, the categorizations of minimal ablative margins between CEUS extracted-overlay fusion imaging and CT-CT/MR-MR fusion imaging were in agreement for 72 tumors (91.1%) (Cohen's quadratic-weighted kappa coefficient 0.66, good agreement, p<0.01). Conclusions: Extracted-overlay fusion imaging combined with CEUS is feasible for the evaluation of RFA and enables intraoperative treatment evaluation without the need to perform contrast-enhanced CT. Copyright (C) 2016 S. Karger AG, Basel肝細胞癌に対する分子標的治療薬開発の現状と将来展望工藤正俊医学あゆみ 258 537 - 543 2016 [Refereed][Invited]Survival Analysis over 28 Years of 173,378 Patients with Hepatocellular Carcinoma in JapanMasatoshi Kudo; Namiki Izumi; Michiie Sakamoto; Yutaka Matsuyama; Takafumi Ichida; Osamu Nakashima; Osamu Matsui; Yonson Ku; Norihiro Kokudo; Masatoshi MakuuchiLIVER CANCER KARGER 5 (3) 190 - 197 2235-1795 2016 [Refereed] Background: Beginning in 1967, the Liver Cancer Study Group of Japan (LCSGJ) started a nationwide prospective registry of all patients with hepatocellular carcinoma (HCC) diagnosed at more than 700 institutions. To determine the effectiveness of surveillance and treatment methods longitudinally, we analyzed improvements over time in overall survival (OS) of 173,378 patients with HCC prospectively entered into the LCSGJ registry between 1978 and 2005. Methods: All patients from more than 700 institutions throughout Japan with HCC were entered into the LCSGJ registry. Patients were grouped by years of diagnosis, with OS and 5-year OS rates being calculated. We also assessed OS and 5-year OS rates in patients who underwent resection, local ablation, transarterial chemoembolization (TACE), and hepatic arterial infusion chemotherapy (HAIC) and in those with baseline serum alpha-fetoprotein (AFP) levels >= 400 ng/ml. Results: The 5- and 10-year OS rates in the cohort of 173,378 patients were 37.9% and 16.5%, respectively. However, over time, the mean maximum tumor size decreased significantly, whereas 5-year OS rates and median survival time increased significantly. Similar findings were observed separately in patients who underwent resection, local ablation, TACE, and HAIC, as well as in patients with AFP levels >= 400 ng/ml. Conclusion: The establishment of a nationwide HCC surveillance program in Japan has contributed to longer median OS and increased OS rates in patients diagnosed with this disease. These findings suggest that the establishment of a surveillance program in other countries with patients at risk for HCC may provide significant survival benefits. Copyright (C) 2016 S. Karger AG, BaselImpact of Tight Junction Protein ZO-1 and TWIST Expression on Postoperative Survival of Patients with Hepatocellular CarcinomaTomoyuki Nagai; Tokuzo Arao; Kazuto Nishio; Kazuko Matsumoto; Satoru Hagiwara; Toshiharu Sakurai; Yasunori Minami; Hiroshi Ida; Kazuomi Ueshima; Naoshi Nishida; Kazuko Sakai; Nagahiro Saijo; Kanae Kudo; Hiroyasu Kaneda; Daisuke Tamura; Keiichi Aomatsu; Hideharu Kimura; Yoshihiko Fujita; Seiji Haji; Masatoshi KudoDIGESTIVE DISEASES KARGER 34 (6) 702 - 707 0257-2753 2016 [Refereed] Background: Epithelial-mesenchymal transition (EMT) is considered to play a critical role in cancer progression and metastasis. However, the impact of EMT on the prognosis of hepatocellular carcinoma (HCC) is still elusive. In this study, we examined the relationship between the expression of EMT markers and recurrence-free survival (RFS) and overall survival (OS) in HCC patients after hepatic resection. Summary:The mRNA expression of 15 genes related to EMT was assessed by quantitative real-time polymerase chain reaction in cancerous tissues from 72 patients who underwent hepatic resection of HCC between January 2005 and December 2010 at our hospital. The upregulation of TWIST and the downregulation of tight junction protein ZO-1 (TJP1) were significantly associated with shorter RFS as well as OS. Increased levels of TWIST and decreased levels of TJP1 should be predictive markers for poor prognosis in patients with HCC after hepatectomy; those could serve as potential biomarkers for the treatment of HCC. Key Messages: A low level of TJP1 and high level of TWIST expression were prognostic factors predicting HCC after hepatic resection. (C) 2016 S. Karger AG, BaselComparison of Two-Dimensional Shear Wave Elastography and Real-Time Tissue Elastography for Assessing Liver Fibrosis in Chronic Hepatitis BTao Wu; Ping Wang; Ting Zhang; Jian Zheng; Shuoyang Li; Jie Zeng; Masatoshi Kudo; Rongqin ZhengDIGESTIVE DISEASES KARGER 34 (6) 640 - 649 0257-2753 2016 [Refereed] Background: Noninvasive assessment of liver fibrosis has important clinical significance. Different techniques including two-dimensional shear-wave elastography (2D SWE) and real-time tissue elastography (RTE) are reported to be useful for the noninvasive diagnosis of hepatic fibrosis. All these techniques are affected by many factors. How to choose a reasonable method needs further studies. Purpose: This study was conducted to comparatively assess the diagnostic performance of 2D SWE and RTE in patients with Chronic Hepatitis B (CHB) and influence of inflammation on the stiffness values obtained by both techniques, so as to objectively assess the reasonable choice between these 2 elastography techniques for noninvasive assessment of hepatic fibrosis in clinical practice. Materials and Methods: Four hundred and thirty-seven patients with CHB meeting the inclusion criteria were enrolled in the study. All patients underwent liver stiffness measurements by using 2D SWE and RTE on the same day. Histologic fibrosis was staged and inflammation activity was graded based on the METAVIR scoring system on liver biopsy specimens. Results: The liver stiffness values by using 2D SWE and RTE both increased in parallel with the degree of liver fibrosis and the grade of inflammation. However, the diagnostic efficacy of significant fibrosis and cirrhosis using 2D SWE was significantly higher than that of RTE. The 2D SWE measurement values were statistically different in different alanine aminotransferase (ALT) levels and METAVIR activity grades; however, no statistically significant differences were observed by using RTE. The diagnostic efficacy of 2D SWE significantly varied with elevated ALT levels compared with RTE. Conclusion: 2D SWE was more accurate than RTE in the assessment of significant fibrosis and cirrhosis in patients with CHB. Compared with RTE, the measurement values and diagnostic performance obtained by 2D SWE were prone to be more easily affected by the inflammation fluctuations. (C) 2016 S. Karger AG, BaselValidation of Kinki Criteria, a Modified Substaging System, in Patients with Intermediate Stage Hepatocellular CarcinomaTadaaki Arizumi; Kazuomi Ueshima; Mina Iwanishi; Tomohiro Minami; Hirokazu Chishina; Masashi Kono; Masahiro Takita; Satoshi Kitai; Tatsuo Inoue; Norihisa Yada; Satoru Hagiwara; Yasunori Minami; Hiroshi Ida; Toshiharu Sakurai; Masayuki Kitano; Naoshi Nishida; Masatoshi KudoDIGESTIVE DISEASES KARGER 34 (6) 671 - 678 0257-2753 2016 [Refereed] Background: The standard treatment option that is available for patients with Barcelona Clinic Liver Cancer (BCLC) stage B hepatocellular carcinoma (HCC) is transarterial chemoembolization (TACE). However, the condition of the patients with BCLC stage B disease is heterogeneous showing different tumor statuses and Child Pugh scores; treatment strategies other than TACE are frequently employed for the patients in this stage. Based on the subclassification system proposed by Bolondi et al. [Semin Liver Dis 2012;32:348-359], we developed the Kinki criteria focusing on a substaging for BCLC stage B disease, which is simpler and should be more suitable in actual clinical setting in Japan. In this study, we evaluated the performance of Kinki criteria. Summary: This study included 1,633 HCC patients who received first line treatment at the Kindai University Hospital. Patients were classified into subgroups based on the Kinki criteria and the survival time was estimated for each group. There were 156 (33.3%) patients in subclass B1, 278 (59.3%) in B2, and 35 (7.4%) in B3. The median overall survival times and 95% CI for BCLC B subclasses B1, B2, and B3 were 4.3 years (3.7-4.9), 2.9 years (2.2-3.4), and 1.1 years (0.5-1.8), respectively (p < 0.001). Key Messages: Classification of HCC patients in BCLC stage B based on the Kinki criteria showed statistically significant differences in survival, indicating the performance of Kinki criteria, which takes Child Pugh score and tumor status into account for determining treatment options for HCC in BCLC stage B. (C) 2016 S. Karger AG, BaselComparison of Contrast-Enhanced Ultrasound and Gadoliniurn-Ethoxybenzyl-Diethylenetriarnine Pentaacetic Acid-Enhanced MIDI for the Diagnosis of Macroscopic Type of Hepatocellular CarcinomaTakayuki Iwamoto; Yasuharu Imai; Sachiyo Kogita; Takumi Igura; Yoshiyuki Sawai; Kazuto Fukuda; Yoshitaka Yamaguchi; Yasushi Matsumoto; Masanori Nakahara; Osakuni Morimoto; Yasushi Seki; Hiroshi Ohashi; Norihiko Fujita; Masatoshi Kudo; Tetsuo TakeharaDIGESTIVE DISEASES KARGER 34 (6) 679 - 686 0257-2753 2016 [Refereed] Objective: We compared the efficacy of contrast-enhanced ultrasound sonography (CEUS) with sonazoid and gadolinium-ethoxybenzyl-diethylenetriamine pentaacetic acid (GdEOB-DTPA)-enhanced MRI for the assessment of macroscopic classification of nodular hepatocellular carcinoma (HCC). Methods: Seventy-seven consecutive patients with 79 surgically resected HCCs who underwent both preoperative CEUS and Gd-EOB-DTPA-enhanced MRI were enrolled in this retrospective study. Based on the macroscopic diagnosis of resected specimens, nodules were categorized into the simple nodular (SN) and non-SN type HCC. Two hepatologists independently assessed image datasets of the post-vascular phase of CEUS and hepatobiliary phase of Gd-EOB-DTPA-enhanced MRI to compare their diagnostic performance. Results: Gd-EOB-DTPA-enhanced MRI enabled the evaluation of macroscopic classification in a significantly larger number of nodules than CEUS (78/79 (98.7%) vs. 70/79 (88.6%), p < 0.05). Of 70 nodules that could be evaluated by both modalities, 41 and 29 nodules were pathologically categorized as SN and non-SN, respectively. The areas under the receiver operating characteristic curve (AUC) for non-SN did not differ between CEUS and Gd-EOB-DTPA-enhanced MRI (reader 1: 0.748 for CEUS, 0.808 for MRI; reader 2: 0.759 for CEUS, 0.787 for MRI). The AUC of combined CEUS and Gd-EOB-DTPA-enhanced MRI for SN HCC was 0.855 (reader 1) and 0.824 (reader 2), indicating higher AUC values for the combined modalities. Conclusions: The diagnostic performance for macroscopic classification of nodular HCC of CEUS was comparable with that of Gd-EOB-DTPA-enhanced MRI, although some HCCs could not be evaluated by CEUS owing to lower detectability. The combination of the 2 modalities had a more accurate diagnostic performance. (C) 2016 S. Karger AG, BaselRadiofrequency Ablation Guided by Contrast-Enhanced Sonography versus B-Mode Sonography for Hepatocellular Carcinoma after Transcatheter Arterial ChemoembolizationToshihiko Kawasaki; Kan-yun Hata; Daisuke Kinoshita; Masaki Takayama; Hideyuki Okuda; Shigeto Mizuno; Masatoshi KudoDIGESTIVE DISEASES KARGER 34 (6) 692 - 695 0257-2753 2016 [Refereed] Purpose: Contrast-enhanced sonography increases negative enhancement in the Kupffer phase after transcatheter arterial chemoembolization (TACE) for hepatocellular carcinoma (HCC). We compared contrast-enhanced sonography with B-mode sonography for guidance of radiofrequency ablation (RFA) of HCC after TACE. Methods: After TACE was performed, 18 nodules in 12 patients were treated by B mode sonography guided RFA, while 22 nodules in 18 patients were treated by contrast-enhanced sonography-guided RFA. Results: The success rate of initial RFA was 83.3% (15/18 nodules) in the B-mode sonography group. On the other hand, the success rate was 100% (22/22 nodules) in the contrast-enhanced sonography group and the difference was significant (p = 0.046). Conclusion: These findings suggest that RFA guided by Kupffer phase contrast-enhanced sonography after TACE is a promising therapeutic option for curing HCC. (C) 2016 S. Karger AG, BaselEfficacy and Safety of Sofosbuvir Plus Ribavirin Treatment for Patients with Chronic Hepatitis C Genotype 2Kayo Sugimoto; Soo Ki Kim; Soo Ryang Kim; Mana Kobayashi; Airi Kato; Eri Morimoto; Susumu Imoto; Chi Wan Kim; Yasuhito Tanaka; Masatoshi Kudo; Yoshihiko Yano; Yoshitake HayashiDIGESTIVE DISEASES KARGER 34 (6) 627 - 631 0257-2753 2016 [Refereed] Objectives: The efficacy of sofosbuvir plus ribavirin (RBV) treatment for hepatitis C virus (HCV) genotype 2 focusing on virological response was compared with that of pegylated interferon (peg-IFN) plus RBV treatment. Safety of the former focusing on the decline in hemoglobin levels was compared with that of the latter and assessed in terms of age and inosine triphosphatase (ITPA). Methods: Patients (n = 17) receiving sofosbuvir plus RBV and those (n = 24) receiving peg-IFN plus RBV diagnosed with chronic HCV genotype 2 were enrolled in this study, and the efficacy and safety of both treatments were assessed. Results: Rapid virological response was attained with sofosbuvir plus RBV treatment compared with peg-IFN plus RBV treatment. All patients under sofosbuvir plus RBV treatment achieved end-of-treatment response compared with 70% who sustained viral response under the peg-IFN plus RBV treatment, with the former demonstrating greater virological response. The decline in hemoglobin levels under the former treatment was greater than that under the latter and in patients over 65 years of age with ITPA gene major. Conclusion: Efficacy and safety of sofosbuvir plus RBV treatment were clearly demonstrated compared with those of peg-IFN plus RBV treatment. The decline in hemoglobin levels was not related to the discontinuation of the former treatment, irrespective of age or the effect of the ITPA gene. (C) 2016 S. Karger AG, BaselProspective Risk Analysis of Hepatocellular Carcinoma in Patients with Chronic Hepatitis C by Ultrasound Strain ElastographyNorihisa Yada; Toshiharu Sakurai; Tomohiro Minami; Tadaaki Arizumi; Masahiro Takita; Satoru Hagiwara; Hiroshi Ida; Kazuomi Ueshima; Naoshi Nishida; Masatoshi KudoDIGESTIVE DISEASES KARGER 34 (6) 650 - 653 0257-2753 2016 [Refereed] Objective: We have reported about real-time tissue elastography (RTE), which displays relative strain by measuring the relative distortion of the tissue, and found this information to be useful for diagnosing liver fibrosis. However, its use in predicting hepatocellular carcinoma has not been reported as yet. Here, we investigated RTE to predict liver carcinogenesis in patients with chronic hepatitis C virus (HCV) infection. Methods: We enrolled 160 patients with chronic HCV, who were followed up for 39.9 +/- 22.9 weeks (median). They underwent RTE and then ultrasounds every 3-6 months. Results: Respective cumulative liver cancer incidences for years 1, 2, 3, 4, and 5 were, for the entire cohort: 2.0, 5.6, 8.8, 13.1, and 23.9%; for those whose liver fibrosis index (LFI) was <= 2.0: 0.0, 0.0, 0.0, 0.0, and 0.0%; for those whose LFI was 2-2.8:0.0, 7.4, 7.4, 13.2 and 19.9%; and for those whose LFI was >2.8: 12.9, 12.9, 21.7, 31.4, and 31.4% (p = 0.011; log-rank test). Conclusions: Measurements of LFI by strain imaging can effectively predict liver cancer risk in patients with chronic HCV infection. (C) 2016 S. Karger AG, BaselCoffee intake and Liver Enzyme Association in Korean immigrants and Japanese: A Comprehensive Cross-Sectional StudySoo Ki Kim; Myung-Hee Shin; Kayo Sugimoto; Soo Ryang Kim; Susumu Imoto; Ke Ih Kim; Miyuki Taniguchi; Hyun-Kyung Oh; Yoshihiko Yano; Yoshitake Hayashi; Masatoshi KudoDIGESTIVE DISEASES KARGER 34 (6) 665 - 670 0257-2753 2016 [Refereed] Objectives: Significant inverse association between coffee intake and the levels of liver enzymes has been reported. We demonstrated higher prevalence of metabolic syndrome in Korean immigrants (KIs) than in indigenous Japanese (Us). The aim of this study was to investigate whether the association between coffee intake and liver enzyme levels was different between the 2 ethnic groups. Methods: This study is a cross-sectional study including a total of 966 subjects comprising KIs and Us. The association between the quintiles of coffee intake and dichotomous values of liver enzymes was evaluated by logistic regression analysis in KIs, Us, a high-risk group (current smokers or alcohol drinkers >= 45 g/day), and a low-risk group (non-smokers and alcohol drinkers <45 g/day). Results: In KIs, a significant inverse association between coffee intake and serum aspartate aminotransferase (AST) levels was observed. In the Us, a significant inverse association between coffee intake and serum alanine aminotransferase levels was observed. In the high-risk-group, a significant inverse association between coffee intake and serum AST and gamma-glutamyltransferase levels was observed. Conclusion: No difference was observed between KIs and Us regarding the association between coffee and liver enzymes. Coffee might inhibit hepatic damage by alcohol drinking and smoking. (C) 2016 S. Karger AG, BaselRecent Trends in the Management of Hepatocellular Carcinoma with Special Emphasis on Treatment with Regorafenib and Immune Checkpoint InhibitorsMasatoshi KudoDIGESTIVE DISEASES KARGER 34 (6) 714 - 730 0257-2753 2016 [Refereed][Invited] Hepatocellular carcinoma (HCC) is the fifth most common cancer and the third leading cause of cancer deaths worldwide. Sonazoid-enhanced ultrasound and gadolinium ethoxybenzyl diethylenetriamine pentaacetic acid-enhanced MRI are the most important imaging modalities in diagnosing HCC. There are 2 non-contradictory HCC treatment algorithms in Japan. Hepatic arterial infusion chemotherapy plays an important role in the treatment of advanced HCC with main or branch portal vein invasion. Regorafenib, as a second-line systemic treatment, prolongs survival in patients with intermediate and advanced HCC who progressed on sorafenib. In recent clinical trials, immune check point inhibitors show promising results for the treatment of HCC. This review describes recent trends in the management of HCC. (C) 2016 S. Karger AG, BaselPrediction of Embolization Area after Conventional Transcatheter Arterial Chemoembolization for Hepatocellular Carcinoma Using SYNAPSE VINCENTChikara Ogawa; Yasunori Minami; Masahiro Morita; Teruyo Noda; Soichi Arasawa; Masako Izuta; Atsushi Kubo; Toshihiro Matsunaka; Hiroyuki Tamaki; Mitsushige Shibatoge; Masatoshi KudoDIGESTIVE DISEASES KARGER 34 (6) 696 - 701 0257-2753 2016 [Refereed] Purpose: Transcatheter arterial chemoembolization (TACE) is one of the most effective therapeutic options for hepatocellular carcinoma (HCC) and it is important to protect residual liver function after treatment as well as the effect. To reduce the liver function deterioration, we evaluated the automatic software to predict the embolization area of TACE in 3 dimensions. Materials and Methods: Automatic prediction software of embolization area was used in chemoembolization of 7 HCCs. Embolization area of chemoembolization was evaluated within 1 week CT findings after TACE and compared simulated area using automatic prediction software. Results: The maximal diameter of these tumors is in the range 12-42 mm (24.6 +/- 9.5 mm). The average time for detecting tumor-feeding branches was 242 s. The total time to detect tumor-feeding branches and simulate the embolization area was 384 s. All cases could detect all tumor-feeding branches of HCC, and the expected embolization area of simulation with automatic prediction software was almost the same as the actual areas, as shown by CT after TACE. Conclusion: This new technology has possibilities to reduce the amount of contrast medium used, protect kidney function, decrease radiation exposure, and improve the therapeutic effect of TACE. (C) 2016 S. Karger AG, BaselUS-US Fusion Imaging in Radiofrequency Ablation for Liver MetastasesYasunori Minami; Tomohiro Minami; Hirokazu Chishina; Masashi Kono; Tadaaki Arizumi; Masahiro Takita; Norihisa Yada; Satoru Hagiwara; Hiroshi Ida; Kazuomi Ueshima; Naoshi Nishida; Masatoshi KudoDIGESTIVE DISEASES KARGER 34 (6) 687 - 691 0257-2753 2016 [Refereed] Objective: Radiofrequency ablation (RFA) induces gas bubbles in ablation zones, and the ablative margin cannot be evaluated accurately on ultrasound (US) during and immediately after RFA. This study assessed the usefulness of US-US fusion imaging to visualize the ablative margin of RFA for liver metastasis. Methods: RFA guided by US-US fusion imaging was performed on 12 targeted tumors in 10 patients. Secondary hepatic malignancies included patients with colorectal cancer (n = 4), breast cancer (n = 2), lung cancer (n = 1), gastrointestinal stromal tumor (n = 1), pancreatic neuroendocrine tumor (n = 1), and adrenocortical carcinoma (n = 1). The maximal diameter of the tumors ranged from 0.8 to 4.0 cm (mean SD 1.6 +/- 0.9 cm). Results: The mean number of electrode insertions was 1.6 per session (range 1-3). Technically, effective ablation was achieved in a single session in all patients, and safety ablative margins were confirmed on contrast-enhanced CT for early assessment of tumor response. There were no serious adverse events or procedure-related complications. During the follow-up period (median 220 days, range 31-417 days), none of the patients showed local tumor progression. Conclusion: US-US fusion imaging could show the tumor images before ablation and the ablative area on US in real time. The image overlay of US-US fusion imaging made it possible to evaluate the ablative margin three dimensionally according to the US probe action. Therefore, US-US fusion imaging can contribute to RFA therapy with a safety margin, that is, the so-called precise RFA. (C) 2016 S. Karger AG, BaselClinical Significance of Epigenetic Alterations in Human Hepatocellular Carcinoma and Its Association with Genetic MutationsNaoshi Nishida; Masatoshi KudoDIGESTIVE DISEASES KARGER 34 (6) 708 - 713 0257-2753 2016 [Refereed] Accumulation of genetic and epigenetic alterations is a hallmark of cancer genomes, including those in hepatocellular carcinoma (HCC). Particularly, in human HCC, epigenetic changes are more frequently observed than genetic changes in a variety of cancer-related genes, suggesting a potential role for epigenetic alterations during hepatocarcinogenesis. Several environmental factors, such as inflammation, obesity, and steatosis, are reported to affect the epigenetic status in hepatocytes, which could play a role in HCC development. In addition, genetic mutations in histone modulators and chromatin regulators would be critical for the acceleration of epigenetic alteration. It is also possible that major genetic mutations of HCC, such as TP53 and CNTTB1 mutations, are associated with the disturbance of epigenetic integrity. For example, specific TP53 mutations frequently induced by aflatoxin B1 exposure might affect histone modifiers and nucleosome remodelers. Generally, epigenetic alteration is reversible, because of which dysregulation of transcription takes place, without affecting protein structure. Therefore, differentiation therapy is one of the potential approaches for HCC with advanced epigenetic alterations. On the other hand, a tumor carrying an accumulation of genetic mutations would result in many abnormal proteins that could be recognized as non-self and could be targets for immune reactions; thus, immune-checkpoint blockers should be effective for HCCs with genetic hypermutation. Although the emergence of genetic and epigenetic alterations could be linked to each other and there could be some crossover or convergence between these cancer pathways, characterization of the mutation spectrum of genetic and epigenetic alterations could influence future HCC treatment. (C) 2016 S. Karger AG, BaselClinical Factors Predicting the Effect of Tolvaptan for Refractory Ascites in Patients with Decompensated Liver CirrhosisHirokazu Chishina; Satoru Hagiwara; Naoshi Nishida; Kazuomi Ueshima; Toshiharu Sakurai; Hiroshi Ida; Yasunori Minami; Masahiro Takita; Masashi Kono; Tomohiro Minami; Mina Iwanishi; Yasuko Umehara; Tomohiro Watanabe; Yoriaki Komeda; Tadaaki Arizumi; Masotoshi KudoDIGESTIVE DISEASES KARGER 34 (6) 659 - 664 0257-2753 2016 [Refereed] Objective: Refractory ascites reduces the quality of life of liver cirrhosis patients. Albumin preparation and diuretics, such as furosemide, have been used to treat refractory ascites, but the effect was poor in many patients. In this study, we analyzed patients treated with tolvaptan (TLV) at our hospital and investigated predictors of the effect. Methods: The subjects were 70 patients for whom TLV was introduced to treat refractory ascites who could be analyzed between November 2013 and March 2015 at our hospital. Patient background before initiation of oral TLV treatment, the dose of diuretics, and each item of biochemical tests of blood and urine were investigated, and factors correlated with the treatment effect were analyzed. An increase of >= 1,000 ml in the daily urine volume from the day before oral treatment or a decrease of kg in the body weight within 7 days as an early effect was observed in 33 patients and not observed in 37 patients. TLV treatment was continued for 60 days or longer in 12 of the 37 patients in whom no early effect was observed, and the presence or absence of a delayed effect and predictors of the effect were investigated. A decrease in as cites on abdominal CT with improvement of subjective symptoms at 60 days was defined as a delayed effect. Results: When early predictors of the effect were investigated by univariate analysis, serum blood urea nitrogen (BUN) and serum creatinine (Cr) were significantly higher in the non responder group (BUN: p = 0.03, Cr: p = 0.04), but no factor independently associated with the treatment effect was extracted on multivariate analysis. The delayed effect was noted in 4 (33.3%) of the 12 patients, but no predictor of the effect before treatment was identified. However, reactions, such as an increase in serum Na and reduction of urinary osmotic pressure, were observed early after TLV administration in some patients in whom the delayed effect was observed. Conclusions: The diuretic effect of TLV may decrease in renal hypofunction patients. Since the delayed effect was noted in a specific ratio of patients, continuation of TLV administration is an option even though the early treatment effect is poor unless ascites aggravates or adverse effects develop. (C) 2016 S. Karger AG, BaselMonoethanolamine Oleate Sclerotherapy for Polycystic Liver DiseaseMasahiro Takita; Mina Iwanishi; Tomohiro Minami; Masashi Kono; Hirokazo Chishina; Tadaaki Arizumi; Norihisa Yada; Satoru Hagiwara; Yasunori Minami; Hiroshi Ida; Kazuomi Ueshima; Nishida Naoshi; Masatoshi KudoDIGESTIVE DISEASES KARGER 34 (6) 654 - 658 0257-2753 2016 [Refereed] Objective: The objective of treatment for polycystic liver disease is to reduce the liver volume and reduce or resolve compression symptoms such as abdominal fullness and abdominal pain due to hepatomegaly. Liver cysts are treated internally by puncture and aspiration of the cyst contents or hepatic artery embolization and surgically by cyst fenestration or hepatectomy, but no clear consensus has been reached concerning their selection. We introduced monoethanolamine oleate (EO) sclerotherapy therapy for liver cysts in 1999 and reported its effectiveness. In this study, cases were added, and the results including those of long-term follow-up were evaluated. Subjects: Twenty-two patients (5 males and 17 females, mean age 65.2) who underwent EO infusion therapy for liver cysts between January 1999 and June 2011 were evaluated. Methods: Liver cysts were punctured under ultrasound guidance, and a 7Fr pigtail catheter was inserted. After aspirating the cyst contents, EO was infused, and a clamp was applied for 24 h. Then, the catheter was declamped, cyst contents were aspirated again, and the catheter was removed. After the treatment, the cyst size was measured, and the patients were followed up. Results: Eight simple cysts in 8 patients (simple cyst group) and 21 cysts in 14 patients with multiple cysts (polycystic liver disease group) were treated and followed up over a median of 78 months (0-203 months). The mean volume reduction rate was 99% in the simple cyst group and 91% in the polycystic liver disease group (p = 0.04). One procedural accident resulting in liver abscess formation was observed in 1 patient 1 week after discharge, and it required drain placement and antibiotic administration. While mild abdominal pain was observed in a few patients, it was resolved spontaneously under observation. Conclusion: EO infusion therapy achieves fairly high treatment response in the volume reduction (99%) and sustained shrinkage over long-term follow-up. Therefore, this is a breakthrough technique in the treatment of polycystic liver disease as well as simple cyst and should be a standard of care in the treatment of this disease. (C) 2016 S. Karger AG, BaselOutcome of Asunaprevir/Daclatasvir Combination Therapy for Chronic Liver Disease Type CSatoru Hagiwara; Naoshi Nishida; Tomohiro Watanabe; Toshiharu Sakurai; Hiroshi Ida; Yasunori Minami; Masahiro Takita; Tomohiro Minami; Mina Iwanishi; Hirokazu Chishina; Kazuomi Ueshima; Yoriaki Komeda; Tadaaki Arizumi; Masatoshi KudoDIGESTIVE DISEASES KARGER 34 (6) 620 - 626 0257-2753 2016 [Refereed] Objective: Treatment for chronic hepatitis C has recently developed in a very rapid manner. In Japan, in September 2014, IFN-free asunaprevir (ASV) and daclatasvir (DCV) became available for combination therapy. We report the treatment outcomes achieved at our hospital using this combination therapy. Methods: Sustained virological response (SVR) 24 could be evaluated in 120 of 125 patients with chronic liver disease type C who visited our hospital and were treated with ASV/DCV after September 2014, and these patients were analyzed. Results: SVR24 was achieved in 106 patients (88%). End-of-treatment response was not achieved in 10 patients (8.3%). Five of them carried multiple-resistant NS3/4A or NS5A region, and administration was discontinued early in 4 patients due to adverse effects. After ASV/DCV treatment, hepatocellular carcinoma (HCC) developed in 2 patients (1.7%) and recurred in 5 (4.2%). Conclusions: ASV/DCV treatment achieved favorable SVR in elderly and hepatic cirrhosis patients and patients in whom HCC was cured. However, an increase in the incidence of HCC development in patients who markedly respond to direct-acting antivirals treatment is expected and surveillance of HCC becomes more important. (C) 2016 S. Karger AG, BaselChronic Liver Diseases and Liver Cancer: State-of-the Art Progress in 2016Masatoshi KudoDIGESTIVE DISEASES KARGER 34 (6) 617 - 619 0257-2753 2016 [Refereed][Invited]座談会「“免疫チェックポイント阻害剤“の基礎から臨床成績および開発動向」工藤正俊; 石田靖雅; 池田公史; 田中真二肝胆膵 73 429 - 443 2016 [Refereed][Invited]免疫チェックポイント阻害剤の限界と課題. 特集「がん治療が変わる-免疫チェックポイント阻害剤の与えるインパクト-」工藤正俊肝胆膵 9 423 - 427 2016 [Refereed][Invited]肝細胞癌における免疫チェックポイント阻害剤の開発. 特集「癌治療が変わる-免疫チェックポイント阻害剤の与えるインパクト-」工藤正俊肝胆膵 9 401 - 412 2016 [Refereed][Invited]医用画像における超音波画像の今日的座標を説く-最新技術がもたらす新しい展開工藤正俊月刊新医療 (8) 80 - 82 2016 [Refereed][Invited]生検で胃癌が疑われたinflammatory fibroid polyp. 特集「粘膜下腫瘍のすべて」松井繁長; 樫田博史; 工藤正俊消化器内視鏡 28 302 - 303 2016 [Refereed]Heterogeneity and Subclassification of Barcelona Clinic Liver Cancer Stage BM. KudoLIVER CANCER KARGER 5 (2) 91 - 96 2235-1795 2016 [Refereed][Invited]Response Evaluation Criteria in Cancer of the Liver (RECICL) (2015 Revised version)Masatoshi Kudo; Kazuomi Ueshima; Shoji Kubo; Michiie Sakamoto; Masatoshi Tanaka; Iwao Ikai; Junji Furuse; Takamichi Murakami; Masumi Kadoya; Norihiro KokudoHEPATOLOGY RESEARCH WILEY 46 (1) 3 - 9 1386-6346 2016/01 [Refereed] The Response Evaluation Criteria in Solid Tumors (RECIST) is inappropriate to assess the direct effects of treatment on hepatocellular carcinoma (HCC) by locoregional therapies such as radiofrequency ablation (RFA) and transarterial chemoembolization (TACE). Therefore, establishment of response evaluation criteria solely devoted to HCC is needed urgently in clinical practice as well as in clinical trials of HCC treatment, such as molecular-targeted therapies, which cause necrosis of the tumor. The Response Evaluation Criteria in Cancer of the Liver (RECICL) was revised in 2015 by the Liver Cancer Study Group of Japan based on the 2009 version of RECICL, which was commonly used in Japan. Major revised points of the RECICL 2015 is to define the target lesions of two lesions per organ or three lesions per liver, up to a maximum of five lesions. The second revised point is that setting the timing at which the overall treatment response has been changed. The third point is that the definition of treatment effect 1 has been changed to more than 50% tumor enlargement, excluding the area of necrosis after treatment. Overall evaluation of treatment response has been amended to make it possible to evaluate the overall response including extrahepatic lesions by systemic therapy, which is similar to RECIST ormodified RECIST. We hope this new treatment response criteria, RECICL, proposed by the Liver Cancer Study Group of Japan will benefit HCC treatment response evaluation in the setting of daily clinical practice and clinical trials, not only in Japan, but also internationally.Treatment of colorectal LST: focus on EMR techniquesY. Komeda; H. Kashida; T. Sakurai; Y. Asakuma; Y. Okazaki; T. Nagai; H. Mine; T. Adachi; R. Tanaka; M. Yamada; M. Kono; K. Okamoto; S. Matsui; M. KudoJOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY WILEY-BLACKWELL 30 191 - 191 0815-9319 2015/12 [Refereed]【病理像から読みとる膵・胆道画像診断のコツ】病理像をイメージした膵・胆道画像診断の実際 病理像と画像診断との対比 膵上皮内癌は画像診断で捉えられるか?山雄 健太郎; 北野 雅之; 工藤 正俊胆と膵 医学図書出版(株) 36 (12) 1325 - 1330 0388-9408 2015/12 膵癌は予後不良な疾患であり、UICC Stage I aでの5年生存率は68.7%と決して満足できるものではない。一方で上皮内癌を意味するStage 0の場合には5年生存率は85.8%と比較的良好である。予後改善のためにはできるだけ早期に膵癌を発見し、治療を行うことが重要である。上皮内癌の主病変は膵管内腔側に突出する丈の低い乳頭状の病変であり、空間分解能に優れるEUSでも上皮内癌自体を直接的に画像所見として捉えることは困難である。上皮内癌を診断するためには主膵管狭窄および尾側膵管の拡張や膵嚢胞、主膵管狭窄部周囲の"淡い低エコー領域"などの間接所見に着目し剥離した上皮細胞を効率よく採取・回収できる膵液細胞診が有用と考えられ、とくに複数回の検体採取をすることができるENPD留置下の連続膵液細胞診を行うことが重要である。(著者抄録)APPLE association president's messageMasatoshi KudoLiver Cancer S. Karger AG 4 (4) 274  1664-5553 2015/12 [Refereed]Effects of RXR Agonists on Cell Proliferation/Apoptosis and ACTH Secretion/Pomc ExpressionAkiko Saito-Hakoda; Akira Uruno; Atsushi Yokoyama; Kyoko Shimizu; Rehana Parvin; Masataka Kudo; Takako Saito-Ito; Ikuko Sato; Naotaka Kogure; Dai Suzuki; Hiroki Shimada; Takeo Yoshikawa; Ikuma Fujiwara; Hiroyuki Kagechika; Yasumasa Iwasaki; Shigeo Kure; Sadayoshi Ito; Akira SugawaraPLOS ONE PUBLIC LIBRARY SCIENCE 10 (12) 1932-6203 2015/12 [Refereed] Various retinoid X receptor (RXR) agonists have recently been developed, and some of them have shown anti-tumor effects both in vivo and in vitro. However, there has been no report showing the effects of RXR agonists on Cushing's disease, which is caused by excessive ACTH secretion in a corticotroph tumor of the pituitary gland. Therefore, we examined the effects of synthetic RXR pan-agonists HX630 and PA024 on the proliferation, apoptosis, ACTH secretion, and pro-opiomelanocortin (Pomc) gene expression of murine pituitary corticotroph tumor AtT20 cells. We demonstrated that both RXR agonists induced apoptosis dose-dependently in AtT20 cells, and inhibited their proliferation at their higher doses. Microarray analysis identified a significant gene network associated with caspase 3 induced by high dose HX630. On the other hand, HX630, but not PA024, inhibited Pomc transcription, Pomc mRNA expression, and ACTH secretion dose-dependently. Furthermore, we provide new evidence that HX630 negatively regulates the Pomc promoter activity at the transcriptional level due to the suppression of the transcription factor Nur77 and Nurr1 mRNA expression and the reduction of Nur77/Nurr1 heterodimer recruiting to the Pomc promoter region. We also demonstrated that the HX630-mediated suppression of the Pomc gene expression was exerted via RXR alpha. Furthermore, HX630 inhibited tumor growth and decreased Pomc mRNA expression in corticotroph tumor cells in female nude mice in vivo. Thus, these results indicate that RXR agonists, especially HX630, could be a new therapeutic candidate for Cushing's disease.A case of endoscopic mucosal resection for gastric perineuriomaMasashi Kono; Shigenaga Matsui; Kazuki Okamoto; Mitsunari Yamada; Rie Tanaka; Teppeiadachi Hiromasa Mine; Tomoyuki Nagai; Yoshihisa Okazaki; Yoriakikomeda; Yutaka Asakuma; Toshiharu Sakurai; Hiroshi Kashida; Masatoshi KudoJOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY WILEY-BLACKWELL 30 103 - 103 0815-9319 2015/12 [Refereed]Endoscopic resection for rectal nets (neuroendocrine tumors): EMR-C (EMR using a cap), EMR-L (EMR with a ligation device), or conventional EMR (EMR)Mitsunari Yamada; Hiroshi Kashida; Yoriaki Komeda; Kazuki Okamoto; Masashi Kono; Rie Tanaka; Teppei Adachi; Hiromasa Mine; Tomoyuki Nagai; Yoshihisa Okazaki; Yutaka Asakuma; Toshiharu Sakurai; Shigenaga Matsui; Masatoshi KudoJOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY WILEY-BLACKWELL 30 18 - 18 0815-9319 2015/12 [Refereed]Usefulness of serum procalcitonin for diagnosis of acute pancreatitisShunsuke Omoto; Masayuki Kitano; Hiroki Sakamoto; Hajime Imai; Kentaro Yamao; Ken Kamata; Takeshi Miyata; Kosuke Minaga; Kumpei Kadosaka; Masatoshi KudoJOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY WILEY-BLACKWELL 30 141 - 141 0815-9319 2015/12 [Refereed]Randomized phase II study of axitinib versus placebo plus best supportive care in second-line treatment of advanced hepatocellular carcinomaY. -K. Kang; T. Yau; J. -W. Park; H. Y. Lim; T. -Y. Lee; S. Obi; S. L. Chan; S. K. Qin; R. D. Kim; M. Casey; C. Chen; H. Bhattacharyya; J. A. Williams; O. Valota; D. Chakrabarti; M. KudoANNALS OF ONCOLOGY OXFORD UNIV PRESS 26 (12) 2457 - 2463 0923-7534 2015/12 [Refereed] Axitinib plus best supportive care failed to meet the primary end point of overall survival in second-line treatment of advanced hepatocellular carcinoma in a randomized phase II study. However, the axitinib arm showed substantially improved progression-free survival, time to tumour progression, and clinical benefit rate compared with the placebo arm, with acceptable safety profile. Background: The efficacy and safety of axitinib, a potent and selective vascular endothelial growth factor receptors 1-3 inhibitor, combined with best supportive care (BSC) was evaluated in a global, randomized, placebo-controlled phase II trial in patients with locally advanced or metastatic hepatocellular carcinoma (HCC). Patients and methods: Patients with HCC and Child-Pugh Class A who progressed on or were intolerant to one prior antiangiogenic therapy were stratified by tumour invasion (presence/absence of extrahepatic spread and/or vascular invasion) and region (Asian/non-Asian) and randomized (2:1) to axitinib/BSC (starting dose 5 mg twice-daily) or placebo/BSC. The primary end point was overall survival (OS). Results: The estimated hazard ratio for OS was 0.907 [95% confidence interval (CI) 0.646-1.274; one-sided stratified P = 0.287] for axitinib/BSC (n = 134) versus placebo/BSC (n = 68), with the median (95% CI) of 12.7 (10.2-14.9) versus 9.7 (5.9-11.8) months, respectively. Results of prespecified subgroup analyses in Asian versus non-Asian patients or presence versus absence of tumour invasion were consistent with the overall population. Improvements favouring axitinib/BSC (P < 0.01) were observed in secondary efficacy end point analyses [progression-free survival (PFS), time to tumour progression (TTP), and clinical benefit rate (CBR)], and were retained among Asian patients in the prespecified subgroup analyses. Overall response rate did not differ significantly between treatments and patient-reported outcomes favoured placebo/BSC. Most common all-causality adverse events with axitinib/BSC were diarrhoea (54%), hypertension (54%), and decreased appetite (47%). Baseline serum analyses identified potential new prognostic (interleukin-6, E-selectin, interleukin-8, angiopoietin-2, migration inhibitory factor, and c-MET) or predictive (E-selectin and stromal-derived factor-1) factors for survival. Conclusions: Axitinib/BSC did not improve OS over placebo/BSC in the overall population or in stratification subgroups. However, axitinib/BSC resulted in significantly longer PFS and TTP and higher CBR, with acceptable toxicity in patients with advanced HCC. Trial Registration: ClinicalTrials.gov, NCT01210495.Multicenter cooperative case survey of hepatitis B virus reactivation by chemotherapeutic agentsHideaki Takahashi; Masafumi Ikeda; Takashi Kumada; Yukio Osaki; Shunsuke Kondo; Shigeru Kusumoto; Kazuyoshi Ohkawa; Seijin Nadano; Junji Furuse; Masatoshi Kudo; Kiyoaki Ito; Masahiro Yokoyama; Takuji Okusaka; Masanori Shimoyama; Masashi MizokamiHEPATOLOGY RESEARCH WILEY-BLACKWELL 45 (12) 1220 - 1227 1386-6346 2015/12 [Refereed] Aim: The purpose of this multicenter cooperative study was to elucidate the clinical features of hepatitis B virus (HBV) reactivation by chemotherapeutic agents and the patient outcomes after HBV reactivation by a retrospective review of accumulated patients' medical records. Methods: Records of a total of 27 patients (hematological malignancy, 14 patients; solid tumor, 13 patients) from 11 institutions who were diagnosed between June 2005 and October 2010 as having HBV reactivation following chemotherapy were reviewed. Results: Of the 27 patients with reactivation, 16 patients were hepatitis B surface antigen (HBsAg) positive and 11 were HBsAg negative prior to the commencement of chemotherapy. Of the 11 patients who were HBsAg negative prior to the chemotherapy, 10 had hematological malignancies and one had a solid tumor. Of the 14 patients with hematological malignancies with HBV reactivation enrolled in the study, the reactivation occurred more than 12 months after the completion of chemotherapy in five patients (36%); on the other hand, none of the patients (0%) with solid tumors developed HBV reactivation more than 12 months after the completion of chemotherapy. Of the 24 patients who had acute liver dysfunction at the diagnosis of HBV reactivation, nine (38%) had severe hepatitis and seven (29%) died of liver failure. Conclusion: Most of the patients with HBV reactivation who were HBsAg negative prior to the chemotherapy had underlying hematological malignancies. Furthermore, patients with hematological malignancies often developed late-onset HBV reactivation. The prognosis of patients who develop acute liver dysfunction as a complication of HBV reactivation is extremely dismal.Impaired expression of ATP-binding cassette transporter G2 and liver damage in erythropoietic protoporphyriaSatoru Hagiwara; Naoshi Nishida; Ah-Mee Park; Toshiharu Sakurai; Akira Kawada; Masatoshi KudoHEPATOLOGY WILEY-BLACKWELL 62 (5) 1638 - 1639 0270-9139 2015/11 [Refereed]Classification of tumors based on the integrated profile of genetic and epigenetic alterations and the biological behavior of human hepatocellular carcinomaNaoshi Nishida; Toshimi Kaido; Masatoshi KudoHEPATOLOGY WILEY-BLACKWELL 62 1151A - 1152A 0270-9139 2015/10 [Refereed]Plasmacytoid Dendritic Cell Activation and IFN-alpha Production Are Prominent Features of Murine Autoimmune Pancreatitis and Human IgG4-Related Autoimmune PancreatitisYasuyuki Arai; Kouhei Yamashita; Katsutoshi Kuriyama; Masahiro Shiokawa; Yuzo Kodama; Toshiharu Sakurai; Kiyomi Mizugishi; Kazushige Uchida; Norimitsu Kadowaki; Akifumi Takaori-Kondo; Masatoshi Kudo; Kazuichi Okazaki; Warren Strober; Tsutomu Chiba; Tomohiro WatanabeJOURNAL OF IMMUNOLOGY AMER ASSOC IMMUNOLOGISTS 195 (7) 3033 - 3044 0022-1767 2015/10 [Refereed] The abnormal immune response accompanying IgG4-related autoimmune pancreatitis (AIP) is presently unclear. In this study, we examined the role of plasmacytoid dendritic cell (pDC) activation and IFN-alpha production in this disease as well as in a murine model of AIP (MRL/Mp mice treated with polyinosinic-polycytidylic acid). We found that the development of AIP in treated MRL/Mp mice occurred in parallel with pancreatic accumulation of pDCs producing IFN-alpha, and with pDC depletion and IFN-alpha-blocking studies, we showed that such accumulation was necessary for AIP induction. In addition, we found that the pancreas of treated MRL/Mp mice contained neutrophil extracellular traps (NETs) shown previously to stimulate pDCs to produce IFN-alpha. Consistent with these findings, we found that patients with IgG4-related AIP also exhibited pancreatic tissue localization of IFN-alpha-expressing pDCs and had significantly higher serum IFN-alpha levels than healthy controls. In addition, the inflamed pancreas of these patients but not controls also contained NETs that were shown to be capable of pDC activation. More importantly, patient pDCs cultured in the presence of NETs produced greatly increased levels of IFN-alpha and induced control B cells to produce IgG4 (but not IgG1) as compared with control pDCs. These data suggest that pDC activation and production of IFN-alpha is a major cause of murine AIP; in addition, the increased pDC production of IFN-alpha and its relation to IgG4 production observed in IgG4-related AIP suggest that this mechanism also plays a role in the human disease.Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trialJordi Bruix; Tadatoshi Takayama; Vincenzo Mazzaferro; Gar-Yang Chau; Jiamei Yang; Masatoshi Kudo; Jianqiang Cai; Ronnie T. Poon; Kwang-Hyub Han; Won Young Tak; Han Chu Lee; Tianqiang Song; Sasan Roayaie; Luigi Bolondi; Kwan Sik Lee; Masatoshi Makuuchi; Fabricio Souza; Marie-Aude Le Berre; Gerold Meinhardt; Josep M. LlovetLANCET ONCOLOGY ELSEVIER SCIENCE INC 16 (13) 1344 - 1354 1470-2045 2015/10 [Refereed] Background There is no standard of care for adjuvant therapy for patients with hepatocellular carcinoma. This trial was designed to assess the efficacy and safety of sorafenib versus placebo as adjuvant therapy in patients with hepatocellular carcinoma after surgical resection or local ablation. Methods We undertook this phase 3, double-blind, placebo-controlled study of patients with hepatocellular carcinoma with a complete radiological response after surgical resection (n=900) or local ablation (n=214) in 202 sites (hospitals and research centres) in 28 countries. Patients were randomly assigned (1: 1) to receive 400 mg oral sorafenib or placebo twice a day, for a maximum of 4 years, according to a block randomisation scheme (block size of four) using an interactive voice-response system. Patients were stratified by curative treatment, geography, Child-Pugh status, and recurrence risk. The primary outcome was recurrence-free survival assessed after database cut-off on Nov 29, 2013. We analysed efficacy in the intention-to-treat population and safety in randomly assigned patients receiving at least one study dose. The final analysis is reported. This study is registered with ClinicalTrials.gov, number NCT00692770. Findings We screened 1602 patients between Aug 15, 2008, and Nov 17, 2010, and randomly assigned 1114 patients. Of 556 patients in the sorafenib group, 553 (> 99%) received the study treatment and 471 (85%) terminated treatment. Of 558 patients in the placebo group, 554 (99%) received the study treatment and 447 (80%) terminated treatment. Median duration of treatment and mean daily dose were 12.5 months (IQR 2.6-35.8) and 577 mg per day (SD 212.8) for sorafenib, compared with 22.2 months (8.1-38.8) and 778.0 mg per day (79.8) for placebo. Dose modification was reported for 497 (89%) of 559 patients in the sorafenib group and 206 (38%) of 548 patients in the placebo group. At final analysis, 464 recurrence-free survival events had occurred (270 in the placebo group and 194 in the sorafenib group). Median follow-up for recurrence-free survival was 8.5 months (IQR 2.9-19.5) in the sorafenib group and 8.4 months (2.9-19.8) in the placebo group. We noted no difference in median recurrence-free survival between the two groups (33.3 months in the sorafenib group vs 33.7 months in the placebo group; hazard ratio [HR] 0.940; 95% CI 0.780-1.134; one-sided p=0.26). The most common grade 3 or 4 adverse events were hand-foot skin reaction (154 [28%] of 559 patients in the sorafenib group vs four [<1%] of 548 patients in the placebo group) and diarrhoea (36 [6%] vs five [< 1%] in the placebo group). Sorafenib-related serious adverse events included hand-foot skin reaction (ten [2%]), abnormal hepatic function (four [< 1%]), and fatigue (three [< 1%]). There were four (< 1%) drug-related deaths in the sorafenib group and two (< 1%) in the placebo group. Interpretation Our data indicate that sorafenib is not an effective intervention in the adjuvant setting for hepatocellular carcinoma following resection or ablation.Safety and efficacy of tigatuzumab plus sorafenib as first-line therapy in subjects with advanced hepatocellular carcinoma: A phase 2 randomized studyAnn-Lii Cheng; Yoon-Koo Kang; Aiwu Ruth He; Ho Yeong Lim; Baek-Yeol Ryoo; Chao-Hung Hung; I-Shyan Sheen; Namiki Izumi; TaShara Austin; Qiang Wang; Jonathan Greenberg; Shinichi Shiratori; Robert A. Beckman; Masatoshi KudoJOURNAL OF HEPATOLOGY ELSEVIER SCIENCE BV 63 (4) 896 - 904 0168-8278 2015/10 [Refereed] Background & Aims: Tigatuzumab is a humanized monoclonal antibody that acts as a death receptor-5 agonist and exerts tumour necrosis factor-related apoptosis-inducing ligand-like activity. In this phase II study, safety and tolerability of the combination of tigatuzumab and sorafenib was evaluated in patients with advanced hepatocellular carcinoma. Methods: Adults with advanced hepatocellular carcinoma, measurable disease, and an Eastern Cooperative Oncology Group performance score <= 1 were enrolled. Eligible subjects were randomly assigned 1: 1: 1 to tigatuzumab (6 mg/kg loading, 2 mg/kg/week maintenance) plus sorafenib 400 mg twice daily; tigatuzumab (6 mg/kg loading, 6 mg/kg/week maintenance) plus sorafenib 400 mg twice daily; or sorafenib 400 mg twice daily. The primary end point was time to progression. Secondary end points included overall survival and safety. Results: 163 subjects were randomized to treatment. Median time to progression was 3.0 months in the tigatuzumab 6/2 mg/kg combination group (p = 0.988 vs. sorafenib), 3.9 months in the tigatuzumab 6/6 mg/kg combination group (p = 0.586 vs. sorafenib), and 2.8 months in the sorafenib alone group. Median overall survival was 12.2 months in the tigatuzumab 6/6 mg/kg combination group (p = 0.659 vs. sorafenib), vs. 8.2 months in both other treatment groups (p = 0.303, tigatuzumab 6/2 mg/kg combination vs. sorafenib). The most common treatment-emergent adverse events were palmar-plantar erythrodysesthesia syndrome, diarrhea, and decreased appetite. Conclusions: Tigatuzumab combined with sorafenib vs. sorafenib alone in adults with advanced hepatocellular carcinoma did not meet its primary efficacy end point, although tigatuzumab plus sorafenib is well tolerated in hepatocellular carcinoma. (C) 2015 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.機能性上部消化管疾患の病態と新規治療 機能性ディスペプシアに早期慢性膵炎が含まれている門阪 薫平; 北野 雅之; 工藤 正俊日本消化器病学会雑誌 (一財)日本消化器病学会 112 (臨増大会) A761 - A761 0446-6586 2015/09SSA/Pの内視鏡診断岡崎 能久; 樫田 博史; 櫻井 俊治; 朝隈 豊; 米田 頼晃; 高山 政樹; 峯 宏昌; 足立 哲平; 田中 梨絵; 山田 光成; 岡元 寿樹; 榎本 英介; 前西 修; 筑後 孝章; 木村 雅友; 佐藤 隆夫; 工藤 正俊Gastroenterological Endoscopy (一社)日本消化器内視鏡学会 57 (Suppl.2) 2145 - 2145 0387-1207 2015/09上腸間膜静脈血栓症による急性腸管虚血に対しTIPSを施行した1例沼本 勲男; 鶴崎 正勝; 柳生 行伸; 渡口 真史; 山川 美帆; 任 誠雲; 松木 充; 村上 卓道; 萩原 智; 工藤 正俊; 吉藤 竹仁; 船内 正憲IVR: Interventional Radiology (一社)日本インターベンショナルラジオロジー学会 30 (3) 283 - 283 1340-4520 2015/09Global patterns of hepatocellular carcinoma management from diagnosis to death: the BRIDGE StudyJoong-Won Park; Minshan Chen; Massimo Colombo; Lewis R. Roberts; Myron Schwartz; Pei-Jer Chen; Masatoshi Kudo; Philip Johnson; Samuel Wagner; Lucinda S. Orsini; Morris ShermanLIVER INTERNATIONAL WILEY-BLACKWELL 35 (9) 2155 - 2166 1478-3223 2015/09 [Refereed] Background & AimsHepatocellular carcinoma (HCC) is the second most common cause of cancer deaths worldwide. The global HCC BRIDGE study was a multiregional, large-scale, longitudinal cohort study undertaken to improve understanding of real-life management of patients with HCC, from diagnosis to death. MethodsData were collected retrospectively from January 2005 to September 2012 by chart reviews of eligible patients newly diagnosed with HCC at participating institutions. ResultsForty-two sites in 14 countries contributed final data for 18031 patients. Asia accounted for 67% of patients, Europe for 20% and North America for 13%. As expected, the most common risk factor was hepatitis C virus in North America, Europe and Japan, and hepatitis B virus in China, South Korea and Taiwan. The most common Barcelona Clinic Liver Cancer stage at diagnosis was C in North America, Europe, China and South Korea, and A in Taiwan and Japan. Across all stages, first HCC treatment was most frequently transarterial chemoembolization in North America, Europe, China and South Korea, percutaneous ethanol injection or radiofrequency ablation in Japan and resection in Taiwan. Survival from first HCC treatment varied significantly by region, with median overall survival not reached for Taiwan and 60, 33, 31, 24 and 23months for Japan, North America, South Korea, Europe and China respectively (P<0.0001). ConclusionsInitial results from the BRIDGE study confirm previously reported regional trends in patient demographic characteristics and HCC risk factors, document the heterogeneity of treatment approaches across regions/countries and underscore the need for earlier HCC diagnosis worldwide.Primary leiomyosarcoma of the colonMasashi Kono; Naoko Tsuji; Nobuto Ozaki; Nozomu Matsumoto; Takehisa Takaba; Naoki Okumura; Masanori Kawasaki; Takafumi Tomita; Yasuko Umehara; Satoko Taniike; Shigeru Hatabe; Sadao Funai; Yukihhiko Ono; Ken Ochiai; Shunji Maekura; Masatoshi KudoClinical Journal of Gastroenterology Springer Tokyo 8 (4) 217 - 222 1865-7265 2015/08 [Refereed] Primary leiomyosarcomas of the gastrointestinal (GI) tract are extremely rare and highly aggressive neoplasms, and only a small number of true cases have been reported since the concept of GI stromal tumors was established. Here, we report a case of a primary leiomyosarcoma of the transverse colon. A 46-year-old Japanese male with a large mass in the right upper abdomen was admitted to our hospital. Computed tomography and magnetic resonance imaging revealed long segments of wall thickening of the transverse colon with large consecutive tumors measuring 12 cm in diameter. A projecting irregular mass with marked mucosal necrosis was found on colonoscopy. Pathological examination revealed a spindle cell tumor growing circumferentially and transmurally to replace the muscularis propria in the transverse colon. The spindle cells were positive for smooth muscle actin, and negative for KIT, CD34, DOG-1, and S-100 protein. The patient has shown repeat recurrence in spite of sufficient surgical excision being promptly performed.経乳頭処置困難総胆管結石症例に対するEUS-rendezvous法の成績山雄 健太郎; 北野 雅之; 工藤 正俊胆道 日本胆道学会 29 (3) 551 - 551 0914-0077 2015/08The role of hepatic resection in the treatment of hepatocellular cancerSasan Roayaie; Ghalib Jibara; Parissa Tabrizian; Joong-Won Park; Jijin Yang; Lunan Yan; Myron Schwartz; Guohong Han; Francesco Izzo; Mishan Chen; Jean-Frederic Blanc; Philip Johnson; Masatoshi Kudo; Lewis R. Roberts; Morris ShermanHEPATOLOGY WILEY-BLACKWELL 62 (2) 440 - 451 0270-9139 2015/08 [Refereed] Current guidelines recommend surgical resection as the primary treatment for a single hepatocellular cancer (HCC) with Child's A cirrhosis, normal serum bilirubin, and no clinically significant portal hypertension. We determined how frequently guidelines were followed and whether straying from them impacted survival. BRIDGE is a multiregional cohort study including HCC patients diagnosed between January 1, 2005 and June 30, 2011. A total of 8,656 patients from 20 sites were classified into four groups: (A) 718 ideal resection candidates who were resected; (B) 144 ideal resection candidates who were not resected; (C) 1,624 nonideal resection candidates who were resected; and (D) 6,170 nonideal resection candidates who were not resected. Median follow-up was 27 months. Log-rank and Cox's regression analyses were conducted to determine differences between groups and variables associated with survival. Multivariate analysis of all ideal candidates for resection (A+B) revealed a higher risk of mortality with treatments other than resection. For all resected patients (A+C), portal hypertension and bilirubin >1 mg/dL were not associated with mortality. For all patients who were not ideal candidates for resection (C+D), resection was associated with better survival, compared to embolization and other treatments, but was inferior to ablation and transplantation. Conclusions: The majority of patients undergoing resection would not be considered ideal candidates based on current guidelines. Not resecting ideal candidates was associated with higher mortality. The study suggests that selection criteria for resection may be modestly expanded without compromising outcomes, and that some nonideal candidates may still potentially benefit from resection over other treatment modalities. (Hepatology 2015;62:440-451Ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib (REACH): a randomised, double-blind, multicentre, phase 3 trialAndrew X. Zhu; Joon Oh Park; Baek-Yeol Ryoo; Chia-Jui Yen; Ronnie Poon; Davide Pastorelli; Jean-Frederic Blanc; Hyun Cheol Chung; Ari D. Baron; Tulio Eduardo Flesch Pfiffer; Takuji Okusaka; Katerina Kubackova; Jorg Trojan; Javier Sastre; Ian Chau; Shao-Chun Chang; Paolo B. Abada; Ling Yang; Jonathan D. Schwartz; Masatoshi KudoLANCET ONCOLOGY ELSEVIER SCIENCE INC 16 (7) 859 - 870 1470-2045 2015/07 [Refereed] Background VEGF and VEGF receptor-2-mediated angiogenesis contribute to hepatocellular carcinoma pathogenesis. Ramucirumab is a recombinant IgG1 monoclonal antibody and VEGF receptor-2 antagonist. We aimed to assess the safety and efficacy of ramucirumab in advanced hepatocellular carcinoma following first-line therapy with sorafenib. Methods In this randomised, placebo-controlled, double-blind, multicentre, phase 3 trial (REACH), patients were enrolled from 154 centres in 27 countries. Eligible patients were aged 18 years or older, had hepatocellular carcinoma with Barcelona Clinic Liver Cancer stage C disease or stage B disease that was refractory or not amenable to locoregional therapy, had Child-Pugh A liver disease, an Eastern Cooperative Oncology Group performance status of 0 or 1, had previously received sorafenib (stopped because of progression or intolerance), and had adequate haematological and biochemical parameters. Patients were randomly assigned (1:1) to receive intravenous ramucirumab (8 mg/kg) or placebo every 2 weeks, plus best supportive care, until disease progression, unacceptable toxicity, or death. Randomisation was stratified by geographic region and cause of liver disease with a stratified permuted block method. Patients, medical staff, investigators, and the funder were masked to treatment assignment. The primary endpoint was overall survival in the intention-to-treat population. This study is registered with ClinicalTrials.gov, number NCT01140347. Findings Between Nov 4, 2010, and April 18, 2013, 565 patients were enrolled, of whom 283 were assigned to ramucirumab and 282 were assigned to placebo. Median overall survival for the ramucirumab group was 9.2 months (95% CI 8.0-10.6) versus 7.6 months (6.0-9.3) for the placebo group (HR 0.87 [95% CI 0.72-1.05]; p=0.14). Grade 3 or greater adverse events occurring in 5% or more of patients in either treatment group were ascites (13 [5%] of 277 patients treated with ramucirumab vs 11 [4%] of 276 patients treated with placebo), hypertension (34 [12%] vs ten [4%]), asthenia (14 [5%] vs five [2%]), malignant neoplasm progression (18 [6%] vs 11 [4%]), increased aspartate aminotransferase concentration (15 [5%] vs 23 [8%]), thrombocytopenia (13 [5%] vs one [<1%]), hyperbilirubinaemia (three [1%] vs 13 [5%]), and increased blood bilirubin (five [2%] vs 14 [5%]). The most frequently reported (>= 1%) treatment-emergent serious adverse event of any grade or grade 3 or more was malignant neoplasm progression. Interpretation Second-line treatment with ramucirumab did not significantly improve survival over placebo in patients with advanced hepatocellular carcinoma. No new safety signals were noted in eligible patients and the safety profile is manageable.[Gastric ulcer, duodenal ulcer].Matsui S; Kashida H; Asakuma Y; Sakurai T; Kudo MNihon rinsho. Japanese journal of clinical medicine 73 (7) 1116 - 1122 0047-1852 2015/07 [Refereed]胃潰瘍・十二指腸潰瘍松井繁長; 樫田博史; 朝隈 豊; 櫻井俊治; 工藤正俊日本臨床 73 (7) 1116 - 1122 2015/07 [Refereed][Invited]Validation of the Hepatoma Arterial Embolization Prognostic Score in European and Asian Populations and Proposed ModificationDavid J. Pinato; Tadaaki Arizumi; Elias Allara; Jeong Won Jang; Carlo Smirne; Young Woon Kim; Masatoshi Kudo; Mario Pirisi; Rohini SharmaCLINICAL GASTROENTEROLOGY AND HEPATOLOGY ELSEVIER SCIENCE INC 13 (6) 1204 - + 1542-3565 2015/06 [Refereed] BACKGROUND & AIMS: Transarterial chemoembolization (TACE) is used to treat hepatocellular carcinoma (HCC), but it is a challenge to predict patient survival. The hepatic arterial embolization prognostic (HAP) score has been shown to predict which patients will have shorter survival times and should not undergo TACE. We aimed to validate this scoring system in a prospective study of patients in Europe and Asia. METHODS: We evaluated the prognostic accuracy of the HAP score in estimating overall survival (OS) of 126 patients with HCC who received TACE in the United Kingdom or Italy (training set) from 2001 through 2013. We also analyzed data from 723 patients treated in Korea and Japan (validation set), including 79 with newly diagnosed HCC, who underwent TACE in Korea or Japan from 2004 through 2013. Response to TACE was determined based on computed tomography analysis. OS was calculated from the time of the first TACE until death or the last follow-up evaluation. RESULTS: OS was associated with hypoalbuminemia, a-fetoprotein level greater than 400 ng/mL, and tumor size greater than 7 cm at diagnosis (P<.01), but not a bilirubin level greater than 17 umol/L (P>.05), in both data sets. The lack of association between OS and bilirubin level was confirmed using receiver operating characteristic analysis. We developed a modified version of the HAP score, based on the level of albumin and a-fetoprotein and tumor size, which predicted OS with increased accuracy in the training and validation cohorts. CONCLUSIONS: In a multicenter validation study, we developed a modified version of the HAP that predicts survival of patients with HCC treated with TACE in Europe and Asia. This system might be used to identify patients with HCC most likely to benefit from TACE in clinical practice.食道・胃静脈瘤松井繁長; 樫田博史; 工藤正俊内科 115 (6) 939 - 943 2015/06 [Refereed]Survey of survival among patients with hepatitis C virus-related hepatocellular carcinoma treated with peretinoin, an acyclic retinoid, after the completion of a randomized, placebo-controlled trialKiwamu Okita; Namiki Izumi; Kenji Ikeda; Yukio Osaki; Kazushi Numata; Masafumi Ikeda; Norihiro Kokudo; Kazuho Imanaka; Shuhei Nishiguchi; Shunsuke Kondo; Yoichi Nishigaki; Susumu Shiomi; Kazuomi Ueshima; Norio Isoda; Yoshiyasu Karino; Masatoshi Kudo; Katsuaki Tanaka; Shuichi Kaneko; Hisataka Moriwaki; Masatoshi Makuuchi; Takuji Okusaka; Norio Hayashi; Yasuo Ohashi; Hiromitsu KumadaJOURNAL OF GASTROENTEROLOGY SPRINGER JAPAN KK 50 (6) 667 - 674 0944-1174 2015/06 [Refereed] This study examined the effects of peretinoin, an acyclic retinoid, on the survival of patients with hepatitis C virus-related hepatocellular carcinoma (HCC) who had completed curative therapy and participated in a randomized, placebo-controlled trial. This study was an investigator-initiated retrospective cohort study. Subjects were all patients who were administered the investigational drug (peretinoin 600 mg/day, peretinoin 300 mg/day, or placebo) in the randomized trial. Survivals between the groups were compared using the log-rank test, and hazard ratios were estimated by Cox regression. Survey data were collected from all patients (n = 392) who participated in the randomized trial, all of whom were then divided into the peretinoin 600 mg/day (n = 132), peretinoin 300 mg/day (n = 131), and placebo (n = 129) groups. At the median follow-up of 4.9 years, 5-year cumulative survival rates for patients in the 600 mg/day, 300 mg/day, and placebo groups were 73.9, 56.8, and 64.3 %, respectively. Comparison of overall survival among patients classified as Child-Pugh A revealed that survival of the 600 mg/day group (n = 105) was significantly longer than that of the placebo group (n = 108) (hazard ratio 0.575, 95 % CI 0.341-0.967; P = 0.0347). Administration of 600 mg/day peretinoin to patients with hepatitis C virus-related HCC who have completed curative therapy may improve survival for those classified as Child-Pugh A, for whom liver function is relatively stable.自己免疫性膵炎治療の現状と課題 自己免疫性膵炎のステロイド治療における再燃リスクの検討大本 俊介; 北野 雅之; 工藤 正俊膵臓 (一社)日本膵臓学会 30 (3) 326 - 326 0913-0071 2015/05切除不能膵癌の治療選択 胃十二指腸ステントおよびステント留置下胆道ドレナージ術の治療成績の検討山雄 健太郎; 北野 雅之; 工藤 正俊; 中島 潤; 岡部 純弘; 大崎 往夫; 萱原 隆久; 石田 悦嗣; 山本 博; 三長 孝輔; 山下 幸孝膵臓 日本膵臓学会 30 (3) 307 - 307 0913-0071 2015/05Therapeutic Strategies for Four Subtypes of Laterally Spreading Tumors of the ColorectumYoriaki Komeda; Hiroshi Kashida; Toshiharu Sakurai; Yutaka Asakuma; Yoshihisa Okazaki; Toshiki Okamoto; Mitsunari Yamada; Rie Tanaka; Teppei Adachi; Hiromasa Mine; Masaki Takayama; Tomoyuki Nagai; Masanori Kawasaki; Shigenaga Matsui; Masatoshi KudoGASTROINTESTINAL ENDOSCOPY MOSBY-ELSEVIER 81 (5) AB219 - AB219 0016-5107 2015/05 [Refereed]FOREWORD TO THE WFUMB GUIDELINES AND RECOMMENDATIONS ON THE CLINICAL USE OF ULTRASOUND ELASTOGRAPHYMasatoshi KudoULTRASOUND IN MEDICINE AND BIOLOGY ELSEVIER SCIENCE INC 41 (5) 1125 - 1125 0301-5629 2015/05 [Refereed]Evaluation of the Response to Chemotherapy in Advanced Gastric Cancer by Contrast-Enhanced Harmonic EUSShigenaga Matsui; Masatoshi Kudo; Masayuki Kitano; Yutaka AsakumaHEPATO-GASTROENTEROLOGY H G E UPDATE MEDICAL PUBLISHING S A 62 (139) 595 - 598 0172-6390 2015/05 [Refereed] Background/Aims: In advanced gastric cancers, a significant correlation exists between the response to chemotherapy in primary gastric cancers and patient prognosis. Therefore, accurate evaluation of the response to chemotherapy in primary gastric cancers is important. We examined the response to chemotherapy in primary gastric cancers by contrast enhanced harmonic endoscopic ultrasonography (CEH-EUS). Methodology: Thirty-five patients with advanced gastric cancer underwent CEH-EUS. Among these patients, 19 patients with stage IV advanced gastric cancer who received chemotherapy and CEH-EUS more than twice were enrolled, and evaluated the response to chemotherapy in primary gastric cancers by CEH-EUS and endoscopy. Results: In PRs evaluated by endoscopic findings, echo intensity ratio (EIR) was decreased, and in PDs EIR was increased significantly by CEH-EUS. Five cases had difficulty in evaluating the response of primary gastric cancers to chemotherapy by endoscopy, while evaluation was possible in those 5 cases by CEH-EUS. Conclusions: CEH-EUS is a new method to evaluate responses to chemotherapy in primary gastric cancers not only by a change in size but also in tumor vascularity. Correct evaluation of primary gastric cancers by CEH-EUS help predicting prognosis of patients.WFUMB GUIDELINES AND RECOMMENDATIONS FOR CLINICAL USE OF ULTRASOUND ELASTOGRAPHY: PART 2: BREASTRichard G. Barr; Kazutaka Nakashima; Dominique Amy; David Cosgrove; Andre Farrokh; Fritz Schafer; Jeffrey C. Bamber; Laurent Castera; Byung Ihn Choi; Yi-Hong Chou; Christoph F. Dietrich; Hong Ding; Giovanna Ferraioli; Carlo Filice; Mireen Friedrich-Rust; Timothy J. Hall; Kathryn R. Nightingale; Mark L. Palmeri; Tsuyoshi Shiina; Shinichi Suzuki; Ioan Sporea; Stephanie Wilson; Masatoshi KudoULTRASOUND IN MEDICINE AND BIOLOGY ELSEVIER SCIENCE INC 41 (5) 1148 - 1160 0301-5629 2015/05 [Refereed] The breast section of these Guidelines and Recommendations for Elastography produced under the auspices of the World Federation of Ultrasound in Medicine and Biology (WFUMB) assesses the clinically used applications of all forms of elastography used in breast imaging. The literature on various breast elastography techniques is reviewed, and recommendations are made on evidence-based results. Practical advice is given on how to perform and interpret breast elastography for optimal results, with emphasis placed on avoiding pitfalls. Artifacts are reviewed, and the clinical utility of some artifacts is discussed. Both strain and shear wave techniques have been shown to be highly accurate in characterizing breast lesions as benign or malignant. The relationship between the various techniques is discussed, and recommended interpretation based on a BI-RADS-like malignancy probability scale is provided. This document is intended to be used as a reference and to guide clinical users in a practical way. (C) 2015 Published by Elsevier Inc. on behalf of World Federation for Ultrasound in Medicine & Biology.WFUMB GUIDELINES AND RECOMMENDATIONS FOR CLINICAL USE OF ULTRASOUND ELASTOGRAPHY: PART 3: LIVERGiovanna Ferraioli; Carlo Filice; Laurent Castera; Byung Ihn Choi; Ioan Sporea; Stephanie R. Wilson; David Cosgrove; Christoph F. Dietrich; Dominique Amy; Jeffrey C. Bamber; Richard Barr; Yi-Hong Chou; Hong Ding; Andre Farrokh; Mireen Friedrich-Rust; Timothy J. Hall; Kazutaka Nakashima; Kathryn R. Nightingale; Mark L. Palmeri; Fritz Schafer; Tsuyoshi Shiina; Shinichi Suzuki; Masatoshi KudoULTRASOUND IN MEDICINE AND BIOLOGY ELSEVIER SCIENCE INC 41 (5) 1161 - 1179 0301-5629 2015/05 [Refereed] The World Federation for Ultrasound in Medicine and Biology (WFUMB) has produced these guidelines for the use of elastography techniques in liver disease. For each available technique, the reproducibility, results, and limitations are analyzed, and recommendations are given. Finally, recommendations based on the international literature and the findings of the WFUMB expert group are established as answers to common questions. The document has a clinical perspective and is aimed at assessing the usefulness of elastography in the management of liver diseases. (C) 2015 Published by Elsevier Inc. on behalf of World Federation for Ultrasound in Medicine & Biology.WFUMB GUIDELINES AND RECOMMENDATIONS FOR CLINICAL USE OF ULTRASOUND ELASTOGRAPHY: PART 1: BASIC PRINCIPLES AND TERMINOLOGYTsuyoshi Shiina; Kathryn R. Nightingale; Mark L. Palmeri; Timothy J. Hall; Jeffrey C. Bamber; Richard G. Barr; Laurent Castera; Byung Ihn Choi; Yi-Hong Chou; David Cosgrove; Christoph F. Dietrich; Hong Ding; Dominique Amy; Andre Farrokh; Giovanna Ferraioli; Carlo Filice; Mireen Friedrich-Rust; Kazutaka Nakashima; Fritz Schafer; Ioan Sporea; Shinichi Suzuki; Stephanie Wilson; Masatoshi KudoULTRASOUND IN MEDICINE AND BIOLOGY ELSEVIER SCIENCE INC 41 (5) 1126 - 1147 0301-5629 2015/05 [Refereed] Conventional diagnostic ultrasound images of the anatomy (as opposed to blood flow) reveal differences in the acoustic properties of soft tissues (mainly echogenicity but also, to some extent, attenuation), whereas ultrasound-based elasticity images are able to reveal the differences in the elastic properties of soft tissues (e.g., elasticity and viscosity). The benefit of elasticity imaging lies in the fact that many soft tissues can share similar ultrasonic echogenicities but may have different mechanical properties that can be used to clearly visualize normal anatomy and delineate pathologic lesions. Typically, all elasticity measurement and imaging methods introduce a mechanical excitation and monitor the resulting tissue response. Some of the most widely available commercial elasticity imaging methods are 'quasi-static' and use external tissue compression to generate images of the resulting tissue strain (or deformation). In addition, many manufacturers now provide shear wave imaging and measurement methods, which deliver stiffness images based upon the shear wave propagation speed. The goal of this review is to describe the fundamental physics and the associated terminology underlying these technologies. We have included a questions and answers section, an extensive appendix, and a glossary of terms in this manuscript. We have also endeavored to ensure that the terminology and descriptions, although not identical, are broadly compatible across the WFUMB and EFSUMB sets of guidelines on elastography (Bamber et al. 2013; Cosgrove et al. 2013). (C) 2015 Published by Elsevier Inc. on behalf of World Federation for Ultrasound in Medicine & Biology.消化管機能異常に対する内視鏡の役割 早期慢性膵炎が機能性ディスペプシアとして診断される可能性について門阪 薫平; 北野 雅之; 工藤 正俊Gastroenterological Endoscopy (一社)日本消化器内視鏡学会 57 (Suppl.1) 653 - 653 0387-1207 2015/04大腸鋸歯状病変の内視鏡診断について岡崎 能久; 樫田 博史; 櫻井 俊治; 朝隈 豊; 米田 頼晃; 高山 政樹; 峯 宏昌; 足立 哲平; 田中 梨絵; 山田 光成; 岡元 寿樹; 榎本 英介; 前西 修; 筑後 孝章; 木村 雅友; 佐藤 隆夫; 工藤 正俊Gastroenterological Endoscopy (一社)日本消化器内視鏡学会 57 (Suppl.1) 829 - 829 0387-1207 2015/04IgG4関連膵胆管病変における内視鏡の役割 自己免疫性膵炎の診断および治療におけるEUSの役割大本 俊介; 北野 雅之; 工藤 正俊Gastroenterological Endoscopy (一社)日本消化器内視鏡学会 57 (Suppl.1) 706 - 706 0387-1207 2015/04Stress Response Links Inflammation and Tumorigenesis in Inflammatory Bowel DiseaseToshiharu Sakurai; Yoshihisa Okazaki; Yoriaki Komeda; Teppei Adachi; Satoru Hagiwara; Shigenaga Matsui; Naoshi Nishida; Hiroshi Kashida; Masatoshi KudoGASTROENTEROLOGY W B SAUNDERS CO-ELSEVIER INC 148 (4) S141 - S141 0016-5085 2015/04 [Refereed]Cold-inducible RNA-binding protein promotes the development of liver cancerToshiharu Sakurai; Norihisa Yada; Tomohiro Watanabe; Tadaaki Arizumi; Satoru Hagiwara; Kazuomi Ueshima; Naoshi Nishida; Jun Fujita; Masatoshi KudoCANCER SCIENCE WILEY-BLACKWELL 106 (4) 352 - 358 1347-9032 2015/04 [Refereed] Most hepatocellular carcinomas (HCCs) develop in the context of chronic liver inflammation. Oxidative stress is thought to play a major role in the pathogenesis of HCC development. In this study, we examined whether cold-inducible RNA-binding protein (Cirp) controls reactive oxygen species (ROS) accumulation and development of HCC by using murine models of hepatocarcinogenesis and human liver samples. Cirp expression, ROS accumulation, and CD133 expression were increased in the liver of tumor-harboring mice. Cirp deficiency reduced production of interleukin-1 and interleukin-6 in Kupffer cells, ROS accumulation, and CD133 expression, leading to attenuated hepatocarcinogenesis. Thioacetamide treatment enhanced hepatic expression of CD133 and phosphorylated signal transducer and activator of transcription 3 (STAT3), which was prevented by treatment with the antioxidant butylated hydroxyanisole. Intriguingly, the risk of human HCC recurrence is positively correlated with Cirp expression in liver. Cirp appears to play a critical carcinogenic function and its expression might be a useful biomarker for HCC risk prediction.Contrast-enhanced harmonic endoscopic ultrasonography for pancreatobiliary diseasesMasayuki Kitano; Ken Kamata; Hajime Imai; Takeshi Miyata; Satoru Yasukawa; Akio Yanagisawa; Masatoshi KudoDIGESTIVE ENDOSCOPY WILEY-BLACKWELL 27 60 - 67 0915-5635 2015/04 [Refereed] The combination of second-generation ultrasound contrast agents and an endoscopic ultrasonography (EUS) system with a broad-band transducer has allowed contrast-enhanced harmonic imaging in the field of EUS. In contrast-enhanced harmonic EUS (CH-EUS), diffuse homogeneous enhancement is obtained in normal parenchyma of the pancreas. The bile duct and pancreatic duct are depicted as non-enhanced ductal structures with strong contrast in comparison to the surrounding parenchyma. CH-EUS identifies pancreatic adenocarcinomas as solid lesions exhibiting hypo-enhancement with a sensitivity and specificity of 88-96% and 88-94%, respectively. In particular, 80-100% of false-negative cases in endoscopic ultrasound-guided fine-needle aspiration (EUS-FNA) are correctly classified by CH-EUS, suggesting CH-EUS complements EUS-FNA. Moreover, CH-EUS improves depiction of some subtle lesions in conventional EUS, thus facilitating EUS-FNA. For quantitative perfusion analysis, a time-intensity curve (TIC) for the region of interest can be generated during CH-EUS. The maximum intensity gain and the echo intensity reduction rate from the peak at 1min obtained by TIC can be used for differentiation of pancreatic adenocarcinoma from other tumors. CH-EUS is also useful for differentiation of invasive intraductal papillary mucinous neoplasms (IPMN) from non-invasive IPMN, identification of malignant lesions in the gallbladder, and T- and N-staging of pancreatobiliary tumors.Heat Shock Protein A4 Controls Cell Migration and Gastric Ulcer HealingToshiharu Sakurai; Hiroshi Kashida; Satoru Hagiwara; Naoshi Nishida; Tomohiro Watanabe; Jun Fujita; Masatoshi KudoDIGESTIVE DISEASES AND SCIENCES SPRINGER 60 (4) 850 - 857 0163-2116 2015/04 [Refereed] Aims and Methods Heat shock protein A4 (HSPA4, also called Apg-2), a member of the HSP110 family, regulates the immune response in the gut. Here, we assessed the involvement of HSPA4 in gastric ulcer healing by using fibroblasts from wild-type and HSPA4-deficient mice, a murine gastric ulcer model, and samples from 65 patients with gastric cancer. Results HSPA4 expression was inversely correlated with gastric ulcer healing following endoscopic resection of gastric cancer. In the human gastric mucosa, the expression of HSPA4 was inversely correlated with the expression of stromal cell-derived factor 1 (SDF-1), its cognate receptor CXC chemokine receptor 4(CXCR4), the stromal cell marker vimentin, and the epithelial-mesenchymal transition regulator Twist. HSPA4 was overexpressed in stromal cells as well as in human gastric cancer cells. HSPA4 deficiency increased the expression of SDF-1 and CXCR4, as well as the number of fibroblast-specific protein 1-positive cells, leading to accelerated ulcer healing in the murine gastric ulcer model. Deletion of HSPA4 promoted cell migration in mouse fibroblasts through increased expression of SDF-1 and Twist. Conclusion HSPA4 regulates the expression of SDF-1 and Twist in fibroblasts, thereby controlling gastric ulcer healing.Value of dynamic contrast enhanced MRI in predicting outcomes of HCC receiving radiotherapyMasatoshi KudoHEPATOLOGY INTERNATIONAL SPRINGER 9 (2) 155 - 156 1936-0533 2015/04 [Refereed]Response evaluation criteria in cancer of the liver (RECICL 2015 revised version)Masatoshi Kudo; Kazuomi Ueshima; Shoji Kubo; Michiie Sakamoto; Masatoshi Tanaka; Iwao Ikai; Junji Furuse; Takamichi Murakami; Masumi Kadoya; Norihiro KokudoActa Hepatologica Japonica Japan Society of Hepatology 56 (3) 116 - 121 1881-3593 2015/03 [Refereed][Invited]早期慢性膵炎の病態と予後 早期慢性膵炎の診断基準と臨床的意義北野 雅之; 門阪 薫平; 工藤 正俊日本消化器病学会雑誌 (一財)日本消化器病学会 112 (臨増総会) A164 - A164 0446-6586 2015/03機能性ディスペプシア診療の現状と将来 機能性ディスペプシア患者における早期慢性膵炎所見について門阪 薫平; 北野 雅之; 工藤 正俊日本消化器病学会雑誌 (一財)日本消化器病学会 112 (臨増総会) A197 - A197 0446-6586 2015/03壊死性膵炎の予後改善を目指した治療の新展開 当院におけるPancreatic fluid collectionに対する治療成績山雄 健太郎; 北野 雅之; 工藤 正俊日本消化器病学会雑誌 (一財)日本消化器病学会 112 (臨増総会) A84 - A84 0446-6586 2015/03A Comparison of the Surgical Outcomes Among Patients With HBV-positive, HCV-positive, and Non-B Non-C Hepatocellular Carcinoma A Nationwide Study of 11,950 PatientsTohru Utsunomiya; Mitsuo Shimada; Masatoshi Kudo; Takafumi Ichida; Osamu Matsui; Namiki Izumi; Yutaka Matsuyama; Michiie Sakamoto; Osamu Nakashima; Yonson Ku; Tadatoshi Takayama; Norihiro KokudoANNALS OF SURGERY LIPPINCOTT WILLIAMS & WILKINS 261 (3) 513 - 520 0003-4932 2015/03 [Refereed] Objective: To compare the prognostic factors and outcomes after hepatic resection among patients with hepatitis B virus (HBV)-positive, hepatitis C virus (HCV)-positive, and negative for hepatitis B surface antigen and hepatitis Cantibody, so-called "NBNC"-hepatocellular carcinoma (HCC) using the data from a nationwide survey. Background: The incidence of NBNC-HCC is rapidly increasing in Japan. Methods: A total of 11,950 patients with HBV-HCC (n = 2194), HCV-HCC (n = 7018), or NBNC-HCC (n = 2738) who underwent a curative hepatic resection were enrolled in this study. The clinicopathological features were compared among the groups. The significant prognostic variables determined by univariate analysis were subjected to a multivariate analysis using a Cox proportional hazard regression model. Results: Liver function in the HCV-HCC group was significantly worse than that in the HBV-HCC and NBNC-HCC groups. The NBNC-HCC group had significantly more advanced HCC than the HCV-HCC group. The 5-year overall survival rates after hepatectomy in the HBV-HCC, HCV-HCC, and NBNC-HCC groups were 65%, 59%, and 68%, respectively. The 5-year recurrence-free survival (RFS) rates in these 3 groups were 41%, 31%, and 47%, respectively. Stratifying the RFS rates according to the TNM stage showed that the NBNC-HCC group had a significantly better prognosis than the HBV-HCC group in stages II, III, and IVA, and a significantly better prognosis than the HCV-HCC group in stages I and II. Multivariate analysis revealed a significantly better RFS rate in the NBNC-HCC group. Conclusions: The findings of this nationwide survey indicated that patients with NBNC-HCC had a significantly lower risk of HCC recurrence than those with HBV-HCC and HCV-HCC.[US].Kitano M; Imai H; Kudo MNihon rinsho. Japanese journal of clinical medicine 73 Suppl 3 50 - 54 0047-1852 2015/03 [Refereed][US].Kitano M; Kamata K; Kudo MNihon rinsho. Japanese journal of clinical medicine 73 Suppl 3 491 - 494 0047-1852 2015/03 [Refereed]胆道癌の画像診断: US北野雅之; 鎌田 研; 工藤正俊日本臨床 73 491 - 494 2015/03 [Refereed][Invited]Comparison Between T1 Relaxation Time of Gd-EOB-DTPA-Enhanced MRI and Liver Stiffness Measurement of Ultrasound Elastography in the Evaluation of Cirrhotic LiverMasahiro Okada; Takamichi Murakami; Norihisa Yada; Kazushi Numata; Minori Onoda; Tomoko Hyodo; Tatsuo Inoue; Kazunari Ishii; Masatoshi KudoJOURNAL OF MAGNETIC RESONANCE IMAGING WILEY-BLACKWELL 41 (2) 329 - 338 1053-1807 2015/02 [Refereed] PurposeTo compare four imaging approaches in cirrhotic estimation; pre-enhancement T1 relaxation time (T1RT), reduction rate (RR) of T1RT, signal-based liver-to-muscle ratio (L/M ratio) on gadolinium ethoxybenzyl diethylenetriaminepentaacetic acid (Gd-EOB-DTPA)-enhanced magnetic resonance imaging (MRI), and liver stiffness measurement (LSM) of US elastography. Materials and MethodsConsecutive 58 patients with chronic liver diseases who underwent both Gd-EOB-DTPA-enhanced MRI and FibroScan were analyzed. Four imaging approaches were evaluated by fibrosis score from liver biopsy and receiver operating characteristic (ROC) analysis. ResultsRR was found to be inversely correlated with LSM (r=-0.65). RR decreased with degree of fibrosis (F0-F1, 58.56.2%, versus F2-F3-F4, 48.8 +/- 11.7%, P=0.010, F0-F1-F2, 58.2 +/- 6.2% versus F3-F4, 45.5 +/- 12.3%, P=0.010 and F0-F1, 58.5 +/- 6.2%, versus F2-F3, 52.1 +/- 12.0%, P=0.0038). LSM increased with degree of fibrosis (F0-F1, 5.4 +/- 2.2 kPa versus F2-F3-F3, 19.3 +/- 15.5 kPa, P=0.0011 and F0-F1-F2, 6.8 +/- 3.6 kPa versus F3-F4, 23.8 +/- 17.1 kPa, P=0.0029 and F0-F1, 5.4 +/- 2.2 kPa, versus F2-F3, 11.4 +/- 7.2 kPa, P=0.0098). Area under ROC curves were 0.83 (F3-F4), 0.72 (F2-F3-F4), 0.68 (F2-F3) for RR and 0.83 (F3-F4), 0.88 (F2-F3-F4), 0.81 (F2-F3) for LSM in discriminating between patients with fibrosis. ConclusionThe capability by LSM was better than those by RR of T1RT, pre-enhancement T1RT, and L/M ratio to differentiate F2, but LSM and RR of T1RT showed the same value to differentiate F3. J. Magn. Reson. Imaging 2015;41:329-338.(c) 2013 Wiley Periodicals, Inc.Peretinoin after curative therapy of hepatitis C-related hepatocellular carcinoma: a randomized double-blind placebo-controlled studyKiwamu Okita; Namiki Izumi; Osamu Matsui; Katsuaki Tanaka; Shuichi Kaneko; Hisataka Moriwaki; Kenji Ikeda; Yukio Osaki; Kazushi Numata; Kohei Nakachi; Norihiro Kokudo; Kazuho Imanaka; Shuhei Nishiguchi; Takuji Okusaka; Yoichi Nishigaki; Susumu Shiomi; Masatoshi Kudo; Kenichi Ido; Yoshiyasu Karino; Norio Hayashi; Yasuo Ohashi; Masatoshi Makuuchi; Hiromitsu KumadaJOURNAL OF GASTROENTEROLOGY SPRINGER JAPAN KK 50 (2) 191 - 202 0944-1174 2015/02 [Refereed] Effective prophylactic therapies have not been established for hepatocellular carcinoma recurrence. Peretinoin represents one novel option for patients with hepatitis C virus-related hepatocellular carcinoma (HCV-HCC), and it was tested in a multicenter, randomized, double-blind, placebo-controlled study. Patients with curative therapy were assigned to one of the following regimens: peretinoin 600, 300 mg/day, or placebo for up to 96 weeks. The primary outcome was recurrence-free survival (RFS). Of the 401 patients initially enrolled, 377 patients were analyzed for efficacy. The RFS rates in the 600-mg group, the 300-mg group, and the placebo group were 71.9, 63.6, and 66.0 % at 1 year, and 43.7, 24.9, and 29.3 % at 3 years, respectively. The primary comparison of peretinoin (300 and 600-mg) with placebo was not significant (P = 0.434). The dose-response relationship based on the hypothesis that "efficacy begins to increase at 600 mg/day" was significant (P = 0.023, multiplicity-adjusted P = 0.048). The hazard ratios for RFS in the 600-mg group vs. the placebo group were 0.73 [95 % confidence interval (CI) 0.51-1.03] for the entire study period and 0.27 (95 % CI 0.07-0.96) after 2 years of the randomization. Common adverse events included ascites, increased blood pressure, headache, presence of urine albumin, and increased transaminases. Although the superiority of peretinoin to placebo could not be validated, 600 mg/day was shown to be the optimal dose, and treatment may possibly reduce the recurrence of HCV-HCC, particularly after 2 years. The efficacy and safety of peretinoin 600 mg/day should continue to be evaluated in further studies.Evidence-based Clinical Practice Guidelines for Hepatocellular Carcinoma: The Japan Society of Hepatology 2013 update (3rd JSH-HCC Guidelines)Norihiro Kokudo; Kiyoshi Hasegawa; Masaaki Akahane; Hiroshi Igaki; Namiki Izumi; Takafumi Ichida; Shinji Uemoto; Shuichi Kaneko; Seiji Kawasaki; Yonson Ku; Masatoshi Kudo; Shoji Kubo; Tadatoshi Takayama; Ryosuke Tateishi; Takashi Fukuda; Osamu Matsui; Yutaka Matsuyama; Takamichi Murakami; Shigeki Arii; Masatoshi Okazaki; Masatoshi MakuuchiHEPATOLOGY RESEARCH WILEY-BLACKWELL 45 (2) 123 - 127 1386-6346 2015/02 [Refereed] The 3rd version of Clinical Practice Guidelines for Hepatocellular Carcinoma was revised by the Japan Society of Hepatology, according to the methodology of evidence-based medicine, which was published in October 2013 in Japanese. Here, we briefly describe new or changed recommendations with a special reference to the two algorithms for surveillance, diagnosis, and treatment.Percutaneous endoscopic gastrostomy with Funada-style gastropexy greatly reduces the risk of peristomal infectionNaoki Okumura; Naoko Tsuji; Nobuto Ozaki; Nozomu Matsumoto; Takehisa Takaba; Masanori Kawasaki; Takafumi Tomita; Yasuko Umehara; Satoko Taniike; Masashi Kono; Masatoshi KudoGASTROENTEROLOGY REPORT OXFORD UNIV PRESS 3 (1) 69 - 74 2052-0034 2015/02 [Refereed] Background and aims: Peristomal wound infections are common complications of percutaneous endoscopic gastrostomy (PEG). The Funada-style gastropexy device has two parallel needles with a wire loop and suture thread, and was developed about 20 years ago in Japan. This kit has allowed us to perform dual gastropexy very easily; PEG with gastropexy has become a very popular technique in Japan. The present study aimed to compare the advantages and disadvantages of PEG with the gastropexy technique with the standard 'pull' method. Methods: We retrospectively reviewed 182 consecutive, non-randomized patients undergoing PEG in our hospital, and a comparative analysis was made between the gastropexy (87 patients) and non-gastropexy (95 patients) groups. Results: The rates of patients having erythema (11.6% vs. 47.9%; P<0.001), exudates (2.3% vs. 14.9%; P<0.01) and infection (0% vs. 6.4%; P=0.01) in the peristomal area were lower in the gastropexy than in the non-gastropexy group. The rate of minor bleeding from the peristomal area was higher in the gastropexy than in the non-gastropexy group (12.8% vs. 2.1%; P<0.01), but no patient required a blood transfusion. Mean procedure time was longer in the gastropexy group than in the non-gastropexy group (31 vs. 24 min; P<0.001). The 30-day mortality rates were 4.7% and 5.3% respectively, and these deaths were not related to the gastrostomy procedure. Conclusion: PEG with gastropexy markedly reduces peristomal inflammation. Although minor bleeding and a longer procedure time were disadvantages, there were no severe complications. The findings suggested that PEG with Funada-style gastropexy was a safe and feasible method for reducing early complications of PEG.【最新肝癌学-基礎と臨床の最新研究動向-】肝癌の治療 化学療法・分子標的治療 Sorafenib上嶋 一臣; 工藤 正俊日本臨床 (株)日本臨床社 73 (増刊1 最新肝癌学) 737 - 742 0047-1852 2015/01Flight Plan for Liverを用いたTACE柳生行伸; 鶴﨑正勝; 南 康範; 工藤正俊; 村上卓道肝胆膵 70 (1) 15 - 23 2015/01 [Refereed]Meeting Report; 第9回国際肝癌学会(ILCA)工藤正俊The Liver Cancer Journal 7 56 - 59 2015 [Refereed][Invited]Immune Checkpoint Blockade in Hepatocellular CarcinomaM. KudoLIVER CANCER KARGER 4 (4) 201 - 207 2235-1795 2015 [Refereed]Molecular Targeted Therapy for Hepatocellular Carcinoma: Where Are We Now?M. KudoLIVER CANCER KARGER 4 (3) I - VII 2235-1795 2015 [Refereed]Locoregional Therapy for Hepatocellular CarcinomaM. KudoLIVER CANCER KARGER 4 (3) 163 - 164 2235-1795 2015 [Refereed]Clinical Practice Guidelines for Hepatocellular Carcinoma Differ between Japan, United States, and EuropeM. KudoLIVER CANCER KARGER 4 (2) 85 - 95 2235-1795 2015 [Refereed]Activin signal promotes cancer progression and is involved in cachexia in a subset of pancreatic cancerYosuke Togashi; Akihiro Kogita; Hiroki Sakamoto; Hidetoshi Hayashi; Masato Terashima; Marco A. de Velasco; Kazuko Sakai; Yoshihiko Fujita; Shuta Tomida; Masayuki Kitano; Kiyotaka Okuno; Masatoshi Kudo; Kazuto NishioCANCER LETTERS ELSEVIER IRELAND LTD 356 (2) 819 - 827 0304-3835 2015/01 [Refereed] We previously reported that activin produces a signal with a tumor suppressive role in pancreatic cancer (PC). Here, the association between plasma activin A and survival in patients with advanced PC was investigated. Contrary to our expectations, however, patients with high plasma activin A levels had a significantly shorter survival period than those with low levels (median survival, 314 days vs. 482 days, P = 0.034). The cellular growth of the MIA PaCa-2 cell line was greatly enhanced by activin A via non-SMAD pathways. The cellular growth and colony formation of an INHBA (beta subunit of inhibin)overexpressed cell line were also enhanced. In a xenograft study, INHBA-overexpressed cells tended to result in a larger tumor volume, compared with a control. The bodyweights of mice inoculated with INHBA-overexpressed cells decreased dramatically, and these mice all died at an early stage, suggesting the occurrence of activin-induced cachexia. Our findings indicated that the activin signal can promote cancer progression in a subset of PC and might be involved in cachexia. The activin signal might be a novel target for the treatment of PC. (C) 2014 Elsevier Ireland Ltd. All rights reserved.Surveillance, Diagnosis, Treatment, and Outcome of Liver Cancer in JapanMasatoshi KudoLIVER CANCER KARGER 4 (1) 39 - 50 2235-1795 2015 [Refereed] Background: Hepatocellular carcinoma (HCC) is the fifth most common type of cancer and the third leading cause of cancer-related death worldwide. HCC is most common in Asia, but its prevalence is rapidly increasing in Western countries; consequently, HCC is a global medical issue that urgently needs to be addressed. Japan is the only developed country that has experienced both hepatitis B-related and hepatitis C-related HCC and has a long history of innovation when it comes to new diagnostic and therapeutic modalities, such as computed tomography angiography, anatomical resection, ablation, and transarterial chemoembolization. Among these innovations, a nationwide surveillance program was well established by the 1980s, and such a long-term national program does not exist anywhere else in the world. Summary: More than 60% of the initially detected HCCs in Japan are Barcelona Clinic Liver Cancer stage 0 or A, which can undergo curative therapies such as resection, ablation, or transplantation. The recent 5-year survival rate of HCC patients in Japan was 43% and the median survival time was 50 months. In addition, both incidence and mortality rates are drastically declining as a result of the successful surveillance program, careful diagnostic flow, and extensive repeated treatments. Key Message: Japan's successful model in the surveillance, diagnosis, and treatment of HCC should be adopted as widely as possible to improve the survival of HCC patients worldwide. Copyright (C) 2015 S. Karger AG, BaselSubclassification of BCLC B Stage Hepatocellular Carcinoma and Treatment Strategies: Proposal of Modified Bolondi's Subclassification (Kinki Criteria)Masatoshi Kudo; Tadaaki Arizumi; Kazuomi Ueshima; Toshiharu Sakurai; Masayuki Kitano; Naoshi NishidaDIGESTIVE DISEASES KARGER 33 (6) 751 - 758 0257-2753 2015 [Refereed] Intermediate stage hepatocellular carcinoma (HCC) is a very heterogeneous tumor in terms of tumor size (>3 cm similar to over 10 cm), tumor number (4 similar to over 20) and liver function (Child-Pugh score 5-9). However, transarterial chemoembolization is the only recommended treatment option according to the Barcelona Clinic Liver Cancer (BCLC) staging. Bolondi's subclassification of BCLC B stage is feasible; however, there are several weak points. Therefore, by modifying Bolondi's subclassification, we have proposed a more simplified subclassification, Kinki criteria. The Kinki criteria consist of 2 factors: liver function (Child-Pugh score 5-7 or 8, 9) and tumor status (Beyond Milan and within up-to-7 criteria; IN and OUT). The Kinki criteria classifies BCLC B stage from B1 (Child-Pugh score 5-7 and within up-to-7), B2 (Child-Pugh score 5-7 and beyond up-to-7) and B3 (Child-Pugh score 8, 9 and any tumor status). These criteria are simple and easy to apply to clinical practice. Therefore, these criteria will stratify the heterogeneous population of BCLC B group patient well and give the treatment indication according to each substage. These criteria should be further validated both retrospectively and prospectively. (C) 2015 S. Karger AG, BaselPhase II Study of Personalized Peptide Vaccination with Both a Hepatitis C Virus-Derived Peptide and Peptides from Tumor-Associated Antigens for the Treatment of HCV-Positive Advanced Hepatocellular Carcinoma PatientsShigeru Yutani; Kazuomi Ueshima; Kazumichi Abe; Atsushi Ishiguro; Junichi Eguchi; Satoko Matsueda; Nobukazu Komatsu; Shigeki Shichijo; Akira Yamada; Kyogo Itoh; Tetsuro Sasada; Masatoshi Kudo; Masanori NoguchiJOURNAL OF IMMUNOLOGY RESEARCH HINDAWI PUBLISHING CORP 2015 473909  2314-8861 2015 [Refereed] Objective. To evaluate safety and immune responses of personalized peptide vaccination (PPV) for hepatitis C virus-(HCV-) positive advanced hepatocellular carcinoma (HCC). Patients and Methods. Patients diagnosed with HCV-positive advanced HCC were eligible for this study. A maximum of four HLA-matched peptides were selected based on the preexisting IgG responses specific to 32 different peptides, which consisted of a single HCV-derived peptide at core protein positions 35-44 (C-35) and 31 peptides derived from 15 different tumor-associated antigens (TAAs), followed by subcutaneous administration once per week for 8 weeks. Peptide-specific cytotoxic T lymphocyte (CTL) and IgG responses were measured before and after vaccination. Results. Forty-two patients were enrolled. Grade 3 injection site skin reaction was observed in 2 patients, but no other PPV-related severe adverse events were noted. Peptide-specific CTL responses before vaccination were observed in only 3 of 42 patients, but they became detectable in 23 of 36 patients tested after vaccination. Peptide-specific IgG responses were also boosted in 19 of 36 patients. Peptide-specific IgG1 responses to both C-35 and TAA-derived peptides could be potentially prognostic for overall survival. Conclusion. Further clinical study of PPV would be warranted for HCV-positive advanced HCC, based on the safety and strong immune induction.Evidence and Consensus on the Management of Hepatocellular Carcinoma: Update 2015Masatoshi KudoONCOLOGY KARGER 89 1 - 3 0030-2414 2015 [Refereed]Imaging Modalities for Assessment of Treatment Response to Nonsurgical Hepatocellular Carcinoma Therapy: Contrast-Enhanced US, CT, and MRIYasunori Minami; Masatoshi KudoLIVER CANCER KARGER 4 (2) 106 - 114 2235-1795 2015 [Refereed] Tumor response and time to progression have been considered pivotal for surrogate assessment of treatment efficacy for patients with hepatocellular carcinoma (HCC). Recent advancements in imaging modalities such as contrast-enhanced ultrasound (US), computed tomography (CT), and magnetic resonance imaging (MRI) are playing an important role in assessing the therapeutic effects of HCC treatments. According to some HCC clinical guidelines, post-therapeutic evaluation of HCC patients is based exclusively on contrast-enhanced dynamic imaging criteria. The recommended techniques are contrast-enhanced CT or contrastenhanced MRI. Contrast-enhanced US is employed more in the positive diagnosis of HCC than in post-therapeutic monitoring. Although contrast enhancement is an important finding on imaging, enhancement does not necessarily depict the same phenomenon across modalities. We need to become well acquainted with the characteristics of each modality, including not only contrast-enhanced CT and MRI but also contrast-enhanced US. Many nonsurgical treatment options are now available for unresectable HCC, and accurate assessment of tumor response is essential to achieve favorable outcomes. For the assessment of successful radiofrequency ablation (RFA), the achievement of a sufficient ablation margin as well the absence of tumor vascular enhancement is essential. To evaluate the response to transcatheter arterial chemoembolization (TACE), enhanced tumor shrinkage is relied on as a measure of antitumor activity. Here, we give an overview of the current status of imaging assessment of HCC response to nonsurgical treatments including RFA and TACE. Copyright (C) 2015 S. Karger AG, BaselEffectiveness of Sorafenib in Patients with Transcatheter Arterial Chemoembolization (TACE) Refractory and Intermediate-Stage Hepatocellular CarcinomaTadaaki Arizumi; Kazuomi Ueshima; Tomohiro Minami; Masashi Kono; Hirokazu Chishina; Masahiro Takita; Satoshi Kitai; Tatsuo Inoue; Norihisa Yada; Satoru Hagiwara; Yasunori Minami; Toshiharu Sakurai; Naoshi Nishida; Masatoshi KudoLIVER CANCER KARGER 4 (4) 253 - 262 2235-1795 2015 [Refereed] Background and Aims: Patients with intermediate-stage hepatocellular carcinoma (HCC) refractory to transcatheter arterial chemoembolization (TACE) are considered to be candidates for sorafenib. The aim of this study was to evaluate the superiority of conversion of treatment to sorafenib on overall survival (OS) for cases refractory to TACE. Methods: This was a retrospective cohort study carried out on 497 patients with HCC who were treated with TACE therapy at our hospital between January 2008 and December 2013. Fifty-six patients were diagnosed as refractory to TACE during their clinical course and they were divided into two cohorts, (1) those who switched from TACE to sorafenib and (2) those who continued TACE. The overall survival (OS) after the time of being refractory to TACE was evaluated between the two groups. Results: After refractoriness to TACE therapy was confirmed, 24 patients continued with TACE (TACE-group) and 32 patients underwent treatment conversion to sorafenib (sorafenib-group). The median OS was 24.7 months in the sorafenib-group and 13.6 months in the TACE-group ( p=0.002). Conclusions: Conversion to sorafenib significantly improves the OS in patients refractory to TACE therapy with intermediate-stage HCC. Administration of sorafenib is therefore recommended in such circumstances of TACE treatment failure. Copyright (C) 2015 S. Karger AG, BaselPhase I/II Study of Sorafenib in Combination with Hepatic Arterial Infusion Chemotherapy Using Low-Dose Cisplatin and 5-FluorouracilKazuomi Ueshima; Masatoshi Kudo; Masatoshi Tanaka; Takashi Kumada; Hobyung Chung; Satoru Hagiwara; Tatsuo Inoue; Norihisa Yada; Satoshi KitaiLIVER CANCER KARGER 4 (4) 263 - 273 2235-1795 2015 [Refereed] We conducted a phase I/II study in patients with advanced hepatocellular carcinoma (HCC) to determine the recommended dose, as well as the safety and efficacy, of combination therapy of sorafenib with hepatic arterial infusion chemotherapy (HAIC) using low dose cisplatin (CDDP) and 5-fluorouracil (5FU). Cohorts consisting of 3-6 patients with HCC received an escalated dose of CDDP and 5-FU until a maximum-tolerated dose was achieved. The treatment regimen was as follows: oral administration of sorafenib (400 mg twice daily for 28 days) combined with HAIC using CDDP (14-20 mg/m(2), on days 1 and 8) and 5-FU (170-330 mg/m(2), continuously on days 1-5 and 8-12) via an implanted catheter system). Each treatment cycle consisted of 28 days and three cycles of combination therapy. At the end of the first cycle, adverse events were evaluated and future dose escalation was determined. Eighteen patients with advanced HCC were enrolled. Dose-limiting toxicity was observed in two patients from cohort 1 (erythema multiforme and grade 4 thrombocytopenia) and in one patient from cohort 2 (erythema multiforme). Seven of the 18 patients achieved a partial response, seven showed stable disease, two were diagnosed as progressive disease, and two were not assessable. The response rate was 38.9% and the disease control rate was 77.8%. The time-to-progression was 9.7 months and the 1-year survival rate was 88.2%. Oral administration of 400 mg of sorafenib twice daily, 20 mg/m(2) of intra-arterial infusion of CDDP, and 5-FU at 330 mg/m(2) are the recommended doses for combination therapy, which was well tolerated and efficacious. This combination therapy may be a promising treatment for patients with advanced HCC. Copyright (C) 2015 S. Karger AG, Basel肝細胞がんに対する術後補助療法の現状と展望上嶋一臣; 工藤正俊腫瘍内科 (有)科学評論社 15 (6) 603 - 607 1881-6568 2015 [Refereed]肝細胞癌ステージングシステムと進行肝癌診療. 特集「進行肝細胞癌の治療戦略」北井 聡; 上嶋一臣; 工藤正俊臨床消化器内科 30 1019 - 1026 2015 [Refereed]Synchronous pancreatic and gastric metastasis from an ovarian adenocarcinoma diagnosed by endoscopic ultrasound-guided fine-needle aspirationKentaro Yamao; Masayuki Kitano; Masatoshi Kudo; Osamu MaenishiENDOSCOPY GEORG THIEME VERLAG KG 47 E596 - E597 0013-726X 2015 [Refereed]胆管ドレナージ(MS). 特集「ERCPマスターへのロードマップ」北野雅之; 今井 元; 山雄健太郎; 鎌田 研; 宮田 剛; 三長孝輔; 大本俊介; 門阪薫平; 松田友彦; 工藤正俊胆と膵 36 969 - 974 2015 [Refereed]Antiviral therapy for chronic hepatitis B: Combination of nucleoside analogs and interferonSatoru Hagiwara; Naoshi Nishida; Masatoshi KudoWorld Journal of Hepatology Baishideng Publishing Group Co 7 (23) 2427 - 2431 1948-5182 2015 [Refereed] The ideal goal of chronic hepatitis B (CHB) treatment should be suppression of emergence of hepatocellular carcinoma through the disappearance of hepatitis B s antigen (HBsAg) rather than the control of serum hepatitis B virus-DNA level. For this purpose, various types of combination therapies using nucleoside analogs (NAs) and interferon (IFN) have been conducted. The therapeutic effects of combination of two different kinds of agents are better than those of the monotherapy using NAs or IFN alone, probably because different pharmaceutical properties might act in a coordinated manner. Recently, combination therapies with NAs and IFN and sequential therapies with NAs administration followed by IFN therapy have been routinely employed. We previously reported that combination therapy using entecavir (ETV) and pegylated (PEG)-IFN showed antiviral effects in 71% of CHB patients the effect of this combination was better than that using lamivudine (LAM) and PEG-IFN. This is partially explained by the better antiviral effects of ETV than those of LAM. In our analysis, the cohort of CHB consisted of the patients who showed a flare-up of hepatitis before antiviral therapy, and their baseline HBsAg levels were relatively low. Therefore, in addition to the combination of the agents, the appropriate selection of patients is critical to achieve a good viral response.Recent Advances in the Management of Chronic Hepatitis B Including Suppression of Hepatocellular Carcinoma by Entecavir and InterferonSoo Ki Kim; Soo Ryang Kim; Susumu Imoto; Madoka Tohyama; Yumi Otono; Tomoko Tamura; Ke Ih Kim; Mana Kobayashi; Aya Ohtani; Kayo Sugimoto; Aya Mizuguchi; Yukiko Hiramatsu; Masatoshi KudoONCOLOGY KARGER 89 60 - 69 0030-2414 2015 [Refereed] At present, for adults with chronic hepatitis B virus (HBV) infection, two new analogues, entecavir (ETV) and tenofovir, are recommended as the first-line therapy by the EASL (European Association for the Study of the Liver), AASLD (American Association for the Study of Liver Diseases), and APASL (Asian Pacific Association for the Study of the Liver) guidelines. The use of pegylated interferon-alpha (PEG IFN-alpha) is recommended as the first-line therapy instead of standard IFN-alpha according to the above 3 guidelines. In this paper, the aim was to assess: (1) the long-term efficacy and safety as well as the resistance to ETV and tenofovir disoproxil fumarate (TDF); (2) the efficacy of PEG IFN-alpha; (3) the role of combination therapy with IFN plus two analogues, such as lamivudine and ETV; (4) the efficacy and safety of two analogues with cirrhosis, and (5) suppression of hepatocellular carcinoma (HCC) by EN and IFN treatment. The results are as follows: (1) both EN and TDF showed long-term efficacy and safety; (2) PEG IFN-alpha resulted in a greater decline in HBV DNA levels and a higher rate of HBeAg seroconversion;(3) combination therapy with IFN plus two analogues did not elevate the rate of sustained responses; (4) both ETV and TDF showed efficacy and safety with cirrhosis (EN especially displayed efficacy and safety with decompensated cirrhosis), and (5) suppression of HCC was observed by EN and IFN. (C) 2015 S. Karger AG, BaselA Newly Developed Shear Wave Elastography Modality: With a Unique Reliability IndexNorihisa Yada; Toshiharu Sakurai; Tomohiro Minami; Tadaaki Arizumi; Masahiro Takita; Satoru Hagiwara; Kazuomi Ueshima; Hiroshi Ida; Naoshi Nishida; Masatoshi KudoONCOLOGY KARGER 89 53 - 59 0030-2414 2015 [Refereed] Objective: The aim of this study was to prospectively assess the usefulness of the reliability index, namely the percentage of the net amount of effective shear wave velocity (VsN). Methods: One hundred and sixty-eight patients with chronic liver disease, who underwent ultrasound elastography, were consecutively enrolled. Shear wave measurement (SWM), FibroScan, virtual touch quantification, and shear wave elastography were performed for all patients, and the variations in the measurement results were compared with VsN. The absolute average value of the difference between SWM_Vs and Vs measured using other elastography devices is termed vertical bar Delta Vs vertical bar. VsN was classified into three groups: 50, <50, and 0 (failure measurement). In these groups, there was a significant difference in abdominal circumference, body mass index, the distance between the ultrasound probe surface and the liver, and vertical bar Delta Vs vertical bar. When the distance between the ultrasound probe surface and the liver was >2cm, VsN tended to be significantly lower (p < 0.001). Results: When VsN was <50, bVsI became high, and there was variation in the results between each device. Conclusions:The results of this study show that VsN is a useful value to decide whether Vs is appropriate or not. (C) 2015 S. Karger AG, BaselValidation of a Modified Substaging System (Kinki Criteria) for Patients with Intermediate-Stage Hepatocellular CarcinomaTadaaki Arizumi; Kazuomi Ueshima; Mina Iwanishi; Tomohiro Minami; Hirokazu Chishina; Masashi Kono; Masahiro Takita; Satoshi Kitai; Tatsuo Inoue; Norihisa Yada; Satoru Hagiwara; Hiroshi Ida; Yasunori Minami; Toshiharu Sakurai; Masayuki Kitano; Naoshi Nishida; Masatoshi KudoONCOLOGY KARGER 89 47 - 52 0030-2414 2015 [Refereed] Introduction: Barcelona Clinic Liver Cancer (BCLC) stage B, an intermediate stage, includes various conditions of hepatocellular carcinoma (HCC). This heterogeneity of the patients with intermediate-stage HCC makes it difficult to predict their survival rates. In the present study, we examined the validity of the modified Bolondi classification (Kinki criteria) as a subclassification of patients with BCLC stage B HCC. Methods: Of 906 patients who underwent conventional transarterial chemoembolization at Kinki University Hospital, 753, who met the inclusion criteria, were examined. Of these 753 patients, 425 (56.4%) with BCLC stage B were subclassified using the Kinki criteria to examine the survival rate. Results: According to the Kinki criteria, 158 (37.2%) were subclassified into subclass B1,236 (55.53) into B2, and 31(7.3%) into B3. The comparison of the survival rates showed that the median overall survival was 3.9 years (95% CI, 3.2-4.6) in the BCLC subclass B1 group, 2.5 years (95% Cl, 2.2-3.1) in the B2 group, and 1.1 years (95% Cl, 0.6-1.5) in the B3 group (p < 0.001). Conclusion: When the BCLC stage B patients were subclassified according to the Kinki criteria, survival curves were stratified with significant differences, suggesting that the Kinki criteria were suitable for the subclassification of the intermediate-stage HCC patients. (C) 2015 S. Karger AG, BaselComparison of Daclatasvir and Asunaprevir for Chronic HCV 1b Infection with Telaprevir and Simeprevir plus Peginterferon and Ribavirin, with a Focus on the Prevention of Occurrence and Recurrence of Hepatocellular CarcinomaKayo Sugimoto; Soo Ryang Kim; Soo Ki Kim; Susumu Imoto; Madoka Tohyama; Ke Ih Kim; Aya Ohtani; Takashi Hatae; Yoshihiko Yano; Masatoshi Kudo; Yoshitake HayashiONCOLOGY KARGER 89 42 - 46 0030-2414 2015 [Refereed] Objectives:The efficacy of the all-oral administration of daclatasvir and asunaprevir for 24 weeks was compared with that of telaprevir for 12 weeks plus pegylated interferon and ribavirin (PEG-IFN/RBV) for 24 weeks, and that of simeprevir for 12 weeks plus PEG-IFN/RBV for 24 weeks, with a focus on the prevention of occurrence and recurrence of hepatocellular carcinoma (HCC). The levels of alanine aminotransferase (ALT) and a-fetoprotein (AFP) as suppressive markers of HCC were also measured. Methods: Patients received daclatasvir and asunaprevir (n = 17), simeprevir plus PEG-IFN/RBV (n = 15) and telaprevir plus PEG-IFN/RBV (n = 25). Sustained virological response (SVR) and the mean change in the level of serum ALT, AFP and platelet (PLT) count were compared among the three groups. Results: No difference in SVR was observed in patients given daclatasvir with asunaprevir (SVR4), telaprevir plus PEGIFN/RBV or simeprevir plus PEG-IFN/RBV (SVR24). Also, no significant difference was observed in the mean change of serum ALT, AFP or PLT count among the three groups. Conclusion: The preventive effect of the IFN-free,all-oral regimen of daclatasvir and asunaprevir was observed with a focus on the occurrence and recurrence of HCC, as was IFN-based treatment with telaprevir or simeprevir plus PEG-IFN/RBV. (C) 2015 S. Karger AG, BaselHyperenhanced Rim Surrounding Liver Metastatic Tumors in the Postvascular Phase of Sonazoid-Enhanced Ultrasonography: A Histological Indication of the Presence of Kupffer CellsHitoshi Tochio; Masafumi Sugahara; Yukihiro Imai; Hiroshi Tei; Yoshiyuki Suginoshita; Nobuhiro Imawsaki; Ichiro Sasaki; Michio Hamada; Kazushi Minowa; Tetsuo Inokuma; Masatoshi KudoONCOLOGY KARGER 89 33 - 41 0030-2414 2015 [Refereed] Aim: A hyperenhanced rim (termed 'HER') in the postvascular phase is detected in some cases of liver metastasis by Sonazoid-enhanced ultrasonography (US). Here, the association of the HER with histological features was investigated to clarify the cause of this characteristic imaging pattern. Subjects and Methods: A total of 13 hepatic nodules obtained from 11 patients with metastatic liver cancer who underwent Sonazoid-enhanced US followed by surgical resection were analyzed. The distribution density of CD68-positive cells in the tumor rim and the nontumor area was calculated and compared between the HER-positive and HER-negative groups. The relation between the pathological features of the tumor rim and the rate of necrosis within the tumor was also investigated. Results: In the HER-positive group (n = 8), the distribution density of CD68-positive cells was 2.9 +/- 0.9, which was significantly higher than that (1.0 +/- 0.3) in the HER-negative group (p < 0.05). Inflammatory cell infiltrates, including CD8-positive lymphocytes, were detected in all the HER-positive cases in the area surrounding the tumor, while fibrosis was observed in all the HER-negative cases. The necrotic area within the tumor was significantly larger in the HER-negative group. Conclusion: The HER-positive sign in liver metastases could reflect an increase in Kupifer cells in the tumor rim. The presence of the HER was associated with inflammatory cell infiltrates including CD8-positive lymphocytes surrounding the metastatic liver tumor. (C) 2015 S. Karger AG, BaselBalloon-Occluded Transcatheter Arterial Chemoembolization for Hepatocellular Carcinoma: A Single-Center ExperienceYasunori Minami; Tomohiro Minami; Hirokazu Chishina; Tadaaki Arizumi; Masahiro Takita; Satoshi Kitai; Norihisa Yada; Satoru Hagiwara; Masakatsu Tsurusaki; Yukinobu Yagyu; Kazuomi Ueshima; Naoshi Nishida; Takamichi Murakami; Masatoshi KudoONCOLOGY KARGER 89 27 - 32 0030-2414 2015 [Refereed] Objective: To investigate whether balloon-occluded transcatheter arterial chemoembolization (b-TACE) can produce a more dense accumulation of iodized oil in various stages of hepatocellular carcinoma (HCC), from single to uncountable, to overcome inferior local control. Materials and Methods: We studied 27 patients with HCC, including single to uncountable multiple lesions, who underwent b-TACE between August 2013 and April 2015. Dynamic CT was performed at baseline and 1-3 months after b-TACE. The treatment effect (TE) after b-TACE was evaluated using the Response Evaluation Criteria in Cancer of the Liver (RECICL) proposed by the Liver Cancer Study Group of Japan. Results: In the countable HCC group, contrast-enhanced CT demonstrated RECICL TE4 in 43.8% (14/32), TE3 in 12.5% (4/32), TE2 in 37.5% (12/32), and TEl in 6.3% (2/32) of patients. For the TACE-naive cohort, the objective response rate was 52.9%. The objective response rate was 60% for the previously lACE-treated cohort. In the uncountable multiple HCC group, the objective response rate was 0% (0/10), with progressive disease in 90% (9/10) of patients. Conclusion: Our observations suggested that b-TACE did not reduce the efficacy of retreatment for HCC with an insufficient outcome from conventional TACE, but it could not improve the efficacy of treatment for uncountable multiple HCCs. (C) 2015 S. Karger AG, BaselPercutaneous Radiofrequency Ablation for Intermediate-Stage Hepatocellular CarcinomaKazuya Kariyama; Akiko Wakuta; Mamoru Nishimura; Masayuki Kishida; Ayano Oonishi; Atsushi Ohyama; Kazuhiro Nouso; Masatoshi KudoONCOLOGY KARGER 89 19 - 26 0030-2414 2015 [Refereed] Objectives: Radiofrequency ablation plays a key role in the treatment of early-stage hepatocellular carcinoma. However, it is not recommended for intermediate-stage hepatocellular carcinoma. The objective of this study was to clarify the efficacy and safety of radiofrequency ablation for treating intermediate-stage hepatocellular carcinoma. Methods: We examined the outcome of 65 consecutive patients who were treated with radiofrequency ablation with or without transarterial chemoembolization for intermediate-stage hepatocellular carcinoma. Results: With a median follow-up of 37 months, overall survival rates of 65 cases at 1,3,5, and 7 years were 90, 70,51, and 36%, respectively. Multivariate analysis of clinical parameters revealed that the multicentric occurrence (MC)/intrahepatic metastasis (IM) was the only significant prognostic factor for overall survival (hazard ratio, 4.9; 95% confidence intervals, 2.1-11.4). Tumor size and tumor number were not significant factors for survival. The overall survival rates of patients with MC (n = 33) at 1, 3, 5, and 7 years were 97, 90, 80, and 59%, respectively; those for patients with IM (n = 32) were 86, 55, 14, and 8%, respectively (p < 0.0001). Two cases (4.9%) had complications of hemothorax and diaphragmatic burn; however, no major complications were observed. Conclusion: Radiofrequency ablation is safe and effective for the treatment of intermediate-stage hepatocellular carcinoma, especially for patients with MC. (C) 2015 S. Karger AG, BaselInitial Experience Performing Percutaneous Ultrasound Examination with Real-Time Virtual Sonography with Color DisplayChikara Ogawa; Yasunori Minami; Turuyo Noda; Soichi Arasawa; Masako Izuta; Atsushi Kubo; Toshihiro Matsunaka; Hiroyuki Tamaki; Mitsunari Shibatoge; Masatoshi KudoONCOLOGY KARGER 89 11 - 18 0030-2414 2015 [Refereed] Purpose: We report the efficacy of percutaneous ultrasound (US) examination using a novel real-time virtual sonography (RVS) method that collates multiple Digital Imaging and Communications in Medicine (DICOM) data sources and displays reference images in color. Materials and Methods: A total of 7 patients with 9 hepatocellular carcinomas were evaluated. Using the SYNAPSE VINCENT volume analyzer, DICOM data of the portal vein, hepatic vein, tumor, and hepatic segment were isolated from contrast-enhanced computed tomography DICOM data. Each portion of DICOM data was uploaded into an US scanner (HI VISION Ascendus, Hitachi Aloka Medical Ltd., Tokyo, Japan) and unified on a US platform to create a single reference image. Each uploaded portion of DICOM data was assigned a different color. Further, conventional RVS was performed using this information. Results: The maximal tumoral diameter ranged from 6.4 to 15 mm (mean +/- SD, 11.0 +/- 2.8). DICOM data could be isolated, enabling the display of color RVS in all patients. Color RVS facilitated superior visibility compared with conventional grayscale RVS and facilitated the comprehension of spatial positioning. Conclusion: RVS with color display demonstrates utility in increasing operator comprehension of spatial and positional relationships during percutaneous US examination. (C) 2015 S. Karger AG, BaselEvaluation of ART Scores for Repeated Transarterial Chemoembolization in Japanese Patients with Hepatocellular CarcinomaTadaaki Arizumi; Kazuomi Ueshima; Mina Iwanishi; Tomohiro Minami; Hirokazu Chishina; Masashi Kono; Masahiro Takita; Satoshi Kitai; Tatsuo Inoue; Norihisa Yada; Satoru Hagiwara; Hiroshi Ida; Yasunori Minami; Toshiharu Sakural; Naoshi Nishida; Masayuki Kitano; Masatoshi KudoONCOLOGY KARGER 89 4 - 10 0030-2414 2015 [Refereed] Objective: Transarterial chemoembolization (TACE) is recommended as a first-line therapy for hepatocellular carcinoma (HCC) patients ineligible for curative therapy and without portal invasion. The Assessment for Retreatment with TACE (ART) scoring system was recently proposed for identifying patients who would not show sufficient survival benefit from repeated TACE. We reevaluated the performance of ART in HCC patients treated in Japan, where selective TACE is commonly used. Methods: Between 2000 and 2013, 988 patients with HCC underwent TACE at Kinki University Hospital, and 627 received >= 2 sessions of TACE. Seventy-six patients who underwent >= 2 TACE sessions within 90 days were investigated for their performance of the ART score in the context of overall survival (OS). Results: Only 12% (76/627) of patients underwent >= 2 TACE sessions within 90 days. Of those, 52 patients showed a low ART score (0-1.5), and 24 had a high ARTscore (>= 2.5); the median OS was 20.2 and 37.6 months, respectively (p = 0.8207). Conclusion:The ART scoring system did not demonstrate a sufficiently predictive impact on OS among the patients who underwent 2 TACE sessions within 90 days. Application of the ART score should be carefully considered because differences in TACE procedures and post-TACE treatment can affect the results while evaluating OS. (C) 2015 S. Karger AG, BaselChallenges of Clinical Research on Hepatocellular CarcinomaMasatoshi Kudo; Masayuki Kitano; Toshiharu Sakurai; Naoshi NishidaDIGESTIVE DISEASES KARGER 33 (6) 780 - 790 0257-2753 2015 [Refereed] Challenges of clinical practice and research on hepatocellular carcinoma (HCC) were reviewed. There are several differences in clinical practice between Japan and the Western countries such as tumor markers, understanding of pathological early HCC, imaging diagnosis, treatment strategy, staging system and subclassification of HCC. Further studies are warranted for the clinical practices of Japan to be adopted in the rest of the world. (C) 2015 5. Karger AG, BaselMolecular Mechanism and Prediction of Sorafenib Chemoresistance in Human Hepatocellular CarcinomaNaoshi Nishida; Masayuki Kitano; Toshiharu Sakurai; Masatoshi KudoDIGESTIVE DISEASES KARGER 33 (6) 771 - 779 0257-2753 2015 [Refereed] Hepatocellular carcinoma (HCC) is the second leading cause of cancer death worldwide, and prognosis remains unsatisfactory when the disease is diagnosed at an advanced stage. Many molecular targeted agents are being developed for the treatment of advanced HCC; however, the only promising drug to have been developed is sorafenib, which acts as a multi-kinase inhibitor. Unfortunately, a subgroup of HCC is resistant to sorafenib, and the majority of these HCC patients show disease progression even after an initial satisfactory response. To date, a number of studies have examined the underlying mechanisms involved in the response to sorafenib, and trials have been performed to overcome the acquisition of drug resistance. The anti-tumor activity of sorafenib is largely attributed to the blockade of the signals from growth factors, such as vascular endothelial growth factor receptor and platelet-derived growth factor receptor, and the downstream RAF/mitogen-activated protein/extracellular signal-regulated kinase (ERK) kinase (MEK)/ERK cascade. The activation of an escape pathway from RAF/MEK/ERK possibly results in chemoresistance. In addition, there are several features of HCCs indicating sorafenib resistance, such as epithelial-mesenchymal transition and positive stem cell markers. Here, we review the recent reports and focus on the mechanism and prediction of chemoresistance to sorafenib in HCC. (C) 2015 S. Karger AG, BaselGeneral Rules for the Clinical and Pathological Study of Primary Liver Cancer, Nationwide Follow-Up Survey and Clinical Practice Guidelines: The Outstanding Achievements of the Liver Cancer Study Group of JapanMasatoshi Kudo; Masayuki Kitano; Toshiharu Sakurai; Naoshi NishidaDIGESTIVE DISEASES KARGER 33 (6) 765 - 770 0257-2753 2015 [Refereed] This review outlines the significance of establishing general rules, a nationwide follow-up survey, and clinical practice guidelines for liver cancer in Japan. The general rules are an essential part of hepatocellular carcinoma (HCC) treatment, enabling a 'common language' to be used in daily clinical practice and for the nationwide follow-up survey. The Japanese General Rules for the Clinical and Pathological Study of Primary Liver Cancer, which provide detailed descriptions of HCC, are excellent and are unique to Japan. Items in the General Rules for the Clinical and Pathological Study of Primary Liver Cancer are used substantially in another important project, the Nationwide Follow-Up Survey of Primary Liver Cancer, which has been rigorously undertaken with great effort by the Liver Cancer Study Group of Japan biannually since 1969. Both evidence-based and consensus-based treatment algorithms for HCC are used to complement each other in clinical practice in Japan. (C) 2015 S. Karger AG, BaselCone-Beam CT Angiography for Hepatocellular Carcinoma: Current StatusYasunori Minami; Takamichi Murakami; Masayuki Kitano; Toshiharu Sakurai; Naoshi Nishida; Masatoshi KudoDIGESTIVE DISEASES KARGER 33 (6) 759 - 764 0257-2753 2015 [Refereed] Cone-beam CT (CBCT) is generated during a rotational sweep of the C-arm around the patient, and can be a valuable imaging technique, providing in situ cross-sectional imaging. It is easy to evaluate the morphologic characteristics of hepatic arteries from multiple views with the use of various reconstruction techniques, such as maximum intensity projection (MIP) and volume rendering. CBCTangiography is capable of providing more information than the standard 2-dimensional angiography in visualizing hepatocellular carcinomas (HCCs) and targeting tumors though precise microcatheter placement in close proximity to HCCs. It can also be useful in evaluating treatment success at the time of the procedure. It is anticipated that CBCT could reduce radiation exposure, the overall procedure time and contrast material use because it allows immediate feedback for an efficient angiographic procedure. Therefore, CBCT angiography is an exciting technology with the potential to significantly impact the practice of interventional radiology. The purpose of this article is to provide a review of the principles, clinical applications and technique of CBCT angiography for HCC treatment. (C) 2015 S. Karger AG, BaselHepatic DNA Methylation Is Affected by Hepatocellular Carcinoma Risk in Patients with and without Hepatitis VirusNaoshi Nishida; Mina Iwanishi; Tomohiro Minami; Hirokazu Chishina; Tadaaki Arizumi; Masahiro Takita; Satoshi Kitai; Norihisa Yada; Hiroshi Ida; Satoru Hagiwara; Yasunori Minami; Kazuomi Ueshirna; Toshiharu Sakurai; Masayuki Kitano; Masatoshi KudoDIGESTIVE DISEASES KARGER 33 (6) 745 - 750 0257-2753 2015 [Refereed] Objectives: Several studies revealed that the proportion of hepatocellular carcinoma (HCC) without hepatitis virus infection (NBNC-HCC) is increasing. On the other hand, epigenetic alterations are reportedly responsible for HCC development. Here, we identified HCC risk factors that are associated with DNA methylation in the background liver tissue of NBNC-HCC patients. Methods: We performed methylation analysis in 37 pairs of virus-positive and 22 pairs of NBNC-HCC and non-cancerous livers using a HumanMethylation450 BeadChip array. After the selection of differentially methylated CpGs (DM-CpGs) in cancerous and non-cancerous livers, we analyzed DNA methylation of DM-CpGs within the adjacent non-cancerous liver tissue that is affected by specific HCC risk factors. Results: A total of 38,331 CpGs were selected as DM-CpGs using the following criteria: difference of beta-value between HCC and non-cancerous liver and false discovery rate (FDR) q < 1.0E-12. We subsequently selected the DM-CpGs that had methylation differences with the background liver tissue (that has FDR q < 0.35). Among the virus-positive patients, the type of hepatitis virus was mostly associated with differences in methylation within the background liver tissues. However, we found that background methylation patterns were most significantly associated with aging in NBNC patients. Interestingly, age-related methylation differences in DM-CpGs were also observed in NBNC-HCC tissues. Conclusions: Hepatitis viruses affect the methylation profiles within background liver tissues. However, difference in background methylation was mostly associated with age in NCBC-HCC patients; some age-related methylation events could contribute to emergence of NBNC-HCC in elderly individuals. (C) 2015 S. Karger AG, BaselReal-Life Clinical Practice with Sorafenib in Advance Hepatocellular Carcinoma: A Single-Center Experience Second AnalysisTadaaki Arizumi; Kazuomi Ueshima; Mina Iwanishi; Hirokazu Chishina; Masashi Kono; Masahiro Takita; Satoshi Kitai; Tatsuo Inoue; Norihisa Yada; Satoru Hagiwara; Hiroshi Ida; Yasunori Minami; Toshiharu Sakurai; Naoshi Nishida; Masayuki Kitano; Masatoshi KudoDIGESTIVE DISEASES KARGER 33 (6) 728 - 734 0257-2753 2015 [Refereed] Objectives: Sorafenib has become a standard therapy for advanced hepatocellular carcinoma following the demonstration of significant increase in progression-free survival as well as overall survival (OS) in the 2-phase III trials. We examined efficacy and adverse events (AEs) in patients treated with sorafenib over a 6-year period since approval in Japan. Methods: Two hundred and forty-one patients treated with sorafenib at the Kinki University Hospital were retrospectively analyzed clinically for the factors related to survival periods, tumor response evaluated by the Response Evaluation Criteria In Cancer of the Liver (RECICL) and AEs. Results: OS was 14.3 months. According to the RECICL, the objective response and disease control rates were 18.6% (43 of 241) and 61.1% (137 of 241), respectively. AEs were seen in 77.3% (187 of 241), with Grade 3 or higher in 23.6% (57 of 241). The most frequent AE was hand-foot skin reaction in 109 patients (45.0%), and 28 patients (11.8%) showed Grade 3 or higher. Significant factors contributing to the OS were treatment duration (p = 0.0204), up-to-7 criteria (p = 0.0400), increase of Child-Pugh score (p = 0.0008) and tumor response determined by the RECICL (p = 0.0007). Conclusion: Based on the analysis, using many cases at a single center, we concluded that continuation of treatment with sorafenib for >= 90 days without decrease of liver function was critical if tumor response was determined as stable disease or higher. (C) 2015 S. Karger AG, BaselCharacteristics of Hypovascular versus Hypervascular Well-Differentiated Hepatocellular Carcinoma Smaller Than 2 cm - Focus on Tumor Size, Markers and Imaging DetectabilityKayo Sugimoto; Soo Ryang Kim; Susumu Imoto; Madoka Tohyama; Soo Ki Kim; Toshiyuki Matsuoka; Yoshihiko Yano; Masatoshi Kudo; Yoshitake HayashiDIGESTIVE DISEASES KARGER 33 (6) 721 - 727 0257-2753 2015 [Refereed] Objectives: The characteristics of hypovascular and hypervascular well-differentiated hepatocellular carcinomas (HCCs) were compared in terms of tumor size, tumor markers and detectability by imaging modalities. Methods: Well-differentiated HCC nodules that are smaller than 2 cm (n = 27) were evaluated in 27 patients using histopathology and divided into 2 groups: hypovascular (n = 10) and hypervascular (n = 17). The diagnostic sensitivity of imaging modalities was then evaluated for efficiency in disclosing tumor size and tumor markers in the 2 types. Results: No difference was observed in tumor size and tumor markers between the 2 types; however, the sensitivity of contrast-enhanced CT, contrast-enhanced ultrasonography and arterioportal angiography was significantly different between the 2 types, whereas that by Gadolinium-ethoxybenzyl-diethylenetriamine pentaacetic acid enhanced magnetic resonance imaging (Gd-EOB-DTPA MRI) demonstrated no difference. Conclusion: Hypovascular HCC could be diagnosed by Gd-EOB-DTPA MRI in the hepatobiliary phase. (C) 2015 S. Karger AG, BaselUsefullness of Cytokeratin-18M65 in Diagnosing Non-Alcoholic Steatohepatitis in Japanese PopulationYutaka Hasegawa; Soo Ryang Kim; Takashi Hatae; Mitsuhiro Ohta; Aya Fujinami; Kayo Sugimoto; Ke Ih Kim; Susumu Imoto; Madoka Tohyama; Soo Ki Kim; Yoshihiro Ikura; Masatoshi KudoDIGESTIVE DISEASES KARGER 33 (6) 715 - 720 0257-2753 2015 [Refereed] Objective:The aim of this study was to evaluate cytokeratin-18M65 (CK-18M65) for distinguishing between simple steatosis (SS) and non-alcoholic steatohepatitis (NASH) against healthy individuals (HIs) in Japanese population. Methods: The serum from 24 HIs, 21 patients with SS and 20 patients with NASH were examined. Serum CK-18M65 was measured by enzyme-linked immunosorbent assay. Results: Aspartate aminotransferase was significantly different between NASH patients and HIs with p < 0.0001 (SS patients and HIs: p < 0.0001), as was alanine aminotransferase between NASH patients and HIs with p < 0.0001 (SS patients and HIs: p < 0.0001). Serum CK-18M65 increased in a stepwise fashion in HIs and also in SS and NASH patients. Multivariate logistic regression analysis revealed that NASH could be diagnosed with the use of CK-18M65 alone (p = 0.0285, OR 1.0038, 95% CI 1.0004-1.0073). At the optimal cut-off level of 548 U/I, CK-18M65 had an AUC value of 0.7369,60.00% sensitivity and 85.70% specificity. In patients with NASH, no significant difference was observed between low fibrosis (Stage 0-1, 794.30 +/- 454.41, n = 10) and high fibrosis (Stage 2-3, 809.70 +/- 641.43, n = 10; p = 0.5967) and between slight steatosis (<33%, 512.89 +/- 229.65, n = 9) and moderate steatosis (>= 33%,655.13 +/- 480.78, n = 32) in patients with non-alcoholic fatty liver disease (NAFLD; p = 0.7647) with the use of CK-18M65. Conclusion: Serum CK-18M65 distinguished NASH from SS, but could not assess the severity of steatosis in NAFLD patients or the grade of fibrosis in NASH patients in Japanese population. (C) 2015 S. Karger AG, BaselEarly Viral Response Predicts the Efficacy of Antiviral Triple Therapy with Simeprevir, Peg-Interferon and Ribavirin in Patients Infected with Hepatitis C Virus Genotype 1Naoshi Nishida; Mina Iwanishi; Tomohiro Minami; Hirokazu Chishina; Tadaaki Arizumi; Masahiro Takita; Satoshi Kitai; Norihisa Yada; Hiroshi Ida; Satoru Hagiwara; Yasunori Minami; Kazuomi Ueshima; Toshiharu Sakurai; Masayuki Kitano; Masatoshi KudoDIGESTIVE DISEASES KARGER 33 (6) 708 - 714 0257-2753 2015 [Refereed] Objectives: Triple therapy using peg-interferon, ribavirin and simeprevir (PEG-IFN/RBV/SMV) has reportedly resulted in high-sustained virological response (SVR) rates in patients with chronic hepatitis C (CHC), especially in naive cases and relapsers to prior PEG-IFN/RBV therapy. Here, we retrospectively analyzed the antiviral response associated with a triple regimen, in the context of early reduction of viral load during treatment. Methods: Forty-six CHC patients with HCV genotype 1b were treated with PEG-IFN/RBV/SMV triple therapy: 20 were naive cases, 12 were relapsers and 14 were non-responders to prior PEG-IFN/RBV therapy. We evaluated rapid virological response (RVR), complete early virological response (EVR), viral clearance at the end of the treatment (EOT) and at 12 weeks after the EOT (SVR12). In addition, we quantified the serum HCV-RNA on the 1st day and the 7th day after initiating treatment. Results: Multivariate analysis revealed that response to prior treatment was identified as an independent factor for achieving SVR12 after triple therapy (p = 0.0005). The achievement of serum HCV-RNA <2 log(10) IU/ml on day 7, RVR, EVR and EOT were associated with SVR12 (p = 0.0050, p = 0.0002, p = 0.0009 and p = 0.0002, respectively). Conclusions: Rapid decline of HCV is a predictive factor for the achievement of SVR12, even in antiviral triple therapy with PEG-IFN/RBV/SMV. An extended treatment period should be applied for patients who show detectable serum HCV-RNA at week 4. (C) 2015 S. Karger AG, BaselChronic Liver Diseases and Liver Cancer: An Update in 2015Masatoshi KudoDIGESTIVE DISEASES KARGER 33 (6) 705 - 707 0257-2753 2015 [Refereed]膵嚢胞性疾患と膵癌. 特集「消化器癌予防up-to-date」鎌田 研; 北野雅之; 工藤正俊臨床消化器内科 30 1451 - 1456 2015 [Refereed][Invited]金属ステント留置後急性胆嚢炎に対するEUS下ガイド下胆嚢ドレナージ術の有用性. 特集「EUS下胆道ドレナージ~EUS-BDの安全な導入へ向けて~」今井 元; 北野雅之; 大本俊介; 門阪薫平; 宮田 剛; 鎌田 研; 三長孝輔; 松田友彦; 山雄健太郎; 工藤正俊胆と膵 医学図書出版(株) 36 (8) 779 - 783 0388-9408 2015 [Refereed][Invited] 「急性胆管炎・胆嚢炎診療ガイドライン2013」において急性胆嚢炎に対するドレナージ治療の一つとして、EUS下吸引生検術を応用したEUS下胆嚢ドレナージ術(EUS-GBD)がある。胃前庭部もしくは十二指腸球部より胆嚢を穿刺し、穿刺後に胆嚢内を生理食塩水にて洗浄する。続いてガイドワイヤーを留置し穿刺孔を拡張する。最後に両端ピッグテイルステントもしくは金属カバーステントを留置する。症例報告ではあるが、手技成功率は97〜100%、臨床症状改善率は100%と概ね良好な結果が得られており、今後、経皮的経肝胆嚢ドレナージ術、経乳頭的胆嚢ドレナージ術と同等の治療効果が期待できる方法として注目される手技である。(著者抄録)肝癌根治的治療後の再発の早期発見工藤正俊; 泉 並木; 金子周一肝癌診療マニュアル 第3版, 日本肝臓学会編集, 医学書院, 東京 168 - 170 2015 [Refereed][Invited]肝癌治療後の再発抑制治療泉 並木; 工藤正俊; 金子周一肝癌診療マニュアル 第3版, 日本肝臓学会編集, 医学書院, 東京 166 - 167 2015 [Refereed][Invited]肝癌全体の治療アルゴリズム工藤正俊; 國土典宏; 川崎誠治; 松井 修; 泉 並木肝癌診療マニュアル 第3版, 日本肝臓学会編集, 医学書院, 東京 146 - 150 2015 [Refereed][Invited]肝動注化学療法と分子標的治療をどう使い分けるか工藤正俊; 小尾俊太郎; 山下竜也肝癌診療マニュアル 第3版, 日本肝臓学会編集, 医学書院, 東京 144 - 146 2015 [Refereed][Invited]TACE不応例に対する治療指針工藤正俊; 松井 修; 角谷眞澄肝癌診療マニュアル 第3版, 日本肝臓学会編集, 医学書院, 東京 140 - 143 2015 [Refereed][Invited]全身化学療法と分子標的治療上嶋一臣; 工藤正俊肝癌診療マニュアル 第3版, 日本肝臓学会編集, 医学書院, 東京 132 - 135 2015 [Refereed][Invited]造影超音波下RFA南 康範; 工藤正俊肝癌診療マニュアル 第3版, 日本肝臓学会編集, 医学書院, 東京 91 - 93 2015 [Refereed][Invited]肝癌診療のためのステージングシステム工藤正俊肝癌診療マニュアル 第3版, 日本肝臓学会編集, 医学書院, 東京 74 - 77 2015 [Refereed][Invited]乏血性肝細胞癌性結節(境界病変, 異型結節, 早期肝癌)はどのような場合に治療すべきか工藤正俊; 泉 並木; 角谷眞澄; 松井 修肝癌診療マニュアル 第3版, 日本肝臓学会編集, 医学書院, 東京 66  2015 [Refereed][Invited]肝細胞癌の診断アルゴリズム工藤正俊; 泉 並木; 角谷眞澄; 松井 修肝癌診療マニュアル 第3版, 日本肝臓学会編集, 医学書院, 東京 62 - 66 2015 [Refereed][Invited]早期肝癌の画像的特徴松井 修; 工藤正俊; 今井康陽; 中島 収; 坂元亨宇肝癌診療マニュアル 第3版, 日本肝臓学会編集, 医学書院, 東京 58 - 61 2015 [Refereed][Invited]どのようなときに造影超音波を行うか工藤正俊肝癌診療マニュアル 第3版, 日本肝臓学会編集, 医学書院, 東京 52 - 58 2015 [Refereed][Invited]どのようなときにGd-EOB-DTPA造影MRIを行うか工藤正俊; 今井康陽; 村上卓道肝癌診療マニュアル 第3版, 日本肝臓学会編集, 医学書院, 東京 47 - 50 2015 [Refereed][Invited]肝癌早期発見のためのスクリーニング法建石良介; 泉 並木; 金子周一; 工藤正俊肝癌診療マニュアル 第3版, 日本肝臓学会編集, 医学書院, 東京 35 - 37 2015 [Refereed][Invited]BCLC Stage B (Intermediate stage) の細分類と治療選択. 特集「肝がん診療ガイドライン: どうする治療選択」工藤正俊肝胆膵 71 321 - 327 2015 [Refereed][Invited]鼎談「肝細胞癌に対するTACE再考」工藤正俊; 松井 修; 田中正俊肝胆膵 70 141 - 158 2015 [Refereed][Invited]Intermediate stagの多様性. 特集「肝細胞癌に対するTACE再考」南 康範; 工藤正俊肝胆膵 70 33 - 38 2015 [Refereed]TACE不応基準をめぐって(日本肝癌研究会2014年改訂版). 特集「肝細胞癌に対するTACE再考」工藤正俊肝胆膵 70 81 - 88 2015 [Refereed][Invited]膵腫瘍性病変における造影US(体外式)による鑑別診断大本俊介; 北野雅之; 前川 清; 工藤正俊胆と膵 36 685 - 389 2015 [Refereed]第5章 肝がん診療ガイドライン工藤正俊最新医学別冊「診断と治療のABC 103 肝がん」 186 - 194 2015 [Refereed][Invited]眼で見る肝がん工藤正俊最新医学別冊「診断と治療のABC 103 肝がん MAP」 7 - 10 2015 [Refereed][Invited]肝癌に対する分子標的治療: 期待と展望. 特集「消化器癌の分子標的治療」上嶋一臣; 工藤正俊細胞 47 (9) 14 - 17 2015 [Refereed][Invited]EUS-FNAによる膵嚢胞性腫瘍診断. 特集「胆膵EUS-FNAのエビデンス2015-この5年間の進歩-」鎌田 研; 北野雅之; 安川 覚; 柳澤昭夫; Bertrand Napoleon; 工藤正俊胆と膵 36 315 - 318 2015 [Refereed]座談会 肝胆膵イメージング: 画像が映す分子病理全 陽; 角谷眞澄; 工藤正俊; 多田 稔肝臓 70 629 - 642 2015 [Refereed][Invited]早期慢性膵炎のEUSが反映する微細所見. 特集「肝胆膵イメージング: 画像が映す分子病理」門阪薫平; 北野雅之; 大本俊介; 鎌田 研; 宮田 剛; 山雄健太郎; 今井 元; 工藤正俊肝胆膵 70 601 - 608 2015 [Refereed]十二指腸静脈瘤の病態と治療方針松井繁長; 樫田博史; 工藤正俊日本門脈圧亢進症学会雑誌 21 19 - 25 2015 [Refereed][Invited]膵腫瘍の画像診断: US北野雅之; 今井 元; 工藤正俊日本臨床 73 50 - 54 2015 [Refereed][Invited]A bridge between multi-omics data and the management of hepatocellular carcinomaNaoshi Nishida; Masatoshi KudoAnnals of Translational Medicine AME Publishing Company 3 (1) 1  2305-5847 2015/01 [Refereed]Linifanib Versus Sorafenib in Patients With Advanced Hepatocellular Carcinoma: Results of a Randomized Phase III TrialCalin Cainap; Shukui Qin; Wen-Tsung Huang; Ik Joo Chung; Hongming Pan; Ying Cheng; Masatoshi Kudo; Yoon-Koo Kang; Pei-Jer Chen; Han-Chong Toh; Vera Gorbunova; Ferry A. L. M. Eskens; Jiang Qian; Mark D. McKee; Justin L. Ricker; Dawn M. Carlson; Saied El-NowiemJOURNAL OF CLINICAL ONCOLOGY AMER SOC CLINICAL ONCOLOGY 33 (2) 172 - U77 0732-183X 2015/01 [Refereed] Purpose This open-label phase III trial evaluated efficacy and tolerability of linifanib versus sorafenib in patients with advanced hepatocellular carcinoma (HCC) without prior systemic therapy. Patients and Methods Patients were randomly assigned in a 1: 1 ratio to linifanib 17.5 mg once daily or sorafenib 400 mg twice daily. Patients were stratified by region (Outside Asia, Japan, and rest of Asia), Eastern Cooperative Oncology Group performance score (ECOG PS; 0 or 1), vascular invasion or extrahepatic spread (yes or no), and hepatitis B virus (HBV) infection (yes or no). The primary end point of the study was overall survival (OS). Secondary end points were time to progression (TTP) and objective response rate (ORR) per RECIST v1.1. Results We randomly assigned 1,035 patients (median age, 60 years; Asian, 66.6%; ECOG PS 0, 65.2%; HBV, 49.1%; vascular invasion or extrahepatic spread, 70.1%). Median OS was 9.1 months on the linifanib arm (95% CI, 8.1 to 10.2) and 9.8 months on the sorafenib arm (95% CI, 8.3 to 11.0; hazard ratio [HR], 1.046; 95% CI, 0.896 to 1.221). For prespecified stratification subgroups, OS HRs ranged from 0.793 to 1.119 and the 95% CI contained 1.0. Median TTP was 5.4 months on the linifanib arm (95% CI, 4.2 to 5.6) and 4.0 months on the sorafenib arm (95% CI, 2.8 to 4.2; HR, 0.759; 95% CI, 0.643 to 0.895; P = .001). Best response rate was 13.0% on the linifanib arm versus 6.9% on the sorafenib arm. Grade 3/4 adverse events (AEs); serious AEs; and AEs leading to discontinuation, dose interruption, and reduction were more frequent with linifanib (all P = .001). Conclusion Linifanib and sorafenib had similar OS in advanced HCC. Predefined superiority and non-inferiority OS boundaries were not met for linifanib and the study failed to meet the primary end point. TTP and ORR favored linifanib; safety results favored sorafenib. (C) 2014 by American Society of Clinical Oncology肝動注化学療法に用いる薬物. 特集「肝癌の薬物療法」上嶋一臣; 工藤正俊Pharma Medica (株)メディカルレビュー社 33 (1) 21 - 23 0289-5803 2015 [Refereed][Invited]Malignant Transformation of Hepatocellular Adenoma: How Frequently Does It Happen?M. KudoLIVER CANCER KARGER 4 (1) 1 - 5 2235-1795 2015 [Refereed]編集: 日本臨床増刊号 最新肝癌学工藤正俊2015 [Refereed]Cone-beam CT angiography(tracking navitation imagingも含めて)南 康範; 村上卓道; 工藤正俊最新肝癌学 73 579 - 581 2015 [Refereed]肝細胞癌の治療アルゴリズム井上達夫; 工藤正俊最新肝癌学 73 457 - 463 2015 [Refereed]取扱い規約・診療ガイドラインを作成する意義工藤正俊最新肝癌学 73 443 - 446 2015 [Refereed]発癌予測バイオマーカーとしてのエピゲノム変化萩原 智; 西田直生志; 工藤正俊最新肝癌学 73 403 - 407 2015 [Refereed]超音波elastography(strain法)矢田典久; 工藤正俊最新肝癌学 73 367 - 371 2015 [Refereed]TNM stage、統合ステージングシステム北井 聡; 工藤正俊最新肝癌学 73 328 - 333 2015 [Refereed]癌遺伝子と癌抑制遺伝子西田直生志; 工藤正俊最新肝癌学 73 164 - 169 2015 [Refereed]肝細胞癌臨床研究の課題と展望工藤正俊最新肝癌学 73 33 - 41 2015 [Refereed]序文工藤正俊最新肝癌学 73 1 - 14 2015 [Refereed]Involvement of Heat Shock Protein A4/Apg-2 in Refractory Inflammatory Bowel DiseaseTeppei Adachi; Toshiharu Sakurai; Hiroshi Kashida; Hiromasa Mine; Satoru Hagiwara; Shigenaga Matsui; Koji Yoshida; Naoshi Nishida; Tomohiro Watanabe; Katsuhiko Itoh; Jun Fujita; Masatoshi KudoINFLAMMATORY BOWEL DISEASES LIPPINCOTT WILLIAMS & WILKINS 21 (1) 31 - 39 1078-0998 2015/01 [Refereed] Background: Expression of heat shock protein A4 (HSPA4, also called Apg-2), a member of the HSP110 family, is induced by several forms of stress. The physiological and pathological functions of HSPA4 in the intestine remain to be elucidated. Methods: We assessed HSPA4 expression and function by generating HSPA4-deficient mice and using 214 human intestinal mucosa samples from patients with inflammatory bowel disease (IBD). Results: In the colonic mucosa of patients with IBD, a significant correlation was observed between the expression of HSPA4 and antiapoptotic protein Bcl-2, a T-cell-derived cytokine IL-17 or stem cell markers, such as Sox2. In refractory ulcerative colitis, a condition associated with increased cancer risk, expression of HSPA4 and Bcl-2 was increased in inflammatory cells of colonic mucosae. HSPA4 was overexpressed both in cancer cells and immune cells of human colorectal cancers. Patients with high expression of HSPA4 or Bmi1 showed significantly lower response rates upon subsequent steroid therapy as compared with patients with low expression of each gene. HSPA4-deficient mice exhibit more apoptosis and less expression of IL-17/IL-23 in inflammatory cells and less number of Sox(2+) cells after administration of dextran sodium sulfate than control mice. Transduction of HspaA4(+/-) bone marrow into wild-type mice reduced the immune response. Conclusions: Upregulation of Bcl-2 and IL-17 by HSPA4 would control apoptosis of inflammatory cells and immune response in the gut, which might develop treatment resistance in IBD. HSPA4 and Bmi1 would be a useful biomarker for refractory clinical course and a promising approach for a therapeutic strategy in patients with IBD.Dynamic changes of the inflammation-based index predict mortality following chemoembolisation for hepatocellular carcinoma: a prospective studyD. J. Pinato; G. Karamanakos; T. Arizumi; D. Adjogatse; Y. W. Kim; J. Stebbing; M. Kudo; J. W. Jang; R. SharmaALIMENTARY PHARMACOLOGY & THERAPEUTICS WILEY-BLACKWELL 40 (11-12) 1270 - 1281 0269-2813 2014/12 [Refereed] BackgroundTransarterial chemoembolisation (TACE) is a standard treatment for unresectable, intermediate stage hepatocellular carcinoma (HCC). Survival after TACE, however, can be highly variable, with no suitable biomarker predicting therapeutic outcome. The inflammation-based index (IBI) has previously been shown to independently predict overall survival (OS) in all stages of HCC. AimTo explore the prognostic ability of IBI as a predictor of survival after TACE. MethodsBaseline staging, biochemical and clinicopathological features including IBI were studied in a derivation set of 64 patients undergoing TACE for intermediate stage HCC. Dynamic changes in IBI before and after TACE were studied as predictors of survival using both a univariate and multivariate Cox regression model and further validated in two independent patient cohorts from Korea (n=76) and Japan (n=577). ResultsPre-treatment IBI predicted for OS in the derivation set (P=0.001). Other univariate predictors of OS included radiological response to TACE (P<0.001), pre-TACE CLIP score (P<0.01), tumour diameter >5cm (P=0.05) and AFP 400 (P<0.001). Normalisation of IBI post-TACE was associated with radiological response by mRECIST criteria and improved OS (P<0.001). Normalisation of IBI remained a significant multivariate predictor of OS in both the derivation and validation sets (P<0.001). ConclusionsNormalisation of IBI after TACE is shown to be an independent predictor of survival and may be integrated into the retreatment criteria for repeat TACE in intermediate stage HCC. IBI and its dynamic changes after treatment are validated as a biomarker allowing the stratification of patients with a significant survival advantage following initial TACE.Comparison of systems for assessment of post-therapeutic response to sorafenib for hepatocellular carcinomaTadaaki Arizumi; Kazuomi Ueshima; Haruhiko Takeda; Yukio Osaki; Masahiro Takita; Tatsuo Inoue; Satoshi Kitai; Norihisa Yada; Satoru Hagiwara; Yasunori Minami; Toshiharu Sakurai; Naoshi Nishida; Masatoshi KudoJOURNAL OF GASTROENTEROLOGY SPRINGER JAPAN KK 49 (12) 1578 - 1587 0944-1174 2014/12 [Refereed] To test the hypothesis that use of the response evaluation criteria in cancer of the liver (RECICL), an improved evaluation system designed to address the limitations of the response evaluation criteria in solid tumors 1.1 (RECIST1.1) and modified RECIST (mRECIST), provides for more accurate evaluation of response of patients with hepatocellular carcinoma (HCC) to treatment with sorafenib, a molecularly targeted agent, as assessed by overall survival (OS). The therapeutic response of 156 patients with advanced HCC who had been treated with sorafenib therapy for more than 1 month was evaluated using the RECIST1.1, mRECIST, and RECICL. After categorization as showing progressive disease (PD), stable disease (SD), or objective response, the association between OS and categorization was examined using the Kaplan-Meier method to develop survival curves. The 141 cases categorized as PD or SD by the RECIST1.1, but objective response by the mRECIST and RECICL, were further analyzed for determination of the association between OS and categorization. Only categorization using the RECICL was found to be significantly correlated with OS (p = 0.0033). Among the patients categorized as SD or PD by the RECIST1.1, reclassification by the RECICL but not the mRECIST was found to be significantly associated with OS and allowed for precise prediction of prognosis (p = 0.0066). Only the use of the RECICL allowed for identification of a subgroup of HCC patients treated with sorafenib with improved prognosis. The RECICL should, therefore, be considered a superior system for assessment of therapeutic response.Small-intestinal mucosal injury induced by non-steroidal anti-inflammatory drugs or antiplatelet agents in our hospitalTomoyuki Nagai; Rie Tanaka; Mitsunari Yamada; Teppei Adachi; Masaki Takayama; Hiromasa Mine; Yoshihisa Okazaki; Yoriaki Komeda; Yutaka Asakuma; Toshiharu Sakurai; Shigenaga Mastui; Hiroshi Kashida; Masatoshi KudoJOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY WILEY-BLACKWELL 29 168 - 168 0815-9319 2014/11 [Refereed]The usefulness of single-balloon endoscopy for the small bowel lesionsTeppei Adachi; Rie Tanaka; Mitsunari Yamada; Masaki Takayama; Hiromasa Mine; Tomoyuki Nagai; Masanori Kawasaki; Yutaka Asakuma; Yoshihisa Okazaki; Yoriaki Komeda; Toshiharu Sakurai; Shigenaga Matsui; Hiroshi Kashida; Masatoshi KudoJOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY WILEY-BLACKWELL 29 3 - 4 0815-9319 2014/11 [Refereed]Endoscopic resection for rectal nets (neuroendocrine tumors): EMR-C (EMR using a cap), EMR-L (EMR with a ligation device), or conventional EMRMitsunari Yamada; Hiroshi Kashida; Rie Tanaka; Teppei Adachi; Hiromasa Mine; Masaki Takayama; Yoshihiro Okazaki; Yoshiaki Nagata; Tomoyuki Nagai; Masanori Kawasaki; Noriaki Komeda; Yutaka Asakuma; Yoshiharu Sakurai; Shigenaga Matsui; Masatoshi KudoJOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY WILEY-BLACKWELL 29 265 - 266 0815-9319 2014/11 [Refereed]Comparison of Japanese primary and secondary regimen of Helicobacter pylori eradicationTeppei Adachi; Rie Tanaka; Mitsunari Yamada; Masaki Takayama; Hiromasa Mine; Tomoyuki Nagai; Masanori Kawasaki; Yutaka Asakuma; Yoshihisa Okazaki; Yoriaki Komeda; Toshiharu Sakurai; Shigenaga Matsui; Hiroshi Kashida; Masatoshi KudoJOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY WILEY-BLACKWELL 29 22 - 22 0815-9319 2014/11 [Refereed]Two cases of gastric amyloidosisShigenaga Matsui; Hiroshi Kashida; Kazuki Okamoto; Yutaka Asakuma; Toshiharu Sakurai; Masatoshi KudoJOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY WILEY-BLACKWELL 29 114 - 114 0815-9319 2014/11 [Refereed]The clinical characteristics and treatment of eosinophilic esophagitisShigenaga Matsui; Hiroshi Kashida; Masanori Kawasaki; Yutaka Asakuma; Toshiharu Sakurai; Masatoshi KudoJOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY WILEY-BLACKWELL 29 114 - 115 0815-9319 2014/11 [Refereed]Brivanib as Adjuvant Therapy to Transarterial Chemoembolization in Patients With Hepatocellular Carcinoma: A Randomized Phase III TrialMasatoshi Kudo; Guohong Han; Richard S. Finn; Ronnie T. P. Poon; Jean-Frederic Blanc; Lunan Yan; Jijin Yang; Ligong Lu; Won-Young Tak; Xiaoping Yu; Joon-Hyeok Lee; Shi-Ming Lin; Changping Wu; Tawesak Tanwandee; Guoliang Shao; Ian B. Walters; Christine Dela Cruz; Valerie Poulart; Jian-Hua WangHEPATOLOGY WILEY-BLACKWELL 60 (5) 1697 - 1707 0270-9139 2014/11 [Refereed] Transarterial chemoembolization (TACE) is the current standard of treatment for unresectable intermediate-stage hepatocellular carcinoma (HCC). Brivanib, a selective dual inhibitor of vascular endothelial growth factor and fibroblast growth factor signaling, may improve the effectiveness of TACE when given as an adjuvant to TACE. In this multinational, randomized, double-blind, placebo-controlled, phase III study, 870 patients with TACE-eligible HCC were planned to be randomly assigned (1: 1) after the first TACE to receive either brivanib 800 mg or placebo orally once-daily. The primary endpoint was overall survival (OS). Secondary endpoints included time to disease progression (TTDP; a composite endpoint based on development of extrahepatic spread or vascular invasion, deterioration of liver function or performance status, or death), time to extrahepatic spread or vascular invasion (TTES/VI), rate of TACE, and safety. Time to radiographic progression (TTP) and objective response rate were exploratory endpoints. The trial was terminated after randomization of 502 patients (brivanib, 249; placebo, 253) when two other phase III studies of brivanib in advanced HCC patients failed to meet OS objectives. At termination, median follow-up was approximately 16 months. Intention-to-treat analysis showed no improvement in OS with brivanib versus placebo (median, 26.4 [95% confidence interval {CI}: 19.1 to not reached] vs. 26.1 months [19.0-30.9]; hazard ratio [HR]: 0.90 [95% CI: 0.66-1.23]; log-rank P50.5280). Brivanib improved TTES/VI (HR, 0.64 [95% CI: 0.45-0.90]), TTP (0.61 [0.48-0.77]), and rate of TACE (0.72 [0.61-0.86]), but not TTDP (0.94 [0.72-1.22]) versus placebo. Most frequent grade 3-4 adverse events included hyponatremia (brivanib, 18% vs. placebo, 5%) and hypertension (13% vs. 3%). Conclusions: In this study, brivanib as adjuvant therapy to TACE did not improve OS.NOD2 downregulates colonic inflammation by IRF4-mediated inhibition of K63-linked polyubiquitination of RICK and TRAF6T. Watanabe; N. Asano; G. Meng; K. Yamashita; Y. Arai; T. Sakurai; M. Kudo; I. J. Fuss; A. Kitani; T. Shimosegawa; T. Chiba; W. StroberMUCOSAL IMMUNOLOGY NATURE PUBLISHING GROUP 7 (6) 1312 - 1325 1933-0219 2014/11 [Refereed] It is well established that polymorphisms of the caspase activation and recruitment domain 15 (CARD15) gene, a major risk factor in Crohn's disease (CD), lead to loss of nucleotide-binding oligomerization domain 2 (NOD2) function. However, a molecular explanation of how such loss of function leads to increased susceptibility to CD has remained unclear. In a previous study exploring this question, we reported that activation of NOD2 in human dendritic cells by its ligand, muramyl dipeptide (MDP), negatively regulates Toll-like receptor (TLR)-mediated inflammatory responses. Here we show that NOD2 activation results in increased interferon regulatory factor 4 (IRF4) expression and binding to tumor necrosis factor receptor associated factor 6 (TRAF6) and RICK (receptor interacting serine-threonine kinase). We then show that such binding leads to IRF4-mediated inhibition of Lys63-linked polyubiquitination of TRAF6 and RICK and thus to downregulation of nuclear factor (NF)-kappa B activation. Finally, we demonstrate that protection of mice from the development of experimental colitis by MDP or IRF4 administration is accompanied by similar IRF4-mediated effects on polyubiquitination of TRAF6 and RICK in colonic lamina propria mononuclear cells. These findings thus define a mechanism of NOD2-mediated regulation of innate immune responses to intestinal microflora that could explain the relation of CARD15 polymorphisms and resultant NOD2 dysfunction to CD.Stress Response Protein Cirp Links Inflammation and Tumorigenesis in Colitis-Associated CancerToshiharu Sakurai; Hiroshi Kashida; Tomohiro Watanabe; Satoru Hagiwara; Tsunekazu Mizushima; Hideki Iijima; Naoshi Nishida; Hiroaki Higashitsuji; Jun Fujita; Masatoshi KudoCANCER RESEARCH AMER ASSOC CANCER RESEARCH 74 (21) 6119 - 6128 0008-5472 2014/11 [Refereed] Colitis-associated cancer (CAC) is caused by chronic intestinal inflammation and is reported to be associated with refractory inflammatory bowel disease (IBD). Defective apoptosis of inflammatory cell populations seems to be a relevant pathogenetic mechanism in refractory IBD. We assessed the involvement of stress response protein cold-inducible RNA-binding protein (Cirp) in the development of intestinal inflammation and CAC. In the colonic mucosa of patients with ulcerative colitis, expression of Cirp correlated significantly with the expression of TNF alpha, IL23/IL17, antiapoptotic proteins Bcl-2 and Bcl-xL, and stem cell markers such as Sox2, Bmi1, and Lgr5. The expression of Cirp and Sox2 was enhanced in the colonic mucosae of refractory ulcerative colitis, suggesting that Cirp expression might be related to increased cancer risk. In human CAC specimens, inflammatory cells expressed Cirp protein. Cirp(-/-) mice given dextran sodium sulfate exhibited decreased susceptibility to colonic inflammation through decreased expression of TNF alpha, IL23, Bcl-2, and Bcl-xL in colonic lamina propria cells compared with similarly treated wild-type (WT) mice. In the murine CAC model, Cirp deficiency decreased the expression of TNF alpha, IL23/IL17, Bcl-2, Bcl-xL, and Sox2 and the number of Dclk1(+) cells, leading to attenuated tumorigenic potential. Transplantation of Cirp(-/-) bone marrow into WT mice reduced tumorigenesis, indicating the importance of Cirp in hematopoietic cells. Cirp promotes the development of intestinal inflammation and colorectal tumors through regulating apoptosis and production of TNF alpha and IL23 in inflammatory cells. (C) 2014 AACR.Current treatment status of polycystic liver disease in JapanKoichi Ogawa; Kiyoshi Fukunaga; Tomoyo Takeuchi; Naoki Kawagishi; Yoshifumi Ubara; Masatoshi Kudo; Nobuhiro OhkohchiHEPATOLOGY RESEARCH WILEY 44 (11) 1110 - 1118 1386-6346 2014/10 [Refereed] AimPolycystic liver disease (PLD) is a genetic disorder characterized by the progressive development of multiple liver cysts. No standardized criteria for the selection of treatment exist because PLD is a rare condition and most patients are asymptomatic. We here aimed to clarify the status of treatment and to present a therapeutic strategy for PLD in Japan. MethodsFrom 1 June 2011 to 20 December 2011, we administered a questionnaire to 202 PLD patients from 86 medical institutions nationwide. ResultsThe patients included 45 men and 155 women, and the median age was 63 years. Two hundred and eighty-one treatments were performed for these patients, as follows: cyst aspiration sclerotherapy (AS) in 152 cases, cyst fenestration (FN) in 53, liver resection (LR) in 44, liver transplantation (LT) in 13 and other treatments in 19. For cases of type I PLD (mild form) according to Gigot's classification, the therapeutic effects of AS, FN and LR were similar. For type II (moderate form), LT demonstrated the best therapeutic effects, followed by LR and FN. For type III (severe form), the effects of LT were the best. The incidences of complications were 23.0% in AS, 28.4% in FN, 31.8% in LR and 61.5% in LT. ConclusionConsidering the therapeutic effects and complications, AS, LR and LT showed good results for type I, type II and type III PLD, respectively. However, LT for PLD was performed in a small number of patients. In Japan, the transplantation therapy is expected to be common in the future.慢性膵炎とその進展予防 早期慢性膵炎におけるEUS画像所見と臨床的意義の検討門阪 薫平; 北野 雅之; 工藤 正俊日本消化器病学会雑誌 (一財)日本消化器病学会 111 (臨増大会) A794 - A794 0446-6586 2014/09重症急性膵炎の病態と有効な初期治療をめざして 急性膵炎の病態把握におけるプロカルシトニンの有用性について大本 俊介; 北野 雅之; 工藤 正俊日本消化器病学会雑誌 (一財)日本消化器病学会 111 (臨増大会) A598 - A598 0446-6586 2014/09Life saving endoscopy 胆膵良性疾患の救命救急におけるEUS下ドレナージ術の位置づけ山雄 健太郎; 北野 雅之; 工藤 正俊Gastroenterological Endoscopy (一社)日本消化器内視鏡学会 56 (Suppl.2) 2973 - 2973 0387-1207 2014/09胆管結石治療困難例への戦略 経乳頭処置困難総胆管結石に対するrendezvous法の手技と成績山雄 健太郎; 北野 雅之; 工藤 正俊Gastroenterological Endoscopy (一社)日本消化器内視鏡学会 56 (Suppl.2) 3007 - 3007 0387-1207 2014/09Endoscopic ultrasonography-guided gallbladder drainage procedures: Is the glass half-full or half-empty?Masayuki Kitano; Ken Kamata; Masatoshi KudoDIGESTIVE ENDOSCOPY WILEY-BLACKWELL 26 (5) 636 - 637 0915-5635 2014/09 [Refereed]Nationwide survey in Japan regarding splenectomy/partial splenic embolization for interferon treatment targeting hepatitis C virus-related chronic liver disease in patients with low platelet countNaoto Ikeda; Hiroyasu Imanishi; Nobuhiro Aizawa; Hironori Tanaka; Yoshinori Iwata; Hirayuki Enomoto; Masaki Saito; Hiroko Iijima; Yuji Iimuro; Jiro Fujimoto; Satoshi Yamamoto; Shozo Hirota; Masatoshi Kudo; Shigeki Arii; Shuhei NishiguchiHEPATOLOGY RESEARCH WILEY-BLACKWELL 44 (8) 829 - 836 1386-6346 2014/08 [Refereed] Aim: In chronic liver disease associated with hepatitis C virus (HCV), a low platelet count is a major obstacle in carrying out interferon (IFN) treatment. We used a questionnaire to clarify the extent to which splenectomy/partial splenic embolization (PSE) is performed before IFN treatment, as well as the efficacy and complications thereof. Methods: Two questionnaires were distributed to 413 medical institutes in Japan specializing in the treatment of liver diseases, and responses were obtained from 204 institutes. Furthermore, a more detailed questionnaire was completed by 10 institutes that experienced cases of death. Results: In patients with HCV genotype 1b and a high viral load (HCV1b/High), the sustained viral response (SVR) rate was 28% for the splenectomy group and 22% for the PSE group, with no significant difference between these groups. In patients that were not HCV1b/High, the SVR rate was higher in those that underwent splenectomy (71%) compared to the PSE group (56%; P = 0.025). There were cases of death in seven of 799 splenectomy cases (0.89%) and four of 474 PSE cases (0.84%). Infectious diseases were involved in nine of 11 cases of death, with a peculiar patient background of Child-Pugh B (6/10) and an age of 60 years or greater (7/11). Conclusion: The application of splenectomy/PSE before IFN treatment should be avoided in patients with poor residual hepatic function and/or elderly patients. In HCV1b/High patients, splenectomy/PSE should be performed only after selecting those in which IFN treatment should be highly effective.Effect of Everolimus on Survival in Advanced Hepatocellular Carcinoma After Failure of Sorafenib The EVOLVE-1 Randomized Clinical TrialAndrew X. Zhu; Masatoshi Kudo; Eric Assenat; Stephane Cattan; Yoon-Koo Kang; Ho Yeong Lim; Ronnie T. P. Poon; Jean-Frederic Blanc; Arndt Vogel; Chao-Long Chen; Etienne Dorval; Markus Peck-Radosavljevic; Armando Santoro; Bruno Daniele; Junji Furuse; Annette Jappe; Kevin Perraud; Oezlem Anak; Dalila B. Sellami; Li-Tzong ChenJAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION AMER MEDICAL ASSOC 312 (1) 57 - 67 0098-7484 2014/07 [Refereed] IMPORTANCE Aside from the multikinase inhibitor sorafenib, there are no effective systemic therapies for the treatment of advanced hepatocellular carcinoma. OBJECTIVE To assess the efficacy of everolimus in patients with advanced hepatocellular carcinoma for whom sorafenib treatment failed. DESIGN, SETTING, AND PARTICIPANTS EVOLVE-1 was a randomized, double-blind, phase 3 study conducted among 546 adults with Barcelona Clinic Liver Cancer stage B or C hepatocellular carcinoma and Child-Pugh A liver function whose disease progressed during or after sorafenib or who were intolerant of sorafenib. Patients were enrolled from 17 countries between May 2010 and March 2012. Randomization was stratified by region (Asia vs rest of world) and macrovascular invasion (present vs absent). INTERVENTIONS Everolimus, 7.5 mg/d, or matching placebo, both given in combination with best supportive care and continued until disease progression or intolerable toxicity. Per the 2: 1 randomization scheme, 362 patients were randomized to the everolimus group and 184 patients to the placebo group. MAIN OUTCOMES AND MEASURES The primary end point was overall survival. Secondary end points included time to progression and the disease control rate (the percentage of patients with a best overall response of complete or partial response or stable disease). RESULTS No significant difference in overall survival was seen between treatment groups, with 303 deaths (83.7%) in the everolimus group and 151 deaths (82.1%) in the placebo group (hazard ratio [HR], 1.05; 95% CI, 0.86-1.27; P=.68; median overall survival, 7.6 months with everolimus, 7.3 months with placebo). Median time to progression with everolimus and placebo was 3.0 months and 2.6 months, respectively (HR, 0.93; 95% CI, 0.75-1.15), and disease control rate was 56.1% and 45.1%, respectively (P=.01). The most common grade 3/4 adverse events for everolimus vs placebo were anemia (7.8% vs 3.3%, respectively), asthenia (7.8% vs 5.5%, respectively), and decreased appetite (6.1% vs 0.5%, respectively). No patients experienced hepatitis C viral flare. Based on central laboratory results, hepatitis B viral reactivation was experienced by 39 patients (29 everolimus, 10 placebo); all cases were asymptomatic, but 3 everolimus recipients discontinued therapy. CONCLUSIONS AND RELEVANCE Everolimus did not improve overall survival in patients with advanced hepatocellular carcinoma whose disease progressed during or after receiving sorafenib or who were intolerant of sorafenib.尿タンパク試験紙にBence Jonesタンパクが反応することの検証井本真由美; 松村 到; 船内正憲; 中川和彦; 鮫島謙一; 前田裕弘; 森嶋祥之; 中江健市; 上硲俊法; 工藤正俊; 櫻林郁之助臨床化学 (一社)日本臨床化学会 43 (3) 217 - 225 0370-5633 2014/07 Bence Jonesタンパク(BJP)は尿タンパク試験紙(以下、試験紙)にはほとんど反応しないことが定説となっている。我々はこの説に疑問を持ち、過去約6年間におけるBJP定性試験(Putnam法)陽性で、免疫電気泳動法(IEP)あるいは免疫固定法(IFE)においてBJP陽性が確認されている患者尿の試験紙反応性について調査した結果、BJP含有尿352検体(66症例)中、試験紙陰性はわずかに10検体(2.8%)で、342検体(97.2%)が±以上の反応(±〜4+)であった。試験紙法陰性検体は経過観察中の多発性骨髄腫患者3例のみであった。しかも、尿総タンパク量は、15mg/dL未満であり、試験紙法の検出限界濃度以下であった。またIgGおよびアルブミンが出現していないBJP陽性尿を用い、試験紙が±以上に反応する濃度(検出限界)を求めた結果、アルブミンの検出感度と同等で15mg/dLであった。さらにIgGが試験紙に反応しがたいことを再確認したうえで、IgGを還元処理してL鎖を遊離させた後は、試験紙の反応性が強くなることを確認した。したがって、尿タンパク試験紙がBJPに反応しない(反応しがたい)という説は見直されるべきであると考える。(著者抄録)肝造影超音波診断. 特集「肝造影検査Update 2014」井上達夫; 前川 清; 工藤正俊画像診断 34 (7) 761 - 770 2014/07 [Refereed][Invited]早期慢性膵炎の現状 早期慢性膵炎画像所見と臨床症状との関係門阪 薫平; 北野 雅之; 工藤 正俊膵臓 (一社)日本膵臓学会 29 (3) 473 - 473 0913-0071 2014/06自己免疫性膵炎の診断、治療におけるEUSの役割大本 俊介; 北野 雅之; 門坂 薫平; 宮田 剛; 鎌田 研; 山雄 健太郎; 今井 元; 坂本 洋城; 工藤 正俊膵臓 (一社)日本膵臓学会 29 (3) 545 - 545 0913-0071 2014/06膵空腸吻合の工夫と術後管理 膵液瘻に対するEUS下ドレナージ術の有用性山雄 健太郎; 北野 雅之; 工藤 正俊; 竹山 宜典膵臓 日本膵臓学会 29 (3) 442 - 442 0913-0071 2014/06Assessment for Retreatment (ART) Score for Repeated Transarterial Chemoembolization in Patients With Hepatocellular CarcinomaMasatoshi Kudo; Tadaaki Arizumi; Kazuomi UeshimaHEPATOLOGY WILEY-BLACKWELL 59 (6) 2424 - 2425 0270-9139 2014/06 [Refereed]特集 肝造影検査Update 2014 肝におけるCT perfusion岡田 真広; 兵頭 朋子; 矢田 典久; 安座間 喜明; 伊良波 裕子; 村山 貞之; 工藤 正俊; 村上 卓道画像診断 学研メディカル秀潤社 34 (7) 753 - 759 0285-0524 2014/05Serum amyloid A and C-reactive protein positive nodule in alcoholic liver cirrhosis, hard to make definite diagnosisSoo Ryang Kim; Fukuo Kondo; Yumi Otono; Susumu Imoto; Kenji Ando; Makoto Hirakawa; Katsumi Fukuda; Madoka Sasaki; Soo Ki Kim; Takamitsu Komaki; Shinobu Tsuchida; Sawako Kobayashi; Toshiyuki Matsuoka; Masatoshi KudoHEPATOLOGY RESEARCH WILEY-BLACKWELL 44 (5) 584 - 590 1386-6346 2014/05 [Refereed] We describe a case of serum amyloid A (SAA) and C-reactive protein (CRP) positive nodule detected by immunohistochemical analysis in a 37-year-old woman with alcohol-related cirrhosis. Imaging studies at first admission pointed to hepatocellular carcinoma (HCC), a dysplastic nodule, an inflammatory pseudotumor or focal nodular hyperplasia (FNH). Ultrasonography-guided biopsy in Segment 2 showed minimal atypical changes, except for a slight increase in cell density and micronodular cirrhosis in the non-nodular portion. gadolinium-ethoxybenzyl-diethylenetriamine pentaacetic acid-enhanced magnetic resonance imaging carried out after a year and a half revealed hypervascularity in the arterial phase and isointensity in the hepatobiliary phase. Three years thereafter, however, the imaging displayed a change from isointensity to a defect in the hepatobiliary phase, and the nodule demonstrated minimal histological atypia. Immunohistochemical staining of the nodule was positive for SAA, CRP, liver fatty acid-binding protein and glutamine synthetase, but negative for beta-catenin, heat shock protein 70 and Glypican 3. Organic anion transporter (OATP)8 staining was weaker in the nodule than in the non-nodular portion of the alcohol-related micronodular cirrhosis. The nodule was diagnosed as an SAA and CRP positive nodule, and HCC was ruled out. Despite the change from isointensity to a defect in the hepatobiliary phase, no evidence of HCC was found in the biopsy specimen. The change may be explained more by the weak OATP8 staining compared with that of alcohol-related liver cirrhosis than by malignant transformation into HCC.GIDEON (Global Investigation of therapeutic DEcisions in hepatocellular carcinoma and Of its treatment with sorafeNib): second interim analysisR. Lencioni; M. Kudo; S. -L. Ye; J. -P. Bronowicki; X. -P. Chen; L. Dagher; J. Furuse; J. F. Geschwind; L. Ladron de Guevara; C. Papandreou; T. Takayama; S. K. Yoon; K. Nakajima; R. Lehr; S. Heldner; A. J. SanyalINTERNATIONAL JOURNAL OF CLINICAL PRACTICE WILEY-BLACKWELL 68 (5) 609 - 617 1368-5031 2014/05 [Refereed] BackgroundGIDEON (Global Investigation of therapeutic DEcisions in hepatocellular carcinoma [HCC] and Of its treatment with sorafeNib) is a global, prospective, non-interventional study undertaken to evaluate the safety of sorafenib in patients with unresectable HCC in real-life practice, including Child-Pugh B patients who were excluded from clinical trials. MethodsPatients with unresectable HCC, for whom the decision to treat with sorafenib, based on the approved label and prescribing guidelines, had been taken by their physician, were eligible for inclusion. Demographic data and disease/medical history were recorded at entry. Sorafenib dosing and adverse events (AEs) were collected at follow-up visits. The second interim analysis was undertaken when similar to 1500 treated patients were followed up for 4months. ResultsOf the 1571 patients evaluable for safety, 61% had Child-Pugh A status and 23% Child-Pugh B. The majority of patients (74%) received the approved 800mg initial sorafenib dose, regardless of Child-Pugh status; however, median duration of therapy was shorter in Child-Pugh B patients. The majority of drug-related AEs were grade 1 or 2, and the most commonly reported were consistent with previous reports. The incidence and nature of drug-related AEs were broadly similar across Child-Pugh, Barcelona Clinic Liver Cancer (BCLC) and initial dosing subgroups, and consistent with the overall population. ConclusionsConsistent with the first interim analysis, overall safety profile and dosing strategy are similar across Child-Pugh subgroups. Safety findings also appear comparable irrespective of initial sorafenib dose or BCLC stage. Final analyses in >3000 patients are ongoing.胆膵疾患におけるInterventional EUS北野雅之; 工藤正俊最新医学 69 (5) 130 - 138 2014/05 [Refereed][Invited]【国際化時代に向けた肝細胞がんの新しい治療戦略-ガラパゴス化を回避する】ソラフェニブの最新情報上嶋 一臣; 工藤 正俊腫瘍内科 (有)科学評論社 13 (5) 637 - 641 1881-6568 2014/05Prospective Multicenter Randomized Controlled Trial of Histological Diagnostic Yield Comparing 25G EUS-FNA Needles With and Without a Core Trap in Patients With Solid Pancreatic MassesAshida R; Yasukawa S; Yanagisawa A; Kamata K; Kudo M; Ogura T; Higuchi K; Fukutake N; Nebiki H; Hirose S; Hoki N; Asada M; Yazumi S; Takaoka M; Okazaki K; Matsuda F; Okabe Y; Kitano MGastrointest Endosc 79 AB111  2014/05 [Refereed]Homozygous deletion of the activin A receptor, type IB gene is associated with an aggressive cancer phenotype in pancreatic cancerYosuke Togashi; Hiroki Sakamoto; Hidetoshi Hayashi; Masato Terashima; Marco A. de Velasco; Yoshihiko Fujita; Yasuo Kodera; Kazuko Sakai; Shuta Tomida; Masayuki Kitano; Akihiko Ito; Masatoshi Kudo; Kazuto NishioMOLECULAR CANCER BIOMED CENTRAL LTD 13 126 - 136 1476-4598 2014/05 [Refereed] Background: Transforming growth factor, beta (TGFB) signal is considered to be a tumor suppressive pathway based on the frequent genomic deletion of the SMAD4 gene in pancreatic cancer (PC); however; the role of the activin signal, which also belongs to the TGFB superfamily, remains largely unclear. Methods and results: We found a homozygous deletion of the activin A receptor, type IB (ACVR1B) gene in 2 out of 8 PC cell lines using array-comparative genomic hybridization, and the absence of ACVR1B mRNA and protein expression was confirmed in these 2 cell lines. Activin A stimulation inhibited cellular growth and increased the phosphorylation level of SMAD2 and the expression level of p21(CIP1/WAF1) in the Sui66 cell line (wild-type ACVR1B and SMAD4 genes) but not in the Sui68 cell line (homozygous deletion of ACVR1B gene). Stable ACVR1B-knockdown using short hairpin RNA cancelled the effects of activin A on the cellular growth of the PC cell lines. In addition, ACVR1B-knockdown significantly enhanced the cellular growth and colony formation abilities, compared with controls. In a xenograft study, ACVR1B-knockdown resulted in a significantly elevated level of tumorigenesis and a larger tumor volume, compared with the control. Furthermore, in clinical samples, 6 of the 29 PC samples (20.7%) carried a deletion of the ACVR1B gene, while 10 of the 29 samples (34.5%) carried a deletion of the SMAD4 gene. Of note, 5 of the 6 samples with a deletion of the ACVR1B gene also had a deletion of the SMAD4 gene. Conclusion: We identified a homozygous deletion of the ACVR1B gene in PC cell lines and clinical samples and proposed that the deletion of the ACVR1B gene may mediate an aggressive cancer phenotype in PC. Our findings provide novel insight into the role of the activin signal in PC.Therapeutic response assessment of RFA for HCC: Contrast-enhanced US, CT and MRIYasunori Minami; Naoshi Nishida; Masatoshi KudoWORLD JOURNAL OF GASTROENTEROLOGY BAISHIDENG PUBLISHING GROUP INC 20 (15) 4160 - 4166 1007-9327 2014/04 [Refereed] Radiofrequency ablation (RFA) is commonly applied for the treatment of hepatocellular carcinoma (HCC) because of the facile procedure, and the safety and effectiveness for the treatment of this type of tumor. On the other hand, it is believed that HCC cells should spread predominantly through the blood flow of the portal vein, which could lead to the formation of intrahepatic micrometastases. Therefore, monitoring tumor response after the treatment is quite important and accurate assessment of treatment response is critical to obtain the most favorable outcome after the RFA. Indeed, several reports suggested that even small HCCs of <= 3 cm in diameter might carry intrahepatic micrometastases and/or microvascular invasion. From this point of view, for preventing local recurrences, RFA should be performed ablating a main tumor as well as its surrounding non-tumorous liver tissue where micrometastases and microvascular invasion might exist. Recent advancement of imaging modalities such as contrast-enhanced ultrasonic, computed tomography, and magnetic resonance imaging are playing an important role on assessing the therapeutic effects of RFA. The local recurrence rate tends to be low in HCC patients who were proven to have adequate ablation margin after RFA; namely, not only disappearance of vascular enhancement of main tumor, but also an adequate ablation margin. Therefore, contrast enhancement gives important findings for the diagnosis of recurrent HCCs on each imaging. However, hyperemia of non-tumorous liver surrounding the ablated lesion, which could be attributed to an inflammation after RFA, may well obscure the findings of local recurrence of HCCs after RFA. Therefore, we need to carefully address to these imaging findings given the fact that diagnostic difficulties of local recurrence of HCC. Here, we give an overview of the current status of the imaging assessment of HCC response to RFA. (C) 2014 Baishideng Publishing Group Co., Limited. All rights reserved.急性胆嚢炎および胆管炎例に対するEUS下胆嚢ドレナージ術の有用性門阪 薫平; 北野 雅之; 工藤 正俊Gastroenterological Endoscopy (一社)日本消化器内視鏡学会 56 (Suppl.1) 1061 - 1061 0387-1207 2014/04造影ハーモニックEUS(CH-EUS)における膵腫瘍の血流評価の有用性について大本 俊介; 田中 梨絵; 門阪 薫平; 鎌田 研; 宮田 剛; 山雄 健太郎; 今井 元; 坂本 洋城; 北野 雅之; 工藤 正俊超音波医学 (公社)日本超音波医学会 41 (Suppl.) S580 - S580 1346-1176 2014/04膵神経内分泌腫瘍に対するEUSの有用性今井 元; 北野 雅之; 工藤 正俊; 大本 俊介; 門阪 薫平; 宮田 剛; 鎌田 研; 山雄 健太郎; 坂本 洋城Gastroenterological Endoscopy (一社)日本消化器内視鏡学会 56 (Suppl.1) 1132 - 1132 0387-1207 2014/04消化管狭窄の内視鏡治療 上部 悪性胃十二指腸狭窄に対する治療戦略 胆道狭窄合併例に対するEUS下胆道ドレナージ術も含めて山雄 健太郎; 北野 雅之; 工藤 正俊Gastroenterological Endoscopy (一社)日本消化器内視鏡学会 56 (Suppl.1) 1033 - 1033 0387-1207 2014/04Prognostic Impact of Spontaneous Tumor Rupture in Patients With Hepatocellular Carcinoma An Analysis of 1160 Cases From a Nationwide SurveyTaku Aoki; Norihiro Kokudo; Yutaka Matsuyama; Namiki Izumi; Takafumi Ichida; Masatoshi Kudo; Yonson Ku; Michiie Sakamoto; Osamu Nakashima; Osamu Matsui; Masatoshi MakuuchiANNALS OF SURGERY LIPPINCOTT WILLIAMS & WILKINS 259 (3) 532 - 542 0003-4932 2014/03 [Refereed] Objective: The aim of the present study was to investigate the background characteriscs of ruptured hepatocellular carcinoma (HCC) and to clarify the true impact of tumor rupture on patient prognosis in a large patient cohort. Background: Spontaneous tumor rupture of HCC has been associated with a very poor patient prognosis and the current TNM staging systems classify ruptured HCC as T4 based on insufficient evidence. Methods: In total, 1106 patients with ruptured HCC were extracted from the database of a nationwide survey conducted in Japan from 2000 to 2005. The clinicopathological parameters associated with HCC rupture were investigated using univariate and multivariate logistic regression models. The survival curves for ruptured and nonruptured HCC were generated and compared to evaluate the impact of the event (rupture) itself on patient prognosis and the TNM staging systems. Results: The multivariate analyses showed that tumor rupture was associated with both a poor liver functional reserve and an advanced tumor status. Analyses of the survival curves stratified according to the baseline TNM staging showed that tumor rupture had an additional impact on the baseline survival curves without rupture, and the impact corresponded to the addition of 0.5 to 2 stages to the baseline tumor staging. Conclusions: The present study suggested that tumor rupture itself had a negative impact on patient survival. However, its impact was not strong enough to cancel the effects of the other tumor-related parameters. Therefore, it may be appropriate to give additional stages to the baseline tumor staging in cases of ruptured HCC.Relevance of the Core 70 and IL-28B polymorphism and response-guided therapy of peginterferon alfa-2a +/- A ribavirin for chronic hepatitis C of Genotype 1b: a multicenter randomized trial, ReGIT-J studyShuhei Nishiguchi; Hirayuki Enomoto; Nobuhiro Aizawa; Hiroki Nishikawa; Yukio Osaki; Yasuhiro Tsuda; Kazuhide Higuchi; Kazuichi Okazaki; Toshihito Seki; Soo Ryang Kim; Yasushi Hongo; Hisato Jyomura; Naoshi Nishida; Masatoshi KudoJOURNAL OF GASTROENTEROLOGY SPRINGER JAPAN KK 49 (3) 492 - 501 0944-1174 2014/03 [Refereed] We conducted a multicenter randomized clinical trial to determine the optimal treatment strategy against chronic hepatitis C virus (HCV) with genotype 1b and a high viral load (G1b/high). The study subjects included 153 patients with G1b/high. Patients were initially treated with PEG-IFN alpha-2a alone and then randomly assigned to receive different treatment regimens. Ribavirin (RBV) was administered to all patients with HCV RNA at week 4. Patients negative for HCV RNA at week 4 were randomly assigned to receive PEG-IFN alpha-2a (group A) or PEG-IFN alpha-2a/RBV (group B). Patients who showed HCV RNA at week 4 but were negative at week 12 were randomly assigned to receive weekly PEG-IFN alpha-2a (group C) or biweekly therapy (group D). Patients who showed HCV RNA at week 12 but were negative at week 24 were randomly assigned to receive PEG-IFN alpha-2a/RBV (group E) or PEG-IFN alpha-2a/RBV/fluvastatin (group F). Overall, the rate of sustained virological response (SVR) was 46 % (70/153). The total SVR rate in the group (A, D, and F) of response-guided therapy was significantly higher than that in the group (B, C, and E) of conventional therapy [70 % (38/54) versus 52 % (32/61), p = 0.049]. Although IL28-B polymorphism and Core 70 mutation were significantly associated with efficacy, patients with rapid virological response (RVR) and complete early virological response (cEVR) achieved high SVR rates regardless of their status of IL-28B polymorphism and Core 70 mutation. In addition to knowing the IL-28B polymorphism and Core 70 mutation status, understanding the likelihood of virological response during treatment is critical in determining the appropriate treatment strategy.FDの亜分類と治療選択 機能性ディスペプシアと早期慢性膵炎との関係性について門阪 薫平; 北野 雅之; 工藤 正俊日本消化器病学会雑誌 (一財)日本消化器病学会 111 (臨増総会) A117 - A117 0446-6586 2014/03消化器領域超音波の最前線 診断からインターベンションまで 当院におけるEUS下胆管および膵管ドレナージの工夫と成績大本 俊介; 北野 雅之; 工藤 正俊超音波医学 (公社)日本超音波医学会 41 (2) 241 - 241 1346-1176 2014/03造影ハーモニックEUS(CH-EUS)における膵腫瘍の血流評価の有用性について大本 俊介; 田中 梨絵; 門阪 薫平; 鎌田 研; 宮田 剛; 山雄 健太郎; 今井 元; 坂本 洋城; 北野 雅之; 工藤 正俊超音波医学 (公社)日本超音波医学会 41 (2) 245 - 245 1346-1176 2014/03造影ハーモニックEUSにおける消化器系疾患の鑑別および悪性度診断大本 俊介; 北野 雅之; 工藤 正俊超音波医学 (公社)日本超音波医学会 41 (2) 256 - 256 1346-1176 2014/03Quantitative Levels of Hepatitis B Virus DNA and Surface Antigen and the Risk of Hepatocellular Carcinoma in Patients with Hepatitis B Receiving Long-Term Nucleos(t)ide Analogue Therapy.Kawanaka Miwa; Nishino Ken; Nakamura Jun; Oka Takahito; Urata Noriyo; Goto Daisuke; Suehiro Mitsuhiko; Kawamoto Hirofumi; Kudo Masatoshi; Yamada GotaroLiver Cancer KARGER 3 (1) 41 - 52 1341-1926 2014/03Prognostic Impact of Spontaneous Tumor Rupture in Patients With Hepatocellular Carcinoma An Analysis of 1160 Cases From a Nationwide SurveyTaku Aoki; Norihiro Kokudo; Yutaka Matsuyama; Namiki Izumi; Takafumi Ichida; Masatoshi Kudo; Yonson Ku; Michiie Sakamoto; Osamu Nakashima; Osamu Matsui; Masatoshi MakuuchiANNALS OF SURGERY LIPPINCOTT WILLIAMS & WILKINS 259 (3) 532 - 542 0003-4932 2014/03 [Refereed] Objective: The aim of the present study was to investigate the background characteriscs of ruptured hepatocellular carcinoma (HCC) and to clarify the true impact of tumor rupture on patient prognosis in a large patient cohort. Background: Spontaneous tumor rupture of HCC has been associated with a very poor patient prognosis and the current TNM staging systems classify ruptured HCC as T4 based on insufficient evidence. Methods: In total, 1106 patients with ruptured HCC were extracted from the database of a nationwide survey conducted in Japan from 2000 to 2005. The clinicopathological parameters associated with HCC rupture were investigated using univariate and multivariate logistic regression models. The survival curves for ruptured and nonruptured HCC were generated and compared to evaluate the impact of the event (rupture) itself on patient prognosis and the TNM staging systems. Results: The multivariate analyses showed that tumor rupture was associated with both a poor liver functional reserve and an advanced tumor status. Analyses of the survival curves stratified according to the baseline TNM staging showed that tumor rupture had an additional impact on the baseline survival curves without rupture, and the impact corresponded to the addition of 0.5 to 2 stages to the baseline tumor staging. Conclusions: The present study suggested that tumor rupture itself had a negative impact on patient survival. However, its impact was not strong enough to cancel the effects of the other tumor-related parameters. Therefore, it may be appropriate to give additional stages to the baseline tumor staging in cases of ruptured HCC.Re-evaluating transarterial chemoembolization for the treatment of Hepatocellular Carcinoma: Consensus recommendations and review by an International Expert PanelAnn Lii Cheng; Deepak Amarapurkar; Yee Chao; Pei-Jer Chen; Jean-Francois Geschwind; Khean L. Goh; Kwang-Hyub Han; Masatoshi Kudo; Han Chu Lee; Rheun-Chuan Lee; Laurentius A. Lesmana; Ho Yeong Lim; Seung Woon Paik; Ronnie T. Poon; Chee-Kiat Tan; Tawesak Tanwandee; Gaojun Teng; Joong-Won ParkLIVER INTERNATIONAL WILEY 34 (2) 174 - 183 1478-3223 2014/02 [Refereed] Patients with unresectable hepatocellular carcinoma (HCC) usually receive transarterial chemoembolization (TACE) or systemic therapies with intermediate and advanced-stage disease. However, intermediate-stage HCC patients often have unsatisfactory clinical outcomes with repeated TACE and there is considerable uncertainty surrounding the criteria for repeating or stopping TACE treatment. In July 2012, an Expert Panel Opinion on Interventions in Hepatocellular Carcinoma (EPOIHCC) was re-convened in Shanghai in an attempt to provide a consensus on the practice of TACE, particularly in regard to evaluating TACE failure'. To that end, current clinical practice throughout Asia was reviewed in detail including safety and efficacy data on TACE alone as well as in combination with targeted systemic therapies for intermediate HCC. This review summarizes the evidence discussed at the meeting and provides expert recommendations regarding the use of TACE for unresectable intermediate-stage HCC. A key consensus of the Expert Panel was that the current definitions of TACE failure are not useful in differentiating between situations where TACE is no longer effective in controlling disease locally vs. systemically. By redefining these concepts, it may be possible to provide a clearer indication of when TACE should be repeated and more importantly, when TACE should be discontinued.Nationwide Study of 4741 Patients With Non-B Non-C Hepatocellular Carcinoma With Special Reference to the Therapeutic ImpactTohru Utsunomiya; Mitsuo Shimada; Masatoshi Kudo; Takafumi Ichida; Osamu Matsui; Namiki Izumi; Yutaka Matsuyama; Michiie Sakamoto; Osamu Nakashima; Yonson Ku; Norihiro Kokudo; Masatoshi MakuuchiANNALS OF SURGERY LIPPINCOTT WILLIAMS & WILKINS 259 (2) 336 - 345 0003-4932 2014/02 [Refereed] Objective: To examine the prognostic factors and outcomes after several types of treatments in patients with hepatocellular carcinoma (HCC) negative for hepatitis B surface antigen and hepatitis C antibody, so-called non-B non-C HCC using the data of a nationwide survey. Background: The proportion of non-B non-C HCC is rapidly increasing in Japan. Methods: A total of 4741 patients with non-B non-C HCC, who underwent hepatic resection (HR, n = 2872), radiofrequency ablation (RFA, n = 432), and transcatheter arterial chemoembolization (TACE, n = 1437) as the initial treatment, were enrolled in this study. The exclusion criteria included extrahepatic metastases and/or Child-Pugh C. Significant prognostic variables determined by a univariate analysis were subjected to a multivariate analysis using a Cox proportional hazard regression model. Results: The degree of liver damage in the HR group was significantly lower than that in the RFA and TACE groups. The HR and TACE groups had significantly more advanced HCC than the RFA group. The 5-year survival rates after HR, RFA, and TACE were 66%, 49%, and 32%, respectively. Stratifying the survival rates, according to the TNM stage and the Japan Integrated Staging (JIS) score, showed the HR group to have a significantly better prognosis than the RFA group in the stage II and in the JIS scores 1 and 2. The multivariate analysis showed 12 independent prognostic factors. HR offers significant prognostic advantages over TACE and RFA. Conclusions: The findings of this large prospective cohort study indicated that HR may be recommended, especially in patients with TNM stage II and JIS scores 1 and 2 of non-B non-C HCC.【最新がん薬物療法学-がん薬物療法の最新知見-】臓器別がんの薬物療法 膵がん・胆道がん・肝細胞がん 肝細胞がん上嶋 一臣; 工藤 正俊日本臨床 (株)日本臨床社 72 (増刊2 最新がん薬物療法学) 391 - 396 0047-1852 2014/02SCREENING METHODS FOR PANCREATOBILIARY DISEASES USING CONVEX ARRAY ENDOSCOPIC ULTRASOUNDKITANO Masayuki; SAKAMOTO Hiroki; KUDO MasatoshiGastroenterological Endoscopy Japan Gastroenterological Endoscopy Society 56 (2) 296 - 308 0387-1207 2014/02 Endoscopic ultrasound with a convex echoendoscope requires positioning of the transducer in three different stations such as the stomach, bulb and descending part of the duodenum. Basic maneuvers include advancement, rotation and deflection by which the bile duct and the duct and parenchyma of the pancreas are continuously observed through confirmation of neighboring organs and vessels. Doppler imaging is employed for discrimination of pancreatobiliary ducts from vessels. The transgastric approach provides images of the liver, the body and tail of the pancreas, and part of the pancreas head. Advancement of the echoendoscope along the portal vein demonstrates the head and body of the pancreas by the confluence. Clockwise rotation of the echoendoscope from the confluence demonstrates the tail of the pancreas. Observation from the bulb of the duodenum provides images of the gallbladder, bile duct, confluence, head of the pancreas, and part of the pancreas body. Clockwise and counterclockwise rotations of the echoendoscope from the confluence demonstrate the head and neck of the pancreas, respectively. Advancement of the echoendoscope along the bile duct demonstrates the proximal side of the duct. Observation from the descending part of the duodenum provides images of the head of the pancreas and the ampulla. After stretching the echoendoscope into the descending part of the duodenum, a longitudinal image of the abdominal aorta is achieved. The lower part of the pancreas head is located at the upper right side of the image. Slow withdrawal of the echoendoscope demonstrates the ampulla.Value of EUS in early detection of pancreatic ductal adenocarcinomas in patients with intraductal papillary mucinous neoplasmsKen Kamata; Masayuki Kitano; Masatoshi Kudo; Hiroki Sakamoto; Kumpei Kadosaka; Takeshi Miyata; Hajime Imai; Kiyoshi Maekawa; Takaaki Chikugo; Masashi Kumano; Tomoko Hyodo; Takamichi Murakami; Yasutaka Chiba; Yoshifumi TakeyamaENDOSCOPY GEORG THIEME VERLAG KG 46 (1) 22 - 29 0013-726X 2014/01 [Refereed] Background and study aims: Pancreatic ductal adenocarcinomas (PDAC) sometimes arise in patients with intraductal papillary mucinous neoplasms (IPMNs). This study examined the incidence of PDACs concomitant to or derived from branch duct IPMNs. The usefulness of endoscopic ultrasonography (EUS) relative to other imaging methods for detecting these tumors was also assessed. Patients and methods: This retrospective study used data from clinical records and imaging studies that were collected prospectively. During 2001-2009, 167 consecutive patients with IPMNs underwent EUS, ultrasonography, computed tomography (CT), and magnetic resonance imaging (MRI). The 102 patients whose branch duct IPMNs lacked mural nodules/symptoms and thus did not qualify for resection were followed up by semiannual EUS and annual ultrasonography, CT, and MRI. The sensitivity and specificity with which the four modalities detected IPMN-derived and -concomitant PDACs at the first examination and throughout the study period were evaluated. The rate of PDAC development during follow-up was analyzed by the Kaplan-Meier method. Results: A total of 17 IPMN-derived and 11 IPMN-concomitant PDACs were diagnosed at the first examination. Lesions that did not qualify for resection or chemotherapy were followed up for a median of 42 months. Seven IPMN-concomitant PDACs and no IPMN-derived PDACs were detected during follow-up. The 3- and 5-year rates of IPMN-concomitant PDAC development were 4.0% and 8.8%, respectively. At the first examination, EUS was superior to other imaging modalities in terms of IPMN-derived and -concomitant PDAC detection. Throughout the study period, including follow-up, EUS was significantly better at detecting IPMN-concomitant PDACs than the other modalities. Conclusions: IPMN-concomitant PDACs are quite often found at diagnosis and during follow-up.EUS examination of the whole pancreas plays an important role in the management of IPMNs as it allows the early detection of these small invasive carcinomas.The Gross Classification of Hepatocellular Carcinoma: Usefulness of Contrast-enhanced USKinuyo Hatanaka; Yasunori Minami; Masatoshi Kudo; Tatsuo Inoue; Hobyung Chung; Seiji HajiJOURNAL OF CLINICAL ULTRASOUND WILEY-BLACKWELL 42 (1) 1 - 8 0091-2751 2014/01 [Refereed] BackgroundThis study investigated the usefulness of postvascular images of contrast-enhanced ultrasonography (CE-US) in the gross classification of hepatocellular carcinoma (HCC) in comparison with contrast-enhanced CT (CE-CT) findings. MethodsThis is a prospective study with consecutive HCC patients who had both CE-US and CE-CT prior to surgical resection. Fifty-one patients (32 men, 19 women; mean age, 68.9 years) with 61 HCCs were enrolled. The maximal diameters of all tumors ranged from 1.0 to 5.0 cm (meanSD, 2.5 cm1.1). Weighted kappa statistics were used to assess the agreement of the sonographic or CT findings versus the results of macroscopic configurations. ResultsThirty-nine tumors were macroscopically diagnosed as simple nodule type; 19 tumors were macroscopically diagnosed as simple nodular type with extranodular growth, and 3 were macroscopically diagnosed as confluent multinodular type from the resected specimen. The diagnostic accuracy was 86.9% (53/61) for CE-US and 65.6% (40/61) for CE-CT. The differences in accuracy between CE-US and CE-CT were statistically significant (McNemar; p=0.007). Agreement analysis between gross classification using CE-US and final macroscopic results gave a kappa value of 0.74 (95% CI: 0.65-0.82), which was considered a good agreement. On the other hand, kappa coefficient value was 0.38 (95% CI: 0.28-0.48) between gross classification using CE-CT and final macroscopic results. ConclusionsCE-US is a more reliable tool than CE-CT to evaluate the gross type of HCC than CE-CT. Accurate gross classification using imaging is considered to be essential for the determination of the correct treatment strategy and the estimates of the patients' prognosis. (c) 2013 Wiley Periodicals, Inc. J Clin Ultrasound42:1-8, 2014Quantitative Levels of Hepatitis B Virus DNA and Surface Antigen and the Risk of Hepatocellular Carcinoma in Patients with Hepatitis B Receiving Long-Term Nucleos(t)ide Analogue TherapyMiwa Kawanaka; Ken Nishino; Jun Nakamura; Takahito Oka; Noriyo Urata; Daisuke Goto; Mitsuhiko Suehiro; Hirofumi Kawamoto; Masatoshi Kudo; Gotaro YamadaLIVER CANCER KARGER 3 (1) 41 - 52 2235-1795 2014 [Refereed] Background: Serum levels of hepatitis B virus (HBV) DNA are an important predictor of the risk of hepatocellular carcinoma (HCC) in patients with chronic HBV infection. However, little is known about whether high levels of hepatitis B surface antigen (HBsAg) increase the risk for HCC. Methods: We investigated 167 patients who were treated with nucleos(t)ide analogues (NA) for at least 2 years (median: 5.8 years, range: 2-13.1 years). Relationships between reduced levels of HBsAg and various factors were evaluated. In addition, we evaluated the usefulness of quantitative serum levels of HBV DNA and HBsAg as predictors of HCC development in patients receiving long-term NA therapy. Results: HCC developed in 9 of the 167 NA-treated patients. In the 9 patients with HCC, HBV DNA was undetectable (<2.1 log copies/ mL), but HBsAg levels were >= 2000 degrees C.O.I. in 7 patients. No maternal transmission, long NA treatment period, HBV DNA levels <3.0 log copies/mL, and reduced hepatitis B e antigen levels during the first 24 weeks of treatment were a significant factor of HBsAg levels <2000 C.O.I.. Conclusions: Hepatocarcinogenesis was observed in patients with high HBsAg levels, despite the negative conversion of HBV DNA as a result of long-term NA therapy. Therefore, to suppress hepatocarcinogenesis, it is important to control not only HBV DNA levels but also HBsAg levels. Copyright (C) 2014 S. Karger AG, BaselTracking Navigation Imaging of Transcatheter Arterial Chemoembolization for Hepatocellular Carcinoma Using Three-Dimensional Cone-Beam CT AngiographyYasunori Minami; Yukinobu Yagyu; Takamichi Murakami; Masatoshi KudoLIVER CANCER KARGER 3 (1) 53 - 61 2235-1795 2014 [Refereed] Purpose: New tracking navigation imaging software was used to evaluate the usefulness of three dimensional (3D) CT angiography for transcatheter arterial chemoembolization (TACE) in patients with hepatocellular carcinoma (HCC). Materials and Methods: Fifty-two patients with 73 HCCs were enrolled in this study retrospectively. Rotational angiography was performed from the hepatic artery for evaluation of the tumor feeding vessels. Arteries feeding the tumor were traced automatically by adjusting the region of interest around the targeted tumor on axial and coronal images using tracking navigation imaging with 3D cone-beam CT angiography. Results: Using final selective angiographic findings as the gold standard, the detection of feeding vessels was 90.4% (66/73) for tracking navigation imaging and 50.7% (37/73) for celiac trunk angiography. This difference was statistically significant (Wilcoxon rank sum test, p < 0.001). The sensitivity, specificity, positive predictive value, and negative predictive value for the detection of feeding arteries were 97.1% (66/68), 80.0% (4/5), 98.5% (66/67), and 66.7% (4/6), respectively. The kappa coefficient had a value of 0.638 (95% CI: 0.471-0.805), which is considered to indicate a good degree of agreement. With the as-sistance of tracking navigation imaging, the disease control rate of TACE for HCC was 67.3% (35/52) according to the modified Response Evaluation Criteria in Solid Tumors. During follow- up periods of 1-11 months, 10 patients (19.2%) remained cancer-free after TACE. Conclusion: Tracking navigation imaging with 3D cone-beam CT angiography should be useful for TACE in HCC patients with complicated feeding arteries. Copyright (C) 2014 S. Karger AG, BaselPrediction of incidence risk of hepatocellular carcinoma by ultrasound elastographyKudo MLiver Cancer 3 1 - 5 2014Reply to kadayifci and bruggeMasayuki Kitano; Ken Kamata; Masatoshi KudoEndoscopy Georg Thieme Verlag 46 (4) 358 - 358 1438-8812 2014 [Refereed]Impact of Histologically Confirmed Lymph Node Metastases on Patient Survival After Surgical Resection for Hepatocellular Carcinoma Report of a Japanese Nationwide SurveyKiyoshi Hasegawa; Masatoshi Makuuchi; Norihiro Kokudo; Namiki Izumi; Takafumi Ichida; Masatoshi Kudo; Yonson Ku; Michiie Sakamoto; Osamu Nakashima; Osamu Matsui; Yutaka MatsuyamaANNALS OF SURGERY LIPPINCOTT WILLIAMS & WILKINS 259 (1) 166 - 170 0003-4932 2014/01 [Refereed] Objective: To clarify the clinical significance of resection of lymph node metastases in patients' hepatocellular carcinoma (HCC). Background: Although the presence of lymph node metastasis form HCC has been considered as a systemic disease, prognosis after resection of them remains unknown. Methods: From the database of a Japanese nationwide survey, 14,872 patients of HCC treated by surgical resection between 2000 and 2005 were enrolled. We modified the current Japanese staging system for HCC, by further dividing stage IVA into stage IVAnon-n1 and stage n1, according to the absence or presence of pathologically proven lymph node metastasis. Thus, the patients classified into 6 disease stages, that is, I (n = 1494), II (n = 8056), III (n = 4243), IVAnon-n1 (n = 701), n1 (n = 112), and IVB (n = 266), and their long-term outcomes were compared. Results: The median follow-up period was 20.6 months. The 3-year overall survival rates of the patients with stage IVAnon-n1, stage n1, and stage IVB were 51.6%, 38.9% and 27.2%, respectively. A multivariate analysis showed that stage IVAnon-n1 would have a similar impact on the survival as stage n1 (hazard ratio: 0.88, 95% confidence interval: 0.59-1.33, P = 0.555), and that stage n1 still represented one class less advanced than stage IVB (hazard ratio: 0.52, 95% confidence interval: 0.34-0.80, P = 0.003). Conclusions: The prognosis of patients with histologically node-positive HCC was similar to that of patients with locally advanced HCC (stage IVA), which supports the validity of the current Japanese staging system and also partially validates the system proposed by the UICC/AJCC.膵充実性腫瘤の造影超音波内視鏡分類. 特集「内視鏡分類update」北野雅之; 坂本洋城; 工藤正俊消化器内視鏡 26 (1) 145 - 147 2014/01ARB affects nicotine-induced gene expression profile in human coronary artery endothelial cells.Kudo M; Matsuda K; Sugawara K; Iki Y; Kogure N; Saito-Ito T; Shimizu K; Sato I; Yoshikawa T; Uruno A; Yokoyama A; Saito-Hakoda A; Ito S; Sugawara AWorld Journal of Hypertension 4 (1) 7 - 14 2014 [Refereed]Erratum: Value of EUS in early detection of pancreatic ductal adenocarcinomas in patients with intraductal papillary mucinous neoplasms (Endoscopy (2014) 46 (22-29))Ken Kamata; Masayuki Kitano; Masatoshi Kudo; Hiroki Sakamoto; Kumpei Kadosaka; Takeshi Miyata; Hajime Imai; Kiyoshi Maekawa; Takaaki Chikugo; Masashi Kumano; Tomoko Hyodo; Takamichi Murakami; Yasutaka Chiba; Yoshifumi TakeyamaEndoscopy Georg Thieme Verlag 46 (4) 358  1438-8812 2014 [Refereed]Pathological feature, oxidative DNA damage and epigenetic alteration of tumor suppressor genes in non-alcoholic fatty liver diseaseNaoshi Nishida; Norihisa Yada; Hirokazu Chishina; Tadaaki Arizumi; Masahiro Takita; Satoshi Kitai; Tatsuo Inoue; Satoru Hagiwara; Yasunori Minami; Kazuomi Ueshima; Toshiharu Sakurai; Masatoshi KudoHEPATOLOGY WILEY-BLACKWELL 60 758A - 758A 0270-9139 2014 [Refereed]Meeting Report: ILCA2013工藤正俊The Liver Cancer Journal 6 48 - 50 2014 [Refereed][Invited]Recent Advances in Bioinformatics Reveal the Molecular Heterogeneity of Hepatocellular CarcinomaM. KudoLIVER CANCER KARGER 3 (2) 68 - 70 2235-1795 2014 [Refereed]Prediction of Hepatocellular Carcinoma Incidence Risk by Ultrasound ElastographyM. KudoLIVER CANCER KARGER 3 (1) 1 - 5 2235-1795 2014 [Refereed]Impact of Histologically Confirmed Lymph Node Metastases on Patient Survival After Surgical Resection for Hepatocellular Carcinoma Report of a Japanese Nationwide SurveyKiyoshi Hasegawa; Masatoshi Makuuchi; Norihiro Kokudo; Namiki Izumi; Takafumi Ichida; Masatoshi Kudo; Yonson Ku; Michiie Sakamoto; Osamu Nakashima; Osamu Matsui; Yutaka MatsuyamaANNALS OF SURGERY LIPPINCOTT WILLIAMS & WILKINS 259 (1) 166 - 170 0003-4932 2014/01 [Refereed] Objective: To clarify the clinical significance of resection of lymph node metastases in patients' hepatocellular carcinoma (HCC). Background: Although the presence of lymph node metastasis form HCC has been considered as a systemic disease, prognosis after resection of them remains unknown. Methods: From the database of a Japanese nationwide survey, 14,872 patients of HCC treated by surgical resection between 2000 and 2005 were enrolled. We modified the current Japanese staging system for HCC, by further dividing stage IVA into stage IVAnon-n1 and stage n1, according to the absence or presence of pathologically proven lymph node metastasis. Thus, the patients classified into 6 disease stages, that is, I (n = 1494), II (n = 8056), III (n = 4243), IVAnon-n1 (n = 701), n1 (n = 112), and IVB (n = 266), and their long-term outcomes were compared. Results: The median follow-up period was 20.6 months. The 3-year overall survival rates of the patients with stage IVAnon-n1, stage n1, and stage IVB were 51.6%, 38.9% and 27.2%, respectively. A multivariate analysis showed that stage IVAnon-n1 would have a similar impact on the survival as stage n1 (hazard ratio: 0.88, 95% confidence interval: 0.59-1.33, P = 0.555), and that stage n1 still represented one class less advanced than stage IVB (hazard ratio: 0.52, 95% confidence interval: 0.34-0.80, P = 0.003). Conclusions: The prognosis of patients with histologically node-positive HCC was similar to that of patients with locally advanced HCC (stage IVA), which supports the validity of the current Japanese staging system and also partially validates the system proposed by the UICC/AJCC.Breakthroughs in the Management of Hepatocellular Carcinoma: Celebrating 50 Years of the Liver Cancer Study Group of JapanMasatoshi KudoONCOLOGY KARGER 87 1 - 6 0030-2414 2014 [Refereed]Surveillance and Diagnostic Algorithm for Hepatocellular Carcinoma Proposed by the Liver Cancer Study Group of Japan: 2014 UpdateMasatoshi Kudo; Osamu Matsui; Namiki Izumi; Hiroko Iijima; Masumi Kadoya; Yasuharu ImaiONCOLOGY KARGER 87 7 - 21 0030-2414 2014 [Refereed] Surveillance and diagnostic algorithms for hepatocellular carcinoma (HCC) have already been described in guidelines published by the American Association for the Study of Liver Diseases (AASLD), the European Association for the Study of the Liver and the European Organisation for Research and Treatment of Cancer (EASL-EORTC), and the Japan Society of Hepatology (JSH), but the content of these algorithms differs slightly. The JSH algorithm mainly differs from the other two algorithms in that it is highly sophisticated and considers the functional imaging techniques of gadolinium ethoxybenzyl diethylenetriamine pentaacetic acid-enhanced MRI (EOB-MRI) and Sonazoid contrast-enhanced ultrasound (CEUS) to be very important diagnostic modalities. In contrast, the AASLD and EASL-EORTC algorithms are less advanced and suggest that a diagnosis be made based solely on hemodynamic findings using dynamic CT/MRI and biopsy findings. A consensus meeting regarding the JSH surveillance and diagnostic algorithm was held at the 50th Liver Cancer Study Group of Japan Congress, and a 2014 update of the algorithm was completed. The new algorithm reaffirms the very important role of EOB-MRI and Sonazoid CEUS in the surveillance and diagnosis of liver cancer and is more sophisticated than those currently used in the United States and Europe. This is now an optimized algorithm that can be used to diagnose early-stage to classical HCC easily and highly accurately. (C) 2014 S. Karger AG, BaselTransarterial Chemoembolization Failure/Refractoriness: JSH-LCSGJ Criteria 2014 UpdateMasatoshi Kudo; Osamu Matsui; Namiki Izumi; Masumi Kadoya; Takuji Okusaka; Shiro Miyayama; Koichiro Yamakado; Kaoru Tsuchiya; Kazuomi Ueshima; Atsushi Hiraoka; Masafumi Ikeda; Sadahisa Ogasawara; Tatsuya Yamashita; Tetsuya MinamiONCOLOGY KARGER 87 22 - 31 0030-2414 2014 [Refereed] In the 2010 version of the Japan Society of Hepatology (JSH) consensus-based treatment algorithm for the management of hepatocellular carcinoma (HCC), transarterial chemoembolization (TACE) failure/refractoriness was defined assuming the use of superselective lipiodol TACE, which has been widely used worldwide and particularly in Japan, and areas with lipiodol deposition were considered to be necrotic. However, this concept is not well accepted internationally. Furthermore, following the approval of microspheres, an embolic material that does not use lipiodol, in February 2014 in Japan, the phrase 'lipiodol deposition' needed to be changed to 'necrotic lesion or viable lesion'. Accordingly, the respective section in the JSH guidelines was revised to define TACE failure as an insufficient response after >= 2 consecutive TACE procedures that is evident on response evaluation computed tomography or magnetic resonance imaging after 1-3 months, even after chemotherapeutic agents have been changed and/or the feeding artery has been reanalyzed. In addition, the appearance of a higher number of lesions in the liver than that recorded at the previous TACE procedure (other than the nodule being treated) was added to the definition of TACE failure/refractoriness. Following the discussion of other issues concerning the continuous elevation of tumor markers, vascular invasion, and extrahepatic spread, descriptions similar to those in the previous version were approved. The revision of these TACE failure definitions was approved by over 85% of HCC experts. (C) 2014 S. Karger AG, BaselValidation of the Criteria of Transcatheter Arterial Chemoembolization Failure or Refractoriness in Patients with Advanced Hepatocellular Carcinoma Proposed by the LCSGJTadaaki Arizumi; Kazuomi Ueshima; Hirokazu Chishina; Masashi Kono; Masahiro Takita; Satoshi Kitai; Tatsuo Inoue; Norihisa Yada; Satoru Hagiwara; Yasunori Minami; Toshiharu Sakurai; Naoshi Nishida; Masatoshi KudoONCOLOGY KARGER 87 32 - 36 0030-2414 2014 [Refereed] Background: Transcatheter arterial chemoembolization (TACE) failure or refractoriness is an indication for sorafenib therapy in patients with advanced hepatocellular carcinoma. The study evaluated the validity of the definition of TACE failure or refractoriness as proposed by the Liver Cancer Study Group of Japan (LCSGJ) through a retrospective analysis of sorafenib treatment. Methods: Out of 265 patients with advanced hepatocellular carcinoma who were treated with sorafenib at our hospital, 45 experienced TACE failure or refractoriness and were included in this study and retrospectively analyzed. Results: Multivariate analysis only identified the number of ineffective TACE procedures performed before starting sorafenib treatment as significant factors. Overall survival (OS) after starting sorafenib was statistically longer in patients treated with <= 2 consecutive ineffective TACE procedures before sorafenib administration than in patients treated with >= 3 consecutive ineffective TACE procedures (p < 0.005). This result matched the LCSGJ criteria. Conclusion: In patients treated with sorafenib, OS was extended with <= 2 consecutive ineffective TACE procedures compared to that with >= 3 consecutive ineffective TACE procedures. Thus, if tumors are uncontrolled, TACE should not be repeated. The result of this study supports the definition of TACE failure or refractoriness proposed by the LCSGJ. (C) 2014 S. Karger AG, BaselPathological Diagnosis of Benign Hepatocellular Nodular Lesions Based on the New World Health Organization ClassificationFukuo Kondo; Toshio Fukusato; Masatoshi KudoONCOLOGY KARGER 87 37 - 49 0030-2414 2014 [Refereed] There are various types of benign hepatocellular nodular lesions, and their diagnostic criteria were formulated in detail. However, in 2010, the new World Health Organization (WHO) classification introduced immunohistochemical diagnostic criteria for hepatocellular adenoma (HCA) reflecting molecular pathological properties, and HCA was classified into 4 subtypes. These criteria were useful for its differential diagnosis from focal nodular hyperplasia (FNH). They were also useful for the diagnosis of HCA, its subtyping, and differentiation from FNH in Japan. However, the new WHO classification is based on principles that differ from those of conventional definitions of disease concepts and methods for the differential diagnosis. Therefore, it has caused disagreements in the diagnosis in some cases. Based on this background, we present a new perspective on the diagnosis of benign hepatocellular nodular lesions. (C) 2014 S. Karger AG, BaselVirtual Sonography for Novice Sonographers: Usefulness of SYNAPSE VINCENT (R) with Pre-Check Imaging of Tumor LocationChikara Ogawa; Yasunori Minami; Yumiko Morioka; Akiyo Noda; Soichi Arasawa; Masako Izuta; Atsushi Kubo; Toshihiro Matsunaka; Noriyuki Tamaki; Mitsushige Shibatouge; Masatoshi KudoONCOLOGY KARGER 87 50 - 54 0030-2414 2014 [Refereed] Purpose: To evaluate the usefulness of a virtual ultrasound (US) imaging device as a tool to assist novice sonographers. Materials and Methods: A prospective blinded pilot study was conducted involving patients with liver lesions. Two sonographers and 2 medical doctors with less than 5 years of experience performed US examinations. The time needed to detect liver lesions on US and the success rate for detecting liver lesions with and without using the virtual US imaging device SYNAPSE VINCENT (R) (Fujifilm Medical Co., Tokyo, Japan) before US examination were evaluated. Results: Thirty-two patients with the following 42 liver lesions were included: liver cyst (n = 24), hemangioma (n = 8), hepatocellular carcinoma (n = 6), and liver metastasis (n = 4). The maximal diameter of these lesions ranged from 0.3 to 1.5 cm (mean +/- SD, 0.8 +/- 0.4). The average time for detecting liver lesions on US was 47.8 s (range, 7-113) with VINCENT and 112.9 s (range, 14-313) without VINCENT before US examination. There were significant differences in the duration of US examination with and without VINCENT (p = 0.0002, Student's t test). The rates for accurately detecting liver lesions were 100 and 76.2% (16/21) in US beginners with and without VINCENT, respectively. Significantly higher detection rates were found in the US beginners who used VINCENT compared to those who did not use VINCENT (p = 0.047, Fisher's exact test). Conclusion: Before US examination, a reference with VINCENT could contribute to the successful detection of liver lesions and could be time-saving for US beginners. (C) 2014 S. Karger AG, BaselCombination Guidance of Contrast-Enhanced US and Fusion Imaging in Radiofrequency Ablation for Hepatocellular Carcinoma with Poor Conspicuity on Contrast-Enhanced US/Fusion ImagingTomohiro Minami; Yasunori Minami; Hirokazu Chishina; Tadaaki Arizumi; Masahiro Takita; Satoshi Kitai; Norihisa Yada; Tatsuo Inoue; Satoru Hagiwara; Kazuomi Ueshima; Naoshi Nishida; Masatoshi KudoONCOLOGY KARGER 87 55 - 62 0030-2414 2014 [Refereed] Purpose: The purpose of this study was to evaluate the usefulness of the combination guidance of contrast-enhanced US (CEUS) and fusion imaging in radiofrequency ablation (RFA) for hepatocellular carcinoma (HCC) with poor conspicuity on B-mode US and CEUS/fusion imaging. Materials and Methods: We conducted a retrospective cohort study, which included 356 patients with 556 HCCs that were inconspicuous on B-mode US. A total of 192 patients with 344 HCCs, 123 patients with 155 HCCs, and 37 patients with 57 HCCs underwent RFA under CEUS guidance, fusion imaging guidance, and the combination of CEUS and fusion imaging guidance. Results: The average number of treatment sessions was 1.1 (range: 1-2) in the CEUS guidance group, 1.1 (range: 1-2) in the fusion imaging guidance group, and 1.1 (range: 1-3) in the combination of CEUS and fusion imaging guidance group. Treatment analysis did not reveal significantly more RFA treatment sessions in the combination guidance group than in the other groups (p = 0.97, Student's t test). During the follow-up period (1.1-85.3 months, mean +/- SD, 43.2 +/- 59.5), the 3-year local tumor progression rates were 4.9, 7.2, and 5.9% in the CEUS guidance group, the fusion imaging guidance group, and the combination guidance group, respectively (p = 0.84, log-rank test). Conclusion: In spite of selection bias, session frequency and local tumor progression were not different under the combination guidance with CEUS and fusion imaging in RFA. The combination of fusion imaging and CEUS guidance in RFA therapy is an effective treatment for HCC with poor conspicuity on B-mode US and CEUS/fusion imaging. (C) 2014 S. Karger AG, BaselNoninvasive Diagnosis of Liver Fibrosis: Utility of Data Mining of Both Ultrasound Elastography and Serological Findings to Construct a Decision TreeNorihisa Yada; Masatoshi Kudo; Norifumi Kawada; Shuichi Sato; Yukio Osaki; Akihisa Ishikawa; Hisaaki Miyoshi; Michiie Sakamoto; Masayoshi Kage; Osamu Nakashima; Akiko TonomuraONCOLOGY KARGER 87 63 - 72 0030-2414 2014 [Refereed] Objective: Although liver biopsy is the gold standard for viral liver disease management, it is invasive and the sampling error rate is problematic. Real-time tissue elastography (RTE), a recently developed method of ultrasound elastography, can be used to assess liver fibrosis noninvasively but the overlap between fibrosis stages limits its ability to assess liver fibrosis adequately when used alone. Methods: A multicenter collaborative study involving 542 patients with chronic viral hepatitis and cirrhosis who were scheduled to undergo liver biopsy compared the image features obtained from RTE image analysis, the liver fibrosis index (LFI), and pathological diagnosis. RTE and a blood test were performed on the same day as the liver biopsy. Data mining was also performed to construct a decision tree, and its diagnostic performance for assessing liver fibrosis was evaluated. Results: The LFI was higher in patients with chronic hepatitis C (CHC) than in those with chronic hepatitis B (CHB). When a decision tree was constructed by data mining of RTE and serological findings, the diagnostic accuracy was very high for all fibrosis stages, with respective rates at F1, F2, F3, and F4 of 94.4, 54.1, 38.7, and 81.3% for patients with CHC and of 97.1, 50.0, 43.8, and 80.6% for patients with CHB. Conclusions: The variation in LFI values between the different etiologies appears to reflect the difference in the development style of liver fibrosis. The decision tree for assessing liver fibrosis constructed by data mining of both RTE and serological findings had a high diagnostic performance in assessing liver fibrosis and shows promising clinical utility. (C) 2014 S. Karger AG, BaselRecent Progress in Radiofrequency Ablation Therapy for Hepatocellular CarcinomaKenji Ikeda; Yukio Osaki; Hiroyuki Nakanishi; Akihiro Nasu; Yusuke Kawamura; Koji Jyoko; Takatomo Sano; Hajime Sunagozaka; Koji Uchino; Yasunori Minami; Yu Saito; Kazumasa Nagai; Ryosuke Inokuchi; Shigehiro Kokubu; Masatoshi KudoONCOLOGY KARGER 87 73 - 77 0030-2414 2014 [Refereed] In order to attain better ablation and more effective management of hepatocellular carcinoma (HCC), new approaches and devices in radiofrequency ablation (RFA) therapy were presented and discussed in a workshop at the 50th Annual Meeting of the Liver Cancer Study Group of Japan. A novel bipolar RFA apparatus was introduced in Japan in January 2013. Hundreds of subjects with HCC were treated with multipolar RFA with varied devices and plans. Among these, no-touch ablation was one of the most useful procedures in the treatment of HCC with the apparatus. In RFA therapy, a few assisting devices and techniques were applied for convenience and improvement of the thermal ablation procedure. Contrast-enhanced ultrasonography and three-dimensional fusion imaging technique using volume data of CT or MRI could improve exact targeting and shorten the treatment time for RFA procedures under ultrasonographic guidance. A more complicated method using a workstation was also reported as being helpful in planning the ablated shape and volume in multineedle RFA. The effective use of sedatives and antianalgesics as well as a novel microwave apparatus with a cooled-tip electrode was also discussed. (C) 2014 S. Karger AG, BaselTreatment Strategies of Intermediate-Stage Hepatocellular Carcinomas in Japan (Barcelona Clinic Liver Cancer Stage B)Koichiro Yamakado; Masatoshi KudoONCOLOGY KARGER 87 78 - 81 0030-2414 2014 [Refereed] Hepatocellular carcinoma (HCC) is the fifth most common cancer in the world, and it shows increasing incidence worldwide. The Barcelona Clinic Liver Cancer (BCLC) staging system has become widely accepted in clinical practice, but in Japan, two clinical practice guidelines have been used for HCC: the Evidence-Based Clinical Practice Guidelines and the Consensus-Based Clinical Practice Guidelines. Although, in Japan, chemoembolization is the first-line treatment of intermediate-stage (stage B) HCC patients in the BCLC staging system, along with chemoembolization, locoregional treatments, such as resection and radiofrequency ablation, and hepatic arterial infusion chemotherapy are incorporated into the treatment algorithm based on the tumor number and size as well as on the liver profile. (C) 2014 S. Karger AG, BaselTreatment of Hepatocellular Carcinoma with Child-Pugh C CirrhosisKazuhiro Nouso; Norihiro Kokudo; Masatoshi Tanaka; Ryoko Kuromatsu; Hiroki Nishikawa; Hidenori Toyoda; Naoki Oishi; Kenji Kuwaki; Masashi Kusanaga; Takuki Sakaguchi; Zenichi Morise; Satoshi Kitai; Masatoshi KudoONCOLOGY KARGER 87 99 - 103 0030-2414 2014 [Refereed] Background: In most guidelines, no other interventional therapy but liver transplantation is recommended for the treatment of hepatocellular carcinoma (HCC) with Child-Pugh C cirrhosis (CP-C). However, in Japan, patients were sometimes treated with expectation of benefit. Summary: A workshop was conducted to explore the state of treatments for CP-C HCC in Japan. After the workshop, a questionnaire on therapies was given to the panelists. Clinical data of 769 patients with CP-C HCC from 8 hospitals as well as analyses of data collected by the Liver Cancer Study Group of Japan (LCSGJ) consisting of 1,344 CP-C HCC cases were presented. Patients who underwent liver transplantation were excluded. In total, 424 out of the 769 patients (55.1%) from the 8 hospitals and 537 out of 828 CP-C HCC cases (64.8%) from the LCSGJ data received interventional therapies, such as local ablation and transcatheter arterial chemoembolization. All panelists agreed that there was a subgroup of CP-C patients who benefitted from the locoregional therapies. The major goals for the therapies were to prevent HCC rupture and avoid obstruction of major vessels by tumor growth, which can lead to a sudden deterioration of the patients' condition. Patient liver function and tumor stage are both important factors for the decision to undergo treatment; however, the inclusion criteria for the treatments varied among the centers. Key Message: There exists a subgroup of CP-C patients who benefit from interventions for HCC. (C) 2014 S. Karger AG, BaselCharacteristics of Long-Term Survivors following Sorafenib Treatment for Advanced Hepatocellular Carcinoma: Report of a Workshop at the 50th Annual Meeting of the Liver Cancer Study Group of JapanKatsuaki Tanaka; Mitsuo Shimada; Masatoshi KudoONCOLOGY KARGER 87 104 - 109 0030-2414 2014 [Refereed] Background: Little data are available on the long-term survival of patients treated with sorafenib for advanced hepatocellular carcinoma (HCC). Summary: During a consensus workshop at the 50th annual meeting of the Liver Cancer Study Group of Japan held in Kyoto (June 5-6, 2014), experts met to discuss the characteristics of long-term (>3 years) survivors of advanced HCC following sorafenib treatment. A total of 70 long-term survivors following sorafenib treatment at eight institutions were included, and the long-term survival rate (>3 years) at each institution ranged from 2.6 to 6.9% (mean, 4.5). The long-term survival-related factors presented can be categorized as follows: (1) conversion options, including hepatic resection following successful sorafenib treatment, (2) additional salvage options when progressive disease is confirmed, (3) long-term sorafenib treatment, (4) effective post-sorafenib options to prolong postprogression survival, and (5) good pretreatment liver function. Sorafenib monotherapy exceeding 3 years is rare, and most of the patients receiving sorafenib required other treatment modalities in the form of multidisciplinary therapy. Conclusion: The overview obtained from the workshop reflects the pattern of management in practice for long-term survivors following sorafenib treatment for HCC in Japan and may also provide valuable information for other countries. (C) 2014 S. Karger AG, BaselEfficacy and Safety of Telaprevir-Based Antiviral Treatment for Elderly Patients with Hepatitis C VirusMasahiro Takita; Satoru Hagiwara; Masatoshi Kudo; Masashi Kono; Hirokazu Chishina; Tadaaki Arizumi; Satoshi Kitai; Norihisa Yada; Tatsuo Inoue; Yasunori Minami; Kazuomi UeshimaONCOLOGY KARGER 87 110 - 117 0030-2414 2014 [Refereed] Background: Telaprevir-based antiviral therapy has been the primary treatment for chronic hepatitis C genotype 1 at a high viral load since November 2011. On the other hand, a number of patients have been reported to require withdrawal from or reduced doses of drugs due to side effects, such as eruptions, anemia, and renal dysfunction. In addition, as hepatitis C patients are growing older, it is imperative to investigate the tolerability of triple combination therapy for elderly patients. Subjects and Methods: The study subjects comprised 35 patients who received telaprevir combination therapy after November 2011. They were divided into group A (age: <65 years; n = 21) and group B (age: >= 65 years; n = 14) in order to compare the treatment completion rate, sustained virological response at week 24 (SVR24), and adverse events between the groups. Results: The treatment completion rate was 82.8% (29/35) in all subjects, 90.4% (19/21) in group A, and 78.5% (11/14) in group B. The rate was lower in group B but without a significant difference between the groups (p = 0.804). The SVR24 rate was 88.5% (31/35) in all subjects, 90.4% (19/21) in group A, and 85.7% (12/14) in group B, without a significant difference between the groups (p = 0.161). Conclusion: Although the incidence of anemia was higher in group B, there was no significant difference in the treatment completion or SVR24 rate between the groups. Telaprevir combination therapy is suggested to be tolerable for elderly hepatitis C patients. (C) 2014 S. Karger AG, BaselUltrasound Elastography Correlates Treatment Response by Antiviral Therapy in Patients with Chronic Hepatitis CNorihisa Yada; Toshiharu Sakurai; Tomohiro Minami; Tadaaki Arizumi; Masahiro Takita; Tatsuo Inoue; Satoru Hagiwara; Kazuomi Ueshima; Naoshi Nishida; Masatoshi KudoONCOLOGY KARGER 87 118 - 123 0030-2414 2014 [Refereed] Objective: To investigate the relationship between tissue elasticity before and after antiviral therapy and shear wave as well as strain elastography. Methods: FibroScan and real-time tissue elastography were performed before and after antiviral therapy for chronic hepatitis C, and treatment efficacy and elastographic findings were comparatively analyzed. Elasticity was evaluated by measuring liver stiffness (LS) in kilopascals using FibroScan, and the liver fibrosis index (LFI) was assessed by real-time tissue elastography. Results: LS and LFI correlated well before and after therapy (r = 0.567, p = 0.003 and r = 0.576, p = 0.002, respectively). In the group without a sustained virological response (SVR), LS increased in 4 of 5 patients. Patients with an increase in both LS and LFI were all in the non-SVR group (3/3, 100%). In addition, LS increased in all patients except 1 in the non-SVR group (4/5, 80%). In the SVR group, both LS and LFI decreased in all patients except 1 (18/19, 94.7%). In the patient with an increase in LS despite achieving SVR, LS decreased quickly after alcohol cessation. Conclusions: With a few exceptions, SVR improved LS. All patients with an increase in LFI were in the non-SVR group, even though LFI decreased in 2 patients. Our findings suggest that an LFI increase indicates lack of treatment efficacy with antiviral therapy. LFI may be useful for the assessment of treatment efficacy in patients with worsening of LS despite achieving SVR with antiviral therapy. (C) 2014 S. Karger AG, BaselJSH Consensus-Based Clinical Practice Guidelines for the Management of Hepatocellular Carcinoma: 2014 Update by the Liver Cancer Study Group of JapanMasatoshi Kudo; Osamu Matsui; Namiki Izumi; Hiroko Iijima; Masumi Kadoya; Yasuharu Imai; Takuji Okusaka; Shiro Miyayama; Kaoru Tsuchiya; Kazuomi Ueshima; Atsushi Hiraoka; Masafumi Ikeda; Sadahisa Ogasawara; Tatsuya Yamashita; Tetsuya Minami; Koichiro YamakadoLIVER CANCER KARGER 3 (3-4) 458 - 468 2235-1795 2014 [Refereed] The Clinical Practice Guidelines for the Management of Hepatocellular Carcinoma proposed by the Japan Society of Hepatology was updated in June 2014 at a consensus meeting of the Liver Cancer Study Group of Japan. Three important items have been updated: the surveillance and diagnostic algorithm, the treatment algorithm, and the definition of transarterial chemoembolization (TACE) failure/refractoriness. The most important update to the diagnostic algorithm is the inclusion of gadolinium-ethoxybenzyl-diethylenetriamine pentaacetic acid-enhanced magnetic resonance imaging as a first line surveillance/diagnostic tool. Another significant update concerns removal of the term "lipiodol" from the definition of TACE failure/refractoriness. Copyright (C) 2014 S. Karger AG, Basel座談会; 肝胆膵腫瘍のバイオインフォマティクス工藤正俊; 坂元亨宇; 山下太郎; 三木大樹肝胆膵 68 471 - 485 2014 [Refereed]肝腫瘍領域の個別化薬物治療の現状. 特集「肝胆膵腫瘍のバイオインフォマティクス」上嶋一臣; 工藤正俊肝胆膵 68 459 - 463 2014 [Refereed]肝癌におけるDNAメチル化プロファイリングの現状と意義. 特集「肝胆膵腫瘍のバイオインフォマティクス」西田直生志; 工藤正俊肝胆膵 (株)アークメディア 68 (3) 353 - 363 0389-4991 2014 [Refereed]ソラフェニブの最新情報上嶋一臣; 工藤正俊腫瘍内科 13 637 - 641 2014 [Refereed]V.肝細胞腺腫の悪性転化. 2)臨床の立場より工藤正俊肝胆膵 69 795 - 799 2014 [Refereed]3.消化器領域の最新動向 2)胆・膵. Ⅰ. 特集「US Today 2014領域別超音波最新動向アプリ&プローブ、モバイル活用法」鎌田 研; 北野雅之; 前川 清; 工藤正俊INNERVISION 29 16 - 19 2014 [Refereed]欧米と日本の診療ガイドラインの相違を解説する. 特集「肝胆膵診療のNew Horizon」工藤正俊肝胆膵 69 967 - 976 2014 [Refereed]Stabilization technique for real-time high-resolution vascular ultrasound using frequency domain interferometryTaki H; Taki K; Yamakawa M; Shiina T; Kudo M; Sato TConf Proc IEEE Eng Med Biol Soc 2014 5085 - 5088 1557-170X 2014 [Refereed] We have proposed an ultrasound imaging method based on frequency domain interferometry (FDI) with an adaptive beamforming technique to depict real-time high-resolution images of human carotid artery. Our previous study has investigated the performance of the proposed imaging method under an ideal condition with a high signal-to-noise ratio (SNR). In the present study, we propose a technique that has the potential to improve accuracy in estimating echo intensity using the FDI imaging method. We investigated the performance of the proposed technique in a simulation study that two flat interfaces were located at depths of 15.0 and 15.2 mm and white noise was added. Because the -6 dB bandwidth of the signal used in this simulation study is 2.6 MHz, the conventional B-mode imaging method failed to depict the two interfaces. Both the conventional and proposed FDI imaging methods succeeded to depict the two interfaces when the SNR ranged from 15 to 30 dB. However, the average error of the estimated echo intensity at the interfaces using the conventional FDI imaging method ranged from 7.2 to 10.5 dB. In contrast, that using the FDI imaging method with the proposed technique ranged from 2.0 to 2.2 dB. The present study demonstrates the potential of the FDI imaging method in depicting robust and high-range-resolution ultrasound images of arterial wall, indicating the possibility to improve the diagnosis of atherosclerosis in early stages.食道疣状扁平上皮癌松井繁長; 樫田博史; 工藤正俊消化器内視鏡 26 (10) 1606 - 1607 2014 [Refereed]胃癌類似形態を呈した胃限局性ATTRアミロイドーシスの1例松井繁長; 樫田博史; 高山政樹; 峯 宏昌; 足立哲平; 永井知行; 川崎正憲; 朝隈 豊; 櫻井俊治; 工藤正俊; 筑後孝章胃と腸 49 (3) 377 - 384 2014 [Refereed]発赤調で粘液の付着を伴う胃粘膜下腫瘍様病変松井繁長; 樫田博史; 工藤正俊消化器内視鏡 26 (7) 1009 - 1010 2014 [Refereed]慢性膵炎の経消化管的治療宮田 剛; 北野雅之; 大本俊介; 門阪薫平; 鎌田 研; 山雄健太郎; 今井 元; 坂本洋城; 工藤正俊胆と膵 35 (5) 455 - 461 2014 [Refereed]造影ハーモニックEUSによる胆・膵疾患の診断 - 造影CTとの違いは?宮田 剛; 北野雅之; 大本俊介; 門阪薫平; 鎌田 研; 山雄健太郎; 今井 元; 坂本洋城; 工藤正俊胆と膵 35 (8) 707 - 713 2014 [Refereed]超音波内視鏡下腹腔神経叢融解術(EUS-CPN) の実際宮田 剛; 北野雅之; 工藤正俊膵・胆道癌FRONTIER メディカルレビュー社 4 (2) 82 - 86 2186-3504 2014 [Refereed]Accuracy of Real-Time Tissue Elastography for the Evaluation of Hepatic Fibrosis in Patients with Chronic Hepatitis B: A Prospective Multicenter StudyTao Wu; Jie Ren; Shu-zhen Cong; Fan-kun Meng; Hong Yang; Yan Luo; Hong-jun Lin; Yan Sun; Xiu-yan Wang; Shu-Fang Pei; Ying Zheng; Yun He; Yang Chen; Yu Hu; Na Yang; Ping Li; Masatoshi Kudo; Rong-qin ZhengDIGESTIVE DISEASES KARGER 32 (6) 791 - 799 0257-2753 2014 [Refereed] Background: The prognosis and management of hepatic fibrosis are closely related to the stage of the disease. The limitations of liver biopsy, which is the gold standard for treatment, include its invasiveness and sampling error. Ultrasound elasticity might be the most promising imaging technology for the noninvasive and accurate assessment of hepatic fibrosis. Real-time tissue elastography (RTE) measures the relative stiffness of the tissue in the region of interest caused by the heartbeat. Many studies have verified that RTE is useful for the diagnosis of hepatic fibrosis in patients with chronic hepatitis C (CHC). Purpose: To determine the formula of the liver fibrosis index for chronic hepatitis B (BLFI) and to validate the diagnostic accuracy of the BLFI for hepatic fibrosis compared with the liver fibrosis index (LFI). Materials and Methods: RTE was performed in 747 prospectively enrolled patients with chronic hepatitis B (CHB) or cirrhosis from 8 centers in China; 375 patients were analyzed as the training set, and 372 patients were evaluated as the validation set. The fibrosis stage was diagnosed from pathological specimens obtained by ultrasound-guided liver biopsy. Nine image features were measured from strain images, and the new formula for the BLFI was obtained by combining the nine imaging features of the RTE images using multiple regression analysis of the training set. The BLFI and LFI were compared with the pathological fibrosis stage at diagnosis, and the diagnostic performances of the indexes were compared. Results: The Spearman correlation coefficient between the BLFI and hepatic fibrosis stages was significantly positive (r = 0.711, p < 0.001), and significant differences were present between all disease stages. The areas under the receiver-operating characteristic (AUROC) curves of the BLFI and LFI for predicting significant fibrosis (S0-S1 vs. S2-S4) were 0.858 and 0.858, respectively. For cirrhosis (S0-S3 vs. S4), the AUROC curves of the BLFI and LFI were 0.868 and 0.862, respectively. Conclusion: The results of this large, multicenter study confirmed that RTE is valuable for the diagnosis of hepatic fibrosis in patients with CHB. However, the diagnostic efficiencies of the new BLFI and the original LFI, which were based on CHC, for the assessment of CHB hepatic fibrosis were similar; thus, the LFI has the potential to be used to directly evaluate the extent of hepatic fibrosis in patients with CHB. (C) 2014 S. Karger AG, BaselClinical Features of Vascular Disorders Associated with Chronic Hepatitis Virus InfectionNaoshi Nishida; Masatoshi KudoDIGESTIVE DISEASES KARGER 32 (6) 786 - 790 0257-2753 2014 [Refereed] Hepatitis virus infections can be accompanied by extrahepatic manifestations that may be caused by the host's immune reaction to the viral infection. Vascular involvement is one of these manifestations and is occasionally associated with life-threatening conditions due to systemic organ failure. The unique profile of hepatitis-related vascular involvement is associated with infection by different types of hepatitis viruses. For example, polyarteritis nodosa is more frequently reported in patients with chronic hepatitis B than those with chronic hepatitis C. Similarly, membranous nephropathy is a notable manifestation among hepatitis B virus-positive patients. In contrast, patients infected with hepatitis C virus are at risk for cryoglobulinemia and membranoproliferative glomerulonephritis. Antiviral therapy is necessary to control these kinds of vasculitis related to hepatitis virus infections; however, imnnunosuppressive agents may be required to treat severe cases. New antiviral drugs for viral hepatitis could improve the prognosis of vascular and renal involvement. (C) 2014 S. Karger AG, BaselIdentification of Epigenetically Inactivated Genes in Human Hepatocellular Carcinoma by Integrative Analyses of Methylation Profiling and Pharmacological UnmaskingNaoshi Nishida; Hirokazu Chishina; Tadaaki Arizumi; Masahiro Takita; Satoshi Kitai; Norihisa Yada; Satoru Hagiwara; Tatsuo Inoue; Yasunori Minami; Kazuomi Ueshima; Toshiharu Sakurai; Masatoshi KudoDIGESTIVE DISEASES KARGER 32 (6) 740 - 746 0257-2753 2014 [Refereed] Objectives: DNA methylation-dependent transcriptional inactivation of tumor suppressor genes (TSGs) is critical for the pathogenesis of hepatocellular carcinoma (HCC). This study identifies potential TSGs in HCCs using methylation profiling and pharmacological unmasking of methylated TSGs. Methods: Methylation profiling was performed on 22 pairs of HCCs and their corresponding noncancerous liver tissues using the Infinium HumanMethylation27 BeadChip. We also determined the gene reexpression after treatment with 5-aza-2'-deoxycytidine (5-Aza-dC) and trichostatin A (TSA) in 5 HCC cell lines. Results: We selected CpGs that exhibited a significant increase in methylation in HCC tissues compared with that of the noncancerous control group. Two hundred and thirteen CpGs on different gene promoters with a mean difference in the beta value >= 0.15 and a value of p < 0.05 were selected. Of the 213 genes, 45 genes were upregulated in 3 or more HCC cell lines with multiplier value of differences after 5-Aza-dC and TSA treatment. Conclusions: We identified several potential TSGs that participate in transcription inactivation through epigenetic interactions in HCC. The results of this study are important for the understanding of functionally important epigenetic alterations in HCC. (C) 2014 S. Karger AG, BaselDecreased Blood Flow after Sorafenib Administration Is an Imaging Biomarker to Predict Overall Survival in Patients with Advanced Hepatocellular CarcinomaTadaaki Arizumi; Kazuomi Ueshima; Hirokazu Chishina; Masashi Kono; Masahiro Takita; Satoshi Kitai; Tatsuo Inoue; Norihisa Yada; Satoru Hagiwara; Yasunori Minami; Toshiharu Sakurai; Naoshi Nishida; Masatoshi KudoDIGESTIVE DISEASES KARGER 32 (6) 733 - 739 0257-2753 2014 [Refereed] Background: Sorafenib is a multikinase inhibitor targeting Raf and protein tyrosine kinases, which are involved in cell growth and tumor angiogenesis. Sorafenib administration induces temporary inhibition of tumor growth and a decrease in arterial blood flow in a considerable number of hepatocellular carcinoma (HCC) patients. We retrospectively evaluated the association between decreased blood flow and the overall survival (OS) of HCC patients after the initiation of sorafenib therapy. Patients and Methods: Therapeutic responses of 158 advanced HCC patients with hypervascular tumors who had received sorafenib for more than 1 month were analyzed. To assess their therapeutic response, patients underwent radiological evaluation before and every 4-6 weeks after the initiation of sorafenib treatment. After the classification of patients into three groups based on the change in arterial enhancement during treatment (no change, decrease and disappearance), the OS of each group was compared using the Kaplan-Meier method. Results:Statistically significant differences in OS were observed among the three groups (p < 0.001). A decrease or disappearance of arterial enhancement was significantly associated with improved OS compared to patients with no change in arterial enhancement; the median OS was 19.9 months (95% confidence interval, CI, 16.4-24.5 months) and 6.0 months (95% CI, 4.0-8.8 months), respectively (p < 0.001). However, there was no difference in OS between the decrease and disappearance groups (p = 0.88). Conclusion: We conclude that decreased arterial enhancement during sorafenib treatment was associated with the longest OS and could therefore reflect an effective response. (C) 2014 S. Karger AG, BaselValidation of Three Staging Systems for Hepatocellular Carcinoma (JIS Score, Biomarker-Combined JIS Score and BCLC System) in 4,649 Cases from a Japanese Nationwide SurveySatoshi Kitai; Masatoshi Kudo; Namiki Izumi; Shuichi Kaneko; Yonson Ku; Norihiro Kokudo; Michiie Sakamoto; Tadatoshi Takayama; Osamu Nakashima; Masumi Kadoya; Yutaka Matsuyama; Takashi MatsunagaDIGESTIVE DISEASES KARGER 32 (6) 717 - 724 0257-2753 2014 [Refereed] Objective: Clinical staging is very important for optimal therapeutic strategy and prognostic prediction in patients with hepatocellular carcinoma (HCC). The Barcelona Clinic Liver Cancer (BCLC) staging system is the most widely used and best-validated method for HCC. Similarly, the conventional Japan Integrated Staging (c-JIS) score and the biomarker-combined JIS (bm-JIS) score have also been reported to effectively stratify HCC patients. The aim of this study was to evaluate the performance of these three staging systems for prognostic prediction. Methods: A total of 4,649 HCC patients were included in this study. A multivariate analysis identified the independent risk factors associated with overall survival. The stratification ability and the suitability as a prognostic model of the three staging systems were compared. Results: Multivariate analysis revealed that male sex, higher Child-Pugh score, tumor size >2.0 cm, multiple tumors, vascular invasion, higher alpha-fetoprotein (AFP) level, higher des-gamma-carboxyprothrombin level, higher Lens culinaris agglutinin-reactive AFP level, and a performance status of 3-4 were independent risk factors in HCC. The independent homogenizing ability and stratification value of the bm-JIS score were higher than those of the c-JIS score and the BCLC system (X-2 = 972.7581, 758.1041 and 679.6832, respectively). Moreover, the bm-JIS score had the lowest Akaike Information Criteria value, followed by the c-JIS score and the BCLC system (9,844.278, 10,054.93 and 10,131.35, respectively). Conclusions: Our results suggest that the bm-JIS score offers good stratification ability and is a better prognostic predictor than the c-JIS score and the BCLC system. (C) 2014 S. Karger AG, BaselDuration of Stable Disease Is Associated with Overall Survival in Patients with Advanced Hepatocellular Carcinoma Treated with SorafenibTadaaki Arizumi; Kazuomi Ueshirna; Hirokazu Chishina; Masashi Kono; Mashiro Takita; Satoshi Kitai; Tatsuo Inoue; Norihisa Yada; Satoru Hagiwara; Yasunori Minami; Toshiharu Sakurai; Naoshi Nishida; Masatoshi KudoDIGESTIVE DISEASES KARGER 32 (6) 705 - 710 0257-2753 2014 [Refereed] Background: Sorafenib is a molecular-targeting agent showing improved overall survival (OS) for advanced hepatocellular carcinoma (HCC). Although tumor dormancy, characterized by stable tumor status or stable disease (SD) without tumor regression, is a unique feature of sorafenib treatment, the contribution of SD to OS remains debatable. This study aimed to clarify the correlation between SD periods and OS in patients with HCC treated with sorafenib. Methods: From May 2009 to January 2013, 269 patients with advanced-stage HCC were treated with sorafenib at the Kinki University Hospital. The antitumor response of sorafenib was evaluated in 158 patients using the modified Response Evaluation Criteria in Solid Tumors, and patients with SD were divided into two subgroups according to the median duration of SD: short SD (<3 months) and long SD (>= 3 months). The relationship between the duration of SD and OS was analyzed among patients with complete (CR) and partial response (PR), and long and short SD using the Kaplan-Meier method. Results:The median OS was 5.7 months in the short SD, 20.8 months in the long SD and 17.9 months in the CR + PR group. Although the duration of OS was significantly longer in the long SD group than the short SD group, no difference in OS was detected between the patients with CR + PR and patients with long SD. The impact of long SD on OS could be as strong as that of CR + PR. Conclusion: Achievement of long SD is one of the important goals for improving survival in patients with HCC treated with sorafenib. (C) 2014 S. Karger AG, BaselUltrasound Fusion Imaging of Hepatocellular Carcinoma: A Review of Current EvidenceYasunori Minami; Masatoshi KudoDIGESTIVE DISEASES KARGER 32 (6) 690 - 695 0257-2753 2014 [Refereed] With advances in technology, imaging techniques that entail fusion of sonography and CT or MRI have been introduced in clinical practice. Ultrasound fusion imaging provides CT or MRI cross-sectional multiplanar images that correspond to the sonographic images, and fusion imaging of B-mode sonography and CT or MRI can be displayed simultaneously and in real time according to the angle of the transducer. Ultrasound fusion imaging helps us understand the three-dimensional relationship between the liver vasculature and tumors, and can detect small liver tumors with poor conspicuity. This fusion imaging is attracting the attention of operators who perform radiofrequency ablation (RFA) for the treatment of hepatic malignancies because this real-time, multimodality comparison can increase monitoring and targeting confidence during the procedure. When RFA with fusion imaging was performed on small hepatocellular carcinomas (HCCs) with poor conspicuity, it was reported that the rates of technical success and local tumor progression were 94.4-100% and 0-8.3%. However, there have been no studies comparing fusion imaging guidance and contrast-enhanced sonography, CT or MRI guidance in ablation. Fusion imaging-guided RFA has proved to be effective for HCCs that are poorly defined on not only conventional B-mode sonography but also contrast-enhanced sonography. In addition, fusion imaging could be useful to assess the treatment response of RFA because of three-dimensional information. Here, we give an overview of the current status of ultrasound fusion imaging for clinical application in the liver. (C) 2014 S. Karger AG, BaselRadiofrequency Ablation for Hepatocellular Carcinoma Measuring 2 cm or Smaller: Results and Risk Factors for Local RecurrenceMasashi Kono; Tatsuo Inoue; Masatoshi Kudo; Hirokazu Chishina; Tadaaki Arizumi; Masahiro Takita; Satoshi Kitai; Norihisa Yada; Satoru Hagiwara; Yasunori Minami; Kazuorni Ueshima; Naoshi Nishida; Takamichi MurakamiDIGESTIVE DISEASES KARGER 32 (6) 670 - 677 0257-2753 2014 [Refereed] Objective:The purpose of this study was to evaluate the risk factors for local recurrence with radiofrequency ablation (RFA) for hepatocellular carcinoma (HCC) measuring <= 2 cm. Methods: This study involved 234 patients with 274 HCCs measuring cm who had undergone RFA as the initial treatment. The mean tumor diameter was 1.478 cm. The median follow-up period was 829 days. We evaluated the post-RFA cumulative local recurrence rate and analyzed the risk factors contributing to clinical outcomes. Results: Cumulative local recurrence rates were 9, 19 and 19% at 1,2 and 3 years, respectively. Among the 145 cases with a complete safety margin (SM) after RFA, only 4 developed local tumor recurrence and the cumulative rates of local tumor recurrence at 1, 2 and 3 years were 2, 3 and 3%, respectively. Among the 129 cases with incomplete SM, local tumor recurrence developed in 34 and the cumulative rates of local tumor progression at 1, 2 and 3 years were 14, 36 and 36%, respectively. In multivariate analysis, significant risk factors were tumor location (liver surface), irregular gross type and SM <5 mm. Conclusion: Even with HCC measuring cm, location and gross type of tumor should be carefully evaluated before RFA is performed. (C) 2014 S. Karger AG, BaselGenome-Wide Profiling of DNA Methylation and Tumor Progression in Human Hepatocellular CarcinomaNaoshi Nishida; Takafumi Nishimura; Takuya Nakai; Hirokazu Chishina; Tadaaki Arizumi; Masahiro Takita; Satoshi Kitai; Norihisa Yada; Satoru Hagiwara; Tatsuo Inoue; Yasunori Minami; Kazuomi Ueshima; Toshiharu Sakurai; Masatoshi KudoDIGESTIVE DISEASES KARGER 32 (6) 658 - 663 0257-2753 2014 [Refereed] Objective: To clarify the progression pattern of abnormal DNA methylation during the development of hepatocellular carcinoma (HCC) using a comprehensive methylation assay. Methods: We used an Infinium HumanMethylation450 BeadChip array that can analyze >485,000 CpG sites distributed throughout the genome for a comprehensive methylation study of 117 liver tissues consisting of 59 HCC and 58 noncancerous livers. Altered DNA nnethylation patterns during tumor progression were also analyzed. Results: We identified 38,330 CpG sites with significant differences in methylation levels between HCCs and noncancerous livers (DM-CpGs) using strict criteria. Of the DM-CpGs, 92% were hypomethylated and only 3,051 CpGs (8%) were hypermethylated in HCC. The DM-CpGs were more prevalent within intergenic regions with isolated CpGs. In contrast, DM-CpGs that were hypermethylated in HCC were predominantly located within promoter regions and CpG islands (p < 0.0001). The association between methylation profiles of DM-CpGs and tumor size was statistically significant, especially in hepatitis C virus (HCV)-positive cases (p = 0.0001). Conclusions: We clarified the unique characteristics of DM-CpGs in human HCCs. The stepwise progression of alterations in DNA methylation was a common feature of HCV-related hepatocarcinogenesis. (C) 2014 S. Karger AG, BaselEmerging Strategies for the Management of Hepatocellular Carcinoma PrefaceMasatoshi KudoDIGESTIVE DISEASES KARGER 32 (6) 655 - 657 0257-2753 2014 [Refereed][Invited]IPMN診療におけるEUSの有用性. 特集「膵管内乳頭粘液性腫瘍(IPMN)の診療の現況」鎌田 研; 北野雅之; 工藤正俊; 山雄健太郎; 今井 元; 坂本洋城臨床消化器内科 29 1709 - 1716 2014 [Refereed]Alteration of Epigenetic Profile in Human Hepatocellular Carcinoma and Its Clinical ImplicationsNaoshi Nishida; Masatoshi KudoLIVER CANCER KARGER 3 (3-4) 417 - 427 2235-1795 2014 [Refereed] Hepatocellular carcinoma (HCC) is a common cancer worldwide and develops against a background of chronic liver damage. A variety of HCC-related genes are known to be altered by genetic and epigenetic mechanisms. Therefore, information regarding alteration of the genetic and epigenetic profiles in HCC is essential for understanding the biology of this type of tumor. Methylation at CpG sites in gene promoters is known to affect the transcription of the corresponding genes. Abnormal regional hypermethylation is observed in the 5' region of several tumor suppressor genes (TSGs) in HCC, and this hypermethylation may promote carcinogenesis through the transcriptional inactivation of downstream TSGs. The DNA damage induced by oxidation is a trigger of abnormal DNA methylation and inactivation of TSGs through recruitment of the polycomb repressive complex to the promoter sequence. Thus, oxidative stress may be responsible for the emergence of HCC from chronic hepatitis and liver cirrhosis through the epigenetic alteration of TSGs. There have been several attempts to apply epigenetic information to the diagnosis and treatment of HCC. The predictive value of selected methylation events on survival in HCC patients has been reported, and the methylation profile of background liver could be associated with recurrence-free survival of HCC patients who have undergone hepatectomy. Another study detected methylated DNA from HCC cells in serum, and the circulating tumor DNA was regarded as a potential tumor marker. In addition, several trials of HCC therapy have targeted the epigenetic machinery and were based upon comprehensive analyses of DNA methylation of this type of tumor. Here, we present an overview of research regarding DNA methylation status in human HCC and describe the clinical application of epigenetic information to HCC. Copyright (C) 2014 S. Karger AG, BaselBiomarkers and Personalized Sorafenib TherapyM. KudoLIVER CANCER KARGER 3 (3-4) 399 - 404 2235-1795 2014 [Refereed]悪性中下部胆道狭窄に対するステンティング. 特集「悪性胆道狭窄に対する診断・治療の進歩」北野雅之; 今井 元; 工藤正俊臨床消化器内科 29 1231 - 1240 2014 [Refereed]膵腫瘍性病変診断における造影ハーモニックEUS検査の有用性山雄健太郎; 北野雅之; 工藤正俊超音波TECHNO 26 76 - 78 2014 [Refereed]Can Low-dose CT with Iterative Reconstruction Reduce Both the Radiation Dose and the Amount of Iodine Contrast Medium in a Dynamic CT Study of the Liver?Takahashi H; Okada M; Kagawa Y; Hyodo T; Hidaka S; Kudo M; Ishii K; Tomiyama N; Murakami TEur J Radiol. Elsevier 83 (4) 684 - 691 0720-048X 2013/12 [Refereed]Brivanib in Patients With Advanced Hepatocellular Carcinoma Who Were Intolerant to Sorafenib or for Whom Sorafenib Failed: Results From the Randomized Phase III BRISK-PS StudyJosep M. Llovet; Thomas Decaens; Jean-Luc Raoul; Eveline Boucher; Masatoshi Kudo; Charissa Chang; Yoon-Koo Kang; Eric Assenat; Ho-Yeong Lim; Valerie Boige; Philippe Mathurin; Laetitia Fartoux; Deng-Yn Lin; Jordi Bruix; Ronnie T. Poon; Morris Sherman; Jean-Frederic Blanc; Richard S. Finn; Won-Young Tak; Yee Chao; Rana Ezzeddine; David Liu; Ian Walters; Joong-Won ParkJOURNAL OF CLINICAL ONCOLOGY AMER SOC CLINICAL ONCOLOGY 31 (28) 3509 - + 0732-183X 2013/10 Purpose Brivanib is a selective dual inhibitor of vascular endothelial growth factor and fibroblast growth factor receptors implicated in tumorigenesis and angiogenesis in hepatocellular carcinoma (HCC). An unmet medical need persists for patients with HCC whose tumors do not respond to sorafenib or who cannot tolerate it. This multicenter, double-blind, randomized, placebo-controlled trial assessed brivanib in patients with HCC who had been treated with sorafenib. Patients and Methods In all, 395 patients with advanced HCC who progressed on/after or were intolerant to sorafenib were randomly assigned (2:1) to receive brivanib 800 mg orally once per day plus best supportive care (BSC) or placebo plus BSC. The primary end point was overall survival (OS). Secondary end points included time to progression (TTP), objective response rate (ORR), and disease control rate based on modified Response Evaluation Criteria in Solid Tumors (mRECIST) and safety. Results Median OS was 9.4 months for brivanib and 8.2 months for placebo (hazard ratio [HR], 0.89; 95.8% CI, 0.69 to 1.15; P = .3307). Adjusting treatment effect for baseline prognostic factors yielded an OS HR of 0.81 (95% CI, 0.63 to 1.04; P = .1044). Exploratory analyses showed a median time to progression of 4.2 months for brivanib and 2.7 months for placebo (HR, 0.56; 95% CI, 0.42 to 0.76; P < .001), and an mRECIST ORR of 10% for brivanib and 2% for placebo (odds ratio, 5.72). Study discontinuation due to treatment-related adverse events (AEs) occurred in 61 brivanib patients (23%) and nine placebo patients (7%). The most frequent treatment-related grade 3 to 4 AEs for brivanib included hypertension (17%), fatigue (13%), hyponatremia (11%), and decreased appetite (10%). Conclusion In patients with HCC who had been treated with sorafenib, brivanib did not significantly improve OS. The observed benefit in the secondary outcomes of TTP and ORR warrants further investigation.The clinical characteristics of small bowel diseases in the eider patients with obscure GI bleedingChishina Hirokazu; Takayama Masaki; Adachi Teppei; Mine Hiromasa; Nagai Tomoyuki; Nagata Yoshiaki; Kawasaki Masanori; Asakuma Yutaka; Sakurai Toshiharu; Matsui Shigenaga; Kashida Hiroshi; Kudo MasatoshiJOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY WILEY-BLACKWELL 28 533 - 533 0815-9319 2013/10 [Refereed]Role of oxidative stress and epigenetic alteration on chronic hepatitis C-related human hepatocarcinogenesisNaoshi Nishida; Masatoshi Kudo; Tadaaki Arizumi; Masahiro Takita; Satoshi Kitai; Norihisa Yada; Tatsuo Inoue; Satoru Hagiwara; Yasunori Minami; Toshiharu Sakurai; Kazuomi Ueshima; Takeshi Nagasaka; Ajay GoelHEPATOLOGY WILEY-BLACKWELL 58 1065A - 1066A 0270-9139 2013/10 [Refereed]Optimal scan timing of hepatic arterial-phase imaging of hypervascular hepatocellular carcinoma determined by multiphasic fast CT imaging technique.Kagawa Y; Okada M; Yagyu Y; Kumano S; Kanematsu M; Kudo M; Murakami TActa radiologica (Stockholm, Sweden : 1987) 54 (8) 843 - 850 0284-1851 2013/10 [Refereed]Brivanib Versus Sorafenib As First-Line Therapy in Patients With Unresectable, Advanced Hepatocellular Carcinoma: Results From the Randomized Phase III BRISK-FL StudyPhilip J. Johnson; Shukui Qin; Joong-Won Park; Ronnie T. P. Poon; Jean-Luc Raoul; Philip A. Philip; Chih-Hung Hsu; Tsung-Hui Hu; Jeong Heo; Jianming Xu; Ligong Lu; Yee Chao; Eveline Boucher; Kwang-Hyub Han; Seung-Woon Paik; Jorge Robles-Avina; Masatoshi Kudo; Lunan Yan; Abhasnee Sobhonslidsuk; Dmitry Komov; Thomas Decaens; Won-Young Tak; Long-Bin Jeng; David Liu; Rana Ezzeddine; Ian Walters; Ann-Lii ChengJOURNAL OF CLINICAL ONCOLOGY AMER SOC CLINICAL ONCOLOGY 31 (28) 3517 - + 0732-183X 2013/10 [Refereed] Purpose Brivanib is a dual inhibitor of vascular-endothelial growth factor and fibroblast growth factor receptors that are implicated in the pathogenesis of hepatocellular carcinoma (HCC). Our multinational, randomized, double-blind, phase III trial compared brivanib with sorafenib as first-line treatment for HCC. Patients and Methods Advanced HCC patients who had no prior systemic therapy were randomly assigned (ratio, 1:1) to receive sorafenib 400 mg twice daily orally (n = 578) or brivanib 800 mg once daily orally (n = 577). Primary end point was overall survival (OS). Secondary end points included time to progression (TTP), objective response rate (ORR), disease control rate (DCR) based on modified Response Evaluation Criteria in Solid Tumors (mRECIST), and safety. Results The primary end point of OS noninferiority for brivanib versus sorafenib in the per-protocol population (n = 1,150) was not met (hazard ratio [HR], 1.06; 95.8% CI, 0.93 to 1.22), based on the prespecified margin (upper CI limit for HR <= 1.08). Median OS was 9.9 months for sorafenib and 9.5 months for brivanib. TTP, ORR, and DCR were similar between the study arms. Most frequent grade 3/4 adverse events for sorafenib and brivanib were hyponatremia (9% and 23%, respectively), AST elevation (17% and 14%), fatigue (7% and 15%), hand-foot-skin reaction (15% and 2%), and hypertension (5% and 13%). Discontinuation as a result of adverse events was 33% for sorafenib and 43% for brivanib; rates for dose reduction were 50% and 49%, respectively. Conclusion Our study did not meet its primary end point of OS noninferiority for brivanib versus sorafenib. However, both agents had similar antitumor activity, based on secondary efficacy end points. Brivanib had an acceptable safety profile, but was less well-tolerated than sorafenib.Brivanib in Patients With Advanced Hepatocellular Carcinoma Who Were Intolerant to Sorafenib or for Whom Sorafenib Failed: Results From the Randomized Phase III BRISK-PS StudyJosep M. Llovet; Thomas Decaens; Jean-Luc Raoul; Eveline Boucher; Masatoshi Kudo; Charissa Chang; Yoon-Koo Kang; Eric Assenat; Ho-Yeong Lim; Valerie Boige; Philippe Mathurin; Laetitia Fartoux; Deng-Yn Lin; Jordi Bruix; Ronnie T. Poon; Morris Sherman; Jean-Frederic Blanc; Richard S. Finn; Won-Young Tak; Yee Chao; Rana Ezzeddine; David Liu; Ian Walters; Joong-Won ParkJOURNAL OF CLINICAL ONCOLOGY AMER SOC CLINICAL ONCOLOGY 31 (28) 3509 - + 0732-183X 2013/10 [Refereed] Purpose Brivanib is a selective dual inhibitor of vascular endothelial growth factor and fibroblast growth factor receptors implicated in tumorigenesis and angiogenesis in hepatocellular carcinoma (HCC). An unmet medical need persists for patients with HCC whose tumors do not respond to sorafenib or who cannot tolerate it. This multicenter, double-blind, randomized, placebo-controlled trial assessed brivanib in patients with HCC who had been treated with sorafenib. Patients and Methods In all, 395 patients with advanced HCC who progressed on/after or were intolerant to sorafenib were randomly assigned (2:1) to receive brivanib 800 mg orally once per day plus best supportive care (BSC) or placebo plus BSC. The primary end point was overall survival (OS). Secondary end points included time to progression (TTP), objective response rate (ORR), and disease control rate based on modified Response Evaluation Criteria in Solid Tumors (mRECIST) and safety. Results Median OS was 9.4 months for brivanib and 8.2 months for placebo (hazard ratio [HR], 0.89; 95.8% CI, 0.69 to 1.15; P = .3307). Adjusting treatment effect for baseline prognostic factors yielded an OS HR of 0.81 (95% CI, 0.63 to 1.04; P = .1044). Exploratory analyses showed a median time to progression of 4.2 months for brivanib and 2.7 months for placebo (HR, 0.56; 95% CI, 0.42 to 0.76; P < .001), and an mRECIST ORR of 10% for brivanib and 2% for placebo (odds ratio, 5.72). Study discontinuation due to treatment-related adverse events (AEs) occurred in 61 brivanib patients (23%) and nine placebo patients (7%). The most frequent treatment-related grade 3 to 4 AEs for brivanib included hypertension (17%), fatigue (13%), hyponatremia (11%), and decreased appetite (10%). Conclusion In patients with HCC who had been treated with sorafenib, brivanib did not significantly improve OS. The observed benefit in the secondary outcomes of TTP and ORR warrants further investigation.JSUM ultrasound elastography practice guidelines: liverMasatoshi Kudo; Tsuyoshi Shiina; Fuminori Moriyasu; Hiroko Iijima; Ryosuke Tateishi; Norihisa Yada; Kenji Fujimoto; Hiroyasu Morikawa; Masashi Hirooka; Yasukiyo Sumino; Takashi KumadaJOURNAL OF MEDICAL ULTRASONICS SPRINGER JAPAN KK 40 (4) 325 - 357 1346-4523 2013/10 [Refereed] In diffuse liver disease, it is extremely important to make an accurate diagnosis of liver fibrosis prior to determining indications for therapy or predicting treatment outcome and malignant potential. Although liver biopsy has long been the gold standard in the diagnosis of liver fibrosis, it is still an invasive method. In addition, the sampling error is an intrinsic problem of liver biopsy. Non-invasive serological methods for the diagnosis of liver fibrosis can be affected by factors unrelated to the liver. Recently, after the introduction of FibroScan, it became possible to measure liver fibrosis directly and non-invasively by elastography, which has attracted attention as a non-invasive imaging diagnostic tool for liver fibrosis. In addition, real-time tissue elastography is currently being used to conduct clinical trials at many institutions. Moreover, virtual touch quantification enables the observation of liver stiffness at any location by simply observing B-mode images. Furthermore, the recently developed ShearWave elastography visualizes liver stiffness on a color map. Elastography is thought to be useful for all types of diffuse liver diseases. Because of its association with portal hypertension and liver carcinogenesis, elastography is expected to function as a novel prognostic tool for liver disease. Although various elastographic devices have been developed by multiple companies, each device has its own measurement principle, method, and outcome, creating confusion in clinical settings. Therefore, it is extremely important to understand the characteristics of each device in advance. The objective of this guideline, which describes the characteristics of each device based on the latest knowledge, is for all users to be able to make the correct diagnosis of hepatic fibrosis by ultrasound elastography.機能性ディスペプシア 診断と治療の現況を巡って 機能性ディスペプシアに早期慢性膵炎が存在する可能性について門阪 薫平; 北野 雅之; 工藤 正俊日本消化器病学会雑誌 (一財)日本消化器病学会 110 (臨増大会) A771 - A771 0446-6586 2013/09膵癌による閉塞性黄疸に対する乳頭括約筋切開術未施行のカバー付金属ステント留置術の成績千品 寛和; 門阪 薫平; 田中 梨絵; 大本 俊介; 宮田 剛; 鎌田 研; 今井 元; 坂本 洋城; 北野 雅之; 工藤 正俊Gastroenterological Endoscopy (一社)日本消化器内視鏡学会 55 (Suppl.2) 2929 - 2929 0387-1207 2013/09消化器癌に対する分子標的薬 最近の動向 肝細胞癌に対する分子標的治療 現状と問題点工藤 正俊; 上嶋 一臣日本消化器病学会雑誌 (一財)日本消化器病学会 110 (臨増大会) A624 - A624 0446-6586 2013/09Erratum: Comparison of resection and ablation for hepatocellular carcinoma: A cohort study based on a Japanese nationwide survey (Journal of Hepatology (2013) 58 (724-729))Kiyoshi Hasegawa; Norihiro Kokudo; Masatoshi Makuuchi; Namiki Izumi; Takafumi Ichida; Masatoshi Kudo; Yonson Ku; Michiie Sakamoto; Osamu Nakashima; Osamu Matsui; Yutaka MatsuyamaJournal of Hepatology 59 (3) 641  0168-8278 2013/09 [Refereed]A randomised phase II study of TSU-68 in patients with hepatocellular carcinoma treated by transarterial chemoembolisationYoshitaka Inaba; Fumihiko Kanai; Takeshi Aramaki; Takanobu Yamamoto; Toshihiro Tanaka; Koichiro Yamakado; Shuichi Kaneko; Masatoshi Kudo; Kazuho Imanaka; Shinichi Kora; Norifumi Nishida; Nobuyuki Kawai; Hiroshi Seki; Osamu Matsui; Hitoshi Arioka; Yasuaki AraiEUROPEAN JOURNAL OF CANCER ELSEVIER SCI LTD 49 (13) 2832 - 2840 0959-8049 2013/09 [Refereed] Background: TSU-68 is an antitumour drug that acts by inhibiting angiogenesis. We evaluated the efficacy and safety of TSU-68 in combination with transarterial chemoembolisation (TACE) in patients with intermediate-stage hepatocellular carcinoma (HCC). Patients and Methods: In this multicenter, open-label phase II study, we randomised patients with HCC who had been treated with a single session of TACE to receive either 200 mg TSU-68 twice daily or no medication. The primary end-point was progression-free survival (PFS). Results: A total of 103 patients were enrolled. Median PFS was 157.0 days (95% confidence interval [CI], 124.0-230.0 days) in the TSU-68 group and 122.0 days (95% CI, 73.0-170.0 days) in the control group. The hazard ratio was 0.699 (95% CI, 0.450-1.088). Fatigue, elevated aspartate aminotransferase (AST), elevated alkaline phosphatase, oedema and anorexia were more frequent in the TSU-68 group than in the control group. The most frequent grade 3/4 adverse events were AST elevation (46% of patients in the TSU-68 group and 12% of controls) and alanine aminotransferase elevation (26% of patients in the TSU-68 group and 8% of controls). Two deaths, grade 5 hepatic failure and melena were noted in the TSU-68 group. Conclusion: This exploratory study shows a trend towards prolonged PFS with TSU-68 treatment after a single session of TACE, but this observation was not statistically significant. The two deaths were related to the study treatment. These results suggest that further examination of the study design is necessary to determine whether TSU-68 has any clinical benefits when combined with TACE. (C) 2013 Elsevier Ltd. All rights reserved.A randomised phase II study of TSU-68 in patients with hepatocellular carcinoma treated by transarterial chemoembolisationYoshitaka Inaba; Fumihiko Kanai; Takeshi Aramaki; Takanobu Yamamoto; Toshihiro Tanaka; Koichiro Yamakado; Shuichi Kaneko; Masatoshi Kudo; Kazuho Imanaka; Shinichi Kora; Norifumi Nishida; Nobuyuki Kawai; Hiroshi Seki; Osamu Matsui; Hitoshi Arioka; Yasuaki AraiEUROPEAN JOURNAL OF CANCER ELSEVIER SCI LTD 49 (13) 2832 - 2840 0959-8049 2013/09 [Refereed] Background: TSU-68 is an antitumour drug that acts by inhibiting angiogenesis. We evaluated the efficacy and safety of TSU-68 in combination with transarterial chemoembolisation (TACE) in patients with intermediate-stage hepatocellular carcinoma (HCC). Patients and Methods: In this multicenter, open-label phase II study, we randomised patients with HCC who had been treated with a single session of TACE to receive either 200 mg TSU-68 twice daily or no medication. The primary end-point was progression-free survival (PFS). Results: A total of 103 patients were enrolled. Median PFS was 157.0 days (95% confidence interval [CI], 124.0-230.0 days) in the TSU-68 group and 122.0 days (95% CI, 73.0-170.0 days) in the control group. The hazard ratio was 0.699 (95% CI, 0.450-1.088). Fatigue, elevated aspartate aminotransferase (AST), elevated alkaline phosphatase, oedema and anorexia were more frequent in the TSU-68 group than in the control group. The most frequent grade 3/4 adverse events were AST elevation (46% of patients in the TSU-68 group and 12% of controls) and alanine aminotransferase elevation (26% of patients in the TSU-68 group and 8% of controls). Two deaths, grade 5 hepatic failure and melena were noted in the TSU-68 group. Conclusion: This exploratory study shows a trend towards prolonged PFS with TSU-68 treatment after a single session of TACE, but this observation was not statistically significant. The two deaths were related to the study treatment. These results suggest that further examination of the study design is necessary to determine whether TSU-68 has any clinical benefits when combined with TACE. (C) 2013 Elsevier Ltd. All rights reserved.ERCP不能な悪性胆道狭窄における急性胆嚢炎および胆管炎例に対するEUS下ドレナージ術の有用性について門阪 薫平; 北野 雅之; 工藤 正俊胆道 (一社)日本胆道学会 27 (3) 519 - 519 0914-0077 2013/08胆管癌として切除された良性胆管病変の4例大本 俊介; 北野 雅之; 工藤 正俊; 中居 卓也; 竹山 宜典胆道 日本胆道学会 27 (3) 600 - 600 0914-0077 2013/08非EST症例に対する経カテーテル胆道内視鏡(Trans-catheter endoscopy;TCE)のコツとピットフォール山雄 健太郎; 坂本 洋城; 北野 雅之; 工藤 正俊胆道 日本胆道学会 27 (3) 443 - 443 0914-0077 2013/08Recurrent hepatocellular carcinomaKazuomi Ueshima; Masatoshi KudoJapanese Journal of Cancer and Chemotherapy 40 (8) 995 - 997 0385-0684 2013/08 [Refereed] The patients with chronic viral hepatitis or cirrhosis are a high-risk group for hepatocellular carcinoma. Thus, those who should be screened for detecting HCC can be specified easily. Early detection of HCC leads to performing the curative therapy. However, HCC is easy to recur because of the underlying viral hepatitis and intrahepatic metastasis. After radical therapy, strict surveillance should be performed and if HCC recurs, strategy of treatment should follow the treatment algorithm of Japanese Clinical Practice Guidelines for hepatocellular carcinoma.Diagnostic value of endoscopic ultrasound-guided directional eFLOW in solid pancreatic lesionsKunal Das; Masatoshi Kudo; Masayuki Kitano; Hiroki Sakamoto; Takamitsu Komaki; Tadayuki Takagi; Kenji YamaoJOURNAL OF MEDICAL ULTRASONICS SPRINGER JAPAN KK 40 (3) 211 - 218 1346-4523 2013/07 [Refereed] Ultrasound using microbubble-based contrast agents is useful for vascular imaging. Directional eFLOW (D-eFLOW) is a novel technology for vascular assessment that provides high spatial and temporal resolution. The purpose of this study was to investigate the utility of endoscopic ultrasound (EUS)-guided D-eFlow before and after administration of an ultrasound contrast agent (USCA) for assessing the vascularity of solid pancreatic lesions. D-eFlow was compared to power Doppler EUS (PD-EUS) or color Doppler EUS (CD-EUS) before and after USCA injection. We also evaluated the Visual Vascular Assessment (ViVA) scale for the estimation of vascularity and investigated its reliability using the interclass correlation coefficient (ICC). From January 2007 to March 2007, 35 patients (mean age, 64.5 years old; age range, 28-81 years) underwent EUS followed by D-eFLOW EUS, PD-EUS, and CD-EUS before and after administration of USCA. The pancreatic parenchymal ViVA score, pancreatic vascular pattern, and ICC were evaluated for all lesions. Concerning the sensitivity for detection of the hypovascular pattern in pancreatic adenocarcinoma, D-eFLOW (before and after USCA) had similar sensitivity to PD-EUS (before and after USCA) and CD-EUS (before and after USCA). D-eFLOW after contrast showed the highest accuracy (82.3 %) and negative predictive value (53.8 %) among all the modalities investigated. There was a good correlation among the ViVA scores for D-eFLOW before contrast, those for D-eFLOW EUS, and those for PD-EUS and CD-EUS. The reliability of the ViVA scale was excellent with an ICC of 0.81. In conclusion, D-eFLOW EUS is a sensitive, reliable, and highly accurate method of assessment of pancreatic vascularity. D-eFLOW EUS with contrast was more sensitive than PD-EUS and CD-EUS for assessment of pancreatic vascularity.【薬の特徴から副作用がなぜ起こるかわかる!ケアポイントが整理できる!!消化器がんの化学療法のキードラッグ事典】ソラフェニブ 商品名:ネクサバール上嶋 一臣; 工藤 正俊消化器外科Nursing (株)メディカ出版 18 (7) 603 - 611 1341-7819 2013/07ミニオーラル105:肝 その他2 P-105-2 本邦における多発肝嚢胞症治療の実態小川光一; 福永 潔; 竹内朋代; 川岸直樹; 乳原善文; 工藤正俊; 大河内,信弘第68回日本消化外科学会総会抄録集 2013/07Senile systemic amyloidosis localized to the stomachShigenaga Matsui; Hiroshi Kashida; Masatoshi KudoDIGESTIVE ENDOSCOPY WILEY-BLACKWELL 25 (4) 468 - 469 0915-5635 2013/07 [Refereed]膵内外分泌相関の新しい展開 早期慢性膵炎EUS画像所見と糖尿病の関連について門阪 薫平; 北野 雅之; 工藤 正俊膵臓 (一社)日本膵臓学会 28 (3) 346 - 346 0913-0071 2013/06分枝型IPMNの診療 内科vs外科vs病理 IPMN経過観察におけるEUSの有用性 造影EUSによる診断も含めて鎌田 研; 北野 雅之; 工藤 正俊; 大本 俊介; 門阪 薫平; 今井 元; 坂本 洋城; 竹山 宜典膵臓 (一社)日本膵臓学会 28 (3) 322 - 322 0913-0071 2013/06Erratum: Estimation of liver function using T2* mapping on gadolinium ethoxybenzyl diethylenetriamine pentaacetic acid enhanced magnetic resonance imaging (European Journal of Radiology (2012) 81:7 (1460-1464))Takashi Katsube; Masahiro Okada; Seishi Kumano; Izumi Imaoka; Yuki Kagawa; Masatoshi Hori; Kazunari Ishii; Noboru Tanigawa; Yasuharu Imai; Masatoshi Kudo; Takamichi MurakamiEuropean Journal of Radiology 82 (6) 1039  0720-048X 2013/06 [Refereed]Impact of peginterferon alpha-2b and entecavir hydrate combination therapy on persistent viral suppression in patients with chronic hepatitis BSatoru Hagiwara; Masatoshi Kudo; Yukio Osaki; Hiroo Matsuo; Tadashi Inuzuka; Akihiro Matsumoto; Eiji Tanaka; Toshiharu Sakurai; Kazuomi Ueshima; Tatsuo Inoue; Norihisa Yada; Naoshi NishidaJournal of Medical Virology 85 (6) 987 - 995 0146-6615 2013/06 [Refereed] The ideal approach to treat chronic hepatitis B remains controversial. This pilot study aimed to evaluate the effectiveness of peginterferon (PEG-IFN) α-2b and entecavir hydrate (ETV) as a combination therapy for patients with chronic hepatitis B, particularly in the context of virological response and the reduction of intrahepatic covalently closed circular DNA (cccDNA). A total of 17 patients with hepatitis B virus (HBV) genotype C were enrolled in this study. All subjects were treated with this combination therapy for 48 weeks and observed for an additional 24 weeks. All patients underwent liver biopsy before and after the therapy period. Changes in cccDNA levels and liver histology were monitored between biopsies. Among the 11 patients who exhibited pre-therapy hepatitis B e antigen (HBeAg), 8 (73%) showed evidence of HBeAg seroconversion by the end of the follow-up period. Serum HBV DNA levels decreased by 5.2 and 3.3log copies/ml (mean) by the end of the therapy and follow-up periods, respectively. In addition, intrahepatic cccDNA decreased significantly to 1.4logcopies/μg (mean) by the end of the therapy period. Among the 11 patients who did not experience viral relapse, only 2 (18%) exhibited high levels of cccDNA (> 4.5logcopies/μg) by the end of the treatment period. In contrast, all relapsed subjects exhibited significantly higher levels of cccDNA than subjects who did not relapse (P=0.027). The combination regimen is a promising approach to treat chronic hepatitis B and may achieve significant reduction in serum HBV DNA and intrahepatic cccDNA. © 2013 Wiley Periodicals, Inc.Noninvasive Assessment of Liver Fibrosis by Measurement of Lf Index in Patients With Chronic Viral HepatitisNorihisa Yada; Satoru Hagiwara; Tadaaki Arizumi; Masahiro Takita; Satoshi Kitai; Tatsuo Inoue; Yasunori Minami; Kazuomi Ueshima; Naoshi Nishida; Masatoshi KudoGASTROENTEROLOGY W B SAUNDERS CO-ELSEVIER INC 144 (5) S1041 - S1041 0016-5085 2013/05 [Refereed] 0Heat Shock Protein 27 Expression Is Inversely Correlated With Intraepithelial Neoplasia and Positively Correlated With Poor Differentiation of Gastric CancerYoshiaki Nagata; Toshiharu Sakurai; Masaki Takayama; Tomoyuki Nagai; Masanori Kawasaki; Yutaka Asakuma; Satoru Hagiwara; Naoshi Nishida; Shigenaga Matsui; Hiroshi Kashida; Masatoshi KudoGASTROENTEROLOGY W B SAUNDERS CO-ELSEVIER INC 144 (5) S883 - S883 0016-5085 2013/05 [Refereed] 0生活習慣病と内視鏡 早期慢性膵炎と糖尿病の関連について門阪 薫平; 北野 雅之; 工藤 正俊Gastroenterological Endoscopy (一社)日本消化器内視鏡学会 55 (Suppl.1) 951 - 951 0387-1207 2013/04慢性膵炎に対する内視鏡治療の現状 当院における膵仮性嚢胞に対するTherapeuticEUSの工夫と成績大本 俊介; 工藤 正俊; 北野 雅之Gastroenterological Endoscopy (一社)日本消化器内視鏡学会 55 (Suppl.1) 946 - 946 0387-1207 2013/04膵腫瘍の診断に最も有用な画像診断法は? 画像診断の現状とピットフォール 膵疾患に対する造影超音波検査今井 元; 北野 雅之; 大本 俊介; 門阪 薫平; 宮田 剛; 鎌田 研; 坂本 洋城; 工藤 正俊超音波医学 (公社)日本超音波医学会 40 (Suppl.) S291 - S291 1346-1176 2013/04TACE施行回数からみたソラフェニブ投与時におけるTACE不応の判断上嶋 一臣; 有住 忠晃; 工藤 正俊肝臓 (一社)日本肝臓学会 54 (Suppl.1) A286 - A286 0451-4203 2013/04Recent advances in EUS-guided biliary drainageMasayuki Kitano; Masatoshi KudoJournal of Japanese Society of Gastroenterology 110 (4) 557 - 567 0446-6586 2013/04 [Refereed]超音波内視鏡下胆嚢ドレナージ術の有用性今井 元; 北野 雅之; 工藤 正俊; 門坂 薫平; 大本 俊介; 鎌田 研; 宮田 剛; 坂本 洋城日本消化器病学会雑誌 (一財)日本消化器病学会 110 (臨増総会) A208 - A208 0446-6586 2013/02Guidelines and Good Clinical Practice Recommendations for Contrast Enhanced Ultrasound (CEUS) in the Liver - Update 2012 A WFUMB-EFSUMB Initiative in Cooperation With Representatives of AFSUMB, AIUM, ASUM, FLAUS and ICUSM. Claudon; C. F. Dietrich; B. I. Choi; D. O. Cosgrove; M. Kudo; C. P. Nolsoe; F. Piscaglia; S. R. Wilson; R. G. Barr; M. C. Chammas; N. G. Chaubal; M. -H. Chen; D. A. Clevert; J. M. Correas; H. Ding; F. Forsberg; J. B. Fowlkes; R. N. Gibson; B. B. Goldberg; N. Lassau; E. L. S. Leen; R. F. Mattrey; F. Moriyasu; L. Solbiati; H. -P. Weskott; H. -X. XuULTRASCHALL IN DER MEDIZIN GEORG THIEME VERLAG KG 34 (1) 11 - 29 0172-4614 2013/02 [Refereed] Initially, a set of guidelines for the use of ultrasound contrast agents was published in 2004 dealing only with liver applications. A second edition of the guidelines in 2008 reflected changes in the available contrast agents and updated the guidelines for the liver, as well as implementing some non-liver applications. Time has moved on, and the need for international guidelines on the use of CEUS in the liver has become apparent. The present document describes the third iteration of recommendations for the hepatic use of contrast enhanced ultrasound (CEUS) using contrast specific imaging techniques. This joint WFUMB-EFSUMB initiative has implicated experts from major leading ultrasound societies worldwide. These liver CEUS guidelines are simultaneously published in the official journals of both organizing federations (i.e., Ultrasound in Medicine and Biology for WFUMB and Ultraschall in der Medizin/European Journal of Ultrasound for EFSUMB). These guidelines and recommendations provide general advice on the use of all currently clinically available ultrasound contrast agents (UCA). They are intended to create standard protocols for the use and administration of UCA in liver applications on an international basis and improve the management of patients worldwide.GUIDELINES AND GOOD CLINICAL PRACTICE RECOMMENDATIONS FOR CONTRAST ENHANCED ULTRASOUND (CEUS) IN THE LIVER - UPDATE 2012 A WFUMB-EFSUMB INITIATIVE IN COOPERATION WITH REPRESENTATIVES OF AFSUMB, AIUM, ASUM, FLAUS AND ICUSMichel Claudon; Christoph F. Dietrich; Byung Ihn Choi; David O. Cosgrove; Masatoshi Kudo; Christian P. Nolsoe; Fabio Piscaglia; Stephanie R. Wilson; Richard G. Barr; Maria C. Chammas; Nitin G. Chaubal; Min-Hua Chen; Dirk Andre Clevert; Jean Michel Correas; Hong Ding; Flemming Forsberg; J. Brian Fowlkes; Robert N. Gibson; Barry B. Goldberg; Nathalie Lassau; Edward L. S. Leen; Robert F. Mattrey; Fuminori Moriyasu; Luigi Solbiati; Hans-Peter Weskott; Hui-Xiong XuULTRASOUND IN MEDICINE AND BIOLOGY ELSEVIER SCIENCE INC 39 (2) 187 - 210 0301-5629 2013/02 [Refereed] Initially, a set of guidelines for the use of ultrasound contrast agents was published in 2004 dealing only with liver applications. A second edition of the guidelines in 2008 reflected changes in the available contrast agents and updated the guidelines for the liver, as well as implementing some non-liver applications. Time has moved on, and the need for international guidelines on the use of CEUS in the liver has become apparent. The present document describes the third iteration of recommendations for the hepatic use of contrast enhanced ultrasound (CEUS) using contrast specific imaging techniques. This joint WFUMB-EFSUMB initiative has implicated experts from major leading ultrasound societies worldwide. These liver CEUS guidelines are simultaneously published in the official journals of both organizing federations (i.e., Ultrasound in Medicine and Biology for WFUMB and Ultraschall in der Medizin/European Journal of Ultrasound for EFSUMB). These guidelines and recommendations provide general advice on the use of all currently clinically available ultrasound contrast agents (UCA). They are intended to create standard protocols for the use and administration of UCA in liver applications on an international basis and improve the management of patients worldwide. (E-mail: [email protected]) (C) 2013 World Federation for Ultrasound in Medicine & Biology.Hypovascular Nodules in Patients with Chronic Liver Disease: Risk Factors for Development of Hypervascular Hepatocellular CarcinomaTomoko Hyodo; Takamichi Murakami; Yasuharu Imai; Masahiro Okada; Masatoshi Hori; Yuki Kagawa; Sachiyo Kogita; Seishi Kumano; Masatoshi Kudo; Teruhito MochizukiRADIOLOGY RADIOLOGICAL SOC NORTH AMERICA 266 (2) 480 - 490 0033-8419 2013/02 [Refereed] Purpose: To identify patient characteristics and magnetic resonance (MR) imaging findings associated with subsequent hypervascularization in hypovascular nodules that show hypointensity on hepatobiliary phase gadoxetic acid-enhanced MR images in patients with chronic liver diseases. Materials and Methods: Institutional review board approval was obtained, and informed consent was waived. At multiple follow-up gadoxetic acid-enhanced MR imaging examinations of 68 patients, 160 hypovascular nodules were retrospectively reviewed. A Cox regression model for hypervascularization was developed to explore the association of baseline characteristics, including patient factors (Child-Pugh classification, etiology of liver disease, history of local therapy for hepatocellular carcinoma [HCC], and coexistence of hypervascular HCC) and MR imaging findings (fat content, signal intensity on T2-weighted images, and nodule size). In addition, the growth rate was calculated as the reciprocal of tumor volume doubling time to investigate its relationship with subsequent hypervascularization by using receiver operating characteristic and Kaplan-Meier analyses. Results: The prevalence of subsequent hypervascularization was 31% (50 of 160 nodules). Independent Cox multivariable predictors of increased risk of hypervascularization were hyperintensity on T2-weighted images (hazard ratio [HR] = 8.7; 95% confidence interval [CI]: 3.6, 20.8), previous local therapy for hypervascular HCC (HR = 5.0; 95% CI: 1.8, 13.6), Child-Pugh B cirrhosis (HR = 3.6; 95% CI: 1.4, 9.5) and coexistence of hypervascular HCC (HR = 2.0; 95% CI: 1.0, 3.8). The mean growth rate was significantly higher in nodules that showed subsequent hypervascularization than in those without hypervascularization. Kaplan-Meier analysis based on the receiver operating characteristic cutoff level (1.8 x 10(-3)/day [tumor volume doubling time, 542 days]) showed that nodules with a higher growth rate had a significantly higher incidence of hypervascularization (P = 5.2 x 10(-8), log-rank test). Conclusion: Hyperintensity on T2-weighted images is an independent and strong risk factor at baseline for subsequent hypervascularization in hypovascular nodules in patients with chronic liver disease. Tumor volume doubling time of less than 542 days was associated with a high rate of subsequent hypervascularization. (C)RSNA, 2013Unique association between global DNA hypomethylation and hromosomal alterations in human hepatocellular carcinomaNishida N; Kudo M; Nishimura T; Arizumi T; Takita M; Kitai S; Yada N; Hagiwara S; Inoue T; Minami Y; Ueshima K; Sakurai T; Yokomichi N; Nagasaka T; Goel APlos One 8 e72312  2013 [Refereed]消化器領域の超音波最新技術と臨床への展開 造影ハーモニックEUS(CH-EUS)を用いた腹部リンパ節の良悪性診断の試み大本 俊介; 坂本 洋城; 宮田 剛; 北野 雅之; 工藤 正俊超音波医学 (公社)日本超音波医学会 40 (1) 54 - 55 1346-1176 2013/01Alpha-fetoprotein-L3: Useful or Useless for Hepatocellular Carcinoma?M. KudoLIVER CANCER KARGER 2 (3-4) 151 - 152 2235-1795 2013 [Refereed]Real-time high-resolution vascular ultrasound using frequency domain interferometry with the ROI-division process.Taki H; Sakamoto T; Taki K; Yamakawa M; Shiina T; Kudo M; Sato TConference proceedings : ... Annual International Conference of the IEEE Engineering in Medicine and Biology Society. IEEE Engineering in Medicine and Biology Society. Annual Conference 2013 1398 - 1401 1557-170X 2013 [Refereed] We have proposed a high-range-resolution ultrasound imaging method for human carotid artery using an adaptive beamforming technique based on frequency domain interferometry (FDI). The method assumes that the received signal consists of multiple echoes of targets and noise, where the waveform of each echo is similar to that of the reference signal. In this study, we examine the dependence of the echo waveform on the target depth, and investigate the proper measurement-range for the FDI imaging method using a reference signal. Furthermore, we propose a ROI-division process, where each sub-ROI has a proper measurement-range for the application of the FDI imaging method. Simulation and experimental results show the efficiency of the ROI-division process in improving the image quality of human carotid artery acquired using the FDI imaging method. We believe that the modified FDI imaging method with the ROI-division process has the potential to facilitate significant progress in the detection of vessel stenosis and in the assessment of cardiovascular disease risk.p38 alpha Inhibits Liver Fibrogenesis and Consequent Hepatocarcinogenesis by Curtailing Accumulation of Reactive Oxygen SpeciesToshiharu Sakurai; Masatoshi Kudo; Atsushi Umemura; Guobin He; Ahmed M. Elsharkawy; Ekihiro Seki; Michael KarinCANCER RESEARCH AMER ASSOC CANCER RESEARCH 73 (1) 215 - 224 0008-5472 2013/01 [Refereed] Most hepatocellular carcinomas (HCC) develop in the context of severe liver fibrosis and cirrhosis caused by chronic liver inflammation, which also results in accumulation of reactive oxygen species (ROS). In this study, we examined whether the stress-activated protein kinase p38 alpha (Mapk14) controls ROS metabolism and development of fibrosis and cancer in mice given thioacetamide to induce chronic liver injury. Liver-specific p38 alpha ablation was found to enhance ROS accumulation, which appears to be exerted through the reduced expression of antioxidant protein HSP25 (Hspb1), a mouse homolog of HSP27. Its reexpression in p38 alpha-deficient liver prevents ROS accumulation and thioacetamide-induced fibrosis. p38 alpha deficiency increased expression of SOX2, a marker for cancer stem cells and the liver oncoproteins c-Jun (Jun) and Gankyrin (Psmd10) and led to enhanced thioacetamide-induced hepatocarcinogenesis. The upregulation of SOX2 and c-Jun was prevented by administration of the antioxidant butylated hydroxyanisole. Intriguingly, the risk of human HCC recurrence is positively correlated with ROS accumulation in liver. Thus, p38 alpha and its target HSP25/HSP27 appear to play a conserved and critical hepatoprotective function by curtailing ROS accumulation in liver parenchymal cells engaged in oxidative metabolism of exogenous chemicals. Augmented oxidative stress of liver parenchymal cells may explain the close relationship between liver fibrosis and hepatocarcinogenesis. Cancer Res; 73(1); 215-24. (C) 2012 AACR.Unique association between global DNA hypomethylation and chromosomal alterations in human hepatocellular carcinoma.Nishida N; Kudo M; Nishimura T; Arizumi T; Takita M; Kitai S; Yada N; Hagiwara S; Inoue T; Minami Y; Ueshima K; Sakurai T; Yokomichi N; Nagasaka T; Goel APloS one 8 (9) e72312  2013 [Refereed] Global DNA hypomethylation is a characteristic feature of cancer cells that closely associates with chromosomal instability (CIN). However, the association between these characteristics during hepatocarcinogenesis remains unclear. Herein, we determined the relationship between hypomethylation and CIN in human hepatocellular carcinoma (HCC) by analyzing 179 HCCs, 178 matched non-tumor livers and 23 normal liver tissues. Hypomethylation at three different repetitive DNA (rDNA) sequences and hypermethylation of 12 CpG loci, including 11 tumor suppressor gene (TSG) promoters, were quantified using MethyLight or combined bisulfite restriction analysis. Fractional allelic loss (FAL) was used as a marker for CIN, calculated by analyzing 400 microsatellite markers. Gains and losses at each chromosome were also determined using semi-quantitative microsatellite analysis. The associations between rDNA hypomethylation and FAL, as well as between TSG hypermethylation and FAL were investigated. Significantly more hypomethylation was observed in HCC tissues than in normal liver samples. Progression of hypomethylation during carcinogenesis was more prominent in hepatitis C virus (HCV)-negative cases, which was in contrast to our previous reports of significantly increased TSG methylation levels in HCV-positive tumors. Absence of liver cirrhosis and higher FAL scores were identified as independent contributors to significant hypomethylation of rDNA in HCC. Among the chromosomal alterations frequently observed in HCC, loss of 8p, which was unique in the earliest stages of hepatocarcinogenesis, was significantly associated with hypomethylation of rDNA by multivariable analysis (p=0.0153). rDNA hypomethylation was also associated with a high FAL score regardless of tumor differentiation (p=0.0011, well-differentiated; p=0.0089, moderately/poorly-differentiated HCCs). We conclude that DNA hypomethylation is an important cause of CIN in the earliest step of HCC, especially in a background of non-cirrhotic liver.Chronic Liver Diseases and Hepatocellular Carcinoma: An Update for 2013 PrefaceMasatoshi KudoDIGESTIVE DISEASES KARGER 31 (5-6) 405 - 407 0257-2753 2013 [Refereed]Outcome of Double-Filtration Plasmapheresis plus Interferon Treatment in Nonresponders to Pegylated Interferon plus Ribavirin Combination TherapyKayo Sugimoto; Soo Ryang Kim; Ahmed El-Shamy; Susumu Imoto; Haruma Fujioka; Ke Ih Kim; Yasuhito Tanaka; Yoshihiko Yano; Soo Ki Kim; Yutaka Hasegawa; Aya Fujinami; Mitsuhiro Ohta; Takashi Hatae; Hak Hotta; Yoshitake Hayashi; Masatoshi KudoDIGESTIVE DISEASES KARGER 31 (5-6) 434 - 439 0257-2753 2013 [Refereed] Objectives: We assessed the outcome of double-filtration plasmapheresis (DFPP) combined with pegylated interferon (PEG-IFN) and ribavirin (RBV) therapy in patients infected with hepatitis C virus (HCV)-1b whose HCV had not disappeared during PEG-IFN/RBV combination therapy, or who had relapsed after the end of the therapy. Additionally, we investigated factors predictive of sustained virological response (SVR), including host and viral genetic factors, to DFPP plus IFN/RBV therapy. Methods: A total of 40 patients infected with HCV-1b whose HCV virus had not been eradicated by previous PEG-IFN/RBV therapy were enrolled for treatment by DFPP plus IFN/RBV. Rapid virological response (RVR) and SVR were assessed, and pretreatment factors associated with SVR the interleukin (IL)28B gene, the IFN/RBV resistance-determining region (IRRDR) and the IFN sensitivity-determining region (ISDR) were analyzed. Results: Of the 40 patients, 9 (23%) achieved RVR and 10 (25%) achieved SVR. The significant factors associated with SVR were IL28B major and RVR, as assessed by multivariate analysis (p = 0.0182, p = 0.0005). Conclusion: Patients whose HCV is not eradicated by previous PEG-IFN/RBV would be good candidates for combined DFPP and IFN/RBV retreatment provided they demonstrate IL28B major and have achieved RVR. (C) 2013 S. Karger AG, BaselHypovascular hepatic nodules showing hypointense on the hepatobiliary-phase image of Gd-EOB-DTPA-enhanced MRI to develop a hypervascular hepatocellular carcinoma: A nationwide retrospective study on their natural course and risk factorsTatsuo Inoue; Tomoko Hyodo; Takamichi Murakami; Yukihisa Takayama; Akihiro Nishie; Atsushi Higaki; Keiko Korenaga; Azusa Sakamoto; Yukio Osaki; Hiroshi Aikata; Kazuaki Chayama; Takeshi Suda; Toru Takano; Kennichi Miyoshi; Masahiko Koda; Kazushi Numata; Hironori Tanaka; Hiroko Iijima; Hironori Ochi; Masashi Hirooka; Yasuharu Imai; Masatoshi KudoDigestive Diseases S. Karger AG 31 (5-6) 472 - 479 1421-9875 2013 [Refereed] Objective: We aimed to investigate the natural outcome of nonhypervascular lesions detected in the hepatobiliary phase of gadolinium ethoxybenzyl diethylenetriamine pentaacetic acid (Gd-EOB-DTPA)-enhanced MRI by performing a longitudinal study retrospectively enrolled in a nationwide manner. Methods: Between February 2008 and March 2011, 224 patients with 504 nodules that were diagnosed as nonhypervascular by imaging were recruited from institutions that participated in the present study. We examined the natural outcome of nonhypervascular lesions and evaluated the risk factors. Results: Of the 504 nodules, 173 (34.3%) showed hypervascular transformation. The overall cumulative incidence of hypervascular transformation was 14.9% at 12 months and 45.8% at 24 months. Multivariate analysis using the Cox regression model revealed previous treatment history for hepatocellular carcinoma (HCC relative risk = 1.498 p = 0.036, 95% CI 1.03-2.19) and hyperintensity on T2-weighted images (relative risk = 1.724 p = 0.015, 95% CI 1.11-2.67) were identified as independent factors for hypervascular transformation. Conclusions: Patients who have a previous treatment history for HCC and with hypointense nodules showing hyperintensity on T2-weighted images need careful follow-up because of the high incidence of hypervascular transformation.Radiofrequency Ablation for Hepatic Malignancies: Is Needle Tract Cauterization Necessary for Preventing Iatrogenic Bleeding?Yasunori Minanni; Sosuke Hayaishi; Masatoshi KudoDIGESTIVE DISEASES KARGER 31 (5-6) 480 - 484 0257-2753 2013 [Refereed] Objective: To evaluate whether iatrogenic hemorrhage can be prevented by intrahepatic tract ablation following radiofrequency ablation (RFA) therapy for hepatic malignancies. Methods: A retrospective cohort study analyzing a prospective database in a single institution was conducted. The incidence of postprocedural complications was compared in two groups: one with cauterization of the needle tracts after RFA and the other without. Results: The complication rates of intraperitoneal hemorrhage were 1.05% (4/380) and 0.92% (6/652) in the nonablation group and the ablation group, respectively (p = 0.90). All of these 10 patients with iatrogenic bleeding were classified as Child-Pugh grade A. Among the 15 hemodialysis patients in this study, hemorrhage was seen in 2 (13.3%), compared with 8 (0.79%) of the nonhemodialysis patients (p = 0.0002). There were no statistically significant differences in the incidence of other complications including pleural effusion, serous ascites, pneumothorax, hemothorax, hepatic infarction, bile duct injury and pericardial effusion between the two groups. Gastrointestinal perforation, peritonitis or tumor seeding were not observed. Conclusion: Our study found a high incidence of bleeding after RFA among hemodialysis patients. Irrespective of tract ablation being after RFA, iatrogenic hemorrhage appeared to be equivalent in this population. (C) 2013 S. Karger AG, BaselUsefulness of the Extracted-Overlay Function in CT/MR-Ultrasonography Fusion Imaging for Radiofrequency Ablation of Hepatocellular CarcinomaYuki Makino; Yasuharu Imai; Takumi Igura; Sachiyo Kogita; Yoshiyuki Sawai; Kazuto Fukuda; Masatoshi Hori; Masatoshi Kudo; Takamichi MurakamiDIGESTIVE DISEASES KARGER 31 (5-6) 485 - 489 0257-2753 2013 [Refereed] Objectives: We developed a novel technique of the extracted-overlay function in CT/MR-ultrasonography (US) fusion imaging for radiofrequency ablation (RFA), in which only a tumor extracted from CT/MR images with a virtual ablative margin of arbitrary thickness is overlaid on US. The usefulness of this function is investigated in this preliminary report. Methods: The volume data of the extracted tumor with a virtual ablative margin were created on an image-processing workstation, and transported into a US unit equipped with a CT/MR-US fusion imaging system. After the positional registration of US and transported images, the extracted tumor with an ablative margin could be overlaid on US. In RFA, using this function, an electrode was inserted targeting the overlaid tumor with an ablative safety margin of 5 mm on US, and the treatment effect was evaluated by dynamic CT. Treatment results of 23 consecutive hepatocellular carcinomas (HCCs) that underwent RFA using this function were retrospectively analyzed. Results: Complete tumor ablation was achieved in 22 (95.7%) and 1 (4.3%) HCCs in 1 and 2 treatment sessions, respectively. Conclusions: Due to the visualization of an extracted tumor with an ablative safety margin on a US image, even during and after ablation, this function is useful for treatment planning and guidance of RFA. (C) 2013 S. Karger AG, BaselMolecular Link between Liver Fibrosis and Hepatocellular CarcinomaToshiharu Sakurai; Masatoshi KudoLIVER CANCER KARGER 2 (3-4) 365 - 366 2235-1795 2013 [Refereed]ソラフェニブ 商品名: ネクサバール®上嶋一臣; 工藤正俊消化器外科ナーシング 18 603 - 611 2013 [Refereed]SILIUS第I相試験とその解釈上嶋一臣; 工藤正俊The Liver Cancer Journal 5 24 - 31 2013 [Refereed]再発肝細胞癌上嶋一臣; 工藤正俊癌と化学療法 40 995 - 997 2013 [Refereed]肝癌診療のEast/Westでの相違とグローバルにおけるコンセンサスの方向性. 特集「肝癌診療のこれまでと今後-アジアをリードする日本の役割」工藤正俊クリニシアン 613 1009 - 1014 2013 [Refereed]自己免疫性肝炎とIgG4関連病態, 特集「IgG4と肝胆膵」矢田典久; 工藤正俊; 鄭 浩柄; 渡邉智裕肝胆膵 67 381 - 387 2013 [Refereed]ADL不良の急性胆嚢炎および胆管炎に対するEUS下ドレナージ術. 特集II「後期高齢者に対する胆石症の治療戦略」門阪薫平; 北野雅之; 大本俊介; 鎌田 研; 宮田 剛; 今井 元; 坂本洋城; 工藤正俊消化器内科 56 663 - 666 2013 [Refereed]【肝細胞癌のすべて2012】治療法の進歩 現在開発中の分子標的薬 Everolimus(RAD001)上嶋 一臣; 工藤 正俊肝・胆・膵 (株)アークメディア 65 (6) 1302 - 1306 0389-4991 2012/12Comparison of different proton pump inhibitors (PPI) in helicobacter pylori eradicationTeppei Adachi; Shigenaga Matsui; Masaki Takayama; Masanori Kawasaki; Yutaka Yutaka; Toshiharu Sakurai; Hiroshi Kashida; Masatoshi KudoJOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY WILEY-BLACKWELL 27 425 - 426 0815-9319 2012/12 [Refereed]A prospective randomized controlled study of a rebamipid monotherapy in the treatment of endoscopic submucosal dissection (ESD)-induced ulcersMasaki Takayama; Shigenaga Matsui; Masanori Kawasaki; Yutaka Asakuma; Hiroshi Kashida; Masatoshi KudoJOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY WILEY-BLACKWELL 27 419 - 419 0815-9319 2012/12 [Refereed]Albumin levels can be a predictive factor for the short-term complications after percutaneous endoscopic gastrostomy in retrospective studyTomoyuki Nagai; Teppei Adachi; Masaki Takayama; Hiromasa Mine; Yoshiaki Nagata; Masanori Kawasaki; Yutaka Asakuma; Toshiharu Sakurai; Shigenaga Matsui; Mikio Shiomi; Hiroshi Kashida; Masatoshi KudoJOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY WILEY-BLACKWELL 27 409 - 409 0815-9319 2012/12 [Refereed]Endoscopic submucosal dissection for the colorectum: Usefulness and feasibilityHiroshi Kashida; Toshiharu Sakurai; Yutaka Asakuma; Masanori Kawasaki; Yoshiaki Nagata; Tomoyuki Nagai; Masaki Takayama; Hiromasa Mine; Teppei Adachi; Shigenaga Matsui; Masatoshi KudoJOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY WILEY-BLACKWELL 27 202 - 202 0815-9319 2012/12 [Refereed]The clinical characteristics and endoscopic treatment of duodenal varicesShigenaga Matsui; Hiroshi Kashida; Masanori Kawasaki; Yutaka Asakuma; Toshiharu Sakurai; Masatoshi KudoJOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY WILEY-BLACKWELL 27 392 - 392 0815-9319 2012/12 [Refereed]The retrospective study of novel anticancer agent, miriplatin in TACE and TAI for unresectable hepatocellular carcinoma in JapanTomoyuki Nagai; Ueshima Kazuomi; Sosuke Hayaishi; Masahiro Takita; Satoshi Kitai; Norihisa Yada; Tatsuo Inoue; Satoru Hagiwara; Yasunori Minami; Naoshi Nishida; Masatoshi KudoJOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY WILEY-BLACKWELL 27 225 - 225 0815-9319 2012/12 [Refereed]【分子標的薬-がんから他疾患までの治癒をめざして-】臨床研究 腫瘍性疾患の分子標的薬 肝臓がん上嶋 一臣; 工藤 正俊日本臨床 (株)日本臨床社 70 (増刊8 分子標的薬) 457 - 462 0047-1852 2012/11Targeted Therapy for Liver Cancer: Updated Review in 2012Masatoshi KudoCURRENT CANCER DRUG TARGETS BENTHAM SCIENCE PUBL LTD 12 (9) 1062 - 1072 1568-0096 2012/11 [Refereed] May 2007, sorafenib (Nexavar (R)) was approved for "unresectable hepatocellular carcinoma (HCC)", and was the first molecular targeted agent for use in HCC. To date, sorafenib is the only molecular-targeted agent, whose survival benefit has been demonstrated in two global phase III randomized controlled trials, and has now been approved worldwide. Phase III clinical trials of other molecular targeted agents comparing them with sorafenib as first-line treatment agents are now ongoing. Phase III clinical trials of several targeted agents comparing them with placebo as second-line treatment agents for patients who failed or was intolerable to sorafenib are also ongoing. In addition, combination of sorafenib with standard treatment such as resection, ablation, transarterial chemoembolization, and hepatic arterial infusion chemotherapy are ongoing. This review outlines the clinical utility of sorafenib in the treatment algorithm of HCC. Furthermore, it also reviews the current status of clinical trials of new agents or combination therapy with sorafenib and standard treatment. Finally, further prospect of the paradigm shift of the HCC treatment is also discussed.Signaling pathway/molecular targets and new targeted agents under development in hepatocellular carcinomaMasatoshi KudoWORLD JOURNAL OF GASTROENTEROLOGY BAISHIDENG PUBL GRP CO LTD 18 (42) 6005 - 6017 1007-9327 2012/11 [Refereed] Advances in molecular cell biology over the last decade have clarified the mechanisms involved in cancer growth, invasion, and metastasis, and enabled the development of molecular-targeted agents. To date, sorafenib is the only molecular-targeted agent whose survival benefit has been demonstrated in two global phase III randomized controlled trials, and has been approved worldwide. Phase III clinical trials of other molecular targeted agents comparing them with sorafenib as first-line treatment agents are ongoing. Those agents target the vascular endothelial growth factor, platelet-derived growth factor receptors, as well as target the epidermal growth factor receptor, insulin-like growth factor receptor and mammalian target of rapamycin, in addition to other molecules targeting other components of the signal transduction pathways. In addition, the combination of sorafenib with standard treatment, such as resection, ablation, transarterial embolization, and hepatic arterial infusion chemotherapy are ongoing. This review outlines the main pathways involved in the development and progression of hepatocellular carcinoma and the new agents that target these pathways. Finally, the current statuses of clinical trials of new agents or combination therapy with sorafenib and standard treatment will also be discussed. (C) 2012 Baishideng. All rights reserved.[Molecular targeted agent for hepatocellular carcinoma].Ueshima K; Kudo MNihon rinsho. Japanese journal of clinical medicine 70 Suppl 8 457 - 462 0047-1852 2012/11 [Refereed]症例(肝がん) HBV陽性Vp4肝細胞癌の一例上嶋 一臣; 田北 雅弘; 工藤 正俊日本癌治療学会誌 (一社)日本癌治療学会 47 (3) 799 - 799 0021-4671 2012/10A randomized phase II trial of intra-arterial chemotherapy using SM-11355 (Miriplatin) for hepatocellular carcinomaTakuji Okusaka; Hiroshi Kasugai; Hiroshi Ishii; Masatoshi Kudo; Michio Sata; Katsuaki Tanaka; Yasukazu Shioyama; Kazuaki Chayama; Hiromitsu Kumada; Masaharu Yoshikawa; Toshihito Seki; Hidetugu Saito; Naoaki Hayashi; Keiko Shiratori; Kiwamu Okita; Isao Sakaida; Masao Honda; Yukio Kusumoto; Takuya Tsutsumi; Kenji SakataINVESTIGATIONAL NEW DRUGS SPRINGER 30 (5) 2015 - 2025 0167-6997 2012/10 [Refereed] Background SM-11355 is a platinum complex developed to treat hepatocellular carcinoma (HCC) via administration into the hepatic artery as a sustained-release suspension in iodized oil. We conducted a multicenter phase II trial in patients with HCC to evaluate the efficacy and safety of SM-11355, using a Zinostatin stimalamer suspension in iodized oil as a reference. Methods Patients with unresectable HCC were randomized 2:1 to receive administration of the SM-11355 or Zinostatin stimalamer suspension into the hepatic artery. A second injection was given 4-12 weeks later. Efficacy was evaluated by CT 3 months after treatment and categorized as therapeutic effect (TE) V to I, where TE V was defined as disappearance or 100% necrosis of all treated tumors. Results A total of 122 patients were evaluated for efficacy and toxicity (SM-11355, n = 83; Zinostatin stimalamer, n = 39). Baseline characteristics were similar in the two groups. The TE V rates were 26.5% (22/83) and 17.9% (7/39) in the SM-11355 and Zinostatin stimalamer groups, respectively. In the SM-11355 group,the most frequent drug-related adverse events (AEs) of a parts per thousand yenaEuro parts per thousand grade 3 were elevated AST, elevated ALT, thrombocytopenia, and hyperbilirubinemia. The AEs with the largest difference between the two groups (SM-11355 vs. Zinostatin stimalamer) were hepatic vascular injury (0 vs. 48.4%) and eosinophilia (84.3 vs. 41.0%). The 2-year and 3-year survival rates were 75.9% vs. 70.3% and 58.4% vs. 48.7%, respectively. Conclusions The results suggest that SM-11355 in iodized oil has similar efficacy to Zinostatin stimalamer and that repeated dosing of SM-11355 is possible without hepatic vascular injury in cases of relapse.Transcatheter endoscopy for pancreaticobiliary duct diseasesHiroki Sakamoto; Masayuki Kitano; Ken Kamata; Takeshi Miyata; Kunpei Kadosaka; Hajime Imai; Yoshifumi Takeyama; Masatoshi KudoGASTROINTESTINAL ENDOSCOPY MOSBY-ELSEVIER 76 (4) 892 - 899 0016-5107 2012/10 [Refereed]75歳以上の後期高齢者に対する胆石症の治療戦略 ADL不良の急性胆嚢炎および胆管炎例に対するEUS下ドレナージ術門阪 薫平; 北野 雅之; 工藤 正俊Gastroenterological Endoscopy (一社)日本消化器内視鏡学会 54 (Suppl.2) 2718 - 2718 0387-1207 2012/09Dual energy CTを用いた肝脂肪の定量評価 ファントム実験と初期臨床経験兵頭 朋子; 岡田 真広; 矢田 典久; 前西 修; 香川 祐毅; 任 誠雲; 柏木 伸夫; 柳生 行伸; 今岡 いずみ; 松木 充; 足利 竜一朗; 石井 一成; 工藤 正俊; 村上 卓道近畿大学医学雑誌 近畿大学医学会 37 (3-4) 18A - 18A 0385-8367 2012/09Assessment of Gd-EOB-DTPA-enhanced MRI for HCC and dysplastic nodules and comparison of detection sensitivity versus MDCTTatsuo Inoue; Masatoshi Kudo; Mina Komuta; Sosuke Hayaishi; Taisuke Ueda; Masahiro Takita; Satoshi Kitai; Kinuyo Hatanaka; Norihisa Yada; Satoru Hagiwara; Hobyung Chung; Toshiharu Sakurai; Kazuomi Ueshima; Michiie Sakamoto; Osamu Maenishi; Tomoko Hyodo; Masahiro Okada; Seishi Kumano; Takamichi MurakamiJOURNAL OF GASTROENTEROLOGY SPRINGER JAPAN KK 47 (9) 1036 - 1047 0944-1174 2012/09 [Refereed] We aimed to evaluate gadolinium ethoxybenzyl diethylenetriamine pentaacetic acid (Gd-EOB-DTPA)-enhanced magnetic resonance imaging (MRI) for the detection of hepatocellular carcinomas (HCCs) and dysplastic nodules (DNs) compared with dynamic multi-detector row computed tomography (MDCT), and to discriminate between HCCs and DNs. Eighty-six nodules diagnosed as HCC or DNs were retrospectively investigated. Gd-EOB-DTPA-enhanced MRI and dynamic MDCT were compared with respect to their diagnostic ability for hypervascular HCCs and detection sensitivity for hypovascular tumors. The ability of hepatobiliary images of Gd-EOB-DTPA-enhanced MRI to discriminate between these nodules was assessed. We also calculated the EOB enhancement ratio of the tumors. For hypervascular HCCs, the diagnostic ability of Gd-EOB-DTPA-enhanced MRI was significantly higher than that of MDCT for tumors less than 2 cm (p = 0.048). There was no difference in the detection of hypervascular HCCs between hepatobiliary phase images of Gd-EOB-DTPA-enhanced MRI (43/45: 96%) and dynamic MDCT (40/45: 89%), whereas the detection sensitivity of hypovascular tumors by Gd-EOB-DTPA-enhanced MRI was significantly higher than that by dynamic MDCT (39/41: 95% vs. 25/41: 61%, p = 0.001). EOB enhancement ratios were decreased in parallel with the degree of differentiation in DNs and HCCs, although there was no difference between DNs and hypovascular well-differentiated HCCs. The diagnostic ability of Gd-EOB-DTPA-enhanced MRI for hypervascular HCCs less than 2 cm was significantly higher than that of MDCT. For hypovascular tumors, the detection sensitivity of hepatobiliary phase images of Gd-EOB-DTPA-enhanced MRI was significantly higher than that of dynamic Gd-EOB-DTPA-enhanced MRI and dynamic MDCT. It was difficult to distinguish between DNs and hypovascular well-differentiated HCCs based on the EOB enhancement ratio.Treatment of advanced hepatocellular carcinomaKUDO MasatoshiNihon Shokakibyo Gakkai Zasshi 109 (8) 1327 - 1334 0446-6586 2012/08【ウイルス肝炎・肝癌制圧の分子基盤】肝癌制圧への治療の開発状況上嶋 一臣; 工藤 正俊BIO Clinica (株)北隆館 27 (8) 748 - 751 0919-8237 2012/08 2009年5月にソラフェニブが切除不能肝細胞癌に対して適応を取得し、それまで局所治療に頼ってきた肝細胞癌治療に全身化学療法という選択肢が加わった。しかしながら、本剤による治療においては、副作用による不耐例・薬剤無効例そして、いったん奏効したもののその後効果が認められなくなる耐性例があり、これを克服する新規分子標的薬の登場が待ち望まれている。また、分子標的薬と従来の治療方法との組み合わせによる予後延長効果が期待されており、多数の臨床試験が行われている。(著者抄録)Estimation of liver function using T2* mapping on gadolinium ethoxybenzyl diethylenetriamine pentaacetic acid enhanced magnetic resonance imagingTakashi Katsube; Masahiro Okada; Seishi Kumano; Izumi Imaoka; Yuki Kagawa; Masatoshi Hori; Kazunari Ishii; Noboru Tanigawa; Yasuharu Imai; Masatoshi Kudo; Takamichi MurakamiEUROPEAN JOURNAL OF RADIOLOGY ELSEVIER IRELAND LTD 81 (7) 1460 - 1464 0720-048X 2012/07 [Refereed] Purpose: To investigate the usefulness of T2* mapping of liver on gadolinium ethoxybenzyl diethylenetriamine pentaacetic acid (Gd-EOB-DTPA)-enhanced MRI for estimating liver function. Materials and methods: 33 patients were classified into 3 groups as follows: normal liver function (NLF) (n = 7); mild liver damage (MLD) (n = 16) with Child-Pugh A; severe liver damage (SLD) (n = 10) with Child-Pugh B. T2*-weighted gradient-echo (T2* W-GRE) and T1-weighted gradient-echo (T1W-GRE) images were obtained before and after Gd-EOB-DTPA administration (3, 8, 13, and 18 min; 5, 10,15, and 20 min; respectively). T2* mapping of liver was calculated from T2* W-GRE, then T2* values of liver and T2* reduction rates of T2* value between pre-and post-contrast enhancement were measured. The increase rates of liver-to-muscle signal intensity (LMS) ratio on T1W-GRE between pre-and post-contrast enhancement were calculated. Results: T2* values on pre-and post-contrast showed no significant differences among three groups. Significant differences in T2* reduction rates were found among groups, and those of LCB were lower than those of other groups (NLF: MLD: SLD, 3.8: 6.0: 0.6% at 3 min, 8.2: 10.3: 1.0% at 8 min, 10.7: 11.5: 1.2% at 13 min, and 16.1: 13.2: 3.5% at 18 min, respectively) (P < 0.05). Significant differences in increase rates of LMS ratio on T1W-GRE were identified (NLF: MLD: SLD, 1.53: 1.46: 1.35 at 5 min, 1.68: 1.64: 1.37 at 10 min, 1.79: 1.76: 1.44 at 15 min, and 1.89: 1.78: 1.49 at 20 min, respectively). Conclusion: T2* reduction rate and increase rate of LMS ratio on T1W-GRE may allow us estimation of liver function according to Child-Pugh score. (C) 2011 Elsevier Ireland Ltd. All rights reserved.Long duration of stable disease may improve overall survival in patients with advanced hepatocellular carcinoma treated with sorafenibARIZUMI Tadaaki; UESHIMA Kazuomi; HAYAISHI Sousuke; TAKITA Masahiro; KITAI Satoshi; INOUE Tatsuo; YADA Norihisa; HAGIWARA Satoru; MINAMI Yasunori; SAKURAI Toshiharu; NISHIDA Naoshi; KUDO MasatoshiKanzo 一般社団法人 日本肝臓学会 53 (6) 348 - 350 0451-4203 2012/06 【PURPOSE】 Sorafenib is a molecularly-targeted drug, which have been proven survival benefit for advanced hepatocellular carcinoma (HCC). Because of the unique side effects of sorafenib such as hand-foot skin reaction (HFSR), the administration of sorafenib is often discontinued. We compared the efficacy of overall survival (OS) in the view of the duration of stable disease (SD). 【METHODS】 112 patients with advanced HCC have been treated with sorafenib in our hospital. They were evaluated the antitumor response according to the modified Response Evaluation Criteria in Solid Tumor. We compared the relationship between the duration of SD and OS. 【RESULTS】 Complete response (CR) was observed in 2 patients, partial response (PR) in 16 patients, SD in 36 patients and progression disease (PD) in 27 patients, respectively. CR+PR patients (CR+PR group) had Child-Pugh A/B=18/0, BCLC stage A/B/C=3/6/9 and HBV/HCV/NBNC=6/8/4. SD patients (SD group) had Child-Pugh A/B=30/6, BCLC stage A/B/C=16/6/14 and HBV/HCV/NBNC=5/20/11. In the SD group the median duration of SD was 3.3 months. The SD group was divided into two groups; less than three months defined as Short SD and more than three months defined as Long SD. We compared the relationship of overall survival between the group of PR, Long SD, and Short SD. In the Short SD group, the median OS was 6.2 months (95%C.I. 4.7-7.3). In the Long SD group, the median OS was 17.6 months (95%C.I. 10.4-23.6). In the CR+PR Group, the median OS was 19.1 months (95%C.I. 14.2-23.8). There was not statistically significant difference between the OS of CR+PR group and the OS of Long SD group, however, there was statistically significant difference between the OS of Long SD group and the OS of Short SD group. 【CONCLUSION】 In the treatment of sorafenib for advanced HCC, long duration of SD improves the OS as same as CR+PR. Controlling the unique side effects of sorafenib such as HFSR is important to obtain the longer treatment duration.Comparison of tumor response in patients treated with sorafenib for hepatocellular carcinomaARIZUMI Tadaaki; UESHIMA Kazuomi; TAKEDA Haruhiko; OSAKI Yukio; HAGIWARA Satoru; INOUE Tatsuo; KITAI Satoshi; YADA Norihisa; SAKURAI Toshiharu; NISHIDA Naoshi; KUDO MasatoshiKanzo 一般社団法人 日本肝臓学会 53 (6) 344 - 347 0451-4203 2012/06 Response Evaluation Criteria In Solid Tumor version 1.1 (RECIST1.1), modified RECIST (mRECIST) and Response Evaluation Criteria In Cancer of the Liver (RECICL) are frequently used as a response evaluation criteria for hepatocellular carcinoma. The overall survival (OS) of the patients treated with sorafenib was evaluated among these criteria respectively. In patients treated with sorafenib over 30 days, OS was stratified by RECICL and mRECIST, but not stratified by RECIST1.1. There was a statistically significant difference in RECICL (p=0.0133). In patients treated with sorafenib over 60 days, OS was also stratified by RECICL and mRECIST, but not stratified by RECIST1.1. There was also a statistically significant difference in the RECICL (p=0.0173). In patients with advanced hepatocellular carcinoma treated with sorafenib, evaluation of the tumor necrosis is considered very important and bidimensional measurement is necessary to measure viable area more precisely. RECICL which evaluates the tumor necrosis and includes bidimensional measurement may be considered the most useful criteria to predict the prognosis in the evaluation of treatment with sorafenib.Welcome to the First Issue of Liver CancerM. KudoLIVER CANCER KARGER 1 (1) 1 - 1 2235-1795 2012/06 [Refereed]p38MAPK suppresses chronic pancreatitis by regulating HSP27 and BAD expressionAh-Mee Park; Masatoshi Kudo; Satoru Hagiwara; Masaki Tabuchi; Tomohiro Watanabe; Hiroshi Munakata; Toshiharu SakuraiFREE RADICAL BIOLOGY AND MEDICINE ELSEVIER SCIENCE INC 52 (11-12) 2284 - 2291 0891-5849 2012/06 [Refereed] Mitogen-activated protein kinases (MAPKs) are ubiquitous proteins that function in both normal and stress-related pathophysiological states of the cell. This study aimed to analyze the importance of p38MAPK in pancreatic injury using WBN/Kob rats with spontaneous chronic pancreatitis. Male WBN/Kob rats were injected with the p38MAPK inhibitor SB203580, starting at the age of 4 weeks, and sacrificed 6 weeks later. Compared with vehicle-treated rats, p38 inhibitor-treated rats exhibited a significant increase in pancreatic cell death and inflammation as assessed by histologic examination and myeloperoxidase activity, respectively. p38 inhibition decreased the expression of heat shock protein 27 (HSP27), an antioxidant protein, and enhanced accumulation of reactive oxygen species (ROS). In addition, the proapoptotic protein BAD was increased in the pancreas of rats treated with p38 inhibitor. In a pancreatic cell line (PANC-1), HSP27 knockdown augmented reactive oxygen species accumulation and cell death induced by tumor necrosis factor-alpha plus actinomycin D. In conclusion, p38MAPK suppresses chronic pancreatitis by upregulating HSP27 expression and downregulating BAD expression. (C) 2012 Elsevier Inc. All rights reserved.Guideline on the use of new anticancer drugs for the treatment of Hepatocellular Carcinoma 2010 updateShuichi Kaneko; Junji Furuse; Masatoshi Kudo; Kenji Ikeda; Masao Honda; Yasunari Nakamoto; Morikazu Onchi; Goshi Shiota; Osamu Yokosuka; Isao Sakaida; Tetsuo Takehara; Yoshiyuki Ueno; Kazumasa Hiroishi; Shuhei Nishiguchi; Hisataka Moriwaki; Kazuhide Yamamoto; Michio Sata; Shuntaro Obi; Shiro Miyayama; Yukinori ImaiHEPATOLOGY RESEARCH WILEY-BLACKWELL 42 (6) 523 - 542 1386-6346 2012/06 [Refereed] The Guideline on the Use of New Anticancer Drugs for the Treatment of Hepatocellular Carcinoma was prepared by the Study Group on New Liver Cancer Therapies established by the Research Project on Emergency Measures to Overcome Hepatitis under the auspices of the Health and Labour Sciences Research Grant. The Guideline brings together data collected by the Study Group on the use and incidence of adverse events in 264 patients with advanced hepatocellular carcinoma (HCC) treated using sorafenib and in 535 patients with advanced HCC treated using miriplatin at 16 participating institutions up until 22 December 2010, as well as referring to the published studies, academic presentations, and reports from the private sector. The aim of this Guideline is to facilitate understanding and current thinking regarding the proper usage of new anticancer drugs towards actual use in therapy. In terms of the format, the Guideline presents clinical questions on issues pertaining to medical care, makes recommendations on diagnosis and treatment in response to each of these clinical questions, and provides a rationale for these recommendations in the form of scientific statements.Can the biliary enhancement of Gd-EOB-DTPA predict the degree of liver function?Masahiro Okada; Kazunari Ishii; Kazushi Numata; Tomoko Hyodo; Seishi Kumano; Masayuki Kitano; Masatoshi Kudo; Takamichi MurakamiHEPATOBILIARY & PANCREATIC DISEASES INTERNATIONAL ZHEJIANG UNIV SCH MEDICINE 11 (3) 307 - 313 1499-3872 2012/06 [Refereed] BACKGROUND: Excretion of gadolinium-ethoxybenzyl-diethylenetriamine pentaacetic acid (Gd-EOB-DTPA) in the bile may be related to liver function, because of elimination from the liver after preferential uptake by hepatocytes. The purpose of this study was to investigate the relation between liver and biliary enhancement in patients with or without liver dysfunction, and to compare the tumor-to-liver contrast in these patients. METHODS: Forty patients [group 1: normal liver and Child-Pugh class A in 20 patients, group 2: Child-Pugh class B in 18 patients and Child-Pugh C in 2] were evaluated. All patients underwent MR imaging of the liver using a 1.5-Tesla system. T1-weighted 3D images were obtained at 5, 10, 15 and 20 minutes after Gd-EOB-DTPA injection. The relation between group 3 (total bilirubin <1.8 mg/dL) and group 4 (total bilirubin >= 1.8 mg/dL) was investigated at 20 minutes. Liver and biliary signals were measured, and compared between groups 1 and 2 or groups 3 and 4. Tumor-to-liver ratio was also evaluated between groups 1 and 2. Scheffes post-hoc test after two-way repeated-measures ANOVA and Pearson's correlation test were used for statistical analysis. RESULTS: Liver enhancement showed significant difference at all time points between groups 1 and 2. Biliary enhancement did not show a significant difference between groups 1 and 2 at 5 minutes, but did at 10, 15 and 20 minutes. At 20 minutes, significant differences between groups 3 and 4 were seen for liver and biliary enhancement. At all time points, liver enhancement correlated with biliary enhancement in both groups. At 5 minutes and 20 minutes, statistical differences between groups 1 and 2 were seen for tumor-to-liver ratio. CONCLUSIONS: The degree of biliary enhancement has a close correlation to that of liver enhancement. It is especially important that insufficient liver enhancement causes lower tumor-to-liver contrast in the hepatobiliary phase of Gd-EOB-DTPA.早期慢性膵炎のEUS画像と臨床所見の比較検討門阪 薫平; 北野 雅之; 竹山 宜典; 工藤 正俊膵臓 (一社)日本膵臓学会 27 (3) 422 - 422 0913-0071 2012/05【肝胆膵悪性腫瘍に対する分子標的療法の近未来的展望】肝細胞癌 Brivanib上嶋 一臣; 工藤 正俊肝・胆・膵 (株)アークメディア 64 (5) 669 - 675 0389-4991 2012/05【肝胆膵悪性腫瘍に対する分子標的療法の近未来的展望】肝細胞癌 Ramucirumab上嶋 一臣; 工藤 正俊肝・胆・膵 (株)アークメディア 64 (5) 697 - 700 0389-4991 2012/05Brivanib上嶋 一臣; 工藤 正俊肝胆膵 64 (5) 669 - 675 2012/05The Gross Classification of Hepatocellular Carcinoma: Usefulness of Contrast-Enhanced Sonography Using Perfluorocarbon Microbubbles (Sonazoid)Yasunori Minami; Kinuyo Hatanaka; Tadaaki Arizumi; Sosuke Hayaishi; Masahiro Takita; Satoshi Kitai; Norihisa Yada; Tatsuo Inoue; Satoru Hagiwara; Kazuomi Ueshima; Naoshi Nishida; Masatoshi KudoGASTROENTEROLOGY W B SAUNDERS CO-ELSEVIER INC 142 (5) S1002 - S1002 0016-5085 2012/05 [Refereed]Usefullness of Contrast-Enhanced Ultrasonography to Evaluate a Post Treatment Effect of Radiofrequentry Ablation About Hepatocellular Carcinoma; Comparion With Contrast-Enhanced CTTatsuo Inoue; Tadaaki Arizumi; Satoshi Kitai; Norihisa Yada; Satoru Hagiwara; Yasunori Minami; Toshiharu Sakurai; Kazuomi Ueshima; Naoshi Nishida; Masatoshi KudoGASTROENTEROLOGY W B SAUNDERS CO-ELSEVIER INC 142 (5) S1002 - S1002 0016-5085 2012/05 [Refereed]Novel Association Between Global DNA Hypomethylation and Chromosomal Instability Phenotype in Human Hepatocellular CarcinomaNaoshi Nishida; Masatoshi Kudo; Tadaaki Arizumi; Sosuke Hayaishi; Masahiro Takita; Satoshi Kitai; Norihisa Yada; Tatsuo Inoue; Satoru Hagiwara; Yasunori Minami; Kazuomi Ueshima; Toshiharu Sakurai; Takeshi Nagasaka; Ajay GoelGASTROENTEROLOGY W B SAUNDERS CO-ELSEVIER INC 142 (5) S910 - S911 0016-5085 2012/05 [Refereed]Activation of JNK in the Non-Cancerous Liver Tissue Predicts a High Risk of Recurrence After Hepatic Resection for Hepatocellular CarcinomaToshiharu Sakurai; Satoru Hagiwara; Tatsuo Inoue; Kazuomi Ueshima; Shigenaga Matsui; Naoshi Nishida; Hiroshi Kashida; Masatoshi KudoGASTROENTEROLOGY W B SAUNDERS CO-ELSEVIER INC 142 (5) S452 - S452 0016-5085 2012/05 [Refereed]早期慢性膵炎におけるEUS画像の臨床的意義門阪 薫平; 北野 雅之; 工藤 正俊超音波医学 (公社)日本超音波医学会 39 (Suppl.) S325 - S325 1346-1176 2012/04慢性膵炎の内視鏡診断と治療 EUSによる早期慢性膵炎の画像所見と臨床症状との関連性の検討門阪 薫平; 北野 雅之; 工藤 正俊Gastroenterological Endoscopy (一社)日本消化器内視鏡学会 54 (Suppl.1) 1004 - 1004 0387-1207 2012/04肝癌診療ガイドラインの活用と改訂への提案 肝癌診療ガイドラインにおける治療アルゴリズムの妥当性 実臨床への展開とその問題点上嶋 一臣; 南 康範; 工藤 正俊肝臓 (一社)日本肝臓学会 53 (Suppl.1) A109 - A109 0451-4203 2012/04進行肝細胞癌に対するソラフェニブ投与における投与後の腫瘍濃染の低下の有無と生存期間の検討有住 忠晃; 上嶋 一臣; 工藤 正俊肝臓 (一社)日本肝臓学会 53 (Suppl.1) A398 - A398 0451-4203 2012/04Effect of Rebamipide for Endoscopic Submucosal Dissection (ESD)-induced Ulcer in Early Gastric Cancer: A Randomized Controlled TrialShigenaga Matsui; Masatoshi Kudo; Hiroshi Kashida; Yutaka Asakuma; Toshiharu Sakurai; Masanori KawasakiGASTROINTESTINAL ENDOSCOPY MOSBY-ELSEVIER 75 (4) 237 - 237 0016-5107 2012/04 [Refereed]近畿大学におけるEOB-MRIの肝細胞相で検出される乏血性結節の自然経過-多血化の危険因子兵頭朋子; 岡田真広; 香川祐毅; 今井康陽; 望月輝一; 工藤正俊; 村上卓道肝胆膵画像 14 (4) 365 - 368 2012/04 [Refereed]Activation of c-Jun N-terminal kinase in non-cancerous liver tissue predicts a high risk of recurrence after hepatic resection for hepatocellular carcinomaSatoru Hagiwara; Masatoshi Kudo; Hobyung Chung; Kazuomi Ueshima; Tatsuo Inoue; Seiji Haji; Tomohiro Watanabe; Ah-Mee Park; Hiroshi Munakata; Toshiharu SakuraiHEPATOLOGY RESEARCH WILEY-BLACKWELL 42 (4) 394 - 400 1386-6346 2012/04 [Refereed] Aim: Hepatocellular carcinoma (HCC) ranks as the third leading cause of cancer deaths worldwide. Hepatic resection is the mainstay of curative treatment for early stage HCC. Although c-Jun N-terminal kinase (JNK) activation contributes to hepatocyte proliferation and HCC development in mice, the extent of involvement of JNK in human HCC development is unknown. The aim of this study is to assess the predictive value of JNK for postoperative recurrence in HCC. Methods: From April 2005 to March 2008, 159 patients underwent curative resection for HCC. From the 159 patients, 20 patients each matched for age, gender and etiology were registered as three groups: (i) without recurrence (no recurrence group), (ii) with recurrence within one year after surgery (early recurrence group), and (iii) with recurrence at one year or more after surgery (late recurrence group) (a cross- sectional control study). We investigated factors contributing to postoperative early and late phase recurrence. Results: Multivariate analysis using a Logistic regression model showed that JNK activity in non- cancerous liver tissue was correlated with postoperative late recurrence. (P = 0.02, odds ratio; 5.79, 95% confidence interval [CI]; 1.33- 25.36). Conclusions: JNK activity in non- cancerous liver tissue is considered as a reliable predictive biomarker for postoperative recurrence in HCC.生活習慣と肝・胆・膵疾患 EUSによる早期慢性膵炎の各画像所見と臨床症状の検討門阪 薫平; 北野 雅之; 工藤 正俊日本消化器病学会雑誌 (一財)日本消化器病学会 109 (臨増総会) A162 - A162 0446-6586 2012/03経皮的ラジオ波焼灼術後の後出血予防における穿刺経路焼灼の有効性の検討早石 宗右; 南 康範; 足立 哲平; 有住 忠晃; 田北 雅弘; 北井 聡; 矢田 典久; 井上 達夫; 萩原 智; 上嶋 一臣; 工藤 正俊; 鄭 浩柄日本消化器病学会雑誌 (一財)日本消化器病学会 109 (臨増総会) A282 - A282 0446-6586 2012/03造影超音波 肝癌に対するラジオ波焼灼療法の治療効果判定造影USと造影CTの比較検討井上 達夫; 有住 忠晃; 早石 宗右; 田北 雅弘; 北井 聡; 矢田 典久; 萩原 智; 南 康範; 上嶋 一臣; 工藤 正俊超音波医学 (公社)日本超音波医学会 39 (2) 191 - 191 1346-1176 2012/03組織弾性イメージング 肝エラストグラフィ 各モダリティーにおける測定原理と結果の解釈矢田 典久; 有住 忠晃; 早石 宗右; 田北 雅弘; 北井 聡; 井上 達夫; 萩原 智; 南 康範; 上嶋 一臣; 工藤 正俊超音波医学 (公社)日本超音波医学会 39 (2) 193 - 193 1346-1176 2012/03非上皮性肝腫瘤2例の造影超音波像について横川 美加; 辻 裕美子; 桑口 愛; 前野 知子; 前川 清; 井上 達夫; 南 康範; 上嶋 一臣; 樫田 博史; 工藤 正俊超音波医学 (公社)日本超音波医学会 39 (2) 198 - 198 1346-1176 2012/03体外式超音波穿刺用コンベックスプローブEUP-B715の使用経験矢田 典久; 有住 忠晃; 早石 宗右; 田北 雅弘; 北井 聡; 井上 達夫; 萩原 智; 南 康範; 上嶋 一臣; 工藤 正俊超音波医学 (公社)日本超音波医学会 39 (2) 201 - 201 1346-1176 2012/03Involvement of activation of toll-like receptors and nucleotide-binding oligomerization domain-like receptors in enhanced IgG4 responses in autoimmune pancreatitisTomohiro Watanabe; Kouhei Yamashita; Saori Fujikawa; Toshiharu Sakurai; Masatoshi Kudo; Masahiro Shiokawa; Yuzo Kodama; Kazushige Uchida; Kazuichi Okazaki; Tsutomu ChibaARTHRITIS AND RHEUMATISM WILEY-BLACKWELL 64 (3) 914 - 924 0004-3591 2012/03 [Refereed] Objective IgG4-related disease is a recently recognized entity affecting multiple organs, including the pancreas, biliary tracts, and salivary glands. Although IgG4-related disease is characterized by systemic IgG4 antibody responses and by infiltration of IgG4-expressing plasma cells, the innate immune responses leading to adaptive IgG4 antibody responses are poorly understood. The aim of this study was to clarify the innate immune responses leading to IgG4 antibody production. Methods. IgG4 and cytokine responses to various nucleotide-binding oligomerization domain (NOD)-like receptor (NLR) and Toll-like receptor (TLR) ligands were examined using peripheral blood mononuclear cells (PBMCs) from healthy control subjects and patients with IgG4-related autoimmune pancreatitis. Results. Activation of NOD-2 in monocytes from healthy control subjects induced IgG4 production by B cells in a BAFF-dependent and T cell-independent manner. In addition, PBMCs from patients with IgG4-related disease produced a large amount of IgG4 upon stimulation with NLR and TLR ligands; this enhanced IgG4 production was associated with the induction of BAFF by NLR and TLR ligands. Monocytes from patients with IgG4-related disease induced IgG4 production by B cells from healthy control subjects upon stimulation with NLR and TLR ligands. Conclusion. The results of these studies suggest that abnormal innate immune responses against microbial antigens may underlie the immunopathogenesis of IgG4-related disease.HCCのカテーテル治療の最前線 分子標的薬とTACE・動注化学療法の併用療法の現状上嶋 一臣; 工藤 正俊日本医学放射線学会学術集会抄録集 (公社)日本医学放射線学会 71回 S84 - S84 0048-0428 2012/02Dual energy CTを用いた肝脂肪の定量評価 ファントム実験と初期臨床経験兵頭 朋子; 岡田 真広; 矢田 典久; 工藤 正幸; 香川 祐毅; 熊野 正士; 石井 一成; 工藤 正俊; 村上 卓道日本医学放射線学会学術集会抄録集 (公社)日本医学放射線学会 71回 S272 - S272 0048-0428 2012/02ASIRを用いた低電圧肝Dynamic-CTによる被曝低減と造影剤量低減に関する報告日高 正二朗; 高橋 洋人; 岡田 真広; 兵頭 朋子; 香川 祐毅; 今岡 いずみ; 石井 一成; 足利 竜一朗; 工藤 正俊; 村上 卓道日本医学放射線学会学術集会抄録集 (公社)日本医学放射線学会 71回 S273 - S273 0048-0428 2012/02High Range Resolution Ultrasonographic Vascular Imaging Using Frequency Domain Interferometry With the Capon MethodHirofumi Taki; Kousuke Taki; Takuya Sakamoto; Makoto Yamakawa; Tsuyoshi Shiina; Motoi Kudo; Toru SatoIEEE TRANSACTIONS ON MEDICAL IMAGING IEEE-INST ELECTRICAL ELECTRONICS ENGINEERS INC 31 (2) 417 - 429 0278-0062 2012/02 [Refereed] For high range resolution ultrasonographic vascular imaging, we apply frequency domain interferometry with the Capon method to a single frame of in-phase and quadrature (IQ) data acquired using a commercial ultrasonographic device with a 7.5 MHz linear array probe. In order to tailor the adaptive beamforming algorithm for ultrasonography we employ four techniques: frequency averaging, whitening, radio-frequency data oversampling, and the moving average. The proposed method had a range resolution of 0.05 mm in an ideal condition, and experimentally detected the boundary couple 0.17 mm apart, where the boundary couple was indistinguishable from a single boundary utilizing a B-mode image. Further, this algorithm could depict a swine femoral artery with a range beam width of 0.054 mm and an estimation error for the vessel wall thickness of 0.009 mm, whereas using a conventional method the range beam width and estimation error were 0.182 and 0.021 mm, respectively. The proposed method requires 7.7 s on a mobile PC with a single CPU for a 1 x 3 cm region of interest. These findings indicate the potential of the proposed method for the improvement of range resolution in ultrasonography without deterioration in temporal resolution, resulting in enhanced detection of vessel stenosis.A case of chronic hepatitis B which achieved hepatitis B surface antigen seroclearance during combination therapy with peginterferon alfa-2b and entecavirINUZUKA Tadashi; OSAKI Yukio; MATSUDA Fumihiro; SAKAMOTO Azusa; HATAMARU Keiichi; HENMI Shinichiro; ISHIKAWA Tetsuro; SAITO Sumio; NISHIKAWA Hiroki; KITA Ryuichi; OKABE Yoshihiro; KIMURA Toru; WAKASA Tomoko; HAGIWARA Satoru; KUDO MasatoshiKanzo 一般社団法人 日本肝臓学会 53 (1) 42 - 47 0451-4203 2012/01 A 65-year-old Japanese male with chronic hepatitis B (CH-B) diagnosed in December 2008 was referred to our department in July 2009. He started combination therapy with peginterferon alfa-2b (80 μg/week) and entecavir (0.5 mg/day) for 48 weeks from December 2009. At the initiation of therapy, his significant laboratory test results were as follows: alanine aminotransferase (ALT) 55 IU/l, aspartate aminotransferase (AST) 37 IU/l, hepatitis B surface antigen (HBsAg) positive, hepatitis B e antigen (HBeAg) positive, hepatitis B virus (HBV) DNA levels 7.9 Log copies/ml. HBV DNA, HBsAg and HBeAg levels decreased progressively with therapy. After 36 weeks, HBV DNA, AST and ALT levels flared up, but after 44 weeks, HBV DNA levels decreased below 2.1 Log copies/ml and HBeAg seroconversion and HBsAg seroclearance were achieved. After 72 weeks he maintained HBsAg seroclearance and achieved a sustained viral response. Cases of spontaneous HBsAg seroclearance have been reported previously, but HBsAg seroclearance caused by combination therapy with peginterferon alfa-2b and entecavir has not been reported. Pre- and post-treatment cccDNA load in liver tissue, hepatitis B virus core-related antigen (HBcrAg) concentration in serum and expression of hepatitis B core antigen (HBcAg) in hepatocyte were compared, and it was found that all were drastically decreased. The present study suggests that these reduction appeared to contribute to the successful outcome of this therapy.Hepatocellular carcinomaYasunori Minami; Masatoshi KudoBiotargets of Cancer in Current Clinical Practice Humana Press Inc. 273 - 287 2012/01 [Refereed]Effects of PPARγ agonists against vascular and renal dysfunctionAkira Sugawara; Akira Uruno; Ken Matsuda; Takako Saito-Ito; Tadao Funato; Akiko Saito-Hakoda; Masataka Kudo; Sadayoshi ItoCurrent Molecular Pharmacology Bentham Science Publishers B.V. 5 (2) 248 - 254 1874-4702 2012 [Refereed] Peroxisome proliferator-activated receptor (PPAR)γ, a nuclear hormone receptor, is activated by its agonists including anti-diabetic thiazolidinediones, and has recently been reported to exert beneficial effects in the vasculature independently of its anti-diabetic effects. We here discuss our recent findings on the beneficial pleiotropic effects of PPARγ agonists. PPARγ agonists have been shown to lower blood pressure in both animals and humans, which may possibly be mediated via the PPARγ agonist-mediated inhibition of the renin-angiotensin-aldosterone system (RAAS) including the suppression of angiotensin (Ang) II type 1 receptor expression/Ang II-mediated signaling pathways and Ang II-induced adrenal aldosterone synthesis/secretion. PPARγ agonists also inhibited the progression of atherosclerosis in both animals and humans. PPARγ agonist-mediated inhibition of the RAAS and the thromboxane A2 system as well as endothelial protection may possibly be involved in the inhibitory effects on blood pressure and atherosclerosis. Furthermore, PPARγ agonists were demonstrated to have reno-protective effects, especially in reducing proteinuria in diabetic nephropathy in both animals and humans. The reno-protective effects of PPARγ agonists were also observed in non-diabetic renal dysfunctions. The effects may possibly be mediated via the PPARγ agonist-mediated blood pressure lowering, endothelial protection, and vasodilation of the glomerular efferent arterioles. Additionally, anti-neoplastic effects of PPARγ agonists have recently received much attention. PPARγ agonists, may therefore, be useful and effective against lifestyle-related diseases. © 2012 Bentham Science Publishers.IL28B型との関連からみたResponse-guided therpy. C型肝炎-新時代の治療戦略萩原 智; 工藤正俊消化器の臨床 15 2012 [Refereed]Japan's Successful Model of Nationwide Hepatocellular Carcinoma Surveillance Highlighting the Urgent Need for Global SurveillanceM. KudoLIVER CANCER KARGER 1 (3-4) 141 - 143 2235-1795 2012 [Refereed]Quantification of tumor vascularity with contrast-enhanced ultrasound for early response of transcatheter arterial chemoembolization for hepatocellular carcinoma: a report of three casesYasunori Minami; Naoya Okumura; Norio Yamamoto; Naoko Tsuji; Yuko Kono; Masatoshi KudoJOURNAL OF MEDICAL ULTRASONICS SPRINGER TOKYO 39 (1) 15 - 19 1346-4523 2012/01 [Refereed] Many contrast-enhanced ultrasound (CE-US) studies have been conducted by qualitative analysis of blood flow, such as classification of enhancement pattern. We evaluated early response of transcatheter arterial chemoembolization (TACE) for hepatocellular carcinoma (HCC) by quantitative analysis of intratumoral vascularity with CE-US in three patients. Three patients (one man, two women) with HCCs were treated in July 2009. CE-US with perfluorocarbon microbubbles (Sonazoid) and CT were performed serially before and 5 days after TACE. Post-processing enhancement intensity on US was analyzed to determine mean transit time (s), time to peak (s), enhancement peak intensity (dB), and "A" (scaling factor) by ultrasound quantification software after the data were fitted to a gamma variate curve. Mean transit time was prolonged by TACE in all three patients. Mean transit time rates on CE-US were 64.3, 33.8, and 65.6%, respectively, whereas the avascular rates on CT were 59.07, 31.71, and 62.25%, respectively. Mean transit time rates on CE-US approximated avascular rates on CT. Mean transit time rate may quantitatively indicate the early response of HCC to TACE.Current Status of Hepatocellular Carcinoma Treatment in Japan Case Study and Discussion-Voting SystemMasatoshi Kudo; Ryosuke Tateishi; Tatsuya Yamashita; Masafumi Ikeda; Junji Furuse; Kenji Ikeda; Norihiro Kokudo; Namiki Izumi; Osamu MatsuiCLINICAL DRUG INVESTIGATION ADIS INT LTD 32 37 - 51 1173-2563 2012 [Refereed] The Toward Integrated Treatment of Advanced Hepatocellular Carcinoma with Nexavar (TiTAN) Symposium was held in August 2010 in Tokyo, Japan, during which the position of sorafenib (Nexavar) in the treatment of HCC in Japan (for which it received approval in 2009) was discussed by a panel of eight expert hepatologists in a session chaired by Dr Kudo. The following article focuses on the discussion that went on during this session, including question and answer sessions regarding the experiences of the 350 conference attendees in treating patients with HCC, as well as some of the more challenging disease management issues. Since 2008, when the phase III Sorafenib Hepatocellular Carcinoma Assessment Randomized Protocol (SHARP) trial demonstrated an increase in the median overall survival (OS) for patients with unresectable HCC treated with sorafenib compared with placebo, international and Japanese guidelines recommend sorafenib as a first-line option for patients with advanced HCC Child-Pugh liver function class A who have extrahepatic metastasis. Sorafenib is also recommended for patients unresponsive to transarterial chemoembolization (TACE) or hepatic arterial infusion chemotherapy (HAIC). Importantly, if HCC is judged to be unresponsive to TACE, treatment should be switched to sorafenib in a timely manner. Almost half of the conference attendees said that they used both the Japan Society of Hepatology clinical practice guidelines and the clinical practice guidelines for HCC when determining treatment strategies for individual HCC patients. Sorafenib should currently not be used as adjuvant therapy or in combination with TACE or HAIC until evidence from ongoing clinical trials shows that it is beneficial in these settings.Hepatic Nodules Associated with an Inferior Mesentric Arteriovenous MalformationKen Takahashi; Hiroshi Kashida; Masatoshi KudoINTERNAL MEDICINE JAPAN SOC INTERNAL MEDICINE 51 (19) 2753 - 2755 0918-2918 2012 [Refereed] Splanchnic arteriovenous malformation (AVM) is a rare condition in which patients present with portal hypertension, which thus causes bleeding varices and ascites. However, to our knowledge, hepatic nodules associated with splanchnic AVM have not yet been described. We herein first report the case of a 78-year-old man with inferior mesenteric AVM presenting with portal hypertension and multiple hepatic nodules dominantly supplied by the portal vein. This unique case not only extends the spectrum of hepatic nodules resulting from abnormal hepatic circulation, but also provides clues for better understanding the etiology of hepatic nodules.Viral Hepatitis and Hepatocellular Carcinoma: Update in 2012Masatoshi KudoDIGESTIVE DISEASES KARGER 30 (6) 539 - 540 0257-2753 2012 [Refereed]Retreatment with Peginterferon alpha-2a+Ribavirin in Patients Who Failed Previous Peginterferon alpha-2b+Ribavirin Combination TherapyTaisuke Ued; Kaoru Tsuchiya; Satoru Hashimot; Taisuke Inoue; Nobuyuki Enomoto; Mie Inao; Atsushi Tanaka; Masahiko Kaito; Fumio Imazeki; Shuhei Nishiguchi; Satoshi Mochida; Osamu Yokosuka; Hiroshi Yatsuhashi; Namiki Izumi; Masatoshi KudoDIGESTIVE DISEASES KARGER 30 (6) 554 - 560 0257-2753 2012 [Refereed] Background/Aims: Peginterferon (PEG-IFN) + ribavirin (RBV) combination therapy is the current standard of care for chronic hepatitis C. However, more than half of the patients cannot achieve sustained viral response (SVR). In Japan, the clinical benefit of retreatment with PEG-IFN + RBV combination retreatment is still unknown. Methods: We collected clinical data in 106 chronic hepatitis C patients who failed to achieve SVR with PEG-IFN alpha-2b + RBV combination therapy and were retreated with PEG-IFN alpha-2a + RBV. This retrospective study examined the efficacy of retreatment with PEG-IFN alpha-2a + RBV by evaluating the time to eradication of hepatitis C virus RNA, early virological response (EVR), and SVR. We compared the results of the previous therapy and retreatment in terms of efficacy and analyzed the factors influencing SVR. Results: The SVR rates in the non-responders and relapsers were 11 and 53%, respectively. EVR and prolonged treatment duration were associated with SVR. We also found that a prior response to PEG-IFN + RBV therapy was more important than the Interleukin-28B genotype for predicting the response to retreatment. Conclusions: Retreatment with PEG-IFN alpha-2a + RBV should be considered for relapsers and partial responders. Our results suggest that prolonged administration is also favorable for EVR cases to attain a higher SVR. Copyright (C) 2012 S. Karger AG, BaselRisk of Hepatocellular Carcinoma Development in Cases of Hepatitis C Treated by Long-Term, Low-Dose PEG-IFN alpha-2aSatoru Hagiwara; Toshiharu Sakurai; Masahiro Takita; Kazuomi Ueshima; Yasunori Minami; Tatsuo Inoue; Norihisa Yada; Satoshi Kitai; Tomoyuki Nagai; Sousuke Hayaishi; Tadaaki Arizumi; Naoshi Nishida; Masatoshi KudoDIGESTIVE DISEASES KARGER 30 (6) 561 - 567 0257-2753 2012 [Refereed] Objective: Increasing evidence suggests the efficacy of maintenance therapy with interferon (IFN) for chronic hepatitis C (CHC) in reducing the risk of hepatocellular carcinoma (HCC). The aim of this study was to determine clinical characteristics on the risk of occurrence of HCC in CHC patients receiving maintenance IFN therapy. Methods: A total of 55 patients were treated in a single center with PEG-IFN alpha-2a monotherapy for CHC and evaluated for variables predictive of the occurrence of HCC. Results: The cumulative incidences of HCC were 0.092, 0.117 and 0.161 at 3, 5 and 7 years, respectively. Serum ALT level (>40 IU/l) in the 6th month after commencement of IFN therapy and BMI >25 were associated with shorter time-to-HCC emergence using multivariate analysis (relative risk 16.034, p = 0.01 for ALT >40 IU/I; relative risk 6.020, p = 0.026 for BMI >25, respectively). The IL28B SNP was extracted as a significant factor for the occurrence of HCC. Conclusions: Maintenance therapy with the use of long-term low-dose PEG-IFN alpha-2a is effective for preventing HCC occurrence irrespective of the IL28B SNP, at least for a subset of CHC patients. The initial response of serum ALT levels and BMI provides a prognostic value for determining the risk of developing HCC later in life. Copyright (C) 2012 S. Karger AG, BaselHepatocellular Carcinoma with Obstructive Jaundice: Endoscopic and Percutaneous Biliary DrainageYasunori Minami; Masatoshi KudoDIGESTIVE DISEASES KARGER 30 (6) 592 - 597 0257-2753 2012 [Refereed] Among patients with later stage hepatocellular carcinoma (HCC), only 1-12% manifest obstructive jaundice as the initial complaint. Endoscopic retrograde binary drainage (ERBD) and percutaneous transhepatic biliary drainage (PTBD) are the two main non-surgical treatment options for obstructive jaundice in patients with HCC. ERBD is usually the first-line treatment because of its low hemorrhage risk. Some have reported that the successful drainage rate ranges from 72 to 100%. Mean stent patency time and mean survival range from 1.0 to 15.9 and 2.8 to 12.3 months, respectively. PTBD is often an important second-line treatment when ERBD is impossible. With regard to materials, metallic stents offer the benefit of longer patency than plastic stents. The dominant effect of biliary drainage suggests that successful jaundice therapy could enhance anti-cancer treatment by increasing life expectancy, decreasing mortality, or both. We present an overview of the efficacy of endoscopic and percutaneous drainage for obstructive jaundice in patients with HCC who are not candidates for surgical resection and summarize the current indications and outcomes of reported clinical use. Copyright (C) 2012 S. Karger AG, Basel肝臓がん上嶋一臣; 工藤正俊日本臨牀 70 457 - 462 2012 [Refereed]新規薬剤の治療開発: 現状と展望(SORとの比較試験、SOR耐性後の試験など)上嶋一臣; 工藤正俊腫瘍内科 9 651 - 658 2012 [Refereed]各施設のまとめ-EOB-MRIの肝細胞相でのみ検出される乏血性結節の自然経過. 特集「早期肝細胞癌の画像診断update」工藤正俊肝胆膵画像 14 369 - 370 2012 [Refereed]早期慢性膵炎のEUS所見と生活習慣病について. 特集「生活習慣病と胆・膵疾患」門阪薫平; 北野雅之; 大本俊介; 鎌田 研; 宮田 剛; 今井 元; 坂本洋城; 工藤正俊胆と膵 33 1247 - 1251 2012 [Refereed]EUSによる膵線維化診断.特集「肝胆膵の線維化/研究と診療の最近の進歩」門阪薫平; 北野雅之; 山田光成; 大本俊介; 鎌田 研; 宮田 剛; 今井 元; 坂本洋城; 工藤正俊肝胆膵 65 371 - 376 2012 [Refereed]分子標的薬を用いた肝癌治療の治療成績 進行肝細胞癌に対するソラフェニブ投与例におけるSDの持続期間と生存期間の検討有住 忠晃; 上嶋 一臣; 早石 宗右; 田北 雅弘; 北井 聡; 矢田 典久; 井上 達夫; 萩原 智; 南 康範; 櫻井 俊治; 工藤 正俊新薬と臨牀 (株)医薬情報研究所 60 (12) 2516 - 2516 0559-8672 2011/12進行肝細胞癌に対するソラフェニブ投与例におけるSDの持続期間と生存期間の検討有住 忠晃; 上嶋 一臣; 工藤 正俊The Liver Cancer Journal (株)メディカルレビュー社 3 (4) 320 - 321 1883-9347 2011/12進行肝細胞癌に対するソラフェニブと低用量シスプラチン/フルオロウラシル肝動注療法の併用化学療法の第I/II相臨床試験上嶋 一臣; 有住 忠晃; 早石 宗右; 田北 雅弘; 北井 聡; 矢田 典久; 井上 達夫; 萩原 智; 南 康範; 櫻井 俊治; 工藤 正俊The Liver Cancer Journal (株)メディカルレビュー社 3 (4) 336 - 337 1883-9347 2011/12ガドキセト酸ナトリウム造影MRI肝細胞相で低信号を呈する乏血性結節の多血化予測兵頭 朋子; 岡田 真広; 香川 祐毅; 熊野 正士; 任 誠雲; 柏木 伸夫; 柳生 行伸; 今岡 いずみ; 足利 竜一朗; 石井 一成; 工藤 正俊; 村上 卓道近畿大学医学雑誌 近畿大学医学会 36 (3-4) 13A - 13A 0385-8367 2011/12【外科医のための最新癌薬物療法】(I章)臓器別薬物療法 肝癌 進行・再発(切除不能を含む)治療上嶋 一臣; 工藤 正俊臨床外科 (株)医学書院 66 (11) 183 - 189 0386-9857 2011/10IMPACT ON ABERRANT METHYLATION OF AN UNIQUE SUBSET OF TUMOR SUPPRESSOR GENES ON THE INITIAL STEPS OF HUMAN HEPATOCARCINOGENESISNaoshi Nishida; Masatoshi Kudo; Takeshi Nagasaka; Ajay GoelHEPATOLOGY WILEY-BLACKWELL 54 462A - 462A 0270-9139 2011/10 [Refereed]肝血管肉腫の2例有住 忠晃; 萩原 智; 大本 俊介; 早石 宗右; 上田 泰輔; 田北 雅弘; 北井 聡; 南 康範; 鄭 浩柄; 上嶋 一臣; 工藤 正俊肝臓 (一社)日本肝臓学会 52 (Suppl.2) A680 - A680 0451-4203 2011/09Signaling pathway and molecular-targeted therapy for hepatocellular carcinomaMasatoshi KudoDigestive Diseases 29 (3) 289 - 302 0257-2753 2011/08 [Refereed] In recent years, molecular-targeted agents have been used clinically to treat various malignant tumors. In May 2009, sorafenib (Nexavar®) was approved in Japan for 'unresectable hepatocellular carcinoma (HCC)', and was the first molecular-targeted agent for use in HCC. To date, sorafenib is the only molecular-targeted agent whose survival benefit has been demonstrated in two global phase III randomized controlled trials, and has now been approved worldwide. Phase III clinical trials of other molecular-targeted agents comparing them with sorafenib as first-line treatment agents are now ongoing. Those agents target the vascular endothelial growth factor, platelet-derived growth factor receptors, as well as target the epidermal growth factor receptor, insulin-like growth factor receptor and mammalian target of rapamycin, in addition to other molecules targeting other components of the signal transduction pathways. This review outlines the main pathways involved in the development and progression of HCC and the agents that target these pathways. Finally, current status and future perspective will also be discussed. Copyright © 2011 S. Karger AG, Basel.MAPKに注目したソラフェニブの治療効果および予後予測因子の同定櫻井 俊治; 萩原 智; 上嶋 一臣; 工藤 正俊The Liver Cancer Journal (株)メディカルレビュー社 3 (2) 150 - 151 1883-9347 2011/06超音波定量診断技術の新展開 Real-time Tissue Elastographyの肝疾患テクスチャ解析外村 明子; 元木 満; 三竹 毅; 藤本 研治; 加藤 道夫; 辰巳 千栄; 矢田 典久; 上嶋 一臣; 工藤 正俊; 椎名 毅超音波医学 (公社)日本超音波医学会 38 (3) 306 - 306 1346-1176 2011/05P38alpha Inhibits Liver Fibrogenesis and Consequent Hepatocarcinogenesis by Curtailing Accumulation of Reactive Oxygen SpeciesToshiharu Sakurai; Masatoshi Kudo; Kazuomi Ueshima; Shigenaga Matsui; Hiroshi Kashida; Michael KarinGASTROENTEROLOGY W B SAUNDERS CO-ELSEVIER INC 140 (5) S927 - S927 0016-5085 2011/05 [Refereed]The Usefulness of Helicobacter pylori Eradication Therapy for the Healing of Artificial Gastric Ulcer After Endoscopic Submucosal Dissection for Early Gastric CancerMasanori Kawasaki; Yutaka Asakuma; Shigenaga Matsui; Toshiharu Sakurai; Hiroshi Kashida; Masatoshi KudoGASTROENTEROLOGY W B SAUNDERS CO-ELSEVIER INC 140 (5) S312 - S312 0016-5085 2011/05 [Refereed]Prevention of Delayed Bleeding After Endoscopic Submucosal Dissection (ESD) for Gastric TumorsYutaka Asakuma; Shigenaga Matsui; Masanori Kawasaki; Toshiharu Sakurai; Hiroshi Kashida; Masatoshi KudoGASTROENTEROLOGY W B SAUNDERS CO-ELSEVIER INC 140 (5) S235 - S235 0016-5085 2011/05 [Refereed][Effects of interferon treatment on recurrence and survival after curative treatment of hepatitis C virus-related hepatocellular carcinoma].Ueda T; Chung H; Kudo MNihon rinsho. Japanese journal of clinical medicine 日本臨床社 69 Suppl 4 319 - 324 0047-1852 2011/05 [Refereed][Efficacy of adjuvant treatment after curative treatment in patients with HBV related hepatocellular carcinoma].Hagiwara S; Kudo MNihon rinsho. Japanese journal of clinical medicine 日本臨床社 69 Suppl 4 546 - 550 0047-1852 2011/05 [Refereed]【最新・消化器がん化学療法と有害事象へのかかわり方】肝臓がん上嶋 一臣; 工藤 正俊消化器肝胆膵ケア 日総研出版 16 (1) 20 - 25 2011/04分子標的治療におけるPIVKA-II評価のポイント上嶋 一臣; 工藤 正俊クリニシアン エーザイ(株) 58 (4) 464 - 469 0387-1541 2011/04C型肝炎治療におけるReal-time Tissue Elastographyを用いた肝線維化の非侵襲的評価法藤本 研治; 石田 哲士; 矢田 典久; 上嶋 一臣; 外村 明子; 三竹 毅; 椎名 毅; 工藤 正俊; 加藤 道夫超音波医学 (公社)日本超音波医学会 38 (Suppl.) S209 - S209 1346-1176 2011/04B型慢性肝炎に対するPEG-IFNα2bとエンテカビル48週併用療法の有効性について萩原 智; 峯 宏昌; 有住 忠晃; 早石 宗右; 上田 泰輔; 田北 雅弘; 畑中 絹世; 北井 聡; 矢田 典久; 井上 達夫; 鄭 浩柄; 櫻井 俊治; 上嶋 一臣; 工藤 正俊; 犬塚 義; 大崎 往夫日本消化器病学会雑誌 (一財)日本消化器病学会 108 (臨増総会) A251 - A251 0446-6586 2011/03Antitumor Activity of BIBF 1120, a Triple Angiokinase Inhibitor, and Use of VEGFR2(+)pTyr(+) Peripheral Blood Leukocytes as a Pharmacodynamic Biomarker In VivoKanae Kudo; Tokuzo Arao; Kaoru Tanaka; Tomoyuki Nagai; Kazuyuki Furuta; Kazuko Sakai; Hiroyasu Kaneda; Kazuko Matsumoto; Daisuke Tamura; Keiichi Aomatsu; Marco A. De Velasco; Yoshihiko Fujita; Nagahiro Saijo; Masatoshi Kudo; Kazuto NishioCLINICAL CANCER RESEARCH AMER ASSOC CANCER RESEARCH 17 (6) 1373 - 1381 1078-0432 2011/03 [Refereed] Purpose: BIBF 1120 is a potent, orally available triple angiokinase inhibitor that inhibits VEGF receptors (VEGFR) 1, 2, and 3, fibroblast growth factor receptors, and platelet-derived growth factor receptors. This study examined the antitumor effects of BIBF 1120 on hepatocellular carcinoma (HCC) and attempted to identify a pharmacodynamic biomarker for use in early clinical trials. Experimental Design: We evaluated the antitumor and antiangiogenic effects of BIBF 1120 against HCC cell line both in vitro and in vivo. For the pharmacodynamic study, the phosphorylation levels of VEGFR2 in VEGF-stimulated peripheral blood leukocytes (PBL) were evaluated in mice inoculated with HCC cells and treated with BIBF 1120. Results: BIBF 1120 (0.01 mu mol/L) clearly inhibited the VEGFR2 signaling in vitro. The direct growth inhibitory effects of BIBF 1120 on four HCC cell lines were relatively mild in vitro (IC50 values: 2-5 mu mol/L); however, the oral administration of BIBF 1120 (50 or 100 mg/kg/d) significantly inhibited the tumor growth and angiogenesis in a HepG2 xenograft model. A flow cytometric analysis revealed that BIBF 1120 significantly decreased the phosphotyrosine (pTyr) levels of VEGFR2(+)CD45(dim) PBLs and the percentage of VEGFR2(+)pTyr(+) PBLs in vivo; the latter parameter seemed to be a more feasible pharmacodynamic biomarker. Conclusions: We found that BIBF 1120 exhibited potent antitumor and antiangiogenic activity against HCC and identified VEGFR2(+)pTyr(+) PBLs as a feasible and noninvasive pharmacodynamic biomarker in vivo. Clin Cancer Res; 17(6); 1373-81. (C)2010 AACR.Gd-EOB-DTPA造影MRI肝細胞相で検出された慢性障害肝の乏血性結節 多血化の危険因子兵頭 朋子; 岡田 真広; 香川 祐毅; 熊野 正士; 堀 雅敏; 石井 一成; 今井 康陽; 望月 輝一; 工藤 正俊; 村上 卓道日本医学放射線学会学術集会抄録集 (公社)日本医学放射線学会 70回 S342 - S343 0048-0428 2011/02Estimation of malignant potential of GI stromal tumors by contrast-enhanced harmonic EUSHiroki Sakamoto; Masayuki Kitano; Shigenaga Matsui; Ken Kamata; Takamitsu Komaki; Hajime Imai; Kensaku Dote; Masatoshi KudoGASTROINTESTINAL ENDOSCOPY MOSBY-ELSEVIER 73 (2) 227 - 237 0016-5107 2011/02 [Refereed] Background: Contrast-enhanced harmonic EUS (CEH-EUS) is a new sonographic technique that uses US contrast agents and depicts intratumoral vessels in real time. Objective: To evaluate whether assessment of tumor vascularity by CEH-EUS can predict the preoperative malignancy risk of GI stromal tumors (GISTs). Design: Prospective study to observe GIST vascularity.. Setting: Kinki University School of Medicine. Patients: Between June 2007 and September 2009, 76 consecutive patients suspected of having subepithelial lesions underwent CEH-EUS. Intervention: CEH-EUS was performed by using a prototype echoendoscope in an extended pure harmonic detection mode. Main Outcome Measurements: Resected GIST specimens in 29 patients who underwent surgical resection were divided into high-grade (n = 16) and low-grade (n = 13) malignancy groups based on mitotic activity. The abilities of EUS-guided FNA and CEH-EUS to diagnose the malignant potential were compared. The sensitivities with which contrast-enhanced multidetector CT, power-Doppler EUS, and CEH-EUS detected intratumoral vessels in high-grade malignancy GISTs also were compared. Results: CEH-EUS identified irregular vessels and thereby predicted GIST malignancies with a sensitivity, specificity, and accuracy of 100%, 63%, and 83%, respectively. Diagnosis of high-grade malignancy GISTs by EUS-guided FNA had a sensitivity, specificity, and accuracy of 63%, 92%, and 81%, respectively. Contrast-enhanced multidetector CT, power-Doppler EUS, and CEH-EUS detected intratumoral vessels in high-grade malignancy GISTs with sensitivities of 31%, 63%, and 100%, respectively (P < .05). Limitations: A single center was involved in this study. Conclusions: CEH-EUS successfully visualized intratumoral vessels and may play an important role in predicting the malignancy risk of GISTs. (Gastrointest Endosc 2011;73:227-37.)Double-Contrast Ultrasound: A Novel Surveillance Tool for Hepatocellular CarcinomaMasatoshi Kudo; Kinuyo Hatanaka; Takashi Kumada; Hidenori Toyoda; Toshifumi TadaAMERICAN JOURNAL OF GASTROENTEROLOGY NATURE PUBLISHING GROUP 106 (2) 368 - 370 0002-9270 2011/02 [Refereed]Management of hepatitis B: Consensus of the Japan Society of Hepatology 2009Osamu Yokosuka; Masayuki Kurosaki; Fumio Imazeki; Yasuji Arase; Yasuhito Tanaka; Kazuaki Chayama; Eiji Tanaka; Hiromitsu Kumada; Namiki Izumi; Masashi Mizokami; Masatoshi KudoHEPATOLOGY RESEARCH WILEY-BLACKWELL PUBLISHING, INC 41 (1) 1 - 21 1386-6346 2011/01 [Refereed] Recently, much progress has been made in the field of hepatitis B, such as natural history of the disease in relation to the amount of hepatitis B virus (HBV) DNA, genotypes of HBV influencing the natural course and treatment effects, mutations of HBV influencing the severity of the disease and development of hepatocellular carcinoma, and antiviral treatment such as nucleos(t)ide analogues and pegylated interferon. To make the consensus for the diagnosis, management and treatment of hepatitis B, a meeting was held during 45th annual meeting of Japan Society of Hepatology (JSH) in June 2009. In the meeting, recommendations and informative statements were discussed on the following subjects: (i) natural history of HBV infection; (ii) clinical implication of HBV genotypes; (iii) HBV mutations and their potential impact on pathogenesis of HBV infection; (iv) indications for antiviral treatment of chronic hepatitis B; (v) nucleos(t)ide analogues for chronic hepatitis B; and (vi) interferon therapy for chronic hepatitis B. The presenters reviewed the data on these subjects and proposed the consensus statements and recommendations. These statements were discussed among the organizers and presenters, and were approved by the participants of the meeting. In the current report, the relevant data were reviewed and the 12 consensus statements and nine recommendations on chronic hepatitis B were described.Pancreatology: PrefaceMasatoshi Kudo; Kenji Yamao; Tooru ShimosegawaPancreatology Elsevier B.V. 11 (2) 1 - 2 1424-3911 2011 [Refereed]Endoscopic Ultrasonography and Contrast-Enhanced Endoscopic UltrasonographyMasayuki Kitano; Masatoshi Kudo; Hiroki Sakamoto; Takamitsu KomakiPANCREATOLOGY KARGER 11 28 - 33 1424-3903 2011 [Refereed] Endoscopic ultrasonography (EUS) is superior to all other imaging modalities in detecting small pancreatic cancers. However, its ability to characterize hypoechoic pancreatic masses is limited: most carcinomas, neuroendocrine tumors, and inflammatory pseudotumors are simply depicted as hypoechoic masses. Contrast enhancement helps EUS to characterize such hypoechoic masses. Intravenous ultrasound (US) agents increase the signal from the blood and, thus, act as amplifiers and improve visualization of blood flow in small vessels using Doppler US. Contrast-enhanced Doppler EUS can differentiate small pancreatic carcinomas that cannot be detected by other imaging modalities. The development of second-generation US contrast agents and an EUS system with a broad-band transducer enabled the visualization of microvessels and the parenchymal perfusion in the pancreas. This contrast-enhanced harmonic EUS has shown that most pancreatic cancers exhibit hypovascular heterogeneous enhancement with irregular network-like microvessels. Moreover, it can diagnose pancreatic cancers with a high sensitivity (89-92%). Copyright (C) 2011 S. Karger AG, Basel and IAPDes-gamma-Carboxyprothrombin May Be a Promising Biomarker to Determine the Therapeutic Efficacy of Sorafenib for Hepatocellular CarcinomaKazuomi Ueshima; Masatoshi Kudo; Masahiro Takita; Tomoyuki Nagai; Chie Tatsumi; Taisuke Ueda; Satoshi Kitai; Emi Ishikawa; Norihisa Yada; Tatsuo Inoue; Satoru Hagiwara; Yasunori Minami; Hobyung Chung; Toshiharu SakuraiDIGESTIVE DISEASES KARGER 29 (3) 321 - 325 0257-2753 2011 [Refereed] Objective: The purpose of this study was to evaluate the role of des-gamma-carboxyprothrombin (DCP) as a marker for the efficacy of sorafenib therapy for hepatocellular carcinoma (HCC). Methods: Patients with advanced HCC treated with sorafenib were retrospectively evaluated, focusing on DCP levels and clinical characteristics. Results: 50 patients with advanced HCC were treated with sorafenib alone. In 25 of these patients, the serum levels of DCP were evaluated twice (pretreatment and within 2 weeks after starting therapy). The time to progression was significantly longer in patients in whom the DCP level at 2 weeks after starting sorafenib was 6 2-fold higher than the pretreatment levels, as compared with patients without an increase in DCP (p = 0.0296). Conclusions: The serum level of DCP is a surrogate marker for tissue hypoxia and can be a predictive marker to assess the tumor response to sorafenib therapy. Copyright (C) 2011 S. Karger AG, BaselOral Branched-Chain Amino Acid Granules Reduce the Incidence of Hepatocellular Carcinoma and Improve Event-Free Survival in Patients with Liver CirrhosisSosuke Hayaishi; Hobyung Chung; Masatoshi Kudo; Emi Ishikawa; Masahiro Takita; Taisuke Ueda; Satoshi Kitai; Tatsuo Inoue; Norihisa Yada; Satoru Hagiwara; Yasunori Minami; Kazuomi UeshimaDIGESTIVE DISEASES KARGER 29 (3) 326 - 332 0257-2753 2011 [Refereed] Background: It has been reported that branched-chain amino acid (BCAA) supplementation can improve nutritional status and prevent liver-related complications in patients with decompensated cirrhosis. We investigated the effects of oral BCAA supplementation on the incidence of hepatocellular carcinoma (HCC) and liver-related events in patients with compensated and decompensated cirrhosis. Methods: We enrolled 211 patients with cirrhosis including 152 patients with Child-Pugh A cirrhosis, but no history of HCC. Of these, 56 received oral administration of 12 g/day BCAA for 6 6 months (BCAA group), and 155 were followed-up without BCAA treatment (control group). The HCC occurrence and event-free survival rates were compared between the two groups. We used a propensity score analysis to overcome selection bias of this retrospective analysis. Results: The HCC occurrence rate was significantly lower and event-free survival rate was significantly higher in the BCAA group than in the control group. Multivariate analyses showed BCAA supplementation was significantly associated with reduced incidence of HCC (hazard ratio (HR) 0.416, 95% confidence interval (CI) 0.216-0.800, p = 0.0085). BCAA supplementation also reduced the incidence of liver-related events in patients with Child-Pugh A cirrhosis, although the difference did not reach statistical significance (HR 0.585, 95% CI 0.336-1.017, p = 0.0575). Conclusions: Oral BCAA supplementation is associated with reduced incidence of HCC in patients with cirrhosis and seems to prevent liver-related events in patients with Child-Pugh A cirrhosis. Copyright (C) 2011 S. Karger AG, BaselManagement of Hepatocellular Carcinoma in Japan: Consensus-Based Clinical Practice Guidelines Proposed by the Japan Society of Hepatology (JSH) 2010 Updated VersionMasatoshi Kudo; Namiki Izumi; Norihiro Kokudo; Osamu Matsui; Michiie Sakamoto; Osamu Nakashima; Masamichi Kojiro; Masatoshi MakuuchiDIGESTIVE DISEASES KARGER 29 (3) 339 - 364 0257-2753 2011 [Refereed] Hepatocellular carcinoma (HCC) is one of the leading causes of cancer death not only in Japan but also worldwide. Clinical practice guidelines for HCC were first published in 2001 by the European Society of Study of the Liver (EASL) followed by the American Association for the Study of Liver Disease (AASLD) published in 2005 and updated in 2010. However, these guidelines have proven to be somewhat unsuitable for Japanese patients. In 2005, supported by the Japanese Ministry of Health, Labour and Welfare, evidence-based clinical practice guidelines for HCC were compiled in Japan. In 2009, a revised version of evidence-based guidelines was published. Based on both 'evidence-based' guidelines and the consensus of an expert panel on HCC, the Japan Society of Hepatology (JSH) published the Consensus-Based Clinical Practice Manual in 2007 and updated in 2010. In this article, the 2010 updated version of this manual, especially issues on prevention, surveillance, pathology, diagnosis, staging, and treatment algorithm are summarized. Copyright (C) 2011 S. Karger AG, BaselAdjuvant Therapy after Curative Treatment for Hepatocellular CarcinomaMasatoshi KudoONCOLOGY KARGER 81 50 - 55 0030-2414 2011 [Refereed] It is widely accepted that hepatocellular carcinoma (HCC) has an annual recurrence rate of approximately 15-20% even after potentially curative treatment, with the 5-year recurrence rate reaching 80-90%. This recurrence rate is also known to be similar after various curative treatments including resection, percutaneous ethanol injection therapy, and radiofrequency ablation. Generally, in treating patients with HCC associated with hepatitis C or liver cirrhosis, aggressive efforts to prevent secondary carcinogenesis are necessary rather than simply observing the clinical course after treatment. Presently, a combination of peg-interferon and ribavirin is known to be highly effective in patients with difficult-to-treat hepatitis C with a high viral load and genotype I virus. Therefore, indications of these treatments must be considered to prevent secondary carcinogenesis in patients with hepatitis C. Recently, long-term follow-up of low-dose, long-term maintenance therapy using pegylated interferon-alpha 2a for cirrhotic patients clearly showed a preventive effect on HCC occurrence and recurrence. Preventing secondary carcinogenesis by suppressing inflammation employing the same treatment as that against primary carcinogenesis is also important. The molecular targeted agent sorafenib markedly suppresses the serine/threonine kinases of Raf in the MAP kinase cascade and inhibits the tyrosine kinases of angiogenesis factor receptors such as vascular endothelial growth factor and platelet-derived growth factor receptors. It thus simultaneously prevents the proliferation of tumors and inhibits angiogenesis. A clinical trial to examine the recurrence-preventing effect of sorafenib by administration of it after curative treatment such as resection or ablation is in progress (STORM trial: http://clinicaltrials.gov.com, NCT00692770). Treatments to prevent recurrence (including intrahepatic metastasis and multicentric carcinogenesis) as well as early detection and early curative treatment are extremely important to improve the prognosis of patients with HCC. Thus, further research on this issue should be carried out, especially in relation to molecular targeted therapy. Copyright (C) 2011 S. Karger AG, BaselDiagnostic Imaging of Hepatocellular Carcinoma: Recent ProgressMasatoshi KudoONCOLOGY KARGER 81 73 - 85 0030-2414 2011 [Refereed] The diagnostic imaging of hepatocellular carcinoma (HCC) has recently undergone marked progress. The advent of the ultrasound (US) contrast agent Sonazoid, approved in January 2007, and magnetic resonance imaging (MRI) with the liver-specific MRI contrast agent gadolinium-ethoxybenzyl-diethylenetriamine pentaacetic acid (Gd-EOB-DTPA-MRI), approved in January 2008, are of particular significance. Sonazoid contrast-enhanced US (Sonazoid-CEUS) is useful not only for the diagnosis of HCC, but also for guiding treatment and assessing treatment response. Sonazoid-CEUS has proven to be particularly effective for screening and staging, which used to be considered impossible with CEUS, through the introduction of the newly developed diagnostic technique of defect reperfusion imaging. It is still not possible if other vascular agents such as SonoVue and Definity are used. In particular, Gd-EOB-DTPA-MRI has been suggested to be much more reliable in the differentiation of early HCC from precancerous dysplastic nodules than any other modalities such as multidetector raw computed tomography, dynamic MRI, and superparamagnetic iron oxide-MRI. A decrease in contrast uptake in the hepatocyte phase observed on EOB-MRI is strongly suggestive of cancer, and the absence of early staining in the arterial phase suggests early HCC. The differential diagnostic capacity of Gd-EOB-DTPA-MRI is considered to far exceed that of what were previously the most useful imaging techniques, computed tomography (CT) during hepatic arteriography or CT during arterial portography, and to be comparable to that of the pathological diagnosis by pathologists specialized in liver. Copyright (C) 2011 S. Karger AG, Basel混合型肝癌の疫学: 全国集計を中心に. 特集「混合型肝癌および胆管形質を示す肝細胞癌: 肝ステム細胞のインパクト」北井 聡; 工藤正俊肝胆膵 63 559 - 563 2011 [Refereed]ソラフェニブによりCRとなった進行肝細胞癌の2症例上嶋 一臣; 土師 誠二; 早石 宗右; 上田 泰輔; 北井 聡; 矢田 典久; 井上 達夫; 萩原 智; 鄭 浩柄; 櫻井 俊治; 工藤 正俊新薬と臨牀 (株)医薬情報研究所 59 (12) 2409 - 2410 0559-8672 2010/12Endoscopic ultrasound (EUS)-guided transluminal endoscopic removal of gallstonesK. Kamata; M. Kitano; M. Kudo; H. Imai; H. Sakamoto; T. KomakiENDOSCOPY GEORG THIEME VERLAG KG 42 E331 - E332 0013-726X 2010/12 [Refereed]Relationship between urinary sodium excretion and pioglitazone-induced edema.Nakamura A; Osonoi T; Terauchi YJournal of diabetes investigation 1 (5) 208 - 211 2040-1116 2010/10 [Refereed]Searching for biological markers of molecular targeting treatment of liver cancer.Arao T; Kudo M; Nishio KGan to kagaku ryoho. Cancer & chemotherapy 37 (10) 1879 - 1882 0385-0684 2010/10 [Refereed]非閉塞性腸管虚血を発症した悪性リンパ腫の一例宮田 剛; 井上 達夫; 有住 忠晃; 早石 宗右; 上田 泰輔; 辰巳 千栄; 田北 雅弘; 北井 聡; 石川 恵美; 矢田 典久; 萩原 智; 鄭 浩柄; 上嶋 一臣; 工藤 正俊日本消化器病学会雑誌 (一財)日本消化器病学会 107 (臨増大会) A828 - A828 0446-6586 2010/09造影エコーによる肝細胞癌の診断能、Gd-EOB-MRI、Dynamic CTとの比較検討井上 達夫; 畑中 絹世; 早石 宗右; 上田 泰輔; 田北 雅弘; 北井 聡; 矢田 典久; 萩原 智; 鄭 浩柄; 上嶋 一臣; 工藤 正俊肝臓 (一社)日本肝臓学会 51 (Suppl.2) A564 - A564 0451-4203 2010/09線維化進行C型肝炎患者における脾摘後のインターフェロン導入における問題点 好中球数の変化について鄭 浩柄; 上田 泰輔; 早石 宗右; 田北 雅弘; 北井 聡; 畑中 絹代; 矢田 典久; 井上 達夫; 萩原 智; 上嶋 一臣; 工藤 正俊; 土師 誠二肝臓 (一社)日本肝臓学会 51 (Suppl.2) A600 - A600 0451-4203 2010/09Liver Cancer Working Group ReportMasatoshi Kudo; Kwang Hyub Han; Norihiro Kokudo; Ann-Lii Cheng; Byung Ihn Choi; Junji Furuse; Namiki Izumi; Joong-Won Park; Ronnie T. Poon; Michiie SakamotoJAPANESE JOURNAL OF CLINICAL ONCOLOGY OXFORD UNIV PRESS 40 i19 - i27 0368-2811 2010/09 [Refereed] Hepatocellular carcinoma is a highly prevalent disease in many Asian countries, accounting for 75-80% of victims worldwide. The incidence of hepatocellular carcinoma varies enormously across Asia, but tends to follow the incidences of hepatitis B infection and liver cirrhosis. The incidence and etiology of hepatocellular carcinoma in Japan are different from the rest of Asia, but similar to that in Western countries because hepatitis C infection is the main etiological factor in Japan. Hepatitis B virus vaccination programs are showing great success in reducing hepatitis B virus-related hepatocellular carcinoma. Screening program improves detection of early hepatocellular carcinoma and has some positive impact on survival, but the majority of hepatocellular carcinoma patients in Asia still present with advanced hepatocellular carcinoma. Long-term outcomes following treatment of even early/intermediate or advanced disease are often unsatisfactory because of a lack of effective adjuvant and systemic therapies. Various clinical practice guidelines for hepatocellular carcinoma have been established and are in use. Clinical diagnosis of hepatocellular carcinoma by imaging diagnosis is replacing diagnosis of hepatocellular carcinoma by pathological confirmation. New imaging and treatment techniques are continuously being developed and guidelines should be updated every 3 or 4 years, incorporating new evidence. New molecularly targeted therapies hold great promise. Sorafenib is the first systemic therapy to demonstrate prolonged survival vs. the placebo in patients with advanced hepatocellular carcinoma. Various other new molecularly targeted agents are currently under investigation.Hepatitis C Virus Core Protein Induces Homotolerance and Cross-Tolerance to Toll-Like Receptor Ligands by Activation of Toll-Like Receptor 2Hobyung Chung; Tomohiro Watanabe; Masatoshi Kudo; Tsutomu ChibaJOURNAL OF INFECTIOUS DISEASES OXFORD UNIV PRESS INC 202 (6) 853 - 861 0022-1899 2010/09 [Refereed] Background. Hepatitis C virus (HCV) activates host innate immune responses mediated by retinoic acid inducing gene-I (RIG-I) and Toll-like receptors (TLRs). Although the nonstructural protein 3/4A (NS3/4A) of HCV disrupts interferon responses by inhibiting RIG-I signaling, the effects of TLR activation by HCV-associated proteins on host innate immune responses are poorly understood. Methods. Proinflammatory cytokine responses to various TLR ligands in human antigen-presenting cells (APCs) were examined either with or without prestimulation by HCV core protein. Results. TLR2 activation by the HCV core protein leads to a decrease in interleukin 6 (IL-6) production by human APCs after subsequent stimulation with TLR2 (homotolerance) ligands and TLR4 (cross-tolerance) ligands. This hyporesponsiveness induced by preexposure to the HCV core protein was partially mediated by the negative regulation of nuclear factor-kappa B activation by the induction of IRAK-M. TLR ligand-induced IL-6 production was significantly reduced in peripheral blood monocytes isolated from HCV-infected patients, compared with those of healthy control subjects. Alloantigen presentation by monocytes isolated from HCV-infected patients results in impaired production of interleukin 17 by naive CD4(+) T cells in the presence of TLR ligands. Conclusions. Chronic stimulation of APCs with HCV core protein is associated with hyporesponsiveness in TLR-mediated innate immunity.Estimation of Liver Function Using T1 Mapping on Gadolinium Ethoxybenzyl Diethylenetriamine Pentaacetic Acid-enhanced Magnetic Resonance Imaging.Katsube T; Okada M; Kumano S; Hori M; Imaoka I; Ishii K; Kudo M; Kitagaki H; Murakami TInvest Radiol Lippincott Williams & Wilkins 46 277 - 283 2010/08 [Refereed]Diagnosis of subepithelial tumors in the upper gastrointestinal tract by endoscopic ultrasonography.Sakamoto H; Kitano M; Kudo MWorld journal of radiology 2 (8) 289 - 297 2010/08 [Refereed]Endoscopic findings of intestinal Behcet's disease complicated with toxic megacolonY. Umehara; M. Kudo; M. KawasakiENDOSCOPY GEORG THIEME VERLAG KG 42 E173 - E174 0013-726X 2010/07 [Refereed]Management of hepatocellular carcinoma: From prevention to molecular targeted therapyMasatoshi KudoOncology 78 (1) 1 - 6 0030-2414 2010/07 [Refereed] Hepatocellular carcinoma is a malignant tumor responsible for approximately 600,000-700,000 deaths worldwide, and is becoming more prevalent not only in South-East Asia and Africa, but also in Western countries therefore, interest in hepatocellular carcinoma has mounted in recent years in the West, where little or no interest was evident 10-20 years ago. Copyright © 2010 S. Karger AG.Response Evaluation Criteria in Cancer of the Liver (RECICL) proposed by the Liver Cancer Study Group of Japan (2009 Revised Version)Masatoshi Kudo; Shouji Kubo; Kenichi Takayasu; Michiie Sakamoto; Masatoshi Tanaka; Iwao Ikai; Junji Furuse; Kenji Nakamura; Masatoshi MakuuchiHEPATOLOGY RESEARCH WILEY-BLACKWELL 40 (7) 686 - 692 1386-6346 2010/07 [Refereed] The World Health Organization (WHO) criteria and Response Evaluation Criteria in Solid Tumors (RECIST) are inappropriate to assess the direct effects of treatment on the hepatocellular carcinoma (HCC) by locoreginal therapies such as radio-frequency ablation (RFA) and transcatheter arterial chemo-embolization (TACE). Therefore, establishment of response evaluation criteria solely devoted for HCC is needed urgently in the clinical practice as well as in the clinical trials of HCC treatment, such as molecular targeted therapies, which cause necrosis of the tumor. Response Evaluation Criteria in Cancer of the Liver (RECICL) was revised in 2009 by Liver Cancer Study Group of Japan based on the 2004 version of RECICL, which was commonly used in Japan. Major revised points of the RECICL 2009 is to provide TE4a (Complete response with enough ablative margin) and TE4b (complete response without enough ablative margin) for local ablation therapy. Second revised point is that setting the timing at which the overall treatment effects are assessed. Third point is that emergence of new lesion in the liver is regarded as progressive disease, different from 2004 version. Finally, 3 tumor markers including alpha-fetoprotein (AFP) and AFP-L3 and des-gamma-carboxy protein (DCP) were also added for the overall treatment response. We hope this new treatment response criteria, RECICL, proposed by Liver Cancer Study Group of Japan will benefit the HCC treatment response evaluation in the setting of the daily clinical practice and clinical trials as well not only in Japan, but also internationally.肝細胞癌の分子標的探索と臨床応用 HCCに対するソラフェニブの治療効果予測について上嶋 一臣; 工藤 正俊肝臓 (一社)日本肝臓学会 51 (Suppl.1) A32 - A32 0451-4203 2010/04Real-time Tissue Elastographyによる非侵襲的肝線維化評価法は炎症の影響を受けない藤本 研治; 外村 明子; 辰巳 千栄; 石田 哲士; 上嶋 一臣; 三竹 毅; 山本 佳司; 椎名 毅; 工藤 正俊; 加藤 道夫肝臓 (一社)日本肝臓学会 51 (Suppl.1) A346 - A346 0451-4203 2010/04組織エラストグラフィーの現況と展望 慢性肝疾患におけるReal-time Tissue Elastographyの精度の検討藤本 研治; 外村 明子; 辰巳 千栄; 石田 哲士; 上嶋 一臣; 三竹 毅; 椎名 毅; 工藤 正俊; 加藤 道夫超音波医学 (公社)日本超音波医学会 37 (Suppl.) S168 - S168 1346-1176 2010/04びまん性肝疾患のUltrasound Functional Imaging C型慢性肝疾患患者に対する非侵襲的肝線維化評価の有用性に関する検討矢田 典久; 辰巳 千栄; 上嶋 一臣; 藤本 研治; 加藤 道夫; 椎名 毅; 外村 明子; 三竹 毅; 工藤 正俊超音波医学 (公社)日本超音波医学会 37 (Suppl.) S280 - S280 1346-1176 2010/04Overall Survival After Transarterial Lipiodol Infusion Chemotherapy With or Without Embolization for Unresectable Hepatocellular Carcinoma: Propensity Score AnalysisKenichi Takayasu; Shigeki Arii; Iwao Ikai; Masatoshi Kudo; Yutaka Matsuyama; Masamichi Kojiro; Masatoshi MakuuchiAMERICAN JOURNAL OF ROENTGENOLOGY AMER ROENTGEN RAY SOC 194 (3) 830 - 837 0361-803X 2010/03 [Refereed] OBJECTIVE. Although iodized oil transarterial chemoembolization (TACE) has been found to have survival benefit in the care of patients with unresectable hepatocellular carcinoma, iodized oil infusion chemotherapy without embolization has not been clearly found inferior to or equal to TACE. The purpose of this study was to determine whether one of these therapies is superior to the other or the two are equal in survival benefit and whether embolization with gelatin sponge particles is indispensable to prolonging survival. SUBJECTS AND METHODS. A prospective nonrandomized observational cohort study was conducted over 8 years. Among 11,030 patients with unresectable hepatocellular carcinoma, 8,507 underwent TACE, and 2,523 underwent transarterial infusion therapy with an emulsion of iodized oil and an anticancer agent as initial treatment. Patients with extrahepatic metastasis or any previous treatment were excluded. The primary end point was all-cause mortality. To minimize selection bias, propensity score analysis was used to compare the two groups. RESULTS. During the follow-up period, 5,044 patients (46%) died. In the analysis of all patients, TACE was associated with a significantly higher survival rate than infusion therapy without embolization (hazard ratio, 0.60; 95% CI, 0.56-0.64; p = 0.0001). The propensity score analysis showed that the hazard ratio for death in the TACE group (n = 1,699 patients) compared with the group who underwent infusion therapy without embolization (n = 1,699) was 0.70 (95% CI, 0.63-0.76; p = 0.0001). The median survival time of the TACE group was 2.74 years, and the 1-, 3-, and 5-year survival rates were 81%, 46%, and 25%. The corresponding values for the group who underwent transarterial infusion therapy without embolization were 1.98 years and 71%, 33%, and 16%. CONCLUSION. Propensity score analysis showed that in the treatment of patients with unresectable hepatocellular carcinoma, TACE was associated with significantly better overall survival rates than was transarterial infusion therapy without embolization. TACE can be recommended as initial treatment of these patients.【消化器がん化学療法看護完全マスターBOOK 分子標的薬と従来型抗がん剤のケア 副作用 治療のしくみがやさしくわかる!】こう変わった!こう変わる!肝がん化学療法上嶋 一臣; 工藤 正俊消化器外科Nursing (株)メディカ出版 (2010臨時増刊) 128 - 129 1341-7819 2010/02MRIおよびCTを用いた画像的肝機能評価岡田 真広; 熊野 正士; 勝部 敬; 香川 祐毅; 栗生 明博; 今岡 いずみ; 石井 一成; 今井 康陽; 工藤 正俊; 村上 卓道日本医学放射線学会学術集会抄録集 (公社)日本医学放射線学会 69回 S134 - S134 0048-0428 2010/02Identification and characterization of IgG4-associated autoimmune hepatitisHobyung Chung; Tomohiro Watanabe; Masatoshi Kudo; Osamu Maenishi; Yoshio Wakatsuki; Tsutomu ChibaLIVER INTERNATIONAL WILEY-BLACKWELL PUBLISHING, INC 30 (2) 222 - 231 1478-3223 2010/02 [Refereed] Background Autoimmune hepatitis (AIH) and autoimmune pancreatitis (AIP) share clinical and pathological features such as high serum levels of immunoglobulin (Ig) G and autoantibodies, and lymphoplasmacytic infiltration, suggesting the presence of common immunological abnormalities. However, little is known about the possible involvement of IgG4, a hallmark of AIP, in AIH. Aims In this study, we examined whether the IgG4 response contributes to the histopathological and clinical findings in AIH. Methods Liver sections from 26 patients with AIH, 10 patients with primary biliary cirrhosis (PBC), three patients with primary sclerosing cholangitis (PSC) and 20 chronic hepatitis patients with hepatitis C virus (HCV) infection were immunostained for IgG4. We investigated the relationship among the histopathology, the responses to steroid therapy and the IgG4 staining. Results Nine of the 26 liver specimens from patients with AIH showed positive staining for IgG4 whereas none of the 10 samples from patients with PBC, the three samples from patients with PSC or the 20 samples from patients with HCV hepatitis were positive. Patients with IgG4-positive AIH also showed increased serum levels of IgG. The numbers of T cells, B cells and plasma cells were significantly increased in the livers of patients with IgG4-positive AIH as compared with those patients with IgG4-negative AIH. Patients with IgG4-positive AIH also showed a marked response to prednisolone therapy. Conclusions AIH may be classified into either an IgG4-associated type or an IgG4 non-associated type with the former showing a marked response to prednisolone treatment.Usefulness of the Post-Vascular Phase of Contrast-Enhanced Ultrasonography with Sonazoid in the Evaluation of Gross Types of Hepatocellular CarcinomaKinuyo Hatanaka; Hobyung Chung; Masatoshi Kudo; Seiji Haji; Yasunori Minami; Kiyoshi Maekawa; Sousuke Hayaishi; Tomoyuki Nagai; Masahiro Takita; Kanae Kudo; Taisuke Ueda; Chie Tatsumi; Satoshi Kitai; Emi Ishikawa; Norihisa Yada; Tatsuo Inoue; Satoru Hagiwara; Kazuomi UeshimaONCOLOGY KARGER 78 53 - 59 0030-2414 2010 [Refereed] Objective: The purpose of this study was to assess the usefulness of post-vascular phase (PVP) images of contrast-enhanced ultrasonography (CE-US) in the evaluation of the gross types of hepatocellular carcinoma (HCC) that is closely related to the malignant potential of the tumor. Methods: A total of 29 patients with 40 HCCs of <5 cm in diameter, who underwent hepatic resection, were enrolled. The gross type of the tumor was evaluated using real-time scanning during the PVP of CE-US with Sonazoid prior to surgery. The tumors were classified into three types based on the macroscopic classification of the Liver Cancer Study Group of Japan: single nodular (SN) type, single nodular with extranodular growth (SNEG) type, and confluent multinodular (CMN) type. The ability of CE-US to correctly depict the gross type of HCC was evaluated. Results: 26 tumors were macroscopically diagnosed as the SN type, 11 tumors as the SNEG type, and 3 tumors as the CMN type. The sensitivity, specificity and accuracy of CE-US were 96, 80 and 90%, respectively. Conclusion: The PVP image of CE-US with Sonazoid is a useful tool in the evaluation of the gross type of HCC and is considered essential in deciding treatment strategy. Copyright (C) 2010 S. Karger AG, BaselChanging Trends in Hepatitis C Infection over the Past 50 Years in JapanHobyung Chung; Taisuke Ueda; Masatoshi KudoINTERVIROLOGY KARGER 53 (1) 39 - 43 0300-5526 2010 [Refereed] In Japan, hepatocellular carcinoma (HCC) is the fourth leading cause of death in males and the fifth in females. Hepatitis C virus (HCV) is a major cause of HCC in Japan, with 70% of cases being HCV related. HCV genotype 1b, the most prevalent subtype in Japan, started to spread in the 1930s among injecting drug users (IDUs) during and after World War II or through medical procedures such as blood transfusion and use of contaminated syringes. The prevalence of HCV infection is much lower in the current younger generation compared with that in the older generation, particularly those aged 1 55 years (0.1-0.2% vs. >= 2%). Therefore, the total number of patients with HCV infection is estimated to decrease, even though sporadic HCV transmission is mainly seen among young IDUs. Of note, HCV genotype 2 seems to be spreading among IDUs, but the response to antiviral therapy in these patients seems to be better than that in older patients, irrespective of the genotype. Although the number of patients who die because of HCC has steadily increased over the last 50 years, the incidence of HCC is now decreasing, mainly because of the decreased prevalence of HCV-related HCC. Copyright (C) 2010 S. Karger AG, BaselDouble-Filtration Plasmapheresis plus IFN for HCV-1b Patients with Non-Sustained Virological Response to Previous Combination Therapy: Early Viral DynamicsSoo Ryang Kim; Susumu Imoto; Masatoshi Kudo; Keiji Mita; Miyuki Taniguchi; Ke Ih Kim; Noriko Sasase; Ikuo Shoji; Motoko Nagano-Fujii; Ahmed El-Shamy; Hak Hotta; Tomoyuki Nagai; Yoshiaki Nagata; Yoshitake HayashiINTERVIROLOGY KARGER 53 (1) 44 - 48 0300-5526 2010 [Refereed] Double-filtration plasmapheresis (DFPP) was approved in Japan in April 2008 for the retreatment of chronic hepatitis C patients with genotype 1b and high viral loads, whose hepatitis C virus was not eradicated by earlier IFN therapy or by pegylated IFN plus ribavirin (PEG-IFN/RBV) combination therapy. In this study, we assessed the early viral dynamics of 9 patients with non-sustained virological response to the combination therapy. The overall viral dynamics of DFPP plus IFN treatment with or without RBV for 4 weeks showed a reduction of 6 1 log in the viral load in 22% (2 of 9 patients), 55.6% (5/9), 77.8% (7/9) and 77.8% (7/9) at 24 h, 1, 2 and 4 weeks after the start of treatment. By contrast, DFPP plus consecutive intravenous IFN-beta for 4 weeks reduced the viral load by >= 1 log in 33% (2/6), 50% (3/6), 83.3% (5/6) and 83.3% (5/6) at 24 h, 1, 2 and 4 weeks. The viral load declined by >= 2 log in 50% (3/6) at 4 weeks after the start of treatment. DFPP plus consecutive intravenous IFN-beta for 4 weeks is a promising treatment for non-sustained virolgical response patients. Copyright (C) 2010 S. Karger AG, BaselOutcome and Early Viral Dynamics with Viral Mutation in PEG-IFN/RBV Therapy for Chronic Hepatitis in Patients with High Viral Loads of Serum HCV RNA Genotype 1bNoriko Sasase; Soo Ryang Kim; Masatoshi Kudo; Ke Ih Kim; Miyuki Taniguchi; Susumu Imoto; Keiji Mita; Yoshitake Hayashi; Ikuo Shoji; Ahmed El-Shamy; Hak HottaINTERVIROLOGY KARGER 53 (1) 49 - 54 0300-5526 2010 [Refereed] We investigated whether sustained virological response (SVR) and non-SVR by chronic hepatitis C patients to pegylated interferon plus ribavirin (PEG-IFN/RBV) combination therapy are distinguishable by viral factors such as the IFN/RBV resistance-determining region (IRRDR) and by on-treatment factors through new indices such as the rebound index (RI). The first RI (RI-1st; the viral load at week 1 divided by the viral load at 24 h) and the second RI (RI-2nd; the viral load at week 2 divided by the viral load at 24 h) were calculated. The subject patients were divided into 3 groups based on RI-1st and RI-2nd: an RI-A group (RI-1st <= 1.0), an RI-B group (RI-1st > 1.0 and RI-2nd <0.7) and an RI-C group (RI-1st > 1.0 and RI-2nd >= 0.7). The SVR rate was 71.4% (10/14) in the RI-A group, 46.2% (6/13) in the RI-B group and 20.0% (3/15) in the RI-C group (p = 0.005 between the RI-A group and the RI-C group). In IRRDR >= 6 and IRRDR <= 5 the SVR rate was 81.3% (13/16) and 23.1% (6/26) (p = 0.0002), respectively. By combining RI and IRRDR as a predicting factor, the SVR rate was 87.5% (7/8) in the RI-A group (>= 6 mutations in the IRRDR) and 7.7% (1/13) in the RI-C group (<= 5 IRRDR mutations) (p = 0.0003). Copyright (C) 2010 S. Karger AG, BaselPEG-IFN alpha/RBV Combination Therapy for Chronic Hepatitis C Patients Increases Serum Ferritin Level while It Improves Sustained Viral Response RateNorihisa Yada; Masatoshi Kudo; Hobyung Chung; Sosuke Hayaishi; Masahiro Takita; Taisuke Ueda; Chie Tatsumi; Kinuyo Hatanaka; Satoshi Kitai; Emi Ishikawa; Tatsuo Inoue; Satoru Hagiwara; Kazuomi UeshimaINTERVIROLOGY KARGER 53 (1) 60 - 65 0300-5526 2010 [Refereed] Objectives: We investigated the significance of serum ferritin levels in pegylated interferon (PEG-IFN) and ribavirin (RBV) combination therapy for chronic hepatitis C (CHC) and examined its correlation with serum alanine aminotransferase (ALT) levels during therapy and response to the therapy. Methods: A total of 175 patients with CHC received the combination therapy. Correlations between serum ferritin levels and serum ALT levels at 12 and 24 weeks of therapy were examined. Differences in serum ferritin levels during therapy between patients with sustained viral response (SVR) and non-SVR were also examined. Results: Only 24 (13.7%) and 20 (11.4%) patients showed elevated serum ALT levels (6 70 IU/l) at 12 and 24 weeks of therapy, respectively. There was no correlation between serum ferritin levels and ALT levels. Ninety-five (54.3%) of 175 patients achieved SVR. Serum ferritin levels increased dramatically in both SVR and non-SVR groups after starting the therapy and were significantly higher in the SVR group throughout the therapy. Conclusions: Serum ferritin level increases during PEG-IFN and RBV combination therapy; however, it did not correlate with either serum ALT level or the total dose of RBV. Higher serum ferritin levels during combination therapy appear to be associated with favorable therapeutic response. Copyright (C) 2010 S. Karger AG, BaselRadiofrequency Ablation for Hepatocellular Carcinoma: Assistant Techniques for Difficult CasesTatsuo Inoue; Yasunori Minami; Hobyung Chung; Sousuke Hayaishi; Taisuke Ueda; Chie Tatsumi; Masahiro Takita; Satoshi Kitai; Kinuyo Hatanaka; Emi Ishikawa; Norihisa Yada; Satoru Hagiwara; Kazuomi Ueshima; Masatoshi KudoONCOLOGY KARGER 78 94 - 101 0030-2414 2010 [Refereed] Purpose: To confirm the safety and effectiveness of techniques to assist radiofrequency ablation (RFA) for difficult cases, we retrospectively evaluated successful treatment rates, early complications and local tumor progressions. Patients and Methods: Between June 1999 and April 2009, a total of 341 patients with 535 nodules were treated as difficult cases. Artificial pleural effusion assisted ablation was performed on 64 patients with 82 nodules. Artificial ascites-assisted ablation was performed on 11 patients with 13 nodules. Cooling by endoscopic nasobiliary drainage (ENBD) tube-assisted ablation was performed on 6 patients with 8 nodules. When the tumors were not well visualized with conventional B-mode ultrasonography (US), contrast-enhanced US-assisted ablation with Levovist (R) or Sonazoid (R) or virtual CT sonography-assisted ablation was performed. Contrast-enhanced US-assisted ablation was performed on 139 patients with 224 nodules and virtual CT sonography-assisted ablation was performed on 121 patients with 209 nodules. Results: In total, complete ablation was achieved in 514 of 535 (96%) nodules in difficult cases. For RFA with artificial pleural effusion, artificial ascites and ENBD, complete response was confirmed in all cases. For contrast-enhanced US-and CT sonography-assisted ablation, complete response was 95%. Early complications were recognized in 24 cases (4.5%). All cases recovered with no invasive treatment. Local tumor recurrence was investigated in 377 nodules of 245 patients, and 69 (18%) nodules were positive. Tumor recurrences in each assisted technique were 14.7% in artificial pleural effusion cases, 7% in artificial ascites, 12.5% in ENBD tube cases, 31% in virtual CT sonography, and 8.5% in contrast-enhanced US. Conclusion: Although local tumor progression needs to be carefully monitored, assisted techniques of RFA for difficult cases are well tolerated and expand the indications of RFA. Copyright (C) 2010 S. Karger AG, BaselPositioning of a Molecular-Targeted Agent, Sorafenib, in the Treatment Algorithm for Hepatocellular Carcinoma and Implication of Many Complete Remission Cases in JapanMasatoshi Kudo; Kazuomi UeshimaONCOLOGY KARGER 78 154 - 166 0030-2414 2010 [Refereed] Sorafenib, a molecular-targeted agent that inhibits tumor cell proliferation and angiogenesis by inhibiting RAF serine-threonine kinase and VEGF, PDGF, Flt-3, c-Kit receptor tyrosine kinase, was approved in Europe and North America in 2007 and in Japan on May 20, 2009. In the 10 months since its approval, sorafenib has been prescribed for more than 3,700 patients with advanced hepatocellular carcinoma (HCC), and its efficacy has been confirmed in many cases. According to the consensus statements of the Japan Society of Hepatology in 2010, sorafenib is recommended for advanced HCC with extrahepatic spread or major vascular invasion such as invasion of the 1st branch of the portal vein or the main portal branch of the portal vein in patients with Child-Pugh A liver function. In addition to that, transcatheter arterial chemoembolization (TACE) or hepatic arterial infusion chemotherapy (HAIC) refractory HCC patients with Child-Pugh A liver function are also candidates of sorafenib monotherapy as a second-line treatment option. To date, 15 cases with complete remission (CR) to sorafenib in metastatic advanced HCC patients have been reported in Japan, an event that is rarely reported in other countries. Of the 90 cases treated by ourselves, 2 achieved CR. Factors indicating systemic cancer spread, including multiple liver lesions, lymph node metastases, adrenal metastases, lung metastases and vascular invasion, were completely absent in both cases of CR by 2 and 1 year, respectively. Similarly, three tumor markers (AFP, PIVKA-II, and AFP-L3) completely returned to normal values. Although cases of CR are rare, it seems that there might be racial differences in terms of gene mutations. Clinical trials for other molecular-targeted agents, including sunitinib, brivanib, or linifanib, are ongoing and their outcomes are eagerly awaited. According to a subanalysis of the SHARP study, it is expected that sorafenib in combination with resection, ablation, TACE or HAIC will markedly prolong the overall survival in early-, intermediate- and advanced-stage HCCs. Copyright (C) 2010 S. Karger AG, Baselペグインターフェロンα-2b/リバビリン併用療法の無効・再燃例に対するペグインターフェロンα-2a/リバビリン併用療法の再治療. 増刊号「C型肝炎の臨床最前線」工藤正俊; 上田泰輔; 土谷 薫; 橋元 悟; 井上泰輔; 稲生実枝; 田中 篤; 垣内雅彦; 今関文夫; 西口修平肝胆膵 61 127 - 133 2010 [Refereed]Transarterial chemotherapy alone versus transarterial chemoembolization for hepatocellular carcinoma: A randomized phase III trialTakuji Okusaka; Hiroshi Kasugai; Yasukazu Shioyama; Katsuaki Tanaka; Masatoshi Kudo; Hiromitsu Saisho; Yukio Osaki; Michio Sata; Shigetoshi Fujiyama; Takashi Kumada; Keiko Sato; Seiichiro Yamamoto; Shiro Hinotsu; Tosiya SatoJOURNAL OF HEPATOLOGY ELSEVIER SCIENCE BV 51 (6) 1030 - 1036 0168-8278 2009/12 [Refereed] Background/Aims: Transcatheter arterial chemoembolization (TACE) is a combination of transarterial infusion chemotherapy (TAI) and embolization, and has been widely used to treat patients with hepatocellular carcinoma (HCC). However, since the impact of adding embolization on the survival of patients treated with TAI had never been evaluated in a phase III study, we conducted a multi-center, open-label trial comparing TACE and TAI to assess the effect of adding embolization on survival. Methods: Patients with newly diagnosed unresectable HCC were randomly assigned to either a TACE group or a TAI group. Zinostatin stimalamer was injected into the hepatic artery, together with gelatin sponge in the TACE group and without gelatin sponge in the TAI group. Treatment was repeated when follow-up computed tomography showed the appearance of new lesions in the liver or re-growth of previously treated tumors. Results: Seventy-nine patients were assigned to the TACE group, and 82 were assigned to the TAI group. The two groups were comparable with respect to their baseline characteristics. At the time of the analysis, 51 patients in the TACE group and 58 in the TAI group had died. The median overall survival time was 646 days in the TACE group and 679 days in the TAI group (p = 0.383). Conclusions: The results of this study suggest that treatment intensification by adding embolization did not increase survival over TAI with zinostatin stimalamer alone in patients with HCC. (C) 2009 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.Contrast-enhanced harmonic ultrasound imaging in ablation therapy for primary hepatocellular carcinoma.Minami Y; Kudo MWorld journal of radiology 1 (1) 86 - 91 2009/12 [Refereed]Small invasive ductal carcinoma of the pancreas distinct from branch duct intraductal papillary mucinous neoplasmHiroki Sakamoto; Masayuki Kitano; Takamitsu Komaki; Hajime Imai; Ken Kamata; Masatomo Kimura; Yoshifumi Takeyama; Masatoshi KudoWORLD JOURNAL OF GASTROENTEROLOGY W J G PRESS 15 (43) 5489 - 5492 1007-9327 2009/11 [Refereed] Endoscopic ultrasonography (EUS) is a highly sensitive diagnostic method for the detection of small pancreatic carcinomas. Recently, there have been some reports describing the utility of contrast-enhanced harmonic EUS (CEH-EUS) which uses sonographic contrast agent for differentiation of a pancreatic mass. This report describes a case of small adenocarcinoma of the pancreas distinct from branch duct intraductal papillary mucinous neoplasm (IPMN) in which investigation by EUS took place every 6 mo and diagnosis was made accurately by additional CEH-EUS during the follow-up of the branch duct IPMN. A 68-year-old female was admitted to our hospital because of a branch duct IPMN in the pancreatic body. She had been followed-up by EUS every 6 mo. However, after 2 years EUS demonstrated a low echoic area distinct from the branch duct IPMN which was; vaguely discernible by EUS, and accurate sizing and differential diagnosis were considered difficult on the EUS imaging. CH-EUS with Sonazoid revealed a hypovascular tumor and we suspected small pancreatic carcinoma. The histopathological diagnosis was adenocarcinoma (10 mm) in the pancreatic tail, distinct from the branch duct IPMN of the pancreatic body. EUS and CEH-EUS may play an important role in the correct diagnosis of small pancreatic tumors, including synchronous and metachronous occurrence of IPMN and ductal adenocarcinoma of the pancreas. (C) 2009 The WJG Press and Baishideng. All rights reserved.Utility of Gd-EOB-DTPA-Enhanced MRI in Diagnosing Small Hepatocellular Carcinoma.Soo Ryang Kim; Susumu Imoto; Taisuke Nakajima; Kenji Ando; Keiji Mita; Katsumi Fukuda; Ryo Nishikawa; Yu-Ichiro Koma; Toshiyuki Matsuoka; Masatoshi Kudo; Yoshitake HayashiCase reports in gastroenterology 3 (2) 187 - 192 1662-0631 2009/07 [Refereed] We describe an 8-mm hepatocellular carcinoma (HCC) with hepatitis C virus-related cirrhosis in a 74-year-old woman. Ultrasound (US) revealed an 8-mm hyperechoic nodule in segment 6 of the liver. Contrast-enhanced computed tomography (CT) and US revealed no hypervascularity in the early phase and no washout in the late phase and the Kupffer phase, respectively. CT during arteriography revealed no hypervascularity and CT during arterial portography disclosed no perfusion defect. Gadolinium-ethoxybenzyl-diethylenetriamine pentaacetic acid (Gd-EOB-DTPA)-enhanced magnetic resonance imaging (MRI) revealed no hypervascularity in the early phase, but disclosed a defect in the hepatobiliary phase. Histologically, the nodule was diagnosed as well-differentiated HCC characterized by more than two-fold the cellularity of the non-tumorous area, with a high nuclear:cytoplasmic ratio, increased cytoplasmic eosinophilia, fatty change, and slight cell atypia with an irregular thin trabecular pattern. Our case demonstrates the utility of Gd-EOB-DTPA-enhanced MRI in the diagnosis of small HCC.Antitumor activity of a novel angiogenesis inhibitor BIBF1120 for hepatocellular carcinoma and a new pharamacodynamic biomarker in blood samples.Kanae Kudo; Tokuzo Arao; Kaoru Tanaka; Hiroyasu Kaneda; Mari Maegawa; Kazuko Matsumoto; Daisuke Tamura; Keiichi Aomatsu; Yoshihiko Fujita; Masatoshi Kudo; Kazuto NishioCANCER RESEARCH AMER ASSOC CANCER RESEARCH 69 0008-5472 2009/05 [Refereed]びまん性肝疾患の超音波による評価 肝疾患におけるReal-time Tissue Elastography(第4報)藤本 研治; 辰巳 千栄; 上嶋 一臣; 外村 明子; 三竹 毅; 金 栄浩; 山本 佳司; 椎名 毅; 工藤 正俊; 加藤 道夫超音波医学 (公社)日本超音波医学会 36 (Suppl.) S204 - S204 1346-1176 2009/04分枝鎖アミノ酸顆粒製剤による肝硬変患者の予後に与える影響に関する検討早石 宗右; 石川 恵美; 辰巳 千栄; 上田 泰輔; 高橋 俊介; 北井 聡; 矢田 典久; 井上 達夫; 南 康範; 鄭 浩柄; 上嶋 一臣; 工藤 正俊肝臓 (一社)日本肝臓学会 50 (Suppl.1) A206 - A206 0451-4203 2009/04進行肝細胞癌に対するS-1、ペグインターフェロン併用療法の有用性矢田 典久; 上嶋 一臣; 早石 宗右; 永井 知行; 田北 雅弘; 辰巳 千栄; 上田 泰輔; 北井 聡; 高橋 俊介; 石川 恵美; 井上 達夫; 南 康範; 鄭 浩柄; 工藤 正俊肝臓 (一社)日本肝臓学会 50 (Suppl.1) A275 - A275 0451-4203 2009/04特異な経過をたどったアルコール性肝硬変に合併した肝細胞癌の一例早石 宗右; 鄭 浩柄; 辰巳 千栄; 永井 知行; 上田 泰輔; 高橋 俊介; 北井 聡; 石川 恵美; 矢田 典久; 井上 達夫; 萩原 智; 南 康範; 上嶋 一臣; 工藤 正俊肝臓 (一社)日本肝臓学会 50 (Suppl.1) A292 - A292 0451-4203 2009/04進行肝細胞癌に対するソラフェニブの有効性に関する検討上嶋 一臣; 早石 宗右; 永井 知行; 田北 雅弘; 辰巳 千栄; 上田 泰輔; 北井 聡; 高橋 俊介; 石川 恵美; 矢田 典久; 井上 達夫; 南 康範; 鄭 浩柄; 工藤 正俊肝臓 (一社)日本肝臓学会 50 (Suppl.1) A359 - A359 0451-4203 2009/04Gd-EOB MRIによる肝細胞癌の診断能 造影超音波検査、Dynamic CTとの比較検討井上 達夫; 畑中 絹世; 早石 宗右; 永井 知行; 田北 雅弘; 上田 泰輔; 高橋 俊介; 北井 聡; 石川 恵美; 矢田 典久; 萩原 智; 南 康範; 鄭 浩柄; 上嶋 一臣; 工藤 正俊肝臓 (一社)日本肝臓学会 50 (Suppl.1) A368 - A368 0451-4203 2009/04Value of Liver Parenchymal Phase Contrast-Enhanced Sonography to Diagnose Premalignant and Borderline Lesions and Overt Hepatocellular CarcinomaTatsuo Inoue; Masatoshi Kudo; Osamu Maenishi; Mina Komuta; Osamu Nakashima; Masamichi Kojiro; Kiyoshi MaekawaAMERICAN JOURNAL OF ROENTGENOLOGY AMER ROENTGEN RAY SOC 192 (3) 698 - 705 0361-803X 2009/03 [Refereed] OBJECTIVE. The objective of our study was to investigate whether liver parenchymal phase contrast-enhanced sonography can provide additional information for assessing histologic grades of hepatocellular carcinoma (HCC). SUBJECTS AND METHODS. Contrast-enhanced sonography using Levovist of 50 hepatic nodules was performed. The vascular and liver parenchymal perfusion patterns were evaluated. The sensitivity, specificity, and accuracy of the histologic diagnosis of the tumors using vascular phase imaging only and systematically combined vascular phase imaging with liver parenchymal phase imaging were calculated. We also performed histologic examination and immunostaining for the detection of Kupffer cells and calculated the Kupffer cell count in the tumorous tissue relative to that in the nontumorous tissue (Kupffer cell ratio) and quantitatively evaluated the relationship between the Kupffer cell ratio and the perfusion patterns seen on liver parenchymal phase imaging. RESULTS. The specificity and accuracy of contrast-enhanced sonography in the diagnosis of dysplastic nodules and of moderately and poorly differentiated HCCs were improved by adding liver parenchymal phase imaging (dysplastic nodules, 74% and 78% vs 83% and 86%, respectively; moderately and poorly differentiated HCCs, 74% and 86% vs 85% and 92%). The diagnostic accuracy of contrast-enhanced sonography for dysplastic nodules showed a trend of improvement with the addition of liver parenchymal phase imaging (p = 0.07). Kupffer cell ratios for tumors that showed hypoperfusion during the liver parenchymal phase were significantly lower than those for tumors showing isoperfusion (p < 0.05). CONCLUSION. Adding liver parenchymal phase imaging to contrast-enhanced sonography protocols may yield additional information that can be used to assess histologic grades of tumor and that leads to an improvement in the differential diagnosis of nodular lesions associated with the cirrhotic liver. Further case studies are required in larger numbers of patients for a longer follow-up period.Radiofrequency ablation for metastatic liver cancerTatsuo Inoue; Masatoshi KudoJapanese Journal of Cancer and Chemotherapy Japanese Journal of Cancer and Chemotherapy Publishers Inc. 36 (8) 1253 - 1255 0385-0684 2009 [Refereed] Radiofrequency ablation (RFA) is widely used as a therapeutic method for hepatocellular carcinoma. It led to more favorable therapeutic results than percutaneous ethanol injection (PEI), which is currently in use. RFA has been used as a new therapeutic tool for metastatic liver cancer. We describe the present situation in our institution regarding RFA therapy for metastatic liver cancer originating from colorectal carcinoma.Hepatocellular carcinoma 2009 and beyond: From the surveillance to molecular targeted therapyMasatoshi KudoOncology 75 (1) 1 - 12 0030-2414 2008/12 [Refereed] Hepatocellular carcinoma (HCC) is a malignant tumor which is becoming more prevalent worldwide. Patients at high risk of developing HCC, namely hepatitis B- and C-related liver cirrhosis patients, should be entered into surveillance programs, which should be performed using both ultrasonography and 3 tumor markers (AFP, PIVKA-II, AFP-L3). The surveillance interval needs to be shortened for patients at higher risk of HCC. Therefore, super-high-risk patients should be screened at 3- to 4-month intervals based on their risk of developing HCC. Sonazoid-enhanced US is extremely useful to characterize hepatic tumors when compared with multidetector-row computed tomography (MDCT). Moreover, Sonazoid-enhanced US with defect reperfusion imaging is a breakthrough approach in the treatment of HCC. This technique will markedly change the therapeutic strategy for liver cancer. Furthermore, diagnostic capability using the new imaging technique Gd-EOB-DTPA MRI is promising. A reduced uptake (low intensity) in the hepatobiliary phase of Gd-EOB-DTPA MRI strongly suggests HCC (including early-stage HCC) or a high-grade dysplastic nodule with high malignant potential. Empirically, intrahepatic arterial infusion chemotherapy using implanted reservoir port is known to be effective for advanced HCC with vascular invasion however, no randomized study exists to prove its efficacy. Further controlled study is necessary to establish this treatment option as a standard of care in a treatment algorithm for HCC. In contrast, sorafenib was established as the first choice of treatment as a standard of care in advanced HCC patients with preserved liver function and vascular invasion/extrahepatic spread. Furthermore, global clinical trials are now ongoing using sorafenib as an adjuvant setting after resection, ablation or TACE. Efficacy of combined use of sorafenib with TACE or intra-arterial infusion chemotherapy is not clear. In order to clarify this issue a randomized clinical trial for intermediate and advanced HCC comparing sorafenib alone versus sorafenib combined with maintenance TACE/intra-arterial infusion chemotherapy and/or intra-arterial infusion chemotherapy is scheduled to be initiated in Japan in 2009. If positive results are obtained by these trials, its impact on treatment strategy for HCC will be drastically changed. Copyright © 2008 S. Karger AG.Epidemiology of hepatocellular carcinoma in Japan and KoreaSoo Ryang Kim; Masatoshi Kudo; Okio Hino; Kwang Hyub Han; Young Hwa Chung; Hyo Suk LeeOncology 75 (1) 13 - 16 0030-2414 2008/12 [Refereed] The worldwide burden of liver cancer has been estimated at 671,000 new cases for the year 2005. Hepatocellular carcinoma (HCC) accounts for between 85 and 90% of primary liver cancer and is one of the most frequent malignancies in Asia. In both Japan and Korea, the incidence exceeds 25 cases/100,000/year and ranks third in cancer deaths after stomach and lung cancer. In Korea the number of deaths from liver cancer increased from approximately 5,789 in 1983 to 9,966 in 1994, and then remained steady at 9,500/100,000 in 2003. In Japan the number of deaths from HCC increased until 2002, and then decreased to 34,089 in 2003, up to 15% of HCC cases are caused by hepatitis B virus (HBV) and ∼80% by hepatitis C virus (HCV) infection the corresponding figures in Korea are ∼70 and ∼20%. Recent clinical data have shown that interferon and lamivudine treatment is effective in preventing the occurrence of HCC attributed to HCV and HBV infection, respectively, and that an aggressive vaccination program against the latter reduces the incidence of HCC. With the enormous efforts of researchers devoted to basic and clinical studies, the incidence of HCC is expected, in the near future, to gradually decline in both countries. Copyright © 2008 S. Karger AG.Impact of interferon therapy after curative treatment of hepatocellular carcinomaMasatoshi KudoOncology 75 (1) 30 - 41 0030-2414 2008/12 [Refereed] Primary and secondary prevention of hepatocellular carcinoma (HCC) which has become endemic worldwide in recent years are the most important issues in reducing mortality of HCC patients. Among several compounds previously reported for secondary prevention, treatment with interferon (IFN) is widely applied and shows encouraging results. To date, there have been 8 published randomized control trials (RCTs) and 6 published non-RCTs on IFN therapy after curative treatment of HCCs. Positive results were shown in 6 of 8 RCTs and in all of 6 non-RCT cohort studies regarding either recurrence rate or patient survival. The impact of IFN therapy after curative treatment of HCC can be summarized as follows: (1) HCC incidence of recurrence is reduced through viral clearance or long-term IFN treatment, even though HCV is not cleared. (2) Low-dose, long-term IFN (maintenance) therapy may suppress HCC recurrence through direct action of IFN on tumor cells. (3) Patient survival is improved through growth inhibition of recurrent tumors, as well as preservation of liver function. (4) According to the above 3 points, there is more chance to receive curative treatment in the IFN than the non-IFN group. (5) Pegylated IFN (PEG-IFN) may be more beneficial than non-PEG-IFN products since IFN concentration is maintained in the body at a high level, which is favorable for its action as a direct anticancer agent. (6) It may be concluded that IFN treatment after curative treatment of HCC is beneficial at least in HCV-related HCC, since it lowers recurrence and improves survival. Copyright © 2008 S. Karger AG.Sonazoid-enhanced ultrasonography for diagnosis of hepatic malignancies: Comparison with contrast-enhanced CTKinuyo Hatanaka; Masatoshi Kudo; Yasunori Minami; Kiyoshi MaekawaOncology 75 (1) 42 - 47 0030-2414 2008/12 [Refereed] Objective: The purpose of this study was to assess the usefulness of Sonazoid-enhanced ultrasonography (US) in the diagnosis of hepatic malignancies in comparison with contrast-enhanced CT findings. Methods: A total of 74 patients with 113 hepatic tumors having or highly suspected of having malignancies were enrolled. These hepatic nodules were diagnosed by typical findings of imaging such as contrast-enhanced CT, dynamic MRI or Sonazoid-enhanced US, tumor markers and histological examinations after surgical resection or biopsy. Results: 108 nodules were diagnosed as malignant tumors (hepatocellular carcinoma: n = 90 metastasis: n = 16 intrahepatic cholangiocarcinoma: n = 2) and the remaining five tumors were diagnosed as benign tumors (dysplastic nodules: n = 5). Sonazoid-enhanced US correctly depicted the presence or absence of tumors in 74 patients, with a sensitivity of 95.4%, an accuracy of 94.7%, and a positive predictive rate of 99%. Contrast-enhanced CT depicted the malignancies with a sensitivity of 85.2%, an accuracy of 82.3%, and a positive predictive rate of 95.8%. There were significant differences between Sonazoid-enhanced US and contrast-enhanced CT for sensitivity and accuracy (both p < 0.05). Conclusion: Sonazoid-enhanced US has a higher sensitivity and accuracy for the diagnosis of hepatic malignancies than contrast-enhanced CT. Copyright © 2008 S. Karger AG.Imaging of hepatocellular carcinoma: Qualitative and quantitative analysis of postvascular phase contrast-enhanced ultrasonography with sonazoidTatsuo Inoue; Masatoshi Kudo; Kinuyo Hatanaka; Syunsuke Takahashi; Satoshi Kitai; Taisuke Ueda; Emi Ishikawa; Satoru Hagiwara; Yasunori Minami; Hobyung Chung; Kazuomi Ueshima; Kiyoshi MaekawaOncology 75 (1) 48 - 54 0030-2414 2008/12 [Refereed] Purpose: To evaluate the usefulness of vascular phase images of contrast-enhanced ultrasonography (CE-US) with Sonazoid for hepatocellular carcinomas (HCCs), a retrospective, comparative study was conducted of images of HCCs obtained by CE-US and superparamagnetic iron oxide (SPIO) magnetic resonance imaging (MRI) and evaluated qualitatively and quantitatively. Methods: Seventy-seven patients with 88 HCCs who received CE-US and SPIO-MRI were reviewed. The ratio of the echogenicity of the tumor and nontumor areas was calculated with postvascular phase CE-US (postvascular phase ratio). The ratio of the intensity of the nontumor to tumor areas on SPIO-enhanced MRI (SPIO intensity index) was also calculated. The Pearson correlations were calculated for all values between the postvascular phase ratio and SPIO intensity index for quantitative comparison. These images were also compared qualitatively for the detection rate of the tumors. Results: The sensitivities of CE-US and SPIO-MRI in detecting tumors were 98 and 95%, respectively (nonsignificant, χ2 test). The postvascular phase ratio correlated with the SPIO intensity index for HCCs (Pearson r = 0.803, p < 0.05). The image conformity of the result from the liver parenchymal phase CE-US and SPIO-MRI was 92%. Dedifferentiation spots of nodule-in-nodule HCCs were detected in 4 (80%) of 5 on postvascular phase images of CE-US, and in 2 (40%) of 5 on SPIO-MRI (nonsignificant, χ2 test). Conclusions: Postvascular phase images of CE-US with Sonazoid appear promising as an alternative to SPIO-enhanced MRI. Further study cases are needed to confirm the usefulness of postvascular phase images of CE-US compared to SPIO-MRI for the detection of dedifferentiation foci in hepatic tumors. Copyright © 2008 S. Karger AG.Intranodular blood supply correlates well with biological malignancy grade determined by tumor growth rate in pathologically proven hepatocellular carcinomaMasatoshi Kudo; Hitoshi TochioOncology 75 (1) 55 - 64 0030-2414 2008/12 [Refereed] This study was carried out to investigate whether intranodular blood supply in histologically proven well-differentiated hepatocellular carcinomas (HCCs) correlates with tumor growth rates. A total of 52 well-differentiated HCCs were enrolled in this study. Ultrasound angiography with intra-arterial CO 2 microbubble injection was performed in all 52 HCCs and computed tomography during arterial portography was performed in 21 of the 52 HCCs. Tumor volume doubling time (TVDT) was measured in all 52 nodules by B-mode ultrasonography performed at 2- to 3-month intervals for a follow-up period of at least 6 months (range: 6 months to 8 years) with respect to arterial vascularity. In the hypervascular (n = 27), isovascular (n = 9), and hypovascular nodules (n = 16), the mean values of TVDT (mean ± SD) were 79 ± 131, 98 ± 227, and 782 ± 324 days, respectively (rs = 0.722, p < 0.0001). Concerning portal blood supply, the mean TVDT in nodules in which the portal supply was reduced (n = 5) was 178 ± 78 days compared with 592 ± 211 days in nodules in which the portal supply was preserved (n = 11), with a significant difference (p < 0.01). Five nodules in which the portal supply was preserved did not enlarge during the follow-up period of 3-5 years. There was a significant correlation among the three groups (rs = 0.804, p < 0.05). In conclusion, intranodular blood flow dynamics in patients with well-differentiated HCC reflect the biological malignancy or cancer progression in the process of multistep hepatocarcinogenesis, suggesting the importance of this parameter in deciding on a treatment strategy. In other words, nodules in which arterial vascularity is present and those in which the portal blood flow is reduced should be treated for reasons such as a short doubling time and the risk of rapid progression to artery-dominant classical HCC. Copyright © 2008 S. Karger AG.Validation of a new prognostic staging system for hepatocellular carcinoma: A comparison of the biomarker-combined Japan integrated staging score, the conventional Japan integrated staging score and the BALAD scoreSatoshi Kitai; Masatoshi Kudo; Yasunori Minami; Seiji Haji; Yukio Osaki; Hiroko Oka; Toshihito Seki; Hiroshi Kasugai; Yo Sasaki; Takashi MatsunagaOncology 75 (1) 83 - 90 0030-2414 2008/12 [Refereed] Objectives: The conventional Japan Integrated Staging (c-JIS) score has been reported to effectively stratify patients with hepatocellular carcinoma (HCC). Recently, two new staging systems, the biomarker-combined JIS (bm-JIS) score and the BALAD score, have been proposed. Both staging systems include three tumor markers: α-fetoprotein (AFP), lens culinaris agglutinin-reactive AFP and des-γ-carboxy prothrombin specific for HCC. The aim of this study is to evaluate the performance of these three staging systems. Methods: A total of 1,173 HCC patients were included in this study. The stratification ability and prognostic predictive power were compared between these three staging systems. Results: These three staging systems effectively predicted the patient survival. When accounting for the best prognostic subgroup of each staging systems (i.e. score of 0), there were significant differences between the bm-JIS score and the BALAD score and, likewise, between the c-JIS score and the BALAD score. The likelihood ratio χ2 test showed the highest value and the Akaike information criterion value was lowest in the bm-JIS score. Conclusions: The bm-JIS score showed good stratification ability and was thus demonstrated to be a better predictor of the prognosis than the c-JIS score and the BALAD score, especially for the patients with a good prognosis. Copyright © 2008 S. Karger AG.PIVKA-II is the best prognostic predictor in patients with hepatocellular carcinoma after radiofrequency ablation therapyShunsuke Takahashi; Masatoshi Kudo; Hobyung Chung; Tatsuo Inoue; Emi Ishikawa; Satoshi Kitai; Chie Tatsumi; Taisuke Ueda; Tomoyuki Nagai; Yasunori Minami; Kazuomi UeshimaOncology 75 (1) 91 - 98 0030-2414 2008/12 [Refereed] Objective: This study was undertaken to assess the prognostic predictor in patients with hepatocellular carcinoma (HCC) after radiofrequency ablation (RFA). Methods: This study retrospectively evaluated clinical outcomes in a cohort of 179 Child-Pugh stage A cirrhotic patients who received curative RFA for naive HCC within Milan criteria. The median follow-up period was 40.5 months. Results: The cumulative survival rate was significantly lower in patients with prothrombin induced by vitamin K absence or antagonist II (PIVKA-II) ≥100 mAU/ml compared with PIVKA-II < 100 mAU/ml (58.0 vs. 84.0% at 5 years p < 0.001). The cumulative recurrence-free survival rates were significantly lower in patients with PIVKA-II ≥100 mAU/ml compared with PIVKA-II < 100 mAU/ml (12.1 vs. 16.9% at 5 years p < 0.032). The cumulative rate of maintaining period within Milan criteria was significantly lower in patients with PIVKA-II ≥100 mAU/ml compared with PIVKA-II < 100 mAU/ml (34.1 vs. 55.6% at 5 years p < 0.001). Cox regression analysis showed that low serum albumin (< 3.5 g/dl p = 0.002, RR 3.75, CI 1.64-8.56), a high level of PIVKA-II (≥100 mAU/ml p = 0.04, RR 3.15, CI 1.45-6.87), and multiple nodules (p = 0.021, RR 2.61, CI 1.15-5.91) were independently significant mortality risk factors. Conclusion: In patients with Child-Pugh stage A HCC, the PIVKA-II level is the best prognostic predictor after curative RFA. Copyright © 2008 S. Karger AG.Response evaluation of transcatheter arterial chemoembolization in hepatocellular carcinomas: The usefulness of sonazoid-enhanced harmonic sonographyYu Xia; Masatoshi Kudo; Yasunori Minami; Kinuyo Hatanaka; Kazuomi Ueshima; Hobyung Chung; Satoru Hagiwara; Tatsuo Inoue; Emi Ishikawa; Satoshi Kitai; Shunsuke Takahashi; Chie Tatsumi; Taisuke Ueda; Sosuke Hayaishi; Kiyoshi MaekawaOncology 75 (1) 99 - 105 0030-2414 2008/12 [Refereed] Background: The purpose of this study was to investigate if Sonazoid-enhanced harmonic ultrasonography (US) could be used to evaluate the responses of hepatocellular carcinomas (HCCs) to treatment with transcatheter arterial chemoembolization (TACE). Patients and Methods: Forty-three HCCs that had been treated by TACE were evaluated by Sonazoid-enhanced harmonic US and dynamic computed tomography (CT) approximately 1 week after their treatment. The detection rates of residual tumor blood supply using the two modalities were compared. Two months after chemoembolization, 16 of the 43 HCCs, which had no additional local treatment, were followed up with dynamic CT. The results of contrast-enhanced harmonic US and dynamic CT 1 week after chemoembolization were analyzed and compared with follow-up dynamic CT results. Results: The detection rates of positive enhancement with Sonazoid-enhanced harmonic US and dynamic CT 1 week after TACE were 25 (58.1%) of 43 lesions and 17 (39.5%) of 43 lesions, respectively. Sonazoid-enhanced harmonic US was significantly more sensitive than dynamic CT in depicting the residual tumor blood supply to HCCs 1 week after TACE (p < 0.01 χ2 test). The Sonazoid-enhanced harmonic US results of the 16 lesions 1 week after chemoembolization were consistent with the follow-up results of dynamic CT 2 months after chemoembolization. Conclusions: Sonazoid-enhanced harmonic US appears to be a highly sensitive and accurate modality for evaluating responses of HCCs shortly after TACE. Copyright © 2008 S. Karger AG.Combination therapy with S-1 and pegylated interferon alpha for advanced hepatocellular carcinomaKazuomi Ueshima; Masatoshi Kudo; Tomoyuki Nagai; Chie Tatsumi; Taisuke Ueda; Shunsuke Takahashi; Kinuyo Hatanaka; Satoshi Kitai; Emi Ishikawa; Tatsuo Inoue; Satoru Hagiwara; Yasunori Minami; Hobyung ChungOncology 75 (1) 106 - 113 0030-2414 2008/12 [Refereed] Purpose: There are currently no effective treatments for patients with advanced hepatocellular carcinoma (HCC) with vascular invasion or extrahepatic metastases. We evaluated the efficacy and safety of combination therapy with S-1 and pegylated interferon (PEG-IFN)-α for advanced HCC. Methods: A total of 22 patients received combination therapy with S-1 and PEG-IFN. One cycle of the combination therapy consists of oral S-1 (80 mg/m2) administration and subcutaneous PEG-IFN injection (PEG-IFN-α-2a 90 μg weekly or PEG-IFN-α-2b 50 μg weekly) for 4 weeks with 1- to 2-week intervals. Results: One patient was evaluated as complete response, 6 as partial response, 8 as stable disease, and 6 as progressive disease. One patient was not evaluable because therapy had to be discontinued as a result of jaundice. The median survival time was 15.3 months (95% CI: 4.4-26.2 months). The 1- and 2-year survival rates were 54.9 and 36.6%, respectively. The overall response rate was 31.8% and the disease control rate was 68.2%. Grade 3 neutropenia (18.2%), leukopenia (9.1%), anemia (9.1%), and thrombocytopenia (18.2%) were observed. Grade 4 toxicities were not observed. Conclusion: Combination therapy with S-1 and PEG-IFN is effective and feasible, and is therefore a promising regimen for advanced HCC. Copyright © 2008 S. Karger AG.肝癌の分子標的治療 進行肝細胞癌に対するソラフェニブの使用経験上嶋 一臣; 南 康範; 工藤 正俊肝臓 (一社)日本肝臓学会 49 (Suppl.2) A424 - A424 0451-4203 2008/09慢性肝炎staging評価のための低周波Real-time Tissue Elastographyの有用性藤本 研治; 辰巳 千栄; 上嶋 一臣; 葛下 典由; 三田 英治; 外村 明子; 三竹 毅; 金 栄浩; 岡本 幸春; 椎名 毅; 工藤 正俊; 加藤 道夫肝臓 (一社)日本肝臓学会 49 (Suppl.2) A522 - A522 0451-4203 2008/09ソナゾイド造影超音波検査におけるpostvascular phase imagingとSPIO-MRIとの比較検討井上 達夫; 畑中 絹世; 上田 泰輔; 辰巳 千栄; 北井 聡; 高橋 俊介; 石川 恵美; 萩原 智; 南 康範; 鄭 浩柄; 上嶋 一臣; 工藤 正俊; 横川 美加; 前野 知子; 市島 真由美; 前川 清肝臓 (一社)日本肝臓学会 49 (Suppl.2) A575 - A575 0451-4203 2008/09進行肝細胞癌に対するS-1・ペグインターフェロン併用療法上嶋 一臣; 早石 宗右; 辰巳 千栄; 上田 泰輔; 北井 聡; 高橋 俊介; 石川 恵美; 井上 達夫; 萩原 智; 南 康範; 鄭 浩柄; 工藤 正俊日本消化器病学会雑誌 (一財)日本消化器病学会 105 (臨増大会) A841 - A841 0446-6586 2008/09Evaluation of Therapeutic Response to Gemcitabine in Pancreatic CancerYoichiro Suetomi; Masayuki Kitano; Masatoshi Kudo; Hiroki Sakamoto; Kiyoshi MaekawaHEPATO-GASTROENTEROLOGY H G E UPDATE MEDICAL PUBLISHING S A 55 (86-87) 1785 - 1788 0172-6390 2008/09 [Refereed] Background/Aims: Due to the development of contrast-enhanced harmonic imaging, ultrasound can reveal more precise hemodynamic information than conventional angiography. In this study, the value of contrast-enhanced harmonic imaging was studied in the evaluation of response in treatment of pancreatic cancer. Methodology: Thirteen pancreatic cancer patients treated with gemcitabine were enrolled in this study. Contrast-enhanced harmonic ultrasonography was performed to evaluate the treatment response during every period of treatment. After intravenously injecting the contrast agent, pancreatic tumors were observed in a real-time and subsequently in an intermittent fashion. Findings obtained by contrast-enhanced harmonic imaging were compared with dynamic CT findings and serum tumor marker levels. Results: Tumor markers were reduced by at least 50% in 6 patients. We could not evaluate tumor size reduction rates on the B-mode US because the tumor margin was unclear. On the other hand, the hypovascular area was clearly depicted on the perfusion image of contrast-enhanced harmonic imaging in all patients throughout the observation period, and changes in tumor size could be easily evaluated. The tumor size reduction rates in these 6 cases were 13.1 +/- 5.5% by dynamic CT and 21.1 +/- 1.41% by contrast-enhanced harmonic imaging. Conclusions: Contrast-enhanced harmonic imaging is useful for evaluating treatment response for pancreatic cancer.[Prevention of recurrence of liver cancer].Kudo MNihon Naika Gakkai zasshi. The Journal of the Japanese Society of Internal Medicine 97 (7) 1681 - 1689 0021-5384 2008/07 [Refereed]Molecular mechanisms of portal vein toleranceTomohiro Watanabe; Masatoshi Kudo; Tsutomu Chiba; Yoshio WakatsukiHEPATOLOGY RESEARCH BLACKWELL PUBLISHING 38 (5) 441 - 449 1386-6346 2008/05 [Refereed] The liver has been considered as a tolerogenic organ in the sense that favors the induction of peripheral tolerance. The administration of antigens (Ags) via the portal vein causes tolerance, which is termed portal vein tolerance and can explain the occurrence of tolerogenic responses in the liver. Here we discuss the fundamental mechanisms accounting for portal vein tolerance. Antigen-presenting cells (APCs) in the liver, especially dendritic cells and sinusoidal endothelial cells, have limited the ability to produce pro-inflammatory cytokines upon stimulation with endotoxin, an effect that could be due to the continuous exposure to bacterial Ags derived from intestinal microflora. Ag presentation by liver APCs results in T cell tolerance through clonal deletion and selection of regulatory T cells. Thus, APCs with immunosuppressive functions are associated with the achievement of portal vein tolerance via the induction of clonal deletion and generation of regulatory T cells.The clinical characteristics, endoscopic treatment, and prognosis for patients presenting with duodenal varicesShigenaga Matsui; Masatoshi Kudo; Tsutomu Ichikawa; Mumon Okada; Yoshio MiyabeHEPATO-GASTROENTEROLOGY H G E UPDATE MEDICAL PUBLISHING S A 55 (84) 959 - 962 0172-6390 2008/05 [Refereed] Background/Aims: This study investigated the clinical characteristics, endoscopic appearances, usefulness of endoscopic treatments, and survival of patients kith duodenal varices. Methodology: Twelve patients were evaluated in whom endoscopy confirmed duodenal varices (13 lesions), and patient data was retrospectively analyzed regarding underlying diseases, hepatic function, endoscopic appearance, previous treatment for other complicated varices, endoscopic treatment for hemorrhage from duodenal varices, and survival. Results: Underlying diseases consisted of liver cirrhosis in 8 patients, and pancreatic cancer-related pylemphraxis in 4 patients. Endoscopic appearances of hemorrhage from duodenal varices revealed negative red color (RC) signs in all 6 lesions, and 5 of 6 lesions were F3 lesions Three of 5 patients with hemorrhagic duodenal varices had received treatment for esophageal varices. Successful. hemostasis and complete eradication by endoscopic treatments was achieved in all 5 patients (6 lesions). The 1, 3, and year cumulative survival rates were 66.7%, 48.6%, and 36.5% in the patients With duodenal varices. Conclusions: The hemorrhagic factor of duodenal varices. is F factor, but not RC sign. Changes of blood flow in the collateral circulatory pathway after treatment for esophageal varices may increase the risk of hemorrhage from duodenal varices. Endoscopic treatment is useful for hemorrhagic duodenal varices.【処方計画法】消化器疾患 肝癌上嶋 一臣; 工藤 正俊綜合臨床 (株)永井書店 57 (増刊) 1050 - 1052 0371-1900 2008/04Defect Re-injection imagingの有用性について畑中 絹世; 南 康範; 北井 聡; 辰巳 千栄; 高橋 俊介; 井上 達夫; 萩原 智; 鄭 浩柄; 上嶋 一臣; 工藤 正俊超音波医学 (公社)日本超音波医学会 35 (Suppl.) S626 - S626 1346-1176 2008/04肝画像診断の進歩 肝線維化評価における非侵襲的測定法(Real-time tissue elastography)の有用性に関する検討辰巳 千栄; 上嶋 一臣; 今井 元; 上田 泰輔; 川崎 正憲; 北井 聡; 萩原 智; 井上 達夫; 石川 恵美; 南 康範; 鄭 浩柄; 工藤 正俊肝臓 (一社)日本肝臓学会 49 (Suppl.1) A55 - A55 0451-4203 2008/04進行肝細胞癌に対するS-1、ペグインターフェロン併用療法上嶋 一臣; 早石 宗右; 辰巳 千栄; 上田 泰輔; 北井 聡; 高橋 俊介; 石川 恵美; 井上 達夫; 萩原 智; 南 康範; 鄭 浩柄; 工藤 正俊肝臓 (一社)日本肝臓学会 49 (Suppl.1) A278 - A278 0451-4203 2008/04Combination therapy of ecabet sodium and proton pump inhibitor (PPI) compared with PPI alone for endoscopic submucosal dissection (ESD)-induced ulcer in gastric cancer: Prospective randomized studyShigenaga Matsui; Masatoshi Kudo; Mumon Okada; Yutaka Asakuma; Tsutomu Ichikawa; Masanori KawasakiGASTROENTEROLOGY W B SAUNDERS CO-ELSEVIER INC 134 (4) A240 - A240 0016-5085 2008/04 [Refereed]Comparison of the outcomes between an anatomical subsegmentectomy and a non-anatomical minor hepatectomy for single hepatocellular carcinomas based on a Japanese nationwide surveySusumu Eguchi; Takashi Kanematsu; Shigeki Arii; Masatoshi Okazaki; Kiwarnu Okita; Masao Omata; Iwao Ikai; Masatoshi Kudo; Masamichi Kojiro; Masatoshi Makuuchi; Morito Monden; Yutaka Matsuyama; Yasuni Nakanuma; Kenichi TakayasuSURGERY MOSBY-ELSEVIER 143 (4) 469 - 475 0039-6060 2008/04 [Refereed] Background. Although a surgical resection is an important modality for the treatment of hepatocellular carcinoma (HCC), the impact of the operative method on both the patient survival and disease-free survival (DTS) still remains controversial. Methods. Using a nationwide Japanese database, 72,744 patients with HCC who underwent a curative liver resection between 1994 and 2001 were divided into two groups based on whether an anatomical subsegmentectomy (AS) or a non-anatomical minor hepatectomy (MH) was performed. A total of 5, 781 patients with single HCCs were selected for the study and divided into 3 subgroups based on the size of the HCCs (less than 2cm, 2 to 5 cm, and greater than 5 cm in diameter). An AS was performed for 2,267 patients while an MH was performed for 3,514 patients. Results. The overall DTS was significantly better after an AS (P = .0089). When the patients were stratified according to the size of the HCC, a better DES was seen in the patients with HCC from 2 to 5 cm after an AS (P < .0005). Further stratification according to liver damage did not show any significant differences between an AS and an MH. Conclusion. An AS is therefore recommended, especially when the size of HCC ranges from 2 to 5 cm.Long-term outcome of percutaneous ethanol injection therapy for minimum-sized hepatocellular carcinomaMiyuki Taniguchi; Soo Ryang Kim; Susumu Imoto; Hirotsugu Ikawa; Kenji Ando; Keiji Mita; Shuichi Fuki; Noriko Sasase; Toshiyuki Matsuoka; Masatoshi Kudo; Yoshitake HayashiWORLD JOURNAL OF GASTROENTEROLOGY BAISHIDENG PUBL GRP CO LTD 14 (13) 1997 - 2002 1007-9327 2008/04 [Refereed] AIM: To evaluate long-term follow-up of minimum-sized hepatocellular carcinoma (HCC) treated with percutaneous ethanol injection (PEI). METHODS: PEI was applied to 42 lesions in 31 patients (23 male and eight female) with HCC < 15 mm in diameter, over the past 15 years. RESULTS: Overall survival rate was 74.1% at 3 years, 49.9% at 5 years, 27.2% at 7 years and 14.5% at 10 years. These results are superior to, or at least the same as those for hepatic resection and radiofrequency ablation. Survival was affected only by liver function, but not by sex, age, etiology of Hepatitis B virus or Hepatitis C virus, a-fetoprotein levels, arterial and portal blood flow, histological characteristics, and tumor multiplicity or size. Patients in Child-Pugh class A and B had 5-, 7- and 10-years survival rates of 76.0%, 42.2% and 15.8%, and 17.1%, 8.6% and 0%, respectively (P = 0.025). CONCLUSION: Treatment with PEI is best indicated for patients with HCC < 15 mm in Child-Pugh class A. (c) 2008 WJG. All rights reserved.Defect Re-injection Testの有用性について畑中 絹世; 北井 聡; 上田 泰輔; 辰巳 千恵; 井上 達夫; 萩原 智; 南 康範; 鄭 浩柄; 上嶋 一臣; 前川 清; 工藤 正俊日本消化器病学会雑誌 (一財)日本消化器病学会 105 (臨増総会) A218 - A218 0446-6586 2008/03難治性C型慢性肝炎(1型高ウイルス量)に対するPEG-IFNα2b/Ribavirin併用療法の長期投与成績と安全性について石川 恵美; 南 康範; 上嶋 一臣; 鄭 浩柄; 早石 宗介; 井上 達夫; 工藤 正俊日本消化器病学会雑誌 (一財)日本消化器病学会 105 (臨増総会) A308 - A308 0446-6586 2008/03Comparison of three current staging systems for hepatocellular carcinoma: Japan integrated staging score, new Barcelona Clinic Liver Cancer staging classification, and Tokyo scoreHobyung Chung; Masatoshi Kudo; Shunsuke Takahashi; Satoru Hagiwara; Yasuhiro Sakaguchi; Tatsuo Inoue; Yasunori Minami; Kazuomi Ueshima; Toyokazu Fukunaga; Takashi MatsunagaJOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY BLACKWELL PUBLISHING 23 (3) 445 - 452 0815-9319 2008/03 [Refereed] Background and Aim: Although various staging systems for hepatocellular carcinoma (HCC) have been developed in recent years, there is no worldwide consensus which staging system is best. The aim of the present study was to compare the performance of the currently developed three staging systems: the Japan integrated staging (JIS) score, new Barcelona Clinic Liver Cancer (BCLC) staging classification, and the Tokyo score. Methods: A total of 290 consecutive patients with HCC before initial treatment at Kinki University between January 1999 and December 2001 were included. The patients were stratified according to the three staging systems, and the performance of the staging systems was compared using survival time as the only outcome measure. Results: There were significant differences between all stages in the JIS score, while no significant difference was found between stages C and D in the BCLC staging classification and between all the scores, except between scores 0 and 1 and 2 and 3 in the Tokyo score. For all patients (n = 290), the radical treatment group (n = 208) and the non-radical treatment group (n = 82), the likelihood ratio chi(2)-test showed the highest value, and the Akaike information criterion value was lowest in the JIS score. Conclusion: The JIS score provided the best prognostic stratification in a Japanese cohort of HCC patients who were mainly diagnosed at early stages and treated with radical therapies.Foreign body granuloma mimicking disseminated tumour recurrence after radiofrequency ablation for hepatocellular carcinomaShunsuke Takahashi; Hobyung Chung; Satoshi Kitai; Tatsuo Inoue; Yasunori Minami; Kazuomi Ueshima; Masatoshi KudoLIVER INTERNATIONAL BLACKWELL PUBLISHING 28 (3) 414 - 415 1478-3223 2008/03 [Refereed]Effects of decorin on the expression of alpha-smooth muscle actin in a human myofibroblast cell lineTatsuya Nakatani; Eiko Honda; Sumio Hayakawa; Mayumi Sato; Ken Satoh; Masatoshi Kudo; Hiroshi MunakataMOLECULAR AND CELLULAR BIOCHEMISTRY SPRINGER 308 (1-2) 201 - 207 0300-8177 2008/01 [Refereed] Myofibroblasts are metabolically and morphologically distinctive fibroblasts expressing alpha-smooth muscle actin (alpha-SMA), and their activation plays a key role in development of the fibrotic response. In an activated state, myofibroblasts cease to proliferate and start to synthesize large amounts of extracellular component proteins. The expression of alpha-SMA correlates with the activation of myofibroblasts. Decorin, a member of the small leucine-rich proteoglycan gene family, has been implicated in the negative control of cell proliferation primarily by upregulating the expression of p21, a potent inhibitor of cyclin-dependent kinase. In order to examine the effect of decorin on myofibroblast cell growth, we rendered a human lung myofibroblast cell line, MRC-5, quiescent by either cell-cell contact or serum starvation, and examined the relationship between decorin and alpha-SMA expression in these cells. The expression of decorin in cells made quiescent by serum starvation was lower than that in cells made quiescent by cell-cell contact. In contrast, the expression of alpha-SMA in cells made quiescent by cell-cell contact was lower than that in cells made quiescent by serum starvation. Furthermore, forced expression of decorin was accompanied by a suppression of alpha-SMA expression, whereas knocking down of decorin expression by RNA interference increased the expression of alpha-SMA.Diagnostic accuracy of imaging for liver cirrhosis compared to histologically proven liver cirrhosisMasatoshi Kudo; Rong Qin Zheng; Soo Ryang Kim; Yoshihiro Okabe; Yukio Osaki; Hiroko Iijima; Toshinao Itani; Hiroshi Kasugai; Masayuki Kanematsu; Katsuyoshi Ito; Norio Usuki; Kazuhide Shimamatsu; Masayoshi Kage; Masamichi KojiroINTERVIROLOGY KARGER 51 17 - 26 0300-5526 2008 [Refereed] Objective: To evaluate the diagnostic accuracy of liver cirrhosis by imaging modalities, including CT, MRI and US, compared to results obtained from histopathological diagnoses of resected specimens. Materials and Methods: CT, MRI and US examinations of 142 patients with chronic liver disease who underwent surgery for complicated hepatocellular carcinoma (< 3 cm in diameter) in 10 institutions were blindly reviewed in a multicenter study by three radiologists experienced in CT, MRI and US. The images were evaluated for five imaging parameters ( irregular or nodular liver surface, blunt liver edge, liver parenchymal abnormalities, liver morphological changes and manifestations of portal hypertension) using a severity scale. The diagnostic imaging impression score was also calculated. Patients were histologically classified into chronic hepatitis ( CH; n = 54), liver cirrhosis ( LC; n = 71) and pre- cirrhosis ( P- LC; n = 17) by three pathologists, independently, who reviewed the resected liver specimens. The results of the three imaging methods were compared to those from histological diagnoses, and a multivariate analysis ( stepwise forward logistic regression analysis) was performed to identify independent predictive signs of cirrhosis. The diagnostic efficacies for LC and early cirrhosis were also compared among CT, MRI and US using a receiver- operating characteristic ( ROC) curve analysis. Results: The differences in the five imaging parameters evaluated by CT, MRI and US between LC and CH were statistically significant ( p < 0.001) except for the manifestations of portal hypertension on US. Irregular or nodular surface, blunt edge or morphological changes in the liver were selected as the best predictive signs for cirrhosis on US whereas liver parenchymal abnormalities, manifestations of portal hypertension and morphological changes in the liver were the best predictive signs on MRI and CT by multivariate analysis. The predictive diagnostic accuracy, sensitivity and specificity in discriminating LC from CH based on the best predictive signs were 71.9, 77.1 and 67.6% by CT; 67.9, 67.5 and 68.3% by MRI, and 66.0, 38.4 ( lower than CT and MRI, p = 0.001) and 88.8% ( higher than CT and MRI, p = 0.001) by US. According to the imaging impression scoring system, diagnostic accuracy, sensitivity and specificity were 67.0, 84.3 and 52.9% by CT; 70.3, 86.7 and 53.9% by MRI, and 64.0, 52.4 ( lower than CT and MRI, p = 0.0001) and 73.5% ( higher than CT and MRI, p < 0.003) by US. ROC analysis showed that MRI and CT were slightly superior to US in the diagnosis of LC but no statistically significant difference was found between them. For the pathological diagnosis of P- LC, cirrhosis was diagnosed in 59.5, 46.7 and 41.7% of the P- LC cases by US, CT and MRI, respectively, with no significant difference among these methods. Conclusion: US, CT and MRI had different independent predictive signs for the diagnosis of LC. MRI and CT were slightly superior to US in predicting cirrhosis, especially regarding sensitivity. Noninvasive imaging techniques play an important role in the diagnosis of cirrhosis, especially in the evaluation of P- LC. Copyright (c) 2008 S. Karger AG, Basel.Noninvasive evaluation of hepatic fibrosis using serum fibrotic markers, transient elastography (FibroScan) and real-time tissue elastographyChie Tatsumi; Masatoshi Kudo; Kazuomi Ueshima; Satoshi Kitai; Shunsuke Takahashi; Tatsuo Inoue; Yasunori Minami; Hobyung Chung; Kiyoshi Maekawa; Kenji Fujimoto; Tonomura Akiko; Mitake TakeshiINTERVIROLOGY KARGER 51 27 - 33 0300-5526 2008 [Refereed] Objective: The aim of this study was to investigate the accuracy of noninvasive tests, e. g. serum fibrotic markers, transient elastography and real-time tissue elastography, in the diagnosis of hepatic fibrosis, and to determine whether they can replace liver biopsy. Methods: 119 patients with chronic liver disease were included in this study. Serum fibrotic markers including hyaluronic acid, type IV collagen, type IV collagen 7S domain and type III procollagen-N-peptide were measured. Aspartate aminotransferase (AST) and platelet counts were also measured to calculate the AST to platelet ratio index ( APRI). Liver stiffness was measured using FibroScan and real-time tissue elastography. Results: The fibrotic stage, determined by histopathological diagnosis of a liver biopsy sample, did not correlate as well with serum fibrotic markers although it was useful to diagnose liver cirrhosis. However, the stage of hepatic fibrosis correlated well with liver stiffness measured by FibroScan. FibroScan was also a much better predictor of liver cirrhosis than APRI. Furthermore, the levels of liver strain measured by real-time tissue elastography correlated well with liver stiffness ( p < 0.05). Conclusion: Serum fibrotic markers and FibroScan are useful for distinguishing liver cirrhosis ( F 4) from chronic hepatitis (F(1)-F(3)). In addition, real- time tissue elastography is a novel and promising method to determine the stage of hepatic fibrosis. Copyright (c) 2008 S. Karger AG, Basel.Usefulness of a new immunoradiometric assay of HCV core antigen to predict virological response during PEG-IFN/RBV combination therapy for chronic hepatitis with high viral load of serum HCV RNA genotype 1bNoriko Sasase; Soo Ryang Kim; Ke Ih Kim; Miyuki Taniguchi; Susumu Imoto; Keiji Mita; Hak Hotta; Ikuo Shouji; Ahmed El-Shamy; Norifumi Kawada; Masatoshi Kudo; Yoshitake HayashiINTERVIROLOGY KARGER 51 70 - 75 0300-5526 2008 [Refereed] We investigated the clinical usefulness of a new immunoradiometric ( IRM) assay of hepatitis C virus ( HCV) core antigen in predicting virological response during pegylated interferon plus ribavirin ( PEG-IFN/RBV) combination therapy for chronic hepatitis with high viral loads of serum HCV RNA genotype 1b. Thirty-nine patients received a regimen of PEG- IFN alpha - 2b ( 1.5 mu g/ kg/ week s. c.) in combination with RBV ( 600 - 1,000 mg/ day). Of the 39 patients, 18 ( 46.2%) achieved sustained virological response ( SVR), 11 ( 28.2%) attained partial response ( PR) and 10 ( 25.6%) showed no response (NR). Four weeks after the start of therapy, 1- and 2-log reductions in the amount of HCV core antigen were observed in 20 (2/10) and 0% (0/10) showing NR, 91 (10/11) and 63.6% 7/ 11) with PRs, and 88.9 (16/18) and 55.6% (10/18) of patients with SVR, respectively. The 1- and 2-log reductions 4 weeks after the start of therapy were not a defining condition for PR and SVR. The amount of HCV core antigen was significantly different between SVR and PR patients on days 1 and 7, and between patients with NR and SVR at all points of time. In conclusion, this new IRM assay is useful in predicting virological response during PEG-IFN/RBV therapy. Copyright (c) 2008 S. Karger AG, Basel.Case of rapidly progressed sarcomatoid hepatocellular carcinoma in a young female without risk factorTatsuo Inoue; Masatoshi Kudo; Yasunori Minami; Hobyung Chung; Toyokazu Fukunaga; Toshihiko KawasakiLIVER INTERNATIONAL WILEY 27 (10) 1428 - 1430 1478-3223 2007/12 [Refereed]Treatment of large and/or multiple hepatic malignancies: Open surgical approaches of radiofrequency ablationYasunori Minami; Toshihiko Kawasaki; Masatoshi Kudo; Seiji Haji; Osamu Shiraishi; Takashi Kawabe; Chikao Yasuda; Takuya Nakai; Yoshihumi Takeyama; Hitoshi ShiozakiHEPATO-GASTROENTEROLOGY H G E UPDATE MEDICAL PUBLISHING S A 54 (80) 2358 - 2360 0172-6390 2007/12 [Refereed] Background/Aims: Patients with hepatic malignancies are often poor candidates for resection because of the lack of hepatic reserve as a result of coexisting cirrhosis or the presence of multiple tumors. The purpose of this study was to determine the safety and efficacy of open intraoperative radiofrequency ablation of unresectable hepatic malignancies with size larger than 4cm in diameter and/or more than three in number. Methodology: Between May 2000 and September 2003, 30 patients (24 men, 6 women; age range, 5972 years; mean age, 63 years) with 51 hepatic malignancies. The maximal diameter of all tumors ranged from 1.0 to 10cm (mean +/- SD, 3.2 +/- 1.8). Results: All tumors achieved necrosis completely in a. single session. The mean follow-up from the initial ablation in this study was 18.9 +/- 10.1 months (range, 0-41). The 1-, 2 and 3-year overall survival rates were 86.1%, 71.6% and 71.6%, respectively. The 1-, 2 and 3-year disease-free survival rates were 70.9%, 37.6% and 25.1%, respectively. Conclusions: Open radiofrequency ablation is a safety and efficient approach for hepatic malignancies sized more than 4cm in diameter and/or located more than three in number.進行肝細胞癌に対するS-1、ペグインターフェロン併用療法南 康範; 上嶋 一臣; 辰巳 千栄; 北井 聡; 高橋 俊介; 井上 達夫; 鄭 浩柄; 工藤 正俊肝臓 (一社)日本肝臓学会 48 (Suppl.2) A467 - A467 0451-4203 2007/09乏血性肝腫瘍の診療アルゴリズム 転移性肝腫瘍・肝内胆管癌の画像診断 超音波診断を中心に上嶋 一臣; 前川 清; 工藤 正俊日本消化器病学会雑誌 (一財)日本消化器病学会 104 (臨増大会) A473 - A473 0446-6586 2007/09Report of the 17th Nationwide Follow-up Survey of Primary Liver Cancer in JapanIwao Ikai; Shigeki Arii; Masatoshi Okazaki; Kiwamu Okita; Masao Omata; Masamichi Kojiro; Kenichi Takayasu; Yasuni Nakanuma; Masatoshi Makuuchi; Yutaka Matsuyama; Morito Monden; Masatoshi KudoHEPATOLOGY RESEARCH BLACKWELL PUBLISHING 37 (9) 676 - 691 1386-6346 2007/09 [Refereed] In the 17th Nationwide Follow-up Survey of Primary Liver Cancer in Japan, 18 213 individuals were newly registered as patients with primary liver cancer at 645 medical institutions over a period of 2 years (from 1 January 2002 to 31 December 2003). Of these patients, 94.2% had hepatocellular carcinoma (HCC) and 4.1% had intrahepatic cholangiocarcinoma (ICC). In addition, 24 705 follow-up patients were registered in the survey. Epidemiological and clinicopathological factors, diagnosis and treatment were investigated in the newly registered patients, and the cumulative survival rates of newly registered patients in the 12th to 17th follow-up surveys conducted between 1992 and 2003 were calculated for each histological type (HCC, ICC, and combined HCC and ICC) and stratified by background factors and treatment. The data obtained in this follow-up survey should contribute to future research and medical practice for primary liver cancer.Role of tumor markers in assessment of tumor progression and prediction of outcomes in patients with hepatocellular carcinomaHidenori Toyoda; Takashi Kumada; Yukio Osaki; Hiroko Oka; Masatoshi KudoHEPATOLOGY RESEARCH BLACKWELL PUBLISHING 37 S166 - S171 1386-6346 2007/09 [Refereed] The efficacies of tumor markers, alfa-fetoprotein (AFP), Lens culinaris agglutinin A-reactive fraction of alfa-fetoprotein (AFP-L3), and des-gamma-carboxy prothrombin (DCP) were evaluated for assessment of progression of hepatocellular carcinoma (HCC) and patient prognosis. The prevalence of elevated levels of each tumor marker increased with progression of tumor stage for all three markers among patients with HCC. Survival was poorer among patients with elevated levels of tumor markers than among those without elevated levels. Evaluation of tumor progression with tumor markers was based only on the results of laboratory tests. The tests are objective, simple to perform, and easy to repeat, and therefore, may be useful to supplement conventional tumor staging for the evaluation of tumor progression and prediction of patient outcome.International comparison of treatment outcomes based on staging systemsMasatoshi KudoHEPATOLOGY RESEARCH BLACKWELL PUBLISHING 37 S216 - S222 1386-6346 2007/09 [Refereed] Treatment outcomes were compared among several countries based on different staging systems. Data were collected from published data. Treatment outcomes based on Cancer of the Liver Italian Program (CLIP) scores 0-3 were best in Japan when compared among several countries. Furthermore, treatment outcomes in Japan based on Japan Integrated Staging (JIS) scores 0-3 were much better than in the USA. However, Barcelona Clinic Liver Cancer (BCLC) staging was not useful forinternational comparison, suggesting that BCLC staging is not helpful for prognostic staging but for treatment allocation staging. This is an extremely important point, which should be kept in mind.Review of 4th single topic conference on HCC - Hepatocellular carcinoma: International consensus and controversiesMasatoshi KudoHEPATOLOGY RESEARCH BLACKWELL PUBLISHING 37 S83 - S87 1386-6346 2007/09 [Refereed]高度進行肝細胞癌に対するS-1、ペグインターフェロン併用療法の有用性上嶋 一臣; 南 康範; 工藤 正俊肝臓 (一社)日本肝臓学会 48 (Suppl.1) A106 - A106 0451-4203 2007/04Radiofrequency ablation combined with reduction of hepatic blood flow: Effect of lipiodol on coagulation diameter and ablation time in normal pig liverHobyung Chung; Masatoshi Kudo; Yasunori Minami; Toshihiko KawasakiHEPATO-GASTROENTEROLOGY H G E UPDATE MEDICAL PUBLISHING S A 54 (75) 701 - 704 0172-6390 2007/04 [Refereed] Background/Aims: We evaluated the effectiveness of radiofrequency (RF) ablation combined with transarterial embolization using Lipiodol and gelatin sponge. Methodology: A total of 18 normal pig liver lobes were randomly assigned to the following three different RF ablation groups, 1) combined with TAE using Lipiodol and gelatin sponge as "LpTAE group"; 2) combined with TAE using gelatin sponge only as "TAE group"; 3) ablation alone as "control group". Ablations were performed under open laparotomy using an RF generator and a 2-cm expandable needle. The diameter of coagulation and the ablation time were compared among the three groups. Results: The characteristic shape of coagulated area differed among the three groups. The long-axis diameter showed no significant difference among the three groups (27.5mm, 27.5mm, 26.7mm; respectively), while the short-axis diameter was significantly larger in the LpTAE group compared with the control groups (25.2min vs. 20.5mm; p < 0.05). The total ablation time was significantly shorter in the LpTAE and TAE groups compared with the control group (166, 204 seconds vs. 309 seconds; p=0.001, p=0.01). Conclusions: RF ablation combined. with LpTAE produced larger and more spherical areas of coagulation in a shorter ablation time. Such an advantage could potentially enhance the clinical effectiveness of RF ablation.【病気と薬の説明ガイド2007】悪性腫瘍・がん疼痛 薬物療法編 医薬品情報編 肝癌 肝細胞癌を中心に上嶋 一臣; 工藤 正俊薬局 (株)南山堂 58 (4) 1751 - 1758 0044-0035 2007/03進行肝癌に対する集学的治療 進行肝細胞癌に対するCDDP+5FU動注化学療法における5FU投与濃度の意義上嶋 一臣; 辰巳 千栄; 工藤 正俊日本消化器病学会雑誌 (一財)日本消化器病学会 104 (臨増総会) A16 - A16 0446-6586 2007/03ステージ4B肝内胆管癌に対するGemcitabine(GEM)をfirst lineとした化学療法と無治療群との比較検討南 康範; 上嶋 一臣; 坂口 康浩; 鄭 浩柄; 福永 豊和; 工藤 正俊日本消化器病学会雑誌 (一財)日本消化器病学会 104 (臨増総会) A155 - A155 0446-6586 2007/03Multistep hepatocarcinogenesis from a dysplastic nodule to well-differentiated hepatocellular carcinoma in a patient with alcohol-related liver cirrhosisSoo Ryang Kim; Hirotsugu Ikawa; Kenji Ando; Keiji Mita; Shuichi Fuki; Michiie Sakamoto; Yoshihiro Kanbara; Toshiyuki Matsuoka; Masatoshi Kudo; Yoshitake HayashiWORLD JOURNAL OF GASTROENTEROLOGY W J G PRESS 13 (8) 1271 - 1274 1007-9327 2007/02 [Refereed] We describe a rare case of the transformation of a dysplastic nodule into well-differentiated hepatocellular carcinoma (HCC) in a 56-year-old man with alcohol related liver cirrhosis. Ultrasound (US) disclosed a 10 mm hypoechoic nodule and contrast enhanced US revealed a hypovascular nodule, both in segment seven. US-guided biopsy revealed a high-grade dysplastic nodule characterized by enhanced cellularity with a high N/C ratio, increased cytoplasmic eosinophilia, and slight cell atypia. One year later, the US pattern of the nodule changed from hypoechoic to hyperechoic without any change in size or hypovascularity. US-guided biopsy revealed well-differentiated HCC of the same features as shown in the first biopsy, but with additional pseudoglandular formation and moderate cell atypia. Moreover, immunohistochemical staining of cyclase-associated protein 2, a new molecular marker of well-differentiated HCC, turned positive. This is the first case of multistep hepatocarcinogenesis from a dysplastic nodule to well-differentiated HCC within one year in alcohol-related liver cirrhosis. (C) 2007 The WJG Press. All rights reserved.Percutaneous radiofrequency ablation of sonographically unidentifiable liver tumors. Feasibility and usefulness of a novel guiding technique with an integrated system of computed tomography and sonographic images.Yasunori Minami; Masatoshi Kudo; Hobyung Chung; Tatsuo Inoue; Shunsuke Takahashi; Kinuyo Hatanaka; Taisuke Ueda; Hitoshi Hagiwara; Satoshi Kitai; Kuzuomi Ueshima; Toyokazu Fukunaga; Hitoshi ShiozakiOncology 72 Suppl 1 111 - 6 2007 OBJECTIVE: The purpose of this study was to evaluate the safety and feasibility of a real-time integrated system with computed tomography (CT) and sonographic images for radiofrequency (RF) ablation of hepatic malignancies poorly defined on B-mode sonography, and to clarify the suitable phase of CT images for using this virtual sonography. METHODS: Between September 2004 and December 2004, 12 patients with 16 hepatocellular carcinomas and two metastatic lesions arising from colorectal adenocarcinoma (n = 1) and rectal carcinoid (n = 1) were treated. The maximum diameter of nodules ranged from 1.0 to 2.5 cm (mean +/- SD; 1.5 +/- 0.6 cm) on CT images. RESULTS: Complete tumor necrosis was achieved in a single session in 19 lesions (90%), while a second session was required for the remaining two lesions (10%). Portal phase multi-planar reconstruction images were displayed under a suitable position corresponding to the ultrasound images in 9 patients (HCC = 7, metastasis = 2), and arterial phase multi-planar reconstruction images were displayed in the 3 remaining patients with hepatocellular carcinoma. CONCLUSION: Percutaneous RF ablation guidance using virtual sonography is an effective treatment for patients with hepatic malignancies. The portal phase of CT images may be the most suitable to indicate the 3-dimensional relationship between the liver vasculature and tumors on virtual sonography.Clinical characteristics of NonBNonC-HCC: Comparison with HBV and HCV related HCCKinuyo Hatanaka; Masatoshi Kudo; Toyokazu Fukunaga; Kazuomi Ueshima; Hobyung Chung; Yasunori Minami; Yasuhiro Sakaguchi; Satoshi Hagiwara; Akio Orino; Yukio OsakiINTERVIROLOGY KARGER 50 (1) 24 - 31 0300-5526 2007 [Refereed] Objective: To clarify the frequency and trends of both HBsAg and HCVAb negative hepatocellular carcinoma (NonBNonC-HCC) in all HCC, to clarify the etiology of NonBNonC-HCC, and to elucidate the clinical characteristics of NonBNonC-HCC compared with those of HBsAg-positive HCC (B-HCC) and HCVAb-positive HCC (C-HCC). Methods: A total of 2,542 patients with HCC examined at three institutions between 1991 and 2004 were categorized based on their serum viral antigen/antibody positivities, and compared between groups for the etiology, annual trend of the incidence, and clinical characteristics. Results: For the etiology, C-HCC was most prevalent, followed by B-HCC, NonBNonC-HCC, and both HBsAg and HCVAb-positive HCC (BC-HCC) in order. For survival, C-HCC had the most favorable prognosis, followed by NonBNonC-HCC, and B-HCC patients had the poorest prognosis in the three groups (C-HCC, B-HCC, and NonBNonC-HCC). In tumor-node metastasis (TNM) stages I+II, however, NonBNonC-HCC patients took the most favorable clinical course. The incidence of NonB-NonC-HCC in all HCC was 5 - 8% from 1991 to 1998, and has increased to 10 - 12% since 1999. Additionally, the incidence of HBcAb-positive HCC in NonBNonC-HCC declined each year. Among NonBNonC-HCC patients, the morbidity of diabetic complications was significantly higher in HBcAb-negative patients than in HBcAb-positive patients. Conclusion: Although the incidence of NonBNonC-HCC among all HCC has an increasing trend recently, the incidence of HBcAb-positive HCC in NonBNonC-HCC has a tendency of decreasing. This fact suggest its etiology might be changing from occult HBV related HCC to unknown etiology such as nonalcoholic fatty liver disease (NAFLD)/nonalcoholic steatohepatitis (NASH) related HCC. The prognosis of NonBNonC-HCC was fairly good if the HCC was found in its early stage.Outcomes of nontransplant potentially curative therapy for early-stage hepatocellular carcinoma in child-pugh stage a cirrhosis is comparable with liver transplantationShunsuke Takahashi; Masatoshi Kudo; Hobyung Chung; Tatsuo Inoue; Miki Nagashima; Satoshi Kitai; Tatsumi Chie; Minami Yasunori; Ueshima Kazuomi; Fukunaga Toyokazu; Seiji HajiDIGESTIVE DISEASES KARGER 25 (4) 303 - 309 0257-2753 2007 [Refereed] Background: This study was undertaken to assess the outcome of potentially curative therapy for early-stage hepatocellular carcinoma (HCC) in patients with Child-Pugh stage A cirrhosis as well as to investigate the impact of low-dose interferon (IFN) therapy after curative therapy on survival. Methods: This study retrospectively evaluated clinical outcomes in a cohort of 224 Child-Pugh stage A cirrhotic patients who received either resection ( 53 cases) or radiofrequency ablation ( RFA: 171 cases) for HCC within Milan criteria. Thirty patients were treated with low-dose maintenance IFN therapy after initial curative therapy. The median follow- up period was 36.7 months. Results: The 5-year survival rate of all patients was 74.9%, with similar rates for the resection and RFA groups (70.4 vs. 76.8%; p = 0.561). The 5-year HCC recurrence rate was higher in the RFA group than the resection group (85.3 vs. 73.2%; p = 0.012). The maintenance IFN-treated group maintained their liver function within Child-Pugh stage A for a significantly longer time (median time 36.9 vs. 32.2 months; p = 0.0025). Conclusion: The 5-year outcomes of resection and RFA in patients with Child-Pugh stage A cirrhosis and early stage HCC were comparable with liver transplantation. Low-dose, long-term maintenance IFN therapy after curative therapy was significantly beneficial on survival.Management of hepatocellular carcinoma in Japan: Consensus-based clinical practice manual proposed by the Japan Society of HepatologyMasatoshi Kudo; Takeshi OkanoueONCOLOGY KARGER 72 2 - 15 0030-2414 2007 [Refereed] Hepatocellular carcinoma (HCC) is one of the leading causes of cancer death not only in Japan but worldwide. Clinical Practice Guidelines for HCC were published in 2001 by the European Society of Study of the Liver (EASL) and in 2005 by the American Association for the Study of Liver Disease (AASLD). However, these guidelines have proven to be somewhat unsuitable for Japanese patients. In 2005, supported by the Japanese Ministry of Health, Labor and Welfare, Evidence-Based Clinical Practice Guidelines for HCC were compiled. Based on 'evidence-based' guidelines and the consensus of an expert panel on HCC, the Japan Society of Hepatology (JSH) published the Consensus-Based Clinical Practice Manual in 2007. In this article, the content of this manual, especially issues on surveillance, diagnosis, staging, and treatment, is summarized.Superiority of CT arterioportal angiography to contrast-enhanced CT and MRI in the diagnosis of hepatocellular carcinoma in nodules smaller than 2 cmSoo Ryang Kim; Kenji Ando; Keiji Mita; Shuichi Fuki; Hirotsugu Ikawa; Yoshihiro Kanbara; Susumu Imoto; Toshiyuki Matsuoka; Yoshitake Hayashi; Masatoshi KudoONCOLOGY KARGER 72 58 - 66 0030-2414 2007 [Refereed] To evaluate the effectiveness of computed tomography (CT) arterioportal angiography in the diagnosis of hepatocellular carcinoma (HCC) in nodules smaller than 2 cm, we compared the findings of CT during arteriography (CTA) and CT during arterial portography (CTAP) with those of enhanced CT and enhanced magnetic resonance imaging (MRI). Sixty-eight nodules smaller than 2 cm in 53 patients with liver cirrhosis were classified into three groups of CTA and CTAP: (group 1) hyperattenuation on CTA, and hypoattenuation on CTAP (56 nodules, 41 patients); (group 2) hypoattenuation on CTA, and hypoattenuation on CTAP (10 nodules, 10 patients); (group 3) hypoattenuation on CTA, and hyperattenuation on CTAP (2 nodules, 2 patients). Histologically, 96% (54/56), 80% (8/10), and 100% (2/2) of the nodules in groups 1, 2 and 3, respectively, were diagnosed as HCC. In group 1, enhanced CT or enhanced MRI confirmed hypervascularity in only 77% (30/39) and venous washout in 21% (8/39). In groups 2 and 3, enhanced CT or enhanced MRI on 7 and 2 nodules, respectively, revealed no hypervascularity (0%). The results suggested that CT arterioportal angiography is superior to enhanced CT and MRI in nodules smaller than 2 cm for diagnosing HCC (p < 0.01 group 1, p < 0.01 group 2).Initial treatment response is essential to improve survival in patients with hepatocellular carcinoma who underwent curative radiofrequency ablation therapyShunsuke Takahashi; Masatoshi Kudo; Hobyung Chung; Tatsuo Inoue; Emi Ishikawa; Satoshi Kitai; Chie Tatsumi; Taisuke Ueda; Yasunori Minami; Kazuomi Ueshima; Seiji HajiONCOLOGY KARGER 72 98 - 103 0030-2414 2007 [Refereed] Objective: This study was undertaken to assess the outcome of potentially curative radiofrequency ablation (RFA) therapy for early-stage hepatocellular carcinoma (HCC) in patients with Child-Pugh stage A cirrhosis. Methods: This study retrospectively evaluated clinical outcomes in a cohort of 171 Child-Pugh stage A cirrhotic patients who received RFA for naive HCC within the Milan criteria. The median follow-up period was 36.7 months. Results: Cumulative survival rates estimated by the Kaplan-Meier method for all patients were 98.8, 91.1 and 76.8% at 1, 3 and 5 years, respectively. Cumulative probabilities of local tumor recurrence at 1, 2 and 3 years were 9.0, 14.1 and 17.7%, respectively. Cumulative survival rates in patients without local tumor recurrence were 96.6, 94.6 and 84.4% at 1, 3 and 5 years, respectively, compared with patients with local tumor recurrence (96.6, 74.8 and 42.1% at 1, 3 and 5 years, respectively; p = 0.0002). Cox regression analysis showed that low serum albumin (p = 0.009, RR 3.04, CI 1.32-6.98), high range of PIVKA-II ( prothrombin induced by vitamin K absence or agonist II) (p = 0.025, RR 2.57, CI 1.13-5.89), with multiple (less than 3) nodules (p = 0.021, RR 2.61, CI 1.15-5.91), and with local tumor recurrence (p = 0.004, RR 3.62, CI 1.51-8.69) were significant risk factors for death. Conclusion: Initial complete response of curative RFA therapy in patients with Child-Pugh stage A cirrhosis and early-stage HCC is associated with improved survival. Therefore, clinicians should aim to achieve complete ablation of all detectable HCC nodules with adequate safety margins.Regulatory failure of serum prohepcidin levels in patients with hepatitis CMiki Nagashima; Masatoshi Kudo; Hobyung Chung; Emi Ishikawa; Satoru Hagiwara; Tatsuya Nakatani; Kensaku DoteHEPATOLOGY RESEARCH BLACKWELL PUBLISHING 36 (4) 288 - 293 1386-6346 2006/12 [Refereed] Background/Aims: Elevated serum ferritin and hepatic iron concentrations are frequently observed in chronic hepatitis C (CHC), which may be related to hepcidin. Because the role of hepcidin in CHC patients remains unknown, we aimed in this study to generate some information about hepcidin in CHC. Methods: To determine whether serum hepcidin correlates with markers of iron status in patients with viral hepatitis, we measured serum prohepcidin levels in patients with hepatitis C virus (HCV) and hepatitis B virus (HBV) infection and in healthy controls. Results: Serum prohepcidin and ferritin levels were negatively correlated (r = -0.182, P = 0.037) in HCV patients and positively correlated in HBV patients and in healthy controls. The total iron scores in liver specimens from HCV patients were also negatively correlated ( r = -0.403, P = 0.013). Serum prohepcidin levels in patients with liver cirrhosis (LC) were significantly lower than in patients with chronic hepatitis (CH). In both CH and LC patients, serum prohepcidin levels were significantly lower in HCV patients than in HBV patients. Conclusion: Failure of homeostatic regulation of serum prohepcidin concentrations may be induced by HCV infection, resulting in elevation of serum ferritin levels, which leads to the progression of liver injury by iron overload in CHC patients. (c) 2006 Elsevier Ireland Ltd. All rights reserved.自然経過が観察し得たアルコール性過形成病変の1例前川 清; 井上 達夫; 南 康範; 鄭 浩柄; 上嶋 一臣; 福永 豊和; 工藤 正俊超音波医学 (公社)日本超音波医学会 33 (6) 708 - 708 1346-1176 2006/11肝細胞癌への経皮的ラジオ波焼灼術におけるReal-time Virtual Sonographyの有用性南 康範; 高橋 俊介; 坂口 康浩; 井上 達夫; 鄭 浩柄; 上嶋 一臣; 福永 豊和; 工藤 正俊日本消化器病学会雑誌 (一財)日本消化器病学会 103 (臨増大会) A968 - A968 0446-6586 2006/09原発性肝癌 手術か非手術的治療か適応を探る 肝細胞癌に対する経皮的ラジオ波焼灼療法の現況鄭 浩柄; 高橋 俊介; 井上 達夫; 南 康範; 上嶋 一臣; 福永 豊和; 工藤 正俊日本癌治療学会誌 (一社)日本癌治療学会 41 (2) 348 - 348 0021-4671 2006/09腹部臓器に発生した神経原性腫瘍のレボビスト造影超音波について市島 真由美; 前野 知子; 橋本 三紀恵; 前川 清; 井上 達夫; 南 康範; 鄭 浩柄; 上嶋 一臣; 福永 豊和; 工藤 正俊超音波医学 (公社)日本超音波医学会 33 (Suppl.) S413 - S413 1346-1176 2006/04レボビスト造影超音波の後血管相から見た肝機能評価について前川 清; 井上 達夫; 南 康範; 鄭 浩柄; 上嶋 一臣; 福永 豊和; 工藤 正俊超音波医学 (公社)日本超音波医学会 33 (Suppl.) S440 - S440 1346-1176 2006/04肝癌の経皮的ラジオ波焼灼術におけるReal-time Virtual Sonographyの有用性について南 康範; 工藤 正俊; 鄭 浩柄; 福永 豊和; 上嶋 一臣; 萩原 智; 坂口 康浩; 高橋 俊介; 畑中 絹代; 井上 達夫日本消化器病学会雑誌 (一財)日本消化器病学会 103 (臨増総会) A144 - A144 0446-6586 2006/03Cecal necrosis due to ischemic colitis mimicking an abscess on sonographyT Watanabe; S Tomita; H Shirane; Y Okabe; A Orino; A Todo; T Chiba; M KudoJOURNAL OF ULTRASOUND IN MEDICINE AMER INST ULTRASOUND MEDICINE 25 (3) 393 - 396 0278-4297 2006/03 [Refereed] Ischemic colitis is a vascular disorder of the colon that causes rectal bleeding and abdominal pain in elderly patients.(1,2) It is classified into gangrenous and nongangrenous forms. Nongangrenous colonic ischemia usually requires only medical treatment and is associated with a good prognosis. In contrast, urgent surgical intervention is required for the treatment of gangrenous colonic ischemia, which is associated with high mortality.(3) Thus, in patients with ischemic colitis, it is especially important to determine whether colonic ischemia is the gangrenous or nongangrenous type. Endoscopic assessment of the colon is the most sensitive and reliable method of evaluating the ischemic colon mucosa(4); however, it is not always possible to perform a colonoscopic examination in patients with gangrenous ischemic colitis because of the severe general condition of these patients. Therefore, a noninvasive and rapid examination procedure is necessary for the diagnosis of gangrenous ischemic colitis. In this regard, a sonographic examination may be useful because it can be easily performed even in patients with shock status. In fact, several studies have reported that bowel wall thickening and decreased arterial flow in the affected colon are characteristic findings of patients with nongangrenous ischemic colitis(5-8); however, few articles have addressed the sonographic findings of gangrenous colonic ischemia. In this report, we describe the case of a patient with cecal necrosis due to ischemic colitis and discuss its unique sonographic findings.What is the best staging system for hepatocellular carcinoma?M KudoJOURNAL OF GASTROENTEROLOGY SPRINGER TOKYO 41 (3) 290 - 291 0944-1174 2006/03 [Refereed]純動脈相超音波造影法(PAP-US)と画像表示に用いる測定時相について前川 清; 井上 達夫; 南 康範; 鄭 浩柄; 上嶋 一臣; 福永 豊和; 工藤 正俊超音波医学 (公社)日本超音波医学会 33 (1) 105 - 105 1346-1176 2006/01Comparison of standard-dose and low-dose gemcitabine regimens in pancreatic adenocarcinoma patients: a prospective randomized trialH Sakamoto; M Kitano; Y Suetomi; Y Takeyama; H Ohyanagi; T Nakai; C Yasuda; M KudoJOURNAL OF GASTROENTEROLOGY SPRINGER TOKYO 41 (1) 70 - 76 0944-1174 2006/01 [Refereed] Background. A prospective, randomized study was performed to determine whether gemcitabine infusion at a low dose (250mg/m(2)) is comparable or superior to the standard-dose infusion (1000mg/m(2)) in terms of the survival period, clinical benefit, and frequency of adverse effects in patients with advanced pancreatic adenocarcinoma. Methods. Twenty-five patients who were histologically proven to have locally advanced pancreatic cancer or pancreatic cancer with distant metastases were initially enrolled in the present study. They were treated with gemcitabine infusion at either a dose of 1000mg/m(2) over 30 min (the standard regimen) on days 1, 8, and 15 of every 4-week cycle or at a dose of 250mg/ m(2) over 30 min every week. Survival time, response rate, time to treatment failure, clinical benefit response, and adverse effects were compared between the two groups. Results. Twenty-one patients received gemcitabine for more than 1 month. The median survival period was 7.2 months for patients who received the low-dose infusion regimen, in contrast to 5.2 months for patients administered the standard-dose infusion regimen. The time to treatment failure was 5.6 months for patients in the low-dose infusion regimen, in contrast to 3.4 months for patients in the standard-dose infusion regimen. There were no significant differences in either survival time to time to treatment failure or clinical benefits between the two groups, but the incidence of adverse reactions in patients administered the low-dose therapy was significantly lower than that in patients receiving the standard-dose therapy (P < 0.05). In particular, patients in the standard infusion regimen group experienced more hematologic toxicity than those in the low-dose regimen. Conclusions. These findings suggest that the low-dose gemcitabine infusion regimen can be continuously administered to patients with locally advanced and systemically spreading pancreatic cancer because of its reduced toxicity, resulting in better quality of life and an improved safety profile as compared to the standard infusion treatment regimen.Hepatic angiomyolipoma: Identification of an efferent vessel as a hepatic vein by contrast-enhanced harmonic sonographyRong Qin Zheng; Masatoshi Kudo; Emi Ishikawa; Hobyung Chung; Yasunori Minami; Chikara Ogawa; Yasuhiro Sakaguchi; Masayuki Kitano; Toshihiko Kawasaki; Kiyoshi MaekawaJournal of Medical Ultrasonics 32 (4) 191 - 195 1346-4523 2005/12 [Refereed] Two cases of hepatic angiomyolipoma were studied by contrast-enhanced harmonic sonography. The special tumor hemodynamics, namely the efferent blood flow of the hepatic angiomyolipoma draining into the hepatic vein, were clearly shown on harmonic imaging, and they corresponded well with those seen on angiography and computed tomography during angiography. Benign hepatic tumors were diagnosed preoperatively in both cases according to the hemodynamic findings. Hepatic angiomyolipoma was finally identified histologically. The special tumor hemodynamics might be one of the important characteristics of hepatic angiomyolipoma. Contrast-enhanced harmonic sonography is useful for the detection of special tumor hemodynamics and may facilitate the differential diagnosis from other hepatic tumors, especially malignant liver tumors. © The Japan Society of Ultrasonics in Medicine 2005.Hemodynamic and morphologic changes of peripheral hepatic vasculature in chronic liver disease: A preliminary study by contrast-enhanced coded phase-inversion harmonic sonographyYasuhiro Sakaguchi; Masatoshi Kudo; Rong Qin Zheng; Hobyung Chung; Yasunori Minami; Chikara Ogawa; Masayuki Kitano; Toshihiko Kawasaki; Kiyoshi MaekawaJournal of Medical Ultrasonics 32 (4) 197 - 204 1346-4523 2005/12 [Refereed] To investigate whether observing the morphology of the peripheral hepatic vasculature and the hemodynamics of microbubble arrival time in these vessels can provide useful information for the diagnosis of liver disease, Five normal volunteers and 16 patients were studied by contrast-enhanced coded phase-inversion harmonic sonography. Vessel images of the peripheral vessels were observed in real time after intravenous injection of Levovist. The time when the microbubbles appeared in the peripheral vessels was measured. Three patterns of morphologic change of the peripheral hepatic vasculature were seen, marked, slight, and no abnormal changes. The microbubble arrival times at the peripheral vessels were all shorter in patients with cirrhosis than chronic hepatitis or normal subjects. Marked, slight, and no abnormal morphologic changes of the peripheral hepatic vasculature in patients with liver cirrhosis were found in five, one and zero of the six patients, respectively. Those patients with chronic hepatitis, were found in one, six and three of the ten patients, respectively. There was a significant difference among the different groups (P < 0.001). Evaluating the hemodynamics and morphology by contrast-enhanced coded pulse-inversion harmonic sonography may offer useful information in the diagnosis of liver disease. © The Japan Society of Ultrasonics in Medicine 2005.Studies on the variation in clinical laboratory data and safety evaluation of pharmaceuticalsM Nomura; T Hata; S Naitoh; H Kuwao; K Moriyama; M Fukuoka; M Kudo; Y TohdaYAKUGAKU ZASSHI-JOURNAL OF THE PHARMACEUTICAL SOCIETY OF JAPAN PHARMACEUTICAL SOC JAPAN 125 (12) 997 - 1004 0031-6903 2005/12 [Refereed] The safety of pharmaceuticals has become increasingly important not only in daily medical treatment but also in clinical trials. Although clinical laboratory data are more objective than clinical symptoms, the determination as to whether they indicate abnormal variations depends largely upon the clinical judgment of physicians. The process of determination has not been sufficiently objectified. The present study investigated the indices of criteria for variations in clinical laboratory data obtained in clinical trials. Then, detection rates of abnormal variations were compared between our determination method that employs the reference change value (RCV) expressing the width of biological variation for each test component and conventional determination methods. The study also demonstrated that by combining standard values and the RCV for determination, abnormal variations were found at a rate greater than 50%. The method we propose was applied to the safety evaluation of pharmaceuticals. In clinical trials on the antiviral drug ribavirin administered alone, components of laboratory tests were selected that should be noted in studies on its effects. Expect for decreases in red blood cell counts and hemoglobin values, which are closely associated with anemic symptoms and well known to hepatologists, the increasing trend in platelet counts and decreasing trend in albumin were found to be laboratory test components that should be paid attention to, even though they may not be obvious.Differential diagnosis of nodular lesions in cirrhotic liver by post-vascular phase contrast-enhanced US with Levovist: comparison with superparamagnetic iron oxide magnetic resonance imagesT Inoue; M Kudo; R Watai; Z Pei; T Kawasaki; Y Minami; H Chung; T Fukunaga; K Awai; O MaenishiJOURNAL OF GASTROENTEROLOGY SPRINGER TOKYO 40 (12) 1139 - 1147 0944-1174 2005/12 [Refereed] Background. We investigated the diagnostic utility of post-vascular phase contrast-enhanced ultrasonography (US) and superparamagnetic iron oxide (SPIO)enhanced magnetic resonance imaging (MRI) as compared to the histological diagnosis of differential grades of hepatocellular carcinomas (HCCs). Methods. Forty-nine patients with histologically characterized liver nodules (well-differentiated HCC, n = 20; moderately differentiated HCC, n = 19; poorly differentiated HCC, n = 1; dysplastic nodule, n = 9) received contrast-enhanced US and SPIO-MRI. Subsequently, we quantitatively evaluated the relationships between the images of the nodules and their histological diagnosis and differential grades. Results. The ratio of the echogenicity of the tumorous area to that of the nontumorous area with post-vascular phase contrast-enhanced US (post-vascular phase ratio) decreased as nodules became less differentiated (P < 0.05; Kruskal-Wallis test). The ratio of the intensity of the nontumorous area to that of the tumorous area on SPIO-enhanced MR images (SPIO intensity index) also decreased as nodules became less differentiated (P < 0.01). The post-vascular phase ratio correlated with the SPIO intensity index for HCCs and dysplastic nodules (r = 0.76). The conformity of the result from the post-vascular phase contrast-enhanced US and SPIO-MRI was 96%. Conclusions. Contrast-enhanced US is a valuable method for predicting the histological grade of HCCs in cirrhotic patients, and may be a good alternative to SPIO-enhanced MRI.Hemodynamic and morphologic changes of peripheral hepatic vasculature in cirrhotic liver disease: A preliminary study using contrast-enhanced coded phase inversion harmonic ultrasonographyRong-Qin Zheng; Bo Zhang; Masatoshi Kudo; Yasuhiro SakaguchiWORLD JOURNAL OF GASTROENTEROLOGY BAISHIDENG PUBL GRP CO LTD 11 (40) 6348 - 6353 1007-9327 2005/10 [Refereed] AIM: To provide the useful information for the diagnosis of liver cirrhosis by observing the morphology of peripheral hepatic vessels and the hemodynamics of microbubble arrival time in these vessels. METHODS: Twenty-one subjects including 5 normal volunteers and 16 patients (liver cirrhosis, n=10; chronic hepatitis, n=6) were studied by contrast-enhanced coded phase inversion harmonic sonography (GE LOGIQ 9 series) using a 6-8 MHz convex-arrayed wide-band transducer. The images of peripheral hepatic artery, portal and hepatic vein were observed in real-time for about 2 min after intravenous injection of Levovist. The time when microbubbles appeared in the peripheral vessels (microbubble arrival time) was also recorded. The morphologic changes of peripheral hepatic vasculature were classified as marked, slight, and no changes based on the regularity in caliber, course, ramification, and the delineation of vessels compared to normal subjects. RESULTS: The microbubble arrival time at peripheral artery, portal, and hepatic vein was shorter in cirrhotic patients than in chronic hepatitis patients and normal subjects. The marked, slight and no morphologic changes of peripheral hepatic vasculature found in 5 (5/6, 83.3%), 1 (1/6, 16.7%), and 0 (0/6, 0%) liver cirrhosis patients, respectively, and in 1 (1/10, 10%), 6 (6/10, 60%), and 3 (3/10, 30%) chronic hepatitis patients, respectively. There was a significant difference between the two groups (P < 0.001). CONCLUSION: Evaluation of the hemodynamics and morphology of peripheral hepatic vasculature by contrast-enhanced coded pulse inversion harmonic sonography can provide useful information for the diagnosis of liver cirrhosis. (C) 2005 The WJG Press and Elsevier Inc. All rights reserved.Imaging findings of biliary hamartomasRong-Qin Zheng; Bo Zhang; Masatoshi Kudo; Hirokazu Onda; Tatsuo InoueWORLD JOURNAL OF GASTROENTEROLOGY BAISHIDENG PUBL GRP CO LTD 11 (40) 6354 - 6359 1007-9327 2005/10 [Refereed] AIM: To evaluate the imaging findings of biliary hamartomas (von Meyenburg complexes, VMCs) and discuss the differential diagnosis with other related diseases. METHODS: Imaging findings of biliary hamartomas on ultrasonography (US), computed tomography (CT), magnetic resonance imaging (MRI), MR cholangiopancreatography (MRCP) and hepatobiliary scintigraphy were retrospectively analyzed in six patients. RESULTS: On ultrasound images, five of the six cases showed multiple small hyper-and hypo-echoic lesions with comet-tail echoes, especially when magnified by us with the usage of zoom function. In all the six cases, multiple tiny hypodense lesions less than 10 mm in diameter were revealed as scattered throughout the liver with no enhancement on CT. These tiny lesions were demonstrated to be hyper-and hypo-intensity on T2- and TI-weighed images, respectively, in three patients who underwent MRI examinations. MRCP was performed in two patients, and clearly showed multiple tiny irregular-and round-shaped hyper-intensity lesions. MRCP and hepatobiliary scintigraphy showed normal appearances of intra-and extra-hepatic bile ducts in two and one patients, respectively. CONCLUSION: Imaging modalities are useful in the diagnosis and differential diagnosis of VMCs. A correct diagnosis might be obtained when typical imaging findings are present even without a histological confirmation. (C) 2005 The WJG Press and Elsevier Inc. All rights reserved.進行肝癌の治療最前線 進行肝癌に対するリザーバー動注化学療法の新たな展開上嶋 一臣; 工藤 正俊; 坂口 康浩肝臓 (一社)日本肝臓学会 46 (Suppl.2) A352 - A352 0451-4203 2005/09進行肝癌の治療最前線 進行肝癌に対するリザーバー動注化学療法の新たな展開上嶋 一臣; 工藤 正俊; 坂口 康浩日本消化器病学会雑誌 (一財)日本消化器病学会 102 (臨増大会) A538 - A538 0446-6586 2005/09Well-differentiated HCC manifesting hyperattenuation on CT during arterial portographyKim, SR; KI Kim; Y Maekawa; S Imoto; T Ninomiya; K Mita; K Ando; K Fukuda; S Fuki; M Kudo; T Matsuoka; N Sasase; M Taniguchi; Y HayashiHEPATO-GASTROENTEROLOGY H G E UPDATE MEDICAL PUBLISHING S A 52 (65) 1559 - 1562 0172-6390 2005/09 [Refereed] A rare case of well-differentiated minute hepatocellular carcinoma (HCC) with hepatitis C virus-related cirrhosis, with unusual radiologic features, is presented, A 10-mm hypoechoic nodule disclosed by ultrasound in segment six showed hypoattenuation on computed tomography hepatic arteriography and hyperattenuation on computed tomography during arterial portography, indicating that the portal vein may have been the dominant vascularity of the nodule. Contrast-enhanced ultrasound revealed hypovascularity in the early arterial phase, isovascularity in the late vascular phase, and the same perfusion as that surrounding the liver parenchyma in the post-vascular phase, with the same pattern observed on the two imaging techniques. These findings were considered not compatible with those of well-differentiated HCC. Ultrasound-guided biopsy showed histological features of well-differentiated HCC with over two-fold the cellularity of the non-tumorous area with a high nuclear/cytoplasmic ratio, increased cytoplasmic eosinophilia, slight atypia and fatty change with an irregular thin trabecular pattern. Further studies may provide insights into the correlation between tumor neovascularity in multistep hepatocarcinogenesis and dual hemodynamics, including the artery and the portal vein.Quantitative tissue blood flow evaluation of pancreatic tumor: Comparison between xenon CT technique and perfusion CT technique based on deconvolution analysisHisashi Abe; Takamichi Murakami; Masaru Kubota; Tonsok Kim; Masatoshi Hori; Masayuki Kudo; Kazuhiko Hashimoto; Shoji Nakamori; Keizo Dono; Kaname Tomoda; Morito Monden; Hironobu NakamuraRadiation Medicine - Medical Imaging and Radiation Oncology 5 23 (5) 364 - 370 0288-2043 2005/08 [Refereed] Purpose: There has been one report that tissue blood flow (TBF) quantification with xenon CT was effective in predicting the therapeutic response to an anticancer drug in pancreatic cancer. The purpose of this study was to evaluate the correlation between the TBF of pancreatic tumors calculated with xenon CT and those with perfusion CT, in order to evaluate whether perfusion CT could replace xenon CT. Materials and Methods: Nine patients with pathologically proved pancreatic tumors who underwent both xenon CT and perfusion CT were included. Results: Quantitative TBF of pancreatic tumors measured by perfusion CT ranged from 22.1 to 196.2 ml/min/100 g (mean±SD, 52.6±54.8 ml/min/100 g). In contrast, those obtained by xenon CT ranged from 10.3 to 173.6 ml/min/100 g (mean±SD, 47.9±49.4 ml/min/100 g). There was a good linear correlation between xenon CT and perfusion CT (y=0.8537x+2.48, R2=0.895: p< 0.05). Conclusion: The TBF of pancreatic tumors measured by xenon CT and perfusion CT techniques showed a close linear correlation. We can expect that perfusion CT based on the deconvolution algorithm may replace xenon CT to predict the effect of pancreatic tumor treatment with anticancer drugs.Ischemia of rat stomach mobilizes ECL cell histamineM Kitano; M Bernsand; Y Kishimoto; P Norlen; R Hakanson; Y Haenuki; M Kudo; J HasegawaAMERICAN JOURNAL OF PHYSIOLOGY-GASTROINTESTINAL AND LIVER PHYSIOLOGY AMER PHYSIOLOGICAL SOC 288 (5) G1084 - G1090 0193-1857 2005/05 [Refereed] Microdialysis was used to study how ischemia-evoked gastric mucosal injury affects rat stomach histamine, which resides in enterochromaffin-like (ECL) cells and mast cells. A microdialysis probe was inserted into the gastric submucosa, and the celiac artery was clamped (30 min), followed by removal of the clamp. Microdialysate histamine was determined by enzyme-linked immunosorbent assay. In addition, we studied the long-term effects of ischemia on the oxyntic mucosal histidine decarboxylase activity in omeprazole-treated rats. Gastric mucosal lesions induced by the ischemia were enlarged on removal of the clamp. The microdialysate histamine concentration increased immediately on clamping (50-fold rise within 30 min) and declined promptly after the clamp was removed. In contrast, histidine decarboxylase activity of the ECL cells was lowered by the ischemia and returned to preischemic values 9 days later. Mast cell-deficient rats responded to ischemia-reperfusion much like wild-type rats with respect to histamine mobilization. Pretreatment with the irreversible inhibitor of histidine decarboxylase, alpha-fluoromethylhistidine, which is known to eliminate histamine from ECL cells, prevented the rise in microdialysate histamine. Pharmacological blockade of acid secretion (cimetidine or omeprazole) prevented the lesions induced by ischemia-reperfusion insult but not the mobilization of histamine. In conclusion, ischemia of the celiac artery mobilizes large amounts of histamine from ECL cells, which occurs independently of the gross mucosal lesions. The prompt reduction of the mucosal histidine decarboxylase activity in response to ischemia probably reflects ECL cell damage. The lesions develop not because of mobilization of histamine per se but because of ischemia plus reperfusion plus gastric acid.【肝胆膵のclinical question】内科からどのような肝細胞癌が外科的治療を依頼されるか?南 康範; 鄭 浩柄; 畑中 絹代; 井上 達夫; 坂口 康浩; 萩原 智; 上嶋 一臣; 福永 豊和; 工藤 正俊; 土師 誠二; 中居 卓也; 大柳 治正胆と膵 医学図書出版(株) 26 (3) 279 - 283 0388-9408 2005/03 ラジオ波焼灼術(RFA)は高い局所制御能から肝細胞癌の局所治療として用いられており,外科治療と共に根治性の高い治療法として位置づけられている.しかし,全ての肝細胞癌がRFAで治療可能である訳ではない.肝細胞癌治療には外科切除,RFA,経カテーテル的治療など複数の選択肢があり,治療法選択には病期や肝予備能に基づいて内科・外科・放射線科など各科を横断したトータル・マネージメントが必要である.基本的に内科より外科治療が考慮される症例として, 1)外科治療の根治性がより高い場合, 2)経皮的RFAが困難な場合, 3)合併症が危惧される場合が挙げられるが,臨床の場で大切なことは内科と外科との意見交換からコンセンサスを築くことである(著者抄録)Estimation of the malignant potential of gastrointestinal stromal tumors: the value of contrast-enhanced coded phase-inversion harmonics USN Fukuta; M Kitano; K Maekawa; T Chikugo; M KudoJOURNAL OF GASTROENTEROLOGY SPRINGER JAPAN KK 40 (3) 247 - 255 0944-1174 2005/03 [Refereed] Background. Recently. contrast agents for ultrasonography (US) such as Levovist have been introduced for routine clinical use. The contrast-enhanced US with Levovist permits evaluation of the intratumoral vascularity of hepatic and pancreatic tumors and is useful for their differential diagnosis. The purpose of the present study was to assess tumor vessels and the parenchymal flow of oastrointestinal stromal tumors (GISTs) by contrast-enhanced coded phase-inversion harmonic US and to evaluate whether vascularity is related to the malignant grade of the GISTs. Methods. Thirteen patients with GISTs were included in the present study. Tumors were observed in a real-time fashion of contrast-enhanced coded phase-inversion harmonic US after the injection of Levovist (400 mg/ml). The Vascular patterns were compared with tumor size, histological diagnosis. KIT mutations, and clinical findings such as metastasis. Results. The contrast-enhanced US images of the GISTs were classified into two types according to the blood flow area of the tumors as seen by real-time continuous imaging of the tumor vessels. The image pattern "Poor" represented vessels flowing only in the peripheral part of the tumor, and "Rich" represented abundant vessels flowing from the periphery to the central part of the tumor. According to the contrast-enhanced US images, five GISTs were classified as "Poor" and the others as "Rich." Based on the final diagnosis, all tumors with "Poor" images were determined to be benign GISTs. and the rest tumors except one with "Rich" images were determined to be malignant GISTs. Conclusions. Contrast-enhanced US image is more closely correlated with the final diagnosis than the histological findings.[Current topics on therapy of hepatocellular carcinoma].Kudo MNihon Naika Gakkai zasshi. The Journal of the Japanese Society of Internal Medicine 94 (3) 464 - 472 0021-5384 2005/03 [Refereed]Primary sclerosing cholangitis and hepatitis C virus infectionKim, SR; S Imoto; M Taniguchi; KI Kim; N Sasase; T Matsuoka; Y Maekawa; T Ninomiya; K Ando; K Mita; S Fuki; T Koterazawa; K Fukuda; M Kudo; H Sakamoto; Y HayashiINTERVIROLOGY KARGER 48 (4) 268 - 272 0300-5526 2005 [Refereed] Two cases of primary sclerosing cholangitis with hepatic C virus infection in a 62-year-old man and a 60-year-old woman are presented. The infection in the man was eradicated with interferon therapy in 1992. Seven years thereafter, endoscopic retrograde cholangiography revealed a diffuse 2.5-cm-long stenotic lesion in the common bile duct which was consequently resected. Histological examination of the resected specimen revealed proliferation of epithelial cells, plasma cell infiltration, and fibrosis in the submucosal layer of the common bile duct. The human leukocyte antigen DR loci were 2 and 9. In the woman, a 6-month course of interferon therapy in 1992 failed to eradicate the infection. Cholangiography in 1999 revealed multiple narrowings and dilatations of intra- and extrahepatic bile ducts. Ultrasound guided biopsy of the liver in 1992 had revealed onionskin lesions around the bile duct epithelium in the portal tract. The human leukocyte antigen DR locus was 2. From these findings, the 2 cases were diagnosed as primary sclerosing cholangitis. Further studies may provide insights into the relation between the pathogenesis of the disease and the infection. Copyright (C) 2005 S. Karger AG, Basel.Validation of a new prognostic staging system for hepatocellular carcinoma: the JIS score compared with the CLIP scoreM Kudo; HY Chung; S Haji; Y Osaki; H Oka; T Seki; H Kasugai; Y Sasaki; T MatsunagaHEPATOLOGY JOHN WILEY & SONS INC 40 (6) 1396 - 1405 0270-9139 2004/12 [Refereed] The Japan Integrated Staging score (JIS score), which combines the Child-Turcotte-Pugh classification and tumor-node-metastasis staging, has been proposed as a better prognostic staging system for hepatocellular carcinoma (HCC) than the Cancer of the Liver Italian Program (CLIP) scoring system. In this study, validation was performed among a larger patient population. A total of 4,525 consecutive patients with HCC who had been diagnosed at five institutions were included. Stratification ability, prognostic predictive power, and reproducibility were analyzed and compared with results from the CLIP scoring system. Only 45% (1,951 of 4,525) of all patients were categorized as early stage HCC according to JIS score (0 or 1), whereas 63% (2,878 of 4,525) of the patients were categorized as having a CLIP score of 0 or 1. Significant differences in survival curves were not observed among CLIP scores 3 to 6. In contrast, survival curves showed significant differences among all the JIS scores. The same JIS scoring subgroups showed a similar prognosis, and good internal reproducibility was observed in each of the institutions. Multivariate analysis of the prognosis in all 4,525 patients proved the JIS score to be the best prognostic factor. Furthermore, the Akaike information criteria proved that the JIS scoring system was statistically a better model for predicting outcome than the CLIP scoring system. In conclusion, the stratification ability and prognostic predictive power of the JIS score were much better than that of the CLIP score and were simple to obtain and remember.[Comparison of treatment methods for hepatocellular carcinoma--based on JIS score].Kudo M; Chung H; Osaki Y; Kasugai H; Oka H; Seki TGan to kagaku ryoho. Cancer & chemotherapy 31 (13) 2100 - 2104 0385-0684 2004/12 [Refereed]Anisakis in a biopsy specimen from the edge of a gastric ulcer: report of a caseM Shiomi; T Kamisako; Yutani, I; R Yoshimoto; M Kudo; R FujiiGASTROINTESTINAL ENDOSCOPY MOSBY, INC 60 (5) 854 - 856 0016-5107 2004/11 [Refereed]Hepatocellular carcinoma that ruptured during radiofrequency ablation therapyT Kawasaki; M Kudo; H Chung; Y MinamiJOURNAL OF GASTROENTEROLOGY SPRINGER TOKYO 39 (10) 1015 - 1016 0944-1174 2004/10 [Refereed]Hypervascular liver nodules in heavy drinkers of alcoholKim, SR; Y Maekawa; S Imoto; M Sugano; M KudoALCOHOLISM-CLINICAL AND EXPERIMENTAL RESEARCH LIPPINCOTT WILLIAMS & WILKINS 28 (8) 174S - 180S 0145-6008 2004/08 [Refereed] Background: Three cases of hypervascular nodules in the liver, without hepatitis B or C virus infection and with a history of alcohol abuse (120 ml/day for 15 to 30 years), are presented. Results: Ultrasound examination revealed hypoechoic nodules in segment 6 (2 cm in diameter, case 1), in the right and left lobes (1-2 cm multiple type, case 2), and in segment 4 (4 cm, case 3). Hepatic angiography and computed tomography during arteriography revealed hypervascular nodules in the three cases. First, hepatocellular carcinoma, focal nodular hyperplasia, hemangioma, hemangioendothelioma, inflammatory pseudotumor, and pseudolymphoma were diagnostically differentiated. Histologically, there was no evidence of hepatocellular carcinoma or of any of the pathologies considered in the differential diagnosis by imaging studies. In case 1, the lesion was composed of an irregular, thin, trabecular-pattemed hepatic acinus with slighter hypercellularity than in the nonnodular area. In cases 2 and 3, the lesions were composed mainly of fibrosis without hyperplasia, showing stellate scar-like fibrosis septa dividing the nodule. Marked pericellular fibrosis, neutrophilic infiltration, and Mallory bodies in the cytoplasm were also observed. In cases 1 and 2, small unpaired arteries explaining the hypervascularity of the nodules were observed. Conclusion: These hypervascular nodules were classified as regenerative, not neoplastic, nodules according to the classification of the International Working Party.[Efficacy of short-duration interferon administration to prevent HCV transmission to medical personnel].Chung H; Kudo MNihon rinsho. Japanese journal of clinical medicine 62 Suppl 7 (Pt 1) 315 - 318 0047-1852 2004/07 [Refereed]Closed continuous hyperthermic peritoneal perfusion model in mice with peritoneal dissemination of colon 26M. Kudo; T. Asao; S. Hashimoto; H. KuwanoInternational Journal of Hyperthermia 20 (4) 441 - 450 0265-6736 2004/06 [Refereed] An original model of closed continuous hyperthermic peritoneal perfusion (CHPP) in mice is presented and was found to support the efficacy of intraperitoneal hyperthermia. Closed CHPP was performed after intraperitoneal inoculation of transplantable colon 26 cells into a mouse. Colon 26 cells (5 × 104) were injected into 18 mice. The mice were then allocated to six groups of three each and subjected to peritoneal perfusion over time. Peritoneal washings from each mouse were sampled and counted by the cytosmear method. On day 10 after inoculation, colonies of the disseminated tumour were seen on the mesentery by staining with 0.1% methylene blue for 5 min. The number of tumour nodules on the mesentery was counted. The number of washed-out tumour cells decreased the most at 24 h after inoculation, and 76% of the inoculated cells did not wash out during the peritoneal perfusion procedure. CHPP was performed after 24 h when colon 26 cells were injected into the peritoneal cavity because this status may represent micrometastasis. The total number of nodules on the mesentery in the CHPP group was significantly smaller than that in the control (p < 0.02). In conclusion, because this treatment model is similar to the clinical CHPP, the biostaining model might be useful for the evaluation of peritoneal dissemination and it was unique and valuable in demonstrating an effective treatment for the prevention of peritoneal dissemination. © 2004 Taylor & Francis Ltd.Percutaneous radiofrequency ablation guided by contrast-enhanced harmonic sonography with artificial pleural effusion for hepatocellular carcinoma in the hepatic domeY Minami; M Kudo; T Kawasaki; H Chung; C Ogawa; H ShiozakiAMERICAN JOURNAL OF ROENTGENOLOGY AMER ROENTGEN RAY SOC 182 (5) 1224 - 1226 0361-803X 2004/05 [Refereed]Characterization of hepatic tumors: Value of contrast-enhanced coded phase-inversion harmonic angioYL Wen; M Kudo; RG Zheng; H Ding; P Zhou; Y Minami; HY Chung; M Kitano; T Kawasaki; K MaekawaAMERICAN JOURNAL OF ROENTGENOLOGY AMER ROENTGEN RAY SOC 182 (4) 1019 - 1026 0361-803X 2004/04 [Refereed] Objective. Our purpose was to evaluate the value of contrast-enhanced. coded phase-inversion harmonic imaging in showing the characteristic intranodular hemodynamics of hepatic tumors. Subjects and Methods. Using a microbubble contrast agent we performed coded harmonic angio in 163 patients with 192 hepatic tumor nodules: 153 hepatocellular carcinomas, 13 metastases, 14 hemangiomas, eight dysplastic nodules, and four focal nodular hyperplasias. After injecting Levovist, we performed real-time scanning, interval-delay fast low-angle shot imaging, and sweep scanning in the early arterial phase, late vascular phase, and postvascular phase, respectively. Results. On contrast-enhanced coded harmonic angio, the typical hemodynamic pattern of hepatocellular carcinomas was shown as abundant tumor vessels supplied from the periphery to the center of the tumor and dense parenchymal tumor staining with fast washout (sensitivity, 92.8%; specificity, 92.3%). The characteristic hemodynamic pattern of metastases was peripheral tumor vessels with a rim parenchymal stain in the vascular phase followed by a perfusion defect in the postvascular phase (sensitivity, 69.2%; specificity, 100%). Hemangiomas were hypovascular in the early arterial phase with gradual spotty or cotton-wool pooling continuing to the late vascular phase (sensitivity, 92.9%; specificity, 100%). Dysplastic nodules were shown as having no early arterial supply with isovascularity in the late vascular phase (sensitivity, 75%; specificity, 100%). Focal nodular hyperplasias were shown to have a spoked wheel pattern of blood vessels accompanied by dense staining in interval-delay scanning (sensitivity, 100%; specificity, 100%). Conclusion. Contrast-enhanced coded harmonic angio is a promising method to provide useful information for the differential diagnosis of hepatic tumors.Comparison of argon plasma coagulation and paravariceal injection sclerotherapy with 1% polidocanol in mucosa-fibrosing therapy for esophageal varicesS Matsui; M Kudo; R Nakaoka; M Shiomi; T KawasakiJOURNAL OF GASTROENTEROLOGY SPRINGER-VERLAG TOKYO 39 (4) 397 - 399 0944-1174 2004/04 [Refereed]Hepatocellular carcinoma and NASHM KudoJOURNAL OF GASTROENTEROLOGY SPRINGER-VERLAG TOKYO 39 (4) 409 - 411 0944-1174 2004/04 [Refereed]Diagnosis of acute cholecystitis in patients with liver cirrhosis: Waveform analysis of the cystic artery by color Doppler imagingHitoshi Tochio; Shin-Ichi Nishiuma; Yoshihiro Okabe; Akio Orino; Masatoshi KudoJournal of Medical Ultrasonics 31 (1) 21 - 28 1346-4523 2004/03 [Refereed] Purpose. The aim of this study was to investigate the possibility of diagnosing acute cholecystitis in patients with liver cirrhosis using color Doppler imaging to demonstrate the hemodynamics. Methods. Color Doppler imaging was used to analyze the waveform of the cystic artery in 28 cirrhotic subjects with thickened gallbladder walls and 56 normal controls. The cirrhotic group was further divided into the cholecystitis group, containing 6 cirrhotic patients with acute cholecystitis, and the liver cirrhosis group, containing 22 cirrhotic patients without acute cholecystitis. Results. Maximum velocity (Vmax) was significantly higher in the cholecystitis group (31.6 ± 23.0cm/s) than in the normal controls (16.1 ± 5.9cm/s) (P < 0.01). The resistance index (RI) was higher in the liver cirrhosis group (0.84 ± 0.04) than in either the normal controls (0.70 ± 0.06) (P < 0.01) or the cholecystitis group (0.72 ± 0.09) (P < 0.01). Sensitivity and specificity were 100% when the diagnostic criteria of acute cholecystitis were a maximum velocity of more than 40cm/s, a resistance index of more than 0.75, or both. Conclusion. A pulsatile signal with a maximum velocity of more than 40cm/s, a resistance index lower than 0.75, or both indicated the presence of acute cholecystitis in patients with liver cirrhosis and a thickened gallbladder wall. © The Japan Society of Ultrasonics in Medicine 2004.Local ablation therapy for hepatocellular carcinoma: current status and future perspectivesM KudoJOURNAL OF GASTROENTEROLOGY SPRINGER-VERLAG TOKYO 39 (3) 205 - 214 0944-1174 2004/03 [Refereed]肝癌治療直接効果判定基準 2004年改訂版日本肝癌研究会肝癌集学的治療効果判定基準作成委員会; 有井滋樹; 江原正明; 岡崎正敏; 岡田周一; 沖田極; 工藤正俊; 久保正二; 坂本亨宇; 佐藤守男; 椎名秀一郎; 関寿人; 高安賢一; 田中正俊; 田伏克惇; 辻井博彦; 中島収; 中沼安二; 松井修; 山岡義生; 山崎晋; 山田龍作肝臓 45 (7) 380-385  0451-4203 2004 [Refereed]Afferent and efferent vessels of premalignant and overt hepatocellular carcinoma: Observation by color Doppler ImagingH Tochio; M KudoINTERVIROLOGY KARGER 47 (3-5) 144 - 153 0300-5526 2004 [Refereed] Afferent and efferent vessels of premalignant and overt hepatocellular carcinoma (HCC) were analyzed using color Doppler imaging. With afferent blood flow, constant waveform signals reflecting portal inflow are a characteristic finding in dysplastic nodules and early well-differentiated HCC. Among advanced HCCs lacking portal blood flow, inflow of arterial pulsatile blood flow signals is characteristic for advanced HCC with increased arterial vascularity. Efferent blood flow enters the hepatic vein of the lowest pressure system in dysplastic nodules and early well-differentiated HCC with afferent portal blood flow. Analysis of waveforms of efferent blood flow signals in advanced HCC detects in the opposite direction adjacent to an accompanying afferent arterial pulsatile blood flow signal. In conclusion, during multistep human hepatocarcinogenesis hemodynamics show characteristic changes; the state of afferent portal blood with low arterial vascularity loses the portal blood flow, and arterial vascularity gradually increases. The efferent blood flow pathway also changes with the pathological multistep development process. Copyright (C) 2004 S. Karger AG, Basel.Detection of intratumoral vascularity in small hepatocellular carcinoma by coded phase inversion harmonicsYL Wen; P Zhou; M KudoINTERVIROLOGY KARGER 47 (3-5) 169 - 178 0300-5526 2004 [Refereed] Objective: To investigate the value of contrast-enhanced coded phase inversion harmonic imaging (PIHI) in the depiction of intratumoral vascularity in small hepatocellular carcinoma (HCC). Methods: Eighty-five patients with 106 HCCs less than or equal to3 cm in diameter were evaluated with coded harmonic angio (CHA), a coded PIHI, with use of an intravenous contrast medium, Levovist. Intratumoral vessels were detected in the early arterial phase, and tumor parenchymal stain was demonstrated in the late vascular phase. The detectability of intratumoral vascularity on contrast-enhanced CHA was compared with that on dynamic computed tomography (CT) and digital subtraction angiography (DSA). Results: With a combination of both vessel images and parenchymal flow images demonstrated by contrast-enhanced CHA, 98 of 106 small HCCs were evaluated as being hypervascular or isovascular. Using the results on dynamic CT as a gold standard, the sensitivity, specificity and accuracy were 95.1, 100 and 95.3%, respectively. The detection rate of intratumoral vascularity by contrast-enhanced CHA was 92.5% (98/106), compared with 97.2% (103/106) on dynamic CT (p=0.14) and 88.9% (40/45) on DSA (p=0.53). Conclusions: Contrast-enhanced coded PIHI is a sensitive tool for depicting intratumoral vascularity of small HCC. Copyright (C) 2004 S. Karger AG, Basel.Hepatobiliary and pancreatic: Inflammatory pseudotumor of the liverRQ Zheng; M KudoJOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY BLACKWELL PUBLISHING ASIA 18 (8) 994 - 994 0815-9319 2003/08 [Refereed]Characterization of focal hepatic lesions with contrast-enhanced C-cube gray scale ultrasonographyWP Wang; H Ding; Q Qi; F Mao; ZZ Xu; M KudoWORLD JOURNAL OF GASTROENTEROLOGY W J G PRESS 9 (8) 1667 - 1674 1007-9327 2003/08 [Refereed] AIM: To characterize enhancement patterns of focal hepatic lesions using C-cube gray scale sonography with a microbubble contrast agent and to evaluate its usefulness in differential diagnosis of hepatic lesions. METHODS: Fifty-four patients with 58 focal hepatic lesions were examined with Levovist-enhanced C-cube gray scale sonography. The final diagnosis of hepatic lesions was 29 primary liver cancers, 4 metastases, 8 hemangiomas, 12 focal nodular hyperplasias, 2 inflammatory pseudotumors of the liver and 3 angiomyolipomas. The initiation time of enhancement in various lesions and enhancement duration after administration of contrast agent were compared. Vascular findings in lesions were classified as peripheral enhancement, homogenous enhancement, mosaic enhancement and no enhancement depending on microbubble signals in the lesion relative to the liver parenchyma. RESULTS: The initiation time of enhancement in hemangioma (48+/-12 s) was significantly later compared to other lesions (P<0.05). The enhancement duration of malignancies (69+/-33 s in primary liver cancer, 61+/-23 s in metastasis) was significantly shorter compared to benign lesions (P<0.05). Intranodular enhancement appearing at arterial phase and decreasing at portal venous phase was considered characteristic for malignancy. Intranodular enhancement did not appear earlier than the liver parenchyma, and peripheral enhancement pattern was regarded as positive findings for hemangioma. Intranodular enhancement appeared in the arterial phase, and homogenous enhancement pattern sustained in the whole portal venous phase were regarded as positive findings for focal nodular hyperplasia. No microbubble signals appeared in two inflammatory pseudotumors of the liver. CONCLUSION: C-cube gray scale sonography can demonstrate dynamic intranodular enhancement in various focal hepatic lesions. The information provided by this methodology may be useful in the differential diagnosis of hepatic lesions.Radiofrequency ablation of hepatocellular carcinoma: Therapeutic response using contrast-enhanced coded phase-inversion harmonic sonographyYL Wen; M Kudo; RQ Zheng; Y Minami; H Chung; Y Suetomi; H Onda; M Kitano; T Kawasaki; K MaekawaAMERICAN JOURNAL OF ROENTGENOLOGY AMER ROENTGEN RAY SOC 181 (1) 57 - 63 0361-803X 2003/07 [Refereed] OBJECTIVE. This study was performed to evaluate the usefulness of contrast-enhanced coded phase-inversion harmonic sonography in assessing the therapeutic response of percutaneous radiofrequency ablation in patients with hepatocellular carcinoma. SUBJECTS AND METHODS. Sixty-seven patients with a total of 107 examinations on 91 hepatocellular carcinoma nodules underwent coded harmonic angio, a technique of coded phase-inversion harmonic sonography, using the IV microbubble contrast agent Levovist before and after percutaneous radiofrequency ablation. The intratumoral blood vessels and tumor parenchymal stain were detected in the early arterial phase and the late vascular phase, respectively. The results of contrast-enhanced imaging with coded harmonic angio were compared with those of three-phase dynamic CT. RESULTS. Before treatment, all examined 107 hepatocellular carcinoma nodules were found to be hypervascular on contrast-enhanced imaging with coded harmonic angio. After radiofrequency ablation, contrast-enhanced coded harmonic angio detected persistent signal enhancement in 41 examined nodules (38.3%), whereas this technique showed no intratumoral enhancement in the remaining 66 (61.7%) examined nodules. Compared with dynamic CT, the sensitivity, specificity, and diagnostic accuracy of contrast-enhanced coded harmonic angio were 95.3%, 100%, and 98.1%, respectively. With contrast-enhanced coded harmonic angio, we found that it was difficult to identify the safety margin that can be detected on dynamic CT. CONCLUSION. Contrast-enhanced imaging with coded harmonic angio may provide an alternative approach that has high diagnostic agreement with dynamic CT in assessing the therapeutic effect of radiofrequency ablation in hypervascular hepatocellular carcinomas, in spite of having limitations in identifying the safety margin.Hepatocellular carcinoma associated with secondary haemochromatosis in non-cirrhotic liver: a case reportHY Chung; M Kudo; T Kawasaki; M Kitano; Y Minami; Y Suetomi; H OndaHEPATOLOGY RESEARCH ELSEVIER SCI IRELAND LTD 26 (3) 254 - 258 1386-6346 2003/07 [Refereed] We describe one case of hepatocellular carcinoma (HCC) arising in secondary haemochromatosis in a non-cirrhotic liver. The patient was a 40-year-old male. He had severe pancytopenia due to myelodysplastic syndrome (MDS) and developed secondary haemochromatosis as a result of a large amount of erythrocyte transfusion. Multiple nodules of the liver appeared about 6 years after the diagnosis of MDS. Needle biopsy of the nodules histologically confirmed them to be moderately differentiated HCCs. The liver parenchyma was shown to be non-cirrhotic and a deposit of hemosiderin was also identified, consistent with a finding of haemochromatosis of the liver. Transarterial chemoembolization was performed to treat multiple HCCs. There are a number of reports describing HCC occurrence in non-cirrhotic patients with hereditary haemochromatosis. However, HCC in secondary haemochromatosis without cirrhosis is extremely rare. (C) 2003 Elsevier Science B.V. All rights reserved.Contrast-enhanced agent detection imaging: Early experience in hepatocellular carcinomaYan Ling Wen; Masatoshi Kudo; Yasunori Minami; Hobyung Chung; Yoichiro Suetomi; Hirokazu Onda; Masayuki Kitano; Toshihiko Kawasaki; Kiyoshi MaekawaJournal of Medical Ultrasonics 30 (SUMMER) 77 - 84 1346-4523 2003/06 [Refereed] Purpose: To investigate the usefulness of contrast-enhanced Agent Detection Imaging in assessing intratumoral vasculature in hepatocellular carcinoma. Materials and Methods: Fourteen hepatocellular carcinoma nodules in 11 patients were studied with contrast-enhanced Agent Detection Imaging, a wide-band color Doppler imaging method, employing Levovistℛ, a microbubble contrast agent. High acoustic power was used with contrast-enhanced Agent Detection Imaging. Intermittent transmission of Agent Detection Imaging was performed at intervals of 200, 500, and 350 milliseconds in the early arterial phase (10 to 40 seconds), late vascular phase (1 to 3 minutes) and postvascular phase (5 to 7 minutes), respectively. The results were compared with those of three-phase dynamic CT. Results: Intratumoral blood vessels in the early arterial phase and tumor parenchymal stain in the late vascular phase were depicted in 12 (88%) of the 14 hepatocellular carcinoma nodules, while all nodules were demonstrated as perfusion defect in the postvascular phase on contrast-enhanced Agent Detection Imaging. The results of Agent Detection Imaging, that were compared with those of dynamic CT, were all 100% : diagnostic sensitivity (12/12), specificity (2/2), and accuracy (14/14). Conclusion: Contrast-enhanced Agent Detection Imaging is a promising method for depicting intratumoral vascularity in hepatocellular carcinoma.Stage IV hepatocellular carcinoma with portal venous tumor thrombus: complete response after combined therapy of repeated arterial chemoembolization and radiofrequency ablationRQ Zheng; M Kudo; Y Minami; K Inui; HY ChungJOURNAL OF GASTROENTEROLOGY SPRINGER-VERLAG TOKYO 38 (4) 406 - 409 0944-1174 2003/04 [Refereed]Assessment of image quality of contrast-enhanced power doppler imaging in hepatocellular carcinoma with the personal ultrasound imager: Comparison with the conventional machine.Wen YL; Kudo M; Minami Y; Chung H; Suetomi Y; Onda H; Kitano M; Kawasaki T; Maekawa KJournal of medical ultrasonics (2001) 30 (1) 31 - 38 1346-4523 2003/03 [Refereed]Prognostic staging system for hepatocellular carcinoma (CLIP score): its value and limitations, and a proposal for a new staging system, the Japan Integrated Staging Score (JIS score)M Kudo; HB Chung; Y OsakiJOURNAL OF GASTROENTEROLOGY SPRINGER-VERLAG TOKYO 38 (3) 207 - 215 0944-1174 2003/03 [Refereed] A clinical staging system for cancer patients provides guidance for patient assessment and making therapeutic decisions. It is useful in deciding whether to treat a patient aggressively, and in avoiding the overtreatment of patients who would not tolerate the treatment or patients whose life expectancy rules out any chance of treatment. Clinical staging is also an essential tool for comparison between groups in therapeutic trials and for comparison between different studies. The current classifications most commonly used for hepatocellular carcinoma (HCC) are the Okuda stages, the Child-Pugh staging system, tumor node metastasis (TNM) staging, and the Cancer of the Liver Italian Program (CLIP) score. Among these, the CLIP score is currently the most commonly used integrated staging score, including both tumor stage and liver disease stage. Although the CLIP score has been well validated by many authors in terms of its prognostic value in HCC patients, this score has some problems and limitations when applied to currently diagnosed HCC patients, who are diagnosed in the early stage of disease. First, the CLIP score can discriminate score 0- to 3-patient populations, but it is not able to discriminate score 4- to 6-patient groups. Second, the definition of tumor morphology in the best prognostic group is too advanced, i.e., uninodular and a tumor extent of less than 50% of the liver. As a result, the prognosis of the CLIP system best prognostic group is not so good. In other words, this system cannot identify the best prognostic group who would benefit from curative and aggressive treatment. Third, nearly 80% of the patient population is classified as having a CLIP score of 0-2, as confirmed by many studies, which shows poor stratification ability. In contrast, a new staging system based on the Liver Cancer Study Group of Japan (LCSGJ), the Japan Integrated Staging (JIS) score is currently proposed in Japan. This staging system combines Child-Pugh grade (grade A, score 0; grade B, score 1; grade C, score 2) and TNM staging by the LCSGJ criteria (stage 1, score 0; stage 11, score 1; stage 111, score 2; stage IV, score 3). The stratification ability of the JIS scoring system is much better than that of the CLIP scoring system. The JIS scoring system also performed better than the CLIP scoring system in selecting the best prognostic patient group. The cumulative 10-year survival rates of the best prognostic groups in the CLIP staging system (CLIP score 0) and JIS staging system (JIS score 0) were 23% and 65%, respectively (P < 0.01). All scoring systems arise as a compromise between simplicity and discriminatory ability. We confirmed that the JIS score increases predictive efficacy, while remaining simple compared with the CLIP score. Because the JIS score is quite easily obtained and is objective, we strongly propose it for widespread use as a prognostic staging system for HCC in clinical practice.Hepatocellular carcinoma mimicking cavernous hemangioma on angiography and contrast enhanced harmonic ultrasonography. A case reportT Kawasaki; M Kudo; K Inui; C Ogawa; H Chung; Y MinamiHEPATOLOGY RESEARCH ELSEVIER SCI IRELAND LTD 25 (2) 202 - 212 1386-6346 2003/02 [Refereed] A 73-year-old man with chronic hepatitis due to hepatitis C virus was referred to our hospital for close examination of hepatic nodule. An abdominal ultrasonography revealed a mosaic pattern nodule with 3.7 cm in diameter. Arterial phase of dynamic CT revealed the small caudal part and marginal area of cranial part of the tumor were enhanced. The enhancement of marginal area of cranial part of the tumor continued up to portal phase and equilibrium phase and enhanced area was gradually filling in to the central area. On the other hand, the caudal part of the tumor was less enhanced compared with surrounding normal hepatic area in portal phase and equilibrium phase. An abdominal angiography revealed spotty tumor staining mimicking cotton-wool appearance, which is a typical finding for cavernous hemangioma. Contrast enhanced harmonic ultrasonography also showed hemangioma like finding (peripheral globular enhancing pattern). Because of these discrepancies on imagings, it was difficult to make final diagnosis of this tumor to be hepatocellular carcinoma since cavernous hemangioma cannot be completely ruled out. The pathological study of the specimen taken by US-guided percutaneous needle biopsy finally confirmed this nodule as hepatocellular carcinoma. In conclusion, we must keep in mind that some hepatocellular carcinomas could mimic hemangioma due to peliotic change or large acinar formation, therefore, needle liver biopsy may be essential for correct diagnosis if there is a discrepancy in several imaging findings. (C) 2002 Elsevier Science B.V. All rights reserved.造影超音波法が診断に有用であった門脈肝静脈短絡症に伴うFNHの1例坂口 康浩; 豊澤 昌子; 中尾 隆美; 石川 恵美; 坂本 洋城; 鄭 永琴; 小川 力; 井上 達夫; 福田 信宏; 末冨 洋一郎; 南 康範; 鄭 浩柄; 中岡 良介; 松井 繁長; 北野 雅彦; 川崎 俊彦; 汐見 幹夫; 工藤 正俊; 前川 清超音波医学 (公社)日本超音波医学会 30 (1) J58 - J58 1346-1176 2003/01Scintigraphic study of regenerative nodules due to fulminant hepatic failureT Watanabe; M Kondo; M Hirasa; H Shirane; Y Okabe; Y Ibuki; S Tomita; A Orino; A Todo; Y Wakatsuki; T Chiba; M KudoJOURNAL OF GASTROENTEROLOGY SPRINGER-VERLAG TOKYO 38 (7) 695 - 699 0944-1174 2003 [Refereed] We report the case of a 25-year-old woman with fulminant hepatic failure (FHF). Liver scintigraphy using Tc-99m-galactosyl human serum albumin (GSA) and Tc-99m-phytate produced interesting findings; regenerative nodules appeared as nodules of increased accumulation of Tc-99m-GSA, whereas these nodules were expressed as defects of accumulation of Tc-99m-phytate. These scintigraphic findings suggested that the functions of hepatocytes in regenerative nodules were maintained, whereas those of Kupffer cells were impaired. Although Tc-99m-GSA scintigraphy indicated hepatic functional reserve enough to survive, she died despite intensive therapy including plasma exchange. Based on this case. it is recommended that not only Tc-99m-GSA scintigraphy but also 99mTc-phytate scintigraphy is required to evaluate the prognosis of patients with FHF.Risk of HCV transmission after needlestick injury, and the efficacy of short-duration interferon administration to prevent HCV transmission to medical personnelH Chung; M Kudo; T Kumada; S Katsushima; A Okano; T Nakamura; Y Osaki; K Kohigashi; Y Yamashita; H Komori; S NishiumaJOURNAL OF GASTROENTEROLOGY SPRINGER-VERLAG TOKYO 38 (9) 877 - 879 0944-1174 2003 [Refereed] Background We carried out this study to assess the risk of hepatitis C virus (HCV) transmission after needlestick injuries in medical personnel, and to evaluate the efficacy of short-duration interferon administration to prevent HCV transmission. Methods. A total of 684 personnel who had been occupationally exposed to an anti-HCV-positive source and followed for more than 3 months were retrospectively examined. Results. Of the 684 subjects, 279 (41%) were treated with 1 to 3 days of interferon either just after or 1 to 12 days after the injury. One case of HCV infection was found in each of the treated (1/279; 0.4%) and nontreated (1/405; 0.2%) groups. There was no significant difference in the transmission of HCV between the two groups. Both infected patients were treated with interferon after developing acute hepatitis, and HCV was subsequently cleared. Conclusions. There is a lower risk of HCV transmission after needlestick accident than previously reported, and short-duration interferon administration at an early stage after the needlestick injury, to prevent HCV transmission, is unnecessary.Contrast advanced dynamic flow imaging and contrast pulse subtraction imaging: Preliminary results in hepatic tumors.Wen YL; Kudo M; Maekawa K; Minami Y; Chung H; Suetomi Y; Onda H; Kitano M; Kawasaki TJournal of medical ultrasonics (2001) 29 (4) 195 - 204 1346-4523 2002/12 [Refereed]Somatic mutation and SNP in the promoter of dbpA and human hepatocarcinogenesisJ Hayashi; K Kajino; T Umeda; S Takano; Y Arakawa; M Kudo; O HinoINTERNATIONAL JOURNAL OF ONCOLOGY PROFESSOR D A SPANDIDOS 21 (4) 847 - 850 1019-6439 2002/10 [Refereed] Human DNA-binding protein (dbpA) is a member of a Y-box binding protein family containing a cold shock domain. The increased expression of Y box binding proteins in somatic cells is associated with cell proliferation and transformation. Recently, we isolated a splicing variant of dbpA as a candidate for the cellular recombinogenic protein that leads to genomic instability and inflammation-mediated hepatocarcinogenesis. The expression of dbpA is enhanced in proliferating cells, but the manner in which it regulates transcription is largely unknown. In this study, we analyzed the transcriptional regulatory region of dbpA, and searched for the mutation in this region by a direct sequence method. In 3 of 55 human hepatocellular carcinoma (HCC) cases, we identified one nucleotide replacement (T-->G transversion) in nucleotide position -6 of the promoter region. Among 3 cases showing this transversion, one HCC case was due to a somatic mutation and the other two were due to single nucleotide polymorphism (SNP). By luciferase assay, we showed that the transcriptional activity of the promoter region with the transversion was significantly higher than that of the wildtype. Using the Southwestern blotting, we also confirmed the existence of a cellular proteins (about 25 and 50 kDa) that specifically bind to the sequence with this transversion. Our results suggested the biological significance of the transversion of dbpA's promoter region as one of the factors accelerating hepatocarcinogenesis.Eosionophilic pseudotumor of the liver due to Ascaris suum infectionKim, SR; Y Maekawa; T Matsuoka; S Imoto; K Ando; K Mita; HB Kim; T Nakajima; KS Ku; T Koterazawa; K Fukuda; Y Yano; M Nakaji; M Kudo; KI Kim; M Hirai; Y HayashiHEPATOLOGY RESEARCH ELSEVIER SCI IRELAND LTD 23 (4) 306 - 314 1386-6346 2002/08 [Refereed] A case of eosinophilic pseudotumor of the liver due to Ascaris (A) suum is described in a 34-year-old-man with a high serum level of immunoglobulin E and hypereosinophilia ascribed to a history of atopic dermatitis since childhood. Multiple hepatic hypoechoic nodules detected by ultrasound were confirmed as low-density nodules on computed tomography (CT), and as low and high signal intensity lesions on T1- and T2-weighted magnetic resonance imaging (MRI), respectively. CT during arteriography (CTA) and arterial portography revealed multiple nodules with ring-shaped enhancement and perfusion defect, respectively. Biopsied liver tissue specimens did not contain tumor cells or atypical cells; instead, they showed marked infiltration of eosinophils with necrosis and Charcot-Leyden crystals in the portal tracts and hepatic sinusoides, suggesting parasitic infection, although neither larvae nor eggs were detected. The diagnosis of visceral larva migrans (VLM) due to A. suum was based on immunoserological tests. The patient was a habitual consumer of raw bovine liver, which may explain the A. suum infection. After drug therapy with albendazole, the hypoechoic nodules disappeared. Differential diagnoses and the possible transfection route of A. suum are discussed. (C) 2002 Elsevier Science B.V. All rights reserved.Development of multicentric hepatocellular carcinoma after completion of interferon therapyKim, SR; T Matsuoka; Y Maekawa; Y Yano; S Imoto; M Kudo; S Shintani; K Ando; K Mita; K Fukuda; T Koterazawa; M Nakaji; H Ikawa; T Ninomiya; KI Kim; M Hirai; Y HayashiJOURNAL OF GASTROENTEROLOGY SPRINGER TOKYO 37 (8) 663 - 668 0944-1174 2002/08 [Refereed] We report a case of multicentric hepatocellular carcinoma that developed in a 74-year-old man 3 and 6 years after interferon (IFN) treatment for chronic hepatitis C, despite sustained virologic, biochemical, and histological improvement. Initially, serum hepatitis C virus RNA was positive and the patients' serum level of alanine aminotransferase (ALT; 82IU/ml) was abnormal. Hepatitis B virus (HBV) in the serum was negative for surface antigen, surface antibody, core antibody, and DNA. The patient was started on 10 x 10(6) international units (IU) of IFNalpha, 3 days a week for a total of 24 weeks. After the IFN therapy, the patient demonstrated a normal serum ALT level, and was continuously negative for HCV-RNA, and histology improved from chronic active hepatitis to chronic persistent hepatitis. Follow-up studies with ultrasonography (US) every 3 months and computed tomography (CT) every 6 months revealed no space-occupying lesion (SOL) for 3 years after IFN treatment. US-guided biopsies of two 15-mm hypoechoic SOLs in segments eight (S8) and seven (S7) 34 and 74 months, respectively, after IFN treatment showed well-differentiated hepatocellular carcinoma (HCC). Clinical data, imaging studies, and histologic examinations showed that both tumors were multicentric HCC. Further studies may provide insights into the possible role of HCV in hepatocarcinogenesis in patients demonstrating HCV eradication by IFN treatment.Intrahepatic huge hematoma due to rupture of small hepatocellular adenoma: A case reportY Minami; M Kudo; T Kawasaki; HB Chung; S Matsui; M Kitano; Y Suetomi; H Ondo; S Funai; K Kou; M YasutomiHEPATOLOGY RESEARCH ELSEVIER SCI IRELAND LTD 23 (2) 145 - 151 1386-6346 2002/06 [Refereed] Hepatocellular. adenoma sometimes causes intraperitoneal hemorrhage. It is, however, rare for small hepatocellular adenoma to cause intrahepatic huge hemorrhage without intraperitoneal bleeding. Here we describe such a rare case of hepatocellular adenoma with huge intrahepatic hemorrhage in a 25-year-old female, who had taken oral contraceptives for the last 2 weeks. She was admitted to our hospital with a sudden onset of right-upper-quadrant abdominal pain and temporally fell in shock state. Plain CT depicted low density area measuring more than 13 cm in diameter in the right lobe of the liver. Huge tumor was also suggested by abdominal ultrasound, contrast enhanced CT, magnetic resonance imaging (MRI) and angiography. The patient was diagnosed as intrahepatic rupture of hepatic tumor. Because of the risk of re-hemorrhage and malignancy, she underwent right hepatic lobectomy. Histopathologial examination of the resected specimen showed a typical small hepatocellular adenoma with the surrounding huge hematoma in the liver. The case presented here is very rare but seems to be suggestive to the natural course and management of hepatocellular adenoma. (C) 2002 Elsevier Science B.V. All rights reserved.CEA producing primary hepatic carcinoidKim, SR; S Imoto; Y Maekawa; T Matsuoka; Y Hayashi; K Ando; K Mita; S Shintani; HB Kim; K Ku; T Koterazawa; K Fukuda; Y Yano; M Nakaji; H Ikawa; T Ninomiya; M Kudo; KH Kim; M HiraiHEPATOLOGY RESEARCH ELSEVIER SCI IRELAND LTD 22 (4) 313 - 321 1386-6346 2002/04 [Refereed] Imaging studies of a hepatic tumor in a 53-year-old woman with elevated serum levels of neuron-specific enolase (NSE), carcinoembryonic antigen (CEA) and 5-hydroxyindole acetic acid (5HIAA) revealed a hypervascular tumor in the right lobe. Grossly, the brownish tumor was measured 13.5 x 12 cm with four daughter nodules. Microscopically, the majority of these columnar and round tumor cells had ribbon-or rosette-like patterns with the expression of neuroendocrine marker proteins, such as Grimelius, NSE, chromogranin A, and synaptophysin, and moderate expression of CEA but without the expression of cytokeratin nos 7,8,14,18,19 and OV-6; the minority had glandular patterns with a strong expression of CEA but without the expression of cytokeratin nos 7,8,14,18,19 and OV-6. Ultrastructurally, most tumor cells contained populations of electron-dense core granules ranging between 100 and 200 nm in diameter. After hepatectomy, serum CEA, NSE, and 5HIAA reverted to normal ranges and persisted for 19 months. These findings suggested that the diagnosis of primary hepatic carcinoid was tenable and that the tumor might derive from hepatic stem cells which acquired the additional nature of producing CEA without cytokeratins characteristic of hepatocytes or bile duct cells. Some molecular based approaches have attributed unique biological behavior and histogenesis to this carcinoid tumor. (C) 2002 Elsevier Science B.V. All rights reserved.Proximal bifurcation of hepatic artery: Novel findings on hepatic arteries demonstrated by ultrasound Doppler imaging, B-flow, and US angiography.Tochio H; Iwasaki N; Nakamura H; Nakayama K; Soga T; Nishiuma S; Fukunaga T; Okabe Y; Kashida H; Hirasa M; Ibuki Y; Fujimoto T; Morimoto Y; Kudo M; Tomita S; Konishi Y; Orino AJournal of medical ultrasonics (2001) 29 (1) 11 - 17 1346-4523 2002/03 [Refereed]Imaging blood flow characteristics of hepatocellular carcinomaM KudoONCOLOGY KARGER 62 48 - 56 0030-2414 2002 [Refereed] Since a close relationship exists between intranodular hemodynamics and the grade of biological/pathological malignancy of a nodule occurring in the cirrhotic liver, an accurate evaluation of intranodular hemodynamics is highly essential. Intranodular hemodynamics in hepatocellular carcinoma (HCC) and borderline lesions can be evaluated correctly by invasive and noninvasive techniques. Invasive techniques such as ultrasound (US) angiography, computed tomographies during arteriography or arterial portography are sensitive in the detection of intranodular arterial and portal supplies, for accurate diagnosis of tumors and assessing grades of biologically malignant potential. However, these approaches require an angiographic procedure, which is not always available. Recently, perfusion imaging techniques under US, including contrast-enhanced harmonic imaging or real-time gray-scale harmonic imaging, have become available for routine clinical use. With these techniques, all the five roles of imaging in the management of HCC, i.e., detection, confirmation, staging, evaluation of malignancy grade, and postoperative follow-up, have become much simpler. Perfusion imaging techniques have reduced the requirement for dynamic CT or MRI and may replace some of their roles in the clinical setting. Since viable cancer cells are accurately imaged on US monitoring with sensitive perfusion imaging techniques, the contrast-enhanced harmonic imaging will be of great advantage in US-guided treatment of HCC. With the advent of rapid and remarkable advances in US harmonic imaging techniques, the diagnostic and therapeutic strategies for HCC are changing drastically. Copyright (C) 2002 S. Karger AG, Basel.Multicenter prospective analysis of newly diagnosed hepatocellular carcinoma with respect to the percentage of Lens culinaris agglutinin-reactive alpha-fetoproteinH Oka; A Saito; K Ito; T Kumada; S Satomura; H Kasugai; Y Osaki; T Seki; M Kudo; M TanakaJOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY BLACKWELL PUBLISHING ASIA 16 (12) 1378 - 1383 0815-9319 2001/12 [Refereed] Background and Aim: The Lens culinaris agglutinin-reactive fraction of alpha-fetoprotein (AFP-L3) has been reported to be a highly useful marker for hepatocellular carcinoma (HCC) compared with a conventional serum AFP concentration, which allows earlier detection of HCC compared with using other imaging modalities and predicting prognosis after therapy. A collaborative prospective study involving nine Japanese hospitals was conducted to analyze the relationships between the tumor characteristics of a HCC patient and the percentage of AFP-L3/AFP total at the initial detection. Methods: Between 1 October 1996 and 30 September 1997, a total of 388 patients with newly diagnosed HCC were registered. Results: The cut-off level of the percentage of AFP-L3 was altered from 15 to 10%. The AFP-L3-positive HCC patients demonstrated the characteristics of having an advanced tumor, such as the number of tumors, maximum diameter, tumor spread, portal vein invasion, tumor stage, and tumor classification. With the conventional cut-off level of 15% of the percentage of AFP-L3, the malignant characteristics were more definite than that of 10%. However, no significant differences of serum AFP concentration were observed for malignant characteristics such as maximum diameter and histopathological grading. Conclusion: Serum AFP concentration does not reveal a malignancy of HCC, however, the AFP-L3-positive HCC has biologically malignant characteristics, especially portal vein invasion and lower tumor classification, and is an advanced tumor regardless of small tumor size and lower serum AFP concentration. As AFP-L3 shows the tumor characteristics, its presence should be an important factor in the determination of therapy and prognosis of patients. (C) 2001 Blackwell Science Asia Pty Ltd.Intrahepatic spontaneous retrograde portal flow in patients with cirrhosis of the liver: Reversal by food intakeH Tochio; M Kudo; S Nishiuma; Y OkabeAMERICAN JOURNAL OF ROENTGENOLOGY AMER ROENTGEN RAY SOC 177 (5) 1109 - 1112 0361-803X 2001/11 [Refereed] OBJECTIVE. The purpose of our study was to assess whether intrahepatic spontaneous retrograde portal flow in patients with cirrhosis of the liver can be reversed to a normal portal venous flow by food intake. CONCLUSION. Of the 18 cirrhotic patients with intrahepatic spontaneous retrograde portal flow, 16 (89%) showed a marked change in portal flow direction after food intake. This evidence strongly suggests that intrahepatic spontaneous retrograde portal flow may be reversible. Furthermore, this finding implies that regular food intake may be important in the maintenance of effective hepatic blood flow in cirrhotic patients.Sonographic diagnosis of pancreatic islet cell tumor: Value of intermittent harmonic imagingH Ding; M Kudo; H Onda; H Nomura; S HajiJOURNAL OF CLINICAL ULTRASOUND JOHN WILEY & SONS INC 29 (7) 411 - 416 0091-2751 2001/09 [Refereed] We describe a case of nonfunctioning islet cell tumor of the pancreas diagnosed preoperatively by intermittent harmonic power Doppler imaging and digital subtraction gray-scale harmonic imaging and the use of the contrast agent SH U 508A (Levovist). Hypervascularity and tumor perfusion were clearly demonstrated with both harmonic imaging techniques in the early arterial phase. Sonographic findings were confirmed by other modalities and by histopathologic examination. (C) 2001 John Wiley & Sons, Inc.Hepatobiliary and pancreatic: Intrahepatic portal vein anomaly - Hepatobiliary and pancreatic: CommentaryYL Wen; M Kudo; T KawasakiJOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY BLACKWELL PUBLISHING ASIA 16 (7) 821 - + 0815-9319 2001/07 [Refereed]A case of disseminated extrahepatic hepatocellular carcinoma after US-guided biopsy and percutaneous ethanol injection therapyKim, SR; T Matsuoka; Y Maekawa; Y Yano; Y Hayashi; M Kudo; K Kim; S Imoto; KB Song; K Ando; S Shintani; T Koterazawa; K Fukuda; K Mita; M TaniguchiHEPATOLOGY RESEARCH ELSEVIER SCI IRELAND LTD 20 (2) 244 - 254 1386-6346 2001/06 [Refereed] A case of disseminated extrahepatic hepatocellular carcinoma (HCC) occurring after ultrasound (US)-guided biopsy and percutaneous ethanol injection therapy is presented. A 72-year-old man with hepatitis-C-virus-related cirrhosis underwent percutanous ethanol injection therapy (PEIT) two times with complete remission: the first for moderately-differentiated HCC in segment six (S6), and the second for well-differentiated HCC in another part of S6. Imaging studies including carbon dioxide (CO2)-US angiography, incremental computed tomography, and dynamic magnet resonance imaging showed that both HCCs were hypovascular. Twenty-one months after the first PEIT and 7 months after the second, a 5.5 x 4.5 cm extrahepatic mass interfaced with S6 of the liver was detected by imaging studies. The patient underwent surgery for extrahepatic HCC. Grossly, the main tumor was 5.5 x 4.5 cm with capsule and septum; the disseminated tumors were detected on the surface of the liver, including the right diaphragm and the fair ligamentosa. Histologically, it was moderately- to poorly-differentiated HCC, which, although not attributed to direct track seeding, was suspected of being induced by the percutaneous US-guided biopsy procedure or by PEIT, irrespective of a hypovascular tumor. Further studies may provide insight into the risk factor engendered by these procedures. (C) 2001 Elsevier Science Ireland Ltd. All rights reserved.Two cases of histopathologically advanced (stage IV) early gastric cancersM Shiomi; T Kamisako; Yutani, I; M Kudo; H Shigeoka; A Tanaka; K Okuno; M YasutomiTUMORI PENSIERO SCIENTIFICO EDITOR 87 (3) 191 - 195 0300-8916 2001/05 [Refereed] We report two cases of early gastric cancer with distant metastases (stage IV). At our institute 1428 cases of primary gastric cancer were resected between 1980 and 1997; 536 were diagnosed as early gastric cancer based on the resected specimens (304 cases of mucosal cancer, Tis - TNM classification - and 232 of submucosal cancer, T1), 528 of these 536 cases were classified as histological stage I, six as stage II, none as stage III and two as stage IV. The incidence of stage IV early gastric cancer was 0.14% of all gastric cancers and 0.37% of the early gastric cancers,The two patients with stage IV early gastric cancer were women. Both tumors were defined as early cancer because they were confined to the submucosa, One was a type 0 IIc + III early cancer, histologically classifiable as a small, moderately differentiated adenocarcinoma (tub2 according to the Japanese Classification of Gastric Carcinoma(1,2), G2; TNM classification: ICD-O C16), size 10 x 8 mm; the other was a surface spreading type 0 lie, classifiable as a signet-ring cell carcinoma (sig, G3), size 50 x 35 mm. Stage IV factors were N3 in the first and ovarian metastasis (Krukenberg tumor) in the second case.Hypervascular hepatocellular carcinoma: Detection with double arterial phase multi-detector row helical CTT Murakami; T Kim; M Takamura; M Hori; S Takahashi; MP Federle; K Tsuda; K Osuga; S Kawata; H Nakamura; M KudoRADIOLOGY RADIOLOGICAL SOC NORTH AMER 218 (3) 763 - 767 0033-8419 2001/03 PURPOSE: To assess whether double arterial phase imaging with multi-detector row helical computed tomography improves detection of hypervascular hepatocellular carcinoma (HCC). MATERIALS AND METHODS: Fifty-one patients with 96 hypervascular HCCs underwent double arterial phase imaging of the entire liver. At measured delay after intravenous administration of 2 mL/kg of contrast medium at a rate of 5 mL/sec, the early and late arterial phase images were obtained serially during a single breath hold with interscan delay of 5.0 seconds. Detector row configuration of 2.5 x 4 mm, pitch of 6, and scanning time of 10.5 seconds for each phase were used. Forty 5-mm-thick reconstruction images were obtained for each phase. Each image set was interpreted separately by three observers, who were unaware of tumor burden in the liver, to detect hypervascular HCC. Sensitivity, positive predictive value, and area below the receiver operating characteristic curve (A(z)) for early and late arterial phases separately and together were calculated. RESULTS: Mean sensitivity and positive predictive value for hypervascular HCC were 54% and 85% for the early arterial phase, 78% and 83% for the late arterial phase, and 86% and 92% for the double arterial phase, respectively. Double arterial phase imaging showed significantly superior sensitivity compared with early or late arterial phase imaging alone for detecting HCC (P < .05). The mean A(z) value for double arterial phase was significantly higher than that for early or late arterial phase imaging alone (P < .05). Double arterial phase imaging showed the lowest number of false-positive lesions. CONCLUSION: Double arterial phase imaging is recommended to improve detection of hypervascular HCCs and reduce false-positive lesions.Vascularity of advanced gastric carcinoma: Evaluation by using power Doppler imagingT Kawasaki; T Ueo; T Itani; M Shibatohge; J Mimura; H Komori; A Todo; M KudoJOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY BLACKWELL SCIENCE ASIA 16 (2) 149 - 153 0815-9319 2001/02 [Refereed] Background: We investigated the vascularity of advanced gastric adenocarcinomas by using percutaneous power Doppler imaging. Methods: Seventeen patients with gastric cancer and 10 without a gastric tumor, but with a slightly thick gastric wall in the B-mode ultrasound, were investigated with the use of power Doppler imaging. The color signals of the gastric lesion were graded as follows: 1, no color signals or the same as the surroundings; 2, color signals were slightly increasing; and 3, color signals were obviously increasing. Results: The color signals of three patients were graded 1, those of eight patients were graded 2 and those of six patients were graded 3 in the gastric cancer group. The color signals of all 10 patients without a gastric tumor were grade 1. This difference was statistically significant (P = 0.0002). Conclusions: Power Doppler imaging showed vascularity of gastric cancer increasing in the majority of patients (14 of 17: 82%). Thus, power Doppler imaging might be a good screening examination method for gastric cancer. (C) 2001 Blackwell Science Asia Pty Ltd.Gastric submucosal microdialysis: A method to monitor ECL-cell histamine mobilization from rat stomach.M Kitano; P Norlen; Y Kishimoto; J Hasegawa; H Kawasaki; M Kudo; T Itoh; R HakansonHISTAMINE RESEARCH IN THE NEW MILLENNIUM ELSEVIER SCIENCE BV 1224 299 - 304 0531-5131 2001 [Refereed]TTV positivity and transfusion history in non-B, non-C hepatocellular carcinoma compared with HBV- and HCV-positive casesKim, SR; Y Hayashi; M Kudo; S Imoto; KB Song; K Ando; S Shintani; T Koterazawa; KI Kim; M TaniguchiINTERVIROLOGY KARGER 43 (1) 13 - 15 0300-5526 2000/01 [Refereed] The prevalence of TT virus (TTV) and its rate of transmission through transfusion were investigated to determine its possible hepatocarcinogenic role in non-B, non-C hepatocellular carcinoma (HCC) as compared with that in hepatitis B virus (HBV)- and hepatitis C virus (HCV)-positive HCC. Its transfection route in TTV-positive cases was also studied. Serum was positive for TTV in 77.8% (7/9) of HBV-positive, 36.4% (12/33) of HCV-positive, and 63.6% (7/11) of non-B, non-C cases of HCC. The rate of transmission through transfusion was 52.4% (11/21) in HBV-positive, 40.1% (61/152) in HCV-positive, 33.3% (2/6) in HBV+HCV-positive, and 40% (8/20) in non-B, non-C HCCs, while it was 48.3% (14/29) in TTV-positive and 39.3% (11/28) in TTV-negative cases. The association between TTV and HCC was limited, and the main route of infection of TTV was not th rough transfusion. Copyright (C) 2000 S. Karger AG, Basel.Cronkhite-Canada syndrome associated with triple gastric cancers: a case reportT Watanabe; M Kudo; H Shirane; H Kashida; S Tomita; A Orino; A Todo; T ChibaGASTROINTESTINAL ENDOSCOPY MOSBY-YEAR BOOK INC 50 (5) 688 - 691 0016-5107 1999/11 [Refereed]Inflammatory pseudotumor of the liver in a patient with chronic hepatitis C: Difficulty in differentiating it from hepatocellular carcinomaKim, SR; Y Hayashi; M Kudo; T Matsuoka; S Imoto; K Sasaki; S Shintani; KB Song; SY Park; JH Kim; K Ando; T Koterazawa; KI Kim; T NinomiyaPATHOLOGY INTERNATIONAL BLACKWELL SCIENCE ASIA 49 (8) 726 - 730 1320-5463 1999/08 [Refereed] A case of an inflammatory pseudotumor of the liver in a 75-year-old female with chronic hepatitis C whose radiologic features simulated that of hepatocellular carcinoma (HCC) is presented. On imaging studies, hypervascularity by CO2 ultrasound (US) angiography, enhancement at an early phase and isodensity at a late phase by incremental dynamic computed tomography (CT), perfusion defect by CT during arteriography (CTAP), and clinical background of hepatitis C virus (HCV) infection strongly suggested HCC. A US-guided needle biopsy revealed a mainly diffuse and polyclonal proliferation of lymphocytes positive for leukocyte common antigen (pan-lymphocyte cells), L-26 (B cell lymphocytes), and UCHL-1 (T cell lymphocytes), negative for both x and lambda light chains and sparsely distributed neutrophils and histiocytes. No lymphoid follicles were observed. The liver tissue around this tumor showed chronic hepatitis with mild activity and mild fibrosis. These histopathologic findings suggested that the diagnosis of inflammatory pseudotumor of the liver was tenable. As it is difficult to differentiate between inflammatory pseudotumor of the liver and HCC by imaging studies alone, supplemental biopsy, where possible, should be obtained when diagnostic imaging of tumors suggesting HCC is carried out. We emphasize that histopathology is a true gold standard in the diagnosis of this disease.High prevalence of anti-hepatitis B virus serological markers in patients with hepatitis C virus related chronic liver disease in JapanH Marusawa; Y Osaki; T Kimura; K Ito; Y Yamashita; T Eguchi; M Kudo; Y Yamamoto; H Kojima; H Seno; F Moriyasu; T ChibaGUT BRITISH MED JOURNAL PUBL GROUP 45 (2) 284 - 288 0017-5749 1999/08 [Refereed] Background/Aims-Evidence is accumulating that hepatitis B virus (HBV) is present in patients who are hepatitis B surface antigen negative but have antibody to hepatitis B core antigen (anti-HBc). Furthermore, recent studies have shown that patients with hepatocellular carcinoma who have antibody to hepatitis C virus (HCV) often possess HBV related serological markers. Data on the seroprevalence of HBV infection in patients with HCV related chronic liver disease were collected to evaluate the significance of the presence of antibodies to HBV. Methods-The prevalence of HBV related serological markers was analysed in a total of 2014 Japanese patients with HCV infection. The control group comprised 352 subjects without Liver disorder. Results-A large number of patients (49.9%) with HCV related chronic liver disease including hepatocellular carcinoma were positive for anti-HBc. In addition, the prevalence of anti-HBc closely correlated with the clinical stage of the liver disease. There was no relation between a past history of blood transfusion and the prevalence of anti-HBc. Notably, anti-HBc was the only serological marker for HBV infection in a significant number of patients with HCV related chronic liver disease (24.1%). Conclusions-Our data provide further evidence for the high prevalence of anti-HBc in patients with HCV related chronic liver disease, particularly those with hepatocellular carcinoma, suggesting that HBV infection, probably including latent infection, may play an important role in carcinogenesis in these patients.Massive rectal bleeding due to ileal tuberculosisT Watanabe; M Kudo; M Kayaba; H Shirane; S Tomita; A Orino; A Todo; T ChibaJOURNAL OF GASTROENTEROLOGY SPRINGER VERLAG 34 (4) 525 - 529 0944-1174 1999/08 [Refereed] A patient with massive rectal bleeding due to ileal tuberculosis is reported. Technetium-99m labelled red blood cell scintigraphy indicated hemorrhage from the ileum, and laparotomy was then carried out. A 70cm segment of ileum containing ulcers and erosions was resected, and epitheloid granuloma with Langhans-type giant cell was found in the resected specimen. Massive rectal bleeding is considered a rare presenting symptom of intestinal tuberculosis. Intestinal tuberculosis, including small intestinal tuberculosis, although uncommon, should be taken into consideration as a cause of rectal bleeding.Determination of the clonal origin of multiple human hepatocellular carcinomas by cloning and polymerase chain reaction of the integrated hepatitis B virus DNAT Yamamoto; K Kajino; M Kudo; Y Sasaki; Y Arakawa; O HinoHEPATOLOGY W B SAUNDERS CO 29 (5) 1446 - 1452 0270-9139 1999/05 [Refereed] The poor prognosis of hepatocellular carcinoma (HCC) is partly the result of the high rate of recurrence that is caused either by intrahepatic metastasis (IM) or independent multicentric occurrence (MO), For convenience, discrimination of IM and MO is based on pathological findings, but reliable parameters are not sufficiently established. In the case of hepatitis B virus (HBV)-associated HCC, molecular discrimination of IM from MO can be achieved by comparison of integrated HBV DNAs. However, Southern blotting cannot be used for this purpose when one tumor is saved in frozen form and the other is in paraffin-embedded form. To solve this problem, we employed polymerase chain reaction (PCR) assays to confirm the clonality of primary and recurrent tumors. From the frozen tissue, we determined the junction between the integrated HBV and flanking genomic DNA by molecular cloning, and checked the existence of an identical junction in the DNA of paraffin-embedded tissue by PCR, Using this method, as well as Southern blotting, we proved in 6 of 8 patients that two nodular HCC lesions resected metachronously or simultaneously were caused by MO, while the remaining 2 cases were caused by IM, In 1 IM case, band patterns between two HCCs detected by Southern blotting were not identical.Detection of Helicobacter pylori gene by means of immunomagnetic separation-based polymerase chain reaction in fecesT Watanabe; S Tomita; M Kudo; M Kurokawa; A Orino; A Todo; T ChibaSCANDINAVIAN JOURNAL OF GASTROENTEROLOGY SCANDINAVIAN UNIVERSITY PRESS 33 (11) 1140 - 1143 0036-5521 1998/11 [Refereed] Background: Detection of Helicobacter pylori is usually performed by culture, polymerase chain reaction (PCR), histology, or urease test on gastric biopsy samples. Although methods based on feces are noninvasive, their sensitivity has been relatively low. In this study, to improve its sensitivity, immunomagnetic separation (LMS) was used as a pre-PCR step for direct detection of H. pylori in feces. Methods: Fresh fecal samples were taken from 72 patients attending for endoscopy. Of these, 57 patients had a positive H. pylori status according to the results of culture, histology, and PCR on gastric biopsy samples. Anti-H. pylori antibody-sensitized immunomagnetic beads were used to concentrate the bacteria. PCR was then performed to detect the H. pylori urease A-encoding gene. Results: Of the 57 H. pylori-positive patients, 35 (61.4%) had positive fecal samples by IMS-based PCR method. None of the 15 H. pylori-negative patients had positive fecal samples. The sensitivity of this method was 61.4%, and the specificity 100.0%. Conclusions: This study confirms that non-invasive diagnosis of H. pylori infection could be made from feces by using IMS-based PCR.Hepatocellular carcinomas infected with the novel TT DNA virus lack viral integrationToshiki Yamamoto; Kazunori Kajino; Masahiro Ogawa; Iori Gotoh; Shunichi Matsuoka; Kazutomo Suzuki; Mitsuhiko Moriyama; Hitoshi Okubo; Masatoshi Kudo; Yasuyuki Arakawa; Okio HinoBiochemical and Biophysical Research Communications Academic Press Inc. 251 (1) 339 - 343 0006-291X 1998/10 [Refereed] A novel DNA virus designated TT virus (TTV) was cloned from a patient with posttransfusion hepatitis and is thought to be a new hepatitis virus. At present, hepatitis B virus (HBV) and hepatitis C virus (HCV) are known to induce hepatocellular carcinoma (HCC). But, actually, in Japan approximately 5 to 10% of HCCs are in HBV-negative and HCV-negative (NBNC) patients. In order to study the possible role of TTV in hepatocarcinogenesis, we investigated the frequency of the TTV genome in liver tissue of 20 HCC patients. As a result, 3 of 8 NBNC HCC patients and 5 of 12 HBV-or HCV-associated HCC patients were TTV positive, and TTV was shown not to be specific for NBNC HCC. For all TTV-positive patients, we also confirmed that the TTV genome was not integrated into host hepatocyte DNA.A case of well-differentiated minute hepatocellular carcinoma with extrahepatic metastasisKim, SR; Y Hayashi; T Matsuoka; SY Park; S Shintani; K Sasaki; J Asano; JH Kim; KIH Kim; S Imoto; H Itoh; M KudoJOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY BLACKWELL SCIENCE 13 (9) 892 - 896 0815-9319 1998/09 [Refereed] A rare case of well-differentiated minute hepatocellular carcinoma (HCC) metastasizing to distant sites in a 77-year-old man with hepatitis C virus (HCV)-related cirrhosis is presented. Ultrasonography (US) disclosed a 9 mm hypoechoic lesion in segment seven (S-7) Of the liver, although computed tomography (CT), magnetic resonance imaging (MRI) and angiography did not reveal any space-occupying lesion. Ultrasound-guided biopsy showed the histological features of well-differentiated HCC. A plain film of the abdomen and CT revealed osteolytic changes in the sacrum and the lumbar vertebra. Ultrasound-guided biopsy of the sacrum revealed well-to-moderately differentiated HCC metastasizing from the liver. Percutaneous ethanol injection therapy (PEIT) effected complete response and completely eliminated the abnormal findings on US. Three months after PEIT, metastasis to the thoracic vertebra was revealed by CT, despite negative alpha-fetoprotein-mRNA in serum. This is the first report describing a well-differentiated HCC with metastatic potential. Further studies may provide insights into metastasis of well-differentiated HCC.Field cancerization of human hepatocellular carcinomas in the hypercarcinogenic state.T Yamamoto; K Kajino; M Kudo; Y Sasaki; Y Arakawa; O HinoHEPATOLOGY W B SAUNDERS CO 26 (4) 2009 - 2009 0270-9139 1997/10 [Refereed]Compartmental analysis of asialoglycoprotein receptor scintigraphy for quantitative measurement of liver function: A multicentre studySang Kil Ha-Kawa; Yoshimasa Tanaka; Shin Hasebe; Yoshio Kuniyasu; Kiyoshi Koizumi; Yasushi Ishii; Kazutaka Yamamoto; Toru Kashiwagi; Akihiko Ito; Masatoshi Kudo; Katsuji Ikekubo; Takaharu Tsuda; Kenya MuraseEuropean Journal of Nuclear Medicine 24 (2) 130 - 137 0340-6997 1997 [Refereed] A multicentre study on multicompartmental analysis of hepatic scintigraphy using technetium-99m labelled galactosyl serum albumin (GSA), which binds to the asialoglycoprotein receptor, was carried out at seven institutions in Japan. Seventy-four patients with liver disease received 3 mg (185 MBq) of 99mTc-GSA by intravenous injection. Sequential scanning was performed 30 min after injection to obtain anterior images of the heart and liver, followed by single-photon emission tomography (SPET). The indices included in this analysis were hepatic blood flow (Q) and maximal receptor binding rate (R(max)), which showed a good correlation with semiquantitative ratio indices for 99mTc-GSA, namely the retention rate in blood (HH15) and the hepatic uptake rate (LHL15). Q and R(max) also showed a significant correlation with other measures of hepatic function. When patients were grouped according to the severity of chronic liver damage (hepatocellular functional damage), Q was reduced in the moderate and severe groups, while R(max) was reduced in proportion to the functional stage. Both parameters showed no inter-institution difference using analysis of co-variance with the functional stage as a co-variant. With regard to the hepatic uptake rate, anterior planar images and SPET im ages gave similar results for Q and R(max). Acquisition times of 15 or 30 min provided the same results. The multicompartmental model analysis permitted comparable results to be obtained at institutions using different gamma cameras, and is therefore considered a universally applicable method. These results indicate that Q and R(max) are useful general indices for evaluating the functional reserve capacity of the liver.カラ−ドプラ法による慢性肝疾患に見られる小結節の良悪性診断−流入する定常性血流シグナルについて−杤尾人司; 冨田周介; 工藤正俊; 岡部純弘; 岩崎信広; 蓑輪和士; 曽我登志子; 田村周二; 森本義人; 渡邉智裕; 福永豊和; 近藤雅彦; 樫田博史; 平佐昌弘; 伊吹康良; 織野彬雄; 藤堂彰男Clinical Information 9 1 - 13 1997 [Refereed]パワードプラ法の臨床応用─肝腫瘤の血流動態からみた質的診断─杤尾人司; 樫田博史; 冨田周介; 岩崎信広; 簑輪和士; 田村周二; 曽我登志子; 森本義人; 渡辺智裕; 福永豊和; 岡部純弘; 平佐昌弘; 伊吹康良; 工藤正俊; 織野彬雄; 藤堂彰男臨床成人病 27 1075 - 1082 1997 [Refereed]脂肪肝に伴う胆嚢床のSpared Areaと肝内胆嚢流出血流との関連: カラードプラ法による検討杤尾人司; 岡部純弘; 冨田周介; 工藤正俊; 樫田博史; 岩崎信広; 蓑輪和士; 田村周二; 曽我登志子; 森本義人; 渡邉智裕; 福永豊和; 平佐昌弘; 伊吹康良; 織野彬雄; 藤堂彰男JMed Ultrasonics 24 1651 - 1661 1997 [Refereed]カラ−ドプラ法にて特徴的な血流動態を観察し得た右胃静脈と考えられる還流異常に伴う肝内過形成結節の1例杤尾人司; 岡部純弘; 冨田周介; 織野彬雄; 岩崎信広; 蓑輪和士; 曽我登志子; 田村周二; 森本義人; 渡邉智裕; 福永豊和; 近藤雅彦; 樫田博史; 平佐昌弘; 伊吹康良; 工藤正俊; 藤堂彰男J Med Ultrasonics 787 - 794 1997 [Refereed]Reversal of portal systemic encephalopathy by shunt preserving disconnection of portal and systemic circulationH. Kashida; M. Kondo; T. Fukunaga; Y. Terai; K. Yamamoto; T. Itani; M. Hirasa; Y. Ibuki; M. Kudo; S. Tomita; A. Orino; A. TodoJapanese Journal of Gastroenterology 93 (2) 96 - 103 0446-6586 1996 [Refereed] Obliteration of portal systemic shunts surgically or by interventional radiological techniques is fairly effective in reversing intractable portal- systemic encephalopathy (PSE), but is often associated with ascites accumulation and/or formation of esophageal varices. This study reports four patients with incapacitating PSE who were treated by interventional radiological techniques via percutaneous transhepatic route. One case had the shunt embolized directly. In the other three the blockage was placed on the proximal part of the splenic vein, whereby disconnecting the mesenteric- portal blood flow from the systemic circulation while preserving the shunt. The patient of shunt closure showed transient correction of encephalopathy, but developed massive ascites and esophageal varices, encephalopathy recurred, resulting in death from hepatic failure two months after the procedure. In the cases of shunt preserving disconnection of portal and systemic circulation (SPDPS) immediate and permanent clearing of encephalopathy was achieved without manifestation of ascites or esophageal varices during the follow-up period of 10 to 31 months. The difference of portal pressure between before and after the procedure was 18mmHg in the shunt closed patient and 3 mmHg in SPDPS group. We conclude from this limited experience that SPDPS can be an effective and safe method in treating PSE in adequately selected patients.十二指腸潰瘍患者におけるHelicobacter pylori除菌療法について冨田周介; 渡邉智裕; 近藤雅彦; 福永豊和; 岡部純弘; 樫田博史; 平佐昌弘; 伊吹康良; 工藤正俊; 織野彬雄; 藤堂彰男; 三木寛二; 大西伸策; 黒川 学神戸市立病院紀要 35 19 - 23 1995 [Refereed]Clinical tracing of small hypovascular hepatic nodules associated with chronic liver diseaseHitoshi Tochio; Syusuke Tomita; Masatoshi Kudo; Yoshihiro Okabe; Hiroshi Kashida; Michio Hamada; Kenji Yamamoto; Yuji Terai; Tomonao Itani; Jun Mimura; Masahiro Hirasa; Yasuyoshi Ibuki; Hideshi Komori; Akio Orino; Akio TodoKanzo 35 (5) 333 - 346 1881-3593 1994 [Refereed] The outcome of 45 small hepatic nodules diagnosed as hypovascular by US angiography were studied with clinical and ultrasonic follow-up carried out more than 1 years. Out of 45 nodules, 23 nodules were performed biopsy under US guidance at first detection, and hypercellularities and/or increasing in N/C ratio were observed in all 23 nodules. Enlargement of the nodule size was observed in 7 (16%) of 45 nodules, while the size has not changed in 20 (44%) nodules. Eighteen nodules (40%) become undetectable with US. Six nodules out of 7 enlarged cases developed into advanced HCCs. Four out of these malignant change group showed “vascular spot” on US angiography and/or perfusion defects on CTAP at the first detect. The remaining two cases also acquired such vascular findings at the later stage when they have enlarged. In this study, the twos of development and extension of HCCs were proved: (1) advanced HCC appear as a hypervascular spot in a benign hypovascular nodule, (2) portal perfusion in the tumor as a whole decreases and arterial vascularity increases in stead in the process of cancer development. It is concluded that, if the nodules which show “vascular spot” on US angiography and/or perfusion defect on CTAP exclude from the subject, only 5% (2/40) of the hypovascular nodules develop into advanced HCC. © 1994, The Japan Society of Hepatology. All rights reserved.Small nodular lesions of the pancreas : Differential diagnosis with ultrasound angiographyHiroshi Kashida; Toshinao Itani; Jun Mimura; Yoshihiro Okabe; Masahiro Hirasa; Yasuyoshi Ibuki; Masatoshi Kudo; Shusuke Tomita; Hideshi Komori; Akio Orino; Akio TodoNippon Shokakibyo Gakkai Zasshi 91 (3) 293 - 302 0446-6586 1994 [Refereed] Ultrasound angiography (USAG), sonographic imaging of the blood flow in an organ or tissue obtained by carbon dioxide infusion into the supplying artery, was performed on 28 pancreatic nodular lesions less than 3 cm in diameter. The hemodynamics of tumors observed with USAG were divided into three groups : hypovascular, isovascular, and hypervascular, compared with the adjacent pancreatic tissue. Most of hypovascular nodules were duct cell carcinoma (sensitivity 94.1%, specificity 90.4%), while isovascular lesion was the characteristic of inflammatory masses (sensitivity 100%, specificity 95.8%). Hypervascular cases included all of the mucin producing tumors and islet cell tumors but only one case of duct cell carcinoma. So you can almost exclude duct cell carcinoma as an diagnosis in vascular rich tumors (negative predictive value 83.3%). These results were compared with those on conventional x-ray angiograms and incremental CT scans. Ultrasound angiography enabled us to detect more slight differences of tumor vascularity than the other modalities. Thus we conclude that USAG can be a useful diagnostic aid in small mass lesions of the pancreas. © 1994, The Japanese Society of Gastroenterology. All rights reserved.Measurement of functioning hepatocyte mass via [99mTc]galactosyl-neoglycoalbuminMasatoshi Kudo; David R. Vera; Robert C. Stadalnik; Carlos O. Esquivel; Walter L. Trudeau; Katsuji Ikekubo; Akio TodoDigestive Diseases and Sciences Kluwer Academic Publishers-Plenum Publishers 38 (12) 2183 - 2188 0163-2116 1993/12 [Refereed] Technetium-99m-galactosyl-neoglycoalbumin (TcNGA) is a synthetic radiolabeled ligand specific for hepatic binding protein (HBP), a receptor that resides exclusively on hepatocytes. In vivo measurement of receptor concentration was obtained via kinetic analysis of liver and blood time-activity data obtained during the hepatic clearance of intravenously administered TcNGA. The purpose of this study was to assess receptor concentration as a measure of the functioning hepatocyte mass. Therefore, TcNGA and dualinjection indocyanine green maximal removal rate (ICG Rmax) studies were performed on nine patients with hepatic cirrhosis associated or not with hepatocellular carcinoma. Receptor concentration was compared with ICG Rmax, which is a validated method for the estimation of the functioning hepatocyte mass. The correlation coefficient was 0.76 (P=0.017). It is concluded that HBP concentration ([HPB]o) as measured by functional imaging is a measure of functioning hepatocyte mass. This implies that measurement of an individual's receptor concentration by using nuclear medicine techniques provides an objective index of hepatic functional mass and supports attempts to rigorously evaluate [HBP]o for its clinical efficacy. © 1993 Plenum Publishing Corporation.INTRAHEPATIC PORTOSYSTEMIC VENOUS SHUNT - DIAGNOSIS BY COLOR DOPPLER IMAGINGM KUDO; S TOMITA; H TOCHIO; K MINOWA; A TODOAMERICAN JOURNAL OF GASTROENTEROLOGY WILLIAMS & WILKINS 88 (5) 723 - 729 0002-9270 1993/05 [Refereed] Intrahepatic portosystemic venous shunt is a rare clinical entity; only 33 such cases have been reported. It may be congenital, or secondary to portal hypertension. Five patients with this disorder are presented, each of whom was diagnosed by color Doppler imaging, including waveform spectral analysis. One patient with clinical evidence of cirrhosis and portal hypertension had episodes of hepatic encephalopathy and elevated blood levels of ammonia. This patient had a large tubular shunt between the posterior branch of the portal vein and the inferior vena cava. Shunts of this type are considered to be collateral pathways which develop in the hepatic parenchyma as a result Of portal hypertension. The other four patients had no evidence of liver disease, and all four evidenced an aneurysmal portohepatic venous shunt within the liver parenchyma. Shunts of this type are considered congenital. The diagnosis of intrahepatic portosystemic venous shunts was established by color Doppler imaging, which demonstrated a direct communication of color flow signals between the portal vein and hepatic vein, in addition to the characterization of the Doppler spectrum at each sampling point from a continuous waveform signal (portal vein) to a turbulent signal (aneurysmal cavity), and finally, to a biphasic waveform signal (hepatic vein). As demonstrated by the rive patients, color Doppler imaging is useful in the diagnosis of an intrahepatic portosystemic hepatic venous shunt, and the measurement of shunt ratio may be useful in the follow-up and determining the therapeutic option.Diagnosis of intrahepatic arterio-portal shunt in hepatocellular carcinoma with color doppler flow imagingHitoshi Tochio; Syusuke Tomita; Masatoshi Kudo; Yoshihiro Okabe; Kazushi Minowa; Hiroshi Kashida; Jun Mimura; Michio Hamada; Masahiro Hirasa; Yasuyoshi Ibuki; Hideshi Komori; Akio Orino; Akio TodoKanzo 34 (8) 597 - 605 1881-3593 1993 [Refereed] It is considered that retrograde portal flow is an evidence for the existence of arterio-portal (A-P) shunt. Fifteen patients with hepatocellular carcinoma (HCC), in whom retrograde portal flow was detected by color Doppler flow imaging, were studied. The correspondence between existence of A-P shunt on angiogram and retrograde portal flow identified by spectral analysis with pulsed Doppler was evaluated. A-P shunt was observed in all 4 cases with pulsatile retrograde portal flow. Out of 11 cases with continuous retrograde portal flow, A-P shunt was observed in 5 cases (45%). In 11 cases with continuous retrograde portal flow, case with A-P shunt showed Mean ± SD of maximum velocity of 10.6 ± 5.3cm/sec, which is significantly higher than that of in cases without A-P shunt. A-P shunt was observed in all cases with maximum velocity of retrograde portal flow more than 10cm/sec. We concluded that pulsatile retrograde portal flow or continuous retrograde portal flow faster than 10cm/sec in velocity is diagnostic of the existence of A-P shunt relating to HCC. © 1993, The Japan Society of Hepatology. All rights reserved.Quantitative assessment of hepatocellular function through in vivo radioreceptor imaging with technetium 99m galactosyl human serum albuminMasatoshi Kudo; Akio Todo; Katsuji Ikekubo; Kazutaka Yamamoto; David R. Vera; Robert C. StadalnikHepatology 17 (5) 814 - 819 1527-3350 1993 [Refereed] Technetium 99m diethylenetriaminepentaacetic acid–galactosyl human serum albumin is a newly developed analog ligand to asialoglycoprotein receptor, which is a hepatic cell surface receptor specific for galactose‐terminated glycoproteins. Hepatic functional imaging, which yields estimates of asialoglycoprotein receptor concentration, was performed after intravenous injection of 3 mg technetium 99m diethylenetriaminepentaacetic acid–galactosyl human serum albumin. A total of 75 human subjects were studied: 6 controls without liver diseases, 51 patients with chronic liver diseases and 18 patients with acute liver diseases. In chronic liver disease the asialoglycoprotein receptor concentration significantly correlated with the clinical severity based on the criteria of the Liver Cancer Study Group of Japan (rs = −0.890, p = 0.0001). Good correlations between the asialoglycoprotein receptor concentration and conventional liver function tests were also observed. In acute liver disease the asialoglycoprotein receptor concentration correlated well with the normotest (r = 0.796, p = 0.0001), prothrombin time (r = 0.701, p = 0.0002) and total serum bilirubin (r = −0.642, p = 0.0007). We conclude that the parameter, asialoglycoprotein receptor concentration, obtained from the kinetic analysis of technetium 99m diethylenetriaminepentaacetic acid–galactosyl human serum albumin time‐activity data, is a sensitive measure of functioning hepatocyte mass in acute and chronic liver disease. (HEPATOLOGY 1993 17:814–819.) Copyright © 1993 American Association for the Study of Liver DiseasesDES-GAMMA-CARBOXY PROTHROMBIN (PIVKA-II) AND ALPHA-FETOPROTEIN-PRODUCING-IIC-TYPE EARLY GASTRIC-CANCERM KUDO; Y TAKAMINE; K NAKAMURA; H SHIRANE; H UCHIDA; S KASAKURA; T KAJIWARA; Y IBUKI; M HIRASA; S TOMITA; A TODOAMERICAN JOURNAL OF GASTROENTEROLOGY WILLIAMS & WILKINS 87 (12) 1859 - 1862 0002-9270 1992/12 [Refereed] We describe the case of a 56-yr-old man with primary gastric adenocarcinoma, who had an extremely high plasma level of des-gamma-carboxy prothrombin (2.45 AU/ml) and of serum alpha-fetoprotein (2810 ng/ml). Histopathologically, the gastric cancer was a IIc type of early cancer which consisted of a combination of a poorly differentiated adenocarcinoma and a well-differentiated tubular adenocarcinoma. The association of a hepatic tumor including hepatocellular carcinoma or liver metastasis was ruled out by ultrasonography, computed tomography, radiocolloid liver scan, magnetic resonance imaging, and angiography. Foci strongly resembling hepatocellular carcinoma (hepatoid differentiation) were noted in the gastric tumor. Localization of des-gamma-carboxy prothrombin and alpha-fetoprotein within the tumor cells, especially within the hepatoid differentiated foci, was demonstrated by the immunohistochemical staining of tissue obtained at biopsy and the resected specimen. This case seems to be the first case reported in which des-gamma-carboxy prothrombin was produced by the gastric cancer. This finding supports the theory of hepatoid differentiation of a gastric cancer.RECEPTOR INDEX VIA HEPATIC ASIALOGLYCOPROTEIN RECEPTOR IMAGING - CORRELATION WITH CHRONIC HEPATOCELLULAR DAMAGEM KUDO; A TODO; K IKEKUBO; M HINOAMERICAN JOURNAL OF GASTROENTEROLOGY WILLIAMS & WILKINS 87 (7) 865 - 870 0002-9270 1992/07 [Refereed] Galactosyl human serum albumin is a newly developed receptor-binding agent, specific for the asialoglycoprotein receptor, which resides exclusively on the plasma membrane of mammalian hepatocytes. The receptor-binding agent was synthesized by the covalent coupling of carbohydrate units to human serum albumin. The clinical utility of technetium-99m-labeled galactosyl human serum albumin was evaluated in six control subjects with normal livers and in 50 patients with chronic liver disease. The parameter, receptor index, was derived from liver and heart time-activity data and is the ratio of radioactivity of the liver over the radioactivity of the liver plus the heart at 15 min after the intravenous injection of 3 mg of labeled ligand. Values for the receptor index in the control subjects and in patients with mild, moderate, and severe liver disease were 0.936 +/- 0.015, 0.909 +/- 0.034, 0.848 +/-0.070, and 0.669 +/- 0.085, respectively. Good correlations were obtained between the receptor index and conventional liver function tests, such as the Child-Turcotte criteria score (r(s) = -0.776, p = 0.0001), prothrombin time (r = 0.736, p = 0.0001), and the plasma disappearance rate of indocyanine green (r = 0.805, p = 0.000 1). These significantly high correlations of the receptor index with classical indicators of hepatic functional reserve suggest that the receptor index is a potentially practical and reliable diagnostic method for estimating the functioning hepatocyte mass and for assessing liver function.ENDOSCOPIC RETROGRADE EXTRACTION OF COMMON BILE-DUCT STONES WITH DRIP INFUSION OF ISOSORBIDE DINITRATEY IBUKI; M KUDO; A TODOGASTROINTESTINAL ENDOSCOPY MOSBY-YEAR BOOK INC 38 (2) 178 - 180 0016-5107 1992/03 [Refereed]Effects of isosorbide dinitrate on Oddi's sphincter.IBUKI YasuyoshiNippon Shokakibyo Gakkai Zasshi The Japanese Society of Gastroenterology 89 (9) 2078 - 2078 1349-7693 1992Color Doppler flow imaging of hepatic focal nodular hyperplasiaM. Kudo; S. Tomita; K. Minowa; H. Tochio; K. Shimada; J. Mimura; Y. Okabe; H. Kashida; M. Hirasa; A. TodoJournal of Ultrasound in Medicine 11 (10) 553 - 557 0278-4297 1992 [Refereed]Intrahepatic Portal-Hepatic Venous Shunt with Portal Aneurysmal Dilatation Diagnosed By Color Doppler Imaging-Report of Two CasesMasatoshi Kudo; Shusuke Tomita; Jun Mimura; Yoshihiro Okabe; Hiroshi Kashida; Masahiro Hirasa; Yasuyoshi Ibuki; Hideji Komori; Akio Orino; Akio TodoKanzo 33 (7) 556 - 564 1881-3593 1992 [Refereed] Presented two cases in this report are 36-year-old man and 78-year-old man with asymptomatic intrahepatic portal-hepatic venous shunt, diagnosed by color Doppler imaging. The patients were admitted for further evaluation of intrahepatic aneurysmal cystic lesion detected by screening ultrasonography. Liver biopsy and laboratory tests showed no abnormality in the liver, and case 1 had no episode of hepatic encephalopathy. Case 2 had an episode of slight encephalopathy. The color signals were obtained in the aneurysmal lesion, which communicates with the portal vein branch and the hepatic vein, on color Doppler imaging. Continuous waveform signals were detected in the aneusysm, the shunt orifice, and the adjacent region in the hepatic vein with the Doppler spectral analysis. The diagnosis was made as intrahepatic portal-hepatic shunt with aneurysmal dilatation by these findings with color Doppler imaging. Color Doppler imaging using pulsed Doppler analysis was also useful in the measurement of shunt ratio, which was calculated by deviding blood flow rate at the shunt orifice by total portal blood flow rate. We conclude that color Doppler imaging is extremely useful in the diagnosis, follow-up, and the determination of the therapeutic indication of the intrahepatic portal-hepatic venous shunt. © 1992, The Japan Society of Hepatology. All rights reserved.Hemodynamic Characteristics of Early Stage Hepatocellular Carcinoma: In Vivo Evaluation with Vascular ImagingsMasatoshi Kudo; Shusuke Tomita; Jun Mlmura; Yoshihiro Okabe; Hiroshi Kashida; Masahiro Hirasa; Yasuyoshi Ibuki; Hideshi Komori; Akio Orino; Akio TodoKanzo 33 (4) 283 - 291 1881-3593 1992 [Refereed] Hemodynamic characteristics were studied by using in vivo vascular imaging techniques in 17 resected early stage hepatocellular carcinoma (e-HCC) by comparing them with 49 resected advanced HCCs (ad-HCC) less than 3 cm in diameter. In this study, e-HCC was defined as the nodule being uniformly composed of well-differentiated HCC or adenomatous hyperplastic nodule containing well-differentiated HCC foci within the nodule. In vivo vascular imaging techniques are as follows US angiography with intraarterial CO2 microbubbles were performed to assess the tumor arterial vascularity, and CT during arterial portography (CTAP) was performed to assess the portal perfusion within the nodule. of 17 e-HCC nodules 5 were hypervascular, 5 were isovascular, 4 were hypovascular, and 3 were vascular spot in hypovascular pattern in contrast to 49 ad-HCC nodules, 43 of which were hypervascular and 6 were isovascular. of 14 e-HCCs, 9 nodules showed perfusion defect and 5 did not on CTAP, whereas all 37 ad-HCCs on which CTAP was performed, showed perfusion defect. Forty-one percent (7/17) of e-HCC showed fatty metamorphosis in contrast to 8% (4/49) of ad-HCC. In conclusion, hemodynamic characteristics of e-HCC are summarized as follows. (1) Arterial tumor neovascularization is relatively low. (2) Portal perfusion is present in some of e-HCC cases. (3) Hypoperfusion state both from arterial and portal supply is present in some of e-HCC cases. (4) Vascular spot in hypovascular pattern is characteristic arterial pattern in AH containing HCC foci. (5) Fatty metamorphosis may be related with hypoperfusion state of the nodule in e-HCC. © 1992, The Japan Society of Hepatology. All rights reserved.Clinical utility of receptor imaging in the assessment of liver functionMasatoshi Kudo; Akio Todo; Jun Mimura; Yoshihiro Okabe; Hiroshi Kashida; Masahiro Hirasa; Yasuyoshi Ibuki; Shusuke Tomita; Hideshi Komori; Akio OrinoNippon Shokakibyo Gakkai Zasshi 89 (6) 1349 - 1359 0446-6586 1992 [Refereed] Technetium-99m diethylene triamine pentaacetic acid-galactosyl human serum albumin (TcGSA) is a newly developed receptor-binding radiopharmaceutical, specific for the asialogycoprotein receptor, which resides exclusively on the plasma membrane of hepatocytes. Clinical utility of TcGSA was evaluated in 3 control subjects with normal livers and in 54 patients with various liver diseases. The parameter, Receptor Index, was derived from liver and heart time-activity data and is the ratio of radioactivity of the liver over the radioactivity of the liver plus heart at 15 min after the intravenous injection of 3 mg of TcGSA. Receptor concentration ([R]0) was obtained by kinetic analysis of liver and heart time-activity data using pharmacokinetic nonlinear modeling. Values for the Receptor Index and [R]0 were statistically different in the control subjects and in patients with mild, moderate, and severe liver diseases. Good correlations were obtained between the Receptor Index, [R]G and conventional liver function tests, such as Child-Turcotte criteria score, prothrombin time, and indocyanine green test. Receptor Index and [R]G were properly estimated even in patients with obstructive jaundice or remarkable portocaval shunt. These data suggest that the receptor imaging as well as its parameters, Receptor Index and [R]G, is a potentially practical and reliable diagnostic method for estimating the functioning hepatocyte mass and for assessing liver function. © 1992, The Japanese Society of Gastroenterology. All rights reserved.Hepatic receptor imaging with Tc-99m GSA: Estimates of liver function in acute liver diseaseMasatoshi Kudo; Akio Todo; Jun Mimura; Yoshihiro Okabe; Hiroshi Kashida; Masahiro Hirasa; Yasuyoshi Ibuki; Shusuke Tomita; Hideshi Komori; Akio OrinoNippon Shokakibyo Gakkai Zasshi 89 (3) 616 - 626 0446-6586 1992 [Refereed] Technetium-99m galactosyl human serum albumin (TcGSA) is a synthesized radiolabeled analog ligand to asialoglycoprotein receptor, which resides only at a mammalian hepatocyte. TcGSA studies were performed on 16 patients with various acute liver disease and 3 controls with normal livers. Dynamic data were obtained by a gamma camera during 35 minutes after an intravenous injection of 3 mg (185 MBq) of TcGSA. The parameters of TcGSA timeactivity curves were obtained by dividing radioactivity of the liver by that of the liver plus heart at 15 min (Receptor Index), and by dividing radioactivity of the liver at 15 min by that at 3 min post injection (Clearance Index). The two parameters correlated well with prothrombin time, clinically estimated staging, and severity of acute liver disease. We have concluded that liver function study by the newly developed receptor imaging with TcGSA can be a sensitive and promising tool in estimating the severity and prognosis of acute liver disease. © 1992, The Japanese Society of Gastroenterology. All rights reserved.Multiple Hemangiopericytomas of the SpleenRyo Hosotani; Hirohito Momoi; Hiroya Uchida; Yoshihiro Okabe; Masatoshi Kudo; Akio Todo; Toshiaki IshikawaThe American Journal of Gastroenterology 87 (12) 1863 - 1865 1572-0241 1992 [Refereed] Splenic tumors are uncommon. Described is a 58‐yr‐old man with multiple hemangiopericytomas of the spleen. Hemangiopericytoma is categorized as a benign vascular tumor, but has a relatively high malignant potential. A review of the literature shows that the case we present is only the second ever reported of a tumor originating from the spleen. Radiological findings and the treatment of the tumor are discussed. Copyright © 1992, Wiley Blackwell. All rights reservedGrowth Speed of Hepatocellular Carcinoma-Relationship with Arterial Vascularity Evaluated by us Angiography-Hitoshi Tocmo; Syusuke Tomita; Masatoshi Kudo; Jun Mimura; Michio Hamada; Kazushi Minowa; Hiroshi Kashida; Yoshihiro Okabe; Masahiro Hirasa; Yasuyoshi Ibuki; Hideshi Komori; Akio Orino; Akio TodoKanzo 33 (10) 758 - 765 1881-3593 1992 [Refereed] Relationship between arterial vascularity and tumor growth speed was evaluated in 41 hepatocellular carcinomas (HCC). Arterial vascularity of HCCs was classified into 3 patients with US angiography during intraarterial carbon dioxide microbubbles: hypervascular (n=25), isovascular (n=7), and hypovascular (n=9) HCCs. Tumor growth speed was determined by the tumor volume doubling time (TVDT) with measuring by US. The logarithmic mean of the doubling time in hypervascular HCCs was statisticaly more rapid than that in isovascular or hypovascular HCCs (p< 0.05, p< 0.001) respectively. Furthermore, the logarithmic mean of TVDT in isovascular HCCs was more rapid than that in hypovascular HCCs (p< 0.05). We concluded that positive correlation between tumor vascularity and the tumor growth speed was observed, i.e., the more vascular the tumor is, the more rapid the growth speed becomes. © 1992, The Japan Society of Hepatology. All rights reserved.SMALL HEPATOCELLULAR-CARCINOMA - DIAGNOSIS WITH US ANGIOGRAPHY WITH INTRAARTERIAL CO-2 MICROBUBBLESM KUDO; S TOMITA; H TOCHIO; J MIMURA; Y OKABE; H KASHIDA; M HIRASA; Y IBUKI; A TODORADIOLOGY RADIOLOGICAL SOC NORTH AMER 182 (1) 155 - 160 0033-8419 1992/01 [Refereed] Ultrasonographic (US) angiography enhanced with intraarterial CO2 microbubbles, a contrast material used in US imaging, was performed of 103 histologically proved hepatocellular carcinomas (HCCs) smaller than 3 cm in diameter in 95 patients. The detection rate for hypervascular HCC with US angiography was compared with the rate of detection with conventional angiography, digital subtraction angiography (DSA), and computed tomography (CT) after intraarterial injection of iodized oil. Sensitivity in detection of hypervascular HCCs with US angiography was 86% (89 of 103 HCCs), compared with 63% (44 of 70 HCCs) detected with conventional angiography, 70% (23 of 33 HCCs) with DSA, and 82% (75 of 91 HCCs) with CT with iodized oil. US angiography depicted small hypervascular HCCs, especially those less than 1 cm in diameter, and helped clarify vascularity as isovascular or hypovascular in angiographically undetectable HCCs. Findings at US angiography assisted the choice of a therapeutic strategy for treatment of HCC, such as transarterial therapy, percutaneous ethanol injection therapy, or resection.SONOGRAPHY WITH INTRAARTERIAL INFUSION OF CARBON-DIOXIDE MICROBUBBLES (SONOGRAPHIC ANGIOGRAPHY) - VALUE IN DIFFERENTIAL-DIAGNOSIS OF HEPATIC-TUMORSM KUDO; S TOMITA; H TOCHIO; J MIMURA; Y OKABE; H KASHIDA; M HIRASA; Y IBUKI; A TODOAMERICAN JOURNAL OF ROENTGENOLOGY AMER ROENTGEN RAY SOC 158 (1) 65 - 74 0361-803X 1992/01 [Refereed] Differential diagnosis of small liver tumors is important, but is not always possible, even with angiography. To solve this problem, we introduced sonographic angiography, which combines sonography and angiography. The vascular pattern of a variety of hepatic nodules was evaluated with sonographic angiography, and the results were compared with those of conventional angiography. Sonographic angiography (sonography performed during intraarterial infusion of carbon dioxide microbubbles) was performed in 184 patients with a total of 222 hepatic nodules: 139 hepatocellular carcinomas, nine adenomatous hyperplasias, seven regenerative nodules, 21 hemangiomas, 33 metastases, seven lymphomas, one granuloma, and five focal nodular hyperplasias. Sonographic angiography detected a hypervascular pattern with peripheral blood supply in cases of hepatocellular carcinoma (sensitivity, 90%; specificity, 89%). Typical vascular patterns of adenomatous hyperplasia, hemangioma, metastasis, and focal nodular hyperplasia on sonographic angiography were hypovascularity (sensitivity, 100%; specificity, 91%), spotty pooling (sensitivity, 100%; specificity, 100%), peripheral hypervascularity (sensitivity, 64%; specificity, 100%), and a central arterial supply (sensitivity, 100%; specificity, 100%), respectively. The detectability of hypervascularity was greater with sonographic angiography than with conventional angiography in hepatocellular carcinoma, metastasis, and hemangioma. Our experience indicates that sonographic angiography depicts characteristic vascular features that reflect the vascular anatomy of specific types of hepatic tumors, and thus is useful in the differential diagnosis of these lesions.Functional hepatic imaging with receptor-binding radiopharmaceutical: Clinical potential as a measure of functioning hepatocyte massMasatoshi Kudo; Akio Todo; Katsuji Ikekubo; Megumu Hino; Yoshiharu Yonekura; Kazutaka Yamamoto; Kanji TorizukaGastroenterologia Japonica Springer-Verlag 26 (6) 734 - 741 0435-1339 1991/12 [Refereed] Asialoglycoprotein receptor (ASGP-R) is a hepatic cell surface receptor specific for galactose-terminated glycoproteins. Technetium-99m diethylenetriaminepentaacetic acid-galactosyl human serum albumin (TcGSA) is a newly developed analog ligand to ASGP-R. Fourteen human subjects were studied: three normal volunteers, one with chronic hepatitis, 6 with liver cirrhosis, and 4 with hepatocellular carcinoma associated with liver cirrhosis. The receptor index parameter (LHL15), was obtained from the liver and heart time-activity data as the ratio of radioactivity of the liver over that of the liver plus heart at 15 min after intravenous injection of 1 mg of TcGSA. Means±standard deviations of LHL15 in normal volunteers (3 cases), patients with mild (4 cases), moderate (2 cases), and severe liver damage (5 cases) were 0.933±0.006, 0.789±0.045, 0.723±0.033, and 0.488±0.094, respectively. The difference between the mean values of each group was statistically significant (P< 0.05). LHL15 correlated well with classical indicators for hepatic functional capacity such as serum albumin level, serum bilirubin level, prothrombin time, ICG R15 or Child-Turcotte criteria score. Our preliminary experiences of high correlations of TcGSA functional imaging data with clinical data suggest that the dynamic data using this receptor-binding radiopharmaceutical provides invaluable information with regard to liver function, and thus, the TcGSA study is potentially a noninvasive practical tool to measure functioning hepatocyte mass. © 1991 The Japanese Society of Gastroenterology.HEPATIC FOCAL NODULAR HYPERPLASIA - SPECIFIC FINDINGS AT DYNAMIC CONTRAST-ENHANCED US WITH CARBON-DIOXIDE MICROBUBBLESM KUDO; S TOMITA; H TOCHIO; H KASHIDA; M HIRASA; A TODORADIOLOGY RADIOLOGICAL SOC NORTH AMER 179 (2) 377 - 382 0033-8419 1991/05 [Refereed] Dynamic contrast material-enhanced ultrasonography (US) with intraarterial infusion of carbon dioxide microbubbles was performed for four cases of histologically proved focal nodular hyperplasia (FNH) in four patients and for 167 cases of various hepatic nodules in 144 patients. No complications due to dynamic US were observed in any of the 148 patients. All FNH nodules were less than 3 cm in diameter. Consistent specific findings of FNH were not obtained with US, computed tomography, magnetic resonance imaging, radiocolloid scanning, or angiography in the four cases of FNH. In contrast, the characteristic vascular pattern (ie, early central hypervascular supply with centrifugal filling to the periphery at the arterial phase and a uniform or lobulated dense stain at the capillary phase) was observed in all four cases of FNH with dynamic US. This vascular pattern demonstrated in FNH with dynamic US was not seen in any of the 167 hepatic nodules, including 44 small hepatocellular carcinomas less than 3 cm in diameter. Therefore, the newly developed, dynamic contrast-enhanced US technique seems to be extremely sensitive and specific for diagnosing FNH and is useful in the differentiation of FNH from other hepatic tumors, especially hepatocellular carcinoma.Early complications following endoscopic sphincterotomy : Clinical features and managementYasuyoshi Ibuki; Masahiro Hirasa; Masatoshi Kudo; Akio Orino; Akio TodoGASTROENTEROLOGICAL ENDOSCOPY 33 (11) 2394 - 2401 0387-1207 1991 [Refereed] We reviewed 142 endoscopic sphincterotomies (EST). The indications (Table 1) included common bile duct stones (78.9%), placing catheters or endoprostheses in patients with malingant stricture of the bile duct (13.4%), papillary stenosis, chronic pancreatitis, and miscellaneous (biopsy, and peroral choledocho-pancreatoscopy). Early complications (Table 2) occurred in 13 patients (9.2%) : hemorrhage in 7, pancreatitis in 4, perforation in 1 and pneumoretroperitoneum in 1. No patients died. Two patients (1.4%) required operation for complications. All patients with hemorrhage following EST (Table 3) were elderly (age > 70, mean 82.7) including 3 patients with no symptoms. All the patients were treated conservatively. Their hemoglobin values reached the bottom 6 to 14 (mean 8.5) days after EST. Five patients did not bleed during EST but bled later. These findings suggest that late bleeding or continuous hemorrhage can occur after EST. Therefore, periodical follow-up of hemoglobin values are important for early detectin of late or continuous bleeding following EST. Perforation of the common bile duct occurred in 1 patient who required surgery, although some reports have suggested that most perforations can be managed conservatively with providing drainage of the bile duct by ensuring adequate sphincterotomy, inserting a pernasal catheter or a biliary stent where appropriate. Precut papillotomy was performed in 6 patients. Two patients developed pancreatitis (Table 4) and three developed hyperamylasemia. The incidences of pancreatitis and hyperamylasemia in patients with precut procedure were much higher than those in patients without percut procedure. Therefore it was concluded that precut procedure should be avoided whenever possible. © 1991, Japan Gastroenterological Endoscopy Society. All rights reserved.Arterial vascularity within the nodules of small hepatocellular carcinoma: Analysis with ultrasound angiography using intraarterial CO2 microbubbles and resected specimenMasatoshi Kudo; Shusuke Tomita; Hitoshi TocfflO; Mitsuo Hamada; Jun Mimura; Yoshihiro Okabe; Hiroshi Kashida; Masahiro Hirasa; Yasuyoshi Ibuki; Hideshi Komori; Akio Orino; Akio TodoKanzo 32 (11) 1008 - 1016 1881-3593 1991 [Refereed] In this report the arterial vascularity within the nodule in small hepatocellular carcinoma (HCC) was evaluated in comparison with histopathological study. For this goal, dynamic contrast-enhanced ultrasonography with intraarterial CO2 microbubbles infusion (US angiography) was performed on 39 patients with surgically resected 44 small HCCs smaller than 3 cm in diameter. The results are as follows: 1) Out of 44 HCCs, 35 were demonstrated as hypervascular, 5 as isovascular, 3 as vascular spot in hypovascular, and 1 as hypovascular. 2) Out of 11 HCCs, which were pathologically classified into Grade I on Edmondson-Steiner scale, 4 were demonstrated as isovascular, 6 were demonstrated as hypervascular, and 1 were demonstrated as hypovascular. 3) Almost all Grade II-III HCCs (29/30) were demonstrated as hypervascular. 4) Out of 13 angiographically undetected HCCs, 4 were isovascular nodules, 3 were hypovascular nodules including vascular lesions, 5 were hypervascular nodules, and 1 was hypovascular nodule. 5) Out of 13 angiographically undetected HCCs, 9 nodules including 2 hypervascular nodules were nonencapusulated HCCs on pathological study of the resected specimen. 6) Sensitivity in demonstrating hypervascularity of the HCC improved to 80% (35/44) by the use of US angiography, compared to 70% (31/44) with conventional angiography or 73% (30/41) with Lipiodol CT. Moreover, sensitivity in evaluating tumor vascularity with US angiography was 100% (44/44). Our conclusions based on these results are as follow: 1) All HCCs except one have arterial vascularity within the tumor. 2) Half of well-differentiated HCC exhibited isovascualr or hypovascular, suggesting immature neovascularization within the tumor. 3) Tumors undetected with angiography or Lipiodol CT are isovascular, non-encapsulated, or considerably small HCCs. 4) US angiography is sensitive in the detection of arterial vascularity within the HCC nodules, and hence, contributory to the diagnosis of small HCCs. © 1991, The Japan Society of Hepatology. All rights reserved.In vivo measurement of hepatic binding protein in chronic liver disease: —Validation as a measure of hepatic functional reserve—Masatoshi Kudo; Akio TodoNippon Shokakibyo Gakkai Zasshi 88 (1) 40 - 50 0446-6586 1991 [Refereed] [Tc-99m] Galactosyl-neoglycoalbumin (TcNGA) is a synthetic radiolabeled ligand specific to the hepatocyte receptor, hepatic binding protein (HBP), a specific receptor to serum asialoglycoprotein. A TcNGA study was performed on 34 humans: normal volunteers (7), chronic hepatitis (6), hepatic cirrhosis (8), and hepatocellular carcinoma superimposed on cirrhosis (13). Heart and liver time activity curves were obtained following intravenous injection of TcNGA (5 mCi, 1.82 × 10–9 mol/kg). HBP concentration ([HBP]) was calculated by curve-fitting techniques using the nonlinear three compartment model, which includes bimolecular reaction between HBP and TcNGA. [HBP] values were compared with conventional liver function tests. [HBP] had a good correlation with prothrombin time (n=34, r=0.694, p=0.0001) thrombotest (n=34, r=0.692, p=0.0001), hepaplastin test (n=26, r=0.787, p=0.0001), albumin (n=34, r=0.712, p=0.0001), cholinesterase (n=34, r=0.801, p=0.0001), ICGR15 (n=33, r=—0.761, p=0.0001), KICG (n=30, r=0.709, p=0.0001), ICG Rmax (n=12, r=0.735, p=0.0064) and Child-Turcotte classification score (n=34, r=—0.819, p=0.0001). We concluded that excellent correlations of [HBP] to conventional liver function tests suggest that in vivo receptor measurement via TcNGA kinetic analysis is a sensitive and promissing method in the estimation of hepatic functional reserve in patients with chronic liver disease. © 1991, The Japanese Society of Gastroenterology. All rights reserved.Tumor hemodynamics in hepatic nodules associated with liver cirrhosis: Relationship between cancer progression and tumor hemodynamic changeMasatoshi Kudo; Shusuke Tomita; Hiroshi Kashida; Jun Mimura; Yoshihiro Okabe; Masahiro Hirasa; Yasuyoshi Ibuki; Hideshi Komori; Akio Orino; Akio TodoNippon Shokakibyo Gakkai Zasshi 88 (8) 1554 - 1565 0446-6586 1991 [Refereed] Tumor hemodynamics including arterial vascularity (AV) and portal perfusion (PP) were evaluated in histologically confirmed 55 hepatic nodules associated with cirrhosis using ultrasonographic (US) angiography during intraaterial carbon dioxide microbubbles injection and CT during arterial portography. Tumor hemodynamic patterns were classified into 6 types as follows: Type I (n=10): PP (+), AV (hypo) Type I' (n=2): PP (+), AV (iso) Type II (n=5): PP (-), AV (hypo) Type III (n=8): PP (-), AV (iso) Type IV (n=25): PP (-), AV (hyper), Type V (n=5): PP (partially +), AV (vascular spot in hypovascular). Eight nodules of Type I were diagnosed as benign nodules histologically including adenomatous hyperplasia (AH) (n=6) and regenerative nodule (n=2). Hundred percent (5/5) of Type II and 88% (7/8) of Type III nodules were well-differentiated HCC, in contrast to 8% (2/25) of Type IV nodules, typical HCCs. Fatty metamorphosis was observed in 75% (6/8) of Type III nodules, in contrast to 16% (4/25) of typical (classical) HCC nodules (Type IV). We concluded that at the malignant transformation from AH to HCC, reduction of portal blood flow in the nodule precedes the initiation of the increase of the arterial tumor vessel. Moreover, early stage HCC could exhibit hypovascular (Type I, II), isovascular (Type III), or vascular spot in hypovascular pattern (Type V) compared with a typical HCC (Type IV). It was also suggested that the more mature as a neoplams the HCC becomes, the more the arterial tumor vessel in the nodule increases and fatty metamorphosis of well-differentiated HCC is highly related with tumor hemodynamic condition, i.e., hypoperfusion state from both arterial and portal vessel. © 1991, The Japanese Society of Gastroenterology. All rights reserved.A resected case of stage IV hepatocellular carcinoma 5 years and 9 months after one shot arterial infusion chemotherapyMasatoshi Kudo; Jun Mimura; Yoshihiro Okabe; Hiroshi Kashida; Masahiro Hirasa; Yasuyoshi Ibuki; Shusuke Tomita; Hideshi Komori; Akio Orino; Akio Todo; Hiroshi Takakuwa; Tomohiko Tani; Toshitaka Okuno; Tatehiro Kajiwara; Hirobumi ShiraneKanzo 31 (12) 1439 - 1445 1881-3593 1990 [Refereed] A 72-year-old female was admitted to our hospital with complaints of general malaise, appetite loss, nausea, and vomiting in January, 1984. CT showed large tumor in the right lobe. Ultrasound revealed large tumor in the right lobe, tumor thrombi in the right main branch of the portal vein, and ascites. A sign of mild hepatic encephalopathy was also observed. Serum α-fetoprotein level was 25118 ng/ml. Angiography revealed multiple small hypervascular nodules in the right lobe and extremely extended arterio-portal shunting (A-P shunt), which is consistent with the diagnosis of hepatocellular carcinoma (HCC). The tumor and A-P shunt drastically disappeared on US, CT, colloid liver scan, and angiography a few months after the injection of 10 mg of mitomycine C through the common hepatic artery. Five years and 9 months after one shot arterial infusion chemotherapy, the recurred HCC, measuring 1.9 cm in size was treated with the second arterial infusion chemotherapy combined with lipiodol followed by a right lobectomy. The histopathology showed total necrosis of HCC, multiple organization and fibrosis in the right lobe, and thickened organized lesion with fibrosis within the portal vein. This case is considered to be rare since stage IV HCC responded extremely well to the single arterial infusion chemotherapy as well as the scars of HCC lesion and tumor thrombi in the portal vein were recognized pathologically more than 5 years later. © 1990, The Japan Society of Hepatology. All rights reserved.Tumor vascularity in small hepatocellular carcinomaTatehiro Kajiwara; Masatoshi Kudo; Shusuke Tomita; Hiroshi Kashida; Jun Mimura; Yoshihiro Okabe; Masahiro Hirasa; Akio Todo; Tomohiko TaniNippon Shokakibyo Gakkai Zasshi 87 (12) 2691  0446-6586 1990 [Refereed]In Vivo Estimates of Hepatic Binding Protein Concentration: Correlation with Classical Indicators of Hepatic Functional ReserveMasatoshi Kudo; David R. Vera; Robert C. Stadalnik; Walter L. Trudeau; Katsuji Ikekubo; Akio TodoThe American Journal of Gastroenterology 85 (9) 1142 - 1148 1572-0241 1990 [Refereed] Hepatic binding protein (HBP) is a hepatic cell surface receptor specific for asialoglycoprotein. In vivo estimates of HBP concentration (IHBPJ) were compared to classical indicators for hepatic functional reserve to clarify the validity of ([HBP]) in estimating the hepatic functional reserve in 30 humans. Estimates of [HBP] were obtained based on kinetic analysis of liver and blood time‐activity data resulting from the hepatic clearance of a single injection of technetium–99m galactosyl‐neoglycoalbumin, which is a synthetic analog radioligand specific to HBP. Estimates of [HBP] ranged 0.054 to 0.720 μM. Estimates of [HBP] in normal volunteers were 0.668 ± 0.050 MM, whereas that in liver cirrhosis were 0.188 ± 0.112 μM. The difference between the mean values of |HBP] estimates was statistically significant (p ‐ 0.0001). Good correlations were observed between [HBP] and prothrombin time (r = 0.625, p ‐ 0.0002), serum albumin level (r = 0.687, p = 0.0001). serum cholinesterase level (r = 0.764, p = 0.0001), indocyanine green plasma disappearance rate (r = 0.602, p = 0.0024), and Child‐Turcotte classification score (Pugh's modification) (r =–0.797, p = 0.0001). We concluded that excellent correlations of |HBP| with classical indicators for hepatic functional reserve suggest potential value of [HBP] as a sensitive measure of functioning hepatocyte mass. Copyright © 1990, Wiley Blackwell. All rights reservedFOCAL FATTY INFILTRATION OF THE LIVER IN ACUTE ALCOHOLIC LIVER-INJURY - HOT SPOTS WITH RADIOCOLLOID SPECT SCANM KUDO; K IKEKUBO; K YAMAMOTO; M HINO; Y IBUKI; S TOMITA; H KOMORI; A ORINO; A TODOAMERICAN JOURNAL OF GASTROENTEROLOGY WILLIAMS & WILKINS 84 (8) 948 - 952 0002-9270 1989/08 [Refereed]DISTINCTION BETWEEN HEMANGIOMA OF THE LIVER AND HEPATOCELLULAR-CARCINOMA - VALUE OF LABELED RBC-SPECT SCANNINGM KUDO; K IKEKUBO; K YAMAMOTO; Y IBUKI; M HINO; S TOMITA; H KOMORI; A ORINO; A TODOAMERICAN JOURNAL OF ROENTGENOLOGY AMER ROENTGEN RAY SOC 152 (5) 977 - 983 0361-803X 1989/05 [Refereed]An attempt at the endoscopic elimination of common bile duct stones through the administration of nitrateYasuyoshi Ibuki; Yoshihiro Okabe; Toshihiko Fukui; Hiroshi Kashida; Masahiro Hirasa; Masatoshi Kudo; Katsuhiko Fujimi; Shusuke Tomita; Hideshi Komori; Akio Orino; Akio ToroGASTROENTEROLOGICAL ENDOSCOPY 30 (1) 94 - 1 0387-1207 1988 [Refereed] Using the relaxing effect of nitrate on the smooth muscle of the Oddi's sphincter, we were able to eliminate stones in four patients with common bile duct stones without endoscopic sphincterotomy (EST). This method employs intravenous injections of nitrate and uses a basket catheter endoscopically inserted into the bile duct to grasp the stone. Removal of the stone can also be accomplished by endoscopically inserting a balloon catheter into the bile duct and pulling out the stone with the catheter. There was no evidence of adverse side effects such as lowered blood pressure excessively. This method was used on a small stone in the bile duct, but is especially useful in cases where EST is contraindicated or inappropriate. The application of this method is also beneficial when catheter insertion is difficult due to strong tension of the Oddi's sphincter during ERCP or EST. © 1988, Japan Gastroenterological Endoscopy Society. All rights reserved.Is liver scintigram necessary for diagnosis of hepatocellular carcinoma?M. Kudo; Y. Ibuki; K. Fujimi; S. Tomita; H. Komori; A. Orino; A. Todo; M. Hino; K. IkekuboJapanese Journal of Clinical Radiology 32 (8) 901 - 908 0009-9252 1987 [Refereed] Clinical necessity of liver scintigram in diagnosing hepatocellular carcinomas (HCCs) were evaluated in 383 patients with HCCs including 40 patients with a total of 50 small HCCs (less than 5 cm in diameter). Liver scintigram including SPECT is considered to be absolutely necessary in 2% (6/383) of patients with HCC and relatively necessary in 7% (25/383) of patients with HCC. The cases categorized into these 2 groups had 2 specific features of HCC one which showed macroscopically infiltrative type and another which were located in the subdiaphragmatic portion of the liver. In conclusion, liver scintigram is still necessary especially in these cases for the diagnosis of HCC.Evaluation of asialoglycoprotein receptor-binding, synthetic radiolabeled glycoprotein in estimating hepatic functional reserveMasatoshi Kudo; Akio Todo; Toshihiko Fukui; Hiroshi Kashida; Yasuyoshi Ibuki; Katsuhiko Fujimi; Shusuke Tomita; Hideshi Komori; Akio Orino; Katsuji Ikekubo; David R. Vera; Robert C. StadalnikKanzo 28 (10) 1277 - 1286 1881-3593 1987 [Refereed] Asialoglycoprortecien pto(rA SGPR)r esideast t hec elslu rfacoef h epatocytewsh,e rei tr ecognizes and binds galactose-terminatgeldy coproteinAs.f ter binding,t he ligand-receptcoor mplex is transported to hepaticl ysozomesw here the ligandi s catabolizedA.l terationo f ASGPR binding has been demonstrated in variousp athologicc onditionso f the liver. Tc-99m-Galactosyl-Neoglycoalbum(iTnc -99m-NGA) is a newly developeda nalog ligando f galactose-terminategdl ycoproteinsW.e evaluatedc linicault ilitoyf Tc-99m-NGA in estimatingh epatic functionalr eServei n 23 clinicacla ses. NGA ReceptorI ndex,w hich isg iven by the radioactivitoyf the liverd ividedb y that of the liver plush earta t 30 min afteri ntravenousi njectioonf Tc-99m-NGA, was decidedt o be a preliminariy ndex of liverf unctionp rovidedb y NGA studiesi n thisr eport-Apositivceo rrelatiowna s observedb etween NGA ReceptorI ndex and CholinesteraseH,e paplastint est,T hrombotest,P rothrombin time and KICG. A negativec orrelatiowna s observed between NGA Receptor Index and ICG R15 and Child- Turcotte CriteriaS core. Analysis of the NGA dynamic curye is a promising method for the estimation of the heaptic functionalr eserve,a s the dynamic curves correlatteo the Asialogycoproteirne ceptorc oncentration. © 1987, The Japan Society of Hepatology. All rights reserved.SMALL HEPATOCELLULAR CARCINOMAS IN CHRONIC LIVER-DISEASE - DETECTION WITH SPECTM KUDO; M HIRASA; H TAKAKUWA; Y IBUKI; K FUJIMI; M MIYAMURA; S TOMITA; H KOMORI; A TODO; Y KITAURA; K IKEKUBO; K TORIZUKARADIOLOGY RADIOLOGICAL SOC NORTH AMER 159 (3) 697 - 703 0033-8419 1986/06 [Refereed]A case of esophageal hemangioma excised by endoscopic polypectomyMasatoshi Kudo; Masahiro Hirasa; Hiroshi Takakuwa; Yasuyoshi Ibuki; Katsuhiko Fujimi; Masami Miyamura; Shusuke Tomita; Hideshi Komori; Akio TodoGASTROENTEROLOGICAL ENDOSCOPY 28 (2) 318 - 325 0387-1207 1986 [Refereed] A 76-year-old male was admitted to our hospital complaining of dysphagia. A barium swallow examination of the esophagus showed a smooth surfaced, soft, 2cm-sized protruded lesion in the upper portion of the esophagus (Figure 1). Esophagoscopy with a fiberoptic endoscope revealed a blue-red colored, pedunculated submucosal tumor 20cm from the incisers (Figure 3 and 4). When pushed with biopsy forceps, the tumor easily indented, suggesting a vascular lesion. Dynamic CT scan with bolus infusion of contrast medium also suggested a vascular tumor in the esophagus (Figure 6). Endoscopic polypectomy was successfully performed following injection of 3.4 ml of ethanol into the stalk of the tumor in order to prevent massive bleeding. No bleeding was observed and the excised specimen measured 2.2X1.2X0.9 cm (Figure 9 and 10). Histologically, the tumor was a capillary hemangioma, which is very rare (Figure 11). Twenty-five cases of esophageal hemangioma have so far been reported in Japan and endoscopic polypectomy was performed in only 4 (including our case) of 25 cases. © 1986, Japan Gastroenterological Endoscopy Society. All rights reserved.Concept of the Clinical Stages of Acute Hepatic FailureHideshi Komori; Masahiro Hirasa; Hiroshi Takakuwa; Yasuyoshi Ibuki; Masatoshi Kudo; Katsuhiko Fujimi; Masami Miyamura; Shusuke Tomita; Akio TodoThe American Journal of Gastroenterology 81 (7) 544 - 549 1572-0241 1986 [Refereed] Serial medical diagnostic imagings were performed on 15 patients with acute hepatic failure to compare liver size and clinical picture. In patients showing hepatatrophy at the onset of coma, the interval between the onsets of disease and coma was long, ascites and edema supervened, high total bilirubin and low glutamic pyrubic transaminase levels tended to he found, and prothrombin time did not respond to treatment. All of these patients died. Based on liver size changes in patients who survived acute hepatic failure, acute hepatic failure was assumed to he classified into swelling, reduction, and recovery stages. The shorter the interval between the onsets of disease and coma, the earlier coma and prolonged prothrombin time occurred before hepatatrophy. In acute hepatic failure, signs of hepatic failure develop with various histological pictures and it is very important to institute the treatment before the liver is atrophied. Copyright © 1986, Wiley Blackwell. All rights reservedA case of suppurative pylephlebitis with development of hepatopetal collaterals (cavernous transformation of the portal vein)IBUKI Yasuyoshi; HIRASA Masahiro; TAKAKUWA Hiroshi; KUDO Masatoshi; FUJIMI Katsuhiko; UEDA Shunji; MIYAMURA Masami; TOMITA Shusuke; KOMORI Hideshi; TODO Akio; KITAURA YasutomoNippon Shokakibyo Gakkai Zasshi The Japanese Society of Gastroenterology 82 (5) 1406 - 1411 1349-7693 1985Accumulation of Tc-99m methylene diphosphonate in calcified metastatic lesions of the liver from colonic carcinoma. Comparison with calcification on X-ray computed tomogramM. Senda; N. Tamaki; K. Torizuka; Y. Fujiwara; M. Kudo; H. Tochio; H. Ito; H. Yamaguchi; Y. Saiki; K. IkekuboClinical Nuclear Medicine 10 (1) 9 - 12 0363-9762 1985 [Refereed]Effect and limitation of endoscopic hemostatic treatments on hemorrhagic gastroduodenal ulcerYasuyoshi Ibuki; Masahiro Hirasa; Hiroshi Takakuwa; Masatoshi Kudo; Katsuhiko Fujimi; Shunji Ueda; Masami Miyamura; Shusuke Tomita; Hideshi Komori; Akio Todo; Yasutomo KitauraGASTROENTEROLOGICAL ENDOSCOPY 27 (4) 474 - 487 0387-1207 1985 [Refereed] In order to evaluate the effect and limitation of endoscopic hemostatic treatments, 422 patients with hemorrhagic gastric and duodenal ulcers admitted to our hospital before (Jan. 1978∼Jul. 1981) and after (Aug. 1981∼Jun. 1984) adopting these treatments were studied. Endoscopic treatments including bipolar electrocoagulation, local injection of hypertonic saline epinephrine solution and local injection of pure ethanol were applied to 68 patients with arterial bleeding or with exposed vessels. 1) Severe hemorrhage was more frequent in those with exposed vessels than in those without exposed vessels (Figure 1, 2, 3). 2) In hemorrhagic gastric and duodenal ulcers with exposed vessels the effective rates of H2-receptor antagonist were 51.1% and 75.0%, respectively. Endoscopic treatments were effective in 91.5% and 100%, respectively (Figure 4). 3) In hemorrhagic gastric and duodenal ulcers without exposed vessels the effective rates of H2-receptor antagonist were 96.7% and 98.5%, respectively. 4) The rates of emergency operation decreased after adopting endoscopic treatments. In hemorrhagic gastric ulcer the rate of emergency operation significantly decreased from 23.7% to 3.7%. In hemorrhagic duodenal ulcer it decreased from 7.4% to 2.4% (Figure 5). 5) Endoscopic treatments were also applied to patients with critical complications who had no operative indication. The re-bleeding rate for these patients was higher than those without serious complications. © 1985, Japan Gastroenterological Endoscopy Society. All rights reserved.A case of hepatic hemangiosarcoma associated with Kasabach-Merritt syndrome and intraperitoneal bleedingMasatoshi Kudo; Masahiro Hirasa; Hiroshi Takakuwa; Yasushi Ibuki; Katsuhiko FujiMi; Shunji Ueda; Shuhsuke Tomita; Hideshi Komori; Akio Todo; Yasutomo Kitaura; Mamoru Sato; Hiroya UchidaKanzo 25 (12) 1605 - 1611 1881-3593 1984 [Refereed] A 71-year-old male was admitted with complaints of subcutaneous purpura and right hypochondrial pain. He had an episode of being injected with Thorotrast for his war wound in 1939. Intraperitoneal bleeding and disseminated intravascular coagulopathy (DIC) were seen on admission. Abdominal ultrasonography (US), computed tomography (CT), liver scintigraphy and right heaptic arteriography revealed two tumors in the liver, one is in the right lobe and the other is in the medial segment of the left lobe. The finding of US shows a mesh-like or honeycomb-like pattern and the angiogram shows a cotton wool like appearance in the capillary phase, which is consistent with cavernous hemangioma. A right hepatectomy was performed and the histological findings of the resected tumor found it to be hemangiosarcoma of the liver, which is very rare. Our reported case is considered to be the first case in Japan, in which Kasabach-Merritt syndrome occurred based on hemangiosarcoma of the liver. © 1984, The Japan Society of Hepatology. All rights reserved.Diagnostic value of liver scintigraphy, computed tomography and ultrasonography of acute hepatitisHideshi Komori; Masahiro Hirasa; Yasuyoshi Ibuki; Hiroshi Takakuwa; Masatoshi Kudo; Katsuhiko Fujimi; Shunji Ueda; Shusuke Tomita; Akio Todo; Yasutomo KitauraGASTROENTEROLOGICAL ENDOSCOPY 26 (5) 711 - 720 0387-1207 1984 [Refereed] Liver scintigraphy, computed tomography (CT) and ultrasonography were performed in 70 patients with acute hepatitis of acute phase, and these findings were compared with the clinical severity and laparoscopic findings in recovered stage. Cases with severe necrotic lesions of the liver on laparoscopy showed severe clinical courses, however, not vice versa. The low-uptake of the liver on scintigraphy were seen in 3 cases and was related to clinical severity and massive hepatic necrosis. The heterogenous RI distribution of the liver and splenomegaly were showen in most cases of A-type and were related to rapid clinical deterioration. Two cases with the finding of a localized low density area of the liver in CT and irregular echo pattern in sonography showed severe massive necrotic lesions on laparoscopy. Scintigraphy, computed tomography and sonography are valuable in the evaluation of acute hepatic failure in patients with acute hepatitis. © 1984, Japan Gastroenterological Endoscopy Society. All rights reserved.重症肝炎急性期の病態 画像診断の側面より小森 英司; 平佐 昌弘; 伊吹 康良; 工藤 正俊; 藤見 勝彦; 上田 俊二; 冨田 周介; 沖本 芳春; 藤堂 彰男; 北浦 保智肝臓 The Japan Society of Hepatology 24 (8) 860 - 869 0451-4203 1983 重症肝炎の画像診断とその経過観察より以下の結果を得た.肝シンチでは肝のRI集積の低下,脾,骨髄像の出現が肝不全に関連したが,急性肝不全の肝シンチ所見は様々であり,生存例の経過観察では一旦縮小した後に腫大した.慢性肝炎の劇症化例では,その半数に左葉腫大を認めた.CTにて限局性低吸収域を認めるのは亜急性肝炎であり,急性肝不全ではDIC合併例においてのみ出現し,前者の低吸収域は組織学的に広汎な壊死に相当した.これらの例では超音波検査にても不均一ないし斑状肝実質エコーパターンを呈した.重症肝炎の超音波検査にて全例に肝静脈の狭少化ないし不明瞭化を認め,生存例ではその回復が認められた.重症肝炎のCT所見での低吸収域は肝静脈周辺を中心として出現するが,肝壊死の進展に二次的肝虚血が関与していると考えられる.Clinical and Histological Study on Prognosis of Patients Survived from Acute Hepatic FailureHideshi Komori; Masatoshi Kudo; Katsuhiko Fujimi; Shusuke Tomita; Yoshihiko Endo; Okimoto Yoshiharu; Akio Todo; Yasutomo Kitaura; Hiroya UchidaNippon Shokakibyo Gakkai Zasshi 78 (12) 2384 - 2394 0446-6586 1981 [Refereed] In 4 of 6 patients survived from acute hepatic failure showed histological findings similar to chronic hepatitis. One of these 4 patients was considered to be acute hepatic failure based on chronic hepatitis. The re-rise of transminase activities was recognized on recovering stage in the remaining 3 cases. These 3 patients were supposedly developed post transfusion hepatitis following blood exchange transfusion for the treatment of acute hepatic failure. According to the survey of literature in the last five years, 44% of 76 patients survived from acute hepatic failure showed histological findings of portal inflammation and 51% of the cases revealed re-rise of serum transaminase during the long term follow up studies. When histological findings similar to chronic hepatitis are seen in the case recovering from acute hepatic failure, we must take into consideration of possibilities that acute hepatic failure based on chronic hepatitis, post transfusion hepatitis following blood exchange transfusion for the treatment of acute hepatic failure or residual histological reaction in recovering stage of acute hepatic failure. © 1981, The Japanese Society of Gastroenterology. All rights reserved.A Randomised Phase 3 Trial of Lenvatinib vs. Sorafenib in First-line Treatment of Patients With Unresectable Hepatocellular CarcinomaKudo M; Finn RS; Qin S; Han KH; Ikeda K; Piscaglia F; Baron AD; Park JW; Han G; Jassem J; Blanc JF; Vogel A; Komov D; Evans TJ; Lopez C; Dutcus C; Guo M; Saito K; Kraljevic S; Tamai T; Ren M; Cheng ALLancet in press [Refereed]Books etcアテゾリズマブ・ベバシズマブ併用療法による肝細胞癌治療小川 力; 福家和諭; 真鍋卓嗣; 柴峠光成; 工藤正俊 (ContributorWnt/βカテニン変異の症例に対するアテゾリズマブ・ベバシズマブ併用療法の使用経験)アークメディア 2021/09アテゾリズマブ・ベバシズマブ併用療法による肝細胞癌治療工藤正俊 (Contributorアテゾリズマブ・ベバシズマブ併用療法の登場による肝細胞癌治療の今後の展開)アークメディア 2021/09アテゾリズマブ・ベバシズマブ併用療法による肝細胞癌治療青木智子; 上嶋一臣; 工藤正俊 (Contributorアテゾリズマブ・ベバシズマブ併用療法のpatient reported outcomes)アークメディア 2021/09アテゾリズマブ・ベバシズマブ併用療法による肝細胞癌治療工藤正俊 (Contributor抗VEGF抗体の役割.)アークメディア 2021/09アテゾリズマブ・ベバシズマブ併用療法による肝細胞癌治療工藤正俊; 池田公史; 森口理久; 小笠原定久; 光冨徹哉; 平岡 淳 (Contributor特別座談会; アテゾリズマブ・ベバシズマブ併用療法により肝癌治療はどう変わるのか.)アークメディア 2021/09アテゾリズマブ・ベバシズマブ併用療法による肝細胞癌治療工藤正俊 (Supervisor)アークメディア 2021/09ラムシルマブによる肝細胞癌治療小川 力, 筒井朱美, 永野拓也, 高口浩一, 谷 丈二, 森下朝洋, 正木 勉, 守屋昭男, 出口章広,工藤正俊 (香川県下におけるラムシルマブの初期使用経験、pp211-215)アークメディア, 東京 2020ラムシルマブによる肝細胞癌治療上嶋一臣,工藤正俊 (肝細胞癌におけるラムシルマブの有害事象とその対策、pp124-129)アークメディア, 東京 2020ラムシルマブによる肝細胞癌治療小川 力,工藤正俊 (レンバチニブの二次治療としてラムシルマブは効果が期待できるか、pp119-123)アークメディア, 東京 2020ラムシルマブによる肝細胞癌治療工藤正俊 (TKIと抗体薬の作用機序の違いはラムシルマブ治療においてどのようなインパクトが期待できるか、pp101-110)アークメディア, 東京 2020ラムシルマブによる肝細胞癌治療工藤正俊 (AFPは予後予測因子か予後規定因子か、pp95-100, 2020)アークメディア, 東京 2020ラムシルマブによる肝細胞癌治療南 康範,工藤正俊 (日本人に対するラムシルマブの有効性と安全性, pp78-81)アークメディア, 東京 2020ラムシルマブによる肝細胞癌治療青木智子, 上嶋一臣, 工藤正俊 (REACH (AFP >400ng/mL)とREACH-2のデータの違いの解釈, pp64-70)アークメディア, 東京 2020ラムシルマブによる肝細胞癌治療工藤正俊 (Supervisor)アークメディア, 東京 2020ラムシルマブによる肝細胞癌治療工藤正俊, 室 圭, 池田公史, 森口理久, 上嶋一臣, 小笠原定久 (特別座談会; 肝細胞癌治療の新たな選択肢ラムシルマブを徹底解剖する)アークメディア, 東京 2020ラムシルマブによる肝細胞癌治療工藤正俊 (Joint work序文)アークメディア, 東京 2020大腸癌に対するレゴラフェニブ治療工藤正俊; 山口研成; 吉野孝之; 沖 英次; 室 圭 (Joint work特別座談会「レゴラフェニブの軌跡(奇跡)」)アークメディア, 東京 2019/03 pp11-29消化器疾患 最新の治療2019-2020工藤正俊 (Joint work肝細胞癌に対する分子標的治療 pp29-34)南江堂 2019/03総監修: レンバチニブによる肝細胞癌治療工藤正俊 アークメディア, 東京 2019消化器内科診療レジデントマニュアル工藤, 正俊 医学書院 2018/11 9784260035972 xvii, 461p肝細胞癌に対するレゴラフェニブ治療工藤, 正俊 アークメディア 2017/12 9784875832287 215p内科學矢崎, 義雄; 赤司, 浩一(大学教員); 渥美, 達也; 伊藤, 裕; 稲垣, 暢也; 神田, 隆; 木下, 芳一; 工藤, 正俊; 小室, 一成; 須永, 真司; 南学, 正臣; 長谷川, 好規; 松本, 哲哉; 楽木, 宏実 朝倉書店 2017/03 9784254322705 46, 2385, 36, 61pソラフェニブ・レゴラフェニブsequential療法の可能性工藤正俊 肝細胞癌に対するレゴラフェニブ治療, アークメディア, 東京 2017 100-107レゴラフェニブの第III相試験の経験症例からわかること-市販後経験例も含めて-上嶋一臣; 工藤正俊 肝細胞癌に対するレゴラフェニブ治療, アークメディア, 東京 2017 77-85特別座談会「レゴラフェニブの登場により肝細胞癌治療のパラダイムはどう変わるのか」工藤正俊; 吉野孝之; 黒崎雅之; 山下竜也; 森口理久 (序文)肝細胞癌に対するレゴラフェニブ治療, アークメディア, 東京 2017 15-40監修: 肝細胞癌に対するレゴラフェニブ治療工藤正俊 アークメディア, 東京 2017IgG4-related disease and innate immunity. In “IgG4-Related Disease”, Curr Top Microbiol Immunol, Okazaki K, edWatanabe T; Yamashita K; Kudo M (Joint workVol. 401, pp115-128)Springer 2017異所性静脈瘤の診断と内視鏡治療松井繁長; 工藤正俊 (門脈圧亢進症診療マニュアル)日本門脈圧亢進症学会編集, 南江堂, 東京 2015/11 177 87-92肝がん工藤, 正俊 最新医学社 2015/04 194p肝膿瘍・肝嚢胞工藤正俊 内科学第11版, 朝倉書店 2015 1120-1122肝腫瘍工藤正俊 内科学第11版, 朝倉書店 2015 1108-1119肝癌診療Q&A, 進行肝癌治療: Q67ソラフェニブの効果が期待できる肝細胞癌を事前に把握できますか?上嶋 一臣; 工藤 正俊 (Joint work)中外医学社 2013/10専門医のための消化器病学(第2版), 膵管非癒合井上 達夫; 工藤 正俊 (Joint work)2013/10検査診断学への展望―臨床検査指針: 測定データ判読のポイント―, 肝癌のエコー検査の進め方と判読時のポイント. 「生理検査領域」井上 達夫; 工藤 正俊 (Joint work)南江堂, 東京 2013/06 監修 第62回日本医学検査学会記念誌編集委員会, 編集 野村 努, 正田孝明, 横田浩充, 香川県臨床検査技師会編集委員会EOB-MRI/Sonazoid超音波による肝癌の診断と治療工藤, 正俊; 國分, 茂博 医学書院 2013/06 9784260017343 xxi, 338p今日の治療指針2011年版-私はこう治療している 医学書院, 東京, 原発性・転移性肝腫瘍(内科).工藤 正俊 (Joint work)2011血管新生阻害薬のベストマネジメント 癌治療と副作用対策, 肝細胞癌(hepatocellular carcinoma).上嶋 一臣; 工藤 正俊 (Joint work)金原出版, 東京 2011新時代のウイルス性肝炎学, B型肝癌根治後の再発抑制治療と有用性.萩原 智; 工藤 正俊 (Joint work)日本臨牀, 大阪 2011新時代のウイルス性肝炎学, C型肝癌根治後の再発抑制治療と有用性.上田 泰輔; 鄭 浩柄; 工藤 正俊 (Joint work)日本臨牀, 大阪 2011臨床薬理学第3版, 肝がん治療薬.工藤 正俊 (Joint work)医学書院, 東京 2011臨床薬理学第3版, 肝不全治療薬.工藤 正俊 (Joint work)医学書院, 東京 2011臨床薬理学第3版, 肝炎治療薬.工藤 正俊 (Joint work)医学書院, 東京 2011Plvs vltre ESD!さらなる挑戦 消化管ESDの課題と展望, 胃ESD後の後出血例の臨床的特徴と予防対策.朝隈 豊; 松井 繁長; 樫田 博史; 工藤 正俊 (Joint work)診断と治療社, 東京 2011ガイドライン/ガイダンス-こう診る・こう考える慢性肝炎, 肝癌診療サーベイランスアルゴリズムについて.工藤 正俊 (Joint work)日本医事新報社, 東京 2011見逃し、誤りを防ぐ!肝・胆・膵癌画像診断アトラス工藤, 正俊; 山雄, 健次 羊土社 2010/10 9784758110426 286p今日の消化器疾患治療指針幕内, 雅敏; 菅野, 健太郎; 工藤, 正俊 医学書院 2010/03 9784260007986 24, 1050p肝疾患Review 2010~2011 日本メディカルセンター, 東京, 肝細胞癌の画像診断の最新の進歩. 第1部 Overview 肝癌の診断・治療工藤 正俊 (Joint work)2010肝疾患Review 2010~2011 日本メディカルセンター, 東京, 日本の肝細胞癌診療: コンセンサスミーティングの結果をふまえた最新の話題. 第1部 Overview 肝癌の診断・治療工藤 正俊 (Joint work)2010肝疾患Review 2010~2011 日本メディカルセンター, 東京, 肝細胞癌に対する分子標的治療. 第1部 Overview 肝癌の診断・治療工藤 正俊 (Joint work)2010肝疾患Review 2010~2011 日本メディカルセンター, 東京, ソラフェニブによる進行肝癌の治療. 第2部 トピックス 肝癌の診断・治療上嶋 一臣; 工藤 正俊 (Joint work)2010見逃し、誤りを防ぐ!肝・胆・膵癌画像診断アトラス, 早期肝細胞癌.井上 達夫; 工藤 正俊 (Joint work)羊土社, 東京 2010見逃し、誤りを防ぐ!肝・胆・膵癌画像診断アトラス, 肝癌.工藤 正俊 (Single work)羊土社, 東京 2010見逃し、誤りを防ぐ!肝・胆・膵癌画像診断アトラス, 序.工藤 正俊 (Single work)羊土社, 東京 2010WHO Classification of Tumours of the Digestive System (Blue Book), Hepatocellular carcinoma.Neil D. THEISE; 工藤 正俊; Maria-Paula CURADO; Silvia FRANCESCHI; Prodromos HYTIROGLOU; Young Nyun PARK; 坂元 亨宇; Michael TORBENSON; Aileen WEE (Joint work)WHO Press World Health Organization, Geneva, Switzerland 2010肝細胞癌の分子標的治療, ソラフェニブによりCRとなった進行肝細胞癌の2症例.上嶋 一臣; 工藤 正俊 (Joint work)アークメディア, 東京 2010肝細胞癌の分子標的治療, 第1回日本肝がん分子標的治療研究会を振り返って.工藤 正俊 (Single work)アークメディア, 東京 2010肝細胞癌の分子標的治療, 肝細胞癌のシグナル伝達系と分子標的治療.工藤 正俊 (Single work)アークメディア, 東京 2010肝細胞癌の分子標的治療, ソラフェニブによる進行肝癌の治療: その有効性・副作用対策と将来展望.工藤 正俊 (Single work)アークメディア, 東京 2010肝細胞癌の分子標的治療, 特別座談会 肝細胞癌の分子標的治療.工藤 正俊; 池田 公史; 古瀬 純司; 沖田 極; 有井 滋樹 (Joint work)アークメディア, 東京 2010肝細胞癌の分子標的治療, 序説.工藤 正俊 (Single work)アークメディア, 東京 2010症例から学ぶウイルス肝炎の治療戦略, C型肝炎 肝癌治癒後にインターフェロン投与行ったが肝癌の再発が認めた症例.上田 泰輔; 鄭 浩柄; 工藤 正俊 (Joint work)診断と治療社, 東京 2010症例から学ぶウイルス肝炎の治療戦略, B型肝炎 ペグインターフェロンとエンテカビル投与によって薬剤フリーが得られているB型肝炎症例.萩原 智; 工藤 正俊 (Joint work)診断と治療社, 東京 2010症例から学ぶウイルス肝炎の治療戦略, B型肝炎 Child-Pugh Cの非代償性肝硬変で核酸アナログ投与によって肝機能が改善した症例.鄭 浩柄; 工藤 正俊 (Joint work)診断と治療社, 東京 2010症例から学ぶウイルス肝炎の治療戦略, 序文.工藤 正俊; 泉 並木 (Joint work)診断と治療社, 東京 2010肝癌診療マニュアル 第2版, 肝癌治療後のフォローアップの仕方 肝癌根治的治療後の再発の早期発見.工藤 正俊; 泉 並木 (Joint work)医学書院, 東京 2010肝癌診療マニュアル 第2版, 肝癌治療後のフォローアップの仕方 肝癌根治後の再発抑制治療.工藤 正俊 (Single work)医学書院, 東京 2010肝癌診療マニュアル 第2版, 肝癌治療のアルゴリズム 肝癌全体の治療アルゴリズム.工藤 正俊; 幕内 雅敏; 國土 典宏; 田中 正俊; 川崎 誠治; 高安 賢一; 松井 修; 泉 並木; 大崎 往夫 (Joint work)医学書院, 東京 2010肝癌診療マニュアル 第2版, 肝癌治療のアルゴリズム 肝動注化学療法と分子標的治療薬をどう使い分けるか.工藤 正俊 (Single work)医学書院, 東京 2010肝癌診療マニュアル 第2版, 肝癌治療のアルゴリズム TACE不応例に対する治療指針工藤 正俊 (Single work)医学書院, 東京 2010肝癌診療マニュアル 第2版, 肝癌の治療 肝癌治療の実際 全身化学療法と分子標的治療工藤 正俊 (Single work)医学書院, 東京 2010肝癌診療マニュアル 第2版, 肝癌の治療 肝癌治療の実際 内科的局所治療 ラジオ波焼灼療法 RFAの適応と除外基準 造影超音波下RFA.南 康範; 工藤 正俊 (Joint work)医学書院, 東京 2010肝癌診療マニュアル 第2版, 肝癌の治療 肝癌診療のためのステージングシステム.工藤 正俊 (Single work)医学書院, 東京 2010肝癌診療マニュアル 第2版, 肝癌の診断 肝癌診断のアルゴリズム 乏血性肝細胞性結節(境界病変, 異型結節, 早期肝癌)はどのような場合に治療すべきか工藤 正俊; 泉 並木; 松井 修 (Joint work)医学書院, 東京 2010肝癌診療マニュアル 第2版, 肝癌の診断 肝癌診断のアルゴリズム 多血性肝細胞癌の診断アルゴリズム.泉 並木; 工藤 正俊; 松井 修 (Joint work)医学書院, 東京 2010肝癌診療マニュアル 第2版, 肝癌の診断 画像診断 早期肝癌の画像的特徴.松井 修; 工藤 正俊; 高安 賢一; 神代 正道 (Joint work)医学書院, 東京 2010肝癌診療マニュアル 第2版, 肝癌の診断 画像診断 どのようなときに造影超音波を行うか.工藤 正俊 (Single work)医学書院, 東京 2010肝癌診療マニュアル 第2版, 肝癌の診断 画像診断 どのようなときにGd-EOB-MRIを行うか.工藤 正俊; 井上 達夫; 村上 卓道 (Joint work)医学書院, 東京 2010肝癌診療マニュアル 第2版, 肝癌早期発見のためのスクリーニング法.建石 良介; 工藤 正俊; 泉 並木; 金子 周一 (Joint work)医学書院, 東京 2010肝疾患Review, 非侵襲的肝線維化測定法-Real-time Tissue ElastographyとFibroscanはどちらが優るか.辰巳 千栄; 工藤 正俊; 上嶋 一臣 (Joint work)日本メディカルセンター, 東京 2010今日の消化器疾患治療指針 第3版, 膵癌の診断と治療方針・疼痛対策.北野 雅之; 工藤 正俊 (Joint work)医学書院, 東京 2010今日の診断指針 第6版, 肝悪性腫瘍.工藤 正俊 (Joint work)医学書院, 東京 2010今日の消化器疾患治療指針 第3版, 科学的根拠に基づく肝癌診療ガイドライン.南 康範; 工藤 正俊 (Joint work)医学書院, 東京 2010今日の消化器疾患治療指針 第3版, 腫瘤形成性膵炎.坂本 洋城; 工藤 正俊 (Joint work)医学書院, 東京 2010今日の消化器疾患治療指針 第3版, 肝結核.井上 達夫; 工藤 正俊 (Joint work)医学書院, 東京 2010今日の消化器疾患治療指針 第3版, 肝細胞癌の治療方針.上嶋 一臣; 工藤 正俊 (Joint work)医学書院, 東京 2010今日の消化器疾患治療指針 第3版, 肝細胞癌のスクリーニングと診断.井上 達夫; 工藤 正俊 (Joint work)医学書院, 東京 2010今日の消化器疾患治療指針 第3版, 造影エコー検査.畑中 絹世; 工藤 正俊 (Joint work)医学書院, 東京 2010今日の消化器疾患治療指針 第3版, 緊急内視鏡.松井 繁長; 工藤 正俊 (Joint work)医学書院, 東京 2010今日の消化器疾患治療指針 第3版, 大腸内視鏡検査.梅原 泰; 工藤 正俊 (Joint work)医学書院, 東京 2010講義録 腫瘍学 メジカルビュー社, 東京, 画像検査.南 康範; 工藤 正俊 (Joint work)2009肝細胞癌治療における局所再発の抑制とsafety/surgical marginの必要性-画像による解析-, 肝細胞癌治療における局所再発の抑制とsafety marginの必要性.工藤 正俊 (Joint work)メディカルトリビューン, 東京 2009内科「肝癌撲滅最前線」, 造影剤エコーによる肝癌診療最前線.畑中 絹世; 工藤 正俊 (Joint work)南江堂, 東京 2009消化器研修ノート, 腹部超音波(エコー)検査.上嶋 一臣; 工藤 正俊 (Joint work)診断と治療社, 東京 2009消化器病学の進歩-原点から未来への情報発信-, 造影ハーモニックEUSによる胆膵疾患の診断.北野 雅之; 坂本 洋城; 工藤 正俊 (Joint work)医学書院 2009胆膵内視鏡診療の実際ー標準的検査法と手技のコツー, 造影EUSによる膵疾患診断.北野 雅之; 坂本 洋城; 工藤 正俊 (Joint work)日本メディカルセンター, 東京 2009肝臓病診療: こんなときどうするQ&A, 肝臓病診断における造影超音波の有用性はどこまでわかっているのか?畑中 絹世; 工藤 正俊 (Joint work)中外医学社, 東京 2009肝臓病診療: こんなときどうするQ&A, 肝癌診療のためのステージングシステムはどうなっているのか?鄭 浩柄; 工藤 正俊 (Joint work)中外医学社, 東京 2009新臨床内科学 第9版, 医学書院, 肝癌.工藤 正俊 (Joint work)2009肝疾患Review 2008~2009, 乏血性結節の診断・治療アルゴリズム.今井 康陽; 工藤 正俊 (Joint work)日本メディカルセンター, 東京 2008ハイパーサーミアがん温熱療法ガイドブック, 肝臓がん(ラジオ波焼灼療法)-原発性肝がんに対するラジオ波焼灼療法-.鄭 浩柄; 井上 達夫; 工藤 正俊 (Joint work)神陵文庫, 兵庫 2008肝疾患Review 2008~2009, 日米欧の肝癌へのアプローチの違い.工藤 正俊 (Joint work)日本メディカルセンター, 東京 2008肝疾患Review 2008~2009, 肝癌治療アルゴリズムをめぐる話題ーEvidence-basedとConsensus (Experience)- basedの溝をどう埋めるか.工藤 正俊 (Joint work)日本メディカルセンター, 東京 2008肝疾患Review 2008~2009 日本メディカルセンター, 東京, 肝癌根治後の再発抑制治療ーOverview.工藤 正俊 (Joint work)2008肝疾患Review 2008~2009, ソナゾイドは肝癌診療をどう変えるか?工藤 正俊 (Joint work)日本メディカルセンター, 東京 2008動画で学ぶ 肝癌ラジオ波凝固療法の実践テクニック, 造影超音波下RFA.南 康範; 畑中 絹世; 工藤 正俊 (Joint work)中山書店, 東京 2008動画で学ぶ 肝癌ラジオ波凝固療法の実践テクニック, 治療アルゴリズムにおけるRFAの位置と今後の展望.工藤 正俊 (Joint work)中山書店, 東京 2008“Textbook of Practical Ultrasound.” Ahuja B ed, USCON Academic Press, New Delhi, India, 2008, Pancreatic Ultrasound with esmphasis on EUS工藤 正俊 (Single work)2008“Textbook of Practical Ultrasound.“ Ahuja B ed, USCON Academic Press, New Delhi, India, 2008, Ultrasonography of diffuse liver diseases工藤 正俊 (Single work)2008これだけは知っておきたい外科Q&A-研修医からの質問528., 超音波の適応と読み方.南 康範; 福永 豊和; 工藤 正俊 (Joint work)2007肝癌診療マニュアル, 肝癌根治後の再発抑制治療.工藤 正俊 (Single work)日本肝臓学会編集, 医学書院 2007肝癌診療マニュアル, 肝癌全体の治療アルゴリズム.工藤 正俊; 幕内 雅敏; 國土 典宏; 田中 正俊; 川崎 誠治; 高安 賢一; 松井 修; 泉 並木; 大崎 往夫 (Joint work)日本肝臓学会編集, 医学書院 2007肝癌診療マニュアル, 造影エコー下RFA.南 康範; 鄭 浩柄; 工藤 正俊 (Joint work)日本肝臓学会編集, 医学書院 2007肝癌診療マニュアル, 肝癌診療のためのステージングシステム.工藤 正俊 (Single work)日本肝臓学会編集, 医学書院 2007肝癌診療マニュアル, 乏血性肝細胞性結節(境界病変, 過形成結節, 早期肝癌)はどのような場合に治療すべきか.工藤 正俊; 泉 並木 (Joint work)日本肝臓学会編集, 医学書院 2007肝癌診療マニュアル, 多血性肝細胞癌の診断アルゴリズム.泉 並木; 工藤 正俊; 松井 修 (Joint work)日本肝臓学会編集, 医学書院 2007肝癌診療マニュアル, どのようなときに造影エコーを行うか.工藤 正俊 (Single work)日本肝臓学会編集, 医学書院 2007ガイドライン外来診療2006, 外来ガイドライン診療―診断、管理・治療―「肝癌」工藤 正俊 (Joint work)日経メディカル 2006/03消化器疾患の診断基準病型分類重症度の用い方 編集 棟方昭博, 小池和彦, 田尻久雄, 肝細胞癌の病型分類(肝癌取扱い規約)と予後予測(JISスコア).工藤 正俊 (Joint work)日本メディカルセンター, 東京 2006肝疾患診療マニュアル(日本医師会雑誌特別号), 肝シンチグラムのポイント工藤 正俊 (Joint work)2006肝細胞癌治療の最近の進歩工藤, 正俊 へるす出版 2004/12 4892694886 179p肝疾患Review 2004. 監修 小俣政男, 編集 河田純男, 白鳥康史, 工藤正俊, 榎本信幸, (3)肝癌の診断・治療の進歩 (2)造影ハーモニック法による肝癌の診断と治療南 康範; 工藤 正俊; 川崎 俊彦 (Joint work)日本メディカルセンター, 東京 2004肝疾患Review 2004. 監修 小俣政男, 編集 河田純男, 白鳥康史, 工藤正俊, 榎本信幸, (4)肝癌の治療の進歩ー治療法の現状・進歩からStaging systemまでー工藤 正俊 (Joint work)日本メディカルセンター, 東京 2004肝疾患Review 2004. 監修 小俣政男, 編集 河田純男, 白鳥康史, 工藤正俊, 榎本信幸, (3) 肝癌の診断の進歩ー肝癌の画像診断・腫瘍マーカー・造影剤の進歩ー工藤 正俊 (Joint work)日本メディカルセンター, 東京 2004消化器病診療-良きインフォームドコンセントに向けて- 財団法人日本消化器病学会 監修, 検査手技「腹部超音波検査」井上 達夫; 工藤 正俊 (Joint work)医学書院, 東京 2004Postgraqduate Course & Current Reviews in HEPATOLOGY. Clinico-patho-radiological Correlation., Newer imaging modality of hepatocellular carcinoma: role of contrast-enhanced coded phase inversion harmonics工藤 正俊 (Joint work)CBS Publishers & Distributors, New Dehli, India 2004消化器疾患の造影エコーup date松井, 修; 工藤, 正俊 南江堂 2003/05 4524235949 xiii, 216p消化器内視鏡臨床手技シリーズ5. 超音波内視鏡up date. 村田洋子, 峯 徹哉, 編集, 膵「炎症と癌の鑑別におけるパワードプラの有用性」北野 雅之; 工藤 正俊 (Joint work)メディカルビュー社, 東京 2003消化器疾患の造影エコー法up date. 松井 修, 工藤正俊, 編集, 人工胸水下造影エコー併用RFAの有用性南 康範; 工藤 正俊; 川崎 俊彦 (Joint work)南江堂, 東京 2003消化器疾患の造影エコー法up date. 松井 修, 工藤正俊, 編集, GIMTの造影エコー検査:体表式造影ハーモニックイメージングおよび超音波内視鏡下造影エコーの意義福田 信宏; 工藤 正俊; 北野 雅之 (Joint work)南江堂, 東京 2003消化器疾患の造影エコー法up date. 松井 修, 工藤正俊, 編集, 造影エコー法の現状と今後の展望工藤 正俊 (Joint work)南江堂, 東京 2003超音波造影ガイドブック-すぐに役立つ基礎から臨床まで-, 森安史典, 別府慎太郎, 久 直史, 編, 超音波造影の装置ならびに映像条件(腹部)工藤 正俊 (Joint work)金原出版, 東京 2003内科学, 杉本恒明, 小俣政男, 水野美邦, 編, 肝膿瘍・肝嚢胞工藤 正俊 (Joint work)朝倉書店, 東京 2003Annual Review 消化器, 肝の画像診断工藤 正俊 (Joint work)中外医学社, 東京 2003超音波造影ガイドブック-わかりやすい基礎知識と臨床応用-, 森安史典, 別府慎太郎, 久 直史, 編, 超音波造影の装置ならびに映像条件(腹部)工藤 正俊 (Joint work)金原出版, 東京 2003Contrast harmonic imaging in the diagnosis and treatment of hepatic tumors工藤 正俊 (Joint work)Springer Verlag, Tokyo 2003Contrast harmonic imaging in the diagnosis and treatment of hepatic tumors工藤 正俊 (Single work)Springer Verlag, Tokyo 2003Contrast harmonic imaging in the diagnosis and treatment of hepatic tumors工藤 正俊 (Single work)Springer Verlag 2003Gastroenterology Navigator, 滝川 一編集, MRIとその応用臼杵則朗; 工藤 正俊 (Joint work)メディカルレビュー社 2002肝臓フォーラム'02記録集, 肝画像診断の進歩工藤 正俊 (Joint work)医事出版社, 東京 2002犬山シンポジウム記録集, B型肝炎急性増悪に対するラミブジンの効果工藤 正俊; 鄭 浩柄; 大崎 往夫 (Joint work)アークメディア, 東京 2002今日の診断指針・第5版, 亀山正邦, 高久史磨, 編集, 腹部の超音波診断工藤 正俊 (Joint work)医学書院, 東京 2002第22回犬山シンポジウム(第II部)記録集, 肝細胞癌の課題: 画像診断の立場から工藤 正俊 (Joint work)アークメディア, 東京 2002「肝疾患診療のコツと落とし穴」, 井廻道夫編, 造影エコー法の肝癌治療への応用工藤 正俊 (Joint work)中山書店 2002「肝疾患診療のコツと落とし穴」, 井廻道夫編, 造影ハーモニックイメージングのコツとpitfall工藤 正俊 (Joint work)中山書店 2002図説消化器病シリーズ3「肝・胆・膵の画像診断」, 肝・胆・膵疾患の超音波診断工藤 正俊 (Joint work)メディカルレビュー社, 東京 2002肝腫瘍の造影ハーモニックイメージング工藤, 正俊 (Single work)医学書院 2001/05 4260138790 xiv,208p特別シンポジウム記録集, 大阪肝穿刺生検治療研究会編, RTCシステムによる肝細胞癌に対する熱凝固療法.肝癌に対するラジオ波熱凝固療法(RFA).工藤 正俊; 遠田弘一; 南 康範; 鄭 浩柄; 末冨 洋一郎; 川崎 俊彦; 前川 清 (Joint work)大阪 2001放射線利用技術データベース「要素データ(医学)」, 造影剤による超音波検査法工藤 正俊 (Joint work)(財)放射線利用振興協会, 科学技術庁, 編 2001看護のための最新医学講座, 検査の目的と検査結果の読み方ー「肝胆膵疾患」画像診断(超音波検査)山本健二; 工藤 正俊 (Joint work)中山書店 2001看護のための最新医学講座, 検査の目的と検査結果の読み方ー「肝胆膵疾患」画像診断(単純X線)山本健二; 工藤 正俊 (Joint work)中山書店 2001消化器病セミナー82, コントラストエコーを用いた癌診断(特集「肝細胞癌治療法の新たな展開」)工藤 正俊 (Joint work)へるす出版 2001「ミレニアム消化器2000」, 多施設共同研究からみた肝硬変の画像診断の限界と役割工藤 正俊; 福永 豊和; 川崎 俊彦; 山本健二; 岡部純弘; 井谷智尚; 大崎征夫; 飯島尋子; 加地 到; 春日井博志; 兼松雅之; 伊東克能; 臼杵則朗; 島松一秀; 鹿毛政義; 神代正道 (Joint work)日本メディカルセンター 2001カラードプラによる肝腫瘍の流出血流動態の描出. 「巨視的レベルよりみた肝微小循環動態と腫瘍血流の流出動態.」工藤 正俊 (Joint work)メディカルトリビューン 2000プラクティカル内科シリーズNo.9「肝硬変・肝細胞癌」, 肝細胞癌の超音波診断工藤 正俊 (Joint work)2000肝癌に関する最近の話題. 「門脈血流を有する高分化型肝癌の治療 ー治療は必要でないとする立場よりー」工藤 正俊; 福永 豊和; 杤尾人司 (Joint work)日本アクセルシュプリンガー出版 2000カラードプラによる肝腫瘍の流出血流動態の描出. 「巨視的レベルよりみた肝微小循環動態と腫瘍血流の流出動態.」工藤 正俊 (Joint work)メディカルトリビューン 2000プラクティカル内科シリーズNo.9「肝硬変・肝細胞癌」, 肝細胞癌の超音波診断工藤 正俊 (Joint work)南江堂 2000血流動態からみた肝癌の肉眼型(辺縁と内部構造)と組織の推定は可能か?: US, US angio, カラードプラ福永 豊和; 工藤 正俊 (Joint work)日本アクセルシュプリンガー出版 2000肝硬変の血流動態: 超音波(US-angio、カラードプラ、パワードプラ、3次元画像)工藤 正俊 (Joint work)日本アクセルシュプリンガー出版 2000急性腹症. 新超音波医学「(2)消化器」工藤 正俊 (Joint work)医学書院 2000図説消化器病シリーズ「肝腫瘍」, 造影エコー法: 動注および静注法工藤 正俊 (Joint work)メデイカルビュー 2000In Dynamic Study of Efferent Tumor Blood Fow, Itai Y, Miura Y, eds, Color Doppler observation of efferent blood flow in liver tumors工藤 正俊; 杤尾人司 (Joint work)BRACCO, Italy 2000"Hepatology in the 21st Century: Diagnosis and Therapy." Tanikawa K, Kojiro M, Gollan J, eds, Advances in diagnostic imaging of hepatocellular carcinoma工藤 正俊 (Joint work)IASL, APASL, and JSH JOINT POST GRADUATE TEXTBOOK, IASL Publ, Fukuoka 2000肝疾患診療マニュアル(日本医師会雑誌特別号), 血管造影のポイント工藤 正俊 (Joint work)1999肝疾患診療マニュアル(日本医師会雑誌特別号), MRI診断のポイント工藤 正俊 (Joint work)1999肝疾患診療マニュアル(日本医師会雑誌特別号), アンギオCT診断のポイント工藤 正俊 (Joint work)1999肝疾患診療マニュアル(日本医師会雑誌特別号), CT診断のポイント工藤 正俊 (Joint work)1999肝疾患診療マニュアル(日本医師会雑誌特別号), エコー診断のポイント工藤 正俊 (Joint work)1999肝疾患診療マニュアル(日本医師会雑誌特別号), 画像診断の読み方とチェックポイント工藤 正俊 (Joint work)1999診断と治療社, 肝内胆管癌の画像診断ーUSー, 肝胆膵フロンティア・胆管細胞癌岡部 純弘; 工藤 正俊 (Joint work)19991. 肝細胞癌の流出静脈は門脈か肝静脈か?板井悠二, 工藤正俊, 監修, その両方とする立場よりーカラードプラ所見を中心にー肝癌に関する最近の話題工藤 正俊; 杤尾人司 (Joint work)1999わかりやすい内科学 井村裕夫 編, 腹部腫瘤工藤 正俊 (Joint work)文光堂, 東京 1999わかりやすい内科学 井村裕夫 編, 腹部膨満工藤 正俊 (Joint work)文光堂, 東京 1999今日の治療指針1999年版, 多賀須幸男, 尾形悦郎, 編, 原発性・転移性肝癌(内科)工藤 正俊 (Joint work)医学書院, 東京 1999各施設での治療選択の実際,肝癌の Bed side ノ-ト, 小俣政男 監修, 肝細胞癌の治療法─どのよう治療法を選択するか福永 豊和; 工藤 正俊 (Joint work)現代医療社, 東京 1999"Abdominal and Gastrointestinal Imaging Multimedia Virtual Textbook", Gourtsoyiannis NE, Yamada R, I, Liver Radiological Examination- Ultrasonography (including Biopsy)工藤 正俊 (Joint work)Medic-Online, Euromultimedia S.A., Luxembourg 1999消化器疾患最新の治療 1999-2000, 戸田剛太郎, 杉町圭蔵, 中村孝司 編, 肝細胞癌の超音波診断-最近の進歩工藤 正俊 (Joint work)南江堂, 東京 1998肝癌診断の最新動向. 小俣政男編, 超音波診断の現状とその展望工藤 正俊 (Joint work)協和企画通信 1998臨床放射線増刊号. 宮本幸夫, 多田信平 編, CO2 アンジオグラフイ- -スクリ-ニングから精査の時代へ-超音波診断 update工藤 正俊 (Joint work)金原出版, 東京 1998「血流動態よりみた肝細胞癌の基礎と臨床」 監修: 板井悠二, カラードプラよりみた流出静脈工藤 正俊; 福永 豊和; 杤尾人司; 冨田周介; 岡部純弘; 岩崎信広; 中村仁美; 曽我登志子; 田村周二; 森本義人; 樫田博史; 渡辺智裕; 平佐昌弘; 伊吹康良; 織野彬雄; 藤堂彰男 (Joint work)日本アクセル・シュプリンガー出版, 東京 1998癌治療Q&A-肝癌-,田口鐵男 監修,今岡真義 編, CO2注入超音波検査による診断とは?工藤 正俊 (Joint work)医薬ジャ-ナル, 大阪 1998「肝癌ー診断と治療ー」, 沖田 極, 市田隆文編, 増感剤を用いた静注US工藤 正俊 (Joint work)日本メデイカルセンター 1997腹部疾患の画像診断, 中村仁信, 松井 修, 高安賢一 編, 肝腫瘍性病変―超音波診断工藤 正俊 (Joint work)最新医学社 1997消化器病 UP TO DATE-Consensus & Controversies, 小林絢三 編, 肝癌の早期診断と治療: 血流動態からみた肝癌の脱分化と進展工藤 正俊 (Joint work)永井書店, 大阪 1997"Diagnosis and Treatment of Hepatocellular Carcinoma", Livraghi T, Makuuchi M, Buscarini, eds, Scintigraphy工藤 正俊 (Joint work)Greenwich Medical Media Limited, London, UK 1997Liver Cancer, Okuda K and Tabor E, eds, Ultrasound Diagnosis工藤 正俊 (Joint work)Churchill Livingstone, London 19972.5 “Gastrointestinal Malignancies”; 2.5.3 Hepatocellular carcinoma. In “ESMO Handbook of Immuno-Oncology”, Haanen J, Lugowska I, Garassino MC, Califano R, ed., 2018, pp191-202.Harding JJ; Watanabe T; El-Dika I; Nishida N; Abou-Alfa GK; Kudo M Conference Activities & Talks特別講演「肝細胞癌の薬物治療における最新トピックス~免疫複合療法とTACEによる新たな治療戦略を考える~」  [Invited]工藤正俊ABC TACEセミナー  2024/03  中外製薬株式会社大崎オフィス, 東京免疫療法時代におけるレンバチニブの位置付け-LEN-TACE療法のポテンシャルを考える-  [Invited]工藤正俊LEN-TACE Academy in 栃木  2024/03  ライトキューブ宇都宮, 栃木特別講演「免疫療法時代におけるレンバチニブの位置付け―LEN-TACE療法のポテンシャルを考える―」  [Invited]工藤正俊第10回東北のHCC治療を考える会  2024/03特別講演「肝細胞癌の薬物治療における最新トピックス~免疫複合療法とTACEによる新たな治療戦略を考える~」  [Invited]工藤正俊Hepatocellular Carcinoma Expert Meeting in埼玉東部  2024/03Atezolizumab plus Bevacisumab versus lenvatinib for BCLC-B stage patients with hepatocellular carcinoma : a large real life worldwide populationVitiello F; Rimini M; Persano M; Tada T; Shimose S; Kudo M; Cheon J; Finkelmeier F; Lim HY; Masi G; Yoo C; Leonardi S; Rossari F; Amadeo E; Suda G; Gardini ACEASL Liver Cancer Summit 2024  2024/02  Rotterdam, Netherlandsα-FAtE: a new predictive score of response to atezolizumab plus evacizumab for unresectable hepatocellular carcinoma incorporating α-Fetoprotein, Alkaline phosphatase and Eosinophil countRossari F; Tada T; Shimose S; Kudo M; Yoo C; Cheon J; Finkelmeier F; Lim HY; Presa J; Masi G; Bergamo F; Amadeo E; Vitiello F; Persano M; Foti S; Piscaglia F; Scartozzi M; Cascinu S; Rimini M; Giardini ACEASL Liver Cancer Summit 2024  2024/02  Rotterdam, NetherlandsThe prognostic impact of viral and non-viral etiologies on advanced hepatocellular carcinoma patients treated with atezolizumab plus bevacizumab: a real-world, multicenter studyRossari F; Tada T; Shimose S; Kudo M; Yoo C; Cheon J; Finkelmeier F; Lim HY; Presa J; Masi G; Bergamo F; Amadeo E; Vitiello F; Persano M; Foti S; Stefanini B; Scartozzi M; Cascinu S; Rimini M; Giardini ACEASL Liver Cancer Summit 2024  2024/02  Rotterdam, NetherlandsLenvatinib (L) versus sorafenib (S) second-line therapy in hepatocellular carcinoma (HCC) patients progressed to atezolizumab plus bevacizumab (AB)Persano M; Rimini M; Tada T; Suda G; Shimose S; Kudo M; Yoo C; Cheon J; Finkelmeier F; Lim HY; Presa J; Masi G; Bergamo F; Iavarone M; Cabibbo G; Foschi FG; Piscaglia F; Foti S; Camera S; Cornara N; Vitiello F; Amadeo E; Rossari F; Cascinu S; Scartozzi M; Gardini ACEASL Liver Cancer Summit 2024  2024/02  Rotterdam, NetherlandsAdverse events (AEs) as potential predictive factors of activity in patients with advanced hepatocellular carcinoma (HCC) treated with atezolizumab plus bevacizumab (AB)Persano M; Rimini M; Tada T; Suda G; Shigeo S; Kudo M; Yoo C; Cheon J; Finkelmeier F; Lim HY; Presa J; Masi G; Bergamo F; Iavarone M; Cabibbo G; Foschi FG; Piscaglia F; Foti S; Camera S; Cornara N; Vitiello F; Amadeo E; Rossari F; Cascinu S; Scartozzi M; Gardini ACEASL Liver Cancer Summit 2024  2024/02  Rotterdam, NetherlandsIdentification of factors associated with primary refractoriness to atezolizumab plus bevacizumab in patients with advanced hepatocellular carcinomaManfredi GF; Fulgenzi C; D'Alessio A; Celsa C; Stefanini B; Cheon J; Ang C; Marron TU; Saeed A; Wietharn B; Pressiani T; Pinter M; Scheiner B; Huang YH; Phen S; Naqash AR; Piscaglia F; Lin PO; Lin CY; Dalbeni A; Vivaldi C; Masi G; Thimme R; Vogel A; Schoenlein M; von Felden J; Schulze K; Wege H; Galle P; Kudo M; Rimassa L; Singal A; Sharma R; Cortellini A; Chon HJ; Burlone M; Pirisi M; Pinato DJEASL Liver Cancer Summit 2024  2024/02  Rotterdam, NetherlandsImpact of body mass index on the prognosis of unresectable HCC patients receiving first line Lenvatinib or Atezolizumab plus BevacizumabCornara N; Stefanini B; Rimini M; Tada T; Suda G; Shimose S; Kudo M; Finkelmeier F; Yoo C; Presa J; Amadeo E; Iavarone M; Marra F; Foschio F; Tamburini E; Rossari F; Vitiello F; Lonardi S; Siletta M; Persano M; Camera S; Cascinu S; Casadei-Gardini A; Piscaglia FEASL Liver Cancer Summit 2024  2024/02  Rotterdam, NetherlandsCharacteristics and outcomes of immunotherapy-related liver injury in patients with hepatocellular carcinoma compared to patients with advanced solid tumoursCelsa C; Cabibbo G; Fulgenzi C; Scheiner B; D'Alessio A; Manfredi G; Marron TU; Saeed A; Pinter M; Huang YH; Pillai A; Schoenlein M; von Felden J; Galle P; Kudo M; Rimassa L; Singal A; Chon HJ; Hsu WF; Stefanini B; Vogel A; Brunetti L; Pinto C; Bersanelli M; Camma C; Cortellini A; Pinato DJEASL Liver Cancer Summit 2024  2024/02  Rotterdam, NetherlandsSafety and efficacy of lenvatinib in very elderly patients with unresectable hepatocellular carcinomaCamera S; Rimini M; Rossari F; Tada T; Suda G; Shimose S; Kudo M; Yoo C; Cheon J; Finkelmeier F; Lim HY; Presa J; Masi G; Bergamo F; Salani F; Marseglia M; Amadeo E; Vitiello F; Kumada T; Sakamoto N; Iwamoto H; Aoki T; Chon HJ; Himmelsbach V; Iavarone M; Cabibbo G; Montes M; Foschi FG; Vivaldi C; Lonardi S; Sho T; Niizeki T; Nishida N; Steup C; Hirooka M; Kariyama K; Tani J; Atsukawa M; Takaguchi K; Itobayashi E; Fukunishi S; Tsuji K; Ishikawa T; Tajiri K; Ochi H; Yasuda S; Toyoda H; Ogawa C; Nishimura T; Hatanaka T; Kakizaki S; Shimada N; Kawata K; Hiraoka A; Tada F; Ohama H; Nouso K; Morishita A; Tsutsui A; Nagano T; Itokawa N; Okubo T; Imai M; Kosaka H; Naganuma A; Koizumi Y; Nakamura S; Kaibori M; Iijima H; Hiasa Y; Persano M; Foti S; Piscaglia F; Scartozzi M; Cascinu S; Gardini ACEASL Liver Cancer Summit 2024  2024/02  Rotterdam, NetherlandsImpact of metformin, statin, aspirin and insulin on the prognosis of unresectable HCC patients receiving first line Lenvatinib or Atezolizumab plus BevacizumabAmadeo E; Rossari F; Rimini M; Vitiello F; Foti MMS; Kudo M; Tada T; Suda G; Shimose S; Leonardi S; Salani F; Finkelmeier F; Antouzzo L; Marra F; Lavorane M; Cabibbo G; Foschio F; Scartozzi M; Camera S; Persano M; Kumada T; Iwamoto H; Hiraoka A; Scartozzi M; Aldrighetti L; Cascinu S; Gardini AC; Presa JEASL Liver Cancer Summit 2024  2024/02  Rotterdam, NetherlandsmRECIST outcomes in EMERALD-1: a Phase 3, randomized, placebo-controlled study of transarterial chemoembolization plus durvalumab with/without bevacizumab in participants with embolization-eligible hepatocellular carcinomaSangro B; Kudo M; Erinjeri J; Qin SD; Ren Z; Chan S; Arai Y; Heo J; Mai A; Escobar J; Chuken YAL; Yoon JH; Tak WY; Suttichaimongkol T; Bouattour M; Lin SM; Żotkiewicz M; Ali S; Cohen G; Lencioni REASL Liver Cancer Summit 2024  2024/02  Rotterdam, NetherlandsKeynote Lecture “Achievement of curative conversion with combination/sequential therapy of resection/locoregional therapy and immunotherapy in TACE unsuitable intermediate-stage HCC”  [Invited]Masatoshi KudoEcological System of Gastgrointestinal & Hepatobiliary Cancer Treatment Forum  2024/02  Shanghai Marriott Hotel, China工藤正俊  [Invited]特別講演; Intermediate Stage肝細胞癌の治療戦略-ABC conversion therapy-」第27回日本肝がん分子標的治療研究会  2024/01  大阪国際会議場, 大阪特別講演「STRIDEレジメンを含めた当院での進行肝細胞癌の診断と治療」  [Invited]工藤正俊中四国IO Expert Seminar  2023/12  JRホテルクラメント高松, 香川特別講演「複合免疫療法時代における最適な治療戦略を考える」  [Invited]工藤正俊北信医療圏における肝がん薬物療法を考える会  2023/12  シャトレーゼホテル長野, 長野特別講演「複合免疫療法時代における最適な治療戦略を考える」  [Invited]工藤正俊Hepatocellular Carcinoma Expert Meeting  2023/12  グランドハイアット福岡, 福岡特別講演「複合免疫療法時代における最適な治療戦略を考える」  [Invited]工藤正俊Meet the Expert on Hepatocellular Carcinoma  2023/12  野村コンファレンスプラザ新宿, 東京特別講演「複合免疫療法時代における最適な治療戦略を考える」  [Invited]工藤正俊Hepatocellular Carcinoma Seminar in OKAYAMA  2023/12  岡山コンベンションセンター, 岡山座長; 特別講演「最新の肝癌治療と合併症対策について」  [Invited]工藤正俊肝癌治療と合併症を考える会  2023/12  フェニーチェ堺, 大阪特別講演「複合免疫療法時代における最適な治療戦略を考える」  [Invited]工藤正俊Gunma HCC Expert Meeting  2023/12  群馬ロイヤルホテル, 群馬切除不能HCCに対するABC conversion療法とclinical CRの現状. ワークショップ「肝がん局所治療の多様性とその到達点」青木智子; 西田直生志; 工藤正俊第45回日本肝臓学会西部会  2023/12  国立京都国際会館, 京都Invited Lecture “Optimized Management in Intermediate-stage HCC”  [Invited]Masatoshi KudoAPDW 2023  2023/12  Bangkok特別講演「Cancer free with drug freeを目指すためのABC」  [Invited]工藤正俊肝細胞癌の集学的治療  2023/12  FUKUI SENKYO bldg, 福井SIERRA: A Phase 3b, single-arm, multicentre study of tremelimumab plus durvalumab for first-line treatment of advanced unresectable hepatocellular carcinomaChan SL; Sangro B; Kudo M; Dane A; Emery C; Paskow MJ; Makowsky M; Nguyen B; Rimassa LESMO-Asia 2023  2023/12  SingaporeIMPACT: Randomized, multicenter, phase III study evaluating the efficacy of immunotherapy (atezolizumab) plus anti-VEGF therapy (bevacizumab) in combination with transcatheter arterial chemoembolization for unresectable hepatocellular carcinoma (HCC)Yamashita T; Inaba Y; Ikeda M; Sone M; Yamakado K; Nioshiofuku H; Tsuchiya K; Tada T; Sato Y; Kodama T; Kuzuya T; Ogasawara S; Ueno M; Iwamoto H; Moriguchi M; Ueshima K; Kodama Y; Takehara T; Hamano T; Kudo MESMO-Asia 2023  2023/12  SingaporeEffectiveness of lenvatinib in patients with unresectable hepatocellular carcinoma: A multicenter observational study in JapanIzumi N; Kudo M; Motomura K; Inaba Y; Katamura Y; Kondo Y; Yabushita K; Motoyoshi K; Furuse JESMO-Asia 2023  2023/12  SingaporeImpact of metformin, statin, aspirin and insulin on the prognosis of unresectable HCC patients receiving first-line lenvatinib or atezolizumab plus bevacizumabRimini M; Amadeo E; Vitiello F; Foti S; Persano M; Tada T; Suda G; Shimose S; Kudo M; Cheon J; Finkelmeier F; Lim HY; Piscaglia F; Masi G; Yoo C; Lonardi S; Rassari F; Camera S; Casadei-Gardini A; Presa JESMO-Asia 2023  2023/12  SingaporeDisease etiology impact on outcomes of hepatocellular carcinoma patients treated with atezolizumab plus bevacizumab: A real-world, multicenter studyRossari F; Tada T; Shimose S; Kudo M; Yoo C; Cheon J; Finkelmeier F; Lim HY; Presa J; Masi G; Bergamo F; Amadeo E; Vitiello F; Foti S; Persano M; Piscaglia F; Scartozzi M; Cascinu S; Rimini M; Casadei-Gardini AESMO-Asia 2023  2023/12  SingaporeLenvatinib (L) versus sorafenib (S) second-line therapy in hepatocellular carcinoma (HCC) patients progressed to atezolizumab plus bevacizumab (AB)Persano M; Rimini M; Tada T; Suda G; Shimose S; Kudo M; Yoo C; Cheon J; Finkelmeier F; Lim HY; Presa J; Masi G; Bergamo F; Iavarone M; Cabibbo G; Foschi FG; Piscaglia F; Cascinu S; Scartozzi M; Casadei-Gardini AESMO-Asia 2023  2023/12  SingaporeRetrospective study of the correlation between proteinuria and renal function in patients (pts) with unresectable hepatocellular carcinoma (uHCC) treated with atezolizumab plus bevacizumab (Atezo+Bev): ARISE studyUeshima K; Nishida N; Hagiwara S; Minami Y; Ida H; Takita M; Chishina M; Morita M; Aoki T; Kudo MESMO-Asia 2023  2023/12  SingaporeAtezolizumab plus bevacizumab (A+B) versus lenvatinib for BCLC-B stage of patients with hepatocellular carcinoma (HCC): A large real-life worldwide populationVitiello F; Rimini M; Persano M; Suda G; Shimose S; Finkelmeier F; Masi G; Rossari F; Amadeo E; Casadei-Gardini A; Tada T; Kudo M; Cheon J; Lim HY; Yoo CESMO-Asia 2023  2023/12  SingaporeBMI impact on the prognosis of unresectable HCC patients receiving first-line lenvatinib or atezolizumab plus bevacizumabAmadeo E; Persano M; Tada T; Suda G; Shimose S; Kudo M; Yoo C; Rassari F; Vitiello F; Casadei-Gardini A; Rimini MESMO-Asia 2023  2023/12  SingaporeAdverse events (AEs) as potential predictive factors of activity in patients with advanced hepatocellular carcinoma (HCC) treated with atezolizumab plus bevacizumab (AB)Persano M; Rimini M; Tada T; Suda G; Shimose S; Kudo M; Yoo C; Cheon J; Finkelmeier F; Lim HY; Presa J; Masi G; Bergamo F; Iavarone M; Cabibbo G; Foschi FG; Piscaglia F; Cascinu S; Scartozzi M; Casadei-Gardini AESMO-Asia 2023  2023/12  SingaporeIMbrave150: Exploratory analyses for investigating associations between Last update: 22-11-2023 12:00:52pm Final Programme overall survival (OS) and depth of response (DpR) or duration of response (DoR) in patients (pts) with unresectable hepatocellular carcinoma (HCC)Kudo M; Yamashita T; Finn RS; Galle P; Ducreux M; Cheng AL; Tsuchiya K; Sakamoto N; Hige S; Take R; Yamada K; Asakawa T; Nakagawa Y; Ikeda MESMO-Asia 2023  2023/12  SingaporeSafety and efficacy of atezolizumab (Atezo) + bevacizumab (Bev) in Japanese patients (pts) with unresectable hepatocellular carcinoma (uHCC): Preliminary analysis of a prospective, multicenter, observational study (ELIXIR)Kuzuya T; Yamashita T; Takehara T; Aikata H; Kato N; Hiasa Y; Nakamura S; Morimoto N; Moriguchi M; Ikeda M; Inoue J; Tani J; Ueno Y; Chayama K; Tateishi R; Kawamura Y; Furuse J; Kudo M; Yamamoto K; Kokudo NESMO-Asia 2023  2023/12  SingaporeFour-year overall survival (OS) update from the phase III HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma (uHCC)Chan SL; Sangro B; Kelly RK; Lau G; Kudo M; Sukeepaisarnjaroen W; De Toni E; Furuse J; Kang YK; Galle P; Rimassa L; Heurgue A; Tam V; Dao T; Thungappa SC; Breder V; Ostapenko Y; Monzon MER; Gupta C; Abou-Alfa GESMO-Asia 2023  2023/12  Singapore特別講演「複合免疫療法時代における最適な治療戦略を考える」  [Invited]工藤正俊Bunkyo HCC Seminar  2023/11特別講演「複合免疫療法時代における最適な治療戦略を考える」  [Invited]工藤正俊信州肝がん薬物療法セミナー  2023/11  ホテルブエナビスタ, 長野Invited Lecture “The Practice in Japan: Insights into Gold Standard HCC Surveillance and Management”  [Invited]Masatoshi KudoAPAC HCC Expert Meeting 2023  2023/11  Bangkok大腸ポリープの3クラス分類問題に対するResidual Networkを用いたAI自動診断. シンポジウム2「先進的な大腸内視鏡検査法の実用化に向けて」玉井龍成; 米田頼晃; 印牧奨真; 樫田博史; 半田久志; 工藤正俊第41回日本大腸検査学会総会  2023/11  ベルサール九段, 東京大腸ESDにおける抗血栓内服者に対する後出血の検討. パネルディスカッション「下部消化管出血の現状と問題点」米田頼晃; 樫田博史; 河野匡志; 工藤正俊第78回日本大腸肛門病学会  2023/11  熊本城ホール, 熊本消化管真菌叢はパーキンソン病感受性遺伝子LRRK2の活性化を介して, 膵炎を重症化させる. ワークショップ21 「腸内微生物叢からみた消化器疾患の病態解明」大塚康生; 三長孝輔; 渡邉智裕第31回日本消化器関連学会週間JDDW 2023(第65回日本消化器病学会大会, 第27回日本肝臓学会大会, 第106回日本消化器内視鏡学会総会)  2023/11  神戸コンベンションセンター, 兵庫ランチョンセミナー「肝細胞癌の薬物治療における最新のトピックス~複合免疫療法時代の最適な治療戦略を考える~」  [Invited]工藤正俊第27回日本肝臓学会大会  2023/11  神戸コンベンションセンター, 兵庫高脂肪食による肥満は自己免疫性膵炎の危険因子である. 統合プログラム1 (S) 「肥満関連消化器疾患治療の現状と課題」瀬海郁衣; 三長孝輔; 渡邉智裕第31回日本消化器関連学会週間JDDW 2023(第65回日本消化器病学会大会, 第27回日本肝臓学会大会, 第106回日本消化器内視鏡学会総会)  2023/11  神戸コンベンションセンター, 兵庫Intermediate stage HCCに対する集学的治療とclinical CR & drug-free strategy. パネルディスカッション「肝細胞癌Intermediate stageに対する治療戦略」青木智子; 上嶋一臣; 工藤正俊第27回日本肝臓学会大会  2023/11  神戸コンベンションセンター, 兵庫司会; ランチョンセミナー33「原発性肝がんのがんゲノム診断と治療―今、消化器医に求められるものー」  [Invited]工藤正俊第27回日本肝臓学会大会  2023/11  神戸コンベンションセンター, 兵庫特別講演「肝癌治療の進化と深化」  [Invited]工藤正俊第27回日本肝臓学会大会  2023/11  神戸コンベンションセンター, 兵庫Special Lecture “All stages of HCC patient benefit from systemic therapy combined with locoregional therapy”  [Invited]Masatoshi KudoAsian Pacific Association for the Study of the Liver (APASL Oncology 2023)  2023/10  Hotel Metropolitan Sendai, MiyagiIMbrave050: Phase 3 study of adjuvant atezolizumab + bevacizumab versus active surveillance in patients with hepatocellular carcinoma at high risk of disease recurrence following resection or ablationYopp A; Chow P; Chen M; Cheng AL; Kaseb A; Kudo M; Lee HC; Zhou J; Wang L; Wen X; Heo J; Tak WY; Nakamura S; Numata K; Uguen T; Hsiehchen D; Cha E; Hack SP; Lian Q; Spahn J; Wu C; Qin SAmerican College of Surgeons Clinical Congress 2023  2023/10  Boston, USAPost-progression outcomes of advanced HCC patients (aHCC pts) treated with first-line atezolizumab/bevacizumab (A/B)Fulgenzi CAM; Huang YH; Saeed A; Rimassa L; Schoenlein M; Piscaglia A; Kaseb A; Vogel A; Bettinger D; Silletta M; Kudo M; Vivaldi C; Scheiner B; Ulahannan S; Galle PR; Hsu WF; Chon HJ; Pinato DJ; Ang CThe European Society for Medical Oncology (ESMO Congress 2023)  2023/10  Madrid, Spain講演「切除不能肝癌の一次治療におけるティスレリズマブ: RATIONALE-301の日本人集団解析」工藤正俊第61回日本癌治療学会学術集会  2023/10  パシフィコ横浜, 神奈川司会; 臓器別シンポジウム1「肝細胞癌における集学的治療の課題と展望: “Sequntial”から”Conversion“まで」  [Invited]工藤正俊第61回日本癌治療学会学術集会  2023/10  パシフィコ横浜, 神奈川Tislelizumab versus sorafenib in first-line treatment of unresectable hepatocellular carcinoma (HCC): RATIONALE-301 Japanese subpopulationKudo M; Hiraoka A; Takayama T; Takikawa Y; Li S; Abdrashitov R; Chen Y; Boisserie F; Ohkawa K; Satoh TThe 61st Annual Meeting of Japan Society of Clinical Oncology (JSCO 2023)  2023/10  Yokohama, Japan特別講演「複合免疫療法時代における最適な治療戦略を考える」  [Invited]工藤正俊城北HCCセミナー  2023/10  ステーションコンファレンス池袋, 東京特別講演;複合免疫療法時代における最適な治療戦略を考える  [Invited]工藤正俊CHCS2023 AUTUMN  2023/10  札幌グランドホテル, 北海道IMbrave050: Phase 3 study of adjuvant atezolizumab + bevacizumab versus active surveillance in patients with hepatocellular carcinoma at high risk of disease recurrence following resection or ablationChow P; Chen M; Cheng AL; Kaseb A; Kudo M; Lee HC; Yopp A; Zhou J; Wang L; Wen X; Heo J; Tak WY; Nakamura S; Numata K; Uguen T; Hsiehchen D; Cha E; Hack SP; Lian Q; Spahn J; Wu C; Qin SThe 20th Annual Meeting of the International Society of Gastrointestinal Oncology (ISGIO 2023)  2023/10  Tempe, Arizona, USA特別講演「肝細胞癌に対する薬物療法の新しい潮流」  [Invited]工藤正俊肝細胞癌治療の現在と未来を考える会  2023/10NOD2の活性化によるI型IFN経路の制御機能が炎症性腸疾患の病態に果たす役割. シンポジウム2 「炎症性腸疾患: 臨床を深める病態研究の最前線」益田康弘; 三長孝輔; 鎌田研; 大塚康生; 本庶元; 正木翔; 瀬海郁衣; 栗本真之; 大丸直哉; 原 茜; 岡井夏輝; 新井康之; 山下浩平; 工藤正俊; 渡邉智裕第60回日本消化器免疫学会総会  2023/10  ホテルイースト21東京, 東京腸内真菌叢はパーキンソン病感受性蛋白LRRK2を介し, 急性膵炎の重症化に関与する. シンポジウム1 「臓器関連から診る消化器免疫疾患の病態と治療」大塚康生; 三長孝輔; 栗本真之; 瀬海郁衣; 原 茜; 鎌田 研; 渡邉智裕; 工藤正俊第60回日本消化器免疫学会総会  2023/10  ホテルイースト21東京, 東京特別講演「複合免疫療法時代における最適な治療戦略を考える」  [Invited]工藤正俊HCC Meet the Expert  2023/10心窩部痛を契機に診断・治療し得た傍神経筋腫の一例中 貴史; 吉田晃浩; 竹中 完; 田中秀和; 福永朋洋; 山﨑友裕; 大本俊介; 三長孝輔; 鎌田 研; 工藤正俊; 松本逸平; 筑後孝章日本消化器病学会近畿支部第119回例会  2023/09  大阪国際交流センター, 大阪カボザンチニブ投与による腫瘍の著名な縮小、腫瘍マーカーの低下を認めたMET遺伝子増幅を伴う肝細胞癌の1例八田寛朗; 萩原 智; 上嶋一臣; 大丸直哉; 松原卓哉; 盛田真弘; 千品寛和; 田北雅弘; 南 康範; 依田 広; 渡邉智裕; 西田直生志; 工藤正俊日本消化器病学会近畿支部第119回例会  2023/09  大阪国際交流センター, 大阪術前診断が困難であった肝限局性過形成(FNH)の一例藤原大輔; 野村健司; 川崎俊彦; 福西香栄; 加藤弘樹; 河野辰哉; 橋本有人; 木下大輔; 水野成人; 福田泰也; 若狭朋子; 工藤正俊日本消化器病学会近畿支部第119回例会  2023/09  大阪国際交流センター, 大阪リザーバー留置後に胃よりカテーテルの逸脱を認めた一例栗本真之; 田北雅弘; 大丸直哉; 松原卓哉; 盛田真弘; 千品寛和; 青木智子; 萩原 智; 南 康範; 依田 広; 上嶋一臣; 西田直生志; 工藤正俊; 鶴崎正勝日本消化器病学会近畿支部第119回例会  2023/09  大阪国際交流センター, 大阪新型コロナワクチン接種後にIgA血管炎を発症し、コロナ感染を契機に再燃を繰り返した1例勝部滉平; 永井知行; 駒谷 真; 有山武尊; 栗本真之; 岡井夏輝; 吉田早希; 半田康平; 正木 翔; 河野匡志; 米田頼晃; 本庶 元; 松井繁長; 渡邉智裕; 辻 直子; 樫田博史; 工藤正俊日本消化器病学会近畿支部第119回例会  2023/09  大阪国際交流センター, 大阪司会; がんゲノム医療の現状と課題  [Invited]工藤正俊日本消化器病学会近畿支部第73回教育講演会  2023/09  大阪国際交流センター, 大阪A phase 1b study of E7386, a CREB-binding protein/β-catenin interaction inhibitor, plus lenvatinib in patients with advanced hepatocellular carcinoma (HCC)Ikeda M; Kato N; Kondo S; Inaba Y; Ueshima K; Sasaki M; Kanzaki H; Ida H; Imaoka H; Minami Y; Mitsunaga S; Nishida N; Ogasawara S; Watanabe K; Sahara T; Hayata N; Yamamuro S; Kimura T; Tamai T; Ma C; Kudo MNew Zealand Society for Oncology (NZSO 2023)  2023/09  Napier, New ZealandChairs: ILCA Radiology Session  [Invited]Masatoshi KudoILCA 2023  2023/09  Amsterdam, The NetherlandsEfficacy and safety analysis of a phase II study of atezolizumab plus bevacizumab for TACE-unsuitable patients with tumor burden beyond up-to-seven criteria in intermediate-stage hepatocellular carcinoma: REPLACEMENT studyKudo M; Ueshima K; Tsuchiya K; Kato N; Yamashita T; Shimose S; Numata K; Kodama Y; Tanaka Y; Kuroda H; Itoh S; Aikata H; Hiraoka A; Moriguchi M; Wada Y; Nakao K; Tateishi R; Ogasawara S; Yamamoto K; Ikeda MILCA 2023  2023/09  Amsterdam, The NetherlandsGAAD and GALAD algorithmic scores demonstrate equivalent clinical performance for detection of early stage hepatocellular carcinoma (HCC) in prospective multicenter biomarker studiesHou J; Berg T; Vogel A; Piratvisuth T; Trojan J; De Toni EN; Kudo M; Malinowsky K; Findeisen P; Hegel JK; Schoning W; Madin K; Kroeniger K; Chan HLY; Sharma AILCA 2023  2023/09  Amsterdam, The NetherlandsIMbrave050: Phase 3 study of adjuvant atezolizumab + bevacizumab versus active surveillance in patients with hepatocellular carcinoma (HCC) at high risk of disease recurrence following resection or ablationChow P; Chen M; Cheng AL; Kaseb A; Kudo M; Lee HC; Qin S; Zhou J; Wang L; Wen X; Heo J; Tak WY; Nakamura S; Numata K; Uguen T; Hsiehchen D; Cha E; Hack SP; Lian Q; Spahn J; Wu C; Yopp AILCA 2023  2023/09  Amsterdam, The NetherlandsAchievement of cancer and drug-free status by atezolizumab plus bevacizumab followed by curative conversion in patients with TACE-unsuitable, intermediate-stage HCC: a multicenter proof-of-concept studyKudo M; Aoki T; Ueshima K; Tsuchiya K; Morita M; Chishina H; Takita M; Hagiwara S; Minami Y; Ida H; Nishida N; Ogawa C; Tomonari T; Nakamura N; Kuroda H; Takebe A; Takeyama Y; Hidaka M; Eguchi S; Chan SL; Kurosaki M; Izumi NILCA 2023  2023/09  Amsterdam, The Netherlands特別講演「複合免疫療法時代における最適な治療戦略を考える」  [Invited]工藤正俊第17回肝癌治療ナビゲーション研究会アフタヌーンセミナー  2023/08  京都産業会館ホール, 京都Tislelizumab versus sorafenib in first-line treatment of unresectable hepatocellular carcinoma: Impact on health-related quality of life in rationale-301 population  [Not invited]Finn RS; Qin S; Kudo M; Meyer T; Boisserie F; Li S; Chen Y; Abdrashitov R; Zhu AX; Vogel AAsia-Pacific Gastroenterology Cancer Summit  2023/08  Academia, SingaporeImpact of risk factors on overall survival (OS) in patients (pts) with unresectable hepatocellular carcinoma (HCC) treated with first-line (1L) tislelizumab (TIS)  [Not invited]Kudo M; Finn RS; Meyer T; Boisserie F; Li S; Chen Y; Abdrashitov R; Zhu AX; Vogel A; Qin SAsia-Pacific Gastroenterology Cancer Summit  2023/08  Academia, Singapore特別講演「複合免疫療法時代における最適な治療戦略を考える」  [Invited]工藤正俊久留米肝がんセミナー  2023/08  萃香園ホテル, 九州Tislelizumab versus sorafenib in first-line treatment of unresectable hepatocellular carcinoma: Impact on health-related quality of life in RATIONALE-301 populationFinn R; Qin S; Kudo M; Meyer T; Boisserie F; Li S; Chen Y; Barnes G; Abdrashitov R; Zhu A; Vogel AASCO Breakthrough 2023  2023/08  Yokohama, JapanKeynote Lecture “Combination Immunotherapy in early and intermediate stage HCC”  [Invited]Kudo MJoint International Conference of Taiwan Liver Cancer Association (TLCA) and Taiwan Academy of Tumor Ablation (TATA) 2023  2023/07  Taipei免疫環境変化によりRechallenge療法にてCRが得られたと考えられたABC conversion、drug freeの一例二宮七海; 小川 力; 松本莉香; 福家和諭; 戸田拓也; 松浦賢史; 野田晃世; 真鍋卓嗣; 久保敦司; 松中寿広; 玉置敬之; 柴峠光成; 工藤正俊第59回日本肝癌研究会  2023/07  大阪国際会議場, 大阪全国原発性肝癌追跡調査データによる分子標的治療支援AIアルゴリズム開発. ワークショップ4「肝腫瘍診療におけるAI/ITの可能性」國土貴嗣; 山田康秀; 建石良介; 浅岡良成; 壁谷佳典; 吉田澄人; 鎌田亜美; 中村悠馬; 先崎心音; 正木 勉; 山下竜也; 飯島尋子; 坂元亨宇; 工藤正俊; 國土典宏第59回日本肝癌研究会  2023/07  大阪国際会議場, 大阪超音波診断を支援する人工知能モデルによる肝内胆管癌の鑑別. ワークショップ4「肝腫瘍診療におけるAI/ITの可能性」西田直生志; 工藤正俊第59回日本肝癌研究会  2023/07  大阪国際会議場, 大阪実臨床におけるアテゾリズマブ・ベバシズマブ併用療法の使用状況-HERITAGE試験から‐. シンポジウム「肝細胞癌に対する免疫チェックポイント阻害剤: 現状と課題」浅岡良成; 建石良介; 山田康秀; 長谷川 潔; 飯島尋子; 加藤直也; 島田光生; 波多野悦朗; 福本 巧; 村上卓道; 矢野博久; 吉満賢吾; 黒崎雅之; 坂元亨宇; 松山 裕; 工藤正俊; 國土典宏第59回日本肝癌研究会  2023/07  大阪国際会議場, 大阪座長; ランチョンセミナー「分子標的薬・重粒子・TACE/RFAによる肝癌・胆管癌のハイブリッド治療—この症例をどうする?-」  [Invited]工藤正俊; 藤元治朗第59回日本肝癌研究会  2023/07  大阪国際会議場, 大阪右下横隔膜動脈からのfeederを造影USで指摘しABC convresion、drug freeを達成したHCCの一例堤 千沙; 小川 力; 松本莉香; 福家和諭; 戸田拓也; 松浦賢史; 野田晃世; 真鍋卓嗣; 久保敦司; 松中寿広; 玉置敬之; 柴峠光成; 工藤正俊第59回日本肝癌研究会  2023/07  大阪国際会議場, 大阪Intermediate stage肝癌における初回アテゾリズマブ+ベバシズマブとレンバチニブの比較・検討多田俊史; 熊田 卓; 豊田秀徳; 平岡 淳; 能祖一裕; 工藤正俊第59回日本肝癌研究会  2023/07  大阪国際会議場, 大阪IMbrave050: 肝細胞癌における切除・焼灼後のAtezo+Bev療法の有用性を検証する多施設共同第III相臨床試験. ワークショップ1「肝細胞癌のコンビネーション治療-術前・術後治療-」工藤正俊; Nakamura S; Numata K; Chen M; Cheng AL; Chow P; Kaseb A; Lee HC; Yopp A; Zhou J; Wang L; Wen X; Heo J; Tak WY; Uguen T; Hsiehchen D; Hack S; Lian Q; Spahn J; Qin S第59回日本肝癌研究会  2023/07  大阪国際会議場, 大阪胆管癌におけるゲノム・エピゲノム変化と腫瘍免疫微小環境. シンポジウム「肝内胆管癌薬物療法の進歩」西田直生志; 青木智子; 盛田真弘; 千品寛和; 田北雅弘; 萩原 智; 依田 広; 南 康範; 上嶋一臣; 工藤正俊第59回日本肝癌研究会  2023/07  大阪国際会議場, 大阪Wnt/β-catenin変異を有するヒト肝細胞癌における免疫微小環境の不均一性に関する検討. シンポジウム「肝癌腫瘍微小環境」青木智子; 西田直生志; 紅林 泰; 坂井和子; 盛田真弘; 千品寛和; 田北雅弘; 萩原 智; 依田 広; 上嶋一臣; 南 康範; 鶴崎正勝; 中居卓也; 坂元亨宇; 西尾和人; 工藤正俊第59回日本肝癌研究会  2023/07  大阪国際会議場, 大阪特別講演「肝細胞癌に対する薬物療法の新しい潮流」  [Invited]工藤正俊第22回関西肝血流動態・機能イメージ研究会  2023/07  エーザイ株式会社大阪コミュニケーションオフィス, 大阪特別講演「複合免疫療法時代における最適な治療戦略を考える」  [Invited]工藤正俊岩手肝癌治療を考える会~BCLC-Bの治療戦略を中心に~  2023/07Keynote Lecture “Insights into Japan’s gold standard in hepatocellular carcinoma surveillance and management”  [Invited]Kudo MWhite Paper Launch Webinar  2023/07特別講演「イミフィンジ・イジュドがもたらす免疫療法の新たな潮流」  [Invited]工藤正俊HCC Semiar in Niigata 2023  2023/07  ホテルイタリア幹新潟, 新潟Invited Lecture “The potential role of systemic therapy in intermediate-stage HCC: A paradigm shift?”.  [Invited]Kudo MThe 13th Asia-Pacific Primary Liver Cancer Expert Meeting (APPLE 2023)  2023/07  Seoul, KoreaSession 3 “New Trends in Management of Intermediate-Stage HCC”  [Invited]Kudo MThe 13th Asia-Pacific Primary Liver Cancer Expert Meeting (APPLE 2023)  2023/07  Seoul, KoreaComparison of background characteristics of patients receiving lenvatinib vs atezolizumab plus bevacizumab in unresectable hepatocellular carcinomaItoh S; Ikeda M; Onozuka D; Tateishi R; Yamashita T; Okusaka T; Kato N; Furuse J; Kudo MThe 13th Asia-Pacific Primary Liver Cancer Expert Meeting (APPLE 2023)  2023/07  Seoul KoreaFour-year overall survival (OS) update from the Phase 3 HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma (uHCC)Sangro B; Chan SL; Kelly RK; Lau G; Kudo M; Sukeepaisarnjaroen W; De Toni EN; Furuse J; Kang YK; Galle PR; Rimassa L; Heurgue A; Tom VC; Dao TV; Thungappa SC; Breder V; Ostapenko Y; Reig M; Makowsky M; Gupta C; Negro A; Abou-Alfa GKThe 13th Asia-Pacific Primary Liver Cancer Expert Meeting (APPLE 2023)  2023/07  Seoul KoreaIMbrave050: Adjuvant atezolizumab + bevacizumab vs active surveillance in hepatocellular carcinoma patients at high risk of disease recurrence following resection or ablation.Lee HC; Cheng AL; Chow P; Kaseb A; Kudo M; Qin S; Yopp A; Becker L; Hernandez S; Kovic B; Lian Q; Ma N; Wu C; Chen MThe 13th Asia-Pacific Primary Liver Cancer Expert Meeting (APPLE 2023)  2023/07  Seoul KoreaChair: Session 4 “From APPLE academy into the future”  [Invited]Kudo MThe 13th Asia-Pacific Primary Liver Cancer Expert Meeting (APPLE 2023)  2023/07  Seoul, KoreaRandomized, Phase 3 study of tislelizumab vs sorafenib as first-line (1L) treatment for unresectable hepatocellular carcinoma (HCC): RATIONALE 301 aged ≥65 years subgroupVogel A; Kudo M; Qin S; Chen Y; Li S; Boisserie F; Abdrashitov R; Finn RS; Meyer T; Zhu AX25th ESMO World Congress on Gastrointestinal Cancer (WCGI)  2023/06  Barcelona, Spain特別講演「複合免疫療法時代における最適な治療戦略を考える」  [Invited]工藤正俊HCC Expert Meeting  2023/06  ANAクラウンプラザホテル富山, 富山Atezolizumab plus bevacizumab is associated with improved survival outcomes in HCC patients with Child-Pugh B dysfunction compared to best supportive therapyFulgenzi C; D’Alessio A; Scheiner B; Ang C; Wietharn B; Pinter M; Nishida N; Parisi A; Huang Y; Bettinger D; Vogel A; Silletta M; Schonlein M; Galle P; Kudo M; Singal A; Cortellini A; Chon H; Stefanini B; Giannini E; Pinato D25th ESMO World Congress on Gastrointestinal Cancer  2023/06  Barcelona, SpainSequential therapies after atezolizumab plus bevacizumab or lenvatinib first-line treatmentsPersano M; Rimini M; Suda G; Shimose S; Kudo M; Cheon J; Finkelmeier F; Presa J; Masi G; Yoo C; Lonardi S; Tovoli F; Piscaglia F; Lavarone M; Marra F; Tamburini E; Cabibbo G; Scartozzi M; Casadei-Gardini A25th ESMO World Congress on Gastrointestinal Cancer  2023/06  Barcelona, SpainA positive cytokine/chemokine feedback loop establishes plasmacytoid dendritic cell-driven autoimmune pancreatitis in IgG4-related diseaseHara A; Otsuka Y; Minaga K; Watanabe T; Kudo M55th EPC meeting in cooperation with the JPS  2023/06  Alpbach, Tyrol, AustriaIPMNの壁在結節におけるDetective flow imaging(DFI)の有用性について. シンポジウム2「膵疾患に対する内視鏡診療の現況と展望」大本俊介; 竹中 完; 工藤正俊第110回日本消化器内視鏡学会近畿支部例会  2023/06  大阪国際交流センター, 大阪選択的胆管挿管に対する新規構造色彩強調機能(Texture and color enhancement Imaging: TXI)の有用性評価. ワークショップ1「胆道内視鏡の現況と展望」田中秀和; 竹中 完; 工藤正俊第110回日本消化器内視鏡学会近畿支部例会  2023/06  大阪国際交流センター, 大阪内視鏡治療できた小腸良性腫瘍症例. ビデオシンポジウム「Best of Endoscopist in Kinkiを目指せ~診断・治療困難例へのアプローチ~」岡井夏輝; 正木 翔; 米田頼晃; 樫田博史; 工藤正俊第110回日本消化器内視鏡学会近畿支部例会  2023/06  大阪国際交流センター, 大阪当院における潰瘍性大腸炎患者に対するLRGの活用性の検討. ワークショップ3「炎症性腸疾患診療における内視鏡検査の現況と展望」河野匡志; 米田頼晃; 工藤正俊第110回日本消化器内視鏡学会近畿支部例会  2023/06  大阪国際交流センター, 大阪造影USにて右下横隔膜動脈からのfeederを指摘しABC conversion、drug freeを達成したHCCの一例竹内沙織; 小川 力; 松本莉香; 福家和諭; 戸田拓也; 松浦賢史; 野田晃世; 真鍋卓嗣; 久保敦司; 松中寿浩; 玉置敬之; 柴峠光成; 工藤正俊第28回日本肝がん分子標的治療研究会  2023/06  京王プラザホテル札幌, 北海道初回AB療法はPDも、Rechallenge療法にてCRが得られたABC conversion、drug freeの一例  [Not invited]近藤由奈; 小川 力; 松本莉香; 福家和諭; 戸田拓也; 松浦賢史; 野田晃世; 真鍋卓嗣; 久保敦司; 松中寿浩; 玉置敬之; 柴峠光成; 小森淳二; 神野真理; 石川雅士; 居村 暁; 熊谷久次郎; 工藤正俊第28回日本肝がん分子標的治療研究会  2023/06  京王プラザホテル札幌, 北海道プレナリーセッション2-4「Intermediate stage肝癌における初回アテゾリズマブ+ベバシズマブとレンバチニブの比較・検討」  [Invited]多田俊史; 熊田 卓; 平岡 淳; 谷 丈二; 厚川正則; 高口浩一; 糸林 詠; 辻 邦彦; 田尻和人; 小川 力; 畑中 健; 柿崎 暁; 能祖一裕; 豊田秀徳; 的野智光; 越智裕紀; 海堀昌樹; 黒田英克; 日浅陽一; 工藤正俊第28回日本肝がん分子標的治療研究会  2023/06  京王プラザホテル札幌, 北海道プレナリーセッション2-2「PRISM試験に登録された初期1,000例のアテゾリズマブ+ベバシズマブとレンバチニブの初回薬物療法例の患者背景の比較」  [Invited]池田公史; 伊藤心二; 小野塚大介; 建石良介; 山下竜也; 奥坂拓志; 加藤直也; 古瀬純司; 工藤正俊第28回日本肝がん分子標的治療研究会  2023/06  京王プラザホテル札幌, 北海道スポンサードセッション「肝細胞癌の薬物治療における最新トピックス~複合免疫療法時代の最適な治療戦略を考える~」  [Invited]工藤正俊第28回日本肝がん分子標的治療研究会  2023/06  京王プラザホテル札幌, 北海道Impact of baseline liver function on overall survival (OS) and safety in patients with unresectable hepatocellular carcinoma (HCC) treated with first-line (1L) tislelizumab: Results from the RATIONALE-301 studyKudo M; Vogel A; Meyer T; Boisserie F; Li S; Abdrashitov R; Chen Y; Zhu AX; Qin S; Finn RSEASL Congress 2023  2023/06  Vienna, Austria座長  [Invited]工藤正俊イジュド発売記念講演会in大阪  2023/06  スイスホテル南海大阪, 大阪高アンモニア血症に対するレボカルニチン自体の効果について萩原 智; 盛田真弘; 千品寛和; 青木智子; 田北雅弘; 南 康範; 依田 広; 上嶋一臣; 西田直生志; 工藤正俊第59回日本肝臓学会総会  2023/06  奈良県コンベンションセンター, JWマリオット・ホテル奈良, 奈良B型慢性肝炎患者に対するTAFの効果および安全性の検討萩原 智; 盛田真弘; 千品寛和; 青木智子; 田北雅弘; 南 康範; 依田 広; 上嶋一臣; 西田直生志; 工藤正俊第59回日本肝臓学会総会  2023/06  奈良県コンベンションセンター, JWマリオット・ホテル奈良, 奈良非アルコール性脂肪肝疾患におけるDNAメチル化に関連する臨床的・病理学的特徴. ワークショップ10「NASH/ASHの病態解明とTransrational Research」萩原 智; 西田直生志; 工藤正俊第59回日本肝臓学会総会  2023/06  奈良県コンベンションセンター, JWマリオット・ホテル奈良, 奈良進行性肝細胞癌患者に対するレンバチニブとペムブロリズマブ併用療法をレンバチニブ単独療法と比較する第III相試験(LEAP-002): 日本人集団の結果. ワークショップ5「肝癌における薬物療法の最前線」  [Invited]工藤正俊; 金子周一; 熊田博光第59回日本肝臓学会総会  2023/06  奈良県コンベンションセンター, JWマリオット・ホテル奈良, 奈良Erythropoietic porphyria(EPP)関連肝障害における瀉血治療の有効性. パネルディスカッション5「遺伝・代謝性肝疾患の未来予想図(現状と課題)」萩原 智; 西田直生志; 工藤正俊第59回日本肝臓学会総会  2023/06  奈良県コンベンションセンター, JWマリオット・ホテル奈良, 奈良免疫チェックポイント阻害剤投与に伴うHBV再活性化および抗ウイルス効果についての検討. シンポジウム3「B型肝炎診療の未来予想図(現状と課題)」萩原 智; 西田直生志; 工藤正俊第59回日本肝臓学会総会  2023/06  奈良県コンベンションセンター, JWマリオット・ホテル奈良, 奈良ランチョンセミナー「複合免疫療法時代におけるレンバチニブの位置づけ」  [Invited]工藤正俊第59回日本肝臓学会総会  2023/06  奈良県コンベンションセンター, JWマリオット・ホテル奈良, 奈良非硬変肝から発生したFontan術後HCCの1例有山武尊; 萩原 智; 西田直生志; 工藤正俊第59回日本肝臓学会総会  2023/06  奈良県コンベンションセンター, JWマリオット・ホテル奈良, 奈良基調講演「根治を見据えた近未来の肝細胞癌治療戦略」  [Invited]工藤正俊第59回日本肝臓学会総会  2023/06  奈良県コンベンションセンター, JWマリオット・ホテル奈良, 奈良.特別講演「Cancer Free with Drug Freeを目指すためのABC」  [Invited]工藤正俊Mee The Expert on Hepatocellular Carcinoma  2023/06Finn R, Qin S, Kudo M, Meyer T, Boisserie F, Li S, Chen Y, Barnes G, Abdrashitov R, Zhu A, Vogel ATislelizumab versus sorafenib in first-line treatment of unresectable hepatocellular carcinoma; Impact on health-related quality of; life in; RATIONALE; populationAnnual Meeting of the American Society of Clinical Oncology (ASCO) 2023  2023/06  Chicago, USAOutcomes by occurrence of immune-mediated adverse events (imAEs) with tremelimumab (T) plus durvalumab (D) in the phase 3 HIMALAYA study in unresectable hepatocellular carcinoma (uHCC)Lau G; Cheng AL; Sangro B; Kudo M; Kelley RK; Tak WY; Gasbarrini A; Reig M; Lim HY; Tougeron D; De Toni EN; Tam VC; Mody K; Gong J; McCoy CL; Gupta C; Makowsky M; Negro A; Abou-Alfa GKAnnual Meeting of the American Society of Clinical Oncology (ASCO) 2023  2023/06  Chicago, USAA phase 1b study of E7386, a CREB-binding protein/β-catenin interaction inhibitor, plus lenvatinib in patients with advanced hepatocellular carcinoma (HCC)Ikeda M; Kato N; Kondo S; Inaba Y; Ueshima K; Sasaki M; Kanzaki H; Ida H; Imaoka H; Minami Y; Mitsunaga S; Nishida N; Ogasawara S; Watanabe K; Sahara T; Hayata N; Yamamuro S; Kimura T; Tamai T; Ma C; Kudo MAnnual Meeting of the American Society of Clinical Oncology (ASCO) 2023  2023/06  Chicago, USAPrimary analysis of a phase II study of atezolizumab plus bevacizumab for TACE-unsuitable patients with tumor burden beyond up-to-seven criteria in intermediate-stage hepatocellular carcinoma: REPLACEMENT studyUeshima K; Kudo M; Tsuchiya K; Kato N; Yamashita T; Shimose S; Numata K; Kodama Y; Tanaka Y; Kuroda H; Itoh S; Aikata H; Hiraoka A; Moriguchi M; Wada Y; Nakao K; Tateishi R; Ogasawara S; Yamamoto K; Ikeda MAnnual Meeting of the American Society of Clinical Oncology (ASCO) 2023  2023/06  Chicago, USAEfficacy, safety and patient reported outcomes (PROs) from the phase III IMbrave050 trial of adjuvant atezolizumab (atezo) + bevacizumab (bev) vs active surveillance in patients with hepatocellular carcinoma (HCC) at high risk of disease recurrence following resection or ablationKudo M; Chen M; Chow PKH; Kaseb AO; Lee HC; Yopp AC; Becker L; Painter SH; Kovic B; Lian Q; Ma N; Wu C; Qin S; Cheng ALAnnual Meeting of the American Society of Clinical Oncology (ASCO) 2023  2023/06  Chicago, USAImpact of risk factors on overall survival (OS) in patients (pts) with unresectable hepatocellular carcinoma (HCC) treated with first-line (1L) tislelizumab (TIS)Kudo M; Finn RS; Meyer T; Boisserie F; Li S; Chen Y; Abdrashitov R; Zhu AX; Vogel A; Qin SAnnual Meeting of the American Society of Clinical Oncology (ASCO) 2023  2023/06  Chicago, USAInvited Lecture “Systemic therapies for HCC in cirrhosis: Expanding and redefining treatment approaches”  [Invited]Masatoshi KudoThe Asian Pacific Association for the Study of the Liver (APASL STC 2023)  2023/05  Manila, Philippines司会; ランチョンセミナー「肝疾患における造影超音波診断最前線」  [Invited]工藤正俊日本超音波医学会第96回学術集会  2023/05  ソニックシティ・パレスホテル大宮, 埼玉造影USが有用であったABC conversion therapyに成功したHCCの2例元木史佳; 小川 力; 松本莉香; 福家和諭; 戸田拓也; 松浦賢史; 真鍋卓嗣; 柴峠光成; 工藤正俊日本超音波医学会第96回学術集会  2023/05  ソニックシティ・パレスホテル大宮, 埼玉切除不能HCCに対するABC conversion療法と造影超音波によるclinical CRの補助診断青木智子; 南 康範; 依田 広; 千品寛和; 田北雅弘; 萩原 智; 上嶋一臣; 鶴崎正勝; 西田直生志; 工藤正俊日本超音波医学会第96回学術集会  2023/05  ソニックシティ・パレスホテル大宮, 埼玉膵・胆管合流異常の診断におけるEUS・造影ハーモニックEUSの意義の検討. シンポジウム消化器3「診断の鍵となる所見」  [Not invited]山﨑友裕; 鎌田 研; 高島耕太; 田中秀和; 福永朋洋; 吉田晃浩; 大本俊介; 三長孝輔; 竹中 完; 工藤正俊日本超音波医学会第96回学術集会  2023/05  ソニックシティ・パレスホテル大宮造影USにて右下横隔膜動脈からのfeederが指摘できたHCCの一例谷 丈二; 小川 力; 福家和諭; 戸田拓也; 真鍋卓嗣; 正木 勉; 工藤正俊日本超音波医学会第96回学術集会  2023/05  ソニックシティ・パレスホテル大宮, 埼玉致死率の高いClostridium perfringens肝膿瘍に造影USが有用であった一例堤 千沙, 小川 力, 福家和諭, 戸田拓也, 松浦賢史, 真鍋卓嗣, 柴峠光成, 工藤正俊日本超音波医学会第96回学術集会  2023/05  ソニックシティ・パレスホテル大宮, 埼玉胆管病変に対するDetective flow imaging (DFI)の有用性について大本俊介; 竹中 完; 吉田晃浩; 福永朋洋; 田中秀和; 高島耕太; 山﨑友裕; 三長孝輔; 鎌田 研; 工藤正俊日本超音波医学会第96回学術集会  2023/05  ソニックシティ・パレスホテル大宮, 埼玉橈骨動脈穿刺による腹部血管造影検査における術前血管USの有用性  [Not invited]福家和諭; 小川 力; 戸田拓也; 真鍋卓嗣; 柴峠光成; 工藤正俊日本超音波医学会第96回学術集会  2023/05  ソニックシティ・パレスホテル大宮, 埼玉膵腫瘍の造影ハーモニックEUS診断. パネルディスカッション消化器6「膵腫瘍(嚢胞性疾患も)の超音波およびEUS診断」  [Not invited]鎌田 研; 大塚康生; 田中秀和; 中井 敦; 山﨑友裕; 大本俊介; 三長孝輔; 竹中 完; 北野雅之; 工藤正俊日本超音波医学会第96回学術集会  2023/05  ソニックシティ・パレスホテル大宮, 埼玉当院におけるスキルス胃癌および下部消化管粘膜下腫瘍に対するEUS精査症例の検討. パネルディスカッション消化器2「消化管がんに対する超音波診断(EUS含む)」  [Not invited]田中秀和; 鎌田 研; 高田隆太郎; 三長孝輔; 竹中 完; 松井繁長; 樫田博史; 工藤正俊日本超音波医学会第96回学術集会  2023/05  ソニックシティ・パレスホテル大宮消化管がんに対する体外式消化管超音波検査の有用性について. パネルディスカッション消化器2「消化管がんに対する超音波診断(EUS含む)」  [Not invited]南 雅人; 中村祐香; 江口香織; 片岡久紗; 横川美香; 市島真由美; 塩見香織; 南 康範; 樫田博史; 工藤正俊日本超音波医学会第96回学術集会  2023/05  ソニックシティ・パレスホテル大宮特別講演「肝腫瘍の超音波人工知能診断の社会実装に向けて: 日本超音波医学会の取り組み」  [Invited]工藤正俊日本超音波医学会第96回学術集会  2023/05  ソニックシティ・パレスホテル大宮, 埼玉弾性線維性仮性黄色腫に合併する消化管病変の内視鏡所見. ワークショップ5 「希少疾患の内視鏡診断」三長孝輔; 山下幸孝; 工藤正俊第105回日本消化器内視鏡学会総会  2023/05  グランドプリンスホテル新高輪 国際館パミール, 東京カプセル小腸内視鏡で得られた大量検査画像からEfficient GANによる小腸病変の高速検出. ワークショップ4「小腸内視鏡による診断、治療の最前線(下部)」印牧奨真; 米田頼晃; 工藤正俊第105回日本消化器内視鏡学会総会  2023/05  グランドプリンスホテル新高輪国際館パミール, 東京潰瘍性大腸炎治療中に腸管症型T細胞リンパ腫を発症した症例. ワークショップ5「希少疾患の内視鏡診断」米田頼晃; 樫田博史; 工藤正俊第105回日本消化器内視鏡学会総会  2023/05  グランドプリンスホテル新高輪国際館パミール, 東京特別講演「複合免疫療法時代における最適な治療戦略を考える」  [Invited]工藤正俊肝細胞癌Webカンファレンス  2023/05特別講演「複合免疫療法時代における最適な治療戦略を考える」  [Invited]工藤正俊HIMEJI Hepatocellular Carcinoma Expert Meeting  2023/05特別講演「切除不能肝細胞がんにおけるSTRIDEレジメンが果たす役割」  [Invited]工藤正俊北海道HCCセミナー  2023/05特別講演「複合免疫療法時代における最適な治療戦略を考える」  [Invited]工藤正俊Hepatocellular Carcinoma Expert Meeting in 城東  2023/05特別講演「複合免疫療法時代における最適な治療戦略を考える」  [Invited]工藤正俊肝細胞がん薬物治療を考える会2023 in WAKAYAMA  2023/05  ダイワロイネットホテル和歌山, 和歌山特別講演;複合免疫療法時代における最適な治療戦略を考える  [Invited]工藤正俊Hepatocellular Carcinoma Expert Meeting in Hiroshima 2023  2023/05  ホテルグランビア広島, 広島特別講演「複合免疫療法時代における最適な治療戦略を考える」  [Invited]工藤正俊肝細胞癌セミナーin神奈川  2023/05特別講演「複合免疫療法時代における最適な治療戦略を考える」  [Invited]工藤正俊Chugai Hepatocellular Carcinoma Seminar in SHIGA  2023/05特別講演「複合免疫療法時代における最適な治療戦略を考える」  [Invited]工藤正俊HCCの未来を考える会in山形  2023/05  ホテルメトロポリタン山形, 山形特別講演「複合免疫療法時代における最適な治療戦略を考える」  [Invited]工藤正俊第3回肝がん治療の最前線~in両毛  2023/05A multicenter prospective validation study on selective endoscopic resection of sessile serrated lesions using magnifying colonoscopy in clinical practiceHirata D; Kashida H; Matsumoto T; Ebisutani C; Teramoto A; Iwatate M; Hattori S; Fujita M; Sano W; Komeda Y; Sano Y; Murakami Y; Kudo MDigestive Disease Week 2023 (DDW 2023)  2023/05  Chicago, USA特別講演「複合免疫療法時代における最適な治療戦略を考える」  [Invited]工藤正俊第4回県央・県北HCC Webセミナー  2023/04特別講演「複合免疫療法時代における最適な治療戦略を考える」  [Invited]工藤正俊中外e-seminar on Hepatocellular Carcinoma  2023/04座長「造影超音波その先へ」  [Invited]工藤正俊第36回日本腹部造影エコー・ドプラ診断研究会  2023/04造影USにて右下横隔膜動脈からのfeederが指摘できたHCCの一例小川 力; 元木史佳; 戸田拓也; 福家和諭; 真鍋卓嗣; 柴峠光成; 工藤正俊第36回日本腹部造影エコー・ドプラ診断研究会  2023/04  ホテルアバローム紀の国, 和歌山胆管病変に対するDetective flow imaging (DFI)の有用性について.大本俊介; 竹中 完; 工藤正俊第36回日本腹部造影エコー・ドプラ診断研究会  2023/04  ホテルアバローム紀の国, 和歌山IMbrave050: Phase 3 study of adjuvant atezolizumab + bevacizumab versus active surveillance in patients with hepatocellular carcinoma (HCC) at high risk of disease recurrence following resection or ablation  [Not invited]Chow P; Chen M; Cheng AL; Kaseb A; Kudo M; Lee HC; Yopp A; Zhou J; Wang L; Wen X; Heo J; Tak WY; Nakamura S; Numata K; Uguen T; Hsiehchen D; Cha E; Hack SP; Lian Q; Spahn J; Wu C; Qin SEASL Liver Cancer Summit 2023  2023/04  Estoril, PortugalSequential therapies after atezolizumab plus bevacizumab or lenvatinib first-line treatments.Persano M; Rimini M; Tada T; Suda G; Shimose S; Kudo M; Cheon J; Finkelmeier F; Presa J; Masi G; Yoo C; Lonardi S; Piscaglia F; Iavarone M; Di Castanzo G; Marra F; Tamburini E; Cabibbo G; Foschi F; Siletta M; Cascinu S; Scartozzi M; Casadei-Gardini AEASL Liver Cancer Summit 2023  2023/04  Estoril, PortugalFeasibility of systemic anti-cancer therapy as an alternative to best supportive care in patients with advanced HCC and Child-Pugh B liver dysfunctionFulgenzi AM; D’Alessio A; Scheiner B; Nishida N; Ang C; Marron T; Wu L; Saeed A; Wietharn B; Cammarota A; Pressiani T; Pinter M; Sharma R; Cheon J; Huang YH; Lee PC; Phen S; Gampa A; Pillai A; Napolitano A; Vivaldi C; Salani F; Masi G; Bettinger D; Thimme R; Vogel A; Schoenlein M; von Felden J; Schulze K; Wege H; Galle P; Pirisi M; Park JW; Kudo M; Rimassa L; Singal A; Cortellini A; Chon HJ; Ghittoni G; Camma C; Stefanini B; Trevisani F; Giannini EG; Pinato DJEASL Liver Cancer Summit 2023  2023/04  Estoril, PortugalReal World Data for Atezolizumab plus Bevacizumab in unresectable Hepatocellular Carcinoma: how does the adherence to the IMbrave150 trial inclusion criteria impact prognosis?Rimini M; Persano M; Tada T; Suda G; Shimose S; Kudo M; Gheon J; Finkelmeier F; Lim HY; Presa J; Masi G; Yoo C; Lonardi S; Piscaglia F; Scartozzi M; Cascinu S; Casadei-Gardini AEASL Liver Cancer Summit 2023  2023/04  Estoril, PortugalThe ALBI grade refines prognostic prediction in advanced hepatocellular cancer and enables risk stratification for bleeding events following atezolizumab plus bevacizumabD’Alessio A; Fulgenzi AM; Scheiner B; Korolewicz J; Cheon J; Nishida N; Ang C; Marron T; Wu L; Saeed A; Wietharn B; Cammarota A; Pressiani T; Pinter M; Balcar L; Huang YH; Mehan A; Phen S; Vivaldi C; Salani F; Masi G; Bettinger D; Vogel A; Schoenlein M; von Felden J; Schulze K; Wege H; Samson A; Galle P; Kudo M; Cortellini A; Singal A; Rimassa L; Sharma R; Chon HJ; Pinato DJEASL Liver Cancer Summit 2023  2023/04  Estoril, PortugalSurvival outcomes from Atezolizumab plus Bevacizumab versus Lenvatinib versus Sorafenib in Child Pugh B unresectable hepatocellular carcinoma patientsRimini M; Persano M; Tada T; Suda G; Shimose S; Kudo M; Gheon J; Finkelmeier F; Lim HY; Presa J; Masi G; Lonardi S; Piscaglia F; Chon HJ; Scartozzi M; Schirripa M; Cascinu S; Casadei-Gardini AEASL Liver Cancer Summit 2023  2023/04  Estoril, PortugalRegorafenib in patients with unresectable hepatocellular carcinoma in real-world practice: Final analysis of the prospective, observational REFINE study in the sorafenib-intolerant patient subgroupFinn RS; Merle P; Ikeda M; klümpen HJ; Masi G; Granito A; Lim HY; Kudo M; Qin S; Gerolami R; Huang YH; Kim DY; Pinter M; Kato N; Kurosaki M; Numata K; Khan J; Awan M; Qzgurdal K; Kim YJEASL Liver Cancer Summit 2023  2023/04  Estoril, PortugalIMbrave050: Identification of Atezolizumab plus Bevacizumab prognostic index via recursive partitioning analysis in advanced hepatocellular carcinoma: the ABE indexPersano M; Rimini M; Tada T; Suda G; Shigeo S; Kudo M; Cheon J; Finkelmeier F; Presa J; Masi G; Yoo C; Lonardi S; Piscaglia F; De Cobelli F; Aldrighetti L; Rimassa L; Cascinu S; Scartozzi M; Gardini ACEASL Liver Cancer Summit 2023  2023/04  Estoril, PortugalIMbrave050: Phase 3 study of adjuvant atezolizumab + bevacizumab versus active surveillance in patients with hepatocellular carcinoma (HCC) at high risk of disease recurrence following resection or ablationChow P; Chen M; Cheng AL; Kaseb A; Kudo M; Lee HC; Yopp A; Zhou J; Wang L; Wen X; Heo J; Tak WY; Nakamura S; Numata K; Uguen T; Hsiehchen D; Cha E; Hack SP; Lian Q; Spahn J; Wu C; Qin SAmerican Association for Cancer Research Annual Meeting 2023 (AACR A 2023)  2023/04  Orlando, USA免疫複合療法時代における切除不能肝細胞癌へのcancer-free strategy. シンポジウム14「進行肝癌の治療戦略」  [Not invited]回日本消化器病学会総会青木智子, 西田直生志, 工藤正俊  2023/04  出島メッセ長崎, 長崎B-mode超音波検査による肝腫瘤診断を支援する人工知能の開発. シンポジウム3「消化器診療におけるAIの現状と展望」  [Not invited]西田直生志; 工藤正俊第109回日本消化器病学会総会  2023/04  出島メッセ長崎, 長崎ランチョンセミナー「肝細胞癌の薬物治療における最新トピックス~複合免疫療法時代の最適な治療戦略を考える~」  [Invited]工藤正俊第109回日本消化器病学会総会  2023/04  出島メッセ長崎, 長崎特別講演「複合免疫療法時代における最適な治療戦略を考える」  [Invited]工藤正俊肝細胞癌診療Up to date meeting in 川越  2023/03特別講演「レンバチニブがもたらした肝細胞癌の治療変革」  [Invited]工藤正俊HCC Expert Meeting in 愛媛  2023/03  ANAクラウンプラザホテル松山, 愛媛特別講演「レンバチニブがもたらした肝細胞癌の治療変革」  [Invited]工藤正俊LENVIMA-HCC適応追加5周年記念Web Seminar  2023/03特別講演「複合免疫療法時代における最適な治療戦略を考える」  [Invited]工藤正俊Meet the Expert on Hepatocellular Carcinoma  2023/03First-line lenvatinib plus pembrolizumab for advanced hepatocellular carcinoma: LEAP-002 Asian subgroup analysis  [Not invited]Qin S; Ikeda M; Xu R; Ryoo BY; Ren Z; Cheng AL; Kim JH; Kaneko S; Kumada H; Lim HY; Pan H; Dechaphunkul A; Wang A; Mody K; Dubrovsky L; Siegel AB; Kudo MThe Japanese Society of Medical Oncology Annual Meeting (JSMO 2023)  2023/03  Fukuoka, Japan特別講演「複合免疫療法時代における最適な治療戦略を考える」  [Invited]工藤正俊山陰HCC Academy  2023/03  松江エクセルホテル東急, 島根特別講演「複合免疫療法時代における最適な治療戦略を考える」  [Invited]工藤正俊鹿児島肝癌フォーラム  2023/03  TKPガーデンシティ鹿児島, 鹿児島特別講演「複合免疫療法時代における最適な治療戦略を考える」  [Invited]工藤正俊城北HCC webセミナー  2023/03State-of-the-Art Lecture “Nobel treatment strategy in intermediate-stage HCC”  [Invited]Kudp MThe Asian Pacific Association for the Study of the Liver (APASL 2023)  2023/02  Taiwan, TaiwanSystemic therapy in intermediate-stage HCC  [Invited]Kudo MThe Asian Pacific Association for the Study of the Liver (APASL Taipei)  2023/02  Taiwan, Taiwan司会; スペシャルシンポジウムパート1/パート2「薬物療法とアブレーション」  [Invited]工藤正俊第1回日本アブレーション研究会  2023/02  東京大学伊藤国際学術研究センター, 東京特別講演「複合免疫療法時代における最適な治療戦略を考える」  [Invited]工藤正俊城北HCC webセミナー  2023/02特別講演「Combination and harmonization of systemic therapy and TACE in intermediate stage HCC」  [Invited]工藤正俊HCC Pioneers Meeting~TACE+TKI併用治療の新時代の幕開け~  2023/01座長; シンポジウム「肝癌薬物治療による画像変化と病理」  [Invited]工藤正俊第29回肝血流動態・機能イメージ研究会  2023/01BCLC stage A/Bの切除不能肝細胞癌に対するABC conversion療法と造影超音波によるcancer-freeの補助診断  [Invited]青木智子; 依田 広; 千品寛和; 田北雅弘; 萩原 智; 上嶋一臣; 南 康範; 鶴崎正勝; 西田直生志; 工藤正俊第29回肝血流動態・機能イメージ研究会  2023/01特別講演「複合免疫療法時代における最適な治療戦略を考える」  [Invited]工藤正俊Hepatocellular Carcinoma Expert Meeting  2023/01  オリエンタルホテル福岡, 福岡特別講演「Combination and harmonization of systemic therapy and TACE in intermediate stage HCC」  [Invited]工藤正俊HCC Pioneers Meeting~TACE+TKI併用治療の新時代の幕開け~  2023/01IL-6応答亢進を伴う潰瘍性大腸炎関連脊椎関節炎の一例. Young Investigator Session 6「大腸1」.藤田峻輔; 本庶 元; 高田隆太郎; 原 茜; 益田康弘; 半田康平; 三長康輔; 渡邉智裕; 工藤正俊; 辻 成佳日本消化器病学会近畿支部第118回例会  2023/01  京都市勧業館みやこめっせ, 京都Health-related quality of life (HRQoL) impact of lenvatinib (len) plus pembrolizumab (pembro) versus len plus placebo (pbo) as first-line (1L) therapy for advanced hepatocellular carcinoma (aHCC): Phase 3 LEAP-002 studyLlovet JM; Kudo M; Merle P; Meyer T; Qin S; Ikeda M; Xu R; Edeline J; Ryoo BY; Ren Z; Cheng AL; Galle P; Kaneko S; Kumada H; Kamble S; Norquist J; Mody K; Dubrovsky L; Siegel A; Finn RGastrointestinal Cancers Symposium (ASCO-GI 2023)  2023/01  San Francisco, USAReal-world dosing of regorafenib in patients with unresectable hepatocellular carcinoma (uHCC): Final analysis of the prospective, observational REFINE studyFinn R; Merle P; Ikeda M; Klümpen HJ; Masi G; Granito A; Lim HY; Kudo M; Qin S; Gerolami R; Huang YH; Kim DY; Pinter M; Kato N; Kurosaki M; Numata K; Khan J; Ozgurdal K; Kim YJGastrointestinal Cancers Symposium (ASCO-GI 2023)  2023/01  San Francisco, USANeutrophil-to-lymphocyte ratio (NLR) and platelet-to-lymphocyte ratio (PLR) as prognostic biomarkers in unresectable hepatocellular carcinoma (HCC) treated with atezolizumab plus bevacizumab (atezo-bev)Wu L; Fulgenzi C; D’Alessio A; Chon HJ; Kudo M; Schönlein M; Felden J; Wietharn B; Phen S; Scheiner B; Balcar L; Huang YH; Pressiani T; Masi G; Naqash AR; Bettinger D; Vogel A; Galle P; Gaillard V; Ang CGastrointestinal Cancers Symposium (ASCO-GI 2023)  2023/01  San Francisco, USARandomized multicenter phase III trial of neoadjuvant gemcitabine + cisplatin + S-1 (GCS) versus surgery first for resectable biliary tract cancer (JCOG1920: NABICAT)Nara S; Ioka T; Ogawa G; Kataoka T; Sano Y; Esaki M; Nagano H; Kudo M; Ikeda M; Kanai M; Yasuda I; Yamazaki K; Shirakawa H; Kobayashi S; Ozaka M; Gotohda N; Hatano E; Furuse J; Okusaka T; Ueno MGastrointestinal Cancers Symposium (ASCO-GI 2023)  2023/01  San Francisco, USAAtezolizumab plus bevacizumab versus lenvatinib for unresectable hepatocellular carcinoma: A large, real-life, worldwide populationRimini M; Casadei-Gardini A; Persano M; Tada T; Suda G; Shimose S; Kudo M; Cheon J; Finkelmeier F; Rimassa L; Presa J; Masi G; Yoo C; Lonardi S; Scatozzi M; Burgio V; Cascinu S; Cucchetti A; Tovoli FGastrointestinal Cancers Symposium (ASCO-GI 2023)  2023/01  San Francisco, USAReal world data of systemic therapy for hepatocellular carcinoma in Japan: HERITAGE studyAsaoka Y; Tateishi R; Yamada Y; Iijima H; Kato N; Shimada M; Hatano E; Fukumoto T; Murakami T; Yano H; Yoshimitsu K; Kurosaki M; Sakamoto M; Matsuyama Y; Kudo M; Kokudo NGastrointestinal Cancers Symposium (ASCO-GI 2023)  2023/01  San Francisco, USARELATIVITY-106: A phase 1/2 trial of nivolumab (NIVO) + relatlimab (RELA) in combination with bevacizumab (BEV) in first-line (1L) hepatocellular carcinoma (HCC)Sangro B; Yau T; Harding J; Rivera MA; Numata K; El-Khoueiry A; Cruz-Correa M; Perez-Callejo D; McLean S; Sparks J; Neely J; Kudo MGastrointestinal Cancers Symposium (ASCO-GI 2023)  2023/01  San Francisco, USATislelizumab versus sorafenib in first-line treatment of unresectable hepatocellular carcinoma: Impact on health-related quality of life in RATIONALE-301 population.Finn R; Qin S; Kudo M; Meyer T; Boisserie F; Li S; Chen Y; Barnes G; Abdrashitov R; Zhu A; Vogel AGastrointestinal Cancers Symposium (ASCO-GI 2023)  2023/01  San Francisco, USAReal-world data in 1000 patients with unresectable hepatocellular carcinoma (HCC) treated with systemic therapy: Patient background in PRISM studyIkeda M; Itoh S; Tateishi R; Yamashita T; Okusaka T; Kato N; Furuse J; Kudo MGastrointestinal Cancers Symposium (ASCO-GI 2023)  2023/01  San Francisco, USAAchievement of cancer- and treatment-free status by atezolizumab plus bevacizumab combined with or without curative conversion in patients with transarterial chemoembolization-unsuitable, intermediate-­stage hepatocellular carcinoma: A multicenter cohort studyKudo M; Aoki T; Ueshima K; Tsuchiya K; Morita M; Hagiwara S; Minami Y; Ida H; Nishida N; Ogawa C; Tomonari T; Nakamura N; Kuroda H; Takebe A; Takeyama Y; Hidaka M; Eguchi S; Chan S; Kurosaki M; Izumi NGastrointestinal Cancers Symposium (ASCO-GI 2023)  2023/01  San Francisco, USAIMbrave150: Exploratory analysis to examine the association between bevacizumab (bev) ever being skipped and bev never being skipped in patients with unresectable hepatocellular carcinoma (HCC) treated with atezolizumab (atezo) + bev in a global phase 3 studyKudo M; Tsuchiya K; Shao YY; Finn RS; Galle PR; Ducreux M; Cheng AL; Yamashita T; Koga H; Aoki K; Yamada K; Asakawa T; Nakagawa Y; Ikeda MGastrointestinal Cancers Symposium (ASCO-GI 2023)  2023/01  San Francisco, USA肝予備能が良好なレンバチニブ投与例における新規inflammation and liver function-based scoreの有用性  [Not invited]村上詩歩; 多田俊史; 熊田 卓; 平岡 淳; 谷 丈二; 福西新弥; 厚; 辻 邦彦; 石川 達; 高口浩一; 糸林 詠; 田尻和人; 島田紀朋; 柴田啓志; 川田一仁; 豊田秀徳; 能祖一裕; 越智裕紀; 日浅陽一; 工藤正俊第27回日本肝がん分子標的治療研究会  2023/01  大阪国際会議場, 大阪Child-Pugh B患者の切除不能肝細胞癌に対するAtezolizumab+BevacizumabとLenvatinibの治療比較  [Not invited]大濱日出子; 多田俊史; 谷 丈二; 厚川正則; 高口浩一; 糸林 詠; 辻 邦彦; 石川 達; 越智裕紀; 豊田秀徳; 畑中 健; 柿崎 曉; 川田一仁; 的野智充; 能祖一裕; 飯島尋子; 海堀昌樹; 日浅陽一; 工藤正俊; 熊田 卓第27回日本肝がん分子標的治療研究会  2023/01  大阪国際会議場, 大阪ランチョンセミナー「肝細胞癌薬物療法の最新知見」  [Invited]工藤正俊第27回日本肝がん分子標的治療研究会  2023/01  大阪国際会議場, 大阪プレナリーセッション1「切除不能肝細胞癌における薬物療法に関する前向き観察研究(PRISM試験)」  [Not invited]伊藤心二; 池田公史; 建石良介; 山下竜也; 奥坂拓志; 加藤直也; 古瀬純司; 工藤正俊第27回日本肝がん分子標的治療研究会  2023/01  大阪国際会議場, 大阪スポンサードセッション3「Intermediate stage肝細胞癌の治療戦略-ABC conversion therapy-」  [Invited]工藤正俊第27回日本肝がん分子標的治療研究会  2023/01  大阪国際会議場, 大阪特別講演「Combination and harmonization of systemic therapy and TACE in intermediate stage HCC」  [Invited]工藤正俊LEN-TACE Academy in香川  2022/12Invited Lecture “Anti-PD-1/PD-L1 plus anti-VEGF combination immunotherapy for unresectable HCC: Japanese clinical experience”  [Invited]Masatoshi KudoCancer Salon: IO+Bev for HCC  2022/12Invited Lecture “The value and significance of using sonazoid in the whole course of diagnosis and treatment of liver cancer”  [Invited]Masatoshi KudoLiver Cancer Diagnosis and Treatment Summit Forum  2022/12特別講演「Combination and harmonization of systemic therapy and TACE in intermediate stage HCC」  [Invited]工藤正俊HCC Pioneers Meeting~TACE+TKI併用治療の新時代の幕開け~(Web)  2022/12特別講演「Combination and harmonization of systemic therapy and TACE in intermediate stage HCC」  [Invited]工藤正俊HCC Pioneers Meeting~TACE+TKI併用治療の新時代の幕開け~  2022/12座長;「肝細胞癌薬物療法におけるClinical decision marking process~カボザンチニブの役割と可能性~」  [Invited]工藤正俊HCC Expert Web Seminar  2022/12特別講演「Combination and harmonization of systemic therapy and TACE in intermediate stage HCC」  [Invited]工藤正俊HCC Pioneers Meeting~TACE+TKI併用治療の新時代の幕開け~  2022/12特別講演「Combination and harmonization of systemic therapy and TACE in intermediate stage HCC」  [Invited]工藤正俊HCC Pioneers Meeting~TACE+TKI併用治療の新時代の幕開け~  2022/12ランチョンセミナー「BCLC-B, C肝細胞癌に対するLEN-TACE治療」  [Invited]工藤正俊第118回日本消化器病学会中国支部例会, 第129回日本消化器内視鏡学会中国支部例会  2022/12  KDDI維新ホール, 山口irAE腸炎による消化管穿孔に対してステロイド前のinfliximab選考投与により救命できた1例萩原 智; 西田直生志; 工藤正俊第44回日本肝臓学会東部会  2022/11  仙台国際センター, 宮城NAFLD関連肝癌における背景肝のエピゲノム変異の蓄積. シンポジウム1「代謝性肝疾患の標準治療確立のためのエビデンス構築」萩原 智; 西田直生志; 工藤正俊第44回日本肝臓学会東部会  2022/11  仙台国際センター, 宮城ランチョンセミナー「肝細胞癌の複合免疫療法-最新の話題を含めて-」  [Invited]工藤正俊第44回日本肝臓学会東部会  2022/11  仙台国際センター, 宮城県座長「がん免疫療法に関する非臨床育薬研究~Mechanism in Non-inflamed Tumor」  [Invited]工藤正俊Chugai Cancer Immunotherapy Forum 2022  2022/11  品川プリンスホテル, 東京座長「肝疾患栄養代謝マネジメント~アンモニア代謝異常潜在期(LAM)における代謝ドミノと亜鉛~」  [Invited]工藤正俊肝疾患の栄養代謝マネジメント  2022/11Invited Lecture “The trends of development in treatment of advanced liver cancer in Japan”  [Invited]Masatoshi KudoNational Launch Conference (web)  2022/11当院におけるEUS-BD事前準備の工夫. シンポジウム2「胆管ドレナージの現状と課題」  [Not invited]福永朋洋; 大本俊介; 山崎友裕; 竹中 完; 工藤正俊第109回日本消化器内視鏡学会近畿支部例会  2022/11  京都リサーチバーク, 京都特別講演「肝細胞癌に対する免疫療法~特にABC Conversionについて~」  [Invited]工藤正俊肝細胞癌セミナー~ABC conversionを中心に~  2022/10  札幌グランドホテル, 北海道腹部超音波動画からの肝腫瘍検出AIシステムの開発. 統合プログラム6「AI研究の実装化に向けた課題」目加田慶人; 西田直生志; 工藤正俊第30回日本消化器関連学会週間JDDW 2022(第26回日本肝臓学会大会・第64回日本消化器病学会・第104回日本消化器内視鏡学会総会合同)  2022/10  福岡サンパレス, 九州肝細胞癌の微小環境と再発予防における免疫チェックポイント阻害剤の効果. 統合プログラム5「消化器癌に対する免疫療法の実態」西田直生志; 上嶋一臣; 工藤正俊第30回日本消化器関連学会週間JDDW 2022(第26回日本肝臓学会大会・第64回日本消化器病学会・第104回日本消化器内視鏡学会総会合同)  2022/10  福岡サンパレス, 九州切除不能肝細胞癌におけるhyper progressive disease (HPD)の頻度と有効な後治療. ワークショップ8「進行肝癌の薬物治療の課題と展望」青木智子; 西田直生志; 工藤正俊第30回日本消化器関連学会週間JDDW 2022(第26回日本肝臓学会大会・第64回日本消化器病学会・第104回日本消化器内視鏡学会総会合同)  2022/10  福岡サンパレス, 九州当院における潰瘍性大腸炎患者に対するベドリズマブの治療成績と有効症例の検討.  [Not invited]河野匡志; 米田頼晃; 工藤正俊第30回日本消化器関連学会週間JDDW 2022(第26回日本肝臓学会大会・第64回日本消化器病学会・第104回日本消化器内視鏡学会総会合同)  2022/10  福岡サンパレス, 九州基調講演「Intermediate stage肝細胞癌の治療戦略」  [Invited]工藤正俊第30回日本消化器関連学会週間JDDW 2022(第26回日本肝臓学会大会・第64回日本消化器病学会・第104回日本消化器内視鏡学会総会合同)  2022/10  マリンメッセ福岡, 九州座長: パネルディスカッション6「肝癌intermediate stageの治療戦略」  [Invited]工藤正俊第30回日本消化器関連学会週間JDDW 2022(第26回日本肝臓学会大会・第64回日本消化器病学会・第104回日本消化器内視鏡学会総会合同)  2022/10  マリンメッセ福岡, 九州ランチョンセミナー「肝内病変に着目した肝細胞癌治療戦略」  [Invited]工藤正俊第26回日本肝臓学会大会(JDDW 2022 Fukuoka)  2022/10  福岡サンパレス, 九州Invited Lecture “New stage of treatment strategies for HCC-focusing on intrahepatic tumors”  [Invited]Masatoshi KudoThe 2022 CJLCA Summit Forum  2022/10特別講演「Intermediate stage肝癌の治療戦略~ABC Conversion Therapy~」  [Invited]工藤正俊CHUGAI Web講演会  2022/10Invited Lecture “Multidisciplinary management of intermediate stage HCC”  [Invited]Masatoshi KudoAsian Pacific Association for the Study of the Liver 2022 (APASL 2022)  2022/10膵性胸水に対して内視鏡的膵管ドレナージが奏功した1例山本智輝; 橋本有人; 森下剛至; 上中大地; 河野辰哉; 木下大輔; 川崎俊彦; 水野成人; 工藤正俊日本消化器病学会近畿支部第117回例会  2022/10  大阪国際交流センター, 大阪空腸濾胞性リンパ腫から形質転換した腹部Double Expressor Lymphoma(DEL)の1例高田隆太郎; 三長孝輔; 渡邉智裕; 工藤正俊日本消化器病学会近畿支部第117回例会  2022/10  大阪国際交流センター, 大阪COVID-19ワクチン接種後のI型インターフェロン反応を特徴とする潰瘍性大腸炎再発の一例.益田康弘; 三長孝輔; 渡邉智裕; 工藤正俊日本消化器病学会近畿支部第117回例会  2022/10  大阪国際交流センター, 大阪診断に難渋した肝限局性脂肪沈着の一例. Young Investigator Session 13「肝3」森下剛至; 川崎俊彦; 山本智輝; 上中大地; 河野辰哉; 橋本有人; 木下大輔; 水野成人; 石川 原; 若狭朋子; 工藤正俊日本消化器病学会近畿支部第117回例会  2022/10  大阪国際交流センター, 大阪急激な経過を辿ったClostridium perfringens肝膿瘍・多臓器ガス壊疽の1例. Young Investigator Session 11「肝2」原 茜; 大塚康生; 三長孝輔; 渡邉智裕; 工藤正俊; 梶山 博日本消化器病学会近畿支部第117回例会  2022/10  大阪国際交流センター, 大阪複合免疫療法時代における切除不能肝細胞癌に対するconversion療法. シンポジウム2「消化器癌に対する薬物療法」.青木智子; 上嶋一臣; 工藤正俊日本消化器病学会近畿支部第117回例会  2022/10  大阪国際交流センター, 大阪特別講演「肝細胞癌に対する免疫療法~特にABC Conversionについて~」  [Invited]工藤正俊テセントリク/アバスチン-肝細胞癌-適正使用カンファレンス  2022/10  レンブラントホテル, 大分特別講演「Intermediate stage肝癌の治療戦略~ABC Conversion Therapy~」  [Invited]工藤正俊Mikawa HCC Clinical Conference  2022/09特別講演「BCLC-B, C肝細胞癌に対するLEN-TACE治療」  [Invited]工藤正俊HCC Expert Meeting in 愛媛  2022/09  ホテルマイステイズ松山, 愛媛Invited Lecture “Combination and harmonization of systemic therapy and TACE in intermediate stage HCC”  [Invited]Masatoshi KudoLenvima-HCC International Exchange Web Seminar  2022/09Invited Lecture “Current best option of systemic therapy in HCC”  [Invited]Masatoshi KudoTaiwan Digestive Disease Week 2022 (TDDW 2022)  2022/09Invited Lecture “New stage of treatment strategies for HCC -Focusing on intrahepatic tumor”  [Invited]Masatoshi KudoThe 6th Northeast Provices Summit Forum on Tumor Interventional and Minimally Invasive Treatment and the 4th Tumor Minimally Invasive Treatment Forum in Dalian  2022/09Invited Lecture “New paradigm of treatment strategy for patients in BCLC B HCC”  [Invited]Masatoshi KudoThe 4th Hubei Provincial Symposium on Precise and Minimally Invasive Comprehensive Diagnosis and Treatment of Hepatobiliary and Pancreatic Tumors  2022/09Luncheon Seminar “Early detection of HCC using HCC biomarkers and GALAD score”  [Invited]Masatoshi KudoTDDW 2022  2022/09リザーバー留置後に胃よりカテーテルの逸脱を認めた一例  [Not invited]大丸直哉; 田北雅弘; 浦瀬篤史; 千品寛和; 青木智子; 萩原 智; 依田 広; 上嶋一臣; 鶴崎正勝; 西田直生志; 工藤正俊第46回リザーバー&ポート研究会  2022/09  久留米シティプラザ, 九州ランチョンセミナー「肝細胞癌に対する分子標的薬・免疫療法ならびに新規治療法の開発」  [Invited]工藤正俊第46回リザーバー&ポート研究会  2022/09  久留米シティプラザ, 九州Final Analysis of RATIONALE-301: Randomized, Phase 3 study of tislelizumab versus sorafenib as first-line treatment for unresectable hepatocellular carcinomaQin S; Kudo M; Meyer T; Finn R; Vogel A; Bai Y; Guo Y; Meng Z; Zhang T; Satho T; Hiraoka A; Marino D; Assenat E; Wyrwicz L; Calvo Campos M; Hsing-Tao K; Boisserie F; Li S; Chen Y; Zhu AESMO Congress 2022  2022/09  Paris, FrancePrimary results from the phase 3 LEAP-002 study: lenvatinib plus pembrolizumab versus lenvatinib as first-line (1L) therapy for advanced hepatocellular carcinoma (aHCC)  [Not invited]Finn R; Kudo M; Merle P; Meyer T; Qin M; Ikeda M; Xu R; Edeline J; Ryoo BY; Ren Z; Cheng AL; Galle P; Kaneko S; Kumada H; Wang A; Mody K; Dubrovsky L; Siegel A; Llovet JESMO Congress 2022  2022/09  Paris, Franceランチョンセミナー「肝細胞癌に対する免疫療法~特にABC Conversionについて~」  [Invited]工藤正俊第29回日本門脈圧亢進症学会総会  2022/09  グランキューブ大阪, 大阪特別講演「肝細胞癌に対する免疫療法~特にABC Conversionについて~」  [Invited]工藤正俊横浜南西部肝細胞がん診療セミナー  2022/09Selection of anti-PD-1 antibody effective group using tumor immunological microenvironment. Workshop 15 “Biomarker research on liver cancer for clinical applications including HCC, CCC and metastatic liver cancer”Morita M; Nishida N; Kudo MAPASL Oncology 2022 Takamatsu  2022/09  Takamatsu, JapanTransition of treatment selection for primary liver cancer and eecompensated cirrhosis in multiple admissions: Analysis of a nationwide registry for advanced liver diseases (REAL). Workshop 14 “Treatment strategies for liver cirrhosis”Okushin K; Tateishi R; Takahashi A; Uchino K; Nakagomi R; Nakatsuka T; Minami T; Sato M; Fujishiro M; Hasegawa K; Eguchi Y; Kanto T; Kubo S; Yoshiji H; Miyata H; Izumi N; Kudo M; Koike KAPASL Oncology 2022 Takamatsu  2022/09  Takamatsu, JapanKeynote Lecture “Treatment of Intermediate-stage Hepatocellular Carcinoma”  [Invited]Masatoshi KudoAPASL Oncology 2022 Takamatsu  2022/09Chair; Workshop 19 “Treatment of Intermediate-stage Hepatocellular Carcinoma”  [Invited]Masatoshi KudoAPASL Oncology 2022 Takamatsu  2022/09Examination of NASH-related liver carcinogenesis from non-developed fibrosis. Workshop 9 “Molecular mechanisms of liver cancer (including HCC, CCC and metastatic liver cancer)Hagiwara S; Nishida N; Kudo MAPASL Oncology 2022 Takamatsu  2022/09  Takamatsu, JapanState-of-the Art Lecture “Sequential therapy for HCC after failure of atezolizumab plus bevacizumab”  [Invited]Masatoshi KudoThe 12th Asia-Pacific Primary Liver Cancer Expert Meeting (APPLE 2022)  2022/08Chair; Topic 2 “The evolution of systemic treatment for HCC”  [Invited]Masatoshi KudoThe 12th Asia-Pacific Primary Liver Cancer Expert Meeting (APPLE 2022)  2022/08司会: 肝臓領域の最近の話題と肝臓学会の将来~C型肝炎治療の残された話題、肝癌治療の今後、B型肝炎・NASHの新規治験も含めて~  [Invited]工藤正俊南大阪肝疾患フォーラム  2022/07  スイスホテル南海大阪, 大阪Invited Lecture “New stage of treatment strategies for HCC -Focusing on intrahepatic tumor”  [Invited]Masatoshi KudoHepatocellular Carcinoma Masterclass 2022  2022/07  Island Shangri-La, Hong Kong司会; 特別講演「B型肝炎創薬研究の現状と臨床応用への展開」  [Invited]工藤正俊第6回関西肝疾患フォーラム  2022/07  シェラトン都ホテル大阪, 大阪特別講演「肝細胞癌に対する免疫療法~特にABC Conversionについて~」  [Invited]工藤正俊Hepatocellular Carcinoma Web Seminar in Aomori  2022/07特別講演「肝細胞癌に対する免疫療法~特にABC Conversionについて~」  [Invited]工藤正俊日本消化器病学会関東支部第370回例会  2022/07特別講演「肝細胞癌の複合免疫療法~最新の話題を含めて~」  [Invited]工藤正俊第3回県央・県北HCC Webセミナー  2022/07特別講演「肝細胞癌に対する免疫療法~特にABC Conversionについて~」  [Invited]工藤正俊SMUO Hepatology 2022-肝細胞がん治療の新たなステージ-  2022/07教育講演「肝細胞癌の薬物療法: 最新の話題」  [Invited]工藤正俊第66回生涯教育講演会  2022/07  日本都市センター, 東京特別講演「肝細胞癌に対する免疫療法~特にABC Conversionについて~」  [Invited]工藤正俊第45回岐阜肝臓病勉強会  2022/07特別講演「肝細胞癌に対する免疫療法~特にABC Conversionについて~」  [Invited]工藤正俊テセントリク・アバスチン適正使用セミナー on Hepatocellular Carcinoma  2022/07特別講演「肝細胞がん治療の現状」  [Invited]工藤正俊Hepatocellular Carcinoma Summit 2022  2022/07特別講演「Intermediate stage肝癌の治療戦略~ABC Conversionを含めて~」  [Invited]工藤正俊HCC Expert Meeting 2022  2022/06  オークスカナルパークホテル富山, 富山ランチョンセミナー「進行肝細胞癌の薬物治療における最新知見~Molecular Markerを含めて~」  [Invited]工藤正俊第26回日本肝がん分子標的治療研究会  2022/06  軽井沢プリンスホテルウエスト, 長野県ABC LEN-TACE Sandwich療法にてcancer free, drug freeが得られたPET陽性肝癌の1例  [Invited]萩原 智; 大丸直哉; 松原卓哉; 千品寛和; 盛田真弘; 青木智子; 田北雅弘; 南 康範; 依田 広; 上嶋一臣; 西田直生志; 工藤正俊第68回大阪肝穿刺生検治療研究会  2022/06特別講演「新たなステージを迎えた肝細胞癌治療戦略」  [Invited]工藤正俊第7回東北のHCC治療を考える会 (Web)  2022/06特別講演「肝細胞癌に対する免疫療法~特にABC Conversionについて~」  [Invited]工藤正俊茨城県南肝がん薬物療法セミナー  2022/06非代償性肝硬変による直腸静脈瘤出血に対して内視鏡的組織接着剤注入術を施行した1例加藤弘樹; 松井繁長; 田北雅弘; 上中大地; 今村瑞貴; 原 茜; 野村健司; 瀬海郁衣; 高田隆太郎; 河野匡志; 正木 翔; 永井知行; 本庶 元; 米田頼晃; 上嶋一臣; 渡邉智裕; 西田直生志; 辻 直子; 樫田博史; 工藤正俊第108回日本消化器内視鏡学会近畿支部例会  2022/06  メルパルク京都, 京都安全に内視鏡治療できた小腸pyogenic granuloma(化膿性肉芽腫)の一例, Young Endoscopist Session 4「小腸1」  [Not invited]有山武尊; 米田頼晃; 加藤弘樹; 瀬海郁衣; 原 茜; 野村健司; 高田隆太郎; 正木 翔; 河野匡志; 永井知行; 本庶 元; 松井繁長; 辻 直子; 樫田博史; 工藤正俊第108回日本消化器内視鏡学会近畿支部例会  2022/06  メルパルク京都, 京都胆嚢結石を合併した総胆管結石に対する内視鏡治療戦略の検討—術前にとるか術後にとるか—, シンポジウム2「胆膵内視鏡治療の工夫とリスクマネージメント」  [Not invited]高島耕太; 三長孝輔; 鎌田 研; 竹中 完; 工藤正俊第108回日本消化器内視鏡学会近畿支部例会  2022/06  メルパルク京都, 京都カプセル内視鏡検査を用いた小腸病変の検出におけるEfficientGANを用いた検出時間の短縮. ワークショップ2「小腸内視鏡診療の現況と課題」  [Not invited]印牧奨真; 半田久志; 羽鳥祥平; 米田頼晃; 工藤正俊第108回日本消化器内視鏡学会近畿支部例会  2022/06  メルパルク京都, 京都特別講演「肝細胞癌に対する免疫療法~特にABC Conversionについて~」  [Invited]工藤正俊第4回岩手肝癌セミナー  2022/06特別講演「肝細胞癌に対する免疫療法~特にABC Conversionについて~」  [Invited]工藤正俊Hepatocellular Carcinoma Expert Meeting  2022/06開会/閉会の辞  [Invited]工藤正俊第19回大阪消化器化学療法懇話会(Web)  2022/05Invited Lecture “Treatment of Intermediate-stage HCC”  [Invited]Masatoshi KudoSociety of Interventional Radiology (SIR), USA  2022/05特別講演;新たなステージを迎えたintermediate;stage HC;治療戦略  [Invited]工藤正俊HCC Expert Meeting in 愛媛~次世代のIntermediate Stage治療アルゴリズム~  2022/04特別講演「肝細胞癌治療のパラダイムチェンジ」  [Invited]工藤正俊Meet the Expert in Hepatocellular Carcinoma (2022 Spring)  2022/04線維化非進展例からの NASH 関連肝癌発症様式の検討. ワークショップ10「肝疾患の遺伝子解析による病態解明と臨床展開」萩原 智; 西田直生志; 工藤正俊第108回日本消化器病学会総会  2022/04  京王プラザホテル, 東京肝癌診療ガイドラインにおける肝動注化学療法の立ち位置と今後の展開. シンポジウム13「病態からみた肝癌治療アルゴリズムの今後」上嶋一臣; 田北雅弘; 工藤正俊第108回日本消化器病学会総会  2022/04  京王プラザホテル, 東京門脈腫瘍栓合併肝細胞癌に対する肝切除・ソラフェニブ治療成績の検討. シンポジウム13「病態からみた肝癌治療アルゴリズムの今後」小松昇平; 工藤正俊; 福本 巧第108回日本消化器病学会総会  2022/04  京王プラザホテル, 東京クローン病疾患感受性遺伝子 NOD2 の欠損は T 細胞依存性腸炎の発症を抑制する. ワークショップ7「消化管疾患の遺伝子解析による病態解明・臨床展開」高田隆太郎; 渡邉智裕; 工藤正俊第108回日本消化器病学会総会  2022/04  京王プラザホテル, 東京自己免疫性膵炎の発症に関わるサイトカイン・ケモカインネットワークの解明と新規バイオマーカーの同定. ワークショップ4「自己免疫性肝胆膵疾患の新展開」原 茜; 渡邉智裕; 工藤正俊第108回日本消化器病学会総会  2022/04  京王プラザホテル, 東京肝細胞癌における腫瘍微小免疫環境と免疫チェックポイント阻害剤の効果. シンポジウム5「消化器癌における免疫治療と分子標的治療の基礎研究と臨床」  [Not invited]西田直生志; 上嶋一臣; 工藤正俊第108回日本消化器病学会総会  2022/04  京王プラザホテル, 東京学術賞受賞講演「肝細胞癌に対する分子標的薬・免疫療法ならびに新規治療法の開発」  [Invited]工藤正俊第108回日本消化器病学会総会  2022/04  京王プラザホテル, 東京イブニングセミナー「進行肝細胞癌に対する二次薬物療法~肝予備能維持を踏まえた治療シークエンス~」  [Invited]工藤正俊第108回日本消化器病学会総会  2022/04  京王プラザホテル, 東京地域連携システムを用いた膵癌早期診断―MAGURO プロジェクトの成績と地域医療機関への意識調査―. ワークショップ15「膵癌の早期診断を目指した病態解明と診療戦略」山雄健太郎; 竹中 完; 工藤正俊第108回日本消化器病学会総会  2022/04  京王プラザホテル, 東京腸管バリアの破壊に伴い,膵臓に定着する Staphylococcus sciuri が自己免疫性膵炎の発症に果たす役割. ワークショップ1「マイクロバイオーム解析による消化器疾患の病態解明と応用」吉川智恵; 渡邉智裕; 工藤正俊第108回日本消化器病学会総会  2022/04  京王プラザホテル, 東京総括; パネルディスカッション7「:進行肝癌の病態解明と治療の展開」  [Invited]工藤正俊第108回日本消化器病学会総会  2022/04  京王プラザ, 東京非ウイルス性切除不能肝癌に対する全身薬物療法:レンバチニブの治療成績. パネルディスカッション7「進行肝癌の病態解明と治療の展開」平岡 淳; 熊田 卓; 工藤正俊第108回日本消化器病学会総会  2022/04  京王プラザホテル, 東京急性膵炎に潜む膵癌症例の検討-MRCP, EUSの早期積極的介入は微小膵癌発見および膵癌予後改善に寄与する-. パネルディスカッション13「胆膵診療ガイドラインの未解決問題に対する病態解明と戦略」吉田晃浩; 山雄健太郎; 竹中 完; 工藤正俊第108回日本消化器病学会総会  2022/04  京王プラザホテル, 東京Invited Lecture “ABC Conversion for Intermediate-stage HCC”  [Invited]Masatoshi KudoSino-Japan HCC Webinar  2022/04Educational Lecture “Treatment of HCC”  [Invited]Masatoshi KudoSociety of International Digestive Disease (SIDD)  2022/04教育講演「肝細胞癌の全身化学療法」  [Invited]工藤正俊第81回日本医学放射線学会総会  2022/04  パシフィコ横浜, 神奈川Pembrolizumab (pembro) for previously treated advanced hepatocellular carcinoma (aHCC): meta-analysis of the phase 3 KEYNOTE-240 and KEYNOTE-394 studies  [Not invited]Finn RS; Gu K; Chen X; Merle P; Lee KH; Bouattour M; Cao P; Wang W; Cheng AL; Zhu L; Lim HY; Kudo M; Pan Y; Chang TT; Edeline J; Li W; Yang P; Li C; Li, J; Siegel AB; Qin SAmerican Association for Cancer Research Annual Meeting (AACR 2022)  2022/04  New Orleans, Louisiana, USA特別講演「肝細胞癌薬物療法2022 up date」  [Invited]工藤正俊第1回大阪消化器・肝臓フォーラム  2022/04  アゴーラリージェンシー大阪堺, 大阪Luncheon Seminar “ABC Conversion Therapy for HCC”  [Invited]Masatoshi Kudo31st Conference of the Asian Pacific Association for the Study of the Liver (APASL 2022)  2022/04Invited Lecture “LEN-TACE Sequential Therapy for Intermediate-stage HCC”  [Invited]Masatoshi KudoChina Doctors Association  2022/03診断に難渋した髄膜腫の既往を持つ症例に発生した膵多発腫瘍の一例吉田晃浩; 山雄健太郎; 竹中 完; 工藤正俊; 松本逸平; 鶴崎正勝; 筑後孝章; 天野良亮第75回消化器画像診断研究会  2022/03  さいたま新都心ホテルブリランテ武蔵野, 東京ランチョンセミナー「肝細胞癌治療のパラダイムチェンジ~ABC conversionを含めて~」  [Invited]工藤正俊第130回日本消化器病学会北海道支部例会, 第124回日本消化器内視鏡学会北海道支部例会ランチョンセミナー  2022/03Invited Lecture “Treatment strategy of intermediate stage HCC”  [Invited]Masatoshi KudoIndian Association of Cancer Research  2022/03Invited Lecture “Hepatocellular Carcinoma Masterclass”  [Invited]Masatoshi KudoChina Japan Liver Cancer Association  2022/02特別講演「新たなステージを迎えたintermediate stage HCC治療戦略」  [Invited]工藤正俊肝癌診療を考える会~免疫療法時代における薬物治療を考える~  2022/02Chair; Medical Seminar 18「Latest treatment strategy on advanced HCC at the ERA of cancer immunotherapy」  [Invited]Masatoshi Kudo2022 the Japanese Society of Medical Oncology Annual Meeting  2022/02  Kyoto International Conference Center, KyotoInvited Lecture “Atezolizumab plus Bevacizumab in Advanced HCC”  [Invited]Masatoshi KudoRoche E Seminar  2022/02特別講演「肝細胞癌治療のパラダイムチェンジ~ABC conversionを含めて~」  [Invited]工藤正俊Meet the Expert webセミナー  2022/02制御性T細胞に依存しない寛解導入が得られたCollagenous Colitisの一例, Young Investigator Session 15「大腸2」  [Not invited]瀬海郁衣; 本庶 元; 今村瑞貴; 松原卓哉; 河野匡志; 原 茜; 栗本真之; 吉川馨介; 益田康弘; 大塚康生; 高田隆太郎; 吉川智恵; 鎌田; 三長孝輔; 松井繁長; 木村雅友; 渡邉智裕; 工藤正俊日本消化器病学会近畿支部第116回例会  2022/02  日本消化器病学会近畿支部第116回例会EUS-FNAにより診断が可能であった、後腹膜DLBCLの1例, Young Investigator Session 12「その他」  [Not invited]大丸直哉; 松原卓哉; 今村瑞貴; 田中秀和; 半田康平; 河野辰哉; 木下大輔; 川崎俊彦; 水野成人; 若狭朋子; 大谷知之; 山田 薫; 花本 仁; 工藤正俊日本消化器病学会近畿支部第116回例会  2022/02  大阪国際会議場, 大阪浸潤性膵管癌、腺扁平上皮癌が重複膵管に同時発生した1例, Young Investigator Session 10「膵1」  [Not invited]加藤弘樹; 大本俊介; 原 茜; 大塚康生; 益田康弘; 高島耕太; 吉田晃浩; 福永朋洋; 岡本彩那; 山崎友裕; 鎌田 研; 三長孝輔; 竹中 完; 筑後孝章; 工藤正俊日本消化器病学会近畿支部第116回例会  2022/02  大阪国際会議場, 大阪腸内細菌に対する炎症性サイトカイン応答の増強を示すクローン病関連脊椎関節炎の1例, Young Investigator Session 8「小腸1」  [Not invited]福西香栄; 本庶 元; 岡井夏輝; 河野匡志; 鎌田 研; 三長孝輔; 米田頼晃; 辻 成佳; 渡邉智裕; 工藤正俊日本消化器病学会近畿支部第116回例会  2022/02  大阪国際会議場, 大阪肝細胞癌根治後に出現したため、肝細胞癌との鑑別診断が困難であった限局性結節性過形成の1例, Young Investigator Session 1「肝1」  [Not invited]松原卓哉; 河野辰哉; 今村瑞貴; 大丸直哉; 田中秀和; 半田康平; 橋本有人; 木下大輔; 川崎俊彦; 水野成人; 若狭朋子; 工藤正俊日本消化器病学会近畿支部第116回例会  2022/02  大阪国際会議場, 大阪上・下腸管膜動静脈奇形に伴う門脈圧亢進から難治性腹水及び循環血液量低下に伴う血圧低下に対し血管内治療(IVR)にて改善しえた1例, Freshman Session 4「大腸」  [Not invited]上原広樹; 田北雅弘; 杉森啓伸; 岡井夏輝; 野村健司; 盛田真弘; 千品寛和; 青木智子; 萩原 智; 依田 広; 南 康範; 上嶋一臣; 西田直生志; 工藤正俊日本消化器病学会近畿支部第116回例会  2022/02  大阪国際会議場, 大阪免疫チェックポイント阻害剤投与後に発現した肝障害の臨床的、病理学的検討, ワークショップ2「免疫チェックポイント阻害剤をめぐる諸問題」  [Not invited]萩原 智; 上嶋一臣; 西田直生志; 工藤正俊日本消化器病学会近畿支部第116回例会  2022/02  大阪国際会議場, 大阪ICI投与とHBVフォローにおける問題点, ワークショップ1「肝炎ウイルスコントロール下における課題へのアプローチ」  [Not invited]盛田真弘; 萩原 智; 西田直生志; 工藤正俊日本消化器病学会近畿支部第116回例会  2022/02  大阪国際会議場, 大阪地域連携システムを用いた膵癌早期診断—MAGURO projectの成績—, シンポジウム「膵癌診療の進歩と今後の展望」  [Not invited]益田康弘; 山雄健太郎; 竹中 完; 工藤正俊日本消化器病学会近畿支部第116回例会  2022/02  大阪国際会議場, 大阪特別講演「新たなステージを迎えたintermediate stage HCC治療戦略」  [Invited]工藤正俊HCC Expert Meeting;免疫療法時代における薬物治療を考える  2022/02Regorafenib in patients with unresectable hepatocellular carcinoma in routine clinical practice: Exploratory analysis of safety and overall survival in the prospective, observational REFINE study  [Not invited]Finn RS; Kudo M; Kim YJ; Lim HY; Merle P; Ikeda M; Masi G; Frenette CT; Klümpen HJ; Gerolami R; Kurosaki M; Numata K; Pisarenko J; Khan J; Ozgurdal K; Qin SEASL Liver Cancer Summit 2022  2022/02Progression patterns and therapeutic sequencing following immune checkpoint inhibition for HCC: an observational study  [Not invited]Talbot T; D’Alessio A; Pinter M; Balcar L; Scheiner B; Marron TU; Jun T; Dharmapuri S; Ang C; Saeed A; Hildebrand H; Muzaffar M; Fulgenzi CAM; Amara S; Naqash AR; Gampa A; Pillai A; Wang Y; Khan U; Lee PC; Huang YH; Bengsch B; Bettinger D; Abugabal YI; Kaseb A; Pressiani T; Personeni N; Rimassa L; Nishida N; Kudo M; Weinmann A; Galle PR; Muhammed A; Cortellini A; Vogel A; Pinato DJEASL Liver Cancer Summit 2022  2022/02特別講演「腫瘍免疫微小環境におけるAtezolizumab+Bevacizumab併用療法の意義」  [Invited]工藤正俊中外Eセミナー  2022/02Wnt/β-cateninおよびHFN4α変異を有する肝細胞癌における免疫チェックポイント阻害薬  [Invited]青木智子; 上嶋一臣; 盛田真弘; 千品寛和; 田北雅弘; 萩原 智; 南 康範; 依田 広; 祖父江慶太郎; 西田直生志; 工藤正俊第28回肝血流動態・機能イメージ研究会  2022/01Invited Lecture “Treatment strategy of intermediate stage HCC”  [Invited]Masatoshi KudoHCC Connect  2022/01特別講演「腹部エコーによる、多発性嚢胞腎のスクリーニング」  [Invited]工藤正俊肝腎連携の会  2022/01特別講演「肝細胞癌治療のパラダイムチェンジ」  [Invited]工藤正俊山口消化器癌セミナー  2022/01  ANAクラウンプラザホテル宇部, 山口Final results of adjuvant nivolumab for hepatocellular carcinoma (HCC) after surgical resection (SR) or radiofrequency ablation (RFA) (NIVOLVE): A phase 2 prospective multicenter single-arm trial and exploratory biomarker analysis  [Not invited]Kudo M; Ueshima K; Nakahira S; Nishida N; Ida H; Minami Y; Nakai T; Wada H; Kubo S; Ohkawa K; Morishita A; Nomi T; Ishida K; Kobayashi S; Umeda M; Tsurusaki M; Chiba Y; Yoshimura K; Sakai K; Nishio KGastrointestinal Cancers Symposium (ASCO-GI 2022)Safety and efficacy of durvalumab plus bevacizumab in unresectable hepatocellular carcinoma: Results from the phase 2 study 22 (NCT02519348)  [Not invited]Lim HY; Heo J; Kim TY; Meng W; Tai D; Kang YK; Lau G; Kudo M; Tak WY; Watras M; Ali SK; Negro A; Abou-Alfa GK; Kelley RKGastrointestinal Cancers Symposium (ASCO-GI 2022)  2022/01Phase 3 randomized, open-label, multicenter study of tremelimumab and durvalumab as first-line therapy in patients with unresectable hepatocellular carcinoma (uHCC): HIMALAYA  [Not invited]Abou-Alfa GK; Chan SL; Kudo M; Lau G; Kelley RK; Furuse J; Sukeepaisarnjaroen W; Kang YK; Tu DV; De Toni EN; Rimassa L; Breder VV; Vasilyev A; Heurgue A; Tam V; Mody K; Thungappa SC; He P; Negro A; Sangro BGastrointestinal Cancers Symposium (ASCO-GI 2022)  2022/01Transcatheter arterial chemoembolization therapy in combination strategy with lenvatnib in patients with unresectable hepatocellular carcinoma (TACTICS-L) in Japan: Final analysis  [Not invited]Ueshima K; Ishikawa T; Saeki I; Morimoto N; Aikata H; Tanabe N; Inaba Y; Wada Y; Kondo Y; Tsuda M; Nakao K; Ikeda M; Moriguchi M; Ito T; Kobayashi M; Koga H; Hino K; Suzuki Y; Yoshimura K; Kudo MGastrointestinal Cancers Symposium (ASCO-GI 2022)  2022/01Regorafenib in patients with unresectable hepatocellular carcinoma (uHCC) in routine clinical practice: Exploratory analysis of overall survival (OS) in the prospective, observational REFINE study  [Not invited]Finn RS; Kudo M; Klumpen HJ; Lim HY; Merle P; Ikeda M; Masi G; Frenette CT; Kim YJ; Gerolami R; Kurosaki M; Numata K; Pisarenko J; Ozgurdal K; Qin SGastrointestinal Cancers Symposium (ASCO-GI 2022)  2022/01LEAP-012 trial in progress: Transarterial chemoembolization (TACE) with or without lenvatinib plus pembrolizumab for intermediate-stage hepatocellular carcinoma (HCC) not amenable to curative treatment  [Not invited]El-Khoueiry AB; Llovet J; Vogel A; Madoff DC; Finn RS; Ogasawara S; Ren Z; Mody K; Li JJ; Siegel AB; Dubrovsky L; Kudo MGastrointestinal Cancers Symposium (ASCO-GI 2022)  2022/01TALENTACE: A phase III, open-label, randomized study of on-demand transarterial chemoembolization combined with atezolizumab + bevacizumab or on-demand transarterial chemoembolization alone in patients with untreated hepatocellular carcinoma  [Not invited]Kudo M; Guo Y; Hua Y; Zhao M; Xing W; Zhang Y; Liu R; Ren Z; Gu S; Lin Z; Lv W; Wang Y; Dong JGastrointestinal Cancers Symposium (ASCO-GI 2022)  2022/01特別講演「肝細胞癌治療のパラダイムチェンジ」  [Invited]工藤正俊岡山肝癌Expert Seminar  2022/01  ホテルグランヴィア岡山, 岡山特別講演「新たなステージを迎えたintermediate stage HCC治療戦略」  [Invited]工藤正俊HCC Pioneers Meeting in 九州  2022/01特別講演「私と肝細胞癌診療~若手医師への提言も含めて~」  [Invited]工藤正俊広島腫瘍セミナー2022  2022/01共催シンポジウム「進行肝細胞癌の薬物治療における最新知見~Molecular Markerを含めて~」  [Invited]工藤正俊第25回日本肝がん分子標的治療研究会  2022/01  ホテル日航福岡, 九州共催シンポジウム「新たなステージを迎えたintermediate stage HCC治療戦略」  [Invited]工藤正俊第25回日本肝がん分子標的治療研究会  2022/01  ホテル日航福岡, 九州特別講演「新たなステージを迎えたintermediate stage HCC治療戦略」  [Invited]工藤正俊HCC Pioneers Meeting in 北海道  2021/12特別講演「新たなステージを迎えたintermediate stage HCC治療戦略」  [Invited]工藤正俊HCC Pioneers Meeting ~新時代のTKI+TACE戦略を考える~  2021/12Invited Lecture “Second line or further therapy in unresectable HCC”  [Invited]Masatoshi KudoTaiwan Association for the Study of the Liver (TASL 2021)  2021/12Chair; Luncheon Seminar 1  [Invited]Masatoshi KudoThe Asian Pacific Association for the Study of the Liver (APASL) Oncology 2021 on “Your Gateway to Oncology in Asia-Pacific Region”  2021/12  The Prince Park Tower Tokyo特別講演「肝癌診療ガイドライン2021に基づいた最新治療」  [Invited]工藤正俊ライブ配信講演会  2021/12小腸ポリープからの出血によると思われる黒色便の1例. Young Endoscopist Session 7「YS7」大丸直哉; 松原卓哉; 今村瑞貴; 河野辰哉; 半田康平; 田中秀和; 木下大輔; 川崎俊彦; 水野成人; 若狭朋子; 大谷知之; 工藤正俊第107回日本消化器内視鏡学会近畿支部例会  2021/12  神戸国際会議場, 兵庫当院における胆管ステント迷入に対する経乳頭的re-interventionへの取り組み. ビデオワークショップ1「胆膵内視鏡 治療困難症例を克服するための工夫」大塚康生; 山雄健太郎; 竹中 完; 工藤正俊第107回日本消化器内視鏡学会近畿支部例会  2021/12  神戸国際会議場, 兵庫膵上皮内癌および良性膵管狭窄症例に特徴的なEUS所見の検討—多施設共同後ろ向き研究—. シンポジウム1「難治性胆膵疾患に対する内視鏡診療の取り組み」山雄健太郎; 竹中 完; 工藤正俊; 南 竜城; 大花正也第107回日本消化器内視鏡学会近畿支部例会  2021/12ランチョンセミナー「新たなステージを迎えたintermediate stage HCC治療戦略」  [Invited]工藤正俊第44回日本肝臓学会西部会  2021/12  岡山コンベンションセンター, 岡山A phase 1b study of lenvatinib plus pembrolizumab in patients with unresectable hepatocellular carcinoma: Study 116 follow-up analysis  [Not invited]Kudo M; Finn RS; Zhu AX; Sung MW; Baron AD; Okusaka T; Kobayashi M; Kumada H; Kaneko S; Pracht M; Meyer T; Nagao S; Saito K; Mody K; Dubrovsky L; Llovet JMESMO Immuno-Oncology Congress 2021  2021/12特別講演「新たなステージを迎えたIntermediate stage HCC治療戦略」  [Invited]工藤正俊HCC Pioneers Meeting~新時代のTKI+TACE戦略を考える~  2021/12特別講演「肝細胞癌治療のパラダイムチェンジ」  [Invited]工藤正俊第2回Chugai HCC Seminar  2021/12教育講演「肝細胞癌の最新治療」  [Invited]工藤正俊第65回四国支部主催生涯教育講演会  2021/12Invited Lecture “Overview of NAFLD/NASH in HCC”  [Invited]Masatoshi KudoHCC Eastern Pioneers Meeting  2021/12特別講演「新たなステージを迎えたintermediate stage HCC治療戦略」  [Invited]工藤正俊東北のHCC治療を考える会  2021/12特別講演「肝細胞癌に対する免疫療法の最先端」  [Invited]工藤正俊第2回埼玉県東部肝がんセミナー  2021/12特別講演「新たなステージを迎えたintermediate stage HCC治療戦略」  [Invited]工藤正俊HCC Pioneers Meeting~新時代のTKI+TACE戦略を考える~  2021/11特別講演「肝細胞癌治療のパラダイムチェンジ~ABC conversionを含めて~」  [Invited]工藤正俊第24回北九州肝癌治療研究会  2021/11特別講演「肝細胞癌治療のパラダイムチェンジ~ABC conversionを含めて~」  [Invited]工藤正俊肝細胞がんExpert Meeting in Okinawa  2021/11特別講演「新たなステージを迎えたintermediate stage HCC治療戦略」  [Invited]工藤正俊HCC Pioneers Meeting~新時代のTKI+TACE戦略を考える~  2021/11特別講演「新たなステージを迎えたintermediate stage HCC治療戦略」  [Invited]工藤正俊HCC Pioneers Meeting~新時代のTKI+TACE戦略を考える~  2021/11特別講演「肝細胞癌治療のパラダイムチェンジ~ABC conversionを含めて~」  [Invited]工藤正俊第4回東海肝癌フォーラム  2021/11Industry-sponsored satellite symposium “An envolving landscape: treatment for intermediate-stage HCC”  [Invited]Masatoshi KudoESMO Asia Virtual Oncology Week  2021/11Education Lecture “Management of HCC: East vs West”Masatoshi KudoMeet-the-Expert Networking Session, AASLD  2021/11肝細胞癌におけるWnt/βカテニン経路活性化と腫瘍免疫環境. シンポジウム8「がん微小環境を標的とした消化器がん治療の新展望」  [Not invited]盛田真弘; 西田直生志; 工藤正俊第25回日本肝臓学会大会, 第63回日本消化器病学会大会, 第102回日本消化器内視鏡学会総会, 第19回日本消化器外科学会大会(JDDW 2021)  2021/11  神戸コンベンションセンター, 兵庫B-mode超音波検査による肝腫瘍検出・診断を支援するAIモデルの開発  [Invited]西田直生志; 工藤正俊第25回日本肝臓学会大会, 第63回日本消化器病学会大会, 第102回日本消化器内視鏡学会総会, 第19回日本消化器外科学会大会(JDDW 2021)  2021/11  神戸コンベンションセンター, 兵庫Keynote Lecture “The state-of-art lecture on the treatment of liver cancer”  [Invited]Masatoshi KudoJapan Digestive Disease Week (JDDW 2021)  2021/11  Kobe Convention Center, HyogoChair: International Session Symposium 3「Advances in the treatment of the liver cancer: the stage-of-the-art researches to provide the precision medicine and improve the prognosis」  [Invited]Masatoshi Kudo第29回日本消化器関連学会週間JDDW 2021(第63回日本消化器病学会大会, 第25回日本肝臓学会大会, 第102回日本消化器内視鏡学会総会)  2021/11  神戸コンベンションセンター, 兵庫.Gd-EOB-DTPA-enhanced MRI肝細胞相で高信号の肝細胞癌は、PD-1/PD-L1療法への一次耐性を反映し予後不良である青木智子; 上嶋一臣; 盛田真弘; 千品寛和; 田北雅弘; 萩原 智; 南 康範; 依田 広; 鶴崎正勝; 西田直生志; 工藤正俊第25回日本肝臓学会大会, 第63回日本消化器病学会大会, 第102回日本消化器内視鏡学会総会, 第19回日本消化器外科学会大会(JDDW 2021)  2021/11  神戸コンベンションセンター, 兵庫免疫チェックポイント阻害剤投与後に発現した肝障害の臨床的、病理学的検討. ワークショップ3「薬物性肝障害の実態」萩原 智; 西田直生志; 工藤正俊第25回日本肝臓学会大会, 第63回日本消化器病学会大会, 第102回日本消化器内視鏡学会総会, 第19回日本消化器外科学会大会(JDDW 2021)  2021/11  神戸コンベンションセンター, 兵庫司会; ランチョンセミナー36「肝細胞癌治療の最新の話題」  [Invited]工藤正俊第29回日本消化器関連学会週間JDDW 2021(第63回日本消化器病学会大会, 第25回日本肝臓学会大会, 第102回日本消化器内視鏡学会総会)  2021/11  神戸コンベンションセンター, 兵庫ランチョンセミナー;肝細胞癌治療の最新の話題  [Invited]工藤正俊JDDW 2021 Kobe  2021/11  神戸国際展示場, 兵庫開会の挨拶  [Invited]工藤正俊第41回南大阪肝疾患研究会  2021/10特別講演「肝細胞癌に対する免疫療法時代の夜明け—ABC conversion therapyを含めて-」  [Invited]工藤正俊第3回Nagasaki HCC Web Seminar new era  2021/10特別講演「肝細胞癌治療における肝予備能維持の重要性」  [Invited]工藤正俊中外Eセミナー  2021/10Invited Lecture “New stage of treatment strategies for intermediate stage HCC”  [Invited]Masatoshi KudoChina-Japan Liver Cancer Alliance Online and Offline Redional Meeting in Wuhan  2021/10教育講演「アテゾリズマブ+ベバシズマブ併用療法による肝細胞癌治療の新しいパラダイム」, 教育シンポジウム「免疫チェックポイント阻害薬の併用療法」  [Invited]工藤正俊第59回日本癌治療学会学術集会  2021/10特別講演「肝細胞癌治療のパラダイムチェンジ~ABC conversionを含めて~」  [Invited]工藤正俊肝細胞がんExpert Meeting in Miyazaki  2021/10  ニューウェルシティ宮崎, 九州特別講演「肝細胞癌治療のパラダイムチェンジ」  [Invited]工藤正俊テセントリク/アバスチンHCC適応拡大1周年記念講演会 in 会津若松  2021/10Invited Lecture “Overview of NAFLD/NASH in HCC”  [Invited]Masatoshi KudoHCC Eastern Pioneers Meeting  2021/10Chair: Luncheon Seminar IV  [Invited]Masatoshi KudoJSH International Liver Conference 2021  2021/10  博多国際展示場&カンファレンスセンター, 福岡特別講演「TACEとレンバチニブによる新時代の治療戦略」  [Invited]工藤正俊LENVIMA-HCC Web Seminar-新展開を迎えたIVR治療とレンバチニブの共存  2021/09特別講演「免疫療法時代における肝細胞癌治療戦略2021」  [Invited]工藤正俊HCC Expert Meeting in Saitama~免疫療法時代における最良の治療を考える~  2021/09Detective flow imaging (DFI)にて特徴的な血流血管を観察し得たIntraductal papillary neoplasm of bile duct (IPNB)の2例. Young Investigator Session 14「胆道」上中大地; 岡本彩那; 大本俊介; 原 茜; 大塚康生; 益田康弘; 高島耕太; 吉田晃浩; 山﨑友裕; 三長孝輔; 鎌田 研; 山雄健太郎; 竹中 完; 工藤正俊日本消化器病学会近畿支部第115回例会(Web)  2021/09肝細胞癌に対してアテゾリズマブ+ベバシズマブ療法を行いirAEと思える髄膜炎をきたした1例. Young Investigator Session 13「肝2」松原卓哉; 今村瑞貴; 大丸直哉; 河野辰也; 半田康平; 田中秀和; 橋本有人; 木下大輔; 川崎俊彦; 水野成人; 塩山実章; 工藤正俊日本消化器病学会近畿支部第115回例会(Web)  2021/09インフリキシマブが有効であった腸型Bechet病のサイトカイン反応の解析. Young Investigator Session 7「大腸1」吉川馨介; 渡邉智裕; 瀬海郁衣; 高田隆太郎; 原 茜; 栗本真之; 益田康弘; 大塚康夫; 吉川智恵; 正木 翔; 鎌田 研; 三長孝輔; 米田頼晃; 工藤正俊; 筑後孝章日本消化器病学会近畿支部第115回例会(Web)  2021/09TNF-αおよびIL-6の関与が考えられた好酸球性胃腸炎の一例. Young Investigator Session 2「胃・十二指腸1」瀬海郁衣; 吉川馨介; 高田隆太郎; 原 茜; 吉川智恵; 鎌田 研; 三長孝輔; 渡邉智裕; 工藤正俊日本消化器病学会近畿支部第115回例会(Web)  2021/09EUS-FNAにて術前診断できた食道schwannomaの一例、Young Investigator Session 1「食道、福西香栄; 松井繁長; 杉森啓伸; 高田隆太郎; 正木 翔; 河野匡志; 永井知行; 米田頼晃; 山﨑友裕; 山雄健太郎; 竹中 完; 本庶 元; 渡邉智裕; 辻 直子; 樫田博史; 工藤正俊; 白石 治; 安田卓司日本消化器病学会近畿支部第115回例会(Web)  2021/09ウステキヌマブの潰瘍性大腸炎への有効性と安全性の検討. シンポジウム5「炎症性腸疾患治療の最前線」永井知行; 樫田博史; 工藤正俊日本消化器病学会近畿支部第115回例会(Web)  2021/09急性膵炎からアプローチする膵癌早期診断. シンポジウム4「胆膵腫瘍の診断と治療up to date」山雄健太郎; 竹中 完; 工藤正俊日本消化器病学会近畿支部第115回例会(Web)  2021/09特別講演「免疫療法時代における肝細胞がん治療戦略2021」  [Invited]工藤正俊肝がん治療最前線in熊本—根治をゴールとした治療戦略—  2021/09Multicenter Phase II trial of lenvatinib plus hepatic intra-arterial infusion chemotherapy with cisplatin for advanced hepatocellular carcinoma: LEOPARD  [Not invited]Ikeda M; Yamashita T; Ogasawara S; Kudo M; Inaba Y; Morimoto M; Tsuchiya K; Shimizu S; Kojima Y; Hiraoka A; Nouso K; Aikata H; Numata K; Sato T; Okusaka T; Furuse JEuropian Society for Medical Oncology (ESMO) congress  2021/09特別講演「肝腫瘍のAI診断up-date: screening動画像からの検出と診断能」  [Invited]工藤正俊日本超音波医学会第42回中部地方会  2021/09ランチョンセミナー「肝細胞癌に対する治療戦略—内科的治療のsimulation/navigationも含めて-」  [Invited]工藤正俊第15回肝癌治療ナビゲーション研究会  2021/09  JRホテルクレメント徳島, 徳島Sorafenib in extended patient populations in real-world clinical practice: Baseline characteristics from OPTIMIS and GIDEON  [Not invited]Kudo M; Lencionia R; Ozgurdal K; Peck-Radosavljevic MThe International Liver Cancer Association (ILCA 2021)  2021/09IMbrave150: Albumin-bilirubin grade analyses in a phase III study of atezolizumab + bevacizumab versus sorafenib in patiens with unresectable hepatocellular carcinoma  [Not invited]Kudo M; Finn RS; Cheng AL; Zhu AX; Ducreux M; Galle P; Gaillard VE; Nicholas A; Vogel AThe International Liver Cancer Association (ILCA 2021)  2021/09Nivolumab (NIVO) in sorafenib (SOR)-naive and -experienced patients with advanced hepatocellular carcinoma (aHCC): 5-year follow-up from CheckMate 040 cohorts 1 and 2  [Not invited]Trojan J; Meyer T; Yau T; Melero I; Kudo M; Hsu C; Kim TY; Choo SP; Kang YK; Yeo W; Chopra A; Soleymani S; Yao J; Neely J; Tschaika M; Welling III TH; Sangro B; El-Khoueiry AThe International Liver Cancer Association (ILCA 2021)  2021/09Regorafenib in patients with unresectable hepatocellular carcinoma in routine clinical practice: Updated interim analysis of the prospective observational REFINE study  [Not invited]Lim HY; Merle P; Ikeda M; Masi G; Finn RS; Frenette C; Klümpen HJ; Kim YJ; Gerolami R; Kurosaki M; Numata K; Zebger-Gong H; Fiala-Buskies S; Ozgurdal K; Kudo M; Qin SThe International Liver Cancer Association (ILCA 2021)  2021/09Invited Lecture “Multidisciplinary management of intermediate stage HCC”  [Invited]Masatoshi KudoTaiwan Association for the Study of the Liver (TASL 2021)  2021/08司会; ランチョンセミナー「高齢化するHCC患者の実情—これからの個別化治療戦略—」  [Invited]工藤正俊第24回日本肝がん分子標的治療研究会  2021/08  富山国際会議場, 富山プレナリーセッション「切除不能肝細胞癌に対する肝動脈化学塞栓療法(TACE)とLenvatinibの併用療法第II相臨床試験(TACTICS-L): 中間解析結果」  [Invited]石川 達; 上嶋一臣; 佐伯一成; 森本直樹; 相方 浩; 田邊暢一; 稲葉吉隆; 和田幸之; 近藤泰輝; 津田政広; 中尾一彦; 池田公史; 森口理久; 葛谷貞二; 小林正宏; 古賀浩徳; 日野啓輔; 鈴木義之; 吉村健一; 工藤正俊第24回日本肝がん分子標的治療研究会  2021/08  富山国際会議場, 富山Plenary Session “Prognositc and predictive factors with ramucirumab in advanced hepatocellular carcinoma and elevated alpha-fetoprotein: two Phase III trials”  [Invited]Kudo M; Llovet JM; Singal AG; Villanueva A; Finn RS; Galle PR; Wang C; Widau RC; Gonzalez GE; Zhu AXThe 24th Japan Society for Molecular Targeted Therapy for HCC  2021/08  Toyama司会; スポンサードシンポジウム「肝癌に対する分子標的薬治療の最前線」  [Invited]沖田 極; 工藤正俊第24回日本肝がん分子標的治療研究会  2021/08  富山国際会議場, 富山基調講演「Earlyからintermediate stageにおける肝細胞癌薬物療法の最前線」, スポンサードシンポジウム「肝癌に対する分子標的薬治療の最前線」  [Invited]工藤正俊第24回日本肝がん分子標的治療研究会  2021/08  富山国際会議場, 富山開会の辞  [Invited]工藤正俊第24回日本肝がん分子標的治療研究会  2021/08  富山国際会議場, 富山Chairs: Session 10 “Systemic Therapy for Advanced HCC”  [Invited]Kudo MThe 11th Asia-Pacific Primary Liver Cancer Expert Meeting (APPLE 2021)  2021/08Invited Lecture “Role of systemic therapy in early HCC patients hepatologist perspectives.  [Invited]Kudo M11th Asian Pacific Association for the Study of the Liver 2021 (APASL 2021)  2021/08特別講演「肝細胞癌に対する免疫療法時代の夜明け—ABC conversion therapyを含めて-」  [Invited]工藤正俊中四国肝細胞薬物療法セミナー  2021/08特別講演「免疫療法時代における肝細胞がん治療戦略2021」  [Invited]工藤正俊HCC Webカンファランスin静岡  2021/08特別講演「免疫療法時代における肝細胞がん治療戦略2021」  [Invited]工藤正俊Intermediate Stage HC治療戦略を考える会  2021/08特別講演「Intermediate Stage肝細胞癌の治療戦略—ABC conversion therapy—」  [Invited]工藤正俊中外Eセミナー  2021/08特別講演「肝細胞癌治療のパラダイムチェンジ」  [Invited]工藤正俊肝細胞がんExpert Meeting in Okinawa  2021/07Invited Lecture “CEUS in small focal liver lesions”  [Invited]Masatoshi KudoEuroson School-Shanghai 2021  2021/07特別講演「免疫療法時代における肝細胞がん治療戦略2021」  [Invited]工藤正俊HCC Expert Meeting in愛媛  2021/07肝癌研究会追跡調査よりみたHCV肝炎関連肝内胆管癌の肝切除後長期成績の検討. ワークショップ4「肝内胆管癌の診断・治療の最前線」  [Not invited]海堀昌樹; 吉井健悟; 柏原康佑; 國土貴嗣; 長谷川 潔; 泉 並木; 村上卓道; 工藤正俊; 椎名秀一朗; 坂元亨宇; 中島 収; 松山 裕; 江口 晋; 山下竜也; 高山忠利; 國土典宏; 久保正二第57回日本肝癌研究会  2021/07  城山ホテル鹿児島, 鹿児島肝細胞癌の腫瘍径・腫瘍個数による手術、TACE、焼灼療法の生存予測(日本肝癌研究会追跡調査). パネルディスカッション2「IT・AIを活用した肝癌診療、病理・画像診断の現状と展望」  [Not invited]河口義邦; 長谷川 潔; De Bellis Mario; Famularo Simone; Panettieri Elena; 松山 裕; 建石良介; 市川智章; 國土貴嗣; 泉 並木; 久保正二; 坂元亨宇; 椎名秀一朗; 高山忠利; 中島 収; 村上卓道; Vauthey Jean-Nicolas; 工藤正俊; 國土典宏第57回日本肝癌研究会  2021/07  城山ホテル鹿児島, 鹿児島Intermediate stage肝細胞癌における分子標的薬の役割. シンポジウム4「Intermediate stage HCCの治療戦略」  [Not invited]上嶋一臣; 青木智子; 工藤正俊第57回日本肝癌研究会  2021/07  城山ホテル鹿児島, 鹿児島EOT造影MRIをbiomarkerとした肝細胞癌のWNT/beta-catenin mutation/activationの評価と治療効果予測. ワークショップ1「肝癌薬物治療の効果予測の新しい試み」  [Not invited]青木智子; 上嶋一臣; 盛田真弘; 千品寛和; 田北雅弘; 南 康範; 萩原 智; 依田 広; 西田直生志; 鶴崎正勝; 工藤正俊第57回日本肝癌研究会  2021/07  城山ホテル鹿児島, 鹿児島SURF trial RCT: 全生存の報告、早期肝細胞癌に対する手術vs. RFA. シンポジウム2「早期肝癌の精度診断・治療」  [Not invited]居村 暁; 島田光生; 長谷川 潔; 河口義邦; 高山忠利; 泉 並木; 山中若樹; 工藤正俊; 猪股雅史; 金子周一; 馬場秀夫; 小池和彦; 小俣政男; 幕内雅敏; 松山 裕; 國土典宏; SURF Trialグループ第57回日本肝癌研究会  2021/07  城山ホテル鹿児島, 鹿児島二次治療以降におけるアテゾリズマブ・ベバシズマブの臨床成績. シンポジウム1「複合免疫療法時代を迎えた新たな進行肝癌治療」  [Not invited]上嶋一臣; 青木智子; 工藤正俊第57回日本肝癌研究会  2021/07  城山ホテル鹿児島, 鹿児島司会: ランチョンセミナー「肝内胆管癌における新たな個別化治療のアプローチ」  [Invited]工藤正俊第57回日本肝癌研究会  2021/07  城山ホテル鹿児島, 鹿児島司会; スポンサードシンポジウム「消化器癌におけるがんゲノム診断と分子標的治療」  [Invited]工藤正俊第57回日本肝癌研究会  2021/07  城山ホテル鹿児島, 鹿児島座長: イブニングセミナー1  [Invited]工藤正俊第57回日本肝癌研究会  2021/07  城山ホテル鹿児島, 鹿児島ランチョンセミナー「肝細胞癌薬物療法新時代における新たな選択肢 ~カボザンチニブの役割~」  [Invited]工藤正俊第57回日本肝癌研究会  2021/07座長「がん免疫療法に関する育薬研究」  [Invited]工藤正俊Chugai Cancer Immunotherapy Forum 2021  2021/07Invited Lecture “Sequential treatment for advanced HCC based on real-world data”  [Invited]Masatoshi KudoIASL annual conference 2021  2021/07Invited Web Lecture “Sequential treatment for advanced HCC based on real-world-data”  [Invited]Masatoshi KudoInternational Association for the Study of the Liver (IASL) Annual Conference  2021/07EUS-FNAにて診断可能であった、肝限局性結節性過形成の一例. Young Endoscopist Session 7「肝胆膵1」今村瑞貴; 福永朋洋; 野村健司; 河野辰也; 半田康平; 木下大輔; 川崎俊彦; 水野成人; 若狭朋子; 太田善夫; 工藤正俊第106回日本消化器内視鏡学会近畿支部例会  2021/07  リーガロイヤルホテル大阪, 大阪胆道Plastic stentドレナージのre-interventionにおけるsnare over the guidewire法の有用性. ワークショップ2「胆膵内視鏡のトラブルマネジメント」吉田晃浩; 竹中 完; 山雄健太郎; 樫田博史; 工藤正俊第106回日本消化器内視鏡学会近畿支部例会  2021/07  リーガロイヤルホテル大阪, 大阪膵上皮内癌におけるEUS所見の検討. パネルディスカッション1「胆膵疾患に対する内視鏡診断・治療の工夫」山雄健太郎; 竹中 完; 樫田博史; 工藤正俊第106回日本消化器内視鏡学会近畿支部例会  2021/07  リーガロイヤルホテル大阪, 大阪カプセルおよびバルーン小腸内視鏡で比較的早期に発見し根治手術を行った原発性小腸癌の一例. Young Endoscopist Session 5「消化管5」吉田早希; 米田頼晃; 原 茜; 益田康弘; 高田隆太郎; 正木 翔; 河野匡志; 永井知行; 本庶 元; 松井繁長; 櫻井俊治; 辻 直子; 樫田博史; 工藤正俊第106回日本消化器内視鏡学会近畿支部例会  2021/07  リーガロイヤルホテル大阪, 大阪内視鏡で保存的に回収できた胃石の一例. Young Endoscopist Session 4「消化管4」杉本啓伸; 本庶 元; 原 茜; 益田康弘; 吉田早希; 高田隆太郎; 河野匡志; 正木 翔; 永井知行; 米田頼晃; 櫻井俊治; 松井繁長; 渡邉智裕; 辻 直子; 樫田博史; 工藤正俊第106回日本消化器内視鏡学会近畿支部例会  2021/07  リーガロイヤルホテル大阪, 大阪アザシチジン投与が有効であったMDS関連腸管潰瘍. シンポジウム2「炎症性腸疾患診断・治療における内視鏡検査の現状と課題」河野匡志; 永井知行; 米田頼晃; 櫻井俊治; 工藤正俊第106回日本消化器内視鏡学会近畿支部例会  2021/07  リーガロイヤルホテル大阪, 大阪Invited Lecture “Recent advances in treatment of intermediate stage HCC”  [Invited]Masatoshi KudoMeet the Expert  2021/07特別講演「免疫療法時代における肝細胞がん治療戦略2021」  [Invited]工藤正俊第67回大阪肝穿刺生検治療研究会  2021/07特別講演「免疫療法時代における肝細胞がん治療戦略2021」  [Invited]工藤正俊HCC Meet the Expert in TAMA  2021/07Relatlimab + nivolumab in patients with advanced hepatocellular carcinoma who are naive to immuno-oncology therapy but progressed on tyrosine kinase inhibitors, a phase 2, randomized, open-label study: RELATIVITY-073  [Not invited]Sangro B; Numata K; Huang Y; Gomez-Martin C; Hiraoka A; Moriguchi M; Shen Y; Horvath A; Feely W; Young T; Neely J; Kudo MESMO World Congress on Gastrointestinal Cancer 2021 (ESMO-GI 2021)  2021/07特別講演「肝細胞癌薬物療法新時代における新たな治療選択カボザンチニブ」  [Invited]工藤正俊カボメディクスWeb Seminar  2021/07Invited Lecture “Emerging role of Lenvatinib in the new era of treatment stragety in HCC”  [Invited]Masatoshi KudoEisai Oncology Liver Webinar~Optimizing the role of MKIs in the new era of HCC treatment~  2021/07特別講演「免疫療法時代における肝細胞がん治療戦略2021」  [Invited]工藤正俊肝がんクラスター講演会2021  2021/06Pembrolizumab/Quavonlimab coformulation in combination with lenvatinib in advanced hepatocellular carcinoma: Phase 2 trial in progress  [Not invited]Li D; Cheng AL; Lim HY; Llovet JM; Zhu Y; Hatogai K; Siegel AB; Kudo MESMO World Congress on Gastrointestinal Cancer 2020 (ESMO-GI 2021)  2021/06Sorafenib in extended patient populations in real-world clinical practice: Baseline characteristics from OPTIMIS and GIDEON.Peck-Radosavljevic M; Lencionia R; Ozgurdal K; Kudo M23rd World Congress on Gastrointestinal Cancer (WCGI 2021)  2021/06特別講演「免疫療法時代における肝細胞がん治療戦略2021」  [Invited]工藤正俊HCC-Expert Meeting~免疫療法時代における薬物治療を考える~  2021/06CheckMate 040: long-term efficacy and safety of nivolumab in patients with Child-Pugh B advanced hepatocellular carcinoma: associations between baseline biomarker analyses and outcomes  [Not invited]Matilla A; Sangro B; El-Khoueiry AB; Santoro A; Melero I; Gracián AC; Acosta-Rivera M; Choo SP; Kuromatsu R; El-Rayes B; Numata K; Itoh Y; De Costanzo F; Crysler O; Reig M; Shen Y; Yao J; Neely J; Tschaika M; Kudo MThe International Liver Congress 2021 (EASL 2021)  2021/06Invited Web Lecture “Advanced HCC: Advances in Targeted and Immune-Therapies”  [Invited]Masatoshi KudoISVHLD GHS 2021 Conference  2021/06Invited Web Lecture “TKIs still have roles for advanced HCC”  [Invited]Masatoshi KudoAsian Pacific Association for the Study of the Liver (APASL 2021)  2021/06ランチョンセミナー「肝細胞癌領域におけるがん免疫療法の最新Topics」  [Invited]工藤正俊第57回日本肝臓学会総会  2021/06Exploratory circulating biomarker analyses: lenvatinib + pembrolizumab (L+P) in a phase 1b trial in unresectable hepatocellular carcinoma (uHCC)  [Not invited]Zhu AX; Llovet JM; Kobayashi M; Ikeda M; Gerolami R; Pracht M; Sung MW; Baron AD; Kudo M; Meyer T; Okusaka T; Kumada H; Kaneko S; Hoshi T; Saito K; Li SD; Funahashi Y; Minoshima Y; Dubrovsky L; Finn RSAmerican Society of Clinical Oncology (ASCO 2021)  2021/06Pembrolizumab (pembro) monotherapy for previously untreated advanced hepatocellular carcinoma (HCC): phase 2 KEYNOTE-224 study  [Not invited]Laethem JLV; Borbath I; Karwal M; Verslype C; Vlierberghe HV; Kardosh A; Zagonel V; Stal P; Sarker D; Palmer DH; Vogel A; Edeline S; Cattan S; Kudo M; Cheng AL; Ogasawara S; Siegel AB; Chisamore MJ; Wang A; Zhu AXAmerican Society of Clinical Oncology (ASCO 2021)  2021/06特別講演「免疫療法時代における肝細胞がん治療戦略2021」  [Invited]工藤正俊HCC Meet the Expert in Tokyo (Web)  2021/06Prognostic and predictive factors in patients treated with ramucirumab (RAM) with advanced hepatocellular carcinoma (aHCC) and elevated alpha-fetoprotein (AFP): results from two Phase III trials.  [Not invited]Llovet JM; Singal AG; Villanueva A; Finn RS; Kudo M; Galle PR; Wang C; Widau RC; Gugel EG; Zhu AXAmerican Society of Clinical Oncology (ASCO 2021)  2021/06Adjuvant nivolumab for hepatocellular carcinoma (HCC) after surgical resection (SR) or radiofrequency ablation (RFA) (NIVOLVE): A phase 2 prospective multicenter single arm trial and exploratory biomarker analysis  [Not invited]Kudo M; Ueshima K; Nakahira S; Nishida N; Ida H; Minami Y; Kobayashi S; Umeda M; Tsurusaki M; Chiba Y; Yoshimura K; Sakai K; Nishio KAmerican Society of Clinical Oncology (ASCO 2021)  2021/06A multicenter randomized controlled trial to evaluate the efficacy of surgery versus radiofrequency ablation for small hepatocellular carcinoma (SURF trial): analysis of overall survival  [Not invited]Kudo M; Hasegawa K; Kawaguchi Y; Takayama T; Izumi N; Yamanaka N; Shimada M; Inomata M; Kaneko S; Baba H; Koike K; Omata M; Makuuchi M; Matsuyama Y; Kokudo NAmerican Society of Clinical Oncology (ASCO 2021)  2021/06GPSマーカーを用いた安全なRFA治療の工夫, ミニワークショップ「消化器」小川 力; 工藤正俊日本超音波医学会第94回学術集会  2021/05  神戸ポートピアホテル, 兵庫胆嚢病変に対するDetective flow imaging (DFI)の有用性について, パネルディスカッション消化器4「胆嚢壁肥厚の鑑別診断」竹中 完; 大本俊介; 工藤正俊日本超音波医学会第94回学術集会  2021/05  神戸ポートピアホテル, 兵庫ラジオ波焼灼術の治療ガイド: US-US overlay fusionの使い方, パネルディスカッション消化器1「最新の超音波技術を用いた肝癌治療支援」南 康範; 工藤正俊日本超音波医学会第94回学術集会  2021/05  神戸ポートピアホテル, 兵庫基調講演「CEUS LI-RADSを知る」, シンポジウム消化器2「超音波による肝腫瘍病変の鑑別診断~造影、各種血流評価方法、硬度測定などの技術を用いて~」南 康範; 工藤正俊日本超音波医学会第94回学術集会  2021/05  神戸ポートピアホテル, 兵庫Walled-off necrosisに対するEUS-guided cyst drainageにおける造影EUSの有用性. シンポジウム消化器1「胆膵領域における超音波内視鏡の最前線」  [Not invited]竹中 完; 工藤正俊日本超音波医学会第94回学術集会  2021/05  神戸ポートピアホテル, 兵庫Invited Web Lecture “Cyramza: A new treatment option reach to hepatocellular carcinoma”  [Invited]Masatoshi KudoCyramza HCC Launch Meeting - Kaohsiung (Web)  2021/05特別講演「免疫療法時代における肝細胞がん治療戦略2021」  [Invited]工藤正俊HCC-Expert Meeting~免疫療法時代における薬物治療を考える~  2021/05特別講演「B型肝炎に対する今後の核酸アナログ製剤の選択は?」  [Invited]工藤正俊第5回関西肝疾患フォーラム  2021/05Invited Web Lecture “Cyramza: A new treatment option reach to hepatocellular carcinoma”  [Invited]Masatoshi KudoCyramza HCC Launch Meeting (Web)  2021/04Invited Web Lecture “Combination immunotherapy for HCC”  [Invited]Masatoshi KudoState Key Laboratory of Liver Research (SKLLR)  2021/04IMbrave150: updated efficacy and safety by risk status in patients (pts) receiving atezolizumab (atezo) + bevacizumab (bev) vs sorafenib (sor) as first-line treatment for unresectable hepatocellular carcinoma (HCC)  [Not invited]Finn RS; Qin S; Ikeda M; Galle PR; Ducreux M; Kim TY; Kudo M; Lim HY; Breder VV; Merle P; Kaseb AO, Li D; Feng YH; Verret W; Nicholas A; Li L; Ma N; Zhu AX; Cheng ALAmerican Association for Cancer Research Annual Meeting (AACR 2021)  2021/04Early antibiotic exposure delays disease progression following immune checkpoint inhibitor therapy for hepatocellular carcinoma: evidence from an observational study  [Not invited]Fessas P; Naeem M; Marron TU; Szafron D; Sharon E; Saeed A; Jun T; Dharmapuri S; Naqash AR; Peeraphatdit T; Gampa A; Wang Y; Khan U; Muzaffar M; Navaid M; Lee CJ; Lee PC; Bulumulle A; Yu B; Paul S; Nimkar N; Bettinger D; Hildebrand H; Abugabal YI; Pressiani T; Personeni N; Nishida N; Kudo M; Kaseb A; Huang YH; Ang C; Pillai A; Rimassa L; Pinato DJAmerican Association for Cancer Research Annual Meeting (AACR 2021)  2021/04Invited Lecture “Multidisplinary approch for better outcomes in intermediate stage HCC”  [Invited]Masatoshi KudoAPASL-TLW Symposium 06 (Multidisciplinary Approach for Achieving Complete Remission), 31st Conference of the Asian Pacific Association for the Study of the Liver (APASL 2022)  2021/04特別講演「免疫療法時代における肝細胞がん治療戦略2021」  [Invited]工藤正俊肝癌治療Meet the Expert (Web)  2021/03特別講演「肝細胞癌治療のパラダイムチェンジ」  [Invited]工藤正俊肝疾患Webセミナー  2021/03ラジオ波焼灼術後の焼灼高エコー域を壊死部とみなしてよいか?  [Not invited]南 康範; 盛田真弘; 千品寛和; 青木智子; 田北雅弘; 萩原 智; 依田 広; 上嶋一臣; 西田直生志; 工藤正俊第34回日本腹部造影エコー・ドプラ診断研究会  2021/03造影USでの早期の治療効果が有効であったHCCに対するAtezolizumab+Bevacizumab療法の一例  [Not invited]福家和諭; 小川 力; 工藤正俊第34回日本腹部造影エコー・ドプラ診断研究会  2021/03特別講演「肝腫瘍の超音波診断のこれまでと今後: 造影エコーの役割とAI診断開発の現状」  [Invited]工藤正俊第34回日本腹部造影エコー・ドプラ診断研究会  2021/03特別講演「肝細胞癌薬物治療新時代における新たな治療選択カボザンチニブ」  [Invited]工藤正俊カボメティクスWebセミナー  2021/03特別講演「肝細胞癌薬物療法新時代における新たな治療選択カボザンチニブ」  [Invited]工藤正俊HCC Web Conference (Web)  2021/03特別講演「免疫療法時代における肝細胞がん治療戦略2021」  [Invited]工藤正俊第3回Saitama HCC Web Conference~肝がん薬物治療を再考する~(Web)  2021/03KEYNOTE-937 trial in progress: adjuvant pembrolizumab for hepatocellular carcinoma and complete radiologic response after surgical resection or local ablationVogel A; Zhu AX; Cheng AL; Yau T; Zhou J; Kim E; Malhotra U; Siegel AB; Kudo MSIR 2021 congress  2021/03特別講演「肝細胞癌薬物療法新時代における新たな治療選択カボザンチニブ」  [Invited]工藤正俊HCC Web Conference (Web)  2021/03特別講演「肝細胞癌薬物療法新時代における新たな治療選択カボザンチニブ」  [Invited]工藤正俊HCC Expert Web Seminar (Web)  2021/03特別講演「免疫療法時代における肝細胞がん治療戦略2021」  [Invited]工藤正俊Lenvatinib HCC Meet the Expert in豊能 (Web)  2021/03特別講演「免疫療法時代における肝細胞がん治療戦略2021」  [Invited]工藤正俊東北のHCC治療を考える会 (Web)  2021/03Invited Web Lecture “Role lf systemic therapy in intermediate-stage hepatocellular carcinoma”  [Invited]Masatoshi KudoThe Liver Week 2021  2021/03特別講演「免疫療法時代における肝細胞がん治療戦略2021」  [Invited]工藤正俊Lenvatinib Meet the Experts in香川 (Web)  2021/03特別講演「肝細胞癌薬物療法新時代における新たな治療選択カボザンチニブ」  [Invited]工藤正俊Hokkaido Hepatology Conference Webセミナー (Web)  2021/03特別講演「肝細胞癌治療におけるAtezo+Bevのエビデンス」  [Invited]工藤正俊Chugai Hepatocellular Carcinoma Symposium (Web)  2021/03特別講演「免疫療法時代における肝細胞がん治療戦略2021」  [Invited]工藤正俊本郷Liver Cancer Forum (Web)  2021/03特別講演「肝細胞癌治療のパラダイムチェンジ」  [Invited]工藤正俊HCC Experts Seminar in Hokusetsu (Web)  2021/03内視鏡治療により診断に至った大腸平滑筋肉腫の一例  [Not invited]櫻根寛之; 木下大輔; 友岡瑞貴; 野村健司; 福永朋洋; 河野辰哉; 半田康平; 川崎俊彦; 水野成人; 太田善夫; 若狭朋子; 工藤正俊日本消化器病学会近畿支部第114回例会 (Web)  2021/02肝外胆管癌のT-stagingに対する造影ハーモニックEUSと造影CTの比較検討. シンポジウム「胆道癌の早期診断と治療における現状と展望」  [Not invited]大塚康生; 鎌田 研; 竹中 完; 工藤正俊日本消化器病学会近畿支部第114回例会  2021/02ランチョンセミナー「肝細胞癌治療における免疫療法時代の到来」  [Invited]工藤正俊日本消化器病学会近畿支部第114回例会 (Web)  2021/02特別講演「肝細胞癌治療のパラダイムチェンジ」  [Invited]工藤正俊香川肝癌Expert Meeting (Web)  2021/02特別講演「肝細胞癌治療のパラダイムチェンジ」  [Invited]工藤正俊埼玉県適応拡大記念講演会 on HCC (Web)  2021/02Invited Web Lecture “Treatment strategy of intermediate/advanced stage HCC”  [Invited]Masatoshi KudoChina Medicine Education Association Online Meeting (Web)  2021/02特別講演「免疫療法時代における肝細胞がん治療戦略2021」  [Invited]工藤正俊Lenvima-HCC Web Seminar (Web)  2021/02特別講演「免疫療法時代における肝細胞がん治療戦略2021」  [Invited]工藤正俊HCC Expert Meeting 三重 (Web)  2021/02特別講演「肝細胞癌治療のパラダイムチェンジ」  [Invited]工藤正俊第25回岡山肝癌研究会 (Web)  2021/02特別講演「肝細胞癌薬物治療の新展開~免疫療法時代におけるラムシルマブの役割~」  [Invited]工藤正俊Lilly HCC Web Conference  2021/02Phase 3 KEYNOTE-937 trial: adjuvant pembrolizumab for hepatocellular carcinoma and complete radiologic response after surgical resection or local ablationVogel A; Zhu A; Kudo M; Yau T; Zhou J; Kim E; Malhotra U; Siegel AB; Cheng ALEuropean Association for the Study of the Liver (EASL) Digital Liver Cancer Summit 2021  2021/02IMbrave150: Updated overall survival (OS) data from a global, randomized, open-label Phase 3 study of atezolizumab (atezo) + bevacizumab (bev) vs sorafenib (sor) in patients (pts) with unresectable hepatocellular carcinoma (HCC)Finn RS; Qin S; Ikeda M; Galle PR; Ducreux M; Kim TY; Lim HY; Kudo M; Breder VV; Merle P; Kaseb AO; Li D; Verret W; Shao H; Liu J; Li L; Zhu AX; Cheng ALEuropean Association for the Study of the Liver (EASL) Digital Liver Cancer Summit 2021  2021/02Invited Web Lecture “Goals and targets for personalized therapies in hepatocellular carcinoma”  [Invited]Masatoshi Kudo30th Annual Conference Asian Pacific Association for the Study of the Liver (APASL 2021) (Web)  2021/02特別講演「肝細胞癌治療における免疫療法時代の到来」  [Invited]工藤正俊日本消化器病学会東北支部第210回例会  2021/02Invited Web Lecture “Combination Immunotherapy for HCC”  [Invited]Masatoshi KudoSociety of Interventional Oncology (Web)  2021/02Characteristics of patients who received regorafenib for unresectable hepatocellular carcinoma in routine clinical practice: interim analysis of the prospective, observational REFINE study.Masi G; Ikeda M; Finn RS; Merle P; Lim HY; Kudo M; Klümpen HJ; Frenette C; Kim YJ; Gerolami R; Kurosaki M; Numata K; Zebger-Gong H; Fiala-Buskies S; Ozgurdal K; Qin SEuropean Association for the Study of the Liver (EASL) Digital Liver Cancer Summit 2021  2021/02特別講演「肝細胞癌治療のパラダイムチェンジ」  [Invited]工藤正俊Hepatocellular Carcinoma Seminar in Mie  2021/02IMbrave150: updated overall survival data from a global, randomized, open-label Phase III study of atezolizumab + bevacizumab vs sorafenib in unresectable hepatocellular carcinomaIkeda M; Lim HY; Kim TY; Qin S; Finn RS; Galle PR; Ducreux M; Breder V; Merle P; Kaseb A; Li D; Zhu AX; Verret W; Shao H; Liu J; Li L; Cheng AL; Kudo M30th Annual Conference Asian Pacific Association for the Study of the Liver (APASL 2021)  2021/02A multicenter observational study of lenvatinib for unresectable hepatocellular carcinoma in Japan -Interim analysisIzumi N; Motoyoshi K; Kudo M; Motomura K; Inaba Y; Katamura Y; Kondo Y; Yabushita K; Furuse J30th Annual Conference Asian Pacific Association for the Study of the Liver (APASL 2021)  2021/02特別講演「肝細胞癌治療のパラダイムチェンジ」  [Invited]工藤正俊Chugai HCC Expert Meeting (Web)  2021/02KEYNOTE-937 trial in progress: adjuvant pembrolizumab for hepatocellular carcinoma and complete radiologic response after surgical resection or local ablation  [Not invited]Uppot RN; Kudo M; Zhu AX; Cheng AL; Yau T; Zhou J; Kim E; Malhotra U; Siegel AB; Vogel ASIO 2021 congress  2021/02切除不能な肝細胞癌患者に対するレンバチニブの多施設観察研究—中間報告—本村健太; 工藤正俊; 泉 並木; 籔下和久; 稲葉吉隆; 片村嘉男; 近藤泰輝; 元吉克明; 古瀬純司第23回日本肝がん分子標的治療研究会  2021/01Plenary Session ”Novel regimen tremelimumab (T) + durvalumab (D) for patients (pts) with unresectable hepatocellular carcinoma (uHCC): efficacy and safety”Kudo M; Okusaka T; Ikeda M; Kelly RK; Sangro B; Harris W; Kang YK; Qin S; Tai DWM; Lim HY; Yau TCC; Yong WP; Cheng AL; Gasbarrini A; Damian S; Bruix J; Borad M; He P; Negro A; Abou-Alfa GKThe 23rd Japan Society for Molecular Targeted Therapy for Liver Cancer  2021/01プレナリーセッション「切除不能肝細胞癌におけるアテゾリズマブ(Atezo)+ベバシズマブ(Bev)療法に関する日本人集団の検討—IMbrave 150部分集団解析—」  [Invited]池田公史; 古賀浩徳; 山下竜也; 河上怜恵; 中川雄貴; 工藤正俊第23回日本肝がん分子標的治療研究会  2021/01ランチョンセミナー「肝細胞癌治療における免疫療法時代の到来」  [Invited]工藤正俊第23回日本肝がん分子標的治療研究会 (Web)  2021/01開会の辞: 工藤正俊  [Invited]工藤正俊第23回日本肝がん分子標的治療研究会  2021/01Nivolumab (NIVO) plus ipilimumab (IPI) combination therapy in patients (pts) with advanced hepatocellular carcinoma (aHCC): Long-term results from CheckMate 040El-Khoueiry A; Yau T; Kang YK; Kim TY; Santoro A; Sangro B; Melero I; Kudo M; Hou MM; Matilla A; Tovoli F; Knox TJ; He AR; El-Rayes BF; Acosta-Rivera M; Lim HY; Memaj A; Sama AR; Hsu CGastrointestinal Cancers Symposium (ASCO-GI 2021)  2021/01A Phase 3, double-blind, randomized study of Nivolumab and Ipilimumab, nivolumab monotherapy, or placebo plus transarterial chemoembolization in patients with intermediate-stage hepatocellular carcinoma  [Not invited]Sangro B; Harding JJ; Johnson M; Palmer D; Edeline J; Abou-Alfa G; Cheng AL; Decaens T; El-Khoueiry AB; Finn R; Galle P; Park JW; Yau T; Begic D; Shen Y; Neely J; Sama A; Kudo MGastrointestinal Cancers Symposium (ASCO-GI 2021)  2021/01Landmark analysis of overall survival (OS) by objective response (OR) in previously treated patients (pts) with advanced hepatocellular carcinoma (HCC): Post hoc analysis of the randomized, phase 3 KEYNOTE-240 study  [Not invited]Edeline J; Cattan S; Merle P; Daniele B; Chan SL; Yau T; Bouattour M; Lim HY; Chao Y; Knox J; Ogasawara S; Garrido M; Cheng AL; Zhu AX; Finn RS; Siegel AB; Rahman A; Liu CC; Kudo MGastrointestinal Cancers Symposium (ASCO-GI 2021) (Virtual)  2021/01特別講演「肝細胞癌薬物療法新時代における新たな治療選択カボザンチニブ」  [Invited]工藤正俊カボメティクス全国WEB講演会  2021/01特別講演「肝細胞癌の治療戦略2021」  [Invited]工藤正俊Abbvie Web-Seminar  2020/12特別講演「肝細胞癌薬物療法新時代における新たな治療選択カボザンチニブ」  [Invited]工藤正俊カボメティクス全国WEB講演会  2020/12分子標的治療をつないで生存利益を得られる切除不能肝癌症例の特徴. パネルディスカッション「肝炎ウイルス制御後の肝癌治療」青木智子; 上嶋一臣; 盛田真弘; 千品寛和; 田北雅弘; 萩原 智; 南 康範; 依田 広; 西田直生志; 鶴崎正勝; 工藤正俊第56回日本肝癌研究会  2020/12  大阪国際会議場, 大阪切除不能肝細胞癌に対するLenvatinib併用TACE療法の初期経験.パネルディスカッション2「TACEにおける進歩と個別化」鶴崎正勝; 上嶋一臣; 青木智子; 沼本勲男; 小田晃義; 柳生行伸; 盛田真弘; 田北雅弘; 萩原 智; 南 康範; 依田 広; 西田直生志; 石井一成; 工藤正俊第56回日本肝癌研究会  2020/12鑑別診断において造影超音波が有用であった多血性の肝内胆管癌の1例  [Not invited]盛田真弘; 南 康範; 青木智子; 田北雅弘; 萩原 智; 依田 広; 上嶋一臣; 西田直生志; 工藤正俊第56回日本肝癌研究会  2020/12CQ解説CQ1 有効なスクリーニング法はあるか?CQ2診断に有用な臨床検査は何か? シンポジウム4「肝内胆管癌診療ガイドラインについて」  [Invited]南 康範; 工藤正俊; 杉本勝俊; 糸井隆夫; 藤永康成; 角谷眞澄; 村上卓道第56回日本肝癌研究会  2020/12座長; ランチョンセミナー「肝癌におけるサポーティブケア」  [Invited]工藤正俊第56回日本肝癌研究会  2020/12Sponsored Symposium “How to put molecular targeting agents into your practice of hepatocellular carcinoma systemic therapy?: Current state and future perspective.”  [Invited]Masatoshi KudoThe 56th Annual Meeting of Liver Cancer Study Group of Japan  2020/12座長; スポンサードシンポジウム「How to put molecular targeting agents into your practice of hepatocellular carcinoma systemic therapy?: Current state and future perspective」  [Invited]工藤正俊第56回日本肝癌研究会  2020/12座長; モーニングセミナー「New LOGIQ E10 Seriesが応える!これからの肝腫瘤性病変の超音波診断と治療」  [Invited]工藤正俊第56回日本肝癌研究会(Web)  2020/12BCLC stage B2肝細胞癌に対するLenvatinib先行投与は標準治療となり得るか. シンポジウム「Intermediate stage 肝癌診療の多様性と個別化」青木智子; 上嶋一臣; 盛田真弘; 千品寛和; 田北雅弘; 萩原 智; 南 康範; 依田 広; 西田直生志; 鶴崎正勝; 小川 力; 和田幸之; 池田公史; 石井 浩; 泉 並木; 工藤正俊第56回日本肝癌研究会  2020/12  大阪国際会議場, 大阪肝細胞癌の遺伝子異常による分類と微小免疫環境. ワークショップ3「肝細胞癌の亜分類」  [Invited]西田直生志; 盛田真弘; 青木智子; 田北雅弘; 萩原 智; 依田 広; 南 康範; 上嶋一臣; 工藤正俊第56回日本肝癌研究会  2020/12  大阪国際会議場, 大阪Invited Web Lecture “Treatment strategy of Intermediate Stage HCC.  [Invited]Masatoshi KudoChina Medicine Education Association (CMEA)  2020/12特別講演「肝細胞癌治療戦略2020」  [Invited]工藤正俊HCC Meet the Expert  2020/12  仙台厚生病院, WebSpecial Web Lecture “Novel treatments for advanced HCC”  [Invited]Masatoshi KudoTASL 2020 Annual Meeting & The 2nd TASL-AASLD Joint Symposium & The 2nd TASL-KASL-JSH Joint Symposium  2020/12特別講演「肝がん」  [Invited]工藤正俊ウイルス肝炎研究財団主催市民公開講座「専門医に聞く肝臓のお話」  2020/12  沖縄県率博物館・美術館 (Web)Invited Web Lecture “REFLECT trial and subsequent study results.”  [Invited]Masatoshi KudoChina Medical Education Association (CMEA) (China)  2020/12特別講演「肝細胞癌治療におけるパラダイムチェンジ」  [Invited]工藤正俊テセントリク適応拡大記念講演会(Web)  2020/12Invited Web Lecture “Surveillance of HCC in high risk patients: role of PIVKA-II and AFP-L3.”  [Invited]Masatoshi KudoJapan-Thailand HCC Tumor Marker Project  2020/12Invited Web Lecture “Treatment strategy of unresecable HCC.”  [Invited]Masatoshi KudoInternational HPB Congress (Malaysia)  2020/12Invited Web Lecture “Treatment strategy of Intermediate Stage HCC.”  [Invited]Masatoshi KudoChina Medicine Education Association (CMEA)  2020/12Invited Lecture “Paradigm change in the treatment strategy of intermediate/advanced stage.”  [Invited]Masatoshi Kudo27th Annual Scientific Meeting of the Indian National Association for the Study of the Liver (INASL)  2020/12難治性腹水に対するデンバーシャント術の試み家村郁衣; 青木智子; 田北雅弘; 盛田真弘; 千品寛和; 萩原 智; 南 康範; 依田 広; 上嶋一臣; 西田直生志; 鶴崎正勝; 工藤正俊第43回日本肝臓学会東部会  2020/12  アイーナ, 岩手進歩する化学療法時代に注意すべき肝細胞癌の遠隔転移吉田早希; 青木智子; 上嶋一臣; 盛田真弘; 千品寛和; 田北雅弘; 萩原 智; 南 康範; 依田 広; 鶴崎正勝; 西田直生志; 工藤正俊第43回日本肝臓学会東部会  2020/12  アイーナ, 岩手特別講演「肝細胞がん治療戦略2020」  [Invited]工藤正俊北河内Lenvatinib Meeting (Web)  2020/12進行肝癌に対する免疫チェックポイント阻害薬後レンバチニブ療法の画像評価青木智子; 依田 広; 盛田真弘; 南 知宏; 田北雅弘; 萩原 智; 南 康範; 上嶋一臣; 西田直生志; 工藤正俊日本超音波医学会第93回学術集会  2020/12  仙台国際センター, 岩手特別講演「Intermediate Stage HCCの症例共有」  [Invited]工藤正俊LENVIMA Web Seminar (Web)  2020/11Invited Web Lecture “Treatment strategies for intermediate stage HCC.”  [Invited]Masatoshi KudoAsia Area Oncology Day  2020/11  Hilton Taipei Sinban (web)座長; 特別講演「複合免疫療法時代をむかえた進行肝細胞癌治療」  [Invited]工藤正俊第40回南大阪肝疾患研究会  2020/11特別講演「肝細胞がん治療戦略2020」  [Invited]工藤正俊LENVIMA Web Seminar  2020/11Invited Web Lecture “The changing paradigm for systemic therapy in unresectable HCC  [Invited]Masatoshi KudoGastroenterological Society of Australia (GESA) Satellite Supported Symposium of Australian Gastroenterology Week (AGW) 2020  2020/11特別講演「肝細胞癌治療戦略2020」  [Invited]工藤正俊Meet The Expert Forum首都圏連携を考える会-肝癌診療マニュアル第4版に準じた実臨床を考える-  2020/11Invited Web Lecture “Results of REFLECT study and subsequent studies.”  [Invited]Masatoshi KudoChina Medicine Education Association (CMEA)  2020/11特別講演「肝細胞癌治療における免疫療法時代の到来」  [Invited]工藤正俊信州肝がん薬物療法Webセミナー  2020/11特別講演「肝細胞癌治療のパラダイムチェンジ」  [Invited]工藤正俊Chugai Hepatocellular Carcinoma Symposium  2020/11  アゴーラリージェンシー堺, 大阪特別講演「肝細胞癌治療のパラダイムチェンジ」  [Invited]工藤正俊肝細胞癌WEB講演会in広島  2020/11司会; 肝がん分子標的治療研究会共催シンポジウム「レンバチニブの新たな可能性を考える」  [Invited]工藤正俊第22回日本肝がん分子標的治療研究会  2020/11  金沢歌劇座, 石川Plenary Session; Ramucirumab for patients with intermediate-stage hepatocellular carcinoma (HCC) and elevated alpha fetoprotein (AFP): Pooled results from two phase III studies (REACH and REACH-2)  [Invited]Kudo M; Finn RS; Morimoto M; Rau KM; Ikeda M; Yen CJ; Galle PR; Llovet JM; Daniele B; Lim HY; Liang K; Shinozaki K; Wang C; Yoshikawa R; Abada P; Widau RC; Zhu AXThe 22nd Japan Society for Molecular Targeted Therapy for Liver Cancer  2020/11  Ishikawa, Japan開会/閉会の挨拶  [Invited]工藤正俊第22回日本肝がん分子標的治療研究会  2020/11  金沢歌劇座, 石川共催セミナー「HCC全身薬物治療: これまでとこれからの10年」  [Invited]工藤正俊第22回日本肝がん分子標的治療研究会  2020/11  金沢歌劇座, 石川プレナリーセッション「免疫チェックポイント阻害薬登場後のレンバチニブの位置づけ」青木智子; 上嶋一臣; 盛田真弘; 千品寛和; 田北雅弘; 萩原 智; 南 康範; 依田 広; 西田直生志; 鶴崎正勝; 工藤正俊第22回日本肝がん分子標的治療研究会  2020/11  金沢歌劇場, 金沢LEAP-012 trial in progress: pembrolizumab, lenvatinib, and transarterial chemoembolization combination therapy for intermediate-stage hepatocellular carcinoma not amenable to curative treatmentVogel A; Llovet JM; El-Khoueiry A; Madoff DC; Finn RS; Ogasawara S; Ren Z; Mody K; Li JJ; Siegel AB; Dubrovsky L; Kudo MAmerican Association for the Study of Liver Diseases (AASLD 2020)  2020/11  Boston, USAKEYNOTE-937 trial in progress: adjuvant pembrolizumab for hepatocellular carcinoma and complete radiologic response after surgical resection or local ablationVogel A; Zhu A; Cheng AL; Yau T; Zhou J; Kim E; Malhotra U; Siegel AB; Kudo MAmerican Association for the Study of Liver Diseases (AASLD 2020)  2020/11  Boston, USA特別講演「肝細胞がん治療戦略2020」  [Invited]工藤正俊LENVIMA-HCC Meet The Expert  2020/11特別講演「肝細胞癌治療に関する最新情報」  [Invited]工藤正俊奈良県消化器癌講演会  2020/11  The Kashihara, 奈良肝細胞癌における腫瘍免疫環境と癌関連分子の遺伝子変異. シンポジウム3「肝癌診療の現状と未来」西田直生志; 盛田真弘; 工藤正俊第28回日本消化器関連学会週間  2020/11切除不能肝細胞癌に対する免疫チェックポイント阻害薬不応後のレンバチニブ二次療法青木智子; 上嶋一臣; 盛田真弘; 千品寛和; 田北雅弘; 萩原 智; 南 康範; 依田 広; 西田直生志; 鶴崎正勝; 工藤正俊第28回日本消化器病関連学会週間(JDDW2020)  2020/11  神戸コンベンションセンター, 兵庫全身化学療法により生存利益を得られる切除不能C型肝細胞癌の特徴  [Not invited]青木智子; 上嶋一臣; 盛田真弘; 千品寛和; 田北雅弘; 萩原 智; 南 康範; 依田 広; 西田直生志; 鶴崎正勝; 工藤正俊第28回日本消化器病関連学会週間(JDDW2020)  2020/11  神戸コンベンションセンター, 兵庫特別講演「肝細胞癌治療のパラダイムチェンジ」  [Invited]工藤正俊Chugai Hepatocellular Carcinoma Seminar in Hokkaido  2020/10  センチュリーロイヤルホテル, 札幌特別講演「新薬上市を見据えた肝細胞がん治療戦略2020」  [Invited]工藤正俊肝癌Expert Meeting—New Paradigm of Treatment Strategy  2020/10Invited Web Lecture “Results of REFLECT study and subsequent studies.”  [Invited]Masatoshi KudoChina Medicine Education Association (CMEA)  2020/10特別講演「肝細胞がん治療戦略2020」  [Invited]工藤正俊LENVIMA-HCC Web Seminar in 高槻  2020/10特別講演「新薬上市を見据えた肝細胞がん治療戦略2020」  [Invited]工藤正俊HCC Expert Meeting—新時代における薬物療法を考える  2020/10Invited Lecture “Treatment strategy of Intermediate Stage HCC.”  [Invited]Masatoshi KudoThe Fifth International Conference on Cancer Precision Medicine Seminar (中国対象 Web)  2020/10Invited Lecture “AI-aided detection and diagnosis of liver tumors.”  [Invited]Masatoshi Kudo2nd Asia Pacific International Symposium on Advances in Medical Ultrasound (APISAMU)  2020/10特別講演「肝細胞癌薬物治療の新たな選択肢—テセントリク、アバスチン併用療法—」  [Invited]工藤正俊中外Eセミナーon Hepatocellular Carcinoma  2020/10  ホテル・アゴーラリージェンシー堺, 大阪特別講演「新薬上市を見据えた肝細胞がん治療戦略2020」  [Invited]工藤正俊肝癌Expert Meeting—New Paradigm of Treatment Strategy—10 (Web)  2020/10特別講演「超音波デジタル画像のナショナルデータベース構築と超音波AI診断の開発」  [Invited]工藤正俊第30回四国地方会学術集会  2020/10  愛媛大学, 四国Invited Lecture “Treatment strategy of Intermediate Stage HCC.”  [Invited]Masatoshi KudoChina Medicine Education Association (CMEA)  2020/10Invited Lecture “New Paradigm of Treatment Strategy for Patients in BCLC B HCC.”  [Invited]Masatoshi KudoIndia Webinar HCC Expert Meeting (インド対象 Web)  2020/10鑑別診断に造影超音波が有用であった多血性の肝内胆管癌の1例吉田早希; 南 康範; 盛田真弘; 青木智子; 田北雅弘; 萩原 智; 依田 広; 上嶋一臣; 西田直生志; 工藤正俊日本消化器病学会近畿支部第113回例会  2020/10  大阪国際会議場, 大阪Detective flow imaging (DFI)にて特徴的な腫瘍内血流を観察し得たIntraductal papillary neoplasm of the bile duct (IPNB)の1例尼崎雅也; 大本俊介; 吉田晃浩; 田中秀和; 石川 嶺; 岡本彩那; 山崎友裕; 中井敦史; 三長孝輔; 鎌田 研; 竹中 完; 工藤正俊日本消化器病学会近畿支部第113回例会  2020/10  大阪国際会議場, 大阪膵神経内分泌腫瘍治癒切除後の肝転移再発を認め切除された一例杉崎俊亮; 川崎俊彦; 福永朋洋; 野村健司; 米澤真衣; 半田康平; 河野辰哉; 橋本有人; 木下大輔; 水野成人; 若狭朋子; 太田善夫; 辻本智之; 橋本和彦; 石川 原; 工藤正俊日本消化器病学会近畿支部第113回例会  2020/10  大阪国際会議場, 大阪Bouveret症候群に対して電気水圧結石破砕術(EHL)が有効であった1症例山岡諭史; 半田康平; 野村健司; 米澤真衣; 河野辰哉; 福永朋洋; 橋本有人; 木下大輔; 川崎俊彦; 水野成人; 工藤正俊日本消化器病学会近畿支部第113回例会  2020/10  大阪国際会議場, 大阪切除不能進行肝癌に対する免疫チェックポイント阻害薬不応後の二次治療を見据えて. シンポジウム「消化管癌化学療法の進歩と課題」青木智子; 萩原 智; 上嶋一臣; 工藤正俊日本消化器病学会近畿支部第113回例会  2020/10  大阪国際会議場, 大阪早期胃胎児消化管上皮類似癌の1例岡井夏輝; 松井繁長; 正木 翔; 栗本真之; 大丸直哉; 友岡瑞貴; 益田康弘; 高田隆太郎; 高島耕太; 河野匡志; 永井知行; 米田頼晃; 本庶 元; 櫻井俊治; 辻 直子; 樫田博史; 工藤正俊日本消化器病学会近畿支部第113回例会  2020/10  大阪国際会議場, 大阪当院における新規胆管ステント留置術. ワークショップ「胆膵領域における内視鏡手技の進歩」田中秀和; 中井敦史; 竹中 完; 工藤正俊日本消化器病学会近畿支部第113回例会  2020/10  大阪国際会議場, 大阪膵腫瘤性病変におけるDetective flow imaging (DFI)の有用性について. パネルディスカッション「胆膵領域癌に対する診断の取り組み」田中隆光; 大本俊介; 竹中 完; 工藤正俊日本消化器病学会近畿支部第113回例会  2020/10  大阪国際会議場, 大阪JAK阻害薬を用いた潰瘍性大腸炎の治療戦略. パネルディスカッション「炎症性腸疾患の現状と課題」友岡瑞貴; 櫻井俊治; 樫田博史; 工藤正俊日本消化器病学会近畿支部第113回例会  2020/10  大阪国際会議場, 大阪ヒマシ油ブースターによる大腸カプセル内視鏡検査の新しい前処置軽減の試み(前向き観察研究). ワークショップ「消化管腫瘍の診断と治療における工夫」  [Not invited]高島耕太; 米田頼晃; 樫田博史; 工藤正俊日本消化器病学会近畿支部第113回例会  2020/10  大阪国際会議場, 大阪胃底腺型胃癌の内視鏡診断と治療. ワークショップ「消化管腫瘍の診断と治療における工夫」  [Not invited]益田康弘; 松井繁長; 櫻井俊治; 工藤正俊日本消化器病学会近畿支部第113回例会  2020/10  大阪国際会議場, 大阪司会; ランチョンセミナー「腹腔内感染症の治療戦略」  [Invited]工藤正俊日本消化器病学会近畿支部第113回例会  2020/10  大阪国際会議場, 大阪特別講演「肝細胞癌治療における免疫療法時代の到来」  [Invited]工藤正俊中外Eセミナーon Hepatocellular Carcinoma  2020/10  ホテル・アゴーラリージェンシー堺, 大阪特別講演「新薬上市を見据えた肝細胞がん治療戦略2020」  [Invited]工藤正俊HCC-Expert Meeting~新時代における薬物療法を考える~(Web)  2020/09特別講演「新薬上市を見据えた肝細胞がん治療戦略2020」  [Invited]工藤正俊HCC Expert Meeting in 熊本  2020/09LEAP-012 trial in progress: pembrolizumab plus Lenvatinib and transarterial chemoembolization (TACE) in patients with intermediate-stage hepatocellular carcinoma (HCC) not amenable to curative treatmentLlovet JM; El-Khoueiry AB; Vogel A; Madoff DC; Finn RS; Ogasawara S; Ren Z; Mody K; Li JJ; Siegel AB; Dubrovsky L; Kudo MEuropian Society for Medical Oncology (ESMO) congress  2020/09  Madrid, SpainKEYNOTE-937 trial in progress: adjuvant pembrolizumab for hepatocellular carcinoma and complete radiologic response after surgical resection or local ablationVogel A; Zhu A; Cheng AL; Yau T; Zhou J; Kim E; Malhotra U; Siegel AB; Kudo MEuropian Society for Medical Oncology (ESMO) congress  2020/09  Madrid, SpainBaseline liver function and outcomes in patients with unresectable hepatocellular carcinoma (HCC) in KEYNOTE-240Vogel A; Merle P; Verslype C; Finn RS; Zhu AX; Cheng AL; Chan SL; Yau T; Ryoo BY; Wei Z; Holynskyj A; Siegel AB; Kudo MEuropian Society for Medical Oncology (ESMO) congress  2020/09  Madrid, SpainLong-term follow-up of bintrafusp alfa, a bifunctional fusion protein targeting TGF-β and PD-L1, in patients with pretreated biliary tract cancerYoo C; Oh DY; Choi HJ; Kudo M; Ueno M; Kondo S; Chen LT; Osada M; Helwig C; Dussault I; Ikeda MEuropian Society for Medical Oncology (ESMO) congress  2020/09The novel regimen of tremelimumab (T) plus durvalumab (D) in patients (Pts) with unresectable hepatocellular carcinoma (uHCC) by viral etiologyQin S; Kelley K; Kudo M; Harris W; Ikeda M; Okusaka T; Kang YK; Tai DWM; Lim HY; Yau T; Yong WP; Cheng AL; Gasbarrini A; Damian S; Bruix J; Borad M; He P; Negro A; Sangro B; Abou-Alfa G23rd Annual Meeting of Chinese Society of Clinical Oncology (CSCO 2020)  2020/09  Xiamen, ChinaEffect of pembrolizumab (pembro) on hepatitis B viral (HBV) load and aminotransferase (ALT) levels in patients (pts) with advanced hepatocellular carcinoma (aHCC) in KEYNOTE-224 (KN224) and KEYNOTE-240 (KN240)Chan SL; Zhu AX; Finn RS; Edeline J; Ogasawara S; Knox JJ; Daniele B; Ryoo BY; Merle P; Bouattour M; Lim HY; Chao Y; Yau T; Haber BA; Malhotra U; Liu CC; Kudo M; Cheng AL23rd Annual Meeting of Chinese Society of Clinical Oncology (CSCO 2020)  2020/09  Xiamen, China特別講演「新薬上市を見据えた肝細胞がん治療戦略2020」  [Invited]工藤正俊HCC Expert Meeting (近畿)  2020/09特別講演「新薬上市を見据えた肝細胞がん治療戦略2020」  [Invited]工藤正俊肝癌Expert Meeting (九州)  2020/09Invited Lecture “Treatment strategy of BCLC B HCC.”  [Invited]Masatoshi KudoEisai Malaysia Virtual Advisory Board Meeting(マレーシア対象 Web)  2020/09特別講演「新薬上市を見据えた肝細胞がん治療戦略2020」  [Invited]工藤正俊第16回広島肝胆膵Web研究会  2020/09IMbrave150: management of adverse events of special interest (AESIs) for atezolizumab and bevacizumab in patients with unresectable hepatocellular carcinomaIkeda M; Zhu AX; Qin S; Kim TY; Lim HY; Kudo M; Breder V; Merle A; Kaseb A; Li D; Ma N; Villalobos M; Stanzel S; Gaillard VE; Xu DZ; Hernandez S; Cheng AL; Finn RS; Galle PR; Ducreux MEuropian Society for Medical Oncology (ESMO) congress  2020/09Leap-012: A randomized, double-blind, phase 3 study of pembrolizumab plus lenvatinib in combination with transarterial chemoembolization (TACE) in patients with Intermediate-stage hepatocellular carcinoma (HCC) not amenable to curative treatmentFinn RS; Ogasawara S; Llovet JM; El-Khoueiry AB; Vogel A; Madoff DC; Ren Z; Mody K; Li JJ; Siegel AB; Dubrovsky L; Kudo M14th Annual Conference International Liver Cancer Association (ILCA 2020)  2020/09Phase 3 KEYNOTE-937: adjuvant pembrolizumab versus placebo in patients with hepatocellular carcinoma and complete radiologic response after surgical resection or local ablationVogel A; Zhu A; Kudo M; Yau T; Zhou J; Kim E; Malhotra U; Siegel AB; Cheng AL14th Annual Conference International Liver Cancer Association (ILCA 2020)  2020/09Effect of pembrolizumab (pembro) on hepatitis B viral (Hbv) load and aminotransferase (Alt) levels in patients (Pts) with advanced hepatocellular carcinoma (Ahcc) in Keynote-224 and Keynote-240Merle P; Chan SL; Zhu AX; Finn RS; Edeline J; Ogasawara S; Knox JJ; Daniele B; Ryoo BY; Merle P; Bouattour M; Lim HY; Chao Y; Yau T; Haber BA; Malhotra U; Liu CC; Kudo M; Cheng AL14th Annual Conference International Liver Cancer Association (ILCA 2020)  2020/09特別講演「新薬上市を見据えた肝細胞がん治療戦略2020」  [Invited]工藤正俊肝癌Expert Meeting—New Paradigm of Treatment Strategy—  2020/09Chair: Sponsored Symporium 4 “Role of the liver tumor board in early- and intermediate-stage HCC”  [Invited]Masatoshi KudoThe 10th Asia-Pacific Primary Liver Cancer Expert Meeting (APPLE 2019)  2020/08  Royton Sapporo, HokkaidoB型慢性肝炎患者に対するETVとTAAFの前向き比較観察研究萩原 智; 盛田真弘; 青木智子; 田北真弘; 南 康範; 依田 広; 上嶋一臣; 西田直生志; 工藤正俊第56回日本肝臓学会総会  2020/08  大阪国際会議場, 大阪人工知能を用いた腹部超音波からのリアルタイム肝腫瘤検出支援. ワークショップ「画像診断の新展開」西田直生志; 工藤正俊第56回日本肝臓学会総会  2020/08  大阪国際会議場, 大阪進行肝癌に対する免疫チェックポイント阻害薬不応後のレンバチニブ療法の有効性の検討. パネルディスカッション2「肝癌に対する分子標的治療および免疫治療」青木智子; 上嶋一臣; 盛田真弘; 南 知宏; 田北雅弘; 萩原 智; 南 康範; 依田 広; 西田直生志; 工藤正俊第56回日本肝臓学会総会  2020/08  大阪国際会議場, 大阪ランチョンセミナー「レンバチニブのすべて」  [Invited]工藤正俊第56回日本肝臓学会総会  2020/08Atezolizumab + bevacizumab versus sorafenib in patients with unresectable hepatocellular carcinoma: safety results from the Phase III IMbrave150 studyDucreux M; Zhu AX; Qin S; Ikeda M; Kim TY; Lim HY; Kudo M; Breder V; Merle P; Kaseb A; Li D; Verret W; Xu D; Hernandez S; Liu J; Shao H; Huang C; Cheng AL; Finn RS; Galle PREASL Digital International Liver Congress (EASL-ILC 2020)  2020/08特別講演「肝細胞癌治療戦略2020」  [Invited]工藤正俊Lenvima-HCC Web Seminar  2020/08Invited Lecture “Lenvatinib 1L treatment for intermediate to advanced stage patients in uHCC.”  [Invited]Masatoshi KudoEisai Oncology Liver Webinar (アジア対象 Web)  2020/08チロシンキナーゼ阻害薬時代に注意すべき肝細胞癌の遠隔転移大塚康生; 青木智子; 南 知宏; 田北雅弘; 萩原 智; 南 康範; 依田 広; 上嶋一臣; 西田直生志; 工藤正俊第106回日本消化器病学会総会  2020/08  リーガロイヤルホテル広島, 広島TACE不適Intermediate-stage肝細胞癌に対するLenvatinib先行投与の有用性~up-to-7 criteria outを対象として~. シンポジウム7「肝癌薬物療法の最前線」青木智子; 上嶋一臣; 工藤正俊第106回日本消化器病学会総会  2020/08  リーガロイヤルホテル広島, 広島特別講演「肝細胞癌薬物治療の新展開~二次治療としてのラムシルマブへの期待~」  [Invited]工藤正俊CYRAMZA HCC Treatment Seminar in Kansai  2020/08  ヒルトン大阪, 大阪特別講演「新薬上市を見据えた肝細胞がん治療戦略2020」  [Invited]工藤正俊LENVIMA Meet the Expert (Web)  2020/07特別講演「新薬上市を見据えた肝細胞癌治療戦略2020」  [Invited]工藤正俊肝癌Expert Meeting—New Paradigm of Treatment Strategy—  2020/07特別講演「新薬上市を見据えた肝細胞癌治療戦略2020」  [Invited]工藤正俊肝癌Expert Meeting—New Paradigm of Treatment Strategy—  2020/07LEAP-012 trial in progress: pembrolizumab plus Lenvatinib and transarterial chemoembolization (TACE) in patients with intermediate-stage hepatocellular carcinoma (HCC) not amenable to curative treatmentLlovet JM; El-Khoueiry AB; Vogel A; Madoff DC; Finn RS; Ogasawara S; Ren Z; Mody K; Li JJ; Siegel AB; Dubrovsky L; Kudo MESMO World Congress on Gastrointestinal Cancer 2020 (ESMO-GI 2020)  2020/07Efficacy and safety of Nivolumab + Ipilimumab in Asian patients with advanced hepatocellular carcinoma: Subanalysis of the CheckMate 040 studyYau T; Hsu C; Kang YK; Kim TY; Hou MM; Lim HY; Chao Y; Kim YH; Ikeda M; Choo SP; Neely J; Shen Y; Tschaika M; Kudo MESMO World Congress on Gastrointestinal Cancer 2020 (ESMO-GI 2020)  2020/07Atezolizumab + bevacizumab versus sorafenib for unresectable hepatocellular carcinoma (HCC): results from older patients enrolled in IMbrave150Li D; Toh HC; Merle P; Kudo M; Tsuchiya K; Hernandez S; Shao H; Mulla S; Ding BESMO World Congress on Gastrointestinal Cancer 2020 (ESMO-GI 2020)  2020/07Invited Lecture “Systemic therapy for HCC”  [Invited]Masatoshi KudoThe Asian Pacific Association for the Study of the Liver (APASL) Hepatology Webinar  2020/06特別講演「BCLC-Bにおける治療方針の考え方の変化」  [Invited]工藤正俊LENVIMA-HCC WEB Seminar 画像による肉眼分類・腫瘍分化度の臨床判断  2020/06特別講演「肝細胞癌セカンドライン スチバーガの役割と今後の展望~クリニカルクエスチョンに応えて~」  [Invited]工藤正俊バイエル薬品株式会社HCC Webカンファレンス~スチバーガ®錠 肝細胞癌発売3周年記念Webカンファレンス~  2020/06特別講演「BCLC-Bにおける治療方針の考え方の変化」  [Invited]工藤正俊LENVIMA-HCC WEB Seminar 画像による肉眼分類・腫瘍分化度の臨床判断  2020/06Invited Lecture “Lenvatinib use in TACE ineligible patients”  [Invited]Masatoshi KudoASCO Virtual Eisai Canada National HCC Advisory Board  2020/06Complete responses (CR) in patients receiving atezolizumab (atezo) + bevacizumab (bev) vs sorafenib (sor) in IMbrave150: a phase III clinical trial for unresectable hepatocellular carcinoma (HCC)Finn RS; Qin S; Ikeda M; Galle PR; Ducreux M; Kim TY; Kudo M; Lim HY; Breder VV; Merle P; Kaseb AO, Li D; Feng YH; Verret W; Xu DZ; Hernandez S; Ding B; Zhu AX; Cheng ALAmerican Society of Clinical Oncology (ASCO 2020)  2020/05A phase 1b study of lenvatinib (LEN) plus pembrolizumab (PEMBRO) in unresectable hepatocellular carcinoma (uHCC)Zhu AX; Finn RS; Ikeda M; Sung MW; Baron AD; Kudo M; Okusaka T; Kobayashi M; Kumada H; Kaneko S; Pracht M; Mamontov K; Meyer T; Mody K; Kubota T; Dutcus CE; Saito K; Siegel AB; Dubrovsky L; Llovet JMAmerican Society of Clinical Oncology (ASCO 2020)  2020/05A multicenter non-randomized controlled trial to evaluate the efficacy of surgery vs. radiofrequency ablation for small hepatocellular carcinoma (SURF Cohort trial)Tateishi R; Hasegawa K; Kawaguchi Y; Takayama T; Izumi N; Yamanaka N; Kudo M; Shimada M; Inomata M; Kaneko S; Koike K; Omata M; Makuuchi M; Matsuyama Y; Kokudo NAmerican Society of Clinical Oncology (ASCO 2020)  2020/05An international cohort study investigating the impact of age on clinical outcome in patients with hepatocellular carcinoma treated with sorafenibSharma R; Hajiev S; Aval LM; Bettinger D; Arizumi T; Pirisi M; Rimassa L; Personeni N; Pressiani T; Giordano L; Kudo M; Thimme R; Park JW; Taddei TH; Kaplan DE; Ramaswami R; Pinato DJ; Allara EAmerican Society of Clinical Oncology (ASCO 2020)  2020/05Ramucirumab in patients with advanced HCC and elevated alpha-fetoprotein (AFP): Outcomes by treatment-emergent ascitesZhu AX; Ikeda M; Galle P; Yamashita T; Llovet J; Liang K; Wang C; Sakaguchi S; Abada P; Widau RC; Kudo MAmerican Society of Clinical Oncology (ASCO 2020)  2020/05Sequential treatment with sorafenib (SOR) followed by regorafenib (REG) in patients with unresectable hepatocellular carcinoma (HCC): Interim analysis of the observational REFINE studyMerle P; Lim HY; Finn RS; Ikeda M; Kudo M; Frenette C; Masi G; Kim YJ; Gerolami R; Kurosaki M; Numata K; Klümpen HJ; Zebger-Gong H; Fiala-Buskies S; Ozgurdal K; Qin S; on behalf of; the; REFINE investigatorsAmerican Society of Clinical Oncology (ASCO 2020)  2020/05Efficacy and tolerability of tremelimumab (T) and durvalumab (D) in combination or as monotherapy for patients (pts) with advanced hepatocellular carcinoma (aHCC)Kelly K; Sangro B; Harris WP; Ikeda M; Okusaka T; Kang YK; Qin S; Tai D; Lim HY; Yau T; Yong WP; Cheng AL; Gasbarrini A; Braud FGD; Bruix J; Borad MJ; He P; Negro A; Kudo M; Abou-Alfa GKAmerican Society of Clinical Oncology (ASCO 2020)  2020/05Effect of pembrolizumab on hepatitis B viral load and transaminase levels in patients with advanced hepatocellular carcinoma in KEYNOTE-224 and KEYNOTE-240  [Not invited]Chan SL, Zhu AX, Finn RS, Edeline J, Ogasawara S, Knox JJ, Daniele B, Ryoo BY, Merle P, Bouattour M, Lim HY, Chao Y, Yau T, Haber BA, Malhotra U, Liu CC, Kudo M, Cheng AL:American Society of Clinical Oncology (ASCO 2020)  2020/05  Chicago, USA特別講演「COVID-19環境下における肝細胞癌治療~各ガイダンスと、いま我々が考えるべき治療戦略~」  [Invited]工藤正俊Lenvatinib-HCC Web Seminar  2020/05特別講演「COVID-19環境下における肝細胞癌治療~各ガイダンスと、いま我々が考えるべき治療戦略~」  [Invited]工藤正俊Lenvatinib-HCC Web Seminar  2020/05特別講演「肝がん分子標的治療薬10年の軌跡と今後の展望~ネクサバール発売10年目を迎えて~」  [Invited]工藤正俊バイエル薬品株式会社HCC Webカンファレンス~肝がん分子標的治療薬 今後の展望~  2020/05Invited Lecture “Treatment strategy of BCLC B HCC”  [Invited]Masatoshi KudoLiver Cancer Intervention Community (LCIC) Kick-off Meeting (Web) (Observer 17,484 people)  2020/05Phase 3 KEYNOTE-937: adjuvant pembrolizumab versus placebo in patients with hepatocellular carcinoma and complete radiologic response after surgical resection or local ablationVogel A; Zhu A; Kudo M; Yau T; Zhou J; Kim E; Malhotra U; Siegel AB; Cheng ALAmerican Association for Cancer Research Annual Meeting (AACR 2020)  2020/04Invited Lecture “Treatment strategy of BCLC B HCC”  [Invited]Masatoshi KudoChina-Japan Intervention Web seminar (Observer 16,000 people)  2020/04特別講演「肝細胞癌における治療方針の考え方の変化」  [Invited]工藤正俊肝細胞癌の画像による肉眼分類・腫瘍分化度の臨床判断座談会  2020/03LEAP-012 trial in progress: Pembrolizumab, lenvatinib, and transarterial chemoembolization combination therapy for intermediate-stage hepatocellular carcinoma not amenable to curative treatment  [Not invited]Maddoff DC; Llovet JM; El-Khoueiry AB; Kudo M; Finn RS; Ogasawara S; Ren Z; Mody K; Li JJ; Siegel AB; Dubrovsky L; Vogel ASIR 2021 congress  2020/03深層学習を用いた超音波肝腫瘤像のAI診断システム開発椎名 毅; 山川 誠; 西田直生志; 工藤正俊日本音響学会2020年春季研究発表会  2020/03Invited Lecture “LENVIMA for first-line treatment for patients with unresectable hepatocellular carcinoma(uHCC): A case-based approach”  [Invited]Masatoshi KudoLenvima HCC National Broadocast  2020/03Invited Lecture “LENVIMA for first-line treatment for patients with unresectable hepatocellular carcinoma(uHCC): A case-based approach”  [Invited]Masatoshi KudoLenvima HCC National Broadocast  2020/03術前診断が困難であった肝多血性腫瘍の1例大丸直哉, 川崎俊彦, 高田隆太郎, 福永朋洋, 橋本有人, 秦 康倫, 木下大輔, 水野成人, 橋本和彦, 石川 原, 若狭朋子, 太田善夫, 工藤正俊日本消化器病学会近畿支部第112回例会  2020/02  京都テルサ, 京都急性膵炎の発症を契機に診断し得た膵IPMCの一例福永朋洋, 高田隆太郎, 橋本有人, 秦 康倫, 木下大輔, 川崎俊彦, 工藤正俊, 石川 原, 若狭朋子, 太田善夫, 水野成人日本消化器病学会近畿支部第112回例会  2020/02  京都テルサ, 京都チロシンキナーゼ阻害薬による抗腫瘍効果と肝予備能青木智子, 上嶋一臣, 南 知宏, 田北雅弘, 萩原 智, 南 康範, 依田 広, 西田直生志, 鶴崎正勝, 工藤正俊第26回肝血流動態機能イメージ研究会  2020/02  石川県立音楽堂Phase 3 KEYNOTE-937: Adjuvant pembrolizumab versus placebo in patients with hepatocellular carcinoma and complete radiologic response after surgical resection or local ablation.  [Not invited]Zhu AX, Kudo M, Vogel A, Yau T, Zhou J, Kim E, Malhotra U, Siegel AB, Cheng ALTherapeutic Agents for Hepatocellular Carcinoma (HCC-TAG Conference 2020)  2020/02  Park City, Utah, USA急激な発熱、腹痛を契機に発見された単純性潰瘍の一例  [Not invited]立野沙織; 奥田英之; 秦 康倫; 木下大輔; 高山政樹; 川崎俊彦; 水野成人; 若狭朋子; 太田善夫; 工藤正俊日本消化器病学会近畿支部第110回例会  2020/02  京都テルサ, 京都特別講演「Intermediate Stage肝癌の治療戦略」  [Invited]工藤正俊Lenvatinib Meet The Expert in Shiga  2020/02  クサツエストピアホテル, 滋賀Invited Lecture “Changing paradigm of treatment strategy in unresectable HCC”  [Invited]Masatoshi KudoMGLS-IASL Joint Symposium Yangon  2020/02  Yangon, MyanmarInvited Lecture “New systemic therapies”  [Invited]Masatoshi KudoThe 24th International Symposium of Yonsei Institute of Gastroenterology  2020/02  Yonsei University Health System, Seoul, Korea特別講演「造影超音波検査の現状と超音波AI診断の開発」  [Invited]工藤正俊第29回日本乳癌画像研究会  2020/02  大阪国際会議場, 大阪膵頭十二指腸切除後に針状の胆管結石を反復する1例橋本有人, 福永朋洋, 高田隆太郎, 木下大輔, 秦 康倫, 川崎俊彦, 水野成人, 石川 原, 井上雅智, 工藤正俊第103回日本消化器内視鏡学会  2020/01  大阪国際交流センター, 大阪食道、胃、小腸に病変が確認できた好酸球性胃腸症の1例秦 康倫, 高田隆太郎, 福永朋洋, 橋本有人, 木下大輔, 川崎俊彦, 水野成人, 阿部洋介, 若狭朋子, 太田善夫, 河野匡志, 工藤正俊第103回日本消化器内視鏡学会  2020/01  大阪国際交流センター, 大阪von Recklinghausen病に合併した多発十二指腸性GISTの1例野村健司, 松井繁長, 吉川馨介, 高島耕太, 山田光成, 正木 翔, 永井知行, 米田頼晃, 本庶 元, 櫻井俊治, 辻 直子, 樫田博史, 工藤正俊, 吉田雄太, 松本逸平, 竹山宜典第103回日本消化器内視鏡学会  2020/01  大阪国際交流センター, 大阪特別講演「肝細胞癌治療のパラダイムシフト」  [Invited]工藤正俊HCC Expert Seminar in Niigata  2020/01  ホテルオークラ新潟, 新潟切除不能肝癌に対するレンバチニブを含むMTA sequential治療成績と予後因子  [Not invited]糸永 詠, 平岡 淳, 熊田 卓, 厚川正則, 広岡昌史, 辻 邦彦, 石川 達, 高口浩一, 狩山和也, 田尻和人, 島田紀朋, 柴田啓志, 越智裕紀, 多田俊史, 豊田秀徳, 能祖一裕, 田中弘教, 玉井 努, 工藤正俊第21回日本肝がん分子標的治療研究会  2020/01  国立がん研究センター, 東京プレナリーセッション2「ソラフェニブ前治療後のAFP高値進行肝細胞癌に対するラムシルマブによるALBIスコアへの影響: REACH試験及びREACH-2試験の日本人部分集団の併合解析」  [Not invited]池田公史, Zhu AX, 奥坂拓志, 本村健太, 森本 学, 瀬尾 智, 和田幸之, 佐藤新平, 山下竜也, 古川正幸, 新槇 剛, Wang C, Widau R, 篠崎健太, 吉川麗月, 工藤正俊第21回日本肝がん分子標的治療研究会  2020/01  国立がん研究センター, 東京10周年特別企画ランチョンセミナー「HCC分子標的薬 10年の軌跡と今後の展望」  [Invited]工藤正俊第21回日本肝がん分子標的治療研究会  2020/01  国立がん研究センター, 東京開会の辞  [Invited]工藤正俊第21回日本肝がん分子標的治療研究会  2020/01  国立がん研究センター, 東京特別講演「肝細胞癌治療のパラダイムシフト」  [Invited]工藤正俊第1回Kobe Liver Conference  2020/01  ホテルオークラ神戸, 兵庫A study on liver tumor detection from an ultrasound image using deep learning.Nakashima T; Tsutsui I; Takami H; Doman K; Mekata Y; Nishida N; Kudo MInternational Workshop on Advanced Image Technology (IWAIT 2020)  2020/01Objective response (OR) by mRECIST to predict overall survival (OS) in patients with hepatocellular carcinoma (HCC) treated with sorafenib in the SILIUS trialKudo M; Ueshima K; Ogawa C; Chiba Y2020 Gastrointeritinal Cancers Symposium (ASCO-GI 2020)  2020/01  San Francisco, USARamucirumab for patients with intermediate-stage hepatocellular carcinoma (HCC) and elevated alpha fetoprotein (AFP): Pooled results from two phase III studies (REACH and REACH-2)Kudo M; Finn RS; Morimoto M; Rau KM; Ikeda M; Yen CJ; Galle PR; Llovet JM; Daniele B; Lim HY; Liang K; Shinozaki K; Wang C; Yoshikawa R; Abada P; Widau RC; Zhu AX2020 Gastrointeritinal Cancers Symposium (ASCO-GI 2020)  2020/01  San Francisco, USAAssociation of objective response by mRECIST with better overall survival (OS) in patients with advanced hepatocellular carcinoma (HCC) treated with systemic therapies: A systematic review and meta-analysis of randomized controlled trialsKudo M; Chiba Y; Meyer T; Lencioni R; Llovet JM2020 Gastrointeritinal Cancers Symposium (ASCO-GI 2020)  2020/01  San Francisco, USASubsequent anticancer procedures following first-line Lenvatinib (LEN): A post hoc analysis from the Phase 3 REFLECT study in unresectable hepatocellular carcinoma (uHCC)Alsina A; Kudo M; Vogel A; Cheng AL; Tak WY; Ryoo BY; Evans TRJ; Lopéz CL; Daniele B; Blanc JF; Ren M; Baldwin RL; Izumi N; Qin S; Finn RS2020 Gastrointeritinal Cancers Symposium (ASCO-GI 2020)  2020/01  San Francisco, USARECIST v1.1 and irRECIST outcomes in advanced HCC treated with pembrolizumab (pembro)  [Not invited]Edeline J; Karwal M; Zhu AX; Finn RS; Cattan S; Ogasawara S; Verslype C; Zagonel V; Fartoux L; Vogel A; Rosmorduc O; Verset G; Chan SL; Knox J; Daniele B; Cheng AL; Goldmacher G; Jensen E; Siegel AB; Kudo M2020 Gastrointeritinal Cancers Symposium (ASCO-GI 2020)  2020/01  San Francisco, USAA phase 1b study of lenvatinib (LEN) plus nivolumab (NIV) in patients (pts) with unresectable hepatocellular carcinoma (uHCC) (Study 117)  [Not invited]Kudo M; Ikeda M; Motomura K; Okusaka T; Kato N; Dutcus CE; Hisai T; Suzuki M; Ikezawa H; Iwata T; Kumada H; Kobayashi M2020 Gastrointeritinal Cancers Symposium (ASCO-GI 2020)  2020/01  San Francisco, USAPhase 3 study of pembrolizumab (pembro) versus best supportive care (BSC) for second-line therapy in advanced hepatocellular carcinoma (aHCC): KEYNOTE-240 Asian subgroup  [Not invited]Kudo M; Lim HY; Cheng AL; Chao Y; Yau T; Ogasawara S; Kurosaki M; Morimoto N; Ohkawa K; Yamashita T; Lee DW; Chen E; Siegel A; Ryoo BY2020 Gastrointeritinal Cancers Symposium (ASCO-GI 2020)  2020/01  San Francisco, USA座長; 特別講演「最新C型慢性肝疾患治療について」  [Invited]工藤正俊South Osaka Liver Summit  2019/12  ホテルモントレグラスミア大阪, 大阪Invited Lecture “Updates of targeted therapies for HCC  [Invited]Masatoshi KudoTaiwan Association for the Study of the Liver (TASL 2019)  2019/12  Taipei, TaiwanRoche Symposium “Recent advances on cancer immunotherapy combination for advanced HCC”  [Invited]Masatoshi KudoTaiwan Association for the Study of the Liver (TASL 2019)  2019/12  Taipei, Taiwanモーニングセミナー「肝細胞癌薬物治療の新展開~2次治療としてのラムシルマブへの期待~」  [Invited]工藤正俊第43回日本肝臓学会西部会  2019/12  海峡メッセ下関, 山口座長: イブニングセミナー「免疫チェックポイント阻害剤の作用機序と免疫関連有害事象について」  [Invited]工藤正俊第43回日本肝臓学会西部会  2019/12  海峡メッセ下関, 山口総括; シンポジウム3「肝癌診療の現状と展開」  [Invited]工藤正俊第43回日本肝臓学会西部会  2019/12  海峡メッセ下関, 山口Keynote Lecture “Changing Paradigm of Treatment Strategy in Intermediate-stage HCC”  [Invited]Masatoshi Kudo17th National Liver Cancer Conference  2019/12  Shanghai, China特別講演「超音波領域におけるAI開発の現状と展望」  [Invited]工藤正俊同志社大学ハリス理化学研究所研究発表会  2019/11  ホテルグランヴィア京都, 京都胆道閉塞に対するantegrade long plastic stent留置術の有用性  [Not invited]中井敦史; 竹中 完; 工藤正俊第27回日本消化器関連学会週間JDDW 2019(第61回日本消化器病学会大会, 第23回日本肝臓学会大会, 第98回日本消化器内視鏡学会総会)  2019/11  神戸コンベンションセンター, 兵庫EUS施行時のプロポフォール持続注入による鎮静の有用性の検討  [Not invited]岡本彩那; 鎌田 研; 竹中 完; 吉川智恵; 石川 嶺; 山﨑友裕; 中井敦史; 大本俊介; 三長孝輔; 山雄健太郎; 工藤正俊第27回日本消化器関連学会週間JDDW 2019(第61回日本消化器病学会大会, 第23回日本肝臓学会大会, 第98回日本消化器内視鏡学会総会)  2019/11  神戸コンベンションセンター, 兵庫PPI長期投与の有無からみた胃底腺ポリープの臨床病理学的検討  [Not invited]松村まり子; 辻 直子; 梅原康湖; 正木 翔; 岡元寿樹; 山田光成; 永井知行; 米田頼晃; 櫻井俊治; 松井繁長; 渡邉智裕; 樫田博史; 工藤正俊第27回日本消化器関連学会週間JDDW 2019(第61回日本消化器病学会大会, 第23回日本肝臓学会大会, 第98回日本消化器内視鏡学会総会)  2019/11  神戸コンベンションセンター, 兵庫膵癌診断のための新たなアプローチ性の提案—3D. シンポジウム5「膵癌/胆道癌における早期診断の進歩」  [Not invited]山雄健太郎; 竹中 完; 工藤正俊第61回日本消化器病学会大会  2019/11  神戸コンベンションセンター, 兵庫Deep neural networkを用いた超音波デジタル画像における肝腫瘍病名判別の試み.  [Not invited]西田直生志; 工藤正俊第23回日本肝臓学会大会  2019/11  神戸コンベンションセンター, 兵庫司会; サテライトシンポジウム89「肝細胞がんにおける薬物療法: 最近の動向」  [Invited]工藤正俊第23回日本肝臓学会大会  2019/11  神戸コンベンションセンター, 兵庫司会; 招待講演「Recent advances in clinical research of HBV and HCC」  [Invited]Masatoshi Kudo第23回日本肝臓学会大会  2019/11  神戸コンベンションセンター, 兵庫司会; サテライトシンポジウム76「切除不能な肝細胞癌の最前線」  [Invited]工藤正俊第23回日本肝臓学会大会  2019/11  神戸コンベンションセンター, 兵庫Lenvatinib as an initial treatment in patients with intermediate-stage hepatocellular carcinoma beyond up-to-seven criteria and Child-Pugh a liver function: a multicenter propensity-score matched study  [Not invited]Kudo M; Ueshima K; Chan SL; Minami T; Chishina H; Aoki T; Takita M; Hagiwara S; Minami Y; Ida H; Takenaka M; Sakurai T; Watanabe T; Morita M; Ogawa C; Wada Y; Ikeda M; Ishii H; Izumi N; Nishida NAmerican Association for the Study of Liver Diseases (AASLD 2019)  2019/11  Boston, USACheckmate 040: efficacy, hepatic safety, and biomarkers of Nivolumab + Ipilimumab combination therapy in patients with advanced hepatocellular carcinoma  [Not invited]Sangro B; Hsu C; Kang YK; Kim TY; El-Khoueiry AB; Santoro A; Melero I; Kudo M; Hou MM; Matilla A; Tovoli F; Knox JJ; He AR; El-Rayes B; Acosta-Rivera M; Lim HY; Neely J; Zhao H; Anderson J; Yau TAmerican Association for the Study of Liver Diseases (AASLD 2019)  2019/11  BostonPhase 3 KEYNOTE-937: adjuvant pembrolizumab versus placebo in patients with hepatocellular carcinoma and complete radiologic response after surgical resection or local ablationKudo M; Zhu AX; Vogel A; Yau T; Zhou J; Chen E; Malhotra U; Siegel AB; Cheng AL34th Annual Meeting & Pre-Conference Programs (SITC 2019)  2019/11  Gaylord National Hotel & Convention Center, Maryland, USADevelopment of AI-aided us diagnosis system of liver tumor using deep neural network.  [Not invited]Nshida N; Yamakawa M; Shiina T; Kudo MAmerican Association for the Study of Liver Diseases (AASLD 2019)  2019/11  Boston, USAClinical significance of tumor markers in surveillance for hepatocellular carcinoma in cirrhostic patients: a multicenter prospective cohort study in Japan.  [Not invited]Ucnino K; Tateishi R; Fujiwara N; Moriyama M; Eguchi Y; Toyoda H; Ida Y; Karino Y; Kudo M; Chuma M; Takuma Y; Kaneko S; Kato N; Chayama K; Izumi N; Itoi T; Sakaida I; Komeda H; Umemura T; Ishikawa T; Nakamuta M; Takaki A; Terai S; Ido A; Enomoto N; Yoshida H; Baba T; Torimura T; Hiasa Y; Ogawa C; Takehara T; Kumada T; Koike KAmerican Association for the Study of Liver Diseases (AASLD 2019)  2019/11  Boston, USAObjective response by mrecist is a prognostic factor for overall survival in unresectable hepatocellular carcinoma treated with systemic therapy: a systematic review and metaanalysis of randomized controlled trials.  [Not invited]Kudo M; Ueshima K; Nishida NAmerican Association for the Study of Liver Diseases (AASLD 2019)  2019/11  Boston, USALenvatinib for unresectable hepatocellular carcinoma in real-world practice: a multicenter analysis of prognostic factors.  [Not invited]Hiraoka A; Kumada T; Atsukawa M; Hirooka M; Ishikawa T; Tsuji K; Takaguchi K; Kariyama K; Itobayashi E; Tajiri K; Shimada N; Shibata H; Ochi H; Tada T; Toyoda H; Nouso K; Tsutsui A; Nagano T; Itokawa N; Hayama K; Imai M; Joko K; Koizumi Y; Hiasa Y; Michitaka K; Kudo MAmerican Association for the Study of Liver Diseases (AASLD 2019)  2019/11  Boston, USA特別講演「急激に変貌する肝細胞癌の薬物療法」  [Invited]工藤正俊第6回北摂津肝疾患連携セミナー  2019/10  千里阪急ホテル, 大阪特別講演「肝細胞癌治療のパラダイムシフト」  [Invited]工藤正俊Asahikawa Hepatocellular Carcinoma Conference  2019/10  星野リゾート OMO7 旭川, 北海道特別講演「超音波診断におけるAI開発の現状と課題」  [Invited]工藤正俊シンポジウム「人工知能時代の放射線画像診断・病理診断と専門医のあり方」  2019/10  日本学術会議講堂, 東京膵癌の門脈浸潤に対する造影ハーモニックEUSの有用性. シンポジウム2「新しい超音波法で腹部を診る(腹部疾患への超音波診断の新たな展開)」  [Not invited]中井敦史; 鎌田 研; 竹中 完; 筑後孝章; 兵頭朋子; 工藤正俊日本超音波医学会第46回関西地方会学術集会  2019/10  大阪国際会議場, 大阪特別企画「超音波デジタル画像のナショナルデータ構築とAI診断—日本超音波医学会のミッション—」  [Invited]工藤正俊日本超音波医学会第46回関西地方会学術集会  2019/10  大阪国際会議場, 大阪胆のう: 胆のう疾患診療における超音波の役割青木智子; 山雄健太郎; 工藤正俊本超音波医学会第46回関西地方会学術集会  2019/10  大阪国際会議場, 大阪Safety and efficacy of Lenvatinib by starting dose based on bodyweight in patients (pts) with unresectable hepatocellular carcinoma (uHCC) in REFLECT  [Not invited]Okusaka T; Ikeda K; Kudo M; Finn RS; Qin S; Han KH; Cheng AL; Piscaglia F; Kobayashi M; Sung M; Chen M; Wyrwicz L; Yoon JH; Ren Z; Dutcus C; Tamai T; Ren M; Hayato S; Kumada H31th Annual Conference, Canadian Association of Nurses in Oncology (CANO 2019)  2019/10  Manitoba, CanadaAssociation between overall survival and adverse events with Lenvatinib treatment in patients with hepatocellular carcinoma (REFLECT)  [Not invited]Sung M; Finn RS; Qin S; Han KH; Ikeda K; Cheng AL; Kudo M; Tateishi R; Ikeda M; Breder V; Rau KM; Ma YT; Alsina A; Ryoo BY; Ren Z; Mody K; Dutcus C; Tamai T; Saito K; Piscaflia F31th Annual Conference, Canadian Association of Nurses in Oncology (CANO 2019)  2019/10  Winnipeg, ManitobaInvited Lecture “Construction of big database of US digital image; Platform for creating artificial intelligence-aided US: Work in progress”  [Invited]Masatoshi KudoThe 1st Asia Pacific International Symposium on Advances in Medical Ultrasound  2019/10  Taipei, TaiwanSubsequent anticancer medication following first-line lenvatinib: a post hoc responder analysis from the phase 3 REFLECT study in unresectable hepatocellular carcinomaAlsina A; Kudo M; Vogel A; Cheng AL; Tak WY; Ryoo BY; Evans TRJ; Lopez C; Daniele B; Misir S; Ren M; Izumi N; Qin S; Finn RS2019 Annual Meeting of the DGHO  2019/10  BerlinSafety and efficacy of 12 mg/d lenvatinib (LEN) in patients with unresectable hepatocellular carcinoma (uHCC) and bodyweight (bw) >80 kg in REFLECT  [Not invited]Vogel A; Kudo M; Cheng AL; Sung MW; Finn RS; Lin AY; Abou-Alfa GK; Alsina A; Breder V; Tebbutt N; Osterlund P; Yen CJ; Ren M; Misir S; Dutcus CE; Palmer D; Merle P; Pinter M; Evans TRJ2019 Annual Meeting of the DGHO  2019/10  Berlin特別講演「肝細胞癌治療のパラダイムシフト Sys-Loco therapyの与えるインパクト」  [Invited]工藤正俊Sys-Loco therapy Meeting in 東海  2019/10  名古屋マリオットアソシアホテル, 愛知特別講演「肝細胞癌治療のパラダイムシフト Sys-Loco therapyの与えるインパクト」  [Invited]工藤正俊Sys-Loco therapyを考える  2019/10  ステーションコンファレンス東京, 東京血清IFN-α/IL-33が治療効果判定に有用と考えられた自己免疫性膵炎/IgG4関連疾患の1例  [Not invited]原 茜; 三長孝輔; 岡本彩那; 石川 嶺; 山崎友裕; 中井敦史; 大本俊介; 鎌田 研; 山雄健太郎; 竹中 完; 渡邉智裕; 工藤正俊; 安川 覚日本消化器病学会近畿支部第111回例会  2019/10  大阪国際交流センター, 大阪肝細胞腺腫の1例  [Not invited]山根雅智; 秦 泰倫; 松村まり子; 福永朋洋; 高田龍太郎; 河野匡志; 木下大輔; 奥田英之; 川崎俊彦; 水野成人; 日向 聖; 石川 原; 井上雅智; 若狭朋子; 太田善夫; 工藤正俊日本消化器病学会近畿支部第111回例会  2019/10  大阪国際交流センター, 大阪自己免疫性胃炎に合併した胃型腺腫の1例  [Not invited]吉川馨介; 松井繁長; 野村健司; 橋本有人; 山田光成; 高島耕太; 正木 翔; 永井知行; 米田頼晃; 本庶 元; 櫻井俊治; 辻 直子; 樫田博史; 工藤正俊日本消化器病学会近畿支部第111回例会  2019/10  大阪国際交流センター, 大阪DLBCLに発症したリンパ管拡張症に対してステロイド投与、食事療法が奏効した1症例  [Not invited]大塚康生; 米田頼晃; 正木 翔; 吉川馨介; 高島耕太; 橋本有人; 山田光成; 本庶 元; 永井知行; 櫻井俊治; 松井繁長; 渡邉智裕; 辻 直子; 樫田博史; 工藤正俊; 筑後孝章日本消化器病学会近畿支部第111回例会  2019/10  大阪国際交流センター, 大阪難症例に対するSOクリップ使用による大腸ESD、SOUTENを使用した大腸hybrid ESDの検討. シンポジウム2「下部消化管腫瘍に対する低侵襲治療の最前線」  [Not invited]正木 翔; 米田頼晃; 樫田博史; 工藤正俊日本消化器病学会近畿支部第111回例会  2019/10  大阪国際交流センター, 大阪急性胆嚢炎治療における内視鏡的経乳頭胆嚢ドレナージ(ENGBD)の位置づけ. ワークショップ2「急性胆嚢炎に対する治療戦略」  [Not invited]武部敦志; 竹山宜典; 竹中 完; 工藤正俊日本消化器病学会近畿支部第111回例会  2019/10  大阪国際交流センター, 大阪特別講演「急速に変貌するIntermediate stage肝癌の治療戦略」  [Invited]工藤正俊第44回リザーバー研究会  2019/10  都メッセ, 京都The interim report of B-RTO using candis systemAoki T; Oda T; Minami T; Takita M; Hagiwara S; Minami Y; Ida H; Nishida N; Tsurusaki M; Kudo MInternational Liver Conference  2019/10  Osaka International Convention CenterClinicopathological and immunohistochemical study of the mechanism of sporadic fundic gland polyp proliferation and enlargement in long-term PPI-users  [Not invited]Matsumura M; Tsuji N; Yoshida S; Tomooka M; Umehara Y; Kudo MUnited European Gastroenterology (UEGW 2019)  2019/10  Barcelona, SpainRamucirumab in patients with advanced hepatocellular carcinoma and elevated alpha fetoprotein: an exposure-response analysis  [Not invited]Llovet JM; Kudo M; Kang YK; Yen CJ; Finn RS; Gale PR; Assenat E; Motomura K; Okusaka T; Berg T; Hsu CH; Ikeda M; Hsu Y; Liang K; Widau R; Schelman W; O’Braian L; Gao L; Zhu AXEuropean Society for Medical Oncology (ESMO 2019)  2019/09  Barcelona, SpainHealth-related quality of life impact of pembrolizumab versus best supportive care in previously systemically treated patients with advanced hepatocellular carcinoma: KEYNOTE-240  [Not invited]Merle P; Kulkarni AS; Ryoo BY; Cheng AL; Kudo M; Bouattour M; Lim HY; Breder V; Edeline J; Chao Y; Ogasawara S; Yau T; Garrido M; Chan SL; Daniele B; Norquist J; Chen E; Siegel AB; Zhu AX; Finn RSEuropean Society for Medical Oncology (ESMO 2019)  2019/09  Barcelona, Spain難治性腹水に対して行われたデンバーシャント術の報告青木智子; 田北雅弘; 大塚康生; 南 知宏; 萩原 智; 南 康範; 依田 広; 上嶋一臣; 西田直生志; 鶴崎正勝; 工藤正俊第26回日本門脈圧亢進症学会総会  2019/09  海峡メッセ下関, 山口特別講演「肝細胞癌治療のパラダイムシフト Sys-Loco therapyの与えるインパクト」  [Invited]工藤正俊Sys-Loco therapyを考える  2019/09  ストリングスホテル東京インターコンチネンタル, 東京特別講演「肝細胞癌治療のパラダイムシフト Sys-Loco therapyの与えるインパクト」  [Invited]工藤正俊Sys-Loco therapyを考えるin 関西  2019/09  ホテルグランヴィア大阪, 大阪特別講演「肝細胞癌治療のパラダイムシフト Sys-Loco therapyの与えるインパクト」  [Invited]工藤正俊Sys-Loco therapy Meeting in中国  2019/09  ホテルグランヴィア広島, 広島Efficacy and safety of ramucirumab for advanced hepatocellular carcinoma with elevated alpha-fetoprotein following sorafenib across age subgroups in two global Phase 3 trials (REACH, REACH-2)Kudo M; Galle PF; Motomura K; Assenat E; Merle P; Brandi G; Daniele B; Okusaka T; Tomasek J; Borg C; Zagonel V; Morimoto M; Pracht M; Finn RS; Llovet J; Homma G; Jen MH; Shinozaki K; Yoshikawa R; Zhu AXEuropean Society for Medical Oncology (ESMO 2019)  2019/09  Barcelona, SpainRamucirumab (RAM) effect on albumin-bilirubin (ALBI) grade during treatment of Japanese patients with hepatocellular carcinoma (HCC) and elevated alpha-fetoprotein (AFP) following sorafenib from two randomized phase 3 studies (REACH, REACH-2)  [Not invited]Kudo M; Okusaka T; Motomura K; Ikeda M; Morimoto M; Seo S; Wada Y; Sato S; Yamashita T; Furukawa M; Aramaki T; Hirota S; Homma G; Chunxiao W; Shinozaki K; Yoshikawa R; Zhu AXEuropean Society for Medical Oncology (ESMO 2019)  2019/09  Barcelona, SpainLEAP-002: Phase 3 Study of First-Line Lenvatinib (len) Plus Pembrolizumab (pembro) for patients with advanced hepatocellular carcinoma (HCC)  [Not invited]Llovet JM; Kudo M; Cheng AL; Finn RS; Galle PR; Kaneko S; Meyer T; Qin S; Dutcus CE; Chen E; Dubrovsky L; Siegel AB; Zhu AXEuropean Society for Medical Oncology (ESMO 2019)  2019/09  Barcelona, SpainAlpha-fetoprotein (AFP) response in patients with unresectable hepatocellular carcinoma (HCC) in the phase 3 RESORCE trial  [Not invited]Bruix J; Reig M; Merle P; Kudo M; Meinhardt G; Zhang M; Ozgurdal KEuropean Society for Medical Oncology (ESMO 2019)  2019/09  Barcelona, SpainSafety profile of Nivolumab (NIVO) plus Ipilimumab (IPI) combination therapy in patients (pts) with advanced hepatocellular carcinoma (HCC) in the CheckMate 040 study  [Not invited]El-Khoueiry AB; Hsu C; Kang YK; Kim TY; Santoro A; Sangro B; Melero I; Kudo M; Hou MM; Matilla A; Tovoli F; Knox JJ; He AR; El-Rayes B; Acosta-Rivera M; Neely J; Shen Y; Baccan C; Yau T13th Annual Conference International Liver Cancer Association (ILCA)  2019/09  Chicago, USACheckMate 040: Health-related quality of life (HRQoL) in patients (Pts) with advanced hepatocellular carcinoma (aHCC) and Child-Pugh B status treated with nivolumab (NIVO)  [Not invited]Sangro B; Matilla A; Santoro A; Cubillo A; El-Khoueiry AB; El-Rayes B; Numata K; Itoh Y; Taylor F; Thompson G; Blum S; Wisniewski T; Baccan C; Kudo M13th Annual Conference International Liver Cancer Association (ILCA)  2019/09  Chicago, USAA Phase 3, randomized, double-blind, placebo-controlled study of transarterial chemoembolization combined with durvalumab or durvalumab plus bevacizumab therapy in patients with locoregional hepatocellular carcinoma (HCC): EMERALD-1  [Not invited]Sangro B; Kudo M; Qin S; Ren Z; Chan S; Erinjeri J; Arai Y; Mann H; Morgan S; Cohen G; Vlahovic G; Lencioni R13th Annual Conference International Liver Cancer Association (ILCA)  2019/09  Chicago, USAA post hoc analysis of neutrophil-lymphocyte ratios (NLR) in the REFLECT study: First-line lenvatinib (LEN) or sorafenib (SOR) in patients with unresectable hepatocellular carcinoma (uHCC)  [Not invited]Evans TRJ; Kudo M; Cheng AL; Gomez-Martin C; Daniele B; Izumi N; Yamashita T; Tateishi R; Lim HJ; Chan SL; Rau KM; Alsina A; Misir S; Dutcus C; Sung MW13th Annual Conference International Liver Cancer Association (ILCA)  2019/09  Chicago, USAPembrolizumab vs placebo as adjuvant therapy in patients with hepatocellular carcinoma (HCC) and complete radiological response following surgical resection or local ablation: Phase 3 KEYNOTE-937 trial  [Not invited]Zhu AX; Cheng AL; Vogel A; Yau T; Zhou J; Chen E; Malhotra U; Siegel AB; Kudo M13th Annual Conference International Liver Cancer Association (ILCA)  2019/09  Chicago, USAFirst-line combination therapy with lenvatinib plus pembrolizumab for patients with advanced hepatocellular carcinoma: Phase 3 Leap-002 study  [Not invited]Llovet JM; Kudo M; Cheng AL; Finn RS; Galle PR; Kaneko S; Meyer T; Qin S; Dutcus CE; Chen E; Dubrovsky L; Zhu AX13th Annual Conference International Liver Cancer Association (ILCA)  2019/09  Chicago, USAChair ; Cheng AL; minar 6 “A combined approach for advanced HCC checkpoint inhibitor plus VEGF blockade”  [Invited]Masatoshi KudoThe 10th Asia-Pacific Primary Liver Cancer Expert Meeting (APPLE 2019)  2019/08  Royton Sapporo, HokkaidoA phase 3 study of transarterial chemoembolization combined with durvalumab or durvalumab plus bevacizumab in patients with locoregional HCC: EMERALD-1  [Not invited]Kudo M; Sangro B; Qin S; Ren Z; Chan S; Erinjeri J; Arai Y; Mann H; Morgan S; Cohen G; Vlahovic G; Lencioni RThe 10th Asia-Pacific Primary Liver Cancer Expert Meeting (APPLE 2019)  2019/08  Royton Sapporo, HokkaidoEfficacy and safety of ramucirumab (RAM) in Asian and non-Asian patients with advanced hepatocellular carcinoma (HCC) and elevated alpha-fetoprotein (AFP): Subgroup analysis from two randomized studies  [Not invited]Okusaka T; Kang YK; Kudo M; Lim HY; Hsu CH; Vogel A; Brandi G; Cheng R; Carton I; Abada P; Hsu Y; Zhu A; Yen CJThe 10th Asia-Pacific Primary Liver Cancer Expert Meeting (APPLE 2019)  2019/08  Royton Sapporo, HokkaidoSubsequent anticancer medication following first-line lenvatinib: Post Hoc responder analysis from the Phase 3 REFLECT study in unresectable hepatocellular carcinoma  [Not invited]Alsina A; Kudo M; Vogel A; Cheng AL; Tak WY; Ryoo BY; Evans TRJ; Lopez C; Daniele B; Misir S; Ren M; Izumi N; Qin S; Finn RSThe 10th Asia-Pacific Primary Liver Cancer Expert Meeting (APPLE 2019)  2019/08  Royton Sapporo, HokkaidoAssociation between overall survival and adverse events with lenvatinib treatment in patients with hepatocellular carcinoma (REFLECT)  [Not invited]Sung M; Finn RS; Qin S; Han KH; Ikeda K; Cheng AL; Kudo M; Tateishi R; Ikeda M; Breder V; Rau KM; Ma YT; Alsina A; Ryoo BY; Ren Z; Mody K; Dutcus C; Tamai T; Saito K; Piscaglia FThe 10th Asia-Pacific Primary Liver Cancer Expert Meeting (APPLE 2019)  2019/08  Royton Sapporo, HokkaidoNivolumab in patients with advanced hepatocellular carcinoma (aHCC) and Child-Pugh (CP) B status: Japanese subanalysis from the CheckMate 040 study  [Not invited]Kudo M; Matilla A; Santoro A; Melero I; Gracian AC; Acosta-Rivera M; Choo SP; El-Khoueiry AB; Kuromatsu R; El-Rayes B; Numata K; Itoh Y; Di Costanzo F; Crysler O; Reig M; Takahashi H; Shen Y; Neely J; Anderson J; Sangro BThe 10th Asia-Pacific Primary Liver Cancer Expert Meeting (APPLE 2019)  2019/08  Royton Sapporo, HokkaidoSafety and efficacy of lenvatinib by starting dose based on bodyweight in patients with unresectable hepatocellular carcinoma (uHCC) in REFLECT  [Not invited]Okusaka T; Ikeda K; Kudo M; Finn RS; Qin S; Han KH; Cheng AL; Piscaglia F; Kobayashi M; Sung M; Chen M; Wyrwicz L; Yoon JH; Ren Z; Dutcus C; Tamai T; Ren M; Hayato S; Kumada HThe 10th Asia-Pacific Primary Liver Cancer Expert Meeting (APPLE 2019)  2019/08  Royton Sapporo, HokkaidoRole of the liver tumor board in early- and intermediate-stage HCC. Sponsored Symposium 4  [Invited]Kudo M; Han KH; Chan SL; Chow PThe 10th Asia-Pacific Primary Liver Cancer Expert Meeting (APPLE 2019)  2019/08  Royton Sapporo, HokkaidoChallenging Precise Ablation: CEUS Guidance & Fusion Imaging Guidance. Symposium 7 “Ablation therapy for hepatocellular carcinoma in Asia”  [Not invited]Minami Y; Kudo MThe 10th Asia-Pacific Primary Liver Cancer Expert Meeting (APPLE 2019)  2019/08  Royton Sapporo, HokkaidoChanging paradigm of treatment strategy for intermediate stage HCC: APPLE expert consensus  [Not invited]Ikeda M; Han KH; Miyayama S; Lin HM; Choo SP; Huang YH; Chan S; Kudo M; Wang CKThe 10th Asia-Pacific Primary Liver Cancer Expert Meeting (APPLE 2019)  2019/08  Royton Sapporo, HokkaidoAnalysis of survival and objective response (OR) in patients with hepatocellular carcinoma in a Phase 3 study of lenvatinib (REFLECT)  [Not invited]Kudo M; Finn RS; Qin S; Han KH; Ikeda K; Cheng AL; Piscaglia F; Ueshima K; Aikata H; Vogel A; Lopez C; Pracht M; Meng Z; Daniele B; Park JW; Palmer D; Dutcus C; Tamai T; Saito K; Lencioni RThe 10th Asia-Pacific Primary Liver Cancer Expert Meeting (APPLE 2019)  2019/08  Royton Sapporo, HokkaidoLuncheon Seminar “Real-world experience with lenvatinib in patients with uHCC from Japan”  [Invited]Masatoshi KudoThe 10th Asia-Pacific Primary Liver Cancer Expert Meeting (APPLE 2019)  2019/08  Royton Sapporo, HokkaidoCurrent and future treatment strategy for TACE failure or refractoriness. Morning Workshop 3  [Invited]Masatoshi KudoThe 10th Asia-Pacific Primary Liver Cancer Expert Meeting (APPLE 2019)  2019/08  Royton Sapporo, HokkaidoAssociation between tumor response by mRECIST and overall survival in patients with poorly differentiated hepatocellular carcinoma (HCC) in REFLECT study  [Not invited]Kudo M; Ueshima K; Aikata H; Tamai T; Saito K; Ikeda KThe 10th Asia-Pacific Primary Liver Cancer Expert Meeting (APPLE 2019)  2019/08  Royton Sapporo, HokkaidoUsing workstation for diagnosis and treatment of hepatocellular carcinoma  [Not invited]Ogawa C; Kudo MThe 10th Asia-Pacific Primary Liver Cancer Expert Meeting (APPLE 2019)  2019/08  Royton Sapporo, Hokkaido特別講演「肝細胞癌二次治療の新時代~REACH試験/REACH-2試験を紐解く~」  [Invited]工藤正俊中四国肝細胞癌薬物療法セミナー  2019/08  JRホテルクレメント高松, 香川特別講演「肝細胞癌二次治療の新時代~REACH試験/REACH-2試験を紐解く~」  [Invited]工藤正俊北海道肝細胞癌薬物療法セミナー  2019/07  札幌グランドホテル, 北海道ランチョンセミナー「肝癌診療ガイドライン 改訂のポイント」  [Invited]工藤正俊第19回臨床消化器病研究会  2019/07  ベルサール高田馬場, 東京教育講演「肝癌薬物治療のup-to-date」  [Invited]工藤正俊日本内科学会北海道支部主催第61回生涯教育講演会  2019/07  北海道大学医学部, 北海道腫瘤性膵炎の再発に対してステロイド投与が著効した一例  [Not invited]鎌田 研; 田中秀和; 橋本有人; 石川 嶺; 吉川智恵; 岡本彩那; 山崎友裕; 中井敦史; 大本俊介; 三長孝輔; 山雄健太郎; 竹中 完; 工藤正俊第102回日本消化器内視鏡学会近畿支部例会  2019/07  大阪国際交流センター, 大阪胆道閉塞に対するantegrade long plastic stent留置術の有用性. ワークショップ「胆膵疾患の内視鏡診断・治療up date」  [Not invited]中井敦史; 竹中 完; 工藤正俊第102回日本消化器内視鏡学会近畿支部例会  2019/07  大阪国際交流センター, 大阪T1直腸癌の内視鏡治療後の経過観察例の検討. シンポジウム2「下部消化管腫瘍の内視鏡診断・治療up date」  [Not invited]高島耕太; 米田頼晃; 櫻井俊治; 樫田博史; 工藤正俊第102回日本消化器内視鏡学会近畿支部例会  2019/07  大阪国際交流センター, 大阪CMV腸炎を合併した紫斑のない成人IgA血管炎の一例  [Not invited]松村まり子; 米田頼晃; 大塚康生; 河野辰哉; 高島耕太; 正木 翔; 岡元寿樹; 山田光成; 永井知行; 櫻井俊治; 松井繁長; 渡邉智裕; 辻 直子; 樫田博史; 工藤正俊; 榎木英介第102回日本消化器内視鏡学会近畿支部例会  2019/07  大阪国際交流センター, 大阪超音波内視鏡ガイド下ラジオ波焼灼術の開発  [Not invited]前島秀哉; 井田良幸; 清水 遼; 川路祐輝; 田村 崇; 幡丸景一; 奴田絢也; 糸永昌弘; 工藤正俊; 北野雅之第55回日本肝癌研究会  2019/07  ホテル椿山荘, 東京OPTIMIS国際共同前向き観察研究: 初回TACE施行後の肝予備能の検討―日本人サブ解析―. パネルディスカッション「再発肝癌の治療選択」  [Not invited]工藤正俊; 泉 並木; 小笠原定久; 中尾一彦; 沼田和司; 平岡 淳; 武冨紹信; 大崎往夫; 池田公史; 和田幸之第55回日本肝癌研究会  2019/07  ホテル椿山荘, 東京ランチョンセミナー「レンバチニブのすべて」  [Invited]工藤正俊第55回日本肝癌研究会  2019/07  ホテル椿山荘, 東京Internation Symposium “Lenvatinib as an initial treatment in patiens with intermediate-stage hepatocellular carcinoma beyond up-to-seven criteria and Child-Pugh A liver function: A Multicentre propensity-score matched study.  [Invited]Masatoshi KudoThe 55th Annual Meeting of Liver Cancer Study Group of Japan  2019/07  Hotel Chinzanso Tokyoレンバチニブの第III相試験 (REFLECT試験)における肝細胞癌患者の生存期間と奏効の解析  [Not invited]上嶋一臣; 工藤正俊; Finn RS; Qin S; Han KH; 池田健次; Cheng AL; Piscaglia F; 相方 浩; Vogel A; Lopez C; Pracht M; Meng Z; Daniele B; Park JW; Palmer D; Dutcus C; 玉井俊行; 齋藤健一; Lencioni R第55回日本肝癌研究会  2019/07  ホテル椿山荘, 東京肝細胞癌切除における幕内基準の検証: 日本肝癌研究会全国集計データ解析結果より  [Not invited]荒牧 修; 高山忠利; 松山 裕; 久保正二; 國土典宏; 泉 並木; 村上卓道; 椎名秀一朗; 工藤正俊; 坂元亨宇; 中島 収第55回日本肝癌研究会  2019/07  ホテル椿山荘, 東京ソラフェニブ不耐のAFP高値肝細胞癌患者に対するラムシルマブ治療: 無作為化第III相試験におけるサブ解析  [Not invited]森本 学; Josep Llovet; Yen CJ; Finn R; Kang YK; Galle P; Assenat E; Godinot N; Wang C; Hsu Y; Schelman W; Zhu A; 工藤正俊第55回日本肝癌研究会  2019/07  ホテル椿山荘, 東京Ramucirumab in advanced hepatocellular carcinoma and elevated alpha-fetoprotein following sorafenib: outcomes by prior transarterial chemoembolisation from two randomised, double-blind, placebo-controlled phase 3 studies (REACH-2 and REACH)  [Not invited]Meyer T; Finn R; Kudo M; Kang YK; Yen CJ; Galle P; Llovet J; Assenat E; Brandi G; Motomura K; Okusaka T; Hubner R; Karwal M; Baron A; Ikeda M; Liang K; Wang C; Widau R; Schelman W; Zhu AESMO 21th World Congress on Gastrointestinal Cancer 2019 (ESMO-WCGC 2019)  2019/07  Barcelona, Spainレンバチニブに対しPD判定となった後も継続投与によってPRが得られた一例  [Not invited]盛田真弘; 小川 力; 工藤正俊第20回日本肝がん分子標的治療研究会  2019/06  ANAクラウンプラザホテル長崎グラバーヒル, 長崎司会; プレナリーセッション2  [Invited]工藤正俊第20回日本肝がん分子標的治療研究会  2019/06  ANAクラウンプラザホテル長崎グラバーヒル, 長崎プレナリーセッション「ソラフェニブ後のAFP高値進行肝細胞癌に対するラムシルマブ: 2つの国際共同無作為化第3相試験の併合解析における日本人患者の有効性と安全性」  [Invited]池田公史; 工藤正俊; 奥坂拓志; 本村健太; 大野 泉; 森本 学; 瀬尾 智; 和田幸之; 佐藤新平; 山下竜也; 古川正幸; 新槇 剛; 瀬野成人; 大川和良; 藤井博文; 工藤敏啓; 古瀬純司; 高井弘基; 本間剛介; 吉川麗月; Zhu AX第20回日本肝がん分子標的治療研究会  2019/06  ANAクラウンプラザホテル長崎グラバーヒル, 長崎開会/閉会の辞  [Invited]工藤正俊第20回日本肝がん分子標的治療研究会  2019/06  ANAクラウンプラザホテル長崎グラバーヒル, 長崎特別講演「肝細胞治療のパラダイムシフト」  [Invited]工藤正俊第10回中国ウイルス肝炎研究会  2019/06  リーガロイヤルホテル広島, 広島Invited Lecture “Recent trends of treatment for intermediate stage HCC: Japanese experience”  [Invited]Masatoshi KudoThe Liver Week 2019  2019/06  BEXCO, Busan, South Korea特別講演「肝細胞治療における最新の知見」  [Invited]工藤正俊第15回倉敷肝疾患研究会  2019/06  倉敷アイビースクエア, 岡山特別講演「最新データから読み解くレンバチニブの導入タイミング」  [Invited]工藤正俊Lenvima-HCC Web Seminar  2019/06  木村情報技術東京第一スタジオ, 東京特別講演「肝細胞癌診療の最近の進歩」  [Invited]工藤正俊北海道消化器癌懇話会  2019/06  札幌プリンスホテル, 北海道Results of KEYNOTE-240: phase 3 study of pembrolizumab (Pembro) vs best supportive care (BSC) for second line therapy in advanced hepatocellular carcinoma (HCC).  [Not invited]Finn RS; Ryoo BY; Merle P; Kudo M; Bouattour M; Lim HY; Breder VV; Edeline J; Chao Y; Ogasawara S; Yau T; Garrido M; Chan SL; Knox JJ; Daniele B; Ebbinghaus S; Chen E; Siegel AB; Zhu AX; Cheng AL; for the KEYNOT; InvestigatorsAmerican Society of Clinical Oncology Annual Meeting (ASCO 2019)  2019/06  Chicago, USAA multicenter randomized controlled trial to evaluate the efficacy of surgery vs. radiofrequency ablation on primary hepatocellular carcinoma (SURF trial)  [Not invited]Izumi N; Hasegawa K; Nishioka Y; Takayama T; Yamanaka N; Kudo M; Shimada M; Inomata M; Kaneko S; Baba H; Koike K; Omata M; Makuuchi M; Matsuyama Y; Kokudo NAmerican Society of Clinical Oncology Annual Meeting (ASCO 2019)  2019/06  Chicago, USARamucirumab (RAM) for sorafenib intolerant patients with hepatocellular carcinoma (HCC) and elevated baseline alpha fetoprotein (AFP): outcomes from two randomized phase 3 studies (REACH, REACH2)  [Not invited]Llovet JM; Yen CJ; Finn RS; Kang YK; Kudo M; Galle PR; Assenat E; Pracht M; Lim Y; Rau KM; Borg C; Hiriart JB; Daniele B; Berg T; Chung HC; Godinot N; Wang C; Hsu Y; Schelman WR; Zhu AXAmerican Society of Clinical Oncology Annual Meeting (ASCO 2019)  2019/06  Chicago, USANivolumab (NIVO) plus ipilimumab (IPI) combination therapy in patients (pts) with advanced hepatocellular carcinoma (aHCC): Results from CheckMate 040  [Not invited]Yau T; Kang YK; Kim TY; El-Khoueiry AB; Santoro A; Sangro B; Melero I; Kudo M; Hou MM; Matilla A; Tovoli F; Knox J; He AR; El-Rayes B; Acosta-Rivera M; Neely J; Shen Y; Baccan C; Dela Cruz C; Hsu CAmerican Society of Clinical Oncology Annual Meeting (ASCO 2019)  2019/06  Chicago, USAFirst-line avelumab + axitinib in patients with advanced hepatocellular carcinoma: results from a phase 1b trial (VEGF Liver 100)  [Not invited]Kudo M; Motomura K; Wada Y; Inaba Y; Sakamoto Y; Kurosaki M; Umeyama Y; Kamei Y; Yoshimitsu J; Fujii Y; Aizawa M; Robbins PB; Furuse JAmerican Society of Clinical Oncology Annual Meeting (ASCO 2019)  2019/06  Chicago, USAEfficacy, safety, and cancer-related symptoms in patients with hepatocellular carcinoma with alpha-fetoprotein ≥400 ng/ml: A pooled analysis from REACH and REACH-2 studies  [Not invited]Borbath I; Kudo M; Finn RS; Galle PR; Llovet JM; Blanc JF; Okusaka T; Chau I; Cella D; Peck-Radosavljevic M; Girvan A; Gable J; Bowman L; Abada P; Hsu Y; Zhu AX; Lee SYOsterreichische Gesellschaft fur Gastroenterologie und Hepatologie (OGGH 2019)  2019/06  Austria汎用ワークステーションを用いた大腰筋の体積の測定とサルコペニアの診断への応用  [Not invited]小川 力; 柴峠光成; 工藤正俊第55回日本肝臓学会総会  2019/05  京王プラザホテル, 東京高AFP肝細胞癌(HCC)患者に対する二次治療ラムシルマブ(RAM)の第3相REACH-2試験におけるAFP動態分析  [Not invited]本村健太; Finn RS; 工藤正俊; Kang YK; Yen CJ; Galle PR; Llovet JM; Assenat E; Brandi G; Lim HY; Pracht M; Rau KM; Merle P; 大野 泉; Daniele B; Shin D; Gerken G; Abada P; Hsu Y; Zhu AX第55回日本肝臓学会総会  2019/05  京王プラザホテル, 東京超音波内視鏡ガイド下ラジオ波焼灼術の開発  [Not invited]前島秀哉; 井田良幸; 清水 遼; 川路佑輝; 田村 崇; 奴田絢也; 幡丸景一; 糸永昌弘; 工藤正俊; 北野雅之第55回日本肝臓学会総会  2019/05  京王プラザホテル, 東京司会; ランチョンセミナー10「知らないと損をする肝硬変診療up-to-date」  [Invited]工藤正俊第55回日本肝臓学会総会  2019/05  京王プラザホテル, 東京司会; シンポジウム3「進行肝癌の治療: 分子標的薬の位置づけ」  [Invited]工藤正俊第55回日本肝臓学会総会  2019/05  京王プラザホテル, 東京特別企画「肝細胞癌治療における免疫チェックポイント阻害薬の開発状況」  [Invited]工藤正俊第55回日本肝臓学会総会  2019/05  京王プラザホテル, 東京司会: 招待講演4「Management of sarcopenia in liver cirrhosis」  [Invited]工藤正俊第55回日本肝臓学会総会  2019/05  京王プラザホテル, 東京超音波検査が診断に有用であった消化管疾患の検討. ワークショップ 消化器2「超音波検査が診断に有用であった消化管疾患の検討」  [Not invited]南 雅人; 横川美加; 桑口 愛; 市島真由美; 塩見香織; 前川 清; 南 康範; 樫田博史; 工藤日本超音波医学会第92回学術集会  2019/05  グランドプリンスホテル新高輪, 東京State-of-the-Art Lecture “IO in liver cancer therapy now and future.”  [Invited]Masatoshi Kudo2019 Joint International Conference of Taiwan Liver Cancer Association and Taiwan Academy of Tumor Ablation: Precision medicine in HCC: research and treatment  2019/05  TaiwanKeynote Lecture “When is the best time for TKI (LEN) be used in BCLC B & C HCC patients."  [Invited]Masatoshi KudoExpert Round Table Meeting for Unresectable Hepatocellular Carcinoma  2019/05  Fullon Hotel, Taiwanレンバチニブ著効症例の残存病変評価に造影エコーが有用であった一例  [Not invited]盛田真弘; 小川 力; 重福亜紀奈; 野田晃世; 久保敦司; 松中寿浩; 玉置敬之; 芝峠光成; 工藤正俊日本超音波医学会第92回学術集会  2019/05  グランドプリンスホテル新高輪, 東京Attenuation coefficient(ATT)による肝脂肪化定量化の検討. パネルディスカッション 消化器5「肝脂肪と超音波:基礎から臨床、そして未来へ」  [Not invited]玉城信治; 小泉洋平; 廣岡昌史; 矢田典久; 中島 収; 工藤正俊; 日浅陽一; 泉 並木日本超音波医学会第92回学術集会  2019/05  グランドプリンスホテル新高輪, 東京南 康範, 依田 広, 工藤正俊: Monopolarラジオ波熱凝固療法の実際とその治療効果判定. パネルディスカッション 消化器3「肝癌診療と超音波: 最新の治療支援と効果判定テクニック」  [Not invited]南 康範; 依田 広; 工藤正俊日本超音波医学会第92回学術集会  2019/05  グランドプリンスホテル新高輪, 東京座長; シンポジウム 消化器1「臨床に活かす超音波検査」  [Invited]工藤正俊日本超音波医学会第92回学術集会  2019/05  グランドプリンスホテル新高輪, 東京超音波画像データベース構築の推進と展望. シンポジウム 領域横断3「AI: 超音波診断の近未来」  [Not invited]西田直生志; 工藤正俊日本超音波医学会第92回学術集会  2019/05  グランドプリンスホテル新高輪, 東京座長; シンポジウム 領域横断3「AI: 超音波診断の近未来」  [Invited]工藤正俊日本超音波医学会第92回学術集会  2019/05  グランドプリンスホテル新高輪, 東京.AMED事業: AI利活用を見据えた超音波画像データベース構築. シンポジウム 領域横断3「AI: 超音波診断の近未来」  [Invited]工藤正俊日本超音波医学会第92回学術集会  2019/05  グランドプリンスホテル新高輪, 東京Histological Diagnosis of pancreatic neuroendocrine tumor using 25G FNA needle with core trap: Multicenter prospective study  [Not invited]Ashida R; Kamata K; Yasukawa S; Chiba Y; Fukutake N; Nebiki H; Kurita A; Takaoka M; Ogura T; Shiomi H; Asada M; Yasuda H; Shigekawa M; Yanagisawa A; Kudo M; Kitano MDigestive Disease Week 2019 (DDW 2019)  2019/05  San Diego, USAValue of the bispectral index monitor during endoscopic ultraosonography under sedation with propofol and midazolam  [Not invited]Okamoto A; Kamata K; Takenaka M; Yoshikawa T; Ishikawa R; Yamazaki T; Nakai A; Omoto S; Minaga K; Yamao K; Kudo MDigestive Disease Week 2019 (DDW 2019)  2019/05  San Diego, USAComputer-aided diagnosis based on convolutional neural network system using artificial intelligence for colorectal polyp classification  [Not invited]Komeda K; Handa H; Matsui R; Sakurai T; Watanabe T; Kashida S; Kudo MDigestive Disease Week 2019 (DDW 2019)  2019/05  San Diego, USAEndoscopic ultrasound-guided choledochoduodenostomy using a thin stent delivery system in patients with unresectable malignant distal biliary obstruction: a prospective mylticenter study  [Not invited]Itonaga M; Kitano M; Hatamaru K; Tamura T; Nuta1 J; Kawaji Y; Takenaka M; Minaga K; Kudo M; Ogura T; Higuchi K; Chiba YDigestive Disease Week 2019 (DDW 2019)  2019/05  San Diego, USA座長: 特別講演「C型肝炎DAAの選択と不成功例・非代謝肝硬変の治療」  [Invited]工藤正俊第4回関西肝疾患フォーラム  2019/05  帝国ホテル大阪, 大阪Invited Lecture “Value of Primovist in HCC screening  [Invited]Masatoshi KudoRole of EOB-MRI in HCC management  2019/05  National University Hospital, SingaporeInvited Lecture “Primovist benefit for HCC treatment particulary in RFA”  [Invited]Masatoshi KudoRole of EOB-MRI in HCC management  2019/05  National University Hospital, SingaporeInvited Lecture “Value of Primovist in HCC screening”  [Invited]Masatoshi KudoRole of EOB-MRI in HCC management  2019/05  Inperial Treasure Super Pekin Duck, SingaporeInvited Lecture “Primovist benefit for HCC treatment particulary in RFA”  [Invited]Masatoshi KudoRole of EOB-MRI in HCC management  2019/05  Inperial Treasure Super Pekin Duck, SingaporeInvited Lecture “Value of Primovist in HCC screening”  [Invited]Masatoshi KudoRole of EOB-MRI in HCC management  2019/05  Changi General Hospital, SingaporeInvited Lecture “Primovist benefit for HCC treatment particulary in RFA”  [Invited]Masatoshi KudoRole of EOB-MRI in HCC management  2019/05  Changi General Hospital, SingaporeInvited Lecture “Value of Primovist in HCC screening”  [Invited]Masatoshi KudoRole of EOB-MRI in HCC management  2019/05  Tan Tock Seng Hospital, SingaporeInvited Lecture “Primovist benefit for HCC treatment particulary in RFA”  [Invited]Masatoshi KudoRole of EOB-MRI in HCC management  2019/05  Tan Tock Seng Hospital, SingaporeInvited Lecture “Value of Primovist in HCC screening”  [Invited]Masatoshi KudoRole of EOB-MRI in HCC management  2019/05  Seng Kang General Hospital, SingaporeInvited Lecture “Primovist benefit for HCC treatment particulary in RFA”  [Invited]Masatoshi KudoRole of EOB-MRI in HCC management  2019/05  Seng Kang General Hospital, SingaporeInvited Lecture “Value of Primovist in HCC screening”  [Invited]Masatoshi KudoRole of EOB-MRI in HCC management  2019/05  Singapore General Hospital, SingaporeInvited Lecture “Primovist benefit for HCC treatment particulary in RFA”  [Invited]Masatoshi KudoRole of EOB-MRI in HCC management  2019/05  Singapore General Hospital, SingaporeInvited Lecture “Value of Primovist in HCC screening”  [Invited]Masatoshi KudoRole of EOB-MRI in HCC management  2019/05  Taipei Veteran General Hospital, TaiwanInvited Lecture “Primovist benefit for HCC treatment particulary in RFA”  [Invited]Masatoshi KudoRole of EOB-MRI in HCC management  2019/05  Taipei Veteran General Hospital, TaiwanInvited Lecture “Value of Primovist in HCC screening”  [Invited]Masatoshi KudoRole of EOB-MRI in HCC management  2019/05  Sheraton Hotel Taipei, TaiwanInvited Lecture “Primovist benefit for HCC treatment particulary in RFA”.  [Invited]Masatoshi KudoRole of EOB-MRI in HCC management  2019/05  Sheraton Hotel Taipei, TaiwanInvited Lecture “Value of Primovist in HCC screening”  [Invited]Masatoshi KudoRole of EOB-MRI in HCC management  2019/05  Chang-Gung Memorial Hospital, TaiwanInvited Lecture “Primovist benefit for HCC treatment particulary in RFA”  [Invited]Masatoshi KudoRole of EOB-MRI in HCC management  2019/05  Chang-Gung Memorial Hospital, TaiwanInvited Lecture “Value of Primovist in HCC screening”.  [Invited]Masatoshi KudoRole of EOB-MRI in HCC management  2019/05  China Medical University, TaiwanInvited Lecture “Primovist benefit for HCC treatment particulary in RFA”  [Invited]Masatoshi KudoRole of EOB-MRI in HCC management  2019/05  China Medical University, TaiwanInvited Lecture “Value of Primovist in HCC screening”.  [Invited]Masatoshi KudoRole of EOB-MRI in HCC management  2019/05  TaiwanInvited Lecture “Primovist benefit for HCC treatment particulary in RFA”.  [Invited]Masatoshi KudoRole of EOB-MRI in HCC management  2019/05  Taiwan術前診断に難渋した膵頭部・尾部同時性多発癌の一例  [Not invited]岡本彩那; 三長孝輔; 竹中 完; 吉川智恵; 石川 嶺; 山﨑友裕; 中井敦史; 大本俊介; 鎌田 研; 山雄健太郎; 松本逸平; 大谷知之; 工藤正俊第105回日本消化器病学会総会  2019/05  ホテル日航金沢, 石川Interventional EUSのトラブルシューティング: 超音波造影剤の併用. ワークショップ14「ERCP・EUS関連手技のトラブルシューティング」  [Not invited]三長孝輔; 竹中 完; 工藤正俊第105回日本消化器病学会総会  2019/05  ホテル日航金沢, 石川司会; シンポジウム9「進行肝癌に対する新たな治療戦略」  [Invited]工藤正俊第105回日本消化器病学会総会  2019/05  石川県立音楽堂, 石川腸内細菌叢からみた膵酵素補充療法の慢性膵炎に対する炎症抑制機序の解明. ワークショップ2「消化器領域における腸内細菌研究と臨床応用」  [Not invited]三長孝輔; 渡邉智裕; 工藤正俊第105回日本消化器病学会総会  2019/05  ANAクラウンプラザホテル金沢, 石川Invited Lecture “Evolving roles of targeted therapy in HCC”  [Invited]Masatoshi Kudothe 3rd Symposium of the Singapore Liver Cancer Consortium (SLCC)  2019/05  SingaporeLenvatinib (lenva) plus pembrolizumab (pembro) for the first-line treatment of patients (pts) with advanced hepatocellular carcinoma (HCC): Phase 3 LEAP-002 study  [Not invited]Llovet J; Kudo M; Cheng AL; Finn R; Galle P; Kaneko S; Meyer T; Qin S; Dutcus C; Chen E; Dubrovsky L; Zhu AAmerican Society of Clinical Oncology Annual Meeting (ASCO 2019)  2019/05  Chicago, USA座長; 男女共同参画委員会企画「医療者のためのアンガーマネジメント入門」  [Invited]工藤正俊日本超音波医学会第92回学術集会  2019/05  グランドプリンスホテル新高輪, 東京Practice patterns and outcomes of transarterial chemoembolization in patients with hepatocellular carcinoma who were ineligible and eligible for transarterial chemoembolization at inclusion: Global OPTIMIS exploratory analysis  [Not invited]Peck-Radosavljevic M; Lee HC; Kudo M; Nakajima K; Bayh I; Cheng AL; Raoul JLThe International Iiver Congress (EASL 2019)  2019/04  Vienna, AustriaA phase 1b trial of Lenvatinib (LEN) plus Pembrolizumab (PEMBRO) in unresectable hepatocellular carcinoma (uHCC): updated results.  [Not invited]Ikeda M; Sung MW; Kudo M; Kobayashi M; Baron AD; Finn RS; Kaneko S; Zhu AX; Kubota T; Kraljevic S; Ikezawa H; Dubrovsky L; Siegel AB; Kumada H; Okusaka TAmerican Association for Cancer Research Annual Meeting (AACR 2019)  2019/04  Atlanta, Georgia, USACan lenvatinib meet clinical needs of patients with unresectable hepatocellular carcinoma? Multicenter analysis.  [Not invited]Hiraoka A; Kumada T; Takaguchi K; Kariyama K; Tsuji K; Itobayashi E; Ochi H; Tajiri K; Hirooka M; Shimada N; Ishikawa T; Tsutsui A; Shibata H; Tada T; Toyoda H; Nouso K; Itokawa N; Joko K; Atsukawa M; Imai M; Michitaka K; Hiasa Y; Kudo MThe International Iiver Congress (EASL 2019)  2019/04  Vienna, AustriaEfficacy and hepatic safety of Nivolumab treatment in patients with Child-Pugh B disease and advanced hepatocellular carcinoma in CheckMate 040  [Not invited]Sangro B; Matilla A; Santoro A; Melero I; Gracian AC; Acosta MR; Choo SP; El-Khoueiry AB; Kuromatsu R; El-Rayes B; Numata K; Itoh Y; Di Costanzo F; Crysler O; Reig M; Shen Y; Neely J; dela Cruz C; Baccan C; Kudo MThe International Iiver Congress (EASL 2019)  2019/04  Vienna, Austria司会; 特別講演「C型肝炎の治療薬選択と経過観察留意点」  [Invited]工藤正俊第15回Kinki Liver Club  2019/03  ホテルモントレグラスミア大阪, 大阪開会の辞: 工藤正俊  [Invited]工藤正俊第15回Kinki Liver Club  2019/03  ホテルモントレグラスミア大阪, 大阪特別講演「肝細胞癌に対する薬物療法の最新の進歩~支持療法の重要性を含めて~」  [Invited]工藤正俊Otsuka Web Seminar  2019/03特別講演「急速に変貌する肝細胞癌の薬物療法」  [Invited]工藤正俊Liver Cancer Forum in Fukuoka  2019/03  ホテルオークラ福岡, 九州特別講演「新たなステージに入った肝細胞癌治療」  [Invited]工藤正俊肝細胞がん治療の新時代を考える会 in 八王子」  2019/02  京王プラザホテル八王子, 東京肝予備能からみたレンバチニブの有効性と安全性の検討. シンポジウム2「進行肝細胞癌治療の現状と課題」  [Not invited]萩原 智; 上嶋一臣; 工藤正俊日本消化器病学会近畿支部第110回例会  2019/02  京都テルサ, 京都膵神経内分泌腫瘍の悪性度評価における造影ハーモニックEUSの有用性. ワークショップ2「胆膵腫瘍診断・治療の進歩と課題」  [Not invited]石川 嶺; 鎌田 研; 竹中 完; 工藤正俊日本消化器病学会近畿支部第110回例会  2019/02  京都テルサ, 京都胃底腺型胃癌の臨床的特徴の検討. シンポジウム1「ピロリ陰性時代の上部消化管診療」  [Not invited]河野辰哉; 松井繁長; 櫻井俊治; 工藤正俊日本消化器病学会近畿支部第110回例会  2019/02  京都テルサ, 京都PPI長期投与例の胃底腺ポリープの特徴. シンポジウム1「ピロリ陰性時代の上部消化管診療」  [Not invited]松村まり子; 辻 直子; 梅原康湖; 工藤正俊日本消化器病学会近畿支部第110回例会  2019/02  京都テルサ, 京都ステロイド抵抗性潰瘍性大腸炎に対するシクロスポリンの使用経験. パネルディスカッション「炎症性腸疾患治療の最前線」  [Not invited]河野匡志; 櫻井俊治; 工藤正俊日本消化器病学会近畿支部第110回例会  2019/02  京都テルサ, 京都Efficacy, safety, and patient-reported outcomes in patients with hepatocellular carcinoma with alpha-fetoprotein ≥400 ng/ml: A pooled analysis from REACH and REACH-2 studies  [Not invited]Borbath I; Kudo M; Finn RS; Galle PR; Llovet JM; Blanc JF; Okusaka T; Chau I; Cella D; Peck-Radosavljevic M; Girvan A; Gable J; Bowman L; Abada P; Hsu Y; Zhu AXBelgian Week of Gastroenterology  2019/02  Antwerp, Belgium座長: シンポジウム2「肝癌治療の画像的効果判定—分子標的治療薬を中心に—」  [Invited]工藤正俊第25回肝血流動態・機能イメージ研究会  2019/02  笹川記念会館, 東京conventional TACEのヨード密度画像による治療効果判定. シンポジウム2「肝癌治療の画像的効果判定—分子標的治療薬を中心に—」  [Not invited]兵頭朋子; 柳生行伸; 河野雄輝; 沼本 勲; 鶴﨑正勝; 上嶋一臣; 工藤正俊; 石井一成第25回肝血流動態・機能イメージ研究会  2019/02  笹川記念会館, 東京US-US overlay fusionを用いたPrecision RFAと早期治療効果判定. シンポジウム1「肝癌治療の画像シミュレーションとナビゲーション」  [Not invited]南 康範; 工藤正俊第25回肝血流動態・機能イメージ研究会  2019/02  笹川記念会館, 東京ラジオ波焼灼術における画像解析ソフトを用いた治療シミュレーションと治療効果判定. シンポジウム1「肝癌治療の画像シミュレーションとナビゲーション」  [Not invited]小川 力; 盛田真弘; 工藤正俊第25回肝血流動態・機能イメージ研究会  2019/02  笹川記念会館, 東京Practice patterns, response rates, and deterioration of liver function after transarterial chemoembolization (TACE) in unresectable hepatocellular carcinoma (uHCC): Final analysis of OPTIMIS in China  [Not invited]Shan H; Lee HC; Raoul JL; Peck-Radosavljevic M; Kudo M; Nakajima K; Bayh I; Yang Y; Wang W; Cheng ALThe 28th Annual Conference of Asian Pacific Association for the Study of the Liver (APASL 2019)  2019/02  Manila, PhilippinesInvited Lecture “Ongoing trials in systemic therapies for HCC”  [Invited]Masatoshi KudoAsian Pacific Association for the Study of the Liver (APASL 2019)  2019/02  Manila, PhilippinesInvited Lecture “Role of the hepatologist”  [Invited]Masatoshi KudoAsian Pacific Association for the Study of the Liver (APASL 2019)  2019/02  Manila, PhilippinesRamucirumab for patients with hepatocellular carcinoma and elevated alpha-fetoprotein following sorafenib treatment: exploratory analysis of REACH-2 trial results by albumin-bilirubin grade and Child-Pugh score  [Not invited]Brandi G; Kudo M; Kang Y; Yen C; Finn R; Galle P; Llovet J; Assenat E; Merle P; Jean-Baptiste H; Chan SL; Palmer D; Wang C; Widau R; Hsu Y; Abada PB; Zhu AEASL HCC Summit 2019  2019/02  Lisbon, Portugal教育講演「肝癌治療のこれから~来たるべきパラダイムシフトへの期待~」  [Invited]工藤正俊第19回日本肝がん分子標的治療研究会  2019/01  ベルサール九段, 東京開会/閉会の挨拶  [Invited]工藤正俊第19回日本肝がん分子標的治療研究会  2019/01  ベルサール九段, 東京特別講演「肝細胞癌治療のパラダイム-最新データを紐解く-」  [Invited]工藤正俊LENVIMA-HCC Web Seminar  2019/01Ramucirumab (RAM) as second-line treatment in patients with advanced hepatocellular carcinoma (HCC) and elevated baseline α-fetoprotein (AFP): an analysis of AFP kinetics in the phase 3 REACH-2 study.  [Not invited]Finn RS; Kudo M; Kang YK; Yen CJ; Galle PR; Llovet JM; Assenat E; Brandi G; Lim HY; Pracht M; Rau KM; Merle P; Motomura K; Ohno I; Daniele B; Shin D; Gerken G; Abada P; Hsu Y; Zhu AXAmerican Society of Clinical Oncology, Gastrointestinal Cancers Symposium (ASCO-GI 2019)  2019/01  San Francisco, USASorafenib versus hepatic arterial infusion chemotherapy in patients with advanced hepatocellular carcinoma: A Japanese multi-center large cohort study  [Not invited]Ogasawara S; Ueshima K; Ikeda M; Yasui Y; Terashima T; Yamashita T; Obi S; Sato S; Aikata H; Ohmura T; Kuroda H; Ohki T; Nagashima K; Kurosaki M; Chayama K; Kaneko S; Izumi N; Kato N; Kudo M; Omata MAmerican Society of Clinical Oncology, 2017 Gastrointestinal Cancers Symposium (ASCO-GI 2019)  2019/01  San Francisco, USACheckMate-040: Nivolumab (NIVO) in patients (Pts) with advanced hepatocellular carcinoma (aHCC) and Child-Pugh B (CPB) status  [Not invited]Kudo M; Matilla A; Santoro A; Melero I; Gracian A; Acosta MR; Choo SP; El-Khoueiry AB; Kuromatsu R; El-Rayes B; Numata K; Itoh Y; Di Costanzo F; Crysler O; Reig M; Shen Y; Neely J; dela Cruz C; Baccan C; Sangro BAmerican Society of Clinical Oncology, 2017 Gastrointestinal Cancers Symposium (ASCO-GI 2019)  2019/01  San Francisco, USAAnalysis of survival and objective response (OR) in patients with hepatocellular carcinoma in a phase 3 study of lenvatinib (REFLECT)  [Not invited]Kudo M; Finn RS; Qin S; Han KH; Ikeda K; Cheng AL; Piscaglia F; Ueshima K; Aikata H; Vogel A; Lopez C; Pracht M; Meng Z; Daniele B; Park JW; Palmer D; Dutcus C; Tamai T; Saito K; Lencioni RAmerican Society of Clinical Oncology, 2017 Gastrointestinal Cancers Symposium (ASCO-GI 2019)  2019/01  San Francisco, USASubsequent anticancer medication following first-line lenvatinib: a posthoc responder analysis from the phase 3 REFLECT study in unresectable hepatocellular carcinoma  [Not invited]Alsina A; Kudo M; Vogel A; Cheng AL; Tak WY; Ryoo BY; Evans TJ; Lopez CL; Daniele B; Misir S; Ren M; Izumi N; Qin S; Finn RSAmerican Society of Clinical Oncology, 2017 Gastrointestinal Cancers Symposium (ASCO-GI 2019)  2019/01  San Francisco, USASafety and efficacy of lenvatinib by starting dose based on bodyweight in patients (pts) with unresectable hepatocellular carcinoma (uHCC) in REFLECT  [Not invited]Okusaka T; Ikeda K; Kudo M; Finn RS; Qin S; Han KH; Cheng AL; Piscaglia F; Kobayashi M; Sung M; Chen M; Wyrxicz L; Yoon JH; Ren Z; Stepan D; Dutcus C; Tamai T; Ren M; Hayato S; Kumada HAmerican Society of Clinical Oncology, 2017 Gastrointestinal Cancers Symposium (ASCO-GI 2019)  2019/01  San Francisco, USAAssociation between overall survival and adverse events with lenvatinib treatment in patients with hepatocellular carcinoma (REFLECT)  [Not invited]Sung M; Finn RS; Qin S; Han KH; Ikeda K; Cheng AL; Kudo M; Tateishi R; Ikeda M; Breder V; Rau KM; Ma YT; Alsina A; Ryoo BY; Ren Z; Mody K; Dutcus C; Tamai T; Saito K; Piscaglia FAmerican Society of Clinical Oncology, 2017 Gastrointestinal Cancers Symposium (ASCO-GI 2019)  2019/01  San Francisco, USARamucirumab as second-line treatment in patients with advanced hepatocellular carcinoma (HCC) and elevated alpha-fetoprotein (AFP) following first-line sorafenib: Pooled efficacy and safety in Japanese patients across two global randomized phase III studi  [Not invited]Kudo M; Okusaka T; Motomura K; Ohno I; Morimoto M; Seo S; Wada Y; Sato S; Yamashita T; Furukawa M; Aramaki T; Nadano S; Ohkawa K; Fujii H; Kudo T; Furuse J; Takai H; Homma G; Yoshikawa R; Zhu AXAmerican Society of Clinical Oncology, 2017 Gastrointestinal Cancers Symposium (ASCO-GI 2019)  2019/01  San Francisco, USAInvited Lecture “HCC and cholangiocarcinoma”  [Invited]Masatoshi KudoHot Topics at AASLD 2018  2018/12  Hyderabad, IndiaInvited Lecture “Newer diagnostic algorithm for a solid tumor [Invited]Masatoshi KudoHot Topics at AASLD 2018  2018/12  Hyderabad, India特別講演「急速に変貌する肝細胞癌の薬物療法」  [Invited]工藤正俊LENVIMA-Meet the Expert 効能・効果追加記念講演会  2018/12  札幌プリンスホテル, 北海道特別講演「新たなステージに入った肝細胞癌治療-薬物療法のもたらす新たなパラダイム」  [Invited]工藤正俊富山LENVIMA-HCC Expert 治療最前線‐臨床へどう反映すべきか-  2018/12  富山大学附属病院, 富山開会/閉会の挨拶  [Invited]工藤正俊第17回大阪消化器化学療法懇話会  2018/12  ホテルモントレグラスミア大阪, 大阪特別講演「新たなステージに入った肝細胞癌治療‐薬物療法のもたらす新たなパラダイム」  [Invited]工藤正俊LENVIMA-Meet the Expert  2018/11  JRタワー名古屋, 愛知特別講演「新たなステージに入った肝細胞癌治療‐薬物療法のもたらす新たなパラダイム」  [Invited]工藤正俊LENVIMA HCC Seminar  2018/11  ホテルグランヴィア和歌山, 和歌山Practice patterns, radiologic tumor response, and deterioration of liver function after transarterial chemoembolization (TACE): Final analysis of OPTIMIS in Korea and other regions  [Not invited]Heo J; Cheng AL; Raoul JL; Peck-Radosavljevic M; Kudo M; Nakajima K; Bayh I; Lin SM; Lee HCEuropean Society for Medical Oncology Congress (ESMO-Asia 2018)  2018/11  SingaporeEfficacy and safety of ramucirumab (RAM) in Asian and non-Asian patients with advanced hepatocellular carcinoma (HCC) and elevated alpha-fetoprotein (AFP): Subgroup analysis from two randomized studies  [Not invited]Kang YK; Kudo M; Lim HY; Hsu CH; Vogel A; Brandi G; Cheng R; Carton I; Abada P; Hsu Y; Zhu A; Yen CJEuropean Society for Medical Oncology Congress (ESMO-Asia 2018)  2018/11  SingaporeM7824 (MSB0011359C), a bifunctional fusion protein targeting transforming growth factor β (TGF-β) and PD-L1, in Asian patients with pretreated biliary tract cancer (BTC): Efficacy by BTC subtype  [Not invited]Yoo C; Oh DY; Choi HJ; Kudo M; Ueno M; Kondo S; Chen LT; Osada M; Helwig C; Dussault I; Ikeda MEuropean Society for Medical Oncology Congress (ESMO-Asia 2018)  2018/11  SingaporePhase 3, randomized KEYNOTE-240 study of pembrolizumab (Pembro) versus best supportive care (BSC) for second-line advanced hepatocellular carcinoma (HCC)  [Not invited]Chan SL; Finn RS; Zhu AX; Knox J; Cheng AL; Siegel AB; Bautista O; Kudo MEuropean Society for Medical Oncology (ESMO)-ASIA 2017  2018/11  SingaporeClinical efficacy and safety of EUS-guided gallbladder drainage replacement of percutaneous drainage: A multicenter retrospective study in Japan  [Not invited]Minaga K; Yamashita Y; Ogura T; Takenaka M; Shimokawa Y; Hisa T; Itonaga M; Kato H; Nishikiori H; Okuda A; Matsumoto H; Uenoyama Y; Watanabe T; Chiba Y; Higuchi K; Kudo M; Kitano MAsian Pacific Digestive Week (APDW 2018)  2018/11  Seoul, KoreaNivolumab in patients with Child-Pugh B advanced hepatocellular carcinoma (aHCC) in the CheckMate-040 study  [Not invited]Kudo M; Matilla A; Santoro A; Melero I; Gracian AC; Acosta MR; Choo SP; El-Khoueiry AB; Kuromatsu R; El-Rayes B; Numata K; Itoh Y; Di Costanzo F; Crysler O; Reig M; Shen Y; Neely J; dela Cruz C; Baccan C; Sangro BAmerican Association for the study of liver diseases (AASLD 2018)  2018/11  San FranciscoNew diagnostic method for hepatic steatosis using attenuation measurement by ultrasound B mode: comparison with controlled attenuation parameter  [Not invited]Koizumi Y; Hirooka M; Yada N; Tamaki N; Izumi N; Kudo M; Hiasa YAmerican Association for the study of liver diseases (AASLD 2018)  2018/11  San FranciscoStem cell feature and immune-suppressive microenvironment in human hepatocellular carcinoma  [Not invited]Nishida N; Kudo MAmerican Association for the study of liver diseases (AASLD 2018)  2018/11  San FranciscoOutcomes of patients (pts) with hepatocellular carcinoma (HCC) treated with transarterial chemoembolization (TACE): Global OPTIMIS final analysis  [Not invited]Peck-Radosavljevic; Kudo M; Raoul JL; Lee HC; Decaens T; Heo J; Lin SM; Shan H; Yang Y; Bayh I; Nakajima K; Cheng ALAmerican Association for the study of liver diseases (AASLD 2018)  2018/11  San FranciscoRamucirumab as second-line treatment in patients with hepatocellular carcinoma (HCC) and elevated alpha-fetoprotein (AFP) following sorafenib: pooled results from two global phase 3 studies (REACH-2 and REACH)  [Not invited]Llovet JM; Kudo M; Finn R; Galle PR; Blanc JF; Okusaka T; Chau I; Abada PB; Hsu Y; Zhu AXAmerican Association for the study of liver diseases (AASLD 2018)  2018/11  San Francisco, USAIPMN切除例からみた新ガイドラインの検証と、造影ハーモニックEUSの有用性について  [Not invited]山崎友裕; 大本俊介; 竹中 完; 吉川智恵; 岡本彩那; 石川 嶺; 中井敦史; 鎌田 研; 三長孝輔; 山雄健太郎; 工藤正俊第101回日本消化器内視鏡学会近畿支部例会  2018/11  大阪国際交流センター, 大阪胆管損傷後のBiloma内でランデブー法にて胆管ステントを留置し得た一例  [Not invited]岡本彩那; 三長孝輔; 竹中 完; 吉川智恵; 石川 嶺; 山崎友裕; 中井敦史; 大本俊介; 鎌田 研; 山雄健太郎; 工藤正俊; 岩崎寿光; 松本逸平; 鶴崎正勝第101回日本消化器内視鏡学会近畿支部例会  2018/11  大阪国際交流センター, 大阪若年性ポリポーシスにより胃切除を施行した2症例  [Not invited]河野辰哉; 松井繁長; 工藤正俊; 樫田博史; 渡邉智裕; 米田頼晃; 山田光成; 河野匡志; 櫻井俊治; 永井知行; 辻 直子; 安田卓司; 白石 治; 木村 豊第101回日本消化器内視鏡学会近畿支部例会  2018/11  大阪国際交流センター, 大阪表在型食道神経内分泌癌の一例  [Not invited]高島耕太; 松井繁長; 岡元寿樹; 山田光成; 正木 翔; 河野匡志; 米田頼晃; 永井知行; 櫻井俊治; 渡邉智裕; 辻 直子; 樫田博史; 工藤正俊第101回日本消化器内視鏡学会近畿支部例会  2018/11  大阪国際交流センター, 大阪急性膵炎を発症した肺腺癌膵転移の一例  [Not invited]久家沙希那; 大本俊介; 竹中 完; 石川 嶺; 岡本彩那; 中井敦史; 鎌田 研; 三長孝輔; 山雄健太郎; 工藤正俊第101回日本消化器内視鏡学会近畿支部例会  2018/11  大阪国際交流センター, 大阪Russell body gastritisの一例  [Not invited]秦 康倫; 木下大輔; 高山政樹; 奥田英之; 川崎俊彦; 水野成人; 工藤正俊; 渡辺敏彦; 若狭朋子; 岩渕三哉第101回日本消化器内視鏡学会近畿支部例会  2018/11  大阪国際交流センター, 大阪クラリスロマイシン耐性とH. pylori除菌法の選択  [Not invited]辻 直子; 梅原康湖; 谷池聡子; 工藤正俊第101回日本消化器内視鏡学会近畿支部例会  2018/11  大阪国際交流センター, 大阪肝外胆管癌のT-stagingにおける造影ハーモニックEUSと造影CT検査の有用性についての検討. パネルディスカッション2「膵胆道癌早期診断への内視鏡的アプローチ」  [Not invited]大塚康生; 鎌田 研; 竹中 完; 工藤正俊第101回日本消化器内視鏡学会近畿支部例会  2018/11  大阪国際交流センター, 大阪当院におけるソナゾイド造影下interventional EUSの検討. シンポジウム1「胆膵内視鏡治療の工夫」  [Not invited]吉川智恵; 三長孝輔; 竹中 完; 工藤正俊第101回日本消化器内視鏡学会近畿支部例会  2018/11  大阪国際交流センター, 大阪EUSガイド下膵管ドレナージのトラブルシューティングにおいてRe-puncture techniqueが有用であった一例. シンポジウム1「胆膵内視鏡治療の工夫」  [Not invited]大本俊介; 竹中 完; 工藤正俊第101回日本消化器内視鏡学会近畿支部例会  2018/11  大阪国際交流センター, 大阪Validation of modified ALBI grade for more detailed assessment of hepatic function in hepatocellular carcinoma patients: multicenter analysis  [Not invited]Hiraoka A; Kumada T; Tsuji K; Takaguchi K; Itobayashi E; Kariyama K; Ochi H; Tajiri K; Hirooka M; Shimada N; Ishikawa T; Tachi Y; Tada T; Toyoda H; Nouso K; Joko K; Hiasa Y; Michitaka K; Kudo MAmerican Association for the study of liver diseases (AASLD 2018)  2018/11  San Francisco司会; サテライトシンポジウム97「がん免疫療法の現状」  [Invited]工藤正俊第26回日本消化器関連学会週刊JDDW 2018(第60回日本消化器病学会大会, 第22回日本肝臓学会大会, 第96回日本消化器内視鏡学会総会)  2018/11  神戸コンベンションセンター, 兵庫術前水平方向進展度診断にSpyGlass DSが有用であった遠位胆管癌の2例  [Not invited]東原久美; 三長孝輔; 岡本彩那; 榎木英介; 石川 嶺; 中井敦史; 大本俊介; 鎌田 研; 山雄健太郎; 竹中 完; 工藤正俊第26回日本消化器関連学会週刊JDDW 2018(第60回日本消化器病学会大会, 第22回日本肝臓学会大会, 第96回日本消化器内視鏡学会総会)  2018/11  神戸コンベンションセンター, 兵庫Cap polyposisにおける腸内細菌叢の解析  [Not invited]岡元寿樹; 渡邉智裕; 工藤正俊第26回日本消化器関連学会週刊JDDW 2018(第60回日本消化器病学会大会, 第22回日本肝臓学会大会, 第96回日本消化器内視鏡学会総会)  2018/11  神戸コンベンションセンター, 兵庫EUS施行時の鎮静に対するBISモニターの有用性の検討  [Not invited]岡本彩那; 鎌田 研; 竹中 完; 石川 嶺; 中井敦史; 大本俊介; 三長孝輔; 山雄健太郎; 工藤正俊第26回日本消化器関連学会週刊JDDW 2018(第60回日本消化器病学会大会, 第22回日本肝臓学会大会, 第96回日本消化器内視鏡学会総会)  2018/11  神戸コンベンションセンター, 兵庫膵癌の門脈浸潤診断における造影ハーモニックEUSと造影CTの診断能の比較検討  [Not invited]中井敦史; 鎌田 研; 竹中 完; 石川 嶺; 岡本彩那; 大本俊介; 三長孝輔; 山雄健太郎; 兵頭朋子; 松本逸平; 竹山宜典; 工藤正俊第26回日本消化器関連学会週刊JDDW 2018(第60回日本消化器病学会大会, 第22回日本肝臓学会大会, 第96回日本消化器内視鏡学会総会)  2018/11  神戸コンベンションセンター, 兵庫腸内細菌叢からみたIgG4関連疾患の発症機序の解明. ワークショップ21「胆膵領域におけるIgG4関連疾患の研究と診療の進歩」  [Not invited]鎌田 研; 渡邉智裕; 工藤正俊第26回日本消化器関連学会週刊JDDW 2018(第60回日本消化器病学会大会, 第22回日本肝臓学会大会, 第96回日本消化器内視鏡学会総会)  2018/11  神戸コンベンションセンター, 兵庫当院でのirAE大腸炎の臨床的特徴  [Not invited]櫻井俊治; 川上尚人; 工藤正俊第26回日本消化器関連学会週刊JDDW 2018(第60回日本消化器病学会大会, 第22回日本肝臓学会大会, 第96回日本消化器内視鏡学会総会)  2018/11  神戸コンベンションセンター, 兵庫良性胆道狭窄(慢性膵炎)に対するfully covered metallic stentの有用性. ワークショップ14「Innovative therapeutic endoscopy良性胆管・膵管狭窄に対する内視鏡治療」  [Not invited]竹中 完; 山雄健太郎; 工藤正俊第26回日本消化器関連学会週間JDDW 2018(第22回日本肝臓学会大会, 第96回日本消化器内視鏡学会総会, 第60回日本消化器病学会大会)  2018/11  神戸コンベンションセンター, 兵庫Ramucirumab as second-line treatment in patients with advanced hepatocellular carcinoma (HCC) and elevated baseline alpha-fetoprotein (AFP) following first-line sorafenib (REACH-2): efficacy, safety, and patient-reported outcome results  [Not invited]Zhu A; Finn R; Galle P; Llovet J; Nipp R; Cella D; Girvan A; Gable J; Bowman L; Abada P; Hsu Y; Kudo MGastrointestinal Oncology Conference 2018 (ISGIO)  2018/11  Arlington, VA, USAランチョンセミナー38「急速に変貌する肝細胞癌の薬物療法」  [Invited]工藤正俊第26回日本消化器関連学会週間JDDW 2018(第22回日本肝臓学会大会, 第96回日本消化器内視鏡学会総会, 第60回日本消化器病学会大会)  2018/11  神戸コンベンションセンター, 兵庫Independent imaging review analysis of REFLECT trial of lenvatinib in HCC. ワークショップ5「生存期間延長を目指す分子機構に立脚した肝癌診療の基礎と臨床」  [Not invited]相方 浩; 工藤正俊; 池田健次第26回日本消化器関連学会週間JDDW 2018(第22回日本肝臓学会大会, 第96回日本消化器内視鏡学会総会, 第60回日本消化器病学会大会)  2018/11  戸コンベンションセンター, 兵庫Special Remarks, International Session (Symposium) 2 “Hepatitis towards the control of HCC-the remaining issues and future directions in Japan and the world”  [Invited]Masatoshi KudoJapan Digestive Disease Week 2018 (JDDW 2018)(the 60th Annual Meeting of the Japanese Society of Gastroenterology, the 96th Congress of the Japan Gastroenterological Endoscopy Society, the 22nd General Meeting of the Japan Society of Hepatology)  2018/11  Kobe Convention Center, HyogoIndependent imaging review analysis of REFLECT trial of lenvatinib in HCC  [Not invited]Aikata H; Kudo M; Ikeda KJapan Digestive Disease Week (JDDW 2018)(The 60th Annual Meeting of the Japanese Society of Gastroenterolgy, the 22nd General Meeting of the Japan Society of Hepatology, the 96th Congress of the Japan Gastroenterological Endoscopy Society)  2018/11  Kobe Convention Center, HyogoPractice patterns in the treatment of unresectablehepatocellular carcinoma with sorafenibin Latin America according to Child–Pugh score: Subgroup analysis of the GIDEON study  [Not invited]Ladron de; Guevara L; Dagher L; Miguel Viana; Arruda V; Nakajima K; Kudo MMexican Society of Oncology 36th National Congress 2018 (SMEO 2018)  2018/11  Guardalajara, Mexico特別講演「急速に変貌する肝細胞癌の薬物療法—ESMOの最新情報を含めて-」  [Invited]工藤正俊NEXT Web Conference  2018/10司会; 特別シンポジウム「超音波デジタル画像のナショナルデータベース構築とAI診断開発」  [Invited]工藤正俊第30回関東甲信越地方会学術集会  2018/10  都市センターホテル, 東京特別講演「急速に変貌する肝細胞癌の薬物療法」  [Invited]工藤正俊The HCC Summit in Shizuoka  2018/10  ホテルセンチュリー静岡, 静岡特別講演「肝細胞癌の薬物治療が大きく変わる」  [Invited]工藤正俊LENVIMA適応追加講演会  2018/10  ホテル日航姫路, 兵庫特別講演「急速に変貌する肝細胞癌の薬物療法」  [Invited]工藤正俊LENVIMA適応追加講演会 日本で生まれた新薬・レンビマの登場  2018/10  ホテル東日本宇都宮, 栃木Global phase 3 study of tislelizumab versus sorafenib as first-line treatment in patients with advanced hepatocellular carcinoma (HCC): A trial-in-progress  [Not invited]Qin S; Finn R; Kudo M; Meyer T; Vogel A; Ducreux M; Macarulla T; Tomasello G; Boisserie F; Hou J; Li C; Song J; Zhu AEuropean Society for Medical Oncology (ESMO 2018)  2018/10  Munich, GermanyPractice patterns and deterioration of liver function after transarterial chemoembolization (TACE) in hepatocellular carcinoma (HCC): Final analysis of OPTIMIS in Europe and Canada  [Not invited]Raoul JL; Decaens T; Burak K; Koskinas J; Villadsen GE; Heurgue-Berlot A; Bayh I; Cheng AL; Kudo M; Lee HC; Nakajima K; Peck-Radosavljevic MEuropean Society for Medical Oncology (ESMO 2018)  2018/10  Munich, GermanyA phase I, open-label, multi-center, dose-escalation study of codrituzumab, an anti-glypican-3 monoclonal antibody, in combination with atezolizumab in patients with locally advanced or metastatic hepatocellular carcinoma  [Not invited]Cheng AL; Yen CJ; Okusaka T; Ikeda M; Hsu CH; Wu SY; Morizane C; Hashimoto Y; Ueshima K; Ohtomo T; Tanaka T; Kudo MEuropean Society for Medical Oncology (ESMO 2018)  2018/10  Munich, GermanyInvited Lecture “HCC Meet the Expert”  [Invited]Masatoshi KudoEuropean Society for Medical Oncology (ESMO 2018)  2018/10  Munich, GermanyFinal analysis of serum biomarkers in patients (pts) from the phase 3 study of lenvatinib (LEN) vs sorafenib (SOR) in unresectable hepatocellular carcinoma (uHCC) [REFLECT]  [Not invited]Finn RS; Kudo M; Cheng AL; Wyrwicz L; Ngan R; Blanc JF; Baron A; Vogel A; Ikeda M; Piscaglia F; Han KH; Qin S; Minoshima Y; Kanekiyo M; Ren M; Dairiki R; Tamai T; Dutcus C; Funahashi Y; Evans TRJEuropean Society for Medical Oncology (ESMO 2018)  2018/10  Munich, Germany膵癌の門脈浸潤に対する造影ハーモニックEUS (CH-EUS)と造影multidetector CT (MDCT)の診断能の比較検討  [Not invited]中井敦史; 鎌田 研; 竹中 完; 松本逸平; 竹山宜典; 兵頭朋子; 筑後孝章; 工藤正俊日本超音波医学会第45回関西地方会学術集会  2018/10  神戸国際会議場, 兵庫診断に難渋したNeurilemmomaの一例  [Not invited]横川美加; 南 雅人; 桑口 愛; 市島真由美; 塩見香織; 前川 清; 南 康範; 依田 広; 樫田博史; 工藤正俊日本超音波医学会第45回関西地方会学術集会  2018/10  神戸国際会議場, 兵庫膵神経内分泌腫瘍における超音波内視鏡下ソナゾイド造影による悪性度診断の有用性  [Not invited]石川 嶺; 鎌田 研; 竹中 完; 大本俊介; 筑後孝章; 松本逸平; 竹山宜典; 工藤正俊日本超音波医学会第45回関西地方会学術集会  2018/10  神戸国際会議場, 兵庫肝癌に対するラジオ波焼灼術の支援画像: US-US overlay fusionの有用性. シンポジウム2「Interventional US」  [Not invited]南 康範; 依田 広; 工藤正俊日本超音波医学会第45回関西地方会学術集会  2018/10  神戸国際会議場, 兵庫Ramucirumab as second-line treatment in patients with advanced hepatocellular carcinoma (HCC) and elevated alpha-fetoprotein (AFP) following first-line sorafenib: patient reported outcome results across two phase 3 studies (REACH-2 and REACH)  [Not invited]Zhu AX; Finn R; Galle P; Llovet JM; Blanc JF; Okusaka T; Chau I; Cella D; Girvan A; Gable J; Bowman L; Hsu Y; Abada P; Kudo MEuropean Society for Medical Oncology (ESMO 2018)  2018/10  Munich, Germany司会: 臓器別シンポジウム6「肝細胞癌: 診断・治療の新たな展開」  [Invited]工藤正俊第56回日本癌治療学会学術集会  2018/10  パシフィコ横浜, 神奈川Invited Lecture “The Role of CEUS in the Detection and Diagnosis of FLL”  [Invited]Masatoshi KudoThe 2018 Convention of Taiwan Society of Ultrasound in Medicine (TSUM)  2018/10  Taipei, Taiwan特別講演「肝細胞癌治療のブレークスルー~薬物療法が変わる~」  [Invited]工藤正俊第45回青森県肝胆膵研究会  2018/10  弘前大学医学部コミュニケーションセンター, 青森特別講演「新たなステージに入った肝細胞癌治療-薬物療法が変わる-」  [Invited]工藤正俊第100回北九州肝腫瘍研究会特別記念講演会  2018/10  ホテルクラウンパレス小倉,福岡特別講演「新たなステージに入った肝細胞癌治療~薬物療法が変わる~」  [Invited]工藤正俊首都圏肝臓交流セミナー  2018/10  八芳園, 東京M7824 (MSB0011359C), a bifunctional fusion protein targeting PD-L1 and TGF-β, in Asian patients with pretreated biliary tract cancer: Preliminary results from a phase I trial  [Not invited]Yoo C; Oh DY; Choi HJ; Kudo M; Ueno M; Kondo S; Chen LT; Osada M; Helwig C; Dussault I; Ikeda MEuropean Society for Medical Oncology (ESMO 2018)  2018/10  Munich, Germanyセルブロック法を用いた内視鏡的経鼻胆嚢ドレナージチューブ下細胞診にて診断し得たIntracystic papillary neoplasmの一例  [Not invited]原 茜; 石川 嶺; 鎌田 研; 大塚康生; 吉川智恵; 山崎友裕; 高田龍太郎; 岡本彩那; 中井敦史; 大本俊介; 三長孝輔; 山雄健太郎; 竹中 完; 工藤正俊; 筑後孝章; 木村雅友; 吉田雄太; 中居卓也; 竹山宜典日本消化器病学会近畿支部第109回例会  2018/09  大阪国際交流センター, 大阪胃、十二指腸への転移を来した悪性中皮腫の一例  [Not invited]永谷奈央; 木下大輔; 秦 康倫; 高山政樹; 奥田英之; 川崎俊彦; 水野成人; 若狭朋子; 太田善夫; 明石雄策; 田村孝雄; 工藤正俊日本消化器病学会近畿支部第109回例会  2018/09  大阪国際交流センター, 大阪FNH類似の造影エコー像を示した肝細胞癌の一切除例  [Not invited]大丸直哉; 永谷奈央; 秦 康倫; 木下大輔; 奥田英之; 高山政樹; 川崎俊彦; 水野成人; 眞鍋弘暢; 辻江正徳; 井上雅智; 若狭朋子; 太田善夫; 工藤正俊; 大谷知之日本消化器病学会近畿支部第109回例会  2018/09  大阪国際交流センター, 大阪術前診断が困難であった膵頭部、尾部重複癌の一例  [Not invited]岡本彩那; 三長孝輔; 大塚康生; 高田龍太郎; 吉川智恵; 石川 嶺; 山崎友裕; 中井敦史; 大本俊介; 鎌田 研; 山雄健太郎; 竹中 完; 工藤正俊; 大谷知之日本消化器病学会近畿支部第109回例会  2018/09  大阪国際交流センター, 大阪慢性偽性腸閉塞に対し、胃瘻造設が有効であった一例  [Not invited]田中秀和; 永井知行; 櫻井俊治; 河野辰哉; 高島耕太; 正木 翔; 岡元寿樹; 河野匡志; 山田光成; 米田頼晃; 渡邉智裕; 松井繁長; 辻 直子; 樫田博史; 工藤正俊日本消化器病学会近畿支部第109回例会  2018/09  大阪国際交流センター, 大阪進行肝細胞癌に対するレゴラフェニブの治療成績. パネルディスカッション「消化器癌治療の現状と未来」  [Not invited]萩原 智; 上嶋一臣; 工藤正俊日本消化器病学会近畿支部第109回例会  2018/09  大阪国際交流センター, 大阪シミュレーションからナビゲーション: 放射線科領域での技術の到達点と今後の展望. シンポジウム3「シミュレーションからナビゲーションへ 放射線科領域」  [Not invited]鶴﨑正勝; 工藤正俊; 村上卓道第13回肝癌治療シミュレーション研究会  2018/09  京王プラザホテル, 東京肝癌に対するラジオ波焼灼術の支援画像: US-US overlay fusionの有用性  [Not invited]南 康範; 依田 広; 工藤正俊第13回肝癌治療シミュレーション研究会  2018/09  京王プラザホテル, 東京Stress response protein RBM3 promotes the development of colitis-associated cancer  [Invited]Sakurai T; Kudo MThe 77th Annual Meeting of the Japanese Cancer Association  2018/09  Osaka International Convention Center, Osaka特別講演「肝細胞癌治療のブレークスルー~薬物療法が変わる~」  [Invited]工藤正俊第33回岐阜肝画像研究会  2018/09  じゅうろくプラザ, 岐阜特別講演「急速に変貌する肝細胞癌の薬物療法」  [Invited]工藤正俊肝胆膵の分子標的治療セミナー  2018/09  ラグナヴェールプレミア, 大阪Systemic therapy for hepatocellular carcinoma: current status and future perspective. Symposia on Specific Tumors “Current status and the future of hepatobiliary and pancreatic cancer research and treatment”  [Invited]Masatoshi KudoThe 77th Annual Meeting of the Japanese Cancer Association  2018/09  Osaka International Convention Center, OsakaChair: Symposia on Specific Tumors “Current status and the future of hepatobiliary and pancreatic cancer research and treatment”  [Invited]Masatoshi KudoThe 77th Annual Meeting of the Japanese Cancer Association  2018/09  Osaka International Convention Center, Osaka肝外胆管癌における造影ハーモニックEUSの有用性についての検討  [Not invited]大塚康生; 鎌田 研; 竹中 完; 石川 嶺; 岡本彩那; 中井敦史; 大本俊介; 三長孝輔; 山雄健太郎; 筑後孝章; 兵頭朋子; 中居卓也; 竹山宜典; 工藤正俊第54回日本胆道学会学術集会  2018/09  幕張メッセ, 千葉特別講演「急速に変貌する肝細胞癌の薬物療法」  [Invited]工藤正俊第38回奈良消化器代謝セミナー  2018/09  奈良ホテル, 奈良内視鏡治療後の再発十二指腸静脈瘤に対するEUSの有用性  [Not invited]松井繁長; 樫田博史; 工藤正俊第25回日本門脈圧亢進症学会総会, 第20回肝不全治療研究会, 第21回B-RTO研究会  2018/09  グランキューブ大阪, 大阪特別講演「新たなステージに入った肝細胞癌診療‐薬物療法が変わる‐」  [Invited]工藤正俊レンバチニブ適応追加講演会  2018/09  オークラフロンティアホテルつくば, 茨城Hand-foot syndrome as a predictor of survival in advanced hepatocellular carcinoma treated with sorafenib: a multicenter study  [Not invited]Ogawa C; Shibatoge M; Takaguchi K; Tani J; Morishita A; Yoneyama H; Masaki T; Moriya A; Ando M; Deguchi A; Kudo M12th Annual Conference International Liver Cancer Association (ILCA)  2018/09  London, United KingdomUrine protein: creatinine ratio (UPCR) vs 24-h urine protein for the management of proteinuria: results from a phase 3 study of lenvatinib (LEN) vs sorafenib (SOR) in hepatocellular carcinoma (HCC)  [Not invited]Evans TR; Kudo M; Finn RS; Han KH; Cheng AL; Kraljevic S; Ren M; Dutcus CE; Piscaglia F; Sung MW12th Annual Conference International Liver Cancer Association (ILCA)  2018/09  London, United KingdomAcute and chronic deterioration in liver function after transarterial chemoembolization (TACE) in patients with hepatocellular carcinoma (HCC): the final analysis of OPTIMIS  [Not invited]Cheng AL; Raoul JL; Lee HC; Bayh I; Nakajima K; Peck-Radosavljevic M; Kudo M12th Annual Conference International Liver Cancer Association (ILCA)  2018/09  London, United KingdomNewly proposed tools for assessment of hepatic function for hepatocellular carcinoma staging and treatment planning-usefulness of modified ALBI grade  [Not invited]Izumoto H; Hiraoka A; Kumada T; Hirooka M; Tsuji K; Itobayashi E; Kariyama K; Ishikawa T; Tajiri K; Ochi H; Tada T; Toyoda H; Nouso K; Joko K; Hiasa Y; Ninomiya T; Michitaka K; Kudo M12th Annual Conference International Liver Cancer Association (ILCA)  2018/09  London, United KingdomIndependent imaging review (IIR) results in a phase 3 trial of lenvatinib (LEN) vs sorafenib (SOR) in first-line treatment of patients (PTS) with unresectable hepatocellular carcinoma (UHCC)  [Not invited]Lencioni R; Kudo M; Finn RS; Qin S; Han KH; Ikeda K; Cheng AL; Piscaglia F; Han G; Ikeda M; Simon K; Komov D; OuYang X; Evans TR; Sung M; Binder T; Damon A; Kraljevic S; Ren M; Ryoo BY12th Annual Conference International Liver Cancer Association (ILCA)  2018/09  London, United KingdomOverall survival (OS) update: 2-year follow-up from the phase 3 RESORCE trial of regorafenib for patients with hepatocellular carcinoma (HCC) progressing on sorafenib  [Not invited]Bruix J; Merle P; Granito A; Huang YH; Bodoky G; Yokosuka O; Rosmorduc O; Breder V; Gerolami R; Masi G; Ross PJ; Qin S; Song T; Bronowicki JP; Ollivier-Houmand I; Kudo M; LeBerre MA; Baumhauer A; Meinhardt G; Han G; on; behalf of the; RESORCE Investigators12th Annual Conference International Liver Cancer Association (ILCA)  2018/09  London, United KingdomA cost-effectiveness analysis of Lenvatinib compared with sorafenib in unresectable hepatocellular carcinoma allowing for AFP adjustment in overall survival in Japan from the reflect phase 3 clinical trial  [Not invited]Kudo M; Izumi N; Kaneko S; Kobayashi M; Azuma MK; Copher R; Meier G; Ishii M; Ikeda S12th Annual Conference International Liver Cancer Association (ILCA)  2018/09  London, United KingdomRandomized, open label, multicenter, phase II trial of transcatheter arterial chemoembolization (TACE) therapy in combination with sorafenib as compared with TACE alone in patients with hepatocellular carcinoma: TACTICS trial  [Not invited]Ueshima K; Kudo M; Ikeda M; Torimura T; Tanabe N; Aikata H; Izumi N; Yamasaki T; Nojiri S; Hino K; Tsumura H; Kuzuya T; Isoda N; Yasui K; Yoshimura K; Okusaka T; Furuse J; Kokudo N; Okita K; Arai Y; TACTICS study group12th Annual Conference International Liver Cancer Association (ILCA)  2018/09  London, United KingdomOutcomes of patients (PTS) with hepatocellular carcinoma (HCC) treated with transarterial chemoembolization (TACE): Global optimis final analysis  [Not invited]Peck-Radosavljevic M; Kudo M; Raoul JL; Lee HC; Decaens T; Heo J; Lin SM; Shan H; Yang Y; Bayh I; Nakajima K; Cheng AL12th Annual Conference International Liver Cancer Association (ILCA)  2018/09  London, United KingdomRamucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma and elevated baseline alpha-fetoprotein following first-line sorafenib (REACH-2): a phase 3, randomized, double-blind, placebo-controlled trial  [Not invited]Galle PR; Kudo M; Kang YK; Yen CJ; Finn R; Llovet JM; Assenat E; Brandi G; Lim HY; Pracht M; Rau KM; Merle P; Motomura K; Ohno I; Daniele B; Shin DB; Gerken G; Abada P; Hsu Y; Zhu AX12th Annual Conference International Liver Cancer Association (ILCA)  2018/09  London, United KingdomChair: General Session 3 “Epidemiology, Diagnosis, Staging”  [Invited]Masatoshi KudoInterntional Liver Cancer Association (ILCA) Annual Conference  2018/09  London, United KingdomEfficacy and safety of Tislelizumab, an anti-PD-1 antibody, versus sorafenib as a potential first-line treatment in patients with advanced hepatocellular carcinoma in a phase 3, randomized, multicenter study: A Trial-in-Progress  [Not invited]Qin S; Finn RS; Kudo M; Meyer T; Vogel A; Ducreux M; Macarulla TM; Tomasello G; Boisserie F; Hou J; Li C; Song J; Zhu AX12th Annual Conference International Liver Cancer Association (ILCA)  2018/09  London, United Kingdom特別講演「急速に変貌する肝細胞癌の薬物療法」  [Invited]工藤正俊Lenvima-Meet the Expert効能・効果追加記念講演会  2018/09  札幌グランドホテル, 北海道特別講演「急速に変貌する肝細胞癌の薬物療法」  [Invited]工藤正俊Lenvima適応追加記念講演会in 広島  2018/09  リーガロイヤルホテル広島, 広島Practice patterns in the treatment of unresectablehepatocellular carcinoma with sorafenibin Latin America according to Child–Pugh score: Subgroup analysis of the GIDEON study  [Not invited]Ladron de; Guevara L; Dagher L; Miguel Viana; Arruda V; Nakajima K; Kudo MALEH 2018  2018/09  International Convention Center, Punta Cana, Dominican RepublicA prospective, observational study to assess the safety and effectiveness of regorafenib in patients with unresectable hepatocellular carcinoma (uHCC) in routine clinical practice (REFINE)  [Not invited]Finn R; Frenette C; Granito A; Ikeda M; Lim HY; Merle P; Ozgurdal K; Kudo M12th Annual Conference International Liver Cancer Association (ILCA)  2018/09  London, United KingdomHand–foot skin reaction (HFSR) and overall survival (OS) in the phase 3 RESORCE trial of regorafenibfor treatment of hepatocellular carcinoma (HCC) progressing on sorafenib  [Not invited]Silva M; Carrilho FJ; Merle P; Granito A; Huang YH; Bodoky G; Yokosuka O; Rosmorduc O; Breder V; Gerolami R; Masi G; Ross PJ; Qin S; Song T; Bronowicki JP; Ollivier-Hourmand I; Kudo M; Xu L; Baumhauer A; Meinhardt G; Han G; Bruix J; on behalf of; the; RESORCE InvestigatorsALEH 2018  2018/09  International Convention Center, Punta Cana, Dominican Republic司会; ランチョンセミナー1「EOB-MRIは肝細胞癌の診療をどのように変えたか?」  [Invited]工藤正俊第69回日本消化器画像診断研究会  2018/08  石川県立音楽堂, 石川特別講演「新たなステージに入った肝細胞癌診療-薬物療法が変わる-」  [Invited]工藤正俊LENVIMA適応追加記念講演会  2018/08  リーガロイヤルホテル大阪, 大阪特別講演「肝細胞癌診療のブレークスルー-薬物療法が変わる-」  [Invited]工藤正俊LENVIMA Meet The Expert南大阪  2018/08  ホテルアゴーラリージェンシー堺, 大阪特別講演「肝癌診療のブレイクスルー-薬物療法が変わる-」  [Invited]工藤正俊中四国エリアレンビマHCC講演会in香川  2018/08  JRホテルクレメント高松, 香川特別講演「肝癌診療のブレイクスルー-薬物療法が変わる-」  [Invited]工藤正俊中四国エリアレンビマHCC講演会in香川  2018/08  JRホテルクレメント高松, 香川Invited Lecture “Eastern perspective”  [Invited]Masatoshi KudoHepatocellular Carcinoma (HCC) Scientific Input Engagement  2018/08  Hoboken, New Jersey特別講演「新たなステージに入った肝細胞癌の薬物療法」  [Invited]工藤正俊LENVIMA適応追加記念講演会 日本で生まれた新薬・レンビマの登場  2018/08  ホテルメトロポリタン山形, 山形特別講演「急速に変貌する肝細胞癌の薬物療法」  [Invited]工藤正俊HCC Meet the Expert in AKITA LENVIMA「肝細胞癌」適応追加記念講演会  2018/08  ホテルメトロポリタン秋田, 秋田特別講演「急速に変貌する肝細胞癌の薬物療法」  [Invited]工藤正俊第171回東北腹部画像診断検討会  2018/08  江陽グランドホテル, 宮城特別講演「新たなステージに入った肝細胞癌治療-薬物療法が変わる-」  [Invited]工藤正俊肝細胞癌Meet The Experts in 岩手  2018/08  ホテルメトロポリタン盛岡, 岩手特別講演「肝癌診療のブレイクスルー薬物療法が変わる」  [Invited]工藤正俊LENVIMA-HCC埼玉適応追加記念講演会  2018/07  パレスホテル大宮, 埼玉特別講演「新たなステージに入った肝細胞癌診療-薬物療法が変わる-」  [Invited]工藤正俊第1回千葉肝がんフォーラム~適応追加記念講演会~  2018/07  京成ホテルミラマーレ, 千葉特別講演「新たなステージに入った肝細胞癌診療-薬物療法が変わる-」  [Invited]工藤正俊LENVIMA-HCC適応拡大記念講演会  2018/07  深志神社, 長野特別講演「肝細胞癌診療のブレイクスルー」  [Invited]工藤正俊第18回関西肝血流動態・機能イメージ研究会  2018/07  エーザイ株式会社大阪コミュニケーションオフィス33階, 大阪テノホビルアラフェナミドの初期使用経験について  [Not invited]萩原 智; 西田直生志; 工藤正俊第60回京都肝疾患懇話会  2018/07  京都ホテルオークラ, 京都Educational Lecture “Phase 3 study of ramucirumab versus placebo in 2nd-line advanced HCC patients with high baseline AFP (REACH-2)”  [Not invited]Masatoshi Kudo16th Annual Meeting of the Japanese Society of Medical Oncology  2018/07  Kobe Convention Center/Kobe Portopia hotelPD-L1陽性肝癌の特徴と腫瘍免疫環境に関する解析. プレナリーセッション2  [Not invited]西田直生志; 工藤正俊第18回日本肝がん分子標的治療研究会  2018/07  東京大学伊藤国際学術研究センター, 東京肝予備能良好なBCLC-B肝細胞癌に対するTACE予後予測・腫瘍マーカースコアの有用性; 肝癌研究会データベース解析  [Not invited]平岡 淳; 道堯浩二郎; 熊田 卓; 泉 並木; 角谷眞澄; 國土典宏; 久保正二; 松山 裕; 中島 収; 坂元亨宇; 高山忠利; 國土貴嗣; 柏原康佑; 江口 晋; 山下達也; 工藤正俊第18回日本肝がん分子標的治療研究会  2018/07  東京大学伊藤国際学術研究センター, 東京司会: プレナリーセッション1  [Invited]工藤正俊第18回日本肝がん分子標的治療研究会  2018/07  東京大学伊藤国際学術研究センター, 東京開会/閉会の辞  [Invited]工藤正俊第18回日本肝がん分子標的治療研究会  2018/07  東京大学伊藤国際学術研究センター, 東京Chair: Oral Poster Presentation “Treatment: clinical trials”  [Invited]Masatoshi KudoThe 9th Asia-Pacific Primary Liver Cancer Expert Meeting (APPLE)  2018/07  Grand Hyatt Seoul, South KoreaPractice patterns and deterioration of liver function after transarterial chemoembolization (TACE): final analysis of OPTIMIS in Asian regions  [Not invited]Masatoshi KudoThe 9th Asia-Pacific Primary Liver Cancer Expert Meeting (APPLE)  2018/07  Grand Hyatt Seoul, South KoreaInvited Lecture “TKI-Based combination therapy: the more the better?”  [Invited]Masatoshi KudoThe 9th Asia-Pacific Primary Liver Cancer Expert Meeting (APPLE)  2018/07  Grand Hyatt Seoul, South KoreaInvited Lecture “TACE refractoriness: definition and treatment options”  [Invited]Masatoshi KudoThe 9th Asia-Pacific Primary Liver Cancer Expert Meeting (APPLE)  2018/07  Grand Hyatt Seoul, South KoreaInvited Lecture “Role of contrast-enhanced ultrasound in diagnosis of early-stage HCC”  [Invited]Masatoshi KudoThe 9th Asia-Pacific Primary Liver Cancer Expert Meeting (APPLE)  2018/07  Grand Hyatt Seoul, South KoreaChair: Session 1 “Update of HCC guidelines”  [Invited]Masatoshi KudoThe 9th Asia-Pacific Primary Liver Cancer Expert Meeting (APPLE)  2018/07  Grand Hyatt Seoul, South KoreaUS-US overlay image fusionを用いたラジオ波焼灼術の有用性:従来治療との比較. ワークショップ4「肝癌治療におけるナビゲーションの有用性と将来性」  [Not invited]南 康範; 工藤正俊第53回日本肝癌研究会  2018/07特別講演「新たなステージに入った肝細胞癌治療~薬物療法が変わる~」  [Invited]工藤正俊HCC Sorafenib-Regorafenib講演会  2018/07  大阪マリオット都ホテル, 大阪Safety and Effectiveness of Regorafenib in Patients with Unresectable Hepatocellular Carcinoma in Routine Clinical Practice: REFINE, a Prospective, Observational Study  [Not invited]Lim HY; Finn RS; Frenette C; Granito A; Ikeda M; Merle P; Ozgurdal K; Kudo MThe 9th Asia-Pacific Primary Liver Cancer Expert Meeting (APPLE)  2018/07  Grand Hyatt Seoul, South Korea教育講演「肝細胞癌の薬物療法: 最近の進歩と将来展望」  [Invited]工藤正俊日本内科学会第58回近畿支部生涯教育講演会  2018/07  大阪国際交流センター, 大阪造影ハーモニックEUSは膵癌の術前治療の効果判定に有用か?  [Not invited]田中秀和; 鎌田 研; 竹中 完; 石川 嶺; 中井敦史; 大本俊介; 三長孝輔; 宮田 剛; 山雄健太郎; 今井 元; 工藤正俊第49回日本膵臓学会大会  2018/06  和歌山県民文化会館, ホテルアバローム紀の国, 和歌山肝癌研究会追跡調査よりみた高齢肝細胞癌に対する至適治療法の検討, ワークショップ7「高齢化時代の肝癌診療」  [Not invited]海堀昌樹; 吉井健悟; 長谷川 潔; 小川朝生; 久保正二; 建石良介; 泉 並木; 角谷眞澄; 工藤正俊; 熊田 卓; 坂元亨宇; 中島 収; 松山 裕; 高山忠利; 國土典宏第54回日本肝癌研究会  2018/06  久留米シティプラザ, 福岡腫瘍マーカースコアによる肝予備能良好なBCLC-B肝細胞癌に対するTACE予後予測: 肝癌研究会データベース解析, ワークショップ6「診断技術(画像、腫瘍マーカー、ゲノム解析など)のイノベーション」  [Not invited]平岡 淳; 道蕘浩二郎; 熊田 卓; 泉 並木; 角谷眞澄; 國土典宏; 久保正二; 松山 裕; 中島 収; 坂元亨宇; 高山忠利; 國土貴嗣; 柏原康佑; 工藤正俊第54回日本肝癌研究会  2018/06  久留米シティプラザ, 福岡TACE施行後のソラフェニブ投与の有無ならびに開始時期が予後へ与える影響を検討した国際共同観察研究, シンポジウム1「肝癌における分子標的薬の新たな治療展開」  [Not invited]工藤正俊; 中島圭子第54回日本肝癌研究会  2018/06  久留米シティプラザ, 福岡肝内胆管癌: 臨床診断, パネルディスカッション5「肝内胆管癌の診断と治療」  [Not invited]工藤正俊; 角谷眞澄; 村上卓道; 糸井隆夫; 海野倫明第54回日本肝癌研究会  2018/06  久留米シティプラザ, 福岡司会; 教育講演「Management of hepatocellular carcinoma and molecularly targeted therapy」  [Invited]工藤正俊第54回日本肝癌研究会  2018/06  久留米シティプラザ, 福岡重症急性膵炎の予後不良予測因子および被包化壊死(WON)合併予測因子の検討  [Not invited]大本俊介; 竹中 完; 松本逸平; 竹山宜典; 工藤正俊第49回日本膵臓学会大会  2018/06  和歌山県民文化会館, ホテルアバローム紀の国, 和歌山術後膵液廔(POPF)に対するEUSドレナージの有用性  [Not invited]中井敦史; 竹中 完; 山雄健太郎; 松本逸平; 竹山宜典; 工藤正俊第49回日本膵臓学会大会  2018/06  和歌山県民文化会館, ホテルアバローム紀の国, 和歌山造影ハーモニックEUSによる膵神経内分泌腫瘍の悪性度評価. ワークショップ1「膵NETの最新の画像診断と治療」  [Not invited]石川 嶺; 鎌田 研; 竹中 完; 田中秀和; 中井敦史; 大本俊介; 宮田 剛; 三長孝輔; 山雄健太郎; 今井 元; 工藤正俊第49回日本膵臓学会大会  2018/06  和歌山県民文化会館, ホテルアバローム紀の国, 和歌山ランチョンセミナー7「レンビマによる肝癌治療のブレークスルー」  [Invited]工藤正俊第54回日本肝癌研究会  2018/06  久留米シティプラザ, 福岡司会: 演者: 豊田秀徳「SVR後肝発癌を見逃さないために~一歩先を見るプリモビストMRIを用いたサーベイランスの工夫」  [Invited]工藤正俊第54回日本肝癌研究会  2018/06  久留米シティプラザ, 福岡汎用型Workstationを用いたTACE治療とその問題点, ワークショップ3「TACE治療の新たな進歩」  [Not invited]盛田真弘; 小川 力; 大村亜紀奈; 久保敦司; 松中寿浩; 玉置敬之; 柴峠光成; 工藤正俊第54回日本肝癌研究会  2018/06  久留米シティプラザ, 福岡汎用型Workstationを用いたHCCの診断、治療の試み. ワークショップ5-13「医用工学の肝癌治療への応用」  [Not invited]小川 力; 盛田真弘; 大村亜紀奈; 久保敦司; 松中寿浩; 玉置敬之; 柴峠光成; 工藤正俊第54回日本肝癌研究会  2018/06  久留米シティプラザ, 福岡切除不能肝細胞癌に対する肝動脈化学塞栓療法とソラフェニブの併用療法第2相臨床試験(TACTICS).シンポジウム1-3「肝癌における分子標的薬の新たな治療展開」  [Not invited]上嶋一臣; 池田公史; 工藤正俊第54回日本肝癌研究会  2018/06  久留米シティプラザ, 福岡シンポジウム「TACE施行後のソラフェニブ投与の有無ならびに開始時期が予後へ与える影響を検討した国際共同観察研究」  [Invited]工藤正俊第54回日本肝癌研究会  2018/06  久留米シティプラザ, 福岡ラジオ波焼灼術の早期治療効果判定: US-US image overlay fusionの有用性. ワークショップ5-10「医用工学の肝癌治療への応用」  [Not invited]南 康範; 工藤正俊第54回日本肝癌研究会  2018/06  久留米シティプラザ, 福岡司会: シンポジウム1「肝癌における分子標的治療薬の新たな治療展開」  [Invited]工藤正俊第54回日本肝癌研究会  2018/06  久留米シティプラザ, 福岡基調講演「Keynote Lecture」  [Invited]工藤正俊第54回日本肝癌研究会  2018/06  久留米シティプラザ, 福岡特別講演「新たなステージに入った肝癌の薬物治療」  [Invited]工藤正俊第49回京都肝癌セミナー  2018/06  京都ホテルオークラ, 京都特別講演「肝細胞癌診療のブレークスルー~薬物療法が変わる~」  [Invited]工藤正俊第2回山口県肝臓癌セミナー, レンビマ®効能・効果追加記念講演会  2018/06  ANAクラウンプラザホテル, 山口特別講演「肝細胞癌の薬物治療が大きく変わる」  [Invited]工藤正俊Lenvatinib-Meet the Expert in 三重  2018/06  三重県総合文化センター, 三重慢性C型肝炎のDAA投与例におけるSVR後のAFP、ALT異常及び肝発癌に関する検討, ワークショップ11「肝炎ウイルスの制御が肝癌診療に及ぼす影響」  [Not invited]河野匡志; 西田直生志; 工藤正俊第54回日本肝臓学会総会  2018/06  大阪国際会議場, 大阪RFA治療の効果判定: Hepatic Guideの有用性, パネルディスカッション5「画像診断の新展開」  [Not invited]南 知宏; 村上卓道; 工藤正俊第54回日本肝臓学会総会  2018/06  大阪国際会議場, 大阪特別講演「肝細胞癌の治療アルゴリズム-穿刺局所療法・TACE・化学療法」, 特別企画5「日本肝臓学会ガイドラインup to date」  [Invited]工藤正俊第54回日本肝臓学会総会  2018/06  大阪国際会議場, 大阪特別講演「これからの肝細胞癌診療」, 特別企画2「肝臓研究の過去から未来への潮流②」  [Invited]工藤正俊第54回日本肝臓学会総会  2018/06  大阪国際会議場, 大阪司会: Jordi Bruix “Understanding current treatment options for HCC and exploring novel approaches”  [Invited]工藤正俊第54回日本肝臓学会総会  2018/06  大阪国際会議場, 大阪遺伝子変化に基づいた肝細胞癌の分子スコアリングと転移再発, シンポジウム1「肝癌治療の新展開」  [Not invited]西田直生志; 海道利実; 工藤正俊第54回日本肝臓学会総会  2018/06  大阪国際会議場, 大阪切除不能肝細胞癌に対する肝動脈化学塞栓療法(TACE)とソラフェニブの併用療法第II相臨床試験TACTICS Trial, シンポジウム1「肝癌治療の新展開」  [Not invited]上嶋一臣; 池田公史; 工藤正俊第54回日本肝臓学会総会  2018/06  大阪国際会議場, 大阪総合司会  [Invited]工藤正俊Lenvima-HCC Web Seminar  2018/06  近畿大学医学部消化器内科第3研究室, 大阪Invited Lecture “Current best practice and future perspective of systemic therapies for unresectable hepatocellular carcinoma”  [Invited]Masatoshi KudoNext Symposium  2018/06  Ho Chi Minh, Vietnam肝膿瘍の視認性に関する低音圧造影tissue harmonic imagingの有用性. シンポジウム消化器7「肝臓 診断 肝腫瘤の診療ガイドラインを考える」  [Not invited]南 康範; 河野匡志; 工藤正俊日本超音波医学会第91回学術集会  2018/06  神戸国際会議場, 神戸ポートピアホテル, 兵庫新しい造影法導入後の問題点. シンポジウム消化器7「肝臓 診断 肝腫瘤の診療ガイドラインを考える」  [Not invited]小川 力; 盛田真弘; 野田晃世; 大村亜紀奈; 久保敦司; 石川哲朗; 松中寿浩; 玉置敬之; 柴峠光成; 工藤正俊日本超音波医学会第91回学術集会  2018/06  神戸国際会議場, 神戸ポートピアホテル, 兵庫肝膿瘍治療指針におけるソナゾイド造影の有用性. シンポジウム消化器6「肝臓 診断 肝膿瘍の悪性度診断~Bモード・エラスト・Sonazoid造影~」  [Not invited]盛田真弘; 小川 力; 大村亜紀奈; 野田晃世; 久保敦司; 松中寿浩; 玉置敬之; 柴峠光成; 大西宏明; 工藤正俊日本超音波医学会第91回学術集会  2018/06  神戸国際会議場, 神戸ポートピアホテル, 兵庫座長: 男女共同参画委員会企画「キャリア継続およびキャリア支援に関する企業での取り組み」  [Invited]工藤正俊日本超音波医学会第91回学術集会  2018/06  神戸ポートピアホテル, 兵庫US-US image overlay fusionを用いたラジオ波焼灼術の有用性: 従来治療との比較. パネルディスカッション消化器3「肝臓 治療 安全かつ確実なRFA治療を目指した超音波技術の工夫」  [Not invited]南 康範; 南 知宏; 千品寛和; 田北雅弘; 萩原 智; 依田 広; 上嶋一臣; 西田直生志; 工藤正俊日本超音波医学会第91回学術集会  2018/06  神戸国際会議場, 神戸ポートピアホテル, 兵庫超音波エラストグラフィ併用による肝線維化・炎症評価. シンポジウム消化器5「肝臓 エラスト エラストグラフィは何を見ている?」  [Not invited]玉城信治; 泉 並木; 小泉洋平; 廣岡昌史; 日浅陽一; 中島 収; 矢田典久; 工藤正俊日本超音波医学会第91回学術集会  2018/06  神戸国際会議場, 神戸ポートピアホテル, 兵庫座長: 会長講演「画像診断の未来」  [Invited]工藤正俊日本超音波医学会第91回学術集会  2018/06  神戸国際会議場, 兵庫Similar efficacy and safety of endoscopic ultrasound-guided biliary drainage via hepaticogastrostomy and choledochoduodenostomy approaches for malignant distal obstruction: a multicenter, prospective randomized trial. Topic Forum “Exploring Newer Indicati  [Not invited]Minaga K; Kitano M; Ogura, T; Shiomi H; Hoki N; Nishikiori H; Yamashita Y; Hisa Takeshi; Kato H; Kamada H; Takenaka, M; Higuchi, K; Chiba Y; Kudo MDigestive Disease Week (DDW 2018)  2018/06  Washington DC, USAREACH-2: A randomized, double-blind, placebo-controlled phase 3 study of ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma (HCC) and elevated baseline alpha-fetoprotein (AFP) following first-line sorafe  [Not invited]Zhu AX; Kang YK; Yen CJ; Finn RS; Galle PR; Llovet JM; Assenat E; Brandi G; Lim HY; Pracht M; Rau KM; Merle P; Motomura K; Ohno I; Daniele B; Shin D; Gerken G; Abada P; Hsu Y; Kudo MAmerican Society of Clinical Oncology Annual Meeting (ASCO 2018)  2018/06  Chicago, USAA phase 3, randomized, open-label, multicenter study to compare the efficacy and safety of tislelizumab, an anti-PD-1 antibody, versus sorafenib as first-line treatment in patients with advanced hepatocellular carcinoma  [Not invited]Qin S; Finn RS; Kudo M; Meyer T; Vogel A; Ducreux M; Mercade TM; Tomasello G; Boisserie F; Hou J; Li C; Song J; Zhu AXAmerican Society of Clinical Oncology Annual Meeting (ASCO 2018)  2018/06  Chicago, USARandomized, open label, multicenter, phase II trial of transcatheter arterial chemoembolization (TACE) therapy in combination with sorafenib as compared with TACE alone in patients with hepatocellular carcinoma: TACTICS trial  [Not invited]Kudo M; Ueshima K; Torimura T; Tanabe N; Ikeda M; Aikata H; Izumi N; Yamasaki T; Nojiri S; Hino K; Tsumura H; Isoda N; Yasui K; Kuzuya T; Okusaka T; Furuse J; Kokudo N; Okita K; Yoshimura K; Arai Y; TACTICS Trial GroupAmerican Society of Clinical Oncology Annual Meeting (ASCO 2018)  2018/06  Chicago, USAOutcomes of patients (pts) with hepatocellular carcinoma (HCC) treated with transarterial chemoembolization (TACE): Global OPTIMIS final analysis  [Not invited]Peck-Radosavljevic M; Kudo M; Raoul JL; Lee HC; Decaens T; Heo J; Lin SM; Shan H; Yang Y; Bayh I; Nakajima K; Cheng ALAmerican Society of Clinical Oncology Annual Meeting (ASCO 2018)  2018/06  Chicago, USAA phase 1b trial of lenvatinib (LEN) plus pembrolizumab (PEM) in patients (pts) with unresectable hepatocellular carcinoma (uHCC)  [Not invited]Ikeda M; Sung MW; Kudo M; Kobayashi M; Baron AD; Finn RS; Kaneko S; Zhu AX; Kubota T; Kraljevic S; Ishikawa K; Siegel AB; Kumada H; Okusaka TAmerican Society of Clinical Oncology Annual Meeting (ASCO 2018)  2018/06  Chicago, USA経口デジタル胆道鏡(SpyGlass DS)が胆管癌の進展度診断に有用であった一例. 一般演題「肝胆膵」  [Not invited]岡本彩那; 三長孝輔; 竹中 完; 石川 嶺; 中井敦史; 大本俊介; 鎌田 研; 宮田 剛; 山雄健太郎; 今井 元; 工藤正俊; 木村雅友第100回日本消化器内視鏡学会近畿支部例会  2018/05  大阪国際交流センター  藤原靖弘ビガトランによる薬剤性食道潰瘍の検討. Young Endoscopist Session 3 食道  [Not invited]益田康弘; 松井繁長; 河野匡志; 岡元寿樹; 山田光成; 米田頼晃; 永井知行; 櫻井俊治; 渡邉智裕; 樫田博史; 工藤正俊第100回日本消化器内視鏡学会近畿支部例会  2018/05  大阪国際交流センター  藤原靖弘閉塞性黄疸が診断の契機となった低分化型食道胃接合部癌の1例. Fresh Endoscopist Session 2 食道・十二指腸  [Not invited]東原久美; 三長孝輔; 岡本彩那; 竹中 完; 石川 嶺; 中井敦史; 大本俊介; 鎌田 研; 山雄健太郎; 工藤正俊; 榎木英介第100回日本消化器内視鏡学会近畿支部例会  2018/05  大阪国際交流センター  藤原靖弘Chasing methodを用いた安全なEUSスクリーニングの標準化、教育の取り組み. ビデオワークショップ「胆膵内視鏡診療におけるdo and don’t」  [Not invited]大本俊介; 竹中 完; 工藤正俊第100回日本消化器内視鏡学会近畿支部例会  2018/05  大阪国際交流センター  藤原靖弘早期直腸癌に対する治療法の選択. パネルディスカッション「アンメットメディカルニーズに対する内視鏡の役割-下部消化管疾患の診断・治療-」  [Not invited]米田頼晃; 樫田博史; 櫻井俊治; 工藤正俊; 奥野清隆第100回日本消化器内視鏡学会近畿支部例会  2018/05  大阪国際交流センター  藤原靖弘経乳頭的re-intervention困難例の悪性肝門部胆道閉塞に対するEUS下胆道ドレナージの有用性. シンポジウム 1「アンメットメディカルニーズに対する内視鏡の役割-胆膵疾患の診断・治療-」  [Not invited]三長孝輔; 竹中 完; 鎌田 研; 山雄健太郎; 工藤正俊第100回日本消化器内視鏡学会近畿支部例会  2018/05  大阪国際交流センター  藤原靖弘“Small HCCs”, Hot Issues: ACUCI “CEUS: how to maker it clear”  [Invited]Masatoshi KudoThe 13th Congress of the Asian Federation of Societies for Ultrasound in Medicine and Biology (AFSUMB 2018)  2018/05  Seoul, Korea迷入膵が原因と思われる胃壁内膿瘍の1例. Fresh Endoscopist Session 1 胃  [Not invited]辻本智之; 秦 康倫; 木下大輔; 高山政樹; 奥田英之; 川崎俊彦; 水野成人; 工藤正俊第100回日本消化器内視鏡学会近畿支部例会  2018/05  大阪国際交流センター  藤原靖弘Expansion of color fusion outside the liver  [Not invited]Ogawa C; Morita M; Shibatoge M; Kudo MThe 13th Congress of the Asian Federation of Societies for Ultrasound in Medicine and Biology (AFSUMB 2018)  2018/05  Seoul, KoreaChair; Consensus Meeting “Guidelines for contrast-enhanced harmonic endoscopic ultrasonography”  [Invited]Masatoshi KudoThe 13th Congress of the Asian Federation of Societies for Ultrasound in Medicine and Biology (AFSUMB 2018)  2018/05  Seoul, KoreaHand-foot syndrome as predictor of survival in advanced HCC treated with sorafenib  [Not invited]Ogawa C; Morita M; Shibatoge M; Takaguchi K; Tani J; Masaki T; Moriya A; Deguchi A; Kudo MAsian Pacific Association for the Study of the Liver (APASL) Single Topic Conference  2018/05  Yokohama, JapanKeynote-224: Pembrolizumab in patients with advanced HCC previously treated with sorafenib  [Not invited]Kudo M; Zhu AX; Finn RS; Cattan S; Edeline J; Palmer D; Verslype C; Zagonel V; Fartoux L; Vogel A; Sarker D; Verset G; Chan S; Knox J; Daniele BAsian Pacific Association for the Study of the Liver (APASL) Single Topic Conference  2018/05  Yokohama, JapanInvited Lecture “Molecular targeted therapy”, Symposium 6 “Aging society and HCC: up to what age do we consider treating patients with HCC in general?”  [Invited]Masatoshi KudoAsian Pacific Association for the Study of the Liver (APASL) Single Topic Conference  2018/05  Yokohama, JapanStudies on AFP, ALT abnormalities and hepatocarcinogenesis after SVR in chronic hepatitis C patients treated with direct acting antivirals  [Not invited]Kono M; Nishida N; Kudo MAsian Pacific Association for the Study of the Liver (APASL) Single Topic Conference  2018/05  Yokohama, JapanChair: Symposium 3 “HCC with vascular invasion: HAIC, radioembolization, radiation therapy, surgery, or systemic therapy?”  [Invited]Masatoshi KudoAsian Pacific Association for the Study of the Liver (APASL) Single Topic Conference  2018/05  Yokohama, JapanInvited Lecture “Current best practice and future perspective of systemic therapies for unresectable hepatocellular carcinoma”  [Invited]Masatoshi KudoNext Symposium  2018/05  Bach Mai Hospital, VietnamKeynote Lecture “The role of TKI in HCC in an immunotherapy world”  [Invited]Masatoshi Kudo5th Asia-Pacific Gastroenterology Cancer Summit 2018  2018/05  SingaporeInvited Lecture “Current best practice and future perspective of systemic therapies for unresectable hepatocellular carcinoma”  [Invited]Masatoshi KudoNext Symposium  2018/04  National Cancer Hospital, Vietnam肝細胞癌診療と造影エコー法. ランチョンセミナー  [Not invited]工藤正俊第31回日本腹部造影エコー・ドプラ診断研究会  2018/03  ホテルアバローム紀の国, 和歌山興味深いEUS像を呈した膵多発Myeloif Sarcomaの1例. Freshman Session 11 膵臓  [Not invited]吉田早希; 三長孝輔; 竹中 完; 石川 嶺; 岡本彩那; 中井敦史; 大本俊介; 宮田 剛; 鎌田 研; 山雄健太郎; 今井 元; 工藤正俊; 井上宏昭; 松村 到; 清水重喜; 佐藤隆夫日本消化器病学会近畿支部第108回例会  2018/03  京都テルサ  安藤 朗mFOLFOX6+Cetuximab併用療法により画像的にComplete Responseが得られた切除不能肝転移を伴うS状結腸癌の1例  [Not invited]塚康生; 永井知行; 櫻井俊治; 福永明洋; 半田康平; 高田隆太郎; 岡元寿樹; 木下 淳; 河野匡志; 山田光成; 米田頼晃; 松井繁長; 渡邉智裕; 汐見幹夫; 樫田博史; 工藤正俊日本消化器病学会近畿支部第108回例会  2018/03  京都テルサ  安藤 朗動注リザーバーシステム留置時に腫瘍の広範な壊死を呈した進行肝細胞癌の一例. Freshman Session 1 肝臓(1)  [Not invited]藤井佳奈子; 岡本彩名; 半田康平; 高田隆太郎; 福永朋洋; 南 知宏; 河野匡志; 千品寛和; 有住忠晃; 田北雅弘; 南 康範; 依田 広; 上嶋一臣; 西田直生志; 工藤正俊日本消化器病学会近畿支部第108回例会  2018/03  京都テルサ  安藤 朗TACE治療時にEmboGuideが有用であった肝細胞癌の1例. Freshman Session 1 肝臓(1)  [Not invited]伊藤智彦; 奥田英之; 秦 康倫; 木下大輔; 高山政樹; 川崎正憲; 岡崎能久; 川崎俊彦; 水野成人; 朝戸信行; 工藤正俊日本消化器病学会近畿支部第108回例会  2018/03  京都テルサ  安藤 朗ステロイド抵抗性潰瘍性大腸炎に対するシクロスポリンの使用経験. シンポジウム1「生物学的製剤時代におけるIBD治療の現状と課題」  [Not invited]河野匡志; 櫻井俊治; 工藤正俊; 樫田博史日本消化器病学会近畿支部第108回例会  2018/03  京都テルサ  安藤 朗セツキシマブを含む抗がん剤にて肺胞出血を来した一例. Young Investigator Session 6 大腸(1)  [Not invited]福永朋洋; 岡元寿樹; 櫻井俊治; 半田康平; 高田隆太郎; 木下 淳; 石川 嶺; 河野匡志; 山田光成; 永井知行; 米田頼晃; 松井繁長; 渡邉智裕; 汐見幹夫; 樫田博史; 工藤正俊日本消化器病学会近畿支部第108回例会  2018/03  京都テルサ  安藤 朗mFOLFIRINOX療法に対するPegfilgrastim 2次予防療法の安全性・有効性の検討. ワークショップ3「外科手術、化学療法を含めた膵癌治療の最前線」  [Not invited]山雄健太郎; 竹中 完; 工藤正俊; 竹山宜典日本消化器病学会近畿支部第108回例会  2018/03  京都テルサ, 京都  安藤 朗開会の辞  [Invited]工藤正俊第14回臨床消化器病フォーラム  2018/03Invited Lecture “Novel management of advanced HCC”  [Invited]Masatoshi Kudo5th Myanmar GI & Liver, International Scientific Meeting and ASEAN Perspective in Liver Diseases (APLD)  2018/02  Yangon, MyanmarInvited Lecture “Systemic therapy for hepatocellular carcinoma: 2018 update”  [Invited]Masatoshi KudoThe 33rd Nagoya International Cancer Treatment Symposium  2018/02  Aichi Cancer CenterRFA治療の効果判定: Hepatic Guideの有用性  [Not invited]南 知宏; 南 康範; 工藤正俊; 鶴﨑正勝; 村上卓道第24回肝血流動態・機能イメージ研究会  2018/02  都久志会館, 福岡Hand-foot skin reaction (HFSR) and overall survival (OS) in the phase 3 RESORCE trial of regorafenib for treatment of hepatocellular carcinoma (HCC) progressing on sorafenib  [Not invited]Bruix J; Merle P; Granito A; Huang YH; Bodoky G; Yokosuka O; Rosmorduc O; Breder VV; Gerolami R; Masi G; Ross PJ; Qin S; Song T; Bronowicki JP; Ollivier-Hourmand I; Kudo M; Xu L; Baumhauer A; Meinhardt G; Han G; on behalf of; the; RESORCE InvestigatorsGastrointestinal Cancers Symposium (ASCO-GI 2018)  2018/01  San Francisco, USAIndependent imaging review (IIR) results in a phase 3 trial of lenvatinib (LEN) versus sorafenib (SOR) in first-line treatment of patients (pts) with unresectable hepatocellular carcinoma (uHCC)  [Not invited]Lencioni R; Kudo M; Finn RS; Qin S; Han KH; Ikeda K; Cheng AL; Piscaglia F; Han G; Ikeda M; Simon K; Komov D; OuYang X; Evans TRJ; Sung MW; Binder TA; Damon A; Kraljevic S; Ren M; Ryoo BYGastrointestinal Cancers Symposium (ASCO-GI 2018)  2018/01  San Francisco, USAKEYNOTE-224: Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib  [Not invited]Zhu AX; Finn RS; Cattan S; Edeline J; Ogasawara S; Palmer DH; Verslype C; Zagonel V; Rosmorduc O; Vogel A; Sarker D; Verset G; Chan SL; Knox JJ; Daniele B; Ebbinghaus S; Ma J; Siegel AB; Cheng AL; Kudo MGastrointestinal Cancers Symposium (ASCO-GI 2018)  2018/01  San Francisco, USADeterioration of liver function after transarterial chemoembolization (TACE) in hepatocellular carcinoma (HCC): A study of ramucirumab (LY3009806) versus placebo in patients with hepatocellular carcinoma and elevated baseline alpha-fetoprotein (REACH-2)  [Not invited]Zhu AX; Galle PR; Kudo M; Finn RS; Qin S; Xu Y; Abada P; Llovet JGastrointestinal Cancers Symposium (ASCO-GI 2018  2018/01  San Francisco, USAImpact of antitumor activity on survival outcomes, and nonconventional benefit, with nivolumab (NIVO) in patients with advanced hepatocellular carcinoma (aHCC): Subanalyses of CheckMate-040  [Not invited]El-Khoueiry AB; Merero I; Yau TC; Crocenzi TS; Kudo M; Hsu C; Choo S; Trojan J; Welling T; Meyer T; Kang YK; Yeo W; Chopra A; Zhao H; Baakili A; dela Cruz CM; Sangro BGastrointestinal Cancers Symposium (ASCO-GI 2018)  2018/01  San Francisco, USARandomized, open label, multicenter, phase II trial comparing transarterial chemoembolization (TACE) plus sorafenib with TACE alone in patients with hepatocellular carcinoma (HCC): TACTICS trial  [Not invited]Kudo M; Ueshima K; Ikeda M; Torimura T; Tanabe N; Aikata H; Izumi N; Yamasaki T; Nojiri S; Hino K; Tsumura H; Kuzuya T; Isoda N; Yasui K; Yoshimura K; Okusaka T; Furuse J; Kokudo N; Okita K; Arai Y; for the TACTICS Trial GroupGastrointestinal Cancers Symposium (ASCO-GI 2018)  2018/01  San Francisco, USADeterioration of liver function after transarterial chemoembolization (TACE) in hepatocellular carcinoma (HCC): An exploratory analysis of OPTIMIS-An international observational study assessing the use of sorafenib after TACE  [Not invited]Kudo M; Raoul JL; Lee HC; Cheng AL; Nakajima K; Peck-Radosavljevic MGastrointestinal Cancers Symposium (ASCO-GI 2018)  2018/01  San Francisco, USA司会: 特別講演「肝細胞がんに対する新たな分子標的治療薬や免疫チェックポイント阻害剤の開発の最前線」  [Invited]工藤正俊第17回日本肝がん分子標的治療研究会  2018/01  パシフィコ横浜, 神奈川急激に変貌する肝癌の薬物療法:免疫療法を含めて. 講演II  [Not invited]工藤正俊中・四国肝疾患研究会  2017/12  JRホテルクレメント高松, 香川座長; ランチョンセミナー4「肝細胞癌における治療戦略~分子標的薬治療の新たなステージへ~」  [Invited]工藤正俊第42回日本肝臓学会西部会  2017/11  ヒルトン福岡シーホーク, 福岡腹壁静脈瘤破裂に対し直接穿刺にて硬化療法を施行した2例. 若手医師症例報告奨励賞  [Not invited]半田康平; 萩原 智; 福永朋洋; 高田隆太郎; 岡本彩那; 南 知宏; 河野匡志; 千品寛和; 有住忠晃; 田北雅弘; 南 康範; 依田 広; 上嶋一臣; 西田直生志; 工藤正俊第42回日本肝臓学会西部会  2017/11  ヒルトン福岡シーホーク, 福岡真性多血症にBudd-Chiari症候群を伴った1例. 若手医師症例報告奨励賞  [Not invited]高田隆太郎; 萩原 智; 福永朋洋; 半田康平; 岡本彩那; 南 知宏; 河野匡志; 千品寛和; 有住忠晃; 田北雅弘; 南 康範; 依田 広; 上嶋一臣; 西田直生志; 工藤正俊第42回日本肝臓学会西部会  2017/11  ヒルトン福岡シーホーク, 福岡胃への遠隔転移を認めた肝細胞癌の一例. 若手医師症例報告奨励賞  [Not invited]福永朋洋; 萩原 智; 半田康平; 高田隆太郎; 岡本彩那; 南 知宏; 河野匡志; 千品寛和; 有住忠晃; 田北雅弘; 南 康範; 依田 広; 上嶋一臣; 西田直生志; 工藤正俊第42回日本肝臓学会西部会  2017/11  ヒルトン福岡シーホーク, 福岡DAA投与におけるSVR後のAFP異常値と関連する臨床背景の検討. 一般演題  [Not invited]河野匡志; 西田直生志; 千品寛和; 南 知宏; 有住忠晃; 田北雅弘; 矢田典久; 萩原 智; 南 康範; 上嶋一臣; 工藤正俊第42回日本肝臓学会西部会  2017/11  ヒルトン福岡シーホーク, 福岡開会/閉会の挨拶  [Invited]工藤正俊第16回大阪消化器化学療法懇話会  2017/11空腸穿通魚骨を小腸内視鏡にて除去し得た一例. Young Endoscopist Session 9「小腸・その他」  [Not invited]福永朋洋; 永井知行; 櫻井俊治; 岡元寿樹; 岡本彩那; 河野匡志; 山田光成; 米田頼晃; 松井繁長; 渡邊智裕; 樫田博史; 工藤正俊第99回日本消化器内視鏡学会近畿支部例会  2017/11大網裂孔ヘルニアによるレイウスの1例. Fresh Endoscopist Session 5「十二指腸・小腸」  [Not invited]吉川馨介; 木下 淳; 櫻井俊治; 高島耕太; 河野辰哉; 石川 嶺; 岡本彩那; 河野匡志; 岡元寿樹; 山田光成; 永井知行; 米田頼晃; 松井繁長; 渡邊智裕; 樫田博史; 工藤正俊第99回日本消化器内視鏡学会近畿支部例会  2017/11止血に難渋した十二指腸静脈瘤出欠の1例. Fresh Endoscopist Session 5「十二指腸・小腸」  [Not invited]中野省吾; 松井繁長; 高島耕太; 河野辰哉; 石川 嶺; 岡元寿樹; 山田光成; 河野匡志; 木下 淳; 米田頼晃; 永井知行; 朝隈 豊; 櫻井俊治; 渡邊智裕; 樫田博史; 工藤正俊第99回日本消化器内視鏡学会近畿支部例会  2017/11術前診断が困難であり経口膵管鏡による直接生検で診断しえた膵神経内分泌癌の1例. Young Endoscopist Session 6「膵臓」  [Not invited]工藤正俊第99回日本消化器内視鏡学会近畿支部例会  2017/11糞便移植を実施した潰瘍性大腸炎患者の2症例. パネルディスカッション2「下部消化管炎症性疾患の診断と治療」  [Not invited]永井知行; 櫻井俊治; 樫田博史; 工藤正俊第99回日本消化器内視鏡学会近畿支部例会  2017/11超音波内視鏡下吸引細胞診(EUS-FNA)にて診断に至ったスキルス胃癌の1例. Fresh Endoscopist Session 2「胃  [Not invited]山田信広; 米田頼晃; 三長孝輔; 河野辰哉; 高島耕太; 木下 淳; 石川 嶺; 岡本彩那; 岡元寿樹; 山田光成; 河野匡志; 永井知行; 櫻井俊治; 松井繁長; 渡邊智裕; 樫田博史; 工藤正俊第99回日本消化器内視鏡学会近畿支部例会  2017/11Stage 0, I膵癌の発見におけるEUSの役割. ワークショップ2「胆膵癌の早期発見における内視鏡の役割」  [Not invited]山雄健太郎; 竹中 完; 樫田博史; 工藤正俊第99回日本消化器内視鏡学会近畿支部例会  2017/11リザーバー留置後に十二指腸よりカテーテルの逸脱を認めた一例. 一般演題「十二指腸・小腸」  [Not invited]岡本彩那; 田北雅弘; 半田康平; 高田隆太郎; 福永朋洋; 南 知宏; 河野匡志; 千品寛和; 有住忠晃; 南 康範; 依田 広; 櫻井俊治; 上嶋一臣; 西田直生志; 工藤正俊第99回日本消化器内視鏡学会近畿支部例会  2017/11ESDにより切除しえた、巨大直腸腫瘍の1例. 一般演題「大腸2」  [Not invited]木下大輔; 秦 康倫; 岡崎能久; 高山政樹; 奥田英之; 川崎正憲; 水野成人; 川崎俊彦; 若狭朋子; 太田善夫; 工藤正俊; 森田圭紀第99回日本消化器内視鏡学会近畿支部例会  2017/11司会;Session1「肝疾患とサルコペニア」  [Invited]工藤正俊OTSUKA Liver Forum 2017  2017/11開会の挨拶  [Invited]工藤正俊第37回南大阪肝疾患研究会  2017/11特別講演「肝細胞癌薬物治療のブレイクスルー」  [Not invited]工藤正俊第168回群馬肝癌検討会特別講演会  2017/11胃前庭部たこいぼびらんとH. pyloriの関連. 一般演題口演74 胃-HP関連  [Not invited]辻直子; 川崎正憲; 梅原康湖; 松本望; 工藤正俊第93回日本消化器内視鏡学会総会  2017/11早期直腸癌に対する内視鏡治療について.パネルディスカッション「早期直腸がんに対する治療戦略」  [Not invited]米田頼晃; 樫田博史; 工藤正俊第72回日本大腸肛門病学会学術集会  2017/11  福岡早期直腸がんに対する治療戦略(肛門温存), パネルディスカッション2  [Not invited]米田頼晃; 樫田博史; 工藤正俊第72回日本大腸肛門病学会学術集会  2017/11losing remarks  [Invited]工藤正俊大阪和歌山消化器疾患カンファレン  2017/11Endoscopic ultrasonography-guided biliary drainage without dilation device using a thin delivery-system stent: A preclinical study  [Not invited]Itonaga M; Kitano M; Kawaji Y; Abe H; Takashi T; Nuta J; Hatamaru K; Omoto S; Minaga K; Kamata K; Miyata T; Yamao K; Imai H; Takenaka M; Kudo M25th UEG Week 2017  2017/10Time course of treatment-emergent adverse events (TEAEs) in the randomized, controlled phase 3 RESORCE trial of regorafenib for patients with hepatocellular carcinoma progressing on sorafenib treatment  [Not invited]Merle P; Granito A; Huang YH; Bodoky G; Pracht M; Yokosuka O; Rosmorduc O; Breder V; Gerolami R; Masi G; Ross P; Qin S; Song T; Bronowicki JP; Ollivier-Hourmand I; Kudo M; Schlief S; Fiala-Buskes S; Meinhardt G; Bruix J on; ehalf; of; h; ESORCE InvestigatorsAmerican Association for the study of liver diseases (AASLD 2017)  2017/10  Washington DC, USA特別講演II「肝細胞癌診療のブレークスルー-薬物療法が変わる-」  [Invited]工藤正俊第18回岡山肝がん研究会  2017/10Significance of surgical margin in patients with single hepatocellular carcinoma undergoing curative hepatic resection: an analysis using nationwide survey data in Japan  [Not invited]Aoki T; Kubota K; Matsumoto T; Izumi N; Kadoya M; Kubo S; Kumada T; Kokudo N; Sakamoto M; Takayama T; Nakashima O; Matsuyama Y; Kudo M; for the Liver; Cancer Study; Group of JapanAASLD 2017  2017/10  Washington DC, USAHealth-related quality of life (HRQOL) and disease symptoms in patients with unresectable hepatocellular carcinoma (HCC) treated with lenvatinib (LEN) or sorafenib (SOR)  [Not invited]Vogel A; Qin S; Kudo M; Hudgens S; Yamashita T; Yoon JH; Fartoux L; Simon K; Lopez C; Sung M; Dutcus C; Kraljevic S; Tamai T; Grunow N; Meier G; Breder VAASLD 2017  2017/10  Washington DC, USATime course of treatment-emergent adverse events (TEAEs) in the randomized, controlled phase 3 RESORCE trial of regorafenib for patients with hepatocellular carcinoma progressing on sorafenib treatment  [Not invited]Philippe Merle; Alessandro Granito; Yi-Hsiang Huang; György Bodoky; Marc Pracht; Osamu Yokosuka; Olivier Rosmorduc; Valeriy Breder; René Gerolami; Gianluca Masi; Paul J Ross; Shukui Qin; Tianqiang Song; Jean-Pierre Bronowicki; Isabelle Ollivier-Hourmand; Masatoshi Kudo; Sarah Schlief; Sabine Fiala-Buskies; Gerold Meinhardt; Jordi Bruix; on behalf of; the; RESORCE InvestigatorsAASLD 2017  2017/10  Geneva, Switzerland,Sonazoid-enhaunced US in the Management of HCC.  [Invited]Masatoshi Kudo2017年日中笹川医学協力プロジェクト超音波実用技術研修  2017/10Special Lecture “CEUS for Pancreatobiliary Diseases.”  [Not invited]Masatoshi KudoThe 9th Asian Conference on Ultrasound Contrast Imaging (ACUCI) 2017  2017/10Special Lecture “US-US Overlay Fusion Imaging in the Evaluation of Treatment Response After RFA.”  [Invited]Masatoshi KudoThe 9th Asian Conference on Ultrasound Contrast Imaging (ACUCI) 2017  2017/10CEUS in the Diagnosis and Treatment for Malignant Liver Tumors.  [Invited]Masatoshi KudoThe 16th World Congress of the world federation for ultrasound in medicine and biology (WFUMB) 2017  2017/10A new strategy to personalize surveillance program for colitis-associated cancer. International Session (Symposium)9 (JGES・JSGE・JSGS) “Surveillance colonoscopy for ulcerative colitis; Up-to-date procedure and therapeutic strategy”  [Invited]akurai T; Kashida H; Kudo MJapan Digestive Disease Week (JDDW) 2017 Fukuoka  2017/10  Fukuoka抗血栓薬内服での大腸 ESD における検討  [Not invited]岡元寿樹; 米田頼晃; 樫田博史; 岡本彩那; 河野匡志; 永井知行; 櫻井俊治; 松井繁長; 渡邉智裕; 工藤正俊第59回日本消化器病学会大会 Japanese Digestive Disease Week (JDDW) 2017 Fukuoka  2017/10  福岡抗血栓薬服用者に対する胃病変の ESD/EMR の安全性評価検討.  [Not invited]永井知行; 松井繁長; 岡本彩那; 岡元寿樹; 河野匡志; 山田光成; 米田頼晃; 櫻井俊治; 渡邉智裕; 樫田博史; 工藤正俊第94回日本消化器内視鏡学会総会 Japanese Digestive Disease Week (JDDW) 2017 Fukuoka  2017/10  福岡特別講演「急激に変貌する肝細胞癌の薬物治療  [Invited]工藤正俊第17回肝癌治療研究会  2017/10特別講演「肝細胞癌診療のブレークスルー~薬物療法が変わる~」  [Not invited]工藤正俊スチバーガ錠HCC承認記念講演会in京都  2017/10How to Improve Survival Outcome and Use Molecular Targeted Agent in HCC Patients? Symposium (XI) ”Innovation and New Approaches in Hepatocellular Carcinoma.”  [Invited]Masatoshi KudoTaiwan Digestive Disease Week 2017 (TDDW)  2017/09Special Lecture (V) “Impact of Surveillance and Diagnosis on Survival in HCC Patients”, Taiwan Digestive Disease Week 2017 (TDDW)  [Invited]Masatoshi KudoTaiwan Digestive Disease Week 2017 (TDDW)  2017/09十二指腸ステント留置下の胆道ドレナージの成績の検討, シンポジウム8「悪性胆管狭窄に対するドレナージ」  [Not invited]山雄健太郎; 竹中 完; 工藤正俊第53回日本胆道学会学術集会  2017/09造影ハーモニックEUS による胆嚢病変の良悪性鑑別~Vessel image とPerfusion image の比較~, シンポジウム6「了せ胆嚢疾患ー胆嚢癌との鑑別困難例に対する診断・治療戦略ー」  [Not invited]鎌田 研; 竹中 完; 工藤正俊第53回日本胆道学会学術集会  2017/09経乳頭処置困難総胆管結石症例に対するEUS下rendezvous technique の有用性, シンポジウム5「高難度胆管結石治療の極意を求めて」  [Not invited]竹中完; 山雄健太郎; 工藤正俊第53回日本胆道学会学術集会  2017/09Roux-en-Y 再建後の輸入脚狭窄に対してショートタイプシングルバルーン内視鏡を用いて消化管ステント留置術を行った1例.Yung Investigator Session10 胃・十二指腸3  [Not invited]田中秀和; 鎌田 研; 三長孝輔; 竹中 完; 中井敦史; 大本俊介; 宮田 剛; 山尾健太郎; 今井 元; 櫻井俊治; 西田直生志; 渡邉智裕; 樫田博史; 工藤正俊日本消化器病学会近畿支部第107回例会  2017/09  大阪国際交流センター, 大阪FNHのLMI-THI造影の検討.一般演題9「消化器3(造影)」  [Not invited]横川 美香; 前野 知子; 市島真由美; 塩見 香織; 前川 清; 依田 広; 南 康範; 工藤 正俊日本超音波医学会 第44回関西地方会学術集会,第21回関西地方講習会  2017/09カテーテルアブレーション後に急性胃拡張を来した2例. Freshman Session 6 胃・十二指腸1  [Not invited]久家沙希那; 永井知行; 松井繁長; 河野辰哉; 高島耕大; 木下 淳; 岡本彩那; 岡元寿樹; 石川 嶺; 山田光成; 河野匡志; 米田頼晃; 櫻井俊治; 渡邊智裕; 樫田博史; 工藤正俊日本消化器病学会近畿支部第107回例会  2017/09食道癌、肺癌、膵臓癌の異時性3重複癌の1例. Freshman Session 3 膵  [Not invited]大賀智行; 宮田 剛; 竹中 完; 中井敦史; 三長孝輔; 鎌田 研; 山雄健太郎; 今井 元; 工藤正俊日本消化器病学会近畿支部第107回例会  2017/09肝原発MCNと鑑別が困難であった腸間膜神経鞘腫の一例. Young Investigator Session 3 肝2  [Not invited]吉田晃浩; 山雄健太郎; 中井敦史; 大本俊介; 鎌田 研; 三長孝輔; 宮田 剛; 今井 元; 竹中 完; 樫田博史; 工藤正俊; 里井俊平; 松本逸平; 竹中宜典; 前西 修日本消化器病学会近畿支部第107回例会  2017/09膵胆道腫瘍のリンパ節転移診断における造影ハーモニックEUSの有用性. パネルディスカッション「胆膵疾患診療の最前線」  [Not invited]中井敦史; 竹中 完; 宮田 剛; 工藤正俊日本消化器病学会近畿支部第107回例会  2017/09開会、閉会挨拶  [Invited]工藤正俊第2回南大阪肝疾患診療連携セミナー  2017/09特別講演「Total SVR時代の肝炎診療」  [Invited]工藤正俊第2回南大阪肝疾患診療連携セミナー  2017/09術前に肝原発嚢胞性病変が疑われた腸間膜由来神経鞘腫の1例. 口演20 肝・その他  [Not invited]竹中 完; 山雄健太郎; 鎌田 研; 三長孝輔; 宮田 剛; 今井 元; 松本逸平; 竹山宜典; 前西 修; 工藤正俊第67回日本消化器画像診断研究会  2017/09巨木型食道静脈瘤に対するmodified EISL. ビデオワークショップ4「EIS―私はこうしている―」  [Not invited]松井繁長; 樫田博史; 工藤正俊第24回日本門脈圧亢進症学会総会  2017/09KEYNOTE-240: Phase 3, Randomized Study of  [Not invited]R.S. Finn; S.L. Chan; A.X. Zhu; J. Knox; A.-L. Cheng; A.B. Siegel; O. Bautista; M. KudoESMO 2017  2017/09特別講演「肝癌の薬物療法が変わる」  [Invited]工藤正俊近畿・中国四国肝疾患研究会  2017/08司会:シンポジウム26「これからの進行肝細胞がん治療」  [Invited]工藤正俊第15回日本臨床腫瘍学会  2017/07Treatment of advanced hepatocellular carcinoma: Future perspective. シンポジウム26「これからの進行肝細胞がん治療」  [Invited]工藤正俊第15回日本臨床腫瘍学会学術集会  2017/07Deterioration of Liver Function after Transarterial Chemoembolization (TACE) in Hepatocellular Carcinoma (HCC): An Exploratory Analysis of OPTIMIS, an International Observational Study Assessing the Use of Sorafenib after TACE  [Not invited]Han Chu Lee; Ann-Lii Cheng; Jean-Luc Raoul; Masatoshi Kudo; Keiko Nakajima; Markus Peck-RadosavljevicILCA 2017  2017/07慢性膵炎に対する径乳頭的金属ステント留置,短期間抜去の有用性. ミニワークショップ3-1「肝疾患診療におけるERCPの役割を見直す」  [Not invited]竹中 完; 大本俊介; 三長孝輔; 鎌田 研; 宮田 剛; 山雄健太郎; 今井 元; 工藤正俊48回日本膵臓学会大会  2017/07当院におけるWONに対するstep-up approachの検討. パネルディスカッション3「急性膵炎の後期合併症に対する手術・インターベンション治療の現状と課題」  [Not invited]竹中 完; 大本俊介; 三長孝輔; 鎌田 研; 宮田 剛; 山雄健太郎; 今井 元; 工藤正俊第48回日本膵臓学会大会  2017/07早期慢性膵炎のEUS所見の妥当性, 早期治療介入の意義について. パネルディスカッション1「慢性膵炎の進展予防を目的とした治療-その適応と限界-」  [Not invited]竹中 完; 大本俊介; 三長孝輔; 鎌田 研; 宮田 剛; 山雄健太郎; 今井 元; 工藤正俊第48回日本膵臓学会大会  2017/07EUSガイド下神経ブロックの成績と治療効果予測因子の検討.ビデオシンポジウム12「超音波内視鏡を用いた膵疾患診療ー基本から応用までー」  [Not invited]三長孝輔; 竹中 完; 宮田 剛; 中井敦史; 大本俊介; 鎌田 研; 山雄健太郎; 今井 元; 渡邉智裕; 工藤正俊第48回日本膵臓学会大会  2017/07肝細胞癌に対する肝切除における、surgical marginの意義の検討:追跡調査データを用いた解析. 一般演題「肝切除(1)」  [Not invited]青木 琢; 窪田敬一; 松本尊嗣; 泉 並木; 角谷眞澄; 久保正二; 熊田 卓; 國土典宏; 坂元亨宇; 高山忠利; 中島 収; 松山裕; 工藤正俊第53回日本肝癌研究会  2017/07レンバチニブ (Lenvatinib)  [Invited]工藤正俊第53回日本肝癌研究会  2017/07司会:シンポジウム4「肝癌診療ガイドライン第4版公聴会:エビデンスとコンセンサス」  [Invited]工藤正俊; 國土典宏第53回日本肝癌研究会  2017/07肝静脈腫瘍栓合併肝細胞癌に対する外科的切除の意義の検討―肝癌研究会追跡調査より.パネルディスカッション4「高度進行肝細胞癌(Vp3以上、Vv2以上)に対する集学的治療:エビデンスとコンセンサス」  [Not invited]國土貴嗣; 長谷川潔; 高山忠利; 泉 並木; 角谷眞澄; 工藤正俊; 久保正二; 坂元亨宇; 中島 収; 熊田 卓; 國土典宏第53回日本肝癌研究会  2017/07肝癌研究会追跡調査よりみた高齢肝細胞癌に対する外科的切除の意義. パネルディスカッション7「超高齢者肝癌の治療(切除か非切除か)」  [Not invited]海堀昌樹; 吉井健悟; 横田 勲; 長谷川潔; 高山忠利; 久保正二; 權 雅憲; 長島文夫; 泉 並木; 角谷眞澄; 工藤正俊; 熊田 卓; 坂元亨宇; 中島 収; 松山 裕; 國土典宏第53回日本肝癌研究会  2017/07第4版改訂のコンセプト. シンポジウム4「肝癌診療ガイドライン第4版公聴会:エビデンスとコンセンサス」  [Invited]國土典宏; 工藤正俊; 長谷川潔第53回日本肝癌研究会  2017/07Intermediate stage HCCの新しい亜分類と治療方針-全国原発性肝癌追跡調査46997例の解析から-. パネルディスカッション1「Intermediate stage肝癌の標準治療はなにか?:エビデンスとコンセンサス」  [Not invited]上嶋一臣; 工藤正俊; 泉 並木; 角谷眞澄; 久保正二; 熊田 卓; 國土典宏; 高山忠利; 坂元亨宇; 中島 収; 松山 裕第53回日本肝癌研究会  2017/07鎮静下RFAにおける3D-GPS markerの使用経験と課題. ワークショップ4「肝癌治療におけるナビゲーションの有用性と将来性」  [Not invited]小川 力; 盛田真弘; 大村亜紀奈; 野田晃世; 出田雅子; 久保敦司; 石川哲朗; 松中寿浩; 玉置敬之; 柴峠光成; 工藤正俊第53回日本肝癌研究会  2017/07TheCurrent Situations and Future Perspectives of the Japanese Nationwide Survey of Patients with Primary Liver Cancer. 国際シンポジウム3「肝悪性腫瘍のRegistry」  [Not invited]Hasegawa K; Kudo M; Izumi N; Kadoya M; Kubo S; Kumada T; Sakamoto M; Takayama T; Nakajima O; Matsuyama Y; Kokudo第53回日本肝癌研究会  2017/07Validation of three staging systems for hepatocellular carcinoma (JIS score, biomarker-combined JIS score and BCLC system) in 4,649 cases from a Japanese nationwide survey. 国際シンポジウム2「肝細胞癌のStaging」  [Not invited]Ueshima K; Kudo M; Izumi N; Kadoya M; Kubo M; Kumada T; Kokudo N; Takayama T; Sakamoto M; Nakashima O; Matsuyama Y第53回日本肝癌研究会  2017/07HCC treatnebt landscape-the Asian perspective- HCC treatment guidelines, Asian perspective- Experience sharing from Japan.  [Invited]Masatoshi KudoNecavar 10-years Anniversary  2017/07特別講演I「肝細胞癌に対する薬物治療の新たな展開~ASCO2017の最新発表を踏まえて~」  [Invited]工藤正俊肝疾患学術講演会  2017/06Updated overall survival (OS) analysis from the international, phase 3, randomized, placebo-controlled RESORCE trial of regorafenib for patients with hepatocellular carcinoma (HCC) who progressed on sorafenib treatment  [Invited]Bruix J; Merle P; Granito A; Huang YH; Bodoky G; Yokosuka O; Rosmorduc O; Breder V; Gerolami R; Masi G; Ross PJ; Qin S; Song T; Bronowicki JP; Ollivier-Hourmand I; Kudo M; LeBerre MA; Baumhauer A; Meinhardt G; Han G; on behalf of; the; RESORCE Investigators19th ESMO World Congress on Gastrointestinal Cancer 2017 (ESMO-GI 2017)  2017/06  Barcelona, SpainEfficacy and safety of nivolumab in patients with advanced hepatocellular carcinoma analyzed by patient age: a sub-analysis of the CheckMate 040 study  [Not invited]Melero I; El-Khoueiry AB; Yau T; Hsu C; Kudo M; Crocenzi T; Kim TY; Choo SP; Trojan J; Willing TH; Kang YK; Yeo W; Chopra A; Baakili A; dela Cruz C; Lang L; Sangro B; Meyer T19th ESMO World Congress on Gastrointestinal Cancer 2017 (ESMO-GI 2017)  2017/06  Barcelona, Spain特別講演「肝細胞癌の分子標的治療:現状と今後の展望」  [Not invited]工藤正俊第16回日本肝癌分子標的治療研究会  2017/06STAT3制御分子に注目した肝細胞癌のソラフェニブ治療効果予測の可能性. プレナリーセッション1.  [Not invited]櫻井俊治; 工藤正俊; 有住忠明; 田北雅弘; 矢田典久; 萩原 智; 南 康範; 依田 広; 上嶋一臣; 西田直生志第16回日本肝がん分子標的治療研究会  2017/06Speaker/ Chairperson: Master Class: Workshop: Master Class for Hepatocellular Carcinoma.  [Invited]Masatoshi Kudo24th Asia Pacific Cancer Conference (APCC)  2017/06特別講演2「肝細胞癌の分子標的治療:最新の話題」  [Invited]工藤正俊第6回香川肝がん分子標的治療研究会  2017/06急性膵炎の経過中に来たした肝障害の原因精査に超音波内視鏡が有用であった一例. Fresh Endoscopist Session 4「胆膵」  [Not invited]大塚康生; 鎌田 研; 竹中 完; 山雄健太郎; 三長孝輔; 宮田 剛; 大本俊介; 今井 元; 工藤正俊第98日本消化器内視鏡学会近畿支部例会  2017/06胃全摘後の総胆管結石性胆管炎に対して超音波内視鏡下管内胆管空腸吻合術が有用であった一例. Fresh Endoscopist Session 4「胆膵」  [Not invited]鎌田 研; 竹中 完; 山雄健太郎; 三長孝輔; 宮田 剛; 大本俊介; 今井 元; 工藤正俊98日本消化器内視鏡学会近畿支部例会  2017/06SpyGlassTM DSを用いた電気水圧衝撃波結石破砕術(EHL)が有用であった巨大総胆管結石の一例. Young Endoscopist Session 8「胆道」  [Not invited]中井敦史; 宮田 剛; 竹中 完; 大本俊介; 鎌田 研; 三長孝輔; 山雄健太郎; 樫田博史; 工藤正俊第98日本消化器内視鏡学会近畿支部例会  2017/06大腸早期印環細胞癌の一例. Young Endoscopist Session 7「小腸・大腸」  [Not invited]高島耕大; 樫田博史; 朝隈 豊; 岡本彩那; 岡元寿樹; 河野匡志; 山田光成; 足立哲平; 米田頼晃; 櫻井俊治; 松井繁長; 渡邉智裕; 工藤正俊第98日本消化器内視鏡学会近畿支部例会  2017/06ESDを施行した胃低腺型胃癌の検討. Young Endoscopist Session 3 「胃」  [Not invited]河野辰哉; 松井繁長; 岡本彩那; 岡元寿樹; 河野匡志; 足立哲平; 米田頼晃; 永井知行; 朝隈 豊; 櫻井俊治; 渡邉智裕; 樫田博史; 工藤正俊第98日本消化器内視鏡学会近畿支部例会  2017/06内視鏡的粘膜下層剥離術にて切除した胃底腺胃癌の1例. Fresh Endoscopist Session 1 消化管1  [Not invited]今村修三; 秦 康倫; 岡崎典久; 木下大輔; 高山政樹; 奥田英之; 川崎俊彦; 水野成人; 工藤正俊; 若狭朋子; 太田善夫; 盛田圭紀; 石黒信吾; 橋本恵介第98日本消化器内視鏡学会近畿支部例会  2017/06当院におけるself-expandable metallic stent留置の工夫~BONASTENTの使用経験を添えて~. ビデオワークショップ「安全で確実なERCP関連処置を目指して―手技のコツからトラブルシューティングまで―」  [Not invited]山雄健太郎; 竹中 完; 樫田博史; 工藤正俊第98日本消化器内視鏡学会近畿支部例会  2017/06径乳頭処置困難総胆管結石症例に対するEUSガイド下治療の成績. ワークショップ1「Interventional EUSによる胆膵診療の現状と新たな展開」  [Not invited]三長孝輔; 竹中 完; 宮田 剛; 樫田博史; 工藤正俊第98日本消化器内視鏡学会近畿支部例会  2017/06大腸ESDにおける抗血栓薬の影響に関する検討. シンポジウム2「下部消化器内視鏡治療の現状と課題」  [Not invited]岡元寿樹; 米田頼晃; 朝隈 豊; 樫田博史; 工藤正俊第98日本消化器内視鏡学会近畿支部例会  2017/06抗血栓薬服用者の胃病変に対する内視鏡的治療の安全の評価検討. シンポジウム1「上部消化管内視鏡治療の現状と課題」  [Not invited]永井知行; 松井繁長; 樫田博史; 工藤正俊第98日本消化器内視鏡学会近畿支部例会  2017/06Systemic Therapy for Hepatocellular Carcinoma: current Status and Future Perspective. KEYNOTE LECTURE II (KL-2-1)  [Invited]Masatoshi KudoAPASL Single Topic Conference 2017 Mongolia, 6th HCV Conference on HCV and CO-INFECTIONS  2017/06特別講演「肝細胞癌に対する分子標的治療:現況と今後の展望」  [Invited]工藤正俊」, Specific MoleculeAntiviral tRestment Tokyo HepatitisC (SMART C)  2017/06肝細胞癌の治療アルゴリズム―穿刺局所療法・TACE・化学療法―. 特別企画2「日本肝臓学会ガイドラインup to date」B型肝炎治療ガイドライン  [Not invited]工藤正俊第53回日本肝臓学会総会  2017/06肝癌診療ガイドライン. 特別企画2「日本肝臓学会ガイドラインup to date」  [Not invited]工藤正俊第53回日本肝臓学会総会  2017/06An international observational study to assess the use of sorafenib after transarterial chemoembolization (TACE) in patients with hepatocellular carcinoma (HCC): OPTIMIS interim analysis  [Not invited]Cheng AL; Raoul JL; Lee HC; Kudo M; Nakajima K; Peck-Radosavljevic M on; behalf of the; OPTIMIS InvestigatorsWorld Conference on Interventional Oncology (WCIO 2017)  2017/06  Boston, USA司会:ランチョンセミナー13「DAA選択時代の課題と今後の展望」  [Invited]工藤正俊第53回日本肝臓学会総会  2017/06US-US overlay image fusionを用いたラジオ波焼灼術の有用性:従来法との比較.セッション(一般公演)  [Not invited]南康範; 西田直生志; 工藤正俊第53回日本肝臓学会総会  2017/06DAA投与におけるSVR後のAFP及びALT異常値と関連する臨床背景の検討.セッション(一般公演)  [Not invited]河野匡志; 西田直生志; 南 知宏; 千品寛和; 有住忠晃; 田北雅弘; 依田 広; 矢田典久; 南 康範; 萩原 智; 上嶋一臣; 工藤正俊第53回日本肝臓学会総会  2017/06散発性急性C型肝炎例に於ける血清type-1 IFNs及びtype-3 IFNs値の動態とその臨床的意義.セッション(一般公演)  [Not invited]井本 勉; 天野恵介; 飯尾悦子; 勝島慎二; 米田俊貴; 福永豊和; 堀江 裕; 鄭 浩柄; 國立裕之; 金 秀基; 金 守良; 工藤正俊; 田中靖人第53回日本肝臓学会総会  2017/06司会:ランチョンセミナー7「進行性肝癌に対する治療戦略-BCAAの意義について-  [Invited]工藤正俊第53回日本肝臓学会総会  2017/06  広島Invited Lecture “Molecular Targeted Therapy for HCC: Current Status and Future Perspective.” Luncheon Seminor 18 “Diagnosis and Treatment od Liver Cancer.”  [Invited]Masatoshi KudoThe 6th Biennial Congress of the Asian-Pacific Hepato-Pancreato-Biliary Association (6th A-PHPBA), The 29th Meeting of Japanese Society of Hepato-Biliary-Pancreatic Surgery (29th JSHBPS)  2017/06  Pacifico Yokohama, KanagawaTreatment Strategy of Intermediate Stage HCC. Symposium 43 (Keynote) ”Strategy for Intermediate Stage of HCC”  [Invited]Masatoshi Kudo第6回アジア太平洋肝胆膵学会(6th A-PHPBA),第29回日本肝胆膵外科学会学術集会(29th JSHBPS)  2017/06Phase 3 randomized study of pembrolizumab vs best supportive care for second-line advanced hepatocellular carcinoma: KEYNOTR-240  [Not invited]Finn RS; Chan SL; Zhu AX; Knox J; Cheng AL; Siegel AB; Bautista O; Kudo MAnnual Meeting of American Society of Clinical Oncology (ASCO 2017)  2017/06Phase 3 trial of lenvatinib (LEN) vs sorafenib (SOR) in first-line treatment of patien(pts) with unresectable hepatocellular carcinoma (uHCC).  [Not invited]Cheng AL; Finn RS; Qin F; Han KH; Ikeda K; Piscaglia F; Baron AD; Park JW; Han G; Jassem J; Blanc JF; Vogel A; Komov D; Evans TRJ; Lopez-Lopez C; Dutcus CE; Ren M; Kraljevic S; Tamai T; Kudo MAnnual Meeting of American Society of Clinical Oncology (ASCO 2017)  2017/06Nivolumab (nivo) in sorafenib (sor)-naive and -experienced pts with advanced hepatocellular carcinoma (HCC): CheckMate 040 study.  [Not invited]Crocenzi TS; El-Khoueiry AB; Yau TC; Melero I; Sangro B; Kudo M; Hsu C; Trojan J; Kim TY; Choo SP; Meyer T; Kang YK; Yeo W; Chopra A; Baakili A; Dela Cruz CM; Lang L; Neely J; Welling TAnnual Meeting of American Society of Clinical Oncology (ASCO 2017)  2017/06ラジオ波焼灼術後のバブルによる高エコー域を壊死部とみなして良いか?ワークショップ 消化器1 肝臓「肝腫瘤に対する穿刺・治療の進歩」  [Not invited]南 康範; 工藤正俊日本超音波医学会第90回学術集会  2017/05早期慢性膵炎EUS所見の臨床的意義について. パネルディスカッション 消化器1 膵臓「慢性膵炎診断における超音波の役割」  [Not invited]竹中 完; 大本俊介; 三長孝輔; 宮田 剛; 鎌田 研; 山雄健太郎; 今井 元; 樫田博史; 工藤正俊日本超音波医学会第90回学術集会  2017/05種超音波エラストグラフィデバイスの進歩とその有用性. シンポジウム 消化器2 消化器横断領域「消化器領域における超音波最新技術」  [Not invited]矢田典久; 依田 広; 工藤正俊日本超音波医学会第90回学術集会  2017/05ディスカッサー: 男女共同参画委員会企画「日本超音波医学会が取り組むキャリア支援」  [Invited]工藤正俊; 長谷川雄一; 小川眞広日本超音波医学会第90回学術  2017/05座長:特別講演(海外招待講演2)Special Lecture (Overeas Invited Lecture 2)  [Not invited]工藤正俊日本超音波医学会第90回学術集会  2017/05座長:シンポジウム 消化器2 消化器横断領域「消化器領域における超音波最新技術」  [Invited]工藤正俊; 森安史典日本超音波医学会第90回学術集会  2017/05造影ハーモニックEUSによる上部消化管粘膜下腫瘍の鑑別診断~EUS-FNA診断との併用~. 奨励賞演題「消化器 奨励賞」  [Not invited]鎌田 研; 竹中 完; 大本俊介; 宮田 剛; 三長孝輔; 山雄健太郎; 今井 元; 筑後孝章; 安田卓司; 工藤正俊日本超音波医学会第90回学術集会  2017/05Speaker/ Chairperson: Latest Advances in Using Molecular Targeted Therapy in Advanced HCC Patients. Concurrent Session 3 “Hepatocellular Cancer”  [Invited]Masatoshi KudoHong Kong International Oncology Forum 2017  2017/05広範囲食道表在癌ESD 後の狭窄に対する治療成績の検討. 一般演題口演36 食道-狭窄2  [Not invited]岡元寿樹; 工藤正俊第93回日本消化器内視鏡学会総会  2017/05当院における小児上部消化管内視鏡検査の現状. 一般演題講演92 胃-その他2  [Not invited]奥田英之; 高山政樹; 木下大輔; 秦 康倫; 岡崎能久; 川崎俊彦; 水野成人; 若狭朋子; 太田善夫; 工藤正俊第93回日本消化器内視鏡学会総会  2017/05硬化性胆管炎と診断された膵癌、閉塞性黄疸の1例. 一般演題ポスター12 膵-症例  [Not invited]中井敦史; 山雄健太郎; 大本俊介; 鎌田研; 三長孝輔; 宮田剛; 今井元; 竹中 完; 松本逸平; 竹山宜典; 筑後孝章; 工藤正俊第93回日本消化器内視鏡学会総会  2017/05当院におけるERCP 教育の工夫(drawing pictures method/CD method). パネルディスカッション14「胆膵内視鏡における安全かつ効果的な教育法」  [Not invited]竹中 完; 東 健; 工藤正俊第93回日本消化器内視鏡学会総会  2017/05経乳頭的re-intervention 困難例の悪性肝門部胆道閉塞に対するEUS 下胆道ドレナージの有用性. パネルディスカッション11「EUS 下胆道ドレナージ(戦略と安全な手技)」  [Not invited]三長孝輔; 竹中 完; 工藤正俊第93回日本消化器内視鏡学会総会  2017/05当院主催のESD/EMR・大腸内視鏡挿入法のハンズオンセミナーの検証. パネルディスカッション10「ハンズオンセミナーを検証する」  [Not invited]永井知行; 樫田博史; 工藤正俊第93回日本消化器内視鏡学会総会  2017/05The Japan NBI Expert Team(JNET)分類Type 2B 病変の取り扱い. パネルディスカッション05「大腸拡大JNET 分類の有用性と今後の課題」  [Not invited]米田頼晃; 樫田博史; 工藤正俊第93回日本消化器内視鏡学会総会  2017/05経乳頭処置困難総胆管結石症例に対するEUS ガイド下治療の意義. ワークショップ04「治療に難渋する胆管結石の治療ストラテジー」  [Not invited]宮田 剛; 竹中 完; 工藤正俊第93回日本消化器内視鏡学会総会  2017/05切除不能悪性胃十二指腸狭窄症例に対する胃十二指腸ステント留置の予後予測因子の検討. ワークショップ01「緩和医療における内視鏡の役割」  [Not invited]山雄健太郎; 竹中 完; 工藤正俊第93回日本消化器内視鏡学会総会  2017/05噴門部静脈瘤合併巨木型食道静脈瘤にはEISL. シンポジウム4「決定版!これが今の食道胃静脈瘤治療だ!」  [Not invited]松井繁長; 樫田博史; 工藤正俊第93回日本消化器内視鏡学会総会  2017/05胃粘膜下腫瘍における造影ハーモニックEUSによる悪性抽出能の検討. パネルディスカッション07「上部消化管粘膜下腫瘍のマネージメントー経験とエビデンスに基づく食道・胃粘膜下腫瘍の診断と治療指針ー」  [Not invited]鎌田 研; 竹中 完; 工藤正俊第93回日本消化器内視鏡学会総会  2017/05Follow-up examination of the recurrence after endoscopic treatment of colorectal tumors.  [Not invited]Komeda Y; Kashida H; Sakurai T; Asakuma Y; Nagai T; Matsui S; Watanabe T; Kudo MDigestive Disease Week (DDW 2017)  2017/05Diagnosis of localized colorectal lesions with magnifying narrow band imaging (NBI) using Japan NBI Expert Team (JNET) classification: a cross sectional study.  [Not invited]Komeda Y; Kashida H; Sakurai T; Asakuma Y; Nagai T; Matsui S; Watanabe T; Kudo MDigestive Disease Week (DDW 2017)  2017/05Outcomes of biliary drainage in pancreatic cancer patients with an indwelling gastroduodenal stent: a multicenter retrospective study in west japan.  [Not invited]Yamao K; Kitano M; Takenaka M; Kayahara T; Ishida E; Yamamoto H; Yoshiawa T; Minaga K; Yamashita Y; Asada M; Okabe Y; Osaki Y; Ikemoto J; Hanada K; Kudo MDigestive Disease Week (DDW 2017),  2017/05座長:モーニングセミナー2「肝炎・肝硬変診療におけるさらなる挑戦慢性肝疾患・残された多くの課題―掻痒症も含めて―」  [Not invited]工藤正俊第103回日本消化器病学会総会  2017/04早期慢性肝炎EUS所見の臨床的意義について. ワークショップ13「早期慢性肝炎をめぐる諸問題」  [Not invited]竹中 完; 山雄健太郎; 工藤正俊第103回日本消化器病学会総会  2017/04汎用型ワークステーションを用いた新しいTACE治療の試み. ワークショップ12「肝画像診断の進歩」  [Not invited]小川 力; 柴峠光成; 工藤正俊第103回日本消化器病学会総会  2017/04US-US image fusionを用いた肝細胞癌へのラジオ派焼灼術の有用性. ワークショップ12「肝画像診断の進歩」  [Not invited]南 康範; 西田直生志; 工藤正俊第130回日本消化器病学会総会  2017/04Strain imaging によるC 型慢性肝疾患の肝発癌リスク予測. ワークショップ12「肝画像診断の進歩」  [Not invited]矢田典久; 櫻井俊治; 工藤正俊第103回日本消化器病学会総会  2017/04司会:ワークショップ12「肝画像診断の進歩」  [Invited]工藤正俊; 泉 並木第103回日本消化器病学会総会  2017/04STAT3 に注目した分子標的薬の治療効果予測.ワークショップ7「進行大腸がん治療のup to date」  [Not invited]櫻井俊治; 樫田博史; 工藤正俊第103回日本消化器病学会総会  2017/04PD-L1陽性肝癌の臨床病理学的特徴と遺伝子変異プロファイル.シンポジウム8「肝発癌メカニズムのパラダイムシフトとこれからの展望」  [Not invited]西田直生志; 工藤正俊第103回日本消化器病学会総会  2017/04EUSによるIPMN併存膵癌の早期発見と問題点. パネルディスカッション「IPMNの診断と治療の進歩」  [Not invited]鎌田 研; 竹中 完; 工藤正俊第103回日本消化器病学会総会  2017/04Nivolumab in sorafenib-experienced patients with advanced hepatocellular carcinoma (HCC) with or without chronic viral hepatitis: CheckMate 040 study.  [Not invited]Sangro B; Yau T; Hsu C; Kudo M; Crocenzi TS; Choo SP; Meyer T; Welling TH; Yeo W; Chopra A; Baakili A; dela Cruz C; Lang L; Neely J; Melero I; El-Khoueiry AB; Trojan JThe International Liver Congress 2017 (EASL 2017)  2017/04Molecular Targeted Therapy for Hepatocellular Carcinoma: Current Status and Future Perspective. シンポジウム4「肝細胞癌の治療戦略」  [Not invited]工藤正俊第76回日本医学放射線学会総会  2017/04New HCC Diagnosis. Session5“HCC-2”  [Invited]Masatoshi KudoThe Asian Pacific Association for the Study of the Liver (APASL STC 2017)  2017/04コンパニオン診断時代における造影USの役割とその啓蒙.  [Not invited]小川 力; 川井伸彦; 三野 智; 盛田真弘; 野田晃世; 出田雅子; 久保敦司; 松中寿浩; 玉置敬之; 紫峠光成; 村川佳子; 日野賢志; 西田知紗; 横井靖世; 河合直之; 丸山哲夫; 木太秀行; 大西宏明; 工藤正俊第30回日本腹部造影エコー・ドプラ診断研究会  2017/04  米子コンベンションセンター, 鳥取.造影USにて診断した虚血性鼠径ヘルニアの一例.  [Not invited]川井伸彦; 小川 力; 三野 智; 盛田真弘; 野田晃世; 出田雅子; 久保敦司; 松中寿浩; 玉置敬之; 紫峠光成; 村川佳子; 日野賢志; 西田知紗; 横井靖世; 河合直之; 丸山哲夫; 木太秀行; 大西宏明; 工藤正俊第30回日本腹部造影エコー・ドプラ診断研究会  2017/04  米子コンベンションセンター, 鳥取.造影USにて破裂性肝膿瘍が予測できた一例.  [Not invited]盛田真弘; 小川 力; 川井伸彦; 三野 智; 野田晃世; 出田雅子; 久保敦司; 松中寿浩; 玉置敬之; 紫峠光成; 村川佳子; 日野賢志; 西田知紗; 横井靖世; 河合直之; 丸山哲夫; 木太秀行; 大西宏明; 工藤正俊第30回日本腹部造影エコー・ドプラ診断研究会  2017/04  米子コンベンションセンター, 鳥取.開会の挨拶  [Invited]工藤正俊第30回日本腹部造影エコー・ドプラ診断研究会  2017/04  米子コンベンションセンター, 鳥取.座長; 「C型肝炎の最新治療と今度の課題」  [Invited]工藤正俊第13回Kinki Liver Club  2017/03  スイスホテル南海大阪, 大阪.開会/閉会の辞  [Invited]工藤正俊第13回Kinki Liver Club  2017/03  スイスホテル南海大阪, 大阪.Prospective risk analysis of hepatocellular carcinoma in patients with chronic hepatitis C by ultrasound strain imaging  [Not invited]Yada N; Sakurai T; Kudo MAmerican Institute of Ultrasound in Medicine (AIUM)  2017/03  Florida, USA開会の辞  [Invited]工藤正俊第13回臨床消化器病フォーラム  2017/03  ホテルグランヴィア大阪, 大阪.シンポジスト; 総合討論・症例提示  [Invited]工藤正俊Radiology Update in Gifu  2017/03  岐阜グランドホテル, 岐阜特別講演「内科医からみた肝画像診断の役割」  [Invited]工藤正俊Radiology Update in Gifu  2017/03  岐阜グランドホテル, 岐阜膵炎を繰り返す膵頭部癌に対して超音波内視鏡下膵管ドレナージ術を施行した一例. Freshman Session 11「膵臓・その他」  [Not invited]中野省吾; 鎌田 研; 竹中 完; 大本俊介; 宮田 剛; 三長孝輔; 山雄健太郎; 工藤正俊第106回日本消化器病学会近畿支部例会  2017/02主膵管狭窄を厳重に経過観察することで診断し得た膵上皮内癌の1例. Freshman Session 10「膵臓」  [Not invited]神山真紀子; 山雄健太郎; 大本俊介; 鎌田 研; 三長孝輔; 宮田 剛; 今井 元; 竹中 完; 工藤正俊; 松本逸平; 竹山宜典; 筑後孝章第106回日本消化器病学会近畿支部例会  2017/02緊急EUS-guided choledochoduodenostomyが有効であった総胆管結石性胆管炎の一例. Freshman Session 9「胆道」  [Not invited]和田祐太郎; 三長孝輔; 竹中 完; 大本俊介; 鎌田研; 宮田 剛; 山雄健太郎; 樫田博史; 工藤正俊第106回日本消化器病学会近畿支部例会  2017/02発する多血性肝腫瘍を認めた若年女性の1例. Freshman Session 8「肝臓(4)」  [Not invited]森本真衣; 奥田英之; 秦 康倫; 木下大輔; 高山政樹; 岡崎典久; 川崎俊彦; 水野成人; 若狭朋子; 太田善夫; 工藤正俊第106回日本消化器病学会近畿支部例会  2017/02PPIによる胃低腺ポリープの変化についての検討. Young Investigator Session1「直動・胃・十二指腸」  [Not invited]岩西美奈; 辻 直子; 川崎正憲; 松本 望; 尾崎信人; 米田 円; 谷池聡子; 井上達夫; 梅原康湖; 富田崇文; 前倉俊治; 落合 健; 工藤正俊第106回日本消化器病学会近畿支部例会  2017/02ERCP後膵炎早期発見におけるERCP直後CT撮影の有用性. ワークショップ2「胆膵領域における診断と治療の新たな展開」  [Not invited]宮田 剛; 竹中 完; 工藤正俊第106回日本消化器病学会近畿支部例会  2017/02座長; 「C型肝炎治療-これまで、これから-」  [Invited]工藤正俊エレルサ®・グラジナ®発売記念講演会in南大阪  2017/02  シェラトン都ホテル大阪, 大阪.開会の辞  [Invited]工藤正俊エレルサ®・グラジナ®発売記念講演会in南大阪  2017/02  シェラトン都ホテル大阪, 大阪.司会; ランチョンセミナー13「腸内細菌制御と炎症性腸疾患」  [Invited]工藤正俊第13回日本消化管学会総会学術集会  2017/02  名古屋国際会議場, 愛知Regional use of sorafenib after transarterial chemoembolization (TACE) in Chinese patients with hepatocellular carcinoma (HCC): results from the second interim analysis of OPTIMIS  [Not invited]Hong S; Cheng AL; Raoul JL; Lee HC; Kudo M; Nakajima K; Peck-Radosavljevic M; on behalf of the; OPTIMIS InvestigatorsThe 26th Conference of the Asian Pacific Association for the Study of the Liver (APASL)  2017/02  Shanghai, ChinaAnalysis of overall survival (OS) by pattern of progression of hepatocellular carcinoma (HCC) during prior sorafenib treatment in the randomized phase 3 RESORCE trial comparing regorafenib with placebo  [Not invited]Bruix J; Merle P; Granito A; Huang YH; Bodoky G; Pracht M; Yokosuka O; Gerolami R; Masi G; Ross PJ; Qin S; Song T; Bronowicki JP; Ollivier-Hourmand I; Kudo M; LeBerre MA; Meinhardt G; Han G; on behalf of; the; RESORCE InvestigatorsThe 26th Conference of the Asian Pacific Association for the Study of the Liver (APASL)  2017/02  Shanghai, ChinaInvited Lecture “TACE”  [Invited]Masatoshi Kudothe 26th Conference of Asian Pacific Association for the Study of the Liver (APASL 2017)  2017/02  Shanghai, China特別講演「肝がんの薬剤治療の現況と薬剤の開発状況」  [Invited]工藤正俊社内サテライト研修  2017/02  エーザイ大阪コミュニケーションオフィス, 大阪大腸腫瘍内視鏡治療後の局所再発に対するサーベイランスについて. ワークショップ7「大腸腫瘍の診断とサーベイランス法の最前線」  [Not invited]米田頼晃; 樫田博史; 橋本有人; 岡元寿樹; 河野匡志; 山田光成; 足立哲平; 峯宏昌; 永井知行; 朝隈 豊; 櫻井俊治; 松井繁長; 渡邉智裕; 工藤正俊第13回日本消化管学会総会学術集会  2017/02Treatment-stage migration maximizes survival outcomes in patients with hepatocellular carcinoma treated with sorafenib: an observational study.  [Not invited]Yen C; Sharma R; Rimassa L; Arizumi T; Bettinger D; Evans J; Pressiani T; Burlone ME; Pirisi M; Giordano L; Howell J; Kudo M; Thimme R; Park JW; Pinato DJThe International Liver Congress 2017 (EASL 2017)  2017/02Time course of treatment-emergent adverse events (TEAEs) in the randomized, controlled phase 3 RESORCE trial of regorafenib for patients with hepatocellular carcinoma progressing on sorafenib treatment.  [Not invited]Merle P; Granito A; Huang YH; Bodoky G; Pracht M; Yokosuka O; Rosmorduc O; Breder V; Gerolami R; Masi G; Ross P; Qin S; Song T; Bronowicki JP; Ollivier-Hourmand I; Kudo M; Schlief S; Fiala-Buskes S; Meinhardt G; Bruix J on; ehalf; of; h; ESORCE InvestigatorsEASL HCC Summit 2017  2017/02Chair: Hepatocellular Carcinoma Symposium “Multidisciplinary Therapy for HCC”  [Invited]Masatoshi Kudo2nd Eastern & Western Association Liver Tumors  2017/01  Seiryo Auditorium, Tohoku UniversitySurvival by pattern of tumor progression during prior sorafenib (SOR) treatment in patients with hepatocellular carcinoma (HCC) in the phase 3 RESORCE trial comparing second-line treatment with regorafenib (REG) or placebo.  [Not invited]Bruix J; Merle P; Granito A; Huang YH; Bodoky G; Pracht M; Yokosuka O; Gerolami R; Masi G; Ross PF; Qin S; Song T; Bronowicki JP; Ollivier-Hourmand I; Kudo M; Le Berre MA; Beinhardt G; Han G; on behalf of; RESORCE investigatorsAmerican Society of Clinical Oncology, 2017 Gastrointestinal Cancers Symposium (ASCO-GI 2017)  2017/01  San Francisco, USAResminostat and sorafenib combination therapy for advanced hepatocellular carcinoma in patients previously untreated with systemic chemotherapy.  [Not invited]Masatoshi KudoAmerican Society of Clinical Oncology, 2017 Gastrointestinal Cancers Symposium (ASCO-GI 2017)  2017/01  San Francisco, USASubgroup analyses of a phase 2 study of lenvatinib (E7080), a multitargeted tyrosine kinase inhibitor, in patients with advanced hepatocellular carcinoma (HCC)  [Not invited]Ikeda M; Ikeda K; Kudo M; Osaki Y; Okusaka T; Tamai T; Suzuki T; Hisai T; Miyagishi H; Okita K; Kumada HAmerican Society of Clinical Oncology, 2017 Gastrointestinal Cancers Symposium (ASCO-GI 2017)  2017/01  San Francisco, USARandomized phase 3 study of pembrolizumab versus best supportive care for second-line advanced hepatocellular carcinoma  [Not invited]Finn RS; Chan SL; Zhu AX; Knox J; Cheng AL; Siegel AB; Bautista O; Kudo MAmerican Society of Clinical Oncology, 2017 Gastrointestinal Cancers Symposium (ASCO-GI 2017)  2017/01  San Francisco, USAPhase 2 study of pembrolizumab in patients with previously treated advanced hepatocellular carcinoma.  [Not invited]Zhu AX; Knox J; Kudo M; Chan S; Finn R; Siegel A; Ma J; Cheng ALAmerican Society of Clinical Oncology, 2017 Gastrointestinal Cancers Symposium (ASCO-GI 2017)  2017/01  San Francisco, USANivolumab dose escalation and expansion in patients with advanced hepatocellular carcinoma (HCC): the CheckMate 040 study  [Not invited]Melero I; Sangro B; Yau T; Hsu C; Kudo M; Crocenzi TS; Kim TY; Choo SP; Trojan J; Meyer T; Welling TH; Yeo W; Chopra A; Anderson J; dela Cruz C; Lang L; Neely J; Tang H; El-Khoueiry ABAmerican Society of Clinical Oncology, 2017 Gastrointestinal Cancers Symposium (ASCO-GI 2017)  2017/01  San Francisco, USAEfficacy and safety of regorafnib versus placebo in patients with hepatocellular carcinoma (HCC) progressing on sorafenib: results of the international, randomized phase 3 RESORCE trial  [Invited]Kudo M; Bruix J; Merle P; Granito A; Huang YH; Bodoky G; Yokosuka O; Rosmorduc O; Breder V; Gerolami R; Masi G; Ross PJ; Qin S; Song T; Bronowicki JP; Ollivier-Hourmand I; LeBerre MA; Baumhauer A; Meinhardt G; Han G; on behalf of; the; RESORCE Investigators15th Japan Association of Molecular Targeted Therapy for HCC  2017/01  Iino hall & Conference Center, TokyoLocked Nucleic Acidsを用いた血清中マイクロRNA定量とソラフェニブ治療に対する反応予測  [Not invited]西田直生志; 岩西美奈; 南 知宏; 千品寛和; 河野匡志; 有住忠晃; 田北雅弘; 矢田典久; 依田 広; 萩原 智; 南 康範; 上嶋一臣; 工藤正俊第15回日本肝がん分子標的治療研究会  2017/01  イイノホール&カンファレンスセンター, 東京司会: 優秀演題2  [Invited]工藤正俊第15回日本肝がん分子標的治療研究会  2017/01  イイノホール&カンファレンスセンター, 東京癌遺伝子ガンキリンは炎症細胞でのSTAT3を活性化することで大腸発癌を促進する  [Not invited]櫻井俊治; 工藤正俊; 渡邊智裕; 樫田博史; 西田直生志; 米田頼晃; 永井知行; 萩原 智第2回G-PLUS  2016/12  ホテルイースト21東京, 東京Invited Lecture “Recent trends of TACE”  [Invited]Masatoshi Kudo57th Annual Conference of Indian Soceity of Gastroenterology (ISGCON 2016)  2016/12  New Delhi, IndiaInvited Lecture “Classification and management algorithm of HCC”  [Invited]Masatoshi Kudo57th Annual Conference of Indian Soceity of Gastroenterology (ISGCON 2016)  2016/12  New Delhi, IndiaInvited Lecture “Detection of early HCC-advance in diagnosis”  [Invited]Masatoshi Kudo57th Annual Conference of Indian Soceity of Gastroenterology (ISGCON 2016)  2016/12  New Delhi, India胆道出血を契機に発見された胆嚢管癌の1例  [Not invited]奥田英之; 秦 康倫; 木下大輔; 高山政樹; 岡崎能久; 川崎俊彦; 辻江正徳; 石川 原; 水野成人; 若狭朋子; 太田善夫; 工藤正俊日本消化器内視鏡学会近畿支部第97回支部例会  2016/11  京都テルサ, 京都当院における小児上部消化管内視鏡検査の状況  [Not invited]水野成人; 奥田英之; 高山政樹; 木下大輔; 秦 康倫; 岡崎能久; 川崎俊彦; 工藤正俊; 一木美穂; 近藤宏樹; 虫明総太朗; 若狭朋子; 太田善夫日本消化器内視鏡学会近畿支部第97回支部例会  2016/11  京都テルサ, 京都EUS-HGSステント閉塞に対しtrough the mesh法でreinterventionしえた1例  [Not invited]上田泰大; 宮田 剛; 竹中 完; 三長孝輔; 大本俊介; 松田友彦; 鎌田 研; 山雄健太郎; 樫田博史; 工藤正俊日本消化器内視鏡学会近畿支部第97回支部例会  2016/11  京都テルサ, 京都胆管合流異常症に合併した拡張胆管内隆起病への1例  [Not invited]吉川和也; 大本俊介; 竹中 完; 宮田 剛; 鎌田 研; 三長孝輔; 山雄健太郎; 工藤正俊; 松本逸平; 竹山宜典; 筑後孝章日本消化器内視鏡学会近畿支部第97回支部例会  2016/11  京都テルサ, 京都自己免疫性膵炎に対するステロイド投与の影響を造影ハーモニックEUSで評価しえた症例  [Not invited]岩津友大; 鎌田 研; 竹中 完; 大本俊介; 三長孝輔; 宮田 剛; 山雄健太郎; 今井 元; 工藤正俊日本消化器内視鏡学会近畿支部第97回支部例会  2016/11  京都テルサ, 京都主膵管狭窄を2年間経過観察し得た膵上皮内癌の1例  [Not invited]橋本有人; 山雄健太郎; 竹中 完; 大本俊介; 鎌田 研; 宮田 剛; 三長孝輔; 樫田博史; 工藤正俊; 松本逸平; 竹山宜典; 筑後孝章日本消化器内視鏡学会近畿支部第97回支部例会  2016/11  京都テルサ, 京都ョートシングルバルーン内視鏡を用いた金属ステント留意が有用であった十二指腸癌術後再発による挙上空腸狭窄の1例  [Not invited]國田裕貴; 三長孝輔; 竹中 完; 大本俊介; 松田友彦; 宮田 剛; 鎌田 研; 山雄健太郎; 樫田博史; 工藤正俊日本消化器内視鏡学会近畿支部第97回支部例会  2016/11  京都テルサ, 京都PTP誤嚥による食道気管支廔に対しOTSCによる閉鎖が奏功した一例  [Not invited]石村香織; 朝隈 豊; 岡元寿樹; 河野匡志; 足立哲平; 峯 宏昌; 永井知行; 米田頼晃; 櫻井俊治; 松井繁長; 樫田博史; 工藤正俊日本消化器内視鏡学会近畿支部第97回支部例会  2016/11  京都テルサ, 京都膵頭十二指腸切除術胃膵部吻合部狭窄に対するEUS-PDの検討. ワークショップ1「膵がんにおけるEUS-FNA関連手技の現状と問題点」  [Not invited]竹中 完; 三長孝輔; 山雄健太郎; 工藤正俊日本消化器内視鏡学会近畿支部第97回支部例会  2016/11  京都テルサ, 京都大腸腫瘍内視鏡治療後の局所再発に対するサーベイランスについて. パネルディスカッション2「大腸腫瘍内視鏡治療後のfollow upの課題」  [Not invited]米田頼晃; 樫田博史; 櫻井俊治; 朝隈 豊; 工藤正俊日本消化器内視鏡学会近畿支部第97回支部例会  2016/11  京都テルサ, 京都Invited Lecture “Immune checkpoint blockade in hepatocellular carcinoma”, Symposium 3 “Emerging Issues in the Management of Advanced Liver Disease”  [Invited]Masatoshi KudoSeoul International Digestive Disease Symposium (SIDDS 2016)  2016/11  Grand Hilton Seoul Hotel, Seoul, Korea閉会の辞: 工藤正俊  [Invited]工藤正俊第15回大阪消化器化学療法懇話会  2016/11  ホテル日航大阪, 大阪座長; 特別講演「大腸癌薬物療法の最新情報」  [Invited]工藤正俊第15回大阪消化器化学療法懇話会  2016/11  ホテル日航大阪, 大阪Invited Lecture “Contrast-enhanced EUS for pancreatobiliary disease”  [Invited]Masatoshi KudoThe Westlake International Forum on Ultrasound in Medicine and Biology (WIFUMB 2016) in conjunction with the International Contrast Ultrasound Society (ICUS) meeting  2016/11  Hongzhou, ChinaInvited Lecture “Fusion imaging for the treatment of liver cancer”.  [Invited]Masatoshi KudoThe Westlake International Forum on Ultrasound in Medicine and Biology (WIFUMB 2016) in conjunction with the International Contrast Ultrasound Society (ICUS) meeting  2016/11  Hongzhou, ChinaInvited Lecture “HCC clinical practice and ongoing trials in Japan”  [Invited]Masatoshi KudoAsia Advisory Board Meeting on GI Tumors  2016/11  Beijing, ChinaNivolumab (Nivo) in patients (Pts) with advanced hepatocellular carcinoma (HCC): the CheckMate 040 study.  [Not invited]Melero I; Sangro B; Yau T; Hsu C; Kudo M; Crocenzi TS; Kim TY; Choo SP; Trojan J; Meyer T; Welling TH; Yeo W; Chopra A; Anderson J; dela Cruz C; Lang L; Neely J; Tang H; El-Khoueiry ABAmerican Association for the Study of Liver Diseases (AASLD 2016)  2016/11形質細胞様樹状細胞が産生するIL-33がIgG4関連疾患の状態に果たす役割. ワークショップ16「消化器領域におけるIgG4関連疾患の病態」  [Not invited]渡邉智裕; 工藤正俊第20回日本肝臓学会大会, 第58回日本消化器病学会大会, 第92回日本消化器内視鏡学会総会, 第14回日本消化器外科学会大会(JDDW 2016)  2016/11  神戸コンベンションセンター, 兵庫Endoscopic ultrasound-guided gallbladder drainage for acute cholecystitis: long-term outcomes after removal of a self-expandable metal stent  [Not invited]Kamata K; Takenaka M; Kudo MAsian Pacific Digestive Week (APDW 2016)  2016/11  Kobe Convention Center, HyogoEUSガイド下胆道ドレナージ困難例に対する治療ルート変更の有用性  [Not invited]三長孝輔; 北野雅之; 工藤正俊第20回日本肝臓学会大会, 第58回日本消化器病学会大会, 第92回日本消化器内視鏡学会総会, 第14回日本消化器外科学会大会, 第54回日本消化器がん検診学会大会(JDDW 2016)  2016/11  神戸コンベンションセンター, 兵庫IPMN併存膵癌の臨床像と早期発見におけるEUSの有用性. ワークショップ10「IPMN併存膵癌における諸問題と対策」  [Not invited]鎌田 研; 北野雅之; 工藤正俊第20回日本肝臓学会大会, 第58回日本消化器病学会大会, 第92回日本消化器内視鏡学会総会, 第14回日本消化器外科学会大会, 第54回日本消化器がん検診学会大会(JDDW 2016)  2016/11  神戸コンベンションセンター, 兵庫司会; ワークショップ12「肝癌分子標的薬導入のタイミング」  [Invited]工藤正俊第20回日本肝臓学会大会, 第58回日本消化器病学会大会, 第92回日本消化器内視鏡学会総会, 第14回日本消化器外科学会大会(JDDW 2016)  2016/11  ポートピアホテル, 兵庫エンテカビルとPEG-IFNα2a/2b 48週併用療法の効果および治療効果予測因子の検討. ワークショップ9「B型肝炎治療のアップデート」  [Not invited]萩原 智; 西田直生志; 工藤正俊第20回日本肝臓学会大会, 第58回日本消化器病学会大会, 第92回日本消化器内視鏡学会総会, 第14回日本消化器外科学会大会(JDDW 2016)  2016/11  神戸コンベンションセンター, 兵庫膵癌の癌性疼痛に対するEUSガイド下神経叢融解術の治療効果予測因子の検討  [Not invited]宮田 剛; 北野雅之; 工藤正俊第20回日本肝臓学会大会, 第58回日本消化器病学会大会, 第92回日本消化器内視鏡学会総会, 第14回日本消化器外科学会大会(JDDW 2016)  2016/11  神戸コンベンションセンター, 兵庫司会; ブレックファーストセミナー2「肝細胞癌の診断と治療の進歩」  [Invited]工藤正俊第20回日本肝臓学会大会, 第58回日本消化器病学会大会, 第92回日本消化器内視鏡学会総会, 第14回日本消化器外科学会大会, 第54回日本消化器がん検診学会大会(JDDW 2016)  2016/11  ポートピアホテル, 兵庫Chair; Liver-S2 “Current therapeutic strategy for HCC”  [Invited]Masatoshi KudoAsian Pacific Digestive Week (APDW 2016)  2016/11  Kobe Convention Center, HyogoEstimation of EUS findings of early chronic pancreatitis in comparison with clinical symptoms. International Session (Workshop) 1“Recent progress in chronic pancreatitis”  [Not invited]Takenaka M; Kitano M; Kudo M第20回日本肝臓学会大会, 第58回日本消化器病学会大会, 第92回日本消化器内視鏡学会総会, 第14回日本消化器外科学会大会(JDDW 2016)  2016/11  ポートピアホテル, 兵庫pTis/pT1a膵癌の診断における内視鏡の役割. パネルディスカッション5「膵・胆道癌の早期発見における内視鏡の役割」  [Not invited]山雄健太郎; 北野雅之; 工藤正俊第20回日本肝臓学会大会, 第58回日本消化器病学会大会, 第92回日本消化器内視鏡学会総会, 第14回日本消化器外科学会大会, 第54回日本消化器がん検診学会大会(JDDW 2016)  2016/11  神戸コンベンションセンター, 兵庫US-US image fusionを用いた肝細胞癌へのラジオ波焼灼術と治療効果判定  [Not invited]南 康範; 工藤正俊第20回日本肝臓学会大会, 第58回日本消化器病学会大会, 第92回日本消化器内視鏡学会総会, 第14回日本消化器外科学会大会(JDDW 2016)  2016/11  神戸コンベンションセンター, 兵庫Identification of fetal liver-type hepatocellular carcinoma based on a methylome analysis and its associations with genetic alterations. International Session (Symposium) 1 “Genomics of hepatocellular carcinoma: hepatitis virus infection and hepatocarcino  [Not invited]Nishida N; Kudo M第20回日本肝臓学会大会, 第58回日本消化器病学会大会, 第92回日本消化器内視鏡学会総会, 第14回日本消化器外科学会大会(JDDW 2016)  2016/11  ポートピアホテル, 兵庫US-US fusion imaging in radiofrequency ablation therapy for hepatocellular carcinoma  [Not invited]Minami Y; Kudo Mthe 3rd Asian Conference on Tumor Ablation (ACTA)  2016/10  Asan Medical Center, Seoul, Korea造影超音波を施行した膵NET肝転移の一例  [Not invited]横川美加; 前野知子; 市島真由美; 塩見香織; 前川 清; 矢田典久; 依田 広; 南 康範; 工藤正俊第43回日本超音波医学会関西地方会  2016/10  大阪国際会議場, 大阪画像解析ソフトを用いた超音波診療の教育システム. シンポジウム1「腹部超音波検査の進歩と新たな展開」  [Not invited]小川 力; 盛田真弘; 野田晃世; 出田雅子; 久保敦司; 石川哲朗; 松中寿浩; 玉置敬之; 芝峠光成; 工藤正俊第43回日本超音波医学会関西地方会  2016/10  大阪国際会議場, 大阪肝病態診断におけるエラストグラフィの有用性. シンポジウム1「腹部超音波検査の進歩と新たな展開」  [Not invited]矢田典久; 工藤正俊第43回日本超音波医学会関西地方会  2016/10  大阪国際会議場, 大阪理事長特別講演「超音波がもたらすイノベーション」  [Invited]工藤正俊第43回日本超音波医学会関西地方会  2016/10  大阪国際会議場, 大阪Moderator; ACTA meets WCIO I: Challenges and solutions in ablation  [Invited]Masatoshi KudoThe 3rd Asian Conference on Tumor Ablation  2016/10  Asan Medical Center, Seoul, KoreaInvited Lecture “CE-US guided RFA for HCC”, Luncheon Symposium I  [Invited]Masatoshi Kudothe 3rd Asian Conference on Tumor Ablation (ACTA)  2016/10  Asan Medical Center, Seoul, KoreaInvited Lecture “CEUS in the evaluation of RFA treatment efficacy”  [Invited]Masatoshi Kudo2016 Annual Convention of Taiwan Society of Ultrasound in Medicine (TSUM)  2016/10  Taipei International Convention Center, TaiwanInvited Lecture “Value of EOB in clinical perspective: Japan”  [Invited]Masatoshi KudoAsia Pacific Liver Imaging Symposium (APLIS 2016)  2016/10  Conrad Beijing, China司会: Session 1「本邦における肝疾患とサルコペア」  [Invited]工藤正俊OTSUKA Liver Forum 2016  2016/10  ホテルニューオータニ東京, 東京特別講演「肝細胞癌診療の最近のtopics」  [Invited]工藤正俊第2回肝疾患Up to Date研究会  2016/10  ANAクラウンプラザホテル新潟, 新潟Combination therapy with peginterferon and entecavir for persistent viral suppression in patients with chronic hepatitis B  [Not invited]Hagiwara S; Nishida N; Kudo M23rd International Symposium on Hepatitis C Virus and Related Viruses (HCV2016)  2016/10  Kyoto International Conference Center, Kyoto, JapanSafety and preliminary efficacy of nivolumab (nivo) in patients (pts) with advanced hepatocellular carcinoma (aHCC): Interim analysis of the phase 1/2 CheckMate-040 study  [Not invited]Melero I; Sangro B; Yau T; Hsu C; Kudo M; Crocenzi T; Kim TY; Choo SP; Trojan J; Meyer T; Willing T; Yeo W; Chopra A; Anderson J; dela Cruz CX; Lang L; Neely J; El-Khoueiry AESMO 2016  2016/10  Copenhagen, DenmarkPembrolizumab in patients with previously treated advanced hepatocellular carcinoma: Phase 2 KEYNOTE-224 study  [Not invited]Zhu A; Knox J; Kudo M; Chan S; Finn R; Siegel A; Ma J; Watson P; Cheng ALESMO 2016  2016/10  Copenhagen, DenmarkPembrolizumab vs best supportive care for second-line advanced hepatocellular carcinoma: Randomized, phase 3 KEYNOTE-240 study  [Not invited]Finn R; Chan S; Zhu A; Knox J; Cheng AL; Siegel A; Bautista O; Watson P; Kudo MESMO 2016  2016/10  Copenhagen, DenmarkA randomized, double-blind, placebo-controlled phase III study of ramucirumab versus placebo as second-line treatment in patients with hepatocellular carcinoma and elevated baseline alpha-fetoprotein following first-line sorafenib (REACH-2)  [Not invited]Zhu A; Galle P; Kudo M; Finn R; Yang L; Abada P; Llovet JESMO 2016  2016/10  Copenhagen, DenmarkEfficacy, safety, and health-related quality of life (HRQoL) of regorafenib in patients with hepatocellular carcinoma (HCC) progressing on sorafenib: Results of the international, double-blind phase 3 RESORCE trial  [Not invited]Bruix J; Merle P; Granito A; Huang YH; Bodoky G; Yokosuka O; Rosmorduc O; Breder V; Gerolami R; Masi G; Ross PJ; Qin S; Song T; Bronowicki JP; Isabelle Ollivier-Hourmang; Kudo M; LeBerre MA; Baumhauer A; Meinhardt G; Han GESMO 2016  2016/10  Copenhagen, Denmark特別講演「肝胆膵領域の超音波診療: 最近の動向」  [Invited]工藤正俊日本超音波医学会第26回四国地方会学術集会  2016/10  愛媛大学医学部40周年記念講堂, 愛媛The oncoprotein gankyrin promotes the development of colitis-associated cancer by mediating STAT3 and ERK activation  [Not invited]Sakurai T; Nagai T; Kashida H; Kudo MThe 75th Annual Meeting of the Japanese Cancer Association  2016/10  acifico Yokohama, KanagawaChair: English Oral Sessions “Hepato-biliary-pancreatic cancer: translational research”  [Invited]Masatoshi KudoThe 75th Annual Meeting of the Japanese Cancer Association  2016/10  Pacifico Yokohama, Kanagawa慢性膵炎合併良性胆道狭窄に対するfully covered metallic stentの有用性  [Not invited]竹中 完; 北野雅之; 工藤正俊第52回日本胆道学会学術集会  2016/09  新横浜プリンスホテル, 神奈川経乳頭的、経皮的治療抵抗性の切除不能肝門部悪性胆道狭窄に対するEUS-guided biliary drainage (EUS-BD)の有用性, ビデオワークショップ「胆道内視鏡のトラブルシューティング」  [Not invited]竹中 完; 北野雅之; 工藤正俊第52回日本胆道学会学術集会  2016/09  新横浜プリンスホテル, 神奈川急性胆嚢炎に対するEUSガイド下胆嚢ドレナージの長期成績~長期成績からみたSEMS早期抜去の有用性~, ワークショップ2「胆道疾患に対する超音波内視鏡の有用性」  [Not invited]鎌田 研; 北野雅之; 工藤正俊第52回日本胆道学会学術集会  2016/09  新横浜プリンスホテル, 神奈川胆嚢病変の治療方針決定における造影ハーモニックEUSの有用性  [Not invited]鎌田 研; 北野雅之; 工藤正俊第52回日本胆道学会学術集会  2016/09  新横浜プリンスホテル, 神奈川Chair; Luncheon Seminar 3 “Significance of anti-viral therapy in patients with HCV-related HCC”  [Invited]Masatoshi Kudo12th JSH Single Topic Conference  2016/09  Hotel Nikko Kanazawa, Kanazawachair; The position of molecular target therapy in HCC, now and future  [Invited]Masatoshi Kudo12th Japan Society of Hepatology  2016/09  Hotel Nikko KanazawaUS-US fusion imaging in radiofrequency ablation therapy for hepatocellular carcinoma  [Not invited]Minami Y; Nishida N; Kudo MThe 12th JSH Single Topic Conference  2016/09  Hotel Nikko Kanazawa, KanazawaInvited Lecture “New subclassification and treatment strategy for intermediate stage HCC”  [Invited]Masatoshi Kudothe 12th JSH Single Topic Conference  2016/09  Hotel Nikko Kanazawa, KanazawaTreatment patterns in >3000 sorafenib-treated patients: final analysis of GIDEON (Global Investigation of therapeutic DEcisions in hepatocellular carcinoma and Of its treatment with sorafeNib)  [Not invited]Ye SL; Lencioni R; Marrero JA; Venook AP; Nakajima K; Kudo MThe 19th Annual Meeting of Chinese Society of Clinical Oncology (CSCO)  2016/09主膵管の著名な拡張を呈したIPMNの一例  [Not invited]森本真衣; 高山政樹; 岡崎能久; 秦 康倫; 木下大輔; 奥田英之; 川崎俊彦; 水野成人; 古形修平; 辻江正徳; 井上雅智; 若狭朋子; 太田善夫; 工藤正俊日本消化器病学会近畿支部第105回例会  2016/09  大阪国際交流センター, 大阪透析患者の胃粘膜組織から炭酸ランタン沈着を証明できた一例  [Not invited]橋本有人; 松井繁長; 岡本寿樹; 河野匡志; 田中梨絵; 山田光成; 足立哲平; 峯 宏昌; 永井知行; 米田頼晃; 朝隈 豊; 櫻井俊治; 渡邉智裕; 樫田博史; 工藤正俊; 榎木英介; 木村雅友日本消化器病学会近畿支部第105回例会  2016/09  大阪国際交流センター, 大阪急性胆嚢炎に対する超音波内視鏡下胆嚢ドレナージ術, ワークショップ2「胆膵疾患診断および治療の最近の進歩」  [Not invited]鎌田 研; 竹中 完; 北野雅之; 工藤正俊日本消化器病学会近畿支部第105回例会  2016/09  大阪国際交流センター, 大阪肝細胞癌治療アルゴリズムの検討. パネルディスカッション「肝細胞癌の治療アルゴリズムをめぐる諸問題」  [Not invited]有住忠晃; 上嶋一臣; 西田直生志; 工藤正俊日本消化器病学会近畿支部第105回例会  2016/09  大阪国際交流センター, 大阪大腸潰瘍の治療法選択におけるJNET分類の診断能に関する検討. シンポジウム2「大腸腫瘍の診断・治療における戦略と展望」  [Not invited]米田頼晃; 樫田博史; 工藤正俊日本消化器病学会近畿支部第105回例会  2016/09  大阪国際交流センター, 大阪開会/閉会の挨拶  [Invited]工藤正俊南大阪肝疾患診療連携セミナー  2016/09  スイスホテル南海大阪, 大阪座長: 特別講演「世界初の核酸型"チェインターミネーター"100%駆除を目指して」  [Invited]工藤正俊南大阪肝疾患診療連携セミナー  2016/09  スイスホテル南海大阪, 大阪Prospective randomized controlled phase III trial comparing the efficacy of sorafenib versus sorafenib in combination with low-dose cisplatin/fluorouracil hepatic arterial infusion chemotherapy in patients with advanced hepatocellular carcinoma  [Not invited]Kudo M; Ueshima K; Yokosuka O; Obi S; Izumi N; Aikata H; Nagano H; Hatano E; Sasaki Y; Hino K; Kumada T; Yamamoto K; Imai Y; Iwadou S; Ogawa C; Okusaka T; Arai Y; Kanai F; Akazawa K10th Annual Conference International Liver Cancer Association (ILCA)  2016/09  Vancouver, CanadaPatients benefit from treatment with sorafenib for more than 28 weeks: analysis from the GIDEON study according to duration of treatment  [Not invited]Ye SL; Lencioni R; Nakajima K; Kudo M10th Annual Conference International Liver Cancer Association (ILCA)  2016/09  Vancouver, CanadaValidation of a proposed substaging system for patients with intermediate hepatocellular carcinoma  [Not invited]Arizumi T; Ueshima K; Kudo M10th Annual Conference International Liver Cancer Association (ILCA)  2016/09  Vancouver, CanadaNew technology to detect of tumor-feeding branches and simulate embolization area of hepatocellular carcinoma with SYNAPSE VINCENT durint transcatheter arterial chemoembolization  [Not invited]Ogawa C; Shibatoge M; Kudo M10th Annual Conference International Liver Cancer Association (ILCA)  2016/09  Vancouver, CanadaA randomized, double-blind, placebo-controlled phase III study of ramucirumab versus placebo as second-line treatment in patients with hepatocellular carcinoma and elevated baseline alpha-fetoprotein following first-line sorafenib (REACH-2)  [Not invited]Zhu AX; Galle PR; Kudo M; Finn RF; Yang L; Abada PB; Llovet JM10th Annual Conference International Liver Cancer Association (ILCA)  2016/09  Vancouver, CanadaAn international observational study to assess the use of sorafenib after transarterial chemoembolization (TACE) in patients with hepatocellular carcinoma (HCC): OPTIMIS interim analysis  [Not invited]Cheng AL; Raoul JL; Lee HC; Kudo M; Nakajima K; Peck-Radosavljevic M on; behalf of the; OPTIMIS Investigators10th Annual Conference International Liver Cancer Association (ILCA)  2016/09  Vancouver, CanadaA propensity score analysis on survival benefit of liver resection for hepatocellular carcinoma associated with portal vein invasion using nationwide survey data in Japan  [Not invited]Kokudo N; Kokudo T; Hasegawa K; Matsuyama Y; Takayama T; Kadoya M; Kudo M; Ku Y; Sakamoto M; Nakashima O; Kaneko S; Izumi N10th Annual Conference International Liver Cancer Association (ILCA)  2016/09  Vancouver, CanadaSafety and antitumour activity of Nivolumab (Nivo) in patients with advanced hepatocellular carcinoma (HCC): Interim analysis of dose-expansion cohorts from the phase 1/2 checkmate-040 study  [Not invited]Sangro B; Melero I; Yau T; Hsu C; Kudo M; Crocenzi T; Kim TY; Choo SP; Trojan J; Meyer T; Kang YK; Anderson J; dela Cruz C; Lang L; Neely J; El-Khoueiry A10th Annual Conference International Liver Cancer Association (ILCA)  2016/09  Vancouver, CanadaNew subclassification of intermediate stage HCC: Analysis of 46,997 Japanese HCC patients from a nationwide survey of the Liver Cancer Study Group of Japan  [Not invited]Ueshima K; Kudo M; Izumi N; Kadoya M; Kaneko S; Ku Y; Kokudo N; Takayama T; Sakamoto M; Nakashima O; Matsuyama Y10th Annual Conference International Liver Cancer Association (ILCA)  2016/09  Vancouver, CanadaChair: ILCA Symposium 2 “Controversies in Liver Cancer”  [Invited]Masatoshi KudoILCA 10th Annual Conference 2016  2016/09  Fairmont Hotel Vancouver, Canadaラジオ出演「C型肝炎について」  [Invited]工藤正俊ラジオ大阪(番組名: 高岡美樹のべっぴんラジオ)  2016/08特別講演「Intermediate Stage 肝癌の多様性と治療戦略」  [Invited]工藤正俊TACE Refractory Focus Expert Meeting  2016/08  JRクレメントホテル高松, 香川座長: 特別講演  [Invited]工藤正俊第58回京都肝疾患懇話会  2016/07  京都ホテルオークラ, 京都Invited Lecture “Global GIDEON data: subgroup analysis of sorafenib dosing pattern in patients with unresectable hepatocellular carcinoma”  [Invited]Masatoshi Kudo14th Annual Meeting of the Japanese Society of Medical Oncology  2016/07  Kobe International Exhibition Hall/Kobe International Conference CenterInvited Lecture “Global GIDEON data: subgroup analysis of sorafenib dosing pattern in patients with unresectable hepatocellular carcinoma”  [Invited]Masatoshi Kudo14th Annual Meeting of the Japanese Society of Medical Oncology  2016/07  Kobe International Exhibition Hall/Kobe International Conference CenterChair; Poster Session “Hepatoma/HCC, Biliary Tract Cancer”  [Invited]Masatoshi Kudo14th Annual Meeting of the Japanese Society of Medical Oncology  2016/07  Kobe International Exhibition Hall/Kobe International Conference Center画像コメンテーター: 肝「炎症を伴う肝腫瘤性病変(非腫瘍性・腫瘍性を含む)」  [Invited]工藤正俊第17回臨床消化器病研究会  2016/07  東京ビッグサイト, 東京Special Lecture “Role of EOB-MRI in the management of HCC”  [Invited]Masatoshi KudoBayer Sponsored Meeting From Diagnosis to Treatment, 7th Asia-Pacific Primary Liver Cancer Expert Meeting (APPLE)  2016/07  Crowne Plaza Hong Kong Kowloon EastChair; Session 17: State-of-the Art Lecture “Systemic Therapy for HCC – The Future and Beyond”  [Invited]Masatoshi KudoThe 7th Asia-Pacific Primary Liver Cancer Expert Meeting (APPLE)  2016/07  Crowne Plaza Hong Kong Kowloon East, Hong KongA randomized, double-blind, placebo-controlled phase III study of ramucirumab versus placebo as second-line treatment in patients with hepatocellular carcinoma and elevated baseline alpha-fetoprotein following first-line Sorafenib (REACH-2)  [Not invited]Zhu AX; Galle PR; Kudo M; Finn RS; Yang L; Abada PB; Llovet JM7th Asia-Pacific Primary Liver Cancer Expert Meeting (APPLE)  2016/07  Crowne Plaza Hong Kong Kowloon EastChair; Session 14: Debate Session  [Invited]Masatoshi KudoThe 7th Asia-Pacific Primary Liver Cancer Expert Meeting (APPLE)  2016/07  Crowne Plaza Hong Kong Kowloon East, Hong KongChair; Consensus Workshop2 “Role of Chemotherapy in HCC”  [Invited]Masatoshi KudoThe 7th Asia-Pacific Primary Liver Cancer Expert Meeting (APPLE)  2016/07  Crowne Plaza Hong Kong Kowloon EastEasy detection of tumor-feeding branches of hepatocellular carcinoma with SYNAPSE VINCENT during transcatheter arterial chemoembolization  [Not invited]Ogawa C; Shibatoge M; Kudo M7th Asia-Pacific Primary Liver Cancer Expert Meeting (APPLE)  2016/07  Crowne Plaza Hong Kong Kowloon EastSafety and antitumor activity of Nivolumab (Nivo) in patients (pts) with advanced hepatocellular carcinoma (HCC): Interim analysis of dose-expansion cohorts from the Phase 1/2 CheckMate-040 study  [Not invited]Sangro B; Melero I; Yau T; Hsu C; Kudo M; Crocenzi TS; Kim TY; Choo SP; Trojan J; Meyer T; Kang YK; Anderson J; dela Cruz C; Lang L; Neely J; El-Khoueiry AB7th Asia-Pacific Primary Liver Cancer Expert Meeting (APPLE)  2016/07  Crowne Plaza Hong Kong Kowloon EastState-of-the Art Lecture “Recent Advancement in HCC Treatment”  [Invited]Masatoshi Kudo7th Asia-Pacific Primary Liver Cancer Expert Meeting (APPLE)  2016/07  Crowne Plaza Hong Kong Kowloon EastChair; Consensus Workshop2 “Role of Chemotherapy in HCC”  [Invited]Masatoshi KudoThe 7th Asia-Pacific Primary Liver Cancer Expert Meeting (APPLE)  2016/07  Crowne Plaza Hong Kong Kowloon EastNASH関連肝発癌における線維化進展と遺伝子変化. ワークショップ2「非ウイルス性肝細胞癌の病態と分類」  [Not invited]萩原 智; 西田直生志; 工藤正俊第52回日本肝癌研究会  2016/07  虎ノ門ヒルズフォーラム, 東京門脈腫瘍栓合併肝細胞癌に対する外科的切除の意義の検討-肝癌研究会追跡調査より. パネルディスカッション3「進行肝細胞癌の治療: 切除、動注、放射線科、分子標的治療薬の役割」  [Not invited]國土貴嗣; 長谷川 潔; 松山 裕; 高山忠利; 泉 並木; 角谷眞澄; 工藤正俊; 具 英成; 坂元亨宇; 中島 収; 金子周一; 國土典宏第52回日本肝癌研究会  2016/07  虎ノ門ヒルズフォーラム, 東京予測塞栓領域を考慮したTACE治療の試み. ビデオセッション3「肝癌・背景肝の画像評」  [Not invited]小川 力; 野田晃世; 荒澤壮一; 出田雅子; 久保敦司; 石川哲朗; 松中寿浩; 玉置敬之; 芝峠光成; 工藤正俊第52回日本肝癌研究会  2016/07  虎ノ門ヒルズフォーラム, 東京ゲノム・エピゲノム・染色体情報に基づいた肝癌の亜分類と転移再発予測. パネルディスカッション2「肝細胞癌の新たなサブクラス分類と治療ストラテジー」  [Not invited]西田直生志; 海道利実; 工藤正俊第52回日本肝癌研究会  2016/07  虎ノ門ヒルズフォーラム, 東京“Proposal of new BCLC stage B subclassification”, Symposium 1 “Improvement of outcome beyond TACE in intermediate stage HCC”  [Invited]Masatoshi Kudo52nd Annual Meeting of Liver Cancer Study Group of Japan  2016/07  虎ノ門ヒルズフォーラムChair: Symposium 1 “Improvement of outcome beyond TACE in intermediate stage HCC”  [Invited]Masatoshi Kudo第52回日本肝癌研究会  2016/07  虎ノ門ヒルズフォーラム, 東京司会: ランチョンセミナー7「肝がん合併肝硬変の治療戦略」  [Invited]工藤正俊第52回日本肝癌研究会  2016/07  虎ノ門ヒルズフォーラム, 東京Efficacy and safety of regorafenib versus placebo in patients with hepatocellular carcinoma (HCC) progressing on sorafenib: Results of the international, randomized phase 3 RESORCE trial  [Not invited]Bruix J; Merle P; Granito A; Huang YH; Bodoky G; Boucher E; Yokosuka O; Rosmorduc O; Breder V; Gerolami R; Masi G; Ross P; Qin S; Song T; Bronowicki JP; Ollivier-Hourmand I; Kudo M; LeBerre MA; Baumhauer A; Meinhardt G; Han G; on behalf of; the; RESORCE investigatorsESMO 18th World Congress on Gastrointestinal Cancer 2016  2016/06  Barcelona, Spain予測塞栓領域を考慮したTACE治療の試み  [Not invited]小川 力; 野田晃世; 盛田真弘; 出田雅子; 久保敦司; 松中寿浩; 玉置敬之; 芝峠光成; 工藤正俊第16回関西肝血流動態・機能イメージ研究会  2016/06  オーバルホール, 大阪当院におけるDrug eluting bead (DEB)-TACEの現況  [Not invited]田北雅弘; 南 知宏; 千品寛和; 有住忠晃; 矢田典久; 萩原 智; 南 康範; 依田 広; 上嶋一臣; 西田直生志; 任 誠雲; 柳生行伸; 松木 充; 鶴崎正勝; 村上卓道; 工藤正俊第16回関西肝血流動態・機能イメージ研究会  2016/06  オーバルホール, 大阪教育講演「免疫チェックポイント阻害剤による肝細胞癌治療への期待」  [Invited]工藤正俊第16回関西肝血流動態・機能イメージ研究会  2016/06  オーバルホール, 大阪ネクサバールでCRが5年間持続後にSOF+RBVを行いSVR12が得られている症例  [Not invited]小川 力; 野田晃世; 出田雅子; 久保敦司; 石川哲郎; 松中寿浩; 玉置敬之; 芝峠光成; 工藤正俊第14回日本肝がん分子標的治療研究会  2016/06  スペース36, 大阪ソラフェニブ国際共同非介入試験GIDEON最終解析~日本における肝癌治療の実際~, シンポジウム2「進行肝癌に対するカテーテル治療」  [Not invited]角谷眞澄; 池田公史; 高山忠利; 沼田和司; 泉 並木; 國土典宏; 古瀬純司; 奥坂拓志; 山下哲史; 奥村正文; 工藤正俊第14回日本肝がん分子標的治療研究会  2016/06  スペース36, 大阪司会: シンポジウム2「進行肝癌に対するカテーテル治療」  [Invited]工藤正俊第14回日本肝がん分子標的治療研究会  2016/06  スペース36, 大阪Phase 1/2 study of durvalumab and tremelimumab as monotherapy and in combination in patients with unresectable hepatocellular carcinoma (HCC)  [Not invited]Abou-Alfa GK; Sangro B; Morse M; Zhu AX; Kim RD; Cheng AL; Kudo M; Kang YK; Chan SL; Antal J; Boice J; Xiao F; Morris SR; Bendell J; Study Group52nd American Society of Clinical Oncologys Annual Meeting 2016 (ASCO 2016)  2016/06  Chicago, IllinoisSurvival benefit of liver resection for hepatocellular carcinoma associated with portal vein invasion: A Japanese nationwide survey  [Not invited]Kokudo T; Hasegawa K; Matsuyama Y; Takayama T; Izumi N; Kadoya M; Kudo M; Ku Y; Sakamoto M; Nakashima O; Kaneko S; Kokudo N52nd American Society of Clinical Oncologys Annual Meeting 2016 (ASCO 2016)  2016/06  Chicago, IllinoisA randomized, double-blind, placebo-controlled phase III study of ramucirumab versus placebo as second-line treatment in patients with hepatocellular carcinoma and elevated baseline alpha-fetoprotein following first-line sorafenib (REACH-2)  [Not invited]Zhu AX; Galle PR; Kudo M; Finn RS; Yang L; Abada P; Llovet JM52nd American Society of Clinical Oncologys Annual Meeting 2016 (ASCO 2016)  2016/06  Chicago, IllinoisSafety and antitumor activity of Nivolumab (nivo) in patients (pts) with advanced hepatocellular carcinoma (HCC): interim analysis of dose-expansion cohorts from the phase 1/2 checkmate 040 study  [Not invited]Sangro B; Melero I; Yau TC; Hsu C; Kudo M; Crocenzi TS; Kim TY; Choo SP; Trojan J; Meyer T; Kang YK; Anderson J; Dela Cruz C; Lang L; Neely J; El-Khoueiry AB52nd American Society of Clinical Oncologys Annual Meeting 2016 (ASCO 2016)  2016/06  Chicago, IllinoisUsefulness of contrast-ehnaced ultrasonography with sonazoid in the preperative evaluation of histological differentiation and gross types of hepatocellular carcinoma  [Not invited]Ogawa C; Minami Y; Kudo M8th Asian Conference on Ultrasound Contrast Imaging (ACUCI), 12th Congress of the Asian Federation of Societies for Ultrasound in Medicine and Biology (AFSUMB), 89th annual meeting of the Japan Society of Ultrasonics in Medicine (JSUM)(Ultrasonic Week 201  2016/05  Kyoto International Conference Center, Kyoto造影ハーモニックEUSの定量的血流評価による膵腫瘍診断, シンポジウム 消化器3「胆膵疾患の造影エコー診断up-to-date」  [Not invited]大本俊介; 北野雅之; 工藤正俊日本超音波医学会第89回学術集会, 第36回日本乳腺甲状腺超音波医学会学術集会, アジア超音波医学生物学会第12回学術集会(AFSUMB), アジア造影超音波会議第8回学術集会(ACUCI)(Ultrasonic Week 2016)  2016/05  国際京都国際会館, 京都転移性肝癌に対するUS-US fusionを用いたラジオ波焼灼術. シンポジウム領域横断2「Image Fusionは診断能・治療成績をどの様に向上させたか?」  [Not invited]南 知宏; 南 康範; 工藤正俊日本超音波医学会第89回学術集会, 第36回日本乳腺甲状腺超音波医学会学術集会, アジア超音波医学生物学会第12回学術集会(AFSUMB), アジア造影超音波会議第8回学術集会(ACUCI)(Ultrasonic Week 2016)  2016/05  国際京都国際会館, 京都シミュレーション機能を用いた超音波検査の教育体制. シンポジウム領域横断2「Image Fusionは診断能・治療成績をどの様に向上させたか?」  [Not invited]小川 力; 荒澤壮一; 芝峠光成; 西田知紗; 村上佳子; 河合直之; 丸山哲夫; 木太秀行; 大西宏明; 工藤正俊日本超音波医学会第89回学術集会, 第36回日本乳腺甲状腺超音波医学会学術集会, アジア超音波医学生物学会第12回学術集会(AFSUMB), アジア造影超音波会議第8回学術集会(ACUCI)(Ultrasonic Week 2016)  2016/05  国際京都国際会館, 京都超音波で観察し得た小児における腸重責症の検討  [Not invited]前野知子; 横川美加; 市島真由美; 塩見香織; 前川 清; 南 康範; 樫田博史; 工藤正俊; 八木 誠日本超音波医学会第89回学術集会, 第36回日本乳腺甲状腺超音波医学会学術集会, アジア超音波医学生物学会第12回学術集会(AFSUMB), アジア造影超音波会議第8回学術集会(ACUCI)(Ultrasonic Week 2016)  2016/05  国際京都国際会館, 京都低音圧Tissue Harmonic Imagingによる造影超音波の検討  [Not invited]横川美加; 前野知子; 塩見香織; 前川 清; 矢田典久; 依田 広; 南 康範; 樫田博史; 工藤正俊日本超音波医学会第89回学術集会, 第36回日本乳腺甲状腺超音波医学会学術集会, アジア超音波医学生物学会第12回学術集会(AFSUMB), アジア造影超音波会議第8回学術集会(ACUCI)(Ultrasonic Week 2016)  2016/05  国際京都国際会館, 京都EUS-guided interventions for walled-off pancreatic necrosis: clinical outcomes of a step-up approach and risk factors for failed endoscopic treatment. シンポジウム 消化器Joint「Role of EUS in diagnosis and treatment of digestive diseases」  [Not invited]Minaga K; Kitano M; Imai H; Yamao K; Kamata K; Miyata T; Matsuda T; Omoto S; Kadosaka K; Kudo M日本超音波医学会第89回学術集会, 第36回日本乳腺甲状腺超音波医学会学術集会, アジア超音波医学生物学会第12回学術集会(AFSUMB), アジア造影超音波会議第8回学術集会(ACUCI)(Ultrasonic Week 2016)  2016/05  国際京都国際会館, 京都Utility of endoscopic ultrasonography for follow-up of IPMN. シンポジウム 消化器Joint「Role of EUS in diagnosis and treatment of digestive diseases」  [Not invited]Kamata K; Kitano M; Kudo M日本超音波医学会第89回学術集会, 第36回日本乳腺甲状腺超音波医学会学術集会, アジア超音波医学生物学会第12回学術集会(AFSUMB), アジア造影超音波会議第8回学術集会(ACUCI)(Ultrasonic Week 2016)  2016/05  国際京都国際会館, 京都Shear wave imagingによる非アルコール性脂肪性肝疾患の病態診断, シンポジウム 消化器2「消化器領域におけるエラストグラフィーの最先端」  [Not invited]矢田典久; 工藤正俊日本超音波医学会第89回学術集会, 第36回日本乳腺甲状腺超音波医学会学術集会, アジア超音波医学生物学会第12回学術集会(AFSUMB), アジア造影超音波会議第8回学術集会(ACUCI)(Ultrasonic Week 2016)  2016/05  国際京都国際会館, 京都日本超音波医学会理事長としてキャリア支援を考える. 医師の立場から, パネルディスカッション領域横断3「日本超音波医学会が取り組むキャリア支援(JSUM男女共同参画委員会共同企画)  [Invited]工藤正俊日本超音波医学会第89回学術集会, 第36回日本乳腺甲状腺超音波医学会学術集会, アジア超音波医学生物学会第12回学術集会(AFSUMB), アジア造影超音波会議第8回学術集会(ACUCI)(Ultrasonic Week 2016)  2016/05  国際京都国際会館, 京都日本超音波医学会男女共同参画委員会 アンケート調査報告. パネルディスカッション領域横断3「日本超音波医学会が取り組むキャリア支援(JSUM男女共同参画委員会共同企画)  [Invited]赤坂和美; 工藤正俊; 飯島尋子; 上原麻理子; 斎藤明子; 椎名 毅; 高野真澄; 谷口信行; 畠 二郎; 平井都始子; 古川まどか; 山口 匡日本超音波医学会第89回学術集会, 第36回日本乳腺甲状腺超音波医学会学術集会, アジア超音波医学生物学会第12回学術集会(AFSUMB), アジア造影超音波会議第8回学術集会(ACUCI)(Ultrasonic Week 2016)  2016/05  国際京都国際会館, 京都US-US image fusion in radiofrequency ablation therapy for hepatocellular carcinoma  [Invited]Minami Y; Minami T; Kudo M8th Asian Conference on Ultrasound Contrast Imaging (ACUCI), 12th Congress of the Asian Federation of Societies for Ultrasound in Medicine and Biology (AFSUMB), 89th annual meeting of the Japan Society of Ultrasonics in Medicine (JSUM)(Ultrasonic Week 201  2016/05  Kyoto International Conference CenterNew US technology using 3D volume analyzer synapse VINCENT  [Invited]Ogawa C; Minami Y; Kudo M8th Asian Conference on Ultrasound Contrast Imaging (ACUCI), 12th Congress of the Asian Federation of Societies for Ultrasound in Medicine and Biology (AFSUMB), 89th annual meeting of the Japan Society of Ultrasonics in Medicine (JSUM)(Ultrasonic Week 201  2016/05  Kyoto International Conference Center, Kyoto, JapanContrast-enhanced harmonic EUS for pancreatic diseases  [Invited]Kitano M; Kamata K; Omoto S; Minaga K; Yamao K; Imai H; Takenaka M; Kudo M8th Asian Conference on Ultrasound Contrast Imaging (ACUCI), 12th Congress of the Asian Federation of Societies for Ultrasound in Medicine and Biology (AFSUMB), 89th annual meeting of the Japan Society of Ultrasonics in Medicine (JSUM)(Ultrasonic Week 201  2016/05  Kyoto International Conference Center, Kyoto, Japanカラー表示RVSを用いた小HCCの診断、およびRFAの治療効果判定  [Not invited]小川 力; 野田晃世; 荒澤壮一; 出田雅子; 久保敦司; 石川哲朗; 松中寿浩; 玉置敬之; 柴峠光成; 工藤正俊第102回日本消化器病学会総会  2016/04  京王プラザホテル, 東京トルバプタンにおける初期、および遅発性効果予測因子の検討  [Not invited]萩原 智; 千品寛和; 工藤正俊第102回日本消化器病学会総会  2016/04  日本消化器病学会総会, 平成28年4月21-23日,US-US fusionを用いた肝細胞癌へのラジオ波焼灼術と治療効果判定, ワークショップ9「新規技術を用いた肝疾患診療の未来~診断から治療へ」  [Not invited]南 康範; 南 知宏; 工藤正俊第102回日本消化器病学会総会  2016/04  京王プラザホテル, 東京PD-L1陽性肝癌の臨床病理学的特徴と遺伝子変異プロファイル  [Not invited]西田直生志; 工藤正俊第103回日本消化器病学会総会  2016/04座長; ランチョンセミナー12「C型肝炎治療におけるDAAの選択基準」  [Invited]工藤正俊第102回日本消化器病学会総会  2016/04  京王プラザホテル, 東京既存治療の効果予測の可能性, プレナリーセッション「IBD 臨床」  [Not invited]櫻井俊治; 樫田博史; 工藤正俊第102回日本消化器病学会総会  2016/04  京王プラザホテル, 東京BCLC Bの細分類と治療選択. パネルディスカッション9: Intermediateから進行肝細胞癌治療の最前線」  [Not invited]有住忠晃; 上嶋一臣; 工藤正俊第102回日本消化器病学会総会  2016/04  京王プラザホテル, 東京司会: パネルディスカッション9: Intermediateから進行肝細胞癌治療の最前線  [Invited]工藤正俊2016/04  京王プラザホテル, 東京大腸腫瘍診断・治療におけるJNET分類の試用結果. パネルディスカッション8「大腸腫瘍の治療法選択としての画像強調観察の意義」  [Not invited]米田頼晃; 樫田博史; 工藤正俊第102回日本消化器病学会総会  2016/04  京王プラザホテル, 東京術後胃に発生した胃石症の特徴と治療  [Not invited]岡元寿樹; 松井繁長; 田中梨絵; 山田光成; 足立哲平; 高山政樹; 峯 宏昌; 永井知行; 岡崎能久; 米田頼晃; 朝隈 豊; 櫻井俊治; 樫田博史; 工藤正俊第102回日本消化器病学会総会  2016/04  京王プラザホテル, 東京An objective model to optimize treatment decisions in advanced hepatocellular carcinoma after sorafenib failure: the SORFA score  [Not invited]Pinato DJ; Yen C; Arizumi T; Giarda P; Howell J; Ramaswami R; Burlone ME; Kudo M; Pirisi M; Sharma RThe International Liver Congress 2016  2016/04  Barcelona, SpainRamucirumab as second-line treatment in patients with advanced hepatocellular carcinoma: Analysis of REACH patients by albumin-bilirubin (ALBI) grade  [Not invited]Blanc JF; Chan SL; Park JO; Ryoo BY; Yen CJ; Kudo M; Poon R; Pastorelli D; Baran A; Pfiffer T; Okusaka T; Kubackova K; Trojan J; Sastre J; Chau I; Abada P; Chang SC; Yang L; Zhu AThe International Liver Congress 2016  2016/04  Barcelona, SpainProspective randomized controlled phase III trial comparing the efficacy of sorafenib versus sorafenib in combination with low-dose cisplatine/fluorouracil hepatic arterial infusion chemotherapy in patients with advanced hepatocellular carcinoma  [Not invited]Kudo M; Ueshima K; Yokosuka O; Obi S; Izumi N; Aikata H; Nagano H; Hatano E; Sasaki Y; Hino K; Kumada T; Yamamoto K; Imai Y; Iwadou S; Ogawa C; Okusaka T; Arai Y; Kanai F; Akazawa K; SILIUS Study GroupThe International Liver Congress 2016  2016/04  Barcelona, Spain特別講演「Intermediate Stage肝癌の細分類と免疫チェックポイント阻害剤への期待」  [Invited]工藤正俊第4回奈良消化器病セミナー  2016/04  橿原ロイヤルホテル, 奈良座長: 特別講演「DAAで広がるC型肝炎治療~治療困難例への取り組み~」  [Invited]工藤正俊南大阪HCV治療セミナー  2016/04  ホテルモントレグラスミア大阪, 大阪膵神経内分泌腫瘍診断における造影ハーモニックEUSの有用性  [Not invited]大本俊介; 北野雅之; 工藤正俊第29回日本腹部造影エコー・ドプラ診断研究会  2016/04  宮崎市エムアールティ・ミック, 北九州病変の視認性に着目した肝腫瘍に対する低音圧造影tissue harmonic imaging (low MI CE-THI)の検討  [Not invited]河野匡志; 南 康範; 工藤正俊第29回日本腹部造影エコー・ドプラ診断研究会  2016/04  宮崎市エムアールティ・ミック, 北九州ラジオ波焼灼術後のバブルによる高エコー域を壊死部とみなして良いか?  [Not invited]南 康範; 岩西美奈; 南 知宏; 千品寛和; 河野匡志; 有住忠晃; 田北雅弘; 矢田典久; 萩原 智; 上嶋一臣; 西田直生志; 工藤正俊第29回日本腹部造影エコー・ドプラ診断研究会  2016/04  宮崎市エムアールティ・ミック, 北九州特別講演「肝細胞癌に対する新規分子標的薬の開発動向と免疫チェックポイント阻害薬への期待」  [Invited]工藤正俊第18回北九州肝癌治療研究会  2016/03  リーガロイヤルホテル小倉, 北九州座長: C型肝炎の新たな治療選択~ヴィキラックスを含めた今後のDAAs治療戦略~  [Invited]工藤正俊アッヴィ肝炎フォーラム  2016/03  スイスホテル南海大阪, 大阪Invited Lecture “Hepatocellular cancer drug development”  [Invited]Masatoshi Kudo8th Annual Asian Oncology Summit (AOS 2016)  2016/03  Kyoto International Community House, Kyoto, JapanPractice patterns, sorafenib dosing and safety in Asian hepatocellular carcinoma patients in GIDEON  [Not invited]Kudo M; Venook A; Lencioni R; Ye SL; Nakajima K; Marrero J25th Conference of the Asian Pacific Association for the Study of the Liver (APASL)  2016/02  International Convention Center Pamir, Tokyo, JapanRegional differences in practice patterns among countries, Luncheon Symposium “New light on the integration of evidence into practice”  [Invited]Masatoshi Kudo25th Conference of the Asian Pacific Association for the Study of the Liver (APASL)  2016/02  International Convention Center Pamir, Tokyo, JapanBiomarker and Imaging Diagnosis of HCC. Symposium 11 “Update of HCC Treatment”  [Not invited]Masatoshi Kudo25th Conference of the Asian Pacific Association for the Study of the Liver (APASL)  2016/02  International Convention Center Pamir, Tokyo, JapanInvited Lecture “Non-Curative Treatment (TACE/Sorafenib) of HCC”  [Invited]Masatoshi Kudo25th Conference of the Asian Pacific Association for the Study of the Liver (APASL)  2016/02  International Convention Center Pamir, Tokyo, JapanRegional Differences in the Use of Transarterial Chemoembolization (TACE) in HCC: Interim Analysis of OPTIMIS, an International Observational Study Assessing the Use of Sorafenib After TACE  [Not invited]Lee HC; Cheng AL; Raoul JL; Peck-Radosavljevic M; Nakajima K; Kudo M; on behalf of the; OPTIMIS Investigators25th Conference of the Asian Pacific Association for the Study of the Liver (APASL)  2016/02  International Convention Center Pamir, Tokyo, JapanInvited Lecture “Immuno-oncology for HCC: Beyond the target therapy”  [Invited]Masatoshi Kudothe 1st anniversary International Symposium of Yonsei Liver Center  2016/02  Newilhan Memorial Hall, Avision BioMedical Research Center, Korea開会の挨拶  [Not invited]工藤正俊日本肝臓学会主催平成27年度「肝がん撲滅運動」  2016/02  堺商工会議所, 大阪司会  [Invited]工藤正俊第4回ディーシービーズ検討会~DEB-TACEの可能性を探る~  2016/02  東京ビッグサイト, 東京特別講演「Intermediate Stageの細分類」  [Invited]工藤正俊第4回ディーシービーズ検討会~DEB-TACEの可能性を探る~  2016/02  東京ビッグサイト, 東京当院でのダクラタスビル/アスナプレビル併用療法の検討  [Not invited]千品寛和; 萩原 智; 岩西美奈; 南 知宏; 有住忠晃; 田北雅弘; 北井 聡; 矢田典久; 依田 広; 南 康範; 上嶋一臣; 西田直生志; 工藤正俊日本消化器病学会近畿支部第104回例会  2016/02  大阪国際交流センター, 大阪造影ハーモニックEUS画像と病理組織像の対比・検討を行った胆嚢癌の一例  [Not invited]吉川智恵; 鎌田 研; 北野雅之; 大本俊介; 門阪薫平; 松田友彦; 三長孝輔; 宮田 剛; 山雄健太郎; 今井 元; 工藤正俊; 榎木英介; 木村雅友日本消化器病学会近畿支部第104回例会  2016/02  大阪国際交流センター, 大阪術前診断が困難であった腸間膜悪性リンパ腫の一例  [Not invited]秦 康倫; 木下大輔; 奥田英之; 高山政樹; 末吉功冶; 岸谷 譲; 川崎俊彦; 水野成人; 辻江正徳; 井上雅智; 若狭朋子; 太田善夫; 工藤正俊日本消化器病学会近畿支部第104回例会  2016/02  大阪国際交流センター, 大阪漢方薬服用者に見られた突発性腸間膜静脈硬化症の2例  [Not invited]岡元寿樹; 樫田博史; 米田頼晃; 河野匡志; 田中梨絵; 山田光成; 足立哲平; 峯 宏昌; 永井知行; 岡崎能久; 朝隈 豊; 櫻井俊治; 松井繁長; 工藤正俊日本消化器病学会近畿支部第104回例会  2016/02  大阪国際交流センター, 大阪自己免疫性溶血性貧血を合併した自己免疫性肝炎の一例  [Not invited]岩西美奈; 依田 広; 高島耕太; 南 知宏; 千品寛和; 有住忠晃; 田北雅弘; 北井 聡; 矢田典久; 萩原 智; 南 康範; 上嶋一臣; 西田直生志; 工藤正俊; 平瀬主税; 前西 修; 筑後孝章日本消化器病学会近畿支部第104回例会  2016/02  大阪国際交流センター, 大阪若年男性に発症した肝細胞腺腫の悪性転化の一例  [Not invited]南 知宏; 萩原 智; 岩西美奈; 千品寛和; 有住忠晃; 田北雅弘; 北井 聡; 矢田典久; 南 康範; 依田 広; 上嶋一臣; 西田直生志; 工藤正俊日本消化器病学会近畿支部第104回例会  2016/02  大阪国際交流センター, 大阪潰瘍性大腸炎症例における重症度別の栄養指標と術後経過の検討. ワークショップ2「消化器疾患の栄養療法」  [Not invited]峯 宏昌; 松井繁長; 樫田博史; 工藤正俊日本消化器病学会近畿支部第104回例会  2016/02  大阪国際交流センター, 大阪周在性の大きな食材表在癌に対する内視鏡治療の有用性. ワークショップ1「消化器腫瘍に対する低侵襲治療」  [Not invited]朝隈 豊; 松井繁長; 樫田博史; 工藤正俊日本消化器病学会近畿支部第104回例会  2016/02  大阪国際交流センター, 大阪膵神経内分泌腫瘍診断におけるEUSの有用性. シンポジウム1「神経内分泌腫瘍の診断と治療」  [Not invited]大本俊介; 北野雅之; 工藤正俊日本消化器病学会近畿支部第104回例会  2016/02  大阪国際交流センター, 大阪直腸NETの内視鏡治療. シンポジウム1「神経内分泌腫瘍の診断と治療」  [Not invited]山田光成; 樫田博史; 米田頼晃; 工藤正俊本消化器病学会近畿支部第104回例会  2016/02  大阪国際交流センター, 大阪USが肝細胞癌との鑑別に有用と思われたリンパ増殖性疾患が疑われた肝腫瘍の一例  [Not invited]出田雅子; 小川 力; 三野 智; 野田晃世; 荒澤壮一; 久保敦司; 石川哲朗; 松中寿浩; 玉置敬之; 柴峠光成; 隈部 力; 中島 収; 工藤正俊第22回肝血流動態・機能イメージ研究会  2016/02  東京ビッグサイト「国際会議場」, 東京次世代型Shear wave imaging測定値の信憑性を表す指標VsNの有用性について  [Not invited]矢田典久; 工藤正俊第22回肝血流動態・機能イメージ研究会  2016/02  東京ビッグサイト「国際会議場」, 東京Color RVSを用いたRFAの治療効果判定  [Not invited]小川 力; 野田晃世; 荒澤壮一; 出田雅子; 久保敦司; 石川哲朗; 松中寿浩; 玉置敬之; 柴峠光成; 工藤正俊第22回肝血流動態・機能イメージ研究会  2016/02  東京ビッグサイト「国際会議場」, 東京座長: 画像による病態解明・造影技術  [Invited]工藤正俊第22回肝血流動態・機能イメージ研究会  2016/02  東京ビッグサイト, 東京高齢者の進行肝細胞癌に対する当院でのソラフェニブ治療の成績  [Invited]有住忠晃; 上嶋一臣; 南 知宏; 千品寛和; 河野匡志; 田北雅弘; 北井 聡; 矢田典久; 萩原 智; 南 康範; 櫻井俊治; 西田直生志; 工藤正俊第11回日本肝がん分子標的治療研究会  2016/01  海運クラブ, 東京司会"肝細胞癌の臨床試験はなぜ上手くいかないのか"  [Invited]工藤正俊第11回日本肝がん分子標的治療研究会  2016/01  海運クラブ, 東京開会の挨拶  [Invited]工藤正俊第11回日本肝がん分子標的治療研究会  2016/01  海運クラブ, 東京特別講演「Intermediate肝癌の細分類と新しい分子標的薬への期待」  [Invited]工藤正俊第12回九州C型肝炎研究会  2016/01  ホテル日航福岡, 九州開会の挨拶  [Invited]工藤正俊第34回南大阪肝疾患研究会  2016/01  ホテル・アゴーラリージェンシー堺, 大阪座長: 特別講演「肝細胞がんサーベイランスにおける血清マーカーの役割」  [Invited]工藤正俊第1回大阪がんフォーラム  2016/01  ウェスティンホテル大阪, 大阪Regional differences in efficacy/safety/biomarkers in a randomised study of axitinib in 2nd line patients (pts) with advanced hepatocellular carcinoma (HCC)  [Not invited]Masatoshi KudoAmerican Society of Clinical Oncology, 2016 Gastrointestinal Cancers Symposium (ASCO GI 2016)  2016/01  San Francisco, USAIdentification of a high-response patient population to S-1 via predictive enrichment strategy analysis of the S-CUBE phase III trial  [Not invited]Kudo M; Okusaka T; Kaneko S; Furuse J; Takeuchi M; Fang X; Date Y; Takeuchi MAmerican Society of Clinical Oncology, 2016 Gastrointestinal Cancers Symposium (ASCO GI 2016)  2016/01  San Francisco, USAA randomized, double-blind, placebo-controlled phase III study of ramucirumab versus placebo as second-line treatment in patients with hepatocellular carcinoma and elevated baseline alpha-fetoprotein following first-line sorafenib (REACH-2)  [Not invited]Zhu A; Galle PR; Kudo M; Finn RS; Yang L; Abada P; Chang SC; Llovet JMAmerican Society of Clinical Oncology, 2016 Gastrointestinal Cancers Symposium (ASCO GI 2016)  2016/01  San Francisco, USAUsefulness of serum procalcitonin for diagnosis of acute pancreatitis  [Not invited]Omoto S; Kitano M; Sakamoto H; Imai H; Yamao K; Kamata K; Miyata T; Minaga K; Kadosaka K; Kudo MAsian Pacific Digestive Week (APDW 2016)  2015/12  Taipei, TaiwanThe analysis of three cases that gastrointestinal bezoars have history of gastrointestinal surgery  [Not invited]Okamoto K; Matsui S; Tanaka R; Yamada M; Adachi T; Takayama M; Mine H; Nagai T; Okazaki Y; Komeda Y; Asakuma Y; Sakurai T; Kashida H; Kudo MAsian Pacific Digestive Week (APDW 2016)  2015/12  Taipei, TaiwanTreatment of colorectal LST: focus on EMR techniques  [Not invited]Komeda Y; Kashida H; Sakurai T; Asakuma Y; Okazaki Y; Nagai T; Mine H; Adachi T; Tanaka R; Yamada M; Kono M; Okamoto K; Matsui S; Kudo MAsian Pacific Digestive Week (APDW 2016)  2015/12  Taipei, TaiwanA case of endoscopic mucosal resection for gastric perineurioma  [Not invited]Kono M; Matsui S; Okamoto K; Yamada M; Tanaka R; Adachi T; Mine H; Nagai T; Okazaki Y; Komeda Y; Asakuma Y; Sakurai T; Kashida H; Kudo MAsian Pacific Digestive Week (APDW 2016)  2015/12  Taipei, TaiwanEndoscopic resection for rectal nets (neuroendocrine tumors): EMR-C (EMR using a cap), EMR-L (EMR with a ligation device), or conventional EMR (EMR)  [Not invited]Yamada M; Kashida H; Komeda Y; Okamoto K; Kono M; Tanaka R; Adachi T; Mine H; Nagai T; Okazaki Y; Asakuma Y; Sakurai T; Matsui S; Kudo MAsian Pacific Digestive Week (APDW 2016)  2015/12  Taipei, Taiwan特別講演「肝癌診療のBreakthroughはあるか?」  [Invited]工藤正俊第130回宮城肝癌治療研究会  2015/11  ホテルメトロポリタン仙台, 宮城Classification of tumors based on the integrated profile of genetic and epigenetic alterations and the biological behavior of human hepatocellular carcinoma  [Not invited]Nishida N; Kaido T; Kudo M66th Annual Meeting, American Association for the Study of Liver Diseases (AASLD 2015)  2015/11  San Francisco, USA当院における上皮内癌および小膵癌の診断  [Not invited]山雄健太郎; 北野雅之; 工藤正俊; 今井 元; 鎌田 研; 宮田 剛; 大本俊介; 門阪薫平; 三長孝輔; 松田友彦; 亀井敬子; 松本逸平; 竹山宜典第64回近畿膵疾患談話会  2015/11  エーザイ株式会社大阪コミュニケーションオフィス, 大阪PALBI-an objective score based on platelets, albumin & Bilirubin Stratifies HCC patients undergoing resection & ablation better than Child’s classification  [Not invited]Roayaie S; Jibara G; Berhane S; Tabrizian P; Park JW; Yang J; Yan L; Han G; Izzo F; Chen M; Blanc JF; Kudo M; Roberts LR; Sherman M; Johnson P66th Annual Meeting, American Association for the Study of Liver Diseases (AASLD 2015)  2015/11  San Francisco, USA粘膜下腫瘍様形態を呈した胃perineuriomaの一例  [Not invited]河野匡志; 松井繁長; 樫田博史; 永井知行; 峯 宏昌; 米田頼晃; 朝隈 豊; 櫻井俊治; 工藤正俊; 筑後孝章日本消化器内視鏡学会近畿支部第95回支部例会  2015/11  大阪国際交流センター, 大阪粘膜下腫瘍様の形態を呈したhamartomatous inverted polypの一例  [Not invited]田中梨絵; 山田光成; 河野匡志; 足立哲平; 峯 宏昌; 永井知行; 朝隈 豊; 米田頼晃; 岡崎能久; 櫻井俊治; 松井繁長; 樫田博史; 工藤正俊日本消化器内視鏡学会近畿支部第95回支部例会  2015/11  大阪国際交流センター, 大阪腎癌術後18年で発見された転移性胃腫瘍の1例  [Not invited]奥田英之; 秦 康倫; 木下大輔; 高山政樹; 岸谷 譲; 川崎友彦; 水野成人; 平山暁秀; 若狭朋子; 太田善夫; 工藤正俊日本消化器内視鏡学会近畿支部第95回支部例会  2015/11  大阪国際交流センター, 大阪腸重積を来したが、内視鏡的に整復、切除し得た巨大大腸脂肪腫  [Not invited]橋本有人; 樫田博史; 米田頼晃; 河野匡志; 岡元寿樹; 山田光成; 田中梨絵; 足立哲平; 峯 宏昌; 永井知行; 岡崎能久; 朝隈 豊; 櫻井俊治; 松井繁長; 工藤正俊; 高山政樹; 川崎正憲; 榎本英介; 木村雅友; 佐藤隆夫日本消化器内視鏡学会近畿支部第95回支部例会  2015/11  大阪国際交流センター, 大阪食道疣状扁平上皮癌の一例. ワークショップ2「希少消化器疾患の内視鏡像」  [Not invited]岡元寿樹; 松井繁長; 工藤正俊日本消化器内視鏡学会近畿支部第95回支部例会  2015/11  大阪国際交流センター, 大阪造影ハーモニックEUSによる膵疾患の診断. シンポジウム2「胆膵腫瘍性疾患の診断と治療における工夫」  [Not invited]松田友彦; 北野雅之; 工藤正俊日本消化器内視鏡学会近畿支部第95回支部例会  2015/11  大阪国際交流センター, 大阪特別講演「Intermediate stage肝癌の再分類と新しい分子標的薬への期待」  [Invited]工藤正俊第30回岐阜肝画像研究会  2015/10  岐阜進行肝細胞癌に対するソラフェニブとシスプラチン肝動注療法のランダム化第II相試験.ワークショップ9「肝臓3: 進行肝細胞がんの集学的治療(1)」  [Not invited]小島康志; 池田公史; 清水 怜; 佐藤俊哉; 森本 学; 稲葉吉隆; 萩原淳司; 萩原敦司; 工藤正俊; 中森正二; 金子周一; 杉本理恵; 佐藤恵子; 石井 浩; 古瀬純司; 奥坂拓志第53回日本癌治療学会学術集会  2015/10  国立京都国際会館, グランドプリンス京都, 京都固形がんに対する化学療法施行時のB型肝炎ウイルス再活性化に関する多施設共同前向き観察研究. ワークショップ12「基礎研究: 基礎研究の臨床応用」  [Not invited]灘野成人; 池田公史; 近藤俊輔; 工藤正俊; 古瀬純司; 大﨑往夫; 熊田 卓; 大川和良; 伊藤清顕; 楠本 茂; 溝上雅史第53回日本癌治療学会学術集会  2015/10  国立京都国際会館, グランドプリンス京都, 京都Predictive factors for outcomes of through-the-scope gastroduodenal stenting in patients with gastric outlet obstruction; a large multicenter retrospective study in West Japan  [Not invited]Yamao K; Kitano M; Kayahara T; Ishida E; Minaga K; Yamashita Y; Nakajima J; Asada M; Okabe S; Chiba Y; Imai H; Kudo M23rd United European Gastroenterology Week (UEGW 2015)  2015/10  Barcelona, SpainEvaluation of anti-migration properties of biliary covered self-expandable metal stents  [Not invited]Minaga K; Kitano M; Harwani Y; Imai H; Kamata K; Miyata T; Yamao K; Kadosaka K; Omoto S; Kudo M23rd United European Gastroenterology Week (UEGW 2015)  2015/10  Barcelona, SpainInvited Lecture “Ultrasound fusion imaging of liver tumor: recent progress and clinical relevance”  [Invited]Masatoshi KudoIEEE International Ultrasonics Symposium  2015/10  Taipei International Convention Center, Taiwan食道癌深達度診断における食道学会分類の検証. ワークショップ13「(JSES Core Session )上部消化管におけるadvanced diagnostic endoscopy (ADE)エビデンスと新たな展開」  [Not invited]朝隈 豊; 松井繁長; 工藤正俊第90回日本消化器内視鏡学会総会  2015/10  グランドプリンスホテル高輪, 東京EUS guided biliary drainage for treatment of biliary obstruction. International Session (Panel Discussion) 2 “Strategy of treatment for biliary stenosis”  [Not invited]Imai H; Kitano M; Kudo M第90回日本消化器内視鏡学会総会  2015/10  グランドプリンスホテル高輪, 東京座長: ブレックファーストセミナー14「肝細胞癌の診断と治療UP-TO-DATE」  [Invited]工藤正俊第19回日本肝臓学会大会  2015/10  グランドプリンスホテル高輪, 東京司会: パネルディスカッション13「肝疾患の診断・治療に伴う侵襲はどこまで減らせるか」  [Not invited]工藤正俊第19回日本肝臓学会大会  2015/10  グランドプリンスホテル高輪, 東京SSA/Pの内視鏡診断  [Not invited]岡崎能久; 樫田博史; 櫻井俊治; 朝隈 豊; 米田頼晃; 高山政樹; 峯 宏昌; 足立哲平; 田中梨絵; 山田光成; 岡元寿樹; 榎本英介; 前西 修; 筑後孝章; 木村雅友; 佐藤隆夫; 工藤正俊第90回日本消化器内視鏡学会総会  2015/10  グランドプリンスホテル高輪, 東京大腸拡大NBI観察におけるJNET分類の有効性に関する検討. ワークショップ6「(JSES Core Session )下部消化管におけるadvanced diagnostic endoscopy (ADE)エビデンスと新たな展開」  [Not invited]米田頼晃; 樫田博史; 工藤正俊第90回日本消化器内視鏡学会総会  2015/10  グランドプリンスホテル高輪, 東京経乳頭治療困難悪性胆管狭窄に対するEUS下hepaticogastrostomyとantegrade stenting併用の有用性の検討. ワークショップ9「(JSES Core Session )Interventional EUS: エビデンスと新たな展開」  [Not invited]今井 元; 北野雅之; 工藤正俊第90回日本消化器内視鏡学会総会  2015/10  グランドプリンスホテル高輪, 東京機能性ディスペプシアに早期慢性膵炎が含まれている.ワークショップ7「機能性上部消化管疾患の病態と新規治療」  [Not invited]門阪薫平; 北野雅之; 工藤正俊第90回日本消化器内視鏡学会総会  2015/10  グランドプリンスホテル高輪, 東京当院において直腸神経内分泌腫瘍に対してEMR-C (EMR using a cap), EMR-L (EMR with a ligation device)を中心とした内視鏡的切除の検討  [Not invited]山田光成; 樫田博史; 岡元寿樹; 田中梨絵; 足立哲平; 峯 宏昌; 高山政樹; 永井知行; 岡崎能久; 米田頼晃; 朝隈 豊; 櫻井俊治; 松井繁長; 工藤正俊第57回日本消化器病学会大会  2015/10  グランドプリンスホテル高輪, 東京転移性肝癌に対してUS-US fusionを用いたラジオ波焼灼術  [Not invited]南 知宏; 南 康範; 千品寛和; 有住忠晃; 田北雅弘; 北井 聡; 矢田典久; 萩原 智; 上嶋一臣; 西田直生志; 工藤正俊第57回日本消化器病学会大会  2015/10  グランドプリンスホテル高輪, 東京プロポフォールを用いた上部消化管内視鏡検査で出現する不随意運動の検討  [Not invited]梅原康湖; 辻 直子; 尾崎信人; 松本 望; 高場雄久; 川崎正憲; 冨田崇文; 谷池聡子; 森村正嗣; 山田 哲; 米田 円; 工藤正俊第57回日本消化器病学会大会  2015/10  グランドプリンスホテル高輪, 東京肝細胞癌に対してUS-US fusionを用いたラジオ波焼灼術  [Not invited]南 知宏; 南 康範; 千品博和; 有住忠晃; 田北雅弘; 北井 聡; 矢田典久; 萩原 智; 上嶋一臣; 西田直生志; 工藤正俊第19回日本肝臓学会大会  2015/10  グランドプリンスホテル高輪, 東京Discussant, International Session (Symposium) 1 “Hepatocellular carcinoma: molecular approaches for diagnosis, prognosis, and therapy”  [Invited]Masatoshi Kudo第19回日本肝臓学会大会  2015/10  グランドプリンスホテル高輪, 東京Tumor characteristics and genetic and epigenetic profile of human hepatocellular carcinoma. International Session (Symposium) 1 “Hepatocellular carcinoma: molecular approaches for diagnosis, prognosis, and therapy”  [Not invited]Nishida N; Kudo M第19回日本肝臓学会大会  2015/10  グランドプリンスホテル高輪, 東京壊死性膵炎後のwalled-off necrosisに対するInterventional EUSの有用性. 統合プログラム1「壊死性膵炎後のwalled-off necrosisに対するベストアプローチ法は?」  [Not invited]三長孝輔; 北野雅之; 工藤正俊第90回日本消化器内視鏡学会総会  2015/10  グランドプリンスホテル高輪, 東京膵癌早期診断におけるEUSの有用性の検討. パネルディスカッション7「膵がんのスクリーニングと事後管理」  [Not invited]宮田 剛; 北野雅之; 工藤正俊第90回日本消化器内視鏡学会総会  2015/10  グランドプリンスホテル高輪, 東京超音波検査が鑑別にもっとも有用であったと考えられた肝原発Castleman病の1例  [Not invited]三野 智; 小川 力; 柴峠光成; 西田知紗; 村川佳子; 河合直之; 丸山哲夫; 木太秀行; 大西宏明; 工藤正俊日本超音波医学会第25回四国地方会学術集会, 第14回四国地方会講習会  2015/10  かがわ国際会議場, 香川カラーRVSを用いた新しいsegment領域の教育方法  [Not invited]小川 力; 野田晃世; 荒澤壮一; 出田雅子; 久保敦司; 石川哲朗; 松中寿浩; 玉置敬之; 柴峠光成; 工藤正俊日本超音波医学会第25回四国地方会学術集会, 第14回四国地方会講習会  2015/10  かがわ国際会議場, 香川特別講演「消化器疾患の診断と治療における超音波の役割」  [Not invited]工藤正俊日本超音波医学会第25回四国地方会学術集会, 第14回四国地方会講習会  2015/10  かがわ国際会議場, 香川特別講演「最新の肝癌診療―診断、治療、予後―」  [Invited]工藤正俊HIV Specialist Forum in Tokyo  2015/10  野村コンファレンスプラザ日本橋, 東京肝臓解析を用いたTACEの塞栓領邦予測の試み~放射線技師との協力~  [Not invited]須和大輔; 坂東 誠; 槇殿元誉; 中川真吾; 西村悟郎; 吉崎康則; 安部一成; 小川 力; 工藤正俊第10回肝癌治療シミュレーション研究会  2015/09  ホテル椿山荘, 東京DICOM dataの統合法によるカラー表示RVSを用いたRFA治療  [Not invited]小川 力; 野田晃世; 荒澤壮一; 出田雅子; 久保敦司; 石川哲朗; 松中寿浩; 玉置敬之; 柴峠光成; 工藤正俊第10回肝癌治療シミュレーション研究会  2015/09  ホテル椿山荘, 東京肝細胞癌に対してUS-US fusionを用いたラジオ波焼灼術. セミナーシンポジウム「Navigationによる肝癌局所療法の最先端」  [Not invited]南 康範; 工藤正俊第10回肝癌治療シミュレーション研究会  2015/09  ホテル椿山荘, 東京非特異的な臨床・画像経過を呈した膵退形成癌(多形細胞型)の一例  [Not invited]松田友彦; 北野雅之; 大本俊介; 門阪薫平; 鎌田 研; 宮田 剛; 三長孝輔; 山雄健太郎; 今井 元; 工藤正俊日本消化器病学会近畿支部第103回例会  2015/09  大阪国際交流センター, 大阪造影ハーモニックEUSが病勢診断に有用であった自己免疫性膵炎の一例  [Not invited]高島耕太; 大本俊介; 門阪薫平; 鎌田 研; 宮田 剛; 三長孝輔; 山雄健太郎; 今井 元; 北野雅之; 工藤正俊日本消化器病学会近畿支部第103回例会  2015/09  大阪国際交流センター, 大阪複数回のENPD下膵液細胞診により診断し得た膵上皮内癌の一例  [Not invited]加藤 寛; 宮田 剛; 大本俊介; 門阪薫平; 鎌田 研; 山雄健太郎; 今井 元; 北野雅之; 工藤正俊日本消化器病学会近畿支部第103回例会  2015/09  大阪国際交流センター, 大阪著明な肝機能障害を呈した骨髄性ポルフィリン症の一例  [Not invited]青山真吾; 萩原 智; 岩西美奈; 南 知宏; 千品寛和; 河野匡志; 有住忠晃; 田北雅弘; 北井 聡; 矢田典久; 南 康範; 依田 広; 上嶋一臣; 櫻井俊治; 西田直生志; 工藤正俊日本消化器病学会近畿支部第103回例会  2015/09  大阪国際交流センター, 大阪Hemosuccus pancreaticusによる出血に対し血管塞栓術にて止血しえた一例  [Not invited]岡元寿樹; 高山政樹; 山雄健太郎; 田中梨絵; 山田光成; 足立哲平; 峯 宏昌; 永井知行; 岡崎能久; 米田頼晃; 朝隈 豊; 櫻井俊治; 松井繁長; 北野雅之; 樫田博史; 工藤正俊日本消化器病学会近畿支部第103回例会  2015/09  大阪国際交流センター, 大阪正常乳頭に近い状態であったため、診断に難渋した十二指腸乳頭部癌の一例  [Not invited]丹正幸祐; 木下大輔; 秦 康倫; 末吉功治; 奥田英之; 高山正樹; 岸谷 譲; 川崎俊彦; 水野成人; 加藤寛章; 辻江正徳; 井上雅智; 若狭朋子; 太田善夫; 工藤正俊日本消化器病学会近畿支部第103回例会  2015/09  大阪国際交流センター, 大阪当院におけるPancreatic fluid collectionに対する予後予測の検討  [Not invited]山雄健太郎; 北野雅之; 工藤正俊日本消化器病学会近畿支部第103回例会  2015/09  大阪国際交流センター, 大阪閉塞性黄疸を契機に発見された先天性胆道拡張症の一例  [Not invited]高場雄久; 尾崎信人; 松本 望; 川崎正憲; 冨田崇文; 梅原康湖; 森村正嗣; 米田 円; 山田 哲; 辻 直子; 落合 健; 前倉俊治; 工藤正俊日本消化器病学会近畿支部第103回例会  2015/09  大阪国際交流センター, 大阪慢性下痢を主訴としたC型慢性肝炎関連クリオグロブリン血症の一例  [Not invited]足立哲平; 岡元寿樹; 河野匡志; 田中梨絵; 山田光成; 峯 宏昌; 永井知行; 朝隈 豊; 米田頼晃; 岡崎能久; 萩原 智; 櫻井俊治; 松井繁長; 樫田博史; 工藤正俊; 野崎祐史; 松村 到; 石井道治日本消化器病学会近畿支部第103回例会  2015/09  大阪国際交流センター, 大阪トルバプタンの治療効果における予測因子の検討  [Not invited]千品寛和; 萩原 智; 岩西美奈; 南 知宏; 河野匡志; 有住忠晃; 田北雅弘; 北井 聡; 矢田典久; 南 康範; 上嶋一臣; 西田直生志; 工藤正俊日本消化器病学会近畿支部第103回例会  2015/09  大阪国際交流センター, 大阪転移性肝癌に対するUS-US fusionを用いたラジオ波焼灼術  [Not invited]南 知宏; 南 康範; 岩西美奈; 千品寛和; 有住忠晃; 田北雅弘; 北井 聡; 矢田典久; 萩原 智; 依田 広; 上嶋一臣; 西田直生志; 工藤正俊日本消化器病学会近畿支部第103回例会  2015/09  大阪国際交流センター, 大阪当院における超音波内視鏡ガイド下腹腔神経叢ブロック術の検討. シンポジウム2「消化器腫瘍に対する内視鏡的アプローチの現況と問題点」  [Not invited]三長孝輔; 北野雅之; 工藤正俊日本消化器病学会近畿支部第103回例会  2015/09  大阪国際交流センター, 大阪Invited Lecture “Hepatologists’ perspectives on EOB-MRI: Pre-& post-operative evaluation in malignant lesions”  [Invited]Masatoshi KudoAsila Pacific Liver Imaging Symposium (APLIS)  2015/09  Seoul, KoreaInvited Lecture; Luncheon Satellite Symposium “Treatment strategies to optimize outcome and experience of patients with HCC”  [Invited]Masatoshi KudoThe Liver Week 2015  2015/09  BEXCO, Busan, KoreaKLCSG & LCSGJ Joint Symposium “HCC nationwide surveillance and out come in Japan”  [Invited]Masatoshi KudoThe Liver Week 2015  2015/09  BEXCO, Busan, KoreaInvited Lecture “HCC nationwide surveillance and outcome in Japan”  [Invited]Masatoshi KudoThe Liver Week 2015  2015/09  BEXCO, Busan, KoreaChairs: “KLCSG & JLCSG Joint Symposium”  [Invited]Masatoshi KudoThe Liver Week 2015  2015/09  BEXCO, Busan, KoreaSpecial Lecture 2”The evolution of HCC treatment”  [Invited]Masatoshi KudoThe Liver Week 2015  2015/09  BEXCO, Busan, KoreaInvited Lecture “The evolution of HCC treatment”  [Invited]Masatoshi KudoThe Liver Week 2015  2015/09  BEXCO, Busan, KoreaA randomized phase 2 trial of sorafenib plus intraarterial cisplatin versus sorafenib alone for advanced hepatocellular carcinoma  [Not invited]Morimoto M; Ikeda M; Shimizu S; Inaba Y; Kojima Y; Hagihara A; Kudo M; Nakamori S; Kaneko S; Sugimoto R; Tahara T; Ohmura T; Yasui K; Sato K; Ishii H; Furuse J; Okusaka T9th Annual Conference International Liver Cancer Association (ILCA)  2015/09  Paris, FranceObjective response by mRECIST predicts survival in hepatocellular carcinoma: a multivariate, time-dependent analysis from the phase 3 BRISK-PS study  [Not invited]Lencioni R; Park JW; Torres F; Decaens T; Boucher E; Raoul JL; Kudo M; Chang C; Boige V; Assenat E; Kang YK; Lim HY; Walters I; Llovet JM9th Annual Conference International Liver Cancer Association (ILCA)  2015/09  Paris, FrancePlatelet count improves prognostic value of A-L-B-I grade: introducting a new P-A-L-B-I score  [Not invited]Roayaie S; Jibara G; Berhane S; Tabrizian P; Park JW; Yang J; Yan L; Han G; Izzo F; Chen M; Blanc JF; Roberts L; Kudo M; Sherman M; Johnson P9th Annual Conference International Liver Cancer Association (ILCA)  2015/09  Paris, FranceEvaluation of detection rate of liver tumor existing deep location from the surface using second generation agent, sorafenib  [Not invited]Izuta M; Ogawa C; Shibatoge M; Kudo M9th Annual Conference International Liver Cancer Association (ILCA)  2015/09  Paris, FranceA randomized, double-blind, placebo-controlled phase 3 study of ramucirumab versus placebo as second-line treatment in patients with hepatocellular carcinoma and elevated baseline alpha-fetoprotein following first-line sorafenib (REACH-2)  [Not invited]Zhu AX; Galle PR; Kudo M; Finn RS; Yang L; Abada P; Chang SC; Llovet JM9th Annual Conference International Liver Cancer Association (ILCA)  2015/09  Paris, FranceAn international observational study to assess the use of sorafenib after transarterial chemoembolization (TACE) in patiens with hepatocellular carcinoma (HCC): OPTIMIS interim analysis  [Not invited]Peck-Radosavljivic M; Raoul JL; Lee HC; Kudo M; Nakajima K; Cheng AL; on behalf of the; OPTIMIS Investigators9th Annual Conference International Liver Cancer Association (ILCA)  2015/09  Paris, FranceSurvival benefit of locoregional therapy for hepatocellular carcinoma with Child-Pugh C liver function: a multicenter nation-wide study  [Not invited]Kudo M; Kitai S; Nishida N; Izumi N; Sakamoto M; Matsuyama Y; Ichida T; Nakashima O; Matsui O; Ku Y; Kokudo N; Makuuchi M; for the Liver; Cancer Study; Group of Japan9th Annual Conference International Liver Cancer Association (ILCA)  2015/09  Paris, FranceUS-US fusion imaging in radiofrequency ablation therapy for hepatocellular carcinoma  [Not invited]Minami Y; Minami T; Kudo M9th Annual Conference International Liver Cancer Association (ILCA)  2015/09  Paris, FranceChair: General Session 2 “Molecular Pathogenesis of Liver Cancer II”  [Invited]Masatoshi KudoInternational Liver Cancer Association 9th Annual Conference (ILCA) 2015  2015/09  Paris, FranceRamucirumab (RAM) as second-line treatment in patients with advanced hepatocellular carcinoma (HCC) following first-line therapy with sorafenib in the randomized Phase III REACH study: analysis ofα-fetoprotein (AFP) kinetics during treatment  [Not invited]Chau I; Park JO; Ryoo BY; Yen CJ; Poon R; Pastorelli D; Blanc JF; Kudo M; Eduardo T; Pfiffer F; Hatano E; Chung HC; Kubackova K; Phelip JM; Brandi G; Ohkawa S; Li CP; Okusaka T; Yang L; Abada PB; Zhu AXEuropean Cancer Congress 2015 (18th ECCO-40th ESMO)  2015/09  Vienna, AustriaRamucirumab as second-line treatment in patients with advanced hepatocellular carcinoma: Japanese subgroup analysis of the phase III REACH trial.  [Not invited]Kudo M; Hatano E; Okusaka T; Ohkawa S; Fujii H; Masumoto A; Furuse J; Wada Y; Ishii H; Obi S; Arai K; Kawazoe S; Yokosuka O; Ikeda M; Ukai K; Morita S; Asou H; Abada PB; Yang L; Zhu AX9th Annual Conference International Liver Cancer Association (ILCA)  2015/09  Paris, FranceInvited Lecture “Assessing treatment effect and treatment failure: when to stop LRTs”  [Invited]Masatoshi Kudo9th Annual Conference International Liver Cancer Association (ILCA)  2015/09  September 4-6, 2015.State of Art Lecture “Benefit of early diagnosis of liver cancer with changed therapeutic paradigm in HCC”  [Invited]Masatoshi Kudo23rd Annual Indian National Association for the Study of Liver (INASL) and Current Perspectives in Liver Diseases (CPLD)  2015/08  Manekshaw Center, New Delhi, IndiaInvited Lecture “Imaging in early HCC-MR advances”  [Invited]Masatoshi Kudo23rd Annual Indian National Association for the Study of Liver (INASL) and Current Perspectives in Liver Diseases (CPLD)  2015/08  Manekshaw Center, New Delhi, IndiaInvited Lecture“HCC: early diagnosis impacts prognosis”  [Invited]Masatoshi Kudo23rd Annual Indian National Association for the Study of Liver (INASL) and Current Perspectives in Liver Diseases (CPLD)  2015/07  Max Hospital, New Delhi, IndiaInvited Lecture“Molecular targeted therapy for HCC: current status and future perspectives”  [Invited]Masatoshi Kudo23rd Annual Indian National Association for the Study of Liver (INASL) and Current Perspectives in Liver Diseases (CPLD)  2015/07  Amity University, New Delhi, India総括発言「DEB-TACEのポジショニング~cTACEとの使い分けはいかにすべきか~」  [Invited]工藤正俊第3回ディーシービーズ症例検討会  2015/07  東京コンファレンスセンター, 東京仮想超音波のDICOM dataを用いたカラー表示USでの造影US、RFA治療方法  [Not invited]小川 力; 野田晃世; 荒澤壮一; 出田雅子; 久保敦司; 石川哲朗; 松中寿浩; 玉置敬之; 柴峠光成; 工藤正俊第51回日本肝癌研究会  2015/07  神戸国際会議場, 兵庫司会: シンポジウム4「肝癌に対する国内外の診療ガイドラインの問題点」  [Invited]工藤正俊第51回日本肝癌研究会  2015/07  神戸国際会議場, 兵庫司会: ランチョンセミナー  [Invited]工藤正俊第51回日本肝癌研究会  2015/07  神戸国際会議場, 兵庫原発性肝癌追跡調査症例の解析結果から検討した肝内胆管癌の病期分類について. パネルディスカッション3「肝内胆管癌の病態と最新の治療戦略」  [Not invited]阪本良弘; 國土典宏; 松山 裕; 坂元亨宇; 泉 並木; 角谷真澄; 金子周一; 具 英成; 工藤正俊; 高山忠利; 中島 収第51回日本肝癌研究会  2015/07  神戸国際会議場, 兵庫肝細胞癌に対してUS-US fusionを用いたラジオ波焼灼術  [Not invited]南 康範; 南 知宏; 千品寛和; 有住忠晃; 田北雅弘; 北井 聡; 矢田典久; 萩原 智; 上嶋一臣; 西田直生志; 工藤正俊第51回日本肝癌研究会  2015/07  神戸国際会議場, 兵庫Ramucirumab (RAM) as second-line treatment in patients (pts) with advanced hepatocellular carcinoma (HCC): Japanese subgroup analysis of the phase III REACH trial  [Not invited]Ohkawa S; Okusaka T; Kudo M; Hatano E; Fujii H; Masumoto A; Furuse J; Wada Y; Ishii H; Obi S; Arai K; Kawazoe S; Yokosuka O; Ikeda M; Ukai K; Morita S; Asou H; Abada PB; Yang L; Zhu AXThe 13th Annual Meeting of Japanese Soceity of Medical Oncology  2015/07  Hotel Sapporo Geibunkan, SapporoActivin signal in pancreatic cancer  [Not invited]Togashi Y; Sakamoto H; Kogita A; de Velasco M; Sakai K; Fujita Y; Tomida S; Kitano M; Kudo M; Nishio KThe 13th Annual Meeting of Japanese Soceity of Medical Oncology  2015/07  Hotel Sapporo Geibunkan, SapporoChair "Poster Session: Biliary Tract and Pancreatic Cancer 2 FOLFIRINOX(2)"  [Invited]Masatoshi KudoThe 13th Annual Meeting of Japanese Society of Medical Oncology  2015/07  Sapporo Education and Culture Hall in SapporoModerator and Commentator “Non-surgical treatment of HCC: achievement from Taiwan over the past quarter century”  [Invited]Masatoshi KudoTaiwan Association for the Study of the Liver 2015 (TASL)  2015/07  Westin Taipei, Taipei, TaiwanModerator and Commentator “Androgen pathway in the mechanisms of liver carcinogenesis and targets for future therapy”  [Invited]Masatoshi KudoTaiwan Association for the Study of the Liver 2015 (TASL)  2015/07  Westin Taipei, Taipei, Taiwan開会の辞  [Invited]工藤正俊第33回南大阪肝疾患研究会  2015/07  ホテル・アゴーラリージェンシー堺, 大阪座長: Special Lectur: 坂本長逸「抗血栓薬と消化管傷害、現状とリスクマネジメント」  [Invited]工藤正俊Scientific Exchange Meeting 2015 in Osaka  2015/07  ホテルグランヴィア大阪, 大阪Opening Remarks  [Invited]工藤正俊Scientific Exchange Meeting 2015 in Osaka  2015/07  ホテルグランヴィア大阪, 大阪特別講演「肝癌に対する分子標的治療: 現状と今後の展望」  [Not invited]工藤正俊第12回消化器癌研究会  2015/07  甲府富士屋ホテル, 山梨Invited Lecture “Subclassification of intermediate stage HCC and treatment strategy”, APPLE Consensus Workshop “Searching consensus for controversies”  [Invited]Masatoshi KudoThe 6th Asia-Pacific Primary Liver Cancer Expert Meeting (APPLE)  2015/07  Hyatt Regency OsakaChair; State-of-the-Art Lecture III “Cholangiocarcinoma: new trends and emerging targets”  [Invited]Masatoshi KudoThe 6th Asia-Pacific Primary Liver Cancer Expert Meeting  2015/07  Hyatt Regency OsakaChair; State-of-the-Art Lecture II “Design of clinical trial in advanced HCC: trial enrichment and stratification”  [Invited]Masatoshi KudoThe 6th Asia-Pacific Primary Liver Cancer Expert Meeting  2015/07  Hyatt Regency OsakaChair; The BCLC B Stage: Debate  [Invited]Masatoshi KudoThe 6th Asia-Pacific Primary Liver Cancer Expert Meeting  2015/07  Hyatt Regency OsakaChair; Memorial Award Ceremony “Prof. Ichio Honjo Award Lecture”  [Invited]Masatoshi KudoThe 6th Asia-Pacific Primary Liver Cancer Expert Meeting  2015/07  Hyatt Regency OsakaChair; Luncheon Seminar “Efficacy & Safety of Lipiodol for Improved Overall Survival in HCC”  [Invited]Masatoshi KudoThe 6th Asia-Pacific Primary Liver Cancer Expert Meeting  2015/07  Hyatt Regency OsakaInvited Lecture “Management of intermediate/advanced HCC in Japan”  [Invited]Masatoshi KudoThe 6th Asia-Pacific Primary Liver Cancer Expert Meeting (APPLE)  2015/07  Hyatt Regency OsakaUS-US fusion imaging in radiofrequency ablation therapy for hepatocellular carcinoma  [Not invited]Minami Y; Minami T; Kudo MThe 6th Asia-Pacific Primary Liver Cancer Expert Meeting (APPLE)  2015/07  Hyatt Regency OsakaEpigenetics in HCC pathogenesis  [Invited]Nishida N; Kudo MThe 6th Asia-Pacific Primary Liver Cancer Expert Meeting (APPLE)  2015/07  Hyatt Regency OsakaChair; New Aspects of Locoregional/Surgical Therapy  [Invited]Masatoshi KudoThe 6th Asia-Pacific Primary Liver Cancer Expert Meeting  2015/07  Hyatt Regency OsakaChair; State-of-the-Art Lecture I  [Invited]Masatoshi KudoThe 6th Asia-Pacific Primary Liver Cancer Expert Meeting  2015/07  Hyatt Regency OsakaChari: Sponsored Seminar“Diagnostic Imaging with EOB-MRI for Malignancy Grade of HCC”  [Invited]Masatoshi KudoThe 6th Asia-Pacific Primary Liver Cancer Expert Meeting  2015/07  Hyatt Regency Osaka, Japan自己免疫性膵炎のステロイド治療における再燃リスクの検討. ミニパネルディスカッション1「自己免疫性膵炎治療の現状と課題」  [Not invited]大本俊介; 北野雅之; 工藤正俊第46回日本膵臓学会大会  2015/06  名古屋国際会議場, 愛知難治性下痢を主訴とし著明な腸管浸潤を認めた成人T細胞白血病の1例  [Not invited]岡崎能久; 樫田博史; 米田頼晃; 櫻井俊治; 朝隈 豊; 高山政樹; 峯 宏昌; 足立哲平; 田中梨絵; 山田光成; 岡元寿樹; 工藤正俊; 筑後孝章; 大山泰世日本消化器内視鏡学会近畿支部第94回支部例会  2015/06  大阪国際交流センター, 大阪下部消化管内視鏡で切除しえた盲腸顆粒細胞腫の一例  [Not invited]尾崎信人; 松本 望; 高場雄久; 川崎正憲; 冨田崇文; 梅原康湖; 森村正嗣; 米田 円; 山田 哲; 辻 直子; 落合 健; 前倉俊治; 工藤正俊日本消化器内視鏡学会近畿支部第94回支部例会  2015/06  大阪国際交流センター, 大阪胃噴門部粘膜下腫瘍に対してLECSを施行した1症例  [Not invited]安部美希子; 木下大輔; 秦 康倫; 貫戸幸星; 奥田英之; 岸谷 譲; 川崎俊彦; 加藤寛章; 井上雅智; 藤原由規; 永井知行; 太田善夫; 若狭朋子; 工藤正俊日本消化器内視鏡学会近畿支部第94回支部例会  2015/06  大阪国際交流センター, 大阪術後胃に発生した胃石症3例の検討  [Not invited]岡元寿樹; 松井繁長; 田中梨絵; 山田光成; 足立哲平; 高山政樹; 峯 宏昌; 永井知行; 岡崎能久; 米田頼晃; 朝隈 豊; 櫻井俊治; 樫田博史; 工藤正俊日本消化器内視鏡学会近畿支部第94回支部例会  2015/06  大阪国際交流センター, 大阪Helicobacter pylori除菌後の内視鏡所見の変化. シンポジウム「ヘリコバクター胃炎除菌時代を迎えて-変わるもの、残るもの-」  [Not invited]松本 望; 辻 直子; 工藤正俊日本消化器内視鏡学会近畿支部第94回支部例会  2015/06  大阪国際交流センター, 大阪大腸LSTの治療方針. パネルディスカッション「大腸LST治療の最前線-内視鏡医・内視鏡外科医の立場から-」  [Not invited]米田頼晃; 樫田博史; 工藤正俊日本消化器内視鏡学会近畿支部第94回支部例会  2015/06  大阪国際交流センター, 大阪胃十二指腸ステントおよびステント留置下胆道ドレナージ術の治療成績の検討. パネルディスカッション2「切除不能膵癌の治療選択」  [Not invited]山雄健太郎; 北野雅之; 工藤正俊; 中島 潤; 岡部純弘; 大﨑往夫; 萱原隆久; 石田悦嗣; 山本 博; 三長孝輔; 山下幸孝第46回日本膵臓学会大会  2015/06  名古屋国際会議場, 愛知進行膵癌の癌性疼痛に対するEUS神経叢・神経節ブロック術の有用性の検討. ビデオシンポジウム1「内視鏡的手技 膵疾患に対するInterventional Endoscopy」  [Not invited]宮田 剛; 北野雅之; 工藤正俊第46回日本膵臓学会大会  2015/06  名古屋国際会議場, 愛知閉会挨拶  [Invited]工藤正俊第17回関西B型肝炎研究会  2015/06  ホテルモントレグラスミア, 大阪座長: 特別講演「これからの肝臓病学」  [Invited]工藤正俊第59回大阪肝穿刺生検治療研究会  2015/06  ホテルグランヴィア大阪, 大阪開会・閉会の辞  [Invited]工藤正俊第59回大阪肝穿刺生検治療研究会  2015/06  ホテルグランヴィア大阪, 大阪Ramucirumab (RAM) as second-line treatment in patients (pts) with advanced hepatocellular carcinoma (HCC): Analysis of REACH pts by Child-Pugh (CP) score  [Not invited]Zhu AX; Baron AD; Malfertheiner P; Kudo M; Kawazoe S; Pezet D; Weissinger F; Brandi G; Barone C; Okusaka T; Wada Y; Park J; Ryoo B; Cho JY; Chung HC; Li C; Yen C; Lee K; Yang L; Chau IAnnual Meeting of American Society of Clinical Oncology (ASCO 2015)  2015/06  Chicago, USAObjective response by mRECIST to predict survival in hepatocellular carcinoma: A multivariate, time-dependent analysis from the phase III BRISK-PS study  [Not invited]Llovet JM; Park J; Torres F; Decaens T; Boucher E; Raoul J; Kudo M; Chang C; Boige V; Assenat E; Kang Y; Lim H; Walters I; Lencioni RAnnual Meeting of American Society of Clinical Oncology (ASCO 2015)  2015/06  Chicago, USARamucirumab (RAM) as second-line treatment in patients (pts) with advanced hepatocellular carcinoma following first-line therapy with sorafenib: Patient-focused outcome (PFO) results from the phase 3 REACH study  [Not invited]Chau I; Peck-Radosavljevic M; Borg C; Malfertheiner P; Seitz J; Park J; Ryoo B; Yen C; Kudo M; Poon RT; Pastorelli D; Blanc J; Chung H; Baron AD; Okusaka T; Cui ZL; Girvan AC; Abada P; Yang L; Zhu AXAnnual Meeting of American Society of Clinical Oncology (ASCO 2015)  2015/06  Chicago, USASorafenib plus intra-arterial cisplatin versus sorafenib alone in patients with advanced hepatocellular carcinoma: A randomized phase II trial  [Not invited]Ikeda M; Shimizu S; Sato T; Morimoto M; Inaba Y; Kojima Y; Hagihara A; Kudo M; Nakamori S; Kaneko S; Sugimoto R; Tahara T; Ohmura T; Yasui K; Sato K; Ishii H; Furuse J; Okusaka TAnnual Meeting of American Society of Clinical Oncology (ASCO 2015)  2015/06  Chicago, USAProposal of a new staging system for intrahepatic cholangiocarcinoma: Analysis of surgical patients from a nationwide survey of Liver Cancer Study Group of Japan  [Not invited]Sakamoto Y; Kokudo N; Matsuyama Y; Sakamoto M; Kadoya M; Kaneko S; Ku Y; Kudo M; Takayama T; Nakashima O; The Liver Cancer Study; Group of JapanAnnual Meeting of American Society of Clinical Oncology (ASCO 2015)  2015/06  Chicago, USAA randomized, double-blind, placebo-controlled phase III study of S-1 in patients with sorafenib refractory advanced hepatocellular carcinoma (S-CUBE)  [Not invited]Kudo M; Moriguchi M; Numata K; Hidaka H; Tanaka H; Ikeda M; Kawazoe S; Ohkawa S; Sato Y; Okusaka TAnnual Meeting of American Society of Clinical Oncology (ASCO 2015)  2015/06  Chicago, USA膵胆道腫瘍のリンパ節転移診断における造影ハーモニックEUSの有用性.ワークショップ13「膵胆道疾患における超音波内視鏡診断の新展開」  [Not invited]宮田 剛; 北野雅之; 工藤正俊第89回日本消化器内視鏡学会総会  2015/05  名古屋国際会議場, 名古屋EUS検査時のミダゾラムとプロポフォールによる鎮静に対するBISモニター(Bis-pectral index monitoring)の有用性の検討.パネルディスカッション1「内視鏡診療における鎮静に関するガイドラインを検証する」  [Not invited]宮田 剛; 北野雅之; 工藤正俊第89回日本消化器内視鏡学会総会  2015/05  名古屋国際会議場, 名古屋大腸鋸歯状病変の内視鏡診断について  [Not invited]岡崎能久; 樫田博史; 櫻井俊治; 朝隈 豊; 米田頼晃; 高山政樹; 峯 宏昌; 足立哲平; 田中梨絵; 山田光成; 岡元寿樹; 榎本英介; 前西 修; 筑後孝章; 木村雅友; 佐藤隆夫; 工藤正俊第89回日本消化器内視鏡学会総会  2015/05  名古屋国際会議場, 名古屋十二指腸静脈瘤の病態と治療方針. ビデオワークショップ1「消化管静脈瘤の診断・治療の現状と将来展望-異所性静脈瘤も含む-」  [Not invited]松井繁長; 樫田博史; 工藤正俊第89回日本消化器内視鏡学会総会  2015/05  名古屋国際会議場, 名古屋自己免疫性膵炎の診断および治療におけるEUSの役割.ワークショップ14「IgG4関連膵胆管病変における内視鏡の役割」  [Not invited]大本俊介; 北野雅之; 工藤正俊第89回日本消化器内視鏡学会総会  2015/05  名古屋国際会議場, 名古屋EUS下胆道ドレナージ術の有用性. JGES Core Session 3-パネルディスカッション「胆膵におけるInterventional EUS: 超音波内視鏡下瘻孔形成術の現状と問題点」  [Not invited]今井 元; 北野雅之; 工藤正俊第89回日本消化器内視鏡学会総会  2015/05  名古屋国際会議場, 名古屋早期慢性膵炎が機能性ディスペプシアとして診断される可能性について.ワークショップ4「消化管機能異常に対する内視鏡の役割」  [Not invited]門阪薫平; 北野雅之; 工藤正俊第89回日本消化器内視鏡学会総会  2015/05  名古屋国際会議場, 名古屋大腸T1癌の治療適応決定における内視鏡診断に関する検討.パネルディスカッション6「大腸T1(SM)癌に対する内視鏡治療の課題と将来展望」  [Not invited]櫻井俊治; 樫田博史; 工藤正俊第89回日本消化器内視鏡学会総会  2015/05  名古屋国際会議場, 名古屋Contrast-enhanced harmonic EUS for differential diagnosis of pancreatic tumors. International Video Session 2 “Advances and education of endoscopic diagnosis and treatment-biliary tract, pancreas-“  [Not invited]Kamata K; Kitano M; Kudo M第89回日本消化器内視鏡学会総会  2015/05  名古屋国際会議場, 名古屋肝細胞癌に対してUS-US fusionを用いたラジオ波焼灼術. シンポジウム 消化器3「消化器疾患における新技術」  [Not invited]南 康範; 工藤正俊JUSM2015 日本超音波医学会第88回学術集会  2015/05  グランドプリンスホテル新高輪, 東京深部病変におけるソナゾイド®造影超音波検査の検出率についての検討  [Not invited]出田雅子; 小川 力; 荒澤壮一; 柴峠光成; 西田知紗; 村川佳子; 河合直之; 丸山哲夫; 木太秀行; 工藤正俊JUSM2015 日本超音波医学会第88回学術集会  2015/05  グランドプリンスホテル新高輪, 東京簡便な小肝腫瘍の検出方法~初心者を対象とした仮想超音波の併用~  [Not invited]小川 力; 荒澤壮一; 出田雅子; 柴峠光成; 西田知紗; 村川佳子; 河合直之; 丸山哲夫; 木太秀行; 工藤正俊JUSM2015 日本超音波医学会第88回学術集会  2015/05  グランドプリンスホテル新高輪, 東京Real-time tissue elastography. ワークショップ 消化器4「肝臓の硬さ診断: その精度と使途」  [Not invited]矢田典久; 工藤正俊JUSM2015 日本超音波医学会第88回学術集会  2015/05  グランドプリンスホテル新高輪, 東京Stage I膵癌診断における超音波検査の役割. ワークショップ 消化器3「腹部悪性腫瘍の早期診断の限界と見逃してはいけない所見」  [Not invited]北野雅之; 宮田 剛; 工藤正俊JUSM2015 日本超音波医学会第88回学術集会  2015/05  グランドプリンスホテル新高輪, 東京ソナゾイド®造影超音波検査が虚血の診断に有用であった鼠径ヘルニアの1例  [Not invited]村上佳子; 小川 力; 荒澤壮一; 出田雅子; 柴峠光成; 西田知紗; 河合直之; 丸山哲夫; 木太秀行; 工藤正俊JUSM2015 日本超音波医学会第88回学術集会  2015/05  グランドプリンスホテル新高輪, 東京司会; ランチョンセミナー「進行肝癌に対する肝動注および塞栓療法について」  [Invited]工藤正俊第51回日本肝臓学会総会  2015/05  鶴屋ホール, 熊本肝細胞癌に対してUS-US fusionを用いたラジオ波焼灼術  [Not invited]南 康範; 工藤正俊第51回日本肝臓学会総会  2015/05  鶴屋東館, 熊本Fusion機能を用いたカラー表示US、および仮想超音波を用いた肝腫瘍の検出と治療  [Not invited]小川 力; 森岡弓子; 野田晃世; 荒澤壮一; 出田雅子; 久保敦司; 石川哲朗; 松中寿浩; 玉置敬之; 柴峠光成; 工藤正俊第51回日本肝臓学会総会  2015/05  鶴屋東館, 熊本司会: ランチョンセミナー「マイクロスフィアを用いた塞栓療法について」  [Not invited]工藤正俊第51回日本肝臓学会総会  2015/05  ホテル日航熊本・熊本ホテルキャッスル・鶴屋ホール, 熊本Shear Wave Measurementによる肝硬変測定  [Not invited]矢田典久; 工藤正俊第51回日本肝臓学会総会  2015/05  鶴屋東館, 熊本intermediate stageの肝細胞癌に対してTACE不応後のTACE継続とソラフェニブの検討  [Not invited]有住忠晃; 上嶋一臣; 南 知宏; 千品寛和; 河野匡志; 田北雅弘; 北井 聡; 矢田典久; 萩原 智; 南 康範; 櫻井俊治; 西田直生志; 工藤正俊第51回日本肝臓学会総会  2015/05  鶴屋東館, 熊本転移性肝癌に対してUS-US fusionを用いたラジオ波焼灼術  [Not invited]南 知宏; 南 康範; 千品寛和; 有住忠晃; 田北雅弘; 北井 聡; 矢田典久; 萩原 智; 上嶋一臣; 西田直生志; 工藤正俊第51回日本肝臓学会総会  2015/05  鶴屋東館, 熊本ストレス応答蛋白の肝発癌リスク予測における可能性. ミニワークショップ4「肝病態を反映する新たなバイオマーカーの探索」  [Not invited]櫻井俊治; 矢田典久; 工藤正俊第51回日本肝臓学会総会  2015/05  鶴屋東館, 熊本変異型HBx遺伝子の肝発癌促進における分子機序の解明. ワークショップ4「肝病態を反映する新たなバイオマーカーの探索」  [Not invited]萩原 智; 西田直生志; 工藤正俊第51回日本肝臓学会総会  2015/05  熊本ホテルキャッスル, 熊本血清中マイクロRNAプロファイルとソラフェニブに対する肝細胞癌の反応性予測. ワークショップ1「肝細胞癌の亜分類と個別化医療」  [Not invited]西田直生志; 工藤正俊第51回日本肝臓学会総会  2015/05  ホテル日航熊本, 熊本司会: ワークショップ1「肝細胞癌の亜分類と個別化医療」  [Invited]工藤正俊第51回日本肝臓学会総会  2015/05  ホテル日航熊本, 熊本分子生物学的特徴に基づいた肝癌のマネージメント. シンポジウム1「肝発癌研究と臨床への展開」  [Not invited]西田直生志; 海道利実; 工藤正俊第51回日本肝臓学会総会  2015/05  ホテル日航熊本, 熊本乳頭括約筋切開術を行わないTrans-catheter biliary endoscopyの有用性の検討. ビデオワークショップ3「胆道・膵疾患の内視鏡診断・治療における進歩」  [Not invited]河野匡志; 北野雅之; 工藤正俊第89回日本消化器内視鏡学会総会  2015/04  名古屋国際会議場, 名古屋全国原発性肝癌追跡調査のNational Clinical Databaceへの移行. シンポジウム15「日本の診断データベース構築へ向けて今、何をすべきか?」  [Not invited]建石良介; 工藤正俊; 小池和彦第101回日本消化器病学会総会  2015/04  仙台国際センター, 宮城EUS下胆道・膵管ドレナージ術の適応と成績. ワークショップ9「膵・胆道内視鏡治療の最先端」  [Not invited]宮田 剛; 北野雅之; 工藤正俊第101回日本消化器病学会総会  2015/04  仙台国際センター, 宮城Invited Lecture “Surveillance, treatment and outcome of HCC in Japan”  [Invited]Masatoshi KudoJoint Workshop EASL-JSH, 50th International Liver Congress of the European Association for the Study of the Liver (EASL)  2015/04  Vienna, Austriaインターフェロン治療前後の状態から考えるShear wave elastographyとStrain elastographyによる複合診断の有用性  [Not invited]矢田典久; 櫻井俊治; 工藤正俊第101回日本消化器病学会総会  2015/04  仙台国際センター, 宮城IPMNの経過観察におけるEUSおよび造影ハーモニックEUSの有用性. パネルディスカッション10「国際診療ガイドラインに基づいたIPMN/MCN診療の課題と対策」  [Not invited]鎌田 研; 北野雅之; 工藤正俊第101回日本消化器病学会総会  2015/04  仙台国際センター, 宮城大腸LSTにおける腫瘍の性格に応じた治療方針. パネルディスカッション4「大腸LSTの病態生理と診断・治療戦略」  [Not invited]米田頼晃; 樫田博史; 工藤正俊第101回日本消化器病学会総会  2015/04  仙台国際センター, 宮城当院におけるPancreatic fluid collectionに対する治療成績. シンポジウム10「壊死性膵炎の予後改善を目指した治療の新展開」  [Not invited]山雄健太郎; 北野雅之; 工藤正俊第101回日本消化器病学会総会  2015/04  仙台国際センター, 宮城An international observational study to assess the use of sorafenib after transarterial chemoembolization (TACE) in patients with hepatocellular carcinoma (HCC): OPTIMIS  [Not invited]Peck-Radosavljevic M; Raoul JL; Lee HC; Kudo M; Nakajima K; Cheng AL50th Annual Meeting of the European Association for the Study of the Liver (EASL 2015)  2015/04  Vienna, AustriaCombined sequential use of HAP and ART scores to predict transarterial chemoembolization failure in hepatocellular carcinoma: a multicenter comparative study  [Not invited]Pinato DJ; Arizumi T; Jang JW; Allara E; Suppiah P; Smirne C; Grossi G; Pirisi M; Kudo M; Sharma R50th Annual Meeting of the European Association for the Study of the Liver, (EASL 2015)  2015/04  Vienna, AustriaGIDEON (Global Investigation of Therapeutic Decisions in Hepatocellular Carcinoma and of Its Treatment with Sorafenib): A retrospective analysis of prognostic factors for survival  [Not invited]Bronowicki JP; Kudo M; Lencioni R; Chen XP; Dagher L; Furuse J; Geschwind JFH; de Guevara LL; Papandreou C; Sanyal AJ; Takayama T; Yoon SK; Nakajima K; Ye SL; Marrero JA50th Annual Meeting of the European Association for the Study of the Liver, (EASL 2015)  2015/04  Vienna, Austria肝細胞癌に対してUS-US Fusionを用いたラジオ波焼灼術. ワークショップ7「Navitationに基づいた肝細胞癌IVR治療の最前線」  [Not invited]南 康範; 西田直生志; 工藤正俊第101回日本消化器病学会総会  2015/04  仙台国際センター, 宮城VINCENTのvirtual sonographyとAWを用いたRFA前の安全なNavigation方法. ワークショップ7「Navitationに基づいた肝細胞癌IVR治療の最前線」  [Not invited]小川 力; 柴峠光成; 工藤正俊第101回日本消化器病学会総会  2015/04  仙台国際センター, 宮城司会: ワークショップ7「Navitationに基づいた肝細胞癌IVR治療の最前線」  [Invited]工藤正俊第101回日本消化器病学会総会  2015/04  仙台国際センター, 宮城ワークショップ7 基調講演「Navigationに基づいた肝細胞癌IVR治療」  [Invited]工藤正俊第101回日本消化器病学会総会  2015/04  仙台国際センター, 宮城機能性ディスペプシア患者における早期慢性膵炎所見について. ワークショップ2「機能性ディスペプシア診療の現状と将来」  [Not invited]門阪薫平; 北野雅之; 工藤正俊第101回日本消化器病学会総会  2015/04  仙台国際センター, 宮城早期慢性膵炎の診断基準と臨床的意義. パネルディスカッション11「早期慢性膵炎の病態と予後」  [Not invited]北野雅之; 門阪薫平; 工藤正俊第101回日本消化器病学会総会  2015/04  仙台国際センター, 宮城Activin signal promotes cancer progression and is involved in cachexia in a subset of pancreatic cancer  [Not invited]Togashi Y; Kogita A; Sakamoto H; Hayashi H; Terashima M; de Velasco MA; Sakai K; Fujita Y; Tomida S; Kitano M; Kudo M; Nishio KAmerican Association for Cancer Research Annual Meeting (AACR 2015)  2015/04  Philadelphia, USAAxitinib safety and pharmacokinetics in Child-Pugh A and Child-Pugh B patients with advanced hepatocellular cancer  [Not invited]Kang YK; Seery TE; Kato M; Chakrabarti D; Valota O; Chen Y; Jie T; Pithavala Y; Kudo MAmerican Association for Cancer Research Annual Meeting (AACR 2015)  2015/04  Philadelphia, USA座長  [Invited]工藤正俊第12回Kinki Liver Clubバニプレビル学術講演会  2015/04  スイスホテル南海大阪, 大阪開会・閉会の辞  [Invited]工藤正俊第12回Kinki Liver Clubバニプレビル学術講演会  2015/04  スイスホテル南海大阪, 大阪ポスターセッション座長  [Not invited]工藤正俊第112回日本内科学会総会  2015/04  みやこめっせ, 京都座長: 医学生研修医ポスターセッション  [Not invited]工藤正俊第112回日本内科学会総会  2015/04  みやこめっせ, 京都Time intensity curve (TIC)を用いた造影ハーモニックEUSによる膵腫瘍血流評価の検討  [Not invited]大本俊介; 北野雅之; 工藤正俊第28回日本腹部造影エコー・ドプラ診断研究会  2015/04  札幌医科大学, 北海道転移性肝癌に対してUS-US fusionを用いたラジオ波焼灼術  [Not invited]南 知宏; 南 康範; 千品寛和; 有住忠晃; 田北雅弘; 北井 聡; 矢田典久; 萩原 智; 上嶋一臣; 西田直生志; 工藤正俊第28回日本腹部造影エコー・ドプラ診断研究会  2015/04  札幌医科大学, 北海道A randomized, double-blind, placebo-controlled phase III trial of TSU-68 (Orantinib) combined with transcatheter arterial chemoembolization in patients with unresectable hepatocellular carcinoma  [Not invited]Park JW; Cheng AL; Kudo M; Park JH; Liang PC; Hidaka H; Izumi N; Heo J; Lee YJ; Sheen IS; Chiu CF; Arioka H; Morita S; Arai Y50th Annual Meeting of the European Association for the Study of the Liver (EASL 2015)  2015/04  Vienna, Austria特別講演「肝細胞癌に対する新規分子標的薬の開発動向と免疫チェックポイント阻害薬への期待」  [Invited]工藤正俊第18回北九州肝癌治療研究会  2015/03  リーガロイヤルホテル小倉, 九州Invited Lecture “WFUMB Guidelines”  [Invited]Masatoshi KudoAmerican Institute of Ultrasound in Medicine Annual Convention (AIUM 2015/WFUMB 2015)  2015/03  Florida, USAInvited Lecture “Liver strain”  [Invited]Masatoshi KudoAmerican Institute of Ultrasound in Medicine Annual Convention (AIUM 2015/WFUMB 2015)  2015/03  Florida, USA特別講演「透析患者におけるC型肝炎治療」  [Invited]工藤正俊南大阪透析患者の肝炎治療を考える会  2015/03  SAYAKAホール, 大阪Multicenter Observational Study of Reactivation of Hepatitis B Virus Caused by Chemotherapy with Sorafenib  [Not invited]Furuse J; Ikeda M; Kondo S; Kudo M; Nadano S; Osaki Y; Kumada T; Ohkawa K; Mizokami M24th Conference of APASL  2015/03  IstanbulMulticenter observational study of reactivation of hepatitis B virus caused by chemotherapy for solid tumors  [Not invited]Furuse J; Ikeda M; Kondo S; Kudo M; Nadano S; Osaki Y; Kumada T; Ohkawa K; Mizokami M24th Conference of APASL  2015/03  IstanbulPlain cone-beam CTによる肝動脈塞栓術の早期治療効果予測  [Not invited]南 康範; 南 知宏; 千品寛和; 有住忠晃; 田北雅弘; 北井 聡; 矢田典久; 萩原 智; 上嶋一臣; 西田直生志; 工藤正俊; 柳生行伸; 鶴崎正勝; 村上卓道第17回関西肝癌局所療法研究会  2015/03  阪急電鉄本社ビル, 大阪Invited Lecture “Recent advances in therapy for advanced hepatocellular carcinoma”  [Invited]Masatoshi KudoThe 24th Annual Conference of Asian Pacific Association for the Study of the Liver (APASL)  2015/03  Istanbul, Turkiye開会の辞  [Invited]工藤正俊第11回臨床消化器病フォーラム  2015/03  ホテルグランヴィア大阪, 大阪座長: 初心者から中級者に対する超音波検査の新しい取り組み~肝疾患を中心に~  [Invited]工藤正俊第9回Kinki GUT Club  2015/02  帝国ホテル大阪, 大阪慢性リンパ性白血病の発症を契機にB型肝炎の再活性化から急性肝不全を来し急速な転帰を辿った一例  [Not invited]渡部由佳子; 萩原 智; 南 知宏; 河野匡志; 千品寛和; 有住忠晃; 田北雅弘; 北井 聡; 矢田典久; 南 康範; 櫻井俊治; 上嶋一臣; 西田直生志; 工藤正俊日本消化器病学会近畿支部第102回例会  2015/02  京都テルサ, 京都ストレス応答蛋白を指標とするサーベイランス最適化の可能性. パネルディスカッション2「炎症性腸疾患関連腫瘍のサーベイランス」  [Not invited]櫻井俊治; 足立哲平; 樫田博史; 工藤正俊日本消化器病学会近畿支部第102回例会  2015/02  京都テルサ, 京都当院においてシングルバルーン小腸内視鏡検査を施行した高齢者OGIB症例の臨床的検討. シンポジウム2「消化管出血に対する診療」  [Not invited]田中梨絵; 樫田博史; 工藤正俊日本消化器病学会近畿支部第102回例会  2015/02  京都テルサ, 京都食道表在癌の日本食道学会拡大内視鏡分類による深達度の検討. ワークショップ10「食道扁平上皮(表在)癌に対する新規拡大内視鏡分類(食道学会分類)の検証」  [Not invited]朝隈 豊; 松井繁長; 山田光成; 田中梨絵; 足立哲平; 高山政樹; 峯 宏昌; 永井知行; 川崎正憲; 岡崎能久; 米田頼晃; 櫻井俊治; 樫田博史; 工藤正俊第11回日本消化管学会総会学術集会  2015/02  京王プラザホテル, 東京大腸ESD施行時の抗血栓薬の取り扱いの検討  [Not invited]足立哲平; 樫田博史; 工藤正俊第11回日本消化管学会総会学術集会  2015/02  京王プラザホテル, 東京司会: シンポジウム1「肝動脈塞栓下での血行動態の変化-B-TACEから得られる所見-」  [Not invited]工藤正俊第21回肝血流動態・機能イメージ研究会  2015/02  東京ビッグサイト「国際会議場」, 東京FNH様の異常門脈域などの示唆に富む病理所見を認めたHCCの一例  [Not invited]荒澤壮一; 小川 力; 野田晃世; 出田雅子; 久保敦司; 石川哲朗; 松中寿浩; 玉置敬之; 柴峠光成; 南 貴人; 北村好史; 西平友彦; 石川 亮; 荻野哲朗; 近藤福雄; 工藤正俊第21回肝血流動態・機能イメージ研究会  2015/02  東京ビッグサイト「国際会議場」, 東京座長: セッション4「画像による病態解析」  [Not invited]工藤正俊第21回肝血流動態・機能イメージ研究会  2015/02  東京ビッグサイト「国際会議場」, 東京plain cone-beam CTによる肝動脈塞栓術の早期治療効果予測(第2報)  [Not invited]南 康範; 村上卓道; 工藤正俊第21回肝血流動態・機能イメージ研究会  2015/02  東京ビッグサイト「国際会議場」, 東京RFA術前のシミュレーションに向けた教育システム. 当院における肝細胞癌に対するディーシービーズ®を用いたDEB-TACEの治療成績  [Not invited]小川 力; 野田晃世; 荒澤壮一; 出田雅子; 久保敦司; 石川哲朗; 松中寿浩; 玉置敬之; 柴峠光成; 工藤正俊第21回肝血流動態・機能イメージ研究会  2015/02  東京ビッグサイト「国際会議場」, 東京当院における肝細胞癌に対するディーシービーズ®を用いたDEB-TACEの治療成績  [Not invited]渡口真史; 鶴崎正勝; 柳生行伸; 沼本勲男; 朝戸信行; 山川美帆; 任 誠雲; 松木 充; 村上卓道; 井上達夫; 萩原 智; 南 康範; 上嶋一臣; 工藤正俊第21回肝血流動態・機能イメージ研究会  2015/02  東京ビッグサイト「国際会議場」, 東京門脈血栓, 肝内胆管拡張に, 流体の変化を伴い安全にB-TACEを行えた一例  [Not invited]出田雅子; 小川 力; 野田晃世; 荒澤壮一; 久保敦司; 石川哲朗; 松中寿浩; 玉置敬之; 柴峠光成; 石川 亮; 荻野哲朗; 工藤正俊第21回肝血流動態・機能イメージ研究会  2015/02  東京ビッグサイト「国際会議場」, 東京C型慢性肝炎のインターフェロン治療効果から考えるStrain elastographyおよびShear wave elastography同時観察による肝の病態把握の可能性  [Not invited]矢田典久; 工藤正俊第21回肝血流動態・機能イメージ研究会  2015/02  東京ビッグサイト「国際会議場」, 東京特別講演「肝がんの分子標的治療~現状と今後の展望~」  [Not invited]工藤正俊肝疾患学術講演会  2015/01  ホテルアバローム紀の国2F, 和歌山特別講演「肝細胞癌診療: 最近の進歩」  [Not invited]工藤正俊第15回兵庫県肝がん撲滅研究会  2015/01  ANAクラウンプラザホテル神戸, 兵庫Invited Lecture “The Eastern point of view”  [Invited]Masatoshi KudoEastern & Western Association Liver Tumors (1st ewalt)  2015/01  Milan, ItalyPhase II study of front-line dovitinib (TKI258) versus sorafenib in patients (Pts) with advanced hepatocellular carcinoma (HCC)  [Not invited]Cheng AL, Thongprasert S; Lim HY; Sukeepaisarnjaroen, W; Yang TS; Wu CC; Chao Y; Chang L; Kudo M; Ikeda M; Kang Y; Pan H; Numata K; Han G; Balsara B; Zhang Y; Rodriguez AM; Zhang Y; Wang Y; Poon RT2015 Gastrointeritinal Cancers Symposium (ASCO-GI 2015)  2015/01  San Francisco, California, USA特別発言  [Invited]工藤正俊TACE Meet the Expert  2015/01  ホテルモントレグラスミア大阪, 大阪司会: パネルディスカッション  [Invited]工藤正俊TACE Meet the Expert  2015/01  ホテルモントレグラスミア大阪, 大阪特別講演「肝癌に対する分子標的治療:現状と今後の展望」  [Invited]工藤正俊第1回東北肝癌分子標的治療セミナー  2014/12  TKP仙台カンファレンスセンター3F, 仙台, 宮城Invited Lecture “Molecular targeted therapy for HCC: Past, present and future perspective”  [Invited]Masatoshi Kudo24th World Congress of the International Association of Surgeons, Gastroenterologists and Oncologists (IASGO 2014)  2014/12  Vienna, AustriaEndoscopic resection for rectal nets (neuroendocrine tumors): EMR-C (EMR using a cap), EMR-L (EMR with a ligation device), or conventional EMR  [Not invited]Yamada M; Kashida H; Tanaka R; Adachi T; Mine H; Takayama M; Okazaki Y; Nagata Y; Nagai T; Kawasaki M; Komeda N; Asakuma Y; Sakurai T; Matsui S; Kudo MAsian Pacific Digetive Week (APDW 2014)  2014/11  Bali, IndonesiaSmall-intestinal mucosal injury induced by non-steroidal anti-inflammatory drugs or antiplatelet agents in our hospital  [Not invited]Nagai T; Tanaka R; Yamada M; Adachi T; Takayama M; Mine H; Okazaki Y; Komeda Y; Asakuma Y; Sakurai T; Matsui S; Kashida H; Kudo MAsian Pacific Digetive Week (APDW 2014)  2014/11  Bali, IndonesiaThe clinical characteristics and treatment of eosinophilic esophagitis  [Not invited]Matsui S; Kashida H; Kawasaki M; Asakuma Y; Sakurai T; Kudo MAsian Pacific Digetive Week (APDW 2014)  2014/11  Bali, IndonesiaTwo cases of gastric amyloidosis  [Not invited]Matsui S; Kashida H; Okamoto K; Asakuma Y; Sakurai T; Kudo MAsian Pacific Digetive Week (APDW 2014)  2014/11  Bali, IndonesiaColorectal endoscopic submucosal dissection is useful and safe  [Not invited]Kashida H; Adachi T; Komeda Y; Sakurai T; Asakuma Y; Takayama M; Mine H; Kudo MAsian Pacific Digetive Week (APDW 2014)  2014/11  Bali, IndonesiaComparison of Japanese primary and secondary regimen of Helicobacter pylori eradication  [Not invited]Adachi T; Tanaka R; Yamada M; Takayama M; Mine H; Nagai T; Kawasaki M; Asakuma Y; Okazaki Y; Komeda Y; Sakurai T; Matsui S; Kashida H; Kudo MAsian Pacific Digetive Week (APDW 2014)  2014/11  Bali, IndonesiaThe usefulness of single-balloon endoscopy for the small bowel lesions  [Not invited]Adachi T; Tanaka R; Yamada M; Takayama M; Mine H; Nagai T; Kawasaki M; Asakuma Y; Okazaki Y; Komeda Y; Sakurai T; Matsui S; Kashida H; Kudo MAsian Pacific Digetive Week (APDW 2014)  2014/11  Bali, Indonesia司会: 特別講演「肝硬変の治療マネジメントup-to date 2014」  [Invited]工藤正俊OTSUKA Liver Forum 2014  2014/11  ホテルニューオータニ東京, 東京特別講演「びまん性肝疾患診療におけるReal-time Tissue Elastographyの役割」  [Invited]工藤正俊日本超音波医学会第41回関西地方会学術集会  2014/11  ホテルグランヴィア京都, 京都低音圧Tissue Harmonic Imagingによる造影下穿刺治療画面の提案  [Not invited]前川 清; 横川美加; 前野知子; 塩見香織; 井上達夫; 南 康範; 工藤正俊日本消化器内視鏡学会近畿支部第93回支部例会  2014/11  大阪国際交流センター, 大阪特別講演「Liver」  [Invited]工藤正俊日本超音波医学会第41回関西地方会学術集会  2014/11  ホテルグランヴィア京都, 京都座長: 特別企画「Elastography診断のデファクトスタンダードに向けて」  [Invited]工藤正俊日本超音波医学会第41回関西地方会学術集会  2014/11  ホテルグランヴィア京都, 京都Chair "Session 5: Hepatocellular carcinoma, basic and therapy"  [Invited]Masatoshi KudoThe 11th JSH Single Topic Conference  2014/11  Hotel Granvia Hiroshima, HiroshimaWalled-off necrosisに対してリタリックステントを用いたEUS下ドレナージ術が有用であった1例  [Not invited]古川健太郎; 北野雅之; 大本俊介; 門阪薫平; 宮田 剛; 鎌田 研; 山雄健太郎; 今井 元; 坂本洋城; 工藤正俊日本消化器内視鏡学会近畿支部第93回支部例会  2014/11  大阪国際交流センター, 大阪腸結核の4例  [Not invited]中尾剛幸; 樫田博史; 米田頼晃; 山田光成; 田中梨絵; 足立哲平; 峯 宏昌; 高山政樹; 岡崎能久; 朝隈 豊; 櫻井俊治; 松井繁長; 工藤正俊; 佐野博幸; 前西 修; 佐藤隆夫日本消化器内視鏡学会近畿支部第93回支部例会  2014/11  大阪国際交流センター, 大阪ステロイドが奏効したCronkhite-Canada症候群の1例  [Not invited]長原 大; 奥田英之; 秦 康倫; 木下大輔; 永井知行; 岸谷 譲; 川崎俊彦; 若狭朋子; 太田善夫; 工藤正俊日本消化器内視鏡学会近畿支部第93回支部例会  2014/11  大阪国際交流センター, 大阪ESDにて切除しえた胃底腺型胃癌の一例  [Not invited]高場雄久; 尾崎信人; 松本 望; 川崎正憲; 冨田崇文; 梅原康湖; 森村正嗣; 米田 円; 山田 哲; 辻 直子; 落合 健; 前倉俊治; 工藤正俊日本消化器内視鏡学会近畿支部第93回支部例会  2014/11  大阪国際交流センター, 大阪肝硬変を合併した限局性強皮症における難治性上部消化管出血にアルゴンプラズマ凝固法が有効であった一例  [Not invited]南 康範; 大本俊介; 松井繁長; 北野雅之; 樫田博史; 工藤正俊日本消化器内視鏡学会近畿支部第93回支部例会  2014/11  大阪国際交流センター, 大阪高齢者または手術不能の急性胆嚢炎に対するEUS下胆嚢ドレナージ術. ワークショップ1「緊急内視鏡の現状とマネージメント」  [Not invited]門阪薫平; 北野雅之; 工藤正俊日本消化器内視鏡学会近畿支部第93回支部例会  2014/11  大阪国際交流センター, 大阪小腸内視鏡から見たovertOGIBの特徴.ワークショップ2「カプセル内視鏡とバルーン内視鏡の現状と展望」  [Not invited]岡﨑能久; 樫田博史; 工藤正俊日本消化器内視鏡学会近畿支部第93回支部例会  2014/11  大阪国際交流センター, 大阪当院におけるEUS-BDの成績. パネルディスカッション2「胆膵疾患における診断と治療」  [Not invited]山雄健太郎; 北野雅之; 工藤正俊日本消化器内視鏡学会近畿支部第93回支部例会  2014/11  大阪国際交流センター, 大阪司会: 特別講演「消化器内視鏡医学の最新動向と今後求められる方向性」  [Invited]工藤正俊2014/11  大阪国際交流センター, 大阪大腸ESD施行時の出血のリスクについての検討. パネルディスカッション1「内視鏡治療における偶発症の予防と対処法」  [Not invited]足立哲平; 樫田博史; 工藤正俊日本消化器内視鏡学会近畿支部第93回支部例会  2014/11  大阪国際交流センター, 大阪開会の挨拶  [Invited]工藤正俊第32回南大阪肝疾患研究会  2014/11  ホテル第一堺, 大阪Involvement of stress response protein crip in refractory inflammatory bowel diseases and colitis-associated cancer. Symposium 1 “Cancer prevention and early diagnosis”  [Not invited]Sakurai T; Kashida H; Kudo MThe 25th Annual Meeting of the Japanese Society for Gastroenterological Carcinogenesis  2014/11  ホテル日航福岡How is BCLC stage C HCC treated in real-word practice and what outcomes are obtained?  [Not invited]Roayaie S; Jibara G; Tabrizian P; Park JW; Yang J; Yan L; Han G; Izzo F; Chen M; Blanc JF; Johnson P; Kudo M; Roberts LR; Sherman M65th Annual Meeting, American Association for the Study of Liver Diseases (AASLD2014)  2014/11  Boston, USAEarly response prediction of hepatocellular carcinoma to conventional transcatheter chemoembolization using intraprocedual plain cone-beam CT  [Not invited]Minami Y; Kudo M65th Annual Meeting, American Association for the Study of Liver Diseases (AASLD2014)  2014/11  Boston, USAPathological feature, oxidative DNA damage and epigenetic alteration of tumor suppressor genes in nonalcoholic fatty liver disease  [Not invited]Nishida N; Yada N; Chishina H; Arizumi T; Takita M; Kitai S; Inoue T; Hagiwara S; Minami Y; Ueshima K; Sakurai T; Kudo M65th Annual Meeting, American Association for the Study of Liver Diseases (AASLD2014)  2014/11  Boston, USAInvited Lecture “Interventaional and contrast EUS for pancreatobiliary disease”  [Invited]Masatoshi KudoThe 11the Congress of the Asian Federation of Societies for Ultrasound and Biology (AFSUMB 2014)  2014/10  Kuala Lumpur, MalaysiaInvited Lecture “Fusion imaging for treatment guidance of hepatic tumours”  [Invited]Masatoshi KudoThe 11the Congress of the Asian Federation of Societies for Ultrasound and Biology (AFSUMB 2014)  2014/10  Kuala Lumpur, MalaysiaH. Pylori陰性C-0胃症例のたこいぼびらんに認めた腸上皮化生についての検討  [Not invited]辻 直子; 尾崎信人; 松本 望; 高場雄久; 川崎正憲; 冨田崇文; 梅原康湖; 谷池聡子; 森村正嗣; 米田 円; 山田 哲; 落合 健; 前倉俊治; 工藤正俊第22回日本消化器関連学会週間JDDW2014(第88回日本消化器内視鏡学会総会, 第56回日本消化器病学会大会, 第18回日本肝臓学会大会, 第12回日本消化器外科学会大会, 第52回日本消化器がん検診学会大会)  2014/10  神戸国際展示場・ポートピアホテル・神戸国際会議場, 兵庫経乳頭処置困難総胆管結石に対するrendezvous法の手技と成績. ワークショップ21「胆管結石治療困難例への戦略《ビデオ》」  [Not invited]山雄健太郎; 北野雅之; 工藤正俊第22回日本消化器関連学会週間JDDW2014(第88回日本消化器内視鏡学会総会, 第56回日本消化器病学会大会, 第18回日本肝臓学会大会, 第12回日本消化器外科学会大会, 第52回日本消化器がん検診学会大会)  2014/10  神戸国際展示場・ポートピアホテル・神戸国際会議場, 兵庫EUSガイド下胆道ドレナージ術における金属ステントの有用性. パネルディスカッション17「悪性消化管・胆管閉塞に対する内視鏡的金属ステント治療の進歩」  [Not invited]今井 元; 北野雅之; 工藤正俊第22回日本消化器関連学会週間JDDW2014(第88回日本消化器内視鏡学会総会, 第56回日本消化器病学会大会, 第18回日本肝臓学会大会, 第12回日本消化器外科学会大会, 第52回日本消化器がん検診学会大会)  2014/10  神戸国際展示場・ポートピアホテル・神戸国際会議場, 兵庫Predictive factors for pain relief after EUS-guided neurolysis in patietnts suffering from upper abdominal cancer pain. International Session (Symposium) 6 “EUS-guided therapy: current status and future directions”  [Not invited]Kitano M; Sakamoto H; Kudo MJapan Digestive Disease Week 2014 (JDDW)  2014/10  KobePPI内服による胃底腺ポリープの変化  [Not invited]河野 匡; 梅原康湖; 辻 直子; 尾崎信人; 松本 望; 高場雄久; 川崎正憲; 冨田崇文; 森村正嗣; 山田 哲; 米田 円; 落合 健; 前倉俊治; 工藤正俊第22回日本消化器関連学会週間JDDW2014(第88回日本消化器内視鏡学会総会, 第56回日本消化器病学会大会, 第18回日本肝臓学会大会, 第12回日本消化器外科学会大会, 第52回日本消化器がん検診学会大会)  2014/10  神戸国際展示場・ポートピアホテル・神戸国際会議場, 兵庫腫瘍径1cm以内の膵癌の特徴と診断ストラテジー. ワークショップ15「微小膵癌発見のための検査・診断法」  [Not invited]宮田 剛; 北野雅之; 工藤正俊第22回日本消化器関連学会週間JDDW2014(第88回日本消化器内視鏡学会総会, 第56回日本消化器病学会大会, 第18回日本肝臓学会大会, 第12回日本消化器外科学会大会, 第52回日本消化器がん検診学会大会)  2014/10  神戸国際展示場・ポートピアホテル・神戸国際会議場, 兵庫早期慢性膵炎におけるEUS画像所見と臨床的意義の検討. ワークショップ14「慢性膵炎とその進展予防」  [Not invited]門阪薫平; 北野雅之; 工藤正俊第22回日本消化器関連学会週間JDDW2014(第88回日本消化器内視鏡学会総会, 第56回日本消化器病学会大会, 第18回日本肝臓学会大会, 第12回日本消化器外科学会大会, 第52回日本消化器がん検診学会大会)  2014/10  神戸国際展示場・ポートピアホテル・神戸国際会議場, 兵庫胆膵良性疾患の救命救急におけるEUS下ドレナージ術の位置づけ. ワークショップ13「Life saving endoscopy」  [Not invited]山雄健太郎; 北野雅之; 工藤正俊第22回日本消化器関連学会週間JDDW2014(第88回日本消化器内視鏡学会総会, 第56回日本消化器病学会大会, 第18回日本肝臓学会大会, 第12回日本消化器外科学会大会, 第52回日本消化器がん検診学会大会)  2014/10  神戸国際展示場・ポートピアホテル・神戸国際会議場, 兵庫NBNC肝癌の背景肝におけるメチル化プロファイルと加齢および糖尿病の影響. シンポジウム14「NBNC肝がんの諸問題」  [Not invited]西田直生志; 工藤正俊第22回日本消化器関連学会週間JDDW2014(第88回日本消化器内視鏡学会総会, 第56回日本消化器病学会大会, 第18回日本肝臓学会大会, 第12回日本消化器外科学会大会, 第52回日本消化器がん検診学会大会)  2014/10  神戸国際展示場・ポートピアホテル・神戸国際会議場, 兵庫嚢胞性膵疾患の鑑別診断および経過観察におけるEUSの有用性~造影法を含めて~  [Not invited]鎌田 研; 北野雅之; 工藤正俊第22回日本消化器関連学会週間JDDW2014(第88回日本消化器内視鏡学会総会, 第56回日本消化器病学会大会, 第18回日本肝臓学会大会, 第12回日本消化器外科学会大会, 第52回日本消化器がん検診学会大会)  2014/10  神戸国際展示場・ポートピアホテル・神戸国際会議場, 兵庫当院における食道表在癌の日本食道学会拡大内視鏡分類による深達度診断の検討  [Not invited]朝隈 豊; 松井繁長; 南 知行; 山田光成; 田中梨絵; 足立哲平; 高山政樹; 峯 宏昌; 永井知行; 櫻井俊治; 樫田博史; 工藤正俊; 白石 治; 安田卓司第22回日本消化器関連学会週間JDDW2014(第88回日本消化器内視鏡学会総会, 第56回日本消化器病学会大会, 第18回日本肝臓学会大会, 第12回日本消化器外科学会大会, 第52回日本消化器がん検診学会大会)  2014/10  神戸国際展示場・ポートピアホテル・神戸国際会議場, 兵庫ピロリ菌感染に対する胃粘膜防御機構. ワークショップ4「胃/十二指腸粘膜防御とその破綻-revisited」  [Not invited]櫻井俊治; 樫田博史; 工藤正俊第22回日本消化器関連学会週間JDDW2014(第88回日本消化器内視鏡学会総会, 第56回日本消化器病学会大会, 第18回日本肝臓学会大会, 第12回日本消化器外科学会大会, 第52回日本消化器がん検診学会大会)  2014/10  神戸国際展示場・ポートピアホテル・神戸国際会議場, 兵庫背景肝によるReal-time Tissue Elastography画像の違い-HBVとHCVとの比較-. パネルディスカッション8「画像診断を駆使した肝疾患治療の最前線」  [Not invited]矢田典久; 河田則文; 工藤正俊第22回日本消化器関連学会週間JDDW2014(第88回日本消化器内視鏡学会総会, 第56回日本消化器病学会大会, 第18回日本肝臓学会大会, 第12回日本消化器外科学会大会, 第52回日本消化器がん検診学会大会)  2014/10  神戸国際展示場・ポートピアホテル・神戸国際会議場, 兵庫司会: パネルディスカッション7「進行肝癌の集学的治療: 予後とQOLの観点から」  [Not invited]工藤正俊第22回日本消化器関連学会週間JDDW2014(第88回日本消化器内視鏡学会総会, 第56回日本消化器病学会大会, 第18回日本肝臓学会大会, 第12回日本消化器外科学会大会, 第52回日本消化器がん検診学会大会)  2014/10  神戸国際展示場, 兵庫座長: ランチョンセミナー34「HCCの診断と治療UP TO DATE」  [Not invited]工藤正俊第22回日本消化器関連学会週間JDDW2014(第88回日本消化器内視鏡学会総会, 第56回日本消化器病学会大会, 第18回日本肝臓学会大会, 第12回日本消化器外科学会大会, 第52回日本消化器がん検診学会大会)  2014/10  ポートピアホテル, 兵庫当院におけるヘリコバクターピロリ除菌の治療成績の検討  [Not invited]足立哲平; 南 知行; 田中梨絵; 山田光成; 高山政樹; 峯 宏昌; 永井知行; 朝隈 豊; 櫻井俊治; 松井繁長; 樫田博史; 工藤正俊第22回日本消化器関連学会週間JDDW2014(第88回日本消化器内視鏡学会総会, 第56回日本消化器病学会大会, 第18回日本肝臓学会大会, 第12回日本消化器外科学会大会, 第52回日本消化器がん検診学会大会)  2014/10  神戸国際展示場・ポートピアホテル・神戸国際会議場, 兵庫腸粘膜防御機構におけるストレス応答蛋白の役割. ワークショップ1「腸粘膜防御機構の維持と再生をめざして」  [Not invited]櫻井俊治; 足立哲平; 工藤正俊第22回日本消化器関連学会週間JDDW2014(第88回日本消化器内視鏡学会総会, 第56回日本消化器病学会大会, 第18回日本肝臓学会大会, 第12回日本消化器外科学会大会, 第52回日本消化器がん検診学会大会)  2014/10  神戸国際展示場・ポートピアホテル・神戸国際会議場, 兵庫当院における肝転移に対する経皮的ラジオ波焼灼術  [Not invited]南 康範; 中居卓也; 工藤正俊第22回日本消化器関連学会週間JDDW2014(第88回日本消化器内視鏡学会総会, 第56回日本消化器病学会大会, 第18回日本肝臓学会大会, 第12回日本消化器外科学会大会, 第52回日本消化器がん検診学会大会)  2014/10  神戸国際展示場・ポートピアホテル・神戸国際会議場, 兵庫VINCENTの仮想超音波システムとGE社のワークステーションAWを用いたRFA前のシミュレーション.  [Not invited]小川 力; 森岡弓子; 野田晃世; 荒澤壮一; 出田雅子; 久保敦司; 松中寿浩; 玉置敬之; 柴峠光成; 工藤正俊第22回日本消化器関連学会週間JDDW2014(第88回日本消化器内視鏡学会総会, 第56回日本消化器病学会大会, 第18回日本肝臓学会大会, 第12回日本消化器外科学会大会, 第52回日本消化器がん検診学会大会)  2014/10  神戸国際展示場・ポートピアホテル・神戸国際会議場, 兵庫B-modeで描出困難な肝癌に対するFusion imaging+造影USガイドでのラジオ波焼灼術  [Not invited]南 知宏; 南 康範; 千品寛和; 有住忠晃; 田北雅弘; 北井 聡; 矢田典久; 井上達夫; 萩原 智; 上嶋一臣; 西田直生志; 工藤正俊第22回日本消化器関連学会週間JDDW2014(第88回日本消化器内視鏡学会総会, 第56回日本消化器病学会大会, 第18回日本肝臓学会大会, 第12回日本消化器外科学会大会, 第52回日本消化器がん検診学会大会)  2014/10  神戸国際展示場・ポートピアホテル・神戸国際会議場, 兵庫Colitc cancerにおけるストレス応答蛋白の役割. パネルディスカッション5「消化管とがん幹細胞」  [Not invited]櫻井俊治; 樫田博史; 工藤正俊第22回日本消化器関連学会週間JDDW2014(第88回日本消化器内視鏡学会総会, 第56回日本消化器病学会大会, 第18回日本肝臓学会大会, 第12回日本消化器外科学会大会, 第52回日本消化器がん検診学会大会)  2014/10  神戸国際展示場・ポートピアホテル・神戸国際会議場, 兵庫急性膵炎の病態把握におけるプロカルシトニンの有用性について. シンポジウム2「重症急性膵炎の病態と有効な初期治療をめざして」  [Not invited]大本俊介; 北野雅之; 工藤正俊第22回日本消化器関連学会週間JDDW2014(第88回日本消化器内視鏡学会総会, 第56回日本消化器病学会大会, 第18回日本肝臓学会大会, 第12回日本消化器外科学会大会, 第52回日本消化器がん検診学会大会)  2014/10  神戸国際展示場・ポートピアホテル・神戸国際会議場, 兵庫Prospective multicenter randomized controlled trial of histological diagnostic yield comparing 25G EUG-FNA needles with and without a core trap in solid pancreatic masses: analysis of factors affecting tissue acquisition and diagnostic accuracy  [Not invited]Nebiki H; Yanagisawa A; Yasukawa S; Kamata K; Kudo M; Ogura T; Higuchi K; Fukutake N; Ashida R; Yamasaki T; Hirose S; Hoki N; Asada M; Yazumi S; Takaoka M; Okazaki K; Matsuda F; Okabe Y; Kitano MUnited European Gastroenterology Week (UEGW 2014)  2014/10  Vienna, AustriaValidation of staging systems for hepatocellular carcinoma: a comparison of the BM-JIS score, the JIS score and the BCLC staging  [Not invited]Kitai S; Kudo M; Nishida N; Izumi N; Sakamoto M; Matsuyama Y; Ichida T; Nakashima O; Matsui O; Ku Y; Kokudo N; Makuuchi M; Liver Cancer Study; Group of JapanUnited European Gastroenterology Week (UEGW 2014)  2014/10  Vienna, Austria悪性消化管、胆道狭窄に対する治療戦略~EUS下胆道ドレナージと消化管ステントによるdouble stentingの有用性~  [Not invited]山雄健太郎; 北野雅之; 工藤正俊第63回近畿膵疾患談話会  2014/10  エーザイ株式会社大阪コミュニケーションオフィス, 大阪甲状腺クリーゼを契機に急性肝不全を発症した1例  [Not invited]山本貴子; 萩原 智; 千品寛和; 河野匡志; 有住忠晃; 田北雅弘; 北井 聡; 井上達夫; 矢田典久; 南 康範; 櫻井俊治; 上嶋一臣; 西田直生志; 工藤正俊; 庭野史丸; 池上博司日本消化器病学会近畿支部第101回例会  2014/10  大阪国際交流センター, 大阪肝左葉切除後の肝門部胆管閉塞に対し超音波内視鏡下胆管胃吻合術(EUS-HGS)が奏効した一例  [Not invited]加藤 寛; 宮田 剛; 北野雅之; 大本俊介; 門阪薫平; 鎌田 研; 山雄健太郎; 今井 元; 坂本洋城; 工藤正俊日本消化器病学会近畿支部第101回例会  2014/10  大阪国際交流センター, 大阪EUS-FNAにて診断可能であった、腎癌膵転移の1例  [Not invited]濱田隆介; 木下大輔; 秦 康倫; 奥田英之; 永井知行; 岸谷 譲; 川崎俊彦; 若狭朋子; 太田善夫; 工藤正俊日本消化器病学会近畿支部第101回例会  2014/10  大阪国際交流センター, 大阪大腸表在癌・腺腫に対する大腸ESDの現況について. ワークショップ1「消化管表在癌に対する内視鏡的治療の現況と位置づけ」  [Not invited]米田頼晃; 樫田博史; 櫻井俊治; 工藤正俊日本消化器病学会近畿支部第101回例会  2014/10  大阪国際交流センター, 大阪潰瘍性大腸炎における腸管感染症の合併. ワークショップ3「急性消化管感染症の臨床」  [Not invited]田中梨絵; 櫻井俊治; 樫田博史; 工藤正俊日本消化器病学会近畿支部第101回例会  2014/10  大阪国際交流センター, 大阪EUS下胆嚢ドレナージ術の有用性. ワークショップ2「肝胆膵疾患の診断と治療の進歩」  [Not invited]今井 元; 北野雅之; 工藤正俊日本消化器病学会近畿支部第101回例会  2014/10  大阪国際交流センター, 大阪当院におけるNSAIDs/LDAによる小腸粘膜傷害の現況. シンポジウム1「NSAIDs/LDAによる薬剤性消化管障害」  [Not invited]永井知行; 樫田博史; 工藤正俊日本消化器病学会近畿支部第101回例会  2014/10  大阪国際交流センター, 大阪An International observational study to assess the use of sorafenib after transarterial chemoembolization (TACE) in patients with hepatocellular carcinoma (HCC): OPTIMIS  [Not invited]Raoul JL; Peck-Radosavljevic M; Lee HC; Kudo M; Nakajima K; Cheng AL; on behalf of the; OPTIMIS investigatorsEuropean Society for Medical Oncology Congress (ESMO 2014)  2014/09  Madrid, SpainRandomised study of axitinib (Axi) plus best supportive care (BSC) versus placebo (Pbo) plus BSC in patients with advanced hepatocellular carcinoma (HCC) following prior antiangiogenic therapy  [Not invited]Kang YK; Yau T; Park JW; Boucher E; Lim HY; Poon RTP; Lee TY; Obi S; Chan SL; Qin SK; Kim RD; Tang J; Valota O; Chakrabarti D; Kudo MEuropean Society for Medical Oncology Congress (ESMO 2014)  2014/09  Madrid, SpainRamucirumab (RAM; IMC-1121B) as Second-Line Treatment in Patients with Advanced Hepatocellular Carcinoma Following First-Line Therapy With Sorafenib: Results from the Randomized Phase III REACH Study  [Invited]Zhu A; Ryoo BY; Yen CJ; Kudo M; Poon R; Pastorelli D; Blanc JF; Chung H; Baron A; Pfiffer T; Okusaka T; Kubackova K; Trojan J; Sastre J; Chau I; Chang SC; Abada P; Yang L; Schwartz J; Park JEuropean Society for Medical Oncology Congress (ESMO 2014)  2014/09  Madrid, SpainStress response protein Cirp links inflammation and tumorigenesis in colitis-associated cancer  [Not invited]Sakurai T; Kudo M; Nishida N; Fujita J; Kashida HThe 73rd Annual Meeting of the Japanese Cancer Association  2014/09  Pacifico YokohamaVINCENTの仮想超音波とAWを併用した経皮的RFAのシミュレーション. シンポジウム2「経皮的治療もしくはInterventional Radiologyにおけるシミュレーション・ナビゲーション技術の最近の工夫」  [Not invited]小川 力; 荒澤壮一; 出田雅子; 柴峠光成; 工藤正俊第9回肝癌治療シミュレーション研究会  2014/09  大阪国際会議場, 大阪座長"症例検討会"  [Invited]工藤正俊第9回肝癌治療シミュレーション研究会  2014/09  大阪国際会議場, 大阪招待講演「造影超音波の新しい展開: 肝癌スクリーニングと肉眼形態診断への応用」  [Invited]工藤正俊日本超音波医学会第24回九州地方会学術集会  2014/09  福岡国際会議場, 福岡座長: 肝細胞癌のサブクラス分類-Molecular Classificationと病理からの視点-  [Invited]工藤正俊第9回大阪肝臓ミーティング  2014/09  ANAクラウンプラザホテル大阪, 大阪座長: C型肝炎に対するDAAs治療-当院の使用経験も含めて-  [Invited]工藤正俊大阪C型肝疾患DAAs治療セミナー  2014/09  スイスホテル南海大阪, 大阪B-mode ultrasonography versus contrast-enhanced ultrasonography for surveillance of hepatocellular carcinoma: a prospective multicenter randomized controlled trial (Nct01507168)  [Not invited]Kudo M; Ueshima K; Osaki Y; Hirooka M; Imai Y; Aso K; Numata K; Ichinose M; Kumada T; Izumi N; Sumino Y; Akazawa K8th Annual Conference, International Liver Cancer Association (ILCA 2014)  2014/09  Kyoto, JapanChair “e-poster viewing tour and networking break”  [Invited]Masatoshi Kudo8th ILCA Annual Conference  2014/09  Hotel Granvia Kyoto, KyotoSTORM: A phase III, randomized, double-blind, placebo-controlled trial of adjuvant sorafenib after resection or ablation to prevent recurrence of hepatocellular carcinoma  [Not invited]Llovet JM; Takayama T; Mazzaferro V; Chau GY; Yang J; Kudo M; Cai J; Poon RT; Han KH; Tak WY; Lee HC; Song T; Roaayaie S; Bolondi L; Lee KS; Makuuchi M; Souza F; Le Berre MA; Meinhardt G; Bruix J; on behalf of the; STORM investigators8th Annual Conference, International Liver Cancer Association (ILCA 2014)  2014/09  Hotel Granvia KyotoNewly simulated virtual ultrasound sonography software before RFA  [Not invited]Ogawa C; Kudo M8th Annual Conference, International Liver Cancer Association (ILCA 2014)  2014/09  Hotel Granvia KyotoProposals for improvement of the AJCC/UICC and Japanese staging systems for intrahepatic cholangiocarcinoma in review of the Japanese nationwide database  [Not invited]Sakamoto Y; Kokudo N; Matsuyama Y; Izumi N; Ichida T; Ku Y; Kudo M; Sakamoto M; Takayama T; Nakashima O; Matsui O8th Annual Conference, International Liver Cancer Association (ILCA 2014)  2014/09  Hotel Granvia Kyoto, JapanEarly response prediction of hepatocellular carcinoma to conventional transcatheter chemoembolization using intraprocedual plain cone-beam CT  [Not invited]Minami Y; Murakami T; Kudo M8th Annual Conference, International Liver Cancer Association (ILCA 2014)  2014/09  Hotel Granvia Kyoto, JapanHow is BCLC stage C HCC treated in real-word practice and what outcomes are obtained? Answers from the Bridge database  [Not invited]Roayaie S; Jibara G; Tabrizian P; Park JW; Yang J; Yan L; Han G; Izzo F; Chen M; Blanc JF; Johnson P; Kudo M; Roberts LR; Sherman M8th Annual Conference, International Liver Cancer Association (ILCA 2014)  2014/09  Hotel Granvia Kyoto, JapanTumor response to transarterial chemoembolization in unresectable hepatocellular carcinoma patients in clinical practice: findings from the GIDEON database  [Not invited]Kudo M; Marrero J; Lencioni R; Nakajima K; Ye SL8th Annual Conference, International Liver Cancer Association (ILCA 2014)  2014/09  Hotel Granvia Kyoto, JapanRandomized phase II trial of intravenous RO5137382/GC33 at 1600 mg every other week and placebo in previously treated patients with unresectable advanced hepatocellular carcinoma (HCC) (NCT01507168)  [Not invited]Kudo M; Yen CJ; Daniele B; Merle P; Park JW; Ross P; Peron JM; Ebert O; Chan S; Poon TP; Colombo M; Okusaka T; Ryoo BY; Minguez B; Tanaka T; Ohtomo T; Rutman O; Chen YC; Lee R; Abou-Alfa GK8th Annual Conference, International Liver Cancer Association (ILCA 2014)  2014/09  Hotel Granvia Kyoto, JapanInvited Lecture “Surveillance, treatment and outcome of HCC in Japan”, ILCA Symposium 3 “Noevel opportunities for treatment in HCC”  [Invited]Masatoshi KudoThe 8th Annual Conference, International Liver Cancer Association (ILCA)  2014/09  Hotel Granvia Kyoto, Japan特別講演「肝細胞癌の分子標的治療: 現状と今後の課題」  [Invited]工藤正俊TACE Refractory Focus Expert Meeting  2014/08  JRクレメントホテル高松, 香川座長"新たなTACE不応の定義をめぐって"  [Not invited]工藤正俊Nexavar HCC Web Conference  2014/07Chair "Symposium 2 “Treatment strategy for advanced stage hepatocellular carcinoma after approval of sorafenib”  [Invited]Masatoshi KudoThe 12th Annual Meeting of Japanese Society of Medical Oncology  2014/07  Fukuoka International Congress Center, FukuokaChair "Session 10 “APPLE consensus workshop: searching consensus for controversies”  [Invited]Masatoshi KudoThe 5th Asia-Pacific Primary Liver Cancer Expert Meeting (APPLE)  2014/07  The Grand Hotel, Taipei, TaiwanChair "Session 5 “Prof. Juei-Low Sung Award Lecture”  [Invited]Masatoshi KudoThe 5th Asia-Pacific Primary Liver Cancer Expert Meeting (APPLE)  2014/07  The Grand Hotel, Taipei, Taiwan当院におけるStage 0/I膵癌の特徴~膵癌早期診断ストラテジーの標準化にむけて~, パネルディスカッション2「膵癌早期診断を目指して」  [Not invited]宮田 剛; 北野雅之; 工藤正俊; 竹山宜典第45回日本膵臓学会大会  2014/07  北九州国際会議場, 北九州膵癌早期診断におけるEUSの位置づけ  [Not invited]北野雅之; 鎌田 研; 工藤正俊第45回日本膵臓学会大会  2014/07  北九州国際会議場, 北九州Invited Lecture “Lessons from the TACE trials”  [Invited]Masatoshi KudoThe 5th Asia-Pacific Primary Liver Cancer Expert Meeting (APPLE)  2014/07  The Grand Hotel, Taipei, TaiwanChair "Session 6 “Future treatment for HCC”  [Invited]Kudo MThe 5th Asia-Pacific Primary Liver Cancer Expert Meeting (APPLE)  2014/07  The Grand Hotel, Taipei, TaiwanChair "Session 4 “State-of-the art lecture: HCC prevention: looking into the future”  [Invited]Kudo MThe 5th Asia-Pacific Primary Liver Cancer Expert Meeting (APPLE)  2014/07  The Grand Hotel, Taipei, TaiwanTreatment patterns in >3000 sorafenib-treated patients: final analysis of GIDEON (Global investigation of therapeutic decisions in hepatocellular carcinoma and of its treatment with sorafenib)  [Not invited]Ye SL; Lencioni R; Marrero JA; Venook AP; Nakajima K; Kudo MThe 5th Asia-Pacific Primary Liver Cancer Expert Meeting (APPLE)  2014/07  Taipei, TaiwanValue of semi-annual follow-up of EUS in patients with IPMN. International Teleconference 2 “Intraductal papillary mucinous neoplasm of the pancreas: clinical experiences in Asian countries”  [Not invited]Kamata K; Kitano M; Kudo Mthe 45th Annual Meeting of the Japan Pancreas Society  2014/07  Kitakyushu International Conference Center, Japan膵液瘻に対するEUS下ドレナージ術の有用性. ミニシンポジウム3「膵空腸吻合の工夫と術後管理」  [Not invited]山雄健太郎; 北野雅之; 工藤正俊; 竹山宜典第45回日本膵臓学会大会  2014/07  北九州国際会議場, 北九州自己免疫性膵炎の診断, 治療におけるEUSの役割  [Not invited]大本俊介; 北野雅之; 門阪薫平; 宮田 剛; 鎌田 研; 山雄健太郎; 今井 元; 坂本洋城; 工藤正俊第45回日本膵臓学会大会  2014/07  北九州国際会議場, 北九州早期慢性膵炎画像所見と臨床症状との関係. ワークショップ1「早期慢性膵炎の現状」  [Not invited]門阪薫平; 北野雅之; 工藤正俊第45回日本膵臓学会大会  2014/07  北九州国際会議場, 北九州膵神経内分泌腫瘍に対するEUSの有用性の検討. パネルディスカッション1「PNET診療ガイドラインをめぐって」  [Not invited]今井 元; 北野雅之; 工藤正俊第45回日本膵臓学会大会  2014/07  北九州国際会議場, 北九州非切除膵癌の癌性疼痛に対するEUS下腹腔内神経叢融解術の治療戦略. シンポジウム2「膵癌に対する新たな治療戦略-非切除膵癌」  [Not invited]坂本洋城; 北野雅之; 工藤正俊第45回日本膵臓学会大会  2014/07  北九州国際会議場, 北九州Invited Lecture “Case-study sharing: sorafenib use in intermediate HCC”  [Not invited]Kudo MExpert Panel Opinion on Interventions in Hepatocellular Carcinoma (EPOIHCC)  2014/07  Grand Hotel Taipei, TaiwanInvited Lecture “HCC guidelines in the region: an update-Japan”  [Invited]Masatoshi KudoExpert Panel Opinion on Interventions in Hepatocellular Carcinoma (EPOIHCC)  2014/07  Grand Hotel Taipei, TaiwanB-modeで描出困難な肝細胞癌に対するFusion-imaging+造影USガイドでのラジオ波焼灼術  [Not invited]南 知宏; 南 康範; 工藤正俊第14回肝血流動態・機能イメージ研究会  2014/07  オーバルホール, 大阪当院における肝細胞癌に対するディーシービーズ®を用いたTACEの初期経験  [Not invited]渡口真史; 鶴﨑正勝; 柳生行伸; 沼本勲男; 朝戸信行; 山川美帆; 任 誠雲; 松木 充; 村上卓道; 井上達夫; 萩原 智; 南 康範; 上嶋一臣; 工藤正俊第14回肝血流動態・機能イメージ研究会  2014/07  オーバルホール, 大阪当院におけるマイクロバルーン閉塞下肝動脈化学塞栓療法(B-TACE)導入後の検討  [Not invited]千品寛和; 田北雅弘; 有住忠晃; 北井 聡; 井上達夫; 矢田典久; 南 康範; 萩原 智; 上嶋一臣; 西田直生志; 朝戸信行; 任 誠雲; 柳生行伸; 松木 充; 鶴﨑正勝; 村上卓道; 工藤正俊第14回肝血流動態・機能イメージ研究会  2014/07  オーバルホール, 大阪司会"Debates Session “大腸がん肝転移の治療戦略を如何に組み立てるか?"  [Not invited]工藤正俊第14回関西肝血流動態・機能イメージ研究会  2014/07  オーバルホール, 大阪Early response prediction of hepatocellular carcinoma to transcatheter therapies using intraprocedual plain cone-beam CT.  [Not invited]Minami Y; Kudo M; Yagyu Y; Murakami TComputer Assisted Radiology and Surgery (CARS 2014), 28th International Congress and Exhibition  2014/06  Fukuoka, Japan術前診断が可能であった胆管原発悪性リンパ腫の1例  [Not invited]秦 康倫; 木下大輔; 奥田英之; 永田嘉昭; 岸谷 譲; 川崎俊彦; 原 譲次; 辻江正徳; 井上雅智; 若狭朋子; 太田善夫; 工藤正俊日本消化器内視鏡学会近畿支部第92回支部例会  2014/06  大阪国際交流センター, 大阪急性壊死性食道炎の1例  [Not invited]池田 守; 足立哲平; 南 知宏; 田中梨絵; 山田光成; 高山政樹; 峯 宏昌; 永井知行; 朝隈 豊; 櫻井俊治; 松井繁長; 樫田博史; 工藤正俊日本消化器内視鏡学会近畿支部第92回支部例会  2014/06  大阪国際交流センター, 大阪プロトンポンプ阻害剤長期投与により胃底腺ポリープが増大したと思われる1例  [Not invited]尾崎信人; 松本 望; 高場雄久; 川崎正憲; 冨田崇文; 梅原康湖; 森村正嗣; 米田 円; 山田 哲; 辻 直子; 落合 健; 前倉俊治; 工藤正俊日本消化器内視鏡学会近畿支部第92回支部例会  2014/06  大阪国際交流センター, 大阪当院で内視鏡治療を施行した表在型バレット食道腺癌の検討. シンポジウム「GERD~バレット食道癌の現状」  [Not invited]高山政樹; 松井繁長; 工藤正俊日本消化器内視鏡学会近畿支部第92回支部例会  2014/06  大阪国際交流センター, 大阪大腸ESD後潰瘍の縫縮における小切開法の導入, ビデオワークショップ1「ESDの工夫―安全性と効率の両立を目指して」  [Not invited]足立哲平; 樫田博史; 工藤正俊日本消化器内視鏡学会近畿支部第92回支部例会  2014/06  大阪国際交流センター, 大阪当院におけるEUS下胆道ドレナージの工夫と成績. ビデオワークショップ2「閉塞性黄疸の治療戦略」  [Not invited]門阪薫平; 北野雅之; 工藤正俊日本消化器内視鏡学会近畿支部第92回支部例会  2014/06  大阪国際交流センター, 大阪ソラフェニブ投与にてPD判定であった進行肝細胞癌患者の検討  [Not invited]有住忠晃; 上嶋一臣; 千品寛和; 田北雅弘; 北井 聡; 井上達夫; 矢田典久; 萩原 智; 南 康範; 櫻井俊治; 西田直生志; 工藤正俊第10回日本肝がん分子標的治療研究会  2014/06  淡路夢舞台国際会議場, 兵庫香川県下におけるソラフェニブの使用経験~開始容量, 肝機能, 副作用の検討~. ワークショップ「分子標的薬に関する多施設共同研究から得られた知見」  [Not invited]小川 力; 荒澤壮一; 柴峠光成; 馬場伸介; 妹尾知典; 永野拓也; 高口浩一; 谷 丈二; 三好久昭; 米山弘人; 正木 勉; 守屋昭男; 安東正晴; 出口章広; 國土泰孝; 工藤正俊第10回日本肝がん分子標的治療研究会  2014/06  淡路夢舞台国際会議場, 兵庫総括発言「新規分子標的薬剤の動向と展望」  [Invited]工藤正俊第10回肝がん分子標的治療研究会  2014/06  淡路夢舞台国際会議場, 兵庫Special Lecture “LCSGJ consensus”  [Not invited]Masatoshi KudoThe 4th International Kyoto Liver Cancer Symposium (IKLS)  2014/06  Kyoto International Conference Center, KyotoSpecial Lecture “GIDEON final analysis data: regional difference”  [Not invited]Masatoshi KudoThe 4th International Kyoto Liver Cancer Symposium (IKLS)  2014/06  Kyoto International Conference Center, KyotoSpecial Lecture “Emerging role of CEUS”  [Not invited]Masatoshi KudoThe 4th International Kyoto Liver Cancer Symposium (IKLS)  2014/06  Kyoto International Conference Center, KyotoChair "Luncheon Seminar II“Current challenges to manage HCC”  [Not invited]Masatoshi KudoThe 4th International Kyoto Liver Cancer Symposium (IKLS)  2014/06  Kyoto International Conference Center, KyotoChair "Luncheon Seminar I“Current challenge to chronic hepatitis C”  [Not invited]Masatoshi KudoThe 4th International Kyoto Liver Cancer Symposium (IKLS)  2014/06  Kyoto International Conference Center, KyotoChair "Session II “Diagnosis of pathological early HCC”  [Not invited]Masatoshi KudoThe 4th International Kyoto Liver Cancer Symposium (IKLS)  2014/06  Kyoto International Conference Center, Kyoto現行のTACE不応基準の妥当性の検証. コンセンサスミーティング2「TACE不応の定義をめぐって」  [Not invited]上嶋一臣; 有住忠晃; 工藤正俊第50回日本肝癌研究会  2014/06  国立京都国際会館, 京都全国原発性肝癌追跡調査データからみた第5版取扱規約における肝内胆管癌の病期分類の問題点について. ワークショップ5「肝内胆管癌に対する治療戦略」  [Not invited]阪本良弘; 國土典宏; 松山 裕; 泉 並木; 市田隆文; 具 英成; 工藤正俊; 坂元亨宇; 高山忠利; 中島 収; 松井 修第50回日本肝癌研究会  2014/06  国立京都国際会館, 京都ソラフェニブ開始後3年以上の長期生存例の臨床的特徴に関する検討. ワークショップ4「進行肝細胞癌に対する分子標的治療開始後の長期生存例(3年以上)」  [Not invited]上嶋一臣; 有住忠晃; 工藤正俊第50回日本肝癌研究会  2014/06  国立京都国際会館, 京都肝細胞癌(HCC)合併の非代償性肝硬変患者に対する局所治療の有用性についての検討. ワークショップ1「Child-Pugh C肝癌に対する治療」  [Not invited]北井 聡; 工藤正俊; 西田直生志; 泉 並木; 坂元亨宇; 松山 裕; 市田隆文; 中島 収; 松井 修; 具 英成; 國土典宏; 幕内雅敏第50回日本肝癌研究会  2014/06  国立京都国際会館, 京都進行肝細胞癌を対象としたソラフェニブとシスプラチン肝動注の併用療法. パネルディスカッション3「肝癌における分子標的治療の近未来展望」  [Not invited]清水 怜; 池田公史; 森本 学; 加藤弥菜; 河田則文; 工藤正俊; 中森正二; 金子周一; 杉本理恵; 古瀬純司; 奥坂拓志第50回日本肝癌研究会  2014/06  国立京都国際会館, 京都進行肝細胞癌に対するソラフェニブ+TACE併用療法. パネルディスカッション3「肝癌における分子標的治療の近未来展望」  [Not invited]有住忠晃; 上嶋一臣; 工藤正俊第50回日本肝癌研究会  2014/06  国立京都国際会館, 京都ヒト肝発癌における酸化ストレスとエピゲノム変異の関連. パネルディスカッション2「ゲノム・エピゲノム解析に基づく肝癌診療の将来展望」  [Not invited]萩原 智; 西田直生志; 工藤正俊第50回日本肝癌研究会  2014/06  国立京都国際会館, 京都Dual-energy CTを用いた肝脂肪定量. パネルディスカッション1「肝画像診断のイノベーション」  [Not invited]兵頭朋子; 矢田典久; 前西 修; 工藤正幸; 朝戸信行; 柳生行伸; 鶴崎正勝; 松木 充; 足利竜一朗; 石井一成; 工藤正俊; 村上卓道第50回日本肝癌研究会  2014/06  国立京都国際会館, 京都Randomized phase II trial of intravenous RO5137382/GC33 at 1600 mg every other week and placebo in previously treated patients with unresectable advanced hepatocellular carcinoma (HCC) (NCT01507168)  [Not invited]Yen CJ; Daniele B; Kudo M; Merle P; Park JW; Ross P; Peron JM; Ebert O; Chan S; Poon TP; Colombo M; Okusaka T; Ryoo BY; Minguez B; Tanaka T; Ohtomo T; Rutman O; Chen YC; Lee R; Abou-Alfa GKAmerican Society of Clinical Oncology (ASCO) 50th Annual Meeting  2014/06  Chicago, USAOPTIMIS: an International observational study to assess the use of sorafenib after transarterial chemoembolization in patients with hepatocellular carcinoma  [Not invited]Peck-Radosavljevic M; Raoul JL; Lee HC; Kudo M; Nakajima K; Cheng AL; on behalf of the; OPTIMIS InvestigatorsAmerican Society of Clinical Oncology (ASCO) 50th Annual Meeting  2014/06  Chicago, USARegorafenib in patients with hepatocellular carcinoma (HCC) progressing following sorafenib: an ongoing randomized, double-blind, phase III trial  [Not invited]Bruix J; Finn RS; Kudo M; Llovet JM; Qin S; Le Berre MA; Wagner A; Cheng ALAmerican Society of Clinical Oncology (ASCO) 50th Annual Meeting  2014/06  Chicago, USASTORM: a phase III, randomized, double-blind, placebo-controlled trial of adjuvant sorafenib after resection or ablation to prevent recurrence of hepatocellular carcinoma  [Not invited]Bruix J; Takayama T; Mazzaferro V; Chau GY; Yang J; Kudo M; Cai J; Poon RT; Han KH; Tak WY; Lee HC; Song T; Roayaie S; Bolondi L; Lee KS; Makuuchi M; Souza F; Le Berree MA; Meinhardt G; Llovet JM on; behalf of the; STORM InvestigatorsAmerican Society of Clinical Oncology (ASCO) 50th Annual Meeting  2014/06  Chicago, USAMulticenter observational study of reactivation of hepatitis B virus caused by chemotherapy for solid tumors  [Not invited]Kondo S; Ikeda M; Kudo M; Nadano S; Furuse J; Osaki Y; Kumada T; Ohkawa K; Mizokami MAmerican Society of Clinical Oncology (ASCO) 50th Annual Meeting  2014/06  Chicago, USAA multicenter, open-label, phase 3 trial to compare the efficacy and safety of Lenvatinib (E7080) versus Sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma  [Not invited]Finn RS; Cheng AL; Ikeda K; Kudo M; Tamai T; Dutcus C; Younger S; Han KH; Qin S; Raymond EAmerican Society of Clinical Oncology (ASCO) 50th Annual Meeting  2014/06  Chicago, USAPrognostic and predictive role of circulating angiopoietin-2 in multiple solid tumors: An analysis of approximately 500 patients treated with lenvatinib across tumor types.  [Not invited]Vergote I; Ball D; Kudo M; Sachdev P; Matijevic M; Kadowaki T; Funahashi Y; Flaherty KAmerican Society of Clinical Oncology (ASCO) 50th Annual Meeting  2014/06  Chicago, USAplain cone-beam CTによる肝動脈塞栓術の定量的治療効果予測. ワークショップ13「肝癌に対する肝動脈塞栓療法の新展開」  [Not invited]南 康範; 村上卓道; 工藤正俊第50回日本肝臓学会総会  2014/05  ホテルニューオータニ, 東京VINCENTの仮想超音波システムを用いた簡便な腫瘍, 走行血管の描出と安全な穿刺ラインの同定方法  [Not invited]小川 力; 柴峠光成; 工藤正俊第50回日本肝臓学会総会  2014/05  ホテルニューオータニ, 東京高齢者Genotype 1b高ウイルス量のC型慢性肝炎患者における治療効果と安全性~ReGIT-J試験の層別解析~  [Not invited]西川浩樹; 榎本平之; 斎藤正紀; 絵澤信弘; 津田泰宏; 樋口和秀; 岡崎和一; 関 寿人; 金 守良; 本合 泰; 城村尚登; 西田直生志; 工藤正俊; 大﨑往夫; 西口修平第50回日本肝臓学会総会  2014/05  ホテルニューオータニ, 東京肝外再発例の肝癌DNAメチル化プロファイルを用いた治癒切除後の早期再発予測  [Not invited]西田直生志; 中居卓也; 工藤正俊第50回日本肝臓学会総会  2014/05  ホテルニューオータニ, 東京超音波エラストグラフィによる肝線維化・炎症の評価. ワークショップ8「肝臓病理に画像診断はどこまで迫れたか」  [Not invited]矢田典久; 工藤正俊第50回日本肝臓学会総会  2014/05  ホテルニューオータニ, 東京特別講演「今後の展望」  [Not invited]工藤正俊第50回日本肝臓学会総会  2014/05  ホテルニューオータニ, 東京悪性胃十二指腸狭窄に対する治療戦略~胆道狭窄合併例に対するEUS下胆道ドレナージ術も含めて~, ワークショップ16「消化管狭窄の内視鏡治療上部」  [Not invited]山雄健太郎; 北野雅之; 工藤正俊第87回日本消化器内視鏡学会総会  2014/05  福岡国際会議場, 福岡胃アミロイドーシスの2例  [Not invited]岡元寿樹; 高山政樹; 峯 宏昌; 山田光成; 足立哲平; 永井知行; 川崎正憲; 櫻井俊治; 松井繁長; 樫田博史; 工藤正俊第87回日本消化器内視鏡学会総会  2014/05  福岡国際会議場, 福岡当院における超高齢者(85歳以上)の下部内視鏡検査・治療の現況  [Not invited]永井知行; 樫田博史; 工藤正俊; 南 知宏; 田中梨絵; 山田光成; 足立哲平; 峯 宏昌; 高山政樹; 川崎正憲; 朝隈 豊; 櫻井俊治; 松井繁長第87回日本消化器内視鏡学会総会  2014/05  福岡国際会議場, 福岡膵神経内分泌腫瘍に対するEUSの有用性  [Not invited]今井 元; 北野雅之; 工藤正俊; 大本俊介; 門阪薫平; 宮田 剛; 鎌田 研; 山雄健太郎; 坂本洋城第87回日本消化器内視鏡学会総会  2014/05  福岡国際会議場, 福岡EUSを主としたIPMNの診断および経過観察の成績~IPMN国際診療ガイドライン2012年度版の妥当性の検証~. シンポジウム6「分枝型膵IPMNの診断・悪性度の評価における内視鏡の役割」  [Not invited]鎌田 研; 北野雅之; 工藤正俊第87回日本消化器内視鏡学会総会  2014/05  福岡国際会議場, 福岡当院におけるEUS-FNAのラーニングカーブについての検討: EUS-FNAの診断率. ワークショップ8「胆膵内視鏡における質の高い技術習得を目指した指導法の工夫」  [Not invited]坂本洋城; 北野雅之; 工藤正俊第87回日本消化器内視鏡学会総会  2014/05  福岡国際会議場当院における直腸内分泌腫瘍(NET)の診断と治療成績  [Not invited]山田光成; 樫田博史; 南 知宏; 田中梨絵; 足立哲平; 高山政樹; 峯 宏昌; 永井知行; 川崎正憲; 朝隈 豊; 櫻井俊治; 松井繁長; 工藤正俊第87回日本消化器内視鏡学会総会  2014/05  福岡国際会議場, 福岡急性胆嚢炎および胆管炎例に対するEUS下胆嚢ドレナージ術の有用性  [Not invited]門阪薫平; 北野雅之; 工藤正俊第87回日本消化器内視鏡学会総会  2014/05  福岡国際会議場, 福岡EUSガイド下胆道ドレナージ術におけるコツとトラブルシューティング. パネルディスカッション3「胆膵インターベンショナルEUSの偶発症とその対策」  [Not invited]今井 元; 北野雅之; 工藤正俊第87回日本消化器内視鏡学会総会  2014/05  福岡国際会議場, 福岡EUS下腹腔内神経叢融解術の偶発症とその対策, パネルディスカッション3「胆膵インターベンショナルEUSの偶発症とその対策」  [Not invited]坂本洋城; 北野雅之; 工藤正俊第87回日本消化器内視鏡学会総会  2014/05  福岡国際会議場, 福岡特別講演「ソナゾイド造影超音波の新たな展開~肝癌スクリーニングと肉眼形態診断への応用~」  [Invited]工藤正俊北信消化器画像セミナー  2014/05  長野  第一三共株式会社ランチョンセミナー17「ソナゾイド造影超音波の新たな展開~肝癌スクリーニングと肉眼形態診断への応用~」  [Not invited]工藤正俊日本超音波医学会第87回学術集会  2014/05  パシフィコ横浜超音波検査で観察し得た新生児chest wall hamartomaの一例  [Not invited]前野知子; 横川美加; 辻 裕美子; 塩見香織; 前川 清; 工藤正俊; 八木 誠; 上杉忠雄; 筑後孝章; 佐藤隆夫日本超音波医学会第87回学術集会  2014/05  パシフィコ横浜Chair: Guideline of CEUS  [Invited]Masatoshi KudoThe 6th Asian Conference on Ultrasound Contrast Imaging (ACUCI 2014)  2014/05  パシフィコ横浜Contrast-enhanced endoscopic ultrasound in pancreatobiliary diseases.  [Not invited]北野雅之; 工藤正俊The 6th Asian Conference on Ultrasound Contrast Imaging (ACUCI 2014)  2014/05  パシフィコ横浜造影ハーモニックEUS(CH-EUS)における膵腫瘍の血流評価の有用性について  [Not invited]大本俊介; 田中梨絵; 門阪薫平; 鎌田 研; 宮田 剛; 山雄健太郎; 今井 元; 坂本洋城; 北野雅之; 工藤正俊日本超音波医学会第87回学術集会  2014/05  パシフィコ横浜ランチョンセミナー3「肝線維化診断におけるReal-time Tissue Elastographyの有用性」  [Invited]工藤正俊日本超音波医学会第87回学術集会  2014/05  パシフィコ横浜エラストグラフィと肝血清マーカーを用いた肝線維化診断-臨床応用に向けて-  [Not invited]矢田典久; 工藤正俊日本超音波医学会第87回学術集会  2014/05  パシフィコ横浜組織弾性評価手法の世界的動向と消化器領域への展開, シンポジウム領域横断2「組織弾性評価手法の現状と将来動向」  [Invited]工藤正俊日本超音波医学会第87回学術集会  2014/05  パシフィコ横浜EUS下膵管ドレナージ術.  [Invited]北野雅之; 工藤正俊日本消化器内視鏡学会附置研究会超音波内視鏡下治療研究会共同企画「消化器領域におけるEUS-FNAの現在とこれから」, 日本超音波医学会第87回学術集会  2014/05  パシフィコ横浜座長: シンポジウム領域横断2「組織弾性評価手法の現状と将来動向」  [Invited]工藤正俊日本超音波医学会第87回学術集会  2014/05  パシフィコ横浜Moderator: Local ablation for hepatic tumors- Part Ⅰ  [Invited]Masatoshi KudoAustralian Council of TESOL Assciatins (ACTA) International Conference 2014  2014/05  Taipei, Taiwan超音波エラストグラフィによる非アルコール性脂肪性肝疾患患者の意識改革  [Not invited]矢田典久; 萩原 智; 工藤正俊第100回日本消化器病学会総会  2014/04  東京国際フォーラム当院におけるNSAIDs・抗血小板薬起因性の小腸粘膜傷害の検討  [Not invited]永井知行; 高山政樹; 岡元寿樹; 千品寛和; 山田光成; 足立哲平; 峯 宏昌; 川崎正憲; 朝隈 豊; 櫻井俊治; 松井繁長; 樫田博史; 工藤正俊第100回日本消化器病学会総会  2014/04  東京国際フォーラム当院における好酸球性食道炎の検討  [Not invited]松井繁長; 樫田博史; 工藤正俊; 川崎正憲; 朝隈 豊; 永井知行; 櫻井俊治第100回日本消化器病学会総会  2014/04  東京国際フォーラムPlain cone-beam CTによる肝動脈塞栓術の定量的治療効果予測  [Not invited]南 康範; 南 知宏; 有住忠晃; 田北雅弘; 北井 聡; 矢田典久; 井上達夫; 萩原 智; 上嶋一臣; 西田直生志; 工藤正俊; 柳生行伸; 村上卓道第100回日本消化器病学会総会  2014/04  東京国際フォーラム癌性疼痛に対するEUS下腹腔内神経叢融解術の有用性とその適応, シンポジウム9「膵胆道疾患におけるInterventional EUSの有用性と問題点」  [Not invited]坂本洋城; 北野雅之; 工藤正俊第100回日本消化器病学会総会  2014/04  東京国際フォーラム分枝型IPMNの経過観察例からみた2012年国際診療ガイドラインの妥当性の検証. パネルディスカッション11「IPMNの経過観察, 治療のタイミングと予後」  [Not invited]鎌田 研; 北野雅之; 工藤正俊第100回日本消化器病学会総会  2014/04  東京国際フォーラム機能性ディスペプシアと早期慢性膵炎との関係性について. パネルディスカッション4「FDの亜分類と治療選択」  [Not invited]門阪薫平; 北野雅之; 工藤正俊第100回日本消化器病学会総会  2014/04  東京国際フォーラム司会: シンポジウム7「早期肝臓癌画像診断の到達点と治療選択」  [Not invited]工藤正俊第100回日本消化器病学会総会  2014/04  東京国際フォーラム, 東京EOB-MRIと造影超音波検査による乏血性結節の多血化因子の検討  [Not invited]井上達夫; 兵頭朋子; 千品寛和; 有住忠晃; 田北雅弘; 北井 聡; 矢田典久; 萩原 智; 上嶋一臣; 西田直生志; 村上卓道; 工藤正俊第27回日本腹部造影エコー・ドプラ診断研究会  2014/04  はまぎんホールヴィアマーレ, 横浜肝炎に続発した肝内多発輪状結節の1例  [Not invited]横川美加; 前野知子; 前川 清; 北井 聡; 井上達夫; 南 康範; 工藤正俊; 川崎俊彦第27回日本腹部造影エコー・ドプラ診断研究会  2014/04  はまぎんホールヴィアマーレ, 横浜B-modeで描出困難な肝癌に対するFusion image+造影USガイドでのラジオ波焼灼術の有用性  [Not invited]南 知宏; 千品寛和; 有住忠晃; 田北雅弘; 北井 聡; 矢田典久; 萩原 智; 井上達夫; 南 康範; 上嶋一臣; 西田直生志; 工藤正俊第27回日本腹部造影エコー・ドプラ診断研究会  2014/04  はまぎんホールヴィアマーレ, 横浜Final analysis of GIDEON (global investigation of therapeutic decisions in hepatocellular carcinoma [HCC] and of its treatment with sorafenib): factors influencing treatment duration and outcomes  [Not invited]Bronowicki JP; 工藤 正俊; Venook A; Marrero J; Ye SL; Nakajima K; Lencion R49th Annual Meeting of the European Association for the Sudy of the Liver (EASL)  2014/04  London, United Kingdom  49th Annual Meeting of the European Association for the Sudy of the Liver (EASL)Once-daily oral lusutrombopag, alternative to platelet transfusion inthrombocytopenic patients with chronic liver disease undergoingradiofrequency ablation: results from a phase 2B, randomized, double-blind study.  [Not invited]Izumi N; 工藤 正俊; Tateishi R; Seike M; Tamai H; Kawazoe S; Tanaka K; Kurokawa M; Osaki Y; Yamamoto K; Imawari M49th Annual Meeting of the European Association for the Sudy of the Liver (EASL)  2014/04  London, United Kingdom  49th Annual Meeting of the European Association for the Sudy of the Liver (EASL)Final analysis of GIDEON (global investigation of therapeutic decisions in hepatocellular carcinoma and of its treatment with sorafenib): treatment practices, safety and outcomes by race  [Not invited]Furuse J; 工藤 正俊; Ye SL; Marrero J; Lencioni R; Venook A; Nakajima KAsian Pacific Association for the Study of the Liver (APASL 2014)  2014/03  Brisbane, Australia  Asian Pacific Association for the Study of the Liver (APASL 2014)Invited Lecture “Current evidence and future perspective of molecular targeted therapies in HCC”  [Not invited]工藤 正俊The 11th World Congress of the International Hepato-Pancreato-Biliary Association  2014/03  Seoul, Korea  The 11th World Congress of the International Hepato-Pancreato-Biliary AssociationInvited Lecture “Contrast enhanced ultrasound of gastrointestinal disorders”  [Invited]Masatoshi Kudo12th Asian Federation of Societies for Ultrasound in Medicine and Biology (AFSUMB) Workshop  2014/03  Kathmandu, NepalContrast-enhanced ultrasound of hepatic tumours with Sonazoid  [Invited]Masatoshi Kudo12th Asian Federation of Societies for Ultrasound in Medicine and Biology (AFSUMB) Workshop  2014/03  Kathmandu, NepalInvited Lecture “Interventional EUS for pancreatobiliary tumours”  [Invited]Masatoshi Kudo12th Asian Federation of Societies for Ultrasound in Medicine and Biology (AFSUMB) Workshop  2014/02  Kathmandu, NepalInvited Lecture “Ultrasound evaluation of diffuse liver diseases”  [Invited]Masatoshi Kudo12th Asian Federation of Societies for Ultrasound in Medicine and Biology (AFSUMB) Workshop  2014/02  Kathmandu, Nepal上行結腸動静脈奇形の1例  [Not invited]千品寛和; 峯 宏昌; 南 知宏; 田中梨絵; 山田光成; 足立哲平; 高山政樹; 永井知行; 川崎正憲; 朝隈 豊; 櫻井俊治; 松井繁長; 樫田博史; 工藤正俊; 杉浦史哲; 上田和毅; 奥野清隆; 筑後孝章; 佐藤隆夫日本消化器病学会近畿支部第100回例会  2014/02Time intensity curve (TIC) を用いた造影ハーモニックEUSによる膵腫瘍血流評価の検討  [Not invited]大本俊介; 北野雅之; 門阪薫平; 宮田 剛; 鎌田 研; 山雄健太郎; 今井 元; 坂本洋城; 工藤正俊日本消化器病学会近畿支部第100回例会  2014/02診断に難渋した十二指腸隆起性潰瘍性病変の一例  [Not invited]岡元寿樹; 永井知行; 山田光成; 足立哲平; 高山政樹; 峯 宏昌; 川崎正憲; 朝隈 豊; 櫻井俊治; 松井繁長; 樫田博史; 工藤正俊; 田中裕美子; 石川 原; 竹山宜典日本消化器病学会近畿支部第100回例会  2014/02機能性ディスペプシアと早期慢性膵炎の鑑別について  [Not invited]門阪薫平; 北野雅之; 大本俊介; 鎌田 研; 宮田 剛; 山雄健太郎; 今井 元; 坂本洋城; 工藤正俊日本消化器病学会近畿支部第100回例会  2014/02TS-1+ Interferon併用療法が奏効した巨大な肝細胞癌の一例  [Not invited]南 知宏; 南 康範; 千品寛和; 有住忠晃; 田北雅弘; 北井 聡; 矢田典久; 井上達夫; 萩原 智; 上嶋一臣; 西田直生志; 工藤正俊日本消化器病学会近畿支部第100回例会  2014/02分岐型IPMNに対する造影EUSのフォローによりIPMN由来癌を早期診断した1例  [Not invited]伊藤貴嶺; 北野雅之; 門阪薫平; 大本俊介; 鎌田 研; 宮田 剛; 山雄健太郎; 今井 元; 坂本洋城; 工藤正俊日本消化器病学会近畿支部第100回例会  2014/02潰瘍性大腸炎の手術適応におけるインフリキシマブの位置づけ. パネルディスカッション2「炎症性腸疾患の内科・外科境界領域」  [Not invited]田中梨絵; 櫻井俊治; 樫田博史; 工藤正俊日本消化器病学会近畿支部第100回例会  2014/02Moderator "Keynote session"  [Not invited]Masatoshi Kudo3rd Investigators Meeting for ORIENTAL  2014/02  Taipei, Taiwan興味のある経過を示した胃アミロイドーシスの1例  [Not invited]岡本寿樹; 高山政樹; 峯 宏昌; 山田光成; 足立哲平; 永井知行; 川崎正憲; 朝隈 豊; 櫻井俊治; 松井繁長; 樫田博史; 工藤正俊第10回日本消化管学会総会学術集会  2014/02  クラッセふくしま, 福島当院においてOGIBと診断され、シングルバルーン小腸内視鏡検査を施工した高齢者症例の臨床的検討  [Not invited]高山政樹; 足立哲平; 峯 宏昌; 永井知行; 川崎正憲; 朝隈 豊; 櫻井俊治; 松井繁長; 樫田博史; 工藤正俊第10回日本消化管学会総会学術集会  2014/02  ホテル福島グリーンパレス, 福島NST介入患者における胃瘻と半固形栄養剤の有用性について  [Not invited]峯 宏昌; 足立哲平; 高山政樹; 永井知行; 川崎正憲; 朝隈 豊; 松井繁長; 樫田博史; 工藤正俊第10回日本消化管学会総会学術集会  2014/02  ホテル福島グリーンパレス, 福島Invited Lecture “Recent trends of management of HCC”  [Invited]Masatoshi KudoThe 22nd International Seoul Radiology Symposium (ISRS 2015)  2014/02  Seoul National University Hospital Beiomedical Research Institute Auditorium, KoreaDual energy CTを用いたdynamicCTによる肝線維化の評価  [Not invited]朝戸 信行; 村上 卓道; 鶴﨑 正勝; 兵頭 朋子; 福井 秀行; 任 誠雲; 栁生 行伸; 岡田 真広; 今岡 いずみ; 松木 充; 足利 竜一朗; 矢田 典久; 前西 修; 工藤 正俊; 工藤 正幸第20回肝血流動態・機能イメージ研究会  2014/02  大阪  第20回肝血流動態・機能イメージ研究会Invited Lecture “Lessons from other TKI trials combined with TACE (tentative)”  [Not invited]工藤 正俊3rd Investigators Meeting for ORIENTAL  2014/02  Taipei, Taiwan  3rd Investigators Meeting for ORIENTAL慢性胃炎性変化の乏しいC-0症例のたこいぼびらんに見られる腸上皮化生についての検討  [Not invited]辻 直子; 丸山 康典; 河野 匡志; 松本 望; 高場 雄久; 奥村 直己; 山本 典雄; 冨田 崇文; 梅原 康湖; 谷池 聡子; 森村 正嗣; 米田 円; 山田 哲; 落合 健; 前倉 俊治; 本庶 元; 工藤 正俊第86回日本消化器内視鏡学会総会(第21回日本消化器関連学会週間JDDW2013)  2014  グランドプリンスホテル新高輪, 東京  第86回日本消化器内視鏡学会総会(第21回日本消化器関連学会週間JDDW2013)TACE不応の進行肝細胞癌に対するソラフェニブ開始時期の検討.  [Not invited]有住 忠晃; 上嶋 一臣; 千品 寛和; 田北 雅弘; 北井 聡; 井上 達夫; 矢田 典久; 萩原 智; 南 康範; 櫻井 俊治; 西田 直生志; 工藤 正俊第9回日本肝がん分子標的治療研究会  2014/01  海運クラブ, 東京  第9回日本肝がん分子標的治療研究会司会:教育講演:治療アルゴリズムにおける分子標的薬の取扱い~エビデンスvs.コンセンサス~  [Not invited]工藤 正俊第9回日本肝がん分子標的治療研究会  2014/01  海運クラブ, 東京  第9回日本肝がん分子標的治療研究会司会"血液検査"  [Not invited]工藤正俊平成25年度日本肝臓学会後期教育講演会  2013/12  長良川国際会議場, 岐阜司会"肝細胞癌"  [Not invited]工藤正俊平成25年度日本肝臓学会後期教育講演会  2013/12  長良川国際会議場, 岐阜Invited Lecture “Ongoing trial with Sonazoid in Japan”  [Not invited]工藤 正俊Workshop for a Clinical Trial of HCC Screening with Sonazoid  2013/12  Seoul, Korea  Workshop for a Clinical Trial of HCC Screening with SonazoidFinal analysis of GIDEON (Global Investigation of therapeutic DEcisions in hepatocellular carcinoma and Of its treatment with sorafeNib): regional trends, safety, and outcomes in patients receiving concomitant transarterial chemoembolization.  [Not invited]Geschwind JF; 工藤 正俊; Marrero J; Venook A; Ye SL; Bronowicki JP; Chen XP; Dagher L; Furuse J; Guevara LL; Papandreou C; Sanyal AJ; Takayama T; Yoon SK; Nakajima K; Lencioni R99th Scientific Assembly and Annual Meeting (RSNA 2013)  2013/12  Chicago, USA  99th Scientific Assembly and Annual Meeting (RSNA 2013)急速な増大を認めた後腹膜嚢胞性腫瘤の一例  [Not invited]前野 知子; 横川 美加; 辻 裕美子; 市島 真由美; 塩見 香織; 前川 清; 樫田 博史; 工藤 正俊日本超音波医学会第40回関西地方会学術集会  2013/11  大阪国際会議場, 大阪  日本超音波医学会第40回関西地方会学術集会Fly thruによる胆嚢(胆石・ポリープ)の描出について  [Not invited]辻 裕美子; 横川 美加; 前野 知子; 市島 真由美; 塩見 香織; 前川 清; 井上 達夫; 南 康範; 工藤 正俊日本超音波医学会第40回関西地方会学術集会  2013/11  大阪国際会議場, 大阪  日本超音波医学会第40回関西地方会学術集会造影ハーモニックEUSにおける消化器系疾患の鑑別および悪性度診断  [Not invited]大本 俊介; 北野 雅之; 工藤 正俊日本超音波医学会第40回関西地方会学術集会  2013/11  大阪国際会議場, 大阪  日本超音波医学会第40回関西地方会学術集会ソナゾイド造影を施行した小腸腫瘍の1例  [Not invited]横川 美加; 辻 裕美子; 前野 知子; 市島 真由美; 塩見 香織; 前川 清; 南 康範; 樫田 博史; 工藤 正俊日本超音波医学会第40回関西地方会学術集会  2013/11  大阪国際会議場, 大阪  日本超音波医学会第40回関西地方会学術集会Fly thruによるPV Shuntの描出  [Not invited]前川 清; 横川 美加; 辻 裕美子; 前野 知子; 市島 真由美; 塩見 香織; 井上 達夫; 南 康範; 工藤 正俊日本超音波医学会第40回関西地方会学術集会  2013/11  大阪国際会議場, 大阪  日本超音波医学会第40回関西地方会学術集会Acoustic structure quantificationによるfocal spared areaの描出の試み  [Not invited]前川 清; 横川 美加; 辻 裕美子; 前野 知子; 市島 真由美; 塩見 香織; 井上 達夫; 南 康範; 工藤 正俊; 矢野 雅彦日本超音波医学会第40回関西地方会学術集会  2013/11  大阪国際会議場, 大阪  日本超音波医学会第40回関西地方会学術集会造影ハーモニックEUS(CH-EUS)における膵腫瘍の血流評価の有用性について  [Not invited]大本 俊介; 田中 梨絵; 門阪 薫平; 鎌田 研; 宮田 剛; 山雄 健太郎; 今井 元; 坂本 洋城; 北野 雅之; 工藤 正俊日本超音波医学会第40回関西地方会学術集会  2013/11  大阪国際会議場, 大阪  日本超音波医学会第40回関西地方会学術集会当院におけるEUS下胆道および膵管ドレナージの工夫と成績. シンポジウム1「消化器領域超音波の最前線-診断からインターベンションまで」  [Not invited]大本 俊介; 北野 雅之; 工藤 正俊日本超音波医学会第40回関西地方会学術集会  2013/11  大阪国際会議場, 大阪  日本超音波医学会第40回関西地方会学術集会特別講演「超音波診断の最新動向: 腹部領域を中心に」  [Not invited]工藤 正俊日本超音波医学会第40回関西地方会学術集会  2013/11  大阪国際会議場, 大阪  日本超音波医学会第40回関西地方会学術集会特別講演「超音波診断の最新動向: 腹部領域を中心に」  [Not invited]工藤 正俊日本超音波医学会第40回関西地方会学術集会  2013/11  大阪国際会議場, 大阪  日本超音波医学会第40回関西地方会学術集会HBs抗原消失を目指したエンテカビルとPEG-IFN48週併用療法の効果について  [Not invited]萩原 智; 西田 直生志; 工藤 正俊第15回葵肝臓研究会  2013/11  メルパルク京都  第15回葵肝臓研究会造影ハーモニックEUS(CH-EUS)による膵腫瘤性病変の血流の定量化の試み  [Not invited]大本 俊介; 北野 雅之; 門阪 薫平; 宮田 剛; 鎌田 研; 山雄 健太郎; 今井 元; 坂本 洋城; 工藤 正俊日本消化器内視鏡学会近畿支部第91回支部例会  2013/11  大阪国際交流センター, 大阪  日本消化器内視鏡学会近畿支部第91回支部例会消化管病変を合併したHenoch-Schonlein紫斑病(HSP)の一例  [Not invited]南 知宏; 松井 繁長; 岡元 寿樹; 足立 哲平; 高山 政樹; 峯 宏昌; 永井 知行; 川崎 正憲; 朝隈 豊; 櫻井 俊治; 樫田 博史; 工藤 正俊日本消化器内視鏡学会近畿支部第91回支部例会  2013/11  大阪国際交流センター, 大阪  日本消化器内視鏡学会近畿支部第91回支部例会潰瘍性大腸炎の加療中に壊疽性膿皮症および下肢深部静脈血栓症を合併した1例  [Not invited]松本 望; 尾崎 信人; 河野 匡志; 丸山 康典; 高場 雄久; 奥村 直己; 山本 典雄; 冨田 崇文; 梅原 康湖; 谷池 聡子; 森村 正嗣; 米田 円; 山田 哲; 辻 直子; 遠藤 英樹; 落合 健; 前倉 俊治; 工藤 正俊日本消化器内視鏡学会近畿支部第91回支部例会  2013/11  大阪国際交流センター, 大阪  日本消化器内視鏡学会近畿支部第91回支部例会陥凹を伴ったSessile serrated adenoma/polyp(SSA/P)の1例  [Not invited]千品 寛和; 朝隈 豊; 南 知宏; 岡元 寿樹; 山田 光成; 田中 梨絵; 足立 哲平; 峯 宏昌; 高山 政樹; 永井 知行; 川崎 正憲; 櫻井 俊治; 松井 繁長; 樫田 博史; 工藤 正俊日本消化器内視鏡学会近畿支部第91回支部例会  2013/11  大阪国際交流センター, 大阪  日本消化器内視鏡学会近畿支部第91回支部例会コーラ溶解法と結石粉砕術で内視鏡的摘出した胃十二指腸動脈瘤の一例  [Not invited]田中 梨絵; 永井 知行; 千品 寛和; 山田 光成; 足立 哲平; 高山 政樹; 峯 宏昌; 川崎 正憲; 朝隈 豊; 松井 繁長; 樫田 博史; 工藤 正俊日本消化器内視鏡学会近畿支部第91回支部例会  2013/11  大阪国際交流センター, 大阪  日本消化器内視鏡学会近畿支部第91回支部例会胃Inverted hamartomatous polypの一例  [Not invited]尾崎 信人; 河野 匡志; 丸山 康典; 松本 望; 高場 雄久; 奥村 直己; 山本 典雄; 冨田 崇文; 梅原 康湖; 谷池 聡子; 森村 正嗣; 米田 円; 山田 哲; 辻 直子; 落合 健; 前倉 俊治; 工藤 正俊日本消化器内視鏡学会近畿支部第91回支部例会  2013/11  大阪国際交流センター, 大阪  日本消化器内視鏡学会近畿支部第91回支部例会食欲不振を契機に発見された巨大脾腫瘍の一例  [Not invited]吉川 恵輔; 奥田 英之; 秦 康倫; 木下 大輔; 清水 昌子; 岸谷 讓; 永田 嘉昭; 川崎 俊彦; 太田 善夫; 工藤 正俊日本消化器内視鏡学会近畿支部第91回支部例会  2013/11  大阪国際交流センター, 大阪  日本消化器内視鏡学会近畿支部第91回支部例会walled-off necrosisの術前の管理においてメタリックステントによるドレナージが有用であった  [Not invited]中田 有紀; 北野 雅之; 大本 俊介; 門阪 薫平; 宮田 剛; 鎌田 研; 山雄 健太郎; 今井 元; 坂本 洋城; 工藤 正俊日本消化器内視鏡学会近畿支部第91回支部例会  2013/11  大阪国際交流センター, 大阪  日本消化器内視鏡学会近畿支部第91回支部例会潰瘍性大腸炎に膵胆管合流異常症を合併した1例  [Not invited]東 千尋; 山雄 健太郎; 田中 梨絵; 大本 俊介; 門阪 薫平; 鎌田 研; 宮田 剛; 今井 元; 坂本 洋城; 北野 雅之; 工藤 正俊日本消化器内視鏡学会近畿支部第91回支部例会  2013/11  大阪国際交流センター, 大阪  日本消化器内視鏡学会近畿支部第91回支部例会血便を契機に発見された上行結腸非上皮性巨大腫瘤の2例  [Not invited]沼本 勲男; 朝隈 豊; 岡元 寿樹; 山田 光成; 千品 寛和; 足立 哲平; 高山 政樹; 峯 宏昌; 永井 知行; 川崎 正憲; 櫻井 俊治; 松井 繁長; 樫田 博史; 工藤 正俊日本消化器内視鏡学会近畿支部第91回支部例会  2013/11  大阪国際交流センター, 大阪  日本消化器内視鏡学会近畿支部第91回支部例会当院におけるEUS下ドレナージ術の成績. ワークショップ1「内視鏡ステント治療の現状と問題点(胆膵)」  [Not invited]山雄 健太郎; 北野 雅之; 工藤 正俊日本消化器内視鏡学会近畿支部第91回支部例会  2013/11  大阪国際交流センター, 大阪  日本消化器内視鏡学会近畿支部第91回支部例会(追加発言3)当院における高齢患者のEMR治療成績と問題点. シンポジウム2「高齢者における内視鏡診療の問題点と対策(消化管)」  [Not invited]永井 知行; 樫田 博史; 工藤 正俊日本消化器内視鏡学会近畿支部第91回支部例会  2013/11  大阪国際交流センター, 大阪  日本消化器内視鏡学会近畿支部第91回支部例会高齢者における大腸ポリペクトミーの安全性と予後. シンポジウム2「高齢者における内視鏡診療の問題点と対策(消化管)」  [Not invited]高場 雄久; 辻 直子; 工藤 正俊日本消化器内視鏡学会近畿支部第91回支部例会  2013/11  大阪国際交流センター, 大阪  日本消化器内視鏡学会近畿支部第91回支部例会高齢者またはADL不良の急性胆嚢炎および胆管炎例に対するEUS下胆嚢ドレナージ術. シンポジウム1「高齢者における内視鏡診療の問題点と対策(胆膵)」  [Not invited]門阪 薫平; 北野 雅之; 工藤 正俊日本消化器内視鏡学会近畿支部第91回支部例会  2013/11  大阪国際交流センター, 大阪  日本消化器内視鏡学会近畿支部第91回支部例会座長: 特別講演:西口修平「C型肝炎治療の今後の展開」  [Not invited]工藤 正俊C型肝炎学術講演会  2013/11  ホテルグランヴィア大阪, 大阪  C型肝炎学術講演会B-mode ultrasonography versus contrast-enhanced ultrasonography for surveillance of hepatocellular carcinoma: a prospective multicenter randomized controlled trial  [Not invited]工藤 正俊; 上嶋 一臣; Yukio Osaki; Masashi Hirooka; Yasuharu Imai; Kazunobu Aso; Kazushi Numata; Masao Ichinose; Takashi Kumada; Namiki Izumi; Yasukiyo Sumino; Kouhei AkazawaThe 64th Annual Meeting of the American Association for the Study of Liver Disease (AASLD)  2013/11  Washington D.C., USA  The 64th Annual Meeting of the American Association for the Study of Liver Disease (AASLD)Role of oxidative stress and epigenetic alteration on chronic hepatitis C-related human hepatocarcinogenesis  [Not invited]西田 直生志; 工藤 正俊; 有住 忠晃; 田北 雅弘; 北井 聡; 矢田 典久; 井上 達夫; 萩原 智; 南 康範; 櫻井 俊治; 上嶋 一臣; Takeshi Nagasaka; Ajay GoelThe 64th Annual Meeting of the American Association for the Study of Liver Disease (AASLD)  2013/11  Washington D.C.  The 64th Annual Meeting of the American Association for the Study of Liver Disease (AASLD)Safety and outcomes by disease etiology in sorafenib-treated uHCC patients in clinical practice: final analysis of GIDEON (Global Investigation of therapeutic DEcisions in hepatocellular carcinoma and Of its treatment with sorafeNib)  [Not invited]Sanyal AJ; 工藤 正俊; Lencioni R; Ye SL; Venook A; Bronowicki JP; Chen XP; Dagher L; Furuse J; Geschwind JF; Guevara LL; Papandreou C; Takayama T; Yoon SK; Nakajima K; Marrero JThe 64th Annual Meeting of the American Association for the Study of Liver Disease (AASLD)  2013/11  Washington D.C., USA  The 64th Annual Meeting of the American Association for the Study of Liver Disease (AASLD)膵癌による閉塞性黄疸に対する乳頭括約筋切開術未施行のカバー付金属ステント留置術の成績  [Not invited]千品寛和; 門阪薫平; 田中梨絵; 大本俊介; 宮田 剛; 鎌田 研; 今井 元; 坂本洋城; 北野雅之; 工藤正俊第86回日本消化器内視鏡学会総会(第21回日本消化器関連学会週間JDDW2013)  2013/10  品川プリンスホテル, 東京EUSにおけるミタゾラムとプロポフォールによる鎮静に対するBISモニター(Bispectral index monitoring)の有用性の検討. ワークショップ25「プロフォールを活用する」  [Not invited]宮田 剛; 北野雅之; 工藤正俊第86回日本消化器内視鏡学会総会(第21回日本消化器関連学会週間JDDW2013)  2013/10  品川プリンスホテル, 東京プロポフォールを用いた外来内視鏡検査の安全性・有用性と患者満足度の検討. ワークショップ25「プロフォールを活用する」  [Not invited]梅原康湖; 辻 直子; 工藤正俊第86回日本消化器内視鏡学会総会(第21回日本消化器関連学会週間JDDW2013)  2013/10  品川プリンスホテル, 東京EUSガイド下胆管ドレナージ術における工夫とトラブルシューティング. ワークショップ23「胆膵内視鏡のトラブルシューティング《ビデオ》」  [Not invited]今井 元; 北野雅之; 工藤正俊第86回日本消化器内視鏡学会総会  2013/10  品川プリンスホテル, 東京Predictive factors for pain relief after endscopicultrasound-guided plexus neurolysis  [Not invited]Sakamoto H; Kitano M; Kudo MJapan Digestive Disease Week 2013 (JDDW)  2013/10  Tokyo, JapanUsefulness of single-balloon endscopy for the small bowel lesions  [Not invited]Adachi T; Matsui S; Kashida HJapan Digestive Disease Week 2013 (JDDW)  2013/10  Tokyo, JapanClostridium difficile感染症例の検討  [Not invited]奥村直己; 工藤正俊; 辻 直子; 高場雄久; 松本 望; 谷池聡子; 河野匡志; 丸山康典; 山田 哲; 森村正嗣; 米田 円; 梅原康湖; 富田崇文第86回日本消化器内視鏡学会総会(第21回日本消化器関連学会週間JDDW2013)  2013/10  品川プリンスホテル, 東京大腸発癌における幹細胞の制御機構  [Not invited]峯 宏昌; 櫻井俊治; 工藤正俊第55回日本消化器病学会大会(第21回日本消化器関連学会週間JDDW2013)  2013/10  品川プリンスホテル, 東京肝発癌および治療抵抗性獲得における幹細胞の役割. ワークショップ16「消化器癌に対する幹細胞研究の現状と展望」  [Not invited]櫻井俊治; 樫田博史; 工藤正俊第55回日本消化器病学会大会(第21回日本消化器関連学会週間JDDW2013)  2013/10  品川プリンスホテル, 東京切除不能胆道狭窄でのEUS下胆道ドレナージの位置づけ. ワークショップ14「胆道癌の胆管ドレナージの標準化-手術症例と非手術症例」  [Not invited]今井 元; 北野雅之; 工藤正俊第86回日本消化器内視鏡学会総会(第21回日本消化器関連学会週間JDDW2013)  2013/10  グランドプリンスホテル新高輪国際パミール, 東京機能性ディスペプシアの早期慢性膵炎が存在する可能性について. ワークショップ12「機能性ディスペプシア-診断と治療の現況を巡って-」  [Not invited]門阪薫平; 北野雅之; 工藤正俊第55回日本消化器病学会大会(第21回日本消化器関連学会週間JDDW2013)  2013/10  グランドプリンスホテル新高輪国際パミール, 東京肝細胞癌に対する分子標的治療: 現状と問題点. シンポジウム15「消化器癌に対する分子標的薬-最近の動向」  [Not invited]工藤正俊; 上嶋一臣第55回日本消化器病学会大会(第21回日本消化器関連学会週間JDDW2013)  2013/10  グランドプリンスホテル新高輪国際パミール, 東京司会: シンポジウム15「消化器癌に対する分子標的薬-最近の動向」  [Invited]工藤正俊第21回日本消化器関連学会週間JDDW 2013(第55回日本消化器病学会大会, 第17回日本肝臓学会大会)  2013/10  グランドプリンスホテル新高輪, 東京司会: サテライトシンポジウム82「肝癌診療は新たな時代へ」  [Not invited]工藤正俊第21回日本消化器関連学会週間JDDW 2013(第17回日本肝臓学会大会, 第17回日本肝臓学会大会)  2013/10  グランドプリンスホテル高輪, 東京当院においてOGIBと診断されシングルバルーン小腸内視鏡検査を施行した高齢者症例の臨床的検討.  [Not invited]高山政樹; 足立哲平; 峯 宏昌; 永田嘉昭; 永井知行; 川崎正憲; 朝隈 豊; 櫻井俊治; 松井繁長; 樫田博史; 工藤正俊第86回日本消化器内視鏡学会総会(第21回日本消化器関連学会週間JDDW2013)  2013/10  グランドプリンスホテル新高輪, 東京座長: ランチョンセミナー29「HCCにおける診断から治療に関する最新の話題」  [Not invited]工藤正俊第21回日本消化器関連学会週間JDDW 2013(第17回日本肝臓学会大会, 第17回日本肝臓学会大会)  2013/10  グランドプリンスホテル新高輪, 東京プロポフォール投与下内視鏡検査における飲酒患者, 睡眠薬・精神安定剤内服患者への注意点  [Not invited]梅原 康湖; 河野 匡志; 丸山 康典; 松本 望; 高場 雄久; 奥村 直己; 谷池 聡子; 冨田 崇文; 森村 正嗣; 山田 哲; 米田 円; 辻 直子; 工藤 正俊第55回日本消化器病学会大会(第21回日本消化器関連学会週間JDDW2013)  2013/10  グランドプリンスホテル新高輪, 東京  第55回日本消化器病学会大会(第21回日本消化器関連学会週間JDDW2013)プロポフォール投与下内視鏡検査で生じる不随意運動の検討  [Not invited]梅原 康湖; 河野 匡志; 丸山 康典; 松本 望; 高場 雄久; 奥村 直己; 谷池 聡子; 冨田 崇文; 森村 正嗣; 山田 哲; 米田 円; 辻 直子; 工藤 正俊第86回日本消化器内視鏡学会総会(第21回日本消化器関連学会週間JDDW2013)  2013/10  グランドプリンスホテル新高輪, 東京  第86回日本消化器内視鏡学会総会(第21回日本消化器関連学会週間JDDW2013)上部消化管内視鏡検査前スクリーニングとして実施した胸部X-rayおよび心電図より得られた所見についての検討  [Not invited]谷池 聡子; 河野 匡志; 丸山 康典; 松本 望; 高場 雄久; 奥村 直己; 冨田 崇文; 梅原 康湖; 森村 正嗣; 米田 円; 山田 哲; 辻 直子; 工藤 正俊86回日本消化器内視鏡学会総会(第21回日本消化器関連学会週間JDDW2013)  2013/10  グランドプリンスホテル新高輪, 東京  86回日本消化器内視鏡学会総会(第21回日本消化器関連学会週間JDDW2013)Chair: Treatment of advanced HCC with macro-vascular invasion (Surgery vs Sorafenib). JDDW International debte session (featured lecture) 1-2 (JDDW)  [Not invited]工藤 正俊Japan Digestive Disease Week 2013 (JDDW)  2013/10  Tokyo, Japan  Japan Digestive Disease Week 2013 (JDDW)EUS-guided hepaticogastrostomy for treatment of obstructive jaundice in patients with malignant hilar biliary stricture after transpillary drainage is ineffective or unsuccessful  [Not invited]北野 雅之; 今井 元; 工藤 正俊Japan Digestive Disease Week 2013 (JDDW)  2013/10  Tokyo, Japan  Japan Digestive Disease Week 2013 (JDDW)The role of EUS in diagnosis and treatment of autoimmune pancreatitis  [Not invited]大本 俊介; 北野 雅之; 工藤 正俊Japan Digestive Disease Week 2013 (JDDW)  2013/10  Tokyo, Japan  Japan Digestive Disease Week 2013 (JDDW)乳頭括約筋切除術を行わないTrans-catheter biliary endoscopyの有用性の検討. ワークショップ6「胆道疾患の診断・治療に有用な画像診断-内視鏡診断から三次元画像診断」  [Not invited]坂本 洋城; 北野 雅之; 工藤 正俊第86回日本消化器内視鏡学会総会(第21回日本消化器関連学会週間JDDW2013)  2013/10  グランドプリンスホテル新高輪国際パミール, 東京  第86回日本消化器内視鏡学会総会(第21回日本消化器関連学会週間JDDW2013)造影ハーモニックEUSのよる胆嚢病変の鑑別診断. ワークショップ6「胆道疾患の診断・治療に有用な画像診断-内視鏡診断から三次元画像診断」  [Not invited]鎌田 研; 北野 雅之; 工藤 正俊第86回日本消化器内視鏡学会総会(第21回日本消化器関連学会週間JDDW2013)  2013/10  グランドプリンスホテル新高輪国際パミール, 東京  第86回日本消化器内視鏡学会総会(第21回日本消化器関連学会週間JDDW2013)IPMN国際診療ガイドライン2012年度版の検証~EUSの位置づけはどこにあるか?~. パネルディスカッション7「IPMN新コンセンサス診療ガイドラインの検証」  [Not invited]鎌田 研; 北野 雅之; 工藤 正俊第55回日本消化器病学会大会(第21回日本消化器関連学会週間JDDW2013)  2013/10  グランドプリンスホテル新高輪国際パミール, 東京  第55回日本消化器病学会大会(第21回日本消化器関連学会週間JDDW2013)肝のう胞に対するオレイン酸モノエタノールアミン注入療法の検討  [Not invited]田北 雅弘; 有住 忠晃; 北井 聡; 井上 達夫; 矢田 典久; 萩原 智; 南 康範; 上嶋 一臣; 西田 直生志; 工藤 正俊第17回日本肝臓学会大会(第21回日本消化器関連学会週間JDDW2013)  2013/10  グランドプリンスホテル新高輪, 東京  第17回日本肝臓学会大会(第21回日本消化器関連学会週間JDDW2013)C型肝炎に対する3剤併用療法の高齢者における認容性の検討  [Not invited]田北 雅弘; 萩原 智; 工藤 正俊第17回日本肝臓学会大会(第21回日本消化器関連学会週間JDDW2013)  2013/10  グランドプリンスホテル新高輪, 東京  第17回日本肝臓学会大会(第21回日本消化器関連学会週間JDDW2013)当院における大腸癌肝転移の治療ストラテジー  [Not invited]南 康範; 工藤 正俊; 中居 卓也第55回日本消化器病学会大会(第21回日本消化器関連学会週間JDDW2013)  2013/10  品川プリンスホテル, 東京  第55回日本消化器病学会大会(第21回日本消化器関連学会週間JDDW2013)Gd-EOB-DTPA MRI肝細胞相で低信号に描出される結節の多血化因子の検討多施設共同retrospective study  [Not invited]井上 達夫; 工藤 正俊第55回日本消化器病学会大会(第21回日本消化器関連学会週間JDDW2013)  2013/10  品川プリンスホテル, 東京  第55回日本消化器病学会大会(第21回日本消化器関連学会週間JDDW2013)各種超音波エラストグラフィによる肝線維化診断. パネルディスカッション5「非侵襲的肝病態評価法の適応と限界」  [Not invited]矢田 典久; 萩原 智; 工藤 正俊第55回日本消化器病学会大会(第21回日本消化器関連学会週間JDDW2013)  2013/10  品川プリンスホテル, 東京  第55回日本消化器病学会大会(第21回日本消化器関連学会週間JDDW2013)The usefulness of the epoch method “Defect re-perfusion imaging”to diagnose HCC using new agent sonazoid  [Not invited]Ogawa C; 工藤 正俊; Shibatouge MThe 5th Asian Conference of Ultrasound Contrast Imaging (ACUCI 2013)  2013/10  Taipei, Taiwan  The 5th Asian Conference of Ultrasound Contrast Imaging (ACUCI 2013)The learning curve of endoscopic submucosal dissection in the colorectum  [Not invited]樫田 博史; 足立 哲平; 櫻井 俊治; 朝隈 豊; 川崎 正憲; 永井 知行; 峯 宏昌; 高山 政樹; 松井 繁長; 工藤 正俊21th United European Gastroenterology Week (UEGW)  2013/10  Berlin, Germany  21th United European Gastroenterology Week (UEGW)Invited Lecture “Diagnosis of Gross Pathological Classification of HCC by Kupffer phase CEUS”  [Not invited]工藤 正俊The 5th Asian Conference of Ultrasound Contrast Imaging (ACUCI)  2013/10  Taipei, Taiwan  The 5th Asian Conference of Ultrasound Contrast Imaging (ACUCI)Invited Lecture “Contrast-enhanced EUS of GI disorders”  [Not invited]工藤 正俊The 5th Asian Conference of Ultrasound Contrast Imaging (ACUCI)  2013/10  Taipei, Taiwan  The 5th Asian Conference of Ultrasound Contrast Imaging (ACUCI)Multimodal treatment of hepatocellular carcinoma. Symposia on specific tumors〝Cancer research on digestive organs: yesterday, today, and tomorrow"  [Not invited]工藤 正俊第72回日本癌学会学術集会  2013/10  パシフィコ横浜, 神奈川  第72回日本癌学会学術集会Special Lecture “Management of Hepatocellular Carcinoma: Recent Progress” “Special Lecture (III)”  [Not invited]工藤 正俊Taiwan Digestive Disease Week 2013 (TDDW)  2013/10  Taipei, Taiwan  Taiwan Digestive Disease Week 2013 (TDDW)Predictive factors for pain relief after endoscopic ultrasound-guided upper plexus neurolysis.  [Not invited]坂本 洋城; 北野 雅之; 工藤 正俊21th United European Gastroenterology Week (UEGW)  2013/10  Berlin, Germany  21th United European Gastroenterology Week (UEGW)Differential diagnosis of SMT and evaluation of malignant potential GISTS by contrast enhanced harmonic EUS  [Not invited]坂本 洋城; 北野 雅之; 工藤 正俊21th United European Gastroenterology Week (UEGW)  2013/10  Berlin, Germany  21th United European Gastroenterology Week (UEGW)Lecture “Diagnosis of diffuse liver diseases.”  [Not invited]工藤 正俊Medical ultrasound society, Singapore 11th Annual Seminar in conjunction with AFSUMB Workshop 2013  2013/09  Singapore  Medical ultrasound society, Singapore 11th Annual Seminar in conjunction with AFSUMB Workshop 2013十二指腸静脈瘤の病態と治療方針. 要望演題11「異所性静脈瘤の病態と治療1」  [Not invited]松井 繁長; 樫田 博史; 朝隈 豊; 川崎 正憲; 工藤 正俊第20回日本民脈圧亢進症学会総会  2013/09  名古屋国際会議場, 愛知  第20回日本民脈圧亢進症学会総会胆管癌として切除された良性胆管病変の4例  [Not invited]大本 俊介; 北野 雅之; 工藤 正俊; 中居 卓也; 竹山 宜典第49回日本胆道学会学術集会  2013/09  ヒルトン東京ベイ, 千葉  第49回日本胆道学会学術集会切除不能胆道癌に対する集学的治療における胆道マネジメントの重要性  [Not invited]宮田 剛; 北野 雅之; 工藤 正俊第49回日本胆道学会学術集会  2013/09  ヒルトン東京ベイ, 千葉  第49回日本胆道学会学術集会ERCP不能な悪性胆道狭窄における急性胆嚢炎および胆管炎例に対するEUS下ドレナージ術の有用性について  [Not invited]門阪 薫平; 北野 雅之; 工藤 正俊第49回日本胆道学会学術集会  2013/09  ヒルトン東京ベイ, 千葉  第49回日本胆道学会学術集会非EST症例に対する経カテーテル胆道内視鏡(Trans-catheter endoscopy; TCE)のコツとピットフォール  [Not invited]山雄 健太郎; 坂本 洋城; 北野 雅之; 工藤 正俊第49回日本胆道学会学術集会  2013/09  第49回日本胆道学会学術集会EUS下胆道ドレナージ術の可能性. シンポジウム1「胆道ドレナージの現状と新たな展開」  [Not invited]今井 元; 北野 雅之; 工藤 正俊第49回日本胆道学会学術集会  2013/09  ヒルトン東京ベイ, 千葉  第49回日本胆道学会学術集会座長: 企業セミナー  [Not invited]工藤 正俊第8回肝癌診療シミュレーション研究会  2013/09  ホテル椿山荘東京, 東京  第8回肝癌診療シミュレーション研究会Final analysis of GIDEON (Global Investigation of therapeutic DE-cisions in hepatocellular carcinoma and Of its treatment with sorafeNib) in>3000 sorafenib-treated patients: prognostic value of baseline characteristics and staging systems  [Not invited]工藤 正俊; ※Bronowicki JP; Lencioni R; Ye SL; Papandreou C; Nakajima K; Venook A; Marrero JPoster presented at the European Cancer Congress 2013 (EC-CO-ESMO-ESTRO)  2013/09  Amsterdam, Netherlands  Poster presented at the European Cancer Congress 2013 (EC-CO-ESMO-ESTRO)Sorafenib treatment for non-hypervascular hepatocellular carcinoma  [Not invited]有住 忠晃; 上嶋 一臣; 田北 雅弘; 北井 聡; 井上 達夫; 矢田 典久; 萩原 智; 南 康範; 櫻井 俊治; 西田 直生志; 工藤 正俊Seventh Annual Conference International Liver Cancer Association (ILCA)  2013/09  Washington D.C.  Seventh Annual Conference International Liver Cancer Association (ILCA)The factors related to the vascularization of border line lesions detected as low intensity on hepatobiliary phase image of GD-EOB-DTPA MRI  [Not invited]井上 達夫; 有住 忠晃; 上嶋 一臣; 西田 直生志; 工藤 正俊Seventh Annual Conference International Liver Cancer Association (ILCA)  2013/09  Washington D.C.  Seventh Annual Conference International Liver Cancer Association (ILCA)Updated results from phase1/2 trial of lenvatinib (E7080), a multi-targeted tyrosine kinase inhibitor, and biomarker correlative analyses in patients (Pts) with advanced hepatocellular carcinoma (HCC).  [Not invited]工藤 正俊; Kumada H; Ikeda K; Kawazoe S; Osaki Y; Ikeda M; Okusaka T; Tamai T; Suzuki T; Kadowaki T; Funahashi Y; O’Brien JP; Okita KSeventh Annual Conference International Liver Cancer Association (ILCA)  2013/09  Washington D.C., USA  Seventh Annual Conference International Liver Cancer Association (ILCA)Effects on survival prognosis by peretinoin, an acyclic retinoid: five-year follow-up of phase 2/3 randomized placebo-controlled trial.  [Not invited]Okita K; 工藤 正俊; Kumada HSeventh Annual Conference International Liver Cancer Association (ILCA)  2013/09  Washington D.C., USA  Seventh Annual Conference International Liver Cancer Association (ILCA)Invited Lecture“Resection vs. ablation in very early HCC”  [Not invited]工藤 正俊Seventh Annual Conference International Liver Cancer Association (ILCA)  2013/09  Washington D.C., USA  Seventh Annual Conference International Liver Cancer Association (ILCA)A randomized, double-blind, multicenter phase 3 study of Brivanib versus placebo as adjuvant therapy to trans-arterial chemoembolization (TACE)in patients with unresectable hepatocellular carcinoma (HCC): Initial results.  [Not invited]工藤 正俊; Finn R; Poon RT; Blanc JF; Han G; Yan L; Yang J; Lu L; Tak WY; Yu X; Lee JH; Lin SM; Wu C; Tanwandee T; Shao G; Walters I; Dela Cruz C; Poulart V; Wang JHSeventh Annual Conference International Liver Cancer Association (ILCA)  2013/09  Washington D.C., USA  Seventh Annual Conference International Liver Cancer Association (ILCA)特別講演「超音波診断の最新動向: 腹部領域を中心に」  [Not invited]工藤 正俊第31回日本乳腺甲状腺超音波医学会学術集会  2013/09  神戸国際会議場, 兵庫  第31回日本乳腺甲状腺超音波医学会学術集会慢性C型肝炎に対するテラプレビル3剤併用療法中に結核性リンパ節炎を発症した1例  [Not invited]千品 寛和; 井上 達夫; 南 知宏; 岡元 寿樹; 山田 光成; 田中 梨絵; 有住 忠晃; 田北 雅弘; 北井 聡; 矢田 典久; 萩原 智; 南 康範; 上嶋 一臣; 西田 直生志; 工藤 正俊日本消化器病学会近畿支部第99回例会  2013/09  大阪国際交流センター, 大阪  日本消化器病学会近畿支部第99回例会Walled off necrosisに対してEUS下内外瘻術を施行後に再発を認めた一例  [Not invited]古川 健太郎; 北野 雅之; 田中 梨絵; 大本 俊介; 門阪 薫平; 鎌田 研; 宮田 剛; 今井 元; 坂本 洋城; 工藤 正俊日本消化器病学会近畿支部第99回例会  2013/09  大阪国際交流センター, 大阪  日本消化器病学会近畿支部第99回例会急激な肝機能低下をきたしたBudd-Chiari症候群の1例  [Not invited]鍵岡 賛典; 萩原 智; 岩西 美奈; 南 知宏; 有住 忠晃; 田北 雅弘; 北井 聡; 矢田 典久; 井上 達夫; 南 康範; 上嶋 一臣; 櫻井 俊治; 工藤 正俊日本消化器病学会近畿支部第99回例会  2013/09  大阪国際交流センター, 大阪  日本消化器病学会近畿支部第99回例会急性発症型自己免疫性肝炎の一例  [Not invited]岩西 美奈; 萩原 智; 鍵岡 賛典; 南 知宏; 有住 忠晃; 田北 雅弘; 北井 聡; 井上 達夫; 矢田 典久; 南 康範; 上嶋 一臣; 櫻井 俊治; 西田 直生志; 工藤 正俊日本消化器病学会近畿支部第99回例会  2013/09  大阪国際交流センター, 大阪  日本消化器病学会近畿支部第99回例会転移性腫瘍との鑑別を要した肝腫瘤を合併した十二指腸乳頭部癌の1例.  [Not invited]谷池 聡子; 尾崎 信人; 丸山 康典; 河野 匡志; 松本 望; 高場 雄久; 奥村 直己; 山本 典雄; 冨田 崇文; 梅原 康湖; 森本 正嗣; 米田 円; 山田 哲; 辻 直子; 船井 貞往; 落合 健; 前倉 俊治; 工藤 正俊日本消化器病学会近畿支部第99回例会  2013/09  大阪国際交流センター, 大阪  日本消化器病学会近畿支部第99回例会当院におけるOGIB症例の検討. シンポジウム2「原因不明消化管出血の診断と治療の最前線」  [Not invited]高山 政樹; 松井 繁長; 樫田 博史; 工藤 正俊日本消化器病学会近畿支部第99回例会  2013/09  大阪国際交流センター, 大阪  日本消化器病学会近畿支部第99回例会進行膵癌に対するGemcitabine(GEM)/Erlotinib併用療法の二次化学療法の治療成績. パネルディスカッション2「根治治療不能進行消化器癌に対する治療選択」  [Not invited]大本 俊介; 北野 雅之; 工藤 正俊日本消化器病学会近畿支部第99回例会  2013/09  大阪国際交流センター, 大阪  日本消化器病学会近畿支部第99回例会TACE不応の進行肝細胞癌患者に対するソラフェニブ開始時期の検討. パネルディスカッション2「根治治療不能進行消化器癌に対する治療選択」  [Not invited]有住忠晃; 上嶋 一臣; 工藤 正俊日本消化器病学会近畿支部第99回例会  2013/09  大阪国際交流センター, 大阪  日本消化器病学会近畿支部第99回例会HBs抗原消失を目指したエンテカビルとPEG-IFNα2b 48週併用療法の効果について. シンポジウム「ウイルス性肝炎治療の最前線」  [Not invited]萩原 智; 工藤 正俊; 大﨑往夫日本消化器病学会近畿支部第99回例会  2013/09  大阪国際交流センター, 大阪  日本消化器病学会近畿支部第99回例会特別講演 肝臓領域「ソノグラファーへの望む!肝臓エコー」  [Not invited]工藤 正俊JSS第20回地方会学術集会  2013/09  神戸国際会議場, 兵庫  JSS第20回地方会学術集会大腸発癌における幹細胞の制御機能. シンポジウム2「発がんとがん予防の科学と実践」  [Not invited]櫻井 俊治; 峯 宏昌; 樫田 博史; 工藤 正俊第24回日本消化器癌発生学会総会  2013/09  石川県立音楽堂, 石川  第24回日本消化器癌発生学会総会Validation of staging systems for hepatocellular carcinoma: a comparison of the Bm-Jis score, the Jis score and the Bclc staging  [Not invited]北井 聡; 工藤 正俊; Izumi N; Sakamoto M; Matsuyama Y; Ichida T; Nakashima O; Matsui O; Ku Y; Kokudo N; Matsunaga T; Makuuchi MSeventh Annual Conference International Liver Cancer Asso-ciation(ILCA)  2013/09  Washington D.C., USA  Seventh Annual Conference International Liver Cancer Asso-ciation(ILCA)Regional differences in treatment history, practices and outcomes: final analysis of GIDEON (Global Investigation of therapeutic DEcisions in hepatocellular carcinoma and Of its treatment with sorafeNib)  [Not invited]工藤 正俊; Lencioni R; Ye SL; Bronowicki JP; Chen XP; Dagher L; Furuse J; Geschwind JF; Guevara LL; Papandreou C; Sanyal AJ; Takayama T; Yoon SK; Venook A; Nakajima K; Marrero JSeventh Annual Conference International Liver Cancer Asso-ciation(ILCA)  2013/09  Washington D.C., USA  Seventh Annual Conference International Liver Cancer Asso-ciation(ILCA)Unique association between global dna hypomethylation and chromosomal alterations in human hepatocellular carcinoma.  [Not invited]西田 直生志; 工藤 正俊; 千品 寛和; 有住 忠晃; 田北 雅弘; 北井 聡; 矢田 典久; 萩原 智; 井上 達夫; 南 康範; 上嶋 一臣; 櫻井 俊治; Yokomichi N; Nagasaka T; Goel ASeventh Annual Conference International Liver Cancer Asso-ciation(ILCA)  2013/09  Washington D.C., USA  Seventh Annual Conference International Liver Cancer Asso-ciation(ILCA)司会: Colorectal Cancer, Supportive Care and QOL/ 大腸がん 支持療法、QOL  [Not invited]工藤 正俊第11回日本臨床腫瘍学会学術集会  2013/08  仙台国際センター, 東北大学百周年記念会館川内萩ホール  第11回日本臨床腫瘍学会学術集会特別講演「肝炎, 肝癌治療の最近の話題」  [Not invited]工藤 正俊東四国ベアネットカンファレンス  2013/08  JRホテルクレメント高松, 香川  東四国ベアネットカンファレンス肝原発神経内分泌腫瘍の1例  [Not invited]田中梨絵; 井上達夫; 千品寛和; 有住忠晃; 田北雅弘; 北井 聡; 矢田典久; 萩原 智; 南 康範; 上嶋一臣; 西田直生志; 工藤正俊; 兵頭朋子; 村上卓道第13回関西肝血流動態イメージ研究会  2013/07  オーバルホール, 大阪EOB造影MRIとSonazoid造影USによる乏血性肝細胞癌の診断  [Not invited]小来田幸世; 村上 卓道; 兵頭 朋子; 岡田 真広; 工藤 正俊; 今井康陽; 井倉; 技; 澤井良之; 福田和人; 中島 収; 関 康; 坂元亭宇第49回日本肝癌研究会  2013/07  東京  第49回日本肝癌研究会Estimation of EUS features of choronic pancreatitis in comparison with clinical symptoms  [Not invited]北野 雅之; 門阪 薫平; 坂本 洋城; 今井 元; 鎌田 研; 宮田 剛; 大本 俊介; 山雄 健太郎; 工藤 正俊International Pancreatic Research Forum 2013 (IPRF)  2013/07  Sendai, Japan  International Pancreatic Research Forum 2013 (IPRF)経乳頭的治療不能悪性胆道狭窄に対するAntegrade drainage併用治療の有用性  [Not invited]今井 元; 北野 雅之; 工藤 正俊第44回日本膵臓学会大会  2013/07  仙台国際センター, 宮城  第44回日本膵臓学会大会早期慢性膵炎EUS画像所見と糖尿病の関連について. パネルディスカッション2「膵内外分泌相関の新しい展開」  [Not invited]門阪 薫平; 北野 雅之; 工藤 正俊第44回日本膵臓学会大会  2013/07  仙台国際センター, 宮城  第44回日本膵臓学会大会急性・慢性膵炎の治療におけるInterventional EUSの有用性. 特別企画2ビデオシンポジウム「急性膵炎・慢性膵炎に対する内視鏡・腹腔鏡治療の最前線」  [Not invited]宮田 剛; 北野 雅之; 工藤 正俊第44回日本膵臓学会大会  2013/07  仙台国際センター, 宮城  第44回日本膵臓学会大会IPMN経過観察におけるEUSの有用性~造影EUSによる診断も含めて~. 特別企画1ディベート「分枝型IPMNの診療: 内科vs外科vs病理」  [Not invited]鎌田 研; 北野 雅之; 工藤 正俊; 大本 俊介; 門阪 薫平; 今井 元; 坂本 洋城; 竹山 宜典第44回日本膵臓学会大会  2013/07  仙台国際センター, 宮城  第44回日本膵臓学会大会Invited Lecture “Interventional and contrast-enhanced EUS for pancreatobiliary diseases.”  [Not invited]工藤 正俊Program of WFUMB COE Launching Workshop  2013/07  Ulaanbaatar, Mongolia  Program of WFUMB COE Launching WorkshopInvited Lecture “Ultrasound elastography for non-invasive diagnosis of liver fibrosis.”  [Not invited]工藤 正俊Program of WFUMB COE Launching Workshop  2013/07  Ulaanbaatar, Mongolia  Program of WFUMB COE Launching Workshop経皮的ラジオ波焼灼術後の穿刺経路焼灼は必要か?: 後出血予防の検討  [Not invited]南 康範; 早石 宗右; 有住 忠晃; 田北 雅弘; 北井 聡; 矢田 典久; 井上 達夫; 萩原 智; 上嶋 一臣; 西田 直生志; 工藤 正俊; 鄭 浩柄第49回日本肝癌研究会  2013/07  京王プラザホテル, 東京  第49回日本肝癌研究会ソラフェニブ治療例の生存期間からみた画像診断法による効果判定規準の問題点と再評価. シンポジウム2「肝細胞癌における画像診断法の最前線」  [Not invited]有住 忠晃; 工藤 正俊; 大﨑 往夫第49回日本肝癌研究会  2013/07  京王プラザホテル, 東京  第49回日本肝癌研究会座長: シンポジウム2「肝細胞癌における画像診断の最前線」  [Not invited]工藤 正俊第49回日本肝癌研究会  2013/07  京王プラザホテル, 東京  第49回日本肝癌研究会近畿大学病院における大腸癌肝転移の治療ストラテジー. パネルディスカッション2「転移性肝癌治療のアルゴリズム」  [Not invited]南 康範; 工藤 正俊; 中居 卓也第49回日本肝癌研究会  2013/07  京王プラザホテル, 東京  第49回日本肝癌研究会TACEと動注化学療法: 分子標的薬との併用. ワークショップ3「肝細胞癌に対するTACE・肝動注化学療法・放射線療法の適応と治療成績」  [Not invited]工藤 正俊第49回日本肝癌研究会  2013/07  京王プラザホテル, 東京  第49回日本肝癌研究会TACEまたは肝動注化学療法とソラフェニブの併用療法の重要性. シンポジウム1「肝癌における分子標的治療の最前線」  [Not invited]上嶋 一臣; 有住 忠晃; 工藤 正俊第49回日本肝癌研究会  2013/07  京王プラザホテル, 東京  第49回日本肝癌研究会司会: Debates Session「TACEはどこまで続けるか?」  [Not invited]工藤 正俊第13回関西肝血流動態イメージ研究会  2013/07  オーバルホール, 大阪  第13回関西肝血流動態イメージ研究会エピゲノム変異からみたヒト肝発癌における喫煙の影響とGST遺伝子多型に関する研究  [Not invited]西田 直生志; 工藤 正俊第28回喫煙科学研究財団助成研究発表会  2013/07  京王プラザホテル  第28回喫煙科学研究財団助成研究発表会特別講演「肝発癌の予測と分子標的治療」, 固形がんの基礎と臨床-インフォメーションからコミュニケーションへ-  [Not invited]工藤 正俊第2回三重先端がんフォーラム  2013/07  三重大学医学部  第2回三重先端がんフォーラムInvited Lecture “Imaging assessment of tumor response” “Controversial issues in early HCC”  [Not invited]工藤 正俊The 4th Asia-Pacific Primary Liver Cancer Expert Meeting (APPLE)  2013/07  Busan, Korea  The 4th Asia-Pacific Primary Liver Cancer Expert Meeting (APPLE)Invited Lecture “What is TACE failure/refractory? Literature update and arriving at consensus” “EPOIHCC”  [Not invited]工藤 正俊The 4th Asia-Pacific Primary Liver Cancer Expert Meeting (APPLE)  2013/07  Busan, Korea  The 4th Asia-Pacific Primary Liver Cancer Expert Meeting (APPLE)Invited Lecture “Treatment strategy for early stage of HCC” “APPLE Consensus Workshop”  [Not invited]工藤 正俊The 4th Asia-Pacific Primary Liver Cancer Expert Meeting (APPLE)  2013/07  Busan, Korea  The 4th Asia-Pacific Primary Liver Cancer Expert Meeting (APPLE)Invited Lecture “Sorafenib in patients with liver dysfunction:Final analysis of GIDEON” “Unresolved Issues for Advanced HCC ”  [Not invited]工藤 正俊The 4th Asia-Pacific Primary Liver Cancer Expert Meeting (APPLE)  2013/07  Busan, Korea  The 4th Asia-Pacific Primary Liver Cancer Expert Meeting (APPLE)Invited Lecture “How to evaluate treatment response in HCC: a mRESIST criterion enough?” “Unresolved Issues for Advanced HCC ”  [Not invited]工藤 正俊The 4th Asia-Pacific Primary Liver Cancer Expert Meeting (APPLE)  2013/07  Busan, Korea  The 4th Asia-Pacific Primary Liver Cancer Expert Meeting (APPLE)Invited Lecture “New druggable targets in HCC” “Early Morning Work Shop 1 II. Hepatocellular Carcinoma: Genomics, Pathways & Targets”  [Not invited]工藤 正俊The 4th Asia-Pacific Primary Liver Cancer Expert Meeting (APPLE)  2013/07  Busan, Korea  The 4th Asia-Pacific Primary Liver Cancer Expert Meeting (APPLE)十二指腸水平部過形成性ポリープをスネアポリペクトミーした1例  [Not invited]丸山 康典; 河野 匡志; 松本 望; 高場 雄久; 奥村 直己; 山本 典雄; 冨田 崇文; 梅原 康湖; 谷池 聡子; 森村 正嗣; 山田 哲; 辻 直子; 落合 健; 前倉 俊治; 南 康範; 工藤 正俊日本消化器内視鏡学会近畿支部第90回例会  2013/06  日本消化器内視鏡学会近畿支部第90回例会Role of contrast-enhanced harmonic EUS in differentiating malignant from benign lymphadenopathy  [Not invited]宮田 剛; 北野 雅之; 工藤 正俊Tokyo Conference of Asian Pancreato-biliary International Endoscopist 2013 (T-CAP 2013)  2013/06  Ito International Research Center, Japan  Tokyo Conference of Asian Pancreato-biliary International Endoscopist 2013 (T-CAP 2013)The role of EUS in diagnosis and treatment of autoimmune pancreatitis  [Not invited]大本 俊介; 北野 雅之; 工藤 正俊Tokyo Conference of Asian Pancreato-biliary International Endoscopist 2013 (T-CAP 2013)  2013/06  Ito International Research Center, Japan  Tokyo Conference of Asian Pancreato-biliary International Endoscopist 2013 (T-CAP 2013)早期慢性膵炎EUS画像所見と糖尿病との関連  [Not invited]門阪 薫平; 北野 雅之; 大本 俊介; 鎌田 研; 宮田 剛; 今井 元; 坂本 洋城; 工藤 正俊日本消化器内視鏡学会近畿支部第90回支部例会  2013/06  大阪国際交流センター, 大阪  日本消化器内視鏡学会近畿支部第90回支部例会経乳頭的治療不能悪性胆道狭窄に対するEUS下胆道ドレナージ術の有用性. ワークショップ「超音波内視鏡を用いた胆膵疾患の診断と治療の現況」  [Not invited]門阪 薫平; 北野 雅之; 工藤 正俊日本消化器内視鏡学会近畿支部第90回支部例会  2013/06  大阪国際交流センター, 大阪  日本消化器内視鏡学会近畿支部第90回支部例会肝がん化学療法からみた肝動注リザーバーの生き残る道~SILIUS Phase Ⅲ trialの重要性~. シンポジウム1「肝細胞癌に対する肝動注療法の生き残る道」  [Not invited]上嶋 一臣; 有住 忠晃; 工藤 正俊第38回リザーバー研究会  2013/06  かがわ国際会議場, 香川  第38回リザーバー研究会座長: 共催シンポジウム「明日に向かって撃て」  [Not invited]工藤 正俊第8回日本肝がん分子標的治療研究会  2013/06  和倉温泉「加賀屋」, 石川  第8回日本肝がん分子標的治療研究会進行肝細胞癌のソラフェニブ治療における腫瘍血流と治療効果との関連. ワークショップ1「分子標的薬の効果予後予測因子から治療法対象を考える」  [Not invited]有住 忠晃; 上嶋 一臣; 田北 雅弘; 北井 聡; 井上 達夫; 矢田 典久; 萩原 智; 南 康範; 櫻井 俊治; 西田 直生志; 工藤 正俊第8回日本肝がん分子標的治療研究会  2013/06  和倉温泉「加賀屋」, 石川  第8回日本肝がん分子標的治療研究会座長: 診断・治療支援の部  [Not invited]工藤 正俊腹部造影超音波フォーラム2013  2013/06  TKPガーデンシティ品川, 東京  腹部造影超音波フォーラム2013特別講演「肝細胞癌治療の現状」  [Not invited]工藤 正俊第3回札幌肝疾患フォーラム  2013/06  ニューオータニイン札幌, 北海道  第3回札幌肝疾患フォーラムQuantitative assessment of liver fat with dual energy CT: comparison with MR spectroscopy  [Not invited]兵頭 朋子; 村上 卓道; 工藤 正俊; 岡田 真広; 矢田 典久; 前西 修; 石井 一成Computer Assisted Radiology and Surgery, 27th Intemational Congress and Exhibition  2013/06  ドイツ  Computer Assisted Radiology and Surgery, 27th Intemational Congress and ExhibitionRegoranib in patients with hepatocellular carcinoma (HCC) progressing following Sorafenib: an ongoing randomized, double-blind, phase Ⅲ trial  [Not invited]Cheng AL; Finn R; Kudo M; Llovet JM; Qin S; Berre ML; Krissel H; Bruix JAmerican Society of Clinical Oncology (ASCO) 49th Annual Meeting  2013/05Special Lecture “a) Liver (Strain)” “Elastography”  [Not invited]工藤 正俊14th World Congress of the world federation for ultrasound in medicine and biology (WFUMB) 2013  2013/05  Sao Paulo, Brazil  14th World Congress of the world federation for ultrasound in medicine and biology (WFUMB) 2013Coordinator: Elastography  [Not invited]工藤 正俊14th World Congress of the world federation for ultrasound in medicine and biology (WFUMB) 2013  2013/05  Sao Paulo, Brazil  14th World Congress of the world federation for ultrasound in medicine and biology (WFUMB) 2013Real-time tissue quantification (VTTQ)による自己免疫性肝炎の治療評価  [Not invited]矢田 典久; 萩原 智; 工藤 正俊日本超音波医学会第86回学術集会  2013/05  大阪国際会議場, 大阪  日本超音波医学会第86回学術集会消化器診断の立場から. パネルディスカッション24「Real-time Tissue Elasstography~10年の歩み~」  [Not invited]工藤 正俊日本超音波医学会第86回学術集会  2013/05  大阪国際会議場, 大阪  日本超音波医学会第86回学術集会肝血管筋脂肪腫の3例  [Not invited]田中 梨絵; 南 康範; 田北 雅弘; 北井 聡; 井上 達夫; 矢田 典久; 萩原 智; 上嶋 一臣; 西田 直生志; 工藤 正俊日本超音波医学会第86回学術集会  2013/05  大阪国際会議場, 大阪  日本超音波医学会第86回学術集会超音波を施行した0歳児の嘔吐症例の検討  [Not invited]前野 知子; 横川 美加; 辻 裕美子; 塩見香織; 前川 清; 井上 達夫; 南 康範; 西田 直生志; 八木 誠; 工藤 正俊日本超音波医学会第86回学術集会  2013/05  大阪国際会議場, 大阪  日本超音波医学会第86回学術集会Defect re-purfusion imagingによる新しいHCCの診断方法とその教育システム  [Not invited]小川 力; 工藤 正俊; 野田晃世; 村川佳子; 河合直之; 木太秀行; 嶋田俊秀; 廣瀬哲朗; 西平日本超音波医学会第86回学術集会  2013/05  大阪国際会議場, 大阪  日本超音波医学会第86回学術集会VINCENTを用いた超音波検査指導の有用性  [Not invited]野田晃世; 工藤 正俊; 小川 力; 森岡弓; 柴峠光成; 村川佳子; 河合直之; 木太秀行; 嶋田俊秀日本超音波医学会第86回学術集会  2013/05  大阪国際会議場, 大阪  日本超音波医学会第86回学術集会Diagnostic performance of liver fibrosis with real-time tissue elastography in chronic viral hepatitis C. International Symposium“Elastography of the liver in Asia”  [Not invited]矢田 典久; 工藤 正俊The 86th Annual Scientific Meeting of the Japan Society of Ultrasonics in Medicine  2013/05  Osaka  The 86th Annual Scientific Meeting of the Japan Society of Ultrasonics in Medicine膵疾患に対する造影超音波検査. パネルディスカッション27「膵腫瘍の診断に最も有用な画像診断法は?: 画像診断の現状とピットフォール」  [Not invited]今井 元; 北野 雅之; 大本 俊介; 門阪 薫平; 宮田 剛; 鎌田 研; 坂本 洋城; 工藤 正俊日本超音波医学会第86回学術集会  2013/05  大阪国際会議場, 大阪  日本超音波医学会第86回学術集会膵疾患診断における造影ハーモニックEUS検査の有用性. パネルディスカッション26「消化器疾患診断に造影超音波は必要か?」  [Not invited]北野 雅之; 坂本 洋城; 工藤 正俊日本超音波医学会第86回学術集会  2013/05  大阪国際会議場, 大阪  日本超音波医学会第86回学術集会EUS-FNAと造影ハーモニックEUSによるステージⅠ膵癌の検討. パネルディスカッション17「小膵癌: 超音波検査を用いたステージⅠへのアプローチ」  [Not invited]坂本 洋城; 北野 雅之; 工藤 正俊日本超音波医学会第86回学術集会  2013/05  大阪国際会議場, 大阪  日本超音波医学会第86回学術集会超音波内視鏡(EUS)による膵疾患の診断と治療. シンポジウム17「体腔内超音波の現状と展望」  [Not invited]坂本 洋城; 北野 雅之; 工藤 正俊日本超音波医学会第86回学術集会  2013/05  大阪国際会議場, 大阪  日本超音波医学会第86回学術集会司会: パネルディスカッション7「進行肝細胞癌に対する化学療法の治療戦略」  [Not invited]工藤 正俊; 金子 周一第99回日本消化器病学会総会  2013/05  城山観光ホテル, かごしま県民交流センター, 鹿児島  第99回日本消化器病学会総会EUS下膵管・胆道ドレナージ術の方法と成績. VTRシンポジウム2「Interventional EUSの進歩」  [Not invited]宮田 剛; 北野 雅之; 工藤 正俊第85回日本消化器内視鏡学会総会  2013/05  国立京都国際会館, 京都  第85回日本消化器内視鏡学会総会胃粘膜下腫瘍のEUS-FNAの成績と造影ハーモニックEUSによる鑑別診断の試み  [Not invited]坂本 洋城; 北野 雅之; 工藤 正俊第85回日本消化器内視鏡学会総会  2013/05  国立京都国際会館, 京都  第85回日本消化器内視鏡学会総会早期慢性膵炎と糖尿病の関連について  [Not invited]門阪 薫平; 北野 雅之; 工藤 正俊第85回日本消化器内視鏡学会総会  2013/05  国立京都国際会館, 京都  第85回日本消化器内視鏡学会総会当院における膵仮性嚢胞に対するTherapeuticEUSの工夫と成績  [Not invited]大本 俊介; 工藤 正俊; 北野 雅之第85回日本消化器内視鏡学会総会  2013/05  国立京都国際会館, 京都  第85回日本消化器内視鏡学会総会Time trends for helicobactor pylori eradication rate of the first-line and second-line Japanese regimens and clarithromycin resistance.  [Not invited]辻 直子; 奥村 直己; 谷池 聡子; 高場 雄久; 松本 望; 河野 匡志; 丸山 康典; 工藤 正俊Digestive Disease Week(DDW) 2013  2013/05  Orlando, USA  Digestive Disease Week(DDW) 2013Verrucous antral gastritis is not related to H. pylori-positive chronic gastritis, but is related to a high BMI and barrett's esophagus.  [Not invited]辻 直子; 奥村 直己; 谷池 聡子; 高場 雄久; 松本 望; 河野 匡志; 丸山 康典; 工藤 正俊Digestive Disease Week(DDW) 2013  2013/05  Orlando, USA  Digestive Disease Week(DDW) 2013Role of contrast-enhanced harmonic EUS in differentiating malignant from benign lymphadenopathy.  [Not invited]宮田 剛; 北野 雅之; 坂本 洋城; 今井 元; 鎌田 研; 門阪 薫平; 大本 俊介; 工藤 正俊Digestive Disease Week(DDW) 2013  2013/05  Orlando, USA  Digestive Disease Week(DDW) 2013EUS-guided drainage for treatment of postoperative complications after pancreatic surgery.  [Not invited]北野 雅之; 竹山 宜典; 宮田 剛; 鎌田 研; 坂本 洋城; 今井 元; 門阪 薫平; 大本 俊介; 工藤 正俊Digestive Disease Week(DDW) 2013  2013/05  Orlando, USA  Digestive Disease Week(DDW) 2013The clinical characteristics and endoscopic treatment of hemorrhagic duodenal varices.  [Not invited]松井 繁長; 工藤 正俊; 樫田 博史; 朝隈 豊; 川崎 正憲; 櫻井 俊治Digestive Disease Week(DDW) 2013  2013/05  Orlando, USA  Digestive Disease Week(DDW) 2013Heat shock protein 27 expression is inversely correlated with intraepithelial neoplasia and positively correlated with poor differentiation of gastris cancer.  [Not invited]永田 嘉昭; 櫻井 俊治; 高山 政樹; 永井 知行; 川崎 正憲; 朝隈 豊; 萩原 智; 西田 直生志; 松井 繁長; 樫田 博史; 工藤 正俊Digestive Disease Week(DDW) 2013  2013/05  Orlando, USA  Digestive Disease Week(DDW) 2013Noninvasive assessment of liver fibrosis by measurement of LF index in patients with chronic viral hepatitis.  [Not invited]矢田 典久; 萩原 智; 有住 忠晃; 田北 雅弘; 北井 聡; 井上 達夫; 南 康範; 上嶋 一臣; 西田 直生志; 工藤 正俊Digestive Disease Week(DDW) 2013  2013/05  Orlando, USA  Digestive Disease Week(DDW) 2013特別講演「肝細胞癌診療の新しいパラダイム」  [Not invited]工藤正俊第10回臨床消化器病フォーラム  2013/04  ウインクあいち,愛知造影ハーモニックEUS(CH-EUS)における膵腫瘍血流評価の検討  [Not invited]大本俊介; 北野雅之; 工藤正俊第26回日本腹部造影エコーー・ドプラ診断研究会  2013/04  ウインクあいち, 愛知造影を行なった小腸良性腫瘍の1例  [Not invited]横川美加; 辻裕美子; 前野知子; 塩見香織; 前川 清; 樫田博史; 工藤正俊第26回日本腹部造影エコーー・ドプラ診断研究会  2013/04  ウインクあいち, 愛知肝原発神経内分泌腫瘍の1例  [Not invited]田中梨絵; 井上達夫; 有住忠晃; 田北雅弘; 北井 聡; 矢田典久; 萩原 智; 南 康範; 上嶋一臣; 西田直生志; 樫田博史; 工藤正俊第26回日本腹部造影エコーー・ドプラ診断研究会  2013/04  ウインクあいち, 愛知特別講演「肝細胞癌診療の新しいパラダイム」  [Not invited]工藤 正俊第10回臨床消化器病フォーラム  2013/04  第10回臨床消化器病フォーラム座長: ランチョンセミナー1「C型慢性肝炎の3剤併用療法-埼玉県のAG&RGTトライアル-」  [Not invited]工藤 正俊第99回日本消化器病学会総会  2013/03  城山観光ホテル, かごしま県民交流センター, 鹿児島  第99回日本消化器病学会総会胃粘膜上皮のHSP27発現は上皮内癌の発生リスクと負の相関を示す  [Not invited]永田 嘉昭; 櫻井 俊治; 足立 哲平; 高山 政樹; 峯 宏昌; 永井 知行; 川崎 正憲; 朝隈 豊; 松井 繁長; 樫田 博史; 工藤 正俊第99回日本消化器病学会総会  2013/03  城山観光ホテル, かごしま県民交流センター, 鹿児島  第99回日本消化器病学会総会慢性膵炎におけるp38MAPK, HSP27の役割  [Not invited]櫻井 俊治; 樫田 博史; 工藤 正俊第99回日本消化器病学会総会  2013/03  城山観光ホテル, かごしま県民交流センター, 鹿児島  第99回日本消化器病学会総会肝血管筋脂肪腫の3例  [Not invited]田中 梨絵; 上嶋 一臣; 千品 寛和; 有住 忠晃; 田北 雅弘; 北井 聡; 井上 達夫; 矢田 典久; 萩原 智; 南 康範; 西田 直生志; 工藤 正俊第99回日本消化器病学会総会  2013/03  かごしま県民交流センター, 鹿児島  第99回日本消化器病学会総会膵仮性嚢胞に対するInterventional EUS  [Not invited]大本 俊介; 北野 雅之; 山田 光成; 門阪 薫平; 宮田 剛; 鎌田 研; 今井 元; 坂本 洋城; 工藤 正俊第99回日本消化器病学会総会  2013/03  城山観光ホテル, かごしま県民交流センター, 鹿児島  第99回日本消化器病学会総会超音波内視鏡下胆嚢ドレナージ術の有用性  [Not invited]今井 元; 北野 雅之; 工藤 正俊; 門阪 薫平; 大本 俊介; 鎌田 研; 宮田 剛; 坂本 洋城第99回日本消化器病学会総会  2013/03  城山観光ホテル, かごしま県民交流センター, 鹿児島  第99回日本消化器病学会総会十二指腸静脈瘤の病態と治療. ワークショップ7「異所性静脈瘤・胃静脈瘤の病態と治療」  [Not invited]松井 繁長; 樫田 博史; 工藤 正俊第49回日本腹部救急医学会総会  2013/03  福岡国際会議場, 福岡  第49回日本腹部救急医学会総会胃粘膜上皮のHSP27発現は上皮内癌の発生リスクと負の相関を示す  [Not invited]永田 嘉昭; 櫻井 俊治; 足立 哲平; 高山 政樹; 峯 宏昌; 永井 知行; 川崎 正憲; 朝隈 豊; 松井 繁長; 樫田 博史; 工藤 正俊第99回日本消化器病学会総会  2013/03  山観光ホテル, かごしま県民交流センター, 鹿児島  第99回日本消化器病学会総会慢性膵炎におけるp38MAPK, HSP27の役割  [Not invited]櫻井 俊治; 樫田 博史; 工藤 正俊第99回日本消化器病学会総会  2013/03  城山観光ホテル, かごしま県民交流センター, 鹿児島  第99回日本消化器病学会総会当院のヘリコバクターピロリ除菌治療におけるPPI別検討  [Not invited]足立 哲平; 高山 政樹; 峯 宏昌; 永井 知行; 永田 嘉昭; 川崎 正憲; 朝隈 豊; 櫻井 俊治; 松井 繁長; 樫田 博史; 工藤 正俊第99回日本消化器病学会総会  2013/03  城山観光ホテル, かごしま県民交流センター, 鹿児島  第99回日本消化器病学会総会EUS下腹腔内神経叢融解術の成績とその適応. ワークショップ「胆膵疾患に対するinterventional EUSの現状」  [Not invited]坂本 洋城; 北野 雅之; 工藤 正俊第99回日本消化器病学会総会  2013/03  城山観光ホテル, かごしま県民交流センター, 鹿児島  第99回日本消化器病学会総会EUS下胆道ドレナージ術の有用性. シンポジウム「非切除胆膵癌に対する内視鏡的interventionの進歩」  [Not invited]今井 元; 北野 雅之; 工藤 正俊第99回日本消化器病学会総会  2013/03  城山観光ホテル, かごしま県民交流センター, 鹿児島  第99回日本消化器病学会総会腸重積を契機に発見された回腸癌の1例  [Not invited]八木澤朋弘; 足立 哲平; 高山 政樹; 峯 宏昌; 永田 嘉昭; 永井 知行; 川崎 正憲; 朝隈 豊; 櫻井 俊治; 松井 繁長; 樫田 博史; 工藤 正俊; 大東 弘治; 吉岡 康多; 上田 和毅; 筑後 孝章日本消化器病学会近畿支部第98回例会  2013/02  神戸ポートピアホテル, 兵庫  日本消化器病学会近畿支部第98回例会同時多発早期胃癌11病変に対し内視鏡治療を施行した1例  [Not invited]南 知宏; 朝隈 豊; 足立 哲平; 高山 政樹; 峯 宏昌; 永田 嘉昭; 永井 知行; 川崎 正憲; 櫻井 俊治; 松井 繁長; 樫田 博史; 工藤 正俊日本消化器病学会近畿支部第98回例会  2013/02  神戸ポートピアホテル, 兵庫  日本消化器病学会近畿支部第98回例会胃粘膜下腫瘍様形態を呈した膵扁平上皮癌の1例  [Not invited]木下 大輔; 川崎 俊彦; 岸谷 讓; 清水 昌子; 宮部 欽生; 茂山 朋広; 奥田 英之; 秦 康倫; 工藤 正俊; 太田 善夫日本消化器病学会近畿支部第98回例会  2013/02  神戸ポートピアホテル, 兵庫  日本消化器病学会近畿支部第98回例会肝細胞癌に合併した膵solid-pseudopapillary neoplasmの1例  [Not invited]茂山 朋広; 秦 康倫; 木下 大輔; 奥田 英之; 宮部 欽生; 清水 昌子; 岸谷 讓; 川崎 俊彦; 佐藤 克明; 辻江 正徳; 井上 雅智; 太田 善夫; 工藤 正俊日本消化器病学会近畿支部第98回例会  2013/02  神戸ポートピアホテル, 兵庫  日本消化器病学会近畿支部第98回例会腫瘍内出血を呈した肉腫様肝癌の1例  [Not invited]千品 寛和; 井上 達夫; 田中 梨絵; 山田 光成; 有住 忠晃; 田北 雅弘; 北井 聡; 矢田 典久; 萩原 智; 南 康範; 上嶋 一臣; 西田 直生志; 工藤 正俊日本消化器病学会近畿支部第98回例会  2013/02  神戸ポートピアホテル, 兵庫  日本消化器病学会近畿支部第98回例会閉塞黄疸を合併した黄色肉芽腫性胆嚢炎の一例  [Not invited]河野 匡志; 丸山 康典; 松本 望; 高場 雄久; 奥村 直己; 山本 典雄; 冨田 崇文; 梅原 康湖; 谷池 聡子; 森村 正嗣; 米田 円; 山田 哲; 辻 直子; 船井 貞往; 落合 健; 前倉 俊治; 南 康範; 工藤 正俊日本消化器病学会近畿支部第98回例会  2013/02  神戸ポートピアホテル, 兵庫  日本消化器病学会近畿支部第98回例会膵腫瘍に対する造影ハーモニックEUS(CH-EUS)の有用性について. シンポジウム1「消化器診療におけるイノベーション」  [Not invited]大本 俊介; 北野 雅之; 工藤 正俊日本消化器病学会近畿支部第98回例会  2013/02  神戸ポートピアホテル, 兵庫  日本消化器病学会近畿支部第98回例会閉塞性黄疸を合併した黄色肉芽腫性胆のう炎の1例  [Not invited]河野 匡志; 丸山 康典; 松本 望; 高場 雄久; 奥村 直己; 山本 典雄; 冨田 崇文; 梅原 康湖; 谷池 聡子; 森村 正嗣; 米田 円; 山田 哲; 辻 直子; 船井 貞往; 落合 健; 前倉 俊治; 南 康範; 工藤 正俊日本消化器病学会近畿支部第98回例会  2013/02  日本消化器病学会近畿支部第98回例会Chair "Luncheon Seminar; Jordi Bruix “Recent progress of chemotherapy for HCC”  [Invited]Masatoshi KudoThe 8th International Meeting of Hepatocellular Carcinoma: Eastern and Western Experiences  2013/02  Ito International Research CenterCTHAと比較したソナゾイドUSによるnodule in noduleのHCCの診断とその問題点. シンポジム2「肝血流・機能イメージのバイオマーカー的意義を探る」  [Not invited]小川 力; 森岡弓子; 野田晃世; 上田祐也; 宮本由貴子; 野上明子; 吉岡正博; 石川哲朗; 松中寿浩; 玉置敬之; 柴峠光成; 河合直之; 山岡竜也; 石川順英; 廣瀬哲朗; 西平友彦; 嶋田俊秀; 荻野哲朗; 工藤正俊第19回肝血流動態イメージ研究会  2013/01  東京ビッグサイト「国際会議場」, 東京司会"シンポジウム「肝血流・機能イメージのバイオマーカー的意義を探る」"  [Not invited]工藤正俊第19回肝血流動態イメージ研究会  2013/01  東京ビッグサイト「国際会議場」, 東京腫瘍内出血を認めた肉腫様肝癌の1例  [Not invited]千品寛和; 井上達夫; 田中梨絵; 山田光成; 有住忠晃; 田北雅弘; 北井 聡; 矢田典久; 萩原 智; 南 康範; 上嶋一臣; 西田直生志; 工藤正俊; 隈部 力; 中島 収第19回肝血流動態イメージ研究会  2013/01  東京ビッグサイト「国際会議場」, 東京First-line Brivanib (BRIV) Versus Sorafenib (SOR) in Unresectable, Advanced Hepatocellular Carcinoma (HCC): Asia/Non-Asia Survival Results in Phase 3 BRISK-FL Study  [Not invited]Cheng AL; 工藤 正俊; Qin S; Park JW; Poon R; Raoul JL; Philip PA; Hsu CH; Hu TH; Heo J; Xu J; Lu L; Chao Y; Boucher E; Han KH; Paik SW; Avina JR; Liu D Ezzeddine R Walters I; Johnson PAsian Pacific Association for the Study of the Liver (APASL) 2013  2013  Singapore  Asian Pacific Association for the Study of the Liver (APASL) 2013当院におけるヘリコバクターピロリ除菌治療成績の検討  [Not invited]足立 哲平; 松井 繁長; 樫田 博史; 工藤 正俊第9回日本消化管学会総会学術集会  2013/01  京王プラザホテル, 東京  第9回日本消化管学会総会学術集会ソラフェニブ治療後の後治療についての検討. シンポジウム「進行肝細胞癌に対してネクサバールを含んだ治療を、どう生命予後改善につなげるか?」  [Not invited]上嶋 一臣; 有住 忠晃; 工藤 正俊第7回日本肝がん分子標的治療研究会  2013/01  じゅうろくプラザ, 岐阜  第7回日本肝がん分子標的治療研究会ソラフェニブ治療におけるJNK活性の重要性-CD133との関連も含めて-  [Not invited]萩原 智; 櫻井 俊治; 工藤 正俊第7回日本肝がん分子標的治療研究会  2013/01  じゅうろくプラザ, 岐阜  第7回日本肝がん分子標的治療研究会特別講演「What we learned from the Negative studies.」  [Not invited]工藤 正俊TACE Refractory Focus Expert Meeting  2012/12  JRクレメントホテル高松, 高松  TACE Refractory Focus Expert MeetingComparison of different proton pump inhibitors (PPI)in helicobacter pylori eradication.  [Not invited]足立 哲平; 松井 繁長; 高山 政樹; 川崎 正憲; 朝隈 豊; 櫻井 俊治; 樫田 博史; 工藤 正俊Asian Pacific Digestive Week (APDW) 2012  2012/12  Bangkok, Thailand  Asian Pacific Digestive Week (APDW) 2012A prospective randomized controlled study of a rebamipid monotherapy in the treatment of endoscopic submucosal dissection (ESD)-induced ulcers.  [Not invited]高山 政樹; 松井 繁長; 川崎 正憲; 朝隈 豊; 樫田 博史; 工藤 正俊Asian Pacific Digestive Week (APDW) 2012  2012/12  Bangkok, Thailand  Asian Pacific Digestive Week (APDW) 2012Albumin levels can be a predictive factor for the short-term complications after percutaneous endoscopic gastrostomy in retrospective study.  [Not invited]永井 知行; 足立 哲平; 高山 政樹; 峯 宏昌; 永田 嘉昭; 川崎 正憲; 朝隈 豊; 櫻井 俊治; 松井 繁長; 汐見 幹夫; 樫田 博史; 工藤 正俊Asian Pacific Digestive Week (APDW) 2012  2012/12  Bangkok, Thailand  Asian Pacific Digestive Week (APDW) 2012The clinical characteristics and endscopic treatment of duodenal varices.  [Not invited]松井 繁長; 樫田 博史; 川崎 正憲; 朝隈 豊; 櫻井 俊治; 工藤 正俊Asian Pacific Digestive Week (APDW) 2012  2012/12  Bangkok, Thailand  Asian Pacific Digestive Week (APDW) 2012The retrospective study of novel anticancer agent, miriplatin in TACE and TAI for unresectable hepatocellular carcinoma in Japan.  [Not invited]永井 知行; 上嶋 一臣; 早石 宗右; 田北 雅弘; 北井 聡; 矢田 典久; 井上 達夫; 萩原 智; 南 康範; 西田 直生志; 工藤 正俊Asian Pacific Digestive Week (APDW) 2012  2012/12  Bangkok, Thailand  Asian Pacific Digestive Week (APDW) 2012Utility of EUS-guided gallbladder drainage for rescue treatment of malignant biliary obstruction.  [Not invited]今井 元; 北野 雅之; 門阪 薫平; 鎌田 研; 宮田 剛; 坂本 洋城; 工藤 正俊Asian Pacific Digestive Week (APDW) 2012  2012/12  Bangkok, Thailand  Asian Pacific Digestive Week (APDW) 2012Endoscopic submucosal dissection for the colorectum: usefulness and feasibility.  [Not invited]樫田 博史; 櫻井 俊治; 朝隈 豊; 川崎 正憲; 永田 嘉昭; 永井 知行; 高山 政樹; 峯 宏昌; 足立 哲平; 松井 繁長; 工藤 正俊Asian Pacific Digestive Week (APDW) 2012  2012/12  Bangkok, Thailand  Asian Pacific Digestive Week (APDW) 2012Trans-catheter endoscopy for pancreaticobiliary duct diseases.  [Not invited]坂本 洋城; 北野 雅之; 今井 元; 宮田 剛; 鎌田 研; 門阪 薫平; 工藤 正俊Asian Pacific Digestive Week (APDW) 2012  2012/12  Bangkok, Thailand  Asian Pacific Digestive Week (APDW) 2012A prospective feasibility study on EUS guided broad plexus neurolysis in combination with celiac ganglion neurolysis.  [Not invited]坂本 洋城; 北野 雅之; 今井 元; 鎌田 研; 宮田 剛; 門阪 薫平; 工藤 正俊Asian Pacific Digestive Week (APDW) 2012  2012/12  Bangkok, Thailand  Asian Pacific Digestive Week (APDW) 2012Diffrential diagnosis of SMT and evaluation of malignant potentioal gists by contrast enhanced harmonic EUS.  [Not invited]坂本 洋城; 北野 雅之; 今井 元; 鎌田 研; 宮田 剛; 門阪 薫平; 工藤 正俊Asian Pacific Digestive Week (APDW) 2012  2012/12  Bangkok, Thailand  Asian Pacific Digestive Week (APDW) 2012特別講演「肝細胞がん診療の新しいパラダイム」  [Not invited]工藤 正俊第7回JULIET  2012/12  野村コンファレンスプラザ日本橋  第7回JULIETInvited Lecture “Interventional and contrast EUS for pancreatobiliary tumors.”  [Not invited]工藤 正俊The 10th Congress of Asian Federation of Societies for Ultrasound in Medicine and Biology (AFSUMB)  2012/11  Bali, Indonesia  The 10th Congress of Asian Federation of Societies for Ultrasound in Medicine and Biology (AFSUMB)Invited Lecture “Sonazoid-enhanced US in the management of HCC.”  [Not invited]工藤 正俊The 10th Congress of Asian Federation of Societies for Ultrasound in Medicine and Biology (AFSUMB)  2012/11  Bali, Indonesia  The 10th Congress of Asian Federation of Societies for Ultrasound in Medicine and Biology (AFSUMB)Invited Lecture “Double contrast US for surveillance of HCC.”  [Not invited]工藤 正俊The 10th Congress of Asian Federation of Societies for Ultrasound in Medicine and Biology (AFSUMB)  2012/11  Bali, Indonesia  The 10th Congress of Asian Federation of Societies for Ultrasound in Medicine and Biology (AFSUMB)Invited Lecture “Interventional US for liver tumors.”  [Not invited]工藤 正俊The 10th Congress of Asian Federation of Societies for Ultrasound in Medicine and Biology (AFSUMB)  2012/11  Bali, Indonesia  The 10th Congress of Asian Federation of Societies for Ultrasound in Medicine and Biology (AFSUMB)HCC challenges: Definition on TACE failure and refractoriness.  [Not invited]工藤 正俊HCC Expert Meeting and Asia Pacific Virtual Meeting -Expert discussion on HCC management-  2012/11  Taipei, Taiwan  HCC Expert Meeting and Asia Pacific Virtual Meeting -Expert discussion on HCC management-Chairs: Session 5: Diagnosis and treatment of HCV-associated HCC  [Not invited]工藤 正俊The 10th JSH Single Topic Conference”Hepatitis C: Best practice based on science.”  2012/11  Keio Plaza Hotel Tokyo, Tokyo, Japan  The 10th JSH Single Topic Conference”Hepatitis C: Best practice based on science.”吐血を契機に発見した妊婦の特発性食道粘膜下血腫の一例  [Not invited]南 知宏; 朝隈 豊; 足立 哲平; 高山 政樹; 峯 宏昌; 永田 嘉昭; 永井 知行; 川崎 正憲; 櫻井 俊治; 松井 繁長; 樫田 博史; 工藤 正俊日本消化器内視鏡学会近畿支部第89回支部例会  2012/11  大阪国際交流センター, 大阪  日本消化器内視鏡学会近畿支部第89回支部例会Inflammatory fibroid polypの一例  [Not invited]木下 大輔; 秦 康倫; 奥田 英之; 茂山 朋広; 宮部 欽生; 清水 昌子; 岸谷 讓; 川崎 俊彦; 太田 善夫; 工藤 正俊日本消化器内視鏡学会近畿支部第89回支部例会  2012/11  大阪国際交流センター, 大阪  日本消化器内視鏡学会近畿支部第89回支部例会リンパ管侵襲を伴う胃粘膜内癌の一例  [Not invited]峯 宏昌; 朝隈 豊; 足立 哲平; 高山 政樹; 永田 嘉昭; 永井 知行; 川崎 正憲; 櫻井 俊治; 松井 繁長; 樫田 博史; 工藤 正俊日本消化器内視鏡学会近畿支部第89回支部例会  2012/11  大阪国際交流センター, 大阪  日本消化器内視鏡学会近畿支部第89回支部例会慢性腎不全合併十二指腸静脈瘤に対して内視鏡的硬化療法治療が奏効した一例  [Not invited]千品 寛和; 松井 繁長; 田北 雅弘; 川崎 正憲; 朝隈 豊; 櫻井 俊治; 樫田 博史; 工藤 正俊日本消化器内視鏡学会近畿支部第89回支部例会  2012/11  大阪国際交流センター, 大阪  日本消化器内視鏡学会近畿支部第89回支部例会腸重積で発見された炎症性線維性ポリープの1例  [Not invited]足立 哲平; 松井 繁長; 高山 政樹; 峯 宏昌; 永井 知行; 永田 嘉昭; 川崎 正憲; 朝隈 豊; 櫻井 俊治; 樫田 博史; 工藤 正俊; 大東 弘治; 上田 和毅; 奥野 清隆日本消化器内視鏡学会近畿支部第89回支部例会  2012/11  大阪国際交流センター, 大阪  日本消化器内視鏡学会近畿支部第89回支部例会生検で消失したバレット腺癌の一例  [Not invited]丸山 康典; 河野 匡志; 松本 望; 高場 雄久; 奥村 直己; 山本 典雄; 富田 崇文; 梅原 康湖; 谷池 聡子; 森村 正嗣; 山田 哲; 辻 直子; 落合 健; 前倉 俊治; 南 康範; 工藤 正俊日本消化器内視鏡学会近畿支部第89回支部例会  2012/11  大阪国際交流センター, 大阪  日本消化器内視鏡学会近畿支部第89回支部例会診断確定に造影ハーモニックEUSが有用であった膵腫瘍の検討  [Not invited]大本 俊介; 北野 雅之; 工藤 正俊日本消化器内視鏡学会近畿支部第89回支部例会  2012/11  大阪国際交流センター, 大阪  日本消化器内視鏡学会近畿支部第89回支部例会当院でのEMRの工夫. ビデオワークショップ2「下部消化管: 大腸内視鏡挿入法とEMRの基本と工夫」  [Not invited]永井 知行; 樫田 博史; 工藤 正俊日本消化器内視鏡学会近畿支部第89回支部例会  2012/11  大阪国際交流センター, 大阪  日本消化器内視鏡学会近畿支部第89回支部例会GIDEON (Global Investigation of therapeutic DEcisions in he-patocellular carcinoma and Of its treatment with SoraeNib) second interim analysis: subgoup analysis by disease aetiology.  [Not invited]Bronowicki JP; 工藤 正俊; Ye SL; Marrero J; Venook A; Nakajima K; Lencioni RThe 63th Annual Meeting of the American Association for the Study of Liver Disease (AASLD)  2012/11  Boston, USA  The 63th Annual Meeting of the American Association for the Study of Liver Disease (AASLD)Invited Lecture “The potential of surveillance -the Japanese experience.”  [Not invited]工藤 正俊Falk Symposium 186  2012/10  Mainz, Germany  Falk Symposium 186Comparison of four different proton pump inhibitors in helicobacter pylori eradication treatment.  [Not invited]足立 哲平; 高山 政樹; 峯 宏昌; 永井 知行; 永田 嘉昭; 川崎 正憲; 朝隈 豊; 櫻井 俊治; 松井 繁長; 樫田 博史; 工藤 正俊20th United European Gastroenterology Week (UEGW)  2012/10  Amsterdam, The Netherlands  20th United European Gastroenterology Week (UEGW)Usefulness of rebamipide for endoscopic submucosal dissection (ESD) -induces ulcer in early gastric cancer: prospective randomized study.  [Not invited]高山 政樹; 松井 繁長; 川崎 正憲; 朝隈 豊; 櫻井 俊治; 樫田 博史; 工藤 正俊20th United European Gastroenterology Week (UEGW)  2012/10  Amsterdam, The Netherlands  20th United European Gastroenterology Week (UEGW)肝がんディベートセッション2 特別講演 ラジオ波の適応と優位性「原発性肝がんに対する治療方針 外科vs RF治療」  [Not invited]工藤 正俊第50回日本癌治療学会学術集会  2012/10  パシフィコ横浜, 神奈川.  第50回日本癌治療学会学術集会ランチョンセミナー「肝胆膵疾患における造影超音波の役割」  [Not invited]工藤 正俊超音波分科会(日本超音波医学会第42回北海道地方会学術集会)  2012/10  札幌医科大学臨床教育研究棟講堂記念ホール, 札幌  超音波分科会(日本超音波医学会第42回北海道地方会学術集会)司会: ブレックファーストセミナー9「肝細胞癌の早期診断と分子標的薬治療の進歩」  [Not invited]工藤 正俊第20回日本消化器関連学会週間JDDW 2012  2012/10  ポートピアホテル, 兵庫  第20回日本消化器関連学会週間JDDW 2012肝細胞癌に対するラジオ波焼灼療法の治療効果判定における造影超音波検査の有用性の検討~造影CTとの比較~  [Not invited]井上 達夫; 有住 忠晃; 早石 宗右; 田北 雅弘; 北井 聡; 矢田 典久; 萩原 智; 南 康範; 上嶋 一臣; 西田 直生志; 工藤 正俊第20回日本消化器関連学会週間JDDW2012  2012/10  神戸国際展示場, 兵庫  第20回日本消化器関連学会週間JDDW2012肝嚢胞に対するオレイン酸モノエタノールアミン注入療法の検討  [Not invited]田北 雅弘; 井上 達夫; 有住 忠晃; 早石 宗右; 北井 聡; 矢田 典久; 萩原 智; 南 康範; 上嶋 一臣; 西田 直生志; 工藤 正俊第20回日本消化器関連学会週間JDDW2012  2012/10  神戸国際展示場, 兵庫  第20回日本消化器関連学会週間JDDW2012Support Vector Machineを用いたReal-time Tissue ElastograhyによるF Stage推定値. ワークショップ11「低侵襲な肝疾患診断法の進歩」  [Not invited]矢田 典久; 工藤 正俊; 藤本 研治第20回日本消化器関連学会週間JDDW2012  2012/10  ポートピアホテル, 兵庫  第20回日本消化器関連学会週間JDDW2012肝癌の遺伝子変化および背景肝組織の男女差に関する検討. ワークショップ7「消化器疾患と性差」  [Not invited]西田 直生志; 工藤 正俊第20回日本消化器関連学会週間JDDW2012(第16回日本肝臓学会大会・第54回日本消化器病学会大会・第84回日本消化器内視鏡学会総会・第10回日本消化器外科学会大会・第50回日本消化器がん検診学会  2012/10  神戸国際会議場, 兵庫  第20回日本消化器関連学会週間JDDW2012(第16回日本肝臓学会大会・第54回日本消化器病学会大会・第84回日本消化器内視鏡学会総会・第10回日本消化器外科学会大会・第50回日本消化器がん検診学会肝発癌における酸化ストレスとエピゲノム変異. パネルディスカッション5「消化器癌と酸化ストレス」  [Not invited]西田 直生志; 工藤 正俊第20回日本消化器関連学会週間JDDW2012(第16回日本肝臓学会大会・第54回日本消化器病学会大会・第84回日本消化器内視鏡学会総会・第10回日本消化器外科学会大会・第50回日本消化器がん検診学会  2012/10  ポートピアホテル, 兵庫  第20回日本消化器関連学会週間JDDW2012(第16回日本肝臓学会大会・第54回日本消化器病学会大会・第84回日本消化器内視鏡学会総会・第10回日本消化器外科学会大会・第50回日本消化器がん検診学会シンポジウム1・特別発言「分子標的治療の限界を超える新しい肝癌治療法の開発」  [Not invited]工藤 正俊第54回日本消化器病学会大会  2012/10  神戸国際展示場, 兵庫  第54回日本消化器病学会大会基調講演 シンポジウム1「分子標的治療の限界を超える新しい肝癌治療法の開発」  [Not invited]工藤 正俊第54回日本消化器病学会大会  2012/10  神戸国際展示場, 兵庫  第54回日本消化器病学会大会司会:シンポジウム1「分子標的治療の限界を超える新しい肝癌治療法の開発」  [Not invited]工藤 正俊第20回日本消化器関連学会週間JDDW 2012(第54回日本消化器病学会大会)  2012/10  神戸国際展示場, 兵庫  第20回日本消化器関連学会週間JDDW 2012(第54回日本消化器病学会大会)当院におけるH.pylori除菌の年次変化(2001年~2010年)  [Not invited]丸山 康典; 辻 直子; 河野 匡志; 松本 望; 高場 雄久; 奥村 直己; 山本 典雄; 冨田 崇文; 梅原 康湖; 森村 正嗣; 米田 円; 山田 哲; 落合 健; 南 康範; 工藤 正俊; 本庶 元第20回日本消化器関連学会週間JDDW2012(第16回日本肝臓学会大会・第54回日本消化器病学会大会・第84回日本消化器内視鏡学会総会・第10回日本消化器外科学会大会・第50回日本消化器がん検診学会  2012/10  神戸国際展示場, 兵庫  第20回日本消化器関連学会週間JDDW2012(第16回日本肝臓学会大会・第54回日本消化器病学会大会・第84回日本消化器内視鏡学会総会・第10回日本消化器外科学会大会・第50回日本消化器がん検診学会腸管重複症に対しSBナイフJrを用いて内視鏡的隔壁切除を施行した1例  [Not invited]宮部 欽生; 木下 大輔; 秦 康倫; 奥田 英之; 茂山 朋広; 清水 昌子; 岸谷 讓; 川崎 俊彦; 米倉 竹夫; 工藤 正俊第20回日本消化器関連学会週間JDDW2012(第16回日本肝臓学会大会・第54回日本消化器病学会大会・第84回日本消化器内視鏡学会総会・第10回日本消化器外科学会大会・第50回日本消化器がん検診学会  2012/10  神戸国際展示場, 兵庫  第20回日本消化器関連学会週間JDDW2012(第16回日本肝臓学会大会・第54回日本消化器病学会大会・第84回日本消化器内視鏡学会総会・第10回日本消化器外科学会大会・第50回日本消化器がん検診学会ランソプラゾールによるcollagenous colitisの4症例  [Not invited]秦 康倫; 木下 大輔; 奥田 英之; 茂山 朋広; 宮部 欽生; 清水 昌子; 岸谷 讓; 川崎 俊彦; 太田 善夫; 工藤 正俊第20回日本消化器関連学会週間JDDW2012(第16回日本肝臓学会大会・第54回日本消化器病学会大会・第84回日本消化器内視鏡学会総会・第10回日本消化器外科学会大会・第50回日本消化器がん検診学  2012/10  神戸国際展示場, 兵庫  第20回日本消化器関連学会週間JDDW2012(第16回日本肝臓学会大会・第54回日本消化器病学会大会・第84回日本消化器内視鏡学会総会・第10回日本消化器外科学会大会・第50回日本消化器がん検診学シングルバルーン小腸内視鏡検査(SBE)にて診断し得た小腸癌について  [Not invited]高山 政樹; 樫田 博史; 足立 哲平; 峯 宏昌; 永田 嘉昭; 永井 知行; 川崎 正憲; 朝隈 豊; 櫻井 俊治; 松井 繁長; 工藤 正俊; 竹山 宜典; 筑後 孝章第20回日本消化器関連学会週間JDDW2012(第16回日本肝臓学会大会・第54回日本消化器病学会大会・第84回日本消化器内視鏡学会総会・第10回日本消化器外科学会大会・第50回日本消化器がん検診学会  2012/10  神戸国際展示場, 兵庫  第20回日本消化器関連学会週間JDDW2012(第16回日本肝臓学会大会・第54回日本消化器病学会大会・第84回日本消化器内視鏡学会総会・第10回日本消化器外科学会大会・第50回日本消化器がん検診学会大腸ESD導入時の治療成績に関する検討.  [Not invited]足立 哲平; 樫田 博史; 大本 俊介; 高山 政樹; 峯 宏昌; 永井 知行; 永田 嘉昭; 川崎 正憲; 朝隈 豊; 櫻井 俊治; 松井 繁長; 工藤 正俊第20回日本消化器関連学会週間JDDW2012(第16回日本肝臓学会大会・第54回日本消化器病学会大会・第84回日本消化器内視鏡学会総会・第10回日本消化器外科学会大会・第50回日本消化器がん検診学会  2012/10  神戸国際展示場, 兵庫  第20回日本消化器関連学会週間JDDW2012(第16回日本肝臓学会大会・第54回日本消化器病学会大会・第84回日本消化器内視鏡学会総会・第10回日本消化器外科学会大会・第50回日本消化器がん検診学会経皮内視鏡的胃?造設術(PEG)の患者背景と早期合併症  [Not invited]永井 知行; 大本 俊介; 高山 政樹; 峯 宏昌; 永田 嘉昭; 川崎 正憲; 朝隈 豊; 櫻井 俊治; 松井 繁長; 汐見 幹夫; 樫田 博史; 工藤 正俊第20回日本消化器関連学会週間JDDW2012(第16回日本肝臓学会大会・第54回日本消化器病学会大会・第84回日本消化器内視鏡学会総会・第10回日本消化器外科学会大会・第50回日本消化器がん検診学会  2012/10  神戸国際展示場, 兵庫  第20回日本消化器関連学会週間JDDW2012(第16回日本肝臓学会大会・第54回日本消化器病学会大会・第84回日本消化器内視鏡学会総会・第10回日本消化器外科学会大会・第50回日本消化器がん検診学会当院における胃ESD症例での多発例の検討  [Not invited]朝隈 豊; 松井 繁長; 足立 哲平; 大本 俊介; 高山 政樹; 峯 宏昌; 永井 知行; 永田 嘉昭; 川崎 正憲; 櫻井 俊治; 樫田 博史; 工藤 正俊第20回日本消化器関連学会週間JDDW2012(第16回日本肝臓学会大会・第54回日本消化器病学会大会・第84回日本消化器内視鏡学会総会・第10回日本消化器外科学会大会・第50回日本消化器がん検診学会  2012/10  神戸国際展示場, 兵庫  第20回日本消化器関連学会週間JDDW2012(第16回日本肝臓学会大会・第54回日本消化器病学会大会・第84回日本消化器内視鏡学会総会・第10回日本消化器外科学会大会・第50回日本消化器がん検診学会プロトンポンプ阻害薬(PPI)内服中GERD患者に対するGerdQによる治療実態の検討  [Not invited]大本 俊介; 松井 繁長; 足立 哲平; 峯 宏昌; 高山 政樹; 永井 知行; 永田 嘉昭; 川崎 正憲; 朝隈 豊; 櫻井 俊治; 樫田 博史; 工藤 正俊第20回日本消化器関連学会週間JDDW2012(第16回日本肝臓学会大会・第54回日本消化器病学会大会・第84回日本消化器内視鏡学会総会・第10回日本消化器外科学会大会・第50回日本消化器がん検診学会  2012/10  神戸国際展示場, 兵庫  第20回日本消化器関連学会週間JDDW2012(第16回日本肝臓学会大会・第54回日本消化器病学会大会・第84回日本消化器内視鏡学会総会・第10回日本消化器外科学会大会・第50回日本消化器がん検診学会当院におけるH.pylori CAM耐性の年次変化(2001年~2010年)  [Not invited]河野 匡志; 辻 直子; 丸山 康典; 松本 望; 高場 雄久; 奥村 直己; 山本 典雄; 冨田 崇文; 梅原 康湖; 森村 正嗣; 米田 円; 山田 哲; 落合 健; 南 康範; 工藤 正俊; 本庶 元第20回日本消化器関連学会週間JDDW2012(第16回日本肝臓学会大会・第54回日本消化器病学会大会・第84回日本消化器内視鏡学会総会・第10回日本消化器外科学会大会・第50回日本消化器がん検診学会  2012/10  神戸国際展示場, 兵庫  第20回日本消化器関連学会週間JDDW2012(第16回日本肝臓学会大会・第54回日本消化器病学会大会・第84回日本消化器内視鏡学会総会・第10回日本消化器外科学会大会・第50回日本消化器がん検診学会Helicobacter pylori除菌前後の内視鏡所見の比較検討  [Not invited]奥村 直己; 辻 直子; 工藤 正俊; 山本 典雄; 高場 雄久; 松本 望; 冨田 崇文; 森村 正嗣; 山田 哲; 米田 円; 南 康範; 丸山 康典; 河野 匡志; 梅原 康湖第20回日本消化器関連学会週間JDDW2012(第16回日本肝臓学会大会・第54回日本消化器病学会大会・第84回日本消化器内視鏡学会総会・第10回日本消化器外科学会大会・第50回日本消化器がん検診学会  2012/10  神戸国際展示場, 兵庫  第20回日本消化器関連学会週間JDDW2012(第16回日本肝臓学会大会・第54回日本消化器病学会大会・第84回日本消化器内視鏡学会総会・第10回日本消化器外科学会大会・第50回日本消化器がん検診学会EUS下胆管ドレナージ術の穿刺ルートおよびステント留置法の使い分けと成績  [Not invited]今井 元; 北野 雅之; 工藤 正俊第20回日本消化器関連学会週間JDDW2012(第16回日本肝臓学会大会・第54回日本消化器病学会大会・第84回日本消化器内視鏡学会総会・第10回日本消化器外科学会大会・第50回日本消化器がん検診学会  2012/10  神戸国際展示場, 兵庫  第20回日本消化器関連学会週間JDDW2012(第16回日本肝臓学会大会・第54回日本消化器病学会大会・第84回日本消化器内視鏡学会総会・第10回日本消化器外科学会大会・第50回日本消化器がん検診学会ADL不良の急性胆嚢炎および胆管炎例に対するEUSドレナージ術. パネルディスカッション26「75歳以上における腹腔鏡下胆嚢摘出術の安全性の検討」  [Not invited]門阪 薫平; 北野 雅之; 工藤 正俊第20回日本消化器関連学会週間JDDW2012(第16回日本肝臓学会大会・第54回日本消化器病学会大会・第84回日本消化器内視鏡学会総会・第10回日本消化器外科学会大会・第50回日本消化器がん検診学会  2012/10  神戸国際会議場, 兵庫  第20回日本消化器関連学会週間JDDW2012(第16回日本肝臓学会大会・第54回日本消化器病学会大会・第84回日本消化器内視鏡学会総会・第10回日本消化器外科学会大会・第50回日本消化器がん検診学会StageO/I膵癌の臨床的特徴. パネルディスカッション4「膵癌早期発見に向けた取組み」  [Not invited]宮田 剛; 北野 雅之; 工藤 正俊第20回日本消化器関連学会週間JDDW2012(第16回日本肝臓学会大会・第54回日本消化器病学会大会・第84回日本消化器内視鏡学会総会・第10回日本消化器外科学会大会・第50回日本消化器がん検診学会  2012/10  ポートピアホテル南館, 兵庫  第20回日本消化器関連学会週間JDDW2012(第16回日本肝臓学会大会・第54回日本消化器病学会大会・第84回日本消化器内視鏡学会総会・第10回日本消化器外科学会大会・第50回日本消化器がん検診学会膵癌診断ストラテジーと各画像検査の比較検討. パネルディスカッション2「超音波検査発見胆膵病変の精密検査のストラテジー」  [Not invited]鎌田 研; 北野 雅之; 工藤 正俊第20回日本消化器関連学会週間JDDW2012(第16回日本肝臓学会大会・第54回日本消化器病学会大会・第84回日本消化器内視鏡学会総会・第10回日本消化器外科学会大会・第50回日本消化器がん検診学会  2012/10  神戸国際展示場, 兵庫  第20回日本消化器関連学会週間JDDW2012(第16回日本肝臓学会大会・第54回日本消化器病学会大会・第84回日本消化器内視鏡学会総会・第10回日本消化器外科学会大会・第50回日本消化器がん検診学会癌性疼痛に対するEUS下腹腔内神経叢/節ブロック術のストラテジー. シンポジウム16「胆膵疾患に対するtherapeutic EUSの現状(EUS-FNAを除く)」  [Not invited]坂本 洋城; 北野 雅之; 工藤 正俊第20回日本消化器関連学会週間JDDW2012(第16回日本肝臓学会大会・第54回日本消化器病学会大会・第84回日本消化器内視鏡学会総会・第10回日本消化器外科学会大会・第50回日本消化器がん検診学会  2012/10  神戸国際会議場, 兵庫  第20回日本消化器関連学会週間JDDW2012(第16回日本肝臓学会大会・第54回日本消化器病学会大会・第84回日本消化器内視鏡学会総会・第10回日本消化器外科学会大会・第50回日本消化器がん検診学会肝胆膵疾患の造影超音波診断  [Not invited]工藤 正俊日本超音波医学会第22回四国地方会学術集会  2012/10  松山市総合コミュニティーセンター, 愛媛  日本超音波医学会第22回四国地方会学術集会1年以上の下痢,下血で受診した腸重積合併1型S状結腸がんの1例  [Not invited]河野 匡志; 丸山 康典; 松本 望; 高場 雄久; 奥村 直己; 冨田 崇文; 梅原 康湖; 谷池 聡子; 森村 正嗣; 米田 円; 山田 哲; 辻 直子; 亀井 敬子; 田中 晃; 落合 健; 前倉 俊治; 南 康範; 工藤 正俊日本消化器病学会近畿支部大97会例会  2012/09  京都市  日本消化器病学会近畿支部大97会例会GIDEON (Global Investigation of therapeutic DEcisions in he-patocellular carcinoma and of its treatment with soraeNib) second interim analysis: subgoup analysis by disease aetiology.  [Not invited]Bronowicki JP; 工藤 正俊; Ye SL; Marrero J; Venook A; Nakajima K; Lencioni RESMO 2012  2012/09  Vienna, Austria  ESMO 2012Final results of a randomized Phase II study of TSU-68 after transarterial chemoembolisation in Japanese patients with unresectable hepatocellular carcinoma. Chemoembolization.  [Not invited]Kaneko S; 工藤 正俊; Unaba Y; Kanai F; Aramaki T; Yamamoto T; Tanaka K; Yamakado K; Imanaka K; Arai YESMO 2012  2012/09  Vienna, Austria  ESMO 2012EUS下胆道ドレナージ術の工夫. ビデオワークショップ「胆道疾患内視鏡治療困難例に対する手技の工夫」  [Not invited]鎌田 研; 北野 雅之; 工藤 正俊第48回日本胆道学会学術集会  2012/09  京王プラザホテル, 東京  第48回日本胆道学会学術集会司会: 教育セミナー6「門脈圧亢進症と超音波診断」  [Not invited]工藤 正俊第19回日本門脈圧亢進症学会総会  2012/09  椿山荘, 東京.  第19回日本門脈圧亢進症学会総会Phase I/II trial of lenvatinib (E7080), a multi-targeted tyrosine kinase inhibitor, in patients with advanced hepatocellular carcinoma (HCC)  [Not invited]Ikeda K; 工藤 正俊; Kumada H; Kawazoe S; Osaki Y; Ikeda M; Okusaka T; Suzuki T; O'Brien JP; Okita KESMO 2012  2012/09  Vienna, Austria  ESMO 2012巨大胆石が十二指腸球部に穿通し胆石イレウスを起こした一例  [Not invited]宮内 正晴; 北野 雅之; 坂本 洋城; 今井 元; 鎌田 研; 宮田 剛; 門阪 薫平; 工藤 正俊日本消化器病学会近畿支部第97回例会  2012/09  京都テルサ, 京都  日本消化器病学会近畿支部第97回例会上部胆管癌との鑑別を要したIgG4関連胆管炎  [Not invited]田中 寛樹; 北野 雅之; 坂本 洋城; 今井 元; 鎌田 研; 宮田 剛; 門阪 薫平; 工藤 正俊日本消化器病学会近畿支部第97回例会  2012/09  京都テルサ, 京都  日本消化器病学会近畿支部第97回例会著明な蛋白漏出性胃腸症を呈し、ステロイドが奏効したCronkhite-Canada症候群の一例  [Not invited]南 康範; 松井 繁長; 足立 哲平; 高山 政樹; 峯 宏昌; 永田 嘉昭; 永井 知行; 川崎 正憲; 朝隈 豊; 櫻井 俊治; 樫田 博史; 工藤 正俊著明な蛋白漏出性胃腸症を呈し、ステロイドが奏効したCronkhite-Canada症候群の一例  2012/09  京都テルサ, 京都  著明な蛋白漏出性胃腸症を呈し、ステロイドが奏効したCronkhite-Canada症候群の一例1年以上の下痢、下血で受診した腸重積合併1型S状結腸癌による成人型腸重積の1例  [Not invited]河野匡志; 南 康範; 工藤 正俊; 丸山康典; 松本; 望; 高場雄久; 奥村直己; 冨田崇文; 梅原康湖; 谷池聡子; 森村正嗣; 辻; 直子; 米田; 円; 山田 哲; 亀井敬子; 田中; 落合 健; 前倉俊治日本消化器病学会近畿支部第97回例会  2012/09  京都テルサ, 京都  日本消化器病学会近畿支部第97回例会無症候性膵内分泌腫瘍の1例  [Not invited]秦 康倫; 工藤 正俊; 木下大輔; 奥田英之; 茂山朋広; 宮部欽生; 清水昌子; 岸谷 譲; 川崎俊彦; 辻江正徳; 太田善夫日本消化器病学会近畿支部第97回例会  2012/09  京都テルサ, 京都  日本消化器病学会近畿支部第97回例会造影ハーモニックEUS(CH-EUS)によってのみ存在診断および境界診断が可能であった膵癌の2例  [Not invited]大本 俊介; 北野 雅之; 山田 光成; 門阪 薫平; 宮田 剛; 鎌田 研; 今井 元; 坂本 洋城; 工藤 正俊日本消化器病学会近畿支部第97回例会  2012/09  京都テルサ, 京都  日本消化器病学会近畿支部第97回例会早期慢性膵炎のEUS所見とその臨床所見について  [Not invited]門阪 薫平; 北野 雅之; 山田 光成; 大本 俊介; 鎌田 研; 宮田 剛; 今井 元; 坂本 洋城; 工藤 正俊日本消化器病学会近畿支部第97回例会  2012/09  京都テルサ, 京都  日本消化器病学会近畿支部第97回例会当院におけるPPI別ヘリコバクターピロリ菌除菌治療成績の検討  [Not invited]足立 哲平; 高山 政樹; 峯 宏昌; 永井 知行; 永田 嘉昭; 川崎 正憲; 朝隈 豊; 櫻井 俊治; 松井 繁長; 樫田 博史; 工藤 正俊日本消化器病学会近畿支部第97回例会  2012/09  京都テルサ, 京都  日本消化器病学会近畿支部第97回例会当院における進行膵癌の癌性疼痛に対する治療戦略. シンポジウム2「進行膵癌に対する治療戦略の現状と展望」  [Not invited]宮田 剛; 北野 雅之; 工藤 正俊日本消化器病学会近畿支部第97回例会  2012/09  京都テルサ, 京都  日本消化器病学会近畿支部第97回例会胆管胆汁細胞診にて診断し得た胆嚢癌の1例  [Not invited]山田 光成; 北野 雅之; 宮田 剛; 坂本 洋城; 門阪 薫平; 鎌田 研; 今井 元; 工藤 正俊日本消化器病学会近畿支部第97回例会  2012/09  京都テルサ, 京都  日本消化器病学会近畿支部第97回例会上腹部痛で発見された低分化型肝癌の一例  [Not invited]高橋一肇; 工藤 正俊; 奥田英之; 秦; 康倫; 木下大輔; 茂山朋広; 宮部欽生; 清水昌子; 岸谷 讓; 川崎俊彦; 太田善夫日本消化器病学会近畿支部第97回例会  2012/09  京都テルサ, 京都  日本消化器病学会近畿支部第97回例会Invited Lecture "Liver biopsy: Is it useful for staging?"  [Not invited]工藤 正俊Sixth Annual Conference International Liver Cancer Association(ILCA)  2012/09  Berlin, Germany  Sixth Annual Conference International Liver Cancer Association(ILCA)Observations of hepatocellular carcinoma (HCC) management patterns from the global HCC BRIDGE study: global comprison of outcomes by staging system.  [Not invited]Morris Sherman; 工藤 正俊; Colombo M; Roberts L; Schwartz M; Degos F; Chen PJ; Chen M; Park JW; Johnson P; Huang B; Wagner S; Orsini LSSixth Annual Conference International Liver Cancer Association(ILCA)  2012/09  Berlin, Germany  Sixth Annual Conference International Liver Cancer Association(ILCA)Brivanib versus placebo in patients with advanced hepatocellular carcinoma who failed or were intolerant to sorafenib: assessment of baseline and on-treatment alpha-fetoprotein levels in the phase III Brisk-Ps study.  [Not invited]Raoul JL; 工藤 正俊; Decaens T; Boucher E; Chang C; Kang YK; Assenat E; Lim HY; Boige V; Mathurin P; Fartoux L; Lin DY; Poon RT; Sherman M; Blanc JF; Finn RS; Tak WY; Chao Y; David Liu; Walters I; Park JW; Llovet JMSixth Annual Conference International Liver Cancer Association(ILCA)  2012/09  Berlin, Germany  Sixth Annual Conference International Liver Cancer Association(ILCA)The decrease of blood flow after administration of sorafenib may improve overall survival in patients with advanced hepatocellular carcinoma.  [Not invited]有住 忠晃; 上嶋 一臣; 工藤 正俊Sixth Annual Conference International Liver Cancer Association(ILCA)  2012/09  Berlin, Germany  Sixth Annual Conference International Liver Cancer Association(ILCA)Brivanib versus placebo in patients with advanced hepatocellular carcinoma (HCC) who failed or were intolerant to sorafenib: results from the phase III Brisk-Ps Study.  [Not invited]Llovet JM; 工藤 正俊; Service d'Hepato-gastro-enterologie; Hopital Henri Mondor; Creteil Cedex; Service d'Oncologie Medicale; Institut Paoli Calmette; Marseille; Service d'Oncologie Medicale; Central Eugene Marquis; Rennes Cedex; France, Liver; Cancer Program; Division of Liver Diseases; Mount Sinai; School of Medicine; New York; United States; Department of Oncology; Asan Medical Center; Seoul, Korea; Service d'Hepato-gastro-enterologie; Hopital Saint Eloi; Montpellier Cedex; France; Division of Hematology-Oncology; Samsung Medical Center; Seoul, Korea; Service de Gastroenterologie; Institut; Gustave Roussy; Villejuif; Service des Maladies de; l'Appareil Digestif; Hopital Claude Huriez; Lille Cedex; Service Hepatologie; Hopital Saint Antoine; Paris, France; Liver Research Unit; Chang Gung Memorial Hospital; Taipei, Taiwan; Liver Unit; Hospital Clinic; University of Barcelona; Barcelona, Spain; Department of Hepatobiliary; Pancreatic Surgery; University of Hong Kong; Hong Kong; Hong Kong; China; Department of Medicine; Toronto General Hospital; Toronto, Canada; Department of Surgery; Saint-Andre Hospital; Bordeaux; France; Department of Medicine; Hematology/Oncology; University of California; Los Angeles; United States; Department of Internal Medicine; Kyungpook National; University Hospital; Daegu, Korea; Department of Medicine; Taipei Veterans General Hospital; Taipei, Taiwan; Bristol-Myers Squibb; Wallingford; United States; Bristol-Myers Squibb, Wallingford; United States; Bristol-Myers Squibb, Wallingford; United States; Center for Liver Cancer; National Cancer Center; Goyang, KoreaSixth Annual Conference International Liver Cancer Association(ILCA)  2012/09  Berlin, Germany  Sixth Annual Conference International Liver Cancer Association(ILCA)Observations of hepatocellular carcinoma (HCC) management patterns from the global HCC BRIDGE Study: An interim analysis of HCC burden of illness in the Asia-Pacific (AP) cohort.  [Not invited]Lucinda S. Orsini; 工藤 正俊; Joong-Won Park; Pei-Jer Chen; Minshan ChenInternational Society for Pharmaco-economics and Outsomes Research (ISPOR) 5th Asia-Pacific Conferen  2012/09  Taipei, Taiwan  International Society for Pharmaco-economics and Outsomes Research (ISPOR) 5th Asia-Pacific ConferenInvited Lecture “Controversies on the role of TACE” “Intermediate HCC”  [Not invited]工藤 正俊Advances in HCC management in Asia  2012/08  Ho Chi Minh , Vietnam  Advances in HCC management in AsiaInvited Lecture “Real life experience with Nexavar: GIDEON 2nd IA” “Advanced HCC: rich evidence for Nexavar”  [Not invited]工藤 正俊Advances in HCC management in Asia  2012/08  Ho Chi Minh , Vietnam  Advances in HCC management in Asiaソラフェニブの上皮間葉移行阻害効果  [Not invited]永井 知行; 木村 英晴; 荒尾 徳三; 松本 和子; 藤田 至彦; 吉田 修平; 林 秀敏; 工藤 正俊; 西尾 和人第10回日本臨床腫瘍学会学術集会  2012/07  大阪国際会議場,大阪.  第10回日本臨床腫瘍学会学術集会Chairs:International Session 1: Hepato-biliary-pancreatic  [Not invited]工藤 正俊The 10th Annual Meeting of Japanese Society of Medical Oncology  2012/07  Osaka International Convention Center, Osaka, Japan.  The 10th Annual Meeting of Japanese Society of Medical Oncologyシンポジウム6 肝細胞癌に対する新しい治療戦略, 総括発言「肝癌治療のアルゴリズムを含めて」  [Not invited]工藤 正俊第10回日本臨床腫瘍学会学術集会  2012/07  大阪国際会議場, 大阪  第10回日本臨床腫瘍学会学術集会基調講演:ワークショップ1「肝癌のバイオマーカー(分子・血液・画像)による悪性度診断・治療効果判定」  [Not invited]工藤 正俊第48回日本肝癌研究会  2012/07  石川県立音楽堂, ANAクラウンプラザホテル金沢, 石川  第48回日本肝癌研究会座長:ワークショップ1「肝癌のバイオマーカー(分子・血液・画像)による悪性診断・治療効果判定」  [Not invited]工藤 正俊; 高安 賢一第48回日本肝癌研究会  2012/07  石川県立音楽堂, ANAクラウンプラザホテル金沢, 石川  第48回日本肝癌研究会座長:シンポジウム1「肝癌診療におけるGd-EOB-DTPA造影MRIの役割」  [Not invited]工藤 正俊; 松井 修第48回日本肝癌研究会  2012/07  石川県立音楽堂, ANAクラウンプラザホテル金沢, 石川  第48回日本肝癌研究会転移性肝癌に対する肝動脈塞栓術とラジオ波焼灼術の併用療法の有用性  [Not invited]南 康範; 有住 忠晃; 早石 宗右; 田北 雅弘; 北井 聡; 矢田 典久; 井上 達夫; 萩原 智; 上嶋 一臣; 西田 直生志; 工藤 正俊第48回日本肝癌研究会  2012/07  石川県立音楽堂, ANAクラウンプラザホテル金沢, 石川  第48回日本肝癌研究会ソナゾイドUSによるnodule in nodule patternのHCCの診断  [Not invited]小川 力; 工藤 正俊; 森岡 弓子; 野田; 晃世; 上田; 祐也; 宮本; 由貴子; 野上; 明子; 吉岡; 正博; 石川; 哲朗; 松中; 寿浩; 玉置; 敬之; 芝峠 光成第48回日本肝癌研究会  2012/07  石川県立音楽堂, ANAクラウンプラザホテル金沢, 石川  第48回日本肝癌研究会進行肝細胞癌に対するソラフェニブ投与における投与後の腫瘍濃染の低下の有無と生存期間の検討  [Not invited]有住 忠晃; 上嶋 一臣; 早石 宗右; 田北 雅弘; 北井 聡; 井上 達夫; 矢田 典久; 萩原 智; 南 康範; 櫻井 俊治; 西田 直生志; 工藤 正俊第48回日本肝癌研究会  2012/07  石川県立音楽堂, ANAクラウンプラザホテル金沢, 石川  第48回日本肝癌研究会肝細胞癌に対するラジオ波焼灼療法の治療効果判定における造影超音波検査の有用性~造影CTとの比較~  [Not invited]井上 達夫; 有住 忠晃; 早石 宗右; 北井 聡; 矢田 典久; 萩原 智; 南 康範; 上嶋 一臣; 西田 直生志; 工藤 正俊第48回日本肝癌研究会  2012/07  石川県立音楽堂, ANAクラウンプラザホテル金沢, 石川  第48回日本肝癌研究会肝細胞癌に対する肝切除と経皮的局所法の長期成績: 全国データに基づく比較検討  [Not invited]長谷川 潔; 工藤 正俊; 國土 典宏; 幕内 雅敏; 泉 並木; 市田 隆文; 具 英成; 坂本 亨宇; 中島 收; 松井 修; 松山 裕第48回日本肝癌研究会  2012/07  石川県立音楽堂, ANAクラウンプラザホテル金沢, 石川  第48回日本肝癌研究会多発性の限局性結節性過形成(FNH)およびFNH様結節に関する検討. ワークショップ2「肝癌類似病変診断の新しい展開: 肝細胞腺腫とFNHを中心に」  [Not invited]喜多 竜一; 工藤 正俊; 西田 直生志; 那須 章洋; 木村; 達; 大﨑; 往夫; 依田 広; 恵荘; 裕嗣; 千葉 勉第48回日本肝癌研究会  2012/07  石川県立音楽堂, ANAクラウンプラザホテル金沢, 石川  第48回日本肝癌研究会Sorafenib国際試験GIDEONの中間解析:TACE施行歴による層別解析. パネルディスカッション4「肝細胞癌分子標的治療: 現状と問題点」  [Not invited]高山 忠利; 工藤 正俊; 池田 公史; 沼田 和司; 泉 並木; 國土 典宏; 古瀬 純司; 奥坂 拓志; 角谷 眞澄; 伊藤 雄一郎第48回日本肝癌研究会  2012/07  石川県立音楽堂, ANAクラウンプラザホテル金沢, 石川  第48回日本肝癌研究会肝血行動態解析によるソラフェニブ治療効果の早期予測-CT perfusionを用いて  [Not invited]兵頭 朋子; 村上 卓道; 岡田 真広; 香川 祐毅; 日高 正二朗; 任 誠雲; 栁生 行伸; 上嶋 一臣; 矢田 典久; 石井 一成; 工藤 正俊; 工藤 正幸第48回日本肝癌研究会  2012/07  石川  第48回日本肝癌研究会High risk noduleの自然経過と多血化因子  [Not invited]今井 康陽; 村上 卓道; 兵頭 朋子; 岡田 真広; 工藤 正俊; 小来田 幸世第48回日本肝癌研究会  2012/07  石川  第48回日本肝癌研究会Dual energy CTを用いた肝脂肪の定量評価:ファントム実験と初期臨床経験  [Not invited]兵頭 朋子; 岡田 真広; 矢田 典久; 前西 修; 香川 祐毅; 任 誠雲; 柏木 伸夫; 栁生 行伸; 今岡 いずみ; 松木 充; 足利 竜一朗; 石井 一成; 工藤 正俊; 村上 卓道第71回近畿大学医学会学術講演会  2012/07  大阪  第71回近畿大学医学会学術講演会Invited Lecture "Japanese treatment algorithm." Session XII "Algorithm Consensus Discussion"  [Not invited]工藤 正俊The 3rd Asia-Pacific Primary Liver Cancer Expert Meeting (APPLE)  2012/07  Shanghai, China  The 3rd Asia-Pacific Primary Liver Cancer Expert Meeting (APPLE)Chair: Session XII: Algorithm Consensus Discussion  [Not invited]工藤 正俊The 3rd Asia-Pacific Primary Liver Cancer Expert Meeting (APPLE)  2012/07  Shanghai, China  The 3rd Asia-Pacific Primary Liver Cancer Expert Meeting (APPLE)Chair: Session XI: Novel Therapy & Ongoing Trials  [Not invited]工藤 正俊The 3rd Asia-Pacific Primary Liver Cancer Expert Meeting (APPLE)  2012/07  Shanghai, China  The 3rd Asia-Pacific Primary Liver Cancer Expert Meeting (APPLE)Chair: Management of TACE Failure  [Not invited]工藤 正俊Expert Panel Opinion on Interventions In Hepatocellular Carcinoma (EPOIHCC)  2012/07  Shanghai, China  Expert Panel Opinion on Interventions In Hepatocellular Carcinoma (EPOIHCC)Chair: Evening Symposium: Recent Observations in the mangement of HCC  [Not invited]工藤 正俊The 3rd Asia-Pacific Primary Liver Cancer Expert Meeting (APPLE)  2012/07  Shanghai, China  The 3rd Asia-Pacific Primary Liver Cancer Expert Meeting (APPLE)Invited Lecture "Observations of hepatocellular carcinoma (HCC) management patterns from the global HCC BRIDGE study: an analysis of the Asian cohort." Evening Symposium "Recent observation in the management of HCC"  [Not invited]工藤 正俊The 3rd Asia-Pacific Primary Liver Cancer Expert Meeting (APPLE)  2012/07  Shanghai, China  The 3rd Asia-Pacific Primary Liver Cancer Expert Meeting (APPLE)膵神経内分泌腫瘍診断におけるEUSの有用性  [Not invited]今井 元; 北野 雅之; 工藤 正俊; 門阪 薫平; 宮田 剛; 鎌田 研; 坂本 洋城; 安田 武生; 竹山 宜典第43回日本膵臓学会大会  2012/06  ホテルメトロポリタン山形, 山形  第43回日本膵臓学会大会早期慢性膵炎のEUS画像と臨床所見の比較検討  [Not invited]門阪 薫平; 北野 雅之; 竹山 宜典; 工藤 正俊第43回日本膵臓学会大会  2012/06  ホテルメトロポリタン山形, 山形  第43回日本膵臓学会大会膵切除後合併症に対するEUSガイド下治療の有用性. シンポジウム5「膵切除の合併症とその対処法」  [Not invited]宮田 剛; 北野 雅之; 竹山 宜典; 工藤 正俊第43回日本膵臓学会大会  2012/06  ホテルメトロポリタン山形  第43回日本膵臓学会大会膵上皮内癌とStageⅠ膵癌の臨床的および病理学的特徴. シンポジウム6「膵癌の早期診断と病理」  [Not invited]坂本 洋城; 北野 雅之; 竹山 宜典; 安田 武生; 中居 卓也; 工藤 正俊第43回日本膵臓学会大会  2012/06  ホテルメトロポリタン山形, 山形  第43回日本膵臓学会大会CT perfusionによる肝血行動態解析:sorafenib投与による背景肝血流の変化と肝細胞癌治療効果  [Not invited]兵頭 朋子; 村上 卓道; 岡田 真広; 香川 祐毅; 日高 正二朗; 栁生 行伸; 上嶋 一臣; 矢田 典久; 松木 充; 石井 一成; 工藤 正俊第12回関西肝血流動態イメージ研究会  2012/06  大阪  第12回関西肝血流動態イメージ研究会特別講演「ネクサバール発売後3年間の治療成績」  [Not invited]工藤 正俊沖縄肝癌治療セミナー  2012/06  沖縄県医師会館, 沖縄  沖縄肝癌治療セミナー司会: ランチョンセミナー  [Not invited]工藤 正俊第48回日本肝臓学会総会  2012/06  石川県立音楽堂, 金沢  第48回日本肝臓学会総会IL28BとPEG-IFN/RBV併用療法をうけたHCVジェノタイプ1型高ウイルス量患者の効果との関連について  [Not invited]田北 雅弘; 萩原 智; 有住 忠晃; 早石 宗右; 上田 泰輔; 北井 聡; 矢田 典久; 井上 達夫; 南 康範; 上嶋 一臣; 櫻井 俊治; 西田 直生志; 工藤 正俊; 鄭 浩柄第48回日本肝臓学会総会  2012/06  JR金沢駅前もてなしドーム, 金沢  第48回日本肝臓学会総会Interventional radiologyにおける新しい支援画像「FlightPlan」の有用性  [Not invited]南 康範; 工藤 正俊第48回日本肝臓学会総会  2012/06  JR金沢駅前もてなしドーム, 金沢  第48回日本肝臓学会総会外科切除標本からの2cm以下のHCCに対するCE-US, 動注CT, EOB-MRIの術前診断の比較, 検討  [Not invited]小川 力; 工藤 正俊; 柴峠 光成第48回日本肝臓学会総会  2012/06  JR金沢駅前もてなしドーム, 金沢  第48回日本肝臓学会総会経皮的ラジオ波焼灼術後の後出血予防における穿刺経路焼灼の有効性の検討.  [Not invited]早石 宗右; 南 康範; 工藤 正俊第48回日本肝臓学会総会  2012/06  石川県立音楽堂, 金沢  第48回日本肝臓学会総会進行肝細胞癌に対するソラフェニブ投与における投与後の腫瘍濃染の低下の有無と生存期間の検討.  [Not invited]有住 忠晃; 上嶋 一臣; 工藤 正俊第48回日本肝臓学会総会  2012/06  石川県立音楽堂, 金沢  第48回日本肝臓学会総会Drug freeを目指したエンテカビルとPEG-IFNα2b 48週併用療法の効果について. ワークショップ22「B型慢性肝炎に対する抗ウイルス療法の継続と終了をめぐって」  [Not invited]萩原 智; 工藤 正俊; 大﨑 往夫第48回日本肝臓学会総会  2012/06  ポルテ金沢, 金沢  第48回日本肝臓学会総会国際共同非介入試験GEDEON第2回中間解析における日本人集団解析結果ならびに投与開始時AFP値での層別解析の検討. ワークショップ13「肝細胞癌に対する分子標的薬開発の基礎から臨床」  [Not invited]奥坂 拓志; 工藤 正俊; 池田 公史; 高山 忠利; 沼田 和司; 泉 並木; 國土 典宏; 古瀬 純司; 角谷 眞済; 木村 丹香子第48回日本肝臓学会総会  2012/06  ANAクラウンプラザホテル金沢, 金沢  第48回日本肝臓学会総会肝癌診療ガイドラインにおける治療アルゴリズムの妥当性~実臨床への展開とその問題点~. ワークショップ12「肝癌診療ガイドラインの活用と改訂への提案」  [Not invited]上嶋 一臣; 南 康範; 工藤 正俊第48回日本肝臓学会総会  2012/06  ANAクラウンプラザホテル金沢, 金沢  第48回日本肝臓学会総会Real-time Tissue Elastographyによる非アルコール性脂肪性肝炎の囲い込み. ワークショップ2「肝疾患における画像診断の課題と新たな展開」  [Not invited]矢田 典久; 工藤 正俊第48回日本肝臓学会総会  2012/06  石川県立音楽堂, 金沢  第48回日本肝臓学会総会司会, パネルディスカッション「肝細胞癌画像診断の進歩」  [Not invited]工藤 正俊第48回日本肝臓学会総会  2012/06  石川県立音楽堂, 金沢  第48回日本肝臓学会総会造影エコーによる肝癌肉眼分類の有用性について. パネルディスカッション「肝細胞癌画像診断の進歩」  [Not invited]早石 宗右; 南 康範; 工藤 正俊第48回日本肝臓学会総会  2012/06  石川県立音楽堂, 金沢  第48回日本肝臓学会総会肝細胞癌の化学療法. シンポジウム3「肝細胞癌の治療戦略」  [Not invited]工藤 正俊第48回日本肝臓学会総会  2012/06  石川県立音楽堂, 金沢  第48回日本肝臓学会総会組織弾性法の領域別臨床応用  [Not invited]工藤 正俊第37回日本超音波検査学会ランチョンセミナーIII  2012/06  札幌コンベンションセンター, 北海道  第37回日本超音波検査学会ランチョンセミナーIII座長: ランチョンセミナーIII「組織弾性法の領域別臨床応用」  [Not invited]工藤 正俊第37回日本超音波検査学会  2012/06  札幌コンベンションセンター  第37回日本超音波検査学会当院における肝細胞癌分子標的治療の現状. パネルディスカッション「ソラフェニブ治療の実践-多数症例の使用経験を踏まえた治療の実践と問題点の解決を示す―」  [Not invited]上嶋 一臣; 有住 忠晃; 早石 宗右; 田北 雅弘; 北井 聡; 矢田 典久; 井上 達夫; 萩原 智; 南 康範; 櫻井 俊治; 西田 直生志; 工藤 正俊第6回日本肝がん分子標的治療研究会  2012/06  ザ・プリンス箱根, 神奈川  第6回日本肝がん分子標的治療研究会Phase 1b dose-escalation study of a phase 2 randomized trial to assess the safety and tolerability of tigatuzumab (CS-1008) in combination with sorafenib in patients (pts) with advanced hepatocellular carcinoma (HCC).  [Not invited]Ann-Lii Cheng; 工藤 正俊; Yoon-Koo Kang; Baek-Yeol Ryoo; Chia-Jui Yen; Ho Yeong Lim; Do-Youn OhASCO 2012 Annual Meeting  2012/06  Chicago, USA  ASCO 2012 Annual MeetingEffect of rebamipide for endoscopic submucosal dissection (ESD)-induced ulcer in early gastric cancer: a randomized controlled trial.  [Not invited]松井 繁長; 工藤 正俊; 樫田 博史; 朝隈 豊; 櫻井 俊治; 川崎 正憲Digestive Disease Week(DDW) 2012  2012/05  San Diego, USA  Digestive Disease Week(DDW) 2012A prospective feasibility study on EUS guided broad plexus in combination of celiac ganglion neurolysis in pancreatic cancer pain  [Not invited]坂本 洋城; 北野 雅之; 工藤 正俊Digestive Disease Week(DDW) 2012  2012/05  San Diego, USA  Digestive Disease Week(DDW) 2012Usefulness of contrast-enhanced ultrasonography to evaluate a post treatment effect of radiofrequentry ablation about hepatocellular carcinoma: comparison with contrast-enhanced CT  [Not invited]井上 達夫; 有住 忠晃; 北井 聡; 矢田 典久; 萩原 智; 南 康範; 櫻井 俊治; 上嶋 一臣; 西田 直生志; 工藤 正俊Digestive Disease Week(DDW) 2012  2012/05  San Diego, USA  Digestive Disease Week(DDW) 2012The gross classification of hepatocellular carcinoma: usefulness of contrast-enhanced sonography using perfluorocarbon microbubbles (sonazoid)  [Not invited]南 康範; 畑中 絹世; 有住 忠晃; 早石 宗右; 田北 雅弘; 北井 聡; 矢田 典久; 井上 達夫; 萩原 智; 上嶋 一臣; 西田 直生志; 工藤 正俊Digestive Disease Week(DDW) 2012  2012/05  San Diego, USA  Digestive Disease Week(DDW) 2012The decrease of blood flow after administration of sorafenib may improve overall survival in patients with advanced hepatocellular carcinoma  [Not invited]有住 忠晃; 上嶋 一臣; 工藤 正俊Digestive Disease Week(DDW) 2012  2012/05  San Diego, USA  Digestive Disease Week(DDW) 2012Activation of JNK in the Non-cancerous liver tissue predicts a high risk of recurrence after hepatic resection for hepatocellular carcinoma  [Not invited]櫻井 俊治; 萩原 智; 井上 達夫; 上嶋 一臣; 松井 繁長; 西田 直生志; 樫田 博史; 工藤 正俊Digestive Disease Week(DDW) 2012  2012/05  San Diego, USA  Digestive Disease Week(DDW) 2012Percutaneous endoscopic gastrostomy with gastropexy greatly reduces the risk of peristomal infection and eases pain after the operation.  [Not invited]奥村 直己; 辻 直子; 工藤 正俊Digestive Disease Week(DDW) 2012  2012/05  San Diego, USA  Digestive Disease Week(DDW) 2012Detection of small concomitant carcinomas distinct from intraductal papillary mucinous neoplasms under surveillance of the whole pancreas using EUS  [Not invited]鎌田 研; 北野 雅之; 工藤 正俊; 今井 元; 坂本 洋城Digestive Disease Week(DDW) 2012  2012/05  San Diego, USA  Digestive Disease Week(DDW) 2012Novel association between global DNA hypomethylation and chromosomal instability phenotype in human hepatocellular carcinoma  [Not invited]西田 直生志; 工藤 正俊; 有住 忠晃; 早石 宗右; 田北 雅弘; 北井 聡; 矢田 典久; 井上 達夫; 萩原 智; 南 康範; 上嶋 一臣; 櫻井 俊治Digestive Disease Week(DDW) 2012  2012/05  San Diego, USA  Digestive Disease Week(DDW) 2012特別講演「肝細胞癌診療の新しいパラダイム」  [Not invited]工藤 正俊第9回城北消化器病研究会  2012/05  ホテルメトロポリタン池袋, 東京  第9回城北消化器病研究会特別講演「肝疾患に対する超音波診断の新展開-Real-time Tissue Elastographyを用いて-」  [Not invited]工藤 正俊日本超音波医学会第85回学術集会ランチョンセミナー12  2012/05  グランドプリンスホテル新高輪, 東京  日本超音波医学会第85回学術集会ランチョンセミナー12ソナゾイド造影超音波におけるAP Shuntの診断について  [Not invited]前川 清; 横川 美加; 辻 裕美子; 前野 知子; 塩見 香織; 井上 達夫; 南 康範; 工藤 正俊日本超音波医学会第85回学術集会  2012/05  グランドプリンスホテル新高輪, 東京  日本超音波医学会第85回学術集会ソナゾイド造影超音波による肝血管腫の診断についての検討  [Not invited]前野 知子; 横川 美加; 辻 裕美子; 塩見 香織; 井上 達夫; 南 康範; 工藤 正俊日本超音波医学会第85回学術集会  2012/05  グランドプリンスホテル新高輪, 東京  日本超音波医学会第85回学術集会当院におけるEUS下胆道ドレナージ術の有用性.  [Not invited]今井 元; 北野 雅之; 工藤 正俊日本超音波医学会第85回学術集会  2012/05  グランドプリンスホテル新高輪, 東京  日本超音波医学会第85回学術集会早期慢性膵炎におけるEUS画像の臨床的意義  [Not invited]門阪 薫平; 北野 雅之; 工藤 正俊日本超音波医学会第85回学術集  2012/05  グランドプリンスホテル新高輪, 東京  日本超音波医学会第85回学術集超音波エラストグラフィーによる非アルコール性脂肪性肝炎診断. ワークショップ6「消化器疾患診療における超音波Elastographyの有用性」  [Not invited]矢田 典久; 工藤 正俊日本超音波医学会第85回学術集会  2012/05  グランドプリンスホテル新高輪, 東京  日本超音波医学会第85回学術集会造影ハーモニックEUS (CH-EUS)を用いた腹部リンパ節の良悪性診断の試み. ワークショップ1「超音波内視鏡の進歩-診断と治療への応用-」  [Not invited]宮田 剛; 北野 雅之; 工藤 正俊日本超音波医学会第85回学術集会  2012/05  グランドプリンスホテル新高輪, 東京  日本超音波医学会第85回学術集会シンポジウム7「肝腫瘍造影超音波過去5年の総括と今後の展望」, 座長: 森安史典, 工藤正俊  [Not invited]工藤 正俊日本超音波医学会第85回学術集会  2012/05  グランドプリンスホテル新高輪  日本超音波医学会第85回学術集会下肢静脈超音波検査における仰臥位での下腿深部静脈血栓症診断の検討. ワークショップ14「静脈エコーで何処まで観るか?: 目的別にみた検査法の工夫」  [Not invited]小谷 敦志; 谷口 京子; 河野 ふみえ; 前川 清; 中江 健市; 保田 知生; 工藤 正俊; 久保田 義則日本超音波医学会第85回学術集会  2012/05  グランドプリンスホテル新高輪, 東京  日本超音波医学会第85回学術集会肝領域における組織弾性評価法: 「硬さ」と「粗さ」の違い. シンポジウム6「組織弾性評価の手法と用語の標準化に向けて」  [Not invited]矢田 典久; 工藤 正俊日本超音波医学会第85回学術集会  2012/05  グランドプリンスホテル新高輪, 東京  日本超音波医学会第85回学術集会パネリスト, シンポジウム「今後の超音波医学の発展のために」  [Not invited]工藤 正俊日本超音波医学会第85回学術集会  2012/05  グランドプリンスホテル新高輪, 東京  日本超音波医学会第85回学術集会Invited Lecture "CEUS as a screening tool of HCC in cirrhotic liver."  [Not invited]工藤 正俊ACUCI 2012, The 4th Asian Conference on Ultrasound Contrast Imaging  2012/05  Korea  ACUCI 2012, The 4th Asian Conference on Ultrasound Contrast ImagingInvited Lecture "CEUS in the pancreatobiliary intervention."  [Not invited]工藤 正俊ACUCI 2012, The 4th Asian Conference on Ultrasound Contrast Imaging  2012/05  Korea  ACUCI 2012, The 4th Asian Conference on Ultrasound Contrast Imaging特別講演「ソナゾイド発売5年」  [Not invited]工藤 正俊日本超音波医学会第85回学術集会ランチョンセミナー2  2012/05  グランドプリンスホテル新高輪, 東京  日本超音波医学会第85回学術集会ランチョンセミナー2Role of contrast-enhanced harmonic EUS in differentiating malignant from benigh lymphadenopathy.  [Not invited]宮田 剛; 北野 雅之; 坂本 洋城; 今井 元; 鎌田 研; 門阪 薫平; 工藤 正俊The 83rd Congress of the Japan Gastroenterological Endoscopy Society  2012/05  Tokyo  The 83rd Congress of the Japan Gastroenterological Endoscopy SocietyIPMNの診断・フォローアップにおけるEUSの役割. ワークショップ9「IPMNの診断・治療における内視鏡の役割」  [Not invited]鎌田 研; 北野 雅之; 工藤 正俊第83回日本消化器内視鏡学会総会  2012/05  グランドプリンスホテル新高輪, 東京  第83回日本消化器内視鏡学会総会十二指腸静脈瘤の臨床的特徴と治療指針. ワークショップ3「異所性静脈瘤の病態と治療指針」  [Not invited]松井 繁長; 川崎 正憲; 工藤 正俊第83回日本消化器内視鏡学会総会  2012/05  グランドプリンスホテル新高輪, 東京  第83回日本消化器内視鏡学会総会当院でのEUS下胆管ドレナージ術の安全性の検討. VTRシンポジウム6「安全かつ効果的な胆道Stentingを求めて」  [Not invited]今井 元; 北野 雅之; 工藤 正俊第83回日本消化器内視鏡学会総会  2012/05  グランドプリンスホテル新高輪, 東京  第83回日本消化器内視鏡学会総会EUSガイド下治療におけるトラブルシューティング. VTRシンポジウム1「内視鏡治療に伴う偶発症の対処法-胆膵病変-」  [Not invited]宮田 剛; 北野 雅之; 工藤 正俊第83回日本消化器内視鏡学会総会  2012/05  グランドプリンスホテル新高輪, 東京  第83回日本消化器内視鏡学会総会噴門部静脈瘤合併巨大型食道静脈瘤の内視鏡的治療の工夫. シンポジウム11「危ない静脈瘤出血の病態と治療」  [Not invited]松井 繁長; 朝隈 豊; 工藤 正俊第83回日本消化器内視鏡学会総会  2012/05  グランドプリンスホテル新高輪, 東京  第83回日本消化器内視鏡学会総会胆石性膵炎の診断・治療におけるEUSの役割. シンポジウム1「胆・膵疾患の救急医療の現状と治療戦略」  [Not invited]鎌田 研; 北野 雅之; 工藤 正俊第83回日本消化器内視鏡学会総会  2012/05  グランドプリンスホテル新高輪, 東京  第83回日本消化器内視鏡学会総会当院におけるEUS下複合神経叢融解術の適応と限界. シンポジウム4「EUSガイド下治療の適応と限界」  [Not invited]坂本 洋城; 北野 雅之; 工藤 正俊第83回日本消化器内視鏡学会総会  2012/05  グランドプリンスホテル新高輪, 東京  第83回日本消化器内視鏡学会総会造影ハーモニックEUSによるSMTの鑑別診断およびGISTの悪性度評価. ワークショップ6「上部消化管粘膜下腫瘍の内視鏡による診断と治療」  [Not invited]坂本 洋城; 北野 雅之; 工藤 正俊第83回日本消化器内視鏡学会総会  2012/05  グランドプリンスホテル新高輪, 東京  第83回日本消化器内視鏡学会総会EUS-guided drainage for biliary obstruction after unsuccessful ERCP. International Symposium “EUS-FNA: Current status and new developments”  [Not invited]北野 雅之; 坂本 洋城; 工藤 正俊Tokyo  2012/05  The 83rd Congress of the Japan Gastroenterological Endoscopy Society  TokyoA prospective study feasibility combination of EUS guided broad plexus-neuro lysis and celiac ganglion neurolysis. International Symposium “EUS-FNA: Current status and new developments”  [Not invited]坂本 洋城; 北野 雅之; 工藤 正俊The 83rd Congress of the Japan Gastroenterological Endoscopy Society  2012/05  Tokyo  The 83rd Congress of the Japan Gastroenterological Endoscopy Society造影ハーモニックEUSによるSMTの鑑別診断およびGISTの悪性度評価. ワークショップ「上部消化管粘膜下腫瘍の内視鏡による診断と治療」  [Not invited]坂本 洋城; 北野 雅之; 工藤 正俊第83回日本消化器内視鏡学会総会  2012/05  グランドプリンスホテル新高輪, 東京  第83回日本消化器内視鏡学会総会A prospective study feasibility combination of EUS guided broad plexus-neuro lysis and celiac ganglion neurolysis. Symposium “EUS-FNA: Current status and new developments”  [Not invited]坂本 洋城; 北野 雅之; 工藤 正俊第83回日本消化器内視鏡学会総会  2012/05  グランドプリンスホテル新高輪, 東京  第83回日本消化器内視鏡学会総会Dual energy CTを用いた肝脂肪の定量評価:ファントム実験と初期臨床経験  [Not invited]兵頭 朋子; 岡田 真広; 村上 卓道; 工藤 正俊; 矢田 典久; 工藤 正幸第71回日本医学放射線学会学術集会  2012/04  横浜  第71回日本医学放射線学会学術集会Invited Lecture "Endoscopic ultrasound in the differential diagnosis of cystic pancreatic lesions: do we always need it?"  [Not invited]工藤 正俊EFSUMB Annual Meeting EUROSON 2012  2012/04  Madrid, Spain  EFSUMB Annual Meeting EUROSON 2012経皮的ラジオ波焼灼術後の後出血予防における穿刺経路焼灼の有効性の検討.  [Not invited]早石 宗右; 南 康範; 足立 哲平; 有住 忠晃; 田北 雅弘; 北井 聡; 矢田 典久; 井上 達夫; 萩原 智; 上嶋 一臣; 工藤 正俊; 鄭 浩柄第98回日本消化器病学会総会  2012/04  京王プラザ  第98回日本消化器病学会総会非上皮性肝悪性腫瘍の3例.  [Not invited]足立 哲平; 有住 忠晃; 早石 宗右; 田北 雅弘; 北井 聡; 矢田 典久; 井上 達夫; 萩原 智; 南 康範; 櫻井 俊治; 上嶋 一臣; 西田 直生志; 工藤 正俊第98回日本消化器病学会総会  2012/04  京王プラザ  第98回日本消化器病学会総会プロトンポンプ阻害薬(PPI)内服中GERD患者に対するGerdQによる治療効果の評価.  [Not invited]大本 俊介; 松井 繁長; 足立 哲平; 峯 宏昌; 高山 政樹; 永井 知行; 永田 嘉昭; 川崎 正憲; 櫻井 俊治; 樫田 博史; 工藤 正俊第98回日本消化器病学会総会  2012/04  京王プラザ  第98回日本消化器病学会総会限局性腫瘤を形成した自己免疫性膵炎におけるEUS所見の検討. ワークショップ10「IgG4関連肝胆膵疾患の診断と治療-非典型例へのアプローチ」  [Not invited]鎌田 研; 北野 雅之; 工藤 正俊第98回日本消化器病学会総会  2012/04  京王プラザ  第98回日本消化器病学会総会超音波エラストグラフィーによる非アルコール性脂肪性肝炎診断. シンポジウム8「臓器線維化(肝・膵を中心)研究・診療の最前線」  [Not invited]矢田 典久; 萩原 智; 工藤 正俊第98回日本消化器病学会総会  2012/04  京王プラザ  第98回日本消化器病学会総会当院におけるStage I膵癌の特徴. シンポジウム5「膵胆道癌の早期診断」  [Not invited]宮田 剛; 北野 雅之; 工藤 正俊第98回日本消化器病学会総会  2012/04  京王プラザ  第98回日本消化器病学会総会Invited Lecture "The role of TACE & Nexavar in HCC treatment."  [Not invited]工藤 正俊HCC Expert Symposium on Tumor Therapy  2012/04  Seoul, Korea  HCC Expert Symposium on Tumor TherapyInvited Lecture "Management of hepatocellular carcinoma.  [Not invited]工藤 正俊2012/04  Yonsei University, Korea司会: シンポジウム4「肝細胞癌集学的治療の現況と再発予防」  [Not invited]工藤 正俊第98回日本消化器病学会総会  2012/04  京王プラザ  第98回日本消化器病学会総会The management of HCC in Japan. The role of TACE in management of HCC: Korea and Japan  [Not invited]工藤 正俊2012 BESTT symposium  2012/04  Seoul, Korea  2012 BESTT symposiumObserved patterns of systemic therapy use in hepatocellular carcinoma (HCC) patients from the multinational HCC BRIDGE Study: Results of a second interim analysis.  [Not invited]Massimo Colombo; 工藤 正俊; Lewis Roberts; Myron Schwartz; Francoise Degos; Morris Sherman; Pei-Jer Chen; Minshan Chen; Joong-Won Park; Phillip Johnson; Baisong Huang47th Annual Meeting of the European Association for the Sudy of the Liver (EASL)  2012/04  Barcelona, Spain  47th Annual Meeting of the European Association for the Sudy of the Liver (EASL)GIDEON (Global Investigation of therapeutic decisions in hepatocellular carcinoma and of its treatment with SoraenibB) Second interim analysis: Clinical findings in Child-pugh B score subgourps.  [Not invited]Jean-Pierre Bronowicki; 工藤 正俊; Sheng-Long Ye; Jorge Marrero; Lucy Dagher; Junji Furuse; Jeff F. Geschwind; Laura Ladron de Guevara; Christos Papandreou; Arun J. Sanyal; Tadatoshi Takayama; Seung Kew Yoon; Riccardo Lencioni47th Annual Meeting of the European Association for the Sudy of the Liver (EASL)  2012/04  Barcelona, Spain  47th Annual Meeting of the European Association for the Sudy of the Liver (EASL)Opening Lectures “Contrast-enhanced EUS of pancreatic tumors”  [Not invited]工藤 正俊EFSUMB Annual Meeting EUROSON 2012  2012/04  Madrid, Spain  EFSUMB Annual Meeting EUROSON 2012座長: 工藤正俊  [Not invited]工藤 正俊第8回Kinki Liver Club  2012/03  スイスホテル南海大阪, 大阪  第8回Kinki Liver ClubManagement of hepatocellular carcinoma: Recent progress.  [Not invited]工藤 正俊the 42nd Annual Meeting of GEST and The 21st Annual Meeting of DEST  2012/03  Taipei, Taiwan  the 42nd Annual Meeting of GEST and The 21st Annual Meeting of DESTFrom JSH treatment guideline to combination therapy.  [Not invited]工藤 正俊HCC Expert Meeting ?New Advances in HCC Management  2012/03  Taipei, Taiwan  HCC Expert Meeting ?New Advances in HCC Management特別講演「肝硬変・肝癌の治療のガイドラインと発癌抑制」  [Not invited]工藤 正俊リーバクト配合顆粒発売15周年記念講演会  2012/03  ホテルオークラ札幌, 北海道  リーバクト配合顆粒発売15周年記念講演会Lemmel症候群の1例. Young Endoscopist Session  [Not invited]木下 大輔; 秦 康倫; 奥田 英之; 茂山 朋広; 宮部 欽生; 豊澤 昌子; 岸谷 讓; 川崎 俊彦; 工藤 正俊第88回日本消化器内視鏡学会近畿地方会  2012/03  大阪国際交流センター, 大阪  第88回日本消化器内視鏡学会近畿地方会シングルバルーン小腸内視鏡検査(SBE)にて診断された小腸血管性病変の検討. Young Endoscopist Session  [Not invited]大本 俊介; 足立 哲平; 高山 政樹; 峯 宏昌; 永田 嘉昭; 永井 知行; 川崎 正憲; 朝隈 豊; 櫻井 俊治; 松井 繁長; 樫田 博史; 工藤 正俊第88回日本消化器内視鏡学会近畿地方会  2012/03  大阪国際交流センター, 大阪  第88回日本消化器内視鏡学会近畿地方会難治性潰瘍性大腸炎に対してIFXが奏功した症例. Fresh Endoscopist Session  [Not invited]田中 梨絵; 峯 宏昌; 大本 俊介; 足立 哲平; 高山 政樹; 永田 嘉昭; 永井 知行; 川崎 正憲; 朝隈 豊; 櫻井 俊治; 松井 繁長; 樫田 博史; 工藤 正俊第88回日本消化器内視鏡学会近畿地方会  2012/03  大阪国際交流センター, 大阪  第88回日本消化器内視鏡学会近畿地方会貧血を契機に発見された腸間膜静脈硬化症の一例. Fresh Endoscopist Session  [Not invited]一木 美穂; 奥田 英之; 宮部 欽生; 茂山 朋広; 豊澤 昌子; 秦 康倫; 木下 大輔; 川崎 俊彦; 太田 善夫; 工藤 正俊第88回日本消化器内視鏡学会近畿地方会  2012/03  大阪国際交流センター, 大阪  第88回日本消化器内視鏡学会近畿地方会リセドロネートによると考えられた十二指腸潰瘍の一例. Fresh Endoscopist Session  [Not invited]高場 雄久; 松本 望; 奥村 直己; 山本 典雄; 冨田 崇文; 梅原 康湖; 森村 正嗣; 米田 円; 山田 哲; 辻 直子; 南 康範; 工藤 正俊第88回日本消化器内視鏡学会近畿地方会  2012/03  大阪国際交流センター, 大阪  第88回日本消化器内視鏡学会近畿地方会当院におけるEUS下複合神経叢溶解術の適応と限界. ワークショップ「EUSによる消化器疾患の診断と治療の進歩」  [Not invited]門阪 薫平; 北野 雅之; 工藤 正俊第88回日本消化器内視鏡学会近畿地方会  2012/03  大阪国際交流センター, 大阪  第88回日本消化器内視鏡学会近畿地方会内視鏡治療における高齢者の特殊性. シンポジウム「高齢者における内視鏡治療の適応と限界(消化管)」  [Not invited]櫻井 俊治; 松井 繁長; 工藤 正俊第88回日本消化器内視鏡学会近畿地方会  2012/03  大阪国際交流センター, 大阪  第88回日本消化器内視鏡学会近畿地方会Prognostic impact of EMT-related genes on post-operative prognosis in hepatocellular carcinoma.  [Not invited]永井 知行; 荒尾 徳三; 松本 和子; 藤田 至彦; 林 秀敏; 木村 英晴; 萩原 智; 櫻井 俊治; 上嶋 一臣; 土師 誠二; 工藤 正俊; 西尾 和人AACR 103rd Annual Meeting 2011  2012/03  Chicago, USA  AACR 103rd Annual Meeting 2011Worldwide trends in locoregional therapy (LRT) for hepatocellular carcinoma (HCC): second interim analysis [1500 patients] of the GIDEON (Global Investigation of therapeutic DEcisions in HCC and Of its treatment with sorafeNib) study.  [Not invited]JF Geschwind; 工藤 正俊; R Lencioni; J Marrero; A Venook; S-L YeSIR 2012  2012/03  San Francisco, USA  SIR 2012アダリムマブにて蛋白尿が改善したCrohn病関連二次性アミロイドーシスの1例  [Not invited]辻 直子; 松本 望; 高場 雄久; 奥村 直己; 山本 典雄; 梅原 康湖; 南 康範; 工藤 正俊第8回日本消化管学会総会  2012/02  仙台市  第8回日本消化管学会総会シングルバルーン小腸内視鏡検査にて診断された小腸血管性病変の検討.  [Not invited]高山 政樹; 川崎 正憲; 峯 宏昌; 永田 嘉昭; 永井 知行; 朝隈 豊; 櫻井 俊治; 松井 繁長; 樫田 博史; 工藤 正俊第8回日本消化管学会総会学術集会  2012/02  仙台国際センター, 宮城  第8回日本消化管学会総会学術集会Real life experience with Sorafenib: GIDEON, the largest prospective global study in HCC. Satellite symposium Advances in HCC management : from diagnosis to treatment  [Not invited]工藤 正俊The 22nd conference of the Asian Pacific Association for the Study of the Liver (APASL 2012)  2012/02  Taipei, Taiwan  The 22nd conference of the Asian Pacific Association for the Study of the Liver (APASL 2012)Hepatocellular carcinoma. APASL-AASLD symposium-When east meets west: Management of the complications of cirrhosis  [Not invited]工藤 正俊The 22nd conference of the Asian Pacific Association for the Study of the Liver (APASL 2012)  2012/02  Taipei, Taiwan  The 22nd conference of the Asian Pacific Association for the Study of the Liver (APASL 2012)Evolving strategies on the treatment of HCC: Physician’s perspective.  [Not invited]工藤 正俊The 22nd conference of the Asian Pacific Association for the Study of the Liver (APASL 2012)  2012/02  Taipei, Taiwan  The 22nd conference of the Asian Pacific Association for the Study of the Liver (APASL 2012)CEUS, EOB-MRI, targeted therapy and Japanese HCC guideline.  [Not invited]工藤 正俊Cancer Genomics: a way to personalized medicine  2012/02  Taipei, Taiwan  Cancer Genomics: a way to personalized medicine特別講演「Sonazoidは肝癌診療をどう変えたか?」  [Not invited]工藤 正俊第17回鈴鹿肝胆膵画像研究会  2012/02  ホテルグリーンパーク鈴鹿, 三重  第17回鈴鹿肝胆膵画像研究会Observations of hepatocellular carcinoma (HCC) management ptterns from the Global HCC BRIDGE Study: An interim analysis of the Asia-Pacific (AP) Cohort.  [Not invited]Pei-Jer Chen; 工藤 正俊; Joon-Won Park; Minshan Chen; Morris Sherman; Phillip Johnson; Massimo Colombo; Lewis Roberts; Baisong HuangAsian Pacific Association for the Study of the Liver (APASL) 2012  2012/02  Taipei, Taiwan  Asian Pacific Association for the Study of the Liver (APASL) 2012GIDEON (Global Investigation of therapeutic DEcisions in hepatocellular carcinoma and Of its Treatment with sorafeNib) second interim analysis (IA): subgroup analysis by race.  [Not invited]Junji Furuse; 工藤 正俊; Sheng-Long Ye; Jorge Marrero; Riccardo Lencioni; Alan VenookAsian Pacific Association for the Study of the Liver (APASL) 2012  2012/02  Taipei, Taiwan  Asian Pacific Association for the Study of the Liver (APASL) 2012特別講演「肝細胞癌診療の新しいパラダイム」  [Not invited]工藤 正俊第3回中四国肝臓病研究会  2012/02  ホテルグランヴィア岡山, 岡山  第3回中四国肝臓病研究会Invited Lecture "Intravascular treatment (TACE, HAIC)"  [Not invited]工藤 正俊10th International Conference ofthe Asian Clinical Oncology Society (ACOS)  2012  Seoul, Korea  10th International Conference ofthe Asian Clinical Oncology Society (ACOS)当院における表在型パレット食道腺癌に対する内視鏡的診断と治療の検討.  [Not invited]朝隈 豊; 松井 繁長; 足立 哲平; 大本 俊介; 高山 政樹; 永田 嘉昭; 川崎 正憲; 櫻井 俊治; 樫田 博史; 工藤 正俊第83回日本消化器内視鏡学会総会  2012  グランドプリンスホテル新高輪, 東京  第83回日本消化器内視鏡学会総会Estination of EUS features of chronic pancreatitis in comparison with clinical symptoms  [Not invited]門阪 薫平; 北野 雅之; 坂本 洋城; 今井 元; 鎌田 研; 宮田 剛; 工藤 正俊The 83rd Congress of the Japan Gastroenterological Endoscopy Society  2012  Tokyo  The 83rd Congress of the Japan Gastroenterological Endoscopy SocietyEUSによる早期慢性膵炎の画像所見と臨床症状との関連性の検討. パネルディスカッション5「慢性膵炎の内視鏡診断と治療」  [Not invited]門阪 薫平; 北野 雅之; 工藤 正俊第83回日本消化器内視鏡学会総会  2012  グランドプリンスホテル新高輪, 東京  第83回日本消化器内視鏡学会総会EUSによる早期慢性膵炎の各画像所見と臨床症状の検討. ワークショップ5「生活習慣と肝・胆・膵疾患」  [Not invited]門阪 薫平; 北野 雅之; 工藤 正俊第98回日本消化器病学会総会  2012  京王プラザ  第98回日本消化器病学会総会Observations of Hepatocellular Carcinoma (HCC) Management Patterns from the Global HCC BRIDGE Study: First Characterization of the Full Study Population.  [Not invited]Joong-Won Park; 工藤 正俊; Morris Sherman; Massimo Colombo; Lewis Roberts Terry Therneau; Myron Schwartz; Francoise Degos; Pei-Jer Chen; Minshan Chen; Phillip Johnson; Baisong HuangASCO 2012 Annual Meeting  2012  Chicago, USA  ASCO 2012 Annual MeetingPercutaneous endoscopic gastrostomy with gastropexy greatly reduces the risk of peristomal infection.  [Not invited]辻 直子; 奥村 直己; 山本 典雄; 高場 雄久; 松本 望; 工藤 正俊Clinical Nutrition Week 2012  2012/01  Florida, USA  Clinical Nutrition Week 2012Interventional radiology における新しい支援画像「FightPlan」の初期臨床経験  [Not invited]南 康範; 有住 忠晃; 早石 宗右; 工藤 正俊; 柳生 行伸; 村上 卓道第18回肝血流動態イメージ研究会  2012/01  神戸  第18回肝血流動態イメージ研究会CE-US、CT-Angio、EOB-MRIと病理の比較~術前診断が2cm以下の肝切除症例~.  [Not invited]小川 力; 工藤 正俊; 大原 芳章; 宮本; 由貴子; 柴峠; 光成; 山岡; 竜也; 廣瀬; 哲朗; 西平; 友彦; 嶋田; 俊秀; 荻野; 哲朗; 河合 直之第18回肝血流動態イメージ研究会  2012/01  神戸ポートピアホテル, 兵庫  第18回肝血流動態イメージ研究会進行肝細胞癌患者に対する分子標的薬(ソラフェニブ)投与における治療効果判定基準の比較.  [Not invited]有住 忠晃; 上嶋 一臣; 早石 宗右; 田北 雅弘; 北井 聡; 矢田 典久; 井上 達夫; 萩原 智; 南 康範; 櫻井 俊治; 西田 直生志; 工藤 正俊; 竹田 治彦; 大﨑第18回肝血流動態イメージ研究会  2012/01  神戸ポートピアホテル, 兵庫  第18回肝血流動態イメージ研究会超音波エラストグラフィーによる非アルコール性脂肪性肝炎診断.  [Not invited]矢田 典久; 萩原 智; 工藤 正俊第18回肝血流動態イメージ研究会  2012/01  神戸ポートピアホテル, 兵庫  第18回肝血流動態イメージ研究会造影エコーによる肝癌肉眼分類の有用性について.  [Not invited]早石 宗右; 南 康範; 畑中 絹世; 有住 忠晃; 田北 雅弘; 北井 聡; 矢田 典久; 井上 達夫; 萩原 智; 上嶋 一臣; 西田 直生志; 工藤 正俊第18回肝血流動態イメージ研究会  2012/01  神戸ポートピアホテル, 兵庫  第18回肝血流動態イメージ研究会Interventional radiologyにおける新しい支援画像「FlightPlan」の初期臨床経験.  [Not invited]南 康範; 有住 忠晃; 早石 宗右; 田北 雅弘; 北井 聡; 矢田 典久; 井上 達夫; 萩原 智; 上嶋 一臣; 工藤 正俊; 柳生 行伸; 村上 卓道第18回肝血流動態イメージ研究会  2012/01  神戸ポートピアホテル, 兵庫  第18回肝血流動態イメージ研究会Percutaneous Endoscopic Gastrostomy with Gastropexy Greatly Reduces the Risk of Peristomal Infection  [Not invited]辻 直子; 奥村 直己; 山本 典雄; 高場 雄久; 松本 望; 工藤 正俊CNW2012 (Clinical Nutrition Week) (ASPEN)  2012/01  Orland  CNW2012 (Clinical Nutrition Week) (ASPEN)脾仮性動脈瘤の胃内穿破に対してIVRによる止血が有用であった一例. Freshman Session「肝胆膵」  [Not invited]平木 洋子; 早石 宗右; 川崎 正憲; 朝隈 豊; 南 康範; 松井 繁長; 工藤 正俊日本消化器病学会近畿支部第96回例会  2012/01  大阪国際交流センター, 大阪  日本消化器病学会近畿支部第96回例会糖尿病に対しインスリン導入後早期に発症した腫瘤形成性膵炎の1例. Freshman Session「肝胆膵」  [Not invited]安達 融; 谷浦 允厚; 河野 匡志; 松本 望; 高場 雄久; 奥村 直己; 山本 典雄; 冨田 崇文; 梅原 康湖; 森村 正嗣; 米田 円; 山田 哲; 辻 直子; 野口 周也; 大野 恭裕; 落合 健; 前倉 俊治; 南 康範; 工藤 正俊日本消化器病学会近畿支部第96回例会  2012/01  大阪国際交流センター, 大阪  日本消化器病学会近畿支部第96回例会微小膵癌との鑑別を要した自己免疫性膵炎の1例. Freshman Session「肝胆膵」  [Not invited]和田 翔太; 宮部 欽生; 木下 大輔; 秦 康倫; 奥田 英之; 茂山 朋広; 豊澤 昌子; 岸谷 讓; 川崎 俊彦; 工藤 正俊日本消化器病学会近畿支部第96回例会  2012/01  大阪国際交流センター, 大阪  日本消化器病学会近畿支部第96回例会虫垂粘液嚢胞腺腫の1例. Freshman Session「消化管」  [Not invited]玉田 博之; 秦 康倫; 木下 大輔; 奥田 英之; 茂山 朋広; 宮部 欽生; 豊澤 昌子; 岸谷 讓; 川崎 俊彦; 工藤 正俊; 佐藤 克明; 木谷 光太郎; 井上 雅智; 太田 善夫日本消化器病学会近畿支部第96回例会  2012/01  大阪国際交流センター, 大阪  日本消化器病学会近畿支部第96回例会成人腸重積で発症した盲腸癌の1例. Freshman Session「消化管」  [Not invited]谷浦 允厚; 安達 融; 河野 匡志; 松本 望; 高場 雄久; 奥村 直己; 山本 典雄; 冨田 崇文; 梅原 康湖; 森村 正嗣; 米田 円; 山田 哲; 辻 直子; 亀井 敬子; 北野 義徳; 田中 晃; 落合 健; 前倉 俊治; 南 康範; 工藤 正俊日本消化器病学会近畿支部第96回例会  2012/01  大阪国際交流センター, 大阪  日本消化器病学会近畿支部第96回例会当院における悪性胃十二指腸狭窄に対する消化管ステントの成績. シンポジウム「手術不能進行癌に対する集学的治療の現況と新たな展開(消化管)」  [Not invited]今井 元; 北野 雅之; 工藤 正俊日本消化器病学会近畿支部第96回例会  2012/01  大阪国際交流センター, 大阪  日本消化器病学会近畿支部第96回例会プロトンポンプ阻害薬内服中GERD患者におけるGerdQの有用性. Young Investigator Session「食道」  [Not invited]大本 俊介; 松井 繁長; 足立 哲平; 川崎 正憲; 高山 政樹; 峯 宏昌; 永井 知行; 永田 嘉昭; 朝隈 豊; 櫻井 俊治; 樫田 博史; 工藤 正俊日本消化器病学会近畿支部第96回例会  2012/01  大阪国際交流センター, 大阪  日本消化器病学会近畿支部第96回例会PEG-IFN α2a/RBV併用療法におけるResponse-Guided TherapyとIL28B多型との関連性の検討: ReGIT-J study. ワークショップ「ウイルス肝炎治療の新たな展開」  [Not invited]津田 泰宏; 工藤 正俊; 樋口 和秀; 西口 修平日本消化器病学会近畿支部第96回例会  2012/01  大阪国際交流センター, 大阪  日本消化器病学会近畿支部第96回例会ペグインターフェロンα-2b・エンテカビル48週間併用療法の治療成績. ワークショップ「ウイルス肝炎治療の新たな展開」  [Not invited]犬塚 義; 工藤 正俊; 木村 達; 大﨑日本消化器病学会近畿支部第96回例会  2012/01  大阪国際交流センター, 大阪  日本消化器病学会近畿支部第96回例会造影エコーによる肝癌肉眼分類の有用性について.  [Not invited]早石 宗右; 南 康範; 畑中 絹世; 有住 忠晃; 田北 雅弘; 北井 聡; 矢田 典久; 井上 達夫; 萩原 智; 西田 直生志; 工藤 正俊日本消化器病学会近畿支部第96回例会  2012/01  大阪国際交流センター, 大阪  日本消化器病学会近畿支部第96回例会Worldwide trends in locoregional therapy for hepatocellular carcinoma (HCC): second interim analysis of the GIDEON (Global Investigation of therapeutic DEcisions in HCC and Of its treatment with sorafeNib) study.  [Not invited]Jeff Geschwind; 工藤 正俊; Riccardo Lencioni; Jorge Marrero; Alan Venook; Sheng-Long Ye2012 Gastrointeritinal Cancers Symposium (ASCO-GI 2012)  2012/01  San Francisco, USA  2012 Gastrointeritinal Cancers Symposium (ASCO-GI 2012)Second interim analysis of GIDEON (Global Investigation of therapeutic DEcisions in unresectable hepatocellular carcinoma and Of its treatment with sorafeNib): differences in adverse-event reporting across physician specialties.  [Not invited]Alan Venook; 工藤 正俊; Riccardo Lencioni; Jorge Marrero; Sheng-Long Ye2012 Gastrointeritinal Cancers Symposium (ASCO-GI 2012)  2012/01  San Francisco, USA  2012 Gastrointeritinal Cancers Symposium (ASCO-GI 2012)講演「肝臓がんの内科的治療」  [Not invited]工藤 正俊近畿大学医学部附属病院がんセンター第35回ともに生きる会  2012/01  近畿大学医学部附属病院PET棟3階 大会議室, 大阪  近畿大学医学部附属病院がんセンター第35回ともに生きる会特別講演「肝疾患最近の話題」  [Not invited]工藤 正俊東四国ベアネットカンファレンス  2011/12  全日空ホテルクレメント高松, 香川  東四国ベアネットカンファレンスDiagnosis of gross pathology of HCC: Value of Kupffer phase of Sonazoid-enhanced US.  [Not invited]工藤 正俊3rd Asia-Pacific Conference on Ultrasound Contrast Imaging, 13th International Symposium on Ultrasou  2011/12  Kunming, China  3rd Asia-Pacific Conference on Ultrasound Contrast Imaging, 13th International Symposium on UltrasouMolecular targeting therapy.  [Not invited]工藤 正俊Session “HCV and HCC I”, The 7th APASL single topic conference  2011/12  Chiba, Japan  Session “HCV and HCC I”, The 7th APASL single topic conference糞線虫症の2例  [Not invited]橋本 知江美; 河野 匡史; 松本 望; 高場 雄久; 奥村 直己; 山本 典雄; 辻 直子; 浦瀬 文明; 梅原 泰; 工藤 正俊第196回 日本内科学会近畿地方会  2011/12  京都市  第196回 日本内科学会近畿地方会尋常性乾癬に対してインフリキシマブを投与中に発症した抗ミトコンドリアM2抗体陽性肝障害の1例  [Not invited]河野 匡史; 橋本 知江美; 松本 望; 高場 雄久; 奥村 直己; 山本 典雄; 梅原 康湖; 辻 直子; 南 康範; 工藤 正俊第196回 日本内科学会近畿地方会  2011/12  京都市  第196回 日本内科学会近畿地方会基調講演「肝癌治療アルゴリズムと治療法の選択」  [Not invited]工藤 正俊第39回日本肝臓学会西部会  2011/12  岡山コンベンションセンター, 岡山  第39回日本肝臓学会西部会Clinical staging systems for HCC. Symposium “HCC staging and response assessment”  [Not invited]工藤 正俊APASL 2nd Hepatocellular catcinmoma conference (APASL STC)  2011/12  Jeju, Korea  APASL 2nd Hepatocellular catcinmoma conference (APASL STC)Observations of hepatocellular carcinoma (HCC) management patterns from the global HCC BRIDGE study: An interim analysis from a South Korean Referral Center.  [Not invited]Joong-Won Park; 工藤 正俊; Hwi Young Kim; Pei-Jer Chen; Minshan Chen; Phillip Johnson; Morris Sherman; Massimo Colombo; Lewis RobertsAPASL 2nd Hepatocellular catcinmoma conference (APASL STC)  2011/12  Jeju, Korea  APASL 2nd Hepatocellular catcinmoma conference (APASL STC)How to Use Liver Imaging Reporting and Data System (LI-RADS) in Patients with Hepatocellular Carcinoma (HCC)  [Not invited]岡田 真広; 村上 卓道; 工藤 正俊; 横浜市立大学付属市民総合医療センター消化器病センター; ミュンヘン大学放射線科; 大船中央病院病理科RSNA - Educational Poster Session  2011/11  Chicago  RSNA - Educational Poster SessionAnalysis of Elasticity Image of Chronic Hepatitis Based on Dynamic Model of Fibrosis Progression.  [Not invited]牧 智紀; 工藤 正俊; 椎名 毅; 山川; 藤本 研治The 32nd Symposium on Ultrasonic Electronics (USE 2011)  2011/11  Kyoto, Japan  The 32nd Symposium on Ultrasonic Electronics (USE 2011)超音波エラストグラフィーは、肝生検の代替になりうるか.  [Not invited]矢田 典久; 萩原 智; 有住 忠晃; 早石 宗右; 田北 雅弘; 北井 聡; 井上 達夫; 南 康範; 上嶋 一臣; 西田 直生志; 工藤 正俊第53回大阪肝穿刺生検治療研究会  2011/11  ホテルグランヴィア大阪, 大阪  第53回大阪肝穿刺生検治療研究会特別講演「分子機序に基づく癌治療戦略」  [Not invited]工藤 正俊第53回大阪肝穿刺生検治療研究会  2011/11  ホテルグランヴィア大阪, 大阪  第53回大阪肝穿刺生検治療研究会特別講演「肝癌診療の新しいパラダイム」  [Not invited]工藤 正俊腹部超音波オープンカンファレンス特別講演会  2011/11  神戸市立医療センター中央市民病院, 兵庫  腹部超音波オープンカンファレンス特別講演会Lecture “Sonazoid-enhanced US in the management of HCC.”  [Not invited]工藤 正俊9th ABDA teaching course in conjuction with AFSIMB Workshop  2011/11  Bali, Indonesia  9th ABDA teaching course in conjuction with AFSIMB WorkshopLecture “Interventional EUS for pancreatobiliary tumors.”  [Not invited]工藤 正俊9th ABDA teaching course in conjuction with AFSIMB Workshop  2011/11  Bali, Indonesia  9th ABDA teaching course in conjuction with AFSIMB WorkshopSecond interim analysis of GIDEON (Global investigation of therapeutic decisions in unresectable HCC [UHCC] and of its treatment with Sorafenib): subgroup analysis by initial sorafenib (Sor) dose.  [Not invited]Jorge A. Marrero; 工藤 正俊; Alan Venook; Sheng-Long Ye; Riccardo LencioniThe 62nd Annual Meeting of the American Association for the Study of Liver Diseases (AASLD)  2011/11  San Francisco, USA  The 62nd Annual Meeting of the American Association for the Study of Liver Diseases (AASLD)Second interim analysis of GIDEON (Global investigation of ther-apeutic decisions in unresectable HCC [UHCC] and of its treatment with Sorafenib): multiregional variation in patient (pt) characteristics, previous treatment history, and sorafenib (Sor) use  [Not invited]工藤 正俊; Sheng-Long Ye; Alan Venook; Jorge A. Marrero; Riccardo LencioniThe 62nd Annual Meeting of the American Association for the Study of Liver Diseases (AASLD)  2011/11  San Francisco, USA  The 62nd Annual Meeting of the American Association for the Study of Liver Diseases (AASLD)Assessment of hepatobiliary phase Gd-EOB-DTPA-enhanced MRI for HCC and dysplastic nodules and comparison of detection ability versus MDCT.  [Not invited]井上 達夫; 工藤 正俊; 有住 忠晃; 早石 宗右; 田北 雅弘; 北井 聡; 矢田 典久; 萩原 智; 南 康範; 上嶋 一臣; 岡田 真広; 兵頭 朋子; 村上 卓道The 62nd Annual Meeting of the American Association for the Study of Liver Diseases (AASLD)  2011/11  San Francisco, USA  The 62nd Annual Meeting of the American Association for the Study of Liver Diseases (AASLD)Impact on aberrant methylation of an unique subset of tumor suppressor genes on the initial steps of human hepatocarcinogenesis.  [Not invited]西田 直生志; 工藤 正俊; Takeshi Nagasaka; Ajay GoelThe 62nd Annual Meeting of the American Association for the Study of Liver Diseases (AASLD)  2011/11  San Francisco, USA  The 62nd Annual Meeting of the American Association for the Study of Liver Diseases (AASLD)特別講演「造影超音波は肝癌診療をどう変えたか?」  [Not invited]工藤 正俊第11回北海道腹部造影エコー・ドプラ診断研究会  2011/11  第一三共株式会社札幌支店, 北海道  第11回北海道腹部造影エコー・ドプラ診断研究会膵仮性嚢胞に伴った膵仮性動脈瘤の1例.  [Not invited]前野 知子; 横川 美加; 辻 裕美子; 桑口 愛; 前川 清; 今井 元; 井上 達夫; 南 康範; 樫田 博史; 工藤 正俊日本超音波医学会第38回関西地方会学術集会  2011/11  大阪国際会議場, 大阪  日本超音波医学会第38回関西地方会学術集会体外式超音波穿刺用コンベックスプローブEUP-B715の使用経験.  [Not invited]矢田 典久; 有住 忠晃; 早石 宗右; 田北 雅弘; 北井 聡; 井上 達夫; 萩原 智; 南 康範; 上嶋 一臣; 工藤 正俊日本超音波医学会第38回関西地方会学術集会  2011/11  大阪国際会議場, 大阪  日本超音波医学会第38回関西地方会学術集会非上皮性肝腫瘤2例の造影超音波像について.  [Not invited]横川 美加; 辻 裕美子; 桑口 愛; 前野 知子; 前川 清; 井上 達夫; 南 康範; 上嶋 一臣; 樫田 博史; 工藤 正俊日本超音波医学会第38回関西地方会学術集会  2011/11  大阪国際会議場, 大阪  日本超音波医学会第38回関西地方会学術集会造影エコーによる肝癌肉眼分類の有用性について.  [Not invited]早石 宗右; 南 康範; 畑中 絹世; 井上 達夫; 工藤 正俊日本超音波医学会第38回関西地方会学術集会  2011/11  大阪国際会議場, 大阪  日本超音波医学会第38回関西地方会学術集会肝エラストグラフィ ?各モダリティ―における測定原理と結果の解釈-. ワークショップ「組織弾性イメージング」  [Not invited]矢田 典久; 有住 忠晃; 早石 宗右; 田北 雅弘; 北井 聡; 井上 達夫; 萩原 智; 南 康範; 上嶋 一臣; 工藤 正俊日本超音波医学会第38回関西地方会学術集会  2011/11  大阪国際会議場, 大阪  日本超音波医学会第38回関西地方会学術集会肝癌に対するラジオ波焼灼療法の治療効果判定 造影USと造影CTの比較検討. パネルディスカッション「造影超音波」  [Not invited]井上 達夫; 有住 忠晃; 早石 宗右; 田北 雅弘; 北井 聡; 矢田 典久; 萩原 智; 南 康範; 上嶋 一臣; 工藤 正俊日本超音波医学会第38回関西地方会学術集会  2011/11  大阪国際会議場, 大阪  日本超音波医学会第38回関西地方会学術集会Non-liver transplantation treatment for hepatocellular carcinoma within the Milan criteria in child-pugh score 10-11 cirrhotic patients has a survival benefit.  [Not invited]北井 聡; 工藤 正俊; 泉 並木; 坂本 穣; 松山 裕; 市田 隆文; 中島 收; 松井 修; 具 英成; 國土 典宏; 幕内 雅敏The 62nd Annual Meeting of the American Association for the Study of Liver Diseases (AASLD)  2011/11  San Francisco, USA  The 62nd Annual Meeting of the American Association for the Study of Liver Diseases (AASLD)Phase I study of Sorafenib in combination with low-dose cisplatin and fluorouracil intra-arterial infusion chemotherapy.  [Not invited]上嶋 一臣; 工藤 正俊; 鄭 浩柄; 萩原 智; 井上 達夫; 矢田 典久; 南 康範; 櫻井 俊治; 田中 正俊; 熊田 卓The 62nd Annual Meeting of the American Association for the Study of Liver Diseases (AASLD)  2011/11  San Francisco, USA  The 62nd Annual Meeting of the American Association for the Study of Liver Diseases (AASLD)Efficacy and safety of sorafenib for hepatocellular carcinoma: a multicenter retrospective study in Japan.  [Not invited]金子 周一; 工藤 正俊; 古瀬 純司; 池田 健次The 62nd Annual Meeting of the American Association for the Study of Liver Diseases (AASLD)  2011/11  San Francisco, USA  The 62nd Annual Meeting of the American Association for the Study of Liver Diseases (AASLD)Drastic improvement of survival in patients with hepatocellular carcinoma over 30 years in Japan: Analysis of nationwide prospective registry of 148,161 patients.  [Not invited]工藤 正俊; 泉 並木; 坂元 享宇; 松山 裕; 市田 隆文; 中島 收; 松井 修; 具 英成; 國土 典宏; 幕内 雅敏The 62nd Annual Meeting of the American Association for the Study of Liver Diseases (AASLD)  2011/11  San Francisco, USA  The 62nd Annual Meeting of the American Association for the Study of Liver Diseases (AASLD)Usefullness of contrast-enhanced ultrasonography to evaluate a post treatment effect of radiofrequentry ablation about hepatocellular carcinoma: Comparion with multidetector row CT.  [Not invited]井上 達夫; 工藤 正俊; 畑中 絹世; 南 康範; 上嶋 一臣; 有住 忠晃; 田北 雅弘; 北井 聡The 62nd Annual Meeting of the American Association for the Study of Liver Diseases (AASLD)  2011/11  San Francisco, USA  The 62nd Annual Meeting of the American Association for the Study of Liver Diseases (AASLD)Updated Liver Function Imaging by MRI and CT: Quantification Analysis for Hepatic Steatosis, Fibrosis, and Siderosis.  [Not invited]岡田 真広; 工藤 正俊; 村上 卓道; 工藤 正幸RSNA - Educational Poster Session  2011/11  Chicago  RSNA - Educational Poster SessionAdvanced CT Evaluation for Liver Imaging: Perfusion CT, Ultrafast Arterial Scanning of Whole Liver and Dual-Energy CT.  [Not invited]山田 浩司; 岡田 真広; 工藤 正俊; 矢田 典久; 村上 卓道; 工藤 正幸RSNA - Educational Poster Session  2011/11  Chicago  RSNA - Educational Poster SessionAtypical Imaging of Liver Hemangioma: Pictorial Review by Gd-EOB-DTPA-enhanced MRI, Dynamic CT and Sonography.  [Not invited]岡田 真広; 兵頭 朋子; 香川 祐毅; 工藤 正俊; 村上 卓道; 沼田 和司RSNA - Scientific Poster Session  2011/11  Chicago  RSNA - Scientific Poster SessionHepatocellular Carcinoma: Pictorial Review for the Planning of Therapy and the Evaluation after Therapy.  [Not invited]岡田 真広; 兵頭 朋子; 香川 祐毅; 工藤 正俊; 村上 卓道; 沼田 和司RSNA - Educational Poster Session  2011/11  Chicago  RSNA - Educational Poster SessionEvaluation of Angiogenesis after Antiangiogenic Therapy Using Liver CT Perfusion: Additional Detailed Capillary-level Hemodynamics in Patients with Advanced Hepatocellular Carcinoma.  [Not invited]岡田 真広; 工藤 正俊; 矢田 典久; 上嶋 一臣; 村上 卓道; 工藤 正幸RSNA - Scientific Poster Session  2011/11  Chicago  RSNA - Scientific Poster SessionEvaluation of Degree of Hepatic Fibrosis: Comparison T1 Mapping Technique of Gd-EOB-DTPA Enhanced MRI with US Elastography.  [Not invited]岡田 真広; 熊野 正士; 工藤 正俊; 矢田 典久; 小野田 農; 村上 卓道RSNA - Scientific Poster Session  2011/11  Chicago  RSNA - Scientific Poster SessionMechanical model analysis for quantitative evaluation of liver fibrosis based on real-time tissue elastography.  [Not invited]Tsuyoshi Shiina; 工藤 正俊; Makoto YamakawaThe 10th International Tissue Elasticity Conference  2011/10  Texas, USA  The 10th International Tissue Elasticity Conferenceステロイド依存性の潰瘍性大腸炎に対する白血球除去療法の有用性と問題点の検討.  [Not invited]大本 俊介; 峯 宏昌; 櫻井 俊治; 高山 政樹; 永井 知行; 永田 嘉昭; 川崎 正憲; 朝隈 豊; 松井 繁長; 樫田 博史; 工藤 正俊第19回日本消化器関連学会週間JDDW 2011(第53回日本消化器病学会大会)  2011/10  福岡国際会議場, 福岡  第19回日本消化器関連学会週間JDDW 2011(第53回日本消化器病学会大会)“Establishing treatment algorithms for hepatocellular carcinoma: What tests do we need?” , Symposium “When East meets West: Management of hepatocellular carcinoma”,  [Not invited]工藤 正俊19th United European Gastroenterology Week (UEGW)  2011/10  Stockholm, Sweden  19th United European Gastroenterology Week (UEGW)Verrucous antral gastritis is not related to H. pylori-positive chronic gastritis, but is related to a high BMI.  [Not invited]辻 直子; 松本 望; 高場 雄久; 奥村 直己; 山本 典雄; 梅原 康湖; 南 康範; 工藤 正俊APDW2011  2011/10  Singapore  APDW2011Malignant gastric outlet obstruction (MGOO)に対するステント留置術と胃空腸吻合術の比較検討  [Not invited]山本 典雄; 松本 望; 高場 雄久; 奥村 直己; 冨田 崇文; 梅原 康湖; 森村 正嗣; 米田 円; 山田 哲; 辻 直子; 南 康範; 工藤 正俊第53回日本消化器病学会大会  2011/10  福岡市  第53回日本消化器病学会大会内視鏡的胃液胆汁色の臨床的意義と評価  [Not invited]松本 望; 辻 直子; 高場 雄久; 奥村 直己; 山本 典雄; 冨田 崇文; 梅原 康湖; 森村 正嗣; 米田 円; 山田 哲; 落合 健; 前倉 俊治; 南 康範; 工藤 正俊; 本庶 元第53回日本消化器病学会大会  2011/10  福岡市  第53回日本消化器病学会大会本邦における多発肝嚢胞症の実態調査.  [Not invited]小川 光一; 工藤 正俊; 福永 潔; 大河内; 信弘; 竹内 朋代; 川岸 直樹第19回日本消化器関連学会週間JDDW 2011(第15回日本肝臓学会大会)  2011/10  福岡国際会議場, 福岡  第19回日本消化器関連学会週間JDDW 2011(第15回日本肝臓学会大会)Diagnostic utility of contrast enhanced harmonic EUS imaging in patients with submucosal tumor of gastrointersinal tract.  [Not invited]坂本 洋城; 北野 雅之; 今井 元; 小牧 孝充; 鎌田 研; 宮田 剛; 門阪 薫平; 工藤 正俊19th United European Gastroenterology Week (UEGW)  2011/10  Stockholm, Sweden  19th United European Gastroenterology Week (UEGW)Long duration of stable disease may improve the overall survival in the patients with advanced hepa-tocellular carcinoma treated with Soraenib.  [Not invited]有住 忠晃; 上嶋 一臣; 工藤 正俊United European Gastroenterology Week (UEGW)  2011/10  Stockholm, Sweden  United European Gastroenterology Week (UEGW)Usefullness of contrast-enhanced ultrasonography to evaluate a post treatment effect of radiofrequentry ablation about hepatocellular carcinoma; comparion eith MDCT.  [Not invited]井上 達夫; 工藤 正俊; 畑中 絹世; 南 康範; 上嶋 一臣; 北井 聡19th United European Gastroenterology Week (UEGW)  2011/10  Stockholm, Sweden  19th United European Gastroenterology Week (UEGW)Endoscopic ultrasonograph (EUS)-guided choledochoduo-denostomy and hepatogastrostomy for treatment of biliary obstruction.  [Not invited]今井 元; 北野 雅之; 坂本 洋城; 鎌田 研; 小牧 孝充; 宮田 剛; 門阪 薫平; 工藤 正俊19th United European Gastroenterology Week (UEGW)  2011/10  Stockholm, Sweden  19th United European Gastroenterology Week (UEGW)特別講演「造影超音波は肝癌診療をどう変えたか?」  [Not invited]工藤 正俊肝炎・肝硬変治療レクチャーミーティング  2011/10  川崎日航ホテル, 神奈川  肝炎・肝硬変治療レクチャーミーティングHepatocellular carcinoma: Recent development of molecular targeted agent.  [Not invited]工藤 正俊JSCO university “Hepatobiliary and pancreas cancers”, 第49回日本癌治療学会学術集会  2011/10  名古屋国際会議場, 愛知  JSCO university “Hepatobiliary and pancreas cancers”, 第49回日本癌治療学会学術集会肝血管肉腫の2例.  [Not invited]有住 忠晃; 萩原 智; 大本 俊介; 早石 宗右; 上田 泰輔; 田北 雅弘; 北井 聡; 南 康範; 鄭 浩柄; 上嶋 一臣; 工藤 正俊第19回日本消化器関連学会週間JDDW 2011(第15回日本肝臓学会大会)  2011/10  福岡国際会議場, 福岡  第19回日本消化器関連学会週間JDDW 2011(第15回日本肝臓学会大会)シングルバルーン小腸内視鏡の有用性について.  [Not invited]川崎 正憲; 峯 宏昌; 永田 嘉昭; 朝隈 豊; 櫻井 俊治; 松井 繁長; 樫田 博史; 工藤 正俊第19回日本消化器関連学会週間JDDW 2011(第82回日本消化器内視鏡学会総会)  2011/10  福岡国際会議場, 福岡  第19回日本消化器関連学会週間JDDW 2011(第82回日本消化器内視鏡学会総会)胃たこいぼびらんの臨床的内視鏡的検討.  [Not invited]辻 直子; 松本 望; 高場 雄久; 奥村 直己; 山本 典雄; 冨田 崇文; 梅原 康湖; 森村 正嗣; 米田 円; 山田 哲; 落合 健; 前倉 俊治; 南 康範; 工藤 正俊; 本庶 元第19回日本消化器関連学会週間JDDW 2011(第82回日本消化器内視鏡学会総会)  2011/10  福岡国際会議場, 福岡  第19回日本消化器関連学会週間JDDW 2011(第82回日本消化器内視鏡学会総会)難治性食道カンジタ症に合併した食道乳頭腫の1例.  [Not invited]永田 嘉昭; 松井 繁長; 峯 宏昌; 高山 政樹; 永井 知行; 川崎 正憲; 朝隈 豊; 櫻井 俊治; 樫田 博史; 工藤 正俊第19回日本消化器関連学会週間JDDW 2011(第82回日本消化器内視鏡学会総会)  2011/10  福岡国際会議場, 福岡  第19回日本消化器関連学会週間JDDW 2011(第82回日本消化器内視鏡学会総会)Barrett食道に発生した表在未分化癌の一例.  [Not invited]朝隈 豊; 松井 繁長; 峯 宏昌; 永田 嘉昭; 川崎 正憲; 櫻井 俊治; 樫田 博史; 工藤 正俊第19回日本消化器関連学会週間JDDW 2011(第82回日本消化器内視鏡学会総会)  2011/10  福岡国際会議場, 福岡  第19回日本消化器関連学会週間JDDW 2011(第82回日本消化器内視鏡学会総会)PEG-IFN α(もしくはIFN)/RBV併用療法でSVRが得られなかったGenotype 2型C型慢性肝炎に対するPEG-IFNα2a/RBV併用療法の有効性および安全性の検討(中間報告)  [Not invited]八橋 弘; 工藤 正俊; 泉 並木日本消化器関連学会週間JDDW 2011(第53回日本消化器病学会大会)  2011/10  福岡国際センター, 福岡  日本消化器関連学会週間JDDW 2011(第53回日本消化器病学会大会)IPMNの悪性度評価およびフォローアップにおける造影法を含めたEUSの有用性. ワークショップ「嚢胞性膵腫瘍の病態からみた治療」  [Not invited]鎌田 研; 北野 雅之; 工藤 正俊第19回日本消化器関連学会週間JDDW 2011(第9回日本消化器外科学会大会・第53回日本消化器病学会大会・第82回日本消化器内視鏡学会総会合同)  2011/10  福岡国際センター, 福岡  第19回日本消化器関連学会週間JDDW 2011(第9回日本消化器外科学会大会・第53回日本消化器病学会大会・第82回日本消化器内視鏡学会総会合同)膵癌の早期診断のストラテジー. パネルディスカッション「膵管癌の危険因子と早期診断」  [Not invited]宮田 剛; 北野 雅之; 工藤 正俊第19回日本消化器関連学会週間JDDW 2011(第53回日本消化器病学会大会・第82回日本消化器内視鏡学会総会・第9回日本消化器外科学会大会・第49回日本消化器がん検診学会大会合同)  2011/10  福岡国際センター, 福岡  第19回日本消化器関連学会週間JDDW 2011(第53回日本消化器病学会大会・第82回日本消化器内視鏡学会総会・第9回日本消化器外科学会大会・第49回日本消化器がん検診学会大会合同)経乳頭的胆管ドレナージ困難例に対するEUS下胆道ドレナージ術の有用性. パネルディスカッション「EUS-FNA関連の手技と工夫《ビデオ》」  [Not invited]今井 元; 北野 雅之; 工藤 正俊第19回日本消化器関連学会週間JDDW 2011(第82回日本消化器内視鏡学会総会・第53回日本消化器病学会大会・第9回日本消化器外科学会大会合同)  2011/10  福岡国際センター, 福岡  第19回日本消化器関連学会週間JDDW 2011(第82回日本消化器内視鏡学会総会・第53回日本消化器病学会大会・第9回日本消化器外科学会大会合同)分岐鎖アミノ酸による肝細胞癌へのNutrigenomics: 肝細胞癌合併肝硬変例に対する癌細胞内シグナル伝達制御. シンポジウム「消化器疾患における栄養マネージメント」  [Not invited]土師 誠二; 工藤 正俊; 荒尾 徳三第19回日本消化器関連学会週間JDDW 2011(第53回日本消化器病学会大会・第15回日本肝臓学会大会・第9回日本消化器外科学会大会・第42回日本消化吸収学会総会合同)  2011/10  福岡国際センター, 福岡  第19回日本消化器関連学会週間JDDW 2011(第53回日本消化器病学会大会・第15回日本肝臓学会大会・第9回日本消化器外科学会大会・第42回日本消化吸収学会総会合同)PEG-IFNα2a/RBV併用療法におけるResponse-Guided TherapyとIL28B多型との関連性の検討: ReGIT-J Study. シンポジウム「C型肝炎個別化医療のための宿主因子・ウイルス因子」  [Not invited]工藤 正俊; 樋口 和秀; 西口 修平第19回日本消化器関連学会週間JDDW 2011(第15回日本肝臓学会大会・第53回日本消化器病学会大会合同)  2011/10  福岡国際センター, 福岡  第19回日本消化器関連学会週間JDDW 2011(第15回日本肝臓学会大会・第53回日本消化器病学会大会合同)癌性疼痛における超音波内視鏡下広範囲腹腔神経叢融解術(EUS-BPN)の有用性.  [Not invited]坂本 洋城; 北野 雅之; 今井 元; 鎌田 研; 宮田 剛; 門阪 薫平; 工藤 正俊第60回近畿膵疾患談話会  2011/10  エーザイ株式会社大阪コミュニケーションオフィス, 大阪  第60回近畿膵疾患談話会Does wire guided cannulation reduce the risk of pancreatic disorder?  [Not invited]鎌田 研; 北野 雅之; 工藤 正俊; 門阪 薫平; 宮田 剛; 坂本 洋城; 今井 元; 小牧 孝充Asian Pacific Digestive Week (APDW) 2011  2011/10  Singapore  Asian Pacific Digestive Week (APDW) 2011Endoscopic ultrasonography (EUS)-guided biliary drainage for treatment of biliary obstruction.  [Not invited]今井 元; 北野 雅之; 鎌田 研; 門阪 薫平; 宮田 剛; 坂本 洋城; 小牧 孝充; 工藤 正俊Asian Pacific Digestive Week (APDW) 2011  2011/10  Singapore  Asian Pacific Digestive Week (APDW) 2011EG-IFN α/RBV併用療法でSVRが得られなかったGenotype 1型C型慢性肝炎に対するPEG-IFNα2a/RBV併用による再治療の有効性および安全性の検討(中間報告)  [Not invited]泉 並木; 工藤 正俊; 八橋 弘日本消化器関連学会週間JDDW 2011(第53回日本消化器病学会大会)  2011/10  福岡国際センター, 福岡  日本消化器関連学会週間JDDW 2011(第53回日本消化器病学会大会)PEG-IFN α2b/RBV併用療法の無効・再燃例に対するPEG-IFN α2a/RBV併用療法の再治療の検討-多施設共同研究RETRY study-.  [Not invited]上田 泰輔; 工藤 正俊; 土谷 薫 泉; 並木; 橋元 悟; 井上 泰輔; 稲生 実枝; 田中 篤; 垣内 雅彦; 今関 文夫; 西口 修平; 八橋 弘日本消化器関連学会週間JDDW 2011(第15回日本肝臓学会大会)  2011/10  福岡国際センター, 福岡  日本消化器関連学会週間JDDW 2011(第15回日本肝臓学会大会)S状結腸穿孔による手術標本により診断されたアレルギー性肉芽腫性血管炎の一例.  [Not invited]峯 宏昌; 大本 俊介; 高山 政樹; 永田 嘉昭; 永井 知行; 川崎 正憲; 朝隈 豊; 櫻井 俊治; 松井 繁長; 樫田 博史; 工藤 正俊; 杉浦 史哲; 上田 和毅; 市橋 秀夫第87回日本消化器内視鏡学会近畿地方会  2011/10  神戸ポートピアホテル, 兵庫  第87回日本消化器内視鏡学会近畿地方会下行結腸狭窄をきたしたCrohn病に対して内視鏡的拡張術とInfliximab投与により寛解維持を得た1症例.  [Not invited]永田 嘉昭; 樫田 博史; 大本 俊介; 高山 政樹; 峯 宏昌; 川崎 正憲; 朝隈 豊; 櫻井 俊治; 松井 繁長; 工藤 正俊第87回日本消化器内視鏡学会近畿地方会  2011/10  神戸ポートピアホテル, 兵庫  第87回日本消化器内視鏡学会近畿地方会Collagenous colitisの1症例.  [Not invited]秦 康倫; 木下 大輔; 奥田 英之; 茂山 朋広; 宮部 欽生; 豊澤 昌子; 岸谷 讓; 川崎 俊彦; 工藤 正俊第87回日本消化器内視鏡学会近畿地方会  2011/10  神戸ポートピアホテル, 兵庫  第87回日本消化器内視鏡学会近畿地方会造影ハーモニックEUSを用いた腹部リンパ節の良悪性診断の試み.  [Not invited]宮田 剛; 坂本 洋城; 北野 雅之; 鎌田 研; 今井 元; 小牧 孝充; 門阪 薫平; 工藤 正俊第87回日本消化器内視鏡学会近畿地方会  2011/10  神戸ポートピアホテル, 兵庫  第87回日本消化器内視鏡学会近畿地方会腹水と下痢を契機に発見された好酸球性胃腸炎の一例.  [Not invited]山本 典雄; 辻 直子; 米田 円; 山田 哲; 森村 正嗣; 梅原 康湖; 冨田 崇文; 奥村 直己; 高場 雄久; 松本 望; 工藤 正俊第87回日本消化器内視鏡学会近畿地方会  2011/10  神戸ポートピアホテル, 兵庫  第87回日本消化器内視鏡学会近畿地方会肝膿瘍を契機に診断されたcholedochoceleの1例.  [Not invited]宮部 欽生; 木下 大輔; 秦 康倫; 奥田 英之; 茂山 朋広; 豊澤 昌子; 岸谷 讓; 川崎 俊彦; 工藤 正俊第87回日本消化器内視鏡学会近畿地方会  2011/10  神戸ポートピアホテル, 兵庫  第87回日本消化器内視鏡学会近畿地方会膵領域診断における造影ハーモニックEUSの有用性の検討. シンポジウム「胆膵領域における内視鏡診断と治療-その基本と工夫」  [Not invited]坂本 洋城; 北野 雅之; 工藤 正俊第87回日本消化器内視鏡学会近畿地方会  2011/10  神戸ポートピアホテル, 兵庫  第87回日本消化器内視鏡学会近畿地方会当院でのESDトレーニングシステム. パネルディスカッション「効率的なESDの技術習得に向けて(Animal Modelを用いたHands-on Training. を含む)」  [Not invited]川崎 正憲; 松井 繁長; 工藤 正俊第87回日本消化器内視鏡学会近畿地方会  2011/10  神戸ポートピアホテル, 兵庫  第87回日本消化器内視鏡学会近畿地方会当院におけるESDデバイスの使い分けについて. シンポジウム「ESDデバイスの使い分け(Animal Modelを用いたLive Demo. を含む)」  [Not invited]朝隈 豊; 松井 繁長; 工藤 正俊第87回日本消化器内視鏡学会近畿地方会  2011/10  神戸ポートピアホテル, 兵庫  第87回日本消化器内視鏡学会近畿地方会特別講演「C型慢性肝炎の最新の治療」  [Not invited]工藤 正俊C型肝炎治療学術講演会  2011/10  ホテルグランヴィア大阪, 大阪  C型肝炎治療学術講演会PEG-IFNα(IFN)/RBV併用療法でSVRが得られなかったGenotype 1型C型慢性肝炎に対するPRG-IFNα2a/RBV併用による再治療の有効性及び安全性の検討(中間報告).  [Not invited]泉 並木; 工藤 正俊; 八橋 弘第19回日本消化器関連学会週間  2011/10  福岡国際センター, 福岡  第19回日本消化器関連学会週間Impact of TJP-1 and TWIST expression on post-operative prognosis in hepatocellular carcinoma.  [Not invited]永井 知行; 荒尾 徳三; 松本 和子; 工藤 可苗; 木村 英晴; 藤田 至彦; 萩原 智; 櫻井 俊治; 上嶋 一臣; 土師 誠二; 工藤 正俊; 西尾 和人70th Annual Meeting of the Japanese Cancer Association  2011/10  Nagoya, Japan  70th Annual Meeting of the Japanese Cancer Association当院におけるEUS-FNAのラーニングカーブについての検討.  [Not invited]坂本 洋城; 北野 雅之; 工藤 正俊第16回日本外科病理学会学術集会  2011/09  大阪ガーデンパレス, 大阪  第16回日本外科病理学会学術集会Second interim results of the GIDEON (Global Investigation of therapeutic DEcisions in HCC and Of its Treatment with sorafeNib) study: Barcelona-Clinic Liver Cancer (BCLC) stage subgroup analysis.  [Not invited]工藤 正俊; Riccardo Lencioni; Alan Venook; Jorge Marrero; Sheng-Long Ye16th ECCO-36th ESMO Multidisciplinary cancer congress  2011/09  Stockholm, Sweden  16th ECCO-36th ESMO Multidisciplinary cancer congressObservations of hepatocellular carcinoma (HCC) management patterns from the HCC BRIDGE Study: An interim analysis of the European cohort.  [Not invited]Massimo Colombo; 工藤 正俊; Robert Lewis Terry Therneau; Myron Schwartz; Fran?oise Degos; Morris Sherman; Pei-Jer Chen; Minshan Chen; Joong-Won Park; Phillip Johnson16th ECCO-36th ESMO Multidisciplinary cancer congress  2011/09  Stockholm, Sweden  16th ECCO-36th ESMO Multidisciplinary cancer congressPreferred strategies for inclusion in comprehensive liver cancer control in Asia.  [Not invited]J. F. Bridges; 工藤 正俊; G. Gallego; KH Han; SL Ye; B. M. BlauveltInternational Liver Cancer Association Fifth Annual Conference (ILCA) 2011  2011/09  Hong Kong, China  International Liver Cancer Association Fifth Annual Conference (ILCA) 2011Long duration of stable disease may improve the overall survival in the patients with advanced hepatocellular carcinoma treated with Sorafenib.  [Not invited]有住 忠晃; 上嶋 一臣; 工藤 正俊International Liver Cancer Association Fifth Annual Conference (ILCA) 2011  2011/09  Hong Kong, China  International Liver Cancer Association Fifth Annual Conference (ILCA) 2011特別講演「肝硬変・肝癌の治療ガイドラインと発癌抑制」  [Not invited]工藤 正俊リーバクト配合顆粒発売15周年講演会  2011/09  城西館, 高知  リーバクト配合顆粒発売15周年講演会Phase I study of Sorafenib in combination with low-dose cisplatin and flurouracil intra-arterilal infusion chemotherapy.  [Not invited]上嶋 一臣; 工藤 正俊; 櫻井 俊治; 鄭 浩柄; 南 康範; 萩原 智; 井上 達夫; 矢田 典久; 北井 聡; 有住 忠晃; 早石 宗右; 田中 正俊; 熊田 卓International Liver Cancer Association Fifth Annual Conference (ILCA) 2011  2011/09  Hong Kong, China  International Liver Cancer Association Fifth Annual Conference (ILCA) 2011Assessment of hepatobiliary phase Gd-EOB-DTPA-Enhanced MRI for HCC and dysplastic nodules and comparison of detection ability versus MDCT.  [Not invited]井上 達夫; 工藤 正俊; 北井 聡; 有住 忠晃; 南 康範; 上嶋 一臣; 岡田 真広; 村上 卓道International Liver Cancer Association Fifth Annual Conference (ILCA) 2011  2011/09  Hong Kong, China  International Liver Cancer Association Fifth Annual Conference (ILCA) 2011Non-liver transplantation treatment for hepatocellular carcinoma within the Milan criteria in child-pugh score 10-11 cirrhotic patients has a survival benefit.  [Not invited]北井 聡; 工藤 正俊; 有井 滋樹; 市田 隆文; 小俣 政男; 坂元 亨宇; 高安 賢一; 中島 收; 幕内 雅敏; 松山 裕; 門田 守人International Liver Cancer Association Fifth Annual Conference (ILCA) 2011  2011/09  Hong Kong, China  International Liver Cancer Association Fifth Annual Conference (ILCA) 2011Second interim analysis of GIDEON (Global investigation of therapeutic decisions in HCC and of its treatment with Sorafenib): Regional variation in patient characteristics and treatment history.  [Not invited]工藤 正俊; R. Lencioni; A. Venook; J. Marrero; SL. YeInternational Liver Cancer Association Fifth Annual Conference (ILCA) 2011  2011/09  Hong Kong, China  International Liver Cancer Association Fifth Annual Conference (ILCA) 2011Benefit and nonsense in oncologic follow-up imaging and the role of US.  [Not invited]工藤 正俊13th World Congress of the world federation for ultrasound in medicine and biology (WFUMB) 2011  2011/09  Vienna, Austria  13th World Congress of the world federation for ultrasound in medicine and biology (WFUMB) 2011特別講演「肝癌治療の現状と今後の展開」  [Not invited]工藤 正俊第7回西濃がん診療研究会学術講演会  2011/09  大垣フォーラムホテル, 岐阜  第7回西濃がん診療研究会学術講演会胆嚢疾患の鑑別における造影ハーモニックEUSの有用性.  [Not invited]鎌田 研; 北野 雅之; 工藤 正俊; 宮田 剛; 今井 元; 坂本 洋城; 小牧 孝充第47回日本胆道学会学術集会  2011/09  ワールドコンベンションセンターサミット, 宮崎  第47回日本胆道学会学術集会EUSによる肝外胆管癌の進展度診断.  [Not invited]小牧 孝充; 北野 雅之; 坂本 洋城; 今井 元; 鎌田 研; 宮田 剛; 門阪 薫平; 工藤 正俊; 中居 卓也; 竹山 宜典第47回日本胆道学会学術集会  2011/09  ワールドコンベンションセンターサミット, 宮崎  第47回日本胆道学会学術集会当院でのEUS下胆道ドレナージ術の成績.  [Not invited]今井 元; 北野 雅之; 工藤 正俊第47回日本胆道学会学術集会  2011/09  ワールドコンベンションセンターサミット, 宮崎  第47回日本胆道学会学術集会Wire Guided Cannulation法はERCP後膵障害のリスクを減少させるか.  [Not invited]鎌田 研; 北野 雅之; 工藤 正俊; 宮田 剛; 今井 元; 坂本 洋城; 小牧 孝充第47回日本胆道学会学術集会  2011/09  ワールドコンベンションセンターサミット, 宮崎  第47回日本胆道学会学術集会CT Perfusionによる肝細胞癌の分子標的薬治療効果予測  [Not invited]兵頭 朋子; 香川 祐毅; 岡田 真広; 日高 正二朗; 柳生 行伸; 熊野 正士; 柏木 伸夫; 小塚 健倫; 今岡 いずみ; 足利 竜一朗; 石井 一成; 工藤 正俊; 北野 雅之; 上嶋 一臣; 井上 達夫; 矢田 典久; 村上 卓道; 工藤 正幸第2回大阪消化器画像・IVR研究会  2011/09  大阪  第2回大阪消化器画像・IVR研究会A randomized, double-blind, placebo-controlled phase III study (EVOLVE-1) evaluating the efficacy and safety of everolimus in advanced HCC after failure of sorafenib treatment.  [Not invited]Andrew X. Zhu; 工藤 正俊; Dalila Sellami Oezlem Anak; Li-Tzong ChenInternational Liver Cancer Association Fifth Annual Conference (ILCA) 2011  2011/09  Hong Kong, China  International Liver Cancer Association Fifth Annual Conference (ILCA) 2011Observed Patterns of Systemic Therapy Use in Hepatocellular Carcinoma (HCC) Patients From the Multinational HCC BRIDGE Study: An Initial Overall Analysis  [Not invited]Lewis Roberts; 工藤 正俊; Massimo Colombo; Myron Schwartz; Fran?oise Degos; Morris Sherman; Pei-Jer Chen; Minshan Chen; Joong-Won Park; Phillip Johnson; Terry Therneau; Baisong HuangInternational Liver Cancer Association Fifth Annual Conference (ILCA) 2011  2011/09  Hong Kong, China  International Liver Cancer Association Fifth Annual Conference (ILCA) 2011Observations of Hepatocellular Carcinoma (HCC) Management Patterns From the Multinational HCC BRIDGE Study: An Interim Overall Analysis  [Not invited]Morris Sherman; 工藤 正俊; Massimo Colombo; Lewis Roberts Terry Therneau; Myron Schwartz; Fran?oise Degos; Pei-Jer Chen; Minshan Chen; Joong-Won Park; Phillip Johnson; Baisong HuangInternational Liver Cancer Association Fifth Annual Conference (ILCA) 2011  2011/09  Hong Kong, China  International Liver Cancer Association Fifth Annual Conference (ILCA) 2011Sorafenib treatment and safety profile in Child Pugh B patients characterized in first interim results of GIDEON (Global Investigation of Therapeutic Decisions In Hepatocellular Carcinoma And Of Its Treatment With Sorafenib).  [Not invited]Jean-Pierre Bronowicki; 工藤 正俊; Ho Yeong Lim; Per St?l; Jorge A. Marrero; Alan Venook; Sheng-Long Ye66th Annual Meeting of the German Society for Digestive and Metabolic Diseases  2011/09  Leipzig, Germany  66th Annual Meeting of the German Society for Digestive and Metabolic DiseasesFuture prospectcs of ultrasound diagnosis for diffuse liver disease. Symposium“Hitachi Aloka Medical Ltd.: The next generation in high-resolution imaging technology and elastography”  [Not invited]工藤 正俊13th World Congress of the world federation for ultrasound in medicine and biology (WFUMB) 2011  2011/08  Vienna, Austria  13th World Congress of the world federation for ultrasound in medicine and biology (WFUMB) 2011US-guided ablation of HCC. “US-guided tumor theraphy”  [Not invited]工藤 正俊13th World Congress of the world federation for ultrasound in medicine and biology (WFUMB) 2011  2011/08  Vienna, Austria  13th World Congress of the world federation for ultrasound in medicine and biology (WFUMB) 2011Lecture “Future prospects of ultrasound diagnosis for diffuse liver disease."  [Not invited]工藤 正俊The next generation in high-resolution imaging technology and elastgraphy  2011/08  Vienna, Austria  The next generation in high-resolution imaging technology and elastgraphy特別講演「肝疾患最近の話題」  [Not invited]工藤 正俊香川ベアネットカンファレンス  2011/08  全日空ホテルクレメント高松, 香川  香川ベアネットカンファレンスInterventional EUS for pancreatic tumours.  [Not invited]工藤 正俊13th World Congress of the world federation for ultrasound in medicine and biology (WFUMB) 2011  2011/08  Vienna, Austria  13th World Congress of the world federation for ultrasound in medicine and biology (WFUMB) 2011Cirrhotic liver.  [Not invited]工藤 正俊; F. Piscaglia13th World Congress of the world federation for ultrasound in medicine and biology (WFUMB) 2011  2011/08  Vienna, Austria  13th World Congress of the world federation for ultrasound in medicine and biology (WFUMB) 2011インフリキシマブが有効であった難治性潰瘍性大腸炎の1例.  [Not invited]高山 政樹; 大本 俊介; 峯 宏昌; 永田 嘉昭; 永井 知行; 川崎 正憲; 朝隈 豊; 櫻井 俊治; 松井 繁長; 樫田 博史; 工藤 正俊; 山本 典雄; 辻 直子; 船井 貞往; 富田 尚裕; 池内日本消化器病学会近畿支部第95回例会  2011/08  大阪国際交流センター, 大阪  日本消化器病学会近畿支部第95回例会難治性潰瘍性大腸炎に対する白血球除去療法の有用性と問題点の検討.  [Not invited]峯 宏昌; 櫻井 俊治; 大本 俊介; 高山 政樹; 永井 知行; 永田 嘉昭; 川崎 正憲; 朝隈 豊; 松井 繁長; 樫田 博史; 工藤 正俊日本消化器病学会近畿支部第95回例会  2011/08  大阪国際交流センター, 大阪  日本消化器病学会近畿支部第95回例会Predicting length of stay in patients admitted with acute upper gastrointestinal bleeding using Rockall score.  [Not invited]Hasmoni Hadzri; 工藤 正俊日本消化器病学会近畿支部第95回例会  2011/08  大阪国際交流センター, 大阪  日本消化器病学会近畿支部第95回例会Interventional radiologyにおける新しい支援画像「FlightPlan」の初期臨床経験.  [Not invited]南 康範; 足立 哲平; 有住 忠晃; 早石 宗右; 田北 雅弘; 北井 聡; 矢田 典久; 井上 達夫; 萩原 智; 上嶋 一臣; 工藤 正俊; 村上 卓道; 柳生 行伸日本消化器病学会近畿支部第95回例会  2011/08  大阪国際交流センター, 大阪  日本消化器病学会近畿支部第95回例会経皮的ラジオ波焼灼術後の後出血予防における穿刺経路焼灼の有効性の検討.  [Not invited]早石 宗右; 南 康範; 足立 哲平; 有住 忠晃; 田北 雅弘; 北井 聡; 矢田 典久; 井上 達夫; 萩原 智; 上嶋 一臣; 工藤 正俊; 鄭 浩柄日本消化器病学会近畿支部第95回例会  2011/08  大阪国際交流センター, 大阪  日本消化器病学会近畿支部第95回例会肝細胞癌に対するラジオ波焼灼療法の治療効果判定~造影超音波検査と造影CTの比較検討~.  [Not invited]井上 達夫; 畑中 絹世; 有住 忠晃; 早石 宗右; 田北 雅弘; 北井 聡; 矢田 典久; 萩原 智; 南 康範; 上嶋 一臣; 工藤 正俊日本消化器病学会近畿支部第95回例会  2011/08  大阪国際交流センター, 大阪  日本消化器病学会近畿支部第95回例会術前診断が困難であった肝血管肉腫の一例.  [Not invited]足立 哲平; 早石 宗右; 有住 忠晃; 田北 雅弘; 北井 聡; 矢田 典久; 井上 達夫; 萩原 智; 南 康範; 上嶋 一臣; 工藤 正俊; 土師 誠二; 武本 昌子; 鄭 浩柄日本消化器病学会近畿支部第95回例会  2011/08  大阪国際交流センター, 大阪  日本消化器病学会近畿支部第95回例会膵尾部腫瘤を形成した自己免疫性膵炎(IgG4関連疾患)の一例.  [Not invited]松本 望; 高場 雄久; 奥村 直己; 山本 典雄; 冨田 崇文; 梅原 康湖; 森村 正嗣; 米田 円; 山田 哲; 辻 直子; 落合 健; 前倉 俊治; 南 康範; 工藤 正俊日本消化器病学会近畿支部第95回例会  2011/08  大阪国際交流センター, 大阪  日本消化器病学会近畿支部第95回例会胃腫瘍ESDにおける後出血例の検討と対策. ワークショップ「上部消化器及び小腸出血における最近の動向」  [Not invited]朝隈 豊; 松井 繁長; 大本 俊介; 高山 政樹; 峯 宏昌; 永井 知行; 永田 嘉昭; 川崎 正憲; 櫻井 俊治; 樫田 博史; 工藤 正俊日本消化器病学会近畿支部第95回例会  2011/08  大阪国際交流センター, 大阪  日本消化器病学会近畿支部第95回例会潰瘍性大腸炎合併colitic cancerに対し大腸全摘及び内肛門括約筋切除術を施行した一例.  [Not invited]千品 寛和; 櫻井 俊治; 高山 政樹; 峯 宏昌; 永田 嘉昭; 永井 知行; 川崎 正憲; 朝隈 豊; 松井 繁長; 樫田 博史; 工藤 正俊; 肥田 仁一日本消化器病学会近畿支部第95回例会  2011/08  大阪国際交流センター, 大阪  日本消化器病学会近畿支部第95回例会進行胃癌にgastric emphysemaを合併した1例.  [Not invited]細本 宜志; 宮部 欽生; 木下 大輔; 秦 康倫; 奥田 英之; 茂山 朋広; 豊澤 昌子; 岸谷 讓; 川崎 俊彦; 工藤 正俊日本消化器病学会近畿支部第95回例会  2011/08  大阪国際交流センター, 大阪  日本消化器病学会近畿支部第95回例会小膵癌におけるUS, MDCT, EUS(CH-EUS)の診断能の比較検討. ワークショップ「膵腫瘍性病変の診断と治療」  [Not invited]宮田 剛; 坂本 洋城; 門阪 薫平; 鎌田 研; 今井 元; 小牧 孝充; 北野 雅之; 工藤 正俊日本消化器病学会近畿支部第95回例会  2011/08  大阪国際交流センター, 大阪  日本消化器病学会近畿支部第95回例会進行肝細胞癌に対する分子標的治療を先行した肝切除の妥当性. シンポジウム「進行肝細胞癌に対する治療戦略」  [Not invited]土師 誠二; 竹山 宜典; 上嶋 一臣; 工藤 正俊日本消化器病学会近畿支部第95回例会  2011/08  大阪国際交流センター, 大阪  日本消化器病学会近畿支部第95回例会進行肝細胞癌に対するソラフェニブ投与例におけるSDの持続期間と生存期間の検討. シンポジウム「進行肝細胞癌に対する治療戦略」  [Not invited]有住 忠晃; 上嶋 一臣; 工藤 正俊日本消化器病学会近畿支部第95回例会  2011/08  大阪国際交流センター, 大阪  日本消化器病学会近畿支部第95回例会診断に苦慮した後腹膜腫瘍の1例.  [Not invited]花田 宗一郎; 奥田 英之; 秦 康倫; 木下 大輔; 茂山 朋広; 宮部 欽生; 豊澤 昌子; 岸谷 讓; 川崎 俊彦; 工藤 正俊日本消化器病学会近畿支部第95回例会  2011/08  大阪国際交流センター, 大阪  日本消化器病学会近畿支部第95回例会瀉血療法が著効したNASHの1例.  [Not invited]木下 大輔; 川崎 俊彦; 茂山 朋広; 秦 康倫; 奥田 英之; 宮部 欽生; 豊澤 昌子; 岸谷 讓; 工藤 正俊日本消化器病学会近畿支部第95回例会  2011/08  大阪国際交流センター, 大阪  日本消化器病学会近畿支部第95回例会保存的治療で軽快した外傷性肝損傷の1例.  [Not invited]秦 康倫; 豊澤 昌子; 木下 大輔; 奥田 英之; 茂山 朋広; 宮部 欽生; 岸谷 讓; 川崎 俊彦; 工藤 正俊日本消化器病学会近畿支部第95回例会  2011/08  大阪国際交流センター, 大阪  日本消化器病学会近畿支部第95回例会Comparative study between EUS-guided celiac plezus neurolysis and EUS-guided broad neurolysis. VTRシンポジウム「Interventional EUSの最前線」  [Not invited]坂本 洋城; 北野 雅之; 工藤 正俊第81回日本消化器内視鏡学会総会  2011/08  名古屋国際会議場, 愛知  第81回日本消化器内視鏡学会総会特徴的な画像所見を呈し、肝転移巣からのEUS-FNAにより退形成癌と診断された1例.  [Not invited]大西 佐代子; 北野 雅之; 工藤 正俊; 門阪 薫平; 宮田 剛; 鎌田 研; 今井 元; 坂本 洋城; 小牧 孝充日本消化器病学会近畿支部第95回例会  2011/08  大阪国際交流センター, 大阪  日本消化器病学会近畿支部第95回例会FDP-PETにて治療経過を観察しえた腫瘤形成型膵炎像を呈した自己免疫性膵炎の一例.  [Not invited]門阪 薫平; 坂本 洋城; 北野 雅之; 小牧 孝充; 今井 元; 鎌田 研; 宮田 剛; 工藤 正俊; 筑後 孝章; 土手 健作; 廣岡 知臣; 高柳日本消化器病学会近畿支部第95回例会  2011/08  大阪国際交流センター, 大阪  日本消化器病学会近畿支部第95回例会Special Lecture “Design and conduct of clinical trials for the design and rational of clinical tirals for the combination of hepatic arterial infusion chemotherapy with molecular targeted agents.”  [Not invited]工藤 正俊The 2nd Asia-Pacific Primary Liver Cancer Expert Meeting (APPLE)  2011/07  Osaka, Japan  The 2nd Asia-Pacific Primary Liver Cancer Expert Meeting (APPLE)Special Lecture “Current situation of HCC management in Japan.”  [Not invited]工藤 正俊The 2nd Asia-Pacific Primary Liver Cancer Expert Meeting (APPLE)  2011/07  Osaka, Japan  The 2nd Asia-Pacific Primary Liver Cancer Expert Meeting (APPLE)Special Lecture “EVOLVE-1 trial.”  [Not invited]工藤 正俊The 2nd Asia-Pacific Primary Liver Cancer Expert Meeting (APPLE)  2011/07  Osaka, Japan  The 2nd Asia-Pacific Primary Liver Cancer Expert Meeting (APPLE)Special Lecture “RECICL.”  [Not invited]工藤 正俊The 2nd Asia-Pacific Primary Liver Cancer Expert Meeting (APPLE)  2011/07  Osaka, Japan  The 2nd Asia-Pacific Primary Liver Cancer Expert Meeting (APPLE)特別講演「肝癌に対する分子標的治療の現状とOngoing Trial」  [Not invited]工藤 正俊肝細胞癌ソラフェニブ治療研究会  2011/07  名古屋東急ホテル, 愛知  肝細胞癌ソラフェニブ治療研究会CT perfusionを用いた肝細胞癌に対するソラフェニブの効果判定の検討  [Not invited]村上 卓道; 香川 祐毅; 岡田 真広; 兵頭 朋子; 日高 正二朗; 柳生 行伸; 熊野 正士; 柏木 伸夫; 小塚 健倫; 今岡 いずみ; 足利 竜一朗; 石井 一成; 工藤 正俊; 北野 雅之; 上嶋 一臣; 井上 達夫; 矢田 典久; 工藤 正幸第11回関西肝血流動態イメージ研究会  2011/07  第11回関西肝血流動態イメージ研究会Sonazoidを用いた造影超音波ガイド下ラジオ波焼灼術の有用性. シンポジウム「超音波を用いた肝細胞癌治療の更なる進歩」  [Not invited]南 康範; 工藤 正俊第47回日本肝癌研究会  2011/07  静岡県コンベンションアーツセンター, 静岡  第47回日本肝癌研究会進行肝細胞癌に対するソラフェニブ投与例におけるSDの持続期間と生存期間の検討.  [Not invited]有住 忠晃; 上嶋 一臣; 工藤 正俊第47回日本肝癌研究会  2011/07  静岡県コンベンションアーツセンター, 静岡  第47回日本肝癌研究会ソラフェニブによりCRとなった進行肝細胞癌2症例の臨床的特徴について. ワークショップ「ソラフェニブによりRECISTにてCR例の集積から特徴を掴む」  [Not invited]上嶋 一臣; 有住 忠晃; 早石 宗右; 北井 聡; 矢田 典久; 萩原 智; 井上 達夫; 南 康範; 櫻井 俊治; 工藤 正俊第47回日本肝癌研究会  2011/07  静岡県コンベンションアーツセンター, 静岡  第47回日本肝癌研究会肝細胞癌治療におけるJNK活性の重要性-ソラフェニブ治療効果との関連も含めて-. シンポジウム「肝細胞癌に対する分子標的治療の基礎と臨床」  [Not invited]萩原 智; 櫻井 俊治; 工藤 正俊第47回日本肝癌研究会  2011/07  静岡県コンベンションアーツセンター, 静岡  第47回日本肝癌研究会シンポジウム・特別発言「超音波を用いた肝細胞癌治療の更なる進歩」  [Not invited]工藤 正俊第47回日本肝癌研究会  2011/07  静岡県コンベンションアーツセンター, 静岡  第47回日本肝癌研究会金属ステントが有用であった良性胆道狭窄の2例.  [Not invited]宮田 剛; 鎌田 研; 今井 元; 坂本 洋城; 小牧 孝充; 北野 雅之; 工藤 正俊第42回日本膵臓学会大会  2011/07  ホテルニューキャッスル, 青森  第42回日本膵臓学会大会IPMNおよび併存膵癌の診断におけるEUSの役割.  [Not invited]鎌田 研; 北野 雅之; 工藤 正俊; 宮田 剛; 今井 元; 坂本 洋城; 小牧 孝充; 安田 武生; 竹山 宜典第42回日本膵臓学会大会  2011/07  ホテルニューキャッスル, 青森  第42回日本膵臓学会大会当院におけるEUS下膵仮性嚢胞ドレナージ術の成績.  [Not invited]今井 元; 北野 雅之; 鎌田 研; 宮田 剛; 門阪 薫平; 坂本 洋城; 小牧 孝充; 工藤 正俊; 竹山 宜典第42回日本膵臓学会大会  2011/07  ホテルニューキャッスル, 青森  第42回日本膵臓学会大会特別講演「肝癌診療の新しいパラダイム」  [Not invited]工藤 正俊第28回烏城消化器カンファレンス  2011/07  岡山プラザホテル, 岡山  第28回烏城消化器カンファレンス肝臓癌におけるmTOR阻害剤開発の現状. シンポジウム「PI3K/Akt/mTOR経路阻害剤の基礎と臨床」  [Not invited]工藤 正俊第9回日本臨床腫瘍学会学術集会  2011/07  パシフィコ横浜, 神奈川  第9回日本臨床腫瘍学会学術集会Phase I/II study of Sorafenib in combination with low-dose cisplatin and fluorouracil intra-arterial infusion chemotherapy. International Session “Hepato-biliary-pancreatic Cancer”  [Not invited]上嶋 一臣; 工藤 正俊; 南 康範; 田中 正俊; 熊田 卓The 9th Annual Meeting of Japanese Society of Medical Ocology  2011/07  Yokohama, Japan  The 9th Annual Meeting of Japanese Society of Medical Ocology膵臓癌の血漿中血管新生関連分子の検討.  [Not invited]木村 英晴; 荒尾 徳三; 松本 和子; 古田 一行; 工藤 可苗; 永井 知行; 坂本 洋城; 北野 雅之; 工藤 正俊; 西尾 和人日本がん分子標的治療学会第15回学術集会  2011/06  ホテル日航東京, 東京  日本がん分子標的治療学会第15回学術集会ソラフェニブは肝細胞癌株のHGF誘導性上皮間葉移行を阻害する.  [Not invited]永井 知行; 荒尾 徳三; 古田 一行; 金田 裕靖; 工藤 可苗; 青松 圭一; 田村 大介; 坂井 和子; 木村 英晴; 藤田 至彦; 松本 和子; 工藤 正俊; 西條 長宏; 西尾 和人日本がん分子標的治療学会第15回学術集会  2011/06  ホテル日航東京, 東京  日本がん分子標的治療学会第15回学術集会噴門部静脈瘤合併巨木型食道静脈瘤の内視鏡的治療.  [Not invited]松井 繁長; 峯 宏昌; 高山 政樹; 永田 嘉昭; 川崎 正憲; 朝隈 豊; 櫻井 俊治; 樫田 博史; 工藤 正俊第20回近畿食道・胃静脈瘤研究会  2011/06  大阪薬業年金会館, 大阪  第20回近畿食道・胃静脈瘤研究会C型代償性肝硬変患者に対するペグインターフェロンα-2a/リバビリン併用療法の有効性及び安全性の検討.  [Not invited]泉 並木; 工藤 正俊; 金子 周一; 西口 修平; 佐田 通夫; 小俣 政男第47回日本肝臓学会総会  2011/06  ホテルグランパシフィック LE DAIBA, 東京  第47回日本肝臓学会総会PEG-IFN α-2a/RBV併用療法におけるResponse-Guided Therapyの有用性: IL28B多型との関連性を踏まえて.  [Not invited]岩井 孝史; 工藤 正俊; 西口 修平; 樋口 和秀; 城村 尚登; 大崎 往夫; 岡崎 和一; 關 壽人; 金 守良第47回日本肝臓学会総会  2011/06  ホテルグランパシフィック LE DAIBA, 東京  第47回日本肝臓学会総会慢性肝疾患においてEOB-MRI肝細胞相で低信号を示す乏血性結節の多血化に関与する因子の検討.  [Not invited]小来田 幸世; 兵頭 朋子; 岡田 真広; 香川 祐毅; 熊野 正士; 工藤 正俊; 村上 卓道; 今井 康陽; 澤井; 良之; 井倉; 枝; 福田 和人; 堀 雅敏第47回日本肝臓学会総会 ワークショップ「肝癌画像診断の進歩」  2011/06  ホテルグランパシフィック LE DAIBA, 東京  第47回日本肝臓学会総会 ワークショップ「肝癌画像診断の進歩」  1541. 2011 小来田幸世, 今井康陽, 兵頭朋子, 岡田真広, 香川祐毅, 澤井良之, 井倉 枝, 福田和人, 熊野正士, 堀 雅敏, 工藤正俊, 村上卓道: , , 平成23年6月2-3日, .肝細胞癌治療におけるJNK活性の重要性-ソラフェニブ治療効果との関連も含めて-.  [Not invited]萩原 智; 櫻井 俊治; 工藤 正俊第47回日本肝臓学会総会 シンポジウム「テーラーメイド医療時代へ向けた肝癌治療」  2011/06  ホテルグランパシフィック LE DAIBA, 東京  第47回日本肝臓学会総会 シンポジウム「テーラーメイド医療時代へ向けた肝癌治療」肝膿瘍の治療経過の中で直腸癌が見つかった1例  [Not invited]丸山 康典; 松本 望; 高場 雄久; 奥村 直己; 山本 典雄; 梅原 康湖; 南 康範; 辻 直子; 落合 健; 工藤 正俊第194回 日本内科学会近畿地方会  2011/06  奈良市  第194回 日本内科学会近畿地方会Special Invited Lecture “Sonazoid-enhanced US in the management of HCC”  [Not invited]工藤 正俊XV Congress of the Latin American Federation for Ultrasound in Medicine and Biology (FLAUS)  2011/06  Asuncion, Paraguay  XV Congress of the Latin American Federation for Ultrasound in Medicine and Biology (FLAUS)Improved survival in patients with hepatocellular carcinoma over 30 years in Japan: Analysis of nationwide prospective registry of 148,161 patients.  [Not invited]工藤 正俊; 泉 並木; 坂元 亨宇; 松山 裕; 市田 隆文; 中島 收; 松井 修; 具 英成; 國土 典宏; 幕内 雅敏American Society of Clinical Oncology (ASCO) 2011 Annual Meeting  2011/06  Chicago, USA  American Society of Clinical Oncology (ASCO) 2011 Annual MeetingGIDEON (Global Investigation Of Therapeutic Decisions In Hepatocellular Carcinoma [HCC] And Of Its Treatment With Sorafenib) 2nd interim analysis in >1500 patients: clinical findings in patients with liver dysfunction.  [Not invited]Jorge Marrero; 工藤 正俊; Riccardo Lencioni; Sheng-Long Ye; Alan VenookAmerican Society of Clinical Oncology (ASCO) 2011 Annual Meeting  2011/06  Chicago, USA  American Society of Clinical Oncology (ASCO) 2011 Annual MeetingPhase 3 trial of sunitinib (Su) versus sorafenib (So) in advanced hepatocellular carcinoma (HCC).  [Not invited]Ann-Lii Cheng; 工藤 正俊; Yoon-Koo Kang; Deng-Yn Lin; Joong-Won Park; Shukui Qin; Masao Omata; Eric RaymondAmerican Society of Clinical Oncology (ASCO) 2011 Annual Meeting  2011/06  Chicago, USA  American Society of Clinical Oncology (ASCO) 2011 Annual MeetingRandomized trial of axitinib versus placebo in patients with advanced hepatocellular carcinoma (HCC) following failure of one prior antiangiogenic therapy.  [Not invited]Ann-Li Cheng; 工藤 正俊; Yoon-Koo Kang; Shukui Qin; Eric RaymondAmerican Society of Clinical Oncology (ASCO) 2011 Annual Meeting  2011/06  Chicago, USA  American Society of Clinical Oncology (ASCO) 2011 Annual Meeting特別講演「肝癌の造影超音波」 お昼の勉強会「Aplioが創る超音波の新潮流」  [Not invited]工藤 正俊第84回日本超音波医学会総会  2011/05  グランドプリンスホテル新高輪, 東京  第84回日本超音波医学会総会Luncheon “Hepatocellular carcinoma: prevention and treatment by interferon.”  [Not invited]工藤 正俊The Japanese Society for Interferon and Cytokine Research-The Japanese Society for Macrophage Molecu  2011/05  Osaka, Japan  The Japanese Society for Interferon and Cytokine Research-The Japanese Society for Macrophage Molecu胆膵領域おけるEUSガイド下ドレナージ術の当院での治療成績.  [Not invited]今井 元; 北野 雅之; 工藤 正俊日本超音波医学会第84回学術集会 特別企画「消化器インターベンションと超音波」  2011/05  グランドプリンスホテル新高輪, 東京  日本超音波医学会第84回学術集会 特別企画「消化器インターベンションと超音波」C型肝炎治療におけるReal-time Tissue Elastographyを用いた肝線維化の非侵襲的評価法.  [Not invited]藤本 研治; 矢田 典久; 上嶋 一臣; 工藤 正俊; 石田 哲士; 椎名 毅; 加藤 道夫日本超音波医学会第84回学術集会 特別企画「びまん性肝疾患2011(組織性状・コントラスト・硬さ評価)」  2011/05  グランドプリンスホテル新高輪, 東京  日本超音波医学会第84回学術集会 特別企画「びまん性肝疾患2011(組織性状・コントラスト・硬さ評価)」内視鏡医の立場からみた消化管超音波検査.  [Not invited]樫田 博史; 前川 清; 工藤 正俊日本超音波医学会第84回学術集会 特別企画「消化管超音波検査を普及させるには?」  2011/05  グランドプリンスホテル新高輪, 東京  日本超音波医学会第84回学術集会 特別企画「消化管超音波検査を普及させるには?」日本超音波医学会と消化器関連学会と連携: 問題点は何か?  [Not invited]工藤 正俊日本超音波医学会第84回学術集会 特別企画「日本超音波医学会の役目は何か?(他の超音波関連学会との連携)」  2011/05  グランドプリンスホテル新高輪, 東京  日本超音波医学会第84回学術集会 特別企画「日本超音波医学会の役目は何か?(他の超音波関連学会との連携)」肝疾患診断と硬さ計測-各モダリティーにおける測定原理と結果の解釈.  [Not invited]矢田 典久; 工藤 正俊日本超音波医学会第84回学術集会 特別企画「硬さの基礎 硬さを測る方法を整理して理解する」  2011/05  グランドプリンスホテル新高輪, 東京  日本超音波医学会第84回学術集会 特別企画「硬さの基礎 硬さを測る方法を整理して理解する」Special Invited Lecture “Sonazoid-enhanced US in the management of HCC”  [Not invited]工藤 正俊The 42nd Annual Congress of the Korean Society of Ultrasound in Medicine (KSUM)  2011/05  Seoul, Korea  The 42nd Annual Congress of the Korean Society of Ultrasound in Medicine (KSUM)特別講演「コンセンサスに基づく肝細胞癌診断アルゴリズム」  [Not invited]工藤 正俊第15回TCEL MR meeting  2011/05  東京コンファレンスセンター, 東京  第15回TCEL MR meetingEUSによる自己免疫性膵炎の検討.  [Not invited]小牧 孝充; 北野 雅之; 坂本 洋城; 今井 元; 鎌田 研; 工藤 正俊第97回日本消化器病学会総会 ミニシンポジウム  2011/05  京王プラザホテル, 東京  第97回日本消化器病学会総会 ミニシンポジウムB型慢性肝炎に対するPRG-IFNa2bとエンテカビル48週併用療法の有効性について.  [Not invited]萩原 智; 峯 宏昌; 有住 忠晃; 早石 宗右; 上田 泰輔; 田北 雅弘; 畑中 絹世; 北井 聡; 矢田 典久; 井上 達夫; 鄭 浩柄; 櫻井 俊治; 上嶋 一臣; 工藤 正俊; 犬塚 義; 大﨑第97回日本消化器病学会総会  2011/05  京王プラザホテル, 東京  第97回日本消化器病学会総会当院における早期慢性膵炎症例.  [Not invited]小牧 孝充; 北野 雅之; 工藤 正俊第97回日本消化器病学会総会 パネルディスカッション「慢性膵炎早期診断への新たなアプローチ~概念、機能、画像診断~  2011/05  京王プラザホテル, 東京  第97回日本消化器病学会総会 パネルディスカッション「慢性膵炎早期診断への新たなアプローチ~概念、機能、画像診断~Role of EUS in detection and follow-up of intraductal papillary mucinous neoplasms and concomitant invasive carcinomas.  [Not invited]鎌田 研; 北野 雅之; 工藤 正俊; 今井 元; 小牧 孝充; 坂本 洋城Digestive Disease Week (DDW) 2011  2011/05  Chicago, USA  Digestive Disease Week (DDW) 2011Dynamic imaging of gallbladder diseases by contrast-enahanced harmonic EUS.  [Not invited]鎌田 研; 北野 雅之; 工藤 正俊; 今井 元; 小牧 孝充; 坂本 洋城Digestive Disease Week (DDW) 2011  2011/05  Chicago, USA  Digestive Disease Week (DDW) 2011EUS-guided gallbladder drainage as an alternative treatment for malignant biliary obstruction after unsuccessful ERCP: Outcomes of long term follow-up.  [Not invited]北野 雅之; 今井 元; 鎌田 研; 小牧 孝充; 坂本 洋城; 工藤 正俊Digestive Disease Week (DDW) 2011  2011/05  Chicago, USA  Digestive Disease Week (DDW) 2011P38alpha inhibits liver fibrogenesis and consequent hepatocarcinogenesis by curtailing accumulation of reactive oxygen species.  [Not invited]櫻井 俊治; 工藤 正俊; 上嶋 一臣; 松井 繁長; 樫田 博史Digestive Disease Week (DDW) 2011  2011/05  Chicago, USA  Digestive Disease Week (DDW) 2011Assessment of hepatobilliary phase Gd-EOB-DTPA-Enhanced MRI for HCC and borderline lesions and comparison of detection ability versus MDCT.  [Not invited]井上 達夫; 工藤 正俊; 岡田 真広; 村上 卓道; 小無田; 美菜; 坂元; 亨Digestive Disease Week (DDW) 2011  2011/05  Chicago, USA  Digestive Disease Week (DDW) 2011The usefulness of helicobacter pylori eradication therapy for the healing artifical gastric ulcer after endoscopic submucosal dissection for early gastric cancer.  [Not invited]川崎 正憲; 朝隈 豊; 松井 繁長; 櫻井 俊治; 樫田 博史; 工藤 正俊Digestive Disease Week (DDW) 2011  2011/05  Chicago, USA  Digestive Disease Week (DDW) 2011Evaluation of the response to chemotherapy in advanced gastric cancer by contrast-enhanced harmonic EUS.  [Not invited]松井 繁長; 工藤 正俊; 岡田 無文; 朝隈 豊; 川崎 正憲; 櫻井 俊治; 樫田 博史Digestive Disease Week (DDW) 2011  2011/05  Chicago, USA  Digestive Disease Week (DDW) 2011Prevention of delayed bleeding after endoscopic submucosal dissection (ESD) for gastric tumors.  [Not invited]朝隈 豊; 松井 繁長; 川崎 正憲; 櫻井 俊治; 樫田 博史; 工藤 正俊Digestive Disease Week (DDW) 2011  2011/05  Chicago, USA  Digestive Disease Week (DDW) 2011Peginterferon alfa-2a (40KD) plus ribavirin for the treatment of patients with chronic hepatitis C and compensated liver cirrhosis in Japan.  [Not invited]泉 並木; 工藤 正俊; 金子 周一; 西口 修平; 佐田 通夫; 小俣 政男Digestive Disease Week (DDW) 2011Chicago, USA  2011/05  Digestive Disease Week (DDW) 2011Chicago, USASpecial Focus Session “Update on endoscopic USG: hoe much for imaging, needling, or therapy?”  [Not invited]工藤 正俊The 42nd Annual Congress of the Korean Society of Ultrasound in Medicine (KSUM)  2011/05  Seoul, Korea  The 42nd Annual Congress of the Korean Society of Ultrasound in Medicine (KSUM)Contrast enhanced harmonic EUS imaging of submucosal tumor of gastrointestinal tract.  [Not invited]坂本 洋城; 北野 雅之; 鎌田 研; 松井 繁長; 朝隈 豊; 工藤 正俊Digestive Disease Week (DDW) 2011  2011/05  Chicago, USA  Digestive Disease Week (DDW) 2011EUS-guided broad plexus-neurolysis over the superior mesenteric artery.  [Not invited]坂本 洋城; 北野 雅之; 鎌田 研; 工藤 正俊Digestive Disease Week (DDW) 2011  2011/05  Chicago, USA  Digestive Disease Week (DDW) 2011胃十二指腸静脈瘤出血に対する内視鏡的止血術.  [Not invited]松井 繁長; 樫田 博史; 峯 宏昌; 永田 嘉昭; 川崎 正憲; 朝隈 豊; 櫻井 俊治; 工藤 正俊第3回集学的静脈瘤治療研究会  2011/04  青森文化会館, 青森  第3回集学的静脈瘤治療研究会切除不能悪性中下部胆道狭窄に対する胆管ステンティングの検討.  [Not invited]今井 元; 北野 雅之; 工藤 正俊; 鎌田 研; 坂本 洋城; 小牧 孝充; 宮田 剛第81回日本消化器内視鏡学会総会  2011/04  ホテル青森, 青森  第81回日本消化器内視鏡学会総会コンベックス型EUSによる胆膵領域のスクリーニング. パネルディスカッション 胆膵内視鏡の基本  [Not invited]鎌田 研; 北野 雅之; 工藤 正俊第81回日本消化器内視鏡学会総会  2011/04  ホテル青森, 青森  第81回日本消化器内視鏡学会総会造影ハーモニックEUSシステムの開発と臨床応用. パネルディスカッション 内視鏡関連機器の進歩と課題  [Not invited]北野 雅之; 坂本 洋城; 工藤 正俊第81回日本消化器内視鏡学会総会  2011/04  ホテル青森, 青森  第81回日本消化器内視鏡学会総会経乳頭的治療困難例におけるEUSガイド下胆道ドレナージ術.  [Not invited]宮田 剛; 鎌田 研; 今井 元; 小牧 孝充; 坂本 洋城; 北野 雅之; 工藤 正俊第81回日本消化器内視鏡学会総会  2011/04  ホテル青森, 青森  第81回日本消化器内視鏡学会総会悪性胃十二指腸狭窄に対するself-expandable-metal-stentの有用性について.  [Not invited]今井 元; 北野 雅之; 工藤 正俊; 鎌田 研; 坂本 洋城; 小牧 孝充第81回日本消化器内視鏡学会総会  2011/04  ホテル青森, 青森  第81回日本消化器内視鏡学会総会シンポジウム 超音波医療の最前線「消化器領域の超音波診療最前線」  [Not invited]工藤 正俊第28回日本医学総会  2011/04  東京国際フォーラム, 東京  第28回日本医学総会Expression levels of EMT-related genes in hepatocellular carcinoma.  [Not invited]永井 知行; 荒尾 徳三; 松本 和子; 工藤 可苗; 萩原 智; 櫻井 俊治; 上嶋 一臣; 土師 誠二; 工藤 正俊; 西尾 和人AACR 102th Annual Meeting 2011  2011/04  Florida, USA  AACR 102th Annual Meeting 2011Serum concentrations of Angiogenesis-related molecules in Patients with Pancreatic Cancer.  [Not invited]木村 英晴; 坂本 洋城; 永井 知行; 工藤 可苗; 古田 一行; 荒尾 徳三; 北野 雅之; 工藤 正俊; 西尾 和人AACR 102th Annual Meeting 2011  2011/04  Florida, USA  AACR 102th Annual Meeting 2011GIDEON (Global Investigation of therapeutic DEcisions in hepatocellular carcinoma and Of its treatment with sorafeNib) study first interim results, Sorafenib dosing across regions and disease subgroups.  [Not invited]Jean-Pierre Bronowicki; 工藤 正俊; Riccardo Lencioni; Alan Venook; Jorge Marrero; Sheng-Long Ye46th Annual Meeting of the European Association for the Sudy of the Liver (EASL)  2011/03  Berlin, Germany  46th Annual Meeting of the European Association for the Sudy of the Liver (EASL)Stakeholder involvement in priority setting of strategies to improve liver cancer control policy in Asia.  [Not invited]John FP Bridges; 工藤 正俊; Gisselle Gallego; BPharm; Kiwamu Okita; Kwang-Hyub Han; Sheng-Long Ye; Barri M Blauvelt46th Annual Meeting of the European Association for the Sudy of the Liver (EASL)  2011/03  Berlin, Germany  46th Annual Meeting of the European Association for the Sudy of the Liver (EASL)Special lecture “Treatment guideline of hepatocellular carcinoma: Asian perspective.”  [Not invited]工藤 正俊Asan Liver Center Opening Symposium  2011/03  Seoul, Korea  Asan Liver Center Opening Symposium早期胃癌と十二指腸MALTリンパ腫を併発した1例.  [Not invited]峯 宏昌; 松井 繁長; 朝隈 豊; 川崎 正憲; 永田 嘉昭; 櫻井 俊治; 樫田 博史; 工藤 正俊第86回日本消化器内視鏡学会近畿地方会  2011/03  京都テルサ, 京都  第86回日本消化器内視鏡学会近畿地方会食道小細胞癌の1例.  [Not invited]奥田 英之; 秦 康倫; 宮部 欽生; 茂山 朋広; 豊澤 昌子; 岸谷 譲; 川崎 俊彦; 池田 光憲; 工藤 正俊第86回日本消化器内視鏡学会近畿地方会  2011/03  京都テルサ, 京都  第86回日本消化器内視鏡学会近畿地方会当院におけるEUS下interventionの成績. シンポジウム「超音波内視鏡下穿刺術の意義と今後の展望」  [Not invited]今井 元; 北野 雅之; 工藤 正俊第86回日本消化器内視鏡学会近畿地方会  2011/03  京都テルサ, 京都  第86回日本消化器内視鏡学会近畿地方会当院における悪性胃十二指腸狭窄に対する消化管ステントの成績.パネルディスカッション「消化管ステント留置の苦痛と限界  [Not invited]今井 元; 北野 雅之; 工藤 正俊第86回日本消化器内視鏡学会近畿地方会  2011/03  京都テルサ, 京都  第86回日本消化器内視鏡学会近畿地方会Malignant gastric outlet obstruction (MGOO)に対するステント留置術と胃空腸吻合術の比較検討.パネルディスカッション「消化管ステント留置の苦痛と限界  [Not invited]山本 典雄; 辻 直子; 工藤 正俊第86回日本消化器内視鏡学会近畿地方会  2011/03  京都テルサ, 京都  第86回日本消化器内視鏡学会近畿地方会Worldwide trends in locoregional therapy for hepatocellular carcinoma (HCC): first interim analysis of the Global Investigation of therapeutic DEcisions in HCC and Of its treatment with sorafeNib (GIDEON) study.  [Not invited]JF Geschwind; 工藤 正俊; R Lencioni; J Marrero; A Venook; S-L YeSIR 36th Annual Scientific 2011 Meeting  2011/03  Chicago, USA  SIR 36th Annual Scientific 2011 Meeting腫瘤形成性膵炎と膵癌との鑑別診断に苦慮した一例.  [Not invited]小牧 孝充; 北野 雅之; 坂本 洋城; 今井 元; 鎌田 研; 工藤 正俊; 筑後 孝章; 竹山 宜典第54回日本消化器画像診断研究会  2011/02  昭和女子大学, 東京  第54回日本消化器画像診断研究会Endoscopic ultrasound (EUS)-guided transluminal endoscopic removal of gallstones.  [Not invited]鎌田 研; 宮田 剛; 今井 元; 坂本 洋城; 小牧 孝充; 北野 雅之; 工藤 正俊第9回FNA-Club Japan  2011/02  東京医科大学, 東京  第9回FNA-Club JapanSpecial lecture “Interventional US for pancreatic malignancy.”  [Not invited]工藤 正俊Innovative Practive in Ultrasound With Live Demonstration  2011/02  Bangkok, Thailand  Innovative Practive in Ultrasound With Live DemonstrationSpecial lecture “Diagnosis of pancreatic tumors by EUS-FNA and CE-EUS.”  [Not invited]工藤 正俊Innovative Practive in Ultrasound With Live Demonstration  2011/02  Bangkok, Thailand  Innovative Practive in Ultrasound With Live DemonstrationSpecial lecture “Sonazoid enhanced US for the management of liver cancer.”  [Not invited]工藤 正俊Innovative Practive in Ultrasound With Live Demonstration  2011/02  Bangkok, Thailand  Innovative Practive in Ultrasound With Live DemonstrationSpecial lecture "Double contrast US for surveillance of hepatoma.”  [Not invited]工藤 正俊Innovative Practive in Ultrasound With Live Demonstration  2011/02  Bangkok, Thailand  Innovative Practive in Ultrasound With Live DemonstrationGIDEON (Global Investigation of therapeutic DEcisions in hepatocellular carcinoma and Of its treatment with sorafeNib) interim results: Child-Pugh status subgroup analysis.  [Not invited]Si-Hyun Bae; 工藤 正俊; S-L Ye; J Marrero; R Lencioni; A VenookThe 21st Conference of the Asian Pacific Association for the Study of the Liver (APASL)  2011/02  Bangkok, Thailand  The 21st Conference of the Asian Pacific Association for the Study of the Liver (APASL)胃ESD後の後出血例の検討と対策.  [Not invited]朝隈 豊; 松井 繁長; 川崎 正憲; 永田 嘉昭; 櫻井 俊治; 樫田 博史; 工藤 正俊第7回日本消化管学会総会学術集会  2011/02  国立京都国際会館, 京都  第7回日本消化管学会総会学術集会Special lecture “Contrast enhanced endoscopic ultrasound value in the diagnosis of small pancreatic cancer.”  [Not invited]工藤 正俊World Federation for Ultrasound in Medicine and Biology (WFUMB) Centre of Excellence Workshop  2011/02  Jakarta, Indonesia  World Federation for Ultrasound in Medicine and Biology (WFUMB) Centre of Excellence WorkshopSpecial lecture “Sonazoid-enhanced US for hepatoma: Value of defect re-perfusion of imaging.”  [Not invited]工藤 正俊World Federation for Ultrasound in Medicine and Biology (WFUMB) Centre of Excellence Workshop  2011/02  Jakarta, Indonesia  World Federation for Ultrasound in Medicine and Biology (WFUMB) Centre of Excellence WorkshopSpecial lecture “Double contrast US for surveillance of hepatoma.”  [Not invited]工藤 正俊World Federation for Ultrasound in Medicine and Biology (WFUMB) Centre of Excellence Workshop  2011/02  Jakarta, Indonesia  World Federation for Ultrasound in Medicine and Biology (WFUMB) Centre of Excellence Workshop特別講演「肝細胞癌診療の新しいパラダイム」  [Not invited]工藤 正俊ウイルス肝炎講習会  2011/02  岐阜県医師会館, 岐阜  ウイルス肝炎講習会特別講演「ウイルス性肝炎」  [Not invited]工藤 正俊平成22年度「肝がん撲滅運動」  2011/02  大阪狭山市さやかホール, 大阪  平成22年度「肝がん撲滅運動」特別講演「肝癌診療ガイドラインと最新治療: 分子標的治療の位置付けを中心に」  [Not invited]工藤 正俊第164回滋賀肝・胆・膵勉強会  2011/02  京都センチュリーホテル, 京都  第164回滋賀肝・胆・膵勉強会肝機能障害精査でHIV感染症が判明した一例.  [Not invited]松本 望; 田村 瑠衣; 高場 雄久; 奥村 直己; 山本 典雄; 富田 崇文; 梅原 康湖; 南 康範; 森村 正嗣; 米田 円; 山田 哲; 辻 直子; 落合 健; 前倉 俊治; 工藤 正俊日本消化器病学会近畿支部第94回例会 Freshman Session「肝」  2011/02  大阪国際会議場, 大阪  日本消化器病学会近畿支部第94回例会 Freshman Session「肝」破壊性甲状腺炎と二次性アミロイドーシスを合併したCrohn病の1例.  [Not invited]田村 瑠衣; 松本 望; 高場 雄久; 奥村 直己; 山本 典雄; 富田 崇文; 梅原 康湖; 南 康範; 森村 正嗣; 米田 円; 山田 哲; 辻 直子; 落合 健; 前倉 俊治; 工藤 正俊日本消化器病学会近畿支部第94回例会 Freshman Session「消化管」  2011/02  大阪国際会議場, 大阪  日本消化器病学会近畿支部第94回例会 Freshman Session「消化管」潰瘍性大腸炎に対する免疫調節剤の有用性と問題点の検討.  [Not invited]櫻井 俊治; 松井 繁長; 樫田 博史; 工藤 正俊日本消化器病学会近畿支部第94回例会  2011/02  大阪国際会議場, 大阪  日本消化器病学会近畿支部第94回例会HTLV-1関連脊髄症(HAM)に合併した難治性食道カンジタ症の1例.  [Not invited]永田 嘉昭; 松井 繁長; 峯 宏昌; 川崎 正憲; 朝隈 豊; 櫻井 俊治; 樫田 博史; 工藤 正俊日本消化器病学会近畿支部第94回例会  2011/02  大阪国際会議場, 大阪  日本消化器病学会近畿支部第94回例会造影ハーモニックEUSによるMSTの鑑別およびGISTの悪性度評価の試み.  [Not invited]坂本 洋城; 北野 雅之; 工藤 正俊日本消化器病学会近畿支部第94回例会 シンポジウム「新しいイメージングテクノロジーによる消化器病診療の進歩」  2011/02  大阪国際会議場, 大阪  日本消化器病学会近畿支部第94回例会 シンポジウム「新しいイメージングテクノロジーによる消化器病診療の進歩」First interim results of the Global Investigation of therapeutic DEcisions in hepatocellular carcinoma (HCC) and Of its treatment with sorafeNib (GIDEON) study: Oncologists and non-oncologists appear to use sorafenib (Sor) differently in the management of  [Not invited]A.Venook; 工藤 正俊; R. Lencioni; J.A. Marrero; S.L. Ye2011 Gastrointeritinal Cancers Symposium (ASCO-GI 2011)  2011/01  San Francisco, USA  2011 Gastrointeritinal Cancers Symposium (ASCO-GI 2011)肝機能障害で紹介されたAIDSの1例  [Not invited]松本 望; 沖本 奈美; 高場 雄久; 奥村 直己; 山本 典雄; 南 康範; 辻 直子; 上田 宏次; 浦瀬 文明; 工藤 正俊日本内科学会近畿支部主催 第193回近畿地方回  2010/12  神戸市  日本内科学会近畿支部主催 第193回近畿地方回α-グルコシダーゼ阻害剤(アカルボース)が原因と考えられた腸管嚢胞様気腫症の1例  [Not invited]沖本 奈美; 松本 望; 高場 雄久; 奥村 直己; 山本 典雄; 冨田 崇文; 梅原 康湖; 南 康範; 辻 直子; 工藤 正俊日本内科学会近畿支部主催 第193回 近畿地方会  2010/12  神戸市  日本内科学会近畿支部主催 第193回 近畿地方会Special lecture “On going trial and future role of molecular targeted agent in HCC.”  [Not invited]工藤 正俊All India Institute of Medical Science (AIIMS)  2010/11  New Delhi, India  All India Institute of Medical Science (AIIMS)Special lecture “Current role of sorafenib in the management of HCC.”  [Not invited]工藤 正俊All India Institute of Medical Science (AIIMS)  2010/11  New Delhi, India  All India Institute of Medical Science (AIIMS)Special lecture “Interventional US for GI & pancreatico biliary disease.”  [Not invited]工藤 正俊9th Congress of Asian Federation of Societies for Ultrasound in Medicine and Biology  2010/11  New Delhi, India  9th Congress of Asian Federation of Societies for Ultrasound in Medicine and BiologySpecial lecture “Endoscopic CEUS for pancreatic lesions.”  [Not invited]工藤 正俊9th Congress of Asian Federation of Societies for Ultrasound in Medicine and Biology  2010/11  New Delhi, India  9th Congress of Asian Federation of Societies for Ultrasound in Medicine and BiologySpecial lecture “Sonazoid-enhanced US in the management of HCC.”  [Not invited]工藤 正俊Medanta University Hospital  2010/11  India  Medanta University HospitalSpecial lecture “Imaging diagnosis of early-stage HCC: Role of EOB-MRI.”  [Not invited]工藤 正俊Medanta University Hospital  2010/11  India  Medanta University HospitalSpecial lecture “Molecular targeted therapy for HCC: Current situation and future prospective.”  [Not invited]工藤 正俊Medanta University Hospital  2010/11  India  Medanta University Hospital特別講演「肝癌診療の新しいパラダイム」,  [Not invited]工藤 正俊阪神肝臓病治療研究会 第三回学術講演会  2010/11  ホテル阪急インターナショナル, 大阪  阪神肝臓病治療研究会 第三回学術講演会特別講演「ウイルス性肝炎の治療」  [Not invited]工藤 正俊肝がん撲滅の為の肝臓病市民公開講座  2010/11  堺市民会館, 大阪  肝がん撲滅の為の肝臓病市民公開講座特別講演「肝細胞癌診療の最新の話題~IFN治療から分子標的治療まで~」  [Not invited]工藤 正俊第3回渋谷消化器病ゼミナール  2010/11  セルリアンタワー東急ホテル, 東京  第3回渋谷消化器病ゼミナール特別講演「B型慢性肝疾患治療の最近の話題~肝がん抑止を目指して~」  [Not invited]工藤 正俊OSAKA HBV SEMINAR ~de novo HEPATITIS & Latest CHB treatment, For Hepatologist and Hematologist~  2010/11  リーガロイヤルホテル堺, 大阪  OSAKA HBV SEMINAR ~de novo HEPATITIS & Latest CHB treatment, For Hepatologist and Hematologist~腹部超音波検査で特発性腸間膜静脈硬化症が疑われた1例 .  [Not invited]横川 美加; 桑口 愛; 前野 知子; 前川 清; 鄭 浩柄; 樫田 博史; 工藤 正俊日本超音波医学会第37回関西地方会学術集会  2010/10  神戸, 兵庫  日本超音波医学会第37回関西地方会学術集会Percutaneous endoscopic gastrosotmy with Funada-style gastropexy, an easy and safe technique, greatly reduce the risk of peristomal infection (Travel Grant)  [Not invited]奥村 直己; 辻 直子; 高場 雄久; 山本 典雄; 南 康範; 工藤 正俊UEGW 2010  2010/10  バルセロナ  UEGW 2010Colonoscopic polypectomy in the very elderly, is it safe?  [Not invited]山本 典雄; 辻 直子; 高場 雄久; 奥村 直己; 南 康範; 工藤 正俊UEGW 2010  2010/10  バルセロナ  UEGW 2010特別講演「ウイルス性肝炎の治療」  [Not invited]工藤 正俊肝がん撲滅の為の肝臓病市民公開講座  2010/10  羽曳野市市民会館, 大阪  肝がん撲滅の為の肝臓病市民公開講座Special lecture “Imaging diagnosis of early HCC.”  [Not invited]工藤 正俊4th International Forum for Liver MRI  2010/10  Seoul Korea  4th International Forum for Liver MRIFirst Interim Results of The Global Investigation of Therapeutic DEcisions in Hepatocellular Carcinoma and Of its Treatment with SorafeNib (GIDEON) Study.  [Not invited]Riccardo Lencioni; 工藤 正俊; HoYeong Lim; Per St?l; Jorge Marrero; Alan Venook; Keiko Nakajima; Sheng-Long YeEuropian Society for Medical Oncology (ESMO) congress  2010/10  Milan, Italy  Europian Society for Medical Oncology (ESMO) congressSorafenib treatment and safety profile in Child Pugh B patients characterized in first interim results of GIDEON (Global Investigation Of Therapeutic Decisions In Hepatocellular Carcinoma And Of Its Treatment With Sorafenib).  [Not invited]Jorge Marrero; 工藤 正俊; HoYeong Lim; Per St?l; Riccardo Lencioni; Alan Venook; Keiko Nakajima; Sheng-Long YeAmerican Association for the Study of Liver Diseases (AASLD) The Liver Meeting 2010  2010/10  Massachusetts, USA  American Association for the Study of Liver Diseases (AASLD) The Liver Meeting 2010悪性胆道狭窄に対するEUS下胆道ドレナージ術の有用性.  [Not invited]今井 元; 北野 雅之; 工藤 正俊第85回日本消化器内視鏡学会近畿地方会, ビデオワークショップ「胆膵疾患における治療の進歩と今後の展開」  2010/10  大阪国際交流センター, 大阪  第85回日本消化器内視鏡学会近畿地方会, ビデオワークショップ「胆膵疾患における治療の進歩と今後の展開」特別講演「肝細胞癌診療の最新の話題: 発癌抑制から分子標的治療まで」  [Not invited]工藤 正俊西神奈川肝炎学術講演会  2010/10  ロワジールホテル厚木, 神奈川  西神奈川肝炎学術講演会Examination of factors of delayed bleeding after endoscopic submucosal dissection (ESD) for gastric tumors.  [Not invited]朝隈 豊; 松井 繁長; 峯 宏昌; 永田 嘉昭; 川崎 正憲; 北井 聡; 坂本 洋城; 井上 達夫; 櫻井 俊治; 樫田 博史; 工藤 正俊18th United European Gastroenterology Week (UEGW) 2010  2010/10  Barcelona, Spain  18th United European Gastroenterology Week (UEGW) 2010The efficacy of helicobacter pylori eradication therapy for the healing of artificial gastric ulcer after endoscopic submucosal dissection early gastric cancer: Prospective randomized study.  [Not invited]朝隈 豊; 松井 繁長; 峯 宏昌; 永田 嘉昭; 川崎 正憲; 北井 聡; 坂本 洋城; 井上 達夫; 櫻井 俊治; 樫田 博史; 工藤 正俊18th United European Gastroenterology Week (UEGW) 2010  2010/10  Barcelona, Spain  18th United European Gastroenterology Week (UEGW) 2010Is the combination therapy of ecabet sodium and proton pump inhibitor (PPI) useful for treating the artificial ulcer after endoscopic submucosal dissection (ESD) treatment of early gastric cancer? : Prospective randomized study.  [Not invited]朝隈 豊; 松井 繁長; 峯 宏昌; 永田 嘉昭; 北井 聡; 坂本 洋城; 井上 達夫; 櫻井 俊治; 樫田 博史; 工藤 正俊18th United European Gastroenterology Week (UEGW) 2010  2010/10  Barcelona, Spain  18th United European Gastroenterology Week (UEGW) 2010特別講演「コンセンサスに基づく肝細胞癌診断アルゴリズム」  [Not invited]工藤 正俊第4回肝癌の診断・治療に関する病診連携セミナー  2010/10  ソニックシティ, 埼玉  第4回肝癌の診断・治療に関する病診連携セミナー造影超音波による血流定量化の試み-肝細胞癌に対するTACEの早期治療効果判定-.  [Not invited]南 康範; 奥村 直己; 山本 典雄; 辻 直子; 工藤 正俊第18回日本消化器関連学会週間(第14回日本肝臓学会大会)  2010/10  パシフィコ横浜, 神奈川  第18回日本消化器関連学会週間(第14回日本肝臓学会大会)肝細胞癌治療における術中造影エコーの有用性.  [Not invited]土師 誠二; 畑中 絹世; 竹山 宜典; 工藤 正俊第18回日本消化器関連学会週間(第14回日本肝臓学会大会)  2010/10  パシフィコ横浜, 神奈川  第18回日本消化器関連学会週間(第14回日本肝臓学会大会)線維化進行C型肝炎患者における脾摘後のインターフェロン導入における問題点-好中球数の変化について-.  [Not invited]鄭 浩柄; 上田 泰輔; 早石 宗右; 田北 雅弘; 北井 聡; 畑中 絹世; 矢田 典久; 井上 達夫; 萩原 智; 上嶋 一臣; 工藤 正俊第18回日本消化器関連学会週間(第14回日本肝臓学会大会)  2010/10  パシフィコ横浜, 神奈川  第18回日本消化器関連学会週間(第14回日本肝臓学会大会)造影エコーによる肝細胞癌の診断能、Gd-EOB-MRI、Dynamic CTとの比較検討.  [Not invited]井上 達夫; 畑中 絹世; 早石 宗右; 上田 泰輔; 田北 雅弘; 北井 聡; 矢田 典久; 萩原 智; 鄭 浩柄; 上嶋 一臣; 工藤 正俊第18回日本消化器関連学会週間(第14回日本肝臓学会大会)  2010/10  パシフィコ横浜, 神奈川  第18回日本消化器関連学会週間(第14回日本肝臓学会大会)PEG-IFN α2b/RBV併用療法の無効・再燃例に対するPEG-IFN α2a/RBV併用療法の再治療の検討-他施設共同研究 RETRY study.  [Not invited]上田 泰輔; 工藤 正俊; 土谷 薫; 橋元 悟; 今関 文夫; 垣内 雅彦第18回日本消化器関連学会週間(第14回日本肝臓学会大会)  2010/10  パシフィコ横浜, 神奈川  第18回日本消化器関連学会週間(第14回日本肝臓学会大会)胆管挿入困難例に対するEUS下ドレナージ術の位置づけ.  [Not invited]今井 元; 北野 雅之; 小牧 孝充; 鎌田 研; 坂本 洋城; 工藤 正俊第18回日本消化器関連学会週間(第80回日本消化器内視鏡学会総会)  2010/10  パシフィコ横浜, 神奈川  第18回日本消化器関連学会週間(第80回日本消化器内視鏡学会総会)高齢者の外来下部消化管内視鏡検査におけるプロポフォール至適導入量の検討.  [Not invited]梅原 康湖; 高場 雄久; 奥村 直己; 山本 典雄; 冨田 崇文; 南 康範; 森村 正嗣; 米田 円; 山田 哲; 辻 直子; 工藤 正俊第18回日本消化器関連学会週間(第80回日本消化器内視鏡学会総会)  2010/10  パシフィコ横浜, 神奈川  第18回日本消化器関連学会週間(第80回日本消化器内視鏡学会総会)胃壁固定併用の経皮内視鏡的胃瘻増設術(PEG)におけるquli法とdirect法の比較検討.  [Not invited]高場 雄久; 辻 直子; 奥村 直己; 山本 典雄; 冨田 崇文; 梅原 康湖; 南 康範; 森村 正嗣; 米田 円; 山田 哲; 工藤 正俊; 本庶 元第18回日本消化器関連学会週間(第80回日本消化器内視鏡学会総会)  2010/10  パシフィコ横浜, 神奈川  第18回日本消化器関連学会週間(第80回日本消化器内視鏡学会総会)経皮内視鏡的胃瘻増設術(PEG)における胃壁固定の有用性と問題点.  [Not invited]奥村 直己; 辻 直子; 高場 雄久; 山本 典雄; 冨田 崇文; 梅原 康湖; 南 康範; 森村 正嗣; 米田 円; 山田 哲; 工藤 正俊; 本庶 元第18回日本消化器関連学会週間(第80回日本消化器内視鏡学会総会)  2010/10  パシフィコ横浜, 神奈川  第18回日本消化器関連学会週間(第80回日本消化器内視鏡学会総会)治療成績からみら胃腫瘍に対するESDの検討.  [Not invited]永田 嘉昭; 松井 繁長; 朝隈 豊; 川崎 正憲; 岡田 無文; 工藤 正俊第18回日本消化器関連学会週間(第80回日本消化器内視鏡学会総会)  2010/10  パシフィコ横浜, 神奈川  第18回日本消化器関連学会週間(第80回日本消化器内視鏡学会総会)消化管悪性リンパ腫の初回内視鏡診断と病理診断の問題点.  [Not invited]山本 典雄; 辻 直子; 高場 雄久; 奥村 直己; 冨田 崇文; 梅原 康湖; 南 康範; 森村 正嗣; 米田 円; 山田 哲; 藤田 純也; 浦瀬 文明; 前倉 俊治; 工藤 正俊; 本庶 元第18回日本消化器関連学会週間(第80回日本消化器内視鏡学会総会)  2010/10  パシフィコ横浜, 神奈川  第18回日本消化器関連学会週間(第80回日本消化器内視鏡学会総会)ヘリコバクターピロリ陽性早期胃癌における除菌治療がESD後人工潰瘍治癒過程に及ぼす影響の検討.  [Not invited]川崎 正憲; 松井 繁長; 峯 宏昌; 永田 嘉昭; 朝隈 豊; 工藤 正俊第18回日本消化器関連学会週間(第80回日本消化器内視鏡学会総会)  2010/10  パシフィコ横浜, 神奈川  第18回日本消化器関連学会週間(第80回日本消化器内視鏡学会総会)非閉塞性腸管虚血を発症した悪性リンパ腫の一例.  [Not invited]宮田 剛; 井上 達夫; 有住 忠晃; 早石 宗右; 上田 泰輔; 辰巳 千栄; 田北 雅弘; 北井 聡; 石川 恵美; 矢田 典久; 萩原 智; 鄭 浩柄; 上嶋 一臣; 工藤 正俊第18回日本消化器関連学会週間(第52回日本消化器病学会),  2010/10  パシフィコ横浜, 神奈川  第18回日本消化器関連学会週間(第52回日本消化器病学会),EUSガイド下治療のコツと工夫.  [Not invited]北野 雅之; 小牧 孝充; 工藤 正俊第18回日本消化器関連学会週間(第80回日本消化器内視鏡学会総会), ワークショップ「胆膵内視鏡治療のエキスパートテクニック<ビデオ>」  2010/10  パシフィコ横浜, 神奈川  第18回日本消化器関連学会週間(第80回日本消化器内視鏡学会総会), ワークショップ「胆膵内視鏡治療のエキスパートテクニック<ビデオ>」癌性疼痛における超音波内視鏡下広範囲腹腔神経叢融解術(EUS-BPN)の有用性.  [Not invited]坂本 洋城; 北野 雅之; 工藤 正俊第18回日本消化器関連学会週間(第80回日本消化器内視鏡学会総会・第8回日本消化器外科学会大会合同)シンポジウム「胆道・膵臓癌に対するInterventional oncology-現在そして将来を展  2010/10  パシフィコ横浜, 神奈川  第18回日本消化器関連学会週間(第80回日本消化器内視鏡学会総会・第8回日本消化器外科学会大会合同)シンポジウム「胆道・膵臓癌に対するInterventional oncology-現在そして将来を展造影ハーモニックEUSによるGISTの悪性度評価.  [Not invited]坂本 洋城; 北野 雅之; 工藤 正俊第18回日本消化器関連学会週間(第52回日本消化器病学会・第80回日本消化器内視鏡学会総会・第8回日本消化器外科学会大会合同)ワークショップ「GISTの基礎と臨床」  2010/10  パシフィコ横浜, 神奈川  第18回日本消化器関連学会週間(第52回日本消化器病学会・第80回日本消化器内視鏡学会総会・第8回日本消化器外科学会大会合同)ワークショップ「GISTの基礎と臨床」EUSを主としたIPMN、IPNBの診療ストラテジー.  [Not invited]鎌田 研; 北野 雅之; 工藤 正俊第18回日本消化器関連学会週間(第14回日本肝臓学会大会・第52回日本消化器病学会・第8回日本消化器外科学会大会合同)ワークショップ「肝胆膵での上皮内腫瘍: 病態解明と治療戦略」  2010/10  第18回日本消化器関連学会週間(第14回日本肝臓学会大会・第52回日本消化器病学会・第8回日本消化器外科学会大会合同)ワークショップ「肝胆膵での上皮内腫瘍: 病態解明と治療戦略」肝細胞癌の肉眼分類評価におけるソナゾイド造影超音波の有用性-造影dynamic CTとの比較.  [Not invited]畑中 絹世; 工藤 正俊; 熊野 正士第18回日本消化器関連学会週間(第52回日本消化器病学会大会・第14回日本肝臓学会大会合同)ワークショップ「肝細胞癌に対する画像診断の進歩と新たな治療戦略」  2010/10  パシフィコ横浜, 神奈川  第18回日本消化器関連学会週間(第52回日本消化器病学会大会・第14回日本肝臓学会大会合同)ワークショップ「肝細胞癌に対する画像診断の進歩と新たな治療戦略」PEG-IFNα/RBV併用療法における血清フェリチン値とSVRとの関係.  [Not invited]矢田 典久; 鄭 浩柄; 工藤 正俊第18回日本消化器関連学会週間(第14回日本肝臓学会大会・第52回日本消化器病学会大会合同)パネルディスカッション「代謝異常(金属代謝を含む)からみたC型肝炎の病態解析」  2010/10  パシフィコ横浜, 神奈川  第18回日本消化器関連学会週間(第14回日本肝臓学会大会・第52回日本消化器病学会大会合同)パネルディスカッション「代謝異常(金属代謝を含む)からみたC型肝炎の病態解析」胆膵疾患に対するEUSガイド下ドレナージ術.  [Not invited]鎌田 研; 北野 雅之; 工藤 正俊第18回日本消化器関連学会週間(第80回日本消化器内視鏡学会総会・第52回日本消化器病学会大会合同)シンポジウム「Interventional EUSの評価」  2010/10  パシフィコ横浜, 神奈川  第18回日本消化器関連学会週間(第80回日本消化器内視鏡学会総会・第52回日本消化器病学会大会合同)シンポジウム「Interventional EUSの評価」教育講演「消化器癌の治療戦略-海外との比較も含めて-」  [Not invited]工藤 正俊第18回日本消化器関連学会週間(第28回日本医学会総会共催)  2010/10  パシフィコ横浜, 神奈川  第18回日本消化器関連学会週間(第28回日本医学会総会共催)Estimation of malignant potential gist by contrast-enhanced harmonic endoscopic ultrasonography.  [Not invited]坂本 洋城; 北野 雅之; 小牧 孝充; 鎌田 研; 今井 元; 工藤 正俊18th United European Gastroenterology Week (UEGW) 2010  2010/10  Barcelona, Spain  18th United European Gastroenterology Week (UEGW) 2010Can Gd-EOB-DTPA-enhanced MRI discriminate between dysplastic nodules and early-to- well-differentiated HCC?  [Not invited]井上 達夫; 工藤 正俊; 早石 宗右; 上田 泰輔; 田北 雅弘; 北井 聡; 畑中 絹世; 矢田 典久; 萩原 智; 南 康範; 鄭 浩柄; 上嶋 一臣; 岡田 真広; 熊野 正士; 村上 卓道; 坂元 亨宇18th United European Gastroenterology Week (UEGW) 2010  2010/10  Barcelona, Spain  18th United European Gastroenterology Week (UEGW) 2010Usefulness of hepatocyte phase imaging of Gd-EOB-DTPA-MRI in detecting borderline lesions which are difficult to detect other imaging modalities.  [Not invited]井上 達夫; 工藤 正俊; 早石 宗右; 上田 泰輔; 田北 雅弘; 北井 聡; 矢田 典久; 萩原 智; 鄭 浩柄; 上嶋 一臣18th United European Gastroenterology Week (UEGW) 2010  2010/10  Barcelona, Spain  18th United European Gastroenterology Week (UEGW) 2010Characterization of small pancreatic neoplasms by contrast-enhanced harmonic EUS.  [Not invited]北野 雅之; 坂本 洋城; 小牧 孝充; 今井 元; 鎌田 研; 工藤 正俊; 高木 忠之; 山雄18th United European Gastroenterology Week (UEGW) 2010  2010/10  Barcelona, Spain  18th United European Gastroenterology Week (UEGW) 2010Utility of evaluation of the response to chemotherapy in advanced gastric cancer by contrast-enhanced harmonic EUS using Sonazoid.  [Not invited]松井 繁長; 工藤 正俊; 岡田 無文; 朝隈 豊; 川崎 正憲; 永田 嘉昭; 樫田 博史18th United European Gastroenterology Week (UEGW) 2010  2010/10  Barcelona, Spain  18th United European Gastroenterology Week (UEGW) 2010Non-liver transplantation treatment for hepatocellular carcinoma within the Milan criteria in child-pugh score 10-11 cirrhotic patients has a survival benefit.  [Not invited]北井 聡; 工藤 正俊; 有井 滋樹; 市田 隆文; 小俣 政男; 坂元 亨宇; 高安 賢一; 中島 収; 幕内 雅敏; 松山 裕; 門田 守人18th United European Gastroenterology Week (UEGW) 2010  2010/10  Barcelona, Spain  18th United European Gastroenterology Week (UEGW) 2010The usefulness of the post-vascular phase of contrast-enhanced ultrasonography with Sonazoid in the evaluation of gross type of hepatocellular carcinoma.  [Not invited]畑中 絹世; 鄭 浩柄; 工藤 正俊; 北井 聡; 井上 達夫; 矢田 典久; 萩原 智; 上嶋 一臣American Association for the Study of Liver Diseases (AASLD) The Liver Meeting 2010  2010/10  Massachusetts, USA  American Association for the Study of Liver Diseases (AASLD) The Liver Meeting 2010Sorafenib inhibits the hepatocyte growth factor-mediated epithelial mesenchymal transition in hepatocellular carcinoma. ソラフェニブは肝細胞癌株において、HGF起因の上皮間葉移行(Epithelial mesenchymal transition)を阻害する.  [Not invited]永井 知行; 荒尾 徳三; 坂井 和子; 工藤 可苗; 金田 裕靖; 田村 大介; 青松 圭一; 木村 英晴; 藤田 至彦; 松本 和子; 西條 長宏; 工藤 正俊; 西尾 和人第69回日本癌学会学術総会  2010/09  大阪国際会議場, 大阪  第69回日本癌学会学術総会特発性腸間膜静脈硬化症の1例.  [Not invited]宮田 剛; 樫田 博史; 峯 宏昌; 川崎 正憲; 永田 嘉昭; 朝隈 豊; 櫻井 俊治; 松井 繁長; 工藤 正俊日本消化器病学会近畿支部第93回例会  2010/09  大阪国際交流センター, 大阪  日本消化器病学会近畿支部第93回例会自己免疫性膵炎の検討: EUSによる膵実質所見.  [Not invited]小牧 孝充; 北野 雅之; 工藤 正俊; 坂本 洋城日本消化器病学会近畿支部第93回例会  2010/09  大阪国際交流センター, 大阪  日本消化器病学会近畿支部第93回例会発熱、及び軽度の肝機能障害に発症した肝サルコイドーシスの1例.  [Not invited]有住 忠晃; 萩原 智; 早石 宗右; 田北 雅弘; 上田 泰輔; 北井 聡; 畑中 絹世; 矢田 典久; 井上 達夫; 鄭 浩柄; 上嶋 一臣; 樫田 博史; 工藤 正俊日本消化器病学会近畿支部第93回例会  2010/09  大阪国際交流センター, 大阪  日本消化器病学会近畿支部第93回例会十二指腸狭窄を契機に診断された十二指腸悪性リンパ腫の一例.  [Not invited]奥村 直己; 高場 雄久; 山本 典雄; 富田 崇文; 梅原 康湖; 南 康範; 森村 正嗣; 米田 円; 山田 哲; 辻 直子; 工藤 正俊日本消化器病学会近畿支部第93回例会  2010/09  大阪国際交流センター, 大阪  日本消化器病学会近畿支部第93回例会十二指腸狭窄を契機に診断された十二指腸悪性リンパ腫の一例  [Not invited]奥村 直己; 高場 雄久; 山本 典雄; 冨田 崇文; 梅原 康湖; 南 康範; 森村 正嗣; 米田 円; 山田 哲; 辻 直子; 工藤 正俊日本消化器病学会近畿支部 第93回例会  2010/09  大阪市  日本消化器病学会近畿支部 第93回例会Luncheon workshop “Novel concepts in HCC staging.”  [Not invited]工藤 正俊4th Annual Conference International Liver Cancer Association (ILCA)  2010/09  Montral, Canada  4th Annual Conference International Liver Cancer Association (ILCA)Special Lecture “Management and outcome of HCC in Japan: Analysis of 51,430 HCC cases registerd in nationwide survey program of Liver Cancer Study Group of Japan.”  [Not invited]工藤 正俊4th Annual Conference International Liver Cancer Association (ILCA)  2010/09  Montral, Canada  4th Annual Conference International Liver Cancer Association (ILCA)EUS-FNA穿刺針の使い分けとコツ.  [Not invited]北野 雅之; 坂本 洋城; 小牧 孝充; 今井 元; 鎌田 研; 工藤 正俊第8回FNA-Club Japan, 特別企画講演「先端施設における膵のEUS-FNA」  2010/09  三井ガーデンホテル広島, 広島  第8回FNA-Club Japan, 特別企画講演「先端施設における膵のEUS-FNA」特別講演「肝細胞癌治療に対する分子標的治療の現状と今後の展望」  [Not invited]工藤 正俊第1回鹿児島肝細胞がん分子標的治療研究会  2010/09  城山観光ホテル, 鹿児島  第1回鹿児島肝細胞がん分子標的治療研究会特別講演「肝細胞癌に対する分子標的治療の現状と今後の展望」  [Not invited]工藤 正俊兵庫HCC分子標的治療セミナー  2010/09  神戸ポートピアホテル, 兵庫  兵庫HCC分子標的治療セミナー特別講演「肝癌治療の新しいパラダイム」  [Not invited]工藤 正俊H22 八尾徳洲会医療連携の会  2010/09  リーガロイヤルホテル大阪, 大阪  H22 八尾徳洲会医療連携の会特別講演「肝細胞癌診療における新しいパラダイム」  [Not invited]工藤 正俊高知肝癌診断治療セミナー  2010/09  高知新阪急ホテル, 高知  高知肝癌診断治療セミナーSonazoidを用いた造影EUSによる胆嚢病変の診断.  [Not invited]鎌田 研; 北野 雅之; 工藤 正俊; 今井 元; 小牧 孝充; 坂本 洋城第46回日本胆道学会学術集会  2010/09  リーガロイヤルホテル広島, 広島  第46回日本胆道学会学術集会EUSによる肝外胆管癌の進展度診断.  [Not invited]小牧 孝充; 北野 雅之; 坂本 洋城; 今井 元; 鎌田 研; 工藤 正俊; 中居 卓也; 竹山 宜典第46回日本胆道学会学術集会  2010/09  リーガロイヤルホテル広島, 広島  第46回日本胆道学会学術集会経乳頭的アプローチ困難例に対するEUS下胆道ドレナージの有用性.ビデオワークショップ「私が薦める胆道内視鏡のコツ~安全性を目指して~」  [Not invited]今井 元; 北野 雅之; 工藤 正俊第46回日本胆道学会学術集会  2010/09  リーガロイヤルホテル広島, 広島  第46回日本胆道学会学術集会The usefulness of helicobacter pylori eradication therapy for the healing of artificial gastric ulcer after endoscopic submucosal dissection for early gastric cancer.  [Not invited]川崎 正憲; 朝隈 豊; 峯 宏昌; 永田 嘉昭; 櫻井 俊治; 松井 繁長; 樫田 博史; 工藤 正俊Asian Pacific Digestive Week (APDW) 2010  2010/09  Kuala Lumpur, Malaysia  Asian Pacific Digestive Week (APDW) 2010特別講演「造影超音波は肝癌診療をどう変えたか?」  [Not invited]工藤 正俊第52回いわき肝疾患研究会  2010/08  いわきワシントンホテル, 福島  第52回いわき肝疾患研究会Special lecture “Ultrasound diagnosis of pancreatic tumors.”  [Not invited]工藤 正俊8 AFSUMB Workshop: 2010  2010/08  Ulaanbaatar, Mogolia  8 AFSUMB Workshop: 2010特別講演「肝細胞癌の最新の話題」  [Not invited]工藤 正俊KBNCの会  2010/08  全日空ホテルクレメント高松, 香川  KBNCの会進行型肝細胞癌に対するSorafenib治療効果判定における肝CT Perfusion検査  [Not invited]岡田 真広; 熊野 正士; 香川祐毅; 上嶋 一臣; 矢田 典久; 井上 達夫; 工藤 正俊; 村上 卓道第10回関西肝血流動態イメージ研究会  2010/07  オーバルホール,大阪  第10回関西肝血流動態イメージ研究会特別講演「肝癌診療ガイドライン2009年版 改訂のポイント」  [Not invited]工藤 正俊第11回臨床消化器病研究会  2010/07  グランドプリンスホテル新高輪, 東京  第11回臨床消化器病研究会特別講演「肝癌診療の新しいパラダイム」  [Not invited]工藤 正俊第21回北海道肝がん研究会  2010/07  ホテルニューオータニ札幌, 北海道  第21回北海道肝がん研究会特別講演「肝細胞癌に対する分子標的治療の現状と今後の展望」  [Not invited]工藤 正俊日本医師会生涯教育講座 第34回肝臓を診る会  2010/07  旭川グランドホテル, 北海道  日本医師会生涯教育講座 第34回肝臓を診る会特別講演「進行性肝細胞癌に対するソラフェニブの使用経験」  [Not invited]工藤 正俊広島ネクサバール承認1周年記念セミナー  2010/07  リーガロイヤルホテル広島, 広島  広島ネクサバール承認1周年記念セミナーBranched-chain amino acid granules reduce the incidence of hepatocellular carcinoma in patients with liver cirrhosis.  [Not invited]早石 宗右; 鄭 浩柄; 工藤 正俊The 7th Japan-Korea Liver Symposium  2010/07  Kyoto, Japan  The 7th Japan-Korea Liver Symposium特別講演「ペグインターフェロン・リバビリン併用療法無効・再燃例に対するペグインターフェロン・リバビリン併用療法による再治療」  [Not invited]工藤 正俊第8回肝臓病研究会シンポジウム  2010/07  六本木アカデミーヒルズ49, 東京  第8回肝臓病研究会シンポジウム特別講演「肝癌診療の最新の話題」  [Not invited]工藤 正俊OK7KK(岡山市中基幹7病院肝疾患研究会)  2010/07  ホテルグランヴィア岡山, 岡山  OK7KK(岡山市中基幹7病院肝疾患研究会)教育セミナー「肝細胞癌 内科の立場から-肝癌の内科治療の将来展望-」  [Not invited]工藤 正俊第13回日本高齢消化器病学会  2010/07  六本木アカデミーヒルズ, 東京  第13回日本高齢消化器病学会ランチョンセミナー「コンセンサスに基づく肝細胞癌診断アルゴリズム」  [Not invited]工藤 正俊第46回日本肝癌研究会  2010/07  大阪国際会議場, 大阪  第46回日本肝癌研究会EUS-guided broad plexus-neurolysis over the superior mesenteric artery using a 25 gauge needle.  [Not invited]坂本 洋城; 北野 雅之; 小牧 孝充; 今井 元; 鎌田 研; 竹山 宜典; 中居 卓也; 安田 武生; 亀井 敬子; 工藤 正俊Joint Meeting of the International Association of Pancreatology and the Japan Pancreas Society 2010  2010/07  Fukuoka, Japan  Joint Meeting of the International Association of Pancreatology and the Japan Pancreas Society 2010Management of IPMNs by endoscopic ultrasonography.  [Not invited]鎌田 研; 北野 雅之; 今井 元; 小牧 孝充; 坂本 洋城; 竹山 宜典; 工藤 正俊Joint Meeting of the International Association of Pancreatology and the Japan Pancreas Society 2010  2010/07  Fukuoka, Japan  Joint Meeting of the International Association of Pancreatology and the Japan Pancreas Society 2010Endoscopic ultrasound-guided drainage for pancreatic diseases. JPS Video Symposium 1 “Cutting edge endoscopic procedures for diagnosis and treatment of panvreatic diseases”  [Not invited]鎌田 研; 北野 雅之; 小牧 孝充; 今井 元; 坂本 洋城; 竹山 宜典; 工藤 正俊Joint Meeting of the International Association of Pancreatology and the Japan Pancreas Society 2010  2010/07  Fukuoka, Japan  Joint Meeting of the International Association of Pancreatology and the Japan Pancreas Society 2010Contrast-enhanced harmonic endosonography in diagnosing pancreatic diseases. JPS Symposium 1 “Recent advances in the imaging studies of pancreatic diseases”  [Not invited]北野 雅之; 小牧 孝充; 今井 元; 坂本 洋城; 竹山 宜典; 工藤 正俊Joint Meeting of the International Association of Pancreatology and the Japan Pancreas Society 2010  2010/07  Fukuoka, Japan  Joint Meeting of the International Association of Pancreatology and the Japan Pancreas Society 2010HCCに対するソラフェニブを用いた血管新生抑制治療の効果予測因子としてのPIVKA-IIの有用性に関する検討.  [Not invited]上嶋 一臣; 工藤 正俊第10回関西肝血流動態イメージ研究会  2010/07  オーバルホール, 大阪  第10回関西肝血流動態イメージ研究会造影超音波による血流定量化の試み-肝細胞癌に対する TACEの早期治療効果判定- Early response of transcatheter arterial chemoembolization for hepatocellular carcinoma: Quantification of tumor vascularity with contrast-enhanced sonography.  [Not invited]南 康範; 奥村 直己; 山本 典雄; 辻 直子; 工藤 正俊; Yuko Kono第10回関西肝血流動態イメージ研究会  2010/07  オーバルホール, 大阪  第10回関西肝血流動態イメージ研究会Workshop “Treatment algorithm for intermediate and advanced stage of HCC: Japan.”  [Not invited]工藤 正俊The 1st Asia-Pacific Primary Liver Cancer Expert Meeting  2010/07  Incheon, Korea  The 1st Asia-Pacific Primary Liver Cancer Expert MeetingWorkshop “Report from working group.”  [Not invited]工藤 正俊The 1st Asia-Pacific Primary Liver Cancer Expert Meeting  2010/07  Incheon, Korea  The 1st Asia-Pacific Primary Liver Cancer Expert Meeting特別講演「肝細胞癌の分子標的治療」  [Not invited]工藤 正俊伊丹市医師会内科医会 第7回消化器勉強会  2010/07  伊丹シティホテル, 兵庫  伊丹市医師会内科医会 第7回消化器勉強会進行型肝細胞癌症例に対するSorafenib治療前後の肝CT prefusion検査  [Not invited]岡田 真広; 熊野 正士; 香川祐毅; 塚部明大; 上嶋 一臣; 矢田 典久; 井上 達夫; 工藤 正俊; 村上 卓道第2回日本肝がん分子標的治療研究会  2010/06  大手町サンケイプラザ,東京  第2回日本肝がん分子標的治療研究会Special lecture “Clinical classification in Asia.”  [Not invited]工藤 正俊Europian Association for the Study of the Liver  2010/06  Dubrovnik, Croatia  Europian Association for the Study of the LiverSorafenibは肝細胞がんの上皮間葉移行を阻害する.  [Not invited]永井 知行; 荒尾 徳三; 工藤 可苗; 工藤 正俊; 西尾 和人第2回日本肝がん分子標的治療研究会  2010/06  大手町サンケイプラザ, 東京  第2回日本肝がん分子標的治療研究会分子標的薬によるがん幹細胞マーカーCD133の発現制御.  [Not invited]荒尾 徳三; 松本 和子; 工藤 可苗; 永井 知行; 工藤 正俊; 西尾 和人第2回日本肝がん分子標的治療研究会  2010/06  大手町サンケイプラザ, 東京  第2回日本肝がん分子標的治療研究会発癌分子機序に基づく新しい肝がん治療薬の可能性.  [Not invited]櫻井 俊治; 萩原 智; 矢田 典久; 井上 達夫; 鄭 浩柄; 上嶋 一臣; 工藤 正俊第2回日本肝がん分子標的治療研究会  2010/06  大手町サンケイプラザ, 東京  第2回日本肝がん分子標的治療研究会ランチョンセミナー「造影超音波は肝癌診療をどう変えたか?」  [Not invited]工藤 正俊日本消化器病学会中国支部例会 第12回教育講演会  2010/06  山口県国際総合センター, 山口  日本消化器病学会中国支部例会 第12回教育講演会特別講演「肝癌に対する分子標的治療への期待と今後の展望」  [Not invited]工藤 正俊肝細胞癌ソラフェニブ治療研究会  2010/06  名古屋マリオットアソシアホテル, 愛知  肝細胞癌ソラフェニブ治療研究会特別講演「肝癌診療の新しいパラダイム」  [Not invited]工藤 正俊第4回消化器疾患地域連携フォーラム  2010/06  ホテルオークラ神戸, 兵庫  第4回消化器疾患地域連携フォーラムSpecial lecture “Defect re-perfusion imaging for HCC.”  [Not invited]工藤 正俊Korean Society of Ultrasound in Medicine 2010 Open  2010/05  Seoul, Korea  Korean Society of Ultrasound in Medicine 2010 OpenSpecial lecture “Sonazoid-enhanced US as a treatment-guidance for HCC.”  [Not invited]工藤 正俊Korean Society of Ultrasound in Medicine 2010 Open  2010/05  Seoul, Korea  Korean Society of Ultrasound in Medicine 2010 OpenReal-time Tissue Elastographyによる非侵襲的肝線維化評価法は炎症の影響を受けない.  [Not invited]藤本 研治; 辰巳 千栄; 上嶋 一臣; 工藤 正俊; 石田 哲士; 山本 佳司; 椎名 毅; 加藤 道夫第46回日本肝臓学会総会  2010/05  ホテルメトロポリタン山形, 山形  第46回日本肝臓学会総会肝細胞癌根治後C型肝癌に対するインターフェロン少量長期維持療法の生命予後改善効果に関する検討.  [Not invited]上田 泰輔; 鄭 浩柄; 工藤 正俊第46回日本肝臓学会総会  2010/05  ホテルメトロポリタン山形, 山形  第46回日本肝臓学会総会根治的治療不能の肝細胞癌に対して肝動脈塞栓化学療法(TACE)を施行した患者を対象としたソラフェニブの日韓共同第III相臨床試験.  [Not invited]工藤 正俊; 今中 和穂; 千田 信之; 仲地 耕平; 高山 忠利; 金子 周一; 坪内 博仁; 林 紀夫; 熊田 博光; 沖田 極2010/05HCCに対するソラフェニブの治療効果予測について.  [Not invited]上嶋 一臣; 工藤 正俊第46回日本肝臓学会総会, シンポジウム「肝細胞癌の分子標的探索と臨床応用」  2010/05  ホテルメトロポリタン山形, 山形  第46回日本肝臓学会総会, シンポジウム「肝細胞癌の分子標的探索と臨床応用」特別企画「肝細胞癌の画像診断up-to-date」  [Not invited]工藤 正俊第46回日本肝臓学会総会  2010/05  ホテルメトロポリタン山形, 山形  第46回日本肝臓学会総会特別講演「肝細胞癌診療の最新の話題」  [Not invited]工藤 正俊第42回生涯教育講演会  2010/05  岡山コンベンションセンター, 岡山  第42回生涯教育講演会Special lecture “Imaging diagnosis of very early stage HCC.”  [Not invited]工藤 正俊Seoul Laennec meeting 2010  2010/05  Seoul, Korea  Seoul Laennec meeting 2010Special lecture “Management of HCC in Japan.”  [Not invited]工藤 正俊Global HCC investigator’s meeting in Taiwan  2010/05  Taipei, Taiwan  Global HCC investigator’s meeting in Taiwan膵腫瘍に対する腹部超音波, 超音波内視鏡, MDCTの部位別検出率の比較検討.  [Not invited]今井 元; 北野 雅之; 鎌田 研; 小牧 孝充; 坂本 洋城; 工藤 正俊日本超音波医学会 第83回学術集会  2010/05  京都国際会議場, 京都  日本超音波医学会 第83回学術集会造影超音波検査による肝細胞癌の診断能-Gd-EOB-MRI, Dynamic CTとの比較検討-.  [Not invited]井上 達夫; 畑中 絹世; 前川 清; 工藤 正俊日本超音波医学会 第83回学術集会  2010/05  京都国際会議場, 京都  日本超音波医学会 第83回学術集会造影ハーモニックEUSによる上部消化管粘膜下腫瘍の鑑別の試み.  [Not invited]坂本 洋城; 北野 雅之; 小牧 孝充; 今井 元; 鎌田 研; 工藤 正俊日本超音波医学会 第83回学術集会  2010/05  京都国際会議場, 京都  日本超音波医学会 第83回学術集会造影エコー撮像法の工夫 ?Defect Re-perfusion imaging-.  [Not invited]南 康範; 畑中 絹世; 工藤 正俊日本超音波医学会 第83回学術集会, 特別企画「肝腫瘍の超音波診断基準の検証」  2010/05  京都国際会議場, 京都  日本超音波医学会 第83回学術集会, 特別企画「肝腫瘍の超音波診断基準の検証」C型慢性肝疾患患者に対する非侵襲的肝線維化評価の有用性に関する検討.  [Not invited]矢田 典久; 辰巳 千栄; 上嶋 一臣; 工藤 正俊; 藤本 研治; 加藤 道夫; 椎名 毅日本超音波医学会 第83回学術集会, ワークショップ「びまん性肝疾患のUltrasound Functional Imaging」  2010/05  京都国際会議場, 京都  日本超音波医学会 第83回学術集会, ワークショップ「びまん性肝疾患のUltrasound Functional Imaging」造影ハーモニックEUSによるGISTの悪性度評価の試み.  [Not invited]坂本 洋城; 北野 雅之; 工藤 正俊日本超音波医学会 第83回学術集会, ワークショップ「胆・膵・消化管疾患による造影エコー法の位置づけ」  2010/05  京都国際会議場, 京都  日本超音波医学会 第83回学術集会, ワークショップ「胆・膵・消化管疾患による造影エコー法の位置づけ」膵疾患に対する超音波内視鏡ガイド下ドレナージ術.  [Not invited]北野 雅之; 小牧 孝充; 坂本 洋城; 今井 元; 鎌田 研; 工藤 正俊日本超音波医学会 第83回学術集会, ワークショップ「消化器疾患におけるInterventional Sonography」  2010/05  京都国際会議場, 京都  日本超音波医学会 第83回学術集会, ワークショップ「消化器疾患におけるInterventional Sonography」Sonazoidを用いた造影EUS検査による膵腫瘍性病変の診断.  [Not invited]小牧 孝充; 北野 雅之; 今井 元; 鎌田 研; 工藤 正俊日本超音波医学会 第83回学術集会, パネルディスカッション「超音波内視鏡の新展開」  2010/05  京都国際会議場, 京都  日本超音波医学会 第83回学術集会, パネルディスカッション「超音波内視鏡の新展開」EUSを用いたIPMN診療.  [Not invited]鎌田 研; 北野 雅之; 工藤 正俊; 坂本 洋城; 小牧 孝充; 今井 元日本超音波医学会 第83回学術集会, シンポジウム「膵疾患の超音波診断」  2010/05  都国際会議場, 京都  日本超音波医学会 第83回学術集会, シンポジウム「膵疾患の超音波診断」慢性肝疾患におけるReal-time Tissue Elastographyの精度の検討.  [Not invited]藤本 研治; 辰巳 千栄; 上嶋 一臣; 工藤 正俊; 石田 哲士; 椎名 毅; 加藤 道夫日本超音波医学会 第83回学術集会, シンポジウム「組織エラストグラフィーの現況と展望」  2010/05  京都国際会議場, 京都  日本超音波医学会 第83回学術集会, シンポジウム「組織エラストグラフィーの現況と展望」造影EUS検査による進行胃癌の化学療法効果判定.  [Not invited]岡田 無文; 松井 繁長; 工藤 正俊日本超音波医学会 第83回学術集会, シンポジウム「消化管疾患における超音波診断」  2010/05  京都国際会議場, 京都  日本超音波医学会 第83回学術集会, シンポジウム「消化管疾患における超音波診断」肝細胞癌の肉眼敬体とSonazoid造影超音波におけるdefect像の比較.  [Not invited]畑中 絹世; 鄭 浩柄; 工藤 正俊; 土師 誠二; 熊野 正士; 岡田 真広日本超音波医学会 第83回学術集会, シンポジウム「肝腫瘍の造影エコーの最先端(術中超音波含む)」  2010/05  京都国際会議場, 京都  日本超音波医学会 第83回学術集会, シンポジウム「肝腫瘍の造影エコーの最先端(術中超音波含む)」Contrast-enhanced harmonic EUS for diagnosis of pancreatic tumors.  [Not invited]北野 雅之; 坂本 洋城; 工藤 正俊第79回日本内視鏡学会総会, Symposium “Therapeutic and diagnostic EUS for pancreatobiliary diseases ?Current pra  2010/05  グランドプリンスホテル新高輪, 東京  第79回日本内視鏡学会総会, Symposium “Therapeutic and diagnostic EUS for pancreatobiliary diseases ?Current pra経乳頭的アプローチ困難例に対するEUS下胆道ドレナージ術の有用性.  [Not invited]鎌田 研; 北野 雅之; 今井 元; 小牧 孝充; 坂本 洋城; 末冨 洋一郎; 工藤 正俊第79回日本消化器内視鏡学会総会  2010/05  グランドプリンスホテル新高輪, 東京  第79回日本消化器内視鏡学会総会EUSを用いたIPMNの診断~診断ハーモニック法を含めて~.  [Not invited]鎌田 研; 北野 雅之; 工藤 正俊第79回日本消化器内視鏡学会総会, ワークショップ「国際診療ガイドラインを踏まえたIPMNの内視鏡診断の現状と問題点」  2010/05  グランドプリンスホテル新高輪, 東京  第79回日本消化器内視鏡学会総会, ワークショップ「国際診療ガイドラインを踏まえたIPMNの内視鏡診断の現状と問題点」造影ハーモニックEUSによるSMTの鑑別およびGISTの悪性度評価の試み.  [Not invited]坂本 洋城; 北野 雅之; 工藤 正俊第79回日本消化器内視鏡学会総会, シンポジウム「上部消化管SMTのマネージメント-GISTとの鑑別と取り扱い」  2010/05  グランドプリンスホテル新高輪, 東京  第79回日本消化器内視鏡学会総会, シンポジウム「上部消化管SMTのマネージメント-GISTとの鑑別と取り扱い」切除不能悪性胆道狭窄に対する胆管ステンティングの検討②.  [Not invited]今井 元; 北野 雅之; 工藤 正俊第79回日本消化器内視鏡学会総会, 特別シンポジウム「胆道ステントの適応と選択」  2010/05  グランドプリンスホテル新高輪, 東京  第79回日本消化器内視鏡学会総会, 特別シンポジウム「胆道ステントの適応と選択」切除不能悪性胆道狭窄に対する胆管ステンティングの検討①  [Not invited]今井 元; 北野 雅之; 工藤 正俊第79回日本消化器内視鏡学会総会, 特別シンポジウム「胆道ステントの適応と選択」  2010/05  グランドプリンスホテル新高輪, 東京  第79回日本消化器内視鏡学会総会, 特別シンポジウム「胆道ステントの適応と選択」特別講演「肝細胞癌治療における分子標的治療への期待と課題」  [Not invited]工藤 正俊大阪外科HCC分子標的治療セミナー  2010/05  ホテル阪急インターナショナル, 大阪  大阪外科HCC分子標的治療セミナー特別講演「肝癌の最新の治療: RFA治療困難例対策から分子標的治療まで」  [Not invited]工藤 正俊第9回神奈川肝炎若手の会  2010/05  横浜ベイシェラトンホテル, 神奈川  第9回神奈川肝炎若手の会EUS-guided choledochoduodenostomy followed by endoscopic antegrade biliary stenting via the fistula for treatment of obstructive jaundice with duodenal stenosis.  [Not invited]北野 雅之; 小牧 孝充; 坂本 洋城; 鎌田 研; 今井 元; 工藤 正俊2010 Digestive Disease Week  2010/05  Louisiana, USA  2010 Digestive Disease WeekEUS-guided gallbladder drainage for treatment of acute cholecystitis and obstructive jaundice.  [Not invited]北野 雅之; 今井 元; 小牧 孝充; 鎌田 研; 坂本 洋城; 工藤 正俊2010 Digestive Disease Week  2010/05  Louisiana, USA  2010 Digestive Disease Week癌性疼痛におけるEUS下広範囲腹腔神経叢融解術の有用性の検討: preliminary study.  [Not invited]坂本 洋城; 北野 雅之; 工藤 正俊ワークショップ「消化器疾患におけるInterventional sonography」, 日本超音波医学会 第83会学術集会  2010/05  京都国際会議場, 京都  ワークショップ「消化器疾患におけるInterventional sonography」, 日本超音波医学会 第83会学術集会Special lecture “Imaging diagnosis of every stage HCC.”  [Not invited]工藤 正俊Liver Group Research Meeting at the Pathology Division of the University of Sao Paulo  2010/04  Sao Paulo, Brazil  Liver Group Research Meeting at the Pathology Division of the University of Sao PauloSpecial lecture “Molecular targeted therapy for hepatocellular carcinoma.”  [Not invited]工藤 正俊Liver Group Research Meeting at the Pathology Division of the University of Sao Paulo  2010/04  Sao Paulo, Brazil  Liver Group Research Meeting at the Pathology Division of the University of Sao PauloSpecial lecture “Advanced in US techniques for treatment guidance for liver tumours.”  [Not invited]工藤 正俊JPR 2010  2010/04  Sao Paulo, Brazil  JPR 2010Special lecture “Enhanced sonography of hepatic nodules.”  [Not invited]工藤 正俊JPR 2010  2010/04  Sao Paulo, Brazil  JPR 2010当院における根治手術不能な膵小細胞癌の治療成績.  [Not invited]小牧 孝充; 北野 雅之; 工藤 正俊; 末冨 洋一郎; 今井 元; 鎌田 研第96回日本消化器病学会総会  2010/04  新潟市民プラザ, 新潟  第96回日本消化器病学会総会難治性胆管炎を伴った胆管癌に対する低容量ジェムザール治療.  [Not invited]小牧 孝充; 北野 雅之; 工藤 正俊; 末冨 洋一郎; 今井 元; 鎌田 研第96回日本消化器病学会総会  2010/04  新潟市民プラザ, 新潟  第96回日本消化器病学会総会Sonazoidを用いた造影EUS検査による膵腫瘍性病変の診断.  [Not invited]小牧 孝充; 北野 雅之; 工藤 正俊第96回日本消化器病学会総会, ワークショップ「胆膵画像診断の進歩」  2010/04  新潟市民プラザ, 新潟  第96回日本消化器病学会総会, ワークショップ「胆膵画像診断の進歩」胆膵疾患に対するEUSガイド下ステント治療の成績.  [Not invited]鎌田 研; 北野 雅之; 工藤 正俊第96回日本消化器病学会総会, パネルディスカッション「消化器ステント治療の進歩と現状」  2010/04  新潟市民プラザ, 新潟  第96回日本消化器病学会総会, パネルディスカッション「消化器ステント治療の進歩と現状」EUSを用いたIPMNの診断とフォローアップ.  [Not invited]鎌田 研; 北野 雅之; 工藤 正俊第96回日本消化器病学会総会, シンポジウム「膵IPMNの手術適応の見直し」  2010/04  新潟市民プラザ, 新潟.  第96回日本消化器病学会総会, シンポジウム「膵IPMNの手術適応の見直し」ポストグラデュエイトコース「肝腫瘍の診断」  [Not invited]工藤 正俊第96回日本消化器病学会総会  2010/04  新潟市民プラザ, 新潟  第96回日本消化器病学会総会特別講演「肝癌診療ガイドラインをめぐる最新の話題」  [Not invited]工藤 正俊肝癌診療の最前線~ミリプラ新発売記念講演会~  2010/04  リーガロイヤルホテル堺, 大阪  肝癌診療の最前線~ミリプラ新発売記念講演会~Special Lecture “Contrast-enhanced US: its role in the management of HCC.”  [Not invited]工藤 正俊26th International Congress of Radiology  2010/04  Shanghai, China  26th International Congress of Radiology特別講演「本当は怖いB型慢性肝疾患」  [Not invited]工藤 正俊第11回府中臨床セミナー  2010/04  府中病院, 大阪  第11回府中臨床セミナー特別講演「ウイルス性肝炎の治療」  [Not invited]工藤 正俊肝がん撲滅の為の肝臓病市民公開講座  2010/04  松原市民文化会館, 大阪  肝がん撲滅の為の肝臓病市民公開講座閉塞性黄疸で発見された悪性リンパ腫の一例.  [Not invited]山本 典雄; 奥村 直己; 冨田 崇文; 梅原 康湖; 南 康範; 森村 正嗣; 米田 円; 山田 哲; 辻 直子; 工藤 正俊; 村上 晴郎; 浦瀬 文明第84回日本消化器内視鏡学会近畿地方会  2010/03  大阪国際交流センター, 大阪  第84回日本消化器内視鏡学会近畿地方会EUSを主としたIPMNの診断とフォローアップ方法.  [Not invited]鎌田 研; 北野 雅之; 工藤 正俊第84回日本消化器内視鏡学会近畿地方会, ワークショップ「?胞性膵疾患の鑑別診断と治療法の選択」  2010/03  大阪国際交流センター, 大阪  第84回日本消化器内視鏡学会近畿地方会, ワークショップ「?胞性膵疾患の鑑別診断と治療法の選択」Special Lecture “The use of TACE in the treatment of hepatocellular carcinoma.”  [Not invited]工藤 正俊The 8th ASIA PACIFIC ONCOLOGY SUMMIT  2010/03  Tokyo, Japan  The 8th ASIA PACIFIC ONCOLOGY SUMMIT特別講演「肝細胞癌の治療」  [Not invited]工藤 正俊第8回日本臨床腫瘍学会学術集会  2010/03  東京ビッグサイト, 東京  第8回日本臨床腫瘍学会学術集会特別講演「肝癌診療の新しいパラダイム」  [Not invited]工藤 正俊第12回長崎肝癌研究会学術講演会  2010/03  長崎全日空ホテルグラバーヒル, 長崎  第12回長崎肝癌研究会学術講演会特別講演「肝がん診療ガイドラインの現状と問題点」  [Not invited]工藤 正俊第2回肝疾患地域連携の会総会「肝疾患診療ネットワーク」  2010/03  筑波大学附属病院, 茨城  第2回肝疾患地域連携の会総会「肝疾患診療ネットワーク」特別講演「肝癌の分子標的治療: Up date」  [Not invited]工藤 正俊第12回関西肝癌局所療法研究会  2010/03  阪急電鉄本社ビル, 大阪  第12回関西肝癌局所療法研究会肝細胞癌外科治療における術中造影エコーの意義.  [Not invited]土師 誠二; 山崎 満夫; 北口 博士; 中多 靖幸; 亀井 敬子; 安田 武生; 石川 原; 中居 卓也; 竹山 宜典; 畑中 絹世; 工藤 正俊第12回関西肝癌局所療法研究会  2010/03  阪急電鉄本社ビル, 大阪  第12回関西肝癌局所療法研究会造影超音波による血流定量化の試み-肝細胞癌に対するTACEの早期治療効果判定-.  [Not invited]南 康範; 奥村 直己; 山本 典雄; 辻 直子; 工藤 正俊第12回関西肝癌局所療法研究会  2010/03  阪急電鉄本社ビル, 大阪  第12回関西肝癌局所療法研究会特別講演「HCC治療における分子標的治療への期待と課題」  [Not invited]工藤 正俊群馬県HCC分子標的治療セミナー  2010/03  前橋マーキュリーホテル, 群馬  群馬県HCC分子標的治療セミナー特別講演「肝癌治療の新しいパラダイム」  [Not invited]工藤 正俊第12回久留米消化器癌セミナー  2010/02  久留米大学筑水会館, 福岡  第12回久留米消化器癌セミナー特別講演「肝癌診療ガイドラインと最新治療: 分子標的治療の位置付けも含めて」  [Not invited]工藤 正俊第22回県北DSC  2010/02  ホテルリソル佐世保, 長崎  第22回県北DSC遊走脾の捻転により脾梗塞をきたした一例.  [Not invited]宮田 剛; 鄭 浩柄; 有住 忠晃; 早石 宗右; 田北 雅弘; 上田 泰輔; 辰巳 千栄; 北井 聡; 畑中 絹世; 石川 恵美; 矢田 典久; 井上 達夫; 萩原 智; 上嶋 一臣; 工藤 正俊; 土師 誠二; 山崎 満夫日本消化器病学会近畿支部第92回例会  2010/02  大阪国際交流センター, 大阪  日本消化器病学会近畿支部第92回例会サイトメガロウイルス検査が陰性を示したガンシクロビル投与により軽快した潰瘍性大腸炎の一例.  [Not invited]林 道友; 奥田 英之; 茂山 朋広; 宮部 欽生; 豊澤 昌子; 岸谷 讓; 鍋島 紀滋; 工藤 正俊日本消化器病学会近畿支部第92回例会  2010/02  大阪国際交流センター, 大阪  日本消化器病学会近畿支部第92回例会潰瘍性大腸炎経過中に発症したClostridium difficile関連腸病変の一例.  [Not invited]奥村 直己; 山本 典雄; 富田 崇文; 梅原 康湖; 南 康範; 森村 正嗣; 米田 円; 山田 哲; 辻 直子; 工藤 正俊日本消化器病学会近畿支部第92回例会  2010/02  大阪国際交流センター, 大阪  日本消化器病学会近畿支部第92回例会癌性疼痛に対しEUS下腹腔神経叢ブロックが有用であった1症例.  [Not invited]湯本 妙子; 今井 元; 鎌田 研; 坂本 洋城; 末冨 洋一郎; 小牧 孝充; 北野 雅之; 工藤 正俊日本消化器病学会近畿支部第92回例会  2010/02  大阪国際交流センター, 大阪  日本消化器病学会近畿支部第92回例会肝機能障害を認めたエルシニア腸炎の一例.  [Not invited]足立 哲平; 萩原 智; 有住 忠晃; 峯 宏昌; 宮田 剛; 早石 宗右; 辰巳 千栄; 上田 泰輔; 田北 雅弘; 畑中 絹世; 北井 聡; 石川 恵美; 矢田 典久; 井上 達夫; 鄭 浩柄; 上嶋 一臣; 工藤 正俊; 梅原 泰日本消化器病学会近畿支部第92回例会  2010/02  大阪国際交流センター, 大阪  日本消化器病学会近畿支部第92回例会C型慢性肝炎SVR後に悪性リンパ腫を発症した一例.  [Not invited]高場 雄久; 宮田 剛; 峯 宏昌; 鎌田 研; 有住 忠晃; 田北 雅弘; 早石 宗右; 永井 知行; 上田 泰輔; 辰巳 千栄; 北井 聡; 畑中 絹世; 矢田 典久; 井上 達夫; 石川 恵美; 萩原 智; 鄭 浩柄; 上嶋 一臣; 工藤 正俊日本消化器病学会近畿支部第92回例会  2010/02  大阪国際交流センター, 大阪  日本消化器病学会近畿支部第92回例会慢性C型肝炎に対してPEG-IFN+Ribavirin併用療法中にITPを発症した1例.  [Not invited]有住 忠晃; 石川 恵美; 宮田 剛; 峯 宏昌; 早石 宗右; 田北 雅弘; 上田 泰輔; 辰巳 千栄; 北井 聡; 畑中 絹世; 矢田 典久; 井上 達夫; 萩原 智; 鄭 浩柄; 上嶋 一臣; 工藤 正俊; 金井 良高日本消化器病学会近畿支部第92回例会  2010/02  大阪国際交流センター, 大阪  日本消化器病学会近畿支部第92回例会癌幹細胞のマーカーであるCD133は進行肝細胞癌に対するS1+PEG-IFNalpha2b治療における効果予測因子である. シンポジウム「消化器癌化学療法の適応と限界-肝胆膵領域-」  [Not invited]萩原 智; 上嶋 一臣; 鄭 浩柄; 工藤 正俊日本消化器病学会近畿支部第92回例会  2010/02  大阪国際交流センター, 大阪  日本消化器病学会近畿支部第92回例会十二指腸ステント留置後にEUS下胆嚢ドレナージ術を行った閉塞性黄疸の一例.  [Not invited]今井 元; 北野 雅之; 末冨 洋一郎; 小牧 孝充; 鎌田 研; 坂本 洋城; 工藤 正俊日本消化器病学会近畿支部第92回例会  2010/02  大阪国際交流センター, 大阪  日本消化器病学会近畿支部第92回例会特別講演「肝細胞癌に対する最新の話題: ネクサバールの有用性とその位置づけ」  [Not invited]工藤 正俊学術講演会  2010/02  メルキュールホテル横須賀, 神奈川  学術講演会特別講演「肝癌治療アルゴリズムにおける分子標的治療の位置づけ」  [Not invited]工藤 正俊第24回冬季札幌がんセミナー  2010/02  北海道  第24回冬季札幌がんセミナーSpecial Lecture “Imaging diagnosis of early HCC: Recent advance.”  [Not invited]工藤 正俊Choshu International Liver Smposium 2010  2010/02  Yamaguchi, Japan  Choshu International Liver Smposium 2010特別講演「世界から見た日本の肝癌治療の現状」  [Not invited]工藤 正俊KBNCの会  2010  全日空ホテルクレメント高松, 香川  KBNCの会Special lecture “Earlier HCC diagnosis: US, CT and MRI aspects ?anatomopathological correlation―US aspects-.”  [Not invited]工藤 正俊JPR 2010  2010  Sao Paulo, Brazil  JPR 2010特別講演「肝細胞癌に対するネクサバール治療: 副作用対策の成功が治療の成功」  [Not invited]工藤 正俊名古屋肝癌セミナー  2010/01  愛知  名古屋肝癌セミナー特別講演「異型結節・早期肝癌の診断、多血性腫瘍への移行 US」  [Not invited]工藤 正俊第16回肝血流動態イメージ研究会 シンポジウム「肝細胞癌多段階発癌の診断: 慢性肝炎、異型結節、進行肝癌の個別化診断に向けて」  2010/01  神戸ポートピアホテル, 兵庫  第16回肝血流動態イメージ研究会 シンポジウム「肝細胞癌多段階発癌の診断: 慢性肝炎、異型結節、進行肝癌の個別化診断に向けて」特別講演「肝癌診療の新しいパラダイム」  [Not invited]工藤 正俊第70回倉敷肝臓臨床談話会  2010/01  岡山  第70回倉敷肝臓臨床談話会特別講演「Sonazoid造影エコー法の新しい展開」  [Not invited]工藤 正俊日本超音波医学会第29回中部地方会学術集会  2010/01  石川  日本超音波医学会第29回中部地方会学術集会肝細胞癌に対してラジオ波焼灼療法(RFA)を施行したCAPDの1例.  [Not invited]中野 志仁; 鮫島 謙一; 木下 浩二; 有馬 秀二; 船内 正憲; 鄭 浩柄; 工藤 正俊; 岩本 一郎第23回大阪CAPD研究会  2009/12  大阪市立大学, 大阪  第23回大阪CAPD研究会Malignancy grading of primary hepatocellular carcinoma by liver-specific contrast agent and hemodynamic alteration  [Not invited]岡田 真広; 熊野 正士; 工藤 正俊; 村上 卓道Radiological Society of North America 2009 95th Scientific Assembly and Annual Meeting(RSNA)  2009/12  Chicago,USA  Radiological Society of North America 2009 95th Scientific Assembly and Annual Meeting(RSNA)Contrast-enhanced harmonic endosonography in pancreatobiliary diseases.  [Not invited]北野 雅之; 坂本 洋城; 小牧 孝充; 工藤 正俊11th International Symposium on Ultrasound Contrast Imaging  2009/12  Kunming, China  11th International Symposium on Ultrasound Contrast ImagingSpecial Lecture “RF Ablation of HCC under CEUS guideline.”  [Not invited]工藤 正俊11th International Symposium on Ultrasound Contrast Imaging  2009/12  Kunming, China  11th International Symposium on Ultrasound Contrast ImagingSpecial Lecture “Defect-Re-perfusion imaging for liver tumors and CEUS in the diagnosis of macroscopic classification of HCC.”  [Not invited]工藤 正俊11th International Symposium on Ultrasound Contrast Imaging  2009/12  Kunming, China  11th International Symposium on Ultrasound Contrast ImagingSpecial Lecture “EOB-MRI in liver tumors: Its role in differentiation berween early HCC and dysplastic nodule.”  [Not invited]工藤 正俊All India Institute of Medical Science (AIIMS)  2009/12  New Delhi, India  All India Institute of Medical Science (AIIMS)Special Lecture and Live Demonstration“Contrast-enhanced US of liver tumors.”  [Not invited]工藤 正俊Institute of Hepatobiliary and Pancreatic Science  2009/12  New Delhi, India  Institute of Hepatobiliary and Pancreatic ScienceSpecial Lecture “Management of HCC: Recent advances.”  [Not invited]工藤 正俊Indian Society of Gastroenterology  2009/12  Colcutta, India  Indian Society of Gastroenterology特別講演「肝癌診療の新しいパラダイム」  [Not invited]工藤 正俊KNBCの会  2009/12  高松  KNBCの会PEG-IFN療法施行中に、ALTおよびフェリチンの上昇をきたしたC型慢性肝炎の3例と、うち瀉血療法が奏効した1例  [Not invited]宮田 央; 工藤 正俊; 宮田 学第38回日本肝臓学会西部会  2009/12  米子コンベンションセンター, 鳥取.  第38回日本肝臓学会西部会Special Lecture “Recent advances in the imaging of HCC.”  [Not invited]工藤 正俊9th PGI-AIIMS Current perspectives in liver diseases-2009 & singl theme conference “Management Issue  2009/12  Department of Hepatology Pgimer, Chandigarh & Department of Gastroenterology AIIMS, New Delhi, India  9th PGI-AIIMS Current perspectives in liver diseases-2009 & singl theme conference “Management IssueSpecial Lecture “Management of HCC: Role of molecular targeted agents. "  [Not invited]工藤 正俊9th PGI-AIIMS Current perspectives in liver diseases-2009 & singl theme conference “Management Issue  2009/12  Department of Hepatology Pgimer, Chandigarh & Department of Gastroenterology AIIMS, New Delhi, India  9th PGI-AIIMS Current perspectives in liver diseases-2009 & singl theme conference “Management Issue特別講演「ネクサバール錠副作用対策」  [Not invited]工藤 正俊第2回山形分子標的治療講演会  2009/12  山形メトロポリタンホテル, 山形  第2回山形分子標的治療講演会特別講演「肝癌診療の新しいパラダイム」  [Not invited]工藤 正俊第4回北里肝臓フォーラム  2009/12  小田急ホテルセンチュリー相模大野, 神奈川  第4回北里肝臓フォーラムEstimation of the malignant potential of gastrointestinal stromal tumors: for a precise management of SMT by CHE-EUS.  [Not invited]坂本 洋城; 北野 雅之; 鎌田 研; 小牧 孝充; 今井 元; 筑後 孝章; 竹山 宜典; 工藤 正俊UEGW  2009/11  London, UK  UEGWDetection rates of pancreatic tumors according to location by contrast-enhanced ultrasonography, endosonography and multidetector row CT.  [Not invited]今井 元; 北野 雅之; 末冨 洋一郎; 坂本 洋城; 小牧 孝充; 野田 佳寿; 鎌田 研; 竹山 宜典; 工藤 正俊East Meets West 40th Anniversary  2009/11  Honolulu, USA  East Meets West 40th AnniversaryPancreas by EUS-guided in vivo microdialysis.  [Not invited]北野 雅之; 坂本 洋城; 小牧 孝充; 今井 元; 鎌田 研; 工藤 正俊East Meets West 40th Anniversary  2009/11  Honolulu, USA  East Meets West 40th AnniversaryEUS-assisted drainage of pancreatic duct for obstructive pancreatitis.  [Not invited]北野 雅之; 坂本 洋城; 小牧 孝充; 今井 元; 鎌田 研; 竹山 宜典; 工藤 正俊East Meets West 40th Anniversary  2009/11  Honolulu, USA  East Meets West 40th AnniversarySpecial Lecture “Hepatocellular Carcinoma in Japan: Epidemiology, Diagnosis and RF Ablatiom.”  [Not invited]工藤 正俊“HBV Now in Asia” The 8th JSH Single Topic Conference by The Japan Society of Hepatolog (JSH)  2009/11  Tokyo, Japan  “HBV Now in Asia” The 8th JSH Single Topic Conference by The Japan Society of Hepatolog (JSH)Special Lecture “Defect re-perfusion imaging for HCC.”  [Not invited]工藤 正俊Italian Society of Ultrasound in Medicine (ISUM)  2009/11  Rome, Italy  Italian Society of Ultrasound in Medicine (ISUM)Special Lecture “Consensus statement of management of HCC in Asia.”  [Not invited]工藤 正俊20th Asia Pacific Cancer Conference (APCC) 2009  2009/11  Tsukuba, Japan  20th Asia Pacific Cancer Conference (APCC) 2009Special Lecture “Ultrasound diagnosis of pancreatic tumors.”  [Not invited]工藤 正俊7th Workshop of Asian Federation of Ultrasound in Medicine and Biology (AFSUMB)  2009/11  Jakarta, Indonesia  7th Workshop of Asian Federation of Ultrasound in Medicine and Biology (AFSUMB)Special Lecture “Color doppler imaging of liver tumors.”  [Not invited]工藤 正俊7th Workshop of Asian Federation of Ultrasound in Medicine and Biology (AFSUMB)  2009/11  Jakarta, Indonesia  7th Workshop of Asian Federation of Ultrasound in Medicine and Biology (AFSUMB)Special Lecture “Sonazoid-enhanced US of Liver Tumors.”  [Not invited]工藤 正俊7th Workshop of Asian Federation of Ultrasound in Medicine and Biology (AFSUMB)  2009/11  Jakarta, Indonesia  7th Workshop of Asian Federation of Ultrasound in Medicine and Biology (AFSUMB)Special Lecture “Radiological diagnosisi of very early-stage HCC.”  [Not invited]工藤 正俊Mini-Symposium “Very-Early HCC”, American Association of Study of the liver Disease (AASLD)  2009/11  Boston, USA  Mini-Symposium “Very-Early HCC”, American Association of Study of the liver Disease (AASLD)特別講演「BCAA顆粒製剤の今後の展望(コホート研究結果を踏まえて)」  [Not invited]工藤 正俊肝臓疾患フォーラム2009 BCAA顆粒製剤の新たな知見「肝癌抑制メカニズムと臨床的意義」  2009/11  品川プリンスホテル, 東京  肝臓疾患フォーラム2009 BCAA顆粒製剤の新たな知見「肝癌抑制メカニズムと臨床的意義」特別講演「肝癌治療の現状と展望」  [Not invited]工藤 正俊北九州肝癌最先端治療講演会  2009/11  ステーションホテル小倉, 福岡  北九州肝癌最先端治療講演会EUS-guided broad plexus-neurolysis over the superior mesenteric artery using a 25 gauge needle. Awarded as a (Best submit abstract)  [Not invited]坂本 洋城; 北野 雅之; 鎌田 研; 小牧 孝充; 今井 元; 筑後 孝章; 竹山 宜典; 工藤 正俊UEGW  2009/11  London, UK  UEGWEstimation of the malignant potential of gastrointestinal stromal tumors: imaging  [Not invited]坂本 洋城; 北野 雅之; 鎌田 研; 小牧 孝充; 今井 元; 筑後 孝章; 竹山 宜典; 工藤 正俊UEGW  2009/11  London, UK  UEGW特別講演「ネクサバールの使用経験とポジショニングについて」  [Not invited]工藤 正俊佐賀県肝癌治療研究会  2009/11  マリトピア, 佐賀  佐賀県肝癌治療研究会特別講演「肝癌診療における画像診断の最新の話題」  [Not invited]工藤 正俊第8回会津肝胆膵画像研究会  2009/11  会津ワシントンホテル, 福島  第8回会津肝胆膵画像研究会特別講演「肝細胞癌診療の最新の話題; EOB-MRIと分子標的治療への期待」  [Not invited]工藤 正俊第9回Hyogo Liver Conference  2009/11  神戸ベイシェラトンホテル&タワーズ, 兵庫  第9回Hyogo Liver Conference特別講演「肝細胞癌の最新治療~ネクサバールの有効性と安全性について」  [Not invited]工藤 正俊第1回栃木肝細胞癌セミナー  2009/11  ホテル東日本宇都宮, 栃木  第1回栃木肝細胞癌セミナーThe cancer stem cell marker CD133 is a predictor of the effectiveness of S1+PEG-IFN α-2b therapy against advanced hepatocellular carcinoma  [Not invited]萩原 智; 工藤 正俊; 上嶋 一臣; 鄭 浩柄; 井上 達夫; 矢田 典久; 北井 聡; 田北 雅弘; 永井 知行; 土師 誠二; 木村 雅友; Ah-Mee Park; 宗像 浩The 60th Annual Meeting of the American Association for the study of liver diseases (AASLD)  2009/11  Boston, USA  The 60th Annual Meeting of the American Association for the study of liver diseases (AASLD)Usefulness of hepatocyte phase imaging of Gd-EOB-DTPA-MRI in detecting HCCs which are difficult to detect other imaging modalities.  [Not invited]井上 達夫; 工藤 正俊The 60th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD)  2009/11  Boston, USA  The 60th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD)シンポジウム・特別発言「肝細胞癌の生命予後改善のための挑戦(再発予防を中心に)」  [Not invited]工藤 正俊第13回日本肝臓学会大会・第51回日本消化器病学会大会  2009/10  グランドプリンスホテル京都, 京都  第13回日本肝臓学会大会・第51回日本消化器病学会大会新規血管新生阻害剤BIBF1120の肝細胞癌に対する有用性.  [Not invited]工藤 可苗; 荒尾 徳三; 坂井 和子; 永井 知行; 田村 大介; 青松 圭一; デベラスコマルコ; 金田 裕靖; 藤田 至彦; 松本 和子; 工藤 正俊; 西尾 和人第68回日本癌学会学術総会  2009/10  パシフィコ横浜, 神奈川  第68回日本癌学会学術総会特別講演「ウイルス性肝炎の治療」  [Not invited]工藤 正俊平成21年度肝がん撲滅運動  2009/10  大阪狭山市さやかホール, 大阪  平成21年度肝がん撲滅運動Special Lecture “Current advances in the management of HCC.”  [Not invited]工藤 正俊HCC Asian Expert Meeting  2009/10  Taipei, Taiwan  HCC Asian Expert MeetingSpecial Lecture “Concept of early HCC and its imaging finding.”  [Not invited]工藤 正俊The 3rd International Forum for Liver MRI  2009/10  Rhome, Italy  The 3rd International Forum for Liver MRI特別講演「肝癌診療の最前線」  [Not invited]工藤 正俊近畿大学関連病院長会議  2009/10  大阪狭山, 大阪  近畿大学関連病院長会議特別講演「肝癌根治後のIFNの役割」  [Not invited]工藤 正俊Hepatitis C Forum 2009 YAMAGATA  2009/10  ホテルメトロポリタン山形, 山形  Hepatitis C Forum 2009 YAMAGATA特別講演「肝発癌進展抑制におけるIFNの役割」  [Not invited]工藤 正俊城北Hepatologyセミナー  2009/10  池袋ホテルメトロポリタン, 東京  城北Hepatologyセミナー特別講演「肝癌診療の最前線」  [Not invited]工藤 正俊第237回青森市消化器病集談会  2009/10  ホテル青森, 青森  第237回青森市消化器病集談会HCV陽性肝癌根治後のPEG-IFNα2b/Ribavirin併用療法は再発を抑制できるか. シンポジウム「肝細胞癌の生命予後改善のための挑戦(再発予防を中心に)」  [Not invited]齋藤 澄夫; 工藤 正俊; 木村 達; 大崎 往夫第13回日本肝臓学会大会  2009/10  国立京都国際会館・グランドプリンスホテル京都, 京都  第13回日本肝臓学会大会PEG-IFNα2b/RBV併用療法の無効・再燃例に対するPEG-IFNα2a/RBV併用療法の再治療の検討-多施設共同研究 RETRY study-. パネルディスカッション「C型慢性肝炎に対するpeg-IFN+RBV併用無効例に対する方策」  [Not invited]上田 泰輔; 工藤 正俊; 橋元 悟; 土谷 薫第13回日本肝臓学会大会  2009/10  国立京都国際会館・グランドプリンスホテル京都, 京都  第13回日本肝臓学会大会Real-time Tissue Elastographyを用いた非侵襲的肝線維化評価法. パネルディスカッション「非侵襲的肝病態評価法の進歩」  [Not invited]藤本 研治; 工藤 正俊; 加藤 道夫第13回日本肝臓学会大会  2009/10  国立京都国際会館・グランドプリンスホテル京都, 京都  第13回日本肝臓学会大会分枝鎖アミノ酸顆粒製剤による肝硬変患者の予後に与える影響に関する検討. シンポジウム「肝炎ウイルス治療ガイドラインの検証」  [Not invited]早石 宗右; 石川 恵美; 工藤 正俊; 熊田 博光第13回日本肝臓学会大会  2009/10  国立京都国際会館・グランドプリンスホテル京都, 京都  第13回日本肝臓学会大会PEG-IFNα2a/Ribavirin併用療法のResponse-Guided Therapyを考慮した至適. シンポジウム「肝炎ウイルス治療ガイドラインの検証」  [Not invited]西口 修平; 工藤 正俊; 樋口 和秀第13回日本肝臓学会大会  2009/10  国立京都国際会館・グランドプリンスホテル京都, 京都  第13回日本肝臓学会大会Antitumor activity of a novel angiogenesis inhibitor BIBF1120 for hepatocellular carcinoma and a new pharamacodynamic biomaker in blood samples.  [Not invited]工藤 正俊; 工藤 可苗; 荒尾 徳三; 西尾 和人The 60th Annual Meeting of the American Association for the study of liver diseases (AASLD)  2009/10  Boston, USA  The 60th Annual Meeting of the American Association for the study of liver diseases (AASLD)特別講演「肝細胞癌診療の最新の進歩~Sonazoid造影超音波は中心に~」  [Not invited]工藤 正俊東北肝疾患病態・治療研究会  2009/10  盛岡グランドホテル, 岩手  東北肝疾患病態・治療研究会特別講演「肝癌治療アルゴリズムにおけるネクサバールの位置付け」  [Not invited]工藤 正俊第1回信州肝癌分子標的治療研究会  2009/10  ホテルブエナビスタ, 長野  第1回信州肝癌分子標的治療研究会高齢者に対する大腸ポリペクトミーの安全性と問題点  [Not invited]山本 典雄; 辻 直子; 奥村 直己; 酒井 清裕; 加納 友環; 冨田 崇文; 西尾 健; 梅原 康湖; 森村 正嗣; 米田 円; 由谷 逸朗; 山田 哲; 今井 元; 工藤 正俊; 本庶 元第78回日本消化器内視鏡学会総会(JDDW2009)  2009/10  京都市  第78回日本消化器内視鏡学会総会(JDDW2009)大腸ポリペクトミークリニカルパスバリアンス分析からみた大腸LSTの問題点  [Not invited]奥村 直己; 辻 直子; 山本 典雄; 加納 友環; 酒井 清裕; 冨田 崇文; 西尾 健; 梅原 康湖; 森村 正嗣; 米田 円; 由谷 逸朗; 山田 哲; 今井 元; 工藤 正俊; 本庶 元第78回日本消化器内視鏡学会総会(JDDW2009)  2009/10  京都市  第78回日本消化器内視鏡学会総会(JDDW2009)患者の安全・満足度から考えるsedation下内視鏡検査、プロポフォール投与下での外来下部消化管内視鏡検査の有用性  [Not invited]梅原 康湖; 辻 直子; 工藤 正俊第78回日本消化器内視鏡学会総会(JDDW2009)  2009/10  京都市  第78回日本消化器内視鏡学会総会(JDDW2009)予後解析からみた大腸ポリペクトミーの意義と問題点  [Not invited]辻 直子; 奥村 直己; 山本 典雄; 加納 友環; 酒井 清裕; 西尾 健; 冨田 崇文; 梅原 康湖; 森村 正嗣; 米田 円; 由谷 逸朗; 山田 哲; 今井 元; 工藤 正俊; 本庶 元第51回日本消化器病学会大会(JDDW2009)  2009/10  京都市  第51回日本消化器病学会大会(JDDW2009)Utility of contrast-enhanced harmonic EUS on diagnosis of intra-abdominal lesions with undertermined origin.  [Not invited]鎌田 研; 北野 雅之; 坂本 洋城; 小牧 孝充; 今井 元; 末冨 洋一郎; 工藤 正俊Asia Pacific Digestive Disease Week (APDW)  2009/09  Taipei, Taiwan  Asia Pacific Digestive Disease Week (APDW)EUS-FNA guided by contrast-enhanced harmonic imaging.  [Not invited]北野 雅之; 坂本 洋城; 小牧 孝充; 今井 元; 鎌田 研; 工藤 正俊Asia Pacific Digestive Disease Week (APDW)  2009/09  Taipei, Taiwan  Asia Pacific Digestive Disease Week (APDW)EUS-BD後の難治性逆行性胆管炎に対するトラブルシューティング.  [Not invited]小牧 孝充; 北野 雅之; 末冨 洋一郎; 今井 元; 鎌田 研; 工藤 正俊第6回FNA-Club Japan  2009/09  東京医科大学, 東京  第6回FNA-Club Japan経乳頭的アプローチ困難例に対するEUSガイド下胆管ドレナージ術の有用性.  [Not invited]鎌田 研; 北野 雅之; 末冨 洋一郎; 坂本 洋城; 小牧 孝充; 今井 元; 工藤 正俊第45回日本胆道学会学術集会  2009/09  千葉県がんセンター, 千葉  第45回日本胆道学会学術集会EUSによる胆管癌の進展度診断.  [Not invited]小牧 孝充; 北野 雅之; 工藤 正俊ワークショップ「ビデオワークショップ 胆道疾患に対する内視鏡診断の進展」, 第45回日本胆道学会学術集会  2009/09  千葉県がんセンター, 千葉  ワークショップ「ビデオワークショップ 胆道疾患に対する内視鏡診断の進展」, 第45回日本胆道学会学術集会IPMNに随伴した膵癌の1例.  [Not invited]小牧 孝充; 北野 雅之; 工藤 正俊第51回日本消化器画像診断研究会  2009/09  仙台市医師会館, 宮城  第51回日本消化器画像診断研究会潰瘍性大腸炎として紹介されたClostridium.difficile関連腸病変の一例.  [Not invited]奥村 直己; 山本 典雄; 富田 崇文; 梅原 康子; 南 康範; 森村 正嗣; 米田 円; 山田 哲; 辻 直子; 工藤 正俊第83回日本消化器内視鏡学会近畿地方会  2009/09  京都テルサ, 京都  第83回日本消化器内視鏡学会近畿地方会Special Lecture “Current topics in HCC: Diagnosis of early HCC and Sonazoid-enhanced US guided ablation.”  [Not invited]工藤 正俊1st Japan Korea Image guided Tumor Ablation Meeting  2009/09  Villa Fontaine Shiodome Conference Center, Tokyo, Japan  1st Japan Korea Image guided Tumor Ablation MeetingSpecial Lecture “Clinical and radiological aspects of preneoplastic liver lesions.”  [Not invited]工藤 正俊3rd Annual Conference International Liver Cancer Association (ILCA)  2009/09  Milan, Italy  3rd Annual Conference International Liver Cancer Association (ILCA)特別講演「肝細胞癌の早期診断と分子標的治療」  [Not invited]工藤 正俊肝癌診断治療講演会  2009/09  高松国際ホテル, 香川  肝癌診断治療講演会特別講演「Future treatment in HCV」  [Not invited]工藤 正俊Hepatitis C Forum 2009 OSAKA  2009/09  ホテルニューオータニ大阪, 大阪  Hepatitis C Forum 2009 OSAKA特別講演「HCC治療における分子標的治療への期待と課題」  [Not invited]工藤 正俊第1回TOKYO HCC EXPERT MEETING  2009/09  アルカディア市ヶ谷, 東京  第1回TOKYO HCC EXPERT MEETING潰瘍性大腸炎として紹介されたClostridium difficile関連腸病変の一例  [Not invited]奥村 直己; 山本 典雄; 冨田 崇文; 梅原 康湖; 南 康範; 森村 正嗣; 米田 円; 山田 哲; 辻 直子; 工藤 正俊第83回日本消化器内視鏡学会近畿地方会  2009/09  京都市  第83回日本消化器内視鏡学会近畿地方会肝細胞癌破裂後に肝切除を行ったが腹腔内播種で再発した一例.  [Not invited]林 道友; 奥田 英之; 茂山 朋広; 宮部 欽生; 豊澤 昌子; 岸谷 讓; 鍋島 紀滋; 村田 賢; 井上 雅智; 工藤 正俊日本消化器病学会近畿支部第91回例会  2009/09  京都テルサ, 京都  日本消化器病学会近畿支部第91回例会抗アクアポリン4抗体陽性視神経炎に合併した自己免疫性肝炎の一例  [Not invited]山本 典雄; 奥村 直己; 冨田 崇文; 梅原 康湖; 南 康範; 森村 正嗣; 米田 円; 山田 哲; 辻 直子; 工藤 正俊; 小長谷 奈美; 中尾 雄三日本消化器病学会近畿支部第91回例会  2009/09  京都市  日本消化器病学会近畿支部第91回例会Evaluation of liver fibrosis progression using real-time tissue elastography.  [Not invited]外村 明子; 辰巳 千栄; 工藤 正俊; 藤本 研治; 三竹 毅; 加藤 道夫; 椎名 毅12th World Congress of the World Federation for Ultrasound in Medicine and Biology  2009/09  Sydney, Australia  12th World Congress of the World Federation for Ultrasound in Medicine and Biology特別講演「ウイルス性肝炎の治療」  [Not invited]工藤 正俊肝がん撲滅の為の肝臓病市民公開講座  2009/08  堺市民会館, 大阪  肝がん撲滅の為の肝臓病市民公開講座食道静脈瘤上に合併した早期食道癌の1例.  [Not invited]松井 繁長; 工藤 正俊第18回近畿食道・胃静脈瘤研究会  2009/08  大阪薬業年金会館, 大阪  第18回近畿食道・胃静脈瘤研究会Special Lecture “Defect Re-perfusion imaging as a treatment guideline for HCC“  [Not invited]工藤 正俊WFUMB  2009/08  Sydney, Australia  WFUMBSpecial Lecture “Sonazoid-enhanced US for liver tumors.”  [Not invited]工藤 正俊WFUMB  2009/08  Sydney, Australia  WFUMB特別講演「肝癌診療におけるネクサバールの位置づけ」  [Not invited]工藤 正俊ネクサバール発売記念シンポジウム 肝細胞癌におけるネクサバールの位置づけ  2009/08  東京  ネクサバール発売記念シンポジウム 肝細胞癌におけるネクサバールの位置づけパネルディスカッション・特別発言「凝固療法の適応と限界及び合併症ー対策と新工夫ー」  [Not invited]工藤 正俊第45回日本肝癌研究会  2009/07  福岡国際会議場, 福岡  第45回日本肝癌研究会切除不能肝細胞癌に対するSM-11355とジノスタリンストマラマーのランダム化比較試験第II相試験.  [Not invited]池田 公史; 工藤 正俊; 奥坂 拓志; 春日井 博志; 石井 浩; 佐田 通夫; 田中 克明; 塩山 靖和; 茶山 一彰; 熊田 博光; 吉川 正治第45回日本肝癌研究会  2009/07  福岡国際会議場, 福岡  第45回日本肝癌研究会Special Lecture “Management of HCC: Current practice guideline.”  [Not invited]工藤 正俊Yonsei University Liver Cancer Symposium  2009/07  Seoul, Korea  Yonsei University Liver Cancer SymposiumSpecial Lecture “The current assessment algprothm for HCC (EASL, AASL, APASL JSH).”  [Not invited]工藤 正俊Hepatocellular Cancer (HCC) International Comprehensive Workshop  2009/07  Freyberg, Germany  Hepatocellular Cancer (HCC) International Comprehensive Workshop特別講演「肝癌再発抑制治療の現状と今後の展望」  [Not invited]工藤 正俊平成21年度京都医師会肝炎ウイルス研修会  2009/07  北九州, 福岡  平成21年度京都医師会肝炎ウイルス研修会造影ハーモニックEUS検査による膵腫瘍性病変診断.  [Not invited]北野 雅之; 坂本 洋城; 小牧 孝充; 竹山 宜典; 工藤 正俊; 高木 忠之; 山雄 健次第40回日本膵臓学会大会  2009/07  京王プラザホテル, 東京  第40回日本膵臓学会大会特別講演「ソナゾイドは肝癌診療をどう変えるか」  [Not invited]工藤 正俊県北肝疾患研究会  2009/07  福島ビューホテル, 福島  県北肝疾患研究会特別講演「診断の進歩と今後の治療アルゴリズム-分子標的治療を含めて-」  [Not invited]工藤 正俊第7回肝臓病研究会シンポジウム  2009/07  品川プリンスホテル, 東京  第7回肝臓病研究会シンポジウムThe current assessment algorithm for HCC (EASL, AASL, APASL) guidelines.  [Not invited]工藤 正俊Advanced Hepatocellular Cancer (HCC): Steps Forward  2009/07  Freyburg, German  Advanced Hepatocellular Cancer (HCC): Steps Forward肝癌患者の治療法別QOL(quality of life)における性差.  [Not invited]中山 伸朗; 工藤 正俊; 名越 澄子; 持田 智; 小俣 政男; 熊田 博光; 佐田 通夫; 國土 典宏; 門田 守人; 兼松 隆之; 江川 裕人; 森脇 久隆; 藤原 研司第5回消化器病における性差医学・医療研究会  2009/07  大阪国際会議場, 大阪  第5回消化器病における性差医学・医療研究会症例4-1  [Not invited]井本 勉; 工藤 正俊; 金 守良; 安藤 健治; 三田 敬二; 和田 純子; 有本 明; 若狭 朋子; 林 祥剛; 全 陽; 中沼 安二; 松岡 利幸問題症例検討会4「肝癌診断困難症例」, 第45回日本肝癌研究会  2009/07  福岡国際会議場, 福岡  問題症例検討会4「肝癌診断困難症例」, 第45回日本肝癌研究会特別講演「肝細胞癌の早期診断と分子標的治療」  [Not invited]工藤 正俊肝癌診断治療講演会  2009/06  高松国際ホテル, 香川  肝癌診断治療講演会新規血管新生阻害剤BIBF1120の肝細胞癌に対する有用性.  [Not invited]工藤 可苗; 荒尾 徳三; 田村 大介; 青松 圭一; 金田 裕靖; 田中 薫; 前川 麻里; 松本 和子; 藤田 至彦; 工藤 正俊; 西尾 和人第13回日本がん分子標的治療学会  2009/06  徳島  第13回日本がん分子標的治療学会Special Lecture “Positioning and indication of Sorafenib in the treatment algorithm and real practice setting: Western and Eastern Approach.”  [Not invited]工藤 正俊3rd International Kobe Liver Symposium on HCC with an International Liver Cancer Association (ILCA)  2009/06  Kobe, Japan  3rd International Kobe Liver Symposium on HCC with an International Liver Cancer Association (ILCA)Luncheon Seminar “The burden of HCC: From the surveillance to molecular targeted therapy.”  [Not invited]工藤 正俊3rd International Kobe Liver Symposium on HCC with an International Liver Cancer Association (ILCA)  2009/06  Kobe, Japan  3rd International Kobe Liver Symposium on HCC with an International Liver Cancer Association (ILCA)Special Lecture “Imaging of early HCC.”  [Not invited]工藤 正俊3rd International Kobe Liver Symposium on HCC with an International Liver Cancer Association (ILCA)  2009/06  Kobe, Japan  3rd International Kobe Liver Symposium on HCC with an International Liver Cancer Association (ILCA)Special Lecture “BCLC staging is good as a treatment selection staging similar to Japanese treatment algorithm and different from prognostic staging.”  [Not invited]工藤 正俊International Symposium “Different Approach to HCC Management Japan, North America and Europe, The  2009/06  Kobe, Japan  International Symposium “Different Approach to HCC Management Japan, North America and Europe, The特別講演「肝細胞癌治療のパラダイムシフト: 分子標的治療への期待」  [Not invited]工藤 正俊C型肝炎対策学術講演会  2009/06  今治国際ホテル, 愛媛  C型肝炎対策学術講演会特別講演「造影エコーの有用性と将来の展望」  [Not invited]工藤 正俊第45回日本肝臓学会総会  2009/06  神戸ポートピアホテル, 兵庫  第45回日本肝臓学会総会特別講演「肝癌診療におけるEOB・プリモビストの役割」  [Not invited]工藤 正俊第1回多摩エリアEOB・プリモビストセミナー  2009/06  三鷹産業プラザ, 東京  第1回多摩エリアEOB・プリモビストセミナーSpecial Lecture “RF Ablation of HCC under CEUS guidance.”  [Not invited]工藤 正俊World Conference on Interventional Oncology 2009  2009/06  Beijing International Convention Center, Beijing, China  World Conference on Interventional Oncology 2009血管新生阻害薬のバイオマーカー研究.  [Not invited]荒尾 徳三; 工藤 正俊; 西尾 和人ワークショップ「肝癌発生・進展の分子機構と臨床への還元」第45回日本肝臓学会総会  2009/06  神戸ポートピアホテル, 兵庫  ワークショップ「肝癌発生・進展の分子機構と臨床への還元」第45回日本肝臓学会総会BCLC staging is good as a treatment selection staging similar to Japanese treatment algorithm and different from prognostic staging.  [Not invited]工藤 正俊シンポジウム「日米欧における肝癌診療の相違をめぐって」第45回日本肝臓学会総会  2009/06  シンポジウム「日米欧における肝癌診療の相違をめぐって」第45回日本肝臓学会総会Gd-EOB MRIによる肝細胞癌の診断能~造影超音波検査, Dynamic CTとの比較検討.  [Not invited]井上 達夫; 畑中 絹世; 早石 宗右; 永井 知行; 田北 雅弘; 上田 泰輔; 高橋 俊介; 北井 聡; 石川 恵美; 矢田 典久; 萩原 智; 南 康範; 鄭 浩柄; 上嶋 一臣; 工藤 正俊第45回日本肝臓学会総会  2009/06  神戸ポートピアホテル, 兵庫  第45回日本肝臓学会総会進行肝細胞癌に対するソラフェニブの有効性に関する検討.  [Not invited]上嶋 一臣; 早石 宗右; 永井 知行; 田北 雅弘; 辰巳 千栄; 上田 泰輔; 北井 聡; 高橋 俊介; 石川 恵美; 矢田 典久; 井上 達夫; 南 康範; 鄭 浩柄; 工藤 正俊第45回日本肝臓学会総会  2009/06  神戸ポートピアホテル, 兵庫  第45回日本肝臓学会総会特異な経緯をたどったアルコール性肝硬変に合併した肝細胞癌の一例.  [Not invited]早石 宗右; 鄭 浩柄; 辰巳 千栄; 永井 知行; 上田 泰輔; 高橋 俊介; 北井 聡; 石川 恵美; 矢田 典久; 井上 達夫; 萩原 智; 南 康範; 上嶋 一臣; 工藤 正俊第45回日本肝臓学会総会  2009/06  神戸ポートピアホテル, 兵庫  第45回日本肝臓学会総会進行肝細胞癌に対するS-1, ペグインターフェロン併用療法の有用性.  [Not invited]矢田 典久; 鄭 浩柄; 早石 宗右; 永井 知行; 田北 雅弘; 辰巳 千栄; 上田 泰輔; 高橋 俊介; 北井 聡; 石川 恵美; 井上 達夫; 南 康範; 上嶋 一臣; 工藤 正俊第45回日本肝臓学会総会  2009/06  神戸ポートピアホテル, 兵庫  第45回日本肝臓学会総会慢性C型肝炎における末梢血血小板数減少のメカニズムについてー免疫血液学的検索を中心に.  [Not invited]永井 知行; 工藤 正俊; 井本 勉; 金 守良; 三田 敬二; 谷口 美幸; 林 祥剛第45回日本肝臓学会総会  2009/06  戸ポートピアホテル, 兵庫  第45回日本肝臓学会総会分子鎖アミノ酸顆粒製剤による肝硬変患者の予後に与える影響に関する検討.  [Not invited]早石 宗右; 石川 恵美; 辰巳 千栄; 上田 泰輔; 高橋 俊介; 北井 聡; 矢田 典久; 井上 達夫; 南 康範; 鄭 浩柄; 上嶋 一臣; 工藤 正俊第45回日本肝臓学会総会  2009/06  神戸ポートピアホテル, 兵庫  第45回日本肝臓学会総会診断(US).  [Not invited]荒井 邦明; 工藤 正俊; 金子 周一特別企画「肝癌診療ガイドライン改訂公開シンポジウム」, 第45回日本肝臓学会総会  2009/06  神戸ポートピアホテル, 兵庫  特別企画「肝癌診療ガイドライン改訂公開シンポジウム」, 第45回日本肝臓学会総会経皮的局所療法.  [Not invited]工藤 正俊; 建石 良介特別企画「肝癌診療ガイドライン改訂公開シンポジウム」, 第45回日本肝臓学会総会  2009/06  神戸ポートピアホテル, 兵庫  特別企画「肝癌診療ガイドライン改訂公開シンポジウム」, 第45回日本肝臓学会総会特別講演「肝癌治療に与えるネクサバールのインパクト」  [Not invited]工藤 正俊第40回京都肝癌セミナー  2009/06  ホテルフジタ京都, 京都  第40回京都肝癌セミナーDynamic imaging by contrast-enhanced harmonic EUS with long-lasting contrast: Role in diagnosis of pancreatic tumors.  [Not invited]北野 雅之; 坂本 洋城; 小牧 孝充; 野田 佳寿; 工藤 正俊Digestive Disease Week  2009/06  Chicago, USA  Digestive Disease WeekContrast-enhanced harmonic EUS of intra-abdominal lesions with undertermined origin: initial observation of vascularity depiction.  [Not invited]北野 雅之; 坂本 洋城; 小牧 孝充; 野田 佳寿; 工藤 正俊Digestive Disease Week  2009/06  Chicago, USA  Digestive Disease WeekEUS-guided in vivo microdialysis of pancreas: A novel technique of potential diagnostic and therapeutic application.  [Not invited]北野 雅之; 坂本 洋城; 小牧 孝充; 工藤 正俊Digestive Disease Week  2009/06  Chicago, USA  Digestive Disease WeekSpecial Lecture “Recent advanced of imaging diagnosis.”  [Not invited]工藤 正俊The Taiwan Liver Cancer Association (TLCA) 2nd Annual Meeting  2009/06  Kaohsiung, Taiwan  The Taiwan Liver Cancer Association (TLCA) 2nd Annual Meeting保存的治癒した非代償性肝硬変合併穿孔性十二指腸潰瘍の1例  [Not invited]加納 友環; 奥村 直己; 山本 典雄; 冨田 崇文; 梅原 康湖; 南 康範; 米田 円; 辻 直子; 工藤 正俊日本内科学会 第188回近畿地方会  2009/06  大阪市  日本内科学会 第188回近畿地方会経皮的局所療法.  [Not invited]工藤 正俊特別企画「肝癌診療ガイドライン改訂公開シンポジウム」, 第45回日本肝臓学会総会  2009/06  神戸ポートピアホテル, 兵庫  特別企画「肝癌診療ガイドライン改訂公開シンポジウム」, 第45回日本肝臓学会総会Special Lecture “Prevention of recurrence after resection and ablation.”  [Not invited]工藤 正俊5th APASL Single Topic Conference  2009/05  Istanbul, Turkey  5th APASL Single Topic Conference特別講演「肝細胞癌の分子標的治療」  [Not invited]工藤 正俊KBNCの会  2009/05  全日空ホテルクレメント高松, 香川  KBNCの会当科における癌性疼痛緩和におけるEUS下腹腔神経叢ブロック術の工夫.  [Not invited]坂本 洋城; 北野 雅之; 小牧 孝充; 工藤 正俊第77回日本消化器内視鏡学会総会  2009/05  名古屋国際会議場, 愛知  第77回日本消化器内視鏡学会総会胆膵疾患に対するTherapeutic EUSの工夫と成績.  [Not invited]坂本 洋城; 北野 雅之; 小牧 孝充; 工藤 正俊第77回日本消化器内視鏡学会総会  2009/05  名古屋国際会議場, 愛知  第77回日本消化器内視鏡学会総会EUSガイド下胆管ドレナージ術後の瘻孔部からのAntegrade stenting法.  [Not invited]小牧 孝充; 北野 雅之; 坂本 洋城; 工藤 正俊第77回日本消化器内視鏡学会総会  2009/05  名古屋国際会議場, 愛知  第77回日本消化器内視鏡学会総会膵腫瘍性病変診断における造影ハーモニックEUS検査の有用性.  [Not invited]北野 雅之; 坂本 洋城; 工藤 正俊シンポジウム「膵癌の診断と治療の新展開」, 第77回日本消化器内視鏡学会総会  2009/05  名古屋国際会議場, 愛知  シンポジウム「膵癌の診断と治療の新展開」, 第77回日本消化器内視鏡学会総会慢性膵炎に対するEUSガイド下治療.  [Not invited]小牧 孝充; 北野 雅之; 工藤 正俊シンポジウム「慢性膵炎に対する最新の治療」, 第77回日本消化器内視鏡学会総会  2009/05  名古屋国際会議場, 愛知  シンポジウム「慢性膵炎に対する最新の治療」, 第77回日本消化器内視鏡学会総会肝細胞癌の自然壊死症例でのviability評価における造影超音波検査の有用性.  [Not invited]矢田 典久; 前川 清; 畑中 絹世; 高橋 俊介; 鄭 浩柄; 土師 誠二; 工藤 正俊日本超音波医学会第82回学術集会  2009/05  東京国際フォーラム, 東京  日本超音波医学会第82回学術集会肝細胞癌の肉眼分類とSonazoid造影超音波におけるdefect像の比較.  [Not invited]畑中 絹世; 南 康範; 工藤 正俊; 土師 誠二日本超音波医学会第82回学術集会  2009/05  東京国際フォーラム, 東京  日本超音波医学会第82回学術集会ソナゾイド造影超音波による肝癌局所療法の効果判定.  [Not invited]前川 清; 工藤 正俊ライブセッション「造影超音波検査の治療への応用」, 日本超音波医学会第82回学術集会  2009/05  東京国際フォーラム, 東京  ライブセッション「造影超音波検査の治療への応用」, 日本超音波医学会第82回学術集会造影ハーモニックEUS検査.  [Not invited]北野 雅之; 鎌田 研; 坂本 洋城; 小牧 孝充; 工藤 正俊パネルディスカッション「各領域の造影超音波の新展開」, 日本超音波医学会第82回学術集会  2009/05  東京国際フォーラム, 東京  パネルディスカッション「各領域の造影超音波の新展開」, 日本超音波医学会第82回学術集会肝疾患におけるReal-time Tissue Elastography-第4報.  [Not invited]藤本 研治; 辰巳 千栄; 上嶋 一臣; 工藤 正俊; 金 栄浩; 山本 佳司; 椎名 毅; 加藤 道夫パネルディスカッション「びまん性肝疾患の超音波による評価」, 日本超音波医学会第82回学術集会  2009/05  東京国際フォーラム, 東京  パネルディスカッション「びまん性肝疾患の超音波による評価」, 日本超音波医学会第82回学術集会Defect Re-perfusion Imagingの有用性とRFA治療支援.  [Not invited]畑中 絹世; 南 康範; 工藤 正俊シンポジウム「肝腫瘍診断における造影超音波の位置づけ」, 日本超音波医学会第82回学術集会  2009/05  東京国際フォーラム, 東京  シンポジウム「肝腫瘍診断における造影超音波の位置づけ」, 日本超音波医学会第82回学術集会  , 平成21年5月22日-24日, .「genotype 1b高ウイルス量」以外のC型慢性肝炎症例に対するPEG-IFNα2a response guided therapy.  [Not invited]鍋島 紀滋; 林 道友; 奥田 英之; 茂山 朋広; 宮部 欽生; 北口 容子; 豊澤 昌子; 岸谷 讓; 工藤 正俊第95回日本消化器病学会総会  2009/05  北海道厚生年金会館, 北海道  第95回日本消化器病学会総会粘膜下異所性胃腺を合併した早期胃癌の2例.  [Not invited]岡田 無文; 松井 繁長; 朝隈 豊; 川崎 正憲; 梅原 泰; 工藤 正俊; 今本 治彦; 筑後 孝章第95回日本消化器病学会総会  2009/05  北海道厚生年金会館, 北海道  第95回日本消化器病学会総会診断に難渋した腹部腫瘤における造影ハーモニック超音波内視鏡検査の有用性.  [Not invited]今井 元; 北野 雅之; 坂本 洋城; 小牧 孝充; 野田 佳寿; 末冨 洋一郎; 鎌田 研; 工藤 正俊第95回日本消化器病学会総会  2009/05  北海道厚生年金会館, 北海道  第95回日本消化器病学会総会IgG4関連自己免疫性肝炎の臨床的特徴象および治療反応性に関する検討.ワークショップ「IgG4関連硬化性疾患ー膵病変と膵外病変をめぐって」  [Not invited]鄭 浩柄; 工藤 正俊; 渡邉 智裕第95回日本消化器病学会総会  2009/05  北海道厚生年金会館, 北海道  第95回日本消化器病学会総会Gd-EOB MRIによる肝細胞癌の診断能 造影超音波検査, Dynamic CTとの比較検討.ワークショップ「肝胆膵領域の画像診断の進歩」  [Not invited]井上 達夫; 畑中 絹世; 工藤 正俊第95回日本消化器病学会総会  2009/05  北海道厚生年金会館, 北海道  第95回日本消化器病学会総会進行胃癌に対するソナゾイドを用いた造影EUSの意義.  [Not invited]工藤 正俊第77回日本消化器内視鏡学会総会  2009/05  名古屋国際会議場, 愛知  第77回日本消化器内視鏡学会総会Surgical resection vs. percutaneous ablation for hepatocellular carcinoma: a preliminary report of the Japanese nationwide survey.  [Not invited]長谷川 潔; 工藤 正俊; 高山 忠利; 國土 典宏; 有井 滋樹; 岡崎 正敏; 沖田 極; 小俣 政男; 神代 正道; 中沼 安二; 高安 賢一; 門田 守人; 松山 裕; 猪飼 伊和夫; 幕内 雅敏The 44th Annual Meeting of the European Association for the Study of the liver  2009/04  Copenhagen, Denmark  The 44th Annual Meeting of the European Association for the Study of the liverAntitumor activity of a novel angiogenesis inhibitor BIBF1120 for hepatocellular carcinoma and a new pharmacodynamic biomarker in blood samples.  [Not invited]工藤 可苗; 荒尾 徳三; 田中 薫; 金田 裕靖; 前川 麻里; 松本 和子; 田村 大介; 青松 圭一; デベラスコ マルコ アントニオ; 藤田 至彦; 工藤 正俊; 西尾 和人AACR 100th Annual Meeting 2009  2009/04  Denver, USA  AACR 100th Annual Meeting 2009特別講演「ソナゾイドは肝癌診療をどう変えるか」  [Not invited]工藤 正俊第24回青森県肝疾患研究会  2009/03  ホテルニューキャッスル, 青森  第24回青森県肝疾患研究会教育講演「肝癌」  [Not invited]工藤 正俊第7回日本臨床腫瘍学会学術集会 教育講演会  2009/03  名古屋, 愛知  第7回日本臨床腫瘍学会学術集会 教育講演会特別講演「腹部領域における3D, 4D超音波の現状」  [Not invited]工藤 正俊Phillips 超音波セミナー  2009/03  東京  Phillips 超音波セミナー特別講演「C型肝炎治療の重要性と最新の情報」  [Not invited]工藤 正俊平成20年度「肝がん撲滅運動」市民公開講座  2009/03  泉佐野市立文化会館泉の森ホール, 大阪  平成20年度「肝がん撲滅運動」市民公開講座肝細胞癌外科治療におけるソナゾイドを用いた術中造影エコーの有用性.  [Not invited]土師 誠二; 安田 武生; 石川 原; 中居 卓也; 竹山 宜典; 大柳 治正; 畑中 絹世; 工藤 正俊第11回関西肝癌局所療法研究会  2009/03  阪急電鉄本社ビル, 大阪  第11回関西肝癌局所療法研究会Special Lecture “Early HCC: Concept and imaging diagnosis.”  [Not invited]工藤 正俊17th Annual Conference of the Indian National Association for Study of Liver(INASL)  2009/03  New Delhi, India  17th Annual Conference of the Indian National Association for Study of Liver(INASL)Special Lecture “Molecular targeted therapy for HCC current status and future prospects.”  [Not invited]工藤 正俊17th Annual Conference of the Indian National Association for Study of Liver(INASL)  2009/03  New Delhi, India  17th Annual Conference of the Indian National Association for Study of Liver(INASL)膵頭部癌に伴う下部胆管閉塞に対し超音波内視鏡下胆道ドレナージ術(EUS-BD)が有用であった1例.  [Not invited]鎌田 研; 坂本 洋城; 小牧 孝充; 野田 佳寿; 末冨 洋一郎; 北野 雅之; 汐見 幹夫; 工藤 正俊第82回日本消化器内視鏡学会近畿地方会  2009/03  大阪国際交流センター, 大阪  第82回日本消化器内視鏡学会近畿地方会IPMNに随伴したTS1膵癌.  [Not invited]有住 忠晃; 坂本 洋城; 小牧 孝充; 野田 佳寿; 末冨 洋一郎; 北野 雅之; 汐見 幹夫; 工藤 正俊; 新垣 亘; 竹山 宜典第82回日本消化器内視鏡学会近畿地方会  2009/03  大阪国際交流センター, 大阪  第82回日本消化器内視鏡学会近畿地方会OGIBの診断、治療にシングルバルーン小腸内視鏡が有用であったBernard-Soulier症候群の1例.  [Not invited]高山 政樹; 松井 繁長; 川崎 正憲; 梅原 泰; 岡田 無文; 朝隈 豊; 工藤 正俊第82回日本消化器内視鏡学会近畿地方会  2009/03  大阪国際交流センター, 大阪  第82回日本消化器内視鏡学会近畿地方会早期胃癌とキサントーマが同一病巣内に存在した1例.  [Not invited]高山 政樹; 松井 繁長; 岡田 無文; 朝隈 豊; 川崎 正憲; 梅原 泰; 工藤 正俊; 筑後 孝章第82回日本消化器内視鏡学会近畿地方会  2009/03  大阪国際交流センター, 大阪  第82回日本消化器内視鏡学会近畿地方会胃悪性リンパ腫の化学療法後に認めた2cの一例.  [Not invited]酒井 清裕; 今井 元; 西尾 健; 冨田 崇文; 梅原 康湖; 森村 正嗣; 米田 円; 由谷 逸郎; 辻 直子; 工藤 正俊; 田中 晃第82回日本消化器内視鏡学会近畿地方会  2009/03  大阪国際交流センター, 大阪  第82回日本消化器内視鏡学会近畿地方会ペグインターフェロンとリバビリン併用医療により著明な胃粘膜障害をきたしたC型慢性肝炎の一例.  [Not invited]茂山 朋広; 宮部 欽生; 林 道友; 北口 容子; 豊澤 昌子; 岸谷 譲; 鍋島 紀滋; 工藤 正俊第82回日本消化器内視鏡学会近畿地方会  2009/03  大阪国際交流センター, 大阪  第82回日本消化器内視鏡学会近畿地方会特別講演「ソナゾイドは肝癌診療をどう変えるか」  [Not invited]工藤 正俊第24回青森県肝疾患研究会  2009/03  ホテルニューキャッスル, 青森  第24回青森県肝疾患研究会ステロイド未使用の潰瘍性大腸炎に対するサイクロスポリン持続静注と経口タクロリムスの比較検討.  [Not invited]梅原 泰; 高山 政樹; 川崎 正憲; 朝隈 豊; 岡田 無文; 松井 繁長; 早石 宗右; 野田 佳寿; 坂本 洋城; 井上 達夫; 石川 恵美; 矢田 典久; 萩原 智; 末冨 洋一郎; 南 康範; 鄭 浩柄; 上嶋 一臣; 北野 雅之; 汐見 幹夫; 工藤 正俊第82回日本消化器内視鏡学会近畿地方会  2009/03  大阪国際交流センター, 大阪  第82回日本消化器内視鏡学会近畿地方会胃ESD後の後出血に関する検討と対策.  [Not invited]岡田 無文; 松井 繁長; 工藤 正俊パネルディスカッション「消化管疾患の内視鏡的治療における偶発症と対策」, 第82回日本消化器内視鏡学会近畿地方会  2009/03  大阪国際交流センター, 大阪  パネルディスカッション「消化管疾患の内視鏡的治療における偶発症と対策」, 第82回日本消化器内視鏡学会近畿地方会シングルバルーン小腸内視鏡による小腸疾患の診断と治療.  [Not invited]川崎 正憲; 梅原 泰; 工藤 正俊シンポジウム「小腸疾患の診断と治療の現況」, 第82回日本消化器内視鏡学会近畿地方会  2009/03  大阪国際交流センター, 大阪  シンポジウム「小腸疾患の診断と治療の現況」, 第82回日本消化器内視鏡学会近畿地方会経乳頭的アプローチ困難例に対するEUSガイド下胆管ドレナージ術の検討.  [Not invited]小牧 孝充; 北野 雅之; 工藤 正俊ワークショップ「胆・膵疾患の内視鏡的治療におけるコツと手技」, 第82回日本消化器内視鏡学会近畿地方会  2009/03  大阪国際交流センター, 大阪  ワークショップ「胆・膵疾患の内視鏡的治療におけるコツと手技」, 第82回日本消化器内視鏡学会近畿地方会胃腫瘍に対するESD治療成績の検討.  [Not invited]朝隈 豊; 松井 繁長; 工藤 正俊シンポジウム「治療成績からみた消化管腫瘍に対するESDの評価」, 第82回日本消化器内視鏡学会近畿地方会  2009/03  大阪国際交流センター, 大阪  シンポジウム「治療成績からみた消化管腫瘍に対するESDの評価」, 第82回日本消化器内視鏡学会近畿地方会胃悪性リンパ腫の化学療法後に認めたIIcの一例  [Not invited]酒井 清裕; 今井 元; 西尾 健; 冨田 崇文; 梅原 康湖; 森村 正嗣; 米田 円; 由谷 逸朗; 辻 直子; 田中 晃; 工藤 正俊第82回日本消化器内視鏡学会近畿地方回  2009/03  大阪市  第82回日本消化器内視鏡学会近畿地方回Special Lecture “Role of molecular targeted therapy in Japan.”  [Not invited]工藤 正俊“State of the Art in HCC Management: From Diagnosis to Treatment” Annual congress of Asia Pacific A  2009/02  Hong Kong Convention and Exhibition Centre, Hong Kong, China  “State of the Art in HCC Management: From Diagnosis to Treatment” Annual congress of Asia Pacific ARound Table Meeting “The role of molecular targeted agent; Optimizing treatment outcomes.”  [Not invited]工藤 正俊he 19th Conference of the Asian Pacific Association for the Study of the Liver (APASL)  2009/02  Hong Kong, China  he 19th Conference of the Asian Pacific Association for the Study of the Liver (APASL)Special Lecture “The burden of HCC in Aisa-Pacific.”  [Not invited]工藤 正俊APASL Hong Kong “State of the Art in HCC Management: From Diagnosis to Treatment”  2009/02  Hong Kong Convention and Exhibition Centre, Hong Kong, China  APASL Hong Kong “State of the Art in HCC Management: From Diagnosis to Treatment”腸間膜血腫を契機に発見された横行結腸がんの1例  [Not invited]今井 元; 奥村 直己; 西尾 健; 冨田 崇文; 梅原 康湖; 森村 正嗣; 由谷 逸朗; 米田 円; 辻 直子; 船井 貞往; 工藤 正俊日本消化器病学会近畿支部第90回例会  2009/02  大阪市  日本消化器病学会近畿支部第90回例会特別講演「肝細胞癌診療の最新の話題」  [Not invited]工藤 正俊第7回Sendai Liver Symposium  2009/02  ホテル仙台プラザ, 宮城  第7回Sendai Liver Symposium特別講演「ソナゾイドは肝癌診療をどう変えるか」  [Not invited]工藤 正俊ソナゾイド学術講演会  2009/02  名鉄トヤマホテル, 富山  ソナゾイド学術講演会特別講演「C型肝炎治療の重要性と最新の情報」  [Not invited]工藤 正俊平成20年度「肝がん撲滅運動」市民公開講座  2009/02  岸和田市立浪切ホール, 大阪  平成20年度「肝がん撲滅運動」市民公開講座特別講演「肝癌診療の最新のトピックス: 分子標的治療も含めて」  [Not invited]工藤 正俊第15回北九州肝疾患勉強会  2009/02  ステーションホテル小倉, 福岡  第15回北九州肝疾患勉強会特別講演「肝細胞癌治療の新しい展開」  [Not invited]工藤 正俊肝疾患学術講演会  2009/02  ホテル日航金沢, 石川  肝疾患学術講演会特別講演「肝腫瘍の画像診断: 最新のトピックス」  [Not invited]工藤 正俊第19回三重腹部画像診断・IVR研究会  2009/02  ホテルグリーンパーク津, 三重  第19回三重腹部画像診断・IVR研究会特別講演「HCC治療における分子標的治療への期待と課題」  [Not invited]工藤 正俊第1回TOKYO HCC EXPERT MEETING  2009  アルカディア市ヶ谷, 東京  第1回TOKYO HCC EXPERT MEETING胆膵疾患に対するEUSガイド下ドレナージ術の成績. ワークショップ「Interventional EUSのコツ」  [Not invited]北野 雅之; 小牧 孝充; 工藤 正俊第78回日本消化器内視鏡学会総会  2009  国立京都国際会館・グランドプリンスホテル京都, 京都  第78回日本消化器内視鏡学会総会特別講演「safety marginの必要性とそのevidence」  [Not invited]工藤 正俊第15回肝血流動態イメージ研究会  2009/01  パシフィコ横浜, 神奈川  第15回肝血流動態イメージ研究会自然退縮した肝細胞癌症例の画像所見と組織所見との比較.  [Not invited]矢田 典久; 前川 清; 高橋 俊介; 鄭 浩柄; 土師 誠二; 工藤 正俊第15回肝血流動態イメージ研究会  2009/01  パシフィコ横浜, 神奈川  第15回肝血流動態イメージ研究会特別講演「肝細胞癌の診断と治療: Up to date」  [Not invited]工藤 正俊第3回大塚リバーシンポジウム静岡  2009/01  ホテルアソシア静岡, 静岡  第3回大塚リバーシンポジウム静岡Gastric Duplication Cyst Mimcking Pancreas pseudocystの一例.  [Not invited]坂本 洋城; 北野 雅之; 小牧 孝充; 野田 佳寿; 今井 元; 末冨 洋一郎; 工藤 正俊; 筑後 孝章; 木村 雅友; 竹山 宜典第50回日本消化器画像診断研究会  2009/01  万国津梁館サミットホール, 沖縄  第50回日本消化器画像診断研究会Special Lecture “Diagnostic algorithm”  [Not invited]工藤 正俊APASL Consensus Development Meeting on Management of Hepatocellular Carcinoma  2008/12  Grand Hyatt Hotel, Nusa Dua, Bali  APASL Consensus Development Meeting on Management of Hepatocellular Carcinoma肝血管筋脂肪腫の一例.  [Not invited]前野 知子; 横川 美加; 市島 真由美; 前川 清; 畑中 絹世; 井上 達夫; 矢田 典久; 鄭 浩柄; 南 康範; 工藤 正俊日本超音波医学会第35回関西地方会学術集会  2008/12  神戸国際会議場, 兵庫.  日本超音波医学会第35回関西地方会学術集会振幅変調法によるソナゾイド造影超音波撮像法の使用経験.  [Not invited]前川 清; 畑中 絹世; 矢田 典久; 南 康範; 鄭 浩柄; 工藤 正俊日本超音波医学会第35回関西地方会学術集会  2008/12  神戸国際会議場, 兵庫.  日本超音波医学会第35回関西地方会学術集会超音波造影剤Sonazoidを用いた造影ハーモニックEUS. パネルディスカッション「造影エコーの現状と未来 -造影イメージから病態解明へ-」  [Not invited]坂本 洋城; 北野 雅之; 工藤 正俊日本超音波医学会第35回関西地方会学術集会  2008/12  神戸国際会議場, 兵庫  日本超音波医学会第35回関西地方会学術集会各種肝腫瘤のソナゾイド造影超音波による質的診断評価. パネルディスカッション「造影エコーの現状と未来 -造影イメージから病態解明へ-」  [Not invited]前川 清; 横川 美加; 前野 知子; 市島 真由美; 畑中 絹世; 矢田 典久; 井上 達夫; 南 康範; 鄭 浩柄; 工藤 正俊日本超音波医学会第35回関西地方会学術集会  2008/12  神戸国際会議場, 兵庫  日本超音波医学会第35回関西地方会学術集会Contrast-enhanced harmonic endosonography with Sonazoid.  [Not invited]北野 雅之; 坂本 洋城; 工藤 正俊10th International Symposium on Ultrasound Contrast Imaging  2008/12  Tokyo, Japan  10th International Symposium on Ultrasound Contrast ImagingSpecial Lecture “Sonazoid-enhanced US for liver tumors: Present status and future perspective.”  [Not invited]工藤 正俊10th International Symposium on Ultrasound Contrast Imaging  2008/12  Tokyo Medical Hospital, Tokyo, Japan  10th International Symposium on Ultrasound Contrast ImagingSpecial Lecture “Treatment of single HCC in 2-5cm: Debate on gray zone. Non-surgical treatment: Eastern experience.”  [Not invited]工藤 正俊6th International Meeting Hepatocellular Carcinoma: Eastern and Western Experiences Current Issues o  2008/12  Asian Medical Center, Seoul, Korea  6th International Meeting Hepatocellular Carcinoma: Eastern and Western Experiences Current Issues oSpecial Lecture “Is adjuvant therapy necessary after curative treatment of HCC? Low-dose, long-term maintenance interferon therapy after curative RFA increases survival in patients with hepatitis C-related HCC.”  [Not invited]工藤 正俊6th International Meeting Hepatocellular Carcinoma: Eastern and Western Experiences Current Issues o  2008/12  Asian Medical Center, Seoul, Korea  6th International Meeting Hepatocellular Carcinoma: Eastern and Western Experiences Current Issues oSpecial Lecture “Ultrasound”  [Not invited]工藤 正俊APASL Consensus Development Meeting on Management of Hepatocellular Carcinooma  2008/12  Grand Hyatt Hotel, Nusa Dua, Bali  APASL Consensus Development Meeting on Management of Hepatocellular CarcinoomaSpecial Lecture “How to screen”  [Not invited]工藤 正俊APASL Consensus Development Meeting on Management of Hepatocellular Carcinooma  2008/12  Grand Hyatt Hotel, Nusa Dua, Bali  APASL Consensus Development Meeting on Management of Hepatocellular CarcinoomaRituximab投与後にHBV再活性化劇症肝炎を発症したDLBCLの1例  [Not invited]宮武 淳一; 頼 晋也; 金井 良高; 高井 俊輔; 平瀬 主税; 川田 修平; 森田 泰慶; 佐野徹明; 川西 一信; 辰巳 陽一; 芦田 隆司; 前田 裕弘; 金丸 昭久; 早石 宗右; 工藤 正俊第9回 大阪リンパ腫研究会  2008/11  大阪  第9回 大阪リンパ腫研究会  <現病歴> 平成20年1月に右鼡径部の皮下腫瘤に気付き増大傾向となったため、大阪労災病院皮膚科受診し生検の結果、び慢性大細胞リンパ腫(DLBCL)と診断され紹介となる。PET-CTでは両腋下・右鼡径部にFDGの集積を認めた。骨髄穿刺ではDLBCL細胞の浸潤を認めなかったことよりStage Ⅲと診断した(IPIはH-I)。4月2日からR-THP-COP療法開始し副作用なく終了し2回目より外来治療となる。6月20日に4回目の同療法後、7月4日に肝障害(GOT 131IU/l, GPT 153IU/l, T-bil 0.8mg/dl, ALP 227IU/l,)を認め、7月20日にはGOT 4625IU/l, GPT 1647IU/l, T-bil 9.3mg/dl, D-bil 7.0mg/dl, ALP 283IU/lと著増し黄疸も認められた。腹部CT・超音波所見でも肝腫大・胆嚢壁肥厚あり急性肝炎で入院となる。 <入院後経過> HBs抗原 98.97IU/ml, HBs抗体陰性、Hbe抗原陰性、HBe抗体 99%、HBc抗体 10.4S/CO、HBV-DNA定量で8.7LGE/mlと上昇しており、平成15年のHBs抗原は陰性で輸血歴もないことより急性B型肝炎の再活性化(reactivation)と診断した。なおDLBCLは寛解状態を持腸間膜血腫を契機に発見された横行結腸癌の1例  [Not invited]奥村 直己; 今井 元; 西尾 健; 冨田 崇文; 梅原 康湖; 由谷 逸朗; 辻 直子; 船井 貞往; 工藤 正俊日本内科学会第187回近畿地方会  2008/11  京都市  日本内科学会第187回近畿地方会十二指腸静脈瘤の臨床的特徴と診断, 治療.  [Not invited]松井 繁長; 工藤 正俊ワークショップ「異所性静脈瘤の診断と治療」, 第15回日本門脈圧亢進症学会総会  2008/11  アクロス福岡, 福岡  ワークショップ「異所性静脈瘤の診断と治療」, 第15回日本門脈圧亢進症学会総会Special Lecture “U/s & EUS in diagnosis of pancreatic tumors”  [Not invited]工藤 正俊6th AFSUMB Workshop Delhi  2008/11  New Delhi, India  6th AFSUMB Workshop Delhi特別講演「肝癌診療の最新の話題」  [Not invited]工藤 正俊第3回「21世紀の肝疾患を考える会」  2008/11  京王プラザホテル, 東京  第3回「21世紀の肝疾患を考える会」特別講演「肝画像診断におけるEOB・プリモビスト注への期待」  [Not invited]工藤 正俊第3回北陸EOB・プリモビストセミナー  2008/11  金沢大学医学部類教育棟, 石川  第3回北陸EOB・プリモビストセミナー特別講演「肝腫瘍における造影エコー法 最前線」  [Not invited]工藤 正俊第7回山梨Body Imaging 研究会  2008/11  ベルクラシック甲府, 山梨  第7回山梨Body Imaging 研究会特別講演「肝臓の画像診断」  [Not invited]工藤 正俊第15回南大阪臨床消化器病学研究会  2008/11  天王寺都ホテル, 大阪  第15回南大阪臨床消化器病学研究会Inhibition of phospho-tyrosine in VEGFR2+CD45dim population as a biomarker for VEGFR2 tyrosine kinase inhibitors.  [Not invited]工藤 可苗; 荒尾 徳三; 松本 和子; 田中 薫; 金田 裕靖; 藤田 至彦; 工藤 正俊; 西尾 和人第67回日本癌学会学術総会  2008/10  名古屋国際会議場, 愛知  第67回日本癌学会学術総会Inhibitation of phospho-tyrosine in VEGFR2+D45dim population as a biomaker for VEGFR2 tyrosine kinase inhibitors.  [Not invited]工藤 可苗; 荒尾 徳三; 田中 薫; 金田 裕靖; 松本 和子; 藤田 至彦; 工藤 正俊; 西尾 和人The 67th Annual Meeting of the Japanese Cnacer Association  2008/10  Nagoya, Japan  The 67th Annual Meeting of the Japanese Cnacer AssociationMass spectrometric analysis of plasma N-glycan in pancreas cancer.  [Not invited]坂本 洋城; 荒尾 徳三; 松本 和子; 北野 雅之; 工藤 正俊; 西尾 和人The 67th Annual Meeting of the Japanese Cnacer Association  2008/10  Nagoya, Japan  The 67th Annual Meeting of the Japanese Cnacer Associationランチョンセミナー「Sonazoidは肝癌診療をどう変えるか」  [Not invited]工藤 正俊第18回日本超音波医学会四国地方会学術集会  2008/10  松山市立総合コミュニティーセンター, 愛媛  第18回日本超音波医学会四国地方会学術集会慢性膵炎に対するInterventional EUS.  [Not invited]野田 佳寿; 北野 雅之; 工藤 正俊第76回日本消化器内視鏡学会総会  2008/10  グランドプリンスホテル新高輪, 東京  第76回日本消化器内視鏡学会総会当院における胆管メタリックステント使用症例の経過解析.  [Not invited]末冨 洋一郎; 北野 雅之; 工藤 正俊第76回日本消化器内視鏡学会総会  2008/10  グランドプリンスホテル新高輪, 東京  第76回日本消化器内視鏡学会総会Value of computed tomography for evaluating the injection site in.  [Not invited]坂本 洋城; 荒尾 徳三; 北野 雅之; 工藤 正俊; 西尾 和人16th United Europian Gastroenterology Week(UEGW)  2008/10  Vienna Asutria  16th United Europian Gastroenterology Week(UEGW)当院におけるHelicobacter pylori(H. pylori)のCAM/AMPC耐成率と除菌治療の年次変化  [Not invited]梅原 康湖; 冨田 崇文; 西尾 健; 森村 正嗣; 米田 円; 由谷 逸朗; 辻 直子; 本庶 元; 工藤 正俊JDDW 2008 第76回日本消化器内視鏡学会総会  2008/10  東京都  JDDW 2008 第76回日本消化器内視鏡学会総会純型・混合型と患者背景・長期予後からみた早期胃がんの治療方針  [Not invited]辻 直子; 西尾 健; 冨田 崇文; 梅原 康湖; 米田 円; 森村 正嗣; 由谷 逸朗; 工藤 正俊; 石黒 信吾; 本庶 元JDDW2008 第76回日本消化器内視鏡学会総会  2008/10  東京都  JDDW2008 第76回日本消化器内視鏡学会総会ESD後胃潰瘍に対するエカベトナトリウムの有用性(Prospective randomized study).  [Not invited]朝隈 豊; 松井 繁長; 岡田 無文; 市川 勉; 川崎 正憲; 梅原 泰; 工藤 正俊第50回日本消化器病学会大会  2008/10  グランドプリンスホテル新高輪, 東京  第50回日本消化器病学会大会Sonazoidを用いた造影EUSによる進行胃癌の化学療法効果判定.  [Not invited]岡田 無文; 松井 繁長; 工藤 正俊シンポジウム「化学療法評価に果たす内視鏡の役割り」, 第76回日本消化器内視鏡学会総会  2008/10  グランドプリンスホテル新高輪, 東京  シンポジウム「化学療法評価に果たす内視鏡の役割り」, 第76回日本消化器内視鏡学会総会Quantitative measurement of whole brain CT perfusion parameters and CT angiography using non-stop detector row CT scanner(MDCT) :initial experience.  [Not invited]工藤 正俊; 村上 卓道12th Asia Oceania Congress of Radiology  2008/10  Seoul  12th Asia Oceania Congress of RadiologyEvaluation of the effectiveness of radiofrequency ablation for hepatic malignancies: Usefulness of virtual CT Sonography using magnetic navigation.  [Not invited]北井 聡; 南 康範; 工藤 正俊; 川崎 正憲; 朝隈 豊16th United Europian Gastroenterology Week(UEGW)  2008/10  Vienna Asutria  16th United Europian Gastroenterology Week(UEGW)Utility of contrast-enhanced endoscopic ultrasonography for diagnosis of small pancreatic carcinomas.  [Not invited]坂本 洋城; 北野 雅之; 末冨 洋一郎; 野田 佳寿; 小牧 孝充; 筑後 孝章; 工藤 正俊16th United Europian Gastroenterology Week(UEGW)  2008/10  Vienna Asutria  16th United Europian Gastroenterology Week(UEGW)Prospective comparative study of the EUS guided 25-gauge FNA needle with the 19-gauge trucut needle and 22-gauge FNA needle in patients with solid pancreatic masses.  [Not invited]坂本 洋城; 北野 雅之; 野田 佳寿; 小牧 孝充; 筑後 孝章; 工藤 正俊16th United Europian Gastroenterology Week(UEGW)  2008/10  Vienna Asutria  16th United Europian Gastroenterology Week(UEGW)Value of computed tomography for evaluating the injection site in.  [Not invited]坂本 洋城; 北野 雅之; 野田 佳寿; 小牧 孝充; 末冨 洋一郎; 工藤 正俊16th United Europian Gastroenterology Week(UEGW)  2008/10  Vienna Asutria  16th United Europian Gastroenterology Week(UEGW)Special Lecture “Impact of primovist on current diagnostic and therapeutic algorithm in HCC”  [Not invited]工藤 正俊The 2nd International Forum for Liver MRI 2008  2008/10  Kyoto, Japan  The 2nd International Forum for Liver MRI 2008Usefullness of single balloon enteroscopy for diagnosis in small intestinal disease.  [Not invited]川崎 正憲; 松井 繁長; 上嶋 一臣; 朝隈 豊; 岡田 無文; 工藤 正俊16th United Europian Gastroenterology Week(UEGW)  2008/10  Vienna Asutria  16th United Europian Gastroenterology Week(UEGW)Combination therapy of ecabet sodium and proton pump inhibitor(PPI) compared with PPI alone for endoscopic submucosal dissection(ESD) ?induced ulcer in early gastric cancers: prospective randomized study.  [Not invited]朝隈 豊; 松井 繁長; 岡田 無文; 川崎 正憲; 北井 聡; 坂本 洋城; 井上 達夫; 工藤 正俊16th United Europian Gastroenterology Week(UEGW)  2008/10  Vienna Asutria  16th United Europian Gastroenterology Week(UEGW)当院でのステロイド未使用の潰瘍性大腸炎に対する白血球除去療法の治療成績.  [Not invited]梅原 泰; 川崎 正憲; 朝隈 豊; 岡田 無文; 市川 勉; 松井 繁長; 今井 元; 野田 佳寿; 坂本 洋城; 石川 恵美; 井上 達夫; 萩原 智; 末冨 洋一郎; 南 康範; 鄭 浩柄; 上嶋 一臣; 北野 雅之; 汐見 幹夫; 工藤 正俊第76回日本消化器内視鏡学会総会  2008/10  グランドプリンスホテル新高輪, 東京  第76回日本消化器内視鏡学会総会当院におけるシングルバルーン小腸内視鏡検査の有用性.  [Not invited]川崎 正憲; 松井 繁長; 梅原 泰; 岡田 無文; 市川 勉; 朝隈 豊; 工藤 正俊第76回日本消化器内視鏡学会総会  2008/10  グランドプリンスホテル新高輪, 東京  第76回日本消化器内視鏡学会総会超音波造影剤Sonazoidを用いた造影ハーモニックEUS.  [Not invited]北野 雅之; 坂本 洋城; 工藤 正俊第76回日本消化器内視鏡学会総会  2008/10  グランドプリンスホテル新高輪, 東京  第76回日本消化器内視鏡学会総会当院におけるTherapeutic EUSの現状.  [Not invited]北野 雅之; 坂本 洋城; 工藤 正俊第76回日本消化器内視鏡学会総会  2008/10  グランドプリンスホテル新高輪, 東京  第76回日本消化器内視鏡学会総会1cm以下の早期膵癌診断の為のアプローチ.  [Not invited]坂本 洋城; 北野 雅之; 工藤 正俊第50回日本消化器病学会大会  2008/10  グランドプリンスホテル新高輪, 東京  第50回日本消化器病学会大会当院におけるTS1膵癌の特徴.  [Not invited]坂本 洋城; 北野 雅之; 工藤 正俊第76回日本消化器内視鏡学会総会,  2008/10  グランドプリンスホテル新高輪, 東京  第76回日本消化器内視鏡学会総会,Child-Pugh C型肝硬変に合併した肝癌は治療すべきか?その是非と治療法選択に関するRetrospectivee多施設共同研究.  [Not invited]大崎 往夫; 工藤 正俊; 松永 隆第12回日本肝臓学会大会  2008/10  グランドプリンスホテル新高輪, 東京  第12回日本肝臓学会大会疼痛緩和により抗癌剤治療が可能となった超音波内視鏡ガイド下腹腔神経叢ブロック術の成績.  [Not invited]小牧 孝充; 北野 雅之; 工藤 正俊第50回日本消化器病学会大会  2008/10  グランドプリンスホテル新高輪, 東京  第50回日本消化器病学会大会難治性C型慢性肝炎に対する治療戦略-後期陰性化症例における検討-.  [Not invited]上田 泰輔; 鄭 浩柄; 工藤 正俊第50回日本消化器病学会大会  2008/10  グランドプリンスホテル新高輪, 東京  第50回日本消化器病学会大会ソナゾイド造影超音波検査におけるpost vascular phase imagingとSPIO-MRIとの比較.  [Not invited]井上 達夫; 畑中 絹世; 上田 泰輔; 辰巳 千栄; 北井 聡; 高橋 俊介; 石川 恵美; 萩原 智; 南 康範; 鄭 浩柄; 上嶋 一臣; 工藤 正俊; 横川 美加; 前野 智子; 市島 真由美; 前川 清第12回日本肝臓学会大会  2008/10  グランドプリンスホテル新高輪, 東京  第12回日本肝臓学会大会肝腫瘍の診断におけるDefect Re-perfusion Imagingの有用性について.  [Not invited]畑中 絹世; 南 康範; 工藤 正俊第12回日本肝臓学会大会  2008/10  グランドプリンスホテル新高輪, 東京  第12回日本肝臓学会大会Sonazoidを用いた造影超音波ガイド下ラジオ波焼灼術の有用性.  [Not invited]南 康範; 畑中 絹世; 工藤 正俊第12回日本肝臓学会大会  2008/10  グランドプリンスホテル新高輪, 東京  第12回日本肝臓学会大会肝予備能良好かつ単発の肝細胞癌患者に対するラジオ波焼灼療法治療成績.  [Not invited]鄭 浩柄; 南 康範; 工藤 正俊第50回日本消化器病学会大会  2008/10  グランドプリンスホテル新高輪, 東京  第50回日本消化器病学会大会肝細胞癌根治後C型肝癌に対するIFN少量長期維持療法の生命予後改善効果に関する検討.  [Not invited]上田 泰輔; 鄭 浩柄; 工藤 正俊第12回日本肝臓学会大会  2008/10  グランドプリンスホテル新高輪, 東京  第12回日本肝臓学会大会進行肝細胞癌に対するソラフェニブの使用経験.  [Not invited]上嶋 一臣; 南 康範; 工藤 正俊第12回日本肝臓学会大会  2008/10  グランドプリンスホテル新高輪, 東京  第12回日本肝臓学会大会特別講演「肝画像診断におけるEOB・プリモビスト注への期待」  [Not invited]工藤 正俊第2回関西EOB・プリモビストセミナー  2008/10  新大阪ワシントンホテルプラザ, 大阪  第2回関西EOB・プリモビストセミナーExperimental and early clinical studies of S-1, a novel oral DPD inhibitor, chemotherapy for advanced hepatocellular carcinoma.  [Not invited]山下 竜也; 工藤 正俊; 上嶋 一臣; 金子 周一; 古瀬 純司; 奥坂 拓志; 仲地 耕平; 池田 公史The 59th Annual Meeting of the American Association for the Study of Liver Diseases(AASLD)  2008/10  San Francisco, USA  The 59th Annual Meeting of the American Association for the Study of Liver Diseases(AASLD)Value of liver parenchymal phase imaging of contrast-enhanced ultrasonography to diagnose the premalignant/borderline lesions and overt HCC.  [Not invited]井上 達夫; 工藤 正俊; 前西 修; 前川 清; 黑木 美奈; 中島 収; 神代 正道16th United Europian Gastroenterology Week(UEGW)  2008/10  Vienna, Austria  16th United Europian Gastroenterology Week(UEGW)Qualitative and quantitative analysis of liver-parenchymal phase contrast-enhanced US with Sonazoid in detecting HCC; Comparison with SPIO-MRI.  [Not invited]井上 達夫; 工藤 正俊; 畑中絹世; 前川 清; 高橋 俊介; 北井 聡; 上田 泰輔; 萩原 智; 南 康範; 鄭 浩柄; 上嶋 一臣16th United Europian Gastroenterology Week(UEGW)  2008/10  Vienna, Austria  16th United Europian Gastroenterology Week(UEGW)経乳頭的アプローチ困難例に対するEUSを用いた胆管ドレナージ術の検討.  [Not invited]小牧 孝充; 北野 雅之; 坂本 洋城; 末冨 洋一郎; 野田 佳寿; 工藤 正俊第44回日本胆道学会学術集会  2008/09  名古屋東急ホテル, 愛知  第44回日本胆道学会学術集会内視鏡的破砕術にて除去した胃石の一例  [Not invited]今井 元; 西尾 健; 由谷 逸朗; 辻 直子; 田中 久夫; 工藤 正俊第81回 日本消化器内視鏡学会近畿地方会  2008/09  大阪市  第81回 日本消化器内視鏡学会近畿地方会当院でのHelocpbacter pyloriのCAM,AMPC耐性率と除菌治療の年次変化(2001~2007年)  [Not invited]梅原 康湖; 辻 直子; 工藤 正俊第81回日本消化器内視鏡学会近畿地方会 シンポジウム  2008/09  大阪市  第81回日本消化器内視鏡学会近畿地方会 シンポジウム特別講演「肝硬変・肝癌診療におけるインターフェロンとソナゾイドの役割」  [Not invited]工藤 正俊第10回岐阜県肝疾患セミナー  2008/09  岐阜グランドホテル, 岐阜  第10回岐阜県肝疾患セミナー肝細胞癌非合併の硬変変症例におけるBCAA製剤投与による生存率への寄与  [Not invited]早石 宗右; 石川 恵美; 南 康範; 工藤 正俊日本消化器病学会近畿支部第89回例会  2008/09  大阪国際交流センター, 大阪  日本消化器病学会近畿支部第89回例会肝細胞癌におけるBiomarker Combined Japan Integrated Staging (bm-JIS) Scoreの有用性  [Not invited]北井 聡; 南 康範; 工藤 正俊日本消化器病学会近畿支部第89回例会  2008/09  大阪国際交流センター, 大阪  日本消化器病学会近畿支部第89回例会原発不明の癌性腹膜炎の1例.  [Not invited]茂山 朋広; 林 道友; 宮部 欽生; 北口 容子; 豊澤 昌子; 岸谷 讓; 鍋島 紀滋; 工藤 正俊日本消化器病学会近畿支部第89回例会  2008/09  大阪国際交流センター, 大阪  日本消化器病学会近畿支部第89回例会肝内胆管癌にTS-1を投与し著効した1例  [Not invited]西尾 健; 今井 元; 冨田 崇文; 梅原 康湖; 森村 正嗣; 米田 円; 由谷 逸朗; 辻 直子; 工藤 正俊; 杉浦 孝宗; 保田 昇平; 家田 泰浩; 長坂 行雄日本消化器病学会近畿支部第89回例会  2008/09  大阪国際交流センター, 大阪  日本消化器病学会近畿支部第89回例会C型慢性肝炎に対するインターフェロン療法著効後に発症した肝細胞癌破裂の1例  [Not invited]峯 宏昌; 萩原 智; 早石 宗右; 辰巳 千栄; 上田 泰輔; 高橋 俊介; 北井 聡; 畑中 絹世; 石川 恵美; 井上 達夫; 南 康範; 鄭 浩柄; 上嶋 一臣; 工藤 正俊日本消化器病学会近畿支部第89回例会  2008/09  大阪国際交流センター, 大阪  日本消化器病学会近畿支部第89回例会悪性リンパ腫治療後にHBVの再活性化をきたした1例.  [Not invited]椋棒 圭子; 林 道友; 加藤 玲明; 茂山 朋広; 宮部 欽生; 豊澤 昌子; 北口 容子; 岸谷 讓; 鍋島 紀滋; 工藤 正俊日本消化器病学会近畿支部第89回例会  2008/09  大阪国際交流センター, 大阪  日本消化器病学会近畿支部第89回例会肝動注用リザーバーのGDAコイルによる難治性十二指腸潰瘍出血を止血し得た1例.  [Not invited]早石 宗右; 辰巳 千栄; 上嶋 一臣; 北井 聡; 高橋 俊介; 石川 恵美; 南 康範; 鄭 浩柄; 工藤 正俊日本消化器病学会近畿支部第89回例会  2008/09  大阪国際交流センター, 大阪  日本消化器病学会近畿支部第89回例会Separate analysis of intranodular blood supply in nodular lesions associated with liver cirrhosis: a novel ultrasound technique “pure arterial phase imaging”  [Not invited]工藤 正俊; 南 康範2nd International Liver Cancer Association(ILCA) 2008 Annual Conference  2008/09  Chicago, USA  2nd International Liver Cancer Association(ILCA) 2008 Annual ConferenceA proposal of novel treatment-assist technique in the Sonazoid-enhanced ultrasonography: value of defect re-perfusion imaging.  [Not invited]工藤 正俊; 南 康範2nd International Liver Cancer Association(ILCA) 2008 Annual Conference  2008/09  Chicago, USA  2nd International Liver Cancer Association(ILCA) 2008 Annual ConferencePhase I/II study of the efficacy and safety of S-1 in patients(PTS) with advanced hepatocellular carcinoma(HCC).  [Not invited]工藤 正俊; 上嶋 一臣; 古瀬 純司; 奥坂 拓志; 金子 周一; 仲地 耕平; 池田 公史; 山下 竜也2nd International Liver Cancer Association(ILCA) 2008 Annual Conference  2008/09  Chicago, USA  2nd International Liver Cancer Association(ILCA) 2008 Annual ConferenceProspective comparative study of the EUS guided 25-gauge FNA needle with the 19-gauge Trucut needle and 22-gauge FNA needle in patients with solid pancreatic masses.  [Not invited]坂本 洋城; 工藤 正俊16th International Symposium on Endoscopic Ultrasound  2008/09  San Francisco, California.  16th International Symposium on Endoscopic UltrasoundDynamic imaging of pancreatic tumors by contrast-enhanced harmonic EUS with long-lastiong contrast.  [Not invited]北野 雅之; 坂本 洋城; Das Kunal; 小牧 孝充; 野田 佳寿; 工藤 正俊; 高木 忠之; 山雄 健次EUS 2008  2008/09  San San Francisco, California.  EUS 2008Invited Lecture “Contrast-enhanced US with new contrast agent, Sonazoid for liver tumors. "  [Not invited]工藤 正俊Australasian Society for Ultrasound in Medicine 38th Annual Scientific Meeting  2008/09  New Zealand.  Australasian Society for Ultrasound in Medicine 38th Annual Scientific Meeting特別講演「ソナゾイドは肝癌診療をどう変えるか?」  [Not invited]工藤 正俊第64回東海総合画像医学研究会  2008/08  名鉄ニューグランドホテル, 愛知  第64回東海総合画像医学研究会Invited Lecture “Hepatocellular carcinoma: current topics in the diagnosis and treatment”  [Not invited]工藤 正俊LAENNEC SOCIETY: SUMMER MEETING  2008/07  Padova, Italy  LAENNEC SOCIETY: SUMMER MEETING膵癌早期診断の為のアプローチ: US, EUSを中心に.  [Not invited]坂本 洋城; 北野 雅之; 竹山 宜典; 工藤 正俊第39回日本膵臓学会大会  2008/07  パシフィコ横浜, 神奈川.  第39回日本膵臓学会大会Invited Lecture “Diffuse liver disease”  [Not invited]工藤 正俊WFUMB 2008 WORKSHOP  2008/07  Ulaanbaatar, Mongolian.  WFUMB 2008 WORKSHOPInvited Lecture “Contrast-enhanced US of hepatic tumors with Sonazoid”  [Not invited]工藤 正俊WFUMB 2008 WORKSHOP  2008/07  Ulaanbaatar, Mongolian.  WFUMB 2008 WORKSHOPInvited Lecture “Direct Re-perfusion Imaging with Sonazoid in the diagnosis and treatment of hepatic malignancies”  [Not invited]工藤 正俊WFUMB 2008 WORKSHOP  2008/07  Ulaanbaatar, Mongolian.  WFUMB 2008 WORKSHOP特別講演「肝胆膵疾患におけるSonazoid造影検査の意義」  [Not invited]工藤 正俊第17回鳥取県西部腹部超音波研究会  2008/07  米子全日空ホテル, 鳥取  第17回鳥取県西部腹部超音波研究会特別講演「日常診療における造影超音波診断」  [Not invited]工藤 正俊第91回姫路消化器病研究会  2008/07  姫路市医師会館, 兵庫  第91回姫路消化器病研究会シンポジウム「日本肝癌研究会全国原発性肝癌追跡調査の現状と課題」  [Not invited]猪飼伊和夫; 工藤 正俊第63回日本消化器外科学会定期学術総会  2008/07  札幌  第63回日本消化器外科学会定期学術総会進行肝細胞癌に対するS-1, ペグインターフェロン併用療法.  [Not invited]上嶋 一臣; 早石 宗右; 辰巳 千栄; 上田 泰輔; 北井 聡; 高橋 俊介; 石川 恵美; 井上 達夫; 萩原 智; 南 康範; 鄭 浩柄; 工藤 正俊第44回日本肝臓学会総会  2008/06  愛媛県県民文化会館, 愛媛  第44回日本肝臓学会総会肝細胞癌バイオマーカー血清TERTmRNAの臨床的有用性の多施設研究.  [Not invited]三浦 典正; 永島 美樹; 工藤 正俊; 大崎 往夫; 河野 通盛; 大山 賢治; 庄盛 浩平; 神戸 貴雅; 岸本 幸広; 丸山 茂雄; 野間 英二郎; 堀江 裕; 坂口 正剛; 川崎 寛中; 長谷川 純一; 汐田 剛史第44回日本肝臓学会総会  2008/06  愛媛県県民文化会館, 愛媛  第44回日本肝臓学会総会特別講演「Sonazoidは肝癌診療をどう変えるか」  [Not invited]工藤 正俊第21回熊本肝癌研究会  2008/06  熊本  第21回熊本肝癌研究会ソナゾイド造影超音波による肝腫瘤の質的診断評価.  [Not invited]前川 清; 畑中 絹世; 井上 達夫; 横川 美加; 前野 知子; 市島 真由美; 内藤 昭智; 上硲 俊法; 高橋 俊介; 南 康範; 鄭 浩柄; 上嶋 一臣; 工藤 正俊第8回関西肝血流動態イメージ研究会  2008/06  オーバルホール, 兵庫  第8回関西肝血流動態イメージ研究会VEGFR2阻害剤に対する耐性株とCEC及びCEPの検討.  [Not invited]工藤 可苗; 荒尾 徳三; 松本 和子; 金田 裕靖; 田中 篤; 前川 麻里; 藤田 至彦; 工藤 正俊; 西尾 和人第12回がん分子標的治療研究会総会  2008/06  学術総合センター, 東京  第12回がん分子標的治療研究会総会MDCT,MRI画像診断によるHCCのRFA治療効果判定  [Not invited]岡田 真広; 熊野 正士; 桑原 雅知; 柳生 行伸; 勝部 敬; 荒木 哲朗; 香川 祐毅; 葉 輝明; 安藤 理奈; 松久保 祐子; 任 誠雲; 米矢 吉宏; 小塚 健倫; 土屋 典生; 下野 太郎; 今岡 いずみ; 足利 竜一朗; 細野 眞; 工藤 正俊; 村上 卓道第44回日本肝癌研究会  2008/05  大阪  第44回日本肝癌研究会特別講演「Sonazoidは肝癌診療をどう変えるか?」  [Not invited]工藤 正俊第44回日本肝癌研究会 ランチョンセミナー  2008/05  大阪国際会議場, 大阪  第44回日本肝癌研究会 ランチョンセミナー特別講演「肝細胞癌根治後のC型慢性肝炎に対するPEG-IFN少量・長期・維持療法の可能性」  [Not invited]工藤 正俊第44回日本肝癌研究会 ランチョンセミナー「肝疾患診療におけるPEG-IFN介入治療の役割」  2008/05  大阪国際会議場, 大阪  第44回日本肝癌研究会 ランチョンセミナー「肝疾患診療におけるPEG-IFN介入治療の役割」特別講演「肝癌に魅せられて30年」  [Not invited]工藤 正俊定例愛光医会  2008/05  松山全日空ホテル, 愛媛.  定例愛光医会膵腫瘍性病変診断におけるTrucut針、25Gおよび22G吸引穿刺針の比較検討.  [Not invited]坂本 洋城; 北野 雅之; 野田 佳寿; 小牧 孝充; 今井 元; 工藤 正俊第4回超音波内視鏡下生検法の診断制度向上のための研究会  2008/05  パシフィコ横浜, 神奈川.  第4回超音波内視鏡下生検法の診断制度向上のための研究会特別講演「肝癌ラジオ波焼灼療法の現状」  [Not invited]工藤 正俊第2回神鋼病診連携消化器病懇話会  2008/05  神鋼病院, 兵庫  第2回神鋼病診連携消化器病懇話会当院での超音波内視鏡下腹腔神経叢ブロックのコツと手技の工夫.  [Not invited]小牧 孝充; 北野 雅之; 工藤 正俊第75回日本消化器内視鏡学会総会  2008/05  パシフィコ横浜, 神奈川  第75回日本消化器内視鏡学会総会胆膵疾患に対するEUSガイド下ドレナージ術.  [Not invited]北野 雅之; 坂本 洋城; 工藤 正俊第75回日本消化器内視鏡学会総会  2008/05  パシフィコ横浜, 神奈川.  第75回日本消化器内視鏡学会総会癌性疼痛緩和における超音波内視鏡ガイド下腹腔神経叢ブロック術の成績.  [Not invited]小牧 孝充; 北野 雅之; 工藤 正俊パネルディスカッション「癌緩和医療における内視鏡の役割」, 第75回日本消化器内視鏡学会総会  2008/05  パシフィコ横浜, 神奈川  パネルディスカッション「癌緩和医療における内視鏡の役割」, 第75回日本消化器内視鏡学会総会当院におけるInterventional EUSの現状. シンポジウム「Interventional EUSの進歩」  [Not invited]坂本 洋城; 北野 雅之; 工藤 正俊第75回日本消化器内視鏡学会総会  2008/05  パシフィコ横浜, 神奈川  第75回日本消化器内視鏡学会総会Defect Re-inection imagingの有用性について.  [Not invited]畑中 絹世; 南 康範; 北井 聡; 辰巳 千栄; 高橋 俊介; 井上 達夫; 萩原 智; 鄭 浩柄; 上嶋 一臣; 工藤 正俊日本超音波医学会第81回学術集会  2008/05  神戸国際会議場, 兵庫  日本超音波医学会第81回学術集会ソナゾイド造影超音波による肝癌局所療法の効果判定『特にDefect-reinjection-testと支援画像表示』  [Not invited]前川 清; 畑中 絹世; 横川 美加; 前野 知子; 市島 真由美; 井上 達夫; 南 康範; 鄭 浩柄; 上嶋 一臣; 工藤 正俊日本超音波医学会第81回学術集会  2008/05  神戸国際会議場, 兵庫  日本超音波医学会第81回学術集会Sonazoidを用いた造影ハーモニックEUS検査. シンポジウム「画像診断に与えた造影超音波のインパクト」  [Not invited]北野 雅之; 坂本 洋城; 工藤 正俊日本超音波医学会第81回学術集会  2008/05  神戸国際会議場, 兵庫  日本超音波医学会第81回学術集会肝臓エラストグラフィの定量化の試みと深部領域の感度の改善. パネルディスカッション「弾性の考え方と診断法: 各領域における見方」  [Not invited]藤本研吾; 辰巳 千栄; 上嶋 一臣; 前川 清; 工藤 正俊; 加藤 道夫; 外村 明子; 山川 誠; 椎名 毅日本超音波医学会第81回学術集会  2008/05  神戸国際会議場, 兵庫  日本超音波医学会第81回学術集会非B非C肝癌の臨床的特徴: B型関連肝癌・C型関連肝癌との比較.  [Not invited]畑中 絹世; 南 康範; 辰巳 千栄; 上田 泰輔; 北井 聡; 高橋 俊介; 石川 恵美; 井上 達夫; 萩原 智; 鄭 浩柄; 上嶋 一臣; 工藤 正俊第44回日本肝癌研究会  2008/05  大阪国際会議場, 大阪.  第44回日本肝癌研究会Multistep hepatocecarcinogenesis: Correlation of imaging with pathology.  [Not invited]工藤 正俊The 94th Annual Meeting of the Japanese Society of Gastroenterology 1st International Forum  2008/05  Fukuoka, Japan.  The 94th Annual Meeting of the Japanese Society of Gastroenterology 1st International ForumClinicopathological time trends for early gastric cancer and helicobacter pylori infection in Japan.  [Not invited]梅原 康湖; 辻 直子; 石黒 信吾; 工藤 正俊DDW (Digestive Disease Week) 2008  2008/05  San Diego, USA.  DDW (Digestive Disease Week) 2008Defect Re-injection Testの有用性とRFA治療支援.  [Not invited]畑中 絹世; 南 康範; 辰巳 千栄; 上田 泰輔; 北井 聡; 高橋 俊介; 石川 恵美; 井上 達夫; 萩原 智; 鄭 浩柄; 上嶋 一臣; 工藤 正俊シンポジウム「RFA-STATE of ARTS」, 第44回日本肝癌研究会  2008/05  大阪.  シンポジウム「RFA-STATE of ARTS」, 第44回日本肝癌研究会特別講演「Sonazoidは肝癌診療をどう変えるか?」  [Not invited]工藤 正俊ランチョンセミナー, 第44回日本肝癌研究会  2008/05  大阪.  ランチョンセミナー, 第44回日本肝癌研究会特別講演「肝細胞癌根治後のC型慢性肝炎に対するPEG-IFN少量・長期・維持療法の可能性.」  [Not invited]工藤 正俊ランチョンセミナー「肝疾患診療におけるPEG-IFN介入治療の役割」, 第44回日本肝癌研究会  2008/05  大阪.  ランチョンセミナー「肝疾患診療におけるPEG-IFN介入治療の役割」, 第44回日本肝癌研究会Cronkhite-Canada症候群に腸重積を合併した1例.  [Not invited]早石 宗右; 石川 恵美; 南 康範; 上田 和毅; 工藤 正俊第94回日本消化器病学会総会  2008/05  福岡.  第94回日本消化器病学会総会難治性C型慢性肝炎(Ⅰ型高ウイルス量)に対するPEG-IFN α2b/Ribavirin併用療法の長期投与成績と安全性について.  [Not invited]石川 恵美; 南 康範; 上嶋 一臣; 鄭 浩柄; 早石 宗右; 井上 達夫; 工藤 正俊第94回日本消化器病学会総会,  2008/05  福岡.  第94回日本消化器病学会総会,Defect Re-injection Testの有用性について.  [Not invited]畑中 絹世; 北井 聡; 上田 泰輔; 辰巳 千栄; 井上 達夫; 萩原 智; 南 康範; 鄭 浩柄; 上嶋 一臣; 前川 清; 工藤 正俊第94回日本消化器病学会総会,  2008/05  福岡.  第94回日本消化器病学会総会,進行肝細胞癌に対するS-1、ペグインターフェロン併用療法.  [Not invited]上嶋 一臣; 辰巳 千栄; 上田 泰輔; 北井 聡; 高橋 俊介; 井上 達夫; 石川 恵美; 南 康範; 鄭 浩柄; 工藤 正俊第94回日本消化器病学会総会  2008/05  福岡.  第94回日本消化器病学会総会造影ハーモニックEUSによる胆膵疾患の診断.  [Not invited]北野 雅之; 坂本 洋城; 工藤 正俊シンポジウム「胆膵画像診断の進歩」, 第94回日本消化器病学会総会  2008/05  福岡.  シンポジウム「胆膵画像診断の進歩」, 第94回日本消化器病学会総会HCV Core抗原、NS3蛋白によるTLR2を介するCross Torelanceの誘導.  [Not invited]鄭 浩柄; 工藤 正俊; 渡邉 知裕シンポジウム「ウイルス肝炎・肝癌に対する生体防御」, 第94回日本消化器病学会総会  2008/05  福岡.  シンポジウム「ウイルス肝炎・肝癌に対する生体防御」, 第94回日本消化器病学会総会Evaluation of the effectiveness of radiofrequency ablation for hepatic malignancies: Usefulness of virtual CT Sonography using magnetic navigation.  [Not invited]北井 聡; 南 康範; 工藤 正俊DDW (Digestive Disease Week) 2008  2008/05  San Diego, America.  DDW (Digestive Disease Week) 2008Combination therapy of ecabet sodium and proton pump inhibitor (PPI) compared with PPI alone for endoscopic submucosal dissection (ESD) ?induced ulcer in gastric cancer: Prospective randomized study.  [Not invited]松井 繁長; 工藤 正俊; 岡田 無文; 朝隈 豊; 市川 勉; 川崎 正憲DDW (Digestive Disease Week) 2008  2008/05  San Diego, America.  DDW (Digestive Disease Week) 2008Contrast enhanced sonography for hepatic malignancies: value of Defect Re-injection Test.  [Not invited]畑中 絹世; 南 康範; 工藤 正俊DDW (Digestive Disease Week) 2008  2008/05  San Diego, America.  DDW (Digestive Disease Week) 2008教育講演「第2世代超音波造影剤による内視鏡的超音波検査(CE-EUS)の開発と臨床応用」  [Not invited]工藤 正俊第75回日本消化器内視鏡学会総会  2008/05  パシフィコ横浜, 神奈川.  第75回日本消化器内視鏡学会総会Phase I/II study of S-1 in patients (pts) with advanced hepatocellular carcinoma (HCC): Results of the pgase II part.  [Not invited]奥坂 拓志; 工藤 正俊; 上嶋 一臣; 古瀬 純司; 金子 周一; 池田 公史; 仲地 耕平; 山下 竜也2008 Annual Meeting, AMERICAN SOCIETY OF CLINICAL ONCOLOGY  2008/05  Chicago, America  2008 Annual Meeting, AMERICAN SOCIETY OF CLINICAL ONCOLOGYSuperiority of atrerioportal angiography to contrast-enhanced CT and MRI in the diagnosis of hepatocellular carcinoma in nodules smaller than 2cm.  [Not invited]金 守良; 工藤 正俊; 井本 勉; 猪川 弘嗣; 安藤 健治; 三田 敬二; 婦木 秀一; 笹瀬 典子; 松岡 利幸; 林 祥The 43rd Annual Meeting of the Europian Association for the Study of the Liver  2008/04  Milan, Italy.  The 43rd Annual Meeting of the Europian Association for the Study of the LiverSonazoid造影超音波によるRFA治療の効果判定: 特にDefect-reinjection-test (D-RIT)と支援画像表示.  [Not invited]前川 清; 横川 美加; 前野 知子; 市島 真由美; 内藤 昭智; 上硲 俊法; 畑中 絹世; 高橋 俊介; 井上 達夫; 南 康範; 鄭 浩柄; 上嶋 一臣; 工藤 正俊ワークショップII 「肝腫瘤性病変のSonazoidr造影超音波「私の工夫」」, 第21回日本腹部造影エコー・ドプラ診断研究会  2008/04  秋葉原コンベンションホール, 東京.  ワークショップII 「肝腫瘤性病変のSonazoidr造影超音波「私の工夫」」, 第21回日本腹部造影エコー・ドプラ診断研究会Sonazoidを用いた造影超音波ガイド下ラジオ波焼灼術の有用性.  [Not invited]南 康範; 今井 元; 上田 泰輔; 辰巳 千栄; 北井 聡; 高橋 俊介; 井上 達夫; 萩原 智; 鄭 浩柄; 上嶋 一臣; 工藤 正俊第21回日本腹部造影エコー・ドプラ診断研究会  2008/04  秋葉原コンベンションホール, 東京.  第21回日本腹部造影エコー・ドプラ診断研究会特別講演「C型肝炎治療の重要性と最新の情報」  [Not invited]工藤 正俊平成19年度「肝がん撲滅運動」市民公開講座  2008/03  岸和田市立浪切ホール, 大阪.  平成19年度「肝がん撲滅運動」市民公開講座特別講演「C型肝炎治療の重要性と最新の情報」  [Not invited]工藤 正俊平成19年度「肝がん撲滅運動」市民公開講座  2008/03  泉佐野市立文化会館泉の森ホール, 大阪.  平成19年度「肝がん撲滅運動」市民公開講座特別講演「肝臓癌」  [Not invited]工藤 正俊第6回日本臨床腫瘍学会学術集会  2008/03  福岡国際会議場, 福岡.  第6回日本臨床腫瘍学会学術集会Live Demonstration "Abdominal Ultrasound."  [Not invited]工藤 正俊The 5th Ultrasound Workshop of the Asian Federation of Societies for Ultrasound in Medicineand Biolo  2008/03  Manila, Phillipine  The 5th Ultrasound Workshop of the Asian Federation of Societies for Ultrasound in Medicineand BioloInvited Lecture “Ultrasound of Pancreas including EUS.”  [Not invited]工藤 正俊6th Philippine Society of Ultrasound in Clinical Medicine, Inc. (PSUCMI)  2008/03  Manila, Phillipine  6th Philippine Society of Ultrasound in Clinical Medicine, Inc. (PSUCMI)Invited Lecture “Ultrasound Diagnosis of Non-alcoholic Steatoheoatitis (NASH).”  [Not invited]工藤 正俊6th Philippine Society of Ultrasound in Clinical Medicine, Inc. (PSUCMI)  2008/03  Manila, Phillipine  6th Philippine Society of Ultrasound in Clinical Medicine, Inc. (PSUCMI)総括.  [Not invited]工藤 正俊第3回 Bay Area Gut Club (BAG)  2008/03  淡路夢舞台国際会議場, 兵庫.  第3回 Bay Area Gut Club (BAG)進行肝細胞癌に対するS-1・ペグインターフェロン併用療法の有用性.  [Not invited]上嶋 一臣; 工藤 正俊第3回 Bay Area Gut Club (BAG)  2008/03  淡路夢舞台国際会議場, 兵庫.  第3回 Bay Area Gut Club (BAG)造影ハーモニック超音波内視鏡検査の新規開発と臨床応用.  [Not invited]北野 雅之; 工藤 正俊第3回 Bay Area Gut Club (BAG)  2008/03  淡路夢舞台国際会議場, 兵庫.  第3回 Bay Area Gut Club (BAG)当院でのペグインターフェロン+リバビリン併用療法について。LVR及び長期投与の検討.  [Not invited]上田 泰輔; 工藤 正俊第3回 Bay Area Gut Club (BAG)  2008/03  淡路夢舞台国際会議場, 兵庫.  第3回 Bay Area Gut Club (BAG)特別講演「Sonazoid造影エコーは肝癌診療をどう変えるか」  [Not invited]工藤 正俊第1回腹部画像診断勉強会  2008/03  大阪.  第1回腹部画像診断勉強会Invited Lecture “Treatment of HCC using Real-time Virtual Sonography and Contrast US”  [Not invited]工藤 正俊The 5th Ultrasound Workshop of the Asian Federation of Societies for Ultrasound in Medicineand Biolo  2008/03  Manila  The 5th Ultrasound Workshop of the Asian Federation of Societies for Ultrasound in Medicineand BioloInvited Lecture “Doppler/Contrast-enhanced US of liver mass”  [Not invited]工藤 正俊The 5th Ultrasound Workshop of the Asian Federation of Societies for Ultrasound in Medicineand Biolo  2008/03  Manila  The 5th Ultrasound Workshop of the Asian Federation of Societies for Ultrasound in Medicineand BioloInvited Lecture “ Application of Sonazoid in the Liver”  [Not invited]工藤 正俊The 5th Ultrasound Workshop of the Asian Federation of Societies for Ultrasound in Medicineand Biolo  2008/03  Manila  The 5th Ultrasound Workshop of the Asian Federation of Societies for Ultrasound in Medicineand Bioloステロイド、免疫調節剤使用歴のないサイトメガロウイルス感染を合併した潰瘍性大腸炎の2例.  [Not invited]梅原 泰; 川崎 正憲; 朝隈 豊; 岡田 無文; 市川 勉; 松井 繁長; 今井 元; 野田 佳寿; 坂本 洋城; 井上 達夫; 石川 恵美; 萩原 智; 末冨 洋一郎; 南 康範; 鄭 浩柄; 上嶋 一臣; 北野 雅之; 汐見 幹夫; 工藤 正俊第80回日本消化器内視鏡学会近畿地方会  2008/03  大阪国際交流センター, 大阪  第80回日本消化器内視鏡学会近畿地方会下痢を初発症状とし急速に進行した完全型ベーチェット病の一例.  [Not invited]冨田 崇文; 西尾 健; 梅原 康湖; 森村 正嗣; 米田 円; 由谷 逸朗; 辻 直子; 工藤 正俊; 本庶 元第80回日本消化器内視鏡学会近畿地方会  2008/03  大阪国際交流センター, 大阪  第80回日本消化器内視鏡学会近畿地方会当院におけるEUS下ドレナージ術の工夫.  [Not invited]野田 佳寿; 北野 雅之; 工藤 正俊第80回日本消化器内視鏡学会近畿地方会  2008/03  大阪国際交流センター, 大阪  第80回日本消化器内視鏡学会近畿地方会十二指腸静脈瘤に対する内視鏡的治療と予後.  [Not invited]松井 繁長; 岡田 無文; 工藤 正俊第80回日本消化器内視鏡学会近畿地方会  2008/03  大阪国際交流センター, 大阪  第80回日本消化器内視鏡学会近畿地方会Invited Lecture “Drug development in TACE. What are some important issues to consider in trial design? "  [Not invited]工藤 正俊AstraZeneca Hepatocellular Carcinoma Advisory Board Meeting  2008/02  Singapore  AstraZeneca Hepatocellular Carcinoma Advisory Board Meeting肝類上皮性血管内皮腫の一例  [Not invited]茂山 朋広; 林 道友; 宮部 欽生; 豊澤 昌子; 加藤 玲明; 岸谷 讓; 鍋島 紀滋; 工藤 正俊第88回日本消化器病学会近畿支部例会  2008/02  大阪  第88回日本消化器病学会近畿支部例会Special Lecture ”Pancreatic ultrasound including EUS”  [Not invited]工藤 正俊WFUMB Workshop Agra in conjunction with 17th Annual Conference of Indian Federataion of Ultrasound  2008/02  Agra, India.  WFUMB Workshop Agra in conjunction with 17th Annual Conference of Indian Federataion of UltrasoundSpecial Lecture ”Diffuse Liver Diseases”  [Not invited]工藤 正俊WFUMB Workshop Agra in conjunction with 17th Annual Conference of Indian Federataion of Ultrasound  2008/02  Agra, India.  WFUMB Workshop Agra in conjunction with 17th Annual Conference of Indian Federataion of UltrasoundLive Demonstration “Color Doppler examination in the adenoma”  [Not invited]工藤 正俊WFUMB Workshop Agra in conjunction with 17th Annual Conference of Indian Federataion of Ultrasound i  2008/02  Agra, India.  WFUMB Workshop Agra in conjunction with 17th Annual Conference of Indian Federataion of Ultrasound iInvited Lecture ”Recent Advances in Management of HCC.”  [Not invited]工藤 正俊2008/02  Fortis Hospital, New Delhi, India.One Day Visitig Professorship “Case Consultation (Session), Ultrtasound Live Demonstration and Ward Round as a Visiting Professor.”  [Not invited]工藤 正俊2008/02  Delhi University School of Medicene, GB Panda Hospital, New Delhi, India.Invited Lecture ”Treatment efficacy of TACE for HCC by use of IVR-CT.”  [Not invited]工藤 正俊2008/02  Delhi University School of Medicene, GB Panda Hospital, New Delhi, India.Invited Lecture ”Novel ultrasound technique “Pure Arterial Phase Imaging” in the diagnosis of liver tumors.”  [Not invited]工藤 正俊2008/02  Delhi University School of Medicene, GB Panda Hospital, New Delhi, India.Invited Lecture ”Sonazoid-enhanced US for the Management of hepatocellular carcinoma.”  [Not invited]工藤 正俊2008/02  Delhi University School of Medicene, GB Panda Hospital, New Delhi, India.Invited Lecture ”Real-time virtual sonography for the treatment of hepatocellular carcinoma.”  [Not invited]工藤 正俊2008/02  Delhi University School of Medicene, GB Panda Hospital, New Delhi, India.Invited Lecture “Radiofrequency ablation for difficult-to-treat HCC cases: How We Do It?”  [Not invited]工藤 正俊2008/02  Delhi University School of Medicene, GB Panda Hospital, New Delhi, India特別講演「肝細胞癌の超音波診断」  [Not invited]工藤 正俊日本超音波医学会第26回中部地方会  2008/02  名古屋国際会議場, 愛知.  日本超音波医学会第26回中部地方会基礎:造影剤と撮像法の工夫(ワークショップ「超音波フローイメージング」)  [Not invited]工藤 正俊第27回日本画像医学会  2008/02  東京コンファレンスセンター・品川, 東京.  第27回日本画像医学会特別講演「肝細胞癌の診断と治療: 最近の進歩」  [Not invited]工藤 正俊病院連携懇談会  2008/02  国家公務員共済組合連合京阪奈病院, 大阪.  病院連携懇談会当院で経験した日本海裂頭条虫症の一例  [Not invited]西尾 健; 冨田 崇文; 梅原 康湖; 森村 正嗣; 米田 円; 由谷 逸朗; 辻 直子; 工藤 正俊; 宇仁 茂彦第88回日本消化器病学会近畿支部例会  2008/02  第88回日本消化器病学会近畿支部例会急速な転帰をとった腸管ベーチェット病の一例  [Not invited]梅原 泰; 川崎 正憲; 有住 忠晃; 朝隈 豊; 岡田 無文; 市川 勉; 松井 繁長; 北野 雅之; 汐見 幹夫; 工藤 正俊; 石丸 英三郎; 沖 貴士; 上田 和毅; 所 忠男; 奥野 清隆第88回日本消化器病学会近畿支部例会  2008/02  大阪国際交流センター, 大阪  第88回日本消化器病学会近畿支部例会シングルバルーン小腸内視鏡が診断に有用だった縦走潰瘍を呈するNSAID小腸潰瘍の一例  [Not invited]川崎 正憲; 梅原 泰; 有住 忠晃; 朝隈 豊; 岡田 無文; 市川 勉; 松井 繁長; 汐見 幹夫; 工藤 正俊第88回日本消化器病学会近畿支部例会  2008/02  大阪国際交流センター, 大阪  第88回日本消化器病学会近畿支部例会高齢発症クローン病に対するTOP-DOWN療法で経時的に粘膜治癒が追えた一例  [Not invited]有住 忠晃; 梅原 泰; 川崎 正憲; 朝隈 豊; 岡田 無文; 市川 勉; 松井 繁長; 今井 元; 野田 佳寿; 坂本 洋城; 石川 恵美; 井上 達夫; 萩原 智; 末冨洋一郎; 南 康範; 鄭 浩柄; 上嶋 一臣; 北野 雅之; 汐見 幹夫; 工藤 正俊第88回日本消化器病学会近畿支部例会  2008/02  大阪国際交流センター, 大阪  第88回日本消化器病学会近畿支部例会Defect Re-injection imagingの有用性について.  [Not invited]畑中 絹世; 南 康範; 上田 泰輔; 辰巳 千栄; 北井 聡; 高橋 俊介; 井上 達夫; 萩原 智; 鄭 浩柄; 上嶋 一臣; 工藤 正俊第88回日本消化器病学会近畿支部例会  2008/02  大阪国際交流センター, 大阪.  第88回日本消化器病学会近畿支部例会Sonazoidを用いた造影超音波ガイド下ラジオ波焼灼術の有用性.  [Not invited]南 康範; 今井 元; 上田 泰輔; 辰巳 千栄; 北井 聡; 高橋 俊介; 井上 達夫; 萩原 智; 鄭 浩柄; 上嶋 一臣; 工藤 正俊第88回日本消化器病学会近畿支部例会  2008/02  大阪国際交流センター, 大阪  第88回日本消化器病学会近畿支部例会特別講演「ウィルス肝炎の長期予後、肝がん・肝硬変との関係」  [Not invited]工藤 正俊肝炎肝がん対策講習会  2008/02  大阪府富田林保健所, 大阪.  肝炎肝がん対策講習会内視鏡の偶発症対策-術前インフォームド・コンセントと電子カルテ.  [Not invited]汐見 幹夫; 末冨 洋一郎; 工藤 正俊第76回日本消化器内視鏡学会総会  2008  グランドプリンスホテル新高輪, 東京  第76回日本消化器内視鏡学会総会肝腫瘤におけるDefect Re-perfusion Imagingの有用性について.  [Not invited]畑中 絹世; 南 康範; 工藤 正俊日本超音波医学会第35回関西地方会学術集会  2008  神戸国際会議場, 兵庫.  日本超音波医学会第35回関西地方会学術集会Special Lecture “Diagnostic algorithm”  [Not invited]工藤 正俊APASL Consensus Development Meeting on Management of Hepatocellular Carcinooma  2008  Grand Hyatt Hotel, Nusa Dua, Bali  APASL Consensus Development Meeting on Management of Hepatocellular Carcinooma特別講演「肝細胞癌診療におけるSonazoid造影エコーの役割」  [Not invited]工藤 正俊学術講演会  2008/01  ウエディングプラザホテルアピオ, 山梨  学術講演会特別講演「肝細胞癌の自然経過と画像診断の役割」  [Not invited]工藤 正俊大阪EOB研究会  2008/01  大阪.  大阪EOB研究会特別講演「RFA治療支援におけるSonazoid造影下Defect Re-Perfusion Imagingの有用性」  [Not invited]工藤 正俊第14回肝血流動態イメージ研究会  2008/01  パシフィコ横浜, 横浜  第14回肝血流動態イメージ研究会ソナゾイド造影超音波による肝癌局所療法の効果判定―特にdefect-reinjection-testによる判定.  [Not invited]前川 清; 横川 美加; 前野 知子; 市島 真由美; 畑中 絹世; 辰巳 千栄; 北井 聡; 高橋 俊介; 石川 恵美; 井上 達夫; 南 康範; 鄭 浩柄; 上嶋 一臣; 工藤 正俊第14回肝血流動態イメージ研究会  2008/01  パシフィコ横浜, 横浜  第14回肝血流動態イメージ研究会Sonazoidを用いた造影超音波ガイド下ラジオ波焼灼術の有用性.  [Not invited]南 康範; 今井 元; 上田 泰輔; 北井 聡; 高橋 俊介; 井上 達夫; 鄭 浩柄; 上嶋 一臣; 工藤 正俊第14回肝血流動態イメージ研究会  2008/01  パシフィコ横浜, 横浜  第14回肝血流動態イメージ研究会Defect re-injection testの有用性について.  [Not invited]畑中 絹世; 南 康範; 鄭 浩柄; 上嶋 一臣; 前川 清; 工藤 正俊第14回肝血流動態イメージ研究会  2008/01  パシフィコ横浜, 横浜  第14回肝血流動態イメージ研究会特別講演「肝細胞癌の診断と治療 ~最近の話題~」  [Not invited]工藤 正俊第25回 神戸肝疾患カンファレンス  2008/01  神戸  第25回 神戸肝疾患カンファレンスC型慢性肝炎例の瀉血施工時における分岐鎖アミノ酸を含む栄養付加効果の検討.  [Not invited]川口雅功; 石川 恵美; 南 康範; 工藤 正俊; 土細工利夫; 高松正剛; 中村浩彦; 高瀬光徳第37回日本肝臓学会西部会  2007/12  長崎.  第37回日本肝臓学会西部会粉末化シスプラチン(アイエーコール)+リピオドール懸濁液による肝細胞癌の治療  [Not invited]林 道友; 鍋島 紀滋; 茂山 朋広; 岸谷 讓; 加藤 玲明; 豊澤 昌子; 宮部 欽生; 工藤 正俊第37回日本肝臓学会西部会  2007/12  長崎  第37回日本肝臓学会西部会下痢を契機に発症した完全型ベーチェット病の1例  [Not invited]安田 宗生; 冨田 崇文; 西尾 健; 梅原 康湖; 森村 正嗣; 米田 円; 由谷 逸朗; 辻 直子; 野崎 祐史; 工藤 正俊第184回日本内科学会近畿地方会  2007/12  京都市  第184回日本内科学会近畿地方会Effects of decorin on the expression of a-smooth muscle actin in a human myofibroblast cell line  [Not invited]仲谷 達也; 本田 映子; 佐藤 真弓; 早川 清雄; 工藤 正俊; 宗像 浩; JR仙台病院2007/12教育セミナー「肝臓癌」  [Not invited]工藤 正俊特定非営利活動法人日本臨床腫瘍学会 教育セミナー  2007/12  東京  特定非営利活動法人日本臨床腫瘍学会 教育セミナー特別講演「肝細胞癌診療におけるSonazoid造影エコーの役割」  [Not invited]工藤 正俊第49回かもがわ肝臓カンファレンス  2007/12  京都  第49回かもがわ肝臓カンファレンス特別講演「明日からできる造影超音波~~入門から応用まで~~」  [Not invited]工藤 正俊島根腹部超音波研究会  2007/12  島根  島根腹部超音波研究会教育講演「肝細胞癌の診断と治療Up To Date」  [Not invited]工藤 正俊第37回日本内科学四国支部生涯教育講演会  2007/12  香川  第37回日本内科学四国支部生涯教育講演会教育講演「肝細胞癌の診断と治療: 最近の進歩」  [Not invited]工藤 正俊第184回日本内科学近畿支部生涯教育講演会  2007/12  京都  第184回日本内科学近畿支部生涯教育講演会ペグインターフェロンがS-1の抗腫瘍効果を増強したと考えられたHCC肺転移の1例.  [Not invited]上嶋 一臣; 今井 元; 辰巳 千栄; 上田 泰輔; 川崎 正憲; 北井 聡; 高橋 俊介; 石川 恵美; 井上 達夫; 萩原 智; 南 康範; 鄭 浩柄; 工藤 正俊第45回 大阪肝穿刺生検治療研究会  2007/12  大阪  第45回 大阪肝穿刺生検治療研究会Development of Dynamic Pitch Helical Reconstruction Algorithm for Continuous Helical Shuttle Scan of 64ch MDCT with Advanced Table Control.  [Not invited]萩原明; 工藤 正俊; 村上 卓道; 柳生行伸93rd Radiological Society of North America  2007/12  Chicago  93rd Radiological Society of North America進行膵癌に対してS-1単剤療法が奏効した2例  [Not invited]茂山 朋広; 加藤 玲明; 宮部 欽生; 林 道友; 豊澤 昌子; 岸谷 讓; 鍋島 紀滋; 工藤 正俊第6回大阪消化器化学療法懇話会  2007/11  大阪  第6回大阪消化器化学療法懇話会Invited Lecture "Novel ultrasonographic technique for the diagnosis and treatment of hepatocellular carcinoma. "  [Not invited]工藤 正俊Asian Federation of Societies for Ultrasound in Medicine and Biology The 8th Congress AFSUMB Thailan  2007/11  Bangkok, Thailand.  Asian Federation of Societies for Ultrasound in Medicine and Biology The 8th Congress AFSUMB ThailanInvited Lecture "Contrast-enhanced ultrasound for liver tumors. "  [Not invited]工藤 正俊Asian Federation of Societies for Ultrasound in Medicine and Biology The 8th Congress AFSUMB Thailan  2007/11  Bangkok, Thailand.  Asian Federation of Societies for Ultrasound in Medicine and Biology The 8th Congress AFSUMB ThailanInvited Lecture “Value of real-time virtual sonography in the ablation theraphy for liver malignancies.  [Not invited]工藤 正俊Asian Federation of Societies for Ultrasound in Medicine and Biology The 8th Congress AFSUMB Thailan  2007/11  Bangkok, Thailand.  Asian Federation of Societies for Ultrasound in Medicine and Biology The 8th Congress AFSUMB ThailanContrast enhanced sonography for hepatic malignancies: Value of defect re-injection test.  [Not invited]畑中 絹世; 南 康範; 工藤 正俊Asian Federation of Societies for Ultrasound in Medicine and Biology The 8th Congress AFSUMB Thaila  2007/11  Bangkok, Thailand.  Asian Federation of Societies for Ultrasound in Medicine and Biology The 8th Congress AFSUMB ThailaA proposal of novel treatment-assist technique in the Sonazoid-enhanced ultrasonography: value of defect re-perfusion imaging.  [Not invited]工藤 正俊; 畑中 絹世; 南 康範; 鄭 浩柄; 前川 清American Association for the Study of liver Diseases (AASLD)  2007/11  Boston, USA.  American Association for the Study of liver Diseases (AASLD)Separate analysis of intranodular blood supply in nodular lesions associated with liver cirrhosis: a novel ultrasound technique “Pure arterial phase imaging”.  [Not invited]工藤 正俊; 畑中 絹世; 南 康範; 鄭 浩柄; 前川 清American Association for the Study of liver Diseases (AASLD)  2007/11  Boston, USA.  American Association for the Study of liver Diseases (AASLD)特別講演「肝疾患とインターフェロン治療」  [Not invited]工藤 正俊お茶の水肝疾患談話会  2007/10  東京  お茶の水肝疾患談話会Radiofrequency ablation of hepatocellular carcinoma: usefulness of real-time virtual CT sonography.  [Not invited]南 康範; 鄭 浩柄; 工藤 正俊; 北井 聡; 高橋 俊介; 井上 達夫; 上嶋 一臣; 福永 豊和; 塩﨑 均15th United European Gastroenterology Week (UEGW)  2007/10  Paris, France  15th United European Gastroenterology Week (UEGW)Expression in noncancerous liver tissue predicts multicentric recurrence of hepatocellular carcinoma. Workshop: Hepatobiliary and pancreatic tuomr(1).  [Not invited]辻 直子; 工藤 正俊; 石黒 信吾; 佐々木 洋66th Annual Meeting of the Japanese Cancer Association  2007/10  Kobe  66th Annual Meeting of the Japanese Cancer Association特別講演「肝腫瘍の造影超音波診断の進歩」  [Not invited]工藤 正俊京都消化器医会例会 10月度  2007/10  京都  京都消化器医会例会 10月度早期胃癌の時代的変遷とH. pyloriの関連  [Not invited]辻 直子; 西尾 健; 冨田 崇文; 梅原 康湖; 森村 正嗣; 米田 円; 由谷 逸朗; 工藤 正俊; 石黒信吾; 本庶 元JDDW2007・第74回日本消化器内視鏡学会総会  2007/10  神戸市  JDDW2007・第74回日本消化器内視鏡学会総会外来下部消化管内視鏡検査(CS)時のsedationの検討  [Not invited]梅原 康湖; 冨田 崇文; 西尾 健; 森村 正嗣; 米田 円; 由谷 逸朗; 辻 直子; 工藤 正俊; 本庶 元JDDW2007 神戸/第74回日本消化器内視鏡学会総会  2007/10  神戸市  JDDW2007 神戸/第74回日本消化器内視鏡学会総会PEG術後合併症からみたその誘因についての検討  [Not invited]冨田 崇文; 西尾 健; 梅原 康湖; 森村 正嗣; 米田 円; 由谷 逸朗; 辻 直子; 工藤 正俊; 本庶 元JDDW2007/第74回日本消化器内視鏡学会総会  2007/10  神戸市  JDDW2007/第74回日本消化器内視鏡学会総会Special Lecture “Recent advances in management of HCC: Newly developed breakthrough imaging technique and long-term IFN maintenance therapy after RFA.”  [Not invited]工藤 正俊Asian pacific Digestive Week 2007  2007/10  Kobe  Asian pacific Digestive Week 2007進行性肝細胞癌に対するS-1、ペグインターフェロン併用療法.  [Not invited]南 康範; 上嶋 一臣; 辰巳 千栄; 北井 聡; 高橋 俊介; 井上 達夫; 鄭 浩柄; 工藤 正俊第11回日本肝臓学会大会,  2007/10  神戸  第11回日本肝臓学会大会,難治性C型慢性肝炎(Ⅰ型高ウイルス量)に対するPEG-IFNα-2b/Ribavirin併用療法の使用成績と安全について.  [Not invited]石川 恵美; 上嶋 一臣; 汐見 幹夫; 北野 雅之; 松井 繁長; 福永 豊和; 仲谷 達也; 鄭 浩柄; 南 康範; 末冨 洋一郎; 福田 信宏; 坂本 洋城; 井上 達夫; 梅原 泰; 永島 美樹; 宮部 欽生; 野田 佳寿; 工藤 正俊第11回日本肝臓学会大会,  2007/10  神戸  第11回日本肝臓学会大会,クローン病に対するインフリキシマブ投与の有効性の検討.  [Not invited]梅原 泰; 工藤 正俊; 仲谷 達也; 福田 信宏; 永島 美樹; 石川 恵美; 坂本 洋城; 井上 達夫; 坂口 康浩; 萩原 智; 南 康範; 末冨 洋一郎; 小牧 孝充; 鄭 浩柄; 上嶋 一臣; 松井 繁長; 福永 豊和; 北野 雅之; 汐見 幹夫第49回日本消化器病学会大会  2007/10  神戸  第49回日本消化器病学会大会健常人に発症し、大量消化管出血を来たしたサイトメガロウイルス腸炎の一例.  [Not invited]今井 元; 永島 美樹; 渡邊 愛可; 仲谷 達也; 工藤 正俊; 坂本 洋城第49回日本消化器病学会大会  2007/10  神戸  第49回日本消化器病学会大会当院における無症状酔眼の診断と予後.ワークショップ「検診発見膵・胆道がんの予後 ?早期発見に向けて」  [Not invited]北野 雅之; 坂本 洋城; 工藤 正俊第49回日本消化器病学会大会  2007/10  神戸  第49回日本消化器病学会大会DPCにおける効率的診断法 肝悪性腫瘍を中心に. シンポジウム「DPC時代の画像診断はどうあるべきか」  [Not invited]井上達夫; 工藤 正俊第49回日本消化器病学会大会  2007/10  神戸  第49回日本消化器病学会大会転移性肝腫瘍・肝内胆管癌の画像診断~超音波診断を中心に~. ワークショップ「乏血性肝腫瘍の診療アルゴリズム」  [Not invited]上嶋 一臣; 前川 清; 工藤 正俊第49回日本消化器病学会大会  2007/10  神戸  第49回日本消化器病学会大会Child-Pugh Aの早期肝細胞癌患者に対するラジオ波焼灼療法治療成績. シンポジウム「肝癌診療ガイドライン改訂に向けて: 切除, ラジオ波, 移植の位置づけ」  [Not invited]鄭 浩柄; 井上 達夫; 工藤 正俊第49回日本消化器病学会大会  2007/10  神戸  第49回日本消化器病学会大会当院におけるEUS下ドレナージ術の成績. ビデオシンポジウム「Interventional EUS」  [Not invited]北野 雅之; 坂本 洋城; 工藤 正俊第47回日本消化器内視鏡学会総会  2007/10  神戸  第47回日本消化器内視鏡学会総会噴門部静脈瘤合併巨木型食道静脈瘤の内視鏡的治療. ワークショップ「食道噴門部静脈瘤に対する治療戦略」  [Not invited]松井 繁長; 岡田 無文; 工藤 正俊第47回日本消化器内視鏡学会総会  2007/10  神戸  第47回日本消化器内視鏡学会総会CD34 expression in noncancerous liver tissue predicts multicentric recurrence of hepatocellular carcinoma  [Not invited]辻 直子; 工藤 正俊; 石黒 信吾; 佐々木 洋第66回 日本癌学会学術総会 ワークショップ  2007/10  横浜  第66回 日本癌学会学術総会 ワークショップ十二指腸血腫による急性膵炎の経過をUSで観察し得た1例.  [Not invited]横川 美加; 前野 智子; 市島 真由美; 前川 清; 内藤 昭智; 上硲 俊法; 野上 隆司; 八木 誠; 鄭 浩柄; 工藤 正俊日本調音波医学会第34回関西地方学術集会  2007/10  大阪  日本調音波医学会第34回関西地方学術集会LOGIQ7を用いたソナゾイド造影超音波検査における新しい支援画像表示の試み.  [Not invited]前川 清; 上硲俊法; 上嶋 一臣; 工藤 正俊; 橋本 浩日本調音波医学会第34回関西地方学術集会  2007/10  大阪  日本調音波医学会第34回関西地方学術集会肝腫瘍治療, パネルディスカッション「造影超音波検査、最新の動向-次世代超音波造影剤の果たせる役割」  [Not invited]南 康範; 工藤 正俊日本調音波医学会第34回関西地方学術集会  2007/10  大阪  日本調音波医学会第34回関西地方学術集会腸間膜静脈血栓症で発症した多発性骨髄腫の一例  [Not invited]豊澤 昌子; 茂山 朋広; 宮部 欽生; 林 道友; 小川 力; 加藤 玲明; 岸谷 讓; 鍋島 紀滋; 工藤 正俊第87回日本消化器病学会近畿支部例会  2007/09  大阪  第87回日本消化器病学会近畿支部例会Educational Lecture “Critical appraisal of the paper and clinical trial design.”  [Not invited]工藤 正俊Train the Trainers workshop, World Gastroenterology Otganization(WGO)  2007/09  Chicago.  Train the Trainers workshop, World Gastroenterology Otganization(WGO)Train the Trainers workshop "Critical appraisal of the paper and clinical trial design. "  [Not invited]工藤 正俊World Gastroenterology Otganization(WGO)  2007/09  Chicago  World Gastroenterology Otganization(WGO)B型肝炎ウィルス感染における発癌リスク因子の検討.  [Not invited]萩原 智; 工藤 正俊第2回大阪肝臓ミーティング-スミフェロン発売20周年記念-  2007/09  大阪  第2回大阪肝臓ミーティング-スミフェロン発売20周年記念-異種様に対するESD後の後出血例の検討.  [Not invited]岡田 無文; 松井 繁長; 永田 嘉昭; 宮部 欽生; 市川 勉; 畑中 絹世; 工藤 正俊第47回日本消化器内視鏡学会総会  2007/09  神戸  第47回日本消化器内視鏡学会総会アレルギー性紫斑病治療中にサイトメガロウイルス関連消化管病変を認めた1例  [Not invited]梅原 康湖; 西尾 健; 冨田 崇文; 森村 正嗣; 米田 円; 由谷 逸朗; 辻 直子; 永禮 靖章; 野崎 祐史; 田中 久夫; 浦瀬 文明; 工藤 正俊; 本庶 元第79回日本消化器内視鏡学会近畿地方会  2007/09  大阪市  第79回日本消化器内視鏡学会近畿地方会3型の本固有株による重症E型肝炎の1例  [Not invited]脇本 麻由子; 由谷 逸朗; 安田 宗生; 西尾 健; 冨田 崇文; 梅原 康湖; 森村 正嗣; 米田 円; 辻 直子; 工藤 正俊; 岡本 宏明第87回日本消化器病学会近畿地方会  2007/09  第87回日本消化器病学会近畿地方会特別講演「肝細胞癌の診断と治療: Up to date」  [Not invited]工藤 正俊第1回HCC Forum in TOYAMA  2007/09  富山  第1回HCC Forum in TOYAMA腸重積を発症したCrinkhite-Canada症候群も1例.  [Not invited]早石 宗右; 石川 恵美; 北井 聡; 高橋 俊介; 井上 達夫; 南 康範; 鄭 浩柄; 上嶋 一臣; 工藤 正俊; 上田 和毅第79回日本消化器内視鏡学会近畿地方会  2007/09  大阪  第79回日本消化器内視鏡学会近畿地方会アレルギー性紫斑病治療中にサイトメガロウィルス関連消化管病変を認めた1例.  [Not invited]梅原 康湖; 西尾 健; 冨田 崇文; 森村 正嗣; 米田 円; 由谷 逸郎; 辻 直子; 永禮 靖章; 野崎 祐史; 田中 久夫; 浦瀬 文明; 工藤 正俊; 本庶 元第79回日本消化器内視鏡学会近畿地方会  2007/09  大阪  第79回日本消化器内視鏡学会近畿地方会Non-invasive methods for the assessment of liver fibrosis: comparision of transient elastography(Fibroscan), real-time tissue elastography and serum fibrotic markers.  [Not invited]辰巳 千栄; 上嶋 一臣; 鄭 浩柄; 南 康範; 工藤 正俊The 4th Korea-Japan Liver Synposium  2007/09  Seoul, Korea  The 4th Korea-Japan Liver SynposiumMaintenance interpheron therapy after curative RFA improves survival in patients with HCC.  [Not invited]工藤 正俊17th World Congress of tg\he international association of surgeons, gastroenterologists and oncologi  2007/09  Bucharest, Rumania.  17th World Congress of tg\he international association of surgeons, gastroenterologists and oncologi特別講演「LOGIQ7におけるSonazoid造影エコー法 ?特に肝癌治療支援におけるDefect Re-perfusion Imagingの有用性について-」  [Not invited]工藤 正俊第10回GE Ultrasound Instractional Seminar  2007/09  大阪  第10回GE Ultrasound Instractional Seminar重症E型肝炎の1例  [Not invited]脇本 麻由子; 由谷 逸朗; 西尾 健; 冨田 崇文; 梅原 康湖; 森村 正嗣; 米田 円; 辻 直子; 工藤 正俊; 岡本宏明第183回日本内科学会近畿地方会  2007/09  神戸市  第183回日本内科学会近畿地方会膵癌と急性膵炎の鑑別が困難であった1症例.  [Not invited]今井 元; 北野 雅之; 坂本 洋城; 前川 清; 筑後 孝章; 工藤 正俊第87回日本消化器病学会近畿支部例会  2007/09  大阪  第87回日本消化器病学会近畿支部例会術前診断が困難であった肝?胞腺癌の一例.  [Not invited]生田 研祐; 北井 聡; 南 康範; 工藤 正俊; 石川 原; 中居 卓也第87回日本消化器病学会近畿支部例会  2007/09  大阪  第87回日本消化器病学会近畿支部例会腸間膜静脈血栓症で発症した多発性骨髄腫の一例.  [Not invited]豊澤 昌子; 工藤 正俊; 茂山 朋広; 林 道友; 宮部 欽生; 小川 力; 加藤 玲明; 岸谷 譲; 鍋島 紀滋第87回日本消化器病学会近畿支部例会  2007/09  大阪  第87回日本消化器病学会近畿支部例会Real-taime Virtual Sonographyを用いたラジオ波焼灼術の治療効果判定.  [Not invited]北井 聡; 南 康範; 工藤 正俊第87回日本消化器病学会近畿支部例会  2007/09  大阪  第87回日本消化器病学会近畿支部例会3型日本固有(株)による重症E型肝炎の一例.  [Not invited]脇本 麻由子; 工藤 正俊; 由谷 逸郎; 安田 宗生; 西尾 健; 冨田 崇文; 梅原 康湖; 森村 正嗣; 辻 直子; 岡本 宏明第87回日本消化器病学会近畿支部例会  2007/09  大阪  第87回日本消化器病学会近畿支部例会当院でのステロイド未使用の潰瘍性大腸炎に対する白血球除去療法の治療成績.  [Not invited]梅原 泰; 工藤 正俊; 福田 信宏第87回日本消化器病学会近畿支部例会  2007/09  大阪  第87回日本消化器病学会近畿支部例会特別講演「Sonazoidは肝癌診療をどう変えるか?」  [Not invited]工藤 正俊第50回滋賀肝疾患研究会  2007/09  クサツエストピアホテル, 滋賀  第50回滋賀肝疾患研究会CEUS of HCC: Up-to-date technology in diagnostic and therapeutic approach.  [Not invited]工藤 正俊9th International Conference in Interventional Ultrasound and Cntraast-enhanced Ultrasound  2007/08  China.  9th International Conference in Interventional Ultrasound and Cntraast-enhanced UltrasoundInvited Lecture “Contrast-enhanced US of HCC: Up-to-date technology in the diagnostic and therapeutic approach.”  [Not invited]工藤 正俊9th International Conference on Interventional Ultrasound and Contrast-enhanced Ultrasound  2007/08  Beijing.  9th International Conference on Interventional Ultrasound and Contrast-enhanced Ultrasound特別講演「肝細胞癌の診断と治療: UP-TO-DATE」  [Not invited]工藤 正俊学術講演会  2007/08  千葉  学術講演会“Imaging diagnosis of early HCC.”  [Not invited]工藤 正俊Laennec Liver Pathlogy Society and ICGHN V  2007/07  Chester Basin  Laennec Liver Pathlogy Society and ICGHN Vソナゾイドを用いた造影超音波によるRFAの治療効果判定の検討.  [Not invited]北井 聡; 畑中 絹世; 上田 泰輔; 辰巳 千栄; 高橋 俊介; 井上 達夫; 南 康範; 鄭 浩柄; 上嶋 一臣; 工藤 正俊; 前川 清第7回関西肝血流動態イメージ研究会  2007/07  大阪  第7回関西肝血流動態イメージ研究会ソナゾイド造影超音波検査による肝腫瘍の鑑別診断の試み.  [Not invited]上嶋 一臣; 上田 泰輔; 辰巳 千栄; 北井 聡; 高橋 俊介; 畑中 絹世; 井上 達夫; 南 康範; 鄭 浩柄; 工藤 正俊; 前川 清第7回関西肝血流動態イメージ研究会  2007/07  大阪  第7回関西肝血流動態イメージ研究会ソナゾイド造影超音波検査における新しい支援画像表示の試み 特にPAP時相及びDefect re-injection testの支援画像について.  [Not invited]前川 清; 上硲 俊法; 上嶋 一臣; 工藤 正俊; 橋本 浩第7回関西肝血流動態イメージ研究会  2007/07  大阪  第7回関西肝血流動態イメージ研究会B型慢性肝炎ウィルス感染における発癌リスク因子の検討.  [Not invited]萩原 智; 高橋 俊介; 北井 聡; 石川 恵美; 井上 達夫; 南 康範; 鄭 浩柄; 上嶋 一臣; 福永 豊和; 仲谷 達也; 工藤 正俊第18回南大阪肝疾患研究会  2007/07  大阪  第18回南大阪肝疾患研究会超音波内視鏡ガイド下で胃膵吻合術を行った一例.  [Not invited]坂本 洋城; 北野 雅之; 小牧 孝充; 竹山 宜典; 工藤 正俊第38回日本膵臓学会大会  2007/06  福岡  第38回日本膵臓学会大会「ソナゾイドは肝癌診療をどう変えるか」  [Not invited]工藤 正俊第43回日本肝癌研究会ランチョンセミナー6  2007/06  東京  第43回日本肝癌研究会ランチョンセミナー6胃動脈瘤出血に対するα-シアノアクリレートによる硬化療法  [Not invited]松井 繁長; 市川 勉; 岡田 無文; 川崎 正憲; 工藤 正俊第16回近畿食道・胃動脈瘤研究会  2007/06  大阪  第16回近畿食道・胃動脈瘤研究会特別講演「肝細胞癌の診断と治療UP TO DATE ?国際比較も含めて- 」  [Not invited]工藤 正俊第6回KMU肝疾患フォーラム  2007/06  石川  第6回KMU肝疾患フォーラム特別講演「肝細胞癌治療の最近の進歩」  [Not invited]工藤 正俊『肝がん撲滅運動』学術講演会  2007/06  大阪  『肝がん撲滅運動』学術講演会診断に苦慮し急速な経過をたどった肉腫様肝癌の一例.  [Not invited]井上 達夫; 辰巳 千栄; 北井 聡; 高橋 俊介; 畑中 絹世; 萩原 智; 南 康範; 鄭 浩柄; 上嶋 一臣; 福永 豊和; 工藤 正俊第43回日本肝癌研究会  2007/06  東京ドームホテル, 東京  第43回日本肝癌研究会TAE併用RFA後に炎症性肉芽腫形成を来たし、播種性腫瘍再発との鑑別が困難であった一例.  [Not invited]高橋 俊介; 鄭 浩柄; 辰巳 千栄; 北井 聡; 井上 達夫; 南 康範; 上嶋 一臣; 福永 豊和; 工藤 正俊; 土師 誠二第43回日本肝癌研究会  2007/06  東京ドームホテル, 東京  第43回日本肝癌研究会進行肝細胞癌に対するS-1, ペグインターフェロン併用療法の有用性.  [Not invited]上嶋 一臣; 辰巳 千栄; 北井 聡; 高橋 俊介; 井上 達夫; 南 康範; 鄭 浩柄; 福永 豊和; 工藤 正俊第43回日本肝癌研究会  2007/06  東京ドームホテル, 東京  第43回日本肝癌研究会肝細胞癌根治治療施行例における治療前腫瘍マーカーの予後におよぼす影響. シンポジウム「術前検査による肝細胞癌の悪性度予測と治療選択」  [Not invited]豊田秀徳; 工藤 正俊; 熊田 卓; 大崎往夫; 岡 博子; 浦野文博; 松永 隆第43回日本肝癌研究会  2007/06  東京ドームホテル, 東京  第43回日本肝癌研究会治療前後のAFP-L3分画値から検討した肝細胞癌治療後の予後予測(前向き多施設共同研究). シンポジウム「術前検査による肝細胞癌の悪性度予測と治療選択」  [Not invited]田中正俊; 工藤 正俊; 斉藤明子; 伊東和樹; 熊田 卓; 岡 博子; 関 寿人; 春日井博志; 大崎往夫第43回日本肝癌研究会  2007/06  東京ドームホテル, 東京  第43回日本肝癌研究会肝細胞癌に対する肝動脈塞栓療法と肝動注化学療法の多施設共同ランダム化比較試験. パネルディスカッション「肝細胞癌診療ガイドライン改訂に向けて; TACE, TAI, 肝動注化学療法の適切な選択」  [Not invited]春日井博志; 工藤 正俊; 佐藤俊哉; 樋之津史郎; 塩山靖和; 田中克明; 税所宏光; 大崎往夫; 佐田通夫; 奥坂拓志第43回日本肝癌研究会  2007/06  東京ドームホテル, 東京  第43回日本肝癌研究会Child-Pugh Aの早期肝細胞癌患者に対するラジオ波焼灼療法治療成績. パネルディスカッション「ガイドライン改訂に向けて; 肝移植, ラジオ波導入時代における肝切除の意義」  [Not invited]鄭 浩柄; 辰巳 千栄; 北井 聡; 高橋 俊介; 井上 達夫; 南 康範; 上嶋 一臣; 福永 豊和; 工藤 正俊; 土師 誠二第43回日本肝癌研究会  2007/06  東京ドームホテル, 東京  第43回日本肝癌研究会全国データに基づく肝切除と経皮療法の長期比較. パネルディスカッション「ガイドライン改訂に向けて; 肝移植, ラジオ波導入時代における肝切除の意義」  [Not invited]長谷川 潔; 工藤 正俊; 幕内雅敏; 高山忠利; 國土典宏; 有井滋樹; 小俣政男; 神代正道; 坂元亨宇; 高安賢一; 林 紀夫; 門田守人; 松山 裕; 猪飼伊和夫第43回日本肝癌研究会  2007/06  東京ドームホテル, 東京  第43回日本肝癌研究会特別講演「肝細胞癌の治療効果判定と穿刺ガイド-Sonazoidの有用性-」  [Not invited]工藤 正俊第1回ソナゾイド研究会第2部「診断と治療支援」  2007/06  東京  第1回ソナゾイド研究会第2部「診断と治療支援」Transarterial infusion chemotherapy alone versus transarterial chemoembolization for the treatment of hepatocellular carcinoma: Results of a multicenter randomized phase Ⅲ traial.  [Not invited]奥坂 拓志; 工藤 正俊; 佐藤 俊哉; 樋之津 史郎; 塩山 靖和; 春日井 博志; 田中 克明; 税所 宏光; 大崎 往夫; 佐田 通夫; 藤山 重俊American Society of Clinical Oncology  2007/06  Chicago, USA  American Society of Clinical Oncology特別講演「肝硬変・肝癌の治療におけるインターフェロンの役割」  [Not invited]工藤 正俊第43回日本肝臓学会総会モーニングセミナー・ランチョンセミナー  2007/06  ホテルグランパシフィックメリディアン, 東京  第43回日本肝臓学会総会モーニングセミナー・ランチョンセミナーパネルディスカッション「患者さんの疑問にこたえるQ&A」  [Not invited]工藤 正俊市民公開講座「ウィルス性肝炎疾患 その最新治療を学ぶ」  2007/05  京都  市民公開講座「ウィルス性肝炎疾患 その最新治療を学ぶ」特別講演「ソナゾイドによる肝細胞癌診療」  [Not invited]工藤 正俊日本インターベンショナルラジオロジー学会総会ランチョンセミナー  2007/05  石川  日本インターベンショナルラジオロジー学会総会ランチョンセミナー特別講演「肝臓ガンの病態と最新治療」  [Not invited]工藤 正俊市民公開講座「ウィルス性肝疾患 その最新治療を学ぶ」  2007/05  京都  市民公開講座「ウィルス性肝疾患 その最新治療を学ぶ」腸重積を呈した横行結腸脂肪腫の1例  [Not invited]旭爪 章統; 梅原 康湖; 冨田 崇文; 西尾 健; 森村 正嗣; 米田 円; 由谷 逸朗; 辻 直子; 工藤 正俊; 本庶 元第182回日本内科学会近畿地方会  2007/05  大阪市  第182回日本内科学会近畿地方会急性膵炎の経過中、腸腰筋膿瘍を合併した1例  [Not invited]田中 意浩; 梅原 康湖; 西尾 健; 冨田 崇文; 森村 正嗣; 米田 円; 由谷 逸朗; 辻 直子; 工藤 正俊; 本庶 元第182回日本内科学会近畿地方会  2007/05  大阪市  第182回日本内科学会近畿地方会内視鏡的ドレナージ術により軽快した感染性膵嚢胞の1例  [Not invited]赤岩 譲; 冨田 崇文; 西尾 健; 梅原 康湖; 森村 正嗣; 米田 円; 由谷 逸朗; 辻 直子; 工藤 正俊; 本庶 元第182回日本内科学会近畿地方会  2007/05  大阪市  第182回日本内科学会近畿地方会腹膜刺激症状を認めなかった胆嚢穿孔の1例  [Not invited]藤田 淳也; 西尾 健; 冨田 崇文; 梅原 康湖; 森村 正嗣; 米田 円; 由谷 逸朗; 辻 直子; 工藤 正俊; 本庶 元第182回日本内科学会近畿地方会  2007/05  大阪市  第182回日本内科学会近畿地方会Clinical application of contrast-enhanced harmonic imaging to endosonography.  [Not invited]北野 雅之; 坂本 洋城; 前川 清; 工藤 正俊; 松井 宇部; 伊藤 安啓; Tammo von SchrenkDDW(Digestive Disease Week) and ASGE  2007/05  Washington, DC  DDW(Digestive Disease Week) and ASGE特別講演「新しい超音波造影剤は肝癌の診療をどう変えるか?」ランチョンセミナー  [Not invited]工藤 正俊日本超音波医学会第80会学術集会  2007/05  鹿児島  日本超音波医学会第80会学術集会造影ハーモニック超音波内視鏡装置の新規開発と臨床応用.  [Not invited]北野 雅之; 坂本 洋城; 前川 清; 工藤 正俊; 松井 宇部; 伊藤 安啓; von Schrenck Tammo日本超音波医学会第80回学術集会  2007/05  鹿児島  日本超音波医学会第80回学術集会Regulatory failure pf serem prohepcidin levels in patients with hepatitis C.  [Not invited]永島 美樹; 工藤 正俊; 鄭 浩柄; 石川 恵美; 萩原 智; 仲谷 達也DDW(Digestive Disease Week) and the 108th Annual Meeting of the AGA  2007/05  Washington, DC.  DDW(Digestive Disease Week) and the 108th Annual Meeting of the AGAMulticentric recurrence of hepatocellular carcinoma and CD-34 expression in background liver.  [Not invited]辻 直子; 石黒 信吾; 工藤 正俊DDW(Digestive Disease Week) and the 108th Annual Meeting of the AGA  2007/05  Washington, DC.  DDW(Digestive Disease Week) and the 108th Annual Meeting of the AGADiagnosis of gallbladder diseases by contrast-enhanced phase-inversion harmonic ultrasonography.  [Not invited]井上 達夫; 北野 雅之; 工藤 正俊; 坂本 洋城DDW(Digestive Disease Week) and the 108th Annual Meeting of the AGA  2007/05  Washington, DC  DDW(Digestive Disease Week) and the 108th Annual Meeting of the AGA新しい超音波造影剤ソナゾイドによる肝腫瘍の造影評価.  [Not invited]前川 清; 井上 達夫; 南 康範; 鄭 浩柄; 上嶋 一臣; 福永 豊和; 工藤 正俊日本超音波医学会第80回学術集会  2007/05  鹿児島  日本超音波医学会第80回学術集会肝疾患におけるTissue Elastography -第2報  [Not invited]藤本 研治; 辰巳 千栄; 上嶋 一臣; 前川 清; 工藤 正俊; 外村 明子; 三竹 毅; 山川 誠; 加藤 道夫; 椎名 毅日本超音波医学会第80回学術集会  2007/05  鹿児島  日本超音波医学会第80回学術集会造影超音波の新しい展開 パネルディスカッション消化器「肝癌診断最近の動向 診断」  [Not invited]南 康範; 工藤 正俊日本超音波医学会第80回学術集会  2007/05  鹿児島  日本超音波医学会第80回学術集会肝膵疾患に対するinterventional EUS シンポジウム消化器「腹部領域におけるInterventional Sonography」  [Not invited]坂本 洋城; 北野 雅之; 工藤 正俊日本超音波医学会第80回学術集会  2007/05  鹿児島  日本超音波医学会第80回学術集会Child-Pugh Aの早期肝細胞癌患者に対するラジオ波焼灼療法治療成績. パネルディスカッション「肝癌診療ガイドラインの検証」.  [Not invited]鄭 浩柄; 福永 豊和; 工藤 正俊第43回日本肝臓学会総会  2007/05  ホテルグランパシフィックメリディアン, 東京  第43回日本肝臓学会総会高度進行肝細胞癌に対するS-1, ペグインターフェロン併用療法の有用性.  [Not invited]上嶋 一臣; 南 康範; 工藤 正俊第43回日本肝臓学会総会  2007/05  ホテルグランパシフィックメリディアン, 東京  第43回日本肝臓学会総会EUS-FNAが診断に有効であった腹腔内リンパ節結核の一例.  [Not invited]小牧 孝充; 北野 雅之; 坂本 洋城; 末冨 洋一郎; 野田 佳寿; 今井 元; 汐見 幹夫; 工藤 正俊第2回超音波内視鏡下生検法の診断精度向上のための研究会  2007/05  国際館パミール, 東京  第2回超音波内視鏡下生検法の診断精度向上のための研究会当院における超音波内視鏡ガイド下治療の現状. ワークショップ「EUS-FNAの現状と将来」  [Not invited]坂本 洋城; 北野 雅之; 工藤 正俊第73回日本消化器内視鏡学会総会  2007/05  グランドプリンスホテル新高輪, 東京  第73回日本消化器内視鏡学会総会次世代超音波造影剤SonoVueを用いた造影ハーモニック超音波内視鏡検査. シンポジウム「超音波内視鏡(EUシンポジウム)による診断・治療の最前線」  [Not invited]北野 雅之; 坂本 洋城; 工藤 正俊第73回日本消化器内視鏡学会総会  2007/05  グランドプリンスホテル新高輪, 東京  第73回日本消化器内視鏡学会総会特別講演「肝細胞癌の診断と治療:Up-to-date」  [Not invited]工藤 正俊第146回愛媛消化器疾患懇話会  2007/04  愛媛  第146回愛媛消化器疾患懇話会粉末化シスプラチン(アイエーコール)+リピオドール懸濁液による肝細胞癌の治療経験  [Not invited]林 道友; 鍋島 紀滋; 小川 力; 水野 成人; 岸谷 讓; 加藤 玲明; 豊澤 昌子; 工藤 正俊第93回日本消化器病学会総会  2007/04  青森市文化会館, 青森  第93回日本消化器病学会総会B型肝炎ウィルス感染における発癌リスク因子の検討  [Not invited]萩原 智; 工藤 正俊; 仲谷 達也; 鄭 浩柄; 大阪赤十字病院; 日本赤十字社和歌山医療センター; 岸和田市民病院第93回日本消化器病学会総会  2007/04  青森市文化会館, 青森  第93回日本消化器病学会総会進行膵癌化学療法効果測定における各腫瘍マーカーの有用性について  [Not invited]野田 佳寿; 坂本 洋城; 北野 雅之; 末冨 洋一郎; 小牧 孝充; 工藤 正俊第93回日本消化器病学会総会  2007/04  青森市文化会館, 青森  第93回日本消化器病学会総会膵癌におけるバイオマーカーとしてのKL-6の有用性.  [Not invited]小牧 孝充; 北野 雅之; 坂本 洋城; 末冨 洋一郎; 野田 佳寿; 汐見 幹夫; 工藤 正俊第93回日本消化器病学会総会  2007/04  青森市文化会館, 青森  第93回日本消化器病学会総会ステージ4B肝内胆管癌に対するGemcitabine (GEM)をfirst lineとした化学療法と無治療群との比較検討.  [Not invited]南 康範; 上嶋 一臣; 坂口 康浩; 鄭 浩柄; 福永 豊和; 工藤 正俊第93回日本消化器病学会総会  2007/04  青森市文化会館, 青森  第93回日本消化器病学会総会進行肝細胞癌に対するCDDP+5FU動注化学療法における5FU投与濃度の意義. シンポジウム「進行肝癌に対する集学的治療」  [Not invited]上嶋 一臣; 辰巳 千栄; 工藤 正俊第93回日本消化器病学会総会  2007/04  青森市文化会館, 青森  第93回日本消化器病学会総会教育講演「肝癌」  [Not invited]工藤 正俊第93回日本消化器病学会総会ポストグラデュエイトコース  2007/04  ウェルシティ青森, 青森  第93回日本消化器病学会総会ポストグラデュエイトコースシンポジウム「超音波造影剤ソナゾイド?を使用した造影超音波検査ー最新ソフトおよび臨床画像を含めてー.」  [Not invited]工藤 正俊第20回日本腹部造影エコー・ドプラ診断研究会  2007/04  今池ガスビル, 名古屋  第20回日本腹部造影エコー・ドプラ診断研究会新しい超音波造影剤ソナゾイドによる肝腫瘍の造影評価.  [Not invited]前川 清; 井上 達夫; 鄭 浩柄; 南 康範; 上嶋 一臣; 工藤 正俊第20回日本腹部造影エコー・ドプラ診断研究会  2007/04  今池ガスビル, 名古屋  第20回日本腹部造影エコー・ドプラ診断研究会Invited Lecture “Novel Sonographic Technique for the Diagnosis and Treatment of Hepatocellular Carcinoma.”  [Not invited]工藤 正俊International HCC Symposium  2007/03  Seoul National University Cancer Institute, Seoul, Korea  International HCC Symposiumステージ4B肝内胆管癌に対するGemcitabine(GEM)をfirst lineとした化学療法と無治療群との比較検討.  [Not invited]南 康範; 上嶋 一臣; 坂口 康浩; 鄭 浩柄; 福永 豊和; 工藤 正俊第5回日本臨床腫瘍学会学術集会  2007/03  札幌コンベンションセンター, 北海道  第5回日本臨床腫瘍学会学術集会Round Table Discussion “Diagnosis and treatment of HCC.”  [Not invited]工藤 正俊Up-to-date prevention and therapy for hepatocellular carcinoma (HCC)  2007/03  Kurume, Japan  Up-to-date prevention and therapy for hepatocellular carcinoma (HCC)PEGインターフェロン併用療法の経験.  [Not invited]上嶋 一臣; 南 康範; 工藤 正俊第5回日本臨床腫瘍学会学術集会  2007/03  札幌コンベンションセンター, 北海道  第5回日本臨床腫瘍学会学術集会Estimation of angiotensin-II and angiotensin-II receptor blocker (TCV-116) on rat pancreatic stellate cells: angiotensin-II type 1 receptor blocker (CV-11974) and angiotensin―converting enzyme inhibitor (perindopril) suppress pancreatitis and fibrosis in  [Not invited]福田 信宏; 工藤 正俊第2回Bay Area Gut Club  2007/03  淡路夢舞台, 淡路  第2回Bay Area Gut ClubC型肝炎患者における血清プロヘプシジン濃度の調節異常.  [Not invited]永島 美樹; 工藤 正俊第2回Bay Area Gut Club  2007/03  淡路夢舞台, 淡路  第2回Bay Area Gut Club当院における超音波内視鏡ガイド下腹腔神経叢ブロックの成績.  [Not invited]坂本 洋城; 工藤 正俊第2回Bay Area Gut Club  2007/03  淡路夢舞台, 淡路  第2回Bay Area Gut Club早期胃癌治療における術前複数周波数超音波内視鏡検査の有用性.  [Not invited]市川 勉; 工藤 正俊第2回Bay Area Gut Club  2007/03  淡路夢舞台, 淡路  第2回Bay Area Gut ClubClinial staging system for hepatocellular carcinoma.  [Not invited]鄭 浩柄; 工藤 正俊17th APASL Conference  2007/03  Kyoto  17th APASL ConferenceEducation Lecture “Imaging diagnosis of early-stage HCC.”  [Not invited]工藤 正俊17th APASL Conference  2007/03  Kyoto  17th APASL ConferenceRegulatory failure of serum prohepcidin levels in patients with hepatitis C.  [Not invited]永島 美樹; 工藤 正俊; 鄭 浩柄; 石川 恵美; 萩原 智; 仲谷 達也17th APASL Conference  2007/03  Kyoto  17th APASL ConferenceReal-time virtual CT sonographic-guided radiofrequency ablation for hepatocellular carcinoma.  [Not invited]南 康範; 鄭 浩柄; 井上 達夫; 上嶋 一臣; 福永 豊和; 工藤 正俊17th APASL Conference  2007/03  Kyoto  17th APASL ConferencePegylated interferon therapy increases serum ferritin and ALT levels in chronic hepatitis C patients.  [Not invited]永島 美樹; 工藤 正俊; 鄭 浩柄; 石川 恵美; 仲谷 達也17th APASL Conference  2007/03  Kyoto  17th APASL ConferenceImpact of pretreatment tumor marker elevations on survival of HCC patients after curative treatment.  [Not invited]工藤 正俊; 豊田 秀徳; 熊田 卓; 大崎 往夫; 岡 博子; 浦野 文博17th APASL Conference  2007/03  Kyoto  17th APASL Conference特別講演「Diagnosis and treatment of early-stage HCC: An Update」  [Not invited]工藤 正俊久留米大学21世紀COEプログラムアジア肝癌フォーラムーUp-to-Date Prevention and Therapy for Hepatocellular Carcinoma (HCC)ー  2007/03  久留米大学, 九州  久留米大学21世紀COEプログラムアジア肝癌フォーラムーUp-to-Date Prevention and Therapy for Hepatocellular Carcinoma (HCC)ーInvited Lecture “Long-dose, Long-term IFN therapy improves survival in patients with HCV-related HCC after curative RFA.”  [Not invited]工藤 正俊Miami Clinical Exchange-Liver Disease in Japan and USA-  2007/03  Miami, USA  Miami Clinical Exchange-Liver Disease in Japan and USA-教育講演「肝臓癌」  [Not invited]工藤 正俊日本臨床腫瘍学会第8回教育セミナーBセッション  2007/03  札幌コンベンションセンター, 北海道  日本臨床腫瘍学会第8回教育セミナーBセッションInvited Lecture “Real-time virtual sonography for liver malignancies.”  [Not invited]工藤 正俊WFUMB Center of Excellence Workshop  2007/03  Dhaka, Bangladesh  WFUMB Center of Excellence WorkshopInvited Lecture “Contrast-enhance ultrasound for liver tumors.”  [Not invited]工藤 正俊WFUMB Center of Excellence Workshop  2007/03  Dhaka, Bangladesh  WFUMB Center of Excellence WorkshopInvited Lecture “Ultrasound diagnosis of pancreatic tumor.”  [Not invited]工藤 正俊WFUMB Center of Excellence Workshop  2007/03  Dhaka, Bangladesh  WFUMB Center of Excellence Workshop吻合部狭窄に対し内視鏡的バルーン拡張術を行い著名な体積増加が得られたクローン病の一例.  [Not invited]梅原 泰; 工藤 正俊; 中岡 良介; 福田 信宏; 永島 美樹; 石川 恵美; 仲谷 達也; 汐見 幹夫第78回日本消化器内視鏡学会近畿地方会  2007/03  大阪国際交流センター, 大阪  第78回日本消化器内視鏡学会近畿地方会内視鏡的に止血し得た盲腸Dieurafoy潰瘍の一例.  [Not invited]梅原 泰; 工藤 正俊; 福田 信宏; 永島 美樹; 石川 恵美; 汐見 幹夫第78回日本消化器内視鏡学会近畿地方会  2007/03  大阪国際交流センター, 大阪  第78回日本消化器内視鏡学会近畿地方会腸重責を呈した横行結腸脂肪腫の一例.  [Not invited]梅原 康湖; 冨田 崇文; 西尾 健; 森村 正嗣; 米田 円; 由谷 逸朗; 辻 直子; 中村 浩一; 井上 潔彦; 田中 晃; 本庶 元; 工藤 正俊第78回日本消化器内視鏡学会近畿地方会  2007/03  大阪国際交流センター, 大阪  第78回日本消化器内視鏡学会近畿地方会内視鏡で経時的に変化が追えた難治性潰瘍性大腸炎の一例.  [Not invited]梅原 泰; 工藤 正俊; 福田 信宏; 永島 美樹; 石川 恵美; 仲谷 達也; 汐見 幹夫第78回日本消化器内視鏡学会近畿地方会  2007/03  大阪国際交流センター, 大阪  第78回日本消化器内視鏡学会近畿地方会当院におけるEUSによる膵疾患の診断と治療の現状. パネルディスカッションII「胆膵領域の内視鏡診断・治療の最前線」  [Not invited]坂本 洋城; 北野 雅之; 工藤 正俊第78回日本消化器内視鏡学会近畿地方会  2007/03  大阪国際交流センター, 大阪  第78回日本消化器内視鏡学会近畿地方会粉末化シスプラチン(アイエーコール)+リピオドール懸濁液による肝細胞癌の治療経験  [Not invited]鍋島 紀滋; 小川 力; 林 道友; 水野 成人; 岸谷 讓; 加藤 玲明; 豊澤 昌子; 工藤 正俊第48回京都肝疾患懇話会  2007/02  京都  第48回京都肝疾患懇話会EUS下胃膵吻合術を行った一症例.  [Not invited]坂本 洋城; 北野 雅之; 末冨 洋一郎; 小牧 孝充; 野田 佳寿; 工藤 正俊1st FNA-Club Conference  2007/02  新宿, 東京  1st FNA-Club Conference進行肝細胞癌に対するS-1、ペグインターフェロン併用療法の経験.  [Not invited]上嶋 一臣; 辰巳 千栄; 北井 聡; 高橋 俊介; 井上 達夫; 南 康範; 鄭 浩柄; 福永 豊和; 工藤 正俊第86回日本消化器病学会近畿支部例会  2007/02  京都テルサ, 京都  第86回日本消化器病学会近畿支部例会腹膜刺激症状を認めずERCPにて診断しえた胆嚢穿孔の一例.  [Not invited]西尾 健; 冨田 崇文; 梅原 康湖; 森村 正嗣; 米田 円; 由谷 逸朗; 辻 直子; 田中 晃; 川邊 高史; 北口 博士; 工藤 正俊第86回日本消化器病学会近畿支部例会  2007/02  京都テルサ, 京都  第86回日本消化器病学会近畿支部例会C型肝硬変に伴う肝内びまん性動門脈シャントに対して肝動脈塞栓術およびバルン閉塞下逆行性シャント閉塞術が奏功した一例.  [Not invited]前川 昌平; 鄭 浩柄; 辰巳 千栄; 北井 聡; 高橋 俊介; 萩原 智; 井上 達夫; 南 康範; 上嶋 一臣; 福永 豊和; 工藤 正俊; 堀 信一第86回日本消化器病学会近畿支部例会  2007/02  京都テルサ, 京都  第86回日本消化器病学会近畿支部例会特別講演「肝癌の診断と治療: Up To Date」  [Not invited]工藤 正俊第3回神奈川肝炎若手の会  2007/02  横浜ベイシェラトンホテル&タワーズ, 横浜  第3回神奈川肝炎若手の会ポリウレタン製PEGの長期留置の有用性について.  [Not invited]中岡 良介; 末冨 洋一郎; 汐見 幹夫; 工藤 正俊; 川端 一史; 中川 裕隆; 山本 博晟第15回クリニカル・ビデオフォーラム(CVF)  2007/02  大手前サンケイプラザ, 東京  第15回クリニカル・ビデオフォーラム(CVF)リザーバー肝動注化学療法が有効であった乳癌肝転移の一症例.  [Not invited]辰巳 千栄; 上嶋 一臣; 上田 泰輔; 北井 聡; 高橋 俊介; 井上 達夫; 鄭 浩柄; 南 康範; 工藤 正俊第87回日本消化器病学会近畿支部例会  2007  大阪  第87回日本消化器病学会近畿支部例会特別講演「肝細胞癌の治療効果判定と穿刺ガイド ?Sonazoidの有用性-」  [Not invited]工藤 正俊第56回山口県難治性肝疾患研究会  2007  山口  第56回山口県難治性肝疾患研究会特別講演「新しい超音波造影剤は肝癌の診療をどう変えるか?」  [Not invited]工藤 正俊日本超音波医学会第80会学術集会 ランチョンセミナー  2007  鹿児島  日本超音波医学会第80会学術集会 ランチョンセミナーレボビスト造影超音波の後血管相における肝と脾臓の輝度評価「特に肝の過形所成結節について」.  [Not invited]前川 清; 井上 達夫; 南 康範; 鄭 浩柄; 上嶋 一臣; 福永 豊和; 工藤 正俊第13回肝血流動態イメージ研究会  2007/01  パシフィコ横浜  第13回肝血流動態イメージ研究会特別講演「肝細胞癌の診断と治療: 最近の進歩」  [Not invited]工藤 正俊宇部・小野田地区学術講演会  2007/01  宇部全日空ホテル, 山口  宇部・小野田地区学術講演会特別講演「ウイルス肝炎治療の最前線」  [Not invited]工藤 正俊肝炎肝がん対策研修会  2007/01  大阪府富田林保健所, 大阪  肝炎肝がん対策研修会Invited Lecture “ Pure arterial phase imaging of liver tumors: an innovative technology in the contrastenhanced ultrasonograhy.”  [Not invited]工藤 正俊8th International Symposium on Ultrasound Contrast Imaging  2006/12  Tokyo Medical University Hospital, Tokyo  8th International Symposium on Ultrasound Contrast ImagingRole of computed tomography in evaluating the injection site in endosonography guided celiac plexus neurolysis.  [Not invited]北野 雅之; 坂本 洋城; 西尾 健; 竹山 宜典; 保田 知生; 工藤 正俊21st International Workshop on Therapeutic Endoscopy  2006/12  Hong Kong  21st International Workshop on Therapeutic EndoscopyInvited Lecture “Pure arterial phase imaging on liver tumors.”  [Not invited]工藤 正俊The 4th AFSUMB Ultrasound Workshop  2006/12  Bangkok, Thailand  The 4th AFSUMB Ultrasound WorkshopInvited Lecture “Real-time virtual sonography for liver malignancies.”  [Not invited]工藤 正俊The 4th AFSUMB Ultrasound Workshop  2006/12  Bangkok, Thailand  The 4th AFSUMB Ultrasound WorkshopAssessment of 4D MDCT abdominal angiography by using non-stop continuous helical shuttle scan technique.  [Not invited]工藤 正俊; 村上 卓道92nd Radiological Society of North America.  2006/11  Chicago.  92nd Radiological Society of North America.Invited Lecture “Diagnosis of early HCC in Japan: value of contrast-enhanced ultrasound.”  [Not invited]工藤 正俊Symposium on Hepatocellular Carcinoma  2006/11  University of Leuven, Belgique  Symposium on Hepatocellular Carcinomaシンポジウム「肝がん治療について」  [Not invited]工藤 正俊がん予防キャンペーン大阪2006シンポジウム「がんの最新治療~早く見つけて上手に治す~」  2006/11  大阪  がん予防キャンペーン大阪2006シンポジウム「がんの最新治療~早く見つけて上手に治す~」特別講演「肝腫瘍の純動脈相イメージング」  [Not invited]工藤 正俊第24回TOYエコーフォーラム  2006/11  京都  第24回TOYエコーフォーラムNon-transplant treatment for hepatocellular carcionoma associated with child-Pugh grade C cirrhosis: a multicenter study on survival benefit.  [Not invited]工藤 正俊; 大崎 往夫; 大阪府立成人病センタ; 大阪府立成人病センタ; 大阪市立総合医療センター14th United European Gastroenterology Week (UEGW2006  2006/11  Berlin  14th United European Gastroenterology Week (UEGW2006特別講演「肝臓がん」  [Not invited]工藤 正俊第44回日本消化器病学会関東支部市民公開講座「消化器の早期がんのお話」  2006/11  横浜市教育会館, 横浜  第44回日本消化器病学会関東支部市民公開講座「消化器の早期がんのお話」特別講演「肝細胞癌の診断と治療: 最近の進歩」  [Not invited]工藤 正俊第42回鹿児島肝疾患懇話会  2006/11  城山観光ホテル, 鹿児島  第42回鹿児島肝疾患懇話会ランチョンセミナー「原発性肝癌の治療」  [Not invited]工藤 正俊日本消化器病学会関東支部第9回教育講演会  2006/11  シェーンバッハ砂防, 東京  日本消化器病学会関東支部第9回教育講演会Value of computed tomography for evaluating the injection site in endoconography-guided celiac plexus neurolysis.  [Not invited]坂本 洋城; 工藤 正俊; 北野 雅之; 西尾 健; 竹山 宜典; 保田 知生14th United European Gastroenterology Week (UEGW2006)  2006/10  Berlin  14th United European Gastroenterology Week (UEGW2006)The utility of endoscopic ultrasonography using multiple miniature endoscopic ultrasound probe in the endoscopic submucosal desection of early gastric cancer.  [Not invited]市川 勉; 工藤 正俊; 松井 繁長; 北野 雅之; 末冨 洋一郎; 岡田 無文14th United European Gastroenterology Week (UEGW2006)  2006/10  Berlin  14th United European Gastroenterology Week (UEGW2006)Novel perfusion imaging technique of the pancreas, contrast-enhanced harmonic endosonography: the first clinical report.  [Not invited]北野 雅之; 工藤 正俊; 坂本 洋城; 松井 繁長; 前川 清14th United European Gastroenterology Week (UEGW2006)  2006/10  Berlin  14th United European Gastroenterology Week (UEGW2006)The novel questionnairee to evaluate health-related quality of life specific for patients with hepatocellular carcinoma.  [Not invited]中山 伸朗; 工藤 正俊; 柿沼 徹; 松井 淳; 名越 澄子; 持田 智; 小俣 政男; 熊田 博光; 佐田 通夫; 國土 典宏; 門田 守人; 兼松 隆之; 田中 宏一; 森脇 久隆; 藤原 研司The Liver Meeting (AASLD)  2006/10  Boston  The Liver Meeting (AASLD)Non-transplant treatment for hepatocellular carcionoma associated with child-Pugh grade C cirrhosis: a multicenter study on survival benefit.  [Not invited]工藤 正俊; 大崎 往夫; 松永 隆; 春日井 博志; 大阪総合医療センタThe Liver Meeting (AASLD)  2006/10  Boston  The Liver Meeting (AASLD)特別講演「消化器・肝臓病学の魅力」  [Not invited]工藤 正俊内科医をめざす若手医師のための教育セミナー  2006/10  石川県地場産業振興センター  内科医をめざす若手医師のための教育セミナー純型・混合型からみた早期胃癌の臨床病理学的検討  [Not invited]辻 直子; 工藤 正俊; 冨田 崇文; 梅原 康湖; 森村 正嗣; 米田 円; 由谷 逸朗; 石黒 信吾; 藤井 恭子; 本庶 元DDW-Japan 2006 第14回日本消化器関連学会週間  2006/10  札幌市  DDW-Japan 2006 第14回日本消化器関連学会週間PEG後腸瘻に移行した症例とPEG症例との背景因子についての比較検討  [Not invited]冨田 崇文; 工藤 正俊; 落合 健; 梅原 康湖; 森村 正嗣; 米田 円; 由谷 逸朗; 辻 直子; 本庶 元DDW-Japan 2006 第14回日本消化器関連学会週間  2006/10  札幌市  DDW-Japan 2006 第14回日本消化器関連学会週間緊急上部消化管内視鏡止血術後の絶食期間の検討  [Not invited]梅原 康湖; 工藤 正俊; 辻 直子; 冨田 崇文; 落合 健; 森村 正嗣; 米田 円; 由谷 逸朗; 本庶 元DDW-Japan 2006 第14回 日本消化器関連学会週間  2006/10  札幌市  DDW-Japan 2006 第14回 日本消化器関連学会週間C型慢性肝炎に対するPEG-IFNα-2a製剤投与中の血清ALT値上昇の原因についての検討.  [Not invited]永島 美樹; 工藤 正俊; 鄭 浩柄; 石川 恵美; 仲谷 達也第10回日本肝臓学会大会(DDW-Japan)  2006/10  札幌コンベンションセンター, 道立総合体育センター, 北海道  第10回日本肝臓学会大会(DDW-Japan)肝細胞癌への経皮的ラジオ波焼灼術におけるReal-time Virtual Sonographyの有用性.  [Not invited]南 康範; 工藤 正俊第48回日本消化器病学会大会(DDW-Japan)  2006/10  札幌コンベンションセンター, 道立総合体育センター, 北海道  第48回日本消化器病学会大会(DDW-Japan)パネルディスカッション「超音波内視鏡ガイド下腹腔神経叢ブロック術におけるCTの役割.  [Not invited]坂本 洋城; 工藤 正俊; 北野 雅之第72回日本消化器内視鏡学会総会(DDW-Japan)  2006/10  札幌コンベンションセンター, 道立総合体育センター, 北海道  第72回日本消化器内視鏡学会総会(DDW-Japan)ビデオワークショップ「食道静脈瘤に対する内視鏡的治療の工夫」.  [Not invited]松井 繁長; 工藤 正俊; 岡田 無文第72回日本消化器内視鏡学会総会(DDW-Japan)  2006/10  札幌コンベンションセンター, 道立総合体育センター, 北海道  第72回日本消化器内視鏡学会総会(DDW-Japan)早期胃癌に対してESD術前に複数周波数を用いた超音波内視鏡検査の有用性.  [Not invited]市川 勉; 工藤 正俊; 松井 繁長; 岡田 無文; 北野 雅之第72回日本消化器内視鏡学会総会(DDW-Japan)  2006/10  札幌コンベンションセンター, 道立総合体育センター, 北海道  第72回日本消化器内視鏡学会総会(DDW-Japan)確定診断までに時間を要した早期胃癌の1例  [Not invited]加藤 玲明; 石川一樹; 林 道友; 豊澤 昌子; 小川 力; 岸谷 讓; 鍋島 紀滋; 水野 成人; 井上 雅智; 太田 善夫; 工藤 正俊第77回日本消化器内視鏡学会近畿地方会  2006/09  京都  第77回日本消化器内視鏡学会近畿地方会Gastric submucosal heterotopiの1例  [Not invited]西尾 健; 工藤 正俊; 由谷 逸朗; 冨田 崇文; 梅原 康湖; 森村 正嗣; 米田 円; 辻 直子; 本庶 元第77会日本消化器内視鏡学会近畿地方会  2006/09  京都市  第77会日本消化器内視鏡学会近畿地方会レボビスト造影超音波の後血管相における肝と脾臓の輝度評価.  [Not invited]前川 清; 工藤 正俊; 井上 達夫; 南 康範; 鄭 浩柄; 上嶋 一臣; 福永 豊和第12回関西超音波造影剤研究会  2006/09  日本シェーリング株式会社本社, 大阪  第12回関西超音波造影剤研究会肝癌に対するTAE・RFA治療後に遅発性胆管気管支瘻が出現した一例.  [Not invited]末冨 洋一郎; 工藤 正俊; 北野 雅之; 坂本 洋城; 西尾 健; 南 康範; 汐見 幹夫第42回日本胆道学会学術集会  2006/09  仙台  第42回日本胆道学会学術集会胆嚢病変診断における造影超音波検査の有用性.  [Not invited]井上 達夫; 工藤 正俊; 坂本 洋城; 北野 雅之; 前川 清第42回日本胆道学会学術集会  2006/09  仙台  第42回日本胆道学会学術集会ERPが診断に有用であった小児膵損傷の1例.  [Not invited]小牧 孝充; 工藤 正俊; 北野 雅之; 末冨 洋一郎; 志村 康彦; 坂本 洋城; 野田 佳寿; 汐見 幹夫; 吉田 洋; 吉田 英樹; 八木 誠; 竹山 宜典; 大柳 治正第77回日本消化器内視鏡学会近畿地方会  2006/09  京都テレサ, 京都  第77回日本消化器内視鏡学会近畿地方会超音波内視鏡下腹水穿刺が治療方針決定に有用であった膵体癌の1例.  [Not invited]坂本 洋城; 工藤 正俊; 北野 雅之; 末冨 洋一郎; 梅原 泰; 汐見 幹夫第77回日本消化器内視鏡学会近畿地方会  2006/09  京都テレサ, 京都  第77回日本消化器内視鏡学会近畿地方会Gastric submucosal heterotopiaの1例.  [Not invited]西尾 健; 工藤 正俊; 由谷 逸朗; 冨田 崇文; 梅原 康湖; 森村 正嗣; 米田 円; 辻 直子; 本庶 元第77回日本消化器内視鏡学会近畿地方会  2006/09  京都テレサ, 京都  第77回日本消化器内視鏡学会近畿地方会診断までに時間を要した胃癌の1例.  [Not invited]加藤 玲明; 工藤 正俊; 石井 一樹; 林 道友; 豊澤 昌子; 小川 力; 岸谷 譲; 鍋島 紀滋; 水野 成人; 小川 稔; 井上 雅智; 太田 善夫第77回日本消化器内視鏡学会近畿地方会  2006/09  京都テレサ, 京都  第77回日本消化器内視鏡学会近畿地方会当院でのinterventional EUSの現状.  [Not invited]坂本 洋城; 工藤 正俊; 北野 雅之第77回日本消化器内視鏡学会近畿地方会  2006/09  京都テレサ, 京都  第77回日本消化器内視鏡学会近畿地方会感染性膵嚢胞に対し内視鏡的経胃嚢胞ドレナージ術が有効であった1例  [Not invited]冨田 崇文; 工藤 正俊; 西尾 健; 梅原 康湖; 森村 正嗣; 米田 円; 由谷 逸朗; 辻 直子; 本庶 元第85会日本消化器病学会近畿支部例会  2006/09  大阪市  第85会日本消化器病学会近畿支部例会嚥下困難で発症したLong Segment Barrett's Esophagusの1例  [Not invited]百谷 起代子; 工藤 正俊; 冨田 崇文; 西尾 健; 梅原 康湖; 森村 正嗣; 米田 円; 由谷 逸朗; 辻 直子; 本庶 元第180回日本内科学会近畿地方会  2006/09  市  第180回日本内科学会近畿地方会ヘルペス食道炎の1例  [Not invited]矢野 智洋; 工藤 正俊; 冨田 崇文; 西尾 健; 梅原 康湖; 森村 正嗣; 米田 円; 由谷 逸朗; 辻 直子; 本庶 元第180回日本内科学会近畿地方会  2006/09  京都市  第180回日本内科学会近畿地方会十二指腸静脈瘤の診断、治療と予後.  [Not invited]松井 繁長; 工藤 正俊; 市川 勉; 岡田 無文第13回日本門脈圧亢進症学会総会  2006/09  ホテルオークラ東京, 東京  第13回日本門脈圧亢進症学会総会消化器内視鏡検査、治療後に偽痛風を発症した2例.  [Not invited]永田 嘉昭; 工藤 正俊; 松井 繁長; 末冨 洋一郎; 岡田 無文; 宮部 欽生; 石川 恵美; 市川 勉第85回日本消化器病学会近畿支部例会  2006/09  大阪国際交流センター, 大阪  第85回日本消化器病学会近畿支部例会感染性膵?胞に対し内視鏡的経胃的?胞ドレナージ術が有効であった1例.  [Not invited]冨田 崇文; 工藤 正俊; 西尾 健; 梅原 康湖; 森村 正嗣; 米田 円; 由谷 逸朗; 辻 直子; 本庶 元第85回日本消化器病学会近畿支部例会  2006/09  大阪国際交流センター, 大阪  第85回日本消化器病学会近畿支部例会膵癌早期診断のためのアプローチ: US、EUSを中心に.  [Not invited]坂本 洋城; 工藤 正俊; 北野 雅之; 竹山 宜典第85回日本消化器病学会近畿支部例会  2006/09  大阪国際交流センター, 大阪  第85回日本消化器病学会近畿支部例会肝動脈塞栓術併用経皮的ラジオ波焼灼術後に炎症性肉芽腫形成を来たし、播種性腫瘍再発との鑑別が困難であった一例.  [Not invited]高橋 俊介; 工藤 正俊; 鄭 浩柄; 北井 聡; 井上 達夫; 坂口 康浩; 南 康範; 上嶋 一臣; 福永 豊和; 土師 誠二第85回日本消化器病学会近畿支部例会  2006/09  大阪国際交流センター, 大阪  第85回日本消化器病学会近畿支部例会S1とペグインターフェロンが奏功したHCC肺転移の1例.  [Not invited]高瀬 徹; 工藤 正俊; 上嶋 一臣; 井上 達夫; 坂口 康浩; 南 康範; 鄭 浩柄; 福永 豊和; 北野 雅之第85回日本消化器病学会近畿支部例会  2006/09  大阪国際交流センター, 大阪  第85回日本消化器病学会近畿支部例会PEG-IFNα2bとribavirin併用治療中に1型糖尿病を発症した一例.  [Not invited]宮本 武明; 工藤 正俊; 小川 力; 岸谷 譲; 鍋島 紀滋; 水野 成人; 加藤 玲明; 豊澤 昌子; 林 道友; 北井 聡第85回日本消化器病学会近畿支部例会  2006/09  大阪国際交流センター, 大阪  第85回日本消化器病学会近畿支部例会B型肝炎ウイルス感染における発癌リスク因子の検討.  [Not invited]萩原 智; 工藤 正俊; 仲谷 達也; 南 康範; 鄭 浩柄; 上嶋 一臣; 福永 豊和第85回日本消化器病学会近畿支部例会  2006/09  大阪国際交流センター, 大阪  第85回日本消化器病学会近畿支部例会成人期の初感染により慢性化したと考えられたB型肝炎の一例.  [Not invited]林 道友; 工藤 正俊; 鍋島 紀滋; 小川 力; 水野 成人; 岸谷 譲; 加藤 玲明; 豊澤 昌子; 北井 聡第85回日本消化器病学会近畿支部例会  2006/09  大阪国際交流センター, 大阪  第85回日本消化器病学会近畿支部例会Invited Lecture “Characterization of liver nodules in cirrhosis by ultrasonography.”  [Not invited]工藤 正俊18th European congress of ultrasound in conjunction with XVIII congresso Nazionale SIUMB  2006/09  Bologna  18th European congress of ultrasound in conjunction with XVIII congresso Nazionale SIUMB特別講演「肝がん治療の最前線」  [Not invited]工藤 正俊日本肝臓学会肝がん撲滅運動市民公開講座~肝臓病で命を失わないために~  2006/08  堺市民会館  日本肝臓学会肝がん撲滅運動市民公開講座~肝臓病で命を失わないために~自然経過が観察し得たアルコール性過形成病変の一例.  [Not invited]前川 清; 工藤 正俊; 井上 達夫; 南 康範; 鄭 浩柄; 上嶋 一臣; 福永 豊和日本超音波医学会第32回関西地方会学術集会  2006/08  大阪国際会議場, 大阪  日本超音波医学会第32回関西地方会学術集会肝領域. シンポジウム「病変を見落とさない超音波診断 私はこうしている」  [Not invited]南 康範; 工藤 正俊日本超音波医学会第32回関西地方会学術集会  2006/08  大阪国際会議場, 大阪  日本超音波医学会第32回関西地方会学術集会Invited Lecture “Diagnosis and treatment of HCC.”  [Not invited]工藤 正俊S.M.S. Hospital & Medical College (Invited by Dr. Ramesh Roop Rai)  2006/08  Jaipur, India  S.M.S. Hospital & Medical College (Invited by Dr. Ramesh Roop Rai)Ward Round as a Visiting Professor.  [Not invited]工藤 正俊All India Institute of Medical Science  2006/08  New Delhi, India  All India Institute of Medical ScienceCase Discussion and Consultation as a Visiting Professor.  [Not invited]工藤 正俊All India Institute of Medical Science  2006/08  New Delhi, India  All India Institute of Medical ScienceInvited Lecture “Role of contrast enhanced ultrasonography for liver tumors.”  [Not invited]工藤 正俊All India Institute of Medical Science (Invited by Prof. Acharya)  2006/08  New Delhi, India  All India Institute of Medical Science (Invited by Prof. Acharya)Invited Lecture “Staging system for HCC”  [Not invited]工藤 正俊All India Hepatology Meeting “Current Perspectie of Liver Disease (CPLD)”  2006/08  Delhi, India  All India Hepatology Meeting “Current Perspectie of Liver Disease (CPLD)”Invited Lecture “Real-time virtual sonography for liver malignancies.”  [Not invited]工藤 正俊All India Hepatology Meeting “Current Perspectie of Liver Disease (CPLD)”  2006/08  Delhi, India  All India Hepatology Meeting “Current Perspectie of Liver Disease (CPLD)”Invited Lecture “FNAC/Biopsy of HCC: Is it required?”  [Not invited]工藤 正俊All India Hepatology Meeting “Current Perspectie of Liver Disease (CPLD)”  2006/08  Delhi, India  All India Hepatology Meeting “Current Perspectie of Liver Disease (CPLD)”Ward Round as a Visiting Professor.  [Not invited]工藤 正俊Post Graduate Institute of Medical Education and Research  2006/07  Chandigarh, India  Post Graduate Institute of Medical Education and ResearchCase Discussion and Consultation as a Visiting Professor.  [Not invited]工藤 正俊Post Graduate Institute of Medical Education and Research (Invited by Prof. Chawla)  2006/07  Chandigarh, India  Post Graduate Institute of Medical Education and Research (Invited by Prof. Chawla)Invited Lecture “Real-time virtual sonography for liver malignancies.”  [Not invited]工藤 正俊Post Graduate Institute of Medical Education and Research (Invited by Prof. Chawla)  2006/07  Chandigarh, India  Post Graduate Institute of Medical Education and Research (Invited by Prof. Chawla)特別講演「肝細胞癌治療の最近の進歩」  [Not invited]工藤 正俊第21回肝臓を診る会  2006/07  旭川グランドホテル  第21回肝臓を診る会PEG-IFNα2bとribavirin併用治療中に1型糖尿病を発症した1例  [Not invited]宮本 武明; 小川 力; 岸谷 讓; 鍋島 紀滋; 水野 成人; 加藤 玲明; 豊澤 昌子; 林 道友; 北井 聡; 工藤 正俊第47回京都肝疾患懇話会  2006/07  京都  第47回京都肝疾患懇話会肝細胞癌への経皮的ラジオ波焼灼術におけるReal-time virtual sonographyの有用性.  [Not invited]南 康範; 工藤 正俊; 高橋 俊介; 坂口 康浩; 井上 達夫; 鄭 浩柄; 上嶋 一臣; 福永 豊和第6回関西肝血流動態イメージ研究会  2006/07  オーバルホール, 大阪  第6回関西肝血流動態イメージ研究会自然経過が観察し得たアルコール性過形成病変の一例.  [Not invited]前川 清; 工藤 正俊; 井上 達夫; 南 康範; 鄭 浩柄; 上嶋 一臣; 福永 豊和第6回関西肝血流動態イメージ研究会  2006/07  オーバルホール, 大阪  第6回関西肝血流動態イメージ研究会教育講演「肝細胞癌の診断と治療: 最近の進歩」  [Not invited]工藤 正俊日本消化器病学会近畿支部第21回教育講演会  2006/07  アバローム紀の国  日本消化器病学会近畿支部第21回教育講演会von Gierke disease(糖尿病I型)に肝細胞癌を合併した一症例.  [Not invited]鄭 浩柄; 工藤 正俊; 高橋 俊介; 萩原 智; 井上 達夫; 坂口 康浩; 南 康範; 上嶋 一臣; 福永 豊和; 中居 卓也第42回日本肝癌研究会  2006/07  東京ドームホテル, 東京  第42回日本肝癌研究会Child-Pugh C肝硬変に合併した肝癌の治療は?その是非と治療法選択に関するRetrospective多施設共同研究.  [Not invited]大崎 往夫; 工藤 正俊; 松永 隆; 春日井博志; 岡 博子; 関 寿人第42回日本肝癌研究会  2006/07  東京ドームホテル, 東京  第42回日本肝癌研究会ステージIVB肝内胆管癌に対するGemcitabine (GEM)をfirst lineとした化学療法と無治療群との比較検討. ワークショップ2「肝内胆管癌の診断と治療ーエビデンスに基づいた次の一手を求めてー」  [Not invited]南 康範; 工藤 正俊; 上嶋 一臣; 坂口 康浩; 鄭 浩柄; 福永 豊和第42回日本肝癌研究会  2006/07  東京ドームホテル, 東京  第42回日本肝癌研究会教育講演「肝細胞癌へのアプローチ: 世界のConsensusとControversies」  [Not invited]工藤 正俊第42回日本肝癌研究会  2006/07  東京ドームホテル, 東京  第42回日本肝癌研究会ペグインターフェロン(PEG-IFN)と5-FUの併用によるp53を介する肝細胞癌抑制効果.  [Not invited]仲谷 達也; 工藤 正俊; 福永 豊和; 上嶋 一臣; 鄭 浩柄; 南 康範; 井上 達夫; 坂口 康浩; 萩原 智第47回京都肝疾患懇話会  2006/07  京都ホテルオークラ, 京都  第47回京都肝疾患懇話会PEG-IFNα2bとribavirin併用治療中に1型糖尿病を発症した1例.  [Not invited]宮本 武明; 工藤 正俊; 小川 力; 岸谷 譲; 鍋島 紀滋; 水野 成人; 加藤 玲明; 豊澤 昌子; 林 道友; 北井 聡第47回京都肝疾患懇話会  2006/07  京都ホテルオークラ, 京都  第47回京都肝疾患懇話会成人期の初感染により慢性化したと考えられたB型肝炎の一例  [Not invited]林 道友; 鍋島 紀滋; 小川 力; 水野 成人; 岸谷 讓; 加藤 玲明; 豊澤 昌子; 北井 聡; 工藤 正俊第8回関西B型肝炎研究会  2006/06  大阪  第8回関西B型肝炎研究会Usefulness and limitation of contrast-enhanced power Doppler EUS for diagnosis of pancreatic diseases.  [Not invited]北野 雅之; 工藤 正俊; 坂本 洋城; 前川 清; 末冨 洋一郎; 西尾 健; 竹山 宜典; 筑後 孝章15th International Symposium on Endoscopic Ultrasonograhy  2006/06  Amsterdam, Netherland  15th International Symposium on Endoscopic Ultrasonograhyワークショップ 「転移性肝腫瘍に対する焼灼療法の治療成績」大腸癌肝転移におけるRFA治療の局所制御能  [Not invited]中居 卓也; 川邊 高史; 吉藤 竹仁; 上田 和毅; 肥田 仁一; 石丸 英三郎; 奥野 清隆; 塩﨑 均; 大柳 治正; 南 康範; 鄭 浩柄; 工藤 正俊第31回日本外科系連合学会  2006/06  金沢  第31回日本外科系連合学会  大腸癌肝転移にRFAを応用し、肝切除にRFA併用すれば化学療法単独治療より予後は改善していた。RFAの局所制御能を肝細胞癌と比較したところ、腫瘍サイズで両者に差はないが、3cmを超えるものは局所再発率が20%を超え適応外と考えられた。特別講演「肝細胞癌のステージングと治療選択」  [Not invited]工藤 正俊第3回肝・消化器・代謝・栄養研究会  2006/06  ホテルグランヴィア大阪  第3回肝・消化器・代謝・栄養研究会特別講演「肝細胞癌の診断と治療ー最近の話題」  [Not invited]工藤 正俊肝がん撲滅運動学術講演会  2006/06  リーガロイヤルホテル堺, 大阪  肝がん撲滅運動学術講演会Relation of tumor vascularity to effect of gemcitabine in pancreastic carcinomas: Value of contrast-enhanced harmonic ultrasonography.  [Not invited]北野 雅之; 工藤 正俊; 坂本 洋城; 末冨 洋一郎; 西尾 健; 竹山 宜典42nd Annual Meeting, American Society of Clinical Oncology  2006/06  Atlanta, Georgia  42nd Annual Meeting, American Society of Clinical Oncology腹部臓器に発生した神経原性腫瘍のレボビスト造影超音波について.  [Not invited]市島 真由美; 工藤 正俊; 前野 知子; 橋本 美紀恵; 前川 清; 井上 達夫; 南 康範; 鄭 浩柄; 上嶋 一臣; 福永 豊和日本超音波医学会第79回学術集会  2006/05  大阪国際会議場  日本超音波医学会第79回学術集会レボビスト造影超音波の後血管相から見た肝機能評価について.  [Not invited]前川 清; 工藤 正俊; 井上 達夫; 南 康範; 鄭 浩柄; 上嶋 一臣; 福永 豊和日本超音波医学会第79回学術集会  2006/05  大阪国際会議場  日本超音波医学会第79回学術集会膵癌早期診断における造影超音波および超音波内視鏡検査の有用性.  [Not invited]坂本 洋城; 工藤 正俊; 北野 雅之; 前川 清日本超音波医学会第79回学術集会  2006/05  大阪国際会議場  日本超音波医学会第79回学術集会Percutaneous radiofrequency ablation of liver tumors: feasibility and usefulness of a novel guidance technique with an integrated system of CT and sonographic images.  [Not invited]南 康範; 工藤 正俊11th Congress of the World Federation for Ultrasound in Medicine and Biology  2006/05  COEX, Seoul, Korea  11th Congress of the World Federation for Ultrasound in Medicine and Biology  Minami Y, Kudo M: PEvaluation of liver function by contrast enhanced coded phase inversion harmonic ultrasonography with levovist using parenchymal imaging of liver and spleen in the post vascular phase.  [Not invited]上嶋 一臣; 工藤 正俊; 前川 清; Chinamnan W; 南 康範; 鄭 浩柄; 福永 豊和11th Congress of the World Federation for Ultrasound in Medicine and Biology  2006/05  COEX, Seoul, Korea  11th Congress of the World Federation for Ultrasound in Medicine and BiologyInvited Lecture “Treatment response and treatment guidance of hepatoccellular carcinoma: value of contrast-enhanced harmonic US and RVS.”  [Not invited]工藤 正俊11th Congress of the World Federation for Ultrasound in Medicine and Biology  2006/05  COEX, Seoul, Korea  11th Congress of the World Federation for Ultrasound in Medicine and Biology肝癌局所治療における最近の超音波検査ーProSound α10を用いてー.  [Not invited]南 康範; 工藤 正俊日本超音波医学会第79回学術集会  2006/05  大阪国際会議場, 大阪  日本超音波医学会第79回学術集会ランチョンセミナー「肝細胞癌のステージ分類: その重要性と問題点」  [Not invited]工藤 正俊第42回日本肝臓学会総会  2006/05  国立京都国際会館, 京都  第42回日本肝臓学会総会EUS-CPN時のエタノール注入部位と疼痛改善度の関連性.  [Not invited]西尾 健; 工藤 正俊; 坂本 洋城; 北野 雅之; 坂口 康浩; 末冨洋一郎; 上嶋 一臣; 汐見 幹夫第2回超音波内視鏡下生検法の診断精度向上のための研究会  2006/05  京王プラザホテル  第2回超音波内視鏡下生検法の診断精度向上のための研究会当院における早期膵癌診断におけるストラテジー.  [Not invited]末冨洋一郎; 工藤 正俊; 北野 雅之第71回日本消化器内視鏡学会  2006/05  京王プラザホテル  第71回日本消化器内視鏡学会Mixed Intestinal and Diffuse Type Histology is a Risk Factor for Lymph Node Metastasis of Early Gastric Cancer  [Not invited]辻 直子; 工藤 正俊; 石黒 信吾Digestive Disease Week 2006  2006/05  Lon Angeles  Digestive Disease Week 2006Peginterferon alpha-2α and 5-fluorouracil suppresses proliferation of human hepatocellular carcinoma in p53-mediated apoptotic response.  [Not invited]仲谷 達也; 工藤 正俊; 坂口 康浩; 木村 雅友; 早川 清雄; 宗像 浩41th Annual Meeting of the European Association for the Study of the Liver (EASL)  2006/04  Vienna, Austria  41th Annual Meeting of the European Association for the Study of the Liver (EASL)Carcinogenic risk factors in hepatitis B rivus infection.  [Not invited]萩原 智; 工藤 正俊; 仲谷 達也; 南 康範; 鄭 浩柄; 上嶋 一臣; 福永 豊和; 宗像 浩41th Annual Meeting of the European Association for the Study of the Liver (EASL)  2006/04  Vienna, Austria  41th Annual Meeting of the European Association for the Study of the Liver (EASL)Comparison of staging systems for hepatocellular carcinoma in Japanese cohort.  [Not invited]鄭 浩柄; 工藤 正俊; 高橋俊介; 南 康範; 井上達夫; 坂口康浩; 萩原 智; 福永 豊和; 上嶋 一臣41th Annual Meeting of the European Association for the Study of the Liver (EASL)  2006/04  Vienn, Austria  41th Annual Meeting of the European Association for the Study of the Liver (EASL)肝癌の経皮的ラジオ波焼灼術におけるReal-time Virtual Sonographyの有用性について.  [Not invited]南 康範; 工藤 正俊; 鄭 浩柄; 福永 豊和; 上嶋 一臣; 萩原 智; 坂口康浩; 高橋俊介; 畑中絹代; 井上達夫第92回日本消化器病学会総会  2006/04  リーガロイヤルホテル小倉, 福岡  第92回日本消化器病学会総会早期肝細胞癌の造影超音波所見: pure arterial phase imagingおよびpost-vascular phase imagingを中心に.  [Not invited]井上達夫; 工藤 正俊; 福永 豊和第92回日本消化器病学会総会  2006/04  リーガロイヤルホテル小倉, 福岡  第92回日本消化器病学会総会Invited Lecture “New Sonographic Techniques for HCC: have they any impact on clinical practice?”  [Not invited]工藤 正俊Joint Meeting of Cancer Research Institute and Liver Research Institute of Seoul National University  2006/04  Seoul  Joint Meeting of Cancer Research Institute and Liver Research Institute of Seoul National Universityランチョンセミナー「肝癌の進展抑制におけるIFNの効果」  [Not invited]工藤 正俊第92回日本消化器病学会総会  2006/04  北九州  第92回日本消化器病学会総会特別講演「肝細胞癌のStagingと治療選択」  [Not invited]工藤 正俊第48回肝臓クリニカルセミナー  2006/04  ソラリア西鉄ホテル, 福岡  第48回肝臓クリニカルセミナー特別講演「腹部造影超音波法の現状と今後の展望」  [Not invited]工藤 正俊第19回日本造影エコー・ドプラ診断研究会  2006/04  神戸商工会議所, 神戸  第19回日本造影エコー・ドプラ診断研究会レボビスト造影超音波で得られた後血管相画像の定量化について  [Not invited]前川 清; 工藤 正俊; 井上達夫; 南 康範; 鄭 浩柄; 上嶋 一臣; 福永 豊和第19回日本造影エコー・ドプラ診断研究会  2006/04  神戸商工会議所, 神戸  第19回日本造影エコー・ドプラ診断研究会肝細胞癌局所再発例に対する造影超音波ガイド下ラジオ波焼灼術- Prospective randomized controlled traial-.  [Not invited]南 康範; 工藤 正俊; 鄭 浩柄; 福永 豊和第19回日本造影エコー・ドプラ診断研究会-. 第19回日本造影エコー・ドプラ診断研究会  2006/04  神戸商工会議所, 神戸  第19回日本造影エコー・ドプラ診断研究会-. 第19回日本造影エコー・ドプラ診断研究会真性多血症に合併したサイトメガロウイルス腸炎の一例  [Not invited]梅原 康湖; 工藤 正俊; 米田 円; 冨田 崇文; 落合 健; 本庶 元; 森村 正嗣; 由谷 逸朗; 辻 直子第76回日本消化器内視鏡学会近畿地方会  2006/03  大阪市  第76回日本消化器内視鏡学会近畿地方会教育講演「肝細胞癌の治療」  [Not invited]工藤 正俊臨床腫瘍学会教育講演会  2006/03  国際会議場, 大阪  臨床腫瘍学会教育講演会レボビストによる純動脈相造影超音波法(PAP-US)の画像評価と腫瘍内の造影剤動態について  [Not invited]前川 清; 工藤 正俊; 井上達夫; 南 康範; 鄭 浩柄; 上嶋 一臣; 福永 豊和第111回大阪超音波研究会  2006/03  ホテルグランヴィア大阪, 大阪  第111回大阪超音波研究会短期間に総胆管への落石と胆嚢炎繰り返し内視鏡的に対処した胆嚢結石症の1例  [Not invited]加藤 玲明; 林 道友; 北井 聡; 豊澤 昌子; 小川 力; 岸谷 讓; 鍋島 紀滋; 水野 成人; 工藤 正俊第76回日本消化器内視鏡学会近畿地方会  2006/03  大阪  第76回日本消化器内視鏡学会近畿地方会特別講演「Real-time virtual sonographyの臨床的有用性について」  [Not invited]工藤 正俊超音波診断装置への今後の期待に関するディスカッション  2006/03  ウェスティンホテル大阪, 大阪  超音波診断装置への今後の期待に関するディスカッション十二指腸静脈瘤の臨床的特徴と治療  [Not invited]松井 繁長; 工藤 正俊; 市川 勉第76回日本消化器内視鏡学会近畿地方会  2006/03  大阪国際交流センター, 大阪  第76回日本消化器内視鏡学会近畿地方会Invited Lecture “Novel Ultrasound techniques & technology”  [Not invited]工藤 正俊APASL (Asian Pacific Asoociation for the Study of the Liver)  2006/03  Manila, Philippines  APASL (Asian Pacific Asoociation for the Study of the Liver)Peginterferon α-2aと5-FUの併用によるp53を介する肝細胞癌に対する抗腫瘍効果.  [Not invited]仲谷 達也; 工藤 正俊Bay Area Digestive  2006/03  淡路夢舞台, 淡路  Bay Area DigestiveB型肝炎ウイルスキャリアにおけるgenotypeおよびCP/PC変異測定の臨床的意義.  [Not invited]萩原 智; 工藤 正俊Bay Area Digestive  2006/03  淡路夢舞台, 淡路  Bay Area Digestive肝癌の経皮的ラジオ波焼灼術におけるReal-time virtual sonographyの有用性について.  [Not invited]南 康範; 工藤 正俊Bay Area Digestive  2006/03  淡路夢舞台, 淡路  Bay Area Digestive肝障害度のスコア化による新分類法の提唱.  [Not invited]鄭 浩柄; 工藤 正俊Bay Area Digestive  2006/03  淡路夢舞台, 淡路  Bay Area Digestive真性多血症に合併したサイトメガロウイルス腸炎の一例  [Not invited]梅原 康湖; 工藤 正俊; 米田 円; 冨田 崇文; 落合 健; 本庶 元; 森村 正嗣; 由谷 逸朗; 辻 直子第76回日本消化器内視鏡学会近畿地方会  2006/03  大阪国際交流センター  第76回日本消化器内視鏡学会近畿地方会短期間に総胆管への落石と胆嚢炎を繰り返し内視鏡的に対処した胆嚢結石症の一例.  [Not invited]加藤 玲明; 工藤 正俊; 林道 友; 北井 聡; 豊澤昌子; 小川 力; 岸谷 譲; 鍋島紀滋; 水野成人第76回日本消化器内視鏡学会近畿地方会  2006/03  大阪国際交流センター, 大阪  第76回日本消化器内視鏡学会近畿地方会シンポジウム2. 消化管内視鏡up to date胆・膵「超音波内視鏡ガイド下腹腔神経叢ブロック術: CTによる注入部造影の有用性について」  [Not invited]坂本 洋城; 工藤 正俊; 北野 雅之第76回日本消化器内視鏡学会近畿地方会  2006/03  大阪国際交流センター, 大阪  第76回日本消化器内視鏡学会近畿地方会腹腔鏡下腹膜生検にて確診しえた結核性腹膜炎の一例  [Not invited]河田奈都子; 鍋島 紀滋; 水野 成人; 岸谷 讓; 加藤 玲明; 小川 力; 豊澤 昌子; 北井 聡; 林 道友; 井上 雅智; 湯川 真生; 岩崎拓也; 太田 善夫; 工藤 正俊第84回日本消化器病学会近畿支部例会  2006/02  神戸  第84回日本消化器病学会近畿支部例会特別講演「肝細胞癌のStagingと治療戦略」  [Not invited]工藤 正俊第5回肝胆膵疾患臨床懇話会  2006/02  スイスホテル南海大阪, 大阪  第5回肝胆膵疾患臨床懇話会気腫性胆嚢炎の一例.  [Not invited]落合 健; 工藤 正俊; 冨田 崇文; 梅原 康湖; 本庶 元; 森村 正嗣; 米田 円; 由谷 逸朗; 辻 直子; 船井 貞往第84回日本消化器病学会近畿支部例会  2006/02  神戸国際会議場  第84回日本消化器病学会近畿支部例会TS1膵癌診断における造影超音波および超音波内視鏡検査の有用性  [Not invited]北野 雅之; 工藤 正俊; 前川 清; 坂本洋城; 西尾 健; 末冨洋一郎; 竹山 宜典; 筑後 孝章日本超音波医学会第31回関西地方会学術集会  2006/02  京都テルサ  日本超音波医学会第31回関西地方会学術集会特別講演「肝細胞癌の診断と治療選択: 最近のトピックス」  [Not invited]工藤 正俊第3回佐賀県医師会癌検診会肝癌部会研修会  2006/01  佐賀県医師会成人病予防センター  第3回佐賀県医師会癌検診会肝癌部会研修会Invited Lecture “Pancreatic ultrasound: is it still useful in 2006?”  [Not invited]工藤 正俊WFUMB 2006 & Workshop  2006/01  Jakarta  WFUMB 2006 & WorkshopInvited Lecture “Ultrasound of malignant liver tumors”  [Not invited]工藤 正俊WFUMB 2006 & Workshop  2006/01  Jakarta  WFUMB 2006 & WorkshopInvited Lecture “Ultrasound of benign liver mass”  [Not invited]工藤 正俊WFUMB 2006 & Workshop  2006/01  Jakarta  WFUMB 2006 & WorkshopCrohn病の経過中に急性出血性大腸炎を合併した1症例  [Not invited]冨田 崇文; 工藤 正俊; 米田 円; 落合 健; 梅原 康湖; 森村 正嗣; 由谷 逸朗; 辻 直子第5回 南大阪大腸内視鏡研究会  2006/01  堺市  第5回 南大阪大腸内視鏡研究会AFP-L3 is the most reliable tumor marker after radiofrequency ablation therapy for hepatocellular carcinoma  [Not invited]小川 力; 工藤 正俊; 南 康範; 鄭 浩柄; 水野 成人; 鍋島 紀滋Fourth JSH Single Topic Conference"Hepatocellular carcinoma: international consensus and controversi  2005/12  Awaji  Fourth JSH Single Topic Conference"Hepatocellular carcinoma: international consensus and controversi食道入口部直下に多発潰瘍を規制したLong Segment Barrett’s Esophagusの一例.  [Not invited]冨田 崇文; 落合 健; 梅原 康湖; 森村 正嗣; 米田 円; 由谷 逸朗; 辻 直子; 工藤 正俊第75回日本消化器内視鏡学会近畿地方会  2005/10  大阪  第75回日本消化器内視鏡学会近畿地方会Histologic heterogeneity is a risk factor for lymph node metastasis of early gastric cancer  [Not invited]辻 直子; 工藤 正俊; 石黒 信吾13th United European Gastroenterology Week  2005/10  Copenhagen, Denmark  13th United European Gastroenterology WeekHelicobacter pyloriクラリスロマイシン耐性と患者背景の動向  [Not invited]落合 健; 工藤 正俊; 田中 陽一; 森村 正嗣; 米田 円; 由谷 逸朗; 辻 直子第70回日本消化器内視鏡学会総会  2005/10  神戸市  第70回日本消化器内視鏡学会総会食道入口部直下に多発潰瘍を形成したLong Segment Barrett's Esophagusの1例  [Not invited]冨田 崇文; 工藤 正俊; 落合 健; 梅原 康湖; 森村 正嗣; 米田 円; 由谷 逸朗; 辻 直子第75回日本消化器内視鏡学会近畿地方会  2005/10  大阪市  第75回日本消化器内視鏡学会近畿地方会著明な大腸狭窄をきたした一例  [Not invited]豊澤 昌子; 北井 聡; 林 道友; 加藤 玲明; 小川 力; 鍋島 紀滋; 水野 成人; 太田 善夫; 工藤 正俊第75回日本消化器内視鏡学会近畿地方会  2005/10  大阪  第75回日本消化器内視鏡学会近畿地方会  症例は70歳代,男性。平成16年2月、吐血にて当院を受診したが、上部消化管に出血源認めず、鼻出血の嚥下が原因と判明し帰宅した。翌朝,意識障害が出現し,当院救命科に搬入された。入院当日下血を認めたため翌日大腸内視鏡施行した。肛門付近を除く直腸からS状結腸まで全周性に粘膜壊死を認めた。CTでは直腸に著明な壁肥厚を認め、S状結腸以深は異常なかった。意識障害も消失し当科に転科した。約1ヶ月後の大腸内視鏡では、直腸下部に正常粘膜を認めたが、その奥に全周性潰瘍の残存を認め、疼痛により深部挿入出来なかった。3月の注腸にて下行結腸に狭窄を認めた。手術予定となるも、総胆管結石による胆管炎をきたし、手術延期となった。5月の大腸内視鏡にて肛門より約10cm以深に潰瘍を認め、20cm以深は狭窄の為挿入出来なかった。6月に左結腸・S状結腸切除術を施行した。術中所見では下行結腸からS状結腸にかけて狭小化、硬化しており、小腸とHP除菌によって内視鏡的に改善した鳥肌胃炎の一例  [Not invited]加藤 玲明; 河田 奈都子; 林 道友; 北井 聡; 豊澤 昌子; 小川 力; 岸谷 讓; 鍋島 紀滋; 水野 成人; 工藤 正俊第27回奈良県胃腸研究会  2005/10  奈良  第27回奈良県胃腸研究会急速に増大し得た胃GISTの1手術例  [Not invited]吉本 理恵; 工藤 正俊; 汐見 幹夫; 末冨 洋一郎; 中岡 良介; 松井 繁長; 北野 雅之; 保田 知生; 大柳 治正第69回日本消化器内視鏡学会近畿地方会  2005/10  大阪  第69回日本消化器内視鏡学会近畿地方会PEG-IFN ALPHA-2a and 5-fluorouracil suppresses proliferation of human hepatocellular carcinoma in node mice  [Not invited]仲谷 達也; 工藤 正俊; 坂口康浩; 木村 雅友; 早川 清雄; 宗像 浩13th united European gastroenterology week (UEGW)  2005/10  Copenhargen  13th united European gastroenterology week (UEGW)腸腰筋膿瘍を合併した急性膵炎の1例  [Not invited]梅原 康湖; 工藤 正俊; 冨田 崇文; 落合 健; 森村 正嗣; 米田 円; 由谷 逸朗; 辻 直子第83回日本消化器病学会近畿支部例会  2005/09  大阪市  第83回日本消化器病学会近畿支部例会純動脈相超音波造影法(PAP-US)と画像表示に用いる測定時相について  [Not invited]前川 清; 工藤 正俊; 井上 達夫; 南 康範; 鄭 浩柄; 上嶋 一臣; 福永 豊和日本超音波医学会第30回関西地方会学術集会  2005/09  千里ライフサイエンスセンター  日本超音波医学会第30回関西地方会学術集会肝細胞癌に対する経撓骨動脈アプローチによる血管造影の有用性  [Not invited]林 道友; 鍋島 紀滋; 北井 聡; 水野 成人; 小川 力; 加藤 玲明; 豊澤 昌子; 工藤 正俊第83回日本消化器病学会近畿支部例会  2005/09  大阪  第83回日本消化器病学会近畿支部例会  【目的】腹部血管造影において患者の不満が最も多いのは、検査後の長時間の安静臥床である。循環器領域では、近年経撓骨動脈アプローチが主流になっているが、腹部血管造影においてもその有用性が報告されている(日消誌Vol 99, 1450-1454, 2002)。2005年4月から我々の施設でも、この報告を参考に若干の工夫を加えて経撓骨動脈アプローチによる腹部血管造影を行っているので報告する。【方法】肝細胞癌と診断され左撓骨動脈より経動脈的治療(TAE、TAI)を行った20例について、造影および治療の成功率、所要時間、合併症について検討した。2004年4月から2005年3月までに大腿動脈からのアプローチで治療を行った58例を比較対象とした。また、過去に大腿動脈からの検査を受けている15例にはアンケートを行った。検査手技は、左撓骨動脈を22G針で穿刺しSeldinger法にて4Frシースを留置した。4Fr 110cmのKAGAWAカテーテルをガイドワイヤーを先行させながら下行大動脈まで誘導し、上腸間膜動脈特別講演「肝細胞癌の診断と治療選択」  [Not invited]工藤 正俊第25回名古屋肝炎セミナー、第108回名古屋肝疾患研究会  2005/09  名古屋マリオットアソシアホテル  第25回名古屋肝炎セミナー、第108回名古屋肝疾患研究会Usefulness of contrast enhancement for diagnosis of pancreatic desease by transabdominal US and EUS  [Not invited]北野 雅之; 工藤 正俊World congress of Gastroenterology 2005  2005/09  Montreal, Canada  World congress of Gastroenterology 2005Invited Lecture “Recent progress in imaging of HCC:from ultrasound to PET Scan”  [Not invited]工藤 正俊Asia Pacific Association of Study of the Liver (APASL)  2005/08  Bali  Asia Pacific Association of Study of the Liver (APASL)Real-time virtual sonography, an integrated system of computer tomography with ultrasound images: value in radiofrequency ablation guidance.  [Not invited]南 康範; 工藤 正俊; 鄭 浩柄; 井上 達夫; 萩原 智; 畑中 絹代; 坂口 康浩; 上嶋 一臣; 福永 豊和15th Asian Pacific Association for the Study of the Liver (APASL)  2005/08  Bali  15th Asian Pacific Association for the Study of the Liver (APASL)特別講演「肝細胞癌の診断と治療: 最新情報」  [Not invited]工藤 正俊日本肝臓学会主催, 平成13年度肝がん撲滅運動市民公開講座  2005/08  堺市民会館, 堺  日本肝臓学会主催, 平成13年度肝がん撲滅運動市民公開講座Invited Lecture “Color Doppler diagnosis of hepatocellular carcinoma.”  [Not invited]工藤 正俊Asia Pacific Association of Study of the Liver (APASL)  2005/08  Bali  Asia Pacific Association of Study of the Liver (APASL)Invited Lecture “Diagnosis of hepatocellular carcinoma.”  [Not invited]工藤 正俊Asia Pacific Association of Study of the Liver (APASL)  2005/08  Bali  Asia Pacific Association of Study of the Liver (APASL)特別講演「肝細胞癌診療の最近の進歩」  [Not invited]工藤 正俊和歌山県立医科大学第二内科同門会学術講演会  2005/07  和歌山  和歌山県立医科大学第二内科同門会学術講演会特別講演「肝細胞癌の診断と治療: 最近の動向」  [Not invited]工藤 正俊第15回光生病院臨床談話会  2005/07  光生病院, 岡山  第15回光生病院臨床談話会膵癌診断における造影超音波および超音波内視鏡検査の有用性. (ワークショップ「膵画像診断の最前線」)  [Not invited]北野 雅之; 工藤 正俊; 坂本洋城第36回日本膵臓学会大会  2005/07  京王プラザホテル, 東京  第36回日本膵臓学会大会教育講演「肝細胞癌診療の最近のトピックス」  [Not invited]工藤 正俊日本消化器病学会中国支部例会教育講演会  2005/06  岡山  日本消化器病学会中国支部例会教育講演会特別講演「肝細胞癌治療と再発抑制」  [Not invited]工藤 正俊平成17年度肝がん撲滅運動学術講演会  2005/06  スイスホテル, 大阪  平成17年度肝がん撲滅運動学術講演会Invited Lecture “Contrast US technology.” EASL Monothematic Conference on HCC.  [Not invited]工藤 正俊EASL・AASLD・JSH Joint Symposium  2005/06  Barcelona, Spain  EASL・AASLD・JSH Joint SymposiumSpecial Lecture “Imaging human hepatocarcinogenesis.”  [Not invited]工藤 正俊Laennec Meeting  2005/06  Bordeaux, France  Laennec MeetingContrast US technology  [Not invited]工藤 正俊EASL Monothematic Conference  2005/06  Barcelona  EASL Monothematic ConferenceUsefulness of contrast-enhanced harmonic ultrasonography for the detection of small tumors in pancreas  [Not invited]坂本洋城; 工藤 正俊; 北野 雅之; 前川 清Euro-EUS2005  2005/06  Copenhagen  Euro-EUS2005Usefulness of contrast-enhanced power Doppler EUS in differential diagnosis of pancreatic tumors  [Not invited]北野 雅之; 工藤 正俊; 坂本洋城; 前川 清Euro-EUS2005  2005/06  Copenhagen  Euro-EUS2005ランチョンセミナー「肝細胞癌診療の最近のトピックス」  [Not invited]工藤 正俊日本消化器病学会中国支部第7回教育講演会  2005/06  岡山コンベンションセンター, 岡山  日本消化器病学会中国支部第7回教育講演会日本肝癌研究会 肝障害度のスコア化による新分類法の提唱. ポスター「肝細胞癌の予後解析1」  [Not invited]鄭 浩柄; 工藤 正俊; 井上達夫; 坂口康浩; 萩原 智; 南 康範; 上嶋 一臣; 福永 豊和; 大崎往夫; 春日井博志; 関 寿人; 岡 博子第41回日本肝癌研究会  2005/06  幕張メッセ国際会議場, 千葉  第41回日本肝癌研究会非B非C肝癌の臨床的特徴像  [Not invited]畑中絹世; 工藤 正俊; 大崎往夫第41回日本肝癌研究会  2005/06  幕張メッセ国際会議場, 千葉  第41回日本肝癌研究会肝癌の経皮的ラジオ波焼灼術におけるReal-time Virtual Sonographyの有用性について. ビデオセッション「経皮的局所療法(II)」  [Not invited]南 康範; 工藤 正俊; 鄭 浩柄; 井上達夫; 坂口康浩; 萩原 智; 畑中絹世; 上嶋 一臣第41回日本肝癌研究会  2005/06  幕張メッセ国際会議場, 千葉  第41回日本肝癌研究会造影超音波検査の新しい作画法Accumulation modeを用いた肝腫瘍性病変の血流評価. ビデオセッション「肝癌診断」  [Not invited]福永 豊和; 工藤 正俊; 前川 清第41回日本肝癌研究会  2005/06  幕張メッセ国際会議場, 千葉  第41回日本肝癌研究会当院における肝細胞癌に対する経皮的ラジオ波治療成績と工夫. パネルディスカッション「より安全で効果的なラジオ波焼灼療法」  [Not invited]鄭 浩柄; 工藤 正俊; 井上達夫; 坂口康浩; 萩原 智; 南 康範; 上嶋 一臣; 福永 豊和第41回日本肝癌研究会  2005/06  幕張メッセ国際会議場, 千葉  第41回日本肝癌研究会大腸癌肝転移に対するラジオ波熱凝固療法後の局所再発  [Not invited]中居 卓也; 川邊 高史; 奥野 清隆; 大柳 治正; 塩﨑 均; 南 康範; 工藤 正俊第106回日本外科学会  2005/05  名古屋  第106回日本外科学会  大腸癌肝転移に対して肝切除以外にRFAも選択してきた。肝転移に対するRFA治療の局所制御能を肝細胞癌の再発率で比較した。その両者で局所再発率に差はなく、合併症もなかった。にんにく療法とL-NAME吸入を試みた肝肺症候群の一例  [Not invited]山藤 緑; 岩永 賢司; 佐藤 隆司; 辻 文生; 宮良 高維; 原口 龍太; 久保 裕一; 東田 有智; 北口 容子; 工藤 正俊第176回日本内科学会近畿地方会  2005/05  大阪  第176回日本内科学会近畿地方会特別講演「肝細胞癌治療と再発抑制」  [Not invited]工藤 正俊肝癌再発予防研究会第8回学術講演会  2005/05  千里ライフサイエンスセンター, 大阪  肝癌再発予防研究会第8回学術講演会報告講演「次世代超音波造影剤対応造影ハーモニックモードを搭載した超音波内視鏡探触子の開発-消化器疾患の微小循環動態評価による診断-」  [Not invited]工藤 正俊第78回日本超音波医学会総会  2005/05  東京国際フォーラム, 東京  第78回日本超音波医学会総会ラジオ出演「肝臓がんの診断と治療(5)」(番組名: 健やかライフ)  [Not invited]工藤 正俊ABCラジオ(朝日放送)  2005/05  大阪  ABCラジオ(朝日放送)ラジオ出演「肝臓がんの診断と治療(4)」(番組名: 健やかライフ)  [Not invited]工藤 正俊ABCラジオ(朝日放送)  2005/05  大阪  ABCラジオ(朝日放送)ラジオ出演「肝臓がんの診断と治療(3)」(番組名: 健やかライフ)  [Not invited]工藤 正俊ABCラジオ(朝日放送)  2005/05  大阪  ABCラジオ(朝日放送)ラジオ出演「肝臓がんの診断と治療(2)」(番組名: 健やかライフ)  [Not invited]工藤 正俊ABCラジオ(朝日放送)  2005/05  大阪  ABCラジオ(朝日放送)ラジオ出演「肝臓がんの診断と治療(1)」(番組名: 健やかライフ)  [Not invited]工藤 正俊ABCラジオ(朝日放送)  2005/05  大阪  ABCラジオ(朝日放送)講演「肝臓がんの早期発見・内科的治療と再発予防の最前線」  [Not invited]工藤 正俊平成17年度日本肝臓学会市民公開講座, 日本肝臓学会  2005/05  有楽町読売ホール, 東京  平成17年度日本肝臓学会市民公開講座, 日本肝臓学会Clinical characteristics and endoscopic treatment of duodenal varices  [Not invited]松井 繁長; 工藤 正俊DDW 2005  2005/05  Chicago  DDW 2005Contrast-enhanced harmonic EUS: a method to visualize microcirculation in digestive organs  [Not invited]北野 雅之; 工藤 正俊DDW 2005  2005/05  Chicago  DDW 2005The utility of endoscopic ultrasonography using 30MHz, 20MHz and 12MHz endoscopic ultrasound probe, endoscopy in the endoscopic submucosal desection of early gastric cancer  [Not invited]市川 勉; 工藤 正俊DDW 2005  2005/05  Chicago  DDW 2005Real-time virtual sonography, an integrated system of computer tomography with ultrasound images: value in radiofrequency ablation guidance  [Not invited]南 康範; 工藤 正俊DDW 2005  2005/05  Chicago  DDW 2005ポスター「内視鏡的に切除した単発性胃粘膜下異所性胃腺の2例ー超音波内視鏡所見を含めてー  [Not invited]吉本理恵; 工藤 正俊; 汐見 幹夫; 上田泰輔; 末冨洋一郎; 中岡 良介; 筑後 孝章第69回日本消化器内視鏡学会総会  2005/05  ホテルニューオータニ東京, 東京  第69回日本消化器内視鏡学会総会パネルディスカッション「膵癌の確定診断における経乳頭的膵液細胞診とEUS下穿刺生検の使い分けに関する検討」  [Not invited]北野 雅之; 工藤 正俊; 坂本洋城第69回日本消化器内視鏡学会総会  2005/05  ホテルニューオータニ東京, 東京  第69回日本消化器内視鏡学会総会パネルディスカッション「十二指腸静脈瘤の内視鏡的診断と治療」  [Not invited]松井 繁長; 工藤 正俊; 市川 勉第69回日本消化器内視鏡学会総会  2005/05  ホテルニューオータニ東京, 東京  第69回日本消化器内視鏡学会総会シンポジウム「超音波内視鏡ガイド下腹腔神経叢ブロック術の成績とその適応; 後方接近法との比較」  [Not invited]坂本洋城; 工藤 正俊; 北野 雅之第69回日本消化器内視鏡学会総会  2005/05  ホテルニューオータニ東京, 東京  第69回日本消化器内視鏡学会総会ビデオシンポジウム「超音波内視鏡ガイド下腹腔神経叢ブロック術の標準的描出法とその成績」  [Not invited]坂本洋城; 工藤 正俊; 北野 雅之第69回日本消化器内視鏡学会総会  2005/05  ホテルニューオータニ東京, 東京  第69回日本消化器内視鏡学会総会ワークショップ(2)「肝癌のラジオ波焼灼術のおけるRVSの有用性」  [Not invited]南 康範; 工藤 正俊; 鄭 浩柄第78回日本超音波医学会総会  2005/05  東京国際フォーラム, 東京  第78回日本超音波医学会総会ワークショップ(1)「膵腫瘍性病変診断におけるEUS下穿刺生検の有用性とその工夫」  [Not invited]坂本洋城; 工藤 正俊; 北野 雅之; 前川 清第78回日本超音波医学会総  2005/05  東京国際フォーラム, 東京  第78回日本超音波医学会総パネルディスカッション(3)「超音波内視鏡探触子による消化器系臓器の微小循環動態の観察」  [Not invited]北野 雅之; 工藤 正俊; 坂本洋城; 前川 清; 南 康範; 中岡 良介; 仲谷 達也第78回日本超音波医学会総会  2005/05  東京国際フォーラム, 東京  第78回日本超音波医学会総会パネルディスカッション(2)「GISTsの悪制度評価における造影超音波の有用性」  [Not invited]福田信宏; 工藤 正俊; 北野 雅之; 前川 清第78回日本超音波医学会総会  2005/05  東京国際フォーラム, 東京  第78回日本超音波医学会総会パネルディスカッション(1)「膵管癌の早期診断と治療効果判定における造影超音波検査の有用性」  [Not invited]坂本洋城; 工藤 正俊; 北野 雅之第78回日本超音波医学会総  2005/05  東京国際フォーラム, 東京  第78回日本超音波医学会総特別講演「肝細胞の治療と再発抑制」  [Not invited]工藤 正俊肝疾患治療フォーラム, ヒルトンホテル  2005/04  大阪  肝疾患治療フォーラム, ヒルトンホテル教育講演Meet-the-Professor「肝癌の診断と集学的な治療の最前線」  [Not invited]工藤 正俊第91回日本消化器病学会総会ポストグラデュエイトコース  2005/04  東京国際フォーラム, 東京  第91回日本消化器病学会総会ポストグラデュエイトコースラジオ出演「肝臓がんの予防」(番組名: 健やかライフ),  [Not invited]工藤 正俊ABCラジオ(朝日放送)  2005/04  大阪  ABCラジオ(朝日放送)Special Lecture “Non-B, non-C HCC-overview.”  [Not invited]工藤 正俊Japan-Korean Liver Symposium  2005/04  Teju, Korea  Japan-Korean Liver Symposium“Therapy for Early HCC.”  [Not invited]工藤 正俊JSGE・AGA Joint Meeting  2005/04  Tokyo Forum, Tokyo  JSGE・AGA Joint MeetingEducation Lecture "Contrast US of pancreato-biliary tumor."  [Not invited]工藤 正俊Informal administrative council meeting of AFSUMB  2005/04  Shanghai, China  Informal administrative council meeting of AFSUMBEducation Lecture "Treatment of HCC using real-time virtual sonography and contrast US."  [Not invited]工藤 正俊Informal administrative council meeting of AFSUMB  2005/04  Shanghai, China  Informal administrative council meeting of AFSUMBEducation Lecture "Doppler/Contrast-enhanced US of liver mass."  [Not invited]工藤 正俊Informal administrative council meeting of AFSUMB  2005/04  Shanghai, China  Informal administrative council meeting of AFSUMBInvited Lecture "Diagnosis and treatment of hepatocellular carcinoma up-to-date."  [Not invited]工藤 正俊The 6th Sino-Japanese symposium on hepato-biliaty-pancreatic deseases  2005/04  Beijing, China  The 6th Sino-Japanese symposium on hepato-biliaty-pancreatic deseasesNon-B Non-C HCC in Japan, overview  [Not invited]畑中絹世; 工藤 正俊The2nd Korea-Japan Liver Symosium(KJLS) 2005  2005/04  Cheju, Korea  The2nd Korea-Japan Liver Symosium(KJLS) 2005Hepatocellular carcinoma up-to date; Diagnosis and treatment of hepatocellular carcinoma up-to date  [Not invited]工藤 正俊6th Sino-Japan Hepato-pancreato-biliary symposium  2005/04  China  6th Sino-Japan Hepato-pancreato-biliary symposiumパネルディスカッション(8)消化器病診断・治療における造影超音波検査の新しい展開-次世代造影剤を含めて「次世代超音波造影剤を用いた造影ハーモニック超音波検査による微小循環動態の観察」  [Not invited]北野 雅之; 工藤 正俊; 坂本洋城第91回日本消化器病学会総会  2005/04  東京国際フォーラム, 東京  第91回日本消化器病学会総会シンポジウム(3)肝細胞癌のラジオ波治療のQualityコントロールと長期予後及び今後の課題「当院における肝細胞癌に対するラジオ波焼灼術治療成績」  [Not invited]井上達夫; 工藤 正俊; 鄭 浩柄第91回日本消化器病学会総会  2005/04  東京国際フォーラム, 東京  第91回日本消化器病学会総会Hepatocellular carcinoma ; Therapies for Early HCC.  [Not invited]工藤 正俊Second joint Meeting of the Japanese Society of Gastroenterology and the American Gastroenterologica  2005/04  Tokyo  Second joint Meeting of the Japanese Society of Gastroenterology and the American GastroenterologicaHepatocellular carcinoma up-to date; Diagnosis and treatment of hepatocellular carcinoma up-to date.  [Not invited]工藤 正俊6th Sino-Japan Hepato-pancreato-biliary symposium  2005/04  China  6th Sino-Japan Hepato-pancreato-biliary symposium慢性関節リウマチ発病後, 比較的短期間のうちに発症した続発性消化管アミロイドーシスの一例.  [Not invited]落合 健; 田中 陽一; 森村 正嗣; 米田 円; 由谷 逸郎; 辻 直子; 工藤 正俊第74回日本消化器内視鏡学会近畿地方会  2005/03  大阪国際会議場, 大阪.  第74回日本消化器内視鏡学会近畿地方会化学療法に一時的に反応した小腸癌の一例  [Not invited]加藤 玲明; 水野 成人; 林 道友; 豊澤 昌子; 小川 力; 渡邉 和彦; 南野 達夫; 工藤 正俊; 藤島 正浩; 村田 賢; 井上 雅智第74回日本消化器内視鏡学会近畿地方会  2005/03  大阪  第74回日本消化器内視鏡学会近畿地方会特別講演「慢性肝疾患治療の最前線」  [Not invited]工藤 正俊慢性肝疾患セミナー  2005/03  リーガロイヤルホテル新居浜, 新居浜  慢性肝疾患セミナー基調講演「肝癌の診療における造影エコーの現状と展望」  [Not invited]工藤 正俊第30回 肝胆膵治療研究会  2005/03  エーザイ(株)東海サポートセンター, 名古屋  第30回 肝胆膵治療研究会当院におけるラジオ波焼灼術の成績と工夫(シンポジウム「安全で確実なラジオ波熱凝固療法施行のために」)  [Not invited]鄭 浩柄; 工藤 正俊; 井上達夫; 萩原 智; 南 康範; 上嶋 一臣; 福永 豊和第7回関西肝癌局所療法研究会  2005/03  ホテルグランヴィア大阪, 大阪  第7回関西肝癌局所療法研究会小腸穿孔の一例  [Not invited]林 道友; 水野 成人; 藤島 正浩; 豊澤 昌子; 小川 力; 渡邉 和彦; 南野 達夫; 新崎 亘; 中山 剛之; 井上 雅智; 太田 善夫; 工藤 正俊第82回日本消化器病学会近畿支部例会  2005/02  京都  第82回日本消化器病学会近畿支部例会非典型的な画像所見を呈したHCCの一例  [Not invited]小川 力; 水野 成人; 藤島 正浩; 林 道友; 豊澤 昌子; 加藤 玲明; 渡邉 和彦; 南野 達夫; 北口 博士; 村田 賢; 井上 雅智; 太田 善夫; 工藤 正俊第82回日本消化器病学会近畿支部例会  2005/02  京都  第82回日本消化器病学会近畿支部例会特別講演「ウイルス性肝炎の最新知識」  [Not invited]工藤 正俊肝炎肝がん啓発普及講習会  2005/02  大阪狭山市保健センター, 大阪  肝炎肝がん啓発普及講習会教育講演「肝細胞癌の診断における最先端の腹部エコー検査法」  [Not invited]工藤 正俊第40回山口大学医師会・山口大学医学部主催医師教育講座  2005/02  山口大学, 山口  第40回山口大学医師会・山口大学医学部主催医師教育講座  教育講演「肝細胞癌の診断における最先端の腹部エコー検査法」教育講演「肝細胞癌の診断と治療:最近の進歩」  [Not invited]工藤 正俊日本消化器病学会近畿支部第17回教育講演会  2005/02  京都テルサ, 京都  日本消化器病学会近畿支部第17回教育講演会特別講演「肝細胞癌の診断と治療:最近のトピックス」  [Not invited]工藤 正俊第15回大分肝炎研究会  2005/02  大分東洋ホテル, 大分  第15回大分肝炎研究会特別講演「肝細胞癌診療の最近の進歩」  [Not invited]工藤 正俊第2回北九州肝癌治療研究会  2005/02  リーガロイヤルホテル小倉, 九州  第2回北九州肝癌治療研究会膵膿瘍を合併した有機リン中毒の一例  [Not invited]荻野 公一; 工藤 正俊; 落合 健; 田中 陽一; 森村 正嗣; 米田 円; 由谷 逸朗; 辻 直子日本消化器病学会第82回近畿支部例会  2005/02  京都  日本消化器病学会第82回近畿支部例会  膵膿瘍を合併した有機リン中毒の症例報告を行った。胆、膵における臨床的有用性について  [Not invited]北野 雅之; 工藤 正俊GE Ultrasound Advanced Symposium 2003  2005  GE Ultrasound Advanced Symposium 2003造影超音波. シンポジウム「早期肝癌ー診断と治療の最前線ー」  [Not invited]工藤 正俊第39回日本医学放射線学会秋季臨床大会  2005  神戸  第39回日本医学放射線学会秋季臨床大会食道静脈瘤に対するELSLの有用性. (ワークショップI 「食道静脈瘤の治療戦略」)  [Not invited]松井 繁長; 工藤 正俊; 中岡 良介第67回日本消化器内視鏡学会近畿地方会  2005  大阪  第67回日本消化器内視鏡学会近畿地方会特別講演「肝疾患診療の最新情報」  [Not invited]工藤 正俊ルミパルス学会  2005/01  ホテルサンルートソプラ神戸, 神戸  ルミパルス学会特別講演「肝細胞癌治療と再発抑制」  [Not invited]工藤 正俊Meet-the-Expert Seminar in Yamanashi 2005  2005/01  甲府, 山梨  Meet-the-Expert Seminar in Yamanashi 2005側方リンパ節転移を認めた直腸カルチノイドの1例  [Not invited]所 忠男; 奥野 清隆; 肥田 仁一; 石丸 英三郎; 内田 寿博; 吉藤 竹仁; 松崎智彦; 安富 正幸; 塩? 均; 南 康範; 工藤 正俊第62回大腸癌研究会  2005/01  第62回大腸癌研究会特別講演「肝細胞癌の診断と治療:最近のトピックス」  [Not invited]工藤 正俊ひだ消化器病研究会  2004/12  高山赤十字病院, 岐阜  ひだ消化器病研究会特別講演ランチョンセミナー「肝細胞癌の診断と治療:最近のトピックス」  [Not invited]工藤 正俊第84回日本消化器病学会九州支部例会  2004/12  福岡国際会議場, 福岡  第84回日本消化器病学会九州支部例会Invited Lecture "Imaging fro parenchymal assessment in chronic liver disease."  [Not invited]工藤 正俊Asian Pacific Association for the Study of the Liver (APASL)  2004/12  New delhi, India  Asian Pacific Association for the Study of the Liver (APASL)Invited Lecture "Newer imaging modalities for hepatocellular carcinoma."  [Not invited]工藤 正俊Asian Pacific Association for the Study of the Liver (APASL)  2004/12  New delhi, India  Asian Pacific Association for the Study of the Liver (APASL)Invited Lecture "Screening for HCC: Is it relevant in Asia pacific: How to screen?"  [Not invited]工藤 正俊Asian Pacific Association for the Study of the Liver (APASL)  2004/12  New delhi, India  Asian Pacific Association for the Study of the Liver (APASL)Invited Lecture "Evaluation of state of lecture in normal and cirrhotic liver."  [Not invited]工藤 正俊Asian Pacific Association for the Study of the Liver (APASL)  2004/12  New delhi, India  Asian Pacific Association for the Study of the Liver (APASL)TS-1にて長期コントロールされている進行胃癌の1例  [Not invited]林 道友; 水野 成人; 加藤 玲明; 豊澤 昌子; 小川 力; 渡邉 和彦; 南野 達夫; 中山 剛之; 井上 雅智; 工藤 正俊; 藤島 正浩第3回大阪消化器化学療法懇話会  2004/11  大阪  第3回大阪消化器化学療法懇話会肝腫瘍の一例  [Not invited]小川 力; 水野 成人; 林 道友; 豊澤 昌子; 加藤 玲明; 渡邉 和彦; 南野 達夫; 工藤 正俊第8回画像診断・治療研究会  2004/11  大阪  第8回画像診断・治療研究会特別講演「肝癌治療と再発予防について」  [Not invited]工藤 正俊京都肝炎友の会  2004/11  ラボール京都, 京都  京都肝炎友の会特別講演「肝細胞がんの早期発見と治療-最近の進歩を含めて-」  [Not invited]工藤 正俊肝癌撲滅運動記念講演会, 日本肝臓学会  2004/11  もくせい会館, 静岡  肝癌撲滅運動記念講演会, 日本肝臓学会特別講演「肝細胞癌診療の最近のトピックス」  [Not invited]工藤 正俊第9回宮城インターベンション研究会  2004/11  良陸会館, 仙台  第9回宮城インターベンション研究会特別講演「肝細胞癌のステージングと治療アルゴリズム」  [Not invited]工藤 正俊第17回南大阪消化器病懇話会  2004/11  リーガロイヤルホテル堺, 大阪  第17回南大阪消化器病懇話会特別講演「RFAによる肝細胞癌根治後のIFN治療による再発抑制効果」  [Not invited]工藤 正俊自治医科大学大学院特別講義  2004/11  自治医科大学, 栃木  自治医科大学大学院特別講義特別講演「消化器領域における造影エコー法の進歩と今後の展望」  [Not invited]工藤 正俊第 回日本超音波医学会四国地方会  2004/11  松山  第 回日本超音波医学会四国地方会特別講演「肝細胞癌の画像診断」  [Not invited]工藤 正俊第 回神奈川肝癌研究会  2004/11  横浜  第 回神奈川肝癌研究会小腸穿孔を来した一例  [Not invited]加藤 玲明; 水野 成人; 林 道友; 豊澤 昌子; 小川 力; 渡邉 和彦; 南野 達夫; 太田 善夫; 工藤 正俊; 新崎 亘; 中山 剛之; 井上 雅智第26回奈良県胃腸研究会  2004/10  奈良  第26回奈良県胃腸研究会肝SOLの1例  [Not invited]水野 成人; 小川 力; 豊澤 昌子; 加藤 玲明; 渡邉 和彦; 南野 達夫; 工藤 正俊第7回関西GEクラブ  2004/10  大阪  第7回関西GEクラブ特別講演「IFNによる肝癌のsecondary prevention」  [Not invited]工藤 正俊イブニングセミナー, DDW2004  2004/10  福岡  イブニングセミナー, DDW2004上部消化管内視鏡検査におけるプロポフォールの安全性と有用性  [Not invited]米田 円; 工藤 正俊; 安藤 理奈; 落合 健; 田中 陽一; 由谷 逸朗; 森村 正嗣; 辻 直子第68回日本消化器内視鏡学会総会  2004/10  福岡  第68回日本消化器内視鏡学会総会sm分化型胃癌リンパ節転移に関する臨床病理学的検討  [Not invited]辻 直子; 工藤 正俊; 落合 健; 田中 陽一; 米田 円; 森村正嗣; 由谷 逸朗; 石黒 信吾第46回日本消化器病学会大会  2004/10  福岡  第46回日本消化器病学会大会  sm分化型胃癌手術症例のリンパ節転移陽性群と陰性群を比較することでリンパ節転移の危険因子について検討した。PEG管理の実情と問題点および安全対策  [Not invited]辻 直子; 工藤 正俊; 落合 健; 田中 陽一; 森村正嗣; 米田 円; 由谷 逸朗第68回日本消化器内視鏡学会総会  2004/10  福岡  第68回日本消化器内視鏡学会総会  堺病院におけるPEG管理の実情と問題点および安全対策について発表した。サテライトシンポジウム4「Interventional Hepatology: 癌の治療とウイルス駆除」癌根治的法と二次予防  [Not invited]工藤 正俊第8回日本肝臓学会総会(DDW)  2004/10  福岡国際会議場, 福岡  第8回日本肝臓学会総会(DDW)パネルディスカッション12・特別発言「肝癌の治療における腹腔鏡の役割」  [Not invited]工藤 正俊第8回日本肝臓学会総会(DDW)  2004/10  福岡国際会議場, 福岡  第8回日本肝臓学会総会(DDW)プレナリーセッション「造影ハーモニック超音波検査による膵管癌治療効果判定の検討」  [Not invited]坂本洋城; 工藤 正俊第46回日本消化器病学会総会(DDW)  2004/10  福岡国際会議場, 福岡  第46回日本消化器病学会総会(DDW)ワークショップ「食道静脈瘤治療におけるEVLの位置付け」  [Not invited]松井 繁長; 工藤 正俊; 市川 勉第46回日本消化器病学会総会(DDW)  2004/10  福岡国際会議場, 福岡  第46回日本消化器病学会総会(DDW)ワークショップ「造影超音波検査による肝腫瘍のpost vascular phaseにおける悪性度評価-SPIO MRI組織学的所見、免疫染色との比較-」  [Not invited]井上達夫; 工藤 正俊; 周 佩第46回日本消化器病学会総会(DDW)  2004/10  福岡国際会議場, 福岡  第46回日本消化器病学会総会(DDW)ワークショップ「EUS下穿刺検体の取扱いの工夫」  [Not invited]中岡 良介; 工藤 正俊; 汐見 幹夫第46回日本消化器病学会総会(DDW)  2004/10  福岡国際会議場, 福岡  第46回日本消化器病学会総会(DDW)ワークショップ・基調講演「肝細胞癌のステージングシステムの確立とその評価」  [Not invited]工藤 正俊第46回日本消化器病学会総会(DDW)  2004/10  福岡国際会議場, 福岡  第46回日本消化器病学会総会(DDW)パネルディスカッション12・特別発言「肝癌の治療における腹腔鏡の役割」  [Not invited]工藤 正俊第46回日本消化器病学会総会(DDW)  2004/10  福岡国際会議場, 福岡  第46回日本消化器病学会総会(DDW)シンポジウム「肝細胞癌に対する経皮的ラジオ波焼灼療法」  [Not invited]鄭 浩柄; 工藤 正俊; 川崎俊彦第46回日本消化器病学会総会(DDW)  2004/10  福岡国際会議場, 福岡  第46回日本消化器病学会総会(DDW)微小浸潤を認めた分枝型IPMTの一例  [Not invited]小川 力; 水野 成人; 林 道友; 豊澤 昌子; 加藤 玲明; 渡邉 和彦; 南野 達夫; 橋本 幸彦; 井上 雅智; 太田 善夫; 工藤 正俊第73回日本消化器内視鏡学会近畿地方会  2004/09  大阪  第73回日本消化器内視鏡学会近畿地方会経皮的アプローチを併用して治療した総胆管結石の一例  [Not invited]加藤 玲明; 水野 成人; 林 道友; 豊澤 昌子; 小川 力; 渡邉 和彦; 南野 達夫; 工藤 正俊; 村田 賢; 井上 雅智第73回日本消化器内視鏡学会近畿地方会  2004/09  大阪  第73回日本消化器内視鏡学会近畿地方会著明な壁肥厚を認めた慢性胆嚢炎の一例  [Not invited]豊澤 昌子; 水野 成人; 小川 力; 加藤 玲明; 渡邉 和彦; 南野 達夫; 中山 剛之; 新崎 亘; 井上 雅智; 工藤 正俊第81回日本消化器病学会近畿支部例会  2004/09  京都  第81回日本消化器病学会近畿支部例会特別講演「肝細胞癌の診断の進歩」  [Not invited]工藤 正俊第63回日本癌学会  2004/09  福岡  第63回日本癌学会特別講演「肝胆道系の画像診断ー最近のトピックスー」  [Not invited]工藤 正俊第40回日本胆道系学会ランチョンセミナー  2004/09  筑波  第40回日本胆道系学会ランチョンセミナー特別講演「超音波血流画像による肝癌の診断と治療」  [Not invited]工藤 正俊第16回阪神肝胆膵懇話会  2004/09  兵庫医科大学  第16回阪神肝胆膵懇話会教育講演「肝細胞癌診療の最近のトピックス」  [Not invited]工藤 正俊平成16年度日本内科学会生涯教育講演会Aセッション(第3回)  2004/09  岡山シンフォニーホール, 岡山  平成16年度日本内科学会生涯教育講演会Aセッション(第3回)特別講演「肝細胞癌診療の最近の進歩」ー造影エコー法を中心にー.  [Not invited]工藤 正俊第26回兵庫肝炎研究会  2004/09  ポートピアホテル, 神戸  第26回兵庫肝炎研究会Changes of lens culinaris agglutinin-reactive alpha-fetoprotein (AFP-L3 fraction) after complete response by radiofrequency ablation for hepatocellular cracinoma  [Not invited]工藤 正俊; 小川 力; 南 康範; 鄭 浩柄; 川崎俊彦12th United European Gastroenterology Week (UEGW)  2004/09  Prague  12th United European Gastroenterology Week (UEGW)Validation study of the new prognostic staging, the Japan integrated staging score (JIS score) for hepatocellular carcinoma in 3,934 Japanese patients: a multicenter collaborative study  [Not invited]工藤 正俊; 鄭 浩柄; 土師 誠二; 大崎往夫; 岡 博子; 春日井博志; 々木; 洋; 関 寿人12th United European Gastroenterology Week (UEGW)  2004/09  Prague  12th United European Gastroenterology Week (UEGW)健常成人に発症したサイトメガロウイルス(CMV)肝炎の一例  [Not invited]落合 健; 米田 円; 田中 陽一; 由谷 逸朗; 辻 直子; 工藤 正俊日本消化器病学会第81回近畿支部例会  2004/09  日本消化器病学会第81回近畿支部例会Usefulness and limitations of the endoscopic argon plasma coagulation treatment for gastric antral vascular ectasia  [Not invited]松井 繁長; 工藤 正俊; 市川 勉; 石川恵美; 中岡 良介; 北野 雅之; 汐見幹夫12th United European Gastroenterology Week (UEGW)  2004/09  Prague  12th United European Gastroenterology Week (UEGW)Estimation of the malignant potential of gastrointestinal stromal tumors: the value of contrast-enhanced coded phase-inversion harmonics US  [Not invited]福田信宏; 工藤 正俊; 北野 雅之; 坂本洋城; 汐見幹夫; 梅原 泰12th United European Gastroenterology Week (UEGW)  2004/09  Prague  12th United European Gastroenterology Week (UEGW)Usefulness of contrast-enhanced harmonic ultrasonography for the detection of small nodules in pancreas  [Not invited]北野 雅之; 工藤 正俊; 前川 清; 坂本洋城; 末冨洋一郎12th United European Gastroenterology Week (UEGW)  2004/09  Prague  12th United European Gastroenterology Week (UEGW)Evaluation of therapeutic response to gemcitabine in pancreatic cancers: value of contrast-enhanced harmonic ultrasonography  [Not invited]坂本洋城; 工藤 正俊; 北野 雅之; 末冨洋一郎; 福田信弘; 井上達夫; 坂口康浩; 梅原 泰; 萩原 智; 市川 勉; 畑中絹世12th United European Gastroenterology Week (UEGW)  2004/09  Prague  12th United European Gastroenterology Week (UEGW)Effect of angiotensin-II and angiotensin-II type 1 receptor blocker on rat pancreatic stellate cells  [Not invited]福田信弘; 工藤 正俊; 仲谷 達也; 北野 雅之; 坂本洋城; 宗像 浩12th United European Gastroenterology Week (UEGW)  2004/09  Prague  12th United European Gastroenterology Week (UEGW)Uptake of Levovist at the post-vascular phase correlates well with CD-68 staining (Kupffer cells), histology, and SPIO-MRI uptake ratio in hepatocellular carcinoma and its premalignant/borderline lesions  [Not invited]工藤 正俊; 井上達夫; 福永 豊和; 前川 清12th United European Gastroenterology Week (UEGW)  2004/09  Prague  12th United European Gastroenterology Week (UEGW)Comparison of posttreatment prognosis between ablation and resection for early-stage hepatocellular carcinoma: standardized analysis of 737 patients by stratification method based of JIS scoring system  [Not invited]工藤 正俊; 鄭 浩柄12th United European Gastroenterology Week (UEGW)  2004/09  Prague  12th United European Gastroenterology Week (UEGW)Prognostic staging system for hepatocellular carcinoma: comparison between JIS score, modified JIS score and CLIP score in 4,525 patients  [Not invited]工藤 正俊; 鄭 浩柄; 大崎往夫; 岡 博子; 春日井博志; 々木; 洋; 関 寿人12th United European Gastroenterology Week (UEGW)  2004/09  Prague  12th United European Gastroenterology Week (UEGW)Low-dose, long-term interferon therapy delays clinical recurrence after curative radiofrequency ablation in patients with hepatitis C related hepatocellular carcinoma  [Not invited]工藤 正俊; 坂口康浩12th United European Gastroenterology Week (UEGW)  2004/09  Prague  12th United European Gastroenterology Week (UEGW)Effects of angiotensin II on rat pancreatic stellate cells  [Not invited]仲谷 達也; 工藤 正俊; 福田信弘; 石川恵美; 南 康範; 鄭 浩柄; 中岡 良介; 福永 豊和; 松井 繁長; 北野 雅之; 川崎俊彦; 汐見幹夫; 宗像 浩12th United European Gastroenterology Week (UEGW)  2004/09  Prague  12th United European Gastroenterology Week (UEGW)経過観察中に胃腺腫を合併した自己免疫性胃炎(A型胃炎)の一例  [Not invited]杉立 紗綾; 工藤 正俊; 落合 健; 田中 陽一; 森村 正嗣; 米田 円; 由谷 逸朗; 辻 直子第73回日本消化器内視鏡学会近畿地方会  2004/09  大阪  第73回日本消化器内視鏡学会近畿地方会  経過観察中に胃腺腫を合併した自己免疫性胃炎(A型胃炎)について症例報告を行った。肝癌および早期病変の画像診断. シンポジウム「肝がんの診断・治療の最先端」  [Not invited]工藤 正俊第63回日本癌学会学術総会  2004/09  福岡国際会議場, 福岡  第63回日本癌学会学術総会肝細胞癌局所再発症例に対する造影超音波ガイド下ラジオ波焼灼術-Prospective randomized controlled study-. シンポジウム「肝腫瘍の局所療法に対する造影超音波の役割」  [Not invited]南 康範; 工藤 正俊; 鄭 浩柄; 福永 豊和第10回関西地方会造影剤研究会  2004/09  ジブラルタ生命千里ホール  第10回関西地方会造影剤研究会ビデオワークショップ「消化管出血に対する内視鏡治療」上部消化管非静脈瘤出血に対する内視鏡的止血術-高周波電気凝固法を中心に-  [Not invited]末冨洋一郎; 工藤 正俊; 汐見 幹夫第73回日本消化器内視鏡学会近畿地方会  2004/09  大阪  第73回日本消化器内視鏡学会近畿地方会ビデオワークショップ「胆膵疾患における新しい内視鏡的診断・治療法-手技の実際と工夫」超音波内視鏡ガイド下腹腔神経叢ブロック術の成績とその適応  [Not invited]坂本洋城; 工藤 正俊; 北野 雅之第73回日本消化器内視鏡学会近畿地方会  2004/09  大阪  第73回日本消化器内視鏡学会近畿地方会特別講演「肝臓の超音波診断up to date」  [Not invited]工藤 正俊第47回東部医師会医学セミナー  2004/08  鳥取県医師会館, 鳥取  第47回東部医師会医学セミナー特別講演「肝臓と消化器を診るー欧州と日本の消化器エコーー最前線ー」  [Not invited]工藤 正俊2004アロカ技術フェアー  2004/07  東京  2004アロカ技術フェアー特別講演「肝細胞癌の診断と治療ーup to date」  [Not invited]工藤 正俊東京肝臓疾患勉強会  2004/07  東京  東京肝臓疾患勉強会特別講演「肝細胞癌局所療法後の造影CT, 造影MRIによる根治の判定について」  [Not invited]工藤 正俊E0167 大阪地区検討会  2004/07  岡山  E0167 大阪地区検討会特別講演「肝がん撲滅のためのインターフェロン療法」C型慢性肝炎~高齢者のインターフェロン治療~  [Not invited]工藤 正俊学術講演会  2004/07  大阪  学術講演会Randomized comparison of dose-intense gemcitabine; standard infusion and low dose infusion in patients with pancreatic adenocarcinoma  [Not invited]坂本洋城; 工藤 正俊; 北野 雅之; 末冨洋一郎The 11th meeting of the International Association of Pancreatolotgy (IAP) and the 35th Annual Meetin  2004/07  Sendai  The 11th meeting of the International Association of Pancreatolotgy (IAP) and the 35th Annual MeetinDynamic imaging of pancreatic disease: Value of contrast-enhanced coded phase-inversion harmonic ultrasonography  [Not invited]北野 雅之; 工藤 正俊; 前川 清; 坂本洋城; 末冨洋一郎; 中岡 良介; 福田信弘; 川崎俊彦The 11th meeting of the International Association of Pancreatolotgy (IAP) and the 35th Annual Meetin  2004/07  Sendai  The 11th meeting of the International Association of Pancreatolotgy (IAP) and the 35th Annual Meetin生存率および再発率からみた画像的根治RFA後の腫瘍マーカーの推移とその変動の意義  [Not invited]小川 力; 工藤 正俊; 南 康範; 鄭 浩柄; 川崎俊彦第40回日本肝臓学会総会  2004/06  シェラトングランデトーキョーベイホテル, 千葉  第40回日本肝臓学会総会非定型的大型高分化型肝癌2切除症例の臨床病理学的検討  [Not invited]金 守良; 工藤 正俊; 金 啓二; 岡部 純弘第40回日本肝臓学会総会  2004/06  シェラトングランデトーキョーベイホテル, 千葉  第40回日本肝臓学会総会肝細胞癌症例における門脈腫瘍栓出現のrisk factorについての検討  [Not invited]萩原 智; 工藤 正俊; 石川恵美; 小川 力; 坂口康浩; 井上達夫; 南 康範; 鄭 浩柄; 福永 豊和; 川崎俊彦第40回日本肝臓学会総会  2004/06  シェラトングランデトーキョーベイホテル, 千葉  第40回日本肝臓学会総会肝細胞癌staging systemの有用性に関する検討  [Not invited]鄭 浩柄; 工藤 正俊; 小川 力; 井上達夫; 坂口康浩; 萩原 智; 石川恵美; 南 康範; 福永 豊和; 川崎俊彦; 大崎 征夫第40回日本肝臓学会総会  2004/06  シェラトングランデトーキョーベイホテル, 千葉  第40回日本肝臓学会総会右横隔膜直下に存在するBモードで同定困難な肝細胞癌に対する治療法: 人工胸水造影超音波下RFAの有用性について  [Not invited]南 康範; 工藤 正俊; 川崎俊彦第40回日本肝臓学会総会  2004/06  シェラトングランデトーキョーベイホテル, 千葉  第40回日本肝臓学会総会膵腫瘍を疑った二例  [Not invited]小川 力; 水野 成人; 豊澤 昌子; 加藤 玲明; 渡邉 和彦; 南野 達夫; 工藤 正俊; 北口 博士; 中山 剛之; 小川 稔; 村田 賢; 湯川 真生; 井上 雅智第26回奈良県肝胆膵研究会  2004/06  奈良  第26回奈良県肝胆膵研究会特別講演「消化器領域における造影超音波の現況と次世代造影剤の動向」  [Not invited]工藤 正俊第5回東海腹部造影エコー研究会  2004/06  名古屋  第5回東海腹部造影エコー研究会教育講演「消化器疾患診療の方向性」  [Not invited]工藤 正俊日本消化器病学会中国支部第6回教育講演会  2004/06  岡山  日本消化器病学会中国支部第6回教育講演会Invited Lecture "Staging system for assessment of HCC status."  [Not invited]工藤 正俊The 12th International Symposium of Yonsei Institute of Gastroenterology  2004/06  Yonsei, Korea  The 12th International Symposium of Yonsei Institute of GastroenterologyInvited Lecture "Contrast-enhanced Harmonic Imaging in the Hepatic Tumors with Special Emphasis on the Application to Its Treatment."  [Not invited]工藤 正俊Euroson Meeting 2004  2004/06  Zacreb, Croatia  Euroson Meeting 2004ワークショップ「肝細胞癌に対する経皮的ラジオ波焼灼術の長期治療成績」  [Not invited]鄭 浩柄; 工藤 正俊; 石川恵美; 井上達夫; 坂口康浩; 小川 力; 萩原 智; 南 康範; 福永 豊和; 川崎俊彦; 土師 誠二; 中居 卓也第40回日本肝癌研究会  2004/06  茨城  第40回日本肝癌研究会ランチョンセミナー「肝腫瘍の治療効果判定において造影超音波はMDCT/ MRIより優れるか?造影超音波の治療ガイドへの応用」  [Not invited]南 康範; 工藤 正俊第40回日本肝癌研究会  2004/06  茨城  第40回日本肝癌研究会超音波内視鏡下穿刺が診断に有用であったparagangliomaの1例.  [Not invited]坂本洋城; 工藤 正俊; 北野 雅之; 末冨洋一郎; 中岡 良介; 朝隈 豊; 北井 聡; 汐見幹夫; 前川 清第4回超音波内視鏡下穿刺吸引法(EUS-FNA)の臨床応用に関する研究会  2004/05  京都  第4回超音波内視鏡下穿刺吸引法(EUS-FNA)の臨床応用に関する研究会汎用パピロトームによる乳頭プレカットの有用性  [Not invited]水野 成人; 工藤 正俊; 豊澤 昌子; 加藤 玲明; 渡邉 和彦; 南野 達夫第67回日本消化器内視鏡学会総会  2004/05  京都  第67回日本消化器内視鏡学会総会EUS下造影エコー法による膵腫瘍性病変の診断ー現状と将来の展望ー  [Not invited]北野 雅之; 工藤 正俊; 坂本洋城第67回日本消化器内視鏡学会総会  2004/05  京都  第67回日本消化器内視鏡学会総会当院における平成15年度ERCP症例の検討  [Not invited]加藤 玲明; 水野 成人; 豊澤 昌子; 小川 力; 渡邉 和彦; 南野 達夫; 工藤 正俊; 中山 剛之; 小川 稔; 村田 賢; 湯川 真生; 井上 雅智第41回奈良県消化器内視鏡研究会  2004/05  奈良  第41回奈良県消化器内視鏡研究会汎用パピロトームによる乳頭プレカットの有用性  [Not invited]水野 成人; 豊澤 昌子; 加藤 玲明; 渡邉 和彦; 南野 達夫; 工藤 正俊; 吉岡 毅; 本庶第67回日本消化器内視鏡学会総会  2004/05  京都  第67回日本消化器内視鏡学会総会特別講演「ウイルス性肝炎と肝癌の最新治療の現状」  [Not invited]工藤 正俊平成16年度肝がん撲滅運動市民公開講座(大阪府)  2004/05  大阪狭山市SAYAKAホール, 大阪  平成16年度肝がん撲滅運動市民公開講座(大阪府)特別講演「肝細胞癌は克服できる」  [Not invited]工藤 正俊平成16年度肝がん撲滅運動市民公開講座  2004/05  岡山県, 津山市  平成16年度肝がん撲滅運動市民公開講座教育講演「肝細胞癌診療の最近のトピックス」  [Not invited]工藤 正俊平成16年度日本内科学会障害教育講演会Aセッション(第2回)  2004/05  東京国際フォーラム, 東京  平成16年度日本内科学会障害教育講演会Aセッション(第2回)教育講演「肝細胞癌の統合ステージングと局所治療」  [Not invited]工藤 正俊第 回日本肝胆膵外科学会  2004/05  大阪  第 回日本肝胆膵外科学会Invited Lecture "Early detection and characterization of HCC."  [Not invited]工藤 正俊The 2nd MMRF Meeting on Viral Hepatitis in Asia  2004/05  Tokyo  The 2nd MMRF Meeting on Viral Hepatitis in AsiaRadiofrequency ablation for liver tumor: can ablated tumor be delineated from the whole ablated area by B-mode sonography and what is the role of contrast-enhanced sonography?  [Not invited]井上達夫; 工藤 正俊; 周 佩; 南 康範; 鄭 浩柄; 福永 豊和; 川崎俊彦; 前川 清Seventh Congress of the Asian Federation of Societies for Ultrasound in Medicine and Biology (AFSUMB  2004/05  Tochigi  Seventh Congress of the Asian Federation of Societies for Ultrasound in Medicine and Biology (AFSUMBPercutaneous ultrasound-guided radiofrequency ablation with the artificial pleural effusion for hepatocellular carcinoma in the hepatic dome  [Not invited]南 康範; 工藤 正俊; 川崎俊彦; 鄭 浩柄; 小川 力; 井上達夫; 坂口康浩; 坂本洋城; 塩崎 均The American Gastroenterological Association and Digestive Disease Week  2004/05  New Orleans  The American Gastroenterological Association and Digestive Disease WeekSurvival and recurrence rates after complete radiofrequency ablation for hepatocellular carcinoma; value of lens culinaris agglutinin-reactive alpha-fetoprotein (AFP-L3 fraction)  [Not invited]小川 力; 工藤 正俊; 南 康範; 鄭 浩柄; 川崎俊彦The American Gastroenterological Association and Digestive Disease Week  2004/05  New Orleans  The American Gastroenterological Association and Digestive Disease WeekChronic respiratory disease is a risk factor for helicobacter pylori clarithromycin resistance  [Not invited]辻 直子; 工藤 正俊The American Gastroenterological Association and Digestive Disease Week  2004/05  New Orleans  The American Gastroenterological Association and Digestive Disease WeekFine needle aspiration guided by endoscopic ultrasonography. Usefulness of blood flow evaluation and gene analysis.  [Not invited]中岡 良介; 工藤 正俊; 北野 雅之Seventh Congress of the Asian Federation of Societies for Ultrasound in Medicine and Biology (AFSUMB  2004/05  Tochigi  Seventh Congress of the Asian Federation of Societies for Ultrasound in Medicine and Biology (AFSUMB特別講演「肝細胞癌局所療法後の造影CT, 造影MRIによる根治の判定について」  [Not invited]工藤 正俊E0167 岡山地区検討会  2004/04  岡山済生会総合病院, 岡山  E0167 岡山地区検討会Low-dose, long-term interferon alfa 2b delays clinical recurrence after curative radiofrequency ablation patients with hepatitis C related hepatocellular carcinoma  [Not invited]工藤 正俊; 坂口康浩The 39th Annual Meeting of the European Association for the Study of the Liver  2004/04  Berlin, Germany  The 39th Annual Meeting of the European Association for the Study of the LiverJIS scoring system combined with 3 tumor makers (modified JIS score) is an exellent prognostic staging system for hepatocellular carcinoma (HCC): analysis of 4525 patients with HCC  [Not invited]工藤 正俊; 鄭 浩柄; 大崎往夫; 岡 博子; 春日井博志; 々木; 洋; 関 寿人The 39th Annual Meeting of the European Association for the Study of the Liver  2004/04  Berlin, Germany  The 39th Annual Meeting of the European Association for the Study of the Liver内視鏡的粘膜切除術(EMR)にて治療しえた十二指腸癌の一例  [Not invited]川崎正憲; 工藤 正俊; 松井 繁長; 末冨洋一郎; 市川 勉; 坂本洋城; 井上達夫; 中岡 良介; 石川恵美; 鄭 浩柄; 福永 豊和; 北野 雅之; 川崎俊彦; 汐見幹夫第72回日本消化器内視鏡学会近畿支部例会  2004/03  奈良県新公会堂, 奈良  第72回日本消化器内視鏡学会近畿支部例会IIc型胃カルチノイドの一例  [Not invited]守口 将典; 工藤 正俊; 由谷 逸朗; 落合 健; 安藤 理奈; 田中 陽一; 森村 正嗣; 米田 円; 辻 直子第72回日本消化器内視鏡学会近畿支部例会  2004/03  奈良県新公会堂, 奈良  第72回日本消化器内視鏡学会近畿支部例会診断に苦慮した大腸潰瘍の一例  [Not invited]豊澤 昌子; 工藤 正俊; 加藤 玲明; 渡邉 和彦; 水野 成人; 南 康範第72回日本消化器内視鏡学会近畿支部例会  2004/03  奈良県新公会堂, 奈良  第72回日本消化器内視鏡学会近畿支部例会パネルディスカッション「緊急内視鏡検査における問題点とその対策」 内視鏡的止血術の成績向上のための工夫.  [Not invited]末冨洋一郎; 工藤 正俊; 汐見幹夫第72回日本消化器内視鏡学会近畿支部例会  2004/03  奈良県新公会堂, 奈良  第72回日本消化器内視鏡学会近畿支部例会パネルディスカッション「肝細胞癌に対するラジオ波焼灼術後のインターフェロン少量・長期・間歇投与の有用性」  [Not invited]坂口康浩; 工藤 正俊第25回大阪肝炎ミーティング学術講演  2004/03  全日空ホテル大阪, 大阪  第25回大阪肝炎ミーティング学術講演特別講演「肝腫瘍に対する造影ハーモニック法-治療への応用も含めて-」  [Not invited]工藤 正俊第13回肝胆膵疾患治療フォーラム  2004/03  神戸  第13回肝胆膵疾患治療フォーラム特別講演「肝細胞癌の診断と治療-最近の話題-」  [Not invited]工藤 正俊第6回北摂肝臓病研究会  2004/03  阪急電鉄本社1階「エコルテホール」, 大阪  第6回北摂肝臓病研究会特別講演「消化器領域における造影エコー法の現況」  [Not invited]工藤 正俊関西造影エコー研究会  2004/03  大阪  関西造影エコー研究会シンポジウム造影超音波検査における肝腫瘍のpost-vascular-phaseにおける悪性度評価組織学的所見との比較検討  [Not invited]井上達夫; 工藤 正俊; 周 佩; 坂口康浩; 萩原 智; 南 康範; 鄭 浩柄; 福永 豊和; 川崎俊彦第9回関西超音波造影剤研究会  2004/03  大阪  第9回関西超音波造影剤研究会パネルディスカッション「緊急内視鏡検査における問題点とその対策」 内視鏡的止血術の成績向上のための工夫  [Not invited]末冨洋一郎; 工藤 正俊; 汐見 幹夫第72回日本消化器内視鏡学会近畿支部例会  2004/03  奈良県新公会堂, 奈良  第72回日本消化器内視鏡学会近畿支部例会パネルディスカッション「肝細胞癌に対するラジオ波焼灼術後のインターフェロン少量・長期・間歇投与の有用性」  [Not invited]坂口康浩; 工藤 正俊第25回大阪肝炎ミーティング学術講演  2004/03  全日空ホテル大阪, 大阪  第25回大阪肝炎ミーティング学術講演  【目的】肝細胞癌(以下HCC)に対してラジオ波焼灼術後の根治例に対してインターフェロンの長期少量投与を行うことが再発を抑制するかについて比較検討を行った。 【方法】1999年6月より2003年7月30日まで局所治療の目的で入院となった3cm、3結節以内のHCCの症例は130例であった。この内、患者の同意を得ることができた24例をインターフェロン投与群とし、残りの106例を非投与群とした。インターフェロン投与群にはIFN-α2b 300万単位を週二回の割合で投与(筋肉注射)した。各群の局所再発または他部位再発に関してKaplan-Meier法(Log-rank検定)によって比較検討した。【成績】両群の患者背景を年齢、性別、ウイルスマーカーで比較したところ、有意差はなかった(投与群:男性17例、女性7例、年齢は56歳~72歳、中央値69歳 HCV陽性23例、HBV陽性1例 非投与群:男性76例、女性30例、年齢は47歳~79歳、中央値67歳、HCV陽性102例、HBV陽性4例)。非投与群の他部位再発率は1年9%、2年22%、3ヘリコバクター・ピロリ感染と胃炎(シドニー分類とMST)  [Not invited]水野 成人; 豊澤 昌子; 加藤 玲明; 渡邉 和彦; 南野 達夫; 工藤 正俊第4回奈良県ヘリコバクター・ピロリ研究会  2004/02  奈良  第4回奈良県ヘリコバクター・ピロリ研究会抗生剤感受性試験導入後のヘリコバクター・ピロリ除菌状況  [Not invited]水野 成人; 豊澤 昌子; 加藤 玲明; 渡邉 和彦; 南野 達夫; 工藤 正俊第4回奈良県ヘリコバクター・ピロリ研究会  2004/02  奈良  第4回奈良県ヘリコバクター・ピロリ研究会多発肝転移をきたしカルチノイド症候群を呈した胆嚢原発と考えられる神経内分泌細胞癌の一例  [Not invited]田中 陽一; 工藤 正俊; 森村 正嗣; 米田 円; 由谷 逸朗; 辻 直子第14回日本消化器病学会近畿支部例会  2004/02  大阪国際会議場, 大阪  第14回日本消化器病学会近畿支部例会成人に発症した腸重積の一例  [Not invited]加藤 玲明; 工藤 正俊; 豊澤 昌子; 渡邉 和彦; 水野 成人; 南野 達夫第80回日本消化器病学会近畿支部例会  2004/02  大阪国際会議場, 大阪  第80回日本消化器病学会近畿支部例会診断に苦慮した肝嚢胞性腫瘍の1例  [Not invited]田北雅弘; 工藤 正俊; 福永 豊和; 永島美樹; 石川恵美; 南 康範; 鄭 浩柄; 中岡 良介; 仲谷 達也; 松井 繁長; 北野 雅之; 川崎俊彦; 汐見幹夫; 前川 清日本超音波医学会第27回関西地方会  2004/02  大阪  日本超音波医学会第27回関西地方会小腸平滑筋肉腫肝転移の1例  [Not invited]辰巳千栄; 工藤 正俊; 福永 豊和; 田北雅弘; 永島美樹; 石川恵美; 南 康範; 鄭 浩柄; 中岡 良介; 仲谷 達也; 松井 繁長; 北野 雅之; 川崎俊彦; 汐見幹夫; 前川 清日本超音波医学会第27回関西地方会  2004/02  大阪  日本超音波医学会第27回関西地方会造影超音波検査が膵癌の胆管ステント内腫瘍進展の診断に有用であった1例  [Not invited]坂本康範; 工藤 正俊; 坂本洋城; 北野 雅之; 萩原 智; 末冨洋一郎; 汐見幹夫; 前川 清日本超音波医学会第27回関西地方会  2004/02  大阪  日本超音波医学会第27回関西地方会乏血性膵腫瘍の1例  [Not invited]坂本洋城; 工藤 正俊; 北野 雅之; 萩原 智; 末冨洋一郎; 汐見幹夫; 前川 清日本超音波医学会第27回関西地方会  2004/02  大阪  日本超音波医学会第27回関西地方会腹部超音波造影診断ー現状と次世代超音波造影剤の動向ー  [Not invited]工藤 正俊日本超音波医学会第27回関西地方会, ランチョンセミナー  2004/02  大阪  日本超音波医学会第27回関西地方会, ランチョンセミナー特別講演「肝癌の診断」  [Not invited]工藤 正俊第14回日本消化器病学会近畿支部例会教育講演会  2004/02  大阪国際会議場, 大阪  第14回日本消化器病学会近畿支部例会教育講演会ランチョンセミナー「消化器領域における造影エコー法の現況」  [Not invited]工藤 正俊第27回日本超音波医学会関西地方会  2004/02  大阪国際会議場, 大阪  第27回日本超音波医学会関西地方会教育講演「肝細胞癌診療の最近のトピックス」  [Not invited]工藤 正俊平成16年度日本内科学会障害教育講演会Aセッション(第1回)  2004/02  大阪国際会議場, 大阪  平成16年度日本内科学会障害教育講演会Aセッション(第1回)特別講演「肝癌診療の最近の話題」  [Not invited]工藤 正俊第11回肝細胞癌治療研究会(藤原研二先生)  2004/02  川越プリンスホテル, 埼玉  第11回肝細胞癌治療研究会(藤原研二先生)  特別講演「肝癌診療の最近の話題」Evaluation of microcirculation in dog gastrointestinal tract and pancreas by contrast-enhanced harmonic sonography with EUS probe.  [Not invited]北野 雅之; 工藤 正俊; 前川 清; 坂本 洋城; 末冨 洋一郎; 南 康範; 中岡 良介; 仲谷 達也4th International Symposium on Endoscopic Ultrasonography  2004  Tokyo, Japan  4th International Symposium on Endoscopic UltrasonographyInvited Lecture "Advances in US for pancreatic diseases"  [Not invited]工藤 正俊2nd Annual Convention, Philippine Society of Ultrasound in Clinical Medicine (PSUCMI)  2004/01  2nd Annual Convention, Philippine Society of Ultrasound in Clinical Medicine (PSUCMI)Invited Lecture "Contrast-enhanced US of the abdomen"  [Not invited]工藤 正俊2nd Annual Convention, Philippine Society of Ultrasound in Clinical Medicine (PSUCMI)  2004/01  2nd Annual Convention, Philippine Society of Ultrasound in Clinical Medicine (PSUCMI)Invited Lecture "Contrast enhanced ultrasound in hepatobiliary and pancreatic tumors"  [Not invited]工藤 正俊Asian Education Project: Training for the Trainers Ultrasound Workshop, WFUMB  2004/01  Quezon, Philippine  Asian Education Project: Training for the Trainers Ultrasound Workshop, WFUMBInvited Lecture "Ultrasound for bowel diseases"  [Not invited]工藤 正俊Asian Education Project: Training for the Trainers Ultrasound Workshop, WFUMB  2004/01  Quezon, Philippine  Asian Education Project: Training for the Trainers Ultrasound Workshop, WFUMBInvited Lecture "Ultrasound for focal liver masses"  [Not invited]工藤 正俊Asian Education Project: Training for the Trainers Ultrasound Workshop, WFUMB  2004/01  Quezon, Philippine  Asian Education Project: Training for the Trainers Ultrasound Workshop, WFUMBInvited Lecture "Ultrasound for pancreatic diseases"  [Not invited]工藤 正俊Asian Education Project: Training for the Trainers Ultrasound Workshop, WFUMB  2004/01  Quezon, Philippine  Asian Education Project: Training for the Trainers Ultrasound Workshop, WFUMBInvited Lecture "Ultrasound diagnosis of acute abdomen"  [Not invited]工藤 正俊Asian Education Project: Training for the Trainers Ultrasound Workshop, WFUMB  2004/01  Quezon, Philippine  Asian Education Project: Training for the Trainers Ultrasound Workshop, WFUMBInvited Lecture "Ultrasound for bowel diseases"  [Not invited]工藤 正俊Ultrasound Workshop Asian Federation of Societies for Ultrasound in Medicine and Biology (AFSUMB)  2004/01  Karachi, Pakistan  Ultrasound Workshop Asian Federation of Societies for Ultrasound in Medicine and Biology (AFSUMB)Invited Lecture "Role of ultrasound in portal hypertension"  [Not invited]工藤 正俊Ultrasound Workshop Asian Federation of Societies for Ultrasound in Medicine and Biology (AFSUMB)  2004/01  Karachi, Pakistan  Ultrasound Workshop Asian Federation of Societies for Ultrasound in Medicine and Biology (AFSUMB)Invited Lecture "Focal Masses in the liver"  [Not invited]工藤 正俊Ultrasound Workshop Asian Federation of Societies for Ultrasound in Medicine and Biology (AFSUMB)  2004/01  Karachi, Pakistan  Ultrasound Workshop Asian Federation of Societies for Ultrasound in Medicine and Biology (AFSUMB)Invited Lecture "Low-dose, long-term interferon alpha-2b therapy after curative treatment by radiofrequency ablation delays clinical recurrence in patients with hepatitis C related hepatocellular carcinoma"  [Not invited]工藤 正俊Prevention of Occurrence and Recurrence in Human Hepatocarcinogenesis, Japan-Korea Liver Symposium  2004/01  Kobe  Prevention of Occurrence and Recurrence in Human Hepatocarcinogenesis, Japan-Korea Liver Symposium造影超音波法を中心とした解析. 教育シンポジウム「肝細胞癌ー発癌・血管新生と血流イメージング」  [Not invited]福永 豊和; 工藤 正俊第10回肝血流動態イメージ研究会  2004/01  東京  第10回肝血流動態イメージ研究会特別講演「超音波所見とJIS scoreから見た肝細胞癌局所療法の適応」  [Not invited]工藤 正俊第22回Hokkaido DD (Digestive Disease) Club  2003/12  北海道厚生年金会館, 札幌  第22回Hokkaido DD (Digestive Disease) Club大腸潰瘍の一例  [Not invited]豊澤 昌子; 水野 成人; 加藤 玲明; 渡邉 和彦; 南野 達夫; 工藤 正俊第25回奈良県胃腸研究会  2003/11  奈良  第25回奈良県胃腸研究会特別講演「肝細胞癌の診療と治療ー最近のトピックスー」  [Not invited]工藤 正俊第9回上町台消化器セミナー  2003/11  都ホテル大阪, 大阪  第9回上町台消化器セミナー特別講演「肝腫瘍の造影ハーモニックイメージングー治療への応用も含めてー」  [Not invited]工藤 正俊第2回山口県総合画像診断研究会  2003/11  宇部全日空ホテル, 山口  第2回山口県総合画像診断研究会特別講演「肝腫瘍の造影ハーモニックイメージングー治療への応用も含めてー」  [Not invited]工藤 正俊第9回栃木県超音波懇話会  2003/11  ホテル東日本宇都宮, 栃木  第9回栃木県超音波懇話会特別講演「肝疾患の早期発見と治療」  [Not invited]工藤 正俊近畿大学薬学部・薬友会平成15年度第3回生涯教育研修会  2003/11  近畿大学本部11月ホール, 東大阪  近畿大学薬学部・薬友会平成15年度第3回生涯教育研修会肝脾腫を呈し,病理組織学的にgranulomaの形成が認められた一例  [Not invited]米田 円; 工藤 正俊; 安藤 理奈; 落合 健; 田中 陽一; 森村正嗣; 由谷 逸朗; 辻 直子第37回大阪肝穿刺生検治療  2003/11  大阪  第37回大阪肝穿刺生検治療Effect of mucosa-fibrosing therapy with argon plasma coagulation on esophageal varices  [Not invited]松井 繁長; 工藤 正俊; 中岡 良介; 北野 雅之; 汐見幹夫; 川崎俊彦11th United European Gastroenterology Weeek (UEGW)  2003/11  Madrid, Spain  11th United European Gastroenterology Weeek (UEGW)Stratification ability of the new prognostic staging system, Japan Integrated Staging score (JIS score) for hepatocellular carcinoma: comprison with CLIP score  [Not invited]工藤 正俊; 鄭 浩柄; 土師 誠二; 南 康範; 小川 力; 福永 豊和; 北野 雅之; 大崎往夫11th United European Gastroenterology Weeek (UEGW)  2003/11  Madrid, Spain  11th United European Gastroenterology Weeek (UEGW)Evaluation of microvasculature in dog pancreas and gastrointestinal tract by contrast-enhanced harmonic sonography: a novel technology available for endosonography  [Not invited]北野 雅之; 工藤 正俊; 前川 清; 坂本洋城; 南 康範; 中岡 良介; 伊藤安啓; 宮; 堀川義人; 藤本11th United European Gastroenterology Weeek (UEGW)  2003/11  Madrid, Spain  11th United European Gastroenterology Weeek (UEGW)Validation study of the new prognostic staging system, the Japan Integrated Staging score (JIS score) for hepatocellular carcinoma in 3,934 Japanese patients: a multicenter collaborative study  [Not invited]工藤 正俊; 鄭 浩柄; 大崎往夫; 岡 博子; 春日井博志; 々木; 洋; 関 寿人11th United European Gastroenterology Weeek (UEGW)  2003/11  Madrid, Spain  11th United European Gastroenterology Weeek (UEGW)十二指腸静脈瘤の診断と治療. ワークショップ「食道胃以外の静脈瘤の診断と治療」  [Not invited]松井 繁長; 工藤 正俊第10回日本門脈圧亢進症学会総会  2003/11  横浜  第10回日本門脈圧亢進症学会総会Evaluation of vascularity in the Primary Gastric Cancer using Color Doppler Imaging  [Not invited]第146回大阪腹部超音波研究会  2003/11  大阪  第146回大阪腹部超音波研究会  胃癌など腺癌では、血流は少ないと考えられてきた。今回、進行胃癌64例の原発巣内の血流を対外式超音波にて観察し、病理学的所見とも対比した結果、血流の増加が認められた。胆道出血を契機に診断した胆嚢癌の1例  [Not invited]加藤 玲明; 水野 成人; 澤本 学; 渡邉 和彦; 南野 達夫; 井上 雅智; 工藤 正俊第71回日本消化器内視鏡学会近畿地方会  2003/10  京都  第71回日本消化器内視鏡学会近畿地方会インターネットによる内視鏡情報配信システム  [Not invited]水野 成人; 南野 達夫; 工藤 正俊; 大野 崇; 辻本; 隆; 渡邊; 元樹; 上尾; 太郎; 吉岡; 毅; 吉本; 貴宜; 本庶; 元; 光本; 保英; 森; 敬弘; 平山; 哲也; 鹿田; 潮; 富岡; 秀夫; 伊藤; 正; 清水; 誠治; 木本 邦彦第66回日本消化器内視鏡学会総会  2003/10  大阪  第66回日本消化器内視鏡学会総会ランチョンセミナー「消化器領域における造影超音波診断の新たな展開」  [Not invited]工藤 正俊第7回日本肝臓学会大会  2003/10  大阪  第7回日本肝臓学会大会特別講演「肝細胞癌の診断と治療: 最近のトピックス」  [Not invited]工藤 正俊第5回葵肝臓研究会  2003/10  京都  第5回葵肝臓研究会Chronic respiratory disease is a risk facter for helicobacter pylori clarithromycin resistance  [Not invited]田中 陽一; 森村 正嗣; 米田 円; 由谷 逸朗; 辻 直子; 飯森 真幸; 工藤 正俊第11回日本消化器関連学会週間  2003/10  大阪  第11回日本消化器関連学会週間  慢性呼吸器疾患や慢性耳鼻科疾患の合併はH.pylori菌のクラリスロマイシン耐性の危険因子であることを報告した。真性多血症に合併したサイトメガロウイルス腸炎の一例  [Not invited]米田 円; 工藤 正俊; 田中 陽一; 森村 正嗣; 由谷 逸朗; 辻 直子第19回大腸内視鏡検査法研究会  2003/10  第19回大腸内視鏡検査法研究会アフタ型クローン病の1例  [Not invited]米田 円; 工藤 正俊; 安藤 理奈; 落合 健; 田中 陽一; 森村正嗣; 由谷 逸朗; 辻 直子第21回IBD Club Jr.  2003/10  東京  第21回IBD Club Jr.被検者の立場からみた上・下部消化管内視鏡検査におけるsedationの必要性  [Not invited]米田 円; 工藤 正俊; 安藤 理奈; 田中 陽一; 森村正嗣; 由谷 逸朗; 辻 直子第66回日本消化器内視鏡学会総会  2003/10  大阪  第66回日本消化器内視鏡学会総会食道多発ヨード不染帯の臨床病理学的検討  [Not invited]辻 直子; 工藤 正俊; 田中 陽一; 森村 正嗣; 米田 円; 由谷 逸朗; 石黒 信吾第45回日本消化器病学大会  2003/10  大阪  第45回日本消化器病学大会Special Lecture "Present status of contrast-enahnced ultrasonography in the hepatobiliary and pancreatic diseases"  [Not invited]工藤 正俊5th International Symposium on Ultrasound Contrast Imaging  2003/10  Kyoto  5th International Symposium on Ultrasound Contrast ImagingSpecial Lecture "Characteristics of AFP-L3 % positive HCC in relation to HCC staging"  [Not invited]工藤 正俊Evening Session, Wako Meeting, 54th AASLD  2003/10  Sheraton Hotel, Boston  Evening Session, Wako Meeting, 54th AASLDInvited Lecture "Prevention of Recumbence after Curative Treatment by RFA for Hepatocellular Carcinoma "  [Not invited]工藤 正俊2003/10  University of Miami, FloridaInvited Lecture "New Prognostic Staging System for Hepatocellular Carcinoma, JIS Score"  [Not invited]工藤 正俊2003/10  University of Miami, Floridaアルコール多飲者に発生したヘルペス食道炎の1例  [Not invited]落合 健; 安藤 理奈; 田中 陽一; 森村 正嗣; 米田 円; 由谷 逸朗; 辻 直子; 工藤 正俊第71回日本消化器内視鏡学会近畿地方会  2003/10  第71回日本消化器内視鏡学会近畿地方会Changes of lens culinaris agglutinin-reactive alpha-fetoprotein (AFP-L3 fraction) after complete radiofrequency ablation for hepatocellular carcinoma: analysis of 186 patients  [Not invited]小川 力; 工藤 正俊; 南 康範; 鄭 浩柄; 中岡 良介; 松井 繁長; 福永 豊和; 北野 雅之; 川崎俊彦; 汐見幹夫The American Association for the Study of Liver Diseases (AASLD)  2003/10  Boston  The American Association for the Study of Liver Diseases (AASLD)Severe complications of radiofrequency ablation therapy for hepatocellular carcinoma: analysis of 3,891 ablation in 2,614 patients  [Not invited]春日井博志; 工藤 正俊; 大崎往夫; 岡 博子; 関 寿人The American Association for the Study of Liver Diseases (AASLD)  2003/10  Boston  The American Association for the Study of Liver Diseases (AASLD)A novel treatment technique for symptomatic huge liver cyst: intracystic injection therapy of monoethanolamine oleate in 12 cases with 15 liver cysts  [Not invited]中岡 良介; 工藤 正俊; 石川恵美; 松井 繁長; 福田信宏; 末冨洋一郎; 南 康範; 鄭 浩柄; 北野 雅之; 川崎俊彦; 汐見幹夫The American Association for the Study of Liver Diseases (AASLD)  2003/10  Boston  The American Association for the Study of Liver Diseases (AASLD)Comparison of posttreatment prognosis between ablation and resection for early-stage hepatocellular carcinoma: standardized analysis of 737 patients by stratification method based on JIS scoring system  [Not invited]工藤 正俊; 鄭 浩柄The American Association for the Study of Liver Diseases (AASLD)  2003/10  Boston  The American Association for the Study of Liver Diseases (AASLD)Validation study of the new prognostic staging system, the Japan integrated staging score (JIS score) for hepatocellular carcinoma in 3,934 Japanese patients: a multicenter collaborative study  [Not invited]工藤 正俊; 鄭 浩柄; 土師 誠二; 大崎往夫; 岡 博子; 春日井博志; 々木; 洋; 関 寿人The American Association for the Study of Liver Diseases (AASLD)  2003/10  Boston  The American Association for the Study of Liver Diseases (AASLD)Stratification abiliaty of the new prognostic staging system, Japan integrated staging score (JIS score) for hepatocellular carcinoma: comparison with CLIP score  [Not invited]鄭 浩柄; 工藤 正俊; 土師 誠二; 南 康範; 小川 力; 福永 豊和; 北野 雅之; 川崎俊彦; 大崎往夫The American Association for the Study of Liver Diseases (AASLD)  2003/10  Boston  The American Association for the Study of Liver Diseases (AASLD)超音波内視鏡ガイド下腹腔神経叢ブロックにおける穿刺部位確認の工夫. シンポジウム「超音波内視鏡の高度先進技術ー消化器腫瘍の診断と治療の新しい到達点ー」  [Not invited]北野 雅之; 工藤 正俊第45回日本消化器病学会大会, 第66回日本消化器内視鏡学会総会(DDW)  2003/10  大阪  第45回日本消化器病学会大会, 第66回日本消化器内視鏡学会総会(DDW)GISTに対する超音波内視鏡下診断の有用性について. シンポジウム「超音波内視鏡の高度先進技術ー消化器腫瘍の診断と治療の新しい到達点ー」  [Not invited]中岡 良介; 工藤 正俊; 北野 雅之第45回日本消化器病学会大会, 第66回日本消化器内視鏡学会総会(DDW)  2003/10  大阪  第45回日本消化器病学会大会, 第66回日本消化器内視鏡学会総会(DDW)GISTの基礎と臨床. ワークショップ7「Gastrointestinal stromal tumor (GIST)における造影ハーモニックイメージング法の意義および組織学的遺伝子学的診断との比較」  [Not invited]福田信宏; 工藤 正俊; 北野 雅之第45回日本消化器病学会大会  2003/10  大阪  第45回日本消化器病学会大会消化器疾患における造影エコー法の位置づけ. ワークショップ6「高分解能Bモード造影ハーモニック法による肝腫瘍の鑑別診断:肝細胞癌の分化度診断の試み」  [Not invited]川崎俊彦; 工藤 正俊; 鄭 浩柄第45回日本消化器病学会大会, 第7回日本肝臓学会大会(DDW)  2003/10  大阪  第45回日本消化器病学会大会, 第7回日本肝臓学会大会(DDW)肝癌に対する局所療法の長期予後-肝切除との比較-. ワークショップ1「統合Staging systemを用いた肝細胞癌に対する局所療法の長期予後」  [Not invited]鄭 浩柄; 工藤 正俊; 大崎往夫第45回日本消化器病学会大会, 第7回日本肝臓学会大会(DDW)  2003/10  大阪  第45回日本消化器病学会大会, 第7回日本肝臓学会大会(DDW)膵癌性疼痛に対する超音波内視鏡ガイド下腹腔神経叢ブロックの有用性. シンポジウム「消化器病における内視鏡診療の最前線」  [Not invited]北野 雅之; 工藤 正俊; 中岡 良介第71回日本消化器内視鏡学会近畿地方  2003/10  京都  第71回日本消化器内視鏡学会近畿地方ビルロートⅡ法再建後の輸入脚に発生したGISTの1例  [Not invited]渡邉 和彦; 水野 成人; 加藤 玲明; 南野 達夫; 小川 稔; 井上 雅智; 太田 善夫; 工藤 正俊第79回日本消化器病学会近畿支部例会  2003/09  奈良  第79回日本消化器病学会近畿支部例会膵管口からの乳頭プレカットの有用性  [Not invited]水野 成人; 加藤 玲明; 渡邉 和彦; 南野 達夫; 工藤 正俊; 吉岡 毅; 木本第39回日本胆道学会学術集会  2003/09  金沢  第39回日本胆道学会学術集会特別講演「腹部超音波造影診断-現状と次世代超音波造影剤の動向-」  [Not invited]工藤 正俊第8回関西超音波造影剤研究会  2003/09  ジブラルタ生命千里ホール, 大阪  第8回関西超音波造影剤研究会教育講演「消化器領域における造影エコー法:最近の進歩」  [Not invited]工藤 正俊日本超音波医学会第39回中国治療会第2回中国地方会講習会  2003/09  ウェルシティ島根, 島根  日本超音波医学会第39回中国治療会第2回中国地方会講習会特別講演「新しい肝細胞癌の臨床:ステージングシステム」  [Not invited]工藤 正俊第8回神戸肝臓疾患勉強会  2003/09  神戸  第8回神戸肝臓疾患勉強会A case of HBV liver cirrhosis with idiopathic thrombocytopenic purpura  [Not invited]田中 陽一; 落合 健; 森村 正嗣; 米田 円; 由谷 逸朗; 辻 直子; 工藤 正俊第79回日本消化器病学会近畿支部例会  2003/09  奈良  第79回日本消化器病学会近畿支部例会  ステロイドとラミブジンの併用療法でB型肝炎の急性増悪を緩解させることが出来た特発性血小板減少性紫斑病合併B型肝硬変の一例について報告した。Comparison of posttreatment prognosis between ablation and resection for early-stage hepatocellular carcinoma: standardized analysis of 737 patients by stratification method based of JIS Scoring system  [Not invited]工藤 正俊; 鄭 浩柄Single Topic Conference on HCC, American Association for the Study of Liver Diseases (AASLD)  2003/09  Atlanta  Single Topic Conference on HCC, American Association for the Study of Liver Diseases (AASLD)Validation study of the new prognostic staging, the Japan integrated staging score (JIS Score) for hepatocellular carcinoma in 3934 Japanese patients: a multicenter collaborative study  [Not invited]工藤 正俊; 鄭 浩柄Single Topic Conference on HCC, American Association for the Study of Liver Diseases (AASLD)  2003/09  Atlanta  Single Topic Conference on HCC, American Association for the Study of Liver Diseases (AASLD)Stratification ability of the new prognostic staging system, Japan Integrated Staging score (JIS Score) for hepatocellular carcinoma: comparison with CLIP score  [Not invited]工藤 正俊; 鄭 浩柄Single Topic Conference on HCC, American Association for the Study of Liver Diseases (AASLD)  2003/09  Atlanta  Single Topic Conference on HCC, American Association for the Study of Liver Diseases (AASLD)Hepatocellular carcinoma, surgical pathology and molecular biology. Symposium XII: GI-Liver Malignancies  [Not invited]林 祥剛; 工藤 正俊8th Asia Pacific Association of Societies of Pathologists Congress-2003  2003/09  Bali  8th Asia Pacific Association of Societies of Pathologists Congress-2003食道静脈瘤に対するアルゴンプラズマ凝固法による地固め療法の有用性. シンポジウム「エビデンスに基づいたアルゴンプラズマ凝固療法の適応と治療効果」  [Not invited]松井 繁長; 工藤 正俊; 中岡 良介第66回日本消化器内視鏡学会総会  2003/09  大阪  第66回日本消化器内視鏡学会総会HCCに対するRFA治療成績と基礎的検討に基づいた成績向上の試み. シンポジウム「消化器病治療の新たな展開ー基礎から臨床へー」  [Not invited]鄭 浩柄; 工藤 正俊; 南 康範第79回日本消化器病学会近畿支部例会  2003/09  奈良  第79回日本消化器病学会近畿支部例会肝細胞癌に対するラジオ波焼灼術後のインターフェロン長期少量投与の有用性について. シンポジウム「肝炎治療の最前線-肝硬変・肝癌はなくせるか?-」  [Not invited]坂口康浩; 工藤 正俊; 川崎俊彦第79回日本消化器病学会近畿支部例  2003/09  奈良  第79回日本消化器病学会近畿支部例特別講演「肝癌は克服できる-最新情報-」  [Not invited]工藤 正俊平成15年度日本肝臓学会主催. 肝がん撲滅運動市民公開講座  2003/08  SAYAKAホール, 大阪狭山市  平成15年度日本肝臓学会主催. 肝がん撲滅運動市民公開講座特別講演「肝細胞癌の診断と治療ー最近のトピックスー」  [Not invited]工藤 正俊第3回三重肝癌研究会  2003/08  ホテルグリーンパーク津, 三重  第3回三重肝癌研究会特別講演「肝癌治療標準化のためのclinical staging system-その重要性と新しいstaging system (JIS score)の意義-」  [Not invited]工藤 正俊第8回京都外科侵襲研究会  2003/08  京都センチュリーホテル, 京都  第8回京都外科侵襲研究会胆道出血を契機に診断した胆嚢癌の一例  [Not invited]水野 成人; 加藤 玲明; 渡邉 和彦; 南野 達夫; 井上 雅智; 工藤 正俊第39回奈良県消化器内視鏡研究会  2003/07  奈良  第39回奈良県消化器内視鏡研究会特別講演「肝疾患診療の最近の話題」  [Not invited]工藤 正俊第16回泉南消化器病研究会  2003/07  貝塚  第16回泉南消化器病研究会特別講演「造影USの最先端」  [Not invited]工藤 正俊第11回日本がん検診・診断学会  2003/07  日本大学会館, 東京  第11回日本がん検診・診断学会特別講演「肝細胞癌の診断と治療:最近の進歩」  [Not invited]工藤 正俊第25回奈良県肝・胆・膵研究会  2003/06  奈良市医師会館  第25回奈良県肝・胆・膵研究会特別講演「肝炎に対するインターフェロン治療と肝がんのラジオ波治療」  [Not invited]工藤 正俊2003/06  富田林市, 富田林内科医会講演「肝がんで命を落とさないコツ」  [Not invited]工藤 正俊日本肝臓学会主催 市民公開講座  2003/06  堺市民会館大ホール  日本肝臓学会主催 市民公開講座Radiofrequency ablation therapy under harmonic imaging guidance for the recurring cancer after local therapy for HCC: a randomized controlled study with RFA under B-mode guidance  [Not invited]工藤 正俊; 南 康範10th Congress of the World Federation for ultrasound in Medicine and Biology (WFUMB)  2003/06  Montreal, Canada  10th Congress of the World Federation for ultrasound in Medicine and Biology (WFUMB)HCCに対するRFA併用療法としてのLpTAEの有用性に関する検討. ワークショップ1 「肝細胞癌に対する手術療法、局所ablation療法の治療成績(生存率)ーTAEはどのような寄与をしているのかー」  [Not invited]鄭 浩柄; 工藤 正俊; 坂本洋城; 井上達夫; 小川 力; 梅原 泰; 坂口康浩; 福田信宏; 末冨洋一郎; 豊沢昌子; 石川恵美; 南 康範; 福永 豊和; 川崎俊彦第39回日本肝癌研究会  2003/06  金沢  第39回日本肝癌研究会血流動態より境界病変と考えられる硬変肝内微小結節性病変の予後. シンポジウム「肝硬変に伴う肝細胞性結節性病変の悪性度診断と生物学的予後」  [Not invited]福永 豊和; 工藤 正俊; 岡部純弘第39回日本肝癌研究会  2003/06  金沢  第39回日本肝癌研究会特別企画「示唆に富む肝結節病変の画像と病理」コメンテイター  [Not invited]工藤 正俊第39回日本肝臓学会総会  2003/05  福岡  第39回日本肝臓学会総会肝細胞癌の治療法の客観評価とその標準化ーJIS scoreとAFP-L3分画を用いてー. ランチョンセミナー「我が国のNASHを考えるー疾患概念と治療を中心にー」  [Not invited]工藤 正俊第39回日本肝臓学会総会  2003/05  福岡  第39回日本肝臓学会総会ランチョンセミナー「肝細胞癌の血流動態はどこまでわかったか?」  [Not invited]工藤 正俊第39回日本肝臓学会総会  2003/05  福岡  第39回日本肝臓学会総会Levovistおよび次世代造影エコー法の現状と展望. ランチョンセミナー「肝腫瘍の診断と治療の最先端ー肝血流評価とコントラストハーモニックエコー」  [Not invited]工藤 正俊日本超音波医学会第76回学術集会  2003/05  札幌  日本超音波医学会第76回学術集会Differential diagnosis of pancreatic diseases by contrast-enhanced power Doppler endosonography  [Not invited]北野 雅之; 工藤 正俊; 中岡 良介; 末冨洋一郎; 坂本洋城; 福田信宏; 松井 繁長; 汐見幹夫; 前川 清DDW (AASLD)  2003/05  Orland  DDW (AASLD)Radiofrequency ablation therapy for hepatocellular carcinoma located at subphrenic region: value of artificial pleural effusion combined with contrast-harmonic imaging  [Not invited]南 康範; 工藤 正俊; 鄭 浩柄; 小川 力; 福田信宏; 石川恵美; 中岡 良介; 松井 繁長; 北野 雅之; 末冨洋一郎; 川崎俊彦; 汐見幹夫DDW (AASLD)  2003/05  Orland  DDW (AASLD)Radiofrequency ablation therapy under contrast-enhanced harmonic imaging guidance for recurrence after local ablation therapy for hepatocellular carcinoma: a randomized controlled study  [Not invited]工藤 正俊; 南 康範; 鄭 浩柄; 小川 力; 福田信宏; 末冨洋一郎; 石川恵美; 中岡 良介; 松井 繁長; 北野 雅之; 川崎俊彦; 汐見幹夫DDW (AASLD)  2003/05  Orland  DDW (AASLD)Usefulness of mucosa-fibrosing therapy with argon plasma coagulation for esophageal varices  [Not invited]松井 繁長; 工藤 正俊; 北野 雅之; 中岡 良介; 汐見幹夫DDW (AASLD)  2003/05  Orland  DDW (AASLD)Esophagus with multiple small lugol's iodine-unstained lesions has high likelihood of developing multicentric esophageal squamous cell carcinoma  [Not invited]辻 直子; 工藤 正俊DDW (AASLD)  2003/05  Orland  DDW (AASLD)Usefulness of contrast-enhanced coded phase-inversion harmonic ultrasonography for differential diagnosis of pancreatic diseases and evaluation of chemotherapy  [Not invited]北野 雅之; 工藤 正俊; 末冨洋一郎; 前川 清; 坂本洋城; 中岡 良介; 川崎俊彦DDW (AASLD)  2003/05  Orland  DDW (AASLD)Evaluation of pancreatic microcirculation by contrast-enhanced endosonography in dogs  [Not invited]北野 雅之; 工藤 正俊; 前川 清; 坂本洋城; 南 康範; 中岡 良介; 宮本 清; 藤本 浩DDW (AASLD  2003/05  Orland  DDW (AASLDValidation and limitation of CLIP scoring system in 722 Japanses patients with hepatocellular carcinoma and a proposal of better prognostic staging system, Japan Integrated Staging Score (JIS score)  [Not invited]工藤 正俊; 鄭 浩柄; 南 康範; 小川 力; 福田信宏; 末冨洋一郎; 石川恵美; 中岡 良介; 松井 繁長; 北野 雅之; 川崎俊彦; 汐見幹夫DDW (AASLD)  2003/05  Orland  DDW (AASLD)Changes of lens culinaris agglutinin-reactive alpha-fetoprotein (AFP-L3 fraction) after complete response by radiofrequency ablation for hepatocellular carcinoma  [Not invited]小川 力; 工藤 正俊; 鄭 浩柄; 南 康範; 福田信宏; 末冨洋一郎; 石川恵美; 中岡 良介; 松井 繁長; 北野 雅之; 川崎俊彦; 汐見幹夫DDW (AASLD) (Topic Forum-oral)  2003/05  Orland  DDW (AASLD) (Topic Forum-oral)統合staging systemによる肝細胞癌の治療法の選択: CLIP scoreとJIS scoreの比較. パネルディスカッション「肝細胞癌の診断・治療の今後の展開」  [Not invited]鄭 浩柄; 工藤 正俊第39回日本肝臓学会総会  2003/05  福岡  第39回日本肝臓学会総会Levovistおよび次世代造影エコー法の現状と展望. ランチョンセミナー「肝腫瘍の診断と治療の最先端ー肝血流評価とコントラストハーモニックエコー」  [Not invited]工藤 正俊日本超音波医学会第76回学術集会  2003/05  札幌  日本超音波医学会第76回学術集会肝細胞癌局所再発に対する造影超音波ガイド下ラジオ波焼灼術. シンポジウム「肝癌診療における超音波の新潮流」  [Not invited]南 康範; 工藤 正俊日本超音波学会 第76回学術集会  2003/05  札幌  日本超音波学会 第76回学術集会Evaluation of vascularity in the Primary Gastric Cancer using Color Doppler Imaging  [Not invited]日本超音波医学会第76回学術集会  2003/05  札幌  日本超音波医学会第76回学術集会  従来、胃癌の原発巣内の血流は低下している例が多いと考えられてきた。今回、進行胃癌64例の原発巣内の血流を対外式超音波にて観察し、病理学的所見とも対比した結果、むしろ血流の増加している症例のほうが多いことが示された。Evaluation of hemodynamics at the superficial region the liver using YM454 Contrast-enhanced ultrasonopraphy: Basic study using dog liver  [Not invited]日本超音波医学会第76回学術集会  2003/05  札幌  日本超音波医学会第76回学術集会  新しい造影剤perfluoropropaneを主成分とした低音圧系造影剤YM454を用いて肝臓の表面浅深部領域の造影能評価を小型犬の肝臓を用いて検討し、10~20μl/kgの経静脈的注入で充分な造影像を示し、TICも良好で臨床応用が可能と考え報告した。造影超音波を用いた各種肝疾患における血流動態の評価  [Not invited]坂口 康浩; 工藤 正俊; 豊澤 昌子; 石川 恵美; 坂本 洋城; 井上 達夫; 小川 力; 福田 信宏; 末冨 洋一郎; 南 康範; 鄭 浩柄; 中岡 良介; 松井 繁長; 北野 雅之; 川崎 俊彦; 汐見 幹夫第89回日本消化器病学会総会  2003/04  埼玉  第89回日本消化器病学会総会CHA (Coded Harmonic Angio)モードを用いた胆嚢隆起性病変の造影ハーモニック像の検討  [Not invited]井上 達夫; 工藤 正俊; 小川 力; 坂口 康浩; 坂本 洋城; 福田 信宏; 末冨 洋一郎; 南 康範; 石川 恵美; 中岡 良介; 鄭 浩柄; 松井 繁長; 北野 雅之; 川崎 俊彦; 汐見 幹夫; 前川 清第89回日本消化器病学会総会  2003/04  埼玉  第89回日本消化器病学会総会肝細胞癌に対する新しい統合ステージングシステムの提唱  [Not invited]鄭 浩柄; 工藤 正俊第8回南大阪肝胆膵懇話会  2003/04  近畿大学  第8回南大阪肝胆膵懇話会造影超音波検査による膵癌の血行動態評価ー鑑別およびGemcitabineの治療効果判定における有用性ー  [Not invited]坂本 洋城; 工藤 正俊; 北野 雅之; 前川 清; 中岡 良介; 井上 達夫; 福田 信宏; 末冨 洋一郎第14回日本腹部造影エコー・ドプラ診断研究会  2003/04  名古屋  第14回日本腹部造影エコー・ドプラ診断研究会教育講演「肝細胞癌の治療: EBMに基づいた体系の確立」  [Not invited]工藤 正俊第89回日本消化器病学会総会  2003/04  ポストグラデュエイトコース, 埼玉  第89回日本消化器病学会総会特別講演「肝細胞癌の診断と治療: 最近の進歩」  [Not invited]工藤 正俊神戸大学大学院特別講演  2003/04  神戸  神戸大学大学院特別講演特別講演「肝細胞癌の診断と治療: 最近のトピックス」  [Not invited]工藤 正俊第6回京都消化器セミナー  2003/04  京都大学  第6回京都消化器セミナー肝細胞癌の統合Staging systemによる治療法の客観的評価: CLIP scoreとJIS scoreを用いた検討. パネルディスカッション「肝細胞癌の治療:EBMに基づいた体系の確立」  [Not invited]鄭 浩柄; 工藤 正俊; 大崎往夫第89回日本消化器病学会総会  2003/04  埼玉  第89回日本消化器病学会総会超音波血流画像による肝腫瘍の病態評価. シンポジウム「形態と機能の統合」  [Not invited]工藤 正俊第62回日本医学放射線学会学術発表会  2003/04  横浜  第62回日本医学放射線学会学術発表会憩室内乳頭の総胆管再発巨大結石に対して乳頭切開、砕石術にて排石し得た一症例  [Not invited]吉本 理恵; 工藤 正俊; 汐見 幹夫; 野田 佳寿; 信夫 清; 石川 恵美; 坂本 洋城; 井上 達夫; 小川 力; 坂口 康浩; 福田 信宏; 末冨 洋一郎; 南 康範; 鄭 浩柄; 中岡 良介; 松井 繁長; 北野 雅之; 川崎 俊彦第70回日本消化器内視鏡学会近畿地方会  2003/03  阿倍野  第70回日本消化器内視鏡学会近畿地方会超音波内視鏡下穿刺生検が診断に有用であった十二指腸GISTの1症例  [Not invited]北井 聡; 工藤 正俊; 石川 恵美; 北野 雅之; 豊澤 昌子; 坂本 洋城; 坂口 康浩; 井上 達夫; 小川 力; 福田 信宏; 末冨 洋一郎; 吉本 理恵; 信夫 清; 南 康範; 鄭 浩柄; 中岡 良介; 松井 繁長; 川崎 俊彦; 汐見 幹夫第70回日本消化器内視鏡学会近畿地方会  2003/03  阿倍野  第70回日本消化器内視鏡学会近畿地方会GAVEに対するAPCの検討  [Not invited]宮部 欽生; 工藤 正俊; 松井 繁長; 信夫 清; 石川 恵美; 坂本 洋城; 福田 信宏; 末冨 洋一郎; 吉本 理恵; 鄭 浩柄; 中岡 良介; 北野 雅之; 川崎 俊彦; 汐見 幹夫第70回日本消化器内視鏡学会近畿地方会  2003/03  阿倍野  第70回日本消化器内視鏡学会近畿地方会特別講演「YM454の使用経験と今後の展望」  [Not invited]工藤 正俊第14回超音波ドプラ研究会  2003/03  野口英世記念会館, 東京  第14回超音波ドプラ研究会Serrated Adenomatous Polyposisの1例  [Not invited]安藤 理奈; 工藤 正俊; 田中 陽一; 森村 正嗣; 米田 円; 由谷 逸朗; 辻 直子第70回日本消化器内視鏡学会近畿地方会  2003/03  大阪  第70回日本消化器内視鏡学会近畿地方会Invited Lecture "Clinical usefulness of new contrast agent, Definity."  [Not invited]工藤 正俊International Symposium of New Advances in Mediical Ultrasound  2003/03  Guang Zhou, China  International Symposium of New Advances in Mediical UltrasoundInvited Lecture "Application of contrast harmonic imaging to the treatment of hepatocellular carcinoma."  [Not invited]工藤 正俊International Symposium of New Advances in Mediical Ultrasound  2003/03  Guang Zhou, China  International Symposium of New Advances in Mediical UltrasoundInvited Lecture "Characterization of hepatic tumors by contrast-enhanced harmonic imaging."  [Not invited]工藤 正俊International Symposium of New Advances in Mediical Ultrasound  2003/03  Guang Zhou, China  International Symposium of New Advances in Mediical Ultrasound肝臓における臨床的有用性についてーVascular Phaseを中心にー  [Not invited]南 康範; 工藤 正俊GE Ultrasound Advanced Symposium 2003  2003/02  GE Ultrasound Advanced Symposium 2003早期胆嚢癌を合併した非拡張型膵胆管合流異常症の一例  [Not invited]田中 陽一; 工藤 正俊; 森村 正嗣; 米田 円; 由谷 逸朗; 辻 直子第78回日本消化器病学会近畿支部例会  2003/02  神戸  第78回日本消化器病学会近畿支部例会2本の太い流出路をもつため、B-RTOが困難であった巨大静脈瘤の一例  [Not invited]朝隈 豊; 工藤 正俊; 川崎俊彦; 坂本洋城; 梅原 泰; 小川 力; 野田佳寿; 福田信宏; 末冨洋一郎; 南 康範; 石川恵美; 鄭 浩柄; 中岡 良介; 松井 繁長; 北野 雅之; 汐見幹夫第78回日本消化器病学会近畿支部例会  2003/02  神戸  第78回日本消化器病学会近畿支部例会超音波検査にて後腹膜神経原性腫瘍が疑われた一症例  [Not invited]前野知子; 工藤 正俊; 桑口 愛; 江口真由美; 前川 清; 川崎俊彦日本超音波医学会第25回関西地方会  2003/02  大阪  日本超音波医学会第25回関西地方会嚢胞内出血を造影エコー法にて診断し得た腎盂腸管瘻合併多発性嚢胞腎の一例  [Not invited]冨田崇文; 工藤 正俊; 石川恵美; 汐見幹夫; 川崎俊彦; 北野 雅之; 松井 繁長; 前川 清日本超音波医学会第25回関西地方会  2003/02  大阪  日本超音波医学会第25回関西地方会超音波内視鏡下穿刺吸引組織診(EUS-FNAB)が診断に有用であった膵ソマトスタチノーマの一例  [Not invited]野田佳寿; 工藤 正俊; 末冨洋一郎; 宮部欽生; 前川 清; 南 康範; 中岡 良介; 北野 雅之; 川崎俊彦; 汐見幹夫; 保田 知生; 大柳 治正日本超音波医学会第25回関西地方会  2003/02  大阪  日本超音波医学会第25回関西地方会特別講演「肝細胞癌診療の最近のトピックス」肝炎セミナー~肝炎・肝癌の現状と今後~  [Not invited]工藤 正俊2003/02  岡山特別講演「治療効果判定と造影ハーモニックガイド下RFA」  [Not invited]工藤 正俊朝日サイエンスセミナー  2003/02  京都  朝日サイエンスセミナー特別講演「肝細胞癌の早期診断」  [Not invited]工藤 正俊平成14年度厚生労働科学研究費肝炎等克服緊急対策研究公開報告会  2003/02  経団連会館, 東京  平成14年度厚生労働科学研究費肝炎等克服緊急対策研究公開報告会特別講演「経皮的ラジオ波焼灼療法(RFA)の現状と展望」  [Not invited]工藤 正俊朝日サイエンスセミナー  2003/02  京都  朝日サイエンスセミナー特別講演「日本における肝癌の早期診断」  [Not invited]工藤 正俊第1回肝癌撲滅アジアフォーラム  2003/02  久留米  第1回肝癌撲滅アジアフォーラム特別講演「肝癌の診断と治療」  [Not invited]工藤 正俊大阪府医師会医学会平成14年度セミナー形式による研修会  2003/02  大阪  大阪府医師会医学会平成14年度セミナー形式による研修会  特別講演「肝癌の診断と治療」特別講演「肝細胞癌の血流動態」  [Not invited]工藤 正俊第9回肝血流動態イメージ研究会  2003/02  東商ホール, 東京  第9回肝血流動態イメージ研究会A suspected case of Retroperitoneal neuogenic tumor by ultrasound  [Not invited]日本超音波医学会第25回関西地方会  2003/02  大阪  日本超音波医学会第25回関西地方会  良性の後腹膜神経鞘腫の1症例を経験した。超音波BモードとTHIはMRI、T1強調画像と酷似した像を示した。また、レボビスト造影超音波は造影CTとおなじ染影動態を示した。今後、超音波検査が神経鞘腫の鑑別に有用となり得ると考える。教育講演「肝癌診療の最新情報(画像診断のこつ)」  [Not invited]工藤 正俊第37回日本成人病(生活習慣病)学会  2003/01  日本都市センター, 東京  第37回日本成人病(生活習慣病)学会Special Lecture "Diagnosis of early, small hepatocellular carcinoma"  [Not invited]工藤 正俊U.S. - Japan Cooperative Medical Sciences Program Joint Annual Meeting of the Hepatitis Panel  2003/01  Diamond Hotel, Tokyo  U.S. - Japan Cooperative Medical Sciences Program Joint Annual Meeting of the Hepatitis Panel難治性C型慢性肝炎(Ib型, 高ウイルス例)に対するIFNα2b+リバビリン併用療法の効果  [Not invited]石川恵美; 工藤 正俊; 福田信宏; 末冨洋一郎; 鄭 浩柄; 南 康範; 中岡 良介; 松井 繁長; 北野 雅之; 川崎俊彦; 汐見幹夫第14回南大阪肝胆膵研究会  2002/12  リーガロイヤル堺  第14回南大阪肝胆膵研究会EISLにて止血し得た十二指腸静脈瘤の1例  [Not invited]松井 繁長; 工藤 正俊; 福田信宏; 末冨洋一郎; 鄭 浩柄; 南 康範; 中岡 良介; 北野 雅之; 川崎俊彦; 汐見幹夫第5回南大阪肝胆膵懇話会  2002/11  大阪狭山  第5回南大阪肝胆膵懇話会当院における経皮的ラジオ波焼灼術の合併症  [Not invited]鄭 浩柄; 工藤 正俊; 豊澤 昌子; 石川恵美; 坂本洋城; 小川 力; 坂口康浩; 井上達夫; 福田信宏; 末冨洋一郎; 南 康範; 中岡 良介; 松井 繁長; 北野 雅之; 川崎俊彦; 汐見幹夫第35回大阪肝穿刺生検治療研究会  2002/11  大阪  第35回大阪肝穿刺生検治療研究会EUSガイド下腹腔神経叢ブロックでコントロールし得た眼精疼痛の1例  [Not invited]福田信宏; 工藤 正俊; 末冨洋一郎; 中岡 良介; 前川 清; 坂本洋城; 石川恵美; 小川 力; 南 康範; 鄭 浩柄; 松井 繁長; 北野 雅之; 川崎俊彦; 汐見幹夫第143回大阪腹部超音波研究会  2002/11  大阪  第143回大阪腹部超音波研究会EUS-FNAが治療方針決定に有用であった進行性膵悪性腫瘍の1例  [Not invited]宮部欽生; 工藤 正俊; 末冨洋一郎; 中岡 良介; 福田信宏; 前川 清; 坂本洋城; 石川恵美; 小川 力; 南 康範; 鄭 浩柄; 松井 繁長; 北野 雅之; 川崎俊彦; 汐見幹夫第143回大阪腹部超音波研究会  2002/11  大阪  第143回大阪腹部超音波研究会特別講演「肝細胞癌の診断と治療-最近の進歩-」  [Not invited]工藤 正俊第97回日本消化器病学科東海支部例会  2002/11  名古屋  第97回日本消化器病学科東海支部例会特別講演「消化器疾患診療の最近の話題」  [Not invited]工藤 正俊第143回青森消化器疾患セミナー  2002/11  青森  第143回青森消化器疾患セミナー特別講演「肝細胞癌の診断と治療ー最近の進歩ー」  [Not invited]工藤 正俊消化器病センターセミナー  2002/11  昭和大学横浜市北部医療センター, 横浜市  消化器病センターセミナー当院におけるアンケート結果から省みた前処置対策  [Not invited]米田 円; 工藤 正俊; 田中 陽一; 森村 正嗣; 由谷 逸朗; 辻 直子第2回南大阪大腸内視鏡研究会  2002/11  大阪  第2回南大阪大腸内視鏡研究会Special Lecture "Pancreatic Diseases "  [Not invited]工藤 正俊AFSUMB ULTRSOUND COURSES 2002  2002/11  Phnom Penh, Cambodia  AFSUMB ULTRSOUND COURSES 2002Special Lecture "Malignant Focal Liver Lesions "  [Not invited]工藤 正俊AFSUMB ULTRSOUND COURSES 2002  2002/11  Phnom Penh, Cambodia  AFSUMB ULTRSOUND COURSES 2002Special Lecture "Diffuse Liver Disease "  [Not invited]工藤 正俊AFSUMB ULTRSOUND COURSES 2002  2002/11  Phnom Penh, Cambodia  AFSUMB ULTRSOUND COURSES 2002Special Lecture "Benign Focal Liver Lesions "  [Not invited]工藤 正俊AFSUMB ULTRSOUND COURSES 2002  2002/11  Phnom Penh, Cambodia  AFSUMB ULTRSOUND COURSES 2002Special Lecture "Liver Cancer in Japan; Advances of Imaging Diagnosis"  [Not invited]工藤 正俊4th Korea-Japan Medical symposium  2002/11  Kobe International Conference Center, Kobe  4th Korea-Japan Medical symposiumSpecial Lecture "AFP-L3 Fraction in the Evaluation of Treatment Respoce for Hepatocellular Carcinoma"  [Not invited]工藤 正俊53th American Association of Study of the Liver  2002/11  Boston, MA, USA  53th American Association of Study of the Liverシンポジウム「US(腫瘍のUSによる治療効果予測・効果判定)」: 肝癌の治療効果判定-ラジオ波治療効果-  [Not invited]南 康範; 工藤 正俊第31回断層映像研究会  2002/11  高知  第31回断層映像研究会Enhanced ultrasonography used Levovist in liver hemangioma  [Not invited]第10回画論  2002/11  東京  第10回画論  肝左葉を占拠する病変に対しレボビストを用いて造影超音波を行った結果、綿花上濃染像が得られ、肝血管腫が同定できた症例を第10回画論にて発表し、超音波検査部門の最優秀賞を受賞した。超音波内視鏡ガイド下腹腔神経叢ブロックが著効を示した膵癌性疼痛の1例  [Not invited]北野 雅之; 工藤 正俊; 末冨洋一郎; 中岡 良介; 福田信宏; 前川 清; 坂本洋城; 石川恵美; 小川 力; 南 康範; 鄭 浩柄; 松井 繁長; 川崎俊彦; 汐見幹夫第64回日本消化器内視鏡学会附置研究会, 第1回EUS-FNAの臨床応用に関する研究会  2002/10  横浜  第64回日本消化器内視鏡学会附置研究会, 第1回EUS-FNAの臨床応用に関する研究会超音波内視鏡下穿刺生検が有用であった進行膵悪性腫瘍の1例  [Not invited]中岡 良介; 工藤 正俊; 南 康範; 福田信宏; 末冨洋一郎; 北野 雅之; 汐見幹夫; 白石 治; 中居 卓也; 塩崎 均第64回日本消化器内視鏡学会附置研究会, 第1回EUS-FNAの臨床応用に関する研究会  2002/10  横浜  第64回日本消化器内視鏡学会附置研究会, 第1回EUS-FNAの臨床応用に関する研究会B-modeにて同定困難な症例における超音波造影下治療の検討  [Not invited]南 康範; 工藤 正俊; 鄭 浩柄; 川崎俊彦第6回日本肝臓学会大会(DDW-Japan)  2002/10  横浜  第6回日本肝臓学会大会(DDW-Japan)肝細胞癌に対するRFA問題点とその対策  [Not invited]鄭 浩柄; 工藤 正俊; 小川 力; 南 康範; 川崎俊彦第6回日本肝臓学会大会(DDW-Japan)  2002/10  横浜  第6回日本肝臓学会大会(DDW-Japan)肝細胞癌に対するRFA治療後の再発とAFP-L3分画の相関関係について  [Not invited]小川 力; 工藤 正俊; 市川 勉; 乾 絹世; 岡田 無文; 北口 容子; 豊澤 昌子; 石川 恵美; 福田 信宏; 末冨 洋一郎; 南 康範; 中岡 良介; 鄭 浩柄; 遠田 弘一; 松井 繁長; 由谷 逸朗; 北野 雅之; 川崎 俊彦; 汐見 幹夫第6回日本肝臓学会大会(DDW-Japan)  2002/10  横浜  第6回日本肝臓学会大会(DDW-Japan)胃幽門部癌性狭窄に対するステント治療とバイパス手術の比較検討  [Not invited]田中 陽一; 工藤 正俊; 森村 正嗣; 米田 円; 由谷 逸朗; 辻 直子第64回日本消化器内視鏡学会総会  2002/10  横浜  第64回日本消化器内視鏡学会総会食道静脈瘤に対するEISL後の地固め療法の検討ーASとAPCの比較ー  [Not invited]松井 繁長; 工藤 正俊; 中岡 良介; 石川 恵美; 福田 信宏; 末冨 洋一郎; 鄭 浩柄; 北野 雅之; 川崎 俊彦; 汐見 幹夫第64回日本消化器内視鏡学会総会  2002/10  横浜  第64回日本消化器内視鏡学会総会造影パワードプラEUSによる膵腫瘍性病変の診断; 体外式造影超音波および造影CT検査との比較  [Not invited]北野 雅之; 工藤 正俊; 末冨 洋一郎; 中岡 良介; 福田 信宏; 松井 繁長; 南 康範; 鄭 浩柄; 川崎 俊彦; 汐見 幹夫第64回日本消化器内視鏡学会総会  2002/10  横浜  第64回日本消化器内視鏡学会総会造影ハーモニックイメージングによる膵癌におけるGemcitabineの治療効果判定ー造影ハーモニックイメージングの意義ー  [Not invited]末冨 洋一郎; 工藤 正俊第44回日本消化器病学会大会(DDW-Japan)  2002/10  横浜  第44回日本消化器病学会大会(DDW-Japan)肝細胞癌に対しLp-TAE後に急性閉塞性化膿性胆管炎を発症した1例  [Not invited]坂本 洋城; 工藤 正俊; 鄭 浩柄; 豊澤 昌子; 石川 恵美; 小川 力; 福田 信宏; 南 康範; 末冨 洋一郎; 中岡 良介; 松井 繁長; 北野 雅之; 川崎 俊彦; 汐見 幹夫第69回日本消化器内視鏡学会近畿地方会  2002/10  大阪  第69回日本消化器内視鏡学会近畿地方会超音波内視鏡ガイド下腹腔内神経叢ブロックが著効を示した膵癌性疼痛の1例  [Not invited]福田 信宏; 工藤 正俊; 北野 雅之; 前川 清; 豊澤 昌子; 石川 恵美; 小川 力; 末冨 洋一郎; 南 康範; 中岡 良介; 鄭 浩柄; 松井 繁長; 川崎 俊彦; 汐見 幹夫第69回日本消化器内視鏡学会近畿地方会  2002/10  大阪  第69回日本消化器内視鏡学会近畿地方会膵腫瘍における造影エコー法の意義  [Not invited]北野 雅之; 工藤 正俊岡山近畿消化器画像診断研究会  2002/10  リーガロイヤルホテル堺, 大阪  岡山近畿消化器画像診断研究会造影ハーモニック法の治療への応用ー治療効果判定と泉誌  [Not invited]南 康範; 工藤 正俊岡山近畿消化器画像診断研究会  2002/10  リーガロイヤルホテル堺, 大阪  岡山近畿消化器画像診断研究会Pulse Subtraction法による肝腫瘍の診断  [Not invited]鄭 浩柄; 工藤 正俊岡山近畿消化器画像診断研究会  2002/10  リーガロイヤルホテル堺, 大阪  岡山近畿消化器画像診断研究会特別講演「肝細胞癌の診断と治療-最近の進歩-」  [Not invited]工藤 正俊第1回肝疾患診療の最前線  2002/10  大阪, ホテルグランヴィア大阪  第1回肝疾患診療の最前線特別講演「肝・胆・膵疾患の造影エコー法の進歩」  [Not invited]工藤 正俊第13回日本腹部造影エコー・ドプラ診断研究会( JACUA),  2002/10  レ・ルミエール, 大阪  第13回日本腹部造影エコー・ドプラ診断研究会( JACUA),ランチョンセミナー「RFA治療と超音波造影剤による効果判定」  [Not invited]工藤 正俊第44回日本消化器病学会(DDW-Japan)  2002/10  横浜  第44回日本消化器病学会(DDW-Japan)ブレックファーストセミナー「RFAによる肝癌治療の今後の展開」  [Not invited]工藤 正俊第6回日本肝臓学会大会(DDW-Japan)  2002/10  横浜  第6回日本肝臓学会大会(DDW-Japan)基調講演「消化器造影エコー診断の現況と展望」  [Not invited]工藤 正俊第44回日本消化器病学会(DDW-Japan)  2002/10  横浜  第44回日本消化器病学会(DDW-Japan)ランチョンセミナー「肝腫瘍における超音波造影法の現状と展望」  [Not invited]工藤 正俊第40回日本癌治療学会総会  2002/10  東京国際フォーラム, 東京  第40回日本癌治療学会総会特別講演「肝癌における効率的局所治療のストラテジー -造影超音波併用の与えるインパクト-」  [Not invited]工藤 正俊腹部造影エコー学術講演会  2002/10  愛知医科大学 本館3F, 愛知  腹部造影エコー学術講演会ハンズオンレクチャー「造影エコーの基本手技」  [Not invited]工藤 正俊愛知医科大学  2002/10  愛知  愛知医科大学特別講演「発癌の血流と病態」  [Not invited]工藤 正俊第2回肝臓フォーラム  2002/10  千里ライフサイエンスセンター, 大阪  第2回肝臓フォーラム大腸腫瘍における間質反応,特に筋線維芽細胞の形態変化についての病理組織学的検討  [Not invited]米田 円; 工藤 正俊; 田中 陽一; 森村正嗣; 由谷 逸朗; 辻 直子第44回日本消化器病学会総会  2002/10  横浜  第44回日本消化器病学会総会接合部腺癌および食道非腺癌における背景粘膜のSSBEと食道胃接合部の病理  [Not invited]辻 直子; 工藤 正俊; 石黒 信吾第64回日消化器内視鏡学会総会  2002/10  横浜  第64回日消化器内視鏡学会総会Special Lecture "Contrast harmonic imaging in the characterization of hepatic tumors"  [Not invited]工藤 正俊Chinese Taipei Society of Ultrasound in Medicine  2002/10  Taipei, Taiwan  Chinese Taipei Society of Ultrasound in MedicineSpecial Lecture "Radofrequency ablation for HCC under contrast-harmonic imaging guidance"  [Not invited]工藤 正俊Chinese Taipei Society of Ultrasound in Medicine  2002/10  Taipei, Taiwan  Chinese Taipei Society of Ultrasound in MedicineComparision of stenting and bypass surgery for unresectable advanced gastric canser with pyloric stenosis  [Not invited]田中 陽一; 森村 正嗣; 米田 円; 由谷 逸朗; 辻 直子; 工藤 正俊第64回日本消化器内視鏡学会総会  2002/10  横浜  第64回日本消化器内視鏡学会総会  胃幽門部狭窄に対してステント治療とバイパス手術を行い、食事開始時期、在院日数、在宅日数などにつき比較検討を行った。Contrast-enhanced power Doppler endoscopic ultrasound in pancreatic diseases: comparison with contrast-enhanced extracorporal harmonic ultrasound and computed tomography  [Not invited]北野 雅之; 工藤 正俊; 中岡 良介; 末冨洋一郎; 汐見幹夫; 福田信宏; 松井 繁長; 川崎俊彦; 前川 清13th International Symposium on Endoscopic Ultrasonography  2002/10  New York  13th International Symposium on Endoscopic UltrasonographyGastrointestinal mesenchymal tumor (GIMT)における体表式造影ハーモニックイメージング法および超音波内視鏡下造影法の有用性. (ワークショップ「消化器疾患における造影エコーup to date」)  [Not invited]福田信宏; 工藤 正俊; 北野 雅之第44回日本消化器病学会大会  2002/10  横浜  第44回日本消化器病学会大会人工胸水下造影超併用RFAの有用性. (ワークショップ「消化器疾患における造影エコーup to date」)  [Not invited]南 康範; 工藤 正俊; 川崎俊彦第44回日本消化器病学会大会  2002/10  横浜  第44回日本消化器病学会大会シンポジウムII「内視鏡診断・治療における新しい展開(肝胆膵)」膵腫瘍におけるEUS下造影、穿刺生検および穿刺治療の有用性  [Not invited]末冨洋一郎; 工藤 正俊; 北野 雅之第69回日本消化器内視鏡学会近畿地方会  2002/10  大阪  第69回日本消化器内視鏡学会近畿地方会シンポジウムI「内視鏡診断・治療における新しい展開(消化管)」食道静脈瘤に対するアルゴンプラズマ凝固法(APC)の有用性  [Not invited]松井 繁長; 工藤 正俊; 中岡 良介第69回日本消化器内視鏡学会近畿地方会  2002/10  大阪  第69回日本消化器内視鏡学会近畿地方会急性肝炎様症状で発症した肝脾型悪性リンパ腫の一例  [Not invited]田中 陽一; 工藤 正俊; 森村 正嗣; 米田 円; 由谷 逸朗; 辻 直子第77回日本消化器病学会近畿支部例会  2002/09  平成14年9月7日, 京都  第77回日本消化器病学会近畿支部例会肝内巨大P-Vシャントに合併した肝FNH様病変の一例  [Not invited]坂口 康浩; 工藤 正俊; 松井 繁長; 坂本 洋城; 井上 達夫; 小川 力; 福田 信宏; 末冨 洋一郎; 南 康範; 中岡 良介; 鄭 浩柄; 北野 雅之; 石川 恵美; 川崎 俊彦; 汐見 幹夫第77回日本消化器病学会近畿支部例会  2002/09  京都  第77回日本消化器病学会近畿支部例会超音波内視鏡下穿刺が有用であった膵endocrine cell tumorの一例  [Not invited]宮部 鉄生; 工藤 正俊; 中岡 良介; 野田 佳寿; 坂本 洋城; 南 康範; 福田 信宏; 末冨 洋一郎; 鄭 浩柄; 松井 繁長; 北野 雅之; 川崎 俊彦; 汐見 幹夫; 塩崎 均第77回日本消化器病学会近畿支部例会  2002/09  京都  第77回日本消化器病学会近畿支部例会胆嚢癌との鑑別が困難であった、CA19-9が著明高値を呈した、腹腔内膿瘍を合併した、急性胆嚢炎の一例  [Not invited]井上 達夫; 工藤 正俊; 北口 容子; 坂本 洋城; 豊澤 昌子; 中尾 隆美; 石川 恵美; 坂口 康浩; 小川 力; 福田 信宏; 末冨 洋一郎; 南 康範; 鄭 浩柄; 中岡 良介; 松井 繁長; 北野 雅之; 川崎 俊彦; 汐見 幹夫第77回日本消化器病学会近畿支部例会  2002/09  京都  第77回日本消化器病学会近畿支部例会体表式造影超音波法が術前診断に有用であった小腸GISTの2例  [Not invited]福田 信宏; 工藤 正俊; 北野 雅之; 石川 恵美; 坂本 洋城; 井上 達夫; 小川 力; 坂口 康浩; 末冨 洋一郎; 南 康範; 中岡 良介; 鄭 浩柄; 松井 繁長; 川崎 俊彦; 汐見 幹夫; 前川 清第77回日本消化器病学会近畿支部例会  2002/09  京都  第77回日本消化器病学会近畿支部例会腹腔内および右肩に認めた巨大脂肪腫の一例  [Not invited]坂本 洋城; 工藤 正俊; 川崎 俊彦; 豊澤 昌子; 石川 恵美; 坂口 康浩; 小川 力; 井上 達夫; 福田 信宏; 末冨 洋一郎; 南 康範; 鄭 浩柄; 中岡 良介; 松井 繁長; 北野 雅之; 汐見 幹夫第77回日本消化器病学会近畿支部例会  2002/09  京都  第77回日本消化器病学会近畿支部例会特別講演「肝画像診断のトピックスー造影エコーを中心にー」  [Not invited]工藤 正俊第7回神戸管と肝研究会  2002/09  生田神社会館, 神戸  第7回神戸管と肝研究会特別講演「超音波血流画像による肝腫瘍の鑑別と癌局所療法への応用」  [Not invited]工藤 正俊第13回播州肝・胆・膵・消化器癌勉強会  2002/09  ホテルサンガーデン姫路, 姫路  第13回播州肝・胆・膵・消化器癌勉強会ランチョンセミナー「肝腫瘍の超音波血流画像と治療への応用」  [Not invited]工藤 正俊第37回日本消化器画像診断研究会  2002/09  愛知県がんセンター国際交流センター, 名古屋  第37回日本消化器画像診断研究会特別講演「肝細胞癌に対するRFA治療と今後の肝癌治療の展望」  [Not invited]工藤 正俊秋田県肝・胆道癌研究会  2002/09  秋田  秋田県肝・胆道癌研究会特別講演「超音波血流画像による肝腫瘍の診断と治療への応用」  [Not invited]工藤 正俊西神・播磨消化器懇話会  2002/09  神戸  西神・播磨消化器懇話会B modeで同定困難な肝細胞癌に対する造影超音波ガイドでのRFAの検討(シンポジウム「診断と治療の最前線ー肝細胞癌」)  [Not invited]南 康範; 工藤 正俊; 川崎俊彦第77回日本消化器病学会近畿支部例会  2002/09  京都  第77回日本消化器病学会近畿支部例会CHA (Coded Harmonic Angio)モードを用いた造影ハーモニックイメージングによる膵腫瘍性病変の診断  [Not invited]北野 雅之; 工藤 正俊; 前川 清; 末冨 洋一郎; 中岡 良介第33回日本膵臓学会大会  2002/08  仙台  第33回日本膵臓学会大会興味あるレボビスト造影像を呈した小腸原発悪性リンパ腫の1例  [Not invited]石川 恵美; 工藤 正俊; 汐見 幹夫; 川崎 俊彦; 北野 雅之; 松井 繁長; 中岡 良介; 鄭 浩柄; 南 康範; 末冨 洋一郎; 福田 信宏; 小川 力; 前川 清日本超音波医学会第24回関西地方会  2002/08  奈良  日本超音波医学会第24回関西地方会興味ある血行動態を示した転移性肝癌のレボビスト造影  [Not invited]小川 力; 工藤 正俊; 豊澤 昌子; 石川 恵美; 坂本 洋城; 井上 達夫; 坂口 康浩; 福田 信宏; 末冨 洋一郎; 南 康範; 鄭 浩柄; 中岡 良介; 松井 繁長; 北野 雅之; 川崎 俊彦; 汐見 幹夫; 前川 清日本超音波医学会第24回関西地方会  2002/08  奈良  日本超音波医学会第24回関西地方会体表式造影エコーおよびEUS造影エコーが診断に有用であった膵臓癌の一例  [Not invited]井上 達夫; 工藤 正俊; 坂本 洋城; 豊澤 昌子; 石川 恵美; 坂口 康浩; 小川 力; 福田 信宏; 末冨 洋一郎; 南 康範; 中岡 良介; 鄭 浩柄; 松井 繁長; 北野 雅之; 川崎 俊彦; 汐見 幹夫; 前川 清日本超音波医学会第24回関西地方会  2002/08  奈良  日本超音波医学会第24回関西地方会興味ある血行動態を示した転移性肝癌のレボビスト造影  [Not invited]坂本 洋城; 工藤 正俊; 豊澤 昌子; 石川 恵美; 坂口 康浩; 小川 力; 井上 達夫; 福田 信宏; 末冨 洋一郎; 南 康範; 鄭 浩柄; 中岡 良介; 松井 繁長; 北野 雅之; 川崎 俊彦; 汐見 幹夫; 前川 清日本超音波医学会第24回関西地方会  2002/08  奈良  日本超音波医学会第24回関西地方会造影超音波法が診断に有用であった門脈肝静脈短絡症に伴うFNHの一例  [Not invited]坂口 康浩; 工藤 正俊; 豊澤 昌子; 中尾 隆美; 石川 恵美; 坂本 洋城; 鄭 栄琴; 小川 力; 井上 達夫; 福田 信宏; 末冨 洋一郎; 南 康範; 鄭 浩柄; 中岡 良介; 松井 繁長; 北野 雅之; 川崎 俊彦; 汐見 幹夫; 前川 清日本超音波医学会第24回関西地方会  2002/08  奈良  日本超音波医学会第24回関西地方会肝区域からみたCoded Harmonic Angioを用いた肝細胞癌の血流評価  [Not invited]前川 清; 工藤 正俊; 前野 知子; 桑口 愛; 江口 真由美; 福田 信宏; 末冨 洋一郎; 南 康範; 鄭 浩柄; 中岡 良介; 松井 繁長; 北野 雅之; 川崎 俊彦; 汐見 幹夫日本超音波医学会第24回関西地方会  2002/08  奈良  日本超音波医学会第24回関西地方会嚢胞腎の経過中に発症した腸管腎盂瘻の1例  [Not invited]石川 恵美; 工藤 正俊; 坂本 洋城; 鄭 浩柄; 井上 達夫; 坂口 康浩; 小川 力; 福田 信宏; 末冨 洋一郎; 南 康範; 鄭 栄琴; 中岡 良介; 松井 繁長; 北野 雅之; 川崎 俊彦; 汐見 幹夫第44回腹部画像診断カンファレンス  2002/08  大阪  第44回腹部画像診断カンファレンス肝内P-Vシャントに合併した肝多発性結節性病変の1例  [Not invited]松井 繁長; 工藤 正俊第3回臨床消化器病研究会  2002/08  ホテルパシフィック東京, 東京  第3回臨床消化器病研究会特別講演「肝細胞癌治療におけるAFPレクチン分画の意義」  [Not invited]工藤 正俊神戸肝疾患勉強会  2002/08  神戸  神戸肝疾患勉強会特別講演「肝腫瘍の血流と病態ー造影ハーモニックイメージングの治療への応用ー」  [Not invited]工藤 正俊第80回東北腹部画像診断検討会  2002/08  艮陵会「記念ホール」, 仙台  第80回東北腹部画像診断検討会特別講演「肝癌における効率的局所治療のストラテジー: 造影超音波併用の与えるインパクト」  [Not invited]工藤 正俊腹部超音波フォーラム  2002/08  横浜エクセルホテル東急, 横浜  腹部超音波フォーラムKey Note Lecture「レボビストの臨床使用における基礎知識」  [Not invited]工藤 正俊腹部超音波フォーラム  2002/08  横浜エクセルホテル東急, 横浜  腹部超音波フォーラムKey Note Lecture「レボビストの臨床使用における基礎知識」  [Not invited]工藤 正俊腹部超音波フォーラム  2002/08  横浜エクセルホテル東急, 横浜  腹部超音波フォーラムHemodynamics of HCC using Contrast-enhanced Ultrasonography for Coded Harmonic Angio mode  [Not invited]日本超音波医学会第24回関西地方会  2002/08  奈良  日本超音波医学会第24回関西地方会  肝細胞癌の大きさ、深さ及び造影パターンごとに分類した結果、腫瘍径についてはvesselおよびPerfusion imageに差がなく、深部病変でPerfusion imageがvessel image比し染影が優れていた。消化管以外の臓器におけるFNAの現況と将来  [Not invited]中岡 良介; 工藤 正俊第7回内視鏡・超音波研究会  2002/07  大阪  第7回内視鏡・超音波研究会胃腎シャントのない孤立性胃静脈瘤破裂に対してPTOを施行し長期経過観察しえた1例  [Not invited]松井 繁長; 工藤 正俊; 井上 良一; 高幣 和郎第11回近畿食道・胃静脈瘤研究会  2002/07  大阪  第11回近畿食道・胃静脈瘤研究会門脈流入結節の造影ハーモニック像の検討  [Not invited]坂本 洋城; 工藤 正俊; 鄭 浩柄; 石川 恵美; 井上 達夫; 坂口 康浩; 小川 力; 福田 信宏; 末冨 洋一郎; 南 康範; 鄭 栄琴; 中岡 良介; 松井 繁長; 北野 雅之; 川崎 俊彦; 汐見 幹夫; 前川 清第2回関西肝血流動態イメージ研究会  2002/07  大阪  第2回関西肝血流動態イメージ研究会特別講演「肝腫瘍の超音波血流画像と癌局所治療への応用」  [Not invited]工藤 正俊第12回府中地区肝臓病研究会  2002/07  府中市、広島県  第12回府中地区肝臓病研究会特別講演「肝腫瘍の血流と病態・治療への応用」  [Not invited]工藤 正俊広島肝疾患ゼミナール  2002/07  広島  広島肝疾患ゼミナール特別講演「肝癌における効率的局所治療のストラテジー: 造影超音波併用の与えるインパクト」  [Not invited]工藤 正俊長崎プリンスホテル  2002/07  長崎  長崎プリンスホテルハンズオンレクチャー「腹部超音波の実際」  [Not invited]工藤 正俊国立長崎医療センター  2002/07  長崎  国立長崎医療センター特別講演「肝細胞癌の血流と病態ー造影ハーモニック法も含めてー」  [Not invited]工藤 正俊県北肝疾患研究会, (佐藤由起夫 福島県立医大教授)  2002/07  福島ビューホテル, 福島  県北肝疾患研究会, (佐藤由起夫 福島県立医大教授)客観的臨床能力試験(OSCE)における医療面接の評価法についての検討  [Not invited]岩本 一郎; 金丸 昭久; 宮崎 俊夫; 北野 雅之; 村木 正人; 木原 幹洋; 北野 元一; 飯田 仁; 福田 寛二; 工藤 正俊; 松尾 理; 安富 正幸第34回日本医学教育学会  2002/07  東京  第34回日本医学教育学会  本学の客観的臨床能力試験(OSCE)における医療面接の評価は、複数のシナリオを用いて2日間にわたって実施するため、客観性の確保に問題があった。本年度は外部評価者を含む複数の教官で評価したのでその客観性につてい検討し報告した。造影US. (シンポジウム「肝癌診断における各種画像診断の位置付け」)  [Not invited]工藤 正俊第37回近畿肝癌談話会  2002/07  第37回近畿肝癌談話会経皮内視鏡的胃瘻造設術(PEG)の現況-PEGの現況に関するアンケート集計報告  [Not invited]汐見 幹夫; 工藤 正俊第8回関西経皮内視鏡的胃瘻造設術研究会  2002/06  大阪  第8回関西経皮内視鏡的胃瘻造設術研究会C型肝炎針刺し事故直後のIFNの有用性に関する検討  [Not invited]鄭 浩柄; 工藤 正俊; 熊田 卓; 勝島 慎二; 岡野 明浩; 中村 武史; 大崎 往夫; 加藤 玲明; 小東 克次; 山下 幸孝; 荻原 智; 小森 英司; 西馬 信一第38回日本肝臓学会総会  2002/06  大阪国際会議場, 大阪  第38回日本肝臓学会総会肝硬変の超音波診断: 多施設共同研究  [Not invited]鄭 栄琴; 工藤 正俊; 川崎 俊彦; 岡部 純弘; 大崎 征夫; 飯島 尋子; 春日井 博志; 兼松 雅之; 伊藤 克能; 神代 正道日本超音波医学会第75回学術集会  2002/06  高松県県民ホール・全日空ホテルクレメント高松, 香川  日本超音波医学会第75回学術集会造影超音波にて肝静脈が流出血流と同定した肝血管筋脂肪腫の2例  [Not invited]南 康範; 工藤 正俊; 川崎 俊彦; 鄭 浩柄; 遠田 弘一; 末冨 洋一郎; 小川 力; 桑口 愛; 江口 真由美; 前川 清日本超音波医学会第75回学術集会  2002/06  高松県県民ホール・全日空ホテルクレメント高松, 香川  日本超音波医学会第75回学術集会CHAリサーチ(H7)を用いた肝腫瘍の造影3D像の検討  [Not invited]前川 清; 工藤 正俊; 桑口 愛; 江口 真由美; 小川 力; 末冨 洋一郎; 南 康範; 鄭 浩柄; 北野 雅之; 川崎 俊彦日本超音波医学会第75回学術集会  2002/06  高松県県民ホール・全日空ホテルクレメント高松, 香川  日本超音波医学会第75回学術集会「人工胸水下造影超音波併用RFA」の初期臨床経験  [Not invited]南 康範; 工藤 正俊; 川崎 俊彦; 鄭 浩柄; 遠田 弘一; 末冨 洋一郎; 小川 力; 桑口 愛; 江口 真由美; 前川 清日本超音波医学会第75回学術集会  2002/06  高松県県民ホール・全日空ホテルクレメント高松, 香川  日本超音波医学会第75回学術集会CHAモードを用いた膵腫瘍性病変の造影超音波像  [Not invited]桑口 愛; 工藤 正俊; 江口 真由美; 前川 清; 福田 信宏; 末冨 洋一郎; 南 康範; 鄭 浩柄; 北野 雅之; 川崎 俊彦日本超音波医学会第75回学術集会  2002/06  高松県県民ホール・全日空ホテルクレメント高松, 香川  日本超音波医学会第75回学術集会局所治療後遺残肝細胞癌 (HCC) に対する造影超音波下RFAの検討  [Not invited]鄭 浩柄; 工藤 正俊; 小川 力; 南 康範; 末冨 洋一郎; 北野 雅之; 川崎 俊彦; 桑口 愛; 江口 真由美; 前川 清日本超音波医学会第75回学術集会  2002/06  高松県県民ホール・全日空ホテルクレメント高松, 香川  日本超音波医学会第75回学術集会超音波内視鏡下造影および穿刺生検のよる膵腫瘍性疾患の診断  [Not invited]北野 雅之; 工藤 正俊; 福田 信宏; 末冨 洋一郎; 南 康範; 中岡 良介; 鄭 浩柄; 松井 繁長; 汐見 幹夫; 川崎 俊彦; 小川 力; 石川 恵美; 由谷 逸朗; 前川 清日本超音波医学会第75回学術集会  2002/06  高松県県民ホール・全日空ホテルクレメント高松, 香川  日本超音波医学会第75回学術集会消化器粘膜下腫瘍における造影超音波法およびEUS下穿刺の有用性  [Not invited]福田 信宏; 工藤 正俊; 北野 雅之; 前川 清; 末冨 洋一郎; 由谷 逸朗; 中岡 良介; 松井 繁長; 川崎 俊彦; 汐見 幹夫日本超音波医学会第75回学術集会  2002/06  高松県県民ホール・全日空ホテルクレメント高松, 香川  日本超音波医学会第75回学術集会肝腫瘍性病変の特徴: CHAモード造影超音波の有用性  [Not invited]文 艶玲; 工藤 正俊; 丁 紅; 南 康範; 鄭 浩柄; 末冨 洋一郎; 遠田 弘一; 北野 雅之; 川崎 俊彦; 前川 清日本超音波医学会第75回学術集会  2002/06  高松県県民ホール・全日空ホテルクレメント高松, 香川  日本超音波医学会第75回学術集会特別講演「肝がんは克服できる-最新情報」  [Not invited]工藤 正俊平成14年度肝がん撲滅運動市民公開講座(日本肝臓学会・大阪府主催)  2002/06  大阪狭山市文化会館(SAYAKAホール), 大阪市  平成14年度肝がん撲滅運動市民公開講座(日本肝臓学会・大阪府主催)ランチョンセミナー: 肝がん治療最近の動向「内科的治療とその効果判定」  [Not invited]工藤 正俊第38回日本肝臓学会総会  2002/06  大阪国際会議場, 大阪  第38回日本肝臓学会総会ランチョンセミナー「肝細胞癌の効率的RFA治療ー造影超音波併用の与えるimpactー」  [Not invited]工藤 正俊第38回日本肝臓学会総会  2002/06  大阪国際会議場, 大阪  第38回日本肝臓学会総会ランチョンセミナー: 肝がん治療最近の動向「内科的治療とその効果判定」  [Not invited]工藤 正俊第38回日本肝臓学会総会  2002/06  大阪国際会議場, 大阪  第38回日本肝臓学会総会  ランチョンセミナー: 肝がん治療最近の動向「内科的治療とその効果判定」教育講演「肝癌局所療法における超音波の役割」  [Not invited]工藤 正俊日本超音波医学会第75回学術集会  2002/06  高松, 香川  日本超音波医学会第75回学術集会Contrast enhanced 3D imaging of hepatic tumors by CHA research mode(H7)  [Not invited]日本超音波医学会第75回学術集会  2002/06  香川  日本超音波医学会第75回学術集会  レボビスト造影において早期相のReal time sweep scanによる撮像にて構築し、腫瘍の同定を試み、腫瘍血管3D像は肝臓腫瘍の血管構築を3次元的に理解する上で有用であった。TAE先行RFAの有用性: 生体豚肝による検討  [Not invited]鄭 浩柄; 工藤 正俊(厚生労働省指定研究「肝細胞がんに対する肝動脈塞栓療法の延命効果に関する研究」班会議)  2002/05  国立がんセンター, 東京  (厚生労働省指定研究「肝細胞がんに対する肝動脈塞栓療法の延命効果に関する研究」班会議)人工胸水造影超音波併用RFAの初期臨床経験  [Not invited]南 康範; 工藤 正俊; 小川 力; 鄭 浩柄; 川崎 俊彦第38回日本肝癌研究会  2002/05  東京ドームホテル, 東京  第38回日本肝癌研究会肝細胞癌に対するラジオ波焼灼療法( RFA)後の腫瘍マーカーの変動とその意義  [Not invited]小川 力; 工藤 正俊; 市川 勉; 乾 絹世; 岡田 無文; 北口 容子; 豊澤 昌子; 石川 恵美; 福田 信宏; 末冨 洋一郎; 南 康範; 中岡 良介; 鄭 浩柄; 遠田 弘一; 松井 繁長; 由谷 逸朗; 北野 雅之; 川崎 俊彦; 汐見 幹夫第38回日本肝癌研究会  2002/05  東京ドームホテル, 東京  第38回日本肝癌研究会肝内PVシャントに合併した肝結節性病変の一例  [Not invited]北口 容子; 工藤 正俊; 松井 繁長; 乾 絹世; 市川 勉; 岡田 無文; 豊澤 昌子; 小川 力; 福田 信宏; 末冨 洋一郎; 南 康範; 石川 恵美; 鄭 浩柄; 中岡 良介; 北野 雅之; 川崎 俊彦; 汐見 幹夫第34回大阪肝穿刺生検治療研究会  2002/05  大阪大林ビル, 大阪  第34回大阪肝穿刺生検治療研究会ラジオ出演「C型肝炎って治るの?(5)」(番組名: 健やかライフ)  [Not invited]工藤 正俊2002/05  ABCラジオ(朝日放送), 大阪ラジオ出演「C型肝炎って治るの?(4)」(番組名: 健やかライフ)  [Not invited]工藤 正俊2002/05  ABCラジオ(朝日放送), 大阪ラジオ出演「C型肝炎って治るの?(3)」(番組名: 健やかライフ)  [Not invited]工藤 正俊2002/05  ABCラジオ(朝日放送), 大阪ラジオ出演「C型肝炎って治るの?(2)」(番組名: 健やかライフ)  [Not invited]工藤 正俊2002/05  ABCラジオ(朝日放送), 大阪ラジオ出演「C型肝炎って治るの?(1)」(番組名: 健やかライフ)  [Not invited]工藤 正俊2002/05  ABCラジオ(朝日放送), 大阪Special Lecture "Application of Harmonic Imaging to the Treatment of hepatocellular Carcinoma.“  [Not invited]工藤 正俊The 8th International Symposium on Interventional Radiology and New Vascular Imaging ( 第8回国際IVR/ 血管造  2002/05  Keio Plaza Hotel, Tokyo, Japan  The 8th International Symposium on Interventional Radiology and New Vascular Imaging ( 第8回国際IVR/ 血管造Argon plasma coagulation  [Not invited]田中 陽一; 森村 正嗣; 米田 円; 辻 直子; 工藤 正俊近大堺カンファレンス  2002/05  大阪  近大堺カンファレンス  アルゴンピラズマ凝固療法の新しい治療方法としての有用性や適応について解説した。Evaluation of treatment response after transcatheter arterial embolization mixed with Lipiodol for hepatocellular carcinoma: utility of coded phase inversion harmonic imaging  [Not invited]工藤 正俊; 南 康範; 鄭 浩柄; 小川 力; 末冨洋一郎; 福田信宏; 中岡 良介; 松井 繁長; 北野 雅之; 川崎俊彦; 汐見 幹夫; 前川 清Digestive Disease Week-2002 (AGA)  2002/05  San Francisco  Digestive Disease Week-2002 (AGA)Radofrequency ablation (RFA) therapy under harmonic image guidance for the recurrence after local therapy for HCC  [Not invited]工藤 正俊; 南 康範; 鄭 浩柄; 小川 力; 末冨洋一郎; 福田信宏; 中岡 良介; 松井 繁長; 北野 雅之; 川崎俊彦; 汐見 幹夫; 前川 清Digestive Disease Week-2002 (AGA)  2002/05  San Francisco  Digestive Disease Week-2002 (AGA)Ultrasonography in pancreatic diseases by contrast-enhanced phase-inversion harmonics with coded pulse  [Not invited]北野 雅之; 工藤 正俊; 前川 清; 鄭 栄琴; 中岡 良介; 末冨洋一郎; 南 康範; 鄭 浩柄; 川崎俊彦Digestive Disease Week-2002 (AGA)  2002/05  San Francisco  Digestive Disease Week-2002 (AGA)2年間の治療成績からみた、HCCに対するRFAによる治療戦略(シンポジウム)  [Not invited]鄭 浩柄; 工藤 正俊; 小川 力; 南 康範; 川崎俊彦第38回日本肝癌研究会  2002/05  東京ドームホテル, 東京  第38回日本肝癌研究会肝細胞癌に対する根治的RFA治療後のAFP-L 3分画の意義  [Not invited]小川 力; 工藤 正俊; 市川 勉; 乾 絹世; 岡田 無文; 北口 容子; 豊澤 昌子; 石川 恵美; 福田 信宏; 末冨 洋一郎; 南 康範; 中岡 良介; 鄭 浩柄; 遠田 弘一; 松井 繁長; 由谷 逸朗; 北野 雅之; 川崎 俊彦; 汐見 幹夫第88回日本消化器病学会総会  2002/04  旭川, 北海道  第88回日本消化器病学会総会真性多血症による食道静脈瘤破裂の1例  [Not invited]松井 繁長; 工藤 正俊; 井上 良一; 中岡 良介; 北野 雅之; 福田 信宏; 末冨 洋一郎; 川崎 俊彦; 汐見 幹夫第63回日本消化器内視鏡学会総会( 附置研究会「第5回食道胃静脈瘤治療のための内視鏡的病態生理研究会」)  2002/04  甲府  第63回日本消化器内視鏡学会総会( 附置研究会「第5回食道胃静脈瘤治療のための内視鏡的病態生理研究会」)食道静脈瘤治療後に出血を来した十二指腸静脈瘤の1例  [Not invited]松井 繁長; 工藤 正俊; 井上 良一; 中岡 良介; 福田 信宏; 末冨 洋一郎; 北野 雅之; 川崎 俊彦; 汐見 幹夫第63回日本消化器内視鏡学会総会( 附置研究会「第5回食道胃静脈瘤治療のための内視鏡的病態生理研究会」)  2002/04  甲府  第63回日本消化器内視鏡学会総会( 附置研究会「第5回食道胃静脈瘤治療のための内視鏡的病態生理研究会」)不整胃潰瘍辺縁から陳旧化したアニサキス虫体片を認めた1例  [Not invited]木下 理恵; 工藤 正俊; 汐見 幹夫; 石川 恵美; 小川 力; 福田 信宏; 南 康範; 末冨 洋一郎; 鄭 浩柄; 中岡 良介; 松井 繁長; 北野 雅之; 由谷 逸朗; 川崎 俊彦第63回日本消化器内視鏡学会総会  2002/04  甲府, 山梨  第63回日本消化器内視鏡学会総会体表式造影超音波検査および超音波内視鏡下造影法による膵腫瘍性病変の診断  [Not invited]北野 雅之; 工藤 正俊; 前川 清; 岡田 無文; 乾 絹世; 市川 勉; 豊澤 昌子; 北口 容子; 石川 恵美; 小川 力; 福田 信宏; 南 康範; 鄭 浩柄; 中岡 良介; 松井 繁長; 川崎 俊彦; 汐見 幹夫第12回日本腹部造影エコードプラ診断研究会  2002/04  広島大学医学部, 広島  第12回日本腹部造影エコードプラ診断研究会特別講演「肝腫瘍の超音波血流画像と治療への応用」  [Not invited]工藤 正俊第90回鹿児島超音波医学研究会  2002/04  鹿児島労働衛生センター, 鹿児島  第90回鹿児島超音波医学研究会特別講演「ラジオ波による肝癌治療: 根治性ならびに効率性向上の試み」  [Not invited]工藤 正俊第2回福岡肝癌局所治療研究会  2002/04  アクロス福岡  第2回福岡肝癌局所治療研究会特別講演「ラジオ波による肝癌治療: 根治性ならびに効率性向上の試み」  [Not invited]工藤 正俊第2回福岡肝癌局所治療研究会  2002/04  アクロス福岡  第2回福岡肝癌局所治療研究会Special Lecture "Imaging diagnosis of small nodular lesions in cirrhoric liver.“  [Not invited]工藤 正俊International Consensus Meeting on Nodular Lesions in Cirrhoric Liver  2002/04  Kurume  International Consensus Meeting on Nodular Lesions in Cirrhoric LiverSpecial Lecture "Clinical Characteristics of early HCC: A view point from vasculature"  [Not invited]工藤 正俊International Consensus Meeting on Small Nodular Lesions in Cirrhotic Liver (Supported by Grant-in A  2002/04  Kurume University School of Medicine, Kurume, Japan  International Consensus Meeting on Small Nodular Lesions in Cirrhotic Liver (Supported by Grant-in AImaging diagnosis of focal nodular hyperplasia  [Not invited]工藤 正俊Laennec Liver Pathology Society (Organizer: Iwan Wanless, Toronto)  2002/04  Karatsu, Japan  Laennec Liver Pathology Society (Organizer: Iwan Wanless, Toronto)体表式造影超音波検査および超音波内視鏡下造影法による膵腫瘍性病変の診断. (ワークショップ「胆管癌、膵癌に対する新しい画像診断と治療体系」)  [Not invited]北野 雅之; 工藤 正俊; 中岡 良介第88回日本消化器病学会総会  2002/04  旭川, 北海道  第88回日本消化器病学会総会肝細胞癌に対するRFA2年間の成績と今後の展望(シンポジウム「肝癌治療の最先端」)  [Not invited]鄭 浩柄; 工藤 正俊; 遠田弘一第88回日本消化器病学会総会  2002/04  旭川, 北海道  第88回日本消化器病学会総会超音波内視鏡下穿刺の有用性と血流評価・遺伝子解析の意義 (シンポジウム「超音波内視鏡下穿刺ー適応と問題点ー」)  [Not invited]中岡 良介; 工藤 正俊; 北野 雅之第63回日本消化器内視鏡学会総会  2002/04  甲府, 山梨  第63回日本消化器内視鏡学会総会人工胸水下造影超音波併用RFAの初期臨床経験  [Not invited]南 康範; 工藤 正俊第1回関西肝癌局所治療研究会  2002/03  大阪  第1回関西肝癌局所治療研究会食道静脈瘤に対するEVL・EIS(EISL)の有用性の検討  [Not invited]松井 繁長; 工藤 正俊; 中岡 良介; 北野 雅之; 川崎 俊彦; 汐見 幹夫第99回日本内科学会  2002/03  名古屋  第99回日本内科学会サイズ、数ともに増加中の多発性肝FNHの1例  [Not invited]鄭 浩柄; 工藤 正俊; 汐見 幹夫; 松井 繁長; 中岡 良介; 南 康範; 福田 信宏; 石川 恵美; 川崎 俊彦; 末冨 洋一郎; 小川 力第34回大阪肝臓病談話会  2002/03  大阪  第34回大阪肝臓病談話会内視鏡的粘膜切除にて治療した胃血管腫の1例  [Not invited]石川 恵美; 工藤 正俊; 松井 繁長; 乾 絹世; 市川 勉; 岡田 無文; 北口 容子; 豊澤 昌子; 小川 力; 福田 信宏; 南 康範; 末冨 洋一郎; 中岡 良介; 鄭 浩柄; 北野 雅之; 川崎 俊彦; 汐見 幹夫第68回日本消化器内視鏡学会近畿地方会  2002/03  京都  第68回日本消化器内視鏡学会近畿地方会術中に内視鏡検査にて出血部位を同定できた小腸毛細血管性血管腫の1例  [Not invited]福田 信宏; 工藤 正俊; 松井 繁長; 石川 恵美; 乾 絹世; 市川 勉; 岡田 無文; 北口 容子; 豊澤 昌子; 小川 力; 南 康範; 末冨 洋一郎; 中岡 良介; 鄭 浩柄; 北野 雅之; 川崎 俊彦; 汐見 幹夫; 保田 知生; 新海 政幸; 十川 佳史; 大柳 治正第68回日本消化器内視鏡学会近畿地方会  2002/03  京都  第68回日本消化器内視鏡学会近畿地方会特別講演「肝疾患におけるハーモニックイメージングー診断から治療応用までー」  [Not invited]工藤 正俊メディカル・コア  2002/03  ホテルB&G, 東京  メディカル・コア特別講演「Coded Harmonic Angioによる肝腫瘍の診断と治療への応用」  [Not invited]工藤 正俊GE Clinical Forum  2002/03  リッツカールトンホテル大阪, 大阪  GE Clinical Forumハンズオンセミナー「肝腫瘍の造影ハーモニックイメージング」  [Not invited]工藤 正俊2002/03  宮崎県立病院, 宮崎特別講演「肝疾患におけるカラードプラと造影エコー法ー基本から実地臨床への応用までー」  [Not invited]工藤 正俊宮崎県腹部超音波懇話会  2002/03  宮崎  宮崎県腹部超音波懇話会特別講演「肝癌の治療のコンセンサス」  [Not invited]工藤 正俊神戸消化器病セミナー  2002/03  神戸  神戸消化器病セミナー特別講演「超音波血流画像による肝腫瘍の診断と治療」  [Not invited]工藤 正俊第20回東海超音波研究会  2002/03  第2豊田ビル, 名古屋  第20回東海超音波研究会特別講演「肝画像診断の進歩」  [Not invited]工藤 正俊第14回肝臓フォーラム(西部)  2002/03  大阪  第14回肝臓フォーラム(西部)A case of angiocentric NK/Tcell lymphoma with massive gastro-intestinal bleeding  [Not invited]田中 陽一; 森村 正嗣; 米田 円; 辻 直子; 工藤 正俊第68回日本消化器内視鏡学界地方会  2002/03  京都  第68回日本消化器内視鏡学界地方会  Angiocentric NK/T細胞リンパ腫に伴う消化管出血は知られているが、内視鏡像の記載は乏しく、今回血管中心性発育によると思われる多発打ち抜き様潰瘍像を内視鏡的にとらえることができたので報告した。体表式造影超音波検査および超音波内視鏡下造影法による膵腫瘍性病変の診断. シンポジウム「各領域における超音波造影検査の現況ーレボビスト超音波造影検査は従来の画像診断をどう変えたか?-」  [Not invited]北野 雅之; 工藤 正俊; 前川 清第5回関西超音波造影剤研究会  2002/03  大阪  第5回関西超音波造影剤研究会膵疾患の鑑別における超音波内視鏡下造影の有用性. ワークショップ「胆膵疾患における最新の内視鏡的アプローチ」  [Not invited]末冨 洋一郎; 工藤 正俊; 北野 雅之第68回日本消化器内視鏡学会近畿地方会  2002/03  京都  第68回日本消化器内視鏡学会近畿地方会上部消化管出血に対するEndoscopic Band Ligation (EBL) と4端子バイポラー高周波電気凝固法の比較検討. シンポジウム「消化管出血に対する止血法の選択」  [Not invited]松井 繁長; 工藤 正俊; 汐見 幹夫第68回日本消化器内視鏡学会近畿地方会  2002/03  京都  第68回日本消化器内視鏡学会近畿地方会胆管ディスプラジアを合併した肝外胆管限局性狭窄の1例  [Not invited]田中 陽一; 工藤 正俊; 森村 正嗣; 米田 円; 辻 直子第76回日本消化器病学会近畿支部例会  2002/02  大阪  第76回日本消化器病学会近畿支部例会消化管出血を契機に発見された小腸GISTの1例  [Not invited]乾 絹世; 工藤 正俊; 松井 繁長; 福田 信宏; 石川 恵美; 小川 力; 南 康範; 末冨 洋一郎; 中岡 良介; 鄭 浩柄; 由谷 逸朗; 北野 雅之; 川崎 俊彦; 汐見 幹夫; 里井 俊平; 保田 知生; 橋本 直樹; 大柳 治正第76回日本消化器病学会近畿支部例会  2002/02  大阪  第76回日本消化器病学会近畿支部例会急速に進行する肝不全で死亡した原発性アミロイドーシスの1例  [Not invited]岡田 無文; 工藤 正俊; 市川 勉; 乾 絹世; 北口 容子; 豊澤 昌子; 石川 恵美; 小川 力; 福田 信宏; 末冨 洋一郎; 南 康範; 鄭 浩柄; 中岡 良介; 遠田 弘一; 松井 繁長; 北野 雅之; 由谷 逸朗; 川崎 俊彦; 汐見 幹夫第76回日本消化器病学会近畿支部例会  2002/02  大阪  第76回日本消化器病学会近畿支部例会DSMを用いたLp-TAE後に急性化化膿性胆管炎を発症した一例  [Not invited]北口容子; 工藤 正俊; 鄭 浩柄; 市川 勉; 乾 絹世; 岡田無文; 豊澤昌子; 石川恵美; 小川 力; 福田信宏; 南 康範; 末冨洋一郎; 中岡 良介; 松井 繁長; 北野 雅之; 由谷逸朗; 川崎俊彦; 汐見幹夫第76回日本消化器病学会近畿支部例会  2002/02  大阪  第76回日本消化器病学会近畿支部例会超音波内視鏡下穿刺生検が診断に有用であった直径2cmの平滑筋肉腫の1例  [Not invited]市川 勉; 工藤 正俊; 福田信宏; 北野 雅之; 乾 絹世; 岡田無文; 北口容子; 豊澤昌子; 石川恵美; 小川 力; 末冨洋一郎; 南 康範; 中岡 良介; 鄭 浩柄; 遠田弘一; 松井 繁長; 由谷逸朗; 川崎俊彦; 汐見幹夫第76回日本消化器病学会近畿支部例会  2002/02  大阪  第76回日本消化器病学会近畿支部例会特別講演「肝疾患の病態・診断・治療ーコンセンサスミーティングをふまえて」  [Not invited]工藤 正俊神戸肝疾患談話会  2002/02  神戸  神戸肝疾患談話会特別講演「超音波血流画像による肝細胞癌の診断と治療」  [Not invited]工藤 正俊第15回日医放・放射線科専門医会共催冬期セミナー  2002/02  千里ライフサイエンスセンター, 大阪  第15回日医放・放射線科専門医会共催冬期セミナー特別講演「肝細胞癌に対する内科的局所治療ーラジオ波焼灼療法を中心にー」  [Not invited]工藤 正俊第6回Surgical Forum in Osaka  2002/02  ホテル阪神, 大阪  第6回Surgical Forum in Osaka講演「肝細胞癌の診断と治療ー最近の進歩ー」  [Not invited]工藤 正俊姫路消化器病研究会  2002/02  姫路市医師会館, 姫路  姫路消化器病研究会「人工胸水下造影超音波併用RFA」の初期臨床経験. シンポジウム「肝胆膵癌治療の新しい展開」  [Not invited]南 康範; 工藤 正俊; 鄭 浩柄第76回日本消化器病学会近畿支部例会  2002/02  大阪  第76回日本消化器病学会近畿支部例会腹部血管造影検査にて出血部位を同定できた小腸毛細血管性血管腫の1例  [Not invited]石川 恵美; 工藤 正俊; 松井 繁長; 小川 力; 福田 信宏; 南 康範; 末冨 洋一郎; 中岡 良介; 鄭 浩柄; 北野 雅之; 川崎 俊彦; 遠田 弘一; 汐見 幹夫; 保田 知生; 新海 政幸; 十川 佳史; 大柳 治正第76回日本消化器病学会近畿支部例会  2002  大阪  第76回日本消化器病学会近畿支部例会Application of harmonic imaging to the treatment of hepatocellular carcinoma  [Not invited]工藤 正俊The 8th Internationl Symposium on Interventional Radiology & New Vascular Imaging  2002  Tokyo  The 8th Internationl Symposium on Interventional Radiology & New Vascular ImagingEUS下穿刺が診断に有用であった腫瘤形成性膵炎の1症例  [Not invited]乾 絹世; 工藤 正俊; 市川 勉; 岡田無文; 北口容子; 豊澤昌子; 石川恵美; 鄭 栄琴; 小川 力; 福田信宏; 末冨洋一郎; 南 康範; 鄭 浩柄; 中岡 良介; 遠田弘一; 松井 繁長; 北野 雅之; 由谷逸朗; 川崎俊彦; 汐見幹夫; 川端久美子; 桑口 愛; 江口真由美; 前川 清日本超音波医学会第23回関西地方会  2002/01  大阪  日本超音波医学会第23回関西地方会新型軽量EUS専用機の使用経験  [Not invited]末冨洋一郎; 工藤 正俊; 市川 勉; 乾 絹世; 岡田無文; 北口容子; 豊澤昌子; 石川恵美; 鄭 栄琴; 小川 力; 福田信宏; 南 康範; 鄭 浩柄; 中岡 良介; 遠田弘一; 松井 繁長; 北野 雅之; 由谷逸朗; 川崎俊彦; 汐見幹夫; 川端久美子; 桑口 愛; 江口真由美; 前川 清日本超音波医学会第23回関西地方会  2002/01  大阪  日本超音波医学会第23回関西地方会胃粘膜下腫瘍におけるEUS下造影エコー法の有用性  [Not invited]北野 雅之; 工藤 正俊; 市川 勉; 乾 絹世; 岡田無文; 北口容子; 豊澤昌子; 石川恵美; 鄭 栄琴; 小川 力; 福田信宏; 末冨洋一郎; 南 康範; 鄭 浩柄; 中岡 良介; 遠田弘一; 松井 繁長; 由谷逸朗; 川崎俊彦; 汐見幹夫; 川端久美子; 桑口 愛; 江口真由美; 前川 清日本超音波医学会第23回関西地方会,  2002/01  大阪  日本超音波医学会第23回関西地方会,体表アプローチによる消化管粘膜下腫瘍の造影エコー法について  [Not invited]福田信宏; 工藤 正俊; 市川 勉; 乾 絹世; 岡田無文; 北口容子; 豊澤昌子; 石川恵美; 鄭 栄琴; 小川 力; 末冨洋一郎; 南 康範; 鄭 浩柄; 中岡 良介; 遠田弘一; 松井 繁長; 北野 雅之; 由谷逸朗; 川崎俊彦; 汐見幹夫; 川端久美子; 桑口 愛; 江口真由美; 前川 清日本超音波医学会第23回関西地方会  2002/01  大阪  日本超音波医学会第23回関西地方会肝癌に対するラジオ波治療後の効果判定における造影エコー法の有用性に関する検討  [Not invited]鄭 浩柄; 工藤 正俊; 市川 勉; 乾 絹世; 岡田無文; 北口容子; 豊澤昌子; 石川恵美; 鄭 栄琴; 小川 力; 福田信宏; 末冨洋一郎; 南 康範; 中岡 良介; 遠田弘一; 松井 繁長; 北野 雅之; 由谷逸朗; 川崎俊彦; 汐見幹夫; 川端久美子; 桑口 愛; 江口真由美; 前川 清日本超音波医学会第23回関西地方会  2002/01  大阪  日本超音波医学会第23回関西地方会造影エコー法により明瞭なnodule in noduleが示された肝細胞癌の2症例  [Not invited]豊澤昌子; 工藤 正俊; 市川 勉; 乾 絹世; 岡田無文; 北口容子; 石川恵美; 鄭 栄琴; 小川 力; 福田信宏; 末冨洋一郎; 南 康範; 鄭 浩柄; 中岡 良介; 遠田弘一; 松井 繁長; 北野 雅之; 由谷逸朗; 川崎俊彦; 汐見幹夫; 川端久美子; 桑口 愛; 江口真由美; 前川 清日本超音波医学会第23回関西地方会  2002/01  大阪  日本超音波医学会第23回関西地方会Coded Harmonic Angio H7 modeにおけるレボビスト造影  [Not invited]前川 清; 工藤 正俊; 市川 勉; 乾 絹世; 岡田無文; 北口容子; 豊澤昌子; 石川恵美; 鄭 栄琴; 小川 力; 福田信宏; 末冨洋一郎; 南 康範; 鄭 浩柄; 中岡 良介; 遠田弘一; 松井 繁長; 北野 雅之; 由谷逸朗; 川崎俊彦; 汐見幹夫; 川端久美子; 桑口 愛; 江口真由美日本超音波医学会第23回関西地方会  2002/01  大阪  日本超音波医学会第23回関西地方会Aplio SSA-770を用いた肝腫瘤病変のレボビスト造影ー特にAdvanced Dynamic FlowとPulse subtractionについてー  [Not invited]鄭 浩柄; 工藤 正俊; 市川 勉; 乾 絹世; 岡田無文; 北口容子; 豊澤昌子; 石川恵美; 鄭 栄琴; 小川 力; 福田信宏; 末冨洋一郎; 南 康範; 中岡 良介; 遠田弘一; 松井 繁長; 北野 雅之; 由谷逸朗; 川崎俊彦; 汐見幹夫; 川端久美子; 桑口 愛; 江口真由美; 前川 清日本超音波医学会第23回関西地方会  2002/01  大阪  日本超音波医学会第23回関西地方会Extended Pure Harmonic Detection (ALOKA SSD-6500)を用いた肝腫瘤病変のレボビスト造影  [Not invited]小川 力; 工藤 正俊; 市川 勉; 乾 絹世; 岡田無文; 北口容子; 豊澤昌子; 石川恵美; 鄭 栄琴; 福田信宏; 末冨洋一郎; 南 康範; 鄭 浩柄; 中岡 良介; 遠田弘一; 松井 繁長; 北野 雅之; 由谷逸朗; 川崎俊彦; 汐見幹夫; 川端久美子; 桑口 愛; 江口真由美; 前川 清日本超音波医学会第23回関西地方会  2002/01  大阪  日本超音波医学会第23回関西地方会診断に難渋した結核性肝腫瘤の1例  [Not invited]石川恵美; 工藤 正俊; 市川 勉; 乾 絹世; 岡田無文; 北口容子; 豊澤昌子; 鄭 栄琴; 小川 力; 福田信宏; 末冨洋一郎; 南 康範; 鄭 浩柄; 中岡 良介; 遠田弘一; 松井 繁長; 北野 雅之; 由谷逸朗; 川崎俊彦; 汐見幹夫; 川端久美子; 桑口 愛; 江口真由美; 前川 清日本超音波医学会第23回関西地方会  2002/01  大阪  日本超音波医学会第23回関西地方会興味ある造影エコー所見を呈した肝内胆管癌の一例  [Not invited]北口容子; 工藤 正俊; 市川 勉; 乾 絹世; 岡田無文; 豊澤昌子; 石川恵美; 鄭 栄琴; 小川 力; 福田信宏; 末冨洋一郎; 南 康範; 鄭 浩柄; 中岡 良介; 遠田弘一; 松井 繁長; 北野 雅之; 由谷逸朗; 川崎俊彦; 汐見幹夫; 川端久美子; 桑口 愛; 江口真由美; 前川 清日本超音波医学会第23回関西地方会  2002/01  大阪  日本超音波医学会第23回関西地方会膵臓「造影ハーモニック法およびEUS下造影による膵疾患の鑑別診断」(シンポジウム「各臓器における超音波血流イメージの現状と展望ー臨床をどうかえたかー」)  [Not invited]北野 雅之; 工藤 正俊; 前川 清; 川崎俊彦日本超音波医学会第23回関西地方会  2002/01  大阪  日本超音波医学会第23回関西地方会特別講演「肝癌の病態・診断と治療 Consensus & Recommendation」  [Not invited]工藤 正俊第2回東神戸消化器疾患セミナー  2002/01  神鋼病院, 神戸  第2回東神戸消化器疾患セミナー特別講演「造影ハーモニック法による肝細胞癌の診断と治療」  [Not invited]工藤 正俊第128回滋賀肝・胆・膵勉強会  2002/01  京都センチュリーホテル, 京都  第128回滋賀肝・胆・膵勉強会特別講演「肝細胞癌の超音波血流画像と治療への応用」  [Not invited]工藤 正俊沖縄肝胆膵疾患研究会  2002/01  ザナハテラス, 那覇  沖縄肝胆膵疾患研究会特別講演「肝細胞癌の診断と治療の最近の進歩ー造影ハーモニック法からラジオ波治療までー」  [Not invited]工藤 正俊第51回近畿大学医学会学術講演会  2002/01  近畿大学医学部大講堂, 大阪狭山市  第51回近畿大学医学会学術講演会Enhanced ultrasonography used Levovist for Code Harmonic Angio (H7) mode  [Not invited]日本超音波医学会第23回関西地方会  2002/01  大阪  日本超音波医学会第23回関西地方会  GE社製LOGIQ700EXPERTに新しく加わったCHA H7モードを使用して肝腫瘍症例を対象にレボビスト造影を 行い、興味ある知見を得たので報告した。膵臓「造影ハーモニック法およびEUS下造影による膵疾患の鑑別診断」(シンポジウム「各臓器における超音波血流イメージの現状と展望ー臨床をどうかえたかー」)  [Not invited]北野 雅之; 工藤 正俊; 前川 清; 川崎俊彦日本超音波医学会第23回関西地方会  2002/01  大阪  日本超音波医学会第23回関西地方会膵疾患に対するEUS-FNAおよびEUS下造影の有用性  [Not invited]北野 雅之; 工藤 正俊; 中岡 良介; 松井 繁長; 汐見幹夫第5回南大阪肝胆膵懇話会  2001/12  近畿大学医学部附属病院, 大阪狭山市  第5回南大阪肝胆膵懇話会Lp-TAEの早期治療効果判定についてー造影超音波ハーモニックイメージングの有用性  [Not invited]南 康範; 工藤 正俊; 小川 力; 鄭 浩柄; 川崎俊彦第6回肝動脈塞栓療法研究会  2001/12  神戸  第6回肝動脈塞栓療法研究会ラジオ出演「ウイルス性肝炎・肝癌の診断と治療」  [Not invited]工藤 正俊毎日放送「家庭医学」  2001/12  大阪  毎日放送「家庭医学」IBDにおけるNKT細胞の役割  [Not invited]八木田 旭邦; 丸山 正二; 助川 寧; 工藤 正俊; 高添正和厚生科学研究費補助金特定疾患対策研究事業「難治性炎症性腸管障害に関する調査研究」平成13年度第2回総会  2001/12  東京  厚生科学研究費補助金特定疾患対策研究事業「難治性炎症性腸管障害に関する調査研究」平成13年度第2回総会講演「C型慢性肝炎における新しい治療戦略」  [Not invited]工藤 正俊コンセンサスミーティング  2001/11  ヒルトンホテル大阪, 大阪  コンセンサスミーティングラジオ出演「肝癌の早期発見と治療」  [Not invited]工藤 正俊毎日放送「家庭医学」  2001/11  大阪  毎日放送「家庭医学」Special Lecture "Has vascular enhancement with Levovist changed diagnosis of liver tumors?"  [Not invited]工藤 正俊The Third International Kyoto Symposium on Ultrasound Contrast Imaging  2001/11  Kyoto, Japan  The Third International Kyoto Symposium on Ultrasound Contrast Imaging消化管間葉系腫瘍の術前診断におけるEUS下穿刺を含めた超音波内視鏡診断の有用性  [Not invited]中岡 良介; 工藤 正俊; 北野 雅之; 松井 繁長; 汐見幹夫第62回日本消化器内視鏡学会総会  2001/10  京都  第62回日本消化器内視鏡学会総会食道静脈瘤に対するEIS・EVL併用療法(EISL)の評価  [Not invited]松井 繁長; 工藤 正俊; 井上良一; 末冨洋一郎; 南 康範; 鄭 浩柄; 中岡 良介; 由谷逸朗; 北野 雅之; 上硲 俊法; 川崎俊彦; 汐見幹夫第62回日本消化器内視鏡学会総会  2001/10  京都  第62回日本消化器内視鏡学会総会CHA( Coded Harmonic Angio)モードを用いた造影ハーモニックイメージングによる膵・胆道領域腫瘍性病変のdynamic image. (パネルディスカッション「膵・胆道領域腫瘍性病変のdynamic image」)  [Not invited]北野 雅之; 工藤 正俊; 川崎俊彦第43回日本消化器病学会大会  2001/10  京都  第43回日本消化器病学会大会サイズ, 数ともに増加傾向を示す多発性肝過形成結節の1例  [Not invited]鄭 浩柄; 工藤 正俊; 市川 勉; 乾 絹世; 岡田無文; 北口容子; 豊澤昌子; 石川恵美; 小川 力; 福田信宏; 南 康範; 末冨洋一郎; 中岡 良介; 中里 勝; 松井 繁長; 北野 雅之; 由谷逸朗; 川崎俊彦; 汐見幹夫第7回南大阪肝疾患研究会  2001/10  リーガロイヤルホテル堺, 大阪  第7回南大阪肝疾患研究会消化管粘膜下腫瘍に対するEUSを用いた血行動態評価およびFNAの有用性. (ワークショップII「消化管粘膜下腫瘍の診断・治療」)  [Not invited]北野 雅之; 工藤 正俊; 中岡 良介第67回日本消化器内視鏡学会近畿地方会  2001/10  大阪  第67回日本消化器内視鏡学会近畿地方会食道静脈瘤に対するELSLの有用性. (ワークショップI 「食道静脈瘤の治療戦略」)  [Not invited]松井 繁長; 工藤 正俊; 中岡 良介第67回日本消化器内視鏡学会近畿地方会  2001/10  大阪  第67回日本消化器内視鏡学会近畿地方会消化管内視鏡検査・治療時のインフォームドコンセント. (シンポジウムII「内視鏡診断・治療のリスクマネージメント」)  [Not invited]汐見幹夫; 工藤 正俊; 由谷逸朗第67回日本消化器内視鏡学会近畿地方会  2001/10  大阪  第67回日本消化器内視鏡学会近畿地方会教育講演「肝細胞癌の画像診断の進歩」  [Not invited]工藤 正俊第6回日本外科病理学会学術総会  2001/10  神戸大学医学部  第6回日本外科病理学会学術総会ランチョンセミナー「造影エコー診断の肝癌局所治療への応用:治療効果判定・局在および穿刺ガイド」  [Not invited]工藤 正俊第20回Microwave Surgery研究会  2001/10  東京ガーデンパレス  第20回Microwave Surgery研究会特別講演「C型肝炎と肝がんは克服できる: 最新情報」  [Not invited]工藤 正俊第5回近畿大学公開講座  2001/10  さやかホール, 大阪狭山市  第5回近畿大学公開講座Evaluation of treatment response after transcatheter arterial embolization mixed with Lipiodol for hepatocellular carcinoma: Utility of coded phase inversion  [Not invited]工藤 正俊; 南 康範; 鄭 浩柄; 末冨洋一郎; 川崎俊彦; 前川 清; 文 艶玲; 北野 雅之2001/10  Kuala Lumpur, MalaysiaCharacterization of hepatic tumours: Value of coded phase inversion harmonics  [Not invited]工藤 正俊; 南 康範; 鄭 浩柄; 末冨洋一郎; 北野 雅之; 川崎俊彦; 前川 清; 文 艶玲2001/10  Kuala Lumpur, MalaysiaRadiofrequency ablation (RFA) therapy under harmonic imaging guidance for recurrence of hepatocellular carcinoma (HCC) after local therapy  [Not invited]工藤 正俊; 南 康範; 鄭 浩柄; 川崎俊彦; 文 艶玲; 北野 雅之; 前川 清2001/10  Kuala Lumpur, MalaysiaCHA (Coded Harmonic Angio)モードを用いた造影ハーモニックイメージングによる膵・胆道領域腫瘍性病変のdynamic image. (パネルディスカッション「膵胆道領域腫瘍性病変のdynamic image」)  [Not invited]北野 雅之; 工藤 正俊; 川崎俊彦第43回日本消化器病学会大会  2001/10  京都  第43回日本消化器病学会大会消化管粘膜下腫瘍に対するEUSを用いた血行動態評価およびFNAの有用性. (ワークショップII「消化管粘膜下腫瘍の診断・治療」)  [Not invited]北野 雅之; 工藤 正俊; 中岡 良介第67回日本消化器内視鏡学会近畿地方会  2001/10  大阪  第67回日本消化器内視鏡学会近畿地方会消化管内視鏡検査・治療時のインフォームドコンセント. (シンポジウムII「内視鏡診断・治療のリスクマネージメント」)  [Not invited]汐見 幹夫; 工藤 正俊; 由谷 逸朗第67回日本消化器内視鏡学会近畿地方会  2001/10  大阪  第67回日本消化器内視鏡学会近畿地方会Levovistを用いた超音波造影撮像法Coded Harmonic Angio (LOGIQ700EXPERT)による肝腫瘍の質的診断  [Not invited]前川 清; 工藤 正俊; 文 艶玲; 鄭 浩柄; 末冨洋一郎; 南 康範; 川崎俊彦第4回関西超音波造影剤研究会  2001/09  大阪  第4回関西超音波造影剤研究会肝脾サルコイドーシスの一例  [Not invited]田中 陽一; 工藤 正俊; 米田 円; 辻 直子第75回日本消化器病学会近畿支部例会  2001/09  大阪国際交流センター  第75回日本消化器病学会近畿支部例会生体豚肝を用いたラジオ波焼灼療法の基礎的検討  [Not invited]鄭 浩柄; 工藤 正俊; 市川 勉; 乾 絹世; 岡田無文; 北口容子; 豊澤昌子; 石川恵美; 小川 力; 福田信宏; 南 康範; 末冨洋一郎; 中岡 良介; 中里 勝; 松井 繁長; 北野 雅之; 由谷逸朗; 川崎俊彦; 汐見幹夫第75回日本消化器病学会近畿支部例会  2001/09  大阪国際交流センター  第75回日本消化器病学会近畿支部例会肝細胞癌(HCC)に対するラジオ波(RFA)後に十二指腸穿通をきたした一例  [Not invited]末冨洋一郎; 工藤 正俊; 松井 繁長; 北口容子; 豊澤昌子; 乾 絹世; 岡田無文; 市川 勉; 石川恵美; 小川 力; 福田信宏; 南 康範; 鄭 浩柄; 中岡 良介; 北野 雅之; 由谷逸朗; 上硲 俊法; 川崎俊彦; 汐見幹夫第75回日本消化器病学会近畿支部例会  2001/09  大阪国際交流センター  第75回日本消化器病学会近畿支部例会肝血管腫に類似した画像所見を呈した肝細胞癌の1例  [Not invited]小川 力; 工藤 正俊; 川崎俊彦; 市川 勉; 乾 絹世; 岡田無文; 北口容子; 豊澤昌子; 石川恵美; 乾 可苗; 福田信宏; 末冨洋一郎; 南 康範; 鄭 浩柄; 中岡 良介; 松井 繁長; 北野 雅之; 由谷逸朗; 汐見幹夫第75回日本消化器病学会近畿支部例会  2001/09  大阪国際交流センター  第75回日本消化器病学会近畿支部例会部分的脾動脈塞栓術後内視鏡的治療が奏効した十二指腸静脈瘤出血の1例  [Not invited]松井 繁長; 工藤 正俊; 井上良一; 中岡 良介; 北野 雅之; 川崎俊彦; 汐見幹夫第8回門脈圧亢進症学会総会  2001/09  金沢  第8回門脈圧亢進症学会総会教育講演「血流で何が解るか-造影ハーモニックイメージング」  [Not invited]南 康範; 工藤 正俊日本超音波医学会第22回関西地方会  2001/09  国立京都国際会館  日本超音波医学会第22回関西地方会Levovist静注Coded Harmonic AngioによるGastro-intestinal stromal tumor (GIST)像の検討  [Not invited]福田信宏; 工藤 正俊; 北野 雅之; 文 艶玲; 小川 力; 南 康範; 末冨洋一郎; 鄭 浩柄; 遠田弘一; 川崎俊彦; 汐見幹夫; 由谷逸朗; 中里 勝; 松井 繁長; 中岡 良介; 石川恵美; 市川 勉; 乾 絹世; 岡田無文; 北口容子; 豊澤昌子; 川端久美子; 桑口 愛; 江口真由美; 前川 清日本超音波医学会第22回関西地方会  2001/09  国立京都国際会館  日本超音波医学会第22回関西地方会画像診断にて脾血管腫が強く疑われた1症例  [Not invited]岡田無文; 工藤 正俊; 川崎俊彦; 文 艶玲; 小川 力; 南 康範; 末冨洋一郎; 鄭 浩柄; 遠田弘一; 汐見幹夫; 由谷逸朗; 北野 雅之; 中里 勝; 松井 繁長; 中岡 良介; 福田信宏; 石川恵美; 市川 勉; 乾 絹世; 北口容子; 豊澤昌子; 川端久美子; 桑口 愛; 江口真由美; 前川 清日本超音波医学会第22回関西地方会  2001/09  国立京都国際会館  日本超音波医学会第22回関西地方会人工胸水併用造影ハーモニックガイド下RFA治療の試み  [Not invited]小川 力; 工藤 正俊; 南 康範; 鄭 浩柄; 文 艶玲; 末冨洋一郎; 遠田弘一; 川崎俊彦; 汐見幹夫; 由谷逸朗; 北野 雅之; 中里 勝; 松井 繁長; 中岡 良介; 福田信宏; 石川恵美; 市川 勉; 乾 絹世; 岡田無文; 北口容子; 豊澤昌子; 川端久美子; 桑口 愛; 江口真由美; 前川 清日本超音波医学会第22回関西地方会  2001/09  国立京都国際会館  日本超音波医学会第22回関西地方会肝炎症性腫瘤の1例  [Not invited]石川恵美; 工藤 正俊; 文 艶玲; 小川 力; 南 康範; 末冨洋一郎; 鄭 浩柄; 遠田弘一; 川崎俊彦; 汐見幹夫; 由谷逸朗; 北野 雅之; 中里 勝; 松井 繁長; 中岡 良介; 福田信宏; 市川 勉; 乾 絹世; 岡田無文; 北口容子; 豊澤昌子; 川端久美子; 桑口 愛; 江口真由美; 前川 清日本超音波医学会第22回関西地方会  2001/09  国立京都国際会館  日本超音波医学会第22回関西地方会Enhanced ultrasonography used Levovist “Classification of hepatic tumor on coded Harmonic Angio(LOGIQ700EXEPERT)”  [Not invited]2001/09  第4回関西超音波造影研究会(大阪)  関西超音波造影研究会  Coded Harmonic Angio(以下CHA、GELOGUQ700EXEPERT)を用いて未治療の肝占拠性病変143症例(肝細胞127例を含む)についてLevovistによる超音波造影を施行し、HCC121例中127例が豊富な血液構築像と早期濃染像を呈し、特徴的なタイプに分類が可能であった。また、転移性肝癌で50%およびAHの75%が特徴的なタイプに分類が可能であった。血行動態パターン分類にて鑑別診断が容易になる可能性について報告した。特別講演「肝におけるカラー/ パワードプラと経静脈的造影超音波の臨床的意義」  [Not invited]工藤 正俊北海道腹部造影エコー・ドプラ診断研究会  2001/09  札幌  北海道腹部造影エコー・ドプラ診断研究会教育講演「肝癌の局所治療」  [Not invited]工藤 正俊日本ハイパーサーミア学会第18回大会  2001/09  東京都文京シビックホール, 東京  日本ハイパーサーミア学会第18回大会特別講演「造影ハーモニック法による肝細胞癌の診断と治療, 最近の新しい展開」  [Not invited]工藤 正俊腹部造影超音波セミナー  2001/09  新潟大学, 新潟  腹部造影超音波セミナーハンズオンセミナー「肝細胞癌の造影ハーモニックイメージングのコツ」  [Not invited]工藤 正俊新潟大学病院  2001/09  新潟  新潟大学病院特別講演「肝細胞癌の診断と治療の最近の進歩-造影エコーからRFAまで」  [Not invited]工藤 正俊山梨外科医会  2001/09  ロイヤルガーデンホテル, 甲府  山梨外科医会ランチョンセミナー「肝細胞癌の発生・進展と血流動態-造影ハーモニック法も含めて-」  [Not invited]工藤 正俊第12回日本消化器癌発生学会総会  2001/09  シェーンバッハ・サボー, 東京  第12回日本消化器癌発生学会総会シンポジウム「消化器疾患診断における最先端(消化管)」: EUS下穿刺及び造影併用超音波内視鏡診断の有用性  [Not invited]中岡 良介; 工藤 正俊; 北野 雅之第75回日本消化器病学会近畿支部例会  2001/09  大阪国際交流センター  第75回日本消化器病学会近畿支部例会特別講演「肝細胞癌治療の課題-画像診断の立場から」  [Not invited]工藤 正俊第22回犬山シンポジウム  2001/08  名鉄犬山ホテル, 犬山市  第22回犬山シンポジウム特別講演「造影ハーモニックイメージングの治療への応用」  [Not invited]工藤 正俊GE Ultrasound Clinical Forum 2001  2001/08  毎日新聞オーバルホール, 大阪  GE Ultrasound Clinical Forum 2001長期間ラミブジンを投与中のB型慢性肝炎の1例  [Not invited]鄭 浩柄; 工藤 正俊; 小川 力; 南 康範; 文 艶玲; 末冨洋一郎; 遠田弘一; 川崎俊彦; 汐見幹夫; 由谷逸朗; 北野 雅之; 中里 勝; 松井 繁長; 中岡 良介; 福田信宏; 石川恵美; 市川 勉; 乾 絹世; 岡田無文; 北口容子; 豊澤昌子第2回関西B型肝炎研究会  2001/07  ガーデンシティ-クラブ大阪  第2回関西B型肝炎研究会特別講演「血流動態からみた肝細胞癌の診断と治療」  [Not invited]工藤 正俊第79回熊本肝疾患懇話会  2001/07  熊本市医師会館, 熊本  第79回熊本肝疾患懇話会特別講演「肝細胞癌の局所治療法:ラジオ波治療を中心に」  [Not invited]工藤 正俊津山肝疾患研究会  2001/07  津山鶴山ホテル, 津山市  津山肝疾患研究会特別講演「肝細胞癌の診断と治療: 最近の新しい展開」  [Not invited]工藤 正俊腹部超音波造影セミナー「Clinical Forum in Nagoya」  2001/07  名古屋市吹上ホール, 名古屋  腹部超音波造影セミナー「Clinical Forum in Nagoya」特別講演「造影ハーモニック法による肝細胞癌の診断と治療」  [Not invited]工藤 正俊GE Ultrasound Clinical Forum  2001/07  仙台国際センター, 仙台  GE Ultrasound Clinical Forum特別講演「造影ハーモニック法による肝細胞癌の診断と治療: 最近の新しい展開」  [Not invited]工藤 正俊超音波クリニカルフォーラム  2001/07  野口英世 記念会館, 東京  超音波クリニカルフォーラム炎症性腸疾患におけるNKT細胞の役割り  [Not invited]八木田 旭邦; 丸山 正二; 若杉慎司; 助川 寧; 工藤 正俊; 高添正和厚生科学研究費補助金特定疾患対策研究事業「難治性炎症性腸管障害に関する調査研究」平成13年度第1回総会  2001/07  厚生科学研究費補助金特定疾患対策研究事業「難治性炎症性腸管障害に関する調査研究」平成13年度第1回総会続発性ヘモクロマトーシスに肝細胞癌(HCC)を合併した1症例  [Not invited]鄭 浩柄; 工藤 正俊; 南 康範; 末冨洋一郎; 川崎俊彦; 金丸 昭久第37回日本肝癌研究会  2001/06  海峡メッセ下関, 下関  第37回日本肝癌研究会肝細胞癌に対する経皮経肝高周波焼灼術にて門脈内血栓の形成を認めた1症例  [Not invited]末冨洋一郎; 工藤 正俊; 永島美樹; 南 康範; 鄭 浩柄; 川崎俊彦第37回日本肝癌研究会  2001/06  海峡メッセ下関, 下関  第37回日本肝癌研究会肝細胞癌におけるCoded Harmonic Angioを用いた血行動態分類と治療効果判定  [Not invited]南 康範; 工藤 正俊; 鄭 浩柄; 末冨洋一郎; 遠田弘一; 川崎俊彦; 文 艶玲; 前川 清第37回日本肝癌研究会  2001/06  海峡メッセ下関, 下関  第37回日本肝癌研究会問題症例検討会,「治療を中心に」  [Not invited]鄭 浩柄; 工藤 正俊; 南 康範; 末冨洋一郎; 川崎俊彦第37回日本肝癌研究会  2001/06  海峡メッセ下関, 下関  第37回日本肝癌研究会特別講演「肝硬変の血流動態: 超音波血流画像解析と病態」  [Not invited]工藤 正俊肝疾患病理研究会  2001/06  東京  肝疾患病理研究会特別講演「肝細胞癌の診断と治療: 最近の進歩」  [Not invited]工藤 正俊日本消化器病学会第77回九州支部例会(北野正剛会長)  2001/06  別府  日本消化器病学会第77回九州支部例会(北野正剛会長)ランチョンセミナー「超音波を用いた肝癌治療のstrategy: 造影超音波の肝癌局所治療への応用」  [Not invited]工藤 正俊第37回日本肝癌研究会  2001/06  海峡 メッセ下関, 下関  第37回日本肝癌研究会Invited Lecture "Recent Advances of Imaging Diagnosis and Ablation of Hepatocellular Carcinoma"  [Not invited]工藤 正俊The 3rd symposium of the Korean Liver Cancer Study Group (KLCSG)  2001/06  Seoul, Korea  The 3rd symposium of the Korean Liver Cancer Study Group (KLCSG)Invited Lecture "Diagnosis and Treatment of Hepatocellular Carcinoma: Recent advances"  [Not invited]工藤 正俊The 857th Radiology Ground Round  2001/06  Seoul National University, Seoul, Korea  The 857th Radiology Ground RoundDoes TAE therapy have a survival benefit in patients with hepatocellular carcinoma?  [Not invited]岡 博子; 工藤 正俊; 山崎 修; 真鍋隆夫; 井上 健; 関 寿人; 大崎往夫; 春日井博志第37回日本肝癌研究会  2001/06  海峡メッセ下関, 下関  第37回日本肝癌研究会肝細胞癌に対するLipiodol TAE療法後の治療効果判定: 造影超音波ハーモニック法の有用性について. (ワークショップ「肝動脈塞栓療法の再評価と今後の展開」)  [Not invited]南 康範; 工藤 正俊; 鄭 浩柄; 末冨 洋一郎; 遠田弘一; 川崎俊彦; 文 艶玲; 前川 清第37回日本肝癌研究会  2001/06  海峡メッセ下関, 下関  第37回日本肝癌研究会オリンパス社製Sonosite 180の画質性能に関する検討  [Not invited]文 艶玲; 工藤 正俊; 鄭 浩柄; 南 康範; 末冨洋一郎; 遠田弘一; 川崎俊彦; 江口真由美; 前川 清; 丁 紅日本超音波医学会第74回学術集会  2001/05  東京ビッグサイト, 東京  日本超音波医学会第74回学術集会肝細胞癌 (HCC)局所治療後の遺残癌に対する造影超音波下RFAの試み  [Not invited]鄭 浩柄; 工藤 正俊; 文 艶玲; 南 康範; 末冨洋一郎; 遠田弘一; 川崎俊彦; 江口真由美; 前川 清; 丁 紅日本超音波医学会第74回学術集会  2001/05  東京ビッグサイト, 東京  日本超音波医学会第74回学術集会肝細胞癌に対するLipiodol TAE療法後の治療効果判定: 造影超音波ハーモニック法の有用性について  [Not invited]南 康範; 工藤 正俊; 鄭 浩柄; 末冨 洋一郎; 遠田弘一; 丁 紅; 文 艶玲; 川崎俊彦; 桑口 愛; 前川 清日本超音波医学会第74回学術集会  2001/05  東京ビッグサイト, 東京  日本超音波医学会第74回学術集会Classification of hemodynamic patterns of hepatic tumor on Coded Harmonic Angio mode  [Not invited]日本超音波医学会第74回学術集会(東京)  2001/05  日本超音波医学会第74回学術集会(東京)  Coded Harmonic Angio(以下CHA、GE LOGIQ700EXPERT)を用いて未治療の肝占拠性病変87症例(肝細胞癌58症例を含む)についてLevovistによる超音波造影を施行し、HCC58例中49例の84.5%が豊富な血管構築像と早期濃染像を呈し、特徴的なタイプに分類が可能であった。また、CCCで50%、転移性肝癌で50%およびAHの75%が特徴的なタイプに分類が可能であった。血行分類パターンにて鑑別診断が容易になる可能性が示唆された。特別講演「肝腫瘤性病変の造影超音波診断」  [Not invited]工藤 正俊超音波造影剤学術講演会  2001/05  新大阪シティプラザ  超音波造影剤学術講演会特別講演「肝細胞診療の最近の進歩: 超音波造影からRFAまで」  [Not invited]工藤 正俊岡山血管造影・INTERVENTIONAL RADIOLOGY症例検討会(SAIRO)  2001/05  岡山大学放射線科カンファレンスルーム, 岡山  岡山血管造影・INTERVENTIONAL RADIOLOGY症例検討会(SAIRO)特別講演「造影エコー法による肝細胞癌の診断と治療」  [Not invited]工藤 正俊第74回佐賀肝臓懇話会  2001/05  ホテルニューオータニ佐賀, 佐賀  第74回佐賀肝臓懇話会特別講演「肝細胞癌診療の最近の進歩: 造影ハーモニック法からRFAまで」  [Not invited]工藤 正俊第41回山口県肝癌治療検討会  2001/05  山口  第41回山口県肝癌治療検討会教育講演「造影エコー診断の治療への応用: 治療効果判定・穿刺ガイド」  [Not invited]工藤 正俊第19回超音波専門医・検査士セミナー  2001/05  パシフィコ横浜, 横浜  第19回超音波専門医・検査士セミナーランチョンセミナー「携帯型超音波の現状と今後の展望」  [Not invited]工藤 正俊第74回日本超音波医学会学術集会  2001/05  横浜  第74回日本超音波医学会学術集会  ランチョンセミナー「携帯型超音波の現状と今後の展望」 , ,ランチョンセミナー「肝細胞癌の診断と治療の最近の進歩:造影エコーからRFAまで」  [Not invited]工藤 正俊第37回日本肝臓学会総会  2001/05  パシフィコ横浜, 横浜  第37回日本肝臓学会総会門脈血流流入結節の造影ハーモニック法の検討.  [Not invited]鄭 浩柄; 工藤 正俊; 南 康範; 末冨 洋一郎; 遠田 弘一; 川崎 俊彦; 大谷真由美; 前川 清; 丁 紅; 文 艶玲日本超音波医学会第74回学術集会  2001/05  東京ビッグサイト, 東京  日本超音波医学会第74回学術集会Levovist造影によるFundamental Power Doppler とHarmonic Power Dopplerの肝腫瘍内血流検出能の比較検討.  [Not invited]文 艶玲; 工藤 正俊; 鄭 浩柄; 南 康範; 末冨 洋一郎; 遠田 弘一; 川崎 俊彦; 大谷真由美; 前川 清; 丁 紅日本超音波医学会第74回学術集会  2001/05  東京ビッグサイト, 東京  日本超音波医学会第74回学術集会FNHにおける造影ハーモニック像の検討.  [Not invited]文 艶玲; 工藤 正俊; 丁 紅; 前川 清; 桑口 愛; 南 康範; 鄭 浩柄; 末冨 洋一郎; 遠田 弘一; 川崎 俊彦日本超音波医学会第74回学術集会  2001/05  東京ビッグサイト, 東京  日本超音波医学会第74回学術集会超小型コンベックスアレイを内蔵したEUSの使用経験.  [Not invited]末冨 洋一郎; 工藤 正俊; 川崎 俊彦; 南 康範; 文 艶玲; 丁 紅; 遠田 弘一; 鄭 浩柄; 前川 清; 桑口 愛日本超音波医学会第74回学術集会  2001/05  東京ビッグサイト, 東京  日本超音波医学会第74回学術集会Coded Harmonic Angioによる肝腫瘍の血行動態的パターン分類の試み.  [Not invited]前川 清; 工藤 正俊; 大谷真由美; 文 艶玲; 丁 紅; 末冨 洋一郎; 鄭 浩柄; 南 康範; 遠田 弘一; 川崎 俊彦日本超音波医学会第74回学術集会  2001/05  東京ビッグサイト, 東京  日本超音波医学会第74回学術集会Levovist(R)静注Coded Harmonic Angioによる肝血管腫像の検討.  [Not invited]川崎 俊彦; 工藤 正俊; 文 艶玲; 南 康範; 末冨 洋一郎; 鄭 浩柄; 遠田 弘一; 江口真由美; 前川 清; 丁 紅日本超音波医学会第74回学術集会  2001/05  東京ビッグサイト, 東京  日本超音波医学会第74回学術集会肝細胞癌 (HCC)局所治療後の遺残癌に対する造影超音波下RFAの試み.  [Not invited]鄭 浩柄; 工藤 正俊; 遠田 弘一; 川崎 俊彦2001/05肝細胞癌に対するLipiodol TAE療法後の治療効果判定: 造影超音波ハーモニック法の有用性について.  [Not invited]南 康範; 工藤 正俊; 鄭 浩柄; 末冨 洋一郎; 北野 雅之; 遠田 弘一; 川崎 俊彦; 文 艶玲; 前川 清第37回日本肝臓学会総会  2001/05  パシフィコ横浜, 横浜  第37回日本肝臓学会総会保存的に治療し得た若年膵管内結石症の1例.  [Not invited]木下 理恵; 工藤 正俊; 汐見 幹夫; 福田 信宏; 南 康範; 末冨 洋一郎; 鄭 浩柄; 中岡 良介; 松井 繁長; 北野 雅之; 由谷 逸朗; 上硲 俊法; 川崎 俊彦第61回日本消化器内視鏡学会総会  2001/05  神戸  第61回日本消化器内視鏡学会総会上部消化管疾患に対するアルゴンプラズマ凝固法 (Argon Plasma Coagulation; APC)治療の有用性の検討.  [Not invited]中岡 良介; 工藤 正俊; 汐見 幹夫; 末冨 洋一郎; 南 康範; 鄭 浩柄; 松井 繁長; 北野 雅之; 由谷 逸朗; 上硲 俊法; 川崎 俊彦第61回日本消化器内視鏡学会総会  2001/05  神戸  第61回日本消化器内視鏡学会総会Role of ECL-cell histamine in acute gastric mucosal damage induced by ischemia-reperfusion  [Not invited]北野 雅之; 工藤 正俊Digestive Disease Week-2001  2001/05  Atlanta, Georgi  Digestive Disease Week-2001肝細胞癌(HCC)に対する経皮的ラジオ波熱凝固療法(RFA)の検討. (シンポジウム「ラジオ波焼灼術の適応・効果・合併症」)  [Not invited]鄭 浩柄; 工藤 正俊; 遠田弘一; 南 康範; 末冨 洋一郎; 川崎俊彦第37回日本肝癌研究会  2001/05  海峡メッセ下関, 下関  第37回日本肝癌研究会東京ビッグサイト, 東京  [Not invited]川崎俊彦; 工藤 正俊日本超音波医学会第74回学術集会  2001/05  日本超音波医学会第74回学術集会高分解能造影モードによる腫瘍血流の動的・形態的解析 (シンポジウム「肝腫瘍における造影エコー法の応用」)  [Not invited]川崎俊彦; 工藤 正俊; 前川 清日本超音波医学会第74回学術集会  2001/05  東京ビッグサイト, 東京  日本超音波医学会第74回学術集会造影エコーの治療的応用. (シンポジウム「 造影エコー法の理論と実際」)  [Not invited]南 康範; 工藤 正俊; 文 艶玲; 末冨 洋一郎; 鄭 浩柄; 遠田弘一; 川崎俊彦日本超音波医学会第74回学術集会  2001/05  東京ビッグサイト, 東京  日本超音波医学会第74回学術集会肝腫瘍診断におけるHarmonic Imaging法の現況と臨床的有用性. (シンポジウム「Tissue Harmonic Imagingの理論と実際」)  [Not invited]鄭 浩柄; 工藤 正俊; 前川 清; 杤尾人司日本超音波医学会第74回学術集会  2001/05  東京ビッグサイト, 東京  日本超音波医学会第74回学術集会血流動態より境界病変と考えられる硬変肝内微少結節性病変の予後 (パネルディスカッション「肝硬変に生じた小結節性病変の診断と対応」)  [Not invited]福永豊和; 工藤 正俊; 織野彬雄第37回日本肝臓学会総会  2001/05  パシフィコ横浜, 横浜  第37回日本肝臓学会総会肝細胞癌に対するRadiofrequency ablation therapy後の造影CT所見についての検討  [Not invited]栁生 行伸; 井上 正昭; 大石 初香; 西村 恭昌; 工藤 正俊; 小野 幸彦第60回日本医学放射線学会総会  2001/04  東京  第60回日本医学放射線学会総会  肝細胞癌に対するRadiofrequency ablation therapy後治療部周囲に生じる造影効果の持続期間、造影効果の範囲について検討した。術直後の造影効果については可逆性であり、熱凝固による血管透過性亢進などが関与していると考えられた特別講演「造影エコー法による肝細胞癌の診断と治療」  [Not invited]工藤 正俊第5回MRI検討会  2001/04  福島テルサ, 福島  第5回MRI検討会TAE治療後にHarmonic Imaging にて血流の残存を認めた肝細胞がん結節の予後. 「肝細胞がんに対する肝動脈塞栓療法の延命効果に関する研究」.  [Not invited]南 康範; 工藤 正俊; 川崎 俊彦平成13年度第1回厚生省班会議  2001/04  国立がんセンター, 東京  平成13年度第1回厚生省班会議肝細胞癌(HCC)に対するLipTAE治療効果判定における造影ハーモニックエコー法(CHA)の有用性.  [Not invited]南 康範; 工藤 正俊; 文 艶玲; 鄭 浩柄; 末冨 洋一郎; 遠田 弘一; 川崎俊彦; 汐見 幹夫; 上硲 俊法; 由谷 逸朗; 北野 雅之; 松井 繁長; 中岡 良介; 石川 恵美; 乾 可苗; 小村 康湖; 永島 美樹; 川端久美子; 桑口 愛; 江口真由美; 谷口真由美; 前川 清日本超音波医学会第21回関西地方会  2001/04  大阪  日本超音波医学会第21回関西地方会特別講演「造影エコー法による肝腫瘍の診断と治療」  [Not invited]工藤 正俊備後肝胆膵研究会  2001/03  福山  備後肝胆膵研究会特別講演「肝臓の超音波解剖と超音波診断」  [Not invited]工藤 正俊全国社会保険協会連合会, 平成12年度 超音波研究会  2001/03  全社連会館, 東京  全国社会保険協会連合会, 平成12年度 超音波研究会間歇的に主乳頭からの粘液排泄が見られた粘液産生膵腫瘍の2手術例.  [Not invited]福田 信宏; 工藤 正俊; 汐見 幹夫; 木下 理恵; 南 康範; 末冨 洋一郎; 鄭 浩柄; 中岡 良介; 松井 繁長; 北野 雅之; 由谷 逸朗; 上硲 俊法; 川崎 俊彦第66回日本消化器内視鏡学会近畿地方会  2001/03  大阪  第66回日本消化器内視鏡学会近畿地方会十二指腸静脈瘤出血の1例.  [Not invited]永島 美樹; 工藤 正俊; 松井 繁長; 小村 康湖; 乾 可苗; 石川 恵美; 末冨 洋一郎; 南 康範; 中岡 良介; 鄭 浩柄; 北野 雅之; 由谷 逸朗; 上硲 俊法; 川崎 俊彦; 汐見 幹夫; 井上 良一第66回日本消化器内視鏡学会近畿地方会  2001/03  大阪  第66回日本消化器内視鏡学会近畿地方会超小型コンベックスアレイを内蔵したEUSが診断に有用であった胃粘膜下腫瘍の1症例.  [Not invited]北野 雅之; 工藤 正俊; 中岡 良介; 前川 清; 末冨 洋一郎; 南 康範; 鄭 浩柄; 松井 繁長; 由谷 逸朗; 上硲 俊法; 川崎 俊彦; 汐見 幹夫第66回日本消化器内視鏡学会近畿地方会  2001/03  大阪  第66回日本消化器内視鏡学会近畿地方会ワークショップIII「肝胆膵疾患とステント」悪性胆道閉塞に対するステント治療  [Not invited]松井 繁長; 工藤 正俊; 中岡 良介; 汐見 幹夫第66回日本消化器内視鏡学会近畿地方会  2001/03  大阪  第66回日本消化器内視鏡学会近畿地方会特別講演「肝細胞癌治療におけるAFP-L3分画の役割と意義」OLM(大阪Liver Meeting)  [Not invited]工藤 正俊大阪大学第一内科消化器グループ関連病院会議  2001/02  大阪  大阪大学第一内科消化器グループ関連病院会議特別講演「肝細胞癌に対するラジオ波熱凝固療法(RFA)の現況」  [Not invited]工藤 正俊第16回神戸消化器病懇話会  2001/02  神戸  第16回神戸消化器病懇話会教育講演「肝疾患における造影エコー法の実際」  [Not invited]工藤 正俊第90回超音波診断法講習会(日本超音波医学会主催)  2001/02  パシフィコ横浜, 横浜  第90回超音波診断法講習会(日本超音波医学会主催)特別講演「肝細胞癌の血流と画像」  [Not invited]工藤 正俊第90回名古屋肝疾患研究会  2001/02  栄ガスビル, 名古屋  第90回名古屋肝疾患研究会特別講演「超音波血流画像による肝細胞癌の血流動態の解析」  [Not invited]工藤 正俊第7回肝血流動態イメージ研究会  2001/02  東京商工会議所, 東京  第7回肝血流動態イメージ研究会Special Lecture "Diagnosis and Treatment of Hepatocellular Carcinoma: Special Emphasis on Harmonic Imaging"  [Not invited]工藤 正俊GE Medical Meeting in Milwaukee  2001/02  Milwaukee  GE Medical Meeting in Milwaukee肝細胞癌に対するLipiodol TAE後の治療効果判定と治療ガイド: Coded Phase-inversion Harmonicsの有用性.  [Not invited]南 康範; 工藤 正俊; 鄭 浩柄; 末冨 洋一郎; 中岡 良介; 遠田 弘一; 北野 雅之; 川崎 俊彦第36回京都肝疾患懇話会  2001/02  京都ホテル, 京都  第36回京都肝疾患懇話会超小型コンベックスアレイを内蔵したEUSの使用経験.  [Not invited]末冨 洋一郎; 工藤 正俊; 北野 雅之; 南 康範; 文 艶玲; 遠田 弘一; 鄭 浩柄; 中岡 良介; 松井 繁長; 由谷 逸朗; 上硲 俊法; 川崎 俊彦; 汐見 幹夫; 前川 清; 江口真由美; 大谷真由美; 桑口 愛; 川端久美子第3回関西超音波造影剤研究会  2001/02  大阪  第3回関西超音波造影剤研究会肝細胞癌(HCC)に対する経皮経肝高周波焼灼術(RFA)後に門脈内血栓の形成を認めた1症例.  [Not invited]永島 美樹; 工藤 正俊; 鄭 浩柄; 南 康範; 末冨 洋一郎; 汐見 幹夫; 中岡 良介; 小村 康湖; 石川 恵美; 乾 可苗; 上硲 俊法第74回日本消化器病学会近畿支部例会  2001/02  京都  第74回日本消化器病学会近畿支部例会動注化学療法及び経皮経肝ラジオ波焼灼術のコンビネーション治療が著効を呈したStage IV-A肝細胞癌の1例.  [Not invited]乾 可苗; 工藤 正俊; 小村 康湖; 由谷 逸朗; 川崎 俊彦; 鄭 浩柄; 南 康範; 末冨 洋一郎; 遠田 弘一; 汐見 幹夫; 上硲 俊法; 北野 雅之; 松井 繁長; 中岡 良介; 永島 美樹; 石川 恵美第74回日本消化器病学会近畿支部例会  2001/02  京都  第74回日本消化器病学会近畿支部例会興味ある画像所見を呈した硬化型肝細胞癌の1例.  [Not invited]小村 康湖; 工藤 正俊; 川崎 俊彦; 鄭 浩柄; 南 康範; 末冨 洋一郎; 遠田 弘一; 汐見 幹夫; 上硲 俊法; 由谷 逸朗; 北野 雅之; 松井 繁長; 中岡 良介; 永島 美樹; 石川 恵美; 乾 可苗第74回日本消化器病学会近畿支部例会  2001/02  京都  第74回日本消化器病学会近畿支部例会続発性ヘモクロマトーシスに肝細胞癌(HCC)を合併した1症例.  [Not invited]鄭 浩柄; 工藤 正俊; 石川 恵美; 乾 可苗; 小村 康湖; 永島 美樹; 南 康範; 末冨 洋一郎; 中岡 良介; 北野 雅之; 松井 繁長; 由谷 逸朗; 上硲 俊法; 川崎 俊彦; 汐見 幹夫; 金丸 昭久第74回日本消化器病学会近畿支部例会  2001/02  京都  第74回日本消化器病学会近畿支部例会OLYMPUS社製Sonosite 180の画像性能に関する検討.  [Not invited]文 艶玲; 工藤 正俊; 鄭 浩柄; 南 康範; 末冨 洋一郎; 遠田 弘一; 川崎 俊彦; 汐見 幹夫; 上硲 俊法; 由谷 逸朗; 北野 雅之; 松井 繁長; 中岡 良介; 石川 恵美; 乾 可苗; 小村 康湖; 永島 美樹; 川端久美子; 桑口 愛; 江口真由美; 谷口真由美; 前川 清日本超音波医学会第21回関西地方会  2001/02  大阪  日本超音波医学会第21回関西地方会レボビスト造影下狙撃生検が有用であった限局性結節性過形成(FNH)の1例.  [Not invited]小村 康湖; 工藤 正俊; 中岡 良介; 文 艶玲; 鄭 浩柄; 南 康範; 末冨 洋一郎; 遠田 弘一; 川崎 俊彦; 汐見 幹夫; 上硲 俊法; 由谷 逸朗; 北野 雅之; 松井 繁長; 石川 恵美; 乾 可苗; 永島 美樹; 川端久美子; 桑口 愛; 江口真由美; 谷口真由美; 前川 清日本超音波医学会第21回関西地方会  2001/02  大阪  日本超音波医学会第21回関西地方会造影超音波検査にて特徴的な血行動態を把握し得た肝血管筋脂肪腫(AML)の1例.  [Not invited]石川 恵美; 工藤 正俊; 南 康範; 文 艶玲; 鄭 浩柄; 末冨 洋一郎; 遠田 弘一; 川崎 俊彦; 汐見 幹夫; 上硲 俊法; 由谷 逸朗; 北野 雅之; 松井 繁長; 中岡 良介; 乾 可苗; 小村 康湖; 永島 美樹; 川端久美子; 桑口 愛; 江口真由美; 谷口真由美; 前川 清日本超音波医学会第21回関西地方会  2001/02  大阪  日本超音波医学会第21回関西地方会超音波内視鏡 (EUS)下レボビスト造影を施行した胃粘膜下腫瘍の1例.  [Not invited]中岡 良介; 工藤 正俊; 北野 雅之; 末冨 洋一郎; 鄭 浩柄; 文 艶玲; 南 康範; 遠田 弘一; 川崎 俊彦; 汐見 幹夫; 上硲 俊法; 由谷 逸朗; 松井 繁長; 石川 恵美; 乾 可苗; 小村 康湖; 永島 美樹; 川端久美子; 桑口 愛; 江口真由美; 谷口真由美; 前川 清日本超音波医学会第21回関西地方会  2001/02  大阪  日本超音波医学会第21回関西地方会肝細胞癌局所治療後の遺残癌に対する造影超音波下RFAの試み.  [Not invited]鄭 浩柄; 工藤 正俊; 文 艶玲; 南 康範; 末冨 洋一郎; 遠田 弘一; 川崎 俊彦; 汐見 幹夫; 上硲 俊法; 由谷 逸朗; 北野 雅之; 松井 繁長; 中岡 良介; 石川 恵美; 乾 可苗; 小村 康湖; 永島 美樹; 川端久美子; 桑口 愛; 江口真由美; 谷口真由美; 前川 清日本超音波医学会第21回関西地方会  2001/02  大阪  日本超音波医学会第21回関西地方会肝細胞癌の多段階発育に伴う流出血管の変遷について: 超音波ドプラ法による検討  [Not invited]杤尾人司; 工藤 正俊; 佐々木一朗; 岩崎信広; 浜田一美; 中村仁美; 中山圭子; 曽我登志子; 藤本敏明; 森本義人; 岡部純弘; 高橋 健; 西本正興; 西馬信一; 上島一臣; 木本直哉; 岡田明彦; 樫田博史; 平佐昌弘; 伊吹康良; 織野彬雄; 冨田周介第7回肝血流動態イメージ研究会  2001/02  東京  第7回肝血流動態イメージ研究会超音波ドプラ法で評価した肝動脈の末梢血管抵抗(Resistant Index)と脾腫との関係: 肝硬変に随伴する脾腫大の機序について.  [Not invited]杤尾人司; 工藤 正俊; 佐々木一朗; 岩崎信広; 浜田一美; 中村仁美; 中山圭子; 曽我登志子; 藤本敏明; 森本義人; 岡部純弘; 高橋 健; 西本正興; 西馬信一; 上島一臣; 木本直哉; 岡田明彦; 樫田博史; 平佐昌弘; 伊吹康良; 織野彬雄; 冨田周介第7回肝血流動態イメージ研究会  2001/02  東京  第7回肝血流動態イメージ研究会肝細胞癌(HCC)局所治療後の遺残癌に対する造影超音波下RFAの試み.  [Not invited]鄭 浩柄; 工藤 正俊; 南 康範; 遠田弘一; 川崎俊彦; 文 艶玲第7回肝血流動態イメージ研究会  2001/02  東京  第7回肝血流動態イメージ研究会シンポジウム「高齢化社会と超音波医学」高齢者における消化器疾患の臨床像と腹部超音波検査の役割  [Not invited]南 康範; 工藤 正俊; 川崎俊彦日本超音波医学会第21回関西地方会  2001/02  大阪  日本超音波医学会第21回関西地方会肝細胞癌に対するLipiodol TAE療法後の治療効果判定: 超音波harmonic imagingの有用性について.  [Not invited]南 康範; 工藤 正俊; 鄭 浩柄; 末富洋一郎; 遠田弘一; 川崎俊彦; 文 艶玲; 前川 清第7回肝血流動態イメージ研究会  2001/02  東京  第7回肝血流動態イメージ研究会B-modeにて同定困難な症例における超音波造影下治療の検討  [Not invited]南 康範; 工藤 正俊; 市川 勉; 乾 絹世; 岡田無文; 北口容子; 豊澤昌子; 石川恵美; 鄭 栄琴; 小川 力; 福田信宏; 末冨洋一郎; 鄭 浩柄; 中岡 良介; 遠田弘一; 松井 繁長; 北野 雅之; 由谷逸朗; 川崎俊彦; 汐見幹夫; 川端久美子; 桑口 愛; 江口真由美; 前川 清日本超音波医学会第23回関西地方会  2001/01  大阪  日本超音波医学会第23回関西地方会肝静脈が主たる流出血管であることが造影エコー法により示された肝血管筋脂肪腫の2症例  [Not invited]鄭 栄琴; 工藤 正俊; 市川 勉; 乾 絹世; 岡田無文; 北口容子; 豊澤昌子; 石川恵美; 小川 力; 福田信宏; 末冨洋一郎; 南 康範; 鄭 浩柄; 中岡 良介; 遠田弘一; 松井 繁長; 北野 雅之; 由谷逸朗; 川崎俊彦; 汐見幹夫; 川端久美子; 桑口 愛; 江口真由美; 前川 清日本超音波医学会第23回関西地方会  2001/01  大阪  日本超音波医学会第23回関西地方会特別講演「肝腫瘍の血流と病態」  [Not invited]工藤 正俊第4回信州肝疾患研究会  2001/01  信州大学附属病院, 松本  第4回信州肝疾患研究会特別講演「肝細胞癌の血流と病態・治療」  [Not invited]工藤 正俊第27回肝臓研究会  2001/01  経団連会館, 東京  第27回肝臓研究会Enhanced ultrasonography of hepatocellular carcinoma  [Not invited]ザ・ベストイメージ2000画論ミレニアム  2000/12  東京  ザ・ベストイメージ2000画論ミレニアム  高分子および中分化域を有する肝細胞癌についてLevovistを用いた造影超音波検査を行い、腫瘍血管造影効果および実質濃染像より腫瘍の分化度に一致した造影効果が得られたので報告した。A case of autoimmune thyroiditis with autoimmune gastritis, pernicious anemia  [Not invited]北野 元一; 青木 矩彦; 藤本 美香; 矢田 裕人; 宮武 利行; 山内 孝哲; 西村 明芳; 荒井 宏司; 大野 恭裕; 松井 繁長; 工藤 正俊第162回日本内科学会近畿地方会  2000/09  大阪  第162回日本内科学会近畿地方会A case of stomach carcinoma:hypervascular imaging in the wall detected by ultrasonography  [Not invited]日本超音波医学会第20回関西地方会  2000/09  大阪  日本超音波医学会第20回関西地方会  GE社製LOGIQ700のリニアプローブを用いて、B-mode、THI、CDI、PDI並びにPFDにて、質的診断が可能であった胃癌症例を経験したので報告した。Classification of hepatic tumor on Coded Harmonic Angio mode  [Not invited]第20回日本超音波医学会関西地方会  2000/09  大阪  第20回日本超音波医学会関西地方会  CHAを用いて肝占拠性病変(肝細胞癌35例、肝血管腫8例、転位性肝癌3例)についてLevovistによる超音波造影を施行し、腫瘍の質的診断が可能であったので報告した。模擬患者、ロールプレイ、OSLEを導入した臨床診断学実習の効果と問題点  [Not invited]石川 欽司; 青木 矩彦; 金丸 昭久; 福岡 正博; 高橋 光雄; 工藤 正俊; 花田 雅憲; 安富 正幸; 大柳 治正; 種子田 護; 浜西 千秋; 星合 昊; 松尾 理; 橋本 重夫第32回日本医学教育学会  2000/07  仙台  第32回日本医学教育学会Clinical assessment of B-Flow technique diagnosis for liver diseases  [Not invited]日本超音波医学会第73回学術集会  2000/05  横浜  日本超音波医学会第73回学術集会  赤血球などの微小な反射信号を画像化するBモ-ド血流表示を用いて肝内の血流を観察した。Bモ-ドで血流を表示するためカラ-ドプラ法に比べ空間分解能やリアルタイム性に優れ、肝疾患における血流動態観察に有用であったため報告した。Enhanced Color Doppler imaging of liver tumor;Detection of tumor parenchmal flow by intermittent imaging  [Not invited]日本超音波医学会第73回学術集会  2000/05  横浜  日本超音波医学会第73回学術集会  新しく開発されたCoded Harmonic Angio法はLevovistを用いた造影において連続送信にて腫瘍の血管構築ならびに腫瘍内血管の描出が注入早期相にて描出され注入後期相では間欠操作によるFlash echoすなわちperfusion imageが得られた肝腫瘍の質的診断に有用な方法として評価し、報告した。A case of atypical FNH of the liver after preserved pylolus pucreatoduodenectomy with portal vein for puncreatoblastoma  [Not invited]山内 勝治; 大柳 治正; 窪田昭男; 米倉 竹夫; 臼井規朗; 廣岡慎治; 小角 卓也; 山崎満夫; 工藤 正俊第37回日本小児外科学会総会  2000/05  福岡  第37回日本小児外科学会総会  膵芽腫に対する門脈合併切除幽門輪温存膵頭十二指腸切除後約1年の5歳男児に非定型的肝限局性結節性過形成(FNH)様病変を生じ、増大傾向を示すため凝固療法を施行した症例を報告した。Intermittent Color Doppler imaging of HCC used Levovist  [Not invited]日本超音波医学会第19回関西地方会  2000/02  神戸  日本超音波医学会第19回関西地方会  肝細胞癌を対象に超音波造影剤Levovist静注によるFundamental Color Doppler法とともにIntermittent Color Doppler法による血流シグナルの増強効果の評価を行い画像上腫瘍の染影効果が認められたので報告した。MISC【薬物療法によって変貌する肝細胞癌治療:2023 Update】肝細胞癌に対する薬物療法 京都コンセンサス2023工藤 正俊; Llovet Josep M.; Finn Richard S.  肝胆膵  87-  (4)  369  -379  2023/10【薬物療法によって変貌する肝細胞癌治療:2023 Update】Early stage肝細胞癌 肝細胞癌での腫瘍免疫微小環境とアジュバント療法における免疫チェックポイント阻害剤の役割西田 直生志; 工藤 正俊  肝胆膵  87-  (4)  381  -387  2023/10【薬物療法によって変貌する肝細胞癌治療:2023 Update】Intermediate-stage肝細胞癌 ABC conversion療法 その効果と適応工藤 正俊  肝胆膵  87-  (4)  425  -437  2023/10【薬物療法によって変貌する肝細胞癌治療:2023 Update】Advanced stage肝細胞癌 IO+抗VEGFとIO+IOの複合免疫療法の使い分け上嶋 一臣; 工藤 正俊  肝胆膵  87-  (4)  453  -458  2023/10第23回全国原発性肝癌追跡調査報告(2014~2015)飯島 尋子; 工藤 正俊; 久保 正二; 黒崎 雅之; 坂元 亨宇; 椎名 秀一朗; 建石 良介; 中島 収; 福本 巧; 松山 裕; 村上 卓道; 國土 典宏; 高橋 新; 宮田 裕章; 田村 利恵; 上妻 智子; 日本肝癌研究会追跡調査委員会  肝臓  64-  (8)  333  -381  2023/08【肝胆膵癌に対する放射線治療:2023 Update】放射線被曝 胆膵領域における放射線被曝の現状竹中 完; 細野 眞; 工藤 正俊  肝胆膵  87-  (1)  91  -99  2023/07【超高齢社会における肝胆膵疾患診療】高齢者に対する肝炎ウイルス治療の留意点萩原 智; 工藤 正俊  肝胆膵  86-  (6)  685  -690  2023/06【急性膵炎診療ガイドライン改訂とPancreatitis Bundlesを読み解く】重症急性膵炎の担送基準と地域ネットワークの有用性竹中 完; 大本 俊介; 工藤 正俊; 松本 逸平; 竹山 宜典  臨床消化器内科  38-  (8)  1041  -1048  2023/06【US Today 2023 超音波検査・診断最前線 腹部領域の最新動向を中心に】腹部領域の技術と臨床の最新動向 AI超音波診断の最新動向と今後の展望西田 直生志; 工藤 正俊  INNERVISION  38-  (5)  40  -43  2023/04【US Today 2023 超音波検査・診断最前線 腹部領域の最新動向を中心に】腹部領域の技術と臨床の最新動向 CEUS LI-RADSの最新動向と今後の展望南 康範; 工藤 正俊  INNERVISION  38-  (5)  54  -57  2023/04肝癌診療ガイドライン2021年版の改訂点竹村 信行; 建石 良介; 山下 竜也; 渡谷 岳行; 海堀 昌樹; 久保 正二; 島田 光生; 永野 浩昭; 波多野 悦朗; 相方 浩; 飯島 尋子; 上嶋 一臣; 大川 和良; 玄田 拓哉; 土谷 薫; 鳥村 拓司; 池田 公史; 古瀬 純司; 赤羽 正章; 小林 聡; 櫻井 英幸; 武田 篤也; 村上 卓道; 本杉 宇太郎; 松山 裕; 工藤 正俊; 長谷川 潔  肝臓  64-  (3)  109  -121  2023/03胆道疾患診療における放射線被ばくの現状と課題竹中 完; 工藤 正俊  胆道  37-  (1)  73  -82  2023/03【肝胆膵がん治療の進歩2023】肝細胞がん Intermediate stageに対するTACEと薬物療法の併用療法青木 智子; 上嶋 一臣; 工藤 正俊  腫瘍内科  31-  (2)  159  -163  2023/02【薬物療法時代の肝細胞癌診断と治療】肝細胞癌に対する薬物療法の進歩青木 智子; 上嶋 一臣; 工藤 正俊  画像診断  43-  (3)  270  -276  2023/02【上部消化管内視鏡のトラブルシューティング】静脈瘤に対する内視鏡治療 十二指腸静脈瘤の内視鏡治療(EVL,clipping)後に出血をきたした松井 繁長; 樫田 博史; 米田 頼晃; 辻 直子; 工藤 正俊  消化器内視鏡  35-  (2)  202  -203  2023/02Contrast-enhanced harmonic endoscopic ultrasonography for diagnosing pancreatic tumors鎌田研; 大塚康生; 田中秀和; 中井敦; 山崎友裕; 大本俊介; 三長孝輔; 竹中完; 北野雅之; 工藤正俊  超音波医学 Supplement  50-  2023【肝細胞癌診療up-to-date】肝細胞癌診療の現状と展望工藤 正俊  日本消化器病学会雑誌  120-  (1)  5  -26  2023/01A review of EUS cases for gastric linitis plastica and Lower gastrointestinal submucosal tumors in our hospital田中秀和; 鎌田研; 高田隆太郎; 三長孝輔; 竹中完; 松井繁長; 樫田博史; 工藤正俊  超音波医学 Supplement  50-  2023Imaging Diagnosis of various HCC subtypes and Its Hypervascular Mimics: Differential Diagnosis Based on Conventional Interpretation and Artificial IntelligenceYasunori Minami; Naoshi Nishida; Masatoshi Kudo  LIVER CANCER  12-  (2)  103  -115  2022/12【肝の超音波を知り尽くす-肝腫瘍の診断と治療支援】腫瘍診断 LI-RADS(超音波,造影超音波)南 康範; 工藤 正俊  臨床消化器内科  37-  (13)  1645  -1652  2022/11【肝の超音波を知り尽くす-肝腫瘍の診断と治療支援】穿刺診断と治療支援 治療支援 a.Fusion画像による肝癌治療支援小川 力; 工藤 正俊  臨床消化器内科  37-  (13)  1718  -1724  2022/11進行肝細胞がんに対する新しい治療戦略と集学的治療の明日 全国原発性肝癌追跡調査データによる分子標的治療支援AIアルゴリズム開発山田 康秀; 壁谷 佳典; 吉田 澄人; 先崎 心智; 鎌田 亜美; 中村 悠馬; 淺岡 良成; 建石 良介; 武冨 紹信; 片村 嘉男; 飯島 尋子; 坂元 亨宇; 工藤 正俊; 高橋 新; 國土 典宏  日本癌治療学会学術集会抄録集  60回-  OWS14  -1  2022/10TRANSITION OF TREATMENT SELECTION FOR PRIMARY LIVER CANCER AND DECOMPENSATED CIRRHOSIS IN MULTIPLE ADMISSIONS: ANALYSIS OF A NATIONWIDE REGISTRY FOR ADVANCED LIVER DISEASES (REAL)Kazuya Okushin; Ryosuke Tateishi; Arata Takahashi; Koji Uchino; Ryo Nakagomi; Takuma Nakatsuka; Tatsuya Minami; Masaya Sato; Mitsuhiro Fujishiro; Kiyoshi Hasegawa; Yuichiro Eguchi; Tatsuya Kanto; Shoji Kubo; Hitoshi Yoshiji; Hiroaki Miyata; Namiki Izumi; Masatoshi Kudo; Kazuhiko Koike  HEPATOLOGY  76-  S1340  -S1341  2022/10【IgG4関連疾患大全-自己免疫性膵炎とIgG4関連硬化性胆管炎を中心に-】IgG4関連疾患の概要 IgG4関連疾患の病因・病態 自然免疫の視点から原 茜; 三長 孝輔; 瀬海 郁衣; 栗本 真之; 大塚 康生; 益田 康弘; 吉川 智恵; 鎌田 研; 渡邉 智裕; 工藤 正俊  胆と膵  43-  (臨増特大)  1049  -1053  2022/10膵腫瘍の診断におけるティッシュハーモニックEUSと造影ハーモニックEUSの比較 多施設共同前向き研究大本 俊介; 北野 雅之; 深澤 光晴; 蘆田 玲子; 加藤 博也; 塩見 英之; 杉森 一哉; 菅野 敦; 千葉 康敬; 高野 伸一; 山本 直樹; 江崎 健; 三輪 治生; 横村 明高; 星川 聖人; 田中 隆光; 工藤 正俊  Gastroenterological Endoscopy  64-  (10)  2323  -2333  2022/10【進化する肝細胞癌の薬物療法:2022 update】進化し続ける肝細胞癌の薬物療法の今を語る工藤 正俊; 土谷 薫; 森口 理久  肝胆膵  85-  (3)  287  -307  2022/09【進化する肝細胞癌の薬物療法:2022 update】薬物療法の最新の話題 Phase II TACTICS-L試験の結果とその解釈佐伯 一成; 上嶋 一臣; 山崎 隆弘; 高見 太郎; 工藤 正俊  肝胆膵  85-  (3)  331  -338  2022/09【進化する肝細胞癌の薬物療法:2022 update】免疫療法の基礎と臨床 肝細胞癌の新たな免疫クラス分類盛田 真弘; 西田 直生志; 工藤 正俊  肝胆膵  85-  (3)  345  -353  2022/09【進化する肝細胞癌の薬物療法:2022 update】免疫療法の基礎と臨床 Wnt/β-catenin変異を有するHCCの二面性(Inflamed and non-inflamed)青木 智子; 西田 直生志; 工藤 正俊  肝胆膵  85-  (3)  369  -374  2022/09【進化する肝細胞癌の薬物療法:2022 update】免疫療法の基礎と臨床 アテゾリズマブ・ベバシズマブはimmune cold tumorをimmune hot tumorに変えるか工藤 正俊  肝胆膵  85-  (3)  375  -382  2022/09【進化する肝細胞癌の薬物療法:2022 update】薬物療法と局所療法の組み合わせ治療 TACTICS試験の最終解析とその結果の解釈上嶋 一臣; 工藤 正俊  肝胆膵  85-  (3)  399  -407  2022/09【進化する肝細胞癌の薬物療法:2022 update】薬物療法と局所療法の組み合わせ治療 ABC conversion療法の適応と成績工藤 正俊  肝胆膵  85-  (3)  417  -427  2022/09【肝の画像診断最前線】造影超音波による肝腫瘍診断南 康範; 工藤 正俊  消化器・肝臓内科  12-  (3)  346  -351  2022/09【肝胆膵疾患とサルコペニア】胆道・膵疾患 急性膵炎とサルコペニア竹中 完; 田中 隆光; 山崎 友祐; 大本 俊介; 三長 孝輔; 鎌田 研; 工藤 正俊  肝胆膵  85-  (2)  229  -238  2022/08【原発性肝癌診療ガイドラインを読み解く】肝癌診療ガイドライン第5版 肝細胞癌に対する穿刺局所療法南 康範; 工藤 正俊  外科  84-  (9)  940  -944  2022/08【胆道・膵疾患を診る-早期診断・早期治療のために】Overview 急性膵炎・急性胆管炎update竹中 完; 大本 俊介; 三長 孝輔; 鎌田 研; 工藤 正俊  内科  130-  (1)  13  -19  2022/07【胆道・膵疾患を診る-早期診断・早期治療のために】ここまで進んだ膵がん早期診断 早期膵がんを疑う画像所見とは?山雄 健太郎; 竹中 完; 鎌田 研; 三長 孝輔; 工藤 正俊  内科  130-  (1)  69  -71  2022/07【肝癌の薬物療法 現状と今後の展望】治療選択にetiologyを考慮すべきか上嶋 一臣; 工藤 正俊  肝臓クリニカルアップデート  8-  (1)  12  -16  2022/07【膵神経内分泌腫瘍-新たなる胎動2022-】画像診断 膵神経内分泌腫瘍の内視鏡診断大塚 康生; 鎌田 研; 山崎 友裕; 大本 俊介; 三長 孝輔; 竹中 完; 樫田 博史; 工藤 正俊  肝胆膵  84-  (6)  783  -788  2022/06CEUS LI-RADSを知る南 康範; 工藤 正俊; 河野 優子  超音波医学  49-  (3)  205  -213  2022/05【肝胆膵癌におけるconversion therapy】肝細胞癌におけるconversion therapy 薬物療法後のconversion(TACE、Ablation) LEN-TACEとABC conversion therapy工藤 正俊; 土谷 薫; 中村 典明  肝胆膵  84-  (5)  613  -624  2022/05【エキスパートが教える最新胆膵内視鏡診断・治療】ERCP関連手技 ERCP関連デバイスの進歩【動画付】竹中 完; 高島 耕太; 田中 秀和; 福永 朋洋; 吉田 晃浩; 山崎 友祐; 大本 俊介; 三長 孝輔; 鎌田 研; 工藤 正俊  胆と膵  43-  (4)  267  -279  2022/04【内視鏡データリファレンスブック2022】臓器別 胆道・膵臓 良性胆道狭窄に対する内視鏡治療竹中 完; 大本 俊介; 三長 孝輔; 鎌田 研; 工藤 正俊  消化器内視鏡  34-  (4)  813  -818  2022/04画像診断と病理 肝細胞癌におけるWnt/β-catenin発現とEOB-MRIの画像所見青木 智子; 西田 直志生; 工藤 正俊  肝臓クリニカルアップデート  7-  (2)  204  -209  2022/04【胆道ドレナージup to date】急性胆管炎における胆道ドレナージ竹中 完; 工藤 正俊  日本消化器病学会雑誌  119-  (4)  285  -294  2022/04【胆石症の診療方針】関連疾患 胆道ジスキネジア竹中 完; 山崎 友裕; 大本 俊介; 三長 孝輔; 鎌田 研; 工藤 正俊  臨床消化器内科  37-  (5)  571  -575  2022/04最先端医療の今 CNNシステムによる大腸ポリープAI自動診断米田 頼晃; 半田 久志; 工藤 正俊  Medical Science Digest  48-  (3)  144  -146  2022/03【消化器疾患と腸内細菌叢の関わり-臨床的意義と治療への影響-】自己免疫性膵炎の病態と腸内細菌鎌田 研; 渡邉 智裕; 吉川 智恵; 原 茜; 三長 孝輔; 工藤 正俊  Progress in Medicine  42-  (3)  259  -263  2022/03Final results of adjuvant nivolumab for hepatocellular carcinoma (HCC) after surgical resection (SR) or radiofrequency ablation (RFA) (NIVOLVE): A phase 2 prospective multicenter single-arm trial and exploratory biomarker analysisMasatoshi Kudo; Kazuomi Ueshima; Shin Nakahira; Naoshi Nishida; Hiroshi Ida; Yasunori Minami; Takuya Nakai; Hiroshi Wada; Shoji Kubo; Kazuyoshi Ohkawa; Asahiro Morishita; Takeo Nomi; Koji Ishida; Shogo Kobayashi; Makoto Umeda; Masakatsu Tsurusaki; Yasutaka Chiba; Kenichi Yoshimura; Kazuko Sakai; Kazuto Nishio  JOURNAL OF CLINICAL ONCOLOGY  40-  (4)  2022/02【非B非C型肝癌を繙く】非B非C型肝癌の治療 穿刺局所療法南 康範; 工藤 正俊  臨床消化器内科  37-  (3)  299  -303  2022/02Transcatheter arterial chemoembolization therapy in combination strategy with lenvatinib in patients with unresectable hepatocellular carcinoma (TACTICS-L) in Japan: Final analysisKazuomi Ueshima; Toru Ishikawa; Issei Saeki; Naoki Morimoto; Hiroshi Aikata; Nobukazu Tanabe; Yoshitaka Inaba; Yoshiyuki Wada; Yasuteru Kondo; Masahiro Tsuda; Kazuhiko Nakao; Masafumi Ikeda; Michihisa Moriguchi; Takanori Ito; Masahiro Kobayashi; Hironori Koga; Keisuke Hino; Yoshiyuki Suzuki; Kenichi Yoshimura; Masatoshi Kudo  JOURNAL OF CLINICAL ONCOLOGY  40-  (4)  2022/02リザーバー留置後に胃よりカテーテルの逸脱を認めた一例大丸直哉; 田北雅弘; 浦瀬篤史; 千品寛和; 青木智子; 萩原智; 依田広; 上嶋一臣; 鶴崎正勝; 鶴崎正勝; 西田直生志; 工藤正俊  リザーバー&ポート研究会プログラム・抄録集  46th-  2022潰瘍性大腸炎関連腫瘍の臨床学的特徴と内視鏡治療時の取り組み米田頼晃; 樫田博史; 工藤正俊; 高田隆太郎; 正木翔; 河野匡志; 永井知行; 本庶元; 松井繁長; 辻直子  Gastroenterological Endoscopy (Web)  64-  (Supplement1)  2022膵管ガイドワイヤー留置法 確実に成功させるコツ竹中 完; 工藤 正俊  Gastroenterological Endoscopy  64-  (1)  70  -78  2022/01肝癌治療効果判定基準(第6版)(2021年改訂版)工藤 正俊; 池田 公史; 上嶋 一臣; 坂元 亨宇; 椎名 秀一朗; 建石 良介; 能祖 一裕; 長谷川 潔; 古瀬 純司; 宮山 士朗; 村上 卓道; 山下 竜也; 國土 典宏; 日本肝癌研究会肝癌治療効果判定基準作成委員会  肝臓  62-  (12)  823  -829  2021/12【消化器癌の薬物治療up-to-date】肝内胆管がん南 康範; 竹中 完; 工藤 正俊  消化器クリニカルアップデート  3-  (1)  43  -46  2021/11CURRENT STATUS OF PRIMARY LIVER CANCER AND DECOMPENSATED CIRRHOSIS IN JAPAN: LAUNCH OF A NATIONWIDE REGISTRYKazuya Okushin; Ryosuke Tateishi; Arata Takahashi; Koji Uchino; Ryo Nakagomi; Yuki Matsushita; Makoto Moriyama; Shigeyuki Kurosaki; Tsuyoshi Fukumoto; Satoshi Kawamura; Yuki Hayata; Tomoharu Yamada; Taijiro Wake; Takuma Nakatsuka; Tatsuya Minami; Masaya Sato; Hayato Nakagawa; Kiyoshi Hasegawa; Yuichiro Eguchi; Tatsuya Kanto; Shoji Kubo; Hitoshi Yoshiji; Hiroaki Miyata; Namiki Izumi; Masatoshi Kudo; Kazuhiko Koike  HEPATOLOGY  74-  629A  -630A  2021/10【TACE再考】Intermediate stage肝癌において薬物治療とTACEは共存共栄工藤 正俊; 田中 正俊; 村上 卓道  肝胆膵  83-  (3)  343  -362  2021/09【ここまできた肝細胞癌の薬物療法:2021 update】最新の肝癌薬物療法を語る工藤 正俊; 土谷 薫; 長谷川 潔  肝胆膵  83-  (2)  163  -179  2021/08【ここまできた肝細胞癌の薬物療法:2021 update】免疫療法の動向 NASH肝癌に対する免疫療法の効果工藤 正俊  肝胆膵  83-  (2)  219  -229  2021/08【ここまできた肝細胞癌の薬物療法:2021 update】現在進行中の第III相試験 切除・局所療法後アジュバント治療に対する臨床試験への期待と概要工藤 正俊  肝胆膵  83-  (2)  317  -324  2021/08Early antibiotic exposure delays disease progression following immune checkpoint inhibitor therapy for hepatocellular carcinoma: Evidence from an observational study.Petros Fessas; Muntaha Naeem; Thomas U. Marron; David Szafron; Elad Sharon; Anwar Saeed; Tomi Jun; Sirish Dharmapuri; Abdul R. Naqash; Thoetchai Peeraphatdit; Anuhya Gampa; Yinghong Wang; Uqba Khan; Mahvish Muzaffar; Musharraf Navaid; ChiehJu Lee; Pei-Chang Lee; Anushi Bulumulle; Bo Yu; Sonal Paul; Neil Nimkar; Dominik Bettinger; Hannah Hildebrand; Yehia I. Abugabal; Tiziana Pressiani; Nicola Personeni; Naoshi Nishida; Masatoshi Kudo; Ahmed Kaseb; Yi-Hsiang Huang; Celina Ang; Anjana Pillai; Lorenza Rimassa; David J. Pinato  CANCER RESEARCH  81-  (13)  2021/07Adjuvant nivolumab for hepatocellular carcinoma (HCC) after surgical resection (SR) or radiofrequency ablation (RFA) (NIVOLVE): A phase 2 prospective multicenter single-arm trial and exploratory biomarker analysis.Masatoshi Kudo; Kazuomi Ueshima; Shin Nakahira; Naoshi Nishida; Hiroshi Ida; Yasunori Minami; Takuya Nakai; Hiroshi Wada; Shoji Kubo; Kazuyoshi Ohkawa; Asahiro Morishita; Takeo Nomi; Koji Ishida; Shogo Kobayashi; Makoto Umeda; Masakatsu Tsurusaki; Yasutaka Chiba; Kenichi Yoshimura; Kazuko Sakai; Kazuto Nishio  JOURNAL OF CLINICAL ONCOLOGY  39-  (15)  2021/05Pembrolizumab (pembro) monotherapy for previously untreated advanced hepatocellular carcinoma (HCC): Phase 2 KEYNOTE-224 study.Jean-Luc Van Laethem; Ivan Borbath; Mark Karwal; Chris Verslype; Hans Van Vlierberghe; Adel Kardosh; Vittorina Zagonel; Per Stal; Debashis Sarker; Daniel H. Palmer; Arndt Vogel; Julien Edeline; Stephane Cattan; Masatoshi Kudo; Ann-Lii Cheng; Sadahisa Ogasawara; Abby B. Siegel; Michael Jon Chisamore; Anran Wang; Andrew X. Zhu  JOURNAL OF CLINICAL ONCOLOGY  39-  (15)  2021/05Landmark analysis of overall survival (OS) by objective response (OR) in previously treated patients (pts) with advanced hepatocellular carcinoma (aHCC): Post hoc analysis of the randomized, phase 3 KEYNOTE-240 study.Andrew X. Zhu; Stephane Cattan; Philippe Merle; Bruno Daniele; Stephen Lam Chan; Thomas Yau; Mohamed Bouattour; Ho Yeong Lim; Yee Chao; Jennifer J. Knox; Sadahisa Ogasawara; Marcelo Garrido; Ann-Lii Cheng; Julien Edeline; Richard S. Finn; Abby B. Siegel; Ahmadur Rahman; Chih-Chin Liu; Masatoshi Kudo  JOURNAL OF CLINICAL ONCOLOGY  39-  (15)  2021/05REPLACEMENT trial in progress: Combination therapy with atezolizumab plus bevacizumab for TACE unsuitable patients with beyond up-to-seven criteria in intermediate stage hepatocellular carcinoma: A phase II study.Kazuomi Ueshima; Masatoshi Kudo; Takeharu Yamanaka; Hiroshi Aikata; Tatsuya Yamashita; Masafumi Ikeda; Ryosuke Tateishi; Michihisa Moriguchi; Atsushi Hiraoka; Kaoru Tsuchiya; Sadahisa Ogasawara; Satoshi Mochida; Shiro Miyayama; Kiyoshi Hasegawa; Kenichi Yoshimura; Tetsuo Takehara  JOURNAL OF CLINICAL ONCOLOGY  39-  (15)  2021/05【消化器癌;診断と治療のすべて】消化器癌の診断・病期分類・治療・成績 肝細胞癌 集学的治療青木 智子; 上嶋 一臣; 工藤 正俊  消化器外科  44-  (6)  855  -861  2021/05第22回全国原発性肝癌追跡調査報告(2012〜2013)工藤 正俊; 泉 並木; 久保 正二; 國土 典宏; 坂元 亨宇; 椎名 秀一朗; 高山 忠利; 建石 良介; 中島 収; 村上 卓道; 松山 裕; 高橋 新; 宮田 裕章; 田村 利恵; 上妻 智子; 日本肝癌研究会追跡調査委員会  肝臓  62-  (5)  251  -299  2021/05【肝細胞癌における薬物治療の進歩】総論 肝細胞癌における薬物療法の進歩と今後の展開工藤 正俊  日本消化器病学会雑誌  118-  (5)  379  -399  2021/05【肝内胆管癌の診断と治療】肝内胆管癌のスクリーニングと診断指針杉本 勝俊; 糸井 隆夫; 南 康範; 工藤 正俊; 藤永 康成; 角谷 眞澄; 村上 卓道  消化器・肝臓内科  9-  (4)  417  -421  2021/04【肝内胆管癌の診断と治療】肝内胆管癌の画像診断藤永 康成; 南 康範; 杉本 勝俊; 糸井 隆夫; 工藤 正俊; 村上 卓道; 角谷 眞澄  消化器・肝臓内科  9-  (4)  422  -428  2021/04キーワード(No.41) Akkermansia muciniphila三長 孝輔; 渡邉 智裕; 工藤 正俊  消化器病学サイエンス  5-  (1)  49  -49  2021/03【ついつい教えたくなる、とっておきのコツ】胆膵 挿入 穿孔させないERCPスコープ挿入のコツ竹中 完; 工藤 正俊  消化器内視鏡  33-  (2)  316  -318  2021/02【ついつい教えたくなる、とっておきのコツ】胆膵 挿入 穿孔させないERCPスコープ挿入のコツ竹中 完; 工藤 正俊  消化器内視鏡  33-  (2)  316  -318  2021/02TACTICS: Final overall survival (OS) data from a randomized, open label, multicenter, phase II trial of transcatheter arterial chemoembolization (TACE) therapy in combination with sorafenib as compared with TACE alone in patients (pts) with hepatocellular carcinoma (HCC)Masatoshi Kudo; Kazuomi Ueshima; Masafumi Ikeda; Takuji Torimura; Hiroshi Aikata; Namiki Izumi; Takahiro Yamasaki; Keisuke Hino; Teiji Kuzuya; Norio Isoda; Kohichiroh Yasui; Hajime Aino; Akio Ido; Naoto Kawabe; Kazuhiko Nakao; Yoshiyuki Wada; Kenichi Yoshimura; Takuji Okusaka; Junji Furuse; Yasuaki Arai  JOURNAL OF CLINICAL ONCOLOGY  39-  (3)  2021/01知らなきゃ損 腸管免疫学っておもしろい!第17回 消化器疾患とかかわる要注意人物~NOD様受容体~渡邉智裕; 三長孝輔; 工藤正俊  消化器病学サイエンス  5-  (3)  179  -184  2021インフリキシマブが有効であった腸型Bechet病のサイトカイン反応の解析吉川馨介; 渡邉智裕; 瀬海郁江; 高田隆太郎; 原茜; 栗本真之; 益田康弘; 大塚康夫; 吉川友恵; 正木翔; 鎌田研; 三長孝輔; 米田頼晃; 筑後孝章; 工藤正俊  日本消化器病学会近畿支部例会プログラム・抄録集  115th-  2021大腸内視鏡挿入における安全で効率的な体位変換,腹部圧迫からのアプローチ米田頼晃; 樫田博史; 高田隆太郎; 正木翔; 河野匡志; 永井知行; 本庶元; 松井繁長; 辻直子; 工藤正俊  日本大腸検査学会総会プログラム・抄録集  39th-  2021切除不能肝細胞癌へのレンバチニブ療法におけるFIB-4 index,ALBI scoreの有用性青木智子; 上嶋一臣; 工藤正俊  日本消化器病学会雑誌(Web)  118-  2021Hepatobiliary phase of Gd-EOB-DTPA-enhanced MRI as an imaging biomarker for WNT/β-catenin mutations for unresectable hepatocellular carcinoma青木智子; 西田直生志; 上嶋一臣; 祖父江慶太郎; 鶴崎正勝; 工藤正俊  肝胆膵  83-  (2)  209  -218  2021The efficacy and safety of nivolumab for hepatocellular carcinoma after surgical resection or radiofrequency ablation (NIVOLVE trial)上嶋一臣; 工藤正俊  肝胆膵  83-  (2)  237  -242  2021切除不能肝細胞癌に対するアテゾリズマブ+ベバシズマブ併用療法の経験(IMbrave150試験より)青木智子; 上嶋一臣; 工藤正俊  日本消化器病学会雑誌(Web)  118-  2021Upfront systemic therapy with subsequent curative conversion for intermediate stage hepatocellular carcinoma: Atezolizumab plus Bevacizumab Curative Conversion(ABC Conversion) therapy工藤正俊; 青木智子; 上嶋一臣; 西田直生志  肝胆膵  83-  (3)  475  -483  2021Sorafenib-TACE sequential therapy (TACTICS trial)上嶋一臣; 工藤正俊  肝胆膵  83-  (3)  417  -423  2021Atezolizumab plus bevacizumab combination therapy for unresectable hepatocellular carcinoma with BCLC stage B青木智子; 上嶋一臣; 西田直生志; 工藤正俊  肝胆膵  83-  (3)  435  -443  2021Usefulness of detective flow imaging(DFI) for gallbladder lesions竹中完; 大本俊介; 工藤正俊  超音波医学 Supplement  48-  2021Usefulness of contrast-enhanced harmonic EUS in EUS-guided cyst drainage for walled-off necrosis(WON)竹中完; 工藤正俊  超音波医学 Supplement  48-  2021肝外胆管癌のT-stagingに対する造影ハーモニックEUSと造影CTの比較検討大塚康生; 鎌田研; 竹中完; 工藤正俊  日本消化器病学会近畿支部例会プログラム・抄録集  114th-  2021Pathogenesis of Acute Cholangitis and Cholecystitis竹中完; 岡本彩那; 山崎友裕; 大本俊介; 三長孝輔; 鎌田研; 山雄健太郎; 工藤正俊  臨床消化器内科  36-  (9)  1109  -1118  2021膵腫瘤におけるDetective flow imaging(DFI)の有用性の検討大本俊介; 竹中完; 工藤正俊  日本消化器病学会雑誌(Web)  118-  2021内視鏡的胆道ドレナージ術における放射線被ばく量評価竹中完; 工藤正俊  日本消化器病学会雑誌(Web)  118-  2021急性膵炎発症時におけるプレサルコペニアの臨床的意義田中隆光; 竹中完; 工藤正俊  日本消化器病学会雑誌(Web)  118-  2021急性膵炎からアプローチする膵癌早期診断山雄健太郎; 竹中完; 工藤正俊  日本消化器病学会雑誌(Web)  118-  2021早期慢性膵炎診断における診断基準改定の影響竹中完; 大塚康生; 石川嶺; 山崎友裕; 竹山宜典; 工藤正俊  膵臓(Web)  36-  (3)  2021Walled-off necrosisに対するContrast enhanced EUS-guided cyst drainageの有用性竹中完; 高島耕太; 田中秀和; 福永朋洋; 吉田晃浩; 岡本彩那; 山崎友裕; 大本俊介; 三長孝輔; 鎌田研; 山雄健太郎; 工藤正俊  膵臓(Web)  36-  (3)  2021IPMNの壁在結節評価におけるDetective flow imaging(DFI)の有用性について竹中完; 高島耕太; 岡本彩那; 大本俊介; 工藤正俊  膵臓(Web)  36-  (3)  2021急性膵炎地域連携モデル構築がもたらす膵炎診療への有効性竹中完; 大本俊介; 竹山宜典; 工藤正俊  膵臓(Web)  36-  (3)  2021Landmark analysis of overall survival (OS) by objective response (OR) in previously treated patients (pts) with advanced hepatocellular carcinoma (aHCC): Post-hoc analysis of the randomized, phase III KEYNOTE-240 study.Julien Edeline; Stephane Cattan; Philippe Merle; Bruno Daniele; Stephen Lam Chan; Thomas Yau; Mohamed Bouattour; Ho Yeong Lim; Yee Chao; Jennifer J. Knox; Sadahisa Ogasawara; Marcelo Garrido; Ann-Lii Cheng; Andrew X. Zhu; Richard S. Finn; Abby B. Siegelb; Ahmadur Rahman; Chih-Chin Liu; Masatoshi Kudo  JOURNAL OF CLINICAL ONCOLOGY  39-  (3)  2021/01Pembrolizumab (pembro) monotherapy for previously untreated advanced hepatocellular carcinoma (HCC): Phase II KEYNOTE-224 study.Jean-Luc Van Laethem; Ivan Borbath; Mark Karwal; Chris Verslype; Hans Van Vlierberghe; Adel Kardosh; Vittorina Zagonel; Per Stal; Debashis Sarker; Daniel H. Palmer; Arndt Vogel; Julien Edeline; Stephane Cattan; Masatoshi Kudo; Ann-Lii Cheng; Sadahisa Ogasawara; Abby B. Siegel; Michael Jon Chisamore; Wang Anran; Andrew X. Zhu  JOURNAL OF CLINICAL ONCOLOGY  39-  (3)  2021/01潰瘍性大腸炎に合併したcolitis associated cancerおよびdyspasia症例の特徴米田頼晃; 櫻井俊治; 樫田博史; 正木翔; 河野匡志; 永井知行; 本庶元; 松井繁長; 渡邉智裕; 辻直子; 工藤正俊  大腸癌研究会プログラム・抄録集  94th-  2021【令和時代のニューノーマル医療トピックス】COVID-19環境下における肝細胞癌 いま我々が考えるべき治療戦略工藤 正俊  クリニシアン  68-  (1)  48  -60  2021/01【IgG4関連疾患-解明されてきた新たな病態】IgG4関連疾患と免疫異常 とくに自然免疫系について渡邉 智裕; 工藤 正俊  医学のあゆみ  276-  (2)  152  -155  2021/01【急性膵炎診療up-to-date】治療 急性膵炎診療における地域連携モデルの構築大本 俊介; 竹中 完; 工藤 正俊; 松本 逸平; 竹山 宜典  肝胆膵  82-  (1)  119  -122  2021/01【令和時代のニューノーマル医療トピックス】COVID-19環境下における肝細胞癌 いま我々が考えるべき治療戦略工藤 正俊  クリニシアン  68-  (1)  48  -60  2021/01画像診断における人工知能の応用と超音波AIの開発西田 直生志; 工藤 正俊  肝臓  61-  (12)  623  -636  2020/12第21回全国原発性肝癌追跡調査報告(2010〜2011)工藤 正俊; 泉 並木; 久保 正二; 國土 典宏; 坂元 亨宇; 椎名 秀一朗; 高山 忠利; 建石 良介; 中島 収; 村上 卓道; 松山 裕; 高橋 新; 宮田 裕章; 田村 利恵; 上妻 智子; 日本肝癌研究会追跡調査委員会  肝臓  61-  (12)  645  -691  2020/12EFFECT OF PEMBROLIZUMAB (PEMBRO) ON HEPATITIS B AND HEPATITIS C VIRAL LOAD AND AMINOTRANSFERASE LEVELS IN PATIENTS WITH ADVANCED HEPATOCELLULAR CARCINOMA IN KEYNOTE-224 AND KEYNOTE-240Stephen L. Chan; Andrew X. Zhu; Richard Finn; Julien Edeline; Sadahisa Ogasawara; Jennifer J. Knox; Bruno Daniele; Baek-Yeol Ryoo; Philippe Merle; Mohamed Bouattour; Ho-Yeong Lim; Yee Chao; Thomas Yau; Barbara Haber; Usha Malhotra; Yanna R. Miteva; Chih-Chin Liu; Masatoshi Kudo; Ann-Lii Cheng  HEPATOLOGY  72-  693A  -693A  2020/11LEAP-012 TRIAL IN PROGRESS: PEMBROLIZUMAB, LENVATINIB, AND TRANSARTERIAL CHEMOEMBOLIZATION COMBINATION THERAPY FOR INTERMEDIATE-STAGE HEPATOCELLULAR CARCINOMA NOT AMENABLE TO CURATIVE TREATMENTArndt Vogel; Josep M. Llovet; Anthony B. El-Khoueiry; David C. Madoff; Richard Finn; Sadahisa Ogasawara; Zhenggang Ren; Kalgi Mody; Jerry J. Li; Abby B. Siegel; Leonid Dubrovsky; Masatoshi Kudo  HEPATOLOGY  72-  697A  -698A  2020/11【肝細胞癌治療のパラダイムチェンジ-進化する薬物療法2020 Update Part II-(分子標的治療)】免疫療法時代における分子標的治療の今後を考える工藤 正俊; 古瀬 純司; 山下 竜也; 森口 理久  肝胆膵  81-  (5)  761  -779  2020/11【肝細胞癌治療のパラダイムチェンジ-進化する薬物療法2020 Update Part II-(分子標的治療)】総論 肝細胞癌の分子標的治療のupdate 分子標的治療薬により肝癌の予後は向上したか シークエンシャル治療の重要性工藤 正俊  肝胆膵  81-  (5)  780  -791  2020/11【肝細胞癌治療のパラダイムチェンジ-進化する薬物療法2020 Update Part II-(分子標的治療)】総論 肝細胞癌の分子標的治療のupdate Intermediate stage肝癌の治療変革工藤 正俊  肝胆膵  81-  (5)  792  -802  2020/11【肝細胞癌治療のパラダイムチェンジ-進化する薬物療法2020 Update Part II-(分子標的治療)】総論 肝細胞癌の分子標的治療のupdate 薬物療法による奏効は予後延長のpredictive/prognostic factorか工藤 正俊  肝胆膵  81-  (5)  803  -812  2020/11【肝細胞癌治療のパラダイムチェンジ-進化する薬物療法2020 Update Part II-(分子標的治療)】総論 肝細胞癌の分子標的治療のupdate APPLE consensus statementの要約工藤 正俊  肝胆膵  81-  (5)  813  -817  2020/11【肝細胞癌治療のパラダイムチェンジ-進化する薬物療法2020 Update Part II-(分子標的治療)】総論 肝細胞癌の分子標的治療のupdate 肝癌診療マニュアル第4版の要約 TACE不適の概念とTACE不適intermediate stage肝癌の治療方針工藤 正俊  肝胆膵  81-  (5)  818  -826  2020/11【肝細胞癌治療のパラダイムチェンジ-進化する薬物療法2020 Update Part II-(分子標的治療)】総論 肝細胞癌の分子標的治療のupdate 米国肝臓学会(AASLD)のposition paper expert panelの推奨工藤 正俊  肝胆膵  81-  (5)  827  -834  2020/11【肝細胞癌治療のパラダイムチェンジ-進化する薬物療法2020 Update Part II-(分子標的治療)】レンバチニブ REFLECT試験のサブ解析上嶋 一臣; 工藤 正俊  肝胆膵  81-  (5)  835  -840  2020/11【肝細胞癌治療のパラダイムチェンジ-進化する薬物療法2020 Update Part II-(分子標的治療)】ラムシルマブ ラムシルマブの日本人における高い有効性南 康範; 工藤 正俊  肝胆膵  81-  (5)  973  -977  2020/11【肝細胞癌治療のパラダイムチェンジ-進化する薬物療法2020 Update Part II-(分子標的治療)】レンバチニブ 切除不能肝細胞癌へのPD-1/PD-L1療法不応後二次治療として投与したレンバチニブ逐次治療の有効性青木 智子; 上嶋 一臣; 鶴崎 正勝; 工藤 正俊  肝胆膵  81-  (5)  874  -880  2020/11【進化するEUS】診断的EUS 造影ハーモニックEUS三長 孝輔; 原 茜; 田中 秀和; 大本 俊介; 鎌田 研; 山雄 健太郎; 竹中 完; 工藤 正俊  消化器内視鏡  32-  (11)  1641  -1649  2020/11トルバプタン不応の難治性腹水に対する腹腔-静脈シャント(デンバーシャント)の有用性青木 智子; 南 康範; 鶴崎 正勝; 盛田 真弘; 南 知宏; 千品 寛和; 田北 雅弘; 萩原 智; 依田 広; 上嶋 一臣; 松井 繁長; 西田 直生志; 樫田 博史; 工藤 正俊  日本門脈圧亢進症学会雑誌  26-  (4)  244  -248  2020/11【なんじゃこりゃ?part2】咽頭・食道 周囲に隆起を伴う陥凹性病変高島 耕太; 松井 繁長; 工藤 正俊  消化器内視鏡  32-  (10)  1405  -1406  2020/10【なんじゃこりゃ?part2】胃 発赤調の小さな隆起性病変松井 繁長; 樫田 博史; 工藤 正俊  消化器内視鏡  32-  (10)  1473  -1474  2020/10【なんじゃこりゃ?part2】胃 巨大で多発した胃ポリープ松井 繁長; 樫田 博史; 工藤 正俊  消化器内視鏡  32-  (10)  1495  -1496  2020/10AFP is elevated more than 10 years before hepatocellular carcinoma development is detected: this observation leads to a practical risk stratification strategyPhilip Johnson; Sarah Berhane; Emily de Groot; Hidenori Toyoda; Toshifumi Tada; Takashi Kumada; Shinji Satomura; Yukio Osaki; Masatoshi Kudo; Naoshi Nishida; Toru Kimura; Ruwanthi Kolamunnage-Dona; Thomas Bird; Ruben Amoros; Marta Garcia-Finana; David M. Hughes  JOURNAL OF HEPATOLOGY  73-  S387  -S388  2020/08【胆膵疾患 胆膵疾患の実地診療Up-to-date】これだけは知っておきたい胆膵疾患の基礎知識 専門医受診を勧めるべきケースとは 急性膵炎竹中 完; 工藤 正俊  Medical Practice  37-  (8)  1229  -1234  2020/08【胆膵疾患の最新画像診断】3D-CT解析を用いた膵実質萎縮による膵癌早期診断山雄 健太郎; 竹中 完; 田中 秀和; 田中 隆光; 吉田 晃浩; 石川 嶺; 岡本 彩那; 中井 敦; 山崎 友裕; 大本 俊介; 鎌田 研; 三長 孝輔; 渡邉 智裕; 工藤 正俊  胆と膵  41-  (8)  713  -718  2020/08【肝胆膵における結石診療のベストプラクティス】胆嚢結石症 Confluence stoneとMirizzi症候群はどう違うのか Biliobiliary fistulaと合わせて竹中 完; 石川 嶺; 岡本 彩那; 山崎 友裕; 中井 敦史; 大本 俊介; 三長 孝輔; 鎌田 研; 山雄 健太郎; 工藤 正俊  肝胆膵  81-  (2)  305  -312  2020/08Effect of pembrolizumab (pembro) on hepatitis B viral (HBV) load and aminotransferase (ALT) levels in patients (pts) with advanced hepatocellular carcinoma (aHCC) in KEYNOTE-224 and KEYNOTE-240.Stephen Lam Chan; Andrew X. Zhu; Richard S. Finn; Julien Edeline; Sadahisa Ogasawara; Jennifer J. Knox; Bruno Daniele; Baek-Yeol Ryoo; Philippe Merle; Mohamed Bouattour; Ho-Yeong Lim; Yee Chao; Thomas Yau; Barbara Anne Haber; Usha Malhotra; Chih-Chin Liu; Masatoshi Kudo; Ann-Lii Cheng  JOURNAL OF CLINICAL ONCOLOGY  38-  (15)  2020/05RECIST v1.1 and irRECIST outcomes in advanced HCC treated with pembrolizumab (pembro)Julien Edeline; Mark Karwal; Andrew X. Zhu; Richard S. Finn; Stephane Cattan; Sadahisa Ogasawara; Chris Verslype; Vincenzo Dadduzio; Laetitia Fartoux; Arndt Vogel; Olivier Rosmorduc; Gontran Verset; Stephen Lam Chan; Jennifer J. Knox; Bruno Daniele; Ann-Lii Cheng; Gregory V. Goldmacher; Erin Jensen; Abby B. Siegel; Masatoshi Kudo  JOURNAL OF CLINICAL ONCOLOGY  38-  (4)  2020/02Phase III study of pembrolizumab (pembro) versus best supportive care (BSC) for second-line therapy in advanced hepatocellular carcinoma (aHCC): KEYNOTE-240 Asian subgroupMasatoshi Kudo; Ho Yeong Lim; Ann-Lii Cheng; Yee Chao; Thomas Yau; Sadahisa Ogasawara; Masayuki Kurosaki; Naoki Morimoto; Kazuyoshi Ohkawa; Tatsuya Yamashita; Kyung-Hun Lee; Erluo Chen; Abby B. Siegel; Baek-Yeol Ryoo  JOURNAL OF CLINICAL ONCOLOGY  38-  (4)  2020/02Updated efficacy and safety of KEYNOTE-224: A phase II study of pembrolizumab (pembro) in patients with advanced hepatocellular carcinoma (HCC)Masatoshi Kudo; Richard S. Finn; Julien Edeline; Stephane Cattan; Sadahisa Ogasawara; Daniel H. Palmer; Chris Verslype; Vittorina Zagonel; Laetitia Fartoux; Arndt Vogel; Debashis Sarker; Gontran Verset; Stephen Lam Chan; Jennifer J. Knox; Bruno Daniele; Ellen B. Gurary; Abby B. Siegel; Lokesh Jain; Ann-Lii Cheng; Andrew X. Zhu  JOURNAL OF CLINICAL ONCOLOGY  38-  (4)  2020/02Objective response (OR) by mRECIST to predict overall survival (OS) in patients with hepatocellular carcinoma (HCC) treated with sorafenib in the SILIUS trialMasatoshi Kudo; Kazuomi Ueshima; Chikara Ogawa; Yasutaka Chiba  JOURNAL OF CLINICAL ONCOLOGY  38-  (4)  2020/02Initial lenvatinib therapy with no prior TACE in patients with intermediate-stage hepatocellular carcinoma beyond up-to-seven criteria and Child-Pugh A liver function: A proof-of-concept studyMasatoshi Kudo; Kazuomi Ueshima; Stephen Lam Chan; Tomoko Aoki; Satoru Hagiwara; Yasunori Minami; Hiroshi Ida; Mamoru Takenaka; Tomohiro Watanabe; Masahiro Morita; Chikara Ogawa; Yoshiyuki Wada; Masafumi Ikeda; Hiroshi Ishii; Namiki Izumi; Atsushi Hiraoka; Hiroshi Aikata; Naoshi Nishida  JOURNAL OF CLINICAL ONCOLOGY  38-  (4)  2020/02薬の知識 ラムシルマブ(サイラムザ) 肝細胞癌への適用について上嶋 一臣; 工藤 正俊  臨床消化器内科  35-  (3)  333  -336  2020/02【慢性膵炎診療2020】基礎研究・病態 腸内細菌は慢性膵炎発症に関連するのか渡邉 智裕; 三長 孝輔; 原 茜; 鎌田 研; 工藤 正俊  肝・胆・膵  80-  (2)  241  -246  2020/02Retrospective Cohort Study of CEUS evaluation of Lenvatinib for Disease Progression after PD-1/PD-L1/CTLA-4 Immune Checkpoint Inhibitor (ICI) in Advanced Hepatocellular Carcinoma青木智子; 依田広; 盛田真弘; 南知宏; 田北雅弘; 萩原智; 南康範; 上嶋一臣; 西田直生志; 工藤正俊  超音波医学 Supplement  47-  2020チロシンキナーゼ阻害薬時代に注意すべき肝細胞癌の遠隔転移大塚康生; 青木智子; 南知宏; 田北雅弘; 萩原智; 南康範; 依田広; 上嶋一臣; 西田直生志; 工藤正俊  日本消化器病学会雑誌(Web)  117-  2020TACE不適Intermediate-stage肝細胞癌に対するLenvatinib先行投与の有用性青木智子; 上嶋一臣; 工藤正俊  日本消化器病学会雑誌(Web)  117-  2020Low-dose gemcitabine plus nab-paclitaxel versus standard-dose gemcitabine plus nab-paclitaxel in elderly patients with metastastic pancreatic cancer: A randomized phase II trial鎌田研; 北野雅之; 竹中完; 今井元; 千葉康敬; 山下幸孝; 西勝久; 加藤隆夫; 工藤正俊  臨床薬理の進歩  (41)  2020胆膵疾患に対する造影ハーモニックEUSの有用性中井敦史; 竹中完; 鎌田研; 工藤正俊  日本消化器病学会近畿支部例会プログラム・抄録集  112th-  2020膵管狭窄症例におけるCT間接所見の検討-微小膵癌と良性膵管狭窄症例の比較-山雄健太郎; 竹中完; 松本逸平; 竹山宜典; 沼本勲男; 鶴崎正勝; 工藤正俊  膵臓(Web)  35-  (3)  2020PanNETG1/G2における造影ハーモニックEUSの悪性度評価の有用性に関する検討石川嶺; 鎌田研; 田中秀和; 岡本彩那; 山崎友裕; 中井敦史; 大本俊介; 三長孝輔; 竹中完; 工藤正俊  膵臓(Web)  35-  (3)  2020「KINDAI20」を用いたコンベックスEUSの教育について大本俊介; 竹中完; 工藤正俊  膵臓(Web)  35-  (3)  2020術後膵液瘻(POPF)に対するEUS下ドレナージの有用性中井敦史; 山雄健太郎; 竹中完; 竹山宜典; 工藤正俊  膵臓(Web)  35-  (3)  2020Walled-off necrosisに対するLAMS with10FrENCD持続洗浄治療の有用性について竹中完; 石川嶺; 岡本彩那; 中井敦史; 山崎友裕; 大本俊介; 三長孝輔; 鎌田研; 山雄健太郎; 松本逸平; 竹山宜典; 工藤正俊  膵臓(Web)  35-  (3)  2020当院における新規胆管ステント留置術”antegrade long PS留置術”の有用性についての検討田中秀和; 中井敦史; 竹中完; 工藤正俊  日本消化器病学会近畿支部例会プログラム・抄録集  113th-  2020当院におけるwalled-off necrosisに対するstep-up approachの成績と内視鏡治療不成功の要因解析大本俊介; 竹中完; 工藤正俊  Gastroenterological Endoscopy (Web)  62-  (Supplement1)  2020Re-interventionを考慮した悪性消化管狭窄における胃・十二指腸ステント療法の検討山崎友裕; 竹中完; 工藤正俊  Gastroenterological Endoscopy (Web)  62-  (Supplement1)  2020術後再建腸管ERCPにおける胆管挿管困難症例に対するUneven Double Lumen Cannulaを用いた胆管挿管法(Uneven method)の有用性竹中完; 工藤正俊  Gastroenterological Endoscopy (Web)  62-  (Supplement1)  2020急性胆管炎に対する初回胆道ドレナージの検討 ENBD vs ERBD中井敦史; 竹中完; 工藤正俊  Gastroenterological Endoscopy (Web)  62-  (Supplement1)  2020EUS施行時の鎮静方法の検討岡本彩那; 鎌田研; 河野辰哉; 田中秀和; 石川嶺; 山崎友裕; 中井敦史; 大本俊介; 三長孝輔; 山雄健太郎; 竹中完; 工藤正俊  日本消化器病学会雑誌(Web)  117-  2020胆膵疾患に対する造影ハーモニックEUSの有用性中井敦史; 鎌田研; 竹中完; 工藤正俊  Gastroenterological Endoscopy (Web)  62-  (Supplement1)  2020KINDAI20を用いたコンベックスEUSの教育について大本俊介; 竹中完; 工藤正俊  Gastroenterological Endoscopy (Web)  62-  (Supplement2)  2020膵癌早期診断のための3D CT解析による膵実質萎縮の検討山雄健太郎; 竹中完; 石川嶺; 沼本勲; 鶴崎正勝; 渡邉智裕; 工藤正俊  日本消化器病学会雑誌(Web)  117-  2020急性膵炎におけるプレサルコペニアの臨床的意義に関しての検討田中隆光; 竹中完; 吉田晃弘; 田中秀和; 吉川智恵; 石川嶺; 岡本彩那; 山崎友裕; 中井敦史; 大本俊輔; 三長孝輔; 鎌田研; 山雄健太郎; 松本逸平; 竹山宜典; 工藤正俊  日本消化器病学会雑誌(Web)  117-  2020内視鏡的乳頭切除術後胆管狭窄に対する予防的金属ステント留置の有用性岡本彩那; 竹中完; 田中隆光; 田中秀和; 吉田晃浩; 吉川智恵; 石川嶺; 山崎友裕; 中井敦史; 大本俊介; 三長孝輔; 鎌田研; 山雄健太郎; 工藤正俊  Gastroenterological Endoscopy (Web)  62-  (Supplement2)  2020内視鏡的乳頭切除術後胆管狭窄に対する予防的金属ステント留置の有用性岡本彩那; 竹中完; 工藤正俊  胆道(Web)  34-  (3)  2020当院におけるERCP・EUSの安全な術前・術中・術後管理への取り組み竹中完; 岡本彩那; 工藤正俊  胆道(Web)  34-  (3)  2020MDS関連IBDに対する治療方法の検討河野匡志; 櫻井俊治; 工藤正俊  Gastroenterological Endoscopy (Web)  62-  (Supplement1)  2020小腸内視鏡診療ガイドラインでのカプセル内視鏡検査の運用の実際米田頼晃; 樫田博史; 櫻井俊治; 松村まり子; 高島耕太; 正木翔; 河野匡志; 山田光成; 本庶元; 永井知行; 松井繁長; 辻直子; 渡邉智裕; 工藤正俊  Gastroenterological Endoscopy (Web)  62-  (Supplement2)  2020拡大観察から見たPPI関連胃底腺ポリープの特徴友岡瑞貴; 辻直子; 高島耕太; 正木翔; 河野匡志; 永井知之; 米田頼晃; 本庶元; 櫻井俊治; 松井繁長; 渡邉智裕; 樫田博史; 工藤正俊  Gastroenterological Endoscopy (Web)  62-  (Supplement2)  2020深層学習を用いた超音波肝腫瘤像のAI診断システム開発椎名毅; 山川誠; 西田直生志; 工藤正俊  日本音響学会研究発表会講演論文集(CD-ROM)  2020-  2020Computer-aided diagnosis of liver and breast tumors by deep learning method using ultrasound images.山川誠; 椎名毅; 西田直生志; 工藤正俊  日本音響学会誌  76-  (12)  2020Construction of nationwide database of US image and development of AI-aided detection and diagnosis system for liver tumor西田直生志; 山川誠; 椎名毅; 目加田慶人; 工藤正俊  超音波医学 Supplement  47-  2020肝硬変と肝腫瘍 4 肝細胞がん患者へのアプローチ(手術療法と薬物治療)上嶋一臣; 工藤正俊  月刊薬事  62-  (2)  2020当院での直腸NENの治療成績からみた治療方法の検討永井知行; 樫田博史; 益田康弘; 友岡瑞貴; 高島耕太; 高田隆太郎; 正木翔; 河野匡志; 米田頼晃; 本庶元; 櫻井俊治; 松井繁長; 渡邉智裕; 辻直子; 工藤正俊  日本大腸肛門病学会雑誌(Web)  73-  (9)  2020十二指腸・空腸静脈瘤に対するcyanoacrylate系薬剤による内視鏡的硬化療法の検討松井繁長; 樫田博史; 工藤正俊  日本門脈圧亢進症学会雑誌  26-  (3)  2020B-RTOにおける奏効率向上の工夫と肝予備能の温存青木智子; 鶴崎正勝; 小田晃義; 沼本勲男; 柳生行伸; 田北雅弘; 萩原智; 南康範; 上嶋一臣; 依田広; 西田直生志; 松井繁長; 樫田博史; 工藤正俊  日本門脈圧亢進症学会雑誌  26-  (3)  2020【消化管症候群(第3版)-その他の消化管疾患を含めて-】胃 炎症性・非腫瘍性 胃嚢胞松井 繁長; 辻 直子; 樫田 博史; 工藤 正俊  日本臨床  別冊-  (消化管症候群I)  152  -155  2019/12ERCP(内視鏡的逆行性胆管膵管造影検査)における水晶体被ばくの現状竹中 完; 細野 眞; 中井 敦史; 大本 俊介; 三長 孝輔; 鎌田 研; 山雄 健太郎; 林 史郎; 西田 勉; 工藤 正俊  日本消化器病学会雑誌  116-  (12)  1053  -1055  2019/12肝胆膵の線維化up‐to‐date 肝臓の線維化―臨床・病理―非侵襲的線維化マーカーによる経時的線維化評価(SWE,VTQなども含めて)青木智子; 飯島尋子; 工藤正俊  肝胆膵  79-  (5)  873‐878  2019/11PPI長期投与の有無からみた胃底腺ポリープの臨床病理学的検討松村 まり子; 辻 直子; 梅原 康湖; 正木 翔; 岡元 寿樹; 山田 光成; 永井 知行; 米田 頼晃; 櫻井 俊治; 松井 繁長; 渡邉 智裕; 樫田 博史; 工藤 正俊  日本消化器病学会雑誌  116-  (臨増大会)  A755  -A755  2019/11鑑別診断において造影超音波が有用であった多血性の肝内胆管癌(腫瘤形成型)の1例友岡 瑞樹; 盛田 真弘; 南 康範; 依田 広; 南 知宏; 青木 智子; 田北 雅弘; 萩原 智; 上嶋 一臣; 西田 直生志; 工藤 正俊  肝臓  60-  (Suppl.3)  A926  -A926  2019/11NATIONWIDE LIVER CANCER REGISTRY工藤正俊; 工藤正俊; 泉並木; 久保正二; 國土典宏; 坂元亨宇; 椎名秀一朗; 高山忠利; 建石良介; 中島収; 松山裕; 村上卓道  日本外科学会雑誌  120-  (6)  676  -680  2019/11分子標的治療薬の併用療法 2 TACEと分子標的治療薬の併用療法上嶋一臣; 工藤正俊  Liver Cancer Journal  11-  (2)  84‐90  2019/10DEVELOPMENT OF AI-AIDED US DIAGNOSIS SYSTEM OF LIVER TUMOR USING DEEP NEURAL NETWORKNaoshi Nishida; Makoto Yamakawa; Tsuyoshi Shiina; Masatoshi Kudo  HEPATOLOGY  70-  1211A  -1212A  2019/10OBJECTIVE RESPONSE BY MRECIST IS A PROGNOSTIC FACTOR FOR OVERALL SURVIVAL IN UNRESECTABLE HEPATOCELLULAR CARCINOMA TREATED WITH SYSTEMIC THERAPY: A SYSTEMATIC REVIEW AND META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALSMasatoshi Kudo; Kazuomi Ueshima; Naoshi Nishida  HEPATOLOGY  70-  221A  -221A  2019/10血清IFN-α/IL-33が治療効果判定に有用と考えられた自己免疫性膵炎/IgG4関連疾患の1例原 茜; 三長 孝輔; 岡本 彩那; 石川 嶺; 山崎 友裕; 中井 敦史; 大本 俊介; 鎌田 研; 山雄 健太郎; 竹中 完; 渡邉 智裕; 安川 覚; 工藤 正俊  日本消化器病学会近畿支部例会プログラム・抄録集  111回-  78  -78  2019/10下部消化管腫瘍に対する低侵襲治療の最前線 難症例に対するSOクリップ使用による大腸ESD、SOUTENを使用した大腸hybrid ESDの検討正木 翔; 消化器内科; 米田 頼晃; 樫田 博史; 工藤 正俊  日本消化器病学会近畿支部例会プログラム・抄録集 111回 Page53(2019.10)  2019/10DLBCLに発症したリンパ管拡張症に対してステロイド投与、食事療法が奏効した1症例大塚 康生; 米田 頼晃; 正木 翔; 筑後 孝章; 吉川 馨介; 高島 耕太; 橋本 有人; 山田 光成; 本庶 元; 永井 知行; 櫻井 俊治; 松井 繁長; 渡邉 智裕; 辻 直子; 樫田 博史; 工藤 正俊  日本消化器病学会近畿支部例会プログラム・抄録集  111回-  91  -91  2019/10自己免疫性胃炎に合併した胃型腺腫の1例吉川 馨介; 松井 繁長; 野村 健司; 橋本 有人; 山田 光成; 高島 耕太; 正木 翔; 永井 知行; 米田 頼晃; 本庶 元; 櫻井 俊治; 辻 直子; 樫田 博史; 工藤 正俊  日本消化器病学会近畿支部例会プログラム・抄録集  111回-  94  -94  2019/10EUS施行時のプロポフォール持続注入による鎮静の有用性の検討岡本 彩那; 鎌田 研; 竹中 完; 吉川 智恵; 石川 嶺; 山崎 友裕; 中井 敦史; 大本 俊介; 三長 孝輔; 山雄 健太郎; 工藤 正俊  Gastroenterological Endoscopy  61-  (Suppl.2)  2182  -2182  2019/10血清IFN-α/IL-33が治療効果判定に有用と考えられた自己免疫性膵炎/IgG4関連疾患の1例原 茜; 三長 孝輔; 岡本 彩那; 石川 嶺; 山崎 友裕; 中井 敦史; 大本 俊介; 鎌田 研; 山雄 健太郎; 竹中 完; 渡邉 智裕; 安川 覚; 工藤 正俊  日本消化器病学会近畿支部例会プログラム・抄録集  111回-  78  -78  2019/10Deep neural networkを用いた超音波デジタル画像における肝腫瘍病名判別の試み西田 直生志; 工藤 正俊  肝臓  60-  (Suppl.2)  A566  -A566  2019/10  [Invited]慢性膵炎渡邉智裕; 三長孝輔; 工藤正俊  検査と技術  47-  (10)  1160  -1165  2019/10遭遇の機会が増えたIPMN/膵嚢胞―現状と課題 2 IPMN/膵嚢胞の診療(4)悪性IPMNとIPMN併存膵癌の診断におけるEUSの役割鎌田研; 原茜; 山雄健太郎; 竹中完; 工藤正俊  臨床消化器内科  34-  (12)  1476  -1481  2019/10胆管空腸吻合部静脈瘤出血に対してシングルバルーン小腸内視鏡を用いた内視鏡的静脈瘤硬化療法の有用性松井繁長; 樫田博史; 高島耕太; 工藤正俊; 木下真樹子; 木下幾晴  日本門脈圧亢進症学会雑誌  25-  (3)  124  2019/09難治性腹水に対して行われたデンバーシャント術の報告青木 智子; 田北 雅弘; 大塚 康生; 南 知宏; 萩原 智; 南 康範; 依田 広; 上嶋 一臣; 西田 直生志; 鶴崎 正勝; 工藤 正俊  日本門脈圧亢進症学会雑誌  25-  (3)  146  -146  2019/09IgG4関連疾患病態解明への挑戦―臓器横断的研究からみえてきたもの!IgG4とはどのような分子か?渡邉智裕; 三長孝輔; 吉川智恵; 原茜; 鎌田研; 工藤正俊  消化器病学サイエンス  3-  (3)  142  -148  2019/09術後内視鏡診療のすべて[各論 消化器手術後の内視鏡検査―サーベイランスと異時性病変の診断―]消化管再建術後における超音波内視鏡を用いたスクリーニング検査鎌田研; 原茜; 田中秀和; 石川嶺; 岡本彩那; 中井敦史; 大本俊介; 三長孝輔; 山雄健太郎; 竹中完; 工藤正俊  消化器内視鏡  31-  (9)  1331  -1336  2019/09膵癌における内視鏡診断・治療の最前線 術後膵液瘻に対する内視鏡的ドレナージの現状竹中完; 中井敦史; 吉川智恵; 石川嶺; 岡本彩那; 山崎友裕; 大本俊輔; 三長孝輔; 鎌田研; 山雄健太郎; 亀井敬子; 松本逸平; 竹山宜典; 工藤正俊  胆と膵  40-  (9)  807  -814  2019/09進化する肝細胞癌の薬物療法―2019 Update(Part 1)ラムシルマブ 日本人肝細胞癌患者におけるラムシルマブの有用性工藤正俊  肝胆膵  79-  (2)  320‐326  2019/08進化する肝細胞癌の薬物療法―2019 Update(Part 1)レンバチニブ REFLECT試験のresponder解析の結果―分子標的治療の奏効は予後の規定因子である―南康範; 工藤正俊  肝胆膵  79-  (2)  187‐190  2019/08進化する肝細胞癌の薬物療法―2019 Update(Part 1)ラムシルマブ ラムシルマブはレンバチニブの二次治療薬として有効か工藤正俊  肝胆膵  79-  (2)  350‐355  2019/08進化する肝細胞癌の薬物療法―2019 Update(Part 1)レンバチニブ レンバチニブ導入早期の肝性脳症の機序と対策工藤正俊  肝胆膵  79-  (2)  239‐246  2019/08進化する肝細胞癌の薬物療法―2019 Update(Part 1)レンバチニブ レンバチニブの奏効とALBI Grade上嶋一臣; 工藤正俊  肝胆膵  79-  (2)  227‐231  2019/08進化する肝細胞癌の薬物療法―2019 Update(Part 1)ソラフェニブ ソラフェニブにおける奏効と予後の関係―SILIUS trialの結果より―工藤正俊  肝胆膵  79-  (2)  270‐277  2019/08肝細胞癌の新たな治療選択肢とは―肝細胞癌治療におけるラムシルマブの位置づけ―工藤正俊  Therapeutic Research  40-  (8)  625‐626  2019/08【進化する肝細胞癌の薬物療法-2019 Update(Part 1)】ラムシルマブ 日本人肝細胞癌患者におけるラムシルマブの有用性工藤 正俊  肝・胆・膵  79-  (2)  320  -326  2019/08【進化する肝細胞癌の薬物療法-2019 Update(Part 1)】ラムシルマブ ラムシルマブはレンバチニブの二次治療薬として有効か工藤 正俊  肝・胆・膵  79-  (2)  350  -355  2019/08【進化する肝細胞癌の薬物療法-2019 Update(Part 1)】レンバチニブ レンバチニブの奏効とALBI Grade上嶋 一臣; 工藤 正俊  肝・胆・膵  79-  (2)  227  -231  2019/08進化する肝細胞癌の薬物療法―2019 Update(Part 1)ラムシルマブ AFP<400ng/mL症例におけるラムシルマブの有効性青木智子; 工藤正俊  肝胆膵  79-  (2)  327  -337  2019/08消化管疾患と緊急内視鏡 上部消化管出血(非静脈瘤)松井繁長; 樫田博史; 高島耕太; 岡元寿樹; 山田光成; 正木翔; 米田頼晃; 永井知行; 本庶元; 櫻井俊治; 辻直子; 工藤正俊  月刊消化器・肝臓内科  6-  (1)  7‐13  2019/07深層学習による超音波画像からの肝腫瘍検出に関する初期的検討堤 一晴; 中島 崇博; 道満 恵介; 目加田 慶人; 西田 直生志; 工藤 正俊  日本医用画像工学会大会予稿集  38回-  48  -48  2019/07肝炎・肝癌 5 肝癌内科治療の最前線上嶋一臣; 工藤正俊  Bio Clinica  34-  (7)  686  -690  2019/07南大阪地域における急性膵炎地域連携モデル構築への取り組み竹中完; 大本俊介; 吉川智恵; 石川嶺; 岡本彩那; 山崎友裕; 中井敦史; 三長孝輔; 鎌田研; 山雄健太郎; 松本逸平; 竹山宜典; 工藤正俊  膵臓(Web)  34-  (3)  A30‐A31(J‐STAGE)  2019/06微小膵癌診断の新たなアプローチ法―3D CTによる膵実質萎縮評価から見えてきたもの―山雄健太郎; 竹中完; 吉川智恵; 石川嶺; 岡本彩那; 中井敦; 山崎友宏; 大本俊介; 鎌田研; 三長孝輔; 松本逸平; 竹山宜典; 鶴崎正勝; 渡邉智裕; 工藤正俊  膵臓(Web)  34-  (3)  A33‐A34(J‐STAGE)  2019/06重症膵炎症例におけるプレサルコペニアと予後の関連性についての検討竹中完; 大本俊介; 竹山宜典; 吉川智恵; 石川嶺; 岡本彩那; 山崎友裕; 中井敦史; 三長孝輔; 鎌田研; 山雄健太郎; 松本逸平; 工藤正俊  膵臓(Web)  34-  (3)  A101‐A102(J‐STAGE)  2019/06VALUE OF CONTRAST-ENHANCED HARMONIC EUS WITH ENHANCEMENT PATTERN FOR DIAGNOSIS OF PANCREATIC CANCER: A META-ANALYSISYasunobu Yamashita; Toshio Shimokawa; Bertrand Napoleon; Pietro Fusaroli; Rodica Gincul; Masatoshi Kudo; Masayuki Kitano  GASTROINTESTINAL ENDOSCOPY  89-  (6)  AB582  -AB582  2019/06急性膵炎:診断と治療の最前線 南大阪地域における急性膵炎地域連携モデル構築への取り組み竹内 完; 大本 俊介; 吉川 智恵; 石川 嶺; 岡本 彩那; 山崎 友裕; 中井 敦史; 三長 孝輔; 鎌田 研; 山雄 健太郎; 松本 逸平; 竹山 宜典; 工藤 正俊  膵臓  34-  (3)  A30  -A31  2019/06膵癌早期診断の最前線 微小膵癌診断の新たなアプローチ法 3D CTによる膵実質萎縮評価から見えてきたもの山雄 健太郎; 竹中 完; 吉川 智恵; 石川 嶺; 岡本 彩那; 中井 敦; 山崎 友宏; 大本 俊介; 鎌田 研; 三長 孝輔; 松本 逸平; 竹山 宜典; 鶴崎 正勝; 渡邉 智裕; 工藤 正俊  膵臓  34-  (3)  A33  -A34  2019/06急性膵炎の重症度分類を再考する 重症膵炎症例におけるプレサルコペニアと予後の関連性についての検討竹中 完; 大本 俊介; 竹山 宜典; 吉川 智恵; 石川 嶺; 岡本 彩那; 山崎 友裕; 中井 敦史; 三長 孝輔; 鎌田 研; 山雄 健太郎; 松本 逸平; 工藤 正俊  膵臓  34-  (3)  A101  -A102  2019/06こんなにある薬剤性消化管傷害[各論 小腸および大腸]免疫チェックポイント阻害薬による大腸病変櫻井俊治; 樫田博史; 永井知行; 米田頼晃; 川上尚人; 中川和彦; 工藤正俊  消化器内視鏡  31-  (6)  928  -933  2019/06Results of KEYNOTE-240: phase 3 study of pembrolizumab (Pembro) vs best supportive care (BSC) for second line therapy in advanced hepatocellular carcinoma (HCC).Richard S. Finn; Baek-Yeol Ryoo; Philippe Merle; Masatoshi Kudo; Mohamed Bouattour; Ho-Yeong Lim; Valeriy Vladimirovich Breder; Julien Edeline; Yee Chao; Sadahisa Ogasawara; Thomas Yau; Marcelo Garrido; Stephen Lam Chan; Jennifer J. Knox; Bruno Daniele; Scot Ebbinghaus; Erluo Chen; Abby B. Siegel; Andrew X. Zhu; Ann-Lii Cheng  JOURNAL OF CLINICAL ONCOLOGY  37-  (15)  2019/05大腸カプセル内視鏡の最新の進歩 ヒマシ油ブースター使用による大腸カプセル内視鏡検査の前処置軽減の取り組み pilot study米田 頼晃; 医学部消化器内科; 櫻井 俊治; 工藤 正俊  Gastroenterological Endoscopy (0387-1207)61巻Suppl.1 Page780(2019.05)  2019/05消化管の拡大内視鏡診断の最新の知見 大腸ポリープ識別のためのAI(人工知能)を用いた拡大内視鏡実施下CNNシステムによるコンピューター自動診断米田 頼晃; 医学部消化器内科; 半田 久志; 工藤 正俊  Gastroenterological Endoscopy (0387-1207)61巻Suppl.1 Page708(2019.05)  2019/05門脈圧亢進症治療の最近の進歩 十二指腸静脈瘤の治療指針松井 繁長; 樫田 博史; 工藤 正俊  Gastroenterological Endoscopy  61-  (Suppl.1)  768  -768  2019/05好酸球性食道炎の臨床的特徴の検討正木 翔; 松井 繁長; 工藤 正俊; 大塚 康生; 松村 まり子; 高島 耕太; 河野 辰哉; 岡元 寿樹; 河野 匡志; 山田 光成; 永井 知行; 米田 頼晃; 櫻井 俊治; 渡邉 智裕; 辻 直子; 樫田 博史  Gastroenterological Endoscopy  61-  (Suppl.1)  963  -963  2019/05胆膵内視鏡診療における偶発症への対策、トラブルシューティング 術後再建腸管ERCPにおける胆管挿管困難症例に対するUneven Double Lumen Cannulaを用いた胆管挿管法(Uneven法)の有用性竹中 完; 三長 孝輔; 工藤 正俊  Gastroenterological Endoscopy  61-  (Suppl.1)  852  -852  2019/05超音波画像診断装置の到達点と今後 最新超音波技術の有用性と将来展望 AI(人工知能)による超音波診断の現状と将来像南康範; 西田直生志; 工藤正俊  月刊新医療  46-  (5)  92  -94  2019/05肝疾患を取り巻くAI・技術革新 6.肝細胞癌に対する焼灼療法におけるナビゲーション南康範; 南知宏; 田北雅弘; 萩原智; 依田広; 上嶋一臣; 西田直生志; 工藤正俊  肝臓クリニカルアップデート  5-  (1)  39  -42  2019/05肝と免疫2019 5 肝細胞癌治療と免疫(1)肝細胞癌に対する免疫チェックポイント阻害薬開発の現況工藤正俊  臨床消化器内科  34-  (5)  543‐554  2019/04Attenuation coefficient(ATT)による肝脂肪化定量化の検討玉城信治; 小泉洋平; 廣岡昌史; 矢田典久; 中島収; 工藤正俊; 日浅陽一; 泉並木  超音波医学  46-  (Supplement (CD-ROM))  S313(J‐STAGE)  2019/04肝脂肪と超音波:基礎から臨床、そして未来へ Attenuation coefficient(ATT)による肝脂肪化定量化の検討玉城 信治; 小泉 洋平; 廣岡 昌史; 矢田 典久; 中島 収; 工藤 正俊; 日浅 陽一; 泉 並木  超音波医学  46-  (Suppl.)  S313  -S313  2019/04AI:超音波診断の近未来 超音波画像データベース構築の推進と展望西田 直生志; 工藤 正俊  超音波医学  46-  (Suppl.)  S187  -S187  2019/04エキスパートへの道―胆・膵 ERCP関連 挿管手技 膵管ガイドワイヤー留置法―確実に成功させるコツ―竹中完; 中井敦史; 工藤正俊  消化器内視鏡  31-  (3)  348‐353  2019/03薬の知識 レンパチニブメシル酸塩(レンビマ)上嶋一臣; 工藤正俊  臨床消化器内科  34-  (4)  448‐450  2019/03薬の知識 レンバチニブメシル酸塩(レンビマ)上嶋 一臣; 工藤 正俊  臨床消化器内科  34-  (4)  448  -450  2019/03術前診断に難渋した膵頭部・尾部同時性多発癌の一例岡本 彩那; 三長 孝輔; 竹中 完; 吉川 智恵; 石川 嶺; 山崎 友裕; 中井 敦史; 大本 俊介; 鎌田 研; 山雄 健太郎; 松本 逸平; 大谷 知之; 工藤 正俊  日本消化器病学会雑誌  116-  (臨増総会)  A406  -A406  2019/03消化器領域における腸内細菌研究と臨床応用 腸内細菌叢からみた膵酵素補充療法の慢性膵炎に対する炎症抑制機序の解明三長 孝輔; 渡邉 智裕; 工藤 正俊  日本消化器病学会雑誌  116-  (臨増総会)  A163  -A163  2019/03ERCP・EUS関連手技のトラブルシューティング Interventional EUSのトラブルシューティング 超音波造影剤の併用三長 孝輔; 竹中 完; 工藤 正俊  日本消化器病学会雑誌  116-  (臨増総会)  A224  -A224  2019/03術前診断に難渋した膵頭部・尾部同時性多発癌の一例岡本 彩那; 三長 孝輔; 竹中 完; 吉川 智恵; 石川 嶺; 山崎 友裕; 中井 敦史; 大本 俊介; 鎌田 研; 山雄 健太郎; 松本 逸平; 大谷 知之; 工藤 正俊  日本消化器病学会雑誌  116-  (臨増総会)  A406  -A406  2019/03自己免疫性膵炎2019 AIPの病因・病態 腸内細菌叢からみた発症機序渡邉智裕; 鎌田研; 吉川智恵; 三長孝輔; 工藤正俊  肝胆膵  78-  (2)  189‐195  2019/02Analysis of survival and objective response (OR) in patients with hepatocellular carcinoma in a phase III study of lenvatinib (REFLECT).Masatoshi Kudo; Richard S. Finn; Shukui Qin; Kwang-Hyub Han; Kenji Ikeda; Ann-Lii Cheng; Fabio Piscaglia; Kazuomi Ueshima; Hiroshi Aikata; Arndt Vogel; Carlos Lopez; Marc Pracht; Zhiqiang Meng; Bruno Daniele; Joong-Won Park; Daniel H. Palmer; Corina E. Dutcus; Toshiyuki Tamai; Kenichi Saito; Riccardo Lencioni  JOURNAL OF CLINICAL ONCOLOGY  37-  (4)  2019/02Sorafenib versus hepatic arterial infusion chemotherapy in patients with advanced hepatocellular carcinoma: A Japanese multi-center large cohort study.Sadahisa Ogasawara; Kazuomi Ueshima; Masafumi Ikeda; Yutaka Yasui; Takeshi Terashima; Tatsuya Yamashita; Shuntaro Obi; Shinpei Sato; Hiroshi Aikata; Takumi Ohmura; Hidekatsu Kuroda; Takamasa Ohki; Kengo Nagashima; Masayuki Kurosaki; Kazuaki Chayama; Shuichi Kaneko; Namiki Izumi; Naoya Kato; Masatoshi Kudo; Masao Omata  JOURNAL OF CLINICAL ONCOLOGY  37-  (4)  2019/02進行肝細胞癌治療の現状と課題 肝予備能からみたレンバチニブの有効性と安全性の検討萩原 智; 上嶋 一臣; 工藤 正俊  日本消化器病学会近畿支部例会プログラム・抄録集  110回-  61  -61  2019/02胃癌実臨床における免疫チェックポイント阻害剤の有効性と安全性河野 匡志; 内科; 櫻井 俊治; 今野 元博; 岡元 寿樹; 山田 光成; 永井 知行; 米田 頼晃; 工藤 正俊  日本胃癌学会総会記事 91回 Page493(2019.02)  2019/02ピロリ陰性時代の上部消化管診療 胃底腺型胃癌の臨床的特徴の検討河野 辰哉; 松井 繁長; 櫻井 俊治; 工藤 正俊  日本消化器病学会近畿支部例会プログラム・抄録集  110回-  57  -57  2019/02タビガトランによる食道潰瘍の臨床的特徴の検討松井繁長; 樫田博史; 米田頼晃; 永井知行; 櫻井俊治; 辻直子; 工藤正俊  日本消化管学会雑誌  3-  (Supplement)  174  2019/02肝細胞癌の薬物療法工藤正俊  医学のあゆみ  268-  (2)  146‐148  2019/01ダビガトランによる食道潰瘍の臨床的特徴の検討松井繁長; 樫田博史; 米田頼晃; 永井知行; 櫻井俊治; 辻直子; 工藤正俊  日本消化管学会雑誌  3-  (Supplement)  2019VALUE OF ADDITIONAL ENDOSCOPIC ULTRASONOGRAPHY FOR SURVEILLANCE AFTER SURGICAL REMOVAL OF INTRADUCTAL PAPILLARY MUCINOUS NEOPLASMS鎌田研; 竹中完; 三長孝輔; 大本俊介; 宮田剛; 山雄健太郎; 今井元; 中井敦史; 田中秀和; 千葉康敬; 渡邉智裕; 櫻井俊治; 西田直生志; 筑後考章; 松本逸平; 竹山宜典; 北野雅之; 工藤正俊  Gastroenterological Endoscopy (Web)  61-  (4)  2019膨張性発育により胆嚢から総胆管内にまで連続性充満をぎたした胆管腺扁平上皮癌の一例大本俊介; 竹中完; 山雄健太郎; 山崎友裕; 前西修; 筑後孝章; 柳生行伸; 鶴崎正勝; 松本逸平; 竹山宜典; 工藤正俊  日本消化器画像診断研究会プログラム・抄録集  70th-  2019膵癌診断のための新たなアプローチ法の提案-3D CT解析による膵実質萎縮の検討-山雄健太郎; 竹中完; 工藤正俊  日本消化器がん検診学会雑誌  57-  (Supplement)  20193D CTによる膵実質萎縮の評価が進展範囲診断に有用であった8mm膵癌の1例山雄健太郎; 三長孝輔; 竹中完; 樫田博史; 松本逸平; 竹山宜典; 鶴崎正勝; 前西修; 筑後孝章; 工藤正俊  日本消化器画像診断研究会プログラム・抄録集  71st-  2019Current status of radiation exposure to crystalline lens in ERCP (endoscopic retrograde cholangiopancreatography)竹中完; 細野眞; 細野眞; 中井敦史; 大本俊介; 三長孝輔; 鎌田研; 山雄健太郎; 林史郎; 西田勉; 工藤正俊  日本消化器病学会雑誌(Web)  116-  (12)  2019急性胆嚢炎治療における内視鏡的経乳頭胆嚢ドレナージ(ENGBD)の位置づけ武部敦志; 竹中完; 工藤正俊; 竹山宜典  日本消化器病学会近畿支部例会プログラム・抄録集  111th-  2019膵神経内分泌腫瘍の悪性度評価における造影ハーモニックEUSの有用性石川嶺; 鎌田研; 竹中完; 工藤正俊  日本消化器病学会近畿支部例会プログラム・抄録集  110th-  2019EUS施行時のプロポフォール持続注入による鎮静の有用性の検討岡本彩那; 鎌田研; 竹中完; 吉川智恵; 石川嶺; 山崎友裕; 中井敦史; 大本俊介; 三長孝輔; 山雄健太郎; 工藤正俊  Gastroenterological Endoscopy (Web)  61-  (Supplement2)  2019術前診断に難渋した膵頭部・尾部同時性多発癌の一例岡本彩那; 三長孝輔; 竹中完; 吉川智恵; 石川嶺; 山崎友裕; 中井敦史; 大本俊介; 鎌田研; 山雄健太郎; 松本逸平; 大谷知之; 工藤正俊  日本消化器病学会雑誌(Web)  116-  2019Interventional EUSのトラブルシューティング:超音波造影剤の併用三長孝輔; 竹中完; 工藤正俊  日本消化器病学会雑誌(Web)  116-  2019術後再建腸管ERCPにおける胆管挿管困難症例に対するUneven Double Lumen Cannulaを用いた胆管挿管法(Uneven法)の有用性竹中完; 三長孝輔; 工藤正俊  Gastroenterological Endoscopy (Web)  61-  (Supplement1)  2019胆道閉塞に対するantegrade long Plastic Stent留置術の有用性中井敦史; 竹中完; 工藤正俊  Gastroenterological Endoscopy (Web)  61-  (Supplement2)  2019好酸球性食道炎の臨床的特徴の検討正木翔; 松井繁長; 工藤正俊; 大塚康生; 松村まり子; 高島耕太; 河野辰哉; 岡元寿樹; 河野匡志; 山田光成; 永井知行; 米田頼晃; 櫻井俊治; 渡邉智裕; 辻直子; 樫田博史  Gastroenterological Endoscopy (Web)  61-  (Supplement1)  2019肝細胞腺腫の1例山根雅智; 秦康倫; 松村まり子; 福永朋洋; 高田隆太郎; 河野匡志; 木下大輔; 奥田英之; 川崎俊彦; 水野成人; 日向聖; 石川原; 井上雅智; 若狭朋子; 太田善夫; 工藤正俊  日本消化器病学会近畿支部例会プログラム・抄録集  111th-  2019ステロイド抵抗性潰瘍性大腸炎に対するシクロスポリンの使用経験河野匡志; 櫻井俊治; 工藤正俊  日本消化器病学会近畿支部例会プログラム・抄録集  110th-  2019膵頭十二指腸切除後の胆管結石に対して細径上部消化管内視鏡下のEHLが有用であった1例福永朋洋; 水野成人; 松村まり子; 高田隆太郎; 河野匡志; 秦康倫; 木下大輔; 奥田英之; 川崎俊彦; 工藤正俊  胆道(Web)  33-  (3)  2019超音波検査が診断に有用であった消化管疾患の検討南雅人; 横川美加; 桑口愛; 市島真由美; 塩見香織; 前川清; 南康範; 樫田博史; 工藤正俊  超音波医学  46-  (Supplement (CD-ROM))  2019【新しい時代を迎える肝細胞癌の薬物治療と展望】肝細胞癌の薬物治療の最近の進歩と将来展望工藤 正俊  日本消化器病学会雑誌  116-  (1)  8  -17  2019/01Response Evaluation Criteria in Cancer of the Liver (RECICL 2019 revised version)工藤正俊; 工藤正俊; 池田公史; 上嶋一臣; 坂元亨宇; 椎名秀一朗; 建石良介; 長谷川潔; 古瀬純司; 宮山四朗; 村上卓道; 山下竜也; 國土典宏; 國土典宏  肝臓  60-  (2)  55‐62(J‐STAGE)  2019膵管内乳頭粘液性腫瘍(IPMN)の診断と経過観察法 3 IPMNに合併・併存する膵癌とその診断法鎌田研; 竹中完; 工藤正俊  週刊日本医事新報  (4940)  36‐40  2018/12選択的胆管挿管100%をめざして―We’re gonna do it!―乳頭形態別の胆管挿管ストラテジー【動画付】竹中完; 向井秀一; 吉川智恵; 石川嶺; 岡本彩那; 山崎友祐; 中井敦史; 大本俊介; 三長孝輔; 鎌田研; 山雄健太郎; 工藤正俊  胆と膵  39-  (12)  1309‐1317  -1317  2018/12PD-L1陽性肝癌の臨床病理学的特徴と免疫環境に関する解析西田 直生志; 工藤 正俊  The Liver Cancer Journal  10-  (Suppl.2)  31  -33  2018/12  [Invited]Interventional EUSの偶発症予防と対処 超音波内視鏡下瘻孔形成術における胆汁漏出の予防鎌田研; 竹中完; 三長孝輔; 石川嶺; 吉川智恵; 岡本彩那; 山崎友裕; 中井敦史; 大本俊介; 山雄健太郎; 工藤正俊  月刊消化器・肝臓内科  4-  (6)  470  -473  2018/12EUSによる消化管疾患の診断―現状と最新の話題 造影ハーモニックEUSによる消化管粘膜下腫瘍の診断鎌田研; 竹中完; 石川嶺; 吉川智恵; 岡本彩那; 山崎友裕; 中井敦史; 大本俊介; 三長孝輔; 山雄健太郎; 櫻井俊治; 松井繁長; 渡邉智裕; 西田直生志; 樫田博史; 工藤正俊  胃と腸  53-  (13)  1795  -1799  2018/12胆膵ドレナージupdate[3.困難例とトラブルシューティング]胆管・膵管プラスチックステント迷入への対処竹中完; 三長孝輔; 鎌田研; 山雄健太郎; 工藤正俊  消化器内視鏡  30-  (11)  1605‐1611  2018/11Biliary access大辞典 III.経乳頭的biliary access~salvage technique~Uneven Double Lumen Cannulaを用いた胆管カニュレーションテクニック(Uneven method)【動画付】竹中完; 吉川智恵; 石川嶺; 岡本彩那; 山崎友祐; 中井敦史; 大本俊介; 三長孝輔; 鎌田研; 山雄健太郎; 有坂好史; 工藤正俊  胆と膵  39-  1013‐1020  2018/11【胆膵ドレナージupdate】 [困難例とトラブルシューティング] 胆管・膵管プラスチックステント迷入への対処竹中 完; 三長 孝輔; 鎌田 研; 山雄 健太郎; 工藤 正俊  消化器内視鏡  30-  (11)  1605  -1611  2018/11IgG4関連疾患の最近の知見 IgG4関連疾患の病因と自然免疫渡邉智裕; 鎌田研; 三長孝輔; 工藤正俊  月刊リウマチ科  60-  (4)  347‐352  2018/10胆膵疾患内視鏡アトラス I.膵臓 1.充実性 特殊型膵癌―腺扁平上皮癌,退形成性膵管癌,腺房細胞癌―竹中完; 筑後孝章; 工藤正俊  消化器内視鏡  30-  54‐57,7  2018/10Stem Cell Feature and Immune-Suppressive Microenvironment in Human Hepatocellular CarcinomaNaoshi Nishida; Masatoshi Kudo  HEPATOLOGY  68-  1271A  -1272A  2018/10膵癌の門脈浸潤診断における造影ハーモニックEUSと造影CTの診断能の比較検討中井 敦史; 鎌田 研; 竹中 完; 石川 嶺; 岡本 彩那; 大本 俊介; 三長 孝輔; 山雄 健太郎; 兵頭 朋子; 松本 逸平; 竹山 宜典; 工藤 正俊  Gastroenterological Endoscopy  60-  (Suppl.2)  2126  -2126  2018/10EUS施行時の鎮静に対するBISモニターの有用性の検討岡本 彩那; 鎌田 研; 竹中 完; 石川 嶺; 中井 敦史; 大本 俊介; 三長 孝輔; 山雄 健太郎; 工藤 正俊  Gastroenterological Endoscopy  60-  (Suppl.2)  2126  -2126  2018/10術前水平方向進展度診断にSpyGlass DSが有用であった遠位胆管癌の2例東原 久美; 三長 孝輔; 岡本 彩那; 榎木 英介; 石川 嶺; 中井 敦史; 大本 俊介; 鎌田 研; 山雄 健太郎; 竹中 完; 工藤 正俊  Gastroenterological Endoscopy  60-  (Suppl.2)  2153  -2153  2018/10外科医が知っておきたい化学放射線療法・癌免疫療法 原発性肝癌(肝細胞癌)工藤正俊  消化器外科  41-  (11)  1507  -1517  2018/10ここまで“見える”最新超音波診断装置[Part2]今“超音波”に求められるものとは 肝癌に対するPrecision RFAと超音波による早期治療効果判定 US‐US overlay fusionの有用性南康範; 工藤正俊  月刊新医療  45-  (9)  114‐117  2018/09急速に変貌する肝細胞癌の薬物療法2018 Update 免疫チェックポイント阻害剤同士のコンビネーション治療 その他のIO+IOの臨床試験の可能性上嶋一臣; 工藤正俊  肝胆膵  77-  (2)  473‐475  -475  2018/08バッドキアリ症候群に伴う急性肝不全に対して肝移植までのbridging therapyとしてTIPSを施行した一例沼本勲男; 鶴崎正勝; 鈴木絢子; 土居秀平; 小田晃義; 門馬智也; 柳生行伸; 石井一成; 上嶋一臣; 工藤正俊  日本門脈圧亢進症学会雑誌  24-  (3)  136  -136  2018/08内視鏡治療後の再発十二指腸静脈瘤に対するEUSの有用性松井繁長; 樫田博史; 工藤正俊  日本門脈圧亢進症学会雑誌  24-  (3)  113  2018/08バッドキアリ症候群に伴う急性肝不全に対して肝移植までのbridging therapyとしてTIPSを施行した一例沼本 勲男; 鶴崎 正勝; 鈴木 絢子; 土居 秀平; 小田 晃義; 門馬 智也; 柳生 行伸; 石井 一成; 上嶋 一臣; 工藤 正俊  日本門脈圧亢進症学会雑誌  24-  (3)  136  -136  2018/08肝外胆管癌における造影ハーモニックEUSの有用性についての検討大塚 康生; 鎌田 研; 竹中 完; 石川 嶺; 岡本 彩那; 中井 敦史; 大本 俊介; 三長 孝輔; 山雄 健太郎; 筑後 孝章; 兵頭 朋子; 中居 卓也; 竹山 宜典; 工藤 正俊  胆道  32-  (3)  567  -567  2018/08知っておこう!遺伝性消化器疾患 常染色体優性多嚢胞性肝疾患(ADPLD)田北雅弘; 南知宏; 千品寛和; 河野匡志; 萩原智; 南康範; 依田広; 上嶋一臣; 西田直生志; 工藤正俊  消化器内視鏡  30-  (8)  1086  -1089  2018/08【レンビマで変わる肝細胞癌の診断と治療】 レンビマ徹底解剖 Phase 3 REFLECT試験工藤 正俊  クリニシアン  65-  (7)  593  -612  2018/07急激に変貌する肝癌の薬物療法 肝細胞癌における免疫チェックポイント阻害薬とその他の治療法との組み合わせ治療工藤 正俊  The Liver Cancer Journal  10-  (1)  49  -55  2018/07【どうする膵嚢胞】 IPMN IPMNの経過観察におけるEUSの今後鎌田 研; 竹中 完; 中井 敦史; 大本 俊介; 宮田 剛; 三長 孝輔; 山雄 健太郎; 今井 元; 樫田 博史; 工藤 正俊  消化器内視鏡  30-  (5)  606  -610  2018/05【膵癌update】 トピックス 膵癌の癌性疼痛に対するEUSガイド下神経叢ブロック(融解)術の有用性宮田 剛; 竹中 完; 工藤 正俊  臨床消化器内科  33-  (7)  950  -957  2018/05膵NETの最新の画像診断と治療 造影ハーモニックEUSによる膵神経内分泌腫瘍の悪性度評価石川 嶺; 鎌田 研; 竹中 完; 田中 秀和; 中井 敦史; 大本 俊介; 宮田 剛; 三長 孝輔; 山雄 健太郎; 今井 元; 工藤 正俊  膵臓  33-  (3)  346  -346  2018/05術後膵液瘻(POPF)に対するEUS下ドレナージの有用性中井 敦史; 竹中 完; 山雄 健太郎; 松本 逸平; 竹山 宜典; 工藤 正俊  膵臓  33-  (3)  399  -399  2018/05重症急性膵炎の予後不良予測因子および被包化壊死(WON)合併予測因子の検討大本 俊介; 竹中 完; 松本 逸平; 竹山 宜典; 工藤 正俊  膵臓  33-  (3)  410  -410  2018/05造影ハーモニックEUSは膵癌の術前治療の効果判定に有用か?田中 秀和; 鎌田 研; 竹中 完; 石川 嶺; 中井 敦史; 大本 俊介; 三長 孝輔; 宮田 剛; 山雄 健太郎; 今井 元; 工藤 正俊  膵臓  33-  (3)  505  -505  2018/05Pembrolizumab (pembro) in patients with advanced hepatocellular carcinoma (HCC): KEYNOTE-224 update.Andrew X. Zhu; Richard S. Finn; Julien Edeline; Stephane Cattan; Sadahisa Ogasawara; Daniel H. Palmer; Chris Verslype; Vittorina Zagonel; Laetitia Fartoux; Arndt Vogel; Debashis Sarker; Gontran Verset; Stephen Lam Chan; Jennifer J. Knox; Bruno Daniele; Scot Ebbinghaus; Junshui Ma; Abby B. Siegel; Ann-Lii Cheng; Masatoshi Kudo  JOURNAL OF CLINICAL ONCOLOGY  36-  (15)  2018/05Randomized, open label, multicenter, phase II trial of transcatheter arterial chemoembolization (TACE) therapy in combination with sorafenib as compared with TACE alone in patients with hepatocellular carcinoma: TACTICS trial.Masatoshi Kudo; Kazuomi Ueshima; Takuji Torimura; Nobukazu Tanabe; Masafumi Ikeda; Hiroshi Aikata; Namiki Izumi; Takahiro Yamasaki; Shunsuke Nojiri; Keisuke Hino; Hidetaka Tsumura; Norio Isoda; Kohichiroh Yasui; Teiji Kuzuya; Takuji Okusaka; Junji Furuse; Norihiro Kokudo; Kiwamu Okita; Kenichi Yoshimura  JOURNAL OF CLINICAL ONCOLOGY  36-  (15)  2018/05バッドキアリ症候群に伴う急性肝不全に対して肝移植までのbridging therapyとしてTIPSを施行した1例沼本勲男; 鶴崎正勝; 小田晃義; 柳生行伸; 鈴木絢子; 土居秀平; 柏木伸夫; 村上卓道; 上嶋一臣; 工藤正俊  IVR  33-  (1)  67  2018/05切除不能肝細胞癌に対する肝動脈化学塞栓療法(TACE)とソラフェニブの併用療法第II相臨床試験TACTICS Trial上嶋一臣; 池田公史; 工藤正俊  肝臓  59-  (Supplement 1)  A72  2018/04肝臓 エラスト エラストグラフィは何を見ている? 超音波エラストグラフィ併用による肝線維化・炎症評価玉城 信治; 泉 並木; 小泉 洋平; 廣岡 昌史; 日浅 陽一; 中島 収; 矢田 典久; 工藤 正俊  超音波医学  45-  (Suppl.)  S304  -S304  2018/04結腸直腸癌の内視鏡的治療後の局所再発を検出するための至適な検査間隔米田 頼晃; 樫田 博史; 工藤 正俊  日本消化器病学会雑誌 (0446-6586)115巻臨増総会 Page A238(2018.04)  2018/04造影ハーモニックEUSによる膵癌の門脈浸潤診断の検討中井 敦史; 鎌田 研; 大本 俊介; 宮田 剛; 三長 孝輔; 山雄 健太郎; 今井 元; 竹中 完; 樫田 博史; 工藤 正俊  Gastroenterological Endoscopy  60-  (Suppl.1)  738  -738  2018/04超音波内視鏡ガイド下治療の現状と問題点 膵癌に伴う疼痛に対するEUSガイド下神経ブロックの有用性三長 孝輔; 竹中 完; 工藤 正俊  日本消化器病学会雑誌  115-  (臨増総会)  A68  -A68  2018/04十二指腸穿破をきたした正中球状靱帯症候群による膵十二指腸動脈瘤の一例高島 耕太; 大本 俊介; 三長 孝輔; 竹中 完; 中井 敦史; 宮田 剛; 鎌田 研; 山雄 健太郎; 今井 元; 米田 頼晃; 松井 繁長; 工藤 正俊  日本消化器病学会雑誌  115-  (臨増総会)  A355  -A355  2018/04膵体部の膵神経内分泌腫瘍に合併した膵性胸水の一例河野 辰哉; 山雄 健太郎; 中井 敦史; 大本 俊介; 鎌田 研; 三長 孝輔; 宮田 剛; 今井 元; 松本 逸平; 竹山 宜典; 田中 伴典; 筑後 孝章; 林 暁洋; 工藤 正俊  日本消化器病学会雑誌  115-  (臨増総会)  A395  -A395  2018/04肝臓 治療 安全かつ確実なRFA治療を目指した超音波技術の工夫 US-US image overlay fusionを用いたラジオ波焼灼術の有用性 従来治療との比較南 康範; 南 知宏; 千品 寛和; 田北 雅弘; 萩原 智; 依田 広; 上嶋 一臣; 西田 直生志; 工藤 正俊  超音波医学  45-  (Suppl.)  S327  -S327  2018/04肝癌治療の新展開 遺伝子変化に基づいた肝細胞癌の分子スコアリングと転移再発西田 直生志; 海道 利実; 工藤 正俊  肝臓  59-  (Suppl.1)  A73  -A73  2018/04肝炎ウイルスの制御が肝癌診療に及ぼす影響 慢性C型肝炎のDAA投与例におけるSVR後のAFP、ALT異常及び肝発癌に関する検討河野 匡志; 西田 直生志; 工藤 正俊  肝臓  59-  (Suppl.1)  A259  -A259  2018/04肝癌診療up to date US-US image overlay fusionを用いたラジオ波焼灼術の早期治療効果判定南 康範; 西田 直生志; 工藤 正俊  日本消化器病学会雑誌  115-  (臨増総会)  A46  -A46  2018/03C型肝炎に対する初回インターフェロンフリー治療不成功例の臨床的特徴吉田 晃浩; 萩原 智; 南 知宏; 千品 寛和; 河野 匡; 田北 雅弘; 依田 広; 上嶋 一臣; 南 康範; 西田 直生志; 工藤 正俊  日本消化器病学会雑誌  115-  (臨増総会)  A308  -A308  2018/03C型肝炎に対するダクラタスビル・アスナプレビル治療奏功後肝発癌についての臨床的特徴田中 秀和; 萩原 智; 南 知宏; 千品 寛和; 河野 匡志; 田北 雅弘; 南 康範; 依田 広; 上嶋 一臣; 西田 直生志; 工藤 正俊  日本消化器病学会雑誌  115-  (臨増総会)  A312  -A312  2018/03【知っておきたい神経感染症】 C型肝炎ウイルス関連クリオグロブリン血管炎南 康範; 工藤 正俊  BRAIN and NERVE: 神経研究の進歩  70-  (2)  133  -137  2018/02KEYNOTE-224: Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib.Andrew X. Zhu; Richard S. Finn; Stephane Cattan; Julien Edeline; Sadahisa Ogasawara; Daniel H. Palmer; Chris Verslype; Vittorina Zagonel; Olivier Rosmorduc; Arndt Vogel; Debashis Sarker; Gontran Verset; Stephen Lam Chan; Jennifer J. Knox; Bruno Daniele; Scot Ebbinghaus; Junshui Ma; Abby B. Siegel; Ann-Lii Cheng; Masatoshi Kudo  JOURNAL OF CLINICAL ONCOLOGY  36-  (4)  2018/02Randomized, open label, multicenter, phase II trial comparing transarterial chemoembolization (TACE) plus sorafenib with TACE alone in patients with hepatocellular carcinoma (HCC): TACTICS trial.Masatoshi Kudo; Kazuomi Ueshima; Masafumi Ikeda; Takuji Torimura; Nobukazu Tanabe; Hiroshi Aikata; Namiki Izumi; Takahiro Yamasaki; Shunsuke Nojiri; Keisuke Hino; Hidetaka Tsumura; Teiji Kuzuya; Norio Isoda; Kohichiroh Yasui; Kenichi Yoshimura; Takuji Okusaka; Junji Furuse; Norihiro Kokudo; Kiwamu Okita; Yasuaki Arai  JOURNAL OF CLINICAL ONCOLOGY  36-  (4)  2018/02肝細胞癌に対するUS-US overlay fusionを用いたラジオ波焼灼術の有用性南 知宏; 南 康範; 千品 寛和; 有住 忠晃; 田北 雅弘; 矢田 典久; 萩原 智; 依田 広; 上嶋 一臣; 西田 直生志; 工藤 正俊  肝臓  59-  (2)  142  -144  2018/02Papillary neoplasm in a common channel in patients with pancreaticobiliary maljunctionYusuke Makutani; Ippei Matsumoto; Shunsuke Omoto; Takaaki Chikugo; Kohei Kawaguchi; Masataka Matsumoto; Takaaki Murase; Keiko Kamei; Shumpei Satoi; Takuya Nakai; Mamoru Takenaka; Masatoshi Kudo; Yoshifumi Takeyama  Japanese Journal of Gastroenterological Surgery  51-  (2)  114  -121  2018パンクレリパーゼ摂取による腸管内および便の腸内細菌叢に対する影響の検討永井知行; 櫻井俊治; 工藤正俊; 西山拓輝; 岡崎能久; 東慶直; 渡邉智裕; 五斗進; 緒方博之  日本消化器病学会雑誌(Web)  115-  2018C型肝炎に対する初回インターフェロンフリー治療不成功例の臨床的特徴吉田晃浩; 萩原智; 南知宏; 千品寛和; 河野匡; 田北雅弘; 依田広; 上嶋一臣; 南康範; 西田直生志; 工藤正俊  日本消化器病学会雑誌(Web)  115-  2018膵癌に伴う疼痛に対するEUSガイド下神経ブロックの有用性三長孝輔; 竹中完; 工藤正俊  日本消化器病学会雑誌(Web)  115-  2018膵胆道腫瘍のリンパ節転移診断における造影ハーモニックEUSの有用性中井敦史; 宮田剛; 竹中完; 工藤正俊  日本消化器病学会雑誌(Web)  115-  2018十二指腸穿破をきたした正中球状靭帯症候群による膵十二指腸動脈瘤の一例高島耕太; 大本俊介; 三長孝輔; 竹中完; 中井敦史; 宮田剛; 鎌田研; 山雄健太郎; 今井元; 米田頼晃; 松井繁長; 工藤正俊  日本消化器病学会雑誌(Web)  115-  2018術後再建腸管ERCPにおける胆管挿管困難症例に対するUneven Double Lumen Cannulaを用いた胆管挿管法(DLC法)の有用性竹中完; 中井敦史; 工藤正俊  Gastroenterological Endoscopy (Web)  60-  (Supplement1)  2018膵癌の門脈浸潤診断における造影ハーモニックEUSと造影CTの診断能の比較検討中井敦史; 鎌田研; 竹中完; 石川嶺; 岡本彩那; 大本俊介; 三長孝輔; 山雄健太郎; 兵頭朋子; 松本逸平; 竹山宜典; 工藤正俊  Gastroenterological Endoscopy (Web)  60-  (Supplement2)  2018EUS施行時の鎮静に対するBISモニターの有用性の検討岡本彩那; 鎌田研; 竹中完; 石川嶺; 中井敦史; 大本俊介; 三長孝輔; 山雄健太郎; 工藤正俊  Gastroenterological Endoscopy (Web)  60-  (Supplement2)  2018良性胆道狭窄(慢性膵炎)に対するfully covered metallic stentの有用性竹中完; 山雄健太郎; 工藤正俊  Gastroenterological Endoscopy (Web)  60-  (Supplement2)  2018術前水平方向進展度診断にSpyGlass DSが有用であった遠位胆管癌の2例東原久美; 三長孝輔; 岡本彩那; 榎木英介; 石川嶺; 中井敦史; 大本俊介; 鎌田研; 山雄健太郎; 竹中完; 工藤正俊  Gastroenterological Endoscopy (Web)  60-  (Supplement2)  2018肝腫瘍の視認性に関する低音圧造影tissue harmonic imagingの有用性南康範; 河野匡志; 工藤正俊  超音波医学  45-  (Supplement (CD-ROM))  2018C型肝炎に対するダクラタスビル・アスナプレビル治療奏功後肝発癌についての臨床的特徴田中秀和; 萩原智; 南知宏; 千品寛和; 河野匡志; 田北雅弘; 南康範; 依田広; 上嶋一臣; 西田直生志; 工藤正俊  日本消化器病学会雑誌(Web)  115-  2018膵管内に発育した5mmの退形性膵癌の1例中井敦史; 山雄健太郎; 竹中完; 松本逸平; 竹山宜典; 鶴崎正勝; 柳生行伸; 筑後孝章; 工藤正俊  日本消化器画像診断研究会プログラム・抄録集  69th-  55  2018術前にIPMN併存癌と診断したlow‐grade PanINの1例山雄健太郎; 竹中完; 松本逸平; 竹山宜典; 筑後孝章; 工藤正俊  日本消化器画像診断研究会プログラム・抄録集  68th-  21  2018/01造影ハーモニックEUSによる膵癌の門脈浸潤診断の検討中井敦史; 鎌田研; 大本俊介; 宮田剛; 三長孝輔; 山雄健太郎; 今井元; 竹中完; 樫田博史; 工藤正俊  Gastroenterological Endoscopy (Web)  60-  (Supplement1)  738(J‐STAGE)  2018A case of gallbladder carcinoma with interesting contrast-enhanced harmonic EUS imageYoshikawa Tomoe; Matsumoto Ippei; Takeyama Yoshifumi; Kudo Masatoshi; Kamata Ken; Takenaka Mamoru; Omoto Shunsuke; Minaga Kosuke; Yamao Kentaro; Imai Hajime; Enoki Eisuke; Kimura Masatomo  Tando  32-  (4)  775  -781  2018キーワード(No.3) パターン認識受容体渡邉 智裕; 工藤 正俊  消化器病学サイエンス  1-  (3)  150  -152  2017/12Phase III Trial of Lenvatinib (LEN) vs Sorafenib (SOR) in First-Line Treatment of Patients (PTS) with Unresectable Hepatocellular Carcinoma (uHCC)Ann-Lii Cheng; Richard S. Finn; Shukui Qin; Kwan-Hyub Han; Kenji Ikeda; Fabio Piscaglia; Ari Baron; Joong-Won Park; Guohong Han; Jacek Jassem; Jean Frederic Blanc; Arndt Vogel; Dmitry Komov; T. R. Jeffry Evans; Carlos Lopez; Corina Dutcus; MinRen; Silvija Kraljevic; Toshiyuki Tamai; John Bower; Masatoshi Kudo  ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY  13-  116  -116  2017/11DAA投与におけるSVR後のAFP異常値と関連する臨床背景の検討河野 匡志; 西田 直生志; 千品 寛和; 南 知宏; 有住 忠晃; 田北 雅弘; 矢田 典久; 萩原 智; 南 康範; 上嶋 一臣; 工藤 正俊  肝臓  58-  (Suppl.3)  A801  -A801  2017/11胃への遠隔転移を認めた肝細胞癌の一例福永 朋洋; 萩原 智; 半田 康平; 高田 隆太郎; 岡本 彩那; 南 知宏; 河野 匡志; 千品 寛和; 有住 忠晃; 田北 雅弘; 南 康範; 依田 広; 上嶋 一臣; 西田 直生志; 工藤 正俊  肝臓  58-  (Suppl.3)  A934  -A934  2017/11真性多血症にBudd-Chiari症候群を伴った1例高田 隆太郎; 萩原 智; 福永 朋洋; 半田 康平; 岡本 彩那; 南 知宏; 河野 匡志; 千品 寛和; 有住 忠晃; 田北 雅弘; 南 康範; 依田 広; 上嶋 一臣; 西田 直生志; 工藤 正俊  肝臓  58-  (Suppl.3)  A940  -A940  2017/11腹壁静脈瘤破裂に対し直接穿刺にて硬化療法を施行した2例半田 康平; 萩原 智; 福永 明洋; 高田 隆太郎; 岡本 彩那; 南 知宏; 河野 匡志; 千品 寛和; 有住 忠晃; 田北 雅弘; 南 康範; 依田 広; 上嶋 一臣; 西田 直生志; 工藤 正俊  肝臓  58-  (Suppl.3)  A943  -A943  2017/11Clinicopathological characteristics and mutational profile of PD-L1 positive hepatocellular carcinomaNaoshi Nishida; Masatoshi Kudo  HEPATOLOGY  66-  87A  -87A  2017/10Prognosis after non-curative resection for hepatocellular carcinoma: an analysis using nationwide survey data in JapanTakatsugu Matsumoto; Keiichi Kubota; Taku Aoki; Namiki Izumi; Masumi Kadoya; Shoji Kubo; Takashi Kumada; Norihiro Kokudo; Michiie Sakamoto; Tadatoshi Takayama; Osamu Nakashima; Yutaka Matsuyama; Masatoshi Kudo  HEPATOLOGY  66-  881A  -881A  2017/10Significance of surgical margin in patients with single hepatocellular carcinoma undergoing curative hepatic resection: an analysis using nationwide survey data in JapanTaku Aoki; Keiichi Kubota; Takatsugu Matsumoto; Namiki Izumi; Masumi Kadoya; Shoji Kubo; Takashi Kumada; Norihiro Kokudo; Michiie Sakamoto; Tadatoshi Takayama; Osamu Nakashima; Yutaka Matsuyama; Masatoshi Kudo  HEPATOLOGY  66-  891A  -892A  2017/10Time course of treatment-emergent adverse events (TEAEs) in the randomized, controlled phase 3 RESORCE trial of regorafenib for patients with hepatocellular carcinoma progressing on sorafenib treatmentPhilippe Merle; Alessandro Granito; Yi-Hsiang Huang; Gyorgy Bodoky; Marc Pracht; Osamu Yokosuka; Olivier Rosmorduc; Valeriy Breder; Rene Gerolami; Gianluca Masi; Paul J. Ross; Shukui Qin; Tianqiang Song; Jean-Pierre Bronowicki; Isabelle Ollivier-Hourmand; Masatoshi Kudo; Sarah Schlief; Sabine Fiala-Buskies; Gerold Meinhardt; Jordi Bruix  HEPATOLOGY  66-  726A  -726A  2017/10Nivolumab in Sorafenib-Naive and -Experienced Patients With Advanced Hepatocellular Carcinoma (HCC): Survival, Hepatic Safety, and Biomarker Assessments in CheckMate 040Bruno Sangro; Ignacio Melero; Thomas Yau; Chiun Hsu; Masatoshi Kudo; Tae-You Kim; Su-Pin Choo; Jorg Trojan; Theodore H. Welling; Timothy Meyer; Yoon-Koo Kang; Winnie Yeo; Akhil Chopra; Adyb Baakili; Christine dela Cruz; Huanyu Zhao; Jaclyn Neely; Todd S. Crocenzi; Anthony B. El-Khoueiry  HEPATOLOGY  66-  82A  -82A  2017/10Health-related Quality of Life (HRQOL) and Disease Symptoms in Patients with Unresectable Hepatocellular Carcinoma (HCC) Treated with Lenvatinib (LEN) or Sorafenib (SOR)Arndt Vogel; Shukui Qin; Masatoshi Kudo; Stacie Hudgens; Tatsuya Yamashita; Jung-Hwan Yoon; Laetitia Fartoux; Krzysztof Simon; Carlos L. Lopez; Max Sung; Corina E. Dutcus; Silvija Kraljevic; Toshiyuki Tamai; Nathan Grunow; Genevieve Meier; Valeriy Breder  HEPATOLOGY  66-  734A  -734A  2017/10Treatment of advanced hepatocellular carcinoma: Future perspectiveMasatoshi Kudo  ANNALS OF ONCOLOGY  28-  2017/10Comparison with Child-Pugh, liver damage and newly proposed ALBI-grade for assessment of hepatic function and predicting prognosis of Japanese patients with hepatocellular carcinomaAtsushi Hiraoka; Takashi Kumada; Masatoshi Kudo; Masashi Hirooka; Kazuya Kariyama; Kazuhiro Nouso; Kunihiko Tsuji; Ei Itobayashi; Toru Ishikawa; Hironori Ochi; Toshifumi Tada; Hidenori Toyoda; Kazuto Tajiri; Kouji Joko; Hideki Kawasaki; Yoichi Hiasa; Kojiro Michitaka  HEPATOLOGY  66-  743A  -743A  2017/10Efficacy and Safety of Nivolumab in Asian Patients (Pts) With Advanced Hepatocellular Carcinoma (HCC): Subanalysis of the CheckMate 040 StudyMasatoshi Kudo; Chiun Hsu; Tae-You Kim; Su-Pin Choo; Yoon-Koo Kang; Ming-Mo Hou; Winnie Yeo; Kazushi Numata; Akhil Chopra; Adyb Baakili; Christine dela Cruz; Huanyu Zhao; Thomas Yau  ANNALS OF ONCOLOGY  28-  2017/10【急性胆嚢炎に対する最新のマネージメント】 急性胆嚢炎の発症機序と鑑別診断のコツ竹中 完; 中井 敦史; 大本 俊介; 宮田 剛; 三長 孝輔; 鎌田 研; 山雄 健太郎; 今井 元; 工藤 正俊  胆と膵  38-  (10)  1137  -1145  2017/10【胆膵EUSを極める-私ならこうする(There is always a better way)-】 治療 胆嚢ドレナージ 私はこうする三長 孝輔; 北野 雅之; 竹中 完; 鎌田 研; 中井 敦史; 大本 俊介; 宮田 剛; 山雄 健太郎; 今井 元; 工藤 正俊  胆と膵  38-  (臨増特大)  1071  -1078  2017/10【胆膵EUSを極める-私ならこうする(There is always a better way)-】 治療 胆嚢ドレナージ 私はこうする三長 孝輔; 北野 雅之; 竹中 完; 鎌田 研; 中井 敦史; 大本 俊介; 宮田 剛; 山雄 健太郎; 今井 元; 工藤 正俊  胆と膵  38-  (臨増特大)  1071  -1078  2017/10【急性胆嚢炎に対する最新のマネージメント】 急性胆嚢炎の発症機序と鑑別診断のコツ竹中 完; 中井 敦史; 大本 俊介; 宮田 剛; 三長 孝輔; 鎌田 研; 山雄 健太郎; 今井 元; 工藤 正俊  胆と膵  38-  (10)  1137  -1145  2017/10膵・胆道癌の早期診断を目指せ!実質内発生の小膵癌 IPMNに併存した小膵癌の解析山雄健太郎; 竹中完; 中井敦史; 大本俊介; 鎌田研; 三長孝輔; 宮田剛; 今井元; 松本逸平; 竹山宜典; 筑後孝章; 工藤正俊  肝胆膵  75-  (3)  611‐619  2017/09JET-HCC: A phase 3 randomized, double-blind, placebo-controlled study of tivantinib as a second-line therapy in patients with c-Met high hepatocellular carcinomaS. Kobayashi; K. Ueshima; M. Moriguchi; T. Takayama; N. Izumi; H. Yoshiji; K. Hino; T. Oikawa; T. Chiba; K. Motomura; J. Kato; K. Yasuchika; A. Ido; J. Kinoshita; T. Sato; M. Ikeda; T. Okusaka; M. Kudo; K. Tamura; J. Furuse  ANNALS OF ONCOLOGY  28-  2017/09抗血栓薬服用者に対する胃病変のESD/EMRの安全性評価検討永井 知行; 松井 繁長; 岡本 彩那; 岡元 寿樹; 河野 匡志; 山田 光成; 米田 頼晃; 櫻井 俊治; 渡邉 智裕; 樫田 博史; 工藤 正俊  Gastroenterological Endoscopy  59-  (Suppl.2)  2130  -2130  2017/09抗血栓薬服用者に対する胃病変のESD/EMRの安全性評価検討永井 知行; 松井 繁長; 岡本 彩那; 岡元 寿樹; 河野 匡志; 山田 光成; 米田 頼晃; 櫻井 俊治; 渡邉 智裕; 樫田 博史; 工藤 正俊  Gastroenterological Endoscopy  59-  (Suppl.2)  2130  -2130  2017/09抗血栓薬内服での大腸ESDにおける検討岡元 寿樹; 米田 頼晃; 樫田 博史; 岡本 彩菜; 河野 匡志; 永井 知行; 櫻井 俊治; 松井 繁長; 渡邊 智裕; 工藤 正俊  日本消化器病学会雑誌  114-  (臨増大会)  A818  -A818  2017/09膵・胆道癌に対する内視鏡的診断法の新たな展開 膵癌肝転移診断におけるKupffer imageを用いた造影EUSの有用性竹中 完; 三長 孝輔; 工藤 正俊  日本消化器病学会雑誌  114-  (臨増大会)  A612  -A612  2017/09膵・胆道癌に対する内視鏡的診断法の新たな展開 膵癌肝転移診断におけるKupffer imageを用いた造影EUSの有用性竹中 完; 三長 孝輔; 工藤 正俊  Gastroenterological Endoscopy  59-  (Suppl.2)  2056  -2056  2017/09【膵・胆道癌の早期診断を目指せ!】 実質内発生の小膵癌 IPMNに併存した小膵癌の解析山雄 健太郎; 竹中 完; 中井 敦史; 大本 俊介; 鎌田 研; 三長 孝輔; 宮田 剛; 今井 元; 松本 逸平; 竹山 宜典; 筑後 孝章; 工藤 正俊  肝・胆・膵  75-  (3)  611  -619  2017/09【Interventional EUSの最新情報-適応、手技、デバイス-】 EUS-guided pancreatic ductal drainage(EUS-PD)の適応と手技のコツ竹中 完; 中井 敦史; 大本 俊介; 三長 孝輔; 宮田 剛; 鎌田 研; 山雄 健太郎; 今井 元; 工藤 正俊  消化器・肝臓内科  2-  (3)  253  -260  2017/09巨木型食道静脈瘤に対するmodified EISL松井繁長; 樫田博史; 工藤正俊  日本門脈圧こう進症学会雑誌  23-  (3)  114  2017/08Updated overall survival (OS) analysis from the international, phase 3, randomized, placebo-controlled RESORCE trial of regorafenib for patients with hepatocellular carcinoma (HCC) who progressed on sorafenib treatmentBruix Jordi; Merle Philippe; Granito Alessandro; Huang Yi-Hsiang; Bodoky Gyorgy; Yokosuka Osamu; Rosmorduc Olivier; Breder Valeriy; Gerolami Rene; Masi Gianluca; Paul J. Ross; Qin Shukui; Song Tianqiang; Bronowicki Jean-Pierre; Ollivier-Hourmand Isabelle; Kudo Masatoshi; LeBerre Marie-Aude; Baumhauer Annette; Meinhardt Gerold; Han Guohong  ANNALS OF ONCOLOGY  28-  2017/06Efficacy and safety of nivolumab in patients with advanced hepatocellular carcinoma analyzed by patient age: A sub-analysis of the CheckMate 040 studyMelero Ignacio; El-Khoueiry Anthony; Yau Thomas; Hsu Chiun; Kudo Masatoshi; Crocenzi Todd; Kim Tae-You; Choo Su-Pin; Trojan Joerg; Welling Theodore; Kang Yoon-Koo; Yeo Winnie; Chopra Akhil; Baakili Adyb; dela Cruz Christine; Zhao Huanyu; Sangro Bruno; Meyer Tim  ANNALS OF ONCOLOGY  28-  2017/06Nivolumab (nivo) in sorafenib (sor)-naive and -experienced pts with advanced hepatocellular carcinoma (HCC): CheckMate 040 study.Todd S. Crocenzi; Anthony B. El-Khoueiry; Thomas Cheung Yau; Ignacio Melero; Bruno Sangro; Masatoshi Kudo; Chiun Hsu; Jorg Trojan; Tae -You Kim; Su -Pin Choo; Tim Meyer; Yoon-Koo Kang; Winnie Yeo; Akhil Chopra; Adyb Baakili; Christine Marie Dela Cruz; Lixin Lang; Jaclyn Neely; Theodore Welling  JOURNAL OF CLINICAL ONCOLOGY  35-  2017/05Phase 3, randomized study of pembrolizumab (pembro) vs best supportive care (BSC) for second-line advanced hepatocellular carcinoma (HCC): KEYNOTE-240.Richard S. Finn; Stephen L. Chan; Andrew X. Zhu; Jennifer J. Knox; Ann-Lii Cheng; Abby B. Siegel; Oliver Bautista; Masatoshi Kudo  JOURNAL OF CLINICAL ONCOLOGY  35-  2017/05Phase III trial of lenvatinib (LEN) vs sorafenib (SOR) in first-line treatment of patients (pts) with unresectable hepatocellular carcinoma (uHCC).Ann-Lii Cheng; Richard S. Finn; Shukui Qin; Kwang-Hyub Han; Kenji Ikeda; Fabio Piscaglia; Ari David Baron; Joong-Won Park; Guohong Han; Jacek Jassem; Jean -Frederic Blanc; Arndt Vogel; Dmitry Komov; T. R. Jeffry Evans; Carlos Lopez -Lopez; Corina E. Dutcus; Min Ren; Silvija Kraljevic; Toshiyuki Tamai; Masatoshi Kudo  JOURNAL OF CLINICAL ONCOLOGY  35-  2017/05慢性膵炎の進展予防を目的とした治療 その適応と限界 早期慢性膵炎のEUS所見の妥当性、早期治療介入の意義について竹中 完; 大本 俊介; 三長 孝輔; 宮田 剛; 鎌田 研; 山雄 健太郎; 今井 元; 工藤 正俊  膵臓  32-  (3)  360  -360  2017/05急性膵炎の後期合併症に対する手術・インターベンション治療の現状と課題 当院におけるWONに対するstep-up approachの検討竹中 完; 大本 俊介; 三長 孝輔; 宮田 剛; 鎌田 研; 山雄 健太郎; 今井 元; 工藤 正俊  膵臓  32-  (3)  377  -377  2017/05膵疾患診療におけるERCPの役割を見直す 慢性膵炎に対する経乳頭的金属ステント留置、短期間抜去の有用性竹中 完; 大本 俊介; 三長 孝輔; 宮田 剛; 鎌田 研; 山雄 健太郎; 今井 元; 工藤 正俊  膵臓  32-  (3)  422  -422  2017/05ソナゾイド造影EUSを用いた膵癌肝転移検出に関する検討三長 孝輔; 竹中 完; 北野 雅之; 中井 敦史; 大本 俊介; 宮田 剛; 鎌田 研; 山雄 健太郎; 今井 元; 渡邉 智裕; 工藤 正俊  膵臓  32-  (3)  552  -552  2017/05悪性黒色腫に対しニボルマブ投与中に潰瘍性大腸炎類似の大腸炎を認めた1例高山 政樹; 大原 裕士郎; 秦 康倫; 木下 大輔; 奥田 英之; 川崎 俊彦; 水野 成人; 若狭 朋子; 太田 善夫; 工藤 正俊  Gastroenterological Endoscopy  59-  (4)  450  -455  2017/04決定版!これが今の食道胃静脈瘤治療だ! 噴門部静脈瘤合併巨木型食道静脈瘤にはEISL松井 繁長; 樫田 博史; 工藤 正俊  Gastroenterological Endoscopy  59-  (Suppl.1)  761  -761  2017/04EUS下胆道ドレナージ(戦略と安全な手技) 経乳頭的re-intervention困難例の悪性肝門部胆道閉塞に対するEUS下胆道ドレナージの有用性三長 孝輔; 竹中 完; 工藤 正俊  Gastroenterological Endoscopy  59-  (Suppl.1)  817  -817  2017/04硬化性胆管炎と診断された膵癌、閉塞性黄疸の1例中井 敦史; 山雄 健太郎; 大本 俊介; 鎌田 研; 三長 孝輔; 宮田 剛; 今井 元; 竹中 完; 松本 逸平; 竹山 宜典; 筑後 孝章; 工藤 正俊  Gastroenterological Endoscopy  59-  (Suppl.1)  1061  -1061  2017/04慢性膵炎診断における超音波の役割 早期慢性膵炎EUS所見の臨床的意義について竹中 完; 大本 俊介; 三長 孝輔; 宮田 剛; 鎌田 研; 山雄 健太郎; 今井 元; 樫田 博史; 工藤 正俊  超音波医学  44-  (Suppl.)  S242  -S242  2017/04造影ハーモニックEUSによる上部消化管粘膜下腫瘍の鑑別診断 EUS-FNA診断との併用鎌田 研; 竹中 完; 大本 俊介; 宮田 剛; 三長 孝輔; 山雄 健太郎; 今井 元; 筑後 孝章; 安田 卓司; 工藤 正俊  超音波医学  44-  (Suppl.)  S438  -S438  2017/04DAA投与におけるSVR後のAFP及びALT異常値と関連する臨床背景の検討河野 匡志; 西田 直生志; 南 知宏; 千品 寛和; 有住 忠晃; 田北 雅弘; 依田 広; 矢田 典久; 南 康範; 萩原 智; 上嶋 一臣; 工藤 正俊  肝臓  58-  (Suppl.1)  A314  -A314  2017/04US-US overlay image fusionを用いたラジオ波焼灼術の有用性 従来法との比較南 康範; 西田 直生志; 工藤 正俊  肝臓  58-  (Suppl.1)  A348  -A348  2017/04Up-to-date chemotherapy for hepatocellular carcinoma上嶋 一臣; 工藤 正俊  腫瘍内科 = Clinical oncology  19-  (3)  246  -251  2017/03肝発癌メカニズムのパラダイムシフトとこれからの展望 PD-L1陽性肝癌の臨床病理学的特徴と遺伝子変異プロファイル西田 直生志; 工藤 正俊  日本消化器病学会雑誌  114-  (臨増総会)  A64  -A64  2017/03肝画像診断の進歩 US-US image fusionを用いた肝細胞癌へのラジオ波焼灼術の有用性南 康範; 西田 直生志; 工藤 正俊  日本消化器病学会雑誌  114-  (臨増総会)  A202  -A202  2017/03【胆管結石・胆管炎をめぐる諸問題】 胆石膵炎竹中 完; 大本 俊介; 三長 孝輔; 宮田 剛; 鎌田 研; 山雄 健太郎; 今井 元; 工藤 正俊  消化器・肝臓内科  1-  (3)  247  -256  2017/03肝癌関連ガイドラインの穿刺局所療法,肝動脈化学塞栓療法 (特集 消化器腫瘍性疾患治療ガイドラインのポイント) -- (肝癌)南 康範; 工藤 正俊  成人病と生活習慣病 : 日本成人病(生活習慣病)学会準機関誌  47-  (2)  217  -223  2017/02消化器内視鏡-私の流儀 EUS スコープのたわみを意識したセッティングを-使えるものはティッシュ箱でも使え!竹中完; 北野雅之; 工藤正俊  消化器内視鏡  29-  (6)  2017早期慢性膵炎のEUS像竹中完; 北野雅之; 工藤正俊  Gastroenterological Endoscopy (Web)  59-  (3)  2017術前に肝原発嚢胞性病変が疑われた腸間膜由来神経鞘腫の1例竹中完; 山雄健太郎; 鎌田研; 三長孝輔; 宮田剛; 今井元; 松本逸平; 竹山宜典; 前西修; 工藤正俊  日本消化器画像診断研究会プログラム・抄録集  67th-  2017造影ハーモニックEUSによる胆嚢病変の良悪性鑑別~Vessel imageとPerfusion imageの比較~鎌田研; 竹中完; 工藤正俊  胆道  31-  (3)  2017膵頭部嚢胞による閉塞性黄疸症例大本俊介; 竹中完; 山雄健太郎; 半田康平; 筑後孝章; 松本逸平; 竹山宜典; 工藤正俊  日本消化器病学会雑誌  114-  (10)  2017当院におけるERCP教育の工夫(drawing pictures method/CD method)竹中完; 東健; 工藤正俊  Gastroenterological Endoscopy (Web)  59-  (Supplement1)  2017胃粘膜下腫瘍における造影ハーモニックEUSによる悪性抽出能の検討鎌田研; 竹中完; 工藤正俊  Gastroenterological Endoscopy (Web)  59-  (Supplement1)  2017経乳頭処置困難総胆管結石症例に対するEUSガイド下治療の意義宮田剛; 竹中完; 工藤正俊  Gastroenterological Endoscopy (Web)  59-  (Supplement1)  2017硬化性胆管炎と診断された膵癌,閉塞性黄疸の1例中井敦史; 山雄健太郎; 大本俊介; 鎌田研; 三長孝輔; 宮田剛; 今井元; 竹中完; 松本逸平; 竹山宜典; 筑後孝章; 工藤正俊  Gastroenterological Endoscopy (Web)  59-  (Supplement1)  2017胆膵EUSの進歩 4 EUS-FNAによる治療(6)腹腔神経叢/神経節ブロック三長孝輔; 北野雅之; 宮田剛; 今井元; 竹中完; 工藤正俊  臨床消化器内科  32-  (8)  2017経乳頭処置困難総胆管結石症例に対するEUS下rendezvous techniqueの有用性竹中完; 山雄健太郎; 工藤正俊  胆道  31-  (3)  2017膵癌治療の最前線-諸問題の解決にむけた取り組み-膵癌の癌性疼痛に対するEUSガイド下神経叢ブロック(融解)術の有用性宮田剛; 竹中完; 工藤正俊  胆と膵  38-  (8)  2017経乳頭的re-intervention困難例の悪性肝門部胆道閉塞に対するEUS下胆道ドレナージの有用性三長孝輔; 竹中完; 工藤正俊  Gastroenterological Endoscopy (Web)  59-  (Supplement1)  2017切除不能悪性胃十二指腸狭窄症例に対する胃十二指腸ステント留置の予後予測因子の検討山雄健太郎; 竹中完; 工藤正俊  Gastroenterological Endoscopy (Web)  59-  (Supplement1)  2017早期慢性膵炎EUS所見の臨床的意義について竹中完; 山雄健太郎; 工藤正俊  日本消化器病学会雑誌  114-  2017EUSによるIPMN併存膵癌の早期発見と問題点鎌田研; 竹中完; 工藤正俊  日本消化器病学会雑誌  114-  2017Real-Life Clinical Practice with Sorafenib in Advanced Hepatocelluar Carcinoma: A Single-Center Experience Second Analysis (vol 33, pg 728, 2015)T. Arizumi; K. Ueshima; M. Iwanishi; H. Chishina; M. Kono; M. Takita; S. Kitai; T. Inoue; N. Yada; S. Hagiwara; H. Ida; Y. Minami; T. Sakurai; N. Nishida; M. Kitano; M. Kudo  DIGESTIVE DISEASES  35-  (6)  625  -626  2017Treatment-stage migration maximizes survival outcomes in patients with hepatocellular carcinoma treated with sorafenib: an observational studyC. Yen; R. Sharma; L. Rimassa; T. Arizumi; D. Bettinger; J. Evans; T. Pressiani; M. E. Burlone; M. Pirisi; L. Giordano; J. Howell; M. Kudo; R. Thimme; J. -W. Park; D. J. Pinato  JOURNAL OF HEPATOLOGY  66-  (1)  S223  -S224  2017Relationship between overall survival and time to progression after transarterial chemoembolization therapy in patients with hepatocellular carcinomaT. Arizumi; K. Ueshima; M. Kudo  JOURNAL OF HEPATOLOGY  66-  (1)  S620  -S620  2017早期直腸がんに対する治療戦略(肛門温存) 早期直腸癌に対する内視鏡治療について米田 頼晃; 樫田 博史; 工藤 正俊  日本大腸肛門病学会雑誌 (0047-1801)70巻抄録号 Page A43(2017.09)  2017大腸拡大JNET分類の有用性と今後の課題 The Japan NBI Expert Team(JNET)分類Type2B病変の取り扱い米田 頼晃; 樫田 博史; 工藤 正俊  Gastroenterological Endoscopy (0387-1207)59巻  2017大腸腫瘍内視鏡治療後の局所再発に対するサーベイランスについて米田頼晃; 樫田博史; 橋本有人; 岡元寿樹; 河野匡志; 山田光成; 足立哲平; 峯宏昌; 永井知行; 朝隈豊; 櫻井俊治; 松井繁長; 渡邉智裕; 工藤正俊  日本消化管学会総会学術集会プログラム・抄録集  13th-  178  2017Nivolumab (Nivo) in Patients (Pts) With Advanced Hepatocellular Carcinoma (HCC): the CheckMate 040 StudyIgnacio Melero; Bruno Sangro; Thomas Yau; Chiun Hsu; Masatoshi Kudo; Todd S. Crocenzi; Tae-You Kim; Su-pin Choo; Jorg Trojan; Timothy Meyer; Theodore Welling; Winnie Yeo; Akhil Chopra; Jeffrey Anderson; Christine Delacruz; Lixin Lang; Jaclyn Neely; Hao Tang; Anthony B. El-Khoueiry  HEPATOLOGY  64-  (6)  1124A  -1124A  2016/12座談会 肝癌に対する肝動注化学療法のエビデンスと今後工藤 正俊; 山下 竜也; 池田 公史; 上嶋 一臣  The liver cancer journal = ザリバーキャンサージャーナル : 季刊学術雑誌  8-  (2)  77  -83  2016/12【肝硬変を理解する-分子機構から実臨床に至るまで-】 疫学 肝細胞癌における成因の経年的変化 世界の状勢と本邦の動向西田 直生志; 工藤 正俊  肝・胆・膵  73-  (6)  865  -872  2016/12Single balloon enteroscopy in the elderlyMitsunari Yamada; Hiroshi Kashida; Yoriaki Komeda; Hiromasa Mine; Tomoyuki Nagai; Yutaka Asakuma; Toshiharu Sakurai; Shigenaga Matui; Tomohiro Watanabe; Masatoshi Kudo  JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY  31-  132  -132  2016/11Endoscopic ultrasound-guided gallbladder drainage for acute cholecystitis: Long-term outcomes after removal of a self-expandable metal stentKen Kamata; Mamoru Takenaka; Masayuki Kitano; Shunsuke Omoto; Kosuke Minaga; Takeshi Miyata; Kentaro Yamao; Hajime Imai; Masatoshi Kudo  JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY  31-  341  -341  2016/11Clinical impact of endoscopic ultrasonography imaging of chronic pancreatitis in the pancreatic parenchyma in patients with intraductal papillary mucinous neoplasmsMamoru Takenaka; Atsuhiro Masuda; Masayuki Kitano; Yoh Zen; Kentarou Yamao; Hideyuki Shiomi; Yonson Ku; Takeshi Azuma; Masatoshi Kudo  JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY  31-  240  -241  2016/11EUS-guided choledochoduodenostomy using a newly designed laser-cut metal stent: Feasibility study in a porcine modelKosuke Minaga; Mamoru Takenaka; Masayuki Kitano; Hajime Imai; Kentaro Yamao; Ken Kamata; Takeshi Miyata; Shunsuke Omoto; Masatoshi Kudo  JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY  31-  222  -222  2016/11【IPMNの診断と治療はどう変わったか?】 診断 IPMN診療におけるEUSの位置付け 有用性とこれからの課題竹中 完; 鎌田 研; 北野 雅之; Napoleon Bertrand; 工藤 正俊  胆と膵  37-  (11)  1475  -1480  2016/11Integration of the cancer-related pro-inflammatory response as a stratifying biomarker of survival benefit with sorafenib in hepatocellular carcinomaJ. Howell; D. Pinato; R. Ramaswami; T. Arizumi; C. Ferrari; A. Gibbin; M. Burlone; G. Guaschino; J. Black; L. Sellers; M. Kudo; M. Pirisi; R. Sharma  JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY  31-  104  -104  2016/10大腸の小ポリープ内視鏡切除 cold snare polypectomy(CSP)とhot forceps biopsy(HFB)の前向きランダム化比較試験米田 頼晃; 樫田 博史; 櫻井 俊治; 橋本 有人; 岡本 寿樹; 河野 匡志; 田中 梨絵; 山田 行成; 足立 哲平; 峯 宏昌; 永井 知行; 岡崎 能久; 朝隈 豊; 松井 繁長; 工藤 正俊  Gastroenterological Endoscopy  58-  (Suppl.2)  1950  -1950  2016/10癌遺伝子ガンキリンは炎症をコントロールすることで大腸癌発生を促進する櫻井 俊治; 永井 知行; 樫田 博史; 工藤 正俊  日本癌学会総会記事  75回-  E  -1071  2016/10IPMN切除例からみた国際診療ガイドラインの妥当性およびEUS実施の意義の検証松田 友彦; 北野 雅之; 大本 俊介; 鎌田 研; 三長 孝輔; 宮田 剛; 山雄 健太郎; 工藤 正俊  Gastroenterological Endoscopy  58-  (Suppl.2)  1976  -1976  2016/10B型肝炎治療のアップデート エンテカビルとPEG-IFNα2a/2b 48週併用療法の効果および治療効果予測因子の検討萩原 智; 西田 直生志; 工藤 正俊  肝臓  57-  (Suppl.2)  A509  -A509  2016/09ReplySatoru Hagiwara; Naoshi Nishida; Masatoshi Kudo  Hepatology  64-  (1)  306  2016/07Global GIDEON data: Subgroup analysis of sorafenib dosing pattern in patients with unresectable hepatocellular carcinomaMasatoshi Kudo; Sheng-Long Ye; Keiko Nakajima; Riccardo Lencioni  ANNALS OF ONCOLOGY  27-  2016/07A randomized, double-blind, placebo-controlled Phase III study of ramucirumab versus placebo as second-line treatment in patients with hepatocellular carcinoma and elevated baseline alpha-fetoprotein following first-line sorafenib (REACH-2)Zhu Andrew; Galle Peter; Kudo Masatoshi; Finn Richard; Yang Ling; Abada Paolo; Llovet Josep  ANNALS OF ONCOLOGY  27-  83  -83  2016/06ReplySatoru Hagiwara; Naoshi Nishida; Masatoshi Kudo  Hepatology  63-  (5)  1744  -1745  2016/05Safety and antitumor activity of nivolumab (nivo) in patients (pts) with advanced hepatocellular carcinoma (HCC): Interim analysis of dose-expansion cohorts from the phase 1/2 CheckMate-040 studyBruno Sangro; Ignacio Melero; Thomas Cheung Yau; Chiun Hsu; Masatoshi Kudo; Todd S. Crocenzi; Tae-You Kim; Supin Choo; Jorg Trojan; Tim Meyer; Yoon-Koo Kang; Jeffrey Anderson; Christine Marie Dela Cruz; Lixin Lang; Jaclyn Neely; Anthony B. El-Khoueiry  JOURNAL OF CLINICAL ONCOLOGY  34-  (15)  2016/05Phase 1/2 study of durvalumab and tremelimumab as monotherapy and in combination in patients with unresectable hepatocellular carcinoma (HCC)Ghassan K. Abou-Alfa; Bruno Sangro; Michael Morse; Andrew X. Zhu; Richard D. Kim; Ann-Lii Cheng; Masatoshi Kudo; Yoon-Koo Kang; Stephen L. Chan; Joyce Antal; Jillian Boice; Feng Xiao; Shannon R. Morris; Johanna Bendell  JOURNAL OF CLINICAL ONCOLOGY  34-  (15)  2016/05Survival benefit of liver resection for hepatocellular carcinoma associated with portal vein invasion: A Japanese nationwide surveyTakashi Kokudo; Kiyoshi Hasegawa; Yutaka Matsuyama; Tadatoshi Takayama; Namiki Izumi; Masumi Kadoya; Masatoshi Kudo; Yonson Ku; Michiie Sakamoto; Osamu Nakashima; Shuichi Kaneko; Norihiro Kokudo  JOURNAL OF CLINICAL ONCOLOGY  34-  (15)  2016/05Impact of vitamin K dosing during sorafenib treatment for hepatocellular carcinoma: Effect on ischemic tumor cell damage caused by sorafenib.Yoshimichi Haruna; Noriko Hasegawa; Kazuho Imanaka; Atsuo Inoue; Masatoshi Kudo  JOURNAL OF CLINICAL ONCOLOGY  34-  (15)  2016/05A randomized, double-blind, placebo-controlled phase III study of ramucirumab versus placebo as second-line treatment in patients with hepatocellular carcinoma and elevated baseline alpha-fetoprotein following first-line sorafenib (REACH-2)Andrew X. Zhu; Peter R. Galle; Masatoshi Kudo; Richard S. Finn; Ling Yang; Paolo Abada; Josep M. Llovet  JOURNAL OF CLINICAL ONCOLOGY  34-  (15)  2016/05大腸LSTに対するアプローチ 内視鏡的治療困難例を含めて米田 頼晃; 樫田 博史; 櫻井 俊治; 朝隈 豊; 岡崎 能久; 永井 知行; 峯 宏昌; 足立 哲平; 山田 光成; 田中 梨絵; 河野 匡志; 岡元 寿樹; 松井 繁長; 工藤 正俊  Gastroenterological Endoscopy  58-  (Suppl.1)  635  -635  2016/04大腸内視鏡挿入におけるスコープ選択と体位変換・圧排のコツ山田 光成; 樫田 博史; 岡元 寿樹; 河野 匡志; 田中 梨絵; 足立 哲平; 峯 宏昌; 永井 知行; 岡崎 能久; 米田 頼晃; 朝隈 豊; 櫻井 俊治; 松井 繁長; 工藤 正俊  Gastroenterological Endoscopy  58-  (Suppl.1)  749  -749  2016/04大腸T1癌の内視鏡治療後経過永井 知行; 樫田 博史; 工藤 正俊; 岡元 寿樹; 河野 匡志; 山田 光成; 田中 梨絵; 足立 哲平; 峯 宏昌; 岡崎 能久; 米田 頼晃; 朝隈 豊; 櫻井 俊治; 松井 繁長  Gastroenterological Endoscopy  58-  (Suppl.1)  780  -780  2016/04NASH関連肝発癌における線維化進展と遺伝子変化萩原 智; 西田 直生志; 工藤 正俊  肝臓  57-  (Suppl.1)  A309  -A309  2016/04HCCに対するDEB-TACE時に発生したVascular lakeの検討沼本 勲男; 鶴崎 正勝; 渡口 真史; 日高 正二朗; 山川 美帆; 任 誠雲; 柳生 行伸; 村上 卓道; 田北 雅弘; 萩原 智; 南 康範; 上嶋 一臣; 西田 直生志; 工藤 正俊; 朝戸 信行  IVR: Interventional Radiology  31-  (Suppl.)  156  -156  2016/04EMR手技のスキルアップを目指して 大腸LSTに対するEMRの工夫米田 頼晃; 樫田 博史; 岡元 寿樹; 河野 匡志; 山田 光成; 田中 梨絵; 足立 哲平; 峯 宏昌; 高山 政樹; 永井 知行; 川崎 正憲; 岡崎 能久; 朝隈 豊; 櫻井 俊治; 松井 繁長; 工藤 正俊  日本大腸検査学会雑誌  32-  (2)  126  -126  2016/03術後胃に発生した胃石症の特徴と治療岡元 寿樹; 松井 繁長; 田中 梨絵; 山田 光成; 足立 哲平; 高山 政樹; 峯 宏昌; 永井 知行; 岡崎 能久; 米田 頼晃; 朝隈 豊; 櫻井 俊治; 樫田 博史; 工藤 正俊  日本消化器病学会雑誌  113-  (臨増総会)  A330  -A330  2016/03A randomized, double-blind, placebo-controlled phase III study of ramucirumab versus placebo as second-line treatment in patients with hepatocellular carcinoma and elevated baseline alpha-fetoprotein following first-line sorafenib (REACH-2).Andrew X. Zhu; Peter R. Galle; Masatoshi Kudo; Richard S. Finn; Ling Yang; Paolo Abada; Shao-Chun Chang; Josep M. Llovet  JOURNAL OF CLINICAL ONCOLOGY  34-  (4)  2016/02Identification of a high-response patient population to S-1 via predictive enrichment strategy analysis of the S-CUBE phase III trial.Masatoshi Kudo; Takuji Okusaka; Shuichi Kaneko; Junji Furuse; Madoka Takeuchi; Xuemin Fang; Yoshito Date; Masahiro Takeuchi  JOURNAL OF CLINICAL ONCOLOGY  34-  (4)  2016/02Regional differences in efficacy/safety/biomarkers in a randomised study of axitinib in 2nd line patients (pts) with advanced hepatocellular carcinoma (HCC).Masatoshi Kudo; Joong-Won Park; Shuntaro Obi; Shukui Qin; Eric Assenat; Yoshiko Umeyama; Debasis Chakrabarti; Olga Valota; Yosuke Fujii; Jean-Francois Martini; James Andrew Williams; Yoon-Koo Kang  JOURNAL OF CLINICAL ONCOLOGY  34-  (4)  2016/02早期慢性膵炎をめぐって 早期慢性膵炎の診断基準と臨床的意義竹中完; 北野雅之; 門阪薫平; 工藤正俊  胆と膵  37-  (4)  2016不定愁訴症候群とどう向き合うか 早期慢性膵炎竹中完; 北野雅之; 工藤正俊  成人病と生活習慣病  46-  (10)  2016膵炎を繰り返すSCNとして切除を行った多房性膵嚢胞性病変の1例山雄健太郎; 竹中完; 大本俊介; 松田友彦; 宮田剛; 北野雅之; 工藤正俊; 松本逸平; 竹山宜典; 榎木英介; 筑後孝章  日本消化器画像診断研究会プログラム・抄録集  65th-  2016慢性膵炎合併良性胆道狭窄に対するfully covered metallic stentの有用性竹中完; 北野雅之; 工藤正俊  胆道  30-  (3)  2016経乳頭的,経皮的治療抵抗性の切除不能肝門部悪性胆道狭窄に対するEUS-guided biliary drainage(EUS-BD)の有用性竹中完; 北野雅之; 工藤正俊  胆道  30-  (3)  2016肝癌合併は肝硬変患者の予後を規定する (肝不全 : その常識は正しいか?) -- (慢性肝不全 : その常識は正しいか?)上嶋 一臣; 工藤 正俊  救急・集中治療  28-  (5)  431  -435  2016AN OBJECTIVE MODEL TO OPTIMIZE TREATMENT DECISIONS IN ADVANCED HEPATOCELLULAR CARCINOMA AFTER SORAFENIB FAILURE: THE SORFA SCORED. J. Pinato; C. Yen; T. Arizumi; P. Giarda; J. Howell; P. Toniutto; R. Ramaswami; M. E. Burlone; M. Kudo; M. Pirisi; R. Sharma  JOURNAL OF HEPATOLOGY  64-  S690  -S690  2016THE ALBI GRADE PROVIDES OBJECTIVE HEPATIC RESERVE PHENOTYPING ACROSS EACH BCLC STAGE OF HEPATOCELLULAR CARCINOMAD. J. Pinato; R. Sharma; C. Yen; T. Arizumi; D. Bettinger; J. W. Jang; C. Smirne; Y. W. Kim; M. Kudo; J. Howell; R. Ramaswami; M. E. Burlone; V. Guerra; R. Thimme; M. Ishizuka; M. Pirisi; J. Stebbing; K. Kubota; B. I. Carr  JOURNAL OF HEPATOLOGY  64-  S196  -S196  2016INTEGRATION OF THE CANCER-RELATED PRO-INFLAMMATORY RESPONSE AS A STRATIFYING BIOMARKER OF SURVIVAL BENEFIT WITH SORAFENIB IN HEPATOCELLULAR CARCINOMAJ. Howell; D. Pinato; R. Ramaswami; T. Arizumi; C. Ferrari; A. Gibbin; M. Burlone; G. Guaschino; J. Black; L. Sellers; M. Kudo; M. Pirisi; R. Sharma  JOURNAL OF HEPATOLOGY  64-  S195  -S195  2016PROSPECTIVE RANDOMIZED CONTROLLED PHASE III TRIAL COMPARING THE EFFICACY OF SORAFENIB VERSUS SORAFENIB IN COMBINATION WITH LOW-DOSE CISPLATIN/FLUOROURACIL HEPATIC ARTERIAL INFUSION CHEMOTHERAPY IN PATIENTS WITH ADVANCED HEPATOCELLULAR CARCINOMAM. Kudo; K. Ueshima; O. Yokosuka; S. Obi; N. Izumi; H. Aikata; H. Nagano; E. Hatano; Y. Sasaki; K. Hino; T. Kumada; K. Yamamoto; Y. Imai; S. Iwadou; C. Ogawa; T. Okusaka; Y. Arai; F. Kanai; K. Akazawa  JOURNAL OF HEPATOLOGY  64-  S209  -S210  2016大腸腫瘍の治療法選択としての画像強調観察の意義 大腸腫瘍診断・治療におけるJNET分類の試用結果米田 頼晃; 樫田 博史; 工藤 正俊  日本消化器病学会雑誌 (0446-6586)113巻臨増総会  2016当院における大腸ステント留置術の検討山田光成; 樫田博史; 岡元寿樹; 河野匡志; 田中梨絵; 足立哲平; 峯宏昌; 永井知行; 岡崎能久; 米田頼晃; 朝隈豊; 櫻井俊治; 松井繁長; 工藤正俊  日本消化管学会総会学術集会プログラム・抄録集  12th-  209  2016直腸NETsに対する内視鏡的治療:EMR‐C(EMR using a cap),EMR‐L(EMR with a ligation device),or conventional EMR(EMR)の比較検討山田光成; 樫田博史; 米田頼晃; 岡元寿樹; 河野匡志; 田中梨絵; 足立哲平; 峯宏昌; 永井知行; 岡崎能久; 朝隈豊; 櫻井俊治; 松井繁長; 工藤正俊  日本消化管学会総会学術集会プログラム・抄録集  12th-  260  2016The analysis of three cases that gastrointestinal bezoars have history of gastrointestinal surgeryKazuki Okamoto; Shigenaga Matsui; Rie Tanaka; Mitsunari Yamada; Teppei Adachi; Masaki Takayama; Hiroaki Mine; Tomoyuki Nagai; Norihisa Okazaki; Yoriaki Komeda; Yutaka Asakuma; Toshiharu Sakurai; Hiroshi Kashida; Masatoshi Kudo  JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY  30-  303  -303  2015/12Predictors of pain response in EUS-guided neurolysis for abdominal pain caused by pancreatic cancerK. Minaga; M. Kitano; H. Sakamoto; H. Imai; K. Yamao; K. Kamata; T. Miyata; S. Omoto; K. Kadosaka; M. Kudo  JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY  30-  246  -247  2015/12Ramucirumab (RAM) as second-line treatment in patients (pts) with advanced hepatocellular carcinoma (HCC): Japanese subgroup analysis of the phase III REACH trialShinichi Ohkawa; Takuji Okusaka; Masatoshi Kudo; Etsuro Hatano; Hirofumi Fujii; Akihide Masumoto; Junji Furuse; Yoshiyuki Wada; Hiroshi Ishii; Shuntaro Obi; Kuniaki Arai; Seiji Kawazoe; Osamu Yokosuka; Masafumi Ikeda; Katsuaki Ukai; Sojiro Morita; Hiroya Asou; Paolo B. Abada; Ling Yang; Andrew X. Zhu  ANNALS OF ONCOLOGY  26-  94  -94  2015/11ダクラタスビル/アスナプレビル併用療法の治療効果と安全性萩原 智; 西田 直生志; 工藤 正俊  肝臓  56-  (Suppl.3)  A935  -A935  2015/11PALBI-An Objective Score Based on Platelets, Albumin & Bilirubin Stratifies HCC Patients Undergoing Resection & Ablation Better than Child's ClassificationSasan Roayaie; Ghalib Jibara; Sarah Berhane; Parissa Tabrizian; Joong-Won Park; Jijin Yang; Lunan Yan; Guohong Han; Francesco Izzo; Minshan Chen; Jean-Frederic Blanc; Masatoshi Kudo; Lewis R. Roberts; Morris Sherman; Phillip Johnson  HEPATOLOGY  62-  631A  -632A  2015/10食道癌深達度診断における食道学会分類の検証朝隈豊; 松井繁長; 工藤正俊  Gastroenterol Endosc  57-  (Supplement 2)  2040  2015/09肝臓 進行肝細胞がんの集学的治療 進行肝細胞癌に対するソラフェニブとシスプラチン肝動注療法のランダム化第II相試験小島 康志; 池田 公史; 清水 怜; 佐藤 俊哉; 森本 学; 稲葉 吉隆; 萩原 淳司; 工藤 正俊; 中森 正二; 金子 周一; 杉本 理恵; 佐藤 恵子; 石井 浩; 古瀬 純司; 奥坂 拓志  日本癌治療学会誌  50-  (3)  169  -169  2015/09目で見る肝癌 S-1+peg-interferon併用療法が奏効した巨大な肝細胞癌の1例南 知宏; 南 康範; 工藤 正俊  The liver cancer journal : 季刊学術雑誌  7-  (3)  163  -168  2015/09Ramucirumab (RAM) as a second-line treatment in patients with advanced hepatocellular carcinoma (HCC) following first-line therapy with sorafenib in the randomized phase III REACH study: Analysis of alpha-fetoprotein (AFP) kinetics during treatmentI. Chau; J. O. Park; B. Y. Ryoo; C. J. Yen; R. Poon; D. Pastorelli; J. F. Blanc; M. Kudo; T. F. Pfiffer; E. Hatano; H. C. Chung; K. Kubackova; J. M. Phelip; G. Brandi; S. Ohkawa; C. P. Li; T. Okusaka; L. Yang; P. Abada; A. Zhu  EUROPEAN JOURNAL OF CANCER  51-  S446  -S446  2015/09肝細胞癌に対してUS-US fusionを用いたラジオ波焼灼術南 知宏; 南 康範; 千品 寛和; 有住 忠晃; 田北 雅弘; 北井 聡; 矢田 典久; 萩原 智; 上嶋 一臣; 西田 直生志; 工藤 正俊  肝臓  56-  (Suppl.2)  A739  -A739  2015/09転移性肝癌に対してUS-US fusionを用いたラジオ波焼灼術南 知宏; 南 康範; 千品 寛和; 有住 忠晃; 田北 雅弘; 北井 聡; 矢田 典久; 萩原 智; 上嶋 一臣; 西田 直生志; 工藤 正俊  日本消化器病学会雑誌  112-  (臨増大会)  A871  -A871  2015/09Molecular targeted therapy for hepatocellular carcinoma : hope and future perspective上嶋 一臣; 工藤 正俊  細胞  47-  (9)  438  -441  2015/08Axitinib safety and pharmacokinetics in Child-Pugh A and Child-Pugh B patients with advanced hepatocellular cancerYoon-Koo Kang; Tara E. Seery; Mina Kato; Debasis Chakrabarti; Olga Valota; Ying Chen; Jie Tang; Yazdi K. Pithavala; Masatoshi Kudo  CANCER RESEARCH  75-  2015/08Activin signal promotes cancer progression and is involved in cachexia in a subset of pancreatic cancerYosuke Togashi; Akihiro Kogita; Hiroki Sakamoto; Hidetoshi Hayashi; Masato Terashima; Marco A. de Velasco; Kazuko Sakai; Yoshihiko Fujita; Shuta Tomida; Masayuki Kitano; Masatoshi Kudo; Kazuto Nishio  CANCER RESEARCH  75-  2015/08乳頭括約筋切開術を行わないTrans-catheter biliopancreatic endoscopyの有用性河野 匡志; 北野 雅之; 工藤 正俊  胆道  29-  (3)  550  -550  2015/08【内科疾患の診断基準・病型分類・重症度】(第2章)消化器 食道・胃静脈瘤松井 繁長; 樫田 博史; 工藤 正俊  内科  115-  (6)  939  -943  2015/06Ramucirumab (RAM) as second-line treatment in patients (pts) with advanced hepatocellular carcinoma (HCC): Analysis of REACH pts by Child-Pugh (CP) scoreAndrew X. Zhu; Ari David Baron; Peter Malfertheiner; Masatoshi Kudo; Seiji Kawazoe; Denis Pezet; Florian Weissinger; Giovanni Brandi; Carlo Barone; Takuji Okusaka; Yoshiyuki Wada; Joon Oh Park; Baek-Yeol Ryoo; Jae Yong Cho; Hyun Cheol Chung; Chung-Pin Li; Chia-Jui Yen; Kuan-Der Lee; Ling Yang; Ian Chau  JOURNAL OF CLINICAL ONCOLOGY  33-  (15)  2015/05Proposal of a new staging system for intrahepatic cholangiocarcinoma: Analysis of surgical patients from a nationwide survey of Liver Cancer Study Group of Japan.Yoshihiro Sakamoto; Norihiro Kokudo; Yutaka Matsuyama; Michiie Sakamoto; Masumi Kadoya; Shuichi Kaneko; Yonson Ku; Masatoshi Kudo; Tadatoshi Takayama; Osamu Nakashima  JOURNAL OF CLINICAL ONCOLOGY  33-  (15)  2015/05Quantitative Perfusion Analysis With Contrast-Enhanced Harmonic EUS in Pancreatic TumorsShunsuke Omoto; Masayuki Kitano; Masatoshi Kudo  GASTROINTESTINAL ENDOSCOPY  81-  (5)  AB550  -AB550  2015/05Prognostic subclassification of Intermediate Hepatocellular Carcinoma (I-HCC): a multicentre cohort study with propensity score analysisRamya Ramaswami; David James Pinato; Keiichi Kubota; Mitsuru Ishizuka; Tadaaki Arizumi; Masatoshi Kudo; Jeong Won Jang; Young Woon Kim; Mario Pirisi; Elias Allara; Rohini Sharma  JOURNAL OF CLINICAL ONCOLOGY  33-  (15)  2015/05Contrast-Enhanced Harmonic Endoscopic Ultrasonography for Diagnosing Cystic Tumors in the PancreasKen Kamata; Masayuki Kitano; Masatoshi Kudo  GASTROINTESTINAL ENDOSCOPY  81-  (5)  AB552  -AB552  2015/05Sorafenib plus intra-arterial cisplatin versus sorafenib alone in patients with advanced hepatocellular carcinoma: A randomized phase II trial.Ikeda, Masafumi; Shimizu, Satoshi; Sato, Tosiya; Morimoto, Manabu; Inaba, Yoshitaka; Kojima, Yasushi; Hagihara, Atsushi; Kudo, Masatoshi; Nakamori, Shoji; Kaneko, Shuichi; Sugimoto, Rie; Tahara, Toshiyuki; Ohmura, Takumi; Yasui, Kohichiroh; Sato, Keiko; Ishii, Hiroshi; Furuse, Junji; Okusaka, Takuji  JOURNAL OF CLINICAL ONCOLOGY  33-  (15)  2015/05A randomized, double-blind, placebo-controlled phase III study of S-1 in patients with sorafenib-refractory advanced hepatocellular carcinoma (S-CUBE)Masatoshi Kudo; Michihisa Moriguchi; Kazushi Numata; Hisashi Hidaka; Hironori Tanaka; Masafumi Ikeda; Seiji Kawazoe; Shinichi Ohkawa; Yozo Sato; Takuji Okusaka  JOURNAL OF CLINICAL ONCOLOGY  33-  (15)  2015/05Ramucirumab (RAM) as second-line treatment in patients (pts) with advanced hepatocellular carcinoma following first-line therapy with sorafenib: Patient-focused outcome (PFO) results from the phase 3 REACH study.Ian Chau; Markus Peck-Radosavljevic; Christophe Borg; Peter Malfertheiner; Jean Francois Seitz; Joon Oh Park; Baek-Yeol Ryoo; Chia-Jui Yen; Masatoshi Kudo; Ronnie Tung-Ping Poon; Davide Pastorelli; Jean-Frederic Blanc; Hyun Cheol Chung; Ari David Baron; Takuji Okusaka; Zhanglin Lin Cui; Allicia C. Girvan; Paolo Abada; Ling Yang; Andrew X. Zhu  JOURNAL OF CLINICAL ONCOLOGY  33-  (15)  2015/05Objective response by mRECIST to predict survival in hepatocellular carcinoma: A multivariate, time-dependent analysis from the phase III BRISK-PS studyJosep M. Llovet; Joong-Won Park; Ferran Torres; Thomas Decaens; Eveline Boucher; Jean-Luc Raoul; Masatoshi Kudo; Charissa Chang; Valerie Boige; Eric Assenat; Yoon-Koo Kang; Ho-Yeong Lim; Ian Walters; Riccardo Lencioni  JOURNAL OF CLINICAL ONCOLOGY  33-  (15)  2015/05十二指腸静脈瘤の病態と治療方針松井繁長; 樫田博史; 工藤正俊  Gastroenterol Endosc  57-  (Supplement 1)  718  2015/04COMBINED SEQUENTIAL USE OF HAP AND ART SCORES TO PREDICT TRANSARTERIAL CHEMOEMBOLIZATION FAILURE IN HEPATOCELLULAR CARCINOMA: A MULTI-CENTER COMPARATIVE STUDYD. J. Pinato; T. Arizumi; J. W. Jang; E. Allara; P. Suppiah; C. Smirne; G. Grossi; M. Pirisi; M. Kudo; R. Sharma  JOURNAL OF HEPATOLOGY  62-  S456  -S456  2015/04GIDEON: A RETROSPECTIVE ANALYSIS OF PROGNOSTIC FACTORS FOR SURVIVALJ. -P. Bronowicki; M. Kudo; R. Lencioni; X. -P. Chen; L. Dagher; J. Furuse; J. -F. H. Geschwind; L. Ladron de Guevara; C. Papandreou; A. J. Sanyal; T. Takayama; S. K. Yoon; K. Nakajima; S. -L. Ye; J. A. Marrero  JOURNAL OF HEPATOLOGY  62-  S451  -S452  2015/04胆道・膵疾患の内視鏡診断・治療における進歩 乳頭括約筋切開術を行わないTrans-catheter biliary endoscopyの有用性の検討河野 匡志; 北野 雅之; 工藤 正俊  Gastroenterological Endoscopy  57-  (Suppl.1)  726  -726  2015/04肝発癌研究と臨床への展開 分子生物学的特徴に基づいた肝癌のマネージメント西田 直生志; 海道 利実; 工藤 正俊  肝臓  56-  (Suppl.1)  A18  -A18  2015/04肝細胞癌の亜分類と個別化医療 血清中マイクロRNAプロファイルとソラフェニブに対する肝細胞癌の反応性予測西田 直生志; 工藤 正俊  肝臓  56-  (Suppl.1)  A102  -A102  2015/04肝病態を反映する新たなバイオマーカーの探索 変異型HBx遺伝子の肝発癌促進における分子機序の解明萩原 智; 西田 直生志; 工藤 正俊  肝臓  56-  (Suppl.1)  A126  -A126  2015/04転移性肝癌に対してUS-US fusionを用いたラジオ波焼灼術南 知宏; 南 康範; 千品 寛和; 有住 忠晃; 田北 雅弘; 北井 聡; 矢田 典久; 萩原 智; 上嶋 一臣; 西田 直生志; 工藤 正俊  肝臓  56-  (Suppl.1)  A326  -A326  2015/04intermediate stageの肝細胞癌に対してTACE不応後のTACE継続とソラフェニブの検討有住 忠晃; 上嶋 一臣; 南 知宏; 千品 寛和; 河野 匡志; 田北 雅弘; 北井 聡; 矢田 典久; 萩原 智; 南 康範; 櫻井 俊治; 西田 直生志; 工藤 正俊  肝臓  56-  (Suppl.1)  A524  -A524  2015/04Navigationに基づいた肝細胞癌IVR治療の最前線 肝細胞癌に対してUS-US Fusionを用いたラジオ波焼灼術南 康範; 西田 直生志; 工藤 正俊  日本消化器病学会雑誌  112-  (臨増総会)  A222  -A222  2015/03トルバプタンの治療効果における予測因子の検討千品 寛和; 井上 達夫; 南 知宏; 河野 匡志; 有住 忠晃; 田北 雅弘; 北井 聡; 矢田 典久; 萩原 智; 南 康範; 上嶋 一臣; 西田 直生志; 工藤 正俊  日本消化器病学会雑誌  112-  (臨増総会)  A364  -A364  2015/03STUDY ON THE EFFICACY AND SAFETY OF PROPOFOL SEDATION FOR OUTPATIENT COLONOSCOPY梅原康湖; 辻直子; 冨田崇文; 谷池聡子; 川崎正憲; 奥村直己; 高場雄久; 松本望; 河野匡; 丸山泰典; 尾崎信人; 工藤正俊  Gastroenterological Endoscopy  57-  (3)  2015Phase II study of front-line dovitinib (TKI258) versus sorafenib in patients (Pts) with advanced hepatocellular carcinoma (HCC)Ann-Lii Cheng; Sumitra Thongprasert; Ho Yeong Lim; Wattana Sukeepaisarnjaroen; Tsai-Sheng Yang; Cheng-Chung Wu; Yee Chao; Stephen Lam Chan; Masatoshi Kudo; Masafumi Ikeda; Yoon-Koo Kang; Hongming Pan; Kazushi Numata; Guohong Han; Binaifer Balsara; Yong Zhang; Ana-Maria Rodriguez; Yi Zhang; Yongyu Wang; Ronnie Tung-Ping Poon  JOURNAL OF CLINICAL ONCOLOGY  33-  (3)  2015/01Ramucirumab (RAM) as second-line treatment in patients (pts) with advanced hepatocellular carcinoma (HCC): Analysis of patients with elevated alpha-fetoprotein (AFP) from the randomized phase III REACH studyAndrew X. Zhu; Baek-Yeol Ryoo; Chia-Jui Yen; Masatoshi Kudo; Ronnie Tung-Ping Poon; Davide Pastorelli; Jean-Frederic Blanc; Hyun Cheol Chung; Ari David Baron; Tulio Eduardo Flesch Pfiffer; Takuji Okusaka; Katerina Kubackova; Jorg Trojan; Javier Sastre; Ian Chau; Shao-Chun Chang; Paolo Abada; Ling Yang; Yanzhi Hsu; Joon Oh Park  JOURNAL OF CLINICAL ONCOLOGY  33-  (3)  2015/01大腸鋸歯状病変SSA/Pの内視鏡診断岡崎 能久; 樫田 博史; 櫻井 俊治; 朝隈 豊; 米田 頼晃; 高山 政樹; 峯 宏昌; 足立 哲平; 田中 梨絵; 山田 光成; 岡元 寿樹; 榎本 英介; 前西 修; 筑後 孝章; 木村 雅友; 佐藤 隆夫; 工藤 正俊  Gastroenterological Endoscopy (0387-1207)57巻  2015大腸LSTの病態生理と診断・治療戦略 大腸LSTにおける腫瘍の性格に応じた治療方針米田 頼晃; 樫田 博史; 工藤 正俊  日本消化器病学会雑誌 (0446-6586)112巻臨増総会  2015下部消化管におけるadvanced diagnostic endoscopy(ADE)エビデンスと新たな展開 大腸拡大NBI観察におけるJNET分類の有効性に関する検討米田 頼晃; 樫田 博史; 工藤 正俊  Gastroenterological Endoscopy (0387-1207)57巻  2015食道表在癌の日本食道学会拡大内視鏡分類による深達度の検討朝隈豊; 松井繁長; 山田光成; 田中梨絵; 足立哲平; 高山政樹; 峯宏昌; 永井知行; 川崎正憲; 岡崎能久; 米田頼晃; 櫻井俊治; 樫田博史; 工藤正俊  日本消化管学会総会学術集会プログラム・抄録集  11th-  183  2015大腸LSTに対するEMRの工夫米田頼晃; 樫田博史; 岡元寿樹; 河野匡志; 山田光成; 田中梨絵; 足立哲平; 峯宏昌; 高山政樹; 永井知行; 川崎正憲; 岡崎能久; 朝隈豊; 櫻井俊治; 松井繁長; 工藤正俊  日本大腸検査学会総会プログラム・抄録集  33rd-  59  2015当院において直腸神経内分泌腫瘍に対してEMR‐C(EMR using a cap),EMR‐L(EMR with a ligation device)を中心とした内視鏡的切除の検討山田光成; 樫田博史; 岡元寿樹; 田中梨絵; 足立哲平; 峯宏昌; 高山政樹; 永井知行; 岡崎能久; 米田頼晃; 朝隈豊; 櫻井俊治; 松井繁長; 工藤正俊  日本消化器病学会大会(Web)  57th-  SHOP‐390 (WEB ONLY)  2015肝画像診断モダリティの進歩 (特集 肝臓病診療のアップデート)矢田 典久; 井上 達夫; 工藤 正俊  診断と治療  102-  (11)  1615  -1625  2014/11Colorectal endoscopic submucosal dissection is useful and safeHiroshi Kashida; Teppei Adachi; Yoriaki Komeda; Toshiharu Sakurai; Yutaka Asakuma; Masaki Takayama; Hiromasa Mine; Masatoshi Kudo  JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY  29-  41  -42  2014/11Homozygous deletion of the activin A receptor, type IB gene is associated with an aggressive cancer phenotype in pancreatic cancerYosuke Togashi; Hiroki Sakamoto; Hidetoshi Hayashi; Masato Terashima; Marco A. de Velasco; Yoshihiko Fujita; Yasuo Kodera; Kazuko Sakai; Shuta Tomida; Masayuki Kitano; Masatoshi Kudo; Kazuto Nishio  CANCER RESEARCH  74-  (19)  2014/10当院における食道表在癌の日本食道学会拡大内視鏡分類による深達度診断の検討朝隈豊; 松井繁長; 南知行; 山田光成; 田中梨絵; 足立哲平; 高山政樹; 峯宏昌; 永井知行; 櫻井俊治; 樫田博史; 工藤正俊; 白石治; 安田卓司  Gastroenterol Endosc  56-  (Supplement 2)  3061  2014/09NBNC肝がんの諸問題 NBNC肝癌の背景肝におけるメチル化プロファイルと加齢および糖尿病の影響西田 直生志; 工藤 正俊  肝臓  55-  (Suppl.2)  A528  -A528  2014/09B-modeで描出困難な肝癌に対するFusion imaging+造影USガイドでのラジオ波焼灼術南 知宏; 南 康範; 千品 寛和; 有住 忠晃; 田北 雅弘; 北井 聡; 矢田 典久; 井上 達夫; 萩原 智; 上嶋 一臣; 西田 直生志; 工藤 正俊  肝臓  55-  (Suppl.2)  A605  -A605  2014/09炎症からの大腸発癌におけるストレス応答蛋白Cirpの役割(Stress response protein Cirp links inflammation and tumorigenesis in colitis-associated cancer)櫻井 俊治; 工藤 正俊; 西田 直生志; 藤田 潤; 樫田 博史  日本癌学会総会記事  73回-  E  -3021  2014/09Local ablation therapy for hepatocellular carcinoma南 康範; 工藤 正俊  外科 = Surgery : 臨床雑誌  76-  (8)  858  -863  2014/08腹部CT (特集 消化器がん検診の現状とこれから) -- (肝臓がん)井上 達夫; 工藤 正俊  成人病と生活習慣病 : 日本成人病(生活習慣病)学会準機関誌  44-  (6)  713  -717,621  2014/06TACE不応の進行肝細胞癌患者に対するソラフェニブの開始時期の検討有住 忠晃; 上嶋 一臣; 千品 寛和; 田北 雅弘; 北井 聡; 井上 達夫; 矢田 典久; 萩原 智; 南 康範; 櫻井 俊治; 西田 直生志; 工藤 正俊  The Liver Cancer Journal  6-  (2)  122  -123  2014/06Interventional EUS for Pancreatobiliary Diseases北野 雅之; 工藤 正俊  最新医学  69-  (5)  1056  -1064  2014/05STORM: A phase III randomized, double-blind, placebo-controlled trial of adjuvant sorafenib after resection or ablation to prevent recurrence of hepatocellular carcinoma (HCC)Jordi Bruix; Tadatoshi Takayama; Vincenzo Mazzaferro; Gar-Yang Chau; Jiamei Yang; Masatoshi Kudo; Jianqiang Cai; Ronnie Tung-Ping Poon; Kwang-Hyub Han; Won-Young Tak; Han Chu Lee; Tianqiang Song; Sasan Roayaie; Luigi Bolondi; Kwan Sik Lee; Masatoshi Makuuchi; Fabricio Souza; Marie-Aude Le Berre; Gerold Meinhardt; Josep M. Llovet  JOURNAL OF CLINICAL ONCOLOGY  32-  (15)  2014/05A multicenter, open-label, phase 3 trial to compare the efficacy and safety of lenvatinib (E7080) versus sorafenib in first-line treatment of subject with unresectable hepatocellular carcinoma.Richard S. Finn; Ann-Lii Cheng; Kenji Ikeda; Masatoshi Kudo; Toshiyuki Tamai; Corina E. Dutcus; Steven Younger; Kwang-Hyub Han; Shukui Qin; Eric Raymond  JOURNAL OF CLINICAL ONCOLOGY  32-  (15)  2014/05Prognostic and predictive role of circulating angiopoietin-2 in multiple solid tumors: An analysis of approximately 500 patients treated with lenvatinib across tumor types.Ignace Vergote; Douglas Wilmot Ball; Masatoshi Kudo; Pallavi Sachdev; Mark Matijevic; Tadashi Kadowaki; Yasuhiro Funahashi; Keith Flaherty  JOURNAL OF CLINICAL ONCOLOGY  32-  (15)  2014/05OPTIMIS: An international observational study to assess the use of sorafenib after transarterial chemoembolization (TACE) in patients with hepatocellular carcinoma (HCC).Markus Peck-Radosavijevic; Jean-Luc Raoul; Han Chu Lee; Masatoshi Kudo; Keiko Nakajima; Ann-Lii Chong  JOURNAL OF CLINICAL ONCOLOGY  32-  (15)  2014/05Randomized phase II trial of intravenous R05137382/GC33 at 1600 mg every other week and placebo in previously treated patients with unresectable advanced hepatocellular carcinoma (HCC; NCT01507168).Chia-Jul Yen; Bruno Daniele; Masatoshi Kudo; Philippe Merle; Joong-Won Park; Paul J. Ross; Jean-Marie Peron; Oliver Ebert; Stephen Lam Chan; Ronnie Tung; Ping Poon; Massimo Colombo; Takuji Okusaka; Baek-Yeol Ryoo; Beatriz Minguez; Takayoshi Tanaka; Toshihiko Ohtomo; Olga Rutman; Ya-Chi Chen; Reuy-min Lee; Ghassan K. Abou-Alfa  JOURNAL OF CLINICAL ONCOLOGY  32-  (15)  2014/05Multicenter observational study of reactivation of hepatitis B virus (HBV) caused by chemotherapy for solid tumors (ST)Shunsuke Kondo; Masafumi Ikeda; Masatoshi Kudo; Seijin Nadano; Junji Furuse; Yukio Osaki; Takashi Kumada; Kazuyoshi Ohkawa; Masashi Mizokami  JOURNAL OF CLINICAL ONCOLOGY  32-  (15)  2014/05当院における直腸内分泌腫瘍(NET)の診断と治療成績山田光成; 樫田博史; 南知宏; 田中梨絵; 足立哲平; 高山政樹; 峯宏昌; 永井知行; 川崎正憲; 朝隈豊; 櫻井俊治; 松井繁長; 工藤正俊  Gastroenterol Endosc  56-  (Supplement 1)  1084  2014/04胃アミロイドーシスの2例岡元寿樹; 高山政樹; 峯宏昌; 山田光成; 足立哲平; 永井知行; 川崎正憲; 櫻井俊治; 松井繁長; 樫田博史; 工藤正俊  Gastroenterol Endosc  56-  (Supplement 1)  1299  2014/04EVALUATION OF ART SCORE FOR REPEATED TRANSARTERIAL CHEMOEMBOLIZATION IN JAPANESE COHORT OF HEPATOCELLULAR CARCINOMAT. Arizumi; K. Ueshima; H. Chishina; M. Takita; S. Kitai; T. Inoue; N. Yada; S. Hagiwara; Y. Minami; T. Sakurai; N. Nishida; M. Kudo  JOURNAL OF HEPATOLOGY  60-  (1)  S253  -S253  2014/04Endoscopic ultrasound-guided fine-needle aspiration for the differential diagnosis of intraductal papillary mucinous neoplasms and size stratification for surveillance ReplyMasayuki Kitano; Ken Kamata; Masatoshi Kudo  ENDOSCOPY  46-  (4)  357  -357  2014/04Value of EUS in early detection of pancreatic ductal adenocarcinomas in patients with intraductal papillary mucinous neoplasms. (vol 46, pg 22, 2014)Ken Kamata; Masayuki Kitano; Masatoshi Kudo; Hiroki Sakamoto; Kumpei Kadosaka; Takeshi Miyata; Hajime Imai; Kiyoshi Maekawa; Takaaki Chikugo; Masashi Kumano; Tomoko Hyodo; Takamichi Murakami; Yasutaka Chiba; Yoshifumi Takeyama  ENDOSCOPY  46-  (4)  358  -358  2014/04画像を診る 鑑別診断のポイント 閉塞性黄疸を合併した黄色肉芽腫性胆嚢炎辻 直子; 河野 匡志; 船井 貞往; 工藤 正俊  消化器の臨床  17-  (2)  176  -178  2014/04当院における超高齢者(85歳以上)の下部内視鏡検査・治療の現況永井 知行; 樫田 博史; 工藤 正俊; 南 知宏; 田中 梨絵; 山田 光成; 足立 哲平; 峯 宏昌; 高山 政樹; 川崎 正憲; 朝隈 豊; 櫻井 俊治; 松井 繁長  Gastroenterological Endoscopy  56-  (Suppl.1)  1277  -1277  2014/04肝外再発例の肝癌DNAメチル化プロファイルを用いた治癒切除後の早期再発予測西田 直生志; 中居 卓也; 工藤 正俊  肝臓  55-  (Suppl.1)  A210  -A210  2014/04高齢者Genotype 1b高ウイルス量のC型慢性肝炎患者における治療効果と安全性 ReGIT-J試験の層別解析西川 浩樹; 榎本 平之; 斎藤 正紀; 会澤 信弘; 津田 泰宏; 樋口 和秀; 岡崎 和一; 関 寿人; 金 守良; 本合 泰; 城村 尚登; 西田 直生志; 工藤 正俊; 大崎 往夫; 西口 修平  肝臓  55-  (Suppl.1)  A233  -A233  2014/04当院におけるNSAIDs・抗血小板薬起因性の小腸粘膜傷害の検討永井 知行; 高山 政樹; 岡元 寿樹; 千品 寛和; 山田 光成; 足立 哲平; 峯 宏昌; 川崎 正憲; 朝隈 豊; 櫻井 俊治; 松井 繁長; 樫田 博史; 工藤 正俊  日本消化器病学会雑誌  111-  (臨増総会)  A387  -A387  2014/03NAFLD/NASHにおける新知見と治療法の進歩 NASH/NAFLDモデルマウスの発癌過程におけるDNA酸化損傷とエピゲノム変異の誘導西田 直生志; 工藤 正俊  日本消化器病学会雑誌  111-  (臨増総会)  A194  -A194  2014/03plain cone-beam CTによる肝動脈塞栓術の定量的治療効果予測南 康範; 南 知宏; 有住 忠晃; 田北 雅弘; 北井 聡; 矢田 典久; 井上 達夫; 萩原 智; 上嶋 一臣; 西田 直生志; 工藤 正俊; 柳生 行伸; 村上 卓道  日本消化器病学会雑誌  111-  (臨増総会)  A275  -A275  2014/03疾患の理解編 (疾患と看護がわかる看護過程 ナーシングプロセス 肝がん)井上 達夫; 工藤 正俊  クリニカルスタディ  35-  (2)  89  -96  2014/02ナーシングプロセス: 肝がん, 疾患の理解編. 特集「国試に出る!統計と法律」井上 達夫; 工藤 正俊  クリニカルスタディ  35-  9  -16  2014/02TACEまたは肝動注化学療法とソラフェニブの併用療法の重要性上嶋一臣; 有住忠晃; 工藤正俊  日本臨床腫瘍学会学術集会(CD-ROM)  12th-  2014Early response prediction of hepatocellular carcinoma to conventional transcatheter chemoembolization using intraprocedual plain cone-beam CTYasunori Minami; Masatoshi Kudo  HEPATOLOGY  60-  865A  -865A  2014EVOLVE-1: Phase 3 study of everolimus for advanced HCC that progressed during or after sorafenib.Andrew X. Zhu; Masatoshi Kudo; Eric Assenat; Stephane Cattan; Yoon-Koo Kang; Ho Yeong Lim; Ronnie Tung Ping Poon; Jean-Frederic Blanc; Arndt Vogel; Chao-Long Chen; Etienne Dorval; Markus Peck-Radosavljevic; Armando Santoro; Bruno Daniele; Junji Furuse; Annette Jappe; Kevin Perraud; Ozlem Anak; Dalila B. Sellami; Li-Tzong Chen  JOURNAL OF CLINICAL ONCOLOGY  32-  (3)  2014/01How Is BCLC Stage C HCC Treated In Real-Word Practice And What Outcomes Are Obtained?Sasan Roayaie; Ghalib Jibara; Parissa Tabrizian; Joong-Won Park; Jijin Yang; Lunan Yan; Guohong Han; Francesco Izzo; Minshan Chen; Jean-Frederic Blanc; Phillip Johnson; Masatoshi Kudo; Lewis R. Roberts; Morris Sherman  HEPATOLOGY  60-  873A  -873A  2014横行結腸原発平滑筋肉腫の1例TSUJI NAOKO; KAWANO MASASHI; OZAKI NOBUTO; MARUYAMA YASUNORI; MATSUMOTO NOZOMU; TAKABA KATSUHISA; OKUMURA NAOKI; TANIIKE SATOKO; HATABE SHIGERU; KITANO YOSHINORI; SAKAI KEN'ICHI; FUNAI SADAYUKI; OCHIAI KEN; MAEKURA TOSHIHARU; KUDO MASATOSHI  日本消化管学会総会学術集会プログラム・抄録集  10th-  299  2014当院におけるヘリコバクターピロリ除菌の治療成績の検討足立哲平; 南知宏; 田中梨絵; 山田光成; 高山政樹; 峯宏昌; 永井知行; 朝隈豊; 櫻井俊治; 松井繁長; 樫田博史; 工藤正俊  日本消化器病学会大会(Web)  56th-  SHOP‐72 (WEB ONLY)  2014興味ある経過を示した胃アミロイドーシスの1例岡元寿樹; 高山政樹; 峯宏昌; 山田光成; 足立哲平; 永井知行; 川崎正憲; 朝隈豊; 櫻井俊治; 松井繁長; 樫田博史; 工藤正俊  日本消化管学会総会学術集会プログラム・抄録集  10th-  296  2014当院においてOGIBと診断され,シングルバルーン小腸内視鏡検査を施行した高齢者症例の臨床的検討高山政樹; 足立哲平; 峯宏昌; 永井知行; 川崎正憲; 朝隈豊; 櫻井俊治; 松井繁長; 樫田博史; 工藤正俊  日本消化管学会総会学術集会プログラム・抄録集  10th-  261  2014臓器癌とmTOR: 肝癌. 特集「mTORと悪性腫瘍」上嶋 一臣; 工藤 正俊  医学のあゆみ  248-  138  -140  2014/01Contrast-enhanced endoscopic ultrasoundMasayuki Kitano; Hiroki Sakamoto; Masatoshi Kudo  DIGESTIVE ENDOSCOPY  26-  79  -85  2014/01造影超音波. 特集「Diagnostic and Interventional EUS-現状と将来展望」鎌田 研; 北野 雅之; 工藤 正俊  臨床 消化器内科  28-  1689  -1696  2013/12Sunitinib Versus Sorafenib in Advanced Hepatocellular Cancer: Results of a Randomized Phase III TrialAnn-Lii Cheng; Yoon-Koo Kang; Deng-Yn Lin; Joong-Won Park; Masatoshi Kudo; Shukui Qin; Hyun-Cheol Chung; Xiangqun Song; Jianming Xu; Guido Poggi; Masao Omata; Susan Pitman Lowenthal; Silvana Lanzalone; Liqiang Yang; Maria Jose Lechuga; Eric Raymond  JOURNAL OF CLINICAL ONCOLOGY  31-  (32)  4067  -+  2013/11Alpha-fetoprotein-L3: Useful or Useless for Hepatocellular Carcinoma?工藤 正俊  Liver Cancer  2-  151  -152  2013/11Oxidative stress and epigenetic instability in human hepatocarcinogenesisNaoshi Nishida; Masatoshi Kudo  Digestive Diseases  31-  (5-6)  447  -453  2013/11Correlation between gankyrin and stemness factors in human colorectal adenomasHiromasa Mine; Toshiharu Sakurai; Masatoshi Kudo  JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY  28-  433  -433  2013/10B-mode Ultrasonography Versus Contrast-enhanced Ultrasonography for Surveillance of Hepatocellular Carcinoma: A Prospective Multicenter Randomized Controlled TrialMasatoshi Kudo; Kazuomi Ueshima; Yukio Osaki; Masashi Hirooka; Yasuharu Imai; Kazunobu Aso; Kazushi Numata; Masao Ichinose; Takashi Kumada; Namiki Izumi; Yasukiyo Sumino; Kouhei Akazawa  HEPATOLOGY  58-  289A  -289A  2013/10Safety and outcomes by disease etiology in sorafenib-treated uHCC patients in clinical practice: final analysis of GIDEON (Global Investigation of therapeutic DEcisions in hepatocellular carcinoma and Of its treatment with sorafeNib)Arun J. Sanyal; Riccardo Lencioni; Sheng-Long Ye; Masatoshi Kudo; Alan Venook; Jean-Pierre Bronowicki; Xiao-Ping Chen; Lucy Dagher; Junji Furuse; Jean-Francois H. Geschwind; Laura Ladron de Guevara; Christos Papandreou; Tadatoshi Takayama; Seung Kew Yoon; Keiko Nakajima; Jorge A. Marrero  HEPATOLOGY  58-  1261A  -1261A  2013/10Brivanib Versus Sorafenib As First-Line Therapy in Patients With Unresectable, Advanced Hepatocellular Carcinoma: Results From the Randomized Phase III BRISK-FL StudyPhilip J. Johnson; Shukui Qin; Joong-Won Park; Ronnie T. P. Poon; Jean-Luc Raoul; Philip A. Philip; Chih-Hung Hsu; Tsung-Hui Hu; Jeong Heo; Jianming Xu; Ligong Lu; Yee Chao; Eveline Boucher; Kwang-Hyub Han; Seung-Woon Paik; Jorge Robles-Avina; Masatoshi Kudo; Lunan Yan; Abhasnee Sobhonslidsuk; Dmitry Komov; Thomas Decaens; Won-Young Tak; Long-Bin Jeng; David Liu; Rana Ezzeddine; Ian Walters; Ann-Lii Cheng  JOURNAL OF CLINICAL ONCOLOGY  31-  (28)  3517  -+  2013/10Effect of hepatic arterial infusion chemotherapy of 5-fluorouracil and cisplatin for advanced hepatocellular carcinoma in the Nationwide Survey of Primary Liver Cancer in JapanK. Nouso; K. Miyahara; D. Uchida; K. Kuwaki; N. Izumi; M. Omata; T. Ichida; M. Kudo; Y. Ku; N. Kokudo; M. Sakamoto; O. Nakashima; T. Takayama; O. Matsui; Y. Matsuyama; K. Yamamoto  BRITISH JOURNAL OF CANCER  109-  (7)  1904  -1907  2013/10[Preface] Chronic liver diseases and hepatocellular carcinoma: update in 2013工藤 正俊  Digest Dis  31-  405  -407  2013/10急性胆嚢炎に対するEUSガイド下ドレナージ術. 特集「ドレナージ大全」今井 元; 北野 雅之; 大本 俊介; 門阪 薫平; 宮田 剛; 鎌田 研; 山雄 健太郎; 坂本 洋城; 工藤 正俊  胆と膵  34-  925  -928  2013/10当院においてOGIBと診断されシングルバルーン小腸内視鏡検査を施行した高齢者症例の臨床的検討高山政樹; 足立哲平; 峯宏昌; 永田嘉昭; 永井知行; 川崎正憲; 朝隈豊; 櫻井俊治; 松井繁長; 樫田博史; 工藤正俊  Gastroenterol Endosc  55-  (Supplement 2)  2832  2013/09Final analysis of GIDEON (Global Investigation of therapeutic DEcisions in hepatocellular carcinoma and of its treatment with sorafeNib) in > 3000 sorafenib-treated patients: Prognostic value of baseline characteristics and staging systemsJ. Bronowicki; R. Lencioni; S. L. Ye; M. Kudo; C. Papandreou; K. Nakajima; A. P. Venook; J. Marrero  EUROPEAN JOURNAL OF CANCER  49-  S617  -S618  2013/09Comparison of resection and ablation for hepatocellular carcinoma: A cohort study based on a Japanese nationwide survey (vol 58, pg 724, 2013)Kiyoshi Hasegawa; Norihiro Kokudo; Masatoshi Makuuchi; Namiki Izumi; Takafumi Ichida; Masatoshi Kudo; Yonson Ku; Michiie Sakamoto; Osamu Nakashima; Osamu Matsui; Yutaka Matsuyama  JOURNAL OF HEPATOLOGY  59-  (3)  641  -641  2013/09慢性胃炎性変化の乏しいC-0症例のたこいぼびらんに見られる腸上皮化生についての検討辻 直子; 丸山 康典; 河野 匡志; 松本 望; 高場 雄久; 奥村 直己; 山本 典雄; 冨田 崇文; 梅原 康湖; 谷池 聡子; 森村 正嗣; 米田 円; 山田 哲; 落合 健; 前倉 俊治; 本庶 元; 工藤 正俊  Gastroenterological Endoscopy  55-  (Suppl.2)  2784  -2784  2013/09上部消化管内視鏡検査前スクリーニングとして実施した胸部X-rayおよび心電図より得られた所見についての検討谷池 聡子; 河野 匡志; 丸山 康典; 松本 望; 高場 雄久; 奥村 直己; 冨田 崇文; 梅原 康湖; 森村 正嗣; 米田 円; 山田 哲; 辻 直子; 工藤 正俊  Gastroenterological Endoscopy  55-  (Suppl.2)  2819  -2819  2013/09プロポフォール投与下内視鏡検査で生じる不随意運動の検討梅原 康湖; 河野 匡志; 丸山 康典; 松本 望; 高場 雄久; 奥村 直己; 谷池 聡子; 冨田 崇文; 森村 正嗣; 山田 哲; 米田 円; 辻 直子; 工藤 正俊  Gastroenterological Endoscopy  55-  (Suppl.2)  2822  -2822  2013/09プロポフォール投与下内視鏡検査における飲酒患者、睡眠薬・精神安定剤内服患者への注意点梅原 康湖; 河野 匡志; 丸山 康典; 松本 望; 高場 雄久; 奥村 直己; 谷池 聡子; 冨田 崇文; 森村 正嗣; 山田 哲; 米田 円; 辻 直子; 工藤 正俊  Gastroenterological Endoscopy  55-  (Suppl.2)  2822  -2822  2013/09Clostridium difficile感染症例の検討奥村 直己; 工藤 正俊; 辻 直子; 高場 雄久; 松本 望; 谷池 聡子; 河野 匡志; 丸山 康典; 山田 哲; 森村 正嗣; 米田 円; 梅原 康湖; 冨田 崇文  Gastroenterological Endoscopy  55-  (Suppl.2)  2844  -2844  2013/09エソメプラゾールを用いたH.pylori除菌療法の検討松本 望; 河野 匡志; 丸山 康典; 高場 雄久; 奥村 直己; 冨田 崇文; 梅原 康湖; 谷池 聡子; 森村 正嗣; 米田 円; 山田 哲; 辻 直子; 工藤 正俊  日本消化器病学会雑誌  110-  (臨増大会)  A895  -A895  2013/09肝のう胞に対するオレイン酸モノエタノールアミン注入療法の検討田北 雅弘; 有住 忠晃; 北井 聡; 井上 達夫; 矢田 典久; 萩原 智; 南 康範; 上嶋 一臣; 西田 直生志; 工藤 正俊  肝臓  54-  (Suppl.2)  A614  -A614  2013/09Efficacy of treatment with rebamipide for endoscopic submucosal dissection-induced ulcersMasaki Takayama; Shigenaga Matsui; Masanori Kawasaki; Yutaka Asakuma; Toshiharu Sakurai; Hiroshi Kashida; Masatoshi Kudo  WORLD JOURNAL OF GASTROENTEROLOGY  19-  (34)  5706  -5712  2013/09十二指腸静脈瘤の病態と治療方針松井繁長; 樫田博史; 朝隈豊; 川崎正憲; 工藤正俊  日本門脈圧こう進症学会雑誌  19-  (3)  112  2013/08【消化器疾患における超音波内視鏡検査-現況と将来展望-】 EUSガイド下治療の現況と将来展望 EUSガイド下胆道ドレナージの実状今井 元; 北野 雅之; 大本 俊介; 門阪 薫平; 宮田 剛; 鎌田 研; 山雄 健太郎; 坂本 洋城; 工藤 正俊  最新医学  68-  (8)  1761  -1769  2013/08Association of Gankyrin and Stemness Factor Expression in Human Colorectal CancerHiromasa Mine; Toshiharu Sakurai; Hiroshi Kashida; Shigenaga Matsui; Naoshi Nishida; Tomoyuki Nagai; Satoru Hagiwara; Tomohiro Watanabe; Masatoshi Kudo  Digestive Diseases and Sciences  58-  (8)  2337  -2344  2013/08胃炎~H. pylori除菌によるアプローチ~松井 繁長; 工藤 正俊  Medicament News Medicament News  (2129)  4  -6  2013/07Senile systemic amyloidosis mimicking gastric cancer松井 繁長; 樫田 博史; 工藤 正俊  Digest Endosc  25-  468  -469  2013/07ソラフェニブ治療におけるJNK活性の重要性 CD133との関連も含めて萩原 智; 櫻井 俊治; 上嶋 一臣; 永井 知行; 西田 直生志; 工藤 正俊  The Liver Cancer Journal  5-  (2)  130  -131  2013/06ソラフェニブ治療におけるJNK活性の重要性-CD133との関連も含めて萩原 智; 櫻井 俊治; 上嶋 一臣; 永井 知行; 西田 直生志; 工藤 正俊  The Liver Cancer Journal The Liver Cancer Journal  5-  58  -59  2013/06Impact of peginterferon alpha-2b and entecavir hydrate combination therapy on persistent viral suppression in patients with chronic hepatitis BSatoru Hagiwara; Masatoshi Kudo; Yukio Osaki; Hiroo Matsuo; Tadashi Inuzuka; Akihiro Matsumoto; Eiji Tanaka; Toshiharu Sakurai; Kazuomi Ueshima; Tatsuo Inoue; Norihisa Yada; Naoshi Nishida  Journal of Medical Virology  85-  (6)  987  -995  2013/06Regorafenib (REG) in patients with hepatocellular carcinoma (HCC) progressing following sorafenib: An ongoing randomized, double-blind, phase III trialAnn-Lii Cheng; Richard S. Finn; Masatoshi Kudo; Josep M. Llovet; Shukui Qin; Marie-Aude Le Berre; Heiko Krissel; Jordi Bruix  JOURNAL OF CLINICAL ONCOLOGY  31-  (15)  2013/05Verrucous Antral Gastritis Is Not Related to H-pylori-Positive Chronic Gastritis, but Is Related to a High BMI and Barrett's EsophagusNaoko Tsuji; Naoki Okumura; Satoko Taniike; Takehisa Takaba; Nozomu Matsumoto; Masashi Kono; Yasunori Maruyama; Masatoshi Kudo  GASTROENTEROLOGY  144-  (5)  S340  -S340  2013/05Consensus recommendations and review by an International Expert Panel on Interventions in Hepatocellular Carcinoma (EPOIHCC) (vol 33, pg 327, 2013)Joong-Won Park; Deepak Amarapurkar; Yee Chao; Pei-Jer Chen; Jean-Francois H. Geschwind; Khean Lee Goh; Kwang-Hyub Han; Masatoshi Kudo; Han Chu Lee; Rheun-Chuan Lee; Laurentius A. Lesmana; Ho Yeong Lim; Seung Woon Paik; Ronnie T. Poon; Chee-Kiat Tan; Tawesak Tanwandee; Gaojun Teng; Ann-Lii Cheng  LIVER INTERNATIONAL  33-  (5)  808  -808  2013/05Time Trends for Helicobacter pylori Eradication Rate of the First-Line and Second-Line Japanese Regimens and Clarithromycin ResistanceNaoko Tsuji; Naoki Okumura; Satoko Taniike; Takehisa Takaba; Nozomu Matsumoto; Masashi Kono; Yasunori Maruyama; Masatoshi Kudo  GASTROENTEROLOGY  144-  (5)  S332  -S332  2013/05Final analysis of GIDEON (Global Investigation of Therapeutic Decisions in Hepatocellular Carcinoma [HCC] and of Its Treatment with Sorafenib [Sor]) in >3000 Sortreated patients (pts): Clinical findings in pts with liver dysfunctionJorge A. Marrero; Riccardo Lencioni; Sheng-Long Ye; Masatoshi Kudo; Jean-Pierre Bronowicki; Xiao-Ping Chen; Lucy Dagher; Junji Furuse; Jean-Francois Geschwind; Laura Ladron de Guevara; Christos Papandreou; Arun J. Sanyal; Tadatoshi Takayama; Seung Kew Yoon; Keiko Nakajima; Alan Paul Venook  JOURNAL OF CLINICAL ONCOLOGY  31-  (15)  2013/05【膵胆道癌の早期診断】 膵上皮内癌とstage I膵癌の臨床的特徴宮田 剛; 北野 雅之; 大本 俊介; 門阪 薫平; 鎌田 研; 今井 元; 坂本 洋城; 工藤 正俊  消化器内科  56-  (5)  552  -557  2013/05Clinical implication of hypovascular hepatocellular carcinoma studied in 4,474 patients with solitary tumour equal or less than 3cmKenichi Takayasu; Shigeki Arii; Michiie Sakamoto; Yutaka Matsuyama; Masatoshi Kudo; Takafumi Ichida; Osamu Nakashima; Osamu Matsui; Namiki Izumi; Yonson Ku; Norihiro Kokudo; Masatoshi Makuuchi  LIVER INTERNATIONAL  33-  (5)  762  -770  2013/05“鎮静”をマスターする〔特定の状況下での鎮静〕緊急内視鏡における鎮静樫田博史; 川崎正憲; 朝隈豊; 櫻井俊治; 松井繁長; 北野雅之; 工藤正俊  消化器内視鏡  25-  (4)  587  -592  2013/04良性肝細胞性結節の諸問題 肝細胞腺腫、限局性結節性過形成を含む過形成結節の基礎と臨床 非定型的な様相を呈する限局性結節性過形成についての検討喜多 竜一; 西田 直生志; 那須 章弘; 西島 規浩; 若狭 朋子; 佐々木 素子; 木村 達; 大崎 征夫; 中島 収; 工藤 正俊; 中沼 安二  肝臓  54-  (Suppl.1)  A80  -A80  2013/04ヒト肝癌に認められるゲノムワイドな脱メチル化と染色体不安定性の関連西田 直生志; 有住 忠晃; 田北 雅弘; 北井 聡; 矢田 典久; 井上 達夫; 萩原 智; 南 康範; 櫻井 俊治; 上嶋 一臣; 工藤 正俊  肝臓  54-  (Suppl.1)  A149  -A149  2013/04乏血性進行肝細胞癌患者に対してソラフェニブ治療の成績有住 忠晃; 上嶋 一臣; 田北 雅弘; 北井 聡; 井上 達夫; 矢田 典久; 萩原 智; 南 康範; 櫻井 俊治; 西田 直生志; 工藤 正俊  肝臓  54-  (Suppl.1)  A284  -A284  2013/04PEG-IFNα2a少量長期療法における発癌リスク因子の検討 IL28B遺伝子多型との関連も含めて萩原 智; 櫻井 俊治; 上嶋 一臣; 南 康範; 井上 達夫; 矢田 典久; 北井 聡; 田北 雅弘; 永井 知行; 有住 忠晃; 田中 梨絵; 西田 直生志; 工藤 正俊  肝臓  54-  (Suppl.1)  A372  -A372  2013/04超音波を施行した0歳児の嘔吐症例の検討前野 知子; 横川 美加; 辻 裕美子; 塩見 香織; 前川 清; 井上 達夫; 南 康範; 西田 直生志; 八木 誠; 工藤 正俊  超音波医学  40-  (Suppl.)  S547  -S547  2013/04肝血管筋脂肪腫の3例田中 梨絵; 南 康範; 田北 雅弘; 北井 聡; 井上 達夫; 矢田 典久; 萩原 智; 上嶋 一臣; 西田 直生志; 工藤 正俊  超音波医学  40-  (Suppl.)  S573  -S573  2013/04Comparison of resection and ablation for hepatocellular carcinoma: A cohort study based on a Japanese nationwide surveyKiyoshi Hasegawa; Norihiro Kokudo; Masatoshi Makuuchi; Namiki Izumi; Takafumi Ichida; Masatoshi Kudo; Yonson Ku; Michiie Sakamoto; Osamu Nakashima; Osamu Matsui; Yutaka Matsuyama  JOURNAL OF HEPATOLOGY  58-  (4)  724  -729  2013/04FGF3/FGF4 amplification and multiple lung metastases in responders to sorafenib in hepatocellular carcinomaTokuzo Arao; Kazuomi Ueshima; Kazuko Matsumoto; Tomoyuki Nagai; Hideharu Kimura; Satoru Hagiwara; Toshiharu Sakurai; Seiji Haji; Akishige Kanazawa; Hisashi Hidaka; Yukihiro Iso; Keiichi Kubota; Mitsuo Shimada; Tohru Utsunomiya; Masashi Hirooka; Yoichi Hiasa; Yoshikazu Toyoki; Kenichi Hakamada; Kohichiroh Yasui; Takashi Kumada; Hidenori Toyoda; Shuichi Sato; Hiroyuki Hisai; Teiji Kuzuya; Kaoru Tsuchiya; Namiki Izumi; Shigeki Arii; Kazuto Nishio; Masatoshi Kudo  HEPATOLOGY  57-  (4)  1407  -1415  2013/04EUSガイド下胆道ドレナージ術の新展開. 今月のテーマ「胆膵疾患に対するInterventional EUSの新展開」北野 雅之; 工藤 正俊  日本消化器病学会雑誌  110-  557  -567  2013/04必修!大腸ESD これから大腸ESDを導入する施設の方へ樫田博史; 足立哲平; 高山政樹; 峯宏昌; 永田嘉昭; 永井知行; 川崎正憲; 朝隈豊; 櫻井俊治; 松井繁長; 工藤正俊  消化器内視鏡  25-  (3)  367  -371  2013/03肝細胞癌の治療効果判定-RECIST, mRECIST, RECICL-工藤 正俊; 土谷 薫; 角谷 眞澄; 池田 公史  The Liver Cancer Journal The Liver Cancer Journal  5-  13  -21  2013/03最近の臨床試験とその解釈①SILIUS第Ⅰ相試験とその解釈上嶋 一臣; 工藤 正俊  The Liver Cancer Journal The Liver Cancer Journal  (5)  24  -31  2013/03Inhibition of hepatocellular carcinoma by PegIFN alpha-2a in patients with chronic hepatitis C: a nationwide multicenter cooperative studyNamiki Izumi; Yasuhiro Asahina; Masayuki Kurosaki; Gotaro Yamada; Tsutomu Kawai; Eiji Kajiwara; Yukishige Okamura; Takayuki Takeuchi; Osamu Yokosuka; Kazuya Kariyama; Joji Toyoda; Mie Inao; Eiji Tanaka; Hisataka Moriwaki; Hiroshi Adachi; Shinji Katsushima; Masatoshi Kudo; Kouichi Takaguchi; Yoichi Hiasa; Kazuaki Chayama; Hiroshi Yatsuhashi; Makoto Oketani; Hiromitsu Kumada  JOURNAL OF GASTROENTEROLOGY  48-  (3)  382  -390  2013/03当院のヘリコバクターピロリ除菌治療におけるPPI別検討足立哲平; 高山政樹; 峯宏昌; 永井知行; 永田嘉昭; 川崎正憲; 朝隈豊; 櫻井俊治; 松井繁長; 樫田博史; 工藤正俊  日本消化器病学会雑誌  110-  A220  2013/02胃粘膜上皮のHSP27発現は上皮内癌の発生リスクと負の相関を示す永田嘉昭; 櫻井俊治; 足立哲平; 高山政樹; 峯宏昌; 永井知行; 川崎正憲; 朝隈豊; 松井繁長; 樫田博史; 工藤正俊  日本消化器病学会雑誌  110-  A408  2013/02Phase III trial of linifanib versus sorafenib in patients with advanced hepatocellular carcinoma (HCC)Calin Cainap; Shukui Qin; Wen-Tsung Huang; Ik-Joo Chung; Hongming Pan; Ying Cheng; Masatoshi Kudo; Yoon-Koo Kang; Pei-Jer Chen; Han Chong Toh; Vera Gorbunova; Ferry Eskens; Jiang Qian; Mark D. McKee; Justin L. Ricker; Dawn M. Carlson; Saied El Nowiem  JOURNAL OF CLINICAL ONCOLOGY  31-  (4)  2013/02異所性静脈瘤・胃静脈瘤の病態と治療 十二指腸静脈瘤の病態と治療松井 繁長; 樫田 博史; 工藤 正俊  日本腹部救急医学会雑誌  33-  (2)  336  -336  2013/02肝血管筋脂肪腫の3例田中 梨絵; 上嶋 一臣; 千品 寛和; 有住 忠晃; 田北 雅弘; 北井 聡; 井上 達夫; 矢田 典久; 萩原 智; 南 康範; 西田 直生志; 工藤 正俊  日本消化器病学会雑誌  110-  (臨増総会)  A342  -A342  2013/02Heat Shock Protein 27 Expression is Inversely Correlated with Atrophic Gastritis and Intraepithelial NeoplasiaYoshiaki Nagata; Masatoshi Kudo; Tomoyuki Nagai; Tomohiro Watanabe; Masanori Kawasaki; Yutaka Asakuma; Satoru Hagiwara; Naoshi Nishida; Shigenaga Matsui; Hiroshi Kashida; Toshiharu Sakurai  DIGESTIVE DISEASES AND SCIENCES  58-  (2)  381  -388  2013/02Toll-like receptor activation in basophils contributes to the development of IgG4-related diseaseTomohiro Watanabe; Kouhei Yamashita; Toshiharu Sakurai; Masatoshi Kudo; Masahiro Shiokawa; Norimitsu Uza; Yuzo Kodama; Kazushige Uchida; Kazuichi Okazaki; Tsutomu Chiba  Journal of Gastroenterology  48-  (2)  247  -253  2013/02Hypovascular Nodules in Patients with Chronic Liver Disease: Risk Factors for Development of Hypervascular Hepatocellular CarcinomaTomoko Hyodo; Takamichi Murakami; Yasuharu Imai; Masahiro Okada; Masatoshi Hori; Yuki Kagawa; Sachiyo Kogita; Seishi Kumano; Masatoshi Kudo; Teruhito Mochizuki  RADIOLOGY  266-  (2)  480  -490  2013/02肝癌の治療 分子標的薬治療. 特集「肝炎から肝硬変・肝癌まで」上嶋 一臣; 工藤 正俊  臨牀と研究  90-  216  -221  2013/02Expression of E-cadherin and vascular endothelial growth factor in noncancerous liver is associated with recurrence of hepatocellular carcinoma after curative resectionMutsuko Minata; Masatoshi Kudo; Kouji H. Harada; Iwao Ikai; Naoshi Nishida  Oncology (Switzerland)  84-  (1)  88  -92  2013/02Assessment of liver fibrosis with real-time tissue elastography in chronic viral hepatitisNorihisa Yada; Masatoshi Kudo; Hiroyasu Morikawa; Kenji Fujimoto; Michio Kato; Norifumi Kawada  Oncology (Switzerland)  84-  (1)  13  -20  2013/02肝細胞癌に対する分子標的治療:現状と問題点工藤正俊; 上嶋一臣  肝臓  54-  (Supplement 2)  2013ADAPTIVE-BEAMFORMER WITH ACCURATE INTENSITY-ESTIMATION TECHNIQUE FOR HIGH-RANGE-RESOLUTION VASCULAR ULTRASOUND IMAGINGHirofumi Taki; Takuya Sakamoto; Makoto Yamakawa; Tsuyoshi Shiina; Toru Sato; Kousuke Taki; Motoi Kudo  2013 IEEE INTERNATIONAL ULTRASONICS SYMPOSIUM (IUS)  797  -800  2013  [Refereed]WFUMB Guidelines and Recommendations on Clinical Use for Ultrasound Elastography –Basic Principles and Technology-M. Yamakawa; T. Shiina; K. R. Nightingale; T. J. Hall; J. C. Bamber; M. L. Palmeri; M. Kudo  Proceedings of the World Congress of Ultrasound in Medicine and Biology  101  2013  [Invited]当院におけるヘリコバクターピロリ除菌治療成績の検討足立哲平; 松井繁長; 樫田博史; 工藤正俊  日本消化管学会総会学術集会プログラム・抄録集  9th-  216  2013Novel Mouse Models of Hepatocarcinogenesis with Stepwise Accumulation of Genetic AlterationsSoo Ki Kim; Hiroyuki Marusawa; Yuji Eso; Tsutomu Chiba; Masatoshi Kudo  DIGESTIVE DISEASES  31-  (5-6)  454  -458  2013Early Hepatocellular Carcinoma: Definition and DiagnosisM. Kudo  LIVER CANCER  2-  (2)  69  -72  2013Usefulness of Contrast-Enhanced Ultrasonography to Evaluate the Post-Treatment Responses of Radiofrequency Ablation for Hepatocellular Carcinoma: Comparison with Dynamic CTTatsuo Inoue; Masatoshi Kudo; Kinuyo Hatanaka; Tadaaki Arizumi; Masahiro Takita; Satoshi Kitai; Norihisa Yada; Satoru Hagiwara; Yasunori Minami; Toshiharu Sakurai; Kazuomi Ueshima; Naoshi Nishida  ONCOLOGY  84-  51  -57  2013Consensus recommendations and review by an International Expert Panel on Interventions in Hepatocellular Carcinoma (EPOIHCC)Joong-Won Park; Deepak Amarapurkar; Yee Chao; Pei-Jer Chen; Jean-Francois H. Geschwind; Khean Lee Goh; Kwang-Hyub Han; Masatoshi Kudo; Han Chu Lee; Rheun-Chuan Lee; Laurentius A. Lesmana; Ho Yeong Lim; Seung Woon Paik; Ronnie T Poon; Chee-Kiat Tan; Tawesak Tanwandee; Gaojun Teng; Ann-Lii Cheng  Liver International  33-  (3)  327  -337  2013コンベックス走査式EUSによる描出法北野 雅之; 坂本 洋城; 工藤 正俊  消化器内視鏡プロフェッショナルの技-上級者へのステップアップのために-, 第83回日本消化器内視鏡学会総会記念出版  100  -104  2013Usefulness of Contrast-Enhanced Ultrasonography to Evaluate the Post-Treatment Responses of Radiofrequency Ablation for Hepatocellular Carcinoma: Comparison with Dynamic CTTatsuo Inoue; Masatoshi Kudo; Kinuyo Hatanaka; Tadaaki Arizumi; Masahiro Takita; Satoshi Kitai; Norihisa Yada; Satoru Hagiwara; Yasunori Minami; Toshiharu Sakurai; Kazuomi Ueshima; Naoshi Nishida  ONCOLOGY  84-  51  -57  2013Molecular Link between Liver Fibrosis and Hepatocellular CarcinomaToshiharu Sakurai; Masatoshi Kudo  LIVER CANCER  2-  (3-4)  365  -366  2013Hepatocellular Carcinoma in Child-Pugh C Cirrhosis: Prognostic Factors and Survival Benefit of Nontransplant TreatmentsMasatoshi Kudo; Yukio Osaki; Takashi Matsunaga; Hiroshi Kasugai; Hiroko Oka; Toshihito Seki  DIGESTIVE DISEASES  31-  (5-6)  490  -498  2013Radiofrequency Ablation for Hepatic Malignancies: Is Needle Tract Cauterization Necessary for Preventing Iatrogenic Bleeding?Yasunori Minanni; Sosuke Hayaishi; Masatoshi Kudo  DIGESTIVE DISEASES  31-  (5-6)  480  -484  2013CD34 Expression in Noncancerous Liver Tissue Predicts Multicentric Recurrence of Hepatocellular CarcinomaNaoko Tsuji; Shingo Ishiguro; Yo Sasaki; Masatoshi Kudo  DIGESTIVE DISEASES  31-  (5-6)  467  -471  2013Reactive oxygen species induce epigenetic instability through the formation of 8-hydroxydeoxyguanosine in human hepatocarcinogenesisNaoshi Nishida; Tadaaki Arizumi; Masahiro Takita; Satoshi Kitai; Norihisa Yada; Satoru Hagiwara; Tatsuo Inoue; Yasunori Minami; Kazuomi Ueshima; Toshiharu Sakurai; Masatoshi Kudo  Digestive Diseases  31-  (5-6)  459  -466  2013Hypothermia Protects against Fulminant Hepatitis in Mice by Reducing Reactive Oxygen Species ProductionToshiharu Sakurai; Masatoshi Kudo; Tomohiro Watanabe; Katsuhiko Itoh; Hiroaki Higashitsuji; Tadaaki Arizumi; Tatsuo Inoue; Satoru Hagiwara; Kazuomi Ueshima; Naoshi Nishida; Manabu Fukumoto; Jun Fujita  DIGESTIVE DISEASES  31-  (5-6)  440  -446  2013Outcome of Double-Filtration Plasmapheresis plus Interferon Treatment in Nonresponders to Pegylated Interferon plus Ribavirin Combination TherapyKayo Sugimoto; Soo Ryang Kim; Ahmed El-Shamy; Susumu Imoto; Haruma Fujioka; Ke Ih Kim; Yasuhito Tanaka; Yoshihiko Yano; Soo Ki Kim; Yutaka Hasegawa; Aya Fujinami; Mitsuhiro Ohta; Takashi Hatae; Hak Hotta; Yoshitake Hayashi; Masatoshi Kudo  DIGESTIVE DISEASES  31-  (5-6)  434  -439  2013Prediction of Response to Pegylated Interferon/Ribavirin Combination Therapy for Chronic Hepatitis C Genotypes 2a and 2b and High Viral LoadSoo Ryang Kim; Ahmed El-Shamy; Susumu Imoto; Ke Ih Kim; Kayo Sugimoto; Soo Ki Kim; Yasuhito Tanaka; Takashi Hatae; Yutaka Hasegawa; Aya Fujinami; Mitsuhiro Ohta; Hak Hotta; Masatoshi Kudo  DIGESTIVE DISEASES  31-  (5-6)  426  -433  2013Factors of Response to Pegylated Interferon/Ribavirin Combination Therapy and Mechanism of Viral ClearanceKayo Sugimoto; Soo Ryang Kim; Ahmed El-Shamy; Susumu Imoto; Kenji Ando; Ke Ih Kim; Yasuhito Tanaka; Yoshihiko Yano; Soo Ki Kim; Yutaka Hasegawa; Aya Fujinami; Mitsuhiro Ohta; Hatae Takashi; Hak Hotta; Yoshitake Hayashi; Masatoshi Kudo  DIGESTIVE DISEASES  31-  (5-6)  421  -425  2013Autoimmune Hepatitis and Immunoglobulin G4-Associated Autoimmune HepatitisNorihisa Yada; Masatoshi Kudo; Hobyung Chung; Tomohiro Watanabe  DIGESTIVE DISEASES  31-  (5-6)  415  -420  2013Clinical and Histological Features of Different Types of Budd-Chiari Syndrome: A Comparison of 4 CasesNaoshi Nishida; Shinichi Iwamura; Hiroshi Ida; Satoshi Hagiwara; Yoshinori Kagioka; Yasunori Minami; Yoji Maetani; Kyo Itoh; Masatoshi Kudo  DIGESTIVE DISEASES  31-  (5-6)  408  -414  2013Recent Advancements in Comprehensive Genetic Analyses for Human Hepatocellular CarcinomaNaoshi Nishida; Masatoshi Kudo  ONCOLOGY  84-  93  -97  2013Quantification of Tumor DNA in Serum and Vascular Invasion of Human Hepatocellular CarcinomaNaoshi Nishida; Tadaaki Arizumi; Masahiro Takita; Tonnoyuki Nagai; Satoshi Kitai; Norihisa Yada; Satoru Hagiwara; Tatsuo Inoue; Yasunori Minami; Kazuonni Ueshima; Toshiharu Sakurai; Hiroshi Ida; Masatoshi Kudo  ONCOLOGY  84-  82  -87  2013The Prognostic Value of Vascular Endothelial Growth Factor in Hepatocellular Carcinoma for Predicting Metastasis after Curative ResectionMutsuko Minata; Kouji H. Harada; Masatoshi Kudo; Iwao Ikai; Naoshi Nishida  ONCOLOGY  84-  (Suppl. 1)  75  -81  2013Therapeutic Response Assessment of Transcatheter Arterial Chemoembolization for Hepatocellular Carcinoma: Ultrasonography, CT and MR ImagingYasunori Minami; Masatoshi Kudo  ONCOLOGY  84-  58  -63  2013Role of Gadolinium-Ethoxybenzyl-Diethylenetriamine Pentaacetic Acid-Enhanced Magnetic Resonance Imaging in the Management of Hepatocellular Carcinoma: Consensus at the Symposium of the 48th Annual Meeting of the Liver Cancer Study Group of JapanMasatoshi Kudo; Osamu Matsui; Michiie Sakamoto; Azusa Kitao; Tonsok Kim; Shun-ichi Ariizumi; Tomoaki Ichikawa; Satoshi Kobayashi; Yasuharu Imai; Namiki Izumi; Yasunari Fujinaga; Shigeki Arii  ONCOLOGY  84-  21  -27  2013Novel Image Analysis Method Using Ultrasound Elastography for Noninvasive Evaluation of Hepatic Fibrosis in Patients with Chronic Hepatitis CKenji Fujimoto; Michio Kato; Masatoshi Kudo; Norihisa Yada; Tsuyoshi Shiina; Kazuomi Ueshima; Yukinori Yamada; Tetsushi Ishida; Masayoshi Azuma; Masaru Yamasaki; Keiji Yamamoto; Norio Hayashi; Tetsuo Takehara  ONCOLOGY  84-  3  -12  2013Advances in Liver Fibrosis Imaging and Hepatocellular Carcinoma: Update in 2013 PrefaceMasatoshi Kudo  ONCOLOGY  84-  1  -2  2013Radiofrequency ablation of liver metastases from colorectal cancer: A literature reviewYasunori Minami; Masatoshi Kudo  Gut and Liver  7-  (1)  1  -6  2013/01Guidelines and good clinical practice recommendations for contrast enhanced ultrasound (CEUS) in the liver - Update 2012M. Claudon; C. F. Dietrich; B. I. Choi; D. O. Cosgrove; M. Kudo; C. P. Nolsoe; F. Piscaglia; S. R. Wilson; R. G. Barr; M. C. Chammas; N. G. Chaubal; M. H. Chen; D. A. Clevert; J. M. Correas; H. Ding; F. Forsberg; J. B. Fowlkes; R. N. Gibson; B. B. Goldberg; N. Lassau; E. L.S. Leen; R. F. Mattrey; F. Moriyasu; L. Solbiati; H. P. Weskott; H. X. Xu  Ultraschall in der Medizin  34-  (1)  11  -29  2013膵腫瘍における体外式超音波検査の進歩. 特集「胆膵癌の早期診断フロントライン」大本 俊介; 北野 雅之; 前川 清; 工藤 正俊  肝胆膵  66-  307  -314  2013/01典型的露出腫瘤型十二指腸乳頭部癌. “とことん知りたいERCPの手技のコツ, もう迷わない!後方斜視鏡の挿入から, 乳頭の観察, 深部挿管まで”大本 俊介; 北野 雅之; 工藤 正俊  消化器内視鏡レクチャー  1-  587  -590  2013/01癌性疼痛に対する超音波内視鏡下腹腔神経叢ブロック. 特集「胆膵内視鏡新潮流」坂本 洋城; 北野 雅之; 今井 元; 鎌田 研; 宮田 剛; 門阪 薫平; 大本 俊介; 千品 寛和; 工藤 正俊  肝胆膵  66-  59  -64  2013/01Utility of EUS-guided gallbladder drainage for rescue treatment of malignant biliary obstructionHajime Imai; Masayuki Kitano; Kunpei Kadosaka; Ken Kamata; Takeshi Miyata; Hiroki Sakamoto; Masatoshi Kudo  JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY  27-  21  -21  2012/12A prospective feasibility study on EUS guided broad plexus neurolysis in combination with celiac ganglion neurolysisHiroki Sakamoto; Masayuki Kitano; Hajime Imai; Ken Kamata; Takesh Miyata; Kunpei Kadosaka; Masatoshi Kudo  JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY  27-  361  -362  2012/12Brivanib (BRI) versus Sorafenib (SOR) as First-line Therapy in Patients with Unresectable, Advanced Hepatocellular Carcinoma (HCC): Results from the Phase 3 BRISK-FL StudyPhillip Johnson; Shukui Qin; Joong-Won Park; Ronnie T. Poon; Jean-Luc Raoul; Philip A. Philip; Chih-Hung Hsu; Tsung-Hui Hu; Jeong Heo; Jianming Xu; Ligong Lu; Yee Chao; Eveline Boucher; Kwang-Hyub Han; Seung Woon Paik; Jorge Robles-Avina; Masatoshi Kudo; David Liu; Rana Ezzeddine; Ian Walters; Ann-Lii Cheng  HEPATOLOGY  56-  (6)  1519  -1520  2012/12Differential diagnosis of SMT and evaluation of malignant potential GISTs by contrast enhanced harmonic EUSHiroki Sakamoto; Masayuki Kitano; Hajime Imai; Ken Kamata; Takesh Miyata; Kunpei Kadosaka; Masatoshi Kudo  JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY  27-  55  -55  2012/12Trans-catheter endoscopy for pancreaticobiliary duct diseasesHiroki Sakamoto; Masayuki Kitano; Hajime Imai; Takesh Miyata; Ken Kamata; Kunpei Kadosaka; Masatoshi Kudo  JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY  27-  79  -79  2012/12A flare of hepatitis B in a patient with HBV-HCV co-infection during the combination therapy of pegylated interferon (PEG-IFN) α2a and ribavirinMIYATA Hiroshi; MIYATA Satoru; KUDO Masatoshi  Kanzo  53-  (12)  846  -852  2012/12編集後記. 特集「肝細胞癌のすべて2012」工藤 正俊  肝胆膵  65-  1384  -1384  2012/12分子標的治療. 特集「肝細胞癌のすべて2012」有住 忠晃; 工藤 正俊  肝胆膵  65-  1370  -1374  2012/12Axitinib. 特集「肝細胞癌のすべて2012」上嶋 一臣; 工藤 正俊  肝胆膵  65-  1307  -1310  2012/12Everolimus(RAD001). 特集「肝細胞癌のすべて2012」上嶋 一臣; 工藤 正俊  肝胆膵  65-  1302  -1306  2012/12肝細胞癌のステージングシステム. 特集「肝細胞癌のすべて2012」北井 聡; 工藤 正俊  肝胆膵  65-  1158  -1163  2012/12巻頭言. 特集「肝細胞癌のすべて2012」工藤 正俊  肝胆膵  65-  931  -934  2012/12Japan's successful model of nationwide hepatocellular carcinoma surveillance highlighting the urgent need for global surveillance.工藤 正俊  Liver Cancer  1-  141  -143  2012/12Septicemia due to Vibrio cholerae serogroup non-O1/non-O139 strain in a cirrhotic patientTatsuo Inoue; Satoshi Kitai; Sousuke Hayaishi; Masatoshi Kudo  Clinical Journal of Gastroenterology  5-  (6)  383  -387  2012/12超音波エラストグラフィによる肝線維化評価. 特集「びまん性肝疾患の画像診断: Update2012」矢田 典久; 工藤 正俊  臨床画像  28-  1470  -1477  2012/12Case of Peutz-Jeghers syndrome with depressed-type early duodenal carcinomaToshiharu Sakurai; Hiroshi Kashida; Masatoshi Kudo  DIGESTIVE ENDOSCOPY  24-  (6)  489  -489  2012/11肝腫瘍の診断・治療に挑む-次世代へのメッセージ. 特集「肝胆膵疾患に挑む-次世代へのメッセージ」工藤 正俊  肝胆膵画像  14-  (7)  578  -583  2012/11Sorafenib Deteriorates Liver Function in Patients with Advanced Hepatocellular Carcinoma: A Multi-center Retrospective Study in JapanHajime Sunagozaka; Shuichi Kaneko; Kenji Ikeda; Junji Furuse; Masatoshi Kudo  HEPATOLOGY  56-  448A  -449A  2012/10Surgical resection for lymph node metastasis from hepatocellular carcinoma: a report of the Japanese nationwide surveyKiyoshi Hasegawa; Masatoshi Makuuchi; Norihiro Kokudo; Namiki Izumi; Takafumi Ichida; Masatoshi Kudo; Yonson Ku; Michiie Sakamoto; Osamu Nakashima; Osamu Matsui; Yutaka Matsuyama  HEPATOLOGY  56-  489A  -489A  2012/10Observations of Hepatocellular Carcinoma (HCC) Management Patterns from the Global HCC BRIDGE Study: Global Comparison of Outcomes by Locoregional TherapyMyron Schwartz; Morris Sherman; Massimo Colombo; Lewis R. Roberts; Francoise Degos; Pei-Jer Chen; Minshan Chen; Joong-Won Park; Masatoshi Kudo; Phillip Johnson; Baisong Huang; Lucinda S. Orsini  HEPATOLOGY  56-  1095A  -1095A  2012/10Role of Hepatic Resection for Hepatocellular Carcinoma: Analysis of the HCC BRIDGE StudySasan Roayaie; Ghalib Jibara; Parissa Tabrizian; Joong-Won Park; Minshan Chen; Masatoshi Kudo; Lunan Yan; Guohong Han; Jijin Yang; Jean-Frederic Blanc; Phillip Johnson; Morris Sherman; Lewis R. Roberts; Myron E. Schwartz  HEPATOLOGY  56-  240A  -240A  2012/10Detection of Small Concomitant Carcinomas Distinct From Intraductal Papillary Mucinous Neoplasms Under the Surveillance of the Whole Pancreas Using EUSK. Kamata; M. Kitano; M. Kudo; H. Sakamoto; K. Kadosaka; T. Miyata; H. Imai; T. Komaki; K. Maekawa; T. Chikugo; M. Kumano; T. Hyodo; T. Murakami; Y. Takeyama  PANCREAS  41-  (7)  1143  -1143  2012/10Predicting the treatment efficacy of sorafenib in patients for hepatocellular carcinoma: a multi-center retrospective study in JapanTatsuya Yamashita; Shuichi Kaneko; Junji Furuse; Masatoshi Kudo; Kenji Ikeda  HEPATOLOGY  56-  468A  -469A  2012/10Efficacy and safety of miriplatin for hepatocellular carcinoma: a multi-center retrospective study in JapanKuniaki Arai; Shuichi Kaneko; Tatsuya Yamashita; Kenji Ikeda; Junji Furuse; Masatoshi Kudo  HEPATOLOGY  56-  454A  -455A  2012/10【胆膵内視鏡のビデオライブデモ2012】 マスターによるテクニックの解説とビデオライブデモ 超音波内視鏡下腹腔神経叢ブロック坂本 洋城; 北野 雅之; 今井 元; 鎌田 研; 宮田 剛; 門阪 薫平; 大本 俊介; 山田 光成; 工藤 正俊  胆と膵  33-  (臨増特大)  1069  -1074  2012/10腹部超音波検査. Ⅲ.消化管疾患の検査法井上 達夫; 工藤 正俊  日本医師会雑誌「消化器疾患診断のすべて」  141-  90  -93  2012/10胃潰瘍・十二指腸潰瘍. 特集「消化管疾患の病態と診断・治療(Ⅰ)」松井 繁長; 樫田 博史; 工藤 正俊  医学と薬学  68-  625  -630  2012/10当院における肝細胞癌分子標的治療の現状上嶋 一臣; 有住 忠晃; 早石 宗右; 田北 雅弘; 北井 聡; 矢田 典久; 井上 達夫; 萩原 智; 南 康範; 櫻井 俊治; 西田 直生志; 工藤 正俊  第6回日本肝がん分子標的治療研究会 記録 SORAFENIB PRACTICE BOOK: Sorafenib治療の実践!!多数症例の使用経験を踏まえた治療の実践と問題点の解決を示す  25  -30  2012/10発刊に寄せて工藤 正俊  第6回日本肝がん分子標的治療研究会 記録 SORAFENIB PRACTICE BOOK: Sorafenib治療の実践!!多数症例の使用経験を踏まえた治療の実践と問題点の解決を示す  2  -2  2012/10肝細胞癌の病型分類(肝癌取扱い規約)と予後予測(JISスコア)工藤 正俊  臨床に役立つ消化器疾患の診断基準・病型分類・重症度の用い方 改訂第2版  2-  215  -223  2012/10Transcatheter endoscopy for pancreaticobiliary duct diseasesHiroki Sakamoto; Masayuki Kitano; Ken Kamata; Takeshi Miyata; Kunpei Kadosaka; Hajime Imai; Yoshifumi Takeyama; Masatoshi Kudo  GASTROINTESTINAL ENDOSCOPY  76-  (4)  892  -899  2012/10Crohn’s病に対するadalimumabによる治療経験峯宏昌; 足立哲平; 大本俊介; 高山政樹; 永田嘉昭; 永井知行; 川崎正憲; 朝隈豊; 櫻井俊治; 松井繁長; 樫田博史; 工藤正俊  日本消化器病学会雑誌  109-  A827  2012/09当院における胃ESD症例での多発例の検討朝隈豊; 松井繁長; 足立哲平; 大本俊介; 高山政樹; 峯宏昌; 永井知行; 永田嘉昭; 川崎正憲; 櫻井俊治; 樫田博史; 工藤正俊  Gastroenterol Endosc  54-  (Supplement 2)  2880  2012/09プロトンポンプ阻害薬(PPI)内服中GERD患者に対するGerdQによる治療実態の検討大本俊介; 松井繁長; 足立哲平; 峯宏昌; 高山政樹; 永井知行; 永田嘉昭; 川崎正憲; 朝隈豊; 櫻井俊治; 樫田博史; 工藤正俊  Gastroenterol Endosc  54-  (Supplement 2)  2846  2012/09シングルバルーン小腸内視鏡検査(SBE)にて診断し得た小腸癌について高山政樹; 樫田博史; 足立哲平; 峯宏昌; 永田嘉昭; 永井知行; 川崎正憲; 朝隈豊; 櫻井俊治; 松井繁長; 工藤正俊; 竹山宜典; 筑後孝章  Gastroenterol Endosc  54-  (Supplement 2)  2971  2012/09高齢者に対する早期胃癌ESDについての検討永田嘉昭; 松井繁長; 足立哲平; 大本俊介; 峯宏昌; 高山政樹; 永井知行; 川崎正憲; 朝隈豊; 櫻井俊治; 樫田博史; 工藤正俊  Gastroenterol Endosc  54-  (Supplement 2)  2874  2012/09大腸ESD導入時の治療成績に関する検討足立哲平; 樫田博史; 大本俊介; 高山政樹; 峯宏昌; 永井知行; 永田嘉昭; 川崎正憲; 朝隈豊; 櫻井俊治; 松井繁長; 工藤正俊  Gastroenterol Endosc  54-  (Supplement 2)  2918  2012/09PHASE I/II TRIAL OF LENVATINIB (E7080), A MULTI-TARGETED TYROSINE KINASE INHIBITOR, IN PATIENTS (PTS) WITH ADVANCED HEPATOCELLULAR CARCINOMA (HCC)K. Ikeda; H. Kumada; M. Kudo; S. Kawazoe; Y. Osaki; M. Ikeda; T. Okusaka; T. Suzuki; J. P. O'Brien; K. Okita  ANNALS OF ONCOLOGY  23-  244  -244  2012/09Helicobacter pylori除菌前後の内視鏡所見の比較検討奥村 直己; 辻 直子; 工藤 正俊; 山本 典雄; 高場 雄久; 松本 望; 冨田 崇文; 森村 正嗣; 山田 哲; 米田 円; 南 康範; 丸山 康典; 河野 匡志; 梅原 康湖  Gastroenterological Endoscopy  54-  (Suppl.2)  2848  -2848  2012/09当院におけるH.pylori CAM耐性の年次変化(2001年〜2010年)河野 匡志; 辻 直子; 丸山 康典; 松本 望; 高場 雄久; 奥村 直己; 山本 典雄; 冨田 崇文; 梅原 康湖; 森村 正嗣; 米田 円; 山田 哲; 落合 健; 本庶 元; 南 康範; 工藤 正俊  Gastroenterological Endoscopy  54-  (Suppl.2)  2848  -2848  2012/09当院におけるH.pylori除菌の年次変化(2001年〜2010年)丸山 康典; 辻 直子; 河野 匡志; 松本 望; 高場 雄久; 奥村 直己; 山本 典雄; 冨田 崇文; 梅原 康湖; 森村 正嗣; 米田 円; 山田 哲; 落合 健; 本庶 元; 南 康範; 工藤 正俊  Gastroenterological Endoscopy  54-  (Suppl.2)  2849  -2849  2012/09腸管重複症に対しSBナイフJrを用いて内視鏡的隔壁切除を施行した1例宮部 欽生; 木下 大輔; 秦 康倫; 奥田 英之; 茂山 朋広; 清水 昌子; 岸谷 譲; 川崎 俊彦; 米倉 竹夫; 工藤 正俊  Gastroenterological Endoscopy  54-  (Suppl.2)  2922  -2922  2012/09経皮内視鏡的胃瘻造設術(PEG)の患者背景と早期合併症永井 知行; 大本 俊介; 高山 政樹; 峯 宏昌; 永田 嘉昭; 川崎 正憲; 朝隈 豊; 櫻井 俊治; 松井 繁長; 汐見 幹夫; 樫田 博史; 工藤 正俊  Gastroenterological Endoscopy  54-  (Suppl.2)  2899  -2899  2012/09消化器癌と酸化ストレス 肝発癌における酸化ストレスとエピゲノム変異西田 直生志; 工藤 正俊  肝臓  53-  (Suppl.2)  A604  -A604  2012/09消化器疾患と性差 肝癌の遺伝子変化および背景肝組織の男女差に関する検討西田 直生志; 工藤 正俊  肝臓  53-  (Suppl.2)  A654  -A654  2012/09肝嚢胞に対するオレイン酸モノエタノールアミン注入療法の検討田北 雅弘; 井上 達夫; 有住 忠晃; 早石 宗右; 北井 聡; 矢田 典久; 萩原 智; 南 康範; 上嶋 一臣; 西田 直生志; 工藤 正俊  肝臓  53-  (Suppl.2)  A697  -A697  2012/09肝細胞癌に対するラジオ波焼灼療法の治療効果判定における造影超音波検査の有用性の検討 造影CTとの比較井上 達夫; 有住 忠晃; 早石 宗右; 田北 雅弘; 北井 聡; 矢田 典久; 萩原 智; 南 康範; 上嶋 一臣; 西田 直生志; 工藤 正俊  肝臓  53-  (Suppl.2)  A724  -A724  2012/09転移性肝癌に対する肝動脈塞栓術とラジオ波焼灼術の併用療法の有用性南 康範; 有住 忠晃; 早石 宗右; 田北 雅弘; 北井 聡; 矢田 典久; 井上 達夫; 萩原 智; 上嶋 一臣; 西田 直生志; 工藤 正俊  日本消化器病学会雑誌  109-  (臨増大会)  A713  -A713  2012/09Characteristic patterns of altered DNA methylation predict emergence of human hepatocellular carcinomaNaoshi Nishida; Masatoshi Kudo; Takeshi Nagasaka; Iwao Ikai; Ajay Goel  HEPATOLOGY  56-  (3)  994  -1003  2012/09各臓器別の最新治療と新薬の動向: 肝細胞がん.上嶋 一臣; 工藤 正俊  抗がん剤治療の最前線: 分子標的薬剤の使用による進歩(後篇), 最新医学,  67-  2220  -2229  2012/09肝がん 2)肝がん化学療法に用いられるレジメン, ③ソラフェニブ単独療法上嶋 一臣; 工藤 正俊  別冊 臨床腫瘍プラクティスⅡ 消化器がん化学療法レジメン  104  -105  2012/09肝がん 2)肝がん化学療法に用いられるレジメン, ②ミリプラチン単独療法上嶋 一臣; 工藤 正俊  別冊 臨床腫瘍プラクティスⅡ 消化器がん化学療法レジメン  102  -103  2012/09肝がん 2)肝がん化学療法に用いられるレジメン, ①シスプラチン(CDDP)単独療法上嶋 一臣; 工藤 正俊  別冊 臨床腫瘍プラクティスⅡ 消化器がん化学療法レジメン  100  -101  2012/09肝がん 1)肝がん化学療法-レジメン選択の基本上嶋 一臣; 工藤 正俊  別冊 臨床腫瘍プラクティスⅡ 消化器がん化学療法レジメン  98  -99  2012/09C型慢性肝炎組織におけるDNAメチル化の出現と肝発癌におけるインパクト(Impact of DNA methylation alterations in chronic hepatitis C on emergence of human hepatocellular carcinoma)西田 直生志; 永坂 岳司; 西村 貴文; 工藤 正俊  日本癌学会総会記事  71回-  255  -255  2012/08Sensing of Commensal Organisms by the Intracellular Sensor NOD1 Mediates Experimental PancreatitisYoshihisa Tsuji; Tomohiro Watanabe; Masatoshi Kudo; Hidenori Arai; Warren Strober; Tsutomu Chiba  IMMUNITY  37-  (2)  326  -338  2012/08C型代償性肝硬変に対するペグインターフェロンα-2a(40KD)とリバビリン併用療法におけるALTおよびAFPに対する効果-臨床第Ⅱ/Ⅲ相試験サブ解析-泉 並木; 工藤 正俊; 西口修平; 金子周一; 佐田通夫; 小俣政男  新薬と 臨床  61-  (8)  1559  -1568  2012/08肝癌制圧への治療の開発状況上嶋 一臣; 工藤 正俊  ウイルス肝炎・肝癌制圧の分子基盤の各論, BIO Clinica  27-  (8)  38  -41  2012/08肝疾患診断と硬さ計測 (特集 超音波で硬さを測る : 超音波エラストグラフィを中心に)矢田 典久; 工藤 正俊  成人病と生活習慣病 : 日本成人病(生活習慣病)学会準機関誌  42-  (7)  805  -810  2012/07【膵管癌の危険因子と早期診断法】 膵癌の早期診断ストラテジー宮田 剛; 北野 雅之; 門阪 薫平; 鎌田 研; 今井 元; 坂本 洋城; 工藤 正俊  消化器内科  55-  (1)  124  -129  2012/07Mechanical Model Analysis for Quantitative Evaluation of Liver Fibrosis Based on Ultrasound Tissue Elasticity ImagingTsuyoshi Shiina; Tomonori Maki; Makoto Yamakawa; Tsuyoshi Mitake; Masatoshi Kudo; Kenji Fujimoto  JAPANESE JOURNAL OF APPLIED PHYSICS  51-  (7)  11  2012/07First interim analysis of the GIDEON (Global Investigation of therapeutic DEcisions in hepatocellular carcinoma and of its treatment with sorafeNib) non-interventional studyR. Lencioni; M. Kudo; S. L. Ye; J. P. Bronowicki; X. P. Chen; L. Dagher; J. Furuse; J. F. Geschwind; L. L. De Guevara; C. Papandreou; A. J. Sanyal; T. Takayama; S. K. Yoon; K. Nakajima; F. Cihon; S. Heldner; J. A. Marrero  International Journal of Clinical Practice  66-  (7)  675  -683  2012/07肝細胞癌の分子標的治療. 特集「肝細胞癌治療の現状と画像診断」上嶋 一臣; 工藤 正俊  画像診断  32-  (9)  930  -937  2012/07わが国での肝細胞癌治療の現状と問題点. 特集「肝細胞癌治療の現状と画像診断」上嶋 一臣; 工藤 正俊  画像診断  32-  (9)  874  -880  2012/07序説・肝細胞癌と鑑別を要する多血性腫瘤工藤 正俊; 井上 達夫  肝胆膵画像  14-  (5)  382  -385  2012/07Welcome to the first issue of Liver Cancer.工藤 正俊  Liver Cancer  1-  (1)  1  -1  2012/07腹部エコー検査と新たな画像診断矢田 典久; 工藤 正俊  medicina  49-  (7)  1150  -1154  2012/07進行肝細胞癌に対するソラフェニブ投与における投与後の腫瘍濃染の低下の有無と生存期間の検討有住 忠晃; 上嶋 一臣; 早石 宗右; 田北 雅弘; 北井 聡; 井上 達夫; 矢田 典久; 萩原 智; 南 康範; 櫻井 俊治; 西田 直生志; 工藤 正俊  The Liver Cancer Journal  4-  (2)  138  -139  2012/06p38MAPK suppresses chronic pancreatitis by regulating HSP27 and BAD expressionAh-Mee Park; Masatoshi Kudo; Satoru Hagiwara; Masaki Tabuchi; Tomohiro Watanabe; Hiroshi Munakata; Toshiharu Sakurai  FREE RADICAL BIOLOGY AND MEDICINE  52-  (11-12)  2284  -2291  2012/06Activation of JNK and high expression level of CD133 predict a poor response to sorafenib in hepatocellular carcinomaS. Hagiwara; M. Kudo; T. Nagai; T. Inoue; K. Ueshima; N. Nishida; T. Watanabe; T. Sakurai  BRITISH JOURNAL OF CANCER  106-  (12)  1997  -2003  2012/06Can the biliary enhancement of Gd-EOB-DTPA predict the degree of liver function?Masahiro Okada; Kazunari Ishii; Kazushi Numata; Tomoko Hyodo; Seishi Kumano; Masayuki Kitano; Masatoshi Kudo; Takamichi Murakami  HEPATOBILIARY & PANCREATIC DISEASES INTERNATIONAL  11-  (3)  307  -313  2012/06序説 早期肝細胞癌の画像診断update工藤 正俊  肝胆膵画像  14-  (4)  285  -288  2012/06肝細胞癌診療の新しいパラダイム工藤 正俊  岐阜県医師会医雑誌  25-  33  -41  2012/06肝細胞癌に対する分子標的治療―治療成績と新規分子標的薬の開発の動向―. 第1部 Overview 肝癌の診断・治療上嶋 一臣; 工藤 正俊  肝疾患Review 2012~2013  54  -63  2012/06肝疾患Review 2012~2013. 河田純男, 横須賀 収, 工藤正俊, 榎本信幸, 編集, 小俣政男, 監修工藤 正俊  2012/06Phase Ib dose-escalation study of a phase II randomized trial to assess the safety and tolerability of tigatuzumab (CS-1008) in combination with sorafenib in patients (pts) with advanced hepatocellular carcinoma (HCC)Ann-Lii Cheng; Yoon-Koo Kang; Baek-Yeol Ryoo; Chia-Jui Yen; Ho Yeong Lim; Do-Youn Oh; TaShara Austin; Qiang Wang; Jonathan Greenberg; Robert A. Beckman; Masatoshi Kudo  JOURNAL OF CLINICAL ONCOLOGY  30-  (15)  2012/05A prospective cohort study using a Japanese nationwide survey to evaluate the therapeutic effects of surgery and percutaneous ablation for hepatocellular carcinomaKiyoshi Hasegawa; Norihiro Kokudo; Masatoshi Makuuchi; Namiki Izumi; Takafumi Ichida; Masatoshi Kudo; Yonson Ku; Michiie Sakamoto; Osamu Nakashima; Osamu Matsui; Yutaka Matsuyama  JOURNAL OF CLINICAL ONCOLOGY  30-  (15)  2012/05Observations of hepatocellular carcinoma (HCC) management patterns from the global HCC bridge study: First characterization of the full study population.Joong-Won Park; Morris Sherman; Massimo Colombo; Lewis R. Roberts; Myron E. Schwartz; Francoise Degos; Pei-Jer Chen; Minshan Chen; Masatoshi Kudo; Philip James Johnson; Baisong Huang; Lucinda S. Orsini  JOURNAL OF CLINICAL ONCOLOGY  30-  (15)  2012/05The Decrease of Blood Flow After Administration of Sorafenib May Improve Overall Survival in Patients With Advanced Hepatocellular CarcinomaTadaaki Arizumi; Kazuomi Ueshima; Masatoshi Kudo  GASTROENTEROLOGY  142-  (5)  S979  -S979  2012/05RFAのための術前画像診断南 康範; 工藤 正俊  肝胆膵画像  14-  (3)  221  -224  2012/05Ramucirumab上嶋 一臣; 工藤 正俊  肝胆膵  64-  (5)  697  -700  2012/05Brivanib上嶋 一臣; 工藤 正俊  肝胆膵  64-  (5)  669  -675  2012/05噴門部静脈瘤合併巨木型食道静脈瘤の内視鏡的治療の工夫松井繁長; 朝隈豊; 工藤正俊  Gastroenterol Endosc  54-  (Supplement 1)  919  2012/04当院における表在型バレット食道腺癌に対する内視鏡的診断と治療の検討朝隈豊; 松井繁長; 足立哲平; 大本俊介; 高山政樹; 永田嘉昭; 川崎正憲; 櫻井俊治; 樫田博史; 工藤正俊  Gastroenterol Endosc  54-  (Supplement 1)  1240  2012/04十二指腸静脈瘤の臨床的特徴と治療指針松井繁長; 川崎正憲; 工藤正俊  Gastroenterological Endoscopy  54-  (Supplement 1)  1020  2012/04THE DECREASE OF BLOOD FLOW AFTER ADMINISTRATION OF SORAFENIB MAY IMPROVE OVERALL SURVIVAL IN PATIENTS WITH ADVANCED HEPATOCELLULAR CARCINOMAT. Arizumi; K. Ueshima; M. Kudo  JOURNAL OF HEPATOLOGY  56-  S273  -S273  2012/04Impact of TJP-1 and TWIST expression on post-operative prognosis in hepatocellular carcinomaTomoyuki Nagai; Tokuzo Arao; Kazuko Matsumoto; Kazuko Sakai; Kanae Kudo; Hiroyasu Kaneda; Daisuke Tamura; Keiichi Aomatsu; Hideharu Kimura; Yoshihiko Fujita; Satoru Hagiwara; Toshiharu Sakurai; Kazuomi Ueshima; Seiji Haji; Masatoshi Kudo; Kazuto Nishio  CANCER RESEARCH  72-  2012/04Detection of Small Concomitant Carcinomas Distinct From Intraductal Papillary Mucinous Neoplasms Under Surveillance of the Whole Pancreas Using EUSKen Kamata; Masayuki Kitano; Masatoshi Kudo; Hajime Imai; Hiroki Sakamoto  GASTROINTESTINAL ENDOSCOPY  75-  (4)  187  -188  2012/04Percutaneous Endoscopic Gastrostomy With Gastropexy Greatly Reduces the Risk of Peristomal Infection and Eases Pain After the OperationNaoki Okumura; Naoko Tsuji; Norio Yamamoto; Masatoshi Kudo  GASTROINTESTINAL ENDOSCOPY  75-  (4)  233  -233  2012/04A Prospective Feasibility Study on EUS Guided Broad Plexus in Combination of Celiac Ganglion Neurolysis in Pancreatic Cancer PainHiroki Sakamoto; Masayuki Kitano; Masatoshi Kudo  GASTROINTESTINAL ENDOSCOPY  75-  (4)  442  -442  2012/04GIDEON (GLOBAL INVESTIGATION OF THERAPEUTIC DECISIONS IN HEPATOCELLULAR CARCINOMA AND OF ITS TREATMENT WITH SORAFENIB) SECOND INTERIM ANALYSIS: CLINICAL FINDINGS IN CHILD-PUGH B SCORE SUBGROUPSJ. -P. Bronowicki; S. -L. Ye; M. Kudo; J. Marrero; L. Dagher; J. Furuse; J. F. Geschwind; L. Ladron de Guevara; C. Papandreou; A. J. Sanyal; T. Takayama; S. K. Yoon; K. Nakajima; R. Lencioni  JOURNAL OF HEPATOLOGY  56-  S48  -S49  2012/04IL28BとPEG-IFN/RBV併用療法をうけたHCVジェノタイプ1型高ウイルス量患者の効果との関連について田北 雅弘; 萩原 智; 有住 忠晃; 早石 宗右; 上田 泰輔; 北井 聡; 矢田 典久; 井上 達夫; 南 康範; 鄭 浩柄; 上嶋 一臣; 櫻井 俊治; 西田 直生志; 工藤 正俊  肝臓  53-  (Suppl.1)  A538  -A538  2012/04Endoscopic Ultrasound: Contrast EnhancementMasayuki Kitano; Hiroki Sakamoto; Masatoshi Kudo  Gastrointestinal Endoscopy Clinics of North America  22-  (2)  349  -358  2012/04Superselective transarterial chemoembolization for hepatocellular carcinoma. Validation of treatment algorithm proposed by Japanese guidelinesKenichi Takayasu; Shigeki Arii; Masatoshi Kudo; Takafumi Ichida; Osamu Matsui; Namiki Izumi; Yutaka Matsuyama; Michiie Sakamoto; Osamu Nakashima; Yonson Ku; Norihiro Kokudo; Masatoshi Makuuchi  JOURNAL OF HEPATOLOGY  56-  (4)  886  -892  2012/04プロトンポンプ阻害薬(PPI)内服中GERD患者に対するGerdQによる治療効果の評価大本俊介; 松井繁長; 足立哲平; 峯宏昌; 高山政樹; 永井知行; 永田嘉昭; 川崎正憲; 櫻井俊治; 樫田博史; 工藤正俊  日本消化器病学会雑誌  109-  A278  2012/03非上皮性肝悪性腫瘍の3例足立 哲平; 有住 忠晃; 早石 宗右; 田北 雅弘; 北井 聡; 矢田 典久; 井上 達夫; 萩原 智; 南 康範; 櫻井 俊治; 上嶋 一臣; 西田 直生志; 工藤 正俊  日本消化器病学会雑誌  109-  (臨増総会)  A294  -A294  2012/03【膵画像診断の最新動向】 膵疾患診断におけるUSの役割今井 元; 北野 雅之; 門阪 薫平; 宮田 剛; 鎌田 研; 坂本 洋城; 小牧 孝充; 工藤 正俊  肝胆膵画像  14-  (2)  106  -112  2012/03Involvement of activation of toll-like receptors and nucleotide-binding oligomerization domain-like receptors in enhanced IgG4 responses in autoimmune pancreatitisTomohiro Watanabe; Kouhei Yamashita; Saori Fujikawa; Toshiharu Sakurai; Masatoshi Kudo; Masahiro Shiokawa; Yuzo Kodama; Kazushige Uchida; Kazuichi Okazaki; Tsutomu Chiba  ARTHRITIS AND RHEUMATISM  64-  (3)  914  -924  2012/03Treatment response assessment of radiofrequency ablation for hepatocellular carcinoma: Usefulness of virtual CT sonography with magnetic navigationYasunori Minami; Satoshi Kitai; Masatoshi Kudo  EUROPEAN JOURNAL OF RADIOLOGY  81-  (3)  E277  -E280  2012/03機能的ゲノム解析から分子診断・分子標的治療へ ②シグナル伝達異常とバイオマーカー探索櫻井 俊治; 工藤 正俊  The Liver Cancer Journal The Liver Cancer Journal  4-  (1)  35  -39  2012/03シングルバルーン小腸内視鏡検査にて診断された小腸血管性病変の検討高山政樹; 川崎正憲; 大本俊介; 峯宏昌; 永田嘉昭; 永井知行; 朝隈豊; 櫻井俊治; 松井繁長; 樫田博史; 工藤正俊  栄養-評価と治療  29-  (1)  91  -92  2012/02Worldwide trends in locoregional therapy for hepatocellular carcinoma (HCC): Second interim analysis of the Global Investigation of Therapeutic Decisions in HCC and of Its Treatment with Sorafenib (GIDEON) studyJeff H. Geschwind; Riccardo Lencioni; Jorge A. Marrero; Alan Paul Venook; Sheng-Long Ye; Keiko Nakajima; Frank Cihon; Masatoshi Kudo  JOURNAL OF CLINICAL ONCOLOGY  30-  (4)  2012/02Phase I/II study of E7080 (lenvatinib), a multitargeted tyrosine kinase inhibitor, in patients (pts) with advanced hepatocellular carcinoma (HCC): Initial assessment of response rate.Kiwamu Okita; Hiromitsu Kumada; Kenji Ikeda; Masatoshi Kudo; Seiji Kawazoe; Yukio Osaki; Masafumi Ikeda; Toshiyuki Tamai  JOURNAL OF CLINICAL ONCOLOGY  30-  (4)  2012/02Second interim analysis of the Global Investigation of Therapeutic Decisions in Unresectable HCC (uHCC) and of Its Treatment with Sorafenib (GIDEON): Differences in AE reporting across physician specialtiesAlan Paul Venook; Riccardo Lencioni; Jorge A. Marrero; Masatoshi Kudo; Keiko Nakajima; Sheng-Long Ye; Frank Cihon  JOURNAL OF CLINICAL ONCOLOGY  30-  (4)  2012/02Transcatheter arterial chemoembolization or chemoinfusion for hepatocellular carcinoma南 康範; 上嶋 一臣; 工藤 正俊  外科  74-  (2)  178  -182  2012/02Plasma Concentrations of Angiogenesis-related Molecules in Patients with Pancreatic CancerHiroki Sakamoto; Hideharu Kimura; Masaru Sekijima; Kazuko Matsumoto; Tokuzo Arao; Takaaki Chikugo; Yasuhide Yamada; Masayuki Kitano; Akihiko Ito; Yoshifumi Takeyama; Masatoshi Kudo; Kazuto Nishio  JAPANESE JOURNAL OF CLINICAL ONCOLOGY  42-  (2)  105  -112  2012/02Characterization of Small Solid Tumors in the Pancreas: The Value of Contrast-Enhanced Harmonic Endoscopic UltrasonographyMasayuki Kitano; Masatoshi Kudo; Kenji Yamao; Tadayuki Takagi; Hiroki Sakamoto; Takamitsu Komaki; Ken Kamata; Hajime Imai; Yasutaka Chiba; Masahiro Okada; Takamichi Murakami; Yoshifumi Takeyama  AMERICAN JOURNAL OF GASTROENTEROLOGY  107-  (2)  303  -310  2012/02Plasma Concentrations of Angiogenesis-related Molecules in Patients with Pancreatic CancerHiroki Sakamoto; Hideharu Kimura; Masaru Sekijima; Kazuko Matsumoto; Tokuzo Arao; Takaaki Chikugo; Yasuhide Yamada; Masayuki Kitano; Akihiko Ito; Yoshifumi Takeyama; Masatoshi Kudo; Kazuto Nishio  JAPANESE JOURNAL OF CLINICAL ONCOLOGY  42-  (2)  105  -112  2012/02肝細胞癌update2012 3.最新の肝動脈塞栓療法南康範; 上嶋一臣; 工藤正俊  外科  74-  (2)  2012ソラフェニブの上皮間葉移行阻害効果永井知行; 永井知行; 木村英晴; 荒尾徳三; 松本和子; 藤田至彦; 吉田修平; 林秀敏; 工藤正俊; 西尾和人  日本臨床腫瘍学会学術集会プログラム・抄録集  10th-  2012Closing remarksMasatoshi Kudo  Clinical Drug Investigation  32-  (2)  52  2012シングルバルーン小腸内視鏡検査にて診断された小腸血管性病変の検討高山政樹; 川崎正憲; 峯宏昌; 永田嘉昭; 永井知行; 朝隈豊; 櫻井俊治; 松井繁長; 樫田博史; 工藤正俊  日本消化管学会総会学術集会プログラム・抄録集  8th-  281  2012Hypovascular Nodules in Chronic Liver Disease: Risk Factors for Developing Hypervascular Hepatocellular Carcinoma.村上 卓道; 兵頭 朋子; 岡田 真広; 香川 祐毅; 工藤 正俊; 今井 康陽; 堀 雅敏; 小来田 幸世; 熊野 正士; 望月 輝一  Radiology  2012Treatment of Advanced Hepatocellular Carcinoma with Emphasis on Hepatic Arterial Infusion Chemotherapy and Molecular Targeted TherapyMasatoshi Kudo  LIVER CANCER  1-  (2)  62  -70  2012Why Does Every Hepatocellular Carcinoma Clinical Trial Using Molecular Targeted Agents Fail?M. Kudo  LIVER CANCER  1-  (2)  59  -60  2012Closing remarks.工藤 正俊  Clin Drug Invest  32-  52  2012EUS下胆嚢ドレナージ門阪薫平; 北野雅之; 鎌田研; 宮田剛; 今井元; 坂本 洋城; 樫田博史; 工藤 正俊  消化器内視鏡  24-  (3)  351  -355  2012Well-differentiated Hepatocellular Carcinoma Detected as Hypovascularity by Only CT during Hepatic ArteriographyJun Saito; Soo Ryang Kim; Masatoshi Kudo; Susumu Imoto; Kenji Ando; Taisuke Nakajima; Katsumi Fukuda; Yumi Otono; Soo Ki Kim; Takamitsu Komaki; Hirohisa Yano; Osamu Nakashima; Kayo Sugimoto; Toshiyuki Matsuoka  INTERNAL MEDICINE  51-  (8)  885  -890  2012Recommendations for liver transplantation for hepatocellular carcinoma: an international consensus conference report.CLAVIEN PA  Lancet Oncol  13-  (1)  e11  -22  2012内視鏡的胆嚢ドレナージ術. 特集: 胆道・膵のドレナージとステント鎌田 研; 北野 雅之; 坂本 洋城; 今井 元; 宮田 剛; 門阪 薫平; 工藤 正俊  臨牀消化器内科  27-  (4)  445  -452  2012肝細胞癌に対する造影超音波検査とDynamic CT, MRIとの比較. 腹部超音波検査up-to-date井上 達夫; 工藤 正俊  臨牀消化器内科  26-  (9)  1241  -1248  2012肝癌に対する抗血管新生療法. 特集: 癌の抗血管新生療法上嶋 一臣; 工藤 正俊  血管医学-Vascular Biology & Medicine-  13-  (1)  51  -57  2012消化器癌の見逃しを防ぐ-早期発見・適切な治療のための診断の実際 胆道癌・膵臓癌. 見逃してはいけない消化器疾患-消化器緊急疾患・消化器癌を中心に-坂本 洋城; 北野 雅之; 今井 元; 宮田 剛; 鎌田 研; 門阪 薫平; 工藤 正俊  消化器の臨床  15-  (1)  82  -88  2012プロトンポンプ阻害薬投与患者におけるGerdQ問診票を使用した治療実態の検討.大本 俊介; 松井 繁長; 櫻井 俊治; 朝隈 豊; 川崎 正憲; 樫田 博史; 工藤 正俊  Pharma Medica Pharma Medica  30-  (2)  77  -81  2012わが国の肝炎・肝癌対策について. Workshop「肝炎・肝癌対策との比較で胃炎・胃癌対策を考える」工藤 正俊  The GI FOREFRONT The GI FOREFRONT  7-  (2)  103  -106  2012異所性静脈瘤に対する内視鏡治療.松井 繁長; 樫田 博史; 朝隈 豊; 川崎 正憲; 櫻井 俊治; 工藤 正俊  臨牀消化器内科  27-  (2)  181  -189  2012肝細胞癌のリスク因子とサーベイランスの影響. “Factors that affect risk for hepatocellular carcinoma effects of surveillance”,南 康範; 工藤 正俊  Review of Gastroenterology & Clinical Gastroenterology and Hepatology Review of Gastroenterology & Clinical Gastroenterology and Hepatology  6-  (4)  64  -67  2012Real-Life Clinical Practice with Sorafenib in Advanced Hepatocellular Carcinoma: A Single-Center ExperienceMasatoshi Kudo; Kazuomi Ueshima; Tadaaki Arizumi  DIGESTIVE DISEASES  30-  (6)  609  -616  2012Novel Non-Trocar Technique for Laparoscopic Radiofrequency AblationShinobu Tsuchida; Takumi Fukumoto; Akihiro Toyokawa; Masahide Awazu; Nobuya Kusunoki; Masahiro Kido; Masanori Takahashi; Motofumi Tanaka; Kaori Kuramitsu; Soo Ryang Kim; Yonson Ku; Masatoshi Kudo  DIGESTIVE DISEASES  30-  (6)  588  -591  2012Histopathological Diagnosis of Early HCC through Biopsy: Efficacy of Victoria Blue and Cytokeratin 7 StainingSawako Kobayashi; Soo Ryang Kim; Susumu Imoto; Kenji Ando; Makoto Hirakawa; Jun Saito; Katsumi Fukuda; Yumi Otono; Madoka Sakaki; Shinobu Tsuchida; Soo Ki Kim; Yoshitake Hayashi; Masayuki Nakano; Masatoshi Kudo  DIGESTIVE DISEASES  30-  (6)  574  -579  2012Risk of Hepatocellular Carcinoma Development in Cases of Hepatitis C Treated by Long-Term, Low-Dose PEG-IFN alpha-2aSatoru Hagiwara; Toshiharu Sakurai; Masahiro Takita; Kazuomi Ueshima; Yasunori Minami; Tatsuo Inoue; Norihisa Yada; Satoshi Kitai; Tomoyuki Nagai; Sousuke Hayaishi; Tadaaki Arizumi; Naoshi Nishida; Masatoshi Kudo  DIGESTIVE DISEASES  30-  (6)  561  -567  2012Retreatment with Peginterferon alpha-2a+Ribavirin in Patients Who Failed Previous Peginterferon alpha-2b+Ribavirin Combination TherapyTaisuke Ued; Kaoru Tsuchiya; Satoru Hashimot; Taisuke Inoue; Nobuyuki Enomoto; Mie Inao; Atsushi Tanaka; Masahiko Kaito; Fumio Imazeki; Shuhei Nishiguchi; Satoshi Mochida; Osamu Yokosuka; Hiroshi Yatsuhashi; Namiki Izumi; Masatoshi Kudo  DIGESTIVE DISEASES  30-  (6)  554  -560  2012Gender Differences in the Livers of Patients with Hepatocellular Carcinoma and Chronic Hepatitis C InfectionNaoshi Nishida; Tadaaki Arizumi; Sosuke Hayaishi; Masahiro Takita; Satoshi Kitai; Norihisa Yada; Satoru Hagiwara; Tatsuo Inoue; Yasunori Minami; Kazuomi Ueshima; Toshiharu Sakurai; Iwao Ikai; Masatoshi Kudo  DIGESTIVE DISEASES  30-  (6)  547  -553  2012Characteristic Pattern of Reactivation of Hepatitis B Virus during Chemotherapy for Solid CancersSatoru Hagiwara; Toshiharu Sakurai; Shinichi Nishina; Kaoru Tanaka; Masafumi Ikeda; Kazuomi Ueshima; Yasunori Minami; Tatsuo Inoue; Norihisa Yada; Satoshi Kitai; Masahiro Takita; Tomoyuki Nagai; Sousuke Hayaishi; Tadaaki Arizumi; Ah-Mee Park; Hiroshi Munakata; Naoshi Nishida; Masatoshi Kudo  DIGESTIVE DISEASES  30-  (6)  541  -546  2012PrefaceKouichi Hagino; Naoyuki Itagaki; Yoshiko Kanada-Enyo; Masayuki Matsuo; Takashi Nakatsukasa; Masayuki Yamagami  Progress of Theoretical Physics Supplement  30-  (196)  539  -540  2012Treatment of advanced hepatocellular carcinomaKUDO Masatoshi  Nippon Shokakibyo Gakkai Zasshi  109-  (8)  1327  -1334  2012A flare of hepatitis B in a patient with HBV-HCV co-infection during the combination therapy of pegylated interferon (PEG-IFN) α2a and ribavirinMiyata Hiroshi; Miyata Satoru; Kudo Masatoshi  Kanzo  53-  (12)  846  -852  2012Demonstration of quality of care measurement using the Japanese liver cancer registryTakahiro Higashi; Kiyoshi Hasegawa; Norihiro Kokudo; Masatoshi Makuuchi; Namiki Izumi; Takafumi Ichida; Masatoshi Kudo; Yonson Ku; Michiie Sakamoto; Osamu Nakashima; Osamu Matsui; Yutaka Matsuyama; Tomotaka Sobue  HEPATOLOGY RESEARCH  41-  (12)  1208  -1215  2011/12Review of dynamic contrast-enhanced ultrasound guidance in ablation therapy for hepatocellular carcinomaYasunori Minami; Masatoshi Kudo  WORLD JOURNAL OF GASTROENTEROLOGY  17-  (45)  4952  -4959  2011/12Diagnostic imaging of hepatocellular carcinoma: Recent progressMasatoshi Kudo  Oncology  81-  (1)  73  -85  2011/12Adjuvant therapy after curative treatment for hepatocellular carcinomaMasatoshi Kudo  Oncology  81-  (1)  50  -55  2011/122Pa5-4 Analysis of Elasticity Image of Chronic Hepatitis Based on Dynamic Model of Fibrosis Progression(Poster Session)Maki Tomonori; Shiina Tsuyoshi; Yamakawa Makoto; Mitake Tsuyoshi; Kudo Masatoshi; Fujimoto Kenji  Proceedings of Symposium on Ultrasonic Electronics  32-  (32)  141  -142  2011/11Identifying and prioritizing strategies for comprehensive liver cancer control in AsiaJohn F. P. Bridges; Gisselle Gallego; Masatoshi Kudo; Kiwamu Okita; Kwang-Hyub Han; Sheng-Long Ye; Barri M. Blauvelt  BMC HEALTH SERVICES RESEARCH  11-  298  2011/11SECOND INTERIM ANALYSIS OF GIDEON (GLOBAL INVESTIGATION OF THERAPEUTIC DECISIONS IN UNRESECTABLE HCC [UHCC] AND OF ITS TREATMENT WITH SORAFENIB): MULTIREGIONAL VARIATION IN PATIENT (PT) CHARACTERISTICS, PREVIOUS TREATMENT HISTORY, AND SORAFENIB (SOR) USEMasatoshi Kudo; Sheng-Long Ye; Alan Venook; Jorge A. Marrero; Keiko Nakajima; Frank Cihon; Riccardo Lencioni  HEPATOLOGY  54-  1385A  -1385A  2011/10PHASE I STUDY OF SORAFENIB IN COMBINATION WITH LOW-DOSE CISPLATIN AND FLUOROURACIL INTRA-ARTERIAL INFUSION CHEMOTHERAPYKazuomi Ueshima; Masatoshi Kudo; Masatoshi Tanaka; Takashi Kumada; Hobyung Chung; Satoru Hagiwara; Tatsuo Inoue; Norihisa Yada; Yasunori Minami; Toshiharu Sakurai  HEPATOLOGY  54-  1402A  -1403A  2011/10DRASTIC IMPROVEMENT OF SURVIVAL IN PATIENTS WITH HEPATOCELLULAR CARCINOMA OVER 30 YEARS IN JAPAN: ANALYSIS OF NATIONWIDE PROSPECTIVE REGISTRY OF 148,161 PATIENTSMasatoshi Kudo; Namiki Izumi; Michiie Sakamoto; Yutaka Matsuyama; Takafumi Ichida; Osamu Nakashima; Osamu Matsui; Yonson Ku; Norihiro Kokudo; Masatoshi Makuuchi  HEPATOLOGY  54-  494A  -495A  2011/10OUTCOMES OF PLANNED MULTIMODALITY THERAPY FOR UNRESECTABLE, UNTRANSPLANTABLE HEPATOCELLULAR CARCINOMAShuichi Kaneko; Junji Furuse; Masatoshi Kudo; Kenji Ikeda  HEPATOLOGY  54-  1403A  -1404A  2011/10SECOND INTERIM ANALYSIS OF GIDEON (GLOBAL INVESTIGATION OF THERAPEUTIC DECISIONS IN UNRESECTABLE HEPATOCELLULAR CARCINOMA [UHCC] AND OF ITS TREATMENT WITH SORAFENIB): SUBGROUP ANALYSIS BY INITIAL SORAFENIB (SOR) DOSEJorge A. Marrero; Alan Venook; Masatoshi Kudo; Sheng-Long Ye; Keiko Nakajima; Frank Cihon; Riccardo Lencioni  HEPATOLOGY  54-  1389A  -1389A  2011/10EFFICACY AND SAFETY OF SORAFENIB FOR HEPATOCELLULAR CARCINOMA: A MULTI-CENTER RETROSPECTIVE STUDY IN JAPANShuichi Kaneko; Junji Furuse; Masatoshi Kudo; Kenji Ikeda  HEPATOLOGY  54-  1403A  -1403A  2011/10ASSESSMENT OF HEPATOBILIARY PHASE GD-EOB-DTPA-ENHANCED MRI FOR HCC AND DYSPLASTIC NODULES AND COMPARISON OF DETECTION ABILITY VERSUS MDCTTatsuo Inoue; Masatoshi Kudo; Arizumi Tadaaki; Sousuke Hayaishi; Masahiro Takita; Satoshi Kitai; Norihisa Yada; Satoru Hagiwara; Yasunori Minami; Kazuomi Ueshima; Masahiro Okada; Hyodo Tomoko; Takamichi Murakami  HEPATOLOGY  54-  899A  -899A  2011/10Endoscopic ultrasonography (EUS)-guided biliary drainage for treatment of biliary obstructionH. Imai; M. Kitano; K. Kamata; K. Kadosaka; T. Miyata; H. Sakamoto; T. Komaki; M. Kudo  JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY  26-  35  -36  2011/10USEFULLNESS OF CONTRAST-ENHANCED ULTRASONOGRAPHY TO EVALUATE A POST TREATMENT EFFECT OF RADIOFREQUENTRY ABLATION ABOUT HEPATOCELLULAR CARCINOMA; COMPARION WITH MULTIDETECTOR ROW CTTatsuo Inoue; Masatoshi Kudo; Kinuyo Hatanaka; Yasunori Minami; Kazuomi Ueshima; Arizumi Tadaaki; Masahiro Takita; Satoshi Kitai  HEPATOLOGY  54-  902A  -902A  2011/10ABSTRACT NON-LIVER TRANSPLANTATION TREATMENT FOR HEPATOCELLULAR CARCINOMA WITHIN THE MILAN CRITERIA IN CHILD-PUGH SCORE 10-11 CIRRHOTIC PATIENTS HAS A SURVIVAL BENEFITSatoshi Kitai; Masatoshi Kudo; Namiki Izumi; Michiie Sakamoto; Yutaka Matsuyama; Takafumi Ichida; Osamu Nakashima; Osamu Matsui; Yonson Ku; Norihiro Kokudo; Masatoshi Makuuchi  HEPATOLOGY  54-  1384A  -1384A  2011/10Phenotype-dependent production of des-gamma-carboxy prothrombin in hepatocellular carcinomaHideto Suzuki; Kazumoto Murata; Takaya Gotoh; Masao Kusano; Hiroshi Okano; Takashi Oyamada; Yoshikazu Yasuda; Masatoshi Imamura; Masatoshi Kudo; Masashi Mizokami; Atsushi Sakamoto  JOURNAL OF GASTROENTEROLOGY  46-  (10)  1219  -1229  2011/10Tissue Biomarkers as Predictors of Outcome and Selection of Transplant Candidates With Hepatocellular CarcinomaJosep M. Llovet; Valerie Paradis; Masatoshi Kudo; Jessica Zucman-Rossi  LIVER TRANSPLANTATION  17-  S67  -S71  2011/10Correlation between hyporesponsiveness to Toll-like receptor ligands and liver dysfunction in patients with chronic hepatitis C virus infectionH. Chung; T. Watanabe; M. Kudo; T. Chiba  JOURNAL OF VIRAL HEPATITIS  18-  (10)  E561  -E567  2011/10ステロイド依存性の潰瘍性大腸炎に対する白血球除去療法の有用性と問題点の検討峯宏昌; 櫻井俊治; 高山政樹; 永井知行; 永田嘉昭; 川崎正憲; 朝隈豊; 松井繁長; 樫田博史; 工藤正俊  日本消化器病学会雑誌  108-  A862  2011/09シングルバルーン小腸内視鏡の有用性について川崎正憲; 峯宏昌; 永田嘉昭; 朝隈豊; 櫻井俊治; 松井繁長; 樫田博史; 工藤正俊  Gastroenterol Endosc  53-  (Supplement 2)  2713  2011/09Barrett食道に発生した表在未分化癌の一例朝隈豊; 松井繁長; 峯宏昌; 永田嘉昭; 川崎正憲; 櫻井俊治; 樫田博史; 工藤正俊  Gastroenterol Endosc  53-  (Supplement 2)  2604  2011/09難治性食道カンジタ症に合併した食道乳頭腫の1例永田嘉昭; 松井繁長; 峯宏昌; 高山政樹; 永井知行; 川崎正憲; 朝隈豊; 櫻井俊治; 樫田博史; 工藤正俊  Gastroenterol Endosc  53-  (Supplement 2)  2610  2011/09Second Interim Results of the GIDEON (Global Investigation of Therapeutic DEcisions in HCC and of Its Treatment With SorafeNib) Study - Barcelona-Clinic Liver Cancer (BCLC) Stage Subgroup AnalysisR. Lencioni; A. P. Venook; J. A. Marrero; M. Kudo; S. L. Ye; K. Nakajima; F. Cihon  EUROPEAN JOURNAL OF CANCER  47-  S441  -S442  2011/09肝細胞癌におけるTJP-1とTwist発現の肝癌切除後の予後への影響(Impact of TJP-1 and TWIST expression on post-operative prognosis in hepatocellular carcinoma)永井 知行; 荒尾 徳三; 松本 和子; 工藤 可苗; 木村 英晴; 藤田 至彦; 萩原 智; 櫻井 俊治; 上嶋 一臣; 土師 誠二; 工藤 正俊; 西尾 和人  日本癌学会総会記事  70回-  368  -368  2011/09Phase III study of sorafenib after transarterial chemoembolisation in Japanese and Korean patients with unresectable hepatocellular carcinomaMasatoshi Kudo; Kazuho Imanaka; Nobuyuki Chida; Kohei Nakachi; Won-Young Tak; Tadatoshi Takayama; Jung-Hwan Yoon; Takeshi Hori; Hiromitsu Kumada; Norio Hayashi; Shuichi Kaneko; Hirohito Tsubouchi; Dong Jin Suh; Junji Furuse; Takuji Okusaka; Katsuaki Tanaka; Osamu Matsui; Michihiko Wada; Iku Yamaguchi; Toshio Ohya; Gerold Meinhardt; Kiwamu Okita  EUROPEAN JOURNAL OF CANCER  47-  (14)  2117  -2127  2011/09Recent Advances in the Management of Chronic Hepatitis BSoo Ryang Kim; Jisin Yang; Masatoshi Kudo; Okio Hino  HEPATITIS MONTHLY  11-  (8)  601  -611  2011/08肝がんに対する新規抗がん剤使用に関する指針 2010年度版 平成22年度厚生労働科学研究費補助金(肝炎等克服緊急対策研究事業)金子 周一; 古瀬 純司; 工藤 正俊; 池田 健次; 本多 政夫; 中本 安成; 恩地 森一; 汐田 剛史; 横須賀 收; 坂井田 功; 竹原 徹郎; 上野 義之; 廣石 和正; 西口 修平; 森脇 久隆; 山本 和秀; 佐田 通夫; 小尾 俊太郎; 宮山 士朗; 今井 幸紀; 新規抗がん剤使用ガイド作成委員会  肝臓  52-  (8)  532  -551  2011/08Effect of Vitamin K2 on the Recurrence of Hepatocellular CarcinomaHaruhiko Yoshida; Yasushi Shiratori; Masatoshi Kudo; Shuichiro Shiina; Toshihiko Mizuta; Masamichi Kojiro; Kyosuke Yamamoto; Yukihiro Koike; Kenichi Saito; Nozomu Koyanagi; Takao Kawabe; Seiji Kawazoe; Haruhiko Kobashi; Hiroshi Kasugai; Yukio Osaki; Yasuyuki Araki; Namiki Izumi; Hiroko Oka; Kunihiko Tsuji; Joji Toyota; Toshihito Seki; Toshiya Osawa; Naohiko Masaki; Masao Ichinose; Masataka Seike; Akihisa Ishikawa; Yoshiyuki Ueno; Kazumi Tagawa; Ryoko Kuromatsu; Shotaro Sakisaka; Hiroshi Ikeda; Hidekatsu Kuroda; Hiroyuki Kokuryu; Tatsuya Yamashita; Isao Sakaida; Tetsuo Katamoto; Kentaro Kikuchi; Minoru Nomoto; Masao Omata  HEPATOLOGY  54-  (2)  532  -540  2011/08【胆道・膵疾患の画像診断】 膵疾患 膵嚢胞性疾患(MCN・SCN・SPN)小牧 孝充; 北野 雅之; 坂本 洋城; 今井 元; 鎌田 研; 宮田 剛; 門阪 薫平; 工藤 正俊  消化器外科  34-  (8)  1223  -1230  2011/07消化器外科周術期における栄養療法の進歩 肝細胞癌外科治療における術前分岐鎖アミノ酸経口投与の意義と癌細胞シグナル伝達制御土師 誠二; 中多 靖幸; 石川 原; 安田 武生; 竹山 宜典; 荒尾 徳三; 西尾 和人; 工藤 正俊; 大柳 治正  日本消化器外科学会総会  66回-  265  -265  2011/07Endoscopic Characteristics of Colorectal Serrated LesionsHiroshi Kashida; Nobunao Ikehara; Shigeharu Hamatani; Shin-ei Kudo; Masatoshi Kudo  HEPATO-GASTROENTEROLOGY  58-  (109)  1163  -1167  2011/07新規血管新生阻害薬BIBF1120の肝細胞癌に対する有用性評価と薬力学的バイオマーカーの開発工藤 可苗; 荒尾 徳三; 永井 知行; 工藤 正俊; 西尾 和人  The Liver Cancer Journal  3-  (2)  154  -155  2011/06Phase I study of sorafenib in combination with low-dose cisplatin and fluorouracil intra-arterial infusion chemotherapy.K. Ueshima; M. Kudo; M. Tanaka; T. Kumada; T. Sakurai; H. Chung; S. Hagiwara; Y. Minami; T. Inoue; N. Yada; S. Kitai; M. Takita; S. Hayaishi  JOURNAL OF CLINICAL ONCOLOGY  29-  (15)  2011/05Assessment of Hepatobilliary Phase Gd-EOB-DTPA-Enhanced MRI for HCC and Borderline Lesions and Comparison of Detection Ability Versus MDCTTatsuo Inoue; Masatoshi Kudo; Mina Komuta; Michiie Sakamoto; Masahiro Okada; Takamichi Murakami  GASTROENTEROLOGY  140-  (5)  S920  -S920  2011/05Peginterferon ALPHA-2A (40KD) Plus Ribavirin for the Treatment of Patients With Chronic Hepatitis C (CHC) and Compensated Liver Cirrhosis in JapanNamiki Izumi; Shuichi Kaneko; Shuhei Nishiguchi; Masatoshi Kudo; Michio Sata; Masao Omata  GASTROENTEROLOGY  140-  (5)  S950  -S950  2011/05NEW TECHNIQUES AND FUTURE PERSPECTIVE OF EUS FOR THE DIFFERENTIAL DIAGNOSIS OF PANCREATIC MALIGNANCIES: CONTRAST HARMONIC IMAGINGMasayuki Kitano; Hiroki Sakamoto; Takamitsu Komaki; Masatoshi Kudo  DIGESTIVE ENDOSCOPY  23-  46  -50  2011/05Serum concentrations of angiogenesis-related molecules in patients with pancreatic cancerHideharu Kimura; Hiroki Sakamoto; Tomoyuki Nagai; Kanae Kudo; Kazuyuki Furuta; Tokuzo Arao; Masayuki Kitano; Masatoshi Kudo; Kazuto Nishio  CANCER RESEARCH  71-  2011/04Expression levels of EMT-related genes in hepatocellular carcinomaTomoyuki Nagai; Tokuzo Arao; Kazuko Matsumoto; Kanae Kudo; Satoru Hagiwara; Toshiharu Sakurai; Kazuomi Ueshima; Seiji Haji; Masatoshi Kudo; Kazuto Nishio  CANCER RESEARCH  71-  2011/04かかりつけ医から専門医への質問 ネクサバール(ソラフェニブ)について教えてください (患者・家族の相談に応える がん診療サポートガイド) -- (肝がん)上嶋 一臣; 工藤 正俊  治療  93-  (0)  890  -893  2011/04Recurrence-free survival more than 10 years after liver resection for hepatocellular carcinomaS. Eguchi; T. Kanematsu; S. Arii; M. Omata; M. Kudo; M. Sakamoto; K. Takayasu; M. Makuuchi; Y. Matsuyama; M. Monden  BRITISH JOURNAL OF SURGERY  98-  (4)  552  -557  2011/04Estimation of Liver Function Using T1 Mapping on Gd-EOB-DTPA-Enhanced Magnetic Resonance ImagingTakashi Katsube; Masahiro Okada; Seishi Kumano; Masatoshi Hori; Izumi Imaoka; Kazunari Ishii; Masatoshi Kudo; Hajime Kitagaki; Takamichi Murakami  INVESTIGATIVE RADIOLOGY  46-  (4)  277  -283  2011/04Optimal Scanning Protocol of Arterial Dominant Phase for Hypervascular Hepatocellular Carcinoma with Gadolinium-Ethoxybenzyl-Diethylenetriamine Pentaacetic Acid-Enhanced MRYuki Kagawa; Masahiro Okada; Seishi Kumano; Takashi Katsube; Izumi Imaoka; Noboru Tanigawa; Kazunari Ishii; Masatoshi Kudo; Takamichi Murakami  JOURNAL OF MAGNETIC RESONANCE IMAGING  33-  (4)  864  -872  2011/04胃十二指腸静脈瘤出血に対する内視鏡的止血術松井繁長; 樫田博史; 峯宏昌; 永田嘉昭; 川崎正憲; 朝隈豊; 櫻井俊治; 工藤正俊  Gastroenterol Endosc  53-  (Supplement 1)  979  2011/03Antitumor Activity of BIBF 1120, a Triple Angiokinase Inhibitor, and Use of VEGFR2(+)pTyr(+) Peripheral Blood Leukocytes as a Pharmacodynamic Biomarker In VivoKanae Kudo; Tokuzo Arao; Kaoru Tanaka; Tomoyuki Nagai; Kazuyuki Furuta; Kazuko Sakai; Hiroyasu Kaneda; Kazuko Matsumoto; Daisuke Tamura; Keiichi Aomatsu; Marco A. De Velasco; Yoshihiko Fujita; Nagahiro Saijo; Masatoshi Kudo; Kazuto Nishio  CLINICAL CANCER RESEARCH  17-  (6)  1373  -1381  2011/03Antitumor Activity of BIBF 1120, a Triple Angiokinase Inhibitor, and Use of VEGFR2(+)pTyr(+) Peripheral Blood Leukocytes as a Pharmacodynamic Biomarker In VivoKanae Kudo; Tokuzo Arao; Kaoru Tanaka; Tomoyuki Nagai; Kazuyuki Furuta; Kazuko Sakai; Hiroyasu Kaneda; Kazuko Matsumoto; Daisuke Tamura; Keiichi Aomatsu; Marco A. De Velasco; Yoshihiko Fujita; Nagahiro Saijo; Masatoshi Kudo; Kazuto Nishio  CLINICAL CANCER RESEARCH  17-  (6)  1373  -1381  2011/03HEPATOCELLULAR CARCINOMAKudo Masatoshi  Journal of Japan Surgical Society  112-  (2)  122  -129  2011/03Utility of contrast-enhanced harmonic endoscopic ultrasonography for diagnosis of pancreatic diseasesKITANO Masayuki; KOMAKI Takamitsu; SAKAMOTO Hiroki; IMAI Hajime; KAMATA Ken; KUDO Masatoshi; YASUDA Takeo; TAKEYAMA Yoshifumi  膵臓 = The Journal of Japan Pancreas Society  26-  (1)  23  -28  2011/02First interim results of the global investigation of therapeutic decisions in hepatocellular carcinoma (HCC) and of its treatment with sorafenib (GIDEON) study: Use of sorafenib (Sor) by oncologists and nononcologists in the management of HCCA. P. Venook; R. Lencioni; J. A. Marrero; M. Kudo; K. Nakajima; S. Ye  JOURNAL OF CLINICAL ONCOLOGY  29-  (4)  2011/02The cancer stem cell marker CD133 is a predictor of the effectiveness of S1+ pegylated interferon alpha-2b therapy against advanced hepatocellular carcinomaSatoru Hagiwara; Masatoshi Kudo; Kazuomi Ueshima; Hobyung Chung; Mami Yamaguchi; Masahiro Takita; Seiji Haji; Masatomo Kimura; Tokuzo Arao; Kazuto Nishio; Ah-Mee Park; Hiroshi Munakata  JOURNAL OF GASTROENTEROLOGY  46-  (2)  212  -221  2011/02Double-Contrast Ultrasound: A Novel Surveillance Tool for Hepatocellular CarcinomaMasatoshi Kudo; Kinuyo Hatanaka; Takashi Kumada; Hidenori Toyoda; Toshifumi Tada  AMERICAN JOURNAL OF GASTROENTEROLOGY  106-  (2)  368  -370  2011/02THE KNACK OF PERFORMING CONTRAST-ENHANCED EUSKITANO Masayuki; KUDO Masatoshi  GASTROENTEROLOGICAL ENDOSCOPY  53-  (1)  76  -86  2011/01Real-time Tissue Elastographyの肝疾患テクスチャ解析外村明子; 元木満; 三竹毅; 藤本研治; 加藤道夫; 辰巳千栄; 矢田典久; 上嶋一臣; 工藤正俊; 椎名毅  超音波医学  38-  (3)  2011Pancreatic Cancer: Hot Topics in 2011 PrefaceMasatoshi Kudo; Kenji Yamao; Tooru Shimosegawa  PANCREATOLOGY  11-  1  -2  2011High range resolution ultrasound imaging of a human carotid artery using frequency domain interferometryHirofumi Taki; Takuya Sakamoto; Makoto Yamakawa; Tsuyoshi Shiina; Toru Sato; Kousuke Taki; Motoi Kudo  2011 IEEE INTERNATIONAL ULTRASONICS SYMPOSIUM (IUS)  2201  -2204  2011  [Refereed]EUS guided biliary drainageKomaki T; Kitano M; Sakamoto H; Imai H; Kamata K; Kudo M  Pancreatology  2011胃ESD後の後出血例の検討と対策朝隈豊; 松井繁長; 川崎正憲; 永田嘉昭; 櫻井俊治; 樫田博史; 工藤正俊  日本消化管学会総会学術集会プログラム・抄録集  7th-  147  2011胆道疾患における造影ハーモニックEUSの有用性. 胆膵系超音波の基礎知識2011鎌田 研; 北野 雅之; 工藤 正俊  胆と膵  32-  695  -700  2011Needs for Hepatocellular Carcinoma Control Policy in the Asia-Pacific RegionJohn F. P. Bridges; Susan M. Joy; Gisselle Gallego; Masatoshi Kudo; Sheng-Long Ye; Kwang-Hyub Han; Ann-Lii Cheng; Barri M. Blauvelt  ASIAN PACIFIC JOURNAL OF CANCER PREVENTION  12-  (10)  2585  -2591  2011Complete Response of Advanced Hepatocellular Carcinoma with Multiple Lung Metastases Treated with Sorafenib: A Case ReportTadashi Inuzuka; Hiroki Nishikawa; Akira Sekikawa; Haruhiko Takeda; Shinichiro Henmi; Azusa Sakamoto; Sumio Saito; Ryuichi Kita; Toru Kimura; Yukio Osaki; Masatoshi Kudo  ONCOLOGY  81-  152  -157  2011Asian Consensus Workshop Report: Expert Consensus Guideline for the Management of Intermediate and Advanced Hepatocellular Carcinoma in AsiaKwang-Hyub Han; Masatochi Kudo; Sheng-Long Ye; Jong Young Choi; Roonni Tung-Ping Poon; Jinsil Seong; Joong-Won Park; Takafumi Ichida; Jin Wook Chung; Pierce Chow; Ann-Lii Cheng  ONCOLOGY  81-  158  -164  2011超音波内視鏡による診断と治療.坂本 洋城; 北野 雅之; 工藤 正俊  近畿大学医学雑誌  36-  (4)  129  -136  2011Meeting Report ILCA2011 International Liver Cancer Association Fifth Annual Conference工藤 正俊  The Liver Cancer Journal The Liver Cancer Journal  3-  (4)  309  -311  2011内視鏡室の紹介.汐見 幹夫; 工藤 正俊  Gastroenterol Endoscopy Gastroenterol Endoscopy  52-  (5)  1451  -1453  2011画像強調による大腸腫瘍の精密診断.樫田 博史; 峯 宏昌; 永田 嘉昭; 川崎 正憲; 朝隈 豊; 櫻井 俊治; 松井 繁長; 工藤 正俊; 和田祥城; 三澤  消化器内視鏡  23-  (4)  790  -796  2011Usefulness of Combination of Imaging Modalities in the Diagnosis of Hepatocellular Carcinoma Using Sonazoid (R)-Enhanced Ultrasound, Gadolinium Diethylene-Triamine-Pentaacetic Acid-Enhanced Magnetic Resonance Imaging, and Contrast-Enhanced Computed TomographyAlshimaa Alaboudy; Tatsuo Inoue; Kinuyo Hatanaka; Hobyung Chung; Tomoko Hyodo; Seishi Kumano; Takamichi Murakami; Ehab Fawzy Abdou Moustafa; Masatoshi Kudo  ONCOLOGY  81-  (S1)  66  -72  2011Adriamycin Enhances Proteasome-Mediated Generation of the Proapoptotic Processed Form of MAGE-A4 in Hepatoma CellsToshiharu Sakurai; Masatoshi Kudo; Katsuhiko Itoh; U. Ryu; Hiroaki Higashitsuji; Jun Fujita  ONCOLOGY  81-  (S1)  30  -35  2011胆・膵-胆膵病変の診断・治療におけるEUSの有用性.坂本 洋城; 北野 雅之; 門阪 薫平; 工藤 正俊  インナービジョン  26-  (12)  50  -52  2011Signaling Pathways Governing Tumor AngiogenesisToshiharu Sakurai; Masatoshi Kudo  ONCOLOGY  81-  (S1)  24  -29  2011Hepatocellular Carcinoma in 2011 and Beyond: From the Pathogenesis to Molecular Targeted Therapy IntroductionMasatoshi Kudo  ONCOLOGY  81-  (S1)  1  -10  2011膵癌.北野 雅之; 工藤 正俊  medicina medicina  48-  (11)  312  -316  2011Association of Interleukin-28B and Hepatitis C Genotype 1 with a High Viral Load and Response to Pegylated Interferon plus Ribavirin TherapyMasahiro Takita; Satoru Hagiwara; Tadaaki Arizumi; Sousuke Hayaishi; Taisuke Ueda; Satoshi Kitai; Norihisa Yada; Tatsuo Inoue; Yasunori Minami; Hobyung Chung; Kazuomi Ueshima; Toshiharu Sakurai; Masatoshi Kudo  DIGESTION  84-  (S1)  56  -61  2011Clinical Characteristics of Non-B Non-C Hepatocellular Carcinoma: A Single-Center Retrospective StudySoo Ki Kim; Hiroyuki Marusawa; Yuji Eso; Hiroki Nishikawa; Yoshihide Ueda; Ryuichi Kita; Toru Kimura; Tsutomu Chiba; Yukio Osaki; Masatoshi Kudo  DIGESTION  84-  (S1)  43  -49  2011Double-Filtration Plasmapheresis plus Interferon-beta for HCV-1b Patients with Non-Sustained Virological Response to Previous Combination TherapySoo Ryang Kim; Jun Saito; Susumu Imoto; Takamitsu Komaki; Yoshiaki Nagata; Ke Ih Kim; Noriko Sasase; Noriyo Kimura; Kanako Sasatani; Erika Konishi; Yutaka Hasegawa; Aya Fujinami; Mitsuhiro Ohta; Ahmed El-Shamy; Yasuhito Tanaka; Masahiko Sugano; Masanori Sakashita; Akira Nakamura; Shinobu Tsuchida; Tetsuya Makino; Tetsumi Kawada; Takatoshi Nakajima; Teruhisa Morikawa; Akira Muramatsu; Hiroshi Kasugai; Hak Hotta; Masatoshi Kudo  DIGESTION  84-  (S1)  10  -16  2011Correlation between Insulin Resistance and Outcome of Pegylated Interferon and Ribavirin Therapy, Hepatic Steatosis, Hepatic Fibrosis in Chronic Hepatitis C-1b and High Viral LoadSoo Ryang Kim; Jun Saito; Susumu Imoto; Takamitsu Komaki; Yoshiaki Nagata; Taisuke Nakajima; Kenji Ando; Katsumi Fukuda; Yumi Otono; Ke Ih Kim; Aya Ohtani; Kayo Sugimoto; Yutaka Hasegawa; Aya Fujinami; Mitsuhiro Ohta; Hak Hotta; Yoko Maekawa; Yoshitake Hayashi; Masatoshi Kudo  DIGESTION  84-  (S1)  5  -9  2011Tailor-Made Therapy for Viral Hepatitis: Recent AdvancesMasatoshi Kudo  DIGESTION  84-  (S1)  1  -4  2011造影ハーモニックEUSによる膵癌の診断.鎌田 研; 北野 雅之; 工藤 正俊  胆と膵  32-  (9)  821  -825  2011C型代償性肝硬変に対するペグインターフェロンα-2a(40KD)とリバビリン併用療法の有効性および安全性の検討-臨床第II/III相試験.泉 並木; 工藤 正俊; 金子 周一; 西口 修平; 佐田 通夫; 小俣 政男  消化器内科  53-  (3)  335  -342  2011マイクロチップ電気泳動法を利用したAFP, AFP-L3%およびPIVKA-II測定の評価-基礎検討、検体安定性およびマイクロフィブリンの影響について-.井本 真由美; 鷹家 優美子; 森嶋 祥之; 中江 健市; 上硲 俊法; 工藤 正俊  医学と薬学  66-  (3)  535  -540  2011第49回日本癌治療学会関連特集=最前線の現場から 肝がん・膵がん.北野 雅之; 上嶋 一臣; 工藤 正俊  Medicament News Medicament News  2064-  9  -12  2011序説・肝細胞癌の化学療法の進歩と効果判定.工藤 正俊  肝胆膵画像  13-  (6)  581  -584  2011肝細胞癌の分子標的治療の進歩と治療成績.工藤 正俊  肝胆膵画像  13-  (6)  593  -601  2011肝臓癌.上嶋 一臣; 工藤 正俊  外来癌化学療法  2-  (2)  86  -91  2011転移性肝癌.南 康範; 工藤 正俊  Surgery Frontier Surgery Frontier  18-  (3)  246  -253  2011巻頭言.工藤 正俊  臨牀消化器内科  26-  (9)  1185  -1186  2011基本的穿刺術.北野 雅之; 坂本 洋城; 樫田 博史; 工藤 正俊  消化器内視鏡  23-  (8)  1312  -1319  2011胆道疾患における造影ハーモニックEUSの有用性.鎌田 研; 北野 雅之; 工藤 正俊  胆と膵  32-  (8)  695  -700  2011Management of Hepatocellular Carcinoma in Japan: Consensus-Based Clinical Practice Guidelines Proposed by the Japan Society of Hepatology (JSH) 2010 Updated VersionMasatoshi Kudo; Namiki Izumi; Norihiro Kokudo; Osamu Matsui; Michiie Sakamoto; Osamu Nakashima; Masamichi Kojiro; Masatoshi Makuuchi  DIGESTIVE DISEASES  29-  (3)  339  -364  2011Oral Branched-Chain Amino Acid Granules Reduce the Incidence of Hepatocellular Carcinoma and Improve Event-Free Survival in Patients with Liver CirrhosisSosuke Hayaishi; Hobyung Chung; Masatoshi Kudo; Emi Ishikawa; Masahiro Takita; Taisuke Ueda; Satoshi Kitai; Tatsuo Inoue; Norihisa Yada; Satoru Hagiwara; Yasunori Minami; Kazuomi Ueshima  DIGESTIVE DISEASES  29-  (3)  326  -332  2011Future Treatment Option for Hepatocellular Carcinoma: A Focus on BrivanibMasatoshi Kudo  DIGESTIVE DISEASES  29-  (3)  316  -320  2011mTOR Inhibitor for the Treatment of Hepatocellular CarcinomaMasatoshi Kudo  DIGESTIVE DISEASES  29-  (3)  310  -315  2011Signaling Pathway and Molecular-Targeted Therapy for Hepatocellular CarcinomaMasatoshi Kudo  DIGESTIVE DISEASES  29-  (3)  289  -302  2011Molecular Targeted Therapy for Hepatocellular Carcinoma: Bench to BedsideMasatoshi Kudo  DIGESTIVE DISEASES  29-  (3)  273  -277  2011Des-gamma-Carboxyprothrombin May Be a Promising Biomarker to Determine the Therapeutic Efficacy of Sorafenib for Hepatocellular CarcinomaKazuomi Ueshima; Masatoshi Kudo; Masahiro Takita; Tomoyuki Nagai; Chie Tatsumi; Taisuke Ueda; Satoshi Kitai; Emi Ishikawa; Norihisa Yada; Tatsuo Inoue; Satoru Hagiwara; Yasunori Minami; Hobyung Chung; Toshiharu Sakurai  DIGESTIVE DISEASES  29-  (3)  321  -325  2011新規分子標的薬の開発状況と肝がん診療の今後の展望. 特集: 肝細胞がん診療の進歩: up-to-date工藤 正俊  最新医学  66-  101  -107  2011肝細胞がんの診断・治療アルゴリズム. 特集: 肝細胞がん診療の進歩: up-to-date井上 達夫; 工藤 正俊  最新医学  66-  43  -51  2011肝細胞がん診療の最近のトピックス. 特集: 肝細胞がん診療の進歩: up-to-date坂元 亨宇; 工藤 正俊; 國土 典宏  最新医学  66-  6  -17  2011序論. 特集: 肝細胞がん診療の進歩: up-to-date工藤 正俊  最新医学  66-  5  2011B型肝癌根治後の再発抑制治療と有用性.萩原 智; 工藤 正俊  日本臨床  69-  (4)  546  -550  2011膵嚢胞性疾患(MCN・SCN・SPN).小牧 孝充; 北野 雅之; 坂本 洋城; 今井 元; 鎌田 研; 宮田 剛; 門阪 薫平; 工藤 正俊  消化器外科  34-  (1223)  1230  2011種々のがん領域で臨床応用への期待が高まるPI3K/Akt/mTOR経路阻害剤.工藤 正俊  JSMO Dialy News JSMO Dialy News  Day 2-  4  2011マルチスライスCTによる肝画像診断の進歩 高速化・高分解能化の動向岡田 真広; 香川 祐毅; 工藤 正俊; 村上 卓道; 工藤 正幸  13-  (1)  37  -44  2011Radiofrequency ablation of hepatocellular carcinoma: A literature review.南 康範; 工藤 正俊  International Journal of Hepatology  2011-  -9  2011Endoscopic Ultrasound-Guided Neurolysis in Pancreatic CancerHiroki Sakamoto; Masayuki Kitano; Takamitsu Komaki; Hajime Imai; Ken Kamata; Masatoshi Kudo  PANCREATOLOGY  11-  52  -58  2011Endoscopic Ultrasonography-Guided Biliary Drainage: Evaluation of a Choledochoduodenostomy TechniqueTakamitsu Komaki; Masayuki Kitano; Hiroki Sakamoto; Masatoshi Kudo  PANCREATOLOGY  11-  47  -51  2011Endoscopic Ultrasonography and Contrast-Enhanced Endoscopic UltrasonographyMasayuki Kitano; Masatoshi Kudo; Hiroki Sakamoto; Takamitsu Komaki  PANCREATOLOGY  11-  28  -33  2011Involvement of Angiotensin II and Reactive Oxygen Species in Pancreatic FibrosisToshiharu Sakurai; Masatoshi Kudo; Nobuhiro Fukuta; Tatsuya Nakatani; Masatomo Kimura; Ah-Mee Park; Hiroshi Munakata  PANCREATOLOGY  11-  7  -13  2011The prognosis of patients with pancreatic cancer is extremely poor. Prefece.工藤 正俊; 山雄 健次; 下瀬川 徹  Pancreatology  11-  1  -2  2011Management of hepatitis B: Consensus of the Japan Society of Hepatology 2009Osamu Yokosuka; Masayuki Kurosaki; Fumio Imazeki; Yasuji Arase; Yasuhito Tanaka; Kazuaki Chayama; Eiji Tanaka; Hiromitsu Kumada; Namiki Izumi; Masashi Mizokami; Masatoshi Kudo  HEPATOLOGY RESEARCH  41-  (1)  1  -21  2011/01肝動脈化学塞栓療法と化学療法の併用の意義は?工藤 正俊  EBMがん化学療法・分子標的治療法2011-2012  121  -124  2011ソラフェニブと異なる作用機序をもつ分子標的薬(ブリバニブ, mTOR阻害剤, CS-1008)の基礎と臨床試験成績.工藤 正俊  医学のあゆみ  236-  (7)  736  -740  2011ソラフェニブと従来の治療法との併用試験の意義.工藤 正俊  医学のあゆみ  236-  (7)  722  -725  2011はじめに.工藤 正俊  医学のあゆみ  236-  (7)  689  2011肝細胞癌の分子標的療法剤-ソラフェニブ.工藤 正俊  Medical Technology Medical Technology  39-  (2)  111  -114  2011肝腫瘍診断のNext Stage ?ソナゾイドR造影: 肝細胞癌のサーベイランスへの応用.工藤 正俊; 畑中 絹世; 熊田 卓  肝胆膵画像  13-  (1)  13  -20  2011Sorafenib Inhibits the Hepatocyte Growth Factor-Mediated Epithelial Mesenchymal Transition in Hepatocellular CarcinomaTomoyuki Nagai; Tokuzo Arao; Kazuyuki Furuta; Kazuko Sakai; Kanae Kudo; Hiroyasu Kaneda; Daisuke Tamura; Keiichi Aomatsu; Hideharu Kimura; Yoshihiko Fujita; Kazuko Matsumoto; Nagahiro Saijo; Masatoshi Kudo; Kazuto Nishio  MOLECULAR CANCER THERAPEUTICS  10-  (1)  169  -177  2011/01下部消化管疾患に対する内視鏡の進歩.樫田 博史; 川崎 正憲; 梅原 泰; 峯 宏昌; 永田 嘉昭; 朝隈 豊; 櫻井 俊治; 松井 繁長; 工藤 正俊  Pharma Medica  28-  (10)  57  -63  2011EUS.小牧 孝充; 北野 雅之; 坂本 洋城; 今井 元; 鎌田 研; 宮田 剛; 工藤 正俊  臨牀消化器内科  26-  (1)  51  -56  2011Sorafenib Inhibits the Hepatocyte Growth Factor-Mediated Epithelial Mesenchymal Transition in Hepatocellular CarcinomaTomoyuki Nagai; Tokuzo Arao; Kazuyuki Furuta; Kazuko Sakai; Kanae Kudo; Hiroyasu Kaneda; Daisuke Tamura; Keiichi Aomatsu; Hideharu Kimura; Yoshihiko Fujita; Kazuko Matsumoto; Nagahiro Saijo; Masatoshi Kudo; Kazuto Nishio  MOLECULAR CANCER THERAPEUTICS  10-  (1)  169  -177  2011/01The status of polycystic liver disease in Japan: A questionnaire survey of patientsKoichi Ogawa; Kiyoshi Fukunaga; Tomoyo Takeuchi; Naoki Kawagishi; Masatoshi Kudo; Nobuhiro Ohkouchi  Acta Hepatologica Japonica  52-  (11)  709  -715  2011動注化学療法と分子標的薬の役割 (Special Articles 多発肝細胞癌治療の今後の展望)上嶋 一臣; 工藤 正俊  ザリバーキャンサージャーナル  2-  (4)  284  -290  2010/12【膵癌up-to-date】 EUS小牧 孝充; 北野 雅之; 坂本 洋城; 今井 元; 鎌田 研; 宮田 剛; 工藤 正俊  臨床消化器内科  26-  (1)  51  -56  2010/12Phase I/II study of the pharmacokinetics, safety and efficacy of S-1 in patients with advanced hepatocellular carcinomaJunji Furuse; Takuji Okusaka; Shuichi Kaneko; Masatoshi Kudo; Kohei Nakachi; Hideki Ueno; Tatsuya Yamashita; Kazuomi Ueshima  CANCER SCIENCE  101-  (12)  2606  -2611  2010/12EUS-Guided Broad Plexus Neurolysis Over the Superior Mesenteric Artery Using a 25-Gauge NeedleHiroki Sakamoto; Masayuki Kitano; Ken Kamata; Takamitsu Komaki; Hajime Imai; Takaaki Chikugo; Yoshifumi Takeyama; Masatoshi Kudo  AMERICAN JOURNAL OF GASTROENTEROLOGY  105-  (12)  2599  -2606  2010/12PIVKA-II is a predictive marker in the treatment response of sorafenib to hepatocellular carcinomaUESHIMA Kazuomi; KUDO Masatoshi  Kanzo  51-  (11)  681  -683  2010/11社団法人日本超音波医学会第83回学術集会を終えて工藤 正俊  Japanese journal of medical ultrasOnics= 超音波医学  37-  (6)  659  -663  2010/11The Challenge of Prognosis and Staging for Hepatocellular CarcinomaJorge A. Marrero; Masatoshi Kudo; Jean-Pierre Bronowicki  ONCOLOGIST  15-  23  -33  2010/11Report of the 18th follow-up survey of primary liver cancer in JapanIwao Ikai; Masatoshi Kudo; Shigeki Arii; Masao Omata; Masamichi Kojiro; Michiie Sakamoto; Kenichi Takayasu; Norio Hayashi; Masatoshi Makuuchi; Yutaka Matsuyama; Morito Monden  HEPATOLOGY RESEARCH  40-  (11)  1043  -1059  2010/11SORAFENIB TREATMENT AND SAFETY PROFILE IN CHILD PUGH B PATIENTS CHARACTERIZED IN FIRST INTERIM RESULTS OF GIDEON (GLOBAL INVESTIGATION OF THERAPEUTIC DECISIONS IN HEPATOCELLULAR CARCINOMA AND OF ITS TREATMENT WITH SORAFENIB)Jorge A. Marrero; Ho Yeong Lim; Per Stal; Riccardo Lencioni; Masatoshi Kudo; Alan Venook; Keiko Nakajima; Sheng-Long Ye  HEPATOLOGY  52-  (4)  1140A  -1140A  2010/10DES-GAMMA-CARBOXY PROTHROMBIN IS A PREDICTIVE MARKER IN THE TREATMENT OF HEPATOCELLULAR CARCINOMA WITH SORAFENIBKazuomi Ueshima; Masatoshi Kudo  HEPATOLOGY  52-  (4)  1182A  -1183A  2010/10FIRST INTERIM RESULTS OF THE GLOBAL INVESTIGATION OF THERAPEUTIC DECISIONS IN HEPATOCELLULAR CARCINOMA AND OF ITS TREATMENT WITH SORAFENIB (GIDEON) STUDYR. Lencioni; H. Y. Lim; P. Stal; J. A. Marrero; M. Kudo; A. P. Venook; K. Nakajima; S. L. Ye  ANNALS OF ONCOLOGY  21-  258  -259  2010/10THE USEFULNESS OF THE POST-VASCULAR PHASE OF CONTRAST-ENHANCED ULTRASONOGRAPHY WITH SONAZOID IN THE EVALUATION OF GROSS TYPE OF HEPATOCELLULAR CARCINOMAKinuyo Hatanaka; Hobyung Chung; Masatoshi Kudo; Satoshi Kitai; Tatsuo Inoue; Norihisa Yada; Satoru Hagiwara; Kazuomi Ueshima  HEPATOLOGY  52-  (4)  962A  -962A  2010/10ヘリコバクターピロリ陽性早期胃癌における除菌治療がESD後人工潰瘍治癒過程に及ぼす影響の検討川崎正憲; 松井繁長; 峯宏昌; 永田嘉昭; 朝隈豊; 工藤正俊  Gastroenterol Endosc  52-  (Supplement 2)  2413  2010/09治療成績からみた胃腫瘍に対するESDの検討永田嘉昭; 松井繁長; 朝隈豊; 川崎正憲; 岡田無文; 工藤正俊  Gastroenterological Endoscopy  52-  (Supplement 2)  2447  2010/09The usefulness of Helicobacter pylori eradication therapy for the healing of artificial gastric ulcer after endoscopic submucosal dissection for early gastric cancerM. Kawasaki; S. Matui; H. Kashida; M. Kudo  JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY  25-  A168  -A168  2010/09Possibilities of the Evaluation in Liver Function with Gd-EOBDTPA Enhanced MRIOkada M; Katsube T; Kagawa Y; Hyodo T; Kumano S; Imaoka I; Ishii K; Imai Y; Kudo M; Murakami T  NICHIDOKU-IHOU  55-  (2)  179  -186  2010/09Characterization of intra-abdominal lesions of undetermined origin by contrast-enhanced harmonic EUSYu Xia; Masayuki Kitano; Masatoshi Kudo; Hajime Imai; Ken Kamata; Hiroki Sakamoto; Takamitsu Komaki  GASTROINTESTINAL ENDOSCOPY  72-  (3)  637  -642  2010/09Hepatitis C Virus Core Protein Induces Homotolerance and Cross-Tolerance to Toll-Like Receptor Ligands by Activation of Toll-Like Receptor 2Hobyung Chung; Tomohiro Watanabe; Masatoshi Kudo; Tsutomu Chiba  JOURNAL OF INFECTIOUS DISEASES  202-  (6)  853  -861  2010/09Diagnostic sensitivity of imaging modalities for hepatocellular carcinoma smaller than 2 cmKeiji Mita; Soo Ryang Kim; Masatoshi Kudo; Susumu Imoto; Taisuke Nakajima; Kenji Ando; Katsumi Fukuda; Toshiyuki Matsuoka; Yoko Maekawa; Yoshitake Hayashi  WORLD JOURNAL OF GASTROENTEROLOGY  16-  (33)  4187  -4192  2010/09膵臓癌の血漿中血管新生関連分子の検討(Plasma concentrations of angiogenic factors in patients with pancreas cancer)坂本 洋城; 荒尾 徳三; 永井 知行; 工藤 可苗; 古田 一行; 北野 雅之; 工藤 正俊; 西尾 和人  日本癌学会総会記事  69回-  451  -451  2010/08Endoscopic findings of intestinal Behcet's disease complicated with toxic megacolonY. Umehara; M. Kudo; M. Kawasaki  ENDOSCOPY  42-  E173  -E174  2010/07PANCREATIC DUCTAL DRAINAGE BY ENDOSCOPIC ULTRASOUND-ASSISTED RENDEZVOUS TECHNIQUE FOR PAIN CAUSED BY DUCTAL STRICTURE WITH CHRONIC PANCREATITISKshaunish Das; Masayuki Kitano; Takamitsu Komaki; Hiroki Sakamoto; Kazu Noda; Yoichiro Suetomi; Masatoshi Kudo  DIGESTIVE ENDOSCOPY  22-  (3)  217  -219  2010/07Response Evaluation Criteria in Cancer of the Liver (RECICL) proposed by the Liver Cancer Study Group of Japan (2009 Revised Version)Masatoshi Kudo; Shouji Kubo; Kenichi Takayasu; Michiie Sakamoto; Masatoshi Tanaka; Iwao Ikai; Junji Furuse; Kenji Nakamura; Masatoshi Makuuchi  HEPATOLOGY RESEARCH  40-  (7)  686  -692  2010/07Management of hepatocellular carcinoma: Report of Consensus Meeting in the 45th Annual Meeting of the Japan Society of Hepatology (2009)Shigeki Arii; Michio Sata; Michiie Sakamoto; Mitsuo Shimada; Takashi Kumada; Shuichiro Shiina; Tatsuya Yamashita; Norihiro Kokudo; Masatoshi Tanaka; Tadatoshi Takayama; Masatoshi Kudo  HEPATOLOGY RESEARCH  40-  (7)  667  -685  2010/07Design and rationale for the non-interventional Global Investigation of therapeutic DEcisions in hepatocellular carcinoma and Of its treatment with sorafeNib (GIDEON) studyR. Lencioni; J. Marrero; A. Venook; S. -L. Ye; M. Kudo  INTERNATIONAL JOURNAL OF CLINICAL PRACTICE  64-  (8)  1034  -1041  2010/07Single HCC between 2 and 5 cm: the grey zone - Hepatologist's perspectiveMasatoshi Kudo; Hobyung Chung  JOURNAL OF HEPATO-BILIARY-PANCREATIC SCIENCES  17-  (4)  434  -437  2010/07The committee for revision of the Clinical Practice Guidelines for Hepatocellular CarcinomaMAKUUCHI Masatoshi; KOKUDO Norihiro; ARII Shigeki; IGAKI Hiroshi; IKAI Iwao; KANEKO Shuichi; KAWASAKI Seiji; KUDO Masatoshi; MATSUYAMA Yutaka; OHTOMO Kuni; OKAZAKI Masatoshi; OMATA Masao; TAKAYAMA Tadatoshi; TAKAYASU Kenichi; TATEISHI Ryosuke; AKAHANE Masaaki; ARAI Kuniaki; IMAMURA Hiroshi; KORA Shinichi; NAKAYAMA Hisashi; TANAKA Shinji; YAMASHITA Tatsuya; INO Kenji; NOJIRI Kayo; ENOOKU Kenichiro; GOTO Eriko; HASEGAWA Kiyoshi; KIRYU Shigeru; SATO Takahisa; SHIMNO Toru; SUGAWARA Yasuhiko; SUGO Hiroyuki; TAKAO Hidemasa; TAMURA Sumihito; UCHINO Yasushi  Hepatology Research  40-  2  -144  2010/06Chapter 6: Local ablation therapyHEPATOLOGY RESEARCH  40-  (S1)  113  -119  2010/06Current status of molecularly targeted therapy for hepatocellular carcinoma: clinical practiceMasatoshi Kudo  INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY  15-  (3)  242  -255  2010/06Asian Pacific Association for the Study of the Liver consensus recommendations on hepatocellular carcinomaMasao Omata; Laurentius A. Lesmana; Ryosuke Tateishi; Pei-Jer Chen; Shi-Ming Lin; Haruhiko Yoshida; Masatoshi Kudo; Jeong Min Lee; Byung Ihn Choi; Ronnie T. P. Poon; Shuichiro Shiina; Ann Lii Cheng; Ji-Dong Jia; Shuntaro Obi; Kwang Hyub Han; Wasim Jafri; Pierce Chow; Seng Gee Lim; Yogesh K. Chawla; Unggul Budihusodo; Rino A. Gani; C. Rinaldi Lesmana; Terawan Agus Putranto; Yun Fan Liaw; Shiv Kumar Sarin  HEPATOLOGY INTERNATIONAL  4-  (2)  439  -474  2010/06A randomized phase II study of TSU-68 in patients (pts) with hepatocellatar carcinoma (HCC) treated by transarterial cheinoembolizabon (TACE)Y. Arai; Y. Inaba; T. Yamamoto; F. Kanai; T. Aramaki; T. Tanaka; K. Yamakado; M. Kudo; S. Kaneko; K. Imanaka  JOURNAL OF CLINICAL ONCOLOGY  28-  (15)  2010/05A novel biomarker TERTmRNA is applicable for early detection of hepatomaNorimasa Miura; Yukio Osaki; Miki Nagashima; Michimori Kohno; Kensho Yorozu; Kohei Shomori; Takamasa Kanbe; Kenji Oyama; Yukihiro Kishimoto; Shigeo Maruyama; Eijiro Noma; Yutaka Horie; Masatoshi Kudo; Seigo Sakaguchi; Yasuaki Hirooka; Hisao Ito; Hironaka Kawasaki; Junichi Hasegawa; Goshi Shiota  BMC GASTROENTEROLOGY  10-  46  -57  2010/05Radiofrequency ablation guided by contrast harmonic sonography using perfluorocarbon microbubbles (Sonazoid) for hepatic malignancies: an initial experienceYasunori Minami; Masatoshi Kudo; Kinuyo Hatanaka; Satoshi Kitai; Tatsuo Inoue; Satoru Hagiwara; Hobyung Chung; Kazuomi Ueshima  LIVER INTERNATIONAL  30-  (5)  759  -764  2010/05造影EUS検査による進行胃癌の化学療法効果判定岡田無文; 松井繁長; 工藤正俊  超音波医学  37-  S162  2010/04EUS-Guided Gallbladder Drainage for Treatment of Acute Cholecystitis and Obstructive JaundiceMasayuki Kitano; Hajime Imai; Takamitsu Komaki; Ken Kamata; Hiroki Sakamoto; Masatoshi Kudo  GASTROINTESTINAL ENDOSCOPY  71-  (5)  AB276  -AB277  2010/04EUS-Guided Choledochoduodenostomy Followed by Endoscopic Antegrade Biliary Stenting via the Fistula for Treatment of Obstructive Jaundice With Duodenal StenosisMasayuki Kitano; Takamitsu Komaki; Hiroki Sakamoto; Ken Kamata; Hajime Imai; Masatoshi Kudo  GASTROINTESTINAL ENDOSCOPY  71-  (5)  AB277  -AB277  2010/04Management of hepatitis C; Report of the Consensus Meeting at the 45th Annual Meeting of the Japan Society of Hepatology (2009)Izumi Namiki; Shuhei Nishiguchi; Keisuke Hino; Fumitaka Suzuki; Hiromitsu Kumada; Yoshihito Itoh; Yusuhiro Asahina; Akihiro Tamori; Naoki Hiramatsu; Norio Hayashi; Masatoshi Kudo  HEPATOLOGY RESEARCH  40-  (4)  347  -368  2010/04【造影超音波は臨床を変えるか】 膵臓疾患に対する造影超音波 通常型膵癌 造影EUS北野 雅之; 小牧 孝充; 鎌田 研; 今井 元; 坂本 洋城; 工藤 正俊  肝・胆・膵  60-  (3)  457  -464  2010/03The 2008 Okuda lecture: Management of hepatocellular carcinoma: From surveillance to molecular targeted therapyMasatoshi Kudo  JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY  25-  (3)  439  -452  2010/03Overall Survival After Transarterial Lipiodol Infusion Chemotherapy With or Without Embolization for Unresectable Hepatocellular Carcinoma: Propensity Score AnalysisKenichi Takayasu; Shigeki Arii; Iwao Ikai; Masatoshi Kudo; Yutaka Matsuyama; Masamichi Kojiro; Masatoshi Makuuchi  AMERICAN JOURNAL OF ROENTGENOLOGY  194-  (3)  830  -837  2010/03Identification and characterization of IgG4-associated autoimmune hepatitisHobyung Chung; Tomohiro Watanabe; Masatoshi Kudo; Osamu Maenishi; Yoshio Wakatsuki; Tsutomu Chiba  LIVER INTERNATIONAL  30-  (2)  222  -231  2010/02Age and immunoglobulin G4-associated autoimmune hepatitis: author's responseHobyung Chung; Tomohiro Watanabe; Masatoshi Kudo; Tsutomu Chiba  LIVER INTERNATIONAL  30-  (2)  333  -333  2010/02COMPARISON OF DIAGNOSTIC CAPABILITY OF CONTRAST-ENHANCED CT, SONAZOID CONTRAST-ENHANCED US, GD-EOB-DTPA MRI AND CT ARTERIOPORTAL ANGIOGRAPHY IN DETECTING HISTOLOGICALLY PROVEN HCC NODULES SMALLER THAN 2CMS. R. Kim; K. Mita; Y. Maekawa; M. Kudo; S. Imoto; T. Nakajima; K. Ando; K. Fukuda; T. Matsuoka; Y. Hayashi  JOURNAL OF HEPATOLOGY  52-  S221  -S222  2010急速な転帰をとった腸管ベーチェット病の1例梅原 泰; 川崎 正憲; 有住 忠晃; 工藤 正俊; 石丸 英三郎; 沖 貴士; 上田 和毅; 所 忠男; 奥野 清隆  Progress in Medicine  30-  (1)  239  -242  2010/01PIVKA-II is a predictive marker in the treatment response of sorafenib to hepatocellular carcinomaKazuomi Ueshima; Masatoshi Kudo  Acta Hepatologica Japonica  51-  (11)  681  -683  2010Diagnosis of subepithelial tumors in the upper gastrointestinal tract by EUS.坂本 洋城; 北野 雅之; 工藤 正俊  World J Radiol  2-  289  -297  2010肝生検: 肝診療との接点 非典型画像を呈する肝腫瘍の画像診断.工藤 正俊  病理と臨床  28-  (2)  1269  -1273  2010近畿大学医学部消化器内科における肝細胞癌治療の取り組み 根治治療も延命治療もベストをめざし、エビデンス集積に尽力.工藤 正俊  The Liver Cancer Journal The Liver Cancer Journal  2-  (3)  219  -225  2010肝がん根治治療後の補助療法.工藤 正俊  腫瘍内科  6-  (5)  455  -464  2010膵腫瘍に対する造影超音波内視鏡.北野 雅之; 工藤 正俊  Pharma Medica Pharma Medica  28-  (10)  45  -49  2010早期膵癌.北野 雅之; 小牧 孝充; 坂本 洋城; 鎌田 研; 今井 元; 工藤 正俊  消化器内視鏡  22-  (12)  1933  -1940  2010膵嚢胞性腫瘍診断.坂本 洋城; 北野 雅之; 工藤 正俊  胆と膵  31-  (10)  1175  -1180  2010ネクサバール.工藤 正俊  肝胆膵  61-  (6)  1155  -1165  2010十二指腸静脈瘤の診断と治療法.松井 繁長; 樫田 博史; 朝隈 豊; 永田 嘉昭; 川崎 正憲; 櫻井 俊治; 工藤 正俊  消化器内視鏡  22-  (11)  1835  -1841  2010Radiofrequency ablation of hepatocellular carcinoma: Current status.MINAMI Y  World J Radiol  2-  (11)  417  -424  2010肝細胞癌に対するペルフルブタン造影エコー法.南 康範; 工藤 正俊  Pharma Medica Pharma Medica  28-  (10)  13  -17  2010特集にあたって.工藤 正俊  Pharma Medica Pharma Medica  28-  (10)  9  -11  2010Liver, Pancreas, Biliary Tract Cancer 肝・胆・膵癌 肝癌分子標的治療の基礎と臨床 肝癌分子標的治療におけるバイオマーカーの探索.荒尾 徳三; 工藤 正俊; 西尾 和人  癌と化学療法(Jpn J Cancer Chemother)  37-  (10)  1879  -1882  2010第18回全国原発性肝癌追跡調査報告(2004~2005).工藤 正俊; 有井 滋樹; 猪飼 伊和夫; 小俣 政男; 神代 正道; 坂元 亨宇; 高安 賢一; 林 紀夫; 幕内 雅敏; 松山 裕; 松山 裕  肝臓  51-  (8)  460  -484  2010Liver cancer working group report.工藤 正俊; Kwang Hyub Han; 國土 典宏; Ann-Li Cheng; Byung Ihn Choi; 古瀬 純司; 泉 並木; Joong-Won Park; Ronnie T. Poon; 坂元 亨宇  Jpn J Clin Oncol  40-  i19  -i27  2010小分子物質 3)Sorafenib.工藤 正俊  腫瘍内科  5-  (6)  617  -629  2010肝癌の内科治療の将来展望.工藤 正俊  クリニシアン  57-  (591)  72  -79  2010出血を伴った胆管?胞腺癌の一例.前川 清; 工藤 正俊; 畑中 絹世; 井上 達夫; 鄭 浩柄; 上嶋 一臣; 石川 原; 土師 誠二; 佐藤 隆夫  Modern Physician Modern Physician  30-  (8)  1113  -1118  2010Hepatic malignancies: Correlation between sonographic findings and pathological features.MINAMI Y  World J Radiol  2-  249  -256  2010肝細胞癌画像診断の進歩 肝細胞癌サーベイランス各国の現状.工藤 正俊  The Liver Cancer Journal The Liver Cancer Journal  2-  100  -108  2010ペグインターフェロンα-2b/リバビリン併用療法の無効・再燃例に対するペグインターフェロンα-2a/リバビリン併用療法の再治療.工藤 正俊; 上田 泰輔; 土谷 薫; 橋元 悟; 井上 泰輔; 稲生 実枝; 田中 篤; 垣内 雅彦; 今関 文夫; 西口 修平  肝胆膵  61-  127  -133  2010Response Evaluation Criteria in Cancer of the Liver (RECICL)Masatoshi Kudo; Shouji Kubo; Kenichi Takayasu; Michiie Sakamoto; Masatoshi Tanaka; Iwao Ikai; Junji Furuse; Kenji Nakamura; Masatoshi Makuuchi  Acta Hepatologica Japonica  51-  (5)  261  -266  2010Clinical practice guidelines for hepatocellular carcinoma ?The Japan Society of Hepatology 2009 update.幕内 雅敏; 工藤 正俊; 國土 典宏; 有井 滋樹; 井垣 浩; 猪飼 伊和夫; 金子 周一; 川崎 誠治; 松山 裕; 大友 邦; 岡崎 正敏; 小俣 政男; 高山 忠利; 高安 賢一; 建石 良介  Heppatol Res  40-  (S1)  1  -144  2010Autoimmune Thrombocytopenic Purpura during Pegylated Interferon alpha Treatment for Chronic Hepatitis CSoo Ryang Kim; Susumu Imoto; Masatoshi Kudo; Taisuke Nakajima; Kenji Ando; Keiji Mita; Katsumi Fukuda; Hyun Soo Hong; Yeong Ho Lee; Keiichi Nakashima; Ikuo Shoji; Motoko Nagano-Fujii; Hak Hotta; Yoshitake Hayashi  INTERNAL MEDICINE  49-  (12)  1119  -1122  2010Cecal Intussusception in an Adult with Cronkhite-Canada Syndrome Relieved by ColonoscopyEmi Ishikawa; Masatoshi Kudo; Yasunori Minami; Kazuomi Ueshima; Satoshi Kitai; Kazuki Ueda  INTERNAL MEDICINE  49-  (12)  1123  -1126  2010Real Practice of Hepatocellular Carcinoma in Japan: Conclusions of the Japan Society of Hepatology 2009 Kobe CongressMasatoshi Kudo  ONCOLOGY  78-  180  -188  2010Positioning of a Molecular-Targeted Agent, Sorafenib, in the Treatment Algorithm for Hepatocellular Carcinoma and Implication of Many Complete Remission Cases in JapanMasatoshi Kudo; Kazuomi Ueshima  ONCOLOGY  78-  154  -166  2010Hepatic Arterial Infusion Chemotherapy Using Low-Dose 5-Fluorouracil and Cisplatin for Advanced Hepatocellular CarcinomaKazuomi Ueshima; Masatoshi Kudo; Masahiro Takita; Tomoyuki Nagai; Chie Tatsumi; Taisuke Ueda; Satoshi Kitai; Emi Ishikawa; Norihisa Yada; Tatsuo Inoue; Satoru Hagiwara; Yasunori Minami; Hobyung Chung  ONCOLOGY  78-  148  -153  2010Radiofrequency Ablation for Hepatocellular Carcinoma: Updated Review in 2010Masatoshi Kudo  ONCOLOGY  78-  113  -124  2010Radiofrequency Ablation for Hepatocellular Carcinoma: Assistant Techniques for Difficult CasesTatsuo Inoue; Yasunori Minami; Hobyung Chung; Sousuke Hayaishi; Taisuke Ueda; Chie Tatsumi; Masahiro Takita; Satoshi Kitai; Kinuyo Hatanaka; Emi Ishikawa; Norihisa Yada; Satoru Hagiwara; Kazuomi Ueshima; Masatoshi Kudo  ONCOLOGY  78-  94  -101  2010Will Gd-EOB-MRI Change the Diagnostic Algorithm in Hepatocellular Carcinoma?Masatoshi Kudo  ONCOLOGY  78-  87  -93  2010Contrast-Enhanced Ultrasound Techniques for Guiding and Assessing Response to Locoregional Treatments for Hepatocellular CarcinomaLorenzo Andreana; Masatoshi Kudo; Kinuyo Hatanaka; Hobyung Chung; Yasunori Minami; Kiyoshi Maekawa; Giuseppe Ruggiero  ONCOLOGY  78-  68  -77  2010Depiction of Portal Supply in Early Hepatocellular Carcinoma and Dysplastic Nodule: Value of Pure Arterial Ultrasound Imaging in Hepatocellular CarcinomaMasatoshi Kudo; Kinuyo Hatanaka; Tatsuo Inoue; Kiyoshi Maekawa  ONCOLOGY  78-  60  -67  2010Newly Developed Novel Ultrasound Technique, Defect Reperfusion Ultrasound Imaging, Using Sonazoid in the Management of Hepatocellular CarcinomaMasatoshi Kudo; Kinuyo Hatanaka; Kiyoshi Maekawa  ONCOLOGY  78-  40  -45  2010Management of Hepatocellular Carcinoma: From Prevention to Molecular Targeted TherapyMasatoshi Kudo  ONCOLOGY  78-  1  -6  2010肝細胞癌.工藤 正俊  消化器の臨床  13-  (2)  113  -123  2010Non-Invasive Evaluation of Hepatic Fibrosis for Type C Chronic HepatitisChie Tatsumi; Masatoshi Kudo; Kazuomi Ueshima; Satoshi Kitai; Emi Ishikawa; Norihisa Yada; Satoru Hagiwara; Tatsuo Inoue; Yasunori Minami; Hobyung Chung; Kiyoshi Maekawa; Kenji Fujimoto; Michio Kato; Akiko Tonomura; Tsuyoshi Mitake; Tsuyoshi Shiina  INTERVIROLOGY  53-  (1)  76  -81  2010PEG-IFN alpha/RBV Combination Therapy for Chronic Hepatitis C Patients Increases Serum Ferritin Level while It Improves Sustained Viral Response RateNorihisa Yada; Masatoshi Kudo; Hobyung Chung; Sosuke Hayaishi; Masahiro Takita; Taisuke Ueda; Chie Tatsumi; Kinuyo Hatanaka; Satoshi Kitai; Emi Ishikawa; Tatsuo Inoue; Satoru Hagiwara; Kazuomi Ueshima  INTERVIROLOGY  53-  (1)  60  -65  2010Prolonged PEG-IFN and RBV Is Effective in Patients with HCV Genotype 1 and High Viral Load Who Achieved Virological Response Later than 24 WeeksTaisuke Ueda; Hobyung Chung; Masatoshi Kudo; Emi Ishikawa; Sousuke Hayaishi; Chie Tatsumi; Tatsuo Inoue; Norihisa Yada; Satoru Hagiwara; Yasunori Minami; Kazuomi Ueshima  INTERVIROLOGY  53-  (1)  55  -59  2010Changing Trends in Hepatitis C Infection over the Past 50 Years in JapanHobyung Chung; Taisuke Ueda; Masatoshi Kudo  INTERVIROLOGY  53-  (1)  39  -43  2010Viral Hepatitis A to E: An Update in 2010Masatoshi Kudo  INTERVIROLOGY  53-  (1)  5  -9  2010超音波造影剤: 最近の進歩.畑中 絹世; 工藤 正俊; 前川 清  映像情報メディカル  41-  14  -22  2010日本超音波医学会第83回学術集会の開催にあたって.工藤 正俊  病院新聞  2124-  3  2010胆・膵におけるUS・EUS診断.坂本 洋城; 北野 雅之; 工藤 正俊  臨牀消化器内科  25-  963  -970  2010超音波内視鏡.坂本 洋城; 北野 雅之; 松井 繁長; 工藤 正俊  臨牀と研究  87-  683  -687  2010造影超音波検査による肝腫瘍の質的診断.前川 清; 工藤 正俊; 上硲 俊法  近畿大学医学雑誌  35-  47  -53  2010早期肝細胞がんの診断・治療におけるアルゴリズム-境界病変の鑑別の可能性 1)内科の立場から工藤 正俊  INNERVISION INNERVISION  25-  (5)  23  -24  2010臓器がん登録の現状と将来展望-臨床へのフィードバックを目指して-.猪飼 伊和夫; 工藤 正俊  外科治療  102-  (4)  372  -377  2010造影EUS.北野 雅之; 小牧 孝充; 鎌田 研; 今井 元; 坂本 洋城; 工藤 正俊  肝胆膵  60-  457  -464  2010Diagnosis of pancreatic tumors by endoscopic ultrasonography坂本 洋城; 北野 雅之; 鎌田 研; 工藤 正俊; Muhammad El-Masry  World J Radiol  2-  (8)  122  -134  2010座談会 造影超音波は臨床を変えるか.有井 滋樹; 工藤 正俊; 森安 史典; 廣岡 芳樹  肝胆膵  60-  479  -499  2010生涯一臨床医のつぶやき「炉辺閑話2010」工藤 正俊  日本医事新報  4471-  55  -56  2010発刊にあたって.工藤 正俊  きずな  3-  1  2010肝癌の診断のアルゴリズム.工藤 正俊  臨牀消化器内科  25-  443  -451  2010わが国の肝がん治療のガイドラインを解釈する.工藤 正俊  肝胆膵  60-  271  -277  2010こう変わった・こう変わる!肝がん化学療法.上嶋 一臣; 工藤 正俊  消化器外科NURSING  臨時増刊-  128  -129  2010病院長からのメッセージ「世界への発信と同時に地域医療への貢献もめざす」工藤 正俊  DOCTOR’S MAGAZINE DOCTOR’S MAGAZINE  124-  20  -21  2010胆膵疾患における超音波内視鏡検査: 造影ならびにFNA の有用性. 特集「消化器領域の画像診断: 肝胆膵を中心に」北野 雅之; 坂本 洋城; 小牧 孝充; 工藤 正俊  映像情報メディカル  42-  277  -282  2010肝細胞癌の診断・治療アルゴリズムにおける画像の役割.特集「消化器領域の画像診断: 肝胆膵を中心に」工藤 正俊  映像情報メディカル  42-  245  -249  2010EUS-guided in vivo microdialysis of the pancreas: a novel technique with potential diagnostic and therapeutic applicationMasayuki Kitano; Hiroki Sakamoto; Kshaunish Das; Takamitsu Komaki; Masatoshi Kudo  GASTROINTESTINAL ENDOSCOPY  71-  (1)  176  -179  2010/01Non-Invasive Evaluation of Hepatic Fibrosis for Type C Chronic HepatitisChie Tatsumi; Masatoshi Kudo; Kazuomi Ueshima; Satoshi Kitai; Emi Ishikawa; Norihisa Yada; Satoru Hagiwara; Tatsuo Inoue; Yasunori Minami; Hobyung Chung; Kiyoshi Maekawa; Kenji Fujimoto; Michio Kato; Akiko Tonomura; Tsuyoshi Mitake; Tsuyoshi Shiina  INTERVIROLOGY  53-  (1)  76  -81  2010PEG-IFN alpha/RBV Combination Therapy for Chronic Hepatitis C Patients Increases Serum Ferritin Level while It Improves Sustained Viral Response RateNorihisa Yada; Masatoshi Kudo; Hobyung Chung; Sosuke Hayaishi; Masahiro Takita; Taisuke Ueda; Chie Tatsumi; Kinuyo Hatanaka; Satoshi Kitai; Emi Ishikawa; Tatsuo Inoue; Satoru Hagiwara; Kazuomi Ueshima  INTERVIROLOGY  53-  (1)  60  -65  2010Prolonged PEG-IFN and RBV Is Effective in Patients with HCV Genotype 1 and High Viral Load Who Achieved Virological Response Later than 24 WeeksTaisuke Ueda; Hobyung Chung; Masatoshi Kudo; Emi Ishikawa; Sousuke Hayaishi; Chie Tatsumi; Tatsuo Inoue; Norihisa Yada; Satoru Hagiwara; Yasunori Minami; Kazuomi Ueshima  INTERVIROLOGY  53-  (1)  55  -59  2010Outcome and Early Viral Dynamics with Viral Mutation in PEG-IFN/RBV Therapy for Chronic Hepatitis in Patients with High Viral Loads of Serum HCV RNA Genotype 1bNoriko Sasase; Soo Ryang Kim; Masatoshi Kudo; Ke Ih Kim; Miyuki Taniguchi; Susumu Imoto; Keiji Mita; Yoshitake Hayashi; Ikuo Shoji; Ahmed El-Shamy; Hak Hotta  INTERVIROLOGY  53-  (1)  49  -54  2010Double-Filtration Plasmapheresis plus IFN for HCV-1b Patients with Non-Sustained Virological Response to Previous Combination Therapy: Early Viral DynamicsSoo Ryang Kim; Susumu Imoto; Masatoshi Kudo; Keiji Mita; Miyuki Taniguchi; Ke Ih Kim; Noriko Sasase; Ikuo Shoji; Motoko Nagano-Fujii; Ahmed El-Shamy; Hak Hotta; Tomoyuki Nagai; Yoshiaki Nagata; Yoshitake Hayashi  INTERVIROLOGY  53-  (1)  44  -48  2010Changing Trends in Hepatitis C Infection over the Past 50 Years in JapanHobyung Chung; Taisuke Ueda; Masatoshi Kudo  INTERVIROLOGY  53-  (1)  39  -43  2010Preface: Viral hepatitis A to E: An update in 2010Masatoshi Kudo  Intervirology  53-  (1)  5  -9  2010/01Endoscopic findings of intestinal Behçets disease complicated with toxic megacolonY. Umehara; M. Kudo; M. Kawasaki  Endoscopy  42-  (2)  E173  -E174  2010JSH Consensus Kobe 2009: Diagnosis and treatment of hepatitis BMasashi Mizokami; Eiji Tanaka; Kazuaki Chayama; Yasuhito Tanaka; Masayuki Kurosak; Namiki Izumi; Yasuji Arase; Hiromitsu Kumada; Fumio Imazeki; Osamu Yokosuka; Masatoshi Kudo  Acta Hepatologica Japonica  51-  (5)  243  -260  2010Elevated serum ALT levels following hyperferritinemia in CHC patients receiving pegylated interferon (PEG-IFN) therapy and availability of phlebotomyHiroshi Miyata; Satoru Miyata; Masatoshi Kudo  Acta Hepatologica Japonica  51-  (7)  371  -378  2010Non-invasive evaluation method of the liver fibrosis using Real-time tissue elastograpy - Usefulness of judgment liver fibrosis stage by Liver fibrosis index (LF index)Kenji Fujimoto; Michio Kato; Akiko Tonomura; Norihisa Yada; Chie Tatsumi; Masahide Oshita; Shigeo Wada; Kazuomi Ueshima; Tetsushi Ishida; Tomoko Furuta; Masaru Yamasaki; Masahiko Tsujimoto; Mitsuru Motoki; Tsuyoshi Mitake; Shigehiro Kim; Keiji Yamamoto; Tsuyoshi Shiina; Masatoshi Kudo; Norio Hayashi  Acta Hepatologica Japonica  51-  (9)  539  -541  2010【胆膵内視鏡のトラブルシューティング】 EUS 胆道ドレナージ 逆行性胆管炎(十二指腸狭窄合併例)北野 雅之; 小牧 孝充; 坂本 洋城; 今井 元; 鎌田 研; 工藤 正俊  消化器内視鏡  21-  (12)  1908  -1910  2009/12Percutaneous Aspiration and Ethanolamine Oleate Sclerotherapy for Sustained Resolution of Symptomatic Polycystic Liver Disease: An Initial ExperienceRyosuke Nakaoka; Kunal Das; Masatoshi Kudo; Hobyung Chung; Tatsuo Innoue  AMERICAN JOURNAL OF ROENTGENOLOGY  193-  (6)  1540  -1545  2009/12Molecular targeted therapy for advanced hepatocellular carcinomaMasatoshi Kudo  Journal of Japanese Society of Gastroenterology  106-  (12)  1712  -1726  2009/12Quantitative Analysis of Myocardial Perfusion Imaging by Using 64 Channels Multi Detector-row Computed TomographyYoshifumi Nakauchi; Shinichiro Ikuta; Masayuki Kudo; Takamichi Murakami; Shunichi Miyazaki  CIRCULATION  120-  (18)  S374  -S374  2009/11Evaluation of Local Pharmacokinetics of 5-Fluorouracil in Dog Pancreas by EUS-Guided In Vivo MicrodialysisM. Kitano; H. Sakamoto; T. Komaki; K. Das; H. Imai; K. Kamata; M. Kudo  PANCREAS  38-  (8)  1017  -1018  2009/11EUS-Assisted Drainage of Pancreatic Duct for Obstructive PancreatitisM. Kitano; H. Sakamoto; T. Komaki; K. Das; H. Imai; K. Kamata; Y. Takeyama; M. Kudo  PANCREAS  38-  (8)  1018  -1018  2009/11Detection Rates of Pancreatic Tumors According to Location by Contrast-Enhanced Ultrasonography, Endosonography and Multidetector Row CTH. Imai; M. Kitano; Y. Suetomi; H. Sakamoto; T. Komaki; K. Noda; K. Kamta; Y. Takeyama; M. Kudo  PANCREAS  38-  (8)  1006  -1006  2009/11Transgastric endoscopic ultrasound (EUS)-guided gallbladder drainage for acute cholecystitisK. Kamata; M. Kitano; T. Komaki; H. Sakamoto; M. Kudo  ENDOSCOPY  41-  E315  -E316  2009/11Small invasive ductal carcinoma of the pancreas distinct from branch duct intraductal papillary mucinous neoplasmHiroki Sakamoto; Masayuki Kitano; Takamitsu Komaki; Hajime Imai; Ken Kamata; Masatomo Kimura; Yoshifumi Takeyama; Masatoshi Kudo  WORLD JOURNAL OF GASTROENTEROLOGY  15-  (43)  5489  -5492  2009/11Utility of Contrast-enhanced harmonic EUS on diagnosis of intra-abdominal lesions with undetermined originK. Kamata; M. Kitano; Y. Xia; H. Sakamoto; T. Komaki; H. Imai; Y. Suetomi; M. Kudo  JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY  24-  A96  -A96  2009/10CD133, A CANCER STEM CELL MARKER, IS A PREDICTOR OF THE EFFECTIVENESS OF S1+PEG-IFN alpha-2B THERAPY AGAINST ADVANCED HEPATOCELLULAR CARCINOMASatoru Hagiwara; Masatoshi Kudo; Mami Yamaguchi; Kazuomi Ueshima; Hobyung Chung; Ah-Mee Park; Hiroshi Munakata  HEPATOLOGY  50-  (4)  1098A  -1098A  2009/10EUS-FNA guided by contrast-enhanced harmonic imagingM. Kitano; H. Sakamoto; T. Komaki; H. Imai; K. Kamata; M. Kudo  JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY  24-  A95  -A96  2009/10USEFULNESS OF HEPATOCYTE PHASE IMAGING OF GD-EOB-DTPA-MRI IN DETECTING BORDERLINE LESIONS WHICH ARE DIFFICULT TO DETECT OTHER IMAGING MODALITIESTatsuo Inoue; Masatoshi Kudo  HEPATOLOGY  50-  (4)  746A  -746A  2009/10ANTITUMOR ACTIVITY OF A NOVEL ANGIOGENESIS INHIBITOR BIBF1 120 FOR HEPATOCELLULAR CARCINOMA AND A NEW PHARAMACODYNAMIC BIOMARKER IN BLOOD SAMPLESMasatoshi Kudo; Kanae Kudo; Tokuzo Arao; Kozuto Nishio  HEPATOLOGY  50-  (4)  1099A  -1099A  2009/10Consensus report of the 2nd International Forum for Liver MRIAkihiro Tanimoto; Jeong Min Lee; Takamichi Murakami; Alexander Huppertz; Masatoshi Kudo; Luigi Grazioli  EUROPEAN RADIOLOGY  19-  S975  -S989  2009/10Consensus report of the 2nd International Forum for Liver MRIAkihiro Tanimoto; Jeong Min Lee; Takamichi Murakami; Alexander Huppertz; Masatoshi Kudo; Luigi Grazioli  EUROPEAN RADIOLOGY  19-  (5)  S975  -S989  2009/10予後解析からみた大腸ポリペクトミーの意義と問題点辻直子; 奥村直己; 山本典雄; 加納友環; 酒井清裕; 西尾健; 冨田崇文; 梅原康湖; 森村正嗣; 米田円; 由谷逸朗; 山田哲; 本庶元; 今井元; 工藤正俊  日本消化器病学会雑誌  106-  (臨増大会)  A842  -A842  2009/09ステロイド未使用の重症潰瘍性大腸炎に対する経口タクロリムスによる寛解導入療法―サイクロスポリン持続静注との比較―梅原泰; 高山政樹; 川崎正憲; 朝隈豊; 岡田無文; 松井繁長; 工藤正俊  日本消化器病学会雑誌  106-  A836  2009/09大腸ポリペクトミークリニカルパスのバリアンス分析からみたLSTの問題点奥村直己; 辻直子; 山本典雄; 加納友環; 酒井清裕; 冨田崇文; 西尾健; 梅原康湖; 森村正嗣; 米田円; 由谷逸朗; 山田哲; 本庶元; 今井元; 工藤正俊  Gastroenterol Endosc  51-  (Supplement 2)  2309  -2309  2009/09高齢者に対する大腸ポリペクトミーの安全性と問題点山本典雄; 辻直子; 奥村直己; 酒井清裕; 加納友環; 冨田崇文; 西尾健; 梅原康湖; 森村正嗣; 米田円; 由谷逸朗; 山田哲; 本庶元; 今井元; 工藤正俊  Gastroenterol Endosc  51-  (Supplement 2)  2309  -2309  2009/09シングルバルーン小腸内視鏡による小腸疾患の診断と治療川崎正憲; 松井繁長; 梅原泰; 岡田無文; 朝隈豊; 工藤正俊  Gastroenterol Endosc  51-  (Supplement 2)  2242  2009/09Comparison of an Ecabet Sodium and Proton Pump Inhibitor (PPI) Combination Therapy with PPI Alone in the Treatment of Endoscopic Submucosal Dissection (ESD) - induced Ulcers in Early Gastric Cancer: Prospective Randomized StudyYutaka Asakuma; Masatoshi Kudo; Shigenaga Matsui; Mumon Okada; Masanori Kawasaki; Yasushi Umehara; Tsutomu Ichikawa; Satoshi Kitai  HEPATO-GASTROENTEROLOGY  56-  (94-95)  1270  -1273  2009/09血液標本における新規薬物動態バイオマーカーの血管新生阻害剤BIBF1120の抗腫瘍活性(Antitumor activity of a novel angiogenesis inhibitor BIBF1120 a new pharamacodynamic biomarker in blood samples)工藤 可苗; 荒尾 徳三; 坂井 和子; 永井 知行; 田村 大介; 青松 圭一; デベラスコ・マルコ; 金田 裕靖; 藤田 至彦; 松本 和子; 工藤 正俊; 西尾 和人  日本癌学会総会記事  68回-  484  -484  2009/08PRESENT STATUS AND FUTURE PERSPECTIVE OF EUS-GUIDED DRAINAGEMasayuki Kitano; Hiroki Sakamoto; Takamitsu Komaki; Masatoshi Kudo  DIGESTIVE ENDOSCOPY  21-  S66  -S70  2009/07Association of genetic polymorphisms with interferon-induced haematologic adverse effects in chronic hepatitis C patientsM. Wada; H. Marusawa; R. Yamada; A. Nasu; Y. Osaki; M. Kudo; M. Nabeshima; Y. Fukuda; T. Chiba; F. Matsuda  JOURNAL OF VIRAL HEPATITIS  16-  (6)  388  -396  2009/06Well-differentiated hepatocellular carcinoma smaller than 15 mm in diameter totally eradicated with percutaneous ethanol injection instead of radiofrequency ablationSoo Ryang Kim; Susumu Imoto; Taisuke Nakajima; Kenji Ando; Keiji Mita; Miyuki Taniguchi; Noriko Sasase; Toshiyuki Matsuoka; Masatoshi Kudo; Yoshitake Hayashi  HEPATOLOGY INTERNATIONAL  3-  (2)  411  -415  2009/06Clinical staging classification for hepatocellular carcinoma鄭 浩柄; 工藤 正俊  Japanese journal of clinical medicine  67-  391  -394  2009/05Evaluation of Liver Fibrosis in Diffuse Liver Disease Using Real-Time Tissue ElastographyKenji Fujimoto; Chie Tatsumi; Kazuomi Ueshima; Tsuyoshi Shiina; Akiko Tonomura; Tsuyoshi Mitake; Keiji Yamamoto; Masatoshi Kudo; Michio Kato  GASTROENTEROLOGY  136-  (5)  A835  -A835  2009/05Hepatectomy versus radiofrequency ablation for early hepatocellular carcinoma: ReplyKiyoshi Hasegawa; Masatoshi Makuuchi; Masatoshi Kudo; Masatoshi Okazaki  JOURNAL OF HEPATOLOGY  50-  (5)  1052  -1053  2009/05Campylobacter fetus Meningitis in a Patient with Crohn's DiseaseYasushi Umehara; Masatoshi Kudo; Masanori Kawasaki  INFLAMMATORY BOWEL DISEASES  15-  (5)  645  -646  2009/05Scirrhous hepatocellular carcinoma displaying atypical findings on imaging studiesSoo Ryang Kim; Susumu Imoto; Taisuke Nakajima; Kenji Ando; Keiji Mita; Katsumi Fukuda; Ryo Nishikawa; Yu-ichiro Koma; Toshiyuki Matsuoka; Masatoshi Kudo; Yoshitake Hayashi  WORLD JOURNAL OF GASTROENTEROLOGY  15-  (18)  2296  -2299  2009/05Small cell carcinoma of the pancreas: role of EUS-FNA and subsequent effective chemotherapy using carboplatin and etoposideHiroki Sakamoto; Masayuki Kitano; Takamitsu Komaki; Kazu Noda; Takaaki Chikugo; Masatoshi Kudo  JOURNAL OF GASTROENTEROLOGY  44-  (5)  432  -438  2009/05Crohn's Disease with Gastroduodenal Mucosa Lesions that Are Similar to the Lesions Caused by Ulcerative ColitisYasushi Umehara; Masatoshi Kudo; Masanori Kawasaki  INFLAMMATORY BOWEL DISEASES  15-  (5)  646  -648  2009/05進行胃癌に対するソナゾイドを用いた造影EUSの意義岡田無文; 松井繁長; 工藤正俊  Gastroenterol Endosc  51-  (Supplement 1)  660  2009/04FNA Guided By Contrast-Enhanced Harmonic EUS in Pancreatic TumorsMasayuki Kitano; Hiroki Sakamoto; Takamitsu Komaki; Masatoshi Kudo  GASTROINTESTINAL ENDOSCOPY  69-  (5)  AB328  -AB329  2009/04EUS-Guided In Vivo Microdialysis of Pancreas: A Novel Technique of Potential Diagnostic and Therapeutic ApplicationMasayuki Kitano; Hiroki Sakamoto; Takamitsu Komaki; Masatoshi Kudo  GASTROINTESTINAL ENDOSCOPY  69-  (5)  AB138  -AB138  2009/04Contrast-Enhanced Harmonic EUS of Intra-Abdominal Lesions with Undetermined Origin: Initial Observation of Vascularity DepictionMasayuki Kitano; Yu Xia; Hiroki Sakamoto; Takamitsu Komaki; Kazu Noda; Masatoshi Kudo  GASTROINTESTINAL ENDOSCOPY  69-  (5)  AB327  -AB327  2009/04Dynamic Imaging By Contrast-Enhanced Harmonic EUS with Long-Lasting Contrast: Role in Diagnosis of Pancreatic TumorsMasayuki Kitano; Tadayuki Takagi; Hiroki Sakamoto; Takamitsu Komaki; Kazu Noda; Kenji Yamao; Masatoshi Kudo  GASTROINTESTINAL ENDOSCOPY  69-  (5)  AB235  -AB236  2009/04肝癌発生・進展の分子機構と臨床への還元 血管新生阻害薬のバイオマーカー研究荒尾 徳三; 工藤 正俊; 西尾 和人  肝臓  50-  (Suppl.1)  A96  -A96  2009/04粘膜下異所性胃腺を合併した早期胃癌の2例岡田無文; 松井繁長; 朝隈豊; 川崎正憲; 梅原泰; 工藤正俊; 今本治彦; 筑後孝章  日本消化器病学会雑誌  106-  A390  2009/03Pathologic diagnosis of early hepatocellular carcinoma: a report of the International Concensus Group for Hepatocellualr Neoplasia (vol 49, pg 658, 2009)Pierre Bedossa; Dina Tiniakos; Masatoshi Kudo  HEPATOLOGY  49-  (3)  1058  -1058  2009/03Prospective comparative study of the EUS guided 25-gauge FNA needle with the 19-gauge Trucut needle and 22-gauge FNA needle in patients with solid pancreatic massesHiroki Sakamoto; Masayuki Kitano; Takamitsu Komaki; Kazu Noda; Takaaki Chikugo; Kensaku Dote; Yoshifumi Takeyama; Kunal Das; Kenji Yamao; Masatoshi Kudo  JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY  24-  (3)  384  -390  2009/03Value of Liver Parenchymal Phase Contrast-Enhanced Sonography to Diagnose Premalignant and Borderline Lesions and Overt Hepatocellular CarcinomaTatsuo Inoue; Masatoshi Kudo; Osamu Maenishi; Mina Komuta; Osamu Nakashima; Masamichi Kojiro; Kiyoshi Maekawa  AMERICAN JOURNAL OF ROENTGENOLOGY  192-  (3)  698  -705  2009/03Dynamic imaging of pancreatic tumors by contrast-enhanced harmonic EUS with long-lasting contrastMasayuki Kitano; Tadayuki Takagi; Hiroki Sakamoto; Kunal Das; Takamitsu Komaki; Kazu Noda; Kenji Yamao; Masatoshi Kudo  GASTROINTESTINAL ENDOSCOPY  69-  (2)  S228  -S228  2009/02肝疾患におけるReal-time Tissue Elastography-第4報藤本研治; 辰巳千栄; 上嶋一臣; 外村明子; 三竹毅; 金栄浩; 山本佳司; 椎名毅; 工藤正俊; 加藤道夫  超音波医学  36-  2009肝細胞癌患者におけるS-1臨床第I/II相試験-臨床第II相試験の成績報告-奥坂拓志; 古瀬純司; 金子周一; 工藤正俊; 池田公史; 仲地耕平; 山下竜也; 上嶋一臣  日本臨床腫瘍学会学術集会プログラム・抄録集  7th-  2009第45回日本肝臓学会総会 工藤正俊会長に聞く.工藤 正俊; 泉 並木; 具 英成  肝臓  50-  (1)  1  -5  2009Gd-EOB-DTPAの登場による肝画像診断におけるMRIの役割と可能性岡田 真広; 熊野 正士; 香川祐毅; 勝部 敬; 今岡 いずみ; 工藤 正俊; 村上 卓道; 今井 康陽  日獨医報  54-  80  -93  2009肝細胞胆道系MRI造影剤で肝画像診断のone-stop shoppingは可能か?村上 卓道; 岡田 真広; 熊野 正士; 中塚 隆之; 香川祐毅; 勝部 敬; 今岡 いずみ; 工藤 正俊; 今井 康陽  肝胆膵画像  11-  539  -551  2009RFA治療後の肝細胞癌再発症例村上 卓道; 岡田 真広; 中居 卓也; 工藤 正俊  EOB-PrimovistR Enhanced MRI Practical Report EOB-PrimovistR Enhanced MRI Practical Report  1-  1  -4  2009座談会 肝細胞癌診療.有井 滋樹; 工藤 正俊; 三代 俊治; 松井 修; 泉 並木; 國土 典宏  肝臓  50-  (8)  407  -426  2009肝細胞癌診療の現況: サーベイランスから分子標的治療まで.沖田 極; 工藤 正俊; Jordi Bruix  日経メディカルCancer Review  9-  18  -21  2009肝細胞癌の分子生物学的病因と分子標的治療: 生存期間延長を目指す最新の療法.工藤 正俊; Jopsep M. Llovet  日経メディカルCancer Review  9-  15  -17  2009分子標的薬がもたらしたパラダイムシフト.工藤 正俊; Jopsep M. Llovet; Jordi Bruix  ミクス  8-  2  -5  2009Transgastric endoscopic ultrasound (EUS)-guided gallbladder drainage for acute cholecystitisK. Kamata; M. Kitano; T. Komaki; H. Sakamoto; M. Kudo  Endoscopy  41-  (2)  E315  -E316  2009EUS下膵?胞ドレナージ術.北野 雅之; 小牧 孝充; 坂本 洋城; 末冨 洋一郎; 工藤 正俊  胆と膵  30-  1239  -1244  2009肝細胞癌のバイオマーカーとしてのAFPレクチン分画とDes-Gammma-Carboxy Prothrombin単独・両者測定の有用性.工藤 正俊  Hepatology World Review Hepatology World Review  1-  1  2009大学病院の機能を最大限に生かすとともに地域医療を支える基幹病院としての役割を果たす.工藤 正俊; 小山 新造  陽だまり  5-  1  -2  2009第45回日本肝臓学会総会の開催に当たって “From the-state-of-the-art science to real practice”, “From the-state-of-the-art science to future science”.工藤 正俊  Medicament News Medicament News  1979-  22  2009超音波造影剤: 最近の進歩.畑中 絹世; 工藤 正俊; 前川 清  映像情報メディカル  2009ウイルス性慢性肝炎.萩原 智; 工藤 正俊  近畿大学医学雑誌  33-  335  -341  2009肝胆膵のIntervention-エキスパートからのメッセージ 経皮経肝的アプローチ-肝嚢胞に対するアブレーション.井上 達夫; 石川 恵美; 南 康範; 鄭 浩柄; 工藤 正俊  肝胆膵画像  11-  117  -120  2009肝細胞癌の画像診断と病理・病態-現状と将来展望-多段階発癌・早期肝細胞癌の画像診断と病理・病態-超音波診断-.井上 達夫; 畑中 絹世; 前川 清; 工藤 正俊  画像診断  2009肝障害を評価する画像解析的アプローチ.井上 達夫; 工藤 正俊  成人病と生活習慣病  39-  407  -411  2009研修医のための教育講座 炎症性腸疾患.梅原 泰; 工藤 正俊  近畿大学医学雑誌  34-  83  -88  2009発刊にあたって.工藤 正俊  きずな  2-  1  2009発刊にあたって.工藤 正俊  きずな  1-  1  2009肝細胞癌の分子標的療法の最前線~ILCA 2009を振り返って~.工藤 正俊; 坂元 亨宇; Andrew X. Zhu  日経メディカルオンライン 癌Experts  2009造影エコーによる肝癌診療最前線.畑中 絹世; 工藤 正俊  内科  104-  696  -701  2009肝癌の診断 肝臓perfusion CT.南 康範; 工藤 正俊; 村上 卓道  日本臨床  67-  342  -345  2009肝癌の進行度判定 病期分類・ステージ分類とその診断法 .鄭 浩柄; 工藤 正俊  日本臨床  67-  342  -345  2009肝腫瘍診断におけるDefect Re-perfusion Imagingの有用性.畑中 絹世; 工藤 正俊  消化器科  48-  454  -463  2009造影ハーモニックEUS検査による膵腫瘍性病変診断 .北野 雅之; 坂本 洋城; 小牧 孝充; 工藤 正俊; 竹山 宜典; 高木忠之; 山雄健次  膵臓  24-  322  2009胆膵疾患におけるUS/EUS診断・治療の最前線 胆膵領域における造影超音波内視鏡 .北野 雅之; 小牧 孝充; 坂本 洋城; 工藤 正俊  胆と膵  30-  723  -729  2009再発大腸癌の診断と治療 肝転移に対するラジオ波治療.井上 達夫; 工藤 正俊  癌と化学療法  2009EUSによる胆管癌の進展度診断.小牧 孝充; 北野 雅之; 工藤 正俊  胆道  23-  432  2009経乳頭的アプローチ困難例に対するEUSガイド下胆管ドレナージ術の有用性.鎌田 研; 北野 雅之; 末冨 洋一郎; 坂本 洋城; 小牧 孝充; 今井 元; 工藤 正俊  胆道  23-  451  2009難治性C型慢性肝炎に対する治療戦略-後期陰性化症例における検討- .上田 泰輔; 鄭 浩柄; 工藤 正俊  消化器科  49-  129  -132  2009胆膵治療内視鏡のエキスパートテクニック EUS関連手技 EUS下膵嚢胞ドレナージ術.北野 雅之; 小牧 孝充; 坂本 洋城; 末冨 洋一郎; 工藤 正俊  胆と膵  30-  1239  -1244  2009肝癌患者の治療法別QOL(quality of life)における性差.中山伸朗; 工藤 正俊; 名越澄子; 持田智; 小俣政男; 熊田博光; 佐田通夫; 國土典宏; 門田守人; 兼松隆之; 江川裕人; 森脇久隆; 藤原研司  医学と薬学  62-  639  2009肝細胞癌診療の現況: サーベイランスから分子標的治療まで.工藤 正俊; 沖田 極; Jordi Bruix  日経メディカルCancer Review  9-  18  -21  2009分子標的薬がもたらしたパラダイムシフト.工藤 正俊; Jopsep M. Llovet; Jordi Bruix  ミクス  8-  2  -5  2009肝細胞癌の分子生物学的病因と分子標的治療: 生存期間延長を目指す最新の療法.工藤 正俊; Jopsep M. Llovet  日経メディカルCancer Review  9-  15  -17  2009座談会「肝癌の分子標的薬治療 新しいパラダイムの幕開け」工藤 正俊; Vincenzo Mazzaferro; Jordi Bruix; Morris Sherman  医学界新聞  2848-  1  -3  2009十二指腸静脈瘤の臨床的特徴と診断, 治療.松井 繁長; 工藤 正俊  日本門脈圧亢進症学会雑誌  15-  1  -5  2009肝細胞癌の治療法の選択.工藤 正俊  コンセンサス癌治療  8-  140  -143  2009肝細胞癌に対する経皮的ラジオ波焼灼療法-最新の進歩工藤 正俊  医学のあゆみ  231-  189  -195  2009原因不明の腫大リンパ節におけるEUS-FNAの有用性. 膵・胆道癌遠隔転移診断: 2009坂本 洋城; 北野 雅之; 末冨 洋一郎; 小牧 孝充; 今井 元; 鎌田 研; 工藤 正俊  胆と膵  30-  973  -978  2009第45回日本肝臓学会総会-新型インフルエンザ神戸直撃下での開催-.工藤 正俊  臨牀消化器内科  24-  1420  2009序説 肝細胞胆道系MRI造影剤は肝画像診断体系を変えるか?工藤 正俊  肝胆膵画像「肝細胞胆道系MRI造影剤のインパクト」  11-  477  -483  2009消化器内科医の立場から.工藤 正俊  肝特異性造影剤の展望を読み解くLiver Imaging Review (LIR)  3-  7  2009Acute pancreatitis associated with pegylated interferon and ribavirin treatment of chronic hepatitis C, genotype 1b with high viral load.ANDO K  Case Rep Gastroenterol  3-  372  -376  2009Contrast-enhanced harmonic ultrasound imaging in ablation therapy for primary hepatocelular carcinoma.南 康範; 工藤 正俊  World J Radiol  31-  86  -91  2009The burden of HCC in Asia-Pacific.工藤 正俊  LIVER MRI  4-  1  -2  2009造影EUS検査による進行胃癌原発巣の化学療法効果判定.岡田 無文; 高山 政樹; 永田 嘉昭; 川崎 正憲; 朝隈 豊; 梅原 泰; 松井 繁長; 北野 雅之; 工藤 正俊  胃と腸  44-  1871  -1877  2009腹部血管造影検査.上嶋 一臣; 鄭 浩柄; 工藤 正俊  消化器now  46-  8  2009肝細胞がんの診断・治療ガイドライン.工藤 正俊  日本医師会雑誌 特集「肝疾患診療の新しい展開」  138-  1125  -1133  2009消化器内科医の立場から.工藤 正俊  肝特異性造影剤の展望を読み解くLiver Imaging Review (LIR)  4-  1  2009EOBプリモビストが肝画像診断体系に与えるインパクト.工藤 正俊  新医療  7-  134  -138  2009非特異的な画像所見を呈した肝腫瘍の1例.早石 宗右; 井上 達夫; 鄭 浩柄; 工藤 正俊  特集・消化器診療 示唆に富む症例, 消化器の臨床  14-  411  -413  2009胆膵領域における造影超音波内視鏡.北野 雅之; 小牧 孝充; 坂本 洋城; 工藤 正俊  胆と膵  30-  723  -729  2009超音波内視鏡ガイド下腹腔神経叢ブロック-抗癌剤治療継続のための疼痛緩和-.小牧 孝充; 北野 雅之; 坂本 洋城; 工藤 正俊  消化器科  48-  687  -691  2009肝細胞癌診療の現状と展望 ①画像診断: 最近の進歩.工藤 正俊  The Liver Cancer Journal The Liver Cancer Journal  6-  12  -24  2009がんの進行を抑え、生存を延ばす肝がん薬物療法時代.工藤 正俊  がんサポート  74-  44  -47  2009超音波内視鏡(EUS)下ソナゾイド造影超音波検査.北野 雅之; 坂本 洋城; 小牧 孝充; 工藤 正俊  INNERVISION INNERVISION  24-  (6)  55  -58  2009Pegylated Interferon plus Ribavirin Combination Therapy for Chronic Hepatitis C with High Viral Load of Serum Hepatitis C Virus RNA, Genotype 1b, Discontinued on Attaining Sustained Virological Response at Week 16 after Onset of Acute PancreatitisSoo Ryang Kim; Susumu Imoto; Keiji Mita; Miyuki Taniguchi; Noriko Sasase; Akira Muramatsu; Masatoshi Kudo; Satoshi Kitai; Ahmed El-Shamy; Hak Hotta; Yoshitake Hayashi  DIGESTION  79-  (1)  36  -39  20091cm以下小膵癌の診断のためのアプローチ-各画像診断の比較-.坂本 洋城; 北野 雅之; 竹山 宜典; 工藤 正俊  胆と膵  30-  (4)  335  -341  2009炎症性腸疾患.梅原 泰; 工藤 正俊  近畿大学医学雑誌  34-  83  -88  2009ソラフェニブの臨床使用経験と今後の展望.工藤 正俊  肝胆膵 「肝胆膵悪性腫瘍に対する分子標的治療の現状と展望」  58-  317  -333  2009Multistep human hepatocarcinogenesis: correlation of imaging with pathologyMasatoshi Kudo  JOURNAL OF GASTROENTEROLOGY  44-  112  -118  2009/01肝癌診療ガイドラインを中心とした肝癌の診断・治療の現状と最近の進歩.工藤 正俊  Pharmacy Today Pharmacy Today  22-  18  -26  2009ソナゾイドは肝癌診療をどう変えるか?工藤 正俊  「第64回東海総合企画画像医学研究会論文集」 映像情報メディカル  41-  74  -75  2009RFA-safety marginの必要性とそのevidence.工藤 正俊  シンポジウム「肝細胞癌治療における局所再発の抑制とSafety/Surgical marginの必要性-画像による判定」, 第15回肝血流動態イメージ研究会 パシフィコ横浜, 神奈川  2009/01SURGICAL RESECTION VS. PERCUTANEOUS ABLATION FOR HEPATOCELLULAR CARCINOMA: A PRELIMINARY REPORT OF THE JAPANESE NATIONWIDE SURVEYK. Hascgawa; T. Takayama; N. Kokudo; S. Arii; M. Okazaki; K. Okita; M. Omata; M. Kudo; M. Kojiro; Y. Nakanuma; K. Takayasu; M. Monden; Y. Matsuyama; I. Ikai; T. Ichida; M. Sakamoto; O. Nakajima; M. Makuuchi  JOURNAL OF HEPATOLOGY  50-  S29  -S29  2009The clinical characteristics, diagnosis and treatment for patients presenting with duodenal varicesMatsui S; Kudo M  Japanese Journal of Portal Hypertension  15-  (2)  190  -194  2009Panel discussion: Management of hepatocellular carcinomaShigeki Arii; Shunji Mishiro; Osamu Matsui; Namiki Izumi; Masatoshi Kudo; Norihiro Kokudo  Acta Hepatologica Japonica  50-  (8)  407  -426  2009JSH consensus Kobe 2009: Diagnosis and treatment of hepatitis CShuhei Nishiguchi; Namiki Izumi; Keisuke Hino; Fumitaka Suzuki; Hiromitsu Kumada; Yoshito Ito; Yasuhiro Asahina; Akihiro Tamori; Naoki Hiramatsu; Norio Hayashi; Masatoshi Kudo  Acta Hepatologica Japonica  50-  (11)  665  -677  2009JSH consensus Kobe 2009; Diagnosis and treatment of NASHTakeshi Okanoue; Toshiji Saibara; Masafumi Ono; Yoshio Sumida; Etsuko Hashimoto; Shinji Tamura; Gotaro Yamada; Sumio Kawada; Masatoshi Kudo  Acta Hepatologica Japonica  50-  (12)  741  -747  2009In situ carcinoma of pancreas diagnosed by EUS-FNAH. Sakamoto; M. Kitano; K. Dote; T. Tchikugo; Y. Takeyama; M. Kudo  ENDOSCOPY  40-  E15  -E16  2008/12Interventional EUS for pancreatic diseasesKITANO Masayuki; SAKAMOTO Hiroki; KUDO Masatoshi  Japanese journal of medical ultrasOnics= 超音波医学  35-  (6)  663  -670  2008/11EXPERIMENTAL AND EARLY CLINICAL STUDIES OF S-1, A NOVEL ORAL DPD INHIBITOR, CHEMOTHERAPY FOR ADVANCED HEPATOCELLULAR CARCINOMATatsuya Yamashita; Shuichi Kaneko; Junji Furuse; Takuji Okusaka; Masatoshi Kudo; Kohei Nakachi; Masafumi Ikeda; Kazuomi Ueshima  HEPATOLOGY  48-  (4)  949A  -949A  2008/10Surgical resection vs. percutaneous ablation for hepatocellular carcinoma: A preliminary report of the Japanese nationwide surveyKiyoshi Hasegawa; Masatoshi Makuuchi; Tadatoshi Takayama; Norihiro Kokudo; Shigeki Arii; Masatoshi Okazaki; Kiwamu Okita; Masao Omata; Masatoshi Kudo; Masamichi Kojiro; Yasuni Nakanuma; Kenichi Takayasu; Morito Monden; Yutaka Matsuyama; Iwao Ikai  JOURNAL OF HEPATOLOGY  49-  (4)  589  -594  2008/10術前イマチニブ投与が有用だった巨大直腸gastrointestinal stromal tumor(GIST)の一症例今井元; 南康範; 梅原泰; 石丸英三郎; 上嶋一臣; 松井繁長; 末冨洋一郎; 鄭浩柄; 石川恵美; 井上達夫; 坂本洋城; 萩原智; 野田佳寿; 北野雅之; 汐見幹夫; 工藤正俊  日本消化器病学会雑誌  105-  A820  2008/09ESD後胃潰瘍に対するエカベトナトリウムの有用性(Prospective randomized study)朝隈豊; 松井繁長; 岡田無文; 市川勉; 川崎正憲; 梅原泰; 工藤正俊  日本消化器病学会雑誌  105-  A760  2008/09Sonazoidを用いた造影EUSによる進行胃癌の化学療法効果判定岡田無文; 松井繁長; 工藤正俊  Gastroenterol Endosc  50-  (Supplement 2)  2079  2008/09当院でのステロイド未使用の潰瘍性大腸炎に対する白血球除去療法の治療成績梅原泰; 川崎正憲; 朝隈豊; 岡田無文; 市川勉; 松井繁長; 今井元; 野田佳寿; 坂本洋城; 石川恵美; 井上達夫; 萩原智; 末冨洋一郎; 南康範; 鄭浩柄; 上嶋一臣; 北野雅之; 汐見幹夫; 工藤正俊  Gastroenterol Endosc  50-  (Supplement 2)  2337  2008/09当院におけるシングルバルーン小腸内視鏡検査の有用性川崎正憲; 松井繁長; 梅原泰; 岡田無文; 市川勉; 朝隈豊; 工藤正俊  Gastroenterol Endosc  50-  (Supplement 2)  2278  2008/09Radiofrequency ablation under sonazoid contrast harmonic sonography guidance for hepatocellular carcinoma that poorly defined with B-mode sonographyY. Minami; M. Kudo  JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY  23-  A52  -A52  2008/09血漿糖鎖解析による膵臓癌の診断(Mass spectrometric analysis of plasma N-glycan in pancreas cancer)坂本 洋城; 荒尾 徳三; 松本 和子; 北野 雅之; 工藤 正俊; 西尾 和人  日本癌学会総会記事  67回-  342  -342  2008/09VEGFR2チロシンキナーゼ阻害剤のフローサイトメトリーによるチロシンリン酸化阻害剤の検討(Inhibition of phospho-tyrosine in VEGFR2+CD45dim population as a biomarker for VEGFR2 tyrosine kinase inhibitors)工藤 可苗; 荒尾 徳三; 松本 和子; 田中 薫; 前川 麻里; 金田 裕靖; 藤田 至彦; 工藤 正俊; 西尾 和人  日本癌学会総会記事  67回-  365  -365  2008/09Endoscopic findings can predict the efficacy of leukocytapheresis for steroid-naive patients with moderately active ulcerative colitisYasushi Umehara; Masatoshi Kudo; Masanori Kawasaki  WORLD JOURNAL OF GASTROENTEROLOGY  14-  (34)  5316  -5321  2008/09Long-term follow-up of atypical progressive focal nodular hyperplasia increasing in size and number implicates its pathogenesisMasatoshi Kudo; Rong Q. Zheng; Hobyung Chung; Takeo Yonekura; Makoto Yagi; Osamu Nakashima; Masamichi Kojiro  AMERICAN JOURNAL OF GASTROENTEROLOGY  103-  (8)  2153  -2155  2008/08Prognostic value of pretreatment levels of tumor markers for hepatocellular carcinoma on survival after curative treatment of patients with HCCHidenori Toyoda; Takashi Kumada; Yuji Kaneoka; Yukio Osaki; Toru Kimura; Akira Arimoto; Hiroko Oka; Osamu Yamazaki; Takao Manabe; Fumihiro Urano; Hobyung Chung; Masatoshi Kudo; Takashi Matsunaga  JOURNAL OF HEPATOLOGY  49-  (2)  223  -232  2008/08Prevention of Recurrence of Liver CancerKudo Masatoshi  Nihon Naika Gakkai Zasshi  97-  (7)  1681  -1689  2008/07Tumor markers after radiofrequency ablation therapy for hepatocellular carcinomaChikara Ogawa; Masatoshi Kudo; Yasunori Minami; Hobyung Chung; Toshihiko Kawasaki  HEPATO-GASTROENTEROLOGY  55-  (85)  1454  -1457  2008/07Multistep progression from a hypovascular nodule to a nodule-in-nodule type hepatocellular carcinoma in hepatitis C-related cirrhosisKaushal Madan; Masatoshi Kudo; Nobuhiro Fukuta  Indian Journal of Gastroenterology  27-  (4)  176  2008/07SY-5-4 日本肝癌研究会全国原発性肝癌追跡調査の現状と課題(シンポジウム5 日本における消化器癌データベース : 真の貢献のための課題を探る,第63回日本消化器外科学会総会)猪飼 伊和夫; 工藤 正俊  日本消化器外科学会雑誌  41-  (7)  2008/07The diagnosis of pancreatic disease by endoscopic ultrasonography坂本 洋城; 北野 雅之; 工藤 正俊  綜合臨床  57-  (6)  1837  -1840  2008/06Radiofrequency ablation of hepatocellular carcinoma: Value of virtual CT sonography with magnetic navigationYasunori Minami; Hobyung Chung; Masatoshi Kudo; Satoshi Kitai; Shunsuke Takahashi; Tatsuo Inoue; Kuzuomi Ueshima; Hitoshi Shiozaki  AMERICAN JOURNAL OF ROENTGENOLOGY  190-  (6)  W335  -W341  2008/06The clinical characteristics, endoscopic treatment, and prognosis for patients presenting with duodenal varicesShigenaga Matsui; Masatoshi Kudo; Tsutomu Ichikawa; Mumon Okada; Yoshio Miyabe  HEPATO-GASTROENTEROLOGY  55-  (84)  959  -962  2008/05Pegylated interferon α-2b/ribavirin combination therapy for elderly patients with chronic hepatitis C with high viral load of HCV genotype 1bKIM Soo Ryang; IMOTO Susumu; FUKI Shuichi; KIM Ke Ih; TANIGUCHI Miyuki; NAGANO Motoko; HOTTA Hak; SHOUJI Ikuo; KANBARA Yoshihiro; MAEKAWA Yoko; KUDO Masatoshi; HAYASHI Yoshitake  Kanzo  49-  (4)  145  -152  2008/04第2世代超音波造影剤による内視鏡的超音波検査(CE-EUS)の開発と臨床応用工藤 正俊  日本消化器内視鏡学会雑誌 = Gastroenterological endoscopy  50-  645  -646  2008/04Contrast-enhanced harmonic EUS with SonazoidKITANO Masayuki; SAKAMOTO Hiroki; KUDO Masatoshi  Japanese journal of medical ultrasOnics= 超音波医学  35-  S137  2008/04Joint Research for the Objective Rating of Hepatic Tissue Characterization Using Real-time Tissue Elastography (3rd report)FUJIMOTO Kenji; TATSUMI Chie; UESHIMA Kazuomi; MAEKAWA Kiyoshi; KATO Michio; KUDO Masatoshi; TONOMURA Akiko; YAMAKAWA Makoto; SHIINA Tsuyoshi  Japanese journal of medical ultrasOnics= 超音波医学  35-  2008/04Study of Ablated valome after RFA using CE-US with Sonazoid, Defect-reinjection-test and new imagingMAEKAWA Kiyoshi; HATANAKA Kinuyo; YOKOGAWA Mika; MAENO Tomoko; ICHIJIMA Mayumi; INOUE Tatuo; MINAMI Yasunori; TEI Hiroshi; UESHIMA Kazuomi; KUDO Masatoshi  Japanese journal of medical ultrasOnics= 超音波医学  35-  2008/04Contrast enhanced sonography for hepatic malignancies : value of Defect Re-injection TestHATANAKA Kinuyo; MINAMI Yasunori; KITAI Satoshi; TATSUMI Chie; TAKAHASHI Syunsuke; INOUE Tatsuo; HAGIWARA Satoru; CHUNG Hobyung; UESHIMA Kazuomi; KUDO Masatoshi  Japanese journal of medical ultrasOnics= 超音波医学  35-  S626  2008/04Evaluation of the effectiveness of radiofrequency ablation for hepatic malignancies: Usefulness of virtual CT sonography using magnetic navigationYasunori Minami; Satoshi Kitai; Masatoshi Kudo  GASTROENTEROLOGY  134-  (4)  A828  -A828  2008/04Clinicopathological time trends for early gastric cancer and Helicobacter pylori infection in JapanNaoko Tsuji; Shingo Ishiguro; Yasuko Umehara; Masatoshi Kudo  GASTROENTEROLOGY  134-  (4)  A613  -A613  2008/04Contrast enhanced sonography for hepatic malignancies: Value of defect RE-injection testKinuyo Hatanaka; Masatoshi Kudo; Yasunori Minami  GASTROENTEROLOGY  134-  (4)  A828  -A828  2008/04Utility of contrast-enhanced endoscopic ultrasonography for diagnosis of small pancreatic carcinomasHiroki Sakamoto; Masayuki Kitano; Yoichiro Suetomi; Kiyoshi Maekawa; Yoshifumi Takeyama; Masatoshi Kudo  ULTRASOUND IN MEDICINE AND BIOLOGY  34-  (4)  525  -532  2008/04Cronkhite-Canada症候群に腸重積を合併した1例早石 宗介; 石川 恵美; 南 康範; 上田 和毅; 工藤 正俊  日本消化器病学会雑誌  105-  (臨増総会)  A383  -A383  2008/03Foreign body granuloma mimicking disseminated tumour recurrence after radiofrequency ablation for hepatocellular carcinomaShunsuke Takahashi; Hobyung Chung; Satoshi Kitai; Tatsuo Inoue; Yasunori Minami; Kazuomi Ueshima; Masatoshi Kudo  LIVER INTERNATIONAL  28-  (3)  414  -415  2008/03Superiority of CT arterioportal angiography to contrast-enhanced CT and MRI in the diagnosis of hepatocellular carcinoma in nodules smaller than 2 cmS. R. Kim; S. Imoto; H. Ikawa; K. Ando; K. Mita; S. Fuki; K. Kim; M. Taniguchi; N. Sasase; T. Matsuoka; M. Kudo; Y. Hayashi  JOURNAL OF HEPATOLOGY  48-  S148  -S148  2008Comparison of endoscopic ultrasound guided directional e-FLOW using microbubble contrast gent with power Doppler and color Doppler in solid pancreatic lesions.Das K; Kitano M; Sakamoto H; Komaki T; Takagi T; Yamao K; Kudo M  Ultrasound Med Biol  2008転移性肝がんの診断【近畿大学医学部附属病院】岡田 真広; 熊野 正士; 畑中 絹世; 工藤 正俊; 村上 卓道  INNEVISION INNEVISION  23-  6  -11  2008造影剤と撮像法の工夫.工藤 正俊  日本画像医学雑誌  26-  (2)  96  2008LOGIQ7を用いたSonazoid造影超音波検査における新しい支援画像表示の試み前川 清; 上硲 俊法; 上嶋 一臣; 工藤 正俊  超音波医学  35-  (2)  251  -252  2008日本肝癌研究会全国原発性肝癌追跡調査の現状と課題.猪飼 伊和夫; 工藤 正俊  日本消化器外科学会雑誌  41-  (7)  1009  2008膵癌早期診断の為のアプローチ:US,EUSを中心に.坂本 洋城; 北野 雅之; 工藤 正俊; 竹山 宜典  膵臓  23-  308  2008経乳頭的アプローチ困難例に対するEUSを用いた胆管ドレナージ術の検討.小牧 孝充; 北野 雅之; 坂本 洋城; 末冨 洋一郎; 野田 佳寿; 工藤 正俊  胆道  22-  (3)  370  2008異物によるイレウスの1症例.横山 美加; 前野 知子; 市島 真由美; 塩見 香織; 前川 清; 内藤 昭智; 上硲 俊法; 石川 恵美; 工藤 正俊  私立医科大学臨床検査技師会誌  47-  6  2008十二指腸血腫による急性膵炎の経過をUSで観察し得た1例横山 美加; 前野 知子; 市島 真由美; 前川 清; 内藤 昭智; 上硲 俊法; 野上 隆司; 鄭 浩柄; 工藤 正俊; 八木 誠  超音波医学  35-  255  2008十二指腸静脈瘤の臨床的特徴と診断,治療.松井 繁長; 工藤 正俊  日本門脈圧亢進症  14-  63  2008消化器内科医の立場から.工藤 正俊  肝特異性造影剤の展望を読み解くLiver Imaging Review (LIR)  2-  7  2008PART1造影 1)基礎編 撮像法畑中 絹世; 工藤 正俊  臨床画像  24-  541  -546  2008肝癌. III. 消化管疾患.上嶋 一臣; 工藤 正俊  綜合臨床  57-  1050  -1052  2008何故書くか、何故書けないか工藤 正俊  近畿大医誌  33-  (3)  2008C型慢性肝炎に対する非侵襲的肝線維化評価: FibroscanとElastgraphy.辰巳 千栄; 工藤 正俊; 上嶋 一臣; 藤本 研治; 加藤 道夫  肝胆膵「C型肝炎のすべて・2009」  57-  749  -754  2008術前診断されたStage 1膵癌の症例と解説.坂本 洋城; 北野 雅之; 竹山 宜典; 筑後 孝章; 土手 健作; 工藤 正俊  消化器画像  10-  (6)  539  -544  2008Philips Academy Seminar: 肝臓イメージングワークシップ “超音波によるアプローチ最前線: Sonazoid造影超音波と3D超音波の意義.”工藤 正俊  映像情報Medical 2008  8-  1  2008肝癌に対する治療支援.工藤 正俊  総合臨牀  57-  2957  -2964  2008Focal Nodular Hyperplasia-like Lesion with Venous Washout in Alcoholic Liver CirrhosisSoo Ryang Kim; Susumu Imoto; Hirotsugu Ikawa; Kenji Ando; Keiji Mita; Kenji Shimizu; Miyuki Taniguchi; Noriko Sasase; Toshiyuki Matsuoka; Masatoshi Kudo; Norifumi Kawada; Yoshitake Hayashi  INTERNAL MEDICINE  47-  (21)  1899  -1903  2008造影超音波検査.畑中 絹世; 工藤 正俊  消化器now  43-  8  2008肝臓の造影超音波と3Dイメージ.畑中 絹世; 工藤 正俊; 前川 清; 土師 誠二  胆と膵  29-  1163  -1172  2008Defect Re-perfusion Imagingの有用性とRFA治療支援.畑中 絹世; 工藤 正俊  INNERVISION INNERVISION  23-  31  -35  2008胆嚢隆起性病変.井上 達夫; 野田 佳寿; 坂本 洋城; 北野 雅之; 工藤 正俊  綜合臨牀  57-  2581  -2584  2008肝腫瘍の造影エコー.畑中 絹世; 工藤 正俊  綜合臨牀  57-  2761  -2766  2008Intracystic Hemorrhage in a Patient of Polycystic Kidney with Renocolic Fistula Diagnosed by Contrast-Enhanced UltrasonographyEmi Ishikawa; Masatoshi Kudo; Yasunori Minami; Kazuomi Ueshima; Hobyung Chung; Sosuke Hayaishi; Kiyoshi Maekawa  INTERNAL MEDICINE  47-  (22)  1977  -1979  2008肝癌.工藤 正俊  Patient Instruction in Cancer Chemotherapy Patient Instruction in Cancer Chemotherapy  16-  2  -7  2008これだけは知っておきたい 肝臓がんの診断と治療.工藤 正俊  がんサポート  623-  84  -85  2008次々に進化する肝臓がんの内科的療法.工藤 正俊  がんサポート  63-  92  -93  2008Defect reperfusion imaging, a newly developed novel technology using sonazoid in the treatment of hepatocellular carcinomaMasatoshi Kudo; Kinuyo Hatanaka; Kiyoshi Maekawa  Journal of Medical Ultrasound  16-  (3)  169  -176  2008コントラストエコー法の基礎と臨床.畑中 絹世; 工藤 正俊; 土師 誠二; 前川 清  「これから広がる生理検査・新たにはじまる生理検査」検査と技術  36-  963  -973  2008日本での経験的療法の検証ともなる. (解説 大型肝細胞がんへの化学塞栓療法・ラジオ波焼灼術併用の優位性)工藤 正俊  The Mainichi Medical Journal The Mainichi Medical Journal  4-  769  2008消化管粘膜下腫瘍.坂本 洋城; 北野 雅之; 工藤 正俊  綜合臨牀  57-  2393  -2395  2008肝細胞癌治療支援におけるSonazoid造影エコー法の有用性: 特にDefect Re-perfusion Imagingを中心に.工藤 正俊  京都府消化器医会会報  24-  9  -17  2008EUS-FNAによる膵腫瘍診断.北野 雅之; 坂本 洋城; 小牧 孝充; 野田 佳寿; 末冨 洋一郎; 工藤 正俊  消化器内視鏡  20-  582  -591  2008膵がん診断とそのポイント-早期発見のてだてはないのか.北野 雅之; 坂本 洋城; 工藤 正俊  臨床腫瘍 プラクティス  4-  111  -117  2008超音波による胃癌の描出.前川 清; 野田 佳寿; 工藤 正俊  綜合臨牀  57-  2219  -2228  2008マイクロダイアリシス法による薬物動態評価.北野 雅之; 坂本 洋城; 工藤 正俊  臨床病理の進歩 2008  88  -92  2008Sonazoid-enhanced ultrasound in the diagnosis and treatment of hepatic tumorsMasatoshi Kudo; Kinuyo Hatanaka; Kiyoshi Maekawa  Journal of Medical Ultrasound  16-  (2)  130  -139  2008救急医療に役立つ画像診断: 腹部超音波検査.井上 達夫; 汐見 幹夫; 工藤 正俊  消化器内視鏡  20-  716  -723  2008座談会「わが国のB型肝癌」池田 健次; 工藤 正俊; 佐田 通夫; 田中 正俊  Expert Opinion on Hepatitis B Expert Opinion on Hepatitis B  5-  2  -5  2008超音波内視鏡による早期胃癌の深達度診断.松井 繁長; 市川 勉; 朝隈 豊; 岡田 無文; 川崎 正憲; 工藤 正俊  綜合臨牀  57-  2032  -2036  2008肝がん.井上 達夫; 工藤 正俊  からだの科学  258-  75  -79  2008EUSによる腹腔神経叢ブロック.北野 雅之; 坂本 洋城; 小牧 孝充; 野田 佳寿; 末冨 洋一郎; 工藤 正俊  臨牀消化器内科  23-  885  -891  2008EUS-FNAによる膵腫瘍診断.北野 雅之; 坂本 洋城; 小牧 孝充; 野田 佳寿; 末冨 洋一郎; 工藤 正俊  消化器内視鏡  20-  582  -591  2008膵(EUS).坂本 洋城; 北野 雅之; 工藤 正俊  総合臨牀  57-  1837  -1840  2008肝癌治療選択のアルゴリズム. 肝がん撲滅へ向けて 肝がんの診断・治療の現状と最近の進歩工藤 正俊  総合臨牀  57-  1750  -1754  2008Usefulness of a new immunoradiometric assay of HCV core antigen to predict virological response during PEG-IFN/RBV combination therapy for chronic hepatitis with high viral load of serum HCV RNA genotype 1bNoriko Sasase; Soo Ryang Kim; Ke Ih Kim; Miyuki Taniguchi; Susumu Imoto; Keiji Mita; Hak Hotta; Ikuo Shouji; Ahmed El-Shamy; Norifumi Kawada; Masatoshi Kudo; Yoshitake Hayashi  INTERVIROLOGY  51-  70  -75  2008EUSガイド下胆管・膵管ドレナージ術.坂本 洋城; 北野 雅之; 末冨 洋一郎; 小牧 孝充; 野田 佳寿; 工藤 正俊  肝胆膵画像  10-  243  -248  2008序説・Interventional USの新しい潮流工藤 正俊  肝胆膵画像  10-  199  -200  2008膵疾患(体外エコー).北野 雅之; 工藤 正俊; 坂本 洋城  綜合臨牀  57-  1664  -1668  2008肝線維化診断のための超音波を利用したTransient Elastography: 系統的レビューとメタ解析. Ultrasound-based transient elastgraphy for the detection of hepatic fibrosis: Systematic review and meta-analysis.工藤 正俊  Review of Gastroenterology & Clinical Gastroenterology and Hepatology Review of Gastroenterology & Clinical Gastroenterology and Hepatology  3-  66  -69  2008肝腫瘍造影と治療評価.畑中 絹世; 工藤 正俊; 前川 清  映像情報メディカル. Sonazoid造影超音波検査の現状と未来.  40-  504  -509  2008撮像法.畑中 絹世; 工藤 正俊; 前川 清  臨床画像  24-  541  -546  2008Noninvasive evaluation of hepatic fibrosis using serum fibrotic markers, transient elastography (FibroScan) and real-time tissue elastographyChie Tatsumi; Masatoshi Kudo; Kazuomi Ueshima; Satoshi Kitai; Shunsuke Takahashi; Tatsuo Inoue; Yasunori Minami; Hobyung Chung; Kiyoshi Maekawa; Kenji Fujimoto; Tonomura Akiko; Mitake Takeshi  INTERVIROLOGY  51-  27  -33  2008A new prognostic staging system for hepatocellular carcinoma: Value of the biomarker combined Japan Integrated Staging scoreSatoshi Kitai; Masatoshi Kudo; Yasunori Minami; Kazuomi Ueshima; Hobyung Chung; Satoru Hagiwara; Tatsuo Inoue; Emi Ishikawa; Shunsuke Takahashi; Yutaka Asakuma; Seiji Haji; Yukio Osaki; Hiroko Oka; Toshihito Seki; Hiroshi Kasugai; Yo Sasaki; Takashi Matsunaga  INTERVIROLOGY  51-  86  -94  2008Elevated serum ALT levels during pegylated interferon monotherapy may be caused by hepatic iron overloadMiki Nagashima; Masatoshi Kudo; Hobyung Chung; Emi Ishikawa; Tatsuo Inoue; Tatsuya Nakatani; Kensaku Dote  INTERVIROLOGY  51-  76  -85  2008Diagnostic accuracy of imaging for liver cirrhosis compared to histologically proven liver cirrhosisMasatoshi Kudo; Rong Qin Zheng; Soo Ryang Kim; Yoshihiro Okabe; Yukio Osaki; Hiroko Iijima; Toshinao Itani; Hiroshi Kasugai; Masayuki Kanematsu; Katsuyoshi Ito; Norio Usuki; Kazuhide Shimamatsu; Masayoshi Kage; Masamichi Kojiro  INTERVIROLOGY  51-  17  -26  2008Differential diagnosis of hepatic tumors: Value of contrast-enhanced harmonic Sonography using the newly developed contrast agent, SonazoidKinuyo Hatanaka; Masatoshi Kudo; Yasunori Minami; Taisuke Ueda; Chie Tatsumi; Satoshi Kitai; Shunsuke Takahashi; Tatsuo Inoue; Satoru Hagiwara; Hobyung Chung; Kazuomi Ueshima; Kiyoshi Maekawa  INTERVIROLOGY  51-  61  -69  2008肝癌.上嶋 一臣; 工藤 正俊  綜合臨牀  57-  248  -250  2008肝癌の病態・診断・治療の実際 消化器内科医が求める画像診断情報. CD-ROM工藤 正俊  バイエル薬品(株)  2008門脈圧亢進症.南 康範; 工藤 正俊  綜合臨牀  57-  796  -801  2008Effects of decorin on the expression of alpha-smooth muscle actin in a human myofibroblast cell lineTatsuya Nakatani; Eiko Honda; Sumio Hayakawa; Mayumi Sato; Ken Satoh; Masatoshi Kudo; Hiroshi Munakata  MOLECULAR AND CELLULAR BIOCHEMISTRY  308-  (1-2)  201  -207  2008/01びまん性肝疾患.上嶋 一臣; 工藤 正俊  綜合臨牀  57-  578  -582  2008肝腫瘍性病変(良性).鄭 浩柄; 工藤 正俊  綜合臨牀  57-  375  -378  2008肝腫瘍性病変(悪性).南 康範; 工藤 正俊  綜合臨牀  57-  167  -171  2008Preliminary study of contrast-enhanced harmonic endosonography with second-generation contrast agentsMasayuki Kitano; Masatoshi Kudo; Hiroki Sakamoto; Tatsuya Nakatani; Kiyoshi Maekawa; Nobuyuki Mizuguchi; Yasuhiro Ito; Motohiro Miki; Uwe Matsui; Tarurno Von Schrenck  JOURNAL OF MEDICAL ULTRASONICS  35-  (1)  11  -18  2008治療を担当する立場から.工藤 正俊  肝特異性造影剤の展望を読み解くLiver Imaging Review (LIR)  1-  7  2008Philips腹部超音波3Dを語ろう会.工藤 正俊; 森 秀明; 丸山 紀史; 堀田 直樹  映像情報Medical  40-  206  -213  2008超音波診断の役割と最新動向.工藤 正俊  クリニシアン  566-  28  -37  20082007年度 JSUM Fellowship研修報告.Kunal Das; 工藤 正俊  超音波医学  35-  118  -123  2008A novel perfusion imaging technique of the pancreas: contrast-enhanced harmonic EUS (with video)Masayuki Kitano; Hiroki Sakamoto; Uwe Matsui; Yasuhiro Ito; Kiyoshi Maekawa; Tammo von Schrenck; Masatoshi Kudo  GASTROINTESTINAL ENDOSCOPY  67-  (1)  141  -150  2008/01(特殊な病態における抗ウィルス療法の現状)肝細胞癌併発例.上嶋 一臣; 工藤 正俊  Modern Phsician Modern Phsician  28-  56  -59  2008Mixed intestinal- and diffuse-type histology is a risk factor for lymph node metastasis of submucosal invasive gastric cancerNaoko Tsuji; Shingo Ishiguro; Yasuko Umehara; Masatoshi Kudo  DIGESTIVE ENDOSCOPY  20-  (1)  17  -21  2008/01Case of rapidly progressed sarcomatoid hepatocellular carcinoma in a young female without risk factorTatsuo Inoue; Masatoshi Kudo; Yasunori Minami; Hobyung Chung; Toyokazu Fukunaga; Toshihiko Kawasaki  LIVER INTERNATIONAL  27-  (10)  1428  -1430  2007/12Dissemination of clinical practice guidelines for hepatocellular carcinoma among Japanese hepatologists and liver surgeonsKOKUDO Norihiro; MAKUUCHI Masatoshi; NAKAYAMA Takeo; ARII Shigeki; OMATA Masao; KUDO Masatoshi; KOJIRO Masamichi; SAKAMOTO Michiie; TAKAYASU Ken-ichi; HAYASHI Norio; MONDEN Morito  Kanzo  48-  (11)  562  -570  2007/11Combination therapy with PEG-IFN-alpha and 5-FU inhibits HepG2 tumour cell growth in nude mice by apoptosis of p53S. Hagiwara; M. Kudo; T. Nakatani; Y. Sakaguchi; M. Nagashima; N. Fukuta; M. Kimura; S. Hayakawa; H. Munakata  BRITISH JOURNAL OF CANCER  97-  (11)  1532  -1537  2007/11Well to moderately differentiated HCC manifesting hyperattenuation on both CT during arteriography and arterial portographySoo Ryang Kim; Susumu Imoto; Hirotsugu Ikawa; Kenji Ando; Keiji Mita; Shuichi Fuki; Michiie Sakamoto; Yoshihiro Kanbara; Toshiyuki Matsuoka; Masatoshi Kudo; Yoshitake Hayashi  WORLD JOURNAL OF GASTROENTEROLOGY  13-  (43)  5775  -5778  2007/11Separate analysis of intranodular blood supply in nodular lesions associated with liver cirrhosis: A novel ultrasound technique "pure arterial phase imaging"Masatoshi Kudo; Kinuyo Hatanaka; Yunori Minami; Hiroshi Tei; Kiyoshi Maekawa  HEPATOLOGY  46-  (4)  402A  -402A  2007/10A proposal of novel treatment-assist technique in the sonazoid-enhanced ultrasonography: Value of defect re-perfusion imagingMasatoshi Kudo; Kinuyo Hatanaka; Yasunori Minami; Hiroshi Tei; Kiyoshi Maekawa  HEPATOLOGY  46-  (4)  423A  -423A  2007/10Small hepatocellular carcinoma presenting with massive metastasis in the peritoneum, mimicking sarcomatous tumorSoo Ryang Kim; Hirotsugu Ikawa; Kenji Ando; Keiji Mita; Shuichi Fuki; Susumu Imoto; Kenji Shimizu; Yoshihiro Kanbara; Koji Sugimoto; Masahiko Fujii; Masatoshi Kudo; Toshiyuki Matsuoka; Yoshitake Hayashi  HEPATOLOGY RESEARCH  37-  (10)  885  -889  2007/10病理学的所見からみた胃癌の時代的変遷ーHelicobacter pylori感染からみて辻 直子; 梅原 康湖; 工藤 正俊; 石黒 信吾; 松村; 生子; 吉里 勝彦  胃と腸 Stomach and Intestine  42-  (6)  931  -936  2007/10クローン病に対するインフリキシマブ投与の有効性の検討梅原泰; 工藤正俊; 仲谷達也; 福田信宏; 永島美樹; 石川恵美; 坂本洋城; 井上達夫; 坂口康浩; 萩原智; 南康範; 末冨洋一郎; 小牧孝充; 鄭浩柄; 上嶋一臣; 松井繁長; 福永豊和; 北野雅之; 汐見幹夫  日本消化器病学会雑誌  104-  A655  2007/09噴門部静脈瘤合併巨木型食道静脈瘤の内視鏡的治療松井繁長; 岡田無文; 工藤正俊  日本消化器病学会雑誌  104-  A502  2007/09難治性C型慢性肝炎(1型高ウイルス量)に対するPEG‐IFNα‐2b/Ribavirin併用療法の使用成績と安全性について石川恵美; 上嶋一臣; 汐見幹夫; 北野雅之; 松井繁長; 福永豊和; 仲谷達也; 鄭浩柄; 南康範; 末冨洋一郎; 福田信宏; 坂本洋城; 井上達夫; 梅原泰; 永島美樹; 宮部欽生; 野田佳寿; 工藤正俊  肝臓  48-  (Supplement 2)  A431  2007/09胃腫瘍に対するESD後の後出血例の検討岡田無文; 松井繁長; 永田嘉昭; 宮部欽生; 市川勉; 畑中絹世; 工藤正俊  Gastroenterol Endosc  49-  (Supplement 2)  2292  2007/09Role of tumor markers in assessment of tumor progression and prediction of outcomes in patients with hepatocellular carcinomaHidenori Toyoda; Takashi Kumada; Yukio Osaki; Hiroko Oka; Masatoshi Kudo  HEPATOLOGY RESEARCH  37-  S166  -S171  2007/09New sonographic techniques treatment of hepatocellular c for the diagnosis and carcinomaMasatoshi Kudo  HEPATOLOGY RESEARCH  37-  S193  -S199  2007/09Review of current staging systems for hepatocellular carcinomaHobyung Chung; Masatoshi Kudo; Shunsuke Takahashi; Satoru Hagiwara; Yasuhiro Sakaguchi; Tatsuo Inoue; Yasunori Minami; Kazuomi Ueshima; Toyokazu Fukunaga  HEPATOLOGY RESEARCH  37-  S210  -S215  2007/09Report of the 17th Nationwide Follow-up Survey of Primary Liver Cancer in JapanIwao Ikai; Shigeki Arii; Masatoshi Okazaki; Kiwamu Okita; Masao Omata; Masamichi Kojiro; Kenichi Takayasu; Yasuni Nakanuma; Masatoshi Makuuchi; Yutaka Matsuyama; Morito Monden; Masatoshi Kudo  HEPATOLOGY RESEARCH  37-  (9)  676  -691  2007/09ENDOSCOPIC ULTRASOUND-GUIDED BILIARY DRAINAGE FOR OBSTRUCTIVE JAUNDICESAKAMOTO Hiroki; KITANO Masayuki; SUETOMI Yoichiro; SHIOMI Mikio; KOMAKI Takahiro; NODA Kazu; TATUMI Chie; UESHIMA Kazuomi; KUDO Masatoshi  Gastroenterol Endosc  49-  (8)  1844  -1847  2007/08A Proposal of Novel Treatment-assist Technique for Hepatocellular Carcinoma in the Sonazoid-enhanced Ultrasonography : Value of Defect Re-Perfusion ImagingKUDO Masatoshi; HATANAKA Kinuyo; CHUNG Hobyung; MINAMI Yasunori; MAEKAWA Kiyoshi  Kanzo  48-  (6)  299  -301  2007/06消化器系疾患の診断・治療に必須なlnterventional EUSの臨床応用 (総特集 進化し続ける超音波診断の到達点) -- (経営・技術面から超音波の有用性を探る)北野 雅之; 工藤 正俊  月刊新医療  34-  (5)  68  -70  2007/05First attempt of boron neutron capture therapy (BNCT) for hepatocellular carcinomaMinoru Suzuki; Yoshinori Sakurai; Satoru Hagiwara; Shinichiro Masunaga; Yuko Kinashi; Kenji Nagata; Akira Maruhashi; Masatoshi Kudo; Koji Ono  JAPANESE JOURNAL OF CLINICAL ONCOLOGY  37-  (5)  376  -381  2007/05Antibody to hepatitis B core antigen and risk for hepatitis C-related hepatocellular carcinoma: A prospective studyKazuki Ikeda; Hiroyuki Marusawa; Yukio Osaki; Takefumi Nakamura; Naoto Kitajima; Yukitaka Yamashita; Masatoshi Kudo; Tosiya Sato; Tsutomu Chiba  ANNALS OF INTERNAL MEDICINE  146-  (9)  649  -656  2007/05腹部領域における Interventional Sonography工藤 正俊; 谷口 信行  Journal of medical ultrasOnics= 超音波医学  34-  S178  2007/04胆膵疾患に対する interventional EUS坂本 洋城; 北野 雅之; 工藤 正俊  Journal of medical ultrasOnics= 超音波医学  34-  S185  2007/04New Situation of Contrast Enhanced SonographyMINAMI Yasunori; KUDOU Masatoshi  Journal of medical ultrasOnics= 超音波医学  34-  S248  2007/04Invention of Contrast-enhanced Harmonic Endosonography and Its Application to Clinical InvestigationsKITANO Masayuki; SAKAMOTO Hiroki; MATSUI Uwe; ITO Yasuhiro; MAEKAWA Kiyoshi; VON SCHRENCK Tammo; KUDO Masatoshi  Journal of medical ultrasOnics= 超音波医学  34-  S285  2007/04Joint Research for the Objective Rating of Hepatic Tissue Characterization Using Real-time Tissue ElastographyFUJIMOTO Kenji; TATSUMI Chie; UESHIMA Kazuomi; MAEKAWA Kiyoshi; TONOMURA Akiko; MITAKE Tsuyoshi; YAMAKAWA Makoto; KATO Michio; KUDOU Msatoshi; SHIINA Tsuyoshi  Journal of medical ultrasOnics= 超音波医学  34-  2007/04Study of Hepatic Tumors Using Contrast-enhanced Ultrasonography with SonazoidMAEKAWA Kiyoshi; INOUE Tatuo; MINAMI Yasunori; TEI Hiroshi; UESHIMA Kazuomi; HUKUNAGA Toyokazu; KUDOU Masatoshi  Journal of medical ultrasOnics= 超音波医学  34-  2007/04EUS‐FNAが診断に有効であった腹腔内リンパ節結核の一例小牧孝充; 北野雅之; 坂本洋城; 末冨洋一郎; 野田佳寿; 今井元; 汐見幹夫; 工藤正俊; 土手健作; 伊藤浩行  Gastroenterol Endosc  49-  (Supplement 1)  1036  2007/04Diagnosis of gallbladder diseases by contrast-enhanced phase-inversion harmonic ultrasonographyTatsuo Inoue; Masayuki Kitano; Masatoshi Kudo; Hiroki Sakamoto  GASTROENTEROLOGY  132-  (4)  A354  -A354  2007/04Clinical application of contrast-enhanced harmonic imaging to endosonographyMasayuki Kitano; Hiroki Sakamoto; Uwe Matsui; Yasuhiro Ito; Kiyoshi Maekawa; Tammo Von Schrenck; Masatoshi Kudo  GASTROINTESTINAL ENDOSCOPY  65-  (5)  AB193  -AB193  2007/04Regulatory failure of serum prohepcidin levels in patients with hepatitis CMiki Nagashima; Masatoshi Kudo  GASTROENTEROLOGY  132-  (4)  A783  -A783  2007/04Multicentric recurrence of hepatocellular carcinoma and CD-34 expression in background liverNaoko Tsuji; Shingo Ishiguro; Masatoshi Kudo  GASTROENTEROLOGY  132-  (4)  A517  -A518  2007/04肝癌. 特集「データで読み解く内科疾患 IV. 肝、胆、膵」鄭 浩柄; 福永 豊和; 工藤 正俊  綜合臨床  56-  387  -393  2007/04肝がんと闘う. 世界に冠たる日本の診療.工藤 正俊; 村上 卓道  INNERVISION INNERVISION  22-  (4)  1  -2  2007/04肝細胞癌.鄭 浩柄; 工藤 正俊  Medical Practice誌2007年臨時増刊号「セカンドオピニオン実践ガイド」  24-  125  -130  2007/04膵癌におけるバイオマーカーとしてのKL‐6の有用性小牧孝充; 北野雅之; 坂本洋城; 末冨洋一郎; 野田佳寿; 汐見幹夫; 工藤正俊  日本消化器病学会雑誌  104-  A121  2007/03Diagnosis of gallbladder diseases by contrast-enhanced phase-inversion harmonic ultrasonographyTatsuo Inoue; Masayuki Kitano; Masatoshi Kudo; Hiroki Sakamoto; Toshihiko Kawasaki; Chikao Yasuda; Kiyoshi Maekawa  ULTRASOUND IN MEDICINE AND BIOLOGY  33-  (3)  353  -361  2007/03Radiofrequency ablation combined with reduction of hepatic blood flow: effect of lipiodol on coagulation diameter and ablation time in normal pig liver.鄭 浩柄; 工藤 正俊; 南 康範; 川崎俊彦  Hepato-Gastroenterol  54-  701  -704  2007/03Philips腹部超音波3D.工藤 正俊; 森 秀明; 丸山 紀史; 掘田 直樹  映像情報Medical  39-  230  -235  2007/03Contrast harmonic sonography guided radiofrequency ablation therapy versus B-mode sonography in hepatocellular carcinoma: Prospective randomized controlled trialYasunori Minami; Masatoshi Kudo; Hobyung Chung; Toshihiko Kawasaki; Yukinobu Yagyu; Taro Shimono; Hitoshi Shiozaki  AMERICAN JOURNAL OF ROENTGENOLOGY  188-  (2)  489  -494  2007/02Multistep hepatocarcinogenesis from a dysplastic nodule to well-differentiated hepatocellular carcinoma in a patient with alcohol-related liver cirrhosisSoo Ryang Kim; Hirotsugu Ikawa; Kenji Ando; Keiji Mita; Shuichi Fuki; Michiie Sakamoto; Yoshihiro Kanbara; Toshiyuki Matsuoka; Masatoshi Kudo; Yoshitake Hayashi  WORLD JOURNAL OF GASTROENTEROLOGY  13-  (8)  1271  -1274  2007/02Endoscopic ultrasound-guided pancreaticogastrostomy reconstructionH. Sakamoto; M. Kitano; T. Komaki; Y. Takeyama; M. Kudo  ENDOSCOPY  39-  E70  -E71  2007/02Contrast harmonic sonography guided radiofrequency ablation therapy versus B-mode sonography in hepatocellular carcinoma: Prospective randomized controlled trialYasunori Minami; Masatoshi Kudo; Hobyung Chung; Toshihiko Kawasaki; Yukinobu Yagyu; Taro Shimono; Hitoshi Shiozaki  AMERICAN JOURNAL OF ROENTGENOLOGY  188-  (2)  489  -494  2007/02Hepatocellular carcinoma鄭 浩柄; 福永 豊和; 工藤 正俊  綜合臨床  56-  1221  -1227  2007S-1,PEGインターフェロン併用療法の経験上嶋一臣; 南康範; 工藤正俊  日本臨床腫瘍学会学術集会プログラム・抄録集  5th-  2007膵疾患に対する超音波/超音波内視鏡の検討.坂本 洋城; 北野 雅之; 小牧 孝充; 野田 佳寿; 末冨 洋一郎; 工藤 正俊  肝胆膵  55-  675  -681  2007Ⅳ. 腹部 5)特殊な腹部エコー 超音波内視鏡. 一般医のためのエコー活用法坂本 洋城; 北野 雅之; 工藤 正俊  medicina  44-  396  -399  2007安全なEUS-FNA.北野 雅之; 坂本 洋城; 小牧 孝充; 末冨 洋一郎; 工藤 正俊  消化器内視鏡  19-  1344  -1348  2007消化器癌の化学(放射線)療法はここまできたー日本の現状は? 肝癌の化学療法はここまできた.上嶋 一臣; 工藤 正俊  成人病と生活習慣病  37-  682  -687  2007肝細胞癌切除後の長期成績向上を目指して. IV. 再発に対する治療. ラジオ波焼灼療法(RFA).南 康範; 鄭 浩柄; 北井 聡; 高橋 俊介; 井上 達夫; 上嶋 一臣; 福永 豊和; 工藤 正俊  外科  69-  (5)  575  -580  2007アルコール性肝硬変にみられた多発性多血性結節の2症例.金 守良; 工藤 正俊; 井本 勉  アルコールと医学生物学  27-  56  -60  2007Sonazoid造影エコー法の新手法 Defect Re-perfusion Imagingは肝細胞癌治療支援のBreakthrough technologyである.工藤 正俊  GE today In Technology GE today In Technology  25-  41  -42  2007Long-term interferon maintenance therapy improves survival in patients with HCV-related hepatocellular carcinoma after curative radiofrequency ablationMasatoshi Kudo; Yasuhiro Sakaguchi; Hobyung Chung; Kinuyo Hatanaka; Satoru Hagiwara; Emi Ishikawa; Shunsuke Takahashi; Satoshi Kitai; Tatsuo Inoue; Yasunori Minami; Kazuomi Ueshima  ONCOLOGY  72-  132  -138  2007Percutaneous radiofrequency ablation of sonographically unidentifiable liver tumorsYasunori Minami; Masatoshi Kudo; Hobyung Chung; Tatsuo Inoue; Shunsuke Takahashi; Kinuyo Hatanaka; Taisuke Ueda; Hitoshi Hagiwara; Satoshi Kitai; Kuzuomi Ueshima; Toyokazu Fukunaga; Hitoshi Shiozaki  ONCOLOGY  72-  111  -116  2007Initial treatment response is essential to improve survival in patients with hepatocellular carcinoma who underwent curative radiofrequency ablation therapyShunsuke Takahashi; Masatoshi Kudo; Hobyung Chung; Tatsuo Inoue; Emi Ishikawa; Satoshi Kitai; Chie Tatsumi; Taisuke Ueda; Yasunori Minami; Kazuomi Ueshima; Seiji Haji  ONCOLOGY  72-  98  -103  2007What is the best time to evaluate treatment response after radiofrequency ablation of hepatocellular carcinoma using contrast-enhanced sonography?Pei Zhou; Masatoshi Kudo; Yasunori Minami; Hobyung Chung; Tatsuo Inoue; Toyokazu Fukunaga; Kiyoshi Maekawa  ONCOLOGY  72-  92  -97  2007Severe complications of radiofrequency ablation therapy for hepatocellular carcinoma: An analysis of 3,891 ablations in 2,614 patientsHiroshi Kasugai; Yukio Osaki; Hiroko Oka; Masatoshi Kudo; Toshihito Seki  ONCOLOGY  72-  72  -75  2007Superiority of CT arterioportal angiography to contrast-enhanced CT and MRI in the diagnosis of hepatocellular carcinoma in nodules smaller than 2 cmSoo Ryang Kim; Kenji Ando; Keiji Mita; Shuichi Fuki; Hirotsugu Ikawa; Yoshihiro Kanbara; Susumu Imoto; Toshiyuki Matsuoka; Yoshitake Hayashi; Masatoshi Kudo  ONCOLOGY  72-  58  -66  2007Development of a novel assay to quantify serum human telomerase reverse transcriptase messenger RNA and its significance as a tumor marker for hepatocellular carcinomaNorimasa Miura; Shigeo Maruyama; Kenji Oyama; Yutaka Horie; Michimori Kohno; Eijiro Noma; Seigo Sakaguchi; Miki Nagashima; Masatoshi Kudo; Yukihiro Kishimoto; Hironaka Kawasaki; Junichi Hasegawa; Goshi Shiota  ONCOLOGY  72-  45  -51  2007Natural course of small nodular lesions with intranodular preserved portal supply in cirrhotic liverToyokazu Fukunaga; Masatoshi Kudo; Hitoshi Tochio; Yoshihiro Okabe; Akio Orino  ONCOLOGY  72-  24  -29  2007Management of hepatocellular carcinoma in Japan: Consensus-based clinical practice manual proposed by the Japan Society of HepatologyMasatoshi Kudo; Takeshi Okanoue  ONCOLOGY  72-  2  -15  2007超音波による肝腫瘍の鑑別診断と治療への応用. 特集「肝胆膵領域における画像診断の新展開」工藤 正俊  肝胆膵  55-  641  -653  2007肝細胞癌治療支援におけるSonazoid 造影エコー法の新手法の提唱: Defect Re-perfusion Imaging の有用性.工藤 正俊  Rad Fan Rad Fan  5-  97  -102  2007Outcomes of nontransplant potentially curative therapy for early-stage hepatocellular carcinoma in child-pugh stage a cirrhosis is comparable with liver transplantationShunsuke Takahashi; Masatoshi Kudo; Hobyung Chung; Tatsuo Inoue; Miki Nagashima; Satoshi Kitai; Tatsumi Chie; Minami Yasunori; Ueshima Kazuomi; Fukunaga Toyokazu; Seiji Haji  DIGESTIVE DISEASES  25-  (4)  303  -309  2007EVL法-出血例.松井 繁長; 工藤 正俊  食道・胃の治療内視鏡  92  -95  2007肝腫瘍の診断-ソナゾイドによる肝腫瘍の検出と鑑別診断.畑中 絹世; 工藤 正俊; 前川 清  INNERVISION INNERVISION  22-  (10)  12  -19  2007International camparision of treatment outcomes based on staging systems.工藤 正俊  Hepatol Res  37-  S216  -S222  2007Hepatocellular carcinoma: international consensus and controversies.工藤 正俊  Hepatol Res  37-  S83  -S87  2007肝腫瘍におけるSonazoidの鑑別診断能.畑中 絹世; 工藤 正俊; 前川 清  消化器画像  9-  439  -447  2007序/Sonazoid造影エコー法は肝癌診療のBreakthroughである.工藤 正俊  消化器画像  9-  423  -429  2007カラー・パワードプラと造影EUSの意義.北野 雅之; 坂本 洋城; 工藤 正俊  消化器内視鏡 特集: 使い熟そうEUS.  19-  937  -945  2007Philips 腹部超音波3Dを語ろう会工藤 正俊; 森 秀明; 丸山 紀史; 掘田 直樹  映像情報 Medical  39-  2007Endoscopic ultrasonography with three miniature probes of different frequency is an accurate diagnostic tool for endoscopic submucosal dissectionTsutomu Ichikawa; Masatoshi Kudo; Shigenaga Matsui; Mumon Okada; Masayuki Kitano  HEPATO-GASTROENTEROLOGY  54-  (73)  325  -328  2007/01肝細胞癌のステージ分類: その重要性と問題点.工藤 正俊  42nd Annual Meeting of Japan Society of Hepatology 42nd Annual Meeting of Japan Society of Hepatology  1  -4  2007消化管・胆嚢の造影エコー北野 雅之; 井上 達夫; 福田 信宏; 坂本 洋城; 工藤 正俊  Rad Fan Rad Fan  5-  (7)  74  -76  2007日本・アジア・欧州における肝癌の診断と治療.神代 正道; 工藤 正俊; Jordi Bruix; Kwang-Hyub Han  Medical Tribune Medical Tribune  40-  (25)  76  -77  2007治療: 局所療法.鄭 浩柄; 南 康範; 工藤 正俊  Pharma Medica Pharma Medica  25-  (6)  45  -49  2007第17回全国原発性肝癌追跡調査報告(2002~2003)工藤 正俊; 有井 滋樹; 猪飼 伊和夫; 岡崎 正俊; 沖田 極; 小俣 政男; 神代 正道; 高安 賢一; 中沼 安二; 幕内 雅敏; 松山 裕; 門田 守人  肝臓  27-  117  -140  2007肝癌.上嶋 一臣; 工藤 正俊  病気と薬の説明ガイド2007  1231  -1238  2007癌対策の現状ー肝癌工藤 正俊  ガイドライン外来診療2007  512  -517  2007Pathological diagnosis of liver cell adenoma and focal nodular hyperplasia: Bordeaux update.Bioulac-Sage P; 工藤 正俊; Balabaud C; Bedossa P; Scoazec JY; Chiche L; Dhillon AP; Ferrell L; Paradis V; Roskams T; Vilgrain V; Wanless IR; Zucman-Rossi J  J Hepatol  46-  521  -527  2007/01画像所見井上 達夫; 工藤 正俊  新しい診断と治療ABC「肝硬変」 最新医学社  58  -62  2007/01統合スコア分類によるラジオ波凝固療法の客観的評価.鄭 浩柄; 工藤 正俊  「肝癌ラジオ波凝固療法―そのノウハウとエビデンス」  146  -151  2007/01腫瘍マーカーの観点からみたRFA.小川 力; 工藤 正俊  「肝癌ラジオ波凝固療法―そのノウハウとエビデンス」  127  -130  2007/01Clinical characteristics of NonBNonC-HCC: Comparison with HBV and HCV related HCCKinuyo Hatanaka; Masatoshi Kudo; Toyokazu Fukunaga; Kazuomi Ueshima; Hobyung Chung; Yasunori Minami; Yasuhiro Sakaguchi; Satoshi Hagiwara; Akio Orino; Yukio Osaki  INTERVIROLOGY  50-  (1)  24  -31  2007Prognostic factors for portal venous invasion in patients with hepatocellular carcinomaSatoru Hagiwara; Masatoshi Kudo; Toshihiko Kawasaki; Miki Nagashima; Yasunori Minami; Hobyung Chung; Toyokazu Fukunaga; Masayuki Kitano; Tatsuya Nakatani  JOURNAL OF GASTROENTEROLOGY  41-  (12)  1214  -1219  2006/12Staging hepatocellular carcinoma by a novel scoring system (BALAD score) based on serum markersHidenori Toyoda; Takashi Kumada; Yukio Osaki; Hiroko Oka; Fumihiro Urano; Masatoshi Kudo; Takashi Matsunaga  CLINICAL GASTROENTEROLOGY AND HEPATOLOGY  4-  (12)  1528  -1536  2006/12Serum proinflammatory cytokines and adhesion molecules in ulcerative colitisYasushi Umehara; Masatoshi Kudo; Ryosuke Nakaoka; Toshihiho Kawasaki; Mikio Shiomi  HEPATO-GASTROENTEROLOGY  53-  (72)  879  -882  2006/11Hepatocellular carcinoma metastasizing to the skull base involving multiple cranial nervesSoo Ryang Kim; Fumio Kanda; Hiroshi Kobessho; Koji Sugimoto; Toshiyuki Matsuoka; Masatoshi Kudo; Yoshitake Hayashi  WORLD JOURNAL OF GASTROENTEROLOGY  12-  (41)  6727  -6729  2006/11I. 肝細胞癌. 1. 総論. 4)Scoringによる予後予測.工藤 正俊  肝胆膵  53-  635  -643  2006/11Percutaneous radiofrequency ablation of liver tumors: usefulness of a novel guidance technique with an integrated system of CT and sonographic imagesY. Minami; M. Kudo  LIVER INTERNATIONAL  26-  67  -67  2006/10The novel questionnaire to evaluate health-related quality of life specific for patients with hepatocellular carcinomaNobuaki Nakayama; Masatoshi Akamatsu; Toru Kakinuma; Atsushi Matsui; Sumiko Nagoshi; Satoshi Mochida; Masao Omata; Masatoshi Kudo; Hiromitsu Kumada; Michio Sata; Norihiro Kokudo; Morito Monden; Takashi Kanematsu; Koichi Tanaka; Hisataka Moriwaki; Kenji Fujiwara  HEPATOLOGY  44-  (4)  503A  -503A  2006/10Non-transplant treatment for hepatocellular carcinoma associated with Child-Pugh grade C cirrhosis: A multicenter study on survival bnenefitMasatoshi Kudo; Yukio Osaki; Takashi Matsunaga; Hiroshi Kasugai; Hiroko Oka; Toshihito Seki  HEPATOLOGY  44-  (4)  502A  -502A  2006/10Case of adult genotype CHBV carrier after acute hepatitis B, losing HBsAg and acquiring HBsAb after IFN and lamivudine treatmentSoo Ryang Kim; Susumu Imoto; Shuichi Fuki; Miyuki Taniguchi; Ke Ih Kim; Keiji Mita; Kenji Ando; Taisuke Nakajima; Hyun Soo Hong; Katsumi Fukuda; Noriko Sasase; Masatoshi Kudo; Yoshitake Hayashi  HEPATOLOGY RESEARCH  36-  (2)  149  -152  2006/10早期胃癌に対してESD術前に複数周波数を用いた超音波内視鏡検査の有用性市川勉; 松井繁長; 岡田無文; 北野雅之; 工藤正俊  Gastroenterol Endosc  48-  (Supplement 2)  2093  2006/09食道静脈瘤に対する内視鏡的治療の工夫松井繁長; 岡田無文; 工藤正俊  日本消化器病学会雑誌  103-  A728  2006/09十二指腸静脈瘤の診断,治療と予後松井繁長; 市川勉; 岡田無文; 工藤正俊  日本門脈圧こう進症学会雑誌  12-  (1)  103  2006/08肝癌に対するTAE・RFA治療後に遅発性胆管気管支瘻が出現した1例末冨洋一郎; 北野雅之; 坂本洋城; 西尾健; 南康範; 汐見幹夫; 工藤正俊  胆道  20-  (3)  419  -419  2006/08Wegener's granulomatosis complicated with aphthoid colitisYasushi Umehara; Masatoshi Kudo; Yasunori Minami; Hiroshi Tei; Kazuomi Ueshima; Toyokazu Fukunaga; Tatsuya Nakatani; Shigenaga Matsui; Masayuki Kitano; Mikio Shiomi  Digestive Endoscopy  18-  (3)  221  -224  2006/07Value of computed tomography for evaluating the injection site in endosonography-guided celiac plexus neurolysisHiroki Sakamoto; Masayuki Kitano; Takeshi Nishio; Yoshifumi Takeyama; Chikao Yasuda; Masatoshi Kudo  Digestive Endoscopy  18-  (3)  206  -211  2006/07Studies on the variation in clinical laboratory data and safety evaluation of pharmaceuticals (vol 125, pg 997, 2005)Morihiro Nomura; Taeko Hata; Shouchi Naitoh; Hiroyuki Kuwano; Kenzo Moriyama; Masahiro Fukuoka; Masatoshi Kudo; Yuji Tohda  YAKUGAKU ZASSHI-JOURNAL OF THE PHARMACEUTICAL SOCIETY OF JAPAN  126-  (6)  438  -438  2006/06Relation of tumor vascularity to effect of gemcitabine in pancreatic carcinomas: Value of contrast-enhanced harmonic ultrasonography.M. Kitano; H. Sakamoto; Y. Suetomi; T. Nishio; T. Nishio; Y. Takeyama; M. Kudo  JOURNAL OF CLINICAL ONCOLOGY  24-  (18)  206S  -206S  2006/06Studies on the variation in clinical laboratory data and safety evaluation of pharmaceuticals (vol 125, pg 1003, 2005)Morihiro Nomura; Taeko Hata; Shouchi Naitoh; Hiroyuki Kuwano; Kenzo Moriyama; Masahiro Fukuoka; Masatoshi Kudo; Yuji Tohda  YAKUGAKU ZASSHI-JOURNAL OF THE PHARMACEUTICAL SOCIETY OF JAPAN  126-  (6)  438  -438  2006/06転移性肝腫瘍に対する焼灼療法の治療成績 大腸癌肝転移におけるRFA治療の局所制御能中居 卓也; 川辺 高史; 吉藤 竹仁; 上田 和毅; 肥田 仁一; 石丸 英三郎; 奥野 清隆; 塩崎 均; 大柳 治正; 南 康範; 鄭 浩柄; 工藤 正俊  日本外科系連合学会誌  31-  (3)  445  -445  2006/06Consensus on extra-hepatic portal vein obstructionSK Sarin; JD Sollano; YK Chawla; D Amarapurkar; S Hamid; M Hashizume; W Jafri; A Kumar; M Kudo; LA Lesmana; BC Sharma; G Shiha; HJ de Silva  LIVER INTERNATIONAL  26-  (5)  512  -519  2006/06肝癌の診断・治療 (5)非B非C肝癌は増えているか.畑中 絹世; 工藤 正俊  肝疾患Review2006~2007 監修 小俣政男, 編集 河田純男, 白鳥康史, 工藤正俊, 榎本信幸  217  -222  2006/05肝癌の診断・治療 (3)造影エコーはどのような場合に行うか.工藤 正俊  肝疾患Review2006~2007 監修 小俣政男, 編集 河田純男, 白鳥康史, 工藤正俊, 榎本信幸  209  -213  2006/05グローバルな視点からみた肝癌の診断 (1)肝癌治療の現況ー日米欧のアプローチの違い.工藤 正俊  肝疾患Review2006~2007 監修 小俣政男, 編集 河田純男, 白鳥康史, 工藤正俊, 榎本信幸  61  -68  2006/05グローバルな視点からみた肝癌の診断 (1)肝癌の画像診断up-to-date.工藤 正俊  肝疾患Review2006~2007 監修 小俣政男, 編集 河田純男, 白鳥康史, 工藤正俊, 榎本信幸  47  -54  2006/05肝癌の治療. I. 肝癌診療のためのステージングシステム.工藤 正俊  消化器内科増刊号「肝癌の診療―最新の進歩」  6-  191  -203  2006/052.画像診断(2)造影エコーによる肝癌の診断.福永 豊和; 工藤 正俊  消化器内科増刊号「肝癌の診療―最新の進歩」  6-  122  -129  2006/05EUS‐CPN時のエタノール注入部位ととう痛改善度の関連性西尾健; 坂本洋城; 北野雅之; 坂口康浩; 末冨洋一郎; 上嶋一臣; 汐見幹夫; 工藤正俊  Gastroenterol Endosc  48-  (Supplement 1)  882  2006/04Mixed intestinal and diffuse type histology is a risk factor for lymph node metastasis of early gastric cancerNaoko Tsuji; Singo Ishiguro; Masatoshi Kudo  GASTROENTEROLOGY  130-  (4)  A418  -A418  2006/04Percutaneous radiofrequency ablation of liver tumors: Usefulness of a novel guidance technique with an integrated system of CT and sonographic imagesYasunori Minami; Masatoshi Kudo  GASTROENTEROLOGY  130-  (4)  A778  -A778  2006/04工藤正俊: 肝細胞癌に対する肝移植の治療法としての位置づけと適応工藤 正俊  医学のあゆみ  3-  263  -267  2006/04Cecal necrosis due to ischemic colitis mimicking an abscess on sonographyT Watanabe; S Tomita; H Shirane; Y Okabe; A Orino; A Todo; T Chiba; M Kudo  JOURNAL OF ULTRASOUND IN MEDICINE  25-  (3)  393  -396  2006/03リザーバー動注化学療法のあらたな展開.上嶋 一臣; 辰巳 千栄; 坂口 康浩; 南 康範; 鄭 浩柄; 福永 豊和; 工藤 正俊  消化器科  43-  (3)  253  -259  2006/03治療しながら自分らしい暮らしを続けるために.医療の現場から「臓器専門医の立場から」.工藤 正俊  がんを生き抜く実践プログラム  212  -213  2006/03画像検査について知ろう.医療の現場から「今、画像検査はここまでできる」.工藤 正俊  がんを生き抜く実践プログラム  34  -38  2006/03肝がんの早期発見・内科的治療と再発予防の最前線工藤 正俊  肝友だより  14-  11  -16  2006/03A proposal of the modified liver damage classification for hepatocellular carcinomaHY Chung; M Kudo; S Haji; Y Osaki; H Oka; T Seki; H Kasugai; Y Sasaki  HEPATOLOGY RESEARCH  34-  (2)  124  -129  2006/02内視鏡教育について思うこと.汐見 幹夫; 工藤 正俊  内視鏡の教育・研修ー各内視鏡医の取り組みー  164  -166  2006/02内視鏡医療の更なる国際化を期待して.汐見 幹夫; 工藤 正俊  内視鏡医療ー創造と実践ー  121  -123  2006/02Comparison of staging systems for hepatocellular carcinoma in a Japanese cohortH. Chung; M. Kudo; S. Takahashi; T. Inoue; Y. Sakaguchi; S. Hagiwara; Y. Minami; K. Ueshima; T. Fukunaga; T. Matsunaga  JOURNAL OF HEPATOLOGY  44-  S99  -S99  2006Carcinogenic risk factors in hepatitis B virus infectionS. Hagiwara; T. Nakatani; Y. Minami; H. Chung; K. Ueshima; T. Fukunaga; M. Kudo; H. Munakata  JOURNAL OF HEPATOLOGY  44-  S172  -S172  2006画像からすすめる腹部疾患診療の実際 肝硬変井上 達夫; 工藤 正俊  Medical Practice Medical Practice  23-  897  -902  2006第5章 肝癌の治療 1. 肝癌診療のためのステージングシステム.工藤 正俊  臨床消化器内科  21-  949  -961  2006肝疾患: 肝膿よう.南 康範; 工藤 正俊  今日の治療  13-  173  -175  2006特集 各科領域におけ腫瘍マーカーの評価「肝臓」小川 力; 鍋島 紀滋; 工藤 正俊  医学と薬学  56-  828  -834  2006肝がん治療について.工藤 正俊  がんの最新治療 早く見つけて上手に治す がん予防キャンペーン大阪2006 シンポジウム  11  -12  2006「肝細胞がん患者にどう対処するか」肝細胞がんの診断見落としを防ぐコツ. 画像診断の進め方.福永 豊和; 工藤 正俊  臨床腫瘍プラクティス  2-  (4)  341  -344  2006「アルコール性肝障害における結節性病変 画像と病理」肝細胞癌と鑑別を要したアルコール性過形成結節の一例.福永 豊和; 田北 雅弘; 辰巳 千栄; 工藤 正俊  消化器画像  8-  573  -577  2006肝の画像診断.井上 達夫; 工藤 正俊  肝臓病学, 編集 井廻道夫, 熊田博光, 坪内博仁, 林 紀夫  128  -141  2006内視鏡的治療ー内視鏡的硬化療法(EIS). Ethanolamine Oleate (EO).松井 繁長; 工藤 正俊; 市川 勉; 岡田 無文; 宮部 欽生  消化器の臨床  9-  (4)  371  -375  2006肝腫瘍に対するRF療法の成績とその現状.南 康範; 工藤 正俊; 鄭 浩柄; 高橋 俊介; 井上 達夫; 上嶋 一臣; 福永 豊和  臨床外科  61-  1193  -1199  2006肝胆膵の画像診断. 超音波検査.井上 達夫; 工藤 正俊; 前川 清  図解 消化器内科学テキスト  127  -131  2006C型肝癌に対する治療戦略.工藤 正俊  Medical Digest. C型肝疾患の治療戦略Up date―肝癌撲滅を目指してー  4-  41  -51  2006EUSの適応と限界.北野 雅之; 工藤 正俊; 坂本 洋城; 西尾 健; 末冨 洋一郎; 前川 清; 竹山 宜典; 筑後 孝章  胆と膵 特集胆道と膵臓の新しい内視鏡診療  27-  289  -297  2006超音波診断ー体外超音波検査.汐見 幹夫; 工藤 正俊  レジデントのための内視鏡診療マニュアル  18-  838  -841  2006What is the best staging system for hepatocellular carcionoma?工藤 正俊  J Gastroenterol  41-  (3)  290  -291  2006Clinical significance of the genotype and core promoter/pre-core mutations in hepatitis B virus carriersS Hagiwara; M Kudo; Y Minami; HY Chung; T Nakatani; T Fukunaga; Y Osaki; Y Yamashita; K Kajimura  INTERVIROLOGY  49-  (4)  200  -206  2006Hemodynamic and morphologic changes of peripheral hepatic vasculare in cirrhotic liver disease: a preliminary study using contrast-enhanced coded phase inversion harmonic ultrasonography.鄭 栄琴; 工藤 正俊; 坂口 康浩  World of Gastroenterol  11-  6348  -6353  2006Imaging findings of biliary hamartomas.鄭 栄琴; 工藤 正俊; 遠田 弘一; 井上 達夫  World of Gastroenterol  11-  6354  -6359  2006膵癌(上皮内癌)坂本洋城; 工藤 正俊; 北野 雅之  消化器診療  71-  12  -13  2006肝癌の診断・治療における日欧の相違「肝疾患をみつめてー現状と今後の展望」工藤 正俊  クリニシアン  53-  167  -173  2006Comparison of standard-dose and low-dose gemcitabine regimens in pancreatic adenocarcinoma patients: a prospective randomized trialH Sakamoto; M Kitano; Y Suetomi; Y Takeyama; H Ohyanagi; T Nakai; C Yasuda; M Kudo  JOURNAL OF GASTROENTEROLOGY  41-  (1)  70  -76  2006/01Hepatocellular carcinoma and NASH.工藤 正俊  J Gastroenterol  39-  409  -411  2006Radiofrequency ablation of hepatocellular carcinoma: therapeutic response using contrast-enhanced coded phase-inversion harmonic sonography文 艶玲; 工藤 正俊; 南 康範; 鄭 浩柄; 末冨洋一郎; 遠田 弘一; 北野 雅之; 川崎 俊彦; 前川 清  AJR  (181)  57  -63  2006膵腫瘍の造影EUS診断北野 雅之; 工藤 正俊; 坂本 洋城; 前川 清  臨床消化器内科  20-  1551  -1558  2006巻頭言工藤 正俊  早期肝細胞癌の画像的診断基準に迫る  1  -2  2006CO2動注US angiography, カラ-ドプラによりいかに肝癌を描出しうるか. 特集「肝癌のタイプ別画像診断と最近のトピックス工藤 正俊  13-  140  -153  2006序説/ 早期肝細胞癌の画像診断の現状と限界. 特集「早期肝細胞癌の画像診断基準に迫る」工藤 正俊  消化器画像  8-  (1)  13  -16  2006序説/ 超音波画像と自然経過からみた早期肝細胞癌の治療適応. 特集「早期肝細胞癌の画像診断基準に迫る」福永 豊和; 工藤 正俊  消化器画像  8-  (1)  51  -58  2006座談会「早期肝細胞癌の画像診断基準に迫る」.工藤 正俊  消化器画像  8-  (1)  65  -78  2006超音波を中心とした肝腫瘍の血流動態診断. 特集「肝腫瘍の血流動態診断」工藤 正俊  Radiology Frontier Radiology Frontier  9-  15  -24  2006肝細胞癌: 最近の話題と治療の展望.工藤 正俊  Minophagen Medical Review Minophagen Medical Review  51-  1  -16  2006超音波を中心とした肝腫瘍の血流動態診断. 特集「肝腫瘍の血流動態診断」工藤 正俊  Radiology Frontier Radiology Frontier  9-  15  -24  2006嘔気・嘔吐.汐見 幹夫; 工藤 正俊  Emergency Care Emergency Care  224  -232  2006/01肝細胞癌: 最近の話題と治療の展望.工藤 正俊  Minophagen Medical Review Minophagen Medical Review  51-  1  -16  2006/01Hepatic angiomyolipoma: Identification of an efferent vessel as a hepatic vein by contrast-enhanced harmonic sonographyRong Qin Zheng; Masatoshi Kudo; Emi Ishikawa; Hobyung Chung; Yasunori Minami; Chikara Ogawa; Yasuhiro Sakaguchi; Masayuki Kitano; Toshihiko Kawasaki; Kiyoshi Maekawa  Journal of Medical Ultrasonics  32-  (4)  191  -195  2005/12Imaging findings of biliary hamartomas (von Meyenburg complexes)Rong Qin Zheng; Masatoshi Kudo; Hirokazu Onda; Tatsuo Inoue; Kiyoshi Maekawa; Yasunori Minami; Hobyung Chung; Masayuki Kitano; Toshihiko Kawasaki  Journal of Medical Ultrasonics  32-  (4)  205  -211  2005/12Hemodynamic and morphologic changes of peripheral hepatic vasculature in chronic liver disease: A preliminary study by contrast-enhanced coded phase-inversion harmonic sonographyYasuhiro Sakaguchi; Masatoshi Kudo; Rong Qin Zheng; Hobyung Chung; Yasunori Minami; Chikara Ogawa; Masayuki Kitano; Toshihiko Kawasaki; Kiyoshi Maekawa  Journal of Medical Ultrasonics  32-  (4)  197  -204  2005/12Multiple metastases from a meningeal hemangiopericytoma associated with severe hypoglycemiaPei Zhou; Masatoshi Kudo; Hobyung Chung; Yasunori Minami; Chikara Ogawa; Yasuhiro Sakaguchi; Masayuki Kitano; Toshihiko Kawasaki; Kiyoshi Maekawa  Journal of Medical Ultrasonics  32-  (4)  187  -190  2005/12肝がんの早期発見・内科的治療と再発予防の最前線.工藤 正俊  東京肝臓のひろば  149-  13  -18  2005/12Vascularity of Gastric Carcinoma : Evaluation using Color Doppler UltrasonographyKUWAGUCHI Ai; KUDO Masatoshi; KAWASAKI Toshihiko; MAENO Tomoko; ICHIZIMA Mayumi; MAEKAWA Kiyoshi; INOUE Tatuo; ITOU Tatuki  Journal of medical ultrasOnics= 超音波医学  32-  (6)  539  -545  2005/11Vascularity of Gastric Carcinoma : Evaluation using Color Doppler UltrasonographyKUWAGUCHI Ai; KUDO Masatoshi; KAWASAKI Toshihiko; MAENO Tomoko; ICHIZIMA Mayumi; MAEKAWA Kiyoshi; INOUE Tatuo; ITOU Tatuki  Japanese journal of medical ultrasOnics= 超音波医学  32-  (6)  539  -545  2005/11肝細胞癌のステージ分類をめぐる最近の話題.鄭 浩柄; 工藤 正俊  新薬と臨床  54-  139  2005/11肝臓癌画像診断の進歩.上嶋 一臣; 工藤 正俊  臨床検査  49-  1193  -1199  2005/11Early detection and curative treatment of early-stage hepatocellular carcinomaMasatoshi Kudo  Clinical Gastroenterology and Hepatology  3-  (2)  S144  -S148  2005/10Hepatic angiomyolipoma: identification of an efferent vessel to be hepatic vein by contrast-enhanced harmonic ultrasoundRQ Zheng; M Kudo  BRITISH JOURNAL OF RADIOLOGY  78-  (934)  956  -960  2005/10超高齢者同時性多発胃癌の1手術例吉本理恵; 汐見幹夫; 工藤正俊; 塩崎均; 松井洋勝  日本消化器病学会雑誌  102-  A735  2005/09EUS‐FNABで確定診断できた上皮内すい癌の一症例坂本洋城; 北野雅之; 西尾健; 末冨洋一郎; 井上達夫; 坂口康浩; 梅原秦; 汐見幹夫; 工藤正俊; 川辺高史; 中居卓也; 竹山宜典; 筑後孝章  Gastroenterol Endosc  47-  (Supplement 2)  2103  2005/09P-635 ペグイントロン・レベトール併用療法の院内における市販直後調査への対応(8.有害事象・副作用(基礎と臨床)3,医療薬学の未来へ翔(はばた)く-薬剤師の薬剤業務・教育・研究への能動的関わり-)家田 正子; 野村 守弘; 桑野 寛行; 森山 健三; 東田 有智; 工藤 正俊  日本医療薬学会年会講演要旨集  15-  387  -387  2005/09グラフィック 画像診断ABC:機器の進歩とその利用(4)2. 機器 超音波前川 清; 工藤 正俊  医薬ジャ-ナル  41-  (8)  5  -14  2005/08胃がんの検査ーここがポイント 1)とにかく、見落とさないためには.汐見 幹夫; 工藤 正俊  臨床腫瘍プラクティス  1-  (1)  15  -18  2005/08包括評価時代の門脈圧こう進症治療 包括医療における食道静脈りゅう治療松井繁長; 市川勉; 工藤正俊  日本門脈圧こう進症学会雑誌  11-  (1)  37  2005/07側方リンパ節転移を認めた直腸カルチノイドの1例所 忠男; 奥野 清隆; 肥田 仁一; 石丸 英三郎; 内田 寿博; 吉藤 竹仁; 松崎 智彦; 安富 正幸; 塩崎 均; 南 康範; 工藤 正俊  日本大腸肛門病学会雑誌  58-  (6)  366  -366  2005/06食道癌、食道胃切郷部腺癌手術例からみたShort Segment Barrett's Esophagusの意義辻 直子; 工藤 正俊; 石黒 信吾; 上堂 文也  Gastroenterological Endoscopy Gastroenterological Endoscopy  47-  (6)  1211  -1219  2005/06Multiple hypervascular liver nodules in a heavy drinker of alcoholKim, SR; Y Maekawa; T Ninomiya; S Imoto; T Matsuoka; K Ando; K Mita; K Ku; T Koterazawa; T Nakajima; K Fukuda; Y Yano; M Nakaji; M Kudo; KI Kim; M Hirai; Y Hayashi  JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY  20-  (5)  795  -799  2005/05Forefront of radiofrequency ablation treatment of hepatic cancer. 1. Treatment indication (positioning of the treatment).Kudo Masatoshi  Kanzo  46-  (4)  160  -164  2005/04内視鏡的に切除した単発性胃粘膜下異所性胃腺の2例―超音波内視鏡所見を含めて―吉本理恵; 汐見幹夫; 上田泰輔; 末冨洋一郎; 中岡良介; 工藤正俊; 筑後孝章  Gastroenterol Endosc  47-  (Supplement 1)  843  2005/04十二指腸静脈りゅうの内視鏡的診断と治療松井繁長; 市川勉; 工藤正俊  Gastroenterol Endosc  47-  (Supplement 1)  680  2005/04早期胃癌に対する切開剥離法における術前超音波内視鏡検査の有用性市川勉; 松井繁長; 工藤正俊; 北野雅之  Gastroenterol Endosc  47-  (Supplement 1)  803  2005/04Usefullness of contrast-enhanced ultrasonography for diagnosis and evaluation of response to chemotherapy in pancreatic ductal carcinomasSAKAMOTO Hiroki; KITANO Masayuki; KUDOU Masatoshi  Journal of medical ultrasOnics= 超音波医学  32-  S173  2005/04Estimation of the Malignant Potential of Gastrointestinal Stromal TumorsFUKUTA Nobuhiro; KITANO Masayuki; MAEKAWA Kiyoshi; KUDO Masatoshi  Journal of medical ultrasOnics= 超音波医学  32-  S186  2005/04Evaluation of microcirculation in digestive organs by EUS probeKITANO Masayuki; SAKAMOTO Hiroki; MAEKAWA Kiyoshi; MINAMI Yasunori; NAKAOKA Ryousuke; NAKATANI Tatsuya; KUDO Masatoshi  Journal of medical ultrasOnics= 超音波医学  32-  S188  2005/04Usefulness and manipulation of EUS-FNAB for diagnosis of pancreatic tumorsSAKAMOTO Hiroki; KITANO Masayuki; MAEKAWA Kiyoshi; KUDO Masatoshi  Journal of medical ultrasOnics= 超音波医学  32-  S196  2005/04Usefulness and indication of EUS-guided celiac plexus neurolysisKITANO Masayuki; SAKAMOTO Hiroki; MAEKAWA Kiyoshi; KUDO Masatoshi  Journal of medical ultrasOnics= 超音波医学  32-  S197  2005/04Real-time Virtual Sonography, an integrated system of computer tomography with ultrasound images : Value in radiofrequency ablation guidanceMINAMI Yasunori; KUDO Masatoshi; TEI Hiroshi  Journal of medical ultrasOnics= 超音波医学  32-  S201  2005/04Detect of early arterial phase in Coded Harmonic Angio mode with Levovist used accumulation and time intensity courveMAEKAWA Kiyoshi; INOUE Tatuo; MINAMI Yasunori; TEI Hiroshi; UESHIMA Kazuomi; HUKUNAGA Toyokazu; KUDOU Masatoshi  Journal of medical ultrasOnics= 超音波医学  32-  S390  2005/04Usefullness of contrast-enhanced ultrasonography for diagnosis and evaluation of response to chemotherapy in pancreatic ductal carcinomasSAKAMOTO Hiroki; KITANO Masayuki; KUDOU Masatoshi  Japanese journal of medical ultrasOnics= 超音波医学  32-  S173  2005/04Estimation of the Malignant Potential of Gastrointestinal Stromal TumorsFUKUTA Nobuhiro; KITANO Masayuki; MAEKAWA Kiyoshi; KUDO Masatoshi  Japanese journal of medical ultrasOnics= 超音波医学  32-  S186  2005/04Evaluation of microcirculation in digestive organs by EUS probeKITANO Masayuki; SAKAMOTO Hiroki; MAEKAWA Kiyoshi; MINAMI Yasunori; NAKAOKA Ryousuke; NAKATANI Tatsuya; KUDO Masatoshi  Japanese journal of medical ultrasOnics= 超音波医学  32-  S188  2005/04Usefulness and manipulation of EUS-FNAB for diagnosis of pancreatic tumorsSAKAMOTO Hiroki; KITANO Masayuki; MAEKAWA Kiyoshi; KUDO Masatoshi  Japanese journal of medical ultrasOnics= 超音波医学  32-  S196  2005/04Usefulness and indication of EUS-guided celiac plexus neurolysisKITANO Masayuki; SAKAMOTO Hiroki; MAEKAWA Kiyoshi; KUDO Masatoshi  Japanese journal of medical ultrasOnics= 超音波医学  32-  S197  2005/04Real-time Virtual Sonography, an integrated system of computer tomography with ultrasound images : Value in radiofrequency ablation guidanceMINAMI Yasunori; KUDO Masatoshi; TEI Hiroshi  Japanese journal of medical ultrasOnics= 超音波医学  32-  S201  2005/04Detect of early arterial phase in Coded Harmonic Angio mode with Levovist used accumulation and time intensity courveMAEKAWA Kiyoshi; INOUE Tatuo; MINAMI Yasunori; TEI Hiroshi; UESHIMA Kazuomi; HUKUNAGA Toyokazu; KUDOU Masatoshi  Japanese journal of medical ultrasOnics= 超音波医学  32-  S390  2005/04大腸癌肝転移に対するラジオ波熱凝固療後の局所再発(第105回日本外科学会定期学術集会)中居 卓也; 川辺 高史; 奥野 清隆; 大柳 治正; 塩崎 均; 南 康範; 工藤 正俊  日本外科学会雑誌  106-  (0)  2005/04Contrast-enhanced harmonic EUS: A method to visualize microcirculation in digestive organsM Kitano; M Kudo; K Maekawa; H Sakamoto; R Nakaoka; Y Minami; T Nakatani; N Mizuguchi  GASTROINTESTINAL ENDOSCOPY  61-  (5)  AB288  -AB288  2005/04Clinical characteristics and endoscopic treatment of duodenal varicesS Matsui; M Kudo; T Ichikawa  GASTROENTEROLOGY  128-  (4)  A669  -A670  2005/04Real-time virtual sonography, an integrated system of computer tomography with ultrasound images: Value in radiofrequency ablation guidanceY Minami; M Kudo  GASTROENTEROLOGY  128-  (4)  A760  -A760  2005/04肝細胞癌診療の最近のトピックス工藤 正俊  日本内科学会雑誌  94-  (3)  464  -472  2005/03Vascularity of gastric carcinoma: Evaluation using color Doppler ultrasonographyAi Kuwaguchi; Masatoshi Kudo; Toshihiko Kawasaki; Tomoko Maeno; Mayumi Ichijima; Kiyoshi Maekawa; Tatsuo Inoue; Tatsuki Ito  Journal of Medical Ultrasonics  32-  (1)  23  -28  2005/03Estimation of the malignant potential of gastrointestinal stromal tumors: the value of contrast-enhanced coded phase-inversion harmonics USN Fukuta; M Kitano; K Maekawa; T Chikugo; M Kudo  JOURNAL OF GASTROENTEROLOGY  40-  (3)  247  -255  2005/03肝血管腫のLOGIQ9(CHA法)によるLevovist造影超音波像について前川清; 井上達夫; 鄭浩柄; 南康範; 福永豊和; 川崎俊彦; 汐見幹夫; 工藤正俊  超音波医学  32-  (1)  48  2005/01体外式造影超音波法による潰よう性大腸炎,虚血性腸炎の検討梅原泰; 永島美樹; 福田信宏; 中岡良介; 川崎俊彦; 汐見幹夫; 工藤正俊; 前川清  超音波医学  32-  (1)  42  2005/01KURでの多発肝腫瘍BNCTにおける線量評価櫻井良憲; 鈴木 実; 永田憲司; 増永慎一郎; 木梨友子; 丸橋 晃; 小野公二; 工藤正俊  第2回日本中性子捕捉療法研究会  2005Early detection and characterization of hepatocellular carcinoma: Value of imaging multistep human hepatocarcinogenesisM Kudo  INTERVIROLOGY  49-  (1-2)  64  -69  2005臨床診断の進め方 超音波内視鏡診断.坂本 洋城; 福田 信宏; 北野 雅之; 工藤 正俊  消化器の臨床  8-  657  -664  2005膵癌の早期診断-TS1症例診断のためのアプローチ: US、EUSを中心に.坂本 洋城; 北野 雅之; 工藤 正俊  消化器外科  28-  141  -148  2005肝転移の画像診断の進歩-US.井上 達夫; 工藤 正俊  消化器画像 特集「肝転移―その特性からみた診断と治療」  7-  468  -474  2005大腸癌.梅原 泰; 工藤 正俊  消化器診療  68-  10  -11  2005Low-dose, long-term, intermittent interferon-alpha-2b therapy after radical treatment by radiofrequency ablation delays clinical recurrence in patients with hepatitis C virus-related hepatocellular carcinomaY Sakaguchi; M Kudo; T Fukunaga; Y Minami; H Chung; T Kawasaki  INTERVIROLOGY  48-  (1)  64  -70  2005Reply "Staging for hepatocellular carcinoma: treatment strategy matters."工藤 正俊  Hepatology  41-  678  -679  2005Response.汐見 幹夫; 工藤 正俊; 上硲 俊法  Gastrointest Endosc  61-  931  2005原発性・転移性肝癌(内科)工藤 正俊  今日の治療指針2005年版  386  -389  2005肝の画像診断ーCT, MRI, US 各画像診断の比較と臨床応用.福永 豊和; 工藤 正俊  Annual Review 消化器  129  -135  2005膵癌の早期診断ーTS1症例診断のためのアプローチ:US, EUSを中心にー. 特集「最新の膵癌の診断と治療」坂本 洋城; 工藤 正俊; 北野 雅之  消化器外科  28-  141  -148  2005特集「肝臓の臨床最前線」肝がん治療の最前線鄭 浩柄; 工藤 正俊; 南 康範  綜合臨床  54-  480  -487  2005座談会「肝癌の診断・治療における日本肝臓学会の国際的役割」林 紀夫; 工藤 正俊; 神代 正道  医学界新聞  2624-  1  -3  2005講義録 消化器病学ー原発性肝癌福永 豊和; 工藤 正俊  医学生向け教科書シリーズ, 上西紀夫, 田中雅夫, 菅野健太郎, 滝川 一, 編  486  -495  2005超音波が可能にする臨床最前線「消化器領域での超音波の進歩」工藤 正俊  新医療  50-  48  -51  20051. 治療適応(治療の位置付け)工藤 正俊  肝臓  46-  (4)  160  -164  2005炎症性腸疾患「消化管狭窄に対する内視鏡的拡張術」.中岡 良介; 工藤 正俊; 梅原 泰  Medical Practice Medical Practice  22-  (5)  843  -847  2005C型肝炎起因肝癌患者に対するRFA治療後の肝癌再発遅延. Interventional Hepatology: 癌の治療とウイルス駆除.工藤 正俊  Medicament News Medicament News  17  2005末梢型肝内胆管癌の内科的治療. 特集「末梢型肝内胆管癌」上嶋 一臣; 工藤 正俊  肝胆膵  50-  (6)  951  -956  2005肝癌の病期分類の問題点. 特集「肝細胞癌ー今日の治療戦略ー」工藤 正俊  外科治療  93-  7  -14  2005食道癌・胃癌.市川 勉; 工藤 正俊; 松井 繁長  消化器診療  68-  14  -15  2005なんでも健康相談「肝血管腫」工藤 正俊  きょうの健康  9-  127  2005肝臓(診断)福永 豊和; 工藤 正俊  専門医のための消化器病学, 小俣政男, 千葉 勉, 監修  396  -405  2005肝癌のTumor ablation工藤 正俊  Cancer Frontier Cancer Frontier  7-  (1)  120  -130  2005超音波の新たな展開-純動脈相イメージングを中心に-特集「肝の循環動態:基礎から臨床への展開」血流動態からみた肝の病態:その新たな展開: 肝細胞癌.前川 清; 工藤 正俊  医薬ジャーナル  41-  5  -14  2005腹部超音波検査と超音波ガイド下肝生検(腫瘍生検を含む)井上 達夫; 工藤 正俊  消化器疾患診療実践ガイド  180  -188  2005肝区域、胆道系の区分、腹部血管像井上 達夫; 工藤 正俊  消化器疾患診療実践ガイド  867  -871  2005超音波の新たな展開-純動脈相イメージングを中心に-特集「肝の循環動態:基礎から臨床への展開」血流動態からみた肝の病態:その新たな展開: 肝細胞癌.工藤 正俊  肝胆膵  51-  (3)  389  -402  2005超音波検査の最前線南 康範; 工藤 正俊; 福永 豊和  「消化器病セミナー・100/肝胆膵疾患の画像診断ー最近の進歩」  1  -12  2005主催者から会議開催に寄せて工藤 正俊  アジェンダ秋号  22-  2005日米欧の肝癌の診断と治療の相違点が浮き彫りに-EASL Monothematic conference 2005-工藤 正俊  Hepatoday Hepatoday  10-  12  2005TS1膵癌の診断と造影ハーモニック超音波検査.坂本 洋城; 工藤 正俊; 北野 雅之  胆と膵  26-  521  -527  2005パネルディスカッション「次世代超音波造影剤を用いた造影超音波による消化器系臓器の微小循環動態の観察」北野 雅之; 工藤 正俊; 坂本 洋城  消化器病学の進歩2005-モノグラフ(消化器病学のニューフロンティア編)  201  -203  2005シンポジウム(3)肝細胞癌のラジオ波治療のQualityコントロールと長期予後及び今後の課題「当院における肝細胞癌に対するラジオ波焼灼術治療成績」井上 達夫; 工藤 正俊; 鄭 浩柄  消化器病学の進歩2005-モノグラフ(肝・胆・膵編)  80  -87  2005診断 4)エコー井上 達夫; 工藤 正俊  「肝転移のすべて」  172  -176  2005自然経過を中心に. 特別シンポジウム:早期肝細胞癌の画像的診断基準を考えるーどこが治療のcritical pointか?福永 豊和; 工藤 正俊  早期肝細胞癌の画像的診断基準に迫る  53  -57  2005血流動態からみた肝の病態:その新たな展開. 特集「肝の循環動態: 基礎から臨床への展開」工藤 正俊  肝胆膵  51-  389  -402  2005肝細胞癌の臨床と研究における日本の果たすべき国際的役割.工藤 正俊  第91回に本消化器病学会総会記念随筆集「消化器病学の共創未来―新しい可能性の扉を拓く」  98  -101  2005肝細胞癌(典型的な1例).工藤 正俊; 前川 清  70-  14  -15  2005早期肝細胞癌の画像的診断基準に迫る工藤 正俊  2005Serologic test for the diagnosis of subclinical gastric anisakiasis [1] (multiple letters)Mitsunobu Matsushita; Kazuichi Okazaki; Mikio Shiomi; Toshinori Kamisako; Masatoshi Kudo  Gastrointestinal Endoscopy  61-  (7)  931  2005Staging system for hepatocellular carcinoma it concept and clinical impactMasatoshi Kudo  Acta Hepatologica Japonica  46-  (2)  53  -63  2005Validation of a new prognostic staging system for hepatocellular carcinoma: the JIS score compared with the CLIP scoreM Kudo; HY Chung; S Haji; Y Osaki; H Oka; T Seki; H Kasugai; Y Sasaki; T Matsunaga  HEPATOLOGY  40-  (6)  1396  -1405  2004/12Characterization of hepatic tumors: Value of contrast-enhanced coded phase-inversion harmonic angio (Vol 182, pg 1019, 2004)YL Wen; M Kudo; RG Zheng; H Ding; P Zhou; Y Minami; HY Chung; M Kitano; T Kawasaki; K Maekawa  AMERICAN JOURNAL OF ROENTGENOLOGY  183-  (4)  1175  -1175  2004/10Hepatocellular carcinoma that ruptured during radiofrequency ablation therapyT Kawasaki; M Kudo; H Chung; Y Minami  JOURNAL OF GASTROENTEROLOGY  39-  (10)  1015  -1016  2004/10林 紀夫 新理事長に聞く岡上 武; 工藤 正俊; 林 紀夫  肝臓 = ACTA HEPATOLOGICA JAPONICA  45-  (9)  454  -458  2004/09当院における胆管結石に対する内視鏡的治療の比較検討由谷逸朗; 落合健; 田中陽一; 森村正嗣; 米田円; 辻直子; 汐見幹夫; 工藤正俊  日本消化器病学会雑誌  101-  A840  2004/09造影ハーモニック超音波検査によるすい管癌治療効果判定の検討坂本洋城; 北野雅之; 萩原智; 末富洋一郎; 中岡良介; 坂口康浩; 汐見幹夫; 工藤正俊  日本消化器病学会雑誌  101-  A669  2004/09EUS下穿刺検体の取り扱いの工夫中岡良介; 汐見幹夫; 工藤正俊  肝臓  45-  (Supplement 2)  A406  2004/09造影ハーモニック超音波検査によるすい管癌治療効果判定の検討坂本洋城; 北野雅之; 萩原智; 朱富洋一郎; 中岡良介; 坂口康浩; 汐見幹夫; 工藤正俊  肝臓  45-  (Supplement 2)  A437  2004/09EUS下穿刺検体の取り扱いの工夫中岡良介; 汐見幹夫; 工藤正俊  日本消化器病学会雑誌  101-  A575  2004/09食道静脈りゅう治療におけるEVLの位置付け松井繁長; 工藤正俊; 市川勉  日本消化器病学会雑誌  101-  A653  2004/09難治性C型慢性肝炎(Ib・高ウイルス)に対するIFN‐α2b・リバビリン併用療法後IFN単独追加投与の効果石川恵美; 工藤正俊; 汐見幹夫; 北野雅之; 川崎俊彦; 松井繁長; 福永豊和; 中岡良介; 鄭浩柄  肝臓  45-  (Supplement 2)  A465  2004/09EUS下穿刺検体の取り扱いの工夫中岡良介; 汐見幹夫; 工藤正俊  Gastroenterol Endosc  46-  (Supplement 2)  1825  2004/09造影ハーモニック超音波検査によるすい管癌治療効果判定の検討坂本洋城; 北野雅之; 萩原智; 末富洋一郎; 中岡良介; 坂口康浩; 汐見幹夫; 工藤正俊  Gastroenterol Endosc  46-  (Supplement 2)  1879  2004/09造影ハーモニック超音波検査によるすい管癌治療効果判定の検討坂本洋城; 北野雅之; 萩原智; 末富洋一郎; 中岡良介; 坂口康浩; 汐見幹夫; 工藤正俊  日本消化器集団検診学会雑誌  42-  (5)  135  2004/09超音波内視鏡ガイド下腹腔神経叢ブロック術の適応と問題点:後方接近法との比較検討坂本洋城; 北野雅之; 中岡良介; 末富洋一郎; 萩原智; 松井繁長; 汐見幹夫; 工藤正俊  Gastroenterol Endosc  46-  (Supplement 2)  2011  2004/09下部胆管に留置したMetallic stentが破損したすい頭部癌の一例吉本理恵; 汐見幹夫; 坂本洋城; 萩原智; 末冨洋一郎; 中岡良介; 松井繁長; 北野雅之; 工藤正俊  Gastroenterol Endosc  46-  (Supplement 2)  1997  2004/09食道静脈りゅう治療におけるEVLの位置付け松井繁長; 工藤正俊; 市川勉  Gastroenterol Endosc  46-  (Supplement 2)  1855  2004/09早期胃癌の内視鏡的粘膜切除術:細径超音波プロープによる周波数別術前深達度診断の検討市川勉; 松井繁長; 石川恵美; 北野雅之; 汐見幹夫; 工藤正俊  Gastroenterol Endosc  46-  (Supplement 2)  1932  2004/09Atypical focal spared area in fatty liver: Evaluation by color Doppler ultrasonographyPei Zhou; Masatoshi Kudo; Hobyung Chung; Yasunori Minami; Chikara Ogawa; Yasuhiro Sakaguchi; Masayuki Kitano; Toshihiko Kawasaki; Kiyoshi Maekawa  Journal of Medical Ultrasonics  31-  (3)  131  -134  2004/09乏血性すい腫ようの1例坂本洋城; 北野雅之; 萩原智; 末冨洋一郎; 汐見幹夫; 工藤正俊; 前川清  超音波医学  31-  (4)  J269  2004/07造影超音波検査がすい癌の胆管ステント内腫よう進展の診断に有用であった1例坂本康明; 坂本洋城; 北野雅之; 萩原智; 末冨洋一郎; 汐見幹夫; 工藤正俊; 前川清  超音波医学  31-  (4)  J269  2004/07Treatment of hepatocellular carcinoma with percutaneous radiofrequency ablation: Usefulness of contrast harmonic sonography for lesions poorly defined with B-mode sonographyY Minami; M Kudo; T Kawasaki; H Chung; C Ogawa; H Shiozaki  AMERICAN JOURNAL OF ROENTGENOLOGY  183-  (1)  153  -156  2004/07関西地区におけるPEGの現況.汐見 幹夫; 工藤 正俊  PEG(胃瘻)栄養ー適切な栄養管理を行うために  132  -137  2004/07Dynamic imaging of pancreatic diseases by contrast enhanced coded phase inversion harmonic ultrasonographyM Kitano; M Kudo; K Maekawa; Y Suetomi; H Sakamoto; N Fukuta; R Nakaoka; T Kawasaki  GUT  53-  (6)  854  -859  2004/06APCによる食道静脈りゅう地固め治療例松井繁長; 工藤正俊; 市川勉  治療学  38-  (5)  574  -576  2004/05Multiple tuberculous abscesses of the liver and the brain in a patient with acute leukemiaRQ Zheng; M Kudo; E Ishikawa; P Zhou  JOURNAL OF GASTROENTEROLOGY  39-  (5)  497  -499  2004/05Percutaneous radiofrequency ablation guided by contrast-enhanced harmonic sonography with artificial pleural effusion for hepatocellular carcinoma in the hepatic domeY Minami; M Kudo; T Kawasaki; H Chung; C Ogawa; H Shiozaki  AMERICAN JOURNAL OF ROENTGENOLOGY  182-  (5)  1224  -1226  2004/05超音波内視鏡下穿刺が診断に有用であったparagangliomaの1例坂本洋城; 北野雅之; 末冨洋一郎; 中岡良介; 朝隈豊; 北井聡; 汐見幹夫; 工藤正俊; 前川清  Gastroenterol Endosc  46-  (Supplement 1)  783  2004/04Comparison of argon plasma coagulation and paravariceal injection selerotherapy of 1% polidocanol in mucosa-fibrosing therapy for esophageal varicesS Matsui; M Kudo; T Ichikawa; R Nakaoka; T Kawasaki; M Shiomi  GASTROINTESTINAL ENDOSCOPY  59-  (5)  AB247  -AB247  2004/04JIS scoring system combined with 3 tumor makers (modified JIS score) is an exellent prognostic staging system for hepatocellular carcinoma (HCC): Analysis of 4525 patients with HCCM Kudo; H Chung; Y Osaki; H Oka; H Kasugai; Y Sasaki; T Seki  JOURNAL OF HEPATOLOGY  40-  80  -80  2004/04Percutaneous ultrasound-guided radiofrequency ablation with the artificial pleural effusion for hepatocellular carcinoma in the hepatic domeY Minami; M Kudo; T Kawasaki; HY Chung; C Ogawa; T Inoue; Y Sakaguchi; H Sakamoto; H Shiozaki  GASTROENTEROLOGY  126-  (4)  A739  -A739  2004/04肝癌の診断と治療 造影超音波検査における肝腫瘍のpost-vascular-phaseにおける悪性度評価 SPIO-MRI,組織学的所見,免疫染色との比較検討井上 達夫; 周 佩; 坂口 康浩; 萩原 智; 南 康範; 鄭 浩柄; 福永 豊和; 川崎 俊彦; 工藤 正俊; 前川 清; 綿井 良輔; 粟井 和夫; 前西 修  肝臓  45-  (Suppl.1)  A28  -A28  2004/04【はじめての当直 病棟篇】 よくナースコールがある症状・症候 軽症と思っても必ず診察しよう 吐血,下血松井 繁長; 工藤 正俊  臨床研修プラクティス  1-  (2)  72  -75  2004/04Comparison of argon plasma coagulation and paravariceal injection sclerotherapy with 1% polidocanol in mucosa-fibrosing therapy for esophageal varicesS Matsui; M Kudo; R Nakaoka; M Shiomi; T Kawasaki  JOURNAL OF GASTROENTEROLOGY  39-  (4)  397  -399  2004/04Characterization of hepatic tumors: Value of contrast-enhanced coded phase-inversion harmonic angioYL Wen; M Kudo; RG Zheng; H Ding; P Zhou; Y Minami; HY Chung; M Kitano; T Kawasaki; K Maekawa  AMERICAN JOURNAL OF ROENTGENOLOGY  182-  (4)  1019  -1026  2004/04【肝癌 今,わかっていること,わかっていないこと】治療 ここまでは大丈夫,これ以上はこれからの問題 経皮的局所療法椎名 秀一朗; 寺谷 卓馬; 佐藤 新平; 建石 良介; 藤島 知則; 近藤 祐嗣; 山敷 宣代; 峯 規雄; 玉木 克佳; 石川 隆; 菅田 美保; 小尾 俊太郎; 吉田 晴彦; 川辺 隆夫; 小俣 政男  カレントテラピー  22-  (5)  485  -489  2004/04Precut sphincterotomy from the pancreatic orifice using a standard papillotomeMIZUNO Shigeto; HONJO Hajime; KUDO Masatoshi  Tando  18-  (1)  23  -28  2004/03Diagnosis of acute cholecystitis in patients with liver cirrhosis: Waveform analysis of the cystic artery by color Doppler imagingHitoshi Tochio; Shin-Ichi Nishiuma; Yoshihiro Okabe; Akio Orino; Masatoshi Kudo  Journal of Medical Ultrasonics  31-  (1)  21  -28  2004/03リバビリン単独投与における臨床検査値の変動および有害事象の検討野村 守弘; 家田 正子; 柳原 喜恵; 桑野 寛行; 森山 健三; 北野 雅之; 石川 恵美; 工藤 正俊  臨床薬理 = JAPANESE JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS  35-  (1)  252S  2004/01造影ハーモニック超音波検査によるすい管癌治療効果判定の検討坂本洋城; 北野雅之; 萩原智; 末富洋一郎; 中岡良介; 坂口康浩; 汐見幹夫; 工藤正俊  日本消化吸収学会総会プログラム・講演抄録集  35th-  140  2004膵仮性?胞を疑った1例.坂本 洋城; 北野 雅之; 工藤 正俊; 土師 誠二; 塩﨑 均; 土手 健作; 筑後 孝章; 須田 耕一  消化器画像  6-  153  -157  2004Detection of intratumoral vascularity in small hepatocellular carcinoma by coded phase inversion harmonicsYL Wen; P Zhou; M Kudo  INTERVIROLOGY  47-  (3-5)  169  -178  2004Atypical large well-differentiated hepatocellular carcinoma with benign nature: A new clinical entityM Kudo  INTERVIROLOGY  47-  (3-5)  227  -237  2004Differentiation of hepatic tumors by color Doppler imaging: Role of the maximum velocity and the pulsatility index of the intratumoral blood flow signalM Kudo; H Tochio; P Zhou  INTERVIROLOGY  47-  (3-5)  154  -161  2004Hepatocellular carcinoma with nodule-in-nodule appearance: Demonstration by contrast-enhanced coded phase inversion harmonic imagingRQ Zheng; P Zhou; M Kudo  INTERVIROLOGY  47-  (3-5)  184  -190  2004Afferent and efferent vessels of premalignant and overt hepatocellular carcinoma: Observation by color Doppler imagingHitoshi Tochio; Masatoshi Kudo  Intervirology  47-  (3-5)  144  -153  2004Local ablation therapy for hepatocellular carcinoma: current status and future perspective.工藤 正俊  J Gastroenterol  (39)  205  -214  2004肝細胞癌「局所療法-Ablation(1)」工藤 正俊  コンセンサス肝疾患治療2004  163  -174  2004超音波血流画像(US angio, カラードプラ, パワードプラ, 3次元画像)による肝硬変の微小血行動態の観察.工藤 正俊  診療と新薬  40-  (11)  23  -29  2004肝の画像診断福永 豊和; 工藤 正俊  Annual Review 消化器  127  -131  2004Prognostic prediction and treatment dicision for hepatocellular carcinoma according to the integrated staging system鄭 浩柄; 工藤 正俊  臨床外科  59-  (3)  273  -278  2004検査手技「腹部超音波検査」.井上 達夫; 工藤 正俊  消化器病診療-良きインフォームドコンセントに向けて-. 財団法人日本消化器病学会 監修  31  -34  2004膵「炎症と癌の鑑別におけるパワードプラの有用性」.北野 雅之; 工藤 正俊  消化器内視鏡臨床手技シリーズ5. 超音波内視鏡up date. 村田洋子, 峯 徹哉, 編集  206  -209  2004吐血・下血「はじめての当直-病棟編- 」松井 繁長; 工藤 正俊  臨床研修グラフティス  1-  72  -75  2004ハーモニックイメージングの最新動向.工藤 正俊  「超音波医学最前線」別冊・医学のあゆみ, 伊東紘一編  38  -44  2004超音波内視鏡ガイド下治療「腹腔神経ブロック」特集「消化器内視鏡の治療の進歩」北野 雅之; 工藤 正俊  治療学  38-  71  -75  2004APCによる食道静脈瘤地固め治療例. 特集「消化器内視鏡治療の進歩」松井 繁長; 工藤 正俊  治療学  38-  96  -98  2004(3) 肝癌の診断の進歩ー肝癌の画像診断・腫瘍マーカー・造影剤の進歩ー.工藤 正俊  肝疾患Review 2004. 監修 小俣政男, 編集 河田純男, 白鳥康史, 工藤正俊, 榎本信幸  39  -46  2004(4)肝癌の診断の進歩ー治療法の現状・進歩からStaging systemまでー.工藤 正俊  肝疾患Review 2004. 監修 小俣政男, 編集 河田純男, 白鳥康史, 工藤正俊, 榎本信幸  47  -54  2004(3)肝癌の診断・治療の進歩. (2)造影ハーモニック法による肝癌の診断と治療.南 康範; 工藤 正俊; 川崎 俊彦  肝疾患Review 2004. 監修 小俣政男, 編集 河田純男, 白鳥康史, 工藤正俊, 榎本信幸  152  -157  2004上部消化管出血に対する内視鏡的止血法の動向.「腹部超音波診断の現在と将来」松井 繁長; 工藤 正俊  内視鏡UP to Date. 映像情報メディカル  534  -538  2004超音波内視鏡下造影エコー法.「腹部超音波診断の現在と将来」北野 雅之; 工藤 正俊  内視鏡UP to Date. 映像情報メディカル  708  -715  2004肝がん治療で医師に求められるのは「高い専門性」と「柔軟な対応力」.工藤 正俊  月刊がん もっといい日  8-  36  2004序/肝癌治療前後の画像診断の盲点. 特集「肝癌治療前後の画像」.工藤 正俊  消化器画像  62-  463  -465  2004内科局所治療の適応は. 特集「肝癌診療の最新の動向」南 康範; 工藤 正俊; 鄭 浩柄  Pharma Medica  22-  35  -39  2004C型肝炎針刺傷直後のIFN投与の有効性ー肝炎ウイルスー最新の研究動向ー鄭 浩柄; 工藤 正俊  日本臨床  62-  315  -318  2004肝癌の超音波診断. 特集「肝炎から肝がんまで」井上 達夫; 工藤 正俊; 萩原 智; 福永 豊和  臨床と研究  81-  59  -65  2004超音波(造影、新技術). 特集「肝イメージング:Today and Tomorrow」福永 豊和; 工藤 正俊  臨床画像  20-  26  -37  2004腹部超音波検査.工藤 正俊  消化器now  26-  8  2004第5章「超音波, CT, MRI」工藤 正俊  Diseases of the Liver and Biliary System (日本語訳), Sherlocks and Dooley J著, 小俣政男監訳  57  -68  2004肝細胞癌の予後予測および治療法標準化のためのstagingシステムの重要性.工藤 正俊  Hepatoday  6-  10  -11  2004包括医療と肝胆膵画像ー検査の流れはどう変わる.工藤 正俊  消化器画像  6-  723  -725  2004EUS下穿刺局注による腹腔神経叢ブロックの効果と問題点. 特集: Interventional EUS.北野 雅之; 工藤 正俊; 坂本 洋城  消化器内視鏡  16-  1313  -1318  2004統合staging systemを用いた肝細胞癌局所療法の長期予後.鄭 浩柄; 工藤 正俊  消化器科  38-  471  -475  2004「肝の微小循環動態」2.超音波ドプラ法による肝腫瘍の微小循環動態杤尾人司; 工藤 正俊  臨床放射線  49-  1587  -1600  2004肝腫瘍の診断ストラテジー肝特異性MRI造影剤をどう活用する?工藤 正俊; 泉 並木; 村上卓道  Rad Fan  2-  (7)  2  -8  2004Image-guided treatment and its evaluation. シンポジウム「肝画像診断の進歩」.南 康範; 工藤 正俊  肝臓フォーラム記録集  82  -101  2004肝画像診断の進歩.工藤 正俊  肝臓フォーラム記録集  37  -108  2004肝細胞癌の治療の進歩ー治療成績の比較.工藤 正俊; 鄭 浩柄; 大崎 往夫; 春日井 博志; 岡 博子; 関 寿人  癌と化学療法  31-  2100  -2104  2004肝細胞癌治療の最近の進歩/序.工藤 正俊  消化器病セミナー97, 編集 工藤正俊  2004肝細胞癌の治療選択・予後予測のためのステージング法の進歩. 肝細胞癌治療の最近の進歩.鄭 浩柄; 工藤 正俊  消化器病セミナー97, 編集 工藤正俊  1  -12  2004造影US下局所治療. 肝細胞癌治療の最近の進歩.南 康範; 工藤 正俊; 鄭 浩柄  消化器病セミナー97, 編集 工藤正俊  67  -76  2004インターフェロン.坂口 康浩; 工藤 正俊  消化器病セミナー97, 編集 工藤正俊  161  -168  2004画像診断の新しい展開 1)超音波.南 康範; 工藤 正俊; 鄭 浩柄; 井上 達夫; 坂口 康浩; 萩原 智; 福永 豊和  肝胆膵  49-  885  -893  2004肝悪性腫瘍の効率的画像診断. 特集「包括医療と肝胆膵画像ー検査の流れはどう変わる?」井上 達夫; 工藤 正俊  消化器画像  6-  753  -758  2004造影EUSによる膵疾患の診断.北野 雅之; 工藤 正俊  胆と膵  25-  617  -621  2004肝細胞癌脈管浸潤の診断. 特集「肝切除における血管合併切除とその成績」萩原 智; 工藤 正俊  外科  66-  (6)  621  -626  2004腹痛患者の問診と理学的所見のチェックポイント松井 繁長; 工藤 正俊  腹痛診断のコツと落とし穴  8  -9  2004肝細胞癌治療の最近の進歩工藤 正俊  消化器病セミナー97  2004肝疾患Review 2004河田純男; 工藤 正俊; 白鳥康史; 榎本信幸  肝疾患Review 2004 監修 小俣政男  2004Mucin phenotypic expression and background mucosa of esophagogastric junctional adenocarcinomaNaoko Tsuji; Shingo Ishiguro; Yoshitane Tsukamoto; Masayuki Mano; Tsutomu Kasugai; Isao Miyashiro; Yuichiro Doki; Hiroyasu Iishi; Masatoshi Kudo  Gastric Cancer  7-  (2)  97  -103  2004A case of central retinal vein occlusion during combination therapy of IFNα-2b and rivabirin for chronic hepatitis CSyuichi Fuki; Soo Ryang Kim; Tosiaki Ninomiya; Yoko Maekawa; Ke Ih Kim; Susumu Imoto; Masatoshi Kudo  Acta Hepatologica Japonica  45-  (12)  666  -670  2004Hepatobiliary and pancreatic: Fatty liver, spared areas and aberrant gastric venous drainageJOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY  18-  (12)  1423  -1423  2003/1220. 膵癌性疼痛に対する超音波内視鏡ガイド下腹腔神経叢ブロックの有用性(第54回近畿大学医学会学術講演会)北野 雅之; 中岡 良介; 坂本 洋城; 汐見 幹夫; 工藤 正俊; 前川 清  近畿大学医学雑誌  28-  (2)  2003/10A novel treatment technique for symptomatic huge liver cyst: Intracystic injection therapy of monoethanolamine oleate in 12 cases with 15 liver cysts.R Nakaoka; E Ishikawa; S Matsui; N Fukuta; Y Suetomi; Y Minami; H Chung; M Kitano; T Kawasaki; M Shiomi; M Kudo  HEPATOLOGY  38-  (4)  762A  -762A  2003/10Changes of Lens culinaris agglutinin-reactive alpha-fetoprotein (AFP-L3 fraction) after complete radiofrequency ablation for hepatocellular carcinoma: Analysis of 186 patients.C Ogawa; Y Minami; H Chung; R Nakaoka; S Matsui; T Fukunaga; M Kitano; T Kawasaki; M Shiomi; M Kudo  HEPATOLOGY  38-  (4)  769A  -769A  2003/10Stratification ability of the new prognostic staging system, Japan Integrated Staging score (JIS score) for hepatocellular carcinoma: Comparison with CLIP score.H Chung; M Kudo; Y Osaki; S Haji; Y Minami; C Ogawa; T Fukunaga; M Kitano; T Kawasaki  HEPATOLOGY  38-  (4)  752A  -752A  2003/10Severe complications of radiofrequency ablation therapy for hepatocellular carcinoma: Analysis of 3,891 ablations in 2,614 patients.H Kasugai; Y Osaki; H Oka; T Seki; M Kudo  HEPATOLOGY  38-  (4)  762A  -763A  2003/10Comparison of posttreatment prognosis between ablation and resection for early-stage hepatocellular carcinoma: Standardized analysis of 737 patients by stratification method based on JIS scoring system.M Kudo; H Chung  HEPATOLOGY  38-  (4)  758A  -758A  2003/10Validation study of the new prognostic staging system, the Japan Integrated Staging Score (JIS Score) for hepatocellular carcinoma in 3,934 Japanese patients: A multicenter collaborative study.M Kudo; H Chung; Y Osaki; H Oka; H Kasugai; Y Sasaki; T Seki; S Haji  HEPATOLOGY  38-  (4)  754A  -754A  2003/10超音波造影剤YM454を用いた肝腫りゅう性病変に対する造影効果の検討坂口康浩; 工藤正俊; 南康範; 鄭浩柄; 川崎俊彦; 汐見幹夫; 北野雅之; 前川清  肝臓  44-  (Supplement 2)  A395  2003/09血流動態より境界病変と考えられる硬変肝内微小結節性病変の予後福永豊和; 工藤正俊; 岡部純弘; 織野彬雄; 汐見幹夫; 川崎俊彦; 北野雅之; 松井繁長; 石川恵美  肝臓  44-  (Supplement 2)  A396  2003/09セロタイプ1型かつ高ウイルス量のC型慢性肝炎に対するIFN‐α2b・リバビリン併用療法の効果石川恵美; 工藤正俊; 汐見幹夫; 川崎俊彦; 北野雅之; 松井繁長; 福永豊和; 鄭浩柄; 豊沢昌子  肝臓  44-  (Supplement 2)  A442  2003/09上部消化管潰よう出血の内視鏡的止血法―止血成績向上のための更なる工夫―吉本理恵; 汐見幹夫; 石川恵美; 坂本洋城; 坂口康浩; 井上達夫; 小川力; 福田信宏; 工藤正俊  Gastroenterol Endosc  45-  (Supplement 2)  1704  2003/09十二指腸静脈りゅうの検討市川勉; 松井繁長; 中岡良介; 坂本洋城; 石川恵美; 鄭浩柄; 朝隈豊; 北野雅之; 工藤正俊  Gastroenterol Endosc  45-  (Supplement 2)  1769  2003/09食道静脈りゅうに対するアルゴンプラズマ凝固法による地固め療法の有用性松井繁長; 工藤正俊; 中岡良介  Gastroenterol Endosc  45-  (Supplement 2)  1559  2003/09内視鏡的治療を行った十二指腸静脈りゅう出血例の検討松井繁長; 市川勉; 中岡良介; 川崎俊彦; 汐見幹夫; 工藤正俊  Gastroenterol Endosc  45-  (Supplement 2)  1842  2003/09試験開腹にて診断し得た大網悪性中皮腫の一例信夫 清; 吉本 理恵; 野田 佳寿; 石川 恵美; 坂本 洋城; 井上 達夫; 小川 力; 坂口 康浩; 福田 信宏; 末富 洋一郎; 南 康範; 鄭 浩柄; 中岡 良介; 松井 繁長; 北野 雅之; 川崎 俊彦; 汐見 幹夫; 工藤 正俊  日本消化器病学会雑誌  100-  (臨増大会)  A631  -A631  2003/09Detection of tumor vascularity in hepatocellular carcinoma with contrast-enhanced dynamic flow imaging: Comparison with contrast-enhanced power Doppler imagingYan Ling Wen; Masatoshi Kudo; Yasunori Minami; Hobyung Chung; Yoichiro Suetomi; Hirokazu Onda; Masayuki Kitano; Toshihiko Kawasaki; Kiyoshi Maekawa  Journal of Medical Ultrasonics  30-  (AUTUMN)  141  -151  2003/09Hepatocellular carcinoma associated with secondary haemochromatosis in non-cirrhotic liver: a case reportHY Chung; M Kudo; T Kawasaki; M Kitano; Y Minami; Y Suetomi; H Onda  HEPATOLOGY RESEARCH  26-  (3)  254  -258  2003/07Images of interest - Hepatobiliary and pancreatic: Arterioportal fistula causing portal hypertensionRQ Zheng; HY Chung; M Kudo  JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY  18-  (7)  873  -873  2003/072.Local ablation therapyKUDO M  Kanzo  44-  (6)  250  -258  2003/06Value of new contrast harmonic technique for detecting tumor vascularity in hepatocellular carcinoma: Preliminary resultsYan Ling Wen; Masatoshi Kudo; Yasunori Minami; Hobyung Chung; Yoichiro Suetomi; Hirokazu Onda; Masayuki Kitano; Toshihiko Kawasaki; Kiyoshi Maekawa  Journal of Medical Ultrasonics  30-  (SUMMER)  85  -92  2003/06Contrast-enhanced agent detection imaging: Early experience in hepatocellular carcinomaYan Ling Wen; Masatoshi Kudo; Yasunori Minami; Hobyung Chung; Yoichiro Suetomi; Hirokazu Onda; Masayuki Kitano; Toshihiko Kawasaki; Kiyoshi Maekawa  Journal of Medical Ultrasonics  30-  (SUMMER)  77  -84  2003/06造影超音波法は臨床をいかに変えたか (総特集 超音波医療の現在) -- (超音波のこれまでとこれから)鄭 浩柄; 工藤 正俊  月刊新医療  30-  (5)  102  -104  2003/05Images of interest - Hepatobiliary and pancreatic: Hyperplastic nodules in cirrhosisRQ Zheng; M Kudo  JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY  18-  (5)  599  -599  2003/05すい癌の治療効果判定における造影超音波検査の有用性末冨洋一郎; 北野雅之; 前川清; 中岡良介; 坂本洋城; 汐見幹夫; 工藤正俊  超音波医学  30-  S305  2003/04症候性肝嚢胞に対するmonoethanolamine oleate注入療法の有用性中岡良介; 松井繁長; 福田信宏; 末冨洋一郎; 南康範; 北野雅之; 川崎俊彦; 汐見幹夫; 工藤正俊  超音波医学  30-  S366  2003/04超音波内視鏡ガイド下腹腔神経叢ブロックにおいて造影剤同時注入を行ったすい癌性とう痛の一症例北野雅之; 中岡良介; 坂本洋城; 朝隈豊; 汐見幹夫; 工藤正俊; 保田知生; 中居卓也; 前川清  Gastroenterological Endoscopy  45-  (Supplement 1)  768  2003/04副乳頭切開と副すい管ステントで長期経過観察中のすい管非癒合・慢性すい炎の一例吉本理恵; 汐見幹夫; 信夫清; 坂本洋城; 福田信宏; 末冨洋一郎; 中岡良介; 工藤正俊; 由谷逸朗  Gastroenterol Endosc  45-  (Supplement 1)  666  2003/04GAVEに対するアルゴンプラズマ凝固法の有用性と問題点松井繁長; 汐見幹夫; 中岡良介; 石川恵美; 吉本理恵; 末冨洋一郎; 福田信宏; 川崎俊彦; 工藤正俊  Gastroenterol Endosc  45-  (Supplement 1)  697  2003/04Radofrequency ablation (RFA) therapy under harmonic imaging guidance for the recurrence after local therapy for HCC: A randomized controlled studyM Kudo; T Kawasaki; M Kitano; H Chung; Y Minami  JOURNAL OF HEPATOLOGY  38-  100  -100  2003/04Usefulness of mucosa-fibrosing therapy with argon plasma coagulation for esophageal varicesS Matsui; M Kudo; M Kitano; R Nakaoka; M Shiomi  GASTROINTESTINAL ENDOSCOPY  57-  (5)  AB142  -AB142  2003/04Evaluation of pancreatic microcirculation by contrast-enhanced endosonography in dogsM Kitano; M Kudo; K Maekawa; H Sakamoto; Y Minami; R Nakaoka; K Miyamoto; H Fujimoto  GASTROINTESTINAL ENDOSCOPY  57-  (5)  AB75  -AB75  2003/04Changes of lens culinaris agglutinin-reactive alpha-fetoprotein (AFP-L3 fraction) after complete radiofrequency ablation for hepatocellular carcinomaC Ogawa; H Chung; Y Minami; N Fukuda; Y Suetomi; E Ishikawa; R Nakaoka; S Matsui; M Kitano; T Kawasaki; M Shiomi; M Kudo  GASTROENTEROLOGY  124-  (4)  A699  -A699  2003/04Radiofrequency ablation therapy under contrast-enhanced harmonic imaging guidance for recurrence after local ablation therapy for hepatocellular carcinoma: A randomized controlled studyM Kudo; Y Minami; H Chung; C Ogawa; N Fukuda; Y Suetomi; E Ishikawa; R Nakaoka; S Matsui; M Kitano; T Kawasaki; M Shiomi  GASTROENTEROLOGY  124-  (4)  A773  -A773  2003/04Radiofrequency ablation therapy for hepatocellular carcinoma located at subphrenic region: Value of artificial pleural effusion combined with contrast-harmonic imagingY Minami; M Kudo; H Chung; C Ogawa; N Fukuda; E Ishikawa; R Nakaoka; S Matsui; M Kitano; Y Suetomi; T Kawasaki; M Shiomi  GASTROENTEROLOGY  124-  (4)  A773  -A773  2003/04Usefulness of contrast-enhanced coded phase-inversion harmonic ultrasonagraphy for differential diagnosis of pancreatic diseases and evaluation of chemotherapyM Kitano; Y Suetomi; K Maekawa; H Sakamoto; R Nakaoka; T Kawasaki; M Kudo  GASTROENTEROLOGY  124-  (4)  A188  -A188  2003/04Validation and limitation of CLIP scoring system in 722 Japanese patients with hepatocellular carcinoma and a proposal of better prognostic staging system, Japan Integrated Staging Score (JIS score)M Kudo; H Chung; Y Minami; C Ogawa; N Fukuda; Y Suetomi; E Ishikawa; R Nakaoka; S Matsui; M Kitano; T Kawasaki; M Shiomi; Y Osaki  GASTROENTEROLOGY  124-  (4)  A699  -A699  2003/04Validation and limitation of clip scoring system in 722 Japanese patients with HCC and a proposal of new prognostic system, Japan Integrated Staging Score (JIS score)M Kudo; T Kawasaki; M Kitano; H Chung; Y Minami; Y Osaki  JOURNAL OF HEPATOLOGY  38-  100  -100  2003/04Differential diagnosis of pancreatic diseases by contrast-enhanced power Doppler endosonographyM Kitano; M Kudo; R Nakaoka; Y Suetomi; H Sakamoto; N Fukuta; S Matsui; M Shiomi; K Maekawa  GASTROINTESTINAL ENDOSCOPY  57-  (5)  AB244  -AB244  2003/04Stage IV hepatocellular carcinoma with portal venous tumor thrombus: Complete response after combined therapy of repeated arterial chemoembolization and radiofrequency ablation [2]Rong Qin Zheng; Masatoshi Kudo; Yasunori Minami; Kanae Inui; Hobyung Chung  Journal of Gastroenterology  38-  (4)  406  -409  2003/04リバビリンカプセルの院内における副作用調査 : 市販直後調査への対応と問題点野村 守弘; 家田 正子; 市川 泰子; 柳原 喜恵; 桑野 寛行; 石田 定廣; 北野 雅之; 工藤 正俊  臨床薬理  34-  (2)  359S  -360S  2003/03CHA(Coded Harmonic Angio)モードを用いた胆嚢隆起性病変の造影ハーモニック像の検討井上達夫; 小川力; 坂口康弘; 坂本洋城; 福田信弘; 末冨洋一郎; 汐見幹夫; 前川清; 工藤正俊  日本消化器病学会雑誌  100-  A161  2003/03症候性肝嚢胞に対するmonoethanolamine oleate(EO)注入療法の有用性の検討中岡良介; 松井繁長; 鄭浩柄; 南康範; 福田信宏; 末冨洋一郎; 北野雅之; 川崎俊彦; 工藤正俊  日本消化器病学会雑誌  100-  A233  2003/03Hepatic nodular lesions caused by abnormal hepatic circulation: etiological and clinical aspectsM Kudo  JOURNAL OF GASTROENTEROLOGY  38-  (3)  308  -310  2003/03Prognostic staging system for hepatocellular carcinoma (CLIP score): its value and limitations, and a proposal for a new staging system, the Japan Integrated Staging Score (JIS score)M Kudo; HB Chung; Y Osaki  JOURNAL OF GASTROENTEROLOGY  38-  (3)  207  -215  2003/03Transcatheter arterial chemoembolization of hepatocellular carcinoma: Usefulness of coded phase-inversion harmonic sonographyY Minami; M Kudo; T Kawasaki; M Kitano; HY Chung; K Maekawa; H Shiozaki  AMERICAN JOURNAL OF ROENTGENOLOGY  180-  (3)  703  -708  2003/03画像診断. (2)大腸癌肝転移の存在診断, 治療法選択, 進行度診断における造影USの有用性について.井上 達夫; 小川 力; 工藤 正俊; 前川 清  早期大腸癌  7-  (3)  218  -222  2003/03Hepatocellular carcinoma mimicking cavernous hemangioma on angiography and contrast enhanced harmonic ultrasonography. A case reportT Kawasaki; M Kudo; K Inui; C Ogawa; H Chung; Y Minami  HEPATOLOGY RESEARCH  25-  (2)  202  -212  2003/02Spontaneous regurgitation of portal blood flow normalized by meal intake in a patient with alcoholic liver cirrhosisYL Wen; M Kudo; RQ Zheng; T Kawaski; H Chung; Y Minami; Y Suetorni; H Onda; M Kitano; K Maekawa  HEPATOLOGY RESEARCH  25-  (2)  143  -148  2003/02アルコール肝硬変にみられた多血性結節病変.金 守良; 工藤 正俊; 前川陽子; 井本 勉  アルコールと医学生物学  23-  47  -52  2003Percutaneous ultrasound-guided radiofrequency ablation with artificial pleural effusion for hepatocellular carcinoma in the hepatic domeY Minami; M Kudo; T Kawasaki; H Chung; C Ogawa; T Inoue; Y Sakaguchi; H Sakamoto; H Shiozaki  JOURNAL OF GASTROENTEROLOGY  38-  (11)  1066  -1070  2003Contrast harmonic imaging in the diagnosis and treatment of hepatic tumors工藤 正俊  Springer Verlag  1  -253  2003Radiofrequency ablation therapy under harmonic imaging guidance for the recurring cancer after local therapy for HCC: a randomized controlled study with RFA under B-mode guidance工藤 正俊; 南 康範  Ultrasound Med Biol  (29)  145  2003Assessment of image quality of contrast-enhanced power Doppler imaging in hepatocellular carcinoma with a personal ultrasound imager: comparison with conventional machine文 艶玲; 工藤 正俊; 南 康範; 鄭 浩柄; 末冨洋一郎; 遠田 弘一; 北野 雅之; 川崎 俊彦; 前川 清  J Medical Ultrasonics  (30)  31  -38  2003Transient portal vein thrombosis caused by radiofrequency ablation for hepatocellular carcinomaRQ Zheng; M Kudo; K Inui; Y Suetomi; Y Minami; H Chung; T Kawasaki  JOURNAL OF GASTROENTEROLOGY  38-  (1)  101  -103  2003/01Contrast advanced dynamic flow imaging and contrast pulse subtraction imaging: preliminary results in hepatic tumors文 艶玲; 工藤 正俊; 前川 清; 南 康範; 鄭 浩柄; 末冨洋一郎; 遠田 弘一; 北野 雅之; 川崎 俊彦  J Medical Ultrasonics  (29)  195  -204  2003食道静脈瘤に対するアルゴンプラズマ凝固法による地固め療法の有用性.松井 繁長; 工藤 正俊; 中岡 良介; 汐見 幹夫  日本門脈圧亢進症学会誌  8-  180  -184  2003胆管性過誤腫. 特集「肝嚢胞性病変ー画像と病理」井上 達夫; 工藤 正俊  消化器画像  5-  83  -88  2003編集後記.工藤 正俊  消化器画像  5-  154  2003肝の画像診断.工藤 正俊  Annual Review 消化器  150  -153  2003パワードプラEUSによる膵腫瘍性病変の診断.北野 雅之; 工藤 正俊; 前川 清; 末冨 洋一郎; 中岡 良介; 汐見 幹夫  消化器の臨床  6-  100  -105  2003肝膿瘍・肝嚢胞.工藤 正俊  内科学, 杉本恒明, 小俣政男, 水野美邦, 編  1154  -1158  2003超音波造影の装置ならびに映像条件(腹部)工藤 正俊  超音波造影ガイドブック-すぐに役立つ基礎から臨床まで-, 森安史典, 別府慎太郎, 久 直史, 編  50  -56  2003造影エコー法の現状と今後の展望.工藤 正俊  消化器疾患の造影エコー法up date. 松井 修, 工藤正俊, 編集  6  -13  2003GIMTの造影エコー検査:体表式造影ハーモニックイメージングおよび超音波内視鏡下造影エコーの意義.福田 信宏; 工藤 正俊; 北野 雅之  消化器疾患の造影エコー法up date. 松井 修, 工藤正俊, 編集  40  -46  2003人工胸水下造影エコー併用RFAの有用性.南 康範; 工藤 正俊; 川崎 俊彦  消化器疾患の造影エコー法up date. 松井 修, 工藤正俊, 編集  136  -140  2003肝細胞癌に対するTAEは生命予後を改善するか?工藤 正俊  Hepatoday  33-  10  -11  2003肝臓がん(肝がん). 肝臓・胆嚢・膵臓の病気.工藤 正俊  別冊NHK今日の健康. 小俣政男, 編集  78  -89  2003肝血管腫. 肝臓・胆嚢・膵臓の病気.工藤 正俊  別冊NHK今日の健康. 小俣政男, 編集  116  2003肝臓診療における画像診断の役割と使い分け. 「肝癌診療の最新情報」工藤 正俊  成人病と生活習慣病  33-  (5)  555  -562  2003腹部造影エコー法.工藤 正俊  内科  91-  (6)  1092  -1093  2003CTA, CTAP.工藤 正俊  内科  91-  (6)  1094  -1095  2003稀な肝悪性腫瘤.工藤 正俊  消化器画像  5-  460  -462  2003肝細胞癌の内科的治療の治療効果判定.南 康範; 工藤 正俊; 川崎 俊彦  医学と薬学  50-  63  -69  2003肝胆膵領域における造影超音波診断の現況.工藤 正俊  肝胆膵  47-  (2)  141  -150  2003最近の肝の画像診断.福永 豊和; 工藤 正俊  「超音波検査」画像診断2003  1004  -1015  2003コントラストエコーによる肝血流の評価.南 康範; 工藤 正俊  機能・代謝・画像診断と分子画像 西村恒彦, 編  207  -213  2003胃粘膜下腫瘍の造影EUS診断.福田 信宏; 工藤 正俊; 北野 雅之  消化器内視鏡  15-  1123  -1129  2003肝細胞癌の血流動態:超音波血流画像による解析と治療への応用.工藤 正俊  シンポジウム「血流動態から病態を探り、診断・治療する」有井滋樹編  63  -78  2003消化器疾患の造影エコーUp Date松井 修; 工藤 正俊  2003Natural history of untreated hepatocellular carcinoma: A retrospective multicenter study of 195 patientsHiroko Oka; Yukio Osaki; Hiroshi Kasugai; Masatoshi Kudo; Toshihito Seki  Acta Hepatologica Japonica  44-  (11)  546  -551  2003The present condition of radiofrequency ablation: A retreospective multicenter study(38 institutions)Hiroshi Kasugai; Yukio Osaki; Hiroko Oka; Masatoshi Kudo; Toshihito Seki  Acta Hepatologica Japonica  44-  (12)  632  -640  2003Impact Factor and Stock MarketKUDO Masatoshi  Journal of medical ultrasOnics= 超音波医学  29-  (6)  J535  -J536  2002/11Changes of lens culinaris agglutinin-reactive alpha-fetoprotein (AFP-13 fraction) after complete ablation for hepatocellular carcinonia.M Kudo; C Ogawa; N Fukuda; Y Suetomi; Y Minami; E Ishikawa; H Chung; R Nakaoka; S Matsui; M Kitano; T Kawasaki; M Shiomi  HEPATOLOGY  36-  (4)  698A  -698A  2002/10Radiofrequency ablation therapy for hepatocellular carcinoma located at surphrenic region: Value of artificial pleural effusion combined with contrast-harmonic imaging.M Kudo; Y Minami; H Chung; C Ogawa; N Fukuda; Y Suetomi; E Ishikawa; R Nakaoka; S Matsui; M Kitano; T Kawasaki; M Shiomi  HEPATOLOGY  36-  (4)  698A  -698A  2002/10Radiofrequency ablation therapy combined with or without subsegmental lipiodol TAE for large hepatocellular carcinoma: A randomized prospective study.M Kudo; H Chung; C Ogawa; N Fukuda; Y Suetomi; Y Minami; E Ishikawa; R Nakaoka; S Matsui; M Kitano; T Kawasaki  HEPATOLOGY  36-  (4)  693A  -693A  2002/10Contrast-enhanced power Doppler endoscopic ultrasound in pancreatic diseases: Comparison with contrast-enhanced extracorporal harmonic ultrasound and computed tomographyM Kitano; M Kudo; R Nakaoka; Y Suetomi; M Shiomi; N Fukuda; S Matsui; T Kawasaki; K Maekawa  GASTROINTESTINAL ENDOSCOPY  56-  (4)  S123  -S123  2002/10肝細胞癌に対するRFA治療後の再発とAFP‐L3分画の相関関係について小川力; 工藤正俊; 市川勉; 乾絹世; 岡田無文; 北口容子; 豊沢昌子; 石川恵美; 汐見幹夫  肝臓  43-  (Supplement 2)  A411  2002/09造影ハーモニックイメージングによるすい癌におけるGemcitabineの治療効果判定 造影ハーモニックイメージングの意義末冨洋一郎; 北野雅之; 前川清; 石川恵美; 小川力; 福田信宏; 南康範; 汐見幹夫; 工藤正俊  日本消化器病学会雑誌  99-  A703  2002/09食道静脈りゅうに対するEISL後の地固め療法の検討 ASとAPCの比較松井繁長; 長岡良介; 石川恵美; 福田信宏; 末冨洋一郎; 鄭浩柄; 北野雅之; 川崎俊彦; 工藤正俊  Gastroenterol Endosc  44-  (Supplement 2)  1491  2002/09造影パワードプラEUSによるすい腫よう性病変の診断 体外式造影超音波および造影CT検査との比較北野雅之; 末冨洋一郎; 中岡良介; 福田信宏; 松井繁長; 南康範; 鄭浩柄; 川崎俊彦; 工藤正俊  Gastroenterol Endosc  44-  (Supplement 2)  1553  2002/09Multidetector CT: Diagnostic impact of slice thickness on detection of hypervascular hepatocellular carcinomaS Kawata; T Murakami; T Kim; M Hori; MP Federle; S Kumano; E Sugihara; S Makino; H Nakamura; M Kudo  AMERICAN JOURNAL OF ROENTGENOLOGY  179-  (1)  61  -66  2002/07II 肝細胞癌の診断と治療の最近の進歩 : 造影ハーモニック法からラジオ波治療まで工藤 正俊  近畿大学医学雑誌  27-  (1)  2002/06Evaluation of Image Quality of Personal Ultrasound Imager : Comparison with the Conventional MachineWEN Yan Ling; KUDO Masatoshi; MAEKAWA Kiyoshi; KAWASAKI Toshihiko; CHUNG Hobyung; MINAMI Yasunori; SUETOMI Yoichiro; ONDA Hirokazu; KITANO Masayuki; MATSUI Shigenaga; EGUCHI Mayumi; KUWAGUCHI Ai; KAWABATA Kumiko  Journal of medical ultrasonics : official journal of the Japan Society of Ultrasonics in Medicine  29-  (3)  41  -46  2002/06超音波内視鏡下造影および穿刺生検によるすい腫よう性疾患の診断北野雅之; 工藤正俊; 福田信宏; 末冨洋一郎; 南康範; 中岡良介; 松井繁長; CHUNG H; 前川清  超音波医学  29-  S331  2002/05消化器粘膜下腫ようにおける造影超音波法およびEUS下穿刺の有用性福田信宏; 北野雅之; 前川清; 末冨洋一郎; 由谷逸朗; 中岡良介; 松井繁長; 川崎俊彦; 工藤正俊  超音波医学  29-  S329  2002/05肝硬変の超音波診断 多施設共同研究鄭 栄琴; 工藤 正俊; 岡部 純弘; 川崎 俊彦; 大崎 征夫; 飯島 尋子; 春日井 博志; 兼松 雅之; 伊東 克能; 神代 正道  超音波医学  29-  (Suppl.)  S403  -S403  2002/05Radofrequency ablation (RFA) therapy under harmonic image guidance for the recurrence after local therapy for HCCM Kudo; Y Minami; H Chung; C Ogawa; Y Suetomi; N Fukuda; R Nakaoka; S Matsui; M Kitano; T Kawasaki; M Shiomi; K Maekawa  GASTROENTEROLOGY  122-  (4)  A664  -A664  2002/04Ultrasonography in pancreatic diseases by contrast-enhanced phase-inversion harmonics with coded pulseM Kitano; M Kudo; K Maekawa; RQ Zheng; R Nakaoka; Y Suetomi; Y Minami; H Chung; T Kawasaki  GASTROENTEROLOGY  122-  (4)  A336  -A336  2002/04Evaluation of treatment response after transcatheter arterial embolization mixed with Lipiodol for hepatocellular carcinoma: Utility of coded phase inversion harmonic imagingM Kudo; Y Minami; HY Chung; C Ogawa; Y Suetomi; Y Fukuda; R Nakaoka; S Matsui; M Kitano; T Kawasaki; M Shiomi; K Maekawa  GASTROENTEROLOGY  122-  (4)  A660  -A660  2002/04肝細胞癌に対する根治的RFA治療後のAFP‐L3分画の意義小川力; 工藤正俊; 市川勉; 乾絹世; 岡田無文; 北口容子; 豊沢昌子; 石川恵美; 汐見幹夫  日本消化器病学会雑誌  99-  A150  2002/03不整胃潰よう辺縁から陳旧化したアニサキス虫体片を認めた1例木下理恵; 汐見幹夫; 石川恵美; 小川力; 福田信宏; 南康範; 工藤正俊; 山住俊晃; 藤井良一  Gastroenterol Endosc  44-  (Supplement 1)  561  2002/03真性多血症による食道静脈りゅう破裂の1例松井繁長; 井上良一; 中岡良介; 北野雅之; 福田信宏; 末冨洋一郎; 川崎俊彦; 汐見幹夫; 工藤正俊  Gastroenterol Endosc  44-  (Supplement 1)  611  2002/03食道静脈りゅう治療後に出血を来した十二指腸静脈りゅうの1例松井繁長; 井上良一; 中岡良介; 福田信宏; 末冨洋一郎; 北野雅之; 川崎俊彦; 汐見幹夫; 工藤正俊  Gastroenterol Endosc  44-  (Supplement 1)  608  2002/03IBDにおけるNKT細胞の役割-特にステロイドとの関連八木田 旭邦; 丸山 正二; 若杉慎司; 助川 寧; 工藤 正俊; 高添正和  厚生科学研究費補助金特定疾患対策研究事業「難治性炎症性腸管障害に関する調査研究」班平成13年度研究報告書  37  -39  2002/03食道静脈りゅうに対するEVL・EIS同時併用療法(EISL)の有用性の検討松井繁長; 中岡良介; 北野雅之; 川崎俊彦; 汐見幹夫; 工藤正俊  日本内科学会雑誌  91-  237  2002/02Endoscopic band ligation for control of nonvariceal upper GI hemorrhage: comparison with bipolar electrocoagulationS Matsui; T Kamisako; M Kudo; R Inoue  GASTROINTESTINAL ENDOSCOPY  55-  (2)  214  -218  2002/02多血性肝腫瘍の鑑別診断工藤 正俊  肝臓  43-  (1)  1  -10  2002/01Multi-detector row helical CT angiography of hepatic vessels: Depiction with dual-arterial phase acquisition during single breath holdS Takahashi; T Murakami; M Takamura; T Kim; M Hori; Y Narumi; H Nakamura; M Kudo  RADIOLOGY  222-  (1)  81  -88  2002/01The efferent blood flow of early hepatocellular carcinoma and borderline lesions: demonstration by color Doppler imaging.TOCHIO Hitoshi; TOMITA Syusuke; KUDO Masatoshi; IWASAKI Nobuhiro; TAMURA Syuji; NAKAMURA Hitomi; SOGA Toshiko; FUKUNAGA Toyokazu; OKABE Yoshihiro; KASHIDA Hiroshi; HIRASA Masahiro; IBUKI Yasuyosi; MORIMOTO Yoshito; ORINO Akio  J Med Ultrasonics  29-  (1)  205  -209  2002なぜ現在の科目を選んだのか-消化器内科-工藤 正俊  日本医事新報 「Junior」  409-  41  2002消化器(肝臓)Power Vision 8000 -Flash Echo Imaging.川崎 俊彦; 工藤 正俊  INNERVISION INNERVISION  17-  72  -75  2002コントラストエコー法.工藤 正俊  INNERVISION INNERVISION  17-  51  -56  2002CHA (Coded Harmonic Angio)による造影ハーモニックイメージング法.工藤 正俊  GE Today GE Today  9-  (2)  35  -38  2002急性腹症の超音波検査.工藤 正俊  消化器画像  4-  5  2002胃十二指腸動脈瘤の上腸管膜静脈穿破による急性門脈圧亢進症.工藤 正俊  消化器画像  4-  286  -271  2002肝癌の局所療法.工藤 正俊  医学のあゆみ  200-  (10)  809  -811  2002肝・胆・膵疾患の超音波診断.工藤 正俊  図説消化器病シリーズ3「肝・胆・膵の画像診断」  18  -35  2002造影ハーモニックイメージングの肝細胞癌治療への応用.工藤 正俊  映像情報  34-  (6)  602  -608  2002超音波造影ハーモニック法.工藤 正俊  肝胆膵  44-  (6)  854  -858  2002肝細胞癌の課題: 画像診断の立場から.工藤 正俊  第22回犬山シンポジウム(第II部)記録集  53  -73  2002肝細胞癌の病態と治療-画像の役割-工藤 正俊  消化器画像  4-  (4)  407  -408  2002造影ハーモニックイメージングの肝細胞癌局所治療への応用.工藤 正俊  消化器画像  4-  (4)  437  -442  2002進行した肝硬変患者における肝動脈のbuffer response.工藤 正俊  消化器画像  4-  (5)  510  -511  2002切除不能肝細胞癌に対する動脈塞栓あるいは動脈化学塞栓療法と対症療法の無作為化比較試験.工藤 正俊  消化器画像  4-  (5)  511  -512  2002造影エコー法の治療への応用. 消化器医学「肝細胞がんのRFA後の治療効果判定」工藤 正俊  INNERVISION INNERVISION  17-  (8)  96  -100  2002造影エコー法の治療への応用. 消化器「肝細胞がんに対する造影超音波ガイド下穿刺治療」鄭 浩柄; 工藤 正俊; 南 康範; 川崎 俊彦  INNERVISION INNERVISION  17-  (9)  81  -83  2002造影エコー診断の肝癌局所治療への応用ー治療効果判定と穿刺ガイド.工藤 正俊  J Microwave Surg J Microwave Surg  20-  17  -25  2002造影US.工藤 正俊  新薬と臨床  51-  (9)  79  2002人工胸水下造影超音波併用RFAの初期臨床経験.南 康範; 工藤 正俊; 小川 力; 鄭 浩柄; 川崎 俊彦  新薬と臨床  51-  (8)  109  -110  2002膵疾患における造影エコー法ーCTとの対比を含めてー.北野 雅之; 工藤 正俊; 前川 清  胆と膵  23-  (7)  511  -518  2002造影ハーモニックイメージングのコツとpitfall.工藤 正俊  「肝疾患診療のコツと落とし穴」, 井廻道夫編  2  -3  2002造影エコー法の肝癌治療への応用.工藤 正俊  「肝疾患診療のコツと落とし穴」, 井廻道夫編  116  -117  2002B型肝炎急性増悪に対するラミブジンの効果.工藤 正俊; 鄭 浩柄; 大崎 往夫  犬山シンポジウム記録集  57  -64  2002腹部の超音波診断.工藤 正俊  今日の診断指針・第5版, 亀山正邦, 高久史磨, 編集  411  -418  2002上部腹部血管性病変と超音波-診断と治療への応用-.鄭 浩柄; 工藤 正俊; 川崎 俊彦; 前川 清  消化器画像  4-  (6)  705  -711  2002造影ハーモニックイメージングの肝細胞癌治療への応用.工藤 正俊  ISIR&JSAIR 2002シンポジウムプロシーディング  14  -18  2002Editorial 「Impact Factorと株価」工藤 正俊  J Med Ultrasonics J Med Ultrasonics  29-  J535  -J536  2002肝画像診断の進歩.工藤 正俊  肝臓フォーラム'02記録集  111  -148  2002Evaluation of image quality of personal ultrasound imager: Comparison with the conventional machineYan Ling Wen; Masatoshi Kudo; Kiyoshi Maekawa; Toshihiko Kawasaki; Hobyung Chung; Yasunori Minami; Yoichiro Suetomi; Hirokazu Onda; Masayuki Kitano; Shigenaga Matsui; Mayumi Eguchi; Ai Kuwaguchi; Kumiko Kawabata  Journal of Medical Ultrasonics  29-  (Summer)  41  -46  2002Contrast harmonic imaging in the characterization of hepatic tumors工藤 正俊  J Society Ultrasound Med ROC  18-  52  -53  2002Radiofrequency ablation for HCC under contrast-harmonic imaging工藤 正俊  J Society Ultrasound Med ROC  18-  48  -50  2002Hepatocellular carcinoma treated with radiofrequency ablation: Evaluation of therapeutic response by contrast-enhanced Coded Harmonic Angio文 艶玲; 工藤 正俊; 川崎 俊彦; 南 康範; 前川 清  Chinese Journal of Ultrasound in Medicine  18-  (6)  452  -455  2002Application of contrast-enhanced ultrasonography to the local treatment of hepatocellular carcinomaKudo Masatoshi  Journal of Microwave Surgery  20-  17  -25  2002Evaluation of posttreatment response of hepatocellular carcinoma with contrast-enhanced coded phase-inversion harmonic US: Comparison with dynamic CTH Ding; M Kudo; H Onda; Y Suetomi; Y Minami; H Chung; T Kawasaki; K Maekawa  RADIOLOGY  221-  (3)  721  -730  2001/12Detection of tumor parenchymal blood flow in hepatic tumors: value of second harmonic imaging with a galactose-based contrast agentH Ding; M Kudo; K Maekawa; Y Suetomi; Y Minami; H Onda  HEPATOLOGY RESEARCH  21-  (3)  242  -251  2001/11画像からみた肝細胞癌の血行動態工藤 正俊  肝臓  42-  (10)  491  -502  2001/10教育シンポジウムクリニカルクラークシップの現状と問題点金丸 昭久; 工藤 正俊  近畿大学医学雑誌  26-  (2)  2001/10消化管間葉系腫ようの術前診断におけるEUS下穿刺を含めた超音波内視鏡診断の有用性中岡良介; 北野雅之; 松井繁長; 汐見幹夫; 工藤正俊  Gastroenterol Endosc  43-  (Supplement 2)  1720  2001/09食道静脈りゅうに対するEIS・EVL併用療法(EISL)の評価松井繁長; 井上良一; 末冨洋一郎; 南康範; 鄭浩柄; 中岡良介; 由谷逸朗; 北野雅之; 工藤正俊  Gastroenterol Endosc  43-  (Supplement 2)  1687  2001/09Sonographic findings of wandering spleenYL Wen; M Kudo; K Maekawa; H Nomura; S Haji; H Ohyanagi  JOURNAL OF GASTROENTEROLOGY  36-  (9)  643  -644  2001/09Cerebral vascular resistance in hepatic insufficiencyM Kudo  JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY  16-  (8)  845  -847  2001/08Hepatocellular carcinoma: Depiction of tumor parenchymal flow with intermittent harmonic power Doppler US during the early arterial phase in dual-display modelH Ding; M Kudo; H Onda; Y Suetomi; Y Minami; K Maekawa  RADIOLOGY  220-  (2)  349  -356  2001/08部分的ひ動脈塞栓術後内視鏡的治療が奏効した十二指腸静脈りゅう出血の1例松井繁長; 井上良一; 中岡良介; 北野雅之; 川崎俊彦; 汐見幹夫; 工藤正俊  日本門脈圧こう進症学会雑誌  7-  (1)  45  2001/07まだら食道の病理辻 直子; 工藤 正俊; 石黒 信吾  胃と腸  36-  1049  -1056  2001/07Imaging diagnosis of hepatocellular carcinoma : recent progressKUDO Masatoshi  Nippon Shokakibyo Gakkai Zasshi  98-  (7)  795  -808  2001/07A case of localized primary sclerosing cholangitis mimicking intrahepatic bile duct cancerT Kawasaki; T Ueo; T Itani; M Shibatohge; J Mimura; H Komori; A Todo; T Okuno; M Kudo  HEPATOLOGY RESEARCH  20-  (2)  259  -264  2001/0614.続発性ヘモクロマトーシスに肝細胞癌(HCC)を合併した1症例鄭 浩柄; 石川 恵美; 乾 可苗; 小村 康湖; 永島 美樹; 南 康範; 末富 洋一郎; 中岡 良介; 北野 雅之; 松井 繁長; 由谷 逸朗; 上硲 俊法; 川崎 俊彦; 汐見 幹夫; 工藤 正俊; 金丸 昭久  近畿大学医学雑誌  26-  (1)  2001/04The usefulness of Harmonic Imaging of liver tumorsTEI H; KUDO M; MAEKAWA K  Journal of medical ultrasOnics= 超音波医学  28-  (3)  J301  2001/04Therapeutic application of the contrast enhanced harmonic ultrasoundMINAMI Y; WEN YL; SUETOMI Y; TEI H; ONDA H; KAWASAKI T; KUDO M; KUWAGUCHI A; MAEKAWA K  Journal of medical ultrasOnics= 超音波医学  28-  (3)  J309  2001/04Hemodynamic and morphologic analysis of hepatic tumors using high resolution contrast enhanced ultrasongraphyKAWASAKI T; KUDO M; MAEKAWA K  Journal of medical ultrasOnics= 超音波医学  28-  (3)  J342  2001/04Hepatic hemangiomas : Levovist^【○!R】enhancement patterns with coded harmonic angioKAWASAKI T; WEN Y; MINAMI Y; SUETOMI Y; TEI H; ONDA K; KUDO M; EGUCHI M; MAEKAWA K; DING H  Journal of medical ultrasOnics= 超音波医学  28-  (3)  J482  2001/04Classification of hemodynamic patterns of Hepatic Tumor on Coded Harmonic Angio modeMAEKAWA K; OTANI M; WEN Y; DING H; SUETOMI Y; TEI H; MINAMI Y; ONDA H; KAWASAKI T; KUDO M  Journal of medical ultrasOnics= 超音波医学  28-  (3)  J485  2001/04Experience of EUS using micro comvex arraySUETOMI Y; KAWASAKI T; MINAMI Y; WEN YL; DING H; TEI H; ONDA H; KUDO M; MAEKAWA K; KUWAGUCHI A  Journal of medical ultrasOnics= 超音波医学  28-  (3)  J504  2001/04Value of Contrast Harmonic Imaging in the Diagnosis of Hepatic Focal Nodular Hyperplasia. H. DingMAEKAWA K; KUWAGUCHI A; MINAMI Y; WEN Y; TEI H; SUETOMI Y; ONDA H; KAWASAKI T; KUDO M  Journal of medical ultrasOnics= 超音波医学  28-  (3)  J524  2001/04Comparision of Enhanced Fundamental Power Doppler with Contrast Harmonic Power Doppler Imaging in the Detection of Intratumoral Flow of Hepatocellular CarcinomaWEN Y; TEI H; MINAMI Y; SUETOMI Y; ONDA H; KAWASAKI T; KUDO M; OHTANI M; MAEKAWA K; DING H  Journal of medical ultrasOnics= 超音波医学  28-  (3)  J525  2001/04Contrast enhanced harmonic ultrasound of hepatic nodules which maintain portal flow as much as surrounding parenchymaTEI H; WEN Y; MINAMI Y; SUETOMI Y; ONDA K; KAWASAKI T; KUDO M; OTANI M; MAEKAWA K; DING H  Journal of medical ultrasOnics= 超音波医学  28-  (3)  J529  2001/04Assessment of the effectafter Lipiodol TAE for HCC : usefulness of the contrast enhancedharmonic ultrasoundMINAMI Y; WEN Y L; DING H; SUETOMI Y; TEI H; ONDA H; KAWASAKI T; KUDO M; KUWAGUCHI A; MAEKAWA K  Journal of medical ultrasOnics= 超音波医学  28-  (3)  J543  2001/04RFA thrapy against the residual HCC after local therapy assisted by Contrast enhanced ultrasonographyTEI H; WEN Y; MINAMI Y; SUETOMI Y; ONDA K; KAWASAKI T; KUDO M; EGUCHI M; MAEKAWA K; DING H  Journal of medical ultrasOnics= 超音波医学  28-  (3)  J544  2001/04Evaluation of Image Quality of Sonosite 180 : Comparison with Toshiba PV 8000WEN Y; TEI H; MINAMI Y; SUETOMI Y; ONDA H; KAWASAKI T; KUDO M; EGUCHI M; MAEKAWA K; DING H  Journal of medical ultrasOnics= 超音波医学  28-  (3)  J551  2001/04Role of ECL-cell histamine in acute gastric mucosal damage induced by ischemia-reperfusion.M Kitano; Y Kishimoto; R Hakanson; Y Haenuki; S Onada; M Kudo; J Hasegawa  GASTROENTEROLOGY  120-  (5)  A136  -A136  2001/04Hepatic peribiliary cysts: clinically harmless disease with potential risk due to gradual increase in size and numberM Kudo  JOURNAL OF GASTROENTEROLOGY  36-  (4)  286  -288  2001/04上部消化管疾患に対するアルゴンプラスマ凝固法(Argon Plasma Coagulation;APC)治療の有用性の検討仲岡良介; 汐見幹夫; 末富洋一郎; 南康範; 鄭浩柄; 松井繁長; 北野雅之; 由谷逸朗; 工藤正俊  Gastroenterol Endosc  43-  (Supplement 1)  718  2001/03保存的に治療し得た若年すい管内結石症の1例木下理恵; 汐見幹夫; 福田信宏; 南康範; 末冨洋一郎; 鄭浩柄; 中岡良介; 松井繁長; 工藤正俊  Gastroenterol Endosc  43-  (Supplement 1)  722  2001/03Contrast-enhanced subtraction harmonic sonography for evaluating treatment response in patients with hepatocellular carcinomaH Ding; M Kudo; H Onda; Y Suetomi; Y Minami; K Maekawa  AMERICAN JOURNAL OF ROENTGENOLOGY  176-  (3)  661  -666  2001/03Intrahepatic portosystemic venous shunt in liver cirrhosis: is it congenital or acquired?工藤 正俊  AJR Am J Roentgenol  160-  421  -422  2001Intrahepatic spontaneous retrograde portal flow in liver cirrhosis can be reversed by meal intake.杤尾人司; 工藤 正俊; 西馬信一; 岡部純弘  AJR  177-  1109  -1112  2001肝細胞癌の早期発見.工藤 正俊  毎日ライフ 特集「肝臓病」  32-  (2)  69  -74  2001肝癌の診断. 再発早期発見に有用なのは画像か、腫瘍マーカーか?工藤 正俊  Frontiers in Gastroenterology Frontiers in Gastroenterology  6-  (1)  14  -20  2001パルスインバージョンハーモニック超音波による肝腫瘍の超音波造影パターン.工藤 正俊  消化器画像  3-  (1)  139  -140  2001ヒト小肝細胞癌における脂肪化の機序についての病理形態学研究.工藤 正俊  消化器画像  3-  (1)  140  -141  2001肝細胞癌の超音波血流画像と病態.工藤 正俊  室医会報  9-  69  -74  2001コントラストエコーを用いた癌診断工藤 正俊  消化器病セミナー82(特集「肝細胞癌治療法の新たな展開」), 小俣政男 編集  39  -52  2001Prosound SSD-5500を用いた造影ハーモニック法.工藤 正俊  日獨医報  45-  (4)  575  -582  2001超音波を巡る現状と展望: 特に超音波造影法の進歩について.工藤 正俊  INNERVISION INNERVISION  16-  (4)  68  -71  2001非癌性肝腫瘤の診断と治療-超音波.工藤 正俊  肝胆膵  42-  (3)  333  -347  2001切除後肝細胞癌の肉眼分類-再発ならびに生存率の予測因子としての意義.工藤 正俊  消化器画像  3-  (2)  275  -276  2001肝細胞癌再発のリスクファクターは感染ウイルスによって異なる-236例の単発肝癌における検討.工藤 正俊  消化器画像  3-  (2)  276  -277  2001RTCシステムによる肝細胞癌に対する熱凝固療法. 肝癌に対するラジオ波熱凝固療法(RFA).工藤 正俊; 遠田 弘一; 南 康範; 鄭 浩柄; 末冨 洋一郎; 川崎 俊彦; 前川 清  特別シンポジウム記録集, 大阪肝穿刺生検治療研究会編  13  -17  2001造影超音波技術のA to Z.工藤 正俊  INNERVISION INNERVISION  16-  (5)  54  -57  2001造影ハーモニックイメージの治療への応用.工藤 正俊  映像情報 Medical (特集「超音波医学の進歩」)  33-  (5)  460  -465  2001超音波ドプラ法による肝疾患の病態評価.杤尾人司; 工藤 正俊; 岡部純弘  映像情報 Medical (特集「超音波医学の進歩」)  33-  (5)  466  -471  2001造影剤による超音波検査法.工藤 正俊  放射線利用技術データベース「要素データ(医学)」(財)放射線利用振興協会, 科学技術庁, 編  2001肝癌の早期発見と早期治療.大崎 往夫; 工藤 正俊; 春日井博志; 岡 博子; 関 寿人  メディカルトリビューン  3-  1  -4  2001超音波からみた肝区域の有用性と問題点.川崎 俊彦; 工藤 正俊  消化器画像(特集「画像で知る肝区域」)  3-  466  -470  2001検査の目的と検査結果の読み方ー「肝胆膵疾患」画像診断(単純X線).山本 健二; 工藤 正俊  看護のための最新医学講座  69  -71  2001検査の目的と検査結果の読み方ー「肝胆膵疾患」画像診断(超音波検査).山本 健二; 工藤 正俊  看護のための最新医学講座  71  -76  2001肝腫瘍の造影超音波検査-検査法と診断のコツ-.工藤 正俊  2001造影エコー法を用いた肝腫瘤の血流動態.工藤 正俊  内科  88-  (4)  654  -652  2001肝細胞癌の診断と治療-最近の進歩.工藤 正俊  HEPATICA HEPATICA  20-  (4)  31  -32  2001肝細胞癌の血流と病態治療.工藤 正俊  肝臓病学の進歩  27-  43  -55  2001肝細胞癌治療の課題: 画像診断立場から.工藤 正俊  The Medical & Test Journal  791-  7  2001経静脈性超音波造影剤 Levovist. 「肝癌の診断と治療」工藤 正俊  日本臨床  59-  306  -313  2001超音波血流画像工藤 正俊  「肝細胞癌の血行動態はどこまでわかったか」神代正道, 岡崎正敏, 板井悠二, 監修  21  -37  2001造影ハーモニックイメージングで流出血流を肝静脈と同定し得た肝血管筋脂肪腫の1例.工藤 正俊  消化器画像  3-  (6)  692  -698  2001門脈圧亢進症の病態と治療: 最近のトピックス.工藤 正俊  消化器画像  3-  (6)  697  -699  2001超音波による門脈圧亢進症の診断.杤尾人司; 工藤 正俊; 岡部純弘  消化器画像  3-  (6)  712  -721  2001門脈血流量の定量法.川崎 俊彦; 工藤 正俊  消化器画像  3-  (6)  735  -741  2001肝癌のラジオ波焼灼療法.工藤 正俊  週刊医学会新聞  2461-  9  2001造影剤による腫瘍血流のイメージング.工藤 正俊  臨床検査  45-  1219  -1224  2001門脈血流.川崎 俊彦; 工藤 正俊  臨床検査  45-  1431  -1435  2001早期肝細胞癌とは「画像からみた特徴」. (特集「早期肝細胞癌の治療と予後」).工藤 正俊  クリニカ  28-  (6)  338  -344  2001造影ハーモニックイメージングによる肝腫瘍の診断.工藤 正俊  臨床消化器内科  17-  41  -52  2001肝腫瘍の造影ハーモニックイメージング.工藤 正俊  1  -220  2001Agenesis of the left lobe of the liver: radiologic features文 艶玲; 工藤 正俊; 鄭 浩柄; 南 康範; 末冨 洋一郎; 遠田 弘一; 北野 雅之; 川崎 俊彦; 前川 清  J Medical Ultrasonics  28-  181  -183  2001Has vascular enhancement with Levovist changed diagnosis of liver tumors?工藤 正俊  Proceedings of 3rd International Kyoto Symposium on Ultrasound Contrast Imaging  54  -56  2001Contrast harmonic ultrasound is a breakthrough technology in the diagnosis and treatment of hepatocellular carcinomaKUDO M  J Medical Ultrasonics  28-  79  -81  2001Imaging blood flow characteristics of hepatocellular carcinomaKUDO M.  Oncology  61-  48  -56  2001Color Doppler observation of efferent blood flow in liver tumors工藤 正俊; 杤尾 人司  Proceeding of the Hepatic Hemodynamic Imaging Study Group Special Symposium, Miura K, Itai Y, eds.  97  -103  2001Intrahepatic portal vein anomaly: a duplicated portal vein文 艶玲; 工藤 正俊; 川崎 俊彦; 前川 清  J Gastroenterol Hepatol  16-  821  -824  2001Recent advances in the imaging and ablation of hepatocellular carcinoma工藤 正俊  Proceedings of 4th Korean Liver Cancer Study Group  35  -44  2001Hepatocellular adenoma in type Ia glycogen storage diseaseM Kudo  JOURNAL OF GASTROENTEROLOGY  36-  (1)  65  -66  2001/01肝腫瘍の造影超音波検査. 検査法と診断のコツ工藤 正俊  20019.肝細胞癌の新しい治療法 : Radio Frequency Ablation(RFA)Therapyについて遠田 弘一; 末富 洋一郎; 中岡 良介; 亀山 千晴; 鄭 浩柄; 北野 雅之; 松井 繁長; 由谷 逸郎; 上硲 俊法; 汐見 幹夫; 工藤 正俊  近畿大学医学雑誌  25-  (2)  41A  2000/12Hepatocellular carcinoma transforming from dysplastic nodule with background of non-B non-C chronic persistent hepatitisKim, SR; Y Hayashi; M Kudo; T Matsuoka; S Imoto; KB Song; Y Maekawa  JOURNAL OF HEPATOLOGY  33-  (5)  857  -858  2000/11Proximal Bifurcation of Hepatic Artery : Novel Findings on Hepatic Arteries Demonstrated by Ultrasound Doppler Imaging , B-Flow and US AngiographyTOCHIO Hitoshi; IWASAKI Nobuhiro; NAKAMURA Hitomi; NAKAYAMA Keiko; SOGA Toshiko; NISHIUMA Shinichi; FUKUNAGA Toyokazu; OKABE Yoshihiro; KASHIDA Hiroshi; HIRASA Masahiro; IBUKI Yasuyoshi; FUJIMOTO Toshiaki; MORIMOTO Yoshito; KUDO Masatoshi; TOMITA Syusuke; KONISHI Yutaka; ORINO Akio  Journal of medical ultrasOnics= 超音波医学  27-  (10)  1303  -1310  2000/10Laparoscopic splenopexy for adult wandering spleen: Sandwich method with two sheets of absorbable knitted meshH Nomura; S Haji; D Kuroda; K Yasuda; H Ohyanagi; M Kudo  SURGICAL LAPAROSCOPY ENDOSCOPY & PERCUTANEOUS TECHNIQUES  10-  (5)  332  -334  2000/10超音波造影剤静注によって流出血流を明瞭に描出し得た肝細胞癌の1例加藤玲明; 浅田卓; 井上達夫; 梅原泰; 汐見幹夫; 山本真由美; 江口真由美; 遠田由紀; 工藤正俊  超音波医学  27-  (8)  1083  2000/08超音波像で典型的なtarget signを呈した腸重積の1例坂口康浩; 浅田卓; 汐見幹夫; 山本真由美; 前川清; 小牧克守; 工藤正俊; 日高敏晴; 大柳治正  超音波医学  27-  (8)  1087  2000/08肝腫ようのLevovist静注によるHarmonic Power Doppler法の初期臨床経験丁紅; 浅田卓; 井上達夫; 梅原泰; 汐見幹夫; 山本真由美; 江口真由美; 遠田由紀; 工藤正俊  超音波医学  27-  (8)  1083  2000/08Repeated hepatic arterial chemoembolization therapy for management of a patient with metastatic carcinoid tumors of the liverR Nakaoka; T Kamisako; M Shiomi; M Kudo  AMERICAN JOURNAL OF GASTROENTEROLOGY  95-  (7)  1842  -1843  2000/07Repeated hepatic arterial chemoembolization therapy for management of a patient with metastatic carcinoid tumors of the liverR Nakaoka; T Kamisako; M Shiomi; M Kudo  AMERICAN JOURNAL OF GASTROENTEROLOGY  95-  (7)  1842  -1843  2000/07E108 膵芽腫根治術後に非定型的肝限局性結節性過形成 (FNH) 様病変を呈した 1 例山内 勝治; 窪田 昭男; 米倉 竹夫; 臼井 規朗; 廣岡 慎治; 小角 卓也; 山崎 満夫; 大柳 治正; 工藤 正俊  日本小児外科学会雑誌  36-  (3)  296  -296  2000/05メシル酸カモスタットが有効であったアルコール性慢性膵炎の疑診例山本 健二; 浅田 卓; 井上 達夫; 梅原 泰; 加藤 玲明; 坂口 康浩; 中岡 良介; 亀山 千晴; 谷池 聡子; 遠田 弘一; 松井 繁長; 由谷 逸郎; 上硲 俊法; 汐見 幹夫; 工藤 正俊  新薬と臨牀  49-  (5)  528  -529  2000/05Multi‐shot Digital Subtraction法を用いたLevovist‐enhanced Harmonic imagingによる肝腫ようの診断DING H; 遠田弘一; 山本健二; 由谷逸朗; 汐見幹夫; 江口真由美; 山本真由美; 遠田由紀; 工藤正俊  超音波医学  27-  (4)  443  2000/04肝腫よう診断におけるLevovist静注Contrast Harmonic Power Doppler法の有用性DING H; 遠田弘一; 中岡良介; 松井繁長; 山本健二; 江口真由美; 山本真由美; 遠田由紀; 工藤正俊  超音波医学  27-  (4)  442  2000/04Clinical Potential of Contrast-enhanced Ultrasonography in Hepatobiliary and Pancreatic Disease.KUDO M; DING H; ONDA H; MAEKAWA K  Journal of medical ultrasOnics= 超音波医学  27-  (4)  377  -377  2000/04Demonstration of Tumor Efferent Blood Flow by Levovist-enhanced Color Doppler Imaging in a case of Hepatocellular Carcinoma.DING H; ONDA H; YAMAMOTO K; INOUE T; UMEHARA Y; EGUCHI M; YAMAMOTO M; ONDA Y; MAEKAWA K; KUDO M  Journal of medical ultrasOnics= 超音波医学  27-  (4)  441  -441  2000/04Usefulness of Intermittent Imaging of Second Harmonic Power Doppler Mode using Intravenous Injection of Levovist.DING H; ONDA H; NAKAOKA R; MATSUI S; YAMAMOTO K; EGUCHI M; YAMAMOTO M; ONDA Y; MAEKAWA K; KUDO M  Journal of medical ultrasOnics= 超音波医学  27-  (4)  442  -442  2000/04Usefulness of Levovist-enhanced Intermittent Second Harmonic Imaging with a Use of Multi-shot Digital Subtraction Technique in the Diagnosis of Liver Tumors.DING H; ONDA H; YAMAMOTO K; YUTANI I; SHIOMI M; EGUCHI E; YAMAMOTO M; ONDA Y; MAEKAWA K; KUDO M  Journal of medical ultrasOnics= 超音波医学  27-  (4)  443  -443  2000/04Enhanced Color Doppler Imaging of Liver Tumors: Detection of Tumor Parenchymal Flow by Intermittent Imaging.MAEKAWA K; EGUCHI M; YAMAMOTO M; ONDA Y; DING H; ONDA H; TANIIKE D; KAMEYAMA C; YAMAMOTO K; KUDO M  Journal of medical ultrasOnics= 超音波医学  27-  (4)  445  -445  2000/04Usefulness of B Flow Imaging in Liver Disease.EGUCHI M; YAMAMOTO M; ONDA Y; MAEKAWA K; DING H; KATO R; ONDA H; MATSUI S; YAMAMOTO K; KUDO M  Journal of medical ultrasOnics= 超音波医学  27-  (4)  459  -459  2000/04US Guided Radio-frequency Abration Therapy for Hepatocellular Carcinoma: Initial ExperienceONDA H; DING J.H; NAKAOKA R; TANIIKE S; KAMEYAMA C; MATSUI S; YUTANI I; YAMAMOTO K; SHIOMI M; KUDO M  Journal of medical ultrasOnics= 超音波医学  27-  (4)  533  -533  2000/04Detection of recurring lesion of hepatocellular carcinoma after radiofrequency ablation therapy using Levovist enhanced second harmonic power Doppler/B mode imaging.M Kudo; K Ding; H Onda; K Maekawa  GASTROENTEROLOGY  118-  (4)  A993  -A993  2000/04Therapeutic results of different treatments for single hepatocellular carcinoma : a retroapective multicenter study (18 institutions)SEKI Toshihito; OSAKI Yukio; KASUGAI Hiroshi; OKA Hiroko; KUDO Masatoshi; OSAKA LIVER CANCER; STUDY GROUP  Kanzo  41-  (3)  169  -182  2000/03A case of gastrointestinal stromal tumor(GIST) in the stomachYUTANI Itsuro; SHIOMI Mikio; KAWABATA Kazuhito; OHNO Yasuhiro; INOUE Ryoichi; KUDO Masatoshi; AOKI Norihiko; YAMAZUMI Toshiaki; YOSHIKAWA Hideto; OKUNO Kiyotaka  Nippon Shokakibyo Gakkai Zasshi  97-  (3)  331  -336  2000/03超音波診断の最前線ー何が進歩したかー「肝胆膵のカラードプラ・造影エコー」工藤 正俊  臨床画像  16-  (2)  186  -193  2000肝硬変の血流動態: 超音波(US-angio、カラードプラ、パワードプラ、3次元画像)工藤 正俊  高安賢一, 板井悠二, 編集  13  -25  2000血流動態からみた肝癌の肉眼型(辺縁と内部構造)と組織の推定は可能か?: US, US angio, カラードプラ.福永 豊和; 工藤 正俊  高安賢一, 板井悠二, 編集  73  -81  2000Editorial「バブル新時代ーClinical Acoustic Bubblologyが開く超音波造影法の新しい世界ー」工藤 正俊  J Medical Ultrasonics J Medical Ultrasonics  26-  (11)  1089  -1090  2000肝癌に関する最近の話題.工藤 正俊; 福永 豊和; 杤尾人司  「門脈血流を有する高分化型肝癌の治療 ー治療は必要でないとする立場よりー」, 工藤正俊, 板井悠二, 監修  3  -8  2000肝癌の血流動態と血管新生.工藤 正俊  Molecular Medicine. 特集「血管新生病としての癌ー病態と治療ー」  37-  (3)  300  -309  2000超音波ドプラ法でみた肝内血流動態異常.工藤 正俊; 上嶋 一臣; 鄭 浩柄; 福永 豊和; 杤尾人司; 岡部純弘; 冨田周介; 岩崎信広; 中村仁美; 太田圭子; 曽我登志子; 西馬信一; 木本直哉; 岡田明彦; 樫田博史; 平佐昌弘; 伊吹康良; 藤本敏明; 森本義人; 織野彬雄  消化器画像  2-  (2)  159  -172  2000細径組織診断によらない肝腫瘍の正確な診断 -prospective study.工藤 正俊  消化器画像  2-  (2)  255  -256  2000肝硬変における再生結節および過形成結節の血管病理形態ー診断と分類上、示唆に富む所見.工藤 正俊  消化器画像  2-  (2)  255  -256  2000門脈圧亢進症の画像所見.岡部 純弘; 工藤 正俊  臨床消化器内科  15-  (5)  509  -519  2000造影エコー法:動注および静注法.工藤 正俊  図説消化器病シリーズ「肝腫瘍」, 沖田 極編  82  -97  2000肝細胞癌の超音波診断.工藤 正俊  プラクティカル内科シリーズNo.9「肝硬変・肝細胞癌」, 沖田 極 編集  35  -47  2000急性腹症.工藤 正俊  医学書院, 東京  233  -248  2000小肝細胞癌の診断末冨 洋一郎; 工藤 正俊  医学と薬学(特集「肝細胞癌の新しい知見」)  43-  (6)  1081  -1087  2000超音波血流画像による肝細胞癌の診断工藤 正俊  外科治療(特集「肝細胞癌の診断と治療ー最近の進歩ー」)  83-  (1)  1  -7  2000Imaging in hepatobiliary and pancreatic disease: a practical clinical approach.工藤 正俊  消化器画像  2-  (4)  509  2000日本腹部造影エコー・ドプラ診断研究会(研究会紹介)工藤 正俊  消化器画像  2-  (3)  394  2000レボビストを用いた肝腫瘍のコントラストハーモニックパワードプライメージング.工藤 正俊; 丁 紅  肝胆膵  41-  (2)  215  -221  2000真性多血症に対してTIPSが奏効した一例.松井 繁長; 工藤 正俊; 上硲 俊法; 井上 良一  日本門脈圧亢進症学会雑誌  6-  (1)  38  -42  2000これからの超音波診断の方向ーTHI, 3D, コントラストエコーを含めて.工藤 正俊  新医療. 特集「超音波診断最新トレンド」  40  -44  2000肝細胞癌の血流動態.工藤 正俊  Minophagen Medical Review Minophagen Medical Review  45-  (254)  259  2000肝細胞癌診療における超音波造影法の進歩と役割.工藤 正俊  日本超音波医学会基礎技術研究会論文集  100-  (2)  15  -18  2000肝硬変の画像診断の役割と限界.工藤 正俊  消化器科 「肝硬変の臨床診断基準」  31-  (2)  190  -194  2000肝細胞癌早期診断のための外来診療.川崎 俊彦; 工藤 正俊  治療. 特集「プライマリケアのための消化器疾患の診方. ー2. 肝胆膵疾患ー」  82-  (10)  2513  -2518  2000造影超音波の臨床応用の現状と展望: 消化器(肝).工藤 正俊; 丁 紅; 前川 清  INNERVISION INNERVISION  15-  (11)  62  -67  2000超音波革命ーハーモニックイメージング. 造影ハーモニックイメージングの臨床「肝疾患」工藤 正俊; 丁 紅; 前川 清  消化器画像  6-  677  -685  2000腹部コントラストエコー法.工藤 正俊  映像情報メディカル  32-  1242  -1247  2000Letter to the Editor 「Reply」工藤 正俊  J Med Ultrasonics J Med Ultrasonics  27-  1063  -1064  2000カラードプラによる肝腫瘍の流出血流動態の描出.工藤 正俊  「巨視的レベルよりみた肝微小循環動態と腫瘍血流の流出動態」三浦行矣, 板井悠二, 監修  95  -101  2000原発性肝癌の治癒切除, あるいは局所根治後の肝細胞癌の再発予防にインターフェロンβは有効である: C型肝炎関連の肝細胞癌に対するprospective randomized study.工藤 正俊  消化器画像  2-  (6)  745  2000肝腫瘍の超音波血流画像下穿刺術.工藤 正俊  臨床外科  55-  (13)  1551  -1555  2000食道顆粒細胞腫. 画像を診るー鑑別診断のポイント.由谷 逸朗; 工藤 正俊; 汐見 幹夫  消化器の臨床  3-  (6)  604  -607  2000肝癌の内科的局所治療法.遠田 弘一; 工藤 正俊  臨床成人病. 特集「Common diseaseのEvidence-based MedicineとExperience-based Medicine」.  30-  (11)  1515  -1526  2000CO2 angiography.工藤 正俊  外科  62-  (13)  1648  -1655  2000腹部コントラストエコー法.工藤 正俊  medicina medicina  37-  (11)  286  -290  2000肝臓癌の診断と治療: 最新情報.工藤 正俊  肝臓友の会誌  87-  8  -22  2000肝疾患における造影ハーモニックイメージングの臨床.工藤 正俊; 丁 紅; 前川 清  消化器画像  2-  (6)  677  -685  2000Editorial. 消化器疾患の急増と超音波検査医・技師ならびに消化器内科医のニーズ.工藤 正俊  J Med Ultrasonics  27-  (10)  1299  -1301  2000肝癌に関する最近の話題. 「1)門脈血流を有する高分化型肝癌の治療 2)大型肝癌に対する治療選択(Child Aの場合)」板井悠二; 工藤 正俊  2000Riedel's Lobe of the Liver and Its Clinical ImplicationMasatoshi Kudo  Internal Medicine  39-  (2)  87  -88  2000MRI angiographyで診断し得た特発性門脈圧亢進症の1男児例安藤 淳; 宮里 裕典; 森口 直彦; 宮田 曠; 吉岡 加寿夫; 工藤 正俊; 井上 良一; 窪田 昭男; 米倉 竹夫; 臼井 規朗  日本小児血液学会雑誌  13-  (4)  274  -274  1999/08非硬変性門脈圧亢進症と肝内結節性病変 小児非硬変性門脈圧亢進症症例の検討 門脈膵頭十二指腸切除後肝FNH様病変をきたした膵芽腫症例を中心に窪田 昭男; 米倉 竹夫; 山内 勝治; 小角 卓也; 廣岡 慎治; 臼井 規朗; 山崎 満夫; 大柳 治正; 工藤 正俊  日本門脈圧亢進症学会雑誌  5-  (2)  117  -117  1999/07The Efferent Blood Flow of Early Hepatocellular Carcinoma and Borderline Lesions : Demonstration by Color Doppler ImagingTOCHIO Hitoshi; TOMITA Syusuke; KUDO Masatoshi; IWASAKI Nobuhiro; TAMURA Syuji; NAKAMURA Hitomi; SOGA Toshiko; FUKUNAGA Toyokazu; OKABE Yoshihiro; KASHIDA Hiroshi; HIRASA Masahiro; IBUKI Yasuyosi; MORIMOTO Yoshito; ORINO Akio  Journal of medical ultrasOnics= 超音波医学  26-  (6)  781  -785  1999/06175 成人の遊走脾(wandering spleen)に対する新しい腹腔鏡下脾固着術(吸収性メッシュシートによるサンドイッチ法)野村 秀明; 土師 誠二; 黒田 大介; 吉田 英樹; 岩崎 拓也; 安田 健司; 庄野 潤; 大柳 治正; 谷池 聡子; 工藤 正俊  日本消化器外科学会雑誌  32-  (6)  1999/06Association between a focal spared area in the fatty liver and intrahepatic efferent blood flow from the gallbladder wall: Evaluation with color Doppler sonographyH Tochio; M Kudo; Y Okabe; Y Morimoto; S Tomita  AMERICAN JOURNAL OF ROENTGENOLOGY  172-  (5)  1249  -1253  1999/05The Draining Vessel of Advanced Hepatocellular Carcinoma: Assessment of Color Doppler Findings in Comparison with Histopathological FindingsTOCHIO Hitoshi; TOMITA Syusuke; UDO Masatoshi; OKABE Yoshihiro; FUKUNAGA Kazutoyo; KASHIDA Hiroshi; HIRASA Masahiro; IBUKI Yasuyoshi; ORINO Akio  Kanzo  40-  (4)  243  -252  1999/04Diagnosis of Hepatic Nodular Lesions : Role of Ultrasonography, Especially of Color Doppler Imaging, in the Next CenturyKUDO M  Journal of medical ultrasOnics= 超音波医学  26-  (4)  290  -290  1999/04Hepatic Hemangioma with Arterio-portal Shunt : A cause of Focal Sparing in Fatty LiverONDA H; KUDO M; AOKI N; YAMAMOTO M; HASEGAWA Y; MAEKAWA K; TOCHIO H; OKABE Y; TOMITA S; ORINO A  Journal of medical ultrasOnics= 超音波医学  26-  (4)  339  -339  1999/04Clinical Usefulness of 3-Dimensional Ultrasonographic Imaging obtained by Fusion 3D techniqueMAEKAWA K; KUDO M; ONDA H; TANIIKE S; KAMEYAMA C; AOKI N; HASEGAWA Y; YAMAMOTO M; HASHIMOTO S; YAMAGATA H  Journal of medical ultrasOnics= 超音波医学  26-  (4)  371  -371  1999/04Usefulness of new endoscopic variceal ligation technique for bleeding esophageal varices; endoscopic extensive ligation.K Takahei; R Inoue; N Ban; K Nagikawa; N Hamato; A Morioka; S Matsui; M Kudo  GASTROENTEROLOGY  116-  (4)  A1281  -A1281  1999/04肝細胞癌の超音波診断-最近の進歩工藤 正俊  消化器疾患最新の治療 1999-2000, 戸田剛太郎, 杉町圭蔵, 中村孝司 編  15  -21  1999肝細胞癌の血流と病態ー超音波血流画像の進歩と意義ー(Editorial)工藤 正俊  肝臓  39-  885  -894  1999肝癌の診断ー超音波検査法(ドプラを含む)工藤 正俊  臨床成人病 特集「目でみる診断法・治療法」  28-  1514  -1515  1999Editorial.工藤 正俊  J Med Ultrasonics J Med Ultrasonics  25-  1055  -1057  1999超音波血流画像.工藤 正俊; 杤尾 人司  画像診断 特集「血流と画像: 消化器を中心に」  19-  (1)  10  -21  1999原発性・転移性肝癌(内科)工藤 正俊  今日の治療方針1999年版, 多賀須幸夫, 尾形悦朗, 編  432  -434  1999肝画像の最先端(序説)工藤 正俊  消化器画像  1-  9  -11  1999超音波ドプラ法による肝腫瘍血管の描出-3次元画像やFFT分析を含めて-杤尾人司; 工藤 正俊; 冨田周介  消化器画像  1-  22  -30  1999TAEは進行肝癌の予後改善に寄与しない?-欧米のrandomized trialの結果をふまえて-工藤 正俊  消化器画像  1-  139  -141  1999肝血流動態イメージ.工藤 正俊  消化器画像  1-  289  1999肝細胞癌に対するTAEはsurvival benefitはない?工藤 正俊  消化器画像  1-  286  -288  1999肝細胞癌患者の移植術前TAE療法: 著明な腫瘍壊死効果はあるが延命効果はない?工藤 正俊  消化器画像  1-  291  1999Stage I肝細胞癌の治療方針と成績-多施設共同研究から.工藤 正俊; 大崎往夫; 春日井博志; 岡 博子; 関 寿人  臨床消化器内科  14-  1017  -1028  1999腹部膨満工藤 正俊  わかりやすい内科学 井村裕夫 編  964  -968  1999腹部腫瘤工藤 正俊  わかりやすい内科学 井村裕夫 編  969  -971  1999肝切除や肝生検は肝細胞の血行性散布をきたす.工藤 正俊  消化器画像  1-  448  -449  1999TAEのインフォームドコンセント工藤 正俊  内科(特集「インフォームドコンセントの実際ー臨床現場で役立つマニュアルー」)  83-  1037  -1039  1999肝細胞癌の診断.工藤 正俊  Medical Test Journal Medical Test Journal  687-  11  1999胆嚢・胆管の超音波診断.岡部 純弘; 工藤 正俊  臨床画像  15-  916  -929  1999肝細胞癌の治療法─どのよう治療法を選択するか。各施設での治療選択の実際福永 豊和; 工藤 正俊  肝癌の Bed side ノ-ト, 小俣政男 監修  173  -183  1999原発性胆汁性肝硬変における発癌率.工藤 正俊  消化器画像  1-  750  1999原発性胆汁性肝硬変における肝内・肝外発癌.工藤 正俊  消化器画像  1-  750  -751  1999肝内胆管癌の画像診断ーUSー岡部 純弘; 工藤 正俊  肝胆膵フロンティア・胆管細胞癌, 辻井 正, 沖田 極, 神代正道, 小林健一, 二川俊二, 編  39  -50  1999超音波造影剤の臨床応用ー肝臓ー.工藤 正俊  綜合臨床  48-  (11)  2709  -2717  1999画像診断の読み方とチェックポイント.工藤 正俊  肝疾患診療マニュアル(日本医師会雑誌特別号), 石井裕正, 井廻道夫, 沖田 極, 熊田博光, 藤原研二, 二川俊二,監修・編集  66  -80  1999エコー診断のポイント.工藤 正俊  肝疾患診療マニュアル(日本医師会雑誌特別号), 石井裕正, 井廻道夫, 沖田 極, 熊田博光, 藤原研二, 二川俊二,監修・編集  66  -70  1999CT診断のポイント.工藤 正俊  肝疾患診療マニュアル(日本医師会雑誌特別号), 石井裕正, 井廻道夫, 沖田 極, 熊田博光, 藤原研二, 二川俊二,監修・編集  71  -72  1999アンギオCT診断のポイント.工藤 正俊  肝疾患診療マニュアル(日本医師会雑誌特別号), 石井裕正, 井廻道夫, 沖田 極, 熊田博光, 藤原研二, 二川俊二,監修・編集  72  -75  1999MRI診断のポイント.工藤 正俊  肝疾患診療マニュアル(日本医師会雑誌特別号)石井裕正, 井廻道夫, 沖田 極, 熊田博光, 藤原研二, 二川俊二,監修・編集  75  -77  1999血管造影のポイント.工藤 正俊  肝疾患診療マニュアル(日本医師会雑誌特別号)石井裕正, 井廻道夫, 沖田 極, 熊田博光, 藤原研二, 二川俊二,監修・編集  77  -78  1999肝シンチグラムのポイント.工藤 正俊  肝疾患診療マニュアル(日本医師会雑誌特別号)石井裕正, 井廻道夫, 沖田 極, 熊田博光, 藤原研二, 二川俊二,監修・編集  78  -80  1999肝細胞癌の流出静脈は門脈か肝静脈か? ーその両方とする立場より工藤 正俊  「肝癌に関する最近の話題」, 板井悠二, 工藤正俊, 監修  12  -16  1999肝臓の血流動態と病態.工藤 正俊  Imaging Imaging  10-  1  -9  1999当院におけるStage IV-A HCCの治療成績.福永 豊和; 工藤 正俊; 織野 彬雄  Radiology Frontier Radiology Frontier  2-  152  1999開放型MRI装置を用いたMRIガイド下の肝腫瘍レーザー温熱焼灼療法ー技術と初期経験ー.工藤 正俊  消化器画像  1-  (6)  872  1999組み込み型HBVDNAのクローニングおよびPCRによるヒト多発肝癌の起源の検索ー多中心性発癌か肝内転移か?工藤 正俊  消化器画像  1-  (6)  872  -873  1999原発性・転移性肝癌(内科)工藤 正俊  今日の治療指針1999年版, 多賀須幸男, 尾形悦郎, 編  432  -434  1999腹部膨満工藤 正俊  わかりやすい内科学 井村裕夫 編  964  -968  1999腹部腫瘤工藤 正俊  わかりやすい内科学 井村裕夫 編  969  -971  199921世紀の画像診断ー超音波.工藤 正俊  第25回日本医学会総会会誌  25-  (III)  79  1999Imaging diagnosis of hepatocellular carcinoma and premalignant/borderline lesionsM Kudo  SEMINARS IN LIVER DISEASE  19-  (3)  297  -309  1999肝癌に関する最近の話題. 「1)TAEは肝癌の自然経過を延長させるか?2)単発肝癌に対する亜区域塞栓術」板井悠二; 工藤 正俊  1999肝癌に関する最近の話題. 「1)肝癌は経門脈性転移か全身散布か?2)肝癌は過形成発癌が主体かde novo発癌が主体か?」板井悠二; 工藤 正俊  1999肝癌に関する最近の話題「1)肝細胞癌の流出静脈は門脈か肝静脈か?2)肝癌のリング状濃染」板井悠二; 工藤 正俊  1999Blood flow and disease state of hepatoma. Advance and significance of the ultrasonic wave blood flow image.工藤 正俊  Kanzo  39-  (12)  885  -894  1998/12Morphological diagnosis of hepatocellular carcinoma: Special emphasis on intranodular hemodynamic imagingM Kudo  HEPATO-GASTROENTEROLOGY  45-  1226  -1231  1998/08The Draining Vessel of Advanced Hepatocellular Carcinoma : Assessment by Color Doppler Imaging in Comparison with Histopathological FindingsTOCHIO H; IWASAKI N; NAKAMURA H; TAMURA S; SOGA T; MORIMOTO Y; OKABE Y; KASHIDA H; KUDO M; TOMITA S  Journal of medical ultrasOnics= 超音波医学  25-  (4)  382  -382  1998/04超音波造影法: 動注法と静注法について工藤 正俊  消化器科 特集「超音波機器の進歩と最近の話題」  25-  418  -426  1998早期肝細胞癌と境界病変-最近の画像診断と治療の進歩-「超音波」工藤 正俊; 杤尾 人司  画像診断  17-  1044  -1050  1998肝細胞癌の第一線診療の現況.工藤 正俊  ドラッグフォーラム大阪  79-  9  -14  1998CO2注入超音波検査による診断とは?工藤 正俊  癌治療Q&A-肝癌-,田口鐵男 監修,今岡真義 編  50  -51  1998超音波による肝細胞癌のステ-ジング-US angio, カラ-ドプラを含めて-.工藤 正俊; 杤尾 人司  肝胆膵  36-  39  -45  1998画像診断による異時性多中心性発癌(二次発癌)と肝内転移の鑑別.工藤 正俊  肝胆膵  36-  209  -216  1998Editorial工藤 正俊  超音波医学  25-  1  -2  1998胆・膵領域における造影エコ-法岡部 純弘; 工藤 正俊  日本臨床 特集「超音波造影法の進歩」─新しい超音波造影剤の登場と映像新技術の開発─.  56-  169  -174  1998体外走査式超音波診断-カラ-ドプラ法, 超音波造影剤も含めて-.岡部 純弘; 工藤 正俊  臨床画像 (特集 : 膵癌の診断と治療 up date)  14-  646  -655  1998肝細胞癌: 診断と治療の進歩.工藤 正俊  奈良県医師会医学会年報  11-  111  -112  1998肝癌の画像診断-エコ-, Helical CT, MRI, Angio, ドプラを含めた最近の検査-.工藤 正俊  Medical Practice  15-  1175  -1182  1998肝腫瘍の血流動態一CO2 angio法と肝動脈CT, 門脈CTとの関係一工藤 正俊  消化器科 特集II「肝血流を用いた肝疾患の診断・治療」  27-  61  -67  1998肝癌の画像診断の進歩.工藤 正俊  臨床成人病  28-  800  -810  1998肝血管筋脂肪腫(症例呈示)「貴方も名医」工藤 正俊  クリニックマガジン  9-  41  1998肝血管筋脂肪腫(解説)「貴方も名医」工藤 正俊  クリニックマガジン  9-  77  -79  1998肝腫瘍診断における超音波の進歩-超音波造影剤を中心に- What's New in Radiology?工藤 正俊  Diagnostic and Interventional Diagnostic and Interventional  3-  42  1998CO2 angio法と肝動脈CT, 門脈CTによる肝癌の血流動態.工藤 正俊  肝胆膵  37-  513  -519  1998CO2 アンジオグラフイ- -スクリ-ニングから精査の時代へ-超音波診断 update.工藤 正俊  臨床放射線増刊号. 宮本幸夫, 多田信平 編  1321  -1326  1998超音波診断の現状とその展望.工藤 正俊  肝癌診断の最新動向.小俣政男編  8  -12  1998Acute portal hypertension due to gastroduodenal aneurysm rupturing and communicating to the superior mesenteric vein鄭 浩柄; 工藤 正俊; 福永 豊和; 岡部 純弘; 樫田 博史; 冨田 周介; 織野 彬雄; 杤尾 人司  Japanese Journal of Portal Hypertension and Esophageal Varices  4-  (4)  368  -373  1998Regenerative nodule of alcoholic cirrhosis revealing hyperperfusion at CT during arterial portography (CTAP) and hypoperfusion at CT during arteriography (CTA)Soo Ryang Kim; Toshiyuki Matsuoka; Yoshitake Hayashi; Masatoshi Kudo; Shigeyuki Shintani; Kazunori Sasaki; Jung Hyo Kim; Susumu Imoto; Ke Ih Kim  Acta Hepatologica Japonica  39-  (3)  175  -180  199814.当科で経験したリウマチ性多発筋痛症(PMR)について末冨 洋一郎; 北野 元一; 岡本 慎司; 高幣 和郎; 岸谷 譲; 雑賀 豊彦; 工藤 正俊; 青木 矩彦  近畿大学医学雑誌  22-  (2)  1997/12Association Between Focal Spared Area at the Gallbladder Bed in the Fatty Liver and Intrahepatic Efferent Blood Flow From the Gallbladder Wall : Evaluation With Color Doppler ImagingTOCHIO Hitoshi; OKABE Yoshihiro; TOMITA Syusuke; KUDO Masatoshi; KASHIDA Hiroshi; IWASAKI Nobuhiro; MINOWA Kazushi; TAMURA Syuji; SOGA Toshiko; MORIMOTO Yoshito; WATANABE Tomohiro; FUKUNAGA Toyokazu; HIRASA Masahiro; IBUKI Yasuyoshi; ORINO Akio; TODO Akio  Journal of medical ultrasOnics= 超音波医学  24-  (10)  43  -53  1997/10Color Doppler Diagnosis of Small Hepatic Nodules Associated With Chronic Liver Diseases : Meaning of Afferent Continuous Waveform SignalsTOCHIO Hitoshi; TOMITA Syusuke; KUDO Masatoshi; OKABE Yoshihiro; KASHIDA Hiroshi; IWASAKI Nobuhiro; MINOWA Kazushi; SOGA Toshiko; TAMURA Syuji; MORIMOTO Yoshito; WATANABE Tomohiro; FUKUNAGA Toyokazu; HIRASA Masahiro; IBUKI Yasuyosi; ORINO Akio; TODO Akio  Journal of medical ultrasOnics= 超音波医学  24-  (8)  21  -29  1997/08Hyperplastic Nodule of the Liver with Aberrant Right Gastric Vein Drainage : Observation by Color Doppler ImagingTOCHIO Hitoshi; OKABE Yoshihiro; TOMITA Syusuke; ORINO Akio; IWASAKI Nobuhiro; MINOWA Kazushi; SOGA Toshiko; TAMURA Syuji; MORIMOTO Yoshito; WATANABE Tomohiro; FUKUNAGA Toyokazu; KONDO Masahiko; KASHIDA Hiroshi; HIRASA Masahiro; IBUKI Yasuyoshi; KUDO Masatoshi; TODO Akio  Journal of medical ultrasOnics= 超音波医学  24-  (5)  37  -44  1997/05Two cases of Wilson's disease with drastically improved Ultrasonographic findings of liver parenchymaTAMURA S.; KUDO H.; TOMITA S.; KASHIDA H.; OKABE Y.; TOCHIO H.; MORIMOTO Y.; MINOWA K.; SOGA T.; IWASAKI N.  Journal of medical ultrasOnics= 超音波医学  24-  (3)  426  -426  1997/03Evaluation of Color Doppler Image in Acute enterocolitisIWASAKI N.; TOCHIO H.; MINOWA K.; HAMADA M.; TAMURA S.; SOGA T.; MORIMOTO Y.; OKABE Y.; KUDO H.; TOMITA S.  Journal of medical ultrasOnics= 超音波医学  24-  (3)  392  -392  1997/03A Case of Acute Portal Hypertension Following Rapidly Progressed Communication between Gastroduodenal Aneurysm and Superior Mesenteric VeinTEI H.; KUDO M.; TOMITA S.; WATANABE T.; KONDO M.; FUKUNAGA T.; OKABE Y.; KASHIDA H.; TODO A.; TOCHIO H.  Journal of medical ultrasOnics= 超音波医学  24-  (3)  443  -443  1997/03Hemodinmic Change of Intra-Hepatic Arterial-Portal Shunting by Meal : Evaluation by Color Doppler ImagingTOCHIO H.; IWASAKI N.; MINOWA K.; TAMURA S.; SOGA T.; MORIMOTO Y.; KASHIDA H.; OKABE Y.; KUDO H.; TOMITA S.  Journal of medical ultrasOnics= 超音波医学  24-  (3)  436  -436  1997/03US Image in Acute enterocolitis by Enterohemorrhagic Escherichia Coli : O-157MINOWA K.; IWASAKI N.; TOCHIO H.; TAMURA S.; SOGA T.; MORIMOTO Y.; WATANABE T.; HIRASA M.; KUDO M.; TOMITA S.  Journal of medical ultrasOnics= 超音波医学  24-  (3)  372  -372  1997/03Diagnosis of Portal Blood Supplying Nodules Associated with Liver Cirrhosis by Power Doppler ImagingKUDO M.; TOMITA S.; TOCHIO H.; MINOWA K.; MORIMOTO Y.; WATANABE T.; KONDO M.; FUKUNAGA T.; OKABE Y.; TODO A.  Journal of medical ultrasOnics= 超音波医学  24-  (3)  331  -331  1997/03カラードプラ法による胆嚢壁から流出する血流に関する検討.濱田充生; 工藤 正俊; 岡部純弘; 冨田周介; 杤尾人司; 簔輪和士; 曽我登志子; 森本義人; 樫田博史; 藤堂彰男  超音波医学  24-  11  -18  1997Ultrasonographic Imaging of Intestinal Malignant LymphomaTOCHIO Hitoshi; TOMITA Syusuke; OKABE Yoshihiro; ORINO Akio; IWASAKI Nobuhiro; HAMADA Kazumi; MINOWA Kazushi; HAMADA Michiko; SOGA Toshiko; TAMURA Syuji; MORIMOTO Yoshito; WATANABE Tomohiro; FUKUNAGA Toyokazu; KONDOH Masahiko; KASHIDA Hiroshi; HIRASA Masahiro; IBUKI Yasuyosi; KUDOH Masatoshi; TODO Akio  J Med Ultrasonics  24-  (1)  21  -28  1997Asgr2(asialogycoprotein receptor minor subunit HL-2)工藤 正俊; 池田 和人  Molecular Medicine臨時増刊号「ノックアウトマウス・データブック」  34-  39  -40  1997慢性肝疾患にみられる小結節性病変に対するカラードプラ診断: 流入する定常性血流の意義を中心に.杤尾人司; 工藤 正俊; 福永 豊和; 冨田周介; 岡部純弘; 樫田博史; 岩崎信広; 蓑輪和士; 曽我登志子; 田村周二; 森本義人; 渡邊智裕; 平佐昌弘; 伊吹康良; 織野彬雄; 藤堂彰男  超音波医学  24-  1025  -1033  1997肝細胞癌診断-超音波の最前線「超音波テクニックを駆使して肝細胞癌の質的診断にどこまで迫れるか!」大石 元; 工藤 正俊; 堀口祐爾  Hepatoma Quarterly  3-  2  -9  199721世紀にむけての肝癌治療の展望.小俣 政男; 工藤 正俊; 多羅尾 和郎; 斉藤 明子  内科  80-  731  -742  1997カラ-ドプラと造影剤エコ-による肝癌診断工藤 正俊  内科(特集「肝癌の診断と治療の進歩」).  80-  666  -672  1997Research最前線. 肝血流動態イメ-ジ研究会.工藤 正俊  内科  80-  460  1997画像診断をどう進めていくか.工藤 正俊  クリニシヤン 特集「肝癌治療最前線」  44-  (458)  33  -39  1997肝癌の画像診断「超音波」-最近の話題を中心に-」工藤 正俊  日獨医報  41-  923  -936  1997パワ-ドプラ法による肝腫瘤の診断--最近の潮流 (特集:臨床第一線における先進超音波診断の現況--カラ-ドプラの最新症例)杤尾 人司; 工藤 正俊  映像情報  28-  (22)  1315  -1316,1325〜1329  1996/11Atypical hepatocellular carcinoma with relatively benign feature a proposal of new clinical entity.M Kudo; H Tochio; S Tomita; Y Okabe; A Todo  GASTROENTEROLOGY  110-  (4)  A1242  -A1242  1996/04Evaluation of Contrast Color Doppler Sonography in Hepatic TumorsHAMADA Michio; KUDO Masatoshi; TOMITA Shusuke; MINOWA Kazushi; TOCHIO Hitoshi; SHIMADA Keiko; HAMADA Kazumi; MORIMOTO Yoshito; OKABE Yasuhiro; KASHIDA Hiroshi; HIRASA Masahiro; ORINO Akio; TODO Akio  Jpn J Med Ultrasonics  23-  (1)  9  -17  1996/01Hemodynamic characteristics of early stage hepatocellular carcinoma: In vivo evaluation with vascular imagings.M Kudo; S Tomita; H Tochio; Y Okabe; A Todo  HEPATOLOGY  23-  (1)  P150  -P150  1996/01Value of enhanced color Doppler study in hepatic tumors: Comparison with US angiography and CT arterial portographyM Kudo; S Tomita; M Hamada; H Tochio; Y Okabe; A Todo  HEPATOLOGY  23-  (1)  P149  -P149  1996/01Receptor concentration via hepatic receptor imaging with a radiolabeled asialoglycoprotein analogue is a sensitive prognostic indicator in acute hepatocellular damageM Kudo; K Ikekubo; A Todo  HEPATOLOGY  23-  (1)  P148  -P148  1996/01HEPATIC ANGIOMYOLIPOMA PREOPERATIVELY DIAGNOSED BY IMAGINGM KUDO; T OKUNO; S TOMITA; T KAJIWARA; H SHIRANE; N USUKI; A TODO  JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY  8-  (5)  483  -488  1993/09Intrahepatic portosystemic venous shunt in liver cirrhosis: Is it congenital or acquired? [9]M. Kudo  American Journal of Roentgenology  160-  (2)  421  -422  1993INTRATUMORAL BLOOD-FLOW IN VARIOUS HEPATIC NODULES STUDIED WITH ULTRASOUND ANGIOGRAPHYH KASHIDA; Y OKABE; J MIMURA; M HIRASA; M KUDO; S TOMITA; A TODO  HEPATOLOGY  16-  (2)  553  -553  1992/08V-34 門脈内バルーンカテーテルを用いた肝細胞癌亜区域切除術(第36回日本消化器外科学会総会)谷 友彦; 梶原 建熈; 小西 豊; 高峰 義和; 橋本 隆; 奧野 敏隆; 細谷 亮; 工藤 正俊; 平佐 昌弘; 樫田 博史  日本消化器外科学会雑誌  23-  (6)  1361  -1361  1990/06Avid accumulation of Ga-67 citrate in adenocarcinoma of pancreasM. Kudo; K. Ikekubo; M. Hino; A. Todo  Clinical Nuclear Medicine  14-  (11)  843  -845  1989IS RADIONUCLIDE LIVER-SCAN ALREADY UNNECESSARY FOR DIAGNOSIS OF HEPATOCELLULAR-CARCINOMAM KUDO; H KASHIDA; M HIRASA; H TAKAKUWA; Y IBUKI; K FUJIMI; S TOMITA; H KOMORI; A ORINO; A TODO; Y SAIKI; H ITO; M HINO; K IKEKUBO  JOURNAL OF NUCLEAR MEDICINE  27-  (6)  1012  -1012  1986/06Awards & Honors2022/04 日本消化器病学会学術賞受賞2021/11 Highly Cited Researchers 2021 受賞(Clarivate Analytics:臨床医学部門)(日本人2名中1名)2021/05 日本超音波医学会 学会特別賞2021/04 近畿大学学術研究褒賞(学校法人 近畿大学)2020/12 インド肝臓学会(INASL)S.R. Naik Memorial Award2020/11 Highly Cited Researcher 2020 (Clarivate Analytics:臨床医学部門)(日本人唯一の選出)2019/11 Highly Cited Researcher 2019 (Clarivate Analytics:臨床医学部門)(日本人唯一の選出)2018/12 Desai Memorial Lecture Award from Education Universe and Care Foundation2018/12 SGHがん特別賞2018/10 台湾超音波医学会名誉会員賞(TSUM Honorary Member Award)2018/06 日本肝臓学会 織田賞受賞2018/05 韓国超音波医学会名誉会員賞(KSUM honorary Award)2014/12 Lorenzo Capussotti Award受賞(from IASGO)2012/11 USE論文賞(応用物理学会論文賞)2011/11 Certificate of Merit Award from Radiological Society of North America (RSNA)2011/06 Romanian Society of Ultrasound in Medicine and Biology (SRUMB) Honorary Award2011/06 日本肝臓学会「日本肝臓学会機関誌 肝臓Highest Citation賞」2011/05 韓国超音波医学会名誉会員賞(KSUM honorary Award)2011/04 米国超音波医学会名誉会員賞(AIUM Honorary Member Award)2010/06 日本肝臓学会「日本肝臓学会機関誌 Highest Citation賞」2010/05 JISAN Lecture Award Presented by Korean Society of Ultrasound in Medicine2009/12 北米放射線学会 Cum Laude賞受賞(7000編の論文中上位10編に採択)2009/03 インド肝臓学会Madangopalan Award2008/12 Certificate of Merit Award from Radiological Society of North America (RSNA)2008/09 Okuda Award presented by Asian Pacific Gastroenterology Society2008/03 フィリピン超音波医学会名誉会員(Honorary Member of PSUCMI)2006/09 ボローニャ大学医学部医学会名誉会員賞2003/06 AIUM Scientific Exhibit Winner1993/11 兵庫県医師会医学研究賞受賞1993/10 日本核医学会賞受賞1992/04 日本消化器病学会奨励賞受賞1992/03 日本対がん協会がん研究助成奨励賞受賞1990/03 兵庫県勤務医学会医学研究賞受賞1989/07 神戸市長賞(医学研究分野)受賞1989/06 米国核医学会 Berson-Yalow Award 受賞Research Grants & Projects免疫チェックポイント阻害剤投与に伴う急速な腫瘍増大(HPD)の発症機序の解析日本学術振興会:科学研究費助成事業Date (from‐to) : 2022/04 -2025/03 Author : 萩原 智; 工藤 正俊; 西田 直生志自己免疫性膵炎・IgG4関連疾患の発症に関わる腸管・膵臓免疫ネットワークの解明日本学術振興会:科学研究費助成事業Date (from‐to) : 2022/04 -2025/03 Author : 渡邉 智裕; 工藤 正俊Identification of resistant clone for the chemotherapy of hepatocellular carcinoma using cell free DNAJapan Society for the Promotion of Science:Grants-in-Aid for Scientific ResearchDate (from‐to) : 2021/04 -2024/03 Author : 工藤 正俊; 西田 直生志 肝細胞癌(肝癌)根治療法後に再発予防目的で免疫チェックポイント阻害剤(ICI)が投与された例を用い、根治療法後の血中のcirculating tumor DNA(ctDNA)が腫瘍再発の予測因子となりうるかを検討した。 ICIをアジュバントで投与された31例を用いた。根治術後血漿よりCAPP-sequenceにてctDNAを検討し、valiantが10 copy/ml以上をminimum residual disease (MRD)陽性とした。さらに、根治術時の腫瘍免疫状態(tumor microenvironment: TME)を解析するため、免疫染色にて腫瘍のCD8、PD-1、PD-L1、Foxp3、β-catenin、glutamine synthetase (GS)陽性細胞を検討した。加えて、Tumor Mutation Load Assayにて肝癌のゲノム解析を行い、遺伝子変異は10 copy以上のvaliant出現を陽性、copy number gain (CNG)は3 copy以上を陽性とした。β-cateninとGSの染色結果より2群(β-catenin経路活性化、非活性化)、TMEの状態により4群(CD8、PD-1、PD-L1とFoxp3染色により、hot型、exhausted型、cold型、Treg型)に分類した。ICI投与による術後無再発生存期間(RFS)はβ-catenin経路非活性化群で活性化群より有意に長く、またhot/exhausted型はcold/Treg型に比較して有意に長かった。β-catenin経路関連遺伝子のCNG陰性例では陽性例と比較し、有意にRFSが延長していた。一方、MRD陰性例は陽性例に比較してRFSが長い傾向にあったが有意ではなかった。MRDの肝癌根治療法後に再発に対する効果の解析にはさらなる検討が必要である。消化器疾患領域の透視下医療処置における被ばく線量測定(全国多施設前向き観察研究)日本学術振興会:科学研究費助成事業Date (from‐to) : 2020/04 -2023/03 Author : 竹中 完; 細野 眞; 工藤 正俊 本研究は各国の医療に用いられる放射線の使用基準に消化器領域の透視下医療処置の記載がほとんどされていないのは、信頼度の高い実際の被ばく量データが存在しないためであり、各透視下処置における、装置から出力される放射線量、患者・医療従事者の被ばく量を明らかにすることは、現在世に存在しない信頼度の高い情報を得られるのみではなく、「消化器領域のさまざまな透視下処置における被ばく量の基準値を定めDRL設定に繋げる」こと、消化器領域のみならず、透視下医療処置全般に関する被ばく量の基準作りにまで繋がることが可能になると考え立案した。唯一の被ばく国として放射線被ばくに関心の高い本邦において、世界に先駆けて、特に消化器領域の透視下医療処置に関する放射線被ばく量の基準を作成し、世界に発信することを目的に立案した。 「実臨床での透視下手技における患者と医療従事者の被ばく線量集計・解析」については当院における患者への透視下内視鏡手技における被ばく線量測定を行い、その数値は十分に防護対策をとらなければ基準値を容易に超える値であることが判明した。この内容は消化器病学会誌の速報に取り上げられ報告し、日本中の消化器内科医の被ばく防護意識改善に寄与したことが予想される。Development of a new treatment targeting RIP2 in inflammatory bowel diseasesJapan Society for the Promotion of Science:Grants-in-Aid for Scientific ResearchDate (from‐to) : 2019/04 -2022/03 Author : WATANABE TOMOHIRO Receptor-interacting protein 2 (RIP2) is a downstream signaling molecule for toll-like receptors (TLRs) and nucleotide-binding oligomerization domain 2 (NOD2). In this study, we addressed whether activation of RIP2 play pathogenic roles in the development of IBD. We found that sensing of commensal intestinal bacteria by TLRs expressed in dendritic cells induces pro-inflammatory cytokine responses through activation of RIP2 and that excessive activation of RIP2 caused the development of experimental colitis. In studies utilizing colonic biopsy samples from IBD patients, activation of RIP2 was parallel to expression of pro-inflammatory cytokines and disease activity. These murine and human IBD studies strongly support that RIP2 can be a novel treatment target for IBD.Precision Medicine in Inflammatory Bowel Disease and CancerJapan Society for the Promotion of Science:Grants-in-Aid for Scientific ResearchDate (from‐to) : 2020/04 -2021/03 Author : 櫻井 俊治; 西尾 和人; 工藤 正俊 がん免疫療法は多くの癌腫において有効性が示され、がん治療戦略を大きく変化させた。一方で、免疫関連副作用(immune-related adverse event: irAE)と呼ばれる副作用のリスクがあり、大腸炎を呈する消化管 (Gastrointestinal: GI) irAEの分子機序は不明な点が多い。臨床症状および内視鏡所見において、GI irAEと潰瘍性大腸炎(UC)は類似し、GI irAEはUCの1つのサブタイプである可能性がある。大腸粘膜と糞便を採取した。次世代シーケンサー(whole transcriptome, 16S sequencing)を用いて、GI irAEとUCの遺伝子発現プロファイルおよび腸内細菌叢を比較検討した。またinteractome解析によりGI irAEにおける宿主と腸内細菌の相互作用を考察した。コントロールと比べて、T細胞を活性化する働きのあるケモカインCXCL10、CXCL11の発現がGI irAEにおいて亢進していた。一方で、腸上皮の恒常性維持に関わるPDCD6IPの発現がUCにおいて低下していた。炎症粘膜では、遺伝子発現および腸内細菌叢において、GI irAEとUCは類似性を認めた。腸内細菌叢と遺伝子発現プロファイルの統合解析により、7つのclusterに分けられ、更にこれらは2つのmega-clusterに分けられた。機能解析では、免疫チェックポイント阻害薬に対する良好な反応は DNA repair やcell cycleが相関し、逆にinnate immune response、NFAT、IFN signaling pathwaysが負に相関することがわかった。炎症による2次的な腸内細菌叢の変化を除外するため、非炎症粘膜での検討を行い、Fusobacterium sp.の増加ががん免疫療法の治療効果と正の相関を示した。Analysis of tumor microimmune environment formed in the presence of liver cancer-induced HBx mutationsJapan Society for the Promotion of Science:Grants-in-Aid for Scientific ResearchDate (from‐to) : 2018/04 -2021/03 Author : Satoru HAGIWARA It was found that the onset of liver cancer was promoted as a result of increased production of active oxygen and activation of the JNK pathway in the presence of the HBx C1485T mutation. In addition, elucidation of the tumor microimmune environment induced in the presence of the HBxC1485T mutation proved that the cell numbers of TAMs and MDSCs were suppressed, which is one of the factors of the antitumor effect.Effect of tyrosine kinase inhibitor for immunological microenviroment of hepatocellular carcinomaJapan Society for the Promotion of Science:Grants-in-Aid for Scientific ResearchDate (from‐to) : 2018/04 -2021/03 Author : KUDO Masatoshi To know how the effectively the response to immune checkpoint inhibitors (ICIs) can be enhanced, we explored the immunological and molecular characteristics of HCCs. Programmed cell death ligand 1 (PD-L1)-positive HCCs frequently showed inflamed phenotype; a subset of HCCs carried mutation in PI3K-Akt pathway. In HCCs with infiltration of TILs, CD8+ cells expressed multiple co-inhibitory receptors, suggesting T-cell exhaustion. On the other hands, PD-L1-negative HCCs showed activating mutations in β-catenin, such tumor exhibited non-inflamed phenotype. Through the analysis of the HCC patients treated with anti-PD-1 therapy, the combined of Wnt/β-catenin activation, PD-L1 expression, and degree of CD8+ TILs in HCC are revealed to be the predicting factor for the response to ICI. Tyrosine kinase inhibitor involving PI3K/Akt pathway, in combination with ICI, might effective in HCC with mutation in PI3K-Akt. Role of β-catenin inhibitor on immune cold HCC should also be explored.Molecular link between stress response and cancer and its clinical implicationJapan Society for the Promotion of Science:Grants-in-Aid for Scientific ResearchDate (from‐to) : 2017/04 -2020/03 Author : SAKURAI Toshiharu Stress responses to chronic inflammation promote the development of colorectal and liver cancer. Using knock-out mice, we clarified the role of Heat shock protein (HSP) 27 for tumorigenesis in the liver and colon. HSP27 is involved in the pathogenesis of liver and colorectal cancer. Gankyrin (GK) is an oncoprotein which regulates inflammatory responses and its inhibition is considered as a possible anti-inflammatory therapy for inflammatory bowel disease (IBD). Unexpectedly, GK-deficiency in the upper small bowel augmented inflammatory activity. Examination of human samples have confirmed that the reduction of GK expression in the small bowel is associated with colonic involvement in human Crohn’s disease. Through the sequencing of bacterial 16S rRNA gene amplicons, bacteria potentially deleterious to intestinal homeostasis were identified. These results provide important insights into the pathogenesis of IBD.Development of innovative techniques of endoscopic ultrasound for early diagnosis of pancreatic cancer and its prognostic improvementJapan Society for the Promotion of Science:Grants-in-Aid for Scientific ResearchDate (from‐to) : 2016/04 -2019/03 Author : KITANO Masayuki We conducted a meta-analysis for usefulness of contrast-enhanced harmonic endoscopic ultrasonography (EUS), which revealed pooled sensitivity and specificity were 93% and 80%, respectively, without a significant publication bias. We developed a new device specific for EUS-guided biliary drainage. Preclinical study and prospective trial showed EUS-guided biliary drainage with the new device is useful and safe for biliary drainage in patients with malignant obstructive jaundice after failed ERCP. Multicenter studies revealed various techniques of EUS-guided biliary drainage including rendezvous technique, choledochoduodenostomy, hepatocogastrosotomy and antegrade stenting are useful and safe in patients with malignant obstructive jaundice after failed ERCP.Development of biomarker for sorafenib treatment using serum microRNA in patients with hepatocellular carcinomaJapan Society for the Promotion of Science:Grants-in-Aid for Scientific ResearchDate (from‐to) : 2015/04 -2018/03 Author : KUDO Masatoshi The aim of this study was to clarify the specific miRNAs in serum that could predict the early response of HCC to sorafenib treatment.Analyzing the sera from screening cohort, we selected five miRNAs. Through further analysis using a validation cohort and healthy control subjects, we found that miR-181a-5p and miR-339-5p showed significant differences in serum levels among patients with partial response (PR), stable disease (SD), and progressive disease (PD). We also analyzed the factors associated with disease control (DC); patients with DC showed a significantly higher level of serum miR-181a-5p than non-DC patients or healthy control subjects. We further conducted multivariate analysis among HCC patients with Barcelona Clinic Liver Cancer stage C using extrahepatic metastasis, serum decarboxiprothrombin and miR-181a-5p levels as covariables; serum miR-181a-5p was the only independent factor for achieving DC and affecting overall survival.Novel molecular target in colorectal cancer and inflammatory bowel diseaseJapan Society for the Promotion of Science:Grants-in-Aid for Scientific ResearchDate (from‐to) : 2014/04 -2017/03 Author : SAKURAI Toshiharu; FUJITA Jun We analyzed gene expression of colon tissues obtained from 354 patients with IBD and CAC and found that expression of gankyrin was much higher in colonic mucosa of patients with refractory IBD than in those with IBD in remission. Expression of gankyrin was upregulated in inflammatory cells as well as tumor cells in colonic mucosa of patients with CAC. The interaction between ganlyrin and SHP-1 leads to inhibition of STAT3 activation and to enhancement of TNF-alpha and IL-17 in inflammatory cells. We created mice with intestinal epithelial cell-specific gankyrin ablation and deletion of gankyrin in myeloid and epithelial cells. Gankyrin deficiency in myeloid cells reduced the activity of ERK and the expression of stem cell markers, leading to attenuated tumorigenic potential. These findings provide important insights into the pathogenesis of CAC and suggest that gankyrin is a promising target for developing therapeutic and preventive strategies against CAC.Ultrasound viscoelastography: development of quantitative imaging of tissue viscoelasticity based on fusion of static and dynamic tissue excitationJapan Society for the Promotion of Science:Grants-in-Aid for Scientific ResearchDate (from‐to) : 2013/05 -2016/03 Author : SHIINA TSUYOSHI; YAMAKAWA MAKOTO; KONDO KENGO; TOI MASAKAZU; KUDO MASAOSHI Ultrasound elastography is now widely used in many clinical fields for visualization of tissue hardness. Although its basic principles are categorized into two methods, there remain problems to be solved: strain image by static method is qualitative, while shear wave imaging by dynamic method is subjective to artifact due to inhomogeneous speed of shear wave. Moreover, imaging of tissue viscosity has not been put in practice. In this research, we aim to develop the viscoelastography, that is, technology of quantitative imaging of viscosity and elasticity of tissue for improvement in diagnosis of diseases such as cancer and chronic hepatitis by integration of static and dynamic excitation of tissueTechnological development of endoscopic ultrasonography for improvement of diagnosis and prognosis of pancreatic diseasesJapan Society for the Promotion of Science:Grants-in-Aid for Scientific ResearchDate (from‐to) : 2013/04 -2016/03 Author : KITANO Masayuki; KUDO Masatoshi; NISHIO Kazuto Contrast-enhanced harmonic endoscopic ultrasonography improved the ability of conventional endoscopic ultrasonography for differentiating malignant from benign cystic lesion in the pancreas as well as diagnosing lymph node metastases of pancreatobiliary tumors. Surveillance of pancreatic cancer using endoscopic ultrasonography in patients with intraductal papillary mucinous neoplasms detected small pancreatic cancer in 7%, which may lead to early diagnosis of pancreatic cancer. Endoscopic ultrasonography-guided bile duct and gallbladder drainage allowed treatment of difficult obstructive jaundice. Preclinical study revealed that radial force and structure of the flare strongly affect the anti-migration property of the biliary metal stent. Neurolysis of both broad plexus and ganglia was a predictor of a good pain response in endoscopic ultrasonography-guided neurolyisis for pancreatic cancer-related pain. The larger number of neurolytic spread areas lead to better outcomes.Prediction of sorafenib response by FGF3 gene amplification for patients with hepatocellular carcinomaJapan Society for the Promotion of Science:Grants-in-Aid for Scientific ResearchDate (from‐to) : 2012/10 -2015/03 Author : NISHIO Kazuto; KUDO Masatoshi We have analyzed the copy number variation of hepatocellular carcinoma (HCC) tumor in a multicenter clinical study. We found increased copy number of FGF19 was a new predictive biomarker for sorafenib response in addition to FGF3/FGF4 gene amplification in HCC. Separately, we conducted DNA and RNA sequencing of tumor FFPE samples in another multicenter clinical trials for HCC patients treated with sorafenib. DNA amplicon sequencing and RNA sequencing targeted 50 candidate genes were performed using FFPE tumor samples obtained by liver core needle biopsy. HCC tumor with low oncogene mutation numbers were sensitive to sorafenib treatment, suggesting that oncogene mutational burden in the tumor might be associated with the clinical response to sorafenib. We have also identified candidate genes (TGF-&#61537;, PECAM1, and NRG1) for the prediction of sorafenib response and progression free survival by RNA sequencing.Translational research focusing on the regulation of proteasome by GankyrinJapan Society for the Promotion of Science:Grants-in-Aid for Scientific ResearchDate (from‐to) : 2011 -2013 Author : SAKURAI Toshiharu; KUDO Masatoshi; FUJITA Jun Liver-specific p38-alpha ablation was found to enhance ROS accumulation, because it reduced the expression ofHSP25. p38-alpha-deficiency also increased the expression of SOX2, c-Jun and Gankyrin and led to enhanced TAA-induced hepatocarcinogenesis. The up-regulation of SOX2 and c-Jun was prevented by administration of the antioxidant butylated hydroxyanisole. The risk of human HCC recurrence is positively correlated with ROS accumulation in the liver. Augmented oxidative stress of liver parenchymal cells may explain the close relationship between liver fibrosis and hepatocarcinogenesis. In addition, expression of CD133, a cancer stem cell marker, was significantly correlated with Gankyrin expression. Gankyrin knockdown decreased the expression of vascular endothelial growth factor (VEGF) and stemness factors such as Nanog and Oct-4 in colorectal and liver cancer cells.Moleculer mechanism of Hepatocarcinogenesis and Development : Combined Analysis with Kupffer phase Contrast-enchanced US and Gene Expression.Japan Society for the Promotion of Science:Grants-in-Aid for Scientific ResearchDate (from‐to) : 2010 -2012 Author : KUDO Masatoshi; INOUE Tatsuo OATP8 epression is observed in dysplastic nodule, but not in early hepatocellular carcinoma (e-HCC),which is shown as low intense on kupffer phase contrast-enhanced US. In addition,Glypican3,HSP70,GS,CAP2,Bmi-1 are highly expressed in e-HCC during multistep hepatocarcinogenesis.Development of systems with endoscopic ultrasonography for diagnosis and treatment of bilio-pancreatic diseasesJapan Society for the Promotion of Science:Grants-in-Aid for Scientific ResearchDate (from‐to) : 2010 -2012 Author : KITANO Masayuki; KUDO Masatoshi; NISHIO Kazuto The usefulness of contrast-enhanced harmonic endoscopic ultrasonography for characterization of solid tumors in the pancreas, characterization of intra-abdominal lesions of undetermined origin and estimation of malignant potential of gastrointestinal stromal tumors was evaluated. In comparison with the other imaging methods, this novel technique improved the diagnostic ability for these diseases. Endoscopic ultrasonography guided broad plexus neurolysis achieved better pain relief than endoscopic ultrasonography guided celiac plexus neurolysis. Development of endoscopic ultrasonography guided drainage allowed salvage drainage treatment for obstruction of bilio-pancreatic system after unsuccessful transpapillary or surgical drainage.Identification of sensitivity determinant factors of srafenib treatment in hepatocellular carcinoma.Japan Society for the Promotion of Science:Grants-in-Aid for Scientific ResearchDate (from‐to) : 2011 -2011 Author : NISHIO Kazuto; KUDO Masatoshi A real-time PCR-based copy number assay revealed that FGF3/FGF4 amplification was observed in responders to sorafenib, but not observed in non-responders(p=0.006). The clinicopathological features showed that multiple lung metastases and a poorly differentiated histological type were frequently observed in responders. Our findings may provide a novel insight into the molecular background of HCC and sorafenib responders, warranting further prospective biomarker studies.Development of endosonography-guided puncture with biosensor and its application to evaluation of local pathophysiology in panereatic diseasesJapan Society for the Promotion of Science:Grants-in-Aid for Scientific ResearchDate (from‐to) : 2006 -2008 Author : KITANO Masayuki; KUDO Masatoshi; TAKEYAMA Yoshifumi; CHIKUGO Takaaki 研究成果の概要:超音波内視鏡下穿刺術とマイクロダイアリシス法を応用して局所における低分子物質量の測定法を開発し、薬物の局所薬物動態評価に成功した。また、超音波内視鏡を用いた膵疾患の局所病態生理を評価する方法として、超音波造影剤による血流評価、超音波内視鏡下穿刺による病理診断があり、その有用性を報告した。Newly Developed Image Analysis Method of Tumor Blood Flow : Separate Quantitative Analysis of Intranodular Arterial and Portal Blood Flow and Its Application to Research on HepatocarcinogenesisJapan Society for the Promotion of Science:Grants-in-Aid for Scientific ResearchDate (from‐to) : 2006 -2008 Author : KUDO Masatoshi; MURAKAMI Takamichi; MUNAKATA Hiroshi 今回われわれはraw data保存を利用して動脈血流と門脈血流を分離評価できる方法を開発した。新規超音波造影剤Sonazoidを用いることにより、そのraw data保存から検査後に腫瘍ならびに腫瘍の外側の動脈や門脈に関心領域(ROI)をおき、その立ち上がりから純粋に動脈のみで栄養される数秒間を装置内でコンピューター解析で同定し、その時間だけのMIP画像を加算してaccumulation画像を作成すると動脈が栄養しているか否かを判定し得ることを明らかにした。また、その後の門脈と動脈の両方が入るmixed phaseにおいては両者の交じり合ったこのphaseで血流が認められれば、それは門脈血流が存在する結節であることが評価できる。Hemodynamic and sinusoidal function change during multistep hepatocarcinogenesis : evaluation by contrast harmonic imagingJapan Society for the Promotion of Science:Grants-in-Aid for Scientific ResearchDate (from‐to) : 2004 -2005 Author : KUDO Masatoshi; MUNAKATA Hiroshi; FUKUNAGA Toyokazu Hepatocarcinogenesis is a multistep process, evolving from a hyperplastic nodule to early HCC, through early overt HCC, eventually to advanced overt hypervascular HCC. During this process, changes in intranodular hemodynamics also occur. We clarified in this research that at the initial phase of carcinogenesis, the hemodynamic pattern shows arterial vascularity with hypovascular and portal perfusion (type I). In the next step, both arterial and portal blood supplies decrease (type II). Subsequently, intranodular arterial vascularity increases to isovascularity (type III), and then to hypervascularity (type IV). Another hemodynamic transition occurs from the initial pattern to nodule-in-nodule pattern (arterial vascularity with regional vascular spots in a hypovascular background of portal perfusion (type V). Pure arterial phase imaging has been developed by a development of several technologies including Raw data management technology and accumulation image technology (MIP image). By this method, separate analysis of intranodular, portal flow from arterial flow has been possible, which is a novel technique. This was not possible by CT or MRI. Hepatocellular carcinoma, dysplastic nodule, and nodule-in-nodule type HCC can be successfully diagnosed by using this technique, pure arterial phase imaging.Evaluation of pancreatic microvasculature by contrast-enhanced endosonography with high resolution -application to diagnosis and treatment-Japan Society for the Promotion of Science:Grants-in-Aid for Scientific ResearchDate (from‐to) : 2003 -2005 Author : KITANO Masayuki; KUDO Masatoshi; MUNAKATA Hiroshi; NAKATANI Tatsuya The purposes of the present study were developing an echoendoscope equipped with contrast-harmonic mode for 2^ generation of contrast agents and establishing the method to observe microcirculation of digestive organs by means of it. During the period from 2003 to 2004, we succeeded to invent contrast-harmonic mode that is suite for 2^ generation of contrast agents and to develop a microconvex probe available for the mode. Furthermore, we observed microcirculation of digestive organs in dogs with the probe. In 2005, we made an animal model of pancreatic carcinomas by ablating a part of the pancreas, which resulted in a hypovascular lesion, and observed the vascularity of the lesion. Those results suggested the possibility to observe microcirculation of pancreatic carcinomas. We also evaluated the clinical significance of the contrast-enhanced harmonic ultrasonography. Through our studies, it was suggested that the contrast-enhanced ultrasonography is useful for depicting pancreatic carcinomas (Gut 2004, 53, 854-859), evaluating the response of pancreatic carcinomas to chemotherapy (J Gastroenterol 2006 in press) and estimating the malignant potential of gastrointestinal stromal tumors (J Gastroenterol 2005, 40, 247-255). We reported that endosonography guided celiac plexus neurolysis required computed tomography when B mode was employed (Digestive Endoscopy 2006, in press). Because the 2^ generation of contrast agents have not been permitted to use in Japan, we performed the clinical trial of contrast-enhanced harmonic endosonography at Bethesda general hospital in Germany where one of 2^ generation of contrast agents, SonoVue, were permitted for clinical use. The contrast-enhanced endosonography was performed in 17 cases. It visualized the parenchymal images of pancreatic and gastrointestinal stromal tumors that previous endosonography failed to depict. This result demonstrated that contrast-enhanced endosonography was available for clinical purpose.Imaging Analysis and Molecular Mechanism of angio architectural Change of the Tumor During Multistep Human HepatocarcinogenesisJapan Society for the Promotion of Science:Grants-in-Aid for Scientific ResearchDate (from‐to) : 2002 -2003 Author : KUDO Masatoshi; KAWASAKI Toshihiko; JIBIKI Takao; MUNAKATA Hiroshi Hepatocarcinogenesis is a multistep process, evolving from a hyperplastic nodule to early HCC, through early overt HCC, eventually to advanced overt hypervascular HCC. During this process, changes in intranodular hemodynamics also occu. We clarified in this research that at the initial phase of carcinogenesis, the hemodynamic pattern shows arterial vascularity with hypovascular and portal perfusion(type I). In the next step, both arterial and portal blood supplies decrease(type II). Subsequently, intranodular arterial vascularity increases to isovascularity(type III), and then to hypervascularity(type IV). Another hemodynamic transition occurs from the initial pattern to nodule-in-nodule pattern(arterial vascularity with regional vascular spots in a hypovascular background of portal perfusiai(type V). Fatty metamorphosis is observed frequently in the nodules classified hemodynamically in type II and III. This is attributed to a relative decrease in the blood supply due to a diminished portal supply and immature arterial neovascularization. Decreased arterial and portal supplies are supported by pathological evidence for decreased densities of arterial and portal vessels in early-stage well-differentiated HCCs. It was hypothesized initially and finally demonstrated that an intranodular hemodynamic transition occurs from type I to type II and then from type II to type III, before proceeding from type III to type IV during human hepatocarcinogenesis. This sequence has been confirmed by a 5-year clinical follow-up. Such studies have suggested the possibility of determining the stage of a nodule in the process of malignant transformation based on blood supplies visualized by a combination of tomographic vascular imaging techniques. An accurate detection of intraocular hemodynamics by these means lead to a reliable diagnosis, whether it is benign or malignantMolecular Mechanism and Blood Flow Imaging of the Formation of Angioarchitech titure during the Occurrence and Progression of Hepatocellular Carcinoma.Japan Society for the Promotion of Science:Grants-in-Aid for Scientific ResearchDate (from‐to) : 1998 -2000 Author : KUDO Masatoshi 1. Change of Intranodular Blood Flow During the Occurrence and Multistep Progression of Hepatocellular Carcinoma. Hepatocellular carcinoma(HCC)occurs as a hyperplastic nodule at its initiation of cancer. During multistep progression, hyperplastic nodule develops to the early well-differentiated HCC, and finally to advanced moderately differentiated HCC.Consistent with this progression, intranodular hemodynamic also changes, from arterially hypovascular and portally iso-perfusion(type I)to hypoperfusion state both from artery and portal vein(type II). Then it develops to the isovascular(type III)and to the classical hypervascular HCC(type II). This alteration can be detected by in vivo vascular imagings, such as US angiography, CTA, and CTAP. 2. Hemodynamic Analysis In addition to invasive vascular imaging, contrast harmonic imaging with intravenous injection of ultrasound contrast agent is extremely useful in the detection of intra nodular vascularity, both arterial and portal venous flow.Other linkresearchmaphttps://researchmap.jp/m-kudoKINDAI University Official WebsiteCopyright © MEDIA FUSION Co.,Ltd. All rights reserved.decorateImageAndButton();-->

18188bet ビーベットブレイキングダウン ライブバカラ - オンラインカジノ オンラインカジノ バカラ 2024
Copyright ©ザワールドダーツ The Paper All rights reserved.